PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	de Sousa, AFL; Teixeira, JRB; Lua, I; Souza, FD; Ferreira, AJF; Schneider, G; de Carvalho, HEF; de Oliveira, LB; Lima, SVMA; de Sousa, AR; de Araujo, TME; Camargo, ELS; Oria, MOB; Craveiro, I; de Araujo, TM; Mendes, IAC; Ventura, CAA; Sousa, I; de Oliveira, RM; Simao, M; Fronteira, I				Lopes de Sousa, Alvaro Francisco; Brito Teixeira, Jules Ramon; Lua, Iracema; Souza, Fernanda de Oliveira; Fortes Ferreira, Andrea Jacqueline; Schneider, Guilherme; Felix de Carvalho, Herica Emilia; de Oliveira, Layze Braz; Melo Almeida Lima, Shirley Veronica; de Sousa, Anderson Reis; Evangelista de Araujo, Telma Maria; Silva Camargo, Emerson Lucas; Batista Oria, Monica Oliveira; Craveiro, Isabel; de Araujo, Tania Maria; Costa Mendes, Isabel Amelia; Aparecida Ventura, Carla Arena; Sousa, Isabel; de Oliveira, Rodrigo Mota; Simao, Manuel; Fronteira, Ines			Determinants of COVID-19 Vaccine Hesitancy in Portuguese-Speaking Countries: A Structural Equations Modeling Approach	VACCINES			English	Article						vaccines; COVID-19; SARS-CoV-2; vaccine hesitancy; global health; disinformation; infodemic		COVID-19 vaccine hesitancy (VH) has caused concerns due to the possible fluctuations that may occur directly impacting the control of the pandemic. In this study, we aimed to estimate the prevalence and factors associated with COVID-19 VH in Portuguese-speaking countries. We developed a web survey (N:6,843) using an online, structured, and validated questionnaire. We used Measurement Models, Exploratory Factor Analysis, Exploratory Structural Equation Models, and Confirmatory Factor Analysis for the data analysis. The overall prevalence of COVID-19 VH in Portuguese-speaking countries was 21.1%. showed a statistically significant direct effect for VH: vaccine-related conspiracy beliefs (VB) (beta = 0.886), perceived stress (PS) (beta = 0.313), COVID-19 Misinformation (MIS) (beta = 0.259) and individual responses to COVID-19 (CIR) (beta = -0.122). The effect of MIS and CIR for VH was greater among men and of PS and VB among women; the effect of PS was greater among the youngest and of VB and CIR among the oldest. No discrepant differences were identified in the analyzed education strata. In conclusion, we found that conspiracy beliefs related to the vaccine strongly influence the decision to hesitate (not to take or to delay the vaccine). Specific characteristics related to gender, age group, social and cognitive vulnerabilities, added to the knowledge acquired, poorly substantiated and/or misrepresented about the COVID-19 vaccine, need to be considered in the planning of vaccination campaigns. It is necessary to respond in a timely, fast, and accurate manner to the challenges posed by vaccine hesitancy.	[Lopes de Sousa, Alvaro Francisco] Inst Hyg & Trop Med, Global Hlth & Trop Med GHTM, P-1349008 Lisbon, Portugal; [Brito Teixeira, Jules Ramon; de Araujo, Tania Maria] Feira Santana State Univ, Epidemiol Ctr, BR-44036900 Feira De Santana, BA, Brazil; [Lua, Iracema] Univ Fed Bahia, Inst Collect Hlth, BR-40170110 Salvador, BA, Brazil; [Souza, Fernanda de Oliveira] Univ Fed Reconcavo Bahia, Hlth Educ & Work Dept, BR-44380000 Santo Antonio De Jesus, Brazil; [Fortes Ferreira, Andrea Jacqueline] Data & Knowledge Integrat Ctr Hlth CIDACS, BR-41745715 Salvador, BA, Brazil; [Schneider, Guilherme; Felix de Carvalho, Herica Emilia; de Oliveira, Layze Braz; Silva Camargo, Emerson Lucas] Univ Sao Paulo, Human Exposome & Infect Dis Network HEID, BR-14040902 Ribeirao Preto, Brazil; [Melo Almeida Lima, Shirley Veronica] Univ Fed Sergipe, Ctr Res Collect Hlth, BR-49100000 Sao Cristovao, Brazil; [de Sousa, Anderson Reis] Univ Fed Bahia, Study Grp Hlth Care, BR-40110909 Salvador, BA, Brazil; [Evangelista de Araujo, Telma Maria] Univ Fed Piaui, Nursing Dept, BR-64049550 Teresina, Brazil; [Batista Oria, Monica Oliveira] Univ Fed Ceara, Nursing Dept, BR-60020181 Fortaleza, Ceara, Brazil; [Craveiro, Isabel; Fronteira, Ines] Univ Nova Lisboa, Inst Hyg & Trop Med, Global Hlth & Trop Med GHTM, P-1349008 Lisbon, Portugal; [Costa Mendes, Isabel Amelia; Aparecida Ventura, Carla Arena; de Oliveira, Rodrigo Mota] Univ Sao Paulo, Ribeirao Preto Coll Nursing, BR-14040902 Ribeirao Preto, Brazil; [Sousa, Isabel] Minist Saude Sao Tome & Principe, Cidade Capital, Sao Tome & Prin; [Simao, Manuel] Agostinho Neto Univ, Higher Inst Hlth Sci, Luanda 56910999, Angola		de Sousa, AFL (通讯作者)，Inst Hyg & Trop Med, Global Hlth & Trop Med GHTM, P-1349008 Lisbon, Portugal.	sousa.alvaromd@gmail.com; julesramon@gmail.com; iracemalua.enfermeira@gmail.com; fernandasouza@ufrb.edu.br; andreaferreiracv@gmail.com; guilherme.schneider@usp.br; hericacarvalho@usp.br; layzebraz@usp.br; shirleymelo.lima@gmail.com; anderson.sousa@ufba.br; telmaevangelista@gmail.com; lucmrg0@gmail.com; profmonicaoria@gmail.com; isabel.mr.craveiro@gmail.com; araujo.tania@uefs.br; iamendes@usp.br; caventura@eerp.usp.br; a21001261@ihmt.unl.pt; rodrigoo@usp.br; msimao40@hotmail.com; ifronteira@ihmt.unl.pt	Schneider, Guilherme/R-9466-2018; Fronteira, Inês/I-2380-2012; de Carvalho, Herica Emilia Félix/AAF-1713-2019; de Sousa, Álvaro Francisco Lopes/C-4505-2016; Ventura, Carla/B-2609-2014; Mendes, Isabel Amelia Costa/J-7966-2012; Craveiro, Isabel/J-4117-2012	Schneider, Guilherme/0000-0002-4244-6217; Fronteira, Inês/0000-0003-1406-4585; de Carvalho, Herica Emilia Félix/0000-0002-5913-8886; de Sousa, Álvaro Francisco Lopes/0000-0003-2710-2122; Ventura, Carla/0000-0003-0379-913X; Mendes, Isabel Amelia Costa/0000-0002-0704-4319; Craveiro, Isabel/0000-0003-4348-1986; Araujo, Tania Maria de/0000-0003-2766-7799; Fortes Ferrreira, Andrea Jacqueline/0000-0002-6884-3624; Camargo, Emerson Lucas Silva/0000-0002-6119-5193; Lima, Shirley/0000-0002-9062-0742; Brito Teixeira, Jules Ramon/0000-0002-8443-7810	FCTPortuguese Foundation for Science and TechnologyEuropean Commission [GHTM-UID/004413-2020]; UNINOVAFAPI/AFYA [22/2021-2022]	FCT for funds to GHTM-UID/004413-2020 and UNINOVAFAPI/AFYA-Process: 22/2021-2022.	Argote P., SHOT MESSAGE MESSENG; Barua Z, 2020, PROG DISASTER SCI, V8, DOI 10.1016/j.pdisas.2020.100119; Bertin P, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.565128; Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136; Brown T.A., 2015, METHODOLOGY SOCIAL S, VSecond; Cacciatore MA, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.1912437117; Pedrozo-Pupo JC, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311x00090520, 10.1590/0102-311X00090520]; Chang KC, 2020, J FORMOS MED ASSOC, V119, P1772, DOI 10.1016/j.jfma.2020.07.032; Cortes TR, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00103115; Curkovic M, 2021, J BIOMED INFORM, V115, DOI 10.1016/j.jbi.2021.103709; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Dordevic JM, 2021, SOC SCI MED, V277, DOI 10.1016/j.socscimed.2021.113930; Eder SJ, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247997; Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5; Galhardi CP, 2020, CIENC SAUDE COLETIVA, V25, P4201, DOI 10.1590/1413-812320202510.2.28922020; Germani F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247642; Glymour MM., 2008, MODERN EPIDEMIOLOGY, P183; Hair J. F., 2009, ANALISE MULTIVARIADA; Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3; Health Europe, IS VACC HES AFR LINK; Hernan MA., 2020, CAUSAL INFERENCE WHA; Hornsey MJ, 2018, HEALTH PSYCHOL, V37, P307, DOI 10.1037/hea0000586; Hviid A, 2019, ANN INTERN MED, V170, P513, DOI 10.7326/M18-2101; Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177; Kline R.B., 2005, METHODOLOGY SOCIAL S; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lo Coco G, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052586; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Machingaidze S, 2021, NAT MED, V27, P1338, DOI 10.1038/s41591-021-01459-7; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Maroco J., 2010, STRUCTURAL EQUATION; Marsh HW, 2009, STRUCT EQU MODELING, V16, P439, DOI 10.1080/10705510903008220; Menezes N.P., AFRICA CAN END POVER; Mesquita Claudio Tinoco, 2020, Int. J. Cardiovasc. Sci., V33, P203, DOI 10.36660/ijcs.20200073; Okubo R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060662; Otu A, 2021, LANCET MICROBE, V2, pE347, DOI 10.1016/S2666-5247(21)00126-9; Pakpour A.H., 2020, J CONCURRENT DISORDE, V2, P58, DOI DOI 10.54127/WCIC8036; Parlapani E, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00821; Pickles K, 2021, J MED INTERNET RES, V23, DOI 10.2196/23805; Ponnam HB, 2021, ASIAN J PHARM RES HE, V13, P123, DOI 10.18311/ajprhc/2021/27648; Rad RE, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10500-w; Razai MS, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n513; Reichenheim ME, 2014, CAD SAUDE PUBLICA, V30, P927, DOI 10.1590/0102-311X00143613; Robertson E, 2021, BRAIN BEHAV IMMUN, V94, P41, DOI 10.1016/j.bbi.2021.03.008; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403; Rosostolato B, 2019, REV BRAS SEX HUM, V30, P55, DOI [10.35919/rbsh.v30i2.92, DOI 10.35919/RBSH.V30I2.92]; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020109; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Shahi Gautam Kishore, 2021, Online Soc Netw Media, V22, P100104, DOI 10.1016/j.osnem.2020.100104; Shapiro GK, 2016, PAPILLOMAVIRUS RES, V2, P167, DOI 10.1016/j.pvr.2016.09.001; Siegrist M, 2021, RISK ANAL, V41, P787, DOI 10.1111/risa.13675; Song SJ, 2021, INFORM PROCESS MANAG, V58, DOI 10.1016/j.ipm.2020.102407; Tang SQ, 2021, GLOBALIZATION HEALTH, V17, DOI 10.1186/s12992-021-00669-5; The conversation, CONVERSATION; Tomljenovic H, 2020, PSYCHOL HEALTH, V35, P538, DOI 10.1080/08870446.2019.1673894; Urrunaga-Pastor D, 2021, TRAVEL MED INFECT DI, V41, DOI 10.1016/j.tmaid.2021.102059; Wardle C, INFORM DISORDER INTE; Werneck GL, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00120416; WHO, 2021, COVID 19 WEEKL EP UP	63	3	3	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1167	10.3390/vaccines9101167			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WU2CW	34696275	Green Published, gold			2022-04-29	WOS:000716359300001
J	Xu, YL; Ye, MX; Zhang, YW; Sun, SH; Luo, J; Jiang, S; Zhang, JJ; Liu, XL; Shao, Q; Cao, Q; Zheng, WL; Meurens, F; Chen, NH; Zhu, JZ				Xu, Yulin; Ye, Mengxue; Zhang, Youwen; Sun, Shaohua; Luo, Jia; Jiang, Sen; Zhang, Jiajia; Liu, Xueliang; Shao, Qi; Cao, Qi; Zheng, Wanglong; Meurens, Francois; Chen, Nanhua; Zhu, Jianzhong			Screening of Porcine Innate Immune Adaptor Signaling Revealed Several Anti-PRRSV Signaling Pathways	VACCINES			English	Article						PRRSV; innate immunity; pattern recognition receptor (PRR); signaling adaptors; ectopic expression; agonist; knockdown	SWINE ALVEOLAR MACROPHAGES; MARC-145 CELLS; VIRUS; REPLICATION; ACTIVATION; INFECTION; RESPONSES; DEFENSE; SYSTEM; TRIF	Porcine reproductive and respiratory syndrome virus (PRRSV) causes PRRS and is known to effectively suppress host innate immunity. The current strategies for controlling PRRSV are limited and complete understanding of anti-PRRSV innate immunity is needed. Here, we utilized nine porcine innate immune signaling adaptors which represent all currently known innate immune receptor signaling pathways for screening of anti-PRRSV activity. The analysis of PRRSV N gene transcription and protein expression both suggested that the multiple ectopic adaptors exhibited varying degrees of anti-PRRSV activities, with TRIF and MAVS most effective. To better quantify the PRRSV replication, the GFP signal of PRRSV from reverse genetics were measured by flow cytometry and similarly varying anti-PRRSV activities by different signaling adaptors were observed. Based on the screening data, and considering the importance of viral nucleic acid in innate immune response, endogenous TRIF, MAVS and STING were selected for further examination of anti-PRRSV activity. Agonist stimulation assay showed that MAVS and STING signaling possessed significant anti-PRRSV activities, whereas siRNA knockdown assay showed that TRIF, MAVS and STING are all involved in anti-PRRSV activity, with TLR3-TRIF displaying discrepancy in anti-PRRSV infection. Nevertheless, our work suggests that multiple pattern recognition receptor (PRR) signaling pathways are involved in anti-PRRSV innate immunity, which may have implications for the development of future antiviral strategies.	[Xu, Yulin; Ye, Mengxue; Zhang, Youwen; Sun, Shaohua; Luo, Jia; Jiang, Sen; Zhang, Jiajia; Liu, Xueliang; Shao, Qi; Cao, Qi; Zheng, Wanglong; Chen, Nanhua; Zhu, Jianzhong] Yangzhou Univ, Coll Vet Med, Yangzhou 225009, Jiangsu, Peoples R China; [Xu, Yulin; Ye, Mengxue; Zhang, Youwen; Sun, Shaohua; Luo, Jia; Jiang, Sen; Zhang, Jiajia; Liu, Xueliang; Shao, Qi; Cao, Qi; Zheng, Wanglong; Chen, Nanhua; Zhu, Jianzhong] Joint Int Res Lab Agr & Agriprod Safety, Yangzhou 225009, Jiangsu, Peoples R China; [Xu, Yulin; Ye, Mengxue; Zhang, Youwen; Sun, Shaohua; Luo, Jia; Jiang, Sen; Zhang, Jiajia; Liu, Xueliang; Shao, Qi; Cao, Qi; Zheng, Wanglong; Chen, Nanhua; Zhu, Jianzhong] Yangzhou Univ, Inst Comparat Med Res Inst, Yangzhou 225009, Jiangsu, Peoples R China; [Xu, Yulin; Ye, Mengxue; Zhang, Youwen; Sun, Shaohua; Luo, Jia; Jiang, Sen; Zhang, Jiajia; Liu, Xueliang; Shao, Qi; Cao, Qi; Zheng, Wanglong; Chen, Nanhua; Zhu, Jianzhong] Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China; [Meurens, Francois] INRAE, Oniris, BIOEPAR, F-44307 Nantes, France; [Meurens, Francois] Univ Saskatchewan, Western Coll Vet Med, Dept Vet Microbiol & Immunol, Saskatoon, SK S7N 5E2, Canada		Chen, NH; Zhu, JZ (通讯作者)，Yangzhou Univ, Coll Vet Med, Yangzhou 225009, Jiangsu, Peoples R China.; Chen, NH; Zhu, JZ (通讯作者)，Joint Int Res Lab Agr & Agriprod Safety, Yangzhou 225009, Jiangsu, Peoples R China.; Chen, NH; Zhu, JZ (通讯作者)，Yangzhou Univ, Inst Comparat Med Res Inst, Yangzhou 225009, Jiangsu, Peoples R China.; Chen, NH; Zhu, JZ (通讯作者)，Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China.	ylxu15650096726@163.com; mengxueyzu@163.com; zyw18252734747@163.com; shaohuas90@sina.com; luojiajia20210518@163.com; jiangsen8888888@163.com; awaw0601@163.com; xueliangaaa@foxmail.com; sq970123@163.com; qc_2021@163.com; 007297@yzu.edu.cn; francois.meurens@inra.fr; hnchen@yzu.edu.cn; jzzhu@yzu.edu.cn	Chen, Nanhua/I-3503-2019; Meurens, Francois JMA/J-3829-2019	Chen, Nanhua/0000-0002-1909-8760; Meurens, Francois JMA/0000-0002-0353-4871; Liu, Xueliang/0000-0002-4120-4822; ZHU, JIANZHONG/0000-0002-7082-1993	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31872450, 31802172]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Natural Science Foundation for Excellent Young Scholars of Jiangsu Province [BK202111603]; High Talent Supporting Program of Yangzhou University; Research Innovation Project of Jiangsu Province Graduate Students	The work was partly supported by the National Natural Science Foundation of China (31872450; 31802172) and is a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). N.C. is supported by Natural Science Foundation for Excellent Young Scholars of Jiangsu Province (BK202111603) and High Talent Supporting Program of Yangzhou University. Y.X. is supported by the Research Innovation Project of Jiangsu Province Graduate Students.	An TQ, 2020, VIRUS RES, V286, DOI 10.1016/j.virusres.2020.197980; Ao D, 2020, MOL IMMUNOL, V121, P20, DOI 10.1016/j.molimm.2020.02.013; Balasuriya UBR, 2017, CURR OPIN VIROL, V27, P57, DOI 10.1016/j.coviro.2017.11.005; Beutler B, 2004, MOL IMMUNOL, V40, P845, DOI 10.1016/j.molimm.2003.10.005; Chang XB, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11121160; Chen NH, 2020, TRANSBOUND EMERG DIS, V67, P1820, DOI 10.1111/tbed.13575; Chen NH, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090875; Chen NH, 2017, IUBMB LIFE, V69, P297, DOI 10.1002/iub.1625; Dong JM, 2015, J GEN VIROL, V96, P3049, DOI 10.1099/jgv.0.000257; Du YK, 2016, ANTIVIR RES, V131, P9, DOI 10.1016/j.antiviral.2016.04.005; Fang JY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156513; Geijtenbeek TBH, 2009, NAT REV IMMUNOL, V9, P465, DOI 10.1038/nri2569; He D, 2011, VET IMMUNOL IMMUNOP, V139, P57, DOI 10.1016/j.vetimm.2010.07.023; Heim VJ, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00208; Huang C, 2015, VIRUS RES, V202, P101, DOI 10.1016/j.virusres.2014.12.014; Iampietro M, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102519; Jiang S, 2020, DEV COMP IMMUNOL, V104, DOI 10.1016/j.dci.2019.103555; Jing HY, 2019, VIRUS RES, V268, P18, DOI 10.1016/j.virusres.2019.05.011; Kappes MA, 2015, VIROLOGY, V479, P475, DOI 10.1016/j.virol.2015.02.012; Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004; Ke WT, 2017, J VIROL, V91, DOI [10.1128/JVI.00827-17, 10.1128/jvi.00827-17]; Li SJ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030369; Li YP, 2015, ANIM GENET, V46, P437, DOI 10.1111/age.12316; Loo YM, 2011, IMMUNITY, V34, P680, DOI 10.1016/j.immuni.2011.05.003; Loving CL, 2015, VET IMMUNOL IMMUNOP, V167, P1, DOI 10.1016/j.vetimm.2015.07.003; Lunney JK, 2016, ANNU REV ANIM BIOSCI, V4, P129, DOI 10.1146/annurev-animal-022114-111025; Mair KH, 2014, DEV COMP IMMUNOL, V45, P321, DOI 10.1016/j.dci.2014.03.022; Murtaugh MP, 2011, VACCINE, V29, P8192, DOI 10.1016/j.vaccine.2011.09.013; Niu P, 2016, VET MICROBIOL, V182, P187, DOI 10.1016/j.vetmic.2015.11.010; Overend C, 2007, J GEN VIROL, V88, P925, DOI 10.1099/vir.0.82585-0; Platnich JM, 2019, ARCH BIOCHEM BIOPHYS, V670, P4, DOI 10.1016/j.abb.2019.02.008; Ruland J, 2019, NAT REV IMMUNOL, V19, P118, DOI 10.1038/s41577-018-0087-2; Sang Yongming, 2011, Animal Health Research Reviews, V12, P149, DOI 10.1017/S1466252311000144; Stehlik C, 2002, J EXP MED, V196, P1605, DOI 10.1084/jem.20021552; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Sun Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168314; Sun Y, 2012, VIRUSES-BASEL, V4, P424, DOI 10.3390/v4040424; Ullah MO, 2016, J LEUKOCYTE BIOL, V100, P27, DOI 10.1189/jlb.2RI1115-531R; Wang R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/315470; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Zhang LL, 2013, ANTIVIR RES, V99, P197, DOI 10.1016/j.antiviral.2013.06.004; Zhao YX, 2019, J VIROL, V93, DOI [10.1128/JVI.00001-19, 10.1128/jvi.00001-19]	43	0	0	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1176	10.3390/vaccines9101176			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI9QM	34696285	Green Published			2022-04-29	WOS:000726436400001
J	Daly, S; O'Sullivan, A; MacLoughlin, R				Daly, Sorcha; O'Sullivan, Andrew; MacLoughlin, Ronan			Cellular Immunotherapy and the Lung	VACCINES			English	Review						cellular immunotherapy; inhalation; respiratory disease; respiratory viruses; antibody; NK cell; DC vaccine; T cell	RESPIRATORY SYNCYTIAL VIRUS; HEMATOPOIETIC STEM-CELL; VIRAL-INFECTIONS; DRUG-DELIVERY; T-LYMPHOCYTES; MUCOSAL IMMUNITY; THERAPY; DIAGNOSIS; CLASSIFICATION; PREVENTION	The new era of cellular immunotherapies has provided state-of-the-art and efficient strategies for the prevention and treatment of cancer and infectious diseases. Cellular immunotherapies are at the forefront of innovative medical care, including adoptive T cell therapies, cancer vaccines, NK cell therapies, and immune checkpoint inhibitors. The focus of this review is on cellular immunotherapies and their application in the lung, as respiratory diseases remain one of the main causes of death worldwide. The ongoing global pandemic has shed a new light on respiratory viruses, with a key area of concern being how to combat and control their infections. The focus of cellular immunotherapies has largely been on treating cancer and has had major successes in the past few years. However, recent preclinical and clinical studies using these immunotherapies for respiratory viral infections demonstrate promising potential. Therefore, in this review we explore the use of multiple cellular immunotherapies in treating viral respiratory infections, along with investigating several routes of administration with an emphasis on inhaled immunotherapies.	[Daly, Sorcha] Natl Univ Ireland, Coll Med Nursing & Hlth Sci, Galway H91 TK33, Ireland; [O'Sullivan, Andrew; MacLoughlin, Ronan] Aerogen Ltd, Res & Dev, Sci & Emerging Technol, Galway Business Pk, Galway H91 HE94, Ireland; [MacLoughlin, Ronan] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin D02 PN40, Ireland; [MacLoughlin, Ronan] Royal Coll Surgeons Ireland, Sch Pharm & Biomol Sci, Dublin D02 YN77, Ireland		MacLoughlin, R (通讯作者)，Aerogen Ltd, Res & Dev, Sci & Emerging Technol, Galway Business Pk, Galway H91 HE94, Ireland.; MacLoughlin, R (通讯作者)，Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin D02 PN40, Ireland.; MacLoughlin, R (通讯作者)，Royal Coll Surgeons Ireland, Sch Pharm & Biomol Sci, Dublin D02 YN77, Ireland.	s.daly37@nuigalway.ie; aosullivan@aerogen.com; rmacloughlin@aerogen.com		MacLoughlin, Ronan/0000-0002-3164-1607			Abdellatif AAH, 2021, J DRUG DELIV SCI TEC, V63, DOI 10.1016/j.jddst.2021.102435; Acosta MAT, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02049-2020; Acosta PL, 2016, CLIN VACCINE IMMUNOL, V23, P189, DOI 10.1128/CVI.00609-15; Adalja A, 2019, EXPERT REV ANTI-INFE, V17, P467, DOI 10.1080/14787210.2019.1635009; Afrough B, 2019, CLIN EXP IMMUNOL, V196, P157, DOI 10.1111/cei.13295; Alard E, 2020, CANCERS, V12, DOI 10.3390/cancers12071826; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; [Anonymous], CLINICALTRIALS GOV N; [Anonymous], CLINICALTRIALS GOV S; Author B.P., 2015, NONINVASIVE INTRATRA, VVolume 5; Azoulay E, 2020, INTENS CARE MED, V46, P298, DOI 10.1007/s00134-019-05906-5; Babu A, 2013, J NANOMATER, V2013, DOI 10.1155/2013/863951; Battles MB, 2019, NAT REV MICROBIOL, V17, P233, DOI 10.1038/s41579-019-0149-x; Benmebarek MR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061283; Bollard CM, 2016, BLOOD, V127, P3331, DOI 10.1182/blood-2016-01-628982; Bollard CM, 2004, BIOL BLOOD MARROW TR, V10, P143, DOI 10.1016/j.bbmt.2003.09.017; Bonam SR, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100016; Boncristiani M.F., 2009, ENCY MICROBIOLOGY, P500, DOI DOI 10.1016/B978-012373944-5.00314-X; Bonilla FA, 2015, J ALLERGY CLIN IMMUN, V136, P1186, DOI 10.1016/j.jaci.2015.04.049; Bont L, 2002, PEDIATR RES, V52, P363, DOI [10.1203/01.PDR.0000028458.76706.C7, 10.1203/00006450-200209000-00009]; Borghardt JM, 2018, CAN RESPIR J, V2018, DOI 10.1155/2018/2732017; Bousfiha A, 2018, J CLIN IMMUNOL, V38, P129, DOI 10.1007/s10875-017-0465-8; Brave H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176435; Brufsky A, 2020, J MED VIROL, V92, P1386, DOI 10.1002/jmv.25902; Burgess G, 2018, EBIOMEDICINE, V35, P67, DOI 10.1016/j.ebiom.2018.07.035; Burrel S, 2021, INT J INFECT DIS, V102, P10, DOI 10.1016/j.ijid.2020.10.040; Calabrese F, 2020, VIRCHOWS ARCH, V477, P359, DOI 10.1007/s00428-020-02886-6; Cevik M, 2020, CLIN MICROBIOL INFEC, V26, P842, DOI 10.1016/j.cmi.2020.04.023; Cortez-Jugo C, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4917181; Dalgleish AG, 2014, HUM VACC IMMUNOTHER, V10, P3369, DOI 10.4161/21645515.2014.980707; De Santi C, 2020, MOL THER, V28, P1190, DOI 10.1016/j.ymthe.2020.02.001; De Santis MM, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01355-2016; Deng H, 2018, J CONTROL RELEASE, V290, P28, DOI 10.1016/j.jconrel.2018.09.026; Dolovich MB, 2011, LANCET, V377, P1032, DOI 10.1016/S0140-6736(10)60926-9; Doroudian M, 2019, THORAX, V74, P965, DOI 10.1136/thoraxjnl-2019-213037; Driscoll KE, 2000, TOXICOL SCI, V55, P24, DOI 10.1093/toxsci/55.1.24; Eain MM, 2021, DRUG DELIV, V28, P1496, DOI 10.1080/10717544.2021.1951893; Ehrmann S, 2013, INTENS CARE MED, V39, P1048, DOI 10.1007/s00134-013-2872-5; Eigentler TK, 2016, CANCER TREAT REV, V45, P7, DOI 10.1016/j.ctrv.2016.02.003; Esmaeilzadeh A, 2021, J CELL PHYSIOL, V236, P2519, DOI 10.1002/jcp.30076; Fernandez EF, 2018, MATERIALS, V11, DOI 10.3390/ma11010122; Ferreras C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.620730; Feucht J, 2015, BLOOD, V125, P1986, DOI 10.1182/blood-2014-06-573725; Fink J., 2005, CRIT CARE, V9, P1, DOI [10.1186/cc3192, DOI 10.1186/CC3192]; Fu WY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.669103; Fujkuyama Y, 2012, EXPERT REV VACCINES, V11, P367, DOI [10.1586/ERV.11.196, 10.1586/erv.11.196]; Galluzzi L, 2014, ONCOTARGET, V5, P12472, DOI 10.18632/oncotarget.2998; Galvin P, 2012, CELL MOL LIFE SCI, V69, P389, DOI 10.1007/s00018-011-0856-6; Gao LP, 2017, NANOTECHNOLOGY, V28, DOI 10.1088/1361-6528/aa7c43; Gatto L, 2020, IMMUNOTHERAPY-UK, V12, P1111, DOI 10.2217/imt-2020-0109; Geethakumari PR, 2021, CURR HEMATOL MALIG R, V16, P345, DOI 10.1007/s11899-021-00635-3; Gerdemann U, 2012, MOL THER, V20, P1622, DOI 10.1038/mt.2012.130; Goyal A, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc7112; Grasselli G, 2020, JAMA INTERN MED, V180, P1345, DOI 10.1001/jamainternmed.2020.3539; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI [10.1056/NEJMc2005203, 10.1056/NEJMoa2002032]; Guilleminault L, 2014, J CONTROL RELEASE, V196, P344, DOI 10.1016/j.jconrel.2014.10.003; Guillon A, 2019, MABS-AUSTIN, V11, P297, DOI 10.1080/19420862.2018.1556081; Hanley PJ, 2009, BLOOD, V114, P1958, DOI 10.1182/blood-2009-03-213256; Hayes C, 2021, IRISH J MED SCI, V190, P41, DOI 10.1007/s11845-020-02264-w; Heslop HE, 2013, HEMATOL-AM SOC HEMAT, P342, DOI 10.1182/asheducation-2013.1.342; Hibbitts A, 2014, J AEROSOL MED PULM D, V27, P466, DOI 10.1089/jamp.2013.1045; Holstein SA, 2020, CLIN PHARMACOL THER, V107, P112, DOI 10.1002/cpt.1674; Hooker KL, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.631211; Huppert LA, 2019, SEMIN RESP CRIT CARE, V40, P31, DOI 10.1055/s-0039-1683996; Jahanshahlu L, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110337; Jang JG, 2021, INT J CHRONIC OBSTR, V16, P1265, DOI 10.2147/COPD.S306916; Jones HM, 2013, CPT-PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.41; Karia Rutu, 2020, SN Compr Clin Med, V2, P2086, DOI 10.1007/s42399-020-00499-3; Keller MD, 2020, BLOOD, V135, P620, DOI 10.1182/blood.2019000924; Kikkert M, 2020, J INNATE IMMUN, V12, P4, DOI 10.1159/000503030; Kishi Y, 2000, BONE MARROW TRANSPL, V26, P573, DOI 10.1038/sj.bmt.1702559; Klichinsky M, 2020, NAT BIOTECHNOL, V38, P947, DOI 10.1038/s41587-020-0462-y; Kyd JM, 2001, VACCINE, V19, P2527, DOI 10.1016/S0264-410X(00)00484-9; Lavorini F, 2019, HANDB EXP PHARMACOL, V260, P143, DOI 10.1007/164_2019_335; Lee L, 2016, J CLIN PHARMACOL, V56, DOI 10.1002/jcph.591; Leen AM, 2006, NAT MED, V12, P1160, DOI 10.1038/nm1475; Lemon G, 2014, BRIT MED BULL, V110, P35, DOI 10.1093/bmb/ldt037; Li F, 2017, ADV MATER, V29, DOI 10.1002/adma.201602432; Li F, 2010, MABS-AUSTIN, V2, P466, DOI 10.4161/mabs.2.5.12720; Li J, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.612950; Li Q, 2016, NEOPLASMA, V63, P342, DOI 10.4149/302_151001N511; Li Y., 2021, J CLIN INVEST, V10; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Lie SA, 2020, CAN J ANESTH, V67, P885, DOI 10.1007/s12630-020-01637-0; Longest W, 2019, J AEROSOL MED PULM D, V32, P317, DOI 10.1089/jamp.2018.1508; Ma MT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.652223; MacLoughlin RJ, 2009, J AEROSOL MED PULM D, V22, P323, DOI 10.1089/jamp.2008.0717; Maillet A, 2008, PHARM RES-DORDR, V25, P1318, DOI 10.1007/s11095-007-9481-3; Market M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01512; Marzi A, 2004, J VIROL, V78, P12090, DOI 10.1128/JVI.78.21.12090-12095.2004; McCright JC, 2020, TISSUE BARRIERS, V8, DOI 10.1080/21688370.2019.1695476; Miller JS, 2013, HEMATOL-AM SOC HEMAT, P247, DOI 10.1182/asheducation-2013.1.247; Mishra SK, 2021, ACTA TROP, V214, DOI 10.1016/j.actatropica.2020.105778; Nelson PN, 2000, J CLIN PATHOL-MOL PA, V53, P111; NIETO GV, 2021, SCI REP-UK, V11, P1; O'Toole C, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-2280; Olchanski N, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy031; Olszewski OZ, 2016, PROCEDIA ENGINEER, V168, P1521, DOI 10.1016/j.proeng.2016.11.451; Papadopoulou A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008825; Paucek RD, 2019, TRENDS IMMUNOL, V40, P292, DOI 10.1016/j.it.2019.02.002; Pawitan JA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/965849; Perez CR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13368-y; Pezeshki PS, 2021, EXPERT OPIN BIOL TH, V21, P1575, DOI 10.1080/14712598.2021.1929919; Pleasants RA, 2018, RESP CARE, V63, P708, DOI 10.4187/respcare.06290; Porcu M, 2019, CANCERS, V11, DOI 10.3390/cancers11030305; Pritchard JN, 2020, DRUG DES DEV THER, V14, P3043, DOI 10.2147/DDDT.S262141; Pritchard JN, 2018, THER DELIV, V9, P121, DOI 10.4155/tde-2017-0102; Ratput MKS, 2018, ACS APPL MATER INTER, V10, P27589, DOI 10.1021/acsami.8b02019; Rawat K, 2021, EUR J PHARMACOL, V892, DOI 10.1016/j.ejphar.2020.173751; Respaud R, 2015, EXPERT OPIN DRUG DEL, V12, P1027, DOI 10.1517/17425247.2015.999039; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Riley RS, 2019, NAT REV DRUG DISCOV, V18, P175, DOI 10.1038/s41573-018-0006-z; Rogliani P, 2017, RESP MED, V124, P6, DOI 10.1016/j.rmed.2017.01.006; Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967; Saadeldin MK, 2021, MED HYPOTHESES, V146, DOI 10.1016/j.mehy.2020.110365; Satia I, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228544; Schlake T, 2019, CELL MOL LIFE SCI, V76, P301, DOI 10.1007/s00018-018-2935-4; Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/S0140-6736(17)30938-8, 10.1016/s0140-6736(17)30938-8]; Siddiqui R, 2020, ACS CHEM NEUROSCI, V11, P1523, DOI 10.1021/acschemneuro.0c00288; Simoes EAF, 2018, INFECT DIS THER, V7, P87, DOI 10.1007/s40121-018-0188-z; Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034; Sorino C, 2020, EUR J INTERN MED, V75, P15, DOI 10.1016/j.ejim.2020.02.023; Stein RT, 2017, PEDIATR PULM, V52, P556, DOI 10.1002/ppul.23570; Su F, 2016, HUM VACC IMMUNOTHER, V12, P1070, DOI 10.1080/21645515.2015.1114195; Sun C, 2015, ACTA PHARMACOL SIN, V36, P1191, DOI 10.1038/aps.2015.41; Thickett DR, 2001, AM J RESP CRIT CARE, V164, P1601, DOI 10.1164/ajrccm.164.9.2011071; Tibboel J, 2014, COPD, V11, P310, DOI 10.3109/15412555.2013.854322; Titov A, 2021, CANCERS, V13, DOI 10.3390/cancers13040743; Todryk S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030284; Toor SM, 2021, IMMUNOLOGY, V162, P30, DOI 10.1111/imm.13262; Tripp RA, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040625; Uhlin M, 2012, CLIN INFECT DIS, V55, P1064, DOI 10.1093/cid/cis625; van Doremalen N, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abh0755; van Erp EA, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030243; Vasileiou S, 2020, HAEMATOLOGICA, V105, P235, DOI 10.3324/haematol.2018.206896; Vencken S, 2019, ERJ OPEN RES, V5, DOI 10.1183/23120541.00161-2018; Verma NK, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-1; Wang Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01574; Wang ZG, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0423-1; Weber EW, 2020, CELL, V181, P46, DOI 10.1016/j.cell.2020.03.001; Weigt SS, 2011, SEMIN RESP CRIT CARE, V32, P471, DOI 10.1055/s-0031-1283286; Widders A, 2020, INFECT DIS HEALTH, V25, P210, DOI 10.1016/j.idh.2020.05.002; Wirsdorfer F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010024; Yu H., 2013, HUNTERS TROPICAL MED, P269; Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427; Zhang JC, 2020, BRAIN BEHAV IMMUN, V87, P59, DOI 10.1016/j.bbi.2020.04.046; Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2; Zhou B, 2020, CLIN INFECT DIS, V71, P2240, DOI 10.1093/cid/ciaa451	149	2	2	3	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1018	10.3390/vaccines9091018			24	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3XD	34579255	gold, Green Published			2022-04-29	WOS:000702140700001
J	Lebeau, G; Lagrave, A; Ogire, E; Grondin, L; Seriacaroupin, S; Moutoussamy, C; Mavingui, P; Hoarau, JJ; Roche, M; Krejbich-Trotot, P; Despres, P; Viranaicken, W				Lebeau, Gregorie; Lagrave, Alise; Ogire, Eva; Grondin, Lauriane; Seriacaroupin, Soundary; Moutoussamy, Cedric; Mavingui, Patrick; Hoarau, Jean-Jacques; Roche, Marjolaine; Krejbich-Trotot, Pascale; Despres, Philippe; Viranaicken, Wildriss			Viral Toxin NS1 Implication in Dengue Pathogenesis Making It a Pivotal Target in Development of Efficient Vaccine	VACCINES			English	Review						arbovirus; dengue; viral hemorrhagic fever; viral immunopathogenesis; viral toxin; NS1; dengue vaccine strategies	NONSTRUCTURAL PROTEIN NS1; PROTECTIVE EFFICACY; ENDOTHELIAL-CELLS; DNA VACCINE; VIRUS; IMMUNOGENICITY; RECOMBINANT; ANTIBODIES; INFECTION; EXPRESSION	The mosquito-borne viral disease dengue is a global public health problem causing a wide spectrum of clinical manifestations ranging from mild dengue fever to severe dengue with plasma leakage and bleeding which are often fatal. To date, there are no specific medications to treat dengue and prevent the risk of hemorrhage. Dengue is caused by one of four genetically related but antigenically distinct serotypes DENV-1-DENV-4. The growing burden of the four DENV serotypes has intensified both basic and applied research to better understand dengue physiopathology. Research has shown that the secreted soluble hexameric form of DENV nonstructural protein-1 (sNS1) plays a significant role in the pathogenesis of severe dengue. Here, we provide an overview of the current knowledge about the role of sNS1 in the immunopathogenesis of dengue disease. We discuss the potential use of sNS1 in future vaccine development and its potential to improve dengue vaccine efficiency, particularly against severe dengue illness.	[Lebeau, Gregorie; Lagrave, Alise; Ogire, Eva; Grondin, Lauriane; Seriacaroupin, Soundary; Moutoussamy, Cedric; Mavingui, Patrick; Hoarau, Jean-Jacques; Roche, Marjolaine; Krejbich-Trotot, Pascale; Despres, Philippe; Viranaicken, Wildriss] Univ Reun, Unite Mixte Proc Infect Milieu Insulaire Trop, Plateforme Technol CYROI, INSERM U1187,CNRS UMR 9192,IRD UMR 249, F-94791 St Clotilde, La Reunion, France		Viranaicken, W (通讯作者)，Univ Reun, Unite Mixte Proc Infect Milieu Insulaire Trop, Plateforme Technol CYROI, INSERM U1187,CNRS UMR 9192,IRD UMR 249, F-94791 St Clotilde, La Reunion, France.	gregorie.lebeau@univ-reunion.fr; alise.lagrave@hotmail.fr; eva.ogire@univ-reunion.fr; laurianegrondin19@gmail.com; 37000589@co.univ-reunion.fr; 36004347@co.univ-reunion.fr; patrick.mavingui@cnrs.fr; jean-jacques.hoarau@univ-reunion.fr; marjolaine.roche@univ-reunion.fr; pascale.krejbich@univ-reunion.fr; philippe.despres@univ-reunion.fr; wildriss.viranaicken@univ-reunion.fr		Krejbich Trotot, Pascale/0000-0001-7329-1716; Lebeau, Gregorie/0000-0002-9664-3486	European Regional Development Fund (ERDF) PO through the RUNDENG project [20202640-0022937]; Reunion University (Ecole doctorale STS) - Region Reunion [DIRED/2021-0161, DIRED/2018-1189]	This work was supported by the European Regional Development Fund (ERDF) PO through the RUNDENG project (No. 20202640-0022937). G.L. and E.O. have PhD degree scholarship from Reunion University (Ecole doctorale STS) funded by DIRED/2021-0161 and DIRED/2018-1189 from Region Reunion, respectively.	Acosta-Ampudia Y, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00116; Akey DL, 2014, SCIENCE, V343, P881, DOI 10.1126/science.1247749; Alayli F, 2016, VIROLOGY, V496, P227, DOI 10.1016/j.virol.2016.06.008; Ambuel Y, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00263; Amorim JH, 2012, VACCINE, V30, P837, DOI 10.1016/j.vaccine.2011.12.034; Avirutnan P, 2011, J IMMUNOL, V187, P424, DOI 10.4049/jimmunol.1100750; Avirutnan P, 2010, J EXP MED, V207, P793, DOI 10.1084/jem.20092545; Beatty PR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3787; Campos JLS, 2018, NAT IMMUNOL, V19, P1189, DOI 10.1038/s41590-018-0210-3; Chen HR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004828; Chen HR, 2015, BIOL OPEN, V4, P244, DOI 10.1242/bio.201410322; Chen JC, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005053; Chuang YC, 2011, J IMMUNOL, V187, P6483, DOI 10.4049/jimmunol.1102218; Conde JN, 2016, J VIROL, V90, P9570, DOI 10.1128/JVI.00912-16; Costa SM, 2007, VIROLOGY, V358, P413, DOI 10.1016/j.virol.2006.08.052; Costa SM, 2006, VACCINE, V24, P4562, DOI 10.1016/j.vaccine.2005.08.022; Espinosa DA, 2019, J IMMUNOL, V202, P1153, DOI 10.4049/jimmunol.1801323; Falconar AKI, 1997, ARCH VIROL, V142, P897, DOI 10.1007/s007050050127; FALCONAR AKI, 1994, ARCH VIROL, V137, P315, DOI 10.1007/BF01309478; Glasner DR, 2018, ANNU REV VIROL, V5, P227, DOI 10.1146/annurev-virology-101416-041848; Glasner DR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006673; Goncalves AJS, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004277; Govindarajan D, 2015, VACCINE, V33, P4105, DOI 10.1016/j.vaccine.2015.06.067; Green AM, 2014, J MOL BIOL, V426, P1148, DOI 10.1016/j.jmb.2013.11.023; Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018; Gutsche I, 2011, P NATL ACAD SCI USA, V108, P8003, DOI 10.1073/pnas.1017338108; Guy B, 2016, NAT REV MICROBIOL, V14, P45, DOI 10.1038/nrmicro.2015.2; Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223; Jearanaiwitayakul T, 2020, VACCINE, V38, P6814, DOI 10.1016/j.vaccine.2020.08.021; Lai YC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07308-3; Libraty DH, 2002, J INFECT DIS, V186, P1165, DOI 10.1086/343813; Lin CF, 2005, J IMMUNOL, V174, P395, DOI 10.4049/jimmunol.174.1.395; Lin CF, 2003, J MED VIROL, V69, P82, DOI 10.1002/jmv.10261; Lin SW, 2012, J INFECTION, V64, P325, DOI 10.1016/j.jinf.2011.11.023; Lindenbach BD, 1999, J VIROL, V73, P4611, DOI 10.1128/JVI.73.6.4611-4621.1999; Lindenbarch B.D., 2007, FIELDS VIROLOGY, V5th, P1101; Liu IJ, 2011, J BIOL CHEM, V286, P9726, DOI 10.1074/jbc.M110.170993; Modhiran N, 2017, IMMUNOL CELL BIOL, V95, P491, DOI 10.1038/icb.2017.5; Modhiran N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3863; Osorio JE, 2016, EXPERT REV VACCINES, V15, P497, DOI 10.1586/14760584.2016.1128328; Pinheiro-Michelsen JR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01252; Pinto PBA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01522; Plaszczyca A, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007736; Puerta-Guardo H, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005738; Redoni M, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2101; Reyes-Sandoval A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01651; Roby JA, 2015, J GEN VIROL, V96, P1551, DOI 10.1099/vir.0.000097; Scaturro P, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005277; Sharma M, 2020, J INFECT DIS, V221, P867, DOI 10.1093/infdis/jiz081; Stiasny K, 2011, AMINO ACIDS, V41, P1159, DOI 10.1007/s00726-009-0370-4; Thiemmeca S, 2016, J IMMUNOL, V197, P4053, DOI 10.4049/jimmunol.1600323; Vigne C, 2017, HUM VACC IMMUNOTHER, V13, P2004, DOI 10.1080/21645515.2017.1333211; Waickman AT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01778; Wan SW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092495; Wu SF, 2003, VACCINE, V21, P3919, DOI 10.1016/S0264-410X(03)00310-4; Zhang H, 2014, INT J INFECT DIS, V26, P57, DOI 10.1016/j.ijid.2014.02.002; Zhang ML, 2020, MOL THER-METH CLIN D, V18, P702, DOI 10.1016/j.omtm.2020.07.013; Zhang NR, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030481	58	1	1	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							946	10.3390/vaccines9090946			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3XQ	34579183	Green Submitted, Green Published, gold			2022-04-29	WOS:000702142000001
J	Lijeskic, O; Klun, I; Djakovic, MS; Gligoric, N; Stajner, T; Srbljanovic, J; Djurkovic-Djakovic, O				Lijeskic, Olivera; Klun, Ivana; Djakovic, Marija Stamenov; Gligoric, Nenad; Stajner, Tijana; Srbljanovic, Jelena; Djurkovic-Djakovic, Olgica			Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report	VACCINES			English	Article						SARS-CoV-2; COVID-19; BNT-162b2; BBIBP-CorV; Gam-COVID-Vac; ChAdOx1-S; specific antibodies; vaccine effectiveness		Real-life data on the performance of vaccines against SARS-CoV-2 are still limited. We here present the rates of detection and levels of antibodies specific for the SARS-CoV-2 spike protein RBD (receptor binding domain) elicited by four vaccines available in Serbia, including BNT-162b2 (BioNTech/Pfizer), BBIBP-CorV (Sinopharm), Gam-COVID-Vac (Gamaleya Research Institute) and ChAdOx1-S (AstraZeneca), compared with those after documented COVID-19, at 6 weeks and 3 months post first vaccine dose or post-infection. Six weeks post first vaccine dose, specific IgG antibodies were detected in 100% of individuals fully vaccinated with BNT-162b2 (n = 100) and Gam-COVID-Vac (n = 12) and in 81.7% of BBIBP-CorV recipients (n = 148), while one dose of ChAdOx1-S (n = 24) induced specific antibodies in 75%. Antibody levels elicited by BNT-162b2 were higher, while those elicited by BBIBP-CorV were lower, than after SARS-CoV-2 infection. By 3 months post-vaccination, antibody levels decreased but remained >= 20-fold above the cut-off in BNT-162b2 but not in BBIBP-CorV recipients, when an additional 30% were seronegative. For all vaccines, antibody levels were higher in individuals with past COVID-19 than in naive individuals. A total of twelve new infections occurred within the first 3 months post-vaccination, eight after the first dose of BNT-162b2 and ChAdOx1-S (one each) and BBIBP-CorV (six), and four after full vaccination with BBIBP-CorV, but none required hospitalization.	[Lijeskic, Olivera; Klun, Ivana; Djakovic, Marija Stamenov; Stajner, Tijana; Srbljanovic, Jelena; Djurkovic-Djakovic, Olgica] Univ Belgrade, Inst Med Res, Dept Microbiol & Parasitol, Belgrade 11129, Serbia; [Gligoric, Nenad] Alfa BK Univ, Fac Informat Technol, Belgrade 11070, Serbia; [Gligoric, Nenad] Zentrix Lab, Pancevo 26000, Serbia		Djurkovic-Djakovic, O (通讯作者)，Univ Belgrade, Inst Med Res, Dept Microbiol & Parasitol, Belgrade 11129, Serbia.	olivera.lijeskic@imi.bg.ac.rs; iklun@imi.bg.ac.rs; marija.stamenov@imi.bg.ac.rs; office@zentrixlab.eu; tijana.stajner@imi.bg.ac.rs; jelena.srbljanovic@imi.bg.ac.rs; olgicadj@imi.bg.ac.rs	Klun, Ivana/B-4759-2012; Štajner, Tijana/ABG-5331-2021; Djurkovic-Djakovic, Olgica/AAD-1811-2020	Klun, Ivana/0000-0001-7976-3104; Štajner, Tijana/0000-0003-3291-6104; Djurkovic-Djakovic, Olgica/0000-0001-7521-8598; Gligoric, Nenad/0000-0002-9054-2799; Lijeskic, Olivera/0000-0002-9009-1924	Ministry of Education, Science and Technological Development of SerbiaMinistry of Education, Science & Technological Development, Serbia [451-03-68/2020-14/200015]	This study was supported by the Ministry of Education, Science and Technological Development of Serbia, through grant (contract No. 451-03-68/2020-14/200015) to Institute for Medical Research, University of Belgrade.	Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; [Anonymous], 2021, STATUS COVID 19 VACC; [Anonymous], DAILY DANAS; Assis R., 2021, SUBSTANTIAL DIFFEREN, V6, P132, DOI [10.1101/2021.04.15.440089, DOI 10.1101/2021.04.15.440089]; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Bruni M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9103188; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Duysburgh E, 2021, LANCET INFECT DIS, V21, P163, DOI 10.1016/S1473-3099(20)30943-9; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Miljanovic D, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.691154; Peluso MJ, 2021, SCI ADV, V7, DOI [10.1126/sciadv.abh3409, 10.1101/2021.03.03.21251639]; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Post N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244126; Renard N, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02292-20; Salazar E, 2020, J CLIN INVEST, V130, P6728, DOI 10.1172/JCI141206; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195	20	1	1	4	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1031	10.3390/vaccines9091031			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3DK	34579268	Green Published, gold			2022-04-29	WOS:000702088700001
J	Shaw, HA; Ozanne, J; Burns, K; Mawas, F				Shaw, Helen A.; Ozanne, James; Burns, Keira; Mawas, Fatme			Multicomponent Vaccines against Group A Streptococcus Can Effectively Target Broad Disease Presentations	VACCINES			English	Article						Group A Streptococcus; Streptococcus pyogenes; vaccine; opsonophagocytosis; IL-8; IgG; SpyCEP; Cpa; Mac-1 IdeS; MalE	M PROTEIN; INVASIVE DISEASE; PYOGENES; SPYCEP; IMMUNOGENICITY; IDENTIFICATION; CANDIDATE; IMMUNITY; EVASION; BURDEN	Group A Streptococcus (GAS) is an important global human pathogen, with a wide range of disease presentations, from mild mucosal infections like pharyngitis to invasive diseases such as toxic shock syndrome. The effect on health and mortality from GAS infections is substantial worldwide, particularly from autoimmune sequelae-like rheumatic heart disease (RHD), and there is currently no licenced vaccine. We investigated protein antigens targeting a broad range of GAS disease presentations as vaccine components in individual and combination formulations. The potency and functional immunity generated were evaluated and compared between groups. Antibodies against all components were found in pooled human IgG (IVIG) and an immune response generated following the subcutaneous immunisation of mice. A combination immunisation showed a reduction in IgG response for SpyCEP but an increase for Cpa and Mac-1 (IdeS). An opsonophagocytosis assay (OPA) showed the killing of GAS with immune sera against M protein and combination groups, with a lower killing activity observed for immune sera against other individual antigens. Specific antigen assays showed functional immunity against SpyCEP and Mac-1 from both individual and combination immunisations, with the activity correlating with antibody titres. However, efficient blocking of the binding activity of Cpa to collagen I and fibronectin could not be demonstrated with immune sera or purified IgG. Our data indicate that combination immunisations, while effective at covering a broader range of virulence factors, can also affect the immune response generated. Further, our results showed that an OPA alone is inadequate for understanding protection from vaccination, particularly when considering protection from immune evasion factors and evaluation of the colonisation leading to pharyngitis.	[Shaw, Helen A.; Ozanne, James; Burns, Keira; Mawas, Fatme] Natl Inst Biol Stand & Control NIBSC, Blanche Lane, London EN6 3QG, England		Shaw, HA (通讯作者)，Natl Inst Biol Stand & Control NIBSC, Blanche Lane, London EN6 3QG, England.	Alexandra.shaw@nibsc.org; james.ozanne@nibsc.org; keira.burns@nibsc.org; Fatme.Mawas@nibsc.org			NIHR Policy Research Programme (NIBSC Regulatory Science Research Unit)	This paper is based on independent research commissioned and funded by the NIHR Policy Research Programme (NIBSC Regulatory Science Research Unit). The views expressed in the publication are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health, 'arms' length bodies or other government departments.	Agniswamy J, 2004, J BIOL CHEM, V279, P52789, DOI 10.1074/jbc.M410698200; Bensi G, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.015693; Caceres CJ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070703; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; Dale JB, 2013, VACCINE, V31, pB216, DOI 10.1016/j.vaccine.2012.09.045; Dale JB, 2011, VACCINE, V29, P8175, DOI 10.1016/j.vaccine.2011.09.005; Davies MR, 2019, NAT GENET, V51, P1035, DOI 10.1038/s41588-019-0417-8; Edwards RJ, 2005, J INFECT DIS, V192, P783, DOI 10.1086/432485; Fluckiger U, 1998, INFECT IMMUN, V66, P974, DOI 10.1128/IAI.66.3.974-979.1998; Hayman WA, 1997, INT IMMUNOL, V9, P1723, DOI 10.1093/intimm/9.11.1723; Jones S, 2018, VACCINE, V36, P3756, DOI 10.1016/j.vaccine.2018.05.056; Kreikemeyer B, 2005, J BIOL CHEM, V280, P33228, DOI 10.1074/jbc.M502896200; Kurupati P, 2010, MOL MICROBIOL, V76, P1387, DOI 10.1111/j.1365-2958.2010.07065.x; Lei BF, 2001, NAT MED, V7, P1298, DOI 10.1038/nm1201-1298; Lei BF, 2004, J INFECT DIS, V189, P79, DOI 10.1086/380491; Lei BF, 2002, INFECT IMMUN, V70, P6880, DOI 10.1128/IAI.70.12.6880-6890.2002; Linke-Winnebeck C, 2014, J BIOL CHEM, V289, P177, DOI 10.1074/jbc.M113.523761; Loh JMS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07602-0; Mawas F, 2005, J INFECT DIS, V191, P58, DOI 10.1086/426396; McGregor R, 2020, METHODS MOL BIOL, V2136, P323, DOI 10.1007/978-1-0716-0467-0_26; McKenna S, 2020, COMPUT STRUCT BIOTEC, V18, P650, DOI 10.1016/j.csbj.2020.03.004; Okumura CYM, 2013, MBIO, V4, DOI 10.1128/mBio.00499-13; Pastural E, 2020, VACCINE, V38, P1384, DOI 10.1016/j.vaccine.2019.12.005; Pointon JA, 2010, J BIOL CHEM, V285, P33858, DOI 10.1074/jbc.M110.149385; Radcliff FJ, 2015, MED MICROBIOL IMMUN, V204, P185, DOI 10.1007/s00430-014-0353-2; Reglinski M, 2016, J INFECTION, V72, P450, DOI 10.1016/j.jinf.2016.02.002; Reglinski M, 2015, SCI REP-UK, V5, DOI 10.1038/srep15825; Rivera-Hernandez T, 2020, MBIO, V11, DOI 10.1128/mBio.00122-20; Rivera-Hernandez T, 2019, MBIO, V10, DOI 10.1128/mBio.00693-19; Rivera-Hernandez T, 2016, MBIO, V7, DOI 10.1128/mBio.00618-16; Sekuloski S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198658; Shelburne SA, 2007, J BACTERIOL, V189, P2610, DOI 10.1128/JB.01539-06; Shelburne SA, 2006, INFECT IMMUN, V74, P4605, DOI 10.1128/IAI.00477-06; Sheppard CL, 2019, GENES-BASEL, V10, DOI 10.3390/genes10090687; Smith WD, 2010, J BACTERIOL, V192, P4651, DOI 10.1128/JB.00071-10; Steer AC, 2016, VACCINE, V34, P2953, DOI 10.1016/j.vaccine.2016.03.073; Tiouajni M, 2014, FEBS J, V281, P5513, DOI 10.1111/febs.13092; Turner CE, 2009, VACCINE, V27, P4923, DOI 10.1016/j.vaccine.2009.06.042; Vekemans J, 2019, CLIN INFECT DIS, V69, P877, DOI 10.1093/cid/ciy1143; von Pawel-Rammingen U, 2012, J INNATE IMMUN, V4, P132, DOI 10.1159/000332940; Walsh NC, 2017, ANNU REV PATHOL-MECH, V12, P187, DOI 10.1146/annurev-pathol-052016-100332; Watkins DA, 2017, NEW ENGL J MED, V377, P713, DOI 10.1056/NEJMoa1603693; Zingaretti C, 2010, FASEB J, V24, P2839, DOI 10.1096/fj.09-145631	43	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1025	10.3390/vaccines9091025			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3BV	34579262	Green Published, gold			2022-04-29	WOS:000702084600001
J	Wang, C; Wang, Y; Han, BF; Zhao, TS; Liu, B; Liu, HY; Chen, LY; Xie, MZ; Zheng, H; Zhang, SH; Zeng, J; Huang, NH; Du, J; Liu, YQ; Lu, QB; Cui, FQ				Wang, Chao; Wang, Yu; Han, Bingfeng; Zhao, Tian-Shuo; Liu, Bei; Liu, Hanyu; Chen, Linyi; Xie, Mingzhu; Zheng, Hui; Zhang, Sihui; Zeng, Jing; Huang, Ning-Hua; Du, Juan; Liu, Yaqiong; Lu, Qing-Bin; Cui, Fuqiang			Willingness and SARS-CoV-2 Vaccination Coverage among Healthcare Workers in China: A Nationwide Study	VACCINES			English	Article						SARS-CoV-2 vaccine; willingness; confidence; coverage; healthcare workers	INFLUENZA VACCINATION; COVID-19; HESITANCY; INTENTION	Background: The SARS-CoV-2 vaccine has been widely rolled out globally in the general populations. However, specific data on vaccination confidence, willingness or coverage among health care workers (HCWs) has been less reported. Methods: A cross-sectional online survey was conducted to specify the basic data and patterns of vaccination confidence, willingness and coverage among HCWs nationwide. Results: In total, 2386 out of 2583 (92.4%) participants were enrolled for analysis, and the rates of confidence in vaccine, professional institutes and government were 75.1%, 85.2% and 85.4%, respectively. The overall vaccination coverage rate was 63.6% which was adjusted as 82.8% for participants under current medical conditions or having contraindications. Confidence in vaccine safety was shown to be the most related factor to willingness among doctors, nurses, medical technicians and hospital administrators, while confidence in vaccine effectiveness as well as trust in government played the key role in formulating public health employees' willingness. 130 (7.1% of 1833) participants reporting willingness still not been vaccinated regardless of contraindications. Multivariate analysis among willingness participants showed that males, aged over 30 years, public health employees and higher vaccination confidence had significantly higher vaccination rates with ORs (95% confidence intervals) as 1.64 (1.08-2.49), 3.14 (2.14-4.62), 2.43 (1.46-4.04) or 2.31 (1.24-4.33). Conclusions: HCWs' confidence, willingness and coverage rates to the vaccine were generally at high levels. Heterogeneity among HCWs should be considered for future vaccination promotion strategies. The population's confidence in vaccination is not only the determinant to their willingness, but also guarantees their actual vaccine uptake.	[Wang, Chao; Wang, Yu; Han, Bingfeng; Zhao, Tian-Shuo; Liu, Bei; Liu, Hanyu; Chen, Linyi; Xie, Mingzhu; Zheng, Hui; Zhang, Sihui; Zeng, Jing; Huang, Ning-Hua; Du, Juan; Liu, Yaqiong; Lu, Qing-Bin; Cui, Fuqiang] Peking Univ, Dept Laboratorial Sci & Technol, Sch Publ Hlth, Beijing 100191, Peoples R China; [Wang, Chao; Wang, Yu; Han, Bingfeng; Zhao, Tian-Shuo; Liu, Bei; Liu, Hanyu; Chen, Linyi; Xie, Mingzhu; Zheng, Hui; Zhang, Sihui; Zeng, Jing; Huang, Ning-Hua; Du, Juan; Liu, Yaqiong; Lu, Qing-Bin; Cui, Fuqiang] Peking Univ, Vaccine Res Ctr, Sch Publ Hlth, Beijing 100191, Peoples R China; [Wang, Chao; Wang, Yu; Han, Bingfeng; Zhao, Tian-Shuo; Liu, Bei; Liu, Hanyu; Chen, Linyi; Xie, Mingzhu; Zheng, Hui; Zhang, Sihui; Lu, Qing-Bin; Cui, Fuqiang] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China		Lu, QB; Cui, FQ (通讯作者)，Peking Univ, Dept Laboratorial Sci & Technol, Sch Publ Hlth, Beijing 100191, Peoples R China.; Lu, QB; Cui, FQ (通讯作者)，Peking Univ, Vaccine Res Ctr, Sch Publ Hlth, Beijing 100191, Peoples R China.; Lu, QB; Cui, FQ (通讯作者)，Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China.	wchao@bjmu.edu.cn; 2011110184@bjmu.edu.cn; hanbingfeng@pku.edu.cn; zts2018@pku.edu.cn; 1916387057@bjmu.edu.cn; liuhanyuu@bjmu.edu.cn; chenlinyi137@pku.edu.cn; 1610306142@pku.edu.cn; zhenghui@chinacdc.cn; zhangsihui@bjmu.edu.cn; zengjing@bjmu.edu.cn; hnh@bjmu.edu.cn; juandu@bjmu.edu.cn; liuyaqiong@bjmu.edu.cn; qingbinlu@bjmu.edu.cn; cuifuq@bjmu.edu.cn		Cui, Fuqiang/0000-0002-9592-4286; Lu, Qing-Bin/0000-0002-2804-0827	Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities; Peking University Health Science CenterPeking University [BMU20170607]; Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation [BMU2021PY005]; Joint Research Fund for Beijing Natural Science Foundation and Haidian Original Innovation [L202007]	This work was supported by Fundamental Research Funds for the Central Universities and Peking University Health Science Center (grant numbers BMU20170607), Peking University Medicine Fund of Fostering Young Scholars' Scientific & Technological Innovation (BMU2021PY005) and Joint Research Fund for Beijing Natural Science Foundation and Haidian Original Innovation (L202007).	Akande OW, 2020, NIGER POSTGRAD MED J, V27, P147, DOI 10.4103/npmj.npmj_157_20; Al-Tawfiq JA, 2012, ANN SAUDI MED, V32, P64, DOI 10.5144/0256-4947.2012.64; Alhumaid S, 2021, ANTIMICROB RESIST IN, V10, DOI 10.1186/s13756-021-00957-0; Biswas N, 2021, J COMMUN HEALTH, V46, P1244, DOI 10.1007/s10900-021-00984-3; Chang D, 2020, LANCET RESP MED, V8, pE13, DOI 10.1016/S2213-2600(20)30066-7; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Di Giuseppe G, 2021, EXPERT REV VACCINES, V20, P881, DOI 10.1080/14760584.2021.1922081; Di Martino G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020248; Dong D, 2020, HEALTH EXPECT, V23, P1543, DOI 10.1111/hex.13140; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Du FX, 2020, VACCINE, V38, P7464, DOI 10.1016/j.vaccine.2020.09.075; Formeister EJ, 2021, JAMA OTOLARYNGOL, V147, P672, DOI 10.1001/jamaoto.2021.0869; Galasso V, 2020, P NATL ACAD SCI USA, V117, P27285, DOI 10.1073/pnas.2012520117; Grech Victor, 2020, Early Hum Dev, P105213, DOI 10.1016/j.earlhumdev.2020.105213; Guner R, 2020, TURK J MED SCI, V50, P571, DOI 10.3906/sag-2004-146; Hanrath AT, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.636160; He S, 2021, J COMMUN HEALTH, V46, P278, DOI 10.1007/s10900-020-00870-4; Kaboli F, 2010, INFECT CONT HOSP EP, V31, P1017, DOI 10.1086/655465; Karlsson LC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224330; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kukreti S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030246; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; La Torre G, 2017, HEALTHCARE-BASEL, V5, DOI 10.3390/healthcare5010013; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lazarus JV, 2020, J HEPATOL, V73, P490, DOI 10.1016/j.jhep.2020.06.008; Li M, 2021, POSTGRAD MED J, DOI 10.1136/postgradmedj-2021-140195; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Palgi Y, 2021, J AFFECT DISORDERS, V287, P352, DOI 10.1016/j.jad.2021.03.064; Papagiannis D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144925; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sun SY, 2021, GLOBALIZATION HEALTH, V17, DOI 10.1186/s12992-021-00665-9; Sun SF, 2021, PREV MED REP, V22, DOI 10.1016/j.pmedr.2021.101350; Torun SD, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-596; Trucchi C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17155278; Tse DMS, 2020, BMC FAM PRACT, V21, DOI 10.1186/s12875-020-01343-2; Udow-Phillips M, 2020, J HOSP MED, V15, P431, DOI 10.12788/jhm.3474; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Wang C, 2021, VACCINE, V39, P2833, DOI 10.1016/j.vaccine.2021.04.020; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang J, 2021, HUM VACC IMMUNOTHER, V17, P2926, DOI 10.1080/21645515.2021.1909328; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Yang RH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010002; Zhang KC, 2020, JMIR PEDIATR PARENT, V3, DOI 10.2196/24827; Zhou PC, 2020, INFECT CONT HOSP EP, V41, P745, DOI 10.1017/ice.2020.60	49	2	2	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							993	10.3390/vaccines9090993			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UZ2SY	34579230	Green Published, gold			2022-04-29	WOS:000702061300001
J	Cocomazzi, G; Piazzolla, V; Squillante, MM; Antinucci, S; Giambra, V; Giuliani, F; Maiorana, A; Serra, N; Mangia, A				Cocomazzi, Giovanna; Piazzolla, Valeria; Squillante, Maria Maddalena; Antinucci, Stefano; Giambra, Vincenzo; Giuliani, Francesco; Maiorana, Alberto; Serra, Nicola; Mangia, Alessandra			Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers	VACCINES			English	Article						anti-S1; BNT162b2 vaccine; COVID-19 antibody decline; healthcare workers		Purpose: Clinical significance and durability of serological response after mRNA COVID-19 vaccines is under investigation. Data on early virological response are limited. To iden-tify potential predictors of antibody durability, circulating antibody levels were longitudinally ex-plored in healthcare workers included in a follow-up program for SARS-CoV-2 infection. Meth-ods: Subjects meeting the inclusion criteria signed an informed consent. Serum samples were col-lected at baseline, before the first BNT162b2 vaccine, at days 7, 21, 31, 90, and 180 days after the first dose. Serological evaluation was performed by QuantiVac Euroimmune anti-S1 antibody as-say. Only subjects followed-up until day 90 are here considered. Results: Of 340 taken into consid-eration, 265 subjects were naive, and 75 COVID-19 experienced. The former showed a progres-sive increase in their antibody levels before day 90 decline, while the latter showed antibody levels reaching a plateau at day 7 and slightly declining at day 90. All showed antibody levels higher than the assay cut-off at day 31 and 90. Among naive, 108 had an early response whose predic-tors were younger age and female gender (OR 0.94, 95% CI 0.91-0.96, p < 0.0001; and OR 2.58, 95% CI 1.48-4.51, p = 0.0009). Naive subjects experienced a day 30/90 decline in antibody levels, whereas experienced did not. Early response was an independent predictor of higher day 30/90 antibody levels decline (OR = 2.05, 95% CI 1.04-4.02; p = 0.037). Conclusions: Our results suggest that in healthcare workers early response might be inversely associated with antibody levels 90 days after BNT162b2 vaccine.	[Cocomazzi, Giovanna; Piazzolla, Valeria; Squillante, Maria Maddalena; Mangia, Alessandra] Fdn IRCCS Casa Sollievo Sofferenza, Liver Unit, I-71013 San Giovanni Rotondo Fg, Fg, Italy; [Antinucci, Stefano] Allergy Diagnost Sect Euroimmun, I-35127 Padua, Italy; [Giambra, Vincenzo] Fdn Casa Sollievo Sofferenza, Regenerat Med & Innovat Therapies ISBReMIT, Inst Stem Cell Biol, I-71013 San Giovanni Rotondo Fg, Fg, Italy; [Giuliani, Francesco] Fdn IRCCS Casa Sollievo Sofferenza, ICT Innovat & Res Unit, I-71013 San Giovanni Rotondo Fg, Fg, Italy; [Maiorana, Alberto] Fdn Casa Sollievo Sofferenza, GSSL Unit, I-71013 San Giovanni Rotondo Fg, Fg, Italy; [Serra, Nicola] Univ Federico II, Dept Publ Hlth, I-80131 Naples, Italy		Mangia, A (通讯作者)，Fdn IRCCS Casa Sollievo Sofferenza, Liver Unit, I-71013 San Giovanni Rotondo Fg, Fg, Italy.	g.cocomazzi@operapadrepio.it; v.piazzolla@operapadrepio.it; m.squillante@operapadrepio.it; s.antinucci@euroimmun.it; v.giambra@operapadrepio.it; f.giuliani@operapadrepio.it; a.maiorana@operapadrepio.it; nicola.serra5@gmail.com; a.mangia@tin.it	Mangia, A/AAL-5357-2020; Cocomazzi, Giovanna/AAC-4581-2022	Mangia, A/0000-0002-2600-3555; Cocomazzi, Giovanna/0000-0003-2831-934X; Serra, Nicola/0000-0001-8086-6362	Ministry of Health of ItalyMinistry of Health, Italy [COVID-2020-12371619]	This study was funded by Ministry of Health of Italy, "Bando Ricerca COVID-19"; project number: COVID-2020-12371619; project title: COVIDIAGNOSTIX-Health Technology Assessment in COVID serological diagnostics.	Abu Jabal K, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.6.2100096; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Balicer RD, 2021, SCIENCE, V372, P663, DOI 10.1126/science.abj3858; Bhatia Aruna, 2014, ScientificWorldJournal, V2014, P159150, DOI 10.1155/2014/159150; Cerullo M., 2021, MODERNA PLANS HAVE 3; Chow D., 2021, COVID 19 BOOSTER SHO; Cromer D, 2021, NAT REV IMMUNOL, V21, P395, DOI 10.1038/s41577-021-00550-x; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Ferrari D., QUANTITATIVE SEROLOG; Goel RR, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi6950; Hunziker P, 2021, MINIMIZING LOSS LIFE, DOI [10.2139/ssrn.3780070, DOI 10.2139/SSRN.3780070]; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Kristiansen PA, 2021, LANCET, V397, P1347, DOI 10.1016/S0140-6736(21)00527-4; Levi Riccardo, 2021, J Clin Invest, V131, DOI 10.1172/JCI149154; Moghadas SM, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001211; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Saadat S, 2021, JAMA-J AM MED ASSOC, V325, P1467, DOI 10.1001/jama.2021.3341; Siegrist CA, 2009, NAT REV IMMUNOL, V9, P185, DOI 10.1038/nri2508; Tehrani ZR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237828; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; Wiedermann U, 2016, HUM VACC IMMUNOTHER, V12, P239, DOI 10.1080/21645515.2015.1093263	25	4	4	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							913	10.3390/vaccines9080913			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH8EO	34452038	gold, Green Published			2022-04-29	WOS:000690157000001
J	Michiels, Y; Houhou-Fidouh, N; Collin, G; Berger, JM; Kohli, E				Michiels, Yves; Houhou-Fidouh, Nadhira; Collin, Gilles; Berger, Jerome; Kohli, Evelyne			Impact of Low-Dose Methotrexate-Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis	VACCINES			English	Article						SARS-CoV-2; mRNA1273 vaccine; antibody response; methotrexate; adalimumab		Patients with rheumatoid arthritis (RA) are treated with drugs that may impact their immune responses to SARS-CoV-2 vaccines. We describe here the anti-Spike (anti-S) IgG and neutralizing antibody responses induced by the mRNA-1273 SARS-CoV-2 vaccine in a 78-years-old patient with RA, who received a low-dose combination therapy of methotrexate and adalimumab, shortly before vaccine administration. Both near-normal and impaired immune responses to vaccines have been reported previously in patients treated with these drugs. Our case report shows that, even at low doses, combined methotrexate-adalimumab therapy can be associated with a weak immune response to the mRNA1273 vaccine in elderly patients.	[Michiels, Yves; Berger, Jerome] Univ Lausanne, Ctr Primary Care & Publ Hlth Unisante Lausanne 10, Community Pharm, CH-1015 Lausanne, Switzerland; [Michiels, Yves] Pharmacie Michiels, F-21600 Longvic, France; [Houhou-Fidouh, Nadhira; Collin, Gilles] Univ Paris Diderot, Hop Bichat, AP HP, Sorbonne Paris Cite,Lab Virol, F-75018 Paris, France; [Berger, Jerome] Univ Geneva, Sch Pharmaceut Sci, CH-1205 Geneva, Switzerland; [Berger, Jerome] Univ Lausanne, Inst Pharmaceut Sci Western Switzerland, CH-1015 Lausanne, Switzerland; [Kohli, Evelyne] Labellisee Ligue Natl Canc & Lab Excellence LipST, INSERM, UMR, Ub,AGROSUP 1231,Team 3 HSP Pathies, F-21000 Dijon, France; [Kohli, Evelyne] Univ Bourgogne, UFR Sci Sante, F-21000 Dijon, France; [Kohli, Evelyne] CHU, F-2100 Dijon, France		Michiels, Y (通讯作者)，Univ Lausanne, Ctr Primary Care & Publ Hlth Unisante Lausanne 10, Community Pharm, CH-1015 Lausanne, Switzerland.; Michiels, Y (通讯作者)，Pharmacie Michiels, F-21600 Longvic, France.	yves.michiels@unisante.ch; nadira.houhou@aphp.fr; gilles.collin@aphp.fr; jerome.berger@unisante.ch; evelyne.kohli@u-bourgogne.fr	Berger, Jérôme/L-1033-2019; evelyne, KOHLI/A-7612-2011	Berger, Jérôme/0000-0003-1177-5453; evelyne, KOHLI/0000-0002-9383-6573; Michiels, yves/0000-0001-6429-6363			Bonelli F, 2021, CLIN CHEM LAB MED, V59, P1463, DOI 10.1515/cclm-2021-0023; Cordtz R, 2021, RHEUMATOLOGY, V60, pSI59, DOI 10.1093/rheumatology/keaa897; Deepak Parakkal, 2021, medRxiv, DOI 10.1101/2021.04.05.21254656; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Favalli EG, 2021, ANN RHEUM DIS, V80, DOI 10.1136/annrheumdis-2020-217615; Favalli EG, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02395-6; Geisen UM, 2021, ANN RHEUM DIS, V80, P1306, DOI 10.1136/annrheumdis-2021-220272; Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI 10.1136/annrheumdis-2020-217871; Gresham LM, 2021, J AM ACAD DERMATOL, V84, P1652, DOI 10.1016/j.jaad.2021.01.047; Kennedy NA, 2021, GUT, V70, P865, DOI 10.1136/gutjnl-2021-324388; Liu L, 2022, IEEE T KNOWL DATA EN, V34, P2293, DOI [10.1101/2020.06.17.153486, 10.1109/TKDE.2020.3004939]; Mikuls TR, 2020, ARTHRITIS RHEUMATOL, V72, P1241, DOI 10.1002/art.41301; Park JK, 2018, ANN RHEUM DIS, V77, P898, DOI 10.1136/annrheumdis-2018-213222; Rondaan C, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-001035; Santos CS, 2021, RMD OPEN, V7, DOI 10.1136/rmdopen-2020-001439; Soy M, 2021, CLIN RHEUMATOL, V40, P3533, DOI 10.1007/s10067-021-05700-z; Wong SY, 2021, GASTROENTEROLOGY, V161, P715, DOI 10.1053/j.gastro.2021.04.025	17	1	1	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							883	10.3390/vaccines9080883			5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6WC	34452007	Green Published, gold			2022-04-29	WOS:000690067400001
J	Agostini, S; Mancuso, R; Costa, AS; Citterio, LA; Guerini, FR; Meloni, M; Navarro, J; Clerici, M				Agostini, Simone; Mancuso, Roberta; Costa, Andrea S.; Citterio, Lorenzo A.; Guerini, Franca R.; Meloni, Mario; Navarro, Jorge; Clerici, Mario			A Possible Role for HSV-1-Specific Humoral Response and PILRA rs1859788 Polymorphism in the Pathogenesis of Parkinson's Disease	VACCINES			English	Article						Parkinson's disease; HSV-1; paired immunoglobulin-like type 2 receptor alpha; antibody titers; rehabilitation	MILD COGNITIVE IMPAIRMENT; DUAL-HIT THEORY; HERPES-SIMPLEX; VIRUS-ANTIBODIES; ALPHA-SYNUCLEIN; VIRAL ANTIBODIES; SERUM; ACCUMULATION; ASSOCIATION; INFECTIONS	The etiology of Parkinson's disease (PD), a progressive nervous system disorder that affects movement, is still unknown; both genetic and environmental factor are believed to be involved in onset of the disease and its development. Herpes simplex virus type 1 (HSV-1), in particular, is suspected to have a role in PD. Paired Immunoglobulin-like type 2 receptor alpha (PILRA) is an inhibitory receptor that down-regulates inflammation and is expressed on innate immune cells. The PILRA rs1859788 polymorphism is protective against Alzheimer's disease, even in relation with HSV-1 antibody titers, but no data are available in PD. We analyzed HSV-1 antibody titers and PILRA rs1859788 in PD (n = 51) and age-and sex-matched healthy controls (HC; n = 73). Results showed that HSV-1, but not cytomegalovirus (CMV) or human herpes virus type 6 (HHV-6) antibody titers were significantly higher in PD compared to HC (p = 0.045). The rs1859788 polymorphism was not differentially distributed between PD and HC, but the minor allele A was more frequently carried by PD (68%) compared to HC (50%) (p = 0.06). Notably, the rs1859788 minor allele A was statically more frequent in male PD (65%) compared to male HC (37%) (p = 0.036). Finally, no relation was found between HSV-1 antibody titers and PILRA genotype. Results herein suggest an involvement of HSV-1 in PD and indicate a possible interaction between PILRA gene polymorphisms and this neuropathology.	[Agostini, Simone; Mancuso, Roberta; Costa, Andrea S.; Citterio, Lorenzo A.; Guerini, Franca R.; Meloni, Mario; Navarro, Jorge; Clerici, Mario] IRCCS Fdn Don Carlo Gnocchi ONLUS, I-20148 Milan, Italy; [Clerici, Mario] Univ Milan, Dept Pathophysiol & Transplantat, I-20122 Milan, Italy		Agostini, S (通讯作者)，IRCCS Fdn Don Carlo Gnocchi ONLUS, I-20148 Milan, Italy.	sagostini@dongnocchi.it; rmancuso@dongnocchi.it; acosta@dongnocchi.it; lcitterio@dongnocchi.it; fguerini@dongnocchi.it; mmeloni@dongnocchi.it; jnavarro@dongnocchi.it; mario.clerici@unimi.it	Citterio, Lorenzo Agostino/AAW-9967-2021; Agostini, Simone/L-7377-2015; Costa, Andrea Saul/Z-5611-2019; Mancuso, Roberta/H-8986-2012	Citterio, Lorenzo Agostino/0000-0002-5218-0475; Agostini, Simone/0000-0002-6214-0645; Costa, Andrea Saul/0000-0002-7353-157X; Mancuso, Roberta/0000-0002-4449-3623; Clerici, Mario/0000-0001-5920-6191	 [2019-2021]	This research was supported by 2019-2021 Ricerca Corrente (Italian Ministry of Health).	Agliardi C, 2021, NEUROBIOL DIS, V148, DOI 10.1016/j.nbd.2020.105185; Agostini S, 2019, CELL MOL NEUROBIOL, V39, P1217, DOI 10.1007/s10571-019-00712-5; Agostini S, 2016, BRAIN BEHAV IMMUN, V58, P254, DOI 10.1016/j.bbi.2016.07.153; Alvarez G, 2012, J NEUROSCI RES, V90, P1020, DOI 10.1002/jnr.23003; Bougea A, 2019, NEUROL SCI, V40, P929, DOI 10.1007/s10072-019-03738-1; Bu XL, 2015, EUR J NEUROL, V22, P1519, DOI 10.1111/ene.12477; Bu XL, 2015, PARKINSONISM RELAT D, V21, P877, DOI 10.1016/j.parkreldis.2015.05.015; Caggiu E, 2017, J NEUROIMMUNOL, V310, P26, DOI 10.1016/j.jneuroim.2017.06.004; Caggiu E, 2016, J NEUROIMMUNOL, V291, P110, DOI 10.1016/j.jneuroim.2016.01.007; Chang CW, 2020, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01388; Cury RG, 2015, J NEUROL SCI, V358, P538, DOI 10.1016/j.jns.2015.10.015; De Chiara G, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007617; De Virgilio A, 2016, AUTOIMMUN REV, V15, P1005, DOI 10.1016/j.autrev.2016.07.022; Du XY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228645; ELIZAN TS, 1979, ARCH NEUROL-CHICAGO, V36, P529, DOI 10.1001/archneur.1979.00500450023002; Emamzadeh FN, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00612; Fatahzadeh M, 2007, J AM ACAD DERMATOL, V57, P737, DOI 10.1016/j.jaad.2007.06.027; Garretti F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00303; Gelders G, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/4784268; Goetz CG, 2008, MOVEMENT DISORD, V23, P2129, DOI 10.1002/mds.22340; Harris MA, 2012, MOVEMENT DISORD, V27, P1111, DOI 10.1002/mds.25077; Hawkes CH, 2009, ANN NY ACAD SCI, V1170, P615, DOI 10.1111/j.1749-6632.2009.04365.x; Jang HM, 2009, P NATL ACAD SCI USA, V106, P14063, DOI 10.1073/pnas.0900096106; Kobayashi N, 2013, BIOCHEM BIOPH RES CO, V430, P907, DOI 10.1016/j.bbrc.2012.12.054; Kohyama M, 2016, EUR J IMMUNOL, V46, P1214, DOI 10.1002/eji.201545897; La Rosa F, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2034-9; Lambert JC, 2013, NAT GENET, V45, P1452, DOI 10.1038/ng.2802; Mahdavi T., 2014, SCI CLIN ASPECTS, P105; Mancuso R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020255; Mancuso R, 2014, J ALZHEIMERS DIS, V38, P741, DOI 10.3233/JAD-130977; MARTTILA RJ, 1982, J NEUROL SCI, V54, P227, DOI 10.1016/0022-510X(82)90184-8; MARTTILA RJ, 1978, J NEUROL SCI, V35, P375, DOI 10.1016/0022-510X(78)90017-5; MARTTILA RJ, 1981, ARCH NEUROL-CHICAGO, V38, P19, DOI 10.1001/archneur.1981.00510010045007; MARTTILA RJ, 1977, EUR NEUROL, V15, P25, DOI 10.1159/000114785; Mori I, 2017, MED HYPOTHESES, V101, P33, DOI 10.1016/j.mehy.2017.02.007; Mori I, 2010, J NEUROVIROL, V16, P203, DOI 10.3109/13550281003739040; Mousseau DD, 2000, J BIOL CHEM, V275, P4467, DOI 10.1074/jbc.275.6.4467; Nicoll MP, 2012, FEMS MICROBIOL REV, V36, P684, DOI 10.1111/j.1574-6976.2011.00320.x; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Olsen Laura K, 2018, Neuronal Signal, V2, pNS20170166, DOI 10.1042/NS20170166; Pfeiffer RF, 2016, PARKINSONISM RELAT D, V22, pS119, DOI 10.1016/j.parkreldis.2015.09.004; Piancone F, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.639646; Postuma RB, 2015, MOVEMENT DISORD, V30, P1591, DOI 10.1002/mds.26424; Rathore N, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007427; Sa ACC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45129-8; Santana S, 2012, J ALZHEIMERS DIS, V30, P815, DOI 10.3233/JAD-2012-112000; Satoh T, 2008, CELL, V132, P935, DOI 10.1016/j.cell.2008.01.043; Simon DK, 2020, CLIN GERIATR MED, V36, P1, DOI 10.1016/j.cger.2019.08.002; Sulzer D, 2017, NATURE, V546, P656, DOI 10.1038/nature22815; Tomlinson CL, 2010, MOVEMENT DISORD, V25, P2649, DOI 10.1002/mds.23429; Von Economo C., 1929, ENCEPHALITIS LETHARG, P394; Wang J., 2014, NAT IMMUNOL, V2, P860; WANG WZ, 1993, NEUROEPIDEMIOLOGY, V12, P209, DOI 10.1159/000110319; World Health Organizaton, 2020, HERPES SIMPLEX VIRUS; Wozniak MA, 2007, NEUROSCI LETT, V429, P95, DOI 10.1016/j.neulet.2007.09.077; Wu WYY, 2015, J VIRAL HEPATITIS, V22, P784, DOI 10.1111/jvh.12392; Yuan H, 2018, J VIROL, V92, DOI 10.1128/JVI.01161-18	57	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							686	10.3390/vaccines9070686			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7AE	34206597	Green Published			2022-04-29	WOS:000677058700001
J	Feher, C; Pastor-Ibanez, R; Leal, L; Plana, M; Arnedo, M; Van den Ham, HJ; Andeweg, AC; Gruters, RA; Diez-Fuertes, F; Alcami, J; Aloy, P; Garcia, F				Feher, Csaba; Pastor-Ibanez, Roque; Leal, Lorna; Plana, Montserrat; Arnedo, Mireia; Van den Ham, Henk-Jan; Andeweg, Arno C.; Gruters, Rob A.; Diez-Fuertes, Francisco; Alcami, Jose; Aloy, Patrick; Garcia, Felipe			Association of Transcriptomic Signatures of Inflammatory Response with Viral Control after Dendritic Cell-Based Therapeutic Vaccination in HIV-1 Infected Individuals	VACCINES			English	Article						dendritic cell-based therapeutic HIV-1 vaccine; differential gene expression; mRNA; miRNA; gene set enrichment analysis	SYSTEMS BIOLOGY; INFECTION; EXPRESSION; MICRORNAS	Systems vaccinology has seldomly been used in therapeutic HIV-1 vaccine research. Our aim was to identify early gene 'signatures' that predicted virus load control after analytical therapy interruption (ATI) in participants of a dendritic cell-based HIV-1 vaccine trial (DCV2). mRNA and miRNA were extracted from frozen post-vaccination PBMC samples; gene expression was determined by microarray method. In gene set enrichment analysis, responders showed an up-regulation of 14 gene sets (TNF-alpha/NFkB pathway, inflammatory response, the complement system, Il6 and Il2 JAK-STAT signaling, among others) and a down-regulation of 7 gene sets (such as E2F targets or interferon alpha response). The expression of genes regulated by three (miR-223-3p, miR-1183 and miR-8063) of the 9 differentially expressed miRNAs was significantly down-regulated in responders. The deregulation of certain gene sets related to inflammatory processes seems fundamental for viral control, and certain miRNAs may be important in fine-tuning these processes.	[Feher, Csaba; Aloy, Patrick] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona 08028, Spain; [Feher, Csaba; Leal, Lorna; Diez-Fuertes, Francisco; Alcami, Jose; Garcia, Felipe] Univ Barcelona, Hosp Clin, Infect Dis Dept, IDIBAPS, Barcelona 08036, Spain; [Pastor-Ibanez, Roque; Leal, Lorna; Plana, Montserrat; Arnedo, Mireia; Garcia, Felipe] Univ Barcelona, Hosp Clin, Retrovirol & Viral Immunopathol Lab, AIDS Res Grp,IDIBAPS, Barcelona 08036, Spain; [Van den Ham, Henk-Jan; Andeweg, Arno C.; Gruters, Rob A.] Erasmus MC, Dept Virosci, NL-3000 CA Rotterdam, Netherlands; [Diez-Fuertes, Francisco; Alcami, Jose] Inst Salud Carlos III, Natl Ctr Microbiol, Majadahonda 28222, Spain; [Aloy, Patrick] Inst Catalana Recerca & Estudis Avancats, Barcelona 08010, Spain		Feher, C (通讯作者)，Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona 08028, Spain.; Feher, C (通讯作者)，Univ Barcelona, Hosp Clin, Infect Dis Dept, IDIBAPS, Barcelona 08036, Spain.	cfeher@clinic.cat; rpastor@dinic.cat; laleal@dinic.cat; mplana@clinic.cat; marnedo@vhebron.net; h.vandenham@enpicom.com; a.andeweg@erasmusmc.nl; r.gruters@erasmusmc.nl; frandifu@icloud.com; ppalcami@isciii.es; paloy@irbbarcelona.org; fgarcia@clinic.cat	, Felipe/F-4242-2014; van den Ham, HJ/ABF-1071-2021; Alcami, Pepe/T-2242-2018; Díez-Fuertes, Francisco/AAA-9427-2019; Leal, Lorna/L-2773-2015	, Felipe/0000-0001-7658-5832; Alcami, Pepe/0000-0003-0023-7377; Arnedo Valero, Mireia/0000-0001-6248-7780; Gruters, Rob/0000-0002-8486-5903; Diez-Fuertes, Francisco/0000-0003-2413-9229; van den Ham, Henk-Jan/0000-0001-8582-5404; Pastor-Ibanez, Roque/0000-0002-0787-4638	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [H2020-SC1-2016-RTD Proposal: 731626]; Spanish Ministry of Economy (MINECO) [SAF2015-66193-R, RTI2018096309-B-I00]; Fondo de Investigacion Sanitaria (FIS)Instituto de Salud Carlos III [PI15/00480, AC16/00051, PI18/00699]; Fondo Europeo para el Desarrollo Regional (FEDER)European Commission; SPANISH AIDS Research Network [RD16/0025/0002-ISCIII-FEDER]; CERCA Program/Generalitat de Catalunya [SGR 615]; amfAR Grant [108821-55-RGRL]; Jose Maria Segovia de Arana contracts; "PhD4MD," a Collaborative Research Training Programme for Medical Doctors - IRB Barcelona (Institute for Research in Biomedicine); IDIBAPS (August Pi i Sunyer Biomedical Research Institute)	This study was supported by the European Commission (grants: H2020-SC1-2016-RTD Proposal: 731626), the Spanish Ministry of Economy (MINECO) (grants: SAF2015-66193-R, RTI2018096309-B-I00), the Fondo de Investigacion Sanitaria (FIS) PI15/00480, AC16/00051, and PI18/00699, amfAR Grant #108821-55-RGRL, the Fondo Europeo para el Desarrollo Regional (FEDER), the SPANISH AIDS Research Network RD16/0025/0002-ISCIII-FEDER (RIS), and the CERCA Program/Generalitat de Catalunya SGR 615. F.G. has received the support of Jose Maria Segovia de Arana contracts. C.F. held a fellowship from "PhD4MD," a Collaborative Research Training Programme for Medical Doctors financed by IRB Barcelona (Institute for Research in Biomedicine) and IDIBAPS (August Pi i Sunyer Biomedical Research Institute) during the study.	Aziz F, 2016, CELL IMMUNOL, V303, P1, DOI 10.1016/j.cellimm.2016.04.003; Biswas S, 2019, EBIOMEDICINE, V43, P307, DOI 10.1016/j.ebiom.2019.04.023; Costanzo MC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03618-w; da Conceicao Viviane N, 2014, Mol Cell Ther, V2, P11, DOI 10.1186/2052-8426-2-11; de Goede AL, 2015, VACCINE, V33, P2922, DOI 10.1016/j.vaccine.2015.04.047; Dey R, 2016, SCI REP-UK, V6, DOI 10.1038/srep28279; Egana-Gorrono L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155245; Egana-Gorrono L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106360; Eklund AC, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-2-r26; Fourati S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10369; Garcia F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004682; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Haneklaus M, 2013, J INTERN MED, V274, P215, DOI 10.1111/joim.12099; Huang JL, 2007, NAT MED, V13, P1241, DOI 10.1038/nm1639; Huttner A, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaj1701; Leal L, 2017, EXPERT REV VACCINES, V16, P587, DOI 10.1080/14760584.2017.1322513; Massanella M, 2013, ANTIVIR RES, V100, P420, DOI 10.1016/j.antiviral.2013.07.017; Munshi SU, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095920; Nakaya HI, 2011, NAT IMMUNOL, V12, P786, DOI 10.1038/ni.2067; Poland GA, 2018, VACCINE, V36, P5350, DOI 10.1016/j.vaccine.2017.07.062; Qi Y., 2017, J PUBLIC HLTH EMERG, V1, P65, DOI DOI 10.21037/JPHE.2017.05.11; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Raeven RHM, 2019, IMMUNOLOGY, V156, P33, DOI 10.1111/imm.13012; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Ru YB, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku631; Thiebaut R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00874; Vahey MT, 2008, AIDS RES HUM RETROV, V24, P1047, DOI 10.1089/aid.2008.0059; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Yahyaei S, 2016, JAIDS-J ACQ IMM DEF, V73, P11, DOI 10.1097/QAI.0000000000001070; Zhang ZN, 2013, CLIN CHEM, V59, P1175, DOI 10.1373/clinchem.2012.197335	30	0	0	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							799	10.3390/vaccines9070799			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6GL	34358215	gold, Green Published			2022-04-29	WOS:000677007400001
J	Gobert, C; Semaille, P; Van der Schueren, T; Verger, P; Dauby, N				Gobert, Cathy; Semaille, Pascal; Van der Schueren, Thierry; Verger, Pierre; Dauby, Nicolas			Prevalence and Determinants of Vaccine Hesitancy and Vaccines Recommendation Discrepancies among General Practitioners in French-Speaking Parts of Belgium	VACCINES			English	Article						vaccine hesitancy; general practice; health-care workers; vaccination	INFLUENZA; SAFETY	General practitioners (GPs) play a critical role in patient acceptance of vaccination. Vaccine hesitancy (VH) is a growing phenomenon in the general population but also affects GPs. Few data exist on VH among GPs. The objectives of this analysis of a population of GPs in the Belgian Wallonia-Brussels Federation (WBF) were to: (1) determine the prevalence and the features of VH, (2) identify the correlates, and (3) estimate the discrepancy in vaccination's behaviors between the GPs' children and the recommendations made to their patients. An online survey was carried out among the population of general practitioners practicing in the WBF between 7 January and 18 March 2020. A hierarchical cluster analysis was carried out based on various dimensions of vaccine hesitancy: perception of the risks and the usefulness of vaccines as well as vaccine recommendations for their patients. A total of 251 GPs answered the survey. The average percentage of moderate to high vaccine hesitancy was 50.6%. Three factors were independently associated with increased risk of vaccine hesitancy: an age <50 years old, having no children, and having no contact with selected vaccine-preventable disease (measles, complicated influenza, chronic hepatitis B (HBV), bacterial meningitis, or cervical cancer) in the past 5 years. VH was associated with controversies on vaccines' safety. GPs who had vaccinated their children against six diseases (MMR, meningococcus C (MenC), HBV, and HPV) tended not to recommend the same vaccines to their patients. Among GPs with all children vaccinated against HBV, only 37.5% recommended catch-up HBV immunization to their patients. In this small cohort of GP, moderate to high VH was associated with controversies on vaccines' safety and with specific personal characteristics (age <50, no children, and no recent experience with a serious VPD). As previously reported, GPs have different vaccine prescription attitude toward their patients and children. These findings should be confirmed in larger cohorts.	[Gobert, Cathy; Dauby, Nicolas] Univ Libre Bruxelles ULB, CHU St Pierre, Dept Infect Dis, B-1000 Brussels, Belgium; [Semaille, Pascal] Univ Libre Bruxelles ULB, Dept Gen Med, B-1070 Brussels, Belgium; [Van der Schueren, Thierry] Sci Soc Gen Practice, B-1060 Brussels, Belgium; [Verger, Pierre] Southeastern Hlth Reg Observ ORS PACA, F-13005 Marseille, France; [Dauby, Nicolas] Univ Libre Bruxelles ULB, Sch Publ Hlth, B-1070 Brussels, Belgium; [Dauby, Nicolas] Univ Libre Bruxelles ULB, Inst Med Immunol, B-1070 Brussels, Belgium		Dauby, N (通讯作者)，Univ Libre Bruxelles ULB, CHU St Pierre, Dept Infect Dis, B-1000 Brussels, Belgium.; Dauby, N (通讯作者)，Univ Libre Bruxelles ULB, Sch Publ Hlth, B-1070 Brussels, Belgium.; Dauby, N (通讯作者)，Univ Libre Bruxelles ULB, Inst Med Immunol, B-1070 Brussels, Belgium.	catgob93@gmail.com; pascal.semaille@stpierre-bru.be; thierry.vanderschueren@ssmg.be; pierre.verger@inserm.fr; nicolas_dauby@stpierre-bru.be	Dauby, Nicolas/F-1235-2011	Dauby, Nicolas/0000-0002-7697-6849			Agrinier N, 2017, CLIN MICROBIOL INFEC, V23, P311, DOI 10.1016/j.cmi.2016.08.019; Bloom DE, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaj2345; Conseil Superieur de la Sante (CSS), 2019, 9141 CSS 9141 CSS; Conseil Superieur de la Sante (CSS), 2019, 9485 CSS 9485 CSS; Cornelissen L, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000278; Gostin LO, 2020, LANCET INFECT DIS, V20, pE11, DOI 10.1016/S1473-3099(19)30558-4; Grammens T, 2017, EUROSURVEILLANCE, V22, P5, DOI 10.2807/1560-7917.ES.2017.22.17.30524; Harrison N, 2018, VACCINE, V36, P4875, DOI 10.1016/j.vaccine.2018.06.065; Karafillakis E, 2018, CLIN MICROBIOL INFEC, V24, P799, DOI 10.1016/j.cmi.2018.04.001; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Karlsson LC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224330; Kerneis S, 2017, AM J PREV MED, V53, pE97, DOI 10.1016/j.amepre.2017.01.014; Killian M, 2016, EUR J CLIN MICROBIOL, V35, P1837, DOI 10.1007/s10096-016-2735-4; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Le Marechal M, 2018, CLIN MICROBIOL INFEC, V24, P858, DOI 10.1016/j.cmi.2017.10.021; Likert R., 1932, ARCH PSYCHOL, V22, P55; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Arias LHM, 2015, VACCINE, V33, P3773, DOI 10.1016/j.vaccine.2015.05.013; McRee AL, 2014, J PEDIATR HEALTH CAR, V28, P541, DOI 10.1016/j.pedhc.2014.05.003; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Plotkin SA, 2020, VACCINE, V38, P1869, DOI 10.1016/j.vaccine.2020.01.024; Ramiere C, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.07.014; Salmon DA, 2015, AM J PREV MED, V49, pS391, DOI 10.1016/j.amepre.2015.06.009; Sarkanen TO, 2018, SLEEP MED REV, V38, P177, DOI 10.1016/j.smrv.2017.06.006; Smith PJ, 2006, PEDIATRICS, V118, pE1287, DOI 10.1542/peds.2006-0923; Verger P, 2016, EUROSURVEILLANCE, V21, P14, DOI 10.2807/1560-7917.ES.2016.21.47.30406; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Wyndham-Thomas C., 2019, D20191444022 D20191444022	30	1	1	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							771	10.3390/vaccines9070771			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5OW	34358187	Green Published, gold			2022-04-29	WOS:000676961700001
J	Gushchin, VA; Dolzhikova, IV; Shchetinin, AM; Odintsova, AS; Siniavin, AE; Nikiforova, MA; Pochtovyi, AA; Shidlovskaya, EV; Kuznetsova, NA; Burgasova, OA; Kolobukhina, LV; Iliukhina, AA; Kovyrshina, AV; Botikov, AG; Kuzina, AV; Grousova, DM; Tukhvatulin, AI; Shcheblyakov, DV; Zubkova, OV; Karpova, OV; Voronina, OL; Ryzhova, NN; Aksenova, EI; Kunda, MS; Lioznov, DA; Danilenko, DM; Komissarov, AB; Tkachuck, AP; Logunov, DY; Gintsburg, AL				Gushchin, Vladimir A.; Dolzhikova, Inna, V; Shchetinin, Alexey M.; Odintsova, Alina S.; Siniavin, Andrei E.; Nikiforova, Maria A.; Pochtovyi, Andrei A.; Shidlovskaya, Elena, V; Kuznetsova, Nadezhda A.; Burgasova, Olga A.; Kolobukhina, Liudmila, V; Iliukhina, Anna A.; Kovyrshina, Anna, V; Botikov, Andrey G.; Kuzina, Aleksandra, V; Grousova, Daria M.; Tukhvatulin, Amir, I; Shcheblyakov, Dmitry, V; Zubkova, Olga, V; Karpova, Oksana, V; Voronina, Olga L.; Ryzhova, Natalia N.; Aksenova, Ekaterina, I; Kunda, Marina S.; Lioznov, Dmitry A.; Danilenko, Daria M.; Komissarov, Andrey B.; Tkachuck, Artem P.; Logunov, Denis Y.; Gintsburg, Alexander L.			Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccine; Sputnik V; VOC; virus neutralizing activity	EFFICACY	Since the beginning of the 2021 year, all the main six vaccines against COVID-19 have been used in mass vaccination companies around the world. Virus neutralization and epidemiological efficacy drop obtained for several vaccines against the B.1.1.7, B.1.351 P.1, and B.1.617 genotypes are of concern. There is a growing number of reports on mutations in receptor-binding domain (RBD) increasing the transmissibility of the virus and escaping the neutralizing effect of antibodies. The Sputnik V vaccine is currently approved for use in more than 66 countries but its activity against variants of concern (VOC) is not extensively studied yet. Virus-neutralizing activity (VNA) of sera obtained from people vaccinated with Sputnik V in relation to internationally relevant genetic lineages B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3 and Moscow endemic variants B.1.1.141 (T385I) and B.1.1.317 (S477N, A522S) with mutations in the RBD domain has been assessed. The data obtained indicate no significant differences in VNA against B.1.1.7, B.1.617.3 and local genetic lineages B.1.1.141 (T385I), B.1.1.317 (S477N, A522S) with RBD mutations. For the B.1.351, P.1, and B.1.617.2 statistically significant 3.1-, 2.8-, and 2.5-fold, respectively, VNA reduction was observed. Notably, this decrease is lower than that reported in publications for other vaccines. However, a direct comparative study is necessary for a conclusion. Thus, sera from "Sputnik V"-vaccinated retain neutralizing activity against VOC B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3 as well as local genetic lineages B.1.1.141 and B.1.1.317 circulating in Moscow.	[Gushchin, Vladimir A.; Dolzhikova, Inna, V; Shchetinin, Alexey M.; Odintsova, Alina S.; Siniavin, Andrei E.; Nikiforova, Maria A.; Pochtovyi, Andrei A.; Shidlovskaya, Elena, V; Kuznetsova, Nadezhda A.; Burgasova, Olga A.; Kolobukhina, Liudmila, V; Iliukhina, Anna A.; Kovyrshina, Anna, V; Botikov, Andrey G.; Kuzina, Aleksandra, V; Grousova, Daria M.; Tukhvatulin, Amir, I; Shcheblyakov, Dmitry, V; Zubkova, Olga, V; Voronina, Olga L.; Ryzhova, Natalia N.; Aksenova, Ekaterina, I; Kunda, Marina S.; Tkachuck, Artem P.; Logunov, Denis Y.; Gintsburg, Alexander L.] Minist Hlth Russian Federat, Fed State Budget Inst, Natl Res Ctr Epidemiol & Microbiol, Moscow 123098, Russia; [Gushchin, Vladimir A.; Pochtovyi, Andrei A.] Lomonosov Moscow State Univ, Biol Fac, Dept Virol, Moscow 119991, Russia; [Siniavin, Andrei E.] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Dept Mol Neuroimmune Signalling, Moscow 117997, Russia; [Burgasova, Olga A.; Kolobukhina, Liudmila, V; Karpova, Oksana, V] Moscow Healthcare Dept, Moscow 127006, Russia; [Burgasova, Olga A.] Peoples Friendship Univ Russia, Dept Infect Dis, RUDN Univ, Moscow 117198, Russia; [Lioznov, Dmitry A.; Danilenko, Daria M.; Komissarov, Andrey B.] Smorodintsev Res Inst Influenza, St Petersburg 197022, Russia; [Lioznov, Dmitry A.] First Pavlov State Med Univ, Dept Infect Dis & Epidemiol, St Petersburg 197022, Russia; [Gintsburg, Alexander L.] IM Sechenov First Moscow State Med Univ, Dept Infectiol & Virol, Fed State Autonomous Educ Inst Higher Educ, Minist Hlth Russian Federat,Sechenov Univ, Moscow 119435, Russia		Gushchin, VA; Dolzhikova, IV (通讯作者)，Minist Hlth Russian Federat, Fed State Budget Inst, Natl Res Ctr Epidemiol & Microbiol, Moscow 123098, Russia.; Gushchin, VA (通讯作者)，Lomonosov Moscow State Univ, Biol Fac, Dept Virol, Moscow 119991, Russia.	wowaniada@gmail.com; i.dolzhikova@gmail.com; shchetinin.alexey@yandex.ru; avocnido.anila@gmail.com; andreysi93@ya.ru; marianikiforova@inbox.ru; a.pochtovyy@gmail.com; lenitsa@gmail.com; nadyakuznetsova0@gmail.com; olgaburgasova@mail.ru; lkolobuchina@yandex.ru; sovanya97@yandex.ru; annkovyrshina@gmail.com; tessey@mail.ru; a.kuzina.v@gmail.com; dgrousova@gmail.com; amir_tuhvatulin@yahoo.com; sdmitryv@yahoo.com; olga-zubkova@yandex.ru; ovk_67@mail.ru; olv550@gmail.com; rynatalia@yandex.ru; aksenoval6@gmail.com; markunda99@gmail.com; dlioznov@yandex.ru; daria.danilenko@influenza.spb.ru; a.b.komissarov@gmail.com; artem.p.tkachuk@gmail.com; ldenisy@gmail.com; gintsburg@gamaleya.org	Tukhvatulin, Amir/E-8183-2014; Gushchin, Vladimir/AAW-8501-2021; Gushchin, Vladimir A/F-7207-2017; Кузина, Александра/ABH-2980-2021; Shchetinin, Alexey/T-3860-2017; Dolzhikova, Inna/E-8295-2014; Voronina, Olga/F-4959-2018	Tukhvatulin, Amir/0000-0001-8506-2339; Gushchin, Vladimir/0000-0002-9397-3762; Gushchin, Vladimir A/0000-0002-9397-3762; Nikiforova, Maria/0000-0001-5823-6508; Kolobukhina, Liudmila/0000-0001-5775-3343; Aksenova, Ekaterina/0000-0003-2704-6730; Shchetinin, Alexey/0000-0003-1842-3899; Shcheblyakov, Dmitry/0000-0002-1289-3411; Siniavin, Andrei/0000-0001-7576-2059; Kuznetsova, Nadezhda/0000-0002-7399-7628; Dolzhikova, Inna/0000-0003-2548-6142; Danilenko, Daria/0000-0001-6174-0836; Voronina, Olga/0000-0001-7206-3594	Ministry of Health of Russia and Russian Direct Investment Fund	Ministry of Health of Russia and Russian Direct Investment Fund.	Alm E, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.32.2001410; Alpert Tara, 2021, medRxiv, DOI 10.1101/2021.02.10.21251540; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bazykin, SPREAD ENDEMIC SARS; Buenestado-Serrano Sergio, 2021, Enferm Infecc Microbiol Clin (Engl Ed), DOI 10.1016/j.eimc.2021.02.006; Byazrova M, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1245; Davies NG, 2021, NATURE, V593, P270, DOI [10.1038/s41586-021-03426-1, 10.1101/2021.02.01.21250959]; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Electronic Source, PREL GEN CHAR EM SAR; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Fratev, 2020, N501Y K417N MUTATION, DOI [10.1101/2020.12.23.424283, DOI 10.1101/2020.12.23.424283]; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006]; GISAID, INITIATIVE; Hoffmann M, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109415; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Komissarov AB, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20880-z; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Leung K, 2021, EUROSURVEILLANCE, V26, P15, DOI 10.2807/1560-7917.ES.2020.26.1.2002106; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Muik A, 2021, SCIENCE, V371, P1152, DOI 10.1126/science.abg6105; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Shen Xiaoying, 2021, Cell Host Microbe, V29, P529, DOI [10.1101/2021.01.27.428516, 10.1016/j.chom.2021.03.002]; Supasa P, 2021, CELL, V184, P2201, DOI 10.1016/j.cell.2021.02.033; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Thomson EC, 2021, CELL, V184, P1171, DOI 10.1016/j.cell.2021.01.037; Utkin Y.N., 2021, SNAKE VENOM PHOSPHOL, DOI [10.1101/2021.01.12.426042, DOI 10.1101/2021.01.12.426042]; Volz E., 2021, TRANSMISSION SARS CO, DOI [10.1101/2020.12.30.20249034, DOI 10.1101/2020.12.30.20249034]; Volz E, 2021, CELL, V184, P64, DOI 10.1016/j.cell.2020.11.020; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Wang R, 2021, GENOMICS, V113, P2158, DOI 10.1016/j.ygeno.2021.05.006; Wang R, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01754-6; Weisblum Yiska, 2020, bioRxiv, DOI 10.1101/2020.07.21.214759; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Xie XP, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01270-4, 10.1101/2021.01.27.427998]; Yadav PD, 2021, TRAVEL MED INFECT DI, V41, DOI 10.1016/j.tmaid.2021.102023; Zakamornaya I.M, 2021, GENOMIC EPIDEMIOLOGY, DOI [10.1101/2021.03.31.21254115v1, DOI 10.1101/2021.03.31.21254115V1]; Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037	41	24	29	3	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							779	10.3390/vaccines9070779			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5CK	34358195	gold, Green Published			2022-04-29	WOS:000676929300001
J	Haese, EC; Thai, VC; Kahler, CM				Haese, Ethan C.; Thai, Van C.; Kahler, Charlene M.			Vaccine Candidates for the Control and Prevention of the Sexually Transmitted Disease Gonorrhea	VACCINES			English	Review						Neisseria gonorrhoeae; gonorrhea; vaccine development; antimicrobial resistance; multi-drug resistance; sexually transmitted infections	RESISTANT NEISSERIA-GONORRHOEAE; PELVIC-INFLAMMATORY-DISEASE; MENINGOCOCCAL B VACCINE; OUTER-MEMBRANE VESICLES; FEMALE SEX WORKERS; SEROGROUP-B; PHARYNGEAL GONORRHEA; ANTIBODY-RESPONSES; UNITED-STATES; MACROPHAGE PLASTICITY	The World Health Organization (WHO) has placed N. gonorrhoeae on the global priority list of antimicrobial resistant pathogens and is urgently seeking the development of new intervention strategies. N. gonorrhoeae causes 86.9 million cases globally per annum. The effects of gonococcal disease are seen predominantly in women and children and especially in the Australian Indigenous community. While economic modelling suggests that this infection alone may directly cost the USA health care system USD 11.0-20.6 billion, indirect costs associated with adverse disease and pregnancy outcomes, disease prevention, and productivity loss, mean that the overall effect of the disease is far greater still. In this review, we summate the current progress towards the development of a gonorrhea vaccine and describe the clinical trials being undertaken in Australia to assess the efficacy of the current formulation of Bexsero (R) in controlling disease.	[Haese, Ethan C.; Thai, Van C.; Kahler, Charlene M.] Univ Western Australia, Marshall Ctr Infect Dis Res & Training, Crawley, WA 6009, Australia		Kahler, CM (通讯作者)，Univ Western Australia, Marshall Ctr Infect Dis Res & Training, Crawley, WA 6009, Australia.	ethan.haese@research.uwa.edu.au; vanchi.thai@research.uwa.edu.au; charlene.kahler@uwa.edu.au		Thai, Van Chi/0000-0003-3801-6166	University of Western Australia; University International Fee Scholarship (UIFS); University Postgraduate Award (International Students) (UPAIS) from the University of Western Australia	E.C.H. is supported by the Research Training Program (RTP) PhD scholarship from the University of Western Australia and V.C.T. is supported by the University International Fee Scholarship (UIFS) and University Postgraduate Award (International Students) (UPAIS) from the University of Western Australia.	Abara WE, 2021, SEX TRANSM DIS, V48, P453, DOI 10.1097/OLQ.0000000000001332; Acevedo R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00121; [Anonymous], 2020, ID NCT04415424 EFF S ID NCT04415424 EFF S; ARKO RJ, 1976, J INFECT DIS, V133, P441, DOI 10.1093/infdis/133.4.441; Arnold R, 2011, VACCINE, V29, P7100, DOI 10.1016/j.vaccine.2011.06.120; Australian New Zealand Clinical Trials Registry, 2019, ID ACTRN126190014781 ID ACTRN126190014781; BARLOW D, 1978, LANCET, V1, P761; Basta NE, 2016, NEW ENGL J MED, V375, P220, DOI 10.1056/NEJMoa1514866; Bellhouse C, 2018, SEX TRANSM INFECT, V94, P212, DOI 10.1136/sextrans-2016-052710; Binker MG, 2007, CELL MICROBIOL, V9, P2153, DOI 10.1111/j.1462-5822.2007.00946.x; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; BOSLEGO JW, 1991, VACCINE, V9, P154, DOI 10.1016/0264-410X(91)90147-X; Boulton IC, 2002, NAT IMMUNOL, V3, P229, DOI 10.1038/ni769; Broutet N, 2014, VACCINE, V32, P1630, DOI 10.1016/j.vaccine.2014.01.053; Brunham RC, 2015, NEW ENGL J MED, V372, P2039, DOI 10.1056/NEJMra1411426; Cabrera O., 2009, VACCIMONITOR, V18, P53; Cahoon LA, 2011, MOL MICROBIOL, V81, P1136, DOI 10.1111/j.1365-2958.2011.07773.x; Callander D., 2019, 2018 AUSTR TRANS GEN 2018 AUSTR TRANS GEN; Callander D, 2019, MED J AUSTRALIA, V211, P406, DOI 10.5694/mja2.50322; Callander D, 2019, SEX HEALTH, V16, P457, DOI 10.1071/SH18097; Callander D, 2018, SEX TRANSM DIS, V45, P199, DOI [10.1097/OLQ.0000000000000714, 10.1097/olq.0000000000000714]; Callander D, 2017, SEX TRANSM INFECT, V93, P299, DOI 10.1136/sextrans-2016-052578; CANNON JG, 1983, INFECT IMMUN, V40, P816, DOI 10.1128/IAI.40.2.816-819.1983; Ortiz MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130713; Chan Philip A, 2016, Infect Dis Obstet Gynecol, V2016, P5758387, DOI 10.1155/2016/5758387; Chateau A, 2016, CELL MICROBIOL, V18, P546, DOI 10.1111/cmi.12529; Chen T, 1997, J EXP MED, V185, P1557, DOI 10.1084/jem.185.9.1557; Chesson HW, 2021, SEX TRANSM DIS, V48, P215, DOI 10.1097/OLQ.0000000000001380; Chesson HW, 2018, SEX TRANSM DIS, V45, P250, DOI 10.1097/OLQ.0000000000000725; Chow EPF, 2019, SEX TRANSM INFECT, V95, P398, DOI 10.1136/sextrans-2018-053957; Cohen MS, 1998, LANCET, V351, P5, DOI 10.1016/S0140-6736(98)90002-2; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; Constable C, 2020, VACCINE, V38, P954, DOI 10.1016/j.vaccine.2019.11.073; Criss AK, 2012, NAT REV MICROBIOL, V10, P178, DOI 10.1038/nrmicro2713; Cuello Maribel, 2009, Vaccimonitor, V18, P78; Edwards JL, 2016, CRIT REV MICROBIOL, V42, P928, DOI 10.3109/1040841X.2015.1105782; Edwards JL, 2004, CLIN MICROBIOL REV, V17, P965, DOI 10.1128/CMR.17.4.965-981.2004; Escobar A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03044; Escobar A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/127017; Eyre DW, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.10.1900147; Eyre DW, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.27.1800323; Feinen B, 2010, MUCOSAL IMMUNOL, V3, P312, DOI 10.1038/mi.2009.139; Ochoa-Azze RF, 2018, HUM VACC IMMUNOTHER, V14, P1064, DOI 10.1080/21645515.2018.1438028; Fifer H, 2016, NEW ENGL J MED, V374, P2504, DOI 10.1056/NEJMc1512757; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Fung M, 2007, SEX TRANSM INFECT, V83, DOI 10.1136/sti.2006.024059; Gala RP, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030060; Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794; Golparian D, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.30.20862; Golparian D, 2018, EUROSURVEILLANCE, V23, P6, DOI 10.2807/1560-7917.ES.2018.23.47.1800617; Gottlieb SL, 2020, VACCINE, V38, P4362, DOI 10.1016/j.vaccine.2020.02.073; Gottlieb SL, 2019, SEX HEALTH, V16, P426, DOI 10.1071/SH19060; Gottlieb SL, 2016, VACCINE, V34, P2939, DOI 10.1016/j.vaccine.2016.03.111; Graham S, 2012, MED J AUSTRALIA, V197, P642, DOI 10.5694/mja12.10163; Gray-Swain MR, 2006, CURR OPIN OBSTET GYN, V18, P503, DOI 10.1097/01.gco.0000242952.87125.69; GREENBERG L, 1971, B WORLD HEALTH ORGAN, V45, P531; GREENBERG L, 1974, CAN J PUBLIC HEALTH, V65, P29; GREENBERG L, 1975, J REPROD MED, V14, P34; Gulati S, 1996, J INFECT DIS, V174, P1223, DOI 10.1093/infdis/174.6.1223; Gulati S, 2019, MBIO, V10, DOI 10.1128/mBio.02552-19; Gulati S, 2015, J INFECT DIS, V212, P311, DOI 10.1093/infdis/jiv024; Gulati S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003559; Sierra-Gonzalez VG, 2019, MEDICC REV, V21, P19, DOI 10.37757/MR2019.V21.N4.4; Harrison OB, 2013, EMERG INFECT DIS, V19, P566, DOI 10.3201/eid1904.111799; Harvey HA, 2001, J AUTOIMMUN, V16, P257, DOI 10.1006/jaut.2000.0477; Hedges SR, 1999, INFECT IMMUN, V67, P3937, DOI 10.1128/IAI.67.8.3937-3946.1999; Hedges SR, 1998, J INFECT DIS, V178, P742, DOI 10.1086/515372; Hobbs MM, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00123; Holst J, 2013, HUM VACC IMMUNOTHER, V9, P1241, DOI 10.4161/hv.24129; Hui B, 2015, SEX TRANSM INFECT, V91, P365, DOI 10.1136/sextrans-2014-051760; Huynh KK, 2007, EMBO J, V26, P313, DOI 10.1038/sj.emboj.7601511; Inhorn MC, 2015, HUM REPROD UPDATE, V21, P411, DOI 10.1093/humupd/dmv016; Jefferson A, 2021, MEDICINES, V8, P11, DOI [10.3390/medicines8020011, DOI 10.3390/MEDICINES8020011]; Jennison AV, 2019, EUROSURVEILLANCE, V24, P15, DOI 10.2807/1560-7917.ES.2019.24.8.1900118; Jerse AE, 2014, VACCINE, V32, P1579, DOI 10.1016/j.vaccine.2013.08.067; Jerse AE, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00107; JOINER KA, 1985, J CLIN INVEST, V76, P1765, DOI 10.1172/JCI112167; Kahler CM, 2018, FUTURE MICROBIOL, V13, P499, DOI 10.2217/fmb-2017-0258; Kirby Institute, 2020, NAT UPD HIV VIR HEP; Kirby Institute, 2018, HIV VIR HEP SEX TRAN; Kirby Institute, 2018, BLOODB VIR SEX TRANS; Kirkcaldy RD, 2019, SEX HEALTH, V16, P401, DOI 10.1071/SH19061; Klyz A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202437; Korenromp EL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170773; Lahra MM, 2020, COMMUN DIS INTELL, V44, DOI 10.33321/cdi.2020.44.58; Lahra MM, 2018, EMERG INFECT DIS, V24, P735, DOI 10.3201/eid2404.171873; Leduc I, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008602; Lefebvre B, 2018, EMERG INFECT DIS, V24, P381, DOI 10.3201/eid2402.171756; Lim KYL, 2021, ANTIBIOTICS-BASEL, V10, DOI 10.3390/antibiotics10020103; Liu Y, 2017, MUCOSAL IMMUNOL, V10, P1594, DOI 10.1038/mi.2017.11; Liu Y, 2012, MUCOSAL IMMUNOL, V5, P320, DOI 10.1038/mi.2012.12; Liu YR, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00421-17; Liu YR, 2013, J INFECT DIS, V208, P1821, DOI 10.1093/infdis/jit354; Longtin J., 2017, OPEN FORUM INFECT S1, V4, pS734, DOI [10.1093/ofid/ofx180.002, DOI 10.1093/OFID/OFX180.002]; Lovett A, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03187; Lujan E, 2017, CLIN INFECT DIS, V65, P1112, DOI 10.1093/cid/cix519; Malott RJ, 2013, P NATL ACAD SCI USA, V110, P10234, DOI 10.1073/pnas.1303738110; Martin-Sanchez M, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-037608; Martin-Sanchez M, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05197-y; Mathew Reshmi, 2021, J Investig Med High Impact Case Rep, V9, p23247096211012194, DOI 10.1177/23247096211012194; Metzger DW, 2010, CYTOKINE, V52, P102, DOI 10.1016/j.cyto.2010.06.011; Metzger DW, 2009, EXPERT REV VACCINES, V8, P515, DOI [10.1586/erv.09.13, 10.1586/ERV.09.13]; Nakayama S, 2016, ANTIMICROB AGENTS CH, V60, P4339, DOI 10.1128/AAC.00504-16; Neto A, 2021, SEX TRANSM DIS, V48, pE48, DOI 10.1097/OLQ.0000000000001251; Azze RFO, 2019, CLIN EXP VACCINE RES, V8, P110, DOI 10.7774/cevr.2019.8.2.110; Ochoa-Azze RF, 2018, MEDICC REV, V20, P22, DOI 10.37757/MR2018.V20.N3.6; Oh S, 2020, J INFECT CHEMOTHER, V26, P995, DOI 10.1016/j.jiac.2020.04.002; Ohnishi M, 2011, EMERG INFECT DIS, V17, P148, DOI 10.3201/eid1701.100397; Ong JJ, 2017, CLIN MICROBIOL INFEC, V23, P555, DOI 10.1016/j.cmi.2017.02.020; Owusu-Edusei K, 2013, SEX TRANSM DIS, V40, P197, DOI 10.1097/OLQ.0b013e318285c6d2; Palmer A, 2018, TRENDS MICROBIOL, V26, P1022, DOI 10.1016/j.tim.2018.07.003; Parikh SR, 2016, LANCET, V388, P2775, DOI 10.1016/S0140-6736(16)31921-3; Paynter J, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010005; Petousis-Harris H, 2017, LANCET, V390, P1603, DOI 10.1016/S0140-6736(17)31449-6; Pizza M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8101521; PLATT R, 1983, JAMA-J AM MED ASSOC, V250, P3205, DOI 10.1001/jama.250.23.3205; PLUMMER FA, 1993, J CLIN INVEST, V91, P339, DOI 10.1172/JCI116190; Poncin T, 2018, EUROSURVEILLANCE, V23, P6, DOI 10.2807/1560-7917; Ramos A, 2014, INFECTION, V42, P425, DOI 10.1007/s15010-013-0541-9; Read PJ, 2013, SEX HEALTH, V10, P460, DOI 10.1071/SH13077; Reekie J, 2018, CLIN INFECT DIS, V66, P437, DOI 10.1093/cid/cix769; Rice P.A., 1996, P 10 INT PATH NEISS P 10 INT PATH NEISS; Rice PA, 2017, ANNU REV MICROBIOL, V71, P665, DOI 10.1146/annurev-micro-090816-093530; Richards C, 2016, INT REV PSYCHIATR, V28, P95, DOI 10.3109/09540261.2015.1106446; Rowley J, 2019, B WORLD HEALTH ORGAN, V97, P548, DOI 10.2471/BLT.18.228486; Russell MW, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02417; SCHOFIELD CBS, 1982, BRIT J VENER DIS, V58, P184; Schwechheimer C, 2015, NAT REV MICROBIOL, V13, P605, DOI 10.1038/nrmicro3525; SEIFERT HS, 1994, J CLIN INVEST, V93, P2744, DOI 10.1172/JCI117290; Semchenko EA, 2019, CLIN INFECT DIS, V69, P1101, DOI 10.1093/cid/ciy1061; Sherrard J, 1996, GENITOURIN MED, V72, P422; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sotolongo Franklin, 2007, MEDICC Rev, V9, P16, DOI 10.37757/MR2007V9.N1.6; STERN A, 1986, CELL, V47, P61, DOI 10.1016/0092-8674(86)90366-1; Tapsall J, 2009, J MED MICROBIOL, V58, P683, DOI 10.1099/jmm.0.007641-0; Taylor BD, 2011, SEX TRANSM DIS, V38, P434, DOI 10.1097/OLQ.0b013e3181ffa7c7; Terkelsen D, 2017, EUROSURVEILLANCE, V22, P6, DOI 10.2807/1560-7917.ES.2017.22.42.17-00659; The Kirby Institute, 2017, HIV VIR HEP SEX TRAN; Toneatto D, 2017, EXPERT REV VACCINES, V16, P433, DOI 10.1080/14760584.2017.1308828; TRAMONT EC, 1985, VACCINE, V3, P3, DOI 10.1016/0264-410X(85)90003-9; Turek EM, 2021, SEX TRANSM DIS, V48, P103, DOI 10.1097/OLQ.0000000000001283; Unemo M, 2012, EUROSURVEILLANCE, V17, P2; Unemo M, 2011, EUROSURVEILLANCE, V16, P5; Unemo M, 2019, SEX HEALTH, V16, P412, DOI 10.1071/SH19023; Vallely LM, 2021, SEX TRANSM INFECT, V97, P104, DOI 10.1136/sextrans-2020-054653; Vidaurrazaga MM, 2020, IDCases, V19, DOI 10.1016/j.idcr.2019.e00662; Viglianti GA, 2021, J VIROL, V95, DOI 10.1128/JVI.02141-20; Vincent LR, 2019, VACCINE, V37, P7419, DOI 10.1016/j.vaccine.2018.02.081; Viola A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01462; Wellcome Trust and BCG, 2018, VACC TACKL DRUG RES VACC TACKL DRUG RES; WESTROM L, 1992, SEX TRANSM DIS, V19, P185, DOI 10.1097/00007435-199207000-00001; Wetzler LM, 2016, CLIN VACCINE IMMUNOL, V23, P656, DOI 10.1128/CVI.00230-16; Whiley DM, 2018, LANCET INFECT DIS, V18, P717, DOI 10.1016/S1473-3099(18)30340-2; WHO, 2016, WHO TECH REP SER, V997, P1; Wi T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002344; Wiesenfeld HC, 2012, OBSTET GYNECOL, V120, P37, DOI 10.1097/AOG.0b013e31825a6bc9; World Health Organization, 2017, GLOBAL PRIORITY LIST, P1; World Hlth Org, 2017, VACCINE, V35, P5753, DOI 10.1016/j.vaccine.2017.05.069; Chen M, 2013, J ANTIMICROB CHEMOTH, V68, P1445, DOI 10.1093/jac/dkt017; Yan FF, 2020, COMPUT STRUCT BIOTEC, V18, P1525, DOI 10.1016/j.csbj.2020.06.008; Zariri A, 2013, VACCINE, V31, P5585, DOI 10.1016/j.vaccine.2013.07.069; Zhu WY, 2018, J BIOL CHEM, V293, P11218, DOI 10.1074/jbc.RA117.001209; Zhu WY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041260	163	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							804	10.3390/vaccines9070804			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6VE	34358218	Green Published, gold			2022-04-29	WOS:000677045700001
J	Tan, MP; Tan, WS; Alitheen, NBM; Yap, WB				Tan, Mei Peng; Tan, Wen Siang; Mohamed Alitheen, Noorjahan Banu; Yap, Wei Boon			M2e-Based Influenza Vaccines with Nucleoprotein: A Review	VACCINES			English	Review						influenza; matrix protein 2 ectodomain (M2e); nucleoprotein (NP); universal vaccine; adjuvant	VIRUS-LIKE PARTICLES; A VIRUS; PANDEMIC INFLUENZA; SEASONAL INFLUENZA; CROSS-PROTECTION; UNITED-STATES; B-VIRUS; IMMUNIZATION PRACTICES; EXTRACELLULAR DOMAIN; MONOCLONAL-ANTIBODY	Discovery of conserved antigens for universal influenza vaccines warrants solutions to a number of concerns pertinent to the currently licensed influenza vaccines, such as annual reformulation and mismatching with the circulating subtypes. The latter causes low vaccine efficacies, and hence leads to severe disease complications and high hospitalization rates among susceptible and immunocompromised individuals. A universal influenza vaccine ensures cross-protection against all influenza subtypes due to the presence of conserved epitopes that are found in the majority of, if not all, influenza types and subtypes, e.g., influenza matrix protein 2 ectodomain (M2e) and nucleoprotein (NP). Despite its relatively low immunogenicity, influenza M2e has been proven to induce humoral responses in human recipients. Influenza NP, on the other hand, promotes remarkable anti-influenza T-cell responses. Additionally, NP subunits are able to assemble into particles which can be further exploited as an adjuvant carrier for M2e peptide. Practically, the T-cell immunodominance of NP can be transferred to M2e when it is fused and expressed as a chimeric protein in heterologous hosts such as Escherichia coli without compromising the antigenicity. Given the ability of NP-M2e fusion protein in inducing cross-protective anti-influenza cell-mediated and humoral immunity, its potential as a universal influenza vaccine is therefore worth further exploration.	[Tan, Mei Peng; Mohamed Alitheen, Noorjahan Banu] Univ Putra Malaysia, Fac Biotechnol & Biomol Sci, Dept Cell & Mol Biol, Serdang 43400, Malaysia; [Tan, Mei Peng; Yap, Wei Boon] Univ Kebangsaan Malaysia, Fac Hlth Sci, Ctr Toxicol & Hlth Risk Studies, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia; [Tan, Wen Siang] Univ Putra Malaysia, Fac Biotechnol & Biomol Sci, Dept Microbiol, Serdang 43400, Malaysia; [Tan, Wen Siang] Univ Putra Malaysia, Inst Biosci, Lab Vaccine & Biomol, Serdang 43400, Malaysia; [Yap, Wei Boon] Univ Kebangsaan Malaysia, Fac Hlth Sci, Biomed Sci Program, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia		Yap, WB (通讯作者)，Univ Kebangsaan Malaysia, Fac Hlth Sci, Ctr Toxicol & Hlth Risk Studies, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia.; Yap, WB (通讯作者)，Univ Kebangsaan Malaysia, Fac Hlth Sci, Biomed Sci Program, Jalan Raja Muda Abdul Aziz, Kuala Lumpur 50300, Malaysia.	meipeng27@gmail.com; wstan@upm.edu.my; noorjahan@upm.edu.my; yapweiboon@ukm.edu.my	Yap, Wei Boon/AFU-9333-2022; Tan, Wen Siang/C-1433-2017	Yap, Wei Boon/0000-0003-2449-8395; Tan, Wen Siang/0000-0001-9452-198X	Malaysia Ministry of Higher Education (MoHE) Fundamental Research Grant Scheme [FRGS/1/2017/STG05/UKM/02/9]	This work was supported by Malaysia Ministry of Higher Education (MoHE) Fundamental Research Grant Scheme (FRGS/1/2017/STG05/UKM/02/9).	Andersson AMC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046395; Asha K, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020192; Babar MM, 2015, INFECT GENET EVOL, V34, P200, DOI 10.1016/j.meegid.2015.06.030; Baldo V, 2016, J Prev Med Hyg, V57, pE19; Barouch DH, 2005, HUM GENE THER, V16, P149, DOI 10.1089/hum.2005.16.149; Beerli RR, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-224; Blokhina EA, 2013, VIROLOGY, V435, P293, DOI 10.1016/j.virol.2012.09.014; Bonmarin I, 2015, VACCINE, V33, P1099, DOI 10.1016/j.vaccine.2015.01.023; BOTH GW, 1983, J VIROL, V48, P52, DOI 10.1128/JVI.48.1.52-60.1983; Neto HB, 2009, PEDIATR INFECT DIS J, V28, P365, DOI 10.1097/INF.0b013e31819219b8; Cardona CJ, 2009, COMP IMMUNOL MICROB, V32, P255, DOI 10.1016/j.cimid.2008.01.001; Carrat F, 2007, VACCINE, V25, P6852, DOI 10.1016/j.vaccine.2007.07.027; Chenavas S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003275; Chowell G, 2009, NEW ENGL J MED, V361, P674, DOI 10.1056/NEJMoa0904023; Christman MC, 2011, INFECT GENET EVOL, V11, P803, DOI 10.1016/j.meegid.2011.02.021; Chung EH, 2014, CLIN EXP VACCINE RES, V3, P50, DOI 10.7774/cevr.2014.3.1.50; Contreras-Gomez A, 2014, BIOTECHNOL PROGR, V30, P1, DOI 10.1002/btpr.1842; Cookenham T, 2020, VACCINE, V38, P5256, DOI 10.1016/j.vaccine.2020.05.085; Corbett KS, 2020, NATURE, V586, P567, DOI 10.1038/s41586-020-2622-0; Costantino C, 2016, J Prev Med Hyg, V57, pE13; Cox Manon M J, 2015, Ther Adv Vaccines, V3, P97, DOI 10.1177/2051013615595595; Cox MMJ, 2008, INFLUENZA OTHER RESP, V2, P211, DOI 10.1111/j.1750-2659.2008.00053.x; De Filette M, 2005, VIROLOGY, V337, P149, DOI 10.1016/j.virol.2005.04.004; de Jong JC, 2000, J INFECTION, V40, P218, DOI 10.1053/jinf.2000.0652; De Villiers PJT, 2009, VACCINE, V28, P228, DOI 10.1016/j.vaccine.2009.09.092; Doherty PC, 2006, NAT IMMUNOL, V7, P449, DOI 10.1038/ni1343; Ebrahimi SM, 2011, VIRUS GENES, V42, P1, DOI 10.1007/s11262-010-0547-7; Eisfeld AJ, 2014, NAT PROTOC, V9, P2663, DOI 10.1038/nprot.2014.180; Eliasson DG, 2018, MUCOSAL IMMUNOL, V11, P273, DOI 10.1038/mi.2017.14; Epstein SL, 2010, EXPERT REV VACCINES, V9, P1325, DOI [10.1586/erv.10.123, 10.1586/ERV.10.123]; Fan JA, 2004, VACCINE, V22, P2993, DOI 10.1016/j.vaccine.2004.02.021; Fernando GJP, 2016, J CONTROL RELEASE, V237, P35, DOI 10.1016/j.jconrel.2016.06.045; Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007; Fukuyama S, 2011, CURR OPIN IMMUNOL, V23, P481, DOI 10.1016/j.coi.2011.07.016; Gallagher JR, 2017, J STRUCT BIOL, V197, P294, DOI 10.1016/j.jsb.2016.12.007; GAO XM, 1989, J IMMUNOL, V143, P3007; Garten RJ, 2009, SCIENCE, V325, P197, DOI 10.1126/science.1176225; Gatherer D, 2009, J CLIN VIROL, V45, P174, DOI 10.1016/j.jcv.2009.06.004; Gerdil C, 2003, VACCINE, V21, P1776, DOI 10.1016/S0264-410X(03)00071-9; Gerhard W, 2006, EMERG INFECT DIS, V12, P569, DOI 10.3201/eid1204.051020; Ghorbani A, 2019, VACCINE, V37, P1356, DOI 10.1016/j.vaccine.2019.01.037; Gonzalez SF, 2008, VACCINE, V26, pI86, DOI 10.1016/j.vaccine.2008.11.057; Gordon E, 2008, PROTEIN EXPRES PURIF, V62, P1, DOI 10.1016/j.pep.2008.07.005; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Grandea AG, 2010, P NATL ACAD SCI USA, V107, P12658, DOI 10.1073/pnas.0911806107; Griffith DA, 2003, FEBS LETT, V553, P45, DOI 10.1016/S0014-5793(03)00952-9; Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1; Grohskopf LA, 2015, AM J TRANSPLANT, V15, P2767, DOI 10.1111/ajt.13505; Guan Y, 2010, PROTEIN CELL, V1, P9, DOI 10.1007/s13238-010-0008-z; Han JP, 1999, VACCINE, V17, pS57, DOI 10.1016/S0264-410X(99)00107-3; Hause BM, 2014, MBIO, V5, DOI 10.1128/mBio.00031-14; Heinen PP, 2001, J GEN VIROL, V82, P2697, DOI 10.1099/0022-1317-82-11-2697; Heinen PP, 2002, J GEN VIROL, V83, P1851, DOI 10.1099/0022-1317-83-8-1851; Huleatt JW, 2008, VACCINE, V26, P201, DOI 10.1016/j.vaccine.2007.10.062; Hutchinson EC, 2018, TRENDS MICROBIOL, V26, P809, DOI 10.1016/j.tim.2018.05.013; Hutchinson EC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5816; Jegaskanda S, 2016, J INFECT DIS, V214, P945, DOI 10.1093/infdis/jiw262; Kapoor S, 2014, INSIGHT INFLUENZA VI, P15; Khan Kishwar Hayat, 2013, Germs, V3, P26, DOI 10.11599/germs.2013.1034; Kilbourne ED, 2004, VIRAL IMMUNOL, V17, P350, DOI 10.1089/vim.2004.17.350; Kim H, 2018, VIRAL IMMUNOL, V31, P174, DOI 10.1089/vim.2017.0141; Kim KH, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6040066; Kim MC, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11040188; Kim MC, 2013, ANTIVIR RES, V99, P328, DOI 10.1016/j.antiviral.2013.06.010; Kim MC, 2013, MOL THER, V21, P485, DOI 10.1038/mt.2012.246; Kim YJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01730; Kitikoon P, 2009, VACCINE, V28, P523, DOI 10.1016/j.vaccine.2009.09.130; Klimek L, 2018, ALLERGO J, V27, P22, DOI 10.1007/s40629-018-0074-y; Koehn Jim, 2009, V498, P1, DOI 10.1007/978-1-59745-196-3_1; Kolpe A, 2017, EXPERT REV VACCINES, V16, P123, DOI 10.1080/14760584.2017.1240041; Kotomina T, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040648; Kreijtz JHCM, 2008, J VIROL, V82, P5161, DOI 10.1128/JVI.02694-07; Lalor PA, 2008, J INFECT DIS, V197, P1643, DOI 10.1086/588431; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; Lang PO, 2012, CLIN INTERV AGING, V7, P55, DOI 10.2147/CIA.S25215; Lee LYH, 2008, J CLIN INVEST, V118, P3478, DOI 10.1172/JCI32460; Lee LYY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01568; Lee SY, 2019, CLIN EXP VACCINE RES, V8, P54, DOI 10.7774/cevr.2019.8.1.54; Lega T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167225; Levi R, 1996, VACCINE, V14, P85, DOI 10.1016/0264-410X(95)00088-I; Lindstrom SE, 2004, VIROLOGY, V328, P101, DOI 10.1016/j.virol.2004.06.009; Liu WL, 2005, MICROBES INFECT, V7, P171, DOI 10.1016/j.micinf.2004.10.006; Liu XY, 2012, VACCINE, V30, P6527, DOI 10.1016/j.vaccine.2012.08.054; Lo CY, 2008, VACCINE, V26, P2062, DOI 10.1016/j.vaccine.2008.02.047; Lukarska M., 2018, THESIS U GRENOBLE AL THESIS U GRENOBLE AL; Luo J, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-286; MacKellar L, 2007, POPUL DEV REV, V33, P429, DOI 10.1111/j.1728-4457.2007.00179.x; Manzoor R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122649; Martini M, 2019, J Prev Med Hyg, V60, pE64, DOI 10.15167/2421-4248/jpmh2019.60.1.1205; Matsuoka Y, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-97; MAZANEC MB, 1995, J VIROL, V69, P1339, DOI 10.1128/JVI.69.2.1339-1343.1995; McLean HQ, 2015, J INFECT DIS, V211, P1529, DOI 10.1093/infdis/jiu647; Mena I, 2016, ELIFE, V5, DOI 10.7554/eLife.16777; Mohn KGI, 2018, HUM VACC IMMUNOTHER, V14, P571, DOI 10.1080/21645515.2017.1377376; Mozdzanowska K, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-118; Neirynck S, 1999, NAT MED, V5, P1157, DOI 10.1038/13484; Ng AKL, 2008, FASEB J, V22, P3638, DOI 10.1096/fj.08-112110; Ng TWY, 2019, J INFECT DIS, V219, P1525, DOI 10.1093/infdis/jiy720; Paules CI, 2018, NEW ENGL J MED, V378, P7, DOI 10.1056/NEJMp1714916; Pera A, 2015, MATURITAS, V82, P50, DOI 10.1016/j.maturitas.2015.05.004; Pizzolla A, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aam6970; Plotkin S, 2017, VACCINE, V35, P4064, DOI 10.1016/j.vaccine.2017.06.003; Portela A, 2002, J GEN VIROL, V83, P723, DOI 10.1099/0022-1317-83-4-723; Praditsuwan Rungnirand, 2005, Journal of the Medical Association of Thailand, V88, P256; Ramos EL, 2015, J INFECT DIS, V211, P1038, DOI 10.1093/infdis/jiu539; Rappazzo CG, 2016, VACCINE, V34, P1252, DOI 10.1016/j.vaccine.2016.01.028; Ravin NV, 2015, VACCINE, V33, P3392, DOI 10.1016/j.vaccine.2015.04.066; Romeli S, 2020, MALAYS J MED SCI, V27, P10, DOI 10.21315/mjms2020.27.2.2; Rondy M, 2017, J INFECTION, V75, P381, DOI 10.1016/j.jinf.2017.09.010; Rosano GL, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00172; ROTA PA, 1990, VIROLOGY, V175, P59, DOI 10.1016/0042-6822(90)90186-U; ROTHBARD JB, 1989, EMBO J, V8, P2321, DOI 10.1002/j.1460-2075.1989.tb08359.x; Saelens X, 2019, J INFECT DIS, V219, pS68, DOI 10.1093/infdis/jiz003; Sautto GA, 2018, VIROL J, V15, DOI 10.1186/s12985-017-0918-y; Schotsaert M, 2009, EXPERT REV VACCINES, V8, P499, DOI 10.1586/ERV.09.6; Sharma P., 2017, ASIAN J PHARMA CLIN, V10, P33, DOI [10.22159/ajpcr.2017.v10i2.15555, DOI 10.22159/AJPCR.2017.V10I2.15555]; Shim BS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027953; Simhadri VR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124677; Simonsen L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001558; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Smetana J, 2018, HUM VACC IMMUNOTHER, V14, P540, DOI 10.1080/21645515.2017.1343226; Smith GJD, 2009, NATURE, V459, P1122, DOI 10.1038/nature08182; Sridhar S, 2015, VACCINES, V3, P373, DOI 10.3390/vaccines3020373; Stamboulian D, 2000, INFECT DIS CLIN N AM, V14, P141, DOI 10.1016/S0891-5520(05)70222-1; Stepanova LA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119520; Stevens MP, 1998, J VIROL, V72, P5307, DOI 10.1128/JVI.72.6.5307-5312.1998; Tam JS, 2007, PEDIATR INFECT DIS J, V26, P619, DOI 10.1097/INF.0b013e31806166f8; Tan TS, 2017, LETT APPL MICROBIOL, V64, P446, DOI 10.1111/lam.12738; Taubenberger JK, 1997, SCIENCE, V275, P1793, DOI 10.1126/science.275.5307.1793; Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230; Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979; Tavakoli S, 2015, NOV BIOMED, V3, P53; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; Terajima M, 2011, J VIROL, V85, P13463, DOI 10.1128/JVI.05193-11; Thomas PG, 2006, EMERG INFECT DIS, V12, P48, DOI 10.3201/eid1201.051237; Thompson MG, 2018, VACCINE, V36, P5916, DOI 10.1016/j.vaccine.2018.07.028; Treanor J, 2004, NEW ENGL J MED, V350, P218, DOI 10.1056/NEJMp038238; Tricco AC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-153; Turley CB, 2011, VACCINE, V29, P5145, DOI 10.1016/j.vaccine.2011.05.041; Vahey MD, 2019, ELIFE, V8, DOI 10.7554/eLife.43764; Valkenburg SA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002544; Verma DK, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110650; Vijaykrishna D, 2015, ELIFE, V4, DOI 10.7554/eLife.05055; Wang L, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/686549; Wang RF, 2008, ANTIVIR RES, V80, P168, DOI 10.1016/j.antiviral.2008.06.002; WEBSTER RG, 1982, NATURE, V296, P115, DOI 10.1038/296115a0; Westcott MM, 2018, VACCINE, V36, P1174, DOI 10.1016/j.vaccine.2018.01.035; Wilkins AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01760; Wong T, 2016, STEPS FORWARDS IN DIAGNOSING AND CONTROLLING INFLUENZA, P87, DOI 10.5772/64369; Woo EJ, 2021, VACCINE, V39, P1812, DOI 10.1016/j.vaccine.2021.02.052; Woo EJ, 2015, CLIN INFECT DIS, V60, P777, DOI 10.1093/cid/ciu948; Wu CY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009784; Xing Z, 2009, EMERG INFECT DIS, V15, P1847, DOI 10.3201/eid1511.090685; Xu R, 2010, SCIENCE, V328, P357, DOI 10.1126/science.1186430; Yao YF, 2019, EMERG MICROBES INFEC, V8, P45, DOI 10.1080/22221751.2018.1558962; Yap W.B., 2018, J SAINS KESIHAT MALA, V16, P51, DOI [10.17576/jskm-2018-1602-07, DOI 10.17576/JSKM-2018-1602-07]; Yap WB, 2012, J BIOSCI BIOENG, V113, P26, DOI 10.1016/j.jbiosc.2011.09.007; Yap WB, 2009, J VIROL METHODS, V160, P125, DOI 10.1016/j.jviromet.2009.04.038; YEWDELL JW, 1985, P NATL ACAD SCI USA, V82, P1785, DOI 10.1073/pnas.82.6.1785; Yolshin N.D, 2021, MIR J, V6, P43, DOI [10.18527/2500-2236-2019-6-1-43-48, DOI 10.18527/2500-2236-2019-6-1-43-48]; Zepeda-Cervantes J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01100; Zhang H, 2014, VIRUSES-BASEL, V6, P1974, DOI 10.3390/v6051974; Zheng M, 2015, HUM VACC IMMUNOTHER, V11, P397, DOI 10.4161/21645515.2014.995056; Zhou DM, 2010, MOL THER, V18, P2182, DOI 10.1038/mt.2010.202; Zhu WD, 2017, J CONTROL RELEASE, V261, P1, DOI 10.1016/j.jconrel.2017.06.017	165	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							739	10.3390/vaccines9070739			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6OB	34358155	gold, Green Published			2022-04-29	WOS:000677027200001
J	Yang, J; Kim, E; Lee, JS; Poo, H				Yang, Jihyun; Kim, Eunjin; Lee, Jong-Soo; Poo, Haryoung			A Murine CD8(+) T Cell Epitope Identified in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein	VACCINES			English	Article						SARS-CoV-2; cell-mediated immunity; CD8 cytotoxic T lymphocyte; epitope; vaccine	VACCINE; VIRUS; RBD	The ongoing COVID-19 pandemic caused by SARS-CoV-2 has posed a devastating threat worldwide. The receptor-binding domain (RBD) of the spike protein is one of the most important antigens for SARS-CoV-2 vaccines, while the analysis of CD8 cytotoxic T lymphocyte activity in preclinical studies using mouse models is critical for evaluating vaccine efficacy. Here, we immunized C57BL/6 wild-type mice and transgenic mice expressing human angiotensin-converting enzyme 2 (ACE2) with the SARS-CoV-2 RBD protein to evaluate the IFN-gamma-producing T cells in the splenocytes of the immunized mice using an overlapping peptide pool by an enzyme-linked immunospot assay and flow cytometry. We identified SARS-CoV-2 S395-404 as a major histocompatibility complex (MHC) class I-restricted epitope for the RBD-specific CD8 T cell responses in C57BL/6 mice.	[Yang, Jihyun; Kim, Eunjin; Poo, Haryoung] Korea Res Inst Biosci & Biotechnol KRIBB, Infect Dis Res Ctr, Daejeon 34141, South Korea; [Kim, Eunjin; Lee, Jong-Soo] Chungnam Natl Univ, Coll Vet Med, Dept Prevent Vet Med, Daejeon 34134, South Korea		Poo, H (通讯作者)，Korea Res Inst Biosci & Biotechnol KRIBB, Infect Dis Res Ctr, Daejeon 34141, South Korea.	jhyang@kribb.re.kr; ejkim1512@gmail.com; jongsool@cnu.ac.kr; haryoung@kribb.re.kr		Yang, Jihyun/0000-0002-1935-8542	Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Program [KGM9942112]	This research was funded by a grant from Korea Research Institute of Bioscience and Biotechnology (KRIBB) Research Initiative Program (KGM9942112).	Appay V, 2008, NAT MED, V14, P623, DOI 10.1038/nm.f.1774; Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14; Cohen J, 2020, SCIENCE, V367, P234, DOI 10.1126/science.367.6475.234; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Golden JW, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.142032; Golding H, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028902; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Habel JR, 2020, P NATL ACAD SCI USA, V117, P24384, DOI 10.1073/pnas.2015486117; Hudrisier D, 1997, VIROLOGY, V234, P62, DOI 10.1006/viro.1997.8627; Ip PP, 2015, VACCINES-BASEL, V3, P203, DOI 10.3390/vaccines3020203; Johansen MD, 2020, MUCOSAL IMMUNOL, V13, P877, DOI 10.1038/s41385-020-00340-z; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Liu ZZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00402-5; Min L, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.671633; Mullard A, 2020, LANCET, V395, P1751, DOI 10.1016/S0140-6736(20)31252-6; Muraoka D, 2020, VACCINE, V38, P7697, DOI 10.1016/j.vaccine.2020.10.039; Oladunni FS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19891-7; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Sims S, 2010, EXPERT REV VACCINES, V9, P765, DOI [10.1586/erv.10.66, 10.1586/ERV.10.66]; Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0; van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; Wang ZF, 2020, AM J RESP CRIT CARE, V202, P606, DOI 10.1164/rccm.202005-1701LE; Winkler Emma S, 2020, bioRxiv, DOI 10.1101/2020.07.09.196188; World Health Organization, 62 WHO; Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zhao K, 2010, VACCINE, V28, P6666, DOI 10.1016/j.vaccine.2010.08.013; Zhou MH, 2006, J IMMUNOL, V177, P2138, DOI 10.4049/jimmunol.177.4.2138	29	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							641	10.3390/vaccines9060641			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ5ZC	34208032	gold, Green Published			2022-04-29	WOS:000666642100001
J	Philip, AA; Patton, JT				Philip, Asha Ann; Patton, John Thomas			Rotavirus as an Expression Platform of Domains of the SARS-CoV-2 Spike Protein	VACCINES			English	Article						rotavirus; rotavirus vaccine; reverse genetics; Reoviridae; expression vector; SARS-CoV-2; COVID-19 vaccine; spike protein	2A PEPTIDES; BINDING; PROTECTION; SEQUENCES; ACE2	Among vaccines administered to children are those targeting rotavirus, a segmented double-stranded RNA virus that represents a major cause of severe gastroenteritis. To explore the feasibility of establishing a combined rotavirus-SARS-CoV-2 vaccine, we generated recombinant (r)SA11 rotaviruses with modified segment 7 RNAs that contained coding cassettes for NSP3, a translational 2A stop-restart signal, and a FLAG-tagged portion of the SARS-CoV-2 spike (S) protein: S1 fragment, N-terminal domain (NTD), receptor-binding domain (RBD), extended RBD (ExRBD), or S2 core (CR) domain. Generation of rSA11 containing the S1 coding sequence required a sequence insertion of 2.2 kbp, the largest such insertion yet introduced into the rotavirus genome. Immunoblotting showed that rSA11 viruses containing the smaller NTD, RBD, ExRBD, and CR coding sequences expressed S-protein products of expected size, with ExRBD expressed at highest levels. These rSA11 viruses were genetically stable during serial passage. In contrast, the rSA11 virus containing the full-length S coding sequence (rSA11/NSP3-fS1) failed to express its expected 80 kDa fS1 product, for unexplained reasons. Moreover, rSA11/NSP3-fS1 was genetically unstable, with variants lacking the S1 insertion appearing during serial passage. Nonetheless, these results emphasize the potential usefulness of rotavirus vaccines as expression vectors of immunogenic portions of the SARS-CoV-2 S protein, including NTD, RBD, ExRBD, and CR, that have sizes smaller than the S1 fragment.	[Philip, Asha Ann; Patton, John Thomas] Indiana Univ, Dept Biol, Bloomington, IN 47405 USA		Patton, JT (通讯作者)，Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	aaphilip@iu.edu; jtpatton@iu.edu	Patton, John/V-7651-2018	Patton, John/0000-0003-1572-0732	National Institute of Allergy and Infectious Diseases of the National Institutes of Health, Bethesda, Maryland, USA [R21AI44881]; Indiana University; Lawrence M. Blatt Endowment	Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, Bethesda, Maryland, USA, under award number R21AI44881. J.T.P. was also supported by Indiana University Start-Up Funding and the Lawrence M. Blatt Endowment.	Ali A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127622; Angel J, 2014, HUM VACC IMMUNOTHER, V10, P3659, DOI 10.4161/hv.34361; [Anonymous], Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets for drug repurposing; Arbeitman CR, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78711-6; Arnold Michelle, 2009, Curr Protoc Microbiol, VChapter 15, DOI 10.1002/9780471729259.mc15c03s15; Arnold MM, 2012, J GEN VIROL, V93, P1483, DOI 10.1099/vir.0.041830-0; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Burke RM, 2019, CURR OPIN INFECT DIS, V32, P435, DOI 10.1097/QCO.0000000000000572; Burnett E, 2020, LANCET GLOB HEALTH, V8, pE1195, DOI 10.1016/S2214-109X(20)30262-X; Chang-Graham AL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46856-8; Clark A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183392; Crawford SE, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.83; Criglar JM, 2020, J VIROL, V94, DOI 10.1128/JVI.00972-20; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; Demers-Mathieu V, 2021, J PERINATOL, V41, P850, DOI 10.1038/s41372-020-00805-w; Desselberger U, 2020, VIRUS RES, V276, DOI 10.1016/j.virusres.2019.197822; Duan LW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.576622; Eaton HE, 2017, J VIROL, V91, DOI 10.1128/JVI.02416-16; Folorunso OS, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030341; Graham Carl, 2021, bioRxiv, DOI 10.1101/2021.02.03.429355; Gratia M, 2015, J VIROL, V89, P8773, DOI 10.1128/JVI.01402-15; Guest JD, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2015149118; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang Y, 2020, ACTA PHARMACOL SIN, V41, P1141, DOI 10.1038/s41401-020-0485-4; Huo JD, 2020, CELL HOST MICROBE, V28, P497, DOI 10.1016/j.chom.2020.07.002; Kanai Y, 2021, VIRUS RES, V295, DOI 10.1016/j.virusres.2021.198296; Kanai Y, 2019, J VIROL, V93, DOI 10.1128/JVI.01774-18; Kanai Y, 2017, P NATL ACAD SCI USA, V114, P2349, DOI 10.1073/pnas.1618424114; Kaur SP, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198114; Komoto S, 2019, J VIROL, V93, DOI 10.1128/JVI.02207-18; Komoto S, 2018, J VIROL, V92, DOI 10.1128/JVI.00588-18; Komoto S, 2017, J VIROL, V91, DOI 10.1128/JVI.00695-17; Leshem E, 2015, JAMA-J AM MED ASSOC, V313, P2282, DOI 10.1001/jama.2015.5571; Liu GF, 2017, HUM VACC IMMUNOTHER, V13, P2357, DOI [10.1080/21645515.2017.1356522, 10.1080/21645515.2017.1365208]; Liu LH, 2020, NATURE, V584, P450, DOI 10.1038/s41586-020-2571-7; Liu ZQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02460-2; Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270; Luke GA, 2010, BIOTECHNOL GENET ENG, V26, P223; Matthijnssens J, 2011, ARCH VIROL, V156, P1397, DOI 10.1007/s00705-011-1006-z; MCINTYRE M, 1987, J GEN VIROL, V68, P2961, DOI 10.1099/0022-1317-68-11-2961; Medina-Enriquez MM, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00519-8; Navarro A, 2013, J VIROL, V87, P6211, DOI 10.1128/JVI.00413-13; Okba NMA, 2020, EMERG MICROBES INFEC, V9, P1080, DOI 10.1080/22221751.2020.1760735; Papa G, 2020, J VIROL, V94, DOI 10.1128/JVI.01110-19; Philip AA, 2020, J VIROL, V94, DOI 10.1128/JVI.00959-20; Philip AA, 2020, JOVE-J VIS EXP, DOI 10.3791/61039; Philip AA, 2019, J VIROL, V93, DOI 10.1128/JVI.01616-19; Philip AA, 2019, MICROBIOL RESOUR ANN, V8, DOI 10.1128/MRA.00523-19; Piron M, 1999, J VIROL, V73, P5411, DOI 10.1128/JVI.73.7.5411-5421.1999; Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5; Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520; Roulston C, 2016, TRAFFIC, V17, P923, DOI 10.1111/tra.12411; Sanchez-Tacuba L, 2020, J VIROL, V94, DOI 10.1128/JVI.01294-20; Shaimardanova AA, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11110580; Sharma P, 2012, NUCLEIC ACIDS RES, V40, P3143, DOI 10.1093/nar/gkr1176; Shi XJ, 2021, STEM CELL RES, V50, DOI 10.1016/j.scr.2020.102125; Soares-Weiser K, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008521.pub4; Sockolosky JT, 2012, P NATL ACAD SCI USA, V109, P16095, DOI 10.1073/pnas.1208857109; Suryadevara N, 2021, CELL, V184, P2316, DOI 10.1016/j.cell.2021.03.029; Trask SD, 2012, NAT REV MICROBIOL, V10, P165, DOI 10.1038/nrmicro2673; Wen B, 2011, ACTA BIOCH BIOPH SIN, V43, P96, DOI 10.1093/abbs/gmq117; Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241; Zost SJ, 2020, NAT MED, V26, DOI [10.1038/s41591-020-0998-x, 10.1101/2020.05.12.091462]	63	6	6	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							449	10.3390/vaccines9050449			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1MX	34063562	Green Published, gold			2022-04-29	WOS:000654591400001
J	Verdikt, R; Hernalsteens, O; Van Lint, C				Verdikt, Roxane; Hernalsteens, Olivier; Van Lint, Carine			Epigenetic Mechanisms of HIV-1 Persistence	VACCINES			English	Review						HIV-1 latency; HIV-1 persistence; reservoirs; epigenetics	IMMUNODEFICIENCY-VIRUS TYPE-1; CD4(+) T-CELLS; CHROMATIN-REMODELING COMPLEX; DNA METHYLATION; LATENT RESERVOIR; GENE-EXPRESSION; HISTONE MODIFICATIONS; HYPERSENSITIVE SITES; TISSUE RESERVOIRS; TRANSCRIPTION	Eradicating HIV-1 in infected individuals will not be possible without addressing the persistence of the virus in its multiple reservoirs. In this context, the molecular characterization of HIV-1 persistence is key for the development of rationalized therapeutic interventions. HIV-1 gene expression relies on the redundant and cooperative recruitment of cellular epigenetic machineries to cis-regulatory proviral regions. Furthermore, the complex repertoire of HIV-1 repression mechanisms varies depending on the nature of the viral reservoir, although, so far, few studies have addressed the specific regulatory mechanisms of HIV-1 persistence in other reservoirs than the well-studied latently infected CD4(+) T cells. Here, we present an exhaustive and updated picture of the heterochromatinization of the HIV-1 promoter in its different reservoirs. We highlight the complexity, heterogeneity and dynamics of the epigenetic mechanisms of HIV-1 persistence, while discussing the importance of further understanding HIV-1 gene regulation for the rational design of novel HIV-1 cure strategies.	[Verdikt, Roxane; Hernalsteens, Olivier; Van Lint, Carine] Univ Libre Bruxelles ULB, Serv Mol Virol, Dept Mol Virol DBM, B-6041 Gosselies, Belgium; [Verdikt, Roxane] Univ Calif Los Angeles, Inst Soc & Genet, Los Angeles, CA 90095 USA		Van Lint, C (通讯作者)，Univ Libre Bruxelles ULB, Serv Mol Virol, Dept Mol Virol DBM, B-6041 Gosselies, Belgium.	Roxane.Verdikt@ulb.be; Olivier.Hernalsteens@ulb.be; Carine.Vanlint@ulb.be		Verdikt, Roxane/0000-0002-1091-6720	Belgian National Fund for Scientific Research (FRS-FNRS, Belgium)Fonds de la Recherche Scientifique - FNRS; European UnionEuropean Commission [691119-EU4HIVCURE-H2020-MSCA-RISE-2015]; Fondation Roi Baudouin; NEAT (European AIDS Treatment Network) program; International Brachet Stiftung; ViiV Healthcare; Walloon Region (Fonds de Maturation); Les Amis des Instituts Pasteur a Bruxelles, ASBL; University of Brussels ("Action de Recherche Concertee" ULB grant); FRIA fellowship (F.R.S-FNRS)Fonds de la Recherche Scientifique - FNRS; Fondation Universitaire de Belgique	The authors thank the members of the ANRS (French National Agency for Research on AIDS and Viral Hepatitis) RHIVIERA (Remission of HIV Era) Consortium for helpful discussions. CVL acknowledges funding from the Belgian National Fund for Scientific Research (FRS-FNRS, Belgium), the European Union's Horizon 2020 research and innovation program (grant agreement 691119-EU4HIVCURE-H2020-MSCA-RISE-2015), the Fondation Roi Baudouin, the NEAT (European AIDS Treatment Network) program, the International Brachet Stiftung, ViiV Healthcare, the Walloon Region (Fonds de Maturation), "Les Amis des Instituts Pasteur a Bruxelles, ASBL" and the University of Brussels ("Action de Recherche Concertee" ULB grant). The laboratory of C.V.L. is part of the ULB-Cancer Research Centre (U-CRC). R.V. is a Belgian American Education Foundation (BAEF) fellow and a scientific collaborator of the ULB. O.H. was a fellow of "Les Amis des Instituts Pasteur a Bruxelles, asbl" and is funded by a FRIA fellowship (F.R.S-FNRS). C.V.L. is "Directeur de Recherches" of the F.R.S-FNRS (Belgium). Published with the support of the "Fondation Universitaire de Belgique".	Ait-Ammar A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82164-w; Ait-Ammar A, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03060; Palacios JA, 2012, J VIROL, V86, P13081, DOI 10.1128/JVI.01741-12; Arts EJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007161; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Barclay RA, 2017, J BIOL CHEM, V292, P11682, DOI 10.1074/jbc.M117.793521; Barichievy S, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00108; Barton K, 2016, TRENDS MICROBIOL, V24, P345, DOI 10.1016/j.tim.2016.01.006; BEDNARIK DP, 1990, EMBO J, V9, P1157, DOI 10.1002/j.1460-2075.1990.tb08222.x; BEDNARIK DP, 1987, J VIROL, V61, P1253, DOI 10.1128/JVI.61.4.1253-1257.1987; Bignami F, 2012, BLOOD, V119, P6259, DOI 10.1182/blood-2011-09-379503; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Blazkova J, 2012, J VIROL, V86, P5390, DOI 10.1128/JVI.00040-12; Blazkova J, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000554; Boehm D, 2017, CELL HOST MICROBE, V21, P569, DOI 10.1016/j.chom.2017.04.011; Bouchat S, 2016, EMBO MOL MED, V8, P117, DOI 10.15252/emmm.201505557; Brussel A, 2004, J VIROL, V78, P11263, DOI 10.1128/JVI.78.20.11263-11271.2004; Buzon MJ, 2014, NAT MED, V20, P139, DOI 10.1038/nm.3445; Chavez L, 2011, METHODS, V53, P47, DOI 10.1016/j.ymeth.2010.05.009; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chereji RV, 2018, BIOPHYS J, V114, P2279, DOI 10.1016/j.bpj.2018.03.015; Cherrier T, 2013, P NATL ACAD SCI USA, V110, P12655, DOI 10.1073/pnas.1220136110; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Chougui G, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00224; Chougui G, 2018, NAT MICROBIOL, V3, P891, DOI 10.1038/s41564-018-0179-6; Chun TW, 2015, NAT IMMUNOL, V16, P584, DOI 10.1038/ni.3152; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Colin L, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-111; Conrad RJ, 2017, MOL CELL, V67, P1001, DOI 10.1016/j.molcel.2017.07.025; Cortes-Rubio CN, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0735-9; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; Darcis G, 2018, CURR TOP MICROBIOL, V417, P1, DOI 10.1007/82_2017_74; Darcis G, 2017, TRENDS IMMUNOL, V38, P217, DOI 10.1016/j.it.2016.12.003; Deeks SG, 2016, NAT MED, V22, P839, DOI 10.1038/nm.4108; Deeks SG, 2013, LANCET, V382, P1525, DOI 10.1016/S0140-6736(13)61809-7; Ding DL, 2013, VIROLOGY, V440, P182, DOI 10.1016/j.virol.2013.02.022; du Chene I, 2007, EMBO J, V26, P424, DOI 10.1038/sj.emboj.7601517; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; Eilebrecht S, 2014, NUCLEIC ACIDS RES, V42, P4962, DOI 10.1093/nar/gku168; Eisele E, 2012, IMMUNITY, V37, P377, DOI 10.1016/j.immuni.2012.08.010; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Friedman J, 2011, J VIROL, V85, P9078, DOI 10.1128/JVI.00836-11; Gagne M, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007802; Gallastegui E, 2011, J VIROL, V85, P3187, DOI 10.1128/JVI.01920-10; Ganor Y, 2019, NAT MICROBIOL, V4, P633, DOI 10.1038/s41564-018-0335-z; Gerard A, 2015, CELL HOST MICROBE, V17, P107, DOI 10.1016/j.chom.2014.12.002; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; He GC, 2002, MOL CELL BIOL, V22, P2965, DOI 10.1128/MCB.22.9.2965-2973.2002; He ZP, 2020, J VIROL, V94, DOI 10.1128/JVI.01923-19; Hermann A, 2004, J BIOL CHEM, V279, P48350, DOI 10.1074/jbc.M403427200; Herskovitz J, 2019, J NEUROIMMUNE PHARM, V14, P52, DOI 10.1007/s11481-018-9785-6; Hiener B, 2017, CELL REP, V21, P813, DOI 10.1016/j.celrep.2017.09.081; Ho YC, 2013, CELL, V155, P540, DOI 10.1016/j.cell.2013.09.020; Holoch D, 2015, NAT REV GENET, V16, P71, DOI 10.1038/nrg3863; Honeycutt JB, 2017, NAT MED, V23, P638, DOI 10.1038/nm.4319; Houzet L, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-118; Huang HC, 2019, NUCLEIC ACIDS RES, V47, P7333, DOI 10.1093/nar/gkz493; Huang JL, 2007, NAT MED, V13, P1241, DOI 10.1038/nm1639; Huber K, 2011, J BIOL CHEM, V286, P22211, DOI 10.1074/jbc.M110.180224; Imai K, 2010, J BIOL CHEM, V285, P16538, DOI 10.1074/jbc.M110.103531; Ishida T, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-69; Jiang GC, 2018, J CLIN INVEST, V128, P1190, DOI 10.1172/JCI98071; Kaikkonen MU, 2011, CARDIOVASC RES, V90, P430, DOI 10.1093/cvr/cvr097; Kandathil AJ, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0323-4; Kantor B, 2009, P NATL ACAD SCI USA, V106, P18786, DOI 10.1073/pnas.0905859106; Karn J, 2011, CURR OPIN HIV AIDS, V6, P4, DOI 10.1097/COH.0b013e328340ffbb; Kauder SE, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000495; Keedy KS, 2009, J VIROL, V83, P4749, DOI 10.1128/JVI.02585-08; Kelly J, 2008, VIROLOGY, V372, P300, DOI 10.1016/j.virol.2007.11.007; Nguyen K, 2017, MBIO, V8, DOI 10.1128/mBio.00133-17; Klutstein M, 2016, CANCER RES, V76, P3446, DOI 10.1158/0008-5472.CAN-15-3278; Kulpa DA, 2015, J VIRUS ERAD, V1, P59; Lange UC, 2020, SEMIN IMMUNOPATHOL, V42, P187, DOI 10.1007/s00281-020-00783-3; Le Douce V, 2016, SCI REP-UK, V6, DOI 10.1038/srep34920; Le Douce V, 2012, NUCLEIC ACIDS RES, V40, P1904, DOI 10.1093/nar/gkr857; Le Douce V, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-32; Lelek M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7483; Lesbats P, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001280; Leung DC, 2012, TRENDS BIOCHEM SCI, V37, P127, DOI 10.1016/j.tibs.2011.11.006; Li J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11730; Li ZC, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007498; Li ZC, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007012; Lucic B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12046-3; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Lusic M, 2013, CELL HOST MICROBE, V13, P665, DOI 10.1016/j.chom.2013.05.006; Lyko F, 2018, NAT REV GENET, V19, P81, DOI 10.1038/nrg.2017.80; Machida S, 2020, P NATL ACAD SCI USA, V117, P6822, DOI 10.1073/pnas.1913754117; Mahmoudi T, 2006, J BIOL CHEM, V281, P19960, DOI 10.1074/jbc.M603336200; Marban C, 2005, NUCLEIC ACIDS RES, V33, P2318, DOI 10.1093/nar/gki529; Marban C, 2007, EMBO J, V26, P412, DOI 10.1038/sj.emboj.7601516; Marban C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00397; Marian CA, 2018, CELL CHEM BIOL, V25, P1443, DOI 10.1016/j.chembiol.2018.08.004; Marini B, 2015, NATURE, V521, P227, DOI 10.1038/nature14226; McDonel P, 2009, INT J BIOCHEM CELL B, V41, P108, DOI 10.1016/j.biocel.2008.07.022; Mizutani T, 2009, J VIROL, V83, P11569, DOI 10.1128/JVI.00742-09; Moyano M, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0133-5; Murr R, 2010, ADV GENET, V70, P101, DOI [10.1016/S0065-2660(10)70005-5, 10.1016/B978-0-12-380866-0.60005-8]; Nakamura M, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-13; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Orzalli MH, 2014, ANNU REV MICROBIOL, V68, P477, DOI 10.1146/annurev-micro-091313-103409; Palmisano I, 2012, P NATL ACAD SCI USA, V109, pE2284, DOI 10.1073/pnas.1202174109; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Pierard V, 2010, J BIOL CHEM, V285, P19434, DOI 10.1074/jbc.M110.107607; Pierson TC, 2002, J VIROL, V76, P4138, DOI 10.1128/JVI.76.8.4138-4144.2002; Pinto DO, 2019, RETROVIROLOGY, V16, DOI 10.1186/s12977-019-0475-0; Pombo A, 2015, NAT REV MOL CELL BIO, V16, P245, DOI 10.1038/nrm3965; Qu D, 2019, NUCLEIC ACIDS RES, V47, P3013, DOI 10.1093/nar/gkz117; Rafati H, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001206; Raices M, 2017, CURR OPIN CELL BIOL, V46, P26, DOI 10.1016/j.ceb.2016.12.006; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Rodgers MJ, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-180; Rohr O, 2003, J LEUKOCYTE BIOL, V74, P736, DOI 10.1189/jlb.0403180; Romerio F, 1997, J VIROL, V71, P9375, DOI 10.1128/JVI.71.12.9375-9382.1997; Rouzine IM, 2015, CELL, V160, P1002, DOI 10.1016/j.cell.2015.02.017; Saayman S, 2014, MOL THER, V22, P1164, DOI 10.1038/mt.2014.29; Saha A, 2006, NAT REV MOL CELL BIO, V7, P437, DOI 10.1038/nrm1945; Sarracino A, 2017, CURR PHARM DESIGN, V23, P4103, DOI 10.2174/1381612823666170803102355; Sattentau QJ, 2016, CELL HOST MICROBE, V19, P304, DOI 10.1016/j.chom.2016.02.013; Sengupta S, 2018, IMMUNITY, V48, P872, DOI 10.1016/j.immuni.2018.04.030; Sharkey M, 2005, J VIROL, V79, P5203, DOI 10.1128/JVI.79.8.5203-5210.2005; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; Sharma AL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12091040; Sheffield NC, 2013, GENOME RES, V23, P777, DOI 10.1101/gr.152140.112; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Sloan RD, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-52; Soriano-Sarabia N, 2014, J VIROL, V88, P14070, DOI 10.1128/JVI.01900-14; Spivak AM, 2018, ANNU REV MED, V69, P421, DOI 10.1146/annurev-med-052716-031710; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 2013, NAT STRUCT MOL BIOL, V20, P267, DOI 10.1038/nsmb.2506; Sun GH, 2012, NUCLEIC ACIDS RES, V40, P2181, DOI 10.1093/nar/gkr961; Sun WW, 2018, MBIO, V9, DOI 10.1128/mBio.02408-17; Tan MJ, 2011, CELL, V146, P1015, DOI 10.1016/j.cell.2011.08.008; Taura M, 2019, P NATL ACAD SCI USA, V116, P2282, DOI 10.1073/pnas.1819386116; Thierry S., 2016, SCI REP-UK, V6, P1; Treand C, 2006, EMBO J, V25, P1690, DOI 10.1038/sj.emboj.7601074; Trejbalova K, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0185-6; Triboulet R, 2007, SCIENCE, V315, P1579, DOI 10.1126/science.1136319; Trojer P, 2007, MOL CELL, V28, P1, DOI 10.1016/j.molcel.2007.09.011; Tyagi M, 2007, EMBO J, V26, P4985, DOI 10.1038/sj.emboj.7601928; Van Duyne R, 2011, J MOL BIOL, V411, P581, DOI 10.1016/j.jmb.2011.06.001; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; Venkatesh S, 2015, NAT REV MOL CELL BIO, V16, P178, DOI 10.1038/nrm3941; Verdikt R, 2019, CURR OPIN VIROL, V38, P63, DOI 10.1016/j.coviro.2019.07.004; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; VERDIN E, 1991, J VIROL, V65, P6790, DOI 10.1128/JVI.65.12.6790-6799.1991; Wang H, 2020, J VIROL, V94, DOI 10.1128/JVI.01057-20; Weber S, 2014, VIROLOGY, V449, P181, DOI 10.1016/j.virol.2013.11.013; West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738; Williams SA, 2006, EMBO J, V25, P139, DOI 10.1038/sj.emboj.7600900; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Wong JK, 2016, CURR OPIN HIV AIDS, V11, P362, DOI 10.1097/COH.0000000000000293; Yurkovetskiy L, 2018, NAT MICROBIOL, V3, P1354, DOI 10.1038/s41564-018-0256-x; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zapata JC, 2017, VIROLOGY, V506, P34, DOI 10.1016/j.virol.2017.03.002; Zerbato JM, 2019, CLIN INFECT DIS, V69, P1919, DOI 10.1093/cid/ciz108; Zhang JS, 2013, J VIROL, V87, P7893, DOI 10.1128/JVI.00556-13; Zhang TY, 2015, EMBO REP, V16, P1467, DOI 10.15252/embr.201540945; Zhang Z, 2017, NUCLEIC ACIDS RES, V45, P9348, DOI 10.1093/nar/gkx550; Zhu H, 2016, NAT REV GENET, V17, P551, DOI 10.1038/nrg.2016.83; Zhu P, 2016, CURR OPIN STRUC BIOL, V36, P106, DOI 10.1016/j.sbi.2016.01.013; Zhu YP, 2018, NATURE, V564, P278, DOI 10.1038/s41586-018-0750-6	170	2	2	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							514	10.3390/vaccines9050514			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1OY	34067608	Green Published, gold			2022-04-29	WOS:000654596700001
J	Yendo, TM; Sato, MN; Branco, ACCC; Pietrobon, AJ; Teixeira, FME; Ramos, YAL; Alberca, RW; Valencio, CG; Arruda, VN; Romiti, R; Arnone, M; Hirayama, ALD; Duarte, AJD; Aoki, V; Orfali, RL				Yendo, Tatiana Mina; Sato, Maria Notomi; Branco, Anna Claudia Calvielli Castelo; Pietrobon, Anna Julia; Teixeira, Franciane Mouradian Emidio; Ramos, Yasmim alefe Leuzzi; Alberca, Ricardo Wesley; Valencio, Cesar Giudice; Arruda, Vivian Nunes; Romiti, Ricardo; Arnone, Marcelo; Hirayama, Andre Luis da Silva; Duarte, Alberto Jose da Silva; Aoki, Valeria; Orfali, Raquel Leao			Impact of Inflammatory Immune Dysfunction in Psoriasis Patients at Risk for COVID-19	VACCINES			English	Article						psoriasis; COVID-19; SARS-COV-2; IL-27; immune response; cytokines	INDUCTION; IL-27	Psoriasis is an immune-mediated dermatosis usually associated with comorbidities. Treatment varies from topicals to systemic drugs and data on susceptibility to viral infections in psoriatic patients are scarce. The objectives of this study were to analyze psoriatic patients on different therapies who were at risk for COVID-19 for seroprevalence of SARS-COV-2, pro-inflammatory cytokine profile, comorbidities and outcomes in order to unveil the immunological mechanisms involved in the anti-viral response in patients with psoriasis. Seventy-five patients with psoriasis were divided according to treatment: immunobiologics, methotrexate, topicals and acitretin. Twenty healthy controls were included. Plasma samples were collected for: IgG SARS-COV-2 (ELISA); IL-27, IL-29 and IL-18 (ELISA); and IL-1 beta, IL-17A, IL-6 and TNF (cytometric array). Seropositivity for SARS-COV-2 was detected in 24 out of 75 psoriasis patients and did not relate to COVID-19 symptoms and/or hospitalization, despite associated comorbidities. Psoriasis patients who were asymptomatic for SARS-COV-2 exhibited immune imbalance with high levels of IL-18, IL-17A and IL-6, and low levels of IL-27 compared to healthy controls. Psoriasis groups showed significant increased cytokine levels only in the group with immunobiologics. Despite immune deviations and lower IL-27, which has a potential antiviral impact, psoriatic patients did not exhibit complications related to COVID-19. An understanding of this kind of proinflammatory profile of psoriatic patients and of the lack of severe outcomes for COVID-19 is essential to establish novel therapeutic approaches and preventive measures, including with regard to the concomitance of viral infections.	[Yendo, Tatiana Mina; Sato, Maria Notomi; Valencio, Cesar Giudice; Arruda, Vivian Nunes; Romiti, Ricardo; Arnone, Marcelo; Hirayama, Andre Luis da Silva; Duarte, Alberto Jose da Silva; Aoki, Valeria; Orfali, Raquel Leao] Univ Sao Paulo, Fac Med, Dept Dermatol, BR-01246903 Sao Paulo, Brazil; [Sato, Maria Notomi; Branco, Anna Claudia Calvielli Castelo; Pietrobon, Anna Julia; Teixeira, Franciane Mouradian Emidio; Ramos, Yasmim alefe Leuzzi; Alberca, Ricardo Wesley; Duarte, Alberto Jose da Silva; Aoki, Valeria; Orfali, Raquel Leao] Univ Sao Paulo, Fac Med, Dept Dermatol, Lab Dermatol & Immunodeficiencies LIM 56, BR-01246903 Sao Paulo, Brazil		Orfali, RL (通讯作者)，Univ Sao Paulo, Fac Med, Dept Dermatol, BR-01246903 Sao Paulo, Brazil.; Orfali, RL (通讯作者)，Univ Sao Paulo, Fac Med, Dept Dermatol, Lab Dermatol & Immunodeficiencies LIM 56, BR-01246903 Sao Paulo, Brazil.	tatiana.yendo@hc.fm.usp.br; marisato@usp.br; annabranco@usp.br; pietrobonaj@usp.br; franciane.mteixeira@usp.br; yasmim.leuzzi@usp.br; ricardowesley@usp.br; cesar.valencio@hc.fm.usp.br; vivian.arruda@hc.fm.usp.br; r.romiti@hc.fm.usp.br; marcelo.arnone@hc.fm.usp.br; andre.hirayama@hc.fm.usp.br; alberto.duarte@hc.fm.usp.br; valeria.aoki@hc.fm.usp.br; raquelleao@usp.br	Alberca, Ricardo Wesley/D-9895-2016; Orfali, Raquel Leao/I-8890-2012; , Maria/C-1196-2012	Alberca, Ricardo Wesley/0000-0002-3602-3306; Orfali, Raquel Leao/0000-0002-2807-1404; Teixeira, Franciane Mouradian Emidio/0000-0001-5622-903X; , Maria/0000-0002-7911-1824	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2018/23211-0]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [88887.503842/2020-00]	This research was funded by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), grant #2018/23211-0, and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), grant #88887.503842/2020-00.	Armstrong AW, 2020, JAMA-J AM MED ASSOC, V323, P1945, DOI 10.1001/jama.2020.4006; Carl JW, 2008, INT J CLIN EXP PATHO, V1, P117; Deng YX, 2016, CLIN REV ALLERG IMMU, V50, P377, DOI 10.1007/s12016-016-8535-x; Elmas OF, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13858; Forouzandeh M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01238; Georgakopoulos JR, 2020, J AM ACAD DERMATOL, V83, P1212, DOI 10.1016/j.jaad.2020.07.021; Gisondi P, 2020, BRIT J DERMATOL, V183, P373, DOI 10.1111/bjd.19158; Cardoso PRG, 2016, EUR CYTOKINE NETW, V27, P1, DOI 10.1684/ecn.2016.0371; Handfield C, 2018, TRENDS IMMUNOL, V39, P328, DOI 10.1016/j.it.2018.02.003; Hawkes JE, 2018, J IMMUNOL, V201, P1605, DOI 10.4049/jimmunol.1800013; Inquerito Sorologico para SARS-COV-2, EVOLUCAO PREVALENCIA; Kwock JT, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay3245; Lario ARV, 2022, J DERMATOL TREAT, V33, P1185, DOI 10.1080/09546634.2020.1790485; Lew W, 2004, TRENDS IMMUNOL, V25, P295, DOI 10.1016/j.it.2004.03.006; Li BB, 2020, IMMUNOL RES, V68, P296, DOI 10.1007/s12026-020-09149-1; Lima XT, 2020, J EUR ACAD DERMATOL, V34, pE776, DOI 10.1111/jdv.16867; Mahil SK, 2021, J ALLERGY CLIN IMMUN, V147, P60, DOI 10.1016/j.jaci.2020.10.007; Morrow KN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01982; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Orfali R.L., 2008, DERMATITIS, V19, P218, DOI [10.1097/01206501-200807000-00042, DOI 10.1097/01206501-200807000-00042]; Owczarczyk-Saczonek A, 2017, POSTEP HIG MED DOSW, V71, P761; Radzikowska U, 2020, ALLERGY, V75, P2829, DOI 10.1111/all.14429; Rendon A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061475; Ricardo JW, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13687; Shibata S, 2010, J INVEST DERMATOL, V130, P1034, DOI 10.1038/jid.2009.349; Takian A, 2020, INT J PUBLIC HEALTH, V65, P521, DOI 10.1007/s00038-020-01398-z; Wang CL, 2020, AUSTRALAS J DERMATOL, V61, P210, DOI 10.1111/ajd.13313; Watanabe M, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3325; Wittmann M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038751; Wolk K, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006245; Yang B, 2017, J INVEST DERMATOL, V137, P1166, DOI 10.1016/j.jid.2017.01.010	31	1	1	4	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							478	10.3390/vaccines9050478			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1HF	34068473	gold, Green Published			2022-04-29	WOS:000654576500001
J	Zimmerman, DH; Mikecz, K; Markovics, A; Carambula, RE; Ciemielewski, JC; Toth, DM; Glant, TT; Rosenthal, KS				Zimmerman, Daniel H.; Mikecz, Katalin; Markovics, Adrienn; Carambula, Roy E.; Ciemielewski, Jason C.; Toth, Daniel M.; Glant, Tibor T.; Rosenthal, Ken S.			Vaccination by Two DerG LEAPS Conjugates Incorporating Distinct Proteoglycan (PG, Aggrecan) Epitopes Provides Therapy by Different Immune Mechanisms in a Mouse Model of Rheumatoid Arthritis	VACCINES			English	Article						peptide vaccine; immunotherapy; rheumatoid arthritis; Proteoglycan (PG, aggrecan); PG G1 domain-induced arthritis	BINDING-SITE; CELL EPITOPE; RESPONSES; TH1; VACCINES; LESSONS; MICE	Rheumatoid arthritis (RA) can be initiated and driven by immune responses to multiple antigenic epitopes including those in cartilage proteoglycan (PG, aggrecan) and type II collagen. RA is driven by T helper 1 (Th1) or Th17 pro-inflammatory T cell responses. LEAPS (Ligand Epitope Antigen Presentation System) DerG peptide conjugate vaccines were prepared using epitopes from PG that elicit immune responses in RA patients: epitope PG70 (DerG-PG70, also designated CEL-4000) and the citrullinated form of another epitope (PG275Cit). The LEAPS peptides were administered alone or together in Seppic ISA51vg adjuvant to mice with PG G1 domain-induced arthritis (GIA), a mouse model of RA. Each of these LEAPS peptides and the combination modulated the inflammatory response and stopped the progression of arthritis in the GIA mouse model. Despite having a therapeutic effect, the DerG-PG275Cit vaccine did not elicit significant antibody responses, whereas DerG-PG70 (alone or with DerG-PG275Cit) induced both therapy and antibodies. Spleen T cells from GIA mice, vaccinated with the DerG LEAPS peptides, preferentially produced anti-inflammatory (IL-4 and IL-10) rather than pro-inflammatory (IFN-gamma or IL-17) cytokines in culture. Similarly, cytokines secreted by CD4+ cells of unvaccinated GIA mice, differentiated in vitro to Th2 cells and treated with either or both DerG vaccine peptides, exhibited an anti-inflammatory (IL-4, IL-10) profile. These results suggest that the two peptides elicit different therapeutic immune responses by the immunomodulation of disease-promoting pro-inflammatory responses and that the combination of the two LEAPS conjugates may provide broader epitope coverage and, in some cases, greater efficacy than either conjugate alone.	[Zimmerman, Daniel H.; Carambula, Roy E.; Ciemielewski, Jason C.] CEL SCI Corp, 8229 Boone Blvd, Vienna, VA 22182 USA; [Mikecz, Katalin; Markovics, Adrienn; Toth, Daniel M.; Glant, Tibor T.] Rush Univ, Med Ctr, Dept Orthoped Surg, 1735 W Harrison St, Chicago, IL 60612 USA; [Toth, Daniel M.] Icahn Sch Med Mt Sinai, Dept Med, Div Rheumatol, 1468 Madison Ave, New York, NY 10029 USA; [Rosenthal, Ken S.] Augusta Univ, Univ Georgia Med Partnership, Dept Basic Med Sci, 1425 Prince Ave, Athens, GA 30602 USA		Zimmerman, DH (通讯作者)，CEL SCI Corp, 8229 Boone Blvd, Vienna, VA 22182 USA.	DZimmerman@cel-sci.com; Katalin_Mikecz@rush.edu; Adrienn_Markovics@rush.edu; RCarambula@cel-sci.com; JCiemielewski@cel-sci.com; Daniel.Toth@mssm.edu; Tibor_Glant@rush.edu; kenneth.rosenthal@uga.edu		Carambula, Roy/0000-0002-2693-0287; Ciemielewski, Jason/0000-0003-4847-9738	National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) of USA [R44 AR063504-02A1]; CEL-SCI Corporation; NIH/NIAMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01 AR064206, R01 AR062991]	Research reported in this publication was supported by the National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) of USA under award number R44 AR063504-02A1 for DH Zimmerman as well as by CEL-SCI Corporation; also supported under award numbers NIH/NIAMS R01 AR064206 and R01 AR062991 for K Mikecz at Rush University Medical Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, CEL-SCI Corporation or Rush University Medical Center. We also acknowledge the excellent work and report by Alison Bendele of Bolder Biopath).	Angelini J, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10071002; Boonnak K, 2013, J CLIN INVEST, V123, P2850, DOI 10.1172/JCI67550; Burisch J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233781; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; Cihakova D, 2008, INT IMMUNOPHARMACOL, V8, P624, DOI 10.1016/j.intimp.2008.01.004; Didona D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00779; Domingues HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015531; du Sert NP, 2020, EXP PHYSIOL, V105, P1459, DOI [10.1113/JP280389, 10.1111/bph.15193, 10.1113/EP088870, 10.1177/0271678X20943823, 10.1371/journal.pbio.3000410, 10.1371/journal.pbio.3000411]; Fragoulis GE, 2019, RHEUMATOLOGY, V58, P43, DOI 10.1093/rheumatology/key276; Giant TT, 2004, METH MOLEC MED, V102, P313; Glant TT, 2011, ARTHRITIS RHEUM-US, V63, P1312, DOI 10.1002/art.30261; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Kang SJ, 2019, IMMUNITY, V50, P1007, DOI 10.1016/j.immuni.2019.03.026; Khmaladze I, 2015, EUR J IMMUNOL, V45, P2243, DOI 10.1002/eji.201545518; Kidd BA, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2523; Ko E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246111; Kobezda T, 2014, NAT REV RHEUMATOL, V10, P160, DOI 10.1038/nrrheum.2013.205; KONIG R, 1995, J EXP MED, V182, P779, DOI 10.1084/jem.182.3.779; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; Kurko J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111815; Lubberts E, 2005, ARTHRITIS RES THER, V7, P29, DOI 10.1186/ar1478; Luckheeram RV, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/925135; Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258; Maresz KJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003627; Markovics A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160284; McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965; Mikecz K, 2017, VACCINE, V35, P4048, DOI 10.1016/j.vaccine.2017.05.009; Miller MC, 2009, ARTHRITIS RHEUM-US, V60, P686, DOI 10.1002/art.24331; Miller SA, 2009, IMMUNOLOGY, V126, P306, DOI 10.1111/j.1365-2567.2008.03040.x; Misjak P, 2013, IMMUNOL LETT, V152, P25, DOI 10.1016/j.imlet.2013.03.005; National Research Council of the National Academies, 2011, GUIDE CARE USE LAB A; PARHAM P, 1983, J BIOL CHEM, V258, P6179; Rafael-Vidal C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197100; Raimondo MG, 2017, DRUG DES DEV THER, V11, P1593, DOI 10.2147/DDDT.S100302; Rodeghero R, 2013, J IMMUNOL, V190, P5423, DOI 10.4049/jimmunol.1203045; Roncarolo MG, 2018, IMMUNITY, V49, P1004, DOI 10.1016/j.immuni.2018.12.001; Rosenthal KS, 2015, EXPERT REV VACCINES, V14, P891, DOI 10.1586/14760584.2015.1026330; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Senolt Ladislav, 2019, F1000Res, V8, DOI 10.12688/f1000research.18688.1; Shen XL, 1996, J IMMUNOL, V157, P87; Tanaka T, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028456; Taylor PR, 2010, VACCINE, V28, P5533, DOI 10.1016/j.vaccine.2010.06.043; Wang B, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/8060375; Yap HY, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7100161; Yu CS, 2018, BIOCONJUGATE CHEM, V29, P719, DOI 10.1021/acs.bioconjchem.7b00632; Yu M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14060-x; Zimmerman D.H., 2012, J VACCINES VACCIN, V3, DOI [10.4172/2157-7560.1000149, DOI 10.4172/2157-7560.1000149]; Zimmerman DH, 2010, INT IMMUNOPHARMACOL, V10, P412, DOI 10.1016/j.intimp.2009.12.016; Zou J, 2003, RHEUMATOLOGY, V42, P846, DOI 10.1093/rheumatology/keg230	49	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							448	10.3390/vaccines9050448			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1SJ	34063326	Green Published, gold			2022-04-29	WOS:000654605600001
J	de Vrij, N; Meysman, P; Gielis, S; Adriaensen, W; Laukens, K; Cuypers, B				de Vrij, Nicky; Meysman, Pieter; Gielis, Sofie; Adriaensen, Wim; Laukens, Kris; Cuypers, Bart			HLA-DRB1 Alleles Associated with Lower Leishmaniasis Susceptibility Share Common Amino Acid Polymorphisms and Epitope Binding Repertoires	VACCINES			English	Article						Leishmania; immunoinformatics; antigen presentation; HLA association; leishmaniasis; vaccine candidates; immunogenetics; human leukocyte antigen	VISCERAL LEISHMANIASIS; CLASS-I; HLA	Susceptibility for leishmaniasis is largely dependent on host genetic and immune factors. Despite the previously described association of human leukocyte antigen (HLA) gene cluster variants as genetic susceptibility factors for leishmaniasis, little is known regarding the mechanisms that underpin these associations. To better understand this underlying functionality, we first collected all known leishmaniasis-associated HLA variants in a thorough literature review. Next, we aligned and compared the protection- and risk-associated HLA-DRB1 allele sequences. This identified several amino acid polymorphisms that distinguish protection- from risk-associated HLA-DRB1 alleles. Subsequently, T cell epitope binding predictions were carried out across these alleles to map the impact of these polymorphisms on the epitope binding repertoires. For these predictions, we used epitopes derived from entire proteomes of multiple Leishmania species. Epitopes binding to protection-associated HLA-DRB1 alleles shared common binding core motifs, mapping to the identified HLA-DRB1 amino acid polymorphisms. These results strongly suggest that HLA polymorphism, resulting in differential antigen presentation, affects the association between HLA and leishmaniasis disease development. Finally, we established a valuable open-access resource of putative epitopes. A set of 14 HLA-unrestricted strong-binding epitopes, conserved across species, was prioritized for further epitope discovery in the search for novel subunit-based vaccines.	[de Vrij, Nicky; Meysman, Pieter; Gielis, Sofie; Laukens, Kris; Cuypers, Bart] Univ Antwerp, Dept Comp Sci, B-2020 Antwerp, Belgium; [de Vrij, Nicky; Adriaensen, Wim] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium; [de Vrij, Nicky; Meysman, Pieter; Gielis, Sofie; Laukens, Kris] Univ Antwerp, Antwerp Unit Data Anal & Computat Immunol & Seque, B-2020 Antwerp, Belgium; [de Vrij, Nicky; Meysman, Pieter; Gielis, Sofie; Laukens, Kris; Cuypers, Bart] Univ Antwerp, Biomed Informat Network Antwerpen Biomina, B-2020 Antwerp, Belgium; [Cuypers, Bart] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium		Laukens, K; Cuypers, B (通讯作者)，Univ Antwerp, Dept Comp Sci, B-2020 Antwerp, Belgium.; Laukens, K (通讯作者)，Univ Antwerp, Antwerp Unit Data Anal & Computat Immunol & Seque, B-2020 Antwerp, Belgium.; Laukens, K; Cuypers, B (通讯作者)，Univ Antwerp, Biomed Informat Network Antwerpen Biomina, B-2020 Antwerp, Belgium.; Cuypers, B (通讯作者)，Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium.	Nicky.deVrij@uantwerpen.be; pieter.meysman@uantwerpen.be; sofie.gielis@uantwerpen.be; wadriaensen@itg.be; kris.laukens@uantwerpen.be; bart.cuypers@uantwerpen.be	Meysman, Pieter/I-1891-2019; Cuypers, Bart/B-4853-2014	Meysman, Pieter/0000-0001-5903-633X; Cuypers, Bart/0000-0002-7198-1470; Adriaensen, Wim/0000-0002-9698-7449	Research Foundation FlandersFWO [1S71721N, 1S48819N, 11O1614N]	This work was supported by the Research Foundation Flanders [1S71721N to N.D.V., 1S48819N to S.G. and 11O1614N to B.C.]	Aebischer T, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00260; Akya A, 2019, INFECT GENET EVOL, V75, DOI 10.1016/j.meegid.2019.103953; Ali SA, 2009, PARASITE IMMUNOL, V31, P373, DOI 10.1111/j.1365-3024.2009.01111.x; Aliaga L, 2019, INFECTION, V47, P739, DOI 10.1007/s15010-019-01297-3; Alvar J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035671; ASLETT M, 2009, MOL SYST BIOL, V38, pD457, DOI DOI 10.1093/NAR/GKP851; Blackwell JM, 2020, HUM GENET, V139, P813, DOI 10.1007/s00439-020-02130-w; BONDINAS GP, 2007, PLOS MED, V59, P539, DOI DOI 10.1007/S00251-007-0224-8; BROWN JH, 1993, J IMMUNOL, V364, P33, DOI DOI 10.1038/364033A0; Cordeiro-Da-Silva A, 2001, INFECT IMMUN, V69, P6588, DOI 10.1128/IAI.69.11.6588-6596.2001; CUYPERS B, 2018, J IMMUNOL, V62, P170, DOI DOI 10.1016/J.MEEGID.2018.04.021; DEY A, 2008, IMMUNOGENETICS, V15, P836, DOI DOI 10.1128/CVI.00433-07; DIKHIT MR, 2018, INT IMMUNOL, V8, P14175, DOI DOI 10.1038/S41598-018-32040-X; DUMETZ F, 2017, BIOINFORMATICS, V8, DOI DOI 10.1128/MBIO.00599-17; El-Mogy Mohamed H., 1993, Journal of Dermatological Science, V5, P89, DOI 10.1016/0923-1811(93)90075-Z; ERLICH H, 2012, VACCINE, V80, P1, DOI DOI 10.1111/J.1399-0039.2012.01881.X; Escobar LE, 2016, SCI REP-UK, V6, DOI 10.1038/srep39150; FAGHIRI Z, 1995, PLOS PATHOG, V45, P258, DOI DOI 10.1159/000154309; Fakhar M, 2008, ANN TROP MED PARASIT, V102, P577, DOI 10.1179/136485908X337526; FAKIOLA M, 2013, J STAT SOFTW, V45, P208, DOI DOI 10.1038/NG.2518; Ferrante A, 2007, J IMMUNOL, V178, P7181, DOI 10.4049/jimmunol.178.11.7181; Gonzalez-Galarza FF, 2015, NUCLEIC ACIDS RES, V43, pD784, DOI 10.1093/nar/gku1166; Hamrouni S, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008093; Hollenbach Jill A, 2012, Methods Mol Biol, V882, P245, DOI 10.1007/978-1-61779-842-9_14; HOV JR, 2011, NATURE, V53, P1967, DOI DOI 10.1002/HEP.24299; HUSSAIN SK, 2016, GENET MOL RES, V100, P2453, DOI DOI 10.1097/TP.0000000000001025; James EA, 2009, J IMMUNOL, V183, P3249, DOI 10.4049/jimmunol.0802228; Kaye PM, 2020, SEMIN IMMUNOPATHOL, V42, P247, DOI 10.1007/s00281-020-00788-y; Kholoud K, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15071542; KUZNETSOVA A, 2017, FRONT IMMUNOL, V82, P26, DOI DOI 10.18637/JSS.V082.I13; LARA ML, 1991, BIOINFORMATICS, V30, P129, DOI DOI 10.1016/0198-8859(91)90081-J; MEYSMAN P, 2018, HEPATOLOGY, V70, P363, DOI DOI 10.1007/S00251-017-1047-X; Meysman P, 2015, J VIROL, V89, P962, DOI 10.1128/JVI.02500-14; Murray HW, 2005, LANCET, V366, P1561, DOI 10.1016/S0140-6736(05)67629-5; Nielsen M, 2020, ANNU REV BIOMED DA S, V3, P191, DOI 10.1146/annurev-biodatasci-021920-100259; Olivo-Diaz A, 2004, HUM IMMUNOL, V65, P255, DOI 10.1016/j.humimm.2003.12.008; PAUL S, 2018, NUCLEIC ACIDS RES, V9, P1795, DOI DOI 10.3389/FIMMU.2018.01795; PETZLERLER ML, 1991, HUM IMMUNOL, V32, P254, DOI 10.1016/0198-8859(91)90088-Q; RAYCHAUDHURI S, 2012, J IMMUNOL, V44, P291, DOI DOI 10.1038/NG.1076; REYNISSON B, 2020, MBIO, V48, pW449, DOI DOI 10.1093/NAR/GKAA379; REZVAN H, 2013, SCI REP-UK, V8, P273; RIBASSILVA RC, 2015, HUM HERED, V14, P14929, DOI DOI 10.4238/2015.NOVEMBER.18.58; Robinson J, 2020, NUCLEIC ACIDS RES, V48, pD948, DOI 10.1093/nar/gkz950; ROSSI M, 2017, CURR OPIN IMMUNOL, V30, P103, DOI DOI 10.1093/INTIMM/DXX075; Samaranayake N, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1626-8; SEMENZA JC, 2018, FEMS MICROBIOL LETT, V365, DOI DOI 10.1093/FEMSLE/FNX244; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Sidney J, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101418; SIEVERS F, 2011, INT J SURG, V7, P539, DOI DOI 10.1038/MSB.2011.75; Silva LP, 2020, PARASITE IMMUNOL, V42, DOI 10.1111/pim.12780; Singh G, 2020, COMPUT BIOL CHEM, V86, DOI 10.1016/j.compbiolchem.2020.107259; Singh T, 2018, J IMMUNOL, V200, P2727, DOI 10.4049/jimmunol.1701764; SOLLID LM, 2014, NAT GENET, V31, P24, DOI DOI 10.1016/J.COI.2014.08.005; STOBER CB, 2006, PARASITE IMMUNOL, V24, P2602, DOI DOI 10.1016/J.VACCINE.2005.12.012; Torres-Guerrero Edoardo, 2017, F1000Res, V6, P750, DOI 10.12688/f1000research.11120.1; Tripathi P, 2007, FEMS IMMUNOL MED MIC, V51, P229, DOI 10.1111/j.1574-695X.2007.00311.x; TROLLE T, 2016, NUCLEIC ACIDS RES, V196, P1480, DOI DOI 10.4049/JIMMUNOL.1501721; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; WAGIH O, 2017, INFECT GENET EVOL, V33, P3645, DOI DOI 10.1093/BIOINFORMATICS/BTX469; WATERHOUSE AM, 2009, IMMUNOGENETICS, V25, P1189, DOI DOI 10.1093/BIOINFORMATICS/BTP033; WHO, 2018, SURV LEISHM WHO EUR, V40, P521; ZHANG WW, 2014, NAT GENET, V10, DOI DOI 10.1371/JOURNAL.PPAT.1004244	62	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							270	10.3390/vaccines9030270			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5CJ	33803005	gold, Green Published			2022-04-29	WOS:000634171700001
J	Kis, Z; Kontoravdi, C; Shattock, R; Shah, NI				Kis, Zoltan; Kontoravdi, Cleo; Shattock, Robin; Shah, Nilay			Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand (vol 9, 3, 2021)	VACCINES			English	Correction									[Kis, Zoltan; Kontoravdi, Cleo; Shah, Nilay] Imperial Coll London, Fac Engn, Dept Chem Engn, Ctr Proc Syst Engn, London SW7 2AZ, England; [Shattock, Robin] Imperial Coll London, Fac Med, Dept Infect Dis, London W2 1PG, England		Kis, Z (通讯作者)，Imperial Coll London, Fac Engn, Dept Chem Engn, Ctr Proc Syst Engn, London SW7 2AZ, England.	z.kis10@imperial.ac.uk; cleo.kontoravdi98@imperial.ac.uk; r.shattock@imperial.ac.uk; n.shah@imperial.ac.uk	; Kis, Zoltan/H-3611-2016	Kontoravdi, Cleo/0000-0003-0213-4830; Kis, Zoltan/0000-0002-6598-8369			Kis Z, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010003	1	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							205	10.3390/vaccines9030205			1	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE4YB		Green Published, gold			2022-04-29	WOS:000634160500001
J	Lebeau, G; Frumence, E; Turpin, J; Begue, F; Hoarau, JJ; Gadea, G; Krejbich-Trotot, P; Despres, P; Viranaicken, W				Lebeau, Gregorie; Frumence, Etienne; Turpin, Jonathan; Begue, Floran; Hoarau, Jean-Jacques; Gadea, Gilles; Krejbich-Trotot, Pascale; Despres, Philippe; Viranaicken, Wildriss			Zika E Glycan Loop Region and Guillain-Barre Syndrome-Related Proteins: A Possible Molecular Mimicry to Be Taken in Account for Vaccine Development	VACCINES			English	Article						ZIKV; Guillain-Barre syndrome; molecular mimicry; calcium channel voltage dependent; heat shock protein; vaccine		The neurological complications of infection by the mosquito-borne Zika virus (ZIKV) include Guillain-Barre syndrome (GBS), an acute inflammatory demyelinating polyneuritis. GBS was first associated with recent ZIKV epidemics caused by the emergence of the ZIKV Asian lineage in South Pacific. Here, we hypothesize that ZIKV-associated GBS relates to a molecular mimicry between viral envelope E (E) protein and neural proteins involved in GBS. The analysis of the ZIKV epidemic strains showed that the glycan loop (GL) region of the E protein includes an IVNDT motif which is conserved in voltage-dependent L-type calcium channel subunit alpha-1C (Ca(v)1.2) and Heat Shock 70 kDa protein 12A (HSP70 12A). Both VSCC-alpha 1C and HSP70 12A belong to protein families which have been associated with neurological autoimmune diseases in central nervous system. The purpose of our in silico analysis is to point out that IVNDT motif of ZIKV E-GL region should be taken in consideration for the development of safe and effective anti-Zika vaccines by precluding the possibility of adverse neurologic events including autoimmune diseases such as GBS through a potent mimicry with Heat Shock 70 kDa protein 12A (HSP70 12A).	[Lebeau, Gregorie; Frumence, Etienne; Turpin, Jonathan; Hoarau, Jean-Jacques; Gadea, Gilles; Krejbich-Trotot, Pascale; Despres, Philippe; Viranaicken, Wildriss] Univ La Reunion 1, Proc Infect Milieu Insulaire & Trop PIMIT, F-97490 St Clotilde, Reunion, France; [Begue, Floran] Univ La Reunion 1, INSERM, UMR Diabete Atherothombose Reunion Ocean Indien D, F-97490 St Clotilde, Reunion, France		Viranaicken, W (通讯作者)，Univ La Reunion 1, Proc Infect Milieu Insulaire & Trop PIMIT, F-97490 St Clotilde, Reunion, France.	greg.lebeau@live.fr; Etienne.frum@gmail.com; jonathan.turpin@univ-reunion.fr; begue.floran@hotmail.fr; jean-jacques.hoarau@univ-reunion.fr; gilles.gadea@inserm.fr; pascale.krejbich@univ-reunion.fr; philippe.despres@univ-reunion.fr; wildriss.viranaicken@univ-reunion.fr		viranaicken, wildriss/0000-0002-0915-8635; Lebeau, Gregorie/0000-0002-9664-3486; HOARAU, Jean-Jacques/0000-0002-7612-2018; Krejbich Trotot, Pascale/0000-0001-7329-1716; Gilles, Gadea/0000-0001-6325-4866; TURPIN, Jonathan/0000-0003-2667-345X	INSERM-transfert (ZIKALIVax program, CoPoC) [MAT-16225-A-02]; POE FEDER 2014-20 of the Conseil Regional de La Reunion (ZIKAlert program) [SYNERGIE RE00001902]; FEDER Region (ZIKALIVax 2.0 program) [SYNERGIE RE0012406]; La Reunion University	This work was supported by grants from INSERM-transfert (ZIKALIVax program, CoPoC No MAT-16225-A-02) and POE FEDER 2014-20 of the Conseil Regional de La Reunion (ZIKAlert program, No SYNERGIE RE00001902). EF received funding from FEDER Region (ZIKALIVax 2.0 program, No SYNERGIE RE0012406) and La Reunion University.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ang CW, 2004, TRENDS IMMUNOL, V25, P61, DOI 10.1016/j.it.2003.12.004; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Barbi L, 2018, BRAZ J INFECT DIS, V22, P137, DOI 10.1016/j.bjid.2018.02.005; Barzan R, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00135; Berger S, 2014, CELL TISSUE RES, V357, P463, DOI 10.1007/s00441-014-1936-3; Bos S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111444; Bos S, 2018, VIROLOGY, V516, P265, DOI 10.1016/j.virol.2017.12.003; Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412; Calvet G, 2016, LANCET INFECT DIS, V16, P653, DOI 10.1016/S1473-3099(16)00095-5; Frumence E, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12111258; Frumence E, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020055; Gubler DJ, 2002, ARCH MED RES, V33, P330, DOI 10.1016/S0188-4409(02)00378-8; Helgeland G, 2010, J NEUROIMMUNOL, V225, P180, DOI 10.1016/j.jneuroim.2010.04.024; Hotta S, 2015, EXP THER MED, V10, P535, DOI 10.3892/etm.2015.2575; Kohm AP, 2003, TRENDS MICROBIOL, V11, P101, DOI 10.1016/S0966-842X(03)00006-4; Krauer F, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002203; Kucukural A, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-018-5362-x; Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329; Li G, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020157; Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651; Munoz LS, 2016, SEMIN REPROD MED, V34, P273, DOI 10.1055/s-0036-1592066; Murshid A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00063; Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15; Musso D, 2015, EMERG INFECT DIS, V21, P359, DOI 10.3201/eid2102.141363; Nakatani Y, 2009, NEUROCHEM RES, V34, P149, DOI 10.1007/s11064-008-9735-4; Oster AM, 2016, MMWR-MORBID MORTAL W, V65, P323, DOI 10.15585/mmwr.mm6512e3; Radons J, 2016, CELL STRESS CHAPERON, V21, P379, DOI 10.1007/s12192-016-0676-6; Romi F, 2011, EUR NEUROL, V66, P65, DOI 10.1159/000329373; Saiz JC, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00496; Sanchez-San Martin C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32400-7; Song BH, 2017, J NEUROIMMUNOL, V308, P50, DOI 10.1016/j.jneuroim.2017.03.001; Striessnig J, 2006, BIOCHEM SOC T, V34, P903, DOI 10.1042/BST0340903; Yonekura K, 2004, J NEUROIMMUNOL, V156, P204, DOI 10.1016/j.jneuroim.2004.07.017; Yuki N, 2001, Lancet Infect Dis, V1, P29	35	3	3	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							283	10.3390/vaccines9030283			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5WR	33808706	Green Published, gold, Green Submitted			2022-04-29	WOS:000634224500001
J	Schreur, PJW; Tacken, M; Gutjahr, B; Keller, M; van Keulen, L; Kant, J; van de Water, S; Lin, YN; Eiden, M; Rissmann, M; von Arnim, F; Konig, R; Brix, A; Charreyre, C; Audonnet, JC; Groschup, MH; Kortekaas, J				Wichgers Schreur, Paul J.; Tacken, Mirriam; Gutjahr, Benjamin; Keller, Markus; van Keulen, Lucien; Kant, Jet; van de Water, Sandra; Lin, Yanyin; Eiden, Martin; Rissmann, Melanie; von Arnim, Felicitas; Koenig, Rebecca; Brix, Alexander; Charreyre, Catherine; Audonnet, Jean-Christophe; Groschup, Martin H.; Kortekaas, Jeroen			Vaccine Efficacy of Self-Assembled Multimeric Protein Scaffold Particles Displaying the Glycoprotein Gn Head Domain of Rift Valley Fever Virus	VACCINES			English	Article						Rift Valley fever virus; bacterial superglue; multimeric protein scaffold particles; sheep; Gn head domain		Compared to free antigens, antigens immobilized on scaffolds, such as nanoparticles, generally show improved immunogenicity. Conventionally, antigens are conjugated to scaffolds through genetic fusion or chemical conjugation, which may result in impaired assembly or heterogeneous binding and orientation of the antigens. By combining two emerging technologies-i.e., self-assembling multimeric protein scaffold particles (MPSPs) and bacterial superglue-these short-comings can be overcome and antigens can be bound on particles in their native conformation. In the present work, we assessed whether this technology could improve the immunogenicity of a candidate subunit vaccine against the zoonotic Rift Valley fever virus (RVFV). For this, the head domain of glycoprotein Gn, a known target of neutralizing antibodies, was coupled on various MPSPs to further assess immunogenicity and efficacy in vivo. The results showed that the Gn head domain, when bound to the lumazine synthase-based MPSP, reduced mortality in a lethal mouse model and protected lambs, the most susceptible RVFV target animals, from viremia and clinical signs after immunization. Furthermore, the same subunit coupled to two other MPSPs (Geobacillus stearothermophilus E2 or a modified KDPG Aldolase) provided full protection in lambs as well.	[Wichgers Schreur, Paul J.; Tacken, Mirriam; van Keulen, Lucien; Kant, Jet; van de Water, Sandra; Lin, Yanyin; Kortekaas, Jeroen] Wageningen Biovet Res, Dept Virol, NL-8221 RA Lelystad, Netherlands; [Gutjahr, Benjamin; Keller, Markus; Eiden, Martin; Rissmann, Melanie; von Arnim, Felicitas; Koenig, Rebecca; Groschup, Martin H.] Friedrich Loeffler Inst, Inst Novel & Emerging Infect Dis, D-17493 Greifswald Insel Riems, Germany; [Brix, Alexander] Boehringer Ingelheim Vet Res Ctr GmbH & Co KG, D-30559 Hannover, Germany; [Charreyre, Catherine; Audonnet, Jean-Christophe] Boehringer Ingelheim GmbH & Co KG, F-69007 Lyon, France; [Kortekaas, Jeroen] Wageningen Univ & Res, Lab Virol, NL-6708 PB Wageningen, Netherlands; [Rissmann, Melanie] Erasmus MC, Dept Virosci, NL-3015 CN Rotterdam, Netherlands		Schreur, PJW (通讯作者)，Wageningen Biovet Res, Dept Virol, NL-8221 RA Lelystad, Netherlands.	paul.wichgersschreur@wur.nl; mirriam.tacken@wur.nl; Benjamin.Gutjahr@fli.de; markus.keller@fli.de; lucien.vankeulen@wur.nl; jet.kant@wur.nl; sandra.vandewater@wur.nl; yanyin.lin@hotmail.com; Martin.Eiden@fli.de; Melanie.Rissmann@fli.de; felicitas.var@mail.de; rebecca.j.koenig@gmail.com; alexander.brix@boehringer-ingelheim.com; catherine.charreyre@boehringer-ingelheim.com; Jean-Christophe.AUDONNET@boehringer-ingelheim.com; Martin.Groschup@fli.de; jeroen.kortekaas@wur.nl	Rissmann, Melanie/AAZ-6477-2021	Groschup, Martin H./0000-0003-0215-185X; Eiden, Martin/0000-0002-1197-8288; Kortekaas, Jeroen/0000-0002-0329-0176; Wichgers Schreur, Paul/0000-0001-9790-2438; Rissmann, Melanie/0000-0002-5298-5919	Zoonotic Anticipation and Preparedness Initiative (ZAPI project; IMI Grant Agreement) [115760]; IMI; European CommissionEuropean CommissionEuropean Commission Joint Research Centre	This study was performed as part of the Zoonotic Anticipation and Preparedness Initiative (ZAPI project; IMI Grant Agreement no. 115760), with the assistance and financial support of IMI and the European Commission, and in-kind contributions from EFPIA partners. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.	Allen ER, 2018, CELL REP, V25, P3750, DOI 10.1016/j.celrep.2018.12.001; Antonis AFG, 2013, VECTOR-BORNE ZOONOT, V13, P601, DOI 10.1089/vbz.2012.1160; Bhardwaj N, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000725; Brune KD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01432; Brune KD, 2016, SCI REP-UK, V6, DOI 10.1038/srep19234; Butkovich N, 2021, WIRES NANOMED NANOBI, V13, DOI 10.1002/wnan.1681; Caivano A, 2010, VIROLOGY, V407, P296, DOI 10.1016/j.virol.2010.08.026; Chrun T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00860; Cruz FM, 2017, ANNU REV IMMUNOL, V35, P149, DOI 10.1146/annurev-immunol-041015-055254; Dalmau M, 2008, BIOTECHNOL BIOENG, V101, P654, DOI 10.1002/bit.21988; de Boer SM, 2010, VACCINE, V28, P2330, DOI 10.1016/j.vaccine.2009.12.062; Escolano A, 2019, NATURE, V570, P468, DOI 10.1038/s41586-019-1250-z; Gomes AC, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5010006; Halldorsson S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02789-2; Hao M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030259; Herzik MA, 2017, NAT METHODS, V14, P1075, DOI [10.1038/NMETH.4461, 10.1038/nmeth.4461]; Hsia Y, 2016, NATURE, V535, P136, DOI 10.1038/nature18010; Janitzek CM, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1574-1; Kading RC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002670; Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202; Kelly HG, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136653; Kortekaas J, 2012, VACCINE, V30, P3423, DOI 10.1016/j.vaccine.2012.03.027; Kortekaas J, 2010, VACCINE, V28, P4394, DOI 10.1016/j.vaccine.2010.04.048; Kortekaas J, 2010, VACCINE, V28, P2271, DOI 10.1016/j.vaccine.2010.01.001; Kortekaas J, 2011, J VIROL, V85, P12622, DOI 10.1128/JVI.00841-11; Kreher F, 2014, EMERG MICROBES INFEC, V3, DOI 10.1038/emi.2014.71; Ladenstein Rudolf, 2020, Biotechnology Reports, V27, pe00494, DOI 10.1016/j.btre.2020.e00494; Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046; Pati R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02224; Sasaki E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14663; Schreur PJW, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00212-4; Schreur PJW, 2020, ELIFE, V9, DOI 10.7554/eLife.52716; Schreur PJW, 2017, J VIROL METHODS, V248, P26, DOI 10.1016/j.jviromet.2017.06.001; Schreur PJW, 2015, VACCINE, V33, P1459, DOI 10.1016/j.vaccine.2015.01.077; Schreur PJW, 2014, J VIROL, V88, P10883, DOI 10.1128/JVI.00961-14; Singh B, 2016, CRIT REV BIOTECHNOL, V36, P59, DOI 10.3109/07388551.2014.923985; Terasaki K, 2013, J VIROL, V87, P676, DOI 10.1128/JVI.02192-12; Thrane S, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0181-1; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; Veggiani G, 2014, TRENDS BIOTECHNOL, V32, P506, DOI 10.1016/j.tibtech.2014.08.001; Wang QH, 2019, NAT MICROBIOL, V4, P1231, DOI 10.1038/s41564-019-0411-z; Wang WJ, 2019, NANOMED-NANOTECHNOL, V16, P69, DOI 10.1016/j.nano.2018.11.009; Warimwe GM, 2016, SCI REP-UK, V6, DOI 10.1038/srep20617; Won SY, 2007, J VIROL, V81, P13335, DOI 10.1128/JVI.01238-07; Wu Y, 2017, P NATL ACAD SCI USA, V114, pE7564, DOI 10.1073/pnas.1705176114; Wuerth JD, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060174; Zakeri B, 2012, P NATL ACAD SCI USA, V109, pE690, DOI 10.1073/pnas.1115485109; Zhang BS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74949-2	48	4	4	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							301	10.3390/vaccines9030301			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5PT	33806789	Green Published, gold			2022-04-29	WOS:000634206500001
J	Han, JY; Ma, YL; Ma, L; Tan, DQ; Niu, HX; Bai, CX; Mi, YJ; Xie, T; Lv, W; Wang, J; Zhu, BD				Han, Jiangyuan; Ma, Yanlin; Ma, Lan; Tan, Daquan; Niu, Hongxia; Bai, Chunxiang; Mi, Youjun; Xie, Tao; Lv, Wei; Wang, Juan; Zhu, Bingdong			Id3 and Bcl6 Promote the Development of Long-Term Immune Memory Induced by Tuberculosis Subunit Vaccine	VACCINES			English	Article						IL-7; Bcl6; Id3; immune memory; vaccine		Long-lived memory cell formation and maintenance are usually regulated by cytokines and transcriptional factors. Adjuvant effects of IL-7 have been studied in the vaccines of influenza and other pathogens. However, few studies investigated the adjuvant effects of cytokines and transcriptional factors in prolonging the immune memory induced by a tuberculosis (TB) subunit vaccine. To address this research gap, mice were treated with the Mycobacterium tuberculosis (M. tuberculosis) subunit vaccine Mtb10.4-HspX (MH) plus ESAT6-Ag85B-MPT64-Mtb8.4-Rv2626c (LT70), together with adeno-associated virus-mediated IL-7 or lentivirus-mediated transcriptional factor Id3, Bcl6, Bach2, and Blimp1 at 0, 2, and 4 weeks, respectively. Immune responses induced by the vaccine were examined at 25 weeks after last immunization. The results showed that adeno-associated virus-mediated IL-7 allowed the TB subunit vaccine to induce the formation of long-lived memory T cells. Meanwhile, IL-7 increased the expression of Id3, Bcl6, and bach2-the three key transcription factors for the generation of long-lived memory T cells. The adjuvant effects of transcriptional factors, together with TB fusion protein MH/LT70 vaccination, showed that both Bcl6 and Id3 increased the production of antigen-specific antibodies and long-lived memory T cells, characterized by high proliferative potential of antigen-specific CD4(+) and CD8(+) T cells, and IFN-gamma secretion in CD4(+) and CD8(+) T cells, respectively, after re-exposure to the same antigen. Overall, our study suggests that IL-7 and transcriptional factors Id3 and Bcl6 help the TB subunit vaccine to induce long-term immune memory, which contributes to providing immune protection against M. tuberculosis infection.	[Han, Jiangyuan; Ma, Yanlin; Ma, Lan; Tan, Daquan; Niu, Hongxia; Bai, Chunxiang; Mi, Youjun; Xie, Tao; Lv, Wei; Wang, Juan; Zhu, Bingdong] Lanzhou Univ, Sch Basic Med Sci, Gansu Prov Key Lab Evidence Based Med & Clin Tran, Lanzhou 730000, Peoples R China; [Han, Jiangyuan; Ma, Yanlin; Ma, Lan; Tan, Daquan; Niu, Hongxia; Bai, Chunxiang; Mi, Youjun; Xie, Tao; Lv, Wei; Wang, Juan; Zhu, Bingdong] Lanzhou Univ, Sch Basic Med Sci, Lanzhou Ctr TB Res, Lanzhou 730000, Peoples R China; [Han, Jiangyuan; Ma, Yanlin; Ma, Lan; Tan, Daquan; Niu, Hongxia; Bai, Chunxiang; Xie, Tao; Lv, Wei; Wang, Juan; Zhu, Bingdong] Lanzhou Univ, Sch Basic Med Sci, Inst Pathogen Biol, Lanzhou 730000, Peoples R China; [Mi, Youjun] Lanzhou Univ, Sch Basic Med Sci, Inst Pathophysiol, Lanzhou 730000, Peoples R China		Zhu, BD (通讯作者)，Lanzhou Univ, Sch Basic Med Sci, Gansu Prov Key Lab Evidence Based Med & Clin Tran, Lanzhou 730000, Peoples R China.; Zhu, BD (通讯作者)，Lanzhou Univ, Sch Basic Med Sci, Lanzhou Ctr TB Res, Lanzhou 730000, Peoples R China.; Zhu, BD (通讯作者)，Lanzhou Univ, Sch Basic Med Sci, Inst Pathogen Biol, Lanzhou 730000, Peoples R China.	hanjy17@lzu.edu.cn; myl19960701@163.com; hanjy14@lzu.edu.cn; tandaquan@163.com; niuhongxia1985@163.com; baichx13@lzu.edu.cn; miyoujun@126.com; xiet18@lzu.edu.cn; lvw18@lzu.edu.cn; wangj19@lzu.edu.cn; bdzhu@lzu.edu.cn		Niu, Hongxia/0000-0001-5367-3813; , Bingdong/0000-0001-8422-4594; Mi, Youjun/0000-0002-9878-8179; , daquan/0000-0001-5035-8105	National Major Science and Technology Projects of China [2018ZX10731301-004-004, 2018ZX10302302002-003]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31470895]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [lzujbky-2018-85]	This research was funded by the National Major Science and Technology Projects of China, grant numbers 2018ZX10731301-004-004, 2018ZX10302302002-003 and the National Natural Science Foundation of China, grant number 31470895 and the Fundamental Research Funds for the Central Universities, grant number lzujbky-2018-85.	Ahmad S, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00291-19; Bai CX, 2018, TUBERCULOSIS, V110, P104, DOI 10.1016/j.tube.2018.04.006; Billeskov R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039909; Chen SW, 2016, MOL CELL BIOL, V36, P2543, DOI 10.1128/MCB.00150-16; Chen Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02826; Clark MR, 2014, NAT REV IMMUNOL, V14, P69, DOI 10.1038/nri3570; Colombetti S, 2009, BLOOD, V113, P6629, DOI 10.1182/blood-2008-05-155309; Diao Huitian, 2019, F1000Res, V8, DOI 10.12688/f1000research.18211.1; Dintwe OB, 2013, EUR J IMMUNOL, V43, P2409, DOI 10.1002/eji.201343454; Geng JL, 2019, J IMMUNOL, V202, P2991, DOI 10.4049/jimmunol.1801626; Hu GN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3830; Ichii H, 2004, J IMMUNOL, V173, P883, DOI 10.4049/jimmunol.173.2.883; Ji Y, 2011, NAT IMMUNOL, V12, P1230, DOI 10.1038/ni.2153; Kaji T, 2016, INT IMMUNOL, V28, P267, DOI 10.1093/intimm/dxv071; Kallies A, 2009, IMMUNITY, V31, P283, DOI 10.1016/j.immuni.2009.06.021; Knop L, 2020, EUR J IMMUNOL, V50, P846, DOI 10.1002/eji.201948368; Kometani K, 2013, IMMUNITY, V39, P136, DOI 10.1016/j.immuni.2013.06.011; Kondrack RM, 2003, J EXP MED, V198, P1797, DOI 10.1084/jem.20030735; Kuo TC, 2007, J EXP MED, V204, P819, DOI 10.1084/jem.20062104; Lenz DC, 2004, P NATL ACAD SCI USA, V101, P9357, DOI 10.1073/pnas.0400640101; Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592; Linterman MA, 2010, J EXP MED, V207, P353, DOI 10.1084/jem.20091738; Liu X, 2016, HUM VACC IMMUNOTHER, V12, P1670, DOI 10.1080/21645515.2016.1141159; Liu ZY, 2019, J IMMUNOL, V203, P323, DOI 10.4049/jimmunol.1900014; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; McHeyzer-Williams M, 2012, NAT REV IMMUNOL, V12, P24, DOI 10.1038/nri3128; Melchionda F, 2005, J CLIN INVEST, V115, P1177, DOI 10.1172/JCI200523134; Mueller SN, 2013, ANNU REV IMMUNOL, V31, P137, DOI 10.1146/annurev-immunol-032712-095954; Nanjappa SG, 2008, J CLIN INVEST, V118, P1027, DOI 10.1172/JCI32020; Niu HX, 2011, VACCINE, V29, P9451, DOI 10.1016/j.vaccine.2011.10.032; Orme IM, 2010, TUBERCULOSIS, V90, P329, DOI 10.1016/j.tube.2010.06.002; Restifo NP, 2013, CURR OPIN IMMUNOL, V25, P556, DOI 10.1016/j.coi.2013.09.003; Rutishauser RL, 2009, IMMUNITY, V31, P296, DOI 10.1016/j.immuni.2009.05.014; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Santoro F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01248; Seo YB, 2014, J VIROL, V88, P8998, DOI 10.1128/JVI.00534-14; Sidwell T, 2016, NAT IMMUNOL, V17, P744, DOI 10.1038/ni.3493; Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; Xin A, 2016, NAT IMMUNOL, V17, P422, DOI 10.1038/ni.3410; Xin Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072745; Xu L, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0214-5; Yang CY, 2011, NAT IMMUNOL, V12, P1221, DOI 10.1038/ni.2158; Yu YM, 2009, J IMMUNOL METHODS, V350, P29, DOI 10.1016/j.jim.2009.07.008	45	2	2	1	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							126	10.3390/vaccines9020126			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6VA	33562631	Green Published			2022-04-29	WOS:000623278000001
J	Mintz, J; Vedenko, A; Rosete, O; Shah, K; Goldstein, G; Hare, JM; Ramasamy, R; Arora, H				Mintz, Joel; Vedenko, Anastasia; Rosete, Omar; Shah, Khushi; Goldstein, Gabriella; Hare, Joshua M.; Ramasamy, Ranjith; Arora, Himanshu			Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics	VACCINES			English	Review						immunotherapy; nitric oxide; prostate cancer; castration; checkpoint inhibitors	NF-KAPPA-B; SOLUBLE GUANYLATE-CYCLASE; CELL LUNG-CANCER; RANDOMIZED PHASE-II; MONOCYTE-DERIVED MACROPHAGES; PROGESTERONE-RECEPTOR STATUS; TUMOR-ASSOCIATED MACROPHAGES; PROTEIN S-NITROSYLATION; PREDICTS POOR SURVIVAL; GROWTH FACTOR-C	Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumorigenic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the level of production, the oxidative/reductive (redox) environment in which this radical is generated, the presence or absence of NO transduction elements, and the tumor microenvironment. Generally, there are four major categories of NO-based anticancer therapies: NO donors, phosphodiesterase inhibitors (PDE-i), soluble guanylyl cyclase (sGC) activators, and immunomodulators. Of these, NO donors are well studied, well characterized, and also the most promising. In this study, we review the current knowledge in this area, with an emphasis placed on the role of NO as an anticancer therapy and dysregulated molecular interactions during the evolution of cancer, highlighting the strategies that may aid in the targeting of cancer.	[Mintz, Joel] Nova Southeastern Univ, Dr Kiran C Patel Coll Allopath Med, Davie, FL 33328 USA; [Vedenko, Anastasia; Hare, Joshua M.; Arora, Himanshu] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA; [Rosete, Omar; Ramasamy, Ranjith; Arora, Himanshu] Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA; [Shah, Khushi] Univ Miami, Coll Arts & Sci, Miami, FL 33146 USA; [Goldstein, Gabriella] Univ Cent Florida, Coll Hlth Profess & Sci, Orlando, FL 32816 USA; [Hare, Joshua M.; Ramasamy, Ranjith; Arora, Himanshu] Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33136 USA; [Hare, Joshua M.] Univ Miami, Miller Sch Med, Dept Med, Cardiol Div, Miami, FL 33136 USA		Arora, H (通讯作者)，Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA.; Ramasamy, R; Arora, H (通讯作者)，Univ Miami, Miller Sch Med, Dept Urol, Miami, FL 33136 USA.; Ramasamy, R; Arora, H (通讯作者)，Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33136 USA.	jm4719@mynsu.nova.edu; axv492@miami.edu; ojrosete@med.miami.edu; khs55@miami.edu; gabigoldstein98@gmail.com; JHare@med.miami.edu; Ramasamy@miami.edu; Hxa287@miami.edu		Shah, Khushi/0000-0003-2879-3607; Rosete, Omar/0000-0002-7735-5390; Goldstein, Gabriella/0000-0002-3412-7224	American Urological Association Research Scholar Award; American Cancer SocietyAmerican Cancer Society; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01 HL137355, 1R01 HL107110, 1R01 HL134558, 5R01 CA136387, 5UM1 HL113460]; Soffer Family Foundation	We would like to thank the American Urological Association Research Scholar Award for H.A. and the American Cancer Society for R.R. J.M.H. is supported by NIH grants 1R01 HL137355, 1R01 HL107110, 1R01 HL134558, 5R01 CA136387, and 5UM1 HL113460, and the Soffer Family Foundation.	Aaltomaa SH, 2001, ANTICANCER RES, V21, P3101; Abusnina A, 2011, CELL SIGNAL, V23, P152, DOI 10.1016/j.cellsig.2010.08.015; Akinleye A, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0779-5; Alimoradi Houman, 2019, Pharmaceutical Nanotechnology, V7, P279, DOI 10.2174/2211738507666190429111306; Allavena P, 2008, IMMUNOL REV, V222, P155, DOI 10.1111/j.1600-065X.2008.00607.x; Altieri R, 2015, TRANSL MED UNISA, V12, P54; Ambs S, 1998, CANCER RES, V58, P334; Andreesen R, 1998, J LEUKOCYTE BIOL, V64, P419, DOI 10.1002/jlb.64.4.419; Arafa ESA, 2011, MUTAT RES-FUND MOL M, V706, P28, DOI 10.1016/j.mrfmmm.2010.10.007; Araki Y, 2003, CANCER RES, V63, P728; Arora H, 2018, P NATL ACAD SCI USA, V115, P11298, DOI 10.1073/pnas.1812704115; Arrieta O, 2014, RADIOTHER ONCOL, V111, P311, DOI 10.1016/j.radonc.2014.01.021; Arsova-Sarafinovska Z, 2009, CLIN BIOCHEM, V42, P1228, DOI 10.1016/j.clinbiochem.2009.05.009; Aulak KS, 2004, AM J PHYSIOL-HEART C, V286, pH30, DOI 10.1152/ajpheart.00743.2003; Bardou VJ, 2003, J CLIN ONCOL, V21, P1973, DOI 10.1200/JCO.2003.09.099; Baritaki S, 2010, CELL CYCLE, V9, P4931, DOI 10.4161/cc.9.24.14229; Bartesaghi S, 2018, REDOX BIOL, V14, P618, DOI 10.1016/j.redox.2017.09.009; Basudhar D, 2017, ANTIOXID REDOX SIGN, V26, P1044, DOI 10.1089/ars.2016.6813; Beigi F, 2012, P NATL ACAD SCI USA, V109, P4314, DOI 10.1073/pnas.1113319109; Bellisarii FI, 2012, CARDIOVASC DRUG THER, V26, P55, DOI 10.1007/s10557-011-6354-0; BENJAMIN N, 1994, NATURE, V368, P502, DOI 10.1038/368502a0; Bentrari F, 2005, LAB INVEST, V85, P624, DOI 10.1038/labinvest.3700267; Bentz BG, 2000, HEAD NECK-J SCI SPEC, V22, P71, DOI 10.1002/(SICI)1097-0347(200001)22:1<71::AID-HED11>3.0.CO;2-G; Bhowmick R, 2014, CANCER LETT, V343, P115, DOI 10.1016/j.canlet.2013.09.025; Bian K, 2012, IUBMB LIFE, V64, P676, DOI 10.1002/iub.1057; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Black KL, 2008, BRAIN RES, V1230, P290, DOI 10.1016/j.brainres.2008.06.122; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Brune B, 2003, CELL DEATH DIFFER, V10, P864, DOI 10.1038/sj.cdd.4401261; Bulut A, 2005, VIRCHOWS ARCH, V447, P24, DOI 10.1007/s00428-005-1250-2; Burke AJ, 2013, CARCINOGENESIS, V34, P503, DOI 10.1093/carcin/bgt034; Califano JA, 2015, CLIN CANCER RES, V21, P30, DOI 10.1158/1078-0432.CCR-14-1716; Cannarile MA, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0257-y; Cardaci S, 2008, MOL PHARMACOL, V74, P1234, DOI 10.1124/mol.108.048975; Carlsson S, 2001, NITRIC OXIDE-BIOL CH, V5, P580, DOI 10.1006/niox.2001.0371; Carvajal JA, 2000, J CELL PHYSIOL, V184, P409, DOI 10.1002/1097-4652(200009)184:3<409::AID-JCP16>3.3.CO;2-B; Chan HP, 2009, LUNG CANCER, V63, P164, DOI 10.1016/j.lungcan.2008.05.020; Chavez AH, 2013, ASIAN J ANDROL, V15, P246, DOI 10.1038/aja.2012.162; Chegaev K, 2017, ACS MED CHEM LETT, V8, P361, DOI 10.1021/acsmedchemlett.7b00016; Chegaev K, 2011, ACS MED CHEM LETT, V2, P494, DOI 10.1021/ml100302t; Chen ZJ, 2002, CANCER LETT, V177, P181, DOI 10.1016/S0304-3835(01)00788-1; CHENAIS B, 1993, BIOCHEM BIOPH RES CO, V196, P1558, DOI 10.1006/bbrc.1993.2429; Cheng HW, 2014, CANCER LETT, V353, P1, DOI 10.1016/j.canlet.2014.07.014; Choe W, 2003, PATHOL INT, V53, P434, DOI 10.1046/j.1440-1827.2003.01501.x; Choudhari SK, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-118; Chuang AT, 1998, J UROLOGY, V160, P257, DOI 10.1016/S0022-5347(01)63100-8; Cianchi F, 2004, CLIN CANCER RES, V10, P2694, DOI 10.1158/1078-0432.CCR-03-0192; Coffelt SB, 2009, BBA-REV CANCER, V1796, P11, DOI 10.1016/j.bbcan.2009.02.004; Coleman JW, 2001, INT IMMUNOPHARMACOL, V1, P1397, DOI 10.1016/S1567-5769(01)00086-8; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Cronauer MV, 2007, ONCOGENE, V26, P1875, DOI 10.1038/sj.onc.1209984; Csont T, 2005, PHARMACOL THERAPEUT, V105, P57, DOI 10.1016/j.pharmthera.2004.10.001; Dai RJ, 2008, BLOOD, V112, P4591, DOI 10.1182/blood-2008-04-152488; Das A, 2015, PHARMACOL THERAPEUT, V147, P12, DOI 10.1016/j.pharmthera.2014.10.003; Davila-Gonzalez D., 2018, P IMM CHECKP AM ASS, pA202; Davila-Gonzalez D, 2017, P NATL ACAD SCI USA, V114, P13591, DOI 10.1073/pnas.1717440114; Davis AS, 2007, PLOS PATHOG, V3, P1887, DOI 10.1371/journal.ppat.0030186; de Oliveira GA, 2017, ANTIOXID REDOX SIGN, V26, P1059, DOI 10.1089/ars.2016.6850; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; den Uil Corstiaan A, 2015, Curr Heart Fail Rep, V12, P87, DOI 10.1007/s11897-014-0230-8; Derbyshire ER, 2012, ANNU REV BIOCHEM, V81, P533, DOI 10.1146/annurev-biochem-050410-100030; DERUBERTIS FR, 1977, J NATL CANCER I, V59, P1741, DOI 10.1093/jnci/59.6.1741; Dianat SS, 2009, BJU INT, V104, P1560, DOI 10.1111/j.1464-410X.2009.08973.x; Dingemans AMC, 2015, ANN ONCOL, V26, P2286, DOI 10.1093/annonc/mdv370; Domvri K, 2017, J CANCER, V8, P3648, DOI 10.7150/jca.21783; Downie IP, 2004, J ORAL MAXIL SURG, V62, P1064, DOI 10.1016/j.joms.2003.12.030; Du Q, 2013, CANCER RES, V73, P6526, DOI 10.1158/0008-5472.CAN-13-1620; Duckles SP, 2010, PFLUG ARCH EUR J PHY, V459, P841, DOI 10.1007/s00424-010-0797-1; DUNCAN C, 1995, NAT MED, V1, P546, DOI 10.1038/nm0695-546; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Ekmekcioglu S, 2006, INT J CANCER, V119, P861, DOI 10.1002/ijc.21767; Fahey JM, 2015, NITRIC OXIDE-BIOL CH, V49, P47, DOI 10.1016/j.niox.2015.05.006; Farkhondeh T, 2017, BIOMED PHARMACOTHER, V96, P1440, DOI 10.1016/j.biopha.2017.12.013; Ferreira JCB, 2012, CIRC J, V76, P15, DOI 10.1253/circj.CJ-11-1133; Flaherty RL, 2019, CANCER LETT, V459, P59, DOI 10.1016/j.canlet.2019.05.027; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; Franchi A, 2006, J PATHOL, V208, P439, DOI 10.1002/path.1892; FRANCIOSA JA, 1972, LANCET, V1, P650; Francis SH, 2010, PHARMACOL REV, V62, P525, DOI 10.1124/pr.110.002907; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Fujimoto H, 1998, JPN J CANCER RES, V89, P696, DOI 10.1111/j.1349-7006.1998.tb03273.x; Furuhashi S, 2012, INT J ONCOL, V40, P807, DOI 10.3892/ijo.2011.1243; Gali-Muhtasib H, 2006, INT J BIOCHEM CELL B, V38, P1249, DOI 10.1016/j.biocel.2005.10.009; Gallina A, 2015, EUR UROL, V68, P750, DOI 10.1016/j.eururo.2015.02.002; Gallo O, 1998, J NATL CANCER I, V90, P587, DOI 10.1093/jnci/90.8.587; Gao S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064189; Gao X, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6470950; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Garrido P, 2017, ONCOTARGET, V8, P80568, DOI 10.18632/oncotarget.19631; Gheorghiade M, 2015, JAMA-J AM MED ASSOC, V314, P2251, DOI 10.1001/jama.2015.15734; Ghofrani HA, 2013, NEW ENGL J MED, V369, P330, DOI 10.1056/NEJMoa1209655; Gladwin MT, 2006, AM J PHYSIOL-HEART C, V291, pH2026, DOI 10.1152/ajpheart.00407.2006; Glynn SA, 2010, J CLIN INVEST, V120, P3843, DOI 10.1172/JCI42059; Gochman E, 2012, ACTA HISTOCHEM, V114, P827, DOI 10.1016/j.acthis.2012.02.004; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; Gonzalez DR, 2010, J BIOL CHEM, V285, P28938, DOI 10.1074/jbc.M110.154948; Gonzalez DR, 2009, J CARDIOVASC PHARM, V54, P188, DOI 10.1097/FJC.0b013e3181b72c9f; Goradel NH, 2019, J CELL PHYSIOL, V234, P5683, DOI 10.1002/jcp.27411; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Graham Charles, 2015, Redox Biol, V5, P417, DOI 10.1016/j.redox.2015.09.022; Granados-Principal S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0527-x; Grek CL, 2013, J BIOL CHEM, V288, P26497, DOI 10.1074/jbc.R113.461368; Groeneveld PHP, 1997, CYTOKINE, V9, P138, DOI 10.1006/cyto.1996.0147; Grosse GM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051798; Guidotti LG, 2000, J EXP MED, V191, P1247, DOI 10.1084/jem.191.7.1247; Habib S, 2011, INDIAN J CLIN BIOCHE, V26, P3, DOI 10.1007/s12291-011-0108-4; Han JY, 2012, ANN ONCOL, V23, P2925, DOI 10.1093/annonc/mds122; Han YY, 2020, AM J CANCER RES, V10, P727; Hare JM, 2005, J CLIN INVEST, V115, P509, DOI 10.1172/JCI200524459; Hare JM, 2004, NEW ENGL J MED, V351, P2112, DOI 10.1056/NEJMe048269; Hare JM, 2002, J AM COLL CARDIOL, V40, P1114, DOI 10.1016/S0735-1097(02)02117-4; Hays E, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090407; Hays E, 2019, DRUG RESIST UPDATE, V43, P10, DOI 10.1016/j.drup.2019.04.001; Heller A, 2008, CHEMMEDCHEM, V3, P1493, DOI 10.1002/cmdc.200800257; Helms C, 2013, FREE RADICAL BIO MED, V61, P464, DOI 10.1016/j.freeradbiomed.2013.04.028; Hennemann B, 1998, CANCER IMMUNOL IMMUN, V45, P250; Hernansanz-Agustin P, 2013, ANTIOXID REDOX SIGN, V18, P288, DOI 10.1089/ars.2012.4765; HESS W, 1984, EUR HEART J, V5, P140, DOI 10.1093/oxfordjournals.eurheartj.a061624; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Hongo F, 2005, BIOCHEM BIOPH RES CO, V336, P692, DOI 10.1016/j.bbrc.2005.08.150; Howell K, 2009, AM J PHYSIOL-LUNG C, V296, pL1042, DOI 10.1152/ajplung.90327.2008; Hsieh YS, 2001, TOXICOL APPL PHARM, V172, P210, DOI 10.1006/taap.2001.9148; Huang ZJ, 2017, J MED CHEM, V60, P7617, DOI 10.1021/acs.jmedchem.6b01672; Huerta S, 2008, INT J ONCOL, V33, P909, DOI 10.3892/ijo_00000079; Huerta-Yepez S, 2004, ONCOGENE, V23, P4993, DOI 10.1038/sj.onc.1207655; Hume DA, 2020, J LEUKOCYTE BIOL, V107, P205, DOI 10.1002/JLB.MR0519-143R; Hussain SP, 2008, CANCER RES, V68, P7130, DOI 10.1158/0008-5472.CAN-08-0410; Ichwan SJA, 2014, CHINESE J PHYSIOL, V57, P249, DOI 10.4077/CJP.2014.BAB190; Iijima K, 2003, CARCINOGENESIS, V24, P1951, DOI 10.1093/carcin/bgg168; Illum H, 2015, SURGERY, V158, P460, DOI 10.1016/j.surg.2015.04.007; Isacoff WH, 2007, J CLIN ONCOL, V25, P1665, DOI 10.1200/JCO.2006.06.7637; Ischiropoulos H, 2009, ARCH BIOCHEM BIOPHYS, V484, P117, DOI 10.1016/j.abb.2008.10.034; Iwakiri Y, 2015, TRENDS PHARMACOL SCI, V36, P524, DOI 10.1016/j.tips.2015.05.001; Iyer AKV, 2008, NITRIC OXIDE-BIOL CH, V19, P146, DOI 10.1016/j.niox.2008.04.019; Jacobs EJ, 2008, CANCER EPIDEM BIOMAR, V17, P972, DOI 10.1158/1055-9965.EPI-07-2787; Jaiswal M, 2001, GASTROENTEROLOGY, V120, P190, DOI 10.1053/gast.2001.20875; Jeannin JF, 2008, NITRIC OXIDE-BIOL CH, V19, P158, DOI 10.1016/j.niox.2008.04.024; Jeon HK, 2005, CELL BIOL TOXICOL, V21, P115, DOI 10.1007/s10565-005-0148-8; Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9; Kaliyaperuma K, 2015, REDOX BIOL, V6, P41, DOI 10.1016/j.redox.2015.07.001; Kamm A, 2019, NITRIC OXIDE-BIOL CH, V93, P102, DOI 10.1016/j.niox.2019.09.005; Kaposzta Z, 2002, CIRCULATION, V106, P3057, DOI 10.1161/01.CIR.0000041251.07332.28; Karupiah G, 1998, J EXP MED, V188, P1541, DOI 10.1084/jem.188.8.1541; Kashfi K, 2005, BIOCHEM SOC T, V33, P701, DOI 10.1042/BST0330701; Kasper HU, 2004, WORLD J GASTROENTERO, V10, P1918; Kees T, 2011, J MAMMARY GLAND BIOL, V16, P189, DOI 10.1007/s10911-011-9224-2; Kelly K, 2017, CLIN CANCER RES, V23, P1186, DOI 10.1158/1078-0432.CCR-16-1207; Kielbik M, 2013, NITRIC OXIDE-BIOL CH, V35, P93, DOI 10.1016/j.niox.2013.09.001; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; Knox S.J., 2015, P THERAPEUTIC AGENTS, pC181; Koh E, 1999, CANCER LETT, V146, P173, DOI 10.1016/S0304-3835(99)00265-7; Kolb H, 1998, IMMUNOL TODAY, V19, P556, DOI 10.1016/S0167-5699(98)01366-8; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; Kseibati MO, 2020, LIFE SCI, V246, DOI 10.1016/j.lfs.2020.117423; Kundu JK, 2008, MUTAT RES-REV MUTAT, V659, P15, DOI 10.1016/j.mrrev.2008.03.002; Lala PK, 2001, LANCET ONCOL, V2, P149, DOI 10.1016/S1470-2045(00)00256-4; Lechner M, 2005, SEMIN CANCER BIOL, V15, P277, DOI 10.1016/j.semcancer.2005.04.004; Lee KM, 2009, CARCINOGENESIS, V30, P621, DOI 10.1093/carcin/bgp028; Lee MR, 2017, BIOMEDICINE-TAIWAN, V7, P31, DOI 10.1051/bmdcn/2017070205; Lenzo JC, 2012, IMMUNOL CELL BIOL, V90, P429, DOI 10.1038/icb.2011.58; Leon L, 2008, NITRIC OXIDE-BIOL CH, V19, P77, DOI 10.1016/j.niox.2008.04.014; Li J, 2018, ANN EPIDEMIOL, V28, P328, DOI 10.1016/j.annepidem.2018.03.001; Li KY, 2020, ECOTOX ENVIRON SAFE, V190, DOI 10.1016/j.ecoenv.2019.110096; Li WQ, 2014, JAMA INTERN MED, V174, P964, DOI 10.1001/jamainternmed.2014.594; Liao WB, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6304851; Lin CW, 2010, CARCINOGENESIS, V31, P2039, DOI 10.1093/carcin/bgq172; Lin YX, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0760-3; Lind M, 2017, BIOMED PHARMACOTHER, V93, P370, DOI 10.1016/j.biopha.2017.06.036; Liu CY, 1998, BRIT J CANCER, V78, P534, DOI 10.1038/bjc.1998.528; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; Liu PF, 2018, CLIN RESPIR J, V12, P23, DOI 10.1111/crj.12471; Liu YS, 2012, EUR RADIOL, V22, P2193, DOI 10.1007/s00330-012-2484-4; Luanpitpong S, 2015, ANTICANCER RES, V35, P4585; LUNDBERG JON, 1994, GUT, V35, P1543, DOI 10.1136/gut.35.11.1543; Maciag AE, 2011, J PHARMACOL EXP THER, V336, P313, DOI 10.1124/jpet.110.174904; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Madrigal JLM, 2002, NEUROPSYCHOPHARMACOL, V26, P155, DOI 10.1016/S0893-133X(01)00292-5; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Markowitz J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14970-0; Martin JHJ, 1999, CANCER LETT, V144, P65, DOI 10.1016/S0304-3835(99)00198-6; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Martinez L, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2547-z; Masri FA, 2005, AM J RESP CRIT CARE, V172, P597, DOI 10.1164/rccm.200411-1523OC; Masri F, 2010, ANN THORAC MED, V5, P123, DOI 10.4103/1817-1737.65036; Massi D, 2001, J PATHOL, V194, P194, DOI 10.1002/1096-9896(200106)194:2<194::AID-PATH851>3.0.CO;2-S; Masters GA, 2006, J THORAC ONCOL, V1, P673; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Mayevska O, 2017, EXP CELL RES, V355, P162, DOI 10.1016/j.yexcr.2017.04.003; McInnes LB, 1996, J EXP MED, V184, P1519, DOI 10.1084/jem.184.4.1519; Megson IL, 2002, EXPERT OPIN INV DRUG, V11, P587; Melillo G, 1996, J IMMUNOL, V157, P2638; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Michl U, 2015, J UROLOGY, V193, P479, DOI 10.1016/j.juro.2014.08.111; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; MILLER RR, 1977, CIRCULATION, V55, P881, DOI 10.1161/01.CIR.55.6.881; MIWA M, 1987, CARCINOGENESIS, V8, P955, DOI 10.1093/carcin/8.7.955; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; Monnet I, 2002, CHEST, V121, P1921, DOI 10.1378/chest.121.6.1921; Monteiro HP, 2019, NITRIC OXIDE-BIOL CH, V89, P1, DOI 10.1016/j.niox.2019.04.009; Mosser David M, 2008, Curr Protoc Immunol, VChapter 14, DOI 10.1002/0471142735.im1402s83; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Muniyan S, 2020, CLIN CANCER RES, V26, P5720, DOI 10.1158/1078-0432.CCR-20-1569; Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; Nagababu E, 2003, J BIOL CHEM, V278, P46349, DOI 10.1074/jbc.M307572200; Nagy G, 2007, IMMUNOL LETT, V111, P1, DOI 10.1016/j.imlet.2007.04.013; Nakamura Y, 2006, CLIN CANCER RES, V12, P1201, DOI 10.1158/1078-0432.CCR-05-1269; Nath N, 2015, MOLECULES, V20, P12481, DOI 10.3390/molecules200712481; Neves-Zaph Susana R, 2017, Adv Neurobiol, V17, P3, DOI 10.1007/978-3-319-58811-7_1; Nizet V, 2009, NAT REV IMMUNOL, V9, P609, DOI 10.1038/nri2607; Pance Alena, 2006, Future Oncol, V2, P275, DOI 10.2217/14796694.2.2.275; Paskas S, 2019, INVEST NEW DRUG, V37, P1014, DOI 10.1007/s10637-019-00733-3; Paul T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190628; Pautz A, 2010, NITRIC OXIDE-BIOL CH, V23, P75, DOI 10.1016/j.niox.2010.04.007; Peak Taylor C, 2016, Sex Med Rev, V4, P74, DOI 10.1016/j.sxmr.2015.10.004; Penarando J, 2019, TRANSL RES, V210, P99, DOI 10.1016/j.trsl.2019.03.003; Peng T, 2018, EUR J MED CHEM, V150, P742, DOI 10.1016/j.ejmech.2018.03.046; Perske C, 2010, AM J PATHOL, V177, P2046, DOI 10.2353/ajpath.2010.091111; Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998; Pervin S, 2001, CANCER RES, V61, P4701; Pignatelli B, 2001, CANCER RES, V61, P778; Pinto RV, 2019, NITRIC OXIDE-BIOL CH, V90, P29, DOI 10.1016/j.niox.2019.05.010; PIPILISYNETOS E, 1995, BRIT J PHARMACOL, V116, P1829, DOI 10.1111/j.1476-5381.1995.tb16670.x; Polytarchou C, 2009, INT J CANCER, V124, P1785, DOI 10.1002/ijc.24084; Porshneva K, 2019, THERANOSTICS, V9, P3918, DOI 10.7150/thno.31461; Pusztai L, 2003, J CLIN ONCOL, V21, P3454, DOI 10.1200/JCO.2003.02.114; Qu XM, 2016, J DENT RES, V95, P1452, DOI 10.1177/0022034516673019; Quan YY, 2017, ONCOTARGET, V8, P29833, DOI 10.18632/oncotarget.16164; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Radi R, 2013, ACCOUNTS CHEM RES, V46, P550, DOI 10.1021/ar300234c; Rahat MA, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00144; Rahat MA, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00045; Ramos LCB, 2018, J BIOL INORG CHEM, V23, P903, DOI 10.1007/s00775-018-1589-x; Rassaf T, 2007, CIRC RES, V100, P1749, DOI 10.1161/CIRCRESAHA.107.152488; Re A, 2011, MOL ENDOCRINOL, V25, P2003, DOI 10.1210/me.2011-1024; Reinmuth N, 2014, LUNG CANCER, V83, P363, DOI 10.1016/j.lungcan.2014.01.001; Ridnour LA, 2007, P NATL ACAD SCI USA, V104, P16898, DOI 10.1073/pnas.0702761104; Ridnour LA, 2006, ANTIOXID REDOX SIGN, V8, P1329, DOI 10.1089/ars.2006.8.1329; Rieder G, 2003, INT J MED MICROBIOL, V293, P403, DOI 10.1078/1438-4221-00280; Rim DE, 2019, J BIOCHEM MOL TOXIC, V33, DOI 10.1002/jbt.22348; Rocha BS, 2009, TOXICOLOGY, V265, P41, DOI 10.1016/j.tox.2009.09.008; Ryan CW, 2005, BJU INT, V95, P963, DOI 10.1111/j.1464-410X.2005.05448.x; Saisongkorh V, 2016, CELL ONCOL, V39, P449, DOI 10.1007/s13402-016-0287-3; Salas E, 1998, HEART, V80, P146, DOI 10.1136/hrt.80.2.146; Sandner Peter, 2021, Handb Exp Pharmacol, V264, P355, DOI 10.1007/164_2018_197; Sandner P, 2018, BIOL CHEM, V399, P679, DOI 10.1515/hsz-2018-0155; Sanhueza C, 2020, CANCERS, V12, DOI 10.3390/cancers12092349; Sanuphan A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/186972; Seabra AB, 2018, EUR J PHARMACOL, V826, P158, DOI 10.1016/j.ejphar.2018.02.040; Seth D, 2011, CURR OPIN CHEM BIOL, V15, P129, DOI 10.1016/j.cbpa.2010.10.012; SHAPIRO B, 1989, ENDOCRIN METAB CLIN, V18, P443, DOI 10.1016/S0889-8529(18)30378-5; Sharifi N, 2005, JAMA-J AM MED ASSOC, V294, P238, DOI 10.1001/jama.294.2.238; Shiva S, 2007, CIRC RES, V100, P654, DOI 10.1161/01.RES.0000260171.52224.6b; Sibmooh N, 2006, BLOOD, V108, p451A, DOI 10.1182/blood.V108.11.1574.1574; Siemens DR, 2009, UROLOGY, V74, P878, DOI 10.1016/j.urology.2009.03.004; Simeone AM, 2004, CANCER RES, V64, P1224, DOI 10.1158/0008-5472.CAN-03-2188; Simeone AM, 2003, ONCOGENE, V22, P6739, DOI 10.1038/sj.onc.1206786; Simoncini T, 2007, HUM REPROD, V22, P2325, DOI 10.1093/humrep/dem109; Sinibaldi VJ, 2006, AM J CLIN ONCOL-CANC, V29, P395, DOI 10.1097/01.coc.0000225411.95479.b4; Snyder AH, 2002, AM J RESP CRIT CARE, V165, P922, DOI 10.1164/ajrccm.165.7.2105032; Song JM, 2018, CARCINOGENESIS, V39, P911, DOI 10.1093/carcin/bgy049; Song P, 2015, NUTRIENTS, V7, P9872, DOI 10.3390/nu7125505; Soni Y, 2020, AM J MENS HEALTH, V14, DOI 10.1177/1557988320903191; Souto S, 2011, J SEX MED, V8, P484, DOI 10.1111/j.1743-6109.2010.02045.x; Spiller F, 2019, NITRIC OXIDE-BIOL CH, V89, P32, DOI 10.1016/j.niox.2019.04.011; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Stasch JP, 2015, CURR OPIN PHARMACOL, V21, P95, DOI 10.1016/j.coph.2014.12.014; Stewart GD, 2010, BJU INT, V105, P8, DOI 10.1111/j.1464-410X.2009.08921.x; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; Stoyanovsky DA, 2005, J AM CHEM SOC, V127, P15815, DOI 10.1021/ja0529135; STUEHR DJ, 1987, J IMMUNOL, V139, P518; Subapriya R, 2002, CLIN BIOCHEM, V35, P489, DOI 10.1016/S0009-9120(02)00340-5; Sun FM, 2019, CANCER RES, V79, P3395, DOI 10.1158/0008-5472.CAN-18-2839; Sun WJ, 2002, CLIN CANCER RES, V8, P3100; Suzuki Y, 2019, INT J CHRONIC OBSTR, V14, P1867, DOI 10.2147/COPD.S214610; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tan CC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2144-6; Tannenbaum SR, 2006, ACS CHEM BIOL, V1, P615, DOI 10.1021/cb600439h; Tarver T, 2012, J CONS HLTH INTERNET, V16, P366, DOI 10.1080/15398285.2012.701177; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Terwel D, 2000, EUR J PHARMACOL, V400, P19, DOI 10.1016/S0014-2999(00)00379-4; Thomas LN, 2012, PROSTATE, V72, P450, DOI 10.1002/pros.21446; THOMSEN LL, 1994, CANCER RES, V54, P1352; Toda N, 2005, PHARMACOL THERAPEUT, V106, P233, DOI 10.1016/j.pharmthera.2004.11.011; Toh Y, 2010, INT J CLIN ONCOL, V15, P135, DOI 10.1007/s10147-010-0057-6; Tuttle TR, 2017, CANCER LETT, V389, P33, DOI 10.1016/j.canlet.2016.12.020; Uotila P, 2001, UROL RES, V29, P25, DOI 10.1007/s002400000148; Utispan K, 2020, ANTICANCER RES, V40, P2657, DOI 10.21873/anticanres.14236; Vakkala M, 2000, CLIN CANCER RES, V6, P2408; Vakkala M, 2000, INT J ONCOL, V17, P667; van Wezel H B, 1987, J Cardiothorac Anesth, V1, P408, DOI 10.1016/S0888-6296(87)96860-8; Venneri MA, 2007, BLOOD, V109, P5276, DOI 10.1182/blood-2006-10-053504; Verovski VN, 1996, BRIT J CANCER, V74, P1734, DOI 10.1038/bjc.1996.623; Walmsley SR, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2632; Wang D, 2007, PROSTATE, V67, P1825, DOI 10.1002/pros.20669; Wang JZ, 2019, WORLD J MENS HEALTH, V37, P313, DOI 10.5534/wjmh.180050; Wang XX, 2009, J BIOL CHEM, V284, P27123, DOI 10.1074/jbc.M109.051235; Wang XD, 2015, MOL MED REP, V12, P4750, DOI 10.3892/mmr.2015.3963; Wang YC, 2019, JAMA ONCOL, V5, P1008, DOI 10.1001/jamaoncol.2019.0393; Wang ZQ, 2012, CANCER LETT, V320, P123, DOI 10.1016/j.canlet.2012.03.009; Weed DT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01206; Weed DT, 2015, CLIN CANCER RES, V21, P39, DOI 10.1158/1078-0432.CCR-14-1711; Weigert A, 2008, NITRIC OXIDE-BIOL CH, V19, P95, DOI 10.1016/j.niox.2008.04.021; Wen HC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125518; Weyerbrock A, 2003, J NEUROSURG, V99, P728, DOI 10.3171/jns.2003.99.4.0728; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Wiernik PH, 2004, LEUKEMIA, V18, P1605, DOI 10.1038/sj.leu.2403494; Windham PF, 2015, SEMIN CANCER BIOL, V31, P106, DOI 10.1016/j.semcancer.2014.06.006; Wink DA, 2011, J LEUKOCYTE BIOL, V89, P873, DOI 10.1189/jlb.1010550; Witta SE, 2004, CLIN CANCER RES, V10, P7229, DOI 10.1158/1078-0432.CCR-03-0181; Wongvaranon P, 2013, ANTICANCER RES, V33, P5433; XIE QW, 1994, J LEUKOCYTE BIOL, V56, P576, DOI 10.1002/jlb.56.5.576; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133; Yallampalli C, 2000, BIOL REPROD, V63, P34, DOI 10.1095/biolreprod63.1.34; Yamada M, 1996, J PHARMACOL TOXICOL, V35, P11, DOI 10.1016/1056-8719(95)00111-5; Yang LQ, 2013, INT IMMUNOPHARMACOL, V17, P383, DOI 10.1016/j.intimp.2013.06.021; Yao XY, 2015, ONCOL LETT, V10, P479, DOI 10.3892/ol.2015.3229; Yarlagadda K, 2017, BBA-REV CANCER, V1868, P500, DOI 10.1016/j.bbcan.2017.09.005; Yasuda H, 2006, J CLIN ONCOL, V24, P688, DOI 10.1200/JCO.2005.04.0436; Yasuoka H, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-340; Ye SJ, 2013, INT J MOL MED, V31, P33, DOI 10.3892/ijmm.2012.1171; Ying L, 2007, CANCER RES, V67, P9286, DOI 10.1158/0008-5472.CAN-07-2238; Yongsanguanchai N, 2015, AM J PHYSIOL-CELL PH, V308, pC89, DOI 10.1152/ajpcell.00187.2014; Yoshikawa T, 2019, INT J PHARMACEUT, V565, P481, DOI 10.1016/j.ijpharm.2019.05.043; Yu S, 2016, MOL THER, V24, P2078, DOI 10.1038/mt.2016.175; Yu S, 2013, CANCER LETT, V328, P83, DOI 10.1016/j.canlet.2012.09.006; ZACHARSKI LR, 1988, J NATL CANCER I, V80, P90, DOI 10.1093/jnci/80.2.90; Zafirellis K, 2010, APMIS, V118, P115, DOI 10.1111/j.1600-0463.2009.02569.x; Zamora R, 2000, MOL MED, V6, P347, DOI 10.1007/BF03401781; Zhang YH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1561-x; Zhu HF, 2011, MOL PHARMACOL, V80, P1076, DOI 10.1124/mol.111.073585; Ziche M, 2009, EUR CYTOKINE NETW, V20, P164, DOI 10.1684/ecn.2009.0169; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804	334	16	16	6	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							94	10.3390/vaccines9020094			39	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7FB	33513777	Green Published, gold			2022-04-29	WOS:000623304600001
J	Perez-Galarza, J; Procel, C; Canadas, C; Aguirre, D; Pibaque, R; Bedon, R; Sempertegui, F; Drexhage, H; Baldeon, L				Perez-Galarza, Jorge; Procel, Cesar; Canadas, Cristina; Aguirre, Diana; Pibaque, Ronny; Bedon, Ricardo; Sempertegui, Fernando; Drexhage, Hemmo; Baldeon, Lucy			Immune Response to SARS-CoV-2 Infection in Obesity and T2D: Literature Review	VACCINES			English	Review						SARS-CoV-2; COVID-19; obesity; T2D; innate; adaptive; immunity	PATTERN-RECOGNITION RECEPTORS; ADIPONECTIN RATIO; T-CELLS; LEPTIN CONCENTRATIONS; TYPE-2; INDEX; MICRORNAS; CTLA-4	In December 2019, a novel coronavirus known as SARS-CoV-2 was first detected in Wuhan, China, causing outbreaks of the coronavirus disease COVID-19 that has now spread globally. For this reason, The World Health Organization (WHO) declared COVID-19 a public health emergency in March 2020. People living with pre-existing conditions such as obesity, cardiovascular diseases, type 2 diabetes (T2D), and chronic kidney and lung diseases, are prone to develop severe forms of disease with fatal outcomes. Metabolic diseases such as obesity and T2D alter the balance of innate and adaptive responses. Both diseases share common features characterized by augmented adiposity associated with a chronic systemic low-grade inflammation, senescence, immunoglobulin glycation, and abnormalities in the number and function of adaptive immune cells. In obese and T2D patients infected by SARS-CoV-2, where immune cells are already hampered, this response appears to be stronger. In this review, we describe the abnormalities of the immune system, and summarize clinical findings of COVID-19 patients with pre-existing conditions such as obesity and T2D as this group is at greater risk of suffering severe and fatal clinical outcomes.	[Perez-Galarza, Jorge; Canadas, Cristina; Aguirre, Diana; Pibaque, Ronny; Baldeon, Lucy] Cent Univ Ecuador, Res Inst Biomed, Quito 170201, Ecuador; [Perez-Galarza, Jorge; Bedon, Ricardo; Sempertegui, Fernando; Baldeon, Lucy] Cent Univ Ecuador, Fac Med, Quito 170403, Ecuador; [Procel, Cesar] Hosp Metropolitano, Quito 170509, Ecuador; [Bedon, Ricardo] Hosp Gen Docente Calderon, Quito 170201, Ecuador; [Drexhage, Hemmo] Erasmus MC, Immunol Dept, NL-3015 Rotterdam, Netherlands		Baldeon, L (通讯作者)，Cent Univ Ecuador, Res Inst Biomed, Quito 170201, Ecuador.; Baldeon, L (通讯作者)，Cent Univ Ecuador, Fac Med, Quito 170403, Ecuador.	jmperez@uce.edu.ec; procelc@gmail.com; cmcanadas@uce.edu.ec; dfaguirre@uce.edu.ec; ronny1995rjps@gmail.com; rgbedon@uce.edu.ec; fersempert@biociencias-ceb.org; h.drexhage@erasmusmc.nl; lybaldeon@uce.edu.ec	Baldeon, Lucy/AAE-6323-2022	Baldeon, Lucy/0000-0002-0447-0136; Bedon Galarza, Ricardo Gabriel/0000-0003-2293-8879; Pibaque, Ronny/0000-0002-2639-4584; Perez-Galarza, Jorge/0000-0003-2742-3727	Central University of Ecuador	The publication fee was supported by the Central University of Ecuador.	Ahmed KA, 2011, J CELL MOL MED, V15, P1458, DOI 10.1111/j.1582-4934.2010.01008.x; Al-Hamodi Z, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-99; ALAMDARI NM, 2020, J INFECT CHEMOTHER, DOI DOI 10.1620/TJEM.252.73; ALTER G, 2018, SEMIN, DOI DOI 10.1016/J.SMIM.2018.05.003; Alvarez-Mon M.A, 2020, MED PROGRAMA FORM ME, V13, P767, DOI [10.1016/j.med.2020.07.010, DOI 10.1016/J.MED.2020.07.010]; Aly O, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234465; Rojas-Osornio SA, 2019, OBES RES CLIN PRACT, V13, P419, DOI 10.1016/j.orcp.2019.05.003; Appay V, 2004, CLIN EXP IMMUNOL, V138, P10, DOI 10.1111/j.1365-2249.2004.02605.x; Ara A, 2018, IMMUNOTARGETS THER, V7, P55, DOI 10.2147/ITT.S163614; AZKUR AK, 2020, NAT REV IMMUNOL, DOI DOI 10.1111/ALL.14364; Bandaru P., 2013, ENDOCRINOL METAB SYN, V2, P2, DOI DOI 10.4172/2161-1017.1000113; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Basso K, 2004, BLOOD, V104, P4088, DOI 10.1182/blood-2003-12-4291; Baumgarth N, 2013, IMMUNOL REV, V255, P82, DOI 10.1111/imr.12094; BECKER RC, 2020, INTENS CARE MED, DOI DOI 10.1007/S11239-020-02230-4; Beumer W, 2012, PSYCHONEUROENDOCRINO, V37, P1901, DOI 10.1016/j.psyneuen.2012.04.001; BHARI S, 2020, INT, DOI DOI 10.1007/S13410-020-00868-7; Bhaskar S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01648; Bidulescu A, 2020, BMC ENDOCR DISORD, V20, DOI 10.1186/s12902-020-0511-z; Bolke E, 2020, NEW ENGL J MED, V383, P1694, DOI 10.1056/NEJMc2027051; Bourgeois C, 2002, SCIENCE, V297, P2060, DOI 10.1126/science.1072615; CAI SH, 2020, INFECT, V9, P5, DOI DOI 10.1186/S40249-020-00703-5; Casazza JP, 2006, J EXP MED, V203, P2865, DOI 10.1084/jem.20052246; Castellino F, 2006, ANNU REV IMMUNOL, V24, P519, DOI 10.1146/annurev.immunol.23.021704.115825; Chaplin DD, 2010, J ALLERGY CLIN IMMUN, V125, pS3, DOI 10.1016/j.jaci.2009.12.980; CHEHREHGOSHA M, 2020, THE J, DOI DOI 10.1007/S12603-020-1505-2; CHEN Z, 2020, CLIN CHIM ACTA, DOI DOI 10.1038/S41577-020-0402-6; Chiappetta S, 2020, INT J OBESITY, V44, P1790, DOI 10.1038/s41366-020-0597-4; Childs BG, 2016, SCIENCE, V354, P472, DOI 10.1126/science.aaf6659; Chiu YL, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00200-1; Condotta SA, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006618; Coppelli A, 2020, DIABETES CARE, V43, P2345, DOI 10.2337/dc20-1380; de Lucena TMC, 2020, DIABETES METAB SYND, V14, P597, DOI 10.1016/j.dsx.2020.05.025; Crotty S, 2015, NAT REV IMMUNOL, V15, P185, DOI 10.1038/nri3803; Cruz-Tapias P, 2013, AUTOIMMUNITY BENCH B; Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397; Dai SP, 2021, J NUTR HEALTH AGING, V25, P18, DOI 10.1007/s12603-020-1486-1; DARYABOR G, 2020, FRONT, DOI DOI 10.3389/FIMMU.2020.01582; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEBIASI S, 2020, NAT MED, DOI DOI 10.1038/S41467-020-17292-4; DeFuria J, 2013, P NATL ACAD SCI USA, V110, P5133, DOI 10.1073/pnas.1215840110; Delhanty PJD, 2013, FASEB J, V27, P1690, DOI 10.1096/fj.12-221143; Deng YT, 2020, CAMB CHINA LIBR, P1; Dorner T, 2007, IMMUNITY, V27, P384, DOI 10.1016/j.immuni.2007.09.002; Eller K, 2011, DIABETES, V60, P2954, DOI 10.2337/db11-0358; EMBGENBROICH M, 2018, FRONT, DOI DOI 10.3389/FIMMU.2018.01643; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Fife BT, 2008, IMMUNOL REV, V224, P166, DOI 10.1111/j.1600-065X.2008.00662.x; Finlay D, 2011, NAT REV IMMUNOL, V11, P109, DOI 10.1038/nri2888; Finucane FM, 2009, DIABETOLOGIA, V52, P2345, DOI 10.1007/s00125-009-1508-3; Francisco V, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00640; Frieman M, 2008, VIRUS RES, V133, P101, DOI 10.1016/j.virusres.2007.03.015; GABARRE P, 2020, MEDIAT INFLAMM, DOI DOI 10.1007/S00134-020-06153-9; Garcia JJ, 2003, MOL CELL BIOCHEM, V254, P299, DOI 10.1023/A:1027345820519; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Ge Q, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/987285; Gonzalez SF, 2010, NAT IMMUNOL, V11, P427, DOI 10.1038/ni.1856; Goossens GH, 2020, OBESITY FACTS, V13, P439, DOI 10.1159/000510719; GREEN WD, 2017, INT J OBESITY, DOI DOI 10.1513/ANNALSATS.201706-447AW; GROM AA, 2010, DIABETES, DOI DOI 10.1097/01.BOR.0000381996.69261.71; Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10; Harty JT, 2000, ANNU REV IMMUNOL, V18, P275, DOI 10.1146/annurev.immunol.18.1.275; HE B, 2020, FRONT, DOI DOI 10.3389/FIMMU.2020.02075; Hegde NR, 2003, TRENDS IMMUNOL, V24, P278, DOI 10.1016/S1471-4906(03)00099-1; HIRAKAWA Y, 2014, FRONT MICROBIOL, DOI DOI 10.2337/DC14-0199; HIRASHIMA T, 2020, EUR J INTERN MED, V27, P76, DOI DOI 10.1016/J.JIAC.2020.09.022; Hoffmann M, 2020, CELL, DOI [10.1016/j.cell.2020.02.052, DOI 10.1016/J.CELL.2020.02.052]; Holloway TL, 2015, CYTOKINE, V76, P328, DOI 10.1016/j.cyto.2015.09.003; HOOIJKAAS H, 1984, EUR J IMMUNOL, V14, P1127, DOI 10.1002/eji.1830141212; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; HU B, 2020, CYTOKINE, DOI DOI 10.1002/JMV.26232; HULME KD, 2017, AM J MED SCI, DOI DOI 10.3389/FMICB.2017.00861; HUSSAIN A, 2020, CRIT CARE, DOI DOI 10.1016/J.ORCP.2020.07.002; IANNELLI A, 2020, OBES, DOI DOI 10.1007/S11695-020-04734-7; IBARRONDO FJ, 2020, LANCET RESP MED, DOI DOI 10.1056/NEJMC2025179; Inoue M, 2005, METABOLISM, V54, P281, DOI 10.1016/j.metabol.2004.09.006; International Diabetes Federation (IDF), 2019, DIABETES ATLAS, V9th; Ip B, 2016, OBESITY, V24, P102, DOI 10.1002/oby.21243; Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021; Janeway CA, 2001, MICROBES INFECT, V3, P1167, DOI 10.1016/S1286-4579(01)01477-0; Joffre OP, 2012, NAT REV IMMUNOL, V12, P557, DOI 10.1038/nri3254; Johns Hopkins University, 2020, COVID 19 MAP JOHNS H; JOUAN Y, 2020, THE J, DOI DOI 10.1084/JEM.20200872; Jurado A, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00194-w; Kang ZY, 2020, INT J OBESITY, V44, P2479, DOI 10.1038/s41366-020-00677-2; KARLSSON EA, 2010, J INFECT DIS, DOI DOI 10.3945/JN.110.123653; KASS DA, 2020, OBESITY, DOI DOI 10.7326/M20-5677; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; KIM YH, 2012, HUM VACC IMMUNOTHER, DOI DOI 10.1093/INFDIS/JIR731; Kolfschoten IGM, 2009, DIABETES OBES METAB, V11, P118, DOI 10.1111/j.1463-1326.2009.01118.x; Kotani K, 2005, DIABETOLOGIA, V48, P2684, DOI 10.1007/s00125-005-0015-4; Kotsias F, 2019, INT REV CEL MOL BIO, V348, P69, DOI 10.1016/bs.ircmb.2019.07.005; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; Lam JH, 2019, J IMMUNOL, V202, P351, DOI 10.4049/jimmunol.1801208; Landrier JF, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080859; Lanzavecchia A, 2001, NAT IMMUNOL, V2, P487, DOI 10.1038/88678; Lee HK, 2007, SEMIN IMMUNOL, V19, P48, DOI 10.1016/j.smim.2006.12.001; Lee JS, 2020, NAT REV IMMUNOL, V20, P585, DOI 10.1038/s41577-020-00429-3; Lee SHG, 2020, CAN MED ASSOC J, V192, pE583, DOI 10.1503/cmaj.200685; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Li SF, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00334-0; LI W, 2005, NEW ENGL J MED, DOI DOI 10.1038/SJ.EMBOJ.7600640; LIANG JJ, 2020, EMBO J, DOI DOI 10.1016/J.DIABRES.2020.108351; Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0; LIU L, 2020, THE J, DOI DOI 10.1111/JDI.13431; LIU R, 2020, TOHOKU J EXP MED, DOI DOI 10.1016/J.CCA.2020.05.019; LIU Y, 2020, CLIN IMMUNOL, DOI DOI 10.1016/J.JINF.2020.04.002; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Machado Paulo R. L., 2004, An. Bras. Dermatol., V79, P647, DOI 10.1590/S0365-05962004000600002; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; MAHMUDPOUR M, 2020, J CLIN INVEST, DOI DOI 10.1016/J.CYTO.2020.155151; Marin BG, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2146; Marshall RJ, 2020, MBIO, V11, DOI 10.1128/mBio.02841-19; Martin-Cordero L, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8120556; Martin-Cordero L, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112721; Martin-Cordero L, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-42; MATHAN TSM, 2013, FRONT, DOI DOI 10.3389/FIMMU.2013.00372; Matsubara M, 2002, EUR J ENDOCRINOL, V147, P173, DOI 10.1530/eje.0.1470173; Mauvais-Jarvis F, 2020, DIABETES, V69, P1857, DOI 10.2337/dbi19-0023; McClelland AD, 2014, CLIN SCI, V126, P95, DOI 10.1042/CS20130079; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; MERAD M, 2020, INFLAMM REGEN, DOI DOI 10.1038/S41577-020-0331-4; Mery G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01714; MICHIELS B, 2011, ANN AM THORAC SOC, DOI DOI 10.1016/J.VACCINE.2011.08.008; Milionis C, 2020, J DIABETES METAB DIS, V19, P2035, DOI 10.1007/s40200-020-00592-3; Mishra Y, 2020, DIABETES METAB SYND, V14, P1927, DOI 10.1016/j.dsx.2020.09.035; MORGAN OW, 2010, OBES RES CLIN PRACT, DOI DOI 10.1371/JOURNAL.PONE.0009694; Mori MA, 2019, CELL METAB, V30, P656, DOI 10.1016/j.cmet.2019.07.011; Mraz M, 2014, J ENDOCRINOL, V222, pR113, DOI 10.1530/JOE-14-0283; MUDALIAR H, 2014, J DIABETES METAB DIS, DOI DOI 10.1371/JOURNAL.PONE.0108844; Muniyappa R, 2020, AM J PHYSIOL-ENDOC M, V318, pE736, DOI 10.1152/ajpendo.00124.2020; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; NEIDICH SD, 2017, NEW ENGL J MED, DOI DOI 10.1038/IJO.2017.131; Nieman DC, 2020, J SPORT HEALTH SCI, V9, P293, DOI 10.1016/j.jshs.2020.05.001; Nishimura S, 2009, NAT MED, V15, P914, DOI 10.1038/nm.1964; Oda N, 2008, METABOLISM, V57, P268, DOI 10.1016/j.metabol.2007.09.011; ORLOV M, 2020, THE J, DOI DOI 10.4049/JIMMUNOL.2000554; ORTEGA E, 2019, ENDOCRINOLOGY, DOI DOI 10.2174/1871530319666190206124520; OTSUKA R, 2020, J MED VIROL, DOI DOI 10.1186/S41232-020-00131-W; Paich HA, 2013, OBESITY, V21, P2377, DOI 10.1002/oby.20383; Pal R, 2021, PRIM CARE DIABETES, V15, P18, DOI 10.1016/j.pcd.2020.08.002; PARK HL, 2014, NAT REV ENDOCRINOL, DOI DOI 10.4161/HV.28332; PEDERSEN SF, 2020, ALLERGY, DOI DOI 10.1172/JCI137647; Qin W, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P648, DOI 10.3760/cma.j.cn112147-20200320-00380; QU R, 2020, INT J HEMATOL, DOI DOI 10.1002/JMV.25767; QUAGLIARO L, 2003, DIABETES CARE, DOI DOI 10.2337/DIABETES.52.11.2795; QUAH P, 2020, BIOMED PHARMACOTHER, DOI DOI 10.1186/S13054-020-03006-1; Quezada SA, 2004, ANNU REV IMMUNOL, V22, P307, DOI 10.1146/annurev.immunol.22.012703.104533; R LB, 2014, PLOS ONE, V9, DOI DOI 10.1371/JOURNAL.PONE.0115209; Ritter A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165793; Rock KL, 2016, TRENDS IMMUNOL, V37, P724, DOI 10.1016/j.it.2016.08.010; Roncon L, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104354; Roos J, 2016, SCI REP-UK, V6, DOI 10.1038/srep38339; Rothaeusler K, 2010, EUR J IMMUNOL, V40, P366, DOI 10.1002/eji.200939798; Ryan PM, 2020, OBESITY, V28, P1191, DOI 10.1002/oby.22843; Sant AJ, 2012, J EXP MED, V209, P1391, DOI 10.1084/jem.20121517; Satoh N, 2004, DIABETES CARE, V27, P2488, DOI 10.2337/diacare.27.10.2488; Satya Krishna Surabhi Venkata, 2013, Indian J Endocrinol Metab, V17, P611, DOI 10.4103/2230-8210.113751; Scheid JF, 2009, NATURE, V458, P636, DOI 10.1038/nature07930; Schluns KS, 2003, NAT REV IMMUNOL, V3, P269, DOI 10.1038/nri1052; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; Schub D, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.142167; Sela-Culang I, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00302; SELL H, 2012, INT J OBESITY, DOI DOI 10.1038/NRENDO.2012.114; Shade KTC, 2013, ANTIBODIES, V2, P392, DOI 10.3390/antib2030392; Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; SHERIDAN PA, 2012, OBESITY, DOI DOI 10.1038/IJO.2011.208; Simar D, 2014, METABOLISM, V63, P1188, DOI 10.1016/j.metabol.2014.05.014; SIMONNET A, 2020, J DIABETES COMPLICAT, DOI DOI 10.1002/OBY.22831; Soghoian DZ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003165; Sonkoly E, 2008, SEMIN CANCER BIOL, V18, P131, DOI 10.1016/j.semcancer.2008.01.005; SOY M, 2020, CLIN, DOI DOI 10.1007/S10067-020-05190-5; Stojanovic SD, 2020, EUR HEART J, V41, P2983, DOI 10.1093/eurheartj/ehz919; Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tatum D, 2020, SHOCK, V54, P652, DOI 10.1097/SHK.0000000000001585; Thorand B, 2010, DIABETIC MED, V27, P1004, DOI 10.1111/j.1464-5491.2010.03043.x; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; UMPIERREZ GE, 2018, PLOS ONE, DOI DOI 10.1016/J.AMJMS.2018.09.010; URRA JM, 2020, J TRANSL MED, DOI DOI 10.1016/J.CLIM.2020.108486; van Dielen FMH, 2001, INT J OBESITY, V25, P1759, DOI 10.1038/sj.ijo.0801825; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; van Montfoort N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00182; Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wang F, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02423-8; WANG W, 2020, DIABETES RES CLIN PR, DOI DOI 10.1002/JCLA.23547; WANG Y, 2020, NEW ENGL J MED, DOI DOI 10.1172/JCI138759; Wang ZL, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00306-4; Winer DA, 2011, NAT MED, V17, P610, DOI 10.1038/nm.2353; Winer S, 2009, NAT MED, V15, P921, DOI 10.1038/nm.2001; WU D, 2020, NAT COMMUN, DOI DOI 10.1016/J.JMII.2020.03.005; Wu ZY, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/5041346; Xia C, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/6494795; Xiang J, 2005, J IMMUNOL, V174, P7497, DOI 10.4049/jimmunol.174.12.7497; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Yan YL, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2020-001343; Yang P, 2021, J MED VIROL, V93, P2168, DOI 10.1002/jmv.26608; Yoshimoto T, 1998, J IMMUNOL, V161, P3400; Yu XC, 2008, NATURE, V455, P532, DOI 10.1038/nature07231; YUAN X, 2020, J INFECTION, DOI DOI 10.1007/S12185-020-02930-W; Zhang N, 2011, IMMUNITY, V35, P161, DOI 10.1016/j.immuni.2011.07.010; Zhang QH, 2020, J DIABETES COMPLICAT, V34, DOI 10.1016/j.jdiacomp.2020.107666; ZHANG Y, 2020, J THROMB THROMBOLYS, DOI DOI 10.1016/J.BIOPHA.2020.110195; ZHAO R, 2020, ANN INTERN MED, DOI DOI 10.1155/2020/6914878; Zhao Y, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00723-1; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674; Zhou Peng, 2020, Nature, V588, pE6, DOI 10.1038/s41586-020-2951-z; ZHOU Y, 2020, PLOS ONE, DOI DOI 10.1002/DMRR.3377; Zhu L, 2020, CARDIORENAL MED, V10, P470, DOI 10.1159/000510916; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zhu YW, 2011, IMMUNITY, V34, P466, DOI 10.1016/j.immuni.2011.04.008; Zou L, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00532; Zuniga E.I, 2008, ENCY VIROLOGY, DOI [10.1016/B978-012374410-4.00581-1, DOI 10.1016/B978-012374410-4.00581-1]	215	7	7	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							102	10.3390/vaccines9020102			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7DF	33572702	Green Published, gold			2022-04-29	WOS:000623299800001
J	He, JY; Lai, HF; Esqueda, A; Chen, Q				He, Junyun; Lai, Huafang; Esqueda, Adrian; Chen, Qiang			Plant-Produced Antigen Displaying Virus-Like Particles Evokes Potent Antibody Responses against West Nile Virus in Mice	VACCINES			English	Article						West Nile virus; virus-like particle (VLP); plant-made vaccine; vaccine; envelope protein; domain III (DIII)		In this study, we developed a hepatitis B core antigen (HBcAg)-based virus-like particle (VLP) that displays the West Nile virus (WNV) Envelope protein domain III (wDIII) as a vaccine candidate for WNV. The HBcAg-wDIII fusion protein was quickly produced in Nicotiana benthamiana plants and reached a high expression level of approximately 1.2 mg of fusion protein per gram of leaf fresh weight within six days post gene infiltration. Electron microscopy and gradient centrifugation analysis indicated that the introduction of wDIII did not interfere with VLP formation and HBcAg-wDIII successfully assembled into VLPs. HBcAg-wDIII VLPs can be easily purified in large quantities from Nicotiana benthamiana leaves to >95% homogeneity. Further analysis revealed that the wDIII was displayed properly and demonstrated specific binding to an anti-wDIII monoclonal antibody that recognizes a conformational epitope of wDIII. Notably, HBcAg-wDIII VLPs were shown to be highly immunogenic and elicited potent humoral responses in mice with antigen-specific IgG titers equivalent to that of protective wDIII antigens in previous studies. Thus, our wDIII-based VLP vaccine offers an attractive option for developing effective, safe, and low-cost vaccines against WNV.	[He, Junyun; Lai, Huafang; Esqueda, Adrian; Chen, Qiang] Arizona State Univ, Biodesign Inst, Tempe, AZ 85287 USA; [Esqueda, Adrian; Chen, Qiang] Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA		Chen, Q (通讯作者)，Arizona State Univ, Biodesign Inst, Tempe, AZ 85287 USA.; Chen, Q (通讯作者)，Arizona State Univ, Sch Life Sci, Tempe, AZ 85287 USA.	junyunhe0123@gmail.com; huafang.lai@asu.edu; Adrian.Esqueda@asu.edu; qiang.chen.4@asu.edu		chen, qiang/0000-0003-1498-7013	NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U01 AI075549, R21 AI101329]	This work was supported in part by NIAID grants number U01 AI075549 and R21 AI101329 to Q. Chen.	Alonso-Padilla J, 2011, VACCINE, V29, P1830, DOI 10.1016/j.vaccine.2010.12.081; [Anonymous], 2012, PLANT CELL REP, V31, P573; Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365; Belmusto-Worn VE, 2005, AM J TROP MED HYG, V72, P189, DOI 10.4269/ajtmh.2005.72.189; Chen Q., 2008, Biological Engineering, V1, P291; Chen Q., 2013, MOL VACCINES, V1, P153, DOI [10.1007/978-3-7091-1419-3_8, DOI 10.1007/978-3-7091-1419-3_8]; Chen Q., 2011, EUROPEAN BIOPHARM RE, V2, P64; Chen Qiang, 2016, F1000Res, V5, DOI 10.12688/f1000research.8010.1; Chen Q, 2016, P NATL ACAD SCI USA, V113, P9404, DOI 10.1073/pnas.1610803113; Chen Q, 2016, METHODS MOL BIOL, V1385, P55, DOI 10.1007/978-1-4939-3289-4_4; Chen Q, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/932161; Chen Q, 2015, BIOTECHNOL J, V10, P671, DOI 10.1002/biot.201400428; Chen Qiang, 2013, Adv Tech Biol Med, V1; Chen Q, 2011, TRANSGENIC HORTICULTURAL CROPS: CHALLENGES AND OPPORTUNITIES, P83; Chen Q, 2013, HUM VACC IMMUNOTHER, V9, P26, DOI 10.4161/hv.22218; Chen Q, 2011, HUM VACCINES, V7, P331, DOI 10.4161/hv.7.3.14262; Chu JHJ, 2007, J IMMUNOL, V178, P2699, DOI 10.4049/jimmunol.178.5.2699; Chu JJH, 2005, J GEN VIROL, V86, P405, DOI 10.1099/vir.0.80411-0; Crill WD, 2004, J VIROL, V78, P13975, DOI 10.1128/JVI.78.24.13975-13986.2004; Demento SL, 2010, J IMMUNOL, V185, P2989, DOI 10.4049/jimmunol.1000768; Dent M, 2016, J GEN VIROL, V97, P3280, DOI 10.1099/jgv.0.000635; Halstead SB, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0022-2014; Hart J, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-248; He JY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/952865; He JH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093541; He JY, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/106783; Heinz FX, 2007, VACCINE, V25, P7559, DOI 10.1016/j.vaccine.2007.08.024; Huang Z, 2009, BIOTECHNOL BIOENG, V103, P706, DOI 10.1002/bit.22299; Hurtado J, 2020, PLANT BIOTECHNOL J, V18, P266, DOI 10.1111/pbi.13194; Jugler C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062140; Lai HF, 2018, VACCINE, V36, P1846, DOI 10.1016/j.vaccine.2018.02.073; Lai HF, 2014, PLANT BIOTECHNOL J, V12, P1098, DOI 10.1111/pbi.12217; Lai HF, 2012, PLANT BIOTECHNOL J, V10, P95, DOI 10.1111/j.1467-7652.2011.00649.x; Lai HF, 2010, P NATL ACAD SCI USA, V107, P2419, DOI 10.1073/pnas.0914503107; Leuzinger K, 2013, JOVE-J VIS EXP, DOI 10.3791/50521; Lim JK, 2008, J INFECT DIS, V197, P262, DOI 10.1086/524691; Martina BE, 2008, VACCINE, V26, P153, DOI 10.1016/j.vaccine.2007.10.055; McDonald WF, 2007, J INFECT DIS, V195, P1607, DOI 10.1086/517613; MORENS DM, 1994, CLIN INFECT DIS, V19, P500, DOI 10.1093/clinids/19.3.500; Nandi S, 2016, MABS-AUSTIN, V8, P1456, DOI 10.1080/19420862.2016.1227901; Nybakken GE, 2006, J VIROL, V80, P11467, DOI 10.1128/JVI.01125-06; Oliphant T, 2005, NAT MED, V11, P522, DOI 10.1038/nm1240; Phoolcharoen W, 2011, P NATL ACAD SCI USA, V108, P20695, DOI 10.1073/pnas.1117715108; Phoolcharoen W, 2011, PLANT BIOTECHNOL J, V9, P807, DOI 10.1111/j.1467-7652.2011.00593.x; Pogue GP, 2010, PLANT BIOTECHNOL J, V8, P638, DOI 10.1111/j.1467-7652.2009.00495.x; Santi L, 2008, VACCINE, V26, P1846, DOI 10.1016/j.vaccine.2008.01.053; Schumacher J, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0363-0; Sun HaiYan, 2018, Prospects of plant-based vaccines in veterinary medicine, P121; Sun HY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010054; Tuse D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/256135; Yang M, 2018, PLANT BIOTECHNOL J, V16, P572, DOI 10.1111/pbi.12796; Yang M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08247-9; Yang M, 2017, VACCINE, V35, P4287, DOI 10.1016/j.vaccine.2017.04.052; Zhao HY, 2016, CELL, V166, P1016, DOI 10.1016/j.cell.2016.07.020	54	7	7	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							60	10.3390/vaccines9010060			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6VU	33477363	gold, Green Published			2022-04-29	WOS:000610810600001
J	Riepler, L; Rossler, A; Falch, A; Volland, A; Borena, W; von Laer, D; Kimpel, J				Riepler, Lydia; Roessler, Annika; Falch, Albert; Volland, Andre; Borena, Wegene; von Laer, Dorothee; Kimpel, Janine			Comparison of Four SARS-CoV-2 Neutralization Assays	VACCINES			English	Article						SARS-CoV-2; neutralizing antibodies; neutralization assay; pseudotype virus	SPIKE PROTEIN	Neutralizing antibodies are a major correlate of protection for many viruses including the novel coronavirus SARS-CoV-2. Thus, vaccine candidates should potently induce neutralizing antibodies to render effective protection from infection. A variety of in vitro assays for the detection of SARS-CoV-2 neutralizing antibodies has been described. However, validation of the different assays against each other is important to allow comparison of different studies. Here, we compared four different SARS-CoV-2 neutralization assays using the same set of patient samples. Two assays used replication competent SARS-CoV-2, a focus forming assay and a TCID50-based assay, while the other two assays used replication defective lentiviral or vesicular stomatitis virus (VSV)-based particles pseudotyped with SARS-CoV-2 spike. All assays were robust and produced highly reproducible neutralization titers. Titers of neutralizing antibodies correlated well between the different assays and with the titers of SARS-CoV-2 S-protein binding antibodies detected in an ELISA. Our study showed that commonly used SARS-CoV-2 neutralization assays are robust and that results obtained with different assays are comparable.	[Riepler, Lydia; Roessler, Annika; Falch, Albert; Volland, Andre; Borena, Wegene; von Laer, Dorothee; Kimpel, Janine] Med Univ Innsbruck, Inst Virol, Dept Hyg Microbiol & Publ Hlth, A-6020 Innsbruck, Austria		Kimpel, J (通讯作者)，Med Univ Innsbruck, Inst Virol, Dept Hyg Microbiol & Publ Hlth, A-6020 Innsbruck, Austria.	lydia.riepler@i-med.ac.at; Annika.Roessler@i-med.ac.at; Albert.Falch@i-med.ac.at; andre.volland@i-med.ac.at; Wegene.Borena@i-med.ac.at; dorothee.von-laer@i-med.ac.at; Janine.kimpel@i-med.ac.at		Kimpel, Janine/0000-0002-5210-7905; Rossler, Annika/0000-0002-5298-0288; Riepler, Lydia/0000-0002-7879-5566; von Laer, Dorothee/0000-0001-5825-7237; Borena, Wegene/0000-0001-8011-5825			Amanat Fatima, 2020, Curr Protoc Microbiol, V58, pe108, DOI 10.1002/cpmc.108; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Cantuti-Castelvetri L, 2020, SCIENCE, V370, P856, DOI 10.1126/science.abd2985; Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513; FIND, SARS COV 2 DIAGNOSTI; Giroglou T, 2004, J VIROL, V78, P9007, DOI 10.1128/JVI.78.17.9007-9015.2004; Grzelak L, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3103; Gupta V, 2021, CLIN INFECT DIS, V73, pE2823, DOI 10.1093/cid/ciaa1451; Hermann FG, 2009, J VIROL, V83, P4844, DOI 10.1128/JVI.00666-08; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022; Hoffmann M, 2010, J GEN VIROL, V91, P2782, DOI 10.1099/vir.0.023978-0; Kellam P, 2020, J GEN VIROL, V101, P791, DOI 10.1099/jgv.0.001439; Knabl L., 2020, 20178533 MEDRXIV; Lin HX, 2011, VIRUS RES, V160, P283, DOI 10.1016/j.virusres.2011.06.029; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Meyer B, 2020, Clin Microbiol Infect, V26, P1386, DOI 10.1016/j.cmi.2020.06.024; Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767; Peterhoff D, 2021, INFECTION, V49, P75, DOI 10.1007/s15010-020-01503-7; Schmidt Fabian, 2020, bioRxiv, DOI 10.1101/2020.06.08.140871; To Kelvin Kai-Wang, 2021, Clin Infect Dis, V73, pe2946, DOI 10.1093/cid/ciaa1275; Tober R, 2014, J VIROL, V88, P4897, DOI 10.1128/JVI.03276-13; Weisblum Yiska, 2020, bioRxiv, DOI 10.1101/2020.07.21.214759; World Health Organization, WHO CORONAVIRUS DIS; Zettl F, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030386; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	26	29	29	5	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							13	10.3390/vaccines9010013			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7AY	33379160	Green Published, gold			2022-04-29	WOS:000610824200001
J	Campbell, J; Sutherland, J; Bucknall, D; O'Hara, L; Heywood, A; Hobbs, M; Ballantyne, A; Gray, L				Campbell, Jessica; Sutherland, Juliet; Bucknall, Danielle; O'Hara, Lily; Heywood, Anita; Hobbs, Matthew; Ballantyne, Angela; Gray, Lesley			Equity in Vaccine Trials for Higher Weight People? A Rapid Review of Weight-Related Inclusion and Exclusion Criteria for COVID-19 Clinical Trials	VACCINES			English	Review						vaccine; vaccination; COVID-19; higher weight; BMI; clinical trial; equity; inequity	ANTIBODY-TITERS; OBESITY; OVERWEIGHT; GUIDANCE; CANCER	Higher weight status, defined as body mass index (BMI) >= 30 kg/m(2), is frequently described as a risk factor for severity and susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (known as COVID-19). Therefore, study groups in COVID-19 vaccine trials should be representative of the weight spectrum across the global population. Appropriate subgroup analysis should be conducted to ensure equitable vaccine outcomes for higher weight people. In this study, inclusion and exclusion criteria of registered clinical trial protocols were reviewed to determine the proportion of trials including higher weight people, and the proportion of trials conducting subgroup analyses of efficacy by BMI. Eligibility criteria of 249 trial protocols (phase I, II, III and IV) were analysed; 51 protocols (20.5%) specified inclusion of BMI > 30, 73 (29.3%) specified exclusion of BMI > 30, and 125 (50.2%) did not specify whether BMI was an inclusion or exclusion criterion, or if BMI was included in any 'health' screenings or physical examinations during recruitment. Of the 58 protocols for trials in phase III and IV, only 2 (3.4%) indicated an intention to report subgroup analysis of vaccine efficacy by weight status. Higher weight people appear to be significantly under-represented in the majority of vaccine trials. This may result in reduced efficacy and acceptance of COVID-19 vaccines for higher weight people and exacerbation of health inequities within this population group. Explicit inclusion of higher weight people in COVID-19 vaccine trials is required to reduce health inequities.	[Campbell, Jessica; Sutherland, Juliet; Bucknall, Danielle] Univ Otago, Otago Med Sch, Christchurch 8011, New Zealand; [O'Hara, Lily] Qatar Univ, QU Hlth, Coll Hlth Sci, Dept Publ Hlth, POB 2713, Doha, Qatar; [Heywood, Anita] Univ New South Wales, Sch Populat Hlth, Sydney, NSW 2052, Australia; [Hobbs, Matthew] Univ Canterbury, Coll Educ Hlth & Human Dev, Sch Hlth Sci, Christchurch 8140, New Zealand; [Hobbs, Matthew] Univ Canterbury, GeoHlth Lab, Christchurch 8140, New Zealand; [Ballantyne, Angela; Gray, Lesley] Univ Otago, Dept Primary Hlth Care & Gen Practice, Wellington 6021, New Zealand; [Ballantyne, Angela] Natl Univ Singapore, Ctr Biomed Eth, Singapore 117597, Singapore; [Gray, Lesley] Massey Univ, Joint Ctr Disaster Res, Wellington 6140, New Zealand		Gray, L (通讯作者)，Univ Otago, Dept Primary Hlth Care & Gen Practice, Wellington 6021, New Zealand.; Gray, L (通讯作者)，Massey Univ, Joint Ctr Disaster Res, Wellington 6140, New Zealand.	camje968@student.otago.ac.nz; sutju965@student.otago.ac.nz; bucda480@student.otago.ac.nz; lohara@qu.edu.qa; a.heywood@unsw.edu.au; matt.hobbs@canterbury.ac.nz; angela.ballantyne@otago.ac.nz; lesley.gray@otago.ac.nz	Gray, Lesley/V-7565-2017	Gray, Lesley/0000-0001-6414-3236; /0000-0001-8398-7485; O'Hara, Lily/0000-0003-3000-7863	National Science FoundationNational Science Foundation (NSF); CONVERGE facility at the Natural HazardsCenter at the University of Colorado Boulder (NSF) [1841338]	Thanks to Izzy Lomax-Sawyers who assisted with initial piloting. This COVID-19 working group came together as part of the National Science Foundation-funded Social ScienceExtreme Events Research (SSEER) network and the CONVERGE facility at the Natural HazardsCenter at the University of Colorado Boulder (NSF #1841338). A link to the published journalarticle will be added to the CONVERGE webpage. Any opinions, findings, and conclusions orrecommendations expressed in this material are those of the authors and do not necessarily reflectthe views of the NSF, SSEER, or CONVERGE	Bacon L, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-9; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Banga N, 2014, VACCINE, V32, P979, DOI 10.1016/j.vaccine.2013.12.019; de Vries ST, 2019, BRIT J CLIN PHARMACO, V85, P1507, DOI 10.1111/bcp.13923; Dolezal L, 2017, MED HUMANIT, V43, P257, DOI 10.1136/medhum-2017-011186; Eisenberger NI, 2017, NEUROPSYCHOPHARMACOL, V42, P242, DOI 10.1038/npp.2016.141; Eliakim A, 2006, AUTOIMMUNITY, V39, P137, DOI 10.1080/08916930600597326; Flint SW, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.02124; Flint SW, 2020, LANCET DIABETES ENDO, V8, P474, DOI 10.1016/S2213-8587(20)30156-X; Frasca D, 2020, INTERD T GERONT GERI, V43, P86, DOI 10.1159/000504440; Fryar Cheryl D, 2020, NCHS Data Brief, P1; Garritty C, 2021, J CLIN EPIDEMIOL, V130, P13, DOI 10.1016/j.jclinepi.2020.10.007; Guidi J, 2020, PSYCHOTHER PSYCHOSOM, V90, P11, DOI 10.1159/000510696; Kapp N, 2015, CONTRACEPTION, V91, P97, DOI 10.1016/j.contraception.2014.11.001; Khalatbari-Soltani S, 2020, J EPIDEMIOL COMMUN H, V74, P620, DOI 10.1136/jech-2020-214297; Mensinger JL, 2018, BODY IMAGE, V25, P139, DOI 10.1016/j.bodyim.2018.03.001; Mitchell RS, 2008, AM J PREV MED, V35, P127, DOI 10.1016/j.amepre.2008.03.031; Moher D, 2016, REV ESP NUTR HUM DIE, V20, P148, DOI 10.14306/renhyd.20.2.223; O'Hara L, 2018, SAGE OPEN, V8, DOI 10.1177/2158244018772888; O'Hara Lily, 2006, Health Promot J Austr, V17, P260; Organisation for Economic Co-operation and Development, 2017, OB UPD; Painter SD, 2015, VACCINE, V33, P4422, DOI 10.1016/j.vaccine.2015.06.101; Pause C, 2021, INT J DISAST RISK RE, V54, DOI 10.1016/j.ijdrr.2020.102021; Pestine E, 2018, ANN ONCOL, V29, P1582, DOI 10.1093/annonc/mdy138; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sheridan PA, 2012, INT J OBESITY, V36, P1072, DOI 10.1038/ijo.2011.208; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Wang MH, 2020, ECLINICALMEDICINE, V26, DOI 10.1016/j.eclinm.2020.100521; Wee CC, 2000, ANN INTERN MED, V132, P697, DOI 10.7326/0003-4819-132-9-200005020-00003; World Health Organization, 2021, OB OV FACT SHEET; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18	31	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1466	10.3390/vaccines9121466			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YK5YE	34960212	Green Published, gold			2022-04-29	WOS:000745287000001
J	Lanfermeijer, J; Nuehn, MM; Emmelot, ME; Poelen, MCM; van Els, CACM; Borghans, JAM; van Baarle, D; Kaaijk, P; de Wit, J				Lanfermeijer, Josien; Nuehn, Marieke M.; Emmelot, Maarten E.; Poelen, Martien C. M.; van Els, Cecile A. C. M.; Borghans, Jose A. M.; van Baarle, Debbie; Kaaijk, Patricia; de Wit, Jelle			Longitudinal Characterization of the Mumps-Specific HLA-A2 Restricted T-Cell Response after Mumps Virus Infection	VACCINES			English	Article						mumps infection; T-cell immunity; MMR vaccination	BONE-MARROW; MEMORY; DYNAMICS; IMMUNITY; VACCINE; DIFFERENTIATION; PROLIFERATION; NETHERLANDS; OUTBREAKS; MEASLES	Waning of the mumps virus (MuV)-specific humoral response after vaccination has been suggested as a cause for recent mumps outbreaks in vaccinated young adults, although it cannot explain all cases. Moreover, CD8(+) T cells may play an important role in the response against MuV; however, little is known about the characteristics and dynamics of the MuV-specific CD8(+) T-cell response after MuV infection. Here, we had the opportunity to follow the CD8(+) T-cell response to three recently identified HLA-A2*02:01-restricted MuV-specific epitopes from 1.5 to 36 months post-MuV infection in five previously vaccinated and three unvaccinated individuals. The infection-induced CD8(+) T-cell response was dominated by T cells specific for the ALDQTDIRV and LLDSSTTRV epitopes, while the response to the GLMEGQIVSV epitope was subdominant. MuV-specific CD8(+) T-cell frequencies in the blood declined between 1.5 and 9 months after infection. This decline was not explained by changes in the expression of inhibitory receptors or homing markers. Despite the ongoing changes in the frequencies and phenotype of MuV-specific CD8(+) T cells, TCR beta analyses revealed a stable MuV-specific T-cell repertoire over time. These insights in the maintenance of the cellular response against mumps may provide hallmarks for optimizing vaccination strategies towards a long-term cellular memory response.	[Lanfermeijer, Josien; Nuehn, Marieke M.; Emmelot, Maarten E.; Poelen, Martien C. M.; van Els, Cecile A. C. M.; van Baarle, Debbie; Kaaijk, Patricia; de Wit, Jelle] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3721 MA Bilthoven, Netherlands; [Lanfermeijer, Josien; Borghans, Jose A. M.; van Baarle, Debbie] Univ Med Ctr Utrecht, Ctr Translat Immunol, NL-3584 CX Utrecht, Netherlands; [van Els, Cecile A. C. M.] Univ Utrecht, Dept Biomol Hlth Sci, Fac Vet Med, NL-3584 CX Utrecht, Netherlands; [van Baarle, Debbie] Univ Med Ctr Groningen, Virol & Immunol Res, Dept Med Microbiol & Infect Prevent, NL-9713 GZ Groningen, Netherlands		de Wit, J (通讯作者)，Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3721 MA Bilthoven, Netherlands.	josien.lanfermeijer@rivm.nl; patricia.kaaijk@rivm.nl; jelle.de.wit@rivm.nl		de Wit, Jelle/0000-0003-2444-6050; van Els, Cecile/0000-0003-1995-8641; Nuhn, Marieke/0000-0002-4360-0431; Lanfermeijer, Josien/0000-0003-0364-5237; Kaaijk, Patricia/0000-0001-9165-1703			Ahn E, 2018, P NATL ACAD SCI USA, V115, P4749, DOI 10.1073/pnas.1718217115; Al-Azzam S, 2020, PEPTIDES, V134, DOI 10.1016/j.peptides.2020.170402; Alp OS, 2015, EUR J IMMUNOL, V45, P975, DOI 10.1002/eji.201445295; Annels NE, 2000, J IMMUNOL, V165, P4831, DOI 10.4049/jimmunol.165.9.4831; Badovinac VP, 2003, J IMMUNOL, V170, P4933, DOI 10.4049/jimmunol.170.10.4933; Badovinac VP, 2002, NAT IMMUNOL, V3, P619, DOI 10.1038/ni804; Becker TC, 2005, J IMMUNOL, V174, P1269, DOI 10.4049/jimmunol.174.3.1269; Co MDT, 2009, IMMUNOLOGY, V128, pe718, DOI 10.1111/j.1365-2567.2009.03070.x; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; David P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00054; Dayan GH, 2008, CLIN INFECT DIS, V47, P1458, DOI 10.1086/591196; Dayan GH, 2008, NEW ENGL J MED, V358, P1580, DOI 10.1056/NEJMoa0706589; de Wit J, 2020, J INFECT DIS, V221, P474, DOI 10.1093/infdis/jiz480; de Wit J, 2019, J VIROL, V93, DOI 10.1128/JVI.01883-18; de Wit J, 2018, J ALLERGY CLIN IMMUN, V141, P1908, DOI 10.1016/j.jaci.2017.11.047; DeWitt WS, 2015, J VIROL, V89, P4517, DOI 10.1128/JVI.03474-14; Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297; Gans H, 2001, J INFECT DIS, V184, P817, DOI 10.1086/323346; Gerritsen B, 2016, BIOINFORMATICS, V32, P3098, DOI 10.1093/bioinformatics/btw339; Goedhart M, 2019, EUR J IMMUNOL, V49, P576, DOI 10.1002/eji.201747438; Gouma S, 2014, J GEN VIROL, V95, P1074, DOI 10.1099/vir.0.062943-0; Groom JR, 2011, EXP CELL RES, V317, P620, DOI 10.1016/j.yexcr.2010.12.017; Iancu EM, 2009, J IMMUNOL, V183, P319, DOI 10.4049/jimmunol.0803647; Jokinen S, 2007, J INFECT DIS, V196, P861, DOI 10.1086/521029; Jubel JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00487; Kaaijk P, 2008, Euro Surveill, V13; Kaaijk P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070699; Kaaijk P, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92926-1; Kaaijk P, 2015, HUM VACC IMMUNOTHER, V11, P1754, DOI 10.1080/21645515.2015.1040967; Kaech SM, 2002, CELL, V111, P837, DOI 10.1016/S0092-8674(02)01139-X; Karagiannis I, 2008, Euro Surveill, V13; Klarenbeek PL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002889; Kurachi M, 2011, J EXP MED, V208, P1605, DOI 10.1084/jem.20102101; Lanfermeijer J., FRONT AGING, V2, DOI [10.3389/fragi.2021.665637, DOI 10.3389/FRAGI.2021.665637]; MacDonald N, 2011, ADV EXP MED BIOL, V697, P197, DOI 10.1007/978-1-4419-7185-2_14; Mamedov IZ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00456; Martin MD, 2012, J IMMUNOL, V188, P1255, DOI 10.4049/jimmunol.1101579; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; Minervina AA, 2020, ELIFE, V9, DOI 10.7554/eLife.53704; Muhlemann K, 2004, INFECT GENET EVOL, V4, P215, DOI 10.1016/j.meegid.2004.02.003; Okhrimenko A, 2014, P NATL ACAD SCI USA, V111, P9229, DOI 10.1073/pnas.1318731111; Palendira U, 2008, BLOOD, V112, P3293, DOI 10.1182/blood-2008-02-138040; Pauken KE, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107827; Plotkin S.A., 2018, VACCINES-BASEL; Rasheed MAU, 2019, P NATL ACAD SCI USA, V116, P19071, DOI 10.1073/pnas.1905570116; Remmerswaal EBM, 2019, EUR J IMMUNOL, V49, P694, DOI 10.1002/eji.201847897; Renkema KR, 2020, J IMMUNOL, V205, P1059, DOI 10.4049/jimmunol.1901512; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sane J, 2014, EMERG INFECT DIS, V20, P643, DOI 10.3201/eid2004.131681; Santak M, 2013, EPIDEMIOL INFECT, V141, P1298, DOI 10.1017/S0950268812001896; Schonrich G, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00207; Slifka MK, 2014, VACCINE, V32, P2948, DOI 10.1016/j.vaccine.2014.03.078; Vandermeulen C, 2009, J INFECT DIS, V199, P1457, DOI 10.1086/598482; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862	55	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1431	10.3390/vaccines9121431			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0UB	34960178	Green Published, gold			2022-04-29	WOS:000737376600001
J	Piazza, MF; Amicizia, D; Paganino, C; Marchini, F; Astengo, M; Grammatico, F; Trucchi, C; Romairone, P; Simonetti, S; Sticchi, C; Ansaldi, F				Piazza, Maria Francesca; Amicizia, Daniela; Paganino, Chiara; Marchini, Francesca; Astengo, Matteo; Grammatico, Federico; Trucchi, Cecilia; Romairone, Paolo; Simonetti, Simona; Sticchi, Camilla; Ansaldi, Filippo			Has Clinical and Epidemiological Varicella Burden Changed over Time in Children? Overview on Hospitalizations, Comorbidities and Costs from 2010 to 2017 in Italy	VACCINES			English	Article						varicella disease; epidemiological burden; economic burden; hospitalization; children; comorbidities; vaccination coverage; outpatient services; pharmaceutical costs	VACCINATION; IMPACT; COMPLICATIONS; MULTICENTER; CHICKENPOX	According to WHO estimates, varicella disease is responsible of a worldwide significant burden in terms of hospitalizations, complications, and deaths, with more than 90% of cases under 12 years old. This study aims at evaluating the clinical, epidemiological, and economic burden of varicella in Ligurian children, about comorbidities, organizational variables, and vaccination coverages from 2010 to 2017, in terms of Emergency Department accesses and hospitalizations. The overall hospitalization rate was 179.76 (per 100,000 inhab.), with a gradual but significant decline since 2015, when universal varicella vaccination was introduced in Liguria (p < 0.0001). The risk of being hospitalized for complicated varicella in subjects with at least one comorbidity was significantly higher than in subjects without comorbidities (p = 0.0016). The economic analysis showed higher costs in subjects with complicated varicella who were 0-3 years old. This age group showed higher costs also considering extra-hospital costs for both outpatient procedures and pharmaceutical costs (p < 0.0001). The results confirm the relevant burden of varicella, especially in the 0-3 age group and in children with comorbidities. Thus, vaccination with the achievement of adequate vaccination coverages is confirmed to be a necessary control strategy to reduce hospitalizations and associated complications with important economic benefits.	[Piazza, Maria Francesca; Amicizia, Daniela; Paganino, Chiara; Marchini, Francesca; Astengo, Matteo; Trucchi, Cecilia; Sticchi, Camilla; Ansaldi, Filippo] Reg Hlth Agcy Liguria ALiSa, I-16121 Genoa, Italy; [Amicizia, Daniela; Grammatico, Federico; Ansaldi, Filippo] Univ Genoa, Dept Hlth Sci DiSSal, I-16132 Genoa, Italy; [Romairone, Paolo; Simonetti, Simona] Liguria Digitale SpA, I-16121 Genoa, Italy		Piazza, MF (通讯作者)，Reg Hlth Agcy Liguria ALiSa, I-16121 Genoa, Italy.	mariafrancesca.piazza@alisa.liguria.it; daniela.amicizia@unige.it; chiara.paganino@alisa.liguria.it; francesca.marchini@alisa.liguria.it; matteo.astengo@alisa.liguria.it; federico.grammatico@alisa.liguria.it; cecilia.trucchi@alisa.liguria.it; p.romairone@liguriadigitale.it; s.simonetti@liguriadigitale.it; camilla.Sticchi@alisa.liguria.it; filippo.ansaldi@alisa.liguria.it		Amicizia, Daniela/0000-0002-9707-5214; Piazza, Maria Francesca/0000-0002-2404-3609	GlaxoSmithKline Biologicals SAGlaxoSmithKline [121-2019]	The Department of Health Sciences of the University of Genoa received a grant from GlaxoSmithKline Biologicals SA (funding number: 121-2019) to support the conduction of the study.	Amodio E, 2015, HUM VACC IMMUNOTHER, V11, P236, DOI 10.4161/hv.36157; [Anonymous], 2016, VACCINE, V34, P198, DOI 10.1016/j.vaccine.2014.07.068; Arvin AM, 1996, CLIN MICROBIOL REV, V9, P361, DOI 10.1128/CMR.9.3.361; Azzari C, 2007, CURR MED RES OPIN, V23, P2945, DOI 10.1185/030079907X242610; Bonanni P, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-26; European Centre for Disease Prevention and Control (ECDC), 2015, VAR VACC EUR UN; Gabutti G, 2016, MINERVA PEDIATR, V68, P213; Gabutti G, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-372; Gershon AA, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.16; Giammanco G, 2009, EUROSURVEILLANCE, V14, P16; Gil A, 2001, VACCINE, V20, P295, DOI 10.1016/S0264-410X(01)00370-X; Grimprel E, 2007, CLIN MICROBIOL INFEC, V13, P546, DOI 10.1111/j.1469-0691.2007.01706.x; Heininger U, 2006, LANCET, V368, P1365, DOI 10.1016/S0140-6736(06)69561-5; Helmuth IG, 2015, VACCINE, V33, P2406, DOI 10.1016/j.vaccine.2015.03.055; Kuter B, 2004, PEDIATR INFECT DIS J, V23, P132, DOI 10.1097/01.inf.0000109287.97518.67; Liese JG, 2008, PEDIATR INFECT DIS J, V27, P119, DOI 10.1097/INF.0b013e3181586665; Marchetto S, 2007, ACTA PAEDIATR, V96, P1490, DOI 10.1111/j.1651-2227.2007.00465.x; Meszner Z, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2575-6; Ministero dell'Economia e delle Finanze, 2007, LIBR VERD SPES PUBBL; Ozdemir H, 2011, TURKISH J PEDIATR, V53, P614; Papaloukas Orestis, 2014, Ther Adv Vaccines, V2, P39, DOI 10.1177/2051013613515621; Piazza MF, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010020; Prymula R, 2014, LANCET, V383, P1313, DOI 10.1016/S0140-6736(12)61461-5; Riera-Montes M, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2445-2; Spackova M, 2010, PEDIATR INFECT DIS J, V29, P884, DOI 10.1097/INF.0b013e3181e2817f; Strategic Advisory Group of Experts on Immunisation Varicella Wroking Group, 2014, SYST REV AV EV EFF D; Tan B, 2012, PEDIATR INFECT DIS J, V31, P956, DOI 10.1097/INF.0b013e318260cc4d; Trucchi C, 2015, J MED MICROBIOL, V64, P1387, DOI 10.1099/jmm.0.000061; Unim B, 2013, HUM VACC IMMUNOTHER, V9, P1932, DOI 10.4161/hv.25228; Varela FH, 2019, HUM VACC IMMUNOTHER, V15, P645, DOI 10.1080/21645515.2018.1546525; Warren-Gash C, 2017, EXPERT REV VACCINES, V16, P1191, DOI 10.1080/14760584.2017.1394843; Waye A, 2013, VACCINE, V31, P4744, DOI 10.1016/j.vaccine.2013.08.022	32	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1485	10.3390/vaccines9121485			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YG8SO	34960231	Green Published, gold			2022-04-29	WOS:000742751200001
J	Timmermann, L; Globke, B; Lurje, G; Schmelzle, M; Schoening, W; Oellinger, R; Pratschke, J; Eberspaecher, B; Drosten, C; Hofmann, J; Eurich, D				Timmermann, Lea; Globke, Brigitta; Lurje, Georg; Schmelzle, Moritz; Schoening, Wenzel; Oellinger, Robert; Pratschke, Johann; Eberspaecher, Bettina; Drosten, Christian; Hofmann, Joerg; Eurich, Dennis			Humoral Immune Response following SARS-CoV-2 Vaccination in Liver Transplant Recipients	VACCINES			English	Article						liver transplantation; anti-SARS-CoV-2-antibodies; COVID-19		As COVID-19 remains an issue in transplantation medicine, a successful vaccination can prevent infections and life-threatening courses. The probability of poor immune response in liver transplant recipients gained attention and insecurity among those patients, leading us to investigate the humoral immune response alongside the influence of underlying diseases and immunosuppressive regimen on seroconversion rates. We included 118 patients undergoing anti-spike-protein-IgG testing at least 21 days after completed SARS-CoV-2 vaccination. Ninety-seven patients also underwent anti-spike-protein-IgA testing. The influence of baseline demographics, immunosuppressive regimen and underlying disease on seroconversion was analyzed, and 92 of 118 patients (78.0%) developed anti-spike-protein-IgG antibodies. Patients with a history of alcoholic liver disease before transplantation showed significantly lower seroconversion rates (p = 0.006). Immunosuppression also significantly influenced antibody development (p < 0.001). Patients run on a mycophenolate mofetil (MMF)-based regimen were more likely not to develop antibodies compared to patients run on a non-MMF regimen (p < 0.001). All patients weaned off immunosuppression were seropositive. The seroconversion rate of 78.0% in our cohort of liver transplant recipients is promising. The identification of alcohol-induced cirrhosis as underlying disease and MMF for immunosuppression as risk factors for seronegativity may serve to identify vaccination non-responder after liver transplantation.	[Timmermann, Lea; Globke, Brigitta; Lurje, Georg; Schmelzle, Moritz; Schoening, Wenzel; Oellinger, Robert; Pratschke, Johann; Eurich, Dennis] Charite Univ Med Berlin, Dept Surg, D-13353 Berlin, Germany; [Timmermann, Lea; Globke, Brigitta; Lurje, Georg; Schmelzle, Moritz; Schoening, Wenzel; Oellinger, Robert; Pratschke, Johann; Drosten, Christian; Hofmann, Joerg; Eurich, Dennis] Humboldt Univ, Freie Univ Berlin, D-13353 Berlin, Germany; [Timmermann, Lea; Globke, Brigitta; Lurje, Georg; Schmelzle, Moritz; Schoening, Wenzel; Oellinger, Robert; Pratschke, Johann; Drosten, Christian; Hofmann, Joerg; Eurich, Dennis] Berlin Inst Hlth, D-13353 Berlin, Germany; [Eberspaecher, Bettina; Hofmann, Joerg] Lab Berlin Charite Vivantes GmbH, D-13353 Berlin, Germany; [Drosten, Christian; Hofmann, Joerg] Univ Med Berlin, Dept Virol, D-13353 Berlin, Germany		Timmermann, L (通讯作者)，Charite Univ Med Berlin, Dept Surg, D-13353 Berlin, Germany.; Timmermann, L (通讯作者)，Humboldt Univ, Freie Univ Berlin, D-13353 Berlin, Germany.; Timmermann, L (通讯作者)，Berlin Inst Hlth, D-13353 Berlin, Germany.	lea.timmermann@charite.de; brigitta.globke@charite.de; georg.lurje@charite.de; moritz.schmelzle@charite.de; wenzel.schoening@charite.de; robert.oellinger@charite.de; johann.pratschke@charite.de; bettina.eberspaecher@laborberlin.com; christian.drosten@charite.de; joerg.hofmann@charite.de; dennis.eurich@charite.de		Ollinger, Robert/0000-0002-4499-1673; Lurje, Georg/0000-0001-9674-0756			Aslam S, 2021, TRANSPL INFECT DIS, V23, DOI 10.1111/tid.13705; Becchetti C, 2020, GUT, V69, P1832, DOI 10.1136/gutjnl-2020-321923; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P1784, DOI 10.1001/jama.2021.4385; Colmenero J, 2021, J HEPATOL, V74, P148, DOI 10.1016/j.jhep.2020.07.040; Del Bello A, 2022, AM J TRANSPLANT, V22, P322, DOI 10.1111/ajt.16775; Dumortier J, 2022, CLIN RES HEPATOL GAS, V46, DOI 10.1016/j.clinre.2021.101743; Dumortier J, 2021, CLIN RES HEPATOL GAS, V45, DOI 10.1016/j.clinre.2021.101639; Georgery H, 2021, TRANSPLANTATION, V105, pE283, DOI 10.1097/TP.0000000000003861; Glatman-Freedman A, 2021, EBIOMEDICINE, V72, DOI 10.1016/j.ebiom.2021.103574; Grupper A, 2021, CLIN TRANSPLANT, V35, DOI 10.1111/ctr.14478; Grupper A, 2021, AM J TRANSPLANT, V21, P2719, DOI 10.1111/ajt.16615; Hall VG, 2021, AM J TRANSPLANT, V21, P3980, DOI 10.1111/ajt.16766; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Kates Olivia S, 2021, Clin Infect Dis, V73, pe4090, DOI 10.1093/cid/ciaa1097; Korth J, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050756; Lakota K, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.611318; Malinis M, 2021, AM J TRANSPLANT, V21, P2916, DOI 10.1111/ajt.16713; Marion O, 2021, ANN INTERN MED, V174, P1336, DOI 10.7326/M21-1341; Rabinowich L, 2021, J HEPATOL, V75, P435, DOI 10.1016/j.jhep.2021.04.020; Ruether DF, 2022, CLIN GASTROENTEROL H, V20, P162, DOI 10.1016/j.cgh.2021.09.003; Sattler A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI150175; Serper M, 2021, TRANSPL INFECT DIS, V23, DOI 10.1111/tid.13722; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Thuluvath PJ, 2021, J HEPATOL, V75, P1434, DOI 10.1016/j.jhep.2021.08.008; Verbeek J, 2022, TRANSPLANTATION, V106, P862, DOI 10.1097/TP.0000000000003955; Villanego F, 2021, AM J TRANSPLANT, DOI 10.1111/ajt.16829; Webb GJ, 2020, LANCET GASTROENTEROL, V5, P1008, DOI 10.1016/S2468-1253(20)30271-5; Westhoff TH, 2021, KIDNEY INT, V100, P1135, DOI 10.1016/j.kint.2021.09.001; Wisnewski AV, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249499	30	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1422	10.3390/vaccines9121422			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9AG	34960168	gold, Green Published			2022-04-29	WOS:000737255600001
J	Xue, SJ; Seo, K; Yang, MS; Cui, CD; Yang, M; Xiang, SY; Yan, ZB; Wu, SJ; Han, JC; Yu, XY; Li, YX; Jin, X				Xue, Shujiang; Seo, Kangseok; Yang, Miaosen; Cui, Chengdu; Yang, Meng; Xiang, Siyu; Yan, Zongbin; Wu, Shengjun; Han, Jincheng; Yu, Xiaoyang; Li, Yunxiao; Jin, Xin			Mycoplasma suis Alpha-Enolase Subunit Vaccine Induces an Immune Response in Experimental Animals	VACCINES			English	Article						Mycoplasma suis; alpha-enolase; subunit vaccine; immune response	LINKED-IMMUNOSORBENT-ASSAY; PORCINE EPERYTHROZOONOSIS; HAEMOTROPHIC MYCOPLASMAS; MOLECULAR-DETECTION; INFECTION; PREVALENCE; EXPRESSION; PROTEOME; ADHESION; ANTIBODY	Recombinant protein technology has emerged as an excellent option for vaccine development. However, prior to our study, the immune induction ability of recombinant Mycoplasma suis alpha-enolase (rMseno) in animals remained unclear. The purpose of this study was to develop a rMseno protein subunit vaccine and to determine its ability to elicit an immunological response. To accomplish this, we cloned the gene into pET-15b, expressed it in BL21 cells, and purified it. Following the establishment of immunity, the immunogenicity and potential for protection of rMseno were evaluated in mice and piglets. The results demonstrate that anti-M. suis serum recognized the pure rMseno protein in both mice and piglets as evidenced by high levels of specific anti-rMseno antibodies, significantly increased levels of IFN-gamma and IL-4 cytokines, and significantly increased T lymphocyte proliferation index. Piglets also had significantly increased levels of specific IgG(1), IgG(2a), CD4(+), and CD8(+) cells. The rMseno findings demonstrated a robust immunological response in mice and piglets, affording partial clinical protective efficacy in piglets.	[Xue, Shujiang; Cui, Chengdu; Xiang, Siyu; Yan, Zongbin; Wu, Shengjun; Han, Jincheng; Yu, Xiaoyang; Jin, Xin] Yanbian Univ, Coll Agr, Dept Vet Med, Yanji 133002, Peoples R China; [Xue, Shujiang; Jin, Xin] Yanbian Univ, Engn Res Ctr North East Cold Reg Beef Cattle Sci, Minist Educ, Yanji 133002, Peoples R China; [Seo, Kangseok] Sunchon Natl Univ, Dept Anim Sci & Technol, Sunchon 57922, South Korea; [Yang, Miaosen] Northeast Elect Power Univ, Dept Chem, Jilin 132011, Jilin, Peoples R China; [Yang, Meng] Jiangsu Food & Pharmaceut Sci Coll, Dept Pharm, Huaian 223023, Peoples R China; [Li, Yunxiao] Shandong Univ, Sch Life Sci, Qingdao 266237, Peoples R China		Jin, X (通讯作者)，Yanbian Univ, Coll Agr, Dept Vet Med, Yanji 133002, Peoples R China.; Jin, X (通讯作者)，Yanbian Univ, Engn Res Ctr North East Cold Reg Beef Cattle Sci, Minist Educ, Yanji 133002, Peoples R China.; Li, YX (通讯作者)，Shandong Univ, Sch Life Sci, Qingdao 266237, Peoples R China.	sjxue@ybu.edu.cn; sks@scnu.ac.kr; 20162684@neepu.edu.cn; cdcui@ybu.edu.cn; 20071005@jsfpc.edu.cn; xiangsiyu1023@163.com; 13843945393@163.com; wushengjunpromab@163.com; hjc15904350685@163.com; yxyang199719@163.com; yunxiao.li@sdu.edu.cn; jinxin@ybu.edu.cn			National Natural Science Foundation Committee of ChinaNational Natural Science Foundation of China (NSFC) [31460657]; Higher Education Discipline Innovation 111 project [D20034]	FundingThis work was financially supported by grants from the National Natural Science Foundation Committee of China (grant number 31460657) and the Higher Education Discipline Innovation 111 project (grant number D20034).	Acosta DB, 2019, ACTA TROP, V194, P165, DOI 10.1016/j.actatropica.2019.04.007; Dias GB, 2019, COMP IMMUNOL MICROB, V63, P94, DOI 10.1016/j.cimid.2019.01.013; Dietz S, 2016, PROTEOMICS, V16, P609, DOI 10.1002/pmic.201500238; Felder KM, 2012, J BACTERIOL, V194, P1505, DOI 10.1128/JB.00002-12; Furesz SE, 1998, VACCINE, V16, P1971, DOI 10.1016/S0264-410X(98)00120-0; Groebel K, 2009, INFECT IMMUN, V77, P576, DOI 10.1128/IAI.00773-08; Hoelzle K, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-194; Hoelzle K, 2010, VET MICROBIOL, V143, P405, DOI 10.1016/j.vetmic.2009.11.015; Hoelzle K, 2009, VACCINE, V27, P5376, DOI 10.1016/j.vaccine.2009.06.072; Hoelzle LE, 2008, VET MICROBIOL, V130, P215, DOI 10.1016/j.vetmic.2007.12.023; Hoelzle LE, 2011, TIERAERZTL PRAX G N, V39, P215; Hoelzle LE, 2007, MICROBES INFECT, V9, P466, DOI 10.1016/j.micinf.2007.01.004; Hoelzle LE, 2007, FEMS IMMUNOL MED MIC, V49, P215, DOI 10.1111/j.1574-695X.2006.00184.x; Hoelzle LE, 2014, VET J, V202, P20, DOI 10.1016/j.tvjl.2014.07.023; Hoelzle LE, 2007, BERL MUNCH TIERARZTL, V120, P34, DOI 10.2376/0005-9366-120-26; Layh-Schmitt G, 2000, MICROBIOL-UK, V146, P741, DOI 10.1099/00221287-146-3-741; Lee YQ, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.645856; Liang ZY, 2017, CAN J VET RES, V81, P313; Liu JZ, 2012, RES VET SCI, V93, P48, DOI 10.1016/j.rvsc.2011.08.016; Liu JZ, 2011, RES VET SCI, V91, pE100, DOI 10.1016/j.rvsc.2011.02.009; Liu MM, 2014, RES VET SCI, V97, P282, DOI 10.1016/j.rvsc.2014.07.003; Meng K, 2014, BIOSENS BIOELECTRON, V55, P396, DOI 10.1016/j.bios.2013.12.048; Messick JB, 2004, VET CLIN PATH, V33, P2, DOI 10.1111/j.1939-165X.2004.tb00342.x; Neimark H, 2002, INT J SYST EVOL MICR, V52, P683, DOI 10.1099/00207713-52-2-683; Neimark H, 2001, INT J SYST EVOL MICR, V51, P891, DOI 10.1099/00207713-51-3-891; Okamba FR, 2007, CLIN VACCINE IMMUNOL, V14, P767, DOI 10.1128/CVI.00415-06; Perez-Casal J, 2016, VACCINE, V34, P1012, DOI 10.1016/j.vaccine.2015.11.072; PUNTARIC V, 1986, LANCET, V2, P868; Ritzmann M, 2009, VET MICROBIOL, V133, P84, DOI 10.1016/j.vetmic.2008.06.015; Schreiner SA, 2012, VET MICROBIOL, V156, P88, DOI 10.1016/j.vetmic.2011.10.010; Serrano FJ, 2001, PARASITE, V8, pS133, DOI 10.1051/parasite/200108s2133; Sokoli A, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-6; Song QQ, 2018, RES VET SCI, V119, P85, DOI 10.1016/j.rvsc.2018.05.001; Song QQ, 2014, PREV VET MED, V117, P215, DOI 10.1016/j.prevetmed.2014.07.006; Stadler J, 2021, BMC VET RES, V17, DOI 10.1186/s12917-021-02919-5; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; Strait EL, 2012, JAVMA-J AM VET MED A, V241, P1666, DOI 10.2460/javma.241.12.1666; Thacker EL, 2000, AM J VET RES, V61, P1384, DOI 10.2460/ajvr.2000.61.1384; Toledo MA, 2016, REV BRAS PARASITOL V, V25, P414, DOI [10.1590/S1984-29612016084, 10.1590/s1984-29612016084]; Wu JS, 2006, ANN NY ACAD SCI, V1081, P280, DOI 10.1196/annals.1373.038; Yuan CL, 2009, AM J VET RES, V70, P890, DOI 10.2460/ajvr.70.7.890; Zhang SF, 2008, J VET MED SCI, V70, P1143, DOI 10.1292/jvms.70.1143	42	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1506	10.3390/vaccines9121506			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XY9TA	34960252	gold, Green Published			2022-04-29	WOS:000737306200001
J	Choo, JJY; McMillan, CLD; Fernando, GJP; Hall, RA; Young, PR; Hobson-Peters, J; Muller, DA				Choo, Jovin J. Y.; McMillan, Christopher L. D.; Fernando, Germain J. P.; Hall, Roy A.; Young, Paul R.; Hobson-Peters, Jody; Muller, David A.			Developing a Stabilizing Formulation of a Live Chimeric Dengue Virus Vaccine Dry Coated on a High-Density Microarray Patch	VACCINES			English	Article						dengue; high-density microarray patch; microneedles; dengue vaccine; chimeric virus; formulation	MICRONEEDLE PATCH; ANTIGEN; DELIVERY; RESPONSES; POTENT	Alternative delivery systems such as the high-density microarray patch (HD-MAP) are being widely explored due to the variety of benefits they offer over traditional vaccine delivery methods. As vaccines are dry coated onto the HD-MAP, there is a need to ensure the stability of the vaccine in a solid state upon dry down. Other challenges faced are the structural stability during storage as a dried vaccine and during reconstitution upon application into the skin. Using a novel live chimeric virus vaccine candidate, BinJ/DENV2-prME, we explored a panel of pharmaceutical excipients to mitigate vaccine loss during the drying and storage process. This screening identified human serum albumin (HSA) as the lead stabilizing excipient. When bDENV2-coated HD-MAPs were stored at 4 & DEG;C for a month, we found complete retention of vaccine potency as assessed by the generation of potent virus-neutralizing antibody responses in mice. We also demonstrated that HD-MAP wear time did not influence vaccine deposition into the skin or the corresponding immunological outcomes. The final candidate formulation with HSA maintained ~100% percentage recovery after 6 months of storage at 4 & DEG;C.	[Choo, Jovin J. Y.; McMillan, Christopher L. D.; Fernando, Germain J. P.; Hall, Roy A.; Young, Paul R.; Hobson-Peters, Jody; Muller, David A.] Univ Queensland, Australian Infect Dis Res Ctr, Sch Chem & Mol Biosci, Brisbane, Qld 4072, Australia; [Fernando, Germain J. P.; Muller, David A.] Vaxxas Pty Ltd, Translat Res Inst, 37 Kent St, Brisbane, Qld 4102, Australia		Muller, DA (通讯作者)，Univ Queensland, Australian Infect Dis Res Ctr, Sch Chem & Mol Biosci, Brisbane, Qld 4072, Australia.; Muller, DA (通讯作者)，Vaxxas Pty Ltd, Translat Res Inst, 37 Kent St, Brisbane, Qld 4102, Australia.	j.choo@uq.net.au; c.mcmillan1@uq.edu.au; g.fernando@uq.edu.au; roy.hall@uq.edu.au; p.young@uq.edu.au; j.peters2@uq.edu.au; d.muller4@uq.edu.au	Young, Paul R/A-6176-2010; Fernando, Germain/C-3733-2009	Young, Paul R/0000-0002-2040-5190; Hobson-Peters, Jody/0000-0003-0139-9829; McMillan, Christopher/0000-0002-5316-0986; Muller, David/0000-0003-4375-7890; Fernando, Germain/0000-0003-3260-0548; Choo, Jovin Jia Ying/0000-0003-4886-9437	National Health and Medical Research Development [APP1139754, APP1178896]	This work was supported by National Health and Medical Research Development grants from the Australian Government, APP1139754 and APP1178896.	Arnemo M, 2016, J INFECT DIS, V213, P930, DOI 10.1093/infdis/jiv532; BEALE AJ, 1962, J HYG-CAMBRIDGE, V60, P113, DOI 10.1017/S002217240003936X; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Choo JJY, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00328-1; Collins MH, 2017, CLIN THER, V39, P1519, DOI 10.1016/j.clinthera.2017.07.001; Combadiere B, 2011, HUM VACCINES, V7, P811, DOI 10.4161/hv.7.8.16274; Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058; Depelsenaire ACI, 2014, J INVEST DERMATOL, V134, P2361, DOI 10.1038/jid.2014.174; Durbin AP, 2013, J INFECT DIS, V207, P957, DOI 10.1093/infdis/jis936; Edens C, 2015, VACCINE, V33, P4712, DOI 10.1016/j.vaccine.2015.02.074; Faust SN, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1425-7; Fernando GJP, 2018, VACCINE, V36, P3779, DOI 10.1016/j.vaccine.2018.05.053; Fernando GJP, 2012, J CONTROL RELEASE, V159, P215, DOI 10.1016/j.jconrel.2012.01.030; Fernando GJP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010266; Forster AH, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003024; Guzman MG, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.55; Holbrook MR, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050097; Islam R, 2015, VIROL SIN, V30, P326, DOI 10.1007/s12250-015-3624-1; Kolluru C, 2019, DRUG DELIV TRANSL RE, V9, P192, DOI 10.1007/s13346-018-00608-9; Laurent PE, 2007, VACCINE, V25, P8833, DOI 10.1016/j.vaccine.2007.10.020; Levin Y, 2015, HUM VACC IMMUNOTHER, V11, P991, DOI 10.1080/21645515.2015.1010871; Li J, 2018, STRUCTURE, V26, P51, DOI 10.1016/j.str.2017.11.017; Limited T.P.C., TAKEDA BEGINS REGULA; McMillan C.L.D., 2021, SCI ADV, V7, DOI [10.1126/sciadv.abj8065, DOI 10.1126/SCIADV.ABJ8065]; Messina JP, 2014, TRENDS MICROBIOL, V22, P138, DOI 10.1016/j.tim.2013.12.011; Mistilis MJ, 2015, J PHARM SCI-US, V104, P740, DOI 10.1002/jps.24283; Muller DA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75169-4; Muller DA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040189; Muller DA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13011-0; Muller DA, 2016, SCI REP-UK, V6, DOI 10.1038/srep22094; Ng HI, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0134-4; Ng HI, 2016, SCI REP-UK, V6, DOI 10.1038/srep29368; Ng HI, 2012, J CONTROL RELEASE, V162, P477, DOI 10.1016/j.jconrel.2012.07.024; Nightingale ZD, 2008, J LEUKOCYTE BIOL, V84, P1028, DOI 10.1189/jlb.0208105; Osorio JE, 2015, VACCINE, V33, P7112, DOI 10.1016/j.vaccine.2015.11.022; Raphael AP, 2013, J CONTROL RELEASE, V166, P87, DOI 10.1016/j.jconrel.2012.12.010; Raymond C.R., 2013, PHARM DEV TECHNOL, V18, P544, DOI [10.3109/10837450.2012.751408, DOI 10.3109/10837450.2012.751408]; REED L. J., 1938, AMER JOUR HYG, V27, P493; Turvey ME, 2019, BIOENG TRANSL MED, V4, DOI 10.1002/btm2.10127; Wan Y, 2021, HUM VACC IMMUNOTHER, V17, P2501, DOI 10.1080/21645515.2021.1887692; Wan Y, 2018, J PHARM SCI-US, V107, P1540, DOI 10.1016/j.xphs.2018.01.027; Wiedmann RT, 2015, VACCINE, V33, P2132, DOI 10.1016/j.vaccine.2015.03.017; Wiggan O, 2011, VACCINE, V29, P7456, DOI 10.1016/j.vaccine.2011.07.054; Wong YH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26800-y	44	0	0	9	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1301	10.3390/vaccines9111301			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH1AV	34835234	gold, Green Published			2022-04-29	WOS:000725175000001
J	Della Polla, G; Pelullo, CP; Di Giuseppe, G; Angelillo, IF				Della Polla, Giorgia; Pelullo, Concetta Paola; Di Giuseppe, Gabriella; Angelillo, Italo Francesco			Changes in Behaviors and Attitudes in Response to COVID-19 Pandemic and Vaccination in Healthcare Workers and University Students in Italy	VACCINES			English	Article						attitudes; behaviors; COVID-19; healthcare workers; Italy; students; vaccination; willingness	RISK PERCEPTION; KNOWLEDGE; FEAR	The objectives of the cross-sectional study were to measure how behaviors and attitudes about preventive measures toward COVID-19 changed over time among Italian vaccinated healthcare workers and university students, and the associated characteristics. The study was carried out between February and March 2021 in the city of Naples, Campania region, Southern Italy. The perceived personal risk of being infected by SARS-CoV-2 after the vaccination was significantly higher among males, in those having a higher perceived personal risk of being infected by SARS-CoV-2 before the vaccination, and in those who were more concerned about the efficacy of the vaccination. The fear of getting the disease as reason to have the COVID-19 vaccination was reported more frequently in younger participants, in those with at least one chronic medical condition, in those with a higher concern about the severity of COVID-19, in those with a higher level of trust in the information received, and in those who acquired information from scientific journals. Overall, 21.3% were willing to engage the three main public health measures (wearing a mask, careful hand washing, physical distancing) after receiving the second dose of the vaccination compared to the behavior before the pandemic began. This willingness was predicted by a higher level of trust in the information received and by a lower self-rated health status. Only 0.1% of participants were willing to engage all three measures after receiving the second dose of the vaccination compared to the behavior before receiving the first dose. These findings are useful in order to develop information strategies regarding vaccine safety and efficacy and the importance of public health measures against COVID-19.	[Della Polla, Giorgia] Univ Campania Luigi Vanvitelli, Teaching Hosp, Hlth Direct, Via Santa Maria di Costantinopoli 104, I-80138 Naples, Italy; [Pelullo, Concetta Paola; Di Giuseppe, Gabriella; Angelillo, Italo Francesco] Univ Campania Luigi Vanvitelli, Dept Expt Med, Via Luciano Armanni 5, I-80138 Naples, Italy		Angelillo, IF (通讯作者)，Univ Campania Luigi Vanvitelli, Dept Expt Med, Via Luciano Armanni 5, I-80138 Naples, Italy.	giorgia.dellapolla@unicampania.it; concettapaola.pelullo@unicampania.it; gabriella.digiuseppe@unicampania.it; italof.angelillo@unicampania.it		Pelullo, Concetta Paola/0000-0003-4228-8703; Angelillo, Italo F/0000-0003-1213-6602			Akarsu B, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13891; Ashkenazi S, 2020, VACCINE, V38, P7292, DOI 10.1016/j.vaccine.2020.09.044; Bricout H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220230; Decreto del Presidente del Consiglio dei Ministri 9 Marzo 2020, GU SER GEN N 62 9 MA; Della Polla G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070695; Della Polla G, 2020, HUM VACC IMMUNOTHER, V16, P2744, DOI 10.1080/21645515.2020.1744367; Della Polla G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17062147; Della Polla G, 2020, HUM VACC IMMUNOTHER, V16, P2422, DOI 10.1080/21645515.2020.1720441; Di Giuseppe G, 2021, EXPERT REV VACCINES, V20, P881, DOI 10.1080/14760584.2021.1922081; Di Giuseppe G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030275; Dib F, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2021.1874218; Ehde DM, 2021, MULT SCLER RELAT DIS, V49, DOI 10.1016/j.msard.2021.102788; Faasse K, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.551004; Germani F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247642; Guillon M, 2021, PUBLIC HEALTH, V198, P200, DOI 10.1016/j.puhe.2021.07.035; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Harrison N, 2016, HUM VACC IMMUNOTHER, V12, P2459, DOI 10.1080/21645515.2016.1168959; Islam MS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251605; Kaim A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18126503; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Ledda C, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052703; Melovic B, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165816; Napolitano F, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18094761; Napolitano F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010063; Napolitano F, 2019, ANTIBIOTICS-BASEL, V8, DOI 10.3390/antibiotics8040177; Napolitano F, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16122070; Napolitano F, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16101807; Napolitano F, 2018, HUM VACC IMMUNOTHER, V14, P1558, DOI 10.1080/21645515.2018.1463943; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Ozmen S, 2021, SOC WORK PUBLIC HLTH, V36, P164, DOI 10.1080/19371918.2021.1877589; Pataka A, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57060611; Pelullo CP, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020148; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Rader B, 2021, LANCET DIGIT HEALTH, V3, pE148, DOI 10.1016/S2589-7500(20)30293-4; Resnicow K, 2021, J MED INTERNET RES, V23, DOI 10.2196/23488; Rodriguez-Blanco N, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18105272; Sit SMM, 2021, TRANSL BEHAV MED, V11, P793, DOI 10.1093/tbm/ibab018; Stata Corporation, 2017, STATA REFERENCE MANU; Stefanoff P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232722; Vrdelja M, 2018, EUR J PUBLIC HEALTH, V28, P934, DOI 10.1093/eurpub/cky114; Weinert S, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18179218; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468; World Health Organization, 2020, WHO DIRECTOR GEN OPE; World Health Organization, WHO DIR GEN STAT IHR	44	4	4	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1276	10.3390/vaccines9111276			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XE3PW	34835207	Green Published, gold			2022-04-29	WOS:000723304800001
J	Khankeh, HR; Farrokhi, M; Khanjani, MS; Momtaz, YA; Forouzan, AS; Norouzi, M; Ahmadi, S; Harouni, GG; Roudini, J; Ghanaatpisheh, E; Hamedanchi, A; Pourebrahimi, M; Alipour, F; Ranjbar, M; Naghikhani, M; Saatchi, M				Khankeh, Hamid Reza; Farrokhi, Mehrdad; Khanjani, Mohammad Saeed; Momtaz, Yadollah Abolfathi; Forouzan, Ameneh Setareh; Norouzi, Mehdi; Ahmadi, Shokoufeh; Harouni, Gholamreza Ghaedamini; Roudini, Juliet; Ghanaatpisheh, Elham; Hamedanchi, Arya; Pourebrahimi, Mohammad; Alipour, Fardin; Ranjbar, Maryam; Naghikhani, Mehrdad; Saatchi, Mohammad			The Barriers, Challenges, and Strategies of COVID-19 (SARS-CoV-2) Vaccine Acceptance: A Concurrent Mixed-Method Study in Tehran City, Iran	VACCINES			English	Article						coronavirus disease 2019 (COVID-19) vaccine; vaccine hesitancy; vaccination acceptance; vaccine efficacy; challenges; trust	HESITANCY	Acceptance and willingness to receive the vaccine are among the main factors in the success or failure of a health system in implementing the vaccination program. The present study was conducted in Tehran, the political and economic capital of Iran, to determine the acceptance of the COVID-19 vaccine and identify its associated factors, and explain the most important barriers and acceptance strategies for vaccination. This research was a concurrent quantitative and qualitative mixed-method study. In the quantitative part, 1200 individuals aged more than 18 years were selected from the households in 22 districts of Tehran City, with a multistage stratified cluster sampling method. Two questionnaires were used to evaluate the acceptance of the COVID-19 vaccine and vaccine acceptance determinants. The qualitative content analysis method addressed the influencing factors, as well as challenges and strategies related to the acceptance of the COVID-19 vaccine in four groups of Tehran inhabitants: the elderly, people with underlying diseases, healthcare workers, and the general population. The related data were simultaneously collected by applying in-depth semi-structural interviews and a data analysis process. Furthermore, we used the Graneheim and Lundman method for data analysis. We analyzed the data of 1200 people with a mean (SD) age of 46.4 (11.1) years, and approximately 58% of them were men. The vaccine acceptance was 83.6% (95% CI: 81.3-85.9). Among those who welcomed vaccination, 58% preferred the imported vaccines, 25% the Iranian ones, and 17% both. There was a significant association between the variables of age (adjusted odds ratio [AOR] = 1.72, 95% CI: 1.01-2.93), being single (AOR = 0.54, 95% CI: 0.41-0.91), moderate pharmacotherapy adherence (AOR = 0.58, 95% CI: 0.4-0.85), and the willingness to receive COVID-19 vaccine. Qualitative study after interviewing 45 people from four study groups showed an insufficient social trust in healthcare system officials, pharmaceutical and vaccine production companies; distrust in the effectiveness of the vaccines, concerns about the vaccine adverse effects, being tracked by microchips after vaccination, traditional anti-vaccination movements, the feeling the inessentiality of vaccination, and uncertainty about the fair distribution of the vaccine. These concerns were the main challenges addressed by the study groups. A good proportion of Tehran residents reported their willingness to receive the COVID-19 vaccine. Additionally, they expressed their critical concerns, such as insufficient trust in the healthcare system, vaccine safeties, and adverse effects that were the significant barriers to vaccine acceptance. It seems that conflicts raised by the shortage of vaccines and their import due to the sanctions have led to intense desire and demand in the general population, and especially the elderly, for vaccination. Besides, vaccination phobia in some individuals requires further investigations.	[Khankeh, Hamid Reza; Farrokhi, Mehrdad; Ahmadi, Shokoufeh; Roudini, Juliet; Ghanaatpisheh, Elham; Ranjbar, Maryam; Saatchi, Mohammad] Univ Social Welf & Rehabil Sci, Hlth Emergency & Disaster Res Ctr, Tehran 1985713871, Iran; [Khankeh, Hamid Reza] Karolinska Inst, Dept Clin Sci & Educ, S-17177 Stockholm, Sweden; [Khanjani, Mohammad Saeed] Univ Social Welf & Rehabil Sci, Dept Counseling, Tehran 1985713871, Iran; [Momtaz, Yadollah Abolfathi; Hamedanchi, Arya] Univ Social Welf & Rehabil Sci, Iranian Res Ctr Aging, Tehran 1985713871, Iran; [Momtaz, Yadollah Abolfathi] Univ Putra Malaysia, Malaysian Res Inst Ageing MyAgeing, Serdang 43400, Malaysia; [Forouzan, Ameneh Setareh; Harouni, Gholamreza Ghaedamini] Univ Social Welf & Rehabil Sci, Social Welf Management Res Ctr, Tehran 1985713871, Iran; [Norouzi, Mehdi] Univ Social Welf & Rehabil Sci, Social Determinants Hlth Res Ctr, Tehran 1985713871, Iran; [Pourebrahimi, Mohammad] Baqiyatallah Univ Med Sci, Nursing Fac, Tehran 1435916471, Iran; [Alipour, Fardin] Univ Social Welf & Rehabil Sci, Dept Social Work, Res Ctr Social Welf Management, Tehran 1985713871, Iran; [Naghikhani, Mehrdad] Univ Social Welf & Rehabil Sci, Dept Basic Sci, Tehran 1985713871, Iran		Saatchi, M (通讯作者)，Univ Social Welf & Rehabil Sci, Hlth Emergency & Disaster Res Ctr, Tehran 1985713871, Iran.	hamid.khankeh@ki.se; me.farrokhi@uswr.ac.ir; saeedkh76@yahoo.com; yabolfathi@gmail.com; noroozimehdi04@gmail.com; Ahmadi.shokoufeh@gmail.com; Qaedamini@gmail.com; Juliet.Roudini@gmail.com; saeedkh76@yahoo.com; dr.hamedanchi@gmail.com; pourebrahimi62@gmail.com; barbodalipour@gmail.com; maryam.ranjbar.75@gmail.com; me.naghikhani@uswr.ac.ir; Mo.Saatchi@uswr.ac.ir	Momtaz, Yadollah Abolfathi/M-7377-2013; Hamedanchi, Arya/AAG-7137-2022; Khankeh, Hamidreza/AAF-4581-2021	Momtaz, Yadollah Abolfathi/0000-0003-1939-1470; Hamedanchi, Arya/0000-0001-5879-5561; 			Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; [Anonymous], 2021, WORLDOMETERS COVID 1; [Anonymous], 2016, STAT CTR IRAN DETAIL; Azimi S.S., 2020, MED J ISLAM REPUB IR, V34, P668; Benham JL, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246941; Bryman, 2006, QUAL RES, V6, P97, DOI [DOI 10.1177/1468794106058877, 10.1177/1468794106058877]; Chowdhury EK, 2021, BUS SOC REV, DOI 10.1111/basr.12219; Cooper LZ, 2008, PEDIATRICS, V122, P149, DOI 10.1542/peds.2008-0987; Costanzo M., 2021, CURR MED CHEM, V28, DOI [10.2174/0929867328666210521164809, DOI 10.2174/0929867328666210521164809]; Creswell JW., 2014, RES DESIGN QUALITATI, V4; Devine D, 2021, POLIT STUD REV, V19, P274, DOI 10.1177/1478929920948684; Dube E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156118; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Ghebreyesus T.A, 2020, DIR GEN OP REM MED B; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Harmsen Irene A, 2012, Adv Prev Med, V2012, P175694, DOI 10.1155/2012/175694; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Karlsson LC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224330; Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kim HK, 2020, SCI COMMUN, V42, P586, DOI 10.1177/1075547020959670; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lazarus JV, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240011; Liu Y, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab124; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Machekanyanga Z, 2017, J RELIG HEALTH, V56, P1683, DOI 10.1007/s10943-017-0428-7; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; McKibbin W, 2021, ASIAN ECON PAP, V20, P1, DOI 10.1162/asep_a_00796; Palmore T.N., 2020, SCRIPTA MED, V51, P101, DOI DOI 10.5937/SCRIPTAMED51-27183; Robichaud P, 2012, VACCINE, V30, P3763, DOI 10.1016/j.vaccine.2012.03.074; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Salathe M, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002199; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Slaoui M, 2020, NEW ENGL J MED, V383, P1701, DOI 10.1056/NEJMp2027405; Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z; Witte K, 2000, HEALTH EDUC BEHAV, V27, P591, DOI 10.1177/109019810002700506; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; World Health Organization, 2014, REP SAGE WORK GROUP; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Zhu H, 2010, OSTEOPOROSIS INT, V21, P765, DOI 10.1007/s00198-009-1010-2	42	1	1	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1248	10.3390/vaccines9111248			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XL2NU	34835179	Green Published, gold			2022-04-29	WOS:000727986700001
J	Stastna-Markova, M; Hamsikova, E; Hainz, P; Hubacek, P; Kroutilova, M; Krystofova, J; Ludvikova, V; Musil, J; Pecherkova, P; Salakova, M; Sroller, V; Vydra, J; Nemeckova, S				Stastna-Markova, Marketa; Hamsikova, Eva; Hainz, Petr; Hubacek, Petr; Kroutilova, Marie; Krystofova, Jitka; Ludvikova, Viera; Musil, Jan; Pecherkova, Pavla; Salakova, Martina; Sroller, Vojtech; Vydra, Jan; Nemeckova, Sarka			Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT	VACCINES			English	Article						human BK polyomavirus 1 and 4 (BKPyV 1 and 4); haemorrhagic cystitis; anti/BKPyV IgG; T-cell response; VP1; LTag; immunocompromised patients; hemopoietic stem cell transplantation	KIDNEY-TRANSPLANT RECIPIENTS; SEROPREVALENCE RATES; REDUCED-INTENSITY; CYTOMEGALOVIRUS; POLYOMAVIRUSES; INFECTION; RESPONSES; CHILDREN; DISEASE; VIREMIA	BK polyomavirus (BKPyV) persists lifelong in renal and urothelial cells with asymptomatic urinary shedding in healthy individuals. In some immunocompromised persons after transplantation of hematopoietic stem cells (HSCT), the BKPyV high-rate replication is associated with haemorrhagic cystitis (HC). We tested whether the status of BKPyV immunity prior to HSCT could provide evidence for the BKPyV tendency to reactivate. We have shown that measurement of pretransplant anti-BKPyV 1 and 4 IgG levels can be used to evaluate the HC risk. Patients with anti-BKPyV IgG in the range of the 1st-2nd quartile of positive values and with positive clinical risk markers have a significantly increased HC risk, in comparison to the reference group of patients with "non-reactive " anti-BKPyV IgG levels and with low clinical risk (LCR) (p = 0.0009). The predictive value of pretransplant BKPyV-specific IgG was confirmed by determination of genotypes of the shed virus. A positive predictive value was also found for pretransplant T-cell immunity to the BKPyV antigen VP1 because the magnitude of IFN-gamma T-cell response inversely correlated with posttransplant DNAuria and with HC. Our novel data suggest that specific T-cells control BKPyV latency before HSCT, and in this way may influence BKPyV reactivation after HSCT. Our study has shown that prediction using a combination of clinical and immunological pretransplant risk factors can help early identification of HSCT recipients at high risk of BKPyV disease.	[Stastna-Markova, Marketa; Hamsikova, Eva; Hainz, Petr; Kroutilova, Marie; Krystofova, Jitka; Ludvikova, Viera; Musil, Jan; Pecherkova, Pavla; Salakova, Martina; Sroller, Vojtech; Vydra, Jan; Nemeckova, Sarka] Inst Hematol & Blood Transfus, Prague 12820, Czech Republic; [Hubacek, Petr] Motol Hosp, Lab Virol, Prague 15006, Czech Republic; [Salakova, Martina; Sroller, Vojtech] Charles Univ Prague, Dept Genet & Microbiol, Fac Sci, Prague 12000, Czech Republic; [Salakova, Martina; Sroller, Vojtech] Charles Univ Prague, Acad Sci, Biotechnol & Biomed Ctr, BIOCEV, Vestec 25250, Czech Republic		Nemeckova, S (通讯作者)，Inst Hematol & Blood Transfus, Prague 12820, Czech Republic.	marketa.markova@uhkt.cz; eva.hamsikova@gmail.com; petr.hainz@uhkt.cz; petr.hubacek@lfmotol.cuni.cz; marie.kroutilova@uhkt.cz; jitka.krystofova@uhkt.cz; viera.ludvikova@uhkt.cz; jan.musil@uhkt.cz; pavla.pecherkova@uhkt.cz; Martina.Salakova@uhkt.cz; vojtech.sroller@uhkt.cz; jan.vydra@uhkt.cz; sarka.nemeckova@uhkt.cz			Ministry of Health of the Czech Republic European regional development fund (ERDF) [NV-17/31593A, CZ.02.1.01/-0.0/0.0/16_025/0007428, 00023736]	This work was financially supported by the grant NV-17/31593A of the Ministry of Health of the Czech Republic European regional development fund (ERDF) project AIIHHP CZ.02.1.01/-0.0/0.0/16_025/0007428, OP RDE and project for conceptual development of the research organisation Nffi 00023736.	Anoop P, 2011, HEMATOLOGY, V16, P213, DOI 10.1179/102453311X13025568941763; Arai Y, 2012, HEMATOLOGY, V17, P207, DOI 10.1179/1607845412Y.0000000010; ARTHUR RR, 1986, NEW ENGL J MED, V315, P230, DOI 10.1056/NEJM198607243150405; Baldanti F, 2008, J CLIN VIROL, V41, P237, DOI 10.1016/j.jcv.2007.12.001; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Bogdanovic G, 2004, J CLIN MICROBIOL, V42, P5394, DOI 10.1128/JCM.42.11.5394-5396.2004; Cesaro S, 2008, BONE MARROW TRANSPL, V41, P363, DOI 10.1038/sj.bmt.1705909; Cesaro S, 2018, J ANTIMICROB CHEMOTH, V73, P12, DOI 10.1093/jac/dkx324; Chen YP, 2006, J VIROL, V80, P3495, DOI 10.1128/JVI.80.7.3495-3505.2006; Dalianis T, 2011, ANTICANCER RES, V31, P939; DRUMMOND JE, 1987, J MED VIROL, V23, P331, DOI 10.1002/jmv.1890230405; El-Zimaity M, 2004, BLOOD, V103, P4674, DOI 10.1182/blood-2003-08-2815; Fleming T, 2010, J MED VIROL, V82, P433, DOI 10.1002/jmv.21727; Giraud G, 2006, HAEMATOLOGICA, V91, P401; Gorczynska E, 2005, BIOL BLOOD MARROW TR, V11, P797, DOI 10.1016/j.bbmt.2005.06.007; Hassan Z, 2007, CLIN TRANSPLANT, V21, P659, DOI 10.1111/j.1399-0012.2007.00705.x; Hrbacek J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-53; Johnston RJ, 2014, CANCER CELL, V26, P923, DOI 10.1016/j.ccell.2014.10.018; Kean JM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000363; Krumbholz A, 2008, INFECT GENET EVOL, V8, P632, DOI 10.1016/j.meegid.2008.05.006; Laskin BL, 2015, PEDIATR BLOOD CANCER, V62, P1670, DOI 10.1002/pbc.25536; Lee YJ, 2014, BIOL BLOOD MARROW TR, V20, P1204, DOI 10.1016/j.bbmt.2014.04.017; Leung AYH, 2002, J VIROL METHODS, V103, P51, DOI 10.1016/S0166-0934(01)00447-5; Leung AYH, 2001, BLOOD, V98, P1971, DOI 10.1182/blood.V98.6.1971; Li ZY, 2020, ONCOGENE, V39, P3611, DOI 10.1038/s41388-020-1239-y; Lunde LE, 2015, BONE MARROW TRANSPL, V50, P1432, DOI 10.1038/bmt.2015.162; McNees AL, 2005, J CLIN VIROL, V34, P52, DOI 10.1016/j.jcv.2004.12.018; Morel V, 2017, J CLIN MICROBIOL, V55, P1177, DOI 10.1128/JCM.01180-16; Oltolini C, 2020, BIOL BLOOD MARROW TR, V26, P1179, DOI 10.1016/j.bbmt.2020.01.013; Orti G, 2019, BONE MARROW TRANSPL, V54, P772, DOI 10.1038/s41409-018-0402-3; Pello OM, 2017, EUR J HAEMATOL, V98, P632, DOI 10.1111/ejh.12848; Ringden O, 2013, J INTERN MED, V274, P153, DOI 10.1111/joim.12056; Rorije NMG, 2014, BIOL BLOOD MARROW TR, V20, P564, DOI 10.1016/j.bbmt.2014.01.014; Schachtner T, 2015, AM J TRANSPLANT, V15, P2159, DOI 10.1111/ajt.13252; Schachtner T, 2011, AM J TRANSPLANT, V11, P2443, DOI 10.1111/j.1600-6143.2011.03693.x; Schneidawind D, 2010, LEUKEMIA LYMPHOMA, V51, P1055, DOI 10.3109/10428191003746323; Seber A, 1999, BONE MARROW TRANSPL, V23, P35, DOI 10.1038/sj.bmt.1701523; Silva LD, 2010, HAEMATOL-HEMATOL J, V95, P1183, DOI 10.3324/haematol.2009.016758; Solis M, 2018, J AM SOC NEPHROL, V29, P326, DOI 10.1681/ASN.2017050532; Sroller V, 2016, J MED VIROL, V88, P1254, DOI 10.1002/jmv.24440; Sroller V, 2014, J MED VIROL, V86, P1560, DOI 10.1002/jmv.23841; Stolt A, 2003, J GEN VIROL, V84, P1499, DOI 10.1099/vir.0.18842-0; Sun J, 2009, NAT MED, V15, P277, DOI 10.1038/nm.1929; Torres C, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2019.104150; Trandem K, 2011, J IMMUNOL, V186, P3642, DOI 10.4049/jimmunol.1003292; Tzannou I, 2017, J CLIN ONCOL, V35, P3547, DOI [10.1200/jco.2017.73.0655, 10.1200/JCO.2017.73.0655]; Uhm J, 2014, BONE MARROW TRANSPL, V49, P1528, DOI 10.1038/bmt.2014.181; Wong ASY, 2007, CLIN INFECT DIS, V44, P830, DOI 10.1086/511863; Wunderink HF, 2019, J CLIN VIROL, V110, P22, DOI 10.1016/j.jcv.2018.11.009; Yamamoto R, 2003, BONE MARROW TRANSPL, V32, P1089, DOI 10.1038/sj.bmt.1704261	50	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1226	10.3390/vaccines9111226			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ5XD	34835157	Green Submitted, gold, Green Published			2022-04-29	WOS:000726859500001
J	Aldakheel, FM; Abrar, A; Munir, S; Aslam, S; Allemailem, KS; Khurshid, M; Ashfaq, UA				Aldakheel, Fahad M.; Abrar, Amna; Munir, Samman; Aslam, Sehar; Allemailem, Khaled S.; Khurshid, Mohsin; Ashfaq, Usman Ali			Proteome-Wide Mapping and Reverse Vaccinology Approaches to Design a Multi-Epitope Vaccine against Clostridium perfringens	VACCINES			English	Article						subtractive proteomics; immuno-iformatics; sub-unit vaccine; Clostridium perfringens; molecular docking	PEPTIDE VACCINE; CODON USAGE; PREDICTION; STRATEGIES; ADJUVANTS	C. perfringens is a highly versatile bacteria of livestock and humans, causing enteritis (a common food-borne illness in humans), enterotoxaemia (in which toxins are formed in the intestine which damage and destroy organs, i.e., the brain), and gangrene (wound infection). There is no particular cure for the toxins of C. perfringens. Supportive care (medical control of pain, intravenous fluids) is the standard treatment. Therefore, a multiple-epitope vaccine (MEV) should be designed to battle against C. perfringens infection. Furthermore, the main objective of this in silico investigation is to design an MEV that targets C. perfringens. For this purpose, we selected the top three proteins that were highly antigenic using immuno-informatics approaches, including molecular docking. B-cells, IFN-gamma, and T cells for target proteins were predicted and the most conserved epitopes were selected for further investigation. For the development of the final MEV, epitopes of LBL5, CTL17, and HTL13 were linked to GPGPG, AAY, and KK linkers. The vaccine N-end was joined to an adjuvant through an EAAK linker to improve immunogenicity. After the attachment of linkers and adjuvants, the final construct was 415 amino acids. B-cell and IFN-gamma epitopes demonstrate that the model structure is enhanced for humoral and cellular immune responses. To validate the immunogenicity and safety of the final construct, various physicochemical properties, and other properties such as antigenicity and non-allergens, were evaluated. Furthermore, molecular docking was carried out for verification of vaccine compatibility with the receptor, evaluated in silico. Also, in silico cloning was employed for the verification of the proper expression and credibility of the construct.	[Aldakheel, Fahad M.] King Saud Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Riyadh 11564, Saudi Arabia; [Abrar, Amna; Munir, Samman; Aslam, Sehar; Ashfaq, Usman Ali] Govt Coll Univ, Dept Bioinformat & Biotechnol, Faisalabad 38000, Pakistan; [Allemailem, Khaled S.] Qassim Univ, Coll Appl Med Sci, Dept Med Labs, Buraydah 51452, Saudi Arabia; [Khurshid, Mohsin] Govt Coll Univ, Dept Microbiol, Faisalabad 38000, Pakistan		Ashfaq, UA (通讯作者)，Govt Coll Univ, Dept Bioinformat & Biotechnol, Faisalabad 38000, Pakistan.	faldakheel@ksu.edu.sa; amnaabrar786@gmail.com; sammanmunirOl@gmail.com; Seharaslam4376@yahoo.com; k.allemailem@qu.edu.sa; mohsin.mic@gmail.com; ashfaqua@gcuf.edu.pk	Khurshid, Mohsin/N-8135-2013; Ashfaq, usman ali/D-7792-2013	Khurshid, Mohsin/0000-0002-3196-2857; Ashfaq, usman ali/0000-0002-5495-805X; Allemailem, Khaled/0000-0002-6486-9835	College of Applied Medical Sciences Research Center; Deanship of Scientific Research at King Saud University, Saudi Arabia	Fahad M. Aldakheel extends his appreciation to the College of Applied Medical Sciences Research Center and the Deanship of Scientific Research at King Saud University, Saudi Arabia for funding this research.	Abdel-Glil MY, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86148-8; Alexander J, 1998, IMMUNOL RES, V18, P79, DOI 10.1007/BF02788751; Alexander Nathan, 2011, IEEE Int Conf Comput Adv Bio Med Sci, V2011, P13, DOI 10.1109/ICCABS.2011.5729867; Arai R, 2001, PROTEIN ENG, V14, P529, DOI 10.1093/protein/14.8.529; Arturo CJ., 2017, VACCINES-BASEL; Arumugam S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-94488-8; Azhagesan K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208722; Bin Sayed S, 2020, INT J PEPT RES THER, V26, P2089, DOI 10.1007/s10989-019-10003-8; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1023, DOI 10.1002/elps.11501401163; Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002; Boutet E, 2016, METHODS MOL BIOL, V1374, P23, DOI 10.1007/978-1-4939-3167-5_2; Broughan J, 2011, EXPERT REV VACCINES, V10, P695, DOI [10.1586/ERV.11.54, 10.1586/erv.11.54]; Bruno L, 2015, CURR OPIN VIROL, V11, P89, DOI 10.1016/j.coviro.2015.03.001; Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153; Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266; Chen LH, 2005, NUCLEIC ACIDS RES, V33, pD325, DOI 10.1093/nar/gki008; Chen LF, 2018, DRUG DISCOV TODAY, V23, P1187, DOI 10.1016/j.drudis.2018.01.015; Chen R, 2012, BIOTECHNOL ADV, V30, P1102, DOI 10.1016/j.biotechadv.2011.09.013; Chew MF, 2017, INT J MED SCI, V14, P1342, DOI 10.7150/ijms.21875; Cooper MD, 2015, NAT REV IMMUNOL, V15, P191, DOI 10.1038/nri3801; COOPER NR, 1984, J INVEST DERMATOL, V83, pS121, DOI 10.1111/1523-1747.ep12281847; Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346; Depla E, 2008, J VIROL, V82, P435, DOI 10.1128/JVI.01505-07; Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30; Dicker D, 2018, LANCET, V392, P1684, DOI 10.1016/s0140-6736(18)31891-9; Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Durdagi S, 2018, J MOL GRAPH MODEL, V85, P122, DOI 10.1016/j.jmgm.2018.07.010; Forti K, 2020, TOXINS, V12, DOI 10.3390/toxins12100650; Fu LM, 2012, BIOINFORMATICS, V28, P3150, DOI 10.1093/bioinformatics/bts565; Gardy JL, 2005, BIOINFORMATICS, V21, P617, DOI 10.1093/bioinformatics/bti057; Gori A, 2013, AMINO ACIDS, V45, P257, DOI 10.1007/s00726-013-1526-9; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Gupta N, 2020, INT J PEPT RES THER, V26, P1303, DOI 10.1007/s10989-019-09933-0; Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957; Heida FH, 2016, CLIN INFECT DIS, V62, P863, DOI 10.1093/cid/ciw016; Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458; Ismail S., 2020, BIORXIV, DOI [10.1101/2020.04.05.026005, DOI 10.1101/2020.04.05.026005]; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Kazi A, 2018, PATHOG GLOB HEALTH, V112, P123, DOI 10.1080/20477724.2018.1446773; Khan SZ, 2019, INFECT GENET EVOL, V73, P390, DOI 10.1016/j.meegid.2019.06.006; Khatoon N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08842-w; Kovacs JA, 2004, PROTEINS, V56, P661, DOI 10.1002/prot.20151; Laskowski RA, 2009, NUCLEIC ACIDS RES, V37, pD355, DOI 10.1093/nar/gkn860; Lavigne R, 2008, RES MICROBIOL, V159, P406, DOI 10.1016/j.resmic.2008.03.005; Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Lucas K, 2013, MOL NEUROBIOL, V48, P190, DOI 10.1007/s12035-013-8425-7; Lund FE, 2008, CURR OPIN IMMUNOL, V20, P332, DOI 10.1016/j.coi.2008.03.003; Mahmood M, 2021, INFECT GENET EVOL, V91, DOI 10.1016/j.meegid.2021.104795; Mahram Atabak, 2010, 24th ACM International Conference on Supercomputing 2010, P73; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mirza MU, 2016, SCI REP-UK, V6, DOI 10.1038/srep37313; Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215; Navarro MA, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00500-20; Naz A, 2015, INFECT GENET EVOL, V32, P280, DOI 10.1016/j.meegid.2015.03.027; Nezafat N, 2016, COMPUT BIOL CHEM, V62, P82, DOI 10.1016/j.compbiolchem.2016.04.006; Nezafat N, 2014, J THEOR BIOL, V349, P121, DOI 10.1016/j.jtbi.2014.01.018; Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238; Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1; Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514; Proctor RA, 2012, VACCINE, V30, P2921, DOI 10.1016/j.vaccine.2011.11.006; Lopez-Blanco JR, 2014, NUCLEIC ACIDS RES, V42, pW271, DOI 10.1093/nar/gku339; Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862; Rappuoli R, 2001, VACCINE, V19, P2688, DOI 10.1016/S0264-410X(00)00554-5; Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078; Samad A, 2022, J BIOMOL STRUCT DYN, V40, P14, DOI 10.1080/07391102.2020.1792347; Seib KL, 2012, CLIN MICROBIOL INFEC, V18, P109, DOI 10.1111/j.1469-0691.2012.03939.x; Shamriz S, 2016, COMPUT BIOL MED, V76, P24, DOI 10.1016/j.compbiomed.2016.06.015; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Shey RA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40833-x; Solanki V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26689-7; ul Qamar MT, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244176; ul Qamar MT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020288; ul Qamar MT, 2021, COMPUT BIOL MED, V132, DOI 10.1016/j.compbiomed.2021.104389; Unni PA, 2019, MOL BIOL REP, V46, P511, DOI 10.1007/s11033-018-4505-0; Uzal FA, 2014, FUTURE MICROBIOL, V9, P361, DOI 10.2217/fmb.13.168; van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014; VanAalten DMF, 1997, J COMPUT CHEM, V18, P169; Wang L, 2008, NAT IMMUNOL, V9, P1122, DOI 10.1038/ni.1647; Wang Y, 2010, J PHYS-CONDENS MAT, V22, DOI 10.1088/0953-8984/22/20/202201; Wen QF, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01236; Yu CS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099368; Zhang LF, 2018, CELL MOL IMMUNOL, V15, P182, DOI 10.1038/cmi.2017.92; Zheng W, 2019, PROTEINS, V87, P1149, DOI 10.1002/prot.25792; Zom GGP, 2012, ADV IMMUNOL, V114, P177, DOI 10.1016/B978-0-12-396548-6.00007-X	86	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1079	10.3390/vaccines9101079			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WM8BB	34696187	Green Published, gold			2022-04-29	WOS:000711303300001
J	Campa, C; Pronce, T; Paludi, M; Weusten, J; Conway, L; Savery, J; Richards, C; Clenet, D				Campa, Cristiana; Pronce, Thierry; Paludi, Marilena; Weusten, Jos; Conway, Laura; Savery, James; Richards, Christine; Clenet, Didier			Use of Stability Modeling to Support Accelerated Vaccine Development and Supply	VACCINES			English	Article						accelerated predictive stability; advanced kinetic modeling; COVAX	PREDICTION	Stability assessment of pharmaceuticals in specific storage and shipment conditions is a key requirement to ensure that safe and efficacious products are administered to patients. This is particularly relevant for vaccines, with numerous vaccines strictly requiring cold storage to remain stable. When stability evaluation is exclusively based on real-time data, it may represent a bottleneck for rapid and effective vaccine access. Stability modeling for vaccines represents a key resource to predict stability based on accelerated stability studies; nevertheless, this approach is not fully exploited for these kinds of products. This is likely because of the complexity and diversity of vaccines, as well as the limited availability of dedicated guidelines or illustrative case studies. This article reports a cross-company perspective on stability modeling for vaccines. Several examples, based on the direct experience of the contributors, demonstrate that modeling approaches can be highly valuable to predict vaccines' shelf life and behavior during shipment or manipulation. It is demonstrated that modeling methodologies need to be tailored to the nature of the vaccine, the available prior knowledge, and the monitored attributes. Considering that the well-established strategies reported in ICH or WHO guidelines are not always broadly applicable to vaccines, this article represents an important source of information for vaccine researchers and manufacturers, setting the grounds for further discussion within the vaccine industry and with regulators.</p>	[Campa, Cristiana; Paludi, Marilena] Tech R&D, GSK, I-53100 Siena, Italy; [Pronce, Thierry] Tech R&D, GSK, B-1330 Rixensart, Belgium; [Weusten, Jos] Ctr Math Sci, MSD, NL-5344 Oss, Netherlands; [Conway, Laura] Merck, Regulatory Affairs CMC Vaccines, North Wales, PA 19454 USA; [Savery, James] AstraZeneca, R&D, Data Sci & Modeling, BioPharmaceuticals Dev, Cambridge 01223, England; [Richards, Christine] Global Qual, Sanof Pasteur, Swiftwater, PA 18370 USA; [Clenet, Didier] Bioproc R&D Dept, Sanofi Pasteur, F-69280 Marcy Letoile, France		Clenet, D (通讯作者)，Bioproc R&D Dept, Sanofi Pasteur, F-69280 Marcy Letoile, France.	cristiana.x.campa@gsk.com; thierry.x.pronce@gsk.com; marilena.x.paludi@gsk.com; jos.weusten@merck.com; laura_conway@merck.com; james.savery@astrazeneca.com; Christine.L.Richards@sanofi.com; Didier.Clenet@sanofi.com		CLENET, Didier/0000-0002-8395-9430	GlaxoSmithKline Biologicals SAGlaxoSmithKline; Sanofi; AstraZenecaAstraZeneca; MSD/MerckMerck & Company	The authors would like to express their sincere thanks to Hermine Achard and Rayanne Seba for their technical support at Sanofi, as well as Valeria Onnis, Elisa Cappelli, and Silvia Martini for their technical support at GSK. This work was (co-)sponsored by GlaxoSmithKline Biologicals SA, MSD/Merck, AstraZeneca, and Sanofi.	ALLISON LMC, 1981, J BIOL STAND, V9, P185, DOI 10.1016/S0092-1157(81)80022-4; [Anonymous], 2021, TOOLBOX GUIDANCE SCI; [Anonymous], 2017, MEAN KINETIC TEMPERA; [Anonymous], 2020, BEST PRACTICES DETER; [Anonymous], 2020, CONSIDERATIONS EVALU; Clenet D, 2020, STP PHARMA PRAT, V4, P12; Clenet D, 2019, EUR J PHARM BIOPHARM, V142, P334, DOI 10.1016/j.ejpb.2019.07.008; Clenet D, 2018, EUR J PHARM BIOPHARM, V125, P76, DOI 10.1016/j.ejpb.2018.01.005; Clenet D, 2014, J PHARM SCI-US, V103, P3055, DOI 10.1002/jps.24117; ClUnet, 2021, QUALITY DESIGN INDIS, P169; Crommelin DJA, 2021, J PHARM SCI-US, V110, P627, DOI 10.1016/j.xphs.2020.11.015; Desai KG, 2020, J PHARM SCI-US, V109, P2131, DOI 10.1016/j.xphs.2020.04.006; European Medicines Agency (EMA), 2021, REFL PAP REG REQ VAC; Evans RK, 2004, J PHARM SCI-US, V93, P2458, DOI 10.1002/jps.20157; Kartoglu U, 2014, EXPERT REV VACCINES, V13, P843, DOI 10.1586/14760584.2014.923761; Kartoglu UH, 2020, VACCINE, V38, P5393, DOI 10.1016/j.vaccine.2020.06.056; Lennard A., 2021, QUALITY DESIGN INDIS, P133; MARINER JC, 1990, VET MICROBIOL, V21, P195, DOI 10.1016/0378-1135(90)90032-Q; McMahon ME, 2021, AAPS J, V23, DOI 10.1208/s12248-021-00641-6; Moriconi A, 2020, VACCINE, V38, P3930, DOI 10.1016/j.vaccine.2020.04.005; Pelliccia M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13520; PRECAUSTA PM, 1980, J CLIN MICROBIOL, V12, P483, DOI 10.1128/JCM.12.4.483-489.1980; Roduit B, 2019, MOLECULES, V24, DOI 10.3390/molecules24122217; Roduit B, 2014, THERMOCHIM ACTA, V579, P31, DOI 10.1016/j.tca.2014.01.005; WHO, 2006, VACC VIAL MON WHO PQ; WHO, 2016, 999 WHO TRS; World Health Organization, 2005, MON VACC WAST COUNTR	27	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1114	10.3390/vaccines9101114			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN9VT	34696222	gold, Green Published			2022-04-29	WOS:000712113500001
J	D'Errico, S; Zanon, M; Concato, M; Peruch, M; Scopetti, M; Frati, P; Fineschi, V				D'Errico, Stefano; Zanon, Martina; Concato, Monica; Peruch, Michela; Scopetti, Matteo; Frati, Paola; Fineschi, Vittorio			"First Do No Harm". No-Fault Compensation Program for COVID-19 Vaccines as Feasibility and Wisdom of a Policy Instrument to Mitigate Vaccine Hesitancy	VACCINES			English	Review						vaccination; COVID-19; no-fault compensation; adverse events; solidarity; vaccine hesitancy	INJURY	Vaccines are so far proven to be safe, although related adverse events cannot be excluded. The urgency for COVID-19 vaccines determined a dilution of the general expectations of safety and efficacy of vaccination (from safe and effective to safe and effective enough). In many countries, a no-fault program was established to compensate individuals who experienced serious vaccine-related injuries. The impressive number of administrations worldwide and the legal indemnity afforded to manufacturers of approved vaccines that cannot be pursued for compensation fed the debate about the availability of a compensation model for COVID-19 vaccine-related injuries. Several European countries have long introduced a system, Vaccine Injury Compensation Programs, to compensate people who suffer physical harm because of vaccination. In Europe, COVID-19 vaccination is strongly recommended for the general population and in many states is declared mandatory for healthcare workers. In 1992, Italy edited Law no. 210 providing legal protection for individuals who reported injuries after mandatory and recommended vaccinations as a no-fault alternative to the traditional tort system. Despite its recommended nature, COVID-19 vaccination is excluded from the no-fault model in several European states, and the Italian government is called to provide clear and firm instructions for the management of the many requests for compensation. The authors provide an overview of the existing compensation models in Europe and analyse available legislative proposals.	[D'Errico, Stefano; Zanon, Martina; Concato, Monica; Peruch, Michela] Univ Trieste, Dept Med Surg & Hlth Sci, Str Fiume 44, I-34149 Trieste, Italy; [Scopetti, Matteo; Frati, Paola; Fineschi, Vittorio] Sapienza Univ Rome, Dept Anat Histol Forens & Orthopaed Sci, Viale Regina Elena 336, I-00185 Rome, Italy; [Frati, Paola; Fineschi, Vittorio] IRCCS Neuromed, Via Atinense 18, I-86077 Pozzilli, Italy		Fineschi, V (通讯作者)，Sapienza Univ Rome, Dept Anat Histol Forens & Orthopaed Sci, Viale Regina Elena 336, I-00185 Rome, Italy.; Fineschi, V (通讯作者)，IRCCS Neuromed, Via Atinense 18, I-86077 Pozzilli, Italy.	sderrico@units.it; martina.zanon@virgilio.it; monica.concato@studenti.units.it; michela.peruch95@gmail.com; matteo.scopetti@uniroma1.it; paolairati@uniroma1.it; vittorio.fineschi@uniroma1.it		Fineschi, Vittorio/0000-0002-1686-3236; Frati, Paola/0000-0002-0358-7965; D'ERRICO, Stefano/0000-0003-3689-0001; Scopetti, Matteo/0000-0002-7259-3090			Barringer PJ, 2008, J HEALTH POLIT POLIC, V33, P725, DOI 10.1215/03616878-2008-014; Bundesgesetz vom 3, JUL 1973 ENTSCH IMPF; D'Errico S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020110; D'Errico S, 2008, FORENSIC SCI INT, V179, pE25, DOI 10.1016/j.forsciint.2008.04.018; EMA European Medicines Agency., 2021, ASTRAZENECAS COVID 1; European Centre for Disease Prevention and Control, COVID 19 VACC TRACK; European Centre for Disease Prevention and Control, SUSP ADV REACT COVID; European Centre for Disease Prevention and Control (ECDC), OV EU EEA COUNTR REC; European Medicines Agency (EMA), 2021, COVID 19 VACC JANSS; European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), 2021, SIGN ASS REP EMB THR; Fairgrieve D, 2021, LANCET INFECT DIS, V21, P448, DOI 10.1016/S1473-3099(21)00065-7; Fineschi V, 1998, TRANSFUSION, V38, P596, DOI 10.1046/j.1537-2995.1998.38698326340.x; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Frati P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090966; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Halabi S, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2030600; Hansen T, 2021, INT J INFECT DIS, V107, P172, DOI 10.1016/j.ijid.2021.04.053; Haynes K, 2020, PHARMACOEPIDEM DR S, V29, P1529, DOI 10.1002/pds.5142; Head 140. Government Secretariat: Food and Health Bureau, IND FUND ADV EV FOLL; Italian Medicine Agency, 7 REP COVID 19 VACC; Keane M., 2019, VACCINE INJURY REDRE; Lee S., S KOREAS COMBATING C; Looker C, 2011, B WORLD HEALTH ORGAN, V89, P371, DOI 10.2471/BLT.10.081901; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Meissner HC, 2021, JAMA-J AM MED ASSOC, V325, P721, DOI 10.1001/jama.2020.26792; Meissner HC, 2021, CLIN INFECT DIS, V72, P309, DOI 10.1093/cid/ciaa697; Millward G, 2017, SOC HIST MED, V30, P429, DOI 10.1093/shm/hkv140; Mungwira RG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233334; Mungwira RG, 2019, VACCINE, V37, P4370, DOI 10.1016/j.vaccine.2019.06.018; Paterlini M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1065; Perata A, 2004, Ann Ig, V16, P69; President of the Italian Council of Ministers, DECR PRES CONS MIN N; President of the Italian Council of Ministers, DECR PRES CONS MIN N; Public Health Agency of Canada, GOV CAN ANN PAN CAN; Rutten LJF, 2021, MAYO CLIN PROC, V96, P699, DOI 10.1016/j.mayocp.2020.12.024; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060559; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Studdert DM, 2007, HEALTH AFFAIR, V26, P215, DOI 10.1377/hlthaff.26.1.215; Thiele T, 2021, BLOOD, V138, P299, DOI 10.1182/blood.2021012217; US Food & Drug Administration (FDA), 2021, JOINT CDC FDA STAT J; US Food Drug Administration (FDA), 2021, COR DIS 2019 COVID 1; Van Tassel K, 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMp2034438; Wilson K, 2012, CAN J PUBLIC HEALTH, V103, P122, DOI 10.1007/BF03404215; World Health Organization (WHO), NO FAULT COMPENSATIO; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	48	3	3	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1116	10.3390/vaccines9101116			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WV3GT	34696224	gold, Green Published, Green Submitted			2022-04-29	WOS:000717125400001
J	Tajima, S; Taniguchi, S; Nakayama, E; Maeki, T; Inagaki, T; Saijo, M; Lim, CK				Tajima, Shigeru; Taniguchi, Satoshi; Nakayama, Eri; Maeki, Takahiro; Inagaki, Takuya; Saijo, Masayuki; Lim, Chang Kweng			Immunogenicity and Protective Ability of Genotype I-Based Recombinant Japanese Encephalitis Virus (JEV) with Attenuation Mutations in E Protein against Genotype V JEV	VACCINES			English	Article						Japanese encephalitis virus; genotype V; reverse genetics; live attenuated vaccine	WEST-NILE-VIRUS; MOLECULAR CLONE; VITRO GROWTH; VACCINE; SA14-14-2; IMMUNIZATION; VIRULENCE; STRAIN; REGION; SAFETY	Genotype V (GV) Japanese encephalitis virus (JEV) has emerged in Korea and China since 2009. Recent findings suggest that current Japanese encephalitis (JE) vaccines may reduce the ability to induce neutralizing antibodies against GV JEV compared to other genotypes. This study sought to produce a novel live attenuated JE vaccine with a high efficacy against GV JEV. Genotype I (GI)-GV intertypic recombinant strain rJEV-E-XZ0934-M41 (E-XZ0934), in which the E region of the GI Mie/41/2002 strain was replaced with that of GV strain XZ0934, was introduced with the same 10 attenuation substitutions in the E region found in the live attenuated JE vaccine strain SA 14-14-2 to produce a novel mutant virus rJEV-E-XZ/SA14142m-M41 (E-XZ/SA14142m). In addition, another mutant rJEV-E-M41/SA14142m-M41 (E-M41/SA14142m), which has the same substitutions in the Mie/41/2002, was also produced. The neuroinvasiveness and neurovirulence of the two mutant viruses were significantly reduced in mice. The mutant viruses induced neutralizing antibodies against GV JEV in mice. The growth of E-XZ/SA14142m was lower than that of E-M41/SA14142m. In mouse challenge tests, a single inoculation with a high dose of the mutants blocked lethal GV JEV infections; however, the protective efficacy of E-XZ/SA14142m was weaker than that of E-M41/SA14142m in low-dose inoculations. The lower protection potency of E-XZ/SA14142m may be ascribed to the reduced growth ability caused by the attenuation mutations.</p>	[Tajima, Shigeru; Taniguchi, Satoshi; Nakayama, Eri; Maeki, Takahiro; Inagaki, Takuya; Saijo, Masayuki; Lim, Chang Kweng] Natl Inst Infect Dis, Dept Virol 1, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan		Tajima, S (通讯作者)，Natl Inst Infect Dis, Dept Virol 1, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	stajima@nih.go.jp; rei-tani@nih.go.jp; nakayama@nih.go.jp; tomaeki@nih.go.jp; tinagaki@nih.go.jp; msaijo@nih.go.jp; ck@nih.go.jp		Lim, Chang Kweng/0000-0001-5823-8300; Taniguchi, Satoshi/0000-0002-2066-1979; Saijo, Masayuki/0000-0001-5458-7298; Nakayama, Eri/0000-0002-0826-3513; Maeki, Takahiro/0000-0002-6001-9278; Shigeru, Tajima/0000-0002-1981-9062	Research Program on Emerging and Re-emerging Infectious Diseases of the Japan Agency for Medical Research and Development (AMED)Japan Agency for Medical Research and Development (AMED) [JP20fk0108123]	This research was supported by the Research Program on Emerging and Re-emerging Infectious Diseases of the Japan Agency for Medical Research and Development (AMED) under Grant Number JP20fk0108123.	Anwar MN, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050552; Arroyo J, 2004, J VIROL, V78, P12497, DOI 10.1128/JVI.78.22.12497-12507.2004; Bae W, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e70; Campbell GL, 2011, B WORLD HEALTH ORGAN, V89, P766, DOI 10.2471/BLT.10.085233; Cao L, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004686; de Wispelaere M, 2015, J VIROL, V89, P5862, DOI 10.1128/JVI.00358-15; Erlanger TE, 2009, EMERG INFECT DIS, V15, P1, DOI 10.3201/eid1501.080311; Gao XY, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002459; Gromowski GD, 2015, J VIROL, V89, P6328, DOI 10.1128/JVI.00219-15; Hameed M, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030357; Ishikawa T, 2015, VIRUS RES, V195, P153, DOI 10.1016/j.virusres.2014.10.010; Kaiser JA, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0146-0; Kim H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116547; Kurane I, 2000, VACCINE, V18, P33, DOI 10.1016/S0264-410X(00)00041-4; Kuwata R, 2020, EMERG INFECT DIS, V26, P125, DOI 10.3201/eid2601.190235; Li MH, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001231; Li X, 2014, HUM VACC IMMUNOTHER, V10, P3579, DOI 10.4161/21645515.2014.980197; Liang JJ, 2009, VACCINE, V27, P2746, DOI 10.1016/j.vaccine.2009.03.007; Maeki T, 2018, JPN J INFECT DIS, V71, P360, DOI 10.7883/yoken.JJID.2018.126; Mishra N, 2020, MBIO, V11, DOI 10.1128/mBio.02494-19; Monath TP, 2015, VACCINE, V33, P62, DOI 10.1016/j.vaccine.2014.10.004; Nerome R, 2007, J GEN VIROL, V88, P2762, DOI 10.1099/vir.0.82941-0; Ni HL, 1996, J GEN VIROL, V77, P1449, DOI 10.1099/0022-1317-77-7-1449; Pierson T.C., 2013, FIELDS VIROLOGY, V6, P747; PUTNAK JR, 1990, J GEN VIROL, V71, P1697, DOI 10.1099/0022-1317-71-8-1697; Satchidanandam V, 2020, CURR TREAT OPT INFEC, V12, P375, DOI 10.1007/s40506-020-00242-5; SCHLESINGER JJ, 1987, J GEN VIROL, V68, P853, DOI 10.1099/0022-1317-68-3-853; Schuh AJ, 2014, J VIROL, V88, P4522, DOI 10.1128/JVI.02686-13; Schuh AJ, 2013, VECTOR-BORNE ZOONOT, V13, P479, DOI 10.1089/vbz.2011.0870; Shirato K, 2005, J VIROL METHODS, V126, P119, DOI 10.1016/j.jviromet.2005.02.001; Solomon T, 2003, J VIROL, V77, P3091, DOI 10.1128/JVI.77.5.3091-3098.2003; SUMIYOSHI H, 1995, J INFECT DIS, V171, P1144, DOI 10.1093/infdis/171.5.1144; Tajima S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070709; Tajima S, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02882; Tajima S, 2015, J GEN VIROL, V96, P2661, DOI 10.1099/vir.0.000213; Tajima S, 2010, VIROLOGY, V396, P298, DOI 10.1016/j.virol.2009.10.035; Takhampunya R, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-449; Nguyen TTT, 2019, JPN J INFECT DIS, V72, P115, DOI 10.7883/yoken.JJID.2018.232; Tsai Theodore F., 2000, Vaccine, V18, P1, DOI 10.1016/S0264-410X(00)00037-2; Uchil PD, 2001, AM J TROP MED HYG, V65, P242, DOI 10.4269/ajtmh.2001.65.242; Woo JH, 2020, EMERG INFECT DIS, V26, P1002, DOI 10.3201/eid2605.190977; Yamshchikov V, 2016, VIROLOGY, V487, P198, DOI 10.1016/j.virol.2015.10.015; Yang J, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9010020; Yoshikawa Akira, 2016, Trop Med Health, V44, P8, DOI 10.1186/s41182-016-0010-0; Yu YX, 2010, VACCINE, V28, P3635, DOI 10.1016/j.vaccine.2010.02.105; Yun SI, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004290; Zhao ZJ, 2005, J GEN VIROL, V86, P2209, DOI 10.1099/vir.0.80638-0; Zheng XC, 2018, J VIROL, V92, DOI [10.1128/JVI.00108-18, 10.1128/jvi.00108-18]; Zhou YY, 2018, ARCH VIROL, V163, P1351, DOI 10.1007/s00705-018-3765-2	49	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1077	10.3390/vaccines9101077			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO1RL	34696184	Green Published, gold			2022-04-29	WOS:000712238600001
J	Teahan, B; Ong, E; Yang, ZH				Teahan, Blaine; Ong, Edison; Yang, Zhenhua			Identification of Mycobacterium tuberculosis Antigens with Vaccine Potential Using a Machine Learning-Based Reverse Vaccinology Approach	VACCINES			English	Article						tuberculosis; vaccines; protective antigens; machine learning; reverse vaccinology	MURINE MODEL; PROTEIN; PREDICTION; RESISTANCE; VIRULENCE; RESPONSES; SURVIVAL; VIRUS	Tuberculosis (TB) is the leading cause of death of any single infectious agent, having led to 1.4 million deaths in 2019 alone. Moreover, an estimated one-quarter of the global population is latently infected with Mycobacterium tuberculosis (MTB), presenting a huge pool of potential future disease. Nonetheless, the only currently licensed TB vaccine fails to prevent the activation of latent TB infections (LTBI). These facts together illustrate the desperate need for a more effective TB vaccine strategy that can prevent both primary infection and the activation of LTBI. In this study, we employed a machine learning-based reverse vaccinology approach to predict the likelihood that each protein within the proteome of MTB laboratory reference strain H37Rv would be a protective antigen (PAg). The proteins predicted most likely to be a PAg were assessed for their belonging to a protein family of previously established PAgs, the relevance of their biological processes to MTB virulence and latency, and finally the immunogenic potential that they may provide in terms of the number of promiscuous epitopes within each. This study led to the identification of 16 proteins with the greatest vaccine potential for further in vitro and in vivo studies. It also demonstrates the value of computational methods in vaccine development.	[Teahan, Blaine; Yang, Zhenhua] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA; [Ong, Edison] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA		Yang, ZH (通讯作者)，Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.	bteahan@umich.edu; edong@umich.edu; zhenhua@umich.edu					Aagaard C, 2011, NAT MED, V17, P189, DOI 10.1038/nm.2285; Andersen P, 2019, NAT REV IMMUNOL, V19, P550, DOI 10.1038/s41577-019-0174-z; [Anonymous], 2020, GLOBAL TUBERCULOSIS; [Anonymous], 2015, END TB STRATEGY; [Anonymous], 2020, SUSTAINABLE DEV GOAL; Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Be NA, 2008, J INFECT DIS, V198, P1520, DOI 10.1086/592447; Behr MA, 2007, NAT MED, V13, P286, DOI 10.1038/nm0307-286; Bell LCK, 2018, NAT REV MICROBIOL, V16, P80, DOI 10.1038/nrmicro.2017.128; Bertholet S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001094; Betts JC, 2002, MOL MICROBIOL, V43, P717, DOI 10.1046/j.1365-2958.2002.02779.x; Bishai W, 2000, NATURE, V406, P683, DOI 10.1038/35021159; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Cadena AM, 2017, NAT REV IMMUNOL, V17, P691, DOI 10.1038/nri.2017.69; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Coler RN, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0057-5; Daniel Thomas M., 1994, P13; Dhanda SK, 2019, NUCLEIC ACIDS RES, V47, pW502, DOI 10.1093/nar/gkz452; Dos Vultos T, 2009, FEMS MICROBIOL REV, V33, P471, DOI 10.1111/j.1574-6976.2009.00170.x; Flynn JL, 2001, INFECT IMMUN, V69, P4195, DOI 10.1128/IAI.69.7.4195-4201.2001; Forrellad MA, 2013, VIRULENCE, V4, P3, DOI 10.4161/viru.22329; Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0; Hmama Z, 2015, IMMUNOL REV, V264, P220, DOI 10.1111/imr.12268; Huynh KK, 2007, MICROBIOL MOL BIOL R, V71, P452, DOI 10.1128/MMBR.00003-07; JARLIER V, 1994, FEMS MICROBIOL LETT, V123, P11, DOI 10.1111/j.1574-6968.1994.tb07194.x; Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889; Kaufmann SHE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01203; Kotturi MF, 2007, J VIROL, V81, P4928, DOI 10.1128/JVI.02632-06; Nguyen L, 2016, ARCH TOXICOL, V90, P1585, DOI 10.1007/s00204-016-1727-6; Luabeya AKK, 2015, VACCINE, V33, P4130, DOI 10.1016/j.vaccine.2015.06.051; McShane H, 2005, TUBERCULOSIS, V85, P47, DOI 10.1016/j.tube.2004.09.015; Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215; Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238; One E, 2020, INFECT GENET EVOL, V80, DOI 10.1016/j.meegid.2020.104186; Ong E, 2021, NUCLEIC ACIDS RES, V49, pW671, DOI 10.1093/nar/gkab279; Ong E, 2020, BIOINFORMATICS, V36, P3185, DOI 10.1093/bioinformatics/btaa119; Qamra R, 2005, TUBERCULOSIS, V85, P385, DOI 10.1016/j.tube.2005.08.014; Ramakrishnan L, 2012, NAT REV IMMUNOL, V12, P352, DOI 10.1038/nri3211; Rappuoli R, 2001, VACCINE, V19, P2688, DOI 10.1016/S0264-410X(00)00554-5; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Rustad TR, 2009, CELL MICROBIOL, V11, P1151, DOI 10.1111/j.1462-5822.2009.01325.x; Seung KJ, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017863; Sidney John, 2008, Immunome Res, V4, P2, DOI 10.1186/1745-7580-4-2; Singh SK, 2013, APPL MICROBIOL BIOT, V97, P5825, DOI 10.1007/s00253-012-4493-2; Southwood S, 1998, J IMMUNOL, V160, P3363; Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555, DOI 10.1038/9858; Tameris MD, 2013, LANCET, V381, P1021, DOI 10.1016/S0140-6736(13)60177-4; Tripathi P, 2020, INT J MED MICROBIOL, V310, DOI 10.1016/j.ijmm.2020.151402; Uplekar M, 2015, LANCET, V385, P1799, DOI 10.1016/S0140-6736(15)60570-0; Van der Meeren O, 2018, NEW ENGL J MED, V379, P1621, DOI 10.1056/NEJMoa1803484; Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568; Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110; Yang B, 2011, NUCLEIC ACIDS RES, V39, pD1073, DOI 10.1093/nar/gkq944	53	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1098	10.3390/vaccines9101098			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO2OH	34696207	gold, Green Published			2022-04-29	WOS:000712298500001
J	Wang, CC; Chiu, L; Ju, JS; Lin, YC; Fang, YF; Yang, CT; Hsu, PC				Wang, Chin-Chou; Chiu, Li-Chung; Ju, Jia-Shiuan; Lin, Yu-Ching; Fang, Yueh-Fu; Yang, Cheng-Ta; Hsu, Ping-Chih			Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study	VACCINES			English	Article						durvalumab; stage III non-small cell lung cancer (NSCLC); concurrent chemoradiation (CCRT); programmed death-ligand 1 (PD-L1); immune checkpoint inhibitors (ICIs); epidermal growth factor receptor (EGFR) mutation	CHECKPOINT INHIBITORS; RADIATION-THERAPY; EGFR; CHEMORADIOTHERAPY; CHEMOTHERAPY; SURVIVAL; NSCLC; RADIOTHERAPY; OSIMERTINIB; MANAGEMENT	Background: The experience of using consolidation durvalumab in post-concurrent chemoradiation (CCRT) unresectable stage III non-small cell lung cancer (NSCLC) is rare in real-world clinical practice, and the factors associated with its efficacy are also unclear. We sought to analyze the efficacy of consolidation durvalumab and the factors associated with its efficacy using a multicenter observational study. Methods: The data for 61 patients with post-CCR unresectable stage III NSCLC receiving consolidation durvalumab at the Chang Gung Memorial Hospitals in Linkou, Keelung, Chiayi, and Kaohsiung from November 2017 to March 2020 were analyzed. (3) Results: The median post-CCRT progression-free survival (PFS) and time to metastatic disease or death (TMDD) for consolidation durvalumab were 14.0 months and 16.7 months, respectively. In multiple variant factors analysis, we found that an epidermal growth factor receptor (EGFR) mutation was an independently unfavorable predictive factor for consolidation durvalumab therapy regarding PFS. The median post-CCRT PFS was 6.50 months for EGFR-mutated patients and 33.63 months for EGFR wild-type and unknown patients (HR = 10.47; 95% CI, 4.55-24.07; p < 0.001). Conclusions: Consolidation durvalumab is effective and safe for post-CCRT unresectable stage III NSCLC in clinical practice, but EGFR mutation is an unfavorable factor for consolidation durvalumab. Thus, searching for a better consolidation therapy for EGFR-mutated patients is warranted.</p>	[Wang, Chin-Chou] Kaohsiung Chang Gung Mem Hosp, Div Pulm & Crit Care Med, Kaohsiung 83301, Taiwan; [Wang, Chin-Chou; Chiu, Li-Chung; Lin, Yu-Ching; Hsu, Ping-Chih] Chang Gung Univ, Dept Med, Coll Med, Taoyuan 33302, Taiwan; [Chiu, Li-Chung; Ju, Jia-Shiuan; Fang, Yueh-Fu; Yang, Cheng-Ta; Hsu, Ping-Chih] Chang Gung Mem Hosp, Div Thorac Med, Dept Internal Med, Taoyuan 33305, Taiwan; [Chiu, Li-Chung] New Taipei Municipal Tu Cheng Hosp, Dept Thorac Med, New Taipei 23652, Taiwan; [Lin, Yu-Ching] Chang Gung Mem Hosp, Chiayi Branch, Div Thorac Oncol, Dept Resp & Crit Care Med, Chiayi 61363, Taiwan; [Lin, Yu-Ching] Chang Gung Univ Sci & Technol, Dept Resp Care, Chiayi Campus, Chiayi, Chiayi 33303, Taiwan; [Yang, Cheng-Ta] Taoyuan Chang Gung Mem Hosp, Dept Internal Med, Taoyuan 33378, Taiwan; [Yang, Cheng-Ta] Chang Gung Univ, Dept Resp Therapy, Coll Med, Taoyuan 33302, Taiwan		Hsu, PC (通讯作者)，Chang Gung Univ, Dept Med, Coll Med, Taoyuan 33302, Taiwan.; Hsu, PC (通讯作者)，Chang Gung Mem Hosp, Div Thorac Med, Dept Internal Med, Taoyuan 33305, Taiwan.	ccwang5202@yahoo.com.tw; pomd54@cgmh.org.tw; 9502008@cgmh.org.tw; lin0927@cgmh.org.tw; dr.fang.yf@gmail.com; cang1946@cgmh.org.tw; 8902049@adm.cgmh.org.tw	Hsu, Ping-Chih/AAS-7146-2020	Hsu, Ping-Chih/0000-0003-0173-7509; Yang, Cheng-Ta/0000-0003-1846-1027; Fang, Yueh-Fu/0000-0003-2211-3076; Chiu, Li-Chung/0000-0003-1660-7715; Lin, Yu-Ching/0000-0002-0702-5169	Taiwan Ministry of Science and Technology (MOST) [109-2628-B-182A-009]; Chang Gung Medical Research Project [CMRPG3K1561, CMRPG8E1661-3, CMRPG8F1441, CMRPG8F1351, CMRPG8H1201, CORPG8F1491-3, CMRPG5H0141]	This study was funded by the Taiwan Ministry of Science and Technology (MOST) (grant no. 109-2628-B-182A-009 to P.C.H.) and the Chang Gung Medical Research Project (grant no. CMRPG3K1561 to P.C.H.; grant no. CMRPG8E1661-3, CMRPG8F1441, CMRPG8F1351, CMRPG8H1201, and CORPG8F1491-3 to C.C.W.; and grant no. CMRPG5H0141 to C.T.Y.).	Albain KS, 2009, LANCET, V374, P379, DOI 10.1016/S0140-6736(09)60737-6; Aredo JV, 2021, J THORAC ONCOL, V16, P1030, DOI 10.1016/j.jtho.2021.01.1628; Arrieta O, 2015, J THORAC ONCOL, V10, P838, DOI 10.1097/JTO.0000000000000481; Belluomini L, 2019, ONCOL THER, V7, P83, DOI 10.1007/s40487-019-0092-z; Biswas T, 2014, EXPERT REV ANTICANC, V14, P333, DOI 10.1586/14737140.2014.867809; Cheung AHK, 2020, PATHOLOGY, V52, P323, DOI 10.1016/j.pathol.2019.12.003; Cobo M, 2021, ONCOL THER, V9, P41, DOI 10.1007/s40487-021-00139-3; Faivre-Finn C, 2021, J THORAC ONCOL, V16, P860, DOI 10.1016/j.jtho.2020.12.015; Ferrara MG, 2020, CANCERS, V12, DOI 10.3390/cancers12051196; Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009; Gotwals P, 2017, NAT REV CANCER, V17, P286, DOI 10.1038/nrc.2017.17; Hsu PC, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8020036; Hsu PC, 2019, THORAC CANCER, V10, P1683, DOI 10.1111/1759-7714.13125; Kris MG, 2017, J CLIN ONCOL, V35, P2960, DOI 10.1200/JCO.2017.72.4401; Lee CK, 2017, J THORAC ONCOL, V12, P403, DOI 10.1016/j.jtho.2016.10.007; Lu S, 2021, CLIN LUNG CANCER, V22, P371, DOI 10.1016/j.cllc.2020.11.004; Mazieres J, 2019, ANN ONCOL, V30, P1321, DOI 10.1093/annonc/mdz167; Metro G, 2020, ONCOL THER, V8, P341, DOI 10.1007/s40487-020-00121-5; Nasser NJ, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13110373; Okita R, 2019, ONCOL REP, V42, P839, DOI 10.3892/or.2019.7185; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pfirschke C, 2016, IMMUNITY, V44, P343, DOI 10.1016/j.immuni.2015.11.024; Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662; Roach C, 2016, APPL IMMUNOHISTO M M, V24, P392, DOI 10.1097/PAI.0000000000000408; Socinski MA, 2000, CANCER-AM CANCER SOC, V89, P534; Tabchi S, 2017, SEMIN ONCOL, V44, P163, DOI 10.1053/j.seminoncol.2017.10.009; Tseng JS, 2012, LUNG CANCER, V77, P128, DOI 10.1016/j.lungcan.2012.02.012; Tsujino K, 2013, J THORAC ONCOL, V8, P1181, DOI 10.1097/JTO.0b013e3182988348; Vaddepally RK, 2020, CANCERS, V12, DOI 10.3390/cancers12030738; Wang XS, 2017, INT J CLIN ONCOL, V22, P229, DOI 10.1007/s10147-016-1074-x; Wu YL, 2020, NEW ENGL J MED, V383, P1711, DOI 10.1056/NEJMoa2027071; Yang JCH, 2019, J THORAC ONCOL, V14, P933, DOI 10.1016/j.jtho.2019.02.001; Yang KL, 2016, CLIN LUNG CANCER, V17, P550, DOI 10.1016/j.cllc.2016.05.013; Zatloukal P, 2004, LUNG CANCER-J IASLC, V46, P87, DOI 10.1016/j.lungcan.2004.03.004; Zhang HJ, 2019, J CELL MOL MED, V23, P535, DOI 10.1111/jcmm.13956; Zhang Yue-Lun, 2016, Oncotarget, V7, P78985, DOI 10.18632/oncotarget.12587	36	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1122	10.3390/vaccines9101122			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO4PB	34696229	Green Published, gold			2022-04-29	WOS:000712437100001
J	Yolanda, H; Krajaejun, T				Yolanda, Hanna; Krajaejun, Theerapong			History and Perspective of Immunotherapy for Pythiosis	VACCINES			English	Review						pythiosis; Pythium insidiosum; antigen; treatment; immunotherapy	PYTHIUM-INSIDIOSUM KERATITIS; MULTICENTRIC CUTANEOUS PYTHIOSIS; LINKED-IMMUNOSORBENT-ASSAY; GASTROINTESTINAL PYTHIOSIS; EQUINE PYTHIOSIS; VASCULAR PYTHIOSIS; IN-VITRO; GASTRIC PYTHIOSIS; CLINICAL PROFILE; BONE-LESIONS	The fungus-like microorganism Pythium insidiosum causes pythiosis, a life-threatening infectious disease increasingly reported worldwide. Antimicrobial drugs are ineffective. Radical surgery is an essential treatment. Pythiosis can resume post-surgically. Immunotherapy using P. insidiosum antigens (PIA) has emerged as an alternative treatment. This review aims at providing up-to-date information of the immunotherapeutic PIA, with the focus on its history, preparation, clinical application, outcome, mechanism, and recent advances, in order to promote the proper use and future development of this treatment modality. P. insidiosum crude extract is the primary source of immunotherapeutic antigens. Based on 967 documented human and animal (mainly horses) pythiosis cases, PIA immunotherapy reduced disease morbidity and mortality. Concerning clinical outcomes, 19.4% of PIA-immunized human patients succumbed to vascular pythiosis instead of 41.0% in unimmunized cases. PIA immunotherapy may not provide an advantage in a local P. insidiosum infection of the eye. Both PIA-immunized and unimmunized horses with pythiosis showed a similar survival rate of ~70%; however, demands for surgical intervention were much lesser in the immunized cases (22.8% vs. 75.2%). The proposed PIA action involves switching the non-protective T-helper-2 to protective T-helper-1 mediated immunity. By exploring the available P. insidiosum genome data, synthetic peptides, recombinant proteins, and nucleic acids are potential sources of the immunotherapeutic antigens worth investigating. The PIA therapeutic property needs improvement for a better prognosis of pythiosis patients.</p>	[Yolanda, Hanna] Mahidol Univ, Ramathibodi Hosp, Fac Med, Sect Translat Med, Bangkok 10400, Thailand; [Yolanda, Hanna] Atma Jaya Catholic Univ Indonesia, Sch Med & Hlth Sci, Dept Parasitol, Jakarta 14440, Indonesia; [Krajaejun, Theerapong] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pathol, Bangkok 10400, Thailand		Krajaejun, T (通讯作者)，Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pathol, Bangkok 10400, Thailand.	hanna.yoa@student.mahidol.ac.th; mr_en@hotmail.com	Krajaejun, Theerapong/P-2550-2017	Krajaejun, Theerapong/0000-0003-0545-3765	Faculty of Graduate Studies, Mahidol University, Thailand; Section for Translational Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand; School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Indonesia; Thailand Research Fund, ThailandThailand Research Fund (TRF) [RSA6280092]; Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand [CF_63008]	This work was funded by Faculty of Graduate Studies, Mahidol University, Thailand (H.Y.); Section for Translational Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand (H.Y.); School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Indonesia (H.Y.); Thailand Research Fund, Thailand (Grant numbers: RSA6280092; T.K.); and Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand (Grant number: CF_63008; T.K.).	Agarwal S, 2019, BRIT J OPHTHALMOL, V103, P296, DOI 10.1136/bjophthalmol-2017-311804; Agarwal S, 2018, BRIT J OPHTHALMOL, V102, P153, DOI 10.1136/bjophthalmol-2017-310604; Ahirwar LK, 2021, EXP EYE RES, V202, DOI 10.1016/j.exer.2020.108345; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; ALFARO AA, 1990, EQUINE VET J, V22, P295, DOI 10.1111/j.2042-3306.1990.tb04273.x; Anutarapongpan O, 2018, CORNEA, V37, P156, DOI 10.1097/ICO.0000000000001466; Ascunce MS, 2016, GENOM DATA, V7, P60, DOI 10.1016/j.gdata.2015.11.019; Atiba A, 2020, IRAN J VET RES, V21, P301, DOI 10.22099/ijvr.2020.37825.5502; Awadin W., 2013, J VET SCI MED DIAGN, V2; Bach BC, 2013, CELL BIOCHEM FUNCT, V31, P476, DOI 10.1002/cbf.2921; Bach BC, 2010, BIOMED PHARMACOTHER, V64, P718, DOI 10.1016/j.biopha.2010.09.016; Badenoch PR, 2009, CLIN EXP OPHTHALMOL, V37, P806, DOI 10.1111/j.1442-9071.2009.02135.x; Badenoch PR, 2001, BRIT J OPHTHALMOL, V85, P502; Bagga B, 2021, OPHTHALMOLOGY, V128, P169, DOI 10.1016/j.ophtha.2020.05.046; Bagga B, 2018, BRIT J OPHTHALMOL, V102, P1629, DOI 10.1136/bjophthalmol-2017-311360; Bandeira A. M. P., 2009, Ciencia Veterinaria nos Tropicos, V12, P46; Barequet IS, 2013, SEMIN OPHTHALMOL, V28, P247, DOI 10.3109/08820538.2013.788676; Bernardo FD, 2015, PESQUI VET BRASIL, V35, P513, DOI 10.1590/S0100-736X2015000600004; Bernheim D, 2019, INT J INFECT DIS, V86, P40, DOI 10.1016/j.ijid.2019.06.011; Berryessa NA, 2008, J VET INTERN MED, V22, P1065, DOI 10.1111/j.1939-1676.2008.0123.x; Bosco SDG, 2005, EMERG INFECT DIS, V11, P715; Pereira DIB, 2010, VET RES COMMUN, V34, P301, DOI 10.1007/s11259-010-9354-9; Cagigi A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010061; Camus AC, 2004, J VET DIAGN INVEST, V16, P567, DOI 10.1177/104063870401600612; Cardona Álvarez José, 2013, Ces. Med. Vet. Zootec., V8, P104; Alvarez JC, 2010, REV CIENT-FAC CIEN V, V20, P590; Cardona-Alvarez J, 2016, REV MVZ CORDOBA, V21, P5511, DOI 10.21897/rmvz.825; del Castillo-Jimenez MC, 2013, ENFERM INFEC MICR CL, V31, P118, DOI 10.1016/j.eimc.2012.07.012; Carrera MV, 2013, PESQUISA VET BRASIL, V33, P476, DOI 10.1590/S0100-736X2013000400011; Carrijo BN, 2021, OZONE-SCI ENG, DOI 10.1080/01919512.2021.1937511; Carvalho A, 2017, CURR FUNGAL INFECT R, V11, P16, DOI 10.1007/s12281-017-0272-y; CHAFFIN MK, 1992, J AM VET MED ASSOC, V201, P310; Chareonsirisuthigul T, 2013, DIAGN MICR INFEC DIS, V76, P42, DOI 10.1016/j.diagmicrobio.2013.02.025; Chatterjee S, 2018, CORNEA, V37, pE8, DOI 10.1097/ICO.0000000000001419; Chechi JL, 2021, J FUNGI, V7, DOI 10.3390/jof7060423; Chetchotisakd Ploenchan, 1992, Journal of the Medical Association of Thailand, V75, P248; Chindamporn Ariya, 2020, Access Microbiol, V2, pacmi000109, DOI 10.1099/acmi.0.000109; Chindamporn A, 2009, CLIN VACCINE IMMUNOL, V16, P330, DOI 10.1128/CVI.00429-08; Chitasombat MN, 2020, PEERJ, V8, DOI 10.7717/peerj.8555; Chitasombat MN, 2018, MED MYCOL CASE REP, V21, P57, DOI 10.1016/j.mmcr.2018.05.003; Chitasombat MN, 2018, INT J INFECT DIS, V71, P33, DOI 10.1016/j.ijid.2018.03.021; Connolly SL, 2012, VET CLIN PATH, V41, P419, DOI 10.1111/j.1939-165X.2012.00447.x; Cridge H, 2020, J AM ANIM HOSP ASSOC, V56, P307, DOI 10.5326/JAAHA-MS-7039; Soares LMC, 2019, CIENC RURAL, V49, DOI 10.1590/0103-8478cr20180448; D'Avila P.P., 2011, REV CIENT ELETRONICA, V9, P1; Da Nobrega D.F., 2013, ARCH VET SCI, V18, P611; da Paz GS, 2021, TRANSBOUND EMERG DIS, DOI 10.1111/tbed.14135; Fonseca AOD, 2014, MYCOPATHOLOGIA, V177, P123, DOI 10.1007/s11046-013-9720-6; Da Silva W.P., 2018, REV SABER DIGIT, V10, P57; Dal Ben V, 2018, MED MYCOL, V56, P485, DOI 10.1093/mmy/myx071; Maciel ICD, 2008, ACTA SCI VET, V36, P293; de Macedo LB, 2014, BRAZ J HYG ANIM SANI, V8, P88, DOI 10.5935/1981-2965.20140136; DECOCK AWAM, 1987, J CLIN MICROBIOL, V25, P344, DOI 10.1128/JCM.25.2.344-349.1987; Dhirachaikulpanich D, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90815-1; Di Filippo P.A., 2020, REV ACAD CIENC ANIM, V18; Dixon DM, 1998, MED MYCOL, V36, P57; do Carmo PMS, 2021, J VET DIAGN INVEST, V33, P20, DOI 10.1177/1040638720968937; Doria RGS, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0472-z; Doria RGS, 2012, VET SURG, V41, P759, DOI 10.1111/j.1532-950X.2012.01019.x; dos Santos CEP, 2014, J EQUINE VET SCI, V34, P270, DOI 10.1016/j.jevs.2013.06.003; Dowling BA, 1999, AUST VET J, V77, P780, DOI 10.1111/j.1751-0813.1999.tb12942.x; Dowst M, 2019, MED MYCOL CASE REP, V26, P57, DOI 10.1016/j.mmcr.2019.10.004; Duncan D., 1992, P 43 M AM COLL VET P, V29, P429; Dycus DL, 2015, J AM ANIM HOSP ASSOC, V51, P385, DOI 10.5326/JAAHA-MS-6217; Dykstra MJ, 1999, MED MYCOL, V37, P427, DOI 10.1046/j.1365-280X.1999.00248.x; EATON SA, 1993, COMP CONT EDUC PRACT, V15, P485; Elkhenany H, 2019, SLOV VET RES, V56, P281, DOI 10.26873/SVR-767-2019; Fernandes CPM, 2012, REV IBEROAM MICOL, V29, P235, DOI 10.1016/j.riam.2012.01.002; de Souto EPF, 2019, ACTA SCI VET, V47, DOI 10.22456/1679-9216.91877; Ferreira JC, 2021, J EQUINE VET SCI, V98, DOI 10.1016/j.jevs.2020.103305; Firmino MO, 2017, ARQ BRAS MED VET ZOO, V69, P623, DOI 10.1590/1678-4162-9107; FISCHER JR, 1994, J VET DIAGN INVEST, V6, P380, DOI 10.1177/104063879400600320; Fortin JS, 2017, ACTA VET SCAND, V59, DOI 10.1186/s13028-017-0330-z; Frade MTS, 2017, PESQUI VET BRASIL, V37, P485, DOI [10.1590/s0100-736x2017000500010, 10.1590/S0100-736X2017000500010]; Franco Dori M, 2010, Burns, V36, pe68, DOI 10.1016/j.burns.2009.08.005; Frey Friedrich Jr., 2007, Revista Portuguesa de Ciencias Veterinarias, V102, P107; Fujimori M, 2016, CIENC RURAL, V46, P526, DOI 10.1590/0103-8478cr20150081; Gaastra W, 2010, VET MICROBIOL, V146, P1, DOI 10.1016/j.vetmic.2010.07.019; Gabriel AL, 2008, PESQUI VET BRASIL, V28, P583, DOI 10.1590/S0100-736X2008001200003; Gaddis KL, 2017, JAVMA-J AM VET MED A, V250, P1231, DOI 10.2460/javma.250.11.1231; Garcia RB, 2007, MYCOL RES, V111, P1352, DOI 10.1016/j.mycres.2007.08.005; Grant D, 2016, MED MYCOL CASE REP, V14, P1, DOI 10.1016/j.mmcr.2016.11.005; Grecco FB, 2009, PESQUI VET BRASIL, V29, P938, DOI 10.1590/S0100-736X2009001100013; Grooters AM, 2002, J VET DIAGN INVEST, V14, P288, DOI 10.1177/104063870201400403; Gurnani B, 2021, INDIAN J OPHTHALMOL, V69, P1095, DOI 10.4103/ijo.IJO_1808_20; Gurnani B, 2021, EUR J OPHTHALMOL, DOI 10.1177/11206721211006564; Hahtapornsawan S, 2014, ANN VASC SURG, V28, DOI 10.1016/j.avsg.2014.04.020; Hasika R, 2019, INDIAN J OPHTHALMOL, V67, P42, DOI [10.4103/ijo.IJO_445_18, 10.4103/ijo.ijo_445_18]; He H, 2016, AM J CASE REP, V17, P982, DOI 10.12659/AJCR.901158; Heath JA, 2002, CLIN INFECT DIS, V35, pE60, DOI 10.1086/342303; Heck LC, 2018, J ZOO WILDLIFE MED, V49, P784, DOI 10.1638/2017-0195.1; Helman RG, 1999, J AM ANIM HOSP ASSOC, V35, P111, DOI 10.5326/15473317-35-2-111; Hensel P, 2003, J AM VET MED ASSOC, V223, P215, DOI 10.2460/javma.2003.223.215; Hnilica KA, 1998, J AM VET MED ASSOC, V212, P1192; Howerth E W, 1989, J Vet Diagn Invest, V1, P81; Htun ZM, 2021, J FUNGI, V7, DOI 10.3390/jof7040242; Htun ZM, 2020, INT J INFECT DIS, V101, P149, DOI 10.1016/j.ijid.2020.09.1430; Hummel J, 2011, MED MYCOL, V49, P539, DOI 10.3109/13693786.2010.543705; Hung C, 2014, CLIN GASTROENTEROL H, V12, pXXI, DOI 10.1016/j.cgh.2014.04.023; Hunning PS, 2010, ARQ BRAS MED VET ZOO, V62, P801, DOI 10.1590/S0102-09352010000400006; IMWIDTHAYA P, 1994, POSTGRAD MED J, V70, P558, DOI 10.1136/pgmj.70.826.558; Inez-Ferreira TM, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00278; Inkomlue R, 2016, J CLIN MICROBIOL, V54, P43, DOI 10.1128/JCM.02113-15; Intaramat A, 2016, MED MYCOL, V54, P641, DOI 10.1093/mmy/myw018; Jaeger GH, 2002, J VET INTERN MED, V16, P598, DOI 10.1892/0891-6640(2002)016&lt;0598:PPIAD&gt;2.3.CO;2; Jaturapaktrarak C, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104-020-04981-y; Jesus FPK, 2016, ANTIMICROB AGENTS CH, V60, P87, DOI 10.1128/AAC.01480-15; Jesus FPK, 2014, ANTIMICROB AGENTS CH, V58, P5621, DOI 10.1128/AAC.02349-14; Jindayok T, 2009, CLIN VACCINE IMMUNOL, V16, P1047, DOI 10.1128/CVI.00113-09; Keeratijarut A, 2015, J MED MICROBIOL, V64, P971, DOI 10.1099/jmm.0.000117; Keeratijarut A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135239; Keeratijarut A, 2014, ASIAN BIOMED, V8, P637, DOI 10.5372/1905-7415.0805.338; Keeratijarut A, 2013, SE ASIAN J TROP MED, V44, P672; Keeratijarut A, 2009, SE ASIAN J TROP MED, V40, P1298; Keoprasom N, 2013, MED MYCOL CASE REP, V2, P25, DOI 10.1016/j.mmcr.2012.12.002; Kepler D, 2019, VET RADIOL ULTRASOUN, V60, pE20, DOI 10.1111/vru.12516; Khunkhet Saranya, 2015, JAAD Case Rep, V1, P399, DOI 10.1016/j.jdcr.2015.09.005; Kirzhner M, 2015, J PEDIAT INF DIS SOC, V4, pE10, DOI 10.1093/jpids/piu015; Kittichotirat W, 2017, DATA BRIEF, V15, P896, DOI 10.1016/j.dib.2017.10.047; Konradt G, 2016, MED MYCOL CASE REP, V14, P24, DOI 10.1016/j.mmcr.2016.11.004; Krajaejun T, 2002, CLIN DIAGN LAB IMMUN, V9, P378, DOI 10.1128/CDLI.9.2.378-382.2002; Krajaejun T, 2004, AM J OPHTHALMOL, V137, P370, DOI 10.1016/S0002-9394(03)00908-5; Krajaejun T, 2006, CLIN INFECT DIS, V43, P569, DOI 10.1086/506353; Krajaejun T, 2006, J CLIN MICROBIOL, V44, P1674, DOI 10.1128/JCM.44.5.1674-1680.2006; Krajaejun T, 2021, BMC RES NOTES, V14, DOI 10.1186/s13104-021-05610-y; Krajaejun Theerapong, 2018, BMC Res Notes, V11, P880, DOI 10.1186/s13104-018-3968-3; Krajaejun T, 2018, INT J INFECT DIS, V77, P61, DOI 10.1016/j.ijid.2018.09.006; Krajaejun T, 2010, SE ASIAN J TROP MED, V41, P1462; Krajaejun T, 2009, CLIN VACCINE IMMUNOL, V16, P506, DOI 10.1128/CVI.00276-08; Krockenberger MB, 2011, AUST VET J, V89, P9, DOI 10.1111/j.1751-0813.2010.00666.x; Kulandai LT, 2020, CORNEA, V39, P775, DOI 10.1097/ICO.0000000000002284; Laohapensang K, 2009, VASCULAR, V17, P234, DOI 10.2310/6670.2008.00073; Laohapensang K, 2005, INT J ANGIOL, V14, P123, DOI 10.1007/s00547-005-2012-3; Leal ABM, 2001, PESQUISA VET BRASIL, V21, P151, DOI 10.1590/S0100-736X2001000400005; Leal AT, 2005, J MYCOL MED, V15, P63, DOI 10.1016/j.mycmed.2005.01.004; LeBlanc CJ, 2008, VET CLIN PATH, V37, P115, DOI 10.1111/j.1939-165X.2008.00015.x; Ledur PC, 2018, IMMUNOBIOLOGY, V223, P294, DOI 10.1016/j.imbio.2017.10.033; Lekhanont K, 2009, CORNEA, V28, P1173, DOI 10.1097/ICO.0b013e318199fa41; Lelievre L, 2015, AM J TROP MED HYG, V92, P270, DOI 10.4269/ajtmh.14-0380; Lemos G., 2018, REV ACAD CIENC ANIM, V16; Lerksuthirat T, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.02352-16, 10.1128/aac.02352-16]; Lerksuthirat T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118547; Liljebjelke KA, 2002, J AM VET MED ASSOC, V220, P1188, DOI 10.2460/javma.2002.220.1188; Lohnoo Tassanee, 2014, Journal of the Medical Association of Thailand, V97, P342; Loreto E.S., 2020, PYTHIUM DIAGNOSIS DI, P1983; Loreto ES, 2019, MED MYCOL, V57, P523, DOI 10.1093/mmy/myy056; Loreto ES, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.01385-18; Loreto ES, 2014, ANTIMICROB AGENTS CH, V58, P7534, DOI 10.1128/AAC.02680-13; Loreto S., 2014, WJI, V4, P88, DOI [10.5411/wji.v4.i2.88, DOI 10.5411/WJI.V4.I2.88]; Maeno Sayo, 2019, Am J Ophthalmol Case Rep, V15, P100498, DOI 10.1016/j.ajoc.2019.100498; Maia LA, 2020, PESQUI VET BRASIL, V40, P340, DOI [10.1590/1678-5150-PVB-6532, 10.1590/1678-5150-pvb-6532]; Maia LA, 2016, J VET DIAGN INVEST, V28, P436, DOI 10.1177/1040638716651467; Manco M. H., 2021, Brazilian Journal of Veterinary Pathology, V14, P50, DOI 10.24070/bjvp.1983-0246.v14i1p50-55; Mani R, 2019, J MED MICROBIOL, V68, P574, DOI 10.1099/jmm.0.000941; Maroneze B.P., 2012, ACTA SCI VET, V40, pS36; Marques Silvio Alencar, 2006, An. Bras. Dermatol., V81, P483, DOI 10.1590/S0365-05962006000500012; Martins TB, 2012, J COMP PATHOL, V146, P122, DOI 10.1016/j.jcpa.2011.06.006; MEIRELES MCA, 1993, MYCOSES, V36, P139, DOI 10.1111/j.1439-0507.1993.tb00702.x; Mendoza A.L., 2004, U.S. Patent, Patent No. [6833136 B2, 6833136]; Mendoza A.L., 2010, U.S. Patent, Patent No. [7846458 B1, 7846458]; Mendoza A.L., 2011, U.S. Patent, Patent No. [2011/0159042 A1, 20110159042]; Mendoza A.L., 2001, U.S. Patent, Patent No. [6287573 B1, 6287573]; Mendoza L, 2005, MED MYCOL, V43, P477, DOI 10.1080/13693780500279882; MENDOZA L, 1986, MYCOPATHOLOGIA, V94, P123, DOI 10.1007/BF00437377; Mendoza L, 2005, MYCOPATHOLOGIA, V159, P219, DOI 10.1007/s11046-004-6618-3; Mendoza L, 2003, VACCINE, V21, P2797, DOI 10.1016/S0264-410X(03)00225-1; MENDOZA L, 1992, J CLIN MICROBIOL, V30, P2980, DOI 10.1128/JCM.30.11.2980-2983.1992; MENDOZA L, 1993, J CLIN MICROBIOL, V31, P2967, DOI 10.1128/JCM.31.11.2967-2973.1993; MENDOZA L, 1992, MYCOPATHOLOGIA, V119, P89, DOI 10.1007/BF00443939; MENDOZA L, 1988, J MED VET MYCOL, V26, P5; MILLER RI, 1983, J AM VET MED ASSOC, V182, P1227; MILLER RI, 1985, J AM VET MED ASSOC, V186, P984; MILLER RI, 1981, AUST VET J, V57, P377, DOI 10.1111/j.1751-0813.1981.tb00526.x; Mittal R, 2017, CORNEA, V36, P1124, DOI [10.1097/ICO.0000000000001244, 10.1097/ico.0000000000001244]; Tondolo JSM, 2013, J MICROBIOL METH, V93, P52, DOI 10.1016/j.mimet.2013.02.002; Mosbah E, 2012, J EQUINE VET SCI, V32, P164, DOI 10.1016/j.jevs.2011.08.014; Murdoch D, 1997, AUST NZ J OPHTHALMOL, V25, P177, DOI 10.1111/j.1442-9071.1997.tb01304.x; Nami S, 2019, BIOMED PHARMACOTHER, V109, P333, DOI 10.1016/j.biopha.2018.10.075; Narkwiboonwong T., 2011, Journal of Infectious Diseases and Antimicrobial Agents, V28, P129; Neufeld A, 2018, CAN J OPHTHALMOL, V53, pE48, DOI 10.1016/j.jcjo.2017.07.002; Nonpassopon M, 2021, CORNEA, V40, P1413, DOI 10.1097/ICO.0000000000002651; Oldenhoff W, 2014, VET DERMATOL, V25, P52, DOI 10.1111/vde.12101; Oliveira LVN, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00294-8; Otta SK, 2018, INDIAN J GEO-MAR SCI, V47, P1036; Pan JH, 2014, INT J SURG CASE REP, V5, P677, DOI 10.1016/j.ijscr.2014.05.018; Parambeth JC, 2019, VET CLIN PATH, V48, P83, DOI 10.1111/vcp.12720; Paterson MJ, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008733; Pathomsakulwong W., 2019, P 57 KAS U ANN C BAN, P1; Patton CS, 1996, J VET INTERN MED, V10, P139, DOI 10.1111/j.1939-1676.1996.tb02046.x; Patumcharoenpol P, 2018, DATA BRIEF, V16, P47, DOI 10.1016/j.dib.2017.11.002; Pereira DIB, 2008, J MYCOL MED, V18, P129, DOI 10.1016/j.mycmed.2008.05.001; Pereira DIB, 2013, MYCOPATHOLOGIA, V176, P309, DOI 10.1007/s11046-013-9683-7; dos Santos CEP, 2011, ACTA SCI VET, V39; Perez RC, 2005, VET MICROBIOL, V109, P121, DOI 10.1016/j.vetmic.2005.04.020; Permpalung N, 2020, MYCOPATHOLOGIA, V185, P801, DOI 10.1007/s11046-019-00412-0; Permpalung N, 2019, MED MYCOL, V57, P923, DOI 10.1093/mmy/myz013; Permpalung N, 2015, J ANTIMICROB CHEMOTH, V70, P1885, DOI 10.1093/jac/dkv008; Pesavento PA, 2008, VET PATHOL, V45, P538, DOI 10.1354/vp.45-4-538; Pires L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085431; Pires L, 2013, VET DERMATOL, V24, P130, DOI 10.1111/j.1365-3164.2012.01112.x; Prado L.G., 2015, R BRAS MED EQUINA, V10, P10; Prasertwitayakij N, 2003, SEMIN ARTHRITIS RHEU, V33, P204, DOI 10.1016/j.semarthrit.2003.09.003; Presser JW, 2015, MED MYCOL, V53, P674, DOI 10.1093/mmy/myv054; Puangsricharern V, 2021, CLIN OPHTHALMOL, V15, P1691, DOI 10.2147/OPTH.S303721; Pupaibool J, 2006, EMERG INFECT DIS, V12, P517, DOI 10.3201/eid1203.051044; PURCELL KL, 1994, J AM VET MED ASSOC, V205, P337; Raghavan Anita, 2018, BMJ Case Rep, V11, DOI 10.1136/bcr-2018-226386; Rakich PM, 2005, J VET DIAGN INVEST, V17, P262, DOI 10.1177/104063870501700310; Ramappa Muralidhar, 2017, Cornea, V36, P511, DOI 10.1097/ICO.0000000000001162; Rathi A, 2018, CORNEA, V37, P519, DOI 10.1097/ICO.0000000000001504; Reagan KL, 2019, J VET INTERN MED, V33, P1434, DOI 10.1111/jvim.15506; Reanpang T, 2015, INT J LOW EXTR WOUND, V14, P245, DOI 10.1177/1534734615599652; Rech R. R., 2004, Clinica Veterinaria, V9, P68; Reis JL, 2003, VET MICROBIOL, V96, P289, DOI 10.1016/j.vetmic.2003.07.005; Rivierre C, 2005, EMERG INFECT DIS, V11, P479; Rodrigues A, 2006, J MYCOL MED, V16, P37, DOI 10.1016/j.mycmed.2005.10.006; Romero A, 2019, PESQUI VET BRASIL, V39, P469, DOI [10.1590/1678-5150-pvb-6256, 10.1590/1678-5150-PVB-6256]; Castellar FR, 2017, AM J HEALTH-SYST PH, V74, P821, DOI 10.2146/ajhp160248; Rossato CK, 2018, ARQ BRAS MED VET ZOO, V70, P641, DOI 10.1590/1678-4162-9568; Rotchanapreeda T, 2021, J FUNGI, V7, DOI 10.3390/jof7060474; Rotchanapreeda T, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04237; Rujirawat T, 2017, INFECT GENET EVOL, V54, P429, DOI 10.1016/j.meegid.2017.08.004; Rujirawat T, 2015, MICROBIOL RESOUR ANN, V3, DOI 10.1128/genomeA.00574-15; Sae-Chew P, 2020, MSYSTEMS, V5, DOI 10.1128/mSystems.00196-20; Salas Y, 2012, MYCOPATHOLOGIA, V174, P511, DOI 10.1007/s11046-012-9562-7; Salipante SJ, 2012, J CLIN MICROBIOL, V50, P1480, DOI 10.1128/JCM.06126-11; Sallis Eliza Simone Viegas, 2003, Cienc. Rural, V33, P899, DOI 10.1590/S0103-84782003000500017; Salomao-Nascimento RB, 2010, REV BRAS MED VET, V32, P105; Santos C. E. P., 2011, Ars Veterinaria, V27, P134; Santos CEP, 2011, CLIN VACCINE IMMUNOL, V18, P1397, DOI 10.1128/CVI.05150-11; Santos Carlos Eduardo P. dos, 2011, Pesq. Vet. Bras., V31, P1083, DOI 10.1590/S0100-736X2011001200008; Santurio JM, 2008, VET REC, V163, P276, DOI 10.1136/vr.163.9.276; Santurio J.M., 2001, COMMUNICATION; Santurio J.M., 2020, INT CLIN PATHOL J, V8, P14; Santurio JM, 2003, VACCINE, V21, P2535, DOI 10.1016/S0264-410X(03)00035-5; Santurio JM, 1998, MYCOPATHOLOGIA, V141, P123, DOI 10.1023/A:1006995407665; SATHAPATAYAVONGS B, 1989, J INFECT DIS, V159, P274, DOI 10.1093/infdis/159.2.274; Schloemer N.J., 2013, INFECT DIS CLIN PRAC, V21, pe24, DOI [10.1097/IPC.0b013e318278f3b5, DOI 10.1097/IPC.0B013E318278F3B5]; Schmiedt CW, 2012, JAVMA-J AM VET MED A, V241, P358, DOI 10.2460/javma.241.3.358; Sedrish SA, 1997, J AM VET MED ASSOC, V211, P464; Sermsathanasawadi N, 2016, J VASC SURG, V64, P411, DOI 10.1016/j.jvs.2015.12.024; Sharma S, 2015, CORNEA, V34, P438, DOI 10.1097/ICO.0000000000000349; Shenep JL, 1998, CLIN INFECT DIS, V27, P1388, DOI 10.1086/515042; Valente JDS, 2020, MED MYCOL, V58, P913, DOI 10.1093/mmy/myz141; Valente JDS, 2019, MED MYCOL, V57, P858, DOI 10.1093/mmy/myy147; Singh S, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007460; Sohn Y. S., 1996, Korean Journal of Veterinary Research, V36, P447; Souto EPF, 2020, J MYCOL MED, V30, DOI 10.1016/j.mycmed.2020.101005; Souto EPF, 2019, ARQ BRAS MED VET ZOO, V71, P1081, DOI 10.1590/1678-4162-10666; Souto EPF, 2016, J COMP PATHOL, V155, P126, DOI 10.1016/j.jcpa.2016.06.005; Sudjaritruk T, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-33; Supabandhu J, 2008, MED MYCOL, V46, P41, DOI 10.1080/13693780701513840; Susaengrat N, 2019, INT J INFECT DIS, V88, P27, DOI 10.1016/j.ijid.2019.08.032; Tanhehco TY, 2011, EYE CONTACT LENS, V37, P96, DOI 10.1097/ICL.0b013e3182043114; TANPHAICHITRA D, 1989, Reviews of Infectious Diseases, V11, pS1629; Tartor YH, 2020, VET DERMATOL, V31, P298, DOI 10.1111/vde.12845; Thanathanee O, 2013, CORNEA, V32, P199, DOI 10.1097/ICO.0b013e3182535841; Thieman KM, 2011, JAVMA-J AM VET MED A, V239, P1232, DOI 10.2460/javma.239.9.1232; Thitithanyanont A, 1998, CLIN INFECT DIS, V27, P1394, DOI 10.1086/515043; Thomas RC, 1998, COMP CONT EDUC PRACT, V20, P63; Tondolo JSM, 2020, MED MYCOL, V58, P1120, DOI 10.1093/mmy/myaa023; Tondolo JSM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177868; Tondolo JSM, 2017, CARBOHYD POLYM, V157, P719, DOI 10.1016/j.carbpol.2016.10.053; Tonpitak Walaiporn, 2018, JMM Case Rep, V5, pe005136, DOI 10.1099/jmmcr.0.005136; Neto RT, 2010, VET DERMATOL, V21, P202, DOI 10.1111/j.1365-3164.2009.00779.x; Torvorapanit P, 2021, J FUNGI, V7, DOI 10.3390/jof7020114; TRISCOTT JA, 1993, J CUTAN PATHOL, V20, P267, DOI 10.1111/j.1600-0560.1993.tb00654.x; Trolezi R, 2017, ANN CLIN MICROB ANTI, V16, DOI 10.1186/s12941-017-0183-3; Vanittanakom N, 2004, J CLIN MICROBIOL, V42, P3970, DOI 10.1128/JCM.42.9.3970-3974.2004; Vanittanakom N, 2014, INT J MED MICROBIOL, V304, P321, DOI 10.1016/j.ijmm.2013.11.016; Videla R, 2012, MED MYCOL, V50, P219, DOI 10.3109/13693786.2011.588970; Vilela R, 2018, ACTA TROP, V185, P344, DOI 10.1016/j.actatropica.2018.06.014; VIRGILE R, 1993, CORNEA, V12, P81, DOI 10.1097/00003226-199301000-00015; Vishwakarma P, 2021, INDIAN J OPHTHALMOL, V69, P1544, DOI 10.4103/ijo.IJO_2356_20; WANACHIWANAWIN W, 1993, T ROY SOC TROP MED H, V87, P296, DOI 10.1016/0035-9203(93)90135-D; Wanachiwanawin W, 2004, VACCINE, V22, P3613, DOI 10.1016/j.vaccine.2004.03.031; Wang X., 2020, CLIN MANIFESTATIONS; Weiblena C, 2019, MED MYCOL, V57, P807, DOI 10.1093/mmy/myy078; Wellehan JFX, 2004, J ZOO WILDLIFE MED, V35, P564, DOI 10.1638/03-098; White SD, 2008, VET DERMATOL, V19, P391, DOI 10.1111/j.1365-3164.2008.00690.x; Worasilchai N, 2019, MED MYCOL, V57, P519, DOI 10.1093/mmy/myy072; Worasilchai N, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.02099-19; Worasilchai N, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/JCM.00610-18, 10.1128/jcm.00610-18]; Worasilchai N, 2018, MED MYCOL, V56, P216, DOI 10.1093/mmy/myx033; Worster AA, 2000, J AM VET MED ASSOC, V216, P1795, DOI 10.2460/javma.2000.216.1795; Xu L, 2020, THERANOSTICS, V10, P8996, DOI 10.7150/thno.45413; Yolanda H, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03737; Zanette RA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118932	288	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1080	10.3390/vaccines9101080			29	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WV3QE	34696188	gold, Green Published			2022-04-29	WOS:000717153500001
J	Shen, CF; Chen, JL; Su, CC; Lin, WL; Hsieh, ML; Liu, CC; Cheng, CL				Shen, Ching-Fen; Chen, Ju-Ling; Su, Chien-Chou; Lin, Wen-Liang; Hsieh, Min-Ling; Liu, Ching-Chun; Cheng, Ching-Lan			Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan	VACCINES			English	Article						community-acquired pneumonia; pneumococcal pneumonia; bacterial pneumonia; 13-valent pneumococcal conjugate vaccine	ROUTINE CHILDHOOD IMMUNIZATION; STREPTOCOCCUS-PNEUMONIAE; DIAGNOSIS; DISEASE; IMPACT	The impact of the 13-valent pneumococcal conjugate vaccine (PCV13) on overall community-acquired pneumonia (CAP) and disease severity still needs thorough evaluation. In this study, we retrieve both pneumococcal CAP (P-CAP) and unspecific CAP (U-CAP) inpatient data from the Taiwan National Health Insurance Database (NHID) between 2005 and 2016. The interrupted time-series (ITS) analysis was performed to compare the incidence trend before and after the implementation of PCV13. After PCV13 implementation, there is a significant decreasing trend of P-CAP hospitalization, especially in children <1 year, 2-5 years, adults aged 19-65 years, 66 years, or older (all p value < 0.05). This corresponds to a 59% reduction in children <1 year, 47% in children aged 2-5 years, 39% in adult aged 19-65 years, and 41% in elderly aged 66 years or older. The intensive care rate (6.8% to 3.9%), severe pneumonia cases (21.7 to 14.5 episodes per 100,000 children-years), and the need for invasive procedures (4.3% to 2.0%) decreased in children aged 2-5 years (p value < 0.0001) with P-CAP. This PCV13 implementation program in Taiwan not only reduced the incidence of P-CAP, but also attenuated disease severity, especially in children aged 2-5 years.	[Shen, Ching-Fen; Hsieh, Min-Ling; Liu, Ching-Chun] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pediat, Tainan 70101, Taiwan; [Shen, Ching-Fen] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 70101, Taiwan; [Chen, Ju-Ling; Su, Chien-Chou; Lin, Wen-Liang; Cheng, Ching-Lan] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pharm, Tainan 70101, Taiwan; [Chen, Ju-Ling; Cheng, Ching-Lan] Natl Cheng Kung Univ, Coll Med, Sch Pharm, Tainan 70101, Taiwan; [Chen, Ju-Ling; Cheng, Ching-Lan] Natl Cheng Kung Univ, Coll Med, Inst Clin Pharm & Pharmaceut Sci, Tainan 70101, Taiwan; [Liu, Ching-Chun] Natl Cheng Kung Univ, Ctr Infect Dis & Signaling Res, Tainan 70101, Taiwan		Cheng, CL (通讯作者)，Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pharm, Tainan 70101, Taiwan.; Cheng, CL (通讯作者)，Natl Cheng Kung Univ, Coll Med, Sch Pharm, Tainan 70101, Taiwan.; Cheng, CL (通讯作者)，Natl Cheng Kung Univ, Coll Med, Inst Clin Pharm & Pharmaceut Sci, Tainan 70101, Taiwan.	drshen@mail2000.com.tw; cicheng@mail.ncku.edu.tw; chienchou.su@gmail.com; linwl@mail.ncku.edu.tw; mactep_8@hotmail.com; liucc@mail.ncku.edu.tw; clcheng@mail.ncku.edu.tw		Cheng, Ching-lan/0000-0002-7201-8491	Clinical Medical Research Center, National Cheng Kung University Hospital, Taiwan [NCKUH-11002017, NCKUH-11009002]; Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [110-2923-B-006-001-MY4]; Higher Education Sprout Project, Ministry of Education; University Advancement at National Cheng Kung University (NCKU)	This work was supported by grants from the Clinical Medical Research Center, National Cheng Kung University Hospital, Taiwan (NCKUH-11002017, NCKUH-11009002) and Ministry of Science and Technology, Taiwan (110-2923-B-006-001-MY4). No additional external funding was received for this study. The research was supported in part by Higher Education Sprout Project, Ministry of Education to the Headquarters of University Advancement at National Cheng Kung University (NCKU).	Alicino C, 2017, VACCINE, V35, P5776, DOI 10.1016/j.vaccine.2017.09.005; Castiglia P, 2014, ADV THER, V31, P1011, DOI 10.1007/s12325-014-0157-1; Cilloniz C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122120; DENNY FW, 1986, J PEDIATR-US, V108, P635, DOI 10.1016/S0022-3476(86)81034-4; Dominguez J, 2003, J CLIN MICROBIOL, V41, P2161, DOI 10.1128/JCM.41.5.2161-2163.2003; Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368; Nuorti J. Pekka, 2010, Morbidity and Mortality Weekly Report, V59, P1; Garcia-Vazquez E, 2004, ARCH INTERN MED, V164, P1807, DOI 10.1001/archinte.164.16.1807; Grijalva CG, 2007, LANCET, V369, P1179, DOI 10.1016/S0140-6736(07)60564-9; Hammitt LL, 2006, J INFECT DIS, V193, P1487, DOI 10.1086/503805; Hsieh YC, 2009, VACCINE, V27, P5513, DOI 10.1016/j.vaccine.2009.06.091; Isturiz R, 2017, EXPERT REV VACCINES, V16, P1007, DOI 10.1080/14760584.2017.1362339; Lindstrand A, 2014, PEDIATRICS, V134, pE1528, DOI 10.1542/peds.2013-4177; Lu CY, 2019, CLIN INFECT DIS, V69, P1581, DOI 10.1093/cid/ciy1127; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Ministry of Economic Affairs, REG GOV FEES COMM IN; Myint TTH, 2013, ADV THER, V30, P127, DOI 10.1007/s12325-013-0007-6; Nair H, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1693-x; Poirier B, 2009, VACCINE, V27, P7105, DOI 10.1016/j.vaccine.2009.09.057; Shen CF, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00680-9; Su VYF, 2014, CAN MED ASSOC J, V186, P415, DOI 10.1503/cmaj.131547; Su WJ, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-020-05721-0; Su WJ, 2016, PEDIATR INFECT DIS J, V35, pE124, DOI 10.1097/INF.0000000000001054; Wang SA, 2013, MMWR-MORBID MORTAL W, V62, P308; World Health Organization, PNEUMONIA	25	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1043	10.3390/vaccines9091043			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3NP	34579280	gold, Green Published			2022-04-29	WOS:000702115400001
J	Ahmed, S; Khan, S; Imran, I; Al Mughairbi, F; Sheikh, FS; Hussain, J; Khan, A; Al-Harrasi, A				Ahmed, Sagheer; Khan, Saeed; Imran, Imran; Al Mughairbi, Fadwa; Sheikh, Fahad Sultan; Hussain, Javid; Khan, Ajmal; Al-Harrasi, Ahmed			Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use	VACCINES			English	Review						COVID-19; vaccine; pharmaceutical companies; global demand	NCOV-19 AZD1222 VACCINE; CORONAVIRUS; EFFICACY	As per the World Health Organization (WHO), more than 288 vaccines against COVID-19 are being developed, with an estimated 184 being presently investigated in the pre-clinical phases, while 104 of these vaccine candidates are at various stages of clinical trials. Twelve of these are in the advanced stages of clinical investigation, and promising results in the phase 3 trials have already paved the way for their regulatory approval and subsequent dissemination for global use. Preliminary and interim results of some of these candidate vaccines are being analyzed for public dissemination. Some of these vaccines have already been rolled out to immunize not only the highest risk individuals but also the general population in several countries. Once their safety and efficacy are established, the next limiting step would be their mass manufacturing by the pharmaceutical companies to fulfill the global demand. The challenge of manufacturing billions of doses of high-quality vaccines is under-appreciated at the moment. A massive vaccination drive would be needed to protect people of all ages. The timely and coordinated execution of the vaccination effort would require unprecedented coordination at the national and international levels for generating funds to purchase the required doses of vaccines, fair distribution of doses and managing the mechanics of delivering vaccines throughout the world.	[Ahmed, Sagheer; Sheikh, Fahad Sultan] Shifa Tameere E Millat Univ, Shifa Coll Pharmaceut Sci, Dept Basic Med Sci, Islamabad 44000, Pakistan; [Khan, Saeed] Dow Univ Hlth Sci, Dow Int Med Coll, Karachi 74200, Pakistan; [Imran, Imran] Bahauddin Zakariya Univ, Fac Pharm, Dept Pharmacol, Multan 60800CB, Pakistan; [Al Mughairbi, Fadwa] UAE Univ, Coll Med & Hlth Sci, Dept Clin Psychol, Al Ain 15551, U Arab Emirates; [Hussain, Javid] Univ Nizwa, Dept Biol Sci & Chem, POB 33, Birkat Al Mauz 616, Nizwa, Oman; [Khan, Ajmal; Al-Harrasi, Ahmed] Univ Nizwa, Nat & Med Sci Res Ctr, POB 33, Birkat Al Mauz 616, Nizwa, Oman		Khan, A; Al-Harrasi, A (通讯作者)，Univ Nizwa, Nat & Med Sci Res Ctr, POB 33, Birkat Al Mauz 616, Nizwa, Oman.	sagheer.scps@stmu.edu.pk; saeed.khan@duhs.edu.pk; imran.ch@bzu.edu.pk; f.almughairbi@uaeu.ac.ae; fssheikh1999@gmail.com; javidhej@unizwa.edu.om; ajmalkhan@unizwa.edu.om; aharrasi@unizwa.edu.om	Imran, Imran/AAL-5734-2020	Imran, Imran/0000-0003-1337-8574; Ahmed, Sagheer/0000-0003-1560-7588	The Oman Research Council (TRC)Ministry of Higher Education, Research & Innovation, OmanThe Research Council Oman [BFP/RGP/HSS/19/198]	The project was supported by grant from The Oman Research Council (TRC) through the funded project BFP/RGP/HSS/19/198).	Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; [Anonymous], 2021, NATURE, V594, P149, DOI 10.1038/d41586-021-01508-8; [Anonymous], 2020, ECONOMIST 1112; [Anonymous], 2021, COMP 3 COV 19 VACC; AstraZeneca, 2021, PHAS 3 OPEN LAB STUD; AstraZeneca, 2021, PHAS 3 RAND DOUBL BL; Atti A., 2021, EFFECTIVENESS BNT162; Au L, 2021, NAT MED, V27, P1362, DOI 10.1038/s41591-021-01387-6; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barnabas RV, 2021, ANN INTERN MED, V174, P552, DOI 10.7326/M20-8060; Bharat Biotech International Limited, 2020, EVENT DRIV PHAS 3 RA; Callaway E, 2021, NATURE, V594, P162, DOI 10.1038/d41586-021-01483-0; Casey RM, 2019, NEW ENGL J MED, V381, P444, DOI 10.1056/NEJMoa1710430; Community N.P.M, VACC PASSP WILL WORS; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Ferreras E, 2018, NEW ENGL J MED, V378, P577, DOI 10.1056/NEJMc1711583; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; Heath PT, 2021, NEW ENGL J MED, V385, P1172, DOI 10.1056/NEJMoa2107659; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Irwin Aisling, 2021, Nature, DOI 10.1038/d41586-021-01048-1; Irwin A, 2021, NATURE, V592, P176, DOI 10.1038/d41586-021-00727-3; Janssen Vaccines Prevention B.V, 2020, RAND DOUBL BLIND PLA; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Konings F, 2021, NAT MICROBIOL, V6, P821, DOI 10.1038/s41564-021-00932-w; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Ledford H, 2021, NATURE, V594, P164, DOI 10.1038/d41586-021-01505-x; Ledford H, 2021, NATURE, V592, P495, DOI 10.1038/d41586-021-00998-w; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Lovelace, US HAS VACCINATED JU; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n597; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n296; Matthews Dean B, 2020, Nat Rev Immunol, V20, P591, DOI 10.1038/s41577-020-00431-9; Medicago, 2020, RAND OBS BLIND PLAC; Muir KL, 2021, NEW ENGL J MED, V384, P1964, DOI 10.1056/NEJMc2105869; Neidleman J., 2021, MRNA VACCINE INDUCED, DOI [10.1101/2021.05.12.443888, DOI 10.1101/2021.05.12.443888]; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; Ostergaard SD, 2021, LANCET, V397, P1441, DOI 10.1016/S0140-6736(21)00762-5; Padma TV, 2021, NATURE, V592, P500, DOI 10.1038/d41586-021-00996-y; Paltiel AD, 2021, ANN INTERN MED, V174, P568, DOI 10.7326/M20-7866; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; PINHO, ASTRAZENECAS COVID 1; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pottegard A, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1114; Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Roukens AH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001993; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Shinde V, 2021, NEW ENGL J MED, V384, P1899, DOI 10.1056/NEJMoa2103055; Stoye Emma, 2021, Nature, DOI 10.1038/d41586-021-00976-2; Tenforde MW, 2021, MMWR-MORBID MORTAL W, V70, P674, DOI 10.15585/mmwr.mm7018e1; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Tuite AR, 2021, ANN INTERN MED, V174, P570, DOI 10.7326/M20-8137; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu JT, 2016, LANCET, V388, P2904, DOI 10.1016/S0140-6736(16)31838-4; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4	77	2	2	6	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							836	10.3390/vaccines9080836			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9ET	34451961	gold, Green Published			2022-04-29	WOS:000690225100001
J	Olivieri, B; Betterle, C; Zanoni, G				Olivieri, Bianca; Betterle, Corrado; Zanoni, Giovanna			Vaccinations and Autoimmune Diseases	VACCINES			English	Review						vaccines; autoimmunity; autoimmune diseases; Guillain-Barre syndrome; thrombocytopenia; SARS-CoV2 vaccines; vaccine-induced immune thrombotic thrombocytopenia	GUILLAIN-BARRE-SYNDROME; POSTLICENSURE SAFETY SURVEILLANCE; HEPATITIS-B VACCINATION; HUMAN PAPILLOMA-VIRUS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; THROMBOCYTOPENIC PURPURA; RUBELLA VACCINATION; DEMYELINATING DISEASES; INFLUENZA VACCINE; ANTERIOR UVEITIS	Vaccines represent one of the most effective measures of public health medicine, saving countless lives and preventing lifelong disabilities. Vaccines are extremely safe, however, no vaccine is completely free from risks and adverse events can occur following vaccination. An adverse event following immunization (AEFI) may be a true adverse reaction caused by the vaccine or an event that temporally occurred after immunization but is not caused by it. Among the adverse reactions to vaccines, one of the most feared is the triggering of autoimmune diseases, which are a heterogeneous group of disorders characterized by dysregulation of the immune system. Currently, no mechanisms have been demonstrated that could explain the correlation between vaccination and the development of autoimmune diseases. Furthermore, epidemiological studies do not support the hypothesis that vaccines cause systemic autoimmune diseases. The only confirmed associations, although very rare, are those between the flu vaccine and Guillain-Barre syndrome, especially with old vaccine preparations, and measles-mumps-rubella (MMR) vaccine and thrombocytopenia. Due to the SARS-CoV2 pandemic, new types of vaccines have been developed and are now available. Close vaccine safety-surveillance is currently underway for these new vaccines.	[Olivieri, Bianca] Univ Verona, Sch Specializat Allergy & Clin Immunol, Dept Med, I-37134 Verona, Italy; [Betterle, Corrado] Univ Padua, Dept Med DIMED Clin Immunol & Allergy, I-35128 Padua, Italy; [Zanoni, Giovanna] Univ Hosp, Immunol Unit, I-37134 Verona, Italy		Zanoni, G (通讯作者)，Univ Hosp, Immunol Unit, I-37134 Verona, Italy.	bianca.olivieri@studenti.univr.it; corrado.betterle@unipd.it; giovanna.zanoni@univr.it		Olivieri, Bianca/0000-0003-1690-6774			Ameratunga R, 2018, AUTOIMMUN REV, V17, P435, DOI 10.1016/j.autrev.2017.11.033; Ameratunga R, 2017, J ALLER CL IMM-PRACT, V5, P1551, DOI 10.1016/j.jaip.2017.06.033; Arnheim-Dahlstom L, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5906; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baker B, 2015, EXPERT OPIN DRUG SAF, V14, P1387, DOI 10.1517/14740338.2015.1073710; Bassendine MF, 2020, EUR J RHEUMATOL, V7, P37, DOI 10.5152/eurjrheum.2019.19152; Bate JF, 2004, J CHILD NEUROL, V19, P405, DOI 10.1177/088307380401900602; Baxter R, 2013, CLIN INFECT DIS, V57, P197, DOI 10.1093/cid/cit222; Bellini WJ, 2005, J INFECT DIS, V192, P1686, DOI 10.1086/497169; Betterle C., 2014, ENDOCRINOLOGO, V15, P260, DOI [10.1007/s40619-014-0080-3, DOI 10.1007/S40619-014-0080-3]; Bonanni P, 2010, VACCINE, V28, P4719, DOI 10.1016/j.vaccine.2010.04.070; Bonetto C, 2016, VACCINE, V34, P6641, DOI 10.1016/j.vaccine.2015.09.026; Bonnet MC, 2006, VACCINE, V24, P7037, DOI 10.1016/j.vaccine.2006.06.049; Bowles L, 2020, NEW ENGL J MED, V383, P288, DOI 10.1056/NEJMc2013656; Cao Sissi, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr-2016-217755; Center KJ, 2009, PEDIATR INFECT DIS J, V28, P438, DOI 10.1097/INF.0b013e318196934a; CHANTLER JK, 1985, NEW ENGL J MED, V313, P1117, DOI 10.1056/NEJM198510313131803; Chao C, 2012, J INTERN MED, V271, P193, DOI 10.1111/j.1365-2796.2011.02467.x; Chen RT, 2001, J AUTOIMMUN, V16, P309, DOI 10.1006/jaut.2000.0491; Chen Y, 2020, EUR J EPIDEMIOL, V35, P363, DOI 10.1007/s10654-019-00596-1; Cines DB, 2021, NEW ENGL J MED, V384, P2254, DOI 10.1056/NEJMe2106315; Classen JB, 1999, BRIT MED J, V319, P1133, DOI 10.1136/bmj.319.7217.1133; Confavreux C, 2001, NEW ENGL J MED, V344, P319, DOI 10.1056/NEJM200102013440501; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; daSilveira CM, 1997, LANCET, V349, P14, DOI 10.1016/S0140-6736(96)07408-9; de Martino M, 2013, INT J IMMUNOPATH PH, V26, P283, DOI 10.1177/039463201302600201; DeStefano F, 2003, ARCH NEUROL-CHICAGO, V60, P504, DOI 10.1001/archneur.60.4.504; DeStefano F, 2019, CLIN INFECT DIS, V69, P726, DOI 10.1093/cid/ciz135; Di Pasquale A, 2016, VACCINE, V34, P6672, DOI 10.1016/j.vaccine.2016.10.039; Di Pietrantonj C, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004407.pub4; Dolcino M, 2015, LUPUS, V24, P419, DOI 10.1177/0961203314558677; Dolcino M, 2013, IMMUNOL RES, V56, P465, DOI 10.1007/s12026-013-8420-0; Duclos Philippe, 2003, Expert Opin Drug Saf, V2, P225, DOI 10.1517/eods.2.3.225.21379; Dudley MZ, 2020, LANCET INFECT DIS, V20, pE80, DOI 10.1016/S1473-3099(20)30130-4; Ehrenfeld M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102597; Elwood JM, 2018, VACCINE, V36, P5796, DOI 10.1016/j.vaccine.2018.07.074; Esposito S, 2014, CLIN MICROBIOL INFEC, V20, P25, DOI 10.1111/1469-0691.12447; European Medicines Agency (EMA), 2012, GUIDELINE BIOANALYTI, P1; Ferrini W, 2013, PEDIATRICS, V132, pE1035, DOI 10.1542/peds.2012-2930; Furer V, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-001041; Furer V, 2020, ANN RHEUM DIS, V79, P39, DOI 10.1136/annrheumdis-2019-215882; Gee J, 2017, VACCINE, V35, P5756, DOI 10.1016/j.vaccine.2017.09.009; Geier D A, 2002, Clin Exp Rheumatol, V20, P767; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Goriely S, 2007, J COMP PATHOL, V137, pS57, DOI 10.1016/j.jcpa.2007.04.013; Graves PM, 1999, DIABETES CARE, V22, P1694, DOI 10.2337/diacare.22.10.1694; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Grimaldi-Bensouda L, 2017, J AUTOIMMUN, V79, P84, DOI 10.1016/j.jaut.2017.01.005; Grimaldi-Bensouda L, 2012, BLOOD, V120, P4938, DOI 10.1182/blood-2012-05-431098; Guillevin L, 2013, BEST PRACT RES CL RH, V27, P19, DOI 10.1016/j.berh.2013.01.004; Gutierrez-Ortiz C, 2020, NEUROLOGY, V95, pE601, DOI 10.1212/WNL.0000000000009619; Halpert G, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102695; Han Steven-Huy B, 2004, Clin Liver Dis, V8, P403, DOI 10.1016/j.cld.2004.02.003; Hansen J, 2018, VACCINE, V36, P2133, DOI 10.1016/j.vaccine.2018.02.107; Isai A, 2012, VACCINE, V30, P7123, DOI 10.1016/j.vaccine.2012.09.032; Islam SMM, 2000, ACTA OPHTHALMOL SCAN, V78, P590, DOI 10.1034/j.1600-0420.2000.078005590.x; Israeli E, 2009, LUPUS, V18, P1217, DOI 10.1177/0961203309345724; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jiang HY, 2019, VACCINE, V37, P3031, DOI 10.1016/j.vaccine.2019.04.049; Jones Veena G, 2020, Hosp Pediatr, V10, P537, DOI 10.1542/hpeds.2020-0123; Karvonen M, 1999, BRIT MED J, V318, P1169, DOI 10.1136/bmj.318.7192.1169; Lai YC, 2015, J DRUGS DERMATOL, V14, P33; Laribiere A, 2005, EUR J CLIN PHARMACOL, V61, P907, DOI 10.1007/s00228-005-0053-3; Lasky T, 1998, NEW ENGL J MED, V339, P1797, DOI 10.1056/NEJM199812173392501; Lazarian G, 2020, BRIT J HAEMATOL, V190, P29, DOI 10.1111/bjh.16794; Le Hello C, 1999, J RHEUMATOL, V26, P191; Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8; Liozon E, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2020.102732; Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022; Lopez C, 2020, BRIT J HAEMATOL, V190, P31, DOI 10.1111/bjh.16786; Lunardi C, 2008, AUTOIMMUN REV, V8, P116, DOI 10.1016/j.autrev.2008.07.005; MacDonald N, 2020, VACCINE, V38, P5364, DOI 10.1016/j.vaccine.2020.05.003; Maillefert JF, 1999, RHEUMATOLOGY, V38, P978, DOI 10.1093/rheumatology/38.10.978; Arias LHM, 2015, VACCINE, V33, P3773, DOI 10.1016/j.vaccine.2015.05.013; Mathieu E, 1996, NEW ENGL J MED, V335, P355, DOI 10.1056/NEJM199608013350516; McIntosh EDG, 2016, J PEDIATR-US, V175, P248, DOI 10.1016/j.jpeds.2016.06.006; Miller E, 2001, ARCH DIS CHILD, V84, P227, DOI 10.1136/adc.84.3.227; Miranda S, 2017, VACCINE, V35, P4761, DOI 10.1016/j.vaccine.2017.06.030; Mok CC, 2013, ANN RHEUM DIS, V72, P659, DOI 10.1136/annrheumdis-2012-201393; Moretti F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70996-x; Muir KL, 2021, NEW ENGL J MED, V384, P1964, DOI 10.1056/NEJMc2105869; Nakafero G, 2019, ANN RHEUM DIS, V78, P1122, DOI [10.1136/annrheumdis-2019-215080, 10.1136/annrheumdis-2019-215086]; Nakayama T, 2007, VACCINE, V25, P570, DOI 10.1016/j.vaccine.2006.05.130; Neau D, 1998, SCAND J INFECT DIS, V30, P115, DOI 10.1080/003655498750003465; Nelson KE, 2012, AM J EPIDEMIOL, V175, P1129, DOI 10.1093/aje/kws194; Norton B, 2019, OXF MED CASE REP, P202, DOI 10.1093/omcr/omz031; Novelli L, 2021, J AUTOIMMUN, V117, DOI 10.1016/j.jaut.2020.102592; OZSOYLU S, 1978, PEDIATRICS, V62, P567; Panozzo CA, 2019, VACCINE, V37, P372, DOI 10.1016/j.vaccine.2018.06.067; Papania MJ, 2014, JAMA PEDIATR, V168, P148, DOI 10.1001/jamapediatrics.2013.4342; Patel SU, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2021-242956; Perricone C, 2013, J AUTOIMMUN, V47, P1, DOI 10.1016/j.jaut.2013.10.004; Phillips A, 2020, VACCINE, V38, P6038, DOI 10.1016/j.vaccine.2020.06.039; Phillips A, 2018, DRUG SAFETY, V41, P329, DOI 10.1007/s40264-017-0625-z; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pope JE, 1998, J RHEUMATOL, V25, P1687; Potter CW, 2001, J APPL MICROBIOL, V91, P572, DOI 10.1046/j.1365-2672.2001.01492.x; Principi N, 2019, VACCINE, V37, P5544, DOI 10.1016/j.vaccine.2018.05.119; Ray P, 1997, JAMA-J AM MED ASSOC, V278, P551, DOI 10.1001/jama.278.7.551; Rodriguez Y, 2020, J AUTOIMMUN, V114, DOI 10.1016/j.jaut.2020.102506; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Salmon DA, 2013, LANCET, V381, P1461, DOI 10.1016/S0140-6736(12)62189-8; Schattner A, 2005, VACCINE, V23, P3876, DOI 10.1016/j.vaccine.2005.03.005; Scheller NM, 2015, JAMA-J AM MED ASSOC, V313, P54, DOI 10.1001/jama.2014.16946; Schuil J, 1998, INT OPHTHALMOL, V22, P345, DOI 10.1023/A:1006396906378; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; Sedaghat Z, 2020, J CLIN NEUROSCI, V76, P233, DOI 10.1016/j.jocn.2020.04.062; Segal Y, 2017, CURR OPIN RHEUMATOL, V29, P331, DOI 10.1097/BOR.0000000000000398; SHAW FE, 1988, AM J EPIDEMIOL, V127, P337, DOI 10.1093/oxfordjournals.aje.a114808; Shoenfeld Y, 2011, J AUTOIMMUN, V36, P4, DOI 10.1016/j.jaut.2010.07.003; Slade BA, 2009, JAMA-J AM MED ASSOC, V302, P750, DOI 10.1001/jama.2009.1201; SLATER PE, 1995, VACCINE, V13, P1529, DOI 10.1016/0264-410X(95)00096-J; Smatti MK, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11080762; Soldevilla HF, 2012, LUPUS, V21, P158, DOI 10.1177/0961203311429556; Soriano A, 2012, LUPUS, V21, P153, DOI 10.1177/0961203311430222; Soybilgic A, 2013, PEDIATR RHEUMATOL, V11, DOI 10.1186/1546-0096-11-29; Toplak N, 2009, ANN NY ACAD SCI, V1173, P619, DOI 10.1111/j.1749-6632.2009.04759.x; Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191; Tourbah A, 1999, NEUROLOGY, V53, P396, DOI 10.1212/WNL.53.2.396; Toussirot E, 2000, ARTHRITIS RHEUM, V43, P2139, DOI 10.1002/1529-0131(200009)43:9<2139::AID-ANR27>3.0.CO;2-3; Toussirot Eric, 2015, Inflammation & Allergy Drug Targets, V14, P94, DOI 10.2174/1871528114666160105113046; Trepo C, 2001, J AUTOIMMUN, V16, P269, DOI 10.1006/jaut.2000.0502; Tsao HS, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-1419; Uyeki TM, 2017, ANN INTERN MED, V167, pITC33, DOI 10.7326/AITC201709050; Velentgas P, 2012, PHARMACOEPIDEM DR S, V21, P1350, DOI 10.1002/pds.3321; Vellozzi C, 2014, AM J PUBLIC HEALTH, V104, P696, DOI 10.2105/AJPH.2013.301651; Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X; Vital C, 2002, J PERIPHER NERV SYST, V7, P163, DOI 10.1046/j.1529-8027.2002.02010.x; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Waheed S, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.13426; Wang LF, 2015, J INTERN MED, V278, P369, DOI 10.1111/joim.12395; Watad A, 2019, CLIN IMMUNOL, V203, P1, DOI 10.1016/j.clim.2019.03.007; Watanabe T, 2017, CURR RHEUMATOL REV, V13, P188, DOI 10.2174/1573397113666170517155443; WHO, 2016, INT TECHN NOT US CHO, P1; Willame C, 2020, PEDIATR INFECT DIS J, V39, P287, DOI 10.1097/INF.0000000000002569; Wise RP, 2000, JAMA-J AM MED ASSOC, V284, P1271, DOI 10.1001/jama.284.10.1271; Wise RP, 2004, JAMA-J AM MED ASSOC, V292, P1702, DOI 10.1001/jama.292.14.1702; Woerner A, 2019, VACCINE, V37, P384, DOI 10.1016/j.vaccine.2017.08.087; World Health Organization, 2018, CAUSALITY ASSESSMENT; World Health Organization, 2013, IMMUNIZATION SAFETY, V2nd; Wraith DC, 2003, LANCET, V362, P1659, DOI 10.1016/S0140-6736(03)14802-7; Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575; Zhao H., 2020, LANCET NEUROL, V19, P383, DOI DOI 10.1016/S1474-4422(20)30109-5	145	5	5	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							815	10.3390/vaccines9080815			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3BO	34451940	Green Published			2022-04-29	WOS:000689811200001
J	Palou, EY; Ramos, MA; Cherenfant, E; Duarte, A; Fuentes-Barahona, IC; Zambrano, LI; Munoz-Lara, F; Montoya-Ramirez, SA; Cardona-Ortiz, AF; Valle-Reconco, JA; Montenegro-Idrogo, JJ; Bonilla-Aldana, DK; Paniz-Mondolfi, AE; Rodriguez-Morales, AJ				Palou, Elsa Yolanda; Ramos, Maria Auxiliadora; Cherenfant, Emec; Duarte, Adoni; Fuentes-Barahona, Itzel Carolina; Zambrano, Lysien I.; Munoz-Lara, Fausto; Montoya-Ramirez, Sandra Aracely; Cardona-Ortiz, Alex Francisco; Valle-Reconco, Jorge Alberto; Montenegro-Idrogo, Juan J.; Bonilla-Aldana, D. Katterine; Paniz-Mondolfi, Alberto E.; Rodriguez-Morales, Alfonso J.			COVID-19 Associated Rhino-Orbital Mucormycosis Complicated by Gangrenous and Bone Necrosis-A Case Report from Honduras	VACCINES			English	Article						SARS-CoV-2; COVID-19; mucormycosis; mucorales; coinfection; opportunistic; honduras	PRIMARY CUTANEOUS MUCORMYCOSIS; TRANSPLANT; SCALP; CHILD	Background: Mucormycosis is a life-threatening invasive fungal infection most commonly observed in immunocompromised patients. Throughout the COVID-19 pandemic, a growing number of Mucorales associated infections, now termed COVID-19 associated mucormycosis (CAM), have been reported. Despite an increase in fatality reports, no cases of rhino-orbital CAM complicated with gangrenous bone necrosis have been described in the literature to date. Case: A 56-year-old male with a recent COVID-19 diagnosis developed rhino-orbital mucormycosis after 22 days of treatment with dexamethasone. Cultures and histopathological assessment of tissue biopsy confirmed the diagnosis. The patient survived after treatment with amphotericin B. Conclusions: Mucormycosis is an invasive fungal infection affecting mostly immunocompromised patients. Along with the COVID-19 pandemic, the inappropriate use of steroids, in addition to concurrent risk factors, such as diabetes, has led to an increase in the occurrence of these devastating mycoses, leading to the development of severe presentations and complications, as observed in many cases. Early diagnosis and prompt treatment are crucial in order to avoid dissemination and fatal outcomes.	[Palou, Elsa Yolanda; Munoz-Lara, Fausto] Univ Nacl Autonoma Honduras, Dept Internal Med, Fac Med Sci, Tegucigalpa 11101, Honduras; [Ramos, Maria Auxiliadora; Munoz-Lara, Fausto] Hosp Escuela Tegucigalpa, Dept Internal Med, Tegucigalpa 11101, Honduras; [Cherenfant, Emec] Univ Nacl Autonoma Honduras, Tegucigalpa 11101, Honduras; [Duarte, Adoni] Univ Nacl Autonoma Honduras, Dept Morphol Sci, Fac Med Sci, Tegucigalpa 11101, Honduras; [Fuentes-Barahona, Itzel Carolina] Univ Nacl Autonoma Honduras, Fac Med Sci, Tegucigalpa 11101, Honduras; [Fuentes-Barahona, Itzel Carolina] Hosp Escuela Tegucigalpa, Dept Gynecol & Obstet, Tegucigalpa 11101, Honduras; [Zambrano, Lysien I.] Univ Nacl Autonoma Honduras, Unit Sci Res UIC, Fac Med Sci, Tegucigalpa 11101, Honduras; [Zambrano, Lysien I.; Montenegro-Idrogo, Juan J.; Bonilla-Aldana, D. Katterine; Paniz-Mondolfi, Alberto E.; Rodriguez-Morales, Alfonso J.] Latin Amer Network Coronavirus Dis 2019 Res LANCO, Pereira 660003, Colombia; [Montoya-Ramirez, Sandra Aracely] Hosp Escuela Tegucigalpa, Dept Mycol, Tegucigalpa 11101, Honduras; [Cardona-Ortiz, Alex Francisco] Univ Nacl Autonoma Honduras, Post Grad Internal Med, Fac Med Sci, Tegucigalpa 11101, Honduras; [Valle-Reconco, Jorge Alberto] Univ Nacl Autonoma Honduras, Fac Ciencias Med, Tegucigalpa 11101, Honduras; [Montenegro-Idrogo, Juan J.] Univ Cientif, Fac Hlth Sci, Lima 15046, Peru; [Montenegro-Idrogo, Juan J.] Hosp Nacl Mayo, Infect & Trop Dis Serv, Lima 15072, Peru; [Bonilla-Aldana, D. Katterine] Fdn Univ Autonoma Ias Amer, Sede Pereira, Semillero Invest Zoonosis SIZOO, Grp Invest GISCA, Pereira 660003, Colombia; [Valle-Reconco, Jorge Alberto] Icahn Sch Med Mt Sinai, Dept Pathol Mol & Cell Based Med, Microbiol Lab, New York, NY 10029 USA; [Valle-Reconco, Jorge Alberto] Inst Invest Biomed IDB Incubadora Veenezolana Cia, Barquisimeto 3001, Venezuela; [Rodriguez-Morales, Alfonso J.] Fdn Univ Autonoma Ias Amer, Grp Invest Biomed, Fac Med, Pereira 660003, Colombia; [Rodriguez-Morales, Alfonso J.] Univ Cientif, Clin Epidemiol & Biostat, Lima 15046, Peru		Rodriguez-Morales, AJ (通讯作者)，Latin Amer Network Coronavirus Dis 2019 Res LANCO, Pereira 660003, Colombia.; Rodriguez-Morales, AJ (通讯作者)，Fdn Univ Autonoma Ias Amer, Grp Invest Biomed, Fac Med, Pereira 660003, Colombia.; Rodriguez-Morales, AJ (通讯作者)，Univ Cientif, Clin Epidemiol & Biostat, Lima 15046, Peru.	elsa.palou@unah.edu.hn; mariaramosynestroza@yahoo.com; investigacion_fcm@unah.edu.hn; adoni.duarte@unah.edu.hn; ixcarol@hotmail.com; lysien.zambrano@unah.edu.hn; faustomunoz@doctor.com; montoyasandra62@yahoo.es; alex_3363007@yahoo.com; jorge_valle@unah.edu.hn; jmontenegroi@cientifica.edu.pe; diana.bonilla@uam.edu.co; alberto.Paniz-mondolfi@mountsinai.org; arodriguezmo@cientifica.edu.pe	Zambrano, Lysien Ivania/R-5628-2019	Zambrano, Lysien Ivania/0000-0001-9002-5807; Munoz Lara, Fausto/0000-0003-1221-0518; Paniz-Mondolfi, Alberto E./0000-0003-1259-1736	Facultad de Ciencias Medicas (FCM) [2-03-01-01]; National Autonomous University of Honduras, Tegucigalpa, MDC, Honduras	The Facultad de Ciencias Medicas (FCM) (2-03-01-01), National Autonomous University of Honduras, Tegucigalpa, MDC, Honduras, supported the publication fees of this article. L.I.Z.	ANDREWS PA, 1994, NEPHROL DIAL TRANSPL, V9, P1194, DOI 10.1093/ndt/9.8.1194; Bhatt Harsh, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2017-224086; Bhatt Kinal, 2021, Discoveries (Craiova), V9, pe126, DOI 10.15190/d.2021.5; Boyd AS, 2003, PEDIATR DERMATOL, V20, P411, DOI 10.1046/j.1525-1470.2003.20508.x; Chandra Smita, 2021, Autops Case Rep, V11, pe2020233, DOI 10.4322/acr.2020.233; CHAUDHURI R, 1992, AM J ROENTGENOL, V159, P1035, DOI 10.2214/ajr.159.5.1414771; Cornely OA, 2019, LANCET INFECT DIS, V19, pE405, DOI 10.1016/S1473-3099(19)30312-3; Damante JH, 1998, J ORAL MAXIL SURG, V56, P267, DOI 10.1016/S0278-2391(98)90883-7; do Monte ES, 2020, CLIN ENDOSC, V53, P746, DOI 10.5946/ce.2020.180; Droll Armin, 2004, Br J Haematol, V126, P441, DOI 10.1111/j.1365-2141.2004.05080.x; He Jianhan, 2021, BMC Pulm Med, V21, P138, DOI 10.1186/s12890-021-01504-8; Hernandez AV, 2020, ANN INTERN MED, V173, P287, DOI 10.7326/M20-2496; Hoang K, 2020, MED MYCOL CASE REP, V29, P22, DOI 10.1016/j.mmcr.2020.05.008; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Huang JS, 2005, BRIT J ORAL MAX SURG, V43, P532, DOI 10.1016/j.bjoms.2005.05.012; Kanagaraju V, 2019, INDIAN J PATHOL MICR, V62, P618, DOI 10.4103/IJPM.IJPM_854_15; Kanwar A, 2021, J FUNGI, V7, DOI 10.3390/jof7030174; Koklu E, 2008, PEDIATR EMERG CARE, V24, P102, DOI 10.1097/PEC.0b013e318163dbf7; Lamontagne F, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n526; Li HM, 2013, MYCOPATHOLOGIA, V176, P123, DOI 10.1007/s11046-013-9654-z; Lucas JB, 2003, OTOLARYNG HEAD NECK, V128, P912, DOI 10.1016/S0194-5998(03)00463-7; Mantero V, 2020, J NEUROVIROL, V26, P277, DOI 10.1007/s13365-019-00804-4; Millan-Onate J, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-020-00358-y; Namendys-Silva SA., 2020, LANCET RESP MED, V8, DOI [10.1016/S2213-2600(20)30110-7, DOI 10.1016/S2213-2600(20)30110-7]; Navarro-Perea C, 2019, CASE REP OPHTHALMOL, V2019, DOI 10.1155/2019/4215989; PAHO, EP AL COVID 19 ASS M; Pan AS, 2013, J AM OSTEOPATH ASSOC, V113, P708, DOI 10.7556/jaoa.2013.037; Park YL, 2021, BMC ORAL HEALTH, V21, DOI 10.1186/s12903-021-01411-8; Patel A, 2021, EMERG INFECT DIS, V27, P2349, DOI 10.3201/eid2709.210934; PATTERSON JE, 1986, YALE J BIOL MED, V59, P453; Petrikkos G, 2012, CLIN INFECT DIS, V54, pS23, DOI 10.1093/cid/cir866; PRICE JC, 1980, LARYNGOSCOPE, V90, P737; Rodriguez-Morales AJ, 2021, THER ADV INFECT DIS, V8, DOI 10.1177/20499361211027065; Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623; RYAN ME, 1982, PEDIATR INFECT DIS J, V1, P110, DOI 10.1097/00006454-198203000-00009; Saaavedra-Trujillo C.H., 2020, INFECTIO, V24, P1, DOI [10.22354/in.v24i3.851, DOI 10.22354/IN.V24I3.851]; Safi Mustafa, 2020, Am J Ophthalmol Case Rep, V19, P100771, DOI 10.1016/j.ajoc.2020.100771; Sawardekar KP, 2018, J TROP PEDIATRICS, V64, P548, DOI 10.1093/tropej/fmx094; Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980; Spellberg B, 2005, CLIN MICROBIOL REV, V18, P556, DOI 10.1128/CMR.18.3.556-569.2005; Stone N, 2021, LANCET MICROBE, V2, pE343, DOI 10.1016/S2666-5247(21)00148-8; Waizel-Haiat S, 2021, CUREUS, V13, DOI 10.7759/cureus.13163	42	2	2	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							826	10.3390/vaccines9080826			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5QB	34451951	gold, Green Published			2022-04-29	WOS:000689984100001
J	Thangam, R; Patel, KD; Kang, H; Paulmurugan, R				Thangam, Ramar; Patel, Kapil D.; Kang, Heemin; Paulmurugan, Ramasamy			Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy-Current Status and Future Perspectives	VACCINES			English	Review						polymer nanoparticles; nano-vaccines; immune cells; immunotherapy; tumor microenvironments; drug delivery	SILK FIBROIN NANOPARTICLES; IMMUNOGENIC CELL-DEATH; BREAST-CANCER; IMMUNE-RESPONSE; DELIVERY-SYSTEM; COMBINING IMMUNOTHERAPY; CHECKPOINT BLOCKADE; CO-DELIVERY; VACCINES; THERAPY	Engineering polymeric nanoparticles for their shape, size, surface chemistry, and functionalization using various targeting molecules has shown improved biomedical applications for nanoparticles. Polymeric nanoparticles have created tremendous therapeutic platforms, particularly applications related to chemo- and immunotherapies in cancer. Recently advancements in immunotherapies have broadened this field in immunology and biomedical engineering, where "immunoengineering" creates solutions to target translational science. In this regard, the nanoengineering field has offered the various techniques necessary to manufacture and assemble multifunctional polymeric nanomaterial systems. These include nanoparticles functionalized using antibodies, small molecule ligands, targeted peptides, proteins, and other novel agents that trigger and encourage biological systems to accept the engineered materials as immune enhancers or as vaccines to elevate therapeutic functions. Strategies to engineer polymeric nanoparticles with therapeutic and targeting molecules can provide solutions for developing immune vaccines via maintaining the receptor storage in T- and B cells. Furthermore, cancer immunotherapy using polymeric nanomaterials can serve as a gold standard approach for treating primary and metastasized tumors. The current status of the limited availability of immuno-therapeutic drugs highlights the importance of polymeric nanomaterial platforms to improve the outcomes via delivering anticancer agents at localized sites, thereby enhancing the host immune response in cancer therapy. This review mainly focuses on the potential scientific enhancements and recent developments in cancer immunotherapies by explicitly discussing the role of polymeric nanocarriers as nano-vaccines. We also briefly discuss the role of multifunctional nanomaterials for their therapeutic impacts on translational clinical applications.	[Thangam, Ramar; Patel, Kapil D.; Kang, Heemin] Korea Univ, Dept Mat Sci & Engn, Seoul 02841, South Korea; [Thangam, Ramar; Kang, Heemin] Korea Univ, Inst High Technol Mat & Devices, Seoul 02841, South Korea; [Kang, Heemin] Korea Univ, Dept Biomicrosyst Technol, Seoul 02841, South Korea; [Paulmurugan, Ramasamy] Stanford Univ, Sch Med, Dept Radiol, Mol Imaging Program Stanford, Palo Alto, CA 94304 USA; [Paulmurugan, Ramasamy] Stanford Univ, Sch Med, Dept Radiol, Canary Ctr Stanford Canc Early Detect, Palo Alto, CA 94304 USA		Thangam, R (通讯作者)，Korea Univ, Dept Mat Sci & Engn, Seoul 02841, South Korea.; Thangam, R (通讯作者)，Korea Univ, Inst High Technol Mat & Devices, Seoul 02841, South Korea.; Paulmurugan, R (通讯作者)，Stanford Univ, Sch Med, Dept Radiol, Mol Imaging Program Stanford, Palo Alto, CA 94304 USA.; Paulmurugan, R (通讯作者)，Stanford Univ, Sch Med, Dept Radiol, Canary Ctr Stanford Canc Early Detect, Palo Alto, CA 94304 USA.	thangam1985@korea.ac.kr; dynamic2020@korea.ac.kr; heeminkang@korea.ac.kr; paulmur8@stanford.edu	Thangam, Ramar/K-7704-2013; Patel, Kapil D/F-3874-2012	Paulmurugan, Ramasamy/0000-0001-7155-4738; Patel, Kapil D/0000-0002-0393-9166	National Research Foundation of Korea (NRF)National Research Foundation of Korea [2021R1I1A1A01046207, 2021R1I1A1A01050661, 2018R1D1A1B07048020]; Ministry of Science and Technology, Republic of KoreaMinistry of Science and Technology (MOST) Korea	The authors wish to thank Korea University for providing facilities. This work was supported by the National Research Foundation of Korea (NRF) grants (2021R1I1A1A01046207, 2021R1I1A1A01050661, and 2018R1D1A1B07048020) and funded by the Ministry of Science and Technology, Republic of Korea.	Aikins ME, 2020, ACCOUNTS CHEM RES, V53, P2094, DOI 10.1021/acs.accounts.0c00456; Akita H, 2010, J CONTROL RELEASE, V143, P311, DOI 10.1016/j.jconrel.2010.01.012; Almalik A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10836-7; Almalik A, 2013, J CONTROL RELEASE, V172, P1142, DOI 10.1016/j.jconrel.2013.09.032; Alshamsan A, 2011, TRANSL ONCOL, V4, P178, DOI 10.1593/tlo.11100; Apetoh L, 2015, ANN ONCOL, V26, P1813, DOI 10.1093/annonc/mdv209; Armand P, 2016, J CLIN ONCOL, V34, P3733, DOI 10.1200/JCO.2016.67.3467; Asadzadeh Z, 2020, CANCERS, V12, DOI 10.3390/cancers12041047; Blondin-Ladrie L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030271; Gondan AIB, 2018, BIOMATERIALS, V170, P95, DOI 10.1016/j.biomaterials.2018.04.003; Bose RJC, 2020, ACS NANO, V14, P5818, DOI 10.1021/acsnano.0c00921; Brubaker SW, 2015, ANNU REV IMMUNOL, V33, P257, DOI 10.1146/annurev-immunol-032414-112240; Byeon Y, 2018, CANCER RES, V78, P6247, DOI 10.1158/0008-5472.CAN-17-3871; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Cao J, 2020, ADV DRUG DELIVER REV, V167, P170, DOI 10.1016/j.addr.2020.06.030; Chang MY, 2019, ADV MATER, V31, DOI 10.1002/adma.201905271; Chen F, 2018, J COLLOID INTERF SCI, V521, P261, DOI 10.1016/j.jcis.2018.02.053; Chen Q, 2019, CHEM SOC REV, V48, P5506, DOI 10.1039/c9cs00271e; Chen Q, 2019, ADV MATER, V31, DOI 10.1002/adma.201802228; Chen Q, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13193; Cheng MA, 2018, HUM GENE THER, V29, P971, DOI 10.1089/hum.2017.197; Cho NH, 2011, NAT NANOTECHNOL, V6, P675, DOI [10.1038/nnano.2011.149, 10.1038/NNANO.2011.149]; Conde J, 2015, ADV FUNCT MATER, V25, P4183, DOI 10.1002/adfm.201501283; Demaria O, 2019, NATURE, V574, P45, DOI 10.1038/s41586-019-1593-5; Dey A, 2020, CYTOKINE, V127, DOI 10.1016/j.cyto.2019.154958; Dijkstra KK, 2016, JAMA ONCOL, V2, P1490, DOI 10.1001/jamaoncol.2016.2214; Dougan M, 2019, NAT MED, V25, P1030, DOI 10.1038/s41591-019-0513-4; Duan F, 2017, BIOMATERIALS, V122, P23, DOI 10.1016/j.biomaterials.2017.01.017; Duan XP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09221-x; Duan XP, 2016, J AM CHEM SOC, V138, P16686, DOI 10.1021/jacs.6b09538; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Fan Q, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201802540; Fan YC, 2017, NANO LETT, V17, P7387, DOI 10.1021/acs.nanolett.7b03218; Fan YC, 2015, VACCINES-BASEL, V3, P662, DOI 10.3390/vaccines3030662; Feng XR, 2019, ADV SCI, V6, DOI 10.1002/advs.201900101; Galstyan A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11719-3; Garcia-Aranda M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092296; Garg AD, 2017, TRENDS IMMUNOL, V38, P577, DOI 10.1016/j.it.2017.05.006; Gonzatti MB, 2019, INT J PHARMACEUT, V565, P123, DOI 10.1016/j.ijpharm.2019.05.013; Grimaldi AM, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28780; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Guo S, 2018, INT J BIOL SCI, V14, P2083, DOI 10.7150/ijbs.25720; Gurbatri CR, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax0876; Habibi N, 2020, ADV THER-GERMANY, V3, DOI 10.1002/adtp.202000100; Hafner AM, 2016, INT J PHARMACEUT, V514, P176, DOI 10.1016/j.ijpharm.2016.07.042; Han HD, 2016, SCI REP-UK, V6, DOI 10.1038/srep38348; Han HD, 2016, INT J NANOMED, V11, P5729, DOI 10.2147/IJN.S109001; Han SY, 2020, NANOSCALE, V12, P413, DOI 10.1039/c9nr08086d; Harari A, 2020, NAT REV DRUG DISCOV, V19, P635, DOI 10.1038/s41573-020-0074-8; He CB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12499; Heo MB, 2014, ACTA BIOMATER, V10, P2169, DOI 10.1016/j.actbio.2013.12.050; Higgins SG, 2020, ADV MATER, V32, DOI 10.1002/adma.201903862; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoshyar N, 2016, NANOMEDICINE-UK, V11, P673, DOI 10.2217/nnm.16.5; Hu QY, 2016, ADV DRUG DELIVER REV, V98, P19, DOI 10.1016/j.addr.2015.10.022; Hu Z, 2018, NAT REV IMMUNOL, V18, P168, DOI 10.1038/nri.2017.131; Huang KW, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax5032; Irvine DJ, 2015, CHEM REV, V115, P11109, DOI 10.1021/acs.chemrev.5b00109; Jadidi-Niaragh F, 2017, J CONTROL RELEASE, V246, P46, DOI 10.1016/j.jconrel.2016.12.012; Jia L, 2013, TRENDS BIOTECHNOL, V31, P99, DOI 10.1016/j.tibtech.2012.11.010; Jiang Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.162; Jin JF, 2019, ACS APPL MATER INTER, V11, P7850, DOI 10.1021/acsami.8b22309; Jin JO, 2017, BIOMATERIALS, V115, P81, DOI 10.1016/j.biomaterials.2016.11.020; Jin Z, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118731; Jo SD, 2017, NANO TODAY, V17, P23, DOI 10.1016/j.nantod.2017.10.008; June CH, 2017, NAT MED, V23, P540, DOI 10.1038/nm.4321; Kabiljo J, 2020, CANCERS, V12, DOI 10.3390/cancers12010079; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kim DY, 2021, J NUCL MED, V62, DOI 10.2967/jnumed.120.245290; Kim H, 2018, BIOMATERIALS, V164, P38, DOI 10.1016/j.biomaterials.2018.02.034; Kim WG, 2016, BIOCONJUGATE CHEM, V27, P2007, DOI 10.1021/acs.bioconjchem.6b00277; Klauber TCB, 2017, ACTA BIOMATER, V53, P367, DOI 10.1016/j.actbio.2017.01.072; Korangath P, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay1601; Kuai R, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aao1736; Kumar S, 2015, J CONTROL RELEASE, V220, P141, DOI 10.1016/j.jconrel.2015.09.069; Kumari P, 2016, J DRUG TARGET, V24, P179, DOI 10.3109/1061186X.2015.1051049; Lan GX, 2018, J AM CHEM SOC, V140, P5670, DOI 10.1021/jacs.8b01072; Lee K, 2020, BIOMATER SCI-UK, V8, P1101, DOI 10.1039/c9bm01564g; Li H, 2016, INT J NANOMED, V11, P4373, DOI 10.2147/IJN.S108633; Li JH, 2018, MOLECULES, V23, DOI 10.3390/molecules23102661; Liu JJ, 2020, ASIAN J PHARM SCI, V15, P576, DOI 10.1016/j.ajps.2019.10.006; Liu X, 2020, BIOMATERIALS, V230, DOI 10.1016/j.biomaterials.2019.119649; Liu Y, 2005, CELL, V121, P567, DOI 10.1016/j.cell.2005.03.007; Liu Y, 2017, ONCOGENE, V36, P6143, DOI 10.1038/onc.2017.209; Liu YJ, 2020, BIOMATERIALS, V242, DOI 10.1016/j.biomaterials.2020.119933; Liu YJ, 2019, CHEM SOC REV, V48, P2053, DOI 10.1039/c8cs00618k; Liu YY, 2018, ACTA BIOMATER, V66, P310, DOI 10.1016/j.actbio.2017.11.010; Lu JQ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01651-9; Lu KD, 2018, NAT BIOMED ENG, V2, P600, DOI 10.1038/s41551-018-0203-4; Luo YL, 2018, ACS NANO, V12, P994, DOI 10.1021/acsnano.7b07874; Lynn GM, 2019, CANCER LETT, V459, P192, DOI 10.1016/j.canlet.2019.114427; Maiyo F, 2019, PHARMACEUTICALS-BASE, V12, DOI 10.3390/ph12040164; Marshall JS, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0278-1; Merkley SD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02914; Min YZ, 2017, NAT NANOTECHNOL, V12, P877, DOI [10.1038/nnano.2017.113, 10.1038/NNANO.2017.113]; Mir M, 2017, COLLOID SURFACE B, V159, P217, DOI 10.1016/j.colsurfb.2017.07.038; Monopoli MP, 2012, NAT NANOTECHNOL, V7, P779, DOI [10.1038/NNANO.2012.207, 10.1038/nnano.2012.207]; Mudgal J, 2019, SCAND J IMMUNOL, V89, DOI 10.1111/sji.12749; Muhammad Q, 2020, BIOMATER SCI-UK, V8, P1490, DOI 10.1039/c9bm01643k; Mukherjee S, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202003054; Mukherjee S, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020147; Munakata L, 2019, J CONTROL RELEASE, V313, P106, DOI 10.1016/j.jconrel.2019.09.011; Najafi M, 2019, J CELL PHYSIOL, V234, P5700, DOI 10.1002/jcp.27425; Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275; Ni J, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110046; O'Donnell JS, 2019, NAT REV CLIN ONCOL, V16, P151, DOI 10.1038/s41571-018-0142-8; Pandolfi F, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/894704; Park JJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21410-1; Patel KD, 2019, MATER HORIZ, V6, P434, DOI 10.1039/c8mh00966j; Pei MY, 2021, COLLOID SURFACE B, V197, DOI 10.1016/j.colsurfb.2020.111378; Phuengkham H, 2019, ADV MATER, V31, DOI 10.1002/adma.201903242; Pierini F, 2018, BIOMACROMOLECULES, V19, P4147, DOI 10.1021/acs.biomac.8b01138; Polo E, 2017, ACS NANO, V11, P2397, DOI 10.1021/acsnano.7b01197; Prakash S, 2021, CURR OPIN COLLOID IN, V52, DOI 10.1016/j.cocis.2020.101408; Qiu H, 2017, WIRES NANOMED NANOBI, V9, DOI 10.1002/wnan.1456; Rafiq S, 2020, NAT REV CLIN ONCOL, V17, P147, DOI 10.1038/s41571-019-0297-y; Rafiq S, 2018, NAT BIOTECHNOL, V36, P847, DOI 10.1038/nbt.4195; Rajendrakumar SK, 2018, BIOMACROMOLECULES, V19, P1869, DOI 10.1021/acs.biomac.8b00460; Ren JT, 2017, CLIN CANCER RES, V23, P2255, DOI 10.1158/1078-0432.CCR-16-1300; Rodriguez-Ruiz ME, 2016, CANCER RES, V76, P5994, DOI 10.1158/0008-5472.CAN-16-0549; Rosalia RA, 2015, BIOMATERIALS, V40, P88, DOI 10.1016/j.biomaterials.2014.10.053; Sau S, 2018, J CONTROL RELEASE, V274, P24, DOI 10.1016/j.jconrel.2018.01.028; Scheetz L, 2019, NAT BIOMED ENG, V3, P768, DOI 10.1038/s41551-019-0436-x; Schietinger A, 2016, IMMUNITY, V45, P389, DOI 10.1016/j.immuni.2016.07.011; Schlom J, 2014, ADV CANCER RES, V121, P67, DOI 10.1016/B978-0-12-800249-0.00002-0; Shang TY, 2020, BIOMATER SCI-UK, V8, P5241, DOI 10.1039/d0bm01158d; Shao FP, 2020, MOL PHARMACEUT, V17, P338, DOI 10.1021/acs.molpharmaceut.9b01113; Shields CW, 2020, ADV MATER, V32, DOI 10.1002/adma.201901633; Shirai S, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03018; Singh AP, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0068-3; Singh RK, 2019, ACS APPL MATER INTER, V11, P288, DOI 10.1021/acsami.8b17958; Singh RK, 2017, ACS APPL MATER INTER, V9, P10309, DOI 10.1021/acsami.6b16505; Siriwon N, 2018, CANCER IMMUNOL RES, V6, P812, DOI 10.1158/2326-6066.CIR-17-0502; Smith WM, 2019, AM J TRANSL RES, V11, P529; Su S, 2016, SCI REP-UK, V6, DOI 10.1038/srep20070; Sukumar UK, 2020, ACS APPL MATER INTER, V12, P11307, DOI 10.1021/acsami.9b20071; Sun LZ, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101759; Sun QX, 2019, CHEM SOC REV, V48, P351, DOI 10.1039/c8cs00473k; Sundarraj S, 2014, TOXICOL APPL PHARM, V275, P232, DOI 10.1016/j.taap.2014.01.012; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Thangam R, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202008698; Thangam R, 2015, RSC ADV, V5, P12209, DOI 10.1039/c4ra14043e; Tian Y, 2014, ADV MATER, V26, P7393, DOI 10.1002/adma.201403562; Tu K, 2020, ACS APPL MATER INTER, V12, P16018, DOI 10.1021/acsami.9b23084; Ulbrich K, 2016, CHEM REV, V116, P5338, DOI 10.1021/acs.chemrev.5b00589; van der Meel R, 2019, NAT NANOTECHNOL, V14, P1007, DOI 10.1038/s41565-019-0567-y; Verbeke R, 2017, J CONTROL RELEASE, V266, P287, DOI 10.1016/j.jconrel.2017.09.041; Vetter V, 2018, ANN MED, V50, P110, DOI 10.1080/07853890.2017.1407035; Vivek R, 2016, ACS APPL MATER INTER, V8, P2262, DOI 10.1021/acsami.5b11103; Vivek R, 2014, ACS APPL MATER INTER, V6, P6469, DOI 10.1021/am406012g; Wang C, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan3682; Wang DG, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau6584; Wang H, 2018, NAT MATER, V17, P761, DOI 10.1038/s41563-018-0147-9; Wang LY, 2020, EUR J PHARM BIOPHARM, V147, P76, DOI 10.1016/j.ejpb.2019.12.013; Wang S, 2019, ADV SCI, V6, DOI 10.1002/advs.201801986; Wang SR, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202000845; Wang Y, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901176; Warashina S, 2011, BIOL PHARM BULL, V34, P1348, DOI 10.1248/bpb.34.1348; Wemeau M, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.82; Wilson DR, 2018, NANOMED-NANOTECHNOL, V14, P237, DOI 10.1016/j.nano.2017.10.013; Wu YH, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9020159; Wu ZL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76416-4; Xie YQ, 2018, WIRES NANOMED NANOBI, V10, DOI 10.1002/wnan.1506; Xie ZJ, 2020, CHEM SOC REV, V49, P8065, DOI 10.1039/d0cs00215a; Yan SQ, 2019, ADV MATER, V31, DOI 10.1002/adma.201905825; Yang WJ, 2020, ACS NANO, V14, P620, DOI 10.1021/acsnano.9b07212; Yang ZG, 2020, WIRES NANOMED NANOBI, V12, DOI 10.1002/wnan.1590; Ye YQ, 2016, ACS NANO, V10, P8956, DOI 10.1021/acsnano.6b04989; Yoon HY, 2018, BIOMATERIALS, V178, P597, DOI 10.1016/j.biomaterials.2018.03.036; Yu WQ, 2019, BIOMATERIALS, V217, DOI 10.1016/j.biomaterials.2019.119309; Zeng ZL, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202004397; Zhang C, 2020, CHEM SOC REV, V49, P4234, DOI 10.1039/c9cs00773c; Zhang F, 2018, CANCER RES, V78, P3718, DOI 10.1158/0008-5472.CAN-18-0306; Zhang HY, 2020, BIOMATERIALS, V245, DOI 10.1016/j.biomaterials.2020.119983; Zhang XD, 2017, SCI CHINA MATER, V60, P487, DOI 10.1007/s40843-017-9025-3; Zhang Y, 2021, CANCERS, V13, DOI 10.3390/cancers13112801; Zhang YX, 2019, NANO LETT, V19, P2774, DOI 10.1021/acs.nanolett.8b04296; Zhao YD, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120552; Zhu GZ, 2017, ACS NANO, V11, P2387, DOI 10.1021/acsnano.7b00978; Zhuang J, 2019, THERANOSTICS, V9, P7826, DOI 10.7150/thno.37216; Zu MH, 2019, COLLOID SURFACE B, V177, P399, DOI 10.1016/j.colsurfb.2019.02.031	181	4	4	8	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							935	10.3390/vaccines9080935			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9PP	34452059	gold, Green Published			2022-04-29	WOS:000690253300001
J	Alzahrani, SH; Baig, M; Alrabia, MW; Algethami, MR; Alhamdan, MM; Alhakamy, NA; Asfour, HZ; Ahmad, T				Alzahrani, Sami H.; Baig, Mukhtiar; Alrabia, Mohammed W.; Algethami, Mohammed R.; Alhamdan, Meshari M.; Alhakamy, Nabil A.; Asfour, Hani Z.; Ahmad, Tauseef			Attitudes toward the SARS-CoV-2 Vaccine: Results from the Saudi Residents' Intention to Get Vaccinated against COVID-19 (SRIGVAC) Study	VACCINES			English	Article						vaccination; hesitancy; COVID-19; Saudi Arabia	UNITED-STATES; BEHAVIOR; ARABIA	Vaccine uptake could influence vaccination efforts to control the widespread COVID-19 pandemic; however, little is known about vaccine acceptance in Saudi Arabia. The present study aimed to assess the Saudi public's intent to get vaccinated against COVID-19 and explore the associated demographic determinants of their intentions as well as the reasons for vaccine hesitancy. A cross-sectional, web-based survey was distributed to public individuals in Saudi Arabia between 25 December 2020 and 15 February 2021. Participants were asked if they were willing to get vaccinated, and the responses, along with demographic data were entered into a multinomial logistic regression model to assess the relative risk ratio (RRR) for responding "no" or "unsure" versus "yes". Among 3048 participants (60.1% female, 89.5% Saudi), 52.9% intend to get vaccinated, 26.8% were unsure, and 20.3% refused vaccination. Vaccine hesitancy was significantly higher among females (RRR = 2.70, p < 0.0001) and those who had not been recently vaccinated for influenza (RRR = 2.63, p < 0.0001). The likelihood was lower among Saudis (RRR = 0.49, p < 0.0001), those with less than a secondary education (RRR = 0.16, p < 0.0001), perceived risks of COVID-19, and residents of the southern region (RRR = 0.46, p < 0.0001). The most often cited reasons for hesitancy were short clinical testing periods and concerns about adverse events or effectiveness. Vaccine hesitancy is mediated by many demographic factors and personal beliefs. To address vaccine-related concerns and amend deeply rooted health beliefs, communication should provide transparent information.	[Alzahrani, Sami H.; Alhamdan, Meshari M.] King Abdulaziz Univ, Fac Med, Family Med Dept, POB 80205, Jeddah 21589, Saudi Arabia; [Baig, Mukhtiar] King Abdulaziz Univ, Fac Med, Jeddah 21589, Saudi Arabia; [Alrabia, Mohammed W.; Asfour, Hani Z.] King Abdulaziz Univ, Fac Med, Dept Med Microbiol & Parasitol, Jeddah 21589, Saudi Arabia; [Algethami, Mohammed R.] Minist Hlth, Prevent Med & Publ Hlth Resident, Jeddah 21577, Saudi Arabia; [Alhakamy, Nabil A.] King Abdulaziz Univ, Fac Pharm, Dept Pharmaceut, Jeddah 21589, Saudi Arabia; [Ahmad, Tauseef] Southeast Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Nanjing 210096, Peoples R China		Alzahrani, SH (通讯作者)，King Abdulaziz Univ, Fac Med, Family Med Dept, POB 80205, Jeddah 21589, Saudi Arabia.	salzahrani4@kau.edu.sa; mbbaig@kau.edu.sa; mwalrabia@kau.edu.sa; abo-reada-511@hotmail.com; malhamdan1@kau.edu.sa; nalhakamy@kau.edu.sa; hasfour@kau.edu.sa; tahmad@seu.edu.cn	Alhakamy, Nabil A/AAD-9804-2019; alzahrani, sami/C-8235-2015; Baig, Mukhtiar/M-7274-2014	Alhakamy, Nabil A/0000-0002-3826-1519; alzahrani, sami/0000-0001-6786-7184; Algethami, Mohammed/0000-0002-0554-4790; Ahmad, Tauseef/0000-0001-8793-273X; Baig, Mukhtiar/0000-0003-0058-2031	KAU, Jeddah [RG-10-140-42]; DSR	This work was funded by the Deanship of Scientific Research (DSR), KAU, Jeddah, under grant No. RG-10-140-42. The authors acknowledge DSR with thanks for their technical and financial support. The funders had no role in the study's design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad T, 2021, HUM VACC IMMUNOTHER, V17, P2367, DOI 10.1080/21645515.2021.1886806; Ahmad T, 2020, PAK J MED SCI, V36, pS73, DOI 10.12669/pjms.36.COVID19-S4.2638; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Algaissi AA, 2020, J INFECT PUBLIC HEAL, V13, P834, DOI 10.1016/j.jiph.2020.04.016; Baig M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243526; Benecke Olivia, 2019, Glob Pediatr Health, V6, p2333794X19862949, DOI 10.1177/2333794X19862949; Brown DJ, 2020, SOC SCI MED, V258, DOI 10.1016/j.socscimed.2020.113085; Burki T, 2020, LANCET DIGIT HEALTH, V2, pE504, DOI 10.1016/S2589-7500(20)30227-2; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; Chapman GB, 2006, HEALTH PSYCHOL, V25, P82, DOI 10.1037/0278-6133.25.1.82; Combe C, 2021, NEPHROL DIAL TRANSPL, V36, P571, DOI 10.1093/ndt/gfab007; Cooper DM, 2021, PEDIATR RES, V90, P966, DOI 10.1038/s41390-021-01402-z; Daly Michael, 2020, medRxiv, DOI 10.1101/2020.11.27.20239970; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Faasse K, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.551004; Grech Victor, 2020, Early Hum Dev, P105213, DOI 10.1016/j.earlhumdev.2020.105213; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin CS, 2020, ANN OPER RES, DOI 10.1007/s10479-020-03572-1; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; McAndrew S., 2020, PSYARXIV; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Ouellette JA, 1998, PSYCHOL BULL, V124, P54, DOI 10.1037/0033-2909.124.1.54; Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353; Piltch-Loeb R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010076; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sarathchandra D, 2018, PREV MED, V109, P1, DOI 10.1016/j.ypmed.2018.01.006; Sheeran P, 2019, SOC SCI MED, V228, P68, DOI 10.1016/j.socscimed.2019.03.015; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Sun C, 2021, LANCET HAEMATOL, V8, pE312, DOI 10.1016/S2352-3026(21)00073-9; Thunstrom L., 2020, HESITANCY COVID 19 V, V94, DOI [DOI 10.2139/SSRN.3593098, 10.2139/ssrn.3593098]; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Weinstein ND, 2007, HEALTH PSYCHOL, V26, P146, DOI 10.1037/0278-6133.26.2.146; WHO, **NON-TRADITIONAL**; World Health Organization, SAUD ARAB WHO COR DI	39	5	5	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							798	10.3390/vaccines9070798			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TO7PW	34358214	gold, Green Published			2022-04-29	WOS:000677099500001
J	Di Giuseppe, G; Pelullo, CP; Paolantonio, A; Della Polla, G; Pavia, M				Di Giuseppe, Gabriella; Pelullo, Concetta P.; Paolantonio, Andrea; Della Polla, Giorgia; Pavia, Maria			Healthcare Workers' Willingness to Receive Influenza Vaccination in the Context of the COVID-19 Pandemic: A Survey in Southern Italy	VACCINES			English	Article						COVID-19 pandemic; healthcare workers; influenza vaccination; Italy; survey; vaccination coverage	ATTITUDES; RATES	This cross-sectional survey was designed to evaluate hospital healthcare workers' (HCWs) willingness to receive the influenza vaccination during the COVID-19 pandemic and to identify the related determinants, since it is plausible that the two epidemics will coexist in future winters. Overall, 68% out of 490 participants expressed their willingness to receive influenza vaccination in the 2020/21 season, with 95% of those ever and 45.8% of those never vaccinated in the previous six influenza seasons. Belief that influenza vaccine is useful in distinguishing influenza symptoms from those of COVID-19 and that the influenza vaccine is useful to prevent influenza in hospital settings, willingness to receive COVID-19 vaccination, having no concern about influenza vaccine side effects, concern about the possibility to transmit influenza to hospitalized patients, and influenza vaccination in previous years were all predictors of willingness to receive influenza vaccination. In the context of the COVID-19 pandemic, a relevant increase in the willingness to undergo influenza vaccination was reported. Therefore, interventions focused primarily on enabling factors are needed to promote the adherence to influenza vaccination in future seasons among HCWs.	[Di Giuseppe, Gabriella; Pelullo, Concetta P.; Paolantonio, Andrea; Pavia, Maria] Univ Campania Luigi Vanvitelli, Dept Expt Med, Via Armanni 5, I-80138 Naples, Italy; [Della Polla, Giorgia] Univ Campania Luigi Vanvitelli, Teaching Hosp, Hlth Direct, Via S Maria di Costantinopoli 104, I-80138 Naples, Italy		Pavia, M (通讯作者)，Univ Campania Luigi Vanvitelli, Dept Expt Med, Via Armanni 5, I-80138 Naples, Italy.	gabriella.digiuseppe@unicampania.it; concettapaola.pelullo@unicampania.it; andrea.paolantonio@studenti.unicampania.it; giorgia.dellapolla@unicampania.it; maria.pavia@unicampania.it		PAVIA, Maria/0000-0003-3879-1322; Pelullo, Concetta Paola/0000-0003-4228-8703			Albano L, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-208; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Boey L, 2018, VACCINE, V36, P3351, DOI 10.1016/j.vaccine.2018.04.044; Bouadma L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038646; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; De Sarro C, 2021, EXPERT REV VACCINES, V20, P753, DOI 10.1080/14760584.2021.1915776; Della Polla G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070695; Di Giuseppe G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030543; Di Pumpo M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030276; Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040711; Doratotaj S, 2008, AM J INFECT CONTROL, V36, P301, DOI 10.1016/j.ajic.2007.10.019; Durando P, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010779; European Centre for Disease Prevention and Control, 2015, VACC HES HEALTHC WOR; European Centre for Disease Prevention and Control, 2018, SEASONAL INFLUENZA V; Gualano MR, 2021, VACCINE, V39, P901, DOI 10.1016/j.vaccine.2020.12.061; Hagemeister MH, 2018, PUBLIC HEALTH, V154, P102, DOI 10.1016/j.puhe.2017.10.027; Italian Ministry of Health, 4 IT MIN HLTH 4 IT MIN HLTH; Lehmann BA, 2016, VACCINE, V34, P1389, DOI 10.1016/j.vaccine.2016.01.046; Lim DW, 2020, HUM VACC IMMUNOTHER, V16, P1118, DOI 10.1080/21645515.2019.1688037; Llupia A, 2010, AM J INFECT CONTROL, V38, P476, DOI 10.1016/j.ajic.2010.01.013; Looijmans-van den Akker I, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-47; Loulergue P, 2009, VACCINE, V27, P4240, DOI 10.1016/j.vaccine.2009.03.039; Maltezou HC, 2019, VACCINE, V37, P4419, DOI 10.1016/j.vaccine.2019.05.095; Maltezou HC, 2019, EXPERT REV VACCINES, V18, P5, DOI 10.1080/14760584.2019.1552141; Moskosky S. B., 2011, Morbidity and Mortality Weekly Report, V60, P1; Napolitano F, 2019, VACCINE, V37, P6900, DOI 10.1016/j.vaccine.2019.09.053; Nowak GJ, 2015, VACCINE, V33, P2741, DOI 10.1016/j.vaccine.2015.04.064; Paget J, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020421; Pastorino R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020070; Pelullo CP, 2014, EUROSURVEILLANCE, V19, P27, DOI 10.2807/1560-7917.ES2014.19.35.20889; Pelullo CP, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020148; Pichon M, 2019, J CLIN VIROL, V116, P29, DOI 10.1016/j.jcv.2019.04.008; Riphagen-Dalhuisen J, 2013, EUROSURVEILLANCE, V18, P10, DOI 10.2807/1560-7917.ES2013.18.26.20512; Robbins T, 2021, J HOSP INFECT, V112, P45, DOI 10.1016/j.jhin.2021.02.024; Rong HG, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020265; Socan M, 2013, EUR J PUBLIC HEALTH, V23, P92, DOI 10.1093/eurpub/cks006; Stata Corporation, 2017, STATA REFERENCE MANU; Stowe J, 2021, INT J EPIDEMIOL, V50, P1124, DOI 10.1093/ije/dyab081; Vasilevska M, 2014, INFECT CONT HOSP EP, V35, P699, DOI 10.1086/676427; World Health Organization, 2019, GLOB INFL START 2019 GLOB INFL START 2019; Yue HH, 2020, J MED VIROL, V92, P2870, DOI 10.1002/jmv.26163; Zimmerman RK, 2003, VACCINE, V21, P1486, DOI 10.1016/S0264-410X(02)00700-4	43	6	6	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							766	10.3390/vaccines9070766			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5FE	34358182	gold, Green Published			2022-04-29	WOS:000676936500001
J	Kamen, AA				Kamen, Amine A.			Vectored-Vaccine Platforms Enabled Rapid Development of Safe and Effective Vaccines in Response to COVID-19 Pandemic Situation	VACCINES			English	Editorial Material									[Kamen, Amine A.] McGill Univ, Dept Bioengn, Montreal, PQ H3A 0E9, Canada		Kamen, AA (通讯作者)，McGill Univ, Dept Bioengn, Montreal, PQ H3A 0E9, Canada.	amine.kamen@mcgill.ca			Canada Research Chair of government of Canada [CRC/240394]	A.A.K. is a recipient of a Canada Research Chair (CRC/240394) of government of Canada.	Baldo A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050453; Benest J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020078; Choi H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050438; Chowdhury SI, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010046; Farnos O, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040654; Folegatti PM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030262; Rohaim MA, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030472; Sawada A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020156; Sun WN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040771	9	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							722	10.3390/vaccines9070722			3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO4NT	34358139	gold, Green Published			2022-04-29	WOS:000676891200001
J	Phumrattanaprapin, W; Pearson, M; Pickering, D; Tedla, B; Smout, M; Chaiyadet, S; Brindley, PJ; Loukas, A; Laha, T				Phumrattanaprapin, Wuttipong; Pearson, Mark; Pickering, Darren; Tedla, Bemnet; Smout, Michael; Chaiyadet, Sujittra; Brindley, Paul J.; Loukas, Alex; Laha, Thewarach			Monoclonal Antibodies Targeting an Opisthorchis viverrini Extracellular Vesicle Tetraspanin Protect Hamsters against Challenge Infection	VACCINES			English	Article						passive immunization; monoclonal antibody; Opisthorchis viverrini; tetraspanin	CARCINOGENIC LIVER FLUKE; STRONGYLOIDES-STERCORALIS; COMPLEMENT; IMMUNITY; LARVAE; MICE	Opisthorchis viverrini causes severe pathology in the bile ducts of infected human hosts, and chronic infection can culminate in bile duct cancer. The prevention of infection by vaccination would decrease opisthorchiasis-induced morbidity and mortality. The tetraspanin protein, Ov-TSP-2, is located on the membrane of secreted extracellular vesicles (EVs), and is a candidate antigen for inclusion in a subunit vaccine. To address the role of anti-Ov-TSP-2 antibodies in protection, we assessed the protective capacity of anti-Ov-TSP-2 monoclonal antibodies (mAbs) against opisthorchiasis. Two anti-TSP-2 IgM mAbs, 1D6 and 3F5, and an isotype control were passively transferred to hamsters, followed by parasite challenge one day later. Hamsters that received 3F5 had 74.5% fewer adult flukes and 67.4% fewer eggs per gram of feces compared to hamsters that received the control IgM. Both 1D6 and 3F5 (but not the control IgM) blocked the uptake of fluke EVs by human bile duct epithelial cells in vitro. This is the first report of passive immunization against human liver fluke infection, and the findings portend the feasibility of antibody-directed therapies for liver fluke infection, bolstering the selection of TSPs as components of a subunit vaccine for opisthorchiasis and fluke infections generally.	[Phumrattanaprapin, Wuttipong; Laha, Thewarach] Khon Kaen Univ, Fac Med, Dept Parasitol, Khon Kaen 40002, Thailand; [Phumrattanaprapin, Wuttipong] Chulabhorn Royal Acad, HRH Princess Chulabhorn Coll Med Sci, Fac Vet Med & Appl Zool, Bangkok 10210, Thailand; [Pearson, Mark; Pickering, Darren; Tedla, Bemnet; Smout, Michael; Loukas, Alex] James Cook Univ, Ctr Mol Therapeut, Australian Inst Trop Hlth & Med, Cairns, Qld 4878, Australia; [Chaiyadet, Sujittra] Khon Kaen Univ, Acad Affairs, Fac Med, Trop Med Grad Program, Khon Kaen 40002, Thailand; [Brindley, Paul J.] George Washington Univ, Sch Med & Hlth Sci, Dept Microbiol, Immunol & Trop Med,Res Ctr Neglected Dis Poverty, Washington, DC 20037 USA		Laha, T (通讯作者)，Khon Kaen Univ, Fac Med, Dept Parasitol, Khon Kaen 40002, Thailand.; Loukas, A (通讯作者)，James Cook Univ, Ctr Mol Therapeut, Australian Inst Trop Hlth & Med, Cairns, Qld 4878, Australia.	wuttipongp@kkumail.com; mark.pearson@jcu.edu.au; darren.pickering@jcu.edu.au; bemnetamare.tedla@jcu.edu.au; michael.smout@jcu.edu.au; sujitch@kku.ac.th; pbrindley@gwu.edu; alex.loukas@jcu.edu.au; thewa_la@kku.ac.th		Pearson, Mark/0000-0002-0002-1544; Brindley, Paul J./0000-0003-1765-0002; Smout, Michael/0000-0001-6937-0112	Thailand Research Fund through the Royal Golden Jubilee PhD ProgramThailand Research Fund (TRF) [PHD/0163/2561]; National Cancer Institute, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA164719]; Research and Graduate Studies, Khon Kaen University; National Health and Medical Research Council, AustraliaNational Health and Medical Research Council (NHMRC) of Australia [1132975, 1117504]	This research was supported by the Thailand Research Fund through the Royal Golden Jubilee PhD Program (grant no. PHD/0163/2561 to W.P. and T.L.), the National Cancer Institute, National Institutes of Health award no. R01CA164719 (T.L., A.L., and P.J.B.) and Research and Graduate Studies, Khon Kaen University (T.L. and S.C.). AL is supported by a senior principal research fellowship (1117504) and program grant (1132975) from the National Health and Medical Research Council, Australia.	AMORNPUNT S, 1991, INT J PARASITOL, V21, P421, DOI 10.1016/0020-7519(91)90099-S; Arimatsu Y, 2020, MOL BIOCHEM PARASIT, V240, DOI 10.1016/j.molbiopara.2020.111323; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Brigandi RA, 1996, EXP PARASITOL, V82, P279, DOI 10.1006/expr.1996.0035; Chaiyadet S, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007450; Chaiyadet S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13527-5; Chaiyadet S, 2015, J INFECT DIS, V212, P1636, DOI 10.1093/infdis/jiv291; Forthal DN, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0019-2014; GRUBMAN SA, 1994, AM J PHYSIOL, V266, pG1060, DOI 10.1152/ajpgi.1994.266.6.G1060; Herbert DR, 2000, J IMMUNOL, V165, P4544, DOI 10.4049/jimmunol.165.8.4544; Hiramoto E, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aau1199; Kaplon H, 2019, MABS-AUSTIN, V11, P219, DOI 10.1080/19420862.2018.1556465; Kearney BJ, 2017, J VIROL METHODS, V242, P9, DOI 10.1016/j.jviromet.2016.12.011; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Lu RM, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0592-z; Phung LT, 2019, PARASITOL RES, V118, P3419, DOI 10.1007/s00436-019-06488-3; Marcet R, 2002, PARASITE IMMUNOL, V24, P103, DOI 10.1046/j.0141-9838.2001.00443.x; Marston HD, 2018, NEW ENGL J MED, V378, P1469, DOI 10.1056/NEJMp1802256; Meningher T, 2017, J INFECT DIS, V215, P378, DOI 10.1093/infdis/jiw539; PARAB PB, 1988, IMMUNOLOGY, V64, P169; Phumrattanaprapin W, 2021, J INFECT DIS, V223, P1445, DOI 10.1093/infdis/jiaa516; Phumrattanaprapin W, 2018, SE ASIAN J TROP MED, V49, P933; SIRISINHA S, 1986, INT J PARASITOL, V16, P341, DOI 10.1016/0020-7519(86)90112-8; SIRISINHA S, 1995, AM J TROP MED HYG, V52, P521, DOI 10.4269/ajtmh.1995.52.521; Sithithaworn P, 2012, LANCET INFECT DIS, V12, P588, DOI 10.1016/S1473-3099(12)70174-3; Sripa B, 2008, CURR OPIN GASTROEN, V24, P349, DOI 10.1097/MOG.0b013e3282fbf9b3; Sripa B, 2012, TRENDS PARASITOL, V28, P395, DOI 10.1016/j.pt.2012.07.006; Wagner EK, 2018, CURR OPIN CHEM ENG, V19, P131, DOI 10.1016/j.coche.2018.01.007; Wang D K, 1992, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V10, P22; Worasith C, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007186; XU CB, 1991, EUR J IMMUNOL, V21, P1801, DOI 10.1002/eji.1830210804	31	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							740	10.3390/vaccines9070740			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO4OC	34358156	gold, Green Published, Green Accepted			2022-04-29	WOS:000676892100001
J	Rosental, H; Shmueli, L				Rosental, Hila; Shmueli, Liora			Integrating Health Behavior Theories to Predict COVID-19 Vaccine Acceptance: Differences between Medical Students and Nursing Students	VACCINES			English	Article						SARS Coronavirus; Health Belief Model; healthcare workers; Theory of Planned Behavior; vaccine acceptance	INFLUENZA VACCINATION; CARE WORKERS; NURSES; INTENTION	Background: This study aimed to explore behavioral-related factors predicting the intention of getting a COVID-19 vaccine among medical and nursing students using an integrative model combining the Health Belief Model (HBM) and the Theory of Planned Behavior (TPB). Methods: A cross-sectional online survey was conducted among medical and nursing students aged > 18 years in their clinical years in Israel between 27 August and 28 September 2020. Hierarchical logistic regression was used to predict acceptance of a COVID-19 vaccine. Results: A total number of 628 participants completed the survey. Medical students expressed higher intentions of getting vaccinated against COVID-19 than nursing students (88.1% vs. 76.2%, p < 0.01). The integrated model based on HBM and TPB was able to explain 66% of the variance (adjusted R-2' = 0.66). Participants were more likely to be willing to get vaccinated if they reported higher levels of perceived susceptibility, benefits, barriers, cues to action, attitude, self-efficacy and anticipated regret. Two interaction effects revealed that male nurses had a higher intention of getting vaccinated than did female nurses and that susceptibility is a predictor of the intention of getting vaccinated only among nurses. Conclusions: This study demonstrates that both models considered (i.e., HBM and TPB) are important for predicting the intention of getting a COVID-19 vaccine among medical and nursing students, and can help better guide intervention programs, based on components from both models. Our findings also highlight the importance of paying attention to a targeted group of female nurses, who expressed low vaccine acceptance.	[Rosental, Hila; Shmueli, Liora] Bar Ilan Univ, Dept Management, IL-52900 Ramat Gan, Israel		Shmueli, L (通讯作者)，Bar Ilan Univ, Dept Management, IL-52900 Ramat Gan, Israel.	hila.rosental@mail.huji.ac.il; liora.shmueli@biu.ac.il					AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; [Anonymous], 2021, BBC NEWS; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Bolin JH, 2014, J EDUC MEAS, V51, P335, DOI 10.1111/jedm.12050; Chou R, 2021, ANN INTERN MED, V174, pW18, DOI 10.7326/L20-1323; Corace K, 2013, AM J INFECT CONTROL, V41, P679, DOI 10.1016/j.ajic.2013.01.014; Corace KM, 2016, VACCINE, V34, P3235, DOI 10.1016/j.vaccine.2016.04.071; Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Flanagan P, 2020, J ADV NURS, V76, P1746, DOI 10.1111/jan.14360; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Godin G, 2010, INFECT CONT HOSP EP, V31, P689, DOI 10.1086/653614; Graitcer S.W, 2016, MMWR-MORBID MORTAL W, V65, P7; Hopman CE, 2011, J HOSP INFECT, V77, P327, DOI 10.1016/j.jhin.2010.10.009; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Looijmans-van den Akker I, 2009, VACCINE, V27, P4724, DOI 10.1016/j.vaccine.2009.05.013; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Maltezou HC, 2019, EXPERT REV VACCINES, V18, P5, DOI 10.1080/14760584.2019.1552141; Maltezou HC, 2010, J INFECTION, V61, P252, DOI 10.1016/j.jinf.2010.06.004; Ng TWY, 2020, VACCINE, V38, P690, DOI 10.1016/j.vaccine.2019.10.041; Nguyen Long H, 2020, medRxiv, DOI [10.1016/S2468-2667(20)30164-X, 10.1101/2020.04.29.20084111]; Padureanu V, 2020, MED-SURG J, V124, P454; Persad G, 2020, JAMA-J AM MED ASSOC, V324, P1601, DOI 10.1001/jama.2020.18513; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P354, DOI 10.1177/109019817400200405; Shahrabani S, 2009, EUR J HEALTH ECON, V10, P227, DOI 10.1007/s10198-008-0124-3; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Shmueli L, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10816-7; The US Food and Drug Administration, 2021, COVID 19 VACC; Thunstrom L., 2020, HESITANCY COVID 19 V, V94, DOI [DOI 10.2139/SSRN.3593098, 10.2139/ssrn.3593098]; Unroe KT, 2021, J AM GERIATR SOC, V69, P593, DOI 10.1111/jgs.17022; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; West S.G., 1991, MULTIPLE REGRESSION, P212; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Zhang J, 2012, VACCINE, V30, P4813, DOI 10.1016/j.vaccine.2012.05.012	35	6	6	5	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							783	10.3390/vaccines9070783			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TO8JO	34358199	Green Published, Green Submitted, gold			2022-04-29	WOS:000677150700001
J	Talarek, E; Warzecha, J; Banasiuk, M; Banaszkiewicz, A				Talarek, Ewa; Warzecha, Joanna; Banasiuk, Marcin; Banaszkiewicz, Aleksandra			Influenza Vaccination Coverage and Intention to Receive Hypothetical Ebola and COVID-19 Vaccines among Medical Students	VACCINES			English	Article						influenza; vaccination; vaccine acceptance; COVID-19; Ebola; medical students	HEALTH-CARE WORKERS; UNITED-STATES; ACCEPTANCE; ATTITUDES; KNOWLEDGE	The study aimed to determine influenza vaccine uptake among medical students and their intention to receive a hypothetical Ebola or COVID-19 vaccine. This cross-sectional questionnaire-based study was performed in 2015 and 2020 on 675 medical students at the Medical University of Warsaw, Poland. In 2020, the influenza vaccination coverage was 36.5%, and students were almost five times more likely to be vaccinated than in 2015 (OR = 4.8; 95% CI: 3.1-7.5). In 2020, the survey was conducted during the first university campaign targeted at free influenza vaccinations for all students, as well as during the first lockdown in Poland due to the COVID-19 pandemic. In 2020, clinical students (4th-6th study year) were significantly more often vaccinated than preclinical students (p < 0.001), in contrast to 2015. A majority-67.0% and 94.6%-of students expressed their intention to receive a hypothetical Ebola or COVID-19 vaccine, respectively. Among the medical students, influenza vaccination status was a predictor of the intention to receive a COVID-19 vaccine. Influenza vaccine uptake among medical students has increased significantly, but it is still not optimal; thus, further educational efforts are needed to convince those who are hesitant regarding vaccines. A high number of students reported their intention to receive a COVID-19 vaccine, and it is crucial to support their positive attitude about it.	[Talarek, Ewa] Med Univ Warsaw, Dept Childrens Infect Dis, PL-02091 Warsaw, Poland; [Warzecha, Joanna] Univ Childrens Hosp Warsaw, PL-02091 Warsaw, Poland; [Banasiuk, Marcin; Banaszkiewicz, Aleksandra] Med Univ Warsaw, Dept Pediat Gastroenterol & Nutr, PL-02091 Warsaw, Poland		Talarek, E (通讯作者)，Med Univ Warsaw, Dept Childrens Infect Dis, PL-02091 Warsaw, Poland.	ewa.talarek@wum.edu.pl; jm.sliwka@gmail.com; mbanasiuk@wum.edu.pl; abanaszkiewicz@wum.edu.pl	Banasiuk, Marcin/ABH-1256-2021; Talarek, Ewa/P-2278-2018	Banasiuk, Marcin/0000-0003-1713-7372; Talarek, Ewa/0000-0002-3466-0782			Banaszkiewicz A, 2016, ADV EXP MED BIOL, V934, P83, DOI 10.1007/5584_2016_20; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Black CL, 2018, MMWR-MORBID MORTAL W, V67, P1050, DOI 10.15585/mmwr.mm6738a2; Bonaccorsi G, 2013, HUM VACC IMMUNOTHER, V9, P2603, DOI 10.4161/hv.26036; Cella P, 2020, J RES HEALTH SCI, V20, DOI 10.34172/jrhs.2020.09; Centers for Disease Control and Prevention, 2014 2016 EB OUTBR W; Dass von Perbandt Evelyn, 2018, GMS Infect Dis, V6, pDoc02, DOI 10.3205/id000037; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Gallone MS, 2017, HUM VACC IMMUNOTHER, V13, P1937, DOI 10.1080/21645515.2017.1320462; Genovese C, 2019, J Prev Med Hyg, V60, pE12, DOI 10.15167/2421-4248/jpmh2019.60.1.1097; Ghandora H, 2019, HUM VACC IMMUNOTHER, V15, P700, DOI 10.1080/21645515.2018.1543523; Grohskopf LA, 2015, AM J TRANSPLANT, V15, P2767, DOI 10.1111/ajt.13505; Haviari S, 2015, HUM VACC IMMUNOTHER, V11, P2522, DOI 10.1080/21645515.2015.1082014; Hernandez-Garcia I, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020238; Hernandez-Garcia I, 2012, VACCINE, V31, P1, DOI 10.1016/j.vaccine.2012.10.104; Kawahara Y, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010052; Lehmann BA, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0929-5; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; Machowicz R, 2010, EUR J MED RES, V15, P235; Maltezou HC, 2016, HEALTHCARE-BASEL, V4, DOI 10.3390/healthcare4030047; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nitsch-Osuch A, 2013, MED PR, V64, P119; Paget J, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020421; Painter JE, 2017, VACCINE, V35, P508, DOI 10.1016/j.vaccine.2016.11.093; Rogers CJ, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6041-1; Rostkowska OM, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18073595; Rubsamen N, 2015, EMERG INFECT DIS, V21, P1012, DOI 10.3201/eid2106.150013; Shefer Abigail, 2011, Morbidity and Mortality Weekly Report, V60, P1; Walker L, 2016, VACCINE, V34, P6193, DOI 10.1016/j.vaccine.2016.10.074; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wicker S, 2013, VACCINE, V31, P5111, DOI 10.1016/j.vaccine.2013.08.070; World Health Organization, 2012, VACC INFL WHO POS PA; Wozniak-Kosek A, 2014, ACTA BIOCHIM POL, V61, P829	33	6	6	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							709	10.3390/vaccines9070709			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7KC	34209128	gold, Green Published			2022-04-29	WOS:000677084500001
J	Yan, E; Lai, DWL; Lee, VWP				Yan, Elsie; Lai, Daniel W. L.; Lee, Vincent W. P.			Predictors of Intention to Vaccinate against COVID-19 in the General Public in Hong Kong: Findings from a Population-Based, Cross-Sectional Survey	VACCINES			English	Article						Hong Kong; COVID-19; intention to vaccinate; health belief model	HEALTH BELIEF MODEL; WILLINGNESS; ACCEPTANCE; ATTITUDES; PERIOD; ADULTS	Vaccination is one of the most effective ways to stop the spread of COVID-19. Understanding factors associated with intention to receive COVID-19 vaccines is the key to a successful vaccination programme. This cross-sectional study explored the rate of vaccination intention and identified its predictors using the health belief model (HBM) in the general population in Hong Kong during the pandemic. Data were collected between December 2020 and January 2021 via telephone surveys. Hierarchical logistic regression analysis was used to identify factors associated with intention to receive COVID-19 vaccines. A total of 1255 adults (>18 years, 53% female) completed the telephone survey. Overall, 42% indicated an intention to vaccinate, 31.5% showed vaccine hesitancy, and 26.5% reported refusal to receive any COVID-19 vaccines. Individuals who were men, older in age, working, with past experiences of other pandemics, less concerned with the vaccine safety, with poorer knowledge about COVID-19, and having greater levels of perceived susceptibility, self-efficacy, cues to action, and acceptance of governmental preventive measures related to COVID-19 were significantly more likely to report an intention to vaccinate. The low intention among the Hong Kong population reflects the importance of developing effective vaccination promotion campaigns with the predictors identified in this study.	[Yan, Elsie; Lee, Vincent W. P.] Hong Kong Polytech Univ, Dept Appl Social Sci, Hong Kong 999077, Peoples R China; [Lai, Daniel W. L.] Baptist Univ Hong Kong, Fac Social Sci, Hong Kong 999077, Peoples R China		Yan, E (通讯作者)，Hong Kong Polytech Univ, Dept Appl Social Sci, Hong Kong 999077, Peoples R China.	elsie.yan@polyu.edu.hk; daniel_lai@hkbu.edu.hk; vwp.lee@polyu.edu.hk		Lee, Vincent W. P./0000-0003-4574-636X	Health and Medical Research Fund [COVID190216]	This research was funded by the Health and Medical Research Fund, Grant Number: COVID190216.	Anderson RM, 2020, LANCET, V396, P587, DOI 10.1016/S0140-6736(20)31689-5; Bono SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050515; Borriello A, 2021, VACCINE, V39, P473, DOI 10.1016/j.vaccine.2020.12.032; Chu HR, 2021, PATIENT EDUC COUNS, V104, P1878, DOI 10.1016/j.pec.2021.02.031; Coe AB, 2022, RES SOC ADMIN PHARM, V18, P2593, DOI 10.1016/j.sapharm.2021.04.023; Department of Health and Social Care Government of the United Kingdom, DEM YOUR COVID 19 VA DEM YOUR COVID 19 VA; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Ditekemena JD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020153; European Union, EU DIG COVID CERT EU DIG COVID CERT; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gatwood J, 2020, VACCINE, V38, P5607, DOI 10.1016/j.vaccine.2020.06.077; Goruntla N, 2021, ASIAN PAC J TROP MED, V14, P165, DOI 10.4103/1995-7645.312512; Han KY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050443; HM Government HM Government, OUR PLAN REB UK GOV; Kabir R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050416; Kukreti S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030246; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Levy R., SOME CANADIAN PROVIN; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Rajamoorthy Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208402; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Reno C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040378; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Santos AJ, 2017, EPIDEMIOL INFECT, V145, P1786, DOI 10.1017/S0950268817000814; Schwarzer R., 1995, MEASURES HLTH PSYCHO, DOI DOI 10.1037/T00393-000; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Shmueli L, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10816-7; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Szilagyi PG, 2021, JAMA-J AM MED ASSOC, V325, P396, DOI 10.1001/jama.2020.26419; Taiwan Centers for Disease Control, CECC ANN COVID 19 VA CECC ANN COVID 19 VA; U.S. Food and Drug Administration, COR COVID 19 UPD FDA; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Wells A., 1995, BEHAV COGN PSYCHOTH, V23, P301, DOI [DOI 10.1017/S1352465800015897, 10.1017/S1352465800015897]; WHO, 2015, SAGE WORK GROUP DEAL; Wilf-Miron R, 2021, JAMA-J AM MED ASSOC, V325, P1503, DOI 10.1001/jama.2021.4300; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; World Health Organization, STAT COVID 19 VACC W; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048; Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu H, 2010, OSTEOPOROSIS INT, V21, P765, DOI 10.1007/s00198-009-1010-2	52	12	12	4	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							696	10.3390/vaccines9070696			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5SV	34202016	gold, Green Published			2022-04-29	WOS:000676972000001
J	Al-Mulla, R; Abu-Madi, M; Talafha, QM; Tayyem, RF; Abdallah, AM				Al-Mulla, Reem; Abu-Madi, Marawan; Talafha, Qusai M.; Tayyem, Reema F.; Abdallah, Atiyeh M.			COVID-19 Vaccine Hesitancy in a Representative Education Sector Population in Qatar	VACCINES			English	Article						COVID-19; vaccine; hesitancy; Qatar; education sector; post vaccine administration program	ATTITUDES	Even though vaccination programs have now started in earnest across the globe and in Qatar, vaccine hesitancy remains a barrier to effectively tackling the pandemic. Many factors influence willingness to take vaccines including safety, efficacy, and side effects. Given their proximity to research and education, university students and employees represent an interesting cohort in which to investigate vaccine hesitancy. The aim of this study was to assess the attitudes of Qatar University employees and students towards the COVID-19 vaccine. In total, 231 employees and 231 students participated in an online cross-sectional study in February 2021. Of the sample, 62.6% were willing to take a vaccine against COVID-19. Participants with or taking postgraduate degrees were more willing to take the vaccine compared to participants with or taking a diploma or bachelor's degree (p < 0.001). Males had a higher rate of vaccine acceptance (p < 0.001). In the group that regarded flu vaccination as important, 13% were unwilling to take COVID-19 vaccine. There were no associations between willingness to vaccinate and vaccine/virus knowledge and social media use. Participants showed a high level of concern regarding vaccine side effects in themselves or their children. Two-thirds agreed or strongly agreed that they would take the vaccine if it was mandatory for international travel. Our participants were neutral to the origin of vaccine development. These findings, which represent data collected after the start of the national vaccination program, show that vaccine hesitancy persists in the Qatari population and that some groups, such as undergraduate students, could benefit from specific, targeted public health campaigns.	[Al-Mulla, Reem; Abu-Madi, Marawan; Abdallah, Atiyeh M.] QU Hlth, Dept Biomed Sci, Coll Hlth Sci, Doha 2713, Qatar; [Abu-Madi, Marawan; Talafha, Qusai M.; Abdallah, Atiyeh M.] Qatar Univ, Biomed & Pharmaceut Res Unit, QU Hlth, Doha 2713, Qatar; [Talafha, Qusai M.] Hashemite Univ, Fac Econ & Adm Sci, Dept Econ, Zarqa 330127, Jordan; [Tayyem, Reema F.] QU Hlth, Dept Nutr, Coll Hlth Sci, Doha 2713, Qatar		Abdallah, AM (通讯作者)，QU Hlth, Dept Biomed Sci, Coll Hlth Sci, Doha 2713, Qatar.; Abdallah, AM (通讯作者)，Qatar Univ, Biomed & Pharmaceut Res Unit, QU Hlth, Doha 2713, Qatar.	ra1305908@student.qu.edu.qa; abumadi@qu.edu.qa; qusai.talafha@hu.edu.jo; reema.tayyem@qu.edu.qa; aabdallah@qu.edu.qa	tayyem, reema f/I-1217-2016; Tayyem, Reema/AGY-6011-2022; Tayyem, Reema/AAA-5326-2019	tayyem, reema f/0000-0003-1640-0511; Tayyem, Reema/0000-0003-1640-0511; Abdallah, Atiyeh/0000-0003-4812-956X; Abu-Madi, Marawan/0000-0001-7843-1255	Qatar university [QUST-1-CHS-2021-9]	The APC was funded by Qatar university, grant #QUST-1-CHS-2021-9.	Al-Qerem WA, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.632914; Alabdulla M, 2021, INFLUENZA OTHER RESP, V15, P361, DOI 10.1111/irv.12847; Alley SJ, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020797; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; [Anonymous], 2015, SITE OFFICIEL PR HEN; Awadhi EA, 2021, RISK MANAG HEALTHC P, V14, P1413, DOI 10.2147/RMHP.S300602; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Calnan M, 2020, HEALTH RISK SOC, V22, P291, DOI 10.1080/13698575.2020.1846687; DeStefano F, 2019, ANNU REV VIROL, V6, P585, DOI 10.1146/annurev-virology-092818-015515; Di Gennaro F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030371; Di Martino G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020248; Di Pietrantonj C, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004407.pub4; Eggertson L, 2010, CAN MED ASSOC J, V182, pE199, DOI 10.1503/cmaj.109-3179; European Centre for Disease Prevention and Control, 2015, VACC HES HEALTHC WOR; Irwin A, 2021, NATURE, V592, P176, DOI 10.1038/d41586-021-00727-3; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; Malina D, 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMms2033790; Moberly T, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n837; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Qunaibi E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050446; Ricco M, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5030117; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030218; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206	26	7	7	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							665	10.3390/vaccines9060665			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY9HU	34207012	gold, Green Published			2022-04-29	WOS:000666191000001
J	Bamouh, Z; Hamdi, J; Fellahi, S; Khayi, S; Jazouli, M; Tadlaoui, KO; Fihri, OF; Tuppurainen, E; Elharrak, M				Bamouh, Zahra; Hamdi, Jihane; Fellahi, Siham; Khayi, Slimane; Jazouli, Mohammed; Tadlaoui, Khalid Omari; Fihri, Ouafaa Fassi; Tuppurainen, Eeva; Elharrak, Mehdi			Investigation of Post Vaccination Reactions of Two Live Attenuated Vaccines against Lumpy Skin Disease of Cattle	VACCINES			English	Article						lumpy skin disease virus; safety; Neethling disease; vaccination; cattle	ADVERSE-REACTIONS; VIRUS; TRANSMISSION; OUTBREAK; EFFICACY; STRAIN; SHEEP	Lumpy skin disease virus (LSDV) causes an economically important disease in cattle. The only method for successful control is early diagnosis and efficient vaccination. Adverse effects of vaccination such as local inflammation at the injection site and localized or generalized skin lesions in some vaccinated animals have been reported with live vaccines. The aim of this work was to compare the safety of two lumpy skin disease (LSD) vaccine strains, Kenyan (Kn) Sheep and Goat Pox (KSGP O-240) and LSDV Neethling (Nt) strain, and to determine the etiology of the post-vaccination (pv) reactions observed in cattle. Experimental cattle were vaccinated under controlled conditions with Nt- and KSGP O-240-based vaccines, using two different doses, and animals were observed for 3 months for any adverse reactions. Three out of 45 cattle vaccinated with LSDV Nt strain (6.7%) and three out of 24 cattle vaccinated with Kn strain (12.5%) presented LSD-like skin nodules, providing evidence that the post-vaccination lesions may not be strain-dependent. Lesions appeared 1-3 weeks after vaccination and were localized in the neck or covering the whole body. Animals recovered after 3 weeks. There is a positive correlation between the vaccine dose and the appearance of skin lesions in vaccinated animals; at the 105 dose, 12% of the animals reacted versus 3.7% at the 104 dose. Both strains induced solid immunity when protection was measured by neutralizing antibody seroconversion.	[Bamouh, Zahra; Hamdi, Jihane; Jazouli, Mohammed; Tadlaoui, Khalid Omari; Elharrak, Mehdi] MCI Sante Anim, Mohammadia 28810, Morocco; [Bamouh, Zahra; Hamdi, Jihane; Fellahi, Siham; Fihri, Ouafaa Fassi] Inst Agron & Vet Hassan II, BP 6202, Rabat 10112, Morocco; [Khayi, Slimane] Natl Inst Agr Res INRA, CRRA Rabat, Rabat 10101, Morocco; [Tuppurainen, Eeva] Friedrich Loeffler Inst Fed Res Inst Anim Hlth, Inst Int Tiergesundheit One Hlth, D-17493 Greifswald, Germany		Bamouh, Z (通讯作者)，MCI Sante Anim, Mohammadia 28810, Morocco.; Bamouh, Z (通讯作者)，Inst Agron & Vet Hassan II, BP 6202, Rabat 10112, Morocco.	z.bamouh@mci-santeanimale.com; jihaneh.hamdi@gmail.com; s.fellahi@iay.ac.ma; slimane.khayi@inra.ma; jazouli_med@yahoo.fr; k.tadlaoui@mci-santeanimale.com; o.fassifihri@iay.ac.ma; eeva.tuppurainen@fli.de; m.elharrak@mci-santeanimale.com	khayi, slimane/T-7735-2019	khayi, slimane/0000-0001-8033-2117; FELLAHI, Siham/0000-0002-1803-3746; bamouh, zahra/0000-0002-1508-0109	MCI (Multi-Chemical Industry) Sante Animale	All authors read and approved the content of this manuscript and contributed significantly to the work. The authors gratefully acknowledge the support for this study from MCI (Multi-Chemical Industry) Sante Animale.	Abutarbush SM, 2016, TRANSBOUND EMERG DIS, V63, pE213, DOI 10.1111/tbed.12257; Abutarbush SM, 2018, TRANSBOUND EMERG DIS, V65, P1657, DOI 10.1111/tbed.12923; Aleksandr K, 2020, ARCH VIROL, V165, P1343, DOI 10.1007/s00705-020-04607-5; Ayelet G, 2013, ANTIVIR RES, V98, P261, DOI 10.1016/j.antiviral.2013.02.008; Babiuk S, 2008, TRANSBOUND EMERG DIS, V55, P299, DOI 10.1111/j.1865-1682.2008.01024.x; Badhy SC, 2021, BMC VET RES, V17, DOI 10.1186/s12917-021-02751-x; Bedekovic T, 2018, TRANSBOUND EMERG DIS, V65, P491, DOI 10.1111/tbed.12730; Ben-Gera J, 2015, VACCINE, V33, P4837, DOI 10.1016/j.vaccine.2015.07.071; Bowden TR, 2008, VIROLOGY, V371, P380, DOI 10.1016/j.virol.2007.10.002; Brenner J, 2009, VACCINE, V27, P1500, DOI 10.1016/j.vaccine.2009.01.020; Buller RM, 2005, VIRUS TAXONOMY CLASS, P117; Calistri P, 2020, EFSA J, V18, DOI 10.2903/j.efsa.2020.6010; Calistri P, 2019, EFSA J, V17, DOI 10.2903/j.efsa.2019.5638; CARN VM, 1995, EPIDEMIOL INFECT, V114, P219, DOI 10.1017/S0950268800052067; Chihota CM, 2001, EPIDEMIOL INFECT, V126, P317, DOI 10.1017/S0950268801005179; Davies F., 1981, LUMPYSKIN DIS; DAVIES FG, 1991, BRIT VET J, V147, P489, DOI 10.1016/0007-1935(91)90019-J; FAO, 2020, INTR SPREAD LUMP SKI; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Gari G, 2015, VACCINE, V33, P3256, DOI 10.1016/j.vaccine.2015.01.035; Gelaye E, 2015, ANTIVIR RES, V119, P28, DOI 10.1016/j.antiviral.2015.04.008; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95; Hamdi J, 2020, VET MICROBIOL, V245, DOI 10.1016/j.vetmic.2020.108689; Katsoulos PD, 2018, TRANSBOUND EMERG DIS, V65, P174, DOI 10.1111/tbed.12646; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Kitching R. P., 2003, VVolume 114, P161; Klement E, 2020, PREV VET MED, V181, DOI 10.1016/j.prevetmed.2018.12.001; Kumar SM, 2011, ASIAN J ANIM VET ADV, V6, P851, DOI 10.3923/ajava.2011.851.859; Lojkic I, 2018, MICROBIOL RESOUR ANN, V6, DOI 10.1128/genomeA.00482-18; Lubinga JC, 2015, TRANSBOUND EMERG DIS, V62, P174, DOI 10.1111/tbed.12102; Milovanovic M, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1831-y; Norian R., 2016, IRAN J VIROL, V10, P1, DOI [10.21859/isv.10.4.1, DOI 10.21859/ISV.10.4.1]; Office of the National Economic and Social Development Board, 2017, PROGR REP SPEC EC DE, P1; OIE, 2016, RES ED OIE TERR AN H, P1; Parlement Europeen et du Conseil de l'Union Europeenne, 2010, J OFF UNION EUR, V276, P1; PROZESKY L, 1982, ONDERSTEPOORT J VET, V49, P167; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Salib FA, 2011, VET WORLD, V4, P162; Samojlovic M, 2019, ACTA VET-BEOGRAD, V69, P47, DOI 10.2478/acve-2019-0003; Sevik M, 2017, TRANSBOUND EMERG DIS, V64, P1268, DOI 10.1111/tbed.12501; Sohier C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56605-6; Sprygin A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207480; Tageldin MH, 2014, TROP ANIM HEALTH PRO, V46, P241, DOI 10.1007/s11250-013-0483-3; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tuppurainen E., 2017, LUMPY SKIN DIS FIELD; Tuppurainen ESM, 2020, PREV VET MED, V181, DOI 10.1016/j.prevetmed.2018.12.006; Tuppurainen ESM, 2017, TRANSBOUND EMERG DIS, V64, P729, DOI 10.1111/tbed.12444; Tuppurainen ESM, 2012, TRANSBOUND EMERG DIS, V59, P40, DOI 10.1111/j.1865-1682.2011.01242.x; Tuppurainen ESM, 2011, TRANSBOUND EMERG DIS, V58, P93, DOI 10.1111/j.1865-1682.2010.01184.x; Tuppurainen ESM, 2014, ANTIVIR RES, V109, P1, DOI 10.1016/j.antiviral.2014.06.009; Vandenbussche F, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.01114-16; WEISS K. E., 1968, Lumpy skin disease virus., P111; YERUHAM I, 1994, VET REC, V135, P330, DOI 10.1136/vr.135.14.330; Zhugunissov K, 2020, VET MICROBIOL, V245, DOI 10.1016/j.vetmic.2020.108695	55	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							621	10.3390/vaccines9060621			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ6OU	34201339	gold, Green Published			2022-04-29	WOS:000666682900001
J	Froneman, C; Kelleher, P; Jose, RJ				Froneman, Claire; Kelleher, Peter; Jose, Ricardo J.			Pneumococcal Vaccination in Immunocompromised Hosts: An Update	VACCINES			English	Review						immunocompromised; respiratory infection; pneumonia; streptococcus pneumoniae; pneumococcus; vaccination; PCV13; PPV23	CONJUGATE VACCINE; POLYSACCHARIDE VACCINATION; STREPTOCOCCUS-PNEUMONIAE; CELL TRANSPLANTATION; ANTIBODY-RESPONSES; PULMONARY-DISEASES; RISK-FACTORS; IMMUNODEFICIENCY; STRATEGIES; INFECTION	Infections with the pathogen, Streptococcus pneumoniae, are a common cause of morbidity and mortality worldwide. It particularly affects those at the extremes of age and immunocompromised individuals. Preventing pneumococcal disease is paramount in at risk individuals, and pneumococcal vaccination should be offered. Here, we discuss the role of pneumococcal vaccination in specific groups of immunocompromised hosts.	[Froneman, Claire; Kelleher, Peter; Jose, Ricardo J.] Royal Brompton Hosp, Dept Resp Med, London SW3 6NP, England; [Kelleher, Peter] Imperial Coll London, Dept Infect Dis, South Kensington Campus, London SW7 2AZ, England; [Jose, Ricardo J.] UCL, Ctr Inflammat & Tissue Repair, London WC1E 6BT, England		Jose, RJ (通讯作者)，Royal Brompton Hosp, Dept Resp Med, London SW3 6NP, England.; Jose, RJ (通讯作者)，UCL, Ctr Inflammat & Tissue Repair, London WC1E 6BT, England.	cfroneman@nhs.net; P.kelleher@rbht.nhs.uk; r.jose@rbht.nhs.uk					ACIP, INT PCV13 PPSV23 VAC; Akamatsu T, 2015, CLIN BIOCHEM, V48, P125, DOI 10.1016/j.clinbiochem.2014.11.005; Alter Miriam J, 2012, Gastroenterol Hepatol (N Y), V8, P120; Andersen MA, 2021, CLIN INFECT DIS, V72, P463, DOI 10.1093/cid/ciaa090; Anderson R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041147; Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9; [Anonymous], 2008, Wkly Epidemiol Rec, V83, P373; [Anonymous], 2014, CLIN INFECT DIS, V58, pE44, DOI DOI 10.1093/cid/cit684; Antin JH, 2005, BIOL BLOOD MARROW TR, V11, P213, DOI 10.1016/j.bbmt.2004.12.330; Berical AC, 2016, ANN AM THORAC SOC, V13, P933, DOI 10.1513/AnnalsATS.201511-778FR; Bingham CO, 2010, ARTHRITIS RHEUM-US, V62, P64, DOI 10.1002/art.25034; Bonilla FA, 2018, J ALLERGY CLIN IMMUN, V141, P474, DOI 10.1016/j.jaci.2017.12.980; Boyd AR, 2011, AGING DIS, V2, P487; Brown AO, 2015, AM J RESP CRIT CARE, V191, P739, DOI 10.1164/rccm.201411-1951PP; Brown AO, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004383; CDC, PNEUM DIS VACC PCV13; Chalmers JD, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0242-0; Chen M, 2007, CLIN VACCINE IMMUNOL, V14, P139, DOI 10.1128/CVI.00336-06; Chilson E, 2020, HUM VACC IMMUNOTHER, V16, P2758, DOI 10.1080/21645515.2020.1735224; Chinen J, 2010, J ALLERGY CLIN IMMUN, V125, pS195, DOI 10.1016/j.jaci.2009.08.040; CKS NICE, SCEN CHILDR 5 YEARS; Cochrane Library, ADJ SYST AS02V ENH H, DOI [10.1002/central/CN-01040122/full, DOI 10.1002/CENTRAL/CN-01040122/FULL]; Cochrane Library, RANDOMIZED CONTROLLE, DOI [10.1002/central/CN-00993521/full, DOI 10.1002/CENTRAL/CN-00993521/FULL]; Dendle C, 2018, VACCINE, V36, P6253, DOI 10.1016/j.vaccine.2018.08.069; Dhingra B, 2020, ECLINICALMEDICINE, V29-30, DOI 10.1016/j.eclinm.2020.100593; Di Sabatino A, 2011, LANCET, V378, P86, DOI 10.1016/S0140-6736(10)61493-6; Dinits-Pensy M, 2005, AM J KIDNEY DIS, V46, P997, DOI 10.1053/j.ajkd.2005.08.032; Dworkin MS, 2001, CLIN INFECT DIS, V32, P794, DOI 10.1086/319218; Elkayaam O, 2007, AUTOIMMUN REV, V6, P312, DOI 10.1016/j.autrev.2006.09.005; Franklin J, 2007, ANN RHEUM DIS, V66, P308, DOI 10.1136/ard.2006.057265; French N, 2010, NEW ENGL J MED, V362, P812, DOI 10.1056/NEJMoa0903029; Garrido HMG, 2020, ECLINICALMEDICINE, V29-30, DOI 10.1016/j.eclinm.2020.100576; Garrido HMG, 2020, CLIN INFECT DIS, V71, P41, DOI 10.1093/cid/ciz728; Goldblatt D, 2005, J INFECT DIS, V192, P387, DOI 10.1086/431524; Gonzalez-Juarbe N, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005337; Goronzy JJ, 2013, NAT IMMUNOL, V14, P428, DOI 10.1038/ni.2588; Grau I, 2014, INT J INFECT DIS, V25, P59, DOI 10.1016/j.ijid.2013.12.013; Gruver AL, 2007, J PATHOL, V211, P144, DOI 10.1002/path.2104; Harris AE, 2015, BONE MARROW TRANSPL, V50, P899, DOI 10.1038/bmt.2015.49; Harris JG, 2015, PEDIATRICS, V136, pE680, DOI 10.1542/peds.2014-2512; Horwitz SM, 2004, BLOOD, V103, P777, DOI 10.1182/blood-2003-04-1257; Ihara H, 2019, VACCINE, V37, P6447, DOI 10.1016/j.vaccine.2019.08.088; Jose RJ, 2017, CURR OPIN PULM MED, V23, P225, DOI 10.1097/MCP.0000000000000369; Jose RJ, 2015, CURR OPIN PULM MED, V21, P212, DOI 10.1097/MCP.0000000000000150; Kapetanovic MC, 2011, ARTHRITIS RHEUM-US, V63, P3723, DOI 10.1002/art.30580; Kausz A, 2004, SEMIN DIALYSIS, V17, P9, DOI 10.1111/j.1525-139X.2004.17104.x; Kumar D, 2007, AM J TRANSPLANT, V7, P1209, DOI 10.1111/j.1600-6143.2006.01705.x; Kuronuma K, 2019, HUM VACC IMMUNOTHER, V15, P859, DOI 10.1080/21645515.2018.1564443; Kyaw MH, 2006, AM J PREV MED, V31, P286, DOI 10.1016/j.amepre.2006.06.007; Lamontagne F, 2008, CAN MED ASSOC J, V179, P773, DOI 10.1503/cmaj.070221; Lazarus R, 2011, CLIN INFECT DIS, V52, P736, DOI 10.1093/cid/cir003; Licciardi PV, 2016, J ALLERGY CLIN IMMUN, V137, P1772, DOI 10.1016/j.jaci.2015.12.1303; Luu S, 2019, INFECT DRUG RESIST, V12, P2839, DOI 10.2147/IDR.S179902; Marra F, 2020, INT J INFECT DIS, V99, P204, DOI 10.1016/j.ijid.2020.07.038; Masomian M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010132; Matanock A, 2019, MMWR-MORBID MORTAL W, V68, P1069, DOI 10.15585/mmwr.mm6846a5; McCashland TM, 2000, J INFECT DIS, V181, P757, DOI 10.1086/315245; Mikulska M, 2019, LANCET INFECT DIS, V19, pE188, DOI 10.1016/S1473-3099(18)30601-7; Nazi I, 2013, BLOOD, V122, P1946, DOI 10.1182/blood-2013-04-494096; Nichol KL, 2007, NEW ENGL J MED, V357, P1373, DOI 10.1056/NEJMoa070844; Orange JS, 2012, J ALLERGY CLIN IMMUN, V130, pS1, DOI 10.1016/j.jaci.2012.07.002; Papadatou I, 2016, CLIN VACCINE IMMUNOL, V23, P388, DOI 10.1128/CVI.00721-15; Pick H, 2020, THORAX, V75, P38, DOI 10.1136/thoraxjnl-2019-213725; Poolman J, 2011, EXPERT REV VACCINES, V10, P307, DOI [10.1586/erv.11.8, 10.1586/ERV.11.8]; Public Health England, 2013, PNEUM GREEN BOOK; Rakoczi Eva, 2017, RMD Open, V3, pe000484, DOI 10.1136/rmdopen-2017-000484; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; Ren S, 2015, OPEN HEART, V2, DOI 10.1136/openhrt-2015-000247; Richi P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030203; Righi E, 2021, INFECT DIS THER, V10, P637, DOI 10.1007/s40121-021-00404-y; Riley TR, 2001, AM FAM PHYSICIAN, V64, P1735; Romero-Steiner S, 2006, CLIN VACCINE IMMUNOL, V13, P165, DOI 10.1128/CVI.13.2.165-169.2006; Schmedt N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220848; ScienceDirect, RISK FACT CARD EV HO; ScienceDirect, BEN CHAR VACC END ST; Shigayeva A, 2016, CLIN INFECT DIS, V62, P139, DOI 10.1093/cid/civ803; Sowden E, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-58; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; van Aalst M, 2018, VACCINE, V36, P5832, DOI 10.1016/j.vaccine.2018.07.039; Williams AE, 2015, AM J PHYSIOL-LUNG C, V308, pL539, DOI 10.1152/ajplung.00141.2014; Wilson R, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006137; Worns MA, 2008, AM J GASTROENTEROL, V103, P138, DOI 10.1111/j.1572-0241.2007.01609.x; Wong A, 2010, EPIDEMIOL INFECT, V138, P1804, DOI 10.1017/S0950268810000919; World Health Organization, PNEUM DIS	84	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							536	10.3390/vaccines9060536			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY9AL	34063785	Green Published, gold			2022-04-29	WOS:000666171700001
J	Hokello, J; Sharma, AL; Tyagi, M				Hokello, Joseph; Sharma, Adhikarimayum Lakhikumar; Tyagi, Mudit			An Update on the HIV DNA Vaccine Strategy	VACCINES			English	Review						lentiviral vectors; DNA vaccines; immunization; HIV; AIDS	IMMUNODEFICIENCY-VIRUS TYPE-1; EFFICIENT GENE-TRANSFER; HIGHLY PATHOGENIC SIV; RESPONSES IN-VITRO; LENTIVIRAL VECTORS; IMMUNE-RESPONSES; DENDRITIC CELLS; T-CELLS; ANTIRETROVIRAL THERAPY; MUCOSAL IMMUNIZATION	In 2020, the global prevalence of human immunodeficiency virus (HIV) infection was estimated to be 38 million, and a total of 690,000 people died from acquired immunodeficiency syndrome (AIDS)-related complications. Notably, around 12.6 million people living with HIIV/AIDS did not have access to life-saving treatment. The advent of the highly active antiretroviral therapy (HAART) in the mid-1990s remarkably enhanced the life expectancy of people living with HIV/AIDS as a result of improved immune functions. However, HAART has several drawbacks, especially when it is not used properly, including a high risk for the development of drug resistance, as well as undesirable side effects such as lipodystrophy and endocrine dysfunctions, which result in HAART intolerability. HAART is also not curative. Furthermore, new HIV infections continue to occur globally at a high rate, with an estimated 1.7 million new infections occurring in 2018 alone. Therefore, there is still an urgent need for an affordable, effective, and readily available preventive vaccine against HIV/AIDS. Despite this urgent need, however, progress toward an effective HIV vaccine has been modest over the last four decades. Reasons for this slow progress are mainly associated with the unique aspects of HIV itself and its ability to rapidly mutate, targeting immune cells and escape host immune responses. Several approaches to an HIV vaccine have been undertaken. However, this review will mainly discuss progress made, including the pre-clinical and clinical trials involving vector-based HIV DNA vaccines and the use of integrating lentiviral vectors in HIV vaccine development. We concluded by recommending particularly the use of integrase-defective lentiviral vectors, owing to their safety profiles, as one of the promising vectors in HIV DNA vaccine strategies both for prophylactic and therapeutic HIV vaccines.	[Hokello, Joseph] Kampala Int Univ, Fac Biomed Sci, Dept Microbiol & Immunol, Western Campus,POB 71, Bushenyi 0256, Uganda; [Sharma, Adhikarimayum Lakhikumar; Tyagi, Mudit] Thomas Jefferson Univ, Ctr Translat Med, 1020 Locust St, Philadelphia, PA 19107 USA		Tyagi, M (通讯作者)，Thomas Jefferson Univ, Ctr Translat Med, 1020 Locust St, Philadelphia, PA 19107 USA.	hokello.joseph@kiu.ac.ug; LakhikumarSharma.Adhikarimayum@jefferson.edu; Mudit.Tyagi@jefferson.edu	Adhikarimayum, Lakhikumar Sharma/AAJ-4302-2020	Adhikarimayum, Lakhikumar Sharma/0000-0002-9969-8642	National Institute on Drug Abuse (NIDA), NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1R01DA041746-01]	This work was supported by a grant from the National Institute on Drug Abuse (NIDA), NIH Grant, 1R01DA041746-01 to M.T. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the U.S. National Institutes of Health.	Achenbach CJ, 2015, LANCET HIV, V2, pE82, DOI 10.1016/S2352-3018(15)00026-0; Ageichik A, 2011, HUM GENE THER, V22, P1249, DOI 10.1089/hum.2010.184; Amirache F, 2014, BLOOD, V123, P1422, DOI 10.1182/blood-2013-11-540641; Anliker B, 2010, NAT METHODS, V7, P929, DOI 10.1038/nmeth.1514; Autran B, 2008, AIDS, V22, P1313, DOI 10.1097/QAD.0b013e3282fdce94; Baekelandt V, 2003, GENE THER, V10, P1933, DOI 10.1038/sj.gt.3302094; Bakari M, 2011, VACCINE, V29, P8417, DOI 10.1016/j.vaccine.2011.08.001; Ban EM, 1997, VACCINE, V15, P811, DOI 10.1016/S0264-410X(96)00263-0; Bartosch B, 2004, CURR GENE THER, V4, P427; Beignon AS, 2009, J VIROL, V83, P10963, DOI 10.1128/JVI.01284-09; Blasi M, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0186-5; Blasi M, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00252-w; Bryson PD, 2013, JOVE-J VIS EXP, DOI 10.3791/50606; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Buffa V, 2006, VIRAL IMMUNOL, V19, P690, DOI 10.1089/vim.2006.19.690; Buffa V, 2006, J GEN VIROL, V87, P1625, DOI 10.1099/vir.0.81706-0; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Chen SC, 1998, J VIROL, V72, P5757, DOI 10.1128/JVI.72.7.5757-5761.1998; Cire S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101644; Cousin C, 2019, CELL REP, V26, P1242, DOI 10.1016/j.celrep.2019.01.025; Daenthanasanmak A, 2012, VACCINE, V30, P5118, DOI 10.1016/j.vaccine.2012.05.063; Dai BB, 2009, P NATL ACAD SCI USA, V106, P20382, DOI 10.1073/pnas.0911742106; Dropulic B, 1996, P NATL ACAD SCI USA, V93, P11103, DOI 10.1073/pnas.93.20.11103; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Esslinger C, 2003, J CLIN INVEST, V111, P1673, DOI 10.1172/JCI200317098; Ferreira V, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00082; Finkelshtein D, 2013, P NATL ACAD SCI USA, V110, P7306, DOI 10.1073/pnas.1214441110; Flatz L, 2012, J VIROL, V86, P7760, DOI 10.1128/JVI.00599-12; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; Fu CM, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040706; Funke S, 2008, MOL THER, V16, P1427, DOI 10.1038/mt.2008.128; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; Gallinaro A, 2020, MOL THER-METH CLIN D, V17, P418, DOI 10.1016/j.omtm.2020.01.013; Gandhi RT, 2009, VACCINE, V27, P6088, DOI 10.1016/j.vaccine.2009.05.016; Goyvaerts C, 2012, GENE THER, V19, P1133, DOI 10.1038/gt.2011.206; Goyvaerts C, 2014, ONCOTARGET, V5, P704, DOI 10.18632/oncotarget.1680; Gray GE, 2011, LANCET INFECT DIS, V11, P507, DOI 10.1016/S1473-3099(11)70098-6; Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927; Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566; Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519; Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003; Hosseinipour MC, 2021, CLIN INFECT DIS, V72, P50, DOI 10.1093/cid/ciz1239; Humbert JM, 2012, J VIROL, V86, P5192, DOI 10.1128/JVI.06283-11; Iglesias MC, 2007, MOL THER, V15, P1203, DOI 10.1038/sj.mt.6300135; Isaguliants MG, 2004, VACCINE, V22, P1576, DOI 10.1016/j.vaccine.2003.09.033; Jin X, 2015, VACCINE, V33, P2347, DOI 10.1016/j.vaccine.2015.03.036; Joachim A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040681; KATSUMI A, 1994, HUM GENE THER, V5, P1335, DOI 10.1089/hum.1994.5.11-1335; Kinloch-de Loes S, 2005, J INFECT DIS, V192, P607, DOI 10.1086/432002; Klavinskis LS, 1997, VACCINE, V15, P818, DOI 10.1016/S0264-410X(96)00278-2; Kuklin N, 1997, J VIROL, V71, P3138, DOI 10.1128/JVI.71.4.3138-3145.1997; Kymalainen H, 2014, HUM GENE THER, V25, P428, DOI 10.1089/hum.2013.172; Lee CL, 2012, BIOTECHNOL BIOENG, V109, P1551, DOI 10.1002/bit.24413; Lemiale F, 2010, VACCINE, V28, P1952, DOI 10.1016/j.vaccine.2009.10.089; Levine BL, 2017, MOL THER-METH CLIN D, V4, P92, DOI 10.1016/j.omtm.2016.12.006; Liu MA, 2003, J INTERN MED, V253, P402, DOI 10.1046/j.1365-2796.2003.01140.x; Livingston JB, 1998, INFECT IMMUN, V66, P322, DOI 10.1128/IAI.66.1.322-329.1998; Merten OW, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.17; Miller EA, 2015, AIDS RES HUM RETROV, V31, P127, DOI [10.1089/aid.2014.0138, 10.1089/AID.2014.0138]; Milone MC, 2009, MOL THER, V17, P1453, DOI 10.1038/mt.2009.83; Msafiri F, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111722; Nakamura-Hoshi M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68267-w; Naldini L, 1998, CURR OPIN BIOTECH, V9, P457, DOI 10.1016/S0958-1669(98)80029-3; Negri D, 2016, MOL THER, V24, P2021, DOI 10.1038/mt.2016.123; Nilsson C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131748; Norton TD, 2015, GENE THER, V22, P227, DOI 10.1038/gt.2014.117; Norton TD, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00243; Pantaleo G, 2019, LANCET HIV, V6, pE737, DOI 10.1016/S2352-3018(19)30262-0; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; ROBINSON HL, 1993, VACCINE, V11, P957, DOI 10.1016/0264-410X(93)90385-B; Sasaki S, 1998, CLIN EXP IMMUNOL, V111, P30; Sasaki S, 1998, J VIROL, V72, P4931, DOI 10.1128/JVI.72.6.4931-4939.1998; Sasaki S, 1998, INFECT IMMUN, V66, P823, DOI 10.1128/IAI.66.2.823-826.1998; Schambach A, 2013, HUM GENE THER, V24, P132, DOI 10.1089/hum.2012.229; Schirmbeck R, 2001, J MOL MED-JMM, V79, P343, DOI 10.1007/s001090100227; Seder RA, 2000, NATURE, V406, P793, DOI 10.1038/35021239; Sekaly RP, 2008, J EXP MED, V205, P7, DOI 10.1084/jem.20072681; Shen XY, 2017, J VIROL, V91, DOI 10.1128/JVI.01077-17; Sirven A, 2001, MOL THER, V3, P438, DOI 10.1006/mthe.2001.0282; Slobod KS, 2004, VACCINE, V22, P3182, DOI 10.1016/j.vaccine.2004.01.053; Smit JM, 1999, J VIROL, V73, P8476, DOI 10.1128/JVI.73.10.8476-8484.1999; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; Stripecke R, 2014, BIOMEDICINES, V2, P229, DOI 10.3390/biomedicines2030229; Symonds GP, 2010, IMMUNOL RES, V48, P84, DOI 10.1007/s12026-010-8169-7; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; Tareen SU, 2014, MOL THER, V22, P575, DOI 10.1038/mt.2013.278; Tebas P, 2013, BLOOD, V121, P1524, DOI 10.1182/blood-2012-07-447250; Tighe H, 1998, IMMUNOL TODAY, V19, P89, DOI 10.1016/S0167-5699(97)01201-2; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Ura T, 2014, VACCINES, V2, P624, DOI 10.3390/vaccines2030624; Vannucci L, 2013, NEW MICROBIOL, V36, P1; Verghese SC, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku082; Viegas EO, 2018, AIDS RES HUM RETROV, V34, P193, DOI [10.1089/aid.2017.0121, 10.1089/AID.2017.0121]; Wang B, 1997, VACCINE, V15, P821; Weiner DB, 1999, SCI AM, V281, P50, DOI 10.1038/scientificamerican0799-50; WILLIAMS RS, 1991, P NATL ACAD SCI USA, V88, P2726, DOI 10.1073/pnas.88.7.2726; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wolstein O, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2013.11; Yang L, 2008, NAT BIOTECHNOL, V26, P326, DOI 10.1038/nbt1390; YANG NS, 1990, P NATL ACAD SCI USA, V87, P9568, DOI 10.1073/pnas.87.24.9568; Zhou S, 2016, MOL THER, V24, P1090, DOI 10.1038/mt.2016.55	102	5	5	5	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							605	10.3390/vaccines9060605			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TA1RP	34198789	gold, Green Published			2022-04-29	WOS:000667031800001
J	Jakuszko, K; Koscielska-Kasprzak, K; Zabinska, M; Bartoszek, D; Poznanski, P; Rukasz, D; Klak, R; Krolak-Olejnik, B; Krajewska, M				Jakuszko, Katarzyna; Koscielska-Kasprzak, Katarzyna; Zabinska, Marcelina; Bartoszek, Dorota; Poznanski, Pawel; Rukasz, Dagna; Klak, Renata; Krolak-Olejnik, Barbara; Krajewska, Magdalena			Immune Response to Vaccination against COVID-19 in Breastfeeding Health Workers	VACCINES			English	Article						breast milk; breastfeeding; anti-SARS-CoV-2 antibodies; lactation; COVID-19; vaccination; mRNA vaccine		Background: Initially, there were no data on the safety of COVID-19 vaccines in lactating women. The aim of our study was to evaluate the immune response to COVID-19 vaccinations in breastfeeding women. Methods: The study included 32 breastfeeding women who, regardless of the study, had decided to be vaccinated. Maternal serum and breast milk samples were simultaneously collected on days 8 +/- 1, 22 +/- 2, 29 +/- 3, and 43 +/- 4 after the first dose of the vaccine. The immune response was assessed by determining the presence of anti-SARS-CoV-2 IgG and IgA. Results: The breast milk IgG level was detectable (6.50 +/- 6.74, median 4.7, and maximum 34.2 BAU/mL) and highly correlated to serum IgG level (r(S) 0.89; p < 0.001). The breast milk ratio of IgA to the cut-off value was higher in serum IgA-positive (4.18 +/- 3.26, median 2.8, and maximum >10) than in serum IgA-negative women (0.56 +/- 0.37, median 0.5, and maximum 1.6; p < 0.001). The highest concentrations of serum and breast milk antibodies were observed on day 29 +/- 3 with a decrease on day 43 +/- 4. Conclusion: The immune response to the vaccination against SARS-CoV-2 is strongest 7 +/- 3 days after the second dose of the vaccine. Lactating mothers breastfeeding their children after vaccination against SARS-CoV-2 may transfer antibodies to their infant.	[Jakuszko, Katarzyna; Koscielska-Kasprzak, Katarzyna; Zabinska, Marcelina; Bartoszek, Dorota; Poznanski, Pawel; Rukasz, Dagna; Klak, Renata; Krajewska, Magdalena] Wroclaw Med Univ, Dept Nephrol & Transplantat Med, PL-50367 Wroclaw, Poland; [Krolak-Olejnik, Barbara] Wroclaw Med Univ, Dept Neonatol, PL-50367 Wroclaw, Poland		Poznanski, P (通讯作者)，Wroclaw Med Univ, Dept Nephrol & Transplantat Med, PL-50367 Wroclaw, Poland.	katarzyna.jakuszko@umed.wroc.pl; katarzyna.koscielska-kasprzak@umed.wroc.pl; marcelina.zabinska@umed.wroc.pl; dorota.bartoszek@umed.wroc.pl; pawel.poznanski@umed.wroc.pl; dagna.rukasz@umed.wroc.pl; renataklak@wp.pl; barbara.krolak-olejnik@umed.wroc.pl; magdalena.krajewska@umed.wroc.pl	Poznański, Paweł/ABA-4175-2021; Poznański, Paweł/AHA-2971-2022	Poznański, Paweł/0000-0003-1235-3551; Bartoszek, Dorota/0000-0001-7720-7163; Koscielska-Kasprzak, Katarzyna/0000-0002-3216-438X; Zabinska, Marcelina/0000-0003-1810-3131; Jakuszko, Katarzyna/0000-0002-1693-5201; Krajewska, Magdalena/0000-0002-2632-2409; Krolak-Olejnik, Barbara/0000-0002-6493-0333	Ministry of Science and Higher Education for maintenance and development of the research capacity of Wroclaw Medical University	The study was financially supported by a subsidy from the Ministry of Science and Higher Education for maintenance and development of the research capacity of Wroclaw Medical University.	Brady RC, 2018, VACCINE, V36, P4663, DOI 10.1016/j.vaccine.2018.06.036; Conover WJ., 1999, PRACTICAL NONPARAMET, V3; Czosnykowska-Lukacka M, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00428; De Schutter S, 2015, PEDIATR INFECT DIS J, V34, pE149, DOI 10.1097/INF.0000000000000675; Demers-Mathieu V, 2021, BREASTFEED MED, V16, P393, DOI 10.1089/bfm.2020.0381; Demers-Mathieu V, 2021, J PERINATOL, V41, P952, DOI 10.1038/s41372-021-01001-0; Demers-Mathieu V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041749; Gray KJ, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.03.023; Halperin BA, 2011, CLIN INFECT DIS, V53, P885, DOI 10.1093/cid/cir538; Hanson Lars A., 1994, Acta Paediatrica Japonica, V36, P557; Mazur NI, 2019, J INFECT DIS, V219, P59, DOI 10.1093/infdis/jiy477; Oddy WH, 2004, J ASTHMA, V41, P605, DOI 10.1081/JAS-200026402; Oliver SE, 2021, MMWR-MORBID MORTAL W, V70, P329, DOI 10.15585/mmwr.mm7009e4; Pace RM, 2021, MBIO, V12, DOI 10.1128/mBio.03192-20; Pandolfi E, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00152; Perl SH, 2021, JAMA-J AM MED ASSOC, V325, P2013, DOI 10.1001/jama.2021.5782; Rasmussen SA, 2021, OBSTET GYNECOL, V137, P408, DOI 10.1097/AOG.0000000000004290; Vassilopoulou E, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.661806	18	11	11	5	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							663	10.3390/vaccines9060663			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ4KI	34204501	Green Published, gold			2022-04-29	WOS:000666535600001
J	Lorent, D; Nowak, R; Roxo, C; Lenartowicz, E; Makarewicz, A; Zaremba, B; Nowak, S; Kuszel, L; Stefaniak, J; Kierzek, R; Zmora, P				Lorent, Dagny; Nowak, Rafal; Roxo, Carolina; Lenartowicz, Elzbieta; Makarewicz, Aleksandra; Zaremba, Bartosz; Nowak, Szymon; Kuszel, Lukasz; Stefaniak, Jerzy; Kierzek, Ryszard; Zmora, Pawel			Prevalence of Anti-SARS-CoV-2 Antibodies in Poznan, Poland, after the First Wave of the COVID-19 Pandemic	VACCINES			English	Article						SARS-CoV-2; seroprevalence; antibodies; COVID-19; pandemic; Poland	INFECTION	In comparison to other European countries, during the first months of the COVID-19 pandemic, Poland reported a relatively low number of confirmed cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. To estimate the scale of the pandemic in Poland, a serosurvey of antibodies against SARS-CoV-2 was performed after the first wave of COVID-19 in Europe (March-May 2020). Within this study, we collected samples from 28 July to 24 September 2020 and, based on the ELISA results, we found that 1.67% (25/1500, 95% CI 1.13-2.45) of the Poznan (Poland) metropolitan area's population had antibodies against SARS-CoV-2 after the first wave of COVID-19. However, the presence of anti-SARS-CoV-2 IgG antibodies was confirmed with immunoblotting in 56% (14/25) samples, which finally resulted in a decrease in seroprevalence, i.e., 0.93% (14/1500, 95% CI 0.56-1.56). The positive anti-SARS-CoV-2 IgG results were associated with age, occupation involving constant contact with people, travelling abroad, non-compliance with epidemiological recommendations and direct contact with the novel coronavirus. Our findings confirm the low SARS-CoV-2 incidence in Poland and imply that the population had little herd immunity heading into the second and third wave of the pandemic, and therefore, that herd immunity contributed little to preventing the high numbers of SARS-CoV-2 infections and COVID-19-related deaths in Poland during these subsequent waves.	[Lorent, Dagny; Nowak, Rafal; Roxo, Carolina; Lenartowicz, Elzbieta; Makarewicz, Aleksandra; Zaremba, Bartosz; Kierzek, Ryszard; Zmora, Pawel] Polish Acad Sci, Inst Bioorgan Chem, PL-61704 Poznan, Poland; [Nowak, Szymon; Stefaniak, Jerzy] Poznan Univ Med Sci, Dept & Clin Trop & Parasit Dis, PL-60355 Poznan, Poland; [Kuszel, Lukasz] Poznan Univ Med Sci, Dept Med Genet, PL-60355 Poznan, Poland		Zmora, P (通讯作者)，Polish Acad Sci, Inst Bioorgan Chem, PL-61704 Poznan, Poland.	dlorent@ibch.poznan.pl; rnowak@ibch.poznan.pl; croxo@ibch.poznan.pl; elenartowicz@ibch.poznan.pl; a.u.makarewicz@gmail.com; bartosz1419@gmail.com; snowak@ump.edu.pl; kuszel@ump.edu.pl; tropiki@spsk2.pl; rkierzek@ibch.poznan.pl; pzmora@ibch.poznan.pl	Nowak, Szymon/AGR-9894-2022; Nowak, Szymon Paweł/AGS-2179-2022; Lenartowicz, Elzbieta/G-3757-2016	Nowak, Szymon/0000-0001-9404-5100; Nowak, Szymon Paweł/0000-0001-9404-5100; Kuszel, Lukasz/0000-0002-7783-6370; Lenartowicz, Elzbieta/0000-0002-3596-4470; Lorent, Dagny/0000-0001-8276-3746; Roxo, Carolina/0000-0001-6563-4192; Zmora, Pawel/0000-0002-2012-7223; Makarewicz, Aleksandra/0000-0001-9310-9643	National Science Centre (Poland)National Science Centre, Poland [UMO-2020/01/0/NZ6/00152]	This research was funded by National Science Centre (Poland), grant number UMO-2020/01/0/NZ6/00152.	Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; [Anonymous], Coronavirus pandemic data portal; [Anonymous], POLISH TOURISM ORG; [Anonymous], COVID 19 PUBLIC MONI; [Anonymous], POLISH MINISTRY HLTH; [Anonymous], European Centre for Disease Prevention and Control COVID-19 Situation Dashboard; Baj J, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061753; Bar-On YM, 2020, ELIFE, V9, DOI 10.7554/eLife.57309; Beavis KG, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104468; Boger B, 2021, AM J INFECT CONTROL, V49, P21, DOI 10.1016/j.ajic.2020.07.011; Booth A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247461; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Drame M, 2020, J MED VIROL, V92, P2312, DOI 10.1002/jmv.25996; Eberhardt KA, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9040733; Gabutti G, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18062942; Holdcroft A, 2007, J ROY SOC MED, V100, P2, DOI 10.1258/jrsm.100.1.2; Kubina R, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10060434; Nikolai LA, 2020, INT J INFECT DIS, V100, P112, DOI 10.1016/j.ijid.2020.08.076; Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020; Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012; Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623; Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5; Pollock AM, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4851; Poustchi Hossein, 2021, Lancet Infect Dis, V21, P473, DOI 10.1016/S1473-3099(20)30858-6; Qiu XT, 2021, CLIN MICROBIOL INFEC, V27, P511, DOI 10.1016/j.cmi.2021.01.011; McQuade ETR, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.35234; Stringhini S, 2020, LANCET, V396, P313, DOI 10.1016/S0140-6736(20)31304-0; Vaportzis E, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.01687; World Health Organization, WORLD HLTH ORG	29	5	5	3	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							541	10.3390/vaccines9060541			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ3GM	34064028	Green Published, Green Submitted, gold			2022-04-29	WOS:000666458000001
J	Tavolacci, MP; Dechelotte, P; Ladner, J				Tavolacci, Marie Pierre; Dechelotte, Pierre; Ladner, Joel			COVID-19 Vaccine Acceptance, Hesitancy, and Resistancy among University Students in France	VACCINES			English	Article						COVID-19; vaccine hesistancy; vaccine resistancy; vaccine acceptance; university student	DETERMINANTS	The objectives were to explore, among university students, the level of COVID-19 vaccine acceptance, hesitancy, and resistancy and to determine the motivations and barriers, and the reasons that may change student vaccination decision making. An online observational cross-sectional study was conducted among students of a French university in January 2021 with questions about the intention to be vaccinated against COVID-19, the motivations and the barriers. The convenience sample included 3089 students, with a mean of age of 20.3 (SD = 1.9). To the question on the intention to vaccinate against the COVID-19, 58.0% of students reported that they would choose to have a vaccination, 17.0% reported that they would not and 25.0% were not sure. The main motivations for vaccine acceptance were "I don ' t want to transmit COVID-19 to others", the main barriers for vaccine resistance or hesitancy were "I prefer to wait until I have more experience with these new vaccines". Age, female gender, being in first three years of study, studied sciences courses and neither sciences nor healthcare courses of study were significantly associated with a higher risk of vaccine hesitancy or resistancy. Self-estimated knowledge of conventional vaccines and COVID-19 vaccines, and confidence in efficiency and safety of conventional vaccination were associated with a lower risk of vaccine hesitancy or resistancy. It is relevant to disseminate evidence-based interventions to promote COVID-19 vaccine acceptability for college students, especially for the students in neither sciences nor healthcare courses of study, as college students will soon be eligible to receive a COVID-19 vaccine.	[Tavolacci, Marie Pierre] Normandie Univ, Clin Invest Ctr, CHU Rouen, U1073, F-76000 Rouen, France; [Dechelotte, Pierre] Normandie Univ, Dept Nutr, CHU Rouen, U1073, F-76000 Rouen, France; [Ladner, Joel] Normandie Univ, Dept Epidemiol & Hlth Promot, CHU Rouen, U1073, F-76000 Rouen, France		Tavolacci, MP (通讯作者)，Normandie Univ, Clin Invest Ctr, CHU Rouen, U1073, F-76000 Rouen, France.	mp.tavolacci@chu-rouen.fr; Pierre.Dechelotte@chu-rouen.fr; joel.ladner@chu-rouen.fr	; Tavolacci, Marie-Pierre/O-8167-2018	DECHELOTTE, Pierre/0000-0001-5224-6166; Tavolacci, Marie-Pierre/0000-0003-3980-819X			Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Chou R, 2020, ANN INTERN MED, V173, P120, DOI 10.7326/M20-1632; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Edwards B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248892; European Medicines Agency, COVID 19 VACC; Figliozzi S, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13362; French J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165893; Germani F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247642; Grech Victor, 2020, Early Hum Dev, P105258, DOI 10.1016/j.earlhumdev.2020.105258; Guilamo-Ramos V, 2021, CLIN INFECT DIS, V73, pS146, DOI 10.1093/cid/ciaa1348; Han DS, 2020, INT J BIOL SCI, V16, P2803, DOI 10.7150/ijbs.48991; Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3; Johnson DK, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020039; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Karlsson LC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224330; Kerneis S, 2017, AM J PREV MED, V53, pE97, DOI 10.1016/j.amepre.2017.01.014; Kreps S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00335-2; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Latkin CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246970; Lepiller Q, 2020, VACCINE, V38, P6794, DOI 10.1016/j.vaccine.2020.08.036; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Lu H, 2021, COMPUT METHOD BIOMEC, V24, P1136, DOI 10.1080/10255842.2020.1869221; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malfait, 2013, EUR J PUBLIC HEALTH, V3, P512; Marco-Franco JE, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020744; Montagni I, 2021, J PUBLIC HEALTH-UK, V43, P695, DOI 10.1093/pubmed/fdab028; Montagni I, 2020, JMIR SERIOUS GAMES, V8, DOI 10.2196/16983; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Rodas JR, 2012, PUBLIC HEALTH, V126, P1007, DOI 10.1016/j.puhe.2012.09.011; Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Smith N, 2019, INFORM COMMUN SOC, V22, P1310, DOI 10.1080/1369118X.2017.1418406; Suresh PS, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-205; Van Bavel JJ, 2020, NAT HUM BEHAV, V4, P460, DOI 10.1038/s41562-020-0884-z; Verger P, 2015, EBIOMEDICINE, V2, P891, DOI 10.1016/j.ebiom.2015.06.018; Viswanath K, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10862-1; Vulpe SN, 2021, VACCINE, V39, P1508, DOI 10.1016/j.vaccine.2021.01.063; WHO, WHO COVID 19 DASHB; World Health Organization, 2020, BEH CONS ACC UPT COV; Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021	47	20	20	12	21	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							654	10.3390/vaccines9060654			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ6KQ	34203847	gold, Green Published			2022-04-29	WOS:000666672100001
J	Baldo, A; Leunda, A; Willemarck, N; Pauwels, K				Baldo, Aline; Leunda, Amaya; Willemarck, Nicolas; Pauwels, Katia			Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2	VACCINES			English	Review						SARS-CoV-2; COVID-19; recombinant viral vector vaccines; environmental risk assessment; vaccination; biosafety	VESICULAR STOMATITIS-VIRUS; T-CELL RESPONSES; MEASLES-VIRUS; IMMUNE-RESPONSES; GENE-THERAPY; ADENOVIRUS VECTORS; CHROMOSOMAL INTEGRATION; NEUTRALIZING ANTIBODY; CLINICAL DEVELOPMENT; INFLUENZA VACCINE	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. Over the past months, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Various platforms are being used for the development of COVID-19 vaccine candidates: recombinant viral vectors, protein-based vaccines, nucleic acid-based vaccines, and inactivated/attenuated virus. Recombinant viral vector vaccine candidates represent a significant part of those vaccine candidates in clinical development, with two already authorised for use in the European Union and one currently under rolling review by the European Medicines Agency (EMA). Since recombinant viral vector vaccine candidates are considered as genetically modified organisms (GMOs), their regulatory oversight includes besides an assessment of their quality, safety and efficacy, also an environmental risk assessment (ERA). The present article highlights the main characteristics of recombinant viral vector vaccine (candidates) against SARS-CoV-2 in the pipeline and discusses their features from an environmental risk point of view.	[Baldo, Aline; Leunda, Amaya; Willemarck, Nicolas; Pauwels, Katia] Sciensano, Serv Biosafety & Biotechnol, Rue Juliette Wytsmanstr 14, B-1050 Brussels, Belgium		Baldo, A (通讯作者)，Sciensano, Serv Biosafety & Biotechnol, Rue Juliette Wytsmanstr 14, B-1050 Brussels, Belgium.	Aline.Baldo@sciensano.be; Amaya.LeundaCasi@sciensano.be; Nicolas.Willemarck@sciensano.be; Katia.Pauwels@sciensano.be		Baldo, Aline/0000-0002-4578-9557	Brussels-Capital Region (IBGE-BIM); Flemish Region (LNE); Wallonia (DGARNE)	This work received support from the Brussels-Capital Region (IBGE-BIM), the Flemish Region (LNE), and Wallonia (DGARNE).	[Anonymous], 2002, OFF J, VL200; [Anonymous], UW MADISON FLUGEN BH; [Anonymous], Merck Stops Developing both of Its COVID-19 Vaccine Candidates; [Anonymous], COVID 19 VACCINE TRA; [Anonymous], 2001, OFF J, VL121, P34; [Anonymous], WHO Coronavirus Disease (COVID-19): Vaccines.; [Anonymous], 2004, OFF J, VL136, P1; [Anonymous], 2020, **NON-TRADITIONAL**, VL 231; Atkinson W., 2009, EPIDEMIOLOGY PREVENT; Awad SS, 2014, CLIN INFECT DIS, V59, P51, DOI 10.1093/cid/ciu219; Baldo A, 2016, HUM VACC IMMUNOTHER, V12, P1102, DOI 10.1080/21645515.2015.1122146; Baldo A, 2013, CURR GENE THER, V13, P385; Bellini WJ, 1998, EMERG INFECT DIS, V4, P29, DOI 10.3201/eid0401.980105; Bergmans Hans, 2008, Environmental Biosafety Research, V7, P1, DOI 10.1051/ebr:2008001; Bergren NA, 2018, HUM VACC IMMUNOTHER, V14, P994, DOI 10.1080/21645515.2017.1412898; Billeter MA, 2009, CURR TOP MICROBIOL, V329, P129; Bodmer BS, 2018, VIROLOGY, V521, P99, DOI 10.1016/j.virol.2018.05.028; Brandon E.F.A., 2008, EFFECT ADM ROUTE BIO; Brown KS, 2011, J VIROL, V85, P12781, DOI 10.1128/JVI.00794-11; Capone S, 2020, BIORXIV, DOI 10.1101/2020.10.22.349951; Case JB, 2020, CELL HOST MICROBE, V28, P475, DOI 10.1016/j.chom.2020.06.021; Case JB, 2020, CELL HOST MICROBE, V28, P465, DOI 10.1016/j.chom.2020.07.018; CDC, SARS COV 2 VAR CLASS; Chinese Clinical Trial Registry (ChiCTR), PHAS 1 CLIN TRIAL IN; Chinese Clinical Trial Registry (ChiCTR), PHAS 2 CLIN TRIAL IN; Chiuppesi F, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19819-1; Clarke DK, 2016, VACCINE, V34, P6597, DOI 10.1016/j.vaccine.2016.06.071; Coller BAG, 2017, VACCINE, V35, P4465, DOI 10.1016/j.vaccine.2017.05.097; Combredet C, 2003, J VIROL, V77, P11546, DOI 10.1128/JVI.77.21.11546-11554.2003; Committee for the Medicinal Product for Human Use (CHMP), 2008, GUID SCI REQ ENV RIS; Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385; Drumond BP, 2008, MICROBES INFECT, V10, P185, DOI 10.1016/j.micinf.2007.11.005; Dutta NK, 2020, J VIROL, V94, DOI 10.1128/JVI.00647-20; Elizabeth G., 2020, COMPLETE PROTECTION, DOI [10.1101/2020.12.08.416297, DOI 10.1101/2020.12.08.416297]; Escriou N, 2014, VIROLOGY, V452, P32, DOI 10.1016/j.virol.2014.01.002; EU Clinical Trial Register, REG PHAS 2A RAND DOU; European Commission Regulation, 2001, OFF J EUR UNION L, P1; European Medicines Agency, 2019, ASS REP EV COMM NAM; Fallaux FJ, 1998, HUM GENE THER, V9, P1909, DOI 10.1089/hum.1998.9.13-1909; Fathi A, 2019, HUM VACC IMMUNOTHER, V15, P2269, DOI 10.1080/21645515.2019.1649532; Forster R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01959; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Frantz PN, 2018, MICROBES INFECT, V20, P493, DOI 10.1016/j.micinf.2018.01.005; Furuyama W, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-019-0155-z; Garbutt M, 2004, J VIROL, V78, P5458, DOI 10.1128/JVI.78.10.5458-5465.2004; Geisbert TW, 2011, J INFECT DIS, V204, pS1075, DOI 10.1093/infdis/jir349; Geisbert TW, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000225; Geisbert TW, 2005, PLOS MED, V2, P537, DOI 10.1371/journal.pmed.0020183; Gilbert SC, 2013, VACCINE, V31, P4241, DOI 10.1016/j.vaccine.2013.03.020; Gimenez-Roig J, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.633946; Goossens M, 2013, CURR GENE THER, V13, P413; Government of Canada, PATH SAF DAT SHEETS; Griffin DE, 2009, CURR TOP MICROBIOL, V330, P191; Hansen H, 2004, VACCINE, V23, P499, DOI 10.1016/j.vaccine.2004.06.032; Harui A, 1999, J VIROL, V73, P6141, DOI 10.1128/JVI.73.7.6141-6146.1999; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Holmes E, 2003, J GEN VIROL, V84, P2691, DOI 10.1099/vir.0.19277-0; Hulswit RJG, 2016, ADV VIRUS RES, V96, P29, DOI 10.1016/bs.aivir.2016.08.004; Im Eung-Jun, 2004, Expert Rev Vaccines, V3, pS89, DOI 10.1586/14760584.3.4.S89; Jones SM, 2005, NAT MED, V11, P786, DOI 10.1038/nm1258; Knuchel MC, 2013, HUM VACC IMMUNOTHER, V9, P599, DOI 10.4161/hv.23241; Koch T, 2020, LANCET INFECT DIS, V20, P827, DOI 10.1016/S1473-3099(20)30248-6; Langenmayer MC, 2018, BIOLOGICALS, V54, P58, DOI 10.1016/j.biologicals.2018.05.004; Letchworth GJ, 1999, VET J, V157, P239, DOI 10.1053/tvjl.1998.0303; Lichtenstein DL, 2004, CANCER GENE THER, V11, P819, DOI 10.1038/sj.cgt.7700765; Liniger M, 2008, VACCINE, V26, P2164, DOI 10.1016/j.vaccine.2008.01.057; Linkov I, 2009, SCI TOTAL ENVIRON, V407, P5199, DOI 10.1016/j.scitotenv.2009.05.004; Liu RQ, 2018, ANTIVIR RES, V150, P30, DOI 10.1016/j.antiviral.2017.12.007; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Lyles D.S., 2007, RHABDOVIRIDAE FIELDS, P1364; Malczyk AH, 2015, J VIROL, V89, P11654, DOI 10.1128/JVI.01815-15; Mauro VP, 2014, TRENDS MOL MED, V20, P604, DOI 10.1016/j.molmed.2014.09.003; McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991; McWilliams IL, 2019, CELL REP, V26, P1718, DOI 10.1016/j.celrep.2019.01.069; MEYER H, 1991, J GEN VIROL, V72, P1031, DOI 10.1099/0022-1317-72-5-1031; Monath TP, 2019, VACCINE-X, V1, DOI 10.1016/j.jvacx.2019.100009; Moss WJ, 2009, CURR TOP MICROBIOL, V330, P173; Moss WJ, 2006, NAT REV MICROBIOL, V4, P900, DOI 10.1038/nrmicro1550; Msaouel P, 2013, EXPERT OPIN BIOL TH, V13, P483, DOI 10.1517/14712598.2013.749851; Perry RT, 2004, J INFECT DIS, V189, pS4, DOI 10.1086/377712; Peters AHFM, 2001, MOL THER, V4, P603, DOI 10.1006/mthe.2001.0500; Pharmaceutical Technology, VAX OR VACC CAND TRI; Rager-Zisman B, 2003, VACCINE, V21, P2580, DOI 10.1016/S0264-410X(03)00053-7; Ramsauer K, 2015, LANCET INFECT DIS, V15, P519, DOI 10.1016/S1473-3099(15)70043-5; Reisinger EC, 2018, LANCET, V392, P2718, DOI 10.1016/S0140-6736(18)32488-7; Rodriguez LL, 2002, VIRUS RES, V85, P211, DOI 10.1016/S0168-1702(02)00026-6; Rozo-Lopez P, 2018, INSECTS, V9, DOI 10.3390/insects9040190; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sarawar S, 2016, VACCINE, V34, P5090, DOI 10.1016/j.vaccine.2016.08.061; Schenk-Braat EAM, 2007, J GENE MED, V9, P910, DOI 10.1002/jgm.1096; Schramm B, 2005, TRAFFIC, V6, P839, DOI 10.1111/j.1600-0854.2005.00324.x; Singh S, 2020, ARCH PHYSIOL BIOCHEM, V126, P348, DOI 10.1080/13813455.2018.1538249; Stephen SL, 2010, J VIROL, V84, P9987, DOI 10.1128/JVI.00751-10; Tanaka S., 2020, BIORXIV, DOI [10.1101/2020.07.29.227595, DOI 10.1101/2020.07.29.227595]; Tell JG, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040779; Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002; Tscherne A, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026207118; U.S. National Institutes of Health ClinicalTrials.gov Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine (COVID-19-101), ClinicalTrials.gov Identifier: NCT04497298; Verheust C, 2012, VACCINE, V30, P2623, DOI 10.1016/j.vaccine.2012.02.016; Volz A, 2017, ADV VIRUS RES, V97, P187, DOI 10.1016/bs.aivir.2016.07.001; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang P, 2019, MBIO, V10, DOI 10.1128/mBio.02180-19; Watanabe S, 2009, J VIROL, V83, P5947, DOI 10.1128/JVI.00450-09; Wohigemuth N, 2017, VACCINE, V35, P6691, DOI 10.1016/j.vaccine.2017.10.018; Wold WSM, 2013, CURR GENE THER, V13, P421; Wong-Chew RM, 2003, J MED VIROL, V70, P276, DOI 10.1002/jmv.10390; World Organisation for Animal Health (OIE), AN HLTH WORLD OV; Youil R, 2002, HUM GENE THER, V13, P311, DOI 10.1089/10430340252769824; Zahn R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044115; Zhang K, 2018, P NATL ACAD SCI USA, V115, pE12218, DOI 10.1073/pnas.1818012115; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3; Zimmer B, 2013, VET MICROBIOL, V162, P78, DOI 10.1016/j.vetmic.2012.08.023	113	3	3	6	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							453	10.3390/vaccines9050453			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1WD	34063733	Green Published, gold			2022-04-29	WOS:000654615400001
J	Fiste, O; Ntanasis-Stathopoulos, I; Gavriatopoulou, M; Liontos, M; Koutsoukos, K; Dimopoulos, MA; Zagouri, F				Fiste, Oraianthi; Ntanasis-Stathopoulos, Ioannis; Gavriatopoulou, Maria; Liontos, Michalis; Koutsoukos, Konstantinos; Dimopoulos, Meletios Athanasios; Zagouri, Flora			The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma	VACCINES			English	Review						intrahepatic cholangiocarcinoma; biliary tract cancer; immunotherapy; tumor microenvironment	BILIARY-TRACT CANCER; TUMOR-INFILTRATING LYMPHOCYTES; NATURAL-KILLER-CELLS; NEUTROPHIL-TO-LYMPHOCYTE; BILE-DUCT CANCER; PHASE-II TRIAL; IMMUNE-CHECKPOINT; DENDRITIC CELLS; METASTATIC CHOLANGIOCARCINOMA; PROGNOSTIC-SIGNIFICANCE	Biliary tract cancer, and intrahepatic cholangiocarcinoma (iCC) in particular, represents a rather uncommon, highly aggressive malignancy with unfavorable prognosis. Therapeutic options remain scarce, with platinum-based chemotherapy is being considered as the gold standard for the management of advanced disease. Comprehensive molecular profiling of tumor tissue biopsies, utilizing multi-omics approaches, enabled the identification of iCC's intratumor heterogeneity and paved the way for the introduction of novel targeted therapies under the scope of precision medicine. Yet, the unmet need for optimal care of patients with chemo-refractory disease or without targetable mutations still exists. Immunotherapy has provided a paradigm shift in cancer care over the past decade. Currently, immunotherapeutic strategies for the management of iCC are under intense research. Intrinsic factors of the tumor, including programmed death-ligand 1 (PD-L1) expression and mismatch repair (MMR) status, are simply the tip of the proverbial iceberg with regard to resistance to immunotherapy. Acknowledging the significance of the tumor microenvironment (TME) in both cancer growth and drug response, we broadly discuss about its diverse immune components. We further review the emerging role of immunotherapy in this rare disease, summarizing the results of completed and ongoing phase I-III clinical trials, expounding current challenges and future directions.	[Fiste, Oraianthi; Ntanasis-Stathopoulos, Ioannis; Gavriatopoulou, Maria; Liontos, Michalis; Koutsoukos, Konstantinos; Dimopoulos, Meletios Athanasios; Zagouri, Flora] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Sch Med, Alexandra Hosp, 80 Vasilissis Sophias, Athens 11528, Greece		Fiste, O (通讯作者)，Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Sch Med, Alexandra Hosp, 80 Vasilissis Sophias, Athens 11528, Greece.	ofiste@med.uoa.gr; johnntanasis@med.uoa.gr; mariagabria@gmail.com; mliontos@gmail.com; koutsoukos.k@gmail.com; mdimop@med.uoa.gr; florazagouri@yahoo.co.uk		Dimopoulos, Meletios/0000-0001-8990-3254; Fiste, Oraianthi/0000-0002-7106-4162; Liontos, Michalis/0000-0001-7192-4575; Ntanasis-Stathopoulos, Ioannis/0000-0002-6328-9783			Abou-Alfa GK, 2020, LANCET ONCOL, V21, P671, DOI 10.1016/S1470-2045(20)30109-1; Acerbi I, 2015, INTEGR BIOL-UK, V7, P1120, DOI 10.1039/c5ib00040h; Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; [Anonymous], 2018, NOBEL PRIZE PHYSL ME; Atanasov G, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1331806; Banales JM, 2020, NAT REV GASTRO HEPAT, V17, P557, DOI 10.1038/s41575-020-0310-z; Bang YJ, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4079; Bjorkstrom NK, 2016, NAT REV IMMUNOL, V16, P310, DOI 10.1038/nri.2016.34; Boulter L, 2015, J CLIN INVEST, V125, P1269, DOI 10.1172/JCI76452; Braicu C, 2015, CELL DEATH DIFFER, V22, P34, DOI 10.1038/cdd.2014.130; Brivio S, 2017, WORLD J HEPATOL, V9, P455, DOI 10.4254/wjh.v9.i9.455; Buettner S, 2018, SURGERY, V164, P411, DOI 10.1016/j.surg.2018.05.002; Cadamuro M, 2018, BBA-MOL BASIS DIS, V1864, P1435, DOI 10.1016/j.bbadis.2017.07.028; Cadamuro M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010149; Caligiuri A, 2020, CANCERS, V12, DOI 10.3390/cancers12082215; Cameron F, 2011, DRUGS, V71, P1093, DOI 10.2165/11594010-000000000-00000; Chabanon RM, 2019, J CLIN INVEST, V129, P1211, DOI 10.1172/JCI123319; Chae YK, 2019, CLIN LUNG CANCER, V20, P88, DOI 10.1016/j.cllc.2018.09.008; Chen WX, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017832; Cheng JT, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.7; Chu AS, 2011, HEPATOLOGY, V53, P1685, DOI 10.1002/hep.24206; Chuaysri C, 2009, ONCOL REP, V21, P957, DOI 10.3892/or_00000309; Chung JW, 2008, STEM CELLS, V26, P2114, DOI 10.1634/stemcells.2008-0370; Clements O, 2020, J HEPATOL, V72, P95, DOI 10.1016/j.jhep.2019.09.007; Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448; Dudley ME, 2010, CLIN CANCER RES, V16, P6122, DOI 10.1158/1078-0432.CCR-10-1297; Dunne RF, 2016, J CLIN ONCOL, V34, DOI 10.1200/jco.2016.34.4_suppl.273; Dussault, 2018, ANN ONCOL, V29, DOI DOI 10.1093/ANNONC/MDY282.140; Fabris L, 2019, LIVER INT, V39, P63, DOI 10.1111/liv.14098; Farshidfar F, 2017, CELL REP, V18, P2780, DOI 10.1016/j.celrep.2017.02.033; Feng KC, 2018, PROTEIN CELL, V9, P838, DOI 10.1007/s13238-017-0440-4; Fontugne J, 2017, ONCOTARGET, V8, P24644, DOI 10.18632/oncotarget.15602; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Fukuda Y, 2020, CANCER SCI, V111, P323, DOI 10.1111/cas.14267; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Gani F, 2016, ANN SURG ONCOL, V23, P2610, DOI 10.1245/s10434-016-5101-y; Garrido F, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5010007; Gentilini A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102885; Ghidini M, 2017, EUR J CANCER, V86, P158, DOI 10.1016/j.ejca.2017.09.005; Goeppert B, 2013, BRIT J CANCER, V109, P2665, DOI 10.1038/bjc.2013.610; Goeppert B, 2015, BRIT J CANCER, V113, P1343, DOI 10.1038/bjc.2015.337; Gu FM, 2012, ANN SURG ONCOL, V19, P2506, DOI 10.1245/s10434-012-2268-8; Guillerey C, 2016, NAT IMMUNOL, V17, P1025, DOI 10.1038/ni.3518; Hasita H, 2010, CANCER SCI, V101, P1913, DOI 10.1111/j.1349-7006.2010.01614.x; Hellmann MD, 2016, ADV IMMUNOL, V130, P251, DOI 10.1016/bs.ai.2015.12.005; Henze AT, 2016, J CLIN INVEST, V126, P3672, DOI 10.1172/JCI84427; Higashi M, 1999, HEPATOLOGY, V30, P1347, DOI 10.1002/hep.510300609; Higuchi R, 2006, SURG TODAY, V36, P559, DOI 10.1007/s00595-006-3201-1; Hogdall D, 2018, TRENDS CANCER, V4, P239, DOI 10.1016/j.trecan.2018.01.007; Jeng YM, 2001, AM J SURG PATHOL, V25, P516, DOI 10.1097/00000478-200104000-00012; Jin MZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00280-x; Jing CY, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0554-8; Job S, 2020, HEPATOLOGY, V72, P965, DOI 10.1002/hep.31092; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Jung IH, 2018, IN VIVO, V32, P771, DOI 10.21873/invivo.11307; Jusakul A, 2017, CANCER DISCOV, V7, P1116, DOI 10.1158/2159-8290.CD-17-0368; Kaida M, 2011, J IMMUNOTHER, V34, P92, DOI 10.1097/CJI.0b013e3181fb65b9; Kasper HU, 2009, WORLD J GASTROENTERO, V15, P5053, DOI 10.3748/wjg.15.5053; Kida A, 2018, LIVER INT, V38, P2040, DOI 10.1111/liv.13885; Kiefer F, 2011, CELL MOL LIFE SCI, V68, P2811, DOI 10.1007/s00018-011-0677-7; Kim Richard, 2018, Oncotarget, V9, P23366, DOI 10.18632/oncotarget.25163; Kim RD, 2020, JAMA ONCOL, V6, P888, DOI 10.1001/jamaoncol.2020.0930; Kitano Y, 2018, BRIT J CANCER, V118, P171, DOI 10.1038/bjc.2017.401; Kitano Y, 2017, ANTICANCER RES, V37, P3229, DOI 10.21873/anticanres.11685; Klein O, 2020, JAMA ONCOL, V6, P1405, DOI 10.1001/jamaoncol.2020.2814; Komuta M, 2020, SEMIN LIVER DIS, V40, P124, DOI 10.1055/s-0039-3402515; Koury J, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/9585614; Krummel MF, 2016, NAT REV IMMUNOL, V16, P193, DOI 10.1038/nri.2015.16; Lamarca A, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4003; Laohaviroj Marut, 2016, Asian Pac J Cancer Prev, V17, P201; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Leoni S, 2020, CANCERS, V12, DOI 10.3390/cancers12040794; Lepisto Andrew J, 2008, Cancer Ther, V6, P955; Li AP, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0784-8; Li JY, 2018, IMMUNITY, V49, P178, DOI 10.1016/j.immuni.2018.06.006; Li L, 2017, HEPATOLOGY, V65, P501, DOI 10.1002/hep.28735; Li ML, 2019, GUT, V68, P1024, DOI 10.1136/gutjnl-2018-316039; Li Z, 2017, J CELL MOL MED, V21, P177, DOI 10.1111/jcmm.12951; Lim YJ, 2015, RADIOTHER ONCOL, V117, P165, DOI 10.1016/j.radonc.2015.07.003; Lin GH, 2016, ONCOTARGET, V7, P50963, DOI 10.18632/oncotarget.7680; Lin YL, 2019, NEOPLASIA, V21, P1133, DOI 10.1016/j.neo.2019.10.005; Lind H, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000433; Loffler MW, 2016, J HEPATOL, V65, P849, DOI 10.1016/j.jhep.2016.06.027; Loilome W, 2014, TUMOR BIOL, V35, P5357, DOI 10.1007/s13277-014-1698-2; Lubner SJ, 2010, J CLIN ONCOL, V28, P3491, DOI 10.1200/JCO.2010.28.4075; Luetke-Eversloh M, 2014, EUR J IMMUNOL, V44, P2074, DOI 10.1002/eji.201344072; Lwin Z, 2020, ANN ONCOL, V31, pS1170, DOI 10.1016/j.annonc.2020.08.2271; Ma C, 2015, BIOCHEM BIOPH RES CO, V458, P234, DOI 10.1016/j.bbrc.2015.01.067; Ma LC, 2019, CANCER CELL, V36, P418, DOI 10.1016/j.ccell.2019.08.007; Malenica I, 2020, CANCERS, V12, DOI 10.3390/cancers12082190; Mall AS, 2010, PATHOL RES PRACT, V206, P805, DOI 10.1016/j.prp.2010.08.004; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Mantovani A, 2011, EUR J IMMUNOL, V41, P2522, DOI 10.1002/eji.201141894; Mao ZY, 2015, WORLD J GASTROENTERO, V21, P4961, DOI 10.3748/wjg.v21.i16.4961; Marks EI, 2015, WORLD J GASTRO ONCOL, V7, P338, DOI 10.4251/wjgo.v7.i11.338; Martin-Sierra C, 2019, CYTOM PART B-CLIN CY, V96, P490, DOI 10.1002/cyto.b.21777; Massarweh NN, 2017, CANCER CONTROL, V24, DOI 10.1177/1073274817729245; Matsumura N, 2002, CANCER-AM CANCER SOC, V94, P1770, DOI 10.1002/cncr.10398; Matsuyama M, 2015, INVEST NEW DRUG, V33, P490, DOI 10.1007/s10637-014-0197-z; Mazzaferro V, 2020, J HEPATOL, V72, P364, DOI 10.1016/j.jhep.2019.11.020; Melero I, 2015, NAT REV CANCER, V15, P457, DOI 10.1038/nrc3973; Meric-Bernstam F, 2021, LANCET, V397, P1010, DOI 10.1016/S0140-6736(20)32598-8; Mertens JC, 2013, CANCER RES, V73, P897, DOI 10.1158/0008-5472.CAN-12-2130; Minicozzi P, 2018, CANCER EPIDEMIOL, V55, P52, DOI 10.1016/j.canep.2018.04.011; Miura T, 2017, ANTICANCER RES, V37, P183, DOI 10.21873/anticanres.11304; Montal R, 2020, J HEPATOL, V73, P315, DOI 10.1016/j.jhep.2020.03.008; Moris D, 2017, SURG ONCOL, V26, P423, DOI 10.1016/j.suronc.2017.08.005; Morisaki T, 2012, ANTICANCER RES, V32, P2249; Morizane C, 2019, ANN ONCOL, V30, P1950, DOI 10.1093/annonc/mdz402; Morvan MG, 2016, NAT REV CANCER, V16, P7, DOI 10.1038/nrc.2015.5; Mouw KW, 2017, CANCER DISCOV, V7, P675, DOI 10.1158/2159-8290.CD-17-0226; Nakamura H, 2015, NAT GENET, V47, P1003, DOI 10.1038/ng.3375; Nakatsuka S, 2006, MODERN PATHOL, V19, P804, DOI 10.1038/modpathol.3800588; Nishimoto N, 2006, NAT CLIN PRACT RHEUM, V2, P619, DOI 10.1038/ncprheum0338; Oh DY, 2020, J CLIN ONCOL, V38; Okabe H, 2009, ANN SURG ONCOL, V16, P2555, DOI 10.1245/s10434-009-0568-4; Okusaka T, 2010, BRIT J CANCER, V103, P469, DOI 10.1038/sj.bjc.6605779; Okusaka T, 2012, J HEPATO-BIL-PAN SCI, V19, P314, DOI 10.1007/s00534-011-0495-1; Oshikiri T, 2003, J SURG ONCOL, V84, P224, DOI 10.1002/jso.10321; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Patel T, 2001, HEPATOLOGY, V33, P1353, DOI 10.1053/jhep.2001.25087; Pawlik TM, 2020, EXPERT REV ANTICANC, V20, P765, DOI 10.1080/14737140.2020.1807333; Personeni N, 2020, CANCERS, V12, DOI 10.3390/cancers12113370; Primrose JN, 2019, LANCET ONCOL, V20, P663, DOI 10.1016/S1470-2045(18)30915-X; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Raggi C, 2017, J HEPATOL, V66, P102, DOI 10.1016/j.jhep.2016.08.012; Rimassa L, 2019, J AUTOIMMUN, V100, P17, DOI 10.1016/j.jaut.2019.03.007; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rizzo Alessandro, 2021, Expert Rev Gastroenterol Hepatol, V15, P527, DOI 10.1080/17474124.2021.1853527; Rizzo A, 2021, CANCERS, V13, DOI 10.3390/cancers13030558; Rizzo A, 2020, IN VIVO, V34, P479, DOI 10.21873/invivo.11798; Robert C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17670-y; Rojas-Sepulveda D, 2018, CANCER IMMUNOL IMMUN, V67, P1897, DOI 10.1007/s00262-018-2157-5; Sabbatino F, 2016, CLIN CANCER RES, V22, P470, DOI 10.1158/1078-0432.CCR-15-0715; Saeed A, 2019, CLIN COLORECTAL CANC, V18, P81, DOI 10.1016/j.clcc.2019.02.005; Salmon H, 2012, J CLIN INVEST, V122, P899, DOI 10.1172/JCI45817; Sansone P, 2012, J CLIN ONCOL, V30, P1005, DOI 10.1200/JCO.2010.31.8907; Santana-Davila R, 2017, JAMA ONCOL, V3, P106, DOI 10.1001/jamaoncol.2016.4574; Sato K, 2018, BBA-MOL BASIS DIS, V1864, P1262, DOI 10.1016/j.bbadis.2017.06.017; Sato K, 2016, AM J PATHOL, V186, P2238, DOI 10.1016/j.ajpath.2016.06.003; Sato K, 2016, J HEPATOL, V65, P213, DOI 10.1016/j.jhep.2016.03.004; Sato Y, 2020, J HEPATO-BIL-PAN SCI, V27, P860, DOI 10.1002/jhbp.788; Sato Y, 2017, PATHOL INT, V67, P163, DOI 10.1111/pin.12511; Scholten D, 2010, GASTROENTEROLOGY, V139, P987, DOI 10.1053/j.gastro.2010.05.005; Schott AF, 2017, CLIN CANCER RES, V23, P5358, DOI 10.1158/1078-0432.CCR-16-2748; Shaib YH, 2004, J HEPATOL, V40, P472, DOI 10.1016/j.jhep.2003.11.030; Sharma A, 2010, J CLIN ONCOL, V28, P4581, DOI 10.1200/JCO.2010.29.3605; Shaul ME, 2019, NAT REV CLIN ONCOL, V16, P601, DOI 10.1038/s41571-019-0222-4; Shigeyasu K, 2014, SURG TODAY, V44, P1975, DOI 10.1007/s00595-013-0669-3; Shih K, 2014, DRUGS, V74, P1993, DOI 10.1007/s40265-014-0305-6; Shimizu K, 2012, J HEPATO-BIL-PAN SCI, V19, P171, DOI 10.1007/s00534-011-0437-y; Shroff RT, 2019, J CLIN ONCOL, V37, P1015, DOI 10.1200/JCO.18.02178; Sirica AE, 2019, HEPATOLOGY, V69, P1803, DOI 10.1002/hep.30289; Sirica AE, 2014, EXP MOL PATHOL, V97, P515, DOI 10.1016/j.yexmp.2014.10.007; Sirica AE, 2012, NAT REV GASTRO HEPAT, V9, P44, DOI 10.1038/nrgastro.2011.222; Sirica AE, 2011, CURR OPIN GASTROEN, V27, P276, DOI 10.1097/MOG.0b013e32834405c3; Song W, 2018, BIOCHEM BIOPH RES CO, V506, P1004, DOI 10.1016/j.bbrc.2018.10.186; Spizzo G, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000682; Stavraka C, 2019, J HEPATOCELL CARCINO, V6, P11, DOI 10.2147/JHC.S159805; Steinberg M, 2010, CLIN THER, V32, P821, DOI 10.1016/j.clinthera.2010.05.007; Strickland KC, 2016, ONCOTARGET, V7, P13587, DOI 10.18632/oncotarget.7277; Stromnes IM, 2007, NAT IMMUNOL, V8, P19, DOI 10.1038/ni0107-19; Subbiah V, 2020, LANCET ONCOL, V21, P1234, DOI 10.1016/S1470-2045(20)30321-1; Subimerb C, 2010, MOL MED REP, V3, P597, DOI 10.3892/mmr_00000303; Takagi S, 2004, HUM PATHOL, V35, P881, DOI 10.1016/j.humpath.2004.03.016; Tao SC, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0319-5; Teo MY, 2018, J CLIN ONCOL, V36, P1685, DOI 10.1200/JCO.2017.75.7740; Thanee Malinee, 2015, Asian Pac J Cancer Prev, V16, P3043; Thepmalee C, 2020, HUM VACC IMMUNOTHER, V16, P2318, DOI 10.1080/21645515.2019.1701913; Thongchot S, 2014, ASIAN PAC J CANCER P, V15, P5873, DOI 10.7314/APJCP.2014.15.14.5873; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Tsilimigras DI, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00261-6; Ueno M., 2018, ANN ONCOL, V29, pmdy282; Ueno M, 2019, LANCET GASTROENTEROL, V4, P611, DOI 10.1016/S2468-1253(19)30086-X; Utaijaratrasmi P, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0760-x; Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721; Vaquero J, 2020, CURR OPIN GASTROEN, V36, P63, DOI 10.1097/MOG.0000000000000609; Vaquero J, 2017, J HEPATOL, V66, P424, DOI 10.1016/j.jhep.2016.09.010; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Vogel A, 2021, EXPERT OPIN INV DRUG, V30, P351, DOI 10.1080/13543784.2021.1868437; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; West J, 2006, BRIT J CANCER, V94, P1751, DOI 10.1038/sj.bjc.6603127; Whiteside TL, 2012, SEMIN CANCER BIOL, V22, P327, DOI 10.1016/j.semcancer.2012.03.004; Wu L, 2019, WORLD J SURG, V43, P1777, DOI 10.1007/s00268-019-04966-4; Yamamoto K, 2005, ANTICANCER RES, V25, P3575; Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973; Yoshitomi M, 2012, EXP THER MED, V3, P463, DOI 10.3892/etm.2011.424; Yuan DT, 2017, CANCER CELL, V31, P771, DOI 10.1016/j.ccell.2017.05.006; Zheng Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0226-x; Zhou SL, 2014, CARCINOGENESIS, V35, P597, DOI 10.1093/carcin/bgt397; Zhu AX, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.266; Zhu Y, 2018, CANCER MANAG RES, V10, P4113, DOI 10.2147/CMAR.S172719	194	1	1	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							422	10.3390/vaccines9050422			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1NP	33922362	gold, Green Published			2022-04-29	WOS:000654593200001
J	Haegeman, A; De Leeuw, I; Mostin, L; Van Campe, W; Aerts, L; Venter, E; Tuppurainen, E; Saegerman, C; De Clercq, K				Haegeman, Andy; De Leeuw, Ilse; Mostin, Laurent; Van Campe, Willem; Aerts, Laetitia; Venter, Estelle; Tuppurainen, Eeva; Saegerman, Claude; De Clercq, Kris			Comparative Evaluation of Lumpy Skin Disease Virus-Based Live Attenuated Vaccines	VACCINES			English	Article						lumpy skin disease; vaccine evaluation; live attenuated vaccines; lumpy skin disease vaccine	RISK-FACTORS; CATTLE; EFFICACY; IMPACT; SEROPREVALENCE; VACCINATION; VALIDATION; INFECTION; OUTBREAKS; LESIONS	Vaccines form the cornerstone of any control, eradication and preventative strategy and this is no different for lumpy skin disease. However, the usefulness of a vaccine is determined by a multiplicity of factors which include stability, efficiency, safety and ease of use, to name a few. Although the vaccination campaign in the Balkans against lumpy skin disease virus (LSDV) was successful and has been implemented with success in the past in other countries, data of vaccine failure have also been reported. It was therefore the purpose of this study to compare five homologous live attenuated LSDV vaccines (LSDV LAV) in a standardized setting. All five LSDV LAVs studied were able to protect against a challenge with virulent LSDV. Aside from small differences in serological responses, important differences were seen in side effects such as a local reaction and a Neethling response upon vaccination between the analyzed vaccines. These observations can have important implications in the applicability in the field for some of these LSDV LAVs.	[Haegeman, Andy; De Leeuw, Ilse; De Clercq, Kris] Sciensano, Infect Dis Anim Exot & Particular Dis, Groeselenberg 99, B-1180 Brussels, Belgium; [Mostin, Laurent; Van Campe, Willem] Sciensano, Expt Ctr Machelen, Kerklaan 68, B-1830 Machelen, Belgium; [Aerts, Laetitia] Sciensano, EURL Dis Caused Capripox Viruses, Groeselenberg 99, B-1180 Brussels, Belgium; [Venter, Estelle] Univ Pretoria, Dept Vet Trop Dis, Fac Vet Sci, ZA-0110 Onderstepoort, South Africa; [Venter, Estelle] James Cook Univ, Coll Publ Hlth Med & Vet Sci, Discipline Vet Sci, Townsville, Qld 4811, Australia; [Tuppurainen, Eeva] Fed Res Inst Anim Hlth, Friedrich Loeffler Inst, Inst Int Tiergesundheit One Hlth, D-17489 Greifswald, Germany; [Saegerman, Claude] Univ Liege, Fundamental & Appl Res Anim & Hlth FARAH Ctr, Res Unit Epidemiol & Risk Anal Appl Vet Sci UREAR, Fac Vet Med, B-4000 Liege, Belgium		Haegeman, A (通讯作者)，Sciensano, Infect Dis Anim Exot & Particular Dis, Groeselenberg 99, B-1180 Brussels, Belgium.	Andy.Haegeman@sciensano.be; Ilse.DeLeeuw@sciensano.be; Laurent.Mostin@sciensano.be; Willem.VanCampe@sciensano.be; Laetitia.Aerts@sciensano.be; estelle.venter@jcu.edu.au; Eeva.Tuppurainen@fli.de; claude.saegerman@uliege.be; kris.declercq@sciensano.be	; Venter, Estelle/O-6953-2014	Haegeman, andy/0000-0003-4056-214X; Saegerman, Claude/0000-0001-9087-7436; Venter, Estelle/0000-0001-7351-0827; De Clercq, Kris/0000-0002-2928-3521	Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1126866]; Belgian Federal Public Service of Health, Food Chain Safety and Environment [RT 15/3]; GALVmed project [CAO-R34A0856]	This research was funded by the Bill & Melinda Gates Foundation project Nr OPP1126866, the GALVmed project Nr CAO-R34A0856 on lumpy skin disease and the Belgian Federal Public Service of Health, Food Chain Safety and Environment through the contract RT 15/3 (LUMPY SKIN 1).	Abera Z, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0432-7; Abutarbush SM, 2016, TRANSBOUND EMERG DIS, V63, pE213, DOI 10.1111/tbed.12257; Agianniotaki EI, 2017, J VIROL METHODS, V249, P48, DOI 10.1016/j.jviromet.2017.08.011; Alemayehu G, 2013, TROP ANIM HEALTH PRO, V45, P1153, DOI 10.1007/s11250-012-0340-9; ALI AA, 1990, VET REC, V127, P549; Ayelet G, 2013, ANTIVIR RES, V98, P261, DOI 10.1016/j.antiviral.2013.02.008; Babiuk S, 2008, TRANSBOUND EMERG DIS, V55, P299, DOI 10.1111/j.1865-1682.2008.01024.x; Babiuk S, 2007, J VET DIAGN INVEST, V19, P486, DOI 10.1177/104063870701900505; Bedekovic T, 2018, TRANSBOUND EMERG DIS, V65, P491, DOI 10.1111/tbed.12730; Ben-Gera J, 2015, VACCINE, V33, P4837, DOI 10.1016/j.vaccine.2015.07.071; Brenner J, 2009, VACCINE, V27, P1500, DOI 10.1016/j.vaccine.2009.01.020; Davies F. G., 1991, World Animal Review, V68, P37; Douglass N, 2019, ARCH VIROL, V164, P3107, DOI 10.1007/s00705-019-04405-8; Elhaig MM, 2017, ONDERSTEPOORT J VET, V84, DOI 10.4102/ojvr.v84i1.1393; European Food Safety, 2017, EFSA J, V15, DOI 10.2903/j.efsa.2017.4773; FAO, 2020, INTR SPREAD LUMP SKI, P183, DOI [10.4060/cb1892en, DOI 10.4060/CB1892EN]; Gari G, 2011, PREV VET MED, V102, P274, DOI 10.1016/j.prevetmed.2011.07.003; Gari G, 2015, VACCINE, V33, P3256, DOI 10.1016/j.vaccine.2015.01.035; GREEN H. F., 1959, Bulletin of epizootic diseases of Africa, V7, P63; GRETH A, 1992, J WILDLIFE DIS, V28, P295, DOI 10.7589/0090-3558-28.2.295; Gumbe A., 2018, J DAIRY VET ANIM RES, V7, P39, DOI DOI 10.15406/JDVAR.2018.07.00187; Haegeman A, 2013, J VIROL METHODS, V193, P446, DOI 10.1016/j.jviromet.2013.07.010; Haegeman A, 2020, J VIROL METHODS, V277, DOI 10.1016/j.jviromet.2019.113800; Howell D.C., 1998, METHODES STATISTIQUE, P762; Katsoulos PD, 2018, TRANSBOUND EMERG DIS, V65, P174, DOI 10.1111/tbed.12646; Klement E, 2020, PREV VET MED, V181, DOI 10.1016/j.prevetmed.2018.12.001; Mathijs E, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.01255-16; Moeller J, 2019, ARCH VIROL, V164, P2931, DOI 10.1007/s00705-019-04411-w; Molla W, 2018, PREV VET MED, V160, P99, DOI 10.1016/j.prevetmed.2018.09.029; Molla W, 2017, PREV VET MED, V147, P100, DOI 10.1016/j.prevetmed.2017.09.003; Munyanduki H, 2020, J GEN VIROL, V101, P645, DOI 10.1099/jgv.0.001423; Obernier JA, 2006, ILAR J, V47, P364, DOI 10.1093/ilar.47.4.364; Ochwo S, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1983-9; Osuagwuh UI, 2007, VACCINE, V25, P2238, DOI 10.1016/j.vaccine.2006.12.010; Parida S, 2006, VACCINE, V24, P964, DOI 10.1016/j.vaccine.2005.08.108; Petrie A., 2013, STAT VET ANIMAL SCI, P414; PROZESKY L, 1982, ONDERSTEPOORT J VET, V49, P167; RAMASWAMY NS, 1994, REV SCI TECH OIE, V13, P195, DOI 10.20506/rst.13.1.758; REED L. J., 1938, AMER JOUR HYG, V27, P493; Salib FA, 2011, VET WORLD, V4, P162; Sanz-Bernardo B, 2020, VET PATHOL, V57, P388, DOI 10.1177/0300985820913268; Sevik M, 2017, TRANSBOUND EMERG DIS, V64, P1268, DOI 10.1111/tbed.12501; Sprygin A, 2018, TRANSBOUND EMERG DIS, V65, P1137, DOI 10.1111/tbed.12897; Tageldin MH, 2014, TROP ANIM HEALTH PRO, V46, P241, DOI 10.1007/s11250-013-0483-3; Tasioudi KE, 2016, TRANSBOUND EMERG DIS, V63, P260, DOI 10.1111/tbed.12497; Tilahun Z, 2014, ACAD J ANIM DIS, V3, P17, DOI [DOI 10.5829/IDOSI.AJAD.2014.3.3.85134, 10.5829/idosi.ajad.2014.3.3.85134]; Tulman ER, 2002, J VIROL, V76, P6054, DOI 10.1128/JVI.76.12.6054-6061.2002; Tuppurainen ESM, 2020, PREV VET MED, V181, DOI 10.1016/j.prevetmed.2018.12.006; Tuppurainen ESM, 2017, TRANSBOUND EMERG DIS, V64, P729, DOI 10.1111/tbed.12444; Tuppurainen ESM, 2013, EPIDEMIOL INFECT, V141, P425, DOI 10.1017/S0950268812000805; Tuppurainen ESM, 2014, ANTIVIR RES, V109, P1, DOI 10.1016/j.antiviral.2014.06.009; Vandenbussche F, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.01114-16; Weiss KK, 1968, VIROL MONOGR, V3, P112; World Organization for Animal Health (OIE), 2019, LUMPY SKIN DIS; YERUHAM I, 1995, VET REC, V137, P91, DOI 10.1136/vr.137.4.91; Yousefi PS, 2017, TRANSBOUND EMERG DIS, V64, P1782, DOI 10.1111/tbed.12565; Zelalem A, 2015, INT J B A VIR, V4, P8, DOI [10.5829/idosi.ijbav.2015.4.1.9117, DOI 10.5829/IDOSI.IJBAV.2015.4.1.9117, 10.5829/idosi.ijbav.2019.01.07, DOI 10.5829/ID0SI.IJBAY.2015.4.1.9117)]	58	9	9	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							473	10.3390/vaccines9050473			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1WF	34066658	Green Accepted, Green Published, gold			2022-04-29	WOS:000654615600001
J	Lamothe-Reyes, Y; Bohorquez, JA; Wang, MM; Alberch, M; Perez-Simo, M; Rosell, R; Ganges, L				Lamothe-Reyes, Yaneysis; Alejandro Bohorquez, Jose; Wang, Miaomiao; Alberch, Monica; Perez-Simo, Marta; Rosell, Rosa; Ganges, Llilianne			Early and Solid Protection Afforded by the Thiverval Vaccine Provides Novel Vaccination Alternatives Against Classical Swine Fever Virus	VACCINES			English	Article						CSFV; vaccination; vaccine; Thiverval strain; immune response; clinical protection; virological protection; challenge	ASSAY	Classical swine fever virus (CSFV) remains a challenge for the porcine industry. Inefficient vaccination programs in some endemic areas may have contributed to the emergence of low and moderate virulence CSFV variants. This work aimed to expand and update the information about the safety and efficacy of the CSFV Thiverval-strain vaccine. Two groups of pigs were vaccinated, and a contact and control groups were also included. Animals were challenged with a highly virulent CSFV strain at 21- or 5-days post vaccination (dpv). The vaccine induced rapid and strong IFN-alpha response, mainly in the 5-day immunized group, and no vaccine virus transmission was detected. Vaccinated pigs showed humoral response against CSFV E2 and E-rns glycoproteins, with neutralising activity, starting at 14 days post vaccination (dpv). Strong clinical protection was afforded in all the vaccinated pigs as early as 5 dpv. The vaccine controlled viral replication after challenge, showing efficient virological protection in the 21-day immunized pigs despite being housed with animals excreting high CSFV titres. These results demonstrate the high efficacy of the Thiverval strain against CSFV replication. Its early protection capacity makes it a useful alternative for emergency vaccination and a consistent tool for CSFV control worldwide.	[Lamothe-Reyes, Yaneysis; Alejandro Bohorquez, Jose; Wang, Miaomiao; Alberch, Monica; Perez-Simo, Marta; Rosell, Rosa; Ganges, Llilianne] Ctr Recerca Sanitat Anim IRTA CReSA, Inst Recerca & Tecnol Agr, OIE Reference Lab Class Swine Fever, Barcelona 08193, Spain; [Lamothe-Reyes, Yaneysis] Univ Concepcion, Sch Biol Sci, Dept Pharmacol, Recombinant Biopharmaceut Lab, Concepcion 4030000, Chile; [Rosell, Rosa] Dept Agr Ramaderia Pesca & Alimentacio DARP, Generalitat De Catalunya 08007, Spain		Ganges, L (通讯作者)，Ctr Recerca Sanitat Anim IRTA CReSA, Inst Recerca & Tecnol Agr, OIE Reference Lab Class Swine Fever, Barcelona 08193, Spain.	yaneysis.lamothe@irta.cat; josealejandro.bohorquez@irta.cat; miaomiao.wang@irta.cat; monica.alberch@irta.cat; marta.perez@irta.cat; Rosa.rosell@irta.cat; llilianne.ganges@irta.cat	; Ganges, Llilianne/O-7342-2017	Lamothe, Yaneysis/0000-0002-7012-2228; Bohorquez Garzon, Jose Alejandro/0000-0002-6715-1757; Rosell, Rosa/0000-0002-8294-1159; Ganges, Llilianne/0000-0002-8644-3560	CEVA Sante Animale, France; Ministerio de Ciencia, e Innovacion from the Spanish government [RTI2018-100887-B-I00]; ANID (ex-CONICYT) PFCHA/Doctorado Nacional [2017-21170713]; Chinese government; Spanish governmentSpanish GovernmentEuropean Commission	This research was funded by CEVA Sante Animale, France and grant RTI2018-100887-B-I00, Ministerio de Ciencia, e Innovacion from the Spanish government. YL-R has a pre-doctoral fellowship the ANID (ex-CONICYT) PFCHA/Doctorado Nacional/2017-21170713. J.A.B has a pre-doctoral fellowship, FPI 2016, Ministerio de Ciencia e Innovacion, from Spanish government. M.W. has a pre-doctoral fellowship, CSC scholarship (2017), from the Chinese government.	Aynaud J M, 1978, Dev Biol Stand, V41, P381; Blome S, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9040086; Coronado L, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1982-x; CORTHIER G, 1977, ANN RECH VET, V8, P159; Ganges L, 2008, VET J, V177, P169, DOI 10.1016/j.tvjl.2007.01.030; Ganges L, 2020, VIRUS RES, V289, DOI 10.1016/j.virusres.2020.198151; Hoffmann B, 2005, J VIROL METHODS, V130, P36, DOI 10.1016/j.jviromet.2005.05.030; Leifer I, 2009, VACCINE, V27, P6522, DOI 10.1016/j.vaccine.2009.08.057; Mearns R, 2007, IN PRACTICE, V29, P40; Mourits MCM, 2010, PREV VET MED, V96, P201, DOI 10.1016/j.prevetmed.2010.06.010; Munoz-Gonzalez S, 2017, VET MICROBIOL, V205, P110, DOI 10.1016/j.vetmic.2017.05.003; Munoz-Gonzalez S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149469; Munoz-Gonzalez S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125692; OIE, 2019, TERR AN HLTH COD; OIE, OFF DIS STAT INT; OIE, 2019, OIE TERR MAN; Postel A, 2019, EMERG INFECT DIS, V25, P1228, DOI 10.3201/eid2506.181578; Qiu HuaJi, 2006, Agricultural Sciences in China, V5, P1, DOI 10.1016/S1671-2927(06)60013-8; REED L. J., 1938, AMER JOUR HYG, V27, P493; RUMENAPF T, 1991, ARCH VIROL, P7; RUMENAPF T, 1993, J VIROL, V67, P3288; Shimizu Y, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.573480; STARK R, 1990, VIROLOGY, V174, P286, DOI 10.1016/0042-6822(90)90076-4; Summerfield A, 2015, FRONT VET SCI, V2, DOI 10.3389/fvets.2015.00010; TERPSTRA C, 1984, VET MICROBIOL, V9, P113, DOI 10.1016/0378-1135(84)90026-9; Wang MM, 2020, J VIROL, V94, DOI 10.1128/JVI.01214-19; WENSVOORT G, 1986, VET MICROBIOL, V12, P101, DOI 10.1016/0378-1135(86)90072-6; Yoo SJ, 2018, TRANSBOUND EMERG DIS, V65, P735, DOI 10.1111/tbed.12798	28	1	1	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							464	10.3390/vaccines9050464			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1NG	34066376	Green Published, gold			2022-04-29	WOS:000654592300001
J	Wang, RT; Liu, M; Liu, J				Wang, Ruitong; Liu, Min; Liu, Jue			The Association between Influenza Vaccination and COVID-19 and Its Outcomes: A Systematic Review and Meta-Analysis of Observational Studies	VACCINES			English	Review						influenza vaccination; COVID-19; infection; outcome; meta-analysis	SEASONAL INFLUENZA; SARS-COV-2; INTERVENTIONS; MORTALITY; EFFICACY; ADULTS; IMPACT	Influenza could circulate in parallel with COVID-19. In the context of COVID-19, some studies observed inverse associations between influenza vaccination and SARS-CoV-2 infection and clinical outcomes, while others did not. We conducted a meta-analysis to assess the association between influenza vaccination and SARS-CoV-2 infection and clinical outcomes, aiming to provide evidence for COVID-19 prevention and vaccination promotion. We searched four databases from inception to 10 March, 2021. Random effects and fixed effects models were used to pool odds ratios (ORs) and adjusted estimates with 95% confidence intervals (CIs). We used funnel plots to evaluate the publication bias, I2 statistics to evaluate the heterogeneity, and conducted subgroup analyses. Sixteen observational studies involving 290,327 participants were included. Influenza vaccination was associated with a lower risk of SARS-CoV-2 infection (pooled adjusted OR: 0.86, 95%CI: 0.81-0.91), while not significantly associated with adverse outcomes (intensive care: adjusted OR 0.63, 95%CI: 0.22-1.81; hospitalization: adjusted OR 0.74, 95%CI: 0.51-1.06; mortality: adjusted OR 0.89, 95%CI: 0.73-1.09). Our findings suggest that influenza vaccination is associated with a lower risk of SARS-CoV-2 infection. It is crucial for policy makers to implement strategies on influenza vaccination, for it may also have benefits for COVID-19 prevention.	[Wang, Ruitong; Liu, Min; Liu, Jue] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China; [Liu, Jue] Peking Univ, Inst Global Hlth & Dev, Beijing 100191, Peoples R China; [Liu, Jue] Natl Hlth Commiss Peoples Republ China, Key Lab Reprod Hlth, Beijing 100083, Peoples R China		Liu, J (通讯作者)，Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China.; Liu, J (通讯作者)，Peking Univ, Inst Global Hlth & Dev, Beijing 100191, Peoples R China.; Liu, J (通讯作者)，Natl Hlth Commiss Peoples Republ China, Key Lab Reprod Hlth, Beijing 100083, Peoples R China.	wangruitong@pku.edu.cn; liumin@bjmu.edu.cn; jueliu@bjmu.edu.cn	Liu, Jue/AAF-7581-2021	Liu, Jue/0000-0002-1938-9365	National Key Research and Development Project of China [2020YFC0846300, 2019YFC1710301]; National Science and Technology Key Projects on Prevention and Treatment ofMajor infectious disease of China [2020ZX10001002]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [71874003, 71934002, 81703240]	This work was funded by the National Key Research and Development Project of China [grant numbers 2020YFC0846300, 2019YFC1710301]; the National Science and Technology Key Projects on Prevention and Treatment ofMajor infectious disease of China (grant number 2020ZX10001002); and the National Natural Science Foundation of China (grant numbers 71874003, 71934002, 81703240).	Amato M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030535; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; [Anonymous], DEPLOYMENT COVID 19; Arokiaraj MC, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00444; Bai L, 2021, CELL RES, V31, P395, DOI 10.1038/s41422-021-00473-1; Belingheri M, 2020, OCCUP MED-OXFORD, V70, P665, DOI 10.1093/occmed/kqaa197; Buchy P, 2020, INT J INFECT DIS, V93, P375, DOI 10.1016/j.ijid.2020.02.040; Cheng YY, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101124; Cocco P, 2021, PREV MED, V143, DOI 10.1016/j.ypmed.2020.106351; Conlon A, 2021, AM J INFECT CONTROL, V49, P694, DOI 10.1016/j.ajic.2021.02.012; Conty MLD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010031; Del Riccio M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217870; Descamps A, 2020, HUM VACC IMMUNOTHER, V16, P1093, DOI 10.1080/21645515.2019.1688035; Fink G, 2021, BMJ EVID-BASED MED, V26, DOI 10.1136/bmjebm-2020-111549; Green I., HUM VACC IMMUNOTHER; Grubaugh ND, 2020, CELL, V182, P794, DOI 10.1016/j.cell.2020.06.040; Hui KPY, 2020, LANCET RESP MED, V8, P687, DOI 10.1016/S2213-2600(20)30193-4; Jehi L, 2020, CHEST, V158, P1364, DOI 10.1016/j.chest.2020.05.580; Kissling E., INFLUENZA OTHER RESP; Kleinnijenhuis J, 2014, CLIN IMMUNOL, V155, P213, DOI 10.1016/j.clim.2014.10.005; Konala Venu Madhav, 2020, Eur J Case Rep Intern Med, V7, P001656, DOI 10.12890/2020_001656; Liu Y, 2021, BMC MED, V19, DOI 10.1186/s12916-020-01872-8; Marin-Hernandez D, 2021, J MED VIROL, V93, P64, DOI 10.1002/jmv.26120; Martinez-Baz I, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040611; Martinez-Huedo MA, 2020, HUM VACC IMMUNOTHER, V16, P95, DOI 10.1080/21645515.2019.1646577; Massoudi N, 2021, J CLIN IMMUNOL, V41, P324, DOI 10.1007/s10875-020-00925-0; Moore JP, 2020, J VIROL, V94, DOI 10.1128/JVI.01083-20; Nelson MI, 2011, J VIROL, V85, P828, DOI 10.1128/JVI.01762-10; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Noale M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030471; Paget J, 2020, VACCINE, V38, P6485, DOI 10.1016/j.vaccine.2020.08.024; Pawlowski C, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83641-y; Quach THT, 2020, MATERN CHILD HLTH J, V24, P229, DOI 10.1007/s10995-019-02844-y; Ragni P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040675; Restivo V, 2018, HUM VACC IMMUNOTHER, V14, P724, DOI 10.1080/21645515.2017.1321722; Rostom A., ROCKVILLE MD AGENCY; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Thindwa D, 2020, VACCINE, V38, P5398, DOI 10.1016/j.vaccine.2020.06.047; Tian CW, 2019, J PUBLIC HEALTH-UK, V41, pE62, DOI 10.1093/pubmed/fdy081; Vila-Corcoles A, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-041577; Vila-Corcoles A, 2020, REV ESP SALUD PUBLIC, V94; Walk J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08659-3; Wang Q, 2018, VACCINE, V36, P7262, DOI 10.1016/j.vaccine.2018.10.045; Wells G.A., NEWCASTLE OTTAWA SCA; Wilcox CR, 2021, BMJ OPEN RESPIR RES, V8, DOI 10.1136/bmjresp-2020-000857; Wilkinson K, 2017, VACCINE, V35, P2775, DOI 10.1016/j.vaccine.2017.03.092; Wolff GG, 2020, VACCINE, V38, P350, DOI 10.1016/j.vaccine.2019.10.005; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Xiang X, 2021, CURR MED SCI, V41, P51, DOI 10.1007/s11596-021-2317-2; Yang MJ, 2021, J AM BOARD FAM MED, V34, pS179, DOI 10.3122/jabfm.2021.S1.200528	50	11	11	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							529	10.3390/vaccines9050529			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1PP	34065294	Green Published, gold			2022-04-29	WOS:000654598400001
J	Watad, A; De Marco, G; Mahajna, H; Druyan, A; Eltity, M; Hijazi, N; Haddad, A; Elias, M; Zisman, D; Naffaa, ME; Brodavka, M; Cohen, Y; Abu-Much, A; Abu Elhija, M; Bridgewood, C; Langevitz, P; McLorinan, J; Bragazzi, NL; Marzo-Ortega, H; Lidar, M; Calabrese, C; Calabrese, L; Vital, E; Shoenfeld, Y; Amital, H; McGonagle, D				Watad, Abdulla; De Marco, Gabriele; Mahajna, Hussein; Druyan, Amit; Eltity, Mailam; Hijazi, Nizar; Haddad, Amir; Elias, Muna; Zisman, Devy; Naffaa, Mohammad E.; Brodavka, Michal; Cohen, Yael; Abu-Much, Arsalan; Abu Elhija, Muhanad; Bridgewood, Charlie; Langevitz, Pnina; McLorinan, Joanna; Bragazzi, Nicola Luigi; Marzo-Ortega, Helena; Lidar, Merav; Calabrese, Cassandra; Calabrese, Leonard; Vital, Edward; Shoenfeld, Yehuda; Amital, Howard; McGonagle, Dennis			Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination	VACCINES			English	Article						vaccine safety; COVID-19; mRNA-based vaccine; adenoviral vector-based vaccine; immune-mediated diseases	COVID-19 VACCINES; ADJUVANTS; AUTOIMMUNITY; INDUCTION	Background: Infectious diseases and vaccines can occasionally cause new-onset or flare of immune-mediated diseases (IMDs). The adjuvanticity of the available SARS-CoV-2 vaccines is based on either TLR-7/8 or TLR-9 agonism, which is distinct from previous vaccines and is a common pathogenic mechanism in IMDs. Methods: We evaluated IMD flares or new disease onset within 28-days of SARS-CoV-2 vaccination at five large tertiary centres in countries with early vaccination adoption, three in Israel, one in UK, and one in USA. We assessed the pattern of disease expression in terms of autoimmune, autoinflammatory, or mixed disease phenotype and organ system affected. We also evaluated outcomes. Findings: 27 cases included 17 flares and 10 new onset IMDs. 23/27 received the BNT - 162b2 vaccine, 2/27 the mRNA-1273 and 2/27 the ChAdOx1 vaccines. The mean age was 54.4 +/- 19.2 years and 55% of cases were female. Among the 27 cases, 21 (78%) had at least one underlying autoimmune/rheumatic disease prior the vaccination. Among those patients with a flare or activation, four episodes occurred after receiving the second-dose and in one patient they occurred both after the first and the second-dose. In those patients with a new onset disease, two occurred after the second-dose and in one patient occurred both after the first (new onset) and second-dose (flare). For either dose, IMDs occurred on average 4 days later. Of the cases, 20/27 (75%) were mild to moderate in severity. Over 80% of cases had excellent resolution of inflammatory features, mostly with the use of corticosteroid therapy. Other immune-mediated conditions included idiopathic pericarditis (n = 2), neurosarcoidosis with small fiber neuropathy (n = 1), demyelination (n = 1), and myasthenia gravis (n = 2). In 22 cases (81.5%), the insurgence of Adverse event following immunization (AEFI)/IMD could not be explained based on the drug received by the patient. In 23 cases (85.2%), AEFI development could not be explained based on the underlying disease/co-morbidities. Only in one case (3.7%), the timing window of the insurgence of the side effect was considered not compatible with the time from vaccine to flare. Interpretation: Despite the high population exposure in the regions served by these centers, IMDs flares or onset temporally-associated with SARS-CoV-2 vaccination appear rare. Most are moderate in severity and responsive to therapy although some severe flares occurred.	[Watad, Abdulla; Shoenfeld, Yehuda; Amital, Howard] Sheba Med Ctr, Zabludowicz Ctr Autoimmune Dis, Dept Med B, IL-10457 Tel Hashomer, Israel; [Watad, Abdulla; Mahajna, Hussein; Druyan, Amit; Brodavka, Michal; Cohen, Yael; Langevitz, Pnina; Lidar, Merav; Shoenfeld, Yehuda; Amital, Howard] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Watad, Abdulla; Druyan, Amit; Brodavka, Michal; Cohen, Yael; Langevitz, Pnina; Lidar, Merav; Amital, Howard] Sheba Med Ctr, Rheumatol Unit, IL-10457 Tel Hashomer, Israel; [Watad, Abdulla; De Marco, Gabriele; Bridgewood, Charlie; Marzo-Ortega, Helena; Vital, Edward; McGonagle, Dennis] Leeds Teaching Hosp NHS Trust, Leeds Biomed Res Ctr, NIHR, Leeds LS9 7TF, W Yorkshire, England; [Watad, Abdulla; De Marco, Gabriele; Bridgewood, Charlie; Marzo-Ortega, Helena; Vital, Edward; McGonagle, Dennis] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds LS9 7TF, W Yorkshire, England; [Mahajna, Hussein] Sheba Med Ctr, Dept Gastroenterol, IL-10457 Tel Aviv, Israel; [Eltity, Mailam] Sheba Med Ctr, Dept Neurol, IL-10457 Tel Aviv, Israel; [Hijazi, Nizar; Haddad, Amir; Elias, Muna; Zisman, Devy; Abu Elhija, Muhanad] Carmel Hosp, Rheumatol Unit, Michal St, IL-3436212 Haifa, Israel; [Haddad, Amir; Elias, Muna; Zisman, Devy; Abu Elhija, Muhanad] Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, IL-3200003 Haifa, Israel; [Naffaa, Mohammad E.] Bar Ilan Univ, Azrieli Fac Med, Galilee Med Ctr, Dept Rheumatol, IL-22100 Safed, Israel; [Abu-Much, Arsalan] Sheba Med Ctr, Leviev Heart Ctr, IL-10457 Tel Aviv, Israel; [McLorinan, Joanna] Mid Yorkshire Hosp, Dept Rheumatol, Wakefield WF8 1PL, W Yorkshire, England; [Bragazzi, Nicola Luigi] York Univ, Ctr Dis Modelling, Dept Math & Stat, Toronto, ON M3J 1P3, Canada; [Bragazzi, Nicola Luigi] York Univ, Fields CQAM Lab Math Publ Hlth MfPH, Toronto, ON M3J 1P3, Canada; [Calabrese, Cassandra; Calabrese, Leonard] Cleveland Clin Fdn, 9500 Euclid Ave,Desk A50, Cleveland, OH 44195 USA		McGonagle, D (通讯作者)，Leeds Teaching Hosp NHS Trust, Leeds Biomed Res Ctr, NIHR, Leeds LS9 7TF, W Yorkshire, England.; McGonagle, D (通讯作者)，Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds LS9 7TF, W Yorkshire, England.; Bragazzi, NL (通讯作者)，York Univ, Ctr Dis Modelling, Dept Math & Stat, Toronto, ON M3J 1P3, Canada.; Bragazzi, NL (通讯作者)，York Univ, Fields CQAM Lab Math Publ Hlth MfPH, Toronto, ON M3J 1P3, Canada.	watad.abdulla@gmail.com; G.DeMarco@leeds.ac.uk; hmahajna@gmail.com; Amit.Druyan@sheba.health.gov.il; mailameltity@gmail.com; NizarHi@clalit.org.il; haddadamir@yahoo.com; nelias1@bezeqint.net; devyzisman@gmail.com; MohammadN@gmc.gov.il; michal.brodavka@sheba.health.gov.il; Yael.cohen2@sheba.health.gov.il; arsalanabumuch1@gmail.com; Mhndhija100@gmail.com; C.D.Bridgewood@leeds.ac.uk; Pnina.Langevitz@sheba.health.gov.il; joanna.mclorinan1@nhs.net; bragazzi@yorku.ca; marzo-ortega@leeds.ac.uk; Merav.Lidar@sheba.health.gov.il; calabrc@ccf.org; calabrl@ccf.org; E.M.J.Vital@leeds.ac.uk; yehuda.shoenfeld@sheba.health.gov.il; Howard.Amital@sheba.health.gov.il; D.G.McGonagle@leeds.ac.uk	De Marco, Gabriele/M-1381-2017; Bragazzi, Nicola/G-1672-2011	De Marco, Gabriele/0000-0003-2406-161X; Mahajna, Hussein/0000-0002-7409-8958; Amital, Howard/0000-0002-5406-7716; Bragazzi, Nicola/0000-0001-8409-868X; Naffaa, Mohammad/0000-0001-9777-2864; watad, abdulla/0000-0002-1404-8027; Marzo-Ortega, Helena/0000-0002-9683-3407; Zisman, Devy/0000-0003-0523-2292	National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (LBRC)National Institute for Health Research (NIHR)	G.D.M., H.M.-O., E.V. and D.M. are supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (LBRC). The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR, or the (UK) Department of Health.	Ameratunga R, 2017, J ALLER CL IMM-PRACT, V5, P1551, DOI 10.1016/j.jaip.2017.06.033; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Ball P, 2021, NATURE, V589, P16, DOI 10.1038/d41586-020-03626-1; Bellavite Paolo, 2020, F1000Res, V9, P170, DOI [10.12688/f1000research.22600.1, 10.12688/f1000research.22600.2]; Benucci M, 2021, CLIN EXP RHEUMATOL, V39, P196; Blumenthal KG, 2021, JAMA-J AM MED ASSOC, V325, P1562, DOI 10.1001/jama.2021.3976; Bonaccorsi G, 2020, P NATL ACAD SCI USA, V117, P15530, DOI 10.1073/pnas.2007658117; Bragazzi NL, 2017, EXPERT REV CLIN IMMU, V13, P939, DOI 10.1080/1744666X.2017.1361321; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; Chandler RE, 2020, NAT REV IMMUNOL, V20, P451, DOI 10.1038/s41577-020-0372-8; Cirillo N, 2021, J ORAL PATHOL MED, V50, P424, DOI 10.1111/jop.13165; Danova J, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4083-4; Dotan A, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102792; Duthie MS, 2011, IMMUNOL REV, V239, P178, DOI 10.1111/j.1600-065X.2010.00978.x; Ehrenfeld M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102597; El-Gabalawy H, 2010, J RHEUMATOL, V37, P2, DOI 10.3899/jrheum.091461; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; Gagnier JJ, 2013, DTSCH ARZTEBL INT, V110, P603, DOI [10.7453/gahmj.2013.008, 10.1186/1752-1947-7-223, 10.1136/bcr-2013-201554, 10.3238/arztebl.2013.0603]; Gherardi R. K., 2016, Morphologie, V100, P85, DOI 10.1016/j.morpho.2016.01.002; Gherardi RK, 2003, REV NEUROL-FRANCE, V159, P162; Golob JL, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.149187; Hussein HM, 2019, CRIT REV MICROBIOL, V45, P394, DOI 10.1080/1040841X.2019.1614904; Klimek L, 2021, INTERNIST, V62, P326, DOI 10.1007/s00108-021-00959-5; Koenig HC, 2011, VACCINE, V29, P913, DOI 10.1016/j.vaccine.2010.10.044; Krug Anne, 2008, V183, P129; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lee H, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010101; Li YD, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00695-2; Liu Y, 2021, CURR OPIN RHEUMATOL, V33, P155, DOI 10.1097/BOR.0000000000000776; Lopez-Gonzalez MD, 2021, ANN RHEUM DIS, V80, DOI 10.1136/annrheumdis-2020-217914; McGonagle D, 2006, PLOS MED, V3, P1242, DOI 10.1371/journal.pmed.0030297; McGonagle D, 2021, LANCET RHEUMATOL, V3, pE224, DOI 10.1016/S2665-9913(20)30420-3; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; Blasco LM, 2018, J ALLER CL IMM-PRACT, V6, P707, DOI 10.1016/j.jaip.2017.11.017; Neerukonda SN, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9060426; Onyeaka H, 2021, CLIN EXP VACCINE RES, V10, P6, DOI 10.7774/cevr.2021.10.1.6; Pellegrino P, 2015, AUTOIMMUN REV, V14, P880, DOI 10.1016/j.autrev.2015.05.014; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Rodero MP, 2016, J EXP MED, V213, P2527, DOI 10.1084/jem.20161596; Saad MA, 2021, CURR RHEUMATOL REV, V17, P193, DOI 10.2174/1573397116666201029155856; Segal Y, 2018, CELL MOL IMMUNOL, V15, P586, DOI 10.1038/cmi.2017.151; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P46, DOI 10.15585/mmwr.mm7002e1; Shoenfeld Y, 2011, J AUTOIMMUN, V36, P4, DOI 10.1016/j.jaut.2010.07.003; Tatematsu M, 2018, J INNATE IMMUN, V10, P398, DOI 10.1159/000494034; Teijaro JR, 2021, NAT REV IMMUNOL, V21, P195, DOI 10.1038/s41577-021-00526-x; Terracina KA, 2021, LANCET RHEUMATOL, V3, pE469, DOI 10.1016/S2665-9913(21)00108-9; Torres-Aguilar H, 2019, CURR OPIN RHEUMATOL, V31, P525, DOI 10.1097/BOR.0000000000000630; Toussirot Eric, 2015, Inflammation & Allergy Drug Targets, V14, P94, DOI 10.2174/1871528114666160105113046; Vera-Lastra O, 2013, EXPERT REV CLIN IMMU, V9, P361, DOI [10.1586/ECI.13.2, 10.1586/eci.13.2]; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wise J, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n954; World Health Organization, 2014, GLOB MAN SURV ADV EV; Wucherpfennig KW, 2001, J CLIN INVEST, V108, P1097, DOI 10.1172/JCI14235; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4	55	80	80	5	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							435	10.3390/vaccines9050435			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1ZU	33946748	Green Submitted, gold, Green Published	Y	N	2022-04-29	WOS:000654624900001
J	Wawrzuta, D; Jaworski, M; Gotlib, J; Panczyk, M				Wawrzuta, Dominik; Jaworski, Mariusz; Gotlib, Joanna; Panczyk, Mariusz			What Arguments against COVID-19 Vaccines Run on Facebook in Poland: Content Analysis of Comments	VACCINES			English	Article						Facebook; vaccine hesitancy; vaccine; COVID-19; infodemiology	SOCIAL MEDIA; REFUSAL	Social media allow anti-vaxxers to quickly spread misinformation and false statements. This situation may lead to an increase in vaccine hesitancy. We wanted to characterize what arguments against COVID-19 vaccines run on Facebook in Poland. We analyzed Facebook comments related to the five events of the introduction of COVID-19 vaccines-announcements of the efficacy of the Pfizer-BioNTech (09.11.2020), Moderna (16.11.2020), and AstraZeneca (23.11.2020) vaccines, registration of the Pfizer-BioNTech vaccine by the European Medicines Agency (21.12.2020), and the first vaccination in Poland (27.12.2020). We collected the comments from fanpages of the biggest Polish media and then established their main anti-vaccine themes. We found that the negative arguments about COVID-19 vaccines can be divided into 12 categories. Seven of them are universal and also apply to other vaccines but five are new and COVID-19' specific. The frequency of arguments from a given category varied over time. We also noticed that, while the comments were mostly negative, the reactions were positive. Created codebook of anti-vaccine COVID-19 arguments can be used to monitor the attitude of society towards COVID-19 vaccines. Real-time monitoring of social media is important because the popularity of certain arguments on Facebook changes rapidly over time.	[Wawrzuta, Dominik; Jaworski, Mariusz; Gotlib, Joanna; Panczyk, Mariusz] Med Univ Warsaw, Dept Educ & Res Hlth Sci, PL-02091 Warsaw, Poland		Wawrzuta, D (通讯作者)，Med Univ Warsaw, Dept Educ & Res Hlth Sci, PL-02091 Warsaw, Poland.	dominik@wawrzuta.pl; mariusz.jaworski@wum.edu.pl; joanna.gotlib@wum.edu.pl; mariusz.panczyk@wum.edu.pl	Wawrzuta, Dominik/ABB-1890-2021; Panczyk, Mariusz/B-4412-2011	Gotlib, Joanna/0000-0002-2717-7741; Wawrzuta, Dominik/0000-0002-0846-8906; Jaworski, Mariusz/0000-0002-5207-8323; Panczyk, Mariusz/0000-0003-1830-2114			Allcott H, 2019, RES POLITICS, V6, DOI 10.1177/2053168019848554; [Anonymous], BBC NEWS; [Anonymous], WIRED; [Anonymous], REUTERS; [Anonymous], COVID TOP 10 CURRENT; [Anonymous], EMA recommends first COVID-19 vaccine for authorisation in the EU; [Anonymous], 1 NEWS; Bagozzi RP, 1999, J ACAD MARKET SCI, V27, P184, DOI 10.1177/0092070399272005; Betsch C, 2010, J HEALTH PSYCHOL, V15, P446, DOI 10.1177/1359105309353647; Blankenship Elizabeth B, 2018, Perm J, V22, P17, DOI 10.7812/TPP/17-138; Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567; Covolo L, 2017, HUM VACC IMMUNOTHER, V13, P1693, DOI 10.1080/21645515.2017.1306159; Craig AT, 2020, LANCET INFECT DIS, V20, P273, DOI 10.1016/S1473-3099(20)30053-0; Donzelli G, 2018, HUM VACC IMMUNOTHER, V14, P1654, DOI 10.1080/21645515.2018.1454572; Dredze M, 2016, AM J PREV MED, V50, P550, DOI 10.1016/j.amepre.2015.10.002; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dube E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156118; European Medicines Agency, 2021, EMA FINDS POSS LINK; Evrony A, 2017, HUM VACC IMMUNOTHER, V13, P1475, DOI 10.1080/21645515.2017.1283467; Fahlquist JN, 2018, SCAND J PUBLIC HEALT, V46, P182, DOI 10.1177/1403494817727162; Food and Drug Administration, 2020, PFIZ COVID 19 VACC E; Ghosh R., 2010, ARXIV10032664; GIBBS RW, 1986, J EXP PSYCHOL GEN, V115, P3, DOI 10.1037/0096-3445.115.1.3; Giuntini FT, 2019, IEEE ACCESS, V7, P53909, DOI 10.1109/ACCESS.2019.2913136; Glanz JM, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-1117; Guidry JPD, 2015, VACCINE, V33, P5051, DOI 10.1016/j.vaccine.2015.08.064; Harvey AM, 2019, HEALTH EDUC BEHAV, V46, P1012, DOI 10.1177/1090198119866886; Hendrie D., 2019, FACEBOOK CHALLENGED; Isaacs D, 2020, J PAEDIATR CHILD H, V56, P175, DOI 10.1111/jpc.14752; Kearney MD, 2019, HEALTH EDUC BEHAV, V46, P37, DOI 10.1177/1090198119859412; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Knoll MD, 2021, LANCET, V397, P72, DOI 10.1016/S0140-6736(20)32623-4; Krippendorff K, 2004, HUM COMMUN RES, V30, P411, DOI 10.1093/hcr/30.3.411; Krippendorff K., 2011, COMPUTING KRIPPENDOR; Kruger J, 2005, J PERS SOC PSYCHOL, V89, P925, DOI 10.1037/0022-3514.89.6.925; Lee C, 2016, VACCINE, V34, P3972, DOI 10.1016/j.vaccine.2016.06.048; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4826; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4759; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4709; Massey PM, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.6670; Monica A., 2021, PEW RES CTR SOCIAL U; Mordini E, 2007, TRENDS BIOTECHNOL, V25, P544, DOI 10.1016/j.tibtech.2007.08.012; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Royal Society For Public Health, 2019, PROM VACC UPT LIF CO; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Schmidt LJ, 2015, EMOTION, V15, P329, DOI 10.1037/emo0000041; Shelby A, 2013, HUM VACC IMMUNOTHER, V9, P1795, DOI 10.4161/hv.24828; Stolle LB, 2020, ADV THER, V37, P4481, DOI 10.1007/s12325-020-01502-y; Uscinski J.E., 2020, HARVARD KENNEDY SCH, V1, DOI 10.37016/mr-2020-015; Vanneste BS, 2014, STRATEGIC MANAGE J, V35, P1891, DOI 10.1002/smj.2198; Venkatraman A, 2015, VACCINE, V33, P1422, DOI 10.1016/j.vaccine.2015.01.078; Wang YX, 2019, SOC SCI MED, V240, DOI 10.1016/j.socscimed.2019.112552; Waszak PM, 2018, HEALTH POLICY TECHN, V7, P115, DOI 10.1016/j.hlpt.2018.03.002; Weibel D, 2018, VACCINE, V36, P6202, DOI 10.1016/j.vaccine.2018.08.008; World Health Organization, 2019, 9 WHO; Yang MC, 2019, INFORM SYST RES, V30, P839, DOI 10.1287/isre.2019.0834; YouGov, 2021, TECHN REP; Zanin GM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093024	58	7	7	15	21	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							481	10.3390/vaccines9050481			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI1FJ	34068500	gold, Green Published			2022-04-29	WOS:000654571600001
J	McKeirnan, K; Colorafi, K; Sun, Z; Daratha, K; Potyk, D; McCarthy, J				McKeirnan, Kimberly; Colorafi, Karen; Sun, Zuan; Daratha, Kristopher; Potyk, Darryl; McCarthy, John			Improving Pneumococcal Vaccination Rates among Rural Older Adults through Academic Detailing: Medicine, Nursing and Pharmacy Partnership	VACCINES			English	Article						pneumococcal vaccination; rural healthcare; academic detailing	BARRIERS	Academic detailing is an educational approach involving provision of evidence-based information by healthcare providers for healthcare providers with the goal of improving clinical decision-making. An interprofessional academic detailing initiative was developed to encourage rural providers to utilize guidelines when deciding which patients to vaccinate against pneumonia. This study utilized a quasi-experimental, single-group, pre-post observational design with physicians, nurses, and staff at two rural medical clinics. The 12-month academic detailing intervention included a needs assessment, workflow assessment of practice-based health information technology, vaccination training for providers and staff, and creation of exam-room posters encouraging patients to discuss vaccination with their provider. Six visits were made to deliver education, discuss needs, select priorities, and develop action plans from recommendations. Data were collected from each site for three years prior to the intervention year and for one year following the intervention. The annual rate of patients vaccinated increased during the five-year study. The cumulative proportion of the sample population that received vaccination also increased over time. Interprofessional academic detailing was well received and increased pneumococcal vaccination rates among rural-dwelling older adults. Given the alarming disparities in health outcomes for rural patients, educational outreach is needed to improve healthcare access and outcomes.	[McKeirnan, Kimberly] Washington State Univ, Coll Pharm & Pharmaceut Sci, Pullman, WA 99202 USA; [Colorafi, Karen] Gonzaga Univ, Sch Nursing & Human Physiol, Spokane, WA 99202 USA; [Sun, Zuan] Whitworth Univ, Sch Business, Spokane, WA 99251 USA; [Daratha, Kristopher] Daratha Analyt, Spokane, WA 99204 USA; [Potyk, Darryl; McCarthy, John] Univ Washington, Sch Med, Spokane, WA 99202 USA		McKeirnan, K (通讯作者)，Washington State Univ, Coll Pharm & Pharmaceut Sci, Pullman, WA 99202 USA.	kimberly.mckeirnan@wsu.edu; colorafi@gonzaga.edu; zsun@whitworth.edu; daratha.analytics@gmail.com; potykd@uw.edu; mccajf@uw.edu		McKeirnan, Kimberly/0000-0002-1039-1311	PFIZER INDEPENDENT GRANTS FOR LEARNING AND CHANGE [20076509]	This research was funded by PFIZER INDEPENDENT GRANTS FOR LEARNING AND CHANGE, grant number 20076509.	Alici DE, 2017, HUM VACC IMMUNOTHER, V13, P213, DOI 10.1080/21645515.2016.1234556; Awali RA, 2014, AM J INFECT CONTROL, V42, P649, DOI 10.1016/j.ajic.2014.02.025; Colorafi K, 2018, CONSULT PHARM, V33, P163, DOI 10.4140/TCP.n.2018.163; Ginsburg AS, 2020, LANCET GLOB HEALTH, V8, pE1453, DOI 10.1016/S2214-109X(20)30444-7; Komlos D., 2019, CRACKING COMPLEXITY; McKeirnan KC, 2019, SR CARE PHARM, V34, P432, DOI 10.4140/TCP.n.2019.432; Morley, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab054, DOI 10.1093/cid/ciab054]; O'Brien MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000409.pub2; PENCHANSKY R, 1981, MED CARE, V19, P127, DOI 10.1097/00005650-198102000-00001; RCW, 1864011 11 DEFINITIO; Rehm SJ, 2012, POSTGRAD MED, V124, P71, DOI 10.3810/pgm.2012.05.2550; Skoufalos A, 2017, POPUL HEALTH MANAG, V20, DOI 10.1089/pop.2017.0177; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; Srivastav A, 2018, VACCINE, V36, P6772, DOI 10.1016/j.vaccine.2018.09.024; Tong S, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3529-4; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; Zimmerman RK, 2003, VACCINE, V21, P1510, DOI 10.1016/S0264-410X(02)00698-9	17	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							317	10.3390/vaccines9040317			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS6LI	33807141	gold, Green Published			2022-04-29	WOS:000643887800001
J	O'Shea, J; Prausnitz, MR; Rouphael, N				O'Shea, Jesse; Prausnitz, Mark R.; Rouphael, Nadine			Dissolvable Microneedle Patches to Enable Increased Access to Vaccines against SARS-CoV-2 and Future Pandemic Outbreaks	VACCINES			English	Article						dissolvable microneedle patch; drug delivery; skin vaccination; vaccine delivery; equity		Vaccines are an essential component of pandemic preparedness but can be limited due to challenges in production and logistical implementation. While vaccine candidates were rapidly developed against severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), immunization campaigns remain an obstacle to achieving herd immunity. Dissolvable microneedle patches are advantageous for many possible reasons: improved immunogenicity; dose-sparing effects; expected low manufacturing cost; elimination of sharps; reduction of vaccine wastage; no need for reconstitution; simplified supply chain, with reduction of cold chain supply through increased thermostability; ease of use, reducing the need for healthcare providers; and greater acceptability compared to traditional hypodermic injections. When applied to coronavirus disease 2019 (COVID-19) and future pandemic outbreaks, microneedle patches have great potential to improve vaccination globally and save many lives.	[O'Shea, Jesse; Rouphael, Nadine] Emory Univ, Sch Med, Emory Vaccine Ctr, Div Infect Dis,Dept Med,Hope Clin, 500 Irvin Court,Suite 200, Atlanta, GA 30030 USA; [Prausnitz, Mark R.] Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA		O'Shea, J (通讯作者)，Emory Univ, Sch Med, Emory Vaccine Ctr, Div Infect Dis,Dept Med,Hope Clin, 500 Irvin Court,Suite 200, Atlanta, GA 30030 USA.	jesse.oshea@emory.edu; prausnitz@gatech.edu; nroupha@emory.edu		Prausnitz, Mark/0000-0002-9076-8448			Ali AA, 2017, NANOMED-NANOTECHNOL, V13, P921, DOI 10.1016/j.nano.2016.11.019; Allen EA, 2016, INT J PHARMACEUT, V500, P1, DOI 10.1016/j.ijpharm.2015.12.052; Alliance T.W.B.G., 2010, IMMUNIZATION FINANCI; [Anonymous], BARDAS RAPIDLY EXPAN; Arya J, 2017, BIOMATERIALS, V128, P1, DOI 10.1016/j.biomaterials.2017.02.040; Arya J, 2016, J CONTROL RELEASE, V240, P135, DOI 10.1016/j.jconrel.2015.11.019; Arya JM, 2016, J CONTROL RELEASE, V239, P19, DOI 10.1016/j.jconrel.2016.08.012; Bachy V, 2013, P NATL ACAD SCI USA, V110, P3041, DOI 10.1073/pnas.1214449110; Becker PD, 2015, VACCINE, V33, P4691, DOI 10.1016/j.vaccine.2015.04.046; Chen F, 2017, J CONTROL RELEASE, V255, P36, DOI 10.1016/j.jconrel.2017.03.397; Chu LY, 2016, PHARM RES-DORDR, V33, P868, DOI 10.1007/s11095-015-1833-9; Chu LY, 2011, J CONTROL RELEASE, V149, P242, DOI 10.1016/j.jconrel.2010.10.033; Cole G, 2018, EUR J PHARM BIOPHARM, V127, P288, DOI 10.1016/j.ejpb.2018.02.029; Corum J., 2020, NEW YORK TIMES, V5; Cuevas MBP, 2018, BIOENG TRANSL MED, V3, P186, DOI 10.1002/btm2.10098; De Perio M.A, 2012, HLTH HAZARD EVALUATI; Deng L, 2018, P NATL ACAD SCI USA, V115, pE7758, DOI 10.1073/pnas.1805713115; Donadei A, 2019, J CONTROL RELEASE, V311, P96, DOI 10.1016/j.jconrel.2019.08.039; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Edens C, 2015, VACCINE, V33, P4712, DOI 10.1016/j.vaccine.2015.02.074; Edens C, 2015, VACCINE, V33, P4683, DOI 10.1016/j.vaccine.2015.01.089; Erdos G, 2020, J INVEST DERMATOL, V140, P2528, DOI 10.1016/j.jid.2020.03.966; Erdos G, 2012, J IMMUNOL, V188; Esser E.S., 2017, SCI REP, V7, P1; Esser ES, 2016, J CONTROL RELEASE, V236, P47, DOI 10.1016/j.jconrel.2016.06.026; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Frew PM, 2020, VACCINE, V38, P7175, DOI 10.1016/j.vaccine.2020.07.064; Gala RP, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030060; Hiraishi Y, 2013, INT J PHARMACEUT, V441, P570, DOI 10.1016/j.ijpharm.2012.10.042; Hirobe S, 2015, BIOMATERIALS, V57, P50, DOI 10.1016/j.biomaterials.2015.04.007; Hirobe S, 2013, PHARM RES-DORDR, V30, P2664, DOI 10.1007/s11095-013-1092-6; Hsueh KJ, 2017, COMP IMMUNOL MICROB, V50, P78, DOI 10.1016/j.cimid.2016.12.001; Joyce JC, 2018, J INFECT DIS, V218, P124, DOI 10.1093/infdis/jiy139; Kim E, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102743; Kim E, 2016, EBIOMEDICINE, V13, P315, DOI 10.1016/j.ebiom.2016.09.028; Kim YC, 2012, EUR J PHARM BIOPHARM, V81, P239, DOI 10.1016/j.ejpb.2012.03.010; Kolluru C, 2019, DRUG DELIV TRANSL RE, V9, P192, DOI 10.1007/s13346-018-00608-9; Kommareddy S, 2012, J PHARM SCI-US, V101, P1021, DOI 10.1002/jps.23019; Kuwentrai C, 2021, BIOENG TRANSL MED, V6, DOI 10.1002/btm2.10202; Lanza JS, 2020, INT J PHARMACEUT, V586, DOI 10.1016/j.ijpharm.2020.119390; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lee BY, 2015, VACCINE, V33, P4727, DOI 10.1016/j.vaccine.2015.02.076; Lee C, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701381; Leone M, 2020, INT J PHARMACEUT, V580, DOI 10.1016/j.ijpharm.2020.119182; Li JW, 2017, CURR MED CHEM, V24, P2413, DOI 10.2174/0929867324666170526124053; Liao JF, 2017, THERANOSTICS, V7, P2593, DOI 10.7150/thno.19894; Littauer EQ, 2018, J CONTROL RELEASE, V276, P1, DOI 10.1016/j.jconrel.2018.02.033; Liu SQ, 2019, VACCINE, V37, P3810, DOI 10.1016/j.vaccine.2019.05.055; Matsuo K, 2012, J CONTROL RELEASE, V160, P495, DOI 10.1016/j.jconrel.2012.04.001; Mistilis MJ, 2017, DRUG DELIV TRANSL RE, V7, P195, DOI 10.1007/s13346-016-0282-2; Mistilis MJ, 2015, J PHARM SCI-US, V104, P740, DOI 10.1002/jps.24283; Moderna Therapeutics, MODERNAS COVID 19 VA; Nakatsukasa A, 2017, VACCINE, V35, P2855, DOI 10.1016/j.vaccine.2017.04.009; Norman JJ, 2014, VACCINE, V32, P1856, DOI 10.1016/j.vaccine.2014.01.076; Pattani A, 2012, J CONTROL RELEASE, V162, P529, DOI 10.1016/j.jconrel.2012.07.039; Poirier D, 2017, BIOMATERIALS, V145, P256, DOI 10.1016/j.biomaterials.2017.08.038; Prausnitz MR, 2017, ANNU REV CHEM BIOMOL, V8, P177, DOI 10.1146/annurev-chembioeng-060816-101514; Prausnitz MR, 2009, CURR TOP MICROBIOL, V333, P369, DOI 10.1007/978-3-540-92165-3_18; Pruss-Ustun A., 2003, SHARPS INJURIES GLOB; Qiu YQ, 2016, DRUG DELIV, V23, P2391, DOI 10.3109/10717544.2014.992497; Quinn HL, 2014, EXPERT OPIN DRUG DEL, V11, P1769, DOI 10.1517/17425247.2014.938635; Raphael AP, 2010, SMALL, V6, P1785, DOI 10.1002/smll.201000326; Resch TK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18973-9; Rodgers AM, 2019, MED DEVICES-EVID RES, V12, P379, DOI 10.2147/MDER.S198220; Rodgers AM, 2018, INT J PHARMACEUT, V549, P87, DOI 10.1016/j.ijpharm.2018.07.049; Rose A., M ALL PRIMARY EFFICA; Rouphael NG, 2017, LANCET, V390, P649, DOI 10.1016/S0140-6736(17)30575-5; Sullivan SP, 2010, NAT MED, V16, P915, DOI 10.1038/nm.2182; Vassilieva EV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18140-0; Vassilieva EV, 2015, DRUG DELIV TRANSL RE, V5, P360, DOI 10.1007/s13346-015-0228-0; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Vrdoljak A, 2016, J CONTROL RELEASE, V225, P192, DOI 10.1016/j.jconrel.2016.01.019; Wang J, 2015, P NATL ACAD SCI USA, V112, P5005, DOI 10.1073/pnas.1500408112; Wang N, 2017, J CONTROL RELEASE, V246, P12, DOI 10.1016/j.jconrel.2016.12.009; Wang T, 2015, COLLOID SURFACE B, V126, P520, DOI 10.1016/j.colsurfb.2015.01.005; Webby RJ, 2003, SCIENCE, V302, P1519, DOI 10.1126/science.1090350; World Health Organization, 2020, WHO CONCEPT FAIR ACC; Yan QY, 2018, VACCINE, V36, P4471, DOI 10.1016/j.vaccine.2018.06.025; Yan QY, 2017, DRUG DELIV, V24, P1648, DOI [10.6084/m9.figshare.5539654.v3, 10.1080/10717544.2017.1391892]; Yang HW, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201600750; Zaric M, 2017, J CONTROL RELEASE, V268, P166, DOI 10.1016/j.jconrel.2017.10.026; Zhu WD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01705; Zhu WD, 2017, J CONTROL RELEASE, V261, P1, DOI 10.1016/j.jconrel.2017.06.017; Zhu ZZ, 2016, J CONTROL RELEASE, V243, P291, DOI 10.1016/j.jconrel.2016.10.019	84	9	9	8	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							320	10.3390/vaccines9040320			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4UE	33915696	gold, Green Published			2022-04-29	WOS:000643775300001
J	Osman, N; Goovaerts, D; Sultan, S; Salt, J; Grund, C				Osman, Nabila; Goovaerts, Danny; Sultan, Serageldeen; Salt, Jeremy; Grund, Christian			Vaccine Quality Is a Key Factor to Determine Thermal Stability of Commercial Newcastle Disease (ND)Vaccines	VACCINES			English	Article						heat stability; Newcastle disease virus; paramyxovirus; vaccine quality; vaccine stability		Vaccination against Newcastle disease (ND), a devastating viral disease of chickens, is often hampered by thermal inactivation of the live vaccines, in particular in tropical and hot climate conditions. In the past, "thermostable" vaccine strains (I-2) were proposed to overcome this problem but previous comparative studies did not include formulation-specific factors of commercial vaccines. In the current study, we aimed to verify the superior thermal stability of commercially formulated I-2 strains by comparing six commercially available ND vaccines. Subjected to 37 degrees C as lyophilized preparations, two vaccines containing I-2 strains were more sensitive to inactivation than a third I-2 vaccine or compared to three other vaccines based on different ND strains. However, reconstitution strains proved to have a comparable tenacity. Interestingly, all vaccines still retained a sufficient virus dose for protection (10(6) EID50) after 1 day at 37 degrees C. These results suggest that there are specific factors that influence thermal stability beyond the strain-specific characteristics. Exposing ND vaccines to elevated temperatures of 51 and 61 degrees C demonstrated that inactivation of all dissolved vaccines including I-2 vaccine strains occurred within 2 to 4 h. The results revealed important differences among the vaccines and emphasize the importance of the quality of a certain vaccine preparation rather than the strain it contains. These data highlight that regardless of the ND strain used for vaccine preparation, the appropriate cold chain is mandatory for keeping live ND vaccines efficiency in hot climates.	[Osman, Nabila] South Valley Univ, Fac Vet Med, Dept Poultry Dis, Qena 83523, Egypt; [Goovaerts, Danny] DGVAC Consulting, B-2460 Antwerp, Belgium; [Goovaerts, Danny; Salt, Jeremy] GALVmed, Edinburgh EH26 0PZ, Midlothian, Scotland; [Sultan, Serageldeen] South Valley Univ, Fac Vet Med, Dept Microbiol, Virol Div, Qena 83523, Egypt; [Grund, Christian] Friedrich Loeffler Inst, Inst Diagnost Virol, Edinburgh EH26 0PZ, Midlothian, Scotland		Grund, C (通讯作者)，Friedrich Loeffler Inst, Inst Diagnost Virol, Edinburgh EH26 0PZ, Midlothian, Scotland.	nabila.osman@vet.svu.edu.eg; Danny.Goovaerts@galvmed.org; sultanserageldeen@gmail.com; Jeremy.Salt@galvmed.org; christian.grund@fli.de	Osman, Nabila/AAA-4555-2022; Sultan, Serageldeen/AAH-6758-2020	Osman, Nabila/0000-0002-0176-0349; Sultan, Serageldeen/0000-0003-3527-7803; salt, jeremy/0000-0003-0404-6535	Bill andMelinda Gates FoundationBill & Melinda Gates Foundation [OPP1176784]; UK aid from the UK Government through GALVmedCGIAR [300504]	This work is based on research funded in part by the Bill andMelinda Gates Foundation (Investment ID OPP1176784) and with UK aid from the UK Government (Project 300504) through GALVmed. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill andMelinda Gates Foundation or the UK Government.	AINI I, 1990, RES VET SCI, V49, P216, DOI 10.1016/S0034-5288(18)31080-4; Alders RG, 2010, WORLD POULTRY SCI J, V66, P433, DOI 10.1017/S0043933910000516; Allan W.H., 1978, FAO ANIMAL PRODUCTIO; Bensink Z, 1999, VET MICROBIOL, V68, P131, DOI 10.1016/S0378-1135(99)00069-3; Bessell PR, 2020, PREV VET MED, V177, DOI 10.1016/j.prevetmed.2020.104975; Boumart Z, 2016, AVIAN DIS, V60, P779, DOI 10.1637/11426-042116-Reg.1; Cattoli G, 2011, J VET DIAGN INVEST, V23, P637, DOI 10.1177/1040638711407887; Ganar K, 2014, VIRUS RES, V184, P71, DOI 10.1016/j.virusres.2014.02.016; GOLDHAFT TM, 1980, AVIAN DIS, V24, P297, DOI 10.2307/1589696; HITCHNER SB, 1975, AVIAN DIS, V19, P215, DOI 10.2307/1588975; ICTV International Committee on Taxonomy of Viruses, 2019, VIRUS TAXONOMY; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; Khatun M., 2018, J ECON BUS, V1, P358, DOI [10.31014/aior.1992.01.03.33, DOI 10.31014/AIOR.1992.01.03.33]; Kumru OS, 2014, BIOLOGICALS, V42, P237, DOI 10.1016/j.biologicals.2014.05.007; Matthias DM, 2007, VACCINE, V25, P3980, DOI 10.1016/j.vaccine.2007.02.052; Mazija H, 2010, AVIAN DIS, V54, P99, DOI 10.1637/8928-051909-Reg.1; Milhomme P, 1993, Can Commun Dis Rep, V19, P33; Nelson C, 2007, VACCINE, V25, P433, DOI 10.1016/j.vaccine.2006.08.017; Office International des Epizooties, 2008, MANUAL DIAGNOSTIC TE, VVolume 1, P576; Pisal S, 2006, AAPS PHARMSCITECH, V7; Rani S, 2014, BIOLOGICALS, V42, P351, DOI 10.1016/j.biologicals.2014.08.006; REED L. J., 1938, AMER JOUR HYG, V27, P493; Samal SK, 2011, BIOLOGY OF PARAMYXOVIRUSES, P69; Schlehuber LD, 2011, VACCINE, V29, P5031, DOI 10.1016/j.vaccine.2011.04.079; Setia S, 2002, VACCINE, V20, P1148, DOI 10.1016/S0264-410X(01)00433-9; Shittu Ismaila, 2016, VirusDisease, V27, P329, DOI 10.1007/s13337-016-0344-6; STEPHENS P, 1968, AUST VET J, V44, P29, DOI 10.1111/j.1751-0813.1967.tb04764.x; Wambura PN, 2011, TROP ANIM HEALTH PRO, V43, P99, DOI 10.1007/s11250-010-9659-2; Wen G., 2012, HUBEI AGR CULT SCI, V51, P5424; Wen GY, 2016, SCI REP-UK, V6, DOI 10.1038/srep22492; Wen GY, 2015, J GEN VIROL, V96, P1219, DOI 10.1099/vir.0.000067; Wen GY, 2013, VIRUS GENES, V46, P542, DOI 10.1007/s11262-012-0871-1; WOOD GW, 1980, J BIOL STAND, V8, P157, DOI 10.1016/S0092-1157(80)80022-9; Young M., 2012, ACIAR MONOGRAPH, V87, P31	35	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							363	10.3390/vaccines9040363			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4XC	33918608	gold, Green Submitted, Green Published			2022-04-29	WOS:000643783000001
J	Pando, R; Stern, S; Nemet, I; Glatman-Freedman, A; Sefty, H; Zuckerman, NS; Drori, Y; Friedman, N; McCauley, JW; Keinan-Boker, L; Mendelson, E; Daniels, RS; Mandelboim, M				Pando, Rakefet; Stern, Shahar; Nemet, Ital; Glatman-Freedman, Aharona; Sefty, Hanna; Zuckerman, Neta S.; Drori, Yaron; Friedman, Nehemya; McCauley, John W.; Keinan-Boker, Lital; Mendelson, Ella; Daniels, Rodney S.; Mandelboim, Michal			Diversity in the Circulation of Influenza A(H3N2) Viruses in the Northern Hemisphere in the 2018-19 Season	VACCINES			English	Article						influenza A; circulation; clade; vaccine		While vaccination is considered the most effective means to prevent influenza infection, its seasonal effectiveness varies, depending on the circulating influenza strains. Here, we characterized the circulation of influenza strains in October-2018 and March-2019 around the world. For this, we used nasopharyngeal samples collected from outpatient and hospitalized patients in Israel and data reported in ECDC, CDC, and WHO databases. Influenza A(H3N2) was dominant in Israel, while in Europe, Asia, and USA, A(H1N1)pdm09 virus circulated first, and then the A(H3N2) virus also appeared. Phylogenetic analysis indicated that A(H3N2) viruses circulating in Israel belonged to clade-3C.3a, while in Europe, Asia, and USA, A(H3N2) viruses belonged to subclade-3C.2a1, but were later replaced by clade-3C.3a viruses in USA. The vaccine A(H3N2) components of that year, A/Singapore/INFIMH-16-0019/2016-(H3N2)-like-viruses, belonged to clade-3C.2a1. The circulation of different influenza subtypes and clades of A(H3N2) viruses in a single season highlights the need for universal influenza vaccines.	[Pando, Rakefet; Glatman-Freedman, Aharona; Sefty, Hanna; Zuckerman, Neta S.; Keinan-Boker, Lital] Israel Minist Hlth, Israel Ctr Dis Control, IL-52621 Ramat Gan, Israel; [Pando, Rakefet; Stern, Shahar; Nemet, Ital; Drori, Yaron; Friedman, Nehemya; Mendelson, Ella; Mandelboim, Michal] Chaim Sheba Med Ctr, Cent Virol Lab, Minist Hlth, IL-52621 Ramat Gan, Israel; [Glatman-Freedman, Aharona; Mendelson, Ella; Mandelboim, Michal] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, IL-6997801 Tel Aviv, Israel; [McCauley, John W.; Daniels, Rodney S.] Francis Crick Inst, Worldwide Influenza Ctr, London NW1 1AT, England; [Keinan-Boker, Lital] Univ Haifa, Sch Publ Hlth, IL-3498838 Haifa, Israel		Mandelboim, M (通讯作者)，Chaim Sheba Med Ctr, Cent Virol Lab, Minist Hlth, IL-52621 Ramat Gan, Israel.; Mandelboim, M (通讯作者)，Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, IL-6997801 Tel Aviv, Israel.	akefet.Pando@sheba.health.gov.il; sternyosha@mail.tau.ac.il; ital.nemet@sheba.health.gov.il; aharona.freedman@moh.gov.il; Hanna.Sefty@MOH.GOV.IL; Neta.Zuckerman@sheba.health.gov.il; Yaron.Drori@sheba.health.gov.il; Nehemya.Friedman@sheba.health.gov.il; John.McCauley@crick.ac.uk; Lital.Keinan2@MOH.GOV.IL; Ella.Mendelson@sheba.health.gov.il; Rod.Daniels@crick.ac.uk; michalman@sheba.health.gov.il		Stern, Shahar/0000-0002-3865-7820; Daniels, Rod/0000-0003-2818-5089; McCauley, John/0000-0002-4744-6347	Francis Crick Institute - Cancer Research UK [FC001030]; UK Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [FC001030]; Wellcome TrustWellcome TrustEuropean Commission [FC001030]	For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. This work was supported in part by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001030), the UK Medical Research Council (FC001030), and the Wellcome Trust (FC001030).	Bedford T, 2015, NATURE, V523, P217, DOI 10.1038/nature14460; Caini S, 2017, EUROSURVEILLANCE, V22, P7, DOI [10.2807/1560-7917.ES.2017.22.35.30606, 10.2807/1560-7917.es.2017.22.35.30606]; Chaves SS, 2013, J INFECT DIS, V208, P1305, DOI 10.1093/infdis/jit316; Davlin SL, 2016, MMWR-MORBID MORTAL W, V65, P567, DOI 10.15585/mmwr.mm6522a3; Debbink K, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006194; Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214; Flannery B, 2020, J INFECT DIS, V221, P8, DOI 10.1093/infdis/jiz543; Gerdil C, 2003, VACCINE, V21, P1776, DOI 10.1016/S0264-410X(03)00071-9; Glatman-Freedman A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010078; Glezen WP, 2013, AM J PUBLIC HEALTH, V103, pE43, DOI 10.2105/AJPH.2012.301137; Kissling E, 2019, EUROSURVEILLANCE, V24, P31, DOI 10.2807/1560-7917.ES.2019.24.48.1900604; Kusznierz G, 2017, J MED VIROL, V89, P1186, DOI 10.1002/jmv.24758; Meningher T, 2014, INFLUENZA OTHER RESP, V8, P422, DOI 10.1111/irv.12249; Pando R, 2018, VACCINE, V36, P1326, DOI 10.1016/j.vaccine.2018.01.085; Pando R, 2017, J CLIN VIROL, V88, P12, DOI 10.1016/j.jcv.2017.01.002; Petrova VN, 2018, NAT REV MICROBIOL, V16, P47, DOI 10.1038/nrmicro.2017.118; Posada D, 2008, MOL BIOL EVOL, V25, P1253, DOI 10.1093/molbev/msn083; Russell CA, 2008, VACCINE, V26, pD31, DOI 10.1016/j.vaccine.2008.07.078; Segaloff H, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.9.1900125; Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211; Tan Y, 2013, J VIROL, V87, P12447, DOI 10.1128/JVI.01039-13; Tsou TP, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.50.17-00767; Vijaykrishna D, 2015, ELIFE, V4, DOI 10.7554/eLife.05055; Zambon MC, 1999, J ANTIMICROB CHEMOTH, V44, P3, DOI 10.1093/jac/44.suppl_2.3	24	1	1	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							375	10.3390/vaccines9040375			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4TE	33924296	gold, Green Published			2022-04-29	WOS:000643772700001
J	Qiu, ZL; Li, ZY; Yan, QH; Li, YW; Xiong, WJ; Wu, KK; Li, XW; Fan, SQ; Zhao, MQ; Ding, HX; Chen, JD				Qiu, Zilong; Li, Zhaoyao; Yan, Quanhui; Li, Yuwan; Xiong, Wenjie; Wu, Keke; Li, Xiaowen; Fan, Shuangqi; Zhao, Mingqiu; Ding, Hongxing; Chen, Jinding			Development of Diagnostic Tests Provides Technical Support for the Control of African Swine Fever	VACCINES			English	Review						African swine fever; ASFV; diagnosis; control; ELISA; epidemic situation	LINKED-IMMUNOSORBENT-ASSAY; ISOTHERMAL AMPLIFICATION; PCR ASSAY; VIRUS; EPIDEMIOLOGY; EXPRESSION; VIRULENCE; PIGS; GENE; TRANSMISSION	African swine fever is a highly contagious global disease caused by the African swine fever virus. Since African swine fever (ASF) was introduced to Georgia in 2007, it has spread to many Eurasian countries at an extremely fast speed. It has recently spread to China and other major pig-producing countries in southeast Asia, threatening global pork production and food security. As there is no available vaccine at present, prevention and control must be carried out based on early detection and strict biosecurity measures. Early detection should be based on the rapid identification of the disease on the spot, followed by laboratory diagnosis, which is essential for disease control. In this review, we introduced the prevalence, transmission routes, eradication control strategies, and diagnostic methods of ASF. We reviewed the various methods of diagnosing ASF, focusing on their technical characteristics and clinical test results. Finally, we give some prospects for improving the diagnosis strategy in the future.	[Qiu, Zilong; Li, Zhaoyao; Yan, Quanhui; Li, Yuwan; Xiong, Wenjie; Wu, Keke; Li, Xiaowen; Fan, Shuangqi; Zhao, Mingqiu; Ding, Hongxing; Chen, Jinding] South China Agr Univ, Coll Vet Med, Dept Microbiol & Immunol, Guangzhou 510642, Peoples R China; [Qiu, Zilong; Li, Zhaoyao; Yan, Quanhui; Li, Yuwan; Xiong, Wenjie; Fan, Shuangqi; Zhao, Mingqiu; Ding, Hongxing; Chen, Jinding] Guangdong Lab Lingnan Modern Agr, Guangzhou 510642, Peoples R China; [Wu, Keke; Li, Xiaowen; Fan, Shuangqi; Zhao, Mingqiu; Ding, Hongxing; Chen, Jinding] Key Lab Zoonosis Prevent & Control Guangdong Prov, Guangzhou 510642, Peoples R China		Chen, JD (通讯作者)，South China Agr Univ, Coll Vet Med, Dept Microbiol & Immunol, Guangzhou 510642, Peoples R China.; Chen, JD (通讯作者)，Guangdong Lab Lingnan Modern Agr, Guangzhou 510642, Peoples R China.; Chen, JD (通讯作者)，Key Lab Zoonosis Prevent & Control Guangdong Prov, Guangzhou 510642, Peoples R China.	qiuzilong@stu.scau.edu.cn; lizhaoyao@stu.scau.edu.cn; yanqh@stu.scau.edu.cn; waner20191028012@stu.scau.edu.cn; wenjiexiong@stu.scau.edu.cn; wukeke@stu.scau.edu.cn; xiaowenlee@stu.scau.edu.cn; shqfan@scau.edu.cn; zmingqiu@scau.edu.cn; dinghx@scau.edu.cn; jdchen@scau.edu.cn	xiaole, wang/AAQ-1953-2021		Science and Technology Program of Guangdong, China [2019B020211003]; Science and Technology Program of Guangzhou, China [201803020005]; Key Research Projects of Universities in Guangdong Province [2019KZDXM026]; Guangdong Major Project of Basic and Applied Basic Research [2020B0301030007]; 111 ProjectMinistry of Education, China - 111 Project [D20008]	This work was supported by grants from the Science and Technology Program of Guangdong, China (2019B020211003), Science and Technology Program of Guangzhou, China (201803020005), the Key Research Projects of Universities in Guangdong Province (2019KZDXM026), Guangdong Major Project of Basic and Applied Basic Research, No. 2020B0301030007, and 111 Project [D20008].	Afonso CL, 2004, J VIROL, V78, P1858, DOI 10.1128/JVI.78.4.1858-1864.2004; Aguero M, 2003, J CLIN MICROBIOL, V41, P4431, DOI 10.1128/JCM.41.9.4431-4434.2003; ALCARAZ C, 1995, J VIROL METHODS, V52, P111, DOI 10.1016/0166-0934(94)00150-F; Alejo A, 2018, J VIROL, V92, DOI 10.1128/JVI.01293-18; ALEXANDER FCM, 1992, ANN NY ACAD SCI, V653, P251, DOI 10.1111/j.1749-6632.1992.tb19654.x; Alonso C, 2018, J GEN VIROL, V99, P613, DOI 10.1099/jgv.0.001049; Andres G, 2002, J VIROL, V76, P12473, DOI 10.1128/JVI.76.24.12473-12482.2002; Andres G, 2001, J VIROL, V75, P6758, DOI 10.1128/JVI.75.15.6758-6768.2001; Andres G, 1997, J VIROL, V71, P2331; Andres G, 2001, J BIOL CHEM, V276, P780, DOI 10.1074/jbc.M006844200; Aslanyan L, 2020, VET WORLD, V13, P2118, DOI 10.14202/vetworld.2020.2118-2125; Bai J, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02830; Basto AP, 2006, ARCH VIROL, V151, P819, DOI 10.1007/s00705-005-0654-2; Belak S, 2001, Expert Rev Mol Diagn, V1, P434; Beltran-Alcrudo D., 2017, AFRICAN SWINE FEVER; Biagetti M, 2018, TALANTA, V184, P35, DOI 10.1016/j.talanta.2018.02.095; Bisimwa PN, 2020, VIROL J, V17, DOI 10.1186/s12985-020-01398-8; BLASCO R, 1989, VIROLOGY, V168, P330, DOI 10.1016/0042-6822(89)90273-0; Blome S, 2013, VIRUS RES, V173, P122, DOI 10.1016/j.virusres.2012.10.026; Boinas FS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020383; Boshoff CI, 2007, VET MICROBIOL, V121, P45, DOI 10.1016/j.vetmic.2006.11.007; Nga BTT, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00392; Gallardo MC, 2015, PORCINE HEALTH MANAG, V1, DOI 10.1186/s40813-015-0013-y; Carrasco L, 2002, J COMP PATHOL, V126, P194, DOI 10.1053/jcpa.2001.0543; Carrascosa Angel L, 2011, Curr Protoc Cell Biol, VChapter 26, DOI 10.1002/0471143030.cb2614s53; Chapman DAG, 2008, J GEN VIROL, V89, P397, DOI 10.1099/vir.0.83343-0; Costard S, 2013, VIRUS RES, V173, P191, DOI 10.1016/j.virusres.2012.10.030; Costard S, 2009, PHILOS T R SOC B, V364, P2683, DOI 10.1098/rstb.2009.0098; Cubillos C, 2013, VIRUS RES, V173, P159, DOI 10.1016/j.virusres.2012.10.021; Cwynar P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040310; D'Agata Roberta, 2012, Artif DNA PNA XNA, V3, P45, DOI 10.4161/adna.21383; Danzetta ML, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00296; de Oliveira VL, 2011, ARCH VIROL, V156, P597, DOI 10.1007/s00705-010-0894-7; De Paula Lyra T M, 1986, Rev Sci Tech, V5, P771, DOI 10.20506/rst.5.3.261; Tran DH, 2021, TRANSBOUND EMERG DIS, V68, P2595, DOI 10.1111/tbed.13879; Dixon LK, 2019, VIRUS RES, V266, P25, DOI 10.1016/j.virusres.2019.04.002; Dixon LK, 2020, ANNU REV ANIM BIOSCI, V8, P221, DOI 10.1146/annurev-animal-021419-083741; Dixon LK, 2013, VIRUS RES, V173, P3, DOI 10.1016/j.virusres.2012.10.020; ENJUANES L, 1976, J GEN VIROL, V32, P479, DOI 10.1099/0022-1317-32-3-479; Erickson A, 2018, TRANSBOUND EMERG DIS, V65, pe272, DOI 10.1111/tbed.12749; Euler M, 2012, J CLIN VIROL, V54, P308, DOI 10.1016/j.jcv.2012.05.006; Fan XX, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01696; FAO, AU IBAR ILRI REGIONA; Feng T, 2018, FOOD CHEM, V245, P641, DOI 10.1016/j.foodchem.2017.08.107; Fernandez-Pinero J, 2013, TRANSBOUND EMERG DIS, V60, P48, DOI 10.1111/j.1865-1682.2012.01317.x; Fraczyk M, 2016, LETT APPL MICROBIOL, V62, P386, DOI 10.1111/lam.12569; Franzoni G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030549; Gabriel C, 2011, EMERG INFECT DIS, V17, P2342, DOI 10.3201/eid1712.110430; Gallardo C, 2006, J CLIN MICROBIOL, V44, P950, DOI 10.1128/JCM.44.3.950-956.2006; Gallardo C, 2015, TRANSBOUND EMERG DIS, V62, P612, DOI 10.1111/tbed.12431; Gallardo C, 2015, J CLIN MICROBIOL, V53, P2555, DOI 10.1128/JCM.00857-15; Gallardo C, 2009, VIRUS GENES, V38, P85, DOI 10.1007/s11262-008-0293-2; Gallardo C, 2019, TRANSBOUND EMERG DIS, V66, P1399, DOI 10.1111/tbed.13132; Gallardo C, 2014, EMERG INFECT DIS, V20, P1544, DOI 10.3201/eid2009.140554; Gallardo C, 2011, EMERG INFECT DIS, V17, P1556, DOI 10.3201/eid1708.101877; Gallardo C, 2009, CLIN VACCINE IMMUNOL, V16, P1012, DOI 10.1128/CVI.00408-08; Gao Y, 2018, SENSOR ACTUAT B-CHEM, V274, P304, DOI 10.1016/j.snb.2018.07.164; Garcia-Escudero R, 1998, J VIROL, V72, P3185; Gaudreault NN, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00215; Gill P, 2008, NUCLEOS NUCLEOT NUCL, V27, P224, DOI 10.1080/15257770701845204; Gomez-Villamandos JC, 2013, VIRUS RES, V173, P140, DOI 10.1016/j.virusres.2013.01.017; Gomez-Villamandos JC, 1998, J COMP PATHOL, V118, P1, DOI 10.1016/S0021-9975(98)80023-6; Gonzague M, 2001, EPIDEMIOL INFECT, V126, P453, DOI 10.1017/S0950268801005465; Guinat C, 2014, VET RES, V45, DOI 10.1186/s13567-014-0093-8; HARESNAPE JM, 1989, EPIDEMIOL INFECT, V102, P507, DOI 10.1017/S0950268800030223; Hu L, 2015, POL J VET SCI, V18, P715, DOI 10.1515/pjvs-2015-0093; Hurtado C, 2010, J VIROL METHODS, V164, P131, DOI 10.1016/j.jviromet.2009.11.030; Hutchings GH, 2006, J VIROL METHODS, V131, P213, DOI 10.1016/j.jviromet.2005.08.009; Iyer LA, 2006, VIRUS RES, V117, P156, DOI 10.1016/j.virusres.2006.01.009; Iyer LM, 2001, J VIROL, V75, P11720, DOI 10.1128/JVI.75.23.11720-11734.2001; James HE, 2010, J VIROL METHODS, V164, P68, DOI 10.1016/j.jviromet.2009.11.034; Jia N, 2017, J VET RES, V61, P135, DOI 10.1515/jvetres-2017-0017; Jori F, 2013, VIRUS RES, V173, P212, DOI 10.1016/j.virusres.2012.10.005; Jurado C, 2018, TRANSBOUND EMERG DIS, V65, P557, DOI 10.1111/tbed.12740; Kazakova AS, 2017, TRANSBOUND EMERG DIS, V64, P1479, DOI 10.1111/tbed.12539; King DP, 2003, J VIROL METHODS, V107, P53, DOI 10.1016/S0166-0934(02)00189-1; Kollnberger SD, 2002, J GEN VIROL, V83, P1331, DOI 10.1099/0022-1317-83-6-1331; Kuboki N, 2003, J CLIN MICROBIOL, V41, P5517, DOI 10.1128/JCM.41.12.5517-5524.2003; Laddomada A, 2019, TRANSBOUND EMERG DIS, V66, P1114, DOI 10.1111/tbed.13138; Leitao A, 2001, J GEN VIROL, V82, P513, DOI 10.1099/0022-1317-82-3-513; Liu L, 2017, TRANSBOUND EMERG DIS, V64, pE31, DOI 10.1111/tbed.12538; Liu S, 2019, CELL HOST MICROBE, V26, P836, DOI 10.1016/j.chom.2019.11.004; Loi F, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030521; Lubisi BA, 2005, ARCH VIROL, V150, P2439, DOI 10.1007/s00705-005-0602-1; Lubisi BA, 2007, VIRUS GENES, V35, P729, DOI 10.1007/s11262-007-0148-2; Luo YZ, 2017, ARCH VIROL, V162, P191, DOI 10.1007/s00705-016-3069-3; MALMQUIST WA, 1960, AM J VET RES, V21, P104; Malogolovkin A, 2015, EMERG INFECT DIS, V21, P312, DOI 10.3201/eid2102.140649; Sanchez-Vizcaino JM, 2013, VET MICROBIOL, V165, P45, DOI 10.1016/j.vetmic.2012.11.030; MCVICAR JW, 1984, AM J VET RES, V45, P1535; Miao FM, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01004; MONTGOMERY R. Eustace, 1921, Journal of Comparative Pathology and Therapeutics, V34, P159; Morelle K, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00378; Moura JA, 2010, REV SCI TECH OIE, V29, P549, DOI 10.20506/rst.29.3.1992; Mur L, 2012, TRANSBOUND EMERG DIS, V59, P526, DOI 10.1111/j.1865-1682.2012.01308.x; Neilan JG, 2004, VIROLOGY, V319, P337, DOI 10.1016/j.virol.2003.11.011; Neilan JG, 1997, VIROLOGY, V230, P252, DOI 10.1006/viro.1997.8481; Notomi T, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.12.e63; OIE, REPORTS ASF OIE WORL; OIE (Office International des Epizooties), 2019, MANUAL DIAGNOSTIC TE; Olesen AS, 2017, VET MICROBIOL, V211, P92, DOI 10.1016/j.vetmic.2017.10.004; Oura CAL, 2013, VIRUS RES, V173, P150, DOI 10.1016/j.virusres.2012.10.022; Oviedo JM, 1997, J VIROL METHODS, V64, P27, DOI 10.1016/S0166-0934(96)02140-4; PAN IC, 1972, CAN J COMPARAT MED, V36, P309; PAN IC, 1982, J CLIN MICROBIOL, V16, P650, DOI 10.1128/JCM.16.4.650-655.1982; PARKER J, 1968, NATURE, V219, P524, DOI 10.1038/219524a0; PASTOR MJ, 1990, J VIROL METHODS, V28, P67, DOI 10.1016/0166-0934(90)90088-W; PASTOR MJ, 1990, AM J VET RES, V51, P1540; PASTOR MJ, 1992, J VET DIAGN INVEST, V4, P254, DOI 10.1177/104063879200400305; PASTOR MJ, 1989, CAN J VET RES, V53, P105; Penrith ML, 2013, VIRUS RES, V173, P228, DOI 10.1016/j.virusres.2012.10.011; Perez-Filgueira DA, 2006, J CLIN MICROBIOL, V44, P3114, DOI 10.1128/JCM.00406-06; Piepenburg O, 2006, PLOS BIOL, V4, P1115, DOI 10.1371/journal.pbio.0040204; PLOWRIGHT W, 1969, NATURE, V221, P1071, DOI 10.1038/2211071a0; Rowlands RJ, 2008, EMERG INFECT DIS, V14, P1870, DOI 10.3201/eid1412.080591; Salas ML, 2013, VIRUS RES, V173, P29, DOI 10.1016/j.virusres.2012.09.016; Salguero FJ, 2002, VET IMMUNOL IMMUNOP, V90, P11, DOI 10.1016/S0165-2427(02)00225-8; Sanchez EG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09948-x; Sanchez-Cordon PJ, 2018, VET J, V233, P41, DOI 10.1016/j.tvjl.2017.12.025; Sanchez-Vizcaino JM, 2015, J COMP PATHOL, V152, P9, DOI 10.1016/j.jcpa.2014.09.003; Sanchez-Vizcaino JM, 2012, TRANSBOUND EMERG DIS, V59, P27, DOI 10.1111/j.1865-1682.2011.01293.x; SANTURDE G, 1988, ARCH VIROL, V98, P117, DOI 10.1007/BF01321012; SANZ A, 1985, J VIROL, V54, P199, DOI 10.1128/JVI.54.1.199-206.1985; Sastre P, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0831-4; Schulz K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020336; TABARES E, 1981, ARCH VIROL, V70, P297, DOI 10.1007/BF01315136; Tignon M, 2011, J VIROL METHODS, V178, P161, DOI 10.1016/j.jviromet.2011.09.007; Vidal MI, 1997, J VIROL METHODS, V66, P211, DOI 10.1016/S0166-0934(97)00059-1; VILLEDA CJ, 1993, ARCH VIROL, V130, P71, DOI 10.1007/BF01318997; VILLEDA CJ, 1993, ARCH VIROL, V133, P467, DOI 10.1007/BF01313784; Wang AP, 2020, TRANSBOUND EMERG DIS, V67, P284, DOI 10.1111/tbed.13350; Wang JC, 2017, CAN J VET RES, V81, P308; Wang N, 2019, SCIENCE, V366, P640, DOI 10.1126/science.aaz1439; WARDLEY RC, 1979, J HYG-CAMBRIDGE, V83, P363, DOI 10.1017/S0022172400026152; WILKINSON PJ, 1981, J COMP PATHOL, V91, P277, DOI 10.1016/0021-9975(81)90033-5; Xiao L, 2018, J VIROL METHODS, V261, P104, DOI 10.1016/j.jviromet.2018.08.017; Xu GL, 2012, SCI REP-UK, V2, DOI [10.1038/srep00986, 10.1038/srep00246]; Yu LS, 2021, J MICROBIOL IMMUNOL, V54, P963, DOI 10.1016/j.jmii.2020.08.003; Zhao DM, 2019, EMERG MICROBES INFEC, V8, P438, DOI 10.1080/22221751.2019.1590128; Zheng FY, 2020, ANAL BIOCHEM, V597, DOI 10.1016/j.ab.2020.113672; Zhu YS, 2020, ANAL CHIM ACTA, V1140, P30, DOI 10.1016/j.aca.2020.10.011; Zsak L, 1998, J VIROL, V72, P1028, DOI 10.1128/JVI.72.2.1028-1035.1998	142	2	2	8	17	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							343	10.3390/vaccines9040343			26	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4OG	33918128	Green Published, gold			2022-04-29	WOS:000643759800001
J	Torracinta, L; Tanner, R; Vanderslott, S				Torracinta, Louis; Tanner, Rachel; Vanderslott, Samantha			MMR Vaccine Attitude and Uptake Research in the United Kingdom: A Critical Review	VACCINES			English	Review						MMR; vaccine hesitancy; critical review; Wakefield; child immunisation; United Kingdom	DECISION-MAKING; MEASLES-MUMPS; UK PARENTS; RUBELLA; IMMUNIZATION; COVERAGE; CHILDREN; BELIEFS; VIEWS; COMMUNITIES	This review critically assesses the body of research about Measles-Mumps-and-Rubella (MMR) vaccine attitudes and uptake in the United Kingdom (UK) over the past 10 years. We searched PubMed and Scopus, with terms aimed at capturing relevant literature on attitudes about, and uptake of, the MMR vaccine. Two researchers screened for abstract eligibility and after de-duplication 934 studies were selected. After screening, 40 references were included for full-text review and thematic synthesis by three researchers. We were interested in the methodologies employed and grouped findings by whether studies concerned: (1) Uptake and Demographics; (2) Beliefs and Attitudes; (3) Healthcare Worker Focus; (4) Experimental and Psychometric Intervention; and (5) Mixed Methods. We identified group and individual level determinants for attitudes, operating directly and indirectly, which influence vaccine uptake. We found that access issues, often ignored within the public "anti-vax" debate, remain highly pertinent. Finally, a consistent theme was the effect of misinformation or lack of knowledge and trust in healthcare, often stemming from the Wakefield controversy. Future immunisation campaigns for children, including for COVID-19, should consider both access and attitudinal aspects of vaccination, and incorporate a range of methodologies to assess progress, taking into account socio-economic variables and the needs of disadvantaged groups.	[Torracinta, Louis; Tanner, Rachel] Univ Oxford, Inst Human Sci, Oxford OX2 6QS, England; [Tanner, Rachel] Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England; [Vanderslott, Samantha] Univ Oxford, Oxford Vaccine Grp, Oxford OX3 7LE, England		Vanderslott, S (通讯作者)，Univ Oxford, Oxford Vaccine Grp, Oxford OX3 7LE, England.	louis.torracinta1@student.lshtm.ac.uk; rachel.tanner@ndm.ox.ac.uk; samantha.vanderslott@paediatrics.ox.ac.uk		Vanderslott, Samantha/0000-0001-8685-7758	GCRF Networks in Vaccines Research and Development VALIDATE Network; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [MR/R005850/1]; National Institute of Health ResearchNational Institute for Health Research (NIHR) [ODA-02-01]	The authors would like to thank Eli Harris and the other healthcare librarians at the Oxford Medical Research Library for their assistance in developing the search queries utilised in the review. RT is funded by a Fellowship from the GCRF Networks in Vaccines Research and Development VALIDATE Network, which is co-funded by the MRC and BBSRC (MR/R005850/1). SV is funded by National Institute of Health Research (ODA-02-01).	Altinoluk-Davis F, 2020, J PUBLIC HEALTH-UK, V42, P416, DOI 10.1093/pubmed/fdaa004; Anderberg D, 2011, J HEALTH ECON, V30, P515, DOI 10.1016/j.jhealeco.2011.01.009; Babalola S, 2011, J PAEDIATR CHILD H, V47, P276, DOI 10.1111/j.1440-1754.2010.01956.x; Baker D, 2011, J EPIDEMIOL COMMUN H, V65, P346, DOI 10.1136/jech.2008.085142; Bell S, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000874; Bell S, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8454-x; Bell S, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028228; Bolton-Maggs D, 2012, VACCINE, V30, P5081, DOI 10.1016/j.vaccine.2012.05.078; Brown K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019381; Brown KF, 2012, VACCINE, V30, P1855, DOI 10.1016/j.vaccine.2011.12.127; Brown KF, 2011, VACCINE, V29, P1700, DOI 10.1016/j.vaccine.2010.12.030; CASP UK, CASP CHECKL; Chang LV, 2018, HEALTH ECON, V27, P1043, DOI 10.1002/hec.3645; Cockman P, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5703; Danis K, 2010, VACCINE, V28, P1861, DOI 10.1016/j.vaccine.2009.11.078; Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212; Edelstein M, 2020, VACCINE, V38, P5297, DOI 10.1016/j.vaccine.2020.05.082; Ellis Nicola, 2020, Br J Nurs, V29, P822, DOI 10.12968/bjon.2020.29.14.822; Emerson E, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7106-5; Forster AS, 2016, SSM-POPUL HLTH, V2, P603, DOI 10.1016/j.ssmph.2016.07.005; Friederichs V, 2006, ARCH DIS CHILD, V91, P465, DOI 10.1136/adc.2005.085944; Gardner B, 2010, PSYCHOL HEALTH MED, V15, P220, DOI 10.1080/13548501003623963; Ghebreyesus T.A, 2020, DIR GEN OP REM MED B; Guillaume Louise, 2008, Health Informatics J, V14, P323, DOI 10.1177/1460458208096654; Haider EA, 2019, VACCINE, V37, P5614, DOI 10.1016/j.vaccine.2019.07.080; Hill MC, 2021, J ADV NURS, V77, P948, DOI 10.1111/jan.14652; Hill Marie C, 2013, Br J Nurs, V22, P893; Hilton S, 2013, VACCINE, V31, P2543, DOI 10.1016/j.vaccine.2013.04.023; Hungerford D, 2016, EPIDEMIOL INFECT, V144, P1201, DOI 10.1017/S0950268815002599; Hutchings HA, 2016, VACCINE, V34, P1773, DOI 10.1016/j.vaccine.2016.02.049; Jackson C, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4178-y; Jackson C, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-475; Jackson C, 2010, HEALTH EDUC J, V69, P74, DOI 10.1177/0017896910363146; Johnson S, 2014, PSYCHOL HEALTH, V29, P861, DOI 10.1080/08870446.2014.892940; Kennedy C, 2014, INT J BEHAV MED, V21, P3, DOI 10.1007/s12529-013-9356-4; Klass P, 2021, NEW ENGL J MED, V384, P589, DOI 10.1056/NEJMp2034765; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lewis J, 2003, NAT REV IMMUNOL, V3, P913, DOI 10.1038/nri1228; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Maduma-Butshe A, 2013, J PUBLIC HEALTH-UK, V35, P27, DOI 10.1093/pubmed/fds052; McClure CC, 2017, CLIN THER, V39, P1550, DOI 10.1016/j.clinthera.2017.07.003; McHale P, 2016, EPIDEMIOL INFECT, V144, P870, DOI 10.1017/S0950268815001909; Moher D, 2009, J CLIN EPIDEMIOL, V62, P1006, DOI 10.1016/j.jclinepi.2009.06.005; Mytton OT, 2013, OCCUP MED-OXFORD, V63, P189, DOI 10.1093/occmed/kqt002; Newton P, 2017, CHILD CARE HLTH DEV, V43, P504, DOI 10.1111/cch.12453; NHS, PUBL HLTH ROL HLTH V; Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477; Osam CS, 2020, EUR J EPIDEMIOL, V35, P879, DOI 10.1007/s10654-020-00632-5; Pearce A, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003152; Perry M, 2020, EUR J PEDIATR, V179, P171, DOI 10.1007/s00431-019-03485-7; Public Health England, 2019, UK MEASL RUB EL STRA; Public Health England, CHILDH VACC COV STAT; Public Health England, MEASL NOT DEATHS ENG; Public Health Northern Ireland, 4 DEC PUBL HLTH NO I; Public Health Scotland, 2000, HLTH SCOTL; Ramsay M, 1994, Commun Dis Rep CDR Rev, V4, pR141; Redman EA, 2011, PUBLIC HEALTH, V125, P142, DOI 10.1016/j.puhe.2010.10.002; Redsell S.A., 2010, PRIMARY HLTH CARE RE, V11, P51, DOI [10.1017/S1463423609990284, DOI 10.1017/S1463423609990284]; Sandford H, 2015, VACCINE, V33, P1218, DOI 10.1016/j.vaccine.2014.12.006; Shourie S, 2013, VACCINE, V31, P6003, DOI 10.1016/j.vaccine.2013.10.025; Smith D, 2017, CRIT PUBLIC HEALTH, V27, P238, DOI 10.1080/09581596.2016.1211254; Tabacchi G, 2016, HUM VACC IMMUNOTHER, V12, P1909, DOI 10.1080/21645515.2016.1151990; Tannous Leen Khader, 2014, JRSM Open, V5, p2054270414523408, DOI 10.1177/2054270414523408; Tickner S, 2010, CHILD CARE HLTH DEV, V36, P190, DOI 10.1111/j.1365-2214.2009.01020.x; Tickner S, 2010, VACCINE, V28, P3350, DOI 10.1016/j.vaccine.2010.02.083; Tomlinson N., 2013, EQUAL HLTH CARE, V10, P101; Tubeuf S, 2014, BRIT J GEN PRACT, V64, pE493, DOI 10.3399/bjgp14X680977; Venkatesh A, 2020, BRIT J GEN PRACT, V70, P110, DOI 10.3399/bjgp20X708401; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; Wallace C, 2006, BMJ-BRIT MED J, V332, P146, DOI 10.1136/bmj.38678.681840.68; Walsh S, 2015, EPIDEMIOL INFECT, V143, P550, DOI 10.1017/S0950268814000752; Wellcome Trust, 2018, WELLC GLOB MON; Wilder-Smith AB, 2020, J EPIDEMIOL GLOB HEA, V10, P46, DOI 10.2991/jegh.k.191117.001; Wilson K, 2003, ARCH PEDIAT ADOL MED, V157, P628, DOI 10.1001/archpedi.157.7.628; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018	76	3	3	1	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							402	10.3390/vaccines9040402			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RS4QP	33921593	Green Published, gold			2022-04-29	WOS:000643765900001
J	Zhou, L; Ge, XN; Yang, HC				Zhou, Lei; Ge, Xinna; Yang, Hanchun			Porcine Reproductive and Respiratory Syndrome Modified Live Virus Vaccine: A "Leaky" Vaccine with Debatable Efficacy and Safety	VACCINES			English	Review						porcine reproductive and respiratory syndrome virus (PRRSV); modified live virus (MLV) vaccine; attenuation; heterologous cross-protection; safety; reversion to virulence; recombination		Porcine reproductive and respiratory syndrome (PRRS) caused by the PRRS virus (PRRSV) is one of the most economically important diseases, that has significantly impacted the global pork industry for over three decades, since it was first recognized in the United States in the late 1980s. Attributed to the PRRSV extensive genetic and antigenic variation and rapid mutability and evolution, nearly worldwide epidemics have been sustained by a set of emerging and re-emerging virus strains. Since the first modified live virus (MLV) vaccine was commercially available, it has been widely used for more than 20 years, for preventing and controlling PRRS. On the one hand, MLV can induce a protective immune response against homologous viruses by lightening the clinical signs of pigs and reducing the virus transmission in the affected herd, as well as helping to cost-effectively increase the production performance on pig farms affected by heterologous viruses. On the other hand, MLV can still replicate in the host, inducing viremia and virus shedding, and it fails to confer sterilizing immunity against PRRSV infection, that may accelerate viral mutation or recombination to adapt the host and to escape from the immune response, raising the risk of reversion to virulence. The unsatisfied heterologous cross-protection and safety issue of MLV are two debatable characterizations, which raise the concerns that whether it is necessary or valuable to use this leaky vaccine to protect the field viruses with a high probability of being heterologous. To provide better insights into the immune protection and safety related to MLV, recent advances and opinions on PRRSV attenuation, protection efficacy, immunosuppression, recombination, and reversion to virulence are reviewed here, hoping to give a more comprehensive recognition on MLV and to motivate scientific inspiration on novel strategies and approaches of developing the next generation of PRRS vaccine.	[Zhou, Lei; Ge, Xinna; Yang, Hanchun] China Agr Univ, Coll Vet Med, Minist Agr & Rural Affairs, Key Lab Anim Epidemiol, Beijing 100193, Peoples R China		Yang, HC (通讯作者)，China Agr Univ, Coll Vet Med, Minist Agr & Rural Affairs, Key Lab Anim Epidemiol, Beijing 100193, Peoples R China.	Leosj@cau.edu.cn; gexn@cau.edu.cn; yanghanchun1@cau.edu.cn		Ge, Xinna/0000-0002-5368-9687; zhou, lei/0000-0002-8837-3965	China Agriculture Research System [CARS-35]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31772759]	This research was funded by the China Agriculture Research System (CARS-35) and the National Natural Science Foundation of China (31772759).	Adams MJ, 2016, ARCH VIROL, V161, P2921, DOI 10.1007/s00705-016-2977-6; An TQ, 2011, VET MICROBIOL, V149, P104, DOI 10.1016/j.vetmic.2010.11.001; Arruda AG, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11080712; Bai XF, 2016, VACCINE, V34, P5540, DOI 10.1016/j.vaccine.2016.09.048; BANNER LR, 1991, VIROLOGY, V185, P441, DOI 10.1016/0042-6822(91)90795-D; BARON T, 1992, ANN RECH VET, V23, P161; Bautista EM, 1997, VIRAL IMMUNOL, V10, P83, DOI 10.1089/vim.1997.10.83; Bian T, 2017, INFECT GENET EVOL, V54, P279, DOI 10.1016/j.meegid.2017.07.016; Bloom DE, 2018, P NATL ACAD SCI USA, V115, P12868, DOI 10.1073/pnas.1717157115; Bottcher J, 2014, BERL MUNCH TIERARZTL, V127, P305, DOI 10.2376/0005-9366-127-305; Botner A, 1999, VET MICROBIOL, V68, P187, DOI 10.1016/S0378-1135(99)00053-X; Botner A, 1997, VET REC, V141, P497, DOI 10.1136/vr.141.19.497; Calvert JG, 2007, J VIROL, V81, P7371, DOI 10.1128/JVI.00513-07; Calvert JG, 2017, VET MICROBIOL, V205, P80, DOI 10.1016/j.vetmic.2017.03.037; Canelli E, 2018, VET MICROBIOL, V226, P89, DOI 10.1016/j.vetmic.2018.10.001; Cano JP, 2007, AM J VET RES, V68, P565, DOI 10.2460/ajvr.68.5.565; Chai WD, 2020, VET MICROBIOL, V248, DOI 10.1016/j.vetmic.2020.108805; Charerntantanakul W, 2018, VET IMMUNOL IMMUNOP, V205, P24, DOI 10.1016/j.vetimm.2018.10.005; Charerntantanakul Wasin, 2012, World J Virol, V1, P23, DOI 10.5501/wjv.v1.i1.23; Chase-Topping M, 2020, VACCINE, V38, P3050, DOI 10.1016/j.vaccine.2020.02.015; Chen ZC, 2006, P NATL ACAD SCI USA, V103, P1882, DOI 10.1073/pnas.0510598103; Choi K, 2016, VET REC, V178, P291, DOI 10.1136/vr.103529; CHRISTIANSON WT, 1993, CAN J VET RES, V57, P262; ChristopherHennings J, 1997, AM J VET RES, V58, P40; Coleman JR, 2008, SCIENCE, V320, P1784, DOI 10.1126/science.1155761; COLLINS JE, 1992, J VET DIAGN INVEST, V4, P117, DOI 10.1177/104063879200400201; Costers S, 2008, ARCH VIROL, V153, P1453, DOI 10.1007/s00705-008-0135-5; Cui JR, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010106; Das PB, 2011, VIROLOGY, V410, P385, DOI 10.1016/j.virol.2010.12.002; Dea S, 1995, Adv Exp Med Biol, V380, P95; Dhakal S, 2019, VET RES, V50, DOI 10.1186/s13567-019-0712-5; Dwivedi V, 2011, VACCINE, V29, P4058, DOI 10.1016/j.vaccine.2011.03.006; Eclercy J, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030296; Ellingson JS, 2010, VACCINE, V28, P2679, DOI 10.1016/j.vaccine.2009.12.073; Foss DL, 2002, VIRAL IMMUNOL, V15, P557, DOI 10.1089/088282402320914502; Galliher-Beckley A, 2015, VACCINE, V33, P3518, DOI 10.1016/j.vaccine.2015.05.058; Gao L, 2015, VIROLOGY, V485, P135, DOI 10.1016/j.virol.2015.07.012; Goldberg TL, 2003, VIROLOGY, V317, P197, DOI 10.1016/j.virol.2003.07.009; Guo BQ, 2013, VIROLOGY, V435, P372, DOI 10.1016/j.virol.2012.09.013; Guo R, 2016, J VIROL, V90, P5163, DOI 10.1128/JVI.00036-16; Han J, 2017, VET MICROBIOL, V209, P30, DOI 10.1016/j.vetmic.2017.02.020; Han K, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-12; Han W, 2009, VIRUS GENES, V38, P276, DOI 10.1007/s11262-008-0322-1; Hou FH, 2020, PEERJ, V8, DOI 10.7717/peerj.8840; Hu J, 2014, TRANSBOUND EMERG DIS, V61, P109, DOI 10.1111/tbed.12016; Huang YW, 2010, VIRUS RES, V154, P141, DOI 10.1016/j.virusres.2010.07.020; Iseki H, 2017, J VET MED SCI, V79, P765, DOI 10.1292/jvms.16-0536; Islam MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171828; Islam MA, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2849-1; Jeong J, 2018, TRANSBOUND EMERG DIS, V65, P1227, DOI 10.1111/tbed.12862; Jeong J, 2018, VET MICROBIOL, V223, P119, DOI 10.1016/j.vetmic.2018.08.008; Jiang YF, 2015, VET MICROBIOL, V179, P242, DOI 10.1016/j.vetmic.2015.06.015; Jiang YF, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00618; Karniychuk UU, 2010, BMC VET RES, V6, DOI 10.1186/1746-6148-6-30; Khatun A, 2016, J VIROL, V90, P4454, DOI 10.1128/JVI.02836-15; Kim T, 2015, CLIN VACCINE IMMUNOL, V22, P631, DOI 10.1128/CVI.00001-15; Kimman TG, 2009, VACCINE, V27, P3704, DOI 10.1016/j.vaccine.2009.04.022; Kiss I, 2006, ARCH VIROL, V151, P2269, DOI 10.1007/s00705-006-0805-0; Ko SS, 2016, VET IMMUNOL IMMUNOP, V172, P43, DOI 10.1016/j.vetimm.2016.02.016; Kupferschmidt K, 2015, SCIENCE, V349, P461, DOI 10.1126/science.349.6247.461; Kvisgaard LK, 2020, TRANSBOUND EMERG DIS, V67, P1786, DOI 10.1111/tbed.13555; Kwon B, 2008, VIROLOGY, V380, P371, DOI 10.1016/j.virol.2008.07.030; Kwon B, 2006, VACCINE, V24, P7071, DOI 10.1016/j.vaccine.2006.07.010; Labarque GG, 2000, J GEN VIROL, V81, P1327, DOI 10.1099/0022-1317-81-5-1327; Lager KM, 2014, VACCINE, V32, P6457, DOI 10.1016/j.vaccine.2014.09.046; Lager KM, 1999, AM J VET RES, V60, P1022; LAI MMC, 1985, J VIROL, V56, P449, DOI 10.1128/JVI.56.2.449-456.1985; LAI MMC, 1992, MICROBIOL REV, V56, P61, DOI 10.1128/MMBR.56.1.61-79.1992; Le Nouen C, 2014, P NATL ACAD SCI USA, V111, P13169, DOI 10.1073/pnas.1411290111; Lee C, 2004, VIRUS RES, V104, P33, DOI 10.1016/j.virusres.2004.03.001; Leng X, 2012, CLIN VACCINE IMMUNOL, V19, P1199, DOI 10.1128/CVI.05646-11; Leng X, 2012, VET MICROBIOL, V157, P50, DOI 10.1016/j.vetmic.2011.12.012; Levi LI, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001163; Li C, 2016, TRANSBOUND EMERG DIS, V63, P474, DOI 10.1111/tbed.12530; Li J, 2012, VIROLOGY, V433, P367, DOI 10.1016/j.virol.2012.08.026; Li X, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/416727; Li YY, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.00330-16; Linhares DCL, 2012, VACCINE, V30, P407, DOI 10.1016/j.vaccine.2011.10.075; Liu P, 2018, VET MICROBIOL, V227, P133, DOI 10.1016/j.vetmic.2018.10.004; Lowe JF, 2006, JAVMA-J AM VET MED A, V228, P1082, DOI 10.2460/javma.228.7.1082; Lowe JF, 2005, JAVMA-J AM VET MED A, V226, P1707, DOI 10.2460/javma.2005.226.1707; Lu WH, 2012, J VIROL, V86, P9543, DOI 10.1128/JVI.01341-12; Lunney JK, 2016, ANNU REV ANIM BIOSCI, V4, P129, DOI 10.1146/annurev-animal-022114-111025; Lunney JK, 2010, VIRUS RES, V154, P1, DOI 10.1016/j.virusres.2010.10.009; Ma ZX, 2017, J GEN VIROL, V98, P1720, DOI 10.1099/jgv.0.000819; Madapong A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58626-y; Martelli P, 2009, VACCINE, V27, P3788, DOI 10.1016/j.vaccine.2009.03.028; Meng XJ, 2012, TRANSBOUND EMERG DIS, V59, P85, DOI 10.1111/j.1865-1682.2011.01291.x; Molina RM, 2008, VET IMMUNOL IMMUNOP, V126, P283, DOI 10.1016/j.vetimm.2008.08.002; Morgan AJ, 2011, VACCINE, V29, pD152, DOI 10.1016/j.vaccine.2011.08.128; Mulupuri P, 2008, J VIROL, V82, P358, DOI 10.1128/JVI.01023-07; Murtaugh MP, 2010, VIRUS RES, V154, P18, DOI 10.1016/j.virusres.2010.08.015; Nan YC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01635; Ni YY, 2014, VIROLOGY, V450, P132, DOI 10.1016/j.virol.2013.12.009; Oh T, 2019, CAN J VET RES, V83, P57; Opriessnig T, 2002, J VIROL, V76, P11837, DOI 10.1128/JVI.76.23.11837-11844.2002; Osorio FA, 2002, VIROLOGY, V302, P9, DOI 10.1006/viro.2002.1612; Ouyang K, 2016, VET RES, V47, DOI 10.1186/s13567-016-0331-3; Park C, 2020, VIROLOGY, V540, P172, DOI 10.1016/j.virol.2019.10.019; Park C, 2015, VET MICROBIOL, V177, P87, DOI 10.1016/j.vetmic.2015.02.020; Park C, 2014, VET MICROBIOL, V172, P432, DOI 10.1016/j.vetmic.2014.05.030; Pileri E, 2017, VET MICROBIOL, V201, P18, DOI 10.1016/j.vetmic.2016.12.012; Pileri E, 2017, PREV VET MED, V138, P147, DOI 10.1016/j.prevetmed.2017.01.008; Pileri E, 2016, VET RES, V47, DOI 10.1186/s13567-016-0391-4; Pileri E, 2015, VET MICROBIOL, V175, P7, DOI 10.1016/j.vetmic.2014.11.007; Prieto C, 2008, VET J, V175, P356, DOI 10.1016/j.tvjl.2007.01.021; Puigbo P, 2008, BIOL DIRECT, V3, DOI 10.1186/1745-6150-3-38; Rahe MC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00247; Rahe MC, 2018, VIRAL IMMUNOL, V31, P1, DOI 10.1089/vim.2017.0073; Rahe MC, 2017, VET IMMUNOL IMMUNOP, V186, P15, DOI 10.1016/j.vetimm.2017.02.002; Read AF, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002198; Renson P, 2017, VET MICROBIOL, V204, P133, DOI 10.1016/j.vetmic.2017.04.021; Renukaradhya GJ, 2015, VACCINE, V33, P4069, DOI 10.1016/j.vaccine.2015.06.092; Renukaradhya GJ, 2015, VACCINE, V33, P3065, DOI 10.1016/j.vaccine.2015.04.102; Robinson SR, 2018, VIRUS RES, V248, P13, DOI 10.1016/j.virusres.2018.01.015; Robinson SR, 2015, VIRUS RES, V203, P56, DOI 10.1016/j.virusres.2015.03.016; Rose N, 2015, VACCINE, V33, P2493, DOI 10.1016/j.vaccine.2015.03.040; Ruansit W, 2020, VACCINE, V38, P3570, DOI 10.1016/j.vaccine.2020.03.019; Sang Yongming, 2011, Animal Health Research Reviews, V12, P149, DOI 10.1017/S1466252311000144; Scortti M, 2006, THERIOGENOLOGY, V66, P1884, DOI 10.1016/j.theriogenology.2006.04.043; Shi M, 2010, VIRUS RES, V154, P7, DOI 10.1016/j.virusres.2010.08.014; Shi M, 2010, J VIROL, V84, P8700, DOI 10.1128/JVI.02551-09; Shrestha B, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000823; Sirinarumitr T, 1998, J GEN VIROL, V79, P2989, DOI 10.1099/0022-1317-79-12-2989; Sirisereewan C, 2018, TROP ANIM HEALTH PRO, V50, P1509, DOI 10.1007/s11250-018-1589-4; Sirisereewan C, 2017, VET IMMUNOL IMMUNOP, V183, P7, DOI 10.1016/j.vetimm.2016.11.002; Su J, 2019, VIROL SIN, V34, P631, DOI 10.1007/s12250-019-00149-6; Sun Y, 2012, VIRUSES-BASEL, V4, P424, DOI 10.3390/v4040424; Suradhat S, 2015, VACCINE, V33, P3997, DOI 10.1016/j.vaccine.2015.06.020; Tian DB, 2020, J GEN VIROL, V101, P1191, DOI 10.1099/jgv.0.001492; Tian KG, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000526; Tian Kegong, 2017, Open Virol J, V11, P59, DOI 10.2174/1874357901711010059; Tian ZJ, 2009, VET MICROBIOL, V138, P34, DOI 10.1016/j.vetmic.2009.03.003; Tsukamoto M, 2011, MOL MED REP, V4, P209, DOI 10.3892/mmr.2011.410; Van Breedam W, 2011, VET IMMUNOL IMMUNOP, V141, P246, DOI 10.1016/j.vetimm.2011.03.008; Vanhee M, 2011, VACCINE, V29, P4794, DOI 10.1016/j.vaccine.2011.04.071; Vu HLX, 2017, VET MICROBIOL, V206, P29, DOI 10.1016/j.vetmic.2016.09.014; Vu HLX, 2015, J VIROL, V89, P12070, DOI 10.1128/JVI.01657-15; Wang G, 2011, VET IMMUNOL IMMUNOP, V142, P170, DOI 10.1016/j.vetimm.2011.05.004; Wang LJ, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.01428-16; Wang R, 2013, VACCINE, V31, P5537, DOI 10.1016/j.vaccine.2013.09.023; Wang T, 2018, J VIROL, V92, DOI 10.1128/JVI.01734-17; Wang XL, 2016, VET MICROBIOL, V197, P68, DOI 10.1016/j.vetmic.2016.11.007; WENSVOORT G, 1993, VET RES, V24, P117; Wissink EHJ, 2005, J VIROL, V79, P12495, DOI 10.1128/JVI.79.19.12495-12506.2005; Yang S, 2020, CAN J VET RES, V84, P172; Yang S, 2020, COMP IMMUNOL MICROB, V69, DOI 10.1016/j.cimid.2020.101423; Yang S, 2019, VET MICROBIOL, V239, DOI 10.1016/j.vetmic.2019.108497; Yang XR, 2012, STRUCTURE, V20, P1519, DOI 10.1016/j.str.2012.06.012; YOON KJ, 1995, J VET DIAGN INVEST, V7, P305, DOI 10.1177/104063879500700302; Yoon KJ, 1996, VIRAL IMMUNOL, V9, P51, DOI 10.1089/vim.1996.9.51; Yu XL, 2015, CLIN VACCINE IMMUNOL, V22, P493, DOI 10.1128/CVI.00722-14; Yuan SS, 1999, VIRUS RES, V61, P87, DOI 10.1016/S0168-1702(99)00029-5; ZEMAN D, 1993, J VET DIAGN INVEST, V5, P522, DOI 10.1177/104063879300500404; Zeng JX, 2014, J VIROL, V88, P4008, DOI 10.1128/JVI.03594-13; Zhang HW, 2018, VIROL SIN, V33, P153, DOI 10.1007/s12250-018-0027-0; Zhang ZD, 2018, INFECT GENET EVOL, V66, P111, DOI 10.1016/j.meegid.2018.09.024; Zhou JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077239; Zhou L, 2017, VET MICROBIOL, V207, P108, DOI 10.1016/j.vetmic.2017.05.031; Zhou L, 2015, EMERG INFECT DIS, V21, P2256, DOI 10.3201/eid2112.150360; Zhou L, 2010, VIRUS RES, V154, P31, DOI 10.1016/j.virusres.2010.07.016; Zhou L, 2009, VIRUS RES, V145, P97, DOI 10.1016/j.virusres.2009.06.014; Zhou L, 2009, J VIROL, V83, P5156, DOI 10.1128/JVI.02678-08	163	7	7	5	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							362	10.3390/vaccines9040362			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5AN	33918580	gold, Green Published			2022-04-29	WOS:000643791900001
J	da Silva, DT; Biello, K; Lin, WY; Valente, PK; Mayer, KH; Hightow-Weidman, L; Bauermeister, JA				da Silva, Daniel Teixeira; Biello, Katie; Lin, Willey Y.; Valente, Pablo K.; Mayer, Kenneth H.; Hightow-Weidman, Lisa; Bauermeister, Jose A.			COVID-19 Vaccine Acceptance among an Online Sample of Sexual and Gender Minority Men and Transgender Women	VACCINES			English	Article						COVID-19; sexual; gender; minority; vaccine; acceptance		Sexual and gender minority (SGM) populations are particularly vulnerable to poor COVID-19 outcomes and are more likely to experience stigma and medical mistrust that may impact COVID-19 vaccine acceptance. This study examined the prevalence of COVID testing and diagnosis and assessed COVID-19 vaccine acceptance among a large sample of SGM. Participants were recruited as part of an online cross-sectional study focused on an HIV biomedical prevention technology willingness in the United States at increased risk for HIV sero-conversion. Multivariate linear analysis was conducted to examine COVID-19 vaccine acceptance. The study sample included 1350 predominately gay (61.6%), Black (57.9%), cis-gender (95.7%) males with a mean age of 32.9 years. Medical mistrust and social concern regarding COVID-19 vaccine stigma were significantly associated with decreased COVID-19 vaccine acceptance, and altruism was significantly associated with increased vaccine acceptance. Black participants were significantly less likely to accept a COVID-19 vaccine, and Asian participants were significantly more likely to accept a vaccine, compared to White peers. As the planning of COVID-19 vaccine rollout efforts is conceptualized and designed, these data may inform equitable implementation strategies and prevent worsening health inequities among SGM populations.	[da Silva, Daniel Teixeira] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; [da Silva, Daniel Teixeira; Lin, Willey Y.; Bauermeister, Jose A.] Univ Penn, Sch Nursing, Dept Family & Community Hlth, Philadelphia, PA 19104 USA; [Biello, Katie; Valente, Pablo K.] Brown Univ, Sch Publ Hlth, Dept Behav & Social Sci, Providence, RI 02912 USA; [Biello, Katie; Mayer, Kenneth H.] Fenway Hlth, Boston, MA 02215 USA; [Mayer, Kenneth H.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; [Hightow-Weidman, Lisa] Univ N Carolina, Dept Med, Sch Med, Chapel Hill, NC 27517 USA		Bauermeister, JA (通讯作者)，Univ Penn, Sch Nursing, Dept Family & Community Hlth, Philadelphia, PA 19104 USA.	teixeird@pennmedicine.upenn.edu; katie_biello@brown.edu; willey@nursing.upenn.edu; pablo_valente@brown.edu; kmayer@fenwayhealth.org; lisa_hightow@med.unc.edu; bjose@nursing.upenn.edu	Valente, Pablo/AAV-1754-2020; Bauermeister, Jose/X-8960-2018	Valente, Pablo/0000-0002-2058-3472; Bauermeister, Jose/0000-0002-9276-2306; Teixeira da Silva, Daniel/0000-0003-3525-605X	National Institutes of Health Adolescent Medicine Trials Network for HIV/AIDS Interventions; National Clinical Scholar Program at the University of Pennsylvania; Agency for Health Care Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [T32HS0226116]; University of North Carolina/Emory Center for Innovative Technology [U19HD089881]	This research was supported by the National Institutes of Health Adolescent Medicine Trials Network for HIV/AIDS Interventions and the University of North Carolina/Emory Center for Innovative Technology (U19HD089881). DTdS is supported by the National Clinical Scholar Program at the University of Pennsylvania and the Agency for Health Care Research and Quality (T32HS0226116). The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH.	Albuquerque GA, 2016, BMC INT HEALTH HUM R, V16, DOI 10.1186/s12914-015-0072-9; [Anonymous], 2020, WASH POST; [Anonymous], 2021, FED, V86, P7189; Artiga S., 2020, RACE HLTH COVID 19 V; Bogart LM, 2021, JAIDS-J ACQ IMM DEF, V86, P200, DOI 10.1097/QAI.0000000000002570; Camargo ELS, 2022, SEX RES SOC POLICY, V19, P391, DOI 10.1007/s13178-021-00550-5; Charlton BM, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020418; Connochie D, 2019, VACCINE, V37, P6494, DOI 10.1016/j.vaccine.2019.08.076; Conron KJ, 2010, AM J PUBLIC HEALTH, V100, P1953, DOI 10.2105/AJPH.2009.174169; Crawford I, 2002, J SEX RES, V39, P179, DOI 10.1080/00224490209552140; Desai MU, 2019, BEHAV MED, V45, P177, DOI 10.1080/08964289.2019.1587589; Earnshaw VA, 2020, TRANSL BEHAV MED, V10, P850, DOI 10.1093/tbm/ibaa090; Eaton LA, 2015, AM J PUBLIC HEALTH, V105, pE75, DOI 10.2105/AJPH.2014.302322; Ferdinand KC, 2020, J NATL MED ASSOC, V112, P681, DOI 10.1016/j.jnma.2020.11.001; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Gibb JK, 2020, AM J HUM BIOL, V32, DOI 10.1002/ajhb.23499; Hatzenbuehler ML, 2013, AM J PUBLIC HEALTH, V103, P813, DOI 10.2105/AJPH.2012.301069; Heslin KC, 2021, MMWR-MORBID MORTAL W, V70, P149, DOI 10.15585/mmwr.mm7005a1; Jackson CL, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3467-1; Jaiswal J, 2020, AIDS BEHAV, V24, P2776, DOI 10.1007/s10461-020-02925-y; Jaiswal J, 2019, BEHAV MED, V45, P79, DOI 10.1080/08964289.2019.1619511; Jarrett Brooke A, 2020, medRxiv, DOI 10.1101/2020.11.02.20224709; Khazanchi R, 2020, J GEN INTERN MED, V35, P2784, DOI 10.1007/s11606-020-05882-3; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Latkin CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246970; Latkin CA, 2021, SOC SCI MED, V270, DOI 10.1016/j.socscimed.2021.113684; LaVeist TA, 2009, HEALTH SERV RES, V44, P2093, DOI 10.1111/j.1475-6773.2009.01017.x; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lee SJ, 2014, VACCINE, V32, P5013, DOI 10.1016/j.vaccine.2014.07.018; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; MacCarthy S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244421; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; McClung N, 2020, MMWR-MORBID MORTAL W, V69, P1782, DOI 10.15585/mmwr.mm6947e3; McConnell Elizabeth A, 2018, Psychol Sex Orientat Gend Divers, V5, P1, DOI 10.1037/sgd0000265; Moore SE, 2021, J HOMOSEXUAL, V68, P577, DOI 10.1080/00918369.2020.1868184; National Academies of Sciences, FRAMEWORK EQUITABLE; Operario D, 2015, AM J PUBLIC HEALTH, V105, pE27, DOI 10.2105/AJPH.2015.302762; Poteat TC, 2020, JAIDS-J ACQ IMM DEF, V85, pE67, DOI 10.1097/QAI.0000000000002490; Poteat Tonia C, 2020, medRxiv, DOI 10.1101/2020.07.21.20159327; Quinn KG, 2020, AIDS BEHAV, V24, P3291, DOI 10.1007/s10461-020-02954-7; Raifman MA, 2020, AM J PREV MED, V59, P137, DOI 10.1016/j.amepre.2020.04.003; Ramos SR, 2019, BEHAV MED, V45, P166, DOI 10.1080/08964289.2019.1570074; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Reiter PL, 2015, AM J PUBLIC HEALTH, V105, P96, DOI 10.2105/AJPH.2014.302095; Rolfe A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004134.pub3; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Ruprecht MM, 2021, J URBAN HEALTH, V98, P27, DOI 10.1007/s11524-020-00497-9; Santos GM, 2021, AIDS BEHAV, V25, P311, DOI 10.1007/s10461-020-02969-0; Suen YT, 2020, PSYCHIAT RES, V292, DOI 10.1016/j.psychres.2020.113365; Wheldon CW, 2018, AM J MENS HEALTH, V12, P1409, DOI 10.1177/1557988316652937; Wilson B.D., 2020, HOMELESSNESS LGBT AD	51	10	10	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							204	10.3390/vaccines9030204			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE6GB	33804530	Green Published, gold			2022-04-29	WOS:000634248900001
J	Ferrantelli, F; Chiozzini, C; Manfredi, F; Giovannelli, A; Leone, P; Federico, M				Ferrantelli, Flavia; Chiozzini, Chiara; Manfredi, Francesco; Giovannelli, Andrea; Leone, Patrizia; Federico, Maurizio			Simultaneous CD8(+) T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and Lungs	VACCINES			English	Article						SARS-CoV-2; extracellular vesicles; CD8(+) T cell immunity; Nef	ACUTE RESPIRATORY SYNDROME; SYNDROME SARS CORONAVIRUS; EBOLA-VIRUS INFECTION; LONGITUDINAL PROFILE; NUCLEOCAPSID PROTEIN; PROTECTION; INFLUENZA; EXOSOMES; VACCINE; ANTIBODY	Most advanced vaccines against severe acute respiratory syndrome coronavirus (SARS-CoV)-2 are designed to induce antibodies against spike (S) protein. Differently, we developed an original strategy to induce CD8(+) T cytotoxic lymphocyte (CTL) immunity based on in vivo engineering of extracellular vesicles (EVs). This is a new vaccination approach based on intramuscular injection of DNA expression vectors coding for a biologically inactive HIV-1 Nef protein (Nef(mut)) with an unusually high efficiency of incorporation into EVs, even when foreign polypeptides are fused to its C-terminus. Nanovesicles containing Nef(mut)-fused antigens released by muscle cells can freely circulate into the body and are internalized by antigen-presenting cells. Therefore, EV-associated antigens can be cross-presented to prime antigen-specific CD8(+) T-cells. To apply this technology to a strategy of anti-SARS-CoV-2 vaccine, we designed DNA vectors expressing the products of fusion between Nef(mut) and different viral antigens, namely N- and C-terminal moieties of S (referred to as S1 and S2), M, and N. We provided evidence that all fusion products are efficiently uploaded in EVs. When the respective DNA vectors were injected in mice, a strong antigen-specific CD8(+) T cell immunity became detectable in spleens and, most important, in lung airways. Co-injection of DNA vectors expressing the diverse SARS-CoV-2 antigens resulted in additive immune responses in both spleen and lungs. Hence, DNA vectors expressing Nef(mut)-based fusion proteins can be proposed for new anti-SARS-CoV-2 vaccine strategies.	[Ferrantelli, Flavia; Chiozzini, Chiara; Manfredi, Francesco; Leone, Patrizia; Federico, Maurizio] Ist Super Sanita, Natl Ctr Global Hlth, Viale Regina Elena 299, I-00161 Rome, Italy; [Giovannelli, Andrea] Ist Super Sanita, Natl Ctr Anim Experimentat & Welf, Viale Regina Elena 299, I-00161 Rome, Italy		Federico, M (通讯作者)，Ist Super Sanita, Natl Ctr Global Hlth, Viale Regina Elena 299, I-00161 Rome, Italy.	flavia.ferrantelli@iss.it; chiara.chiozzini@iss.it; francesco.manfredi@iss.it; andrea.giovannelli@iss.it; patrizia.leone@iss.it; maurizio.federico@iss.it	Manfredi, Francesco/ABA-7166-2021; Ferrantelli, Flavia/J-7794-2016; Federico, Maurizio/J-5867-2016	Ferrantelli, Flavia/0000-0002-0768-1078; Leone, Patrizia/0000-0002-5281-4917; Federico, Maurizio/0000-0003-4154-1025; Chiozzini, Chiara/0000-0002-4153-0927	Ministero degli Affari Esteri e della Cooperazione Internazionale, Italy [PGR00810]	This work was supported by the grant PGR00810 from Ministero degli Affari Esteri e della Cooperazione Internazionale, Italy.	Anticoli S, 2018, BIOTECHNOL J, V13, DOI 10.1002/biot.201700443; Anticoli S, 2018, J MOL MED, V96, P211, DOI 10.1007/s00109-017-1617-2; Arenaccio C, 2019, CURR DRUG TARGETS, V20, P87, DOI 10.2174/1389450119666180521100409; BAUER S, 1995, SCAND J IMMUNOL, V42, P317, DOI 10.1111/j.1365-3083.1995.tb03662.x; Braun J, 2020, MEDRXIV, DOI [10.1101/2020.04.17.20061440, DOI 10.1101/2020.04.17.20061440]; Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; Chang SC, 2005, CLIN DIAGN LAB IMMUN, V12, P1455, DOI 10.1128/CDLI.12.12.1455-1457.2005; Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14; Chiozzini C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020243; D'Aloja P, 2001, J GEN VIROL, V82, P2735, DOI 10.1099/0022-1317-82-11-2735; Di Bonito P, 2017, INT J NANOMED, V12, P4579, DOI 10.2147/IJN.S131309; Di Bonito P, 2015, VIRUSES-BASEL, V7, P1079, DOI 10.3390/v7031079; Cargnelutti DE, 2013, BIOENGINEERED, V4, P374, DOI 10.4161/bioe.23573; Fan YY, 2009, ARCH VIROL, V154, P1093, DOI 10.1007/s00705-009-0409-6; de Oliveira LMF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138686; Ferrantelli F, 2018, MOL BIOTECHNOL, V60, P773, DOI 10.1007/s12033-018-0114-3; Ferretti AP, 2020, IMMUNITY, V53, P1095, DOI 10.1016/j.immuni.2020.10.006; Gasper DJ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006064; Gattinger P, 2021, ALLERGY, V76, P878, DOI 10.1111/all.14523; Green LA, 2009, J BIOL CHEM, V284, P13363, DOI 10.1074/jbc.M806631200; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Guan WD, 2015, EMERG INFECT DIS, V21, P2278, DOI 10.3201/eid2112.151232; Gupta M, 2005, J IMMUNOL, V174, P4198, DOI 10.4049/jimmunol.174.7.4198; Hartenian E, 2020, J BIOL CHEM, V295, P12910, DOI 10.1074/jbc.REV120.013930; Hensley LE, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000904; Huang J, 2007, VACCINE, V25, P6981, DOI 10.1016/j.vaccine.2007.06.047; Jang YH, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00344; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kawano M, 2014, VIROLOGY, V448, P159, DOI 10.1016/j.virol.2013.10.010; Kohlmeier JE, 2009, ANNU REV IMMUNOL, V27, P61, DOI 10.1146/annurev.immunol.021908.132625; Lattanzi L, 2012, VACCINE, V30, P7229, DOI 10.1016/j.vaccine.2012.10.010; Lee SY, 2019, CLIN EXP VACCINE RES, V8, P54, DOI 10.7774/cevr.2019.8.1.54; Li JH, 2013, NAT IMMUNOL, V14, P793, DOI 10.1038/ni.2647; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158; Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469; Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006; Mo HY, 2006, RESPIROLOGY, V11, P49, DOI 10.1111/j.1440-1843.2006.00783.x; Muratori C, 2009, CELL HOST MICROBE, V6, P218, DOI 10.1016/j.chom.2009.06.009; Netland J, 2013, VIRUSES-BASEL, V5, P2573, DOI 10.3390/v5102573; Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; Nie YC, 2004, J INFECT DIS, V190, P1119, DOI 10.1086/423286; Oh HLJ, 2011, J VIROL, V85, P10464, DOI 10.1128/JVI.05039-11; Olinger GG, 2005, J VIROL, V79, P14189, DOI 10.1128/JVI.79.22.14189-14196.2005; Peng H, 2006, VIROLOGY, V351, P466, DOI 10.1016/j.virol.2006.03.036; Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732; Rome S, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00929; Sakabe S, 2018, P NATL ACAD SCI USA, V115, pE7578, DOI 10.1073/pnas.1806200115; Schotsaert M, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/863985; Shedlock DJ, 2013, MOL THER, V21, P1432, DOI 10.1038/mt.2013.61; Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820; Sullivan NJ, 2011, NAT MED, V17, P1128, DOI 10.1038/nm.2447; Sun F, 2017, BIO-PROTOCOL, V7, DOI 10.21769/BioProtoc.2287; Takamura S, 2019, J EXP MED, V216, P2736, DOI 10.1084/jem.20190557; Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Temperton NJ, 2005, EMERG INFECT DIS, V11, P411, DOI 10.3201/eid1103.040906; Thery C, 2002, NAT IMMUNOL, V3, P1156, DOI 10.1038/ni854; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Valkenburg SA, 2016, P NATL ACAD SCI USA, V113, P4440, DOI 10.1073/pnas.1603106113; Van Hoecke L, 2017, JOVE-J VIS EXP, DOI 10.3791/55398; van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071; Wen J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01669-z; Wilson JA, 2001, J VIROL, V75, P2660, DOI 10.1128/JVI.75.6.2660-2664.2001; Woo PCY, 2004, CLIN DIAGN LAB IMMUN, V11, P665, DOI 10.1128/CDLI.11.4.665-668.2004; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576; Wu T, 2014, J LEUKOCYTE BIOL, V95, P215, DOI 10.1189/jlb.0313180; Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82; Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10; Zhi Y, 2005, VIROLOGY, V335, P34, DOI 10.1016/j.virol.2005.01.050; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	76	5	5	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							240	10.3390/vaccines9030240			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5UO	33801926	gold, Green Published, Green Submitted			2022-04-29	WOS:000634219000001
J	Hu, CF; Liao, XY; Xu, DD; Ruan, YB; Gao, FG				Hu, Chun Fang; Liao, Xiao Yan; Xu, Dan Dan; Ruan, Yi Bin; Gao, Feng Guang			K48-Linked Ubiquitination Contributes to Nicotine-Augmented Bone Marrow-Derived Dendritic-Cell-Mediated Adaptive Immunity	VACCINES			English	Article						adaptive immunity; ubiquitin; nicotine; dendritic cells; bone marrow precursor cells; K48 ubiquitination		K48-linked ubiquitination determining antigen degradation and the endosomal recruitments of p97 and Sec61 plays vital roles in dendritic cell (DC) cross-presentation. Our previous studies revealed that nicotine treatment increases bone marrow-derived dendritic cell (BM-DC) cross-presentation and promotes BM-DC-based cytotoxic T lymphocyte (CTL) priming. But the effect of nicotine on K48-linked ubiquitination and the mechanism of nicotine-increased BM-DC cross-presentation are still uncertain. In this study, we first demonstrated that ex vivo nicotine administration obviously increased K48-linked ubiquitination in BM-DC. Then, we found that K48-linked ubiquitination was essential for nicotine-augmented cross-presentation, BM-DC-based CTL priming, and thereby the superior cytolytic capacity of DC-activated CTL. Importantly, K48-linked ubiquitination was verified to be necessary for nicotine-augmented endosomal recruitments of p97 and Sec61. Importantly, mannose receptor (MR), which is an important antigenic receptor for cross-presentation, was exactly catalyzed with K48-linked ubiquitination by the treatment with nicotine. Thus, these data suggested that K48-linked ubiquitination contributes to the superior adaptive immunity of nicotine-administrated BM-DC. Regulating K48-linked ubiquitination might have therapeutic potential for DC-mediated immune therapy.	[Hu, Chun Fang; Liao, Xiao Yan; Xu, Dan Dan; Gao, Feng Guang] Xiamen Univ, Sch Med, Dept Basic Med Sci, Xiamen 361102, Peoples R China; [Ruan, Yi Bin] China Tobacco Guizhou Ind Co Ltd, Technol Ctr, Guiyang 550003, Peoples R China		Gao, FG (通讯作者)，Xiamen Univ, Sch Med, Dept Basic Med Sci, Xiamen 361102, Peoples R China.; Ruan, YB (通讯作者)，China Tobacco Guizhou Ind Co Ltd, Technol Ctr, Guiyang 550003, Peoples R China.	24520141153463@stu.xmu.edu.cn; 24520181154677@stu.xmu.edu.cn; 24520151154264@stu.xmu.edu.cn; ybruan@xmu.edu.cn; gfengguang@xmu.edu.cn		Gao, Feng Guang/0000-0003-2371-1799	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81771669, 81273203]; Young Elite Scientists Sponsorship Program of China Association for Science and Technology [81771669, 2016QNRC001]	This research was funded by the National Natural Science Foundation of China, grant number No.81771669, No.81273203 and the Young Elite Scientists Sponsorship Program of China Association for Science and Technology (NO. 2016QNRC001). The APC was funded by No.81771669.	Burgdorf S, 2007, SCIENCE, V316, P612, DOI 10.1126/science.1137971; Cao XF, 2018, CLIN EXP PHARMACOL P, V45, P198, DOI 10.1111/1440-1681.12865; Di Chiara G, 2000, EUR J PHARMACOL, V393, P295, DOI 10.1016/S0014-2999(00)00122-9; Embgenbroich M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01643; Figueroa C, 2017, J NEUROIMMUNOL, V303, P99, DOI 10.1016/j.jneuroim.2016.12.014; Gao FG, 2007, CLIN CANCER RES, V13, P3706, DOI 10.1158/1078-0432.CCR-07-0028; Gao FG, 2011, J CLIN IMMUNOL, V31, P80, DOI 10.1007/s10875-010-9459-5; Goldszmid RS, 2009, J EXP MED, V206, P399, DOI 10.1084/jem.20082108; Grotzke JE, 2017, P NATL ACAD SCI USA, V114, pE5910, DOI 10.1073/pnas.1705242114; Grumati P, 2018, J BIOL CHEM, V293, P5404, DOI 10.1074/jbc.TM117.000117; Jang HD, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0156-y; Jin HJ, 2013, J CLIN IMMUNOL, V33, P246, DOI 10.1007/s10875-012-9761-5; Jin HJ, 2012, IMMUNOL LETT, V146, P40, DOI 10.1016/j.imlet.2012.02.015; Joffre OP, 2012, NAT REV IMMUNOL, V12, P557, DOI 10.1038/nri3254; Lin M, 2016, MOL CELL, V64, P267, DOI 10.1016/j.molcel.2016.08.029; Massaly N, 2015, FRONT MOL NEUROSCI, V7, DOI 10.3389/fnmol.2014.00099; Rezvani K, 2007, J NEUROSCI, V27, P10508, DOI 10.1523/JNEUROSCI.3353-07.2007; Rudd-Schmidt JA, 2019, METHOD ENZYMOL, V629, P291, DOI 10.1016/bs.mie.2019.07.034; Teng YF, 2015, BIOCHEM PHARMACOL, V97, P518, DOI 10.1016/j.bcp.2015.08.084; Villadangos JA, 2007, TRENDS IMMUNOL, V28, P45, DOI 10.1016/j.it.2006.12.008; Wan CH, 2018, MOL CARCINOGEN, V57, P1626, DOI 10.1002/mc.22885; Wang F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105636; Wang YY, 2016, ONCOTARGET, V7, P38451, DOI 10.18632/oncotarget.9498; Wang YY, 2015, ANAL CELL PATHOL, V2015, DOI 10.1155/2015/741487; Weck MM, 2007, BLOOD, V109, P3890, DOI 10.1182/blood-2006-04-015719; Wessler IK, 2001, PULM PHARMACOL THER, V14, P423, DOI 10.1006/pupt.2001.0313; Xu DD, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030539; You X, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/5070573; Zehner M, 2015, IMMUNITY, V42, P850, DOI 10.1016/j.immuni.2015.04.008; Zehner M, 2013, MOL IMMUNOL, V55, P146, DOI 10.1016/j.molimm.2012.10.010; Zhang LX, 2020, J LEUKOCYTE BIOL, V108, P177, DOI 10.1002/JLB.1MA0220-337RR; Zhang MY, 2018, PHARMACOL BIOCHEM BE, V175, P47, DOI 10.1016/j.pbb.2018.09.004; Zhang MX, 2019, J IMMUNOL, V202, P2397, DOI 10.4049/jimmunol.1801447; Zhang X, 2020, NATURE, V581, P204, DOI 10.1038/s41586-020-2235-7; Zheng N, 2017, ANNU REV BIOCHEM, V86, P129, DOI 10.1146/annurev-biochem-060815-014922	35	1	1	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							278	10.3390/vaccines9030278			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5CU	33808531	Green Published, gold			2022-04-29	WOS:000634172800001
J	Malik, MS; Teige, LH; Braaen, S; Olsen, AB; Nordberg, M; Amundsen, MM; Dhamotharan, K; Svenning, S; Edholm, ES; Takano, T; Jorgensen, JB; Wessel, O; Rimstad, E; Dahle, MK				Malik, Muhammad Salman; Teige, Lena H.; Braaen, Stine; Olsen, Anne Berit; Nordberg, Monica; Amundsen, Marit M.; Dhamotharan, Kannimuthu; Svenning, Steingrim; Edholm, Eva Stina; Takano, Tomokazu; Jorgensen, Jorunn B.; Wessel, Oystein; Rimstad, Espen; Dahle, Maria K.			Piscine Orthoreovirus (PRV)-3, but Not PRV-2, Cross-Protects against PRV-1 and Heart and Skeletal Muscle Inflammation in Atlantic Salmon	VACCINES			English	Article						heart and skeletal muscle inflammation; Piscine orthoreovirus; vaccine; atlantic salmon; antibodies; immune response		Heart and skeletal muscle inflammation (HSMI), caused by infection with Piscine orthoreovirus-1 (PRV-1), is a common disease in farmed Atlantic salmon (Salmo salar). Both an inactivated whole virus vaccine and a DNA vaccine have previously been tested experimentally against HSMI and demonstrated to give partial but not full protection. To understand the mechanisms involved in protection against HSMI and evaluate the potential of live attenuated vaccine strategies, we set up a cross-protection experiment using PRV genotypes not associated with disease development in Atlantic salmon. The three known genotypes of PRV differ in their preference of salmonid host species. The main target species for PRV-1 is Atlantic salmon. Coho salmon (Oncorhynchus kisutch) is the target species for PRV-2, where the infection may induce erythrocytic inclusion body syndrome (EIBS). PRV-3 is associated with heart pathology and anemia in rainbow trout, but brown trout (S. trutta) is the likely natural main host species. Here, we tested if primary infection with PRV-2 or PRV-3 in Atlantic salmon could induce protection against secondary PRV-1 infection, in comparison with an adjuvanted, inactivated PRV-1 vaccine. Viral kinetics, production of cross-reactive antibodies, and protection against HSMI were studied. PRV-3, and to a low extent PRV-2, induced antibodies cross-reacting with the PRV-1 sigma 1 protein, whereas no specific antibodies were detected after vaccination with inactivated PRV-1. Ten weeks after immunization, the fish were challenged through cohabitation with PRV-1-infected shedder fish. A primary PRV-3 infection completely blocked PRV-1 infection, while PRV-2 only reduced PRV-1 infection levels and the severity of HSMI pathology in a few individuals. This study indicates that infection with non-pathogenic, replicating PRV could be a future strategy to protect farmed salmon from HSMI.	[Malik, Muhammad Salman; Teige, Lena H.; Braaen, Stine; Dhamotharan, Kannimuthu; Wessel, Oystein; Rimstad, Espen] Norwegian Univ Life Sci, Fac Vet Med, N-0454 Oslo, Norway; [Olsen, Anne Berit; Amundsen, Marit M.; Dahle, Maria K.] Norwegian Vet Inst, Dept Fish Hlth, N-0454 Oslo, Norway; [Nordberg, Monica; Svenning, Steingrim; Edholm, Eva Stina; Jorgensen, Jorunn B.; Dahle, Maria K.] UiT Arctic Univ Norway, Fac Biosci Fisheries & Econ, Norwegian Coll Fishery Sci, N-9019 Tromso, Norway; [Takano, Tomokazu] Japan Fisheries Res & Educ Agcy, Natl Res Inst Aquaculture, Nansei, Mie 5160193, Japan		Dahle, MK (通讯作者)，Norwegian Vet Inst, Dept Fish Hlth, N-0454 Oslo, Norway.; Dahle, MK (通讯作者)，UiT Arctic Univ Norway, Fac Biosci Fisheries & Econ, Norwegian Coll Fishery Sci, N-9019 Tromso, Norway.	muhammad.salman.malik@nmbu.no; l.h.teige@medisin.uio.no; stine.braaen@nmbu.no; anne-berit.olsen@vetinst.no; mno085@post.uit.no; marit.masoy.Amundsen@vetinst.no; dhamotharan.kannimuthu@hi.no; steingrim.svenning@uit.no; eva-stina.i.edholm@uit.no; takanoto@fra.affrc.go.jp; jorunn.jorgensen@uit.no; oystein.wessel@nmbu.no; espen.rimstad@nmbu.no; maria.dahle@vetinst.no	Dahle, Maria K/AAK-5130-2021	Dahle, Maria K/0000-0003-0380-084X; Wessel, Oystein/0000-0002-0811-7305; Malik, Muhammad Salman/0000-0001-9754-7069; jorgensen, jorunn/0000-0002-8163-6777; Rimstad, Espen/0000-0001-9911-5948; Teige, Lena Hammerlund/0000-0002-2669-7032; Kannimuthu, Dhamotharan/0000-0003-0892-1747	Research Council of NorwayResearch Council of Norway [280847/E40]; UiT the Arctic University of Norway	The research was funded by the Research Council of Norway, grant number 280847/E40 (ViVaAct), and UiT the Arctic University of Norway.	Adams A, 2019, FISH SHELLFISH IMMUN, V90, P210, DOI 10.1016/j.fsi.2019.04.066; Bjorgen H, 2015, VET RES, V46, DOI 10.1186/s13567-015-0244-6; Byrne KA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01099; Dahle MK, 2019, FISH SHELLFISH IMMUN, V87, P421, DOI 10.1016/j.fsi.2019.01.043; Dahle MK, 2015, FISH SHELLFISH IMMUN, V45, P780, DOI 10.1016/j.fsi.2015.05.049; Dhamotharan K, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020143; Dhamotharan K, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11050465; Dhamotharan K, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040170; Di Cicco E, 2018, FACETS, V3, P599, DOI 10.1139/facets-2018-0008; Di Cicco E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171471; Ferguson HW, 2005, J FISH DIS, V28, P119, DOI 10.1111/j.1365-2761.2004.00602.x; Finstad OW, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-35; Finstad OW, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-27; Garseth AH, 2013, J FISH DIS, V36, P483, DOI 10.1111/j.1365-2761.2012.01450.x; Garseth AH, 2019, J FISH DIS, V42, P391, DOI 10.1111/jfd.12943; Garver KA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146229; Haatveit HM, 2018, VACCINE, V36, P7599, DOI 10.1016/j.vaccine.2018.10.094; Hauge H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180293; Hauge H, 2016, VET RES, V47, DOI 10.1186/s13567-016-0343-z; Johansen LH, 2016, MOL IMMUNOL, V73, P138, DOI 10.1016/j.molimm.2016.04.007; Johansen LH, 2015, FISH SHELLFISH IMMUN, V46, P612, DOI 10.1016/j.fsi.2015.07.023; Key T, 2013, J GEN VIROL, V94, P1039, DOI 10.1099/vir.0.048637-0; Kibenge MJT, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1148-2; Kongtorp RT, 2004, DIS AQUAT ORGAN, V59, P217, DOI 10.3354/dao059217; Krasnov A, 2016, FISH SHELLFISH IMMUN, V55, P56, DOI 10.1016/j.fsi.2016.05.012; Lovoll M, 2012, DIS AQUAT ORGAN, V99, P7, DOI 10.3354/dao02451; Lund M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181109; Madhun AS, 2018, J FISH DIS, V41, P797, DOI 10.1111/jfd.12785; Malik MS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090824; Markussen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070075; McDonald SM, 2016, NAT REV MICROBIOL, V14, P448, DOI 10.1038/nrmicro.2016.46; Mikalsen AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037269; Olsen AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131638; Palacios G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011487; Pham PH, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9100833; Polinski MP, 2020, J FISH DIS, V43, P1331, DOI 10.1111/jfd.13228; Polinski MP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40025-7; Purcell MK, 2020, J FISH DIS, V43, P719, DOI 10.1111/jfd.13182; Sanchez-Sampedro L, 2015, VIRUSES-BASEL, V7, P1726, DOI 10.3390/v7041726; Segner H, 2012, FISH PHYSIOL BIOCHEM, V38, P85, DOI 10.1007/s10695-011-9517-9; Takano T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165424; Teige LH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02119; Teige LH, 2017, FISH SHELLFISH IMMUN, V63, P491, DOI 10.1016/j.fsi.2017.02.043; Veenstra KA, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040725; Vendramin N, 2019, VET RES, V50, DOI 10.1186/s13567-019-0632-4; Wessel O, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9121050; Wessel O, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03182; Wessel O, 2018, J FISH DIS, V41, P1411, DOI 10.1111/jfd.12835; Wessel O, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183781; Wessel O, 2015, VET RES, V46, DOI 10.1186/s13567-015-0154-7; Wessel O, 2015, VIRUS RES, V198, P22, DOI 10.1016/j.virusres.2015.01.001; Yue ZY, 1997, VIROLOGY, V234, P364, DOI 10.1006/viro.1997.8664	52	2	2	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							230	10.3390/vaccines9030230			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5RL	33800725	Green Published, gold, Green Submitted			2022-04-29	WOS:000634210900001
J	Scott, NR; Mann, B; Tuomanen, EI; Orihuela, CJ				Scott, Ninecia R.; Mann, Beth; Tuomanen, Elaine I.; Orihuela, Carlos J.			Multi-Valent Protein Hybrid Pneumococcal Vaccines: A Strategy for the Next Generation of Vaccines	VACCINES			English	Review						Streptococcus pneumoniae; pneumococcal vaccine; hybrid vaccine		Streptococcus pneumoniae (Spn) is a bacterial pathogen known to colonize the upper respiratory tract and cause serious opportunistic diseases such as pneumonia, bacteremia, sepsis and meningitis. As a consequence, millions of attributable deaths occur annually, especially among infants, the elderly and immunocompromised individuals. Although current vaccines, composed of purified pneumococcal polysaccharide in free form or conjugated to a protein carrier, are widely used and have been demonstrated to be effective in target groups, Spn has continued to colonize and cause life-threatening disease in susceptible populations. This lack of broad protection highlights the necessity of improving upon the current "gold standard" pneumococcal vaccines to increase protection both by decreasing colonization and reducing the incidence of sterile-site infections. Over the past century, most of the pneumococcal proteins that play an essential role in colonization and pathogenesis have been identified and characterized. Some of these proteins have the potential to serve as antigens in a multi-valent protein vaccine that confers capsule independent protection. This review seeks to summarize the benefits and limitations of the currently employed vaccine strategies, describes how leading candidate proteins contribute to pneumococcal disease development, and discusses the potential of these proteins as protective antigens-including as a hybrid construct.	[Scott, Ninecia R.; Orihuela, Carlos J.] Univ Alabama Birmingham, Sch Med, Dept Microbiol, Birmingham, AL 35294 USA; [Mann, Beth; Tuomanen, Elaine I.] St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA		Orihuela, CJ (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Microbiol, Birmingham, AL 35294 USA.	nrscott@uab.edu; beth.mann@stjude.org; elaine.tuomanen@stjude.org; corihuel@uab.edu	Tuomanen, Elaine/N-3081-2018	Tuomanen, Elaine/0000-0003-0349-8716; Mann, Beth/0000-0001-6283-7680	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI128756, AI114800, AI146149, AI148368, AI156898]; ALSACAmerican Lebanese Syrian Associated Charities (ALSAC); American Heart AssociationAmerican Heart Association [18TPA34110195]	This research was funded by NIH grant AI128756 and ALSAC to E.I.T. Additionally, by NIH grants AI114800, AI146149, AI148368 and AI156898 as well as American Heart Association grant 18TPA34110195 to C.J.O. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the review.	Adamou JE, 2001, INFECT IMMUN, V69, P949, DOI 10.1128/IAI.69.2.949-958.2001; Adler H, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00004-17; Africano HF, 2021, CLIN INFECT DIS, V72, pE711, DOI 10.1093/cid/ciaa1427; Alhamdi Y, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004836; Alicino C, 2017, VACCINE, V35, P5776, DOI 10.1016/j.vaccine.2017.09.005; Alouf JE, 2000, INT J MED MICROBIOL, V290, P351; Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9; Babb R, 2016, CLIN SCI, V130, P697, DOI 10.1042/CS20150699; Backhaus E, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1648-2; Balachandran P, 2002, INFECT IMMUN, V70, P2526, DOI 10.1128/IAI.70.5.2526-2534.2002; Barricarte A, 2007, CLIN INFECT DIS, V44, P1436, DOI 10.1086/516779; Beno SM, 2020, J INFECT DIS, V222, P1882, DOI 10.1093/infdis/jiaa295; Beurg M, 2005, J PHYSIOL-LONDON, V568, P211, DOI 10.1113/jphysiol.2005.092478; Bologa M, 2012, VACCINE, V30, P7461, DOI 10.1016/j.vaccine.2012.10.076; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Briles DE, 2000, J INFECT DIS, V182, P1694, DOI 10.1086/317602; Brissac T, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00569-17; Brooks WA, 2015, VACCINE, V33, P4610, DOI 10.1016/j.vaccine.2015.06.078; Campo JJ, 2018, ELIFE, V7, DOI 10.7554/eLife.37015; Carter R, 2014, CELL HOST MICROBE, V15, P587, DOI 10.1016/j.chom.2014.04.005; CDC, 2015, ACT BACT COR SURV RE; Chen A, 2015, CLIN VACCINE IMMUNOL, V22, P1079, DOI 10.1128/CVI.00293-15; Choi EH, 2016, CLIN VACCINE IMMUNOL, V23, P162, DOI 10.1128/CVI.00591-15; Christenson B, 2004, EUR RESPIR J, V23, P363, DOI 10.1183/09031936.04.00063504; Coats MT, 2005, VACCINE, V23, P4257, DOI 10.1016/j.vaccine.2005.03.039; Control CfD, 2020, DRUG RESISTANCE; D'Mello A, 2020, P NATL ACAD SCI USA, V117, P33507, DOI 10.1073/pnas.2010428117; Daniels Calvin C, 2016, J Pediatr Pharmacol Ther, V21, P27, DOI 10.5863/1551-6776-21.1.27; De Ste Croix M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58684-2; de Vos AF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118181; Farrand AJ, 2010, P NATL ACAD SCI USA, V107, P4341, DOI 10.1073/pnas.0911581107; Fattom A, 1999, VACCINE, V17, P126, DOI 10.1016/S0264-410X(98)00162-5; Feikin DR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001517; Feldman C, 2014, J INFECTION, V69, P309, DOI 10.1016/j.jinf.2014.06.006; Ganaie F, 2020, MBIO, V11, DOI 10.1128/mBio.00937-20; Geno KA, 2015, CLIN MICROBIOL REV, V28, P871, DOI 10.1128/CMR.00024-15; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; Glover DT, 2008, INFECT IMMUN, V76, P2767, DOI 10.1128/IAI.01126-07; Gonzalez-Juarbe N, 2017, CELL DEATH DIFFER, V24, P917, DOI 10.1038/cdd.2017.49; Gor DO, 2005, INFECT IMMUN, V73, P1304, DOI 10.1128/IAI.73.3.1304-1312.2005; Graham RMA, 2006, INFECT IMMUN, V74, P6739, DOI 10.1128/IAI.00954-06; Grijalva CG, 2007, LANCET, V369, P1179, DOI 10.1016/S0140-6736(07)60564-9; Hamel J, 2004, INFECT IMMUN, V72, P2659, DOI 10.1128/IAI.72.5.2659-2670.2004; Hammerschmidt S, 1999, INFECT IMMUN, V67, P1683; Hammitt LL, 2019, VACCINE, V37, P7482, DOI 10.1016/j.vaccine.2019.09.076; Harboe ZB, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000081; Hathaway LJ, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.150269; Hava D, 2002, MOL MICROBIOL, V45, P1389, DOI 10.1046/j.1365-2958.2002.03106.x; Hicks LA, 2007, J INFECT DIS, V196, P1346, DOI 10.1086/521626; Hoffman JA, 2003, PEDIATRICS, V112, P1095, DOI 10.1542/peds.112.5.1095; Hollingshead SK, 2000, INFECT IMMUN, V68, P5889, DOI 10.1128/IAI.68.10.5889-5900.2000; Huo Z, 2004, VACCINE, V22, P1157, DOI 10.1016/j.vaccine.2003.09.025; Hurwitz JL, 2016, MBIO, V7, DOI 10.1128/mBio.00137-16; Hyams C, 2010, INFECT IMMUN, V78, P704, DOI 10.1128/IAI.00881-09; Jackson LA, 2003, NEW ENGL J MED, V348, P1747, DOI 10.1056/NEJMoa022678; Jakubovics NS, 2001, MICROBIOL-SGM, V147, P1709, DOI 10.1099/00221287-147-7-1709; JOHNSON MK, 1977, FEMS MICROBIOL LETT, V2, P243; Johnston JW, 2006, INFECT IMMUN, V74, P1171, DOI 10.1128/IAI.74.2.1171-1180.2006; Kamtchoua T, 2013, VACCINE, V31, P327, DOI 10.1016/j.vaccine.2012.11.005; Keech CA, 2020, PEDIATR INFECT DIS J, V39, P345, DOI 10.1097/INF.0000000000002567; Keller LE, 2016, MBIO, V7, DOI 10.1128/mBio.01792-15; Khan MN, 2012, MICROBES INFECT, V14, P1102, DOI 10.1016/j.micinf.2012.06.007; Kietzman CC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10859; Kirkham AS, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00497-16; Leroux-Roels G, 2014, VACCINE, V32, P6838, DOI 10.1016/j.vaccine.2014.02.052; Li Y, 2013, INFECT IMMUN, V81, P4519, DOI 10.1128/IAI.00724-13; Lochen A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75691-5; Loughran AJ, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0004-2018; Lu L, 2003, J BIOL CHEM, V278, P48178, DOI 10.1074/jbc.M306906200; Lu L, 2006, J BIOL CHEM, V281, P15464, DOI 10.1074/jbc.M602404200; Luck JN, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.613287; MACLEOD CM, 1945, J EXP MED, V82, P445, DOI 10.1084/jem.82.6.445; Malley R, 2001, INFECT IMMUN, V69, P4870, DOI 10.1128/IAI.69.8.4870-4873.2001; Mann B, 2014, J INFECT DIS, V209, P1116, DOI 10.1093/infdis/jit502; Marriott HM, 2008, CURR MOL MED, V8, P497, DOI 10.2174/156652408785747924; Masomian M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010132; Melin M, 2010, INFECT IMMUN, V78, P5262, DOI 10.1128/IAI.00740-10; Melin M, 2009, INFECT IMMUN, V77, P676, DOI 10.1128/IAI.01186-08; Morrill HJ, 2014, INFECT DIS THER, V3, P19, DOI 10.1007/s40121-014-0025-y; Mukerji R, 2012, J IMMUNOL, V189, P5327, DOI 10.4049/jimmunol.1201967; Musher DM, 2001, J INFECT DIS, V183, P827, DOI 10.1086/318833; Nabors GS, 2000, VACCINE, V18, P1743, DOI 10.1016/S0264-410X(99)00530-7; Odutola A, 2017, VACCINE, V35, P2531, DOI 10.1016/j.vaccine.2017.03.071; Ogunniyi AD, 2007, INFECT IMMUN, V75, P350, DOI 10.1128/IAI.01103-06; Ogunniyi AD, 2000, INFECT IMMUN, V68, P3028, DOI 10.1128/IAI.68.5.3028-3033.2000; Ogunniyi AD, 2001, INFECT IMMUN, V69, P5997, DOI 10.1128/IAI.69.10.5997-6003.2001; Orihuela CJ, 2009, J CLIN INVEST, V119, P1638, DOI 10.1172/JCI36759; Orihuela CJ, 2004, J INFECT DIS, V190, P1661, DOI 10.1086/424596; PATON JC, 1993, ANNU REV MICROBIOL, V47, P89, DOI 10.1146/annurev.mi.47.100193.000513; Pick H, 2020, THORAX, V75, P38, DOI 10.1136/thoraxjnl-2019-213725; Price KE, 2009, J BACTERIOL, V191, P2163, DOI 10.1128/JB.01489-08; Ramos-Sevillano E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00358; Regev-Yochay G, 2004, CLIN INFECT DIS, V38, P632, DOI 10.1086/381547; Rolo D, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-80; Rosch JW, 2014, HUM VACC IMMUNOTHER, V10, P3000, DOI 10.4161/21645515.2014.970496; Rosenow C, 1997, MOL MICROBIOL, V25, P819, DOI 10.1111/j.1365-2958.1997.mmi494.x; Rowe HM, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00253-19; Rowe HM, 2019, CELL HOST MICROBE, V25, P884, DOI 10.1016/j.chom.2019.04.012; Salha D, 2012, INFECT IMMUN, V80, P2212, DOI 10.1128/IAI.06348-11; Sanchez-Beato AR, 1998, FEMS MICROBIOL LETT, V164, P207, DOI 10.1016/S0378-1097(98)00206-7; SCHEUHAMMER AM, 1985, BIOCHIM BIOPHYS ACTA, V840, P163, DOI 10.1016/0304-4165(85)90115-1; Seiberling M, 2012, VACCINE, V30, P7455, DOI 10.1016/j.vaccine.2012.10.080; Silva-Costa C, 2018, EMERG INFECT DIS, V24, P1307, DOI 10.3201/eid2407.180029; Smith BL, 2000, J INFECT DIS, V182, P497, DOI 10.1086/315722; Stupka John E, 2009, Aging health, V5, P763, DOI 10.2217/ahe.09.74; Troeger C, 2017, LANCET INFECT DIS, V17, P1133, DOI 10.1016/S1473-3099(17)30396-1; van Aalst M, 2018, TRAVEL MED INFECT DI, V24, P89, DOI 10.1016/j.tmaid.2018.05.016; van der Linden M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131494; Verhoeven D, 2014, VACCINE, V32, P3205, DOI 10.1016/j.vaccine.2014.04.004; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; WALKER JA, 1987, INFECT IMMUN, V55, P1184, DOI 10.1128/IAI.55.5.1184-1189.1987; Walker MM, 2016, J IMMUNOL, V196, P2239, DOI 10.4049/jimmunol.1402518; Walsh RL, 2011, MBIO, V2, DOI 10.1128/mBio.00092-11; Weiser JN, 2018, NAT REV MICROBIOL, V16, P354, DOI 10.1038/s41579-018-0001-8; Welte T, 2012, THORAX, V67, P71, DOI 10.1136/thx.2009.129502; Wiese AD, 2019, EXPERT REV VACCINES, V18, P327, DOI 10.1080/14760584.2019.1582337; Wilson R, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006137; Witzenrath M, 2011, J IMMUNOL, V187, P434, DOI 10.4049/jimmunol.1003143; Wolfe S., 2015, EPIDEMIOLOGY PREVENT, V13th ed; Wright AE, 1914, LANCET, V1, P87; Xu QF, 2015, VACCINE, V33, P993, DOI 10.1016/j.vaccine.2015.01.014; Zarei AE, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/7203587; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4; Zhang Y, 2001, INFECT IMMUN, V69, P3827, DOI 10.1128/IAI.69.6.3827-3836.2001; Zhou FJ, 2007, ARCH PEDIAT ADOL MED, V161, P1162, DOI 10.1001/archpedi.161.12.1162	125	4	4	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							209	10.3390/vaccines9030209			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5CT	33801372	gold, Green Published			2022-04-29	WOS:000634172700001
J	Blakney, AK; Ip, S; Geall, AJ				Blakney, Anna K.; Ip, Shell; Geall, Andrew J.			An Update on Self-Amplifying mRNA Vaccine Development	VACCINES			English	Review						RNA; self-amplifying RNA; replicon; vaccine; drug delivery	IN-VITRO TRANSCRIPTION; LARGE-SCALE PRODUCTION; LIPID NANOPARTICLES; NONVIRAL DELIVERY; PROTECTIVE IMMUNITY; TOXOPLASMA-GONDII; POLYPLEX DELIVERY; MOLECULAR-WEIGHT; VIRUS; INFLUENZA	This review will explore the four major pillars required for design and development of an saRNA vaccine: Antigen design, vector design, non-viral delivery systems, and manufacturing (both saRNA and lipid nanoparticles (LNP)). We report on the major innovations, preclinical and clinical data reported in the last five years and will discuss future prospects.	[Blakney, Anna K.] Univ British Columbia, Sch Biomed Engn, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada; [Ip, Shell; Geall, Andrew J.] Precis Nanosyst Inc, Vancouver, BC V6P 6T7, Canada		Blakney, AK (通讯作者)，Univ British Columbia, Sch Biomed Engn, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada.	anna.blakney@msl.ubc.ca; sip@precision-nano.com; ageall@precision-nano.com		Geall, Andrew/0000-0003-3138-9218; Blakney, Anna/0000-0002-5812-9689	European Commission H2020 Marie SklodowskaCurie Individual Fellowship [794059]	A.K.B. acknowledges funding from the European Commission H2020 Marie SklodowskaCurie Individual Fellowship (794059).	Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Ajbani SP, 2015, INT J BIOL MACROMOL, V81, P794, DOI 10.1016/j.ijbiomac.2015.09.010; Akinc A, 2019, NAT NANOTECHNOL, V14, P1084, DOI 10.1038/s41565-019-0591-y; Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3; Alnylam Pharmaceuticals Press Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, 2018, ONPATTRO PAT TREATM; Alwis R.d., 2020, 280446 BIORXIV, DOI [10.1101/2020.09.03.280446, DOI 10.1101/2020.09.03.280446]; Anderluzzi G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020212; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 2021, REUTERS NOVARTIS A H; Ansaldi F, 2009, VACCINE, V27, P3345, DOI 10.1016/j.vaccine.2009.01.081; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Baiersdorfer M, 2019, MOL THER-NUCL ACIDS, V15, P26, DOI 10.1016/j.omtn.2019.02.018; BAILEY AL, 1994, BIOCHEMISTRY-US, V33, P12573, DOI 10.1021/bi00208a007; BANGHAM AD, 1964, J MOL BIOL, V8, P660, DOI 10.1016/S0022-2836(64)80115-7; Baronti L, 2018, ANAL BIOANAL CHEM, V410, P3239, DOI 10.1007/s00216-018-0943-8; Batey RT, 2014, CURR OPIN STRUC BIOL, V26, P1, DOI 10.1016/j.sbi.2014.01.014; Beissert T, 2017, HUM GENE THER, V28, P1138, DOI 10.1089/hum.2017.121; Beissert T, 2020, MOL THER, V28, P119, DOI 10.1016/j.ymthe.2019.09.009; Belliveau NM, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.28; Blakney AK, 2021, MOL THER, V29, P1174, DOI 10.1016/j.ymthe.2020.11.011; Blakney AK, 2020, ACS NANO, V14, P5711, DOI 10.1021/acsnano.0c00326; Blakney AK, 2020, BIOMACROMOLECULES, V21, P2482, DOI 10.1021/acs.biomac.0c00445; Blakney AK, 2019, J CONTROL RELEASE, V304, P65, DOI 10.1016/j.jconrel.2019.04.043; Blakney AK, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00071; Blakney AK, 2018, BIOMACROMOLECULES, V19, P2870, DOI 10.1021/acs.biomac.8b00429; Bloom K, 2021, GENE THER, V28, P117, DOI 10.1038/s41434-020-00204-y; Bogers WM, 2015, J INFECT DIS, V211, P947, DOI 10.1093/infdis/jiu522; Brazzoli M, 2016, J VIROL, V90, P332, DOI 10.1128/JVI.01786-15; BRENNER S, 1961, NATURE, V190, P576, DOI 10.1038/190576a0; Brito LA, 2015, ADV GENET, V89, P179, DOI 10.1016/bs.adgen.2014.10.005; Brito LA, 2014, MOL THER, V22, P2118, DOI 10.1038/mt.2014.133; Brunelle JL, 2013, METHOD ENZYMOL, V530, P101, DOI 10.1016/B978-0-12-420037-1.00005-1; Carrasco L, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020070; Center for Leading Innovation, 2020, SAF IMM STUD 2019 NC; Chahal JS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00193-w; Chahal JS, 2016, P NATL ACAD SCI USA, V113, pE4133, DOI 10.1073/pnas.1600299113; ClinicalTrials.gov, NOV CELL BAS A H1N1; ClinicalTrials.gov, CSL VACCINE A H1N1; ClinicalTrials.gov, 2021, J J CLIN TRIAL START; ClinicalTrials.gov, NOV CLIN TRIAL START; ClinicalTrials.gov, 2021, MOD CLIN TRIAL START; Cohen J, 2020, SCIENCE, V368, P14, DOI 10.1126/science.368.6486.14; CONRY RM, 1995, CANCER RES, V55, P1397; Control Center for Disease, H1N1 09 PHEIC DECL; Control Center for Disease, H1N1 09 SWIN FLU PAN; Control Center for Disease, H1N1 09 PAND DECL; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Davis Robert H., 1995, Current Opinion in Biotechnology, V6, P213, DOI 10.1016/0958-1669(95)80035-2; Deering RP, 2014, EXPERT OPIN DRUG DEL, V11, P885, DOI 10.1517/17425247.2014.901308; DeFrancesco L, 2017, NAT BIOTECHNOL, V35, P193, DOI 10.1038/nbt.3812; deHaro C, 1996, FASEB J, V10, P1378, DOI 10.1096/fasebj.10.12.8903508; Demoulins T, 2016, NANOMED-NANOTECHNOL, V12, P711, DOI 10.1016/j.nano.2015.11.001; Demoulinsa T, 2017, J CONTROL RELEASE, V266, P256, DOI 10.1016/j.jconrel.2017.09.018; Diken M, 2017, CURR ISSUES MOL BIOL, V22, P113, DOI 10.21775/cimb.022.113; Dolgin E, 2021, NATURE, V589, P189, DOI 10.1038/d41586-021-00019-w; Elli EM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01186; Englezou PC, 2018, MOL THER-NUCL ACIDS, V12, P118, DOI 10.1016/j.omtn.2018.04.019; Erasmus JH, 2020, MOL THER-METH CLIN D, V18, P402, DOI 10.1016/j.omtm.2020.06.011; Erasmus JH, 2018, MOL THER, V26, P2507, DOI 10.1016/j.ymthe.2018.07.010; ERASMUS JH, 2020, SCI, V12, DOI DOI 10.1126/SCITRANSLMED.ABC9396; FDA, H1N1 SWIN FLU EUA; FDA, MOD COVID 19 VACC AP; FDA, FDA APPR H1N1 VACC; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Fiedler K, 2016, RECENT RESULTS CANC, V209, P61, DOI 10.1007/978-3-319-42934-2_5; Finn JD, 2018, CELL REP, V22, P2227, DOI 10.1016/j.celrep.2018.02.014; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Fros JJ, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060166; Funk CD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00937; Garcia AB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05041-7; Geall AJ, 2013, SEMIN IMMUNOL, V25, P152, DOI 10.1016/j.smim.2013.05.001; Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109; Gholamalipour Y, 2018, NUCLEIC ACIDS RES, V46, P9253, DOI 10.1093/nar/gky796; Goswami R, 2019, ACS INFECT DIS, V5, P1546, DOI 10.1021/acsinfecdis.9b00084; Gotte B, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10030105; Gurnani P, 2020, BIOMACROMOLECULES, V21, P3242, DOI 10.1021/acs.biomac.0c00698; Hekele A, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.54; Houseley J, 2009, CELL, V136, P763, DOI 10.1016/j.cell.2009.01.019; Huysmans H, 2019, MOL THER-NUCL ACIDS, V17, P867, DOI 10.1016/j.omtn.2019.08.001; Hyde JL, 2015, VIRUS RES, V206, P99, DOI 10.1016/j.virusres.2015.01.016; Iavarone C, 2017, EXPERT REV VACCINES, V16, P871, DOI 10.1080/14760584.2017.1355245; Iwasaki A, 2015, NAT IMMUNOL, V16, P343, DOI 10.1038/ni.3123; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jackson NAC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0159-8; Jeffs LB, 2005, PHARM RES-DORDR, V22, P362, DOI 10.1007/s11095-004-1873-z; Jemielity J, 2003, RNA, V9, P1108, DOI 10.1261/rna.5430403; Jenning V, 2002, J MICROENCAPSUL, V19, P1, DOI 10.1080/713817583; Kaiser J., 2020, SCIENCE, DOI [10.1126/science.abf7422, DOI 10.1126/SCIENCE.ABF7422]; Kallen KJ, 2013, HUM VACC IMMUNOTHER, V9, P2263, DOI 10.4161/hv.25181; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kim J, 2020, CELL MOL BIOENG, V13, P463, DOI 10.1007/s12195-020-00619-y; Kis Z, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201970055; Koirala A, 2020, PAEDIATR RESPIR REV, V35, P43, DOI 10.1016/j.prrv.2020.06.010; Kose N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw6647; Kreiter S, 2011, CANCER RES, V71, P6132, DOI 10.1158/0008-5472.CAN-11-0291; Kunath K, 2003, J CONTROL RELEASE, V89, P113, DOI 10.1016/S0168-3659(03)00076-2; Kwon H, 2018, BIOMATERIALS, V156, P172, DOI 10.1016/j.biomaterials.2017.11.034; Laczko D, 2020, IMMUNITY, V53, P724, DOI 10.1016/j.immuni.2020.07.019; Lazzaro S, 2015, IMMUNOLOGY, V146, P312, DOI 10.1111/imm.12505; Lee J, 2018, ACTA BIOMATER, V80, P31, DOI 10.1016/j.actbio.2018.08.033; Lello LS, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008825; Li YZ, 2020, NAT CANCER, V1, P882, DOI 10.1038/s43018-020-0095-6; Li YZ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43422-0; Liang SL, 2006, IUBMB LIFE, V58, P508, DOI 10.1080/15216540600838232; Liu MA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020037; Liu MA, 2005, ADV GENET, V55, P25, DOI 10.1016/S0065-2660(05)55002-8; Liu Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48559-6; Ljungberg K, 2015, EXPERT REV VACCINES, V14, P177, DOI 10.1586/14760584.2015.965690; Lou G, 2020, J CONTROL RELEASE, V325, P370, DOI 10.1016/j.jconrel.2020.06.027; Luisi K, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba5068; Lundstrom K, 2021, METHODS MOL BIOL, V2183, P63, DOI 10.1007/978-1-0716-0795-4_6; Lundstrom K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145130; Luo FJ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00605; Lutz J, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0032-6; Magini D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161193; Manara C, 2019, VACCINE, V37, P4204, DOI 10.1016/j.vaccine.2019.04.028; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; MARTINON F, 1993, EUR J IMMUNOL, V23, P1719, DOI 10.1002/eji.1830230749; Martins R, 2014, J CHROMATOGR A, V1355, P1, DOI 10.1016/j.chroma.2014.05.075; Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020; Maruggi G, 2017, VACCINE, V35, P361, DOI 10.1016/j.vaccine.2016.11.040; Maurus, 2020, CONCURRENT HUMAN ANT; McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9; Melo M, 2019, MOL THER, V27, P2080, DOI 10.1016/j.ymthe.2019.08.007; Moon Stephanie L, 2012, Methods Mol Biol, V941, P171, DOI 10.1007/978-1-62703-113-4_13; Moyo N, 2019, MOL THER-METH CLIN D, V12, P32, DOI 10.1016/j.omtm.2018.10.010; Mu X, 2018, NUCLEIC ACIDS RES, V46, P5239, DOI 10.1093/nar/gky177; Muchow M, 2008, DRUG DEV IND PHARM, V34, P1394, DOI 10.1080/03639040802130061 ; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Mulligan MJ, 2020, PHASE 1 2 STUDY DESC, DOI [10.1101/2020.06.30. 20142570., DOI 10.1101/2020.06.30.20142570, 10.1038/s41586-020-2639-4]; Ngono AE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb2154; Oberfeld B, 2020, CELL, V181, P954, DOI 10.1016/j.cell.2020.04.013; Pardi N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05482-0; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Peng ZH, 2002, ORG LETT, V4, P161, DOI 10.1021/ol0167715; Pepini T, 2017, J IMMUNOL, V198, P4012, DOI 10.4049/jimmunol.1601877; Perche F, 2019, MOL THER-NUCL ACIDS, V17, P767, DOI 10.1016/j.omtn.2019.07.014; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Pfizer, 2020, PFIZ BIONT ACH 1 AUT, DOI [1006304/en/, DOI 1006304/EN]; Pietla MK, 2017, VIRUS RES, V234, P44, DOI 10.1016/j.virusres.2017.01.007; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pollard C, 2013, MOL THER, V21, P251, DOI 10.1038/mt.2012.202; Rauch S, 2020, MRNA BASED SARS COV2, V2020, DOI [10.23.351775, 10.1101/2020.10.23.351775., DOI 10.1101/2020.10.23.351775, 10.1101/2020.10.23.351775]; Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040; Rupp JC, 2015, J GEN VIROL, V96, P2483, DOI 10.1099/jgv.0.000249; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; Samnuan K., 2021, DESIGN OF EXPT IN VI, DOI [10.1101/2021.01.08.425833, DOI 10.1101/2021.01.08.425833]; Samsa MM, 2019, MOL THER, V27, P850, DOI 10.1016/j.ymthe.2018.12.013; Saviano F, 2020, J MATER CHEM B, V8, P4940, DOI 10.1039/d0tb00942c; Scheuber A., IMPERIAL SOCIAL ENTE; Scorza FB, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020020; Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602; Shegokar R, 2011, INT J PHARMACEUT, V416, P461, DOI 10.1016/j.ijpharm.2010.08.014; Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034; Sorgi FL, 1996, INT J PHARMACEUT, V144, P131, DOI 10.1016/S0378-5173(96)04733-3; Stokes A, 2020, REGUL TOXICOL PHARM, V113, DOI 10.1016/j.yrtph.2020.104648; Suschak JJ, 2017, HUM VACC IMMUNOTHER, V13, P2837, DOI 10.1080/21645515.2017.1330236; Tews BA, 2017, METHODS MOL BIOL, V1499, P15, DOI 10.1007/978-1-4939-6481-9_2; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298; Ulmer JB, 2015, EXPERT OPIN DRUG DIS, V10, P101, DOI 10.1517/17460441.2015.996128; Vaidyanathan S, 2018, MOL THER-NUCL ACIDS, V12, P530, DOI 10.1016/j.omtn.2018.06.010; Veiga N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06936-1; VEMURI S, 1990, DRUG DEV IND PHARM, V16, P2243, DOI 10.3109/03639049009043797; Viger-Gravel J, 2018, J PHYS CHEM B, V122, P2073, DOI 10.1021/acs.jpcb.7b10795; Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017; Walker SE, 2013, METHOD ENZYMOL, V530, P337, DOI 10.1016/B978-0-12-420037-1.00019-1; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wayment-Steele HK, 2021, NUCLEIC ACIDS RES, V49, P10604, DOI [10.1101/2020.08.22.262931, 10.1093/nar/gkab764]; Weide B, 2009, J IMMUNOTHER, V32, P498, DOI 10.1097/CJI.0b013e3181a00068; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; World Health Organization, COVID 19 DECL PAND; World Health Organization, 2021, COVID 19 DECL PHEIC; Wu MZ, 2020, RNA, V26, P345, DOI 10.1261/rna.073858.119; Yaghi NK, 2017, NEURO-ONCOLOGY, V19, P372, DOI 10.1093/neuonc/now198; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; Yoshioka N, 2013, CELL STEM CELL, V13, P246, DOI 10.1016/j.stem.2013.06.001; Zhong ZF, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030096; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	179	30	30	25	51	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							97	10.3390/vaccines9020097			26	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6SO	33525396	Green Published, Green Submitted, gold			2022-04-29	WOS:000623271600001
J	Dumrisilp, T; Wongpiyabovorn, J; Buranapraditkun, S; Tubjaroen, C; Chaijitraruch, N; Prachuapthunyachart, S; Sintusek, P; Chongsrisawat, V				Dumrisilp, Termpong; Wongpiyabovorn, Jongkonnee; Buranapraditkun, Supranee; Tubjaroen, Chomchanat; Chaijitraruch, Nataruks; Prachuapthunyachart, Sittichoke; Sintusek, Palittiya; Chongsrisawat, Voranush			Impact of Obesity and Being Overweight on the Immunogenicity to Live Attenuated Hepatitis A Vaccine in Children and Young Adults	VACCINES			English	Article						hepatitis A; obesity; overweight; immunogenicity; vaccine		Prior results investigating a correlation between obesity and hepatitis A virus (HAV) vaccine response have been inconclusive, with limited data involving live attenuated HAV vaccines. The aim of this study is to evaluate the effect of overweight and obesity on the response to live attenuated HAV vaccine in children and young adults. This prospective cohort study was conducted in Thailand with subjects ranging in age from seven to twenty-five years. The subjects were administered 0.5 mL of MEVAC (TM)-A and tested for anti-HAV antibodies before and at 8-9 weeks after vaccination. Baseline seronegative subjects (anti-HAV antibodies < 20 mIU/mL) were divided into non-obese (underweight/normal weight) and obese (overweight/obesity/severe obesity) groups. A total of 212 (117 non-obese and 95 obese) subjects completed the study (mean age (SD) = 13.95 (3.90) years). The seroprotection rates were 100%. Postvaccination geometric mean titers (95% CI) were 429.51 (401.97, 458.94) and 467.45 (424.47, 514.79) mIU/mL in the non-obese and obese groups, respectively. Females (p = 0.013) and subjects with truncal obesity (p = 0.002) had significantly higher titers than other participants. Live attenuated HAV vaccine is safe and has comparably high immunogenicity in both underweight/normal weight and overweight/obese persons.	[Dumrisilp, Termpong; Tubjaroen, Chomchanat; Chaijitraruch, Nataruks; Prachuapthunyachart, Sittichoke; Sintusek, Palittiya; Chongsrisawat, Voranush] Chulalongkorn Univ, Fac Med, Dept Pediat, Div Gastroenterol & Hepatol, Bangkok 10330, Thailand; [Dumrisilp, Termpong; Wongpiyabovorn, Jongkonnee; Buranapraditkun, Supranee; Tubjaroen, Chomchanat; Chaijitraruch, Nataruks; Prachuapthunyachart, Sittichoke; Sintusek, Palittiya; Chongsrisawat, Voranush] King Chulalongkorn Mem Hosp, Bangkok 10330, Thailand; [Wongpiyabovorn, Jongkonnee] Chulalongkorn Univ, Fac Med, Dept Microbiol, Div Immunol, Bangkok 10330, Thailand; [Buranapraditkun, Supranee] Chulalongkorn Univ, Fac Med, Dept Med, Allergy & Clin Immunol Unit, Bangkok 10330, Thailand		Chongsrisawat, V (通讯作者)，Chulalongkorn Univ, Fac Med, Dept Pediat, Div Gastroenterol & Hepatol, Bangkok 10330, Thailand.; Chongsrisawat, V (通讯作者)，King Chulalongkorn Mem Hosp, Bangkok 10330, Thailand.	jusmax_63@hotmail.com; jongkonnee.w@chula.ac.th; bsuprane@chula.ac.th; chomchanat.t@chulahospital.org; Suttiruk.J@chula.ac.th; Sittichoke.P@chula.ac.th; Palittiya.S@chula.ac.th; voranush.c@chula.ac.th		Sintusek, Palittiya/0000-0003-4441-0151; dumrisilp, termpong/0000-0001-7110-0664; Chongsrisawat, Voranush/0000-0002-6106-0504			Ahmad N, 2016, INT J PREVENTIVE MED, V7, DOI 10.4103/2008-7802.183654; Andersen CJ, 2016, ADV NUTR, V7, P66, DOI 10.3945/an.115.010207; [Anonymous], 2013, VACCINE, V31, P285, DOI 10.1016/j.vaccine.2012.10.102; [Anonymous], ASIA PACIFIC PERSPEC; Averhoff F, 1998, AM J PREV MED, V15, P1, DOI 10.1016/S0749-3797(98)00003-8; Bandaru P., 2013, ENDOCRINOL METAB SYN, V2, P2, DOI DOI 10.4172/2161-1017.1000113; Batra A, 2012, DIGEST DIS, V30, P70, DOI 10.1159/000335722; Batra A, 2010, ENDOCRINOLOGY, V151, P56, DOI 10.1210/en.2009-0565; Beasley LE, 2009, OBESITY, V17, P1062, DOI 10.1038/oby.2008.627; Bhave S., 2014, VACCINE DEV THER, V4, P1, DOI [10.2147/VDT.S52736, DOI 10.2147/VDT.S52736]; Bhave S, 2006, INDIAN PEDIATR, V43, P983; Bollaerts K, 2019, VACCINE-X, V1, DOI 10.1016/j.jvacx.2019.100007; Callahan ST, 2014, J INFECT DIS, V210, P1270, DOI 10.1093/infdis/jiu245; Chen S, 2015, OBES RES CLIN PRACT, V9, P35, DOI 10.1016/j.orcp.2013.12.006; de Onis M, 2006, PUBLIC HEALTH NUTR, V9, P942, DOI 10.1017/PHN20062005; de Onis M, 2006, ACTA PAEDIATR, V95, P76, DOI 10.1080/08035320500495548; Eliakim A, 2006, AUTOIMMUNITY, V39, P137, DOI 10.1080/08916930600597326; Estrada LD, 2020, J IMMUNOL, V204; Faridi MMA, 2009, INDIAN PEDIATR, V46, P29; Fruhbeck Gema, 2008, V456, P1, DOI 10.1007/978-1-59745-245-8_1; Giefing-Kroll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326; GOUBAU P, 1992, VACCINE, V10, pS114, DOI 10.1016/0264-410X(92)90561-W; Honce R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01071; Jacobsen KH, 2004, EPIDEMIOL INFECT, V132, P1005, DOI 10.1017/S0950268804002857; Jitnarin N, 2011, EAT WEIGHT DISORD-ST, V16, pE242, DOI 10.1007/BF03327467; Jolliffe CJ, 2007, J AM COLL CARDIOL, V49, P891, DOI 10.1016/j.jacc.2006.08.065; Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9; Koh YK, 2016, PEDIATR GASTROENTERO, V19, P251, DOI 10.5223/pghn.2016.19.4.251; Kulkarni PS, 2006, VACCINE, V24, P3457, DOI 10.1016/j.vaccine.2006.02.008; Lim J, 2014, YONSEI MED J, V55, P126, DOI 10.3349/ymj.2014.55.1.126; Ma GS, 2010, BIOMED ENVIRON SCI, V23, P21, DOI 10.1016/S0895-3988(10)60027-X; Magnuson A, 2015, INTEGR OBESITY DIABE, V1, DOI [10.15761/IOD.1000124, DOI 10.15761/IOD.1000124]; Minana JS, 1996, VACCINE, V14, P103, DOI 10.1016/0264-410X(95)00176-2; Painter SD, 2015, VACCINE, V33, P4422, DOI 10.1016/j.vaccine.2015.06.101; Park HS, 2005, DIABETES RES CLIN PR, V69, P29, DOI 10.1016/j.diabres.2004.11.007; Rao S, 2016, HUM VACC IMMUNOTHER, V12, P3160, DOI 10.1080/21645515.2016.1216286; Reuman PD, 1997, VACCINE, V15, P1157, DOI 10.1016/S0264-410X(96)00310-6; Sa-Nguanmoo P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151304; Sheridan PA, 2012, INT J OBESITY, V36, P1072, DOI 10.1038/ijo.2011.208; Siddiqui K., 2013, WORLD APPL SCI J, V27, P285, DOI [10.5829/idosi.wasj.2013.27.02.889, DOI 10.5829/ID0SI.WASJ.2013.27.02.889, DOI 10.5829/IDOSI.WASJ.2013.27.02.889]; Stoddart ML, 2002, DIABETES CARE, V25, P1009, DOI 10.2337/diacare.25.6.1009; Teerawattananon Y, 2017, OBESITY THAILAND ITS; Ullman JB, 2013, USING MULTIVARIATE S, P117; Van der Wielen M, 2006, VACCINE, V24, P5509, DOI 10.1016/j.vaccine.2006.04.016; Vashishtha VM, 2014, INDIAN PEDIATR, V51, P785, DOI 10.1007/s13312-014-0504-y; WAGNER G, 1993, VACCINE, V11, P1027, DOI 10.1016/0264-410X(93)90128-K; Wang XY, 2007, VACCINE, V25, P446, DOI 10.1016/j.vaccine.2006.08.004; World Health Organization, IMMUNOLOGICAL BASIS; Young KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082779; Zhang XS, 2016, HUM VACC IMMUNOTHER, V12, P2322, DOI 10.1080/21645515.2015.1134069; Zheng Hui, 2009, Zhongguo Yi Miao He Mian Yi, V15, P371; Ziccardi P, 2002, CIRCULATION, V105, P804, DOI 10.1161/hc0702.104279	52	0	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							130	10.3390/vaccines9020130			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6PG	33562009	Green Published, gold			2022-04-29	WOS:000623263000001
J	Liao, YF; Reddy, SM; Khan, OA; Sun, AJ; Lupiani, B				Liao, Yifei; Reddy, Sanjay M.; Khan, Owais A.; Sun, Aijun; Lupiani, Blanca			A Novel Effective and Safe Vaccine for Prevention of Marek's Disease Caused by Infection with a Very Virulent Plus (vv+) Marek's Disease Virus	VACCINES			English	Article						Marek's disease virus; Meq; vIL8; lymphoid organ atrophy; vaccine		Marek's disease virus (MDV) is a highly contagious alphaherpesvirus that causes rapid onset lymphoma in chickens. Marek's disease (MD) is effectively controlled using vaccination; however, MDV continues to break through vaccinal immunity, due to the emergence of highly virulent field strains. Earlier studies revealed that deletion of the meq gene from MDV resulted in an attenuated virus that protects against MD in chickens challenged with highly virulent field strains. However, the meq deleted virus retains the ability to induce significant lymphoid organ atrophy. In a different study, we found that the deletion of the vIL8 gene resulted in the loss of lymphoid organ atrophy in inoculated chickens. Here, we describe the generation of a recombinant MDV from which both meq and vIL8 genes were deleted. In vitro studies revealed that the meq and vIL8 double deletion virus replicated at levels similar to the parental very virulent plus (vv+) virus. In addition, in vivo studies showed that the double deletion mutant virus (686BAC-Delta Meq Delta vIL8) conferred protection comparable to CVI988, a commercial vaccine strain, when challenged with a vv+ MDV virus, and significantly reduced lymphoid organ atrophy, when compared to meq null virus, in chickens. In conclusion, our study describes the development of a safe and effective vaccine candidate for prevention of MD in chickens.	[Liao, Yifei; Reddy, Sanjay M.; Khan, Owais A.; Sun, Aijun; Lupiani, Blanca] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, College Stn, TX 77843 USA; [Khan, Owais A.] Texas A&M Vet Med Diagnost Lab, Canyon, TX 79016 USA; [Sun, Aijun] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China		Sun, AJ; Lupiani, B (通讯作者)，Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, College Stn, TX 77843 USA.; Sun, AJ (通讯作者)，Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou 450002, Peoples R China.	liao.yifei@tamu.edu; SReddy@cvm.tamu.edu; owais.khan@tvmdl.tamm.edu; sunaijun225@163.com; blupiani@tamm.edu	Liao, Yifei/AAA-5506-2021	Liao, Yifei/0000-0002-0081-9548; Lupiani, Blanca/0000-0002-0633-3143; Khan, Owais/0000-0002-7219-1673	Texas AM University	This research was funded by Texas A&M University.	Ajithdoss DK, 2009, VIRUS RES, V142, P57, DOI 10.1016/j.virusres.2009.01.008; ANDERSON AS, 1992, VIROLOGY, V189, P657, DOI 10.1016/0042-6822(92)90589-H; Brown AC, 2009, J VIROL, V83, P11142, DOI 10.1128/JVI.01393-09; BULOW VV, 1977, AVIAN PATHOL, V6, P395, DOI 10.1080/03079457708418248; Calnek BW, 2001, CURR TOP MICROBIOL, V255, P25; CHURCHILL AE, 1969, J GEN VIROL, V4, P557, DOI 10.1099/0022-1317-4-4-557; CHURCHILL AE, 1967, NATURE, V215, P528, DOI 10.1038/215528a0; Cui XP, 2005, AVIAN DIS, V49, P199, DOI 10.1637/7277-091004; Cui XP, 2004, J VIROL, V78, P4753, DOI 10.1128/JVI.78.9.4753-4760.2004; CUI ZZ, 1991, J VIROL, V65, P6509, DOI 10.1128/JVI.65.12.6509-6515.1991; Davison AJ, 2009, ARCH VIROL, V154, P171, DOI 10.1007/s00705-008-0278-4; Davison F, 2005, EXPERT REV VACCINES, V4, P77, DOI 10.1586/14760584.4.1.77; Dunn JR, 2012, AVIAN DIS, V56, P494, DOI 10.1637/10062-011812-Reg.1; Faiz NM, 2016, AVIAN PATHOL, V45, P606, DOI 10.1080/03079457.2016.1191618; Gandon S, 2001, NATURE, V414, P751, DOI 10.1038/414751a; Gimeno IM, 2018, AVIAN DIS, V62, P272, DOI 10.1637/11841-041318-Review.1; Gimeno IM, 2004, AVIAN PATHOL, V33, P59, DOI 10.1080/0307945031000163264; Gimeno IM, 2008, VACCINE, V26, pC31, DOI 10.1016/j.vaccine.2008.04.009; Hildebrandt E, 2015, AVIAN PATHOL, V44, P254, DOI 10.1080/03079457.2015.1041366; Hildebrandt E, 2015, AVIAN DIS, V59, P94, DOI 10.1637/10929-090314-Reg; Jarosinski KW, 2005, J VIROL, V79, P11647, DOI 10.1128/JVI.79.18.11647-11659.2005; JONES D, 1992, P NATL ACAD SCI USA, V89, P4042, DOI 10.1073/pnas.89.9.4042; Lee LF, 2000, P NATL ACAD SCI USA, V97, P6091, DOI 10.1073/pnas.97.11.6091; LEE LF, 1983, J IMMUNOL, V130, P1003; Lee LF, 2008, VACCINE, V26, P1887, DOI 10.1016/j.vaccine.2008.01.046; Lee LF, 2012, VACCINE, V30, P5151, DOI 10.1016/j.vaccine.2012.05.043; Lee LF, 2011, AVIAN DIS, V55, P172, DOI 10.1637/9575-101510-Reg.1; Lee LF, 2010, VACCINE, V28, P1294, DOI 10.1016/j.vaccine.2009.11.022; Levy AM, 2005, P NATL ACAD SCI USA, V102, P14831, DOI 10.1073/pnas.0506849102; Liao YF, 2020, J VIROL, V94, DOI 10.1128/JVI.00892-20; Liu JL, 1998, J VIROL, V72, P388, DOI 10.1128/JVI.72.1.388-395.1998; Lupiani B, 2004, P NATL ACAD SCI USA, V101, P11815, DOI 10.1073/pnas.0404508101; Lupiani B, 2013, AVIAN DIS, V57, P427, DOI 10.1637/10445-110412-ResNote.1; Nair V, 2004, DEV BIOLOGICALS, V119, P147; NAZERIAN K, 1968, P SOC EXP BIOL MED, V127, P177, DOI 10.3181/00379727-127-32650; OKAZAKI W, 1970, AVIAN DIS, V14, P413, DOI 10.2307/1588488; Osterrieder N, 2006, NAT REV MICROBIOL, V4, P283, DOI 10.1038/nrmicro1382; Parcells MS, 2001, J VIROL, V75, P5159, DOI 10.1128/JVI.75.11.5159-5173.2001; Reddy SM, 2017, VET MICROBIOL, V206, P113, DOI 10.1016/j.vetmic.2016.11.024; Reddy SM, 2013, AVIAN DIS, V57, P469, DOI 10.1637/10444-110412-ResNote.1; RISPENS BH, 1972, AVIAN DIS, V16, P108, DOI 10.2307/1588905; RISPENS BH, 1972, AVIAN DIS, V16, P126, DOI 10.2307/1588906; Schumacher D, 2000, J VIROL, V74, P11088, DOI 10.1128/JVI.74.23.11088-11098.2000; Suchodolski PF, 2010, VIROLOGY, V399, P312, DOI 10.1016/j.virol.2010.01.006; Suchodolski PF, 2009, J VIROL, V83, P859, DOI 10.1128/JVI.01630-08; Tischer BK, 2006, BIOTECHNIQUES, V40, P191, DOI 10.2144/000112096; Tulman ER, 2000, J VIROL, V74, P7980, DOI 10.1128/JVI.74.17.7980-7988.2000; Witter R., 1992, 4 INT S MAR DIS 19 W; Witter RL, 2004, AVIAN DIS, V48, P768, DOI 10.1637/7203-050304R; WITTER RL, 1995, AVIAN DIS, V39, P269, DOI 10.2307/1591868; Witter RL, 2002, AVIAN DIS, V46, P925, DOI 10.1637/0005-2086(2002)046[0925:IOSPBV]2.0.CO;2; WITTER RL, 1987, AVIAN DIS, V31, P752, DOI 10.2307/1591027; WITTER RL, 1984, AVIAN PATHOL, V13, P75, DOI 10.1080/03079458408418510; Witter RL, 1997, AVIAN DIS, V41, P149, DOI 10.2307/1592455; WITTER RL, 1970, AM J VET RES, V31, P525	55	6	6	5	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							159	10.3390/vaccines9020159			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7BF	33669421	gold, Green Published			2022-04-29	WOS:000623294500001
J	Pance, A				Pance, Alena			The Stem Cell Revolution Revealing Protozoan Parasites' Secrets and Paving the Way towards Vaccine Development	VACCINES			English	Review						protozoan parasites; stem cells; induced pluripotent stem cells; organoids; vaccines; treatments	IN-VITRO MODEL; INTESTINAL EPITHELIAL-CELLS; TRYPANOSOMA-CRUZI; TOXOPLASMA-GONDII; LIVER-STAGE; ORGANOIDS; INFECTION; MALARIA; CULTURE; TISSUE	Protozoan infections are leading causes of morbidity and mortality in humans and some of the most important neglected diseases in the world. Despite relentless efforts devoted to vaccine and drug development, adequate tools to treat and prevent most of these diseases are still lacking. One of the greatest hurdles is the lack of understanding of host-parasite interactions. This gap in our knowledge comes from the fact that these parasites have complex life cycles, during which they infect a variety of specific cell types that are difficult to access or model in vitro. Even in those cases when host cells are readily available, these are generally terminally differentiated and difficult or impossible to manipulate genetically, which prevents assessing the role of human factors in these diseases. The advent of stem cell technology has opened exciting new possibilities to advance our knowledge in this field. The capacity to culture Embryonic Stem Cells, derive Induced Pluripotent Stem Cells from people and the development of protocols for differentiation into an ever-increasing variety of cell types and organoids, together with advances in genome editing, represent a huge resource to finally crack the mysteries protozoan parasites hold and unveil novel targets for prevention and treatment.	[Pance, Alena] Wellcome Sanger Inst, Genome Campus, Hinxton CB10 1SA, Cambs, England		Pance, A (通讯作者)，Wellcome Sanger Inst, Genome Campus, Hinxton CB10 1SA, Cambs, England.	alena.pance@sanger.ac.uk	Pance, Alena/AAH-2878-2021	Pance, Alena/0000-0002-9017-2644			Allahverdiyev AM, 2011, AM J TROP MED HYG, V85, P535, DOI 10.4269/ajtmh.2011.11-0037; Arrowood MJ, 2002, CLIN MICROBIOL REV, V15, P390, DOI 10.1128/CMR.15.3.390-400.2002; Bahmad HF, 2021, CURR STEM CELL RES T, V16, P262, DOI 10.2174/1574888X15999200831160710; Barbosa JF, 2015, RECENT PATENTS ENDOC, V9, P90, DOI 10.2174/1872214809666150921111956; Baydoun M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17304-2; Bei AK, 2010, J INFECT DIS, V202, P1722, DOI 10.1086/657157; Benere E, 2010, PARASITOL INT, V59, P634, DOI 10.1016/j.parint.2010.08.001; Betancourt ED, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00046; Blader IJ, 2015, ANNU REV MICROBIOL, V69, P463, DOI 10.1146/annurev-micro-091014-104100; Bosshart H, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.08.53; Bozzi A, 2019, STEM CELL REP, V12, P1232, DOI 10.1016/j.stemcr.2019.04.017; Breyner NM, 2020, ACTA TROP, V202, DOI 10.1016/j.actatropica.2019.105262; Bustamante LY, 2013, VACCINE, V31, P373, DOI 10.1016/j.vaccine.2012.10.106; Castellanos-Gonzalez A, 2013, INFECT IMMUN, V81, P1996, DOI 10.1128/IAI.01131-12; Crosnier C, 2011, NATURE, V480, P534, DOI 10.1038/nature10606; Cross MJ, 2015, BRIT J PHARMACOL, V172, P957, DOI 10.1111/bph.12979; Dermine JF, 2005, CELL MICROBIOL, V7, P1263, DOI 10.1111/j.1462-5822.2005.00550.x; Douglas AD, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1615; Dutta D, 2019, JOVE-J VIS EXP, DOI 10.3791/59610; Egan ES, 2015, SCIENCE, V348, P711, DOI 10.1126/science.aaa3526; Espinosa DA, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00498-16; Fatehullah A, 2016, NAT CELL BIOL, V18, P246, DOI 10.1038/ncb3312; Flegr J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090203; Fonseca-Berzal C, 2018, PARASITOL RES, V117, P3367, DOI 10.1007/s00436-018-6084-3; Funkhouser-Jones LJ, 2020, MBIO, V11, DOI 10.1128/mBio.00052-20; Grzybek M, 2018, APPL MICROBIOL BIOT, V102, P4629, DOI 10.1007/s00253-018-8927-3; Gunalan K, 2020, TRENDS PARASITOL, V36, P512, DOI 10.1016/j.pt.2020.04.002; Gunasekera S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050715; Harbuzariu A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55631-8; Hares MF, 2021, PARASITE IMMUNOL, V43, DOI 10.1111/pim.12765; Heo I, 2018, NAT MICROBIOL, V3, P814, DOI 10.1038/s41564-018-0177-8; Hong A, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9100809; Karanis P, 2011, INT J PARASITOL, V41, P1231, DOI 10.1016/j.ijpara.2011.08.001; Khalil IA, 2018, LANCET GLOB HEALTH, V6, pE758, DOI 10.1016/S2214-109X(18)30283-3; Khan Asis, 2017, Curr Protoc Microbiol, V44, DOI 10.1002/cpmc.26; Kim J, 2020, NAT REV MOL CELL BIO, V21, P571, DOI 10.1038/s41580-020-0259-3; Kim S, 2019, ADV THER-GERMANY, V2, DOI 10.1002/adtp.201800087; Klebanov N, 2018, CUREUS, V10, DOI 10.7759/cureus.3210; Klotz C, 2012, INT J MED MICROBIOL, V302, P203, DOI 10.1016/j.ijmm.2012.07.010; Kudyba HM, 2018, JOVE-J VIS EXP, DOI 10.3791/57747; Kumano K, 2013, INT J HEMATOL, V98, P145, DOI 10.1007/s12185-013-1385-x; Lara LD, 2018, MICROBES INFECT, V20, P312, DOI 10.1016/j.micinf.2018.03.002; Lewis MD, 2014, CELL MICROBIOL, V16, P1285, DOI 10.1111/cmi.12297; Li M, 2019, NEW ENGL J MED, V380, P569, DOI 10.1056/NEJMra1806175; Luu L, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00300; Martinelli A, 2018, PARASITOLOGY, V145, P41, DOI 10.1017/S0031182016001335; Matsui T, 2020, CURR PHARM BIOTECHNO, V21, P807, DOI 10.2174/1389201021666200422090952; MATTOCK NM, 1975, ANN TROP MED PARASIT, V69, P349, DOI 10.1080/00034983.1975.11687019; McCracken KW, 2011, NAT PROTOC, V6, P1920, DOI 10.1038/nprot.2011.410; Mead JR, 2014, HUM VACC IMMUNOTHER, V10, P1505, DOI 10.4161/hv.28485; Mohring F, 2019, ELIFE, V8, DOI 10.7554/eLife.45829; Moreau T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11208; Ng S, 2015, STEM CELL REP, V4, P348, DOI 10.1016/j.stemcr.2015.01.002; O'Keeffe A, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8060831; Ogwang C, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa2373; Ortega YR, 2010, CLIN MICROBIOL REV, V23, P218, DOI 10.1128/CMR.00026-09; Pance A.L.B., STEM CELLS TOOL STUD; Pance A, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111748; Payne RO, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.96381; PIRAS R, 1983, CIBA F SYMP, V99, P31; RePass MAD, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00731-16; Sass G, 2019, AM J TROP MED HYG, V101, P1359, DOI 10.4269/ajtmh.19-0350; Sass G, 2019, AM J TROP MED HYG, V101, P383, DOI 10.4269/ajtmh.19-0023; Satchwell TJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11790-w; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Schaefer DA, 2016, J INFECT DIS, V214, P1856, DOI 10.1093/infdis/jiw488; Schafer C, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101381; Scully EJ, 2019, AM J HEMATOL, V94, P963, DOI 10.1002/ajh.25543; Seo HH, 2020, EMERG MICROBES INFEC, V9, P1943, DOI 10.1080/22221751.2020.1812435; Sheoran A, 2012, J INFECT DIS, V205, P1019, DOI 10.1093/infdis/jir874; Silberstein E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195879; SKORICH DN, 1988, INVEST OPHTH VIS SCI, V29, P1871; Spence JR, 2011, NATURE, V470, P105, DOI 10.1038/nature09691; Srivastava S, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1553-y; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tanaka N, 2016, MICROBES INFECT, V18, DOI 10.1016/j.micinf.2016.03.012; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; Trakarnsanga K, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14750; Tripathi J, 2020, STEM CELL REP, V14, P1123, DOI 10.1016/j.stemcr.2020.04.010; Tyagi RK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02550; Varughese EA, 2014, J MICROBIOL METH, V106, P47, DOI 10.1016/j.mimet.2014.07.017; Vazin T, 2010, RESTOR NEUROL NEUROS, V28, P589, DOI 10.3233/RNN-2010-0543; Warren CA, 2008, J INFECT DIS, V198, P143, DOI 10.1086/588819; Wesley M, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01856; WHO, 2013, WORLD MALARIA REPORT 2013, P1; Wilke G, 2020, METHODS MOL BIOL, P351, DOI 10.1007/978-1-4939-9748-0_20; Wilke G, 2019, CELL HOST MICROBE, V26, P123, DOI 10.1016/j.chom.2019.05.007; Yiangou L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158238; Yui SR, 2012, NAT MED, V18, P618, DOI 10.1038/nm.2695; Zhang XT, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.13060	91	1	1	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							105	10.3390/vaccines9020105			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6TL	33572549	Green Published			2022-04-29	WOS:000623273900001
J	Zanella, B; Bechini, A; Bonito, B; Del Riccio, M; Ninci, A; Tiscione, E; Bonanni, P; Boccalini, S				Zanella, Beatrice; Bechini, Angela; Bonito, Benedetta; Del Riccio, Marco; Ninci, Alessandra; Tiscione, Emilia; Bonanni, Paolo; Boccalini, Sara		Working Grp DHS; Working Grp AOUMeyer; Working Grp AUSLTC	A Study of Varicella Seroprevalence in a Pediatric and Adolescent Population in Florence (Italy). Natural Infection and Vaccination-Acquired Immunization	VACCINES			English	Article						varicella; vaccination coverage; immunization; notification; Italy; pediatric; adolescent; seroprevalence; Tuscany; underreporting		Background: Varicella is a well-known infectious disease that can have severe complications, also in young children. The Universal Varicella Vaccination (UVV) program was introduced in Tuscany (Italy) in 2003, with a two-dose vaccine schedule given to children between their 13th and 15th month, and at 5-6 years old, as a monovalent for varicella (V) or tetravalent (measles, mumps, rubella and varicella (MMRV)) formulation. Although varicella notifications have dramatically fallen in the last two decades, varicella disease underreporting remains a challenge. Methods: A qualitative immunoenzymatic test (ELISA) was used to measure the presence of anti-varicella antibodies in 165 sera of subjects aged 1-18 years residing in the province of Florence (Italy). Information regarding the anamnestic and vaccination status (including disease notification) was also collected. Results: Our study showed an overall varicella seropositivity of 75.8% (reaching the maximum at 96.3% in the 15-18 years age group). We found that varicella disease notification had been recorded for only 7/165 subjects; however, since 42/165 recalled having had the disease, we can hypothesize that some of them must have been underreported. Furthermore, our study showed that the presence of antibodies after the varicella vaccination remained over time, lasting up to 12 years. Conclusions: Although varicella seroprevalence is <95% in almost all our age groups (except for the 15-18 years age group), our data are encouraging and reflect the success of the introduction of the UVV program and the vaccination campaigns promoted in the Tuscany region.	[Zanella, Beatrice; Bechini, Angela; Bonito, Benedetta; Tiscione, Emilia; Bonanni, Paolo; Boccalini, Sara] Univ Florence, Dept Hlth Sci, I-50134 Florence, Italy; [Del Riccio, Marco; Ninci, Alessandra; Working Grp DHS] Univ Florence, Med Specializat Sch Hyg & Prevent Med, I-50134 Florence, Italy; [Working Grp AOUMeyer] Meyer Childrens Hosp, I-50139 Florence, Italy; [Working Grp AUSLTC] AUSL Toscana Ctr, I-50122 Florence, Italy		Bechini, A (通讯作者)，Univ Florence, Dept Hlth Sci, I-50134 Florence, Italy.	beatrice.zanella@unifi.it; angela.bechini@unifi.it; benedetta.bonito@unifi.it; marco.delriccio@unifi.it; alessandra.ninci@unifi.it; emilia.tiscione@unifi.it; paolo.bonanni@unifi.it; sara.boccalini@unifi.it	DEL RICCIO, MARCO/ABB-3559-2020	DEL RICCIO, MARCO/0000-0002-2742-0297; Zanella, Beatrice/0000-0001-6718-1932; Ninci, Alessandra/0000-0002-1196-7060; Bonanni, Paolo/0000-0003-2875-3744; Boccalini, Sara/0000-0002-9695-7549; Bechini, Angela/0000-0002-6013-8779; Bonito, Benedetta/0000-0002-6116-8777			Garcia FJA, 2020, AN PEDIATR, V92, DOI 10.1016/j.anpedi.2019.10.007; ARS Toscana, 2019, SORV EP MAL INF TOSC; Bechini A, 2015, HUM VACC IMMUNOTHER, V11, P63, DOI 10.4161/hv.34311; Best J.M., 2008, IMMUNIZATION VACCINE, P1; Bonanni P, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-26; CDC, PREV VAR REC ADV COM; Degli Atti MLC, 2002, EPIDEMIOL INFECT, V128, P479, DOI 10.1017/S0950268802006878; European Centre for Disease Prevention and Control, VACC SCHED; European Centre for Disease Prevention and Control, 2015, ECDC GUID VAR VACC E; Fiore Anthony E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Fornaro P, 1999, PEDIATR INFECT DIS J, V18, P414, DOI 10.1097/00006454-199905000-00004; Galil K, 2002, J INFECT DIS, V186, P102, DOI 10.1086/341089; GeoDemo Istat, POP RES 1 GENN 2017; Gershon AA, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.16; Holmes CN, 2005, CAN FAM PHYSICIAN, V51, P60; Istat, NAT FEC POP RES ANN, V444; Izurieta HS, 1997, JAMA-J AM MED ASSOC, V278, P1495, DOI 10.1001/jama.278.18.1495; Kauffmann F, 2020, EXPERT REV VACCINES, V19, P843, DOI 10.1080/14760584.2020.1825947; Kuter B, 2004, PEDIATR INFECT DIS J, V23, P132, DOI 10.1097/01.inf.0000109287.97518.67; Lopez AS, 2006, PEDIATRICS, V117, pE1070, DOI 10.1542/peds.2005-2085; Marin M., 2007, MMWR-MORBID MORTAL W; Michalik DE, 2008, J INFECT DIS, V197, P944, DOI 10.1086/529043; Ministero della Salute, PIAN NAZ PREV VACC 2; Ministero della Salute Direzione Generale della Prevenzione Sanitaria, UFF 5 PREV MAL TRASM; Sauerbrei A, 2000, J Perinatol, V20, P548, DOI 10.1038/sj.jp.7200457; Spoulou V, 2019, PEDIATR INFECT DIS J, V38, P181, DOI 10.1097/INF.0000000000002233; TAKAHASH.M, 1974, LANCET, V2, P1288, DOI 10.1016/S0140-6736(74)90144-5; WATSON B, 1995, J INFECT DIS, V172, P217, DOI 10.1093/infdis/172.1.217; WHO, VAR VACC PREV DIS 20; Zanella B, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040599; Zanella B, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030512; Zanella B, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020156	32	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							152	10.3390/vaccines9020152			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6PI	33672915	gold, Green Published			2022-04-29	WOS:000623263200001
J	Feleszko, W; Lewulis, P; Czarnecki, A; Waszkiewicz, P				Feleszko, Wojciech; Lewulis, Piotr; Czarnecki, Adam; Waszkiewicz, Pawel			Flattening the Curve of COVID-19 Vaccine Rejection-An International Overview	VACCINES			English	Article						COVID-19; vaccines; vaccine hesitancy; herd immunity		Background: If globally implemented, a safe coronavirus disease 2019 (COVID-19) vaccination program will have broad clinical and socioeconomic benefits. However, individuals who anticipate that the coronavirus vaccine will bring life back to normality may be disappointed, due to the emerging antivaccination attitude within the general population. Methods: We surveyed a sample of adult Polish citizens (n = 1066), and compared it with the data on international COVID-19 vaccine reluctance. Results: In 20 national surveys, the vaccine averseness for the anticipated COVID-19 vaccine varied from meager (2-6% China) to very high (43%, Czech Republic, and 44%, Turkey) and in most countries was much higher than regular vaccination reluctance, which varies between 3% (Egypt) and 55% (Russia). Conclusions: These results suggest that a 67% herd immunity may be possible only if mandatory preventive vaccination programs start early and are combined with coordinated education efforts supported by legislative power and social campaigns.	[Feleszko, Wojciech] Med Univ Warsaw, Dept Pediat Pulmonol & Allergy, PL-02091 Warsaw, Poland; [Lewulis, Piotr; Waszkiewicz, Pawel] Univ Warsaw, Dept Criminalist, PL-00927 Warsaw, Poland; [Czarnecki, Adam] Market Res Inst, ARC Rynek & Opinia, PL-01627 Warsaw, Poland		Feleszko, W (通讯作者)，Med Univ Warsaw, Dept Pediat Pulmonol & Allergy, PL-02091 Warsaw, Poland.	wojciech.feleszko@wum.edu.pl; p.lewulis@wpia.uw.edu.pl; adam.czarnecki@arc.com.pl; p.waszkiewicz@uw.edu.pl	Czarnecki, Adam/ABE-7782-2021; Waszkiewicz, Paweł/AAV-3115-2021	Waszkiewicz, Paweł/0000-0001-9608-1586; Lewulis, Piotr/0000-0002-8303-0971; Feleszko, Wojciech/0000-0001-6613-2012	Warsaw University; Medical University of Warsaw Federation [1W34/NUW1/20:MAT]	This research was funded by the joint grant from the Warsaw University and the Medical University of Warsaw Federation No: 1W34/NUW1/20:MAT.	Abdelhafiz AS, 2020, J COMMUN HEALTH, V45, P881, DOI 10.1007/s10900-020-00827-7; Adams J., NEW POLL SHOWS 16 NE; All-Russian Public Opinion Research Center (VTsIOM), VACC COVID 2019 PROS; Almohaithef MA., 2020, DETERMINANTS COVID 1, DOI [10.1101/2020.05.27.20114413, DOI 10.1101/2020.05.27.20114413]; [Anonymous], 2020, NATURE, V587, P522, DOI 10.1038/d41586-020-03334-w; [Anonymous], 2020, ERGEBNISSE WIEDERHOL; Ball P, 2020, NATURE, V581, P251, DOI 10.1038/d41586-020-01423-4; Bjorkqvist A., UUTISSUOMALAINEN MAJ; Chan MPS, 2020, VACCINE, V38, P6236, DOI 10.1016/j.vaccine.2020.07.054; Cipolla A., QUEL 21 ITALIANI CHE; Cody J., 43 CZECHS DONT WANT; Cohen J., 2020, SCIENCE, V10, DOI [10.1126/science.abe2848, DOI 10.1126/SCIENCE.ABE2848]; Csaba M., MAGYAROK FELE FEL AT; Economic Research Istanbul, KOR VIR AS BUL YAPTR; Fu Chuanxi, 2020, ACCEPTANCE PREFRENCE, DOI [10.1101/2020.04.09.20060103, DOI 10.1101/2020.04.09.20060103, 0.1101/2020.04.09.2006010314]; Institutul Roman Pentru Evaluare si Strategie-IRES, 10 CONCL DUP STAR UR; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; McBride O., 2020, MONITORING PSYCHOL I; Monitor Wellcome Global, 2018, DOES WORLD FEEL SCI; Mrva M., 2020, SLOVAKIA PANDEMIC 1; Neergaard L, 2020, AP NORC POLL HALF AM; Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477; Paterson P, 2018, VACCINE, V36, P5397, DOI 10.1016/j.vaccine.2017.08.016; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Poll Conducted by Research Co, COVID 19 OUTBR CAN; Randall T.C.C., MORE 44000000 SHOTS; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Rodriguez-Coira J, 2021, ALLERGY, V76, P1922, DOI 10.1111/all.14714; Royal Society for Public Health and Practice, ON 5 PUBL UNS GETT C; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Simonsen C., SJU TI VIL TA FREMTI; van Prooijen JW, 2017, MEM STUD, V10, P323, DOI 10.1177/1750698017701615	33	38	38	12	22	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							44	10.3390/vaccines9010044			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7BB	33451104	Green Published, gold	Y	N	2022-04-29	WOS:000610824500001
J	Mustafa, A				Mustafa, Abu Salim			Immunological Characterization of Proteins Expressed by Genes Located in Mycobacterium tuberculosis-Specific Genomic Regions Encoding the ESAT6-like Proteins	VACCINES			English	Review						M; tuberculosis; RD genomic segments; ESAT6-like proteins; diagnosis; vaccine		The 6 kDa early secreted antigen target (ESAT6) is a low molecular weight and highly immunogenic protein of Mycobacterium tuberculosis with relevance in the diagnosis of tuberculosis and subunit vaccine development. The gene encoding the ESAT6 protein is located in the M. tuberculosis-specific genomic region known as the region of difference (RD)1. There are 11 M. tuberculosis-specific RDs absent in all of the vaccine strains of BCG, and three of them (RD1, RD7, and RD9) encode immunodominant proteins. Each of these RDs has genes for a pair of ESAT6-like proteins. The immunological characterizations of all the possible proteins encoded by genes in RD1, RD7 and RD9 have shown that, besides ESAT-6 like proteins, several other proteins are major antigens useful for the development of subunit vaccines to substitute or supplement BCG. Furthermore, some of these proteins may replace the purified protein derivative of M. tuberculosis in the specific diagnosis of tuberculosis by using interferon-gamma release assays and/or tuberculin-type skin tests. At least three subunit vaccine candidates containing ESAT6-like proteins as antigen components of multimeric proteins have shown efficacy in phase 1 and phase II clinical trials in humans.	[Mustafa, Abu Salim] Kuwait Univ, Dept Microbiol, Fac Med, Safat 13110, Kuwait		Mustafa, A (通讯作者)，Kuwait Univ, Dept Microbiol, Fac Med, Safat 13110, Kuwait.	abu.mustafa@ku.edu.kw		Mustafa, AbuSalim/0000-0002-6074-1041	Kuwait University Research Sector [MI04/05, SRUL02/13]	This research was supported by Kuwait University Research Sector grants MI04/05 and SRUL02/13.	Aagaard CS, 2009, J IMMUNOL, V183, P2659, DOI 10.4049/jimmunol.0900947; Agger EM, 2003, IMMUNOLOGY, V110, P507, DOI 10.1111/j.1365-2567.2003.01763.x; Aguilo N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16085; Ahmad S, 2003, PROTEIN EXPRES PURIF, V29, P167, DOI 10.1016/S1046-5928(03)00052-4; Ahmad S, 1999, SCAND J IMMUNOL, V49, P515; Al-Attiyah R, 2008, INFECT IMMUN, V76, P4190, DOI 10.1128/IAI.00199-08; Al-Attiyah R, 2004, CLIN EXP IMMUNOL, V138, P139, DOI 10.1111/j.1365-2249.2004.02609.x; Al-Attiyah R, 2012, SCAND J IMMUNOL, V75, P623, DOI 10.1111/j.1365-3083.2012.02692.x; Al-Attiyah R, 2003, FEMS IMMUNOL MED MIC, V38, P249, DOI 10.1016/S0928-8244(03)00166-4; Al-Attiyah RJ, 2009, CLIN EXP IMMUNOL, V158, P64, DOI 10.1111/j.1365-2249.2009.04000.x; Al-Attiyah R, 2010, FEMS IMMUNOL MED MIC, V59, P177, DOI 10.1111/j.1574-695X.2010.00677.x; Al-Khodari NY, 2011, CLIN VACCINE IMMUNOL, V18, P477, DOI 10.1128/CVI.00405-10; Al-Orainey IO, 2009, ANN THORAC MED, V4, P5, DOI 10.4103/1817-1737.44778; Alvarez AH, 2019, EXPERT REV VACCINES, V18, P1219, DOI 10.1080/14760584.2019.1704263; Amoudy HA, 2007, SCAND J IMMUNOL, V66, P422, DOI 10.1111/j.1365-3083.2007.01961.x; Amoudy HA, 2006, MED PRIN PRACT, V15, P137, DOI 10.1159/000090919; Amoudy HA, 2008, MED PRIN PRACT, V17, P378, DOI 10.1159/000141501; Amoudy Hanady A, 2016, Int J Mycobacteriol, V5 Suppl 1, pS84, DOI 10.1016/j.ijmyco.2016.10.033; Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211; ANDERSEN P, 1995, J IMMUNOL, V154, P3359; Ansari MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022889; Arend SM, 2008, TUBERCULOSIS, V88, P249, DOI 10.1016/j.tube.2007.11.004; Arend SM, 2001, CLIN DIAGN LAB IMMUN, V8, P1089, DOI 10.1128/CDLI.8.6.1089-1096.2001; Arend SM, 2000, INFECT IMMUN, V68, P3314, DOI 10.1128/IAI.68.6.3314-3321.2000; Arregui S, 2016, PEERJ, V4, DOI 10.7717/peerj.1513; Bai CX, 2018, TUBERCULOSIS, V110, P104, DOI 10.1016/j.tube.2018.04.006; Baldwin SL, 2016, CLIN VACCINE IMMUNOL, V23, P137, DOI 10.1128/CVI.00458-15; Baldwin SL, 2014, CLIN VACCINE IMMUNOL, V21, P1309, DOI 10.1128/CVI.00372-14; Barreto Mauricio L., 2006, J. Pediatr. (Rio J.), V82, ps45, DOI 10.1590/S0021-75572006000400006; Barreto ML, 2014, VACCINE, V32, P3759, DOI 10.1016/j.vaccine.2014.05.042; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Bekker LG, 2020, ECLINICALMEDICINE, V21, DOI 10.1016/j.eclinm.2020.100313; Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195; Billeskov R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161217; Bin Cha S, 2016, VACCINE, V34, P2179, DOI 10.1016/j.vaccine.2016.03.029; Black GF, 2003, CLIN DIAGN LAB IMMUN, V10, P602, DOI 10.1128/CDLI.10.4.602-611.2003; Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8; Bottai D, 2015, VACCINE, V33, P2710, DOI 10.1016/j.vaccine.2015.03.083; Brandt L, 2002, INFECT IMMUN, V70, P672, DOI 10.1128/IAI.70.2.672-678.2002; Brandt L, 1996, J IMMUNOL, V157, P3527; Brandt L, 2000, INFECT IMMUN, V68, P791, DOI 10.1128/IAI.68.2.791-795.2000; Brazier B, 2020, SEMIN IMMUNOPATHOL, V42, P315, DOI 10.1007/s00281-020-00794-0; Brock I, 2004, J CLIN MICROBIOL, V42, P2379, DOI 10.1128/JCM.42.6.2379-2387.2004; Brock I, 2001, INT J TUBERC LUNG D, V5, P462; Brodin P, 2006, INFECT IMMUN, V74, P88, DOI 10.1128/IAI.74.1.88-98.2006; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Buddle BM, 1999, CLIN DIAGN LAB IMMUN, V6, P1; Buddle BM, 2002, VACCINE, V20, P1126, DOI 10.1016/S0264-410X(01)00436-4; Carranza C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02006; Chen YY, 2017, J MICROBIOL IMMUNOL, V50, P90, DOI 10.1016/j.jmii.2014.11.019; Chiappini E, 2012, INT J IMMUNOPATH PH, V25, P335, DOI 10.1177/039463201202500203; Choi HG, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020300; Clemmensen HS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585359; Cockle PJ, 2002, INFECT IMMUN, V70, P6996, DOI 10.1128/IAI.70.12.6996-7003.2002; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Coler RN, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0057-5; Coppola M, 2018, SEMIN IMMUNOL, V39, P88, DOI 10.1016/j.smim.2018.07.001; Dai FY, 2017, HUM VACC IMMUNOTHER, V13, P1425, DOI 10.1080/21645515.2017.1279771; Daugelat S, 2003, MICROBES INFECT, V5, P1082, DOI 10.1016/S1286-4579(03)00205-3; Davenne T, 2016, EXPERT REV VACCINES, V15, P1009, DOI 10.1586/14760584.2016.1170599; de Lisle GW, 2005, TUBERCULOSIS, V85, P73, DOI 10.1016/j.tube.2004.09.007; Demangel C, 2005, INFECT IMMUN, V73, P2190, DOI 10.1128/IAI.73.4.2190-2196.2005; Demangel C, 2004, INFECT IMMUN, V72, P2170, DOI 10.1128/IAI.72.4.2170-2176.2004; Dewi DNSS, 2019, BRAZ J INFECT DIS, V23, P246, DOI 10.1016/j.bjid.2019.07.001; Dey B, 2009, VACCINE, V28, P63, DOI 10.1016/j.vaccine.2009.09.121; Dockrell HM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01134; Dosanjh DPS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028754; Duthie MS, 2014, INFECT IMMUN, V82, P3979, DOI 10.1128/IAI.02145-14; Ellis A, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.01009-16; FARER LS, 1979, AM J EPIDEMIOL, V109, P205, DOI 10.1093/oxfordjournals.aje.a112675; Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192; Fatima S, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117594; Fox A, 2007, T ROY SOC TROP MED H, V101, P691, DOI 10.1016/j.trstmh.2007.03.001; Ganguly N, 2008, TUBERCULOSIS, V88, P510, DOI 10.1016/j.tube.2008.05.002; Garcia EA, 2020, INT J MYCOBACT, V9, P417, DOI 10.4103/ijmy.ijmy_180_20; Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x; Groschel MI, 2017, CELL REP, V18, P2752, DOI 10.1016/j.celrep.2017.02.057; Guinn KM, 2004, MOL MICROBIOL, V51, P359, DOI 10.1046/j.1365-2958.2003.03844.x; Guler SA, 2015, MED PRIN PRACT, V24, P75, DOI 10.1159/000365511; Hanif SNM, 2011, SCAND J IMMUNOL, V74, P554, DOI 10.1111/j.1365-3083.2011.02604.x; Hanif SNM, 2010, SCAND J IMMUNOL, V72, P408, DOI 10.1111/j.1365-3083.2010.02452.x; Hanif SNM, 2010, SCAND J IMMUNOL, V71, P353, DOI 10.1111/j.1365-3083.2010.02388.x; Hanif SNM, 2010, INT J TUBERC LUNG D, V14, P489; Hanif S.N.M., 2011, MYCOBACT DIS, V1, P105; Hanif SNM, 2008, MED PRIN PRACT, V17, P244, DOI 10.1159/000117800; Harboe M, 1998, INFECT IMMUN, V66, P717, DOI 10.1128/IAI.66.2.717-723.1998; Hawn TR, 2014, MICROBIOL MOL BIOL R, V78, P650, DOI 10.1128/MMBR.00021-14; He H, 2015, EUR J CLIN MICROBIOL, V34, P1103, DOI 10.1007/s10096-015-2335-8; Hill PC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000183; Hinks TSC, 2009, INFECT IMMUN, V77, P5486, DOI 10.1128/IAI.01436-08; Huard RC, 2003, J CLIN MICROBIOL, V41, P1637, DOI 10.1128/JCM.41.4.1637-1650.2003; Hussein J, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2354-0; Johnson PDR, 1999, CLIN DIAGN LAB IMMUN, V6, P934, DOI 10.1128/CDLI.6.6.934-937.1999; Jones GJ, 2010, CLIN VACCINE IMMUNOL, V17, P1344, DOI 10.1128/CVI.00261-10; Jones GJ, 2010, INFECT IMMUN, V78, P1326, DOI 10.1128/IAI.01246-09; Kalra M, 2007, CLIN IMMUNOL, V125, P173, DOI 10.1016/j.clim.2007.07.007; Kamala T, 1996, INDIAN J MED RES, V103, P201; Kamath AT, 1999, INFECT IMMUN, V67, P1702; Kasempimolporn S, 2019, J MED MICROBIOL, V68, P1314, DOI 10.1099/jmm.0.001037; Khan A, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040047; Kim A, 2020, YONSEI MED J, V61, P789, DOI 10.3349/ymj.2020.61.9.789; Kunst H, 2006, RESP MED, V100, P2098, DOI 10.1016/j.rmed.2006.02.032; Kwon KW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52146-0; Lalvani A, 1998, CLIN SCI, V95, P531, DOI 10.1042/CS19980201; Larsen SE, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020030; Latorre I, 2010, EUR RESPIR J, V35, P338, DOI 10.1183/09031936.00196608; Legesse M, 2013, SCAND J IMMUNOL, V78, P266, DOI 10.1111/sji.12080; Lenz N, 2015, CLIN VACCINE IMMUNOL, V22, P688, DOI 10.1128/CVI.00092-15; Lewinsohn DM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067016; Lewis KN, 2003, J INFECT DIS, V187, P117, DOI 10.1086/345862; Lin PL, 2012, J CLIN INVEST, V122, P303, DOI 10.1172/JCI46252; Litwin CM, 2007, J IMMUNOTOXICOL, V4, P219, DOI 10.1080/15476910701385646; Liu XQ, 2004, INFECT IMMUN, V72, P2574, DOI 10.1128/IAI.72.5.2574-2581.2004; Liu ZQ, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/7486425; Lozes E, 1997, SCAND J IMMUNOL, V46, P16, DOI 10.1046/j.1365-3083.1997.d01-99.x; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Mahasha Phetole Walter, 2019, BMJ Open, V9, pe027033, DOI 10.1136/bmjopen-2018-027033; Mahmood A, 2011, FEBS J, V278, P341, DOI 10.1111/j.1742-4658.2010.07958.x; Mahmoudi S, 2017, EUR CYTOKINE NETW, V28, P36, DOI 10.1684/ecn.2017.0391; Mamishi S, 2019, PROTEIN PEPTIDE LETT, V26, P281, DOI 10.2174/0929866526666190119165805; Martin C, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10072632; McLaughlin B, 2007, PLOS PATHOG, V3, P1051, DOI 10.1371/journal.ppat.0030105; McShane H, 2011, PHILOS T R SOC B, V366, P2782, DOI 10.1098/rstb.2011.0097; Mearns H, 2017, VACCINE, V35, P132, DOI 10.1016/j.vaccine.2016.11.023; Meier NR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02476; Moreno S, 2001, ARCH INTERN MED, V161, P1760, DOI 10.1001/archinte.161.14.1760; Morris S, 2000, VACCINE, V18, P2155, DOI 10.1016/S0264-410X(99)00540-X; Mostowy S, 2004, J BACTERIOL, V186, P104, DOI 10.1128/JB.186.1.104-109.2003; Mostowy S, 2002, J INFECT DIS, V186, P74, DOI 10.1086/341068; Mukherjee P, 2007, CLIN MICROBIOL INFEC, V13, P146, DOI 10.1111/j.1469-0691.2006.01660.x; Mustafa A, 2013, J MYCOBAC DIS, V3, P2, DOI [10.4172/2161-1068.1000129, DOI 10.4172/2161-1068.1000129]; Mustafa AS, 2006, INFECT IMMUN, V74, P4566, DOI 10.1128/IAI.01660-05; Mustafa AS, 2005, MED PRIN PRACT, V14, P27, DOI 10.1159/000086182; Mustafa A. S., 2001, Current Pharmaceutical Biotechnology, V2, P157, DOI 10.2174/1389201013378707; Mustafa AS, 2009, SCAND J IMMUNOL, V69, P213, DOI 10.1111/j.1365-3083.2008.02221.x; Mustafa A.S., 2004, KUWAIT MED J, V36, P171; Mustafa A.S., 2003, J POSTGRAD MED, V49, P129; Mustafa AS, 2008, CLIN VACCINE IMMUNOL, V15, P916, DOI 10.1128/CVI.00056-08; Mustafa AS, 2008, MED PRIN PRACT, V17, P325, DOI 10.1159/000129614; Mustafa AS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103679; Mustafa AS, 2011, CLIN VACCINE IMMUNOL, V18, P1752, DOI 10.1128/CVI.05260-11; Mustafa A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040736; Mustafa A, 2013, MED PRIN PRACT, V22, P43, DOI 10.1159/000354206; Mustafa AS, 2012, MED PRIN PRACT, V21, P195, DOI 10.1159/000337919; Mustafa AS, 2011, MICROBIOL IMMUNOL, V55, P267, DOI 10.1111/j.1348-0421.2011.00307.x; Mustafa AS, 2010, MED PRIN PRACT, V19, P367, DOI 10.1159/000316375; Mustafa A, 2010, KUWAIT MED J, V42, P98; Mustafa AS, 2010, MED PRIN PRACT, V19, P122, DOI 10.1159/000273073; Mustafa AS, 2009, EXPERT REV VACCINES, V8, P1309, DOI [10.1586/erv.09.93, 10.1586/ERV.09.93]; Mustafa AS, 2009, MED PRIN PRACT, V18, P385, DOI 10.1159/000226293; Mustafa AS, 2009, INDIAN J EXP BIOL, V47, P498; Mustafa AD, 2018, BMC BIOTECHNOL, V18, DOI 10.1186/s12896-018-0461-y; Mustafa AS, 2000, INFECT IMMUN, V68, P3933, DOI 10.1128/IAI.68.7.3933-3940.2000; Mustafa AS, 2006, TUBERCULOSIS, V86, P115, DOI 10.1016/j.tube.2005.05.001; Mustafa AS, 2005, FOCUS ON TUBERCULOSIS RESEARCH, P47; Mustafa AS, 2005, TUBERCULOSIS, V85, P367, DOI 10.1016/j.tube.2005.08.006; Mustafa AS, 2005, MED PRIN PRACT, V14, P140, DOI 10.1159/000084629; Mustafa AS, 2003, SCAND J IMMUNOL, V57, P125, DOI 10.1046/j.1365-3083.2003.01204.x; Mustafa AS, 2002, CLIN EXP IMMUNOL, V130, P37, DOI 10.1046/j.1365-2249.2002.01937.x; Mustafa AS, 1998, SCAND J IMMUNOL, V48, P535; Mustafa AS, 2000, CLIN INFECT DIS, V30, pS201, DOI 10.1086/313862; Nadolinskaia NI, 2020, APPL BIOCHEM MICRO+, V56, P497, DOI 10.1134/S0003683820050129; Okkels LM, 2003, INFECT IMMUN, V71, P6116, DOI 10.1128/IAI.71.11.6116-6123.2003; One E, 2020, INFECT GENET EVOL, V80, DOI 10.1016/j.meegid.2020.104186; Pai M, 2005, Indian J Med Microbiol, V23, P151; Pais TF, 1998, IMMUNOLOGY, V95, P69; PALMER CE, 1966, AM REV RESPIR DIS, V94, P553; Park IN, 2017, KOREAN J INTERN MED, V32, P302, DOI 10.3904/kjim.2016.199; Parsons LM, 2002, J CLIN MICROBIOL, V40, P2339, DOI 10.1128/JCM.40.7.2339-2345.2002; Penn-Nicholson A, 2018, LANCET RESP MED, V6, P287, DOI 10.1016/s2213-2600(18)30077-8; Pollock JM, 1997, J INFECT DIS, V175, P1251, DOI 10.1086/593686; Pollock NR, 2008, INFECT CONT HOSP EP, V29, P878, DOI 10.1086/590262; Pym AS, 2003, NAT MED, V9, P533, DOI 10.1038/nm859; Pym AS, 2002, MOL MICROBIOL, V46, P709, DOI 10.1046/j.1365-2958.2002.03237.x; Rao PVR, 2009, INT J INFECT DIS, V13, P613, DOI 10.1016/j.ijid.2008.09.022; Ravn P, 1999, J INFECT DIS, V179, P637, DOI 10.1086/314640; Reither K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114602; Ren NN, 2018, MICROB BIOTECHNOL, V11, P893, DOI 10.1111/1751-7915.13291; Roche PW, 1996, SCAND J IMMUNOL, V43, P662, DOI 10.1046/j.1365-3083.1996.d01-260.x; Rodo MJ, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007643; Ruhwald M, 2017, LANCET RESP MED, V5, P259, DOI [10.1016/s2213-2600(16)30436-2, 10.1016/S2213-2600(16)30436-2]; Sable SB, 2005, INFECT IMMUN, V73, P3547, DOI 10.1128/IAI.73.6.3547-3558.2005; Safar HA, 2020, ANN CLIN MICROB ANTI, V19, DOI 10.1186/s12941-020-00402-x; Safar HA, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.532199; Safar HA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228381; Shaban K, 2013, CLIN VACCINE IMMUNOL, V20, P1230, DOI 10.1128/CVI.00090-12; Sidibe A, 2015, LANCET INFECT DIS, V15, P1003, DOI 10.1016/S1473-3099(15)00233-9; Singh S., 2015, TUBERC RES TREAT, V2015; Slogotskaya L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208705; SORENSEN AL, 1995, INFECT IMMUN, V63, P1710; Suliman S, 2019, AM J RESP CRIT CARE, V199, P220, DOI 10.1164/rccm.201802-0366OC; Sun JJ, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00331; Tafreshi S.H., 2016, VACCINE RES, V3, P36, DOI [10.29252/vacres.3.8.9.36, DOI 10.29252/VACRES.3.8.9.36]; Talbot EA, 1997, J CLIN MICROBIOL, V35, P566, DOI 10.1128/JCM.35.3.566-569.1997; Tameris M, 2019, LANCET RESP MED, V7, P757, DOI 10.1016/S2213-2600(19)30251-6; Tebianian Majid, 2016, Int J Mycobacteriol, V5 Suppl 1, pS254, DOI 10.1016/j.ijmyco.2016.11.011; Teo Jeanette W P, 2013, BMC Res Notes, V6, P434, DOI 10.1186/1756-0500-6-434; Teutschbein J, 2009, MICROBIOL RES, V164, P253, DOI 10.1016/j.micres.2006.11.016; Tkachuk AP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176784; Tkachuk AP, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040652; Ulrichs T, 2000, INFECT IMMUN, V68, P6073, DOI 10.1128/IAI.68.10.6073-6076.2000; van Dissel JT, 2010, VACCINE, V28, P3571, DOI 10.1016/j.vaccine.2010.02.094; van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000; Vasina DV, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040166; Vordermeier HM, 2001, CLIN DIAGN LAB IMMUN, V8, P571, DOI 10.1128/CDLI.8.3.571-578.2001; Wang C, 2011, MED MICROBIOL IMMUN, V200, P165, DOI 10.1007/s00430-011-0188-z; Wani R. L. S., 2013, South Sudan Medical Journal, V6, P52; Weldingh K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001978; Whitlow E, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040586; Wilson ME, 2000, CLIN INFECT DIS, V30, pS262, DOI 10.1086/313886; Wu XQ, 2010, CLIN CHIM ACTA, V411, P1520, DOI 10.1016/j.cca.2010.06.014; Xu JN, 2012, CLIN VACCINE IMMUNOL, V19, P536, DOI 10.1128/CVI.05708-11; Xu J, 2007, MOL MICROBIOL, V66, P787, DOI 10.1111/j.1365-2958.2007.05959.x; Yan ZH, 2018, INT J TUBERC LUNG D, V22, P959, DOI 10.5588/ijtld.18.0060; Yang EZ, 2014, MICROB PATHOGENESIS, V69-70, P53, DOI 10.1016/j.micpath.2014.03.011; Young C, 2020, MUCOSAL IMMUNOL, V13, P190, DOI 10.1038/s41385-019-0226-5; Zellweger JP, 2020, MED LAV, V111, P170, DOI 10.23749/mdl.v111i3.9983; Zhang H, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05413-9; Zhang X, 2013, INT J MOL MED, V31, P751, DOI 10.3892/ijmm.2013.1254; Zhu M, 2019, CLIN LAB, V65, P1385, DOI 10.7754/Clin.Lab.2019.181109	220	2	2	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							27	10.3390/vaccines9010027			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6TL	33430286	Green Published, gold			2022-04-29	WOS:000610804400001
J	Toor, SM; Nair, VS; Murshed, K; Abu Nada, M; Elkord, E				Toor, Salman M.; Sasidharan Nair, Varun; Murshed, Khaled; Abu Nada, Mohamed; Elkord, Eyad			Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors	VACCINES			English	Article						colorectal cancer; T cells; B cells; NK cells; immune checkpoints; dMMR; MSI-H; MSS		Immune checkpoint inhibition is an effective anti-cancer therapeutic approach but has shown limited efficacy in treating colorectal cancer (CRC) patients. Importantly, immune constituents of the tumor microenvironment (TME) can influence therapy response and cancer progression. We investigated the expression of immune checkpoints (ICs) on lymphoid populations within the CRC TME and compared with cells from normal colon tissues using samples from 50 patients with varying disease stages. We found that the levels of B cells, T cells, and NK cells were similar, IC-expressing CD4(+) and CD4(+)CD8(+) double positive T cells were higher, while CD8(+) T cells and CD4(-)CD8(-) double negative T cells were significantly lower in CRC tumors. Notably, patients with mismatch-repair deficiency/microsatellite instability-high tumors had higher levels of IC-expressing CD4(+) and CD8(+) T cells than patients with proficient MMR and microsatellite stable tumors. Lastly, The Cancer Genome Atlas Colon Adenocarcinoma datasets showed associations between low expression of selective genes and poorer progression-free interval. Our findings highlight differential expression of ICs on lymphoid cells in CRC tumors in the era of cancer immunotherapy, which at present is solely approved for anti-PD-1 therapy in patients with dMMR/MSI-H tumors. Further investigations into their functionality have potentials for deciphering resistance mechanisms to IC inhibition.	[Toor, Salman M.; Sasidharan Nair, Varun] Hamad Bin Khalifa Univ HBKU, Qatar Fdn QF, Qatar Biomed Res Inst QBRI, Canc Res Ctr, Doha 34110, Qatar; [Murshed, Khaled] Hamad Med Corp, Dept Pathol, Doha 34110, Qatar; [Abu Nada, Mohamed] Hamad Med Corp, Dept Surg, Doha 34110, Qatar; [Elkord, Eyad] Univ Salford, Sch Sci Engn & Environm, Biomed Res Ctr, Manchester M5 4WT, Lancs, England		Elkord, E (通讯作者)，Univ Salford, Sch Sci Engn & Environm, Biomed Res Ctr, Manchester M5 4WT, Lancs, England.	mstoor@hbku.edu.qa; vsnair@hbku.edu.qa; kmurshed@hamad.qa; mabunada@hamad.qa; e.elkord@salford.ac.uk	Nair, Varun Sasidharan/AAQ-5533-2021; Toor, Salman M/AAY-4682-2021; Murshed, Khaled/AAE-9720-2019	Nair, Varun Sasidharan/0000-0001-5047-2338; Murshed, Khaled/0000-0001-8045-363X; Elkord, Eyad/0000-0002-3868-0318; M Toor, Salman/0000-0002-4683-3329	Qatar Foundation [VR04]	This research was funded by Qatar Foundation, grant number VR04.	Andre T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Atreya I, 2008, EXPERT REV ANTICANC, V8, P561, DOI 10.1586/14737140.8.4.561; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen G, 2020, ONCOL LETT, V20, P517, DOI 10.3892/ol.2020.11605; Coppola A, 2015, FRONT MED, V2, DOI 10.3389/fmed.2015.00033; Dahlin AM, 2011, MODERN PATHOL, V24, P671, DOI 10.1038/modpathol.2010.234; Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0191-1; Di Blasi D, 2020, CELL MOL GASTROENTER, V9, P195, DOI 10.1016/j.jcmgh.2019.08.004; Dolcetti R, 1999, AM J PATHOL, V154, P1805, DOI 10.1016/S0002-9440(10)65436-3; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287; Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x; Goldstein J, 2014, ANN ONCOL, V25, P1032, DOI 10.1093/annonc/mdu100; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Jacobs J, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/158038; Jochems C, 2011, EXP BIOL MED, V236, P567, DOI 10.1258/ebm.2011.011007; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kawakami H, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0348-2; Khaja ASS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00619; Kitsou M, 2020, INT J ONCOL, V57, P237, DOI 10.3892/ijo.2020.5062; Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Marin-Acevedo JA, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0582-8; Mlecnik B, 2011, CANCER METAST REV, V30, P5, DOI 10.1007/s10555-011-9270-7; Naito Y, 1998, CANCER RES, V58, P3491; Ndhlovu LC, 2012, BLOOD, V119, P3734, DOI 10.1182/blood-2011-11-392951; Nirschl CJ, 2013, CLIN CANCER RES, V19, P4917, DOI 10.1158/1078-0432.CCR-12-1972; Nosho K, 2010, J PATHOL, V222, P350, DOI 10.1002/path.2774; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Picard E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00369; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ren DX, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1144-6; Sahin IH, 2019, BRIT J CANCER, V121, P809, DOI 10.1038/s41416-019-0599-y; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Saleh R, 2020, CANCER IMMUNOL IMMUN, V69, P1989, DOI 10.1007/s00262-020-02593-w; Sarrabayrouse G, 2011, INT J CANCER, V128, P2923, DOI 10.1002/ijc.25640; Schwartz M, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0145-x; Scurr M, 2014, MUCOSAL IMMUNOL, V7, P428, DOI 10.1038/mi.2013.62; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Sherwood AM, 2013, CANCER IMMUNOL IMMUN, V62, P1453, DOI 10.1007/s00262-013-1446-2; Shimabukuro-Vornhagen A, 2014, ONCOTARGET, V5, P4651, DOI 10.18632/oncotarget.1701; Smyrk TC, 2001, CANCER, V91, P2417, DOI 10.1002/1097-0142(20010615)91:12<2417::AID-CNCR1276>3.0.CO;2-U; Toor SM, 2020, SEMIN CANCER BIOL, V65, P1, DOI 10.1016/j.semcancer.2019.06.021; Toor SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02936; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Yang ZZ, 2020, CLIN CANCER RES, V26, P5217, DOI 10.1158/1078-0432.CCR-20-0558; Zappasodi R, 2018, CANCER CELL, V33, P581, DOI 10.1016/j.ccell.2018.03.005; Zhang ZX, 2000, NAT MED, V6, P782, DOI 10.1038/77513	49	2	2	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							64	10.3390/vaccines9010064			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6VY	33477864	Green Published, gold			2022-04-29	WOS:000610811000001
J	Wolff, J; Moritz, T; Schlottau, K; Hoffmann, D; Beer, M; Hoffmann, B				Wolff, Janika; Moritz, Tom; Schlottau, Kore; Hoffmann, Donata; Beer, Martin; Hoffmann, Bernd			Development of a Safe and Highly Efficient Inactivated Vaccine Candidate against Lumpy Skin Disease Virus	VACCINES			English	Article						capripox; inactivated vaccine; LSDV; lumpy skin disease; vaccine; adjuvants		Capripox virus (CaPV)-induced diseases (lumpy skin disease, sheeppox, goatpox) are described as the most serious pox diseases of livestock animals, and therefore are listed as notifiable diseases under guidelines of the World Organisation for Animal Health (OIE). Until now, only live-attenuated vaccines are commercially available for the control of CaPV. Due to numerous potential problems after vaccination (e.g., loss of the disease-free status of the respective country, the possibility of vaccine virus shedding and transmission as well as the risk of recombination with field strains during natural outbreaks), the use of these vaccines must be considered carefully and is not recommended in CaPV-free countries. Therefore, innocuous and efficacious inactivated vaccines against CaPV would provide a great tool for control of these diseases. Unfortunately, most inactivated Capripox vaccines were reported as insufficient and protection seemed to be only short-lived. Nevertheless, a few studies dealing with inactivated vaccines against CaPV are published, giving evidence for good clinical protection against CaPV-infections. In our studies, a low molecular weight copolymer-adjuvanted vaccine formulation was able to induce sterile immunity in the respective animals after severe challenge infection. Our findings strongly support the possibility of useful inactivated vaccines against CaPV-infections, and indicate a marked impact of the chosen adjuvant for the level of protection.	[Wolff, Janika; Moritz, Tom; Schlottau, Kore; Hoffmann, Donata; Beer, Martin; Hoffmann, Bernd] Fed Res Inst Anim Hlth, Friedrich Loeffler Inst, Inst Diagnost Virol, Sudufer 10, D-17493 Greifswald, Germany		Hoffmann, B (通讯作者)，Fed Res Inst Anim Hlth, Friedrich Loeffler Inst, Inst Diagnost Virol, Sudufer 10, D-17493 Greifswald, Germany.	janika.wolff@fli.de; Tom.Moritz@gmx.de; kore.schlottau@fli.de; donata.hoffmann@fli.de; martin.beer@fli.de; bernd.hoffmann@fli.de		Hoffmann, Bernd/0000-0001-5358-6445; Wolff, Janika/0000-0002-2434-687X; Hoffmann, Donata/0000-0003-4552-031X	Friedrich-Loeffler-Institut (Insel Riems, Germany); Zoetis (Olot, Spain) [Ri-0613]	The proof-of-concept-study was financed by the Friedrich-Loeffler-Institut (Insel Riems, Germany). Zoetis (Olot, Spain) funded the vaccine-efficacy study (grant number Ri-0613).	Aarthi D, 2004, BIOLOGICALS, V32, P153, DOI 10.1016/j.biologicals.2004.09.001; Abdelwahab M.G., 2016, J AM SCI, V12, P38, DOI [10.7537/marsjas121016.06, DOI 10.7537/MARSJAS121016.06]; Abutarbush SM, 2016, TRANSBOUND EMERG DIS, V63, pE213, DOI 10.1111/tbed.12257; Annandale CH, 2014, TRANSBOUND EMERG DIS, V61, P443, DOI [10.1111/tbed.12045, 10.1111/tbed]; Awad Manal, 2003, Egypt J Immunol, V10, P67; Babiuk S, 2008, TRANSBOUND EMERG DIS, V55, P263, DOI 10.1111/j.1865-1682.2008.01043.x; Babiuk S, 2008, TRANSBOUND EMERG DIS, V55, P299, DOI 10.1111/j.1865-1682.2008.01024.x; Bachh AS, 1997, INDIAN J ANIM SCI, V67, P263; BAHNEMANN HG, 1976, J CLIN MICROBIOL, V3, P209; Bastian M, 2011, VACCINE, V29, P5267, DOI 10.1016/j.vaccine.2011.05.012; Beard PM, 2016, VET REC, V178, P557, DOI 10.1136/vr.i2800; Bedekovic T, 2018, TRANSBOUND EMERG DIS, V65, P491, DOI 10.1111/tbed.12730; Ben-Gera J, 2015, VACCINE, V33, P4837, DOI 10.1016/j.vaccine.2015.07.071; Boumart Z, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0754-0; Bowden TR, 2008, VIROLOGY, V371, P380, DOI 10.1016/j.virol.2007.10.002; Brenner J, 2009, VACCINE, V27, P1500, DOI 10.1016/j.vaccine.2009.01.020; CARN VM, 1993, VACCINE, V11, P1275, DOI 10.1016/0264-410X(93)90094-E; CARN VM, 1995, ARCH VIROL, V140, P503, DOI 10.1007/BF01718427; CARN VM, 1995, EPIDEMIOL INFECT, V114, P219, DOI 10.1017/S0950268800052067; Chihota CM, 2003, MED VET ENTOMOL, V17, P294, DOI 10.1046/j.1365-2915.2003.00445.x; Chihota CM, 2001, EPIDEMIOL INFECT, V126, P317, DOI 10.1017/S0950268801005179; Davies F. G., 1991, World Animal Review, V68, P37; DAVIES FG, 1985, J COMP PATHOL, V95, P565, DOI 10.1016/0021-9975(85)90026-X; DAVIES FG, 1991, BRIT VET J, V147, P489, DOI 10.1016/0007-1935(91)90019-J; Dietze K, 2018, VET MICROBIOL, V221, P44, DOI 10.1016/j.vetmic.2018.05.022; Gari G, 2015, VACCINE, V33, P3256, DOI 10.1016/j.vaccine.2015.01.035; HAIG D. A., 1957, Bulletin of epizootic diseases of Africa, V5, P421; Hamdi J, 2020, VET MICROBIOL, V245, DOI 10.1016/j.vetmic.2020.108689; Hoffmann B, 2006, J VIROL METHODS, V136, P200, DOI 10.1016/j.jviromet.2006.05.020; Hunter P, 2001, J S AFR VET ASSOC, V72, P68; Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914; Katsoulos PD, 2018, TRANSBOUND EMERG DIS, V65, P174, DOI 10.1111/tbed.12646; Kavitha KL, 2009, INDIAN J ANIM SCI, V79, P1018; KING A. M. Q., 2012, VIRUS TAXONOMY, P291; KITCHING P, 1983, Vaccine, V1, P4, DOI 10.1016/0264-410X(83)90004-X; Kitching R. P., 2003, VVolume 114, P161; Klement E, 2020, PREV VET MED, V181, DOI 10.1016/j.prevetmed.2018.12.001; Kononov A, 2019, ARCH VIROL, V164, P1575, DOI 10.1007/s00705-019-04229-6; MELLOR PS, 1987, RES VET SCI, V43, P109, DOI 10.1016/S0034-5288(18)30753-7; Moeller J, 2019, ARCH VIROL, V164, P2931, DOI 10.1007/s00705-019-04411-w; Morgenstern M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020324; MVP-Adjuvants, INF POL; Norian R., 2016, IRAN J VIROL, V10, P1, DOI [10.21859/isv.10.4.1, DOI 10.21859/ISV.10.4.1]; OIE, 2019, MANUAL DIAGNOSTIC TE; Pal J. K., 1992, Indian Journal of Virology, V8, P86; Roth J. A., 2003, VVolume 114, P5; Sohier C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56605-6; SOLYOM F, 1982, ACTA MICROBIOL HUNG, V29, P69; Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x; Spickler A.R., LUMPY SKIN DIS; SRIVASTAVA RN, 1980, INDIAN J ANIM SCI, V50, P861; Tuppurainen ESM, 2017, TRANSBOUND EMERG DIS, V64, P729, DOI 10.1111/tbed.12444; Tuppurainen ESM, 2015, TICKS TICK-BORNE DIS, V6, P134, DOI 10.1016/j.ttbdis.2014.11.002; Tuppurainen ESM, 2013, EPIDEMIOL INFECT, V141, P425, DOI 10.1017/S0950268812000805; Tuppurainen ESM, 2012, TRANSBOUND EMERG DIS, V59, P40, DOI 10.1111/j.1865-1682.2011.01242.x; Tuppurainen ESM, 2011, TRANSBOUND EMERG DIS, V58, P93, DOI 10.1111/j.1865-1682.2010.01184.x; Tuppurainen ESM, 2014, ANTIVIR RES, V109, P1, DOI 10.1016/j.antiviral.2014.06.009; Tuppurainen ESM, 2013, TICKS TICK-BORNE DIS, V4, P329, DOI 10.1016/j.ttbdis.2013.01.006; Tuppurainen ESM, 2005, ONDERSTEPOORT J VET, V72, P153; van Rooyen P J, 1969, Onderstepoort J Vet Res, V36, P165; Varshovi H. R., 2017, Iranian Journal of Veterinary Science and Technology, V9, P33; WEISS K. E., 1968, Lumpy skin disease virus., P111; Wolff J, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12070768; Yadav M. P., 1986, Indian Journal of Virology, V2, P207; YERUHAM I, 1994, VET REC, V135, P330, DOI 10.1136/vr.135.14.330; Zoetis, HERB LS	66	7	7	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							4	10.3390/vaccines9010004			30	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6ZP	33374808	gold, Green Published			2022-04-29	WOS:000610820700001
J	Cox, MMJ				Cox, Manon M. J.			Innovations in the Insect Cell Expression System for Industrial Recombinant Vaccine Antigen Production	VACCINES			English	Article						baculovirus; insect cell culture; protein production; antigen; vectors	FED-BATCH CULTURE; PROTEIN-PRODUCTION; CHO-CELLS; VECTOR; GENE; SERUM; BACULOVIRUSES; ACCUMULATION; SUPPRESSION; TECHNOLOGY	The insect cell expression system has previously been proposed as the preferred biosecurity strategy for production of any vaccine, particularly for future influenza pandemic vaccines. The development and regulatory risk for new vaccine candidates is shortened as the platform is already in use for the manufacturing of the FDA-licensed seasonal recombinant influenza vaccine Flublok(R). Large-scale production capacity is in place and could be used to produce other antigens as well. However, as demonstrated by the 2019 SARS-CoV-2 pandemic the insect cell expression system has limitations that need to be addressed to ensure that recombinant antigens will indeed play a role in combating future pandemics. The greatest challenge may be the ability to produce an adequate quantity of purified antigen in an accelerated manner. This review summarizes recent innovations in technology areas important for enhancing recombinant-protein production levels and shortening development timelines. Opportunities for increasing product concentrations through vector development, cell line engineering, or bioprocessing and for shortening timelines through standardization of manufacturing processes will be presented.	[Cox, Manon M. J.] NextWaveBio LLC, East Haven, CT 06512 USA		Cox, MMJ (通讯作者)，NextWaveBio LLC, East Haven, CT 06512 USA.						Alldread RM, 2014, IND SCALE SUSPENSION, P410; BEDARD C, 1993, BIOTECHNOL PROGR, V9, P615, DOI 10.1021/bp00024a008; Bhatia R, 1997, CYTOTECHNOLOGY, V24, P1, DOI 10.1023/B:CYTO.0000010410.24541.dd; Birch JR, 2006, ADV DRUG DELIVER REV, V58, P671, DOI 10.1016/j.addr.2005.12.006; Buckland B, 2014, VACCINE, V32, P5496, DOI 10.1016/j.vaccine.2014.07.074; Burky JE, 2007, BIOTECHNOL BIOENG, V96, P281, DOI 10.1002/bit.21060; Butler M, 2015, CELL ENG, V9, P223, DOI 10.1007/978-3-319-10320-4_8; Chavez-Pena C, 2018, BIOTECHNOL ADV, V36, P443, DOI 10.1016/j.biotechadv.2018.01.008; Correia R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040589; Cox MMJ, 2012, VACCINE, V30, P1759, DOI 10.1016/j.vaccine.2012.01.016; Cox MMJ, 2011, J INVERTEBR PATHOL, V107, pS31, DOI 10.1016/j.jip.2011.05.003; Drugmand JC, 2012, BIOTECHNOL ADV, V30, P1140, DOI 10.1016/j.biotechadv.2011.09.014; Fernandes B, 2020, J BIOTECHNOL, V307, P139, DOI 10.1016/j.jbiotec.2019.10.004; Gomez-Sebastian S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096562; GOODWIN RH, 1991, IN VITRO CELL DEV B, V27, P470, DOI 10.1007/BF02631147; Granados R.R, 1994, U.S. Patent, Patent No. [5,300,435, 5300435]; Grose C, 2021, PROTEIN EXPRES PURIF, V186, DOI 10.1016/j.pep.2021.105924; Gwak WS, 2020, J ASIA-PAC ENTOMOL, V23, P909, DOI 10.1016/j.aspen.2020.07.016; Habib S, 1996, DNA CELL BIOL, V15, P737, DOI 10.1089/dna.1996.15.737; Hebert CG, 2009, BIOTECHNOL BIOENG, V104, P390, DOI 10.1002/bit.22411; Hebert CG, 2009, INSECT BIOCHEM MOLEC, V39, P113, DOI 10.1016/j.ibmb.2008.10.009; Heffner KM, 2021, ADV BIOCHEM ENG BIOT, V175, P37, DOI 10.1007/10_2017_57; Hitchman RB, 2010, CELL BIOL TOXICOL, V26, P57, DOI 10.1007/s10565-009-9133-y; Huang YM, 2010, BIOTECHNOL PROGR, V26, P1400, DOI 10.1002/btpr.436; Ikonomou L, 2003, APPL MICROBIOL BIOT, V62, P1, DOI 10.1007/s00253-003-1223-9; Jehle JA, 2006, ARCH VIROL, V151, P1257, DOI 10.1007/s00705-006-0763-6; Jiang Z, 2008, BIOTECHNOL BIOENG, V100, P189, DOI 10.1002/bit.21726; Kim EJ, 2007, BIOTECHNOL BIOENG, V98, P645, DOI 10.1002/bit.21353; KITTS PA, 1993, BIOTECHNIQUES, V14, P810; Konz JO, 1998, BIOTECHNOL PROGR, V14, P393, DOI 10.1021/bp980021l; KOOL M, 1991, VIROLOGY, V183, P739, DOI 10.1016/0042-6822(91)91003-Y; Kurasawa JH, 2020, MOL THER-METH CLIN D, V19, P330, DOI 10.1016/j.omtm.2020.09.018; Lai YK, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-83; Fabre ML, 2020, EMERGING AND REEMERGING VIRAL PATHOGENS, VOL 2: APPLIED VIROLOGY APPROACHES RELATED TO HUMAN, ANIMAL AND ENVIRONMENTAL PATHOGENS, P197, DOI 10.1016/B978-0-12-814966-9.00011-1; Lee HS, 2015, VIRUS RES, V199, P68, DOI 10.1016/j.virusres.2015.01.015; Li WF, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.646363; Lopez-Vidal J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140039; Lou Y, 2018, PROTEIN EXPRES PURIF, V149, P7, DOI 10.1016/j.pep.2018.04.005; Manohar SL, 2010, BIOTECHNOL BIOENG, V107, P909, DOI 10.1002/bit.22896; Marek M, 2011, BIOTECHNOL BIOENG, V108, P1056, DOI 10.1002/bit.23028; Meghrous J, 2015, BIOTECHNOL BIOENG, V112, P2267, DOI 10.1002/bit.25634; Meghrous J, 2009, VACCINE, V28, P309, DOI 10.1016/j.vaccine.2009.10.048; Miller L.K., 1981, GENETIC ENG PLANT SC, P203; MitchellLogean C, 1997, BIOTECHNOL PROGR, V13, P875, DOI 10.1021/bp970078s; Mitsuhashi J., 1989, P3; Mundhada H, 2017, METAB ENG, V39, P141, DOI 10.1016/j.ymben.2016.11.008; Ng Wern Hann, 2020, F1000Res, V9, DOI 10.12688/f1000research.25998.1; OHMAN L, 1995, APPL MICROBIOL BIOT, V43, P1006; Palomares LA, 2021, ADV BIOCHEM ENG BIOT, V175, P71, DOI 10.1007/10_2018_61; PAPOUTSAKIS ET, 1991, TRENDS BIOTECHNOL, V9, P316, DOI 10.1016/0167-7799(91)90102-N; Pijlman GP, 2003, J GEN VIROL, V84, P2669, DOI 10.1099/vir.0.19438-0; Pijlman GP, 2001, VIROLOGY, V283, P132, DOI 10.1006/viro.2001.0854; Possee RD, 2008, BIOTECHNOL BIOENG, V101, P1115, DOI 10.1002/bit.22002; REUVENY S, 1992, ANN NY ACAD SCI, V665, P230, DOI 10.1111/j.1749-6632.1992.tb42587.x; REUVENY S, 1993, BIOTECHNOL BIOENG, V42, P235, DOI 10.1002/bit.260420211; Roldao A., 2014, IND SCALE SUSPENSION, P348; Pastor AR, 2019, VACCINE, V37, P6962, DOI 10.1016/j.vaccine.2019.06.029; Salem TZ, 2013, VIROLOGY, V435, P225, DOI 10.1016/j.virol.2012.10.022; Schultz KLW, 2009, J VIROL, V83, P11123, DOI 10.1128/JVI.01199-09; SMITH GE, 1983, MOL CELL BIOL, V3, P2156, DOI 10.1128/MCB.3.12.2156; Spenger A, 2004, PROTEIN EXPRES PURIF, V38, P17, DOI 10.1016/j.pep.2004.08.001; Spens E, 2007, BIOTECHNOL BIOENG, V98, P1183, DOI 10.1002/bit.21509; Steele KH, 2017, BIOTECHNOL PROGR, V33, P1496, DOI 10.1002/btpr.2516; Stolt-Bergner P, 2018, J STRUCT BIOL, V203, P71, DOI 10.1016/j.jsb.2018.03.004; Sung YH, 2005, BIOTECHNOL PROGR, V21, P50, DOI 10.1021/bp049892n; Sunley K, 2008, BIOTECHNOL PROGR, V24, P898, DOI [10.1002/btpr.9, 10.1021/bp.9]; Teng CY, 2013, APPL MICROBIOL BIOT, V97, P8505, DOI 10.1007/s00253-013-5098-0; van Oers MM, 2006, ADV VIRUS RES, V68, P193, DOI 10.1016/S0065-3527(06)68006-8; van Oers MM, 2015, J GEN VIROL, V96, P6, DOI 10.1099/vir.0.067108-0; Wagner JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094401; Wang Q, 2016, MOL BIOTECHNOL, V58, P319, DOI 10.1007/s12033-016-9931-4; Wu HC, 2013, J BIOTECHNOL, V168, P55, DOI 10.1016/j.jbiotec.2013.08.017; Yun ZY, 2001, J BIOSCI BIOENG, V91, P581, DOI 10.1263/jbb.91.581; Zhang XY, 2021, BIOTECHNOL BIOENG, V118, P2977, DOI 10.1002/bit.27807	74	0	0	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1504	10.3390/vaccines9121504			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0HD	34960250	Green Published, gold			2022-04-29	WOS:000737342900001
J	Lee, YK; Huang, YH				Lee, Yu-Kuei; Huang, Yi-Hsun			Ocular Manifestations after Receiving COVID-19 Vaccine: A Systematic Review	VACCINES			English	Article						adverse events; coronavirus disease 2019 (COVID-19); ophthalmology; vaccines	THROMBOCYTOPENIA SYNDROME; THROMBOSIS; REJECTION; IMMUNIZATION	The coronavirus disease 2019 (COVID-19) pandemic has had profound and lasting consequences since 2019. Although vaccines against COVID-19 have been developed and approved under emergency use authorization, various adverse events have also been reported after COVID-19 vaccination. This review was undertaken to help clinicians recognize the possible manifestations and systemic pathogenesis, especially those related to the eye, after receiving COVID-19 vaccination. A systemic search was performed on 22 August 2021 through Embase, Medline, and Cochrane Library for publications on ocular manifestations after COVID-19 vaccination. Two case-control studies/retrospective cohort studies, one cross-sectional study, three case series, sixteen case reports, two images, and seven letters were included. Ocular manifestations after receiving COVID-19 vaccines may appear on the eyelid, cornea and ocular surface, retina, uvea, nerve, and vessel. The ocular manifestations occurred up to forty-two days after vaccination, and vaccine-induced immunologic responses may be responsible. Although the incidence rate of ocular symptoms is considerably lower in the vaccinated subjects than in COVID-19 patients, physicians should be aware of the possible associations between COVID-19 vaccines and ocular symptoms for the early diagnosis and treatment of vision problems or life-threatening complications.	[Lee, Yu-Kuei; Huang, Yi-Hsun] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Ophthalmol, Tainan 704, Taiwan		Huang, YH (通讯作者)，Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Ophthalmol, Tainan 704, Taiwan.	jackhyh@gmail.com		Lee, Yu-Kuei/0000-0002-7200-1067; Huang, Yi-Hsun/0000-0002-4150-5481	Ministry of Science and Technology [110-2628-B-006-018]	FundingSupported by Grants Ministry of Science and Technology 110-2628-B-006-018.	Aga QAA, 2021, J MED VIROL, V93, P6588, DOI 10.1002/jmv.27214; Arashkia A, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2183; Bayas A, 2021, LANCET, V397, pE11, DOI 10.1016/S0140-6736(21)00872-2; Bhavsar KV, 2016, SURV OPHTHALMOL, V61, P538, DOI 10.1016/j.survophthal.2016.03.003; Blauenfeldt RA, 2021, J THROMB HAEMOST, V19, P1771, DOI 10.1111/jth.15347; Bohler AD, 2022, EYE, V36, P644, DOI 10.1038/s41433-021-01610-1; Book BAJ, 2021, JAMA OPHTHALMOL, V139, DOI 10.1001/jamaophthalmol.2021.2471; Castelli GP, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03572-y; Crnej A, 2021, J FR OPHTALMOL, V44, pE445, DOI 10.1016/j.jfo.2021.06.001; Cunningham ET, 2019, OCUL IMMUNOL INFLAMM, V27, P517, DOI 10.1080/09273948.2019.1626188; Dias L, 2021, J STROKE CEREBROVASC, V30, DOI 10.1016/j.jstrokecerebrovasdis.2021.105906; Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385; Dockery DM, 2020, J EMERG MED, V59, P137, DOI 10.1016/j.jemermed.2020.04.060; Douxfils J, 2021, THROMB RES, V203, P163, DOI 10.1016/j.thromres.2021.05.010; Eric K., 2021, RES SQ, DOI [10.21203/rs.3.rs-558954/v1, DOI 10.21203/RS.3.RS-558954/V1]; Furer V, 2021, ANN RHEUM DIS, V80, P200, DOI 10.1136/annrheumdis-2021-eular.5096; Furer V, 2021, RHEUMATOLOGY, V60, pSI90, DOI 10.1093/rheumatology/keab345; Gabka K, 2021, OPHTHALMOLOGE, V118, P735, DOI 10.1007/s00347-021-01435-z; Goyal M, 2021, OCUL IMMUNOL INFLAMM, V29, P753, DOI 10.1080/09273948.2021.1957123; Heinz FX, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00369-6; Helmchen C, 2022, J NEUROL, V269, P49, DOI 10.1007/s00415-021-10647-x; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; JAMA Network, OP INSTR AUTH RAT QU; Kadali RAK, 2021, INT J INFECT DIS, V106, P376, DOI 10.1016/j.ijid.2021.04.047; Le Ng X, 2021, OCUL IMMUNOL INFLAMM, V29, P1216, DOI 10.1080/09273948.2021.1976221; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Lundstrom K, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11071020; MacIntyre CR, 2021, VACCINE, V39, P4784, DOI 10.1016/j.vaccine.2021.07.013; MacNeil JR, 2021, MMWR-MORBID MORTAL W, V70, P651, DOI 10.15585/mmwr.mm7017e4; Maleki A, 2021, J OPHTHAL VIS RES, V16, P490, DOI 10.18502/jovr.v16i3.9443; Mambretti M, 2021, OCUL IMMUNOL INFLAMM, V29, P730, DOI 10.1080/09273948.2021.1946567; Mazzatenta C, 2021, J EUR ACAD DERMATOL, V35, pE543, DOI 10.1111/jdv.17340; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535; Mudie LI, 2021, OCUL IMMUNOL INFLAMM, V29, P741, DOI 10.1080/09273948.2021.1949478; Panovska-Stavridis I, 2021, MEDITERR J HEMATOL I, V13, DOI 10.4084/MJHID.2021.048; Papasavvas I, 2021, J OPHTHALMIC INFLAMM, V11, DOI 10.1186/s12348-021-00251-5; Phylactou M, 2021, BRIT J OPHTHALMOL, V105, P893, DOI 10.1136/bjophthalmol-2021-319338; Ravichandran S, 2021, INDIAN J OPHTHALMOL, V69, P1953, DOI 10.4103/ijo.IJO_1028_21; Renisi G, 2021, INT J INFECT DIS, V110, P95, DOI 10.1016/j.ijid.2021.07.035; Reyes-Capo DP, 2021, J AAPOS, V25, P302, DOI 10.1016/j.jaapos.2021.05.003; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Santovito LS, 2021, INFLAMM RES, V70, P931, DOI 10.1007/s00011-021-01476-9; See I, 2021, JAMA-J AM MED ASSOC, V325, P2448, DOI 10.1001/jama.2021.7517; Sopp NM, 2021, OPTOMETRY VISION SCI, V98, P429, DOI 10.1097/OPX.0000000000001687; Subramony R, 2021, J EMERG MED, V61, pE146, DOI 10.1016/j.jemermed.2021.07.034; Suresh P, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2021-243931; Wasser LM, 2021, CORNEA, V40, P1070, DOI 10.1097/ICO.0000000000002761; Wolf ME, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081599	49	1	1	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1404	10.3390/vaccines9121404			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0SI	34960150	Green Published, gold			2022-04-29	WOS:000737372100001
J	Lemon, JL; McMenamy, MJ				Lemon, Joanne L.; McMenamy, Michael J.			A Review of UK-Registered and Candidate Vaccines for Bovine Respiratory Disease	VACCINES			English	Article						vaccination; pathogens; efficacy; non-microbial risks; candidate	SYNCYTIAL VIRUS BRSV; CELL-MEDIATED-IMMUNITY; DIARRHEA-VIRUS; MODIFIED-LIVE; MOUTH-DISEASE; DNA VACCINATION; RISK-FACTORS; VETERINARY VACCINES; VIRAL-INFECTIONS; FEEDLOT CATTLE	Vaccination is widely regarded as a cornerstone in animal or herd health and infectious disease management. Nineteen vaccines against the major pathogens implicated in bovine respiratory disease are registered for use in the UK by the Veterinary Medicines Directorate (VMD). However, despite annual prophylactic vaccination, bovine respiratory disease is still conservatively estimated to cost the UK economy approximately 80 pound million per annum. This review examines the vaccine types available, discusses the surrounding literature and scientific rationale of the limitations and assesses the potential of novel vaccine technologies.	[Lemon, Joanne L.] Agrifood & Biosci Inst, Sustainable Agrifood & Sci Div, Newforge Lane, Belfast BT9 5PX, Antrim, North Ireland; [McMenamy, Michael J.] Agrifood & Biosci Inst, Vet Sci Div, Belfast BT4 3SD, Antrim, North Ireland		Lemon, JL (通讯作者)，Agrifood & Biosci Inst, Sustainable Agrifood & Sci Div, Newforge Lane, Belfast BT9 5PX, Antrim, North Ireland.	joanne.lemon@afbini.gov.uk; michael.mcmenamy@afbini.gov.uk					AFBI/DAERA, 2016, ALL ISL DIS SURV REP; Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3; Kornuta CA, 2021, VACCINE, V39, P1007, DOI 10.1016/j.vaccine.2020.11.071; ALEXANDER BH, 1989, J AM VET MED ASSOC, V195, P207; Allen M, 2016, NO IRELANDS AGRI FOO; Anderson J, 2011, VET REC, V169, P10, DOI 10.1136/vr.d4011; Antonis AFG, 2007, VACCINE, V25, P4818, DOI 10.1016/j.vaccine.2007.04.002; Antonis AFG, 2003, J VIROL, V77, P12067, DOI 10.1128/JVI.77.22.12067-12073.2003; Atuhaire DK, 2020, VET PARASITOL, V288, DOI 10.1016/j.vetpar.2020.109304; Babiuk S., 2008, ENCY VIROLOGY, V3rd, P51; Baccili CC, 2018, ARQ BRAS MED VET ZOO, V70, P391, DOI 10.1590/1678-4162-9496; Baptista AL, 2017, J INFECT DEV COUNTR, V11, P791, DOI 10.3855/jidc.9296; Bastien N, 1997, VACCINE, V15, P1385, DOI 10.1016/S0264-410X(97)00033-9; Batra SA, 2017, VACCINE, V35, P1630, DOI 10.1016/j.vaccine.2017.02.006; Beadling C, 2004, CURR OPIN INFECT DIS, V17, P185, DOI 10.1097/00001432-200406000-00003; Bell CJ, 2014, J VET DIAGN INVEST, V26, P631, DOI 10.1177/1040638714540166; Bell RL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040337; Belsham GJ, 2020, ACTA VET SCAND, V62, DOI 10.1186/s13028-020-00519-1; Bilge-Dagalp S, 2021, BRAZ J MICROBIOL, V52, P1119, DOI 10.1007/s42770-021-00525-z; Blakebrough-Hall C, 2020, J ANIM SCI, V98, DOI 10.1093/jas/skaa005; Blodorn K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100392; Briggs RE, 2012, MICROB PATHOGENESIS, V52, P302, DOI 10.1016/j.micpath.2012.02.008; BRYSON DG, 1985, VET CLIN N AM-FOOD A, V1, P237, DOI 10.1016/S0749-0720(15)31326-8; Burakova Y, 2018, VIRAL IMMUNOL, V31, P11, DOI 10.1089/vim.2017.0049; Callan RJ, 2002, VET CLIN N AM-FOOD A, V18, P57, DOI 10.1016/S0749-0720(02)00004-X; Cameron A, 2016, J ANIM SCI BIOTECHNO, V7, DOI 10.1186/s40104-016-0127-3; Carine L, 2008, VACCINE, V26, P4840, DOI 10.1016/j.vaccine.2008.06.100; Cavirani S, 2019, LARGE ANIM REV, V25, P17; Cerbu C, 2021, MOLECULES, V26, DOI 10.3390/molecules26030523; Chamorro MF, 2020, VET CLIN N AM-FOOD A, V36, P461, DOI 10.1016/j.cvfa.2020.03.006; Chase CCL, 2008, VET CLIN N AM-FOOD A, V24, P87, DOI 10.1016/j.cvfa.2007.11.001; Chowdhury SI, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010046; Clem AS, 2011, J GLOB INFECT DIS, V3, P73, DOI 10.4103/0974-777X.77299; Cohn LA, 2011, VET CLIN N AM-SMALL, V41, P1273, DOI 10.1016/j.cvsm.2011.07.006; COLLINS JK, 1988, AM J VET RES, V49, P1316; Combadiere B, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030105; Cortese VS, 2009, VET CLIN N AM-FOOD A, V25, P221, DOI 10.1016/j.cvfa.2008.10.003; Crisci E, 2012, VET IMMUNOL IMMUNOP, V148, P211, DOI 10.1016/j.vetimm.2012.04.026; DALY PA, 1981, MON LABOR REV, V104, P11; Dane H, 2019, TRANSBOUND EMERG DIS, V66, P2184, DOI 10.1111/tbed.13273; Dar P, 2013, VACCINE, V31, P3327, DOI 10.1016/j.vaccine.2013.05.078; Delabouglise A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189090; Demasius W, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-93; Department for Environment Food and Rural Affairs, 2021, TOT INC FARM UK 1 ES; Department of Health and Department for Environment Food and Rural Affairs, 2013, UK 5 YEAR ANT RES ST; Dhama K, 2008, VET RES COMMUN, V32, P341, DOI 10.1007/s11259-008-9040-3; Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320; Dolgin E, 2021, NATURE, V597, P318, DOI 10.1038/d41586-021-02483-w; Draayer H, 2011, PROCEDIA VACCINOL, V5, P171, DOI 10.1016/j.provac.2011.10.016; Dudek K, 2014, RES VET SCI, V97, P32, DOI 10.1016/j.rvsc.2014.04.005; Dunham SP, 2002, RES VET SCI, V73, P9, DOI 10.1016/S0034-5288(02)00032-2; Ellis J, 2007, JAVMA-J AM VET MED A, V230, P233, DOI 10.2460/javma.230.2.233; Ellis J, 2014, CAN VET J, V55, P1180; Ellis JA, 2013, JAVMA-J AM VET MED A, V243, P1602, DOI 10.2460/javma.243.11.1602; Ellis John A., 2009, Animal Health Research Reviews, V10, P149, DOI 10.1017/S146625230999020X; Fahkrajang W, 2021, VET MICROBIOL, V255, DOI 10.1016/j.vetmic.2021.109017; Faye L, 2010, PLANT BIOTECHNOL J, V8, P525, DOI 10.1111/j.1467-7652.2010.00521.x; Ficht TA, 2009, VACCINE, V27, pD40, DOI 10.1016/j.vaccine.2009.08.058; Delgado MF, 2009, NAT MED, V15, P34, DOI 10.1038/nm.1894; FRANZ J, 1992, ACTA VET BRNO, V61, P37, DOI 10.2754/avb199261010037; Fulton RW, 2004, VACCINE, V22, P643, DOI 10.1016/j.vaccine.2003.08.033; Gershwin LJ, 2017, VACCINE, V35, P1954, DOI 10.1016/j.vaccine.2017.01.059; Gershwin LJ, 2005, VET IMMUNOL IMMUNOP, V107, P119, DOI 10.1016/j.vetimm.2005.04.004; Gershwin LJ, 1998, VACCINE, V16, P1225, DOI 10.1016/S0264-410X(98)80123-0; Glenn GM, 2013, VACCINE, V31, P524, DOI 10.1016/j.vaccine.2012.11.009; Glover I. D., 2017, Livestock, V22, P230, DOI 10.12968/live.2017.22.5.230; Goldsby RA, 2003, IMMUNOLOGY; Gomez M, 2021, VACCINE, V39, P5025, DOI 10.1016/j.vaccine.2021.07.002; Goncalves VS, 2021, RES VET SCI, V136, P185, DOI 10.1016/j.rvsc.2021.02.014; Greenwood DLV, 2008, VACCINE, V26, P2706, DOI 10.1016/j.vaccine.2008.03.025; Guzman E, 2015, MOL IMMUNOL, V66, P48, DOI 10.1016/j.molimm.2014.12.004; Hagglund S, 2007, VET J, V173, P585, DOI 10.1016/j.tvjl.2006.02.010; Hagglund S, 2011, VACCINE, V29, P8719, DOI 10.1016/j.vaccine.2011.07.146; Hamers C, 2007, J COMP PATHOL, V137, pS35, DOI 10.1016/j.jcpa.2007.04.010; Hartel H, 2004, ACTA VET SCAND, V45, P193, DOI 10.1186/1751-0147-45-193; Hay KE, 2016, PREV VET MED, V127, P37, DOI 10.1016/j.prevetmed.2016.02.006; Henderson DA, 2011, VACCINE, V29, pD7, DOI 10.1016/j.vaccine.2011.06.080; Hill K, 2019, VACCINE, V37, P7455, DOI 10.1016/j.vaccine.2019.09.080; Hotchkiss EJ, 2010, VET REC, V167, P555, DOI 10.1136/vr.c4827; Hulbert LE, 2016, J DAIRY SCI, V99, P3199, DOI 10.3168/jds.2015-10198; Jaberolansar N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10415-w; Jackson NAC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0159-8; Johnson JC, 2008, VET THER, V9, P53; Johnson KK, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00189; Johnston D, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88878-1; Johnston D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51094-z; Kalina WV, 2005, VACCINE, V23, P4625, DOI 10.1016/j.vaccine.2005.04.032; Kamdi B, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104165; Kamstrup S, 1999, VACCINE, V17, P1057, DOI 10.1016/S0264-410X(98)00322-3; Kardani K, 2016, VACCINE, V34, P413, DOI 10.1016/j.vaccine.2015.11.062; Kavanagh OV, 2013, RES VET SCI, V95, P786, DOI 10.1016/j.rvsc.2013.06.023; Kerkhofs P, 2004, VET J, V167, P208, DOI 10.1016/S1090-0233(03)00078-9; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; KIMMAN TG, 1987, J CLIN MICROBIOL, V25, P1097, DOI 10.1128/JCM.25.6.1097-1106.1987; Knight-Jones TJD, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2013.2839; Knudson CJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004757; Kohara J, 1997, J VET MED SCI, V59, P1023, DOI 10.1292/jvms.59.1023; Kotla S, 2016, VET MICROBIOL, V193, P106, DOI 10.1016/j.vetmic.2016.07.007; Kudirkiene E, 2021, VET MICROBIOL, V259, DOI 10.1016/j.vetmic.2021.109135; Kurcubic V., 2018, ACTA AGRIC SERBICA, V23, P85, DOI [10.5937/AASer1845085K, DOI 10.5937/AASER1845085K]; Larsen LE, 2001, ACTA VET SCAND, V42, P113, DOI 10.1186/1751-0147-42-113; Lava M, 2016, PREV VET MED, V126, P121, DOI 10.1016/j.prevetmed.2016.02.002; Levings RL, 2013, ANIM HEALTH RES REV, V14, P103, DOI 10.1017/S1466252313000054; LOUCKS ME, 1985, J DAIRY SCI, V68, P1841, DOI 10.3168/jds.S0022-0302(85)81037-7; Loy JD, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-35; Lu S, 2009, CURR OPIN IMMUNOL, V21, P346, DOI 10.1016/j.coi.2009.05.016; Mackay D, 2021, BIOLOGICALS, V70, P7, DOI 10.1016/j.biologicals.2021.03.001; MACVEAN DW, 1986, AM J VET RES, V47, P2676; Makoschey B, 2021, BMC VET RES, V17, DOI 10.1186/s12917-021-02935-5; Manohar P, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01434; Mansoor F, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0481-y; Mapletoft JW, 2010, CLIN VACCINE IMMUNOL, V17, P23, DOI 10.1128/CVI.00250-09; Mawhinney IC, 2005, VET REC, V156, P139, DOI 10.1136/vr.156.5.139; Miao C, 2004, AM J VET RES, V65, P725, DOI 10.2460/ajvr.2004.65.725; Mitra N, 2016, J GEN VIROL, V97, P1771, DOI 10.1099/jgv.0.000492; Mogil JS, 2004, PAIN, V112, P12, DOI 10.1016/j.pain.2004.09.028; Nakagami H, 2014, VACCINES-BASEL, V2, P832, DOI 10.3390/vaccines2040832; National Office of Animal Health, 2021, COMP DAT SHEETS AN M; Neibergs HL, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1164; Nelson G, 2012, VACCINE, V30, P4499, DOI 10.1016/j.vaccine.2012.04.068; Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446; Nobiron I, 2003, VACCINE, V21, P2082, DOI 10.1016/S0264-410X(02)00745-4; Obando RC, 1999, PREV VET MED, V41, P271, DOI 10.1016/S0167-5877(99)00049-5; Ohlson A, 2013, VET J, V197, P395, DOI 10.1016/j.tvjl.2013.01.028; Oshop GL, 2002, VET IMMUNOL IMMUNOP, V89, P1, DOI 10.1016/S0165-2427(02)00189-7; Paarlberg PL, 2002, J AM VET MED ASSOC, V220, P988, DOI 10.2460/javma.2002.220.988; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Parker R, 2009, PROCEDIA VACCINOL, V1, P140, DOI 10.1016/j.provac.2009.07.026; Patel JR, 2004, AM J VET RES, V65, P417, DOI 10.2460/ajvr.2004.65.417; Patial S, 2007, VACCINE, V25, P4020, DOI 10.1016/j.vaccine.2007.02.051; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Pinchak WE, 2004, J ANIM SCI, V82, P2773; Playfair D., 2018, NO IRELAND AGRI FOOD; Poulet H, 2007, VACCINE, V25, P5606, DOI 10.1016/j.vaccine.2006.11.066; Power UF, 1997, VIROLOGY, V230, P155, DOI 10.1006/viro.1997.8465; Pretty J, 2010, INT J AGR SUSTAIN, V8, P219, DOI 10.3763/ijas.2010.0534; Prysliak T, 2011, CAN VET J, V52, P1195; Reagan KL, 2020, VET CLIN N AM-SMALL, V50, P405, DOI 10.1016/j.cvsm.2019.10.009; Redding L, 2009, EXPERT REV VACCINES, V8, P1251, DOI 10.1586/erv.09.77; Ren Q, 2009, PUBLIC HEALTH REP, V124, P745, DOI 10.1177/003335490912400517; RIBBLE CS, 1995, CAN J VET RES, V59, P167; Richeson JT, 2020, VET CLIN N AM-FOOD A, V36, P473, DOI 10.1016/j.cvfa.2020.03.013; Richeson JT, 2019, VET CLIN N AM-FOOD A, V35, P575, DOI 10.1016/j.cvfa.2019.07.003; Riffault S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020231; Roeder PL, 2011, PREV VET MED, V102, P98, DOI 10.1016/j.prevetmed.2011.04.004; Roser, 2013, EMPLOYMENT AGR; Rossi PS, 2021, VET QUART, V41, P97, DOI 10.1080/01652176.2020.1870019; Rybicki EP, 2010, PLANT BIOTECHNOL J, V8, P620, DOI 10.1111/j.1467-7652.2010.00507.x; Saade G, 2020, VET RES, V51, DOI 10.1186/s13567-020-00807-8; Salerno-Goncalves R, 2006, TRENDS MICROBIOL, V14, P536, DOI 10.1016/j.tim.2006.10.004; Sanders B., 2014, VACCINE ANAL STRATEG, P45, DOI [10.1007/978-3- 662-45024-6_2, DOI 10.1007/978-3-662-45024-6_2]; Saylor K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00283; Schneider UA, 2011, AGR SYST, V104, P204, DOI 10.1016/j.agsy.2010.11.003; Schrijver RS, 1997, VACCINE, V15, P1908, DOI 10.1016/S0264-410X(97)00129-1; Scott P., 2016, RESP DIS DAIRY BEEF; Scott PR, 2011, VET CLIN N AM-FOOD A, V27, P175, DOI 10.1016/j.cvfa.2010.10.016; Singh K, 2016, J POSTGRAD MED, V62, P4, DOI 10.4103/0022-3859.173187; Sivakumar SM, 2011, SAUDI PHARM J, V19, P197, DOI 10.1016/j.jsps.2011.06.003; Six A, 2012, MICROB BIOTECHNOL, V5, P295, DOI 10.1111/j.1751-7915.2011.00321.x; Smith RA, 2020, VET CLIN N AM-FOOD A, V36, P239, DOI 10.1016/j.cvfa.2020.03.009; Solis-Calderon JJ, 2007, PREV VET MED, V82, P102, DOI 10.1016/j.prevetmed.2007.05.013; Stevens Elliot T., 2011, Bovine Practitioner, V45, P23; Tardon MC, 2019, CURR OPIN PHARMACOL, V47, P20, DOI 10.1016/j.coph.2019.01.007; Taylor G, 2005, VACCINE, V23, P1242, DOI 10.1016/j.vaccine.2004.09.005; Taylor G, 1997, J GEN VIROL, V78, P3195, DOI 10.1099/0022-1317-78-12-3195; Taylor G, 1998, J GEN VIROL, V79, P1759, DOI 10.1099/0022-1317-79-7-1759; Taylor JD, 2010, CAN VET J, V51, P1351; The European Agency for the Evaluation of Veterinary Medicines, 2001, EMEACVMP85299; Tibbo M, 2001, TROP ANIM HEALTH PRO, V33, P355, DOI 10.1023/A:1010565905004; Timsit E, 2018, VET MICROBIOL, V221, P105, DOI 10.1016/j.vetmic.2018.06.007; Tregoning JS, 2013, P NATL ACAD SCI USA, V110, P5576, DOI 10.1073/pnas.1214247110; TRUDEL M, 1991, VIROLOGY, V185, P749, DOI 10.1016/0042-6822(91)90546-N; TRUDEL M, 1989, VACCINE, V7, P12, DOI 10.1016/0264-410X(89)90004-2; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Uttenthal A, 2000, VET MICROBIOL, V76, P329, DOI 10.1016/S0378-1135(00)00261-3; Van Boeckel TP, 2015, P NATL ACAD SCI USA, V112, P5649, DOI 10.1073/pnas.1503141112; van der Fels-Klerx HJ, 2000, LIVEST PROD SCI, V66, P35, DOI 10.1016/S0301-6226(00)00163-9; van der Sluijs MTW, 2010, BMC VET RES, V6, DOI 10.1186/1746-6148-6-2; Vangeel I, 2007, VET J, V174, P627, DOI 10.1016/j.tvjl.2006.10.013; Wang CY, 2002, VACCINE, V20, P2603, DOI 10.1016/S0264-410X(02)00148-2; West K, 1999, VACCINE, V17, P809, DOI 10.1016/S0264-410X(98)00265-5; Williams PD, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1450-z; Wilson-Welder JH, 2020, VACCINE, V38, P3464, DOI 10.1016/j.vaccine.2020.02.086; Woolums AR, 1999, VACCINE, V17, P1293, DOI 10.1016/S0264-410X(98)00379-X; Wright PF, 2000, J INFECT DIS, V182, P1331, DOI 10.1086/315859; Xue WZ, 2010, VACCINE, V28, P3784, DOI 10.1016/j.vaccine.2010.03.043; Zhang ZW, 2015, APPL MICROBIOL BIOT, V99, P1389, DOI 10.1007/s00253-014-6129-1; Zolnik BS, 2010, ENDOCRINOLOGY, V151, P458, DOI 10.1210/en.2009-1082	188	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1403	10.3390/vaccines9121403			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0KD	34960149	gold, Green Published			2022-04-29	WOS:000737350700001
J	Li, SQ; Jia, XH; Yu, F; Wang, Q; Zhang, TT; Yuan, J				Li, Saiqun; Jia, Xiuhua; Yu, Fei; Wang, Qian; Zhang, Tingting; Yuan, Jin			Herpetic Keratitis Preceded by COVID-19 Vaccination	VACCINES			English	Article						herpetic keratitis; COVID-19 vaccination; inactivated vaccine	HERPESVIRUS INFECTIONS; REACTIVATION; REJECTION	The global Coronavirus Disease 2019 (COVID-19) pandemic has accelerated vaccine development at an unprecedented rate. A large population of people have received COVID-19 vaccines, while the vaccine safety data are limited. Here, we reported two cases of herpetic keratitis that occurred soon after receiving the inactivated COVID-19 vaccines. Case 1 was a 60-year-old woman who underwent penetrating keratoplasty (PKP) one year ago for corneal scarring caused by herpes simplex keratitis (HSK), and case 2 was a 51-year-old man with an unremarkable medical history. Both patients developed herpetic keratitis (HSK and varicella-zoster virus corneal endotheliitis, respectively) soon after receiving the inactivated COVID-19 vaccines (Sinovac). Herpetic keratitis was treated successfully with topical or plus oral antiviral ganciclovir. The short latency time in these two cases suggested that an inactivated COVID-19 vaccine may have a risk of triggering ocular herpes virus reactivation. Both clinicians and patients should be aware of this phenomenon. However, a causal relationship awaits confirmation.	[Li, Saiqun; Yu, Fei; Wang, Qian; Zhang, Tingting; Yuan, Jin] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510623, Peoples R China; [Jia, Xiuhua] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Ophthalmol, Guangzhou 510630, Peoples R China		Li, SQ; Yuan, J (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510623, Peoples R China.	lisq9@mail.sysu.edu.cn; jiaxiuh@mail.sysu.edu.cn; xiaolu7886@126.com; wangqian920920@foxmail.com; wangjbnew@163.com; yuanjincornea@126.com					Cheng JY, 2022, SURV OPHTHALMOL, V67, P293, DOI 10.1016/j.survophthal.2021.04.001; Crnej A, 2021, J FR OPHTALMOL, V44, pE445, DOI 10.1016/j.jfo.2021.06.001; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; ElSheikh RH, 2021, OCUL IMMUNOL INFLAMM, V29, P1207, DOI 10.1080/09273948.2021.1962917; Fathy RA, 2022, J EUR ACAD DERMATOL, V36, pE6, DOI 10.1111/jdv.17646; Grillo AP, 2017, DRUG TODAY, V53, P393, DOI 10.1358/dot.2017.53.7.2667582; Harris RJ, 2021, NEW ENGL J MED, V385, P759, DOI 10.1056/NEJMc2107717; Hassman LM, 2016, IDCases, V6, P47, DOI 10.1016/j.idcr.2016.09.012; Jampol LM, 2021, JAMA OPHTHALMOL, V139, P1135, DOI 10.1001/jamaophthalmol.2021.3483; Mao QY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00621-4; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Perry RJ, 2021, LANCET, V398, P1147, DOI 10.1016/S0140-6736(21)01608-1; Phylactou M, 2021, BRIT J OPHTHALMOL, V105, P893, DOI 10.1136/bjophthalmol-2021-319338; Pichi F, 2021, JAMA OPHTHALMOL, V139, P1131, DOI 10.1001/jamaophthalmol.2021.3477; Psichogiou M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060572; RAND KH, 1977, NEW ENGL J MED, V296, P1372, DOI 10.1056/NEJM197706162962402; Richardson-May J, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2021-245792; Rothova A, 2011, BRIT J OPHTHALMOL, V95, P291, DOI 10.1136/bjo.2010.185983; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Walter R, 1999, LANCET, V353, P810, DOI 10.1016/S0140-6736(99)00623-6; Wasser LM, 2021, CORNEA, V40, P1070, DOI 10.1097/ICO.0000000000002761	22	3	3	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1394	10.3390/vaccines9121394			5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YA5RS	34960139	Green Published, gold			2022-04-29	WOS:000738390700001
J	Pan, FM; Zhao, HY; Nicholas, S; Maitland, E; Liu, RG; Hou, QZ				Pan, Fengming; Zhao, Hongyu; Nicholas, Stephen; Maitland, Elizabeth; Liu, Rugang; Hou, Qingzhen			Parents' Decisions to Vaccinate Children against COVID-19: A Scoping Review	VACCINES			English	Article						COVID-19; vaccine hesitancy; acceptance; willingness; children; scoping review	UNITED-STATES; WILLINGNESS; ACCEPTANCE; INFECTION; TRIALS	Since 2019, the COVID-19 pandemic has resulted in sickness, hospitalizations, and deaths of the old and young and impacted global social and economy activities. Vaccination is one of the most important and efficient ways to protect against the COVID-19 virus. In a review of the literature on parents' decisions to vaccinate their children, we found that widespread vaccination was hampered by vaccine hesitancy, especially for children who play an important role in the coronavirus transmission in both family and school. To analyze parent vaccination decision-making for children, our review of the literature on parent attitudes to vaccinating children, identified the objective and subjective influencing factors in their vaccination decision. We found that the median rate of parents vaccinating their children against COVID-19 was 59.3% (IQR 48.60~73.90%). The factors influencing parents' attitudes towards child vaccination were heterogeneous, reflecting country-specific factors, but also displaying some similar trends across countries, such as the education level of parents. The leading reason in the child vaccination decision was to protect children, family and others; and the fear of side effects and safety was the most important reason in not vaccinating children. Our study informs government and health officials about appropriate vaccination policies and measures to improve the vaccination rate of children and makes specific recommendations on enhancing child vaccinate rates.	[Pan, Fengming; Zhao, Hongyu; Hou, Qingzhen] Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Dept Biostat, Jinan 250012, Peoples R China; [Pan, Fengming; Zhao, Hongyu; Hou, Qingzhen] Shandong Univ, Natl Inst Hlth Data Sci China, Jinan 250002, Peoples R China; [Nicholas, Stephen] Australian Natl Inst Management & Commerce, Sydney, NSW 2015, Australia; [Nicholas, Stephen] Guangdong Univ Foreign Studies, Res Inst Int Strategies, Guangzhou 510420, Peoples R China; [Nicholas, Stephen] Tianjin Normal Univ, Sch Econ, Tianjin 300074, Peoples R China; [Nicholas, Stephen] Tianjin Normal Univ, Sch Management, Tianjin 300074, Peoples R China; [Nicholas, Stephen] Univ Newcastle, Newcastle Business Sch, Newcastle, NSW 2308, Australia; [Maitland, Elizabeth] Univ Liverpool, Sch Management, Chatham Bldg,Chatham St, Liverpool L69 7ZH, Merseyside, England; [Liu, Rugang] Nanjing Med Univ, Sch Hlth Policy & Management, Nanjing 211166, Peoples R China; [Liu, Rugang] Nanjing Med Univ, Ctr Global Hlth, Nanjing 211166, Peoples R China; [Liu, Rugang] Nanjing Med Univ, Inst Hlth Jiangsu Dev, Nanjing 211166, Peoples R China		Hou, QZ (通讯作者)，Shandong Univ, Cheeloo Coll Med, Sch Publ Hlth, Dept Biostat, Jinan 250012, Peoples R China.; Hou, QZ (通讯作者)，Shandong Univ, Natl Inst Hlth Data Sci China, Jinan 250002, Peoples R China.; Liu, RG (通讯作者)，Nanjing Med Univ, Sch Hlth Policy & Management, Nanjing 211166, Peoples R China.; Liu, RG (通讯作者)，Nanjing Med Univ, Ctr Global Hlth, Nanjing 211166, Peoples R China.; Liu, RG (通讯作者)，Nanjing Med Univ, Inst Hlth Jiangsu Dev, Nanjing 211166, Peoples R China.	pfengming@mail.sdu.edu.cn; zhaohongyuu2019@mail.sdu.edu.cn; stephen.nicholas@newcastle.edu.au; e.maitland@liverpool.ac.uk; rugangliu@njmu.edu.cn; houqingzhen@sdu.edu.cn		Nicholas, Stephen/0000-0001-6770-7105; Liu, Rugang/0000-0002-4270-9507; Hou, Qingzhen/0000-0002-7655-0899; zhao, hongyu/0000-0002-8942-8323; pan, fengming/0000-0003-4751-5012	Young Scholars Program of Shandong University [21320082064101]; Nanjing Medical University [2019LX027]; Project of Philosophy and Social Science Research in Colleges and Universities in Jiangsu Province [2019SJA0294]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [71904089]; Excellent Innovation Team of Philosophy and Social Sciences in the Universities and Colleges of Jiangsu Province "the Public Health Policy and Management Innovation Research Team"	This research was funded by Young Scholars Program of Shandong University, grant number 21320082064101; Nanjing Medical University, grant number 2019LX027; The Project of Philosophy and Social Science Research in Colleges and Universities in Jiangsu Province, grant number 2019SJA0294; National Natural Science Foundation of China, grant number 71904089; The Excellent Innovation Team of Philosophy and Social Sciences in the Universities and Colleges of Jiangsu Province "the Public Health Policy and Management Innovation Research Team".	Abu-Farha RK, 2020, PATIENT PREFER ADHER, V14, P2451, DOI 10.2147/PPA.S284385; Akarsu B, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13891; Al-Jayyousi GF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060548; Al-Mulla R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060665; Alamoodi AH, 2021, COMPUT BIOL MED, V139, DOI 10.1016/j.compbiomed.2021.104957; Alvarado-Socarras JL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030287; American Academy of Pediatrics, CHILDR COVID 19 STAT; [Anonymous], 2021, WHO COVID 19 WEEKLY; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Bramer CA, 2020, AM J TRANSPLANT, V20, P1930, DOI 10.1111/ajt.16112; Brandstetter S, 2021, EUR J PEDIATR, V180, P3405, DOI 10.1007/s00431-021-04094-z; Butter S, 2022, BRIT J HEALTH PSYCH, V27, P13, DOI 10.1111/bjhp.12530; Carcelen AC, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2021.1948784; Castagnoli R, 2020, JAMA PEDIATR, V174, P882, DOI 10.1001/jamapediatrics.2020.1467; Choi W, 2020, J THEOR BIOL, V505, DOI 10.1016/j.jtbi.2020.110422; Davico C, 2021, J CLIN PSYCHIAT, V82, DOI 10.4088/JCP.20m13467; Denina M, 2020, PEDIATR INFECT DIS J, V39, pE458, DOI 10.1097/INF.0000000000002937; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Duly K, 2022, AM J HEALTH-SYST PH, V79, P63, DOI 10.1093/ajhp/zxab344; Esposito S, 2020, JAMA PEDIATR, V174, P921, DOI 10.1001/jamapediatrics.2020.1892; Fedele F, 2021, HUM VACC IMMUNOTHER, V17, P3348, DOI 10.1080/21645515.2021.1928460; Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718; Francia M, 2019, SOC NETW ANAL MIN, V9, DOI 10.1007/s13278-019-0590-x; Goldman RD, 2021, HUM VACC IMMUNOTHER, V17, P1607, DOI 10.1080/21645515.2020.1834325; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Gonullu E, 2021, HUM VACC IMMUNOTHER, V17, P2389, DOI 10.1080/21645515.2021.1896319; Greenhawt M, 2021, J GEN INTERN MED, V36, P1327, DOI 10.1007/s11606-020-06554-y; He KD, 2022, J COMMUN HEALTH, V47, P39, DOI 10.1007/s10900-021-01017-9; Hetherington Erin, 2021, CMAJ Open, V9, pE548, DOI 10.9778/cmajo.20200302; Holtz D, 2020, P NATL ACAD SCI USA, V117, P19837, DOI 10.1073/pnas.2009522117; Ikiisik H, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.14336; Kelly BJ, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06023-9; Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218; Largent EA, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.33324; Laxminarayan Ramanan, 2020, Science, V370, P691, DOI 10.1126/science.abd7672; Litvinova M, 2019, P NATL ACAD SCI USA, V116, P13174, DOI 10.1073/pnas.1821298116; Lu J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050472; Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1525, DOI 10.1111/apa.15371; Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270; Maldonado YA, 2021, PEDIATRICS, V148, DOI 10.1542/peds.2021-052336; Marquez RR, 2021, J AM DENT ASSOC, V152, P730, DOI 10.1016/j.adaj.2021.03.004; Mathieu E., CORONAVIRUS PANDEMIC; Mbaeyi S, 2020, PEDIATR ANN, V49, pE523, DOI 10.3928/19382359-20201115-02; McDonald HI, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.19.2000848; Milan S, 2021, J PEDIATR PSYCHOL, V46, P526, DOI 10.1093/jpepsy/jsab043; ModernaTX Inc, STUD EV SAF EFF MRNA; Montalti M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040366; Nindrea RD, 2021, CLIN EPIDEMIOL GLOB, V12, DOI 10.1016/j.cegh.2021.100899; Opel DJ, 2021, ANN INTERN MED, V174, P698, DOI 10.7326/M21-0055; Orenstein WA, 2017, P NATL ACAD SCI USA, V114, P4031, DOI 10.1073/pnas.1704507114; Pierantoni L, 2021, ACTA PAEDIATR, V110, P942, DOI 10.1111/apa.15614; Posfay-Barbe KM, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-1576; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Raman R, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11070993; Ruggiero KM, 2021, J PEDIATR HEALTH CAR, V35, P509, DOI 10.1016/j.pedhc.2021.04.005; Saha P, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.628931; Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2; Scherer AM, 2021, MMWR-MORBID MORTAL W, V70, DOI 10.15585/mmwr.mm7028e1; Scott EM, 2021, VACCINE, V39, P1058, DOI 10.1016/j.vaccine.2021.01.022; Siegel M, 2021, J RACIAL ETHN HEALTH, DOI 10.1007/s40615-021-01173-7; Silva MT, 2021, IMPLEMENT SCI, V16, DOI 10.1186/s13012-021-01164-6; Skjefte M, 2021, EUR J EPIDEMIOL, V36, P197, DOI 10.1007/s10654-021-00728-6; Teasdale CA, 2021, J PEDIATR-US, V237, P292, DOI 10.1016/j.jpeds.2021.07.021; Thunstrom L, 2021, ECOHEALTH, V18, P44, DOI 10.1007/s10393-021-01524-0; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; U.S. Food and Drug Administration, FDA APPR 1 COVID 19; U.S Food and Drug Administration, FDA AUTH PFIZ BIONTE; Walker KK, 2021, HUM VACC IMMUNOTHER, V17, P3355, DOI 10.1080/21645515.2021.1942713; Wang Q, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040342; Wang ZX, 2021, HUM VACC IMMUNOTHER, V17, P3322, DOI 10.1080/21645515.2021.1917232; WHO, COVID 19 VACC TRACK; Wirrell EC, 2020, J CHILD NEUROL, V35, P924, DOI 10.1177/0883073820940189; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Xie ZD, 2020, PEDIATR INVEST, V4, P1, DOI 10.1002/ped4.12178; Xu YC, 2021, J AFFECT DISORDERS, V292, P552, DOI 10.1016/j.jad.2021.06.003; Yigit M, 2021, PEDIATR INFECT DIS J, V40, pE134, DOI 10.1097/INF.0000000000003042; Yilmaz M, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.14364; Yilmazbas P, 2021, ERCIYES MED J, V43, P130, DOI 10.14744/etd.2020.85451; Zhou YH, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11174-0; Zhu YS, 2021, CLIN INFECT DIS, V72, pE1146, DOI 10.1093/cid/ciaa1825; Zimet GD, 2021, J PEDIATR-US, V231, P254, DOI 10.1016/j.jpeds.2020.11.002	81	1	1	12	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1476	10.3390/vaccines9121476			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ2SN	34960221	Green Published, gold			2022-04-29	WOS:000737507800001
J	Walkowiak, MP; Walkowiak, JB; Walkowiak, D				Walkowiak, Marcin Piotr; Walkowiak, Justyna B.; Walkowiak, Dariusz			COVID-19 Passport as a Factor Determining the Success of National Vaccination Campaigns: Does It Work? The Case of Lithuania vs. Poland	VACCINES			English	Article						COVID-19; vaccination; vaccination coverage; trust in vaccines; interventions to increase vaccination coverage; public health		As the ongoing COVID-19 pandemic poses a global threat, it is of utmost importance that governments should find effective means of combating vaccine hesitancy and encouraging their citizens to vaccinate. In our article, we compare the vaccination outcomes in the past months in two neighbouring post-communist EU states, Lithuania and Poland. Both introduced COVID-19 certificates, but only the former followed with gradual limitations for those who failed to get vaccinated, beginning with restricted access to restaurants, sports facilities and indoor events, and finally banning residents without a certificate from entering supermarkets or larger shops and using most services. By contrast, in Poland, the certificate remained a tool for international travel only. We show using statistical data that Lithuania's strict policy, regardless of its social implications, led to markedly higher vaccination outcomes in all age groups than those in Poland at the time.	[Walkowiak, Marcin Piotr] Poznan Univ Med Sci, Dept Prevent Med, PL-60781 Poznan, Poland; [Walkowiak, Justyna B.] Adam Mickiewicz Univ, Dept Language Policy & Minor Studies, PL-61712 Poznan, Poland; [Walkowiak, Dariusz] Poznan Univ Med Sci, Dept Org & Management Hlth Care, Przybyszewskiego 39, PL-60356 Poznan, Poland		Walkowiak, D (通讯作者)，Poznan Univ Med Sci, Dept Org & Management Hlth Care, Przybyszewskiego 39, PL-60356 Poznan, Poland.	MarcinWalkowiak@wir.pl; justwalk@amu.edu.pl; dariuszwalkowiak@ump.edu.pl	Walkowiak, Dariusz/AAV-6786-2020	Walkowiak, Dariusz/0000-0001-8874-2401; Walkowiak, Marcin/0000-0002-2862-7687			Aburto JM, 2022, INT J EPIDEMIOL, V51, P63, DOI 10.1093/ije/dyab207; Afifi TO, 2021, VACCINE, V39, P3473, DOI 10.1016/j.vaccine.2021.05.026; [Anonymous], CZECH REPUBLIC IMPOS; [Anonymous], RKI CORONAVIRUS SARS; [Anonymous], BNS NENORINCIUJU SKI; [Anonymous], MEASURES CONTAIN SPR; [Anonymous], LETS TALK PROTECTION; [Anonymous], TRUST DEFICIT STALLS; [Anonymous], RESTRICTIONS BE LOOS; [Anonymous], STANDARD EUROBAROMET; [Anonymous], EKONOMIKOS IRINOVACI; [Anonymous], 2021, ECONOMIST 1113; [Anonymous], COVID 19 HLTH PASSES; [Anonymous], COVID PASS ESTONIA E; [Anonymous], WHO-EURO-2020-1160-40906-55390-Eng.Pdf; [Anonymous], COVID 19 VACCINE TRA; [Anonymous], MACRON GAMBLED CORON; [Anonymous], GALIMYBIU PASAS SALI; [Anonymous], SIULO NAUJA TVARKA D; [Anonymous], 2021, BBC NEWS; [Anonymous], Statistics | Eurostat; [Anonymous], BNS DAUGIAU VEIKLU R; [Anonymous], POLSATU POLSAT NEWS; [Anonymous], IPSOS WEF GLOBAL VIE; [Anonymous], EU DIGITAL COVID CER; BNS U.A, PROT PRIES GAL PAS V; Bono SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050515; Boytchev H, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2412; Butterwick R, 2021, HIST TODAY, V71, P50; Chwalba A., 2020, POLISH LITHUANIAN CO; Covidvax, LIV LIV COVID 19 VAC; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040711; Edwards B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248892; Feleszko W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010044; Fuchs-Schundeln N, 2020, J ECON PERSPECT, V34, P172, DOI 10.1257/jep.34.2.172; Giuffrida A., 2021, GUARDIAN; Grzymala-Busse A, 2016, CURR HIST, V115, P89; Henley J., 2021, GUARDIAN; Islam N, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj-2021-066768; Jung F, 2020, CLIN HEMORHEOL MICRO, V75, P13, DOI 10.3233/CH-209006; Kluver H, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2109543118; Kourlaba G, 2021, GLOB HEALTH RES POL, V6, DOI 10.1186/s41256-021-00188-1; Mackinnon A, 2000, COMPUT BIOL MED, V30, P127, DOI 10.1016/S0010-4825(00)00006-8; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Niestadt M., 69876326 PE; Parode Tyrimas., KIEK LIETUVOS GYVENT; Paterlini M, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2575; Petravic L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030247; Raciborski F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9091000; Saban M, 2021, PREV MED, V153, DOI 10.1016/j.ypmed.2021.106763; Saeima Adopts, LAW; Safaei J., 2012, EC RES INT, V2012, P1, DOI [10.1155/2012/137412, DOI 10.1155/2012/137412]; Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Senjorams Ismokos., PASISKIEPIJUSIEMS NU; Simko V., 2013, J POL SCI PUB AFF, V2, P123, DOI [10.4172/2332-0761.1000123, DOI 10.4172/2332-0761.1000123]; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Sowa P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080876; Tyrimas, VILN NUST SKIEP PRIE; Walkowiak MP, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101153	61	4	4	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1498	10.3390/vaccines9121498			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YG3MM	34960245	Green Published, gold			2022-04-29	WOS:000742396600001
J	Alcendor, DJ				Alcendor, Donald J.			Targeting COVID Vaccine Hesitancy in Rural Communities in Tennessee: Implications for Extending the COVID-19 Pandemic in the South	VACCINES			English	Review						COVID-19; Tennessee; rural; urban; vaccine hesitancy; vaccination rate	UNITED-STATES	Approximately 40% of Tennesseans are vaccinated fully, due mainly to higher vaccination levels within urban counties. Significantly lower rates are observed in rural counties. Surveys suggest COVID-19 vaccine hesitancy is entrenched mostly among individuals identifying as white, rural, Republican, and evangelical Christian. Rural counties represent 70 of the total 95 counties in Tennessee, and vaccine hesitancy signifies an immediate public health crisis likely to extend the COVID-19 pandemic. Tennessee is a microcosm of the pandemic's condition in the Southern U.S. Unvaccinated communities are the greatest contributors of new COVID-19 infections, hospitalizations, and deaths. Rural Tennesseans have a long history of cultural conservatism, poor health literacy, and distrust of government and medical establishments and are more susceptible to misinformation and conspiracy theories. Development of novel strategies to increase vaccine acceptance is essential. Here, I examine the basis of COVID-19 following SARS-CoV-2 infection and summarize the pandemic's extent in the South, current vaccination rates and efforts across Tennessee, and underlying factors contributing to vaccine hesitancy. Finally, I discuss specific strategies to combat COVID-19 vaccine hesitancy. We must develop novel strategies that go beyond financial incentives, proven ineffective toward vaccinations. Successful strategies for vaccine acceptance of rural Tennesseans could increase acceptance among unvaccinated rural U.S. populations.	[Alcendor, Donald J.] Meharry Med Coll, Sch Med, Dept Microbiol Immunol & Physiol, Ctr AIDS Hlth Dispar Res, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA; [Alcendor, Donald J.] Meharry Med Coll, Sch Med, Dept Internal Med, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA		Alcendor, DJ (通讯作者)，Meharry Med Coll, Sch Med, Dept Microbiol Immunol & Physiol, Ctr AIDS Hlth Dispar Res, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA.; Alcendor, DJ (通讯作者)，Meharry Med Coll, Sch Med, Dept Internal Med, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA.	dalcendor@mmc.edu			Research Centers in Minority Institutions (RCMI) program [U54MD007586-01]; NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [1OT2HL156812-01, 19-312-0217571-66101L]	D.J.A. is supported by the Research Centers in Minority Institutions (RCMI) program grant (U54MD007586-01). D.J.A was also supported by NHLBI: 1OT2HL156812-01/Subcontract Number 19-312-0217571-66101L.	Adunlin G, 2021, J RURAL HEALTH, V37, P153, DOI 10.1111/jrh.12439; Altmann DM, 2021, SCIENCE, V371, P1103, DOI 10.1126/science.abg7404; Aschwanden C, 2020, NATURE, V587, P26, DOI 10.1038/d41586-020-02948-4; BASSETTI M, 2020, EUR J CLIN INVE 0131, DOI DOI 10.1111/eci.13209; Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1; Chan JFW, 2013, TRENDS MICROBIOL, V21, P544, DOI 10.1016/j.tim.2013.05.005; Coustasse A, 2021, J AMBUL CARE MANAG, V44, P71, DOI 10.1097/JAC.0000000000000360; Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9; Du Toit A, 2020, NAT REV MICROBIOL, V18, P123, DOI 10.1038/s41579-020-0332-0; Gatwood J, 2021, AM J HEALTH-SYST PH, V78, P879, DOI 10.1093/ajhp/zxab099; Hamel L., 2020, KFF COVID 19 VACCINE; Hartenian E, 2020, J BIOL CHEM, V295, P12910, DOI 10.1074/jbc.REV120.013930; Hildreth JEK, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050489; Huang CZ, 2020, LIMIT ANALYSIS THEORY OF THE SOIL MASS AND ITS APPLICATION, P1, DOI 10.1007/978-981-15-1572-9_1; International Committee on Taxonomy of Viruses, VIR TAX 2017 REL; Jha A., HLTH AFFAIRS AM HOSP; Jin J, 2021, NAT MED, V27, P264, DOI 10.1038/s41591-020-01191-8; Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924; Li Qun, 2020, N Engl J Med, V382, P1199, DOI 10.1056/NEJMoa2001316; Livingston Edward H, 2021, JAMA, V325, P1575, DOI 10.1001/jama.2021.2927; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; McLaughlin JM, 2021, CLIN INFECT DIS, V73, pE1814, DOI 10.1093/cid/ciaa1729; Murthy BP, 2021, MMWR-MORBID MORTAL W, V70, P759, DOI 10.15585/mmwr.mm7020e3; Oliver SE, 2021, MMWR-MORBID MORTAL W, V69, P1653, DOI 10.15585/mmwr.mm695152e1; Otto SP, 2021, CURR BIOL, V31, pR918, DOI 10.1016/j.cub.2021.06.049; Peters DJ, 2020, J RURAL HEALTH, V36, P446, DOI 10.1111/jrh.12477; Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686; Privor-Dumm L, 2020, J HEALTH COMMUN, V25, P827, DOI 10.1080/10810730.2021.1873463; Prusaczyk Beth, 2021, Open Forum Infect Dis, V8, pofab152, DOI 10.1093/ofid/ofab152; Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433; Satija N, 2007, ANN NY ACAD SCI, V1102, P26, DOI 10.1196/annals.1408.002; Self WH, 2021, MMWR-MORBID MORTAL W, V70, P1337, DOI 10.15585/mmwr.mm7038e1; Singh J, 2021, NAT MED, V27, P1131, DOI 10.1038/s41591-021-01397-4; Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003; Traynor K, 2021, AM J HEALTH-SYST PH, V78, P1162, DOI 10.1093/ajhp/zxab185; Turner PJ, 2021, J ALLER CL IMM-PRACT, V9, P3568, DOI 10.1016/j.jaip.2021.06.035; Walensky RP, 2021, JAMA-J AM MED ASSOC, V325, P1037, DOI 10.1001/jama.2021.2294; Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839; Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11; World Health Organization, 2020, GLOBAL TUBERCULOSIS	40	3	3	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1279	10.3390/vaccines9111279			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XH3IB	34835210	Green Published, gold			2022-04-29	WOS:000725331200001
J	Hammad, NM; Marei, A; El-Didamony, G; Mortada, Z; Elradi, M; Afifi, AHM; Kadry, HM				Hammad, Noha M.; Marei, Ayman; El-Didamony, Gamal; Mortada, Zeinb; Elradi, Mona; Afifi, Amira Hamed Mohamed; Kadry, Heba M.			Predictors of the Therapeutic Response to Intralesional Bivalent HPV Vaccine in Wart Immunotherapy	VACCINES			English	Article						anogenital warts; bivalent HPV vaccine; cutaneous warts; human papillomavirus; interferon-gamma; interleukin-4; wart immunotherapy	HUMAN-PAPILLOMAVIRUS TYPE-16; IMMUNE-RESPONSES; MULTIPLE WARTS; INNATE; MUMPS; ASSOCIATION; MEASLES; CANDIDA	Variable intralesional immunotherapies have recently been proposed as a means of achieving a successful eradication of recurrent and recalcitrant human papillomavirus (HPV)-induced cutaneous and anogenital warts. The bivalent HPV vaccine is one of the newly proposed immunotherapeutic agents. We investigated the role of interleukin-4 (IL-4) and interferon-gamma (IFN-gamma) as ex vivo immunologic predictors to estimate the response to the bivalent HPV vaccine as a potential immunotherapy for cutaneous and anogenital warts. Heparinized blood samples were withdrawn from forty patients with multiple recurrent recalcitrant cutaneous and anogenital warts and forty matched healthy control subjects. Whole blood cultures were prepared with and without bivalent HPV vaccine stimulation. Culture supernatants were harvested and stored for IL-4 and IFN-gamma measurements using an enzyme-linked immunosorbent assay. A comparative analysis of IL-4 and IFN-gamma levels in culture supernatants revealed a non-significant change between the patient and control groups. The bivalent HPV vaccine stimulated cultures exhibited a non-significant reduction in IL-4 levels within both groups. IFN-gamma was markedly induced in both groups in response to bivalent HPV vaccine stimulation. The bivalent HPV vaccine can give a sensitive IFN-gamma immune response ex vivo, superior to IL-4 and sufficient to predict both the successful eradication of HPV infection and the ultimate clearance of cutaneous and anogenital warts when the bivalent HPV vaccine immunotherapy is applied.	[Hammad, Noha M.; Marei, Ayman; Kadry, Heba M.] Zagazig Univ, Fac Med, Dept Med Microbiol & Immunol, Zagazig 44519, Egypt; [Hammad, Noha M.] Viral Infect Working Grp Int Soc Antimicrobial Ch, London, England; [El-Didamony, Gamal; Mortada, Zeinb] Zagazig Univ, Fac Sci, Dept Bot & Microbiol, Zagazig 44519, Egypt; [Elradi, Mona] Zagazig Univ, Fac Med, Dept Dermatol Venereol & Androl, Zagazig 44519, Egypt; [Afifi, Amira Hamed Mohamed] Zagazig Univ, Fac Med, Dept Clin Pathol, Zagazig 44519, Egypt		Hammad, NM (通讯作者)，Zagazig Univ, Fac Med, Dept Med Microbiol & Immunol, Zagazig 44519, Egypt.; Hammad, NM (通讯作者)，Viral Infect Working Grp Int Soc Antimicrobial Ch, London, England.	nmhammad@medicine.zu.edu.eg; ayman1067@hotmail.com; eldidamonyg@gmail.com; Hopema1900@hotmail.com; mona.radi86@gmail.com; amira_hamed79@hotmail.com; hmshalapy@medicine.zu.edu.eg	Hammad, Noha/X-7531-2019	Hammad, Noha/0000-0002-9400-7822; El- Didamony, Gamal/0000-0003-3342-307X			Aldahan AS, 2016, DERMATOL THER, V29, P197, DOI 10.1111/dth.12352; Amador-Molina A, 2013, VIRUSES-BASEL, V5, P2624, DOI 10.3390/v5112624; Amer A, 2021, DERMATOL THER, V34, DOI 10.1111/dth.14667; Arany I, 1999, ANTIVIR RES, V43, P55, DOI 10.1016/S0166-3542(99)00033-9; Ault KA, 2007, GYNECOL ONCOL, V107, pS31, DOI 10.1016/j.ygyno.2007.08.059; Boghdadi G., 2017, EGYPT J MED MICROBIO, V38, P1, DOI [10.12816/0046295, DOI 10.12816/0046295]; Bossart S, 2020, ACTA DERM-VENEREOL, V100, DOI 10.2340/00015555-3437; Casella CR, 2008, CELL MOL LIFE SCI, V65, P3231, DOI 10.1007/s00018-008-8228-6; Castro F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00847; Cheng YP, 2012, DERMATOL SIN, V30, P85, DOI 10.1016/j.dsi.2012.04.002; Choi YJ, 2016, J GYNECOL ONCOL, V27, DOI 10.3802/jgo.2016.27.e21; Dai Y, 2008, INT J GYNECOL CANCER, V18, P295, DOI 10.1111/j.1525-1438.2007.01024.x; Daniel BS, 2013, JAMA DERMATOL, V149, P370, DOI 10.1001/jamadermatol.2013.1463; Deenadayalan Anbarasu, 2013, BMC Res Notes, V6, P120, DOI 10.1186/1756-0500-6-120; Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474; Fields JR, 2020, PEDIATR DERMATOL, V37, P265, DOI 10.1111/pde.14094; Gattoc L, 2013, OBSTET GYN CLIN N AM, V40, P177, DOI 10.1016/j.ogc.2013.03.007; Gonçalves Maria Alice Guimarães, 2004, Braz J Infect Dis, V8, P1, DOI 10.1590/S1413-86702004000100001; Hammad NM, 2020, BRAZ J MICROBIOL, V51, P1673, DOI 10.1007/s42770-020-00322-0; Harper DM, 2009, EXPERT REV VACCINES, V8, P1663, DOI 10.1586/ERV.09.123; Herrin DM, 2014, HUM VACC IMMUNOTHER, V10, P3446, DOI 10.4161/hv.34408; Hong JH, 2010, INT J GYNECOL CANCER, V20, P1011, DOI 10.1111/IGC.0b013e3181e513e5; Horn TD, 2005, ARCH DERMATOL, V141, P589, DOI 10.1001/archderm.141.5.589; Junttila IS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00888; Keam SJ, 2008, DRUGS, V68, P359, DOI 10.2165/00003495-200868030-00007; Kuan LY, 2017, J AM ACAD DERMATOL, V76, pAB159; Monie A, 2008, BIOL-TARGETS THER, V2, P107; Nofal A, 2020, J AM ACAD DERMATOL, V82, P94, DOI 10.1016/j.jaad.2019.07.070; Nofal A, 2017, INT J DERMATOL, V56, P1003, DOI 10.1111/ijd.13709; Nofal A, 2015, INT J DERMATOL, V54, P667, DOI 10.1111/ijd.12480; Nofal A, 2013, AM J CLIN DERMATOL, V14, P253, DOI 10.1007/s40257-013-0018-8; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Leto MDP, 2011, AN BRAS DERMATOL, V86, P306, DOI 10.1590/S0365-05962011000200014; Renoux VM, 2011, EUR J IMMUNOL, V41, P3240, DOI 10.1002/eji.201141693; Scott M, 2001, CLIN DIAGN LAB IMMUN, V8, P209, DOI 10.1128/CDLI.8.2.209-220.2001; Shaheen A.A., 2019, EGYPT J MED MICROBIO, V28, P129; Shaheen MA, 2015, DERMATOL THER, V28, P194, DOI 10.1111/dth.12230; Signore RJ, 2002, CUTIS, V70, P185; Sinha S, 2015, INDIAN J DERMATOL, V60, P118, DOI 10.4103/0019-5154.152502; Spurgeon ME, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080219; Stanley MA, 2009, INDIAN J MED RES, V130, P266; Sterling JC, 2014, BRIT J DERMATOL, V171, P696, DOI 10.1111/bjd.13310; Thappa Devinder M, 2016, Indian Dermatol Online J, V7, P364; WIDEROFF L, 1995, J INFECT DIS, V172, P1425, DOI 10.1093/infdis/172.6.1425; Yang MY, 2019, J DERMATOL TREAT, V30, P405, DOI 10.1080/09546634.2018.1527006	45	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1280	10.3390/vaccines9111280			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH9FA	34835211	gold, Green Published			2022-04-29	WOS:000725730300001
J	Kajungu, D; Nambasa, V; Muhoozi, M; Tusabe, J; Kampmann, B; Todd, J				Kajungu, Dan; Nambasa, Victoria; Muhoozi, Michael; Tusabe, Joan; Kampmann, Beate; Todd, Jim			Using Population-Based Structures to Actively Monitor AEFIs during a Mass Immunization Campaign-A Case of Measles-Rubella and Polio Vaccines	VACCINES			English	Article						active monitoring; pharmacovigilance; AEFIs; mass vaccination campaigns	EVENTS FOLLOWING IMMUNIZATION; HEALTH; RISK; AGE	Active vaccine pharmacovigilance complements the standard passive or spontaneous surveillance system, which suffers from low reporting rates. This study aimed at utilizing population-based structures to report and profile adverse events following immunization (AEFI) with the measles and rubella vaccine (MR), or MR in combination with the bivalent oral polio vaccine (bOPV 1 & 3) (MR & bOPV), during mass vaccination in Uganda. Caretakers of children at home (less than 5 years) and schoolgoing children were followed up on and encouraged to report any AEFIs on day one, 2-3 days, 10 days, and 14 days after vaccination at school by their teachers and at-home, community-based village health teams. Out of 9798 children followed up on, 382 (3.9%) reported at least one AEFI, and in total, 517 AEFIs were reported. For MR, high temperature (21%), general feeling of weakness (19.3%), and headache (13%) were the most reported AEFIs, though there were variations on the days when they were reported. For the combination dose of MR & bOPV, high temperature (44%), rash (17%), general feeling of weakness (13%), and diarrhoea (8%) were the most common adverse events following immunization reported by caretakers. All 382 children cleared the AEFIs within 2 days, with 343 (90%) children reporting mild or moderate AEFIs and only 39 (10%) reporting severe AEFIs. The reported AEFIs are known and are mentioned in the vaccine leaflets with similar severity classification. Rates of AEFIs differed with the number of days after receiving the immunization. Conclusion: Active surveillance for AEFIs provides additional important information to national vaccine regulatory bodies. It reassures the public that vaccines are safe and that their safety is being taken seriously in Uganda, which would improve vaccine acceptability and confidence in the health system. Piggybacking on existing structures such as village health team members (for children at home) and teachers (for schoolgoing children) facilitates reaching vaccine recipients and increases reporting rates. Therefore, studies using active reporting of AEFIs should be conducted at regular intervals to report the overall incidence of AEs and to monitor trends and changes.	[Kajungu, Dan; Muhoozi, Michael; Tusabe, Joan] Makerere Univ, Makerere Univ Ctr Hlth & Populat Res MUCHAP, POB 7062, Kampala, Uganda; [Kajungu, Dan] Stellenbosch Univ, Dept Global Hlth, ZA-7602 Stellenbosch, South Africa; [Nambasa, Victoria] Natl Drug Author NDA, Natl Pharmacovigilance Ctr, POB 23096, Kampala, Uganda; [Kampmann, Beate] London Sch Hyg & Trop Med, Vaccine Ctr, Keppel St, London WC1E 7HT, England; [Todd, Jim] London Sch Hyg & Trop Med, Dept Populat Hlth, Keppel St, London WC1E 7HT, England		Kajungu, D (通讯作者)，Makerere Univ, Makerere Univ Ctr Hlth & Populat Res MUCHAP, POB 7062, Kampala, Uganda.; Kajungu, D (通讯作者)，Stellenbosch Univ, Dept Global Hlth, ZA-7602 Stellenbosch, South Africa.	dan.kajungu@gmail.com; vnambasa@nda.or.ug; muhoozimusi@gmail.com; jtusab@gmail.com; Beate.Kampmann@lshtm.ac.uk; Jim.Todd@lshtm.ac.uk	Muhoozi, Michael/AAD-4563-2022	Muhoozi, Michael/0000-0003-2460-9980; Kampmann, Beate/0000-0002-6546-4709; Todd, Jim/0000-0001-5918-4914; Kajungu PhD, Dan/0000-0002-3363-7062	European and Developing Countries Clinical Trials Partnership (EDCTP) [TMA2016CDF-1563]; IMPRINT Network [ITCR079018]	This research was funded by the European and Developing Countries Clinical Trials Partnership (EDCTP), grant number TMA2016CDF-1563. The APC is funded by IMPRINT Network (Grant Number: ITCR079018).	Aherkar R., 2016, INT J BASIC CLIN PHA, P609, DOI [10.18203/2319-2003.ijbcp20161423, DOI 10.18203/2319-2003.IJBCP20161423]; Ahrion A., 2016, WEEKLY EPIDEMIOLOGIC, V91, P13; [Anonymous], WHO Module 3: Adverse Events following Immunization; Casey JA, 2016, ANNU REV PUBL HEALTH, V37, P61, DOI 10.1146/annurev-publhealth-032315-021353; Chen RT, 2015, VACCINE, V33, pD46, DOI 10.1016/j.vaccine.2015.06.073; Danova J, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4083-4; Gattinara G.C., 2017, VACCINES-BASEL, DOI [10.5772/intechopen.68697, DOI 10.5772/INTECHOPEN.68697]; Gault N, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-016-0278-0; Kajungu D, 2020, INT J EPIDEMIOL, V49, P1082, DOI 10.1093/ije/dyaa064; Khazaei S, 2016, INT J PEDIATR-MASSHA, V4, P1697; Kiguba R, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005869; Klein NP, 2010, PEDIATRICS, V126, pE1, DOI 10.1542/peds.2010-0665; Lindley MC, 2008, PEDIATRICS, V121, pS46, DOI 10.1542/peds.2007-1115F; Masuka JT, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7482-x; Mihigo R., 2018, J IMMUNOL SCI, V2, P80, DOI [10.29245/2578-3009/2018/si.1112, DOI 10.29245/2578-3009/2018/SI.1112]; Ministry of Health Uganda Ministry of Health, 2019, PRESS STAT UPD NAT M; Nzolo D, 2013, PATHOG GLOB HEALTH, V107, P381, DOI 10.1179/2047773213Y.0000000113; Remy Vanessa, 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.27041; Rowhani-Rahbar A, 2013, JAMA PEDIATR, V167, P1111, DOI 10.1001/jamapediatrics.2013.2745; Sebastian Juny, 2019, Ther Adv Vaccines Immunother, V7, p2515135519889000, DOI 10.1177/2515135519889000; Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035; Swissmedic, 2017, SUMM ADV EV FOLL IMM; Swissmedic, 2016, SUMM ADV EV FOLL IMM; WHO, 2014, MUMPS RUB VACC; WHO, 2008, WHO GUID STAND EC EV; WHO, 2018, MOD 10 PHARM GLOB HL; Who U. World Bank, 2009, STAT WORLDS VACC IMM, P130; Woodruff B, 2014, USE EPIDEMIOLOGICAL; Zhou W., 2003, SURVEILLANCE SAFETY	29	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1293	10.3390/vaccines9111293			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI0FQ	34835224	gold, Green Published, Green Accepted			2022-04-29	WOS:000725799500001
J	Li, ZW; Liu, XT; Liu, MY; Wu, ZY; Liu, Y; Li, WM; Liu, MM; Wang, XN; Gao, B; Luo, YX; Li, X; Tao, LX; Wang, W; Guo, XH				Li, Zhiwei; Liu, Xiangtong; Liu, Mengyang; Wu, Zhiyuan; Liu, Yue; Li, Weiming; Liu, Mengmeng; Wang, Xiaonan; Gao, Bo; Luo, Yanxia; Li, Xia; Tao, Lixin; Wang, Wei; Guo, Xiuhua			The Effect of the COVID-19 Vaccine on Daily Cases and Deaths Based on Global Vaccine Data	VACCINES			English	Article						COVID-19 cases; COVID-19 deaths; vaccination; prediction; worldwide		Background: Coronavirus disease 2019 (COVID-19), a global pandemic, has caused over 216 million cases and 4.50 million deaths as of 30 August 2021. Vaccines can be regarded as one of the most powerful weapons to eliminate the pandemic, but the impact of vaccines on daily COVID-19 cases and deaths by country is unclear. This study aimed to investigate the correlation between vaccines and daily newly confirmed cases and deaths of COVID-19 in each country worldwide. Methods: Daily data on firstly vaccinated people, fully vaccinated people, new cases and new deaths of COVID-19 were collected from 187 countries. First, we used a generalized additive model (GAM) to analyze the association between daily vaccinated people and daily new cases and deaths of COVID-19. Second, a random effects meta-analysis was conducted to calculate the global pooled results. Results: In total, 187 countries and regions were included in the study. During the study period, 1,011,918,763 doses of vaccine were administered, 540,623,907 people received at least one dose of vaccine, and 230,501,824 people received two doses. For the relationship between vaccination and daily increasing cases of COVID-19, the results showed that daily increasing cases of COVID-19 would be reduced by 24.43% [95% CI: 18.89, 29.59] and 7.50% [95% CI: 6.18, 8.80] with 10,000 fully vaccinated people per day and at least one dose of vaccine, respectively. Daily increasing deaths of COVID-19 would be reduced by 13.32% [95% CI: 3.81, 21.89] and 2.02% [95% CI: 0.18, 4.16] with 10,000 fully vaccinated people per day and at least one dose of vaccine, respectively. Conclusions: These findings showed that vaccination can effectively reduce the new cases and deaths of COVID-19, but vaccines are not distributed fairly worldwide. There is an urgent need to accelerate the speed of vaccination and promote its fair distribution across countries.	[Li, Zhiwei; Liu, Xiangtong; Liu, Mengyang; Wu, Zhiyuan; Liu, Yue; Li, Weiming; Liu, Mengmeng; Wang, Xiaonan; Gao, Bo; Luo, Yanxia; Tao, Lixin; Guo, Xiuhua] Capital Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, 10 Xi Tou Tiao,You An Men St, Beijing 100069, Peoples R China; [Li, Zhiwei; Liu, Xiangtong; Liu, Mengyang; Wu, Zhiyuan; Liu, Yue; Li, Weiming; Liu, Mengmeng; Wang, Xiaonan; Gao, Bo; Luo, Yanxia; Tao, Lixin; Wang, Wei; Guo, Xiuhua] Capital Med Univ, Beijing Municipal Key Lab Clin Epidemiol, Beijing 100071, Peoples R China; [Li, Xia] La Trobe Univ, Dept Math & Stat, Melbourne, Vic 3086, Australia; [Wang, Wei; Guo, Xiuhua] Edith Cowan Univ, Ctr Precis Hlth, Perth, WA 6027, Australia		Guo, XH (通讯作者)，Capital Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, 10 Xi Tou Tiao,You An Men St, Beijing 100069, Peoples R China.; Guo, XH (通讯作者)，Capital Med Univ, Beijing Municipal Key Lab Clin Epidemiol, Beijing 100071, Peoples R China.; Guo, XH (通讯作者)，Edith Cowan Univ, Ctr Precis Hlth, Perth, WA 6027, Australia.	lizhiwei@ccmu.edu.cn; xiangtongl@ccmu.edu.cn; ysq@mail.ccmu.edu.cn; wuxiaozhi@ccmu.edu.cn; liuyue@ccmu.edu.cn; lwming@ccmu.edu.cn; liumengmeng@ccmu.edu.cn; xiaonanw@ccmu.edu.cn; gaobo@ccmu.edu.cn; lyx100@ccmu.edu.cn; x.li2@latrobe.edu.au; taolixin@ccmu.edu.cn; wei.wang@ecu.edu.au; statguo@ccmu.edu.cn		Guo, Xiuhua/0000-0001-6657-6940; wang, wei/0000-0002-1430-1360	Program of the Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [82003559]	This study was supported by grants from the Program of the Natural Science Fund of China (No. 82003559). The sponsors of the study had no role in the study design, data collection, data analysis, interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.	Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P1423, DOI 10.1016/j.jaip.2020.12.047; Barco A Asunsolo Del, 2020, Medicine (Madr), V13, P1297, DOI 10.1016/j.med.2020.12.011; Brisse M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583077; Choi EPH, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103740; Chung JY, 2021, ADV DRUG DELIVER REV, V170, P1, DOI 10.1016/j.addr.2020.12.011; Funk CD, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030418; Garcia-Montero C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050433; Habas K, 2020, EXPERT REV ANTI-INFE, V18, P1201, DOI 10.1080/14787210.2020.1797487; Haynes BF, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abe0948; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Kis Z, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201800376; Li YD, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00695-2; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Lu S, 2009, CURR OPIN IMMUNOL, V21, P346, DOI 10.1016/j.coi.2009.05.016; Majumder J, 2021, AAPS J, V23, DOI 10.1208/s12248-020-00532-2; Marian AJ, 2021, CARDIOVASC PATHOL, V50, DOI 10.1016/j.carpath.2020.107278; Mathieu E, 2021, NAT HUM BEHAV, V5, P947, DOI 10.1038/s41562-021-01122-8; Mehrotra DV, 2021, ANN INTERN MED, V174, P221, DOI 10.7326/M20-6169; Mohamadian M, 2021, J GENE MED, V23, DOI 10.1002/jgm.3303; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pollard CA, 2020, PHYSIOL GENOMICS, V52, P549, DOI 10.1152/physiolgenomics.00089.2020; Prata DN, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.138862; Qi HC, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138778; Saad-Roy CM, 2021, SCIENCE, V372, P363, DOI 10.1126/science.abg8663; Soiza RL, 2021, AGE AGEING, V50, P279, DOI 10.1093/ageing/afaa274; Soleimanpour S, 2021, EXPERT REV VACCINES, V20, P23, DOI [10.1080/14760584.2021.1875824, 10.1080/14760584.2021.1875824CrossMarkLogo]; Spencer AJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23173-1; Talevi D, 2020, RIV PSICHIATR, V55, P137, DOI 10.1708/3382.33569; Tebas P, 2019, J INFECT DIS, V220, P400, DOI 10.1093/infdis/jiz132; Telenti A, 2021, NATURE, V596, P495, DOI 10.1038/s41586-021-03792-w; Dao TL, 2021, EUR J CLIN MICROBIOL, V40, P13, DOI 10.1007/s10096-020-04088-z; Trevor Hastie RT, 1990, GEN ADDITIVE MODELS; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Zhang CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00594	36	0	0	11	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1328	10.3390/vaccines9111328			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG0ZG	34835259	Green Published, gold			2022-04-29	WOS:000724489300001
J	Liang, HR; Zhang, LX; Fu, XZ; Lin, Q; Liu, LH; Niu, YJ; Luo, X; Huang, ZB; Li, NQ				Liang, Hongru; Zhang, Lixi; Fu, Xiaozhe; Lin, Qiang; Liu, Lihui; Niu, Yinjie; Luo, Xia; Huang, Zhibin; Li, Ningqiu			Development of a Double-Antibody Sandwich ELISA for Rapid Detection of the MCP Antigen Concentration in Inactivated ISKNV Vaccines	VACCINES			English	Article						ISKNV; double-antibody sandwich ELISA; monoclonal antibody; inactivated vaccine; antigen concentration	KIDNEY NECROSIS VIRUS; INFECTIOUS SPLEEN; SINIPERCA-CHUATSI; FISH; PROTEIN; CANDIDATE	Infectious spleen and kidney necrosis virus (ISKNV) resulted in severe systemic diseases with high morbidity and mortality in Siniperca chuatsi. Vaccination is the primary method for effective prevention and control of these diseases. The development of inactivated ISKNV vaccines made some progress, but the technique of quality evaluation is scarce. Herein, a measurement of the MCP (major capsid protein) antigen concentration for the inactivated ISKNV vaccine was developed by double-antibody sandwich ELISA. Firstly, mouse monoclonal antibodies against ISKNV particles and MCP were generated. Then, a double-antibody sandwich ELISA was developed using the monoclonal antibody 1C8 1B9 as the capture antibody and Biotin-3B12 6B3 as the detection antibody. A standard curve was generated using the MCP concentration versus OD value with the linear range of concentration of 4.69~300 ng/mL. The assay sensitivity was 0.9 ng/mL. The antigen content of three batches of inactivated ISKNV vaccines was quantitatively detected using the double-antibody sandwich ELISA. The results showed that MCP antigen contents of inactivated ISKNV vaccines were positively correlated with the viral titers. The newly established double-antibody sandwich ELISA provided a useful tool for the detection of antigen quality for ISKNV inactivated vaccines.	[Liang, Hongru; Zhang, Lixi; Fu, Xiaozhe; Lin, Qiang; Liu, Lihui; Niu, Yinjie; Luo, Xia; Huang, Zhibin; Li, Ningqiu] Chinese Acad Fishery Sci, Pearl River Fisheries Res Inst, Minist Agr & Rural Affairs,Key Lab Fishery Drug D, Guangdong Prov Key Lab Aquat Anim Immune Technol, Guangzhou 510380, Peoples R China		Li, NQ (通讯作者)，Chinese Acad Fishery Sci, Pearl River Fisheries Res Inst, Minist Agr & Rural Affairs,Key Lab Fishery Drug D, Guangdong Prov Key Lab Aquat Anim Immune Technol, Guangzhou 510380, Peoples R China.	hrliang10@hotmail.com; zhanglixi2021@163.com; fuxiaozhe-1998@163.com; lin9902057@163.com; lhliu0614@163.com; niuyinjie0530@163.com; lxwenhao@163.com; hzb1393@163.com; liningq@126.com			National Key Research and Development Program of China [2019YFD0900103]; National Natural Science FundNational Natural Science Foundation of China (NSFC) [31872589]; Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2020A1515011574]; China-ASEAN Maritime Cooperation Fund; Guangdong Provincial Special Fund for Modern Agriculture Industry Technology Innovation Teams [2019KJ140, 2019KJ141]	FundingThis work was funded by the National Key Research and Development Program of China (2019YFD0900103), the National Natural Science Fund (31872589), the Natural Science Foundation of Guangdong Province (grant number 2020A1515011574), China-ASEAN Maritime Cooperation Fund and Guangdong Provincial Special Fund for Modern Agriculture Industry Technology Innovation Teams (2019KJ140, 2019KJ141).	Balachandra D, 2021, ACTA TROP, V221, DOI 10.1016/j.actatropica.2021.105986; Boonyalit T., 2021, PROTEIN EXPR PURIFIC, V184; Chen SL, 2016, J IMMUNOL METHODS, V436, P16, DOI 10.1016/j.jim.2016.05.011; Ding XX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108623; Feng X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149569; Fu X, 2015, J FISH BIOL, V86, P32, DOI 10.1111/jfb.12540; Fu XZ, 2015, FISH SHELLFISH IMMUN, V46, P200, DOI 10.1016/j.fsi.2015.05.052; Fu XZ, 2014, FISH SHELLFISH IMMUN, V40, P259, DOI 10.1016/j.fsi.2014.07.012; Fu YT, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13081617; Hartati L., 2020, V454, P012182, DOI 10.1088/1755-1315/454/1/012182; He JG, 2002, AQUACULTURE, V204, P11, DOI 10.1016/S0044-8486(01)00639-1; Hnasko L.H., 2015, ELISA; Jia KT, 2013, J VIROL, V87, P3027, DOI 10.1128/JVI.00552-12; Jung-Schroers V, 2016, DIS AQUAT ORGAN, V119, P239, DOI 10.3354/dao02995; Krebs T, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251414; Li NQ, 2015, FISH SHELLFISH IMMUN, V42, P88, DOI 10.1016/j.fsi.2014.10.008; Lin Q, 2017, MICROB PATHOGENESIS, V111, P422, DOI 10.1016/j.micpath.2017.09.002; Sas MA, 2018, ANTIVIR RES, V151, P24, DOI 10.1016/j.antiviral.2018.01.006; Zhu LJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep16092	19	0	0	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1264	10.3390/vaccines9111264			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG7XJ	34835196	Green Published, gold			2022-04-29	WOS:000724962400001
J	Mohanraj, D; Bicknell, K; Bhole, M; Webber, C; Taylor, L; Whitelegg, A				Mohanraj, Dinesh; Bicknell, Kelly; Bhole, Malini; Webber, Caroline; Taylor, Lorna; Whitelegg, Alison			Antibody Responses to SARS-CoV-2 Infection-Comparative Determination of Seroprevalence in Two High-Throughput Assays versus a Sensitive Spike Protein ELISA	VACCINES			English	Article						SARS-CoV-2; Roche Elecsys SARS-CoV-2 antibody assay; Abbott IgG antibody assay; The Binding Site total antibody assay		Robust assay development for SARS-CoV-2 serological testing requires assessment of asymptomatic and non-hospitalised individuals to determine if assays are sensitive to mild antibody responses. Our study evaluated the performance characteristics of two high-throughput SARS-CoV-2 IgG nucleocapsid assays (Abbott Architect and Roche) and The Binding Site (TBS) Anti-Spike IgG/A/M ELISA kit in samples from healthcare workers (HCWs). The 252 samples were collected from multi-site NHS trusts and analysed for SARS-CoV-2 serology. Assay performance was evaluated between these three platforms and ROC curves were used to redefine the Abbott threshold. Concordance between Abbott and TBS was 66%. Any discrepant results were analysed using Roche, which showed 100% concordance with TBS. Analysis conducted in HCWs within 58 days post-PCR result demonstrated 100% sensitivity for both Abbott and Roche. Longitudinal analysis for > 100 days post-PCR led to sensitivity of 77.2% and 100% for Abbott and Roche, respectively. A redefined Abbott threshold (0.64) increased sensitivity to 90%, producing results comparable to TBS and Roche. The manufacturer's threshold set by Abbott contributes to lower sensitivity and elevated false-negative occurrences. Abbott performance improved upon re-optimisation of the cut-off threshold. Our findings provided evidence that TBS can be used as bespoke alternative for SARS-CoV-2 serology analysis where high-throughput platforms are not feasible on site.	[Mohanraj, Dinesh] Univ Manchester, Fac Med Biol & Hlth, Manchester M13 9PL, Lancs, England; [Bicknell, Kelly] Portsmouth Hosp Univ NHS Trust, Dept Med Microbiol, Portsmouth PO6 3LY, Hants, England; [Bhole, Malini] Dudley Grp NHS Fdn Trust, Dept Clin Immunol, Dudley DY1 2HQ, W Midlands, England; [Bhole, Malini] Black Country Pathol Serv BCPS, Dudley DY1 2HQ, W Midlands, England; [Webber, Caroline; Taylor, Lorna] Black Country Pathol Serv BCPS, Dept Clin Immunol, Dudley DY1 2HQ, W Midlands, England; [Whitelegg, Alison] Portsmouth Hosp Univ NHS Trust, Dept Blood Sci, Portsmouth PO6 3LY, Hants, England		Mohanraj, D (通讯作者)，Univ Manchester, Fac Med Biol & Hlth, Manchester M13 9PL, Lancs, England.	Dinesh.Mohanraj@postgrad.manchester.ac.uk; Kelly.bicknell@porthosp.nhs.uk; malini.bhole@nhs.net; caroline.webber@nhs.net; Lorna.Taylorl@nhs.net; Alison.whitelegg@porthosp.nhs.uk	Mohanraj, Dinesh/AGN-7872-2022	Whitelegg, Alison/0000-0002-4896-4795; Mohanraj, Dinesh/0000-0002-3747-7465	The Binding Site Ltd	The Binding Site Ltd. (Birmingham, UK) provided the study with free of cost evaluation kits. The Binding Site Ltd. had no other direct involvement in this study. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.	Abbott, ARCHITECT ANTISARS C; Adams Emily R, 2020, Wellcome Open Res, V5, P139, DOI 10.12688/wellcomeopenres.15927.1; Bryan A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00941-20; Center for Systems Science and Engineering, 2020, COVID 19 DASHB; Cetin AE, 2014, LIGHT-SCI APPL, V3, DOI 10.1038/lsa.2014.3; Faustini Sian E, 2020, medRxiv, DOI 10.1101/2020.06.16.20133025; Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179; Johansson MA, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.35057; Manalac J, 2020, CLIN CHIM ACTA, V510, P687, DOI 10.1016/j.cca.2020.09.002; Meschi S, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104539; Park SW, 2020, EPIDEMICS-NETH, V31, DOI 10.1016/j.epidem.2020.100392; Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5; Public Health England, 2020, COR COVID 19 GUID; Riley S., 2020, REACT 1 ROUND 7 INTE, DOI [10.1101/2020.11.30.20239806, DOI 10.1101/2020.11.30.20239806]; Roche, ELECSYS ANTISARS COV; Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259; To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1; UK Medicines and Healthcare products Regulatory Agency, 2020, TARG PROD PROF ENZ I; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195	19	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1310	10.3390/vaccines9111310			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH1JX	34835241	Green Published, gold			2022-04-29	WOS:000725198600001
J	Petrova, E; Farinholt, T; Joshi, TP; Moreno, H; Al Mohajer, M; Patel, SM; Petrosino, J; Anandasabapathy, S				Petrova, Elena; Farinholt, Timothy; Joshi, Tejas P.; Moreno, Hannah; Al Mohajer, Mayar; Patel, Shital M.; Petrosino, Joseph; Anandasabapathy, Sharmila			A Community-Based Management of COVID-19 in a Mobile Container Unit	VACCINES			English	Article						mobile clinic; relocatable medical facility; underserved community; coronavirus; vaccination; infection control; decontamination	INFECTION-CONTROL; VACCINE; CURTAINS	Vaccine uptake is a multifactor measure of successful immunization outcomes that includes access to healthcare and vaccine hesitancy for both healthcare workers and communities. The present coronavirus disease (COVID-19) pandemic has highlighted the need for novel strategies to expand vaccine coverage in underserved regions. Mobile clinics hold the promise of ameliorating such inequities, although there is a paucity of studies that validate environmental infection in such facilities. Here, we describe community-based management of COVID-19 through a Smart Pod mobile clinic deployed in an underserved community area in the United States (Aldine, Harris County, TX, USA). In particular, we validate infection control and biological decontamination of the Smart Pod by testing surfaces and the air-filtration system for the COVID-19 virus and bacterial pathogens. We show the Smart Pod to be efficacious in providing a safe clinical environment for vaccine delivery. Moreover, in the Smart Pod, up-to-date education of community healthcare workers was provided to reduce vaccine hesitancy and improve COVID-19 vaccine uptake. The proposed solution has the potential to augment existing hospital capacity and combat the COVID-19 pandemic locally and globally.	[Petrova, Elena; Joshi, Tejas P.; Anandasabapathy, Sharmila] Baylor Coll Med, Baylor Global Hlth, Houston, TX 77030 USA; [Petrova, Elena; Anandasabapathy, Sharmila] Baylor Coll Med, Dept Med Gastroenterol, Houston, TX 77030 USA; [Farinholt, Timothy; Moreno, Hannah; Petrosino, Joseph; Anandasabapathy, Sharmila] Baylor Coll Med, Alkek Ctr Metagen & Microbiome Res Mol Virol & Mi, Houston, TX 77030 USA; [Al Mohajer, Mayar; Patel, Shital M.] Baylor Coll Med, Dept Med Infect Dis, Houston, TX 77030 USA		Petrova, E; Anandasabapathy, S (通讯作者)，Baylor Coll Med, Baylor Global Hlth, Houston, TX 77030 USA.; Petrova, E; Anandasabapathy, S (通讯作者)，Baylor Coll Med, Dept Med Gastroenterol, Houston, TX 77030 USA.	elena.petrova@bcm.edu; timothy.farinholt@bcm.edu; tejas.joshi@bcm.edu; hannah.moreno@bcm.edu; mayar.almohajer@bcm.edu; shitalp@bcm.edu; jpetrosi@bcm.edu; sharmila.anandasabapathy@bcm.edu		Joshi, Tejas/0000-0001-7897-2940			Abedi V, 2021, J RACIAL ETHN HEALTH, V8, P732, DOI [10.1007/s40615-020-00833-4, 10.1101/2020.04.26.20079756]; Allman M., 2020, RAPIDLY DEPLOYABLE S; [Anonymous], TMC NEWS; Aung K., 2015, EMERGING BUSINESS MO; Baker DR, 2021, POPUL HEALTH MANAG, V24, P657, DOI 10.1089/pop.2021.0066; Bertoncello C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020276; Bhushan S., 2019, IMPROVING HLTH EQUIT; Burke JP, 2003, NEW ENGL J MED, V348, P651, DOI 10.1056/NEJMhpr020557; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; CDC, 2019, COMM WORK SCH; Chen XJ, 2020, LANCET INFECT DIS, V20, P397, DOI 10.1016/S1473-3099(20)30110-9; Chirico F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17176052; Correia G, 2020, MED HYPOTHESES, V141, DOI 10.1016/j.mehy.2020.109781; Corwin C, 2021, J AGROMEDICINE, V26, P346, DOI 10.1080/1059924X.2021.1913272; Dash U., 2008, ACCESS HLTH SERVICES; George S, 2014, IHI TEAMS LEADING MO, P1; Gianfredi V, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060574; Katzman JG, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18094900; Krol DM, 2007, J HEALTH CARE POOR U, V18, P331, DOI 10.1353/hpu.2007.0038; Lei H, 2020, INFLUENZA OTHER RESP, V14, P688, DOI 10.1111/irv.12783; Lopez L, 2021, JAMA-J AM MED ASSOC, V325, P719, DOI 10.1001/jama.2020.26443; Lyu Hanjia, 2022, Intell Med, V2, P1, DOI 10.1016/j.imed.2021.08.001; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Momplaisir FM, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.21931; Morawska L, 2020, ENVIRON INT, V142, DOI 10.1016/j.envint.2020.105832; Nelson R, 2020, LANCET INFECT DIS, V20, P546, DOI 10.1016/S1473-3099(20)30304-2; Petrova E.V., 2020, J VIS EXP, pE6424, DOI [10.3791/6424, DOI 10.3791/6424]; Petrova E.V., 2020, J VIS EXP, pE6423; Petrova E.V., 2020, J VIS EXP, V2, pE6425; Petrova EV, 2019, JOVE-J VIS EXP, DOI 10.3791/59188; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Rodriguez N., 2021, P IDWEEK VIRTUAL 202; Rutala W.A., CDC GUIDELINE DISINF; Samouei R., 2016, INT J HLTH SYST DISA, V4, P1, DOI [10.4103/2347-9019.175669, DOI 10.4103/2347-9019.175669]; Schweizer M, 2012, INFECT CONT HOSP EP, V33, P1081, DOI 10.1086/668022; Shadmi E, 2020, INT J EQUITY HEALTH, V19, DOI 10.1186/s12939-020-01218-z; Sydnor ERM, 2011, CLIN MICROBIOL REV, V24, P141, DOI 10.1128/CMR.00027-10; Thies Kathleen M, 2021, J Prim Care Community Health, V12, p21501327211019286, DOI 10.1177/21501327211019286; Tulledge-Scheitel S, 2021, J AM GERIATR SOC, V69, P868, DOI 10.1111/jgs.17090; Wilson G, 2020, AM J INFECT CONTROL, V48, P862, DOI 10.1016/j.ajic.2019.12.024; Yu SWY, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0671-2	41	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1362	10.3390/vaccines9111362			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF2AD	34835293	gold, Green Published			2022-04-29	WOS:000723877700001
J	Powell, RM; Peeters, MJW; Rahbech, A; Aehnlich, P; Seremet, T; Straten, PT				Powell, Richard M.; Peeters, Marlies J. W.; Rahbech, Anne; Aehnlich, Pia; Seremet, Tina; Straten, Per Thor			Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8(+) T Cells	VACCINES			English	Article						MERTK; FLT3; CD8(+) T cells; T lymphocytes; receptor tyrosine kinases; small molecule inhibitors	RECEPTOR TYROSINE KINASES; LEUKEMIA; QUIZARTINIB; ACTIVATION; DASATINIB; PROLIFERATION; COMBINATION; EXPRESSION; APOPTOSIS; UNC2025	There is an increasing interest in the development of Receptor Tyrosine Kinases inhibitors (RTKIs) for cancer treatment, as dysregulation of RTK expression can govern oncogenesis. Among the newer generations of RTKIs, many target Mer Tyrosine Kinase (MERTK) and Fms related RTK 3 (FLT3). Next to being overexpressed in many cancers, MERTK and FLT3 have important roles in immune cell development and function. In this study, we address how the new generation and potent RTKIs of MERTK/FLT3 affect human primary CD8(+) T cell function. Using ex vivo T cell receptor (TCR)-activated CD8(+) T cells, we demonstrate that use of dual MERTK/FLT3 inhibitor UNC2025 restricts CD8(+) T proliferation at the G2 phase, at least in part by modulation of mTOR signaling. Cytokine production and activation remain largely unaffected. Finally, we show that activated CD8(+) T cells express FLT3 from day two post activation, and FLT3 inhibition with AC220 (quizartinib) or siRNA-mediated knockdown affects cell cycle kinetics. These results signify that caution is needed when using potent RTKIs in the context of antitumor immune responses.	[Powell, Richard M.; Peeters, Marlies J. W.; Rahbech, Anne; Aehnlich, Pia; Seremet, Tina; Straten, Per Thor] Univ Hosp Herlev, Natl Ctr Canc Immune Therapy CCIT DK, Dept Oncol, DK-2730 Herlev, Denmark; [Straten, Per Thor] Univ Copenhagen, Dept Immunol & Microbiol, Inflammat & Canc Grp, DK-2200 Copenhagen, Denmark		Straten, PT (通讯作者)，Univ Hosp Herlev, Natl Ctr Canc Immune Therapy CCIT DK, Dept Oncol, DK-2730 Herlev, Denmark.; Straten, PT (通讯作者)，Univ Copenhagen, Dept Immunol & Microbiol, Inflammat & Canc Grp, DK-2200 Copenhagen, Denmark.	richardpowell1000@gmail.com; marlies.peeters@regionh.dk; anne.rahbech@regionh.dk; pia.aehnlich@regionh.dk; tina.juanita.seremet@regionh.dk; per.thor.straten@regionh.dk		thor Straten, Per/0000-0002-4731-4969; Powell, Richard/0000-0003-2466-9625	Danish Council for Independent ResearchDet Frie Forskningsrad (DFF) [DFF-1331-00095B]; Danish Cancer SocietyDanish Cancer Society [R72-A4396-13-S2]; Training Network for the Immunotherapy of Cancer - EU (IMMUTRAIN; H2020 grant) [641549]; Danielsen Foundation; Axel Musfeldts fond; Dagmar Marshalls Fond; Else og MogensWedell-Wedellsborg Fond; AP Moller Fonden; Den Bohmske Fond	This study was supported by the Danish Council for Independent Research (grant no. DFF-1331-00095B), the Danish Cancer Society (grant no. R72-A4396-13-S2), the Training Network for the Immunotherapy of Cancer funded by the EU (IMMUTRAIN; H2020 grant no. 641549 to M.J.W. Peeters and P. thor Straten), The Danielsen Foundation, Axel Musfeldts fond, Dagmar Marshalls Fond, Else og MogensWedell-Wedellsborg Fond, AP Moller Fonden, and Den Bohmske Fond.	Astier AL, 2010, J IMMUNOL, V184, P685, DOI 10.4049/jimmunol.0902443; Bosurgi L, 2013, P NATL ACAD SCI USA, V110, P13091, DOI 10.1073/pnas.1302507110; Cabezon R, 2015, J LEUKOCYTE BIOL, V97, P751, DOI 10.1189/jlb.3A0714-334R; Caetano MS, 2019, CLIN CANCER RES, V25, P7576, DOI 10.1158/1078-0432.CCR-19-0795; Callahan MK, 2014, CANCER IMMUNOL RES, V2, P70, DOI 10.1158/2326-6066.CIR-13-0160; Carow CE, 1996, BLOOD, V87, P1089, DOI 10.1182/blood.V87.3.1089.bloodjournal8731089; Chklovskaia E, 2001, BLOOD, V97, P1027, DOI 10.1182/blood.V97.4.1027; Cortes JE, 2013, J CLIN ONCOL, V31, P3681, DOI 10.1200/JCO.2013.48.8783; Cummings CT, 2015, MOL CANCER THER, V14, P2014, DOI 10.1158/1535-7163.MCT-15-0116; DeRyckere D, 2017, CLIN CANCER RES, V23, P1481, DOI 10.1158/1078-0432.CCR-16-1330; Du ZF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0782-4; Fei F, 2008, EXP HEMATOL, V36, P1297, DOI 10.1016/j.exphem.2008.05.002; Frumento G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00468; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Ginhoux F, 2009, J EXP MED, V206, P3115, DOI 10.1084/jem.20091756; Giroud P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.564133; Graham DK, 2014, NAT REV CANCER, V14, P769, DOI 10.1038/nrc3847; Gunawardane RN, 2013, MOL CANCER THER, V12, P438, DOI 10.1158/1535-7163.MCT-12-0305; Guy CS, 2013, NAT IMMUNOL, V14, P262, DOI 10.1038/ni.2538; Jin LH, 2013, CANCER LETT, V329, P45, DOI 10.1016/j.canlet.2012.09.020; Kampa-Schittenhelm KM, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-19; Kasikara C, 2019, CANCER RES, V79, P2669, DOI 10.1158/0008-5472.CAN-18-2614; Lee-Sherick AB, 2013, ONCOGENE, V32, P5359, DOI 10.1038/onc.2013.40; Lee-Sherick AB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97941; Li J, 2017, ONCOTARGET, V8, P93785, DOI 10.18632/oncotarget.21078; Majothi S, 2020, SYST REV-LONDON, V9, DOI 10.1186/s13643-020-01540-1; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; Minson KA, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85630; Mondino A, 2007, SEMIN IMMUNOL, V19, P162, DOI 10.1016/j.smim.2007.02.008; Peeters MJW, 2019, CANCER IMMUNOL RES, V7, P1472, DOI 10.1158/2326-6066.CIR-18-0841; Peschel I, 2017, HAEMATOLOGICA, V102, P1378, DOI 10.3324/haematol.2016.160101; Pottier C, 2020, CANCERS, V12, DOI 10.3390/cancers12030731; Ravandi F, 2009, BLOOD, V114, P806, DOI 10.1182/blood.V114.22.636.636; Ray RJ, 1996, EUR J IMMUNOL, V26, P1504, DOI 10.1002/eji.1830260715; Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034; Sandmaier BM, 2018, AM J HEMATOL, V93, P222, DOI 10.1002/ajh.24959; Sato T, 2011, BLOOD, V117, P3286, DOI 10.1182/blood-2010-01-266742; Schade AE, 2008, BLOOD, V111, P1366, DOI 10.1182/blood-2007-04-084814; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Sinik L, 2019, MOL CANCER THER, V18, P278, DOI 10.1158/1535-7163.MCT-18-0456; Sufit A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165107; Taylor SJ, 2012, BLOOD, V120, P4049, DOI 10.1182/blood-2012-06-436675; Tworkoski K, 2011, MOL CANCER RES, V9, P801, DOI 10.1158/1541-7786.MCR-10-0512; Waskow C, 2008, NAT IMMUNOL, V9, P676, DOI 10.1038/ni.1615; Wolleschak D, 2014, HAEMATOLOGICA, V99, pE90, DOI 10.3324/haematol.2014.104331; Wu J, 2018, NEURO-ONCOLOGY, V20, P92, DOI 10.1093/neuonc/nox111; Yokoyama Y, 2019, CANCER RES, V79, P1996, DOI 10.1158/0008-5472.CAN-18-2022; Zarrinkar PP, 2009, BLOOD, V114, P2984, DOI 10.1182/blood-2009-05-222034; Zhang WH, 2014, J MED CHEM, V57, P7031, DOI 10.1021/jm500749d; Zhou Y, 2020, IMMUNITY, V52, P357, DOI 10.1016/j.immuni.2020.01.014	50	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1294	10.3390/vaccines9111294			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XE4TR	34835225	gold, Green Published			2022-04-29	WOS:000723382400001
J	Zerna, G; Rathinasamy, VA; Toet, H; Anderson, G; Dempster, R; Spithill, TW; Beddoe, T				Zerna, Gemma; Rathinasamy, Vignesh A.; Toet, Hayley; Anderson, Glenn; Dempster, Robert; Spithill, Terry W.; Beddoe, Travis			Evaluation of Immunogenicity and Efficacy of Fasciola hepatica Tetraspanin 2 (TSP2) Fused to E. coli Heat-Labile Enterotoxin B Subunit LTB Adjuvant Following Intranasal Vaccination of Cattle	VACCINES			English	Article						vaccine; Fasciola hepatica; LTB; AB(5) toxin; tetraspanin; tegument membrane; mucosal immunity; cattle	SYSTEMIC IMMUNE-RESPONSES; CATHEPSIN-L PROTEINASES; SCHISTOSOMA-MANSONI; LIVER FLUKE; MOLECULAR CHARACTERIZATION; PROTEOMIC ANALYSIS; IN-VITRO; PROTECTION; SURFACE; INFECTION	Fasciolosis, caused by the liver flukes Fasciola hepatica and F. gigantica, is an economically important and globally distributed zoonotic disease. Liver fluke infections in livestock cause significant losses in production and are of particular concern to regions where drug resistance is emerging. Antigens of the F. hepatica surface tegument represent promising vaccine candidates for controlling this disease. Tetraspanins are integral tegumental antigens that have shown partial protection as vaccine candidates against other trematode species. The Escherichia coli heat-labile enterotoxin's B subunit (LTB) is a potent mucosal adjuvant capable of inducing an immune response to fused antigens. This study investigates the potential of F. hepatica tetraspanin 2 extracellular loop 2 (rFhTSP2) as a protective vaccine antigen and determines if fusion of FhTSP2 to LTB can enhance protection in cattle. Cattle were immunised subcutaneously with rFhTSP2 mixed in the Freund's adjuvant and intranasally with rLTB-FhTSP2 in saline, accounting for equal molar ratios of tetraspanin in both groups. Vaccination with rFhTSP2 stimulated a strong specific serum IgG response, whereas there was no significant serum IgG response following rLTB-FhTSP2 intranasal vaccination. There was no substantial antigen specific serum IgA generated in all groups across the trial. Contrastingly, after the fluke challenge, a rise in antigen specific saliva IgA was observed in both vaccination groups on Day 42, with the rLTB-FhTSP2 vaccination group showing significant mucosal IgA production at Day 84. However, neither vaccine group showed a significant reduction of fluke burden nor faecal egg output. These results suggest that intranasal vaccination with rLTB-FhTSP2 does elicit a humoral mucosal response but further work is needed to evaluate if mucosal delivery of liver fluke antigens fused to LTB is a viable vaccine strategy.	[Zerna, Gemma; Rathinasamy, Vignesh A.; Toet, Hayley; Spithill, Terry W.; Beddoe, Travis] La Trobe Univ, Plant & Soil Sci & Ctr AgriBiosci, Dept Anim, Bundoora, Vic 3083, Australia; [Anderson, Glenn] Intens Livestock Fisheries & Aquaculture Res Dev, Dept Agr & Fisheries, Dutton Park, Qld 4102, Australia; [Dempster, Robert] Virbac Australia Pty Ltd, Milperra, NSW 2214, Australia; [Rathinasamy, Vignesh A.] James Cook Univ, Australian Inst Trop Hlth & Med, Cairns, Qld 4870, Australia		Beddoe, T (通讯作者)，La Trobe Univ, Plant & Soil Sci & Ctr AgriBiosci, Dept Anim, Bundoora, Vic 3083, Australia.	gmzerna@students.latrobe.edu.au; Vignesh.ambothirathinasamy@jcu.edu.au; H.Toet@latrobe.edu.au; glenn.anderson23@bigpond.com; robert.dempster@virbac.com.au; T.spithill@latrobe.edu.au; T.Beddoe@latrobe.edu.au		Beddoe, Travis/0000-0003-4550-2277	Australian Research CouncilAustralian Research Council [LP130100943, LP160100442]; Virbac (Australia) Pty. Ltd.; La Trobe University, Melbourne, Australia; Victoria India Doctoral Scholarship - Government of Victoria; La Trobe University; La Trobe University School of Life Sciences Postgraduate Publication Award; Australian Research Training Program scholarship	The research in the T.W.S. and T.B. laboratories was supported by funds from Linkage Project LP130100943 "Development of a novel vaccine targeting parasite tegument proteins for liver fluke disease in livestock" and Linkage Project LP160100442 "Optimisation of a novel hybrid vaccine for liver fluke disease in cattle" funded by the Australian Research Council, in collaboration with Virbac (Australia) Pty. Ltd. In addition, support was obtained from La Trobe University, Melbourne, Australia. V.A.R. was supported by a Victoria India Doctoral Scholarship funded by Government of Victoria and administered by the Australia India Institute, a PhD scholarship from La Trobe University, and a La Trobe University School of Life Sciences Postgraduate Publication Award. G.Z. is supported by an Australian Research Training Program scholarship.	Ayalew S, 2009, VET IMMUNOL IMMUNOP, V132, P295, DOI 10.1016/j.vetimm.2009.06.005; Beddoe T, 2010, TRENDS BIOCHEM SCI, V35, P411, DOI 10.1016/j.tibs.2010.02.003; Boyaka PN, 2003, J IMMUNOL, V170, P454, DOI 10.4049/jimmunol.170.1.454; Braschi S, 2006, PROTEOMICS, V6, P1471, DOI 10.1002/pmic.200500368; Braschi S, 2006, MOL CELL PROTEOMICS, V5, P347, DOI 10.1074/mcp.M500287-MCP200; Brockwell YM, 2013, VET PARASITOL, V196, P417, DOI 10.1016/j.vetpar.2013.04.012; Brockwell YM, 2014, INT J PARASITOL-DRUG, V4, P48, DOI 10.1016/j.ijpddr.2013.11.005; Cai PF, 2008, BIOCHEM BIOPH RES CO, V372, P197, DOI 10.1016/j.bbrc.2008.05.042; Cameron TC, 2017, INT J PARASITOL, V47, P555, DOI 10.1016/j.ijpara.2017.02.004; Chaiyadet S, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007450; Chaiyadet S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13527-5; Charlier J, 2014, PARASITOLOGY, V141, P326, DOI 10.1017/S0031182013001662; Chen HM, 2000, J CONTROL RELEASE, V67, P117, DOI 10.1016/S0168-3659(00)00199-1; Chia MY, 2011, VET IMMUNOL IMMUNOP, V140, P215, DOI 10.1016/j.vetimm.2011.01.002; Cunha CEP, 2014, VACCINE, V32, P214, DOI 10.1016/j.vaccine.2013.11.025; Cwiklinski K, 2016, PARASITE IMMUNOL, V38, P558, DOI 10.1111/pim.12343; Cwiklinski K, 2015, MOL CELL PROTEOMICS, V14, P3258, DOI 10.1074/mcp.M115.053934; Cwiklinski K, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0632-2; da Hora VP, 2011, VACCINE, V29, P1538, DOI 10.1016/j.vaccine.2010.11.091; Dalton JP, 2013, VET PARASITOL, V195, P272, DOI 10.1016/j.vetpar.2013.04.008; Dalton JP, 1996, INFECT IMMUN, V64, P5066, DOI 10.1128/IAI.64.12.5066-5074.1996; Dominguez MF, 2018, VET PARASITOL, V258, P46, DOI 10.1016/j.vetpar.2018.06.011; Duan QD, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00292; Elliott T, 2014, VET PARASITOL, V200, P90, DOI 10.1016/j.vetpar.2013.11.019; Eyayu T, 2020, PARASITE EPIDEM CONT, V11, DOI 10.1016/j.parepi.2020.e00176; Fairweather I, 2020, INT J PARASITOL-DRUG, V12, P39, DOI 10.1016/j.ijpddr.2019.11.003; Golden O, 2010, VACCINE, V28, P5551, DOI 10.1016/j.vaccine.2010.06.039; Gonzalez-Miguel J, 2021, TRENDS PARASITOL, V37, P35, DOI 10.1016/j.pt.2020.09.007; Grassmann AA, 2012, CLIN VACCINE IMMUNOL, V19, P740, DOI 10.1128/CVI.05720-11; HANNA REB, 1980, EXP PARASITOL, V50, P103, DOI 10.1016/0014-4894(80)90012-0; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Jin Z, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118731; Keitel WA, 2019, VACCINE, V37, P6500, DOI 10.1016/j.vaccine.2019.08.075; Kelley JM, 2016, TRENDS PARASITOL, V32, P458, DOI 10.1016/j.pt.2016.03.002; LAMMAS DA, 1983, VET PARASITOL, V12, P165, DOI 10.1016/0304-4017(83)90005-5; Phung LT, 2019, PARASITOL RES, V118, P3419, DOI 10.1007/s00436-019-06488-3; Marchioro SB, 2014, VET MICROBIOL, V173, P166, DOI 10.1016/j.vetmic.2014.07.009; McCusker P, 2020, VET PARASITOL, V286, DOI 10.1016/j.vetpar.2020.109244; McNeilly Tom N, 2014, Parasite, V21, P51, DOI 10.1051/parasite/2014051; McNulty SN, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006537; Mendes RE, 2010, VACCINE, V28, P2832, DOI 10.1016/j.vaccine.2010.01.055; Molina-Hernandez V, 2015, VET PARASITOL, V208, P101, DOI 10.1016/j.vetpar.2015.01.004; Morrison CA, 1996, VACCINE, V14, P1603, DOI 10.1016/S0264-410X(96)00147-8; Mudrak B, 2010, TOXINS, V2, P1445, DOI 10.3390/toxins2061445; Mulvenna J, 2010, INT J PARASITOL, V40, P543, DOI 10.1016/j.ijpara.2009.10.002; Mulvenna J, 2010, PROTEOMICS, V10, P1063, DOI 10.1002/pmic.200900393; Ng NM, 2013, STRUCTURE, V21, P2003, DOI 10.1016/j.str.2013.08.024; Norbury LJ, 2018, VET PARASITOL, V258, P14, DOI 10.1016/j.vetpar.2018.05.008; Pearson MS, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001564; Piacenza L, 1999, INFECT IMMUN, V67, P1954; Piedrafita D, 2004, CAN J ZOOL, V82, P233, DOI [10.1139/z03-216, 10.1139/Z03-216]; Piedrafita D, 2001, PARASITE IMMUNOL, V23, P473, DOI 10.1046/j.1365-3024.2001.00404.x; Piedrafita D, 2007, INFECT IMMUN, V75, P1954, DOI 10.1128/IAI.01034-06; Pinheiro CS, 2014, PARASITE IMMUNOL, V36, P303, DOI 10.1111/pim.12118; Pleasance J, 2011, VET PARASITOL, V178, P264, DOI 10.1016/j.vetpar.2011.01.037; Roberts JA, 1997, VET PARASITOL, V73, P215, DOI 10.1016/S0304-4017(97)00119-2; Conceicao FR, 2006, VACCINE, V24, P5734, DOI 10.1016/j.vaccine.2006.04.036; SANDKVIST M, 1993, MOL MICROBIOL, V10, P635, DOI 10.1111/j.1365-2958.1993.tb00935.x; Schweizer G, 2005, VET REC, V157, P188, DOI 10.1136/vr.157.7.188; Shi YL, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.555730; Sotillo J, 2015, INT J PARASITOL, V45, P505, DOI 10.1016/j.ijpara.2015.03.004; Spithill T.W., 2021, FASCIOLOSIS, V2nd ed; Su F, 2019, J VET MED SCI, V81, P1475, DOI 10.1292/jvms.19-0057; Sulaiman AA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005991; Toet H, 2014, INT J PARASITOL, V44, P915, DOI 10.1016/j.ijpara.2014.07.011; Tran MH, 2006, NAT MED, V12, P835, DOI 10.1038/nm1430; Tran MH, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000840; van Deventer SJ, 2017, BIOCHEM SOC T, V45, P741, DOI 10.1042/BST20160284; Wedrychowicz H, 2007, VET PARASITOL, V147, P77, DOI 10.1016/j.vetpar.2007.03.023; Weltzin R, 2000, INFECT IMMUN, V68, P2775, DOI 10.1128/IAI.68.5.2775-2782.2000; Wesolowska A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02592; Williams NA, 1999, IMMUNOL TODAY, V20, P95, DOI 10.1016/S0167-5699(98)01397-8; Wilson RA, 2011, INT J PARASITOL, V41, P1347, DOI 10.1016/j.ijpara.2011.08.003; Yokomizo Y, 2002, VET IMMUNOL IMMUNOP, V87, P291, DOI 10.1016/S0165-2427(02)00055-7; Yuan CA, 2010, EXP PARASITOL, V126, P456, DOI 10.1016/j.exppara.2010.05.018; Zerna G, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11061819; Zhang WB, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001166	77	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1213	10.3390/vaccines9111213			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XL2RR	34835144	Green Published, Green Accepted, gold			2022-04-29	WOS:000727997000001
J	Umakanthan, S; Patil, S; Subramaniam, N; Sharma, R				Umakanthan, Srikanth; Patil, Sonal; Subramaniam, Naveen; Sharma, Ria			COVID-19 Vaccine Hesitancy and Resistance in India Explored through a Population-Based Longitudinal Survey	VACCINES			English	Article						COVID-19; public health; prevention; decline; government		Background: The World Health Organization has recommended that individual governments identify vaccine hesitancy areas. It is proposed that the governments, with the aid of local organizations, educate and implement social insights on the vaccination so that high population levels are covered with this safe immune program. Methods: A longitudinal online survey covered 3000 adults from India. We examined the demography, behavioral (socio-economic) attitude, vaccine hesitancy, vaccine resistance for the COVID-19 vaccine. The specific reasons for the COVID-19 vaccine decline were also evaluated. Results: Our survey revealed 59% definite response, 29% low-level response, and 7% high-level response for vaccine hesitancy, while 6% had resistant views on the COVID-19 vaccine. Individuals who had higher income levels, lived in a society, maintained social distancing, had downloaded the COVID-19 update app, showed a positive attitude towards their government, and more confidence in their healthcare system were more inclined towards the vaccination. On the contrary, individuals who had overstated the risks of COVID-19 and had a religious and populistic attitude towards vaccination were more hesitant/resistant to vaccination. The respondents who declined vaccine administration were further evaluated for their specific reason for their response. The most common reasons for declining the COVID-19 vaccine were post-vaccine scare of adverse health effects and accepting the information spread by social media. Conclusions: The results in our study show that by identifying population "hot spots " that have negative or unclear information on the COVID-19 vaccination, these "hot spots " can be addressed by involving friendly organizations that can clear their strong disbeliefs and increase the percentage of vaccine-definite people within the population. The role of government-induced COVID-19 vaccine policy measures can always be beneficial to cause this shift from disbelief to confidence within the population.</p>	[Umakanthan, Srikanth] Univ West Indies, Dept Para Clin Sci, Fac Med Sci, St Augustine, Trinidad Tobago; [Patil, Sonal; Subramaniam, Naveen] RRN Hosp & Res Ctr, Dept Community Med, Madurai 625501, Tamil Nadu, India; [Sharma, Ria] RRN Hosp & Res Ctr, Med Resident, Madurai 625501, Tamil Nadu, India		Umakanthan, S (通讯作者)，Univ West Indies, Dept Para Clin Sci, Fac Med Sci, St Augustine, Trinidad Tobago.	Srikanth.Umakanthan@sta.uwi.edu; sonaldrpatil@gmail.com; naveen.subbu.rrn@gmail.com; ria.sharma.dr@gmail.com	Umakanthan, Srikanth/ABE-4754-2021; Umakanthan, Srikanth/AAD-7903-2022	Umakanthan, Srikanth/0000-0002-6713-2265			Bartsch SM, 2020, AM J PREV MED, V59, P493, DOI 10.1016/j.amepre.2020.06.011; Cooper S, 2018, HUM VACC IMMUNOTHER, V14, P2355, DOI 10.1080/21645515.2018.1460987; Demurtas J, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101118; Dube E, 2021, ANNU REV PUBL HEALTH, V42, P175, DOI 10.1146/annurev-publhealth-090419-102240; Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212; Fokoun C, 2018, HUM VACC IMMUNOTHER, V14, P1580, DOI 10.1080/21645515.2018.1458807; Francis AI, 2021, POSTGRAD MED J, DOI 10.1136/postgradmedj-2021-140654; Gualano MR, 2019, HUM VACC IMMUNOTHER, V15, P918, DOI 10.1080/21645515.2018.1564437; Habersaat KB, 2020, NAT HUM BEHAV, V4, P677, DOI 10.1038/s41562-020-0906-x; Herbert C, 2021, BMC PSYCHOL, V9, DOI 10.1186/s40359-021-00574-x; Hickler B, 2015, VACCINE, V33, P4155, DOI 10.1016/j.vaccine.2015.04.034; Islam MS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251605; Kaarthigeyan K, 2012, INDIAN J MED PAEDIAT, V33, P7, DOI 10.4103/0971-5851.96961; Kadam AB, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa057; Krishnamoorthy Y, 2019, J FAM MED PRIM CARE, V8, P3962, DOI 10.4103/jfmpc.jfmpc_790_19; Kumar VM, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00327-2; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Le Houezec D, 2014, IMMUNOL RES, V60, P219, DOI 10.1007/s12026-014-8574-4; Mello MM, 2020, NEW ENGL J MED, V383, P1296, DOI 10.1056/NEJMp2020926; Ministry of Health and Family Welfare Government of India, 2020, COVID 19 VACC OP GUI; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Recio-Roman A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060617; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Rotondo JC, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13091687; Rozbroj T, 2019, PATIENT EDUC COUNS, V102, P172, DOI 10.1016/j.pec.2018.08.027; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Stillo M, 2015, EXPERT OPIN DRUG SAF, V14, P697, DOI 10.1517/14740338.2015.1013532; Suppli CH, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6268-x; Thunstrom L., 2020, HESITANCY COVID 19 V, V94, DOI [DOI 10.2139/SSRN.3593098, 10.2139/ssrn.3593098]; Umakanthan S, 2021, AIMS PUBLIC HEALTH, V8, P137, DOI 10.3934/publichealth.2021011; Umakanthan S, 2020, POSTGRAD MED J, V96, P753, DOI 10.1136/postgradmedj-2020-138234	34	6	6	7	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1064	10.3390/vaccines9101064			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN6DT	34696172	gold, Green Published			2022-04-29	WOS:000711857700001
J	van Aalst, R; Gravenstein, S; Mor, V; Mahmud, SM; Wilschut, J; Postma, M; Chit, A				van Aalst, Robertus; Gravenstein, Stefan; Mor, Vincent; Mahmud, Salaheddin M.; Wilschut, Jan; Postma, Maarten; Chit, Ayman			Economic Assessment of High-Dose Versus Adjuvanted Influenza Vaccine: An Evaluation of Hospitalization Costs Based on a Cohort Study	VACCINES			English	Article						high-dose; adjuvanted; aIIV3; HD-IIV3; influenza vaccine; economic assessment	EVENT RATE RATIO; OLDER-ADULTS; ADJUSTMENT	Two influenza vaccines are licensed in the U.S. exclusively for the 65 years and older population: a trivalent inactivated high-dose influenza vaccine (HD-IIV3) and a trivalent inactivated adjuvanted influenza vaccine (aIIV3). In a recent publication, we estimated a relative vaccine effectiveness (rVE) of HD-IIV3 vs. aIIV3 of 12% (95% CI: 3.3-20%) for influenza-related hospitalizations using a retrospective study design, but did not report the number of prevented hospitalizations nor the associated avoided cost. In this paper we report estimations for both. Methods: Leveraging the rVE of a cohort study over two influenza seasons (2016/17 and 2017/18), we collected cost data for healthcare provided to the same study population. Vaccine costs were obtained from the Medicare pricing schedule. Our economic assessment compared cost of vaccination and hospital care for patients experiencing acute respiratory or cardiovascular illness. Results: We analyzed 1.9 million HD-IIV3 and 223,793 aIIV3 recipients. Average vaccine list prices were $46.23 for HD-IIV3 and $48.26 for aIIV3. The hospitalization rates for respiratory disease in HD-IIV3 and aIIV3 recipients were 187 (95% CI: 185-189) and 212 (195-231) per 10,000 persons-years, respectively. Attributing the average cost per hospitalization of $12,652 ($12,214-$13,090) to the difference in hospitalization rates, we estimate net savings of HD-IIV3 to be $34 ($10-$62) per recipient. Conclusion: Pooled over two predominantly A/H3N2 respiratory seasons, vaccination with HD-IIV3 was associated with lower hospitalization rates and associated costs compared to aIIV3 in senior members of a large national managed health care company in the U.S. Reduced hospitalizations affect healthcare utilization overall, and therefore other costly health outcomes	[van Aalst, Robertus; Postma, Maarten] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, NL-9700 AB Groningen, Netherlands; [van Aalst, Robertus; Chit, Ayman] Vaccine Epidemiol & Modelling Sanofi Pasteur, Swiftwater, PA 18370 USA; [Gravenstein, Stefan; Mor, Vincent] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Pract, Providence, RI 02903 USA; [Gravenstein, Stefan; Mor, Vincent] Providence VA Med Ctr, Ctr LongTerm Serv & Support, Providence, RI 02908 USA; [Gravenstein, Stefan] Ctr Gerontol & Healthcare Res, Providence, RI 02903 USA; [Gravenstein, Stefan] Brown Univ, Warren Alpert Med Sch, Providence, RI 02903 USA; [Mahmud, Salaheddin M.] Univ Manitoba, Rady Coll Med, Dept Commun Hlth Sci, Winnipeg, MB R3E 0W3, Canada; [Wilschut, Jan] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol, NL-9700 AB Groningen, Netherlands; [Postma, Maarten] Univ Groningen, Dept Pharm, Unit PharmacoTherapy Epidemiol & Econ PTE2, NL-9700 AB Groningen, Netherlands; [Postma, Maarten] Univ Groningen, Fac Econ & Business, Dept Econ Econometr & Finance, NL-9700 AB Groningen, Netherlands; [Chit, Ayman] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 3M2, Canada		van Aalst, R (通讯作者)，Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, NL-9700 AB Groningen, Netherlands.; van Aalst, R (通讯作者)，Vaccine Epidemiol & Modelling Sanofi Pasteur, Swiftwater, PA 18370 USA.	rob.vanaalst@sanofi.com; stefan_gravenstein@brown.edu; vincent_mor@brown.edu; Salah.Mahmud@umanitoba.ca; jcwilschut@gmail.com; m.j.postma@rug.nl; Ayman.Chit@sanofi.com		Gravenstein, Stefan/0000-0001-6000-6859; van Aalst, Robertus/0000-0003-3025-7811	Sanofi Pasteur, Inc., Swiftwater, PA, USA	This study was partially funded by Sanofi Pasteur, Inc., Swiftwater, PA, USA. S.G., S.M.M., V.M., M.P. and J.W. did not receive financial compensation for their contributions to this manuscript.	Ainslie KEC, 2019, EXPERT REV VACCINES, V18, P615, DOI 10.1080/14760584.2019.1622419; Centers for Medicare Medicaid Services, FEE SCHED GEN INF; Garten R, 2018, MMWR-MORBID MORTAL W, V67, P634, DOI 10.15585/mmwr.mm6722a4; Izurieta HS, 2019, J INFECT DIS, V220, P1255, DOI 10.1093/infdis/jiy716; Lambert ND, 2012, EXPERT REV VACCINES, V11, P985, DOI [10.1586/ERV.12.61, 10.1586/erv.12.61]; Lin NX, 2016, STAT MED, V35, P5149, DOI 10.1002/sim.7051; Pelton SI, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030446; Putri WCWS, 2018, VACCINE, V36, P3960, DOI 10.1016/j.vaccine.2018.05.057; Rolfes MA, 2019, CLIN INFECT DIS, V69, P1845, DOI 10.1093/cid/ciz075; Tannen RL, 2008, PHARMACOEPIDEM DR S, V17, P671, DOI 10.1002/pds.1584; Tannen RL, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b81; U. S. Department of Health and Human Services, GUIDANCE REGARDING M; van Aalst R, 2021, AM J EPIDEMIOL, V190, P142, DOI 10.1093/aje/kwaa122; van Aalst R, 2020, VACCINE, V38, P372, DOI 10.1016/j.vaccine.2019.09.105; van Aalst R, 2019, VACCINE, V37, P4499, DOI 10.1016/j.vaccine.2019.06.066; Young-Xu YN, 2018, J INFECT DIS, V217, P1718, DOI 10.1093/infdis/jiy088; Yu MG, 2012, PHARMACOEPIDEM DR S, V21, P60, DOI 10.1002/pds.3235	17	0	0	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1065	10.3390/vaccines9101065			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO9YV	34696173	Green Published			2022-04-29	WOS:000712801200001
J	Domnich, A; Grassi, R; Fallani, E; Spurio, A; Bruzzone, B; Panatto, D; Marozzi, B; Cambiaggi, M; Vasco, A; Orsi, A; Icardi, G				Domnich, Alexander; Grassi, Riccardo; Fallani, Elettra; Spurio, Alida; Bruzzone, Bianca; Panatto, Donatella; Marozzi, Barbara; Cambiaggi, Maura; Vasco, Alessandro; Orsi, Andrea; Icardi, Giancarlo			Changes in Attitudes and Beliefs Concerning Vaccination and Influenza Vaccines between the First and Second COVID-19 Pandemic Waves: A Longitudinal Study	VACCINES			English	Article						influenza; COVID-19; vaccination; vaccine hesitancy; attitudes; survey; Italy	ADULTS; BENEFITS	Perceptions of the risks of vaccine-preventable diseases and preventive behaviors change over time. The ongoing COVID-19 pandemic may have modified laypeople's attitudes towards routine vaccinations. In this longitudinal study, we aimed to assess changes in attitudes and beliefs concerning (influenza) vaccines between the first and second COVID-19 pandemic waves. A total of 1979 participants completed both 2020 and 2021 surveys. After one year, more interviewees agreed that vaccines were fundamental and should be mandatory (77.3% vs. 75.0%). Analogously, willingness to undergo influenza vaccination increased (p < 0.001) from 44.1% to 48.6%. This increase was seen in subjects aged >= 35 years. Previous influenza vaccinations, receipt of a COVID-19 vaccine, positive attitudes towards (influenza) vaccination, male sex, and older age were the main correlates of willingness to receive the 2021/22 influenza vaccine. Totals of 12.6% and 11.8% had no intention to receive the next seasonal influenza and COVID-19 vaccines, respectively. Most respondents favored a hypothetical combined influenza/COVID-19 vaccine (73.7%) or influenza and COVID-19 vaccine co-administration (67.5%). In Italy, influenza and COVID-19 vaccination hesitancy and refusal are common. Effective public health strategies to pursue higher uptake of both vaccines are urgently needed.	[Domnich, Alexander; Bruzzone, Bianca; Orsi, Andrea; Icardi, Giancarlo] San Martino Policlin Hosp, Hyg Unit, IRCCS Oncol & Neurosci, I-16132 Genoa, Italy; [Grassi, Riccardo; Spurio, Alida] SWG SpA, I-34133 Trieste, Italy; [Fallani, Elettra; Cambiaggi, Maura; Vasco, Alessandro] Seqirus SRL, I-53035 Monteriggioni, Italy; [Fallani, Elettra] Univ Siena, Dept Life Sci, I-53100 Siena, Italy; [Panatto, Donatella; Orsi, Andrea; Icardi, Giancarlo] Univ Genoa, Dept Hlth Sci DISSAL, I-16132 Genoa, Italy; [Marozzi, Barbara] Univ Genoa, Fac Med & Surg, I-16126 Genoa, Italy		Domnich, A (通讯作者)，San Martino Policlin Hosp, Hyg Unit, IRCCS Oncol & Neurosci, I-16132 Genoa, Italy.	alexander.domnich@hsanmartino.it; riccardo.grassi@swg.it; elettra.fallani@seqirus.com; alida.spurio@swg.it; bianca.bruzzone@hsanmartino.it; panatto@unige.it; s3509432@studenti.unige.it; maura.cambiaggi@seqirus.com; alessandro.vasco@seqirus.com; andrea.orsi@unige.it; icardi@unige.it	Orsi, Andrea/AAC-7431-2022	Orsi, Andrea/0000-0002-2433-9610; Panatto, Donatella/0000-0002-2677-0551	Seqirus S.R.L.	This project was fully funded by Seqirus S.R.L.	Karim SAS, 2021, NEW ENGL J MED, V384, P1866, DOI 10.1056/NEJMc2100362; Adlhoch C, 2021, EUROSURVEILLANCE, V26, P2, DOI 10.2807/1560-7917.ES.2021.26.11.2100221; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Bachtiger P, 2021, JMIR PUBLIC HLTH SUR, V7, DOI 10.2196/26734; Bodemer N, 2012, VACCINE, V30, P3747, DOI 10.1016/j.vaccine.2012.03.005; Boggavarapu S, 2014, VACCINE, V32, P7085, DOI 10.1016/j.vaccine.2014.10.068; Bosa I, 2022, HEALTH ECON POLICY L, V17, P1, DOI 10.1017/S1744133121000141; Boytchev H, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n414; Campbell F, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.24.2100509; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Cavaleri M, 2021, LANCET, V397, P355, DOI 10.1016/S0140-6736(21)00085-4; CDC, INT CLIN CONS US COV; Centers for Disease Control and Prevention (CDC), VACC EFF WELL DO FLU; Chaparian R.R., INFLUENZA VIRAL PART, DOI [10.1101/2021.04.30.441968v1.full.pdf, DOI 10.1101/2021.04.30.441968V1.FULL.PDF]; D'Angiolella LS, 2018, ANN I SUPER SANITA, V54, P49, DOI 10.4415/ANN_18_01_10; de Waure C, 2012, HUM VACC IMMUNOTHER, V8, P119, DOI 10.4161/hv.8.1.18420; Di Pumpo M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030276; Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442; Dodd D, 2003, AM J MANAG CARE, V9, pS6; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040711; European Centre for Disease Prevention and Control (ECDC), INFL VACC COV RAT EU; European Commission, STAT VACC CONF EU UK; Fabiani M, 2019, VACCINE, V37, P5314, DOI 10.1016/j.vaccine.2019.07.054; Fridman A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250123; Gal I, 2002, INT STAT REV, V70, P1; Galle F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060638; Gilchrist SAN, 2012, AM J PUBLIC HEALTH, V102, P596, DOI 10.2105/AJPH.2011.300512; Head KJ, 2020, SCI COMMUN, V42, P698, DOI 10.1177/1075547020960463; Ibuka Y, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-296; Italian Ministry of Health, INFL VACC COV; Italian Ministry of Health, PREV CONTR INFL REC; Italian National Institute of Statistics (ISTAT), ISTAT CLASS IT ED QU; Kaplan RM, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021726118; King JP, 2018, INFLUENZA OTHER RESP, V12, P808, DOI 10.1111/irv.12593; Larsson A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220897; Laurie KL, 2021, INFLUENZA OTHER RESP, V15, P573, DOI 10.1111/irv.12866; Massare M.J., COMBINATION RESP VAC, DOI [10.1101/2021.05.05.442782v1.full.pdf, DOI 10.1101/2021.05.05.442782V1.FULL.PDF]; Nagata JM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-388; National Institute of Health, FLUN IT; Odone A, 2020, ACTA BIOMED, V91; Okoli GN, 2021, ACTA OBSTET GYN SCAN, V100, P997, DOI 10.1111/aogs.14079; Organisation for Economic Co-operation and Development (OECD), INFL VACC RAT; R-Core-Team, R LANG ENV STAT COMP; Sah P, 2018, P NATL ACAD SCI USA, V115, P5151, DOI 10.1073/pnas.1802479115; Sarria-Santamera A, 2003, EUR J PUBLIC HEALTH, V13, P133, DOI 10.1093/eurpub/13.2.133; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Tentori K, 2021, SOC SCI MED, V289, DOI 10.1016/j.socscimed.2021.114273; Toback S., SAFETY IMMUNOGENICIT, DOI [10.1101/2021.06.09.21258556v1, DOI 10.1101/2021.06.09.21258556V1]; Vatcheva Kristina P, 2016, Epidemiology (Sunnyvale), V6; Wang Q, 2021, PREV MED, V150, DOI 10.1016/j.ypmed.2021.106694; Wang RT, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050529; World Health Organization, TRACK SARS COV 2 VAR; Yeung MPS, 2016, J PUBLIC HEALTH-UK, V38, P746, DOI 10.1093/pubmed/fdv194; Zhao L, 2019, Can Commun Dis Rep, V45, P156, DOI 10.14745/ccdr.v45i06a02	54	6	6	6	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1016	10.3390/vaccines9091016			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UZ3UX	34579253	gold, Green Published			2022-04-29	WOS:000702134700001
J	Netfa, F; King, C; Davies, C; Rashid, H; Tashani, M; Booy, R; Skinner, SR				Netfa, Faeza; King, Catherine; Davies, Cristyn; Rashid, Harunor; Tashani, Mohamed; Booy, Robert; Skinner, S. Rachel			Knowledge, Attitudes, and Perceptions of the Arabic-Speaking Community in Sydney, Australia, toward the Human Papillomavirus (HPV) Vaccination Program: A Qualitative Study	VACCINES			English	Article						adolescent; attitudes; cultural beliefs; knowledge; human papillomavirus; parents	CERVICAL-CANCER; ADOLESCENT; WOMEN; IMMUNIZATION; PREVENTION; NEOPLASIA; NEEDS	Background: Little is known about acceptability of the human papillomavirus (HPV) vaccine among parents of adolescents from culturally and linguistically diverse backgrounds in Australia. This study aimed to explore the knowledge and attitudes of parents from Arabic backgrounds towards HPV vaccination offered to their children in the national school-based vaccination program. Methods: Qualitative interviews were conducted in Western Sydney, with parents of adolescents from Arabic backgrounds. Recruitment was via informal personal contacts and passive snowballing. Face-to-face semi-structured interviews were conducted in Arabic. These were audio-recorded, transcribed, and translated into English. Thematic analysis was used to identify emerging themes. Results: Commonly identified themes across fifteen interviews included: (1) lack of awareness and knowledge of HPV and its vaccination, (2) awareness and understanding of the government vaccination information sheet, (3) parents' preferences for information provision, (4) the role of parents' religious beliefs in forming attitudes about HPV vaccination, and (5) lost opportunities to educate parents about HPV vaccination during general practitioner (GP) visits. Conclusion: The findings point to the need to address cultural, language, and communication barriers to improve awareness and acceptability of HPV vaccination in the Arabic community. Educational strategies should be tailored to this community based on their specific information needs and preferences.	[Netfa, Faeza; King, Catherine; Davies, Cristyn; Rashid, Harunor; Tashani, Mohamed; Booy, Robert; Skinner, S. Rachel] Univ Sydney, Childrens Hosp Westmead, Sch Clin, Discipline Child & Adolescent Hlth, Westmead, NSW 2145, Australia; [Netfa, Faeza; Davies, Cristyn; Skinner, S. Rachel] Childrens Hosp, Kids Res, Westmead, NSW 2145, Australia; [King, Catherine; Rashid, Harunor] Childrens Hosp, Natl Ctr Immunisat Res & Surveillance, Westmead, NSW 2145, Australia; [Tashani, Mohamed] Univ Tripoli, Fac Med, Tripoli 13275, Libya		Netfa, F (通讯作者)，Univ Sydney, Childrens Hosp Westmead, Sch Clin, Discipline Child & Adolescent Hlth, Westmead, NSW 2145, Australia.; Netfa, F (通讯作者)，Childrens Hosp, Kids Res, Westmead, NSW 2145, Australia.	fnet2280@uni.sydney.edu.au; catherine.king@health.nsw.gov.au; cristyn.davies@sydney.edu.au; harunor.rashid@health.nsw.gov.au; mohamed.tashani@health.nsw.gov.au; robert.booy@health.nsw.gov.au; rachel.skinner@health.nsw.gov.au	; Skinner, Rachel/J-8455-2017	Rashid, Harunor/0000-0003-2286-5139; Tashani, Mohamed/0000-0003-1669-1494; Skinner, Rachel/0000-0003-1970-9792			Abdi I, 2019, VACCINE, V37, P6724, DOI 10.1016/j.vaccine.2019.09.025; Achampong Y, 2018, J CANC THER, P9, DOI [10.4236/jct.2018.91009, DOI 10.4236/JCT.2018.91009]; Agius PA, 2010, VACCINE, V28, P4416, DOI 10.1016/j.vaccine.2010.04.038; Ahmed A, 2018, J INFECT PUBLIC HEAL, V11, P153, DOI 10.1016/j.jiph.2017.09.007; Allen JD, 2012, J ONCOL, V2012, DOI 10.1155/2012/401979; Australian Bureau of Statistics, 2021, MIGR AUSTR STAT AUST; Australian Bureau of Statistics, 2017, MULT 2016 CENS CENS; Ayash C, 2018, J COMMUN HEALTH, V43, P89, DOI 10.1007/s10900-017-0391-y; Barroso Luis F 2nd, 2011, Curr Infect Dis Rep, V13, P175, DOI 10.1007/s11908-010-0163-7; Bonville CA, 2019, HUM VACC IMMUNOTHER, V15, P1570, DOI 10.1080/21645515.2019.1627822; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI DOI 10.1191/1478088706QP063OA; Braun V, 2019, QUAL RES SPORT EXERC, V11, P589, DOI 10.1080/2159676X.2019.1628806; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brotherton JML, 2014, VACCINE, V32, P592, DOI 10.1016/j.vaccine.2013.11.075; Clyne M., 2006, INT J SOCIOL LANG, V180, P7, DOI [10.1515/IJSL.2006.037, DOI 10.1515/IJSL.2006.037]; Davies C., 2021, MED TODAY, V22, P57; Davies C, 2021, VACCINE, V39, P4190, DOI 10.1016/j.vaccine.2021.05.051; Davies C, 2017, SEX EDUC-SEX SOC LEA, V17, P256, DOI 10.1080/14681811.2017.1300770; de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716; Downs LS, 2010, GYNECOL ONCOL, V117, P486, DOI 10.1016/j.ygyno.2010.02.011; Elasbali AM, 2012, INFECT AGENTS CANCER, V7, DOI 10.1186/1750-9378-7-17; Fu LY, 2014, VACCINE, V32, P1901, DOI 10.1016/j.vaccine.2014.01.091; Garland SM, 2018, VACCINE, V36, P3221, DOI 10.1016/j.vaccine.2018.04.080; Garland SM, 2016, INT J CANCER, V139, P2812, DOI 10.1002/ijc.30391; Garland SM, 2011, PREV MED, V53, pS29, DOI 10.1016/j.ypmed.2011.08.015; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Hussain AN, 2016, J FAM COMMUNITY MED, V23, P145, DOI 10.4103/2230-8229.189107; Kpozehouen E, 2017, AUST NZ J PUBL HEAL, V41, P118, DOI 10.1111/1753-6405.12602; Kulasingam S, 2007, SEX HEALTH, V4, P165, DOI 10.1071/SH07043; Martins TR, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0594-3; Mortensen GL, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-68; Netfa F, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5020058; Olagbegi B., 2020, HUMAN PAPILLOMAVIRUS; Patel C, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.2018.23.41.1700737; Robbins SCC, 2010, HEALTH PSYCHOL, V29, P618, DOI 10.1037/a0021449; Salman KF, 2012, HEALTH CARE WOMEN IN, V33, P45, DOI 10.1080/07399332.2011.610536; Shah SM, 2008, J IMMIGR MINOR HEALT, V10, P429, DOI 10.1007/s10903-007-9106-2; Skinner SR, 2008, MED J AUSTRALIA, V188, P238, DOI 10.5694/j.1326-5377.2008.tb01593.x; Skinner SR, 2016, EXPERT REV VACCINES, V15, P367, DOI 10.1586/14760584.2016.1124763; Smith A, 2018, ASIA-PAC J CLIN ONCO, V14, P52, DOI 10.1111/ajco.12818; Spradley J., 1979, ETHNOGRAPHIC INTERVI; Wong LP, 2010, VACCINE, V28, P4499, DOI 10.1016/j.vaccine.2010.04.043; Wong LP, 2009, VACCINE, V27, P1410, DOI 10.1016/j.vaccine.2008.12.045; Bosch FX, 2008, VACCINE, V26, pK1, DOI 10.1016/j.vaccine.2008.05.064; Yang YT, 2017, JAMA-J AM MED ASSOC, V317, P803, DOI 10.1001/jama.2017.0123	46	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							940	10.3390/vaccines9090940			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UW3CW	34579177	Green Published, gold			2022-04-29	WOS:000700039400001
J	Tubiana, S; Labarere, J; Levraut, J; Michelet, P; de Vaux, FJ; Doumenc, B; Hausfater, P; Choquet, C; Plaisance, P; Schmidt, J; Mattei, V; Gacia, O; Storme, D; Ray, P; Sahakian, GD; Kouka, MC; Jainsky, L; Raude, J; Duval, X; Claessens, YE				Tubiana, Sarah; Labarere, Jose; Levraut, Jacques; Michelet, Pierre; de Vaux, Fleur Jourda; Doumenc, Benoit; Hausfater, Pierre; Choquet, Christophe; Plaisance, Patrick; Schmidt, Jeannot; Mattei, Veronique; Gacia, Olivier; Storme, Didier; Ray, Patrick; Der Sahakian, Guillaume; Kouka, Marie-Clement; Jainsky, Laure; Raude, Jocelyn; Duval, Xavier; Claessens, Yann-Erick			Effectiveness of a Multifaceted Informational-Based and Text Message Reminders on Pneumococcal and Influenza Vaccinations in Hospital Emergency Departments: A Cluster-Randomized Controlled Trial	VACCINES			English	Article						pneumococcal vaccine; influenza vaccine; reminder systems; emergency departments; cluster-randomized trial	CONJUGATE VACCINE; ADULTS; PNEUMONIA; RISK	Objectives. We aimed to evaluate the effectiveness of a multifaceted procedure in improving pneumococcal and influenza vaccinations 6 months after an emergency department (ED) visit among patients aged 65 years and older. Methods. We conducted a cluster-randomized, controlled, parallel-group, open-label implementation trial in 18 EDs in France and Monaco. Participants were recruited from November 2015 to September 2016. EDs were randomly assigned with a 1:1 ratio to provide either a multifaceted procedure that combined structured information about pneumococcal and influenza vaccines and three text message reminders sent to patients every two weeks (intervention arm) or nonstructured information only (control arm). The outcomes were self-reported pneumococcal vaccination and influenza vaccination rates within 6 months of enrollment. Results. A total of 9 EDs were randomized to the intervention arm (n = 780 patients) and 9 to the control arm (n = 695 patients). The median age for all enrolled patients was 74 years (25-75th percentiles, 69 to 82): 50.1% were male, 34.9% had at least one underlying condition, and 30.7% were at risk for invasive pneumococcal infection. In the intention-to-treat analysis, the multifaceted intervention did not alter the pneumococcal vaccination rate (6.4% versus 4.6%, absolute difference: 1.8; 95% CI: [-0.9 to 4.4]; p = 0.19), whereas it improved the influenza vaccination rate (52.1% versus 40.0%, absolute difference: 12.1; 95% CI: [2.4 to 21.8]; p = 0.01). At 12 months, mortality did not differ between the intervention (9.7%) and control (11.2%) arms (p = 0.35). Conclusions. A multifaceted intervention based on text message reminders provides an opportunity to increase anti-influenza vaccination among elderly patients visiting the ED. Efforts are warranted to provide better information on pneumococcal diseases and the benefits of pneumococcal vaccines, especially in the elderly.	[Tubiana, Sarah; Duval, Xavier] Hop Bichat Claude Bernard, AP HP, Ctr Invest Clin, INSERM CIC 1425, F-75018 Paris, France; [Tubiana, Sarah; Duval, Xavier] Univ Paris, IAME, INSERM, F-75018 Paris, France; [Labarere, Jose] Univ Grenoble Alpes, CNRS, TIMC UMR 5525, F-38041 Grenoble, France; [Labarere, Jose] Grenoble Univ Hosp, F-38043 Grenoble, France; [Levraut, Jacques] CHU Nice, Dept Med Urgence, Hop Pasteur II, F-06001 Nice, France; [Michelet, Pierre] Aix Marseille Univ, Dept Med Urgence, Hop Timone, AP HM,UMR C2VN, F-13005 Marseille, France; [de Vaux, Fleur Jourda] Hop Nord Marseille, APHM, EMSP & Urgences Adultes, F-13015 Marseille, France; [Doumenc, Benoit] Hop Cochin, AP HP, Serv Accueil Urgences, F-75014 Paris, France; [Hausfater, Pierre] Sorbonne Univ, Hop Pitie Salpetriere, AP HP, Serv Accueil Urgences,GRC 14 BIOSFAST, F-75651 Paris, France; [Choquet, Christophe] Hop Bichat Claude Bernard, APHP, Serv Accueil Urgences, F-75018 Paris, France; [Plaisance, Patrick] Hop Lariboisiere, APHP, Serv Accueil Urgences, F-75010 Paris, France; [Schmidt, Jeannot] CHU Clermont Ferrand, Serv Accueil Urgences, F-63003 Clermont Ferrand, France; [Mattei, Veronique] CH Menton, Serv Accueil Urgences, F-06507 Menton, France; [Gacia, Olivier] HIA Laveran, SSA, Serv Accueil Urgences, F-13384 Marseille, France; [Storme, Didier] CH Jacques Lacarin, Serv Accueil Urgences, F-03207 Vichy, France; [Ray, Patrick] Univ Bourgogne, Dept Univ Med Urgence, CHU Mitterrand, F-21000 Dijon, France; [Der Sahakian, Guillaume] FMI Nord Vaucluse, Ctr Hosp Orange, F-84104 Orange, France; [Kouka, Marie-Clement] Hop Delafontaine, Serv Accueil Urgences, F-93200 St Denis, France; [Jainsky, Laure] CH Paul Ardier Issoire, Serv Accueil Urgences, F-63500 Issoire, France; [Raude, Jocelyn] EHESP Sch Publ Hlth, F-35043 Rennes, France; [Claessens, Yann-Erick] Hop Princesse Grace, Serv Accueil Urgences, MC-98012 Monaco, Monaco		Tubiana, S (通讯作者)，Hop Bichat Claude Bernard, AP HP, Ctr Invest Clin, INSERM CIC 1425, F-75018 Paris, France.; Tubiana, S (通讯作者)，Univ Paris, IAME, INSERM, F-75018 Paris, France.	sarah.tubiana@aphp.fr; JLabarere@chu-grenoble.fr; levraut.j@chu-nice.fr; pierre.michelet@ap-hm.fr; fleur.jourda-de-vaux@ap-hm.fr; benoit.doumenc@aphp.fr; pierre.hausfater@aphp.fr; Christophe.choquet@aphp.fr; patrick.plaisance@aphp.fr; jschmidt@chu-clermontferrand.fr; v.mattei@ch-menton.fr; olivier.gacia@intradef.gouv.fr; didier.storme@ch-vichy.fr; patrick.ray@chu-dijon.fr; dersahakian@hotmail.fr; marie-clement.kouka@ch-stdenis.fr; ljainsky@ch-issoire.fr; Jocelyn.Raude@ehesp.fr; xavier.duval@aphp.fr; yann-erick.claessens@chpg.mc	Labarère, José/N-1688-2014	Labarère, José/0000-0001-7621-6586; tubiana, sarah/0000-0002-6526-6403; , Guillaume/0000-0002-1594-5299; Raude, Jocelyn/0000-0001-8020-4975	Centre Scientifique de Monaco [03/2012]; Pfizer company [53234817]	The study was granted by Centre Scientifique de Monaco (03/2012) with institutional support of the Pfizer company (Grant ID: 53234817).	[Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544; Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764; Briggs L, 2019, VACCINE, V37, P4454, DOI 10.1016/j.vaccine.2019.06.079; Campbell MK, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5661; Demicheli V, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004876.pub4; Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368; Habersaat KB, 2020, BUNDESGESUNDHEITSBLA, V63, P32, DOI 10.1007/s00103-019-03063-0; Herrett E., 2016, BMJ Open, V6, pe010069, DOI 10.1136/bmjopen-2015-010069; Ho HJ, 2019, AM J PUBLIC HEALTH, V109, P1776, DOI 10.2105/AJPH.2019.305328; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Kopp A, 2021, HUM VACC IMMUNOTHER, V17, P162, DOI 10.1080/21645515.2020.1756669; Loubet P, 2015, VACCINE, V33, P3703, DOI 10.1016/j.vaccine.2015.06.012; Naouri D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198474; Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017; Pallin DJ, 2005, VACCINE, V23, P1048, DOI 10.1016/j.vaccine.2004.06.053; Regan AK, 2017, ANN FAM MED, V15, P507, DOI 10.1370/afm.2120; Rimple D, 2006, ACAD EMERG MED, V13, P922, DOI 10.1197/j.aem.2006.04.022; Stockwell MS, 2012, JAMA-J AM MED ASSOC, V307, P1702, DOI 10.1001/jama.2012.502; Thomas RE, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005188.pub4; Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822; Torres A, 2013, THORAX, V68, P1057, DOI 10.1136/thoraxjnl-2013-204282; Tubiana S, 2020, HUM VACC IMMUNOTHER, V16, P851, DOI 10.1080/21645515.2019.1674598; Vann JCJ, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003941.pub3; Vietri J, 2020, HUM VACC IMMUNOTHER, V16, P161, DOI 10.1080/21645515.2019.1632683	25	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							962	10.3390/vaccines9090962			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW0NK	34579199	gold, Green Published			2022-04-29	WOS:000699863800001
J	Butler, C; Ellis, C; Folegatti, PM; Swayze, H; Allen, J; Bussey, L; Bellamy, D; Lawrie, A; Eagling-Vose, E; Yu, LM; Shanyinde, M; Mair, C; Flaxman, A; Ewer, K; Gilbert, S; Evans, TG				Butler, Chris; Ellis, Chris; Folegatti, Pedro M.; Swayze, Hannah; Allen, Julie; Bussey, Louise; Bellamy, Duncan; Lawrie, Alison; Eagling-Vose, Elizabeth; Yu, Ly-Mee; Shanyinde, Milensu; Mair, Catherine; Flaxman, Amy; Ewer, Katie; Gilbert, Sarah; Evans, Thomas G.		INVICTUS Investigators	Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS)	VACCINES			English	Article						MVA; influenza; vaccination; elderly; nucleoprotein	INFLUENZA VACCINE; SEASONAL INFLUENZA; IMMUNOGENICITY; PROTECTION; MVA-NP+M1; ILLNESS; BURDEN; ADULTS; US	Background: Pre-existing T cell responses to influenza have been correlated with improved clinical outcomes in natural history and human challenge studies. We aimed to determine the efficacy, safety and immunogenicity of a T-cell directed vaccine in older people. Methods: This was a multicentre, participant- and safety assessor-blinded, randomised, placebo-controlled trial of the co-administration of Modified Vaccinia Ankara encoding nucleoprotein and matrix protein 1 (MVA-NP+M1) and annual influenza vaccine in participants >= 65. The primary outcome was the number of days with moderate or severe influenza-like symptoms (ILS) during the influenza season. Results: 846 of a planned 2030 participants were recruited in the UK prior to, and throughout, the 2017/18 flu season. There was no evidence of a difference in the reported rates of days of moderate or severe ILS during influenza-like illness episodes (unadjusted OR = 0.95, 95% CI: 0.54-1.69; adjusted OR = 0.91, 95% CI: 0.51-1.65). The trial was stopped after one season due to a change in the recommended annual flu vaccine, for which safety of the new combination had not been established. More participants in the MVA-NP+M1 group had transient moderate or severe pain, redness, and systemic responses in the first seven days. Conclusion: The MVA-NP+M1 vaccine is well tolerated in those aged 65 years and over. Larger trials would be needed to determine potential efficacy.	[Butler, Chris; Swayze, Hannah; Allen, Julie; Yu, Ly-Mee; Shanyinde, Milensu] Univ Oxford, Nuffield Dept Primary Hlth Care Sci, Oxford OX2 6GG, England; [Ellis, Chris; Bussey, Louise; Eagling-Vose, Elizabeth; Evans, Thomas G.] Vaccitech Ltd, Oxford OX4 4GE, England; [Folegatti, Pedro M.; Bellamy, Duncan; Lawrie, Alison; Mair, Catherine; Flaxman, Amy; Ewer, Katie; Gilbert, Sarah] Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England		Evans, TG (通讯作者)，Vaccitech Ltd, Oxford OX4 4GE, England.	christopher.butler@phc.ox.ac.uk; chris.ellis@vaccitech.co.uk; pedro.folegatti@ndm.ox.ac.uk; hannah.swayze@phc.ox.ac.uk; julie.allen@phc.ox.ac.uk; louise.bussey@vaccitech.co.uk; duncan.bellamy@ndm.ox.ac.uk; alison.lawrie@ndm.ox.ac.uk; elizabeth.eagling-vose@vaccitech.co.uk; ly-mee.yu@phc.ox.ac.uk; milensu.shanyinde@phc.ox.ac.uk; 2177110M@student.gla.ac.uk; amy.flaxman@ndm.ox.ac.uk; katie.ewer@ndm.ox.ac.uk; sarah.gilbert@ndm.ox.ac.uk; tom.evans@vaccitech.co.uk	Folegatti, Pedro/AAD-5238-2019; Ewer, Katie/B-4328-2011	Folegatti, Pedro/0000-0001-5330-0240; Ewer, Katie/0000-0001-9827-9836; Bellamy, Duncan/0000-0003-3614-0032; Flaxman, Amy/0000-0001-6460-1372; Butler, Christopher/0000-0002-0102-3453	Vaccitech Ltd of Oxford, UK	This research was funded by Vaccitech Ltd of Oxford, UK.	Antrobus RD, 2014, MOL THER, V22, P668, DOI 10.1038/mt.2013.284; Antrobus RD, 2014, MOL THER, V22, P233, DOI 10.1038/mt.2013.162; Antrobus RD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048322; Berthoud TK, 2011, CLIN INFECT DIS, V52, P1, DOI 10.1093/cid/ciq015; Coughlan L, 2018, EBIOMEDICINE, V29, P146, DOI 10.1016/j.ebiom.2018.02.011; Cowling BJ, 2012, CLIN INFECT DIS, V54, P1778, DOI 10.1093/cid/cis307; Dawood FS, 2012, LANCET INFECT DIS, V12, P687, DOI 10.1016/S1473-3099(12)70121-4; Dunkle LM, 2017, NEW ENGL J MED, V376, P2427, DOI [10.1056/NEJMoa1608862, 10.1056/nejmoa1608862]; Folegatti PM, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010033; Goepfert PA, 2011, J INFECT DIS, V203, P610, DOI 10.1093/infdis/jiq105; Hayward AC, 2015, AM J RESP CRIT CARE, V191, P1422, DOI 10.1164/rccm.201411-1988OC; Hayward AC, 2014, LANCET RESP MED, V2, P445, DOI 10.1016/S2213-2600(14)70034-7; Howles S, 2010, VACCINE, V28, P7306, DOI 10.1016/j.vaccine.2010.08.077; Jang YH, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00344; Kimani D, 2014, MOL THER, V22, P1992, DOI 10.1038/mt.2014.109; Lee LYH, 2008, J CLIN INVEST, V118, P3478, DOI 10.1172/JCI32460; Lillie PJ, 2012, CLIN INFECT DIS, V55, P19, DOI 10.1093/cid/cis327; McElhaney JE, 2017, J INFECT DIS, V216, P399, DOI 10.1093/infdis/jix269; Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046; Nickbakhsh S, 2019, P NATL ACAD SCI USA, V116, P27142, DOI 10.1073/pnas.1911083116; Scriba TJ, 2010, EUR J IMMUNOL, V40, P279, DOI 10.1002/eji.200939754; Shay DK, 2017, J INFECT DIS, V215, P510, DOI 10.1093/infdis/jiw641; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; Swadling L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009185; van Beek J, 2017, J INFECT DIS, V216, P415, DOI 10.1093/infdis/jix268; Vu T, 2002, VACCINE, V20, P1831, DOI 10.1016/S0264-410X(02)00041-5; Zheng XY, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2888-5	27	2	2	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							851	10.3390/vaccines9080851			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3VR	34451976	gold, Green Published			2022-04-29	WOS:000689863500001
J	Chatterjee, R; Ghosh, M; Sahoo, S; Padhi, S; Misra, N; Raina, V; Suar, M; Son, YO				Chatterjee, Rahul; Ghosh, Mrinmoy; Sahoo, Susrita; Padhi, Santwana; Misra, Namrata; Raina, Visakha; Suar, Mrutyunjay; Son, Young-Ok			Next-Generation Bioinformatics Approaches and Resources for Coronavirus Vaccine Discovery and Development-A Perspective Review	VACCINES			English	Review						bioinformatics resources; coronavirus; immunoinformatics; vaccine; epitope	EPIDEMIOLOGY; RECOGNITION	COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To fight this pandemic, which has caused a massive death toll around the globe, researchers are putting efforts into developing an effective vaccine against the pathogen. As genome sequencing projects for several coronavirus strains have been completed, a detailed investigation of the functions of the proteins and their 3D structures has gained increasing attention. These high throughput data are a valuable resource for accelerating the emerging field of immuno-informatics, which is primarily aimed toward the identification of potential antigenic epitopes in viral proteins that can be targeted for the development of a vaccine construct eliciting a high immune response. Bioinformatics platforms and various computational tools and databases are also essential for the identification of promising vaccine targets making the best use of genomic resources, for further experimental validation. The present review focuses on the various stages of the vaccine development process and the vaccines available for COVID-19. Additionally, recent advances in genomic platforms and publicly available bioinformatics resources in coronavirus vaccine discovery together with related immunoinformatics databases and advances in technology are discussed.	[Chatterjee, Rahul; Sahoo, Susrita; Misra, Namrata; Raina, Visakha; Suar, Mrutyunjay] Kalinga Inst Ind Technol, Sch Biotechnol, Bhubaneswar 751024, India; [Ghosh, Mrinmoy; Padhi, Santwana; Misra, Namrata; Suar, Mrutyunjay] KIIT Technol Business Incubator, Bhubaneswar 751024, India; [Son, Young-Ok] Jeju Natl Univ, Fac Biotechnol, Dept Anim Biotechnol, Jeju 63243, South Korea; [Son, Young-Ok] Jeju Natl Univ, Biohlth Mat Core, Facil Ctr, Jeju 63243, South Korea; [Son, Young-Ok] Jeju Natl Univ, Pract Translat Res Ctr, Jeju 63243, South Korea; [Son, Young-Ok] Jeju Natl Univ, Interdisciplinary Grad Program Adv Convergence Te, Jeju 63243, South Korea		Suar, M (通讯作者)，Kalinga Inst Ind Technol, Sch Biotechnol, Bhubaneswar 751024, India.; Suar, M (通讯作者)，KIIT Technol Business Incubator, Bhubaneswar 751024, India.; Son, YO (通讯作者)，Jeju Natl Univ, Fac Biotechnol, Dept Anim Biotechnol, Jeju 63243, South Korea.; Son, YO (通讯作者)，Jeju Natl Univ, Biohlth Mat Core, Facil Ctr, Jeju 63243, South Korea.; Son, YO (通讯作者)，Jeju Natl Univ, Pract Translat Res Ctr, Jeju 63243, South Korea.; Son, YO (通讯作者)，Jeju Natl Univ, Interdisciplinary Grad Program Adv Convergence Te, Jeju 63243, South Korea.	rahulksbt@gmail.com; mringhs2010@gmail.com; ss.sahoo8976@gmail.com; santwana@kiitincubator.in; namrata@kiitincubator.in; vraina@kiitbiotech.ac.in; mrutyunjay@kiitincubator.in; sounagi@jejunu.ac.kr	Ghosh, Mrinmoy/ABB-4479-2021	Ghosh, Mrinmoy/0000-0001-6817-622X; Son, Youngok/0000-0003-0154-4061; Misra, Namrata/0000-0003-1813-6478	National Research Foundation of Korea (NRF) - Korean government (MSIT) [2020R1A2C2004128]; Korea Basic Science Institute (National Research Facilities and Equipment Center) - Ministry of Education [2020R1A6C101A188]	The authors are thankful to the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (2020R1A2C2004128), the Korea Basic Science Institute (National Research Facilities and Equipment Center) grant funded by the Ministry of Education (2020R1A6C101A188).	Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011; Alsulami A.F., 2020, BRIEF BIOINFORM, DOI [10.1101/2020.02.05.920009, DOI 10.1101/2020.02.05.920009]; Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007; Bennekov T, 2006, EUR J IMMUNOL, V36, P3346, DOI 10.1002/eji.200636128; Berger G., 2015, MED HYPOTHESES, V85, P664, DOI [10.1016/j.mehy.2015.08.010, DOI 10.1016/j.mehy.2015.08.010]; Calina D, 2020, INT J MOL MED, V46, P3, DOI 10.3892/ijmm.2020.4596; Ceraolo C, 2020, J MED VIROL, V92, P522, DOI 10.1002/jmv.25700; Chu HT, 2013, NAT IMMUNOL, V14, P668, DOI 10.1038/ni.2635; Conway DJ, 2015, TRENDS GENET, V31, P97, DOI 10.1016/j.tig.2014.12.005; Corey L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7732; Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227; Gowthaman R, 2021, NUCLEIC ACIDS RES, V49, pD282, DOI 10.1093/nar/gkaa731; Guirimand T, 2015, NUCLEIC ACIDS RES, V43, pD583, DOI 10.1093/nar/gku1121; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Hoffman SL, 2015, VACCINE, V33, pD13, DOI 10.1016/j.vaccine.2015.07.091; Hwang TJ, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3434; Iwasaki A, 2020, NAT REV IMMUNOL, V20, P339, DOI 10.1038/s41577-020-0321-6; Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6; Kahn JP, 2020, P NATL ACAD SCI USA, V117, P28538, DOI 10.1073/pnas.2021189117; Kaur SP, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198114; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Lim Yvonne Xinyi, 2016, Diseases, V4, DOI 10.3390/diseases4030026; Martin R, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101297; Mastelic B, 2013, BIOLOGICALS, V41, P458, DOI 10.1016/j.biologicals.2013.08.006; Meng G.A., 2020, DATABASE-OXFORD, pBAAA070, DOI [10.1093/database/baaa070, DOI 10.1093/database/baaa070]; O'Hagan DT, 2003, NAT REV DRUG DISCOV, V2, P727, DOI 10.1038/nrd1176; Ostaszewski M, 2020, SCI DATA, V7, DOI 10.1038/s41597-020-0477-8; Patiyal Sumeet, 2020, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, V39, DOI 10.1089/mab.2020.0035; Pelton SI, 2016, J ADOLESCENT HEALTH, V59, pS3, DOI 10.1016/j.jadohealth.2016.04.012; Pinto VV, 2012, VACCINE, V30, P572, DOI 10.1016/j.vaccine.2011.11.068; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Rappuoli R, 2001, VACCINE, V19, P2688, DOI 10.1016/S0264-410X(00)00554-5; Rappuoli R, 2011, NATURE, V473, P463, DOI 10.1038/nature10124; Rawat K, 2021, EUR J PHARMACOL, V892, DOI 10.1016/j.ejphar.2020.173751; Raybould Matthew I J, 2021, Bioinformatics, V37, P734, DOI 10.1093/bioinformatics/btaa739; Rezaei S., 2021, AUTHOREA PREPR, DOI [10.22541/au.161659301.15541515/v1, DOI 10.22541/AU.161659301.15541515/V1]; Rouse BT, 2010, NAT REV IMMUNOL, V10, P514, DOI 10.1038/nri2802; Sahoo S, 2021, COMPUT BIOL MED, V129, DOI 10.1016/j.compbiomed.2020.104131; Shen ZJ, 2020, CLIN INFECT DIS, V71, P713, DOI 10.1093/cid/ciaa203; Shrotri M, 2021, LANCET GLOB HEALTH, V9, pE590, DOI 10.1016/S2214-109X(21)00043-7; Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494; Tzou PL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12091006; Ward D, 2021, GENOME MED, V13, DOI 10.1186/s13073-020-00822-6; Wu JC, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.572249; Wu SC, 2020, BIOTECHNOL J, V15, DOI 10.1002/biot.202000147; Bosch FX, 2013, VACCINE, V31, pH1, DOI [10.1016/j.vaccine.2013.10.003, 10.1016/j.vaccine.2013.07.026]; Zhu ZL, 2021, GENOME BIOL EVOL, V13, DOI 10.1093/gbe/evab015; Zhu ZL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78703-6	49	4	4	5	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							812	10.3390/vaccines9080812			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6GQ	34451937	gold, Green Published			2022-04-29	WOS:000690027200001
J	Duran-Olivencia, MA; Kalliadasis, S				Duran-Olivencia, Miguel A.; Kalliadasis, Serafim			Understanding Soaring Coronavirus Cases and the Effect of Contagion Policies in the UK	VACCINES			English	Article						COVID-19; SARS-CoV-2; SIR		The number of new daily SARS-CoV-2 infections experienced an abrupt increase during the last quarter of 2020 in almost every European country. The phenomenological explanation offered was a new mutation of the virus, first identified in the UK. We use publicly available data in combination with a time-delayed controlled SIR model, which captures the effects of preventive measures on the spreading of the virus. We are able to reproduce the waves of infection occurred in the UK with a unique transmission rate, suggesting that the new SARS-CoV-2 variant is as transmissible as previous strains. Our findings indicate that the sudden surge in cases was, in fact, related to the relaxation of preventive measures and social awareness. We also simulate the combined effects of restrictions and vaccination campaigns in 2021, demonstrating that lockdown policies are not fully effective to flatten the curve. For effective mitigation, it is critical that the public keeps on high alert until vaccination reaches a critical threshold.	[Duran-Olivencia, Miguel A.; Kalliadasis, Serafim] Imperial Coll London, Dept Chem Engn, London SW7 2AZ, England		Kalliadasis, S (通讯作者)，Imperial Coll London, Dept Chem Engn, London SW7 2AZ, England.	m.duran-olivencia@imperial.ac.uk; s.kalliadasis@imperial.ac.uk		Duran-Olivencia, Miguel A./0000-0003-3835-654X; Kalliadasis, Serafim/0000-0001-9858-3504	Engineering and Physical Sciences Research Council of the UKUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/L020564/1]	This research was funded by the Engineering and Physical Sciences Research Council of the UK via grant No. EP/L020564/1.	[Anonymous], 2020, BBC NEWS 0918; [Anonymous], 2020, PM COMMONS STATEMENT; Clark, 2021, SUN; Cooper I, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110057; Hasell J, 2020, SCI DATA, V7, DOI 10.1038/s41597-020-00688-8; Hindmarsh A.C., 1983, SCI COMPUTING, P55; Katul GG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239800; Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Macfarlane, 2021, SCOTSMAN; Nguemdjo U, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237832; Virtanen P, 2020, NAT METHODS, V17, P261, DOI 10.1038/s41592-019-0686-2; Volz E., 2021, TRANSMISSION SARS CO, DOI [10.1101/2020.12.30.20249034, DOI 10.1101/2020.12.30.20249034]; Weitz JS, 2020, NAT MED, V26, P849, DOI 10.1038/s41591-020-0895-3	14	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							735	10.3390/vaccines9070735			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5II	34358151	Green Published, Green Submitted, gold			2022-04-29	WOS:000676944700001
J	Wagner, R; Hildt, E; Grabski, E; Sun, YS; Meyer, H; Lommel, A; Keller-Stanislawski, B; Muller-Berghaus, J; Cichutek, K				Wagner, Ralf; Hildt, Eberhard; Grabski, Elena; Sun, Yuansheng; Meyer, Heidi; Lommel, Annette; Keller-Stanislawski, Brigitte; Mueller-Berghaus, Jan; Cichutek, Klaus			Accelerated Development of COVID-19 Vaccines: Technology Platforms, Benefits, and Associated Risks	VACCINES			English	Article						SARS-CoV-2; vaccine development; clinical trials; marketing authorization	INFECTION	Multiple preventive COVID-19 vaccines have been developed during the ongoing SARS coronavirus (CoV) 2 pandemic, utilizing a variety of technology platforms, which have different properties, advantages, and disadvantages. The acceleration in vaccine development required to combat the current pandemic is not at the expense of the necessary regulatory requirements, including robust and comprehensive data collection along with clinical product safety and efficacy evaluation. Due to the previous development of vaccine candidates against the related highly pathogenic coronaviruses SARS-CoV and MERS-CoV, the antigen that elicits immune protection is known: the surface spike protein of SARS-CoV-2 or specific domains encoded in that protein, e.g., the receptor binding domain. From a scientific point of view and in accordance with legal frameworks and regulatory practices, for the approval of a clinic trial, the Paul-Ehrlich-Institut requires preclinical testing of vaccine candidates, including general pharmacology and toxicology as well as immunogenicity. For COVID-19 vaccine candidates, based on existing platform technologies with a sufficiently broad data base, pharmacological-toxicological testing in the case of repeated administration, quantifying systemic distribution, and proof of vaccination protection in animal models can be carried out in parallel to phase 1 or 1/2 clinical trials. To reduce the theoretical risk of an increased respiratory illness through infection-enhancing antibodies or as a result of Th2 polarization and altered cytokine profiles of the immune response following vaccination, which are of specific concern for COVID-19 vaccines, appropriate investigative testing is imperative. In general, phase 1 (vaccine safety) and 2 (dose finding, vaccination schedule) clinical trials can be combined, and combined phase 2/3 trials are recommended to determine safety and efficacy. By applying these fundamental requirements not only for the approval and analysis of clinical trials but also for the regulatory evaluation during the assessment of marketing authorization applications, several efficacious and safe COVID-19 vaccines have been licensed in the EU by unprecedentedly fast and flexible procedures. Procedural and regulatory-scientific aspects of the COVID-19 licensing processes are described in this review.	[Wagner, Ralf; Hildt, Eberhard; Grabski, Elena; Sun, Yuansheng; Meyer, Heidi; Lommel, Annette; Keller-Stanislawski, Brigitte; Mueller-Berghaus, Jan; Cichutek, Klaus] Paul Ehrlich Inst, Fed Inst Vaccines & Biomed, D-63225 Langen, Germany		Cichutek, K (通讯作者)，Paul Ehrlich Inst, Fed Inst Vaccines & Biomed, D-63225 Langen, Germany.	ralf.wagner@pei.de; Eberhard.Hildt@pei.de; elena.grabski@pei.de; Yuansheng.sun@pei.de; Heidi.Meyer@pei.de; Annette.Lommel@pei.de; brigitte.keller-stanislawski@pei.de; Jan.Mueller-Berghaus@pei.de; klaus.cichutek@pei.de		hildt, eberhard/0000-0002-3020-9564			Acosta PL, 2016, CLIN VACCINE IMMUNOL, V23, P189, DOI 10.1128/CVI.00609-15; Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688; European Medicines Agency, EMEACHMPSWP2836707 EMEACHMPSWP2836707; European Medicines Agency, COND MARK AUTH; European Medicines Agency, COVID 19 VACC AUTH; Garcia-Nicolas O, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.644574; Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI 10.1073/pnas.2009799117; Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027; Li QQ, 2021, CELL, V184, P2362, DOI 10.1016/j.cell.2021.02.042; Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158; Munoz-Fontela C, 2020, NATURE, V586, P509, DOI 10.1038/s41586-020-2787-6; Rathnasinghe Raveen, 2021, medRxiv, DOI 10.1101/2021.01.19.21249592; Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5; Smatti MK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02991; Defendi HGT, 2021, J PHARM INNOV, DOI 10.1007/s12247-021-09535-8; Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006; Waris ME, 1996, J VIROL, V70, P2852, DOI 10.1128/JVI.70.5.2852-2860.1996; Wen JQ, 2020, INT J INFECT DIS, V100, P483, DOI 10.1016/j.ijid.2020.09.015; WHO, 2004, WHO TECHN REP SER, V924; Winkler ES, 2020, NAT IMMUNOL, V21, P1327, DOI 10.1038/s41590-020-0778-2; World Health Organization, DRAFT LANDSC COVID 1; World Health Organization, WHO TECHN REP SER, V927; World Health Organization, COR DIS COVID 19 WEE	23	0	0	7	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							747	10.3390/vaccines9070747			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8RJ	34358163	gold, Green Published			2022-04-29	WOS:000677171000001
J	Zhang, SX; Tang, XM; Wang, S; Shi, FY; Duan, CH; Bi, FF; Suo, JX; Hu, DD; Liu, J; Wang, CY; Suo, X; Liu, XY				Zhang, Sixin; Tang, Xinming; Wang, Si; Shi, Fangyun; Duan, Chunhui; Bi, Feifei; Suo, Jingxia; Hu, Dandan; Liu, Jie; Wang, Chaoyue; Suo, Xun; Liu, Xianyong			Establishment of Recombinant Eimeria acervulina Expressing Multi-Copies M2e Derived from Avian Influenza Virus H9N2	VACCINES			English	Article						Eimeria acervulina; wing vein; stable transfection; live vaccine vector	STABLE TRANSFECTION; LIVE VACCINES; TENELLA; SPOROZOITES; DELIVERY; PROTEIN	The potential of Eimeria parasites as live vaccine vectors has been reported with successful genetic manipulation on several species like E. tenella, E. mitis and E. necatrix. Among seven Eimeria species infecting chickens, E. acervulina is a highly prevalent, moderately pathogenic species. Thus, it is valuable for the study of transfection and for use as a potential as vaccine vector. In this study, a plasmid containing expression cassette with enhanced yellow fluorescent protein (EYFP), red fluorescent protein (RFP) and 12 copies of extracellular domain of H9N2 avian influenza virus M2 (M2e) protein was used for the transfection. Nucleofected sporozoites were inoculated into birds through wing vein. Recombinant E. acervulina oocysts with 0.1% EYFP+ and RFP+ populations were collected from the feces of the inoculated birds. The fluorescent rate of transgenic parasites reached over 95% after nine successive propagations with a pyrimethamine selection in vivo and fluorescent-activated cell sorting (FACS) of progeny oocysts. The expression of M2e in the transgenic parasites (EaM2e) was confirmed byWestern blot and its cytoplasm localization in sporozoites was displayed by an indirect immunofluorescent assay (IFA). Meanwhile, we found that the fecundity of EaM2e was equivalent to that of wild type E. acervulina (EaWT). Taken together, the stable transfection of E. acervulina was successfully established. Future studies will focus on whether transgenic E. acervulina can serve as a live vaccine vector.	[Zhang, Sixin; Wang, Si; Shi, Fangyun; Duan, Chunhui; Bi, Feifei; Suo, Jingxia; Hu, Dandan; Liu, Jie; Wang, Chaoyue; Suo, Xun; Liu, Xianyong] China Agr Univ, Coll Vet Med, Natl Anim Protozoa Lab, Beijing 100193, Peoples R China; [Tang, Xinming] Chinese Acad Agr Sci, Inst Anim Sci, Beijing 100193, Peoples R China		Liu, XY (通讯作者)，China Agr Univ, Coll Vet Med, Natl Anim Protozoa Lab, Beijing 100193, Peoples R China.	zhangsixin@cau.edu.cn; tangxinming@caas.cn; wangsi@cau.edu.cn; shifangyun@cau.edu.cn; chunhuiduan@cau.edu.cn; bifeifei@cau.edu.cn; suojingxia@cau.edu.cn; B20153050195@cau.edu.cn; bs20193050493@cau.edu.cn; bs20173050413@cau.edu.cn; suoxun@cau.edu.cn; liuxianyong@cau.edu.cn		Hu, Dandan/0000-0001-9917-4817; Tang, Xinming/0000-0003-0127-1235	National Key Research and Development Program of China [2018YFD0500300, 2016YFD0501300, 2017YFD0501200]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31873007, 31772728]	This research was supported National Key Research and Development Program of China (2018YFD0500300, 2016YFD0501300 and 2017YFD0501200) and the National Natural Science Foundation of China (31873007 and 31772728).	Blake DP, 2020, VET RES, V51, DOI 10.1186/s13567-020-00837-2; Chapman HD, 2014, INT J PARASITOL-DRUG, V4, P214, DOI 10.1016/j.ijpddr.2014.10.002; Chumakov K, 2020, SCIENCE, V368, P1187, DOI 10.1126/science.abc4262; Clark JD, 2008, MOL BIOCHEM PARASIT, V162, P77, DOI 10.1016/j.molbiopara.2008.07.006; Clark JD, 2012, VACCINE, V30, P2683, DOI 10.1016/j.vaccine.2012.02.002; de Waal DT, 2006, VET PARASITOL, V138, P88, DOI 10.1016/j.vetpar.2006.01.042; Duan CH, 2019, MOL BIOCHEM PARASIT, V228, P1, DOI 10.1016/j.molbiopara.2019.01.002; Fetterer RH, 2003, J PARASITOL, V89, P553, DOI 10.1645/GE-3159; Garg N, 1997, J IMMUNOL, V158, P3293; Gregg B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022936; Hu DD, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00128; Kelleher M, 1998, MOL BIOCHEM PARASIT, V97, P21, DOI 10.1016/S0166-6851(98)00128-5; Kim JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018556; Kim K, 2004, INT J PARASITOL, V34, P423, DOI 10.1016/j.ijpara.2003.12.009; Li ZR, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00533; Liu XY, 2008, MOL BIOCHEM PARASIT, V161, P72, DOI 10.1016/j.molbiopara.2008.06.006; Liu XY, 2013, VET PARASITOL, V193, P1, DOI 10.1016/j.vetpar.2012.12.019; LONG P L, 1976, Folia Veterinaria Latina, V6, P201; Ma JH, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-227; MARTIN A, 1995, AVIAN DIS, V39, P538, DOI 10.2307/1591807; NORTON AJ, 1994, J PATHOL, V173, P371, DOI 10.1002/path.1711730413; Pastor-Fernandez I, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-04210-2; Qin M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114188; ROSE ME, 1991, PARASITOLOGY, V102, P317, DOI 10.1017/S0031182000064258; Sateriale A, 2020, METHODS MOL BIOL, P219, DOI 10.1007/978-1-4939-9748-0_13; SCHMATZ DM, 1984, J PROTOZOOL, V31, P181, DOI 10.1111/j.1550-7408.1984.tb04314.x; Shi TY, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00807; Tang XM, 2020, VET RES, V51, DOI 10.1186/s13567-020-00766-0; Tang XM, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00861-19; Tang XM, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01982; Tang XM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29379; Tang XM, 2016, VET RES, V47, DOI 10.1186/s13567-016-0351-z; Tao GR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00002; Tian YH, 2019, GASTROENTEROLOGY, V156, P2281, DOI 10.1053/j.gastro.2019.02.023; Williams RB, 2002, AVIAN DIS, V46, P775, DOI 10.1637/0005-2086(2002)046[0775:FYOAVF]2.0.CO;2; Yan WC, 2009, INT J PARASITOL, V39, P109, DOI 10.1016/j.ijpara.2008.06.013; Zhang ZC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115411	37	0	0	4	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							791	10.3390/vaccines9070791			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7AB	34358207	gold, Green Published			2022-04-29	WOS:000677058400001
J	Abu-Hammad, O; Alduraidi, H; Abu-Hammad, S; Alnazzawi, A; Babkair, H; Abu-Hammad, A; Nourwali, I; Qasem, F; Dar-Odeh, N				Abu-Hammad, Osama; Alduraidi, Hamza; Abu-Hammad, Shaden; Alnazzawi, Ahmed; Babkair, Hamzah; Abu-Hammad, Abdalla; Nourwali, Ibrahim; Qasem, Farah; Dar-Odeh, Najla			Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines	VACCINES			English	Article						COVID-19; AstraZeneca vaccine; Pfizer-Bionteck vaccine; SinoPharm; side effects; healthcare professionals; physicians; nurses; dentists		Background Distribution of COVID-19 vaccines has been surrounded by suspicions and rumors making it necessary to provide the public with accurate reports from trustworthy experts such as healthcare professionals. Methods We distributed a questionnaire in Jordan among physicians, dentists and nurses who received a COVID-19 vaccine to explore the side effects (SE) they encountered after the first or the second dose of one of three vaccines namely: AstraZeneca Vaxzevria (AZ), Pfizer-BioNTeck (PB), and SinoPharm (SP) vaccines. Results A total of 409 professionals participated. Approximately 18% and 31% of participants reported no SE after the first dose and second dose, respectively. The remainder had mostly local side effects related to injection site (74%). Systemic side effects in the form of fatigue (52%), myalgia (44%), headache (42%), and fever (35%) prevailed mainly after the first dose. These were significantly associated with AZ vaccine, and age <= 45 years (p = 0.000 and 0.01, respectively). No serious SE were reported. Conclusions We can conclude that SE of COVID-19 vaccines distributed in Jordan are within the common range known so far for these vaccines. Further studies are needed to include larger sample size and longer follow-up period to monitor possible serious and long-term SE of the vaccines.	[Abu-Hammad, Osama; Alnazzawi, Ahmed; Babkair, Hamzah; Nourwali, Ibrahim; Dar-Odeh, Najla] Taibah Univ, Coll Dent, Al Madinah Al Munawara 43353, Saudi Arabia; [Abu-Hammad, Osama; Dar-Odeh, Najla] Univ Jordan, Sch Dent, Amman 11942, Jordan; [Alduraidi, Hamza] Univ Jordan, Sch Nursing, Amman 11942, Jordan; [Abu-Hammad, Shaden] Comprehens Amman Healthcare Ctr, Amman 11192, Jordan; [Abu-Hammad, Abdalla] Univ Jordan, Sch Med, Amman 11942, Jordan; [Qasem, Farah] Univ Jordan Hosp, Amman 11942, Jordan		Dar-Odeh, N (通讯作者)，Taibah Univ, Coll Dent, Al Madinah Al Munawara 43353, Saudi Arabia.; Dar-Odeh, N (通讯作者)，Univ Jordan, Sch Dent, Amman 11942, Jordan.	oabuhammad@taibahu.edu.sa; h.alduraidi@ju.edu.jo; Shadenabuhammad@gmail.com; anazawi@taibahu.edu.sa; hbabkair@taibahu.edu.sa; abdullah018ju@gmail.com; Ibrahim_germany@hotmail.com; farahqasem@outlook.com; ndarodeh@taibahu.edu.sa	; Dar-Odeh, Najla/E-6099-2011; Alduraidi, Hamza/X-1292-2019	Alnazzawi, Ahmad/0000-0003-4041-4083; Dar-Odeh, Najla/0000-0002-6577-2373; Babkair, Hamzah/0000-0001-7079-4684; Alduraidi, Hamza/0000-0003-1762-0575			Abu-Hammad O, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8030216; Abu-Hammad S, 2022, ORAL DIS, V28, P933, DOI 10.1111/odi.13498; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Ashraf MU, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020171; Baraniuk C, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n912; Cavaleri M, 2021, LANCET, V397, P355, DOI 10.1016/S0140-6736(21)00085-4; Dar-Odeh N, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093151; Elsayed SA, 2020, J CRANIOFAC SURG, V31, pE643, DOI 10.1097/SCS.0000000000006752; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; Hammoudeh A, 2020, INT J CLIN CARDIOL, V7, P185; Khan YH, 2020, AM J TROP MED HYG, V103, P603, DOI 10.4269/ajtmh.20-0654; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; Ostergaard SD, 2021, LANCET, V397, P1441, DOI 10.1016/S0140-6736(21)00762-5; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Rodriguez-Coira J, 2021, ALLERGY, V76, P1922, DOI 10.1111/all.14714; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wise J, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n921; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699	20	24	24	10	22	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							577	10.3390/vaccines9060577			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ0UD	34205917	gold, Green Published			2022-04-29	WOS:000666290700001
J	Itzhaki, RF				Itzhaki, Ruth F.			Overwhelming Evidence for a Major Role for Herpes Simplex Virus Type 1 (HSV1) in Alzheimer's Disease (AD); Underwhelming Evidence against	VACCINES			English	Review						Alzheimer's disease; herpes simplex virus type 1 (HSV1); apolipoprotein E (APOE); brain; antivirals	MILD COGNITIVE IMPAIRMENT; VARICELLA-ZOSTER-VIRUS; CALMETTE-GUERIN BCG; APOLIPOPROTEIN-E; APOE EPSILON-4; FOLLOW-UP; BRAIN; INFECTION; RISK; POLYSACCHARIDES	This review describes investigations of specific topics that lie within the general subject of HSV1's role in AD/dementia, published in the last couple of years. They include studies on the following: relationship of HSV1 to AD using neural stem cells; the apparent protective effects of treatment of HSV1 infection or of VZV infection with antivirals prior to the onset of dementia; the putative involvement of VZV in AD/dementia; the possible role of human herpes virus 6 (HHV6) in AD; the seemingly reduced risk of dementia after vaccination with diverse types of vaccine, and the association shown in some vaccine studies with reduced frequency of HSV1 reactivation; anti-HSV serum antibodies supporting the linkage of HSV1 in brain with AD in APOE-epsilon 4 carriers, and the association between APOE and cognition, and association of APOE and infection with AD/dementia. The conclusions are that there is now overwhelming evidence for HSV1's role-probably causal-in AD, when it is present in brain of APOE-epsilon 4 carriers, and that further investigations should be made on possible prevention of the disease by vaccination, or by prolonged antiviral treatment of HSV1 infection in APOE-epsilon 4 carriers, before disease onset.	[Itzhaki, Ruth F.] Univ Oxford, Inst Populat Ageing, 66 Banbury Rd, Oxford OX2 6PR, England		Itzhaki, RF (通讯作者)，Univ Oxford, Inst Populat Ageing, 66 Banbury Rd, Oxford OX2 6PR, England.	ruth.itzhaki@manchester.ac.uk			Advantage Foundation	I thank Dana Cairns and David Kaplan for devising and providing Figure 1. I thank the Advantage Foundation for financial support.	Abrahamson EE, 2021, J VIROL, V95, DOI 10.1128/JVI.02219-20; Adesanya OA, 2021, AIMS MICROBIOL, V7, P96, DOI 10.3934/microbiol.2021007; Agostini S, 2016, BRAIN BEHAV IMMUN, V58, P254, DOI 10.1016/j.bbi.2016.07.153; Agostini S, 2014, EXPERT REV ANTI-INFE, V12, P275, DOI 10.1586/14787210.2014.887442; Allnutt MA, 2020, NEURON, V105, P1027, DOI 10.1016/j.neuron.2019.12.031; Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010; Bae S, 2021, EUR ARCH PSY CLIN N, V271, P987, DOI 10.1007/s00406-020-01157-4; Cairns DM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay8828; Chen VCH, 2018, J CLIN PSYCHIAT, V79, DOI 10.4088/JCP.16m11312; Choi SH, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0139-7; Chorlton SD, 2020, J BIOINF COMPUT BIOL, V18, DOI 10.1142/S0219720020500122; Cummings J, 2021, MOL NEURODEGENER, V16, DOI 10.1186/s13024-021-00424-9; D'Aiuto L, 2019, J VIROL, V93, DOI 10.1128/JVI.00111-19; De Chiara G, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007617; Dobson CB, 2006, J INFECT DIS, V193, P442, DOI 10.1086/499280; Doll JR, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008296; Duarte LF, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00046; Gege C, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf8668; Gharbi-Meliani A, 2021, ALZHEIMERS RES THER, V13, DOI 10.1186/s13195-020-00740-0; Gofrit ON, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224433; Grahn A, 2013, J NEUROL, V260, P2761, DOI 10.1007/s00415-013-7057-1; Harden EA, 2009, ANTIVIR RES, V83, P282, DOI 10.1016/j.antiviral.2009.06.007; Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597; Hemling N, 2003, ANN NEUROL, V54, P267, DOI 10.1002/ana.10662; Heneka MT, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00640-3; HIPPMANN G, 1992, WIEN KLIN WOCHENSCHR, V104, P200; Itzhaki RF, 2002, CAN MED ASSOC J, V167, P13; Itzhaki RF, 1997, LANCET, V349, P241, DOI 10.1016/S0140-6736(96)10149-5; Itzhaki RF, 2008, J NEUROVIROL, V14, P1, DOI 10.1080/13550280701802543; Itzhaki RF, 2020, J ALZHEIMERS DIS, V76, P85, DOI 10.3233/JAD-200210; Itzhaki RF, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00324; Itzhaki RF, 2018, J ALZHEIMERS DIS, V64, P363, DOI 10.3233/JAD-180266; Itzhaki RF, 2017, FASEB J, V31, P3216, DOI 10.1096/fj.201700360; Itzhaki RF, 2009, APOPROTEIN RESEARCH, P99; JAMIESON GA, 1991, J MED VIROL, V33, P224, DOI 10.1002/jmv.1890330403; Kelly BA, 2007, FEBS J, V274, P4511, DOI 10.1111/j.1742-4658.2007.05981.x; Kobayashi N, 2013, BIOCHEM BIOPH RES CO, V430, P907, DOI 10.1016/j.bbrc.2012.12.054; Kristen H, 2018, NEUROBIOL AGING, V68, P5, DOI 10.1016/j.neurobiolaging.2018.03.025; Kuo CL, 2020, J GERONTOL A-BIOL, V75, P2231, DOI 10.1093/gerona/glaa131; Kwon PS, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-00192-8; Le Balc'h P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03252-3; Leentjens J, 2015, J INFECT DIS, V212, P1930, DOI 10.1093/infdis/jiv332; Letenneur L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003637; Lin WR, 2002, J PATHOL, V197, P395, DOI 10.1002/path.1127; Linard M, 2020, ALZHEIMERS DEMENT, V16, P200, DOI 10.1002/alz.12008; Lindman KL, 2019, ALZH DEMENT-TRCI, V5, P697, DOI 10.1016/j.trci.2019.09.014; Lindman KL, 2021, ALZH DEMENT-TRCI, V7, DOI 10.1002/trc2.12119; Lovheim H, 2019, J ALZHEIMERS DIS, V67, P211, DOI 10.3233/JAD-171162; Mancuso R, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00285; Mancuso R, 2014, J ALZHEIMERS DIS, V38, P741, DOI 10.3233/JAD-130977; Montagne A, 2020, NATURE, V581, P70, DOI 10.1038/s41586-020-2247-3; Montagne A, 2015, NEURON, V85, P296, DOI 10.1016/j.neuron.2014.12.032; Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020; Muir K.R., 2021, PLOS ONE; Muir K.R., 2021, BR MED J OPEN; Murphy MJ, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87963-9; Pandey JP, 2020, J IMMUNOL, V205, P1318, DOI 10.4049/jimmunol.2000351; Pirttila T, 2000, ACTA NEUROL SCAND, V102, P94, DOI 10.1034/j.1600-0404.2000.102002094.x; Pittet LF, 2021, PEDIATR INFECT DIS J, V40, pS16, DOI 10.1097/INF.0000000000002846; Pradeepkiran JA, 2020, AGEING RES REV, V64, DOI 10.1016/j.arr.2020.101191; Protto V, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8070972; Readhead B, 2018, NEURON, V99, P64, DOI 10.1016/j.neuron.2018.05.023; Reddy PH, 2004, HUM MOL GENET, V13, P1225, DOI 10.1093/hmg/ddh140; Schnier C, 2020, NEUROLOGY, V95, pE1686, DOI 10.1212/WNL.0000000000010358; Simonnet A, 2021, INFECT DIS NOW, V51, P296, DOI 10.1016/j.idnow.2021.01.005; Thakur KT, 2021, BRAIN, V144, P2696, DOI 10.1093/brain/awab148; Tsai MC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188490; Tzeng NS, 2018, NEUROTHERAPEUTICS, V15, P417, DOI 10.1007/s13311-018-0611-x; Verreault R, 2001, CAN MED ASSOC J, V165, P1495; Waisner H, 2019, J VIROL, V93, DOI 10.1128/JVI.01258-19; Wang W, 2012, MAR DRUGS, V10, P2795, DOI 10.3390/md10122795; Wozniak MA, 2002, HEPATOLOGY, V36, P456, DOI 10.1053/jhep.2002.34745; Wozniak M, 2015, INT J BIOL MACROMOL, V74, P530, DOI 10.1016/j.ijbiomac.2015.01.003; Wozniak MA, 2007, EUR J HUM GENET, V15, P672, DOI 10.1038/sj.ejhg.5201812; Wozniak MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025152; Wozniak Matthew A, 2010, Ther Adv Neurol Disord, V3, P141, DOI 10.1177/1756285610370069; Xiao SF, 2021, ALZHEIMERS RES THER, V13, DOI 10.1186/s13195-021-00795-7; Xu R, 2020, BRIT J DERMATOL, V183, P1145, DOI 10.1111/bjd.19484; Zhao C, 2020, NEUROL-GENET, V6, DOI 10.1212/NXG.0000000000000462; Zuo ZJ, 2017, NEUROBIOL DIS, V101, P27, DOI 10.1016/j.nbd.2017.02.001	80	5	5	3	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							679	10.3390/vaccines9060679			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TA6ZR	34205498	Green Published, gold			2022-04-29	WOS:000667397000001
J	Ma, CY; McClean, S				Ma, Chaoying; McClean, Siobhan			Mapping Global Prevalence of Acinetobacter baumannii and Recent Vaccine Development to Tackle It	VACCINES			English	Review						Acinetobacter baumannii; antimicrobial resistance; ESKAPE; virulence factors; vaccines; immune response	OUTER-MEMBRANE-PROTEIN; GAMMA-GLUTAMYL-TRANSFERASE; ELICITS PROTECTIVE IMMUNITY; K1 CAPSULAR POLYSACCHARIDE; TRIMERIC AUTOTRANSPORTER; ANTIBIOTIC-RESISTANCE; EPITHELIAL-CELLS; SP NOV.; PROGNOSTIC-FACTORS; BIOFILM FORMATION	Acinetobacter baumannii is a leading cause of nosocomial infections that severely threaten public health. The formidable adaptability and resistance of this opportunistic pathogen have hampered the development of antimicrobial therapies which consequently leads to very limited treatment options. We mapped the global prevalence of multidrug-resistant A. baumannii and showed that carbapenem-resistant A. baumannii is widespread throughout Asia and the Americas. Moreover, when antimicrobial resistance rates of Acinetobacter spp. exceed a threshold level, the proportion of A. baumannii isolates from clinical samples surges. Therefore, vaccines represent a realistic alternative strategy to tackle this pathogen. Research into anti-A. baumannii vaccines have enhanced in the past decade and multiple antigens have been investigated preclinically with varying results. This review summarises the current knowledge of virulence factors relating to A. baumannii-host interactions and its implication in vaccine design, with a view to understanding the current state of A. baumannii vaccine development and the direction of future efforts.	[Ma, Chaoying; McClean, Siobhan] Univ Coll Dublin, Sch Biomol & Biomed Sci, Dublin D04 V1W8 4, Ireland		McClean, S (通讯作者)，Univ Coll Dublin, Sch Biomol & Biomed Sci, Dublin D04 V1W8 4, Ireland.	chaoying.ma@ucdconnect.ie; siobhan.mcclean@ucd.ie		Ma, Chaoying/0000-0002-5277-1603	University College Dublin [CSC202008300014]; European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grantSKA South Africa [860325]; China Scholarship CouncilChina Scholarship Council	C.M. holds a dChina Scholarship Council studentship with University College Dublin under grant number CSC202008300014. S.McC. is in receipt of funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 860325.	Aghajani Z, 2019, APMIS, V127, P753, DOI 10.1111/apm.12992; Ainsworth S, 2017, VACCINE, V35, P3387, DOI 10.1016/j.vaccine.2017.05.017; Al Atrouni A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00049; Al Bayssari C, 2015, J ANTIMICROB CHEMOTH, V70, P950, DOI 10.1093/jac/dku469; Al-Kadmy IMS, 2020, MICROB DRUG RESIST, V26, P616, DOI 10.1089/mdr.2019.0243; [Anonymous], 2019, SURV ANT EUR 2018 AN; [Anonymous], 2019, CENTR AS EUR SURV AN; Ansari H, 2019, IRAN J BASIC MED SCI, V22, P669, DOI 10.22038/ijbms.2019.30799.7427; Anstey NM, 2002, J CLIN MICROBIOL, V40, P685, DOI 10.1128/JCM.40.2.685-686.2002; Antunes LCS, 2014, PATHOG DIS, V71, P292, DOI 10.1111/2049-632X.12125; Bannister B.A., 2000, INFECT DIS-NOR, V2nd ed.; BEIJERINCK MW, 1911, VERSL KONINKLIJKE AK, V19, P1092; Bentancor LV, 2012, INFECT IMMUN, V80, P3381, DOI 10.1128/IAI.06096-11; Bentancor LV, 2012, J BACTERIOL, V194, P3950, DOI 10.1128/JB.06769-11; Bentancor LV, 2012, INFECT IMMUN, V80, P651, DOI 10.1128/IAI.05653-11; Bolourchi N., 2020, REV MED MICROBIOL, DOI [10.1097/MRM.0000000000000238, DOI 10.1097/MRM.0000000000000238]; Boluki E, 2017, PHOTODIAGN PHOTODYN, V18, P1, DOI 10.1016/j.pdpdt.2017.01.003; Boo TW, 2009, J MED MICROBIOL, V58, P209, DOI 10.1099/jmm.0.004911-0; Bouvresse S, 2011, COMP IMMUNOL MICROB, V34, P475, DOI 10.1016/j.cimid.2011.08.007; Brossard KA, 2012, INFECT IMMUN, V80, P228, DOI 10.1128/IAI.05913-11; Bulens SN, 2018, EMERG INFECT DIS, V24, P727, DOI 10.3201/eid2404.171461; Byrne-Bailey KG, 2009, ANTIMICROB AGENTS CH, V53, P696, DOI 10.1128/AAC.00652-07; Cai Bin, 2017, Open Forum Infect Dis, V4, pofx176, DOI 10.1093/ofid/ofx176; Carruthers MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059388; Casey WT, 2016, VACCINE, V34, P2616, DOI 10.1016/j.vaccine.2016.03.088; Catel-Ferreira M, 2016, FEBS LETT, V590, P224, DOI 10.1002/1873-3468.12050; Centers for Disease Control and Prevention (CDC), 2004, MMWR MORB MORTAL WKL, V53, P1063; Cerqueira GM, 2014, J INFECT DIS, V210, P46, DOI 10.1093/infdis/jiu024; Chen MZ, 2001, CHEST, V120, P1072, DOI 10.1378/chest.120.4.1072; Chen WX, 2015, HUM VACC IMMUNOTHER, V11, P2495, DOI 10.1080/21645515.2015.1052354; Chen X, 2020, APPL MICROBIOL BIOT, V104, P7777, DOI 10.1007/s00253-020-10814-6; Choi CH, 2005, CELL MICROBIOL, V7, P1127, DOI 10.1111/j.1462-5822.2005.00538.x; Choi CH, 2008, CELL MICROBIOL, V10, P309, DOI 10.1111/j.1462-5822.2007.01041.x; Choi CH, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-216; Choi JY, 2005, INTERN MED J, V35, P599, DOI 10.1111/j.1445-5994.2005.00925.x; Cosgaya C, 2016, INT J SYST EVOL MICR, V66, P4105, DOI 10.1099/ijsem.0.001318; de Breij A, 2009, RES MICROBIOL, V160, P213, DOI 10.1016/j.resmic.2009.01.002; De Gregorio E, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2136-6; Dexter C, 2015, EXPERT REV ANTI-INFE, V13, P567, DOI 10.1586/14787210.2015.1025055; Doi Y, 2015, SEMIN RESP CRIT CARE, V36, P85, DOI 10.1055/s-0034-1398388; Eijkelkamp BA, 2013, INFECT IMMUN, V81, P2574, DOI 10.1128/IAI.00065-13; Eijkelkamp BA, 2011, FEMS MICROBIOL LETT, V323, P44, DOI 10.1111/j.1574-6968.2011.02362.x; Elhosseiny NM, 2020, J INFECT DIS, V222, P871, DOI 10.1093/infdis/jiaa262; Elhosseiny NM, 2015, INT J MED MICROBIOL, V305, P114, DOI 10.1016/j.ijmm.2014.11.008; Ermis H, 2013, POL ARCH MED WEWN, V123, P85, DOI 10.20452/pamw.1617; Erridge C, 2007, J MED MICROBIOL, V56, P165, DOI 10.1099/jmm.0.46823-0; Eveillard M, 2013, INT J INFECT DIS, V17, pE802, DOI 10.1016/j.ijid.2013.03.021; Falagas ME, 2006, CRIT CARE, V10, DOI [10.1186/cc4869, 10.1186/cc4910]; Farrugia DN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058628; Fattahian Y, 2011, MICROB PATHOGENESIS, V51, P402, DOI 10.1016/j.micpath.2011.09.004; Fiester SE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167068; Fournier PE, 2006, PLOS GENET, V2, P62, DOI 10.1371/journal.pgen.0020007; Furlan JPR, 2018, J APPL MICROBIOL, V125, P506, DOI 10.1111/jam.13885; Gaddy JA, 2012, INFECT IMMUN, V80, P1015, DOI 10.1128/IAI.06279-11; Garcia-Quintanilla M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114410; Gebhardt MJ, 2015, MBIO, V6, DOI 10.1128/mBio.01660-15; Girlich D, 2010, ANTIMICROB AGENTS CH, V54, P578, DOI 10.1128/AAC.00861-09; Goic-Barisic I, 2017, MICROB DRUG RESIST, V23, P494, DOI 10.1089/mdr.2016.0229; Griffith ME, 2007, INFECT CONT HOSP EP, V28, P720, DOI 10.1086/518966; Griffith ME, 2006, INFECT CONT HOSP EP, V27, P659, DOI 10.1086/506596; Garcia-Patino MG, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00441; Guo SJ, 2018, BIOMED ENVIRON SCI, V31, P155, DOI 10.3967/bes2018.019; Hamouda A, 2011, INT J ANTIMICROB AG, V38, P314, DOI 10.1016/j.ijantimicag.2011.06.007; Harding CM, 2018, NAT REV MICROBIOL, V16, P91, DOI 10.1038/nrmicro.2017.148; Hare JM, 2012, MICROBIOL-SGM, V158, P601, DOI 10.1099/mic.0.054668-0; Henderson JC, 2016, ANNU REV MICROBIOL, V70, P255, DOI 10.1146/annurev-micro-102215-095308; Higgins PG, 2018, WATER RES, V140, P261, DOI 10.1016/j.watres.2018.04.057; Houang ETS, 2001, J CLIN MICROBIOL, V39, P228, DOI 10.1128/JCM.39.1.228-234.2001; Hounsome JDA, 2011, INFECT IMMUN, V79, P4332, DOI 10.1128/IAI.05469-11; Hrenovic J, 2014, APPL ENVIRON MICROB, V80, P2860, DOI 10.1128/AEM.00312-14; Huang WW, 2016, SCI REP-UK, V6, DOI 10.1038/srep37242; Huang WW, 2016, SCI REP-UK, V6, DOI 10.1038/srep20724; Huang WW, 2015, VACCINE, V33, P4479, DOI 10.1016/j.vaccine.2015.07.031; Inchai J, 2015, J INTENSIVE CARE, V3, DOI 10.1186/s40560-015-0077-4; Islam AHMS, 2011, DIAGN MICR INFEC DIS, V69, P38, DOI 10.1016/j.diagmicrobio.2010.09.008; Iwashkiw JA, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002758; Jacobs AC, 2010, INFECT IMMUN, V78, P1952, DOI 10.1128/IAI.00889-09; Jahangiri A, 2018, J MICROBIOL METH, V144, P79, DOI 10.1016/j.mimet.2017.11.008; Jahangiri A, 2017, MICROB PATHOGENESIS, V105, P201, DOI 10.1016/j.micpath.2017.02.028; Johansson MM, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8040612; Juttukonda LJ, 2016, MBIO, V7, DOI 10.1128/mBio.01475-16; Kang YS, 2011, J MICROBIOL, V49, P29, DOI 10.1007/s12275-011-0315-y; Keen EF, 2010, BURNS, V36, P819, DOI 10.1016/j.burns.2009.10.013; Kempf M, 2012, INT J INFECT DIS, V16, pE680, DOI 10.1016/j.ijid.2012.05.1024; Kim HW, 2014, LUNG, V192, P719, DOI 10.1007/s00408-014-9616-3; Kittinger C, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15010052; Klotz P, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00272; Koenigs A, 2016, J INFECT DIS, V213, P1388, DOI 10.1093/infdis/jiv601; KuoLee R, 2015, VACCINE, V33, P260, DOI 10.1016/j.vaccine.2014.02.083; La Scola B, 2004, EMERG INFECT DIS, V10, P1671, DOI 10.3201/eid1009.040242; Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P505, DOI 10.1016/j.jmii.2020.05.013; Lee CR, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00055; Lee YC, 2011, J ANTIMICROB CHEMOTH, V66, P1839, DOI 10.1093/jac/dkr200; Lees-Miller RG, 2013, MOL MICROBIOL, V89, P816, DOI 10.1111/mmi.12300; Lei LH, 2019, MOL BIOL REP, V46, P5397, DOI 10.1007/s11033-019-04994-2; Leung AS, 2006, CHEST, V129, P102, DOI 10.1378/chest.129.1.102; Lin L, 2013, VACCINE, V31, P313, DOI 10.1016/j.vaccine.2012.11.008; Lin L, 2012, MBIO, V3, DOI 10.1128/mBio.00312-12; Liou ML, 2014, J MICROBIOL IMMUNOL, V47, P275, DOI 10.1016/j.jmii.2012.12.004; Liu XB, 2020, INFECT DRUG RESIST, V13, P3195, DOI 10.2147/IDR.S264391; Lob SH, 2016, INT J ANTIMICROB AG, V47, P317, DOI 10.1016/j.ijantimicag.2016.01.015; Lopinska A, 2020, POL J MICROBIOL, V69, P85, DOI 10.33073/pjm-2020-011; Luke NR, 2010, INFECT IMMUN, V78, P2017, DOI 10.1128/IAI.00016-10; Luo GPS, 2012, PLOS ONE, V7, P46, DOI 10.1371/journal.pone.0029446; Lynch JP, 2017, SEMIN RESP CRIT CARE, V38, P311, DOI 10.1055/s-0037-1599225; Manikal VM, 2000, CLIN INFECT DIS, V31, P101, DOI 10.1086/313902; Mateo-Estrada V, 2019, GENOME BIOL EVOL, V11, P2531, DOI 10.1093/gbe/evz178; May HC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218505; McConnell MJ, 2013, FEMS MICROBIOL REV, V37, P130, DOI 10.1111/j.1574-6976.2012.00344.x; McConnell MJ, 2011, VACCINE, V29, P5705, DOI 10.1016/j.vaccine.2011.06.001; McConnell MJ, 2011, INFECT IMMUN, V79, P518, DOI 10.1128/IAI.00741-10; McConnell MJ, 2010, VACCINE, V29, P1, DOI 10.1016/j.vaccine.2010.10.052; McQueary CN, 2012, J MICROBIOL, V50, P434, DOI 10.1007/s12275-012-1555-1; Metan G, 2007, J ANTIMICROB CHEMOTH, V60, P197, DOI 10.1093/jac/dkm181; Moradi Jale, 2015, Osong Public Health Res Perspect, V6, P79, DOI 10.1016/j.phrp.2014.12.006; Mortensen BL, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00095; Nairn BL, 2016, CELL HOST MICROBE, V19, P826, DOI 10.1016/j.chom.2016.05.007; Nemec A, 2015, INT J SYST EVOL MICR, V65, P934, DOI 10.1099/ijs.0.000043; Nemec A, 2011, RES MICROBIOL, V162, P393, DOI 10.1016/j.resmic.2011.02.006; Nie D, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-0617-7; Nowak J, 2017, J ANTIMICROB CHEMOTH, V72, P3277, DOI 10.1093/jac/dkx322; O'Connor A, 2017, CURR MED CHEM, V24, P3970, DOI 10.2174/0929867324666170124145543; Oncul O, 2002, J HOSP INFECT, V51, P47, DOI 10.1053/jhin.2002.1205; Ong CWM, 2009, RESPIROLOGY, V14, P1200, DOI 10.1111/j.1440-1843.2009.01630.x; Peleg AY, 2008, CLIN MICROBIOL REV, V21, P538, DOI 10.1128/CMR.00058-07; Perez A, 2017, VIRULENCE, V8, P959, DOI 10.1080/21505594.2016.1262313; Perez S, 2020, MMWR-MORBID MORTAL W, V69, P1827, DOI 10.15585/mmwr.mm6948e1; Poirel L, 2012, EMERG INFECT DIS, V18, P523, DOI 10.3201/eid1803.111330; Quinones D., 2015, New Microbes and New Infections, V7, P52, DOI 10.1016/j.nmni.2015.06.002; Rafei R, 2015, APPL ENVIRON MICROB, V81, P2359, DOI 10.1128/AEM.03824-14; Rafei R, 2014, INT J INFECT DIS, V21, P21, DOI 10.1016/j.ijid.2014.01.004; Rasooli I, 2020, INT J PEPT RES THER, V26, P2653, DOI 10.1007/s10989-020-10056-0; Repizo GD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138265; Rice LB, 2008, J INFECT DIS, V197, P1079, DOI 10.1086/533452; Rooney AP, 2016, INT J SYST EVOL MICR, V66, P3566, DOI 10.1099/ijsem.0.001234; ROSSAU R, 1991, INT J SYST BACTERIOL, V41, P310, DOI 10.1099/00207713-41-2-310; Roussin M, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02450; Rumbo C, 2014, INFECT IMMUN, V82, P4666, DOI 10.1128/IAI.02034-14; Russo TA, 2013, INFECT IMMUN, V81, P915, DOI 10.1128/IAI.01184-12; Russo TA, 2010, INFECT IMMUN, V78, P3993, DOI 10.1128/IAI.00366-10; Scott P, 2007, CLIN INFECT DIS, V44, P1577, DOI 10.1086/518170; Seder RA, 2000, NATURE, V406, P793, DOI 10.1038/35021239; Seifert H, 1997, J CLIN MICROBIOL, V35, P2819, DOI 10.1128/JCM.35.11.2819-2825.1997; Sharifipour E, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05374-z; Shu MH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22332; Singh R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12789-3; Smani Y, 2013, J INFECT DIS, V208, P1561, DOI 10.1093/infdis/jit386; Smani Y, 2012, J BIOL CHEM, V287, P26901, DOI 10.1074/jbc.M112.344556; Smith MG, 2007, GENE DEV, V21, P601, DOI 10.1101/gad.1510307; Sobouti Behnam, 2020, Med J Islam Repub Iran, V34, P24, DOI 10.34171/mjiri.34.24; Stahl J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138360; Sun DQ, 2016, LIFE SCI, V148, P31, DOI 10.1016/j.lfs.2016.02.015; Tacconelli E, 2018, LANCET INFECT DIS, V18, P318, DOI [10.1016/S1473-3099(17)30753-3, 10.1016/s1473-3099(17)30753-3]; Tan K, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00783; Tao C, 2009, DIAGN MICR INFEC DIS, V63, P268, DOI 10.1016/j.diagmicrobio.2008.11.009; Tohidinia M, 2020, INT J PEPT RES THER, V26, P1185, DOI 10.1007/s10989-019-09923-2; Tomaras AP, 2008, MICROBIOL-SGM, V154, P3398, DOI 10.1099/mic.0.2008/019471-0; Weidensdorfer M, 2019, VIRULENCE, V10, P68, DOI 10.1080/21505594.2018.1558693; Weidensdorfer M, 2016, INFECT IMMUN, V84, P711, DOI 10.1128/IAI.01502-15; Weiss N., 2021, LIST PROKARYOTIC NAM; Wendt C, 1997, J CLIN MICROBIOL, V35, P1394, DOI 10.1128/JCM.35.6.1394-1397.1997; Wilharm G, 2017, ENVIRON MICROBIOL, V19, P4349, DOI 10.1111/1462-2920.13931; Wisplinghoff H, 2012, J INFECTION, V64, P282, DOI 10.1016/j.jinf.2011.12.008; Wizemann TM, 1999, EMERG INFECT DIS, V5, P395, DOI 10.3201/eid0503.990310; Wood CR, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00442-18; Wyres KL, 2020, MICROB GENOMICS, V6, DOI 10.1099/mgen.0.000339; Yan ZH, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9834020; Yang AQ, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12769; Zhang HZ, 2013, WORLD J EMERG MED, V4, P169, DOI [10.5847/wjem.j.issn.1920-8642.2013.03.002, 10.5847/wjem.j.1920-8642.2013.03.002]; Zhang XJ, 2016, MICROB PATHOGENESIS, V96, P20, DOI 10.1016/j.micpath.2016.04.019; Zimbler DL, 2012, J BACTERIOL, V194, P2884, DOI 10.1128/JB.00213-12	171	3	3	10	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							570	10.3390/vaccines9060570			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ2LL	34205838	gold, Green Published			2022-04-29	WOS:000666403300001
J	Nalubega, P; Karafillakis, E; Atuhaire, L; Akite, P; Zalwango, F; Chantler, T; Cochet, M; Seeley, J; Le Doare, K				Nalubega, Phiona; Karafillakis, Emilie; Atuhaire, Lydia; Akite, Pamela; Zalwango, Flavia; Chantler, Tracey; Cochet, Madeleine; Seeley, Janet; Le Doare, Kirsty			Maternal Vaccination in Uganda: Exploring Pregnant Women, Community Leaders and Healthcare Workers' Perceptions	VACCINES			English	Article						vaccine hesitancy; maternal vaccines; vaccine safety; vaccine confidence	IMMUNIZATION	Background: We investigated pregnant women, community leaders, healthcare workers (HCWs) and programme managers' perceptions of maternal vaccination in Kampala, Uganda. Methods: We conducted focus group discussions, key informant interviews and in-depth discussions with HCWs (3), community leaders (3), pregnant women (8) and programme managers (10) between November 2019 and October 2020. Data were analysed thematically. Results: Pregnant women, community leaders and some HCWs had limited maternal immunisation knowledge. There was confusion over what constitutes a vaccine. Pregnant women may not receive vaccines because of mistrust of government; use of expired vaccines; reliance on traditional medicine; religious beliefs; fear of side effects; HCWs attitudes; and logistical issues. The key facilitators of maternal vaccination were a desire to prevent diseases, positive influences from HCWs and information about vaccine side effects. Community leaders and some pregnant women highlighted that pregnant women do not make decisions about maternal vaccination independently and are influenced by different individuals, including other pregnant women, older people, partners, relatives (parents), community leaders, HCWs and the government. Conclusions: Our results indicate that public health messaging should target all community members, including partners and parents of pregnant women as well as HCWs, to improve knowledge of and confidence in maternal vaccines.	[Nalubega, Phiona; Atuhaire, Lydia; Zalwango, Flavia; Seeley, Janet; Le Doare, Kirsty] Uganda Virus Res Inst, Med Res Council, POB 49, Entebbe, Uganda; [Nalubega, Phiona; Atuhaire, Lydia; Zalwango, Flavia; Seeley, Janet; Le Doare, Kirsty] London Sch Hyg & Trop Med, Uganda Res Unit, POB 49, Entebbe, Uganda; [Karafillakis, Emilie; Akite, Pamela; Chantler, Tracey; Seeley, Janet] London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England; [Cochet, Madeleine; Le Doare, Kirsty] St Georges Univ London, London SW17 0RE, England		Le Doare, K (通讯作者)，Uganda Virus Res Inst, Med Res Council, POB 49, Entebbe, Uganda.; Le Doare, K (通讯作者)，London Sch Hyg & Trop Med, Uganda Res Unit, POB 49, Entebbe, Uganda.; Karafillakis, E (通讯作者)，London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.; Le Doare, K (通讯作者)，St Georges Univ London, London SW17 0RE, England.	phiona.nalubega@mrcuganda.org; Emilie.Karafillakis@lshtm.ac.uk; latuhaire@gmail.com; pamela.akite1@alumni.lshtm.ac.uk; Flavia.Zalwango@mrcuganda.org; Tracey.Chantler@lshtm.ac.uk; mcochet@sgul.ac.uk; Janet.Seeley@LSHTM.ac.uk; kiledoar@sgul.ac.uk		Cochet, Madeleine/0000-0002-0436-4843; Seeley, Janet/0000-0002-0583-5272; Akite, Pamela/0000-0002-0355-7301; Karafillakis, Emilie/0000-0001-8648-906X; Chantler, Tracey/0000-0001-7776-7339	European and Developing Countries Clinical Trials Partnership [RIA2018V-2304]; National Institute for Healthcare Research Mucosal and Respiratory Pathogens Unit (KLD2019); UK Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); UK Department for International Development (DFID) under the MRC/DFID Concordat agreementUK Research & Innovation (UKRI)Medical Research Council UK (MRC); European UnionEuropean Commission	This work was supported by the European and Developing Countries Clinical Trials Partnership [RIA2018V-2304]; the National Institute for Healthcare Research Mucosal and Respiratory Pathogens Unit (KLD2019); and the UK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement and is also part of the EDCTP2 programme supported by the European Union, which funds F.Z. and J.S.	Ali SA., 2018, J PREG NEONATAL MED, V2, P41; Awor P, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00651-0; Babirye JN, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-723; Bergin N, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15050847; Chantler T, 2019, APPL HEALTH ECON HEA, V17, P265, DOI 10.1007/s40258-019-00460-z; Godongwana M, 2021, HELIYON, V7, DOI 10.1016/j.heliyon.2021.e05926; Kajungu D, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243834; Ko LK, 2019, PAPILLOMAVIRUS RES, V7, P21, DOI 10.1016/j.pvr.2018.12.003; Larson H. J, 2020, STUCK VACCINE RUMORS; Maertens K, 2020, EUR J PEDIATR, V179, P235, DOI 10.1007/s00431-019-03563-w; Malande OO, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212270; Marchant A, 2017, LANCET INFECT DIS, V17, pE197, DOI 10.1016/S1473-3099(17)30229-3; Martin S, 2020, VACCINE, V38, P6627, DOI 10.1016/j.vaccine.2020.07.072; Mason L, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0453-z; Ministry of Health, UG NAT EXP PROGR IMM; Nesane K, 2016, AFR J PRIM HEALTH CA, V8, DOI 10.4102/phcfm.v8i2.929; Nganga SW, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4537-8; Ngomane S, 2012, MIDWIFERY, V28, P30, DOI 10.1016/j.midw.2010.11.002; Otieno NA, 2020, HUM VACC IMMUNOTHER, V16, P2429, DOI 10.1080/21645515.2020.1723364; Pathirana J, 2015, VACCINE, V33, P2971, DOI 10.1016/j.vaccine.2015.04.070; Pugliese-Garcia M, 2018, VACCINE, V36, P5617, DOI [10.1016/j.vaccine.2017.10.108, 10.1016/j.vaccine.2018.07.042]; Statistics U.B.O, 2018, UG DEM HLTH SURV 201; Uganda Bureau of Statistics, 2017, NAT POP HOUS CENS 20; Vandelaer J, 2003, VACCINE, V21, P3442, DOI 10.1016/S0264-410X(03)00347-5; Wilson RJ, 2015, VACCINE, V33, P6420, DOI 10.1016/j.vaccine.2015.08.046; World Health Organization, REL VACC NAM TOP GLO; World Health Organization, NEWB IMPR SURV WELL	27	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							552	10.3390/vaccines9060552			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY4PM	34070536	Green Published, Green Accepted, gold			2022-04-29	WOS:000665872100001
J	Psichogiou, M; Samarkos, M; Mikos, N; Hatzakis, A				Psichogiou, Mina; Samarkos, Michael; Mikos, Nikolaos; Hatzakis, Angelos			Reactivation of Varicella Zoster Virus after Vaccination for SARS-CoV-2	VACCINES			English	Article						SARS-CoV-2; mRNA vaccines; herpes zoster	HERPES-ZOSTER; CAUSALITY	Seven immunocompetent patients aged > 50 years old presented with herpes zoster (HZ) infection in a median of 9 days (range 7-20) after vaccination against SARS-CoV-2. The occurrence of HZ within the time window 1-21 days after vaccination defined for increased risk and the reported T cell-mediated immunity involvement suggest that COVID-19 vaccination is a probable cause of HZ. These cases support the importance of continuing assessment of vaccine safety during the ongoing massive vaccination for the COVID-19 pandemic and encourage reporting and communication of any vaccination-associated adverse event.	[Psichogiou, Mina; Samarkos, Michael] Natl & Kapodistrian Univ Athens, Med Sch, Dept Med 1, Athens 11527, Greece; [Mikos, Nikolaos] Laikon Gen Hosp, Allergol Dept, Athens 11527, Greece; [Hatzakis, Angelos] Natl & Kapodistrian Univ Athens, Med Sch, Dept Hyg Epidemiol & Med Stat, Athens 11527, Greece		Psichogiou, M (通讯作者)，Natl & Kapodistrian Univ Athens, Med Sch, Dept Med 1, Athens 11527, Greece.	mpsichog@med.uoa.gr; msamarkos@med.uoa.gr; allergiologikotmemalaiko@gmail.com; ahatzak@med.uoa.gr	Samarkos, Michael/Q-5104-2019	Samarkos, Michael/0000-0001-9630-9712; psichogiou, mina/0000-0002-3000-8447			Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], CDC WONDER ON LIN DA; Bayas JM, 2007, J TRAVEL MED, V14, P65, DOI 10.1111/j.1708-8305.2006.00098.x; BOSTAN E, 2021, COSMET DERMATOL, DOI DOI 10.1111/JOCD.14035; Castells MC, 2021, NEW ENGL J MED, V384, P643, DOI 10.1056/NEJMra2035343; Creech, 2020, NEW ENGL J MED, DOI [10.1056/NENJMoa2035389, DOI 10.1056/NENJMOA2035389]; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5; Elsaie ML, 2020, CUTIS, V106, P318, DOI 10.12788/cutis.0133; Ferreira ACAD, 2020, EUR J NEUROL, V27, P1748, DOI 10.1111/ene.14361; Furer V, 2021, RHEUMATOLOGY, V60, pSI90, DOI 10.1093/rheumatology/keab345; Garcia-Montero C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050433; Georgoudis G, 2000, EUR J PAIN-LONDON, V4, P275, DOI 10.1053/eujp.2000.0186; Gnann JW, 2002, NEW ENGL J MED, V347, P340, DOI 10.1056/NEJMcp1302674; Halsey NA, 2012, VACCINE, V30, P5791, DOI 10.1016/j.vaccine.2012.04.005; Harpaz R, 2019, CLIN INFECT DIS, V69, P341, DOI 10.1093/cid/ciy953; Kawai K, 2016, CLIN INFECT DIS, V63, P221, DOI 10.1093/cid/ciw296; Loughlin AM, 2012, VACCINE, V30, P7253, DOI 10.1016/j.vaccine.2012.09.074; Martinez E, 1998, CLIN INFECT DIS, V27, P1510, DOI 10.1086/515019; Peitersen E, 2002, ACTA OTO-LARYNGOL, V122, P4, DOI 10.1080/000164802320401694; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Psichogiou M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243025; Rothova A, 2011, BRIT J OPHTHALMOL, V95, P291, DOI 10.1136/bjo.2010.185983; Saati A, 2020, CUREUS, V12, DOI 10.7759/cureus.8998; Schmader K, 2001, CLIN INFECT DIS, V32, P1481, DOI 10.1086/320169; Shimabukuro, 2021, P ADV COMM IMM PRACT; Sweeney CJ, 2001, J NEUROL NEUROSUR PS, V71, P149, DOI 10.1136/jnnp.71.2.149; Tartari F, 2020, INT J DERMATOL, V59, P1028, DOI 10.1111/ijd.15001; Tozzi AE, 2013, VACCINE, V31, P5041, DOI 10.1016/j.vaccine.2013.08.087; Tseng HF, 2020, J INFECT DIS, V222, P798, DOI 10.1093/infdis/jiz652; VEENSTRA J, 1995, AIDS, V9, P1153, DOI 10.1097/00002030-199510000-00006; Vogler I, 2020, BNT 162B2 INDUCES SA, DOI [10.1101/2020.12.09.20245175, DOI 10.1101/2020.12.09.20245175]; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walter R, 1999, LANCET, V353, P810, DOI 10.1016/S0140-6736(99)00623-6; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n567; World Health Organization (WHO), 2020, WHO CORONAVIRUS COVI; Yawn BP, 2011, MAYO CLIN PROC, V86, P88, DOI 10.4065/mcp.2010.0618	38	29	29	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							572	10.3390/vaccines9060572			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY6GI	34205861	gold, Green Published			2022-04-29	WOS:000665983700001
J	Wang, HW; Zeng, XM; Cao, L; He, Q; Lin, J				Wang, Huiwen; Zeng, Ximin; Cao, Liu; He, Qiang; Lin, Jun			Passive Immunization of Chickens with Anti-Enterobactin Egg Yolk Powder for Campylobacter Control	VACCINES			English	Article						anti-enterobactin egg yolk antibody; passive immunity; Campylobacter jejuni; chicken; food safety	IMMUNOGLOBULINS; ANTIBODIES; IGY; COLONIZATION; DISEASES; POULTRY; RELEASE	Enterobactin (Ent) is a highly conserved and important siderophore for the growth of many Gram-negative bacterial pathogens. Therefore, targeting Ent for developing innovative intervention strategies has attracted substantial research interest in recent years. Recently, we developed a novel Ent conjugate vaccine that has been demonstrated to be effective for controlling Gram-negative pathogens using both in vitro and in vivosystems. In particular, active immunization of chickens with the Ent conjugate vaccine elicited strong immune responses and significantly reduced intestinal colonization of Campylobacter jejuni, the leading foodborne bacterial pathogen. Given that hyperimmune egg yolk immunoglobulin Y (IgY) has been increasingly recognized as a promising and practical non-antibiotic approach for passive immune protection against pathogens in livestock, in this study, we assessed the efficacy of oral administration of broiler chickens with the anti-Ent hyperimmune egg yolk powder to control C. jejuni colonization in the intestine. However, supplementation of feed with 2% (w/w) of anti-Ent egg yolk powder failed to reduce C. jejuni colonization when compared to the control group. Consistent with this finding, the ELISA titers of the specific IgY in cecum, ileum, duodenum, gizzard, and serum contents were similar between the two groups throughout the trial. Chicken intestinal microbiota also did not change in response to the egg yolk powder treatment. Subsequently, to examine ex vivo stability of the egg yolk IgY, the chicken gizzard and duodenum contents from two independent sources were spiked with the egg yolk antibodies, incubated at 42 degrees C for different lengths of time, and subjected to ELISA analysis. The specific IgY titers were dramatically decreased in gizzard contents (up to 2048-fold) but were not changed in duodenum contents. Collectively, oral administration of broiler chickens with the anti-Ent egg yolk powder failed to confer protection against intestinal colonization of C. jejuni, which was due to instability of the IgY in gizzard contents as demonstrated by both in vivo and ex vivo evidence.	[Wang, Huiwen; Zeng, Ximin; Cao, Liu; Lin, Jun] Univ Tennessee, Dept Anim Sci, Knoxville, TN 37996 USA; [Cao, Liu; He, Qiang] Univ Tennessee, Dept Civil & Environm Engn, Knoxville, TN 37996 USA		Lin, J (通讯作者)，Univ Tennessee, Dept Anim Sci, Knoxville, TN 37996 USA.	hwang83@vols.utk.edu; xzeng3@utk.edu; lcao5@vols.utk.edu; qianghe@utk.edu; jlin6@utk.edu	He, Qiang/G-9061-2011	He, Qiang/0000-0002-7155-6474; Cao, Liu/0000-0002-6560-154X; ZENG, XIMIN/0000-0003-2795-6988	United States Department of Agriculture National Institute of Food and Agriculture (NIFA) [2018-67015-28295]	This research was funded by the United States Department of Agriculture National Institute of Food and Agriculture (NIFA) Award No. 2018-67015-28295.	Awad WA, 2018, AVIAN PATHOL, V47, P352, DOI 10.1080/03079457.2018.1475724; BOHAK Z, 1969, J BIOL CHEM, V244, P4638; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107; Crevieu-Gabriel I, 1999, REPROD NUTR DEV, V39, P443, DOI 10.1051/rnd:19990404; Cui YF, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040747; Dai L, 2020, TRANSL RES, V223, P76, DOI 10.1016/j.trsl.2020.04.009; Diraviyam T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097716; Dozois CM, 2003, P NATL ACAD SCI USA, V100, P247, DOI 10.1073/pnas.232686799; Foley SL, 2013, MICROBIOL MOL BIOL R, V77, P582, DOI 10.1128/MMBR.00015-13; Gadde U, 2015, ANIM HEALTH RES REV, V16, P163, DOI 10.1017/S1466252315000195; Glockner FO, 2017, J BIOTECHNOL, V261, P169, DOI 10.1016/j.jbiotec.2017.06.1198; Gu LP, 2021, FOOD HYDROCOLLOID, V112, DOI 10.1016/j.foodhyd.2020.106349; Gurtler M, 2004, J VET MED B, V51, P129, DOI 10.1111/j.1439-0450.2004.00739.x; HATTA H, 1993, BIOSCI BIOTECH BIOCH, V57, P1077, DOI 10.1271/bbb.57.1077; Kadhim KK, 2011, AFR J BIOTECHNOL, V10, P108; Kovacs-Nolan J, 2005, J IMMUNOL METHODS, V296, P199, DOI 10.1016/j.jim.2004.11.017; Kovacs-Nolan J, 2012, ANNU REV FOOD SCI T, V3, P163, DOI 10.1146/annurev-food-022811-101137; Li XY, 2007, J AGR FOOD CHEM, V55, P2911, DOI 10.1021/jf062900q; Lin J, 2009, FOODBORNE PATHOG DIS, V6, P755, DOI 10.1089/fpd.2008.0247; Liu X, 2019, VACCINE, V37, P3785, DOI 10.1016/j.vaccine.2019.05.082; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Mead GC, 2002, WORLD POULTRY SCI J, V58, P169, DOI 10.1079/WPS20020016; Miethke M, 2007, MICROBIOL MOL BIOL R, V71, P413, DOI 10.1128/MMBR.00012-07; Nochi T, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00060; Peebles ED, 2018, POULTRY SCI, V97, P2322, DOI 10.3382/ps/pey081; Rhee JH, 2020, MUCOSAL VACCINES: INNOVATION FOR PREVENTING INFECTIOUS DISEASES, 2ND EDITION, P325, DOI 10.1016/B978-0-12-811924-2.00019-5; Ruiz-Palacios GM, 2007, CLIN INFECT DIS, V44, P701, DOI 10.1086/509936; Sheppard S.K., 2014, CAMPYLOBACTER ECOLOG, P111; Sonje J, 2020, MOL PHARMACEUT, V17, P3075, DOI 10.1021/acs.molpharmaceut.0c00492; Svihus B, 2014, J APPL POULTRY RES, V23, P306, DOI 10.3382/japr.2014-00937; Tang YZ, 2017, ANIM HEALTH RES REV, V18, P87, DOI 10.1017/S1466252317000135; Wang HW, 2020, VACCINE, V38, P7764, DOI 10.1016/j.vaccine.2020.10.040; Wang HW, 2019, APPL ENVIRON MICROB, V85, DOI 10.1128/AEM.00358-19; Wang ZB, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1958-x; Xu YP, 2011, BIOTECHNOL ADV, V29, P860, DOI 10.1016/j.biotechadv.2011.07.003; Zeng XM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.629480	38	1	1	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							569	10.3390/vaccines9060569			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5HB	34205835	Green Published, gold			2022-04-29	WOS:000665917800001
J	Chu, KB; Quan, FS				Chu, Ki-Back; Quan, Fu-Shi			Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development	VACCINES			English	Review						Toxoplasma gondii; vaccine; immune response; protection	PROVIDES PARTIAL PROTECTION; ENHANCING IMMUNE-RESPONSES; T-CELL EPITOPES; DNA VACCINE; PARTICLE VACCINE; CONGENITAL TOXOPLASMOSIS; GENETIC ADJUVANT; DELETION MUTANT; MICE; PROTEIN	Toxoplasmosis, caused by the apicomplexan parasite Toxoplasma gondii, is one of the most damaging parasite-borne zoonotic diseases of global importance. While approximately one-third of the entire world's population is estimated to be infected with T. gondii, an effective vaccine for human use remains unavailable. Global efforts in pursuit of developing a T. gondii vaccine have been ongoing for decades, and novel innovative approaches have been introduced to aid this process. A wide array of vaccination strategies have been conducted to date including, but not limited to, nucleic acids, protein subunits, attenuated vaccines, and nanoparticles, which have been assessed in rodents with promising results. Yet, translation of these in vivo results into clinical studies remains a major obstacle that needs to be overcome. In this review, we will aim to summarize the current advances in T. gondii vaccine strategies and address the challenges hindering vaccine development.	[Chu, Ki-Back] Kyung Hee Univ, Grad Sch, Dept Biomed Sci, Seoul 02447, South Korea; [Quan, Fu-Shi] Kyung Hee Univ, Grad Sch, Sch Med, Med Res Ctr Bioreact React Oxygen Species, Seoul 02447, South Korea; [Quan, Fu-Shi] Kyung Hee Univ, Grad Sch, Sch Med, Inst Biomed Sci, Seoul 02447, South Korea; [Quan, Fu-Shi] Kyung Hee Univ, Sch Med, Dept Med Zool, Seoul 02447, South Korea		Quan, FS (通讯作者)，Kyung Hee Univ, Grad Sch, Sch Med, Med Res Ctr Bioreact React Oxygen Species, Seoul 02447, South Korea.; Quan, FS (通讯作者)，Kyung Hee Univ, Grad Sch, Sch Med, Inst Biomed Sci, Seoul 02447, South Korea.; Quan, FS (通讯作者)，Kyung Hee Univ, Sch Med, Dept Med Zool, Seoul 02447, South Korea.	kbchu@khu.ac.kr; fsquan@khu.ac.kr			National Research Foundation of Korea (NRF)National Research Foundation of Korea [2018R1A6A1A03025124]; Ministry of Health & Welfare, Republic of KoreaMinistry of Health & Welfare, Republic of Korea [HV20C0085, HV20C0142]	yThis research was funded by the National Research Foundation of Korea (NRF), grant number 2018R1A6A1A03025124, and the Ministry of Health & Welfare, Republic of Korea [HV20C0085, HV20C0142].	Adeyemi OS, 2018, ARTIF CELL NANOMED B, V46, pS86, DOI 10.1080/21691401.2018.1489267; Adeyemi OS, 2017, INT J NANOMED, V12, P1647, DOI 10.2147/IJN.S122178; Ahmadpour E, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12419; Ahmadpour E, 2017, IMMUNOL LETT, V185, P40, DOI 10.1016/j.imlet.2017.03.006; Alizadeh P, 2019, J CELL PHYSIOL, V234, P10782, DOI 10.1002/jcp.27747; Arcon N, 2021, VACCINE, V39, P933, DOI 10.1016/j.vaccine.2020.12.072; Astronomo RD, 2010, NAT REV DRUG DISCOV, V9, P308, DOI 10.1038/nrd3012; Bastos LM, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00059; Chahal JS, 2016, P NATL ACAD SCI USA, V113, pE4133, DOI 10.1073/pnas.1600299113; Chen K, 2017, PARASITE, V24, DOI 10.1051/parasite/2017045; Ching XT, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00609; Ching XT, 2017, AM J TROP MED HYG, V96, P1441, DOI 10.4269/ajtmh.16-0548; Chu KB, 2021, CURR TOP MICROBIOL, V433, P77, DOI 10.1007/82_2021_232; Chuang SC, 2017, PARASITE, V24, DOI 10.1051/parasite/2017004; Costa IN, 2021, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.623947; Czarnewski P, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00142; da Costa A, 2020, INT J RADIAT BIOL, V96, P697, DOI 10.1080/09553002.2020.1704298; da Costa A, 2018, BIOMED PHARMACOTHER, V106, P599, DOI 10.1016/j.biopha.2018.06.155; Di Cristina M, 2018, PARASITOLOGY, V145, P1119, DOI 10.1017/S003118201800001X; Dimier-Poisson I, 2015, BIOMATERIALS, V50, P164, DOI 10.1016/j.biomaterials.2015.01.056; Dubey JP, 2009, VET PARASITOL, V163, P1, DOI 10.1016/j.vetpar.2009.02.026; Ducournau C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02183; Ducournau C, 2017, FUTURE MICROBIOL, V12, P393, DOI 10.2217/fmb-2016-0146; Dunay IR, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00057-17; Effio CL, 2015, BIOTECHNOL J, V10, P715, DOI 10.1002/biot.201400392; El Bissati K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73210-0; El Bissati K, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0024-6; El Bissati K, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85955; Elbez-Rubinstein A, 2009, J INFECT DIS, V199, P280, DOI 10.1086/595793; Fereig RM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176324; Foroutan M, 2020, MICROB PATHOGENESIS, V147, DOI 10.1016/j.micpath.2020.104435; Fox BA, 2015, INFECT IMMUN, V83, P2148, DOI 10.1128/IAI.02756-14; Gallant Joel, 2015, Open Forum Infect Dis, V2, pofv177, DOI 10.1093/ofid/ofv177; Gatkowska J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040724; Gotze S, 2015, GLYCOBIOLOGY, V25, P984, DOI 10.1093/glycob/cwv040; Guo JJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00592; Guo JJ, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00163; Halonen Sandra K, 2013, Handb Clin Neurol, V114, P125, DOI 10.1016/B978-0-444-53490-3.00008-X; HOWE DK, 1995, J INFECT DIS, V172, P1561, DOI 10.1093/infdis/172.6.1561; Hu LY, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/1295038; Huang SY, 2019, MICROB PATHOGENESIS, V133, DOI 10.1016/j.micpath.2019.103560; Innes EA, 2019, FOOD WATERB PARASIT, V15, DOI 10.1016/j.fawpar.2019.e00053; Kang HJ, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12100989; Kang HJ, 2021, PARASITE IMMUNOL, V43, DOI 10.1111/pim.12799; Kang HJ, 2020, PARASITE IMMUNOL, V42, DOI 10.1111/pim.12716; Kang HJ, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11070342; Kim MJ, 2020, MICROB PATHOGENESIS, V142, DOI 10.1016/j.micpath.2020.104090; King A, 2019, NATURE, V575, pS51, DOI 10.1038/d41586-019-03639-5; Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083; Lagal V, 2015, INFECT IMMUN, V83, P2475, DOI 10.1128/IAI.02606-14; Lakhrif Z, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00317; Le Roux D, 2020, VACCINE, V38, P1457, DOI 10.1016/j.vaccine.2019.11.076; Lee DH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161231; Lee DH, 2016, ACTA TROP, V164, P77, DOI 10.1016/j.actatropica.2016.08.025; Lee SH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220865; Lee SH, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03073; Lee SH, 2018, VACCINE, V36, P5692, DOI 10.1016/j.vaccine.2018.08.016; Lee SH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175644; Li L, 2012, J BIOTECHNOL, V162, P171, DOI 10.1016/j.jbiotec.2012.08.012; Li XZ, 2016, INFECT GENET EVOL, V45, P447, DOI 10.1016/j.meegid.2016.10.006; Li YW, 2018, EXPERT OPIN BIOL TH, V18, P273, DOI 10.1080/14712598.2018.1413086; Li ZY, 2020, INT J MED MICROBIOL, V310, DOI 10.1016/j.ijmm.2020.151432; Li ZY, 2018, PARASITE, V25, DOI 10.1051/parasite/2018040; Liang QL, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8030352; Liu K, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00813; Liu ZZ, 2016, BMC IMMUNOL, V17, DOI 10.1186/s12865-016-0173-9; Liu ZZ, 2016, VACCINE, V34, P989, DOI 10.1016/j.vaccine.2015.10.067; Lu G, 2018, PARASITE IMMUNOL, V40, DOI 10.1111/pim.12578; Lung PS, 2020, NANOSCALE, V12, P5746, DOI 10.1039/c9nr08958f; Luo FJ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00605; Maeda Y, 2011, PROG LIPID RES, V50, P411, DOI 10.1016/j.plipres.2011.05.002; Maeta M, 2020, MOL PHARMACEUT, V17, P1237, DOI 10.1021/acs.molpharmaceut.9b01262; Mavi SA, 2019, INFECT DRUG RESIST, V12, P2519, DOI 10.2147/IDR.S209270; Montazeri M, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02587; Myhr AI, 2017, CURR ISSUES MOL BIOL, V22, P79, DOI 10.21775/cimb.022.079; Pagheh AS, 2021, INT J BIOCHEM CELL B, V132, DOI 10.1016/j.biocel.2021.105920; Pagheh AS, 2019, MICROB PATHOGENESIS, V134, DOI 10.1016/j.micpath.2019.103601; Rahman M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02223; Ramakrishnan C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37671-8; Rashid I, 2017, MED MICROBIOL IMMUN, V206, P53, DOI 10.1007/s00430-016-0483-9; Remy Vanessa, 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.27041; Robinson HL, 2000, ADV VIRUS RES, V55, P1, DOI 10.1016/S0065-3527(00)55001-5; Roozbehani M, 2018, VACCINE, V36, P6124, DOI 10.1016/j.vaccine.2018.08.068; Sanchez-Lopez EF, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3362-6; Sonaimuthu P, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00808; Sun H, 2020, MICROB PATHOGENESIS, V147, DOI 10.1016/j.micpath.2020.104441; Teimouri A, 2018, INT J NANOMED, V13, P1341, DOI 10.2147/IJN.S158736; Vartak A, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4020012; Wang JL, 2020, J IMMUNOL, V204, P1562, DOI 10.4049/jimmunol.1900410; Wang JL, 2019, TRENDS PARASITOL, V35, P239, DOI 10.1016/j.pt.2019.01.005; Wang JL, 2018, J INFECT DIS, V218, P768, DOI 10.1093/infdis/jiy211; Wang JL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00730; Wang LJ, 2018, VACCINE, V36, P3943, DOI 10.1016/j.vaccine.2018.05.072; Wang LY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010016; Wang T, 2017, PARASITE, V24, DOI 10.1051/parasite/2017013; Wang WH, 2017, VIRAL IMMUNOL, V30, P508, DOI 10.1089/vim.2016.0135; Wu MM, 2019, ACTA TROP, V199, DOI 10.1016/j.actatropica.2019.105148; Xia NB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01814; Xu XP, 2019, PARASITE, V26, DOI 10.1051/parasite/2019050; Yang J, 2020, MICROB BIOTECHNOL, V13, P2057, DOI 10.1111/1751-7915.13668; Yang WB, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01875; Yang WB, 2017, ACTA TROP, V176, P427, DOI 10.1016/j.actatropica.2017.09.007; Yeh MT, 2020, CELL HOST MICROBE, V27, P736, DOI 10.1016/j.chom.2020.04.003; Yu ZQ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040731; Zhang DC, 2019, VACCINE, V37, P1118, DOI 10.1016/j.vaccine.2018.12.044; Zhang NZ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02965; Zhang NZ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01505; Zhang ZC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020158; Zhang ZC, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00909; Zhao GH, 2017, ACTA TROP, V171, P17, DOI 10.1016/j.actatropica.2017.02.030; Zheng B, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00734; Zheng B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00418; Zheng B, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00216; Zheng LN, 2017, ACTA TROP, V166, P336, DOI 10.1016/j.actatropica.2016.12.004; Zhou J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01733; Zhu YC, 2020, PARASITE, V27, DOI 10.1051/parasite/2020021; Zhuo XH, 2021, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.616688	117	6	6	12	18	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							413	10.3390/vaccines9050413			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1OV	33919060	Green Published, gold			2022-04-29	WOS:000654596400001
J	Lin, YJ; Yen, CF; Chang, YP; Wang, PW				Lin, Yen-Ju; Yen, Cheng-Fang; Chang, Yu-Ping; Wang, Peng-Wei			Comparisons of Motivation to Receive COVID-19 Vaccination and Related Factors between Frontline Physicians and Nurses and the Public in Taiwan: Applying the Extended Protection Motivation Theory	VACCINES			English	Article						COVID-19; health care worker; motivation; prevention motivation theory; vaccination	HEALTH-CARE WORKERS; FEAR APPEALS; METAANALYSIS; INTENTION; EFFICACY; LESSONS	This study aimed to compare the differences in motivation to receive a COVID-19 vaccination between frontline physicians and nurses and the Taiwanese public. The associations of threat and coping appraisals, as described in Protection Motivation Theory (PMT), with motivation to receive COVID-19 vaccination were compared between these groups, too. We recruited 279 frontline physicians and nurses and 768 members of the public by a Facebook advertisement. Participants' motivation to receive COVID-19 vaccination, perceived severity of and vulnerability to COVID-19, self-efficacy and response efficacy of COVID-19 vaccination, response cost of COVID-19 vaccination, and knowledge about the mechanism of COVID-19 vaccination in light of PMT were determined. The results demonstrated that frontline health workers had higher motivation to receive COVID-19 vaccination than the public. Response efficacy and knowledge of COVID-19 vaccination were positively associated with motivation to receive COVID-19 vaccination in both frontline health workers and the public, whereas perceived vulnerability, perceived severity, and response cost of COVID-19 vaccination were positively associated with motivation in the public but not in frontline physicians and nurses. The factors related to motivation to receive COVID-19 vaccination should be considered when designing programs to increase motivation to receive COVID-19 vaccination among frontline health workers and the public.	[Lin, Yen-Ju; Yen, Cheng-Fang; Wang, Peng-Wei] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Psychiat, Kaohsiung 80708, Taiwan; [Lin, Yen-Ju; Yen, Cheng-Fang; Wang, Peng-Wei] Kaohsiung Med Univ, Dept Psychiat, Kaohsiung 80708, Taiwan; [Chang, Yu-Ping] SUNY Buffalo, Sch Nursing, Buffalo, NY 14260 USA		Wang, PW (通讯作者)，Kaohsiung Med Univ, Coll Med, Sch Med, Dept Psychiat, Kaohsiung 80708, Taiwan.; Wang, PW (通讯作者)，Kaohsiung Med Univ, Dept Psychiat, Kaohsiung 80708, Taiwan.	1040457@kmuh.org.tw; chfaye@cc.kmu.edu.tw; yc73@buffalo.edu; 990107@gap.kmu.edu.tw		Chang, Yu-Ping/0000-0003-2328-6876; Yen, Cheng-Fang/0000-0003-1156-4939	Kaohsiung Medical University Hospital [KMUH109-9M54]	This study was supported by the grants awarded by Kaohsiung Medical University Hospital (KMUH109-9M54).	Alajmi J, 2020, INT J INFECT DIS, V100, P386, DOI 10.1016/j.ijid.2020.09.027; Alessi EJ, 2010, SOC WORK RES, V34, P122, DOI 10.1093/swr/34.2.122; Andrews D, 2003, INT J HUM-COMPUT INT, V16, P185, DOI 10.1207/S15327590IJHC1602_04; Bae S, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e115; Ball HL, 2019, J HUM LACT, V35, P413, DOI 10.1177/0890334419848734; Bandyopadhyay S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003097; Bernard H. R., 2011, RES METHODS ANTHR QU; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Bobkowski P, 2013, MEDIA CULT SOC, V35, P771, DOI 10.1177/0163443713491517; Camerini AL, 2019, SSM-POPUL HLTH, V7, DOI 10.1016/j.ssmph.2018.11.005; Central News Agency, 1 WAV ASTRAZENECA VA; Cheng HY, 2020, J FORMOS MED ASSOC, V119, P771, DOI 10.1016/j.jfma.2020.03.007; Chou WP, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17249329; Donnelly SC, 2020, QJM-INT J MED, V113, P611, DOI 10.1093/qjmed/hcaa248; Floyd DL, 2000, J APPL SOC PSYCHOL, V30, P407, DOI 10.1111/j.1559-1816.2000.tb02323.x; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Kuter BJ, 2021, VACCINE, V39, P1693, DOI 10.1016/j.vaccine.2021.02.029; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lee K, 2009, GLOB INST, P1; Liao QY, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-169; MADDUX JE, 1983, J EXP SOC PSYCHOL, V19, P469, DOI 10.1016/0022-1031(83)90023-9; Meyer D, 2018, AM J PUBLIC HEALTH, V108, pS188, DOI 10.2105/AJPH.2018.304527; Meyer MN, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.5344; Ministry of Health and Welfare, 2021, COVID 19 VACC PROGR; Ministry of Health and Welfare, 2021, ASTRAZENECA COVID 19; Murata S, 2021, DEPRESS ANXIETY, V38, P233, DOI 10.1002/da.23120; Nguyen LH, 2020, LANCET PUBLIC HEALTH, V5, pE475, DOI 10.1016/S2468-2667(20)30164-X; Okuhara T, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8040475; Praschan N, 2021, LANCET RESP MED, V9, P230, DOI 10.1016/S2213-2600(20)30575-0; ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803; Sabetian G, 2021, VIROL J, V18, DOI 10.1186/s12985-021-01532-0; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Schulz PJ, 2021, HEALTH COMMUN, V36, P1505, DOI 10.1080/10410236.2020.1771119; Shaw J, 2021, CLIN INFECT DIS, V73, P1776, DOI 10.1093/cid/ciab054; Taiwan Centers for Disease Control, COVID 19 PAND; TANNER JF, 1991, J MARKETING, V55, P36, DOI 10.2307/1252146; United News Network, ONL 17245 PEOPL HAV; Vetter V, 2018, ANN MED, V50, P110, DOI 10.1080/07853890.2017.1407035; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Wang PW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040380; Webb TL, 2006, PSYCHOL BULL, V132, P249, DOI 10.1037/0033-2909.132.2.249; World Health Organization, WHO SAG ROADM PRIOR; Yeh YC, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030297	45	8	8	7	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							528	10.3390/vaccines9050528			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI3CD	34065222	Green Published, gold			2022-04-29	WOS:000654702300001
J	Lopez-Serrano, S; Neila-Ibanez, C; Costa-Hurtado, M; Mahmmod, Y; Martinez-Martinez, J; Galindo-Cardiel, IJ; Darji, A; Rodriguez, F; Sibila, M; Aragon, V				Lopez-Serrano, Sergi; Neila-Ibanez, Carlos; Costa-Hurtado, Mar; Mahmmod, Yasser; Martinez-Martinez, Jorge; Galindo-Cardiel, Ivan Jose; Darji, Ayub; Rodriguez, Fernando; Sibila, Marina; Aragon, Virginia			Sow Vaccination with a Protein Fragment against Virulent Glaesserella (Haemophilus) parasuis Modulates Immunity Traits in Their Offspring	VACCINES			English	Article						swine; bacteria; disease; vaccine; Glaesserella parasuis	IMMUNOLOGICAL OUTCOMES; IMMUNIZATION; ANTIBODIES; INFECTION; STRAINS; PIGLETS; BETA; PCR	Glaesserella (Haemophilus) parasuis, an early colonizer of the nasal cavity in piglets, is a highly heterogeneous species, comprising both commensal and virulent strains. Virulent G. parasuis strains can cause fibrinous polyserositis called Glasser's disease. Colostrum is a source of passive immunity for young piglets. When vaccinating sows, protective antibodies are transferred to their offspring through the colostrum. Here, sow vaccination was performed with a protein fragment, F4, from the outer membrane trimeric autotransporters VtaAs exclusively found in virulent G. parasuis. Piglets were allowed to suckle for 3 weeks, following which a challenge with two virulent strains of G. parasuis was performed. A group of nonvaccinated sows and their piglets were included as a control. Antibodies against F4 were confirmed using ELISA in the vaccinated sows and their offspring before the G. parasuis challenge. Compared to the control group, F4-vaccination also resulted in an increased level of serum TGF-beta both in vaccinated sows and in their offspring at early time points of life. After the challenge, a lower body temperature and a higher weight were observed in the group of piglets from vaccinated sows. One piglet from the non-vaccinated group succumbed to the infection, but no other significant differences in clinical signs were noticed. At necropsy, performed 2 weeks after the virulent challenge, the level of surfactant protein D (SP-D) in bronchoalveolar lavage was higher in the piglets from vaccinated sows. Vaccination did not inhibit the nasal colonization of the piglets by the challenge strains.	[Lopez-Serrano, Sergi; Neila-Ibanez, Carlos; Costa-Hurtado, Mar; Mahmmod, Yasser; Martinez-Martinez, Jorge; Darji, Ayub; Rodriguez, Fernando; Sibila, Marina; Aragon, Virginia] UAB, Ctr Recerca Sanitat Anim CReSA, IRTA, Campus Univ Autonoma Barcelona, Barcelona 08193, Spain; [Mahmmod, Yasser] Zagazig Univ, Fac Vet Med, Dept Anim Med, Zagazig 44511, Egypt; [Mahmmod, Yasser] Al Ain Mens Coll, Div Hlth Sci, Sect Vet Sci, Higher Coll Technol, Al Ain 17155, U Arab Emirates; [Martinez-Martinez, Jorge; Darji, Ayub; Rodriguez, Fernando; Sibila, Marina; Aragon, Virginia] OIE Collaborating Ctr Res & Control Emerging & Re, Bellaterra 08193, Spain; [Martinez-Martinez, Jorge] UAB, Fac Vet, Dept Sanitat & Anat Anim, Bellaterra 08193, Spain; [Galindo-Cardiel, Ivan Jose] WorldPathol, Calle Ajedrea 20,Nave 22C, Zaragoza 50720, Spain		Aragon, V (通讯作者)，UAB, Ctr Recerca Sanitat Anim CReSA, IRTA, Campus Univ Autonoma Barcelona, Barcelona 08193, Spain.; Aragon, V (通讯作者)，OIE Collaborating Ctr Res & Control Emerging & Re, Bellaterra 08193, Spain.	sergi.lopez@irta.cat; Carlos.neila@irta.cat; mar.costahurtado@gmail.com; mar.costahurtado@gmail.com; Jorge.martinez@irta.cat; ivan.galindo@worldpathol.com; Ayub.darji@irta.cat; fernando.rodriguez@irta.cat; marina.sibila@irta.cat; virginia.aragon@irta.cat	Aragon, Virginia/M-1611-2014	Aragon, Virginia/0000-0002-3470-6015; Neila Ibanez, Carlos Maria/0000-0001-7233-2475; Lopez-Serrano, Sergi/0000-0002-0968-7713; Rodriguez, Fernando/0000-0001-7361-8408	Ministry of Economy of Spain (MINECO) [AGL2016-77361-R]; Ministry of Economy of Spain (MINECO) of the Spanish government	This study was funded by the Ministry of Economy of Spain (MINECO) under the project number AGL2016-77361-R awarded to MS and VA. MC-H is a recipient of a Juan de la Cierva fellowship from the same ministry of the Spanish government.	Arsenakis I, 2019, VET REC, V184, DOI 10.1136/vr.104972; Beilage EG, 2005, DEUT TIERARZTL WOCH, V112, P256; Bischoff AL, 2015, PEDIATR INFECT DIS J, V34, P84, DOI 10.1097/INF.0000000000000529; Blanco I, 2004, VET MICROBIOL, V103, P21, DOI 10.1016/j.vetmic.2004.06.011; Braat H, 2007, GUT, V56, P351, DOI 10.1136/gut.2006.099861; Cerda-Cuellar M, 2010, VET MICROBIOL, V145, P315, DOI 10.1016/j.vetmic.2010.04.002; Correa-Fiz F, 2017, VET MICROBIOL, V198, P116, DOI 10.1016/j.vetmic.2016.12.015; Costa-Hurtado M, 2020, VET MICROBIOL, V242, DOI 10.1016/j.vetmic.2020.108595; Costa-Hurtado M, 2019, VET RES, V50, DOI 10.1186/s13567-019-0687-2; Costa-Hurtado M, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-57; Dodagatta-Marri E, 2014, METHODS MOL BIOL, V1100, P273, DOI 10.1007/978-1-62703-724-2_22; Nguyen DN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117608; Galofre-Mila N, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1041-4; Guzman-Bautista ER, 2014, IMMUNOLOGY, V141, P609, DOI 10.1111/imm.12222; Hou CL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119505; Howell KJ, 2015, J CLIN MICROBIOL, V53, P3812, DOI 10.1128/JCM.01991-15; Li YF, 2016, VET MICROBIOL, V196, P18, DOI 10.1016/j.vetmic.2016.10.012; Liu HS, 2016, VET IMMUNOL IMMUNOP, V180, P53, DOI 10.1016/j.vetimm.2016.09.002; Matias J, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040048; MILLER GA, 1986, HYBRIDOMA, V5, P353, DOI 10.1089/hyb.1986.5.353; Oddy WH, 2011, CLIN EXP ALLERGY, V41, P783, DOI 10.1111/j.1365-2222.2011.03762.x; Oddy WH, 2010, PEDIAT ALLERG IMM-UK, V21, P47, DOI 10.1111/j.1399-3038.2009.00913.x; Oliver-Ferrando S, 2018, VET MICROBIOL, V214, P148, DOI 10.1016/j.vetmic.2017.12.011; Olvera A, 2011, VACCINE, V29, P2797, DOI 10.1016/j.vaccine.2011.01.105; Olvera A, 2009, VET RES, V40, DOI 10.1051/vetres/2009007; Poonsuk K, 2018, ANIM HEALTH RES REV, V19, P31, DOI 10.1017/S1466252317000123; Rooke JA, 2002, LIVEST PROD SCI, V78, P13, DOI 10.1016/S0301-6226(02)00182-3; Salmon H, 2009, DEV COMP IMMUNOL, V33, P384, DOI 10.1016/j.dci.2008.07.007; Sorensen GL, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00018; Stryhn H., 2009, VET EPIDEMIOLOGIC RE; VAHLE JL, 1995, J VET DIAGN INVEST, V7, P476, DOI 10.1177/104063879500700409; WANNEMUEHLER MJ, 1994, VET IMMUNOL IMMUNOP, V43, P117, DOI 10.1016/0165-2427(94)90127-9; Wilkinson JM, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-455	33	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							534	10.3390/vaccines9050534			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1SX	34065547	Green Published, gold			2022-04-29	WOS:000654607000001
J	Catma, S; Varol, S				Catma, Serkan; Varol, Serkan			Willingness to Pay for a Hypothetical COVID-19 Vaccine in the United States: A Contingent Valuation Approach	VACCINES			English	Article						willingness to pay; contingent valuation; COVID-19; vaccine preference	DEMAND	Our objective was to estimate the individual willingness to pay (WTP) for a COVID-19 vaccine and evaluate its predictors in the United States. A double-bounded dichotomous choice contingent valuation with open-ended question technique was implemented based on the responses to a national survey administered during the first week of November 2020. The final sample size was 1285. The results showed that individual WTP values increased with income, whether a household member had any pre-existing condition, and perceived threat of the virus. The vaccine efficacy rate and duration of protection were found to be important factors for the respondents. The mean WTP for a vaccine with a 95 percent efficacy rate and 3-year protection (US$318.76) was approximately 35 percent greater than the vaccine with a 50 percent efficacy rate and 1-year protection (US$236.85). The initial aggregate direct benefit of the current vaccination program was estimated to be between 20 and 35.6 billion US dollars depending on the vaccine protection duration.	[Catma, Serkan] Univ South Carolina Beauft, Dept Business Adm, 1 Univ Blvd,Hargray 224, Bluffton, SC 29909 USA; [Varol, Serkan] Univ Tennessee, Dept Engn Management & Technol, EMCS 235,615 McCallie Ave, Chattanooga, TN 37403 USA		Catma, S (通讯作者)，Univ South Carolina Beauft, Dept Business Adm, 1 Univ Blvd,Hargray 224, Bluffton, SC 29909 USA.	catma@uscb.edu; Serkan-Varol@utc.edu	Varol, Serkan/AAX-7054-2021; Catma, Serkan/AAW-7122-2021	catma, serkan/0000-0002-7996-1271; VAROL, SERKAN/0000-0003-1771-3499	University of Tennessee Chattanooga	This study was supported by research funding fromthe University of Tennessee Chattanooga.	Aizaki H, 2014, STATED PREFERENCE ME; Al-Shomrani AA, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3476-7; [Anonymous], WHO CORONAVIRUS COVI; Asgary A, 2012, SCAND J PUBLIC HEALT, V40, P412, DOI 10.1177/1403494812453884; Bateman I.J., 2002, EC VALUATION STATED; Borriello A, 2021, VACCINE, V39, P473, DOI 10.1016/j.vaccine.2020.12.032; Boyle K.J., 2017, PRIMER NONMARKET VAL; Centers for Disease Control and Prevention, KEY THINGS KNOW COVI; Centers for Disease Control and Prevention, 2020, FLU VACCINATION COVE; CICCHETTI CJ, 1973, SOC SCI RES, V2, P15, DOI DOI 10.1016/0049-089X(73)90019-7; Davis R.K., 1963, THESIS HARVARD U CAM; Docea AO, 2020, INT J MOL MED, V45, P1631, DOI 10.3892/ijmm.2020.4555; Dong D, 2020, HEALTH EXPECT, V23, P1543, DOI 10.1111/hex.13140; Garcia LY, 2020, VACCINE, V38, P5424, DOI 10.1016/j.vaccine.2020.06.068; Harapan H, 2020, HUM VACC IMMUNOTHER, V16, P3074, DOI 10.1080/21645515.2020.1819741; Heinzen RR, 2008, INT J TECHNOL ASSESS, V24, P481, DOI 10.1017/S026646230808063X; Khan NI, 2014, J ENVIRON MANAGE, V143, P151, DOI 10.1016/j.jenvman.2014.04.018; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Lin CT, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051810; Lin PJ, 2016, PHARMACOECONOMICS, V34, P1255, DOI 10.1007/s40273-016-0435-7; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Neumann PJ, 2012, HEALTH ECON, V21, P238, DOI 10.1002/hec.1704; Palanca-Tan R, 2008, VACCINE, V26, P914, DOI 10.1016/j.vaccine.2007.12.011; Pew Research Center, 2020, INT GET COVID 19 VAC; Ravert RD., 2012, ADV PREV MED, P242518, DOI [10.1155/2012/242518, DOI 10.1155/2012/242518]; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Sarasty O, 2020, VACCINE, V38, P8090, DOI 10.1016/j.vaccine.2020.11.013; Sun CW, 2016, J CLEAN PROD, V112, P1635, DOI 10.1016/j.jclepro.2015.04.121; United States Census Bureau, 2020, NAT POP CHAR 2010 20; United States Government, 2020, ACC OFF COVID 19 FED; United States Senate, 2020, COMM COMM SCI TRANSP; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279	32	4	4	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							318	10.3390/vaccines9040318			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RS4QZ	33915680	gold, Green Published			2022-04-29	WOS:000643766900001
J	Jahn, M; Korth, J; Dorsch, O; Anastasiou, OE; Sorge-Hadicke, B; Tyczynski, B; Gackler, A; Witzke, O; Dittmer, U; Dolff, S; Wilde, B; Kribben, A				Jahn, Michael; Korth, Johannes; Dorsch, Oliver; Anastasiou, Olympia Evdoxia; Sorge-Haedicke, Burkhard; Tyczynski, Bartosz; Gaeckler, Anja; Witzke, Oliver; Dittmer, Ulf; Dolff, Sebastian; Wilde, Benjamin; Kribben, Andreas			Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis	VACCINES			English	Article						SARS-CoV-2; mRNA-vaccines; hemodialysis; chronic kidney disease; COVID-19; antibody titers		mRNA-based SARS-CoV-2 vaccines offer a preventive strategy against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections that is of interest in the care of patients on hemodialysis (HDP). We measured humoral immune responses in 72 HDP after standard vaccination with two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 (Pfizer-BioNTech). Antibody responses were evaluated with an anti-SARS-CoV-2 IgG ChemiLuminescent ImmunoAssay (CLIA) two weeks after the second dose. In addition, SARS-CoV-2 IgG was determined in a control of 16 healthy healthcare workers (HCW). The control group of HCW has shown a strong antibody response with a median (MD (Q1; Q3)) antibody titer of 800.0 AU/mL (520.5; 800.0). In comparison to HCW, HDP under 60 years of age responded equally (597.0 AU/mL (410.5; 800.0), p = 0.051). However, the antibody responses of the HDP negatively correlated with age (r(2) = 0.2954 p < 0.0001), leading to significantly lower antibody titers in HDP over 60 years (280.0 AU/mL (45.7; 477.0), p < 0.0001). To thoroughly understand the immunogenicity of the new mRNA-based vaccines in HDP, longitudinal data on the effectiveness and durability of antibody responses are needed. Modifications of immunization schedules should be considered in HDP with low or without antibody responsiveness after standard vaccination to boost immune reactivity and prolong protective effects in these vulnerable patients.	[Jahn, Michael; Korth, Johannes; Tyczynski, Bartosz; Gaeckler, Anja; Wilde, Benjamin; Kribben, Andreas] Univ Duisburg Essen, Univ Hosp Essen, Dept Nephrol, Hufelandstr 55, D-45147 Essen, Germany; [Dorsch, Oliver] KfH Kuratorium Dialyse & Nierentransplantat eV, KfH Nierenzentrum Friesener Str 37a, D-96317 Kronach, Germany; [Anastasiou, Olympia Evdoxia; Dittmer, Ulf] Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, Virchowstr 179, D-45147 Essen, Germany; [Sorge-Haedicke, Burkhard] KfH Kuratorium Dialyse & Nierentransplantat eV, KfH Nierenzentrum Alfried Krupp Str 43, D-45131 Essen, Germany; [Witzke, Oliver; Dolff, Sebastian] Univ Duisburg Essen, Univ Hosp Essen, West German Ctr Infect Dis, Dept Infect Dis, Hufelandstr 55, D-45147 Essen, Germany		Jahn, M (通讯作者)，Univ Duisburg Essen, Univ Hosp Essen, Dept Nephrol, Hufelandstr 55, D-45147 Essen, Germany.	michael.jahn@uk-essen.de; johannes.korth@uk-essen.de; oliver.dorsch@kfh.de; olympiaevdoxia.anastasiou@uk-essen.de; burkhard.sorge-haedicke@kfh-dialyse.de; bartosz.tyzcynski@uk-essen.de; anja.gaeckler@uk-essen.de; oliver.witzke@uk-essen.de; ulf.dittmer@uk-essen.de; sebastian.dolff@uk-essen.de; benjamin.wilde@uk-essen.de; andreas.kribben@uk-essen.de		Anastasiou, Olympia/0000-0003-2178-3182; Korth, Johannes/0000-0003-4898-0389	Open Access Publication Fund of the University of Duisburg-Essen	The authors would like to thank Hannah Pfeng, Assia Omairatte, Emel Karaca, Jessica Ackermann, and Rebecca Blinzler for assistance. We acknowledge support by the Open Access Publication Fund of the University of Duisburg-Essen.	Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Asan A, 2017, INT UROL NEPHROL, V49, P1845, DOI 10.1007/s11255-017-1616-9; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Banatvala J, 2000, LANCET, V355, P561, DOI 10.1016/S0140-6736(99)07239-6; Bradley T, 2021, NEW ENGL J MED, V384, P1959, DOI 10.1056/NEJMc2102051; Fabrizi F, 2011, ALIMENT PHARM THER, V33, P815, DOI 10.1111/j.1365-2036.2011.04589.x; Fabrizi F, 2012, DIGEST DIS SCI, V57, P1366, DOI 10.1007/s10620-011-1987-1; Gandjour A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231375; Geisen UM, 2021, ANN RHEUM DIS, V80, P1306, DOI 10.1136/annrheumdis-2021-220272; Hoxha E, 2021, DTSCH ARZTEBL INT, V118, P195, DOI 10.3238/arztebl.m2021.0160; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Kong NCT, 2008, KIDNEY INT, V73, P856, DOI 10.1038/sj.ki.5002725; Krueger KM, 2020, AM J KIDNEY DIS, V75, P417, DOI 10.1053/j.ajkd.2019.06.014; Mastalerz-Migas A, 2013, ADV EXP MED BIOL, V756, P285, DOI 10.1007/978-94-007-4549-0_35; Mitra S, 2016, CLIN VACCINE IMMUNOL, V23, P884, DOI 10.1128/CVI.00153-16; Ortiz A, 2021, NEPHROL DIAL TRANSPL, V36, P87, DOI 10.1093/ndt/gfaa314; Ott U, 2012, MED MICROBIOL IMMUN, V201, P297, DOI 10.1007/s00430-012-0231-8; Patel N, 2015, SOUTH MED J, V108, P567, DOI 10.14423/SMJ.0000000000000343; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Razzaghi Hilda, 2020, MMWR Morb Mortal Wkly Rep, V69, P945, DOI 10.15585/mmwr.mm6929a1; Taji L, 2021, CAN MED ASSOC J, V193, pE278, DOI 10.1503/cmaj.202601; Vaziri ND, 2012, J RENAL NUTR, V22, P149, DOI 10.1053/j.jrn.2011.10.020; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Weinberger B, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-017-0107-2; Windpessl M, 2021, NAT REV NEPHROL, V17, P291, DOI 10.1038/s41581-021-00406-6	25	32	33	2	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							360	10.3390/vaccines9040360			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4UJ	33918085	gold, Green Published			2022-04-29	WOS:000643775800001
J	Kerr, JR; Freeman, ALJ; Marteau, TM; van der Linden, S				Kerr, John R.; Freeman, Alexandra L. J.; Marteau, Theresa M.; van der Linden, Sander			Effect of Information about COVID-19 Vaccine Effectiveness and Side Effects on Behavioural Intentions: Two Online Experiments	VACCINES			English	Article						COVID-19; vaccination; hesitancy; communication; vaccine messaging	HEALTH BELIEF MODEL; HERD-IMMUNITY; COMMUNICATION; HESITANCY	The success of mass COVID-19 vaccination campaigns rests on widespread uptake. However, although vaccinations provide good protection, they do not offer full immunity and while they likely reduce transmission of the virus to others, the extent of this remains uncertain. This produces a dilemma for communicators who wish to be transparent about benefits and harms and encourage continued caution in vaccinated individuals but not undermine confidence in an important public health measure. In two large pre-registered experimental studies on quota-sampled UK public participants we investigate the effects of providing transparent communication-including uncertainty-about vaccination effectiveness on decision-making. In Study 1 (n = 2097) we report that detailed information about COVID-19 vaccines, including results of clinical trials, does not have a significant impact on beliefs about the efficacy of such vaccines, concerns over side effects, or intentions to receive a vaccine. Study 2 (n = 2217) addressed concerns that highlighting the need to maintain protective behaviours (e.g., social distancing) post-vaccination may lower perceptions of vaccine efficacy and willingness to receive a vaccine. We do not find evidence of this: transparent messages did not significantly reduce perceptions of vaccine efficacy, and in some cases increased perceptions of efficacy. We again report no main effect of messages on intentions to receive a vaccine. The results of both studies suggest that transparently informing people of the limitations of vaccinations does not reduce intentions to be vaccinated but neither does it increase intentions to engage in protective behaviours post-vaccination.	[Kerr, John R.; Freeman, Alexandra L. J.] Univ Cambridge, Winton Ctr Risk & Evidence Commun, Cambridge CB3 0WA, England; [Kerr, John R.; van der Linden, Sander] Univ Cambridge, Dept Psychol, Cambridge CB2 3EB, England; [Marteau, Theresa M.] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB2 0SR, England		Kerr, JR (通讯作者)，Univ Cambridge, Winton Ctr Risk & Evidence Commun, Cambridge CB3 0WA, England.; Kerr, JR (通讯作者)，Univ Cambridge, Dept Psychol, Cambridge CB2 3EB, England.	jk803@cam.ac.uk; af621@cam.ac.uk; tm388@medschl.cam.ac.uk; sv395@cam.ac.uk	Kerr, John/AAX-1806-2020	Kerr, John/0000-0002-6606-5507; Freeman, Alexandra/0000-0002-4115-161X	David and Claudia Harding Foundation	This study was funded by theWinton Centre for Risk and Evidence Communication which is supported by the David and Claudia Harding Foundation.	Altay S., 2021, INFORM DELIVERED CHA, DOI [10.31234/OSF.IO/EB2GT, DOI 10.31234/OSF.IO/EB2GT]; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; [Anonymous], 2021, LANCET MICROBE, V2, pE1, DOI 10.1016/S2666-5247(20)30226-3; [Anonymous], 2020, NATURE, V586, P8, DOI 10.1038/d41586-020-02738-y; Ansell B., COPING COVID 2 WAVE; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Balog-Way DHP, 2020, J RISK RES, V23, P838, DOI 10.1080/13669877.2020.1758192; Betsch C, 2018, NAT HUM BEHAV, V2, P881, DOI 10.1038/s41562-018-0478-1; Betsch C, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-017-0056; Blastland M, 2020, NATURE, V587, P362, DOI 10.1038/d41586-020-03189-1; Borriello A, 2021, VACCINE, V39, P473, DOI 10.1016/j.vaccine.2020.12.032; Brick C, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.190876; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; Carpenter CJ, 2010, HEALTH COMMUN, V25, P661, DOI 10.1080/10410236.2010.521906; Chowdhury EK, 2021, BUS SOC REV, DOI 10.1111/basr.12219; Cohen AF, 2020, BRIT J CLIN PHARMACO, V86, P2107, DOI 10.1111/bcp.14581; Cousins S, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028576; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Duquette N., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3705504, DOI 10.2139/SSRN.3705504]; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; European Centre for Disease Prevention and Control, 2017, CAT INT ADDR VACC HE; European Medicines Agency, COVID 19 VACC MOD; FDA, FDA BRIEF DOC MOD CO; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Frank K., CANADIANS WILLINGNES; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Godinho CA, 2016, PREV MED, V89, P104, DOI 10.1016/j.ypmed.2016.05.025; Goritz A.S., 2012, OXFORD HDB INTERNET; Hotez PJ, 2020, MICROBES INFECT, V22, P162, DOI 10.1016/j.micinf.2020.05.010; Jarosz AF, 2014, J PROBL SOLVING, V7, P2, DOI 10.7771/1932-6246.1167; Jones CL, 2015, HEALTH COMMUN, V30, P566, DOI 10.1080/10410236.2013.873363; Kadkhoda K, 2021, AM J CLIN PATHOL, V155, P471, DOI 10.1093/ajcp/aqaa272; Kaplan RM, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021726118; Karlsson LC, 2021, PERS INDIV DIFFER, V172, DOI 10.1016/j.paid.2020.110590; Kitta A, 2017, CRIT PUBLIC HEALTH, V27, P506, DOI 10.1080/09581596.2016.1235259; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Krupnikov Y., 2015, OXFORD HDB POLLING P, P483; Larson HJ, 2010, JAMA-J AM MED ASSOC, V303, P271, DOI 10.1001/jama.2009.2023; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Lockyer B., 2020, UNDERSTANDING COVID, DOI [10.1101/2020.12.22.20248259, DOI 10.1101/2020.12.22.20248259]; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; MAIMAN LA, 1974, HEALTH EDUC QUART, V2, P336, DOI 10.1177/109019817400200404; Marco-Franco JE, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020744; Marcus GE, 2017, POLIT SCI RES METH, V5, P733, DOI 10.1017/psrm.2015.65; McDowell Michelle, 2016, MDM Policy Pract, V1, p2381468316665365, DOI 10.1177/2381468316665365; McPhetres J, 2019, J ENVIRON PSYCHOL, V64, P21, DOI 10.1016/j.jenvp.2019.04.012; Motta M., 2021, FRONTIERS POLITICAL, V3, P1, DOI [DOI 10.3389/FPOS.2021.630133, 10.3389/fpos.2021.630133]; Motta M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113642; NHS, YOUV HAD COVID 19 VA; Nkwihoreze H., 2021, CLIN INFECT DIS, pCIAB102, DOI [10.1093/cid/ciab102, DOI 10.1093/CID/CIAB102]; Nuki P., OXFORDS VACCINE IS P; Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017; O'Neill J., COVID 19 VACCINE INF; O'Neill J, 2022, J MED ETHICS, V48, P106, DOI 10.1136/medethics-2020-106068; O'Neill O, 2003, J MED ETHICS, V29, P4, DOI 10.1136/jme.29.1.4; OCONNOR AM, 1995, MED DECIS MAKING, V15, P25, DOI 10.1177/0272989X9501500105; Opel DJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25672; Palm R., 2021, EFFECT FRAMES COVID, V3, P661257, DOI [10.3389/fpos.2021.661257, DOI 10.1101/2021.01.04.21249241]; Parmet Wendy E, 2005, J Health Care Law Policy, V8, P71; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Pearl R., QUEENS GAMBIT COVID; Pennings S, 2021, J MED ETHICS, V47, P709, DOI 10.1136/medethics-2020-107076; Penta MA, 2018, HEALTH COMMUN, V33, P299, DOI 10.1080/10410236.2016.1266574; Petersen M.B., 2020, TRANSPARENCY IS NECE, DOI [10.31234/OSF.IO/VX84N, DOI 10.31234/OSF.IO/VX84N]; Prasad V., OP ED THROW AWAY YOU; Public Health England, EV YOUV HAD YOUR COV; Quinn SC, 2021, AM J PUBLIC HEALTH, V111, P355, DOI 10.2105/AJPH.2020.306036; Quintana DS, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1761-4; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Ranney MA, 2016, TOP COGN SCI, V8, P49, DOI 10.1111/tops.12187; Reiss DR, 2019, AM J LAW MED, V45, P357, DOI 10.1177/0098858819892745; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Rossen I, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01483; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020109; Saladino V, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.577684; Schneider C.R., 2021, EFFECTS QUALIT UNPUB; Schwartz LM, 2013, P NATL ACAD SCI USA, V110, P14069, DOI 10.1073/pnas.1214646110; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Simis MJ, 2016, PUBLIC UNDERST SCI, V25, P400, DOI 10.1177/0963662516629749; Su Zhaohui, 2021, Brain Behav Immun Health, V12, P100204, DOI 10.1016/j.bbih.2021.100204; Torjesen I, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n295; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; van der Linden S., 2020, PREDICTORS COVID 19, DOI [10.1101/2020.12.09.20246439, DOI 10.1101/2020.12.09.20246439]; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wood T, 2019, POLIT BEHAV, V41, P135, DOI 10.1007/s11109-018-9443-y; Yigit M, 2021, PEDIATR INFECT DIS J, V40, pE134, DOI 10.1097/INF.0000000000003042; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048	93	19	19	4	23	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							379	10.3390/vaccines9040379			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RS4SM	33924542	gold, Green Published, Green Submitted			2022-04-29	WOS:000643770900001
J	Varoni, EM; Lodi, G; Del Fabbro, M; Sardella, A; Carrassi, A; Iriti, M; Tripputi, P				Varoni, Elena M.; Lodi, Giovanni; Del Fabbro, Massimo; Sardella, Andrea; Carrassi, Antonio; Iriti, Marcello; Tripputi, Pasquale			Sex-Related Differences in Allelic Frequency of the Human Beta T Cell Receptor SNP rs1800907: A Retrospective Analysis from Milan Metropolitan Area	VACCINES			English	Article						genotype distribution; polymorphism; heterozygosis; homozygosis		This paper aims at retrospectively re-analyzing the different distribution, between males and females, in the allelic frequency of the human beta T cell receptor (TCR beta) single nucleotide polymorphism (SNPs) rs1800907 in Caucasian patients in the Milan metropolitan area. The allelic frequency significantly differed between sexes. Females showed higher frequency of C/C genotype than males, but lower T/C genotype (p < 0.0001). Heterozygous (T/C) versus homozygous (T/T + C/C) genotypes resulted in a different distribution of frequencies in males than in females, the latter possessing higher homozygosis (p < 0.0001). Within the limitations of this work (small number of included studies that concerned just a specific geographical area), allelic distribution according to sex might account the role of TCR beta-related SNPs in autoimmune diseases and further investigations are required to explain better this genetic background, in the perspective of a sex-related T cell immune responsiveness and auto-immunity.	[Varoni, Elena M.; Lodi, Giovanni; Del Fabbro, Massimo; Sardella, Andrea; Carrassi, Antonio; Tripputi, Pasquale] Univ Milan, Dipartimento Sci Biomed Chirurg & Odontoiatr, Via Beldiletto 1, I-20142 Milan, Italy; [Varoni, Elena M.; Iriti, Marcello] Natl Interuniveristy Consortium Mat Sci & Technol, I-50121 Florence, Italy; [Del Fabbro, Massimo] IRCCS Orthoped Inst Galeazzi, I-20161 Milan, Italy; [Iriti, Marcello] Univ Milan, Dept Agr & Environm Sci, I-20142 Milan, Italy; [Iriti, Marcello] Univ Napoli Federico II, BAT Ctr, Interuniv Ctr Studies Bioinspired Agroenvironm Te, I-80055 Naples, Italy		Tripputi, P (通讯作者)，Univ Milan, Dipartimento Sci Biomed Chirurg & Odontoiatr, Via Beldiletto 1, I-20142 Milan, Italy.; Iriti, M (通讯作者)，Natl Interuniveristy Consortium Mat Sci & Technol, I-50121 Florence, Italy.; Iriti, M (通讯作者)，Univ Milan, Dept Agr & Environm Sci, I-20142 Milan, Italy.; Iriti, M (通讯作者)，Univ Napoli Federico II, BAT Ctr, Interuniv Ctr Studies Bioinspired Agroenvironm Te, I-80055 Naples, Italy.	elena.varoni@unimi.it; giovanni.lodi@unimi.it; massimo.delfabbro@unimi.it; andrea.sardella@unimi.it; antonio.carrassi@unimi.it; marcello.iriti@unimi.it; pasquale.tripputi@unimi.it	IRITI, MARCELLO/Q-8580-2017	IRITI, MARCELLO/0000-0002-5063-1236; Varoni, Elena Maria/0000-0002-7287-2188; Tripputi, Pasquale/0000-0003-3394-8503; SARDELLA, ANDREA/0000-0003-4491-4640			Clark VJ, 2007, GENETICS, V175, P795, DOI 10.1534/genetics.106.064964; DEMAINE AG, 1988, IMMUNOGENETICS, V27, P19, DOI 10.1007/BF00404439; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Hou XL, 2016, GENES IMMUN, V17, P153, DOI 10.1038/gene.2016.9; ITO M, 1989, J CLIN ENDOCR METAB, V69, P100, DOI 10.1210/jcem-69-1-100; Khan D, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00635; King R.A., 2002, GENETIC BASIS COMMON; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Lotter H, 2019, SEMIN IMMUNOPATHOL, V41, P133, DOI 10.1007/s00281-018-00728-x; MANABE K, 1994, GASTROENTEROLOGY, V106, P1321, DOI 10.1016/0016-5085(94)90025-6; Marschall HU, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47890-2; Matos TR, 2017, J INVEST DERMATOL, V137, pE131, DOI 10.1016/j.jid.2017.04.001; McCombe PA, 2009, CURR MOL MED, V9, P1058, DOI 10.2174/156652409789839116; MILLWARD BA, 1987, CLIN EXP IMMUNOL, V70, P152; Mor G, 2010, AM J REPROD IMMUNOL, V63, P425, DOI 10.1111/j.1600-0897.2010.00836.x; Ngo ST, 2014, FRONT NEUROENDOCRIN, V35, P347, DOI 10.1016/j.yfrne.2014.04.004; Ober C, 2008, NAT REV GENET, V9, P911, DOI 10.1038/nrg2415; Ortona Elena, 2016, Ann Ist Super Sanita, V52, P205, DOI 10.4415/ANN_16_02_12; Payami H, 2005, HUM GENET, V118, P322, DOI 10.1007/s00439-005-0057-1; Redden DT, 2003, J NUTR, V133, P3323, DOI 10.1093/jn/133.11.3323; Roved J, 2017, HORM BEHAV, V88, P95, DOI 10.1016/j.yhbeh.2016.11.017; Selmi Carlo, 2003, Ann Ital Med Int, V18, P149; Spagnolo PA, 2020, ANN INTERN MED, V173, P385, DOI 10.7326/M20-1941; Subrahmanyan L, 2001, AM J HUM GENET, V69, P381, DOI 10.1086/321297; Taneja V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01931; Tatsuma N, 1997, Nihon Jinzo Gakkai Shi, V39, P734; Tripputi P, 2008, BIOCHEM GENET, V46, P733, DOI 10.1007/s10528-008-9188-0; Tripputi P, 2008, INT J IMMUNOGENET, V35, P141, DOI 10.1111/j.1744-313X.2008.00751.x; Tripputi P, 2000, MOL CELL PROBE, V14, P195, DOI 10.1006/mcpr.2000.0301; TRIPPUTI P, 1988, SCIENCE, V241, P1205, DOI 10.1126/science.2842865; Tripputi P., 2012, ADV STUD BIOL, V4, P521; Tripputi P, 2014, HUM PATHOL, V45, P368, DOI 10.1016/j.humpath.2013.09.016; Tripputi P, 2011, J OBSTET GYNAECOL RE, V37, P1405, DOI 10.1111/j.1447-0756.2011.01551.x; Watson CT, 2011, GENES IMMUN, V12, P59, DOI 10.1038/gene.2010.65; Weiss LA, 2006, NAT GENET, V38, P218, DOI 10.1038/ng1726	35	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							333	10.3390/vaccines9040333			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5BE	33915945	Green Published, gold			2022-04-29	WOS:000643793600001
J	Wan, SF; Cao, SB; Wang, XG; Zhou, YF; Yan, WD; Gu, XB; Wu, TC; Pang, XW				Wan, Shengfeng; Cao, Shengbo; Wang, Xugang; Zhou, Yanfei; Yan, Weidong; Gu, Xinbin; Wu, Tzyy-Choou; Pang, Xiaowu			Evaluation of Vertebrate-Specific Replication-Defective Zika Virus, a Novel Single-Cycle Arbovirus Vaccine, in a Mouse Model	VACCINES			English	Article						vertebrate-specific replication-defective Zika virus; single-cycle arbovirus vaccine; artificial insect-specific virus; cellular and humoral immune response; immunity; safety		The flavivirus Zika (ZIKV) has emerged as a global threat, making the development of a ZIKV vaccine a priority. While live-attenuated vaccines are known to induce long-term immunity but reduced safety, inactivated vaccines exhibit a weaker immune response as a trade-off for increased safety margins. To overcome the trade-off between immunogenicity and safety, the concept of a third-generation flavivirus vaccine based on single-cycle flaviviruses has been developed. These third-generation flavivirus vaccines have demonstrated extreme potency with a high level of safety in animal models. However, the production of these single-cycle, encapsidation-defective flaviviruses requires a complicated virion packaging system. Here, we investigated a new single-cycle flavivirus vaccine, a vertebrate-specific replication-defective ZIKV (VSRD-ZIKV), in a mouse model. VSRD-ZIKV replicates to high titers in insect cells but can only initiate a single-round infection in vertebrate cells. During a single round of infection, VSRD-ZIKV can express all the authentic viral antigens in vertebrate hosts. VSRD-ZIKV immunization elicited a robust cellular and humoral immune response that protected against a lethal ZIKV challenge in AG129 mice. Additionally, VSRD-ZIKV-immunized pregnant mice were protected against vertically transferring a lethal ZIKV infection to their offspring. Immunized male mice were protected and prevented viral accumulation in the testes after being challenged with lethal ZIKV. Overall, our results indicate that VSRD-ZIKV induces a potent protective immunity against ZIKV in a mouse model and represents a promising approach to develop novel single-cycle arbovirus vaccines.	[Wan, Shengfeng; Cao, Shengbo; Wang, Xugang; Yan, Weidong] Huazhong Agr Univ, State Key Lab Agr Microbiol, Wuhan 430070, Peoples R China; [Wan, Shengfeng; Yan, Weidong; Gu, Xinbin; Pang, Xiaowu] Howard Univ, Coll Dent, Dept Oral Pathol, Washington, DC 20059 USA; [Zhou, Yanfei] Tegen Biomed Co, Rockville, MD 20851 USA; [Wu, Tzyy-Choou] Johns Hopkins Med Inst, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA		Pang, XW (通讯作者)，Howard Univ, Coll Dent, Dept Oral Pathol, Washington, DC 20059 USA.	sfwan@webmail.hzau.edu.cn; sbcao@mail.hzau.edu.cn; wxg13277278849@163.com; Yanfei.Zhou@milliporesigma.com; yanwd2007@163.com; xgu@howard.edu; wutc@jhmi.edu; xpang@howard.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P20CA192989, R41AI129119, HZAUMO-2016-035]	The National Institutes of Health grants P20CA192989 and R41AI129119. The Huazhong Agricultural University IACUC approved all animal experiments (Ethic code: HZAUMO-2016-035). The research conducted in Huazhong Agricultural University received no external funding.	Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157; Amanna IJ, 2009, ANTIVIR RES, V84, P119, DOI 10.1016/j.antiviral.2009.08.008; Boigard H, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005608; Caine EA, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110598; DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4; Dowd KA, 2016, SCIENCE, V354, P237, DOI 10.1126/science.aai9137; Freitas DA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242367; Gatherer D, 2016, J GEN VIROL, V97, P269, DOI 10.1099/jgv.0.000381; Gulland A, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i657; Heinz FX, 2012, VACCINE, V30, P4301, DOI 10.1016/j.vaccine.2011.09.114; Hoft DF, 2011, J INFECT DIS, V204, P845, DOI 10.1093/infdis/jir436; Katz I, 2019, CURR OPIN RHEUMATOL, V31, P484, DOI 10.1097/BOR.0000000000000629; Lambert PH, 2005, NAT MED, V11, pS54, DOI 10.1038/nm1216; Larocca RA, 2016, NATURE, V536, P474, DOI 10.1038/nature18952; Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010; Li XF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02975-w; Mason PW, 2006, VIROLOGY, V351, P432, DOI 10.1016/j.virol.2006.04.003; McNeil CJ, 2017, J TROP PEDIATRICS, V63, P242, DOI 10.1093/tropej/fmw080; Modjarrad K, 2018, LANCET, V391, P563, DOI 10.1016/S0140-6736(17)33106-9; Morel PA, 2004, VACCINE, V22, P447, DOI 10.1016/j.vaccine.2003.07.012; Morrison TE, 2017, J VIROL, V91, DOI 10.1128/JVI.00009-17; Pang XW, 2014, VACCINE, V32, P3854, DOI 10.1016/j.vaccine.2014.03.091; Pattnaik A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020266; Pielnaa P, 2020, VIROLOGY, V543, P34, DOI 10.1016/j.virol.2020.01.015; Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040; Shan C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00737-8; Uraki R, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602899; Wan SF, 2021, VIROLOGY, V552, P73, DOI 10.1016/j.virol.2020.09.001; Wen JS, 2017, J INTERF CYTOK RES, V37, P475, DOI 10.1089/jir.2017.0106; Widman DG, 2008, ADV VIRUS RES, V72, P77, DOI 10.1016/S0065-3527(08)00402-8; Xie XP, 2018, CELL HOST MICROBE, V24, P487, DOI 10.1016/j.chom.2018.09.008; Yang M, 2018, PLANT BIOTECHNOL J, V16, P572, DOI 10.1111/pbi.12796; Yang RH, 2021, VACCINE, V39, P915, DOI 10.1016/j.vaccine.2020.12.077	33	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							338	10.3390/vaccines9040338			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4NC	33916109	Green Published, gold			2022-04-29	WOS:000643756700001
J	Kim, AY; Kim, H; Park, SY; Park, SH; Kim, JS; Park, JW; Park, JH; Ko, YJ				Kim, Ah-Young; Kim, Hyejin; Park, Sun Young; Park, Sang Hyun; Kim, Jae-Seok; Park, Jung-Won; Park, Jong-Hyeon; Ko, Young-Joon			Development of a Potent Stabilizer for Long-Term Storage of Foot-and-Mouth Disease Vaccine Antigens	VACCINES			English	Article						foot-and-mouth disease (FMD); buffer; excipient; stabilizer; virus; vaccine antigen		A local virus isolate, O/SKR/JC/2014 (O JC), has been considered as a candidate vaccine strain in the development of a domestic foot-and-mouth disease (FMD) vaccine in Korea. However, producing and preserving a sufficient quantity of intact vaccine antigens from the O JC strain was difficult owing to its distinctive structural instability compared to other candidate vaccine strains. Based on this feature, the O JC strain was adopted as a model virus for the stabilization study to determine the optimal stabilizer composition, which enables long-term storage of the FMD vaccine antigen in both aqueous and frozen phases. In contrast to O JC vaccine antigens stored in routinely used Tris-buffered or phosphate-buffered saline, those stored in Tris-KCl buffer showed extended shelf-life at both 4 degrees C and -70 degrees C. Additionally, the combined application of 10% sucrose and 5% lactalbumin hydrolysate could protect O JC 146S particles from massive structural breakdown in an aqueous state for up to one year. The stabilizer composition was also effective for other FMDV strains, including serotypes A and Asia 1. With this stabilizer composition, FMD vaccine antigens could be flexibly preserved during the general production process, pending status under refrigeration and banking under ultrafreezing.	[Kim, Ah-Young; Kim, Hyejin; Park, Sun Young; Park, Sang Hyun; Kim, Jae-Seok; Park, Jung-Won; Park, Jong-Hyeon; Ko, Young-Joon] Anim & Plant Quarantine Agcy, Gimcheon 39660, Gyeonsangbuk Do, South Korea		Ko, YJ (通讯作者)，Anim & Plant Quarantine Agcy, Gimcheon 39660, Gyeonsangbuk Do, South Korea.	mochsha@korea.kr; hyejin86@korea.kr; sun3730@korea.kr; shpark0205@korea.kr; kimjs0728@korea.kr; parkjw6254@korea.kr; parkjhvet@korea.kr; koyoungjoon@korea.kr		Park, Jong-Hyeon/0000-0003-0825-8121; Kim, Ah-Young/0000-0003-0600-1816	Animal and Plant Quarantine Agency, Republic of Korea [M-1543386-2020-22-01]	This research was supported by the Animal and Plant Quarantine Agency, Republic of Korea (grant number M-1543386-2020-22-01).	Arakawa T, 2007, AMINO ACIDS, V33, P587, DOI 10.1007/s00726-007-0506-3; Arakawa T, 2007, BIOPHYS CHEM, V127, P1, DOI 10.1016/j.bpc.2006.12.007; BAHNEMANN HG, 1975, ARCH VIROL, V47, P47, DOI 10.1007/BF01315592; BARTELING SJ, 1974, ARCH GES VIRUSFORSCH, V45, P362, DOI 10.1007/BF01242879; Bu GH, 2013, DAIRY SCI TECHNOL, V93, P211, DOI 10.1007/s13594-013-0113-x; Cardoso FMC, 2017, ACTA VIROL, V61, P231, DOI 10.4149/av_2017_301; Darcy H, 1856, FONTAINES PUBLIQUES; DOEL TR, 1982, DEV BIOL STAND, V50, P209; DOEL TR, 1982, ARCH VIROL, V73, P185, DOI 10.1007/BF01314726; FELLOWES ON, 1965, APPL MICROBIOL, V13, P496, DOI 10.1128/AEM.13.3.496-499.1965; FERRIS NP, 1990, J VIROL METHODS, V29, P43, DOI 10.1016/0166-0934(90)90006-2; Gokarn YR, 2011, PROTEIN SCI, V20, P580, DOI 10.1002/pro.591; Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004; Harmsen MM, 2015, VACCINE, V33, P2477, DOI 10.1016/j.vaccine.2015.03.066; Harmsen MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00960; Hutber AM, 2011, VET J, V188, P18, DOI 10.1016/j.tvjl.2010.02.018; Jo HE, 2019, J VET SCI, V20, DOI 10.4142/jvs.2019.20.e42; Kamerzell TJ, 2011, ADV DRUG DELIVER REV, V63, P1118, DOI 10.1016/j.addr.2011.07.006; Kim YS, 2003, PROTEIN SCI, V12, P1252, DOI 10.1110/ps.0242603; Kolhe P, 2010, BIOTECHNOL PROGR, V26, P727, DOI 10.1002/btpr.377; Li BY, 2019, CHEM ENG SCI, V208, DOI 10.1016/j.ces.2019.115162; Lopez-Arguello S, 2019, J VIROL, V93, DOI 10.1128/JVI.02293-18; Loughney JW, 2014, ANAL BIOCHEM, V461, P49, DOI 10.1016/j.ab.2014.05.004; Malenovska H, 2014, J APPL MICROBIOL, V117, P1810, DOI 10.1111/jam.12654; Malik N, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006607; Ohmori K, 2007, VET IMMUNOL IMMUNOP, V115, P166, DOI 10.1016/j.vetimm.2006.10.005; Pastorino B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118963; Pelliccia M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13520; Porta C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003255; Schley D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030435; Scott KA, 2017, J VIROL, V91, DOI [10.1128/jvi.02312-16, 10.1128/JVI.02312-16]; Spitteler MA, 2019, VACCINE, V37, P5288, DOI 10.1016/j.vaccine.2019.07.051; Telis VRN, 2007, INT J FOOD PROP, V10, P185, DOI 10.1080/10942910600673636; Walters RH, 2014, J PHARM SCI-US, V103, P2673, DOI 10.1002/jps.23998; World Health Organization, 2007, 56 WHO EXP COMM BIOL; Yang YL, 2017, VACCINE, V35, P2413, DOI 10.1016/j.vaccine.2017.03.037; Yuan H, 2020, APPL MICROBIOL BIOT, V104, P1683, DOI 10.1007/s00253-019-10280-9	37	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							252	10.3390/vaccines9030252			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6FW	33809252	Green Published, gold			2022-04-29	WOS:000634248400001
J	Norton, JE; Kommineni, S; Akrivoulis, P; Gutierrez, DA; Hazuda, DJ; Swaminathan, G				Norton, James E., Jr.; Kommineni, Sushma; Akrivoulis, Patricia; Gutierrez, Dario A.; Hazuda, Daria J.; Swaminathan, Gokul			Primary Human Dendritic Cells and Whole-Blood Based Assays to Evaluate Immuno-Modulatory Properties of Heat-Killed Commensal Bacteria	VACCINES			English	Article						immune modulation; host-microbiome interactions; commensal bacteria; microbiome; dendritic cells; innate immunity		There is mounting evidence that the microbiome plays a critical role in training and maturation of the host immune system. Pre-clinical and clinical studies have shown that microbiome perturbation is correlated with sub-optimal host responses to vaccines and cancer immunotherapy. As such, identifying species of commensal bacteria capable of modulating immunological outcomes is of considerable interest. Currently, the lack of reliable primary immune cell-based assays capable of differentiating immuno-modulatory properties of various commensal bacteria is a major limitation. Here, we demonstrate that primary human monocyte-derived dendritic cells (MoDC) are capable of stratifying different strains of live and heat-killed commensal bacteria in an in vitro culture system. Specifically, heat-killed bacterial strains were able to differentially modulate co-stimulation/maturation markers CD80, CD83, and HLA-DR, as well as cytokine/chemokine signatures, such as IL-1b, MIP-1a, and TNFa in primary human MoDC. We further validated our observations using the TruCulture(R) (Myriad RBM, Inc., Austin, TX, USA) whole-blood ex vivo culture system. Using this ex vivo system allowed us to measure immune-altering effects of commensal bacteria in primary human whole-blood. As such, we report that both these primary in vitro and ex vivo systems are robust and enable identification, stratification, and differentiation of various commensal bacteria as potential modulators of host immunity.	[Norton, James E., Jr.; Kommineni, Sushma; Akrivoulis, Patricia; Gutierrez, Dario A.; Hazuda, Daria J.; Swaminathan, Gokul] Merck & Co Inc, Exploratory Sci Ctr, MRL, Cambridge, MA 02141 USA; [Akrivoulis, Patricia] Novartis Inst Biomed Res NIBR, Cambridge, MA 02139 USA; [Gutierrez, Dario A.] TCR2 Therapeut, Cambridge, MA 02142 USA		Swaminathan, G (通讯作者)，Merck & Co Inc, Exploratory Sci Ctr, MRL, Cambridge, MA 02141 USA.	james.norton@merck.com; sushma.kommineni@merck.com; Patricia.Akrivoulis@novartis.com; dario.gutierrez@tcr2.com; daria.hazuda@merck.com; gokul.swaminathan@merck.com		Swaminathan, Gokul/0000-0002-0946-1335			Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bene K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00427; Bermudez-Humaran LG, 2018, NAT BIOTECHNOL, V36, P816, DOI 10.1038/nbt.4248; Blanco P, 2008, CYTOKINE GROWTH F R, V19, P41, DOI 10.1016/j.cytogfr.2007.10.004; Casasanta MA, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aba9157; Chanput W, 2014, INT IMMUNOPHARMACOL, V23, P37, DOI 10.1016/j.intimp.2014.08.002; Derrien M, 2017, MICROB PATHOGENESIS, V106, P171, DOI 10.1016/j.micpath.2016.02.005; Dimmitt RA, 2010, J PEDIATR GASTR NUTR, V51, P262, DOI 10.1097/MPG.0b013e3181e1a114; Disis ML, 2014, SEMIN ONCOL, V41, pS3, DOI 10.1053/j.seminoncol.2014.09.004; Duffy D, 2017, CLIN IMMUNOL, V183, P325, DOI 10.1016/j.clim.2017.09.019; Duffy D, 2014, IMMUNITY, V40, P436, DOI 10.1016/j.immuni.2014.03.002; Fink LN, 2007, FEMS IMMUNOL MED MIC, V51, P535, DOI 10.1111/j.1574-695X.2007.00333.x; Forster R, 2008, NAT REV IMMUNOL, V8, P362, DOI 10.1038/nri2297; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Goradel NH, 2019, J CELL PHYSIOL, V234, P2337, DOI 10.1002/jcp.27250; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Hagan T, 2019, CELL, V178, P1313, DOI 10.1016/j.cell.2019.08.010; He F, 2002, MICROBIOL IMMUNOL, V46, P781, DOI 10.1111/j.1348-0421.2002.tb02765.x; Hoarau C, 2006, J ALLERGY CLIN IMMUN, V117, P696, DOI 10.1016/j.jaci.2005.10.043; Howard C. J., 2004, Animal Health Research Reviews, V5, P1, DOI [10.1079/AHRR200464, 10.1079/AHR200468]; Huda MN, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-1489; Ivanov II, 2012, CELL HOST MICROBE, V12, P496, DOI 10.1016/j.chom.2012.09.009; Kasper SH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62139-z; Kim D, 2016, NAT MED, V22, P524, DOI 10.1038/nm.4075; Kuhn KA, 2013, SEMIN IMMUNOL, V25, P364, DOI 10.1016/j.smim.2013.10.002; Lathrop SK, 2011, NATURE, V478, P250, DOI 10.1038/nature10434; Leylabadlo HE, 2020, MICROB PATHOGENESIS, V149, DOI 10.1016/j.micpath.2020.104344; Li ZD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01312; Ma YP, 2012, MICROBIOL-SGM, V158, P498, DOI 10.1099/mic.0.049932-0; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Mathewson ND, 2016, NAT IMMUNOL, V17, P505, DOI 10.1038/ni.3400; Ostman S, 2006, EUR J IMMUNOL, V36, P2336, DOI 10.1002/eji.200535244; Perez CR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13368-y; Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039; Rao K, 2015, INFECT DIS CLIN N AM, V29, P109, DOI 10.1016/j.idc.2014.11.009; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Sanchez B, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/479140; Stappers MHT, 2012, CYTOKINE, V60, P861, DOI 10.1016/j.cyto.2012.08.019; Tanoue T, 2019, NATURE, V565, P600, DOI 10.1038/s41586-019-0878-z; Valdezi Y, 2014, TRENDS IMMUNOL, V35, P526, DOI 10.1016/j.it.2014.07.003; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Wculek SK, 2020, NAT REV IMMUNOL, V20, P7, DOI 10.1038/s41577-019-0210-z; Worbs T, 2017, NAT REV IMMUNOL, V17, P30, DOI 10.1038/nri.2016.116; Zamaraeva MV, 2005, CELL DEATH DIFFER, V12, P1390, DOI 10.1038/sj.cdd.4401661; Zheng Y, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0650-9; Ziegler-Heitbrock L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00423; Zimmermann P, 2018, VACCINE, V36, P4433, DOI 10.1016/j.vaccine.2018.04.066	48	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							225	10.3390/vaccines9030225			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6FH	33807734	Green Published, gold			2022-04-29	WOS:000634246900001
J	Siak, PY; Wong, KY; Song, AAL; Rahim, RA; In, LLA				Siak, Pui Yan; Wong, Kuan Yee; Song, Adelene Ai-Lian; Rahim, Raha Abdul; In, Lionel Lian Aun			K-Ras Peptide Mimotope Induces Antigen Specific Th1 and B-Cell Immune Responses against G12A-Mutated K-Ras Antigen in Balb/c Mice	VACCINES			English	Article						KRAS; Lactococcus lactis; tetanus toxoid; peptide-based vaccine	LACTIC-ACID BACTERIA; LACTOCOCCUS-LACTIS; ORAL IMMUNIZATION; PROTEIN SECRETION; VACCINE DELIVERY; COLORECTAL-CARCINOMA; MUTATIONS; EFFICIENT; SIGNAL; IMMUNOGENICITY	KRAS G12A somatic point mutation in adenocarcinomas is categorized clinically as ineligibility criteria for anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapies. In this study, a modified G12A-K-ras epitope (139A) with sequence-specific modifications to improve immunogenicity was developed as a potential vaccine against G12A-mutant KRAS cancers. Additionally, coupling of the 139A epitope with a tetanus toxoid (TTD) universal T-cell epitope to improve antigenicity was also reported. To facilitate convenient oral administration, Lactococcus lactis, which possesses innate immunomodulatory properties, was chosen as a live gastrointestinal delivery vehicle. Recombinant L. lactis strains secreting a G12A mutated K-ras control and 139A with and without TTD fusion were generated for comparative immunogenicity assessment. BALB/c mice were immunized orally, and high survivability of L. lactis passage through the gastrointestinal tract was observed. Elevations in B-cell count with a concomitant titre of antigen-specific IgG and interferon-gamma secreting T-cells were observed in the 139A treated mice group. Interestingly, an even higher antigen-specific IgA response and interferon-gamma secreting T-cell counts were observed in 139A-TTD mice group upon re-stimulation with the G12A mutated K-ras antigen. Collectively, these results indicated that an antigen-specific immune response was successfully stimulated by 139A-TTD vaccine, and a TTD fusion was successful in further enhancing the immune responses.	[Siak, Pui Yan; Wong, Kuan Yee; In, Lionel Lian Aun] UCSI Univ, Fac Sci Appl, Dept Biotechnol, Kuala Lumpur 56000, Malaysia; [Song, Adelene Ai-Lian] Univ Putra Malaysia, Dept Microbiol, Fac Biotechnol & Biomol Sci, Serdang 43400, Malaysia; [Rahim, Raha Abdul] Tech Univ Malaysia Malacca, Malacca 76100, Malaysia		In, LLA (通讯作者)，UCSI Univ, Fac Sci Appl, Dept Biotechnol, Kuala Lumpur 56000, Malaysia.	spysiak@hotmail.my; kuanyee96@gmail.com; adelene@upm.edu.my; raha@upm.edu.my; lionelin@ucsiuniversity.edu.my	IN, LIONEL/AAI-9847-2020	IN, LIONEL/0000-0001-7182-112X; Tan, Ee Wern/0000-0002-2106-1449; Song, Adelene/0000-0002-5413-3314; siak, pui yan/0000-0003-4099-4647	Ministry of Higher Education (MOHE) through the Fundamental Research Grant Scheme [FRGS/1/2017/STG05/UCSI/03/2]; Ministry of Science Technology and Innovation (MOSTI)Ministry of Energy, Science, Technology, Environment and Climate Change (MESTECC), Malaysia [02-02-22-SF0011]; UCSI University Pioneer Scientist Initiative Fund (PSIF) [Proj-In-FAS-061]	This work was supported by the grants from the Ministry of Higher Education (MOHE) through the Fundamental Research Grant Scheme (FRGS/1/2017/STG05/UCSI/03/2), the Ministry of Science Technology and Innovation (MOSTI) (02-02-22-SF0011) and the UCSI University Pioneer Scientist Initiative Fund (PSIF) (Proj-In-FAS-061).	Adachi K, 2010, VACCINE, V28, P2810, DOI 10.1016/j.vaccine.2010.02.005; Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170; Asensi GF, 2013, MICROB CELL FACT, V12, DOI 10.1186/1475-2859-12-32; Azizpour Maryam, 2017, Avicenna Journal of Medical Biotechnology, V9, P163; Baradaran A, 2013, BIOTECHNOL LETT, V35, P233, DOI 10.1007/s10529-012-1059-4; Bermudez-Humaran LG, 2005, J IMMUNOL, V175, P7297, DOI 10.4049/jimmunol.175.11.7297; Bermudez-Humaran LG, 2009, HUM VACCINES, V5, P264, DOI 10.4161/hv.5.4.7553; Buhrman JD, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23492; Buhrman JD, 2013, IMMUNOL RES, V55, P34, DOI 10.1007/s12026-012-8348-9; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Diethelm-Okita BM, 2000, J INFECT DIS, V181, P1001, DOI 10.1086/315324; Dieye Y, 2003, APPL ENVIRON MICROB, V69, P7281, DOI 10.1128/AEM.69.12.7281-7288.2003; Donnet-Hughes A, 1999, J DAIRY SCI, V82, P863, DOI 10.3168/jds.S0022-0302(99)75304-X; Emens LA, 2008, EXPERT OPIN EMERG DR, V13, P295, DOI 10.1517/14728214.13.2.295 ; Hahn HP, 2003, FEMS IMMUNOL MED MIC, V37, P87, DOI 10.1016/S0928-8244(03)00092-0; Haider S.R., 2012, PROTEIN ELECTROPHORE, V869; Hazebrouck S, 2007, MICROB CELL FACT, V6, DOI 10.1186/1475-2859-6-12; Hirayama K, 1999, ANTON LEEUW INT J G, V76, P391; HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989; Hoo W.P.Y., 2020, ASIA PAC J MOL BIOL, P22, DOI [10.35118/apjmbb.2020.028.3.03, DOI 10.35118/APJMBB.2020.028.3.03]; Jancik S, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/150960; Joan SSX, 2016, BIOTECHNOL LETT, V38, P793, DOI 10.1007/s10529-016-2034-2; Kang SH, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10090948; Katsuda M., 2017, TRENDS IMMUNOTHER, V1, P10; KIM H S, 1988, Cultured Dairy Products Journal, V23, P6; Kim WS, 1999, FEMS MICROBIOL LETT, V171, P57, DOI 10.1111/j.1574-6968.1999.tb13412.x; KLIJN N, 1995, APPL ENVIRON MICROB, V61, P2771, DOI 10.1128/AEM.61.7.2771-2774.1995; Knittelfelder R, 2009, EXPERT OPIN BIOL TH, V9, P493, DOI [10.1517/14712590902870386, 10.1517/14712590902870386 ]; Le Loir Y, 2005, MICROB CELL FACT, V4, DOI 10.1186/1475-2859-4-2; Lebeer S, 2010, NAT REV MICROBIOL, V8, P171, DOI 10.1038/nrmicro2297; Li XY, 2014, PATHOG DIS, V72, P78, DOI 10.1111/2049-632X.12173; Mathiesen G, 2008, J APPL MICROBIOL, V105, P215, DOI 10.1111/j.1365-2672.2008.03734.x; Miyoshi A, 2004, FEMS MICROBIOL LETT, V239, P205, DOI 10.1016/j.femsle.2004.08.018; Moodie Z, 2010, CANCER IMMUNOL IMMUN, V59, P1489, DOI 10.1007/s00262-010-0875-4; Morello E, 2008, J MOL MICROB BIOTECH, V14, P48, DOI 10.1159/000106082; Ng AWR, 2018, PEERJ, V6, DOI 10.7717/peerj.5056; Ng DTW, 2013, APPL ENVIRON MICROB, V79, P347, DOI 10.1128/AEM.02667-12; Ogra P.L., 2015, MUCOSAL IMMUNOL, V4th ed.; Parkhurst MR, 1996, J IMMUNOL, V157, P2539; Parra MD, 2004, J PHYSIOL BIOCHEM, V60, P85, DOI 10.1007/BF03168444; Pouwels PH, 1998, INT J FOOD MICROBIOL, V41, P155, DOI 10.1016/S0168-1605(98)00048-8; RAFTER JJ, 1995, SCAND J GASTROENTERO, V30, P497, DOI 10.3109/00365529509089779; Rajasekharan SK, 2013, CENT EUR J BIOL, V8, P609, DOI 10.2478/s11535-013-0158-5; Reilly R T, 2001, Curr Opin Investig Drugs, V2, P133; Reilly RT, 2001, CANCER RES, V61, P880; Riemer AB, 2007, IMMUNOL LETT, V113, P1, DOI 10.1016/j.imlet.2007.07.008; Santos PM, 2018, J IMMUNOL, V200, P443, DOI 10.4049/jimmunol.1701024; Schagger H., 2006, PROTOC, V1, P22, DOI [10.1038/nprot.2006.4, DOI 10.1038/NPROT.2006.4]; Seaman WE, 2000, ARTHRITIS RHEUM-US, V43, P1204, DOI 10.1002/1529-0131(200006)43:6<1204::AID-ANR3>3.0.CO;2-I; Seegers JFML, 2002, TRENDS BIOTECHNOL, V20, P508, DOI 10.1016/S0167-7799(02)02075-9; Seifert S, 2011, J NUTR, V141, P978, DOI 10.3945/jn.110.136440; Shakya AK, 2016, J CONTROL RELEASE, V240, P394, DOI 10.1016/j.jconrel.2016.02.014; Speck M. L., 1978, Developments in Industrial Microbiology, V19, P95; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Tan C, 2012, WORLD J GASTROENTERO, V18, P5171, DOI 10.3748/wjg.v18.i37.5171; Tan EW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219912; Tayeb I., 2007, International Journal of Probiotics and Prebiotics, V2, P49; Tong JHM, 2014, CANCER BIOL THER, V15, P768, DOI 10.4161/cbt.28550; van Krieken JHJM, 2008, VIRCHOWS ARCH, V453, P417, DOI 10.1007/s00428-008-0665-y; van Wely KHM, 2001, FEMS MICROBIOL REV, V25, P437, DOI 10.1016/S0168-6445(01)00062-6; VANASSELDONK M, 1993, MOL GEN GENET, V240, P428, DOI 10.1007/BF00280397; Wada S, 2017, EXPERT REV PRECIS ME, V2, P371, DOI 10.1080/23808993.2017.1403286; Xin KQ, 2003, BLOOD, V102, P223, DOI 10.1182/blood-2003-01-0110; Yang J, 2015, INT J MOL MED, V35, P17, DOI 10.3892/ijmm.2014.2000; Yano A, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/786501; Yu ZY, 2004, J CLIN INVEST, V114, P551, DOI 10.1172/JCI200421695; Zhang HM, 2018, J CANCER, V9, P1773, DOI 10.7150/jca.24577; Zhao L, 2008, EXPERT REV VACCINES, V7, P1547, DOI 10.1586/14760584.7.10.1547	68	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							195	10.3390/vaccines9030195			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5KG	33652552	gold, Green Published			2022-04-29	WOS:000634192200001
J	Iriti, M; Vitalini, S				Iriti, Marcello; Vitalini, Sara			Plant Immunity and Crop Yield: A Sustainable Approach in Agri-Food Systems	VACCINES			English	Editorial Material						innate immunity; systemic acquired resistance; plant activators; elicitors; priming		Innate immunity represents a trait common to animals and plants. Indeed, similar to animals, plants also evolved a complex defense machinery to defend against pest and pathogen attacks. Due to the concerns posed by the intensive use of agrochemicals, the possibility to stimulate the plant immune system with environmentally friendly and low-risk chemical and biological inducers is intriguing. Therefore, some plant protection products are commercially available to trigger the plant's immune system, with benefits in terms of consumer health and environmental protection.	[Iriti, Marcello; Vitalini, Sara] Univ Milan, Dept Agr & Environm Sci, I-20122 Milan, Italy; [Iriti, Marcello; Vitalini, Sara] Natl Interuniv Consortium Mat Sci & Technol INSTM, I-50121 Florence, Italy; [Iriti, Marcello] Univ Napoli Federico II, BAT Ctr Interuniv Ctr Studies Bioinspired Agroenv, I-80055 Naples, Italy		Iriti, M (通讯作者)，Univ Milan, Dept Agr & Environm Sci, I-20122 Milan, Italy.; Iriti, M (通讯作者)，Natl Interuniv Consortium Mat Sci & Technol INSTM, I-50121 Florence, Italy.; Iriti, M (通讯作者)，Univ Napoli Federico II, BAT Ctr Interuniv Ctr Studies Bioinspired Agroenv, I-80055 Naples, Italy.	marcello.iriti@unimi.it; sara.vitalini@unimi.it	; IRITI, MARCELLO/Q-8580-2017	Vitalini, Sara/0000-0001-7557-9473; IRITI, MARCELLO/0000-0002-5063-1236			de Melo PC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030524; Iriti M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010042; Lakhssassi N, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030349; Nguyen NH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030503; Panigrahi GK, 2021, PHYSIOL MOL PLANT P, V113, DOI 10.1016/j.pmpp.2020.101568; Satturu V, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040608; Weiller F, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030388; Yakura H, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030541	8	2	2	8	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							121	10.3390/vaccines9020121			3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6PA	33546315	Green Published			2022-04-29	WOS:000623262400001
J	Rameshbabu, S; Labadie, BW; Argulian, A; Patnaik, A				Rameshbabu, Srikrishnan; Labadie, Brian W.; Argulian, Anna; Patnaik, Akash			Targeting Innate Immunity in Cancer Therapy	VACCINES			English	Review						cancer immunotherapy; STING; NLRP3; tumor-associated macrophages; RIG-I; TLRs; CD40; NK cells; oncolytic viruses; pattern recognition receptors; innate immunity; cancer	TUMOR-ASSOCIATED MACROPHAGES; NATURAL-KILLER-CELLS; NLRP3 INFLAMMASOME ACTIVATION; SUPPRESSOR-CELLS; BREAST-CANCER; DENDRITIC CELLS; PROSTATE-CANCER; MAST-CELLS; NK CELLS; RIG-I	The majority of current cancer immunotherapy strategies target and potentiate antitumor adaptive immune responses. Unfortunately, the efficacy of these treatments has been limited to a fraction of patients within a subset of tumor types, with an aggregate response rate of approximately 20% to date across all malignancies. The success of therapeutic inhibition of programmed death protein 1 (PD-1), protein death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) with immune checkpoint inhibitors (ICI) has been limited to "hot" tumors characterized by preexisting T cell infiltration, whereas "cold" tumors, which lack T cell infiltration, have not achieved durable benefit. There are several mechanisms by which "cold" tumors fail to generate spontaneous immune infiltration, which converge upon the generation of an immunosuppressive tumor microenvironment (TME). The role of the innate immune system in tumor immunosurveillance and generation of antitumor immune responses has been long recognized. In recent years, novel strategies to target innate immunity in cancer therapy have emerged, including therapeutic stimulation of pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs); the DNA sensing cGAS/STING pathway; nucleotide-binding oligomerization domain-like receptors (NLRs), such as NLRP3; and the retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs). In addition, therapeutic modulation of key innate immune cell types, such as macrophages and natural killer cells, has been investigated. Herein, we review therapeutic approaches to activate innate immunity within the TME to enhance antitumor immune responses, with the goal of disease eradication in "cold" tumors. In addition, we discuss rational immune-oncology combination strategies that activate both innate and adaptive immunity, with the potential to enhance the efficacy of current immunotherapeutic approaches.	[Rameshbabu, Srikrishnan; Labadie, Brian W.; Argulian, Anna; Patnaik, Akash] Univ Chicago, Sect Hematol Oncol, Dept Med, Chicago, IL 60637 USA		Patnaik, A (通讯作者)，Univ Chicago, Sect Hematol Oncol, Dept Med, Chicago, IL 60637 USA.	srikrishnanrameshbabu@medicine.bsd.uchicago.edu; blabadie@bsd.uchicago.edu; annaargulian@uchicago.edu; apatnaik@medicine.bsd.uchicago.edu		Labadie, Brian/0000-0002-3648-4663; Rameshbabu, Srikrishnan/0000-0002-9952-2591			Adams S, 2009, IMMUNOTHERAPY-UK, V1, P949, DOI [10.2217/imt.09.70, 10.2217/IMT.09.70]; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Anagnostou E, 2006, BIOORGAN MED CHEM, V14, P181, DOI 10.1016/j.bmc.2005.08.010; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Armeanu S, 2005, CANCER RES, V65, P6321, DOI 10.1158/0008-5472.CAN-04-4252; Autio KA, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2548; Baginska J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00490; Bajor DL, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1468956; Bald T, 2020, NAT IMMUNOL, V21, P835, DOI 10.1038/s41590-020-0728-z; Barnes TA, 2018, BRIT J CANCER, V118, DOI 10.1038/bjc.2017.417; Barsoum J, 2017, CANCER IMMUNOL RES, V5, DOI 10.1158/2326-6074.TUMIMM16-B44; Beatty GL, 2017, EXPERT REV ANTICANC, V17, P175, DOI 10.1080/14737140.2017.1270208; Beatty GL, 2015, CLIN CANCER RES, V21, P687, DOI 10.1158/1078-0432.CCR-14-1860; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Benevides L, 2015, CANCER RES, V75, P3788, DOI 10.1158/0008-5472.CAN-15-0054; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Beutner KR, 1998, J AM ACAD DERMATOL, V38, P230, DOI 10.1016/S0190-9622(98)70243-9; Binnewies M, 2019, CELL, V177, P556, DOI 10.1016/j.cell.2019.02.005; Bird L, 2010, NAT REV IMMUNOL, V10, DOI 10.1038/nri2877; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58; Buhtoiarov IN, 2005, J IMMUNOL, V174, P6013, DOI 10.4049/jimmunol.174.10.6013; Byrne KT, 2016, CELL REP, V15, P2719, DOI 10.1016/j.celrep.2016.05.058; Byrne KT, 2016, J IMMUNOL, V197, P179, DOI 10.4049/jimmunol.1600146; Cai GF, 1999, EUR J IMMUNOL, V29, P2658, DOI 10.1002/(SICI)1521-4141(199909)29:09<2658::AID-IMMU2658>3.0.CO;2-G; Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828; Casella CR, 2008, CELL MOL LIFE SCI, V65, P3231, DOI 10.1007/s00018-008-8228-6; Cathcart J, 2015, GENES DIS, V2, P26, DOI 10.1016/j.gendis.2014.12.002; Cheever MA, 2011, CLIN CANCER RES, V17, P3520, DOI 10.1158/1078-0432.CCR-10-3126; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen L, 2018, CELL MOL LIFE SCI, V75, P2045, DOI 10.1007/s00018-017-2720-9; Chitadze G, 2013, INT J CANCER, V133, P1557, DOI 10.1002/ijc.28174; Chow MT, 2012, CANCER RES, V72, P5721, DOI 10.1158/0008-5472.CAN-12-0509; Chung W, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15081; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Cohen EEW, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.6039; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Creelan BC, 2019, NAT REV CLIN ONCOL, V16, P277, DOI 10.1038/s41571-019-0182-8; Dajon M, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1505174; Daley D, 2017, J EXP MED, V214, P1711, DOI 10.1084/jem.20161707; Dauletbaev N, 2015, J IMMUNOL, V195, P2829, DOI 10.4049/jimmunol.1400840; de Andrade LF, 2018, SCIENCE, V359, P1537, DOI 10.1126/science.aao0505; Dehnel N, 2017, CURR OPIN PHARMACOL, V35, P12, DOI 10.1016/j.coph.2017.04.007; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Diefenbach A, 2001, NATURE, V413, P165, DOI 10.1038/35093109; Ding CY, 2020, ACTA PHARMACOL SIN B, V10, P2272, DOI 10.1016/j.apsb.2020.03.001; Dupaul-Chicoine J, 2015, IMMUNITY, V43, P751, DOI 10.1016/j.immuni.2015.08.013; Elgueta R, 2009, IMMUNOL REV, V229, P152, DOI 10.1111/j.1600-065X.2009.00782.x; Elion David L, 2018, Oncotarget, V9, P29007, DOI 10.18632/oncotarget.25626; Escamilla J, 2015, CANCER RES, V75, P950, DOI 10.1158/0008-5472.CAN-14-0992; Fang WB, 2016, ONCOTARGET, V7, P49349, DOI 10.18632/oncotarget.9885; Flood BA, 2019, IMMUNOL REV, V290, P24, DOI 10.1111/imr.12765; Franchi L, 2009, IMMUNOL REV, V227, P106, DOI 10.1111/j.1600-065X.2008.00734.x; Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510; Fridlender ZG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031524; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Fu J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4306; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gajewski TF, 2010, CANCER J, V16, P399, DOI 10.1097/PPO.0b013e3181eacbd8; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Gangloff M, 2012, TRENDS BIOCHEM SCI, V37, P92, DOI 10.1016/j.tibs.2011.11.003; Gao JW, 2018, ONCOL REP, V40, P1971, DOI 10.3892/or.2018.6634; Gauthier L, 2019, CELL, V177, P1701, DOI 10.1016/j.cell.2019.04.041; GERRARD TL, 1981, J NATL CANCER I, V66, P483; Ghaffari A, 2018, BRIT J CANCER, V119, P440, DOI 10.1038/s41416-018-0188-5; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; Glodde N, 2017, IMMUNITY, V47, P789, DOI 10.1016/j.immuni.2017.09.012; Gong T, 2018, TRENDS IMMUNOL, V39, P393, DOI 10.1016/j.it.2018.01.009; Gooch JL, 1998, CANCER RES, V58, P4199; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Guerriero JL, 2017, NATURE, V543, P428, DOI 10.1038/nature21409; Guo BC, 2016, SCI REP-UK, V6, DOI 10.1038/srep36107; Halama N, 2016, CANCER CELL, V29, P587, DOI 10.1016/j.ccell.2016.03.005; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao Bo, 2018, Oncotarget, V9, P13088, DOI 10.18632/oncotarget.24178; Harlin H, 2009, CANCER RES, V69, P3077, DOI 10.1158/0008-5472.CAN-08-2281; HARRINGTON KJ, 2018, ANN ONCOL S8, V29, P712, DOI DOI 10.1093/ANNONC/MDY424.015; Hashimoto W, 1999, J IMMUNOL, V163, P583; He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139; Heidegger S, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau8943; HENDERSON WR, 1981, J EXP MED, V153, P520, DOI 10.1084/jem.153.3.520; Hervieu A, 2013, J INVEST DERMATOL, V133, P499, DOI 10.1038/jid.2012.273; Hu BY, 2020, CANCER RES, V80, P1707, DOI 10.1158/0008-5472.CAN-19-2254; Hughes MM, 2018, IMMUNOL REV, V281, P88, DOI 10.1111/imr.12608; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Jamieson AM, 2002, IMMUNITY, V17, P19, DOI 10.1016/S1074-7613(02)00333-3; Jeannin P, 2018, FEBS J, V285, P680, DOI 10.1111/febs.14343; Ji RR, 2012, CANCER IMMUNOL IMMUN, V61, P1019, DOI 10.1007/s00262-011-1172-6; Jiang XD, 2019, J EXP MED, V216, P2854, DOI 10.1084/jem.20190801; Jiang XM, 2012, IMMUNITY, V36, P959, DOI 10.1016/j.immuni.2012.03.022; Jin B, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/836485; Johansson A, 2010, AM J PATHOL, V177, P1031, DOI 10.2353/ajpath.2010.100070; Jones M, 2017, J MED VIROL, V89, P1620, DOI 10.1002/jmv.24809; Martinez-Garcia JJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10626-x; Jouhi L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00638; Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834; Kaneda MM, 2016, CANCER DISCOV, V6, P870, DOI 10.1158/2159-8290.CD-15-1346; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Karki R, 2017, CANCER IMMUNOL RES, V5, P94, DOI 10.1158/2326-6066.CIR-16-0269; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461; Khubchandani S, 2009, CURR OPIN INVEST DR, V10, P579; Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x; Kinkead HL, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122857; Kivimae S., 2018, P AM ASSOC CANC RES, V78, P3755; Kopalli SR, 2018, RECENT PAT ANTI-CANC, V13, P106, DOI 10.2174/1574892812666171027102627; Kwon J, 2020, CANCER DISCOV, V10, P26, DOI 10.1158/2159-8290.CD-19-0761; Kyi C, 2018, CLIN CANCER RES, V24, P4937, DOI 10.1158/1078-0432.CCR-17-1866; Labadie BW, 2019, CLIN CANCER RES, V25, P1462, DOI 10.1158/1078-0432.CCR-18-2882; Law AMK, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030561; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Li HQ, 2009, J IMMUNOL, V182, P240, DOI 10.4049/jimmunol.182.1.240; Lin EY, 2007, CANCER RES, V67, P5064, DOI 10.1158/0008-5472.CAN-07-0912; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Linehan MM, 2018, SCI ADV, V4, DOI 10.1126/sciadv.1701854; Liu J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137345; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Long KB, 2016, CANCER DISCOV, V6, P400, DOI 10.1158/2159-8290.CD-15-1032; Loo YM, 2011, IMMUNITY, V34, P680, DOI 10.1016/j.immuni.2011.05.003; Lopez-Soto A, 2009, ONCOGENE, V28, P2370, DOI 10.1038/onc.2009.117; Lopez-Soto A, 2017, CANCER CELL, V32, P135, DOI 10.1016/j.ccell.2017.06.009; Luqman M, 2008, BLOOD, V112, P711, DOI 10.1182/blood-2007-04-084756; Lv M, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0797-3; Ma HS, 2019, CANCER IMMUNOL RES, V7, P428, DOI 10.1158/2326-6066.CIR-18-0061; Malfettone A, 2013, J CELL MOL MED, V17, P1025, DOI 10.1111/jcmm.12073; Mantovani A, 2009, HUM IMMUNOL, V70, P325, DOI 10.1016/j.humimm.2009.02.008; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Marty-Roix R, 2016, J BIOL CHEM, V291, P1123, DOI 10.1074/jbc.M115.683011; Meric-Bernstam F, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2507; Middleton MR, 2018, ANN ONCOL, V29; Mildner A, 2014, IMMUNITY, V40, P642, DOI 10.1016/j.immuni.2014.04.016; Miller JS, 2019, ANNU REV CANC BIOL, V3, P77, DOI 10.1146/annurev-cancerbio-030518-055653; Miller JS, 2005, BLOOD, V105, P3051, DOI 10.1182/blood-2004-07-2974; Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731; Moon YW, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0094-9; MORALES A, 1984, J UROLOGY, V132, P457, DOI 10.1016/S0022-5347(17)49690-X; Morris DR, 2006, CANCER RES, V66, P307, DOI 10.1158/0008-5472.CAN-05-1735; Mullins SR, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0724-8; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nagarajan K, 2019, TRANSL ONCOL, V12, P925, DOI 10.1016/j.tranon.2019.04.010; Nefedova Y, 2005, J IMMUNOL, V175, P4338, DOI 10.4049/jimmunol.175.7.4338; Ngiow SF, 2016, CANCER RES, V76, P6266, DOI 10.1158/0008-5472.CAN-16-2141; Nowak AK, 2015, ANN ONCOL, V26, P2483, DOI 10.1093/annonc/mdv387; Nywening TM, 2016, LANCET ONCOL, V17, P651, DOI 10.1016/S1470-2045(16)00078-4; O'Sullivan T, 2012, J EXP MED, V209, P1869, DOI 10.1084/jem.20112738; O'Sullivan T, 2011, J IMMUNOL, V187, P3538, DOI 10.4049/jimmunol.1100413; Oldfield V, 2005, AM J CLIN DERMATOL, V6, P195, DOI 10.2165/00128071-200506030-00006; Papadopoulos KP, 2017, CLIN CANCER RES, V23, P5703, DOI 10.1158/1078-0432.CCR-16-3261; Pawelec G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01099; Peng JY, 2019, CELL RES, V29, P725, DOI 10.1038/s41422-019-0195-y; Petrova PS, 2017, CLIN CANCER RES, V23, P1068, DOI 10.1158/1078-0432.CCR-16-1700; Pienta KJ, 2013, INVEST NEW DRUG, V31, P760, DOI 10.1007/s10637-012-9869-8; Poeck H, 2010, NAT IMMUNOL, V11, P63, DOI 10.1038/ni.1824; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Raghavan S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0666-1; Rajput AB, 2008, BREAST CANCER RES TR, V107, P249, DOI 10.1007/s10549-007-9546-3; Ramanjulu JM, 2018, NATURE, V564, P439, DOI 10.1038/s41586-018-0705-y; Rao HL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030806; Ribas A, 2018, CANCER DISCOV, V8, P1250, DOI 10.1158/2159-8290.CD-18-0280; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Roberts EW, 2016, CANCER CELL, V30, P324, DOI 10.1016/j.ccell.2016.06.003; Rodell CB, 2018, NAT BIOMED ENG, V2, P578, DOI 10.1038/s41551-018-0236-8; Rodriguez PC, 2004, CANCER RES, V64, P5839, DOI 10.1158/0008-5472.CAN-04-0465; Sagiv JY, 2015, CELL REP, V10, P562, DOI 10.1016/j.celrep.2014.12.039; Saier MH, 2007, WATER AIR SOIL POLL, V181, P1, DOI 10.1007/s11270-007-9372-6; Saito T, 2008, CANCER SCI, V99, P2028, DOI 10.1111/j.1349-7006.2008.00907.x; Salaun B, 2006, J IMMUNOL, V176, P4894, DOI 10.4049/jimmunol.176.8.4894; Salazar AM, 2014, CANCER IMMUNOL RES, V2, P720, DOI 10.1158/2326-6066.CIR-14-0024; Salcedo R, 2010, J EXP MED, V207, P1625, DOI 10.1084/jem.20100199; Sanchez-Paulete AR, 2016, CANCER DISCOV, V6, P71, DOI 10.1158/2159-8290.CD-15-0510; Santarpia M, 2015, CANCER BIOL MED, V12, P74, DOI 10.7497/j.issn.2095-3941.2015.0022; Sato-Kaneko F, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93397; Satoh T, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD-0040-2016; Schmidt H, 2005, BRIT J CANCER, V93, P273, DOI 10.1038/sj.bjc.6602702; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Shen JF, 2019, CANCER RES, V79, P311, DOI 10.1158/0008-5472.CAN-18-1003; Shen MX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098259; Shiao SL, 2015, CANCER IMMUNOL RES, V3, P518, DOI 10.1158/2326-6066.CIR-14-0232; Sikic BI, 2019, J CLIN ONCOL, V37, P946, DOI 10.1200/JCO.18.02018; Sivick KE, 2019, CELL REP, V29, P785, DOI 10.1016/j.celrep.2019.09.089; Smyth MJ, 2001, INT IMMUNOL, V13, P459, DOI 10.1093/intimm/13.4.459; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Spranger S, 2016, P NATL ACAD SCI USA, V113, pE7759, DOI 10.1073/pnas.1609376113; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; Steggerda SM, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0308-4; Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0; Takanami I, 2001, J THORAC CARDIOV SUR, V121, P1058, DOI 10.1067/mtc.2001.113026; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Terheyden P., 2018, ANN ONCOL, V29, pVIII466, DOI [10.1093/annonc/mdy289.061, DOI 10.1093/ANNONC/MDY289.061]; Theivanthiran B, 2020, J CLIN INVEST, V130, P2570, DOI 10.1172/JCI133055; Todryk SM, 2001, J IMMUNOL METHODS, V248, P139, DOI 10.1016/S0022-1759(00)00349-5; Torikai H, 2013, BLOOD, V122, P1341, DOI 10.1182/blood-2013-03-478255; Toth T, 2000, HUM PATHOL, V31, P955; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; Trzonkowski P, 2004, CLIN IMMUNOL, V112, P258, DOI 10.1016/j.clim.2004.04.003; Tseng D, 2013, P NATL ACAD SCI USA, V110, P11103, DOI 10.1073/pnas.1305569110; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Ugel S, 2015, J CLIN INVEST, V125, P3365, DOI 10.1172/JCI80006; Vales-Gomez M, 2008, CANCER RES, V68, P1546, DOI 10.1158/0008-5472.CAN-07-2973; van Dalen FJ, 2019, MOLECULES, V24, DOI 10.3390/molecules24010009; van Hall T, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0761-3; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; van Mierlo GJD, 2002, P NATL ACAD SCI USA, V99, P5561, DOI 10.1073/pnas.082107699; van Montfoort N, 2018, CELL, V175, P1744, DOI 10.1016/j.cell.2018.10.028; Varadhachary G., 2019, P AM ASS CANC RES AN; Varner J.A., 2019, P AM ASSOC CANC RES, V2019, P79; Varricchi G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00424; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Vergadi E, 2017, J IMMUNOL, V198, P1006, DOI 10.4049/jimmunol.1601515; Vermaelen K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00008; Vidyarthi A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01650; Villegas FR, 2002, LUNG CANCER-J IASLC, V35, P23, DOI 10.1016/S0169-5002(01)00292-6; Vinay DS, 2015, SEMIN CANCER BIOL, V35, pS185, DOI 10.1016/j.semcancer.2015.03.004; Vonderheide RH, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23033; Wang H, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4403-9; Wang S, 2016, P NATL ACAD SCI USA, V113, pE7240, DOI 10.1073/pnas.1608555113; Wang-Gillam A, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.TPS465; Wculek SK, 2020, NAT REV IMMUNOL, V20, P7, DOI 10.1038/s41577-019-0210-z; Wei Q, 2019, ONCOL RES, V27, P827, DOI 10.3727/096504018X15462920753012; Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126; Welsh TJ, 2005, J CLIN ONCOL, V23, P8959, DOI 10.1200/JCO.2005.01.4910; Winograd R, 2015, CANCER IMMUNOL RES, V3, P399, DOI 10.1158/2326-6066.CIR-14-0215; Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017; Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963; Wu JJ, 2020, MED RES REV, V40, P1117, DOI 10.1002/med.21649; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Xia XJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1883-8; Yang YP, 2004, NAT IMMUNOL, V5, P508, DOI 10.1038/ni1059; Yu XJ, 2018, CANCER CELL, V33, P664, DOI 10.1016/j.ccell.2018.02.009; Zaidi NE, 2019, JOVE-J VIS EXP, DOI 10.3791/60281; Zhang QW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050946; Zhang Y, 2011, J IMMUNOL, V186, P1963, DOI 10.4049/jimmunol.1002320; Zhu Y, 2014, CANCER RES, V74, P5057, DOI 10.1158/0008-5472.CAN-13-3723	243	13	13	6	21	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							138	10.3390/vaccines9020138			26	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7IT	33572196	Green Published			2022-04-29	WOS:000623314200001
J	Yang, YP; Shi, W; Abiona, OM; Nazzari, A; Olia, AS; Ou, L; Phung, E; Stephens, T; Tsybovsky, Y; Verardi, R; Wang, SS; Werner, A; Yap, C; Ambrozak, D; Bylund, T; Liu, T; Nguyen, R; Wang, LS; Zhang, BS; Zhou, TQ; Chuang, GY; Graham, BS; Mascola, JR; Corbett, KS; Kwong, PD				Yang, Yongping; Shi, Wei; Abiona, Olubukola M.; Nazzari, Alexandra; Olia, Adam S.; Ou, Li; Phung, Emily; Stephens, Tyler; Tsybovsky, Yaroslav; Verardi, Raffaello; Wang, Shuishu; Werner, Anne; Yap, Christina; Ambrozak, David; Bylund, Tatsiana; Liu, Tracy; Nguyen, Richard; Wang, Lingshu; Zhang, Baoshan; Zhou, Tongqing; Chuang, Gwo-Yu; Graham, Barney S.; Mascola, John R.; Corbett, Kizzmekia S.; Kwong, Peter D.			Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses	VACCINES			English	Article						neutralizing antibody; Newcastle disease virus; prefusion-stabilized spike; SARS-CoV-2; S-2P stabilization; vaccine; virus-like particle; VLP	VACCINE; PROTECTION; OUTBREAK	The COVID-19 pandemic highlights an urgent need for vaccines that confer protection from SARS-CoV-2 infection. One approach to an effective COVID-19 vaccine may be through the display of SARS-CoV-2 spikes on the surface of virus-like particles, in a manner structurally mimicking spikes on a native virus. Here we report the development of Newcastle disease virus-like particles (NDVLPs) displaying the prefusion-stabilized SARS-CoV-2 spike ectodomain (S2P). Immunoassays with SARS-CoV-2-neutralizing antibodies revealed the antigenicity of S2P-NDVLP to be generally similar to that of soluble S2P, and negative-stain electron microscopy showed S2P on the NDVLP surface to be displayed with a morphology corresponding to its prefusion conformation. Mice immunized with S2P-NDVLP showed substantial neutralization titers (geometric mean ID50 = 386) two weeks after prime immunization, significantly higher than those elicited by a molar equivalent amount of soluble S2P (geometric mean ID50 = 17). Neutralizing titers at Week 5, two weeks after a boost immunization with S2P-NDVLP doses ranging from 2.0 to 250 mu g, extended from 2125 to 4552, and these generally showed a higher ratio of neutralization versus ELISA than observed with soluble S2P. Overall, S2P-NDVLP appears to be a promising COVID-19 vaccine candidate capable of eliciting substantial neutralizing activity.	[Yang, Yongping; Shi, Wei; Abiona, Olubukola M.; Nazzari, Alexandra; Olia, Adam S.; Ou, Li; Phung, Emily; Verardi, Raffaello; Wang, Shuishu; Werner, Anne; Yap, Christina; Ambrozak, David; Bylund, Tatsiana; Liu, Tracy; Nguyen, Richard; Wang, Lingshu; Zhang, Baoshan; Zhou, Tongqing; Chuang, Gwo-Yu; Graham, Barney S.; Mascola, John R.; Corbett, Kizzmekia S.; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Stephens, Tyler; Tsybovsky, Yaroslav] Leidos Biomed Res Inc, Electron Microscopy Lab, Canc Res Technol Program, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA		Kwong, PD (通讯作者)，NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	yongpiny@niaid.nih.gov; shiw@mail.nih.gov; olubukola.abiona@nih.gov; alexandra.nazzari@nih.gov; adam.olia@nih.gov; li.ou@nih.gov; emily.phung@nih.gov; tyler.stephens@nih.gov; yaroslav.tsybovsky@nih.gov; raffaello.verardi@nih.gov; shuishu.wang@nih.gov; anne.werner@nih.gov; christina.yap@nih.gov; dambroza@mail.nih.gov; tatsiana.bylund@nih.gov; tracy.liu@nih.gov; rnguyen@mail.nih.gov; wangling@niaid.nih.gov; baoshan.zhang@nih.gov; tzhou@mail.nih.gov; gwo-yu.chuang@nih.gov; bgraham@mail.nih.gov; jmascola@mail.nih.gov; kizzmekia.corbett@nih.gov; pdkwong@nih.gov		Nazzari, Alexandra/0000-0003-1891-8541; Verardi, Raffaello/0000-0002-2613-1223; Wang, Shuishu/0000-0002-0865-4522; Werner, Anne/0000-0003-2322-6830; Wang, Lingshu/0000-0002-8404-4910; Phung, Emily/0000-0001-9684-9698; Olia, Adam/0000-0003-0805-1331	Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA	This research was funded by the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA.	Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11; Boson B., 2020, SARS COV 2 ENVELOPE, DOI [10.1101/2020.08.24.260901, DOI 10.1101/2020.08.24.260901]; Cai Yongfei, 2020, bioRxiv, DOI 10.1101/2020.05.16.099317; Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y; Case JB, 2020, CELL HOST MICROBE, V28, P465, DOI 10.1016/j.chom.2020.07.018; Conzelmann K.-K., 2020, BIORXIV, DOI [10.1101/2020.10.02.324046, DOI 10.1101/2020.10.02.324046]; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312; Czub M, 2005, VACCINE, V23, P2273, DOI 10.1016/j.vaccine.2005.01.033; Deming D, 2006, PLOS MED, V3, P2359, DOI 10.1371/journal.pmed.0030525; Erasmus Jesse H, 2020, bioRxiv, DOI 10.1101/2020.05.28.121640; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Fuenmayor J, 2017, NEW BIOTECHNOL, V39, P174, DOI 10.1016/j.nbt.2017.07.010; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; He LL, 2021, SCI ADV, V7, DOI [10.1126/sciadv.abf1591, 10.1101/2020.09.14.296715]; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Ke ZL, 2020, NATURE, V588, P498, DOI 10.1038/s41586-020-2665-2; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kurup D, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00248-6; Laczko D, 2020, IMMUNITY, V53, P724, DOI 10.1016/j.immuni.2020.07.019; Liu LH, 2020, NATURE, V584, P450, DOI 10.1038/s41586-020-2571-7; Liu ZQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02460-2; Marian AJ, 2021, CARDIOVASC PATHOL, V50, DOI 10.1016/j.carpath.2020.107278; McGinnes Lori W, 2013, Curr Protoc Microbiol, V30, DOI 10.1002/9780471729259.mc1802s30; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; Nichols WW, 1995, ANN NY ACAD SCI, V772, P30, DOI 10.1111/j.1749-6632.1995.tb44729.x; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Pantua HD, 2006, J VIROL, V80, P11062, DOI 10.1128/JVI.00726-06; Plummer EM, 2011, WIRES NANOMED NANOBI, V3, P174, DOI 10.1002/wnan.119; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413; Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Roy S., 2020, BIORXIV, V2020, DOI [10.1101/2020.09.16.298992, DOI 10.1101/2020.09.16.298992]; Schmidt MR, 2014, J VIROL, V88, P10165, DOI 10.1128/JVI.01250-14; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0; Sun WN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040771; Vashishtha VM, 2021, HUM VACC IMMUNOTHER, V17, P1635, DOI 10.1080/21645515.2020.1845524; Walls Alexandra C, 2020, bioRxiv, DOI [10.1016/j.cell.2020.10.043, 10.1101/2020.08.11.247395]; Walsh Edward E, 2020, medRxiv, DOI 10.1101/2020.08.17.20176651; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu SP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17972-1; Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241; Yahalom-Ronen Y, 2020, 160655 BIORXIV, DOI [10.1101/2020.06.18.160655, DOI 10.1101/2020.06.18.160655]; Yao HP, 2020, CELL, V183, P730, DOI 10.1016/j.cell.2020.09.018; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zhang Baoshan, 2020, bioRxiv, DOI [10.1101/2020.06.11.147496, 10.1038/s41598-020-74949-2]; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhou TQ, 2020, CELL REP, V33, DOI [10.1016/j.celrep.2020.108322, 10.1101/2020.06.22.166033]; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3; Zost SJ, 2020, NATURE, V584, P443, DOI 10.1038/s41586-020-2548-6	57	10	11	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							73	10.3390/vaccines9020073			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6XF	33494381	gold, Green Published			2022-04-29	WOS:000623283900001
J	Zeevat, F; Dvortsin, E; Wondimu, A; Wilschut, JC; Boersma, C; Postma, MJ				Zeevat, Florian; Dvortsin, Evgeni; Wondimu, Abrham; Wilschut, Jan C.; Boersma, Cornelis; Postma, Maarten J.			Rotavirus Vaccination of Infants Delayed and Limited within the National Immunization Programme in the Netherlands: An Opportunity Lost	VACCINES			English	Article						National Immunization Programme; vaccination; public health; rotavirus vaccine; costs and effects	COST-EFFECTIVENESS; GASTROENTERITIS; CHILDREN; ENGLAND; IMPACT	In this study, we estimated the benefits of rotavirus vaccination for infants had the rotavirus vaccine been introduced in the Netherlands as of its market authorization in 2006. An age-structured, deterministic cohort model was developed to simulate different birth cohorts over a period of 15 years from 2006 until 2021, comparing both universal and targeted high-risk group vaccination to no vaccination. Different scenarios for the duration of protection (5 or 7 years) and herd immunity (only for universal vaccination) were analyzed. All birth cohorts together included 2.6 million infants, of which 7.9% were high-risk individuals, and an additional 13.2 million children between 1-15 years born prior to the first cohort in 2006. The costs and health outcomes associated with rotavirus vaccination were calculated per model scenario and discounted at 4% and 1.5%, respectively. Our analysis reveals that, had rotavirus vaccination been implemented in 2006, it would have prevented 356,800 (51% decrease) and 32,200 (5% decrease) cases of rotavirus gastroenteritis after universal and targeted vaccination, respectively. Over the last 15 years, this would have led to significant avoided costs and quality-adjusted life year losses for either vaccination strategy with the most favorable outcomes for universal vaccination. Clearly, an opportunity has been lost.	[Zeevat, Florian; Wondimu, Abrham; Boersma, Cornelis; Postma, Maarten J.] Univ Groningen, Univ Med Ctr, Dept Hlth Sci, NL-9713 AV Groningen, Netherlands; [Dvortsin, Evgeni] Asc Academics, NL-9713 GH Groningen, Netherlands; [Wondimu, Abrham] Univ Gondar, Coll Med & Hlth Sci, Sch Pharm, Dept Pharmaceut, Gondar POB 196, Gondar, Ethiopia; [Wilschut, Jan C.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol & Infect Prevent, NL-9713 AV Groningen, Netherlands; [Boersma, Cornelis] Open Univ, Fac Management Sci, NL-6419 AT Heerlen, Netherlands; [Postma, Maarten J.] Univ Groningen, Fac Econ & Business, Dept Econ Econometr & Finance, NL-9700 AV Groningen, Netherlands		Zeevat, F (通讯作者)，Univ Groningen, Univ Med Ctr, Dept Hlth Sci, NL-9713 AV Groningen, Netherlands.	f.zeevat@rug.nl; evgeni@ascacademics.com; a.w.dagne@rug.nl; jcwilschut@gmail.com; m.j.postma@rug.nl		Postma, Maarten/0000-0002-6306-3653; Zeevat, Florian/0000-0001-6427-4172; Dagne, Abrham Wondimu/0000-0002-3922-287X; Boersma, Cornelis/0000-0002-1190-2638			Aballea S, 2013, HUM VACC IMMUNOTHER, V9, P1272, DOI 10.4161/hv.24253; [Anonymous], 2017, GEZONDHEIDSRAAD VACC, P1; [Anonymous], KOSTENHANDLEIDING ME; [Anonymous], CENTRAAL BUREAU STAT; Atkins KE, 2012, VACCINE, V30, P552, DOI 10.1016/j.vaccine.2011.11.064; Banyai K, 2006, EPIDEMIOL INFECT, V134, P908, DOI 10.1017/S0950268806006091; Blank PR, 2013, VACCINE, V31, P2862, DOI 10.1016/j.vaccine.2013.04.039; Blokhuis P, 2020, KAMERBRIEF VERZAMELB; Blokhuis P., BRIEF REGERING UITST; Brisson M, 2010, PEDIATR INFECT DIS J, V29, P73, DOI 10.1097/INF.0b013e3181b41506; Bruijning-Verhagen P, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1134-3; Bruijning-Verhagen P, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-112; Crawford SE, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.83; de Hoog MLA, 2018, HUM VACC IMMUNOTHER, V14, P1027, DOI 10.1080/21645515.2017.1412019; de Wit MAS, 2001, EMERG INFECT DIS, V7, P82, DOI 10.3201/eid0701.010113; European Medicine Agency (EMA, 2018, ROTATEQ EPAR PROD IN; European Medicine Agency (EMA), 2019, ROT EPAR PROD INF; Gezondheidsraad Het Individuele,, COLL PUBL BEL VACC A; Houweling H, 2010, VACCINE, V28, P2924, DOI 10.1016/j.vaccine.2010.02.021; Mangen MJJ, 2010, VACCINE, V28, P2624, DOI 10.1016/j.vaccine.2010.01.014; Marlow R, 2015, EUROSURVEILLANCE, V20, P21, DOI 10.2807/1560-7917.ES.2015.20.48.30077; Montagna MT, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030379; Payne DC, 2015, CLIN INFECT DIS, V61, P1792, DOI 10.1093/cid/civ872; Poelaert D, 2018, VACCINE, V36, P2243, DOI 10.1016/j.vaccine.2018.02.080; RIVM Vaccinaties Tegen Infectieziekten, 2018, RIJKSV; Rozenbaum MH, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-462; Sullivan Gail M, 2012, J Grad Med Educ, V4, P279, DOI 10.4300/JGME-D-12-00156.1; Thomas SL, 2017, VACCINE, V35, P680, DOI 10.1016/j.vaccine.2016.11.057; Tweede Kamer der Staten-Generaal, 2020, KAMERBRIEF INFECTIEZ, V478; Tweede Kamer der Staten-Generaal, 2018, KAMERBRIEF PREVENTIE, V321; Van Lier E.A., 2020, VACCINATIEGRAAD JAAR, P21; van Wijhe M, 2016, LANCET INFECT DIS, V16, P592, DOI 10.1016/S1473-3099(16)00027-X; Vesikari T, 2009, VACCINE, V28, P345, DOI 10.1016/j.vaccine.2009.10.041; Zorginstituut Nederland, 2017, ADV INZ BESCH VACC V	34	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							144	10.3390/vaccines9020144			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6UP	33579025	Green Published, gold			2022-04-29	WOS:000623276900001
J	Ogunlade, ST; Meehan, MT; Adekunle, AI; Rojas, DP; Adegboye, OA; McBryde, ES				Ogunlade, Samson T.; Meehan, Michael T.; Adekunle, Adeshina I.; Rojas, Diana P.; Adegboye, Oyelola A.; McBryde, Emma S.			A Review: Aedes-Borne Arboviral Infections, Controls and Wolbachia-Based Strategies	VACCINES			English	Review						Aedes-borne; arboviruses; Wolbachia; vectors; controls	YELLOW-FEVER VIRUS; BIDIRECTIONAL CYTOPLASMIC INCOMPATIBILITY; HAMSTER MESOCRICETUS-AURATUS; LIFE-SHORTENING WOLBACHIA; ZIKA VIRUS; CHIKUNGUNYA VIRUS; VECTOR CONTROL; COMMUNITY EFFECTIVENESS; CLINICAL PRESENTATION; GLOBAL DISTRIBUTION	Arthropod-borne viruses (Arboviruses) continue to generate significant health and economic burdens for people living in endemic regions. Of these viruses, some of the most important (e.g., dengue, Zika, chikungunya, and yellow fever virus), are transmitted mainly by Aedes mosquitoes. Over the years, viral infection control has targeted vector population reduction and inhibition of arboviral replication and transmission. This control includes the vector control methods which are classified into chemical, environmental, and biological methods. Some of these control methods may be largely experimental (both field and laboratory investigations) or widely practised. Perceptively, one of the biological methods of vector control, in particular, Wolbachia-based control, shows a promising control strategy for eradicating Aedes-borne arboviruses. This can either be through the artificial introduction of Wolbachia, a naturally present bacterium that impedes viral growth in mosquitoes into heterologous Aedes aegypti mosquito vectors (vectors that are not natural hosts of Wolbachia) thereby limiting arboviral transmission or via Aedes albopictus mosquitoes, which naturally harbour Wolbachia infection. These strategies are potentially undermined by the tendency of mosquitoes to lose Wolbachia infection in unfavourable weather conditions (e.g., high temperature) and the inhibitory competitive dynamics among co-circulating Wolbachia strains. The main objective of this review was to critically appraise published articles on vector control strategies and specifically highlight the use of Wolbachia-based control to suppress vector population growth or disrupt viral transmission. We retrieved studies on the control strategies for arboviral transmissions via arthropod vectors and discussed the use of Wolbachia control strategies for eradicating arboviral diseases to identify literature gaps that will be instrumental in developing models to estimate the impact of these control strategies and, in essence, the use of different Wolbachia strains and features.	[Ogunlade, Samson T.; Meehan, Michael T.; Adekunle, Adeshina I.; Adegboye, Oyelola A.; McBryde, Emma S.] James Cook Univ, Australian Inst Trop Hlth & Med, Townsville, Qld 4811, Australia; [Ogunlade, Samson T.; McBryde, Emma S.] James Cook Univ, Coll Med & Dent, Townsville, Qld 4811, Australia; [Rojas, Diana P.; Adegboye, Oyelola A.] James Cook Univ, Coll Publ Hlth Med & Vet Sci, Townsville, Qld 4811, Australia		Ogunlade, ST (通讯作者)，James Cook Univ, Australian Inst Trop Hlth & Med, Townsville, Qld 4811, Australia.; Ogunlade, ST (通讯作者)，James Cook Univ, Coll Med & Dent, Townsville, Qld 4811, Australia.	samson.ogunlade@my.jcu.edu.au; michael.meehan1@jcu.edu.au; adeshina.adekunle@jcu.edu.au; diana.rojasalvarez@jcu.edu.au; oyelola.adegboye@jcu.edu.au; emma.mcbryde@jcu.edu.au	Adegboye, Oyelola A/A-2987-2015	Adegboye, Oyelola A/0000-0002-9793-8024; Adekunle, Adeshina/0000-0002-1811-1310; Ogunlade, Samson/0000-0003-3938-3769; McBryde, Emma/0000-0002-9570-9172	National Health and Medical Research Council's Centre of Research Excellence in Tuberculosis Control [1153493]	M.T.M. is funded by a postdoctoral research fellowship from the National Health and Medical Research Council's Centre of Research Excellence in Tuberculosis Control on Both Sides of Our Border (Project ID: 1153493).	ACHEE NL, 2015, PLOS NEGLECT TROP D, V9, DOI DOI 10.1371/JOURNAL.PNTD.0003655; Adekunle AI, 2019, INFECT DIS MODEL, V4, P265, DOI 10.1016/j.idm.2019.10.001; Aguiar M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005179; Alphey L, 2013, PATHOG GLOB HEALTH, V107, P170, DOI 10.1179/2047773213Y.0000000095; ANDERSON RM, 1979, NATURE, V280, P361, DOI 10.1038/280361a0; ANDERSON RM, 1989, PARASITOLOGY, V99, pS59, DOI 10.1017/S0031182000083426; Ant TH, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006815; Atyame CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119288; Axford JK, 2016, AM J TROP MED HYG, V94, P507, DOI 10.4269/ajtmh.15-0608; Ayhan N, 2020, CLIN MICROBIOL INFEC, V26, P1017, DOI 10.1016/j.cmi.2019.12.015; Bae HG, 2005, J CLIN VIROL, V33, P274, DOI 10.1016/j.jcv.2004.12.001; Barba-Spaeth G, 2016, NATURE, V536, P48, DOI 10.1038/nature18938; Barnett ED, 2007, CLIN INFECT DIS, V44, P850, DOI 10.1086/511869; Beckham J David, 2015, Continuum (Minneap Minn), V21, P1599, DOI 10.1212/CON.0000000000000240; Bergman A, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12121441; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Blagrove MSC, 2012, P NATL ACAD SCI USA, V109, P255, DOI 10.1073/pnas.1112021108; Bogoch II, 2016, LANCET, V387, P335, DOI 10.1016/S0140-6736(16)00080-5; Brady OJ, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002755; Brady OJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001760; Branca A, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-185; Brandler S, 2013, VIRUSES-BASEL, V5, P2384, DOI 10.3390/v5102384; Brasil P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004636; Brooks JT, 2016, MMWR-MORBID MORTAL W, V65, P745, DOI 10.15585/mmwr.mm6529e2; Buhler C, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007420; Campbell CL, 2014, INSECT MOL BIOL, V23, P132, DOI 10.1111/imb.12070; Campo-Duarte DE, 2018, J MATH BIOL, V76, P1907, DOI 10.1007/s00285-018-1213-2; Causa R, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311X00110519, 10.1590/0102-311x00110519]; CDC, 2019, CTR DIS CONTROL PREV; Chan M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050972; Charlier C, 2017, LANCET CHILD ADOLESC, V1, P134, DOI 10.1016/S2352-4642(17)30021-4; Chen HL, 2015, J CHIN MED ASSOC, V78, P271, DOI 10.1016/j.jcma.2014.12.009; Chen Lin H, 2016, N Engl J Med, V375, pe32, DOI 10.1056/NEJMc1610671; Chen LH, 2016, ANN INTERN MED, V164, P574, DOI 10.7326/L16-0075; Chiuya T, 2021, TRANSBOUND EMERG DIS, V68, P2429, DOI 10.1111/tbed.13911; Choi L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012736.pub2; Chung HN, 2018, J INSECT SCI, V18, DOI 10.1093/jisesa/iey103; Ciota AT, 2010, VIRUSES-BASEL, V2, P2594, DOI 10.3390/v2122594; Costard S, 2013, VIRUS RES, V173, P191, DOI 10.1016/j.virusres.2012.10.030; Couderc T, 2012, J INFECT DIS, V206, P851, DOI 10.1093/infdis/jis296; Crain PR, 2011, BMC EVOL BIOL, V11, DOI 10.1186/1471-2148-11-290; da Silva PAN, 2020, EUR J CLIN MICROBIOL, V39, P827, DOI 10.1007/s10096-019-03792-9; de Almeida F, 2011, INFECT GENET EVOL, V11, P2138, DOI 10.1016/j.meegid.2011.08.022; de Melo AB, 2011, AM J TROP MED HYG, V85, P739, DOI 10.4269/ajtmh.2011.10-0496; Costa MCD, 2019, ACTA TROP, V190, P395, DOI 10.1016/j.actatropica.2018.12.019; Deviatkin AA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020247; DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4; Dickens BL, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw103; Dorigatti I, 2018, TRENDS PARASITOL, V34, P102, DOI 10.1016/j.pt.2017.11.002; Dubrulle M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005895; Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715; Duron O, 2006, MOL ECOL, V15, P3061, DOI 10.1111/j.1365-294X.2006.02996.x; Dusfour I, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007615; Dutton TJ, 2004, INSECT MOL BIOL, V13, P317, DOI 10.1111/j.0962-1075.2004.00490.x; Dyer KA, 2004, GENETICS, V168, P1443, DOI 10.1534/genetics.104.027854; Eckerle I, 2018, CLIN MICROBIOL INFEC, V24, P240, DOI 10.1016/j.cmi.2018.01.007; Eder M, 2018, INFECT DIS POVERTY, V7, DOI 10.1186/s40249-018-0475-7; Ferguson NM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010370; Flor M, 2007, J EVOLUTION BIOL, V20, P696, DOI 10.1111/j.1420-9101.2006.01252.x; Flores HA, 2018, NAT REV MICROBIOL, V16, P508, DOI 10.1038/s41579-018-0025-0; Fourie T, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy261; Frentiu FD, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002688; Fu GL, 2010, P NATL ACAD SCI USA, V107, P4550, DOI 10.1073/pnas.1000251107; Fukusumi M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004924; Ganesan VK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120368; Garcia A, 2015, RECENT PATENTS INFLA, V9, P31, DOI 10.2174/1872213X09666150223114226; Garcia GA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-56766-4; Gill AC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003224; Goh GKM, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110710; Gould E, 2017, ONE HEALTH-AMSTERDAM, V4, P1, DOI 10.1016/j.onehlt.2017.06.001; Gould LH, 2008, T ROY SOC TROP MED H, V102, P1247, DOI 10.1016/j.trstmh.2008.04.014; Guerbois M, 2016, J INFECT DIS, V214, P1349, DOI 10.1093/infdis/jiw302; Gumel AB, 2012, J MATH ANAL APPL, V395, P355, DOI 10.1016/j.jmaa.2012.04.077; Guzman MG, 2015, LANCET, V385, P453, DOI 10.1016/S0140-6736(14)60572-9; Hague MTJ, 2020, GENETICS, V215, P1117, DOI 10.1534/genetics.120.303330; Hamel R, 2016, MICROBES INFECT, V18, DOI 10.1016/j.micinf.2016.03.009; Han WW, 2015, TROP MED INT HEALTH, V20, P1239, DOI 10.1111/tmi.12538; Hanley KA, 2008, ORIGIN AND EVOLUTION OF VIRUSES, 2ND EDITION, P351, DOI 10.1016/B978-0-12-374153-0.00016-3; Hedges LM, 2008, SCIENCE, V322, P702, DOI 10.1126/science.1162418; Hertig M, 1924, J MED RES, V44, P329; Hethcote HW, 2000, J MATH BIOL, V40, P3, DOI 10.1007/s002850050003; Heydari N, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14020196; Hilgenboecker K, 2008, FEMS MICROBIOL LETT, V281, P215, DOI 10.1111/j.1574-6968.2008.01110.x; Hladish TJ, 2020, P NATL ACAD SCI USA, V117, P3319, DOI 10.1073/pnas.1903496117; Hoffmann AA, 2011, NATURE, V476, P454, DOI 10.1038/nature10356; HOFFMANN AA, 1994, GENETICS, V136, P993; Hoffmann AA, 2015, EVOL APPL, V8, P751, DOI 10.1111/eva.12286; Horstick O, 2017, SE ASIAN J TROP MED, V48, P181; Hughes H, 2013, B MATH BIOL, V75, P796, DOI 10.1007/s11538-013-9835-4; Huigens ME, 2000, NATURE, V405, P178, DOI 10.1038/35012066; Hunter P, 2016, EMBO REP, V17, P1370, DOI 10.15252/embr.201643233; Hussain M, 2011, P NATL ACAD SCI USA, V108, P9250, DOI 10.1073/pnas.1105469108; Iwashita H, 2018, TROP MED HEALTH, V46, DOI 10.1186/s41182-018-0095-8; Javelle E, 2014, J CLIN VIROL, V59, P270, DOI 10.1016/j.jcv.2014.01.011; Johansson MA, 2014, T ROY SOC TROP MED H, V108, P482, DOI 10.1093/trstmh/tru092; Johansson MA, 2010, AM J TROP MED HYG, V83, P183, DOI 10.4269/ajtmh.2010.09-0782; Joubert DA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005434; Jupatanakul N, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005187; Kambris Z, 2009, SCIENCE, V326, P134, DOI 10.1126/science.1177531; Kamgang B, 2019, EMERG MICROBES INFEC, V8, P1636, DOI 10.1080/22221751.2019.1688097; Kamtchum-Tatuene J, 2017, CURR OPIN INFECT DIS, V30, P108, DOI 10.1097/QCO.0000000000000342; Karunamoorthi K, 2011, CLIN MICROBIOL INFEC, V17, P1608, DOI 10.1111/j.1469-0691.2011.03664.x; Kittayapong P, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007771; Klitting R, 2018, GENES-BASEL, V9, DOI 10.3390/genes9060291; Krejbich-Trotot P, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-432; Kriesner P, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003607; Krow-Lucal ER, 2017, EMERG INFECT DIS, V23, P841, DOI 10.3201/eid2305.161715; Kularatne SAM, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4661; Kulkarni R, 2020, DYNAMICS OF IMMUNE ACTIVATION IN VIRAL DISEASES, P9, DOI 10.1007/978-981-15-1045-8_2; Lazaro A, 2015, TROP MED INT HEALTH, V20, P685, DOI 10.1111/tmi.12485; Lee WS, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3433-8; Lenglet Y, 2006, J Gynecol Obstet Biol Reprod (Paris), V35, P578; Li M, 2020, ELIFE, V9, DOI 10.7554/eLife.51701; Lima EP, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-5; Lin YP, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1379-4; Lowe R, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4385; Madewell ZJ, 2020, SOUTH MED J, V113, P520, DOI 10.14423/SMJ.0000000000001152; Mancini MV, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0007926; Marston HD, 2016, NEW ENGL J MED, V375, P1209, DOI 10.1056/NEJMp1607762; Mathai D, 2009, J GLOB INFECT DIS, V1, P4, DOI 10.4103/0974-777X.52975; Mavian C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010011; May RM, 2005, CURR BIOL, V15, pR922, DOI 10.1016/j.cub.2005.10.063; McMeniman CJ, 2009, SCIENCE, V323, P141, DOI 10.1126/science.1165326; Meany MK, 2019, EVOLUTION, V73, P1278, DOI 10.1111/evo.13745; Messina JP, 2019, NAT MICROBIOL, V4, P1508, DOI 10.1038/s41564-019-0476-8; Miner JJ, 2015, ARTHRITIS RHEUMATOL, V67, P1214, DOI 10.1002/art.39027; Moreira LA, 2009, CELL, V139, P1268, DOI 10.1016/j.cell.2009.11.042; Motta IJF, 2016, NEW ENGL J MED, V375, P1101, DOI 10.1056/NEJMc1607262; Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761; Mustafa M S, 2011, Med J Armed Forces India, V67, P192, DOI 10.1016/S0377-1237(11)60035-X; Mutebi JP, 2001, J VIROL, V75, P6999, DOI 10.1128/JVI.75.15.6999-7008.2001; Nakkhara P, 2013, T ROY SOC TROP MED H, V107, P789, DOI 10.1093/trstmh/trt083; Navarro-Paya D, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008876; Nayar S K, 2007, Med J Malaysia, V62, P335; Nazni WA, 2019, CURR BIOL, V29, P4241, DOI 10.1016/j.cub.2019.11.007; Ndii MZ, 2012, ANZIAM J, V53, P213, DOI 10.1017/S1446181112000132; O'Connor L, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001797; O'Reilly KM, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1396-4; Ogunlade ST, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73819-1; Pan XL, 2018, ISME J, V12, P277, DOI 10.1038/ismej.2017.174; Parola P, 2006, EMERG INFECT DIS, V12, P1493, DOI 10.3201/eid1210.060610; Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371; Perez-Staples D, 2021, NEOTROP ENTOMOL, V50, P172, DOI 10.1007/s13744-020-00817-3; Priyamvada L, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.42; Qu ZL, 2018, SIAM J APPL MATH, V78, P826, DOI 10.1137/17M1130800; Rainey SM, 2014, J GEN VIROL, V95, P517, DOI 10.1099/vir.0.057422-0; Rances Edwige, 2012, PLoS Pathog, V8, pe1002548, DOI 10.1371/journal.ppat.1002548; Rapley LP, 2009, AM J TROP MED HYG, V81, P94, DOI 10.4269/ajtmh.2009.81.94; Rasgon JL, 2003, GENETICS, V165, P2029; Rasic G, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-275; Rather IA, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00336; Reeves RG, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001502; Resnik DB, 2014, DEV WORLD BIOETH, V14, P37, DOI 10.1111/dewb.12011; Rodriguez-Andres J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002977; Rogers DJ, 2006, ADV PARASIT, V62, P181, DOI 10.1016/S0065-308X(05)62006-4; Roiz D, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006845; Ross PA, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007357; Ross PA, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006006; ROUSSET F, 1991, TRENDS ECOL EVOL, V6, P54, DOI 10.1016/0169-5347(91)90123-F; Rudolph KE, 2014, AM J TROP MED HYG, V90, P882, DOI 10.4269/ajtmh.13-0403; Rust RS, 2012, SEMIN PEDIATR NEUROL, V19, P130, DOI 10.1016/j.spen.2012.03.002; Saldana MA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005760; Sbrana E, 2004, AM J TROP MED HYG, V71, P306, DOI 10.4269/ajtmh.2004.71.306; Schaefer T. J., 2019, DENGUE FEVER; Schraiber JG, 2012, J THEOR BIOL, V297, P26, DOI 10.1016/j.jtbi.2011.12.006; Scott LJ, 2016, DRUGS, V76, P1301, DOI 10.1007/s40265-016-0626-8; Shaw AE, 2012, J VIROL, V86, P9015, DOI 10.1128/JVI.00131-12; Sicard M, 2014, J INVERTEBR PATHOL, V121, P28, DOI 10.1016/j.jip.2014.06.007; Siettos CI, 2013, VIRULENCE, V4, P295, DOI 10.4161/viru.24041; Sim S, 2014, VIRUSES-BASEL, V6, P4479, DOI 10.3390/v6114479; Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265; SINKINS SP, 1995, P ROY SOC B-BIOL SCI, V261, P325, DOI 10.1098/rspb.1995.0154; Smatti MK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02991; Snyder RE, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008841; Suhrcke M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020724; Sutton ER, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-928; Teixeira L, 2008, PLOS BIOL, V6, P2753, DOI 10.1371/journal.pbio.1000002; Telschow A, 2005, J THEOR BIOL, V235, P265, DOI 10.1016/j.jtbi.2005.01.008; Telschow A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000701; Terradas G, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4212-z; Tesh RB, 2001, J INFECT DIS, V183, P1431, DOI 10.1086/320199; Thomas P, 2011, DEV COMP IMMUNOL, V35, P360, DOI 10.1016/j.dci.2010.11.007; Tissera HA, 2018, TROP MED INT HEALTH, V23, P229, DOI 10.1111/tmi.13015; Nguyen TH, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1174-x; TURELLI M, 1995, GENETICS, V140, P1319; Turley AP, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000516; Udayanga L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216140; Ulrich JN, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004873; van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6; van den Hurk AF, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001892; Vargas V, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63402-z; Voronin D, 2012, P NATL ACAD SCI USA, V109, pE1638, DOI 10.1073/pnas.1203519109; Waggoner JJ, 2016, CLIN INFECT DIS, V63, P1584, DOI 10.1093/cid/ciw589; Walker T, 2011, NATURE, V476, P450, DOI 10.1038/nature10355; Wasay M, 2015, NEUROLOGY, V84, P421, DOI 10.1212/WNL.0000000000001177; Weaver SC, 2015, NEW ENGL J MED, V372, P1231, DOI 10.1056/NEJMra1406035; Weaver SC, 2010, ANTIVIR RES, V85, P328, DOI 10.1016/j.antiviral.2009.10.008; Werren JH, 1997, ANNU REV ENTOMOL, V42, P587, DOI 10.1146/annurev.ento.42.1.587; Whitehorn J, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003025; WHO, 2017, FACT SHEETS CHIKUNGU; WHO, 2016, WHO MOSQUITO CONTROL; Wieten RW, 2016, J INFECTION, V72, P713, DOI 10.1016/j.jinf.2016.02.017; Wilder-Smith A, 2019, LANCET, V394, P2151, DOI 10.1016/S0140-6736(19)32525-5; Winokur OC, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008047; Wressnigg N, 2015, CLIN VACCINE IMMUNOL, V22, P267, DOI 10.1128/CVI.00546-14; Xiao SY, 2001, J INFECT DIS, V183, P1437, DOI 10.1086/320200; Xu ZW, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008118; Xue L, 2017, J BIOL DYNAM, V11, P216, DOI 10.1080/17513758.2016.1229051; Yeap HL, 2011, GENETICS, V187, P583, DOI 10.1534/genetics.110.122390; Yen PS, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050404; Zabalou S, 2004, P NATL ACAD SCI USA, V101, P15042, DOI 10.1073/pnas.0403853101; Zhang DH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0226736; Zheng B, 2018, J MATH BIOL, V76, P235, DOI 10.1007/s00285-017-1142-5; Zhong Y, 2014, MICROB ECOL, V68, P463, DOI 10.1007/s00248-014-0425-2; Zhou WG, 1998, P ROY SOC B-BIOL SCI, V265, P509, DOI 10.1098/rspb.1998.0324; Zug R, 2015, BIOL REV, V90, P89, DOI 10.1111/brv.12098	216	6	6	5	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							32	10.3390/vaccines9010032			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7BD	33435566	Green Published, Green Accepted, gold			2022-04-29	WOS:000610824700001
J	Palya, V; Tatar-Kis, T; Arafa, ASA; Felfoldi, B; Mato, T; Setta, A				Palya, Vilmos; Tatar-Kis, Timea; Arafa, Abdel Satar A.; Felfoldi, Balazs; Mato, Tamas; Setta, Ahmed			Efficacy of a Turkey Herpesvirus Vectored Newcastle Disease Vaccine against Genotype VII.1.1 Virus: Challenge Route Affects Shedding Pattern	VACCINES			English	Article						Newcastle disease virus; vaccine; recombinant turkey herpesvirus; genotype VII; challenge route; shedding		The control of Newcastle disease (ND) highly relies on vaccination. Immunity provided by a ND vaccine can be characterized by measuring the level of clinical protection and reduction in challenge virus shedding. The extent of shedding depends a lot on the characteristics of vaccine used and the quality of vaccination, but influenced also by the genotype of the challenge virus. We demonstrated that vaccination of SPF chicks with recombinant herpesvirus of turkey expressing the F-gene of genotype I ND virus (rHVT-ND) provided complete clinical protection against heterologous genotype VII.1.1 ND virus strain and reduced challenge virus shedding significantly. 100% of clinical protection was achieved already by 3 weeks of age, irrespective of the challenge route (intra-muscular or intra-nasal) and vaccination blocked cloacal shedding almost completely. Interestingly, oro-nasal shedding was different in the two challenge routes: less efficiently controlled following intra-nasal than intra-muscular challenge. Differences in the shedding pattern between the two challenge routes indicate that rHVT-ND vaccine induces strong systemic immunity, that is capable to control challenge virus dissemination in the body (no cloacal shedding), even when it is a heterologous strain, but less efficiently, although highly significantly (p < 0.001) suppresses the local replication of the challenge virus in the upper respiratory mucosa and consequent oro-nasal shedding.	[Palya, Vilmos; Tatar-Kis, Timea; Felfoldi, Balazs; Mato, Tamas] Ceva Phylaxia Co Ltd, Sci Support & Invest Unit, Ceva Anim Hlth, 5 Szallas Utca, H-1107 Budapest, Hungary; [Arafa, Abdel Satar A.] Agr Res Ctr, Anim Hlth Res Inst, Cent Lab Qual Control Poultry Prod, 7 Nadi El Seid St, Giza 12618, Egypt; [Setta, Ahmed] Ceva Anim Hlth, 5 St 277, Cairo 11435, Egypt		Palya, V (通讯作者)，Ceva Phylaxia Co Ltd, Sci Support & Invest Unit, Ceva Anim Hlth, 5 Szallas Utca, H-1107 Budapest, Hungary.	vilmos.palya@ceva.com; timea.tatar@ceva.com; abd.arafa@gmail.com; balazs.felfoldi@ceva.com; tamas.mato@ceva.com; ahmed.setta@ceva.com	Setta, Ahmed/ABF-1346-2021	Setta, Ahmed/0000-0002-9088-6233; Palya, Vilmos/0000-0003-3319-9995			Alfonso C.L., 2018, MANUAL DIAGNOSTIC TE, P964; [Anonymous], CURRENT FUTURE APPL; Awad A, 2015, INT J CURR RES, V7, P12925; BENNEJEAN G, 1978, AVIAN PATHOL, V7, P15, DOI 10.1080/03079457808418256; Cho SH, 2008, J CLIN MICROBIOL, V46, P1541, DOI 10.1128/JCM.00187-08; Czegledi A, 2006, VIRUS RES, V120, P36, DOI 10.1016/j.virusres.2005.11.009; Dimitrov KM, 2019, INFECT GENET EVOL, V74, DOI 10.1016/j.meegid.2019.103917; Dimitrov KM, 2017, VET MICROBIOL, V206, P126, DOI 10.1016/j.vetmic.2016.12.019; Dimitrov KM, 2016, INFECT GENET EVOL, V39, P22, DOI 10.1016/j.meegid.2016.01.008; Dortmans JCFM, 2014, VET MICROBIOL, V172, P100, DOI 10.1016/j.vetmic.2014.05.004; Dortmans JCFM, 2012, VET MICROBIOL, V160, P17, DOI 10.1016/j.vetmic.2012.05.003; Esaki M, 2013, AVIAN DIS, V57, P750, DOI 10.1637/10540-032613-Reg.1; Gallili GE, 1998, BIOTECHNOL ADV, V16, P343, DOI 10.1016/S0734-9750(97)00081-5; Hines Nichole L, 2012, Vet Med Int, V2012, P708216, DOI 10.1155/2012/708216; Hu ZL, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-208; Kapczynski DR, 2005, VACCINE, V23, P3424, DOI 10.1016/j.vaccine.2005.01.140; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]; Liu HJ, 2018, VACCINE, V36, P3917, DOI 10.1016/j.vaccine.2018.05.074; Meulemans G., 1988, Newcastle disease., P318; Miller PJ, 2007, VACCINE, V25, P7238, DOI 10.1016/j.vaccine.2007.07.017; Miller PJ, 2015, INFECT GENET EVOL, V29, P216, DOI 10.1016/j.meegid.2014.10.032; Miller PJ, 2009, AVIAN DIS, V53, P39, DOI 10.1637/8407-071208-Reg.1; Mohamed MHA, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-237; MORGAN RW, 1992, AVIAN DIS, V36, P858, DOI 10.2307/1591544; Nagai Y, 1989, Prog Vet Microbiol Immunol, V5, P16; Orabi A, 2017, ARCH VIROL, V162, P3069, DOI 10.1007/s00705-017-3483-1; Palya V, 2012, AVIAN DIS, V56, P282, DOI 10.1637/9935-091511-Reg.1; Palya V, 2014, VET IMMUNOL IMMUNOP, V158, P105, DOI 10.1016/j.vetimm.2013.11.008; Rauw F, 2010, VACCINE, V28, P823, DOI 10.1016/j.vaccine.2009.10.049; Saad AM, 2017, ARCH VIROL, V162, P1985, DOI 10.1007/s00705-017-3336-y; Sonoda K, 2000, J VIROL, V74, P3217, DOI 10.1128/JVI.74.7.3217-3226.2000; Tatar-Kis T, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040614; van Boven M, 2008, AVIAN PATHOL, V37, P1, DOI 10.1080/03079450701772391; Wise MG, 2004, J CLIN MICROBIOL, V42, P329, DOI 10.1128/JCM.42.1.329-338.2004; Zenglei H., 2015, BR J VIROL, V2, P25; Zhang R, 2010, VET MICROBIOL, V141, P246, DOI 10.1016/j.vetmic.2009.09.020	36	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							37	10.3390/vaccines9010037			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6UA	33440698	Green Published, gold			2022-04-29	WOS:000610805900001
J	Price, NB; Grose, C				Price, Nathan B.; Grose, Charles			Corticosteroids Contribute to Serious Adverse Events Following Live Attenuated Varicella Vaccination and Live Attenuated Zoster Vaccination	VACCINES			English	Review						varicella-zoster virus; severe combined immunodeficiency; natural killer cells; RNA polymerase III; chronic lymphocytic leukemia; HIV; rheumatoid arthritis; prednisone; varicella meningitis; herpes zoster	HERPES-ZOSTER; FATAL VARICELLA; STRAIN; VIRUS; INFECTION; CHILD; PREDNISONE; THERAPY; TERM; REACTIVATION	Corticosteroids, when given in high dosages, have long been recognized as a risk factor for severe infection with wild-type varicella-zoster virus in both children and adults. The goal of this review is to assess the degree to which both low-dosage and high-dosage corticosteroids contribute to serious adverse events (SAEs) following live varicella vaccination and live zoster vaccination. To this end, we examined multiple published reports of SAEs following varicella vaccination (Varivax(TM)) and zoster vaccination (Zostavax(TM)). We observed that five of eight viral SAEs following varicella vaccination, including two deaths, occurred in children receiving corticosteroids, while one of three fatal viral SAEs following live zoster vaccination occurred in an adult being treated with low-dosage prednisone. The latter death after live zoster vaccination occurred in a 70 year-old man with rheumatoid arthritis, being treated with prednisone 10 mg daily. Thus, corticosteroids contributed to more severe infectious complications in subjects immunized with each of the two live virus vaccines. Further, when we surveyed the rheumatology literature as well as individual case reports, we documented examples where daily dosages of 7.5-20 mg prednisone were associated with increased rates of severe wild-type varicella-zoster virus infections in children and adults.	[Price, Nathan B.] Univ Arizona, Dept Pediat, Div Infect Dis, Tucson, AZ 85724 USA; [Grose, Charles] Univ Iowa, Dept Pediat, Div Infect Dis, Virol Lab, Iowa City, IA 52242 USA		Grose, C (通讯作者)，Univ Iowa, Dept Pediat, Div Infect Dis, Virol Lab, Iowa City, IA 52242 USA.	pricen@peds.arizona.edu; charles-grose@uiowa.edu		Grose, Charles/0000-0001-6884-6668	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI153817]	Research by C.G. is funded in part by NIH grant AI153817, which supports research to advance vaccine safety.	Alexander KE, 2018, VACCINE, V36, P3890, DOI 10.1016/j.vaccine.2018.05.078; Bacon G E, 1965, J Pediatr, V67, P763; BALLOW M, 1985, J CLIN IMMUNOL, V5, P180, DOI 10.1007/BF00915509; Banovic T, 2011, J INFECT DIS, V204, P1893, DOI 10.1093/infdis/jir660; Baxter R, 2012, VACCINE, V30, P6636, DOI 10.1016/j.vaccine.2012.08.070; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Carter-Timofte ME, 2018, TRENDS MOL MED, V24, P904, DOI 10.1016/j.molmed.2018.07.009; Choi WS, 2013, CLIN EXP VACCINE RES, V2, P92, DOI 10.7774/cevr.2013.2.2.92; Costa E, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2015-212688; CUPPS TR, 1982, IMMUNOL REV, V65, P133, DOI 10.1111/j.1600-065X.1982.tb00431.x; Damm O, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1861-8; DOWELL SF, 1993, PEDIATRICS, V92, P223; Dubey V, 2019, CAN MED ASSOC J, V191, pE1025, DOI 10.1503/cmaj.190270; Dutmer CM, 2015, J CLIN IMMUNOL, V35, P754, DOI 10.1007/s10875-015-0207-8; FAUCI AS, 1976, CLIN EXP IMMUNOL, V24, P54; Ferreira JCOA, 2016, LUPUS, V25, P754, DOI 10.1177/0961203315627203; Galea SA, 2008, J INFECT DIS, V197, pS165, DOI 10.1086/522125; GELFAND ML, 1951, JAMA-J AM MED ASSOC, V145, P560, DOI 10.1001/jama.1951.72920260003008a; GERSHON AA, 1995, PEDIATR INFECT DIS J, V14, P742, DOI 10.1097/00006454-199509000-00003; Gershon M, 2018, J INFECT DIS, V218, pS113, DOI 10.1093/infdis/jiy407; Ghaffar F, 2000, PEDIATR INFECT DIS J, V19, P764, DOI 10.1097/00006454-200008000-00022; Goda V, 2018, J ALLER CL IMM-PRACT, V6, P1769, DOI 10.1016/j.jaip.2018.01.015; GOOD RA, 1957, PEDIATRICS, V19, P95; Grose C, 2005, J CLIN VIROL, V33, P89, DOI 10.1016/j.jcv.2005.02.003; Grose C, 1996, INFECT DIS CLIN N AM, V10, P489, DOI 10.1016/S0891-5520(05)70310-X; HAGGERTY RJ, 1956, PEDIATRICS, V18, P160; Harpaz R, 2019, CLIN INFECT DIS, V69, P345, DOI 10.1093/cid/ciy954; Heusel EH, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101078; Hill G, 2005, PEDIATRICS, V116, pE525, DOI 10.1542/peds.2005-0219; HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106; KAHL LE, 1994, J RHEUMATOL, V21, P84; Kennedy PGE, 2015, J GEN VIROL, V96, P1581, DOI 10.1099/vir.0.000128; Kimberlin DW, 2007, NEW ENGL J MED, V356, P1338, DOI 10.1056/NEJMct066061; Kramer MS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e35; Krause PR, 2000, NAT MED, V6, P451, DOI 10.1038/74715; Leung J, 2018, HUM VACC IMMUNOTHER, V14, P2460, DOI 10.1080/21645515.2018.1480283; Leung J, 2014, HUM VACC IMMUNOTHER, V10, P146, DOI 10.4161/hv.26200; Levy O, 2003, J INFECT DIS, V188, P948, DOI 10.1086/378503; Mainka C, 1998, J MED VIROL, V56, P91, DOI 10.1002/(SICI)1096-9071(199809)56:1<91::AID-JMV15>3.0.CO;2-Z; Miller ER, 2018, HUM VACC IMMUNOTHER, V14, P1963, DOI 10.1080/21645515.2018.1456598; Moodley A, 2019, J CHILD NEUROL, V34, P184, DOI 10.1177/0883073818821498; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; OZAKI T, 1994, J MED VIROL, V42, P47, DOI 10.1002/jmv.1890420110; Pappas DA, 2015, ARTHRIT CARE RES, V67, P1671, DOI 10.1002/acr.22628; Ramachandran V, 2020, J CHILD NEUROL, V35, P889, DOI 10.1177/0883073820938597; Sabry A, 2014, J ALLERGY CLIN IMMUN, V133, P1225, DOI 10.1016/j.jaci.2013.11.031; Schmidt SAJ, 2017, VACCINE, V35, P5589, DOI 10.1016/j.vaccine.2017.08.065; Schrauder A, 2007, LANCET, V369, P1232, DOI 10.1016/S0140-6736(07)60567-4; Seward JF, 2008, J INFECT DIS, V197, pS82, DOI 10.1086/522145; SHEE JC, 1953, BRIT MED J, V2, P82, DOI 10.1136/bmj.2.4827.82; SLADE JD, 1983, J LAB CLIN MED, V101, P479; Su JR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199229; Sullivan NL, 2019, CURR OPIN IMMUNOL, V59, P25, DOI 10.1016/j.coi.2019.02.005; Takahashi N, 2004, EXPERT OPIN BIOL TH, V4, P199, DOI 10.1517/14712598.4.2.199; Takiguchi H, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1147-2; Varela FH, 2019, HUM VACC IMMUNOTHER, V15, P645, DOI 10.1080/21645515.2018.1546525; Woo EJ, 2015, HUM VACC IMMUNOTHER, V11, P679, DOI 10.1080/21645515.2014.1004034; Woodward M, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz295; Wu CT, 2008, PEDIATR DERMATOL, V25, P484, DOI 10.1111/j.1525-1470.2008.00720.x; Yang YW, 2011, CAN MED ASSOC J, V183, pE275, DOI 10.1503/cmaj.101137; Zamora LD, 2020, INT J RHEUM DIS, V23, P197, DOI 10.1111/1756-185X.13725; Zhang W, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-019-4716-6	62	3	3	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							23	10.3390/vaccines9010023			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6XC	33418856	Green Published			2022-04-29	WOS:000610814100001
J	Williams, L; Flowers, P; McLeod, J; Young, D; Rollins, L				Williams, Lynn; Flowers, Paul; McLeod, Julie; Young, David; Rollins, Lesley		CATALYST Project Team	Social Patterning and Stability of Intention to Accept a COVID-19 Vaccine in Scotland: Will Those Most at Risk Accept a Vaccine?	VACCINES			English	Article						COVID-19; vaccination; vaccine hesitancy; interventions; social patterning; inequalities	BEHAVIOR-CHANGE; INFLUENZA VACCINATION; HESITANCY; IMPLEMENTATION; PROGRAMS	Vaccination is central to controlling COVID-19. Its success relies on having safe and effective vaccines and also on high levels of uptake by the public over time. Addressing questions of population-level acceptability, stability of acceptance, and sub-population variation in acceptability are imperative. Using a prospective design, a repeated measures two-wave online survey was conducted to assess key sociodemographic variables and intention to accept a COVID-19 vaccine. The first survey (Time 1) was completed by 3436 people during the period of national lockdown in Scotland and the second survey (n = 2016) was completed two months later (Time 2) when restrictions had been eased. In the first survey, 74% reported being willing to receive a COVID-19 vaccine. Logistic regression analyses showed that there were clear sociodemographic differences in intention to accept a vaccine for COVID-19 with intention being higher in participants of white ethnicity as compared with Black, Asian, and minority ethnic (BAME) groups, and in those with higher income levels and higher education levels. Intention was also higher in those who had "shielding" status due to underlying medical conditions. Our results suggest that future interventions, such as mass media and social marketing, need to be targeted at a range of sub-populations and diverse communities.	[Williams, Lynn; Flowers, Paul; McLeod, Julie; Young, David; Rollins, Lesley; CATALYST Project Team] Univ Strathclyde, Sch Psychol Sci & Hlth, Glasgow G1 1QE, Lanark, Scotland		Williams, L (通讯作者)，Univ Strathclyde, Sch Psychol Sci & Hlth, Glasgow G1 1QE, Lanark, Scotland.	lynn.williams@strath.ac.uk; paul.flowers@strath.ac.uk; julie.mcleod.2020@uni.strath.ac.uk; david.young@strath.ac.uk; lesleyanne.rollins@strath.ac.uk		Williams, Lynn/0000-0003-2735-9219; Young, David/0000-0002-3652-0513; Rollins, Lesley-Anne/0000-0002-5088-8875; McLeod, Julie/0000-0001-6787-1511; Flowers, Paul/0000-0001-6239-5616	Chief Scientist Office in Scotland [COV/SCL/20/09]	This research was funded by the Chief Scientist Office in Scotland (ref COV/SCL/20/09).	[Anonymous], 2018, WELLCOME TRUST WELLC; [Anonymous], OFFICE NATL STAT DEA; Bartsch SM, 2020, AM J PREV MED, V59, P493, DOI 10.1016/j.amepre.2020.06.011; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521; Brien S, 2012, VACCINE, V30, P1255, DOI 10.1016/j.vaccine.2011.12.089; Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Dube E, 2018, VACCINE, V36, P1509, DOI 10.1016/j.vaccine.2017.12.012; Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041; Fabry P, 2011, VACCINE, V29, P1824, DOI 10.1016/j.vaccine.2010.12.109; Han YKJ, 2016, PREV MED, V84, P57, DOI 10.1016/j.ypmed.2015.12.018; IPSOS MORI, NEWS 3 4 AD GLOB SAY; Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Michie S., 2014, BEHAV CHANGE WHEEL G; Michie S, 2013, ANN BEHAV MED, V46, P81, DOI 10.1007/s12160-013-9486-6; Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-42; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Seale H, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-99; Thomson A, 2018, VACCINE, V36, P6457, DOI 10.1016/j.vaccine.2018.08.031; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468	30	31	31	2	18	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							17	10.3390/vaccines9010017			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PY2AD	33406762	Green Accepted, Green Published, Green Submitted, gold			2022-04-29	WOS:000611850700001
J	Zuo, L; Yan, WJ; Song, Z; Li, H; Xie, X; Gu, K; Ma, P; Tian, YM; Zhou, CY; Zhao, Y; Yang, X; Wang, HN				Zuo, Lei; Yan, Wenjun; Song, Zhou; Li, Hao; Xie, Xin; Gu, Kui; Ma, Peng; Tian, Yiming; Zhou, Changyu; Zhao, Yu; Yang, Xin; Wang, Hongning			Design and Characterization of a DNA Vaccine Based on Spike with Consensus Nucleotide Sequence against Infectious Bronchitis Virus	VACCINES			English	Article						infectious bronchitis virus; spike ectodomain; consensus nucleotide sequence; DNA vaccine; heterologous challenge		Avian coronavirus infectious bronchitis virus (IBV) causes severe economic losses in the poultry industry, but its control is hampered by the continuous emergence of new genotypes and the lack of cross-protection among different IBV genotypes. We designed a new immunogen based on a spike with the consensus nucleotide sequence (S_con) that may overcome the extraordinary genetic diversity of IBV. S_con was cloned into a pVAX1 vector to form a new IBV DNA vaccine, pV-S_con. pV-S_con could be correctly expressed in HD11 cells with corresponding post-translational modification, and induced a neutralizing antibody response to the Vero-cell-adapted IBV strain Beaudette (p65) in mice. To further evaluate its immunogenicity, specific-pathogen-free (SPF) chickens were immunized with the pV-S_con plasmid and compared with the control pVAX1 vector and the H120 vaccine. Detection of IBV-specific antibodies and cell cytokines (IL-4 and IFN-gamma) indicated that vaccination with pV-S_con efficiently induced both humoral and cellular immune responses. After challenge with the heterologous strain M41, virus shedding and virus loading in tissues was significantly reduced both by pV-S_con and its homologous vaccine H120. Thus, pV-S_con is a promising vaccine candidate for IBV, and the consensus approach is an appealing method for vaccine design in viruses with high variability.	[Zuo, Lei; Yan, Wenjun; Song, Zhou; Li, Hao; Xie, Xin; Gu, Kui; Ma, Peng; Tian, Yiming; Zhou, Changyu; Zhao, Yu; Yang, Xin; Wang, Hongning] Sichuan Univ, Coll Life Sci, Anim Dis Prevent & Food Safety Key Lab Sichuan Pr, Key Lab Bioresource & Ecoenvironm,Minist Educ, Chengdu 610064, Peoples R China		Wang, HN (通讯作者)，Sichuan Univ, Coll Life Sci, Anim Dis Prevent & Food Safety Key Lab Sichuan Pr, Key Lab Bioresource & Ecoenvironm,Minist Educ, Chengdu 610064, Peoples R China.	zuolei0104@foxmail.com; yanwenjunibv@163.com; bazhongsongzhou@163.com; lihaoibv@163.com; 2017141241124@stu.scu.edu.cn; gukui0404@stu.scu.edu.cn; MA_peng99@163.com; tymgood@126.com; l1z2l3y4@163.com; 2020322040035@stu.scu.edu.cn; yangxin0822@163.com; whongning@163.com		Zuo, Lei/0000-0002-8246-6319; Tian, yiming/0000-0002-0566-7010	National Key R&D program of China [2017YFD0500703]; China Agriculture Research System National System for Layer Production Technology [CARS-40K14]; Major Science and Technology Special Program of Sichuan Province [2018NZDZX0006]	This research was funded by the National Key R&D program of China (2017YFD0500703), the China Agriculture Research System National System for Layer Production Technology (CARS-40K14), and the Major Science and Technology Special Program of Sichuan Province (2018NZDZX0006).	Bagarazzi ML, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004414; Bande F, 2017, ANIM HEALTH RES REV, V18, P70, DOI 10.1017/S1466252317000044; Bande F, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/424860; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Belkasmi SFZ, 2017, AVIAN DIS, V61, P466, DOI [10.1637/11686-060817-Reg.1, 10.1637/11686-060817-reg.1]; CAVANAGH D, 1986, J GEN VIROL, V67, P1435, DOI 10.1099/0022-1317-67-7-1435; CAVANAGH D, 1988, VIRUS RES, V11, P141, DOI 10.1016/0168-1702(88)90039-1; Cavanagh D, 2007, VET RES, V38, P281, DOI 10.1051/vetres:2006055; Chen MW, 2008, P NATL ACAD SCI USA, V105, P13538, DOI 10.1073/pnas.0806901105; Chen YQ, 2017, VET MICROBIOL, V198, P108, DOI 10.1016/j.vetmic.2016.12.017; Cook JKA, 2012, AVIAN PATHOL, V41, P239, DOI 10.1080/03079457.2012.680432; de Wit JJ, 2014, AVIAN PATHOL, V43, P485, DOI 10.1080/03079457.2014.974504; Eldemery F, 2017, VACCINE, V35, P5864, DOI 10.1016/j.vaccine.2017.09.013; Ellis S, 2018, J VIROL, V92, DOI 10.1128/JVI.01473-18; Farsang A, 2002, AVIAN PATHOL, V31, P229, DOI 10.1080/03079450220136530; Guo SH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020282; Guy JS, 2015, METHODS MOL BIOL, V1282, P63, DOI 10.1007/978-1-4939-2438-7_7; Han XX, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080198; Han ZX, 2020, VET MICROBIOL, V240, DOI 10.1016/j.vetmic.2019.108513; Han ZX, 2017, VET MICROBIOL, V203, P125, DOI 10.1016/j.vetmic.2017.01.039; Jackwood MW, 2012, AVIAN DIS, V56, P634, DOI 10.1637/10227-043012-Review.1; Job ER, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0093-1; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Kint J, 2015, METHODS MOL BIOL, V1282, P89, DOI 10.1007/978-1-4939-2438-7_9; Ma TX, 2019, VET MICROBIOL, V230, P178, DOI 10.1016/j.vetmic.2019.01.020; Molenaar RJ, 2020, AVIAN PATHOL, V49, P243, DOI 10.1080/03079457.2020.1713987; Moore KM, 1997, ARCH VIROL, V142, P2249, DOI 10.1007/s007050050239; Muthumani K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7462; Okino CH, 2013, VIRAL IMMUNOL, V26, P259, DOI 10.1089/vim.2013.0015; Ping XQ, 2018, VACCINE, V36, P4837, DOI 10.1016/j.vaccine.2018.06.048; Santra S, 2008, P NATL ACAD SCI USA, V105, P10489, DOI 10.1073/pnas.0803352105; Sheng J, 2020, POULTRY SCI, V99, P5440, DOI 10.1016/j.psj.2020.08.037; Tan L, 2016, VACCINE, V34, P5209, DOI 10.1016/j.vaccine.2016.09.022; Valastro V, 2016, INFECT GENET EVOL, V39, P349, DOI 10.1016/j.meegid.2016.02.015; Vu HLX, 2015, J VIROL, V89, P12070, DOI 10.1128/JVI.01657-15; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Wickramasinghe INA, 2014, VIRUS RES, V194, P37, DOI 10.1016/j.virusres.2014.10.009; Winter C, 2008, J VIROL, V82, P2765, DOI 10.1128/JVI.02064-07; Wu X, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030254; Xie XC, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01630; Xu LW, 2018, INFECT GENET EVOL, V66, P82, DOI 10.1016/j.meegid.2018.09.018; Yan J, 2018, VACCINE, V36, P3079, DOI 10.1016/j.vaccine.2017.09.086; Zhang J, 2014, VACCINE, V32, P664, DOI 10.1016/j.vaccine.2013.12.006; Zhao R, 2017, VACCINE, V35, P2435, DOI 10.1016/j.vaccine.2017.03.045; Zhao Y, 2016, J GEN VIROL, V97, P1566, DOI 10.1099/jgv.0.000464	45	1	1	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							50	10.3390/vaccines9010050			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6XH	33466810	Green Published, gold			2022-04-29	WOS:000610814600001
J	Hein, S; Benz, NI; Eisert, J; Herrlein, ML; Oberle, D; Dreher, M; Stingl, JC; Hildt, C; Hildt, E				Hein, Sascha; Benz, Nuka Ivalu; Eisert, Jonathan; Herrlein, Marie-Luise; Oberle, Doris; Dreher, Michael; Stingl, Julia C.; Hildt, Christoph; Hildt, Eberhard			Comirnaty-Elicited and Convalescent Sera Recognize Different Spike Epitopes	VACCINES			English	Article						SARS-CoV-2 spike; linear epitopes; convalescent; peptide array; stabilized spike protein	SARS-COV-2	Many of the approved SARS-CoV-2 vaccines are based on a stabilized variant of the spike protein. This raises the question of whether the immune response against the stabilized spike is identical to the immune response that is elicited by the native spike in the case of a SARS-CoV-2 infection. Using a peptide array-based approach, we analysed the binding of antibodies from Comirnaty-elicited, convalescent, and control sera to the peptides covering the spike protein. A total of 37 linear epitopes were identified. A total of 26 of these epitopes were almost exclusively recognized by the convalescent sera. Mapping these epitopes to the spike structures revealed that most of these 26 epitopes are masked in the pre-fusion structure. In particular, in the conserved central helix, three epitopes that are only exposed in the post-fusion conformation were identified. This indicates a higher spike-specific antibody diversity in convalescent sera. These differences could be relevant for the breadth of spike-specific immune response.	[Hein, Sascha; Benz, Nuka Ivalu; Eisert, Jonathan; Herrlein, Marie-Luise; Hildt, Eberhard] Paul Ehrlich Inst, Dept Virol, Paul Ehrlich St 51-59, D-63225 Langen, Germany; [Oberle, Doris] Paul Ehrlich Inst, Div Pharmacovigilance, Paul Ehrlich St 51-59, D-63325 Langen, Germany; [Dreher, Michael] RWTH Aachen Univ Hosp Aachen, Dept Pneumol & Intens Care Med, Pauwelsstr 30, D-52074 Aachen, Germany; [Stingl, Julia C.] RWTH Aachen Univ Hosp Aachen, Inst Clin Pharmacol, Pauwelsstr 30, D-52074 Aachen, Germany; [Hildt, Christoph] Main Kinzig Kliniken, Herzbachweg 14, D-63571 Gelnhausen, Germany		Hein, S; Hildt, E (通讯作者)，Paul Ehrlich Inst, Dept Virol, Paul Ehrlich St 51-59, D-63225 Langen, Germany.	Sascha.Hein@pei.de; nuka.benz@pei.de; jonathan.eisert@pei.de; Marie-Luise.Herrlein@pei.de; doris.oberle@pei.de; mdreher@ukaachen.de; jstingl@ukaachen.de; Christoph.Hildt@mkkliniken.de; Eberhard.Hildt@pei.de	; Stingl, Julia/H-2410-2013	hildt, eberhard/0000-0002-3020-9564; Hein, Sascha/0000-0001-7257-4538; Stingl, Julia/0000-0002-1566-8156; Herrlein, Marie-Luise/0000-0003-2466-5114			Amanat F, 2020, NAT MED, V26, P1033, DOI [10.1038/s41591-020-0913-5, 10.1101/2020.03.17.20037713]; Becker M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-20973-3; Boson B, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.016175; Cerutti G, 2021, CELL HOST MICROBE, V29, P819, DOI 10.1016/j.chom.2021.03.005; Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742; Fan XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17371-6; Heinz FX, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00369-6; Hornich BF, 2021, J VIROL, V95, DOI 10.1128/JVI.00002-21; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Holenya P, 2021, EUR J IMMUNOL, V51, P1839, DOI 10.1002/eji.202049101; Hsieh YC, 2008, J BIOMED SCI, V15, P707, DOI 10.1007/s11373-008-9278-3; Kemp SA, 2021, NATURE, V592, P277, DOI 10.1038/s41586-021-03291-y; Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7; Kuhne Y, 2015, INT ARCH ALLERGY IMM, V166, P213, DOI 10.1159/000381344; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Li Y, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108915; Liu C, 2020, STRUCTURE, V28, P1218, DOI 10.1016/j.str.2020.10.001; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; Mishra N, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01743-9; Musico A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010035; Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Shrock E, 2020, SCIENCE, V370, P1058, DOI 10.1126/science.abd4250; Tolah AMK, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11060994; Tortorici MA, 2020, SCIENCE, V370, P950, DOI 10.1126/science.abe3354; Vogel A.B., 2020, BIORXIV, V370, P1022, DOI 10.1101/2020.09.08.280818; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang L, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84840-3; Zahn T, 2021, ALLERGY, DOI 10.1111/all.15138; Zhang YW, 2021, BMC MICROBIOL, V21, DOI 10.1186/s12866-021-02241-y	31	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1419	10.3390/vaccines9121419			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YE9HO	34960165	Green Published, gold			2022-04-29	WOS:000741429200001
J	Kennedy, EB; Daoust, JF; Vikse, J; Nelson, V				Kennedy, Eric B.; Daoust, Jean-Francois; Vikse, Jenna; Nelson, Vivian			"Until I Know It's Safe for Me": The Role of Timing in COVID-19 Vaccine Decision-Making and Vaccine Hesitancy	VACCINES			English	Article						vaccine; COVID-19; vaccine hesitancy; risk aversion; timing; public health	ENDORSEMENT; STRATEGIES; INTERPLAY	Managing the COVID-19 pandemic-and other communicable diseases-involves broad societal uptake of vaccines. As has been demonstrated, however, vaccine uptake is often uneven and incomplete across populations. This is a substantial challenge that must be addressed by public health efforts. To this point, significant research has focused on demographic and attitudinal correlates with vaccine hesitancy to understand uptake patterns. In this study, however, we advance understandings of individual decision-making processes involved in vaccine uptake through a mixed-methods investigation of the role of timing in COVID-19 vaccine choices. In the first step, a survey experiment, we find the timing of vaccine rollout (i.e., when a vaccine becomes available to the respondent) has a significant impact on public decision-making. Not only is there a higher level of acceptance when the vaccine becomes available at a later time, but delayed availability is correlated with both lower levels of 'desire to wait' and 'total rejection' of the vaccine. In a second step, we explore associated qualitative data, finding that temporal expressions (i.e., professing a desire to wait) can serve as a proxy for underlying non-temporal rationales, like concerns around safety, efficacy, personal situations, or altruism. By identifying these patterns, as well as the complexities of underlying factors, through a mixed-methods investigation, we can inform better vaccine-related policy and public messaging, as well as enhance our understanding of how individuals make decisions about vaccines in the context of COVID-19.	[Kennedy, Eric B.] York Univ, Sch Adm Studies, Disaster & Emergency Management, Toronto, ON M3J 1P3, Canada; [Daoust, Jean-Francois] Univ Edinburgh, Sch Social & Polit Sci, Polit & Int Relat, Edinburgh EH8 9YL, Midlothian, Scotland; [Vikse, Jenna; Nelson, Vivian] Univ Guelph, Dept Psychol, Publ Lab, Discourse,Sci, Guelph, ON N1G 2W1, Canada		Kennedy, EB (通讯作者)，York Univ, Sch Adm Studies, Disaster & Emergency Management, Toronto, ON M3J 1P3, Canada.	ebk@yorku.ca; jf.daoust@ed.ac.uk; jvikse@uoguelph.ca; nelsonv@uoguelph.ca		Kennedy, Eric B./0000-0003-0056-1521; Daoust, Jean-Francois/0000-0002-2736-7430	Social Sciences and Humanities Research CouncilSocial Sciences and Humanities Research Council of Canada (SSHRC) [1006-2019-0001]	FundingThis project is supported in part by funding from the Social Sciences and Humanities Research Council (1006-2019-0001).	[Anonymous], ANGUS REID COVID 19; Bartsch SM, 2021, J INFECT DIS, V224, P938, DOI 10.1093/infdis/jiab233; Berry SD, 2021, J AM GERIATR SOC, V69, P1140, DOI 10.1111/jgs.17136; Boerner F, 2013, HUM VACC IMMUNOTHER, V9, P1477, DOI 10.4161/hv.24427; Bokemper SE, 2021, VACCINE, V39, P825, DOI 10.1016/j.vaccine.2020.12.048; Butcher P, 2021, NAT ELECTRON, V4, P7, DOI 10.1038/s41928-020-00532-2; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; Callaghan T, 2019, SOC SCI MED, V238, DOI 10.1016/j.socscimed.2019.112407; Cascio MA, 2019, FIELD METHOD, V31, P116, DOI 10.1177/1525822X19838237; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Daoust JF, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249914; Daoust JF, 2021, J EXP POLIT SCI, V8, P310, DOI 10.1017/XPS.2020.25; Darko J, 2021, BRIT J GEN PRACT, V71, P170, DOI [10.3399/bjgp21X715433, 10.3399/bjgp21X15433]; Demuyakor J, 2021, ONLINE J COMMUN MEDI, V11, DOI 10.30935/ojcmt/11200; Dib F, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2021.1874218; Dube E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156118; Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041; Emerging Science Group of the Public Health Agency of Canada, 2021, CAN COMMUN DIS REP, V47, P92; Fridman A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250123; Galle F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060638; Goldenberg M.J., 2021, VACCINE HESITANCY PU; Goldenberg Maya J., 2016, Perspectives on Science, V24, P552, DOI 10.1162/POSC_a_00223; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Jean-Jacques M, 2021, JAMA-J AM MED ASSOC, V325, P829, DOI 10.1001/jama.2021.1205; Jennings W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060593; Jin Q, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070757; Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061; Karlsson LC, 2021, PERS INDIV DIFFER, V172, DOI 10.1016/j.paid.2020.110590; Kazemian S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0254127; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Larsen M., 2020, J BEHAV PUBLIC ADM, V3, P1, DOI [10.30636/jbpa.32.164, DOI 10.31234/OSF.IO/CY4HK]; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Latkin C, 2021, VACCINE, V39, P2237, DOI 10.1016/j.vaccine.2021.02.058; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Lynch M, 2017, SOC STUD SCI, V47, P593, DOI 10.1177/0306312717720308; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; MacGregor-Fors I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056794; Madraki G, 2021, WEB CONFERENCE 2021: COMPANION OF THE WORLD WIDE WEB CONFERENCE (WWW 2021), P213, DOI 10.1145/3442442.3452304; Momplaisir F, 2021, CLIN INFECT DIS, V73, P1784, DOI 10.1093/cid/ciab102; Motta M., 2021, FRONTIERS POLITICAL, V3, P1, DOI [DOI 10.3389/FPOS.2021.630133, 10.3389/fpos.2021.630133]; Motta M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113642; Motta M, 2018, SOC SCI MED, V211, P274, DOI 10.1016/j.socscimed.2018.06.032; Mutz DC, 2019, AM STAT, V73, P32, DOI 10.1080/00031305.2017.1322143; Nan XL, 2012, HEALTH COMMUN, V27, P559, DOI 10.1080/10410236.2011.617243; Nelson V, 2021, THESIS U GUELPH GUEL; Ogilvie GS, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11098-9; Ohmura H., 2021, MEDRXIV, DOI [10.1101/2021.06.13.21258654, DOI 10.1101/2021.06.13.21258654]; Palm R., 2021, EFFECT FRAMES COVID, V3, P661257, DOI [10.3389/fpos.2021.661257, DOI 10.1101/2021.01.04.21249241]; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Razai MS, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n513; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013; Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Sheeran P, 2014, PSYCHOL BULL, V140, P511, DOI 10.1037/a0033065; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Smith J, 2011, LANCET, V378, P428, DOI 10.1016/S0140-6736(11)60478-9; Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Sweileh WM, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09368-z; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; Zintel S., GENDER DIFFERENCES I	66	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1417	10.3390/vaccines9121417			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XY8UI	34960162	Green Published, gold			2022-04-29	WOS:000737240100001
J	Penner, RC				Penner, Robert Clark			Mutagenic Distinction between the Receptor-Binding and Fusion Subunits of the SARS-CoV-2 Spike Glycoprotein and Its Upshot	VACCINES			English	Article						SARS-CoV-2 spike; mutagenic pressure; backbone free energy; vaccinology		We observe that a residue R of the spike glycoprotein of SARS-CoV-2 that has mutated in one or more of the current variants of concern or interest, or under monitoring, rarely participates in a backbone hydrogen bond if R lies in the S-1 subunit and usually participates in one if R lies in the S2 subunit. A partial explanation for this based upon free energy is explored as a potentially general principle in the mutagenesis of viral glycoproteins. This observation could help target future vaccine cargos for the evolving coronavirus as well as more generally. A related study of the Delta and Omicron variants suggests that Delta was an energetically necessary intermediary in the evolution from Wuhan-Hu-1 to Omicron.	[Penner, Robert Clark] Inst Hautes Etud Sci, 35 Route Chartres, F-91440 Bures Sur Yvette, France; [Penner, Robert Clark] Univ Calif Los Angeles, Dept Math, Los Angeles, CA 90095 USA		Penner, RC (通讯作者)，Inst Hautes Etud Sci, 35 Route Chartres, F-91440 Bures Sur Yvette, France.; Penner, RC (通讯作者)，Univ Calif Los Angeles, Dept Math, Los Angeles, CA 90095 USA.	rpenner@ihes.fr					Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bollavaram K, 2021, PROTEIN SCI, V30, P1131, DOI 10.1002/pro.4073; Carugo O, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2083-8; Dimmock N. J., 2007, INTRO MODERN VIROLOG; Finkelstein A V, 1995, Subcell Biochem, V24, P1; Finkelstein A.V., 2016, PROTEIN PHYS COURSE; FINKELSTEIN AV, 1995, PROTEINS, V23, P142, DOI 10.1002/prot.340230204; Gobeil SMC, 2021, SCIENCE, V373, P641, DOI [10.1126/science.abi6226, 10.1101/2021.03.11.435037]; Gobeil SMC, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108630; Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456; Henderson R, 2020, NAT STRUCT MOL BIOL, V27, P925, DOI 10.1038/s41594-020-0479-4; Juraszek J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20321-x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; McCallum M, 2020, NAT STRUCT MOL BIOL, V27, P942, DOI 10.1038/s41594-020-0483-8; Penner R ., 2021, COMPUT MATH BIOPHYS, V9, P81, DOI [10.1515/cmb-2020-0119, DOI 10.1515/CMB-2020-0119]; Penner RC, 2020, J COMPUT BIOL, V27, P1622, DOI 10.1089/cmb.2020.0193; Penner RC, 2020, J COMPUT BIOL, V27, P1495, DOI 10.1089/cmb.2020.0120; Penner RC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6803; POHL FM, 1971, NATURE-NEW BIOL, V234, P277, DOI 10.1038/newbio234277a0; Toelzer C, 2020, SCIENCE, V370, P725, DOI 10.1126/science.abd3255; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; White JM, 2008, CRIT REV BIOCHEM MOL, V43, P189, DOI [10.1080/10409230802058320, 10.1080/10409230802058320 ]; Wrobel AG, 2020, NAT STRUCT MOL BIOL, V27, P763, DOI 10.1038/s41594-020-0468-7; Xu C, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe5575; Yan RH, 2021, CELL RES, V31, P717, DOI 10.1038/s41422-021-00490-0; Zhang C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20465-w; Zhou Tongqing, 2020, bioRxiv, DOI 10.1101/2020.07.04.187989	28	2	2	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1509	10.3390/vaccines9121509			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YB3PN	34960255	gold, Green Published			2022-04-29	WOS:000738928700001
J	Girbardt, C; Busch, C; Al-Sheikh, M; Gunzinger, JM; Invernizzi, A; Xhepa, A; Unterlauft, JD; Rehak, M				Girbardt, Christian; Busch, Catharina; Al-Sheikh, Mayss; Gunzinger, Jeanne Martine; Invernizzi, Alessandro; Xhepa, Alba; Unterlauft, Jan Darius; Rehak, Matus			Retinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines-A Case Series	VACCINES			English	Article						post-vaccination; COVID-19 vaccination; vascular complication; retinal vascular complication	OCCLUSION; VEIN	Background: To describe cases of retinal vascular events shortly after administration of mRNA or adenoviral-vectored COVID-19 vaccines. Design: Retrospective, multicenter case series. Methods: Six cases of retinal vascular events shortly after receiving COVID-19 vaccines. Results: A 38-year-old, otherwise healthy male patient presented with branch retinal arterial occlusion four days after receiving his second dose of SARS-CoV-2 vaccination with Comirnaty(R) (BioNTech(R), Mainz, Germany; Pfizer(R), New York City, NY, USA). An 81-year-old female patient developed visual symptoms twelve days after the second dose of SARS-CoV-2 vaccination with Comirnaty(R) and was diagnosed with a combined arterial and venous occlusion in her right eye. A 40-year-old male patient noticed blurry vision five days after his first dose of SARS-CoV-2 vaccination with Comirnaty(R) and was diagnosed with venous stasis retinopathy in his left eye. A 67-year-old male was diagnosed with non-arteritic anterior ischemic optic neuropathy in his right eye four days after receiving the first dose of Vaxzevria(R) (AstraZeneca(R), Cambridge, UK). A 32-year-old man presented with a sudden onset of a scotoma two days after receiving the second dose of SARS-CoV-2 vaccination with Spikevax(R) (Moderna, Cambridge, UK) and was diagnosed with a circumscribed nerve fiber infarction. A 21-year-old female patient developed an acute bilateral acute macular neuroretinopathy three days after receiving the first dose of SARS-CoV2-vaccine Vaxzevria(R) (AstraZeneca(R), Cambridge, UK). Conclusion: This case series describes six cases of retinal vascular events shortly after receiving mRNA or adenoviral-vectored COVID-19 vaccines. The short time span between received vaccination and occurrence of the observed retinal vascular events raises the question of a direct correlation. Our case series adds to further reports of possible side effects with potential serious post-immunization complications of COVID-19 vaccinations.	[Girbardt, Christian; Busch, Catharina; Unterlauft, Jan Darius; Rehak, Matus] Univ Hosp Leipzig, Dept Ophthalmol, Med Ctr, D-04103 Leipzig, Germany; [Al-Sheikh, Mayss; Gunzinger, Jeanne Martine] Univ Hosp Zurich, Dept Ophthalmol, CH-8091 Zurich, Switzerland; [Invernizzi, Alessandro; Xhepa, Alba] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, I-20157 Milan, Italy; [Invernizzi, Alessandro] Univ Sydney, Save Sight Inst Discipline Ophthalmol, Sydney Med Sch, Sydney, NSW 2000, Australia; [Unterlauft, Jan Darius] Univ Hosp Bern, Dept Ophthalmol, Inselspital, CH-3010 Bern, Switzerland		Busch, C (通讯作者)，Univ Hosp Leipzig, Dept Ophthalmol, Med Ctr, D-04103 Leipzig, Germany.	christian.girbardt@medizin.uni-leipzig.de; busch.catharina@gmail.com; mayss.alsheikh@gmail.com; Jeanne.gunzinger@usz.ch; alessandro.invernizzi@gmail.com; xhepaalba@yahoo.com; J.D.Unterlauft@gmx.de; matus.rehak@medizin.uni-leipzig.de		Girbardt, Christian/0000-0002-7843-9617			Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Alderson Jennifer, 2021, Oxf Open Immunol, V2, piqab010, DOI 10.1093/oxfimm/iqab010; Bhavsar KV, 2016, SURV OPHTHALMOL, V61, P538, DOI 10.1016/j.survophthal.2016.03.003; Bohler AD, 2022, EYE, V36, P644, DOI 10.1038/s41433-021-01610-1; Cai CJ, 2021, MOL THER, V29, P2794, DOI 10.1016/j.ymthe.2021.08.001; Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000; Devin F, 1996, LANCET, V347, P1626, DOI 10.1016/S0140-6736(96)91112-5; Diener HC, 2018, NERVENARZT, V89, P1143, DOI 10.1007/s00115-018-0609-y; Fallico M, 2020, EYE, V34, P683, DOI 10.1038/s41433-019-0576-y; Kido A, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-041104; Klein NP, 2021, JAMA-J AM MED ASSOC, V326, P1390, DOI 10.1001/jama.2021.15072; Kolar P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/724780; Konstantinides SV, 2021, EUR RESPIR J, V58, DOI 10.1183/13993003.01111-2021; Laouri M, 2011, EYE, V25, P981, DOI 10.1038/eye.2011.92; Le Ng X, 2021, OCUL IMMUNOL INFLAMM, V29, P1216, DOI 10.1080/09273948.2021.1976221; Leavitt JA, 2011, AM J OPHTHALMOL, V152, P820, DOI 10.1016/j.ajo.2011.05.005; Liu Jeffrey C, 2018, Am J Ophthalmol Case Rep, V10, P96, DOI 10.1016/j.ajoc.2018.02.008; Sharma S, 1997, CAN J OPHTHALMOL, V32, P38; Smadja DM, 2021, EUR RESPIR J, V58, DOI 10.1183/13993003.00956-2021; Williams Gwyn Samuel, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-211971	20	3	3	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1349	10.3390/vaccines9111349			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK4OL	34835280	gold, Green Published			2022-04-29	WOS:000727447000001
J	Guenther, A; Braemer, D; Pletz, MW; Kamradt, T; Baumgart, S; Mayer, TE; Baier, M; Autsch, A; Mawrin, C; Schoenborn, L; Greinacher, A; Thiele, T				Guenther, Albrecht; Braemer, Dirk; Pletz, Mathias W.; Kamradt, Thomas; Baumgart, Sabine; Mayer, Thomas E.; Baier, Michael; Autsch, Angelina; Mawrin, Christian; Schoenborn, Linda; Greinacher, Andreas; Thiele, Thomas			Complicated Long Term Vaccine Induced Thrombotic Immune Thrombocytopenia-A Case Report	VACCINES			English	Article						vaccine; COVID-19; thrombocytopenia; cerebral thrombosis; autoimmune; case report	ANTIBODIES	Background and Objectives: Vaccine induced thrombotic thrombocytopenia (VITT) may occur after COVID-19 vaccination with recombinant adenoviral vector-based vaccines. VITT can present as cerebral sinus and venous thrombosis (CSVT), often complicated by intracranial hemorrhage. Today it is unclear, how long symptomatic VITT can persist. Here, we report the complicated long-term course of a VITT patient with extremely high titers of pathogenic anti-platelet factor 4 (PF4)-IgG antibodies. Methods: Clinical and laboratory findings are presented, including the course of platelet counts, D-Dimer levels, clinical presentation, imaging, SARS-CoV-2-serological and immunological, platelet activating anti-PF4-IgG, as well as autopsy findings. Results: The patient presented with extended superior sagittal sinus thrombosis with accompanying bifrontal intracerebral hemorrhage. Repeated treatment with intravenous immune globuline (IVIG) resolved recurrent episodes of thrombocytopenia. Moreover, the patient's serum remained strongly positive for platelet-activating anti-PF4-IgG over three months. After a period of clinical stabilization, the patient suffered a recurrent and fatal intracranial hemorrhage. Conclusions: Complicated VITT with extremely high anti-PF4-IgG titers over three months can induce recurrent thrombocytopenia despite treatment with IVIG and anticoagulation. Plasma exchange, immunoadsorption, and /or immunosuppressive treatment may be considered in complicated VITT to reduce extraordinarily high levels of anti-PF4-IgG. Long-term therapy in such cases must take the individual bleeding risk and CSVT risk into account.	[Guenther, Albrecht; Braemer, Dirk] Jena Univ Hosp, Hans Berger Dept Neurol, D-07743 Jena, Germany; [Pletz, Mathias W.] Jena Univ Hosp, Inst Infect Dis & Infect Control, D-07743 Jena, Germany; [Kamradt, Thomas; Baumgart, Sabine] Jena Univ Hosp, Inst Immunol, Core Facil Cytometry, D-07743 Jena, Germany; [Mayer, Thomas E.] Jena Univ Hosp, Dept Neuroradiol, D-07743 Jena, Germany; [Baier, Michael] Jena Univ Hosp, Inst Med Microbiol, D-07743 Jena, Germany; [Autsch, Angelina; Mawrin, Christian] Jena Univ Hosp, Forens Med Dept, D-07743 Jena, Germany; [Mawrin, Christian] Univ Hosp Magdeburg, Dept Neuropathol, D-39120 Magdeburg, Germany; [Schoenborn, Linda; Greinacher, Andreas; Thiele, Thomas] Univ Med Greifswald, Inst Immunol & Transfus Med, Dept Transfus Med, D-17487 Greifswald, Germany		Guenther, A (通讯作者)，Jena Univ Hosp, Hans Berger Dept Neurol, D-07743 Jena, Germany.	albrecht.guenther@med.uni-jena.de; dirk.braemer@med.uni-jena.de; Mathias.pletz@med.uni-jena.de; thomas.kamradt@med.uni-jena.de; sabine.baumgart@med.uni-jena.de; t.e.mayer@med.uni-jena.de; michael.baier@med.uni-jena.de; angelina.autsch@med.uni-jena.de; christian.mawrin@med.ovgu.de; linda.schoenborn@med.uni-greifswald.de; andreas.greinacher@med.uni-greifswald.de; thomas.thiele@med.uni-greifswald.de		Baier, Michael/0000-0002-3625-1544; Pletz, Mathias/0000-0001-8157-2753			Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Chen R.T., UPDATED PROPOSED BRI; Dugas M, 2021, INT J INFECT DIS, V105, DOI 10.1016/j.ijid.2021.02.085; Greinacher A, 2017, J THROMB HAEMOST, V15, P2099, DOI 10.1111/jth.13813; Greinacher A, 2021, BLOOD, V138, P2256, DOI 10.1182/blood.2021013231; Greinacher Andreas, 2021, Blood, V138, P1269, DOI 10.1182/blood.2021012938; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Handtke S, 2021, BLOOD, V137, P3656, DOI 10.1182/blood.2021012064; Juhl D, 2006, EUR J HAEMATOL, V76, P420, DOI 10.1111/j.1600-0609.2005.00621.x; Kowoll CM, 2016, NEUROCRIT CARE, V25, P392, DOI 10.1007/s12028-016-0256-8; Kreimann M, 2014, BLOOD, V124, P2442, DOI 10.1182/blood-2014-03-559518; Muir KL, 2021, NEW ENGL J MED, V384, P1964, DOI 10.1056/NEJMc2105869; Oldenburg J, 2021, HAMOSTASEOLOGIE, V41, P184, DOI 10.1055/a-1469-7481; Passariello M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168562; Patriquin CJ, 2021, NEW ENGL J MED, V385, P857, DOI 10.1056/NEJMc2109465; Pavord S, 2021, NEW ENGL J MED, V385, P1680, DOI 10.1056/NEJMoa2109908; Perry RJ, 2021, LANCET, V398, P1147, DOI 10.1016/S0140-6736(21)01608-1; Salih F, 2021, NEW ENGL J MED, V385, P2103, DOI 10.1056/NEJMc2112974; Schonborn L, 2021, NEW ENGL J MED, V385, P1815, DOI 10.1056/NEJMc2112760; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; Stoesser N, 2020, LANCET INFECT DIS, V20, P1390, DOI 10.1016/S1473-3099(20)30634-4; Tan BEX, 2020, AM J MED, V133, pE375, DOI 10.1016/j.amjmed.2019.11.027; van Kammen MS, 2021, JAMA NEUROL, V78, P1314, DOI 10.1001/jamaneurol.2021.3619; Wanke-Jellinek L, 2016, J LEUKOCYTE BIOL, V99, P483, DOI 10.1189/jlb.4A0315-115RR; Yamaguchi T, 2021, INT J INFECT DIS, V109, P261, DOI 10.1016/j.ijid.2021.07.015	26	4	4	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1344	10.3390/vaccines9111344			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF5TU	34835275	gold, Green Published			2022-04-29	WOS:000724133700001
J	Hsu, L; Gruene, B; Buess, M; Joisten, C; Klobucnik, J; Niessen, J; Patten, D; Wolff, A; Wiesmueller, GA; Kossow, A; Hurrass, J				Hsu, Lea; Gruene, Barbara; Buess, Michael; Joisten, Christine; Klobucnik, Jan; Niessen, Johannes; Patten, David; Wolff, Anna; Wiesmueller, Gerhard A.; Kossow, Annelene; Hurrass, Julia			COVID-19 Breakthrough Infections and Transmission Risk: Real-World Data Analyses from Germany's Largest Public Health Department (Cologne)	VACCINES			English	Article						COVID-19; vaccination; breakthrough infections; SARS-CoV-2 pandemic; SARS-CoV-2 transmission	VACCINE	Background and Methods: Vaccination is currently considered the most successful strategy for combating the SARS-CoV-2 virus. According to short-term clinical trials, protection against infection is estimated to reach up to 95% after complete vaccination (& GE;14 days after receipt of all recommended COVID-19 vaccine doses). Nevertheless, infections despite vaccination, so-called breakthrough infections, are documented. Even though they are more likely to have a milder or even asymptomatic course, the assessment of further transmission is highly relevant for successful containment. Therefore, we calculated the real-world transmission risk from fully vaccinated patients (vaccination group, VG) to their close contacts (CP) compared with the risk from unvaccinated reference persons matched according to age, sex, and virus type (control group = CG) utilizing data from Cologne's health department. Results: A total of 357 breakthrough infections occurred among Cologne residents between 27 December 2020 (the date of the first vaccination in Cologne) and 6 August 2021. Of the 979 CPs in VG, 99 (10.1%) became infected. In CG, 303 of 802 CPs (37.8%) became infected. Factors promoting transmission included non-vaccinated status (beta = 0.237; p < 0.001), male sex (beta = 0.079; p = 0.049), the presence of symptoms (beta = -0.125; p = 0.005), and lower cycle threshold value (beta = -0.125; p = 0.032). This model explained 14.0% of the variance (corr. R-2). Conclusion: The number of transmissions from unvaccinated controls was three times higher than from fully vaccinated patients. These real-world data underscore the importance of vaccination in enabling the relaxation of stringent and restrictive general pandemic control measures.	[Hsu, Lea; Gruene, Barbara; Buess, Michael; Joisten, Christine; Klobucnik, Jan; Niessen, Johannes; Patten, David; Wolff, Anna; Wiesmueller, Gerhard A.; Kossow, Annelene; Hurrass, Julia] Publ Hlth Dept Cologne, Infekt & Umwelthyg, D-50667 Cologne, Germany; [Hsu, Lea; Wiesmueller, Gerhard A.] Rhein Westfal TH Aachen, Univ Hosp, Inst Occupat Med & Social Med, Med Fac, D-52056 Aachen, Germany; [Joisten, Christine] German Sport Univ Cologne, Inst Movement & Neurosci, Dept Phys Act Publ Hlth, Sportpk Mungersdorf 6, D-50933 Cologne, Germany; [Kossow, Annelene] Univ Hosp Muenster, Inst Hyg, D-48149 Munster, Germany		Hsu, L (通讯作者)，Publ Hlth Dept Cologne, Infekt & Umwelthyg, D-50667 Cologne, Germany.; Hsu, L (通讯作者)，Rhein Westfal TH Aachen, Univ Hosp, Inst Occupat Med & Social Med, Med Fac, D-52056 Aachen, Germany.	Lea.hsu@stadt-koeln.de; barbara.gruene@stadt-koeln.de; michael.buess@stadt-koeln.de; c.joisten@dshs-koeln.de; jan.klobucnik@dozent.ism.de; johannes.niessen@stadt-koeln.de; wilfried.patten@stadt-koeln.de; anna.wolff@stadt-koeln.de; gerharda.wiesmueller@stadt-koeln.de; annelene.kossow@stadt-koeln.de; julia.hurrass@stadt-koeln.de		Kossow, Annelene/0000-0002-4648-4851			Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Braeye T, 2021, VACCINE, V39, P5456, DOI 10.1016/j.vaccine.2021.08.060; Brown CM, 2021, MMWR-MORBID MORTAL W, V70, P1059, DOI 10.15585/mmwr.mm7031e2; Chia Po Ying, 2022, Clin Microbiol Infect, V28, DOI 10.1016/j.cmi.2021.11.010; Curran J., 2021, PUBLIC HLTH HLTH SYS, DOI [10.1101/2021.05.20.21257517, DOI 10.1101/2021.05.20.21257517]; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; ElBagoury M, 2021, J INFECT PUBLIC HEAL, V14, P389, DOI 10.1016/j.jiph.2020.12.025; European Centre for Disease Prevention and Control (ECDC), GUID DISCH END IS PE; Favresse J, 2021, EMERG MICROBES INFEC, V10, P1495, DOI 10.1080/22221751.2021.1953403; Grothmann, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab381, DOI 10.1093/CID/CIAB381]; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Harris RJ, 2021, NEW ENGL J MED, V385, P759, DOI 10.1056/NEJMc2107717; Hsu L., 2021, IN PRESS; Ioannou P, 2021, INFECT DIS-NOR, V53, P876, DOI 10.1080/23744235.2021.1945139; Levine-Tiefenbrun M, 2021, NAT MED, V27, P790, DOI 10.1038/s41591-021-01316-7; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Michalakis Y, 2021, TRENDS MICROBIOL, V29, P970, DOI 10.1016/j.tim.2021.08.008; Neuhann F., 2020, EPID B, V23, P3, DOI [DOI 10.25646/6923, 10.25646/6923]; Purver M., 2021, MEDRXIV, DOI [10.1101/2021.09.28.21264260, DOI 10.1101/2021.09.28.21264260]; Riemersma K.K., 2021, SHEDDING INFECT SARS, DOI [10.1101/2021.07.31.21261387, DOI 10.1101/2021.07.31.21261387]; Robert Koch Institut, WOCH LAG RKI COR KRA; Robert-Koch-Institut, KONT NACHV BEI SARS; Robert-Koch-Institut, ANZ ANT VOC VOI DEUT; Robert-Koch-Institut, WOC LAG RKI COR KRAN; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070781; Singanayagam A, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.32.2001483; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242	27	4	4	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1267	10.3390/vaccines9111267			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XE8DE	34835198	gold, Green Published			2022-04-29	WOS:000723611800001
J	Komine-Aizawa, S; Mizuno, S; Matsuo, K; Namiki, T; Hayakawa, S; Honda, M				Komine-Aizawa, Shihoko; Mizuno, Satoru; Matsuo, Kazuhiro; Namiki, Takahiro; Hayakawa, Satoshi; Honda, Mitsuo			Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against Mycobacterium kansasii	VACCINES			English	Article						Mycobacterium kansasii; CD8(+) T Cells; CD4(+) T Cells; recombinant BCG	HUMAN-IMMUNODEFICIENCY-VIRUS; BACILLUS-CALMETTE-GUERIN; IMMUNE-RESPONSES; NONTUBERCULOUS MYCOBACTERIA; T-CELLS; TUBERCULOSIS; DISEASE; AVIUM; VACCINATION; COMPLEX	The incidence of infections with nontuberculous mycobacteria (NTM) has been increasing worldwide. The emergence of multidrug-resistant NTM is a serious clinical concern, and a vaccine for NTM has not yet been developed. We previously developed a new recombinant Bacillus Calmette-Guerin (rBCG) vaccine encoding the antigen 85B (Ag85B) protein of Mycobacterium kansasii-termed rBCG-Mkan85B-which was used together with a booster immunization with plasmid DNA expressing the same M. kansasii Ag85B gene (DNA-Mkan85B). We reported that rBCG-Mkan85B/DNA-Mkan85B prime-boost immunization elicited various NTM strain-specific CD4(+) and CD8(+) T cells and induced Mycobacterium tuberculosis-specific immunity. In this study, to investigate the protective effect against M. kansasii infection, we challenged mice vaccinated with a rBCG-Mkan85B or rBCG-Mkan85B/DNA-Mkan85B prime-boost strategy with virulent M. kansasii. Although BCG and rBCG-Mkan85B immunization each suppressed the growth of M. kansasii in the mouse lungs, the rBCG-Mkan85B/DNA-Mkan85B prime-boost vaccination reduced the bacterial burden more significantly. Moreover, the rBCG-Mkan85B/DNA-Mkan85B prime-boost vaccination induced antigen-specific CD4(+) and CD8(+) T cells. Our data suggest that rBCG-Mkan85B/DNA-Mkan85B prime-boost vaccination effectively enhances antigen-specific T cells. Our novel rBCG could be a potential alternative to clinical BCG for preventing various NTM infections.	[Komine-Aizawa, Shihoko; Hayakawa, Satoshi; Honda, Mitsuo] Nihon Univ, Sch Med, Dept Pathol & Microbiol, Div Microbiol, Tokyo 1738610, Japan; [Mizuno, Satoru; Matsuo, Kazuhiro] Japan BCG Lab, Tokyo 2040022, Japan; [Namiki, Takahiro] Nihon Univ, Sch Med, Tokyo 1738610, Japan		Komine-Aizawa, S; Honda, M (通讯作者)，Nihon Univ, Sch Med, Dept Pathol & Microbiol, Div Microbiol, Tokyo 1738610, Japan.	aizawa.shihoko@nihon-u.ac.jp; s-mizuno@bcg.gr.jp; matsuo@bcg.gr.jp; meta16076@g.nihon-u.ac.jp; hayakawa.satoshi@nihon-u.ac.jp; mitsuo77777@gmail.com		xiang ze, zhi bao zi/0000-0001-9417-0315; Namiki, Takahiro/0000-0003-0356-1877	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)	This research was funded by the JSPS KAKENHI, grant number 19K08939 to S.K.-A.	Abate G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00234; Ami Y, 2005, J VIROL, V79, P12871, DOI 10.1128/JVI.79.20.12871-12879.2005; Bermudez LE, 1999, INFECT IMMUN, V67, P3108, DOI 10.1128/IAI.67.6.3108-3111.1999; Brode SK, 2014, INT J TUBERC LUNG D, V18, P1370, DOI 10.5588/ijtld.14.0120; Chapman R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103314; Chen CY, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000392; de Mello KGC, 2013, EMERG INFECT DIS, V19, P393, DOI [10.3201/eid1903.120735, http://dx.doi.org/10.3201/eid/1903.120735]; Gilbertson B, 2004, INFECT IMMUN, V72, P6884, DOI 10.1128/IAI.72.12.6884-6891.2004; Griffith DE, 2007, AM J RESP CRIT CARE, V175, P367, DOI 10.1164/rccm.200604-571ST; HONDA M, 1995, P NATL ACAD SCI USA, V92, P10693, DOI 10.1073/pnas.92.23.10693; Honda M, 2009, J IMMUNOL, V183, P2425, DOI 10.4049/jimmunol.0900581; Horsburgh CR, 1996, J INFECT DIS, V174, P1212, DOI 10.1093/infdis/174.6.1212; Kanekiyo M, 2005, J VIROL, V79, P8716, DOI 10.1128/JVI.79.14.8716-8723.2005; Kariyone A, 2003, INT IMMUNOL, V15, P1183, DOI 10.1093/intimm/dxg115; Kasperbauer SH, 2015, CLIN CHEST MED, V36, P67, DOI 10.1016/j.ccm.2014.10.004; KATILA ML, 1987, TUBERCLE, V68, P291, DOI 10.1016/0041-3879(87)90070-5; Kilpelainen A, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030078; Komine-Aizawa S, 2019, EUR J IMMUNOL, V49, P1399, DOI 10.1002/eji.201847988; Kwon BE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02542; LAUNOIS P, 1994, INFECT IMMUN, V62, P3679, DOI 10.1128/IAI.62.9.3679-3687.1994; Launois P, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/640309; Lee YM, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57070720; Maekura R, 2005, J CLIN MICROBIOL, V43, P3150, DOI 10.1128/JCM.43.7.3150-3158.2005; Mazzaccaro RJ, 1996, P NATL ACAD SCI USA, V93, P11786, DOI 10.1073/pnas.93.21.11786; Namkoong H, 2016, EMERG INFECT DIS, V22, P1116, DOI 10.3201/eid2206.151086; Ottenhoff THM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002607; Prevots DR, 2015, CLIN CHEST MED, V36, P13, DOI 10.1016/j.ccm.2014.10.002; ROMANUS V, 1995, TUBERCLE LUNG DIS, V76, P300, DOI 10.1016/S0962-8479(05)80028-0; Ryan AA, 2009, J IMMUNOL, V182, P7172, DOI 10.4049/jimmunol.0801694; Silwal P, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.728742; Someya K, 2006, J IMMUNOL, V176, P1784, DOI 10.4049/jimmunol.176.3.1784; Stabel JR, 2013, CLIN VACCINE IMMUNOL, V20, P848, DOI 10.1128/CVI.00051-13; TRNKA L, 1994, TUBERCLE LUNG DIS, V75, P348, DOI 10.1016/0962-8479(94)90080-9; WIKER HG, 1992, MICROBIOL REV, V56, P648, DOI 10.1128/MMBR.56.4.648-661.1992; Winthrop K, 2016, AM J RESP CELL MOL, V54, P170, DOI 10.1165/rcmb.2015-0256RC; Woodworth JSM, 2006, CRIT REV IMMUNOL, V26, P317, DOI 10.1615/CritRevImmunol.v26.i4.30; Zimmermann P, 2018, J INFECT DIS, V218, P679, DOI 10.1093/infdis/jiy207	37	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1260	10.3390/vaccines9111260			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH1TK	34835191	Green Published, gold			2022-04-29	WOS:000725224300001
J	Mirpuri, P; Rovin, RA				Mirpuri, Pranav; Rovin, Richard A.			COVID-19 and Historic Influenza Vaccinations in the United States: A Comparative Analysis	VACCINES			English	Article						COVID-19 vaccination; vaccine hesitancy; SARS-CoV-2; coronavirus; demographic factors; socioeconomic status; political preference; race	ADULTS	The COVID-19 vaccination effort is a monumental global challenge. Recognizing and addressing the causes of vaccine hesitancy will improve vaccine uptake. The primary objective of this study was to compare the COVID-19 vaccination rates in US counties to historical vaccination rates for influenza in persons aged 65 and older. The secondary objective was to identify county-level demographic, socioeconomic, and political factors that influence vaccination rates. County level data were obtained from publicly available databases for comparison and to create predictive models. Overall, in US counties the COVID-19 vaccination rate exceeded influenza vaccination rates amongst those aged 65 or older (69.4.0% vs. 44%, p < 0.0001). 2690 (83.4%) of 3224 counties had vaccinated 50% or more of their 65 and older residents in the first seven months of the COVID-19 vaccination roll out. There were 467 (14.5%) of 3223 counties in which the influenza vaccination rate exceeded the COVID-19 vaccination rate. Most of these counties were in the Southern region, were considered politically "red " and had a significantly higher non-Hispanic Black resident population (14.4% vs. 8.2%, p < 0.0001). Interventions intended to improve uptake should account for nuances in vaccine access, confidence, and consider factual social media messaging, especially in vulnerable counties.	[Mirpuri, Pranav] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, N Chicago, IL 60064 USA; [Rovin, Richard A.] Aurora Neurosci & Innovat Inst, Dept Neurosurg, Milwaukee, WI 53215 USA		Mirpuri, P (通讯作者)，Rosalind Franklin Univ Med & Sci, Chicago Med Sch, N Chicago, IL 60064 USA.	pranav.mirpuri@my.rfums.org; Richard.rovin@aah.org		Mirpuri, Pranav/0000-0001-5860-610X; Rovin, Richard/0000-0003-2408-036X			[Anonymous], 2020, LANCET INFECT DIS, V20, P875, DOI 10.1016/S1473-3099(20)30565-X; Bahta Lynn, 2015, Minn Med, V98, P33; Beleche T., COVID 19 VACCINE HES; Braveman P, 2014, PUBLIC HEALTH REP, V129, P19, DOI 10.1177/00333549141291S206; CDC, COVID DAT TRACK; Census Bureau, 2010 2019 COUNT LEV; Copper FA, 2021, LANCET GLOB HEALTH, V9, pE742, DOI 10.1016/S2214-109X(21)00051-6; Flanagan BE, 2018, J ENVIRON HEALTH, V80, P34; Flanagan BE, 2011, J HOMEL SECUR EMERG, V8, DOI 10.2202/1547-7355.1792; Fridman A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250123; Hardeman A, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.15653; Hawkins RB, 2020, PUBLIC HEALTH, V189, P129, DOI 10.1016/j.puhe.2020.09.016; Kaiser Family Foundation (KFF), 2021, COVID 19 VACC MON DA; Keilman LJ, 2019, NURS CLIN N AM, V54, P227, DOI 10.1016/j.cnur.2019.02.009; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lau H, 2021, PULMONOLOGY, V27, P110, DOI 10.1016/j.pulmoe.2020.05.015; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Nicholls LAB, 2021, VACCINE, V39, P3520, DOI 10.1016/j.vaccine.2021.04.062; Press VG., 2021, JAMA HLTH FORUM, V2, pe210264; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Surgo Ventures. The U.S, US COVID 19 VACC COV; Ten Health Issues, 10 HLTH ISS WHO WILL; Thomas CM, 2021, AM J TROP MED HYG, V104, P1963, DOI 10.4269/ajtmh.21-0199; Thomas CM, 2021, AM J TROP MED HYG, V104, P433, DOI 10.4269/ajtmh.20-1614; Williams WW, 2015, MMWR-MORBID MORTAL W, V64, P95; Wolkin A, 2015, J HOMEL SECUR EMERG, V12, P809, DOI 10.1515/jhsem-2014-0104; Ye XY, 2021, J PUBLIC HEALTH-UK, DOI 10.1093/pubmed/fdab364; Zanettini Claudio, 2020, medRxiv, DOI 10.1101/2020.06.24.20129817	31	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1284	10.3390/vaccines9111284			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XI0QX	34835215	Green Published, gold			2022-04-29	WOS:000725828800001
J	Oliveira, GS; Oliveira, MLS; Miyaji, EN; Rodrigues, TC				Oliveira, Giuliana S.; Oliveira, Maria Leonor S.; Miyaji, Eliane N.; Rodrigues, Tasson C.			Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies	VACCINES			English	Review						Streptococcus pneumoniae; pneumococcus; vaccine; PCV; PPV; whole cell; recombinant protein; new technologies	SOLUBLE SPECIFIC SUBSTANCE; NCOV-19 AZD1222 VACCINE; PASSIVELY PROTECT MICE; STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; ANTIBODY-RESPONSE; DNA VACCINE; PHASE-II; IMMUNE-RESPONSES; HERD PROTECTION	The importance of Streptococcus pneumoniae has been well established. These bacteria can colonize infants and adults without symptoms, but in some cases can spread, invade other tissues and cause disease with high morbidity and mortality. The development of pneumococcal conjugate vaccines (PCV) caused an enormous impact in invasive pneumococcal disease and protected unvaccinated people by herd effect. However, serotype replacement is a well-known phenomenon that has occurred after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) and has also been reported for other PCVs. Therefore, it is possible that serotype replacement will continue to occur even with higher valence formulations, but the development of serotype-independent vaccines might overcome this problem. Alternative vaccines are under development in order to improve cost effectiveness, either using proteins or the pneumococcal whole cell. These approaches can be used as a stand-alone strategy or together with polysaccharide vaccines. Looking ahead, the next generation of pneumococcal vaccines can be impacted by the new technologies recently approved for human use, such as mRNA vaccines and viral vectors. In this paper, we will review the advantages and disadvantages of the addition of new polysaccharides in the current PCVs, mainly for low- and middle-income countries, and we will also address future perspectives.	[Oliveira, Giuliana S.; Oliveira, Maria Leonor S.; Miyaji, Eliane N.; Rodrigues, Tasson C.] Inst Butantan, Lab Bacteriol, BR-05503900 Sao Paulo, SP, Brazil		Oliveira, MLS; Miyaji, EN (通讯作者)，Inst Butantan, Lab Bacteriol, BR-05503900 Sao Paulo, SP, Brazil.	giuliana.oliveira@esib.butantan.gov.br; marialeonor.oliveira@butantan.gov.br; eliane.miyaji@butantan.gov.br; tasson.rodrigues@esib.butantan.gov.br	Miyaji, Eliane N/D-7642-2012; Oliveira, Maria Leonor S/F-4988-2012	Miyaji, Eliane N/0000-0003-1689-5366; 	CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [CNPq 303072/2018-0]; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [FAPESP 2017/26090-7, FAPESP 2021/04996-0, FAPESP 2019/06190-2, FAPESP 2018/25165-6, FAPESP 2019/15961-2]; Fundacao Butantan	This research was funded by CNPq (CNPq 303072/2018-0 for ENM), FAPESP (FAPESP 2018/25165-6 and FAPESP 2021/04996-0 for ENM and FAPESP 2019/06190-2 for MLSO) and Fundacao Butantan. GSO received a studentship from FAPESP (FAPESP 2019/15961-2). TCR received a studenship from FAPESP (FAPESP 2017/26090-7).	Afonso ET, 2013, EMERG INFECT DIS, V19, P589, DOI 10.3201/eid1904.121198; Al-Halifa S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00022; Alderson MR, 2016, VACCINE, V34, P2959, DOI 10.1016/j.vaccine.2016.03.107; Aldon Y, 2021, MOL THER-NUCL ACIDS, V25, P483, DOI 10.1016/j.omtn.2021.06.008; Ali K, 2021, NEW ENGL J MED, V385, P2241, DOI 10.1056/NEJMoa2109522; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Andrade AL, 2016, HUM VACC IMMUNOTHER, V12, P285, DOI 10.1080/21645515.2015.1117713; Andrade AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098128; [Anonymous], 2019, Weekly Epidemiological Record, V94, P85; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129; [Anonymous], 2007, Wkly Epidemiol Rec, V82, P93; [Anonymous], 2008, Wkly Epidemiol Rec, V83, P373; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], VAXCYTE OUR PIPELINE; Athlin S, 2014, CLIN VACCINE IMMUNOL, V21, P1541, DOI 10.1128/CVI.00259-14; Azuar A, 2021, BIOCONJUGATE CHEM, V32, P2307, DOI 10.1021/acs.bioconjchem.1c00333; Azzari C, 2016, HUM VACC IMMUNOTHER, V12, P344, DOI 10.1080/21645515.2015.1102811; Bechini A, 2009, VACCINE, V27, P3285, DOI 10.1016/j.vaccine.2009.01.058; Berman-Rosa M, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-0377; Bloom K, 2021, GENE THER, V28, P117, DOI 10.1038/s41434-020-00204-y; Bobo D, 2016, PHARM RES-DORDR, V33, P2373, DOI 10.1007/s11095-016-1958-5; Bologa M, 2012, VACCINE, V30, P7461, DOI 10.1016/j.vaccine.2012.10.076; Brandileone MCC, 2018, VACCINE, V36, P2559, DOI 10.1016/j.vaccine.2018.04.010; Briles DE, 2000, J INFECT DIS, V182, P1694, DOI 10.1086/317602; Broker M, 2009, VACCINE, V27, P5574, DOI 10.1016/j.vaccine.2009.07.036; Brooks WA, 2015, VACCINE, V33, P4610, DOI 10.1016/j.vaccine.2015.06.078; Bryant KA, 2010, PEDIATRICS, V125, P866, DOI 10.1542/peds.2009-1405; Martinez AC, 2019, VACCINE, V37, P176, DOI 10.1016/j.vaccine.2018.07.023; Chatzikleanthous D, 2020, J CONTROL RELEASE, V323, P125, DOI 10.1016/j.jconrel.2020.04.001; Choi CW, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/7931982; Ciruela P, 2018, VACCINE, V36, P7744, DOI 10.1016/j.vaccine.2018.05.026; Corbett KS, 2020, NATURE, V586, P567, DOI 10.1038/s41586-020-2622-0; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Croucher NJ, 2011, SCIENCE, V331, P430, DOI 10.1126/science.1198545; Dagan R, 2004, INFECT IMMUN, V72, P5383, DOI 10.1128/IAI.72.9.5383-5391.2004; Dagan R, 2010, VACCINE, V28, P5513, DOI 10.1016/j.vaccine.2010.06.026; Dopazo J, 2001, MICROB DRUG RESIST, V7, P99, DOI 10.1089/10766290152044995; Dorosti H, 2019, MOL CELL PROBE, V48, DOI 10.1016/j.mcp.2019.101446; Dykman LA, 2020, EXPERT REV VACCINES, V19, P465, DOI 10.1080/14760584.2020.1758070; EKWURZEL G. M., 1938, Public Health Reports, V53, P1877, DOI 10.2307/4582686; Ellis TN, 2010, MICROBIOL MOL BIOL R, V74, P81, DOI 10.1128/MMBR.00031-09; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; ENGLISH PC, 1987, PERSPECT BIOL MED, V30, P170; Entwisle C, 2017, VACCINE, V35, P7181, DOI 10.1016/j.vaccine.2017.10.076; [European Centre for Disease Prevention and Control ECDC], 2019, ECDC ANN EP REP 2017; Fairman J, 2021, VACCINE, V39, P3197, DOI 10.1016/j.vaccine.2021.03.070; Ferreira DM, 2010, MICROB PATHOGENESIS, V48, P205, DOI 10.1016/j.micpath.2010.02.009; Ferreira DM, 2009, MICROB PATHOGENESIS, V47, P157, DOI 10.1016/j.micpath.2009.05.005; Frater J, 2021, LANCET HIV, V8, pE474, DOI 10.1016/S2352-3018(21)00103-X; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Frey SE, 2013, VACCINE, V31, P4874, DOI 10.1016/j.vaccine.2013.07.049; Fries L, 2020, J INFECT DIS, V222, P572, DOI 10.1093/infdis/jiz518; Fukuyama Y, 2015, MUCOSAL IMMUNOL, V8, P1144, DOI 10.1038/mi.2015.5; Ganaie F, 2020, MBIO, V11, DOI 10.1128/mBio.00937-20; Geno KA, 2015, CLIN MICROBIOL REV, V28, P871, DOI 10.1128/CMR.00024-15; GlaxoSmithKline Biologicals S.A., SYNFLORIX; Goncalves VM, 2019, EXPERT REV VACCINES, V18, P781, DOI 10.1080/14760584.2019.1643719; Grabenstein JD, 2012, CLIN MICROBIOL INFEC, V18, P15, DOI 10.1111/j.1469-0691.2012.03943.x; Hammerschmidt S, 2005, INFECT IMMUN, V73, P4653, DOI 10.1128/IAI.73.8.4653-4667.2005; Hammitt LL, 2019, VACCINE, V37, P7482, DOI 10.1016/j.vaccine.2019.09.076; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Hathaway LJ, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.150269; Hausdorff WP, 2016, HUM VACC IMMUNOTHER, V12, P358, DOI 10.1080/21645515.2015.1118593; HEIDELBERGER M, 1948, J EXP MED, V88, P369, DOI 10.1084/jem.88.3.369; Heidelberger M, 1924, J EXP MED, V40, P301, DOI 10.1084/jem.40.3.301; Heidelberger M, 1923, J EXP MED, V38, P0073, DOI 10.1084/jem.38.1.73; Heidelberger M, 1925, J EXP MED, V42, P727, DOI 10.1084/jem.42.5.727; Helou DG, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009627; Hicks LA, 2007, J INFECT DIS, V196, P1346, DOI 10.1086/521626; Hollingshead SK, 2000, INFECT IMMUN, V68, P5889, DOI 10.1128/IAI.68.10.5889-5900.2000; Hsieh YC, 2013, J INFECT DIS, V208, P203, DOI 10.1093/infdis/jit145; Htar MTT, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1147-x; Hurley D, 2021, CLIN INFECT DIS, V73, pE1489, DOI 10.1093/cid/ciaa1045; Huss A, 2009, CAN MED ASSOC J, V180, P48, DOI 10.1503/cmaj.080734; Ingrole RSJ, 2021, VACCINE, V39, P4800, DOI 10.1016/j.vaccine.2021.07.032; Isturiz RE, 2019, VACCINE, V37, P3352, DOI 10.1016/j.vaccine.2019.04.087; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Kamtchoua T, 2013, VACCINE, V31, P327, DOI 10.1016/j.vaccine.2012.11.005; KAUFMAN P, 1947, ARCH INTERN MED, V79, P518, DOI 10.1001/archinte.1947.00220110058004; Keech CA, 2020, PEDIATR INFECT DIS J, V39, P345, DOI 10.1097/INF.0000000000002567; Kuipers K, 2015, VACCINE, V33, P2022, DOI 10.1016/j.vaccine.2015.03.010; Kunda NK, 2015, INT J PHARMACEUT, V495, P903, DOI 10.1016/j.ijpharm.2015.09.034; Kye YC, 2019, ACTA BIOMATER, V90, P362, DOI 10.1016/j.actbio.2019.03.049; Lee P, 2021, IMMUNE NETW, V21, DOI 10.4110/in.2021.21.e4; Leroux-Roels G, 2014, VACCINE, V32, P6838, DOI 10.1016/j.vaccine.2014.02.052; Leroux-Roels I, 2015, VACCINE, V33, P577, DOI 10.1016/j.vaccine.2013.10.052; Lesinski GB, 2001, VACCINE, V19, P1717, DOI 10.1016/S0264-410X(00)00397-2; Lewnard Joseph A, 2021, Clin Infect Dis, V73, pe1423, DOI 10.1093/cid/ciaa1860; Liniger M, 2007, EXPERT REV VACCINES, V6, P255, DOI 10.1586/14760584.6.2.255; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Lundstrom K, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020317; MACLEOD CM, 1945, J EXP MED, V82, P445, DOI 10.1084/jem.82.6.445; Marangu D, 2019, PAEDIATR RESPIR REV, V32, P3, DOI 10.1016/j.prrv.2019.06.001; Marques JM, 2012, IMMUNOBIOLOGY, V217, P420, DOI 10.1016/j.imbio.2011.10.012; Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020; Masomian M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010132; McFetridge R, 2015, VACCINE, V33, P2793, DOI 10.1016/j.vaccine.2015.04.025; Mehanny M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00080; Merck & Co. Inc, PNEUM 23; Micoli F, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101433; Min YJ, 2021, NANOMEDICINE-UK, V16, P1747, DOI 10.2217/nnm-2021-0023; Miyaji EN, 2001, VACCINE, V20, P805, DOI 10.1016/S0264-410X(01)00395-4; Miyaji EN, 2002, INFECT IMMUN, V70, P5086, DOI 10.1128/IAI.70.9.5086-5090.2002; Moffitt KL, 2011, CELL HOST MICROBE, V9, P158, DOI 10.1016/j.chom.2011.01.007; Mohammadzadeh M, 2017, IRAN J MICROBIOL, V9, P381; Morais V, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040151; Nabors GS, 2000, VACCINE, V18, P1743, DOI 10.1016/S0264-410X(99)00530-7; Najafi A, 2021, LIFE SCI, V282, DOI 10.1016/j.lfs.2021.119806; Nakahashi-Ouchida R, 2021, VACCINE, V39, P3353, DOI 10.1016/j.vaccine.2021.04.069; Nelson SA, 2021, J VIROL, V95, DOI 10.1128/JVI.00841-21; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Ochs MM, 2016, HUM VACC IMMUNOTHER, V12, P2946, DOI 10.1080/21645515.2016.1202389; Odutola A, 2016, HUM VACC IMMUNOTHER, V12, P393, DOI 10.1080/21645515.2015.1111496; Odutola A, 2017, VACCINE, V35, P2531, DOI 10.1016/j.vaccine.2017.03.071; Pardi N, 2019, MOL THER-NUCL ACIDS, V15, P36, DOI 10.1016/j.omtn.2019.03.003; Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007; Pauksens K, 2014, CLIN VACCINE IMMUNOL, V21, P651, DOI 10.1128/CVI.00807-13; Pelton SI, 2003, VACCINE, V21, P1562, DOI 10.1016/S0264-410X(02)00681-3; Peterson JT, 2019, HUM VACC IMMUNOTHER, V15, P540, DOI 10.1080/21645515.2018.1532250; Pichichero ME, 2017, EXPERT REV VACCINES, V16, P1181, DOI 10.1080/14760584.2017.1393335; Price NL, 2016, SCI REP-UK, V6, DOI 10.1038/srep24931; Prymula R, 2017, VACCINE, V35, P4603, DOI 10.1016/j.vaccine.2017.07.008; Prymula R, 2014, VACCINE, V32, P3025, DOI 10.1016/j.vaccine.2014.03.066; Prymula R, 2009, EXPERT REV VACCINES, V8, P1479, DOI 10.1586/ERV.09.113; Ramirez M., 2015, STREPTOCOCCUS PNEUMO, P3; Richards L, 2010, IMMUNOBIOLOGY, V215, P251, DOI 10.1016/j.imbio.2009.12.004; Rodrigues TC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191692; Rupp R, 2019, HUM VACC IMMUNOTHER, V15, P549, DOI 10.1080/21645515.2019.1568159; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Saunders KO, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00307-6; Seiberling M, 2012, VACCINE, V30, P7455, DOI 10.1016/j.vaccine.2012.10.080; Shaper M, 2004, INFECT IMMUN, V72, P5031, DOI 10.1128/IAI.72.9.5031-5040.2004; Sharma O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585354; Stacey HL, 2019, HUM VACC IMMUNOTHER, V15, P530, DOI 10.1080/21645515.2018.1532249; Tettelin H, 2001, SCIENCE, V293, P498, DOI 10.1126/science.1061217; Tettelin H., 2015, STREPTOCOCCUS PNEUMO, P81; Thompson A, 2019, VACCINE, V37, P6201, DOI 10.1016/j.vaccine.2019.08.048; Troeger C, 2017, LANCET INFECT DIS, V17, P1133, DOI 10.1016/S1473-3099(17)30396-1; Trzcinski K, 2005, INFECT IMMUN, V73, P7043, DOI 10.1128/IAI.73.10.7043-7046.2005; Tsaban G, 2017, VACCINE, V35, P2882, DOI 10.1016/j.vaccine.2017.04.032; Vadesilho CFM, 2012, MICROB PATHOGENESIS, V53, P243, DOI 10.1016/j.micpath.2012.08.007; Wagner-Muniz DA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00325; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8; WEISER JN, 1994, INFECT IMMUN, V62, P2582, DOI 10.1128/IAI.62.6.2582-2589.1994; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; WHO, LEAD CAUS DEATH DIS; World Health Organization, PNEUMONIA; World Health Organization, COVID 19 LANDSC NOV; Wu JW, 2018, BIOMATERIALS, V155, P152, DOI 10.1016/j.biomaterials.2017.11.018; Wyeth Pharmaceuticals Inc, PREVNAR13; Wyllie AL, 2016, SCI REP-UK, V6, DOI 10.1038/srep34888; Xie JF, 2020, PEDIATR INFECT DIS J, V39, P70, DOI 10.1097/INF.0000000000002522; Yang F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.606569; Zaheer T, 2021, PROCESS BIOCHEM, V100, P237, DOI 10.1016/j.procbio.2020.09.028	157	0	0	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1338	10.3390/vaccines9111338			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI2ET	34835269	Green Published, gold			2022-04-29	WOS:000725932500001
J	Campo, F; Venuti, A; Pimpinelli, F; Abril, E; Blandino, G; Conti, L; De Virgilio, A; De Marco, F; Di Noia, V; Di Domenico, EG; Di Martino, S; Ensoli, F; Giannarelli, D; Mandoj, C; Mazzola, F; Moretto, S; Petruzzi, G; Petrone, F; Pichi, B; Pontone, M; Vidiri, A; Vujovic, B; Piaggio, G; Sperandio, E; Rosati, V; Cognetti, F; Morrone, A; Ciliberto, G; Pellini, R				Campo, Flaminia; Venuti, Aldo; Pimpinelli, Fulvia; Abril, Elva; Blandino, Giovanni; Conti, Laura; De Virgilio, Armando; De Marco, Federico; Di Noia, Vincenzo; Di Domenico, Enea Gino; Di Martino, Simona; Ensoli, Fabrizio; Giannarelli, Diana; Mandoj, Chiara; Mazzola, Francesco; Moretto, Silvia; Petruzzi, Gerardo; Petrone, Fabrizio; Pichi, Barbara; Pontone, Martina; Vidiri, Antonello; Vujovic, Branka; Piaggio, Giulia; Sperandio, Eleonora; Rosati, Valentina; Cognetti, Francesco; Morrone, Aldo; Ciliberto, Gennaro; Pellini, Raul			Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers	VACCINES			English	Article						COVID-19; SARS-CoV-2; mRNA vaccine; BNT162b2; antibody response	VACCINATION; SARS-COV-2	Background: We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection. Methods: An immunogenicity evaluation was carried out among health care workers (HCW) vaccinated at the Istituti Fisioterapici Ospitalieri (IFO). All HCW were asked to be vaccine by the national vaccine campaign at the beginning of 2021. Serum samples were collected on day 1 just prior to the first dose of the vaccine and on day 21 just prior to the second vaccination dose. Thereafter sera samples were collected 28, 49, 84 and 168 days after the first dose of BNT162b2. Quantitative measurement of IgG antibodies against S1/S2 antigens of SARS-CoV-2 was performed with a commercial chemiluminescent immunoassay. Results: Two hundred seventy-four HWCs were analyzed, 175 women (63.9%) and 99 men (36.1%). The maximum antibody geometric mean concentration (AbGMC) was reached at T2 (299.89 AU/mL; 95% CI: 263.53-339.52) with a significant increase compared to baseline (p < 0.0001). Thereafter, a progressive decrease was observed. At T5, a median decrease of 59.6% in COVID-19 negative, and of 67.8% in COVID-19 positive individuals were identified with respect to the highest antibody response. At T1, age and previous COVID-19 were associated with differences in antibody response, while at T2 and T3 differences in immune response were associated with age, gender and previous COVID-19. At T4 and T5, only COVID-19 positive participants demonstrated a greater antibody response, whereas no other variables seemed to influence antibody levels. Conclusions: Overall our study clearly shows antibody persistence at 6 months, albeit with a certain decline. Thus, the use of this vaccine in addressing the COVID-19 pandemic is supported by our results that in turn open debate about the need for further boosts.	[Campo, Flaminia; Mazzola, Francesco; Moretto, Silvia; Petruzzi, Gerardo; Pichi, Barbara; Rosati, Valentina; Pellini, Raul] IRCCS Regina Elena Natl Canc Inst, Dept Otolaryngol Head & Neck Surg, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Venuti, Aldo] Ist Fisioterap Ospitalieri IFO, HPV Unit, IRCCS Regina Elena Natl Canc Inst, UOSD Tumor Immunol & Immunotherapy, I-00144 Rome, Italy; [Pimpinelli, Fulvia; Abril, Elva; Di Domenico, Enea Gino; Ensoli, Fabrizio; Pontone, Martina] IRCCS San Gallicano Dermatol Inst, Dept Microbiol & Virol, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Blandino, Giovanni] IRCCS Regina Elena Natl Canc Inst, Oncogen & Epigenet Unit, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Conti, Laura; Mandoj, Chiara] IRCCS Regina Elena Natl Canc Inst, Dept Clin Pathol & Canc Biobank, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [De Virgilio, Armando] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20072 Milan, Italy; [De Virgilio, Armando] IRCCS Humanitas Res Hosp, Via Manzoni 56, I-20089 Milan, Italy; [De Marco, Federico] IRCCS Regina Elena Natl Canc Inst, RIDAIT Dept, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Di Noia, Vincenzo; Cognetti, Francesco] IRCCS Regina Elena Natl Canc Inst, Med Oncol, I-00144 Rome, Italy; [Di Martino, Simona] IRCCS Regina Elena Natl Canc Inst, Dept Pathol, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Giannarelli, Diana] IRCCS Regina Elena Natl Canc Inst, Biostat Unit, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Petrone, Fabrizio] IRCCS Regina Elena Natl Canc Inst, Ist Fisioterap Ospitalieri IFO, UOC DITRAR, I-00144 Rome, Italy; [Vidiri, Antonello] IRCCS Regina Elena Natl Canc Inst, Dept Radiol & Diagnost Imaging, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Vujovic, Branka] IRCCS Regina Elena Natl Canc Inst, Med Direct, I-00144 Rome, Italy; [Vujovic, Branka] San Gallicano Inst, I-00144 Rome, Italy; [Piaggio, Giulia] IRCSS Technol Innovat & Adv Diagnost, Dept Res, Regina Elena Natl Canc Inst, I-00144 Rome, Italy; [Sperandio, Eleonora] IRCCS Regina Elena Natl Canc Inst, UOSD Clin Trial Ctr, Ist Fisioterap Ospitalieri IFO, Biostat & Bionformat, I-00144 Rome, Italy; [Morrone, Aldo] IRCCS San Gallicano Dermatol Inst, Ist Fisioterap Ospitalieri IFO, Sci Direct, I-00144 Rome, Italy; [Ciliberto, Gennaro] IRCCS Regina Elena Natl Canc Inst, Ist Fisioterap Ospitalieri IFO, Sci Direct, I-00144 Rome, Italy		Venuti, A (通讯作者)，Ist Fisioterap Ospitalieri IFO, HPV Unit, IRCCS Regina Elena Natl Canc Inst, UOSD Tumor Immunol & Immunotherapy, I-00144 Rome, Italy.	flaminiacampo@gmail.com; aldo.venuti@ifo.gov.it; fulvia.pimpinelli@ifo.gov.it; elva.abril@ifo.gov.it; giovanni.blandino@ifo.gov.it; laura.conti@ifo.gov.it; armando.devirgilio@gmail.com; federico.demarco@ifo.gov.it; vincenzo.dinoia@ifo.gov.it; enea.didomenico@ifo.gov.it; simona.dimartino@ifo.gov.it; fabrizio.ensoli@ifo.gov.it; diana.giannarelli@ifo.gov.it; Chiara.mandoj@ifo.gov.it; francesco.mazzola@ifo.gov.it; silvia.moretto@ifo.gov.it; gerardo.petruzzi@ifo.gov.it; fabrizio.petrone@ifo.gov.it; barbara.pichi@ifo.gov.it; martina.pontone@ifo.gov.it; antonello.vidiri@ifo.gov.it; branka.vujovic@ifo.gov.it; giulia.piaggio@ifo.gov.it; eleonora.sperandio@ifo.gov.it; valentina_rosati@hotmail.it; francesco.cognetti@ifo.gov.it; Aldo.morrone@ifo.gov.it; gennaro.ciliberto@ifo.gov.it; Raul.pellini@ifo.gov.it	Di Noia, Vincenzo/AAU-6725-2020; Petruzzi, Gerardo/AAD-4276-2022; Piaggio, Giulia/AAD-7336-2022; Ciliberto, Gennaro/J-4131-2017; Venuti, Aldo/K-9637-2016; Giannarelli, Diana/T-5507-2017; Di Domenico, Enea Gino/G-9387-2018	Di Noia, Vincenzo/0000-0003-2009-5791; Petruzzi, Gerardo/0000-0003-0371-7667; Ciliberto, Gennaro/0000-0003-2851-8605; Venuti, Aldo/0000-0003-2322-6857; Sperandio, Eleonora/0000-0002-8572-6788; Abril, Elva Ermita/0000-0001-9256-4820; Campo, Flaminia/0000-0002-9249-7573; Giannarelli, Diana/0000-0002-6085-1195; Di Domenico, Enea Gino/0000-0001-6295-6006; De Marco, Federico/0000-0002-1173-2843; De Virgilio, Armando/0000-0003-0738-8223; pellini, raul/0000-0001-6051-3041			Amodio E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070714; Bignucolo A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080825; Bonelli F, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01224-20; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Di Noia V., IMMUNOGENICITY SAFET; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Engler RJM, 2008, ARCH INTERN MED, V168, P2405, DOI 10.1001/archinternmed.2008.513; Favresse J, 2021, EMERG MICROBES INFEC, V10, P1495, DOI 10.1080/22221751.2021.1953403; Frasca D, 2016, VACCINE, V34, P2834, DOI 10.1016/j.vaccine.2016.04.023; Frasca D, 2010, VACCINE, V28, P8077, DOI 10.1016/j.vaccine.2010.10.023; Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111; Hao Y, 2011, BLOOD, V118, P1294, DOI 10.1182/blood-2011-01-330530; Kulkarni PS, 2018, VIRAL IMMUNOL, V31, P195, DOI 10.1089/vim.2017.0147; Nipper AJ, 2018, CLIN IMMUNOL, V193, P80, DOI 10.1016/j.clim.2018.02.003; Peckham H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19741-6; Pellini R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070685; Pellini R, 2021, ECLINICALMEDICINE, V36, DOI 10.1016/j.eclinm.2021.100928; Poland GA, 2018, VACCINE, V36, P5350, DOI 10.1016/j.vaccine.2017.07.062; Ralli M, 2020, EUR REV MED PHARMACO, V24, P9705, DOI 10.26355/eurrev_202009_23062; Rubtsov AV, 2011, BLOOD, V118, P1305, DOI 10.1182/blood-2011-01-331462; Salvagno GL, 2021, J INFECTION, V83, pE4, DOI 10.1016/j.jinf.2021.06.024; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Verschoor CP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131531; Voigt EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00180; Weir CB, 2020, STATPEARLS	25	8	8	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1125	10.3390/vaccines9101125			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WV3TS	34696233	gold, Green Published			2022-04-29	WOS:000717163300001
J	Chen, YL; Lin, YJ; Chang, YP; Chou, WJ; Yen, CF				Chen, Yi-Lung; Lin, Yen-Ju; Chang, Yu-Ping; Chou, Wen-Jiun; Yen, Cheng-Fang			Differences in Sources of Information, Risk Perception, and Cognitive Appraisals between People with Various Latent Classes of Motivation to Get Vaccinated against COVID-19 and Previous Seasonal Influenza Vaccination: Facebook Survey Study with Latent Profile Analysis in Taiwan	VACCINES			English	Article						COVID-19; vaccine; motivation; seasonal influenza	SARS-COV-2; INTENTION; LESSONS; ADULTS; NUMBER	The present study aimed (1) to identify distinct latent classes of motivation to get vaccinated against coronavirus disease 2019 (COVID-19) and previous seasonal influenza vaccination among people in Taiwan and (2) to examine the roles of sources of information, risk perception, and cognitive appraisals of vaccination against COVID-19 in these classes. We recruited 1047 participants through a Facebook advertisement. The participants' motivation to get vaccinated against COVID-19, previous seasonal influenza vaccination, sources of information about COVID-19 vaccination, risk perception of COVID-19, and cognitive appraisals of vaccination against COVID-19 were determined. We examined the participants' motivation for COVID-19 vaccination and previous seasonal influenza vaccination through latent profile analysis. Four latent classes of motivation were identified: participants with high motivation for COVID-19 vaccination and high seasonal influenza vaccination, those with high motivation for COVID-19 vaccination but low seasonal influenza vaccination, those with low motivation for COVID-19 vaccination but high seasonal influenza vaccination, and those with low motivation for COVID-19 vaccination and low seasonal influenza vaccination. Compared with participants in the latent class of high motivation for COVID-19 vaccination and high seasonal influenza vaccination, those in the other three latent classes had lower levels of positive appraisals of COVID-19 vaccination; participants in the latent class of low motivation for COVID-19 vaccination and low seasonal influenza vaccination had lower risk perception of COVID-19 and were also less likely to obtain information about COVID-19 vaccination from the internet, friends, and family members. The various motivations and behaviors for vaccination, sources of information, risk perception, and cognitive appraisals of vaccination against COVID-19 should be considered in intervention programs aiming to increase people's motivation to get vaccinated against COVID-19.	[Chen, Yi-Lung] Asia Univ, Dept Healthcare Adm, Taichung 41354, Taiwan; [Chen, Yi-Lung] Asia Univ, Dept Psychol, Taichung 41354, Taiwan; [Lin, Yen-Ju; Yen, Cheng-Fang] Kaohsiung Med Univ, Sch Med, Dept Psychiat, Coll Med, Kaohsiung 80708, Taiwan; [Lin, Yen-Ju; Yen, Cheng-Fang] Kaohsiung Med Univ Hosp, Dept Psychiat, Kaohsiung 80708, Taiwan; [Chang, Yu-Ping] SUNY Buffalo, Sch Nursing, Buffalo, NY 14214 USA; [Chou, Wen-Jiun] Chang Gung Univ, Sch Med, Taoyuan 33302, Taiwan; [Chou, Wen-Jiun] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Child & Adolescent Psychiat, Kaohsiung 83301, Taiwan; [Yen, Cheng-Fang] Natl Pingtung Univ Sci & Technol, Coll Profess Studies, Pingtung 91201, Taiwan		Yen, CF (通讯作者)，Kaohsiung Med Univ, Sch Med, Dept Psychiat, Coll Med, Kaohsiung 80708, Taiwan.; Yen, CF (通讯作者)，Kaohsiung Med Univ Hosp, Dept Psychiat, Kaohsiung 80708, Taiwan.; Chou, WJ (通讯作者)，Chang Gung Univ, Sch Med, Taoyuan 33302, Taiwan.; Chou, WJ (通讯作者)，Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Child & Adolescent Psychiat, Kaohsiung 83301, Taiwan.; Yen, CF (通讯作者)，Natl Pingtung Univ Sci & Technol, Coll Profess Studies, Pingtung 91201, Taiwan.	elong@asia.edu.tw; yc73@buffalo.edu; wjchou@cgmh.org.tw; chfaye@cc.kmu.edu.tw		Chen, Yi-Lung/0000-0003-2934-5814	Kaohsiung Medical University Hospital [KMUH109-9M54]	FundingThis study was supported by grants awarded by Kaohsiung Medical University Hospital (KMUH109-9M54).	Ajzen I., 1985, ACTION CONTROL, P11, DOI 10.1007/978-3-642-69746-3_2; Alessi EJ, 2010, SOC WORK RES, V34, P122, DOI 10.1093/swr/34.2.122; Alfageeh EI, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030226; Behrouzi B, 2020, J AM COLL CARDIOL, V76, P1777, DOI 10.1016/j.jacc.2020.08.028; Binagwaho A, 2022, INT J HEALTH POLICY, V11, P100, DOI 10.34172/ijhpm.2021.49; Bobkowski P, 2013, MEDIA CULT SOC, V35, P771, DOI 10.1177/0163443713491517; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Celeux G, 1996, J CLASSIF, V13, P195, DOI 10.1007/BF01246098; Chou WP, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17249329; Conti P, 2021, J BIOL REG HOMEOS AG, V35, P1; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040711; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; El-Elimat T, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250555; Fadda M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2200-9; Fan CW, 2021, HUM VACC IMMUNOTHER, V17, P3413, DOI 10.1080/21645515.2021.1933687; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Germani F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247642; Grochowska M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050475; Hernandez Antonio F, 2021, Toxicol Rep, V8, P871, DOI 10.1016/j.toxrep.2021.04.003; Honein MA, 2020, MMWR-MORBID MORTAL W, V69, P1860, DOI 10.15585/mmwr.mm6949e2; Hu T, 2021, J MED INTERNET RES, V23, DOI 10.2196/30854; Huang PC, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9091046; Jones Abbey M, 2012, Adv Prev Med, V2012, P932741, DOI 10.1155/2012/932741; Kennedy A, 2011, PEDIATRICS, V127, pS92, DOI 10.1542/peds.2010-1722N; Ko NY, 2020, BRAIN BEHAV IMMUN, V87, P153, DOI 10.1016/j.bbi.2020.05.019; Li Q, 2020, MATH BIOSCI, V325, DOI 10.1016/j.mbs.2020.108378; Lin YJ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050528; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Mercadante AR, 2021, RES SOC ADMIN PHARM, V17, P1596, DOI 10.1016/j.sapharm.2020.12.012; Meyer D, 2018, AM J PUBLIC HEALTH, V108, pS188, DOI 10.2105/AJPH.2018.304527; Nagin D.S., 2005, GROUP BASED MODELING; Peacock G, 2021, DISABIL HEALTH J, V14, DOI 10.1016/j.dhjo.2020.101058; ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803; Rosenberg J., 2018, J OPEN SOURCE SOFTW, V3, P978, DOI [10.21105/joss.00978, DOI 10.21105/JOSS.00978]; ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Science and Engineering at Johns Hopkins, MOD 2019 NCOV; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Shmueli L, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10816-7; Su CP, 2019, J FORMOS MED ASSOC, V118, P657, DOI 10.1016/j.jfma.2018.12.022; Tan Jasmine, 2021, medRxiv, DOI 10.1101/2021.04.14.21255448; Tein JY, 2013, STRUCT EQU MODELING, V20, P640, DOI 10.1080/10705511.2013.824781; Thindwa D, 2020, VACCINE, V38, P5398, DOI 10.1016/j.vaccine.2020.06.047; Vallee-Tourangeau G, 2018, VACCINE, V36, P6540, DOI 10.1016/j.vaccine.2017.08.025; Waite NM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040346; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Wang PW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040380; Wang SQ, 2021, APPL SPAT ANAL POLIC, V14, P703, DOI 10.1007/s12061-020-09368-x; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; World Health Organization, 2014, REP SAGE WORK GROUP; World Health Organization, WHO SAG ROADM PRIOR; Yeh YC, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030297; Zampetakis LA, 2021, APPL PSYCHOL-HLTH WE, V13, P469, DOI 10.1111/aphw.12262	57	0	0	12	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1203	10.3390/vaccines9101203			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR9WP	34696311	gold, Green Published			2022-04-29	WOS:000714843100001
J	Davis, WC; Abdellrazeq, GS; Mahmoud, AH; Park, KT; Elnaggar, MM; Donofrio, G; Hulubei, V; Fry, LM				Davis, William C.; Abdellrazeq, Gaber S.; Mahmoud, Asmaa H.; Park, Kun-Taek; Elnaggar, Mahmoud M.; Donofrio, Gaetano; Hulubei, Victoria; Fry, Lindsay M.			Advances in Understanding of the Immune Response to Mycobacterial Pathogens and Vaccines through Use of Cattle and Mycobacterium avium subsp. paratuberculosis as a Prototypic Mycobacterial Pathogen	VACCINES			English	Review						paratuberculosis; tuberculosis; vaccines; CD8 cytotoxic T cells; bovine	DIFFERENTIATION ANTIGENS; PROPIDIUM MONOAZIDE; TUBERCULOSIS; INFECTION; MUTANTS; IDENTIFICATION; DOMESTICATION; LYMPHOCYTES; PERSISTENCE; IMMUNOLOGY	Lack of understanding of the immune response to mycobacterial pathogens has impeded progress in development of vaccines. Infection leads to development of an immune response that controls infection but is unable to eliminate the pathogen, resulting in a persistent infection. Although this puzzle remains to be solved, progress has been made using cattle as a model species to study the immune response to a prototypic mycobacterium, Mycobacterium a. paratuberculosis (Map). As chronicled in the review, incremental advances in characterizing the immune response to mycobacteria during the last 30 years with increases in information on the evolution of mycobacteria and relA, a gene regulating the stringent response, have brought us closer to an answer. We provide a brief overview of how mycobacterial pathogens were introduced into cattle during the transition of humankind to nomadic pastoralists who domesticated animals for food and farming. We summarize what is known about speciation of mycobacteria since the discovery of Mybacterium tuberculsis Mtb, M. bovis Mbv, and Map as zoonotic pathogens and discuss the challenges inherent in the development of vaccines to mycobacteria. We then describe how cattle were used to characterize the immune response to a prototypic mycobacterial pathogen and development of novel candidate vaccines.	[Davis, William C.; Abdellrazeq, Gaber S.; Mahmoud, Asmaa H.; Elnaggar, Mahmoud M.; Hulubei, Victoria; Fry, Lindsay M.] Washington State Univ, Dept Vet MicroBiol & Pathol, Pullman, WA 99164 USA; [Abdellrazeq, Gaber S.; Elnaggar, Mahmoud M.] Alexandria Univ, Fac Vet Med, Dept Microbiol, Alexandria 22758, Egypt; [Mahmoud, Asmaa H.] Minist Agr & Land Reclamat, Gen Org Vet Serv, Vet Quarantine Alexandria, Dokki 12611, Giza, Egypt; [Park, Kun-Taek] Inje Univ, Dept Biotechnol, Injero 197, Kimhae Si 50834, South Korea; [Donofrio, Gaetano] Univ Parma, Dept Med Vet Sci, I-43126 Parma, Italy; [Fry, Lindsay M.] USDA ARS, Anim Dis Res Unit, Pullman, WA 99164 USA		Davis, WC (通讯作者)，Washington State Univ, Dept Vet MicroBiol & Pathol, Pullman, WA 99164 USA.	pkt9138@hotmail.com; gaetano.donofrio@unipr.it		Mahmoud, Asmaa/0000-0001-5304-5470	National Institute of Food and Agriculture-Agriculture and Food Research Initiative Competitive Grant [2018-67015-28744]; WSU CVM Animal Health Research Center [10s-2540-8803]; WSU Monoclonal Antibody Center (WSUMAC)	YYY The writing of the review was supported in part by the National Institute of Food and Agriculture-Agriculture and Food Research Initiative Competitive Grant 2018-67015-28744 (W.C.D.), the WSU CVM Animal Health Research Center 10s-2540-8803, and the WSU Monoclonal Antibody Center (WSUMAC).	ABABOU A, 1994, J LEUKOCYTE BIOL, V56, P182, DOI 10.1002/jlb.56.2.182; Abdellrazeq GS, 2020, TUBERCULOSIS, V120, DOI 10.1016/j.tube.2020.101904; Abdellrazeq GS, 2020, VACCINE, V38, P2016, DOI 10.1016/j.vaccine.2019.12.052; Abdellrazeq GS, 2019, VACCINE, V37, P2783, DOI 10.1016/j.vaccine.2019.04.040; Abdellrazeq GS, 2018, VET RES, V49, DOI 10.1186/s13567-018-0549-3; Allen AJ, 2011, VET IMMUNOL IMMUNOP, V141, P258, DOI 10.1016/j.vetimm.2011.03.014; Allen AJ, 2009, CLIN VACCINE IMMUNOL, V16, P453, DOI 10.1128/CVI.00347-08; Bachmann NL, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03019; Bannantine JP, 2008, INFECT IMMUN, V76, P739, DOI 10.1128/IAI.00915-07; Bannantine JP, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00126; Bannantine JP, 2003, MICROBIOL-SGM, V149, P2061, DOI 10.1099/mic.0.26323-0; Bardarov S, 2002, MICROBIOL-SGM, V148, P3007, DOI 10.1099/00221287-148-10-3007; Black M, 2010, EXPERT REV VACCINES, V9, P157, DOI [10.1586/erv.09.160, 10.1586/ERV.09.160]; Bollongino R, 2012, MOL BIOL EVOL, V29, P2101, DOI 10.1093/molbev/mss092; Capocefalo A, 2013, VACCINE, V31, P3906, DOI 10.1016/j.vaccine.2013.06.052; Cavaignac SM, 2000, ARCH MICROBIOL, V173, P229, DOI 10.1007/s002039900132; CHIODINI RJ, 1992, MICROB PATHOGENESIS, V13, P447, DOI 10.1016/0882-4010(92)90012-D; CHIODINI RJ, 1984, J CLIN MICROBIOL, V20, P966, DOI 10.1128/JCM.20.5.966-971.1984; Chung JN, 2018, AM J CLIN DERMATOL, V19, P867, DOI 10.1007/s40257-018-0382-5; Corripio-Miyar Y, 2015, VET RES, V46, DOI 10.1186/s13567-015-0246-4; Dahl JL, 2003, P NATL ACAD SCI USA, V100, P10026, DOI 10.1073/pnas.1631248100; Dalebroux ZD, 2010, MICROBIOL MOL BIOL R, V74, P171, DOI 10.1128/MMBR.00046-09; Davis W.C., 1984, HYDRIDOMA TECHNOLOGY, P121; DAVIS WC, 1987, VET IMMUNOL IMMUNOP, V15, P337, DOI 10.1016/0165-2427(87)90005-5; Davis WC, 2018, EC GASTROENTEROL DIG, V5, P752; Dockrell HM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01134; Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93; Franceschi V, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02859; Frothingham R, 1999, MED HYPOTHESES, V52, P95, DOI 10.1054/mehy.1997.0622; Gcebe N, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00015; Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5; Harris NB, 1999, FEMS MICROBIOL LETT, V175, P21, DOI 10.1111/j.1574-6968.1999.tb13597.x; Hauryliuk V, 2015, NAT REV MICROBIOL, V13, P298, DOI 10.1038/nrmicro3448; JOHNE H. A., 1895, DTSCH Z TIERMED PATH, V21, P438; Koch, 1884, MITT KAISER GESUNDH, V2, P1, DOI [10.1007/BF01765224, DOI 10.1007/BF01765224]; Koo HC, 2004, INFECT IMMUN, V72, P6870, DOI 10.1128/IAI.72.12.6870-6883.2004; Kralik P, 2010, INT J FOOD MICROBIOL, V141, pS80, DOI 10.1016/j.ijfoodmicro.2010.03.018; Kuenstner JT, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8122054; Kundra S, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.601417; Lurie MB, 1934, J EXP MED, V60, P163, DOI 10.1084/jem.60.2.163; MORRISON WI, 1991, VET IMMUNOL IMMUNOP, V27, P71, DOI 10.1016/0165-2427(91)90082-N; Naessens J, 1996, VET IMMUNOL IMMUNOP, V52, P213, DOI 10.1016/0165-2427(96)05566-3; Nocker A, 2007, APPL ENVIRON MICROB, V73, P5111, DOI 10.1128/AEM.02987-06; Nocker A, 2006, J MICROBIOL METH, V67, P310, DOI 10.1016/j.mimet.2006.04.015; Park KT, 2008, APPL ENVIRON MICROB, V74, P1687, DOI 10.1128/AEM.01208-07; Park KT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165247; Park KT, 2011, VACCINE, V29, P4709, DOI 10.1016/j.vaccine.2011.04.090; Prasanna AN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071248; Ratnatunga CN, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00303; Reva O, 2015, BMC EVOL BIOL, V15, DOI 10.1186/1471-2148-15-S1-S2; Rideout B., 2003, DIAGNOSIS CONTROL JO; Shin SJ, 2006, INFECT IMMUN, V74, P3825, DOI 10.1128/IAI.01742-05; Singh SV, 2016, FRONT MED-LAUSANNE, V3, DOI 10.3389/fmed.2016.00049; Tortoli E, 2006, FEMS IMMUNOL MED MIC, V48, P159, DOI 10.1111/j.1574-695X.2006.00123.x; Walburger A, 2004, SCIENCE, V304, P1800, DOI 10.1126/science.1099384; Waters WR, 2003, INFECT IMMUN, V71, P5130, DOI 10.1128/IAI.71.9.5130-5138.2003; WIJNGAARD PLJ, 1994, J IMMUNOL, V152, P3476; Worku S, 2003, INFECT IMMUN, V71, P1763, DOI 10.1128/IAI.71.4.1763-1773.2003; Wu CW, 2007, INFECT IMMUN, V75, P2110, DOI 10.1128/IAI.01739-06; Zeder MA, 2000, SCIENCE, V287, P2254, DOI 10.1126/science.287.5461.2254; Zeder MA, 2008, P NATL ACAD SCI USA, V105, P11597, DOI 10.1073/pnas.0801317105	61	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1085	10.3390/vaccines9101085			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP3NB	34696193	Green Published, gold			2022-04-29	WOS:000713041700001
J	Guan, LJ; Song, JJ; Xue, Y; Ai, X; Liu, ZJ; Si, LF; Li, MY; Zhao, ZQ				Guan, Li-Jun; Song, Ji-Jian; Xue, Yun; Ai, Xia; Liu, Zhi-Jun; Si, Li-Fang; Li, Meng-Yun; Zhao, Zhan-Qin			Immune Protective Efficacy of China's Traditional Inactivated and Attenuated Vaccines against the Prevalent Strains of Pasteurella multocida in Mice	VACCINES			English	Article						Pasteurella multocida; traditional vaccines; mice; immune protection	HEMORRHAGIC SEPTICEMIA; GENETIC ORGANIZATION; CAPSULE; SWINE	Capsular type A and D strains of Pasteurella multocida are the main epidemic serogroups in pigs in China. In this study, we preliminarily evaluated the immune protective efficacy of the two traditional vaccines, an inactivated C44-1 aluminum-hydroxide-gel-adjuvanted (Alh-C44-1) vaccine and a live EO630 vaccine, against currently circulating strains of P. multocida in a mouse model. Mice immunized twice with conventional vaccines generated higher antibody titers, and significantly higher levels of IgG were observed in the mice inoculated with the inactivated Alh-C44-1 vaccine on day 35 (p < 0.05) than those with the live EO630 vaccine. The mice immune protection test showed that the vaccination groups had a 57% or 71% protection effect against the serogroup B strain, but had no protective effect against epidemic strains. In conclusion, our study found that the widely used traditional P. multocida vaccines in China provide good protection against homologous strains, but could not provide cross-protection against heterologous strains in a mouse model.	[Guan, Li-Jun; Song, Ji-Jian; Xue, Yun; Liu, Zhi-Jun; Si, Li-Fang; Li, Meng-Yun; Zhao, Zhan-Qin] Henan Univ Sci & Technol, Coll Anim Sci & Technol, Lab Vet Biol Engn, Luoyang 471023, Peoples R China; [Guan, Li-Jun; Song, Ji-Jian; Xue, Yun; Liu, Zhi-Jun; Si, Li-Fang; Li, Meng-Yun; Zhao, Zhan-Qin] Henan Univ Sci & Technol, Coll Anim Sci & Technol, Key Discipline Lab Safety Environm, Luoyang 471023, Peoples R China; [Ai, Xia] Tianjin Agr Univ, Coll Anim Sci & Vet Med, Tianjin Key Lab Agr Anim Breeding & Hlth Husb, Tianjin 300384, Peoples R China		Zhao, ZQ (通讯作者)，Henan Univ Sci & Technol, Coll Anim Sci & Technol, Lab Vet Biol Engn, Luoyang 471023, Peoples R China.; Zhao, ZQ (通讯作者)，Henan Univ Sci & Technol, Coll Anim Sci & Technol, Key Discipline Lab Safety Environm, Luoyang 471023, Peoples R China.	gliguanlijun@163.com; songjijian0702@163.com; xueyun6688@163.com; aixialucky@163.com; lzj_2132007@163.com; slif2004@163.com; mengyunli@163.com; zhaozhanqin@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [U1704117, 32072899]; Research and Development Foundation of Henan University of Science and Technology [2015ZDCXY04]	This study was supported by grants from the National Natural Science Foundation of China (U1704117 and 32072899) and the Research and Development Foundation of Henan University of Science and Technology (2015ZDCXY04).	Abdulrahman RF, 2021, BMC MICROBIOL, V21, DOI 10.1186/s12866-021-02155-9; Abusalab Sarah, 2013, Pak J Biol Sci, V16, P1388, DOI 10.3923/pjbs.2013.1388.1392; Aida Y, 2019, RESPIR MED CASE REP, V26, P31, DOI 10.1016/j.rmcr.2018.11.004; [Anonymous], 1976, CHENGDU VET BIOPHARM, V2, P18; Arif J, 2013, BIOLOGICALS, V41, P339, DOI 10.1016/j.biologicals.2013.05.003; Ayas MF, 2021, CUREUS, V13, DOI 10.7759/cureus.14232; Boyce J.D., 2010, PATHOGENESIS BACTERI, P325; Boyce JD, 2000, VET MICROBIOL, V72, P121, DOI 10.1016/S0378-1135(99)00193-5; Boyce JD, 2000, J BIOTECHNOL, V83, P153, DOI 10.1016/S0168-1656(00)00309-6; Cappellano G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060606; CARTER GR, 1952, CAN J MED SCI, V30, P48, DOI 10.1139/cjms52-008; de Cecco BS, 2021, J VET DIAGN INVEST, V33, P1156, DOI 10.1177/10406387211034484; Devi LB, 2018, VET WORLD, V11, P348, DOI 10.14202/vetworld.2018.348-354; Ewers C, 2006, VET MICROBIOL, V114, P304, DOI 10.1016/j.vetmic.2005.12.012; Guan LJ, 2019, RES VET SCI, V127, P82, DOI 10.1016/j.rvsc.2019.10.011; Harper M, 2017, TOXINS, V9, DOI 10.3390/toxins9080254; Homayoon M, 2018, J MED MICROBIOL, V67, P1383, DOI 10.1099/jmm.0.000794; Hsuan SL, 2009, VACCINE, V27, P2923, DOI 10.1016/j.vaccine.2009.03.005; Katsuda K, 2013, VET MICROBIOL, V167, P737, DOI 10.1016/j.vetmic.2013.09.029; Kim J, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1861-5; Kubatzky KF, 2012, CURR TOP MICROBIOL, V361, P53, DOI 10.1007/82_2012_204; Liu HS, 2017, IRISH VET J, V70, DOI 10.1186/s13620-016-0080-7; Meeusen ENT, 2007, CLIN MICROBIOL REV, V20, P489, DOI 10.1128/CMR.00005-07; OKERMAN L, 1987, VACCINE, V5, P315, DOI 10.1016/0264-410X(87)90158-7; Peng Zhong, 2019, Acta Veterinaria et Zootechnica Sinica, V50, P1064; Puspitasari Y, 2020, BMC VET RES, V16, DOI 10.1186/s12917-020-02415-2; Qureshi S, 2014, VET WORLD, V7, P224, DOI 10.14202/vetworld.2014.224-228; Ran XH, 2019, MICROB PATHOGENESIS, V132, P208, DOI 10.1016/j.micpath.2019.04.016; REED L. J., 1938, AMER JOUR HYG, V27, P493; Register KB, 2007, VACCINE, V25, P6118, DOI 10.1016/j.vaccine.2007.05.028; RIMLER RB, 1987, J CLIN MICROBIOL, V25, P615, DOI 10.1128/JCM.25.4.615-618.1987; Shah NH, 2001, VET REC, V149, P583, DOI 10.1136/vr.149.19.583; Silveira M., 2014, BMC P, V8, P153, DOI [10.1186/1753-6561-8-S4-P153, DOI 10.1186/1753-6561-8-S4-P153]; Sisco Lauren, 2019, Proc (Bayl Univ Med Cent), V32, P574, DOI 10.1080/08998280.2019.1627804; Soriano-Vargas E, 2012, TROP ANIM HEALTH PRO, V44, P935, DOI 10.1007/s11250-011-9995-x; Tao Q.X.C., 2021, HEILONGJIANG ANIM SC, V5, P127; Townsend KM, 2001, J CLIN MICROBIOL, V39, P924, DOI 10.1128/JCM.39.3.924-929.2001; Wang M., 2013, RES CATTLE BIVALENT; Wu F.G, 1987, CHIN J VET MED, V12, P2; Wu F.G, 1997, CHIN J VET MED, V8, P14; Zhang JS, 2018, VACCINE, V36, P4477, DOI 10.1016/j.vaccine.2018.06.023; Zhao GF, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.687922; Zhao Z.Q., 2006, CHIN J PREV VET MED, V38, P366	44	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1155	10.3390/vaccines9101155			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WY6OA	34696263	Green Published, gold			2022-04-29	WOS:000719397400001
J	Hajjo, R; Sabbah, DA; Bardaweel, SK; Tropsha, A				Hajjo, Rima; Sabbah, Dima A.; Bardaweel, Sanaa K.; Tropsha, Alexander			Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients	VACCINES			English	Article						COVID-19; myocarditis; pericarditis; SARS-CoV-2; systems biology; vaccine; VAERS	INTERFERON-GAMMA; DILATED CARDIOMYOPATHY; SMALLPOX VACCINATION; MYOPERICARDITIS; CORTICOSTEROIDS; ACTIVATION; THERAPY; VIRUS; RNA	Myocarditis and pericarditis have been linked recently to COVID-19 vaccines without exploring the underlying mechanisms, or compared to cardiac adverse events post-non-COVID-19 vaccines. We introduce an informatics approach to study post-vaccine adverse events on the systems biology level to aid the prioritization of effective preventive measures and mechanism-based pharmacotherapy by integrating the analysis of adverse event reports from the Vaccine Adverse Event Reporting System (VAERS) with systems biology methods. Our results indicated that post-vaccine myocarditis and pericarditis were associated most frequently with mRNA COVID-19 vaccines followed by live or live-attenuated non-COVID-19 vaccines such as smallpox and anthrax vaccines. The frequencies of cardiac adverse events were affected by vaccine, vaccine type, vaccine dose, sex, and age of the vaccinated individuals. Systems biology results suggested a central role of interferon-gamma (INF-gamma) in the biological processes leading to cardiac adverse events, by impacting MAPK and JAK-STAT signaling pathways. We suggest that increasing the time interval between vaccine doses minimizes the risks of developing inflammatory adverse reactions. We also propose glucocorticoids as preferred treatments based on system biology evidence. Our informatics workflow provides an invaluable tool to study post-vaccine adverse events on the systems biology level to suggest effective mechanism-based pharmacotherapy and/or suitable preventive measures.	[Hajjo, Rima; Sabbah, Dima A.] Al Zaytoonah Univ Jordan, Fac Pharm, Dept Pharm, Amman 11733, Jordan; [Hajjo, Rima; Tropsha, Alexander] Univ North Carlina Chapel Hill, Div Chem Biol & Med Chem, Lab Mol Modeling, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA; [Hajjo, Rima] Natl Ctr Epidem & Communicable Dis Control, Amman 11942, Jordan; [Bardaweel, Sanaa K.] Univ Jordan, Sch Pharm, Dept Pharmaceut Sci, Amman 11942, Jordan		Hajjo, R (通讯作者)，Al Zaytoonah Univ Jordan, Fac Pharm, Dept Pharm, Amman 11733, Jordan.; Hajjo, R (通讯作者)，Univ North Carlina Chapel Hill, Div Chem Biol & Med Chem, Lab Mol Modeling, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.; Hajjo, R (通讯作者)，Natl Ctr Epidem & Communicable Dis Control, Amman 11942, Jordan.	r.hajjo@zuj.edu.jo; dima.sabbah@zuj.edu.jo; s.bardaweel@qu.edu.jo; alex_tropsha@unc.edu		Sabbah, Dima/0000-0003-1428-5097; Bardaweel, Sanaa/0000-0002-4823-0708	Deanship of Scientific Research at Al-Zaytoonah University of Jordan [2020-2019/17/03]	FundingR.H. and D.A.S. acknowledge support from the Deanship of Scientific Research at Al-Zaytoonah University of Jordan (Grant number 2020-2019/17/03).	Allanore Y, 2006, ANN RHEUM DIS, V65, P249, DOI 10.1136/ard.2005.038679; Aomatsu M, 2013, BIOCHEM BIOPH RES CO, V441, P220, DOI 10.1016/j.bbrc.2013.10.042; Arness MK, 2004, AM J EPIDEMIOL, V160, P642, DOI 10.1093/aje/kwh269; Arunachalam PS, 2021, NATURE, V596, P410, DOI 10.1038/s41586-021-03791-x; Bardaweel SK, 2021, ACTA PHARMACEUT, V71, P175, DOI 10.2478/acph-2021-0013; Barton M, 2008, PEDIATR INFECT DIS J, V27, P831, DOI 10.1097/INF.0b013e31816ff7b2; Garcia JB, 2021, REV ESP CARDIOL, V74, P812, DOI [10.1016/j.rec.2021.04.005, 10.1016/j.recesp.2021.03.009]; Blanton RM, 2019, AM J PHYSIOL-HEART C, V317, pH124, DOI 10.1152/ajpheart.00028.2019; Calcaterra G, 2021, PEDIATRIC REP, V13, P530, DOI 10.3390/pediatric13030061; Cassimatis DC, 2004, J AM COLL CARDIOL, V43, P1503, DOI 10.1016/j.jacc.2003.11.053; CDC, 2021, VACC DIS; CDC, 2021, COVID 19 VAST TECHN; CDC, 2021, CTR DIS CONTROL PREV; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P492; Chen HS, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004471.pub3; Chin KL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/5212910; Cooper LT, 2009, NEW ENGL J MED, V360, P1526, DOI 10.1056/NEJMra0800028; Coyle Justin, 2020, JACC Case Rep, V2, P1331, DOI 10.1016/j.jaccas.2020.04.025; Engler RJM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118283; Fathima T., 2020, INT J CUR RES REV, V12, P91, DOI [10.31782/IJCRR.2020.SP42, DOI 10.31782/IJCRR.2020.SP42]; FDA, 2021, FACT SHEET REC CAR E; Fenner F., 1988, SMALLPOX ITS ERADICA, V6, P1; FINLAYJONES LR, 1964, NEW ENGL J MED, V270, P41, DOI 10.1056/NEJM196401022700108; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Gadotti AC, 2020, VIRUS RES, V289, DOI 10.1016/j.virusres.2020.198171; Garlapati S, 2012, EXPERT REV VACCINES, V11, P1307, DOI [10.1586/ERV.12.111, 10.1586/erv.12.111]; Grabellus F, 2005, HISTOPATHOLOGY, V46, P89, DOI 10.1111/j.1365-2559.2005.01999.x; Hajjo R, 2020, ACS OMEGA, V5, P29765, DOI 10.1021/acsomega.0c03597; Hajjo R, 2020, PHARM RES-DORDR, V37, DOI 10.1007/s11095-020-02930-9; Hajjo R, 2012, J MED CHEM, V55, P5704, DOI 10.1021/jm2011657; Hayney MS, 2003, PHARMACOTHERAPY, V23, P431, DOI 10.1592/phco.23.4.431.32127; He Qian, 2021, Emerging Microbes & Infections, V10, P629, DOI 10.1080/22221751.2021.1902245; Hu ZJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585647; Huang GP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01110; Huber JP, 2011, IMMUNOLOGY, V132, P466, DOI 10.1111/j.1365-2567.2011.03412.x; Husseini AA, 2021, ERCIYES MED J, V43, P116, DOI 10.14744/etd.2020.40326; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Kak Gunjan, 2018, BioMolecular Concepts, V9, P64, DOI 10.1515/bmc-2018-0007; Kakkar RM, 2013, J CLIN IMAG SCI, V3, DOI 10.4103/2156-7514.114211; Kounis NG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030221; Kuhl U, 1995, EUR HEART J, V16, P168, DOI 10.1093/eurheartj/16.suppl_O.168; Li YN, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00342; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; Mei R, 2018, INT J CARDIOL, V273, P183, DOI 10.1016/j.ijcard.2018.09.054; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; MITTERMAYER C, 1976, BEITR PATHOL, V158, P212; Morgan J, 2008, CLIN INFECT DIS, V46, pS242, DOI 10.1086/524747; Murira A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00609; Murphy JG, 2003, LANCET, V362, P1378, DOI 10.1016/S0140-6736(03)14635-1; Neves PCC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081953; NLM, PERICARDIUM; NLM, MYOCARDITIS; Osokine I, 2014, P NATL ACAD SCI USA, V111, P7409, DOI 10.1073/pnas.1401662111; Pober JS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01907; Sabbah DA, 2021, CURR TOP MED CHEM, V21, P571, DOI 10.2174/1568026621666210119111409; Sabbah DA, 2021, CURR TOP MED CHEM, V21, P442, DOI 10.2174/1568026620666201207095117; Sagar S, 2012, LANCET, V379, P738, DOI 10.1016/S0140-6736(11)60648-X; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sayedahmed EE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040574; Shimabukuro TT, 2021, OBSTET GYNECOL SURV, V76, P729, DOI [10.1056/NEJMoa2104983, 10.1056/NEJMx210016, 10.1097/01.ogx.0000802676.57373.17]; Su JR, 2021, VACCINE, V39, P839, DOI 10.1016/j.vaccine.2020.12.046; Teijaro JR, 2021, NAT REV IMMUNOL, V21, P195, DOI 10.1038/s41577-021-00526-x; TOMIOKA N, 1986, J AM COLL CARDIOL, V7, P868, DOI 10.1016/S0735-1097(86)80349-7; Tsukada B, 2009, HUM PATHOL, V40, P1015, DOI 10.1016/j.humpath.2008.12.017; VAERS, 2021, VACC ADV EV REP SYST; van den Elsen PJ, 2004, CURR OPIN IMMUNOL, V16, P67, DOI 10.1016/j.coi.2003.11.015; Yanagisawa T, 2011, INT HEART J, V52, P110, DOI 10.1536/ihj.52.110; Zhang LL, 2020, CIRCULATION, V141, P2031, DOI 10.1161/CIRCULATIONAHA.119.044703	68	8	8	12	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1186	10.3390/vaccines9101186			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WT0XC	34696294	Green Published, gold			2022-04-29	WOS:000715595400001
J	Rather, IA; Choi, SB; Kamli, MR; Hakeem, KR; Sabir, JSM; Park, YH; Hor, YY				Rather, Irfan A.; Choi, Sy-Bing; Kamli, Majid Rasool; Hakeem, Khalid Rehman; Sabir, Jamal S. M.; Park, Yong-Ha; Hor, Yan-Yan			Potential Adjuvant Therapeutic Effect of Lactobacillus plantarum Probio-88 Postbiotics against SARS-COV-2	VACCINES			English	Article						Lactobacillus plantarum; SARS-COV-2; COVID-19; postbiotics; plantaricin; helicase; viral replication; ROS; ERK; inflammatory	WEB SERVER; CORONAVIRUS; INHIBITORS; INFECTION	In response to the ongoing COVID-19 pandemic, the global effort to develop high efficacy countermeasures to control the infection are being conducted at full swing. While the efficacy of vaccines and coronavirus drugs are being tested, the microbiome approach represents an alternative pathophysiology-based approach to prevent the severity of the infection. In the current study, we evaluated the action of a novel probiotic Lactobacillus plantarum Probio-88 against SARS-COV-2 replication and immune regulation using an in vitro and in silico study. The results showed that extract from this strain (P88-CFS) significantly inhibited the replication of SARS-COV-2 and the production of reactive oxygen species (ROS) levels. Furthermore, compared with infected cells, P88-CFS treated cells showed a significant reduction in inflammatory markers such as IFN-alpha, IFN-beta, and IL-6. Using an in silico molecular docking approach, it was postulated that the antiviral activity of L. plantarum Probio-88 was derived from plantaricin E (PlnE) and F (PlnF). The high binding affinity and formation of hydrogen bonding indicated that the association of PlnE and PlnF on SARS-COV-2 helicase might serve as a blocker by preventing the binding of ss-RNA during the replication of the virus. In conclusion, our study substantiated that P88-CFS could be used as an integrative therapeutic approach along with vaccine to contain the spread of the highly infectious pathogen and possibly its variants.</p>	[Rather, Irfan A.; Kamli, Majid Rasool; Hakeem, Khalid Rehman; Sabir, Jamal S. M.] King Abdulaziz Univ, Fac Sci, Dept Biol Sci, Jeddah 21589, Saudi Arabia; [Choi, Sy-Bing] Perdana Univ, Ctr Bioinformat, Sch Data Sci, Suite 9-2 9th Fl, Kuala Lumpur 50490, Malaysia; [Park, Yong-Ha; Hor, Yan-Yan] Yeungnam Univ, Dept Biotechnol, 280 Daehak Ro, Gyongsan 38541, Gyeongbuk Do, South Korea; [Park, Yong-Ha] Probion Corp Jeonbuk Inst Food Bioind, 111-18 Wonjangdong Gil, Jeonju 54810, South Korea; [Park, Yong-Ha] Yeungnam Univ, PYH Lab, 280 Daehak Ro, Gyongsan 38541, Gyeongbukd Do, South Korea		Rather, IA (通讯作者)，King Abdulaziz Univ, Fac Sci, Dept Biol Sci, Jeddah 21589, Saudi Arabia.; Hor, YY (通讯作者)，Yeungnam Univ, Dept Biotechnol, 280 Daehak Ro, Gyongsan 38541, Gyeongbuk Do, South Korea.	ammm@kau.edu.sa; sybing.choi@perdanauniversity.edu.my; mkamli@kau.edu.sa; kur.hakeem@gmail.com; jsabir2622@gmail.com; peter@yu.ac.kr; yanyanhor@yu.ac.kr	Rather, Irfan A./AAH-1425-2019; Choi, Sy Bing/AGZ-6475-2022; Hakeem, Khalid Rehman/D-4335-2013	Hakeem, Khalid Rehman/0000-0001-7824-4695; Sabir, Jamal/0000-0003-4785-9894; Rather (PhD.), Irfan A./0000-0003-2752-0519; Choi, Sy Bing/0000-0003-3189-904X; kamli, majid/0000-0003-0553-0046	Deanship of Scientific Research (DSR); King Abdulaziz University [GCV19-27-1441]	Funding This project was funded by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, under the grant no. GCV19-27-1441. The authors, therefore, acknowledge with thanks the DSR technical and financial support.	Al Kassaa I, 2014, PROBIOTICS ANTIMICRO, V6, P177, DOI 10.1007/s12602-014-9162-6; Al Kassaa I., 2017, NEW INSIGHTS ANTIVIR, P1, DOI [10.1007/978-3-319-49688-7_1, DOI 10.1007/978-3-319-49688-7_1]; Angurana SK, 2018, CRIT CARE MED, V46, P1656, DOI 10.1097/CCM.0000000000003279; Anwar F, 2021, J BIOMOL STRUCT DYN, V39, P4175, DOI 10.1080/07391102.2020.1775123; Bousquet J, 2021, ALLERGY, V76, P735, DOI 10.1111/all.14549; Chen IY, 2010, J VIROL, V84, P7703, DOI 10.1128/JVI.02560-09; Custodero C, 2018, AGEING RES REV, V46, P42, DOI 10.1016/j.arr.2018.05.004; d'Ettorre G, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00389; Dreyer L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47843-9; Frick DN, 2006, CURR PHARM DESIGN, V12, P1315, DOI 10.2174/138161206776361147; Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759; Ghasemnejad-Berenji M, 2021, PHARMACOLOGY, V106, P119, DOI 10.1159/000511280; Habtemariam S, 2020, ARCH MED RES, V51, P733, DOI 10.1016/j.arcmed.2020.05.024; Hoseinifar SH, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02429; Huang Y, 2020, ACTA PHARMACOL SIN, V41, P1141, DOI 10.1038/s41401-020-0485-4; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jia ZX, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e124; Kim SW, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13100266; Klemm C, 2017, SCI REP-UK, V7, DOI 10.1038/srep42473; Kumar VJR, 2010, TROP ANIM HEALTH PRO, V42, P1855, DOI 10.1007/s11250-010-9648-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lehtoranta L, 2020, NUTRIENTS, V12, DOI 10.3390/nu12103163; Lei XB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17665-9; Lim JY, 2014, ACTA VIROL, V58, P253, DOI 10.4149/av_2014_03_253; Matheson NJ, 2020, SCIENCE, V369, P510, DOI 10.1126/science.abc6156; Nainu F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01220; Newman JA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25166-6; Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012; Salman J.A.S., 2020, OPEN ACCESS MACED J, V8, P496, DOI [10.3889/oamjms.2020.5483, DOI 10.3889/OAMJMS.2020.5483]; Schwarz KB, 1996, FREE RADICAL BIO MED, V21, P641, DOI 10.1016/0891-5849(96)00131-1; Singh K, 2021, NUTR RES, V87, P1, DOI 10.1016/j.nutres.2020.12.014; Song PP, 2020, CLIN CHIM ACTA, V509, P280, DOI 10.1016/j.cca.2020.06.017; Tiwari SK, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01877; Tsai CJ, 1997, PROTEIN SCI, V6, P53; van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014; Villena J, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9040683; Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427; Wegh CAM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194673; White MA, 2020, J PHYS CHEM LETT, V11, P9144, DOI 10.1021/acs.jpclett.0c02421; World Health Organization, 2020, PNEUM UNK CAUS CHIN; Wypych TP, 2019, NAT IMMUNOL, V20, P1279, DOI 10.1038/s41590-019-0451-9; Xue LC, 2016, BIOINFORMATICS, V32, P3676, DOI 10.1093/bioinformatics/btw514; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z; Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737; Zrelli S, 2021, J MED VIROL, V93, P3288, DOI 10.1002/jmv.26746	45	4	4	8	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1067	10.3390/vaccines9101067			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO7GQ	34696175	Green Published, gold			2022-04-29	WOS:000712618700001
J	Adegbite, A; McCarthy, PC				Adegbite, Ayobami; McCarthy, Pumtiwitt C.			Recent and Future Advances in the Chemoenzymatic Synthesis of Homogeneous Glycans for Bacterial Glycoconjugate Vaccine Development	VACCINES			English	Review						glycoconjugate vaccines; bacterial pathogens; chemoenzymatic synthesis	NEISSERIA-MENINGITIDIS SEROGROUP; DIRECTED EVOLUTION; CAPSULE POLYMERASES; REPEATING UNIT; OLIGOSACCHARIDES; IMMUNOGENICITY; GLYCOSYNTHASE	Vaccines are important in preventing disease outbreaks and controlling the spread of disease in a population. A variety of vaccines exist, including subunit, recombinant, and conjugate vaccines. Glycoconjugate vaccines have been an important tool to fight against diseases caused by a number of bacteria. Glycoconjugate vaccines are often heterogeneous. Vaccines of the future are becoming more rationally designed to have a defined oligosaccharide chain length and position of conjugation. Homogenous vaccines could play an important role in assessing the relationship between vaccine structure and immune response. This review focuses on recent advances in the chemoenzymatic production of defined bacterial oligosaccharides for vaccine development with a focus on Neisseria meningitidis and selected WHO-prioritized antibacterial resistant-pathogens. We also provide some perspective on future advances in the chemoenzymatic synthesis of well-defined oligosaccharides.	[Adegbite, Ayobami] Morgan State Univ, Bioenvironm Sci Program, Baltimore, MD 21251 USA; [Adegbite, Ayobami; McCarthy, Pumtiwitt C.] Morgan State Univ, Dept Chem, Baltimore, MD 21251 USA		McCarthy, PC (通讯作者)，Morgan State Univ, Dept Chem, Baltimore, MD 21251 USA.	ayade9@morgan.edu; Pumtiwitt.McCarthy@morgan.edu		McCarthy, Pumtiwitt/0000-0003-4096-1677	National Institute of General Medical Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5SC2GM125517-03]	This research in the McCarthy Lab is supported in part by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number 5SC2GM125517-03. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Abrahams K, 2021, CURR OPIN MICROBIOL, V60, P58, DOI 10.1016/j.mib.2021.01.012; Aharoni A, 2006, NAT METHODS, V3, P609, DOI 10.1038/NMETH899; Avci FY, 2011, NAT MED, V17, P1602, DOI 10.1038/nm.2535; Baliban SM, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005493; Bashiri S, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12100965; Bonam SR, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105684; Brinkac L, 2017, MICROB ECOL, V74, P1001, DOI 10.1007/s00248-017-0985-z; Britton J, 2017, NAT PROTOC, V12, P2423, DOI 10.1038/nprot.2017.102; Claus H, 2009, MOL MICROBIOL, V71, P960, DOI 10.1111/j.1365-2958.2008.06580.x; Danieli E, 2012, BIOORGAN MED CHEM, V20, P6403, DOI 10.1016/j.bmc.2012.08.048; Feldman MF, 2019, P NATL ACAD SCI USA, V116, P18655, DOI 10.1073/pnas.1907833116; Fiebig T, 2018, J BIOL CHEM, V293, P953, DOI 10.1074/jbc.RA117.000488; Fiebig T, 2014, J BIOL CHEM, V289, P19395, DOI 10.1074/jbc.M114.575142; Fiebig T, 2014, GLYCOBIOLOGY, V24, P150, DOI 10.1093/glycob/cwt102; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Gao QQ, 2020, MICROB DRUG RESIST, V26, P1195, DOI 10.1089/mdr.2019.0439; Hagen B, 2017, ORG LETT, V19, P2514, DOI 10.1021/acs.orglett.7b00747; Harding CM, 2019, GLYCOBIOLOGY, V29, P519, DOI 10.1093/glycob/cwz031; Henriques P, 2020, P NATL ACAD SCI USA, V117, P29795, DOI 10.1073/pnas.2011385117; Hlozek J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040643; Hu ZY, 2017, CHEM-ASIAN J, V12, P419, DOI 10.1002/asia.201600819; Iwasaki A, 2020, CELL, V183, P290, DOI 10.1016/j.cell.2020.09.040; Janesch B, 2019, GLYCOBIOLOGY, V29, P588, DOI 10.1093/glycob/cwz021; Kaplonek P, 2018, P NATL ACAD SCI USA, V115, P13353, DOI 10.1073/pnas.1811862115; Kay E, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0110-z; Kim YW, 2004, J BIOL CHEM, V279, P42787, DOI 10.1074/jbc.M406890200; Kuttel MM, 2021, GLYCOCONJUGATE J, V38, P411, DOI 10.1007/s10719-021-09991-x; Li RY, 2020, J ORG CHEM, V85, P16157, DOI 10.1021/acs.joc.0c02134; Li RY, 2020, ACS CATAL, V10, P2791, DOI 10.1021/acscatal.9b05597; Li WQ, 2019, CARBOHYD RES, V472, P86, DOI 10.1016/j.carres.2018.11.014; Li ZH, 2020, EUR J MED CHEM, V204, DOI 10.1016/j.ejmech.2020.112578; McCarthy PC, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6010012; McCarthy PC, 2013, GLYCOCONJUGATE J, V30, P857, DOI 10.1007/s10719-013-9490-x; McNamara LA, 2020, MMWR-MORBID MORTAL W, V69, P735, DOI 10.15585/mmwr.mm6924a2; Ming SA, 2019, BIOCHEMISTRY-US, V58, P679, DOI 10.1021/acs.biochem.8b01114; Ming SA, 2018, GLYCOBIOLOGY, V28, P100, DOI 10.1093/glycob/cwx100; Mitra A, 2016, CARBOHYD RES, V426, P1, DOI 10.1016/j.carres.2016.03.012; Moliva JI, 2015, VACCINE, V33, P5035, DOI 10.1016/j.vaccine.2015.08.033; Mosley SL, 2010, BIOCATAL BIOTRANSFOR, V28, P41, DOI 10.3109/10242420903388694; Muindi KM, 2014, GLYCOBIOLOGY, V24, P139, DOI 10.1093/glycob/cwt091; Oldrini D, 2018, ACS CHEM BIOL, V13, P984, DOI 10.1021/acschembio.7b01057; Ortiz C, 2019, CATAL SCI TECHNOL, V9, P2380, DOI 10.1039/c9cy00415g; Panza M, 2018, CHEM REV, V118, P8105, DOI 10.1021/acs.chemrev.8b00051; Petrovsky N, 2015, DRUG SAFETY, V38, P1059, DOI 10.1007/s40264-015-0350-4; Plotkin S, 2014, P NATL ACAD SCI USA, V111, P12283, DOI 10.1073/pnas.1400472111; Pollard AJ, 2009, NAT REV IMMUNOL, V9, P212, DOI 10.1038/nri2494; Ravenscroft N, 2019, GLYCOBIOLOGY, V29, P669, DOI 10.1093/glycob/cwz044; Reina JJ, 2008, ORG BIOMOL CHEM, V6, P2743, DOI 10.1039/b802144a; Robbins JB, 2009, P NATL ACAD SCI USA, V106, P7974, DOI 10.1073/pnas.0900891106; Rodrigues CMC, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01526; Romanow A, 2014, J BIOL CHEM, V289, P33945, DOI 10.1074/jbc.M114.597773; Romanow A, 2013, J BIOL CHEM, V288, P11718, DOI 10.1074/jbc.M113.452276; Schijns V, 2020, IMMUNOL REV, V296, P169, DOI 10.1111/imr.12889; SCHNEERSON R, 1980, J EXP MED, V152, P361, DOI 10.1084/jem.152.2.361; Seeberger PH, 2007, NATURE, V446, P1046, DOI 10.1038/nature05819; Sharyan Abeer, 2018, BMC Res Notes, V11, P482, DOI 10.1186/s13104-018-3596-y; Shim JH, 2012, PROTEIN ENG DES SEL, V25, P465, DOI 10.1093/protein/gzs045; Stephens DS, 2007, FEMS MICROBIOL REV, V31, P3, DOI 10.1111/j.1574-6976.2006.00051.x; Tan YM, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw8451; Tzeng YL, 2016, CRIT REV MICROBIOL, V42, P759, DOI 10.3109/1040841X.2015.1022507; Verez-Bencomo V, 2004, SCIENCE, V305, P522, DOI 10.1126/science.1095209; Wang PF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030222; World Health Organization, 2015, GLOB ACT PLAN ANT RE; World Health Organization (WHO), GLOB TUB REP; Wu Z, 2019, P NATL ACAD SCI USA, V116, P8852, DOI 10.1073/pnas.1901979116; Yang GY, 2010, J AM CHEM SOC, V132, P10570, DOI 10.1021/ja104167y; Yang GY, 2009, CHEMBIOCHEM, V10, P2704, DOI 10.1002/cbic.200900384; Zhang QJ, 2019, ACS CENTRAL SCI, V5, P1407, DOI 10.1021/acscentsci.9b00454	68	1	1	6	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1021	10.3390/vaccines9091021			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3AB	34579258	gold, Green Published			2022-04-29	WOS:000702080000001
J	Cugno, M; Consonni, D; Lombardi, A; Bono, P; Oggioni, M; Renteria, SU; Pesatori, AC; Castaldi, S; Riboldi, L; Bordini, L; Nava, CD; Ceriotti, F; Torri, A; Tafuri, F; Ghigliazza, G; Peyvandi, F; Bandera, A; Gori, A				Cugno, Massimo; Consonni, Dario; Lombardi, Andrea; Bono, Patrizia; Oggioni, Massimo; Uceda Renteria, Sara; Pesatori, Angela Cecilia; Castaldi, Silvana; Riboldi, Luciano; Bordini, Lorenzo; Nava, Carlo Domenico; Ceriotti, Ferruccio; Torri, Adriana; Tafuri, Francesco; Ghigliazza, Gabriele; Peyvandi, Flora; Bandera, Alessandra; Gori, Andrea			Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors	VACCINES			English	Article						angioedema; urticaria; COVID-19 vaccination; mRNA vaccination; ACE inhibitors; heath care workers	BRADYKININ; ACTIVATION; PLASMA; ANGIOEDEMA; PATHWAYS; CASCADE; SYSTEM	Urticarial eruptions and angioedema are the most common cutaneous reactions in patients undergoing mRNA COVID-19 vaccinations. The vasoactive peptide bradykinin has long been known to be involved in angioedema and recently also in urticaria. Bradykinin is mainly catabolized by angiotensin-converting enzyme (ACE), which is inhibited by ACE inhibitors, a commonly employed class of antihypertensive drugs. We evaluated the risk of developing urticaria/angioedema after inoculation with the BNT162b2 mRNA COVID-19 vaccine in a population of 3586 health care workers. The influences of ACE inhibitors and selected potential confounding variables (sex, age, previous SARS-CoV-2 infection, and allergy history) were evaluated by fitting univariate and multivariable Poisson regression models. The overall cumulative incidence of urticaria/angioedema was 1.8% (65 out of 3586; 95% CI: 1.4-2.3%). Symptoms were mild, and no subject consulted a physician. Subjects taking ACE inhibitors had an adjusted three-fold increased risk of urticaria/angioedema (RR 2.98, 95% CI: 1.12-7.96). When we restricted the analysis to those aged 50 years or more, the adjusted RR was 3.98 (95% CI: 1.44-11.0). In conclusion, our data indicate that subjects taking ACE inhibitors have an increased risk of urticaria/angioedema after vaccination with the BNT162b2 mRNA COVID-19 vaccine. Symptoms are mild and self-limited; however, they should be considered to adequately advise subjects undergoing vaccination.	[Cugno, Massimo; Torri, Adriana; Tafuri, Francesco; Ghigliazza, Gabriele; Peyvandi, Flora] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Internal Med, Dept Pathophysiol & Transplantat, I-20122 Milan, Italy; [Consonni, Dario; Pesatori, Angela Cecilia] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Epidemiol Unit, I-20122 Milan, Italy; [Lombardi, Andrea; Bandera, Alessandra; Gori, Andrea] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, Infect Dis Unit, I-20122 Milan, Italy; [Bono, Patrizia; Oggioni, Massimo; Uceda Renteria, Sara; Ceriotti, Ferruccio] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Clin Lab, I-20122 Milan, Italy; [Pesatori, Angela Cecilia] Univ Milan, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy; [Castaldi, Silvana] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Biomed Sci Hlth, Qual Unit, I-20122 Milan, Italy; [Riboldi, Luciano; Bordini, Lorenzo; Nava, Carlo Domenico] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Occupat Hlth Unit, I-20122 Milan, Italy; [Bandera, Alessandra; Gori, Andrea] Univ Milan, Ctr Multidisciplinary Res Hlth Sci MACH, I-20122 Milan, Italy		Cugno, M (通讯作者)，Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Internal Med, Dept Pathophysiol & Transplantat, I-20122 Milan, Italy.	massimo.cugno@unimi.it; dario.consonni@unimi.it; andrea.lombardi@unimi.it; patrizia.bono@policlinico.mi.it; massimo.oggioni@policlinico.mi.it; sara.ucedarenteria@policlinico.mi.it; angela.pesatori@unimi.it; silvana.castaldi@unimi.it; luciano.riboldi@policlinico.mi.it; lorenzo.bordini@policlinico.mi.it; carlo.nava@policlinico.mi.it; ferruccio.ceriotti@policlinico.mi.it; adriana.torri@fastwebnet.it; francesco.tafuri@unimi.it; gabriele.ghigliazza@unimi.it; flora.peyvandi@unimi.it; alessandra.bandera@unimi.it; andrea.gori@unimi.it	Lombardi, Andrea/U-4323-2019; Gori, Andrea/AAC-6078-2022; Renteria, Sara Uceda/AAY-4348-2020; Bandera, Alessandra/AAC-6081-2022; Castaldi, Silvana/L-1493-2016; Cugno, Massimo/K-8106-2016; Consonni, Dario/K-7943-2016; pesatori, angela/K-5742-2016	Lombardi, Andrea/0000-0002-0383-9579; Renteria, Sara Uceda/0000-0002-2027-8478; BANDERA, ALESSANDRA/0000-0001-9440-4601; Castaldi, Silvana/0000-0003-1716-6624; Cugno, Massimo/0000-0002-9918-0763; Ferruccio, Ceriotti/0000-0002-0958-5354; Consonni, Dario/0000-0002-8935-3843; pesatori, angela/0000-0002-0261-3252			Adam A, 2002, LANCET, V359, P2088, DOI 10.1016/S0140-6736(02)08914-6; Agostoni A, 1999, IMMUNOPHARMACOLOGY, V44, P21, DOI 10.1016/S0162-3109(99)00107-1; Bien BY, 2010, J MANAGE CARE PHARM, V16, P671, DOI 10.18553/jmcp.2010.16.9.671; Cicardi M, 2010, NEW ENGL J MED, V363, P532, DOI 10.1056/NEJMoa0906393; Cugno M, 1997, BLOOD, V89, P3213, DOI 10.1182/blood.V89.9.3213; Cugno M, 2017, CLIN EXP ALLERGY, V47, P139, DOI 10.1111/cea.12869; Cugno M, 2003, INT IMMUNOPHARMACOL, V3, P311, DOI 10.1016/S1567-5769(02)00162-5; Cugno M, 2009, TRENDS MOL MED, V15, P69, DOI 10.1016/j.molmed.2008.12.001; Dendorfer A, 2001, AM J PHYSIOL-HEART C, V280, pH2182, DOI 10.1152/ajpheart.2001.280.5.H2182; Duan QL, 2005, AM J HUM GENET, V77, P617, DOI 10.1086/496899; GREENLAND S, 1987, AM J EPIDEMIOL, V125, P761, DOI 10.1093/oxfordjournals.aje.a114593; Hofman Z, 2016, CLIN REV ALLERG IMMU, V51, P152, DOI 10.1007/s12016-016-8540-0; Hofman ZLM, 2020, CLIN EXP ALLERGY, V50, P343, DOI 10.1111/cea.13558; Joseph K, 2002, INT IMMUNOPHARMACOL, V2, P1851, DOI 10.1016/S1567-5769(02)00186-8; Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316; Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2; Lombardi A, 2021, J INFECT PUBLIC HEAL, V14, P1120, DOI 10.1016/j.jiph.2021.07.005; Mahmoudpour SH, 2015, INT J CLIN PHARM-NET, V37, P1095, DOI 10.1007/s11096-015-0159-3; Maurer M, 2011, ALLERGY, V66, P1397, DOI 10.1111/j.1398-9995.2011.02686.x; McMahon DE, 2021, J AM ACAD DERMATOL, V85, P46, DOI 10.1016/j.jaad.2021.03.092; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Nussberger J, 2002, NEW ENGL J MED, V347, P621, DOI 10.1056/NEJM200208223470820; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sala-Cunill A, 2015, J ALLERGY CLIN IMMUN, V135, P1031, DOI 10.1016/j.jaci.2014.07.057; Schmaier AH, 2007, J THROMB HAEMOST, V5, P2323, DOI 10.1111/j.1538-7836.2007.02770.x; Schmaier AH, 2016, J THROMB HAEMOST, V14, P28, DOI 10.1111/jth.13194; Sellaturay P, 2021, CLIN EXP ALLERGY, V51, P861, DOI 10.1111/cea.13874; Shariat-Madar Z, 2002, J BIOL CHEM, V277, P17962, DOI 10.1074/jbc.M106101200; Zanichelli A, 2017, J ALLER CL IMM-PRACT, V5, P1307, DOI 10.1016/j.jaip.2016.12.032; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	30	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1011	10.3390/vaccines9091011			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW4PZ	34579248	Green Published, gold			2022-04-29	WOS:000700141200001
J	Said, MA; Khan, DJO; Al-Blewi, FF; Al-Kaff, NS; Ali, AA; Rezki, N; Aouad, MR; Hagar, M				Said, Musa A.; Khan, Daoud J. O.; Al-Blewi, Fawzia F.; Al-Kaff, Nadia S.; Ali, Adeeb A.; Rezki, Nadjet; Aouad, Mohamed Reda; Hagar, Mohamed			New 1,2,3-Triazole Scaffold Schiff Bases as Potential Anti-COVID-19: Design, Synthesis, DFT-Molecular Docking, and Cytotoxicity Aspects	VACCINES			English	Article						1,2,3-triazole; Schiff base (SB); DFT-QSAR; COVID-19; molecular docking; cytotoxicity	CLICK CHEMISTRY; MAIN PROTEASE; 1,2,4-TRIAZOLE; SEQUENCE; 1,3,4-THIADIAZOLE; 1,3,4-OXADIAZOLE; DERIVATIVES; TRIAZOLE; MANNICH; MOIETY	Schiff bases encompassing a 1,2,3-triazole motif were synthesized using an efficient multi-step synthesis. The formations of targeted Schiff base ligands were confirmed by different spectroscopic techniques (FT-IR, H-1 NMR, C-13 NMR, and CHN analysis). The spectral data analysis revealed that the newly designed hydrazones exist as a mixture of trans-E and cis-E diastereomers. Densityfunctional theory calculations (DFT) for the Schiff bases showed that the trans-trans form has the lowest energy structure with maximum stability compared to the other possible geometrical isomers that could be present due to the orientation of the amidic NH-C=O group. The energy differences between the trans-trans on one side and syn-syn and syn-trans isomers on the other side were 9.26 and 5.56 kcal/mol, respectively. A quantitative structure-activity relationship investigation was also performed in terms of density functional theory. The binding affinities of the newly synthesized bases are, maybe, attributed to the presence of hydrogen bonds together with many hydrophobic interactions between the ligands and the active amino acid residue of the receptor. The superposition of the inhibitor N3 and an example ligand into the binding pocket of 7BQY is also presented. Further interesting comparative docking analyses were performed. Quantitative structure-activity relationship calculations are presented, illustrating possible inhibitory activity. Further computer-aided cytotoxicity analysis by Drug2Way and PASS online software was carried out for Schiff base ligands against various cancer cell lines. Overall, the results of this study suggest that these Schiff base derivatives may be considered for further investigation as possible therapeutic agents for COVID-19.	[Said, Musa A.; Khan, Daoud J. O.; Al-Blewi, Fawzia F.; Ali, Adeeb A.; Rezki, Nadjet; Aouad, Mohamed Reda] Taibah Univ, Coll Sci, Dept Chem, Al Madinah Al Munawarah 30002, Saudi Arabia; [Al-Kaff, Nadia S.] Taibah Univ, Coll Sci, Dept Biol, Al Madinah Al Munawarah 30002, Saudi Arabia; [Hagar, Mohamed] Taibah Univ, Coll Sci, Chem Dept, Yanbu 30799, Saudi Arabia; [Hagar, Mohamed] Alexandria Univ, Fac Sci, Chem Dept, Alexandria 21321, Egypt		Said, MA; Aouad, MR (通讯作者)，Taibah Univ, Coll Sci, Dept Chem, Al Madinah Al Munawarah 30002, Saudi Arabia.	masaid@taibahu.edu.sa; dnnimnd@hotmail.com; fbalawi@taibahu.edu.sa; nkaff@taibahu.edu.sa; aksheikhali@taibahu.edu.sa; nrezki@taibahu.edu.sa; maouad@taibahu.edu.sa; mhagar@taibahmedu.sa		Al-KAFF, Nadia/0000-0001-8344-136X			Agalave SG, 2011, CHEM-ASIAN J, V6, P2696, DOI 10.1002/asia.201100432; Alafeefy AM, 2015, BIOORG MED CHEM LETT, V25, P179, DOI 10.1016/j.bmcl.2014.11.088; Ali AA, 2017, BIOORG MED CHEM LETT, V27, P3698, DOI 10.1016/j.bmcl.2017.07.008; Allouche AR, 2011, J COMPUT CHEM, V32, P174, DOI 10.1002/jcc.21600; Almehmadi MA, 2021, J MOL STRUCT, V1225, DOI 10.1016/j.molstruc.2020.129148; Alsafi MA, 2020, ACTA CRYSTALLOGR C, V76, P1043, DOI 10.1107/S2053229620014217; Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327; Angell YL, 2007, CHEM SOC REV, V36, P1674, DOI 10.1039/b701444a; Ton AT, 2020, MOL INFORM, V39, DOI 10.1002/minf.202000028; Aouad MR, 2015, J BRAZIL CHEM SOC, V26, P2105, DOI 10.5935/0103-5053.20150196; Aouad MR, 2014, MOLECULES, V19, P18897, DOI 10.3390/molecules191118897; Aouad MR, 2015, ACTA PHARMACEUT, V65, P117, DOI 10.1515/acph-2015-0011; Asai A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082839; Bayrak H, 2009, EUR J MED CHEM, V44, P1057, DOI 10.1016/j.ejmech.2008.06.019; Bonandi E, 2017, DRUG DISCOV TODAY, V22, P1572, DOI 10.1016/j.drudis.2017.05.014; Bursulaya BD, 2003, J COMPUT AID MOL DES, V17, P755, DOI 10.1023/B:JCAM.0000017496.76572.6f; Chaturvedi D., 2016, CHEM SCI J, V7, DOI [10.4172/2150-3494.1000e114, DOI 10.4172/2150-3494.1000E114, https://doi.org/10.4172/2150-3494.1000e114]; Chauhan N., 2020, CHEMRXIV20201116, V1, P1, DOI [10.26434/chemrxiv.11985231.v1, DOI 10.26434/CHEMRXIV.11985231.V1]; Coxon GD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053162; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; D'yakonov VA, 2007, TETRAHEDRON LETT, V48, P8583, DOI 10.1016/j.tetlet.2007.10.065; de Magalhaes CS, 2004, GENET MOL BIOL, V27, P605, DOI 10.1590/S1415-47572004000400022; Delano W.L, 2004, PYMOL REFERENCE GUID; Dheer D, 2017, BIOORG CHEM, V71, P30, DOI 10.1016/j.bioorg.2017.01.010; El-Naggar M, 2020, MOLECULES, V25, DOI 10.3390/molecules25030672; Florindo HF, 2020, NAT NANOTECHNOL, V15, P630, DOI 10.1038/s41565-020-0732-3; Hall DC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101646; Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y; Kandile NG, 2017, J ENZYM INHIB MED CH, V32, P119, DOI 10.1080/14756366.2016.1238365; Khalaj A., 1998, Pharmacy and Pharmacology Communications, V4, P477; Kumar P, 2017, CHEM CENT J, V11, DOI 10.1186/s13065-017-0344-7; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; Li HY, 2013, MOLECULES, V18, P9797, DOI 10.3390/molecules18089797; Muller T, 2011, ANGEW CHEM INT EDIT, V50, P11844, DOI 10.1002/anie.201105707; Narasimharao K, 2016, INT J ELECTROCHEM SC, V11, P7282, DOI 10.20964/2016.08.43; Ortega JT, 2020, EXCLI J, V19, P400, DOI 10.17179/excli2020-1189; PALLA G, 1986, TETRAHEDRON, V42, P3649, DOI 10.1016/S0040-4020(01)87332-4; Patorski P, 2013, J SPECTROSC, V2013, DOI 10.1155/2013/197475; Ren ZL, 2013, PROTEIN CELL, V4, P248, DOI 10.1007/s13238-013-2841-3; Rezki N, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050766; Rezki N, 2015, MOLECULES, V20, P16048, DOI 10.3390/molecules200916048; Schiff H., 1864, LIEBIGS ANN CHEM, V131, P118, DOI DOI 10.1002/JLAC.18641310113; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Sharma OP, 2009, FOOD CHEM, V113, P1202, DOI 10.1016/j.foodchem.2008.08.008; Shawon J, 2018, INTERDISCIP SCI, V10, P525, DOI 10.1007/s12539-016-0186-3; Sidorov N. G., 2019, MICROBIOLOGY INDEPEN, V6, P10, DOI [10.18527/2500-2236-2019-6-1-10-17, DOI 10.18527/2500-2236-2019-6-1-10-17]; Smit FJ, 2019, MED CHEM RES, V28, P2279, DOI 10.1007/s00044-019-02458-7; Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559; Tanoli ST, 2019, BIOORG CHEM, V83, P336, DOI 10.1016/j.bioorg.2018.10.035; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22677; Wang QD, 2017, CELL DEATH DIFFER, V24, P458, DOI 10.1038/cdd.2016.142; Wang YY, 2018, BIOORG MED CHEM LETT, V28, P2979, DOI 10.1016/j.bmcl.2018.06.049; Wasilenko WJ, 1996, INT J CANCER, V68, P259, DOI 10.1002/(SICI)1097-0215(19961009)68:2<259::AID-IJC20>3.0.CO;2-4; World Health Organization, 2020, COVID 19 STRAT DAT, V3, P18; Wyrzykiewicz E, 1998, J HETEROCYCLIC CHEM, V35, P381, DOI 10.1002/jhet.5570350221; Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07; Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100; Zhang K, 2014, BIOORG MED CHEM LETT, V24, P5154, DOI 10.1016/j.bmcl.2014.09.086; Zhang S, 2017, EUR J MED CHEM, V138, P501, DOI 10.1016/j.ejmech.2017.06.051	60	1	1	9	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1012	10.3390/vaccines9091012			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3CK	34579249	Green Published, gold			2022-04-29	WOS:000702086100001
J	Sohi, AN; Kiani, J; Arefian, E; Khosrojerdi, A; Fekrirad, Z; Ghaemi, S; Zim, MK; Jalili, A; Bostanshirin, N; Soleimani, M				Sohi, Alireza Naderi; Kiani, Jafar; Arefian, Ehsan; Khosrojerdi, Arezou; Fekrirad, Zahra; Ghaemi, Shokoofeh; Zim, Mohammad Kazem; Jalili, Arsalan; Bostanshirin, Nazila; Soleimani, Masoud			Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque	VACCINES			English	Article						mRNA-vaccine; lipid nanoparticle; LNP; SARS-CoV-2; spike protein		Among the vaccines have been developed thus far against SARS-CoV-2, the mRNA-based ones have demonstrated more promising results regarding both safety and efficacy. Two remarkable features of the mRNA vaccines introduced by the Pfizer/BioNTech and Moderna companies are the use of (N-1-methyl-pseudouridine-) modified mRNA and the microfluidics-based production of lipid nanoparticles (LNPs) as the carrier. In the present study, except Anti-Reverse Cap Analog (ARCA), no other nucleoside analogs were employed to synthesize Spike-encoding mRNA using the in vitro transcription (IVT) method. Furthermore, LNPs were prepared via the ethanol injection method commonly used for liposome formation as an alternative for microfluidics-based approaches. The produced mRNA-LNP vaccine was evaluated for nanoparticles characteristics, encapsulation and transfection efficiencies, in vitro cytotoxicity as well as stability and storability. The safety of vaccine was assessed in Balb/c mice injected with mRNA-LNPs containing 10 mu g of spike-encoding mRNA. Eventually, the vaccine efficacy in inducing an immune response against SARS-CoV-2 was studied in Balb/c and C57BL/6 mice (received either 1 or 10 mu g of mRNA) as well as in rhesus macaque monkeys (infused with mRNA-LNPs containing 100 mu g of mRNA). The ELISA and virus neutralizing test (VNT) results showed a significant augmentation in the level of neutralizing antibodies against SARS-CoV-2. Moreover, the ELISA assay showed virus-specific IFN-gamma secretion in immunized mice as a marker of T(H)1 cell-based immune response, whereas favorably no change in the production of IL-4 was detected.	[Sohi, Alireza Naderi] Celltech Pharmed Co, Tehran 1371616312, Iran; [Kiani, Jafar] Iran Univ Med Sci, Fac Adv Technol Med, Dept Mol Med, Tehran 1449614535, Iran; [Arefian, Ehsan; Fekrirad, Zahra; Ghaemi, Shokoofeh] Univ Tehran, Coll Sci, Sch Biol, Dept Microbiol, Tehran 1417935840, Iran; [Khosrojerdi, Arezou] Tarbiat Modares Univ, Fac Med Sci, Dept Immunol, Tehran 1411713116, Iran; [Zim, Mohammad Kazem] Univ Tehran, Coll Sci, Dept Biotechnol, Tehran 1417935840, Iran; [Jalili, Arsalan] ACER, Cell Sci Res Ctr, Dept Stem Cells & Dev Biol, Royan Inst Stem Cell Biol & Technol, Tehran 16635148, Iran; [Jalili, Arsalan; Soleimani, Masoud] Shahid Beheshti Univ Med Sci, Hematopoiet Stem Cell Res Ctr, Tehran 1983969411, Iran; [Bostanshirin, Nazila] Alborz Univ Med Sci, Sch Med Sci, Dept Microbiol, Karaj 3149779453, Iran; [Soleimani, Masoud] Tarbiat Modares Univ, Fac Med Sci, Dept Hematol, Tehran 1411713116, Iran; [Soleimani, Masoud] Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Appl Cell Sci, Tehran 1983969411, Iran		Soleimani, M (通讯作者)，Shahid Beheshti Univ Med Sci, Hematopoiet Stem Cell Res Ctr, Tehran 1983969411, Iran.; Soleimani, M (通讯作者)，Tarbiat Modares Univ, Fac Med Sci, Dept Hematol, Tehran 1411713116, Iran.; Soleimani, M (通讯作者)，Shahid Beheshti Univ Med Sci, Sch Adv Technol Med, Dept Tissue Engn & Appl Cell Sci, Tehran 1983969411, Iran.	nanosohi@strc.ac.ir; kiani.ja@iums.ac.ir; arefian@ut.ac.ir; arezou.khosrojerdi@modares.ac.ir; fekrirad@ut.ac.ir; shokoofeh.ghaemi@gmail.com; mk.zim73@ut.ac.ir; Jalili.arsalan@royaninstitute.org; n.bostan@abzums.ac.ir; soleim_m@modares.ac.ir	Sohi, Alireza Naderi/AAF-2638-2019	Sohi, Alireza Naderi/0000-0002-6671-7528; Soleimani, Masoud/0000-0003-1972-7771; Arefian, Ehsan/0000-0002-0758-4710	Celltech Pharmed Company	This work was funded entirely by Celltech Pharmed Company.	Arteta MY, 2018, P NATL ACAD SCI USA, V115, pE3351, DOI 10.1073/pnas.1720542115; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Buschmann MD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010065; Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227; Dispinseri S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22958-8; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Hassett KJ, 2021, J CONTROL RELEASE, V335, P237, DOI 10.1016/j.jconrel.2021.05.021; Hekele A, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.54; Jackson NAC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0159-8; Kalnin KV, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00324-5; Lutz J, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0032-6; Maeki M, 2018, ADV DRUG DELIVER REV, V128, P84, DOI 10.1016/j.addr.2018.03.008; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pepini T, 2017, J IMMUNOL, V198, P4012, DOI 10.4049/jimmunol.1601877; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ryals RC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241006; Sabnis S, 2018, MOL THER, V26, P1509, DOI 10.1016/j.ymthe.2018.03.010; Sahin U, 2020, NATURE, V585, P107, DOI 10.1038/s41586-020-2537-9; Schoenmaker L, 2021, INT J PHARMACEUT, V601, DOI 10.1016/j.ijpharm.2021.120586; Tam Yuen Yi C, 2013, Pharmaceutics, V5, P498, DOI 10.3390/pharmaceutics5030498; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Webb C, 2020, INT J PHARMACEUT, V582, DOI 10.1016/j.ijpharm.2020.119266; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Zeng Chunxi, 2020, Curr Top Microbiol Immunol, DOI 10.1007/82_2020_217; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024	29	1	1	21	30	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1007	10.3390/vaccines9091007			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3UZ	34579244	Green Published, gold			2022-04-29	WOS:000702134900001
J	Orangi, S; Pinchoff, J; Mwanga, D; Abuya, T; Hamaluba, M; Warimwe, G; Austrian, K; Barasa, E				Orangi, Stacey; Pinchoff, Jessie; Mwanga, Daniel; Abuya, Timothy; Hamaluba, Mainga; Warimwe, George; Austrian, Karen; Barasa, Edwine			Assessing the Level and Determinants of COVID-19 Vaccine Confidence in Kenya	VACCINES			English	Article						COVID-19; vaccination; vaccine hesitancy; vaccine confidence; vaccine hesitancy predictors; Kenya		The government of Kenya has launched a phased rollout of COVID-19 vaccination. A major barrier is vaccine hesitancy; the refusal or delay of accepting vaccination. This study evaluated the level and determinants of vaccine hesitancy in Kenya. We conducted a cross-sectional study administered through a phone-based survey in February 2021 in four counties of Kenya. Multilevel logistic regression was used to identify individual perceived risks and influences, context-specific factors and vaccine-specific issues associated with COVID-19 vaccine hesitancy. COVID-19 vaccine hesitancy in Kenya was high: 36.5%. Factors associated with vaccine hesitancy included: Rural regions, perceived difficulty in adhering to government regulations on COVID-19 prevention, no perceived COVID-19 infection risk, concerns regarding vaccine safety and effectiveness, and religious and cultural reasons. There is a need for the prioritization of interventions to address vaccine hesitancy and improve vaccine confidence as part of the vaccine roll-out plan. These messaging and/or interventions should be holistic to include the value of other public health measures, be focused and targeted to specific groups, raise awareness on the risks of COVID-19 and effectively communicate the benefits and risks of vaccines.	[Orangi, Stacey; Barasa, Edwine] KEMRI Wellcome Trust Res Program, Hlth Econ Res Unit HERU, POB 43640-00100, Nairobi, Kenya; [Orangi, Stacey] Strathmore Univ, Inst Healthcare Management, POB 59857-0200, Nairobi, Kenya; [Pinchoff, Jessie] Populat Council, New York, NY 10017 USA; [Mwanga, Daniel; Abuya, Timothy; Austrian, Karen] Populat Council, POB 17643-00500, Nairobi, Kenya; [Hamaluba, Mainga; Warimwe, George] KEMRI Wellcome Trust Res Programme, POB 230-80108, Kilifi, Kenya; [Hamaluba, Mainga; Warimwe, George; Barasa, Edwine] Univ Oxford, Nuffield Dept Med, Oxford OX3 7LG, England		Orangi, S (通讯作者)，KEMRI Wellcome Trust Res Program, Hlth Econ Res Unit HERU, POB 43640-00100, Nairobi, Kenya.; Orangi, S (通讯作者)，Strathmore Univ, Inst Healthcare Management, POB 59857-0200, Nairobi, Kenya.	sorangi@kemri-wellcome.org; jpinchoff@popcouncil.org; dmwanga@popcouncil.org; tabuya@popcouncil.org; mhamaluba@kemri-wellcome.org; gwarimwe@kemri-wellcome.org; kaustrian@popcouncil.org; ebarasa@kemri-wellcome.org		Austrian, Karen/0000-0001-5464-7908	University of California San DiegoUniversity of California System; Kenya Executive Office of the President Policy and Strategy Unit; UK Foreign Commonwealth and Development Office; International Decision Support Initiative (IDSI); Wellcome TrustWellcome TrustEuropean Commission [092654]; Innovations for Poverty Action	This research was funded by Innovations for Poverty Action, the University of California San Diego, the Kenya Executive Office of the President Policy and Strategy Unit, and UK Foreign Commonwealth and Development Office. Additional funds from the International Decision Support Initiative (IDSI), and a Wellcome Trust core grant awarded to the KEMRI-Wellcome Trust Research Program (#092654) supported this work.	Abuya T., 2020, EXPERIENCES ADULTS A; Afolabi AA, 2021, PAN AFR MED J, V38, DOI 10.11604/pamj.2021.38.3.27401; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Almaghaslah D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040330; [Anonymous], 52 S AFR DONT WANT C; [Anonymous], WHO COR DIS COVID 19; Anyiam-Osigwe T., COVID 19 VACCINES AR; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Aschwanden C, 2021, NATURE, V591, P520, DOI 10.1038/d41586-021-00728-2; Austrian K., EVALUATION NISITU PR; Austrian K, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2888-1; Barasa E., 2020, HLTH SOCIOECONOMIC I; Barasa E., 2021, 570 CGD; Dinga JN, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020175; Ditekemena JD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020153; Dyer O, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1933; Dzinamarira T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030250; Edwards B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248892; Gallup, 2019, WELLC GLOB MON 1 WAV; Kyobutungi C., INS OUTS KENYAS COVI; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Lawes-Wickwar S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020072; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Muthengi E, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0586-4; Nachega JB, 2021, LANCET GLOB HEALTH, V9, pE746, DOI 10.1016/S2214-109X(21)00097-8; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; WHO (World Health Organisation), 2020, COORD GLOB RES ROADM; World Health Organization, 2014, SAGE WORK GROUP VACC; World Health Organization, 2020, BEH CONS ACC UPT COV; World Health Organization, DRAFT LANDSC TRACK C	31	3	3	7	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							936	10.3390/vaccines9080936			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH2NB	34452061	Green Published, gold, Green Submitted			2022-04-29	WOS:000689773500001
J	Stepanek, L; Janosikova, M; Nakladalova, M; Stepanek, L; Borikova, A; Vildova, H				Stepanek, Ladislav; Janosikova, Magdalena; Nakladalova, Marie; Stepanek, Lubomir; Borikova, Alena; Vildova, Helena			Motivation to COVID-19 Vaccination and Reasons for Hesitancy in Employees of a Czech Tertiary Care Hospital: A Cross-Sectional Survey	VACCINES			English	Article						COVID-19; vaccination; motivation; hesitancy; vaccine safety; vaccine efficacy	WORKERS	High vaccination coverage among healthcare workers (HCWs) is crucial for managing the COVID-19 pandemic. The aim was to determine the demand for vaccination among all employees (n = 4553) of a tertiary care hospital after several weeks of the vaccine's availability, and to analyze motives for acceptance and reasons for hesitancy through an anonymous online questionnaire. Upon the completion of data collection, the hospital's vaccination coverage was at 69.8%. A total of 3550 completed questionnaires were obtained (2657 from vaccinated, 893 from unvaccinated employees). Significant predictors of vaccine acceptance were: age (odds ratio (OR) 1.01, 95% confidence interval (CI) 1.01-1.02), sex (OR (females) 0.58, 95% CI 0.45-0.75), job type (OR (non-physician HCWs) 0.54, 95% CI 0.41-0.72; OR (non-HCWs) 0.51, 95% CI 0.37-0.71), fear of COVID-19 (OR 1.4, 95% CI 1.34-1.46), history of COVID-19 (OR 0.41, 95% CI 0.34-0.49) and of influenza vaccination (OR 2.74, 95% CI 2.12-3.57). The most frequent motive for acceptance was the effort to protect family members (84%), while concerns about vaccine safety and side effects (49.4%), followed by distrust in the vaccine's efficacy (41.1%) were the top reasons for hesitancy. To increase vaccination coverage among HCWs, it is necessary to raise awareness of vaccine safety and efficacy.	[Stepanek, Ladislav; Janosikova, Magdalena; Nakladalova, Marie; Borikova, Alena; Vildova, Helena] Palacky Univ Olomouc, Fac Med & Dent, Dept Occupat Med, IP Pavlova 185-6, Olomouc 77900, Czech Republic; [Stepanek, Lubomir] Charles Univ Prague, Inst Biophys & Informat, Fac Med 1, Salmovska 1, Prague 12000 2, Czech Republic		Stepanek, L (通讯作者)，Palacky Univ Olomouc, Fac Med & Dent, Dept Occupat Med, IP Pavlova 185-6, Olomouc 77900, Czech Republic.	stepanek.ladislav@gmail.com; magdalena.janosikova@fnol.cz; marie.nakladalova@fnol.cz; lubomir.stepanek@lf1.cuni.cz; alena.borikova@fnol.cz; helena.vildova@fnol.cz	Stepanek, Lubomir/AGS-5496-2022	Janosikova, Magdalena/0000-0002-1210-9906; Stepanek, Ladislav/0000-0002-7261-1412	MH CZ-DRO [00098892]; Palacky University Fund [61989592]	The study was supported by MH CZ-DRO (FNOl, 00098892) and the Palacky University Fund (RVO, 61989592).	Abuown A, 2021, OCCUP MED-OXFORD, V71, P211, DOI 10.1093/occmed/kqab057; Biswas N, 2021, J COMMUN HEALTH, V46, P1244, DOI 10.1007/s10900-021-00984-3; Collantoni E, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071465; Dzieciolowska S, 2021, AM J INFECT CONTROL, V49, P1152, DOI 10.1016/j.ajic.2021.04.079; European Centre for Disease Prevention and Control, OV IMPL COVID 19 VAC; Fares Samar, 2021, J Prim Care Community Health, V12, p21501327211013303, DOI 10.1177/21501327211013303; Gabarda A, 2021, HEALTH PROMOT PRACT, V22, P611, DOI 10.1177/15248399211016463; Gholami M, 2021, INT J INFECT DIS, V104, P335, DOI 10.1016/j.ijid.2021.01.013; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Hammer CC, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821001114; Hughes K, 2021, CURR MED RES OPIN, V37, P907, DOI 10.1080/03007995.2021.1908245; Janssen C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060547; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Kwok KO, 2020, J INFECTION, V80, pE32, DOI 10.1016/j.jinf.2020.03.027; Ministry of the Interior of the Czech Republic, VACC TIM; Prazeres F, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18010220; Raftopoulos V, 2021, HUM VACC IMMUNOTHER, V17, P2397, DOI 10.1080/21645515.2021.1896907; Rutten LJF, 2021, MAYO CLIN PROC, V96, P699, DOI 10.1016/j.mayocp.2020.12.024; Stepanek L, 2021, HUM VACC IMMUNOTHER, V17, P3113, DOI 10.1080/21645515.2021.1911212; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030218; Taormina RJ, 2013, AM J PSYCHOL, V126, P155, DOI 10.5406/amerjpsyc.126.2.0155; Taylor S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.575950; WHO, COVID 19 VACC; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8	24	8	8	1	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							863	10.3390/vaccines9080863			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9OZ	34451988	Green Published, gold			2022-04-29	WOS:000690251700001
J	Yan, HB; Chen, WX				Yan, Hongbin; Chen, Wangxue			The Promise and Challenges of Cyclic Dinucleotides as Molecular Adjuvants for Vaccine Development	VACCINES			English	Review						cyclic dinucleotide; c-di-GMP; bacterial second messenger; immunostimulation; vaccine adjuvant	C-DI-GMP; 3',5'-CYCLIC DIGUANYLIC ACID; PROTECTIVE IMMUNE-RESPONSES; STING AGONISTS; CELLULOSE SYNTHESIS; I IFN; INTRANASAL VACCINATION; ACETOBACTER-XYLINUM; INNATE IMMUNITY; PILZ DOMAIN	Cyclic dinucleotides (CDNs), originally discovered as bacterial second messengers, play critical roles in bacterial signal transduction, cellular processes, biofilm formation, and virulence. The finding that CDNs can trigger the innate immune response in eukaryotic cells through the stimulator of interferon genes (STING) signalling pathway has prompted the extensive research and development of CDNs as potential immunostimulators and novel molecular adjuvants for induction of systemic and mucosal innate and adaptive immune responses. In this review, we summarize the chemical structure, biosynthesis regulation, and the role of CDNs in enhancing the crosstalk between host innate and adaptive immune responses. We also discuss the strategies to improve the efficient delivery of CDNs and the recent advance and future challenges in the development of CDNs as potential adjuvants in prophylactic vaccines against infectious diseases and in therapeutic vaccines against cancers.	[Yan, Hongbin] Brock Univ, Dept Chem, St Catharines, ON L2S 3A1, Canada; [Chen, Wangxue] Natl Res Council Canada, Human Hlth & Therapeut Res Ctr, Ottawa, ON K1A 0R6, Canada; [Chen, Wangxue] Brock Univ, Dept Biol Sci, St Catharines, ON L2S 3A1, Canada		Yan, HB (通讯作者)，Brock Univ, Dept Chem, St Catharines, ON L2S 3A1, Canada.; Chen, WX (通讯作者)，Natl Res Council Canada, Human Hlth & Therapeut Res Ctr, Ottawa, ON K1A 0R6, Canada.; Chen, WX (通讯作者)，Brock Univ, Dept Biol Sci, St Catharines, ON L2S 3A1, Canada.	tyan@brocku.ca; Wangxue.Chen@nrc.gc.ca			Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR [RGPIN-2020-07040]; National Research Council Canada	This work was supported by the Natural Sciences and Engineering Research Council of Canada (RGPIN-2020-07040) and the National Research Council Canada (Vaccine Program and Vaccine and Immunotherapeutics Program). The view expressed here (W.C.) is solely the responsibility of the author and does not necessarily represent the official views of the National Research Council Canada.	Abdul-Sater AA, 2013, EMBO REP, V14, P900, DOI 10.1038/embor.2013.132; Ager CR, 2017, CANCER IMMUNOL RES, V5, P676, DOI 10.1158/2326-6066.CIR-17-0049; Ahn J, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0333-0; Alberti AS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00128; Allen AC, 2018, MUCOSAL IMMUNOL, V11, P1763, DOI 10.1038/s41385-018-0080-x; Alm RA, 1996, J BACTERIOL, V178, P46, DOI 10.1128/jb.178.1.46-53.1996; Alyaqoub FS, 2016, J IMMUNOL, V196, P1741, DOI 10.4049/jimmunol.1501272; Amikam D, 2006, BIOINFORMATICS, V22, P3, DOI 10.1093/bioinformatics/bti739; An MG, 2018, NANOSCALE, V10, P9311, DOI 10.1039/c8nr01376d; Atukorale PU, 2019, CANCER RES, V79, P5394, DOI 10.1158/0008-5472.CAN-19-0381; Azegami T, 2017, MUCOSAL IMMUNOL, V10, P1351, DOI 10.1038/mi.2016.137; Azegami T, 2018, J HYPERTENS, V36, P387, DOI 10.1097/HJH.0000000000001519; Barber GN, 2014, TRENDS IMMUNOL, V35, P88, DOI 10.1016/j.it.2013.10.010; Becker M, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11040590; Bielecki PA, 2021, NANOSCALE HORIZ, V6, P156, DOI 10.1039/d0nh00446d; Blaauboer SM, 2015, ELIFE, V4, DOI 10.7554/eLife.06670; Blaauboer SM, 2014, J IMMUNOL, V192, P492, DOI 10.4049/jimmunol.1301812; Borriello F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01772; Bridgeman A, 2015, SCIENCE, V349, P1228, DOI 10.1126/science.aab3632; Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429; Chandra D, 2014, CANCER IMMUNOL RES, V2, P901, DOI 10.1158/2326-6066.CIR-13-0123; Chang D, 2020, P NATL ACAD SCI USA, V117, P27502, DOI 10.1073/pnas.2015919117; Chen J, 2020, HUM VACC IMMUNOTHER, V16, P2849, DOI 10.1080/21645515.2020.1744364; Chen JJ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf1244; Chen NH, 2018, J CONTROL RELEASE, V289, P114, DOI 10.1016/j.jconrel.2018.09.020; Chen YP, 2020, ACS APPL MATER INTER, V12, P56741, DOI 10.1021/acsami.0c16728; Cheng N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120638; Christen M, 2007, P NATL ACAD SCI USA, V104, P4112, DOI 10.1073/pnas.0607738104; Collier MA, 2018, MOL PHARMACEUT, V15, P4933, DOI 10.1021/acs.molpharmaceut.8b00579; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Dahlstrom KM, 2017, ANNU REV MICROBIOL, V71, P179, DOI 10.1146/annurev-micro-090816-093325; Darling RJ, 2019, VACCINE, V37, P2721, DOI 10.1016/j.vaccine.2019.04.004; Davies BW, 2012, CELL, V149, P358, DOI 10.1016/j.cell.2012.01.053; Demoulins T, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.622385; Dey RJ, 2020, J INFECT DIS, V221, P1048, DOI 10.1093/infdis/jiz116; Dorostkar F, 2021, INFECT AGENTS CANCER, V16, DOI 10.1186/s13027-021-00346-7; Dubensky Thomas W Jr, 2013, Ther Adv Vaccines, V1, P131, DOI 10.1177/2051013613501988; Ebensen T, 2007, CLIN VACCINE IMMUNOL, V14, P952, DOI 10.1128/CVI.00119-07; Ebensen T, 2007, VACCINE, V25, P1464, DOI 10.1016/j.vaccine.2006.10.033; Ebensen T, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00031; Ebensen T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01223; Ebensen T, 2011, VACCINE, V29, P5210, DOI 10.1016/j.vaccine.2011.05.026; EGLI M, 1990, P NATL ACAD SCI USA, V87, P3235, DOI 10.1073/pnas.87.8.3235; Elahi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109778; Elmanfi S, 2019, J ORAL MICROBIOL, V11, DOI 10.1080/20002297.2018.1538927; Fatima M, 2013, POULTRY SCI, V92, P2644, DOI 10.3382/ps.2013-03143; Fazli M, 2011, MOL MICROBIOL, V82, P327, DOI 10.1111/j.1365-2958.2011.07814.x; Flores-Valdez MA, 2012, INT J TUBERC LUNG D, V16, P774, DOI 10.5588/ijtld.11.0735; Foote JB, 2017, CANCER IMMUNOL RES, V5, P468, DOI 10.1158/2326-6066.CIR-16-0284; Francica BJ, 2018, CANCER IMMUNOL RES, V6, P422, DOI 10.1158/2326-6066.CIR-17-0263; Gadkaree SK, 2017, HEAD NECK-J SCI SPEC, V39, P1086, DOI 10.1002/hed.24704; Gil C, 2020, VET RES, V51, DOI 10.1186/s13567-019-0730-3; Gogoi H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01674; Gogoi H, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030453; Gravekamp C, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.988463; Gray PM, 2012, CELL IMMUNOL, V278, P113, DOI 10.1016/j.cellimm.2012.07.006; Guo JJ, 2019, CHEMBIOCHEM, V20, P1838, DOI 10.1002/cbic.201900051; Gutjahr A, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125107; Hanson MC, 2015, J CLIN INVEST, V125, P2532, DOI 10.1172/JCI79915; Hickman JW, 2008, MOL MICROBIOL, V69, P376, DOI 10.1111/j.1365-2958.2008.06281.x; Hu DL, 2009, VACCINE, V27, P4867, DOI 10.1016/j.vaccine.2009.04.053; Hu HG, 2020, BIOCONJUGATE CHEM, V31, P2499, DOI 10.1021/acs.bioconjchem.0c00522; Imanishi T, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201800282; Ito H, 2019, VIROLOGY, V531, P233, DOI 10.1016/j.virol.2019.03.013; Jin L, 2011, J IMMUNOL, V187, P2595, DOI 10.4049/jimmunol.1100088; Johnson BM, 2021, J IMMUNOL, V206, P2015, DOI 10.4049/jimmunol.2001317; Junkins RD, 2018, J CONTROL RELEASE, V270, P1, DOI 10.1016/j.jconrel.2017.11.030; Karaolis DKR, 2007, INFECT IMMUN, V75, P4942, DOI 10.1128/IAI.01762-06; Karaolis DKR, 2007, J IMMUNOL, V178, P2171, DOI 10.4049/jimmunol.178.4.2171; Kelly SH, 2021, ACS BIOMATER SCI ENG, V7, P1876, DOI 10.1021/acsbiomaterials.0c01429; Kocabas BB, 2020, J CONTROL RELEASE, V328, P587, DOI 10.1016/j.jconrel.2020.09.040; Koestler BJ, 2014, CLIN VACCINE IMMUNOL, V21, P1550, DOI 10.1128/CVI.00471-14; Konno H, 2018, CELL REP, V23, P1112, DOI 10.1016/j.celrep.2018.03.115; Konno H, 2013, CELL, V155, P688, DOI 10.1016/j.cell.2013.09.049; Korovashkina AS, 2013, J BIOTECHNOL, V164, P276, DOI 10.1016/j.jbiotec.2012.12.006; Koshy ST, 2017, ADV BIOSYST, V1, DOI 10.1002/adbi.201600013; Kuse N, 2019, EBIOMEDICINE, V42, P109, DOI 10.1016/j.ebiom.2019.03.078; Landi A, 2017, VACCINE, V35, P6949, DOI 10.1016/j.vaccine.2017.10.072; Latanova AA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26281-z; Latasa C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161216; Launer-Felty KD, 2018, NUCLEIC ACIDS RES, V46, P2765, DOI 10.1093/nar/gky137; Leach DG, 2018, BIOMATERIALS, V163, P67, DOI 10.1016/j.biomaterials.2018.01.035; Lee ER, 2010, SCIENCE, V329, P845, DOI 10.1126/science.1190713; Lee E, 2016, ACTA BIOMATER, V29, P271, DOI 10.1016/j.actbio.2015.10.025; Lee MJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02509; Li J, 2019, RSC ADV, V9, P41481, DOI 10.1039/c9ra08310c; Li LY, 2014, NAT CHEM BIOL, V10, P1043, DOI [10.1038/NChemBio.1661, 10.1038/nchembio.1661]; Li Z, 2012, J BIOL CHEM, V287, P30191, DOI 10.1074/jbc.M112.378273; Libanova R, 2010, VACCINE, V28, P2249, DOI 10.1016/j.vaccine.2009.12.045; Liu Y, 2016, ACTA BIOCH BIOPH SIN, V48, P909, DOI 10.1093/abbs/gmw078; Luo J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02274; Madhun AS, 2011, VACCINE, V29, P4973, DOI 10.1016/j.vaccine.2011.04.094; Major D, 2015, HUM VACC IMMUNOTHER, V11, P1235, DOI 10.4161/21645515.2014.988554; Mansouri S, 2021, J IMMUNOL, V206, P2233, DOI 10.4049/jimmunol.2001347; Martin GR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50656-5; Martin TL, 2017, VACCINE, V35, P2511, DOI 10.1016/j.vaccine.2017.02.064; Martinez-Granero F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087608; Matos MN, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005300; Matthijs AMF, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01087; McFarland AP, 2017, IMMUNITY, V46, P433, DOI 10.1016/j.immuni.2017.02.014; Miao L, 2020, THERANOSTICS, V10, P498, DOI 10.7150/thno.37745; Mittal A, 2015, J CONTROL RELEASE, V206, P140, DOI 10.1016/j.jconrel.2015.03.017; Miyabe H, 2014, J CONTROL RELEASE, V184, P20, DOI 10.1016/j.jconrel.2014.04.004; Moore E, 2016, CANCER IMMUNOL RES, V4, P1061, DOI 10.1158/2326-6066.CIR-16-0104; Gonzalez FM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01775; Nakamura T, 2015, J CONTROL RELEASE, V216, P149, DOI 10.1016/j.jconrel.2015.08.026; Neuhaus V, 2014, VACCINE, V32, P3216, DOI 10.1016/j.vaccine.2014.04.011; Newell PD, 2009, P NATL ACAD SCI USA, V106, P3461, DOI 10.1073/pnas.0808933106; Nicolai CJ, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aaz2738; Ning HH, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.647220; Ning HH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01519; Ogunniyi AD, 2008, VACCINE, V26, P4676, DOI 10.1016/j.vaccine.2008.06.099; Ohkuri T, 2017, CANCER IMMUNOL IMMUN, V66, P705, DOI 10.1007/s00262-017-1975-1; Ohkuri T, 2014, CANCER IMMUNOL RES, V2, P1199, DOI 10.1158/2326-6066.CIR-14-0099; Ouyang SY, 2012, IMMUNITY, V36, P1073, DOI 10.1016/j.immuni.2012.03.019; Ozasa K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02212; Parvatiyar K, 2012, NAT IMMUNOL, V13, P1155, DOI 10.1038/ni.2460; Pedersen GK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026973; Pedroza-Roldan C, 2016, VACCINE, V34, P4763, DOI 10.1016/j.vaccine.2016.08.035; Pratt JT, 2007, J BIOL CHEM, V282, P12860, DOI 10.1074/jbc.M611593200; Quintana I, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02100; Rao F, 2009, ANAL BIOCHEM, V389, P138, DOI 10.1016/j.ab.2009.03.031; Rosenthal K, 2020, CHEMBIOCHEM, V21, P3225, DOI 10.1002/cbic.202000433; ROSS P, 1986, CARBOHYD RES, V149, P101, DOI 10.1016/S0008-6215(00)90372-0; ROSS P, 1985, FEBS LETT, V186, P191, DOI 10.1016/0014-5793(85)80706-7; ROSS P, 1987, NATURE, V325, P279, DOI 10.1038/325279a0; ROSS P, 1990, J BIOL CHEM, V265, P18933; Roy Ankita Basu, 2013, Bio Protoc, V3; Rueckert C, 2017, FASEB J, V31, P3107, DOI 10.1096/fj.201601093R; Ryjenkov DA, 2006, J BIOL CHEM, V281, P30310, DOI 10.1074/jbc.C600179200; Alberti AS, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0010-z; Sanchez MV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104824; Schulze K, 2017, NANOMED-NANOTECHNOL, V13, P2463, DOI 10.1016/j.nano.2017.08.015; Schulze K, 2017, NANOMED-NANOTECHNOL, V13, P2169, DOI 10.1016/j.nano.2017.05.012; Shae D, 2020, ACS NANO, V14, P9904, DOI 10.1021/acsnano.0c02765; Shae D, 2019, NAT NANOTECHNOL, V14, P269, DOI 10.1038/s41565-018-0342-5; Shakya AK, 2018, MOL PHARMACEUT, V15, P5437, DOI 10.1021/acs.molpharmaceut.8b00768; Shchokolova AS, 2015, NUCLEOS NUCLEOT NUCL, V34, P416, DOI 10.1080/15257770.2015.1006775; Shin JH, 2020, DRUG DELIV TRANSL RE, V10, P815, DOI 10.1007/s13346-020-00728-1; Shu C, 2014, CYTOKINE GROWTH F R, V25, P641, DOI 10.1016/j.cytogfr.2014.06.006; Skouboe MK, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006976; Skrnjug I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110150; Skrnjug I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095728; Smith KD, 2011, P NATL ACAD SCI USA, V108, P7757, DOI 10.1073/pnas.1018857108; Smith TT, 2017, J CLIN INVEST, V127, P2176, DOI 10.1172/JCI87624; Stulke J, 2020, ANNU REV MICROBIOL, V74, P159, DOI 10.1146/annurev-micro-020518-115943; Sudarsan N, 2008, SCIENCE, V321, P411, DOI 10.1126/science.1159519; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Svindland SC, 2013, INFLUENZA OTHER RESP, V7, P1181, DOI 10.1111/irv.12056; Takaki Hiromi, 2017, Med Sci (Basel), V5, DOI 10.3390/medsci5040035; Temizoz B, 2015, EUR J IMMUNOL, V45, P1159, DOI 10.1002/eji.201445132; Van Dis E, 2018, CELL REP, V23, P1435, DOI 10.1016/j.celrep.2018.04.003; Vassilieva EV, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583251; Vassilieva EV, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03006; Volckmar J, 2019, VACCINE, V37, P4963, DOI 10.1016/j.vaccine.2019.07.019; Wagner DA, 2019, ACTA BIOMATER, V100, P326, DOI 10.1016/j.actbio.2019.10.016; Walker MM, 2018, J IMMUNOL, V201, P2641, DOI 10.4049/jimmunol.1701405; Wang CH, 2017, J AM CHEM SOC, V139, P16154, DOI 10.1021/jacs.7b06141; Wang J, 2020, SCIENCE, V367, P869, DOI 10.1126/science.aau0810; Wang J, 2016, J INVEST DERMATOL, V136, P2183, DOI 10.1016/j.jid.2016.05.105; Wang ZL, 2015, CANCER IMMUNOL IMMUN, V64, P1057, DOI 10.1007/s00262-015-1713-5; Wang-Bishop L, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000282; Wehbe M, 2021, J CONTROL RELEASE, V330, P1118, DOI 10.1016/j.jconrel.2020.11.017; Wilson DR, 2018, NANOMED-NANOTECHNOL, V14, P237, DOI 10.1016/j.nano.2017.10.013; Witte G, 2008, MOL CELL, V30, P167, DOI 10.1016/j.molcel.2008.02.020; Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963; Wu JJ, 2020, MED RES REV, V40, P1117, DOI 10.1002/med.21649; Wu JJ, 2018, CHEM COMMUN, V54, P9655, DOI 10.1039/c8cc04860f; Yamamoto T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42253-3; Yan HB, 2008, BIOORG MED CHEM LETT, V18, P5631, DOI 10.1016/j.bmcl.2008.08.088; Yan HB, 2009, BIOCHEM BIOPH RES CO, V387, P581, DOI 10.1016/j.bbrc.2009.07.061; Yi GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077846; Yildiz S, 2015, EUR J IMMUNOL, V45, P1170, DOI 10.1002/eji.201445133; Yin W, 2020, FEMS MICROBIOL REV, V44, P701, DOI 10.1093/femsre/fuaa019; Zhang X, 2013, MOL CELL, V51, P226, DOI 10.1016/j.molcel.2013.05.022; Zhao L, 2011, INT IMMUNOPHARMACOL, V11, P1378, DOI 10.1016/j.intimp.2011.03.024; Zhu YY, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1087-y	177	1	1	5	16	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							917	10.3390/vaccines9080917			31	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9FI	34452042	gold, Green Published			2022-04-29	WOS:000690226600001
J	Franzoni, G; Anfossi, A; De Ciucis, CG; Mecocci, S; Carta, T; Dei Giudici, S; Fruscione, F; Zinellu, S; Vito, G; Graham, SP; Oggiano, A; Chessa, B; Razzuoli, E				Franzoni, Giulia; Anfossi, Antonio; De Ciucis, Chiara Grazia; Mecocci, Samanta; Carta, Tania; Dei Giudici, Silvia; Fruscione, Floriana; Zinellu, Susanna; Vito, Guendalina; Graham, Simon Paul; Oggiano, Annalisa; Chessa, Bernardo; Razzuoli, Elisabetta			Targeting Toll-Like Receptor 2: Polarization of Porcine Macrophages by a Mycoplasma-Derived Pam2cys Lipopeptide	VACCINES			English	Article						pig; macrophages; TLR2 agonist; cytokines; surface markers; IFN-alpha subtypes; toll-like receptors; IL-10	CD8(+) T-CELLS; INTERFERON-ALPHA; SWINE; MODEL; EXPRESSION; PROTECTION; PIG; IMMUNOLOGY; ACTIVATION; INFLUENZA	Toll-like receptor 2 (TLR2) ligands are attracting increasing attention as prophylactic and immunotherapeutic agents against pathogens and tumors. We previously observed that a synthetic diacylated lipopeptide based on a surface protein of Mycoplasma agalactiae (Mag-Pam2Cys) strongly activated innate immune cells, including porcine monocyte-derived macrophages (moM Phi). In this study, we utilized confocal microscopy, flow cytometry, multiplex cytokine ELISA, and RT-qPCR to conduct a comprehensive analysis of the effects of scalar doses of Mag-Pam2Cys on porcine moM Phi. We observed enhanced expression of activation markers (MHC class I, MHC class II DR, CD25), increased phagocytotic activity, and release of IL-12 and proinflammatory cytokines. Mag-Pam2Cys also upregulated the gene expression of several IFN-alpha subtypes, p65, NOS2, and molecules with antimicrobial activities (CD14, beta defensin 1). Overall, our data showed that Mag-Pam2Cys polarized porcine macrophages towards a proinflammatory antimicrobial phenotype. However, Mag-Pam2Cys downregulated the expression of IFN-alpha 3, six TLRs (TLR3, -4, -5, -7, -8, -9), and did not interfere with macrophage polarization induced by the immunosuppressive IL-10, suggesting that the inflammatory activity evoked by Mag-Pam2Cys could be regulated to avoid potentially harmful consequences. We hope that our in vitro results will lay the foundation for the further evaluation of this diacylated lipopeptide as an immunopotentiator in vivo.	[Franzoni, Giulia; Carta, Tania; Dei Giudici, Silvia; Zinellu, Susanna; Oggiano, Annalisa] Ist Zooprofilatt Sperimentale Sardegna, Dept Anim Hlth, I-07100 Sassari, Italy; [Anfossi, Antonio; Carta, Tania; Chessa, Bernardo] Univ Sassari, Sch Vet Med, I-07100 Sassari, Italy; [De Ciucis, Chiara Grazia; Fruscione, Floriana; Vito, Guendalina; Razzuoli, Elisabetta] Ist Zooprofilatt Sperimentale Piemonte, Natl Reference Ctr Vet & Comparat Oncol CEROVEC, Piazza Borgo Pila 39-24, I-16129 Genoa, Italy; [Mecocci, Samanta] Univ Perugia, Dept Vet Med, I-06123 Perugia, Italy; [Graham, Simon Paul] Pirbright Inst, Ash Rd, Woking GU24 0NF, Surrey, England		Franzoni, G (通讯作者)，Ist Zooprofilatt Sperimentale Sardegna, Dept Anim Hlth, I-07100 Sassari, Italy.; Chessa, B (通讯作者)，Univ Sassari, Sch Vet Med, I-07100 Sassari, Italy.	giulia.franzoni@izs-sardegna.it; aanfossi@uniss.it; chiaragrazia.deciucis@izsto.it; samanta.mecocci@studenti.unipg.it; tania.carta@izs-sardegna.it; Silvia.DeiGiudici@izs-sardegna.it; floriana.fruscione@izsto.it; Susanna.Zinellu@izs-sardegna.it; Guendalina.vito@izsto.it; simon.graham@pirbright.ac.uk; Annalisa.Oggiano@izs-sardegna.it; bchessa@uniss.it; elisabetta.razzuoli@izsto.it	Graham, Simon P/C-8337-2011; razzuoli, elisabetta/J-6018-2012	Graham, Simon P/0000-0003-4852-405X; razzuoli, elisabetta/0000-0002-6597-475X; Oggiano, Annalisa/0000-0002-3167-0942; Franzoni, Giulia/0000-0003-0987-3863; , Silvia/0000-0003-1803-4666; Anfossi, Antonio Giovanni/0000-0002-4954-9702; Mecocci, Samanta/0000-0003-2998-0412	Italian Ministry of HealthMinistry of Health, Italy [IZSUM PSRC 1/2018, IZS PLV 08/19 RC]; UKRI Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Programme GrantUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BBS/E/I/00007031]; BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BBS/E/I/00007031] Funding Source: UKRI	This research was funded by the Italian Ministry of Health, grant IZSUM PSRC 1/2018, and grant IZS PLV 08/19 RC. S.P.G. is supported by an UKRI Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Programme Grant to the Pirbright Institute (BBS/E/I/00007031).	Allan GM, 2000, J VET DIAGN INVEST, V12, P3, DOI 10.1177/104063870001200102; Amadori Massimo, 2014, Front Vet Sci, V1, P2, DOI 10.3389/fvets.2014.00002; Anfossi A.G., 2014, P S IMM VET FLOR IT P S IMM VET FLOR IT; Cacciotto C, 2016, CELL MICROBIOL, V18, P1751, DOI 10.1111/cmi.12613; Carta T, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11041098; Cheng G, 2006, GENE, V382, P28, DOI 10.1016/j.gene.2006.06.013; Chinsangaram J, 2003, J VIROL, V77, P1621, DOI 10.1128/JVI.77.2.1621-1625.2003; Chua Brendon Y., 2008, V494, P247, DOI 10.1007/978-1-59745-419-3_14; Deliyannis G, 2006, EUR J IMMUNOL, V36, P770, DOI 10.1002/eji.200535217; Elahi S, 2006, INFECT IMMUN, V74, P2338, DOI 10.1128/IAI.74.4.2338-2352.2006; Fairbairn L, 2011, J LEUKOCYTE BIOL, V89, P855, DOI 10.1189/jlb.1110607; Feng YX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10354-2; Fernandez-Sainz I, 2015, VIROLOGY, V483, P284, DOI 10.1016/j.virol.2015.04.024; Franchi L, 2012, NAT IMMUNOL, V13, P325, DOI 10.1038/ni.2231; Franzoni G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030549; Franzoni G, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030209; Franzoni G, 2018, VIRUS RES, V258, P73, DOI 10.1016/j.virusres.2018.10.007; Franzoni G, 2017, VET IMMUNOL IMMUNOP, V187, P80, DOI 10.1016/j.vetimm.2017.04.006; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gugliandolo E, 2019, SHOCK, V51, P221, DOI 10.1097/SHK.0000000000001137; Jackson DC, 2004, P NATL ACAD SCI USA, V101, P15440, DOI 10.1073/pnas.0406740101; Kapetanovic R, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-581; Kapetanovic R, 2012, J IMMUNOL, V188, P3382, DOI 10.4049/jimmunol.1102649; Kaser T, 2021, MOL IMMUNOL, V135, P95, DOI 10.1016/j.molimm.2021.04.004; Kaufmann A, 1999, INFECT IMMUN, V67, P6303; Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461; Li CL, 2013, PROTEIN EXPRES PURIF, V88, P47, DOI 10.1016/j.pep.2012.11.015; Luchner M, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020142; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Mecocci S, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10030244; Meurens F, 2012, TRENDS MICROBIOL, V20, P50, DOI 10.1016/j.tim.2011.11.002; Mifsud EJ, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00079; Miyake K, 2007, SEMIN IMMUNOL, V19, P3, DOI 10.1016/j.smim.2006.12.002; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Pabst R, 2020, CELL TISSUE RES, V380, P287, DOI 10.1007/s00441-020-03206-9; Petersen CB, 2007, DEV COMP IMMUNOL, V31, P729, DOI 10.1016/j.dci.2006.05.016; Proud PC, 2021, EBIOMEDICINE, V63, DOI 10.1016/j.ebiom.2020.103153; Rath M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00532; Razzuoli E, 2018, TOXICOL LETT, V287, P92, DOI 10.1016/j.toxlet.2018.02.005; Razzuoli E, 2011, SCAND J IMMUNOL, V74, P412, DOI 10.1111/j.1365-3083.2011.02586.x; Razzuoli E, 2017, VET MICROBIOL, V207, P219, DOI 10.1016/j.vetmic.2017.07.002; Razzuoli E, 2013, J INTERF CYTOK RES, V33, P597, DOI 10.1089/jir.2012.0127; Reppe K, 2009, AM J RESP CELL MOL, V40, P474, DOI 10.1165/rcmb.2008-0071OC; Sang YM, 2010, PHYSIOL GENOMICS, V42, P248, DOI 10.1152/physiolgenomics.00198.2009; Sautter CA, 2018, DEV COMP IMMUNOL, V84, P181, DOI 10.1016/j.dci.2018.01.018; Schenk M, 2009, IMMUNITY, V31, P847, DOI 10.1016/j.immuni.2009.11.008; Singleton H, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00832; Sosan O, 2012, CYTOKINE, V59, P552, DOI 10.1016/j.cyto.2012.06.192; Surnmerfield A, 2015, MOL IMMUNOL, V66, P14, DOI 10.1016/j.molimm.2014.10.023; Tan ACL, 2012, MOL PHARMACEUT, V9, P2710, DOI 10.1021/mp300257x; Tan ACL, 2012, ANTIVIR RES, V94, P168, DOI 10.1016/j.antiviral.2012.03.009; Urban-Wojciuk Z, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02388; VanderWaal K, 2018, P NATL ACAD SCI USA, V115, P11495, DOI 10.1073/pnas.1806068115; Veldhuizen EJA, 2008, MOL IMMUNOL, V45, P386, DOI 10.1016/j.molimm.2007.06.001; Yoo I, 2019, THERIOGENOLOGY, V125, P173, DOI 10.1016/j.theriogenology.2018.11.003; Zanotti C, 2015, J INTERF CYTOK RES, V35, P990, DOI 10.1089/jir.2015.0076; Zeng WG, 2002, J IMMUNOL, V169, P4905, DOI 10.4049/jimmunol.169.9.4905	60	0	0	0	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							692	10.3390/vaccines9070692			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6CP	34201691	Green Published			2022-04-29	WOS:000676997400001
J	Guo, LP; Xie, H; Zhang, Z; Wang, Z; Peng, SH; Niu, YJ; Shang, ZQ				Guo, Linpei; Xie, Hui; Zhang, Zheng; Wang, Zhun; Peng, Shuanghe; Niu, Yuanjie; Shang, Zhiqun			Fusion Protein Vaccine Based on Ag85B and STEAP1 Induces a Protective Immune Response against Prostate Cancer	VACCINES			English	Article						Ag85B; Mycobacterium tuberculosis; STEAP1; six-transmembrane epithelial antigen of the prostate 1; immune response; prostate cancer; castration-resistant prostate cancer (CRPC)	MYCOBACTERIUM-TUBERCULOSIS; BREAST-CANCER; ALPHA-ANTIGEN; IMMUNOGENICITY; BOVIS; FIBRONECTIN; INDUCTION; EFFICACY; CELLS; MODEL	(1) Background: There are currently limited treatments for castration-resistant prostate cancer. Immunotherapy involving Sipuleucel-T has increasingly drawn attention for prostate cancer management. BCG plays a vital role in treating bladder cancer, mainly by inducing immune activation, but is rarely used for prostate cancer. (2) Methods: The TCGA database, PCR, and Western blotting were used to analyze the expression of STEAP1 in mouse and human tissues. Then, we constructed a fusion protein vaccine with Mycobacterium tuberculosis Ag85B and three repeated octapeptide epitopes of a six-transmembrane epithelial antigen of the prostate 1 (STEAP1(186-193)), Ag85B-3xSTEAP1(186-193). The uptake of the fusion protein vaccine by DCs was evaluated by confocal microscopy, and DC markers were detected using flow cytometry after incubation with the fusion protein. The immune response against prostate cancer was evaluated by the LDH assay and xenografts in vitro and in vivo. Then, the tumor microenvironment was determined using IHC and ELISA. In addition, the epitope was mutated using CRISPR-Cas9 to illustrate that the fusion protein elicited immunization against STEAP1. (3) Results: The TCGA database analysis, PCR, and Western blotting showed that STEAP1 was highly expressed in human and murine prostate cancer. After the uptake of the purified fusion protein vaccine by DCs, CD11c, CD80, CD86, and MHC II were upregulated and triggered a cytotoxic T lymphocyte (CTL) response against TRAMP-C1 and RM1 cells in vitro. Furthermore, the fusion protein vaccine inhibited tumor growth and improved the tumor microenvironment in vivo, with more CD3(+) cells and fewer FOXP3(+) cells in the tumor. Serum IFN-gamma and IL-2 were significantly higher than in the control group, while IL-4 expression was lower, indicating that the fusion protein vaccine activated Th1 immunity. The immune response against prostate cancer was greatly suppressed when the antigen targets were knocked out using CRISPR-Cas9. (4) Conclusion: In summary, our results provide the first evidence that a vaccine based on a fusion protein consisting of Ag85B and a prostate cancer octapeptide epitope with complete Freund's adjuvant (CFA), triggers a robust immune response and inhibits tumor growth in murine prostate cancer.	[Guo, Linpei; Xie, Hui; Zhang, Zheng; Wang, Zhun; Niu, Yuanjie; Shang, Zhiqun] Tianjin Med Univ, Tianjin Inst Urol, Hosp 2, Tianjin 300211, Peoples R China; [Peng, Shuanghe] Tianjin Med Univ, Dept Pathol, Hosp 2, Tianjin 300211, Peoples R China		Niu, YJ; Shang, ZQ (通讯作者)，Tianjin Med Univ, Tianjin Inst Urol, Hosp 2, Tianjin 300211, Peoples R China.	guolinpei@tmu.edu.cn; xhinfinit@tmu.edu.cn; zhangzheng0602@126.com; 18853734760@163.com; womiu001@163.com; niuyuanjie68@163.com; szq1589465@126.com			Natural Science Foundation of TianjinNatural Science Foundation of Tianjin [18PTLCSY00030, 19JCYBJC24900]	This work was supported by the Natural Science Foundation of Tianjin (18PTLCSY00030 and 19JCYBJC24900).	ABOUZEID C, 1988, INFECT IMMUN, V56, P3046, DOI 10.1128/IAI.56.12.3046-3051.1988; Ahmed MS, 2014, CLIN EXP VACCINE RES, V3, P113, DOI 10.7774/cevr.2014.3.2.113; Atherton MJ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1445459; Aung H, 1996, J CLIN INVEST, V98, P1261, DOI 10.1172/JCI118910; Azumi M, 2010, J UROLOGY, V183, P2036, DOI 10.1016/j.juro.2009.12.094; Barroca-Ferreira J, 2018, CURR CANCER DRUG TAR, V18, P222, DOI 10.2174/1568009617666170427103732; Belisle JT, 1997, SCIENCE, V276, P1420, DOI 10.1126/science.276.5317.1420; Burnell SEA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220456; Capoun O, 2016, ANTICANCER RES, V36, P2019; Cappuccini F, 2016, CANCER IMMUNOL IMMUN, V65, P701, DOI 10.1007/s00262-016-1831-8; Castro F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00847; Chen X, 2019, BIOMED PHARMACOTHER, V111, P1124, DOI 10.1016/j.biopha.2019.01.012; Fan XL, 2009, MICROBIOL RES, V164, P374, DOI 10.1016/j.micres.2007.04.006; Gandhi J, 2018, PROSTATE CANCER P D, V21, P22, DOI 10.1038/s41391-017-0023-8; Garcia-Hernandez MDL, 2007, CANCER RES, V67, P1344, DOI 10.1158/0008-5472.CAN-06-2996; Gomes IM, 2014, UROL ONCOL-SEMIN ORI, V32, DOI 10.1016/j.urolonc.2013.08.028; Gomes IM, 2012, MOL CANCER RES, V10, P573, DOI 10.1158/1541-7786.MCR-11-0281; Gulley JL, 2014, CANCER IMMUNOL RES, V2, P133, DOI 10.1158/2326-6066.CIR-13-0108; Hayashi S, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-191; HUYGEN K, 1992, INFECT IMMUN, V60, P2880, DOI 10.1128/IAI.60.7.2880-2886.1992; Ihlaseh-Catalano SM, 2013, HISTOPATHOLOGY, V63, P678, DOI 10.1111/his.12226; Kariyone A, 2003, INT IMMUNOL, V15, P1183, DOI 10.1093/intimm/dxg115; Kim S, 2009, PROSTATE, V69, P938, DOI 10.1002/pros.20942; Kuo CJ, 2012, J BIOL CHEM, V287, P1892, DOI 10.1074/jbc.M111.298687; Kuromatsu I, 2001, CANCER GENE THER, V8, P483, DOI 10.1038/sj.cgt.7700330; Li ZY, 2012, INT J CANCER, V131, P2584, DOI 10.1002/ijc.27572; Maia CJB, 2008, ENDOCRINE, V34, P108, DOI 10.1007/s12020-008-9113-7; Manzo T, 2011, J IMMUNOL, V186, P1361, DOI 10.4049/jimmunol.1002030; Mustafa AS, 2000, INFECT IMMUN, V68, P3933, DOI 10.1128/IAI.68.7.3933-3940.2000; Nappo G, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.23; Ong CEB, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03117; Palma C, 2007, CELL MICROBIOL, V9, P1455, DOI 10.1111/j.1462-5822.2007.00884.x; PEAKE P, 1993, INFECT IMMUN, V61, P4828, DOI 10.1128/IAI.61.11.4828-4834.1993; Prendergast KA, 2016, VACCINE, V34, P2608, DOI 10.1016/j.vaccine.2016.03.089; PROCTOR RA, 1987, REV INFECT DIS, V9, pS412; ROCHE PW, 1994, INFECT IMMUN, V62, P5319, DOI 10.1128/IAI.62.12.5319-5326.1994; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590; Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551; Sun JL, 2019, J CELL BIOCHEM, V120, P11172, DOI 10.1002/jcb.28393; Takatsu K, 2003, INT IMMUNOPHARMACOL, V3, P783, DOI 10.1016/S01567-5769(02)00209-6; Trikha P, 2014, BBA-REV CANCER, V1846, P55, DOI 10.1016/j.bbcan.2014.04.003; Valenti MT, 2009, CANCER LETT, V273, P122, DOI 10.1016/j.canlet.2008.07.037; Zaidi MR, 2019, J INTERF CYTOK RES, V39, P30, DOI 10.1089/jir.2018.0087; Zhang SH, 2019, CANCER IMMUNOL RES, V7, P1237, DOI 10.1158/2326-6066.CIR-18-0940; Zhou F, 2009, INT REV IMMUNOL, V28, P239, DOI 10.1080/08830180902978120	45	1	1	5	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							786	10.3390/vaccines9070786			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5RU	34358202	Green Published			2022-04-29	WOS:000676969300001
J	Harris, R				Harris, Richard			Experiences with Testing, Self-Isolation and Vaccination in North East England during the COVID Pandemic	VACCINES			English	Article						vaccine hesitancy; COVID-19; ethnicity; multivariate regression		This study was based on a (population weighted) sample of some 4533 responses to a household survey conducted in March 2021 that looked at the impact of COVID-19 on residents in most of the local authorities covering the North East of England. It considered the outcomes relating to needing a COVID test, self-isolating, whether residents agreed that UK government and NHS-approved vaccines were 'very safe', and whether they had enough information in order to make an informed decision about whether or not to get vaccinated. Modelling these outcomes using multivariate regression produced a range of results that showed that all of the following were important: the impact of age, living in deprived areas, ethnicity, religious affiliation, disability, industry, occupation, economic status, changes in household income, sexual orientation, and household composition. Thus, the results showed that there are complex socioeconomic factors associated with the willingness to get a test, self-isolate, and the levels of vaccine hesitancy, such that, in future ensuring that (re-)vaccination and 'track and trace' programmes are successful, may need to be better nuanced by references to such factors rather than adopting programmes that mostly just rely on age as the criteria for roll-outs.	[Harris, Richard] Univ Durham, Dept Econ & Finance, Durham DH1 3LB, England		Harris, R (通讯作者)，Univ Durham, Dept Econ & Finance, Durham DH1 3LB, England.	r.i.d.harris@durham.ac.uk					BBC News, BBC NEWS; BBC News, 2021, BBC NEWS; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Harris, 2021, EXPERIENCES TESTING; HCLG, 2019, ENGL IND SOC DEPR; Idependent, 2021, IDEPENDENT; Jain A, 2017, VACCINE, V35, P2315, DOI 10.1016/j.vaccine.2017.03.013; Mangtani P, 2005, PREV MED, V41, P545, DOI 10.1016/j.ypmed.2005.02.001; NIHR, 2020, FACT ASS VACC INT AD; ONS, 2018, REG ETHN DIV; ONS, 2021, Q LAB FORC SURV 1992; OpenSAFELY, 2021, COLL TRENDS REG VAR, DOI [10.1101/2021.01.25.21250356v1, DOI 10.1101/2021.01.25.21250356V1]; Orsini, 2021, QUIT MOCKING ANTI VA; Osama T, 2021, J ROY SOC MED, V114, P240, DOI 10.1177/01410768211001581; Razai MS, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n513; Robertson E, 2021, BRAIN BEHAV IMMUN, V94, P41, DOI 10.1016/j.bbi.2021.03.008; Royal Society for Public Health, 2020, NEW POLL FINDS ETHN; Scientific Advisory Group for Emergencies (SAGE), 2021, FACTORS INFLUENCING; Smith TC, 2020, MICROBES INFECT, V22, P608, DOI 10.1016/j.micinf.2020.11.001; UK government, 2021, COVID 19 VACC 1 PHAS; Williams L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010017; World Health Organisation, 2014, REP SAG WORK GROUP V	22	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							759	10.3390/vaccines9070759			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6AB	34358175	Green Accepted, Green Published, gold			2022-04-29	WOS:000676990800001
J	Kaaijk, P; Emmelot, ME; Kerkhof, J; van Els, CACM; Meiring, HD; de Wit, J; Bodewes, R				Kaaijk, Patricia; Emmelot, Maarten E.; Kerkhof, Jeroen; van Els, Cecile A. C. M.; Meiring, Hugo D.; de Wit, Jelle; Bodewes, Rogier			Genetic Analysis Reveals Differences in CD8(+) T Cell Epitope Regions That May Impact Cross-Reactivity of Vaccine-Induced T Cells against Wild-Type Mumps Viruses	VACCINES			English	Article						T cell epitopes; T cell response; cytotoxic CD8(+) T cells; mumps virus; Jeryl-Lynn mumps vaccine; wild-type strains; HLA-I; immunoinformatics; antigenic variation; T cell cross-reactivity	MMR VACCINE; NEUTRALIZATION; OUTBREAK; ANTIGEN; STRAIN	Nowadays, mumps is re-emerging in highly vaccinated populations. Waning of vaccine-induced immunity plays a role, but antigenic differences between vaccine and mumps outbreak strains could also contribute to reduced vaccine effectiveness. CD8(+) T cells play a critical role in immunity to viruses. However, limited data are available about sequence variability in CD8(+) T cell epitope regions of mumps virus (MuV) proteins. Recently, the first set of naturally presented human leukocyte antigen Class I (HLA-I) epitopes of MuV was identified by us. In the present study, sequences of 40 CD8(+) T cell epitope candidates, including previously and newly identified, obtained from Jeryl-Lynn mumps vaccine strains were compared with genomes from 462 circulating MuV strains. In 31 epitope candidates (78%) amino acid differences were detected, and in 17 (43%) of the epitope candidates the corresponding sequences in wild-type strains had reduced predicted HLA-I-binding compared to the vaccine strains. These findings suggest that vaccinated persons may have reduced T cell immunity to circulating mumps viruses due to antigenic differences.	[Kaaijk, Patricia; Emmelot, Maarten E.; Kerkhof, Jeroen; van Els, Cecile A. C. M.; de Wit, Jelle; Bodewes, Rogier] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3721 MA Bilthoven, Netherlands; [van Els, Cecile A. C. M.] Univ Utrecht, Fac Vet Med, NL-3584 CL Utrecht, Netherlands; [Meiring, Hugo D.] Intravacc Inst Translat Vaccinol, NL-3721 MA Bilthoven, Netherlands		Kaaijk, P (通讯作者)，Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3721 MA Bilthoven, Netherlands.	patricia.kaaijk@rivm.nl; maarten.emmelot@rivm.nl; jeroen.kerkhof@rivm.nl; cecile.van.els@rivm.nl; hugo.meiring@intravacc.nl; jelle.de.wit@rivm.nl; rogier.bodewes@rivm.nl		Kaaijk, Patricia/0000-0001-9165-1703; de Wit, Jelle/0000-0003-2444-6050	Dutch Ministry of Health, Welfare and Sport	This work was supported by the Dutch Ministry of Health, Welfare and Sport.	Almansour I, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01999; Amexis G, 2002, VIROLOGY, V300, P171, DOI 10.1006/viro.2002.1499; Berkhoff EGM, 2007, J GEN VIROL, V88, P530, DOI 10.1099/vir.0.82120-0; Buseyne F, 2001, INT IMMUNOL, V13, P941, DOI 10.1093/intimm/13.7.941; Cardemil CV, 2017, NEW ENGL J MED, V377, P947, DOI 10.1056/NEJMoa1703309; Chambers P, 2009, J GEN VIROL, V90, P2973, DOI 10.1099/vir.0.013946-0; Cohen C, 2007, EMERG INFECT DIS, V13, P12; Connell AR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02089; Dayan GH, 2008, CLIN INFECT DIS, V47, P1458, DOI 10.1086/591196; de Wit J, 2020, J INFECT DIS, V221, P474, DOI 10.1093/infdis/jiz480; de Wit J, 2019, J VIROL, V93, DOI 10.1128/JVI.01883-18; de Wit J, 2018, J ALLERGY CLIN IMMUN, V141, P1908, DOI 10.1016/j.jaci.2017.11.047; Fiebelkorn AP, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu094; Gouma S, 2016, VACCINE, V34, P4166, DOI 10.1016/j.vaccine.2016.06.063; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95; Han WDGH, 2016, J IMMUNOL METHODS, V431, P52, DOI 10.1016/j.jim.2016.02.010; Homan EJ, 2014, HUM VACC IMMUNOTHER, V10, P290, DOI 10.4161/hv.27139; Jenkins GM, 2002, J MOL EVOL, V54, P156, DOI 10.1007/s00239-001-0064-3; Jokinen S, 2007, J INFECT DIS, V196, P861, DOI 10.1086/521029; Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893; Kaaijk P, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa505; Kaaijk P, 2020, J INFECT DIS, V221, P902, DOI 10.1093/infdis/jiz188; Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]; May M, 2018, INT J INFECT DIS, V66, P1, DOI 10.1016/j.ijid.2017.09.024; Mei ST, 2020, MOL CELL PROTEOMICS, V19, P1236, DOI 10.1074/mcp.RA119.001846; R Core Team, 2020, R LANGUAGE ENV STAT; Rasheed MAU, 2019, P NATL ACAD SCI USA, V116, P19071, DOI 10.1073/pnas.1905570116; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Rubin S, 2016, PEDIATR INFECT DIS J, V35, P799, DOI 10.1097/INF.0000000000001182; Rubin SA, 2008, J INFECT DIS, V198, P508, DOI 10.1086/590115; Santak M, 2013, EPIDEMIOL INFECT, V141, P1298, DOI 10.1017/S0950268812001896; Schellens IM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00546; Schmidt ME, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00678; Skipper JCA, 1996, J EXP MED, V183, P527, DOI 10.1084/jem.183.2.527; Ueno T, 2007, J IMMUNOL, V178, P5513, DOI 10.4049/jimmunol.178.9.5513; van Els CACM, 2000, EUR J IMMUNOL, V30, P1172, DOI 10.1002/(SICI)1521-4141(200004)30:4<1172::AID-IMMU1172>3.0.CO;2-J	37	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							699	10.3390/vaccines9070699			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7NB	34202193	Green Published, gold			2022-04-29	WOS:000677092200001
J	Lo, SY; Li, SCS; Wu, TY				Lo, Shih-Yu; Li, Shu-Chu Sarrina; Wu, Tai-Yee			Exploring Psychological Factors for COVID-19 Vaccination Intention in Taiwan	VACCINES			English	Article						COVID-19; vaccination intention; conspiracy theories; mental models; powerlessness	CONSPIRACY THEORIES; HERD-IMMUNITY; BELIEF	To underpin the psychological factors for vaccination intention, we explored the variables related to positive and negative attitudes toward COVID-19 vaccination in Taiwan. The data were collected via an online survey platform with a sample size of 1100 in April 2021. We found that people's interpretations of the origin of the virus were relevant. People who tended to believe that the virus was artificially created felt powerless and were more concerned about the possible side-effects of the vaccines, which was negatively associated with their vaccination intention. The source of vaccine recommendation was found to be relevant to vaccination intention. People's vaccination intention was highest if the vaccines were recommended by health professionals, followed by friends and the government, and then mainstream media and social media. The analysis of the demographic variables showed that men tended to be more receptive to vaccines than women. Our findings should provide insights into developing communication strategies to effectively promote vaccination intentions.	[Lo, Shih-Yu; Li, Shu-Chu Sarrina; Wu, Tai-Yee] Natl Yang Ming Chiao Tung Univ, Inst Commun Studies, Hsinchu 30010, Taiwan; [Lo, Shih-Yu; Li, Shu-Chu Sarrina; Wu, Tai-Yee] Natl Chiao Tung Univ, Inst Commun Studies, Hsinchu 30010, Taiwan		Lo, SY (通讯作者)，Natl Yang Ming Chiao Tung Univ, Inst Commun Studies, Hsinchu 30010, Taiwan.; Lo, SY (通讯作者)，Natl Chiao Tung Univ, Inst Commun Studies, Hsinchu 30010, Taiwan.	shihyulo@nctu.edu.tw; shuchu@mail.nctu.edu.tw; taiyeewu@nycu.edu.tw	Wu, Tai-Yee/AAE-7601-2021	Wu, Tai-Yee/0000-0003-0905-1886; Lo, Shih-Yu/0000-0002-9930-8253	Higher Education Sprout Project of National Yang Ming Chiao Tung University (NYCU); Ministry of Education, TaiwanMinistry of Education, Taiwan; Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST 108-2628-H-009-001-MY2]	This work was supported by the Higher Education Sprout Project of National Yang Ming Chiao Tung University (NYCU), the Ministry of Education, Taiwan, as well as the Ministry of Science and Technology, Taiwan [grant number: MOST 108-2628-H-009-001-MY2 to S.-Y.L.].	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; ANDERSON RM, 1985, NATURE, V318, P323, DOI 10.1038/318323a0; Baumgaertner B, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003354; Bertin P, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.565128; Biddlestone M, 2020, BRIT J SOC PSYCHOL, V59, P663, DOI 10.1111/bjso.12397; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Bogart LM, 2006, J NATL MED ASSOC, V98, P1144; Brien S, 2012, VACCINE, V30, P1255, DOI 10.1016/j.vaccine.2011.12.089; Douglas KM, 2011, BRIT J SOC PSYCHOL, V50, P544, DOI 10.1111/j.2044-8309.2010.02018.x; Dyer O, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1359; Freeman D., PSYCHOL MED; GOERTZEL T, 1994, POLIT PSYCHOL, V15, P731, DOI 10.2307/3791630; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Hayes AF., 2017, INTRO MEDIATION MODE; Holyoak K. J., 2012, OXFORD HDB THINKING, P134, DOI 10.10- 93/oxfordhb/9780199734689.013.0009; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Johnson-Laird P. N., 1983, MENTAL MODELS COGNIT; Johnson-Laird PN, 2010, P NATL ACAD SCI USA, V107, P18243, DOI 10.1073/pnas.1012933107; Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177; Jolley D, 2014, BRIT J PSYCHOL, V105, P35, DOI 10.1111/bjop.12018; Joseph J.G., 1987, PSYCHOL HEALTH, V1, P73; Mathieu E., NAT HUM BEHAV; MCCAULEY C, 1979, J PERS SOC PSYCHOL, V37, P637, DOI 10.1037/0022-3514.37.5.637; Moran KR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164541; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; National Development Council, 2019 DIG OPP SURV IN 2019 DIG OPP SURV IN; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Pivetti M, 2021, SOC SCI-BASEL, V10, DOI 10.3390/socsci10030108; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Rogers R.W., 1997, HDB HLTH BEHAV RES 1, DOI DOI 10.1007/978-1-4899-1760-7_21; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Soveri A, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10643-w; Swami V, 2010, PSYCHOLOGIST, V23, P560; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Williams L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010017; Wood MJ, 2012, SOC PSYCHOL PERS SCI, V3, P767, DOI 10.1177/1948550611434786; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048	40	1	1	12	21	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							764	10.3390/vaccines9070764			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6KH	34358180	gold, Green Published			2022-04-29	WOS:000677017400001
J	Pastor-Ibanez, R; Diez-Fuertes, F; Sanchez-Palomino, S; Alcami, J; Plana, M; Torrents, D; Leal, L; Garcia, F				Pastor-Ibanez, Roque; Diez-Fuertes, Francisco; Sanchez-Palomino, Sonsoles; Alcami, Jose; Plana, Montserrat; Torrents, David; Leal, Lorna; Garcia, Felipe			Impact of Transcriptome and Gut Microbiome on the Response of HIV-1 Infected Individuals to a Dendritic Cell-Based HIV Therapeutic Vaccine	VACCINES			English	Article						microbiota; transcriptomics; dendritic cell; vaccine; antiretroviral; HIV-1	DIVERSITY	Therapeutic vaccines based on dendritic cells offer a good approach to HIV-specific T-cell responses and partial control of the viral load after antiretroviral therapy interruption. The aim of the present study was to identify mRNA expression profiles and to assess the impact of the gut microbiome composition for predicting the viral load control after antiretroviral therapy interruption. We enrolled 29 patients to receive either placebo or a monocyte-derived dendritic cell vaccine. Patients with a decrease in their viral load of >0.5 log(10) copies/mL by 12 weeks after antiretroviral therapy interruption were considered responders. In total, 66 genes were considered differentially expressed between responders and non-responders. Enrichment analysis revealed several upregulated pathways involved in the host defense response to a virus via the type I interferon signaling pathway. Regarding the gut microbiota, responders showed enriched levels of Bacteroidetes (p < 0.005) and Verrucomicrobia (p = 0.017), while non-responders were enriched with Tenericutes (p = 0.049) and Actinobacteria (p < 0.005). We also found important differences at the genus level. However, we did not discover any effect of the dendritic cell vaccine on the transcriptome or the gut microbiota. An alternative analysis did characterize that the microbiota from responders were associated with the metabolic production of short-chain fatty acids, which are key metabolites in the regulation of intestinal homeostasis. The evidence now consistently shows that short-chain fatty acid depletion occurs in HIV-infected individuals receiving antiretroviral treatment.	[Pastor-Ibanez, Roque; Sanchez-Palomino, Sonsoles; Alcami, Jose; Plana, Montserrat; Leal, Lorna; Garcia, Felipe] Univ Barcelona, Hosp Clin, IDIBAPS, AIDS Res Grp, Barcelona 08036, Spain; [Diez-Fuertes, Francisco; Alcami, Jose] Inst Salud Carlos III, Ctra Pozuelo 28, Madrid 28222, Spain; [Torrents, David] Barcelona Supercomp Ctr BSC, Computat Genom Grp, Placa Eusebi Guell 1-3, Barcelona 08034, Spain; [Leal, Lorna; Garcia, Felipe] Univ Barcelona, Hosp Clin, Infect Dis Dept, IDIBAPS, Villarroel 170, Barcelona 08036, Spain		Leal, L (通讯作者)，Univ Barcelona, Hosp Clin, IDIBAPS, AIDS Res Grp, Barcelona 08036, Spain.; Leal, L (通讯作者)，Univ Barcelona, Hosp Clin, Infect Dis Dept, IDIBAPS, Villarroel 170, Barcelona 08036, Spain.	rpastor@clinic.cat; frandifu@icloud.com; ssanchez@clinic.cat; alcami@clinic.cat; mplana@clinic.cat; david.torrents@bsc.es; laleal@clinic.cat; fgarcia@clinic.cat	Alcami, Pepe/T-2242-2018; , Felipe/F-4242-2014; Díez-Fuertes, Francisco/AAA-9427-2019; Leal, Lorna/L-2773-2015; Torrents, David/G-5785-2015	Alcami, Pepe/0000-0003-0023-7377; , Felipe/0000-0001-7658-5832; Diez-Fuertes, Francisco/0000-0003-2413-9229; Torrents, David/0000-0002-6086-9037; Pastor-Ibanez, Roque/0000-0002-0787-4638	SPANISH AIDS Research Network (RIS) projects [RD16/0025/0002, RD16/0025/0013]; Spanish Carlos III Institute of Health (ISCIII) - European Regional Development Fund (FEDER); Fondo de Investigacion Sanitaria (FIS)Instituto de Salud Carlos III [AC16/00051, PI18/00699]; Gilead grants in Biomedical research in HIV, hepatic, and hemooncology fromthe SpanishMinistry of Economy (MINECO) [SAF201566193-R, RTI2018-096309-B-I00]; Europe in the Regional Development (FEDER); CERCA Programme/Generalitat de Catalunya [SGR 615, SGR 653]	This study was partially supported by the SPANISH AIDS Research Network (RIS) projects RD16/0025/0002 and RD16/0025/0013 integrated in the State Plan for Scientific and Technical Research and Innovation from the General Sub-Directorate for research assessment and promotion; Spanish Carlos III Institute of Health (ISCIII) co-funded by the European Regional Development Fund (FEDER); the Fondo de Investigacion Sanitaria (FIS), AC16/00051 and PI18/00699; Gilead grants in Biomedical research in HIV, hepatic, and hemooncology fromthe SpanishMinistry of Economy (MINECO) (grants: SAF201566193-R and RTI2018-096309-B-I00); and the income found from Europe in the Regional Development (FEDER) and the CERCA Programme/Generalitat de Catalunya SGR 615 and SGR 653. Felipe Garcia received the support of Jose Maria Segovia de Arana contracts.	Adeva-Andany MM, 2019, MITOCHONDRION, V46, P73, DOI 10.1016/j.mito.2018.02.009; Bradley KC, 2019, CELL REP, V28, P245, DOI 10.1016/j.celrep.2019.05.105; Castellano P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39898-5; Collins N, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028860; Costanzo MC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03618-w; Dalile B, 2019, NAT REV GASTRO HEPAT, V16, P461, DOI 10.1038/s41575-019-0157-3; de Goede AL, 2015, VACCINE, V33, P2922, DOI 10.1016/j.vaccine.2015.04.047; Dillon SM, 2017, AIDS, V31, P510, DOI 10.1097/QAD.0000000000001366; Doyle T, 2015, NAT REV MICROBIOL, V13, P403, DOI 10.1038/nrmicro3449; Earley H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51878-3; Eloe-Fadrosh EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062026; Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110; Ferreira RBR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001190; Garcia F, 2011, J INFECT DIS, V203, P473, DOI 10.1093/infdis/jiq077; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; Lamouse-Smith ES, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027662; Martin M, 2011, EMBNET J, V17, P10, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; McKay PF, 2019, ELIFE, V8, DOI 10.7554/eLife.46149; Mikhailova A, 2020, J VIROL, V94, DOI 10.1128/JVI.00611-20; Noguera-Julian M, 2016, EBIOMEDICINE, V5, P135, DOI 10.1016/j.ebiom.2016.01.032; Nowak P, 2015, AIDS, V29, P2409, DOI 10.1097/QAD.0000000000000869; Nozza S, 2020, J ANTIMICROB CHEMOTH, V75, P2700, DOI 10.1093/jac/dkaa231; Oh JZ, 2014, IMMUNITY, V41, P478, DOI 10.1016/j.immuni.2014.08.009; Ouyang J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00645; PANDE SV, 1971, J BIOL CHEM, V246, P5384; Park J, 2015, MUCOSAL IMMUNOL, V8, P80, DOI 10.1038/mi.2014.44; Pinto-Cardoso S, 2018, CURR OPIN HIV AIDS, V13, P53, DOI [10.1097/coh.0000000000000428, 10.1097/COH.0000000000000428]; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Rocafort M, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0687-5; Saez-Cirion A, 2021, NAT REV IMMUNOL, V21, P5, DOI 10.1038/s41577-020-0381-7; Seekatz AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064212; Sprooten J, 2019, INT REV CEL MOL BIO, V348, P217, DOI 10.1016/bs.ircmb.2019.06.001; Thiebaut R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00874; Valdezi Y, 2014, TRENDS IMMUNOL, V35, P526, DOI 10.1016/j.it.2014.07.003; Vesterbacka J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06675-1; Vlasova AN, 2019, CURR OPIN VIROL, V37, P16, DOI 10.1016/j.coviro.2019.05.001; Xie C, 2011, NUCLEIC ACIDS RES, V39, pW316, DOI 10.1093/nar/gkr483; Zhai R, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00239; Zheng L, 2017, J IMMUNOL, V199, P2976, DOI 10.4049/jimmunol.1700105; Zhu Z, 2014, ASIAN AUSTRAL J ANIM, V27, P179, DOI 10.5713/ajas.2013.13373	40	2	2	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							694	10.3390/vaccines9070694			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO4NW	34202658	gold, Green Published			2022-04-29	WOS:000676891500001
J	Scardina, G; Ceccarelli, L; Casigliani, V; Mazzilli, S; Napoletano, M; Padovan, M; Petillo, A; Sironi, D; Brilli, C; Gattini, V; Tavoschi, L; Foddis, R; Guglielmi, G; Privitera, GP; Baggiani, A				Scardina, Giuditta; Ceccarelli, Luca; Casigliani, Virginia; Mazzilli, Sara; Napoletano, Marco; Padovan, Martina; Petillo, Armando; Sironi, Daniele; Brilli, Cinzia; Gattini, Vittorio; Tavoschi, Lara; Foddis, Rudy; Guglielmi, Giovanni; Privitera, Gaetano Pierpaolo; Baggiani, Angelo			Evaluation of Flu Vaccination Coverage among Healthcare Workers during a 3 Years' Study Period and Attitude towards Influenza and Potential COVID-19 Vaccination in the Context of the Pandemic	VACCINES			English	Article						healthcare workers; vaccine hesitancy; vaccine coverage; flu vaccination campaigns; COVID-19 vaccine	SEASONAL INFLUENZA; PREVALENCE; KNOWLEDGE; HESITANCY; IMPACT	(1) Background: vaccination of healthcare workers (HCWs) against seasonal influenza is considered the most effective way to protect HCWs, ensure patient's safety and to maintain essential health care services during influenza epidemics. With the present study we aimed to evaluate the efficacy of incremental bundles of measures implemented during the last three flu campaigns and to assess the attitudes towards influenza vaccination and a potential vaccine against COVID-19 among HCWs, in a large university hospital in Pisa, Italy. (2) Methods: We described measures implemented during 2018/2019, 2019/2020 and 2020/2021 and assessed their impact on flu vaccine coverage (VC) among employees and residents in Pisa university hospital. We considered sex, profession and ward to investigate differences in uptake. In addition, in 2020 a survey was developed and distributed to all employees to evaluate flu and COVID-19 vaccines attitudes. (3) Results: during the 2018/19 and 2019/20 flu campaigns the overall VC rate among HCWs was, respectively, 10.2% and 11.9%. In 2020/21 the overall VC rate jumped to 39.3% (+ 230.6%). Results from the survey indicated a more positive attitude towards flu vaccine as compared to COVID-19 vaccines among the 10.6% of the staff members who responded to the survey. In addition, 70.97% of HCWs totally agreed that being vaccinated against influenza would be more important than the previous years because of COVID-19 emergency. (4) Conclusions: a significant increase in VC was observed in 2020/21, especially among those sub-groups with consistently lower uptake in previous years. The COVID-19 pandemic positively influenced flu vaccination uptake during the 2020/21 season.	[Scardina, Giuditta; Ceccarelli, Luca; Casigliani, Virginia; Mazzilli, Sara; Napoletano, Marco; Padovan, Martina; Petillo, Armando; Sironi, Daniele; Tavoschi, Lara; Foddis, Rudy; Privitera, Gaetano Pierpaolo; Baggiani, Angelo] Univ Pisa, Dept Translat Res & New Technol Med & Surg, I-56121 Pisa, Italy; [Mazzilli, Sara] Scuola Normale Super Pisa, I-56121 Pisa, Italy; [Brilli, Cinzia; Gattini, Vittorio; Guglielmi, Giovanni] Santa Chiara Hosp, Div Occupat & Prevent Med, I-56121 Pisa, Italy		Ceccarelli, L (通讯作者)，Univ Pisa, Dept Translat Res & New Technol Med & Surg, I-56121 Pisa, Italy.	giudittascardina7@yahoo.it; luca.ceccarelli3@studenti.unipi.it; v.casigliani7@gmail.com; sara.mazzill@gmail.com; marco.napoletano@ao-pisa.toscana.it; padovan.martina@gmail.com; armando.petillo@virgilio.it; daniele.sironi@outlook.it; c.brilli@ao-pisa.toscanalt; v.gattini@ao-pisa.toscana.it; lara.tavoschi@unipi.it; rudyfoddis@med.unipi.it; g.guglielmi@ao-pisa.toscana.it; gaetano.privitera@unipi.it; angelo.baggiani@med.unipi.it	Baggiani, Angelo/AAC-4596-2022; Tavoschi, Lara/K-1729-2018	Baggiani, Angelo/0000-0003-2615-7308; Sironi, Daniele/0000-0001-8170-3506; Tavoschi, Lara/0000-0002-2217-4664; PADOVAN, MARTINA/0000-0001-8461-1527; Casigliani, Virginia/0000-0002-4184-2648			Adlhoch C, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.42.2001816; Alicino C, 2015, HUM VACC IMMUNOTHER, V11, P95, DOI 10.4161/hv.34362; Azienda Ospedaliero Universitaria Pisana, AZIENDA OSPEDALIERO; Barbara A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010085; Bautista D, 2006, INFECT CONT HOSP EP, V27, P73, DOI 10.1086/499148; Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; La Colla L, 2020, J INFECT PUBLIC HEAL, V13, P1253, DOI 10.1016/j.jiph.2020.06.010; Di Gennaro F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030371; Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Durando P, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010779; Durovic A, 2020, AM J INFECT CONTROL, V48, P1139, DOI 10.1016/j.ajic.2020.02.004; Fortunato F, 2015, HUM VACC IMMUNOTHER, V11, P133, DOI 10.4161/hv.34415; Galanakis E, 2013, EUROSURVEILLANCE, V18, P23, DOI 10.2807/1560-7917.ES2013.18.45.20627; Graffigna G, 2020, RECOMMENDATIONS PROM, P2020020016, DOI [10.20944/preprints202002.0016.v1, DOI 10.20944/PREPRINTS202002.0016.V1]; Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3; Istituto Superiore di Sanita, I SUPERIORE SANITA E; Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; La Torre G, 2011, HUM VACCINES, V7, P728, DOI 10.4161/hv.7.7.15413; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mannocci A, 2010, REV HEALTH CARE, V1, P27, DOI 10.7175/rhc.v1i1.15; Mereckiene J, SEASONAL INFLUENZA V; Moberly T, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n837; Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046; Ng TWY, 2020, VACCINE, V38, P690, DOI 10.1016/j.vaccine.2019.10.041; Quinn SC, 2019, VACCINE, V37, P1168, DOI 10.1016/j.vaccine.2019.01.033; Robbins T, 2021, J HOSP INFECT, V112, P45, DOI 10.1016/j.jhin.2021.02.024; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Tabacchi G, 2017, HUM VACC IMMUNOTHER, V13, P339, DOI 10.1080/21645515.2017.1264733; Toy WC, 2005, AM J INFECT CONTROL, V33, P473, DOI 10.1016/j.ajic.2005.06.003; Vallee-Tourangeau G, 2018, VACCINE, V36, P6540, DOI 10.1016/j.vaccine.2017.08.025; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; World Health Organisation, IMPL SEAS INFL VACC	35	2	2	10	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							769	10.3390/vaccines9070769			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8VR	34358185	gold, Green Published			2022-04-29	WOS:000677182200001
J	Alhazmi, A; Alamer, E; Daws, D; Hakami, M; Darraj, M; Abdelwahab, S; Maghfuri, A; Algaissi, A				Alhazmi, Abdulaziz; Alamer, Edrous; Daws, Dalia; Hakami, Mashael; Darraj, Majid; Abdelwahab, Siddig; Maghfuri, Amani; Algaissi, Abdullah			Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccine; side effects		Background: Pfizer-BioNTech and Oxford-AstraZeneca are recently introduced vaccines to combat COVID-19 pandemic. During clinical trials, mild to moderate side effects have been associated with these vaccines. Thus, we aimed to evaluate short-term post-vaccination side effects. Methods: Cross-sectional, retrospective study using an online questionnaire was conducted among COVID-19 vaccines recipients in Saudi Arabia. General and demographic data were collected, and vaccine-associated side effects after receiving at least one dose of each vaccine were evaluated. Results: Our final sample consisted of 515 participants with a median age of 26 years. Most of the study participants were female (57%). Nearly 13% of the study subjects have reported previous infections with SARS-CoV-2. Oxford-AstraZeneca and Pfizer-BioNTech vaccines have been received by 75% and 25% of the study participants, respectively. Side effects associated with COVID-19 vaccines have been reported by 60% of the study subjects, and most of them reported fatigue (90%), pain at the site of the injections (85%). Conclusion: Side effects that are reported post Oxford-AstraZeneca and Pfizer-BioNTech vaccines among our study participants are not different from those that were reported in the clinical trials, indicating safe profiles for both vaccines. Further studies are needed to evaluate the effectiveness of the current vaccines in protection against SARS-CoV-2 reinfections.	[Alhazmi, Abdulaziz] Jazan Univ, Coll Med, Dept Microbiol & Parasitol, Jazan 45142, Saudi Arabia; [Alhazmi, Abdulaziz; Daws, Dalia; Hakami, Mashael] Jazan Univ, Jazan Univ Hosp, Jazan 45142, Saudi Arabia; [Alhazmi, Abdulaziz; Alamer, Edrous; Abdelwahab, Siddig; Algaissi, Abdullah] Jazan Univ, Med Res Ctr, Jazan 45142, Saudi Arabia; [Alamer, Edrous; Algaissi, Abdullah] Jazan Univ, Coll Appl Med Sci, Dept Med Labs Technol, Jazan 45142, Saudi Arabia; [Darraj, Majid] Jazan Univ, Coll Med, Dept Med, Jazan 45142, Saudi Arabia; [Maghfuri, Amani] Jazan Univ, Coll Med, Jazan 45142, Saudi Arabia		Algaissi, A (通讯作者)，Jazan Univ, Med Res Ctr, Jazan 45142, Saudi Arabia.; Algaissi, A (通讯作者)，Jazan Univ, Coll Appl Med Sci, Dept Med Labs Technol, Jazan 45142, Saudi Arabia.	abalhazmi@jazanu.edu.sa; ealamer@jazanu.edu.sa; ddous@jazanu.edu.sa; mashael@jazanu.edu.sa; mdarraj@jazanu.edu.sa; sadiqa@jazanu.edu.sa; Amanimgf@gmail.com; aalgaissi@jazanu.edu.sa	Darraj, Majid/ABB-2736-2021	HAKAMI, MASHAEL/0000-0001-7037-9333; ALAMER, EDROUS/0000-0002-9700-1610; Algaissi, Abdullah/0000-0002-5386-406X; , abdulaziz/0000-0002-4260-6540	Jazan University, Jazan [Cov19-56]	The authors acknowledge the sponsorship of Deanship of Scientific Research, Jazan University, Jazan (Project number: Cov19-56).	Al-Qahtani WS, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030274; Alfageeh EI, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030226; Algaissi AA, 2020, J INFECT PUBLIC HEAL, V13, P834, DOI 10.1016/j.jiph.2020.04.016; [Anonymous], 2020, ARAB NEWS; Arashkia A, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2183; Bono SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050515; Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397; Dal-Re R, 2021, ANN INTERN MED, V174, P258, DOI 10.7326/M20-7357; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; El-Shitany NA, 2021, INT J GEN MED, V14, P1389, DOI 10.2147/IJGM.S310497; Funk CD, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030418; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Ledford H, 2020, NATURE, V588, P205, DOI 10.1038/d41586-020-03441-8; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Sreepadmanabh M, 2020, J BIOSCIENCES, V45, DOI 10.1007/s12038-020-00114-6; Tumban E, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010054; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1	19	28	28	11	29	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							674	10.3390/vaccines9060674			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TA0QU	34207394	gold, Green Published			2022-04-29	WOS:000666960800001
J	Paploski, IAD; Pamornchainavakul, N; Makau, DN; Rovira, A; Corzo, CA; Schroeder, DC; Cheeran, MCJ; Doeschl-Wilson, A; Kao, RDR; Lycett, S; VanderWaal, K				Paploski, Igor A. D.; Pamornchainavakul, Nakarin; Makau, Dennis N.; Rovira, Albert; Corzo, Cesar A.; Schroeder, Declan C.; Cheeran, Maxim C-J.; Doeschl-Wilson, Andrea; Kao, Rowland R.; Lycett, Samantha; VanderWaal, Kimberly			Phylogenetic Structure and Sequential Dominance of Sub-Lineages of PRRSV Type-2 Lineage 1 in the United States	VACCINES			English	Article						porcine reproductive and respiratory syndrome virus; phylogenetic analysis; principal component analyses; mutations; viral population dynamics; whole genome; multi-strain dynamics	RESPIRATORY SYNDROME VIRUS; GENETIC-VARIATION; NORTH-AMERICAN; IMMUNE-RESPONSES; FIELD STRAINS; EMERGENCE; GP5; DIVERSITY; EVOLUTION; INFECTION	The genetic diversity and frequent emergence of novel genetic variants of porcine reproductive and respiratory syndrome virus type-2 (PRRSV) hinders control efforts, yet drivers of macro-evolutionary patterns of PRRSV remain poorly documented. Utilizing a comprehensive database of >20,000 orf5 sequences, our objective was to classify variants according to the phylogenetic structure of PRRSV co-circulating in the U.S., quantify evolutionary dynamics of sub-lineage emergence, and describe potential antigenic differences among sub-lineages. We subdivided the most prevalent lineage (Lineage 1, accounting for approximately 60% of available sequences) into eight sub-lineages. Bayesian coalescent SkyGrid models were used to estimate each sub-lineage's effective population size over time. We show that a new sub-lineage emerged every 1 to 4 years and that the time between emergence and peak population size was 4.5 years on average (range: 2-8 years). A pattern of sequential dominance of different sub-lineages was identified, with a new dominant sub-lineage replacing its predecessor approximately every 3 years. Consensus amino acid sequences for each sub-lineage differed in key GP5 sites related to host immunity, suggesting that sub-lineage turnover may be linked to immune-mediated competition. This has important implications for understanding drivers of genetic diversity and emergence of new PRRSV variants in the U.S.	[Paploski, Igor A. D.; Pamornchainavakul, Nakarin; Makau, Dennis N.; Rovira, Albert; Corzo, Cesar A.; Schroeder, Declan C.; Cheeran, Maxim C-J.; VanderWaal, Kimberly] Univ Minnesota, Dept Vet Populat Med, St Paul, MN 55108 USA; [Rovira, Albert] Univ Minnesota, Vet Diagnost Lab, St Paul, MN 55108 USA; [Schroeder, Declan C.] Univ Reading, Sch Biol Sci, Reading RG6 6AS, Berks, England; [Doeschl-Wilson, Andrea; Kao, Rowland R.; Lycett, Samantha] Univ Edinburgh, Roslin Inst, Edinburgh EH25 9RG, Midlothian, Scotland		VanderWaal, K (通讯作者)，Univ Minnesota, Dept Vet Populat Med, St Paul, MN 55108 USA.	ipaplosk@umn.edu; pamor001@umn.edu; dmakau@umn.edu; rove0010@umn.edu; corzo@umn.edu; dcschroe@umn.edu; cheeran@umn.edu; andrea.wilson@roslin.ed.ac.uk; Rowland.Kao@ed.ac.uk; samantha.lycett@ed.ac.uk; kvw@umn.edu	Cheeran, Maxim C-J/C-2135-2009; Schroeder, Declan C./O-9131-2019; Lycett, Samantha/F-9598-2013	Cheeran, Maxim C-J/0000-0002-5331-4746; Schroeder, Declan C./0000-0001-5991-2838; Lycett, Samantha/0000-0003-3159-596X; VanderWaal, Kimberly/0000-0002-5764-6430; Makau, Dennis/0000-0002-1802-2545; Wilson, Andrea/0000-0002-2658-6973; Kao, Rowland/0000-0003-0919-6401; Pamornchainavakul, Nakarin/0000-0003-0378-0316	USDA National Institute of Food and AgricultureUnited States Department of Agriculture (USDA); NIFA-NSF-NIH-BBSRC Ecology and Evolution of Infectious Disease award [2019-67015-29918, BB/T004401/1]; BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/T004401/1] Funding Source: UKRI	This project was supported by the USDA National Institute of Food and Agriculture, and by the joint NIFA-NSF-NIH-BBSRC Ecology and Evolution of Infectious Disease award 2019-67015-29918 and BB/T004401/1.	Alkhamis MA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04628-2; Ansari IH, 2006, J VIROL, V80, P3994, DOI 10.1128/JVI.80.8.3994-4004.2006; Brar MS, 2015, J GEN VIROL, V96, P1570, DOI 10.1099/vir.0.000104; Cano JP, 2007, AM J VET RES, V68, P565, DOI 10.2460/ajvr.68.5.565; Cha SH, 2004, J CLIN MICROBIOL, V42, P4462, DOI 10.1128/JCM.42.10.4462-4467.2004; Chen J, 2006, BIOCHEM GENET, V44, P425, DOI 10.1007/s10528-006-9039-9; Christianson W. T., 1994, Swine Health and Production, V2, P10; Correas I, 2017, VACCINE, V35, P782, DOI 10.1016/j.vaccine.2016.12.040; Dea S, 2000, ARCH VIROL, V145, P659, DOI 10.1007/s007050050662; Delisle B, 2012, INFECT GENET EVOL, V12, P1111, DOI 10.1016/j.meegid.2012.03.015; Diaz I, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-30; Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214; Faaberg KS, 2006, VIRAL IMMUNOL, V19, P294, DOI 10.1089/vim.2006.19.294; Geldhof MF, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-182; Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407; Do HQ, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0885-3; Han GW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39059-8; Hanada K, 2005, MOL BIOL EVOL, V22, P1024, DOI 10.1093/molbev/msi089; Hill V, 2019, MOL BIOL EVOL, V36, P2620, DOI 10.1093/molbev/msz172; Holtkamp DJ, 2013, J SWINE HEALTH PROD, V21, P72; Hong SF, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1906-9; Hu HX, 2009, ARCH VIROL, V154, P391, DOI 10.1007/s00705-009-0316-x; Jiang YF, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00618; Jombart T, 2008, BIOINFORMATICS, V24, P1403, DOI 10.1093/bioinformatics/btn129; Kapur V, 1996, J GEN VIROL, V77, P1271, DOI 10.1099/0022-1317-77-6-1271; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Key KF, 2001, VET MICROBIOL, V83, P249, DOI 10.1016/S0378-1135(01)00427-8; Kikuti M, OUTBREAK TYPE UNPUB; Kim WI, 2013, VET MICROBIOL, V162, P10, DOI 10.1016/j.vetmic.2012.08.005; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; Kwon T, 2019, VIRUS RES, V260, P12, DOI 10.1016/j.virusres.2018.11.004; Lalonde C, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00097-20; Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300; Larochelle R, 2003, VIRUS RES, V96, P3, DOI 10.1016/S0168-1702(03)00168-0; Larsson A, 2014, BIOINFORMATICS, V30, P3276, DOI 10.1093/bioinformatics/btu531; Lee JA, 2016, INFECT GENET EVOL, V40, P288, DOI 10.1016/j.meegid.2015.11.001; Li J, 2015, VIROLOGY, V478, P86, DOI 10.1016/j.virol.2015.02.013; Li X, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/416727; Liu YY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22494-4; Makau DN, 2022, TRANSBOUND EMERG DIS, V69, P524, DOI 10.1111/tbed.14016; Mateu E, 2008, VET J, V177, P345, DOI 10.1016/j.tvjl.2007.05.022; Miller M.A., 2010, P GAT COMP ENV WORKS, P1, DOI [10.1109/GCE.2010.5676129, DOI 10.1109/GCE.2010.5676129]; Murtaugh MP, 2010, VIRUS RES, V154, P18, DOI 10.1016/j.virusres.2010.08.015; Ostrowski M, 2002, J VIROL, V76, P4241, DOI 10.1128/JVI.76.9.4241-4250.2002; Paploski IAD, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02486; Pejsak Z, 1997, VET MICROBIOL, V55, P317, DOI 10.1016/S0378-1135(96)01326-0; Popescu LN, 2017, VET MICROBIOL, V209, P90, DOI 10.1016/j.vetmic.2017.04.016; R Development Core Team, 2019, R LANG ENV STAT COMP; Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032; Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007; Rowland RRR, 1999, VIROLOGY, V259, P262, DOI 10.1006/viro.1999.9789; Sagulenko P, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vex042; Schroeder D, GENOMES PORCINE REPR; Shi M, 2010, VIRUS RES, V154, P7, DOI 10.1016/j.virusres.2010.08.014; Shi M, 2010, J VIROL, V84, P8700, DOI 10.1128/JVI.02551-09; Solano GI, 1997, VET MICROBIOL, V55, P247, DOI 10.1016/S0378-1135(96)01325-9; Stadejek T, 2013, VET MICROBIOL, V165, P21, DOI 10.1016/j.vetmic.2013.02.029; StataCorp, 2017, STATA STAT SOFTWARE; Tian KG, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000526; Tousignant SJP, 2015, CAN VET J, V56, P1087; VanderWaal K, 2020, PREV VET MED, V178, DOI 10.1016/j.prevetmed.2020.104977; VanderWaal K, 2018, P NATL ACAD SCI USA, V115, P11495, DOI 10.1073/pnas.1806068115; Wang X, 2015, VIRUS RES, V210, P34, DOI 10.1016/j.virusres.2015.07.004; Wesley RD, 1998, J VET DIAGN INVEST, V10, P140, DOI 10.1177/104063879801000204; Xu M, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-184; Zhou L, 2010, VIRUS RES, V154, P31, DOI 10.1016/j.virusres.2010.07.016	66	4	4	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							608	10.3390/vaccines9060608			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY8XI	34198904	Green Published			2022-04-29	WOS:000666163600001
J	Ferorelli, D; Spagnolo, L; Marrone, M; Corradi, S; Silvestre, M; Misceo, F; Bianchi, FP; Stefanizzi, P; Solarino, B; Dell'Erba, A; Tafuri, S				Ferorelli, Davide; Spagnolo, Lorenzo; Marrone, Maricla; Corradi, Serena; Silvestre, Maria; Misceo, Federica; Bianchi, Francesco Paolo; Stefanizzi, Pasquale; Solarino, Biagio; Dell'Erba, Alessandro; Tafuri, Silvio			Off-Label Use of COVID-19 Vaccines from Ethical Issues to Medico-Legal Aspects: An Italian Perspective	VACCINES			English	Article						COVID-19; SARS-CoV-2; off-label use; vaccine; ethics; forensic sciences; public health; vaccine strategies; safety of vaccines		During the COVID-19 outbreak, the lack of official recommendations on the treatment has led healthcare workers to use multiple drugs not specifically tested and approved for the new insidious disease. After the availability of the first COVID-19 vaccines (Comirnaty Pfizer-BioNTech and Moderna COVID19 vaccine), an authorization was issued by national and international Drug Regulatory Agencies in order to speed up their introduction on the market and their administration on a large scale. Despite the authorization, the off-label use of these vaccines may still be possible especially to answer specific concerns as the lack of vaccine doses, the delay in the delivery of planned doses or the pressure from public opinion and political influence also in relation to the evolution of the pandemic. This paper aims to assess the possible off-label use of COVID-19 vaccines and the ethical and medico-legal implications of this eventuality. The scope of this paper is to point out the possible consequences of off-label use of COVID-19 vaccines and possible mitigation and preventive measures to be taken by healthcare workers involved in vaccination procedures.	[Ferorelli, Davide; Spagnolo, Lorenzo; Marrone, Maricla; Corradi, Serena; Silvestre, Maria; Misceo, Federica; Solarino, Biagio; Dell'Erba, Alessandro] Univ Bari, Interdisciplinary Dept Med, Sect Legal Med, I-70121 Bari, Italy; [Bianchi, Francesco Paolo; Stefanizzi, Pasquale; Tafuri, Silvio] Aldo Moro Univ Bari, Dept Biomed Sci & Human Oncol, I-70121 Bari, Italy		Spagnolo, L (通讯作者)，Univ Bari, Interdisciplinary Dept Med, Sect Legal Med, I-70121 Bari, Italy.	davideferorelli@gmail.com; lorenzospagnolo90@gmail.com; mariclamarrone@hotmail.it; serenacorradi10@gmail.com; maria-silve@libero.it; misceo.federica@gmail.com; frapabi@gmail.com; pasquale.stefanizzi@uniba.it; biagio.solarino@uniba.it; alessandro.dellerba@uniba.it; silvio.tafuri@uniba.it	Bianchi, Francesco Paolo/AAU-2597-2020	Bianchi, Francesco Paolo/0000-0002-9659-0193; Misceo, Federica/0000-0001-8956-8230; Marrone, Maricla/0000-0002-1058-7269; Ferorelli, Davide/0000-0001-8150-7476; tafuri, silvio/0000-0003-4194-0210			AIFA, RIASS CAR PROD COM; [Anonymous], World Health Organization Guidance on Developing a National Deployment and Vaccination Plan for COVID-19 Vaccines: Interim Guidance; [Anonymous], EUROPEAN MED AGENCY; [Anonymous], EARLY ACCESS OFF LAB; [Anonymous], 2017, EUROPEAN COMMISSION; [Anonymous], US FOOD DRUG ADM UND; [Anonymous], 2015, FOOD DRUG ADM INVEST, P1; Barbui C, 2004, ACTA PSYCHIAT SCAND, V109, P275, DOI 10.1111/j.1600-0447.2003.00283.x; Bright R, 2020, LETT AUTHORIZATION C; Burgess R, 2020, NEW PRINCIPLES BEST; CDC, 2021, INT CLIN CONS US MRN, P1; Cuzzolin L, 2016, EUR J CLIN PHARMACOL, V72, P117, DOI 10.1007/s00228-015-1962-4; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Dresser R, 2009, J LAW MED ETHICS, V37, P476, DOI 10.1111/j.1748-720X.2009.00408.x; Englund TR, 2020, ACR OPEN RHEUMATOL, V2, P760, DOI 10.1002/acr2.11207; European Medicines Agency, 2021, GUID GOOD PHARM PRAC; FDA, VACC REL BIOL PROD A; Ferorelli D, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56120691; Goodman JL, 2020, JAMA-J AM MED ASSOC, V323, P1899, DOI 10.1001/jama.2020.6434; Keusch G, 2017, INTEGRATING CLIN RES; Lumley SF, 2021, NEW ENGL J MED, V384, P533, DOI 10.1056/NEJMoa2034545; Martowirono K, 2012, J EVAL CLIN PRACT, V18, P76, DOI 10.1111/j.1365-2753.2010.01544.x; Ministero Della Salute, 2021, DIR GEN PREV SAN VAC; Moderna TX Inc, FACT SHEET HEALTHC P; Neels P, 2017, VACCINE, V35, P2329, DOI 10.1016/j.vaccine.2017.02.056; Pfizer Inc, PFIZ COVID 19 VACC E; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Quinn SC, 2021, AM J PUBLIC HEALTH, V111, P355, DOI 10.2105/AJPH.2020.306036; Radley DC, 2006, ARCH INTERN MED, V166, P1021, DOI 10.1001/archinte.166.9.1021; Saiyed MM, 2017, J CLIN PHARM THER, V42, P251, DOI 10.1111/jcpt.12507; STROM BL, 1985, AM J MED, V78, P475, DOI 10.1016/0002-9343(85)90341-9; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; World Health Organization, 2002, WHO WELLC TRUST M RE	34	1	1	3	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							423	10.3390/vaccines9050423			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI1IX	33922415	Green Published, gold			2022-04-29	WOS:000654580900001
J	Garcia-Montero, C; Fraile-Martinez, O; Bravo, C; Torres-Carranza, D; Sanchez-Trujillo, L; Gomez-Lahoz, AM; Guijarro, LG; Garcia-Honduvilla, N; Asunsolo, A; Bujan, J; Monserrat, J; Serrano, E; Alvarez-Mon, M; De Leon-Luis, JA; Alvarez-Mon, MA; Ortega, MA				Garcia-Montero, Cielo; Fraile-Martinez, Oscar; Bravo, Coral; Torres-Carranza, Diego; Sanchez-Trujillo, Lara; Gomez-Lahoz, Ana M.; Guijarro, Luis G.; Garcia-Honduvilla, Natalio; Asunsolo, Angel; Bujan, Julia; Monserrat, Jorge; Serrano, Encarnacion; Alvarez-Mon, Melchor; De Leon-Luis, Juan A.; Alvarez-Mon, Miguel A.; Ortega, Miguel A.			An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times	VACCINES			English	Review						SARS-CoV-2; coronavirus; COVID-19; vaccination programs; vaccine acceptance; vaccine hesitancy; pandemic management; mRNA vaccines; adenovirus-based vaccines; inactivated virus vaccines	MESSENGER-RNA VACCINES; CORONAVIRUS VACCINE; COVID-19 VACCINE; MECHANISMS; INFECTION; IMMUNITY; DESIGN; HEALTH; SAFETY; TRANSMISSION	Since the worldwide COVID-19 pandemic was declared a year ago, the search for vaccines has become the top priority in order to restore normalcy after 2.5 million deaths worldwide, overloaded sanitary systems, and a huge economic burden. Vaccine development has represented a step towards the desired herd immunity in a short period of time, owing to a high level of investment, the focus of researchers, and the urge for the authorization of the faster administration of vaccines. Nevertheless, this objective may only be achieved by pursuing effective strategies and policies in various countries worldwide. In the present review, some aspects involved in accomplishing a successful vaccination program are addressed, in addition to the importance of vaccination in a pandemic in the face of unwillingness, conspiracy theories, or a lack of information among the public. Moreover, we provide some updated points related to the landscape of the clinical development of vaccine candidates, specifically, the top five vaccines that are already being assessed in Phase IV clinical trials (BNT162b2, mRNA-1273, AZD1222, Ad26.COV2.S, and CoronaVac).	[Garcia-Montero, Cielo; Fraile-Martinez, Oscar; Sanchez-Trujillo, Lara; Gomez-Lahoz, Ana M.; Garcia-Honduvilla, Natalio; Bujan, Julia; Monserrat, Jorge; Alvarez-Mon, Melchor; Alvarez-Mon, Miguel A.; Ortega, Miguel A.] Univ Alcala, Fac Med & Hlth Sci, Dept Med & Med Special, Alcala De Henares 28801, Spain; [Bravo, Coral] Univ Complutense Madrid, Sch Med, Dept Publ & Maternal & Child Hlth, Madrid 28040, Spain; [Bravo, Coral; De Leon-Luis, Juan A.] Univ Hosp Gregorio Maranon, Dept Obstet & Gynecol, Madrid 28009, Spain; [Bravo, Coral; De Leon-Luis, Juan A.] Hlth Res Inst Gregorio Maranon, Madrid 28009, Spain; [Torres-Carranza, Diego; De Leon-Luis, Juan A.] First May Hlth Ctr, Hlth Area 1, Madrid 28521, Spain; [Sanchez-Trujillo, Lara] Hosp Univ Principe Asturias, Serv Pediat, Alcala De Henares 28801, Spain; [Guijarro, Luis G.] Univ Alcala, Dept Syst Biol, Unit Biochem & Mol Biol CIBEREHD, Alcala De Henares 28801, Spain; [Garcia-Honduvilla, Natalio; Asunsolo, Angel; Bujan, Julia; Monserrat, Jorge; Alvarez-Mon, Melchor; Alvarez-Mon, Miguel A.; Ortega, Miguel A.] Ramon y Cajal Inst Sanitary Res IRYCIS, Madrid 28034, Spain; [Asunsolo, Angel] Univ Alcala, Fac Med & Hlth Sci, Dept Surg Med & Social Sci, Alcala De Henares 28801, Spain; [Serrano, Encarnacion] Los Fresnos Hlth Ctr, Hlth Area 3, Madrid 28850, Spain; [Alvarez-Mon, Melchor] Univ Hosp Principe Asturias, Immune Syst Dis Rheumatol, Oncol Serv Internal Med, Alcala De Henares 28806, Spain; [Alvarez-Mon, Miguel A.] Hosp Univ Infanta Leonor, Dept Psychiat & Med Psychol, Madrid 28031, Spain; [Ortega, Miguel A.] Hosp Univ Principe Asturias, Canc Registry & Pathol Dept, Alcala De Henares 28806, Spain		De Leon-Luis, JA (通讯作者)，Univ Hosp Gregorio Maranon, Dept Obstet & Gynecol, Madrid 28009, Spain.; De Leon-Luis, JA (通讯作者)，Hlth Res Inst Gregorio Maranon, Madrid 28009, Spain.; De Leon-Luis, JA (通讯作者)，First May Hlth Ctr, Hlth Area 1, Madrid 28521, Spain.	cielogar@ucm.es; oscar.fraile@edu.uah.es; coral.bravo@salud.madrid.org; dtorresc@salud.madrid.org; lstrujillo@salud.madrid.org; anam.gomez@uah.es; luis.gonzalez@uah.es; natalio.garcia@uah.es; angel.asunsolo@uah.es; mjulia.bujan@uah.es; jorge.monserrat@uah.es; encarnacion.serrano@uah.es; mademons@uah.es; jaleon@ucm.es; maalvarez.gonzalez@salud.madrid.org; miguelangel.ortega@edu.uah.es	Asúnsolo, Ángel/D-8050-2018; De LeÃ³n-Luis, Juan/ABI-5828-2020; De Leon-Luis, Juan/H-5325-2017	Asúnsolo, Ángel/0000-0001-7898-4685; Monserrat Sanz, Jorge/0000-0003-1775-4645; Ana Maria, Gomez Lahoz/0000-0003-3981-5138; Fraile Martinez, Oscar/0000-0002-4494-6397; Ortega, Miguel A/0000-0003-2588-1708; Garcia Montero, Cielo/0000-0001-6016-7855; De Leon-Luis, Juan/0000-0002-6320-2668; Sanchez-Trujillo, Lara/0000-0002-0908-7566; Alvarez de Mon, Miguel Angel/0000-0002-1987-0394; bujan, Julia/0000-0003-2419-2476	Fondo de Investigacion de la Seguridad Social, Instituto de Salud Carlos III, Spain [PI18/00912]; Programa de Actividades de I+D de la Comunidad de Madrid en Biomedicina, Madrid, Spain [B2017/BMD3804]; Instituto de Salud Carlos III CIBER Enfermedades hepaticas y Digestivas, Spain	This work was partially supported by grants from the Fondo de Investigacion de la Seguridad Social, Instituto de Salud Carlos III (PI18/00912), Spain; Programa de Actividades de I+D de la Comunidad de Madrid en Biomedicina (B2017/BMD3804), Madrid, Spain; and Instituto de Salud Carlos III CIBER Enfermedades hepaticas y Digestivas, Spain.	Abdelrahman Z, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.552909; Ahammad I, 2020, INT J BIOL MACROMOL, V162, P820, DOI 10.1016/j.ijbiomac.2020.06.213; Ahmadpoor P, 2020, TRANSPL INT, V33, P824, DOI 10.1111/tri.13611; Alvarez-Mon M, 2021, J PERS MED, V11, DOI 10.3390/jpm11010036; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 2020, LANCET, V395, P1587, DOI 10.1016/S0140-6736(20)31200-9; [Anonymous], COVID 19 VACC ROLL R; [Anonymous], STAT ASTRAZENECA COV; [Anonymous], Inactivated Virus Vaccine-An Overview | ScienceDirect Topics; [Anonymous], 2020, DRAFT LANDSC COVID 1; [Anonymous], Comparing COVID-19 Vaccine Schedule Combinations-Com-COV; Baraniuk C, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n743; Baraniuk C, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n421; Barco A Asunsolo Del, 2020, Medicine (Madr), V13, P1297, DOI 10.1016/j.med.2020.12.011; Benest J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020078; Bettini E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020147; Bosmuller H, 2021, VIRCHOWS ARCH, V478, P137, DOI 10.1007/s00428-021-03053-1; Brooks-Wilson AR, 2013, HUM GENET, V132, P1323, DOI 10.1007/s00439-013-1342-z; Burton DR, 2020, CELL HOST MICROBE, V27, P695, DOI 10.1016/j.chom.2020.04.022; Buschmann MD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010065; Cagigi A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010061; Canedo-Marroquin G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.569760; Carlsen B, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1466-7; Chen YY, 2021, AGEING RES REV, V65, DOI 10.1016/j.arr.2020.101205; Choi EPH, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103740; Chung YH, 2020, ACS NANO, V14, P12522, DOI 10.1021/acsnano.0c07197; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Cunarro-Lopez Y, 2021, J CLIN MED, V10, DOI 10.3390/jcm10020360; Cunarro-Lopez Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113552; Cylus J, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00453-1; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Daou A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020120; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Dawood RM, 2021, J INFECT PUBLIC HEAL, V14, P169, DOI 10.1016/j.jiph.2020.12.006; Deal CE, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020108; Delrue I, 2012, EXPERT REV VACCINES, V11, P695, DOI [10.1586/erv.12.38, 10.1586/ERV.12.38]; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dudley MZ, 2020, LANCET INFECT DIS, V20, pE80, DOI 10.1016/S1473-3099(20)30130-4; Dwyer MJ, 2020, SCAND J MED SCI SPOR, V30, P1291, DOI 10.1111/sms.13710; Eberhardt CS, 2021, PEDIAT ALLERG IMM-UK, V32, P9, DOI 10.1111/pai.13401; Edwards KM, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-2146; Ejaz H, 2020, J INFECT PUBLIC HEAL, V13, P1833, DOI 10.1016/j.jiph.2020.07.014; Ezaj MMA, 2021, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2021.1886171; Favara DM, 2020, EMERG MICROBES INFEC, V9, P2728, DOI 10.1080/22221751.2020.1858699; Fisk RJ, 2021, GHJ, V5, P51, DOI [10.1016/j.glohj.2021.02.005, DOI 10.1016/J.GLOHJ.2021.02.005]; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Frederiksen LSF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01817; Fujino T, 2021, EMERG INFECT DIS, V27, P1243, DOI 10.3201/eid2704.210138; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Gao WT, 2003, LANCET, V362, P1895, DOI 10.1016/S0140-6736(03)14962-8; Gioia M, 2020, BIOCHEM PHARMACOL, V182, DOI 10.1016/j.bcp.2020.114225; Gould KA, 2017, DIMENS CRIT CARE NUR, V36, P145, DOI 10.1097/DCC.0000000000000250; Graham RL, 2012, NAT MED, V18, P1820, DOI 10.1038/nm.2972; Hakim MS, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2222; Han HJ, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107247; Hansen CH, 2021, LANCET, V397, P1204, DOI 10.1016/S0140-6736(21)00575-4; Harrison AG, 2020, TRENDS IMMUNOL, V41, P1100, DOI 10.1016/j.it.2020.10.004; Helfert SM, 2015, CURR DRUG SAF, V10, P5, DOI 10.2174/157488631001150407103723; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Humphreys IR, 2018, IMMUNOLOGY, V153, P1, DOI 10.1111/imm.12829; Huremovic D., 2019, PSYCHIAT PANDEMICS, P7, DOI [DOI 10.1007/978-3-030-15346-5_2, 10.1007/978-3-030- 15346-5_2]; Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179; Iddir M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12061562; Ilic M, 2017, TRAVEL MED INFECT DI, V17, P69, DOI 10.1016/j.tmaid.2017.05.010; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6; Jylhava J, 2017, EBIOMEDICINE, V21, P29, DOI 10.1016/j.ebiom.2017.03.046; Karpenko LI, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020076; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Keikha R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020074; Kellam P, 2020, J GEN VIROL, V101, P791, DOI 10.1099/jgv.0.001439; Khan T, 2021, BIOCATAL AGR BIOTECH, V31, DOI 10.1016/j.bcab.2020.101890; Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011; Kim E, 2021, ADV MATER, V33, DOI 10.1002/adma.202005927; Kim SJ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020220; Kim YC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0188-3; Kis Z, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010003; Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793; Klass P, 2021, NEW ENGL J MED, V384, P589, DOI 10.1056/NEJMp2034765; Kleine-Tebbe Jorg, 2021, Allergol Select, V5, P26, DOI 10.5414/ALX02215E; Klimek L, 2021, INTERNIST, V62, P326, DOI 10.1007/s00108-021-00959-5; Knezevic I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020081; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Kowalczyk A, 2016, VACCINE, V34, P3882, DOI 10.1016/j.vaccine.2016.05.046; Kremer EJ, 2020, MOL THER, V28, P2303, DOI 10.1016/j.ymthe.2020.10.002; Lawes-Wickwar S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020072; Lee CS, 2017, GENES DIS, V4, P43, DOI 10.1016/j.gendis.2017.04.001; Lee EJ, 2021, AM J HEMATOL, V96, P534, DOI 10.1002/ajh.26132; Leung K, 2021, EUROSURVEILLANCE, V26, P15, DOI 10.2807/1560-7917.ES.2020.26.1.2002106; Li JX, 2021, LANCET INFECT DIS, V21, P891, DOI 10.1016/S1473-3099(21)00094-3; Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Lu S, 2009, CURR OPIN IMMUNOL, V21, P346, DOI 10.1016/j.coi.2009.05.016; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3846; Majhen D, 2014, HUM GENE THER, V25, P301, DOI 10.1089/hum.2013.235; Makoni M, 2021, LANCET, V397, P566, DOI 10.1016/S0140-6736(21)00362-7; Malik YA, 2020, MALAYS J PATHOL, V42, P3; Martines RB, 2020, EMERG INFECT DIS, V26, P2005, DOI 10.3201/eid2609.202095; McKee M, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00441-5; Mo PKH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020129; Nims RW, 2013, BIOLOGICALS, V41, P63, DOI 10.1016/j.biologicals.2012.09.011; Ortega MA, 2021, INT J MOL MED, V47, P415, DOI 10.3892/ijmm.2020.4828; Padoan A, 2020, CLIN CHIM ACTA, V507, P164, DOI 10.1016/j.cca.2020.04.026; Pai SM, 2021, J CLIN PHARMACOL, V61, P277, DOI 10.1002/jcph.1794; Pal R, 2020, POSTGRAD MED J, V96, P429, DOI 10.1136/postgradmedj-2020-137742; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pastorino R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020070; Pepperrell T, 2021, GLOBAL HEALTH ACTION, V14, DOI 10.1080/16549716.2021.1892309; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Perrotta F, 2020, AGING CLIN EXP RES, V32, P1599, DOI 10.1007/s40520-020-01631-y; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Pinto Dora, 2020, bioRxiv, DOI 10.1101/2020.04.07.023903; Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Principi N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020127; Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Rosen B, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00440-6; Rowan NJ, 2021, SCI TOTAL ENVIRON, V772, DOI 10.1016/j.scitotenv.2021.145530; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020109; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Safronetz D, 2013, CURR OPIN VIROL, V3, P205, DOI 10.1016/j.coviro.2013.01.001; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Samnuan K., 2021, BIORXIV PREPRINT, P428665, DOI [10.1101/2021.01.28.428665, DOI 10.1101/2021.01.28.428665V1]; Sariol A, 2020, IMMUNITY, V53, P248, DOI 10.1016/j.immuni.2020.07.005; Schlake T, 2012, RNA BIOL, V9, P1319, DOI 10.4161/rna.22269; Self WH, 2020, MMWR-MORBID MORTAL W, V69, P1762, DOI 10.15585/mmwr.mm6947a2; Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y; Sharfstein JM, 2021, JAMA-J AM MED ASSOC, V325, P1153, DOI 10.1001/jama.2021.1961; Shimabukuro T, 2021, JAMA-J AM MED ASSOC, V325, P780, DOI 10.1001/jama.2021.0600; Sim F, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00451-3; Singh K, 2016, J POSTGRAD MED, V62, P4, DOI 10.4103/0022-3859.173187; Smith DR, 2019, VET CLIN N AM-FOOD A, V35, P593, DOI 10.1016/j.cvfa.2019.07.001; Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008; Sokolowska M, 2021, ALLERGY, V76, P1629, DOI 10.1111/all.14739; Soleimanpour S, 2021, EXPERT REV VACCINES, V20, P23, DOI [10.1080/14760584.2021.1875824, 10.1080/14760584.2021.1875824CrossMarkLogo]; Song Y, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106080; Tai DBG, 2021, CLIN INFECT DIS, V72, P703, DOI 10.1093/cid/ciaa815; Talevi D, 2020, RIV PSICHIATR, V55, P137, DOI 10.1708/3382.33569; Tang JLW, 2021, J INFECTION, V82, pE8, DOI 10.1016/j.jinf.2021.01.007; Tatsis N, 2006, GENE THER, V13, P421, DOI 10.1038/sj.gt.3302675; Tatsis N, 2004, MOL THER, V10, P616, DOI 10.1016/j.ymthe.2004.07.013; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; Uddin M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050526; Walker LM, 2018, NAT REV IMMUNOL, V18, P297, DOI 10.1038/nri.2017.148; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Wang W, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4704; WHO, COR DIS COVID 19 DAS; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Won JH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249775; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Wu D, 2020, INT J ACCOUNT INF MA, V28, P184, DOI [10.1108/IJAIM-12-2018-0148, 10.1016/j.ijid.2020.03.004]; Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Xie B, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.607583; Yuksel D, 2021, SLEEP HEALTH, V7, P134, DOI 10.1016/j.sleh.2020.12.008; Zhang Y., 2020, IMMUNOGENICITY SAFET, DOI [DOI 10.1101/2020.07.31.20161216, 10.1101/2020.07.31.20161216]; Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zimet GD, 2021, J PEDIATR-US, V231, P254, DOI 10.1016/j.jpeds.2020.11.002	166	34	34	5	22	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							433	10.3390/vaccines9050433			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1QJ	33925526	Green Published, gold			2022-04-29	WOS:000654600400001
J	Li, L; Wang, J; Leng, AL; Nicholas, S; Maitland, E; Liu, RG				Li, Lu; Wang, Jian; Leng, Anli; Nicholas, Stephen; Maitland, Elizabeth; Liu, Rugang			Will COVID-19 Vaccinations End Discrimination against COVID-19 Patients in China? New Evidence on Recovered COVID-19 Patients	VACCINES			English	Article						COVID-19; discrimination; vaccination; determinant	STIGMA; WORKERS	(1) Background: By April 2021, over 160 million Chinese have been vaccinated against coronavirus disease 2019 (COVID-19). This study analyzed the impact of vaccination on discrimination against recovered COVID-19 patients and the determinants of discrimination among intended vaccinated people. (2) Methods: A self-designed questionnaire was used to collect data on COVID-19 associated discrimination from nine provinces in China. Pearson chi-square tests and a multivariate ordered logistic regression analyzed the determinants of COVID-19-related discrimination. (3) Results: People who intended to be COVID-19 vaccinated displayed a high level of discrimination against recovered COVID-19 patients, with only 37.74% of the intended vaccinated without any prejudice and 34.11% displaying severe discrimination. However, vaccinations reduced COVID-19-related discrimination against recovered COVID-19 patients from 79.76% to 62.26%. Sex, age, education level, occupation, geographical region, respondents' awareness of vaccine effectiveness and infection risk, and COVID-19 knowledge score had a significant influence on the COVID-19 related discrimination (p < 0.05). (4) Conclusions: Vaccination significantly reduced COVID-19 associated discrimination, but discrimination rates remained high. Among the intended vaccinated respondents, females, the older aged, people with high school and above education level, retirees, migrant workers, and residents in central China were identified as key targets for information campaigns to reduce COVID-19 related discrimination.	[Li, Lu] Jiangsu Vocat Inst Commerce, Sch Business Adm, Nanjing 211168, Peoples R China; [Wang, Jian] Wuhan Univ, Dong Fureng Econ & Social Dev Sch, Beijing 100010, Peoples R China; [Wang, Jian] Wuhan Univ, Ctr Hlth Econ & Management, Sch Econ & Management, Wuhan 430072, Peoples R China; [Leng, Anli] Shandong Univ, Inst Governance, Sch Polit Sci & Publ Adm, Qingdao 266237, Peoples R China; [Nicholas, Stephen] Australian Natl Inst Management & Commerce, Sydney, NSW 2015, Australia; [Nicholas, Stephen] Guangdong Univ Foreign Studies, Res Inst Int Strategies, Guangzhou 510420, Peoples R China; [Nicholas, Stephen] Tianjin Normal Univ, Sch Econ, Tianjin 300074, Peoples R China; [Nicholas, Stephen] Tianjin Normal Univ, Sch Management, Tianjin 300074, Peoples R China; [Nicholas, Stephen] Univ Newcastle, Newcastle Business Sch, Newcastle, NSW 2308, Australia; [Maitland, Elizabeth] Univ Liverpool, Sch Management, Chatham Bldg,Chatham St, Liverpool L69 7ZH, Merseyside, England; [Liu, Rugang] Nanjing Med Univ, Sch Hlth Policy & Management, Nanjing 211166, Peoples R China; [Liu, Rugang] Nanjing Med Univ, Ctr Global Hlth, Nanjing 211166, Peoples R China		Liu, RG (通讯作者)，Nanjing Med Univ, Sch Hlth Policy & Management, Nanjing 211166, Peoples R China.; Liu, RG (通讯作者)，Nanjing Med Univ, Ctr Global Hlth, Nanjing 211166, Peoples R China.	200015@jvic.edu.cn; wangjian993@whu.edu.cn; lenganli@sdu.edu.cn; stephen.nicholas@newcastle.edu.au; e.maitland@liverpool.ac.uk; rugangliu@njmu.edu.cn	Leng, Anli/ABG-3086-2021; NICHOLAS, STEPHEN/ABE-4726-2021; Maitland, Elizabeth T/O-7703-2018	Maitland, Elizabeth T/0000-0003-1551-4787; Nicholas, Stephen/0000-0001-6770-7105; WANG, JIAN/0000-0001-8769-7928; leng, anli/0000-0002-6775-2085; Liu, Rugang/0000-0002-4270-9507	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [71904089]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2019M662392]; Qingdao Postdoctoral Foundation; Excellent Innovation Team of Philosophy and Social Sciences in the Universities and Colleges of Jiangsu Province "the Public Health Policy and Management Innovation Research Team"	This research was funded by National Natural Science Foundation of China, grant number 71904089; the China Postdoctoral Science Foundation, grant number 2019M662392; the Qingdao Postdoctoral Foundation; and the Excellent Innovation Team of Philosophy and Social Sciences in the Universities and Colleges of Jiangsu Province "the Public Health Policy and Management Innovation Research Team".	Abdelhafiz AS, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00429; [Anonymous], COVID 19 VACCINATION; [Anonymous], CHINA MAKE RULES PRO; [Anonymous], REAL TIME BIG DATA R; [Anonymous], SOCIAL STIGMA ASS CO; [Anonymous], CORONAVIRUS COVID 19; [Anonymous], DISCRIMINATION HEPAT; Bagcchi S, 2020, LANCET INFECT DIS, V20, P782, DOI 10.1016/S1473-3099(20)30498-9; Bao YP, 2020, LANCET, V395, pE37, DOI 10.1016/S0140-6736(20)30309-3; Bartoszek A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17207417; Bhanot D, 2021, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.577018; Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8., 10.1016/S0140-6736(20)30460-8]; Cavalcanti T, 2016, ECON J, V126, P109, DOI 10.1111/ecoj.12303; Chopra K K, 2020, Indian J Tuberc, V67, P284, DOI 10.1016/j.ijtb.2020.07.012; Eguchi H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076921; Grover S, 2020, ASIAN J PSYCHIATR, V53, DOI 10.1016/j.ajp.2020.102381; Gunnell D, 2020, LANCET PSYCHIAT, V7, P468, DOI 10.1016/S2215-0366(20)30171-1; Huang JX, 2016, LIVER INT, V36, P1595, DOI 10.1111/liv.13168; Kyriakou G, 2021, CLIN EXP DERMATOL, V46, P762, DOI 10.1111/ced.14619; Lee H, 2019, PAC ECON REV, V24, P659, DOI 10.1111/1468-0106.12285; Leng AL, 2016, HUM VACC IMMUNOTHER, V12, P1164, DOI 10.1080/21645515.2015.1131883; Li L, 2007, INT J EPIDEMIOL, V36, P178, DOI 10.1093/ije/dyl256; Liu RG, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2021.1913966; Liu RG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030292; Logie CH, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25504; Logie CH, 2020, AIDS BEHAV, V24, P2003, DOI 10.1007/s10461-020-02856-8; Peprah P, 2020, ARCH GERONTOL GERIAT, V90, DOI 10.1016/j.archger.2020.104149; Prah J, 2020, J PUBLIC HEALTH AFR, V11, P8, DOI 10.4081/jphia.2020.1020; Singh R, 2020, ASIAN J PSYCHIATR, V53, DOI 10.1016/j.ajp.2020.102222; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030218; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; Tehrani H, 2020, GERIATR GERONTOL INT, V20, P796, DOI 10.1111/ggi.13985; van Daalen KR, 2021, J EPIDEMIOL COMMUN H, V75, P313, DOI 10.1136/jech-2020-214436; Whiteside-Mansell L, 2020, J NATL MED ASSOC, V112, P668, DOI 10.1016/j.jnma.2020.06.012; World Health Organization, DIRECTOR GEN STATEME; Yadav, 2017, COMMUNITY ACQUIRED I, V4, P6, DOI [10.4103/2225-6482.203265, DOI 10.4103/2225-6482.203265]; Yang T, 2011, LANCET, V378, P1059, DOI 10.1016/S0140-6736(11)61460-8; Yu LJ, 2016, HUM VACC IMMUNOTHER, V12, P70, DOI 10.1080/21645515.2015.1069932	38	2	2	24	34	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							490	10.3390/vaccines9050490			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI1ZF	34064737	gold, Green Published			2022-04-29	WOS:000654623400001
J	Lu, J; Wen, XS; Guo, Q; Ji, MD; Zhang, F; Wagner, AL; Lu, YH				Lu, Jia; Wen, Xiaosa; Guo, Qi; Ji, Mengdi; Zhang, Felici; Wagner, Abram L.; Lu, Yihan			Sensitivity to COVID-19 Vaccine Effectiveness and Safety in Shanghai, China	VACCINES			English	Article						COVID-19 vaccination; vaccine hesitancy; China; urban health		Several COVID-19 vaccines have been on the market since early 2021 and may vary in their effectiveness and safety. This study characterizes hesitancy about accepting COVID-19 vaccines among parents in Shanghai, China, and identifies how sensitive they are to changes in vaccine safety and effectiveness profiles. Schools in each township of Minhang District, Shanghai, were sampled, and parents in the WeChat group of each school were asked to participate in this cross-sectional Internet-based survey. Parents responded to questions about hesitancy and were given information about five different COVID-19 vaccine candidates, the effectiveness of which varied between 50 and 95% and which had a risk of fever as a side effect between 5 and 20%. Overall, 3673 parents responded to the survey. Almost 90% would accept a vaccine for themselves (89.7%), for their child (87.5%) or for an elderly parent (88.5%) with the most ideal attributes (95% effectiveness with 5% risk of fever). But with the least ideal attributes (50% effectiveness and a 20% risk of fever) these numbers dropped to 33.5%, 31.3%, and 31.8%, respectively. Vaccine hesitancy, age at first child's birth, and relative income were all significantly related to sensitivity to vaccine safety and effectiveness. Parents showed a substantial shift in attitudes towards a vaccine based on its safety and effectiveness profile. These findings indicate that COVID-19 vaccine acceptance may be heavily influenced by how effective the vaccine actually is and could be impeded or enhanced based on vaccines already on the market.	[Lu, Jia; Wen, Xiaosa; Guo, Qi] Minhang Ctr Dis Control & Prevent, Dept Immunizat, Shanghai 201101, Peoples R China; [Ji, Mengdi; Zhang, Felici; Wagner, Abram L.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA; [Lu, Yihan] Fudan Univ, Sch Publ Hlth, Minist Educ, Key Lab Publ Hlth Safety, Shanghai 200433, Peoples R China		Wagner, AL (通讯作者)，Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.	cpulj@126.com; xiaosasmmu@163.com; qif0713@163.com; mengdiji@umich.edu; fyzhang@umich.edu; awag@umich.edu; luyihan@fudan.edu.cn		Wagner, Abram/0000-0003-4691-7802; Lu, Yihan/0000-0003-4651-9433	National Science Foundation, Division of Social and Economic SciencesNational Science Foundation (NSF) [2027836]	A.L.W. received salary support from the National Science Foundation, Division of Social and Economic Sciences (#2027836).	Akel KB, 2021, HUM VACC IMMUNOTHER, V17, P2639, DOI 10.1080/21645515.2021.1884476; [Anonymous], Pfizer-BioNTech COVID-19 Vaccine-Fact Sheet for Healthcare Providers Administering Vaccine; [Anonymous], Moderna COVID-19 vaccine overview and safety; [Anonymous], **NON-TRADITIONAL**; [Anonymous], HIST VACCINES ED RES; Brothers W., TIMELINE COVID 19 VA; Centers for Disease Control and Prevention (CDC), ENS COVID 19 VACC WO; Creech CB, 2021, JAMA-J AM MED ASSOC, V325, P1318, DOI 10.1001/jama.2021.3199; Gualano MR, 2018, VACCINE, V36, P3368, DOI 10.1016/j.vaccine.2018.04.029; Guthmann JP, 2012, VACCINE, V30, P4648, DOI 10.1016/j.vaccine.2012.04.098; Hamel L., 2020, KFF COVID 19 VACCINE; Harapan H, 2019, VACCINE, V37, P1398, DOI 10.1016/j.vaccine.2019.01.062; Hopkins D.C., 2021, NATL PUBLIC RADIO; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Randall T, MORE 108 MILLION SHO; Smith J., DOES ASTRAZENECA COV; Su S, 2021, NAT REV MICROBIOL, V19, P211, DOI 10.1038/s41579-020-00462-y; Trogen B, 2020, JAMA-J AM MED ASSOC, V323, P2460, DOI 10.1001/jama.2020.8917; Wagner AL, 2021, AM J PREV MED, V60, pS77, DOI 10.1016/j.amepre.2020.09.003; World Health Organization, 2004, GUID CLIN EV VACC RE; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zimmer C., NEW YORK TIME	23	9	9	5	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							472	10.3390/vaccines9050472			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI2ZE	34067141	Green Published, gold			2022-04-29	WOS:000654694600001
J	Cao, H; Wang, YF; Luan, N; Liu, CB				Cao, Han; Wang, Yunfei; Luan, Ning; Liu, Cunbao			Immunogenicity of Varicella-Zoster Virus Glycoprotein E Formulated with Lipid Nanoparticles and Nucleic Immunostimulators in Mice	VACCINES			English	Article						herpesvirus 3; human; varicella; chickenpox; herpes zoster; shingles; humoral immunity; cell-mediated immunity; nucleic acid immunostimulator; Poly I:C (polyinosinic-polycytidylic acid); CpG ODN (CpG oligodeoxynucleotide); lipid nanoparticle	T-CELL RESPONSES; HERPES-ZOSTER; VIRAL REPLICATION; SUBUNIT VACCINE; EPITOPE-VACCINE; CPG-DNA; VZV; PROTECTION; SAFETY; EFFICACY	Theoretically, the subunit herpes zoster vaccine Shingrix(TM) could be used as a varicella vaccine that avoids the risk of developing shingles from vaccination, but bedside mixing strategies and the limited supply of the adjuvant component QS21 have made its application economically impracticable. With lipid nanoparticles (LNPs) that were approved by the FDA as vectors for severe acute respiratory syndrome coronavirus 2 vaccines, we designed a series of vaccines efficiently encapsulated with varicella-zoster virus glycoprotein E (VZV-gE) and nucleic acids including polyinosinic-polycytidylic acid (Poly I:C) and the natural phosphodiester CpG oligodeoxynucleotide (CpG ODN), which was approved by the FDA as an immunostimulator in a hepatitis B vaccine. Preclinical trial in mice showed that these LNP vaccines could induce VZV-gE IgG titers more than 16 times those induced by an alum adjuvant, and immunized serum could block in vitro infection completely at a dilution of 1:80, which indicated potential as a varicella vaccine. The magnitude of the cell-mediated immunity induced was generally more than 10 times that induced by the alum adjuvant, indicating potential as a zoster vaccine. These results showed that immunostimulatory nucleic acids together with LNPs have promise as safe and economical varicella and zoster vaccine candidates.	[Cao, Han; Wang, Yunfei; Luan, Ning; Liu, Cunbao] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming 650118, Yunnan, Peoples R China		Liu, CB (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Kunming 650118, Yunnan, Peoples R China.	caohan@imbcams.com.cn; wangyf@imbcams.com.cn; luanning@imbcams.com.cn; cunbao_liu@163.com		Liu, Cunbao/0000-0002-2101-2612	CAMS Initiative for Innovative Medicine [2017-I2M-3-022]; Major Science and Technology Special Projects of Yunnan Province [202002AA100009]; Basic Research Projects of Yunnan Province; Funds for the Training of High-level Health Technical Personnel in Yunnan Province, China [H-2019063]	This research was financially funded by the CAMS Initiative for Innovative Medicine (grant number 2017-I2M-3-022), the Major Science and Technology Special Projects of Yunnan Province (grant number 202002AA100009), the Basic Research Projects of Yunnan Province, and the Funds for the Training of High-level Health Technical Personnel in Yunnan Province, China (grant number H-2019063).	Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Arruti M, 2017, J NEUROVIROL, V23, P451, DOI 10.1007/s13365-017-0519-y; Asada H, 2019, VACCINE, V37, P6776, DOI 10.1016/j.vaccine.2019.09.031; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Ball RL, 2017, INT J NANOMED, V12, P305, DOI 10.2147/IJN.S123062; Berarducci B, 2006, J VIROL, V80, P9481, DOI 10.1128/JVI.00533-06; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]; Breuer J, 2018, J INFECT DIS, V218, pS75, DOI 10.1093/infdis/jiy279; Chlibek R, 2013, J INFECT DIS, V208, P1953, DOI 10.1093/infdis/jit365; Cohen JI, 2015, NEW ENGL J MED, V372, P2149, DOI 10.1056/NEJMe1505050; Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800; Cunningham AL, 2018, J INFECT DIS, V217, P1750, DOI 10.1093/infdis/jiy095; Dendouga N, 2012, VACCINE, V30, P3126, DOI 10.1016/j.vaccine.2012.01.088; GarciaValcarcel M, 1997, VACCINE, V15, P709, DOI 10.1016/S0264-410X(96)00228-9; GARNETT GP, 1992, EPIDEMIOL INFECT, V108, P513, DOI 10.1017/S0950268800050019; Gilbert PB, 2014, J INFECT DIS, V210, P1573, DOI 10.1093/infdis/jiu279; Gilderman LI, 2008, CLIN VACCINE IMMUNOL, V15, P314, DOI 10.1128/CVI.00310-07; Haberthur K, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002367; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Haumont M, 1996, VIRUS RES, V40, P199, DOI 10.1016/0168-1702(95)01270-2; Heyward WL, 2013, VACCINE, V31, P5300, DOI 10.1016/j.vaccine.2013.05.068; Iqbal M, 2015, INT J PHARMACEUT, V496, P173, DOI 10.1016/j.ijpharm.2015.10.057; Kalimuddin S, 2017, VACCINE, V35, P7127, DOI 10.1016/j.vaccine.2017.10.097; Krause PR, 2000, NAT MED, V6, P451, DOI 10.1038/74715; Lefeber DJ, 2003, INFECT IMMUN, V71, P6915, DOI 10.1128/IAI.71.12.6915-6920.2003; Leroux-Roels I, 2012, J INFECT DIS, V206, P1280, DOI 10.1093/infdis/jis497; Levin MJ, 2018, J CLIN INVEST, V128, P4429, DOI [10.1172/JCI121484, 10.1172/jci121484]; Levin MJ, 2017, EXPERT REV VACCINES, V16, P1217, DOI 10.1080/14760584.2017.1395703; Liu CB, 2021, VACCINE, V39, P263, DOI 10.1016/j.vaccine.2020.12.005; Liu CB, 2018, INT J PHARMACEUT, V553, P327, DOI 10.1016/j.ijpharm.2018.10.054; Liu CB, 2018, HUM VACC IMMUNOTHER, V14, P931, DOI 10.1080/21645515.2017.1420446; Malavige GN, 2008, CLIN EXP IMMUNOL, V152, P522, DOI 10.1111/j.1365-2249.2008.03633.x; Maurer T, 2002, EUR J IMMUNOL, V32, P2356, DOI 10.1002/1521-4141(200208)32:8<2356::AID-IMMU2356>3.0.CO;2-Z; Meyer C, 2015, J VIROL, V89, P1781, DOI 10.1128/JVI.03124-14; Moffat J, 2004, J VIROL, V78, P12406, DOI 10.1128/JVI.78.22.12406-12415.2004; Monslow MA, 2020, VACCINE, V38, P5793, DOI 10.1016/j.vaccine.2020.06.062; Moodley A, 2019, J CHILD NEUROL, V34, P184, DOI 10.1177/0883073818821498; MOUNTFORD AP, 1994, PARASITE IMMUNOL, V16, P521, DOI 10.1111/j.1365-3024.1994.tb00306.x; Oxman MN, 2005, NEW ENGL J MED, V352, P2271, DOI 10.1056/NEJMoa051016; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040; Richner JM, 2017, CELL, V169, P176, DOI 10.1016/j.cell.2017.03.016; Rietwyk S, 2017, ACS NANO, V11, P7572, DOI 10.1021/acsnano.7b04734; Sergeeva OV, 2016, BIOCHEMISTRY-MOSCOW+, V81, P709, DOI 10.1134/S0006297916070075; Steain M, 2014, J VIROL, V88, P2704, DOI 10.1128/JVI.03445-13; Uebe B, 2002, EUR J PEDIATR, V161, P442, DOI 10.1007/s00431-002-0981-1; Upadhyay S, 2018, PLANTA, V248, P519, DOI 10.1007/s00425-018-2911-0; Wang YF, 2021, VIROL SIN, V36, P122, DOI 10.1007/s12250-020-00261-y; Wang YF, 2021, J MED VIROL, V93, P892, DOI 10.1002/jmv.26320; Weinberg A, 2010, CURR TOP MICROBIOL, V342, P341, DOI 10.1007/82_2010_31; WROBLEWSKA Z, 1993, MICROB PATHOGENESIS, V15, P141, DOI 10.1006/mpat.1993.1064; Wui SR, 2019, VACCINE, V37, P2131, DOI 10.1016/j.vaccine.2019.02.048; Zerboni L, 2014, NAT REV MICROBIOL, V12, P197, DOI 10.1038/nrmicro3215; Zhu R, 2016, VACCINE, V34, P1589, DOI 10.1016/j.vaccine.2016.02.007	54	4	4	5	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							310	10.3390/vaccines9040310			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4PS	33805880	Green Published, gold			2022-04-29	WOS:000643763600001
J	Hu, YY; Zou, S; Wang, Z; Liu, Y; Ren, L; Hao, YL; Sun, SS; Hu, XT; Ruan, YH; Ma, LY; Shao, YM; Hong, KX				Hu, Yuanyuan; Zou, Sen; Wang, Zheng; Liu, Ying; Ren, Li; Hao, Yanling; Sun, Shasha; Hu, Xintao; Ruan, Yuhua; Ma, Liying; Shao, Yiming; Hong, Kunxue			Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B ' Infected Plasma Donor with Broadly Neutralizing Activity	VACCINES			English	Article						HIV-1; envelope gene; recombination; broadly neutralizing activity; neutralizing antibodies		We sought to analyze the evolutionary characteristics and neutralization sensitivity of viruses in a human immunodeficiency virus type 1 (HIV-1) subtype B ' infected plasma donor with broadly neutralizing activity, which may provide information for new broadly neutralizing antibodies (bNAbs) isolation and immunogen design. A total of 83 full-length envelope genes were obtained by single-genome amplification (SGA) from the patient's plasma at three consecutive time points (2005, 2006, and 2008) spanning four years. In addition, 28 Env-pseudotyped viruses were constructed and their neutralization sensitivity to autologous plasma and several representative bNAbs were measured. Phylogenetic analysis showed that these env sequences formed two evolutionary clusters (Cluster I and II). Cluster I viruses vanished in 2006 and then appeared as recombinants two years later. In Cluster II viruses, the V1 length and N-glycosylation sites increased over the four years of the study period. Most viruses were sensitive to concurrent and subsequent autologous plasma, and to bNAbs, including 10E8, PGT121, VRC01, and 12A21, but all viruses were resistant to PGT135. Overall, 90% of Cluster I viruses were resistant to 2G12, while 94% of Cluster II viruses were sensitive to 2G12. We confirmed that HIV-1 continued to evolve even in the presence of bNAbs, and two virus clusters in this donor adopted different escape mechanisms under the same humoral immune pressure.	[Hu, Yuanyuan; Zou, Sen; Wang, Zheng; Liu, Ying; Ren, Li; Hao, Yanling; Sun, Shasha; Hu, Xintao; Ruan, Yuhua; Ma, Liying; Shao, Yiming; Hong, Kunxue] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing 102206, Peoples R China; [Hu, Xintao] NCI, Human Retrovirus Pathogenesis Sect, Vaccine Branch, Ctr Canc Res, Frederick, MD 21702 USA		Hong, KX (通讯作者)，Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing 102206, Peoples R China.	yyh5223@163.com; zousen@hotmail.com; wangzheng@chinaaids.cn; yingliu@chinaaids.cn; li.ren@chinaaids.cn; haoyl@chinaaids.cn; sha837982611@hotmail.com; xth38302@gmail.com; ruanyuhua92@chinaaids.cn; mal@chinaaids.cn; yshao@bjmu.edu.cn; hongkx@chinaaids.cn		Zou, Sen/0000-0002-6593-0618; Hu, Xintao/0000-0002-6552-9357	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81172809, 81872680]; National Major Project for Infectious Disease Control and Prevention [2018ZX10731-101]; SKLID key project [2019SKLID602]	This research was supported by the grant from the National Natural Science Foundation of China (81172809, 81872680), the National Major Project for Infectious Disease Control and Prevention (2018ZX10731-101), and the SKLID key project (2019SKLID602).	Bhiman JN, 2015, NAT MED, V21, P1332, DOI 10.1038/nm.3963; Binley JM, 2008, J VIROL, V82, P11651, DOI 10.1128/JVI.01762-08; Bonsignori M, 2016, CELL, V165, P449, DOI 10.1016/j.cell.2016.02.022; Bunnik EM, 2008, J VIROL, V82, P7932, DOI 10.1128/JVI.00757-08; Bunnik EM, 2010, NAT MED, V16, P995, DOI 10.1038/nm.2203; Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515; Caskey M, 2019, NAT MED, V25, P547, DOI 10.1038/s41591-019-0412-8; Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Freund NT, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2144; Gao F, 2014, CELL, V158, P481, DOI 10.1016/j.cell.2014.06.022; Gautam R, 2016, NATURE, V533, P105, DOI 10.1038/nature17677; Hu XT, 2012, J GEN VIROL, V93, P2267, DOI 10.1099/vir.0.043802-0; Huang JH, 2016, IMMUNITY, V45, P1108, DOI 10.1016/j.immuni.2016.10.027; Julg B, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4235; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Kong L, 2016, IMMUNITY, V44, P939, DOI 10.1016/j.immuni.2016.03.006; Kumar S, 2019, J VIROL, V93, DOI 10.1128/JVI.01495-18; Lengauer T, 2007, NAT BIOTECHNOL, V25, P1407, DOI 10.1038/nbt1371; Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005; Li YX, 2009, J VIROL, V83, P1045, DOI 10.1128/JVI.01992-08; Liao HX, 2013, NATURE, V496, P469, DOI 10.1038/nature12053; Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999; Mikell I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001251; Mittler JE, 1999, AIDS, V13, P1415, DOI 10.1097/00002030-199907300-00023; Moore PL, 2009, CURR OPIN HIV AIDS, V4, P358, DOI 10.1097/COH.0b013e32832ea7e8; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Salazar-Gonzalez JF, 2008, J VIROL, V82, P3952, DOI 10.1128/JVI.02660-07; Sather DN, 2014, J VIROL, V88, P12968, DOI 10.1128/JVI.01816-14; Sather DN, 2009, J VIROL, V83, P757, DOI 10.1128/JVI.02036-08; Scheepers C, 2017, AIDS, V31, P2199, DOI 10.1097/QAD.0000000000001643; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Simon-Loriere E, 2011, NAT REV MICROBIOL, V9, P617, DOI 10.1038/nrmicro2614; Simon-Loriere E, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000418; Steichen JM, 2019, SCIENCE, V366, P1216, DOI 10.1126/science.aax4380; Stephenson KE, 2020, ANNU REV IMMUNOL, V38, P673, DOI 10.1146/annurev-immunol-080219-023629; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Wu XL, 2018, ADV EXP MED BIOL, V1075, P53, DOI 10.1007/978-981-13-0484-2_3; Wu XL, 2012, J VIROL, V86, P5844, DOI 10.1128/JVI.07139-11; Zhang D, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01096; Zhang XY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003992	43	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							311	10.3390/vaccines9040311			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4YF	33805985	Green Published, gold			2022-04-29	WOS:000643785900001
J	Parize, P; Somme, J; Schaeffer, L; Ribadeau-Dumas, F; Benabdelkader, S; Durand, A; Tarantola, A; Cailhol, J; Goesch, J; Kergoat, L; Le Guern, AS; Mousel, ML; Dacheux, L; Consigny, PH; Fontanet, A; Francuz, B; Bourhy, H				Parize, Perrine; Somme, Jeremie; Schaeffer, Laura; Ribadeau-Dumas, Florence; Benabdelkader, Sheherazade; Durand, Agnes; Tarantola, Arnaud; Cailhol, Johann; Goesch, Julia; Kergoat, Lauriane; Le Guern, Anne-Sophie; Mousel, Marie-Laurence; Dacheux, Laurent; Consigny, Paul-Henri; Fontanet, Arnaud; Francuz, Beata; Bourhy, Herve			Systematic Booster after Rabies Pre-Exposure Prophylaxis to Alleviate Rabies Antibody Monitoring in Individuals at Risk of Occupational Exposure	VACCINES			English	Article						rabies; pre-exposure prophylaxis; humoral immunity; booster immunization; occupational health	VACCINATION; IMMUNITY	Pre-exposure rabies prophylaxis (PrEP) is recommended for people at frequent or increased risk of professional exposure to lyssavirus (including rabies virus). PrEP provides protection against unrecognized exposure. After the primary vaccination, one's immune response against rabies may decline over time. We aimed to evaluate the immune response to rabies in individuals immunized for occupational reasons before and after a booster dose of the rabies vaccine. With this aim, we retrospectively documented factors associated with an inadequate response in individuals vaccinated for occupational purposes. Our findings analyzed data from 498 vaccinated individuals and found that 17.2% of participants had an inadequate antibody titration documented after their primary vaccination without the booster, while inadequate response after an additional booster of the vaccine was evidenced in 0.5% of tested participants. This study showed that a single booster dose of vaccine after PrEP conferred a high and long-term immune response in nearly all individuals except for rare, low responders. A systematic rabies booster after primary vaccination may result in alleviating the monitoring strategy of post-PrEP antibody titers among exposed professionals.	[Parize, Perrine; Ribadeau-Dumas, Florence; Benabdelkader, Sheherazade; Tarantola, Arnaud; Kergoat, Lauriane; Dacheux, Laurent; Bourhy, Herve] Inst Pasteur, Natl Reference Ctr Rabies, Unit Lyssavirus Epidemiol & Neuropathol, F-75015 Paris, France; [Parize, Perrine; Ribadeau-Dumas, Florence; Benabdelkader, Sheherazade; Tarantola, Arnaud; Kergoat, Lauriane; Dacheux, Laurent; Bourhy, Herve] WHO Collaborating Ctr Reference & Res Rabies, F-75015 Paris, France; [Somme, Jeremie; Mousel, Marie-Laurence; Francuz, Beata] Inst Pasteur, Occupat Hlth Dept, F-75015 Paris, France; [Schaeffer, Laura; Fontanet, Arnaud] Inst Pasteur, Ctr Global Hlth Res & Educ, Emerging Dis Epidemiol Unit, F-75015 Paris, France; [Durand, Agnes] Lab Cerballiance, F-75017 Paris, France; [Cailhol, Johann; Goesch, Julia; Consigny, Paul-Henri] Inst Pasteur, Ctr Infectiol Necker Pasteur, Ctr Med, F-75015 Paris, France; [Le Guern, Anne-Sophie] Inst Pasteur, Lab Med Ctr, F-75015 Paris, France; [Fontanet, Arnaud] Conservatoire Natl Arts & Metiers, F-75003 Paris, France		Parize, P (通讯作者)，Inst Pasteur, Natl Reference Ctr Rabies, Unit Lyssavirus Epidemiol & Neuropathol, F-75015 Paris, France.; Parize, P (通讯作者)，WHO Collaborating Ctr Reference & Res Rabies, F-75015 Paris, France.	perrine.parize@pasteur.fr; somme.j@chu-toulouse.fr; laura.schaeffer@pasteur.fr; florencesibadeau-dumas@intradef.gouv.fr; sherazben@yahoo.fr; agnes.durand@cerballiance.fr; arnaud.tarantola@santepubliquefrance.fr; johann.cailhol@aphp.fr; julia.goesch@pasteur.fr; lauriane.kergoat@pasteur.fr; anne-sophiele-guern@pasteur.fr; marie-laurence.mousel@pasteur.fr; laurent.dacheux@pasteur.fr; paul-henri.consigny@pasteur.fr; arnaud.fontanet@pasteur.fr; beata.francuz@pasteur.fr; herve.bourhy@pasteur.fr	Tarantola, Arnaud/D-2149-2015	Tarantola, Arnaud/0000-0002-6946-7958; SOMME, JEREMIE/0000-0002-5804-0123; Dacheux, Laurent/0000-0002-4401-3706; , arnaud/0000-0002-5239-6110	Sante Publique France; French Directorate for Health and Pasteur Institute	This research was funded by Sante Publique France, the French Directorate for Health and Pasteur Institute.	[Anonymous], ACIP Timing and Spacing Guidelines for Immunization. Recommendations; Banga N, 2014, VACCINE, V32, P979, DOI 10.1016/j.vaccine.2013.12.019; Cook IF, 2008, VACCINE, V26, P3551, DOI 10.1016/j.vaccine.2008.04.054; Dougas G, 2020, VECTOR-BORNE ZOONOT, V20, P303, DOI 10.1089/vbz.2019.2526; Feyssaguet M, 2007, VACCINE, V25, P2244, DOI 10.1016/j.vaccine.2006.12.012; Fooks AR, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.91; Furuya-Kanamori L, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa006; Hampson K, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003709; Hemachudha T, 2013, LANCET NEUROL, V12, P498, DOI 10.1016/S1474-4422(13)70038-3; Kessels JA, 2017, B WORLD HEALTH ORGAN, V95, P210, DOI 10.2471/BLT.16.173039; Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9; Langedijk AC, 2018, CLIN INFECT DIS, V67, P1932, DOI 10.1093/cid/ciy420; Lim PL, 2010, INT J INFECT DIS, V14, pE511, DOI 10.1016/j.ijid.2009.08.008; Mansfield KL, 2016, VACCINE, V34, P5959, DOI 10.1016/j.vaccine.2016.09.058; Medeiros R, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004920; Mills DJ, 2011, J TRAVEL MED, V18, P327, DOI 10.1111/j.1708-8305.2011.00540.x; Venkataswamy MM, 2015, CLIN EXP VACCINE RES, V4, P68, DOI 10.7774/cevr.2015.4.1.68; Verthelyi D, 2001, INT IMMUNOPHARMACOL, V1, P983, DOI 10.1016/S1567-5769(01)00044-3; WHO, 2018, WHO TECH REP SER, V1012, P1; WHO, 2013, WHO TECH REP SER, V982, P1; World Hlth Org, 2018, VACCINE, V36, P5500, DOI 10.1016/j.vaccine.2018.06.061; Zhao RQ, 2019, VACCINE, V37, P6060, DOI 10.1016/j.vaccine.2019.08.043	22	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							309	10.3390/vaccines9040309			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4XQ	33805019	gold, Green Published			2022-04-29	WOS:000643784400001
J	Renson, P; Deblanc, C; Bougon, J; Le Dimna, M; Gorin, S; Mahe, S; Barbier, N; Paboeuf, F; Simon, G; Bourry, O				Renson, Patricia; Deblanc, Celine; Bougon, Juliette; Le Dimna, Mireille; Gorin, Stephane; Mahe, Sophie; Barbier, Nicolas; Paboeuf, Frederic; Simon, Gaelle; Bourry, Olivier			Concomitant Swine Influenza A Virus Infection Alters PRRSV1 MLV Viremia in Piglets but Does Not Interfere with Vaccine Protection in Experimental Conditions	VACCINES			English	Article						porcine reproductive and respiratory syndrome; swine influenza A virus; modified-live vaccine; interference; interferon	RESPIRATORY SYNDROME VIRUS; MATERNALLY-DERIVED ANTIBODIES; IMMUNE-RESPONSES; ALPHA; PIGS; REPLICATION; INNATE; TIME; TRANSMISSION; EXPRESSION	Modified-live vaccines (MLVs) against porcine reproductive and respiratory syndrome viruses (PRRSVs) are usually administrated to piglets at weaning when swine influenza A virus (swIAV) infections frequently occur. SwIAV infection induces a strong interferon alpha (IFNa) response and IFNa was shown to abrogate PRRSV2 MLV replication and an inherent immune response. In this study, we evaluated the impacts of swIAV infection on the replication of a PRRSV1 MLV (MLV1), post-vaccine immune responses and post-challenge vaccine efficacy at both the systemic and pulmonary levels. Piglets were either swIAV inoculated and MLV1 vaccinated 6 h apart or singly vaccinated or mock inoculated and mock vaccinated. Four weeks after vaccination, the piglets were challenged with a PRRSV1 field strain. The results showed that swIAV infection delayed MLV1 viremia by six days and post-vaccine seroconversion by four days. After the PRRSV1 challenge, the swIAV enhanced the PRRSV1-specific cell-mediated immunity (CMI) but the PRRSV1 field strain viremia was not better controlled. High IFNa levels that were detected early after swIAV infection could have been responsible for both the inhibition of MLV1 replication and CMI enhancement. Thus, whereas swIAV infection had a negative impact on humoral responses post-vaccination, it did not interfere with the protective effectiveness of the PRRSV MLV1 in our experimental conditions.	[Renson, Patricia; Deblanc, Celine; Bougon, Juliette; Le Dimna, Mireille; Gorin, Stephane; Mahe, Sophie; Barbier, Nicolas; Simon, Gaelle; Bourry, Olivier] Agence Natl Securite Sanit Alimentat Environm & T, Unite Virol Immunol Porcines, BP 53, F-22440 Ploufragan, France; [Bougon, Juliette] Univ Rennes UNIR, Cite Int, 1 Pl Paul Ricoeur,CS 54417, F-35044 Rennes, France; [Paboeuf, Frederic] Anses, Serv Prod Pores Assainis & Expt, BP 53, F-22440 Ploufragan, France		Renson, P (通讯作者)，Agence Natl Securite Sanit Alimentat Environm & T, Unite Virol Immunol Porcines, BP 53, F-22440 Ploufragan, France.	patricia.renson@anses.fr; celine.deblanc@anses.fr; juliette.bougon@anses.fr; mireille.ledimna@anses.fr; stephane.gorin@anses.fr; sophie.mahe@anses.fr; nicolas.barbier@anses.fr; frederic.paboeuf@anses.fr; gaelle.simon@anses.fr; olivier.bourry@anses.fr	Simon, Gaelle/ABI-1479-2020	Simon, Gaelle/0000-0003-1099-5075; Patricia, RENSON/0000-0001-8329-8479; BOURRY, Olivier/0000-0003-0220-0922	European PRRS Research Award 2017; Universite de Rennes (UNIR), France; Region Bretagne, FranceRegion Bretagne; Conseil Departemental des Cotes d'Armor, France; Saint-Brieuc Armor Agglomeration, France	This work was supported by a "European PRRS Research Award 2017". J.B. received a PhD thesis fellowship from Universite de Rennes (UNIR), France, in the framework of grant agreements with Region Bretagne, Conseil Departemental des Cotes d'Armor and Saint-Brieuc Armor Agglomeration, France.	Barbe F, 2011, VET J, V187, P48, DOI 10.1016/j.tvjl.2009.12.012; Boikos C, 2017, HUM VACC IMMUNOTHER, V13, P1254, DOI 10.1080/21645515.2017.1287641; Brockmeier SL, 2009, VIRAL IMMUNOL, V22, P173, DOI 10.1089/vim.2008.0075; Brockmeier SL, 2017, VET MICROBIOL, V212, P48, DOI 10.1016/j.vetmic.2017.11.004; Brockmeier SL, 2012, CLIN VACCINE IMMUNOL, V19, P508, DOI 10.1128/CVI.05490-11; Buddaert W, 1998, ADV EXP MED BIOL, V440, P461; Cador C, 2016, VET RES, V47, DOI 10.1186/s13567-016-0365-6; Charley B, 2006, ANN NY ACAD SCI, V1081, P130, DOI 10.1196/annals.1373.014; Charpin C, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-69; Chepngeno J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00780; Crisci E, 2019, VET SCI, V6, DOI 10.3390/vetsci6010026; Deblanc C., 2018, VET MICROBIOL, V216, P142, DOI [10.1016/j.vetmic.2018.01.019, DOI 10.1016/j.vetmic.2018.01.019]; Deblanc C, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101155; Diaz A, 2017, J VIROL, V91, DOI 10.1128/JVI.00745-17; Essaidi-Laziosi M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66748-6; Fablet C, 2016, VET MICROBIOL, V192, P175, DOI 10.1016/j.vetmic.2016.07.014; Fablet C, 2016, VET MICROBIOL, V192, P10, DOI 10.1016/j.vetmic.2016.06.006; Herve S., 2011, P JOURN RECH PORC PA, P281; Herve S, 2019, VET MICROBIOL, V239, DOI 10.1016/j.vetmic.2019.108477; Ito S, 1999, BLOOD, V93, P1456, DOI 10.1182/blood.V93.5.1456; Jamin A, 2006, VET IMMUNOL IMMUNOP, V114, P224, DOI 10.1016/j.vetimm.2006.08.009; Martinez-Lobo FJ, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-115; Kuhn JH, 2016, ARCH VIROL, V161, P755, DOI 10.1007/s00705-015-2672-z; Le Bon A, 2002, CURR OPIN IMMUNOL, V14, P432, DOI 10.1016/S0952-7915(02)00354-0; Liu K, 2019, VET MICROBIOL, V229, P28, DOI 10.1016/j.vetmic.2018.12.015; Lunney JK, 2010, VIRUS RES, V154, P1, DOI 10.1016/j.virusres.2010.10.009; Luo R, 2011, ANTIVIR RES, V91, P99, DOI 10.1016/j.antiviral.2011.04.017; Madapong A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58626-y; Madapong A, 2017, ARCH VIROL, V162, P139, DOI 10.1007/s00705-016-3084-4; Martelli P, 2009, VACCINE, V27, P3788, DOI 10.1016/j.vaccine.2009.03.028; MEROLLA R, 1995, AM J RESP CRIT CARE, V152, P1358, DOI 10.1164/ajrccm.152.4.7551395; Nathues H, 2017, PREV VET MED, V142, P16, DOI 10.1016/j.prevetmed.2017.04.006; Pardo FOC, 2017, FRONT VET SCI, V4, DOI 10.3389/fvets.2017.00167; Petrov A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108910; Pomorska-Mol M, 2014, ARCH VIROL, V159, P2605, DOI 10.1007/s00705-014-2116-1; Renson P, 2019, VACCINE, V37, P4318, DOI 10.1016/j.vaccine.2019.06.045; Renson P, 2017, VET RES, V48, DOI 10.1186/s13567-017-0420-y; Rose N, 2015, VACCINE, V33, P2493, DOI 10.1016/j.vaccine.2015.03.040; Rowland RRR, 2003, VET MICROBIOL, V96, P219, DOI 10.1016/j.vetmic.2003.07.006; Royaee AR, 2004, VET IMMUNOL IMMUNOP, V102, P199, DOI 10.1016/j.vetimm.2004.09.018; Saade G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030508; Saade G, 2020, VET RES, V51, DOI 10.1186/s13567-020-00807-8; Siddell SG, 2019, ARCH VIROL, V164, P943, DOI 10.1007/s00705-018-04136-2; Turlewicz-Podbielska H, 2021, BMC VET RES, V17, DOI 10.1186/s12917-020-02722-8; Van Reeth K, 2013, CURR TOP MICROBIOL, V370, P173, DOI 10.1007/82_2012_266; Wang R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/315470	46	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							356	10.3390/vaccines9040356			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4NG	33917103	Green Published, gold			2022-04-29	WOS:000643757100001
J	Trevisan, A; Mason, P; Nicolli, A; Maso, S; Scarpa, B; Moretto, A; Scapellato, ML				Trevisan, Andrea; Mason, Paola; Nicolli, Annamaria; Maso, Stefano; Scarpa, Bruno; Moretto, Angelo; Scapellato, Maria Luisa			Vaccination and Immunity toward Measles: A Serosurvey in Future Healthcare Workers	VACCINES			English	Article						measles; vaccination schedule; vaccination response; students; healthcare workers	RESPONSES; ANTIBODIES; PREVALENCE; STUDENTS; VIRUS; SEX	Measles is a very contagious infectious disease, and vaccination is the only medical aid to counter the spread of the infection. The aim of this study was to evaluate the influence of vaccination schedule and type of vaccine, number of doses, and sex on the immune response. In a population of Italian medical students (8497 individuals born after 1980 with certificate of vaccination and quantitative measurement of antibodies against measles), the prevalence of positive antibodies to measles and antibody titer was measured. Vaccination schedule such as number of doses and vaccine type (measles alone or combined as measles, mumps and rubella (MMR)) and sex were the variables considered to influence the immune response. The vaccination schedule depends on the year of birth: students born before 1990 were prevalently vaccinated once and with measles vaccine alone (not as MMR). One dose of vaccine induces a significantly (p < 0.0001) higher positive response and antibody titer than two doses, in particular when measles alone is used (p < 0.0001). Females have a significantly higher percentage of positive response (p = 0.0001) than males but only when the MMR formulation was used. Multiple linear regression confirms that sex significantly influences antibody titer when only MMR is used, after one (p = 0.0002) or two (p = 0.0060) doses. In conclusion, vaccination schedule and, partially, sex influence immune response to measles vaccination. Most notably, the measles vaccine alone (one dose) is more effective than one and two doses of MMR.	[Trevisan, Andrea; Mason, Paola; Nicolli, Annamaria; Maso, Stefano; Moretto, Angelo; Scapellato, Maria Luisa] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, I-35128 Padua, Italy; [Scarpa, Bruno] Univ Padua, Dept Stat Sci, I-35128 Padua, Italy; [Scarpa, Bruno] Univ Padua, Dept Math Tullio Levi Civita, I-35128 Padua, Italy		Trevisan, A (通讯作者)，Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, I-35128 Padua, Italy.	andrea.trevisan@unipd.it; paola.mason.1@unipd.it; annamaria.nicolli@unipd.it; stefano.maso@unipd.it; bruno.scarpa@unipd.it; angelo.moretto@unipd.it; marialuisa.scapellato@unipd.it	Trevisan, Andrea/E-5325-2013; MASON, PAOLA/AAE-9023-2019	Trevisan, Andrea/0000-0002-0764-1084; MASON, PAOLA/0000-0003-3941-6698; SCARPA, BRUNO/0000-0002-9628-5164			Abramowitz Lara K, 2014, J Genomics, V2, P77, DOI 10.7150/jgen.8123; ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P205; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; [Anonymous], 2001, DECR PRES CONS MIN P; [Anonymous], 2017, PLAN NAZ PREV VACC 2; [Anonymous], 2017, GLMPIOS, V7, P155; Atti MLC, 2004, VACCINE, V22, P4351, DOI 10.1016/j.vaccine.2004.04.026; Bester JC, 2017, J BIOETHIC INQ, V14, P375, DOI 10.1007/s11673-017-9799-4; Bianchi FP, 2021, HUM VACC IMMUNOTHER, V17, P2078, DOI 10.1080/21645515.2020.1871296; Bianchi FP, 2020, J INFECT DIS, V221, P721, DOI 10.1093/infdis/jiz508; Burioni R, 2018, NATURE, V555, P27, DOI 10.1038/d41586-018-02267-9; Cook IF, 2008, VACCINE, V26, P3551, DOI 10.1016/j.vaccine.2008.04.054; Davidkin I, 2008, J INFECT DIS, V197, P950, DOI 10.1086/528993; Di Martino G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020248; Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111; Genovese C, 2019, J Prev Med Hyg, V60, pE12, DOI 10.15167/2421-4248/jpmh2019.60.1.1097; Hannah MF, 2008, BRAIN BEHAV IMMUN, V22, P503, DOI 10.1016/j.bbi.2007.10.005; KATZ SL, 1962, AM J DIS CHILD, V103, P340, DOI 10.1001/archpedi.1962.02080020352031; Kennedy RB, 2019, VACCINE, V37, P1775, DOI 10.1016/j.vaccine.2019.02.030; Kennedy RB, 2009, VACCINE, V27, P3319, DOI 10.1016/j.vaccine.2009.01.086; Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9; Lochlainn LMN, 2019, LANCET INFECT DIS, V19, P1246, DOI 10.1016/S1473-3099(19)30396-2; Ministero della Salute, 1999, 12 MIN HLTH ROM 12 MIN HLTH ROM; Ministero della Sanita, 1979, 41 MIN HLTH ROM; Rota MC, 2008, VACCINE, V26, P4403, DOI 10.1016/j.vaccine.2008.05.094; Signorelli C, 2018, LANCET INFECT DIS, V18, P26, DOI 10.1016/S1473-3099(17)30696-5; Trevisan A, 2006, VACCINE, V24, P171, DOI 10.1016/j.vaccine.2005.07.062; Trevisan A, 2007, INFECT CONT HOSP EP, V28, P564, DOI 10.1086/516657; Trevisan A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010104; Trevisan A, 2015, FUTURE VIROL, V10, P817, DOI 10.2217/FVL.15.50; Valsecchi M, 2018, EPIDEMIOL PREV, V42, P196, DOI 10.19191/EP18.3-4.P196.058; Voigt EA, 2016, VACCINE, V34, P4913, DOI 10.1016/j.vaccine.2016.08.060; Watson JC, 1996, PEDIATRICS, V97, P613; World Health Organization (WHO), 2012, GLOB MEAS RUB STRAT	35	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							377	10.3390/vaccines9040377			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5GS	33924547	gold, Green Published			2022-04-29	WOS:000643808100001
J	Chang, YT; Ling, TC; Cheng, YY; Sun, CY; Wu, JL; Tai, CH; Wang, JR; Sung, JM				Chang, Yu-Tzu; Ling, Tsai-Chieh; Cheng, Ya-Yun; Sun, Chien-Yao; Wu, Jia-Ling; Tai, Ching Hui; Wang, Jen-Ren; Sung, Junne-Ming			Comparison of Immunogenicity and Safety between a Single Dose and One Booster Trivalent Inactivated Influenza Vaccination in Patients with Chronic Kidney Disease: A 20-Week, Open-Label Trial	VACCINES			English	Article						non-dialysis-dependent chronic kidney disease; influenza virus; vaccine; booster dosage; immune response	GUILLAIN-BARRE-SYNDROME; RENAL-TRANSPLANT RECIPIENTS; HEMODIALYSIS-PATIENTS; IMMUNE DYSFUNCTION; RISK; SEROCONVERSION; IMMUNIZATION; DIALYSIS; STAGE	Background: Non-dialysis-dependent chronic kidney disease (CKD-ND) patients are recommended to receive a one-dose influenza vaccination annually. However, studies investigating vaccine efficacy in the CKD-ND population are still lacking. In this study, we aimed to evaluate vaccine efficacy between the one-dose and two-dose regimen and among patients with different stages of CKD throughout a 20-week follow-up period. Methods: We conducted a single-center, non-randomized, open-label, controlled trial among patients with all stages of CKD-ND. Subjects were classified as unvaccinated, one-dose, and two-dose groups (4 weeks apart) after enrollment. Serial changes in immunological parameters (0, 4, 8, and 20 weeks after enrollment), including seroprotection, geometric mean titer (GMT), GMT fold-increase, seroconversion, and seroresponse, were applied to evaluate vaccine efficacy. Results: There were 43, 84, and 71 patients in the unvaccinated, one-dose, and two-dose vaccination groups, respectively. At 4-8 weeks after vaccination, seroprotection rates in the one- and two-dose group for H1N1, H3N2, and B ranged from 82.6-95.8%, 97.4-100%, and 73.9-100%, respectively. The concomitant seroconversion and GMT fold-increases nearly met the suggested criteria for vaccine efficacy for the elderly population. Although the seroprotection rates for all of the groups were adequate, the seroconversion and GMT fold-increase at 20 weeks after vaccination did not meet the criteria for vaccine efficacy. The two-dose regimen had a higher probability of achieving seroprotection for B strains (Odds ratio: 3.5, 95% confidence interval (1.30-9.40)). No significant differences in vaccine efficacy were found between early (stage 1-3) and late (stage 4-5) stage CKD. Conclusions: The standard one-dose vaccination can elicit sufficient protective antibodies. The two-dose regimen induced a better immune response when the baseline serum antibody titer was low. Monitoring change in antibody titers for a longer duration is warranted to further determine the current vaccine strategy in CKD-ND population.	[Chang, Yu-Tzu; Ling, Tsai-Chieh; Sun, Chien-Yao; Wu, Jia-Ling; Sung, Junne-Ming] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Internal Med, Coll Med, Tainan 704, Taiwan; [Cheng, Ya-Yun] Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Tai, Ching Hui; Wang, Jen-Ren] Natl Cheng Kung Univ, Dept Med Lab Sci & Biotechnol, Coll Med, Tainan 704, Taiwan; [Wang, Jen-Ren] Natl Hlth Res Inst, Natl Inst Infect Dis & Vaccinol, Tainan 704, Taiwan		Sung, JM (通讯作者)，Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Internal Med, Coll Med, Tainan 704, Taiwan.	kangxiemperor@gmail.com; perfect5751@hotmail.com; b507092063@tmu.edu.tw; chienyaosun@gmail.com; balletwu72@gmail.com; e480216@hotmail.com; jrwang@mail.ncku.edu.tw; jmsung@mail.ncku.edu.tw	CHENG, YA-YUN/AAK-5272-2020; Chang, Yu-Tzu/AAE-6781-2022	CHENG, YA-YUN/0000-0003-2571-4707; Sun, Chien-Yao/0000-0001-6236-6022; Chang, Yu-Tzu/0000-0003-1449-9431	National Cheng-Kung University Hospital, Tainan, Taiwan, ROC [NCKUH-10205003, NCKUH10902065, NCKUH-11002022]; Ministry of Science and Technology, Taipei, Taiwan, ROC [MOST 109-2314-B-006-061]	This research was partly supported by the grants from NCKUH-10205003, NCKUH10902065, and NCKUH-11002022 to Chang YT from the National Cheng-Kung University Hospital, Tainan, Taiwan, ROC and MOST 109-2314-B-006-061-to Sung JM from the Ministry of Science and Technology, Taipei, Taiwan, ROC. None of the funding sources had any role in the study design, analysis, and interpretation of the data, the preparation, review, or approval of the manuscript.	Adlhoch C, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz462; [Anonymous], ADVISORY COMMITTEE I; Beyer WEP, 2004, VIRUS RES, V103, P125, DOI 10.1016/j.virusres.2004.02.024; Bosaeed M, 2018, HUM VACC IMMUNOTHER, V14, P1311, DOI 10.1080/21645515.2018.1445446; Center for Biologics Evaluation and Research, 2007, GUID IND CLIN DAT NE; Chang YT, 2016, SCI REP-UK, V6, DOI 10.1038/srep20725; Chang YT, 2012, VACCINE, V30, P5009, DOI 10.1016/j.vaccine.2012.05.016; Chi C., 2012, GUIDELINE VACCINATIN; Cordero E, 2017, CLIN INFECT DIS, V64, P829, DOI 10.1093/cid/ciw855; Cordero E, 2012, TRANSPLANTATION, V93, P847, DOI 10.1097/TP.0b013e318247a6ef; DaRoza G, 2003, AM J KIDNEY DIS, V42, P1184, DOI 10.1053/j.ajkd.2003.08.019; Dikow R, 2011, AM J KIDNEY DIS, V57, P716, DOI 10.1053/j.ajkd.2010.11.031; European Committee for Proprietary Medicinal Products, 1997, CPMPBWP21496 EUR AG; European Committee for Proprietary Medicinal Products, 2004, CPMPVEG471703 EUR AG; Ghadiani MH, 2012, J RES MED SCI, V17, P527; Gianchecchi E, 2019, HUM VACC IMMUNOTHER, V15, P1021, DOI 10.1080/21645515.2019.1565269; Gong YN, 2018, BIOMED J, V41, P234, DOI 10.1016/j.bj.2018.08.002; Hansen A, 2012, AM J KIDNEY DIS, V59, P471, DOI 10.1053/j.ajkd.2011.11.024; Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179; Inker LA, 2014, AM J KIDNEY DIS, V63, P713, DOI 10.1053/j.ajkd.2014.01.416; Ishigami J, 2019, CLIN EXP NEPHROL, V23, P437, DOI 10.1007/s10157-018-1641-8; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Krueger KM, 2020, AM J KIDNEY DIS, V75, P417, DOI 10.1053/j.ajkd.2019.06.014; Kumar D, 2016, TRANSPLANTATION, V100, P662, DOI 10.1097/TP.0000000000000861; Kwong JC, 2013, LANCET INFECT DIS, V13, P769, DOI 10.1016/S1473-3099(13)70104-X; Labriola L, 2011, NEPHROL DIAL TRANSPL, V26, P1424, DOI 10.1093/ndt/gfq782; Le Corre N, 2012, VACCINE, V30, P7522, DOI 10.1016/j.vaccine.2012.10.047; Liao ZF, 2016, HUM VACC IMMUNOTHER, V12, P2909, DOI 10.1080/21645515.2016.1201623; Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6; Lu ChunYi, 2016, Trials in Vaccinology, V5, P48; Mastalerz-Migas A, 2013, ADV EXP MED BIOL, V756, P285, DOI 10.1007/978-94-007-4549-0_35; Miskulin DC, 2018, CLIN J AM SOC NEPHRO, V13, P1703, DOI 10.2215/CJN.03390318; Mombelli M, 2018, VACCINE, V36, P6163, DOI 10.1016/j.vaccine.2018.08.057; Natori Y, 2018, CLIN INFECT DIS, V66, P1698, DOI 10.1093/cid/cix1082; Noh JY, 2016, HUM VACC IMMUNOTHER, V12, P2902, DOI 10.1080/21645515.2016.1191717; Scharpe J, 2008, AM J TRANSPLANT, V8, P332, DOI 10.1111/j.1600-6143.2007.02066.x; Skowronski DM, 2008, J INFECT DIS, V197, P490, DOI 10.1086/524146; Song JY, 2006, AM J NEPHROL, V26, P206, DOI 10.1159/000093306; Syed-Ahmed M, 2019, ADV CHRONIC KIDNEY D, V26, P8, DOI 10.1053/j.ackd.2019.01.004; Vellozzi C, 2014, CLIN INFECT DIS, V58, P1149, DOI 10.1093/cid/ciu005; Vellozzi C, 2014, AM J PUBLIC HEALTH, V104, P696, DOI 10.2105/AJPH.2013.301651; Wang HE, 2011, AM J NEPHROL, V34, P330, DOI 10.1159/000330673; World Health Organization Global Influenza Surveillance Network, 2011, MAN LAB DIAGN VIR SU; Yang JR, 2017, HEALTH SECUR, V15, P154, DOI 10.1089/hs.2016.0104	44	2	2	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							192	10.3390/vaccines9030192			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5MO	33669067	gold, Green Published			2022-04-29	WOS:000634198200001
J	Garcovich, S; Maurelli, M; Gisondi, P; Peris, K; Yosipovitch, G; Girolomoni, G				Garcovich, Simone; Maurelli, Martina; Gisondi, Paolo; Peris, Ketty; Yosipovitch, Gil; Girolomoni, Giampiero			Pruritus as a Distinctive Feature of Type 2 Inflammation	VACCINES			English	Review						chronic pruritus; itch; skin diseases; pruritogenic mediator; T-helper type 2 cells; interleukin 31; interleukin-4; interleukin-13; dupilumab; atopic dermatitis; prurigo	ATOPIC-DERMATITIS; IMMUNE-RESPONSE; SARCOPTES-SCABIEI; MYCOSIS-FUNGOIDES; SENSORY NEURONS; KALLIKREIN 5; ITCH; SKIN; IL-31; CELLS	Pruritus is a common symptom of several skin diseases, both inflammatory and neoplastic. Pruritus might have a tremendous impact on patients' quality of life and strongly interfere with sleep, social, and work activities. We review the role of type-2 inflammation and immunity in the pathogenesis of chronic pruritic conditions of the skin. Type 2 cytokines, including IL-4, IL-13, thymic stromal lymphopoietin, periostin, IL-31, IL-25, and IL-33 are released by mast cells, innate lymphoid cells 2, keratinocytes, and type 2 T lymphocytes, and are master regulators of chronic itch. These cytokines might act as direct pruritogen on primary sensory neurons (pruriceptors) or alter the sensitivity to other itch mediators Type 2 inflammation- and immunity-dominated skin diseases, including atopic dermatitis, prurigo nodularis, bullous pemphigoid, scabies, parasitic diseases, urticaria, and Sezary syndrome are indeed conditions associated with most severe pruritus. In contrast, in other skin diseases, such as scleroderma, lupus erythematosus, hidradenitis suppurativa, and acne, type 2 inflammation is less represented, and pruritus is milder or variable. Th2 inflammation and immunity evolved to protect against parasites, and thus, the scratching response evoked by pruritus might have developed to alert about the presence and to remove parasites from the skin surface.	[Garcovich, Simone; Peris, Ketty] Univ Cattolica Sacro Cuore, Dermatol, I-00168 Rome, Italy; [Garcovich, Simone; Peris, Ketty] Fdn Policlin Univ A Gemelli IRCCS, Dermatol Unit, I-00168 Rome, Italy; [Maurelli, Martina; Gisondi, Paolo; Girolomoni, Giampiero] Univ Verona, Dept Med, Sect Dermatol & Venereol, I-37126 Verona, Italy; [Yosipovitch, Gil] Univ Miami, Miami Itch Ctr, Dr Phillip Frost Dept Dermatol & Cutaneous Surg, Miller Sch Med, Miami, FL 33136 USA		Garcovich, S (通讯作者)，Univ Cattolica Sacro Cuore, Dermatol, I-00168 Rome, Italy.; Garcovich, S (通讯作者)，Fdn Policlin Univ A Gemelli IRCCS, Dermatol Unit, I-00168 Rome, Italy.	simone.garcovich@unicatt.it; maurelli.martina@gmail.com; paolo.gisondi@univr.it; ketty.peris@unicatt.it; gyosipovitch@med.miami.edu; giampiero.girolomoni@univr.it	GIROLOMONI, Giampiero/AAC-3405-2022	girolomoni, giampiero/0000-0001-8548-0493; GISONDI, Paolo/0000-0002-1777-9001			Abdat R, 2020, J AM ACAD DERMATOL, V83, P46, DOI 10.1016/j.jaad.2020.01.089; Andersen HH, 2018, PAIN, V159, P1185, DOI 10.1097/j.pain.0000000000001220; Andoh T, 2015, EXP DERMATOL, V24, P978, DOI 10.1111/exd.12828; Andrade A, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013128.pub2; [Anonymous], STUDY INVESTIGATE US; [Anonymous], STUDY EVALUATE EFFIC; Bao K, 2015, CYTOKINE, V75, P25, DOI 10.1016/j.cyto.2015.05.008; Barbarot S, 2018, ALLERGY, V73, P1284, DOI 10.1111/all.13401; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Bhat SA, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2320-4; Boozalis E, 2018, J AM ACAD DERMATOL, V79, P714, DOI 10.1016/j.jaad.2018.04.047; Campion M, 2019, EXP DERMATOL, V28, P1501, DOI 10.1111/exd.14034; Carstens E, 2016, CURR PROBL DERMATOL, V50, P11, DOI 10.1159/000446011; Cedeno-Laurent F, 2015, CLIN IMMUNOL, V158, P1, DOI 10.1016/j.clim.2015.02.014; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; Chiricozzi A, 2020, IMMUNOTARGETS THER, V9, P151, DOI 10.2147/ITT.S260370; Chiricozzi A, 2020, J AM ACAD DERMATOL, V83, P39, DOI 10.1016/j.jaad.2020.03.049; Chung Keshi, 2019, Neurobiol Pain, V6, P100032, DOI 10.1016/j.ynpai.2019.100032; Cork MJ, 2020, J DERMATOL TREAT, V31, P606, DOI 10.1080/09546634.2019.1612836; Cozzani E, 2018, EUR J DERMATOL, V28, P440, DOI 10.1684/ejd.2018.3366; Darlenski R, 2014, CLIN DERMATOL, V32, P409, DOI 10.1016/j.clindermatol.2013.11.007; de Bruin-Weller M, 2020, J EUR ACAD DERMATOL, V34, P1026, DOI 10.1111/jdv.16003; Eyerich K, 2018, J EUR ACAD DERMATOL, V32, P692, DOI 10.1111/jdv.14673; Feld M, 2016, J ALLERGY CLIN IMMUN, V138, P500, DOI 10.1016/j.jaci.2016.02.020; Fostini AC, 2015, J DERMATOL SCI, V80, P13, DOI 10.1016/j.jdermsci.2015.06.004; Fourzali K, 2020, EXPERT OPIN EMERG DR, V25, P273, DOI 10.1080/14728214.2020.1801632; Furue M, 2015, J DERMATOL, V42, P941, DOI 10.1111/1346-8138.13083; Girolomoni G., 2020, GIORN ITAL DERMAT V, DOI [10.23736/S0392-0488.20.06562-1, DOI 10.23736/S0392-0488.20.06562-1]; Gudjonsson JE, 2020, J ALLERGY CLIN IMMUN, V146, P8, DOI 10.1016/j.jaci.2020.05.009; Guo CXJ, 2020, J INVEST DERMATOL, V140, P1244, DOI 10.1016/j.jid.2019.10.022; Gupta RK, 2017, CYTOKINE GROWTH F R, V38, P22, DOI 10.1016/j.cytogfr.2017.09.005; Gutierrez DA, 2013, IMMUNITY, V39, P803, DOI 10.1016/j.immuni.2013.10.015; Hashimoto T, 2021, ACTA DERM-VENEREOL, V101, DOI 10.2340/00015555-3702; Hashimoto T, 2021, EXP DERMATOL, V30, P804, DOI 10.1111/exd.14279; Hashimoto T, 2020, J AM ACAD DERMATOL, V83, P53, DOI 10.1016/j.jaad.2019.07.060; Hashimoto T, 2019, ALLERGY, V74, P1727, DOI 10.1111/all.13870; Hawro T, 2014, ALLERGY, V69, P113, DOI 10.1111/all.12316; He R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177733; Hendricks AJ, 2021, J DERMATOL TREAT, V32, P19, DOI 10.1080/09546634.2019.1689227; Ikoma A, 2004, NEUROLOGY, V62, P212, DOI 10.1212/WNL.62.2.212; Jain A, 2020, J IMMUNOL, V204, P257, DOI 10.4049/jimmunol.1900818; Johansson O, 2002, ARCH DERMATOL RES, V293, P614, DOI 10.1007/s00403-001-0285-8; Kabashima K, 2019, NAT REV IMMUNOL, V19, P19, DOI 10.1038/s41577-018-0084-5; Kim BS, 2019, J AM ACAD DERMATOL, V81, P1223, DOI 10.1016/j.jaad.2019.06.038; Kobayashi T, 2020, TRENDS IMMUNOL, V41, P100, DOI 10.1016/j.it.2019.12.004; Kolkhir P, 2020, ANN ALLERG ASTHMA IM, V124, P2, DOI 10.1016/j.anai.2019.08.014; Kollipara R, 2016, J AM ACAD DERMATOL, V75, P19, DOI 10.1016/j.jaad.2016.04.032; Komi DEA, 2018, CLIN REV ALLERG IMMU, V54, P386, DOI 10.1007/s12016-017-8597-4; Lalli PN, 2004, J PARASITOL, V90, P711, DOI 10.1645/GE-214R; Lewis DJ, 2018, J EUR ACAD DERMATOL, V32, P1652, DOI 10.1111/jdv.15075; Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI 10.1016/j.jaci.2020.04.006; Liang Y, 2000, J CUTAN PATHOL, V27, P359, DOI 10.1034/j.1600-0560.2000.027007359.x; Litman T, 2019, APMIS, V127, P386, DOI 10.1111/apm.12934; Liu BY, 2016, P NATL ACAD SCI USA, V113, pE7572, DOI 10.1073/pnas.1606608113; Mack MR, 2018, TRENDS IMMUNOL, V39, P980, DOI 10.1016/j.it.2018.10.001; Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978; Matterne U, 2013, ACTA DERM-VENEREOL, V93, P532, DOI 10.2340/00015555-1572; Maurelli M, 2018, EUR J DERMATOL, V28, P44, DOI 10.1684/ejd.2017.3183; Mendez-Samperio P, 2016, INFECT DIS-NOR, V48, P715, DOI 10.1080/23744235.2016.1194529; Messingham KN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02331; Mishra SK, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.03.036; Mobus L, 2021, J ALLERGY CLIN IMMUN, V147, P213, DOI 10.1016/j.jaci.2020.06.012; Mounsey KE, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003498; Moy AP, 2016, J CUTAN PATHOL, V43, P372, DOI 10.1111/cup.12673; Murdaca G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235856; Najafi P, 2021, J EUR ACAD DERMATOL, V35, P1058, DOI 10.1111/jdv.17029; Nakajima R, 2018, BRIT J DERMATOL, V178, P1373, DOI 10.1111/bjd.16237; Nattkemper LA, 2016, ACTA DERM-VENEREOL, V96, P894, DOI 10.2340/00015555-2417; Norgan AP, 2018, ADV ANAT PATHOL, V25, P106, DOI 10.1097/PAP.0000000000000183; Nosanchuk JD, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01463; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; Oh MH, 2013, J IMMUNOL, V191, P5371, DOI 10.4049/jimmunol.1300300; Ohtsuka E, 2001, JPN J PHARMACOL, V86, P97, DOI 10.1254/jjp.86.97; Park K, 2011, EUR J DERMATOL, V21, P135, DOI 10.1684/ejd.2010.1196; Pereira MP, 2020, J EUR ACAD DERMATOL, V34, P2373, DOI 10.1111/jdv.16309; Pereira MP, 2018, J EUR ACAD DERMATOL, V32, P1059, DOI 10.1111/jdv.14570; Pogatzki-Zahn EM, 2020, J INVEST DERMATOL, V140, P203, DOI 10.1016/j.jid.2019.05.029; Prickett KA, 2014, SEMIN CUTAN MED SURG, V33, P128, DOI 10.12788/j.sder.0108; Raap U, 2017, CLIN EXP ALLERGY, V47, P499, DOI 10.1111/cea.12875; Reddy VB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8864; Retzinger AC, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110257; Roh YS, 2021, J ALLER CL IMM-PRACT, V9, P2513, DOI 10.1016/j.jaip.2021.01.034; Rudrich U, 2018, ACTA DERM-VENEREOL, V98, P766, DOI 10.2340/00015555-2951; Salao K, 2020, BIOMARK INSIGHTS, V15, DOI 10.1177/1177271920940712; Sanders KM, 2019, J INVEST DERMATOL, V139, P971, DOI 10.1016/j.jid.2018.09.032; Schmelz M, 2015, HANDB EXP PHARMACOL, V227, P285, DOI 10.1007/978-3-662-46450-2_14; Schwendinger-Schreck J, 2015, HANDB EXP PHARMACOL, V226, P177, DOI 10.1007/978-3-662-44605-8_10; Shimizu K, 2019, EUR J DERMATOL, V29, P268, DOI 10.1684/ejd.2019.3560; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Stander S, 2007, ACTA DERM-VENEREOL, V87, P291, DOI 10.2340/00015555-0305; Stander S, 2006, EUR J PAIN, V10, P473, DOI 10.1016/j.ejpain.2006.03.005; Stander S, 2020, NEW ENGL J MED, V382, P706, DOI 10.1056/NEJMoa1908316; Steck O, 2021, J EUR ACAD DERMATOL, V35, P1331, DOI 10.1111/jdv.17001; Tabatabaei-Panah PS, 2022, IMMUNOL INVEST, V51, P343, DOI 10.1080/08820139.2020.1832113; Takahashi N, 2016, CANCER RES, V76, P6241, DOI 10.1158/0008-5472.CAN-16-0992; Talagas M, 2020, ANN NEUROL, V88, P1205, DOI 10.1002/ana.25912; Tatsuno K, 2016, J DERMATOL SCI, V82, P145, DOI 10.1016/j.jdermsci.2016.04.010; Thangam EB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01873; Tominaga M, 2014, J DERMATOL, V41, P205, DOI 10.1111/1346-8138.12317; Tsoi LC, 2020, J ALLERGY CLIN IMMUN, V145, P1406, DOI 10.1016/j.jaci.2019.11.047; Tsoi LC, 2019, J INVEST DERMATOL, V139, P1480, DOI 10.1016/j.jid.2018.12.018; Tubau C, 2021, EXPERT REV CLIN IMMU, V17, P15, DOI 10.1080/1744666X.2020.1858802; van Laarhoven AIM, 2019, PAIN, V160, P2661, DOI 10.1097/j.pain.0000000000001678; Walton SF, 2010, PARASITE IMMUNOL, V32, P532, DOI 10.1111/j.1365-3024.2010.01218.x; Walton SF, 2010, CLIN VACCINE IMMUNOL, V17, P1428, DOI 10.1128/CVI.00195-10; Wang F, 2019, JAMA DERMATOL, V155, P1426, DOI 10.1001/jamadermatol.2019.2804; Webb LM, 2017, PARASITOLOGY, V144, P1288, DOI 10.1017/S0031182017000488; Weisshaar E, 2016, CURR PROBL DERMATOL, V50, P5, DOI 10.1159/000446010; Wilson SR, 2013, CELL, V155, P285, DOI 10.1016/j.cell.2013.08.057; WIRTZ RA, 1984, ANNU REV ENTOMOL, V29, P47, DOI 10.1146/annurev.en.29.010184.000403; Xu M, 2017, IMMUNOL REV, V278, P185, DOI 10.1111/imr.12558; Yosipovitch G, 2020, J EUR ACAD DERMATOL, V34, P239, DOI 10.1111/jdv.15973; Yosipovitch G, 2018, J ALLERGY CLIN IMMUN, V142, P1375, DOI 10.1016/j.jaci.2018.09.005; Zhai Lisa L, 2019, Medicines (Basel), V6, DOI 10.3390/medicines6030072; Zhang Q, 2008, CYTOKINE GROWTH F R, V19, P347, DOI 10.1016/j.cytogfr.2008.08.003; Zhong WL, 2019, ACTA DERM-VENEREOL, V99, P579, DOI 10.2340/00015555-3150	116	9	10	6	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							303	10.3390/vaccines9030303			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5VA	33807098	Green Published, gold			2022-04-29	WOS:000634220200001
J	Haselbeck, AH; Tadesse, BT; Park, J; Gibani, MM; Espinoza, LMC; Abreu, A; Van Rensburg, C; Owusu-Ansah, M; Twuamsi-Ankrah, S; Owusu, M; Aguna, I; Picot, V; Jeon, H; Higginson, E; Park, S; Mojares, ZR; Im, J; Carey, ME; Khanam, F; Tonks, S; Dougan, G; Kim, D; Sugimoto, J; Mogasale, V; Neuzil, KM; Qadri, F; Adu-Sarkodie, Y; Owusu-Dabo, E; Clemens, J; Marks, F				Haselbeck, Andrea Haekyung; Tadesse, Birkneh Tilahun; Park, Juyeon; Gibani, Malick M.; Espinoza, Ligia Maria Cruz; Abreu, Ariane; Van Rensburg, Craig; Owusu-Ansah, Michael; Twuamsi-Ankrah, Sampson; Owusu, Michael; Aguna, Isaac; Picot, Valentina; Jeon, Hyonjin; Higginson, Ellen; Park, Sunju; Mojares, Zenaida R.; Im, Justin; Carey, Megan E.; Khanam, Farhana; Tonks, Susan; Dougan, Gordon; Kim, Deokryun; Sugimoto, Jonathan; Mogasale, Vittal; Neuzil, Kathleen M.; Qadri, Firdausi; Adu-Sarkodie, Yaw; Owusu-Dabo, Ellis; Clemens, John; Marks, Florian			Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana (TyVEGHA) Using a Cluster-Randomized Controlled Phase IV Trial: Trial Design and Population Baseline Characteristics	VACCINES			English	Article						typhoid conjugate vaccine; typhoid fever; cluster randomized trial; Ghana	AFRICA PROGRAM; FEVER; CHILDREN; METHODOLOGY; SAFETY; ADULTS; RISK	Typhoid fever remains a significant health problem in sub-Saharan Africa, with incidence rates of >100 cases per 100,000 person-years of observation. Despite the prequalification of safe and effective typhoid conjugate vaccines (TCV), some uncertainties remain around future demand. Real-life effectiveness data, which inform public health programs on the impact of TCVs in reducing typhoid-related mortality and morbidity, from an African setting may help encourage the introduction of TCVs in high-burden settings. Here, we describe a cluster-randomized trial to investigate population-level protection of TYPBAR-TCV(R), a Vi-polysaccharide conjugated to a tetanus-toxoid protein carrier (Vi-TT) against blood-culture-confirmed typhoid fever, and the synthesis of health economic evidence to inform policy decisions. A total of 80 geographically distinct clusters are delineated within the Agogo district of the Asante Akim region in Ghana. Clusters are randomized to the intervention arm receiving Vi-TT or a control arm receiving the meningococcal A conjugate vaccine. The primary study endpoint is the total protection of Vi-TT against blood-culture-confirmed typhoid fever. Total, direct, and indirect protection are measured as secondary outcomes. Blood-culture-based enhanced surveillance enables the estimation of incidence rates in the intervention and control clusters. Evaluation of the real-world impact of TCVs and evidence synthesis improve the uptake of prequalified/licensed safe and effective typhoid vaccines in public health programs of high burden settings. This trial is registered at the Pan African Clinical Trial Registry, accessible at Pan African Clinical Trials Registry (ID: PACTR202011804563392).	[Haselbeck, Andrea Haekyung; Tadesse, Birkneh Tilahun; Park, Juyeon; Espinoza, Ligia Maria Cruz; Abreu, Ariane; Van Rensburg, Craig; Jeon, Hyonjin; Park, Sunju; Mojares, Zenaida R.; Im, Justin; Kim, Deokryun; Mogasale, Vittal; Clemens, John; Marks, Florian] Int Vaccine Inst, Seoul 08826, South Korea; [Park, Juyeon; Jeon, Hyonjin; Higginson, Ellen; Carey, Megan E.; Tonks, Susan; Dougan, Gordon; Marks, Florian] Univ Cambridge, Cambridge Inst Therapeut Immunol & Infect Dis, Cambridge CB2 0SL, England; [Gibani, Malick M.] Imperial Coll Med, Dept Infect Dis, London SW7 2AZ, England; [Owusu-Ansah, Michael; Twuamsi-Ankrah, Sampson; Owusu, Michael; Aguna, Isaac; Adu-Sarkodie, Yaw; Owusu-Dabo, Ellis] Kwame Nkrumah Univ Sci & Technol, Sch Publ Hlth, Kumasi 00000, Ghana; [Picot, Valentina] Fdn Merieux, F-69002 Lyon, France; [Khanam, Farhana; Qadri, Firdausi; Clemens, John] Int Ctr Diarrhoeal Dis Res, Dhaka 1212, Bangladesh; [Sugimoto, Jonathan] US Dept Vet Affairs, Seattle Epidemiol Res & Informat Ctr, Cooperat Studies Program, Off Res & Dev, Seattle, WA 98174 USA; [Sugimoto, Jonathan] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; [Sugimoto, Jonathan] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Neuzil, Kathleen M.] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA; [Clemens, John] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA; [Marks, Florian] Univ Antananarivo, Lab Microbiol & Parasitol, Antananarivo 566, Madagascar		Haselbeck, AH; Marks, F (通讯作者)，Int Vaccine Inst, Seoul 08826, South Korea.; Marks, F (通讯作者)，Univ Cambridge, Cambridge Inst Therapeut Immunol & Infect Dis, Cambridge CB2 0SL, England.; Marks, F (通讯作者)，Univ Antananarivo, Lab Microbiol & Parasitol, Antananarivo 566, Madagascar.	andrea.haselbeck@ivi.int; birkneh.tadesse@ivi.int; juyeon.park@ivi.int; m.gibani@imperial.ac.uk; lcruz@ivi.int; ariane.abreu@ivi.int; craig.rensburg@ivi.int; mikeansah@yahoo.com; sampson.ankrah@yahoo.com; michaelowusu80@gmail.com; isaacaguna98@gmail.com; valentina.picot@fondation-merieux.org; hyonjin.jeon@ivi.int; eeh48@cam.ac.uk; sunju.park@ivi.int; zenaida.mojares@ivi.int; justin.im@ivi.int; mec82@cam.ac.uk; farhanak@icddrb.org; st823@cam.ac.uk; gd312@medschl.cam.ac.uk; drkim@ivi.int; jons@fredhutch.org; vmogasale@ivi.int; kneuzil@som.umaryland.edu; fqadri@icddrb.org; yasax@hotmail.co.uk; owusudabo@yahoo.com; jclemens@icddrb.org; fmarks@ivi.int	Qadri, Firdausi/AAF-4583-2019	Abreu, Ariane/0000-0002-5599-0991; Mogasale, Vittal/0000-0003-0596-8072; Marks, Florian/0000-0002-6043-7170; Gibani, Malick/0000-0003-1781-0053; CRUZ ESPINOZA, LIGIA MARIA/0000-0003-0429-4723; Owusu-Ansah, Michael/0000-0003-3631-0564	European UnionEuropean Commission [RIA2017S-2027]; Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR [OPP1205877]; EDCTP Association	This research funded as part of the EDCTP2 programme supported by the European Union (RIA2017S-2027) and as a grant from the Bill & Melinda Gates Foundation (OPP1205877). Disclaimer: This manuscript reflects only the authors' view and does not necessarily represent the official position of the Bill & Melinda Gates Foundation and the EDCTP Association. The EDCTP Association is not responsible for any use that may be made of the information this manuscript contains.	Bhutta ZA, 2014, LANCET INFECT DIS, V14, P119, DOI 10.1016/S1473-3099(13)70241-X; Buckle Geoffrey C, 2012, J Glob Health, V2, P010401, DOI 10.7189/jogh.02.010401; Capeding MR, 2020, ECLINICALMEDICINE, V27, DOI 10.1016/j.eclinm.2020.100540; Clemens J, 2011, LANCET INFECT DIS, V11, P482, DOI 10.1016/S1473-3099(10)70318-2; Crump JA, 2004, B WORLD HEALTH ORGAN, V82, P346; Cutler D, 2005, DEMOGRAPHY, V42, P1, DOI 10.1353/dem.2005.0002; Date K, 2020, CLIN INFECT DIS, V71, pS172, DOI 10.1093/cid/ciaa597; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hayes RJ, 2017, CLUSTER RANDOMISED T, Vsecond, P424; Im J, 2021, CLIN INFECT DIS, V72, pE720, DOI 10.1093/cid/ciaa1429; Jeon HJ, 2019, CLIN INFECT DIS, V69, pS417, DOI 10.1093/cid/ciz629; John J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004616; Kossaczka Z, 1999, INFECT IMMUN, V67, P5806, DOI 10.1128/IAI.67.11.5806-5810.1999; Lee JS, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2074-1; Ludbrook J, 2009, ANZ J SURG, V79, P565, DOI 10.1111/j.1445-2197.2009.04994.x; Marks F, 2017, LANCET GLOB HEALTH, V5, pE310, DOI 10.1016/S2214-109X(17)30022-0; Mogasale V, 2014, LANCET GLOB HEALTH, V2, pE570, DOI 10.1016/S2214-109X(14)70301-8; Neuzil K.M., 2020, MORE TYPHOID CONJUGA; Neuzil KM, 2020, CLIN INFECT DIS, V71, pS155, DOI 10.1093/cid/ciaa370; Pak GD, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021438; Park SE, 2019, CLIN INFECT DIS, V69, pS422, DOI 10.1093/cid/ciz715; Parry C, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.k5322; Qamar FN, 2020, VACCINE, V38, P3518, DOI 10.1016/j.vaccine.2020.03.028; Ramani E, 2019, CLIN INFECT DIS, V69, pS459, DOI 10.1093/cid/ciz608; Capeding MR, 2020, VACCINE, V38, P4476, DOI 10.1016/j.vaccine.2019.09.074; Capeding MR, 2018, VACCINE, V36, P3794, DOI 10.1016/j.vaccine.2018.05.038; Sabin Vaccine Institute, 2017, P 10 INT C TYPH OTH; Shakya M, 2019, NEW ENGL J MED, V381, P2209, DOI 10.1056/NEJMoa1905047; Stanaway JD, 2019, LANCET INFECT DIS, V19, P369, DOI 10.1016/S1473-3099(18)30685-6; Theiss-Nyland K, 2019, CLIN INFECT DIS, V68, pS74, DOI 10.1093/cid/ciy1107; Voysey M, 2018, CLIN INFECT DIS, V67, P18, DOI 10.1093/cid/cix1145; World Health Organization, 2019, WHO GUID STAND EC EV; World Hlth Org, 2019, VACCINE, V37, P214, DOI 10.1016/j.vaccine.2018.04.022	33	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							281	10.3390/vaccines9030281			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5NF	33808924	Green Published, gold			2022-04-29	WOS:000634199900001
J	Szmyd, B; Karuga, FF; Bartoszek, A; Staniecka, K; Siwecka, N; Bartoszek, A; Blaszczyk, M; Radek, M				Szmyd, Bartosz; Karuga, Filip Franciszek; Bartoszek, Adrian; Staniecka, Katarzyna; Siwecka, Natalia; Bartoszek, Agnieszka; Blaszczyk, Maciej; Radek, Maciej			Attitude and Behaviors towards SARS-CoV-2 Vaccination among Healthcare Workers: A Cross-Sectional Study from Poland	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccination; healthcare workers; depression; anxiety; stress		Healthcare workers are particularly exposed to biological risk during their daily occupational activities. Nowadays, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become one of the most widespread infectious agents. In the current study, we performed a survey on the attitude and behavior of Polish healthcare workers (HCW), which comprise physicians (MD) and administrative healthcare assistants (HA) towards the Coronavirus Disease 2019 (COVID-19) vaccination. Our study involved 2300 subjects (42.17% female; 10.96% MD; 5.87% HA). The evaluation was conducted using a Google Forms survey based on original questions and the Depression, Anxiety and Stress Scale-21 Items questionnaire. HCW significantly more often demonstrated their willingness to get vaccinated against the SARS-CoV-2 as compared to the control group (82.95% vs. 54.31%, respectively). The main concern, as regards all groups, was the development of long-term side effects after getting COVID-19 vaccine. The study revealed that depression significantly affects the willingness to get vaccinated. The readiness was significantly strengthened by positive medical history of recommended vaccinations, fear of catching COVID-19, as well as fear of passing on the disease to the relatives. Overall, the percentage of HCW, who want to be vaccinated against COVID-19 remains unsatisfactory. Further works exploring this subject are needed to take a step closer to achieving the herd immunity in the era of the COVID-19 pandemic.	[Szmyd, Bartosz; Karuga, Filip Franciszek; Bartoszek, Adrian; Staniecka, Katarzyna; Siwecka, Natalia; Blaszczyk, Maciej; Radek, Maciej] Med Univ Lodz, Dept Neurosurg Spine & Peripheral Nerves Surg, PL-90549 Lodz, Poland; [Karuga, Filip Franciszek] Med Univ Lodz, Dept Sleep Med & Metab Disorders, PL-92215 Lodz, Poland; [Bartoszek, Adrian] Med Univ Lublin, Dept Pathophysiol, PL-20090 Lublin, Poland; [Siwecka, Natalia] Med Univ Lodz, Dept Clin Chem & Biochem, PL-90419 Lodz, Poland; [Bartoszek, Agnieszka] Med Univ Lublin, Dept Family Med & Community Nursing, PL-20081 Lublin, Poland		Karuga, FF (通讯作者)，Med Univ Lodz, Dept Neurosurg Spine & Peripheral Nerves Surg, PL-90549 Lodz, Poland.; Karuga, FF (通讯作者)，Med Univ Lodz, Dept Sleep Med & Metab Disorders, PL-92215 Lodz, Poland.	bartoszmyd@gmail.com; filipfranciszek439@gmail.com; adrian.bartoszek@stud.umed.lodz.pl; katarzyna.staniecka@stud.umed.lodz.pl; natalia.siwecka@stud.umed.lodz.pl; agabartoszek@wp.pl; maciej.blaszczyk@umed.lodz.pl; maciej.radek@umed.lodz.pl	Szmyd, Bartosz/AAM-8025-2021	Szmyd, Bartosz/0000-0002-4051-0887; Bartoszek, Adrian/0000-0002-6840-7320; Radek, Maciej/0000-0003-3544-1482; Siwecka, Natalia/0000-0002-0308-580X; Karuga, Filip/0000-0002-6551-6804; Blaszczyk, Maciej/0000-0003-3430-6027; Bartoszek, Agnieszka/0000-0003-0974-0761	Department of Neurosurgery, Spine and Peripheral Nerves Surgery and Medical University of Lodz	The APC was funded by the Department of Neurosurgery, Spine and Peripheral Nerves Surgery and Medical University of Lodz.	[Anonymous], Power/Sample Size Calculator; [Anonymous], Pierwszy Miesiac Szczepien Przeciw Covid-19 za Nami-Szczepienie Przeciwko COVID-19-Portal Gov.pl; [Anonymous], Pfizer-BioNTech COVID-19 Vaccine-Fact Sheet for Healthcare Providers Administering Vaccine; [Anonymous], NARODOWY PROGRAM SZC; [Anonymous], WHO Coronavirus Disease (COVID-19): Vaccines.; Bagcchi S, 2020, LANCET INFECT DIS, V20, P782, DOI 10.1016/S1473-3099(20)30498-9; Bartoszek A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17207417; Davidson M, 2017, DIALOGUES CLIN NEURO, V19, P403; Di Martino G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020248; Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442; Duplaga M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217818; Esprit A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040776; Feleszko W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010044; Freeman D, 2022, PSYCHOL MED, V52, P251, DOI 10.1017/S0033291720001890; French J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165893; Gabryelska A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051599; Georgiou N, 2020, PERS INDIV DIFFER, V166, DOI 10.1016/j.paid.2020.110201; Goertzel T, 2010, EMBO REP, V11, P493, DOI 10.1038/embor.2010.84; Hoffman BL, 2019, VACCINE, V37, P2216, DOI 10.1016/j.vaccine.2019.03.003; Hunter E, 2020, LANCET, V395, pE77, DOI 10.1016/S0140-6736(20)30970-3; Iyengar KP, 2020, DIABETES METAB SYND, V14, P1743, DOI 10.1016/j.dsx.2020.09.003; Jolley D, 2020, BRIT J SOC PSYCHOL, V59, P628, DOI 10.1111/bjso.12394; Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022; Khuroo MS, 2020, J CLIN EXP HEPATOL, V10, P610, DOI 10.1016/j.jceh.2020.06.003; Lastrucci V, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040778; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Michno DA, 2021, J PUBLIC HEALTH-UK, V43, P479, DOI 10.1093/pubmed/fdaa271; Morgantini Luca A, 2020, medRxiv, DOI 10.1101/2020.05.17.20101915; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Pivetti M, 2020, INT J QUAL STUD HEAL, V15, DOI 10.1080/17482631.2020.1754086; Pradhan D, 2020, ARCH MED RES, V51, P363, DOI 10.1016/j.arcmed.2020.04.020; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Rosner B, 2016, FUNDAMENTALS BIOSTAT; Shi Yudong, 2020, Brain Behav Immun Health, V4, P100064, DOI 10.1016/j.bbih.2020.100064; Shreffler J, 2020, WEST J EMERG MED, V21, P1059, DOI 10.5811/westjem.2020.7.48684; Sochal M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092921; Sotgiu G, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02461-2020; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; Szmyd B, 2021, SLEEP MED REV, V55, DOI 10.1016/j.smrv.2020.101380; Taylor S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.575950; Zheng C, 2020, J HOSP INFECT, V106, P325, DOI 10.1016/j.jhin.2020.07.025	42	48	48	5	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							218	10.3390/vaccines9030218			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE5EG	33806641	Green Published, gold	Y	N	2022-04-29	WOS:000634176600001
J	Tapia-Conyer, R; Betancourt-Cravioto, M; Montoya, A; Falcon-Lezama, JA; Alfaro-Cortes, MM; Saucedo-Martinez, R				Tapia-Conyer, Roberto; Betancourt-Cravioto, Miguel; Montoya, Alejandra; Falcon-Lezama, Jorge Abelardo; Alfaro-Cortes, Myrna Maria; Saucedo-Martinez, Rodrigo			A Call for a Reform of the Influenza Immunization Program in Mexico: Epidemiologic and Economic Evidence for Decision Making	VACCINES			English	Article						influenza; vaccination; immunization; cost-effectiveness; burden of disease; Mexico; middle-income countries		Limited information is available to determine the effectiveness of Mexico's national influenza vaccination guidelines and inform policy updates. We aim to propose reforms to current influenza vaccination policies based on our analysis of cost-effectiveness studies. This cross-sectional epidemiological study used influenza case, death, discharge and hospitalization data from several influenza seasons and applied a one-year decision-analytic model to assess cost-effectiveness. The primary health outcome was influenza cases avoided; secondary health outcomes were influenza-related events associated with case reduction. By increasing vaccination coverage to 75% in the population aged 12-49 years with risk factors (diabetes, high blood pressure, morbid obesity, chronic renal failure, asthma, pregnancy), and expanding universal vaccination coverage to school-aged children (5-11 years) and adults aged 50-59 years, 7142-671,461 influenza cases; 1-15 deaths; 7615-262,812 healthcare visits; 2886-154,143 emergency room admissions and 2891-97,637 hospitalizations could be prevented (ranges correspond to separate age and risk factor groups), with a net annual savings of 3.90 to 111.99 million USD. Such changes to the current vaccination policy could potentially result in significant economic and health benefits. These data could be used to inform the revision of a vaccination policy in Mexico with substantial social value.	[Tapia-Conyer, Roberto; Betancourt-Cravioto, Miguel; Montoya, Alejandra; Falcon-Lezama, Jorge Abelardo; Alfaro-Cortes, Myrna Maria; Saucedo-Martinez, Rodrigo] Soc Mexicana Salud Publ, Vaccinol Sect, Mexico City 11590, DF, Mexico; [Tapia-Conyer, Roberto] Univ Nacl Autonoma Mexico, Sch Med, Mexico City 04510, DF, Mexico		Falcon-Lezama, JA (通讯作者)，Soc Mexicana Salud Publ, Vaccinol Sect, Mexico City 11590, DF, Mexico.	tapiaconyer@yahoo.com.mx; betancom70@gmail.com; airain.montoya@gmail.com; jfalcon@fundacioncarlosslim.org; myrna.alfaro.fcs@gmail.com; rosaucedo@gmail.com		Tapia-Conyer, Roberto/0000-0001-9425-7322; Falcon-Lezama, Jorge Abelardo/0000-0001-9081-4064	Sanofi Pasteur	This research and the article processing charges were fully funded by Sanofi Pasteur.	Falcon-Lezama JA, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4948-5; [Anonymous], Organizacion Panamericana de la Salud [Pan American Health Organization]; [Anonymous], SISTEMA VIGILANCIA E; [Anonymous], Direccion General de Epidemiologia [General Directorate of Epidemiology]; [Anonymous], CONSEJO NACL POBLACI; [Anonymous], SECRETAR A SALUD SEE; [Anonymous], CTR DIS CONTR PREV; [Anonymous], SECRETAR A SALUD SAE; Baguelin M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001527; Basto-Abreu A, 2020, SALUD PUBLICA MEXICO, V62, P50, DOI 10.21149/10752; Betancourt-Cravioto M., 2021, VACCINES-BASEL, V9, P188, DOI [10.3390/vaccines9030188, DOI 10.3390/VACCINES9030188]; Campos-Nonato I, 2018, SALUD PUBLICA MEXICO, V60, P233, DOI 10.21149/8813; Centro Nacional de Excelencia Tecnologica en Salud (CENETEC), SECR SAL; Cowling BJ, 2014, VACCINE, V32, P5278, DOI 10.1016/j.vaccine.2014.07.084; Danovaro M.C., IMMUNIZATION REGISTR; Danovaro-Holliday MC, 2019, REV PANAM SALUD PUBL, V43, DOI 10.26633/RPSP.2019.28; Ehreth J, 2003, VACCINE, V21, P596, DOI 10.1016/S0264-410X(02)00623-0; Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1; Leidner AJ, 2019, VACCINE, V37, P226, DOI 10.1016/j.vaccine.2018.11.056; Mereckiene J, 2014, EUROSURVEILLANCE, V19, P29, DOI 10.2807/1560-7917.ES2014.19.16.20780; Mertz D, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5061; Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046; Nichol KL, 2011, VACCINE, V29, P7554, DOI 10.1016/j.vaccine.2011.08.015; Nowak GJ, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15040711; Nowak GJ, 2015, VACCINE, V33, P2741, DOI 10.1016/j.vaccine.2015.04.064; O'Halloran AC, 2016, AM J PREV MED, V50, pE15, DOI 10.1016/j.amepre.2015.06.008; Pannaraj PS, 2014, CLIN INFECT DIS, V59, P325, DOI 10.1093/cid/ciu340; Petrie JG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075339; Romero-Martinez M, 2019, SALUD PUBLICA MEXICO, V61, P917, DOI 10.21149/11095; Ryder Hilary F, 2009, Semin Spine Surg, V21, P216; Savy V, 2013, INFLUENZA OTHER RESP, V7, P1017, DOI 10.1111/irv.12036; Skowronski DM, 2019, EUROSURVEILLANCE, V24, P32, DOI 10.2807/1560-7917.ES.2019.24.15.1900104; Tapia-Conyer R, 2013, VACCINE, V31, P3826, DOI 10.1016/j.vaccine.2012.12.062; Weidemann F, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2344-6; WHO, GUID COST EFF AN; Yang KC, 2018, INT J INFECT DIS, V73, P102, DOI 10.1016/j.ijid.2018.05.024	36	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							286	10.3390/vaccines9030286			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE5XZ	33808916	Green Published, gold			2022-04-29	WOS:000634227900001
J	Velazquez-Moctezuma, R; Augestad, EH; Castelli, M; Olesen, CH; Clementi, N; Clementi, M; Mancini, N; Prentoe, J				Velazquez-Moctezuma, Rodrigo; Augestad, Elias H.; Castelli, Matteo; Holmboe Olesen, Christina; Clementi, Nicola; Clementi, Massimo; Mancini, Nicasio; Prentoe, Jannick			Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies	VACCINES			English	Review						hepatitis C virus; antibody escape; B-cell vaccine; virus neutralization		Hepatitis C virus (HCV) is a major causative agent of acute and chronic hepatitis. It is estimated that 400,000 people die every year from chronic HCV infection, mostly from severe liver-related diseases such as cirrhosis and liver cancer. Although HCV was discovered more than 30 years ago, an efficient prophylactic vaccine is still missing. The HCV glycoprotein complex, E1/E2, is the principal target of neutralizing antibodies (NAbs) and, thus, is an attractive antigen for B-cell vaccine design. However, the high genetic variability of the virus necessitates the identification of conserved epitopes. Moreover, the high intrinsic mutational capacity of HCV allows the virus to continually escape broadly NAbs (bNAbs), which is likely to cause issues with vaccine-resistant variants. Several studies have assessed the barrier-to-resistance of vaccine-relevant bNAbs in vivo and in vitro. Interestingly, recent studies have suggested that escape substitutions can confer antibody resistance not only by direct modification of the epitope but indirectly through allosteric effects, which can be grouped based on the breadth of these effects on antibody susceptibility. In this review, we summarize the current understanding of HCV-specific NAbs, with a special focus on vaccine-relevant bNAbs and their targets. We highlight antibody escape studies pointing out the different methodologies and the escape mutations identified thus far. Finally, we analyze the antibody escape mechanisms of envelope protein escape substitutions and polymorphisms according to the most recent evidence in the HCV field. The accumulated knowledge in identifying bNAb epitopes as well as assessing barriers to resistance and elucidating relevant escape mechanisms may prove critical in the successful development of an HCV B-cell vaccine.	[Velazquez-Moctezuma, Rodrigo; Augestad, Elias H.; Holmboe Olesen, Christina; Prentoe, Jannick] Univ Copenhagen, Dept Immunol & Microbiol, Fac Hlth & Med Sci, Copenhagen Hepatitis C Program CO HEP, DK-2200 Copenhagen, Denmark; [Velazquez-Moctezuma, Rodrigo; Augestad, Elias H.; Holmboe Olesen, Christina; Prentoe, Jannick] Hvidovre Univ Hosp, Dept Infect Dis, DK-2650 Hvidovre, Denmark; [Castelli, Matteo; Clementi, Nicola; Clementi, Massimo; Mancini, Nicasio] Univ Vita Salute San Raffaele, Lab Microbiol & Virol, I-20132 Milan, Italy		Prentoe, J (通讯作者)，Univ Copenhagen, Dept Immunol & Microbiol, Fac Hlth & Med Sci, Copenhagen Hepatitis C Program CO HEP, DK-2200 Copenhagen, Denmark.; Prentoe, J (通讯作者)，Hvidovre Univ Hosp, Dept Infect Dis, DK-2650 Hvidovre, Denmark.	rodrigo.velazquez.moctezuma@regionh.dk; elias.augestad@regionh.dk; castelli.matteo@hsr.it; fpk237@sund.ku.dk; clementi.nicola@hsr.it; clementi.massimo@hsr.it; mancini.nicasio@hsr.it; jprentoe@sund.ku.dk	Clementi, Nicola/G-8545-2014	Clementi, Nicola/0000-0002-1822-9861; Prentoe, Jannick/0000-0003-2203-9478; Olesen, Christina Holmboe/0000-0002-0575-1597; Velazquez-Moctezuma, Rodrigo/0000-0001-9865-152X	Lundbeck FoundationLundbeckfonden [R3032018-3396, R324-2019-1375, R335-2019-2052]	This manuscript was supported by a postdoc grant from the Lundbeck Foundation (R3032018-3396 To RVM), a Ph.D. stipend from the Candy Foundation (CHO), an Experiment grant from the Lundbeck Foundation (grant number: R324-2019-1375 to JP) and a Lundbeck Foundation Fellowship (grant number: R335-2019-2052 to JP).	Albecka A, 2011, J VIROL, V85, P1777, DOI 10.1128/JVI.02170-10; Augestad EH, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb5938; Babcock GJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100325; Bailey JR, 2015, J CLIN INVEST, V125, P437, DOI 10.1172/JCI78794; Ball JK, 2014, ANTIVIR RES, V105, P100, DOI 10.1016/j.antiviral.2014.02.013; Bankwitz D, 2017, J HEPATOL, V67, P480, DOI 10.1016/j.jhep.2017.04.010; Bankwitz D, 2014, J VIROL, V88, P12644, DOI 10.1128/JVI.01145-14; Bankwitz D, 2010, J VIROL, V84, P5751, DOI 10.1128/JVI.02200-09; Barth H, 2003, J BIOL CHEM, V278, P41003, DOI 10.1074/jbc.M302267200; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Boo I, 2012, BIOCHEM J, V443, P85, DOI 10.1042/BJ20110868; Borgia SM, 2018, J INFECT DIS, V218, P1722, DOI 10.1093/infdis/jiy401; Brazzoli M, 2008, J VIROL, V82, P8316, DOI 10.1128/JVI.00665-08; Broering TJ, 2009, J VIROL, V83, P12473, DOI 10.1128/JVI.01138-09; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; Bukh J, 2016, J HEPATOL, V65, pS2, DOI 10.1016/j.jhep.2016.07.035; Bukh J, 2015, J VIROL, V89, P9128, DOI 10.1128/JVI.01194-15; Castelli M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00320-7; Chung RT, 2013, AM J TRANSPLANT, V13, P1047, DOI 10.1111/ajt.12083; de Jong YP, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009512; Desombere I, 2017, ANTIVIR RES, V148, P53, DOI 10.1016/j.antiviral.2017.10.015; Dhillon S, 2010, J VIROL, V84, P5494, DOI 10.1128/JVI.02153-09; Domingo E, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008271; Dowd KA, 2018, ANNU REV VIROL, V5, P185, DOI 10.1146/annurev-virology-092917-043300; Drummer HE, 2006, J VIROL, V80, P7844, DOI 10.1128/JVI.00029-06; Drummer HE, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00329; Duan H, 2010, VACCINE, V28, P4138, DOI 10.1016/j.vaccine.2010.04.024; Dubuisson J, 2007, WORLD J GASTROENTERO, V13, P2406, DOI 10.3748/wjg.v13.i17.2406; El-Diwany R, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006235; Falson P, 2015, J VIROL, V89, P10333, DOI 10.1128/JVI.00991-15; Farci P, 1996, P NATL ACAD SCI USA, V93, P15394, DOI 10.1073/pnas.93.26.15394; Farci P, 1997, SPRINGER SEMIN IMMUN, V19, P5, DOI 10.1007/BF00945022; Farquhar MJ, 2012, J VIROL, V86, P4305, DOI 10.1128/JVI.06996-11; Fauvelle C, 2016, GASTROENTEROLOGY, V150, P206, DOI 10.1053/j.gastro.2015.09.014; Flint M, 1999, J VIROL, V73, P6782, DOI 10.1128/JVI.73.8.6782-6790.1999; Freedman H, 2016, ACS INFECT DIS, V2, P749, DOI 10.1021/acsinfecdis.6b00110; Fuerst TR, 2018, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02692; Gal-Tanamy M, 2008, P NATL ACAD SCI USA, V105, P19450, DOI 10.1073/pnas.0809879105; Giang E, 2012, P NATL ACAD SCI USA, V109, P6205, DOI 10.1073/pnas.1114927109; Gopal R, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006735; Gottwein JM, 2008, ADV VIRUS RES, V71, P51, DOI 10.1016/S0065-3527(08)00002-X; Greaney AJ, 2021, CELL HOST MICROBE, V29, P463, DOI 10.1016/j.chom.2021.02.003; Grove J, 2008, J VIROL, V82, P12020, DOI 10.1128/JVI.01569-08; Gu J, 2018, J VIROL, V92, DOI 10.1128/JVI.02066-17; Guan M, 2012, J BIOL CHEM, V287, P35631, DOI 10.1074/jbc.M112.382341; Jensen TB, 2008, J INFECT DIS, V198, P1756, DOI 10.1086/593021; Johansson DX, 2007, P NATL ACAD SCI USA, V104, P16269, DOI 10.1073/pnas.0705522104; Johnson JE, 2003, ADV PROTEIN CHEM, V64, P197; Kalemera M, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006905; Keck ML, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01194; Keck ZY, 2008, J VIROL, V82, P6061, DOI 10.1128/JVI.02475-07; Keck ZY, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007772; Keck ZY, 2016, J VIROL, V90, P3112, DOI 10.1128/JVI.02458-15; Keck ZY, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004297; Keck ZY, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002653; Keck ZY, 2011, J VIROL, V85, P10451, DOI 10.1128/JVI.05259-11; Keck Z, 2013, J VIROL, V87, P37, DOI 10.1128/JVI.01941-12; Keck ZY, 2005, J VIROL, V79, P13199, DOI 10.1128/JVI.79.21.13199-13208.2005; Keck ZY, 2004, J VIROL, V78, P9224, DOI 10.1128/JVI.78.17.9224-9232.2004; Khan AG, 2014, NATURE, V509, P381, DOI 10.1038/nature13117; Kim WR, 2009, GASTROENTEROLOGY, V137, P1680, DOI 10.1053/j.gastro.2009.07.047; Kong L, 2016, P NATL ACAD SCI USA, V113, P12768, DOI 10.1073/pnas.1609780113; Kong L, 2015, CURR OPIN VIROL, V11, P148, DOI 10.1016/j.coviro.2015.04.001; Kong L, 2013, SCIENCE, V342, P1090, DOI 10.1126/science.1243876; Kong L, 2012, J VIROL, V86, P13085, DOI 10.1128/JVI.01939-12; Kong L, 2012, P NATL ACAD SCI USA, V109, P9499, DOI 10.1073/pnas.1202924109; Krey T, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003364; Kuhn RJ, 2015, VIROLOGY, V479, P508, DOI 10.1016/j.virol.2015.03.025; Lavie M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00910; Law M, 2008, NAT MED, V14, P25, DOI 10.1038/nm1698; Li GD, 2017, ANTIVIR RES, V142, P83, DOI 10.1016/j.antiviral.2017.02.014; Li YL, 2015, J BIOL CHEM, V290, P10117, DOI 10.1074/jbc.M115.643528; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Liu SF, 2009, J VIROL, V83, P2011, DOI 10.1128/JVI.01888-08; Liu ZM, 2021, CELL HOST MICROBE, V29, P477, DOI 10.1016/j.chom.2021.01.014; Makowski L, 2008, J MOL BIOL, V383, P731, DOI 10.1016/j.jmb.2008.08.038; Mathiesen CK, 2015, J VIROL, V89, P7758, DOI 10.1128/JVI.00039-15; McCaffrey K, 2011, J GEN VIROL, V92, P112, DOI 10.1099/vir.0.026385-0; Meola A, 2015, J VIROL, V89, P2170, DOI 10.1128/JVI.02190-14; Meuleman P, 2011, HEPATOLOGY, V53, P755, DOI 10.1002/hep.24171; Micallef JM, 2006, J VIRAL HEPATITIS, V13, P34, DOI 10.1111/j.1365-2893.2005.00651.x; Morin TJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002895; Olesen C.H., IN VITRO ADAPTATION; Osburn WO, 2014, HEPATOLOGY, V59, P2140, DOI 10.1002/hep.27013; Osburn WO, 2010, GASTROENTEROLOGY, V138, P315, DOI 10.1053/j.gastro.2009.09.017; Owsianka A, 2005, J VIROL, V79, P11095, DOI 10.1128/JVI.79.17.11095-11104.2005; Owsianka AM, 2008, J GEN VIROL, V89, P653, DOI 10.1099/vir.0.83386-0; Owsianka AM, 2006, J VIROL, V80, P8695, DOI 10.1128/JVI.00271-06; Pantua H, 2013, J MOL BIOL, V425, P1899, DOI 10.1016/j.jmb.2013.02.025; Pestka JM, 2007, P NATL ACAD SCI USA, V104, P6025, DOI 10.1073/pnas.0607026104; Potter JA, 2012, J VIROL, V86, P12923, DOI 10.1128/JVI.02052-12; Prentoe J, 2019, P NATL ACAD SCI USA, V116, P10039, DOI 10.1073/pnas.1822002116; Prentoe J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02146; Prentoe J, 2016, GUT, V65, P1988, DOI 10.1136/gutjnl-2015-310300; Prentoe J, 2016, HEPATOLOGY, V64, P1881, DOI 10.1002/hep.28705; Prentoe J, 2011, J VIROL, V85, P2224, DOI 10.1128/JVI.01594-10; Prentoe J, 2011, VIROLOGY, V409, P148, DOI 10.1016/j.virol.2010.10.034; Robertson B, 1998, ARCH VIROL, V143, P2493, DOI 10.1007/s007050050479; Romano L, 2015, HUM VACC IMMUNOTHER, V11, P53, DOI 10.4161/hv.34306; Rosenthal ES, 2016, INFECT AGENTS CANCER, V11, DOI 10.1186/s13027-016-0071-z; Sabo MC, 2012, VIROLOGY, V422, P174, DOI 10.1016/j.virol.2011.10.023; Sabo MC, 2011, J VIROL, V85, P7005, DOI 10.1128/JVI.00586-11; Sasayama M, 2012, J MED VIROL, V84, P229, DOI 10.1002/jmv.22257; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Simmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819; Simmonds P, 2017, J GEN VIROL, V98, P2, DOI 10.1099/jgv.0.000672; Smith DB, 2014, HEPATOLOGY, V59, P318, DOI 10.1002/hep.26744; Stejskal L, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007710; TANIGUCHI S, 1993, VIROLOGY, V195, P297, DOI 10.1006/viro.1993.1378; Thimme R, 2021, J HEPATOL, V74, P220, DOI 10.1016/j.jhep.2020.09.022; Thursz M, 2014, NAT REV GASTRO HEPAT, V11, P28, DOI 10.1038/nrgastro.2013.179; Troesch M, 2006, VIROLOGY, V352, P357, DOI 10.1016/j.virol.2006.05.015; Tzarum N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb5642; Tzarum N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01315; Vanwolleghem T, 2008, HEPATOLOGY, V47, P1846, DOI 10.1002/hep.22244; Velazquez-Moctezuma R, 2019, J VIROL, V93, DOI 10.1128/JVI.01909-18; Velazquez-Moctezuma R, 2019, J INFECT DIS, V219, P68, DOI 10.1093/infdis/jiy481; Velazquez-Moctezuma R, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006214; Vieyres G, 2010, J VIROL, V84, P10159, DOI 10.1128/JVI.01180-10; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wasilewski LN, 2016, J VIROL, V90, P3773, DOI 10.1128/JVI.02837-15; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; WHO, HEP C; Zhang P, 2007, P NATL ACAD SCI USA, V104, P8449, DOI 10.1073/pnas.0703039104; Zhang P, 2009, P NATL ACAD SCI USA, V106, P7537, DOI 10.1073/pnas.0902749106; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102; Zibert A, 1997, HEPATOLOGY, V25, P1245, DOI 10.1002/hep.510250530; Zuiani A, 2016, J VIROL, V90, P10499, DOI 10.1128/JVI.01011-16	128	2	2	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							291	10.3390/vaccines9030291			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5JV	33804732	gold, Green Published			2022-04-29	WOS:000634191100001
J	Martinez-Perez, AG; Perez-Trujillo, JJ; Garza-Morales, R; Ramirez-Avila, NE; Loera-Arias, MJ; Gomez-Gutierrez, JG; Saucedo-Cardenas, O; Garcia-Garcia, A; Rodriguez-Rocha, H; Montes-de-Oca-Luna, R				Martinez-Perez, Alejandra G.; Perez-Trujillo, Jose J.; Garza-Morales, Rodolfo; Ramirez-Avila, Norma E.; Loera-Arias, Maria J.; Gomez-Gutierrez, Jorge G.; Saucedo-Cardenas, Odila; Garcia-Garcia, Aracely; Rodriguez-Rocha, Humberto; Montes-de-Oca-Luna, Roberto			An Oncolytic Adenovirus Encoding SA-4-1BBL Adjuvant Fused to HPV-16 E7 Antigen Produces a Specific Antitumor Effect in a Cancer Mouse Model	VACCINES			English	Article						4-1BBL; cancer vaccines; oncolytic virus; HPV-16 antigen		Human papillomaviruses (HPVs) are responsible for about 25% of cancer cases worldwide. HPV-16 E7 antigen is a tumor-associated antigen (TAA) commonly expressed in HPV-induced tumors; however, it has low immunogenicity. The interaction of 4-1BBL with its receptor induces pleiotropic effects on innate, adaptive, and regulatory immunity and, if fused to TAAs in DNA vaccines, can improve the antitumor response; however, there is low transfection and antitumor efficiency. Oncolytic virotherapy is promising for antitumor gene therapy as it can be selectively replicated in tumor cells, inducing cell lysis, and furthermore, tumor cell debris can be taken in by immune cells to potentiate antitumor responses. In this study, we expressed the immunomodulatory molecule SA-4-1BBL fused to E7 on an oncolytic adenovirus (OAd) system. In vitro infection of TC-1 tumor cells and NIH-3T3 non-tumor cells with SA/E7/4-1BBL OAd demonstrated that only tumor cells are selectively destroyed. Moreover, protein expression is targeted to the endoplasmic reticulum in both cell lines when a signal peptide (SP) is added. Finally, in an HPV-induced cancer murine model, the therapeutic oncolytic activity of OAd can be detected, and this can be improved when fused to E7 and SP.	[Martinez-Perez, Alejandra G.; Perez-Trujillo, Jose J.; Ramirez-Avila, Norma E.; Loera-Arias, Maria J.; Saucedo-Cardenas, Odila; Garcia-Garcia, Aracely; Rodriguez-Rocha, Humberto; Montes-de-Oca-Luna, Roberto] Autonomous Univ Nuevo Leon, Sch Med, Dept Histol, Monterrey 64460, NL, Mexico; [Garza-Morales, Rodolfo; Gomez-Gutierrez, Jorge G.] Univ Louisville, Sch Med, Dept Surg, Louisville, KY 40202 USA; [Saucedo-Cardenas, Odila] Mexican Inst Social Secur IMSS, Northeast Biomed Res Ctr, Dept Mol Genet, Monterrey 64000, NL, Mexico		Montes-de-Oca-Luna, R (通讯作者)，Autonomous Univ Nuevo Leon, Sch Med, Dept Histol, Monterrey 64460, NL, Mexico.	alejandra.martinezpr@uanl.edu.mx; jperez.me0052@uanl.edu.mx; rodolfo.garzamorales@utrgv.edu; nramireza@avantsante.com; mdjesus.loeraars@uanl.edu.mx; jgguti01@louisville.edu; odila.saucedocr@uanl.edu.mx; aracely.garciagr@uanl.edu.mx; humberto.rodriguezrc@uanl.edu.mx; rrrmontes@gmail.com	Garcia-Garcia, Aracely/ABC-8905-2021; Garza-Morales, Rodolfo/AAI-2513-2020	Garcia-Garcia, Aracely/0000-0002-1699-9678; Loera-Arias, Maria de Jesus/0000-0001-9561-3624; Martinez-Perez, Alejandra G./0000-0001-8535-3910; Gomez-Gutierrez, Jorge G./0000-0003-3610-260X; Garza Morales, Rodolfo/0000-0002-3613-521X	National Council for Science and Technology (CONACYT)Consejo Nacional de Ciencia y Tecnologia (CONACyT) [255725]; Jewish Heritage Fund for Excellence Research Enhancement Grant Program at the University of Louisville, School of Medicine [OGMN190574M]; CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT)	This study received funding through a grant from the National Council for Science and Technology (CONACYT, grant No. 255725 (R.M.-d.-O.-L.) and in part by Jewish Heritage Fund for Excellence Research Enhancement Grant Program at the University of Louisville, School of Medicine (award #OGMN190574M, JGG). A-G.M-P. and N.E.R.-A. were recipients of scholarships from CONACYT.	Anand SK, 2013, ADV VIROL, V2013, DOI 10.1155/2013/738794; BLAIR GE, 1989, VIRUS RES, V14, P339, DOI 10.1016/0168-1702(89)90026-9; Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7; Deisseroth A, 2013, CANCER GENE THER, V20, P65, DOI 10.1038/cgt.2012.87; DUNCAN SJ, 1978, J GEN VIROL, V40, P45, DOI 10.1099/0022-1317-40-1-45; Ganly I, 2000, J VIROL, V74, P2895, DOI 10.1128/JVI.74.6.2895-2899.2000; Garza-Morales R, 2019, CANCERS, V11, DOI 10.3390/cancers11010096; Helmy KY, 2013, THER DELIV, V4, P1307, DOI [10.4155/TDE.13.88, 10.4155/tde.13.88]; Howells A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00195; Jiang H, 2011, J VIROL, V85, P4720, DOI 10.1128/JVI.02032-10; Jin CH, 2015, ONCOL REP, V33, P2837, DOI 10.3892/or.2015.3901; Jogler C, 2006, J VIROL, V80, P3549, DOI 10.1128/JVI.80.7.3549-3558.2006; Kamensek U, 2018, CANCER IMMUNOL IMMUN, V67, P785, DOI 10.1007/s00262-018-2133-0; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Khan Kishwar Hayat, 2013, Germs, V3, P26, DOI 10.11599/germs.2013.1034; Kim JW, 2017, MOL THER-ONCOLYTICS, V5, P97, DOI 10.1016/j.omto.2017.05.001; Klein SR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153814; Lee CS, 2017, GENES DIS, V4, P43, DOI 10.1016/j.gendis.2017.04.001; Lee HW, 2002, J IMMUNOL, V169, P4882, DOI 10.4049/jimmunol.169.9.4882; Li SY, 2013, CLIN PHARMACOL-ADV A, V5, P47, DOI 10.2147/CPAA.S46199; Lin KY, 1996, CANCER RES, V56, P21; Loera-Arias MJ, 2010, J CELL MOL MED, V14, P890, DOI 10.1111/j.1582-4934.2009.00934.x; Lopes A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1154-7; Luo J, 2007, NAT PROTOC, V2, P1236, DOI 10.1038/nprot.2007.135; Lyle C, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-148; Ma J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2236-3; Perez-Trujillo JJ, 2017, ONCOL LETT, V13, P1569, DOI 10.3892/ol.2017.5635; Plummer M, 2016, LANCET GLOB HEALTH, V4, pE609, DOI 10.1016/S2214-109X(16)30143-7; Ragonnaud E, 2016, VACCINE, V34, P2147, DOI 10.1016/j.vaccine.2015.06.087; Rai Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19930-w; Vinay DS, 2012, MOL CANCER THER, V11, P1062, DOI 10.1158/1535-7163.MCT-11-0677; Wold WSM, 2013, CURR GENE THER, V13, P421; Wu Q., ADENOVIRUS MEDIATED	33	6	6	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							149	10.3390/vaccines9020149			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6XS	33673295	Green Published, gold			2022-04-29	WOS:000623285200001
J	Penkert, RR; Patel, N; Webby, RJ; Ross, TM; Hurwitz, JL				Penkert, Rhiannon R.; Patel, Nehali; Webby, Richard J.; Ross, Ted M.; Hurwitz, Julia L.			Month of Influenza Virus Vaccination Influences Antibody Responses in Children and Adults	VACCINES			English	Article						month; influenza virus; immune response; vaccination; hemagglutination inhibition		The improvement of influenza virus vaccines and the development of a universal product have been long-standing goals in pre-clinical and clinical research. To meet these goals and to understand the strengths and weaknesses of current vaccine strategies, scientists routinely study human responses toward seasonal influenza vaccines. This research is frequently performed with clinical samples taken throughout an influenza season, often without strict attention to the month of inoculation for each study participant. Here, we ask how the timing of vaccination affects outcomes. Results demonstrate significant influences of inoculation month on the immune response. During the progression from fall to winter months, there are changes in host lifestyles and in the frequencies of clinical/sub-clinical viral infections that can significantly alter vaccine immunogenicity. We now recommend routine assessment of inoculation month during clinical studies to inform data interpretation and expedite the development of successful vaccines. This recommendation is pertinent to numerous vaccine development efforts within and outside the influenza virus field.	[Penkert, Rhiannon R.; Patel, Nehali; Webby, Richard J.; Hurwitz, Julia L.] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; [Webby, Richard J.; Hurwitz, Julia L.] Univ Tennessee, Ctr Hlth Sci, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA; [Ross, Ted M.] Univ Georgia, Dept Infect Dis, Ctr Vaccines & Immunol, Athens, GA 30602 USA		Hurwitz, JL (通讯作者)，St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA.; Hurwitz, JL (通讯作者)，Univ Tennessee, Ctr Hlth Sci, Dept Microbiol Immunol & Biochem, Memphis, TN 38163 USA.	rhiannon.penkert@stjude.org; nehali.patel@stjude.org; Richard.Webby@STJUDE.ORG; tedross@uga.edu; julia.hurwitz@stjude.org		Ross, Ted/0000-0003-1947-7469; Patel, Nehali/0000-0001-8329-9017	National Institutes of Health (NIH), National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA21765]; Collaborative Influenza Vaccine Innovation Centers (CIVIC) by the National Institute of Allergy and Infectious Diseases, a component of the NIH, Department of Health and Human Services [75N93019C00052]; Georgia Research Alliance as an Eminent Scholar	This study was supported in part by the National Institutes of Health (NIH), National Cancer Institute P30CA21765, ALSAC, and by the Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract by the National Institute of Allergy and Infectious Diseases, a component of the NIH, Department of Health and Human Services, under contract 75N93019C00052. Ted M. Ross was also funded, in part, by the Georgia Research Alliance as an Eminent Scholar.	Blanton L, 2017, MMWR-MORBID MORTAL W, V66, P668, DOI 10.15585/mmwr.mm6625a3; Chesney RW, 2010, J PEDIATR-US, V156, P698, DOI 10.1016/j.jpeds.2010.02.002; Chow EJ, 2018, MMWR-MORBID MORTAL W, V67, P1178, DOI 10.15585/mmwr.mm6742a3; de Bourcy CFA, 2017, P NATL ACAD SCI USA, V114, P1105, DOI 10.1073/pnas.1617959114; Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103; Furuya-Kanamori L, 2018, EMERG INFECT DIS, V24, P950, DOI 10.3201/eid2405.180075; Hayward AC, 2014, LANCET RESP MED, V2, P445, DOI 10.1016/S2213-2600(14)70034-7; Lopez CE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030434; Patel N, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100907; Huang FS, 2021, HUM VACC IMMUNOTHER, V17, P554, DOI 10.1080/21645515.2020.1779517; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906	11	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							68	10.3390/vaccines9020068			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6UH	33498232	gold, Green Published			2022-04-29	WOS:000623276100001
J	Wang, GR; Zhao, JL; Zhao, YS; Wang, SB; Feng, SJ; Gu, GF				Wang, Guirong; Zhao, Jielin; Zhao, Yisheng; Wang, Subo; Feng, Shaojie; Gu, Guofeng			Immunogenicity Assessment of Different Segments and Domains of Group a Streptococcal C5a Peptidase and Their Application Potential as Carrier Protein for Glycoconjugate Vaccine Development	VACCINES			English	Article						group A streptococcus; group A streptococcal C5a peptidase; subunit protein vaccine; immunogenicity; carrier protein		Group A streptococcal C5a peptidase (ScpA) is a highly conserved surface virulence factor present on group A streptococcus (GAS) cell surfaces. It has attracted much more attention as a promising antigenic target for GAS vaccine development due to its high antigenicity to stimulate specific and immunoprotective antibodies. In this study, a series of segments of ScpA were rationally designed according to the functional domains described in its crystal structure, efficiently prepared and immunologically evaluated so as to assess their potential as antigens for the development of subunit vaccines. Immunological studies revealed that Fn, Fn2, and rsScpA193 proteins were promising antigen candidates worthy for further exploration. In addition, the potential of Fn and Fn2 as carrier proteins to formulate effective glycoconjugate vaccine was also investigated.	[Gu, Guofeng] Shandong Univ, Natl Glycoengn Res Ctr, 72 Binhai Rd, Qingdao 266237, Peoples R China; Shandong Univ, Shandong Key Lab Carbohydrate Chem & Glycobiol, 72 Binhai Rd, Qingdao 266237, Peoples R China		Gu, GF (通讯作者)，Shandong Univ, Natl Glycoengn Res Ctr, 72 Binhai Rd, Qingdao 266237, Peoples R China.	wanggr@mail.sdu.edu.cn; zjl8212175@163.com; shrinelibra@gmail.com; wang_subo@163.com; fengsj1989@126.com; guofenggu@sdu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [21877074]; Science and Technology Development Project of Shandong Province [2019GSF108018]	This research was funded by the National Natural Science Foundation of China (grant number 21877074) and the Science and Technology Development Project of Shandong Province (grant number 2019GSF108018).	Anderson ET, 2002, EUR J BIOCHEM, V269, P4839, DOI 10.1046/j.1432-1033.2002.03183.x; Auzanneau FI, 2013, BIOORG MED CHEM LETT, V23, P6038, DOI 10.1016/j.bmcl.2013.09.042; Batzloff MR, 2003, J INFECT DIS, V187, P1598, DOI 10.1086/374800; Bensi G, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.015693; Bi S, 2019, MBIO, V10, DOI 10.1128/mBio.02600-19; Bonam SR, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105684; Brown CK, 2005, P NATL ACAD SCI USA, V102, P18391, DOI 10.1073/pnas.0504954102; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; CHEN CC, 1990, J BIOL CHEM, V265, P3161; Chmouryguina I, 1996, INFECT IMMUN, V64, P2387, DOI 10.1128/IAI.64.7.2387-2390.1996; Cleary PP, 2004, VACCINE, V22, P4332, DOI 10.1016/j.vaccine.2004.04.030; CLEARY PP, 1992, INFECT IMMUN, V60, P4239, DOI 10.1128/IAI.60.10.4239-4244.1992; CLEARY PP, 1992, INFECT IMMUN, V60, P5219, DOI 10.1128/IAI.60.12.5219-5223.1992; Cunningham MW, 2008, ADV EXP MED BIOL, V609, P29, DOI 10.1007/978-0-387-73960-1_3; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Dale JB, 2020, CURR OPIN INFECT DIS, V33, P244, DOI 10.1097/QCO.0000000000000644; Dale JB, 2013, VACCINE, V31, pB216, DOI 10.1016/j.vaccine.2012.09.045; Dale JB, 2011, VACCINE, V29, P8175, DOI 10.1016/j.vaccine.2011.09.005; Feng SJ, 2020, ACS INFECT DIS, V6, P2181, DOI 10.1021/acsinfecdis.0c00260; Georgousakis MM, 2009, EXPERT REV VACCINES, V8, P747, DOI [10.1586/erv.09.33, 10.1586/ERV.09.33]; Guilherme L, 2009, METHODS, V49, P316, DOI 10.1016/j.ymeth.2009.03.024; Henningham A, 2013, CURR TOP MICROBIOL, V368, P207, DOI 10.1007/82_2012_284; Ji YD, 1996, INFECT IMMUN, V64, P503, DOI 10.1128/IAI.64.2.503-510.1996; Ji YD, 1997, INFECT IMMUN, V65, P2080, DOI 10.1128/IAI.65.6.2080-2087.1997; Kabanova A, 2010, VACCINE, V29, P104, DOI 10.1016/j.vaccine.2010.09.018; Kagawa TF, 2009, J MOL BIOL, V386, P754, DOI 10.1016/j.jmb.2008.12.074; Kotloff KL, 2004, JAMA-J AM MED ASSOC, V292, P709, DOI 10.1001/jama.292.6.709; Lefeber DJ, 2003, INFECT IMMUN, V71, P6915, DOI 10.1128/IAI.71.12.6915-6920.2003; Li H, 2017, RSC ADV, V7, P42056, DOI 10.1039/c7ra07923k; Manthey HD, 2009, INT J BIOCHEM CELL B, V41, P2114, DOI 10.1016/j.biocel.2009.04.005; Mazumdar T, 2004, VACCINE, V22, P1162, DOI 10.1016/j.vaccine.2003.09.030; McNeil SA, 2005, CLIN INFECT DIS, V41, P1114, DOI 10.1086/444458; Michaelsen TE, 2004, SCAND J IMMUNOL, V59, P34, DOI 10.1111/j.0300-9475.2004.01362.x; Mygind T, 2004, FEMS IMMUNOL MED MIC, V40, P129, DOI 10.1016/S0928-8244(03)00300-6; OCONNOR SP, 1991, J INFECT DIS, V163, P109, DOI 10.1093/infdis/163.1.109; Pitirollo O, 2020, BIOORG CHEM, V99, DOI 10.1016/j.bioorg.2020.103815; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; Rivera-Hernandez T, 2020, MBIO, V11, DOI 10.1128/mBio.00122-20; Rivera-Hernandez T, 2019, MBIO, V10, DOI 10.1128/mBio.00693-19; Rodriguez-Ortega MJ, 2006, NAT BIOTECHNOL, V24, P191, DOI 10.1038/nbt1179; Sabharwal H, 2006, J INFECT DIS, V193, P129, DOI 10.1086/498618; Sheel M, 2016, EXPERT REV VACCINES, V15, P227, DOI 10.1586/14760584.2016.1116946; Shet A, 2003, J INFECT DIS, V188, P809, DOI 10.1086/377700; Stafslien DK, 2000, J BACTERIOL, V182, P3254, DOI 10.1128/JB.182.11.3254-3258.2000; Steer AC, 2013, PEDIATR INFECT DIS J, V32, P180, DOI 10.1097/INF.0b013e318281da11; Steer AC, 2009, CURR OPIN INFECT DIS, V22, P544, DOI 10.1097/QCO.0b013e328332bbfe; van Sorge NM, 2014, CELL HOST MICROBE, V15, P729, DOI 10.1016/j.chom.2014.05.009; Walker MJ, 2014, CLIN MICROBIOL REV, V27, P264, DOI 10.1128/CMR.00101-13; Wang SB, 2020, ACS INFECT DIS, V6, P281, DOI 10.1021/acsinfecdis.9b00347; Watkins DA, 2017, NEW ENGL J MED, V377, P713, DOI 10.1056/NEJMoa1603693; Xu ZH, 2020, ACS INFECT DIS, V6, P1770, DOI 10.1021/acsinfecdis.0c00047; Zhao YS, 2019, ORG CHEM FRONT, V6, P3589, DOI 10.1039/c9qo00651f	52	0	0	4	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							139	10.3390/vaccines9020139			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6YZ	33572233	Green Published			2022-04-29	WOS:000623288600001
J	Zeng, WW; Wang, YY; Hu, HZ; Wang, Q; Bergmann, SM; Wang, YH; Li, B; Lv, YF; Li, H; Yin, JY; Li, YY				Zeng, Weiwei; Wang, Yingying; Hu, Huzi; Wang, Qing; Bergmann, Sven M.; Wang, Yahui; Li, Bo; Lv, Yuefeng; Li, Hua; Yin, Jiyuan; Li, Yingying			Cell Culture-Derived Tilapia Lake Virus-Inactivated Vaccine Containing Montanide Adjuvant Provides High Protection against Viral Challenge for Tilapia	VACCINES			English	Article						inactivated vaccine; tilapia lake virus; adjuvant; protection	GINBUNA CRUCIAN CARP; OREOCHROMIS-NILOTICUS; NILE TILAPIA; YERSINIA-RUCKERI; INFECTION; EFFICACY; IDENTIFICATION; TILV; FISH; VIRULENCE	Tilapia lake virus (TiLV) is a newly emerging pathogen responsible for high mortality and economic losses in the global tilapia industry. Currently, no antiviral therapy or vaccines are available for the control of this disease. The goal of the present study was to evaluate the immunological effects and protective efficacy of formaldehyde- and beta-propiolactone-inactivated vaccines against TiLV in the presence and absence of the Montanide IMS 1312 VG adjuvant in tilapia. We found that beta-propiolactone inactivation of viral particles generated a vaccine with a higher protection efficacy against virus challenge than did formaldehyde. The relative percent survivals of vaccinated fish at doses of 10(8), 10(7), and 10(6) 50% tissue culture infectious dose (TCID50)/mL were 42.9%, 28.5%, and 14.3% in the absence of the adjuvant and 85.7%, 64.3%, and 32.1% in its presence, respectively. The vaccine generated specific IgM and neutralizing antibodies against TiLV at 3 weeks following immunization that were significantly increased after a second booster immunization. The steady state mRNA levels of the genes tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), interferon gamma (IFN-gamma), cluster of differentiation 4 (CD4), major histocompatibility complex (MHC)-Ia, and MHC-II were all increased and indicated successful immune stimulation against TiLV. The vaccine also significantly lowered the viral loads and resulted in significant increases in survival, indicating that the vaccine may also inhibit viral proliferation as well as stimulate a protective antibody response. The beta-propiolactone-inactivated TiLV vaccine coupled with the adjuvant Montanide IMS 1312 VG and booster immunizations can provide a high level of protection from virus challenge in tilapia.	[Zeng, Weiwei; Li, Hua; Yin, Jiyuan] Foshan Univ, Sch Life Sci & Engn, Guangdong Prov Key Lab Anim Mol Design & Precise, Foshan 528000, Peoples R China; [Zeng, Weiwei; Wang, Yingying; Hu, Huzi; Wang, Qing; Wang, Yahui; Li, Bo; Lv, Yuefeng; Li, Yingying] Chinese Acad Fishery Sci, Pearl River Fisheries Res Inst, Key Lab Aquat Anim Immune Technol, Minist Agr,Key Lab Fishery Drug Dev, Guangzhou 510380, Peoples R China; [Bergmann, Sven M.] Friedrich Loffler Inst FLI, Inst Infectol, Fed Res Inst Anim Hlth, D-17493 Greifswald, Germany		Zeng, WW (通讯作者)，Foshan Univ, Sch Life Sci & Engn, Guangdong Prov Key Lab Anim Mol Design & Precise, Foshan 528000, Peoples R China.; Zeng, WW; Wang, Q (通讯作者)，Chinese Acad Fishery Sci, Pearl River Fisheries Res Inst, Key Lab Aquat Anim Immune Technol, Minist Agr,Key Lab Fishery Drug Dev, Guangzhou 510380, Peoples R China.	davy988@prfri.ac.cn; eagles5257@prfri.ac.cn; huhuzi@liyang-tech.com; wangqing@prfri.ac.cn; Sven.Bergmann@fli.de; 1904028156@stu.tjau.edu.cn; m190100122@st.shou.edu.cn; 1904028142@stu.tjau.edu.cn; okhuali@fosu.edu.cn; yinjiyuan@prfri.ac.cn; liyingying@prfri.ac.cn		Bergmann, Sven M./0000-0002-3685-7159	Guangdong Provincial Special Fund For Modern Agriculture Industry Technology Innovation Teams [2020KJ119]; Natural Science Foundation of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2018A030313757]	Funding for this research was provided by Guangdong Provincial Special Fund For Modern Agriculture Industry Technology Innovation Teams (2020KJ119) and Natural Science Foundation of Guangdong Province (2018A030313757).	Acharya V, 2019, MOL BIOTECHNOL, V61, P945, DOI 10.1007/s12033-019-00217-y; Amal MNA, 2018, AQUACULTURE, V485, P12, DOI 10.1016/j.aquaculture.2017.11.019; Amend DF., 1981, FISH BIOLOGICS SEROD, V49, P447; Angenvoort J, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-41; [Anonymous], 2019, TIL LAK VIR US IMM N; Arita M, 2011, CLIN VACCINE IMMUNOL, V18, P1889, DOI 10.1128/CVI.05225-11; Assis GBN, 2017, J FISH DIS, V40, P51, DOI 10.1111/jfd.12493; Aucouturier J, 2000, ANN NY ACAD SCI, V916, P600, DOI 10.1111/j.1749-6632.2000.tb05343.x; Bacharach E, 2016, MBIO, V7, DOI 10.1128/mBio.00431-16; BAHNEMANN HG, 1990, VACCINE, V8, P299, DOI 10.1016/0264-410X(90)90083-X; Brudeseth BE, 2013, FISH SHELLFISH IMMUN, V35, P1759, DOI 10.1016/j.fsi.2013.05.029; del-Pozo J, 2017, VET PATHOL, V54, P164, DOI 10.1177/0300985816658100; Delrue I, 2012, EXPERT REV VACCINES, V11, P695, DOI [10.1586/erv.12.38, 10.1586/ERV.12.38]; Dinesh R., 2017, J ENTOMOL ZOOL STUD, V5, P605; Dong HT, 2017, AQUACULTURE, V479, P579, DOI 10.1016/j.aquaculture.2017.06.035; Dong HT, 2017, AQUACULTURE, V476, P111, DOI 10.1016/j.aquaculture.2017.04.019; Ellis A.E., 1988, FISH VACCINATION, P2; Evensen O, 2013, FISH SHELLFISH IMMUN, V35, P1751, DOI 10.1016/j.fsi.2013.10.021; Eyngor M, 2014, J CLIN MICROBIOL, V52, P4137, DOI 10.1128/JCM.00827-14; FAO, 2004, REP FAO INERA WORKSH; FAO, GLOBAL AQUACULTURE P; FAO, 2016, STATE WORLD FISHERIE; FAO, 2018, STATE WORLD FISHERIE; Fathi M, 2017, AQUACULTURE, V473, P430, DOI 10.1016/j.aquaculture.2017.03.014; Ferguson HW, 2014, J FISH DIS, V37, P583, DOI 10.1111/jfd.12142; Figueiredo HCP, 2005, J FISH DIS, V28, P199, DOI 10.1111/j.1365-2761.2005.00616.x; Frazatti-Gallina NM, 2004, VACCINE, V23, P511, DOI 10.1016/j.vaccine.2004.06.014; Gallage S, 2016, FISH SHELLFISH IMMUN, V51, P271, DOI 10.1016/j.fsi.2016.02.024; Hassan Mohamed A., 2017, Egyptian Journal of Aquatic Research, V43, P161; Hjeltnes B, 2017, HLTH SITUATION NORWE; Hu HZ, 2020, AQUACULTURE, V520, DOI 10.1016/j.aquaculture.2019.734756; Pulido LLH, 2019, AQUACULTURE, V510, P61, DOI 10.1016/j.aquaculture.2019.04.058; Huang HY, 2014, VACCINE, V32, P7014, DOI 10.1016/j.vaccine.2014.08.039; Hwang JY, 2017, FISH SHELLFISH IMMUN, V60, P420, DOI 10.1016/j.fsi.2016.12.011; Jansen M.D., 2017, FISH04 CGIAR RES PRO; Jansen MD, 2019, REV AQUACULT, V11, P725, DOI 10.1111/raq.12254; Jiang HY, 2019, FISH SHELLFISH IMMUN, V84, P768, DOI 10.1016/j.fsi.2018.10.008; Khimmakthong U, 2013, MICROB PATHOGENESIS, V59-60, P33, DOI 10.1016/j.micpath.2013.03.001; Koesharyani I., 2018, JURNAL RISET AKUAKUL, V13, P85; Li XY, 2017, FISH SHELLFISH IMMUN, V70, P1, DOI 10.1016/j.fsi.2017.08.042; Liamnimitr P, 2018, AQUACULTURE, V486, P75, DOI 10.1016/j.aquaculture.2017.12.015; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo SX, 2015, J MICROBIOL BIOTECHN, V25, P2135, DOI 10.4014/jmb.1505.05041; Matsuura Y, 2019, FISH SHELLFISH IMMUN, V95, P236, DOI 10.1016/j.fsi.2019.09.031; Mian GF, 2009, VET MICROBIOL, V136, P180, DOI 10.1016/j.vetmic.2008.10.016; Mo XB, 2020, AQUACULTURE, V518, DOI 10.1016/j.aquaculture.2019.734774; Monath TP, 2011, NEW ENGL J MED, V364, P1326, DOI 10.1056/NEJMoa1009303; Mugimba KK, 2018, J FISH DIS, V41, P1181, DOI 10.1111/jfd.12790; NACA, 2017, URG UPD POSS WORLDW; Nanthini R, 2019, J FISH DIS, V42, P1543, DOI 10.1111/jfd.13075; Nayak SK, 2014, FISH SHELLFISH IMMUN, V39, P354, DOI 10.1016/j.fsi.2014.05.015; Hai NV, 2015, FISH SHELLFISH IMMUN, V45, P592, DOI 10.1016/j.fsi.2015.05.026; Nicholson P, 2017, J FISH DIS, V40, P1925, DOI 10.1111/jfd.12650; O'Hagan Derek T, 2003, Expert Rev Vaccines, V2, P269, DOI 10.1586/14760584.2.2.269; OIE, 2019, TIL LAK VIR DIS TILV; OIE, 2017, TIL LAK VIR TILV NOV; Overgard AC, 2012, MOL BIOL REP, V39, P2201, DOI 10.1007/s11033-011-0969-x; Pamela N., 2020, AQUACULTURE, V520; Pang JC, 2013, FISH SHELLFISH IMMUN, V34, P486, DOI 10.1016/j.fsi.2012.11.048; Pereira RC, 2015, VACCINE, V33, P4261, DOI 10.1016/j.vaccine.2015.03.077; POLI G, 1995, INT J CLIN LAB RES, V25, P128, DOI 10.1007/BF02592553; Rao YL, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/670437; Silva MSE, 2013, VACCINE, V31, P1045, DOI 10.1016/j.vaccine.2012.12.044; Salonius K, 2007, CURR OPIN INVEST DR, V8, P635; Senapin S, 2018, AQUACULTURE, V487, P51, DOI 10.1016/j.aquaculture.2018.01.007; Soltani M, 2014, FISH SHELLFISH IMMUN, V37, P60, DOI 10.1016/j.fsi.2013.12.027; Somamoto T, 2005, DEV COMP IMMUNOL, V29, P693, DOI 10.1016/j.dci.2004.11.006; Sommerset I, 2005, EXPERT REV VACCINES, V4, P89, DOI 10.1586/14760584.4.1.89; Soto-Rodriguez SA, 2013, J APPL MICROBIOL, V115, P654, DOI 10.1111/jam.12280; Stauffer Fausto, 2006, Recent Pat Antiinfect Drug Discov, V1, P291, DOI 10.2174/157489106778777673; Surachetpong W, 2017, EMERG INFECT DIS, V23, P1031, DOI 10.3201/eid2306.161278; Tattiyapong P, 2017, VET MICROBIOL, V207, P170, DOI 10.1016/j.vetmic.2017.06.014; Thammatorn W, 2019, J FISH DIS, V42, P3, DOI 10.1111/jfd.12924; Tsofack JEK, 2017, J CLIN MICROBIOL, V55, P759, DOI 10.1128/JCM.01808-16; Wang QC, 2020, FISH SHELLFISH IMMUN, V96, P223, DOI 10.1016/j.fsi.2019.12.010; Wang Wei, 2012, Journal of Shanghai Ocean University, V21, P976; Wang YY, 2018, J FISH DIS, V41, P1803, DOI 10.1111/jfd.12889; Woo PTK, 2017, FISH VIRUSES AND BACTERIA: PATHOBIOLOGY AND PROTECTION, pXI, DOI 10.1079/9781780647784.0000; Yamkasem J, 2019, J FISH DIS, V42, P1293, DOI 10.1111/jfd.13050; Yang M, 2010, FISH SHELLFISH IMMUN, V28, P289, DOI 10.1016/j.fsi.2009.11.007; Yao YY, 2019, FISH SHELLFISH IMMUN, V86, P999, DOI 10.1016/j.fsi.2018.12.060; Zeng WW, 2016, FISH SHELLFISH IMMUN, V54, P473, DOI 10.1016/j.fsi.2016.04.133; Zou Jun, 2016, Biology-Basel, V5, P23, DOI 10.3390/biology5020023	83	8	8	1	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							86	10.3390/vaccines9020086			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6ZJ	33503930	gold, Green Published			2022-04-29	WOS:000623289600001
J	Gao, T; Gao, CX; Wu, SY; Wang, YY; Yin, JY; Li, YY; Zeng, WW; Bergmann, SM; Wang, Q				Gao, Ting; Gao, Caixia; Wu, Siyu; Wang, Yingying; Yin, Jiyuan; Li, Yingying; Zeng, Weiwei; Bergmann, Sven M.; Wang, Qing			Recombinant Baculovirus-Produced Grass Carp Reovirus Virus-Like Particles as Vaccine Candidate That Provides Protective Immunity against GCRV Genotype II Infection in Grass Carp	VACCINES			English	Article						grass carp reovirus (GCRV); genotype II; virus-like particles; vaccine; grass carp		Grass carp reovirus (GCRV) leads to severe hemorrhagic disease in grass carp (Ctenopharyngodon idella) and causes economic losses in grass carp aquaculture. Recent epidemiological investigations showed that GCRV genotype II is the dominant subtype in China. Therefore, it is very important to develop a novel vaccine for preventing diseases caused by GCRV genotype II. In this study, we employed a bac-to-bac expression system to generate GCRV-II-based virus-like particles (VLPs). Previous studies have shown that the structural proteins VP3, VP4, and VP38 encoded by the segments S3, S6, and S10 of type II GCRV are immunogenic. Hence, the GCRV-VLPs were produced by co-infection of sf9 cells with recombinant baculoviruses PFBH-VP3, PFBH-VP4, and PFBH-VP38. The expressions of VP3, VP4, and VP38 proteins in GCRV-VLPs were tested by IFA and Western blot analysis. By electron microscopic observations of ultrathin sections, purified VLPs showed that the expressed proteins are similar in shape to GCRV genotype II with a size range from 40 nm to 60 nm. The immunogenicity of GCRV-VLPs was evaluated by the injection immunization of grass carp. The analysis of serum-specific IgM antibody showed that grass carp immunized with GCRV-VLPs produced GCRV-specific antibodies. Furthermore, injection with GCRV-VLPs increased the expressions of immune-related genes (IgM, IFN, TLR3, TLR7) in the spleen and kidney. In addition, grass carp immunized with a GCRV-VLPs-based vaccine showed a relative percent survival rate (RPS) of 83.33% after challenge. The data in this study showed that GCRV-VLPs demonstrated an excellent immunogenicity and represent a promising approach for vaccine development against GCRV genotype II infection.	[Gao, Ting; Gao, Caixia; Wu, Siyu; Wang, Yingying; Yin, Jiyuan; Li, Yingying; Wang, Qing] Chinese Acad Fishery Sci, Pearl River Fisheries Res Inst, Key Lab Aquat Anim Immune Technol Guangdong Prov, Key Lab Fishery Drug Creat,Minist Agr & Rural Are, Guangzhou 510380, Peoples R China; [Gao, Ting; Gao, Caixia] Tianjin Agr Univ, Dept Aquatecture, Tianjin 300384, Peoples R China; [Zeng, Weiwei] Foshan Univ, Key Lab Anim Mol Design & Precise Breeding, Guangdong Prov Key Lab Anim Mol Design & Precise, Guangdong Higher Educ Inst,Sch Life Sci & Engn, Foshan 440605, Peoples R China; [Bergmann, Sven M.] Fed Res Inst Anim Hlth, Friedrich Loeffler Inst FLI, Inst Infectiol, D-17493 Greifswald, Germany		Wang, Q (通讯作者)，Chinese Acad Fishery Sci, Pearl River Fisheries Res Inst, Key Lab Aquat Anim Immune Technol Guangdong Prov, Key Lab Fishery Drug Creat,Minist Agr & Rural Are, Guangzhou 510380, Peoples R China.	gaoting@prfri.ac.cn; gaocaixia@prfri.ac.cn; wusiyu@prfri.ac.cn; eagles5257@prfri.ac.cn; yinjiyuan@prfri.ac.cn; liyingying@prfri.ac.cn; davy988@prfri.ac.cn; Sven.Bergmann@fli.de; wangqing@prfri.ac.cn	Gao, Caixia/AAE-9570-2021	Bergmann, Sven M./0000-0002-3685-7159	National Key R&D Program of China [2019YFD0900103]; China Agriculture Research System [CARS-45]; Science and Technology Planning Project of Guangdong Province [2016B020234003]; Guangdong Provincial Special Fund For Modern Agriculture Industry Technology Innovation Teams [2019KJ119, 2019KJ150]; The Dedicated Fund for Promoting High-Quality Economic Development in Guangdong Province (Marine Economic Development Project) [GDOE [2019] A29]	1 1 This work was supported by the National Key R&D Program of China (2019YFD0900103), the China Agriculture Research System (Grant No. CARS-45), The Science and Technology Planning Project of Guangdong Province (2016B020234003), Guangdong Provincial Special Fund For Modern Agriculture Industry Technology Innovation Teams (2019KJ119; 2019KJ150), and The Dedicated Fund for Promoting High-Quality Economic Development in Guangdong Province (Marine Economic Development Project) (GDOE [2019] A29).	Ailor E, 1999, CURR OPIN BIOTECH, V10, P142, DOI 10.1016/S0958-1669(99)80024-X; Attoui H, 2002, J GEN VIROL, V83, P1941, DOI 10.1099/0022-1317-83-8-1941; Berger I, 2004, NAT BIOTECHNOL, V22, P1583, DOI 10.1038/nbt1036; Cao L, 2015, SCIENCE, V347, P133, DOI 10.1126/science.1260149; Chan HLY, 2011, J HEPATOL, V55, P1121, DOI 10.1016/j.jhep.2011.06.006; Chang LJ, 2014, LANCET, V384, P2046, DOI 10.1016/S0140-6736(14)61185-5; Chen DD, 2018, FISH SHELLFISH IMMUN, V75, P66, DOI 10.1016/j.fsi.2018.01.047; Chen LJ, 2013, FISH SHELLFISH IMMUN, V34, P909, DOI 10.1016/j.fsi.2013.01.003; Collins C, 2019, FISH SHELLFISH IMMUN, V85, P106, DOI 10.1016/j.fsi.2018.07.012; Fan YD, 2018, FISH SHELLFISH IMMUN, V72, P629, DOI 10.1016/j.fsi.2017.11.044; Fang Q, 2000, BIOCHEM BIOPH RES CO, V274, P762, DOI 10.1006/bbrc.2000.3215; Feng XL, 2014, DEV COMP IMMUNOL, V45, P278, DOI 10.1016/j.dci.2014.03.018; Fillatreau S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00028; FRAENKELCONRAT H, 1955, P NATL ACAD SCI USA, V41, P690, DOI 10.1073/pnas.41.10.690; Gao Y, 2018, VACCINE, V36, P3613, DOI 10.1016/j.vaccine.2018.05.043; Han X, 2020, FISH SHELLFISH IMMUN, V98, P962, DOI 10.1016/j.fsi.2019.11.062; Ho JKT, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020126; Jeong KH, 2020, FISH SHELLFISH IMMUN, V100, P49, DOI 10.1016/j.fsi.2020.02.060; Ji QY, 2020, IMMUNOL LETT, V226, P46, DOI 10.1016/j.imlet.2020.07.002; Jiang HY, 2019, FISH SHELLFISH IMMUN, V84, P768, DOI 10.1016/j.fsi.2018.10.008; Li GX, 2017, FISH SHELLFISH IMMUN, V60, P400, DOI 10.1016/j.fsi.2016.12.012; Lin CF, 2018, FISH SHELLFISH IMMUN, V74, P551, DOI 10.1016/j.fsi.2018.01.029; Liu SX, 2019, MICROB PATHOGENESIS, V136, DOI 10.1016/j.micpath.2019.103715; Lu LF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.545302; Luu VT, 2017, J MICROBIOL, V55, P655, DOI 10.1007/s12275-017-7218-5; Magadan S, 2015, RESULTS PROBL CELL D, V57, P235, DOI 10.1007/978-3-319-20819-0_10; Marsian J, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00880; Mohsen MO, 2020, IMMUNOL REV, V296, P155, DOI 10.1111/imr.12863; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Mu CY, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9110945; Qiu T, 2001, DIS AQUAT ORGAN, V44, P69, DOI 10.3354/dao044069; Rao YL, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/670437; Roden RBS, 2018, NAT REV CANCER, V18, P240, DOI 10.1038/nrc.2018.13; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Stefan KL, 2020, CELL, V183, P1312, DOI 10.1016/j.cell.2020.10.047; Su H, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10040560; Su H, 2018, FISH SHELLFISH IMMUN, V83, P84, DOI 10.1016/j.fsi.2018.09.003; Subramanian K, 1997, J GEN VIROL, V78, P1385, DOI 10.1099/0022-1317-78-6-1385; Tian YY, 2013, FISH SHELLFISH IMMUN, V35, P351, DOI 10.1016/j.fsi.2013.04.022; Wang B, 2014, DEV COMP IMMUNOL, V47, P140, DOI 10.1016/j.dci.2014.07.006; Wang Q, 2012, J VIROL, V86, P12466, DOI 10.1128/JVI.02333-12; Zeng WW, 2018, J FISH DIS, V41, P1811, DOI 10.1111/jfd.12890; Zeng WW, 2016, FISH SHELLFISH IMMUN, V54, P473, DOI 10.1016/j.fsi.2016.04.133; Zhang QY, 2015, SCI CHINA LIFE SCI, V58, P156, DOI 10.1007/s11427-015-4802-y	44	1	1	9	16	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							53	10.3390/vaccines9010053			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6WP	33466933	Green Published, gold			2022-04-29	WOS:000610812800001
J	Jalkh, G; Nahed, RA; Macaron, G; Rensel, M				Jalkh, Georges; Abi Nahed, Rachelle; Macaron, Gabrielle; Rensel, Mary			Safety of Newer Disease Modifying Therapies in Multiple Sclerosis	VACCINES			English	Review						multiple sclerosis; disease modifying therapies; safety; long-term outcomes	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; NON-HODGKIN-LYMPHOMA; TUMEFACTIVE DEMYELINATION; FINGOLIMOD TREATMENT; DIMETHYL FUMARATE; NATALIZUMAB; PATIENT; INFECTIONS; RISK; TERIFLUNOMIDE	In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly. Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions are increasingly used early in the disease course. These newer DMTs include oral therapies (teriflunomide, dimethyl fumarate, fingolimod, siponimod, ozanimod, and cladribine) and infusion therapies (natalizumab, alemtuzumab, and ocrelizumab), and are associated with better control of disease activity and long-term outcomes in patients with MS compared to older injectable therapies (interferon beta and glatiramer acetate). However, they are associated with safety concerns and subsequent monitoring requirements. Adverse events are initially observed in phase 2 and 3 clinical trials, and further long-term data are collected in phase 3 extension studies, case series, and post-marketing reports, which highlight the need to periodically re-evaluate and adjust monitoring strategies to optimize treatment safety in an individualized approach.	[Jalkh, Georges; Abi Nahed, Rachelle; Macaron, Gabrielle] Univ St Joseph, Fac Med, Dept Neurol, BP 11-5076, Beirut, Lebanon; [Jalkh, Georges; Abi Nahed, Rachelle; Macaron, Gabrielle] Hotel Dieu France Hosp, Dept Neurol, Beirut 166830, Lebanon; [Macaron, Gabrielle; Rensel, Mary] Cleveland Clin Fdn, Neurol Inst, Mellen Ctr Multiple Sclerosis, 9500 Euclid Ave, Cleveland, OH 44195 USA		Rensel, M (通讯作者)，Cleveland Clin Fdn, Neurol Inst, Mellen Ctr Multiple Sclerosis, 9500 Euclid Ave, Cleveland, OH 44195 USA.	georges.jalkh@net.usj.edu.lb; rachelle.abinahed@net.usj.edu.lb; gabrielle.macaron@hdf.usj.edu.lb; renselm@ccf.org		Rensel, Mary/0000-0001-9613-8394; Macaron, Gabrielle/0000-0002-7303-2332			Abbi KKS, 2010, LEUKEMIA RES, V34, pE154, DOI 10.1016/j.leukres.2010.02.036; Achtnichts L, 2015, JAMA NEUROL, V72, P1203, DOI 10.1001/jamaneurol.2015.1746; Alping P, 2020, ANN NEUROL, V87, P688, DOI 10.1002/ana.25701; Alstadhaug KB, 2017, J CLIN VIROL, V88, P17, DOI 10.1016/j.jcv.2016.12.005; Anene-Maidoh TI, 2018, INTERDISCIP NEUROSUR, V12, P8, DOI 10.1016/j.inat.2017.10.005; [Anonymous], 2018, Drug Ther Bull, V56, P38, DOI 10.1136/dtb.2018.4.0604; Aruta F, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.102023; Avasarala Jagannadha, 2015, F1000Res, V4, P1450, DOI 10.12688/f1000research.7513.3; Azevedo CJ, 2019, LANCET NEUROL, V18, P329, DOI 10.1016/S1474-4422(19)30076-6; Barclay K, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00253; Barmettler S, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.4169; Barmettler S, 2015, J ALLERGY CLIN IMMUN, V136, P1407, DOI 10.1016/j.jaci.2015.06.035; Barrero F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230846; Barton J, 2017, NEUROLOGY, V88, P1004, DOI 10.1212/WNL.0000000000003694; Beattie W, 2019, J CLIN NEUROSCI, V60, P158, DOI 10.1016/j.jocn.2018.10.055; Behrangi N, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010024; Belani R, 2006, HEMATOL ONCOL CLIN N, V20, P1109, DOI 10.1016/j.hoc.2006.06.008; Benedetti MD, 2018, MULT SCLER RELAT DIS, V23, P24, DOI 10.1016/j.msard.2018.04.018; Berger JR, 2018, NEUROLOGY, V90, pE1815, DOI 10.1212/WNL.0000000000005529; Berger JR, 2018, J NEUROVIROL, V24, P323, DOI 10.1007/s13365-018-0615-7; Berghoff M, 2013, LEUKEMIA LYMPHOMA, V54, P1340, DOI 10.3109/10428194.2012.740669; Bermel RA, 2007, NEUROTHERAPEUTICS, V4, P633, DOI 10.1016/j.nurt.2007.07.001; Bermel RA, 2013, ANN NEUROL, V73, P95, DOI 10.1002/ana.23758; Bezabeh S, 2010, ALIMENT PHARM THER, V31, P1028, DOI 10.1111/j.1365-2036.2010.04262.x; Bianco A, 2020, MULT SCLER RELAT DIS, V37, DOI 10.1016/j.msard.2019.101450; Bibbins-Domingo K, 2016, JAMA-J AM MED ASSOC, V316, P429, DOI 10.1001/jama.2016.8465; Bierhansl Laura, 2019, Neurol Res Pract, V1, P40, DOI 10.1186/s42466-019-0045-x; Bittner S, 2017, THER ADV NEUROL DISO, V10, P51, DOI 10.1177/1756285616666741; Blair HA, 2019, DRUGS, V79, P1965, DOI 10.1007/s40265-019-01229-3; Bloomgren G, 2012, NEW ENGL J MED, V366, P1870, DOI 10.1056/NEJMoa1107829; BORNSTEIN MB, 1987, NEW ENGL J MED, V317, P408, DOI 10.1056/NEJM198708133170703; Brown JWL, 2019, JAMA-J AM MED ASSOC, V321, P175, DOI 10.1001/jama.2018.20588; Brownlee WJ, 2017, MULT SCLER J, V23, P876, DOI 10.1177/1352458517693440; Bruck W, 2013, JAMA NEUROL, V70, P1315, DOI 10.1001/jamaneurol.2013.3510; Buiter HJC, 2019, EUR J HOSP PHARM, V26, P246, DOI 10.1136/ejhpharm-2019-002026; Calabresi PA, 2014, LANCET NEUROL, V13, P657, DOI 10.1016/S1474-4422(14)70068-7; Calabresi PA, 2014, LANCET NEUROL, V13, P545, DOI 10.1016/S1474-4422(14)70049-3; Cambridge G, 2003, ARTHRITIS RHEUM-US, V48, P2146, DOI 10.1002/art.11181; Carpenter AF, 2017, MULT SCLER J, V23, P297, DOI 10.1177/1352458516670732; Carubbi F, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016399; Chakraborty S, 2011, CASE REP ONCOL, V4, P136, DOI 10.1159/000326851; Chisari CG, 2019, EXPERT OPIN DRUG SAF, V18, P925, DOI 10.1080/14740338.2019.1658741; Chitnis T, 2018, NEW ENGL J MED, V379, P1017, DOI 10.1056/NEJMoa1800149; Chong I, 2019, CLIN IMAG, V54, P53, DOI 10.1016/j.clinimag.2018.11.005; Christou EAA, 2017, INT REV IMMUNOL, V36, P352, DOI 10.1080/08830185.2017.1346092; Chun J, 2010, CLIN NEUROPHARMACOL, V33, P91, DOI 10.1097/WNF.0b013e3181cbf825; Ciardi MR, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofy356; Claussen MC, 2012, CLIN IMMUNOL, V142, P49, DOI 10.1016/j.clim.2011.02.011; Clerico M, 2017, EXPERT OPIN DRUG SAF, V16, P963, DOI 10.1080/14740338.2017.1346082; Cohen BA, 2019, NEUROLOGY, V92, P435, DOI 10.1212/WNL.0000000000006924; Cohen J, 2015, JAMA NEUROL, V72, P1433, DOI 10.1001/jamaneurol.2015.2154; Cohen JA, 2019, THER ADV NEUROL DISO, V12, DOI 10.1177/1756286419878324; Cohen JA, 2019, LANCET NEUROL, V18, P1021, DOI 10.1016/S1474-4422(19)30238-8; Cohen JA, 2016, LANCET NEUROL, V15, P373, DOI 10.1016/S1474-4422(16)00018-1; Cohen JA, 2016, J NEUROL NEUROSUR PS, V87, P468, DOI 10.1136/jnnp-2015-310597; Cohen JA, 2012, LANCET, V380, P1819, DOI 10.1016/S0140-6736(12)61769-3; Cohen JA, 2011, ANN NEUROL, V69, P759, DOI 10.1002/ana.22426; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Coles AJ, 2006, J NEUROL, V253, P98, DOI 10.1007/s00415-005-0934-5; Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670; Coles AJ, 2017, NEUROLOGY, V89, P1117, DOI 10.1212/WNL.0000000000004354; Coles AJ, 2012, LANCET, V380, P1829, DOI 10.1016/S0140-6736(12)61768-1; Comi G, 2020, MULT SCLER J, V26, P1866, DOI 10.1177/1352458519888610; Comi G, 2019, LANCET NEUROL, V18, P1009, DOI 10.1016/S1474-4422(19)30239-X; Confavreux C, 2014, LANCET NEUROL, V13, P247, DOI 10.1016/S1474-4422(13)70308-9; Cook S, 2011, MULT SCLER J, V17, P578, DOI 10.1177/1352458510391344; Cook S, 2019, MULT SCLER RELAT DIS, V29, P157, DOI 10.1016/j.msard.2018.11.021; Cossburn MD, 2013, NEUROLOGY, V80, P55, DOI 10.1212/WNL.0b013e31827b5927; Cox AL, 2005, EUR J IMMUNOL, V35, P3332, DOI 10.1002/eji.200535075; Curry SJ, 2018, JAMA-J AM MED ASSOC, V320, P674, DOI [10.1001/jama.2018.10897, 10.1097/01.ogx.0000549540.69362.81]; Damato V, 2016, JAMA NEUROL, V73, P1342, DOI 10.1001/jamaneurol.2016.1637; Darwin E., 2018, DERMATOL ONLINE J, V24; Deeks ED, 2016, DRUGS, V76, P243, DOI 10.1007/s40265-015-0528-1; Demko S, 2008, ONCOLOGIST, V13, P167, DOI 10.1634/theoncologist.2007-0218; Derfuss T., 2016, MULT SCLER J, DOI [10.1177/1352458516663086, DOI 10.1177/1352458516663086]; Derfuss T, 2020, LANCET NEUROL, V19, P336, DOI 10.1016/S1474-4422(19)30391-6; Derouiche F, 2015, MULT SCLER J, DOI [10.1177/1352458515602639, DOI 10.1177/1352458515602639]; Devonshire V, 2018, J NEUROL, V265, P2494, DOI 10.1007/s00415-018-8822-y; Diaz C, 2019, MULT SCLER RELAT DIS, V30, P215, DOI 10.1016/j.msard.2019.01.039; Diebold M, 2019, MULT SCLER J, V25, P1682, DOI 10.1177/1352458519852100; Downing NS, 2014, JAMA-J AM MED ASSOC, V311, P368, DOI 10.1001/jama.2013.282034; Dudek MIR, 2019, J NEUROL, V266, P2322, DOI 10.1007/s00415-019-09391-0; Durand-Dubief F, 2020, MULT SCLER J, V26, P381, DOI 10.1177/1352458519828663; Ellrichmann G, 2019, J NEUROL, V266, P57, DOI 10.1007/s00415-018-9092-4; Enginar AU, 2019, ARCH RHEUMATOL, V34, P225, DOI 10.5606/ArchRheumatol.2019.7020; European Medicines Agency, MOV WITHDR MARK AUTH; European Medicines Agency, US MULT SCLER MED LE; European Medicines Agency, MABTHERA; Evdoshenko E P, 2019, Zh Nevrol Psikhiatr Im S S Korsakova, V119, P110, DOI 10.17116/jnevro201911910110; Faissner S, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000680; Farrell Kaitlin, 2020, Mo Med, V117, P133; Faulkner M, 2015, EXPERT OPIN DRUG SAF, V14, P1737, DOI 10.1517/14740338.2015.1093620; Felli V, 2014, NEURORADIOL J, V27, P657, DOI 10.15274/NRJ-2014-10087; Fernandez O, 2013, THER ADV NEUROL DISO, V6, P69, DOI 10.1177/1756285612470401; Ferreira VFM, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000589; Fine AJ, 2013, CLIN INFECT DIS, V57, P849, DOI 10.1093/cid/cit376; Ford C, 2018, MULT SCLER J, DOI [10.1177/1352458518798582, DOI 10.1177/1352458518798582]; Fox EJ, 2019, NEUROL-CLIN PRACT, V9, P53, DOI 10.1212/CPJ.0000000000000567; Fox RJ, 2012, NEW ENGL J MED, V367, P1087, DOI 10.1056/NEJMoa1206328; Frampton JE, 2020, AM J CLIN DERMATOL, V21, P149, DOI 10.1007/s40257-019-00497-9; Freedman Mark S, 2013, J Clin Cell Immunol, V4; Freedman MS, 2013, THER ADV CHRONIC DIS, V4, P192, DOI 10.1177/2040622313492810; Giovannoni G, 2018, MULT SCLER J, V24, P1594, DOI 10.1177/1352458517727603; Gold R., P 35 C EUR COMM TREA; Gold R, 2016, NEUROL THER, V5, P45, DOI 10.1007/s40120-016-0042-8; Gold R, 2015, NEUROL THER, V4, P93, DOI 10.1007/s40120-015-0033-1; Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287; Goodman AD, 2009, NEUROLOGY, V72, P806, DOI 10.1212/01.wnl.0000343880.13764.69; Grebenciucova E, 2016, MULT SCLER RELAT DIS, V9, P158, DOI 10.1016/j.msard.2016.07.015; Guarnera C, 2017, DRUG DES DEV THER, V11, P2193, DOI 10.2147/DDDT.S137572; Gundacker ND, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw038; Gyang TV, 2016, NEUROLOGY, V86, P1843, DOI 10.1212/WNL.0000000000002654; Hall EC, 2015, TRANSPLANTATION, V99, P1051, DOI 10.1097/TP.0000000000000449; Hanaway MJ, 2011, NEW ENGL J MED, V364, P1909, DOI 10.1056/NEJMoa1009546; Hardy TA, 2013, J NEUROL NEUROSUR PS, V84, P1047, DOI 10.1136/jnnp-2012-304498; Harirchian MH, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.102021; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; Havrdova E, 2017, NEUROLOGY, V89, P1107, DOI 10.1212/WNL.0000000000004313; HOFFMAN M, 1994, J CLIN ONCOL, V12, P788, DOI 10.1200/JCO.1994.12.4.788; Holmoy T, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4507-6; Holmoy T, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0848-8; Hutas G, 2008, CURR OPIN INVEST DR, V9, P1206; Ishikawa Y, 2018, THER CLIN RISK MANAG, V14, P1149, DOI 10.2147/TCRM.S167109; Ishizawa K, 2017, JPN J CLIN ONCOL, V47, P54, DOI 10.1093/jjco/hyw146; Ismail A, 2009, J NEUROL, V256, P1771, DOI 10.1007/s00415-009-5200-9; Jaafar N, 2018, MULT SCLER RELAT DIS, DOI [10.1016/j.msard.2018.10.101, DOI 10.1016/J.MSARD.2018.10.101]; Jeung L, 2020, MULT SCLER RELAT DIS, V40, DOI 10.1016/j.msard.2020.101978; Kapoor R, 2018, LANCET NEUROL, V17, P405, DOI 10.1016/S1474-4422(18)30069-3; Kappos L, 2018, LANCET, V391, P1263, DOI 10.1016/S0140-6736(18)30475-6; Kappos L, 2015, NEUROLOGY, V84, P1582, DOI 10.1212/WNL.0000000000001462; Kappos L, 2014, MULT SCLER RELAT DIS, V3, P494, DOI 10.1016/j.msard.2014.03.002; Kappos L, 2011, LANCET, V378, P1779, DOI 10.1016/S0140-6736(11)61649-8; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Kawai H, 2020, LEUKEMIA LYMPHOMA, V61, P959, DOI 10.1080/10428194.2019.1691197; Kelly Deirdre, 2016, Radiol Case Rep, V11, P251, DOI 10.1016/j.radcr.2016.06.003; Khouy RA, 2019, J NEUROIMMUNOL, V328, P94, DOI 10.1016/j.jneuroim.2018.12.009; Killestein J, 2014, CASE REP NEUROL MED, V2014, DOI 10.1155/2014/307872; Kim SH, 2015, JAMA NEUROL, V72, P989, DOI 10.1001/jamaneurol.2015.1276; Kim SH, 2013, JAMA NEUROL, V70, P1110, DOI 10.1001/jamaneurol.2013.3071; Koller G, 2019, CLIN RHEUMATOL, V38, P2015, DOI 10.1007/s10067-019-04577-3; Kresa-Reahl K, 2018, CLIN THER, V40, P2077, DOI 10.1016/j.clinthera.2018.10.011; Kridin K, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102466; Kwok AMF, 2019, CLIN J GASTROENTEROL, V12, P310, DOI 10.1007/s12328-019-00954-2; Lattanzi S, 2020, ACTA NEUROL BELG, V120, P231, DOI 10.1007/s13760-019-01227-y; Leandro MJ, 2006, ARTHRITIS RHEUM-US, V54, P613, DOI 10.1002/art.21617; Lebrun C, 2008, MULT SCLER J, V14, P399, DOI 10.1177/1352458507083625; Lee JM, 2015, PATIENT PREFER ADHER, V9, DOI 10.2147/PPA.S57354; Leist TP, 2014, LANCET NEUROL, V13, P257, DOI 10.1016/S1474-4422(14)70005-5; London F, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.102012; Lu MC, 2020, J FORMOS MED ASSOC, V119, P886, DOI 10.1016/j.jfma.2019.10.012; Luna G, 2020, JAMA NEUROL, V77, P184, DOI 10.1001/jamaneurol.2019.3365; Ma SB, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2019.101923; Macaron G, 2019, MULT SCLER J, V25, P1550, DOI 10.1177/1352458518813109; Macaron G, 2018, LANCET NEUROL, V17, P658, DOI 10.1016/S1474-4422(18)30248-5; Machan Achraf, 2020, Case Rep Rheumatol, V2020, P3549491, DOI 10.1155/2020/3549491; Madeley Jarrett, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2018-226588; Manouchehri N, 2018, MULT SCLER RELAT DIS, V19, P121, DOI 10.1016/j.msard.2017.11.012; Marcinno A, 2018, NEUROL-NEUROIMMUNOL, V5, DOI 10.1212/NXI.0000000000000498; Marques PT, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.102029; Martinot M, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-04988-7; Mayer L, 2019, MULT SCLER RELAT DIS, V30, P236, DOI 10.1016/j.msard.2019.01.044; McCaughan Georgia, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr-2017-223016; McGuigan C, 2016, J NEUROL NEUROSUR PS, V87, P117, DOI 10.1136/jnnp-2015-311100; Melsens K, 2018, ACTA CLIN BELG, V73, P119, DOI 10.1080/17843286.2017.1372244; Miller AE, 2019, MULT SCLER RELAT DIS, V33, P131, DOI 10.1016/j.msard.2019.05.014; Moiola L, 2017, MULT SCLER J, DOI [10.1177/1352458517731285, DOI 10.1177/1352458517731285]; Montalban X, 2017, NEW ENGL J MED, V376, P209, DOI 10.1056/NEJMoa1606468; Moss BP, 2019, MULT SCLER J, V25, P1560, DOI 10.1177/1352458519845106; Moss BP, 2017, NEUROTHERAPEUTICS, V14, P999, DOI 10.1007/s13311-017-0563-6; Muccilli A, 2019, J NEUROL SCI, V403, P119, DOI 10.1016/j.jns.2019.06.025; Mulero P, 2018, THER ADV NEUROL DISO, V11, DOI 10.1177/1756286418773025; Murk JL, 2015, J NEUROL SCI, V357, pE6, DOI 10.1016/j.jns.2015.08.099; Myro AZ, 2018, BMC PHARMACOL TOXICO, V19, DOI 10.1186/s40360-018-0267-5; Na A, 2014, J CLIN NEUROSCI, V21, P1068, DOI 10.1016/j.jocn.2013.10.018; Navardi S, 2020, REV NEUROL-FRANCE, V176, P289, DOI 10.1016/j.neurol.2019.08.008; Navardi S, 2018, MULT SCLER RELAT DIS, DOI [10.1016/j.msard.2018.10.099, DOI 10.1016/J.MSARD.2018.10.099]; Nelson SML, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006097.pub3; Nicolini LA, 2019, JAMA NEUROL, V76, P866, DOI 10.1001/jamaneurol.2019.0522; Nieuwkamp DJ, 2015, NEW ENGL J MED, V372, P1474, DOI 10.1056/NEJMc1413724; Nixon M, 2018, WORLD NEUROSURG, V109, P152, DOI 10.1016/j.wneu.2017.09.131; Nylund M, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102058; O'Brien SM, 2006, CLIN LYMPHOMA MYELOM, V7, P125, DOI 10.3816/CLM.2006.n.049; O'Connor P, 2016, NEUROLOGY, V86, P920, DOI 10.1212/WNL.0000000000002441; O'Connor P, 2011, NEW ENGL J MED, V365, P1293, DOI 10.1056/NEJMoa1014656; Oh J, 2014, THER ADV NEUROL DISO, V7, P239, DOI 10.1177/1756285614546855; Okai AF, 2019, NEUROL THER, V8, P367, DOI 10.1007/s40120-019-00159-2; Ontaneda D, 2019, LANCET NEUROL, V18, P973, DOI 10.1016/S1474-4422(19)30151-6; Ontaneda D, 2012, THER ADV DRUG SAF, V3, P291, DOI 10.1177/2042098612462599; Pagnini C, 2017, EXPERT OPIN BIOL TH, V17, P1433, DOI 10.1080/14712598.2017.1366444; Pakpoor J, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000158; Pappolla A, 2019, NEUROLOGY, V92, P296, DOI 10.1212/WNL.0000000000006801; Parisinos CA, 2011, THORAX, V66, P1109, DOI 10.1136/thx.2010.155762; Pham Chengde, 2017, BMJ Case Rep, V2017, DOI 10.1136/bcr-2017-220026; Phillips JT, 2013, SEMIN NEUROL, V33, P56, DOI 10.1055/s-0033-1343796; Pisa M, 2019, MULT SCLER RELAT DIS, V27, P403, DOI 10.1016/j.msard.2018.11.029; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Raffray L, 2020, EXPERT OPIN BIOL TH, V20, P899, DOI 10.1080/14712598.2020.1748597; Rasche L, 2018, EXPERT OPIN PHARMACO, V19, P2073, DOI 10.1080/14656566.2018.1540592; Rastetter W, 2004, ANNU REV MED, V55, P477, DOI 10.1146/annurev.med.55.091902.104249; Rau D, 2015, INT J MOL SCI, V16, P14669, DOI 10.3390/ijms160714669; Rieckmann P, 2009, J NEUROL SCI, V277, pS42, DOI 10.1016/S0022-510X(09)70012-7; Roll P, 2008, ARTHRITIS RHEUM-US, V58, P1566, DOI 10.1002/art.23473; Rolla S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061396; Romba MC, 2019, MULT SCLER RELAT DIS, V34, P100, DOI 10.1016/j.msard.2019.06.022; Rosenkranz T, 2015, NEW ENGL J MED, V372, P1476, DOI 10.1056/NEJMc1415408; Rotstein D, 2019, NAT REV NEUROL, V15, P287, DOI 10.1038/s41582-019-0170-8; Rubbert-Roth A, 2010, RHEUMATOLOGY, V49, P1683, DOI 10.1093/rheumatology/keq116; Rudick RA, 2006, NEW ENGL J MED, V354, P911, DOI 10.1056/NEJMoa044396; Saarela M, 2018, NEUROLOGY, V90, P849, DOI 10.1212/WNL.0000000000005420; Sabol RA, 2017, CANCER MED-US, V6, P1541, DOI 10.1002/cam4.1098; Samudralwar Rohini D, 2019, Int J MS Care, V21, P275, DOI 10.7224/1537-2073.2018-080; Schowinsky J, 2012, ACTA NEUROPATHOL, V123, P751, DOI 10.1007/s00401-012-0967-7; Seto H, 2016, INTERNAL MED, V55, P3383, DOI 10.2169/internalmedicine.55.7255; Shenoy ES, 2011, J NEUROVIROL, V17, P288, DOI 10.1007/s13365-011-0027-4; Shepshelovich D, 2019, MAYO CLIN PROC, V94, P74, DOI 10.1016/j.mayocp.2018.07.027; Stabler S, 2021, CLIN INFECT DIS, V72, P727, DOI 10.1093/cid/ciaa127; Stuve O, 2007, CNS DRUG REV, V13, P79, DOI 10.1111/j.1527-3458.2007.00003.x; Sunjaya DB, 2020, INFLAMM BOWEL DIS, V26, pE49, DOI 10.1093/ibd/izaa057; Tallantyre EC, 2015, MULT SCLER J, V21, P67, DOI 10.1177/1352458514538333; Tan PSC, 2019, RESPIROL CASE REP, V7, DOI 10.1002/rcr2.414; Terrier B, 2010, ARTHRITIS RHEUM-US, V62, P2458, DOI 10.1002/art.27541; Theriault M, 2020, MULT SCLER RELAT DIS, V38, DOI 10.1016/j.msard.2019.101866; Thery-Casari C, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102505; Thompson AJ, 2018, LANCET NEUROL, V17, P162, DOI 10.1016/S1474-4422(17)30470-2; Tony HP, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3337; Tran JQ, 2018, CLIN PHARM DRUG DEV, V7, P634, DOI 10.1002/cpdd.409; Triplett J, 2019, MULT SCLER J, V25, P1547, DOI 10.1177/1352458518807088; Trouvin AP, 2015, CLIN EXP IMMUNOL, V180, P11, DOI 10.1111/cei.12481; Tzartos JS, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000711; U.S. Food and Drug Administration, TECF; U.S. Food & Drug Administration, FDA WORK MAN WITHDR; Valenzuela RM, 2014, J NEUROL SCI, V340, P109, DOI 10.1016/j.jns.2014.03.007; Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586; van Meerten T, 2010, SEMIN HEMATOL, V47, P199, DOI 10.1053/j.seminhematol.2010.01.007; Velter C, 2019, EUR J CANCER, V113, P75, DOI 10.1016/j.ejca.2019.03.011; Vital EM, 2010, ARTHRITIS RHEUM-US, V62, P1273, DOI 10.1002/art.27359; Wallach JD, 2018, CLIN TRIALS, V15, P219, DOI 10.1177/1740774518770648; Wang Y, 2021, JCR-J CLIN RHEUMATOL, V27, pS565, DOI 10.1097/RHU.0000000000000997; Ward MD, 2014, EXPERT OPIN DRUG SAF, V13, P989, DOI 10.1517/14740338.2014.920820; Wendtner CM, 2004, LEUKEMIA, V18, P1093, DOI 10.1038/sj.leu.2403354; Wills A., 2019, DERMATOL ONLINE J, V25; Wray S, 2019, MULT SCLER J, V25, P1605, DOI 10.1177/1352458518796675; Yousry TA, 2006, NEW ENGL J MED, V354, P924, DOI 10.1056/NEJMoa054693; Zanetta C, 2020, J NEUROL SCI, V409, DOI 10.1016/j.jns.2019.116603; Zappulo E, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz445; Zhang X, 2013, J IMMUNOL, V191, P5867, DOI 10.4049/jimmunol.1301926; Ziemseen T., P 71 AM AC NEUR AAN; Zoehner G, 2019, THER ADV NEUROL DISO, V12, DOI 10.1177/1756286419878340	248	5	5	5	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							12	10.3390/vaccines9010012			30	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6TG	33375365	Green Published, gold			2022-04-29	WOS:000610803900001
J	Falco, A; Bello-Perez, M; Diaz-Puertas, R; Mold, M; Adamek, M				Falco, Alberto; Bello-Perez, Melissa; Diaz-Puertas, Rocio; Mold, Matthew; Adamek, Mikolaj			Update on the Inactivation Procedures for the Vaccine Development Prospects of a New Highly Virulent RGNNV Isolate	VACCINES			English	Article						viral nervous necrosis; betanodavirus; nervous necrosis virus; autogenous vaccine; virus inactivation; virus-inactivated vaccine	NERVOUS-NECROSIS-VIRUS; EUROPEAN SEA BASS; EPINEPHELUS-SEPTEMFASCIATUS THUNBERG; SEVENBAND GROUPER; GILTHEAD SEABREAM; GENE-EXPRESSION; VIRAL VACCINES; OLIVE FLOUNDER; CELL-LINE; FISH	Viral nervous necrosis (VNN) caused by the nervous necrosis virus (NNV) affects a broad range of primarily marine fish species, with mass mortality rates often seen among larvae and juveniles. Its genetic diversification may hinder the effective implementation of preventive measures such as vaccines. The present study describes different inactivation procedures for developing an inactivated vaccine against a new NNV isolate confirmed to possess deadly effects upon the European seabass (Dicentrarchus labrax), an important Mediterranean farmed fish species that is highly susceptible to this disease. First, an NNV isolate from seabass adults diagnosed with VNN was rescued and the sequences of its two genome segments (RNA1 and RNA2) were classified into the red-spotted grouper NNV (RGNNV) genotype, closely clustering to the highly pathogenic 283.2009 isolate. The testing of different inactivation procedures revealed that the virus particles of this isolate showed a marked resistance to heat (for at least 60 degrees C for 120 min with and without 1% BSA) but that they were fully inactivated by 3 mJ/cm(2) UV-C irradiation and 24 h 0.2% formalin treatment, which stood out as promising NNV-inactivation procedures for potential vaccine candidates. Therefore, these procedures are feasible, effective, and rapid response strategies for VNN control in aquaculture.	[Falco, Alberto; Bello-Perez, Melissa; Diaz-Puertas, Rocio] Miguel Hernandez Univ, Inst Res Dev & Innovat Healthcare Biotechnol Elch, Elche 03202, Spain; [Mold, Matthew] Keele Univ, Lennard Jones Labs, Birchall Ctr, Keele ST5 5BG, Staffs, England; [Adamek, Mikolaj] Univ Vet Med, Inst Parasitol, Fish Dis Res Unit, D-30559 Hannover, Germany		Falco, A (通讯作者)，Miguel Hernandez Univ, Inst Res Dev & Innovat Healthcare Biotechnol Elch, Elche 03202, Spain.	alber.falco@umh.es; melissa.bello@alu.umh.es; rocio.diaz01@goumh.umh.es; matthew.j.mold@gmail.com; mikolaj.adamek@tiho-hannover.de	Mold, Matthew/AAH-2947-2019; Adamek, Mikolaj/I-7872-2012; Adamek, Mikolaj/T-5010-2019; Falco, Alberto/A-3250-2012	Mold, Matthew/0000-0002-4616-6204; Adamek, Mikolaj/0000-0003-4890-3164; Adamek, Mikolaj/0000-0003-4890-3164; Falco, Alberto/0000-0001-7726-6577	Spanish Ministry of Economy and CompetitivenessSpanish Government; European ERDF Funds (MCIU/AEI/FEDER, EU) [RTI2018-101969-J-I00]; German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)German Research Foundation (DFG) [426513195]	This research was funded by the Spanish Ministry of Economy and Competitiveness and European ERDF Funds (MCIU/AEI/FEDER, EU) (RTI2018-101969-J-I00 to Alberto Falco). Mikolaj Adamek was supported by German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)-project number 426513195.	ARIMOTO M, 1992, FISH PATHOL, V27, P191, DOI 10.3147/jsfp.27.191; Barsoe S, 2021, AQUACULT REP, V19, DOI 10.1016/j.aqrep.2021.100621; Bejar J, 1997, AQUACULTURE, V150, P143, DOI 10.1016/S0044-8486(96)01469-X; Bello-Perez M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57501-0; Brudeseth BE, 2013, FISH SHELLFISH IMMUN, V35, P1759, DOI 10.1016/j.fsi.2013.05.029; Cattoli G, 2019, MANUAL DIAGNOSTIC TE; Cerezuela R, 2013, FISH SHELLFISH IMMUN, V34, P843, DOI 10.1016/j.fsi.2012.12.026; Chambers MA, 2016, METHODS MOL BIOL, V1404, P3, DOI 10.1007/978-1-4939-3389-1_1; Chaves-Pozo E, 2012, FISH SHELLFISH IMMUN, V33, P1159, DOI 10.1016/j.fsi.2012.09.002; Chen NC, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005203; Clem AS, 2011, J GLOB INFECT DIS, V3, P73, DOI 10.4103/0974-777X.77299; Costa J.Z., 2005, B CELL EPITOPES FISH; Costa JZ, 2016, FISH SHELLFISH IMMUN, V53, P35, DOI 10.1016/j.fsi.2016.03.033; Dalla Valle L, 2005, VET MICROBIOL, V110, P167, DOI 10.1016/j.vetmic.2005.07.014; De Clercq E, 2016, CLIN MICROBIOL REV, V29, P695, DOI 10.1128/CMR.00102-15; Delrue I, 2012, EXPERT REV VACCINES, V11, P695, DOI [10.1586/erv.12.38, 10.1586/ERV.12.38]; Dhar Arun K., 2014, VirusDisease, V25, P1, DOI 10.1007/s13337-013-0186-4; Dixon PF, 2012, J FISH DIS, V35, P51, DOI 10.1111/j.1365-2761.2011.01324.x; Falco A, 2008, MOL IMMUNOL, V45, P757, DOI 10.1016/j.molimm.2007.06.358; Fenner BJ, 2006, J VIROL, V80, P6822, DOI 10.1128/JVI.00079-06; Frerichs GN, 2000, AQUACULTURE, V185, P13, DOI 10.1016/S0044-8486(99)00337-3; FRERICHS GN, 1991, J GEN VIROL, V72, P2537, DOI 10.1099/0022-1317-72-10-2537; Fukuda Y, 1996, FISH PATHOL, V31, P165, DOI 10.3147/jsfp.31.165; Glazebrook J.S., 1987, ACIAR Proceedings, P204; Grotmol S, 2000, DIS AQUAT ORGAN, V39, P89, DOI 10.3354/dao039089; Gye HJ, 2018, AQUACULTURE, V484, P65, DOI 10.1016/j.aquaculture.2017.10.034; Hwang JY, 2017, FISH SHELLFISH IMMUN, V62, P221, DOI 10.1016/j.fsi.2017.01.016; Hwang JY, 2017, FISH SHELLFISH IMMUN, V60, P420, DOI 10.1016/j.fsi.2016.12.011; Ike AC, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010020; Iwamoto T, 2005, J GEN VIROL, V86, P2807, DOI 10.1099/vir.0.80902-0; Iwamoto T, 2000, DIS AQUAT ORGAN, V43, P81, DOI 10.3354/dao043081; Kai YH, 2008, VACCINE, V26, P1450, DOI 10.1016/j.vaccine.2007.12.043; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; LeBreton A, 1997, J FISH DIS, V20, P145, DOI 10.1046/j.1365-2761.1997.00284.x; Leiva-Rebollo R, 2020, J APPL MICROBIOL, V128, P41, DOI 10.1111/jam.14454; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez-Doriga MV, 2001, FISH SHELLFISH IMMUN, V11, P505, DOI 10.1006/fsim.2000.0330; Ma J, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7110569; Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268; Mori K, 2003, DIS AQUAT ORGAN, V57, P19, DOI 10.3354/dao057019; Munday BL, 2002, J FISH DIS, V25, P127, DOI 10.1046/j.1365-2761.2002.00350.x; Munday BL, 1997, WORLD J MICROB BIOT, V13, P375, DOI 10.1023/A:1018516014782; NaveenKumar S, 2013, VIRUS RES, V173, P377, DOI 10.1016/j.virusres.2013.01.003; NISHIZAWA T, 1995, J GEN VIROL, V76, P1563, DOI 10.1099/0022-1317-76-7-1563; Nishizawa T, 1997, APPL ENVIRON MICROB, V63, P1633, DOI 10.1128/AEM.63.4.1633-1636.1997; Nunez-Ortiz N, 2016, VET RES, V47, DOI 10.1186/s13567-016-0376-3; Olveira JG, 2009, J GEN VIROL, V90, P2940, DOI 10.1099/vir.0.013912-0; Pakingking R, 2009, J FISH DIS, V32, P457, DOI 10.1111/j.1365-2761.2009.01040.x; Pakingking R, 2010, FISH SHELLFISH IMMUN, V28, P525, DOI 10.1016/j.fsi.2009.12.004; Panzarin V, 2010, ARCH VIROL, V155, P1193, DOI 10.1007/s00705-010-0701-5; Panzarin V, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-56; Panzarin V, 2012, INFECT GENET EVOL, V12, P63, DOI 10.1016/j.meegid.2011.10.007; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rivas-Aravena A, 2015, FISH SHELLFISH IMMUN, V45, P157, DOI 10.1016/j.fsi.2015.03.033; Salgado-Miranda C, 2013, EXPERT REV VACCINES, V12, P567, DOI [10.1586/ERV.13.38, 10.1586/erv.13.38]; Sanders B., 2014, VACCINE ANAL STRATEG, P45, DOI [10.1007/978-3- 662-45024-6_2, DOI 10.1007/978-3-662-45024-6_2]; Schulz P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030476; Shetty M, 2012, INDIAN J VIROL, V23, P114, DOI 10.1007/s13337-012-0088-x; Skliris GP, 2001, VIRUS RES, V75, P59, DOI 10.1016/S0168-1702(01)00225-8; Tanaka S, 2001, J FISH DIS, V24, P15, DOI 10.1046/j.1365-2761.2001.00259.x; Toffan A, 2016, DIS AQUAT ORGAN, V119, P231, DOI 10.3354/dao03003; Toffolo V, 2007, MOL PHYLOGENET EVOL, V43, P298, DOI 10.1016/j.ympev.2006.08.003; Tso CH, 2018, FISH SHELLFISH IMMUN, V76, P224, DOI 10.1016/j.fsi.2018.03.009; Valero Y, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050458; Valero Y, 2018, DEV COMP IMMUNOL, V86, P171, DOI 10.1016/j.dci.2018.05.013; Vendramin N, 2014, J FISH DIS, V37, P371, DOI 10.1111/jfd.12117; Wu MS, 2012, J FISH DIS, V35, P215, DOI 10.1111/j.1365-2761.2012.01341.x; Yamashita H, 2005, FISH PATHOL, V40, P15, DOI 10.3147/jsfp.40.15; Yamashita H, 2009, J FISH DIS, V32, P767, DOI 10.1111/j.1365-2761.2009.01054.x; Yong CY, 2017, PEERJ, V5, DOI 10.7717/peerj.3841; YOSHIKOSHI K, 1990, J FISH DIS, V13, P69, DOI 10.1111/j.1365-2761.1990.tb00758.x; Zeng WW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020086; Zhang LL, 2016, FISH SHELLFISH IMMUN, V49, P344, DOI 10.1016/j.fsi.2016.01.003	73	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1441	10.3390/vaccines9121441			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ2TJ	34960187	gold, Green Published			2022-04-29	WOS:000737510000001
J	Giannotta, G; Giannotta, N				Giannotta, Girolamo; Giannotta, Nicola			mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship	VACCINES			English	Review						SARS-CoV-2; SARS-CoV-2 mRNA vaccines; COVID-19 vaccines; immune memory after COVID-19 disease; immune memory after COVID-19 vaccination; long-lived plasma cells after mRNA COVID-19 vaccines	ANTIGEN-PRESENTING CELLS; MEMORY B-CELLS; VACCINATION; ACTIVATION; GENERATION; MECHANISM; DELIVERY; SPACE; SPIKE; CD19	mRNA COVID-19 vaccines have hegemonized the world market, and their administration to the population promises to stop the pandemic. However, the waning of the humoral immune response, which does not seem to last so many months after the completion of the vaccination program, has led us to study the molecular immunological mechanisms of waning immunity in the case of mRNA COVID-19 vaccines. We consulted the published scientific literature and from the few articles we found, we were convinced that there is an immunological memory problem after vaccination. Although mRNA vaccines have been demonstrated to induce antigen-specific memory B cells (MBCs) in the human population, there is no evidence that these vaccines induce the production of long-lived plasma cells (LLPCs), in a SARS-CoV-2 virus naive population. This obstacle, in our point of view, is caused by the presence, in almost all subjects, of a cellular T and B cross-reactive memory produced during past exposures to the common cold coronaviruses. Due to this interference, it is difficult for a vaccination with the Spike protein alone, without adjuvants capable of prolonging the late phase of the generation of the immunological memory, to be able to determine the production of protective LLPCs. This would explain the possibility of previously and completely vaccinated subjects to become infected, already 4-6 months after the completion of the vaccination cycle.	[Giannotta, Girolamo] Azienda Sanitaria Provinciale Vibo Valentia, I-89900 Vibo Valentia, Italy; [Giannotta, Nicola] Magna Graecia Univ Catanzaro, Fac Med, Med & Surg Sci, I-88100 Catanzaro, Italy		Giannotta, G (通讯作者)，Azienda Sanitaria Provinciale Vibo Valentia, I-89900 Vibo Valentia, Italy.			Giannotta, Nicola/0000-0003-1701-7696			Abbas A.K., 2015, CELLULAR MOL IMMUNOL, P107; Abbas A.K., 2015, CELLULAR MOL IMMUNOL, P199; Abbas A.K., 2015, CELLULAR MOL IMMUNOL, P239; AbdelMassih AF, 2021, J GENET ENG BIOTECHN, V19, DOI 10.1186/s43141-021-00179-2; Angelin-Duclos C, 2000, J IMMUNOL, V165, P5462, DOI 10.4049/jimmunol.165.10.5462; Auladell M, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1090; Baumjohann D, 2021, EUR J IMMUNOL, V51, P1325, DOI 10.1002/eji.202049148; Bayart JL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101092; Bertoletti A, 2021, CELL MOL IMMUNOL, V18, P2307, DOI 10.1038/s41423-021-00743-3; Besin Gilles, 2019, Immunohorizons, V3, P282, DOI 10.4049/immunohorizons.1900029; Buckland J, 2002, NAT REV IMMUNOL, V2, P629, DOI 10.1038/nri903; Cohen KW, 2021, CELL REP MED, V2, DOI [10.1016/j.xcrm.2021.100354, 10.1101/2021.04.19.21255739]; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Costello S.M., SARS COV 2 SPIKE REV, DOI [10.1101/2021.07.11.451855v1, DOI 10.1101/2021.07.11.451855V1]; Cotugno N, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108852; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; DERIE MA, 1989, CELL IMMUNOL, V118, P368, DOI 10.1016/0008-8749(89)90385-7; Dijkstra Johannes M, 2020, F1000Res, V9, P285, DOI [10.12688/f1000research.23458.1, 10.12688/f1000research.23458.2]; Eifer M, 2022, J NUCL MED, V63, P134, DOI 10.2967/jnumed.121.262194; Fazilleau N, 2009, IMMUNITY, V30, P324, DOI 10.1016/j.immuni.2009.03.003; Gallais F., 2020, INFECT DIS EXCEPT HI, DOI [10.1101/2020.06.21.20132449, DOI 10.1101/2020.06.21.20132449]; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Grifoni A, 2020, J VIROL, V94, DOI 10.1128/JVI.00089-20; Hilligan KL, 2020, CELL MOL IMMUNOL, V17, P587, DOI 10.1038/s41423-020-0465-0; Iavarone C, 2017, EXPERT REV VACCINES, V16, P871, DOI 10.1080/14760584.2017.1355245; Israel A, 2022, VACCINES-BASEL, V10, DOI [10.3390/vaccines10010064, 10.1101/2021.08.19.21262111]; Israel Ariel, 2021, medRxiv, DOI 10.1101/2021.08.03.21261496; Jo DH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101145; Kalimuddin S, 2021, MED-CAMBRIDGE, V2, P682, DOI 10.1016/j.medj.2021.04.003; Kanasty RL, 2012, MOL THER, V20, P513, DOI 10.1038/mt.2011.294; Kowalczyk A, 2016, VACCINE, V34, P3882, DOI 10.1016/j.vaccine.2016.05.046; Lazzaro S, 2015, IMMUNOLOGY, V146, P312, DOI 10.1111/imm.12505; Lederer K, 2020, IMMUNITY, V53, P1281, DOI 10.1016/j.immuni.2020.11.009; Lehman CD, 2021, J AM COLL RADIOL, V18, P843, DOI 10.1016/j.jacr.2021.03.001; Leist SR, 2020, CELL, V183, P1070, DOI 10.1016/j.cell.2020.09.050; Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583; Liang F, 2017, MOL THER, V25, P2635, DOI 10.1016/j.ymthe.2017.08.006; Lightman SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00965; Lipsitch M, 2020, NAT REV IMMUNOL, V20, P709, DOI 10.1038/s41577-020-00460-4; Loyal L, 2021, SCIENCE, V374, P171, DOI 10.1126/science.abh1823; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; McDade TW, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-96879-3; Mei HE, 2015, BLOOD, V125, P1739, DOI 10.1182/blood-2014-02-555169; Moran I, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05772-7; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Naaber P, 2021, LANCET REG HEALTH-EU, V10, DOI 10.1016/j.lanepe.2021.100208; Nguyen DC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02138; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Oberhardt V, 2021, NATURE, V597, P268, DOI 10.1038/s41586-021-03841-4; Pape KA, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109823; Patel S, 2017, NANO LETT, V17, P5711, DOI 10.1021/acs.nanolett.7b02664; Purtha WE, 2011, J EXP MED, V208, P2599, DOI 10.1084/jem.20110740; Qi H, 2016, NAT REV IMMUNOL, V16, P612, DOI 10.1038/nri.2016.94; Rijkers GT, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080848; Roth K, 2014, CYTOM PART A, V85A, P15, DOI 10.1002/cyto.a.22355; Saad-Roy CM, 2021, SCIENCE, V372, P363, DOI 10.1126/science.abg8663; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Schroeder HW, 2019, CLIN IMMUNOLOGY BOOK, P107, DOI DOI 10.1016/B978-0-7020-6896-6.00007-7; Schulien I, 2021, NAT MED, V27, P78, DOI 10.1038/s41591-020-01143-2; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Shitrit P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.39.2100822; Shrotri M, 2021, LANCET, V398, P385, DOI 10.1016/S0140-6736(21)01642-1; Shubinsky G, 1997, IMMUNITY, V7, P315, DOI 10.1016/S1074-7613(00)80353-2; Song G, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23074-3; Song WZ, 2019, IMMUNOL REV, V288, P85, DOI 10.1111/imr.12740; SSeydoux E., 2020, IMMUNITY, V53; Stebegg M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02469; Takemori T, 2014, EUR J IMMUNOL, V44, P1258, DOI 10.1002/eji.201343716; Tan HM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9111251; Tangye SG, 2003, J IMMUNOL, V170, P686, DOI 10.4049/jimmunol.170.2.686; ten Broeke T, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a016873; Turner JS, 2021, NATURE, V596, P109, DOI 10.1038/s41586-021-03738-2; Turner JS, 2021, NATURE, V595, P421, DOI 10.1038/s41586-021-03647-4; Vinuesa CG, 2016, ANNU REV IMMUNOL, V34, P335, DOI 10.1146/annurev-immunol-041015-055605; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; Weisel FJ, 2016, IMMUNITY, V44, P116, DOI 10.1016/j.immuni.2015.12.004; Welsh RA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.677036; Wong Lok-Yin Roy, 2020, STAR Protoc, V1, P100169, DOI 10.1016/j.xpro.2020.100169; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu YCB, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00081; Yang Q, 2016, ANAL CHEM, V88, P11804, DOI 10.1021/acs.analchem.6b03437; Yasar H, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0401-y	82	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1503	10.3390/vaccines9121503			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YA3PY	34960249	gold, Green Published			2022-04-29	WOS:000738250600001
J	Nath, R; Imtiaz, A; Nath, SD; Hasan, E				Nath, Rima; Imtiaz, Asif; Nath, Shobod Deba; Hasan, Emran			Role of Vaccine Hesitancy, eHealth Literacy, and Vaccine Literacy in Young Adults' COVID-19 Vaccine Uptake Intention in a Lower-Middle-Income Country	VACCINES			English	Article						vaccine uptake intention; vaccine hesitancy; eHealth literacy; vaccine literacy; COVID-19		Various control measures, including vaccination, have been taken to flatten the COVID-19 epidemic curve across the globe. However, in Bangladesh, many young adults, considered the asymptomatic transmitter of the disease, are waiting to get their first shot. Therefore, the potential predictors of the young adults' vaccine uptake intention are significant to ensure their maximum vaccination when available to them. This study examined how vaccine hesitancy, eHealth literacy, and vaccine literacy are associated with young adults' COVID-19 vaccine uptake intention in a lower-middle-income country. A total of 343 young adults participated in the study. Using ordinary least square and probit estimation, we examined the effect of the explanatory variables of interest on vaccine uptake intention. Vaccine hesitancy emerged as the strongest predictor of vaccine uptake intention. eHealth literacy shared a positive association with vaccine uptake intention, while vaccine literacy had no significant association. To make young adults feel more confident about the vaccine, transmitting the latest vaccine safety updates through authentic channels is essential. The government can aim to enhance the eHealth literacy of young adults as an increased level of eHealth literacy will enable young adults to extract reliable health-related information more efficiently than ever.	[Nath, Rima] North South Univ, Dept Publ Hlth, Dhaka 1229, Bangladesh; [Imtiaz, Asif] Univ Dhaka, Dept MIS, Dhaka 1000, Bangladesh; [Imtiaz, Asif] London Sch Econ & Polit Sci LSE, Dept Hlth Policy, London WC2A 2AE, England; [Nath, Shobod Deba] Univ Dhaka, Dept Int Business, Dhaka 1205, Bangladesh; [Hasan, Emran] Bangladesh Univ Profess BUP, Dept Econ, Dhaka 1216, Bangladesh		Nath, SD (通讯作者)，Univ Dhaka, Dept Int Business, Dhaka 1205, Bangladesh.	rima.nath@northsouth.edu; asifimtiaz.mis@du.ac.bd; shobod@du.ac.bd; emran.hasan@bup.edu.bd		Imtiaz, Asif/0000-0002-6282-5863			Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x; Alzoubi H, 2020, J PURE APPL MICROBIO, V14, P17, DOI 10.22207/JPAM.14.1.04; Anwar S, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00154; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Bhagavathula AS, 2020, JMIR PUBLIC HLTH SUR, DOI 10.1101/2020.03.09.2003338; Biasio LR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030268; Biasio LR, 2021, HUM VACC IMMUNOTHER, V17, P1304, DOI 10.1080/21645515.2020.1829315; Britt RK, 2015, COMMUN RES REP, V32, P208, DOI 10.1080/08824096.2015.1052963; Chen L, 2021, HEALTH COMMUN, V36, P1343, DOI 10.1080/10410236.2020.1751384; Conte C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020309; Dodd RH, 2021, LANCET INFECT DIS, V21, P161, DOI 10.1016/S1473-3099(20)30926-9; Ferdous MZ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239254; Hinton P, 2014, SPSS EXPLAINED; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Hong KJ, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9050573; Hossain MA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239646; Hossain MB, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.711066; Imtiaz A, 2021, J PUBLIC HEALTH-HEID, DOI 10.1007/s10389-020-01453-2; Jae Jeong H., 2016, BIOMETRICS BIOSTATIS, V4, DOI [10.15406/bbij.2016.04.00100, DOI 10.15406/BBIJ.2016.04.00100]; Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177; Kaur SP, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198114; Aslan GK, 2021, INT J NURS PRACT, V27, DOI 10.1111/ijn.12921; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mathieu E, 2021, NAT HUM BEHAV, V5, P947, DOI 10.1038/s41562-021-01122-8; Michalos, 2014, ENCY QUALITY LIFE WE, DOI [10.1007/978-94-007-0753-5_2008, DOI 10.1007/978-94-007-0753-5_2008]; Muturi N, 2020, COMMUN RES REP, V37, P74, DOI 10.1080/08824096.2020.1763942; Norman CD, 2006, J MED INTERNET RES, V8, DOI 10.2196/jmir.8.4.e27; Norman G, 2010, ADV HEALTH SCI EDUC, V15, P625, DOI 10.1007/s10459-010-9222-y; Norris CM, 2006, J CLIN EPIDEMIOL, V59, P448, DOI 10.1016/j.jclinepi.2005.09.007; Noushad M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080835; Painter EM, 2021, MMWR-MORBID MORTAL W, V70, P174, DOI 10.15585/mmwr.mm7005e1; Pillai S, 2020, ARCH MED RES, V51, P723, DOI 10.1016/j.arcmed.2020.05.015; Robitzsch A, 2020, FRONT EDUC, V5, DOI 10.3389/feduc.2020.589965; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Smith LE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240399; Syunyaev G., 2021, COVID 19 VACCINE ACC; TBS, 2021, COV 19 YOUTH DEATHS; Wolf MS, 2020, ANN INTERN MED, V173, P100, DOI 10.7326/M20-1239; World Health Organization, 2020, GLOBAL TUBERCULOSIS; Wright L, 2021, PREV MED, V153, DOI 10.1016/j.ypmed.2021.106713; Zhong BL, 2020, INT J BIOL SCI, V16, P1745, DOI 10.7150/ijbs.45221; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	45	1	1	7	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1405	10.3390/vaccines9121405			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0RW	34960151	Green Accepted, Green Published, gold			2022-04-29	WOS:000737370900001
J	Ochieng, C; Anand, S; Mutwiri, G; Szafron, M; Alphonsus, K				Ochieng, Candy; Anand, Sabrita; Mutwiri, George; Szafron, Michael; Alphonsus, Khrisha			Factors Associated with COVID-19 Vaccine Hesitancy among Visible Minority Groups from a Global Context: A Scoping Review	VACCINES			English	Article						vaccines; COVID-19; vaccine hesitancy; vaccine acceptance; visible minority; public health; vaccine concerns; vaccine intentions	BLACK-AMERICANS; UNITED-STATES; ACCEPTANCE; ADULTS; TRUST	Vaccine hesitancy is one of the top ten greatest threats to global health. During the COVID-19 era, vaccine hesitancy poses substantial risks, especially in visible minorities, who are disproportionately affected by the pandemic. Although evidence of vaccine hesitancy exists, there is minimal focus on visible minorities and the reasons for hesitancy in this group are unclear. Identifying these populations and their reasons for vaccine hesitancy is crucial in improving vaccine uptake and curbing the spread of COVID-19. This scoping review follows a modified version of the Arksey and O'Malley strategy. Using comprehensive search strategies, advanced searches were conducted on Medline, CINAHL, and PubMed databases to acquire relevant articles. Full-text reviews using inclusion and exclusion criteria were performed to extract themes of vaccine hesitancy. Themes were grouped into factors using thematic qualitative analysis and were objectively confirmed by principal component analysis (PCA). To complement both analyses, a word cloud of titles and abstracts for the final articles was generated. This study included 71 articles. Themes were grouped into 8 factors and the top 3 recurring factors were safety and effectiveness of the vaccine, mistrust, and socioeconomic characteristics. Shedding light on these factors could help mitigate health inequities and increase overall vaccine uptake worldwide through interventions and policies targeted at these factors. Ultimately, this would help achieve global herd immunity.	[Ochieng, Candy; Anand, Sabrita; Mutwiri, George; Szafron, Michael; Alphonsus, Khrisha] Univ Saskatchewan, Sch Publ Hlth, Saskatoon, SK S7N 5B5, Canada		Alphonsus, K (通讯作者)，Univ Saskatchewan, Sch Publ Hlth, Saskatoon, SK S7N 5B5, Canada.	candy.ochieng@usask.ca; saa541@mail.usask.ca; george.mutwiri@usask.ca; michael.szafron@usask.ca; khrisha.alphonsus@usask.ca		Ochieng, Candy/0000-0001-9517-078X			Ali SN, 2021, LANCET, V397, P1443, DOI 10.1016/S0140-6736(21)00779-0; Allen JD, 2021, TRANSL BEHAV MED, V11, P785, DOI 10.1093/tbm/ibab014; Andersson O., 2021, ANTICIPATION COVID 1, DOI 10.2139/ssrn.3765329; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [10.1080/1364557032000119616, DOI 10.1080/1364557032000119616]; Bogart LM, 2021, JAIDS-J ACQ IMM DEF, V86, P200, DOI 10.1097/QAI.0000000000002570; Bunch L, 2021, HEC FORUM, V33, P143, DOI 10.1007/s10730-021-09440-0; Cascini F, 2021, ECLINICALMEDICINE, V40, DOI 10.1016/j.eclinm.2021.101113; Chui T., WOMEN CANADA GENDER; Corpuz JCG, 2021, J PUBLIC HEALTH-UK, V43, pE370, DOI 10.1093/pubmed/fdab085; Coustasse A, 2021, J AMBUL CARE MANAG, V44, P71, DOI 10.1097/JAC.0000000000000360; Coyne-Beasley T, 2021, J ADOLESCENT HEALTH, V68, P844, DOI 10.1016/j.jadohealth.2021.02.008; Dong D, 2020, HEALTH EXPECT, V23, P1543, DOI 10.1111/hex.13140; Dube E, 2016, Can Commun Dis Rep, V42, P246; Freeman D, 2021, LANCET PUBLIC HEALTH, V6, pE416, DOI 10.1016/S2468-2667(21)00096-7; Gatwood J, 2021, AM J HEALTH-SYST PH, V78, P879, DOI 10.1093/ajhp/zxab099; Gramacho WG, 2021, VACCINE, V39, P2608, DOI 10.1016/j.vaccine.2021.03.080; Green MS, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00458-w; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kreps SE, 2021, VACCINE, V39, P3250, DOI 10.1016/j.vaccine.2021.04.044; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Latkin C, 2021, VACCINE, V39, P2237, DOI 10.1016/j.vaccine.2021.02.058; Laurencin CT, 2021, J RACIAL ETHN HEALTH, V8, P543, DOI 10.1007/s40615-021-01025-4; Leng AL, 2021, VACCINE, V39, P247, DOI 10.1016/j.vaccine.2020.12.009; Lurie N, 2006, HEALTH SERV RES, V41, P1519, DOI 10.1111/j.1475-6773.2006.00553.x; Lux M, 1998, Can Bull Med Hist, V15, P277; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Machingaidze S, 2021, NAT MED, V27, P1338, DOI 10.1038/s41591-021-01459-7; Minority Rights Group International Canada, WORLD DIR MIN IND PE; Mosby I, 2021, CAN MED ASSOC J, V193, pE381, DOI 10.1503/cmaj.210112; Nikolovski J, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251963; Ogilvie GS, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11098-9; Okorodudu DO, 2021, LANCET RESP MED, V9, P228, DOI 10.1016/S2213-2600(21)00002-3; Perkins DEK, 2021, AM J NURS, V121, P11, DOI 10.1097/01.NAJ.0000737224.48167.78; Qin W, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250112; Razai MS, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n513; Reid JA, 2021, ISR J HEALTH POLICY, V10, DOI 10.1186/s13584-021-00467-9; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Salmon DA, 2021, VACCINE, V39, P2698, DOI 10.1016/j.vaccine.2021.03.034; Scott EM, 2021, VACCINE, V39, P1058, DOI 10.1016/j.vaccine.2021.01.022; Thompson HS, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.11629; Unroe KT, 2021, J AM GERIATR SOC, V69, P593, DOI 10.1111/jgs.17022; Urrunaga-Pastor D, 2021, TRAVEL MED INFECT DI, V41, DOI 10.1016/j.tmaid.2021.102059; Viswanath K, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10862-1; Wang C, 2021, VACCINE, V39, P2833, DOI 10.1016/j.vaccine.2021.04.020; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Woko C, 2020, J HEALTH COMMUN, V25, P819, DOI 10.1080/10810730.2020.1864521; Woolf K, 2021, LANCET REG HEALTH-EU, V9, DOI 10.1016/j.lanepe.2021.100180; World Health Organization World Health Organization, 10 THREATS GLOB HLTH	49	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1445	10.3390/vaccines9121445			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XZ8FZ	34960192	Green Published, gold			2022-04-29	WOS:000737884200001
J	Valdivia-Olivares, RY; Rodriguez-Fernandez, M; Alvarez-Figueroa, MJ; Kalergis, AM; Gonzalez-Aramundiz, JV				Valdivia-Olivares, Rayen Yanara; Rodriguez-Fernandez, Maria; alvarez-Figueroa, Maria Javiera; Kalergis, Alexis M.; Gonzalez-Aramundiz, Jose Vicente			The Importance of Nanocarrier Design and Composition for an Efficient Nanoparticle-Mediated Transdermal Vaccination	VACCINES			English	Article						transdermal vaccines; needle-free immunization; nanomedicine; nanoparticle design; nano vaccines	FALCIPARUM SURFACE-ANTIGEN; MESSENGER-RNA VACCINES; TRANSCUTANEOUS IMMUNIZATION; STRATUM-CORNEUM; MICRONEEDLE ARRAYS; MODIFIED ETHOSOMES; DENDRITIC CELLS; HYALURONIC-ACID; RECENT PROGRESS; DELIVERY	The World Health Organization estimates that the pandemic caused by the SARS-CoV-2 virus claimed more than 3 million lives in 2020 alone. This situation has highlighted the importance of vaccination programs and the urgency of working on new technologies that allow an efficient, safe, and effective immunization. From this perspective, nanomedicine has provided novel tools for the design of the new generation of vaccines. Among the challenges of the new vaccine generations is the search for alternative routes of antigen delivery due to costs, risks, need for trained personnel, and low acceptance in the population associated with the parenteral route. Along these lines, transdermal immunization has been raised as a promising alternative for antigen delivery and vaccination based on a large absorption surface and an abundance of immune system cells. These features contribute to a high barrier capacity and high immunological efficiency for transdermal immunization. However, the stratum corneum barrier constitutes a significant challenge for generating new pharmaceutical forms for transdermal antigen delivery. This review addresses the biological bases for transdermal immunomodulation and the technological advances in the field of nanomedicine, from the passage of antigens facilitated by devices to cross the stratum corneum, to the design of nanosystems, with an emphasis on the importance of design and composition towards the new generation of needle-free nanometric transdermal systems.	[Valdivia-Olivares, Rayen Yanara; alvarez-Figueroa, Maria Javiera] Pontificia Univ Catolica Chile, Dept Farm Escuela Quim & Farm, Fac Quim & Farm, Santiago 7820436, Chile; [Valdivia-Olivares, Rayen Yanara; Rodriguez-Fernandez, Maria] Pontificia Univ Catolica Chile, Inst Biol & Med Engn, Sch Engn, Santiago 7820436, Chile; [Valdivia-Olivares, Rayen Yanara; Rodriguez-Fernandez, Maria] Pontificia Univ Catolica Chile, Inst Biol & Med Engn, Sch Med & Biol Sci, Santiago 7820436, Chile; [Kalergis, Alexis M.] Pontificia Univ Catolica Chile, Millennium Inst Immunol & Immunotherapy, Dept Genet Mol & Microbiol, Fac Ciencias Biol, Av Libertador Bernardo Higgins 340, Santiago 7810000, Chile; [Kalergis, Alexis M.] Pontificia Univ Catolica Chile, Dept Endocrinol, Escuela Med, Santiago 7810000, Chile; [Gonzalez-Aramundiz, Jose Vicente] Pontificia Univ Catolica Chile, Millennium Inst Immunol & Immunotherapy, Dept Farm, Fac Quim Farm,Escuela Quim & Farm, Santiago 7820436, Chile; [Gonzalez-Aramundiz, Jose Vicente] Pontificia Univ Catolica Chile, Ctr Invest Nanotecnol & Mat Avanzados CIEN UC, Santiago 7810000, Chile		Kalergis, AM (通讯作者)，Pontificia Univ Catolica Chile, Millennium Inst Immunol & Immunotherapy, Dept Genet Mol & Microbiol, Fac Ciencias Biol, Av Libertador Bernardo Higgins 340, Santiago 7810000, Chile.; Kalergis, AM (通讯作者)，Pontificia Univ Catolica Chile, Dept Endocrinol, Escuela Med, Santiago 7810000, Chile.; Gonzalez-Aramundiz, JV (通讯作者)，Pontificia Univ Catolica Chile, Millennium Inst Immunol & Immunotherapy, Dept Farm, Fac Quim Farm,Escuela Quim & Farm, Santiago 7820436, Chile.; Gonzalez-Aramundiz, JV (通讯作者)，Pontificia Univ Catolica Chile, Ctr Invest Nanotecnol & Mat Avanzados CIEN UC, Santiago 7810000, Chile.	ryvaldivia@uc.cl; marodriguezf@uc.cl; mjalvare@uc.cl; akalergis@bio.puc.cl; jvgonzal@uc.cl	; Rodriguez-Fernandez, Maria/I-7193-2016	Alvarez-Figueroa, Maria Javiera/0000-0001-5911-7543; Kalergis, Alexis/0000-0001-7622-5263; Rodriguez-Fernandez, Maria/0000-0003-1966-2920; Gonzalez Aramundiz, Jose Vicente/0000-0001-7856-9211	FONDECYTComision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT [1201482, 1190830]; Interdisciplinary Grant 2020 by Pontificia Universidad Catolica de Chile; Millennium Institute on Immunology and Immunotherapy [ICN09_016]	This research was funded by FONDECYT grants No 1201482 and No 1190830, Interdisciplinary Grant 2020 by Pontificia Universidad Catolica de Chile and The Millennium Institute on Immunology and Immunotherapy ICN09_016.	Abhyankar MM, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0060-x; Ahmed KS, 2019, MAT SCI ENG C-MATER, V99, P1448, DOI 10.1016/j.msec.2019.02.095; Akhtar N, 2020, BIOMED ENG-BIOMED TE, V65, P243, DOI 10.1515/bmt-2019-0019; Alfagih IM, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010045; Alkilani AZ, 2015, PHARMACEUTICS, V7, P438, DOI 10.3390/pharmaceutics7040438; Alvarez-Figueroa MJ, 2020, PHARM RES-DORDR, V37, DOI 10.1007/s11095-020-02925-6; Arnouts H, 2012, TECHNOMETRICS, V54, P355, DOI 10.1080/00401706.2012.715834; Atmar RL, 2010, EXPERT REV VACCINES, V9, P1399, DOI [10.1586/erv.10.134, 10.1586/ERV.10.134]; Baghaei B, 2017, J APPL POLYM SCI, V134, DOI 10.1002/app.45145; Bal SM, 2008, EUR J PHARM SCI, V35, P193, DOI 10.1016/j.ejps.2008.06.016; Baldwin Susan L., 2021, PLoS One, V16, pe0247990, DOI 10.1371/journal.pone.0247990; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BANKSSCHLEGEL SP, 1982, J CELL BIOL, V93, P551, DOI 10.1083/jcb.93.3.551; Bao LL, 2022, DRUG DELIV TRANSL RE, V12, P395, DOI 10.1007/s13346-021-01045-x; Baroli B, 2007, J INVEST DERMATOL, V127, P1701, DOI 10.1038/sj.jid.5700733; Bernardi DS, 2016, NANOMED-NANOTECHNOL, V12, P2439, DOI 10.1016/j.nano.2016.07.001; Bernelin-Cottet C, 2019, J CONTROL RELEASE, V308, P14, DOI 10.1016/j.jconrel.2019.06.041; Bhardwaj P, 2020, J DRUG DELIV SCI TEC, V56, DOI 10.1016/j.jddst.2020.101581; Bhattaccharjee S, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12050472; BHOWMIK D, 2012, PHARM INNOV, V1, P9; Bolhassani A, 2014, HUM VACC IMMUNOTHER, V10, P321, DOI 10.4161/hv.26796; BOMMANNAN D, 1991, J CONTROL RELEASE, V16, P299, DOI 10.1016/0168-3659(91)90006-Y; Boone CE, 2020, ACS APPL NANO MATER, V3, P8037, DOI 10.1021/acsanm.0c01506; Botting RA, 2020, IMMUNOLOGY, V160, P149, DOI 10.1111/imm.13192; Brosh-Nissimov T, 2021, CLIN MICROBIOL INFEC, V27, P1652, DOI 10.1016/j.cmi.2021.06.036; Brown S, 2018, ANAL BIOANAL CHEM, V410, P7249, DOI 10.1007/s00216-018-1336-8; Bussio JI, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11050246; Bussio JI, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8090659; Chagla Z, 2021, ANN INTERN MED, V174, pJC15, DOI 10.7326/ACPJ202102160-015; Chambers ES, 2020, IMMUNOLOGY, V160, P116, DOI 10.1111/imm.13152; Chaudhury S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35452-x; Chen Xiao, 2020, Eur J Pharm Sci, V151, P105410, DOI 10.1016/j.ejps.2020.105410; Chen YY, 2020, 2020 IEEE 5TH INTERNATIONAL CONFERENCE ON INTELLIGENT TRANSPORTATION ENGINEERING (IEEE ICITE 2020), P55, DOI 10.1109/ICITE50838.2020.9231419; Chen YL, 2020, ANNU REV IMMUNOL, V38, P171, DOI 10.1146/annurev-immunol-082919-093554; Chen ZJ, 2018, DRUG DISCOV TODAY, V23, P181, DOI 10.1016/j.drudis.2017.09.017; Choi YH, 2019, J INFECT DIS, V220, P1926, DOI 10.1093/infdis/jiz399; Chopra M, 2020, B WORLD HEALTH ORGAN, V98, P146, DOI 10.2471/BLT.19.241620; Coccia M, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0027-3; Coolen NA, 2010, ARCH DERMATOL RES, V302, P47, DOI 10.1007/s00403-009-0989-8; Carabineiro SAC, 2017, MOLECULES, V22, DOI 10.3390/molecules22050857; Cortes-Rios J, 2020, J FOOD ENG, V276, DOI 10.1016/j.jfoodeng.2019.109883; Crecente-Campo J, 2019, BIOENG TRANSL MED, V4, P38, DOI 10.1002/btm2.10118; Crecente-Campo J, 2018, J CONTROL RELEASE, V286, P20, DOI 10.1016/j.jconrel.2018.07.018; DEPANFILIS G, 1988, J INVEST DERMATOL, V91, P283, DOI 10.1111/1523-1747.ep12470473; Dhawan S., 2020, NANOFORMULATIONS HUM, P287; Dorigatti I, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06006-6; Du GS, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2476-4; Du HJ, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006006; El Zaafarany GM, 2010, INT J PHARMACEUT, V397, P164, DOI 10.1016/j.ijpharm.2010.06.034; Engelke L, 2018, EUR J PHARM BIOPHARM, V128, P119, DOI 10.1016/j.ejpb.2018.04.008; Ferreira SLC, 2007, ANAL CHIM ACTA, V597, P179, DOI 10.1016/j.aca.2007.07.011; Fotoran WL, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040619; Gadkari R, 2014, J COSMET DERMATOL-US, V13, P38, DOI 10.1111/jocd.12071; Goyal R, 2016, J CONTROL RELEASE, V240, P77, DOI 10.1016/j.jconrel.2015.10.049; GRIT M, 1993, CHEM PHYS LIPIDS, V64, P3, DOI 10.1016/0009-3084(93)90053-6; Grupper A, 2021, CLIN J AM SOC NEPHRO, V16, P1037, DOI 10.2215/CJN.03500321; Guillot AJ, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12060569; Gupta A, 2015, LANGMUIR, V31, P1556, DOI 10.1021/la5044969; Gupta PN, 2005, INT J PHARMACEUT, V293, P73, DOI 10.1016/j.ijpharm.2004.12.022; Gupta PN, 2005, J PHARM PHARMACOL, V57, P295, DOI 10.1211/0022357055515; Gupta R, 2017, SCI REP-UK, V7, DOI 10.1038/srep45292; Hasan M, 2020, ADV DRUG DELIVER REV, V154, P227, DOI 10.1016/j.addr.2020.06.016; Hashemi V, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106446; He N, 2004, J PHARM SCI-US, V93, P1415, DOI 10.1002/jps.20030; He YP, 2018, ACS NANO, V12, P10272, DOI 10.1021/acsnano.8b05373; Hernandez-Franco JF, 2021, J IMMUNOL, V206, P700, DOI 10.4049/jimmunol.2000703; Hesse-Macabata J, 2019, J EUR ACAD DERMATOL, V33, P1177, DOI 10.1111/jdv.15472; Huang H, 2021, J CONTROL RELEASE, V335, P449, DOI 10.1016/j.jconrel.2021.05.024; Ibrahim SA, 2010, PHARM RES-DORDR, V27, P115, DOI 10.1007/s11095-009-9985-0; Inoh Y, 2017, EUR J PHARM SCI, V102, P230, DOI 10.1016/j.ejps.2017.03.023; Ita K, 2017, PHARM DEV TECHNOL, V22, P458, DOI 10.3109/10837450.2015.1116566; Ita K, 2016, BIOMED PHARMACOTHER, V83, P1080, DOI 10.1016/j.biopha.2016.08.026; Jasim A, 2017, NANOTECHNOLOGY-BASED APPROACHES FOR TARGETING AND DELIVERY OF DRUGS AND GENES, P62, DOI 10.1016/B978-0-12-809717-5.00002-6; Alvarez-Figueroa MJ, 2019, PHARM DEV TECHNOL, V24, P630, DOI 10.1080/10837450.2018.1550789; Joyce JC, 2018, J INFECT DIS, V218, P124, DOI 10.1093/infdis/jiy139; Kang L, 2007, J CONTROL RELEASE, V120, P211, DOI 10.1016/j.jconrel.2007.05.006; Kang NW, 2021, EXPERT OPIN DRUG DEL, V18, P929, DOI 10.1080/17425247.2021.1828860; Karami Z, 2016, DRUG DISCOV TODAY, V21, P789, DOI 10.1016/j.drudis.2016.01.004; Kim BS, 2014, J IMMUNOL, V193, P3717, DOI 10.4049/jimmunol.1401307; Kim KS, 2016, ADV FUNCT MATER, V26, P2512, DOI 10.1002/adfm.201504879; Kitaoka M, 2016, BIOTECHNOL J, V11, P1375, DOI 10.1002/biot.201600081; Kojarunchitt T, 2011, INT J PHARMACEUT, V408, P20, DOI 10.1016/j.ijpharm.2011.01.037; Kolli CS, 2015, THER DELIV, V6, P1081, DOI 10.4155/tde.15.67; Kopecna M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51226-5; Koutsonanos DG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004773; Lane ME, 2013, INT J PHARMACEUT, V447, P12, DOI 10.1016/j.ijpharm.2013.02.040; Lanza JS, 2020, INT J PHARMACEUT, V586, DOI 10.1016/j.ijpharm.2020.119390; Lee BY, 2017, VACCINE, V35, P4475, DOI 10.1016/j.vaccine.2017.05.096; Lee JW, 2008, BIOMATERIALS, V29, P2113, DOI 10.1016/j.biomaterials.2007.12.048; Leung A, 2012, CURR OPIN PEDIATR, V24, P371, DOI 10.1097/MOP.0b013e3283535790; Liu C, 2016, EUR J PHARM SCI, V93, P437, DOI 10.1016/j.ejps.2016.08.048; Liu P, 2009, J PHARM SCI-US, V98, P565, DOI 10.1002/jps.21459; Liu S, 2014, EUR J PHARM BIOPHARM, V86, P267, DOI 10.1016/j.ejpb.2013.10.001; Lopez PA, 2017, J DERMATOL SCI, V87, P252, DOI 10.1016/j.jdermsci.2017.06.012; MAHASE E, 2020, BMJ-BRIT MED J, V371, P51975, DOI DOI 10.1136/BMJ.M4826; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4709; Mahor S, 2007, INT J PHARMACEUT, V340, P13, DOI 10.1016/j.ijpharm.2007.03.006; Mann JL, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aba6676; Mansury D, 2019, ARTIF CELL NANOMED B, V47, P370, DOI 10.1080/21691401.2018.1557674; Marianecci C, 2014, ADV COLLOID INTERFAC, V205, P187, DOI 10.1016/j.cis.2013.11.018; Maurya A, 2015, NOVEL DELIVERY SYSTEMS FOR TRANSDERMAL AND INTRADERMAL DRUG DELIVERY, P147; McAllister L, 2014, LANCET, V384, P674, DOI 10.1016/S0140-6736(14)60524-9; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Merad M, 2008, NAT REV IMMUNOL, V8, P935, DOI 10.1038/nri2455; Mittal A, 2015, J CONTROL RELEASE, V206, P140, DOI 10.1016/j.jconrel.2015.03.017; Mittal A, 2015, NANOMED-NANOTECHNOL, V11, P147, DOI 10.1016/j.nano.2014.08.009; Montis C, 2015, J COLLOID INTERF SCI, V449, P317, DOI 10.1016/j.jcis.2014.11.056; Nagarkar R, 2020, J DRUG DELIV SCI TEC, V59, DOI 10.1016/j.jddst.2020.101923; Natsheh H, 2020, MOLECULES, V25, DOI 10.3390/molecules25132959; O'Shea J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040320; Okore VC, 2011, INDIAN J PHARM SCI, V73, P323, DOI 10.4103/0250-474X.93515; Okumura K, 2020, ONCOGENE, V39, P4756, DOI 10.1038/s41388-020-1323-3; Opatha SAT, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090855; Oshio T, 2017, J DERMATOL SCI, V85, P106, DOI 10.1016/j.jdermsci.2016.10.008; Page A, 2020, CANCERS, V12, DOI 10.3390/cancers12040962; Paiva-Santos AC, 2021, PHARM RES-DORDR, V38, P947, DOI 10.1007/s11095-021-03053-5; Pamornpathomkul B, 2018, AAPS PHARMSCITECH, V19, P481, DOI 10.1208/s12249-017-0855-5; Patrick T.S., 2009, CUBOSOMES BICONTINUO; Peleteiro M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00791; Pellegrini M, 2016, SCI REP-UK, V6, DOI 10.1038/srep34986; Perrie Y, 2001, VACCINE, V19, P3301, DOI 10.1016/S0264-410X(00)00432-1; Pilishvili T, 2021, MMWR-MORBID MORTAL W, V70, P753, DOI 10.15585/mmwr.mm7020e2externalicon; Pippa N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060558; Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504; Qiu YQ, 2016, DRUG DELIV, V23, P2391, DOI 10.3109/10717544.2014.992497; Quan P, 2021, J ETHNOPHARMACOL, V265, DOI 10.1016/j.jep.2020.113294; Rai S, 2017, NANO REV EXP, V8, DOI 10.1080/20022727.2017.1325708; Rattanapak T, 2013, J CONTROL RELEASE, V172, P894, DOI 10.1016/j.jconrel.2013.08.018; Rattanapak T, 2012, J PHARM PHARMACOL, V64, P1560, DOI 10.1111/j.2042-7158.2012.01535.x; Rey-Jurado E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00026; Rostami H, 2017, IMMUNOL LETT, V187, P19, DOI 10.1016/j.imlet.2017.05.002; Cordeiro AS, 2015, BIOTECHNOL ADV, V33, P1279, DOI 10.1016/j.biotechadv.2015.05.010; Saremi SS, 2018, IRAN J BASIC MED SCI, V21, P536, DOI 10.22038/IJBMS.2018.25976.6391; Schatzlein A, 1998, BRIT J DERMATOL, V138, P583; Souto EB, 2020, EXPERT OPIN DRUG DEL, V17, P357, DOI 10.1080/17425247.2020.1727883; Su R, 2017, ONCOTARGET, V8, P38214, DOI 10.18632/oncotarget.17130; Subongkot T, 2020, DRUG DELIV, V27, P1087, DOI 10.1080/10717544.2020.1797244; Tadros AR, 2020, NAT MED, V26, P341, DOI 10.1038/s41591-020-0787-6; Takeuchi I, 2021, COLLOID SURFACE A, V608, DOI 10.1016/j.colsurfa.2020.125607; Tammam SN, 2021, J CONTROL RELEASE, V337, P258, DOI 10.1016/j.jconrel.2021.07.028; Tayeb HH, 2021, COLLOID INTERFAC SCI, V45, DOI 10.1016/j.colcom.2021.100533; Toyoda M, 2015, INT J PHARMACEUT, V483, P110, DOI 10.1016/j.ijpharm.2015.02.024; Tyagi RK, 2016, HUM VACC IMMUNOTHER, V12, P990, DOI 10.1080/21645515.2015.1116656; Tyagi RK, 2015, VACCINE, V33, P4630, DOI 10.1016/j.vaccine.2015.06.054; Um JY, 2003, INT J PHARMACEUT, V253, P71, DOI 10.1016/S0378-5173(02)00673-7; Uskokovic V, 2021, NANOMEDICINE-UK, V16, P1203, DOI 10.2217/nnm-2021-0024; van Hoogevest P, 2014, EUR J LIPID SCI TECH, V116, P1088, DOI 10.1002/ejlt.201400219; Varypataki EM, 2015, AAPS J, V17, P216, DOI 10.1208/s12248-014-9686-4; Verbeke R, 2021, J CONTROL RELEASE, V333, P511, DOI 10.1016/j.jconrel.2021.03.043; Gonzalez-Aramundiz JV, 2015, EUR J PHARM BIOPHARM, V97, P51, DOI 10.1016/j.ejpb.2015.09.019; Vicente S, 2014, NANOMEDICINE-UK, V9, P2273, DOI [10.2217/NNM.14.10, 10.2217/nnm.14.10]; Waghule T, 2019, BIOMED PHARMACOTHER, V109, P1249, DOI 10.1016/j.biopha.2018.10.078; Wang Y, 2021, ACS APPL BIO MATER, V4, P4953, DOI 10.1021/acsabm.1c00240; Wong TW, 2014, J CONTROL RELEASE, V193, P257, DOI 10.1016/j.jconrel.2014.04.045; Xia DN, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2110817118; Xie J, 2018, COLLOID SURFACE B, V172, P323, DOI 10.1016/j.colsurfb.2018.08.061; Yan B, 2020, J CELL MOL MED, V24, P11646, DOI 10.1111/jcmm.15834; Yang HW, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201600750; Yang J, 2016, NAT IMMUNOL, V17, P48, DOI 10.1038/ni.3312; Yang L, 2017, INT J NANOMED, V12, P3357, DOI 10.2147/IJN.S134708; Yang XX, 2020, J CONTROL RELEASE, V327, P88, DOI 10.1016/j.jconrel.2020.07.047; Yin Y, 2021, ACS NANO, V15, P14347, DOI 10.1021/acsnano.1c03252; Yu Q, 2020, J BIOMED NANOTECHNOL, V16, P1776, DOI 10.1166/jbn.2020.3007; Yusuf H, 2017, INT J PHARMACEUT, V533, P179, DOI 10.1016/j.ijpharm.2017.09.011; Zhang YB, 2018, COLLOID SURFACE B, V163, P184, DOI 10.1016/j.colsurfb.2017.12.031; Zhang YB, 2017, INT J PHARMACEUT, V516, P225, DOI 10.1016/j.ijpharm.2016.11.011; Zhang YT, 2019, THERANOSTICS, V9, P48, DOI 10.7150/thno.29715	167	0	0	11	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1420	10.3390/vaccines9121420			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YG8DJ	34960166	gold, Green Published			2022-04-29	WOS:000742711600001
J	Abakushina, EV; Popova, LI; Zamyatnin, AA; Werner, J; Mikhailovsky, NV; Bazhin, AV				Abakushina, Elena V.; Popova, Liubov I.; Zamyatnin, Andrey A., Jr.; Werner, Jens; Mikhailovsky, Nikolay V.; Bazhin, Alexandr V.			The Advantages and Challenges of Anticancer Dendritic Cell Vaccines and NK Cells in Adoptive Cell Immunotherapy	VACCINES			English	Review						cancer immunotherapy; adoptive cell therapy; cancer vaccines; dendritic cells; tumor antigens; NK cells; NKG2D; cell-mediated immunity	NATURAL-KILLER-CELLS; T-CELLS; PHASE-I; ANTITUMOR-ACTIVITY; VIVO EXPANSION; CANCER; ACTIVATION; THERAPY; NKG2D; CYTOKINE	In the last decade, an impressive advance was achieved in adoptive cell therapy (ACT), which has improved therapeutic potential and significant value in promising cancer treatment for patients. The ACT is based on the cell transfer of dendritic cells (DCs) and/or immune effector cells. DCs are often used as vaccine carriers or antigen-presenting cells (APCs) to prime naive T cells ex vivo or in vivo. Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are used as major tool effector cells for ACT. Despite the fact that NK cell immunotherapy is highly effective and promising against many cancer types, there are still some limitations, including insignificant infiltration, adverse conditions of the microenvironment, the immunosuppressive cellular populations, and the low cytotoxic activity in solid tumors. To overcome these difficulties, novel methods of NK cell isolation, expansion, and stimulation of cytotoxic activity should be designed. In this review, we discuss the basic characteristics of DC vaccines and NK cells as potential adoptive cell preparations in cancer therapy.	[Abakushina, Elena V.; Popova, Liubov I.; Mikhailovsky, Nikolay V.] LLC Tecon Med Devices, Dept Dev & Res Immunol, Moscow 123298, Russia; [Zamyatnin, Andrey A., Jr.] Lomonosov Moscow State Univ, Belozersky Inst Physicochem Biol, Moscow 119992, Russia; [Zamyatnin, Andrey A., Jr.] Sechenov First Moscow State Med Univ, Inst Mol Med, Moscow 119991, Russia; [Zamyatnin, Andrey A., Jr.] Sirius Univ Sci & Technol, Dept Biotechnol, 1 Olymp Ave, Soci 354340, Russia; [Werner, Jens; Bazhin, Alexandr V.] Ludwig Maximilians Univ Munchen, Dept Gen Visceral & Transplant Surg, D-81377 Munich, Germany; [Werner, Jens; Bazhin, Alexandr V.] German Canc Consortium DKTK, Partner Site Munich, D-81377 Munich, Germany; [Werner, Jens] Bavarian Canc Res Ctr BZKF, D-91054 Erlangen, Germany		Abakushina, EV (通讯作者)，LLC Tecon Med Devices, Dept Dev & Res Immunol, Moscow 123298, Russia.	abakushina@mail.ru; ljubovprokudina@gmail.com; zamyat@belozersky.msu.ru; jens.werner@med.uni-muenchen.de; nickmikh.mrrc@gmail.com; alexandr.bazhin@med.uni-muenchen.de	Zamyatnin, Andrey A./D-6443-2012	Zamyatnin, Andrey A./0000-0002-3046-4565			Abakushina EV, 2019, BIOCHEMISTRY-MOSCOW+, V84, P720, DOI 10.1134/S0006297919070046; [Абакушина Елена Вячеславовна. Abakushina E.V.], 2016, [Российский иммунологический журнал, Russian Journal of Immunology, Rossiiskii immunologicheskii zhurnal], V10 (19), P131; Alici E, 2008, BLOOD, V111, P3155, DOI 10.1182/blood-2007-09-110312; Arij B, 2020, IMMUNOL INVEST, V49, P498, DOI 10.1080/08820139.2019.1690506; Bachanova V, 2010, CANCER IMMUNOL IMMUN, V59, P1739, DOI 10.1007/s00262-010-0896-z; Barkholt L, 2009, IMMUNOTHERAPY, V1, P753, DOI 10.2217/IMT.09.47; Barry KC, 2018, NAT MED, V24, P1178, DOI 10.1038/s41591-018-0085-8; Basar R, 2020, BLOOD ADV, V4, P5868, DOI 10.1182/bloodadvances.2020002547; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Fuertes MB, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.713158; Biederstadt A, 2021, INT J HEMATOL, V114, P554, DOI 10.1007/s12185-021-03209-4; Bodder J, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.631713; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Buddingh EP, 2011, CANCER IMMUNOL IMMUN, V60, P575, DOI 10.1007/s00262-010-0965-3; Campbell KS, 2013, J ALLERGY CLIN IMMUN, V132, P536, DOI 10.1016/j.jaci.2013.07.006; Carrega P, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00347; Cheng M, 2013, CELL MOL IMMUNOL, V10, P230, DOI 10.1038/cmi.2013.10; Chitadze G, 2013, SCAND J IMMUNOL, V78, P120, DOI 10.1111/sji.12072; Chongqing Public Health Medical Center, 2020, PHAS 1 2 STUD UN OFF; Cifuentes-Rius A, 2021, NAT NANOTECHNOL, V16, P37, DOI 10.1038/s41565-020-00810-2; Claus M, 2008, FRONT BIOSCI-LANDMRK, V13, P956, DOI 10.2741/2735; Cursons J, 2019, CANCER IMMUNOL RES, V7, P1162, DOI 10.1158/2326-6066.CIR-18-0500; Decot V, 2010, EXP HEMATOL, V38, P351, DOI 10.1016/j.exphem.2010.02.006; Del Zotto G, 2017, CYTOM PART B-CLIN CY, V92, P100, DOI 10.1002/cyto.b.21508; Dhar P, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02440-3; Dougall WC, 2017, IMMUNOL REV, V276, P112, DOI 10.1111/imr.12518; Fan JQ, 2018, THERANOSTICS, V8, P5784, DOI 10.7150/thno.29035; Fang F, 2017, SEMIN IMMUNOL, V31, P37, DOI 10.1016/j.smim.2017.07.009; Fares Charlene M, 2019, Am Soc Clin Oncol Educ Book, V39, P147, DOI 10.1200/EDBK_240837; Fearnley DB, 1999, BLOOD, V93, P728, DOI 10.1182/blood.V93.2.728.402k03_728_736; Fehniger TA, 1999, J IMMUNOL, V162, P4511; Ferris RL, 2010, J CLIN ONCOL, V28, P4390, DOI 10.1200/JCO.2009.27.6360; Fujiwara Y, 2020, CANC DRUG RESIST, V3, P252; Gao J, 2017, CANCER SCI, V108, P1934, DOI 10.1111/cas.13324; Garofano F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174307; Gerosa F, 2002, J EXP MED, V195, P327, DOI 10.1084/jem.20010938; Glienke W, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00021; Granzin M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00458; Guo CQ, 2013, ADV CANCER RES, V119, P421, DOI 10.1016/B978-0-12-407190-2.00007-1; Hamilton G, 2021, BIOL-TARGETS THER, V15, P265, DOI 10.2147/BTT.S290305; Hart D, 2011, ASIAN J ANDROL, V13, P183, DOI 10.1038/aja.2010.146; Iliopoulou EG, 2010, CANCER IMMUNOL IMMUN, V59, P1781, DOI 10.1007/s00262-010-0904-3; Jinushi M, 2006, P NATL ACAD SCI USA, V103, P9190, DOI 10.1073/pnas.0603503103; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Knorr DA, 2014, SEMIN IMMUNOL, V26, P161, DOI 10.1016/j.smim.2014.02.002; Lapteva N, 2012, CYTOTHERAPY, V14, P1131, DOI 10.3109/14653249.2012.700767; Lee DA, 2019, IMMUNOL REV, V290, P85, DOI 10.1111/imr.12793; Lee SJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-2034-y; Lim O, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00286; Linhares AD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01909; Liu SZ, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-020-01014-w; Liu X, 2012, IMMUNOL LETT, V143, P208, DOI 10.1016/j.imlet.2012.02.014; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; Lu SJ, 2015, CLIN CANCER RES, V21, P4819, DOI 10.1158/1078-0432.CCR-15-0845; Ma DY, 2009, SEMIN IMMUNOL, V21, P265, DOI 10.1016/j.smim.2009.05.010; Ma Minh, 2020, bioRxiv, DOI 10.1101/2020.08.11.247320; Marcenaro E, 2003, EUR J IMMUNOL, V33, P3367, DOI 10.1002/eji.200324425; Marofi F, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.673276; Martinet L, 2016, ENCYCLOPEDIA OF IMMUNOBIOLOGY, VOL 2: MOLECULAR IMMUNOLOGY, P404, DOI 10.1016/B978-0-12-374279-7.02010-5; Martinet L, 2015, NAT REV IMMUNOL, V15, P243, DOI 10.1038/nri3799; Miller JS, 2005, BLOOD, V105, P3051, DOI 10.1182/blood-2004-07-2974; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Myers JA, 2021, NAT REV CLIN ONCOL, V18, P85, DOI 10.1038/s41571-020-0426-7; Navarro AG, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00202; Ni J, 2012, J EXP MED, V209, P2351, DOI 10.1084/jem.20120944; Nkarta Inc, 2020, PHAS 1 STUD NKX101 A; O'Donnell JS, 2020, SEMIN CANCER BIOL, V65, P189, DOI 10.1016/j.semcancer.2019.11.013; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Pasero C, 2015, ONCOTARGET, V6, P14360, DOI 10.18632/oncotarget.3965; Reindl LM, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1777651; Rezvani K, 2017, MOL THER, V25, P1769, DOI 10.1016/j.ymthe.2017.06.012; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Roberts EW, 2016, CANCER CELL, V30, P324, DOI 10.1016/j.ccell.2016.06.003; Rochman Y, 2009, NAT REV IMMUNOL, V9, P480, DOI 10.1038/nri2580; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; Rubnitz JE, 2010, J CLIN ONCOL, V28, P955, DOI 10.1200/JCO.2009.24.4590; Sakamoto N, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0632-8; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sangiolo D, 2008, INT IMMUNOL, V20, P841, DOI 10.1093/intimm/dxn042; Saxena M, 2021, NAT REV CANCER, V21, P360, DOI 10.1038/s41568-021-00346-0; Seliger B, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00419; Shah N, 2017, BRIT J HAEMATOL, V177, P457, DOI 10.1111/bjh.14570; Shimasaki N, 2020, NAT REV DRUG DISCOV, V19, P200, DOI 10.1038/s41573-019-0052-1; Shin MH, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e14; Sivori S, 2003, EUR J IMMUNOL, V33, P3439, DOI 10.1002/eji.200324533; Spanholtz J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020740; Stringaris K, 2014, HAEMATOLOGICA, V99, P836, DOI 10.3324/haematol.2013.087536; Sutlu T, 2009, J INTERN MED, V266, P154, DOI 10.1111/j.1365-2796.2009.02121.x; Tarazona R, 2020, CANCER IMMUNOL IMMUN, V69, P879, DOI 10.1007/s00262-020-02532-9; The Third Affiliated Hospital of Guangzhou Medical University, 2019, PILOT STUD NKG2D LIG; Torres N, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000233; Veluchamy JP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00087; Verdijk P, 2009, CLIN CANCER RES, V15, P2531, DOI 10.1158/1078-0432.CCR-08-2729; Vitale M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01415; Wong JL, 2013, CANCER RES, V73, P4653, DOI 10.1158/0008-5472.CAN-12-4366; Xie GZ, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102975; Yoshida Y, 2017, ANTICANCER RES, V37, P3941, DOI 10.21873/anticanres.11777; Yuan X, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000024519; Zhou XL, 2018, CANCER MANAG RES, V10, P5363, DOI 10.2147/CMAR.S173201; Zingoni A, 2016, CRIT REV IMMUNOL, V36, P445, DOI 10.1615/CritRevImmunol.2017020166	101	1	1	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1363	10.3390/vaccines9111363			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH1FU	34835294	gold, Green Published			2022-04-29	WOS:000725187900001
J	Bruzzese, E; Pagano, F; Diana, A; Punzi, L; Guarino, A				Bruzzese, Eugenia; Pagano, Federica; Diana, Alfredo; Punzi, Liana; Guarino, Alfredo			Protection of Vaccine Preventable Diseases in a Population of HIV-Infected Children: A 3 Years Prospective Study	VACCINES			English	Article						HIV infection; vaccines; immune response; children	MEASLES VACCINATION; UNINFECTED CHILDREN; EXPOSED CHILDREN; B-CELLS; IMMUNITY; IMMUNOGENICITY; ANTIBODIES; COVERAGE	Human Immunodeficiency Virus (HIV) infected children have a 30-70% chance of being incompletely immunized and may not respond serologically with the same magnitude or durability as uninfected children. The aim of the study was to describe the rate of protective antibodies titre and the persistence of the response against four recommended vaccinations in HIV infected children and adolescents. A two-phase observational study was performed in which protective IgG antibodies to measles, mumps, rubella and hepatitis B were determined and monitored for 12 and 24 months, in 26 perinatally HIV-infected children. The rate of protection for rubella and hepatitis B was significantly lower in the HIV group compared to the control group (92% vs. 65% for rubella and 78.4% vs. 45.4% for hepatitis B; p < 0.05). Children who received primary vaccination after initiating combination antiretroviral therapy (cART) had a higher rate of response. Seronegative patients who received a booster dose of vaccine had a good immunological response. HIV infection is associated with a lower response to vaccines against rubella and hepatitis. The beginning of cART before vaccination may be associated with a better response. The evaluation of the serological response is crucial in children with HIV infection in order to evaluate the protection of vaccine preventable diseases.	[Bruzzese, Eugenia; Pagano, Federica; Diana, Alfredo; Punzi, Liana; Guarino, Alfredo] Univ Federico II Naples, Dept Translat Med Sci, Sect Pediat, I-80100 Naples, Italy		Bruzzese, E (通讯作者)，Univ Federico II Naples, Dept Translat Med Sci, Sect Pediat, I-80100 Naples, Italy.	eugbruzz@unina.it; paganofederica1405@gmail.com; alfredodiana93@gmail.com; punziliana@gmail.com; alfguari@unina.it	Bruzzese, Eugenia/AAC-5988-2022; Guarino, Alfredo/AAC-4812-2022	Guarino, Alfredo/0000-0003-0199-0336			Adetokunboh OO, 2019, HUM VACC IMMUNOTHER, V15, P2590, DOI 10.1080/21645515.2019.1599676; [Anonymous], PANEL OPPORTUNISTIC; Bayhan GI, 2021, HUM VACC IMMUNOTHER, V17, P2768, DOI 10.1080/21645515.2021.1902724; Bekker V, 2006, PEDIATRICS, V118, pE315, DOI 10.1542/peds.2005-2616; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P471; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P893; Chaiwarith R, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1499-x; Choudhury SA, 2013, INT J INFECT DIS, V17, pE1249, DOI 10.1016/j.ijid.2013.07.008; Das Bhattacharya S, 2014, INDIAN J PEDIATR, V81, P850, DOI 10.1007/s12098-013-1049-0; Helfand RF, 2008, J INFECT DIS, V198, P1457, DOI 10.1086/592756; Iwajomo OH, 2015, J INFECTION, V70, P616, DOI 10.1016/j.jinf.2014.10.011; Jallow S, 2017, J CLIN VIROL, V94, P50, DOI 10.1016/j.jcv.2017.07.009; Menson EN, 2012, HIV MED, V13, P333, DOI 10.1111/j.1468-1293.2011.00982.x; Moir S, 2010, BLOOD, V116, P5571, DOI 10.1182/blood-2010-05-285528; Moss WJ, 2008, CLIN INFECT DIS, V46, P523, DOI 10.1086/526525; Mutsaerts EAML, 2018, ECLINICALMEDICINE, V1, P28, DOI 10.1016/j.eclinm.2018.06.002; Pensierosoa S, 2009, P NATL ACAD SCI USA, V106, P7939, DOI 10.1073/pnas.0901702106; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Shapiro ED, 2011, J INFECT DIS, V203, P312, DOI 10.1093/infdis/jiq052; Shen R, 2021, INFECT DIS POVERTY, V10, DOI 10.1186/s40249-021-00797-5; Siberry GK, 2015, CLIN INFECT DIS, V61, P988, DOI 10.1093/cid/civ440; Simani OE, 2019, EXPERT REV VACCINES, V18, P95, DOI 10.1080/14760584.2019.1547195; Simani OE, 2014, AIDS, V28, P531, DOI 10.1097/QAD.0000000000000127; Slogrove AL, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00164; Stermole BM, 2011, VACCINE, V29, P2874, DOI 10.1016/j.vaccine.2011.02.013; Su JR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199229; Succi RCM, 2018, PEDIATR INFECT DIS J, V37, P304, DOI 10.1097/INF.0000000000001831; Sutcliffe CG, 2010, LANCET INFECT DIS, V10, P630, DOI 10.1016/S1473-3099(10)70116-X; Tchidjou HK, 2016, HUM VACC IMMUNOTHER, V12, P540, DOI 10.1080/21645515.2015.1069451	29	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1331	10.3390/vaccines9111331			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI6SP	34835262	gold, Green Published			2022-04-29	WOS:000726239000001
J	Cai, J; Zhang, BD; Li, YQ; Zhu, WF; Akihisa, T; Li, W; Kikuchi, T; Liu, WY; Feng, F; Zhang, J				Cai, Jing; Zhang, Bodou; Li, Yuqi; Zhu, Wanfang; Akihisa, Toshihiro; Li, Wei; Kikuchi, Takashi; Liu, Wenyuan; Feng, Feng; Zhang, Jie			Prophylactic and Therapeutic EBV Vaccines: Major Scientific Obstacles, Historical Progress, and Future Direction	VACCINES			English	Review						Epstein-Barr virus; vaccine; T cells; antibodies; oncogenic	EPSTEIN-BARR-VIRUS; T-CELL RESPONSES; PHASE-I TRIAL; ACUTE INFECTIOUS-MONONUCLEOSIS; ENVELOPE GLYCOPROTEIN GP340; NEUTRALIZING ANTIBODY-RESPONSE; NATURAL-KILLER-CELLS; COTTONTOP TAMARINS; NASOPHARYNGEAL CARCINOMA; RECOMBINANT VACCINIA	The Epstein-Barr virus (EBV) infects more than 95% of adults worldwide and is associated with various malignant tumors and immune diseases, imparting a huge disease burden on the human population. Available EBV vaccines are imminent. Prophylactic vaccines can effectively prevent the spread of infection, whereas therapeutic vaccines mainly stimulate cell-mediated immunity and kill infected cells, thus curbing the development of malignant tumors. Nevertheless, there are still no approved EBV vaccines after decades of effort. The complexity of the EBV life cycle, the lack of appropriate animal models, and the limited reports on adjuvant selection and immune responses are gravely impeding progress in EBV vaccines. The soluble gp350 vaccine could reduce the incidence of infectious mononucleosis (IM), which seemed to offer hope, but could not prevent EBV infection. Continuous research and vaccine trials provide deep insights into the structural biology of viruses, the designs for immunogenicity, and the evolving vaccine platforms. Moreover, the new vaccine candidates are expected to achieve further success via combined immunization to elicit both a dual protection of B cells and epithelial cells, and sustainable immunization against infected cells at several phases of infection.	[Cai, Jing; Zhang, Bodou; Li, Yuqi; Akihisa, Toshihiro; Feng, Feng; Zhang, Jie] China Pharmaceut Univ, Sch Tradit Chinese Pharm, Nanjing 210009, Peoples R China; [Zhu, Wanfang; Liu, Wenyuan] China Pharmaceut Univ, Sch Pharm, Nanjing 210009, Peoples R China; [Akihisa, Toshihiro] Tokyo Univ Sci, Res Inst Sci & Technol, Chiba 2788510, Japan; [Li, Wei; Kikuchi, Takashi] Toho Univ, Fac Pharmaceut Sci, Chiba 2748510, Japan; [Feng, Feng; Zhang, Jie] Jiangsu Food & Pharmaceut Sci Coll, Huaian 223003, Japan		Zhang, J (通讯作者)，China Pharmaceut Univ, Sch Tradit Chinese Pharm, Nanjing 210009, Peoples R China.; Zhang, J (通讯作者)，Jiangsu Food & Pharmaceut Sci Coll, Huaian 223003, Japan.	3220020316@stu.cpu.edu.cn; 1821020421@stu.cpu.edu.cn; 3219020456@stu.cpu.edu.cn; 3119010060@stu.cpu.edu.cn; akihisa_toshihiro@yahoo.co.jp; liwei@phar.toho-u.ac.jp; t.kikuchi@gly.oups.ac.jp; liuwenyuan@cpu.edu.cn; fengfeng@cpu.edu.cn; 1020152495@cpu.edu.cn	Kikuchi, Takashi/AAJ-7978-2020	Kikuchi, Takashi/0000-0001-8832-5720	"Double First-Class" University project [CPU2018GY34]	This research was funded by the "Double First-Class" University project (grant no. CPU2018GY34).	Abbott RJM, 2013, J IMMUNOL, V191, P5398, DOI 10.4049/jimmunol.1301629; Abolhassani H, 2017, J EXP MED, V214, P91, DOI 10.1084/jem.20160849; Ackerman ME, 2017, IMMUNOL REV, V275, P262, DOI 10.1111/imr.12503; Adhikary D, 2006, J EXP MED, V203, P995, DOI 10.1084/jem.20051287; Adhikary D, 2008, J VIROL, V82, P3903, DOI 10.1128/JVI.02227-07; Al-Samkari H, 2018, ANNU REV PATHOL-MECH, V13, P27, DOI 10.1146/annurev-pathol-020117-043625; Alfieri C, 1996, BLOOD, V87, P812, DOI 10.1182/blood.V87.2.812.bloodjournal872812; Amyes E, 2003, J EXP MED, V198, P903, DOI 10.1084/jem.20022058; Ascherio A, 2012, NAT REV NEUROL, V8, P602, DOI 10.1038/nrneurol.2012.198; Azzi T, 2014, BLOOD, V124, P2533, DOI 10.1182/blood-2014-01-553024; Balfour HH, 2014, CURR OPIN VIROL, V6, P1, DOI 10.1016/j.coviro.2014.02.005; Balfour HH, 2013, J INFECT DIS, V207, P80, DOI 10.1093/infdis/jis646; Bencun M, 2018, NUCLEIC ACIDS RES, V46, P2802, DOI 10.1093/nar/gky129; Benninger-Doring G, 1999, VIROLOGY, V264, P289, DOI 10.1006/viro.1999.9996; Bharadwaj M, 2001, VACCINE, V19, P3769, DOI 10.1016/S0264-410X(01)00085-8; Bihl F, 2006, J IMMUNOL, V176, P4094, DOI 10.4049/jimmunol.176.7.4094; Black S, 2011, PEDIATR INFECT DIS J, V30, P1081, DOI 10.1097/INF.0b013e3182367662; BOGEDAIN C, 1995, J VIROL, V69, P4872, DOI 10.1128/JVI.69.8.4872-4879.1995; Bollard CM, 2018, J CLIN ONCOL, V36, P1128, DOI 10.1200/JCO.2017.74.3179; Bollard CM, 2014, J CLIN ONCOL, V32, P798, DOI 10.1200/JCO.2013.51.5304; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Brooks JM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005549; Bu W, 2019, IMMUNITY, V50, P1305, DOI 10.1016/j.immuni.2019.03.010; Bu W, 2016, CLIN VACCINE IMMUNOL, V23, P363, DOI 10.1128/CVI.00674-15; Burrows SR, 2011, IMMUNOL CELL BIOL, V89, P352, DOI 10.1038/icb.2010.136; BURROWS SR, 1990, J EXP MED, V171, P345, DOI 10.1084/jem.171.1.345; Butler LM, 2010, TROP MED INT HEALTH, V15, P442, DOI 10.1111/j.1365-3156.2010.02474.x; Casey CG, 2005, JAMA-J AM MED ASSOC, V294, P2734, DOI 10.1001/jama.294.21.2734; Chen Y, 2021, MSPHERE, V6, DOI 10.1128/mSphere.00093-21; Chen Y, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007535; Chesnokova LS, 2011, J VIROL, V85, P13214, DOI 10.1128/JVI.05580-11; Chia WK, 2012, ANN ONCOL, V23, P997, DOI 10.1093/annonc/mdr341; Chijioke O, 2013, CELL REP, V5, P1489, DOI 10.1016/j.celrep.2013.11.041; Cohen JI, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002878; Coleman CB, 2017, J INFECT DIS, V216, P670, DOI 10.1093/infdis/jix363; Coleman CB, 2015, J VIROL, V89, P2301, DOI 10.1128/JVI.03001-14; Connolly SA, 2021, NAT REV MICROBIOL, V19, P110, DOI 10.1038/s41579-020-00448-w; Cortese M, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a038596; Crawford DH, 2006, CLIN INFECT DIS, V43, P276, DOI 10.1086/505400; Cui XL, 2016, VACCINE, V34, P4050, DOI 10.1016/j.vaccine.2016.06.021; Cui XL, 2013, VACCINE, V31, P3039, DOI 10.1016/j.vaccine.2013.04.071; Dai W, 2008, J STRUCT BIOL, V161, P428, DOI 10.1016/j.jsb.2007.10.010; DETHE G, 1978, NATURE, V274, P756, DOI 10.1038/274756a0; Di Trolio R, 2006, INT J IMMUNOPATH PH, V19, P105; Dunmire SK, 2018, J CLIN VIROL, V102, P84, DOI 10.1016/j.jcv.2018.03.001; Dunmire SK, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005286; Duraiswamy J, 2003, BLOOD, V101, P3150, DOI 10.1182/blood-2002-10-3092; Elliott SL, 2008, J VIROL, V82, P1448, DOI 10.1128/JVI.01409-07; EMINI EA, 1989, J MED VIROL, V27, P120, DOI 10.1002/jmv.1890270210; EPSTEIN MA, 1973, ANNU REV MICROBIOL, V27, P413, DOI 10.1146/annurev.mi.27.100173.002213; EPSTEIN MA, 1985, NATURE, V318, P287, DOI 10.1038/318287a0; EPSTEIN MA, 1986, CLIN EXP IMMUNOL, V63, P485; EPSTEIN MA, 1965, J EXP MED, V121, P761, DOI 10.1084/jem.121.5.761; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; EPSTEIN MA, 1976, J NATL CANCER I, V56, P697, DOI 10.1093/jnci/56.4.697; Escalante GM, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020169; Ewer KJ, 2016, CURR OPIN IMMUNOL, V41, P47, DOI 10.1016/j.coi.2016.05.014; Farrell PJ, 2019, ANNU REV PATHOL-MECH, V14, P29, DOI 10.1146/annurev-pathmechdis-012418-013023; Feederle R, 2005, J VIROL, V79, P7641, DOI 10.1128/JVI.79.12.7641-7647.2005; FINERTY S, 1992, J GEN VIROL, V73, P449, DOI 10.1099/0022-1317-73-2-449; FINERTY S, 1994, VACCINE, V12, P1180, DOI 10.1016/0264-410X(94)90240-2; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; Fukayama M, 2010, PATHOL INT, V60, P337, DOI 10.1111/j.1440-1827.2010.02533.x; GERBER P, 1969, LANCET, V1, P593; Gottschalk S, 2015, CURR TOP MICROBIOL, V391, P427, DOI 10.1007/978-3-319-22834-1_15; Granato M, 2008, J VIROL, V82, P4042, DOI 10.1128/JVI.02436-07; Grimm JM, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.48; Grunewald K, 2003, SCIENCE, V302, P1396, DOI 10.1126/science.1090284; GU SY, 1995, DEV BIOL STAND, V84, P171; Guo R, 2020, MOL CELL, V78, P653, DOI 10.1016/j.molcel.2020.03.025; Hagn M, 2015, CLIN TRANSL IMMUNOL, V4, DOI 10.1038/cti.2015.10; Halder S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007214; Hambleton S, 2008, J INFECT DIS, V197, pS196, DOI 10.1086/522131; Hartlage AS, 2015, CANCER IMMUNOL RES, V3, P787, DOI 10.1158/2326-6066.CIR-14-0242; Heeke DS, 2016, VACCINE, V34, P2562, DOI 10.1016/j.vaccine.2016.04.012; HENLE W, 1987, P NATL ACAD SCI USA, V84, P570, DOI 10.1073/pnas.84.2.570; Hettich E, 2006, GENE THER, V13, P844, DOI 10.1038/sj.gt.3302714; HEWETSON JF, 1973, J INFECT DIS, V128, P283, DOI 10.1093/infdis/128.3.283; Hislop AD, 2007, ANNU REV IMMUNOL, V25, P587, DOI 10.1146/annurev.immunol.25.022106.141553; HOAGLAND RJ, 1955, AM J MED SCI, V229, P262; HOFFMAN GJ, 1980, P NATL ACAD SCI-BIOL, V77, P2979, DOI 10.1073/pnas.77.5.2979; HORWITZ CA, 1985, J INFECT DIS, V151, P1150, DOI 10.1093/infdis/151.6.1150; Hui EP, 2013, CANCER RES, V73, P1676, DOI 10.1158/0008-5472.CAN-12-2448; Huo SF, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001588; Isobe Y, 2004, CANCER RES, V64, P2167, DOI 10.1158/0008-5472.CAN-03-1562; Jackman WT, 1999, VACCINE, V17, P660, DOI 10.1016/S0264-410X(98)00248-5; Johannsen E, 2004, P NATL ACAD SCI USA, V101, P16286, DOI 10.1073/pnas.0407320101; Johnson KH, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.28; JONDAL M, 1976, CLIN EXP IMMUNOL, V25, P1; Kalra M, 2019, CYTOTHERAPY, V21, P212, DOI 10.1016/j.jcyt.2018.08.001; Kanai K, 2010, VIRUS RES, V153, P172, DOI 10.1016/j.virusres.2010.07.026; Kanda T, 2019, CANCER SCI, V110, P1132, DOI 10.1111/cas.13954; Kanekiyo M, 2015, CELL, V162, P1090, DOI 10.1016/j.cell.2015.07.043; Kelleher CA, 1996, SEMIN CANCER BIOL, V7, P197, DOI 10.1006/scbi.1996.0027; Khanna R, 1999, J IMMUNOL, V162, P3063; KHANNA R, 1992, J EXP MED, V176, P169, DOI 10.1084/jem.176.1.169; Khanna R, 1997, J VIROL, V71, P7429, DOI 10.1128/JVI.71.10.7429-7435.1997; KHYATTI M, 1991, J VIROL, V65, P996, DOI 10.1128/JVI.65.2.996-1001.1991; Kim Y, 2020, ANGEW CHEM INT EDIT, V59, P14628, DOI 10.1002/anie.202006117; Klasse PJ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe8065; Klinker MW, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00144; Kuppers R, 2003, NAT REV IMMUNOL, V3, P801, DOI 10.1038/nri1201; Kutok JL, 2006, ANNU REV PATHOL-MECH, V1, P375, DOI 10.1146/annurev.pathol.1.110304.100209; Landtwing V, 2016, J CLIN INVEST, V126, P3772, DOI 10.1172/JCI86923; Leskowitz R, 2014, J VIROL, V88, P4721, DOI 10.1128/JVI.03744-13; Leskowitz RM, 2013, J VIROL, V87, P8351, DOI 10.1128/JVI.00852-13; Li F, 2013, J IMMUNOTHER, V36, P208, DOI 10.1097/CJI.0b013e31828bd87b; LI QX, 1995, J VIROL, V69, P3987, DOI 10.1128/JVI.69.7.3987-3994.1995; Li W, 2013, ACTA VIROL, V57, P51, DOI 10.4149/av_2013_01_51; Li ZH, 2020, CELL RES, V30, P873, DOI 10.1038/s41422-020-0363-0; Lieberman PM, 2014, SCIENCE, V343, P1323, DOI 10.1126/science.1252786; Lieberman PM, 2013, NAT REV MICROBIOL, V11, P863, DOI 10.1038/nrmicro3135; Lin CL, 2002, CANCER RES, V62, P6952; Lin XY, 2016, CELL MOL IMMUNOL, V13, P492, DOI 10.1038/cmi.2015.29; Liu FY, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P27; Liu GY, 2011, VACCINE, V29, P7414, DOI 10.1016/j.vaccine.2011.07.063; Liu GY, 2009, CELL MOL IMMUNOL, V6, P423, DOI 10.1038/cmi.2009.54; Liu H, 2020, BIOMATERIALS, V255, DOI 10.1016/j.biomaterials.2020.120158; Liu H, 2020, MEDITERR J HEMATOL I, V12, DOI 10.4084/MJHID.2020.016; Lopez-Montanes M, 2017, J IMMUNOL, V199, P656, DOI 10.4049/jimmunol.1601574; LUNG ML, 1985, LANCET, V1, P889; MACKETT M, 1985, EMBO J, V4, P3229, DOI 10.1002/j.1460-2075.1985.tb04070.x; McKenzie J, 2015, CURR TOP MICROBIOL, V391, P237, DOI 10.1007/978-3-319-22834-1_8; Moghaddam A, 1998, J VIROL, V72, P3205, DOI 10.1128/JVI.72.4.3205-3212.1998; MORGAN AJ, 1988, J GEN VIROL, V69, P2093, DOI 10.1099/0022-1317-69-8-2093; MORGAN AJ, 1988, J MED VIROL, V25, P189, DOI 10.1002/jmv.1890250209; MORGAN AJ, 1984, J MED VIROL, V13, P281, DOI 10.1002/jmv.1890130310; Moutschen M, 2007, VACCINE, V25, P4697, DOI 10.1016/j.vaccine.2007.04.008; Munz C, 2019, NAT REV MICROBIOL, V17, P691, DOI 10.1038/s41579-019-0249-7; Munz C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01658; Murata T, 2014, MICROBIOL IMMUNOL, V58, P307, DOI 10.1111/1348-0421.12155; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; NEMEROW GR, 1989, CELL, V56, P369, DOI 10.1016/0092-8674(89)90240-7; Ngo MC, 2014, J IMMUNOTHER, V37, P193, DOI 10.1097/CJI.0000000000000014; Nii S, 1998, Nihon Rinsho, V56, P22; Noh KW, 2016, BMB REP, V49, P226, DOI 10.5483/BMBRep.2016.49.4.260; Ogembo JG, 2013, CELL REP, V3, P371, DOI 10.1016/j.celrep.2013.01.023; Ogembo JG, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0415-2; Ohga S, 2002, CRIT REV ONCOL HEMAT, V44, P203, DOI 10.1016/S1040-8428(02)00112-9; Paludan SR, 2011, NAT REV IMMUNOL, V11, P143, DOI 10.1038/nri2937; Pan JQ, 2009, MOL CANCER THER, V8, P2754, DOI 10.1158/1535-7163.MCT-08-1176; Panikkar A, 2015, J INFECT DIS, V212, P1957, DOI 10.1093/infdis/jiv340; Panikkar A, 2015, J VIROL, V89, P9137, DOI 10.1128/JVI.01293-15; Pappworth IY, 2007, J VIROL, V81, P474, DOI 10.1128/JVI.01777-06; Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731; Parrino J, 2007, VACCINE, V25, P1513, DOI 10.1016/j.vaccine.2006.10.047; Patel M, 2013, J INFECT DIS, V208, P284, DOI 10.1093/infdis/jit166; Pavlova S, 2013, J VIROL, V87, P2011, DOI 10.1128/JVI.02533-12; PEARSON G, 1970, JNCI-J NATL CANCER I, V45, P989; Precopio ML, 2003, J IMMUNOL, V170, P2590, DOI 10.4049/jimmunol.170.5.2590; QUALTIERE LF, 1982, J IMMUNOL, V129, P814; Rees L, 2009, TRANSPLANTATION, V88, P1025, DOI 10.1097/TP.0b013e3181b9d918; Rickinson AB, 1997, ANNU REV IMMUNOL, V15, P405, DOI 10.1146/annurev.immunol.15.1.405; Rivailler P, 2004, BLOOD, V104, P1482, DOI 10.1182/blood-2004-01-0342; Ruhl J, 2020, CELL MOL LIFE SCI, V77, P4315, DOI 10.1007/s00018-020-03538-3; Ruiss R, 2011, J VIROL, V85, P13105, DOI 10.1128/JVI.05598-11; Sanchez-Sampedro L, 2015, VIRUSES-BASEL, V7, P1726, DOI 10.3390/v7041726; Sashihara J, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002308; Sathiyamoorthy K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13557; Sathiyamoorthy K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004309; Saulquin X, 2000, EUR J IMMUNOL, V30, P2531, DOI 10.1002/1521-4141(200009)30:9<2531::AID-IMMU2531>3.0.CO;2-O; Schelcher C, 2005, J VIROL, V79, P13822, DOI 10.1128/JVI.79.21.13822-13828.2005; Servat E, 2015, VACCINE, V33, P6771, DOI 10.1016/j.vaccine.2015.10.024; Sestak K, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100544; Shannon-Lowe C, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00713; SHAPIRO RS, 1988, BLOOD, V71, P1234; Si YF, 2016, CHEM PHARM BULL, V64, P1118, DOI 10.1248/cpb.c16-00114; Silveira ELV, 2013, J VIROL, V87, P13904, DOI 10.1128/JVI.01947-13; Singh S, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100033; Sitki-Green D, 2003, J VIROL, V77, P1840, DOI 10.1128/JVI.77.3.1840-1847.2003; Small JC, 2011, CURR OPIN VIROL, V1, P241, DOI 10.1016/j.coviro.2011.07.009; Smith C, 2012, CANCER RES, V72, P1116, DOI 10.1158/0008-5472.CAN-11-3399; Snijder J, 2018, IMMUNITY, V48, P799, DOI 10.1016/j.immuni.2018.03.026; Sokal EM, 2007, J INFECT DIS, V196, P1749, DOI 10.1086/523813; STRNAD BC, 1982, J VIROL, V41, P258, DOI 10.1128/JVI.41.1.258-264.1982; SUMAYA CV, 1986, J INFECT DIS, V154, P842, DOI 10.1093/infdis/154.5.842; Sun C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.677027; Takashima K, 2008, J MED VIROL, V80, P455, DOI 10.1002/jmv.21102; Tanner JE, 2018, CANCERS, V10, DOI 10.3390/cancers10040112; Tanner JE, 2015, J VIROL, V89, P4932, DOI 10.1128/JVI.03269-14; Tashiro H, 2017, CELL RES, V27, P59, DOI 10.1038/cr.2016.153; Taylor GS, 2015, ANNU REV IMMUNOL, V33, P787, DOI 10.1146/annurev-immunol-032414-112326; Taylor GS, 2014, CLIN CANCER RES, V20, P5009, DOI 10.1158/1078-0432.CCR-14-1122-T; Tellam J, 2004, J EXP MED, V199, P1421, DOI 10.1084/jem.20040191; TOSONIPITTONI E, 1989, BIOCHEM BIOPH RES CO, V158, P676, DOI 10.1016/0006-291X(89)92774-5; Toussirot E, 2008, BEST PRACT RES CL RH, V22, P883, DOI 10.1016/j.berh.2008.09.007; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; Trottier H, 2012, TRANSFUSION, V52, P2653, DOI 10.1111/j.1537-2995.2012.03611.x; Tugizov SM, 2003, NAT MED, V9, P307, DOI 10.1038/nm830; Turk SM, 2006, J VIROL, V80, P9628, DOI 10.1128/JVI.00622-06; Ura T, 2014, VACCINES, V2, P624, DOI 10.3390/vaccines2030624; van Diemen FR, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005701; van Wijhe M, 2016, LANCET INFECT DIS, V16, P592, DOI 10.1016/S1473-3099(16)00027-X; van Zyl DG, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00104; van Zyl DG, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007464; Verghese PS, 2015, TRANSPLANTATION, V99, P1186, DOI 10.1097/TP.0000000000000490; WALLACE LE, 1991, J VIROL, V65, P3821, DOI 10.1128/JVI.65.7.3821-3828.1991; Walling DM, 2003, J VIROL, V77, P6546, DOI 10.1128/JVI.77.11.6546-6550.2003; Wang M, 2013, APPL MICROBIOL BIOT, V97, P6251, DOI 10.1007/s00253-013-4967-x; Wang Z, 2011, SCI CHINA LIFE SCI, V54, P263, DOI 10.1007/s11427-011-4147-0; Williams H, 2005, BRIT J HAEMATOL, V129, P266, DOI 10.1111/j.1365-2141.2005.05452.x; Wilson JB, 2018, CANCERS, V10, DOI 10.3390/cancers10040109; Woodberry T, 2005, J INFECT DIS, V192, P1513, DOI 10.1086/491741; Xiao JQ, 2009, VIROLOGY, V388, P335, DOI 10.1016/j.virol.2009.03.030; YAO QY, 1991, INT J CANCER, V48, P45; YAO QY, 1991, J GEN VIROL, V72, P1579, DOI 10.1099/0022-1317-72-7-1579; Young KA, 2007, J BIOL CHEM, V282, P36614, DOI 10.1074/jbc.M706324200; Younger DS, 2016, NEUROL CLIN, V34, P1035, DOI 10.1016/j.ncl.2016.05.004; Zhang X, 2020, THERANOSTICS, V10, P5704, DOI 10.7150/thno.42494; ZIMMERMANN J, 1995, J VIROL, V69, P3147, DOI 10.1128/JVI.69.5.3147-3155.1995	210	1	1	12	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1290	10.3390/vaccines9111290			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF4OQ	34835222	Green Published, gold			2022-04-29	WOS:000724051800001
J	Ferrari, D; Clementi, N; Criscuolo, E; Ambrosi, A; Corea, F; Di Resta, C; Tomaiuolo, R; Mancini, N; Locatelli, M; Plebani, M; Banfi, G				Ferrari, Davide; Clementi, Nicola; Criscuolo, Elena; Ambrosi, Alessandro; Corea, Francesca; Di Resta, Chiara; Tomaiuolo, Rossella; Mancini, Nicasio; Locatelli, Massimo; Plebani, Mario; Banfi, Giuseppe			Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine	VACCINES			English	Article						COVID-19; serological test; mRNA vaccine; Roche Anti-SARS-CoV-2-S; immune response; vaccination	SPIKE; 1ST	Background: Studies reporting the long-term humoral response after receiving the BNT162b2 COVID-19 vaccine are important to drive future vaccination strategies. Yet, available literature is scarce. Covidiagnostix is a multicenter study designed to assess the antibody response in > 1000 healthcare professionals (HCPs) who received the BNT162b2 vaccine. Methods: Serum was tested at time-0 (T-0), before the first dose, T-1, T-2,T- and T-3, respectively, 21, 42, and 180 days after T-0. Antibodies against the SARS-CoV-2 nucleocapsid-protein were measured to assess SARS-CoV-2 infections, whereas antibodies against the receptor-binding domain of the spike protein were measured to assess the vaccine response. Neutralization activity against the D614G, B.1.1.7, and B.1.351 variants were also analyzed. Results: Six months post-vaccination HCPs showed an antibody titer decrease of approximately 70%, yet, the titer was still one order of magnitude higher than that of seropositive individuals before vaccination. We identified 12 post-vaccination infected HCPs. None showed severe symptoms. Interestingly, most of them showed titers at T-2 above the neutralization thresholds obtained from the neutralization activity experiments. Conclusion: Vaccination induces a humoral response which is well detectable even six months post-vaccination. Vaccination prevents severe COVID-19 cases, yet post-vaccination infection is possible even in the presence of a high anti-S serum antibody titer.	[Ferrari, Davide] Univ Parma, Sci Chim Vita & Sostenibilita Ambientale CVSA Dep, I-43121 Parma, Italy; [Clementi, Nicola; Criscuolo, Elena; Mancini, Nicasio] Univ Vita Salute San Raffaele, Lab Microbiol & Virol, I-20158 Milan, Italy; [Clementi, Nicola; Corea, Francesca; Di Resta, Chiara; Mancini, Nicasio; Locatelli, Massimo] IRCCS Osped San Raffaele, Lab Med Serv, I-20158 Milan, Italy; [Ambrosi, Alessandro; Tomaiuolo, Rossella; Banfi, Giuseppe] Univ Vita Salute San Raffaele, Surg & Med Dept, I-20158 Milan, Italy; [Plebani, Mario] Univ Padua, Dept Lab Med, Sch Med, I-35100 Padua, Italy; [Banfi, Giuseppe] IRCCS Orthoped Inst Galeazzi, Lab Clin Chem & Microbiol, I-20161 Milan, Italy		Ferrari, D (通讯作者)，Univ Parma, Sci Chim Vita & Sostenibilita Ambientale CVSA Dep, I-43121 Parma, Italy.	davide.ferrari@unipr.it; dementi.nicola@hsr.it; criscuolo.elena@hsr.it; ambrosi.alessandro@hsr.it; corea.francesca@hsr.it; diresta.chiara@hsr.it; tomaiuolo.rossella@hsr.it; mancini.nicasio@hsr.it; locatelli.massimo@hsr.it; mario.plebani@unipd.it; banfi.giuseppe@hsr.it	Ambrosi, Alessandro/H-4424-2011; Clementi, Nicola/G-8545-2014; Criscuolo, Elena/I-1918-2019	Ambrosi, Alessandro/0000-0003-1976-5663; Clementi, Nicola/0000-0002-1822-9861; Criscuolo, Elena/0000-0003-0185-3147; DI RESTA, Chiara/0000-0003-2880-6631; Tomaiuolo, Rossella/0000-0002-2828-782X; ferrari, davide/0000-0001-7084-6800; MANCINI, Nicasio/0000-0003-0637-0910	Ministry of Health of Italy, "Bando Ricerca COVID-19" [COVID-2020-12371619]	This project was supported by Ministry of Health of Italy, "Bando Ricerca COVID-19"; project number: COVID-2020-12371619; project title: COVIDIAGNOSTIX-Health Technology Assessment in Covid serological diagnostics.	Berkeley L.J., 2021, PFIZER CEO SAYS 3 CO; Castelli M, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13081514; Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010; Cocomazzi G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080913; Criscuolo E, 2021, J MED VIROL, V93, P2160, DOI 10.1002/jmv.26605; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Di Resta C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050522; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Favresse J, 2021, EMERG MICROBES INFEC, V10, P1495, DOI 10.1080/22221751.2021.1953403; Favresse J, 2020, CLIN CHEM, V66, P1104, DOI 10.1093/clinchem/hvaa131; FDA, 2021, FDA APPR 1 COVID 19; Ferrari D, 2021, CLIN CHEM LAB MED, V59, P2019, DOI [10.1515/cclm-2021-0364, 10.17632/SBPM4NTYGR.1, 10.17632/SBPM4NTYGR]; Ferrari D, 2021, CLIN CHIM ACTA, V522, P144, DOI [10.17632/576CHJW8TP, 10.1016/j.cca.2021.08.024, 10.17632/576CHJW8TP.1]; Ferrari D, 2021, VACCINE, V39, P4256, DOI [10.17632/DPRSVXZVJ9.1, 10.1016/j.vaccine.2021.06.020, 10.17632/DPRSVXZVJ9]; Ferrari D, 2020, CLIN CHEM LAB MED, V58, P1095, DOI 10.1515/cclm-2020-0398; Ferrari D, 2018, FORENSIC SCI INT, V288, P211, DOI 10.1016/j.forsciint.2018.04.038; Howard J., 2021, 3 DOSE COVID 19 VACC; JONCKHEERE AR, 1954, BIOMETRIKA, V41, P133, DOI 10.2307/2333011; Kittel M, 2021, INT J INFECT DIS, V103, P590, DOI 10.1016/j.ijid.2020.12.003; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; Liu W, 2017, STAT METHODS MED RES, V26, P1373, DOI 10.1177/0962280215579476; Liu Y, 2021, NEW ENGL J MED, V384, P1466, DOI 10.1056/NEJMc2102017; Manisty C, 2021, LANCET, V397, P1057, DOI 10.1016/S0140-6736(21)00501-8; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Padoan A, 2021, CLIN CHIM ACTA, V519, P60, DOI 10.1016/j.cca.2021.04.006; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Perkmann T, 2020, CLIN CHEM, V66, P1405, DOI 10.1093/clinchem/hvaa198; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prendecki M, 2021, LANCET, V397, P1178, DOI 10.1016/S0140-6736(21)00502-X; Saadat S, 2021, JAMA-J AM MED ASSOC, V325, P1467, DOI 10.1001/jama.2021.3341; Tomaiuolo R, 2021, INT J TECHNOL ASSESS, V37, DOI 10.1017/S0266462321000441; Wiedermann U, 2016, HUM VACC IMMUNOTHER, V12, P239, DOI 10.1080/21645515.2015.1093263; Worldometers, COVID 19 STAT; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; YOHAI VJ, 1987, ANN STAT, V15, P642, DOI 10.1214/aos/1176350366	35	2	2	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1357	10.3390/vaccines9111357			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XE3WX	34835288	Green Published, gold			2022-04-29	WOS:000723323100001
J	Shaikh, N; Pelzer, PT; Thysen, SM; Roy, P; Harris, RC; White, RG				Shaikh, Nabila; Pelzer, Puck T.; Thysen, Sanne M.; Roy, Partho; Harris, Rebecca C.; White, Richard G.			Impact of COVID-19 Disruptions on Global BCG Coverage and Paediatric TB Mortality: A Modelling Study	VACCINES			English	Article						BCG; immunization; mathematical model; paediatric mortality; COVID-19; tuberculosis	TUBERCULOSIS MORTALITY; VACCINATION; PROTECTION; SERVICES; DISEASE	The impact of COVID-19 disruptions on global Bacillus Calmette-Guerin (BCG) coverage and paediatric tuberculosis (TB) mortality is still unknown. To fill this evidence-gap and guide mitigation measures, we estimated the impact of COVID-19 disruptions on global BCG coverage and paediatric TB mortality. First, we used data from multiple sources to estimate COVID-19-disrupted BCG vaccination coverage. Second, using a static mathematical model, we estimated the number of additional paediatric TB deaths in the first 15 years of life due to delayed/missed vaccinations in 14 scenarios-varying in duration of disruption, and magnitude and timing of catch-up. We estimated a 25% reduction in global BCG coverage within the disruption period. The best-case scenario (3-month disruption, 100% catch-up within 3 months) resulted in an additional 886 (0.5%) paediatric TB deaths, and the worst-case scenario (6-month disruption with no catch-up) resulted in an additional 33,074 (17%) deaths. The magnitude of catch-up was found to be the most influential variable in minimising excess paediatric TB mortality. Our results show that ensuring catch-up vaccination of missed children is a critical priority, and delivery of BCG alongside other routine vaccines may be a feasible way to achieve catch-up. Urgent action is required to support countries with recovering vaccination coverages to minimise paediatric deaths.	[Shaikh, Nabila; Harris, Rebecca C.; White, Richard G.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, TB Ctr, TB Modelling Grp, London WC1E 7HT, England; [Pelzer, Puck T.] KNCV TB, Tech Div, Maanweg 174, NL-2516 AB The Hague, Netherlands; [Thysen, Sanne M.] Bispebjerg & Frederiksberg Hosp, Ctr Clin Res & Prevent, DK-2004 Frederiksberg, Denmark; [Thysen, Sanne M.] Bandim Hlth Project, Apartado 861, Bissau 1004, Guinea Bissau; [Roy, Partho] Publ Hlth England, Natl Infect Serv, Immunisat & Countermeasures, London NW9 5EQ, England; [Harris, Rebecca C.] Sanofi Pasteur, South Beach Tower 18-11, Singapore 189767, Singapore		Shaikh, N (通讯作者)，London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, TB Ctr, TB Modelling Grp, London WC1E 7HT, England.	nabila.shaikh17@gmail.com; puck.pelzer@kncvtbc.org; samt@dadlnet.dk; Partho.Roy@phe.gov.uk; Rebecca.harris@lshtm.ac.uk; Richard.white@lshtm.ac.uk	White, Richard G/D-5407-2009	White, Richard G/0000-0003-4410-6635	TB Modelling Group at LSHTM; Wellcome TrustWellcome TrustEuropean Commission [218261/Z/19/Z]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01AI147321-01]; EDTCP [RIA208D-2505B]; UK MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [CCF17-7779]; ESRCUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/P008011/1]; BMGF [OPP1084276, OPP1135288, INV-001754]; WHOWorld Health Organization [2020/985800-0]	N.S. is funded by the TB Modelling Group at LSHTM. R.G.W. is funded by the Wellcome Trust (218261/Z/19/Z), NIH (1R01AI147321-01), EDTCP (RIA208D-2505B), UK MRC (CCF17-7779 via SET Bloomsbury), ESRC (ES/P008011/1), BMGF (OPP1084276, OPP1135288 & INV-001754), and the WHO (2020/985800-0).	Abubakar I, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17370; Beaumont P., 2021, GUARDIAN; Buonsenso D, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00517; Chandir S, 2020, LANCET GLOB HEALTH, V8, pE1118, DOI 10.1016/S2214-109X(20)30290-4; Chiappini E, 2021, ACTA PAEDIATR, V110, P2529, DOI 10.1111/apa.15949; Clark A, 2009, LANCET, V373, P1543, DOI 10.1016/S0140-6736(09)60317-2; Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4; Delamou A, 2017, LANCET GLOB HEALTH, V5, pE448, DOI [10.1016/S2214-109X(17)30078-5, 10.1016/s2214-109x(17)30078-5]; Dodd PJ, 2017, LANCET GLOB HEALTH, V5, pE898, DOI [10.1016/S2214-109X(17)30289-9, 10.1016/s2214-109x(17)30289-9]; Dunleavy K., VERY STRESSED SERUM, P2021; Durrheim DN, 2021, NAT MED, V27, P360, DOI 10.1038/s41591-021-01237-5; Harris RC, 2021, LANCET REG HEALTH-W, V10, DOI 10.1016/j.lanwpc.2021.100140; Harris RC, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0685-4; Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170; Lazzerini M, 2020, LANCET CHILD ADOLESC, V4, pE10, DOI 10.1016/S2352-4642(20)30108-5; Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790; Masresha BG, 2020, PAN AFR MED J, V37, DOI 10.11604/pamj.supp.2020.37.12.26107; McQuaid CF, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01718-2020; Migliori GB, 2020, EMERG INFECT DIS, V26, P2709, DOI 10.3201/eid2611.203163; Prentice S, 2021, LANCET INFECT DIS, V21, P993, DOI 10.1016/S1473-3099(20)30653-8; Ritchie H., 2020, CORONAVIRUS PANDEMIC; Roy P, 2019, LANCET GLOB HEALTH, V7, pE1655, DOI 10.1016/S2214-109X(19)30444-9; Rukmini S., 2020, INDIASPEND; Safi M, GUARDIAN, P2021; Syakriah A., 2020, JAKARTA POST; The BCG Atlas A Database of Global BCG Vaccination Policies and Practices, BCG ATL DAT GLOB BCG; Thysen SM, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-006127; Thysen SM, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1037; Tsilika M., 2021, ACTIVATE 2 DOUBLE BL, DOI [10.1101/2021.05.20.21257520, DOI 10.1101/2021.05.20.21257520]; UNICEF, COVID 19 IMP ASS OUT; UNICEF, 2020, UNICEF HAILS IMM PRO; UNICEF Supply Division, BAC CALM GUER BCG SU; UNICEF Supply Division, 2019, BAC CALM GUER BCG SU; UNICEF UN Department of Economic and Social Affairs Population Division UNICEF, GEN PAL BRIEF NOT IM; UNICEF United Nations Department of Economic and Social Affairs Population Division UNICEF, MAT NEWB HLTH COV DA; United Nations Department of Economic and Social Affairs Population Division, WORLD POPULATION PRO; World Health Organisation, 2020, GAV UNICEF LEAST 80; World Health Organisation, PULS SURV CONT ESS H; World Health Organisation, 2021, IMP COVID 19 PAND TB; World Health Organization, 2020, GLOBAL TUBERCULOSIS	40	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1228	10.3390/vaccines9111228			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK5ZN	34835161	Green Accepted, Green Published, gold			2022-04-29	WOS:000727543400001
J	Vogt, ACS; Roesti, ES; Mohsen, MO; Leonchiks, A; Vogel, M; Bachmann, MF				Vogt, Anne-Cathrine S.; Roesti, Elisa S.; Mohsen, Mona O.; Leonchiks, Ainars; Vogel, Monique; Bachmann, Martin F.			Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes	VACCINES			English	Article						islet amyloid polypeptide (IAPP); amyloid; type 2 diabetes (T2DM); monoclonal antibody (mAb); amylin	ISLET AMYLOID POLYPEPTIDE; BETA-CELL APOPTOSIS; INSULIN-RESISTANCE; AMYLIN; MECHANISMS	Type 2 Diabetes Mellitus (T2DM) is a chronic progressive disease, defined by insulin resistance and insufficient insulin secretion to maintain normoglycemia. Amyloidogenic aggregates are a hallmark of T2DM patients; they are cytotoxic for the insulin producing beta-cells, and cause inflammasome-dependent secretion of IL-1 beta. To avoid the associated beta-cell loss and inflammation in advanced stage T2DM, we developed a novel monoclonal therapy targeting the major component of aggregates, islet amyloid polypeptide (IAPP). The here described monoclonal antibody (mAb) m81, specific for oligomeric and fibrils, but not for soluble free IAPP, is able to prevent oligomer growth and aggregate formation in vitro, and blocks islet inflammation and disease progression in vivo. Collectively, our data show that blocking fibril formation and prevention of new amyloidogenic aggregates by monoclonal antibody therapy may be a potential therapy for T2DM.	[Vogt, Anne-Cathrine S.; Roesti, Elisa S.; Mohsen, Mona O.; Vogel, Monique; Bachmann, Martin F.] Univ Hosp, Dept Rheumatol & Immunol RI, CH-3010 Bern, Switzerland; [Vogt, Anne-Cathrine S.; Roesti, Elisa S.; Mohsen, Mona O.; Vogel, Monique; Bachmann, Martin F.] Univ Bern, Dept BioMed Res DBMR, CH-3008 Bern, Switzerland; [Leonchiks, Ainars] Latvian Biomed Res & Study Ctr, Ratsupites 1 K1, LV-1067 Riga, Latvia; [Bachmann, Martin F.] Univ Oxford, Ctr Cellular & Mol Physiol CCMP, Jenner Inst, Nuffield Dept Med, Oxford OX3 7BN, England		Bachmann, MF (通讯作者)，Univ Hosp, Dept Rheumatol & Immunol RI, CH-3010 Bern, Switzerland.; Bachmann, MF (通讯作者)，Univ Bern, Dept BioMed Res DBMR, CH-3008 Bern, Switzerland.; Bachmann, MF (通讯作者)，Univ Oxford, Ctr Cellular & Mol Physiol CCMP, Jenner Inst, Nuffield Dept Med, Oxford OX3 7BN, England.	anne-cathrine.vogt@students.unibe.ch; Elisa.roesti@rmit.edu.au; mona.mohsen@dbmr.unibe.ch; ainleo@biomed.lu.lv; Monique.vogel@dbmr.unibe.ch; martin.bachmann@dbmr.unibe.ch		Bachmann, Martin/0000-0003-4370-2099	Swiss National Foundation (SNF)Swiss National Science Foundation (SNSF)	These studies were funded by a project grant from the Swiss National Foundation (SNF grant 310039_185114 to Martin F. Bachmann).	Benede-Ubieto R, 2020, DIABETES METAB SYNDR, V13, P439, DOI 10.2147/DMSO.S234665; Bhowmick DC, 2018, J BIOL CHEM, V293, P14210, DOI 10.1074/jbc.RA118.002414; Butler AE, 2003, DIABETES, V52, P2304, DOI 10.2337/diabetes.52.9.2304; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Chaari A, 2019, INT J BIOL MACROMOL, V136, P57, DOI 10.1016/j.ijbiomac.2019.06.050; CLARK A, 1988, DIABETES RES CLIN EX, V9, P151; Davis MK, 2015, AM J TRANSPLANT, V15, P650, DOI 10.1111/ajt.13025; Denroche HC, 2018, J MOL ENDOCRINOL, V60, pR57, DOI 10.1530/JME-17-0138; Donath MY, 2019, NAT REV IMMUNOL, V19, P734, DOI 10.1038/s41577-019-0213-9; Haataja L, 2008, ENDOCR REV, V29, P303, DOI 10.1210/er.2007-0037; Hull RL, 2004, J CLIN ENDOCR METAB, V89, P3629, DOI 10.1210/jc.2004-0405; Janson J, 1996, P NATL ACAD SCI USA, V93, P7283, DOI 10.1073/pnas.93.14.7283; Jurgens CA, 2011, AM J PATHOL, V178, P2632, DOI 10.1016/j.ajpath.2011.02.036; KAHN SE, 1990, DIABETES, V39, P634, DOI 10.2337/diabetes.39.5.634; Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482; Kahn SE, 2014, LANCET, V383, P1068, DOI 10.1016/S0140-6736(13)62154-6; Kiriyama Y, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7080095; Lascar N, 2018, LANCET DIABETES ENDO, V6, P69, DOI 10.1016/S2213-8587(17)30186-9; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; Lutz TA, 2009, INT J OBESITY, V33, pS24, DOI 10.1038/ijo.2009.13; Maiorino MI, 2017, J DIABETES COMPLICAT, V31, P288, DOI 10.1016/j.jdiacomp.2016.10.009; Milardi D, 2021, CHEM REV, V121, P1845, DOI 10.1021/acs.chemrev.0c00981; Montemurro C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10444-1; Muoio DM, 2008, NAT REV MOL CELL BIO, V9, P193, DOI 10.1038/nrm2327; Pumpens P, 2016, INTERVIROLOGY, V59, P74, DOI 10.1159/000449503; Raleigh D, 2017, J MOL ENDOCRINOL, V59, pR121, DOI 10.1530/JME-17-0105; Roesti ES, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010116; Sigal RJ, 2006, DIABETES CARE, V29, P1433, DOI 10.2337/dc06-9910; WESTERMARK P, 1972, UPSALA J MED SCI, V77, P91, DOI 10.1517/03009734000000014; Westermark P, 2011, PHYSIOL REV, V91, P795, DOI 10.1152/physrev.00042.2009; Young A, 1998, NUTRITION, V14, P524	31	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1316	10.3390/vaccines9111316			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI0DX	34835247	Green Published, gold			2022-04-29	WOS:000725795000001
J	Bianchi, F; Tafuri, S; Migliore, G; Vimercati, L; Martinelli, A; Lobifaro, A; Diella, G; Stefanizzi, P				Bianchi, Francesco; Tafuri, Silvio; Migliore, Giovanni; Vimercati, Luigi; Martinelli, Andrea; Lobifaro, Annamaria; Diella, Giusy; Stefanizzi, Pasquale		Control Room Working Grp	BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study	VACCINES			English	Article						COVID-19; documented infection; vaccine effectiveness; healthcare workers		To combat the COVID-19 pandemic, a mass vaccination campaign was initiated in Italy on 27 December 2020. The vaccine available to immunize Italian healthcare workers (HCWs) was the BNT162b2 mRNA COVID-19 vaccine (Comirnaty). This study evaluated the effectiveness of the vaccine against documented SARS-CoV-2 infection and symptomatic diseases in the medium- to long-term. HCWs at Bari Policlinico University-Hospital (Italy) who completed the vaccination schedule were matched with HCWs who had refused vaccination; the two groups were followed-up for 5 months (January-May 2021). Vaccine effectiveness (VE) against infection was 97.7% (95.4-99.0%) at 14-34 days after the first dose, and 94.8% (87.0-97.8%), 83.0% (65.0-92.0%), and 81.0% (42.0-94.0%) at 14-41, 42-69, and > 69 days, respectively, after the second dose. The estimated VE for documented symptomatic disease was 99.2% (96.4-99.8%) at 14-34 days after the first dose and 97.2% (90.3-99.2%), 85.0% (63.0-94.2%), and 88.0% (42.0-97.6%) at 14-41, 42-69, and > 69 days, respectively, after the second dose. Efforts to increase vaccination rates should be strengthened, including mandatory vaccination for HCWs and greater incentives to increase vaccine acceptance by the general population.	[Bianchi, Francesco; Tafuri, Silvio; Martinelli, Andrea; Lobifaro, Annamaria; Diella, Giusy; Stefanizzi, Pasquale] Aldo Moro Univ Bari, Dept Biomed Sci & Human Oncol, Piazza Giulio Cesare 11, I-70124 Bari, Italy; [Migliore, Giovanni] Bari Policlin Gen Hosp, I-70124 Bari, Italy; [Vimercati, Luigi] Aldo Moro Univ Bari, Dept Interdisciplinary Med, I-70124 Bari, Italy		Tafuri, S (通讯作者)，Aldo Moro Univ Bari, Dept Biomed Sci & Human Oncol, Piazza Giulio Cesare 11, I-70124 Bari, Italy.	francesco.bianchi@asl.brindisi.it; silvio.tafuri@uniba.it; giovanni.migliore@policlinico.ba.it; luigi.vimercati@uniba.it; andrea.martinelli@uniba.it; annamarialobifaro@gmail.com; giusy.diella@uniba.it; pasquale.stefanizzi@uniba.it	Bianchi, Francesco Paolo/AAU-2597-2020	Bianchi, Francesco Paolo/0000-0002-9659-0193; Martinelli, Andrea/0000-0002-8068-6246; tafuri, silvio/0000-0003-4194-0210			[Anonymous], WHO COR DIS COVID 19; Apulia Region, COVID 19 EP UPD; Benenson S, 2021, NEW ENGL J MED, V384, P1775, DOI 10.1056/NEJMc2101951; Bianchi FP, 2021, J INFECT DIS, V224, P431, DOI 10.1093/infdis/jiab262; Bianchi FP, 2020, AM J INFECT CONTROL, V48, P368, DOI 10.1016/j.ajic.2019.09.024; CDC, CDC REAL WORLD STUD; CDC, PFIZER BIONTECH COVI; CDC, IMP COVID 19 VACC HE; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; ECDC, COVID 19 SIT UPD EUE; Ioannou P, 2021, INFECT DIS-NOR, V53, P876, DOI 10.1080/23744235.2021.1945139; Istituto Superiore di Sanita, COVID 19 INT SURV DA; Italian Ministry of Health, VACC COM PFIZ BIONTE; Morales-Nunez JJ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070742; Keehner J, 2021, NEW ENGL J MED, V384, P1774, DOI 10.1056/NEJMc2101927; Mahase E, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1116; Pedote PD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040358; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; WHO, US LAB METH SARS DIA; World Health Organization, Q A COR COVID 19	20	3	3	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1143	10.3390/vaccines9101143			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WU9TF	34696252	Green Published, gold			2022-04-29	WOS:000716879600001
J	Bonam, SR; Renia, L; Tadepalli, G; Bayry, J; Kumar, HMS				Bonam, Srinivasa Reddy; Renia, Laurent; Tadepalli, Ganesh; Bayry, Jagadeesh; Kumar, Halmuthur Mahabalarao Sampath			Plasmodium falciparum Malaria Vaccines and Vaccine Adjuvants	VACCINES			English	Review						anti-malarial drugs; malaria vaccine; Plasmodium falciparum; vaccine adjuvants	CD8(+) T-CELLS; ANTIGEN-PRESENTING CELLS; BLOOD-STAGE MALARIA; PHASE 2A TRIAL; IMMUNE-RESPONSES; DENDRITIC CELLS; LIVER-STAGE; CIRCUMSPOROZOITE PROTEIN; IMMUNOLOGICAL EVALUATION; INNATE IMMUNITY	Malaria-a parasite vector-borne disease-is a global health problem, and Plasmodium falciparum has proven to be the deadliest among Plasmodium spp., which causes malaria in humans. Symptoms of the disease range from mild fever and shivering to hemolytic anemia and neurological dysfunctions. The spread of drug resistance and the absence of effective vaccines has made malaria disease an ever-emerging problem. Although progress has been made in understanding the host response to the parasite, various aspects of its biology in its mammalian host are still unclear. In this context, there is a pressing demand for the development of effective preventive and therapeutic strategies, including new drugs and novel adjuvanted vaccines that elicit protective immunity. The present article provides an overview of the current knowledge of anti-malarial immunity against P. falciparum and different options of vaccine candidates in development. A special emphasis has been made on the mechanism of action of clinically used vaccine adjuvants.</p>	[Bonam, Srinivasa Reddy; Bayry, Jagadeesh] Univ Paris, Sorbonne Univ, Inst Natl Sante & Rech Med, Ctr Rech Cordeliers,Equipe Immunopathol & Immunoi, F-75006 Paris, France; [Renia, Laurent] ASTAR, Infect Dis Labs, 8A Biomed Grove, Singapore 138648, Singapore; [Renia, Laurent] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 308232, Singapore; [Renia, Laurent] Nanyang Technol Univ, Sch Biol Sci, Singapore 308232, Singapore; [Tadepalli, Ganesh; Kumar, Halmuthur Mahabalarao Sampath] CSIR Indian Inst Chem Technol, Organ Synth & Proc Chem Div, Vaccine Immunol Lab, Hyderabad 500007, India; [Bayry, Jagadeesh] Indian Inst Technol Palakkad, Biol Sci & Engn, Palakkad 678623, India		Bonam, SR (通讯作者)，Univ Paris, Sorbonne Univ, Inst Natl Sante & Rech Med, Ctr Rech Cordeliers,Equipe Immunopathol & Immunoi, F-75006 Paris, France.; Renia, L (通讯作者)，ASTAR, Infect Dis Labs, 8A Biomed Grove, Singapore 138648, Singapore.; Renia, L (通讯作者)，Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 308232, Singapore.; Renia, L (通讯作者)，Nanyang Technol Univ, Sch Biol Sci, Singapore 308232, Singapore.; Kumar, HMS (通讯作者)，CSIR Indian Inst Chem Technol, Organ Synth & Proc Chem Div, Vaccine Immunol Lab, Hyderabad 500007, India.	bsrpharmacy90@gmail.com; renia_laurent@idlabs.a-star.edu.sg; ganeshbabutmln@gmail.com; jagadeesh.bayry@crc.jussieu.fr; sampath@iict.res.in	BONAM, SRINIVASA REDDY/I-1342-2016	BONAM, SRINIVASA REDDY/0000-0002-2888-2418; Bayry, Jagadeesh/0000-0003-0498-9808	A*STAR ID labs given by the Agency of Science, Technology and Research (A*STAR)Agency for Science Technology & Research (ASTAR); Department of Biotechnology (DBT), Government of India, India;  [H2020-SC1-2019-874653-INDIGO]	Laurent Renia was supported by core funding to the A*STAR ID labs given by the Agency of Science, Technology and Research (A*STAR). G.T. is a Research Associate-II funded by the Department of Biotechnology (DBT), Government of India, India.	Abagna HB, 2018, MALARIA J, V17, DOI 10.1186/s12936-017-2167-3; Abdulla S, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-11; Aimanianda V, 2009, TRENDS PHARMACOL SCI, V30, P287, DOI 10.1016/j.tips.2009.03.005; Aitken EH, 2020, IMMUNOL CELL BIOL, V98, P264, DOI 10.1111/imcb.12320; Aliprandini E, 2018, NAT MICROBIOL, V3, P1224, DOI 10.1038/s41564-018-0254-z; Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6; Andrews KT, 2014, INT J PARASITOL-DRUG, V4, P95, DOI 10.1016/j.ijpddr.2014.02.002; Antony Hiasindh Ashmi, 2016, Trop Parasitol, V6, P30, DOI 10.4103/2229-5070.175081; Arora G, 2018, ELIFE, V7, DOI 10.7554/eLife.36806; Aucouturier Jerome, 2002, Expert Rev Vaccines, V1, P111, DOI 10.1586/14760584.1.1.111; Audran R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007304; Thu AM, 2017, FEBS J, V284, P2569, DOI 10.1111/febs.14127; Baer K, 2007, PLOS PATHOG, V3, P1651, DOI 10.1371/journal.ppat.0030171; Barfod L, 2011, P NATL ACAD SCI USA, V108, P12485, DOI 10.1073/pnas.1103708108; Baudner BC, 2009, PHARM RES-DORDR, V26, P1477, DOI 10.1007/s11095-009-9859-5; Bejon P, 2011, J INFECT DIS, V204, P9, DOI 10.1093/infdis/jir222; Belnoue E, 2002, J IMMUNOL, V169, P6369, DOI 10.4049/jimmunol.169.11.6369; Belnoue E, 2004, J IMMUNOL, V172, P2487, DOI 10.4049/jimmunol.172.4.2487; Belnoue E, 2008, J IMMUNOL, V181, P8552, DOI 10.4049/jimmunol.181.12.8552; BERENDT AR, 1994, PARASITOL TODAY, V10, P412, DOI 10.1016/0169-4758(94)90238-0; Berry AA, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2637-x; Bhatt TK, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1522; Bhunia D, 2015, ARCH PHARM, V348, P689, DOI 10.1002/ardp.201500143; Blagborough AM, 2009, VACCINE, V27, P5187, DOI 10.1016/j.vaccine.2009.06.069; Blank A, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0160-2; Blasco B, 2017, NAT MED, V23, P917, DOI 10.1038/nm.4381; Bojang KA, 2005, VACCINE, V23, P4148, DOI 10.1016/j.vaccine.2005.03.019; Bonam SR, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105684; Bonam SR, 2018, J CARBOHYD CHEM, V37, P30, DOI 10.1080/07328303.2017.1413193; Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002; Bongfen SE, 2007, J IMMUNOL, V178, P7054, DOI 10.4049/jimmunol.178.11.7054; BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633; BOUHAROUNTAYOUN H, 1995, J EXP MED, V182, P409, DOI 10.1084/jem.182.2.409; Bousheri S, 2008, TRENDS PARASITOL, V24, P199, DOI 10.1016/j.pt.2008.02.003; Boyle MJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax4489; Boyle MJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005041; Boyle MJ, 2015, IMMUNITY, V42, P580, DOI 10.1016/j.immuni.2015.02.012; Brando C, 2007, INFECT IMMUN, V75, P838, DOI 10.1128/IAI.01075-06; BROWN J, 1980, CLIN EXP IMMUNOL, V41, P423; Buffet PA, 2011, BLOOD, V117, P381, DOI 10.1182/blood-2010-04-202911; Carter R, 2000, NAT MED, V6, P241, DOI 10.1038/73062; Carvalho LH, 2002, NAT MED, V8, P166, DOI 10.1038/nm0202-166; Chakravarty S, 2007, NAT MED, V13, P1035, DOI 10.1038/nm1628; Chan JA, 2014, CELL MOL LIFE SCI, V71, P3633, DOI 10.1007/s00018-014-1614-3; Chang ZG, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11537; Chen QF, 2014, P NATL ACAD SCI USA, V111, P1479, DOI 10.1073/pnas.1323318111; Cheng Q, 1998, MOL BIOCHEM PARASIT, V97, P161, DOI 10.1016/S0166-6851(98)00144-3; Chioato A, 2010, CLIN VACCINE IMMUNOL, V17, P1952, DOI 10.1128/CVI.00175-10; Chirke SS, 2017, CHEMISTRYSELECT, V2, P7309, DOI 10.1002/slct.201701377; CLARK IA, 1994, PARASITOL TODAY, V10, P410, DOI 10.1016/0169-4758(94)90237-2; Claudianos C, 2002, MOL MICROBIOL, V45, P1473, DOI 10.1046/j.1365-2958.2002.03118.x; Coccia M, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0027-3; Cockburn IA, 2018, NAT IMMUNOL, V19, P1199, DOI 10.1038/s41590-018-0228-6; Cockburn IA, 2013, P NATL ACAD SCI USA, V110, P9090, DOI 10.1073/pnas.1303858110; Coelho CH, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0035-3; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; Coler RN, 2009, PARASITE IMMUNOL, V31, P520, DOI 10.1111/j.1365-3024.2009.01142.x; Coler RN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016333; Collins KA, 2017, SCI REP-UK, V7, DOI 10.1038/srep46621; Cooke BM, 2014, BIORHEOLOGY, V51, P99, DOI 10.3233/BIR-140654; Coppel RL, 2009, TRENDS PARASITOL, V25, P205, DOI 10.1016/j.pt.2009.02.006; Corradin Giampietro, 2005, Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, V4, P185, DOI 10.2174/1568014053507113; Courtin D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007590; Cowman AF, 2016, CELL, V167, P610, DOI 10.1016/j.cell.2016.07.055; Cox FEG, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-5; Dagen M., 2020, ANTIMALARIAL AGENTS, P1, DOI DOI 10.1016/B978-0-08-101210-9.00001-9; Dantzler KW, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav3963; de Jong RM, 2020, IMMUNOL REV, V293, P190, DOI 10.1111/imr.12828; de Souza JB, 2014, PARASITE IMMUNOL, V36, P131, DOI 10.1111/pim.12086; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; Dent AE, 2015, J INFECT DIS, V212, P1429, DOI 10.1093/infdis/jiv224; Deroost K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02973; Detienne S, 2016, SCI REP-UK, V6, DOI 10.1038/srep39475; deWalick S, 2007, J IMMUNOL, V178, P6033, DOI 10.4049/jimmunol.178.10.6033; Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632; Didierlaurent AM, 2014, J IMMUNOL, V193, P1920, DOI 10.4049/jimmunol.1400948; Dobano C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00439; Dobbs KR, 2016, PARASITOLOGY, V143, P129, DOI 10.1017/S0031182015001626; Doll KL, 2016, J IMMUNOL, V196, P4253, DOI 10.4049/jimmunol.1600155; Draheim M, 2017, EMBO MOL MED, V9, P1605, DOI [10.15252/emmm.201708123, 10.15252/emmm.2017081231]; Draper SJ, 2008, NAT MED, V14, P819, DOI 10.1038/nm.1850; Draper SJ, 2018, CELL HOST MICROBE, V24, P43, DOI 10.1016/j.chom.2018.06.008; Draper SJ, 2015, VACCINE, V33, P7433, DOI 10.1016/j.vaccine.2015.09.093; Druilhe P., 1998, MALARIA PARASITE BIO; Dunachie SJ, 2003, J EXP BIOL, V206, P3771, DOI 10.1242/jeb.00642; Duncan CJA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022271; Dups JN, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00625; Dutta S, 2005, INFECT IMMUN, V73, P5936, DOI 10.1128/IAI.73.9.5936-5944.2005; Engwerda C, 2005, CURR TOP MICROBIOL, V297, P103; Epstein JE, 2011, SCIENCE, V334, P475, DOI 10.1126/science.1211548; Fernandez-Ruiz D, 2016, IMMUNITY, V45, P889, DOI 10.1016/j.immuni.2016.08.011; FERREIRA A, 1986, MOL BIOCHEM PARASIT, V19, P103, DOI 10.1016/0166-6851(86)90114-3; Figueiredo MM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006484; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Fox CB, 2012, CLIN VACCINE IMMUNOL, V19, P1633, DOI 10.1128/CVI.00235-12; Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635; Gazzinelli RT, 2014, NAT REV IMMUNOL, V14, P744, DOI 10.1038/nri3742; Genton B, 2008, EXPERT REV VACCINES, V7, P597, DOI 10.1586/14760584.7.5.597; Goh YS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159347; Gola A, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aap9128; Gomes PS, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01617; Goncalves RM, 2010, INFECT IMMUN, V78, P4763, DOI 10.1128/IAI.00578-10; Goodier MR, 2020, IMMUNOL REV, V293, P25, DOI 10.1111/imr.12798; Gowda DC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03006; GREGORIADIS G, 1990, IMMUNOL TODAY, V11, P89, DOI 10.1016/0167-5699(90)90034-7; Gupta S, 1999, NAT MED, V5, P340, DOI 10.1038/6560; Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681; Hansen DS, 2017, INT J PARASITOL, V47, P105, DOI 10.1016/j.ijpara.2016.09.004; Hart GT, 2019, J EXP MED, V216, P1280, DOI 10.1084/jem.20181681; Head MG, 2017, LANCET GLOB HEALTH, V5, pE772, DOI 10.1016/S2214-109X(17)30245-0; Hemingway J, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002380; Hermsen CC, 2007, VACCINE, V25, P2930, DOI 10.1016/j.vaccine.2006.06.081; Hill AVS, 2010, HUM VACCINES, V6, P78, DOI 10.4161/hv.6.1.10116; Hoffman SL, 2015, VACCINE, V33, pD13, DOI 10.1016/j.vaccine.2015.07.091; HogenEsch H, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0089-x; Holz LE, 2018, CELL REP, V25, P68, DOI 10.1016/j.celrep.2018.08.094; Hopp C.S., 2020, PLASMODIUM FALCIPARU, DOI [10.1101/2020.04.12.030049, DOI 10.1101/2020.04.12.030049]; Horii T, 2010, PARASITOL INT, V59, P380, DOI 10.1016/j.parint.2010.05.002; Horne-Debets JM, 2016, SCI REP-UK, V6, DOI 10.1038/srep26210; Horne-Debets JM, 2013, CELL REP, V5, P1204, DOI 10.1016/j.celrep.2013.11.002; Horowitz A, 2012, J IMMUNOL, V188, P5054, DOI 10.4049/jimmunol.1102710; Huisjes R, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00656; Illingworth J, 2013, J IMMUNOL, V190, P1038, DOI 10.4049/jimmunol.1202438; Imai T, 2015, ELIFE, V4, DOI 10.7554/eLife.04232; Jaleta D., 2016, J BACTERIOL PARASITO, V7, P1, DOI [10.9734/JGEESI/2016/26606, DOI 10.9734/JGEESI/2016/26606, DOI 10.4172/2155-9597.1000300]; Jiang LB, 2010, P NATL ACAD SCI USA, V107, P2224, DOI 10.1073/pnas.0913396107; Jide C., 2009, J MED COLL PLA, V24, P118, DOI [10.1016/S1000-1948(09)60027-7, DOI 10.1016/S1000-1948(09)60027-7]; John CC, 2005, AM J TROP MED HYG, V73, P222, DOI 10.4269/ajtmh.2005.73.222; John CC, 2008, J INFECT DIS, V197, P519, DOI 10.1086/526787; Julien JP, 2019, NAT REV IMMUNOL, V19, P761, DOI 10.1038/s41577-019-0209-5; Kalantari P, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6010013; Kaminski LC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02917; Kana IH, 2018, J INFECT DIS, V218, P956, DOI 10.1093/infdis/jiy258; Kantipakala R, 2019, PHARM DEV TECHNOL, V24, P269, DOI 10.1080/10837450.2018.1469150; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kester KE, 2008, VACCINE, V26, P2191, DOI 10.1016/j.vaccine.2008.02.048; Kester KE, 2009, J INFECT DIS, V200, P337, DOI 10.1086/600120; Klinman Dennis M, 2004, Nat Rev Immunol, V4, P249, DOI 10.1038/nri1329; Krettli AU, 2001, CURR BIOL, V11, pR409, DOI 10.1016/S0960-9822(01)00221-4; Kumar A, 2007, AM J TROP MED HYG, V77, P69, DOI 10.4269/ajtmh.2007.77.69; Kurtovic L, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1054-2; Kurup SP, 2019, NAT REV IMMUNOL, V19, P457, DOI 10.1038/s41577-019-0158-z; Kurup SP, 2019, CELL HOST MICROBE, V25, P565, DOI 10.1016/j.chom.2019.02.014; Kurup SP, 2017, NAT MED, V23, P1220, DOI 10.1038/nm.4395; Kusi KA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185303; Kwenti TE, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2654-9; Kyes SA, 1999, P NATL ACAD SCI USA, V96, P9333, DOI 10.1073/pnas.96.16.9333; Lee WC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01444; Lefebvre MN, 2020, TRENDS PARASITOL, V36, P147, DOI 10.1016/j.pt.2019.11.004; Leiriao P, 2005, J INFECT DIS, V191, P1576, DOI 10.1086/429635; Leroux-Roels G, 2014, HUM VACC IMMUNOTHER, V10, P2211, DOI 10.4161/hv.29375; Leroux-Roels I, 2013, VACCINE, V31, P2196, DOI 10.1016/j.vaccine.2012.05.035; Liang F, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2094; Liehl P, 2014, NAT MED, V20, P47, DOI 10.1038/nm.3424; Lingamurthy M, 2017, TETRAHEDRON, V73, P1473, DOI 10.1016/j.tet.2017.01.059; Loharungsikul S, 2008, ACTA TROP, V105, P10, DOI 10.1016/j.actatropica.2007.08.002; Lopez C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00126; Lopez JA, 2001, EUR J IMMUNOL, V31, P1989, DOI 10.1002/1521-4141(200107)31:7&lt;1989::AID-IMMU1989&gt;3.0.CO;2-M; Lubell Y, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-452; Lusingu JPA, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-48; Marsh K, 2006, PARASITE IMMUNOL, V28, P51, DOI 10.1111/j.1365-3024.2006.00808.x; Marty-Roix R, 2016, J BIOL CHEM, V291, P1123, DOI 10.1074/jbc.M115.683011; Mata E, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/282913; Mauduit M, 2012, IMMUNOL RES, V53, P115, DOI 10.1007/s12026-012-8269-7; MCGREGOR IA, 1964, AM J TROP MED HYG, V13, P237, DOI 10.4269/ajtmh.1964.13.237; McGuinness DH, 2003, TRENDS PARASITOL, V19, P312, DOI 10.1016/S1471-4922(03)00123-5; Michon P, 2000, INFECT IMMUN, V68, P3164, DOI 10.1128/IAI.68.6.3164-3171.2000; Moon JJ, 2012, P NATL ACAD SCI USA, V109, P1080, DOI 10.1073/pnas.1112648109; Mosca F, 2008, P NATL ACAD SCI USA, V105, P10501, DOI 10.1073/pnas.0804699105; Mpina M, 2017, J IMMUNOL, V199, P107, DOI 10.4049/jimmunol.1601989; Mullen GED, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002940; Nalla N, 2015, BIOORGAN MED CHEM, V23, P5846, DOI 10.1016/j.bmc.2015.06.070; Ndungu Francis M, 2019, Wellcome Open Res, V4, P42, DOI 10.12688/wellcomeopenres.15002.1; Near KA, 2002, INFECT IMMUN, V70, P692, DOI 10.1128/IAI.70.2.692-701.2002; Ng HI, 2016, SCI REP-UK, V6, DOI 10.1038/srep29368; NUDELMAN S, 1989, J IMMUNOL, V143, P996; NUSSENZWEIG RS, 1972, AM J TROP MED HYG, V21, P722, DOI 10.4269/ajtmh.1972.21.722; Nussler AK, 1995, RES IMMUNOL, V146, P671, DOI 10.1016/0923-2494(96)84915-7; Nyirenda TS, 2015, J PEDIAT INF DIS SOC, V4, P232, DOI 10.1093/jpids/piu140; O'Hagan DT, 2015, VACCINE, V33, pB14, DOI 10.1016/j.vaccine.2015.01.088; O'Hagan DT, 2003, NAT REV DRUG DISCOV, V2, P727, DOI 10.1038/nrd1176; Oliyier M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00025; Osier FHA, 2008, INFECT IMMUN, V76, P2240, DOI 10.1128/IAI.01585-07; Osier FHA, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-108; Osii RS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01597; Ott G, 1995, Pharm Biotechnol, V6, P277; Pallikkuth S, 2020, ELIFE, V9, DOI 10.7554/eLife.51889; Paul AS, 2015, CURR OPIN HEMATOL, V22, P220, DOI 10.1097/MOH.0000000000000135; Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017; Perez-Mazliah D, 2017, EBIOMEDICINE, V24, P216, DOI 10.1016/j.ebiom.2017.08.030; Perez-Mazliah D, 2015, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00671; Petrovsky N, 2015, DRUG SAFETY, V38, P1059, DOI 10.1007/s40264-015-0350-4; Phillips MA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.50; Pinkevych M, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002729; Pinzon-Charry A, 2013, J EXP MED, V210, P1635, DOI [10.1084/jem.20121972, 10.1084/jem.]; Pirahmadi S, 2019, INFECT IMMUN, V87, DOI [10.1128/IAI.00911-18, 10.1128/iai.00911-18]; Plebanski M, 2005, IMMUNOL CELL BIOL, V83, P307, DOI 10.1111/j.1440-1711.2005.01325.x; Plebanski M, 2008, TRENDS PARASITOL, V24, P532, DOI 10.1016/j.pt.2008.09.006; Polhemus ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006465; Radosevic K, 2010, CLIN VACCINE IMMUNOL, V17, P1687, DOI 10.1128/CVI.00311-10; Radtke AJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40312; Rampling T, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0084-2; Rappuoli R, 2011, NATURE, V473, P463, DOI 10.1038/nature10124; READ D, 1994, PARASITE IMMUNOL, V16, P511, DOI 10.1111/j.1365-3024.1994.tb00305.x; Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409; Regules JA, 2011, EXPERT REV VACCINES, V10, P589, DOI [10.1586/erv.11.57, 10.1586/ERV.11.57]; RENIA L, 1990, EUR J IMMUNOL, V20, P1445, DOI 10.1002/eji.1830200706; Renia L, 2006, J INFECT DIS, V193, P163, DOI 10.1086/498536; RENIA L, 1991, P NATL ACAD SCI USA, V88, P7963, DOI 10.1073/pnas.88.18.7963; RENIA L, 1993, J IMMUNOL, V150, P1471; Renia L, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00463; Riggle BA, 2020, J CLIN INVEST, V130, P1128, DOI 10.1172/JCI133474; Roeffen W, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0972-0; Roestenberg M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003960; Rosenkrands I, 2011, VACCINE, V29, P6283, DOI 10.1016/j.vaccine.2011.06.040; Ross LS, 2019, CELL HOST MICROBE, V26, P35, DOI 10.1016/j.chom.2019.06.001; Rutishauser T, 2020, J IMMUNOL, V204, P180, DOI 10.4049/jimmunol.1900669; Sack BK, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0028-2; Sagara I, 2018, LANCET INFECT DIS, V18, P969, DOI 10.1016/S1473-3099(18)30344-X; Sandeep A, 2016, J CARBOHYD CHEM, V35, P326, DOI 10.1080/07328303.2016.1238480; Sauerwein RW, 2015, VACCINE, V33, P7423, DOI 10.1016/j.vaccine.2015.10.092; Sauerwein RW, 2011, NAT REV IMMUNOL, V11, P57, DOI 10.1038/nri2902; Schofield L, 2002, NATURE, V418, P785, DOI 10.1038/nature00937; Schofield L, 1996, IMMUNOL CELL BIOL, V74, P555, DOI 10.1038/icb.1996.89; SCHOFIELD L, 1987, NATURE, V330, P664, DOI 10.1038/330664a0; Scholzen A, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000543; Schwartz L, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-11; Schwenk R, 2011, VACCINE, V29, P8847, DOI 10.1016/j.vaccine.2011.09.098; Seder RA, 2013, SCIENCE, V341, P1359, DOI 10.1126/science.1241800; Seubert A, 2008, J IMMUNOL, V180, P5402, DOI 10.4049/jimmunol.180.8.5402; Silvie O, 2017, CURR OPIN MICROBIOL, V40, P160, DOI 10.1016/j.mib.2017.12.001; Sinnis P, 1997, TRENDS MICROBIOL, V5, P52, DOI 10.1016/S0966-842X(97)84657-4; Sirima SB, 2020, LANCET INFECT DIS, V20, P585, DOI 10.1016/S1473-3099(19)30739-X; Soon MSF, 2020, NAT IMMUNOL, V21, P1597, DOI 10.1038/s41590-020-0800-8; Spellberg B, 2001, CLIN INFECT DIS, V32, P76, DOI 10.1086/317537; Sravanthi V, 2015, J DRUG DELIV SCI TEC, V28, P56, DOI 10.1016/j.jddst.2015.05.007; Stanisic DI, 2015, INFECT IMMUN, V83, P646, DOI 10.1128/IAI.02398-14; Stanisic DI, 2009, INFECT IMMUN, V77, P1165, DOI 10.1128/IAI.01129-08; Stoute JA, 1998, J INFECT DIS, V178, P1139, DOI 10.1086/515657; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Tan J, 2016, NATURE, V529, P105, DOI 10.1038/nature16450; Todryk SM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002027; Tom JK, 2019, TRENDS BIOTECHNOL, V37, P373, DOI 10.1016/j.tibtech.2018.10.004; Tougan T, 2013, HUM VACC IMMUNOTHER, V9, P283, DOI 10.4161/hv.22950; Traore B, 2009, VACCINE, V27, P7299, DOI 10.1016/j.vaccine.2009.08.023; Trimnell A, 2009, J IMMUNOL, V183, P5870, DOI 10.4049/jimmunol.0900302; Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900; Urban BC, 2001, P NATL ACAD SCI USA, V98, P8750, DOI 10.1073/pnas.151028698; Valencia-Hernandez AM, 2020, CELL HOST MICROBE, V27, P950, DOI 10.1016/j.chom.2020.04.010; Van Braeckel-Budimir N, 2016, CURR OPIN IMMUNOL, V42, P91, DOI 10.1016/j.coi.2016.06.008; van den Berg RA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00557; van Kooyk Y, 2019, NAT MATER, V18, P94, DOI 10.1038/s41563-018-0267-2; Vanderberg JP, 2004, INT J PARASITOL, V34, P991, DOI 10.1016/j.ijpara.2004.05.005; Vaughan AM, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a025486; Vekemans J, 2008, EXPERT REV VACCINES, V7, P223, DOI 10.1586/14760584.7.2.223; Verma YK, 2016, ACS MED CHEM LETT, V7, P172, DOI 10.1021/acsmedchemlett.5b00340; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Villa E, 2018, TRENDS CELL BIOL, V28, P882, DOI 10.1016/j.tcb.2018.07.004; Voepel N, 2014, BIOTECHNOL J, V9, P1435, DOI 10.1002/biot.201400350; Volohonsky G, 2010, TRENDS PARASITOL, V26, P1, DOI 10.1016/j.pt.2009.10.003; Wack A, 2008, VACCINE, V26, P552, DOI 10.1016/j.vaccine.2007.11.054; Weaver R, 2016, SCI REP-UK, V6, DOI 10.1038/srep33094; WEISS WR, 1988, P NATL ACAD SCI USA, V85, P573, DOI 10.1073/pnas.85.2.573; Welsby I, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00663; WHO, 2013, WORLD MALARIA REPORT 2013, P1; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WHO, GUID TREATM MAL; Winkel BMF, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008799; Wolf AS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00212; World Health Organization, THIS YEARS WORLD MAL; Wu YM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002636; Wykes MN, 2018, NAT REV IMMUNOL, V18, P91, DOI 10.1038/nri.2017.112; Yang ASP, 2017, CELL REP, V18, P3105, DOI 10.1016/j.celrep.2017.03.017; Yap XZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01096; Yap XZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00357	276	0	0	11	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1072	10.3390/vaccines9101072			35	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WV1TX	34696180	Green Published			2022-04-29	WOS:000717021300001
J	He, W; Pan, HY; Lin, B; Zhong, XN				He, Wei; Pan, Haiying; Lin, Bing; Zhong, Xiaoni			Analysis of HPV Vaccination Willingness amongst HIV-Negative Men Who Have Sex with Men in China	VACCINES			English	Article						MSM; HPV; vaccine; vaccination willingness	HUMAN-PAPILLOMAVIRUS VACCINATION; GENITAL WARTS; PREVENTION; ACCEPTABILITY; PERCEPTIONS; COVERAGE	Objective: Men who have sex with men (MSM) are high-risk groups of human papillomavirus (HPV) infection, the best measure to prevent this is the HPV vaccine. However, few studies have investigated HPV vaccination willingness in the MSM population in China. We aimed to explore the willingness of human immunodeficiency virus (HIV)-negative MSM for HPV vaccination and the factors affecting their willingness to vaccinate. Methods: We adopted a non-probability sampling method to recruit HIV-negative MSM volunteers. Participants completed a questionnaire, including sociodemographic characteristics, sexual behavior characteristics, HPV infection and vaccine-related knowledge, risk perception, and HPV vaccination willingness and promotion attitudes. Results: Of the 406 HIV-negative MSM surveyed, 86.21% were willing to receive HPV vaccine. HPV infection and vaccine-related knowledge (odds ratio [OR] = 2.167, 95% confidence interval [CI] = 1.049-4.474), HPV infection risk perception (OR = 5.905, 95% CI = 1.312-26.580), and HPV vaccine promotion attitude (OR = 6.784, 95% CI = 3.164-14.546) were all related to HPV vaccination willingness. Conclusion: MSM have a high willingness for HPV vaccination. Strengthening health education for MSM, raising their awareness of HPV infection and vaccines, and promoting their risk perception of HPV infection will help increase their willingness for HPV vaccination.	[He, Wei; Pan, Haiying; Lin, Bing; Zhong, Xiaoni] Chongqing Med Univ, Sch Publ Hlth & Management, Chongqing 400016, Peoples R China		Zhong, XN (通讯作者)，Chongqing Med Univ, Sch Publ Hlth & Management, Chongqing 400016, Peoples R China.	2020111423@stu.cqmu.edu.cn; 2020111428@stu.cqmu.edu.cn; 2019110918@stu.cqmu.edu.cn; zhongxiaoni@cqmu.edu.cn		Pan, Haiying/0000-0001-8890-4853; He, Wei/0000-0002-0348-2063	National Key Project for Infectious Diseases of the Ministry of Science and Technology of China [2018ZX10721102-005]	This work was supported by the National Key Project for Infectious Diseases of the Ministry of Science and Technology of China (2018ZX10721102-005).	Alzghoul Bashar I, 2015, Glob J Health Sci, V8, P154, DOI 10.5539/gjhs.v8n6p154; Arie S, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l6765; Brotherton JML, 2017, MED J AUSTRALIA, V206, P262, DOI 10.5694/mja16.00958; Burk RD, 2013, VIROLOGY, V445, P232, DOI 10.1016/j.virol.2013.07.018; Castellsague X, 2015, VACCINE, V33, P6892, DOI 10.1016/j.vaccine.2015.06.088; Castle PE, 2016, EPIDEMIOL INFECT, V144, P449, DOI 10.1017/S0950268815002198; Chang IJ, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-916; Chesson HW, 2014, SEX TRANSM DIS, V41, P660, DOI 10.1097/OLQ.0000000000000193; Cohen PA, 2019, LANCET, V393, P169, DOI 10.1016/S0140-6736(18)32470-X; Cooper DL, 2017, VACCINE, V35, P2661, DOI 10.1016/j.vaccine.2017.03.083; De Groot AS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171631; Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055; Gallagher KE, 2018, VACCINE, V36, P4761, DOI 10.1016/j.vaccine.2018.02.003; Jiang S, 2017, CURR PROB CANCER, V41, P323, DOI 10.1016/j.currproblcancer.2017.02.006; Lei JY, 2020, NEW ENGL J MED, V383, P1340, DOI 10.1056/NEJMoa1917338; Li J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030499; Li J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1682-2; Liu JX, 2021, RISK MANAG HEALTHC P, V14, P1749, DOI 10.2147/RMHP.S295114; Machalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3; Nadarzynski T, 2014, SEX TRANSM INFECT, V90, P515, DOI 10.1136/sextrans-2013-051357; Nickel Brooke, 2017, Prev Med Rep, V8, P169, DOI 10.1016/j.pmedr.2017.10.005; Park IU, 2015, CLIN INFECT DIS, V61, pS849, DOI 10.1093/cid/civ813; Patel C, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.2018.23.41.1700737; Petit B, 2020, VACCINE, V38, P2160, DOI 10.1016/j.vaccine.2020.01.049; Petrosky E, 2015, MMWR-MORBID MORTAL W, V64, P300; Sadlier C, 2016, HUM VACC IMMUNOTHER, V12, P1536, DOI 10.1080/21645515.2016.1151588; Schiffman Mark, 2003, J Natl Cancer Inst Monogr, P14; Soon JM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235870; Spinner C, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-1902; Stanley M, 2014, HUM VACC IMMUNOTHER, V10, P2106, DOI 10.4161/hv.29137; Stephens Dionne P, 2016, Hisp Health Care Int, V14, P184; Swedish KA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093393; Swedish KA, 2012, CLIN INFECT DIS, V54, P891, DOI 10.1093/cid/cir1036; Wang RJ, 2020, CANCER LETT, V471, P88, DOI 10.1016/j.canlet.2019.11.039; Wang ZX, 2013, VACCINE, V31, P4675, DOI 10.1016/j.vaccine.2013.06.090; Zhang SK, 2015, ANN EPIDEMIOL, V25, P231, DOI 10.1016/j.annepidem.2014.12.009; Zhao Y, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.600273; Zou ZR, 2020, LANCET GLOB HEALTH, V8, pE1335, DOI 10.1016/S2214-109X(20)30277-1	38	0	0	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1069	10.3390/vaccines9101069			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WQ1XQ	34696177	Green Published			2022-04-29	WOS:000713615300001
J	Li, TT; Qi, XL; Li, Q; Tang, WG; Su, K; Jia, MM; Yang, WZ; Xia, Y; Xiong, Y; Qi, L; Feng, LZ				Li, Tingting; Qi, Xiaoling; Li, Qin; Tang, Wenge; Su, Kun; Jia, Mengmeng; Yang, Weizhong; Xia, Yu; Xiong, Yu; Qi, Li; Feng, Luzhao			A Systematic Review and Meta-Analysis of Seasonal Influenza Vaccination of Health Workers	VACCINES			English	Review						influenza vaccination; health workers; meta-analysis; incidence of laboratory-confirmed influenza; absenteeism rate	CARE WORKERS; IMMUNIZATION; ABSENTEEISM; DETERMINANTS; MORTALITY; KNOWLEDGE; COVERAGE; EFFICACY; POLICY; VIRUS	A systematic review and meta-analysis was conducted to estimate the pooled effect of influenza vaccinations for health workers (HWs). Nine databases were screened to identify randomized clinical trials and comparative observational studies that reported the effect of influenza vaccination among HWs. The risk ratio (RR), standardized mean difference, and 95% confidence interval (CI) were employed to study the effect size using fixed/random-effect models. Subgroup analyses and sensitivity analyses were conducted accordingly. Publication bias was examined. Sixteen studies (involving 7971 HWs from nine countries) were included after a comprehensive literature search. The combined RR regarding the incidence of laboratory-confirmed influenza was 0.36 (95% CI: 0.25 to 0.54), the incidence of influenza-like illness (ILI) was 0.69 (95% CI: 0.45 to 1.06), the absenteeism rate was 0.63 (95% CI: 0.46 to 0.86), and the integrated standardized mean difference of workdays lost was -0.18 (95% CI: -0.28 to -0.07) days/person. The subgroup analysis indicated that vaccination significantly decreases the incidence of laboratory-confirmed influenza in different countries, study populations, and average-age vaccinated groups. Influenza vaccinations could effectively reduce the incidence of laboratory-confirmed influenza, absenteeism rates, and workdays lost among HWs. It is advisable, therefore, to improve the coverage and increase the influenza vaccination count among HWs, which may benefit both workers and medical institutions.	[Li, Tingting; Li, Qin; Tang, Wenge; Su, Kun; Xia, Yu; Xiong, Yu; Qi, Li] Chongqing Municipal Ctr Dis Control & Prevent, Chongqing 400016, Peoples R China; [Qi, Xiaoling] Chongqing Med Univ, Affiliated Stomatol Hosp, Chongqing 400016, Peoples R China; [Jia, Mengmeng; Yang, Weizhong; Feng, Luzhao] Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Beijing 100005, Peoples R China		Qi, L (通讯作者)，Chongqing Municipal Ctr Dis Control & Prevent, Chongqing 400016, Peoples R China.; Feng, LZ (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Beijing 100005, Peoples R China.	Lee712ting@126.com; 501044@hospital.cqmu.edu.cn; liqin2006@163.com; twg@cqcdc.org; sukun325@163.com; jiamengmeng@cams.cn; yangweizhong@cams.cn; xiayucq4@hotmail.com; Yuri811320@163.com; qili19812012@126.com; fengluzhao@cams.cn		Li, Tingting/0000-0002-8268-5132	Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences [2020-I2M-1-001]; Senior Medical Talents Program of Chongqing for Young and Middle-aged from Chongqing Health Commission Program [2019GDRC014]	This work was funded by Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (No. 2020-I2M-1-001), and Senior Medical Talents Program of Chongqing for Young and Middle-aged from Chongqing Health Commission Program (No. 2019GDRC014).	Alshammari TM, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4054-9; Amodio E., 2010, ITAL J PUBLIC HLTH, V7, P311; Andayi F, 2021, VACCINE, V39, P3991, DOI 10.1016/j.vaccine.2021.05.057; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Atamna Z, 2016, ISR MED ASSOC J, V18, P5; Barbara M, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-17; Bert F, 2020, J EVAL CLIN PRACT, V26, P1205, DOI 10.1111/jep.13295; Black CL, 2018, MMWR-MORBID MORTAL W, V67, P1050, DOI 10.15585/mmwr.mm6738a2; Brammer L, 2013, MMWR-MORBID MORTAL W, V62, P473; Burls A, 2006, VACCINE, V24, P4212, DOI 10.1016/j.vaccine.2005.12.043; Chan ALF, 2008, PHARM WORLD SCI, V30, P39, DOI 10.1007/s11096-007-9137-8; Chan SSW, 2007, AM J EMERG MED, V25, P808, DOI 10.1016/j.ajem.2007.02.002; Cheng Y, 2021, J MED VIROL, V93, P2947, DOI 10.1002/jmv.26817; Cherian T, 2019, VACCINE, V37, P6255, DOI 10.1016/j.vaccine.2019.07.079; Choucair K, 2021, J EPIDEMIOL GLOB HEA, V11, P34, DOI 10.2991/jegh.k.200906.001; Colombo Giorgio L, 2006, Ther Clin Risk Manag, V2, P219, DOI 10.2147/tcrm.2006.2.2.219; Cuadrado-Payan E, 2020, LANCET, V395, pE84, DOI 10.1016/S0140-6736(20)31052-7; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442; Durando P, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010779; Fahim M, 2021, JMIR PUBLIC HLTH SUR, V7, DOI 10.2196/27433; Frederick J, 2018, INFECT CONT HOSP EP, V39, P452, DOI 10.1017/ice.2018.9; Gianino MM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182510; Gilca R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132195; Grey Literature Network Service 2021, GREYNET INT; Harada Hiroko, 2003, Nihon Koshu Eisei Zasshi, V50, P547; Haridi HK, 2017, J HOSP INFECT, V96, P268, DOI 10.1016/j.jhin.2017.02.005; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Imai C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198685; Ishikane M, 2016, J INFECT CHEMOTHER, V22, P777, DOI 10.1016/j.jiac.2016.03.011; Ito Yoichiro, 2006, Journal of Infection and Chemotherapy, V12, P70, DOI 10.1007/s10156-005-0424-9; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jones C., 1999, AUST INFECT CONTROL, V4, P14, DOI [10.1071/HI99314, DOI 10.1071/HI99314]; Kheok SW, 2008, ANN ACAD MED SINGAP, V37, P465; Kuster SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026239; Lee VJ, 2011, AM J EPIDEMIOL, V174, P468, DOI 10.1093/aje/kwr113; Lemaitre M, 2009, J AM GERIATR SOC, V57, P1580, DOI 10.1111/j.1532-5415.2009.02402.x; Li Q., PROSPERO 2020; Lietz J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162061; Lorenc T, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2703-4; Maltezou HC, 2019, VACCINE, V37, P7576, DOI 10.1016/j.vaccine.2019.09.061; Min L., 2006, CHIN GEN PRACT, V9, P708; Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535; Murti M, 2019, VACCINE, V37, P4001, DOI 10.1016/j.vaccine.2019.06.014; Ng ANM, 2011, J HOSP INFECT, V79, P279, DOI 10.1016/j.jhin.2011.08.004; Nishi K, 2001, Kansenshogaku Zasshi, V75, P851; Paget J, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.020421; Pereira M, 2017, CLIN MED, V17, P484, DOI 10.7861/clinmedicine.17-6-484; Public Health England, SEAS FLU VACC UPT HE; Riphagen-Dalhuisen J, 2013, EUROSURVEILLANCE, V18, P10, DOI 10.2807/1560-7917.ES2013.18.26.20512; Ritsuko S., 2001, ENV INFECT, V16, P303; Saxen H, 1999, PEDIATR INFECT DIS J, V18, P779, DOI 10.1097/00006454-199909000-00007; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Sock Hui L., 2008, HEALTHC INFECT, V13, P4, DOI [10.1071/HI08003, DOI 10.1071/HI08003]; Song Y, 2017, VACCINE, V35, P4060, DOI 10.1016/j.vaccine.2017.06.054; Srinivasan A, 2009, JAMA-J AM MED ASSOC, V302, P1903, DOI 10.1001/jama.2009.1494; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Tamburrano A, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16112006; Thakkinstian A, 2005, STAT MED, V24, P1291, DOI 10.1002/sim.2010; Thomas RE, 2014, VACCINE, V32, P2143, DOI 10.1016/j.vaccine.2014.02.059; To KW, 2016, J HOSP INFECT, V94, P133, DOI 10.1016/j.jhin.2016.07.003; Van Buynder PG, 2015, VACCINE, V33, P1625, DOI 10.1016/j.vaccine.2015.01.048; Vasilevska M, 2014, INFECT CONT HOSP EP, V35, P699, DOI 10.1086/676427; WEINGARTEN S, 1988, J GEN INTERN MED, V3, P32, DOI 10.1007/BF02595754; WHO, INFL SEAS; Wilde JA, 1999, JAMA-J AM MED ASSOC, V281, P908, DOI 10.1001/jama.281.10.908; World Health Organization, GLOB INFL STRAT 2019; World Health Organization, VACC TIM; Yang J, 2016, VACCINE, V34, P5724, DOI 10.1016/j.vaccine.2016.10.013; Yassi A, 1991, Can J Infect Dis, V2, P101; Yu JX, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040134; Zaffina S, 2019, EXPERT REV VACCINES, V18, P411, DOI 10.1080/14760584.2019.1586541	73	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1104	10.3390/vaccines9101104			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WV2KB	34696212	gold, Green Published			2022-04-29	WOS:000717065600001
J	Liao, QY; Dong, MH; Yuan, JH; Lam, WWT; Cowling, BJ; So, HC; Ip, DKM				Liao, Qiuyan; Dong, Meihong; Yuan, Jiehu; Lam, Wendy Wing Tak; Cowling, Benjamin J.; So, Hau Chi; Ip, Dennis Kai Ming			A Mixed-Methods Study to Evaluate Elementary School Staff's Acceptability, Delivery Challenges, and Communication Regarding the Implementation of School-Located Influenza Vaccination Program in Hong Kong	VACCINES			English	Article						school-located influenza vaccination; acceptability; delivery; communication	CHILDREN; IMPACT; HOSPITALIZATION; EXPERIENCES; ATTITUDES; VACCINES; STUDENTS	This was a mixed-methods study comprising a questionnaire-based survey, a qualitative study, and analysis of school newsletters to evaluate elementary school staff's acceptability, delivery challenges and communication about school-located influenza vaccination program (SIVP) in Hong Kong. We found that school staff with lower intention to implement SIVP perceived greater logistical difficulties in arranging SIVP. Challenges regarding program delivery included schools' limited infrastructure, the burden of paperwork, the fear of being overwhelmed by multiple school-based vaccination schedules, lacking confidence in communicating with parents about influenza vaccines, and the difficulties in managing vaccination-related anxiety among children with intellectual disability. School staff were generally passive in communicating with parents and students about influenza vaccines. We also found that schools may use the school newsletters as a substitute of the formal informed consent forms. Good partnerships among government, service providers and schools should be established to minimize the burden of paperwork for school staff, facilitate early planning of SIVP, and support schools with limited infrastructure and the vaccination of children with intellectual disabilities. Training is needed to enhance school staff's confidence in communicating with parents and students about influenza vaccines and improve information delivery to support parents' informed decisions for children's vaccination.	[Liao, Qiuyan; Dong, Meihong; Yuan, Jiehu; Lam, Wendy Wing Tak] Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Div Behav Sci, Hong Kong, Peoples R China; [Cowling, Benjamin J.; So, Hau Chi; Ip, Dennis Kai Ming] Univ Hong Kong, Li Ka Shing Fac Med, Ctr Infect Dis Epidemiol & Control Collaborating, Sch Publ Hlth,WHO, Hong Kong, Peoples R China; [Cowling, Benjamin J.] Lab Data Discovery Hlth, Hong Kong Sci & Technol Pk, Hong Kong, Peoples R China		Liao, QY (通讯作者)，Univ Hong Kong, Li Ka Shing Fac Med, Sch Publ Hlth, Div Behav Sci, Hong Kong, Peoples R China.	qyliao11@hku.hk; meihong@hku.hk; jhyuan@connect.hku.hk; wwtlam@hku.hk; bcowling@hku.hk; haso9150@hku.hk; dkmip@hku.hk		So, Hau Chi/0000-0003-3119-1527	Government of the Hong Kong Special Administrative Region; Health and Medical Research Fund; Food and Health Bureau; Hong Kong SAR Government (DKMI) [INF-HKU-2]	This study was supported by funding from the Government of the Hong Kong Special Administrative Region, the Health and Medical Research Fund of the Food and Health Bureau of the Hong Kong SAR Government (DKMI, grant number: INF-HKU-2).	Allison MA, 2010, PEDIATR INFECT DIS J, V29, P751, DOI 10.1097/INF.0b013e3181d8562c; Alsuhaibani M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040581; Benjamin-Chung J, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003238; Berman PP, 2010, HEALTH PROMOT PRACT, V11, P807, DOI 10.1177/1524839909331552; Boddington NL, 2021, CLIN INFECT DIS, V73, P1722, DOI 10.1093/cid/ciab270; Cawley J, 2010, J SCHOOL HEALTH, V80, P167, DOI 10.1111/j.1746-1561.2009.00482.x; Chiu SS, 2012, VACCINE, V30, P1895, DOI 10.1016/j.vaccine.2011.12.027; Cummings GE, 2012, PEDIATRICS, V129, pS88, DOI 10.1542/peds.2011-0737H; Gallagher N, 2018, VACCINE, V36, P521, DOI 10.1016/j.vaccine.2017.12.003; Herlitz L, 2020, IMPLEMENT SCI, V15, DOI 10.1186/s13012-019-0961-8; Hong Kong Department of Health, 2021, STAT VACC PROGR 3 YE; Hull HF, 2011, HUM VACCINES, V7, P153, DOI 10.4161/hv.7.2.13668; Ishiwada N, 2020, HUM VACC IMMUNOTHER, V16, P2752, DOI 10.1080/21645515.2020.1732163; Kassianos G, 2020, VACCINE, V38, P5747, DOI 10.1016/j.vaccine.2020.06.065; Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022; Keren R, 2005, JAMA-J AM MED ASSOC, V294, P2188, DOI 10.1001/jama.294.17.2188; Kwong JC, 2015, VACCINE, V33, P535, DOI 10.1016/j.vaccine.2014.11.044; Kwong KL, 2009, J PAEDIATR CHILD H, V45, P660, DOI 10.1111/j.1440-1754.2009.01591.x; Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977; Lau YL, 2020, HUM VACC IMMUNOTHER, V16, P823, DOI 10.1080/21645515.2019.1678357; Lee RLT, 2011, J CLIN NURS, V20, P2968, DOI 10.1111/j.1365-2702.2011.03782.x; Lee RLT, 2010, J CLIN NURS, V19, P1462, DOI 10.1111/j.1365-2702.2009.03057.x; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; McLenon J, 2019, J ADV NURS, V75, P30, DOI 10.1111/jan.13818; National Association of County and City Health Officials, 2011, INFL SCH LOC VACC SL; National Association of School Nurses, 2017, SCH LOC VACC POS STA; National Center for Immunization and Respiratory Diseases, 2011, VACC INF STAT; Pebody RG, 2018, EUROSURVEILLANCE, V23, P35, DOI 10.2807/1560.7917.ES.2o18.23.25.1700496; Perman S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4168-0; Reiss DR, 2019, AM J LAW MED, V45, P357, DOI 10.1177/0098858819892745; Santibanez TA, 2018, VACCINE, V36, P7300, DOI 10.1016/j.vaccine.2018.10.042; Schieber RA, 2012, PEDIATRICS, V129, pS68, DOI 10.1542/peds.2011-0737E; Sohn YJ, 2020, INT J INFECT DIS, V99, P199, DOI 10.1016/j.ijid.2020.07.032; Somes MP, 2018, VACCINE, V36, P3199, DOI 10.1016/j.vaccine.2018.04.063; Sreenivasan MV, 2014, PUBLIC HEALTH REP, V129, P229, DOI 10.1177/003335491412900304; Sugaya N, 2018, VACCINE, V36, P1063, DOI 10.1016/j.vaccine.2018.01.024; The Government of the Hong Kong Special Administrative Region, 2021, SEASONAL INFLUENZA V; The Government of the Hong Kong Special Administrative Region, 2019 2020 SEAS INFL; Weinberg GA, 2020, J PEDIAT INF DIS SOC, V9, pS19, DOI 10.1093/jpids/piaa007; Williams V, 2012, J SCH NURS, V28, P256, DOI 10.1177/1059840512438776; Yin JK, 2017, CLIN INFECT DIS, V65, P719, DOI 10.1093/cid/cix420	41	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1175	10.3390/vaccines9101175			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS3UT	34696283	Green Published			2022-04-29	WOS:000715110800001
J	Lundstrom, K				Lundstrom, Kenneth			Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer	VACCINES			English	Review						self-replicating RNA viruses; vaccines; infectious diseases; cancer; immune response; tumor regression; protection; approval	SEMLIKI-FOREST-VIRUS; VESICULAR STOMATITIS-VIRUS; ONCOLYTIC MEASLES-VIRUS; TETRAVALENT DENGUE VACCINE; PROTECTS NONHUMAN-PRIMATES; HUMORAL IMMUNE-RESPONSES; SINDBIS VIRAL VECTORS; HIV TYPE-1 ENVELOPE; INFLUENZA-A VIRUS; T-CELL RESPONSES	Alphaviruses, flaviviruses, measles viruses and rhabdoviruses are enveloped single-stranded RNA viruses, which have been engineered for recombinant protein expression and vaccine development. Due to the presence of RNA-dependent RNA polymerase activity, subgenomic RNA can replicate close to 10(6) copies per cell for translation in the cytoplasm providing extreme transgene expression levels, which is why they are named self-replicating RNA viruses. Expression of surface proteins of pathogens causing infectious disease and tumor antigens provide the basis for vaccine development against infectious diseases and cancer. Self-replicating RNA viral vectors can be administered as replicon RNA at significantly lower doses than conventional mRNA, recombinant particles, or DNA plasmids. Self-replicating RNA viral vectors have been applied for vaccine development against influenza virus, HIV, hepatitis B virus, human papilloma virus, Ebola virus, etc., showing robust immune response and protection in animal models. Recently, paramyxovirus and rhabdovirus vector-based SARS-CoV-2 vaccines as well as RNA vaccines based on self-amplifying alphaviruses have been evaluated in clinical settings. Vaccines against various cancers such as brain, breast, lung, ovarian, prostate cancer and melanoma have also been developed. Clinical trials have shown good safety and target-specific immune responses. Ervebo, the VSV-based vaccine against Ebola virus disease has been approved for human use.</p>	[Lundstrom, Kenneth] PanTherapeut, CH-1095 Lutry, Switzerland		Lundstrom, K (通讯作者)，PanTherapeut, CH-1095 Lutry, Switzerland.						Ajbani SP, 2017, IMMUNOL LETT, V190, P221, DOI 10.1016/j.imlet.2017.08.019; Allen C, 2013, GENE THER, V20, P444, DOI 10.1038/gt.2012.62; Ammour Y, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020173; Andersson C, 2001, SCAND J IMMUNOL, V54, P117, DOI 10.1046/j.1365-3083.2001.00951.x; Aref S, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8100294; Avogadri F, 2014, CANCER IMMUNOL RES, V2, P448, DOI 10.1158/2326-6066.CIR-13-0220; Avogadri F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012670; Awano M, 2016, CANCER SCI, V107, P1647, DOI 10.1111/cas.13064; BERGLUND P, 1993, BIO-TECHNOL, V11, P916, DOI 10.1038/nbt0893-916; Bogers WM, 2015, J INFECT DIS, V211, P947, DOI 10.1093/infdis/jiu522; Boisgerault N, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/387362; Brand D, 1998, AIDS RES HUM RETROV, V14, P1369, DOI 10.1089/aid.1998.14.1369; Brandsma JL, 2007, J VIROL, V81, P5749, DOI 10.1128/JVI.02835-06; Bredenbeek PJ, 2006, VIROLOGY, V345, P299, DOI 10.1016/j.virol.2005.12.001; Cabrera A, 2009, IMMUNOBIOLOGY, V214, P467, DOI 10.1016/j.imbio.2008.11.016; Callaway E, 2020, NATURE, V584, P334, DOI 10.1038/d41586-020-02386-2; Cantarella G, 2009, VACCINE, V27, P3385, DOI 10.1016/j.vaccine.2009.01.061; Case JB, 2020, CELL HOST MICROBE, V28, P465, DOI 10.1016/j.chom.2020.07.018; Castanha PMS, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12121371; Chattopadhyay A, 2018, VACCINE, V36, P3894, DOI 10.1016/j.vaccine.2018.05.095; Crosby EJ, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001662; Crosby EJ, 2019, CLIN CANCER RES, V25, P2725, DOI 10.1158/1078-0432.CCR-18-3102; Daemen T, 2003, VACCINE, V21, P1082, DOI 10.1016/S0264-410X(02)00558-3; DAVIS NL, 1989, VIROLOGY, V171, P189, DOI 10.1016/0042-6822(89)90526-6; de Alwis R, 2021, MOL THER, V29, P1970, DOI 10.1016/j.ymthe.2021.04.001; de Felipe Pablo, 2004, Genet Vaccines Ther, V2, P13, DOI 10.1186/1479-0556-2-13; del Valle JR, 2007, J VIROL, V81, P10597, DOI 10.1128/JVI.00923-07; Demoulins T, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.622385; Dold C, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.21; Durso RJ, 2007, CLIN CANCER RES, V13, P3999, DOI 10.1158/1078-0432.CCR-06-2202; Ebert O, 2003, CANCER RES, V63, P3605; Erasmus JH, 2018, MOL THER, V26, P2507, DOI 10.1016/j.ymthe.2018.07.010; Fan ZC, 2008, VIRUS RES, V138, P97, DOI 10.1016/j.virusres.2008.08.015; Fleeton MN, 2001, J INFECT DIS, V183, P1395, DOI 10.1086/319857; Frolov I, 1996, P NATL ACAD SCI USA, V93, P11371, DOI 10.1073/pnas.93.21.11371; Fukuhara H, 2016, CANCER SCI, V107, P1373, DOI 10.1111/cas.13027; Furuyama W, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-019-0155-z; Kramer MG, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1618-x; Galanis E, 2010, CANCER RES, V70, P875, DOI 10.1158/0008-5472.CAN-09-2762; Garcia-Hernandez MD, 2008, CANCER RES, V68, P861, DOI 10.1158/0008-5472.CAN-07-0445; Garcia-Hernandez MDL, 2007, CANCER RES, V67, P1344, DOI 10.1158/0008-5472.CAN-06-2996; Gehrke R, 2003, J VIROL, V77, P8924, DOI 10.1128/JVI.77.16.8924-8933.2003; Geisbert TW, 2011, J INFECT DIS, V204, pS1075, DOI 10.1093/infdis/jir349; Giraud A, 1999, J VIROL METHODS, V79, P75, DOI 10.1016/S0166-0934(99)00009-9; Granot T, 2012, CANCER GENE THER, V19, P588, DOI 10.1038/cgt.2012.33; Granot T, 2014, MOL THER, V22, P112, DOI 10.1038/mt.2013.215; Griifin D.E., 2016, NEUROTROPIC VIRAL IN, P175; Grossardt C, 2013, HUM GENE THER, V24, P644, DOI 10.1089/hum.2012.205; Gupta G, 2016, VACCINE, V34, P4724, DOI 10.1016/j.vaccine.2016.07.051; Guy B, 2010, HUM VACCINES, V6, P696, DOI 10.4161.hv.6.9.12739; Harty RN, 2001, J MOL MICROB BIOTECH, V3, P513; Harvey TJ, 2003, J VIROL, V77, P7796, DOI 10.1128/JVI.77.14.7796-7803.2003; Hasegawa K, 2006, CLIN CANCER RES, V12, P1868, DOI 10.1158/1078-0432.CCR-05-1803; Hasegawa K, 2006, CLIN CANCER RES, V12, P6170, DOI 10.1158/1078-0432.CCR-06-0992; Hastie E, 2013, J VIROL, V87, P10283, DOI 10.1128/JVI.01412-13; Heikkila JE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008603; Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6; Henao-Restrepo AM, 2015, LANCET, V386, P857, DOI 10.1016/S0140-6736(15)61117-5; Herbert AS, 2013, J VIROL, V87, P4952, DOI 10.1128/JVI.03361-12; Son HA, 2018, CANCER INVEST, V36, P106, DOI 10.1080/07357907.2018.1434539; Hoang-Le D, 2009, GENE THER, V16, P190, DOI 10.1038/gt.2008.169; Horner C, 2020, P NATL ACAD SCI USA, V117, P32657, DOI 10.1073/pnas.2014468117; Howley, 2007, FIELDS VIROLOGY, P1364; Hromic-Jahjefendic A, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8030060; Hu HM, 2016, HUM VACC IMMUNOTHER, V12, P1678, DOI 10.1080/21645515.2016.1143576; Ito N, 2003, MICROBIOL IMMUNOL, V47, P613, DOI 10.1111/j.1348-0421.2003.tb03424.x; Ito T, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020149; Jansen KA, 2013, MED ANTHROPOL, V32, P174, DOI 10.1080/01459740.2012.679981; Jiang XH, 2011, VACCINE, V29, P1248, DOI 10.1016/j.vaccine.2010.11.079; Johnson DM, 2020, VACCINE, V38, P2949, DOI 10.1016/j.vaccine.2020.02.053; Jones M, 2005, J VIROL, V79, P5414, DOI 10.1128/JVI.79.9.5414-5420.2005; Kelvin AA, 2011, J INFECT DEV COUNTR, V5, P441, DOI 10.3855/jidc.2171; Khalil SM, 2014, VACCINE, V32, P4068, DOI 10.1016/j.vaccine.2014.05.053; Khromykh AA, 1998, J VIROL, V72, P5967, DOI 10.1128/JVI.72.7.5967-5977.1998; Kimpel J, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10030108; Knudsen ML, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117042; Komdeur FL, 2021, MOL THER, V29, P611, DOI 10.1016/j.ymthe.2020.11.002; Krishnavajhala HR, 2018, ARCH VIROL, V163, P483, DOI 10.1007/s00705-017-3578-8; Kurup D, 2020, MEASLES BASED ZIKA V, DOI [10.1101/2020.09.17.301622, DOI 10.1101/2020.09.17.301622]; Lachman LB, 2001, CANCER GENE THER, V8, P259, DOI 10.1038/sj.cgt.7700300; Lamb YN, 2021, DRUGS, V81, P495, DOI 10.1007/s40265-021-01480-7; Levin Y, 2021, VACCINE, V39, P2821, DOI 10.1016/j.vaccine.2021.04.017; Li JQ, 2017, HUM VACC IMMUNOTHER, V13, P986, DOI 10.1080/21645515.2016.1276125; Liao JB, 2008, CLIN VACCINE IMMUNOL, V15, P817, DOI 10.1128/CVI.00343-07; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; Liu RQ, 2018, ANTIVIR RES, V150, P30, DOI 10.1016/j.antiviral.2017.12.007; Lorin C, 2004, J VIROL, V78, P146, DOI 10.1128/JVI.78.1.146-157.2004; Lukashevich IS, 2016, EXPERT REV VACCINES, V15, P1135, DOI 10.1080/14760584.2016.1184575; Lundstrom K, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020317; Lundstrom K, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12111324; Lundstrom K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145130; Lyons JA, 2007, GENE THER, V14, P503, DOI 10.1038/sj.gt.3302889; Maatta AM, 2008, INT J CANCER, V123, P1704, DOI 10.1002/ijc.23646; Martikainen M, 2015, J VIROL, V89, P10637, DOI 10.1128/JVI.01868-15; Marzi A, 2015, SCIENCE, V349, P739, DOI 10.1126/science.aab3920; Mateo M, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw3163; Maxmen A., 2017, NATURE, DOI [10.1038/nature.2017.22024, DOI 10.1038/NATURE.2017.22024]; McAllister A, 2000, J VIROL, V74, P9197, DOI 10.1128/JVI.74.19.9197-9205.2000; McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9; Melo M, 2019, MOL THER, V27, P2080, DOI 10.1016/j.ymthe.2019.08.007; Molenkamp R, 2003, J VIROL, V77, P1644, DOI 10.1128/JVI.77.2.1644-1648.2003; Morse MA, 2010, J CLIN INVEST, V120, P3234, DOI 10.1172/JCI42672; Msaouel P, 2009, PROSTATE, V69, P82, DOI 10.1002/pros.20857; Muhlebach MD, 2017, METHODS MOL BIOL, V1581, P151, DOI 10.1007/978-1-4939-6869-5_9; Murphy AM, 2000, GENE THER, V7, P1477, DOI 10.1038/sj.gt.3301263; Murphy AM, 2012, J VIROL, V86, P3073, DOI 10.1128/JVI.05640-11; Ohara S, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.001.2009; Oliver SE, 2021, MMWR-MORBID MORTAL W, V69, P1653, DOI 10.15585/mmwr.mm695152e1; Osakada F, 2013, NAT PROTOC, V8, P1583, DOI 10.1038/nprot.2013.094; Patel MR, 2015, ONCOTARGET, V6, P33165, DOI 10.18632/oncotarget.5320; Patel MR, 2014, J THORAC ONCOL, V9, P1101, DOI 10.1097/JTO.0000000000000214; Pijlman GP, 2006, EXPERT OPIN BIOL TH, V6, P135, DOI 10.1517/14712598.6.2.135; Pushko P, 2001, J VIROL, V75, P11677, DOI 10.1128/JVI.75.23.11677-11685.2001; Pyankov OV, 2015, J INFECT DIS, V212, pS368, DOI 10.1093/infdis/jiv019; RADECKE F, 1995, EMBO J, V14, P5773, DOI 10.1002/j.1460-2075.1995.tb00266.x; Ramsauer K, 2015, LANCET INFECT DIS, V15, P519, DOI 10.1016/S1473-3099(15)70043-5; Ravel G, 2017, VACCINE, V35, P5918, DOI 10.1016/j.vaccine.2017.08.071; Reed DS, 2014, J VIROL, V88, P12077, DOI 10.1128/JVI.01406-14; Reisinger EC, 2018, LANCET, V392, P2718, DOI 10.1016/S0140-6736(18)32488-7; Reynolds TD, 2015, J VIROL, V89, P10407, DOI 10.1128/JVI.01184-15; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Rossi SL, 2019, J INFECT DIS, V220, P735, DOI 10.1093/infdis/jiz202; Ryder AB, 2015, J VIROL, V89, P2820, DOI 10.1128/JVI.03246-14; Safronetz D, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003736; Savar NS, 2021, MOL CELL PROBE, V59, DOI 10.1016/j.mcp.2021.101749; Scaglione A., 2021, COMBINATION SINDBIS, DOI [10.1101/2021.05.28.446009, DOI 10.1101/2021.05.28.446009]; Schnell MJ, 1996, P NATL ACAD SCI USA, V93, P11359, DOI 10.1073/pnas.93.21.11359; Schultz-Cherry S, 2000, VIROLOGY, V278, P55, DOI 10.1006/viro.2000.0635; Sheahan T, 2011, J VIROL, V85, P217, DOI 10.1128/JVI.01805-10; Shi PY, 2002, VIROLOGY, V296, P219, DOI 10.1006/viro.2002.1453; Singh M, 1999, J VIROL, V73, P4823, DOI 10.1128/JVI.73.6.4823-4828.1999; Slovin SF, 2013, VACCINE, V31, P943, DOI 10.1016/j.vaccine.2012.11.096; Smerdou C, 1999, J VIROL, V73, P1092, DOI 10.1128/JVI.73.2.1092-1098.1999; Stettler P, 2002, VIRUS RES, V85, P173, DOI 10.1016/S0168-1702(02)00044-8; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Subissi L, 2018, J INFECT DIS, V218, pS287, DOI 10.1093/infdis/jiy280; Sugiyama T, 2013, GENE THER, V20, P338, DOI 10.1038/gt.2012.44; Tani H, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2011.00272; Tao J, 2020, J VIROL METHODS, V279, DOI 10.1016/j.jviromet.2020.113842; Thomas JM, 2009, CLIN VACCINE IMMUNOL, V16, P1696, DOI 10.1128/CVI.00173-09; Thompson JM, 2008, VACCINE, V26, P4267, DOI 10.1016/j.vaccine.2008.05.046; Torresi J, 2017, HUM VACC IMMUNOTHER, V13, P1059, DOI 10.1080/21645515.2016.1261770; Tretyakova I, 2020, VACCINE, V38, P3378, DOI 10.1016/j.vaccine.2020.02.007; Tretyakova I, 2019, VACCINE, V37, P3317, DOI 10.1016/j.vaccine.2019.04.072; Tseng JC, 2004, NAT BIOTECHNOL, V22, P70, DOI 10.1038/nbt917; Tsuji M, 1998, J VIROL, V72, P6907, DOI 10.1128/JVI.72.8.6907-6910.1998; Urbiola C, 2018, INT J CANCER, V143, P1786, DOI 10.1002/ijc.31556; van de Wall S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1487913; Vasilevska J, 2012, CANCER GENE THER, V19, P579, DOI 10.1038/cgt.2012.37; Velders MP, 2001, CANCER RES, V61, P7861; Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017; Wang XY, 2005, BREAST CANCER RES, V7, pR580, DOI 10.1186/bcr1199; Weaver SC, 1996, LANCET, V348, P436, DOI 10.1016/S0140-6736(96)02275-1; Wecker M, 2012, CLIN VACCINE IMMUNOL, V19, P1651, DOI 10.1128/CVI.00258-12; XIONG C, 1989, SCIENCE, V243, P1188, DOI 10.1126/science.2922607; Yahalom-Ronen Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20228-7; Yamanaka R, 2005, DNA CELL BIOL, V24, P317, DOI 10.1089/dna.2005.24.317; Yamanaka R, 2003, J NEUROSURG, V99, P746, DOI 10.3171/jns.2003.99.4.0746; Yamanaka R, 2001, CANCER GENE THER, V8, P796, DOI 10.1038/sj.cgt.7700367; Yin XT, 2015, BIOCHEM BIOPH RES CO, V465, P239, DOI 10.1016/j.bbrc.2015.08.003; Ying H, 1999, NAT MED, V5, P823, DOI 10.1038/10548; Zamarin D, 2012, FUTURE MICROBIOL, V7, P347, DOI [10.2217/fmb.12.4, 10.2217/FMB.12.4]; Zhang JY, 2021, ONCOGENE, V40, P4783, DOI 10.1038/s41388-021-01869-4; Zhang X, 2018, VIROLOGY, V522, P244, DOI 10.1016/j.virol.2018.06.018; Zhang YQ, 2010, MOL THER, V18, P692, DOI 10.1038/mt.2009.318; Zhao DH, 2013, ONCOL REP, V29, P199, DOI 10.3892/or.2012.2109; Zhao X, 2014, INT J CLIN EXP MED, V7, P1204; Zoulim F, 2020, HUM VACC IMMUNOTHER, V16, P388, DOI 10.1080/21645515.2019.1651141	168	1	1	14	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1187	10.3390/vaccines9101187			28	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WQ4OY	34696295	gold, Green Published			2022-04-29	WOS:000713798900001
J	Mintoff, D; Borg, I; Pace, NP				Mintoff, Dillon; Borg, Isabella; Pace, Nikolai Paul			The Clinical Relevance of the Microbiome in Hidradenitis Suppurativa: A Systematic Review	VACCINES			English	Review						hidradenitis suppurativa; microbiome	GUT-SKIN AXIS; PROPIONIBACTERIUM-ACNES; BACTERIAL BIOFILM; DIVERSITY; INVERSA; LESIONS; COMMENSAL; SURGERY; STAPHYLOCOCCI; COLONIZATION	Hidradenitis suppurativa is a chronic disease of the pilosebaceous unit. The name of the condition is a testament to the presumed relationship between the disease and the microbiome. The pathophysiology of hidradenitis suppurativa is, however, complex and believed to be the product of a multifactorial interplay between the interfollicular epithelium, pilosebaceous unit, microbiome, as well as genetic and environmental factors. In this review we assimilate the existing literature regarding the role played by the human microbiome in HS in various contexts of the disease, including the pathophysiologic, therapeutic, and potentially, diagnostic as well prognostic. In conclusion, the role played by the microbiome in HS is extensive and relevant and can have bench-to-bedside applications.</p>	[Mintoff, Dillon; Borg, Isabella] Univ Malta, Fac Med & Surg, Dept Pathol, Msida 2080, Malta; [Mintoff, Dillon] Mater Hosp, Dept Dermatol, Triq Id Donaturi Tad Demm, Msida 2090, Malta; [Borg, Isabella; Pace, Nikolai Paul] Univ Malta, Fac Med & Surg, Ctr Mol Med & Biobanking, Msida 2080, Malta; [Borg, Isabella] Mater Hosp, Dept Pathol, Med Genet Unit, Msida 2090, Malta		Mintoff, D (通讯作者)，Univ Malta, Fac Med & Surg, Dept Pathol, Msida 2080, Malta.; Mintoff, D (通讯作者)，Mater Hosp, Dept Dermatol, Triq Id Donaturi Tad Demm, Msida 2090, Malta.	isabella.borg@um.edu.mt	Mintoff, Dillon/ABG-2301-2020	Mintoff, Dillon/0000-0003-3705-0119; Pace, Nikolai Paul/0000-0002-7332-874X; Borg, Isabella/0000-0003-0639-3055	Eau Thermale Avene	The APC was funded by Eau Thermale Avene.	Aboud C, 2020, SURGERY, V167, P1012, DOI 10.1016/j.surg.2019.12.015; Alatas ET, 2019, DERMATOL THER, V32, DOI 10.1111/dth.13044; Amarante-Mendes GP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02379; Andersen RK, 2019, EXP DERMATOL, V28, P312, DOI 10.1111/exd.13885; Ardon CB, 2019, J EUR ACAD DERMATOL, V33, pE248, DOI 10.1111/jdv.15523; Ardon CB, 2019, J EUR ACAD DERMATOL, V33, P170, DOI 10.1111/jdv.15183; Assan F, 2020, J ALLERGY CLIN IMMUN, V146, P461, DOI 10.1016/j.jaci.2020.04.016; Assan F, 2020, J ALLERGY CLIN IMMUN, V146, P452, DOI 10.1016/j.jaci.2020.01.045; Baldrian P, 2014, APPL MICROBIOL BIOT, V98, P1531, DOI 10.1007/s00253-013-5457-x; Belkaid Y, 2017, IMMUNITY, V46, P562, DOI 10.1016/j.immuni.2017.04.008; Belkaid Y, 2016, NAT REV IMMUNOL, V16, P353, DOI 10.1038/nri.2016.48; Belkaid Y, 2014, SCIENCE, V346, P954, DOI 10.1126/science.1260144; Benhadou Farida, 2018, Diseases, V6, DOI 10.3390/diseases6020047; Bettoli V, 2019, J EUR ACAD DERMATOL, V33, P930, DOI 10.1111/jdv.15332; Bjerre RD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53599-z; Blakeley-Ruiz JA, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0631-8; Boer J, 2018, J EUR ACAD DERMATOL, V32, pE195, DOI 10.1111/jdv.14707; Boer J, 1999, J AM ACAD DERMATOL, V40, P73, DOI 10.1016/S0190-9622(99)70530-X; Breitwieser FP, 2019, BRIEF BIOINFORM, V20, P1125, DOI 10.1093/bib/bbx120; Brown CT, 2015, NATURE, V523, P208, DOI 10.1038/nature14486; Bruggemann H, 2004, SCIENCE, V305, P671, DOI 10.1126/science.1100330; Byrd AL, 2018, NAT REV MICROBIOL, V16, P143, DOI 10.1038/nrmicro.2017.157; Byrd AL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4651; Cannistra C, 2013, SURGERY, V154, P1126, DOI 10.1016/j.surg.2013.04.018; Chen LH, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.589726; Chng KR, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.106, 10.1038/nmicrobiol.2016.106]; Clooney AG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148028; Coates M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216249; Corazza M, 2021, EUR J CLIN MICROBIOL, V40, P77, DOI 10.1007/s10096-020-04002-7; Dinh KM, 2020, BRIT J DERMATOL, V183, P387, DOI 10.1111/bjd.18962; Dreno B, 2020, AM J CLIN DERMATOL, V21, P18, DOI 10.1007/s40257-020-00531-1; Duchatelet Sabine, 2019, JAAD Case Rep, V5, P525, DOI 10.1016/j.jdcr.2019.04.001; Eloe-Fadrosh EA, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2015.32, 10.1038/nmicrobiol.2015.32]; Eppinga H, 2016, J CROHNS COLITIS, V10, P1067, DOI 10.1093/ecco-jcc/jjw070; Faith JJ, 2013, SCIENCE, V341, P44, DOI 10.1126/science.1237439; Findley K, 2013, NATURE, V498, P367, DOI 10.1038/nature12171; Fitz-Gibbon S, 2013, J INVEST DERMATOL, V133, P2152, DOI 10.1038/jid.2013.21; Franzosa EA, 2015, NAT REV MICROBIOL, V13, P360, DOI 10.1038/nrmicro3451; Frew JW, 2019, THER ADV CHRONIC DIS, V10, DOI 10.1177/2040622319830646; Gallagher CG, 2019, CLIN EXP DERMATOL, V44, P777, DOI 10.1111/ced.13944; Gallo RL, 2012, NAT REV IMMUNOL, V12, P503, DOI 10.1038/nri3228; Garrett WS, 2015, SCIENCE, V348, P80, DOI 10.1126/science.aaa4972; Gevers D, 2014, CELL HOST MICROBE, V15, P382, DOI 10.1016/j.chom.2014.02.005; Gildner TE, 2020, EVOL MED PUBLIC HLTH, P45, DOI 10.1093/emph/eoaa007; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; GRIBBON EM, 1993, J GEN MICROBIOL, V139, P1745, DOI 10.1099/00221287-139-8-1745; Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537; Grice EA, 2009, SCIENCE, V324, P1190, DOI 10.1126/science.1171700; Guet-Revillet H, 2014, EMERG INFECT DIS, V20, P1990, DOI 10.3201/eid2012.140064; Guo XL, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/9474896; Gurung M, 2020, EBIOMEDICINE, V51, DOI 10.1016/j.ebiom.2019.11.051; Hannigan GD, 2015, MBIO, V6, DOI 10.1128/mBio.01578-15; Hanski I, 2012, P NATL ACAD SCI USA, V109, P8334, DOI 10.1073/pnas.1205624109; Haskin A, 2016, JAMA DERMATOL, V152, P1276, DOI 10.1001/jamadermatol.2016.2337; Hendricks AJ, 2021, DERMATOLOGY, V237, P81, DOI 10.1159/000503605; Hispan P, 2020, ARCH DERMATOL RES, V312, P159, DOI 10.1007/s00403-019-01965-2; Huang YJ, 2015, J ALLERGY CLIN IMMUN, V135, P25, DOI 10.1016/j.jaci.2014.11.011; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Jahns AC, 2014, APMIS, V122, P804, DOI 10.1111/apm.12220; Jiang HY, 2015, BRAIN BEHAV IMMUN, V48, P186, DOI 10.1016/j.bbi.2015.03.016; Join-Lambert O, 2015, J AM ACAD DERMATOL, V73, pS66, DOI 10.1016/j.jaad.2015.07.040; Juviler PG, 2019, INT J SURG CASE REP, V55, P50, DOI 10.1016/j.ijscr.2019.01.006; Kam S, 2021, J INVEST DERMATOL, V141, P225, DOI 10.1016/j.jid.2020.04.017; Kennedy EA, 2017, J ALLERGY CLIN IMMUN, V139, P166, DOI 10.1016/j.jaci.2016.07.029; Kim J, 2005, DERMATOLOGY, V211, P193, DOI 10.1159/000087011; Kim M, 2020, MBIO, V11, DOI 10.1128/mBio.03186-19; Kong HH, 2017, J INVEST DERMATOL, V137, P561, DOI 10.1016/j.jid.2016.10.033; Kravvas G, 2018, J DERMATOL TREAT, V29, P202, DOI 10.1080/09546634.2017.1360989; Kromann CB, 2014, ACTA DERM-VENEREOL, V94, P553, DOI 10.2340/00015555-1800; Kvehaugen Anne Stine, 2017, BMC Obes, V4, P28, DOI 10.1186/s40608-017-0164-2; Lam SY, 2021, J DERMATOL SCI, V101, P218, DOI 10.1016/j.jdermsci.2020.12.008; Lapins J, 1999, BRIT J DERMATOL, V140, P90; Larochette V, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00204; Lee SY, 2018, ALLERGY ASTHMA IMMUN, V10, P354, DOI 10.4168/aair.2018.10.4.354; Leiphart P, 2019, J AM ACAD DERMATOL, V80, P821, DOI 10.1016/j.jaad.2018.10.063; Lomholt HB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012277; Manus MB, 2022, AM J HUM BIOL, V34, DOI 10.1002/ajhb.23584; Maraki S, 2017, ANAEROBE, V43, P43, DOI 10.1016/j.anaerobe.2016.11.010; Marchesi JR, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0094-5; MARPLES RR, 1971, J INVEST DERMATOL, V56, P127, DOI 10.1111/1523-1747.ep12260695; Matusiak L, 2010, J AM ACAD DERMATOL, V62, P706, DOI 10.1016/j.jaad.2009.09.021; Mintoff D, 2021, INT J DERMATOL, DOI 10.1111/ijd.15910; Molnar J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01730; Murdoch TB, 2012, INFLAMM BOWEL DIS, V18, P1743, DOI 10.1002/ibd.22884; Naik HB, 2020, J INVEST DERMATOL, V140, P1688, DOI 10.1016/j.jid.2020.03.946; Naik HB, 2020, J INVEST DERMATOL, V140, P922, DOI 10.1016/j.jid.2019.08.445; Naik S, 2012, SCIENCE, V337, P1115, DOI 10.1126/science.1225152; Nedomansky J, 2016, INFECTION, V44, P247, DOI 10.1007/s15010-015-0814-6; Nielsen VW, 2020, CLIN CASE REP, V8, P504, DOI 10.1002/ccr3.2608; Nikolakis G, 2017, ACTA DERM-VENEREOL, V97, P493, DOI 10.2340/00015555-2591; Nikolakis G, 2015, J AM ACAD DERMATOL, V73, pS12, DOI 10.1016/j.jaad.2015.07.041; Ogai K, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02362; Oh J, 2016, CELL, V165, P854, DOI 10.1016/j.cell.2016.04.008; Oh J, 2014, NATURE, V514, P59, DOI 10.1038/nature13786; Okoye GA, 2017, BRIT J DERMATOL, V176, P241, DOI 10.1111/bjd.14805; Ott SJ, 2006, GUT, V55, P1207; Pascual JC, 2019, EXP DERMATOL, V28, P13; Patel N, 2021, J DERMATOL TREAT, V32, P473, DOI 10.1080/09546634.2019.1670779; Pothmann A, 2019, AM J CLIN DERMATOL, V20, P749, DOI 10.1007/s40257-019-00467-1; Proctor LM, 2014, CELL HOST MICROBE, V16, P276, DOI 10.1016/j.chom.2014.08.014; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Ragab MA, 2018, DERMATOL THER, V31, DOI 10.1111/dth.12715; Reiger M, 2020, J ALLERGY CLIN IMMUN, V145, P93, DOI 10.1016/j.jaci.2019.11.004; Ring HC, 2022, CLIN EXP DERMATOL, V47, P139, DOI 10.1111/ced.14838; Ring HC, 2019, J EUR ACAD DERMATOL, V33, P1775, DOI 10.1111/jdv.15597; Ring HC, 2018, J EUR ACAD DERMATOL, V32, P125, DOI 10.1111/jdv.14538; Ring HC, 2017, BRIT J DERMATOL, V176, P993, DOI 10.1111/bjd.15007; Ring HC, 2020, J INVEST DERMATOL, V140, P1473, DOI 10.1016/j.jid.2019.11.011; Ring HC, 2017, JAMA DERMATOL, V153, P897, DOI 10.1001/jamadermatol.2017.0904; Ring HC, 2017, ACTA DERM-VENEREOL, V97, P208, DOI 10.2340/00015555-2503; Riverain-Gillet E, 2020, J INVEST DERMATOL, V140, P1847, DOI 10.1016/j.jid.2020.02.046; Salem I, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01459; Salter SJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0087-z; Sartorius K, 2006, DERMATOLOGY, V213, P305, DOI 10.1159/000096194; Scala E, 2019, BRIT J DERMATOL, V181, P1038, DOI 10.1111/bjd.17854; Scharschmidt TC, 2015, IMMUNITY, V43, P1011, DOI 10.1016/j.immuni.2015.10.016; Scheinfeld Noah, 2006, Dermatol Online J, V12, P6; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; Schoch CL, 2012, P NATL ACAD SCI USA, V109, P6241, DOI 10.1073/pnas.1117018109; Scholz M, 2016, NAT METHODS, V13, P435, DOI [10.1038/NMETH.3802, 10.1038/nmeth.3802]; Searle T, 2020, AUSTRALAS J DERMATOL, V61, P307, DOI 10.1111/ajd.13401; Sellheyer K, 2005, INT J DERMATOL, V44, P535, DOI 10.1111/j.1365-4632.2004.02536.x; Sender R, 2016, CELL, V164, P337, DOI 10.1016/j.cell.2016.01.013; Shanmugam VK, 2019, CLIN EXP DERMATOL, V44, P882, DOI 10.1111/ced.13959; Snyder Alan, 2021, JAAD Case Rep, V9, P86, DOI 10.1016/j.jdcr.2021.01.017; Song H, 2016, J ALLERGY CLIN IMMUN, V137, P852, DOI 10.1016/j.jaci.2015.08.021; Stergianou D, 2021, DERMATOLOGY, V237, P372, DOI 10.1159/000512617; Strimbu K, 2010, CURR OPIN HIV AIDS, V5, P463, DOI 10.1097/COH.0b013e32833ed177; Szanto M, 2019, EXP DERMATOL, V28, P1210, DOI 10.1111/exd.14016; Tampa M, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/5823684; Tilg H, 2014, GUT, V63, P1513, DOI 10.1136/gutjnl-2014-306928; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; van Straalen KR, 2020, J ALLERGY CLIN IMMUN, V146, P461, DOI 10.1016/j.jaci.2020.04.017; Weinberg JM, 2005, CUTIS, V75, P6; Weiss S, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0237-y; Yin W, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143423; Zouboulis CC, 2021, J EUR ACAD DERMATOL, V35, pE251, DOI 10.1111/jdv.16976; Zouboulis CC, 2020, EXP DERMATOL, V29, P1154, DOI 10.1111/exd.14214	139	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1076	10.3390/vaccines9101076			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO8DB	34696185	gold, Green Published			2022-04-29	WOS:000712677000001
J	Mir, H; Haq, I; Koul, PA				Mir, Hyder; Haq, Inaamul; Koul, Parvaiz A.			Poor Vaccine Effectiveness against Influenza B-Related Severe Acute Respiratory Infection in a Temperate North Indian State (2019-2020): A Call for Further Data for Possible Vaccines with Closer Match	VACCINES			English	Article						influenza; vaccine; vaccine effectiveness; influenza B; SARI	UNITED-STATES; SERIAL VACCINATION; PROTECTION; VIRUSES	Background: Influenza vaccine uptake in India is poor, and scant data exist regarding the effectiveness of influenza vaccine against hospitalization. Methods: From October 2019 to March 2020, vaccination status of 1219 patients (males n = 571, aged 5-107 years; median, 50 years) hospitalized with severe acute respiratory illness (SARI) was assessed. The patients were tested for influenza viruses and their subtypes by RT PCR. Sequencing of the HA gene was performed. Vaccine effectiveness (VE) against influenza subtypes was estimated by the test negative design. Results: A total of 336 (27.5%) patients were influenza-positive, with influenza B/Victoria accounting for 49.7% (n = 167), followed by influenza A/H1N1 (47.6%; n = 155) and influenza A/H3N2 (4.4%; n = 15). About 6.8% and 8.6% of the influenza-positive and influenza-negative patients, respectively, had been vaccinated. Adjusted VE for any influenza strain was 13% (95% CI -42 to 47), which for influenza B was 0%. HA sequencing revealed that influenza B samples mainly belonged to subclade V1A.3/133R with deletion of residues 163-165, as against the 2-aa deletion in influenza B/Colorado/06/2017 strain, contained in the vaccine. VE for influenza A/H1N1 was 55%. Conclusions: Poor VE due to a genetic mismatch between the circulating strain and the vaccine strain calls for efforts to reduce the mismatch.</p>	[Mir, Hyder] SKIMS, Influenza Lab, Internal & Pulm Med, Srinagar 190011, J&K, India; [Haq, Inaamul] Govt Med Coll, Dept Community Med, Srinagar 190011, J&K, India; [Koul, Parvaiz A.] Sheri Kashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar 190011, J&K, India		Koul, PA (通讯作者)，Sheri Kashmir Inst Med Sci, Dept Internal & Pulm Med, Srinagar 190011, J&K, India.	mirhyder8@gmail.com; haqinaam@yahoo.co.in; parvaizk@gmail.com	Koul, Parvaiz/B-1666-2017; Haq, Inaamul/M-9181-2015	Koul, Parvaiz/0000-0002-1700-9285; Haq, Inaamul/0000-0001-8559-8010	GIHSN network of the Foundation for Influenza, France; Lina Bruno of Cnr Virus Des Infections Respiratoires France Sud, Lyon, France	The study was supported in part by the GIHSN network of the Foundation for Influenza, France. The authors acknowledge the support of Lina Bruno of Cnr Virus Des Infections Respiratoires France Sud, Lyon, France, for support with genome sequencing and submission of the sequences to the GISAID.	[Anonymous], 2009, CDC PROT REAL TIM RT; Bali NK, 2013, INFLUENZA OTHER RESP, V7, P540, DOI 10.1111/j.1750-2659.2012.00416.x; Bartley JM, 2021, IMMUNOL INVEST, V50, P810, DOI 10.1080/08820139.2021.1909617; Baselga-Moreno V, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6713-5; Belongia EA, 2017, EXPERT REV VACCINES, V16, P723, DOI 10.1080/14760584.2017.1334554; Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8; Centers for Disease Control and Prevention, 2014, MMWR-MORBID MORTAL W, V62, P119; Chen H, 2019, CLIN INFECT DIS, V69, P1198, DOI 10.1093/cid/ciy1065; Dawood FS, 2020, MMWR-MORBID MORTAL W, V69, P177, DOI 10.15585/mmwr.mm6907a1; European Centre for Disease Prevention and Control, INFL CAS DEF 2005 20; Flannery B, 2020, J INFECT DIS, V221, P8, DOI 10.1093/infdis/jiz543; Flannery B, 2019, CLIN INFECT DIS, V68, P1798, DOI 10.1093/cid/ciy775; Flannery B, 2016, J INFECT DIS, V214, P1010, DOI 10.1093/infdis/jiw181; Flannery B, 2014, MMWR-MORBID MORTAL W, V63, P137; Foppa IM, 2016, INT J EPIDEMIOL, V45, P2052, DOI 10.1093/ije/dyw022; Gaglani M, 2016, J INFECT DIS, V213, P1546, DOI 10.1093/infdis/jiv577; Gnatiuc L, 2015, INT J TUBERC LUNG D, V19, P21, DOI 10.5588/ijtld.14.0263; Gomez GB, 2021, SCIENCE, V372, P1043, DOI 10.1126/science.abh3986; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Koul P.A., 2014, J DIABETOL, V2, P5; Koul P, 2020, INDIAN J OCCUP ENVIR, V24, P3, DOI 10.4103/ijoem.IJOEM_50_20; Koul PA, 2020, LUNG INDIA, V37, pS1, DOI 10.4103/lungindia.lungindia_628_20; Koul Parvaiz A., 2018, VirusDisease, V29, P553, DOI 10.1007/s13337-018-0487-8; Koul PA, 2018, VACCINE, V36, P3569, DOI 10.1016/j.vaccine.2018.04.039; Koul PA, 2017, INDIAN HEART J, V69, P28, DOI 10.1016/j.ihj.2016.07.012; Koul PA, 2014, INT J GYNECOL OBSTET, V127, P234, DOI 10.1016/j.ijgo.2014.05.021; Koul PA, 2014, EMERG INFECT DIS, V20, P1723, DOI 10.3201/eid2010.140431; Koul PA, 2011, INFLUENZA OTHER RESP, V5, pR521, DOI 10.1111/j.1750-2659.2011.00261.x; Lafond KE, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003550; Lo CY, 2021, VACCINE, V39, P4628, DOI 10.1016/j.vaccine.2021.06.072; McLean HQ, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a038315; McLean HQ, 2015, J INFECT DIS, V211, P1529, DOI 10.1093/infdis/jiu647; Ministry of Health and Family Welfare Directorate General of Health Services, SEAS INFL GUID VACC; Morris DH, 2018, TRENDS MICROBIOL, V26, P102, DOI 10.1016/j.tim.2017.09.004; Moss AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071376; Muruganathan A., 2016, J ASS PHYS INDIA, V64, P3; Narayan VV, 2020, J GLOB HEALTH, V10, DOI 10.7189/jogh.10.010402; Neher RA, 2016, P NATL ACAD SCI USA, V113, pE1701, DOI 10.1073/pnas.1525578113; Puig-Barbera J, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4017-0; Puig-Barbera J, 2015, INFLUENZA OTHER RESP, V9, P277, DOI 10.1111/irv.12335; Ramsay LC, 2019, BMC MED, V17, DOI 10.1186/s12916-018-1239-8; Rose A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.10.2000153; Skowronski DM, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.7.2000103; Skowronski DM, 2019, CLIN INFECT DIS, V68, P1754, DOI 10.1093/cid/ciy876; Skowronski DM, 2017, J INFECT DIS, V215, P1059, DOI 10.1093/infdis/jix074; Skowronski DM, 2016, CLIN INFECT DIS, V63, P21, DOI 10.1093/cid/ciw176; Skowronski DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092153; US Food and Drug Administration, 2019, CDC HUM INFL VIR REA; Virk RK, 2020, P NATL ACAD SCI USA, V117, P619, DOI 10.1073/pnas.1916585116; Wen SM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664024; WHO, WHO REC COMP INFL VI; World Health Organization, REC COMP INFL VIR VA	52	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1094	10.3390/vaccines9101094			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO7OS	34696202	Green Published, gold			2022-04-29	WOS:000712639700001
J	Otani, J; Ohta, R; Sano, C				Otani, Jun; Ohta, Ryuichi; Sano, Chiaki			Association between Immunoglobulin G Levels and Adverse Effects Following Vaccination with the BNT162b2 Vaccine among Japanese Healthcare Workers	VACCINES			English	Article						BNT162b2 vaccine; adverse reactions; immunologic response	RESPONSES; COVID-19; IMMUNITY	The purpose of the study was to assess the association between the amount of immunoglobulin G (IgG) and the duration of adverse effects of COVID-19 vaccinations in the Japanese population. This cross-sectional study was conducted from April 2020 to August 2021 among workers at a community hospital. All participants received two doses of the BNT162b2 vaccine (Pfizer-BioNTech) in March and April 2021. Vaccine side effects were measured using a self-administered questionnaire. Serum anti-SARS-CoV-2 IgG was measured 3 months after vaccination. There was a total of 338 participants (mean age: 44.7 years). The incidence of adverse reactions after vaccination was higher in women. Adverse reactions associated with higher IgG levels included: erythema at the injection site after the first dose; induration and inflammation at the injection site; and systemic symptoms, e.g., fever and headache after the second dose. IgG levels were higher in younger participants. These findings could mitigate fears regarding the mild adverse effects of the COVID-19 vaccine and encourage uptake of the BNT162b2 vaccine.</p>	[Otani, Jun; Ohta, Ryuichi] Unnan City Hosp, Community Care, Daito Cho, Unnan, Shimane 6991221, Japan; [Sano, Chiaki] Shimane Univ, Fac Med, Dept Community Med Management, Izumo, Shimane 6938501, Japan		Ohta, R (通讯作者)，Unnan City Hosp, Community Care, Daito Cho, Unnan, Shimane 6991221, Japan.	blackjack.otani@nifty.ne.jp; ryuichiohta0120@gmail.com; sanochi@med.shimane-u.ac.jp		Ohta, Ryuichi/0000-0003-2593-091X; Sano, Chiaki/0000-0002-9796-5161			Bhagianadh D, 2022, J APPL GERONTOL, V41, P4, DOI 10.1177/07334648211037507; Bogdanov G, 2021, CLIN DERMATOL, V39, P523, DOI 10.1016/j.clindermatol.2021.04.001; Chadwick A, 2021, SOC MEDIA SOC, V7, DOI 10.1177/20563051211008817; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; Cheng HY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060582; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Fink AL, 2018, CURR OPIN PHYSIOL, V6, P16, DOI 10.1016/j.cophys.2018.03.010; Fischinger S, 2019, SEMIN IMMUNOPATHOL, V41, P239, DOI 10.1007/s00281-018-0726-5; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Garcia-Montero C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050433; Graupensperger S, 2021, J PRIM PREV, V42, P309, DOI 10.1007/s10935-021-00633-4; Herron RV, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18063028; Hoffmann MA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080911; Israeli E, 2009, LUPUS, V18, P1217, DOI 10.1177/0961203309345724; Jacobson RM, 2001, VACCINE, V19, P2418, DOI 10.1016/S0264-410X(00)00466-7; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Karako K, 2021, BIOSCI TRENDS, V15, P1, DOI 10.5582/bst.2021.01019; Khan M, 2021, MOLECULES, V26, DOI 10.3390/molecules26010039; Klein SL, 2010, LANCET INFECT DIS, V10, P338, DOI 10.1016/S1473-3099(10)70049-9; Klugar M, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10080752; Kurita J., EFFECT EMERGENCY DEC, DOI [10.1101/2020.04.16.20067447v2, DOI 10.1101/2020.04.16.20067447V2]; Lau H, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa037; Lewnard JA, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020028; Lindinger-Sternart S, 2021, COUNS PSYCHOTHER RES, V21, P290, DOI 10.1002/capr.12387; Liu TR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060649; Lo Sasso B, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11071135; Love AS, 2021, J PRIM CARE COMMUNIT, V12, DOI 10.1177/21501327211007393; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Ohta R, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18115924; Ohta R, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020574; Ohta R, 2021, RURAL REMOTE HEALTH, V21, DOI 10.22605/RRH6406; Ohta R, 2021, QUAL SOC WORK, V20, P423, DOI 10.1177/1473325020973343; Panda A, 2010, J IMMUNOL, V184, P2518, DOI 10.4049/jimmunol.0901022; Pascual-Iglesias A, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10081030; Pormohammad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050467; Raude J, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.584500; Rogliani P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030227; SCHEIFELE DW, 1994, CAN MED ASSOC J, V150, P14; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035; Singh R, 2020, ASIAN J PSYCHIATR, V53, DOI 10.1016/j.ajp.2020.102222; Thompson MG, 2021, NEW ENGL J MED, V385, P320, DOI 10.1056/NEJMoa2107058; Vannabouathong C, 2020, J BONE JOINT SURG AM, V102, P734, DOI 10.2106/JBJS.20.00396; Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729; Woof JM, 2006, J PATHOL, V208, P270, DOI 10.1002/path.1877; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048; Zurac S, 2021, MOL MED REP, V24, DOI 10.3892/mmr.2021.12217	48	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1149	10.3390/vaccines9101149			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO0YW	34696257	Green Published, gold			2022-04-29	WOS:000712189900001
J	Riad, A; Huang, Y; Abdulqader, H; Morgado, M; Domnori, S; Koscik, M; Mendes, JJ; Klugar, M; Kateeb, E				Riad, Abanoub; Huang, Yi; Abdulqader, Huthaifa; Morgado, Mariana; Domnori, Silvi; Koscik, Michal; Mendes, Jose Joao; Klugar, Miloslav; Kateeb, Elham		IADS-SCORE	Universal Predictors of Dental Students' Attitudes towards COVID-19 Vaccination: Machine Learning-Based Approach	VACCINES			English	Article						COVID-19 vaccines; decision making; decision trees; dental education; international association of dental students; machine learning; mass vaccination; regression analysis	INFECTION-CONTROL MEASURES; MEDICAL-STUDENTS; HESITANCY	Background: young adults represent a critical target for mass-vaccination strategies of COVID-19 that aim to achieve herd immunity. Healthcare students, including dental students, are perceived as the upper echelon of health literacy; therefore, their health-related beliefs, attitudes and behaviors influence their peers and communities. The main aim of this study was to synthesize a data-driven model for the predictors of COVID-19 vaccine willingness among dental students. Methods: a secondary analysis of data extracted from a recently conducted multi-center and multi-national cross-sectional study of dental students' attitudes towards COVID-19 vaccination in 22 countries was carried out utilizing decision tree and regression analyses. Based on previous literature, a proposed conceptual model was developed and tested through a machine learning approach to elicit factors related to dental students' willingness to get the COVID-19 vaccine. Results: machine learning analysis suggested five important predictors of COVID-19 vaccination willingness among dental students globally, i.e., the economic level of the country where the student lives and studies, the individual's trust of the pharmaceutical industry, the individual's misconception of natural immunity, the individual's belief of vaccines risk-benefit-ratio, and the individual's attitudes toward novel vaccines. Conclusions: according to the socio-ecological theory, the country's economic level was the only contextual predictor, while the rest were individual predictors. Future research is recommended to be designed in a longitudinal fashion to facilitate evaluating the proposed model. The interventions of controlling vaccine hesitancy among the youth population may benefit from improving their views of the risk-benefit ratio of COVID-19 vaccines. Moreover, healthcare students, including dental students, will likely benefit from increasing their awareness of immunization and infectious diseases through curricular amendments.	[Riad, Abanoub; Koscik, Michal; Klugar, Miloslav] Masaryk Univ, Dept Publ Hlth, Fac Med, Brno 62500, Czech Republic; [Riad, Abanoub; Abdulqader, Huthaifa; Morgado, Mariana; Domnori, Silvi] Int Assoc Dent Students IADS, CH-1216 Geneva, Switzerland; [Riad, Abanoub; Klugar, Miloslav] Masaryk Univ, Czech Natl Ctr Evidence Based Healthcare & Knowle, Czech EBHC JBI Ctr Excellence, Masaryk Univ GRADE Ctr,Inst Biostat & Anal,Fac Me, Kamenice 5, Brno 62500, Czech Republic; [Huang, Yi] Masaryk Univ, Fac Social Studies, Dept Psychol, Brno 60200, Czech Republic; [Huang, Yi] Masaryk Univ, Inst Res Children Youth & Family, Fac Social Studies, Brno 60200, Czech Republic; [Morgado, Mariana; Mendes, Jose Joao] Egas Moniz Cooperat Ensino Super, Clin Res Unit CRU, P-2829511 Almada, Portugal; [Kateeb, Elham] Al Quds Univ, Oral Hlth Res & Promot Unit, Fac Dent, Jerusalem 51000, Palestine; [Kateeb, Elham] World Dent Federat FDI, Publ Hlth Comm, CH-1216 Geneva, Switzerland		Riad, A (通讯作者)，Masaryk Univ, Dept Publ Hlth, Fac Med, Brno 62500, Czech Republic.; Riad, A (通讯作者)，Int Assoc Dent Students IADS, CH-1216 Geneva, Switzerland.; Riad, A (通讯作者)，Masaryk Univ, Czech Natl Ctr Evidence Based Healthcare & Knowle, Czech EBHC JBI Ctr Excellence, Masaryk Univ GRADE Ctr,Inst Biostat & Anal,Fac Me, Kamenice 5, Brno 62500, Czech Republic.	abanoub.riad@med.muni.cz; yihuang@mail.muni.cz; ekateeb@staff.alquds.edu	Riad, Abanoub/AAU-7046-2020; Klugar, Miloslav/E-5748-2018; Issa, Julien/AAT-7458-2021; Huang, Yi/AAZ-3392-2021; Kateeb, Elham/Q-5207-2018	Riad, Abanoub/0000-0001-5918-8966; Klugar, Miloslav/0000-0002-2804-7295; BALTAZAR MENDES, JOSE JOAO/0000-0003-0167-4077; Issa, Julien/0000-0002-6498-7989; Huang, Yi/0000-0003-4194-2611; Koscik, Michal/0000-0002-9243-6391; Morgado, Mariana/0000-0002-2402-2277; AbdulQader, Huthaifa/0000-0001-6677-0276; Kateeb, Elham/0000-0003-2077-3257	Masaryk University [MUNI/IGA/1543/2020, MUNI/A/1608/2020]; INTEREXCELLENCE grant [LTC20031]	This study was funded by Masaryk University, grant numbers MUNI/IGA/1543/2020 and MUNI/A/1608/2020. The work of A.R. and M.K. (Miloslav Klugar) was supported by the INTEREXCELLENCE grant number LTC20031--"Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic".	Acheampong T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080814; Afolabi AA, 2021, PAN AFR MED J, V38, DOI 10.11604/pamj.2021.38.3.27401; Al-Jayyousi GF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060548; Alawia R., 2021, J ORAL MED ORAL SURG, V27, P17, DOI [10.1051/mbcb/2020056, DOI 10.1051/MBCB/2020056]; Alawia R, 2022, ORAL DIS, V28, P975, DOI 10.1111/odi.13593; Alhazmi A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060674; Almaghaslah D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040330; dos Santos JA, 2021, J DENT RES, V100, P1321, DOI 10.1177/00220345211029637; Aw J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080900; Barari S., 2020, EVALUATING COVID 19, DOI [10.1101/2020.03.27.20042820, DOI 10.1101/2020.03.27.20042820]; Barber SJ, 2021, J GERONTOL B-PSYCHOL, V76, pE17, DOI 10.1093/geronb/gbaa068; Belingheri M, 2019, MED LAV, V110, P155, DOI 10.23749/mdl.v110i2.7573; Benis A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040315; Bertoncello C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020276; Biswas N, 2021, J COMMUN HEALTH, V46, P1244, DOI 10.1007/s10900-021-00984-3; Boerner F, 2013, HUM VACC IMMUNOTHER, V9, P1477, DOI 10.4161/hv.24427; Callaghan T., 2020, CORRELATES DISPARITI, DOI DOI 10.2139/SSRN.3667971; Carrieri V, 2021, HEALTH ECON, V30, P3248, DOI 10.1002/hec.4430; Ceccato I, 2021, AGING MENT HEALTH, V25, P1305, DOI 10.1080/13607863.2020.1856781; Chadwick A, 2021, SOC MEDIA SOC, V7, DOI 10.1177/20563051211008817; Crescitelli MED, 2020, PUBLIC HEALTH, V180, P38, DOI 10.1016/j.puhe.2019.10.027; D'Souza G., WHAT IS HERD IMMUNIT; de Souza RA, 2006, J PUBLIC HEALTH DENT, V66, P282; Dinga JN, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020175; Dudley MZ, 2020, VACCINE, V38, P709, DOI 10.1016/j.vaccine.2019.11.056; Eskola J, 2015, VACCINE, V33, P4215, DOI 10.1016/j.vaccine.2015.04.043; Farsi Nada J, 2020, Asian Pac J Cancer Prev, V21, P3595, DOI 10.31557/APJCP.2020.21.12.3595; Frank E, 2007, PREV MED, V44, P76, DOI 10.1016/j.ypmed.2006.07.018; Giambi C, 2018, VACCINE, V36, P779, DOI 10.1016/j.vaccine.2017.12.074; Griffith J, 2021, J MED INTERNET RES, V23, DOI 10.2196/26874; Guastafierro E, 2021, J GERONTOL SOC WORK, V64, P585, DOI 10.1080/01634372.2020.1870606; Gunasekeran DV, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00412-9; Hatmal MM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060556; Alba LH, 2015, FRONT MED-PRC, V9, P251, DOI 10.1007/s11684-015-0393-z; Hockova B, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040581; Huang SG, 2021, INT J BIOL SCI, V17, P1581, DOI 10.7150/ijbs.58855; Hussain A, 2021, J MED INTERNET RES, V23, DOI 10.2196/26627; International Association of Dental Students (IADS), DEL LIST; International Association of Dental Students (IADS), WORKFORCE; Islam MS, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11880-9; Iyer P, 2020, J DENT EDUC, V84, P718, DOI 10.1002/jdd.12163; Jeskowiak I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050502; Juvinya-Canal D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072273; Kalok A, 2020, VACCINE, V38, P2183, DOI 10.1016/j.vaccine.2020.01.043; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Kateeb E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090954; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Klugar M, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10080752; Kollamparambil U., 2021, BMC Public Health, V21, DOI 10.1186/s12889-021-12196-4; Lam A, VACCINATION RECOMMEN; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Liao JQ, 2020, INNOVATION-AMSTERDAM, V1, DOI 10.1016/j.xinn.2020.04.001; Lobelo F, 2009, BRIT J SPORT MED, V43, P89, DOI 10.1136/bjsm.2008.055426; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; Machado RA, 2020, BRAZ ORAL RES, V34, DOI 10.1590/1807-3107bor-2020.vol34.0083; Maraqa B, 2021, PREV MED, V149, DOI 10.1016/j.ypmed.2021.106618; Mendels DA, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2019893118; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Miko D, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55060282; Olaimat AN, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00254; PAHO, 2021, INTR COVID 19 VACC G; Proton Technologies AG, GEN DAT PROT REG GDP; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Raude J, 2016, EXPERT REV VACCINES, V15, P937, DOI 10.1080/14760584.2016.1184092; Reno C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040378; Rey D, 2018, EUROSURVEILLANCE, V23, P30, DOI [10.2807/1560-7917.ES.23.17.17-00816, 10.2807/1560-7917.ES.2018.23.17.17-00816]; Riad A, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14090873; Riad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090948; Riad A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18157859; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122629; Riad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060673; Riad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060566; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071428; Riad A, 2021, J COSMET DERMATOL-US, V20, P1580, DOI 10.1111/jocd.14066; Riad A, 2021, DERMATOL THER, V34, DOI 10.1111/dth.14735; Riad A, 2021, SPEC CARE DENT, V41, P282, DOI 10.1111/scd.12547; Riad A, 2022, ORAL DIS, V28, P988, DOI 10.1111/odi.13635; Riad A, 2021, INT J PAEDIATR DENT, V31, P35, DOI 10.1111/ipd.12694; Riad A, 2022, ORAL DIS, V28, P968, DOI 10.1111/odi.13571; Rungkitwattanakul D, 2021, HEMODIAL INT, V25, P410, DOI 10.1111/hdi.12922; Russo AG, 2021, VACCINE, V39, P2517, DOI 10.1016/j.vaccine.2021.03.076; Rutkoski H, 2020, J CANCER EDUC, V35, P1017, DOI 10.1007/s13187-019-01561-y; Sandhofer MJ, 2017, WIEN KLIN WOCHENSCHR, V129, P59, DOI 10.1007/s00508-016-1062-1; Shetty S, 2019, HUM VACC IMMUNOTHER, V15, P1656, DOI 10.1080/21645515.2019.1565260; Singh A, 2011, J DENT EDUC, V75, P421; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Sovicova M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18136815; Strategic Advisory Group of Experts on Immunization (SAGE), 2014, REP SAG WORK GROUP V; Sukys S, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8516843; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030218; Umeizudike KA, 2021, J DENT EDUC, V85, P187, DOI 10.1002/jdd.12423; van der Schaar M, 2021, MACH LEARN, V110, P1, DOI 10.1007/s10994-020-05928-x; von Elm E, 2007, LANCET, V370, P1453, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120, 10.1371/journal.pmed.0040296]; Vozikis A, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-15; World Bank World Bank, COUNTR LEND GROUPS; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Wu DT, 2020, EUR J DENT EDUC, V24, P825, DOI 10.1111/eje.12561	98	11	11	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1158	10.3390/vaccines9101158			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XJ6BR	34696266	gold, Green Published			2022-04-29	WOS:000726871300001
J	Ritzau-Jost, J; Hutloff, A				Ritzau-Jost, Julia; Hutloff, Andreas			T Cell/B Cell Interactions in the Establishment of Protective Immunity	VACCINES			English	Review						follicular helper T cells; peripheral helper T cells; germinal center reaction; vaccination; inflamed tissues; cytokines	FOLLICULAR-HELPER-CELLS; MEMORY B-CELLS; GERMINAL CENTER RESPONSES; VACCINE ADJUVANT; DENDRITIC CELLS; ANTIBODY-RESPONSES; INFLUENZA-VIRUS; TFH CELLS; SJOGRENS-SYNDROME; FH CELLS	Follicular helper T cells (Tfh) are the T cell subset providing help to B cells for the generation of high-affinity antibodies and are therefore of key interest for the development of vaccination strategies against infectious diseases. In this review, we will discuss how the generation of Tfh cells and their interaction with B cells in secondary lymphoid organs can be optimized for therapeutic purposes. We will summarize different T cell subsets including Tfh-like peripheral helper T cells (Tph) capable of providing B cell help. In particular, we will highlight the novel concept of T cell/B cell interaction in non-lymphoid tissues as an important element for the generation of protective antibodies directly at the site of pathogen invasion.</p>	[Ritzau-Jost, Julia; Hutloff, Andreas] Univ Hosp Schleswig Holstein, Inst Immunol, D-24105 Kiel, Germany		Hutloff, A (通讯作者)，Univ Hosp Schleswig Holstein, Inst Immunol, D-24105 Kiel, Germany.	andreas.hutloff@uksh.de	Hutloff, Andreas/D-1781-2014	Hutloff, Andreas/0000-0002-0572-8151	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [HU 1294/8-1, TRR 130 TP23]	This work was funded by grants from the Deutsche Forschungsgemeinschaft HU 1294/8-1 and TRR 130 TP23 to A.H.	Adachi Y, 2015, J EXP MED, V212, P1709, DOI 10.1084/jem.20142284; Afkarian M, 2002, NAT IMMUNOL, V3, P549, DOI 10.1038/ni794; Agren LC, 1997, J IMMUNOL, V158, P3936; Aimanianda V, 2009, TRENDS PHARMACOL SCI, V30, P287, DOI 10.1016/j.tips.2009.03.005; Akiba H, 2005, J IMMUNOL, V175, P2340, DOI 10.4049/jimmunol.175.4.2340; Akkaya M, 2020, NAT REV IMMUNOL, V20, P229, DOI 10.1038/s41577-019-0244-2; Aljurayyan AN, 2016, ANTIVIR RES, V132, P122, DOI 10.1016/j.antiviral.2016.05.021; Allie SR, 2019, NAT IMMUNOL, V20, P97, DOI 10.1038/s41590-018-0260-6; Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; Andersen TK, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0101-0; [Anonymous], 2009, Wkly Epidemiol Rec, V84, P349; Asrir A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00843-7; Avancena P, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2100576118; Baldwin SL, 2016, VACCINE, V34, P2207, DOI 10.1016/j.vaccine.2016.03.016; Ballesteros-Tato A, 2012, IMMUNITY, V36, P847, DOI 10.1016/j.immuni.2012.02.012; Barker KA, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI141810; Bauer L, 2021, AM J RESP CRIT CARE, V204, P1403, DOI 10.1164/rccm.202012-4423OC; Baumjohann D, 2013, IMMUNITY, V38, P596, DOI 10.1016/j.immuni.2012.11.020; Bemark M, 2011, J IMMUNOL, V186, P1399, DOI 10.4049/jimmunol.1002881; Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191; Bingaman AW, 2005, EUR J IMMUNOL, V35, P3173, DOI 10.1002/eji.200526004; Blokland SLM, 2017, ARTHRITIS RHEUMATOL, V69, P2038, DOI 10.1002/art.40182; Bocharnikov AV, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130062; Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002; Bossaller L, 2006, J IMMUNOL, V177, P4927, DOI 10.4049/jimmunol.177.7.4927; Boswell KL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003853; Brenna E, 2020, CELL REP, V30, P137, DOI 10.1016/j.celrep.2019.12.016; Budroni S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00337-0; Calabro S, 2011, VACCINE, V29, P1812, DOI 10.1016/j.vaccine.2010.12.090; Calder Philip C, 2021, Eur J Clin Nutr, V75, P1309, DOI 10.1038/s41430-021-00949-8; Cardeno A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20740-3; Carnathan DG, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01213; Chakarov S, 2014, EMBO MOL MED, V6, P590, DOI 10.1002/emmm.201403841; Chauveau L, 2021, EMBO REP, V22, DOI 10.15252/embr.202152447; Choi YS, 2013, J IMMUNOL, V190, P3049, DOI 10.4049/jimmunol.1203032; Christophersen A, 2019, NAT MED, V25, P734, DOI 10.1038/s41591-019-0403-9; Cicalese MP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01761; Cirelli KM, 2019, CELL, V177, P1153, DOI 10.1016/j.cell.2019.04.012; CLAASSEN E, 1992, RES IMMUNOL, V143, P478, DOI 10.1016/0923-2494(92)80057-R; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Counoupas C, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00255-7; Cuburu N, 2012, J CLIN INVEST, V122, P4606, DOI 10.1172/JCI63287; Cyster JG, 2019, CELL, V177, P524, DOI 10.1016/j.cell.2019.03.016; da Silva SR, 2021, J INFECT DIS, V223, P1842, DOI 10.1093/infdis/jiab195; Van V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10875; Darrah PA, 2020, NATURE, V577, P95, DOI 10.1038/s41586-019-1817-8; De Donato S, 1999, VACCINE, V17, P3094, DOI 10.1016/S0264-410X(99)00138-3; Deenick EK, 2010, IMMUNITY, V33, P241, DOI 10.1016/j.immuni.2010.07.015; Deng J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23220-x; Dhenni R, 2020, IMMUNOL REV, V296, P62, DOI 10.1111/imr.12862; Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474; Diehl SA, 2012, IMMUNOL CELL BIOL, V90, P802, DOI 10.1038/icb.2012.17; Dienz O, 2009, J EXP MED, V206, P69, DOI 10.1084/jem.20081571; DiToro D, 2018, SCIENCE, V361, P1086, DOI 10.1126/science.aao2933; Dorward DA, 2021, AM J RESP CRIT CARE, V203, P192, DOI 10.1164/rccm.202008-3265OC; Eddahri F, 2009, BLOOD, V113, P2426, DOI 10.1182/blood-2008-04-154682; Eriksson AM, 2004, J IMMUNOL, V173, P3310, DOI 10.4049/jimmunol.173.5.3310; Fang DF, 2018, J EXP MED, V215, P2705, DOI 10.1084/jem.20180927; Fazilleau N, 2007, NAT IMMUNOL, V8, P753, DOI 10.1038/ni1472; Ferreira-Gomes M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22210-3; Fleige H, 2014, J EXP MED, V211, P643, DOI 10.1084/jem.20131737; Florido M, 2018, MUCOSAL IMMUNOL, V11, P1743, DOI 10.1038/s41385-018-0065-9; FORSTER R, 1994, BLOOD, V84, P830; Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635; Gary E, 2020, VACCINE, V38, P3821, DOI 10.1016/j.vaccine.2020.03.047; Gavillet BM, 2015, J IMMUNOL, V194, P4836, DOI 10.4049/jimmunol.1402071; GeurtsvanKessel CH, 2009, J EXP MED, V206, P2339, DOI 10.1084/jem.20090410; Ghimire TR, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0972-0; Giannini SL, 2006, VACCINE, V24, P5937, DOI 10.1016/j.vaccine.2006.06.005; Gibson SJ, 2002, CELL IMMUNOL, V218, P74, DOI 10.1016/S0008-8749(02)00517-8; Gitlin AD, 2014, NATURE, V509, P637, DOI 10.1038/nature13300; Givord C, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0058-4; Glatigny S, 2019, J IMMUNOL, V202, P1373, DOI 10.4049/jimmunol.1801425; Glenny AT, 1930, BMJ-BRIT MED J, V1930, P244, DOI 10.1136/bmj.2.3632.244; Godot V, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009025; Goenka R, 2011, J IMMUNOL, V187, P1091, DOI 10.4049/jimmunol.1100853; Groom JR, 2012, IMMUNITY, V37, P1091, DOI 10.1016/j.immuni.2012.08.016; Gu-Trantien C, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91487; Hardtke S, 2005, BLOOD, V106, P1924, DOI 10.1182/blood-2004-11-4494; Haynes NM, 2007, J IMMUNOL, V179, P5099, DOI 10.4049/jimmunol.179.8.5099; He J, 2013, IMMUNITY, V39, P770, DOI 10.1016/j.immuni.2013.09.007; Heesters BA, 2014, NAT REV IMMUNOL, V14, P495, DOI 10.1038/nri3689; Heit A, 2017, J EXP MED, V214, P2139, DOI 10.1084/jem.20161794; Herati RS, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aag2152; Hercor M, 2017, J LEUKOCYTE BIOL, V101, P5, DOI 10.1189/jlb.1HI1115-511R; Hill DL, 2019, J EXP MED, V216, P1857, DOI 10.1084/jem.20190301; Ho NI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02874; Hogan RJ, 2001, J EXP MED, V193, P981, DOI 10.1084/jem.193.8.981; Hutchison S, 2012, FASEB J, V26, P1272, DOI 10.1096/fj.11-184556; Hutloff A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01707; Jacquemin C, 2015, IMMUNITY, V42, P1159, DOI 10.1016/j.immuni.2015.05.012; Johnston RJ, 2012, J EXP MED, V209, P243, DOI 10.1084/jem.20111174; Joo HM, 2008, P NATL ACAD SCI USA, V105, P3485, DOI 10.1073/pnas.0800003105; Joo HM, 2010, VACCINE, V28, P2186, DOI 10.1016/j.vaccine.2009.12.058; Kasturi SP, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb1025; Kingstad-Bakke B, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.559382; Klinman DM, 1998, ANTISENSE NUCLEIC A, V8, P181, DOI 10.1089/oli.1.1998.8.181; Knight FC, 2019, ACS NANO, V13, P10939, DOI 10.1021/acsnano.9b00326; Knudsen NPH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19570; Kool M, 2012, J MED MICROBIOL, V61, P927, DOI 10.1099/jmm.0.038943-0; Koutsakos M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan8405; Krishnaswamy JK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02169; Krishnaswamy JK, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aam9169; Kuo TY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77077-z; Lahmann A, 2021, METHODS MOL BIOL, V2285, P77, DOI 10.1007/978-1-0716-1311-5_6; Lambert PH, 2008, VACCINE, V26, P3197, DOI 10.1016/j.vaccine.2008.03.095; Lapuente D, 2018, MUCOSAL IMMUNOL, V11, P1265, DOI 10.1038/s41385-018-0017-4; Lederer K, 2020, IMMUNITY, V53, P1281, DOI 10.1016/j.immuni.2020.11.009; Lee SK, 2012, IMMUNITY, V37, P880, DOI 10.1016/j.immuni.2012.10.010; Leroux-Roels G, 2016, CLIN IMMUNOL, V169, P16, DOI 10.1016/j.clim.2016.05.007; Leroux-Roels I, 2015, VACCINE, V33, P577, DOI 10.1016/j.vaccine.2013.10.052; Li JH, 2016, NATURE, V533, P110, DOI 10.1038/nature17947; Li YY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010144; Liang F, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2094; Linterman MA, 2014, ELIFE, V3, DOI 10.7554/eLife.03180; Lirussi D, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020188; Liu D, 2015, NATURE, V517, P214, DOI 10.1038/nature13803; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; Lu LL, 2018, NAT REV IMMUNOL, V18, P46, DOI 10.1038/nri.2017.106; Lu L, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040754; Luthje K, 2012, NAT IMMUNOL, V13, P491, DOI 10.1038/ni.2261; Ma CS, 2012, BLOOD, V119, P3997, DOI 10.1182/blood-2011-11-392985; Martini H, 2011, CLIN EXP IMMUNOL, V164, P381, DOI 10.1111/j.1365-2249.2011.04377.x; Masopust D, 2019, ANNU REV IMMUNOL, V37, P521, DOI 10.1146/annurev-immunol-042617-053214; McHeyzer-Williams M, 2012, NAT REV IMMUNOL, V12, P24, DOI 10.1038/nri3128; Merkenschlager J, 2021, NATURE, V591, P458, DOI 10.1038/s41586-021-03187-x; Miyauchi K, 2016, NAT IMMUNOL, V17, P1447, DOI 10.1038/ni.3563; Moon JJ, 2012, P NATL ACAD SCI USA, V109, P1080, DOI 10.1073/pnas.1112648109; Moris P, 2011, J CLIN IMMUNOL, V31, P443, DOI 10.1007/s10875-010-9490-6; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Moyron-Quiroz JE, 2004, NAT MED, V10, P927, DOI 10.1038/nm1091; Mukherjee AK, 2012, INT IMMUNOPHARMACOL, V12, P565, DOI 10.1016/j.intimp.2012.02.002; Nakayamada S, 2011, IMMUNITY, V35, P919, DOI 10.1016/j.immuni.2011.11.012; Nguyen NDNT, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0157-x; Nguyen-Contant P, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10030355; Nielsen CM, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100207; Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009; Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676; O'Hagan DT, 2007, EXPERT REV VACCINES, V6, P699, DOI 10.1586/14760584.6.5.699; Obeng-Adjei N, 2015, CELL REP, V13, P425, DOI 10.1016/j.celrep.2015.09.004; Oestreich KJ, 2012, NAT IMMUNOL, V13, P405, DOI 10.1038/ni.2242; Oestreich KJ, 2011, J EXP MED, V208, P1001, DOI 10.1084/jem.20102144; Oja AE, 2018, MUCOSAL IMMUNOL, V11, P654, DOI 10.1038/mi.2017.94; Onodera T, 2012, P NATL ACAD SCI USA, V109, P2485, DOI 10.1073/pnas.1115369109; Papillion A, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw7636; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Pauthner M, 2017, IMMUNITY, V46, P1073, DOI 10.1016/j.immuni.2017.05.007; Pichyangkul S, 2008, INFECT IMMUN, V76, P229, DOI 10.1128/IAI.00977-07; Pontarini E, 2020, ANN RHEUM DIS, V79, P1588, DOI 10.1136/annrheumdis-2020-217646; Pratama A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7436; Pulendran B, 2021, NAT REV DRUG DISCOV, V20, P454, DOI 10.1038/s41573-021-00163-y; Purtha WE, 2011, J EXP MED, V208, P2599, DOI 10.1084/jem.20110740; Qi H, 2016, NAT REV IMMUNOL, V16, P612, DOI 10.1038/nri.2016.94; Qi H, 2014, ANNU REV CELL DEV BI, V30, P141, DOI 10.1146/annurev-cellbio-100913-013254; Rakhra K, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abd8003; Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810; Regules JA, 2016, J INFECT DIS, V214, P762, DOI 10.1093/infdis/jiw237; Reif K, 2002, NATURE, V416, P94, DOI 10.1038/416094a; Reinhardt RL, 2009, NAT IMMUNOL, V10, P385, DOI 10.1038/ni.1715; Rendeiro AF, 2021, NATURE, V593, P564, DOI 10.1038/s41586-021-03475-6; Rioux G, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/1477-3155-12-19; Riteau N, 2016, J IMMUNOL, V197, P3884, DOI 10.4049/jimmunol.1600883; Robinson C, 2019, HUM VACC IMMUNOTHER, V15, P909, DOI 10.1080/21645515.2018.1558697; Sakai S, 2014, J IMMUNOL, V192, P2965, DOI 10.4049/jimmunol.1400019; Schijns V, 2020, IMMUNOL REV, V296, P169, DOI 10.1111/imr.12889; Scholz J, 2021, ALLERGY, V76, P1109, DOI 10.1111/all.14581; Schultz BT, 2016, IMMUNITY, V44, P167, DOI 10.1016/j.immuni.2015.12.011; Schussek S, 2020, MUCOSAL IMMUNOL, V13, P545, DOI 10.1038/s41385-020-0253-2; Seo YB, 2014, J VIROL, V88, P8998, DOI 10.1128/JVI.00534-14; Seydoux E, 2018, J IMMUNOL, V201, P98, DOI 10.4049/jimmunol.1701604; Shi JW, 2018, IMMUNITY, V49, P264, DOI 10.1016/j.immuni.2018.06.012; Shi ST, 2019, VACCINE, V37, P3167, DOI 10.1016/j.vaccine.2019.04.055; Shin C, 2015, CELL REP, V11, P1929, DOI 10.1016/j.celrep.2015.05.042; Shulman Z, 2014, SCIENCE, V345, P1058, DOI 10.1126/science.1257861; Simpson N, 2010, ARTHRITIS RHEUM-US, V62, P234, DOI 10.1002/art.25032; Son YM, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abb6852; Sparwasser T, 2000, EUR J IMMUNOL, V30, P3591, DOI 10.1002/1521-4141(200012)30:12<3591::AID-IMMU3591>3.0.CO;2-J; Spensieri F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157066; Spensieri F, 2013, P NATL ACAD SCI USA, V110, P14330, DOI 10.1073/pnas.1311998110; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Suan D, 2015, IMMUNITY, V42, P704, DOI 10.1016/j.immuni.2015.03.002; Sudfeld CR, 2010, INT J EPIDEMIOL, V39, P48, DOI 10.1093/ije/dyq021; Sulczewski FB, 2020, EUR J IMMUNOL, V50, P1895, DOI 10.1002/eji.202048694; Swarnalekha N, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abb6808; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tam HH, 2016, P NATL ACAD SCI USA, V113, pE6639, DOI 10.1073/pnas.1606050113; Tan HX, 2018, MUCOSAL IMMUNOL, V11, P994, DOI 10.1038/mi.2017.89; Taylor DK, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaf5307; Teijaro JR, 2011, J IMMUNOL, V187, P5510, DOI 10.4049/jimmunol.1102243; Teijaro JR, 2010, J VIROL, V84, P9217, DOI 10.1128/JVI.01069-10; Thome JJC, 2014, CELL, V159, P814, DOI 10.1016/j.cell.2014.10.026; Thompson EA, 2019, CELL REP, V28, P1127, DOI 10.1016/j.celrep.2019.06.087; Thompson EA, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120692; Treanor JJ, 2013, VACCINE, V31, P5760, DOI 10.1016/j.vaccine.2013.08.064; Van DV, 2018, AM J RESP CELL MOL, V59, P437, DOI 10.1165/rcmb.2017-0309OC; van Dissel JT, 2011, VACCINE, V29, P2100, DOI 10.1016/j.vaccine.2010.12.135; van Doorn E, 2016, HUM VACC IMMUNOTHER, V12, P159, DOI 10.1080/21645515.2015.1071455; Van Hoeven N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149610; Vandepapeliere P, 2008, VACCINE, V26, P1375, DOI 10.1016/j.vaccine.2007.12.038; Vella LA, 2019, J CLIN INVEST, V129, P3185, DOI 10.1172/JCI125628; Victora GD, 2010, CELL, V143, P592, DOI 10.1016/j.cell.2010.10.032; Vogelzang A, 2008, IMMUNITY, V29, P127, DOI 10.1016/j.immuni.2008.06.001; Vono M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00381; Wang H, 2021, J ALLERGY CLIN IMMUN, V147, P1692, DOI 10.1016/j.jaci.2020.12.623; Wang J, 2020, SCIENCE, V367, P869, DOI 10.1126/science.aau0810; Wang ZB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010128; Weber JP, 2015, J EXP MED, V212, P217, DOI 10.1084/jem.20141432; Weber JP, 2012, EUR J IMMUNOL, V42, P1981, DOI 10.1002/eji.201242540; Weinstein JS, 2018, J EXP MED, V215, P337, DOI 10.1084/jem.20170457; Wong MT, 2016, IMMUNITY, V45, P442, DOI 10.1016/j.immuni.2016.07.007; Xia JY, 2020, J IMMUNOL, V205, P2077, DOI 10.4049/jimmunol.2000597; Xu HP, 2013, NATURE, V496, P523, DOI 10.1038/nature12058; Yang CM, 2021, SCI TOTAL ENVIRON, V762, DOI 10.1016/j.scitotenv.2020.144103; Zacharias ZR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01953; Zhang J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46533-w; Zhao JC, 2016, IMMUNITY, V44, P1379, DOI 10.1016/j.immuni.2016.05.006; Zou YR, 2021, J INVEST DERMATOL, V141, P2141, DOI 10.1016/j.jid.2021.01.030	217	1	1	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1074	10.3390/vaccines9101074			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP0YC	34696182	Green Published			2022-04-29	WOS:000712866900001
J	Xin, MQ; Luo, ST; She, R; Chen, X; Li, LP; Li, LJ; Chen, XJ; Lau, JTF				Xin, Meiqi; Luo, Sitong; She, Rui; Chen, Xi; Li, Liping; Li, Lijuan; Chen, Xiaojun; Lau, Joseph T. F.			The Impact of Social Media Exposure and Interpersonal Discussion on Intention of COVID-19 Vaccination among Nurses	VACCINES			English	Article						social media; interpersonal discussion; vaccination intention; COVID-19; nurse	COMMUNICATION; PERCEPTION; BEHAVIORS; MODEL	COVID-19 vaccine hesitancy among nurses is a global public health concern and it is imperative to understand associated factors. Information environment plays a critical role in shaping health behaviors, while few studies explored such effects in the context of COVID-19 vaccination. A cross-sectional survey was conducted among 1902 nurses in China. The study investigated the effects of social media exposure/interpersonal discussion on intention of COVID-19 vaccination and tested whether perceived effectiveness of COVID-19 vaccines (perceived vaccine efficacy, perceived duration of protection, and perceived effectiveness in preventing resurgences) mediated such associations. Results showed that about 68.0% and 56.5% of the participants had an intention of free and self-paid COVID-19 vaccinations, respectively. Frequent social media exposure and interpersonal discussion were positively associated with vaccination intentions. Perceived vaccine efficacy significantly mediated the effects of frequent social media exposure and interpersonal discussion, whereas perceived effectiveness in preventing resurgences suppressed the effects of frequent social media exposure. In conclusion, the prevalence of intention of COVID-19 vaccination was relatively low among Chinese nurses and health promotion is needed. Frequent social media exposure and interpersonal discussion potentially enhanced vaccination intentions via increased perceived vaccine efficacy. The findings can help inform the development of relevant health communication interventions.</p>	[Xin, Meiqi; She, Rui; Lau, Joseph T. F.] Chinese Univ Hong Kong, Ctr Hlth Behav Res, Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China; [Luo, Sitong] Tsinghua Univ, Vanke Sch Publ Hlth, Beijing 100083, Peoples R China; [Chen, Xi] Hunan Prov Ctr Dis Control & Prevent, Changsha 410007, Peoples R China; [Li, Liping] Shantou Univ, Sch Publ Hlth, Med Coll, Shantou 515041, Peoples R China; [Li, Lijuan] Dali Univ, Sch Publ Hlth, Dali 671003, Peoples R China; [Chen, Xiaojun] Shantou Univ, Affiliated Hosp 1, Med Coll, Shantou 515041, Peoples R China		Lau, JTF (通讯作者)，Chinese Univ Hong Kong, Ctr Hlth Behav Res, Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China.	meiqixin@link.cuhk.edu.hk; sitongluo@mail.tsinghua.edu.cn; sherryshe0319@link.cuhk.edu.hk; chenxi161@sohu.com; lpli@stu.edu.cn; lelejuan@dali.edu.cn; xjchen@stu.edu.cn; jlau@cuhk.edu.hk		She, Rui/0000-0002-8948-2792; Lau, Joseph/0000-0003-2344-7107; XIN, Meiqi/0000-0002-8636-4918; LI, Liping/0000-0003-3306-779X			AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Al-Dmour H, 2020, J MED INTERNET RES, V22, DOI 10.2196/19996; Allington, 2020, MODE FREQUENCY COVID; Allington D, 2021, PSYCHOL MED, V51, P1763, DOI [10.1017/S0033291721000593, 10.1017/S003329172000224X]; Bartsch SM, 2020, AM J PREV MED, V59, P493, DOI 10.1016/j.amepre.2020.06.011; Bauchner H, 2020, JAMA-J AM MED ASSOC, V324, P1296, DOI 10.1001/jama.2020.18860; Bendau A, 2021, INT IMMUNOPHARMACOL, V97, DOI 10.1016/j.intimp.2021.107724; Biswas N, 2021, J COMMUN HEALTH, V46, P1244, DOI 10.1007/s10900-021-00984-3; Catton H, 2020, INT NURS REV, V67, P157, DOI 10.1111/inr.12593; Cavanaugh AM, 2021, MMWR-MORBID MORTAL W, V70, P639, DOI 10.15585/mmwr.mm7017e2; Chan AKM, 2020, ANAESTHESIA, V75, P1579, DOI 10.1111/anae.15057; Cho HC, 2013, HEALTH COMMUN, V28, P146, DOI 10.1080/10410236.2012.664805; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gerend MA, 2012, ANN BEHAV MED, V44, P171, DOI 10.1007/s12160-012-9366-5; Godin G, 2010, INFECT CONT HOSP EP, V31, P689, DOI 10.1086/653614; Goel A, 2020, JCR-J CLIN RHEUMATOL, V26, P220, DOI 10.1097/RHU.0000000000001508; Haug N, 2020, NAT HUM BEHAV, V4, DOI 10.1038/s41562-020-01009-0; Hinyard LJ, 2007, HEALTH EDUC BEHAV, V34, P777, DOI 10.1177/1090198106291963; Ho SS, 2013, J HEALTH COMMUN, V18, P773, DOI 10.1080/10810730.2012.743624; Hou ZY, 2021, J MED INTERNET RES, V23, DOI 10.2196/27632; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Jang K, 2019, HEALTH COMMUN, V34, P991, DOI 10.1080/10410236.2018.1449552; Kahn JA, 2007, AMBUL PEDIATR, V7, P367, DOI 10.1016/j.ambp.2007.05.010; Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061; Klompas M, 2021, ANN INTERN MED, V174, P1305, DOI 10.7326/M21-2366; Labetoulle R, 2020, EXPERT REV VACCINES, V19, P937, DOI 10.1080/14760584.2020.1843432; Lai CH, 2018, COMPUT HUM BEHAV, V88, P37, DOI 10.1016/j.chb.2018.06.023; Larson HJ, 2018, LANCET, V392, P2244, DOI 10.1016/S0140-6736(18)32608-4; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin CA, 2013, COMMUN RES REP, V30, P127, DOI 10.1080/08824096.2012.762907; Lin YL, 2020, J MED INTERNET RES, V22, DOI 10.2196/19982; Ludolph R, 2018, J HEALTH COMMUN, V23, P1, DOI 10.1080/10810730.2017.1388455; Luo ST, 2021, EPIDEMIOL INFECT, V149, DOI 10.1017/S0950268821000947; Moreno MA, 2014, ALCOHOL RES-CURR REV, V36, P91; Nery, 2021, COVID 19 VACCINES AV; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Our World In Data team, 2021, COR COVID 19 VACC EN; Padureanu V, 2020, MED-SURG J, V124, P454; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Pan YH, 2020, J MED INTERNET RES, V22, DOI 10.2196/22596; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Piltch-Loeb R, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251095; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Rodrigues UM, 2020, MEDIA INT AUST, V177, P125, DOI 10.1177/1329878X20948202; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Shaw R, 2020, PROG DISASTER SCI, V6, DOI 10.1016/j.pdisas.2020.100090; Southwell B.G., 2007, COMMUNICATION YB, V31, P419, DOI [https://doi.org/10.1080/23808985.2007.11679072, DOI 10.1080/23808985.2007.11679072, 10.1080/23808985.2007.11679072]; Sultana J, 2020, EXPERT REV VACCINES, V19, P919, DOI 10.1080/14760584.2020.1825951; U.S. CDC, 2021, INT INF PREV CONTR R; Valente TW, 1999, ANN AM ACAD POLIT SS, V566, P55, DOI 10.1177/0002716299566001005; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Wang ZX, 2020, J MED INTERNET RES, V22, DOI 10.2196/17894; Wilson R, 2020, VACCINE, V38, P1144, DOI 10.1016/j.vaccine.2019.11.018; World Health Organization, 2021, WEEKLY EPIDEMIOLOGIC; Yang J, 2021, BMC MED, V19, DOI 10.1186/s12916-021-01923-8; Zahn-Waxler C., 1994, CENTURY DEV PSYCHOL, P473, DOI DOI 10.1037/10155-016.	61	2	2	12	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1204	10.3390/vaccines9101204			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR7CY	34696312	gold, Green Published			2022-04-29	WOS:000714655500001
J	De Pooter, D; Van Gulck, E; Chen, A; Evans, CF; Neefs, JM; Horton, H; Boden, D				De Pooter, Dorien; Van Gulck, Ellen; Chen, Antony; Evans, Claire F.; Neefs, Jean-Marc; Horton, Helen; Boden, Daniel			A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates	VACCINES			English	Article						therapeutic vaccination; hepatitis B surface antigen (HBsAg); hepatitis B virus (HBV) specific T-cells; HBV functional cure; non-human primate; electroporation	MOUSE MODEL; EXPRESSION; ELECTROPORATION; DELIVERY	Despite the availability of an effective prophylactic vaccine for more than 30 years, nearly 300 million people worldwide are chronically infected with the hepatitis B virus (HBV), leading to 1 death every 30 s mainly from viral hepatitis-related cirrhosis and liver cancer. Chronic HBV patients exhibit weak, transient, or dysfunctional CD8(+) T-cell responses to HBV, which contrasts with high CD8+ T-cell responses seen for resolvers of acute HBV infection. Therefore, a therapeutic DNA vaccine was designed, expressing both HBV core and polymerase proteins, and was sequence optimized to ensure high protein expression and secretion. Although the vaccine, administered intramuscularly via electroporation, had no effect on plasma viral parameters in a mouse model of persistent HBV infection, it did induce robust HBV-specific immune responses in healthy and adeno-associated hepatitis B virus (AAV-HBV) infected mice as well as in healthy non-human primates.	[De Pooter, Dorien; Van Gulck, Ellen; Chen, Antony; Horton, Helen] Div Janssen Pharmaceut NV, Janssen Res & Dev, Janssen Infect Dis, Turnhoutseweg 30, B-2340 Beerse, Belgium; [Evans, Claire F.] Ichor Med Syst Inc, 6310 Nancy Ridge Dr,Suite 107, San Diego, CA 92121 USA; [Neefs, Jean-Marc] Div Janssen Pharmaceut NV, Janssen Res & Dev, Discovery Sci, Turn Houtseweg 30, B-2340 Beerse, Belgium; [Boden, Daniel] Div Janssen Pharmaceut NV, Janssen Infect Dis, 260 E Grand Ave, San Francisco, CA 94080 USA		De Pooter, D (通讯作者)，Div Janssen Pharmaceut NV, Janssen Res & Dev, Janssen Infect Dis, Turnhoutseweg 30, B-2340 Beerse, Belgium.	ddepoote@its.jnj.com; EVANGULC@its.jnj.com; achen39@ITS.JNJ.com; cevans@ichorms.com; JNEEF1@its.jnj.com; helen.horton@touchlight.com; dboden@its.jnj.com			JanssenJohnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc	The authors would like to acknowledge Ichor Medical Systems for providing the TriGrid electroporation system and training on how to use it. We thank Nicola La Monica for setting up this collaboration with Ichor. We also thank the Janssen Infectious Diseases in vivo group, Beerse, Belgium, and Charles River Laboratories Beerse, Belgium for all their hard work in generating the mouse vaccine data packages. The authors thank Ian Woolveridge and Jackie Phillipson of Ashfield MedComms, an Ashfield Health company, who provided support with technical editing of the first draft, assembling tables and figures, collating author comments, grammatical editing, and referencing); this support was funded by Janssen.	ARTELT P, 1991, GENE, V99, P249, DOI 10.1016/0378-1119(91)90134-W; Bayat B., 2020, J HEPATOL, V73, pS571, DOI [DOI 10.1016/S0168-8278(20)31615-9, 10.1016/S0168-8278(20)31615-9]; Berke JM, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00560-17, 10.1128/aac.00560-17]; Bernard P, 1996, BIOTECHNIQUES, V21, P320; Cheng Y, 2021, IMMUNITY, V54, P1825, DOI [10.1016/j.immuni.2021.06.013, 10.17632/67JDVHW2TF, 10.17632/67JDVHW2TF.1, 10.17632/67jdvhw2tf.1]; Chu TH, 2014, J VIROL, V88, P2530, DOI 10.1128/JVI.03235-13; Dembek C, 2018, CURR OPIN VIROL, V30, P58, DOI 10.1016/j.coviro.2018.04.003; Dolter KE, 2011, VACCINE, V29, P795, DOI 10.1016/j.vaccine.2010.11.011; Dong Xiao-yan, 2010, Chinese Journal of Virology, V26, P425; Edwards K.M., 2018, PLOTKINS VACCINES, P7, DOI [10.1016/B978-0-323-35761-6.00002-X, DOI 10.1016/B978-0-323-35761-6.00002-X]; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; Gary EN, 2020, CURR OPIN IMMUNOL, V65, P21, DOI 10.1016/j.coi.2020.01.006; Gehring AJ, 2019, GASTROENTEROLOGY, V156, P325, DOI 10.1053/j.gastro.2018.10.032; Hehle V, 2020, J EXP MED, V217, DOI 10.1084/jem.20200840; Hobernik D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113605; Hollingsworth RE, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0103-y; Jahanafrooz Z, 2020, DRUG DISCOV TODAY, V25, P552, DOI 10.1016/j.drudis.2019.12.003; Karamyshev AL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072538; Kim JH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58870-2; King TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101904; Kjaer J, 2018, J VIROL, V92, DOI 10.1128/JVI.02218-17; Knittel D, 2016, VACCINE, V34, P3093, DOI 10.1016/j.vaccine.2016.04.073; Kosinska AD, 2017, CURR OPIN VIROL, V23, P75, DOI 10.1016/j.coviro.2017.03.011; Kratzer R, 2018, HUM VACC IMMUNOTHER, V14, P1417, DOI 10.1080/21645515.2018.1433970; Lambricht L, 2016, EXPERT OPIN DRUG DEL, V13, P295, DOI 10.1517/17425247.2016.1121990; Lau GKK, 2002, GASTROENTEROLOGY, V122, P614, DOI 10.1053/gast.2002.31887; Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; Li JQ, 2017, HUM VACC IMMUNOTHER, V13, P986, DOI 10.1080/21645515.2016.1276125; Lim SG, 2019, J VIRAL HEPATITIS, V26, P803, DOI 10.1111/jvh.13085; Liu Jia, 2014, Virologica Sinica, V29, P10, DOI 10.1007/s12250-014-3410-5; Lobaina Y, 2010, VIRAL IMMUNOL, V23, P521, DOI 10.1089/vim.2010.0024; Loglio A, 2020, HEPATOL COMMUN, V4, P5, DOI 10.1002/hep4.1476; Lok AS, 2017, HEPATOLOGY, V66, P1296, DOI 10.1002/hep.29323; Lopes A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1154-7; Martin P, 2015, GUT, V64, P1961, DOI 10.1136/gutjnl-2014-308041; Michler T, 2020, GASTROENTEROLOGY, V158, P1762, DOI 10.1053/j.gastro.2020.01.032; Nicolini LA, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16183307; Pal S, 2019, ALIMENT PHARM THER, V49, P1346, DOI 10.1111/apt.15226; Revill PA, 2019, LANCET GASTROENTEROL, V4, P545, DOI 10.1016/S2468-1253(19)30119-0; Rezaei T, 2019, J CONTROL RELEASE, V316, P116, DOI 10.1016/j.jconrel.2019.10.045; Rivino L, 2018, J CLIN INVEST, V128, P668, DOI [10.1172/JCI92812, 10.1172/jci92812]; Sardesai NY, 2011, CURR OPIN IMMUNOL, V23, P421, DOI 10.1016/j.coi.2011.03.008; Somiya M, 2016, VIROLOGY, V497, P23, DOI 10.1016/j.virol.2016.06.024; Suschak JJ, 2017, HUM VACC IMMUNOTHER, V13, P2837, DOI 10.1080/21645515.2017.1330236; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Terrault NA, 2018, HEPATOLOGY, V67, P1560, DOI 10.1002/hep.29800; Ura T, 2014, VACCINES, V2, P624, DOI 10.3390/vaccines2030624; Vasan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019252; Velkov S, 2018, GENES-BASEL, V9, DOI 10.3390/genes9100495; Watanabe H, 2004, SHOCK, V22, P460, DOI 10.1097/01.shk.0000142249.08135.e9; Williams JA, 2014, CURR GENE THER, V14, P170, DOI 10.2174/156652321403140819122538; Woltman AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015324; World Health Organization, 2020, HEP B; Yang D, 2014, CELL MOL IMMUNOL, V11, P71, DOI 10.1038/cmi.2013.43; Yoshida O., 2020, J HEPATOL, V73, pS887, DOI [10.1016/S0168-8278(20)32212-1, DOI 10.1016/S0168-8278(20)32212-1]; Zoulim F, 2020, HUM VACC IMMUNOTHER, V16, P388, DOI 10.1080/21645515.2019.1651141; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999	58	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							969	10.3390/vaccines9090969			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3BJ	34579206	Green Published, gold			2022-04-29	WOS:000702083400001
J	Musa, S; Dergaa, I; Abdulmalik, MA; Ammar, A; Chamari, K; Ben Saad, H				Musa, Sarah; Dergaa, Ismail; Abdulmalik, Mariam Ali; Ammar, Achraf; Chamari, Karim; Ben Saad, Helmi			BNT162b2 COVID-19 Vaccine Hesitancy among Parents of 4023 Young Adolescents (12-15 Years) in Qatar	VACCINES			English	Article						asymptomatic; herd immunity; mRNA; public health; vaccine acceptance	ACCEPTANCE	Parental vaccine hesitancy (VH) remains a barrier to full population inoculation, hence herd immunity against the SARS-CoV-2 virus. We aimed to determine parental VH rate, subgroups and influencing factors related to the BNT162b2 COVID-19 vaccine among their young adolescents (12-15 years old) in Qatar. A retrospective, cross-sectional study was conducted from 17 May to 3 June using vaccination booking records of 4023 young adolescents. Sociodemographic characteristics (i.e., age, sex, and nationality), health status and BNT162b2 COVID-19 vaccination booking status were analysed. Among respondents, the VH rate was 17.9%. Parents of 12-years adolescents were more hesitant (21.6%) as compared to the 13- (16.0%) and 15- (15.2%) years groups (p < 0.05). Parents of adolescents belonging to Gulf Countries (97% Qatari) were more hesitant (35.2%) as compared to the four remaining groups of nationalities (Asiatic; excluding Gulf Countries), North-African, African (excluding North-African), and European/American/Oceanian, 13.3-20.4%, (p < 0.001). Parental VH rates were higher when adolescents suffered from chronic disease as compared to those without the chronic disease (21.3% vs. 17.4%, p < 0.05) or who previously were COVID-19 infected as compared to non-previously COVID-19 infected (24.1 vs. 17.5%, p < 0.01). Results of logistic regression revealed that age groups, nationalities, and recovery from COVID-19 were the main predictors of VH level. Precisely, parents of 12 years old adolescents were 38% more likely to be hesitant as compared to the parents of the 15 years old adolescents (OR = 1.38; 95%CI: 1.12-1.70). Compared with the Gulf countries, parents of adolescents belonging to the other nationality categories; namely North-African, African, Asiatic and European/American/Oceanian were 48% (95%CI: 0.36-0.65), 41% (95% CI: 0.27-0.62), 38% (95%CI: 0.29-0.50) and 34% (95% CI 0.21-0.56) less likely to be hesitant, respectively. Furthermore, parents of young adolescents being previously COVID-19 infected were 37% more likely to be hesitant as compared to those with no previous COVID-19 infection (OR = 1.37; 95%CI: 1.02-1.84). Effective communication strategies specifically targeting Gulf Country populations, parents of younger children aged 12 years and of those with chronic disease or have been previously infected with COVID-19 are crucial to build community trust and vaccine confidence, thereby increasing COVID-19 vaccine uptake.	[Musa, Sarah; Dergaa, Ismail; Abdulmalik, Mariam Ali] Primary Hlth Care Corp PHCC, POB 26555, Doha, Qatar; [Ammar, Achraf] Otto von Guericke Univ, Inst Sport Sci, D-39104 Magdeburg, Germany; [Ammar, Achraf] Paris Nanterre Univ, Interdisciplinary Lab Neurosci Physiol & Psychol, UFR STAPS, UPL, F-92000 Nanterre, France; [Chamari, Karim] Aspetar, Orthopaed & Sports Med Hosp, FIFA Med Ctr Excellence, POB 29222, Doha, Qatar; [Ben Saad, Helmi] Univ Sousse, Farhat HACHED Hosp, Heart Failure Res Lab LR12SP09, Sousse 4054, Tunisia		Musa, S (通讯作者)，Primary Hlth Care Corp PHCC, POB 26555, Doha, Qatar.	smusa@phcc.gov.qa; idergaa@phcc.gov.qa; mabdulmalik@phcc.gov.qa; achraf1.ammar@ovgu.de; karim.chamari@aspetar.com; helmi.bensaad@rns.tn	Dergaa, Ismail/AAB-8260-2021; SAAD, Helmi BEN/C-8263-2018; Achraf, Ammar/B-8455-2018	Dergaa, Ismail/0000-0001-8091-1856; SAAD, Helmi BEN/0000-0002-7477-2965; , Sarah/0000-0002-4457-9953; Chamari, Karim/0000-0001-9178-7678; Achraf, Ammar/0000-0003-0347-8053	Primary Health Care Corporation (PHCC), Doha, Qatar	Open access has been funded by Primary Health Care Corporation (PHCC), Doha, Qatar. The authors would like to extend their gratitude to the Ministry of Public Health of Qatar (MoPH) and PHCC for their commendable effort in the vaccine awareness campaign as well for making the COVID-19 vaccines accessible and totally free for the entire population of Qatar. We thank all the Wellness staff of RAK-HC for their devotion in booking appointments and the RAK vaccine team for their organisation in accepting a high number of patients in such short time. We also want to extend our appreciation to all the parents and their children who participated in this study.	Aknin LB, 2013, J PERS SOC PSYCHOL, V104, P635, DOI 10.1037/a0031578; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alabdulla M, 2021, INFLUENZA OTHER RESP, V15, P361, DOI 10.1111/irv.12847; Bambra C, 2020, J EPIDEMIOL COMMUN H, V74, P964, DOI 10.1136/jech-2020-214401; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; British Society of Immunology, 2021, IMM COVID 19; Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]; Dergaa I, 2021, ANN APPL SPORT SCI, V9, DOI 10.29252/aassjournal.1032; Dergaa I, 2021, BIOL SPORT, V38, P677, DOI 10.5114/biolsport.2021.103568; El-Elimat T, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250555; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Food and Drug Administration, 2021, COR COVID 19 UPD FDA; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Gerussi V, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020172; Hacisuleyman E, 2021, NEW ENGL J MED, V384, P2212, DOI [10.1056/NEJMc2107808, 10.1056/NEJMoa2105000]; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Havers FP, 2021, MMWR-MORBID MORTAL W, V70, P851, DOI 10.15585/mmwr.mm7023e1; Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1791, DOI 10.1002/art.41454; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Magadmi RM, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11501-5; Marquez RR, 2021, J AM DENT ASSOC, V152, P730, DOI 10.1016/j.adaj.2021.03.004; Millner VS, 2010, SOUTH MED J, V103, P993, DOI 10.1097/SMJ.0b013e3181eda3d5; Montalti M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040366; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Musa S., 2021, PHYS ACT HLTH, V5, DOI [10.5334/paah.90, DOI 10.5334/PAAH.90]; Paterson P, 2018, VACCINE, V36, P5397, DOI 10.1016/j.vaccine.2017.08.016; Qunaibi E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050446; Qunaibi EA, 2021, ELIFE, V10, DOI 10.7554/eLife.68038; Reno C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040378; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Rubens JH, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n385; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Shmueli L, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10816-7; Simonson M., 2021, COVID STATES PROJECT, DOI [10.31219/osf.io/e95bc, DOI 10.31219/OSF.IO/E95BC]; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Stafstrom CE, 2020, CHILDREN-BASEL, V7, DOI 10.3390/children7090133; Trabelsi K, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18084329; Trabelsi K, 2021, BIOL SPORT, V38, P495, DOI 10.5114/biolsport.2021.101605; Tsabouri S, 2021, PEDIATR CLIN N AM, V68, P321, DOI 10.1016/j.pcl.2020.07.014; Varma A, 2021, EXPERT REV ENDOCRINO, V16, P147, DOI 10.1080/17446651.2021.1909472; Ventola C Lee, 2014, P T, V39, P491; Viner RM, 2021, JAMA PEDIATR, V175, P143, DOI 10.1001/jamapediatrics.2020.4573; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; WHO, INT TRAV HLTH CHAPT, pCH6; World Health Organization, 2021, CALL ACT VACC EQ; Yilmaz M, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.14364; Zhang KC, 2020, JMIR PEDIATR PARENT, V3, DOI 10.2196/24827	49	7	7	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							981	10.3390/vaccines9090981			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2XF	34579218	Green Published, gold			2022-04-29	WOS:000702072500001
J	Rechavi, Y; Shashar, M; Lellouche, J; Yana, M; Yakubovich, D; Sharon, N				Rechavi, Yoav; Shashar, Moshe; Lellouche, Jonathan; Yana, Moshe; Yakubovich, Daniel; Sharon, Nechama			Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccine; vaccination hesitancy; BNT162b2; antibodies; adverse reactions	RNA	Promoting SARS-CoV-2 vaccination has been a global mission since the first vaccines were approved for emergency use. Alongside the excitement following the possibility of eradicating SARS-CoV-2 and ending the COVID-19 pandemic, there has been ample vaccine hesitancy, some due to the abundant reporting of adverse reactions. We report here that the occurrence of BNT162b2 vaccine adverse reactions is associated with enhanced antibody response. We found a statistically significant correlation between having an adverse reaction, whether local or systemic, and higher antibody levels. No sex difference was observed in antibody levels. However, as was recently reported, the antibody response was found to be lower among older vaccinees. The demonstration of a clear correlation between adverse reactions and antibody levels may help reduce vaccination hesitancy by reassuring that the presence of such reactions is an indication of a well-functioning immune system.	[Rechavi, Yoav] Tel Aviv Univ, Sackler Fac Med, IL-6997801 Tel Aviv, Israel; [Shashar, Moshe] Technion, Ruth & Bruce Rappaport Fac Med, IL-3525433 Haifa, Israel; [Shashar, Moshe] Laniado Hosp, Nephrol Sect, IL-4244916 Netanya, Israel; [Lellouche, Jonathan] Laniado Hosp, Clin Labs Dept, IL-4244916 Netanya, Israel; [Yana, Moshe; Sharon, Nechama] Laniado Hosp, Pediat Hematooncol Dept, IL-4244916 Netanya, Israel; [Yakubovich, Daniel] Schneider Childrens Hosp, Dept Neonatol, IL-4920235 Petah Tiqwa, Israel; [Yakubovich, Daniel] Laniado Hosp, Sanz Med Ctr, Preterm Follow Clin, IL-4244916 Netanya, Israel		Rechavi, Y (通讯作者)，Tel Aviv Univ, Sackler Fac Med, IL-6997801 Tel Aviv, Israel.	rechavi@gmail.com; mshashar@laniado.org.il; jlellouche@laniado.org.il; myana@laniado.org.il; danial@tauex.tau.ac.il; nsharon@laniado.org.il	Lellouche, Jonathan/AAP-2312-2021	Lellouche, Jonathan/0000-0002-0564-4409; shashar, moshe/0000-0002-9744-856X; Rechavi, Yoav/0000-0001-7501-4405	Laniado Hospital	This research was funded by Laniado Hospital.	Alwan NA, 2021, SCIENCE, V373, P491, DOI 10.1126/science.abg7113; Bergwerk M, 2021, NEW ENGL J MED, V385, P1474, DOI 10.1056/NEJMoa2109072; Cinelli M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73510-5; Crook H, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1648; Earle KA, 2021, VACCINE, V39, P4423, DOI 10.1016/j.vaccine.2021.05.063; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Lustig Y, 2021, LANCET RESP MED, V9, P999, DOI 10.1016/S2213-2600(21)00220-4; Mendrone A, 2021, TRANSFUSION, V61, P1181, DOI 10.1111/trf.16268; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Nersesjan V, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.598272; ONS, 2020, COR SOC IMP GREAT BR; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Razai MS, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n513; Wadhera RK, 2020, JAMA-J AM MED ASSOC, V323, P2192, DOI 10.1001/jama.2020.7197; Woolf SH, 2021, JAMA-J AM MED ASSOC, V325, P123, DOI 10.1001/jama.2020.24865; Wu K., 2021, PRELIMINARY ANAL SAF, DOI [DOI 10.1101/2021.05.05.21256716, 10.1101/2021.05.05.21256716v1]; Xu SQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186582	20	2	2	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							977	10.3390/vaccines9090977			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2WP	34579214	Green Published, gold			2022-04-29	WOS:000702070900001
J	Sherburn, R; Tolbert, WD; Gottumukkala, S; Hederman, AP; Beaudoin-Bussieres, G; Stanfield-Oakley, S; Tuyishime, M; Ferrari, G; Finzi, A; Ackerman, ME; Pazgier, M				Sherburn, Rebekah; Tolbert, William D.; Gottumukkala, Suneetha; Hederman, Andrew P.; Beaudoin-Bussieres, Guillaume; Stanfield-Oakley, Sherry; Tuyishime, Marina; Ferrari, Guido; Finzi, Andres; Ackerman, Margaret E.; Pazgier, Marzena			Incorporating the Cluster A and V1V2 Targets into a Minimal Structural Unit of the HIV-1 Envelope to Elicit a Cross-Clade Response with Potent Fc-Effector Functions	VACCINES			English	Article						HIV-1; ID2; ADCC; ADCP; Fc-effector functions; vaccines	DEPENDENT CELLULAR CYTOTOXICITY; BROADLY NEUTRALIZING ANTIBODIES; ANTIGENIC PROPERTIES; VACCINE EFFICACY; MEDIATING ANTIBODIES; SHIV CHALLENGE; GP120; ADCC; EPITOPES; GLYCOPROTEIN	The generation of a potent vaccine for the prevention and/or control of HIV-1 has been unsuccessful to date, despite decades of research. Existing evidence from both infected individuals and clinical trials support a role for non-neutralizing or weakly neutralizing antibodies with potent Fc-effector functions in the prevention and control of HIV-1 infection. Vaccination strategies that induce such antibodies have proven partially successful in preventing HIV-1 infection. This is largely thought to be due to the polyclonal response that is induced in a vaccine setting, as opposed to the infusion of a single therapeutic antibody, which is capable of diverse Fc-effector functions and targets multiple but highly conserved epitopes. Here, we build on the success of our inner domain antigen, ID2, which incorporates conformational CD4-inducible (CD4i) epitopes of constant region 1 and 2 (C1C2 or Cluster A), in the absence of neutralizing antibody epitopes, into a minimal structural unit of gp120. ID2 has been shown to induce Cluster A-specific antibodies in a BALB/c mouse model with Fc-effector functions against CD4i targets. In order to generate an immunogen that incorporates both epitope targets implicated in the protective Fc-effector functions of antibodies from the only partially successful human vaccine trial, RV144, we incorporated the V1V2 domain into our ID2 antigen generating ID2-V1V2, which we used to immunize in combination with ID2. Immunized BALB/c mice generated both Cluster A- and V1V2-specific antibodies, which synergized to significantly improve the Fc-mediated effector functions compared to mice immunized with ID2 alone. The sera were able to mediate both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). We therefore conclude that ID2-V1V2 + ID2 represents a promising vaccine immunogen candidate for the induction of antibodies with optimal Fc-mediated effector functions against HIV-1.	[Sherburn, Rebekah; Tolbert, William D.; Gottumukkala, Suneetha; Pazgier, Marzena] Uniformed Serv Univ Hlth Sci, Dept Med, Infect Dis Div, Bethesda, MD 20814 USA; [Hederman, Andrew P.; Ackerman, Margaret E.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Beaudoin-Bussieres, Guillaume; Finzi, Andres] Univ Montreal, Dept Microbiol Infectiol & Immunol, CHUM, Ctr Rech, Montreal, PQ H2X 0A9, Canada; [Stanfield-Oakley, Sherry; Tuyishime, Marina; Ferrari, Guido] Duke Sch Med, Dept Med, Durham, NC 27710 USA		Pazgier, M (通讯作者)，Uniformed Serv Univ Hlth Sci, Dept Med, Infect Dis Div, Bethesda, MD 20814 USA.	rebekah.sherburn.ctr@usuhs.edu; William.tolbert.ctr@usuhs.edu; Suneetha.Gottumukkala.ctr@usuhs.edu; Andrew.P.Hederman.TH@dartmouth.edu; guillaume.beaudoin-bussieres@umontreal.ca; sherry.oakley@duke.edu; marina.tuyishime@duke.edu; gflmp@duke.edu; andres.finzi@umontreal.ca; margaret.e.ackerman@dartmouth.edu; marzena.pazgier@usuhs.edu	Sherburn, Rebekah/AAB-5414-2022	Pazgier, Marzena/0000-0003-0594-5057	NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01 AI116274, P01 AI120756, R01 AI129769]; CIHR foundationCanadian Institutes of Health Research (CIHR) [352417, RCHS0235 950-232424]; FRQS fellowship	This research was funded by NIAID R01 AI116274, P01 AI120756 and R01 AI129769 to M.P., and A.F.'s work was supported by a CIHR foundation grant no. 352417. A.F. is the recipient of Canada Research Chair on Retroviral Entry no. RCHS0235 950-232424. G.B.-B. is supported by a FRQS fellowship.	Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016; Anand SP, 2019, J VIROL, V93, DOI 10.1128/JVI.01823-18; Barouch DH, 2013, CELL, V155, P531, DOI 10.1016/j.cell.2013.09.061; Bonsignori M, 2012, J VIROL, V86, P11521, DOI 10.1128/JVI.01023-12; Burton DR, 2015, NAT IMMUNOL, V16, P571, DOI 10.1038/ni.3158; Burton DR, 2011, P NATL ACAD SCI USA, V108, P11181, DOI 10.1073/pnas.1103012108; Chung AW, 2015, CELL, V163, P988, DOI 10.1016/j.cell.2015.10.027; Corey L, 2021, NEW ENGL J MED, V384, P1003, DOI 10.1056/NEJMoa2031738; Dahabieh MS, 2015, ANNU REV MED, V66, P407, DOI 10.1146/annurev-med-092112-152941; DeVico A, 2007, P NATL ACAD SCI USA, V104, P17477, DOI 10.1073/pnas.0707399104; DeVico AL, 2007, CURR HIV RES, V5, P561, DOI 10.2174/157016207782418560; Duchemin M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01141; Dugast AS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097229; Dupuy FP, 2019, MBIO, V10, DOI 10.1128/mBio.02690-19; Easterhoff D, 2020, J VIROL, V94, DOI 10.1128/JVI.01120-19; Ferrari G, 2011, J VIROL, V85, P7029, DOI 10.1128/JVI.00171-11; Finnegan CM, 2002, J VIROL, V76, P12123, DOI 10.1128/JVI.76.23.12123-12134.2002; Finnegan CM, 2001, J VIROL, V75, P11096, DOI 10.1128/JVI.75.22.11096-11105.2001; Fischinger S, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140925; Fischinger S, 2019, J IMMUNOL METHODS, V473, DOI 10.1016/j.jim.2019.07.002; Fouts TR, 2000, J VIROL, V74, P11427, DOI 10.1128/JVI.74.24.11427-11436.2000; Garber DA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16928-9; Guan YJ, 2013, P NATL ACAD SCI USA, V110, pE69, DOI 10.1073/pnas.1217609110; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; JENKINS M, 1993, PEDIATR RES, V33, P469, DOI 10.1203/00006450-199305000-00010; Julg B, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1321; Karasavvas N, 2012, AIDS RES HUM RETROV, V28, P1444, DOI 10.1089/aid.2012.0103; Kwong PD, 2013, NAT REV IMMUNOL, V13, P693, DOI 10.1038/nri3516; Lewis GK, 2017, AIDS RES HUM RETROV, V33, P760, DOI [10.1089/aid.2016.0299, 10.1089/AID.2016.0299]; Lewis GK, 2014, CURR OPIN HIV AIDS, V9, P263, DOI 10.1097/COH.0000000000000055; Liao HX, 2013, IMMUNITY, V38, P176, DOI 10.1016/j.immuni.2012.11.011; Liu PH, 2013, J VIROL, V87, P7828, DOI 10.1128/JVI.02737-12; LUBECK MD, 1985, J IMMUNOL, V135, P1299; Mengistu M, 2017, P NATL ACAD SCI USA, V114, pE9893, DOI 10.1073/pnas.1705074114; Mengistu M, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004772; Moore JP, 1996, J VIROL, V70, P1863, DOI 10.1128/JVI.70.3.1863-1872.1996; Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435; Orlandi C, 2016, J IMMUNOL METHODS, V433, P51, DOI 10.1016/j.jim.2016.03.002; Pancera M, 2010, P NATL ACAD SCI USA, V107, P1166, DOI 10.1073/pnas.0911004107; Pegu A, 2017, IMMUNOL REV, V275, P296, DOI 10.1111/imr.12511; Pollara J, 2014, J VIROL, V88, P7715, DOI 10.1128/JVI.00156-14; Pollara J, 2013, CURR HIV RES, V11, P378, DOI 10.2174/1570162X113116660059; Powell RL, 2020, J VIROL, V94, DOI 10.1128/JVI.01175-20; Prevost J, 2018, J VIROL, V92, DOI 10.1128/JVI.00484-18; Ray K, 2014, J VIROL, V88, P1795, DOI 10.1128/JVI.03048-13; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Richard J, 2018, TRENDS MICROBIOL, V26, P253, DOI 10.1016/j.tim.2017.10.007; Rolland M, 2012, NATURE, V490, P417, DOI 10.1038/nature11519; Sherburn R, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8101490; Tolbert WD, 2020, BMC BIOL, V18, DOI 10.1186/s12915-020-00819-y; Tolbert WD, 2020, MBIO, V11, DOI 10.1128/mBio.00208-20; Tolbert WD, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010069; Tolbert WD, 2016, STRUCTURE, V24, P697, DOI 10.1016/j.str.2016.03.005; van Eeden C, 2018, CELL REP, V25, P3123, DOI 10.1016/j.celrep.2018.11.058; Veillette M, 2016, CURR HIV RES, V14, P9, DOI 10.2174/1570162X13666150827093449; Veillette M, 2015, J VIROL, V89, P545, DOI 10.1128/JVI.02868-14; Veillette M, 2014, J VIROL, V88, P2633, DOI 10.1128/JVI.03230-13; Visciano ML, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00677; Wang Q, 2020, TRENDS MICROBIOL, V28, P655, DOI 10.1016/j.tim.2020.03.007; Williams KL, 2015, EBIOMEDICINE, V2, P1464, DOI 10.1016/j.ebiom.2015.09.001; Zolla-Pazner S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087572	61	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							975	10.3390/vaccines9090975			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2TR	34579212	Green Published, gold			2022-04-29	WOS:000702063200001
J	Uddin, MN; Roni, MA				Uddin, Mohammad N.; Roni, Monzurul A.			Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines	VACCINES			English	Review						COVID-19; mRNA vaccine; SARS-CoV-2; stability; storage	LONG-TERM STORAGE; LIPID NANOPARTICLE FORMULATIONS; DELIVERY; SIRNA	In December 2019, a new and highly pathogenic coronavirus emerged-coronavirus disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), quickly spread throughout the world. In response to this global pandemic, a few vaccines were allowed for emergency use, beginning in November 2020, of which the mRNA-based vaccines by Moderna (Moderna, Cambridge, MA, USA) and BioNTech (BioTech, Mainz, Germany)/Pfizer (Pfizer, New York, NY, USA) have been identified as the most effective ones. The mRNA platform allowed rapid development of vaccines, but their global use is limited by ultracold storage requirements. Most resource-poor countries do not have cold chain storage to execute mass vaccination. Therefore, determining strategies to increase stability of mRNA-based vaccines in relatively higher temperatures can be a game changer to address the current global pandemic and upcoming new waves. In this review, we summarized the current research strategies to enhance stability of the RNA vaccine delivery system.	[Uddin, Mohammad N.] Mercer Univ, Coll Pharm, Atlanta, GA 30341 USA; [Roni, Monzurul A.] Univ Illinois, Coll Med, Peoria, IL 61605 USA		Roni, MA (通讯作者)，Univ Illinois, Coll Med, Peoria, IL 61605 USA.	uddin_mn@mercer.edu; roni@uic.edu		, Mohammad/0000-0003-1986-6544			Aldosari BN, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020206; Amorij JP, 2008, PHARM RES-DORDR, V25, P1256, DOI 10.1007/s11095-008-9559-6; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Ball RL, 2018, NANO LETT, V18, P3814, DOI 10.1021/acs.nanolett.8b01101; Ball RL, 2017, INT J NANOMED, V12, P305, DOI 10.2147/IJN.S123062; Basha G, 2011, MOL THER, V19, P2186, DOI 10.1038/mt.2011.190; Batty CJ, 2021, ADV DRUG DELIVER REV, V169, P168, DOI 10.1016/j.addr.2020.12.006; Binzel DW, 2021, CHEM REV, V121, P7398, DOI 10.1021/acs.chemrev.1c00009; Blakney AK, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020097; Cohen J, 2021, SCIENCE, V372, P1381, DOI 10.1126/science.372.6549.1381; Craven J, COVID 19 VACCINE TRA; Crommelin DJA, 2021, J PHARM SCI-US, V110, P997, DOI 10.1016/j.xphs.2020.12.006; Crommelin DJA, 2021, J PHARM SCI-US, V110, P627, DOI 10.1016/j.xphs.2020.11.015; Dolgin E., COVID 19 VACCINES PO; Ehrengruber Markus U, 2011, Curr Protoc Neurosci, VChapter 4, DOI 10.1002/0471142301.ns0422s57; European Medicines Agency, MOR FLEX STOR COND B; Gao Y., 2021, ENCYCLOPEDIA, V1, P773, DOI [10.3390/encyclopedia1030059, DOI 10.3390/ENCYCLOPEDIA1030059]; Gebre M., 2021, OPTIMIZATION NONCODI, DOI [10.1101/2021.08.13.456316, DOI 10.1101/2021.08.13.456316]; Gerhardt A., 2021, THERMOSTABLE FLEXIBL, DOI [10.1101/2021.02.01.429283, 10.1101/2021.02.01.429283y, DOI 10.1101/2021.02.01.429283]; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Hong HC, 2021, MRNA VACCINE SARS CO, DOI [10.1101/2021.03.22.436375, DOI 10.1101/2021.03.22.436375]; Houseley J, 2009, CELL, V136, P763, DOI 10.1016/j.cell.2009.01.019; Huang QR, 2021, J GENET GENOMICS, V48, P107, DOI 10.1016/j.jgg.2021.02.006; John Hopkins University, COVID 19 DASHB; Jones KL, 2007, BIOTECHNIQUES, V43, P675, DOI 10.2144/000112593; Kaczmarek JC, 2016, ANGEW CHEM INT EDIT, V55, P13808, DOI 10.1002/anie.201608450; Klauer AA, 2012, WIRES RNA, V3, P649, DOI 10.1002/wrna.1124; Lacroix C, 2020, PHARM RES-DORDR, V37, DOI 10.1007/s11095-019-2749-6; Lundstrom K, 2019, GENES-BASEL, V10, DOI 10.3390/genes10030189; Lundstrom Kenneth, 2003, Expert Rev Vaccines, V2, P447; Pascolo S, 2004, EXPERT OPIN BIOL TH, V4, P1285, DOI 10.1517/14712598.4.8.1285; Pascolo S, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020270; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rauch S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00311-w; Rietwyk S, 2017, ACS NANO, V11, P7572, DOI 10.1021/acsnano.7b04734; Roth N., 2021, CV2COV ENHANCED MRNA, DOI [10.1101/2021.05.13.443734, DOI 10.1101/2021.05.13.443734]; Rozovics JM, 2012, MBIO, V3, DOI 10.1128/mBio.00431-12; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Schoenmaker L, 2021, INT J PHARMACEUT, V601, DOI 10.1016/j.ijpharm.2021.120586; Schott JW, 2016, MOL THER, V24, P1513, DOI 10.1038/mt.2016.143; Stitz L, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006108; Suzuki Y, 2015, J CONTROL RELEASE, V220, P44, DOI 10.1016/j.jconrel.2015.10.024; Tregoning JS, 2020, CLIN EXP IMMUNOL, V202, P162, DOI 10.1111/cei.13517; de Ilarduya CT, 2010, EUR J PHARM SCI, V40, P159, DOI 10.1016/j.ejps.2010.03.019; Ulkoski D, 2019, EXPERT OPIN DRUG DEL, V16, P1149, DOI 10.1080/17425247.2019.1663822; Verbeke R, 2019, NANO TODAY, V28, DOI 10.1016/j.nantod.2019.100766; Wadhwa A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020102; Wang CG, 2019, INT J PHARMACEUT, V569, DOI 10.1016/j.ijpharm.2019.118576; Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7; Wang W, 2000, INT J PHARMACEUT, V203, P1, DOI 10.1016/S0378-5173(00)00423-3; Wayment-Steele HK, 2021, NUCLEIC ACIDS RES, V49, P10604, DOI [10.1101/2020.08.22.262931, 10.1093/nar/gkab764]; World Health Organization, 2005, MON VACC WAST COUNTR; Yonezawa S, 2020, ADV DRUG DELIVER REV, V154, P64, DOI 10.1016/j.addr.2020.07.022; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zhao PX, 2020, BIOACT MATER, V5, P358, DOI 10.1016/j.bioactmat.2020.03.001; Zhao WY, 2018, CELL MOL BIOENG, V11, P397, DOI 10.1007/s12195-018-0536-9	56	8	8	32	36	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1033	10.3390/vaccines9091033			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3JJ	34579270	Green Published, gold			2022-04-29	WOS:000702104400001
J	Chang, AM; Chen, CC; Hou, DL; Ke, GM; Lee, JW				Chang, Ai-Mei; Chen, Chen-Chih; Hou, Ding-Liang; Ke, Guan-Ming; Lee, Jai-Wei			Effects of a Recombinant Gonadotropin-Releasing Hormone Vaccine on Reproductive Function in Adult Male ICR Mice	VACCINES			English	Article						gonadotropin-releasing hormone; immunocontraception; fertility control; mammal	WHITE-TAILED DEER; T-HELPER EPITOPES; ACTIVE IMMUNIZATION; SPERM MORPHOLOGY; TESTIS SIZE; GNRH-I; FEMALE; IMMUNOCONTRACEPTION; POPULATIONS; FORMULATION	Gonadotropin-releasing hormone (GnRH) regulates the reproductive endocrine system in mammals. The GnRH immunocontraception vaccine can aid animal population control and management. We evaluated a recombinant GnRH fusion protein with the adjuvant MONTANIDE ISA 206 VG as a GnRH vaccine in adult male ICR mice by evaluating anti-GnRH antibodies; concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and testosterone; testis size and histomorphology; and semen quality. Response was assessed after intramuscular administration of the vaccine to mice in weeks 0, 4, and 8. The vaccine induced specific antibody response by week 5, with peak of antibody levels observed by week 13 and a declining level thereafter until the end of the study at week 24. Furthermore, it reduced serum FSH, LH, and testosterone concentrations. The vaccinated mice exhibited testicular atrophy and reduced sperm quality, concentration, morphology, and viability compared to control males. The outcomes of pairings of treated males with untreated females revealed reduced mating, pregnancy rates and number of litters compared to control pairings. Assessment of this GnRH vaccine in different species could assist its development for future applications.	[Chang, Ai-Mei; Ke, Guan-Ming; Lee, Jai-Wei] Natl Pingtung Univ Sci & Technol, Int Program Anim Vaccine Technol, Int Coll, Pingtung 91201, Taiwan; [Chang, Ai-Mei; Chen, Chen-Chih; Ke, Guan-Ming] Natl Pingtung Univ Sci & Technol, Res Ctr Anim Biol, Pingtung 91201, Taiwan; [Chen, Chen-Chih] Natl Pingtung Univ Sci & Technol, Inst Wildlife Conservat, Coll Vet Med, Pingtung 91201, Taiwan; [Chen, Chen-Chih; Hou, Ding-Liang; Ke, Guan-Ming] Natl Pingtung Univ Sci & Technol, Dept Vet Med, Coll Vet Med, Pingtung 91201, Taiwan; [Ke, Guan-Ming] Natl Pingtung Univ Sci & Technol, Inst Anim Vaccine, Coll Vet Med, Pingtung 91201, Taiwan; [Lee, Jai-Wei] Natl Pingtung Univ Sci & Technol, Dept Trop Agr & Int Cooperat, Int Coll, Pingtung 91201, Taiwan		Lee, JW (通讯作者)，Natl Pingtung Univ Sci & Technol, Int Program Anim Vaccine Technol, Int Coll, Pingtung 91201, Taiwan.; Chen, CC (通讯作者)，Natl Pingtung Univ Sci & Technol, Res Ctr Anim Biol, Pingtung 91201, Taiwan.; Chen, CC (通讯作者)，Natl Pingtung Univ Sci & Technol, Inst Wildlife Conservat, Coll Vet Med, Pingtung 91201, Taiwan.; Chen, CC (通讯作者)，Natl Pingtung Univ Sci & Technol, Dept Vet Med, Coll Vet Med, Pingtung 91201, Taiwan.; Lee, JW (通讯作者)，Natl Pingtung Univ Sci & Technol, Dept Trop Agr & Int Cooperat, Int Coll, Pingtung 91201, Taiwan.	j10685002@g4e.npust.edu.tw; ccchen@mail.npust.edu.tw; belicekevin@gmail.com; kegm@mail.npust.edu.tw; joeylee@mail.npust.edu.tw	Chen, Chen-Chih/AAY-8956-2021	Chen, Chen-Chih/0000-0002-9001-5323	Ministry of Science and Technology [MOST 107-2321-B-006-016]; Council of Agriculture in Taiwan [109-2.7.1-U2]	This research was funded by Ministry of Science and Technology and Council of Agriculture in Taiwan, the grant number was MOST 107-2321-B-006-016 and 109-2.7.1-U2, respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwal A., 2016, ANDROLOGICAL EVALUAT, P73; Aucouturier J, 2006, VACCINE, V24, pS44, DOI 10.1016/j.vaccine.2005.01.116; Baker DL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201570; Barnett PV, 1996, VACCINE, V14, P1187, DOI 10.1016/S0264-410X(96)00055-2; BERNDTSON WE, 1990, J ANDROL, V11, P429; Bertschinger HJ, 2016, REPROD DOMEST ANIM, V51, P18, DOI 10.1111/rda.12783; Bishop DK, 1996, J ANIM SCI, V74, P1092; Bomford M., 1992, P VERTEBRATE PEST C; Boyce AM, 2012, J CLIN ENDOCR METAB, V97, pE1782, DOI 10.1210/jc.2012-1791; Carter SP, 2007, P ROY SOC B-BIOL SCI, V274, P2769, DOI 10.1098/rspb.2007.0998; CHECK JH, 1992, ARCH ANDROLOGY, V28, P39, DOI 10.3109/01485019208987678; Chen Y, 2011, REPROD TOXICOL, V31, P551, DOI 10.1016/j.reprotox.2011.02.006; CLARKE IJ, 1978, J ENDOCRINOL, V78, P39, DOI 10.1677/joe.0.0780039; CLASSEN DC, 1987, J CLIN MICROBIOL, V25, P600, DOI 10.1128/JCM.25.4.600-604.1987; Croft S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238429; DIDION BA, 1989, GAMETE RES, V22, P51, DOI 10.1002/mrd.1120220106; Driscoll DA, 2019, ECOL MANAG RESTOR, V20, P63, DOI 10.1111/emr.12357; Duka Toni, 2005, Ecological Management & Restoration, V6, P172, DOI 10.1111/j.1442-8903.2005.00234.x; ESBENSHADE KL, 1985, BIOL REPROD, V33, P569, DOI 10.1095/biolreprod33.3.569; Fagerstone KA, 2008, WILDLIFE RES, V35, P586, DOI 10.1071/WR07166; Fagerstone KA, 2010, INTEGR ZOOL, V5, P15, DOI 10.1111/j.1749-4877.2010.00185.x; Ferro VA, 2002, AM J REPROD IMMUNOL, V48, P361, DOI 10.1034/j.1600-0897.2002.01120.x; Food U., 2006, FREEDOM INFORM SUMMA, P141; Fox J.G., 2006, MOUSE BIOMEDICAL RES, V3; FRASER HM, 1978, J ENDOCRINOL, V77, P85, DOI 10.1677/joe.0.0770085; Ganaie JA, 2008, IRAN J REPROD MED, V6, P119; Gupta JC, 2004, PROTEIN EXPRES PURIF, V37, P1, DOI 10.1016/j.pep.2004.03.018; Hsu MJ, 2009, AM J PRIMATOL, V71, P214, DOI 10.1002/ajp.20638; Hughes J, 2013, BIOL CONSERV, V157, P341, DOI 10.1016/j.biocon.2012.07.005; Hull E.M., 2002, HORMONES BRAIN BEHAV, P3; Junco JA, 2007, VACCINE, V25, P8460, DOI 10.1016/j.vaccine.2007.09.033; Khan MAH, 2008, VACCINE, V26, P1365, DOI 10.1016/j.vaccine.2007.12.052; Khan MAH, 2007, VACCINE, V25, P3544, DOI 10.1016/j.vaccine.2007.01.089; Killian G., 2005, P 11 WILDL DAM MAN C; KIMURA K, 1988, Okajimas Folia Anatomica Japonica, V65, P35; Kirkpatrick JF, 2011, AM J REPROD IMMUNOL, V66, P40, DOI 10.1111/j.1600-0897.2011.01003.x; Klein D.R., 1981, P119; Krause SK, 2015, J WILDLIFE MANAGE, V79, P1255, DOI 10.1002/jwmg.961; Lawton C, 2007, BIOL ENVIRON, V107B, P19, DOI 10.3318/BIOE.2007.107.1.19; Lee VHY, 2008, FEBS J, V275, P5458, DOI 10.1111/j.1742-4658.2008.06676.x; Leenaars PPAM, 1998, LAB ANIM-UK, V32, P387, DOI 10.1258/002367798780599884; LESCHEID DW, 1995, REGUL PEPTIDES, V55, P299, DOI 10.1016/0167-0115(94)00118-H; Lieury N, 2015, J WILDLIFE MANAGE, V79, P425, DOI 10.1002/jwmg.850; Loydi A, 2009, HERBACEOUS PLANT ECOLOGY: RECENT ADVANCES IN PLANT ECOLOGY, P107, DOI 10.1007/978-90-481-2798-6_9; Luthfi MJ., 2015, BIOL MED NAT PROD CH, V4, P1, DOI [10.14421/biomedich.2015.41.1-3, DOI 10.14421/BIOMEDICH.2015.41.1-3]; Massei G., 2011, P COMP OFF INT EP GL, P181; Massei G, 2014, WILDLIFE RES, V41, P1, DOI 10.1071/WR13141; Massei G, 2013, THERIOGENOLOGY, V80, P829, DOI 10.1016/j.theriogenology.2013.07.016; Massei G, 2010, WILDLIFE RES, V37, P428, DOI 10.1071/WR08179; McLeod SR, 2014, ECOL MODEL, V273, P1, DOI 10.1016/j.ecolmodel.2013.10.016; Millar RP, 2005, ANIM REPROD SCI, V88, P5, DOI 10.1016/j.anireprosci.2005.05.032; Miller LA, 2000, AM J REPROD IMMUNOL, V44, P266, DOI 10.1111/j.8755-8920.2000.440503.x; Miller LA, 2013, J ZOO WILDLIFE MED, V44, pS84, DOI 10.1638/1042-7260-44.4S.S84; MISRO MM, 1992, ARCH ANDROLOGY, V29, P69, DOI 10.3109/01485019208987711; Naz RK, 2016, AM J REPROD IMMUNOL, V75, P426, DOI 10.1111/aji.12431; Naz RK, 2014, EXPERT REV VACCINES, V13, P145, DOI 10.1586/14760584.2014.869420; Naz RK, 2005, HUM REPROD, V20, P3271, DOI 10.1093/humrep/dei256; Pepin KM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183441; PHOENIX CH, 1959, ENDOCRINOLOGY, V65, P369, DOI 10.1210/endo-65-3-369; Pitetti JL, 2013, MOL ENDOCRINOL, V27, P814, DOI 10.1210/me.2012-1258; Pourentezari Majid, 2014, Iran J Reprod Med, V12, P335; Quy RJ, 2014, WILDLIFE RES, V41, P185, DOI 10.1071/WR14035; Ramaswamy S., 2015, SPERMATOGENESIS, V4, DOI [10.1080/21565562.2014.996025, DOI 10.1080/21565562.2014.996025]; Reed GF, 2002, CLIN DIAGN LAB IMMUN, V9, P1235, DOI 10.1128/CDLI.9.6.1235-1239.2002; Rima U., 2015, J VACCIN, V6; Romagnoli S, 2015, J FELINE MED SURG, V17, P743, DOI 10.1177/1098612X15594987; Ross MH., 2006, HISTOLOGY; Rowan A.N., 1992, SHELTERS PET OVERPOP; Sabeur K, 2003, REPRODUCTION, V125, P801, DOI 10.1530/rep.0.1250801; Scudamore CL., 2014, PRACTICAL GUIDE HIST, V1st; Sharma S, 2012, J PHARM BIOALLIED SC, V4, P258, DOI 10.4103/0975-7406.103231; Siel D, 2016, THERIOGENOLOGY, V86, P1589, DOI 10.1016/j.theriogenology.2016.05.019; Spears J, 2013, THERIOGENOLOGY, V79, P566, DOI 10.1016/j.theriogenology.2012.11.014; Stewart CM, 2007, J WILDLIFE MANAGE, V71, P1525, DOI 10.2193/2006-351; Talwar GP, 2004, VACCINE, V22, P3713, DOI 10.1016/j.vaccine.2004.03.014; Vargas-Pino F, 2013, VACCINE, V31, P4442, DOI 10.1016/j.vaccine.2013.06.061; Wang Y., 2002, CURR PROTOC TOXICOL, V14, P1, DOI [10.1002/0471140856.tx1606s14, DOI 10.1002/0471140856.TX1606S14]; Warren RJ, 2011, ANIM PROD SCI, V51, P259, DOI 10.1071/AN10214; WYROBEK AJ, 1983, MUTAT RES, V115, P1, DOI 10.1016/0165-1110(83)90014-3	79	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							808	10.3390/vaccines9080808			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5MG	34451933	Green Published			2022-04-29	WOS:000689974200001
J	Hong, JP; Wang, Q; Wu, Q; Chen, JY; Wang, XJ; Wang, YB; Chen, YX; Xia, NS				Hong, Junping; Wang, Qian; Wu, Qian; Chen, Junyu; Wang, Xijing; Wang, Yingbin; Chen, Yixin; Xia, Ningshao			Rabbit Monoclonal Antibody Specifically Recognizing a Linear Epitope in the RBD of SARS-CoV-2 Spike Protein	VACCINES			English	Article						SARS-CoV-2; spike protein; RBD; rabbit monoclonal antibody; IHC; linear B-cell epitope	CORONAVIRUS	To date, SARS-CoV-2 pandemic has caused more than 188 million infections and 4.06 million deaths worldwide. The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein has been regarded as an important target for vaccine and therapeutics development because it plays a key role in binding the human cell receptor ACE2 that is required for viral entry. However, it is not easy to detect RBD in Western blot using polyclonal antibody, suggesting that RBD may form a complicated conformation under native condition and bear rare linear epitope. So far, no linear epitope on RBD is reported. Thus, a monoclonal antibody (mAb) that recognizes linear epitope on RBD will become valuable. In the present study, an RBD-specific rabbit antibody named 9E1 was isolated from peripheral blood mononuclear cells (PBMC) of immunized rabbit by RBD-specific single B cell sorting and mapped to a highly conserved linear epitope within twelve amino acids (480)CNGVEGFNCYFP(491) on RBD. 9E1 works well in Western blot on S protein and immunohistochemistry on the SARS-CoV-2 infected tissue sections. The results demonstrated that 9E1 can be used as a useful tool for pathological and functional studies of SARS-CoV-2.	[Hong, Junping; Wang, Qian; Wu, Qian; Wang, Xijing; Chen, Yixin; Xia, Ningshao] Xiamen Univ, Natl Inst Diagnost & Vaccine Dev Infect Dis, Sch Life Sci, Xiamen 361102, Peoples R China; [Hong, Junping; Wang, Qian; Wu, Qian; Chen, Junyu; Wang, Xijing; Wang, Yingbin; Chen, Yixin; Xia, Ningshao] Xiamen Univ, Sch Publ Hlth, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China		Chen, YX (通讯作者)，Xiamen Univ, Natl Inst Diagnost & Vaccine Dev Infect Dis, Sch Life Sci, Xiamen 361102, Peoples R China.; Wang, YB; Chen, YX (通讯作者)，Xiamen Univ, Sch Publ Hlth, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen 361102, Peoples R China.	21620180155490@stu.xmu.edu.cn; 21620191152709@stu.xmu.edu.cn; wuqiann@stu.xmu.edu.cn; JunyuChen@xmu.edu.cn; 21620200156503@stu.xmu.edu.cn; ybwang@xmu.edu.cn; yxchen2008@xmu.edu.cn; nsxia@xmu.edu.cn		chen, yixin/0000-0002-9591-634X; Xia, Ningshao/0000-0003-0179-5266	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [82041038]	This research was funded by National Natural Science Foundation of China, grant number 82041038.	Amrun SN, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102911; Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y; Rocha AB, 2020, LAB INVEST, V100, P1485, DOI 10.1038/s41374-020-0464-x; Chen N, 2020, LANCET, V395, P507, DOI [DOI 10.1016/S0140-6736(20)30183-5, 10.1016/S0140-6736(20)30183-5]; Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027; Kuhn JH, 2004, CELL MOL LIFE SCI, V61, P2738, DOI 10.1007/s00018-004-4242-5; Li Y, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108915; Liu J, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139042; Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2; Ravichandran S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3539; Sauter JL, 2020, HISTOPATHOLOGY, V77, P915, DOI 10.1111/his.14201; Shieh WJ, 2005, HUM PATHOL, V36, P303, DOI 10.1016/j.humpath.2004.11.006; Starkie DO, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152282; Szabolcs M, 2021, APPL IMMUNOHISTO M M, V29, P5, DOI 10.1097/PAI.0000000000000878; Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang KH, 2019, ANTIVIR RES, V164, P154, DOI 10.1016/j.antiviral.2019.02.013; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	23	0	0	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							829	10.3390/vaccines9080829			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6YF	34451954	Green Published, gold			2022-04-29	WOS:000690072900001
J	Meyer, G; Combes, M; Teillaud, A; Pouget, C; Bethune, MA; Cassard, H				Meyer, Gilles; Combes, Mickael; Teillaud, Angelique; Pouget, Celine; Bethune, Marie-Anne; Cassard, Herve			Vaccination of Sheep with Bovine Viral Diarrhea Vaccines Does Not Protect against Fetal Infection after Challenge of Pregnant Ewes with Border Disease Virus	VACCINES			English	Article						Border Disease Virus; sheep; vaccination; fetus; protection; Bovine Viral Diarrhea Virus	MEDIATED IMMUNE-RESPONSES; ANTIBODY-RESPONSES; SYSTEMIC INFECTION; BVDV VACCINE; CATTLE; IMMUNIZATION; PESTIVIRUS; INDUCTION; ANTIGEN; TITERS	Border Disease (BD) is a major sheep disease characterized by immunosuppression, congenital disorders, abortion, and birth of lambs persistently infected (PI) by Border Disease Virus (BDV). Control measures are based on the elimination of PI lambs, biosecurity, and frequent vaccination which aims to prevent fetal infection and birth of PI. As there are no vaccines against BDV, farmers use vaccines directed against the related Bovine Viral Diarrhea Virus (BVDV). To date, there is no published evidence of cross-effectiveness of BVDV vaccination against BDV infection in sheep. We tested three commonly used BVDV vaccines, at half the dose used in cattle, for their efficacy of protection against a BDV challenge of ewes at 52 days of gestation. Vaccination limits the duration of virus-induced leukopenia after challenge, suggesting partial protection in transient infection. Despite the presence of BDV neutralizing antibodies in vaccinated ewes on the day of the challenge, fetuses of vaccinated and unvaccinated sheep were, two months after, highly positive for BDV RNA loads and seronegative for antibodies. Therefore, BVDV vaccination at half dose was not sufficient to prevent ovine fetal infection by BDV in a severe challenge model and can only be reconsidered as a complementary mean in BD control.	[Meyer, Gilles; Teillaud, Angelique; Cassard, Herve] Univ Toulouse, INRAE, ENVT, Interact Hotes Agents Pathogenes IHAP, F-31100 Toulouse, France; [Combes, Mickael] Grp Vet St Leonard, F-87400 St Leonard De Noblat, France; [Pouget, Celine] Federat Organ Def Sanitaire Aveyron, F-12000 Rodez, France; [Bethune, Marie-Anne] RT1 Port Laguerre, BP 106, F-98890 New Caledonia, France		Meyer, G (通讯作者)，Univ Toulouse, INRAE, ENVT, Interact Hotes Agents Pathogenes IHAP, F-31100 Toulouse, France.	gilles.meyer@envt.fr; mika-combes@hotmail.fr; angelique.teillaud@envt.fr; celine.pouget.gds12@reseaugds.com; marieannebethune@gmail.com; herve.cassard@envt.fr		Meyer, Gilles/0000-0001-8934-5774	French Regional (Occitanie) Federation of "groupements de defense sanitaire"; Federation des Organismes de Defense Sanitaire de l'Aveyron	This research was funded by the French Regional (Occitanie) Federation of "groupements de defense sanitaire" and the "Federation des Organismes de Defense Sanitaire de l'Aveyron "which are French public breeders' associations for health protection.	Alvarez M, 2012, VET J, V191, P371, DOI 10.1016/j.tvjl.2011.03.004; ANDERSON CA, 1987, AM J VET RES, V48, P499; Anne S., 2012, THESIS PAUL SABATIER; Arias P, 2003, VET MICROBIOL, V96, P327, DOI 10.1016/j.vetmic.2003.09.009; BARLOW RM, 1972, J COMP PATHOL, V82, P151, DOI 10.1016/0021-9975(72)90057-6; Becher P, 2003, VIROLOGY, V311, P96, DOI 10.1016/S0042-6822(03)00192-2; Beer M, 2000, VET MICROBIOL, V77, P195, DOI 10.1016/S0378-1135(00)00276-5; Bethune M.-A., 2015, THESIS PAUL SABATIER; BOLIN SR, 1995, AM J VET RES, V56, P755; Bolin SR, 2004, VET CLIN N AM-FOOD A, V20, P51, DOI 10.1016/j.cvfa.2003.11.009; BOLIN SR, 1993, VET MICROBIOL, V37, P263, DOI 10.1016/0378-1135(93)90028-6; Chappuis G., 1986, Pestiviroses des ovins et des bovins. Journees nationales de la Societe Francaise de Buiatrie, Paris, 6-7 Novembre 1986, P55; Collen T, 2000, VIRUS RES, V67, P67, DOI 10.1016/S0168-1702(00)00131-3; Collen T, 2002, VET IMMUNOL IMMUNOP, V87, P235, DOI 10.1016/S0165-2427(02)00088-0; Downey-Slinker ED, 2016, VACCINE, V34, P5053, DOI 10.1016/j.vaccine.2016.08.087; Fernandez F, 2009, REV ARGENT MICROBIOL, V41, P86; Fulton RW, 2020, VACCINE, V38, P4032, DOI 10.1016/j.vaccine.2020.03.058; Fulton RW, 2015, ANIM HEALTH RES REV, V16, P40, DOI 10.1017/S1466252315000079; Garcia-Perez AL, 2009, J VET DIAGN INVEST, V21, P331, DOI 10.1177/104063870902100304; Graham DA, 2003, VET REC, V152, P795, DOI 10.1136/vr.152.26.795; Hamers C, 2002, VET J, V163, P61, DOI 10.1053/tvjl.2001.0638; HUSSIN AA, 1994, RES VET SCI, V56, P201, DOI 10.1016/0034-5288(94)90105-8; Kelling CL, 2007, AM J VET RES, V68, P788, DOI 10.2460/ajvr.68.7.788; Lambot M, 1997, J GEN VIROL, V78, P1041, DOI 10.1099/0022-1317-78-5-1041; Makoschey B, 2007, VACCINE, V25, P6140, DOI 10.1016/j.vaccine.2007.01.110; Meyer G, 2012, VET J, V192, P242, DOI 10.1016/j.tvjl.2011.05.011; Meyers G, 2007, J VIROL, V81, P3327, DOI 10.1128/JVI.02372-06; Nettleton PF, 1998, VET RES, V29, P327; Newcomer BW, 2017, VET MICROBIOL, V206, P78, DOI 10.1016/j.vetmic.2017.04.003; Newcomer BW, 2015, THERIOGENOLOGY, V83, P360, DOI 10.1016/j.theriogenology.2014.09.028; Platt R, 2006, AM J VET RES, V67, P1179, DOI 10.2460/ajvr.67.7.1179; Platt R, 2008, VET IMMUNOL IMMUNOP, V122, P8, DOI 10.1016/j.vetimm.2007.11.009; Platt R, 2017, VET IMMUNOL IMMUNOP, V187, P20, DOI 10.1016/j.vetimm.2017.03.003; Pouget C., 2010, BORDER DIS MALADIES; Raue R, 2011, VET J, V187, P330, DOI 10.1016/j.tvjl.2009.12.013; Ridpath JF, 2013, BIOLOGICALS, V41, P14, DOI 10.1016/j.biologicals.2012.07.003; Righi C, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13060950; Riitho V, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101134; Rodning SP, 2010, THERIOGENOLOGY, V73, P1154, DOI 10.1016/j.theriogenology.2010.01.017; Smith DB, 2017, J GEN VIROL, V98, P2106, DOI 10.1099/jgv.0.000873; Sozzi E, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030374; Thabti F, 2002, VET RES, V33, P35, DOI 10.1051/vetres:2001004; Theurer ME, 2015, JAVMA-J AM VET MED A, V246, P126, DOI 10.2460/javma.246.1.126; VANTSIS JT, 1980, J COMP PATHOL, V90, P39, DOI 10.1016/0021-9975(80)90026-2; VILCEK S, 1994, ARCH VIROL, V136, P309, DOI 10.1007/BF01321060; Vilcek S, 2014, VET MICROBIOL, V171, P87, DOI 10.1016/j.vetmic.2014.03.028; Wernike K, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050274; Zimmer GM, 2002, VET MICROBIOL, V89, P255, DOI 10.1016/S0378-1135(02)00203-1	48	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							805	10.3390/vaccines9080805			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH8KN	34451930	Green Published			2022-04-29	WOS:000690172500001
J	Murata, K; Onoyama, S; Yamamura, K; Mizuno, Y; Furuno, K; Matsubara, K; Hatae, K; Masuda, K; Nomura, Y; Ohno, T; Kinumaki, A; Miura, M; Sakai, Y; Ohga, S; Fukushima, W; Kishimoto, J; Nakamura, Y; Hara, T				Murata, Kenji; Onoyama, Sagano; Yamamura, Kenichiro; Mizuno, Yumi; Furuno, Kenji; Matsubara, Keita; Hatae, Ken; Masuda, Kiminori; Nomura, Yuichi; Ohno, Takuro; Kinumaki, Akiko; Miura, Masaru; Sakai, Yasunari; Ohga, Shouichi; Fukushima, Wakaba; Kishimoto, Junji; Nakamura, Yosikazu; Hara, Toshiro			Kawasaki Disease and Vaccination: Prospective Case-Control and Case-Crossover Studies among Infants in Japan	VACCINES			English	Article						Kawasaki disease; vaccines; infant; case-control study; case-crossover study; Nationwide Survey of Kawasaki disease in Japan	CONTROLLED CASE-SERIES; CELL-DEATH; B VACCINE; EXPRESSION; CHILDREN; RISK; GENE	The causal effects of vaccines on Kawasaki disease (KD) remain elusive. We aimed to examine the association between vaccines administered during infancy and the development of KD in Japan. We conducted a multicenter prospective case-control study using questionnaires and compared the vaccination status of infants (age: 6 weeks to 9 months) who developed KD (KD group; n = 102) and those who did not develop KD (non-KD group; n = 139). Next, we performed a case-crossover study of 98 cases in the KD group and compared the status of vaccinations between the case and control periods. We also compared the incidence of KD in children for each 5-year period before and after the addition of new vaccines (2012-2013) using data from the Nationwide Survey of KD. In the case-control study, the vaccination status of the KD and control groups did not differ to a statistically significant extent. Multivariable analysis of the vaccination status and patient backgrounds showed no significant association between vaccination and KD development. In the case-crossover study, the status of vaccinations during the case and control periods did not differ to a statistically significant extent. In the analysis of data from the Nationwide Survey of KD, the incidence of KD in children of ages subject to frequent vaccination showed no significant increases in the latter five years, 2014-2018. Based on these prospective analyses, we confirmed that vaccination in early infancy did not affect the risk of KD.	[Murata, Kenji; Onoyama, Sagano; Mizuno, Yumi; Furuno, Kenji; Hara, Toshiro] Fukuoka Childrens Hosp, Kawasaki Dis Ctr, Fukuoka 8130017, Japan; [Onoyama, Sagano; Hatae, Ken] Japanese Red Cross Fukuoka Hosp, Dept Pediat, Fukuoka 8158555, Japan; [Yamamura, Kenichiro] Kyushu Univ, Grad Sch Med Sci, Dept Perinatal & Pediat Med, Fukuoka 8128582, Japan; [Matsubara, Keita] Hiroshima City Funairi Citizens Hosp, Dept Pediat, Hiroshima 7300844, Japan; [Masuda, Kiminori; Nomura, Yuichi] Kagoshima City Hosp, Dept Pediat, Kagoshima 8908760, Japan; [Ohno, Takuro] Oita Prefectural Hosp, Dept Pediat, Oita 8708511, Japan; [Kinumaki, Akiko] Tokyo Metropolitan Childrens Med Ctr, Dept Gen Pediat, Fuchu, Tokyo 1838561, Japan; [Miura, Masaru] Tokyo Metropolitan Childrens Med Ctr, Dept Cardiol, Fuchu, Tokyo 1838561, Japan; [Sakai, Yasunari; Ohga, Shouichi] Kyushu Univ, Grad Sch Med Sci, Dept Pediat, Fukuoka 8128582, Japan; [Fukushima, Wakaba] Osaka City Univ, Grad Sch Med, Dept Publ Hlth, Res Ctr Infect Dis Sci, Osaka 5588585, Japan; [Kishimoto, Junji] Kyushu Univ Hosp, Ctr Clin & Translat Res, Fukuoka 8128582, Japan; [Nakamura, Yosikazu] Jichi Med Univ, Dept Publ Hlth, Shimotsuke, Tochigi 3290498, Japan		Hara, T (通讯作者)，Fukuoka Childrens Hosp, Kawasaki Dis Ctr, Fukuoka 8130017, Japan.	murata.k@fcho.jp; sonoyama178@gmail.com; yamamura@pediatr.med.kyushu-u.ac.jp; mizuno.y@fcho.jp; furuno.k@fcho.jp; keitamatsubara3@gmail.com; hatae.k@fukuoka-med.jrc.or.jp; masaru10miura@gmail.com; yasunari@med.kyushu-u.ac.jp; ohnot55@yahoo.co.jp; kinumaki-tky@umin.ac.jp; masaru10miura@gmail.com; yasunari@med.kyushu-u.ac.jp; ohgas@pediatr.med.kyushu-u.ac.jp; wakaba@med.osaka-cu.ac.jp; j_kishi@digital.med.kyushu-u.ac.jp; nakamuyk@jichi.ac.jp; hara.t@fcho.jp	Murata, Kenji/AAO-8899-2021; Sakai, Yasunari/S-7965-2018	Murata, Kenji/0000-0002-2698-7160; Sakai, Yasunari/0000-0002-5747-8692; Nakamura, Yosikazu/0000-0001-6654-1481; Mizuno, Yumi/0000-0003-4887-0577	Fukuoka Children's Hospital Research Grant	This research was funded by a Fukuoka Children's Hospital Research Grant.	Abe J, 2005, J IMMUNOL, V174, P5837, DOI 10.4049/jimmunol.174.9.5837; Abrams JY, 2015, VACCINE, V33, P382, DOI 10.1016/j.vaccine.2014.10.044; Ae R, 2020, J PEDIATR-US, V225, P23, DOI 10.1016/j.jpeds.2020.05.034; Antas PRZ, 2019, J INFLAMM-LOND, V16, DOI 10.1186/s12950-019-0223-1; Ayusawa M, 2005, PEDIATR INT, V47, P232, DOI 10.1111/j.1442-200x.2005.02033.x; Baker MA, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002844; Banday AZ, 2021, CLIN RHEUMATOL, V40, P849, DOI 10.1007/s10067-020-05328-5; Barnett KC, 2020, INNATE IMMUN-LONDON, V26, P4, DOI 10.1177/1753425919852695; Bonaldo G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70653-3; Chang A, 2018, PEDIATR INT, V60, P613, DOI 10.1111/ped.13590; Chang LY, 2014, J FORMOS MED ASSOC, V113, P148, DOI 10.1016/j.jfma.2013.12.008; Chen MR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.632890; Evans PC, 2020, CARDIOVASC RES, V116, P2177, DOI 10.1093/cvr/cvaa230; Foell D, 2003, LANCET, V361, P1270, DOI 10.1016/S0140-6736(03)12986-8; FUJITA Y, 1989, PEDIATRICS, V84, P666; Fukazawa R, 2020, CIRC J, V84, P1348, DOI 10.1253/circj.CJ-19-1094; Fukushima W, 2017, VACCINE, V35, P4817, DOI 10.1016/j.vaccine.2017.07.007; Hara T, 2016, CLIN EXP IMMUNOL, V186, P134, DOI 10.1111/cei.12832; Hara T, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1284; He YE, 2020, J CARDIOVASC TRANSL, V13, P204, DOI 10.1007/s12265-019-09908-y; HogenEsch H, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0089-x; Horinouchi T, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0497-2; Hoshina T, 2008, SCAND J RHEUMATOL, V37, P445, DOI 10.1080/03009740802144143; Jamieson N, 2013, INT J PEDIAT, V2013, DOI 10.1155/2013/645391; Jia C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2021-3; Jorgensen I, 2015, IMMUNOL REV, V265, P130, DOI 10.1111/imr.12287; KAWASAKI T, 1974, PEDIATRICS, V54, P271; Ki M, 2003, AM J EPIDEMIOL, V157, P158, DOI 10.1093/aje/kwf167; Kobayashi T, 2020, PEDIATR INT, V62, P1135, DOI 10.1111/ped.14326; Layton JB, 2018, PAEDIATR PERINAT EP, V32, P448, DOI 10.1111/ppe.12496; Makino N, 2019, PEDIATR INT, V61, P397, DOI 10.1111/ped.13809; Makino N, 2018, PEDIATR INT, V60, P581, DOI 10.1111/ped.13544; Makino N, 2015, J EPIDEMIOL, V25, P239, DOI 10.2188/jea.JE20140089; MATSUNO S, 1983, J INFECT DIS, V148, P177, DOI 10.1093/infdis/148.1.177; Mellone NG, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01075; Ministry of Internal Affairs and Communications of Japan, CLASS STRUCT EXPL NO; Nakamura Y, 2012, J EPIDEMIOL, V22, P216, DOI 10.2188/jea.JE20110126; Nakamura Y, 2010, J EPIDEMIOL, V20, P302, DOI 10.2188/jea.JE20090180; Nakashima Y, 2021, CARDIOVASC RES, V117, P96, DOI 10.1093/cvr/cvz305; O'Ryan M, 2014, DRUGS, V74, P15, DOI 10.1007/s40265-013-0155-7; Phuong LK, 2017, VACCINE, V35, P1770, DOI 10.1016/j.vaccine.2016.09.033; Ponte C, 2018, HUM VACC IMMUNOTHER, V14, P28, DOI 10.1080/21645515.2017.1382788; Rowley AH, 2008, NAT REV MICROBIOL, V6, P394, DOI 10.1038/nrmicro1853; Rypdal M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33124-4; Stowe J, 2020, VACCINE, V38, P4935, DOI 10.1016/j.vaccine.2020.05.089; TAKESHITA S, 1994, PEDIATR RES, V35, P179, DOI 10.1203/00006450-199402000-00010; Tang J, 2018, BMC IMMUNOL, V19, DOI 10.1186/s12865-018-0240-5; Truong DA, 2019, CIRCULATION, V140; U.S. Food and Drug Administration, PACK INS ROTATEQ; YANAGAWA H, 1988, J INFECT DIS, V158, P1296, DOI 10.1093/infdis/158.6.1296; Yung CF, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51137-5; Zeng C, 2019, INT J BIOL SCI, V15, P1345, DOI 10.7150/ijbs.33568	52	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							839	10.3390/vaccines9080839			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH4ML	34451964	Green Published, gold			2022-04-29	WOS:000689907100001
J	Schmitt, HJ; Dobler, G; Zavadska, D; Freimane, Z; Fousteris, D; Erber, W; Jodar, L; Palmborg, A				Schmitt, Heinz-J.; Dobler, Gerhard; Zavadska, Dace; Freimane, Zane; Fousteris, Dimitrios; Erber, Wilhelm; Jodar, Luis; Palmborg, Andreas			TBE Vaccination Breakthrough Cases-Does Age Matter?	VACCINES			English	Article						tick-borne encephalitis; vaccine failure; vaccination failure; older adults; Sweden	TICK-BORNE ENCEPHALITIS; CENTRAL-NERVOUS-SYSTEM; INFECTIONS; COVERAGE	Tick-borne encephalitis (TBE) vaccines are highly effective in preventing TBE and vaccine failures (VF) are rare events. In this study, we compared the age distribution of TBE cases and TBE VF in three endemic countries: Sweden, Southern Germany, and Latvia. While the age distribution of TBE cases was similar for those <50 years versus those >= 50 years in all three countries, in Sweden, a higher proportion of VF cases was >= 50 years, whereas most VF cases in Latvia were <50 years of age and more evenly distributed between those <50 years versus those >= 50 in Southern Germany. Here, theoretical explanations were provided, including differences in diagnostic practices, vaccine uptake between age groups, behavioral patterns and underlying medical conditions, as to why VF were generally older in Sweden than the other countries. There is no scientific rationale to give an extra priming dose of TBE vaccine to subjects >= 50 years of age.	[Schmitt, Heinz-J.; Jodar, Luis] Pfizer Vaccines, Med Dev Sci & Clin Affairs, Collegeville, PA 19426 USA; [Dobler, Gerhard] Bundeswehr Inst Microbiol, Dept Virol & Rickettsiol, German Natl TBE Consiliary Lab, D-85748 Munich, Germany; [Zavadska, Dace; Freimane, Zane] Riga Stradins Univ, Dept Paediat, Childrens Clin Univ Hosp, LV-1007 Riga, Latvia; [Fousteris, Dimitrios; Erber, Wilhelm] Pfizer Vaccines, Global Med Sci & Clin Affairs, A-1210 Vienna, Austria; [Palmborg, Andreas] Pfizer Vaccines, Med Dev & Sci Affairs, S-19138 Stockholm, Sweden		Palmborg, A (通讯作者)，Pfizer Vaccines, Med Dev & Sci Affairs, S-19138 Stockholm, Sweden.	qi.yan2@pfizer.com; gerharddobler@msn.com; dace.zavadska@rsu.lv; Zane.Freimane@rsu.lv; fousteris.dimitrio@gmail.com; Wilhelm.Erber@pfizer.com; Luis.Jodar@pfizer.com; Andreas.Palmborg@pfizer.com			Pfizer Inc.Pfizer	This study was sponsored by Pfizer Inc.	Askling HH, 2015, VACCINE, V33, P4962, DOI 10.1016/j.vaccine.2015.07.030; Baroutsou V, 2020, VACCINE, V38, P7825, DOI 10.1016/j.vaccine.2020.10.022; Dobler G., 2019, TBE BOOK, DOI [10.33442/978-981-14-0914-1_7, DOI 10.33442/978-981-14-0914-1_7]; Engman ML, 2012, PEDIATR INFECT DIS J, V31, P570, DOI 10.1097/INF.0b013e31824f23c0; Erber W, 2018, TICKS TICK-BORNE DIS, V9, P768, DOI 10.1016/j.ttbdis.2018.02.007; FSME-IMMUN, SUMM PROD CHAR; Hansson KE, 2020, CLIN INFECT DIS, V70, P245, DOI 10.1093/cid/ciz176; Heinz FX, 2013, EMERG INFECT DIS, V19, P69, DOI 10.3201/eid1901.120458; Konior R, 2017, VACCINE, V35, P3607, DOI 10.1016/j.vaccine.2017.03.059; Schosser R, 2014, VACCINE, V32, P2375, DOI 10.1016/j.vaccine.2014.01.072; Sundin M, 2012, EUR J PEDIATR, V171, P347, DOI 10.1007/s00431-011-1542-2; Wanke K.H.L., 2012, P EUR C CLIN MICR IN	12	3	3	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							932	10.3390/vaccines9080932			5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3BA	34452056	Green Published, gold			2022-04-29	WOS:000689809800001
J	Anand, G; Biswas, S; Yadav, N; Mukherjee, P; Chauhan, VS				Anand, Gaurav; Biswas, Saikat; Yadav, Nitin; Mukherjee, Paushali; Chauhan, Virander Singh			Production and Immunogenicity of a Tag-Free Recombinant Chimera Based on PfMSP-1 and PfMSP-3 Using Alhydrogel and Dipeptide-Based Hydrogels	VACCINES			English	Article						malaria; recombinant vaccine; fusion chimera; dipeptide; hydrogel; immunogenicity	MEROZOITE SURFACE PROTEIN-1; C-TERMINAL FRAGMENT; PLASMODIUM-FALCIPARUM; ERYTHROCYTE INVASION; MALARIA; VACCINE; ANTIBODIES; ADJUVANTS; RESPONSES; PARASITE	A fusion chimeric vaccine comprising multiple protective domains of different blood-stage Plasmodium falciparum antigens is perhaps necessary for widening the protective immune responses and reducing the morbidity caused by the disease. Here we continue to build upon the prior work of developing a recombinant fusion chimera protein, His-tagged PfMSP-Fu24, by producing it as a tag-free recombinant protein. In this study, tag-free recombinant PfMSPFu24 (rFu24) was expressed in Escherichia coli, and the soluble protein was purified using a three-step purification involving ammonium sulphate precipitation followed by 2-step ion exchange chromatography procedures and shown that it was highly immunogenic with the human-compatible adjuvant Alhydrogel. We further investigated two dipeptides, phenylalanine-alpha, beta-dehydrophenylalanine (F Delta F) and Leucine-alpha, beta-dehydrophenylalanine (L Delta F) based hydrogels as effective delivery platforms for rFu24. These dipeptides self-assembled spontaneously to form a highly stable hydrogel under physiological conditions. rFu24 was efficiently entrapped in both the F increment F and L increment F hydrogels, and the three-dimensional (3D) mesh-like structures of the hydrogels remained intact after the entrapment of the antigen. The two hydrogels significantly stimulated rFu24-specific antibody titers, and the sera from the immunized mice showed an invasion inhibitory activity comparable to that of Alhydrogel. Easily synthesized dipeptide hydrogels can be used as an effective antigen delivery platform to induce immune responses.	[Anand, Gaurav; Biswas, Saikat; Yadav, Nitin; Chauhan, Virander Singh] Int Ctr Genet Engn & Biotechnol ICGEB, Mol Med Grp, New Delhi 110067, India; [Mukherjee, Paushali] Int Ctr Genet Engn & Biotechnol, Multi Vaccines Dev Program, ICGEB Campus, New Delhi 110067, India		Chauhan, VS (通讯作者)，Int Ctr Genet Engn & Biotechnol ICGEB, Mol Med Grp, New Delhi 110067, India.	gauravanandicgeb@gmail.com; saikat.biswas334@gmail.com; nitin.acp@gmail.com; paushali.mukherjee@mvdp.org.in; viranderschauhan@gmail.com		BISWAS, SAIKAT/0000-0002-9667-678X	Department of Biotechnology, New Delhi, IndiaDepartment of Biotechnology (DBT) India [BT/PR31130/MED/15/197/2019]	This research was funded by the Department of Biotechnology, New Delhi, India (Grant No. BT/PR31130/MED/15/197/2019).	Alam S, 2012, INT J NANOMED, V7, P4207, DOI 10.2147/IJN.S33015; Alonso PL, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000406; Azmi F, 2014, HUM VACC IMMUNOTHER, V10, P778, DOI 10.4161/hv.27332; Baldwin MR, 2015, BLOOD, V125, P2704, DOI 10.1182/blood-2014-11-611707; Banquy X, 2009, SOFT MATTER, V5, P3984, DOI 10.1039/b821583a; Black KA, 2015, TISSUE ENG PT A, V21, P1333, DOI [10.1089/ten.tea.2014.0297, 10.1089/ten.TEA.2014.0297]; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; Boyle MJ, 2010, P NATL ACAD SCI USA, V107, P14378, DOI 10.1073/pnas.1009198107; CHAPPEL JA, 1993, MOL BIOCHEM PARASIT, V60, P303, DOI 10.1016/0166-6851(93)90141-J; Chitnis N, 2008, B MATH BIOL, V70, P1272, DOI 10.1007/s11538-008-9299-0; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Courtin D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007590; Crompton PD, 2010, P NATL ACAD SCI USA, V107, P6958, DOI 10.1073/pnas.1001323107; Das S, 2015, CELL HOST MICROBE, V18, P433, DOI 10.1016/j.chom.2015.09.007; Dent AE, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-162; Dondorp AM, 2010, NAT REV MICROBIOL, V8, P272, DOI 10.1038/nrmicro2331; Draper SJ, 2015, VACCINE, V33, P7433, DOI 10.1016/j.vaccine.2015.09.093; Egan A, 1997, INFECT IMMUN, V65, P3024, DOI 10.1128/IAI.65.8.3024-3031.1997; Egan AF, 1996, J INFECT DIS, V173, P765, DOI 10.1093/infdis/173.3.765; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Eksi S, 2006, MOL MICROBIOL, V61, P991, DOI 10.1111/j.1365-2958.2006.05284.x; Friedrich BM, 2016, VACCINE, V34, P5479, DOI 10.1016/j.vaccine.2016.09.044; Goodman AL, 2010, ANN TROP MED PARASIT, V104, P189, DOI 10.1179/136485910X12647085215534; Gupta M, 2007, ADV MATER, V19, P858, DOI 10.1002/adma.200601774; Gupta PK, 2014, CLIN VACCINE IMMUNOL, V21, P886, DOI 10.1128/CVI.00179-14; He T, 2021, MATER DESIGN, V197, DOI 10.1016/j.matdes.2020.109232; Healer J, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a025627; Holder AA, 2009, PARASITOLOGY, V136, P1445, DOI 10.1017/S0031182009990515; Jin JH, 2019, J MATER CHEM B, V7, P1637, DOI 10.1039/c8tb02547a; Karavasili C, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2442-1; Khatri A, 2017, J BIOMED NANOTECHNOL, V13, P35, DOI 10.1166/jbn.2017.2325; Kobsa S, 2008, PEDIATR RES, V63, P513, DOI 10.1203/PDR.0b013e318165f14d; Lambrecht BN, 2009, CURR OPIN IMMUNOL, V21, P23, DOI 10.1016/j.coi.2009.01.004; Lee ALZ, 2019, NANOMED-NANOTECHNOL, V21, DOI 10.1016/j.nano.2019.102056; Liu F, 2016, VIROLOGY, V492, P197, DOI 10.1016/j.virol.2016.02.024; Magiri R, 2018, CELL TISSUE RES, V374, P465, DOI 10.1007/s00441-018-2929-4; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Mazumdar S, 2010, BIOPROC BIOSYST ENG, V33, P719, DOI 10.1007/s00449-009-0394-x; Mazumdar S, 2010, INFECT IMMUN, V78, P872, DOI 10.1128/IAI.00427-09; Miura K, 2016, EXPERT REV VACCINES, V15, P765, DOI 10.1586/14760584.2016.1141680; Miyaji EN, 2011, BRAZ J MED BIOL RES, V44, P500, DOI 10.1590/S0100-879X2011007500064; Nishimura A, 2012, EUR J PHARM SCI, V45, P1, DOI 10.1016/j.ejps.2011.10.013; O'Donnell RA, 2006, J CELL BIOL, V174, P1023, DOI 10.1083/jcb.200604136; Oeuvray C, 2000, INFECT IMMUN, V68, P2617, DOI 10.1128/IAI.68.5.2617-2620.2000; Ogutu BR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004708; Panda JJ, 2008, BIOMACROMOLECULES, V9, P2244, DOI 10.1021/bm800404z; Panda JJ, 2013, NANOMEDICINE-UK, V8, P1927, DOI 10.2217/nnm.12.201; Panda JJ, 2010, ACS APPL MATER INTER, V2, P2839, DOI 10.1021/am1005173; Pattnaik P, 2007, VACCINE, V25, P806, DOI 10.1016/j.vaccine.2006.09.048; Pizarro JC, 2003, J MOL BIOL, V328, P1091, DOI 10.1016/S0022-2836(03)00376-0; Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409; Rosenkrands I, 2011, VACCINE, V29, P6283, DOI 10.1016/j.vaccine.2011.06.040; Roth GA, 2020, ACS CENTRAL SCI, V6, P1800, DOI 10.1021/acscentsci.0c00732; Rudra JS, 2010, P NATL ACAD SCI USA, V107, P622, DOI 10.1073/pnas.0912124107; Schwartz L, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-11; Sirima SB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007549; Song HJ, 2019, THERANOSTICS, V9, P2299, DOI 10.7150/thno.30577; Takala SL, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000257; Tanner M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0384-6; Thera MA, 2011, NEW ENGL J MED, V365, P1004, DOI 10.1056/NEJMoa1008115; Thota CK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31167; Tiendrebeogo RW, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv044; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; van den Berg M, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3391-7; WHO, 2013, WORLD MALARIA REPORT 2013, P1; Wright GJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003943; Zhang HY, 2017, ACTA BIOMATER, V55, P183, DOI 10.1016/j.actbio.2017.03.041	67	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							782	10.3390/vaccines9070782			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6DV	34358198	Green Published			2022-04-29	WOS:000677000600001
J	Jeong, N; Kim, Y; Kim, C; Park, S; Lee, J; Choi, N				Jeong, Nayoung; Kim, Yejee; Kim, Chungjong; Park, Sangmin; Lee, Joongyub; Choi, Namkyong			Association between Influenza Vaccination and the Risk of Bell's Palsy in the Korean Elderly	VACCINES			English	Article						influenza vaccine; Bell's palsy; elderly people; adverse events; large-linked database; self-controlled risk interval design	CONTROLLED CASE SERIES; SAFETY DATALINK; H1N1; SURVEILLANCE; VACCINES; RECEIPT; DESIGN	Previous studies have shown controversial results on the risk of Bell's palsy after influenza vaccination. Since the antigenic components of influenza vaccine can vary from season to season, continuous safety monitoring is required. The aim of the present study was to determine whether there was an increased risk of Bell's palsy in the elderly after influenza vaccination between the 2015/2016 and 2017/2018 flu seasons. This study included the elderly who received influenza vaccinations for three flu seasons using a large-linked database of vaccination registration data from the Korea Disease Control and Prevention Agency and the National Health Insurance Service claims data. We used a self-controlled risk interval design with a risk interval of 1 to 42 days and a control interval of 57 to 98 days postvaccination and calculated the incidence rate ratio. To ensure the robustness of the results, sensitivity analyses were also carried out with different risk and control intervals. Of 4,653,440 elderly people who received the influenza vaccine, there was no statistically significant increase in the risk of Bell's palsy (IRR: 0.99, 95% CI: 0.92-1.07). Similar results were found in analysis results for each season and the results of the sensitivity analyses excluding the 2017/2018 season. In conclusion, we found no evidence of an increased risk of Bell's palsy after influenza vaccination. The results of our study provide reassurance about the safety of the influenza vaccine NIP program. However, it is necessary to continuously monitor the risk of Bell's palsy during future flu seasons.	[Jeong, Nayoung; Choi, Namkyong] Ewha Womans Univ, Dept Hlth Convergence, Seoul 03760, South Korea; [Kim, Yejee] Univ Ulsan, Asan Med Ctr, Dept Clin Epidemiol & Biostat, Coll Med, Seoul 05505, South Korea; [Kim, Chungjong] Ewha Womans Univ, Dept Internal Med, Seoul Hosp, Seoul 07804, South Korea; [Park, Sangmin] Seoul Natl Univ Hosp, Dept Family Med, Seoul 03080, South Korea; [Park, Sangmin] Seoul Natl Univ, Seoul Natl Univ Grad Sch, Dept Biomed Sci, Coll Med, Seoul 03080, South Korea; [Lee, Joongyub] Seoul Natl Univ, Dept Prevent Med, Coll Med, Seoul 03080, South Korea		Choi, N (通讯作者)，Ewha Womans Univ, Dept Hlth Convergence, Seoul 03760, South Korea.	jny4311@gmail.com; kimyejee@amc.seoul.kr; erinus00@gmail.com; smpark3.snuh@gmail.com; tp240@naver.com; nchoi@ewha.ac.kr		Jeong, Na-Young/0000-0003-2130-1286; Kim, Ye-Jee/0000-0002-3307-2970	Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HG18C0067]	This research was supported by grants from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (Government-wide R&D Fund project for infectious disease research, HG18C0067).	Baker MA, 2015, AM J EPIDEMIOL, V181, P608, DOI 10.1093/aje/kwu322; Campbell KE, 2002, AM J EPIDEMIOL, V156, P32, DOI 10.1093/aje/kwf009; DAVENPORT FM, 1962, JAMA-J AM MED ASSOC, V182, P121; De Diego JI, 1999, OTOLARYNG HEAD NECK, V120, P269, DOI 10.1016/S0194-5998(99)70418-3; Ensari N., 2019, MED SCI INT MED J, DOI [10.5455/medscience.2019.08.9053, DOI 10.5455/MEDSCIENCE.2019.08.9053]; Gilden DH, 2004, NEW ENGL J MED, V351, P1323, DOI 10.1056/NEJMcp041120; Glanz JM, 2006, J CLIN EPIDEMIOL, V59, P808, DOI 10.1016/j.jclinepi.2005.11.012; Greco A, 2012, AUTOIMMUN REV, V12, P323, DOI 10.1016/j.autrev.2012.05.008; Greene SK, 2012, AM J EPIDEMIOL, V175, P1100, DOI 10.1093/aje/kws195; Hawken S, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0225-0; Holland NJ, 2004, BMJ-BRIT MED J, V329, P553, DOI 10.1136/bmj.329.7465.553; Kim JA, 2017, J KOREAN MED SCI, V32, P718, DOI 10.3346/jkms.2017.32.5.718; Lee GM, 2011, AM J PREV MED, V41, P121, DOI 10.1016/j.amepre.2011.04.004; Lee SY, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019568; Li RX, 2016, PHARMACOEPIDEM DR S, V25, P928, DOI 10.1002/pds.3996; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; Murakami S, 1996, ANN INTERN MED, V124, P27, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00005; Nicholson K G, 1992, Semin Respir Infect, V7, P26; Park J.J., 2016, PUBLIC HLTH WKLY REP, V9, P866; Peitersen E, 2002, ACTA OTO-LARYNGOL, V122, P4, DOI 10.1080/000164802320401694; Piercy J, 2005, BRIT MED J, V330, P1374, DOI 10.1136/bmj.330.7504.1374; Rothberg MB, 2008, AM J MED, V121, P258, DOI 10.1016/j.amjmed.2007.10.040; Rowhani-Rahbar A, 2012, NEUROEPIDEMIOLOGY, V38, P252, DOI 10.1159/000338303; Rowlands S, 2002, EUR J NEUROL, V9, P63, DOI 10.1046/j.1468-1331.2002.00343.x; Schirm J, 1997, APMIS, V105, P815, DOI 10.1111/j.1699-0463.1997.tb05089.x; Seong SC, 2017, INT J EPIDEMIOL, V46, P799, DOI 10.1093/ije/dyw253; Spengos K, 2006, EUR NEUROL, V55, P84, DOI 10.1159/000092779; Stowe J, 2006, HUM VACCINES, V2, P110, DOI 10.4161/hv.2790; Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302; Yih WK, 2012, AM J EPIDEMIOL, V175, P1120, DOI 10.1093/aje/kws197; Yun JW, 2017, INFECT CHEMOTHER, V49, P247, DOI 10.3947/ic.2017.49.4.247; Zandian A, 2014, MED SCI MONITOR, V20, P83, DOI 10.12659/MSM.889876; Zhao H, 2017, EUR NEUROL, V77, P168, DOI 10.1159/000455073	33	1	1	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							746	10.3390/vaccines9070746			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO6QB	34358162	Green Published, gold			2022-04-29	WOS:000677032400001
J	Nnaji, CA; Wiysonge, CS; Lesosky, M; Mahomed, H; Ndwandwe, D				Nnaji, Chukwudi A.; Wiysonge, Charles S.; Lesosky, Maia; Mahomed, Hassan; Ndwandwe, Duduzile			COVID-19 and the Gaping Wounds of South Africa's Suboptimal Immunisation Coverage: An Implementation Research Imperative for Assessing and Addressing Missed Opportunities for Vaccination	VACCINES			English	Article						missed opportunities for vaccination; immunisation coverage; COVID-19; implementation research; quality improvement; South Africa	MIDDLE-INCOME COUNTRIES; QUALITY IMPROVEMENT; HEALTH SYSTEM; BENEFITS; VACCINES; CAPE	Despite South Africa's substantial investments in and efforts at ensuring universal access to immunisation services, progress has stalled and remains suboptimal across provinces and districts. An additional challenge is posed by the ongoing coronavirus disease 2019 (COVID-19) pandemic, which has disrupted immunisation services globally, including in South Africa. While there is growing evidence that missed opportunities for vaccination (MOV) are a major contributor to suboptimal immunisation progress globally, not much is known about the burden and determinants of MOV in the South African context. Herein, we make a case for assessing MOV as a strategy to address current immunisation coverage gaps while mitigating the adverse impacts of the COVID-19 pandemic on immunisation services. We illustrate a practical implementation research approach to assessing the burden of MOV among children in primary care settings; for understanding the factors associated with MOV; and for designing, implementing, and evaluating context-appropriate quality improvement interventions for addressing missed opportunities. Such efforts are vital for building health system resilience and maintaining immunisation programme capacity to optimally deliver essential health services such as routine childhood immunisation, even during pandemics.	[Nnaji, Chukwudi A.; Wiysonge, Charles S.; Lesosky, Maia] Univ Cape Town, Sch Publ Hlth & Family Med, Div Epidemiol & Biostat, Anzio Rd, ZA-7925 Cape Town, South Africa; [Nnaji, Chukwudi A.; Wiysonge, Charles S.; Ndwandwe, Duduzile] South African Med Res Council, Cochrane South Africa, Francie Van Zijl Dr, ZA-7501 Cape Town, South Africa; [Wiysonge, Charles S.] Stellenbosch Univ, Dept Global Hlth, Div Epidemiol & Biostat, Francie Van Zijl Dr, ZA-7505 Cape Town, South Africa; [Mahomed, Hassan] Western Cape Prov Dept Hlth, 8 Riebeeck St, ZA-8001 Cape Town, South Africa; [Mahomed, Hassan] Stellenbosch Univ, Dept Global Hlth, Div Hlth Syst & Publ Hlth, Francie Van Zijl Dr, ZA-7505 Cape Town, South Africa		Nnaji, CA (通讯作者)，Univ Cape Town, Sch Publ Hlth & Family Med, Div Epidemiol & Biostat, Anzio Rd, ZA-7925 Cape Town, South Africa.; Nnaji, CA (通讯作者)，South African Med Res Council, Cochrane South Africa, Francie Van Zijl Dr, ZA-7501 Cape Town, South Africa.	nnjchu001@myuct.ac.za; charles.wiysonge@mrc.ac.za; maia.lesosky@uct.ac.za; hassan.mahomed@westerncape.gov.za; duduzile.ndwandwe@mrc.ac.za	Ndwandwe, Duduzile/L-2296-2013	Ndwandwe, Duduzile/0000-0001-7129-3865; Nnaji, Chukwudi/0000-0002-4132-1922; Wiysonge, Charles/0000-0002-1273-4779; Lesosky, Maia/0000-0002-2026-958X	National Research Foundation of South Africa's Thuthuka funding instrument (NRF Rating Track) [117840]; South African Medical Research CouncilSouth African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [43553]	This work was supported by funding from the National Research Foundation of South Africa's Thuthuka funding instrument (NRF Rating Track, grant number 117840) and the South African Medical Research Council (project code 43553).	Abbas K, 2020, LANCET GLOB HEALTH, V8, pE1264, DOI [10.1016/S2214-109X(20)30308-9, 10.1016/52214-109X(20)30308-9]; Acharya M, 2015, FRONT PUBLIC HEALTH, V3, DOI 10.3389/fpubh.2015.00238; Adamu AA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218572; Adedokun ST, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4137-7; Batalden PB, 2007, QUAL SAF HEALTH CARE, V16, P2, DOI 10.1136/qshc.2006.022046; Birken SA, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0656-y; Bloom DE, 2011, ADV EXP MED BIOL, V697, P1, DOI 10.1007/978-1-4419-7185-2_1; Burnett RJ, 2019, S AFR J SCI, V115, P22, DOI 10.17159/sajs.2019/6060; Burnett RJ, 2018, INT HEALTH, V10, P376, DOI 10.1093/inthealth/ihy036; Buse K, 2015, GLOBALIZATION HEALTH, V11, DOI 10.1186/s12992-015-0098-8; Chin Marshall H, 2009, Pediatrics, V124 Suppl 3, pS224, DOI 10.1542/peds.2009-1100K; Coovadia H, 2009, LANCET, V374, P817, DOI 10.1016/S0140-6736(09)60951-X; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Department of Health, 2012, QUALITY IMPROVEMENT; Department of Health, 2011, NAT COR STAND HLTH E NAT COR STAND HLTH E; Eccles MP, 2006, IMPLEMENT SCI, V1, DOI 10.1186/1748-5908-1-1; Etana B, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-566; Foy R, 2011, BMJ QUAL SAF, V20, P453, DOI 10.1136/bmjqs.2010.047993; Hargreaves S, 2019, JAIDS-J ACQ IMM DEF, V81, P487, DOI 10.1097/QAI.0000000000002085; HUTCHINS SS, 1993, B WORLD HEALTH ORGAN, V71, P549; Jacob N, 2015, SAMJ S AFR MED J, V105, P917, DOI [10.7196/SAMJ.2015.v105i11.10194, 10.7196/SAMJ.2015.V105I11.10194]; Jessani NS, 2018, HEALTH RES POLICY SY, V16, DOI 10.1186/s12961-018-0342-9; Kaslow DC, 2017, VACCINE, V35, pA10, DOI 10.1016/j.vaccine.2016.10.088; KEJA K, 1988, World Health Statistics Quarterly, V41, P59; le Roux K., 2017, S AFR MED J, V107, P2016; Leatherman S, 2010, INT J QUAL HEALTH C, V22, P237, DOI 10.1093/intqhc/mzq028; Li AJ, 2019, VACCINE, V37, P4281, DOI 10.1016/j.vaccine.2019.06.041; Magadzire Bvudzai Priscilla, 2017, Gates Open Res, V1, P5, DOI 10.12688/gatesopenres.12761.1; Maurice J.M., 2009, STATE WORLDS VACCINE; Mbunge E, 2020, DIABETES METAB SYND, V14, P1809, DOI 10.1016/j.dsx.2020.09.016; METCALF CA, 1994, S AFR MED J, V84, P149; Mothiba TM, 2016, AFR J PRIM HEALTH CA, V8, DOI 10.4102/phcfm.v8i2.923; National Institute for Communicable Diseases (NICD), 2017, MEASL OUTBR DISTR W MEASL OUTBR DISTR W; Ndwandwe D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040705; Ndwandwe D, 2021, HUM VACC IMMUNOTHER, V17, P247, DOI 10.1080/21645515.2020.1791509; Nnaji CA, 2021, INT HEALTH, V13, P653, DOI 10.1093/inthealth/ihz120; Nnaji CA, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-041721; Nyasulu J, 2020, AFR J PRIM HEALTH CA, V12, DOI 10.4102/phcfm.v12i1.2480; Ogbuanu IU, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210648; Okeibunor Joseph C, 2018, J Immunol Sci, VSuppl, P46; Ozawa S, 2012, VACCINE, V31, P96, DOI 10.1016/j.vaccine.2012.10.103; Sambala EZ, 2018, HUM VACC IMMUNOTHER, V14, P2365, DOI 10.1080/21645515.2018.1460985; Siedner MJ, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-043763; Siedner Mark J, 2020, medRxiv, DOI 10.1101/2020.05.15.20103226; Sridhar S, 2014, VACCINE, V32, P6870, DOI 10.1016/j.vaccine.2014.10.063; Uthman OA, 2018, HUM VACC IMMUNOTHER, V14, P2397, DOI 10.1080/21645515.2018.1504524; VanderEnde Kristin, 2018, MMWR Morb Mortal Wkly Rep, V67, P1261, DOI 10.15585/mmwr.mm6745a2; Wang HD, 2017, LANCET, V390, P1084, DOI 10.1016/S0140-6736(17)31833-0; Wilder-Smith A, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0911-8; Wiysonge CS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037905; Wiysonge CS, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-578; World Health Organization, 2017, IMM COV; World Health Organization, WHO UNICEF EST NAT I; World Health Organization, 2018, HDB NAT QUAL POL STR HDB NAT QUAL POL STR; World Health Organization, IMM COV; World Health Organization, 2017, METH ASS MISS OPP VA; Yismaw AE, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4276-2; Zida-Compaore WIC, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4115-5	58	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							691	10.3390/vaccines9070691			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7DU	34201684	Green Published, gold			2022-04-29	WOS:000677068100001
J	Aebischer, A; Wernike, K; Konig, P; Franzke, K; Schreur, PJW; Kortekaas, J; Vitikainen, M; Wiebe, M; Saloheimo, M; Tchelet, R; Audonnet, JC; Beer, M				Aebischer, Andrea; Wernike, Kerstin; Koenig, Patricia; Franzke, Kati; Wichgers Schreur, Paul J.; Kortekaas, Jeroen; Vitikainen, Marika; Wiebe, Marilyn; Saloheimo, Markku; Tchelet, Ronen; Audonnet, Jean-Christophe; Beer, Martin			Development of a Modular Vaccine Platform for Multimeric Antigen Display Using an Orthobunyavirus Model	VACCINES			English	Article						emerging infectious disease; zoonosis; modular vaccine; epitope; lumazine synthase; Schmallenberg virus; SpyCatcher/SpyTag; C1 production host	PROTEIN CAGE NANOPARTICLES; VIRUS-LIKE PARTICLES; SCHMALLENBERG VIRUS; LUMAZINE SYNTHASE; GLYCOPROTEIN GC; DOMAIN; CORONAVIRUS; SUPERGLUE; DELIVERY; CELL	Emerging infectious diseases represent an increasing threat to human and animal health. Therefore, safe and effective vaccines that could be available within a short time frame after an outbreak are required for adequate prevention and control. Here, we developed a robust and versatile self-assembling multimeric protein scaffold particle (MPSP) vaccine platform using lumazine synthase (LS) from Aquifex aeolicus. This scaffold allowed the presentation of peptide epitopes by genetic fusion as well as the presentation of large antigens by bacterial superglue-based conjugation to the pre-assembled particle. Using the orthobunyavirus model Schmallenberg virus (SBV) we designed MPSPs presenting major immunogens of SBV and assessed their efficacy in a mouse model as well as in cattle, a target species of SBV. All prototype vaccines conferred protection from viral challenge infection and the multivalent presentation of the selected antigens on the MPSP markedly improved their immunogenicity compared to the monomeric subunits. Even a single shot vaccination protected about 80% of mice from an otherwise lethal dose of SBV. Most importantly, the MPSPs induced a virtually sterile immunity in cattle. Altogether, LS represents a promising platform for modular and rapid vaccine design.	[Aebischer, Andrea; Wernike, Kerstin; Koenig, Patricia; Franzke, Kati; Beer, Martin] Friedrich Loeffler Inst, D-17493 Greifswald, Germany; [Wichgers Schreur, Paul J.; Kortekaas, Jeroen] Wageningen Biovet Res, Lab Virol, NL-8221 RA Lelystad, Netherlands; [Vitikainen, Marika; Wiebe, Marilyn; Saloheimo, Markku] VTT Tech Res Ctr Finland Ltd, Espoo 02150, Finland; [Tchelet, Ronen] Dyad Netherland BV, NL-6709 PA Wageningen, Netherlands; [Audonnet, Jean-Christophe] Boehringer Ingelheim Anim Hlth, F-69800 St Priest, France		Beer, M (通讯作者)，Friedrich Loeffler Inst, D-17493 Greifswald, Germany.	andrea.aebischer@fli.de; kerstin.wernike@fli.de; patricia.koenig@fli.de; kati.franzke@fli.de; paul.wichgersschreur@wur.nl; jeroen.kortekaas@wur.nl; Marika.Vitikainen@vtt.fi; Marilyn.Wiebe@vtt.fi; markku.saloheimo@vtt.fi; rtchelet@dyadic.com; Jean-Christophe.AUDONNET@boehringer-ingelheim.com; martin.beer@fli.de		Wiebe, Marilyn/0000-0002-4535-2427; Franzke, Kati/0000-0003-0827-5407; Wichgers Schreur, Paul/0000-0001-9790-2438; Kortekaas, Jeroen/0000-0002-0329-0176; Wernike, Kerstin/0000-0001-8071-0827	Zoonoses Anticipation and Preparedness Initiative (ZAPI project) [115760]; IMI; European CommissionEuropean CommissionEuropean Commission Joint Research Centre	This research was performed as part of the Zoonoses Anticipation and Preparedness Initiative (ZAPI project; IMI Grant Agreement no115760), with the assistance and financial support of IMI and the European Commission, and in kind contributions from EFPIA partners.	A CG, 2019, VACCINES-BASEL, V7, P47, DOI DOI 10.3390/VACCINES7020047; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Barrett J., 2020, ANGEW CHEM INT EDIT, DOI [10.1002/anie.202009663, DOI 10.1002/ANIE.202009663]; Beer M, 2013, EPIDEMIOL INFECT, V141, P1, DOI 10.1017/S0950268812002245; Berka RM, 2011, NAT BIOTECHNOL, V29, P922, DOI 10.1038/nbt.1976; Bilk S, 2012, VET MICROBIOL, V159, P236, DOI 10.1016/j.vetmic.2012.03.035; Brune KD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01432; Brune KD, 2017, BIOCONJUGATE CHEM, V28, P1544, DOI 10.1021/acs.bioconjchem.7b00174; Brune KD, 2016, SCI REP-UK, V6, DOI 10.1038/srep19234; Bruun TUJ, 2018, ACS NANO, V12, P8855, DOI 10.1021/acsnano.8b02805; Butler JE, 1998, REV SCI TECH OIE, V17, P43, DOI 10.20506/rst.17.1.1096; Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y; Chuan YP, 2013, BIOTECHNOL BIOENG, V110, P2343, DOI 10.1002/bit.24907; Correia BE, 2014, NATURE, V507, P201, DOI 10.1038/nature12966; de Jongh WA, 2013, PHARM BIOPROCESS, V1, P197, DOI 10.4155/PBP.13.18; Ellwanger JH, 2019, J INFECT PUBLIC HEAL, V12, P313, DOI [10.1016/j.jiph.2019.01.010, 10.1016/j.jiph.2019.03.010]; Geiser M, 2001, BIOTECHNIQUES, V31, P88, DOI 10.2144/01311st05; Gomes AC, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5010006; Goodswen SJ, 2014, BIOINFORMATICS, V30, P2381, DOI 10.1093/bioinformatics/btu300; Graham BS, 2018, NAT IMMUNOL, V19, P20, DOI 10.1038/s41590-017-0007-9; Gravelat Fabrice N, 2012, Methods Mol Biol, V845, P119, DOI 10.1007/978-1-61779-539-8_8; Gusakov AV, 2008, CARBOHYD RES, V343, P48, DOI 10.1016/j.carres.2007.10.014; Hassell JM, 2017, TRENDS ECOL EVOL, V32, P55, DOI 10.1016/j.tree.2016.09.012; Hellert J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08832-8; Hemida MG, 2014, EMERG INFECT DIS, V20, P1231, DOI 10.3201/eid2007.140571; Hoffmann B, 2012, EMERG INFECT DIS, V18, P469, DOI 10.3201/eid1803.111905; Janitzek CM, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1574-1; Jegerlehner A, 2010, VACCINE, V28, P5503, DOI 10.1016/j.vaccine.2010.02.103; Jennings GT, 2008, BIOL CHEM, V389, P521, DOI 10.1515/BC.2008.064; Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536; Kainz E, 2008, APPL ENVIRON MICROB, V74, P1076, DOI 10.1128/AEM.01058-07; Karch CP, 2016, BIOCHEM PHARMACOL, V120, P1, DOI 10.1016/j.bcp.2016.05.001; Keeble AH, 2019, P NATL ACAD SCI USA, V116, P26523, DOI 10.1073/pnas.1909653116; Li L, 2014, J MOL BIOL, V426, P309, DOI 10.1016/j.jmb.2013.10.021; Lopez-Sagaseta J, 2016, COMPUT STRUCT BIOTEC, V14, P58, DOI 10.1016/j.csbj.2015.11.001; Marini A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02931; McCluskie MJ, 2016, IMMUNOPHARM IMMUNOT, V38, P184, DOI 10.3109/08923973.2016.1165246; Metz SW, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006793; Min J, 2014, RSC ADV, V4, P48596, DOI 10.1039/c4ra10187a; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Okba NMA, 2020, EMERG MICROBES INFEC, V9, P1080, DOI 10.1080/22221751.2020.1760735; Purcell AW, 2007, NAT REV DRUG DISCOV, V6, P404, DOI 10.1038/nrd2224; Ra JS, 2014, CLIN EXP VACCINE RES, V3, P227, DOI 10.7774/cevr.2014.3.2.227; Rantasalo A, 2018, NUCLEIC ACIDS RES, V46, DOI 10.1093/nar/gky558; Roman-Sosa G, 2017, J GEN VIROL, V98, P1259, DOI 10.1099/jgv.0.000810; Roman-Sosa G, 2016, J GEN VIROL, V97, P571, DOI 10.1099/jgv.0.000377; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Sharma J, 2020, ACS APPL MATER INTER, V12, P18211, DOI 10.1021/acsami.9b21776; Singh SK, 2017, VACCINE, V35, P3726, DOI 10.1016/j.vaccine.2017.05.054; Soria-Guerra RE, 2015, J BIOMED INFORM, V53, P405, DOI 10.1016/j.jbi.2014.11.003; Tan M, 2014, CURR OPIN VIROL, V6, P24, DOI 10.1016/j.coviro.2014.02.009; Tan TK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20654-7; Thrane S, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0181-1; Veggiani G, 2014, TRENDS BIOTECHNOL, V32, P506, DOI 10.1016/j.tibtech.2014.08.001; Visser H., 2011, IND BIOTECHNOL, V7, P214, DOI [10.1089/ind.2011.7.214, DOI 10.1089/IND.2011.7.214]; Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9; Wernike K, 2018, VACCINE, V36, P5116, DOI 10.1016/j.vaccine.2018.07.047; Wernike K, 2017, SCI REP-UK, V7, DOI 10.1038/srep42500; Wernike K, 2015, EMERG INFECT DIS, V21, P1202, DOI 10.3201/eid2107.150180; Wernike K, 2014, PREV VET MED, V116, P423, DOI 10.1016/j.prevetmed.2014.03.021; Wernike K, 2013, VACCINE, V31, P3558, DOI 10.1016/j.vaccine.2013.05.062; Wernike K, 2013, VET MICROBIOL, V165, P155, DOI 10.1016/j.vetmic.2013.01.040; Wernike K, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-84; Wernike K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040380; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Zakeri B, 2012, P NATL ACAD SCI USA, V109, pE690, DOI 10.1073/pnas.1115485109; Zanluca C, 2016, MICROBES INFECT, V18, P295, DOI 10.1016/j.micinf.2016.03.003; Zhang XF, 2001, J MOL BIOL, V306, P1099, DOI 10.1006/jmbi.2000.4435	69	3	3	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							651	10.3390/vaccines9060651			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY4QN	34203630	Green Published			2022-04-29	WOS:000665874800001
J	Betti, M; Bragazzi, N; Heffernan, J; Kong, JD; Raad, A				Betti, Mattew; Bragazzi, Nicola; Heffernan, Jane; Kong, Jude; Raad, Angie			Could a New COVID-19 Mutant Strain Undermine Vaccination Efforts? A Mathematical Modelling Approach for Estimating the Spread of B.1.1.7 Using Ontario, Canada, as a Case Study	VACCINES			English	Article						mutant strains; emerging infectious diseases; COVID-19 pandemic; mathematical model	PATHOGEN EVOLUTION	Infections represent highly dynamic processes, characterized by evolutionary changes and events that involve both the pathogen and the host. Among infectious agents, viruses, such as Severe Acute Respiratory Syndrome-related Coronavirus type 2 (SARS-CoV-2), the infectious agent responsible for the currently ongoing Coronavirus disease 2019 (COVID-2019) pandemic, have a particularly high mutation rate. Taking into account the mutational landscape of an infectious agent, it is important to shed light on its evolution capability over time. As new, more infectious strains of COVID-19 emerge around the world, it is imperative to estimate when these new strains may overtake the wild-type strain in different populations. Therefore, we developed a general-purpose framework to estimate the time at which a mutant variant is able to take over a wild-type strain during an emerging infectious disease outbreak. In this study, we used COVID-19 as a case-study; however, the model is adaptable to any emerging pathogen. We devised a two-strain mathematical framework to model a wild- and a mutant-type viral population and fit cumulative case data to parameterize the model, using Ontario as a case study. We found that, in the context of under-reporting and the current case levels, a variant strain was unlikely to dominate until March/April 2021. The current non-pharmaceutical interventions in Ontario need to be kept in place longer even with vaccination in order to prevent another outbreak. The spread of a variant strain in Ontario will likely be observed by a widened peak of the daily reported cases. If vaccine efficacy is maintained across strains, then it is still possible to achieve high levels of immunity in the population by the end of 2021. Our findings have important practical implications in terms of public health as policy- and decision-makers are equipped with a mathematical tool that can enable the estimation of the take-over of a mutant strain of an emerging infectious disease.	[Betti, Mattew] Mt Allison Univ, Dept Math & Comp Sci, Sackville, NB E4L 1E2, Canada; [Bragazzi, Nicola; Heffernan, Jane; Kong, Jude; Raad, Angie] York Univ, Dept Math & Stat, Toronto, ON M3J 1P3, Canada; [Bragazzi, Nicola] York Univ, Lab Ind & Appl Math, Toronto, ON M3J 1P3, Canada; [Heffernan, Jane; Kong, Jude; Raad, Angie] York Univ, Ctr Dis Modeling, Toronto, ON M3J 1P3, Canada		Betti, M (通讯作者)，Mt Allison Univ, Dept Math & Comp Sci, Sackville, NB E4L 1E2, Canada.	mbetti@mta.ca; bragazzi@yorku.ca; jmheffer@yorku.ca; jdkong@yorku.ca; angieraad15@gmail.com	Bragazzi, Nicola/G-1672-2011	Bragazzi, Nicola/0000-0001-8409-868X; Betti, Matthew/0000-0002-1458-5359; Kong, Jude/0000-0002-7557-5672			Alam I, 2020, LANCET INFECT DIS, V21, P602, DOI 10.1016/S1473-3099(21)00078-5; [Anonymous], 2021, EPIDEMIOLOGICAL UPDA; Arenas M, 2018, INFECT GENET EVOL, V63, P295, DOI 10.1016/j.meegid.2017.09.029; Betti MI, 2021, INFECT DIS MODEL, V6, P313, DOI 10.1016/j.idm.2021.01.002; Binder S, 1999, SCIENCE, V284, P1311, DOI 10.1126/science.284.5418.1311; BONHOEFFER S, 1994, P NATL ACAD SCI USA, V91, P8062, DOI 10.1073/pnas.91.17.8062; Burch CL, 2000, NATURE, V406, P625, DOI 10.1038/35020564; CDC, 2021, NEW VAR VIR CAUS COV; Cobey S, 2014, ANN NY ACAD SCI, V1320, P1, DOI 10.1111/nyas.12493; Duffy S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000003; Duhon J, 2021, SCI TOTAL ENVIRON, V760, DOI 10.1016/j.scitotenv.2020.144325; Duong D, 2021, CAN MED ASSOC J, V193, pE141, DOI 10.1503/cmaj.1095915; Heesterbeek H, 2015, SCIENCE, V347, P1216, DOI 10.1126/science.aaa4339; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Koyama T, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050324; MacLean RC, 2010, DISCOV MED, V10, P112; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n158; Martins NE, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003601; Office of the Premier, 2020, ONT DEL 1 COV 19 VAC; Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02501-x; Public Health Ontario, 2020, COVID 19 UK VAR VOC; Raad A., 2021, INTEGRATED VACCINATI, DOI [10.1101/2021.01.06.21249272, DOI 10.1101/2021.01.06.21249272]; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Stern A., 2016, VIRAL PATHOGENESIS, V3rd, P233, DOI DOI 10.1016/B978-0-12-800964-2.00017-3; Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260; van Oosterhout C, 2021, VIRULENCE, V12, P507, DOI 10.1080/21505594.2021.1877066	27	3	3	4	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							592	10.3390/vaccines9060592			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY7AU	34204918	Green Published, gold			2022-04-29	WOS:000666037000001
J	Milito, C; Soccodato, V; Collalti, G; Lanciarotta, A; Bertozzi, I; Rattazzi, M; Scarpa, R; Cinetto, F				Milito, Cinzia; Soccodato, Valentina; Collalti, Giulia; Lanciarotta, Alison; Bertozzi, Ilaria; Rattazzi, Marcello; Scarpa, Riccardo; Cinetto, Francesco			Vaccination in PADs	VACCINES			English	Review						immunodeficiency; antibody deficiency; immunization; vaccination recommendations	ANTIBODY-PRODUCTION DEFICIENCY; PRIMARY IMMUNODEFICIENCY; VACCINES; RECOMMENDATIONS; TOOL; IGM	Primary antibody deficiencies (PADs) are the most common primary immunodeficiencies (PIDs). They can be divided into the following groups, depending on their immunological features: agammaglobulinemia; common variable immunodeficiency (CVID) isotype; hyper IgM isotype; light chain or functional deficiencies with normal B cell count; specific antibody deficiency with normal Ig concentrations and normal numbers of B cells and transient hypogammaglobulinemia of infancy. The role of vaccination in PADs is recognized as therapeutic, diagnostic and prognostic and may be used in patients with residual B-cell function to provide humoral immunity to specific infective agents. According to their content and mechanisms, vaccines are grouped as live attenuated, inactivated (conjugated, polysaccharide), mRNA or replication-deficient vector vaccines. Vaccination may be unsafe or less effective when using certain vaccines and in specific types of immunodeficiency. Inactivated vaccines can be administered in PAD patients even if they could not generate a protective response; live attenuated vaccines are not recommended in major antibody deficiencies. From December 2020, European Medicines Agency (EMA) approved vaccines against COVID-19 infection: according to ESID advises, those vaccinations are recommended in patients with PADs. No specific data are available on safety and efficacy in PAD patients.	[Milito, Cinzia; Soccodato, Valentina; Collalti, Giulia] Sapienza Univ Rome, Dept Mol Med, I-00161 Rome, Italy; [Lanciarotta, Alison; Bertozzi, Ilaria; Rattazzi, Marcello; Scarpa, Riccardo; Cinetto, Francesco] Univ Padua, Dept Med, I-35122 Padua, Italy; [Lanciarotta, Alison; Bertozzi, Ilaria; Rattazzi, Marcello; Scarpa, Riccardo; Cinetto, Francesco] Ca Foncello Hosp, Internal Med 1, I-10103 Treviso, Italy		Milito, C (通讯作者)，Sapienza Univ Rome, Dept Mol Med, I-00161 Rome, Italy.	valentina.soccodato@gmail.com; valentina.soccodato@gmail.com; giulia.collalti86@gmail.com; alison.brokenspear@gmail.com; ilariabertozzi2@gmail.com; marcello.rattazzi@unipd.it; scarpa.riccardo@gmail.com; francesco.cinetto@unipd.it	Cinetto, Francesco/J-7386-2018	Cinetto, Francesco/0000-0001-8486-5850; Soccodato, Valentina/0000-0001-5286-2057; Milito, Cinzia/0000-0003-2581-9250			[Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Bausch-Jurken MT, 2017, J CLIN IMMUNOL, V37, P427, DOI 10.1007/s10875-017-0406-6; Bonilla FA, 2020, IMMUNOL ALLERGY CLIN, V40, P421, DOI 10.1016/j.iac.2020.03.004; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Carsetti R, 2005, J ALLERGY CLIN IMMUN, V115, P412, DOI 10.1016/j.jaci.2004.10.048; Cavaliere FM, 2013, J CLIN IMMUNOL, V33, P838, DOI 10.1007/s10875-012-9856-z; Centers for Disease Control and Prevention, 2016, CDC YELLOW BOOK 2016; Cinetto F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247717; Durandy A, 2013, NAT REV IMMUNOL, V13, P519, DOI 10.1038/nri3466; Eibl MM, 2015, IMMUNOTHERAPY-UK, V7, P1273, DOI 10.2217/IMT.15.74; Goldacker S, 2007, CLIN IMMUNOL, V124, P294, DOI 10.1016/j.clim.2007.04.011; Guevara-Hoyer K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00654; Kinoshita H, 2021, J CLIN IMMUNOL, V41, P1146, DOI 10.1007/s10875-021-01046-y; Kroger A.T., 2016, MMWR RECOMM REP, V55, P1; MacLennan C, 2004, LANCET, V363, P1509, DOI 10.1016/S0140-6736(04)16150-3; Martins I, 2021, EUR J OBSTET GYN R B, V262, P256, DOI 10.1016/j.ejogrb.2021.05.021; Martire B, 2018, VACCINE, V36, P3541, DOI 10.1016/j.vaccine.2018.01.061; Meyts I, 2021, J ALLERGY CLIN IMMUN, V147, P520, DOI 10.1016/j.jaci.2020.09.010; Mieves JF, 2017, CURR ALLERGY ASTHM R, V17, DOI 10.1007/s11882-017-0749-3; Orange JS, 2012, J ALLERGY CLIN IMMUN, V130, pS1, DOI 10.1016/j.jaci.2012.07.002; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Principi N, 2014, VACCINE, V32, P3725, DOI 10.1016/j.vaccine.2014.05.022; Pulvirenti F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01283; Pulvirenti F, 2020, J ALLER CL IMM-PRACT, V8, P1894, DOI 10.1016/j.jaip.2020.04.003; Quinti I, 2007, J CLIN IMMUNOL, V27, P308, DOI 10.1007/s10875-007-9075-1; Quinti I, 2021, EXPERT REV CLIN IMMU, V17, P163, DOI 10.1080/1744666X.2021.1873767; Quinti I, 2011, J CLIN IMMUNOL, V31, P315, DOI 10.1007/s10875-011-9511-0; Rubin LG, 2014, CLIN INFECT DIS, V58, P309, DOI [10.1093/cid/cit684, 10.1093/cid/cit816]; Sanchez-Ramon S, 2016, CLIN IMMUNOL, V169, P80, DOI 10.1016/j.clim.2016.05.006; Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P961, DOI 10.1016/j.jaci.2013.11.043; Sobh A, 2016, J ALLER CL IMM-PRACT, V4, P1066, DOI 10.1016/j.jaip.2016.09.012; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Wall LA, 2015, IMMUNOL ALLERGY CLIN, V35, P659, DOI 10.1016/j.iac.2015.07.003	37	3	3	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							626	10.3390/vaccines9060626			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TA6RA	34207916	Green Published, gold			2022-04-29	WOS:000667374500001
J	Recio-Roman, A; Recio-Menendez, M; Roman-Gonzalez, MV				Recio-Roman, Almudena; Recio-Menendez, Manuel; Roman-Gonzalez, Maria Victoria			Global Vaccine Hesitancy Segmentation: A Cross-European Approach	VACCINES			English	Article						vaccine hesitancy; segmentation; social marketing	GENERAL-PRACTITIONERS; MARKETING STRATEGY; STANDARDIZATION; TRUST	Vaccine-preventable diseases are global mainly in a globalized world that is characterized by a continuous movement of people and goods across countries. Vaccine hesitancy, the reluctance or refusal to vaccinate despite the availability of vaccines, is rising worldwide. What if the problem of vaccine hesitancy could be most effectively managed when treated globally rather than on a national or regional basis? What if a global vaccine-hesitant segment exists and the differences among countries are not so significant? Based on the Global Marketing Strategy paradigm, this paper shows that seven different cross-European segments exist based on the beliefs, attitudes, and behaviors collected in 28 European countries. These pan-European segments are differentiable (people in those segments have similar characteristics that are visibly dissimilar from the ones in other segments) and actionable (organizations would be able to propose interventions to the hesitant segments based on their profiles). With segmentation being the starting point of many public health intervention strategies for avoiding vaccine-hesitancy, the results recommend moderating the full-adaptation strategy that follows the "context matters" principle suggested by several political and public health international organizations. Embracing a more standardized strategy will allow the development of better services and strategies that support and enable desirable vaccination behaviors.	[Recio-Roman, Almudena; Recio-Menendez, Manuel; Roman-Gonzalez, Maria Victoria] Univ Almeria, Dept Econ & Business, Carretera Sacramento S-N, Almeria 04120, Spain		Recio-Roman, A (通讯作者)，Univ Almeria, Dept Econ & Business, Carretera Sacramento S-N, Almeria 04120, Spain.	arr306@inlumine.ual.es; mrecio@ual.es; mvroman@ual.es		RECIO MENENDEZ, MANUEL/0000-0001-7052-6225; RECIO-ROMAN, ALMUDENA/0000-0001-5560-5830			Ahmed I, 2021, NAT MED, V27, P366, DOI 10.1038/s41591-021-01260-6; [Anonymous], 2020, EC CONSPIRACY THEORI; [Anonymous], **NON-TRADITIONAL**; Aurifeille JM, 2002, INT MARKET REV, V19, P369, DOI 10.1108/02651330210435672; Bahri P, 2019, VACCINE, V37, P401, DOI 10.1016/j.vaccine.2018.11.082; Bolton RN, 2003, J MARKETING, V67, P108, DOI 10.1509/jmkg.67.3.108.18655; Brock G, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i04; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Dube E, 2021, ANNU REV PUBL HEALTH, V42, P175, DOI 10.1146/annurev-publhealth-090419-102240; Dube E, 2018, VACCINE, V36, P1509, DOI 10.1016/j.vaccine.2017.12.012; European Commission, 2019, SPECIAL EUROBAROMETE; European Commission, 2018, EN DIG TRANSF HLTH C; European Commission, 2019, EUR 91 2 MARCH 2019; European Communities, 2005, EUR 63 4 BAS BIL QUE; European Parliament, RES 19 APR 2018 VACC; Fournet N, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5103-8; Fox J, Polycor: Polychoric and Polyserial Correlations R Package Version 0.7-10; French J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165893; Friendly M, 2001, TECHNOMETRICS, V43, P498; Funk S., CRITICAL IMMUNITY TH; Goldstein S, 2015, VACCINE, V33, P4212, DOI 10.1016/j.vaccine.2015.04.042; Hair J., 2010, MULTIVARIATE DATA AN, p7e; Hallsworth M., 2016, APPL BEHAV INSIGHTS; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; JAIN SC, 1989, J MARKETING, V53, P70, DOI 10.2307/1251525; Kennedy J, 2019, EUR J PUBLIC HEALTH, V29, P512, DOI 10.1093/eurpub/ckz004; Killian M, 2016, EUR J CLIN MICROBIOL, V35, P1837, DOI 10.1007/s10096-016-2735-4; Larson HJ, 2018, NATURE, V562, P309, DOI 10.1038/d41586-018-07034-4; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Little L.C, 1907, CRIMES COWPOX RING; Meyer D, 2006, J STAT SOFTW, V17; Mikulic M., GLOBAL PHARM IND STA; Nowak GJ, 2015, VACCINE, V33, P4204, DOI 10.1016/j.vaccine.2015.04.039; Opel DJ, 2009, ARCH PEDIAT ADOL MED, V163, P432, DOI 10.1001/archpediatrics.2009.42; Osborne J.W., 2014, BEST PRACTICES EXPLO; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Prematunge C, 2012, VACCINE, V30, P4733, DOI 10.1016/j.vaccine.2012.05.018; Rawal H, 2018, STATE VACCINE CONFID; Savalei V, 2011, STRUCT EQU MODELING, V18, P253, DOI 10.1080/10705511.2011.557339; Schilke O, 2009, J INT MARKETING, V17, P24, DOI 10.1509/jimk.17.4.24; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Shore DA, 2003, J HEALTH COMMUN, V8, P13, DOI 10.1080/10810730390224839; Siegrist M, 2014, EUR PSYCHOL, V19, P23, DOI 10.1027/1016-9040/a000169; Tabachnick BG., 2019, USING MULTIVARIATE S, V7; Tan Q, 2013, MANAGE INT REV, V53, P711, DOI 10.1007/s11575-013-0172-5; TeellMe, TRANSPARENT COMMUNIC; UNICEF, HUM CTR DES 4 HLTH; Washington State Department of Health, 2020, SOC MARK REC COVID 1; Williams G., ORIGINAL ANTIVAXXERS; Wilson RJI, 2020, INT J QUAL STUD HEAL, V15, DOI 10.1080/17482631.2020.1757336; World Health Organization UNICEF, WHO UNICEF COV EST; World Health Organization [WHO], 2018, TAIL IMM PROGR TIP I; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Yong AG, 2013, TUTOR QUANT METHODS, V9, P79, DOI 10.20982/tqmp.09.2.p079; Zou SM, 2002, J MARKETING, V66, P40, DOI 10.1509/jmkg.66.4.40.18519	56	4	4	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							617	10.3390/vaccines9060617			28	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY8RP	34201130	gold, Green Published			2022-04-29	WOS:000666148500001
J	Riad, A; Abdulqader, H; Morgado, M; Domnori, S; Koscik, M; Mendes, JJ; Klugar, M; Kateeb, E				Riad, Abanoub; Abdulqader, Huthaifa; Morgado, Mariana; Domnori, Silvi; Koscik, Michal; Mendes, Jose Joao; Klugar, Miloslav; Kateeb, Elham		IADS-SCORE	Global Prevalence and Drivers of Dental Students' COVID-19 Vaccine Hesitancy	VACCINES			English	Article						COVID-19 vaccines; cross-sectional studies; decision making; dental education; dental students; international association of dental students; mass vaccination; multicentre study; social determinants of health	INFECTION-CONTROL MEASURES; MEDICAL-STUDENTS; HEALTH; DETERMINANTS; AWARENESS	Background: Acceleration of mass vaccination strategies is the only pathway to overcome the COVID-19 pandemic. Healthcare professionals and students have a key role in shaping public opinion about vaccines. This study aimed to evaluate the attitudes of dental students globally towards COVID-19 vaccines and explore the potential drivers for students' acceptance levels. Methods: A global cross-sectional study was carried out in February 2021 using an online questionnaire. The study was liaised by the scientific committee of the International Association of Dental Students (IADS), and data were collected through the national and local coordinators of IADS member organizations. The dependent variable was the willingness to take the COVID-19 vaccine, and the independent variables included demographic characteristics, COVID-19-related experience, and the drivers of COVID-19 vaccine-related attitude suggested by the WHO SAGE. Results: A total of 6639 students from 22 countries, representing all world regions, responded to the questionnaire properly. Their mean age was 22.1 +/- 2.8 (17-40) years, and the majority were females (70.5%), in clinical years (66.8%), and from upper-middle-income economies (45.7%). In general, 22.5% of dental students worldwide were hesitant, and 13.9% rejected COVID-19 vaccines. The students in low- and lower-middle-income (LLMI) economies had significantly higher levels of vaccine hesitancy compared to their peers in upper-middle- and high-income (UMHI) economies (30.4% vs. 19.8%; p < 0.01). Conclusions: The global acceptance level of dental students for COVID-19 vaccines was suboptimal, and their worrisome level of vaccine hesitancy was influenced by the socioeconomic context where the dental students live and study. The media and social media, public figures, insufficient knowledge about vaccines, and mistrust of governments and the pharmaceutical industry were barriers to vaccination. The findings of this study call for further implementation of epidemiology (infectious diseases) education within undergraduate dental curricula.	[Riad, Abanoub; Koscik, Michal; Klugar, Miloslav] Masaryk Univ, Fac Med, Dept Publ Hlth, Brno 62500, Czech Republic; [Riad, Abanoub; Abdulqader, Huthaifa; Morgado, Mariana; Domnori, Silvi] Int Assoc Dent Students IADS, CH-1216 Geneva, Switzerland; [Riad, Abanoub; Klugar, Miloslav] Masaryk Univ, Czech EBHC JBI Ctr Excellence, Fac Med,GRADE Ctr,Inst Biostat & Anal, Czech Natl Ctr Evidence Based Healthcare & Knowle, Brno 62500, Czech Republic; [Morgado, Mariana; Mendes, Jose Joao] Egas Moniz Cooperat Ensino Super, Clin Res Unit CRU, P-2829511 Almada, Portugal; [Kateeb, Elham] Al Quds Univ, Fac Dent, Oral Hlth Res & Promot Unit, Jerusalem 51000, Palestine; [Kateeb, Elham] World Dent Federat FDI, Publ Hlth Comm, CH-1216 Geneva, Switzerland		Riad, A (通讯作者)，Masaryk Univ, Fac Med, Dept Publ Hlth, Brno 62500, Czech Republic.; Riad, A (通讯作者)，Int Assoc Dent Students IADS, CH-1216 Geneva, Switzerland.; Riad, A (通讯作者)，Masaryk Univ, Czech EBHC JBI Ctr Excellence, Fac Med,GRADE Ctr,Inst Biostat & Anal, Czech Natl Ctr Evidence Based Healthcare & Knowle, Brno 62500, Czech Republic.	abanoub.riad@med.muni.cz; vpsr@iads-web.org; mmorgado@egasmoniz.edu.pt; vppr@iads-web.org; koscik@med.muni.cz; jmendes@egasmoniz.edu.pt; klugar@med.muni.cz; ekateeb@staff.alquds.edu	Kateeb, Elham/Q-5207-2018; Mendes, J João/AAU-6390-2021; Firoozi, Parsa/ABF-3148-2020; Klugar, Miloslav/E-5748-2018; Riad, Abanoub/AAU-7046-2020; Issa, Julien/AAT-7458-2021; Morgado, Mariana/AAU-4026-2020	Kateeb, Elham/0000-0003-2077-3257; Mendes, J João/0000-0003-0167-4077; Firoozi, Parsa/0000-0001-5595-1485; Klugar, Miloslav/0000-0002-2804-7295; Riad, Abanoub/0000-0001-5918-8966; Issa, Julien/0000-0002-6498-7989; Morgado, Mariana/0000-0002-2402-2277; Abdalla, Ahmed/0000-0003-2909-7910; Hom, Anita/0000-0002-0916-8980; Aghamohseni, MohammadMostafa/0000-0003-4356-4431; KOPARAN, Berk/0000-0002-8416-6651; Tjokroadiredjo, Viandra/0000-0001-7189-9701; Romanovska, Kristine/0000-0002-8627-4664; Domnori, Silvi/0000-0002-7153-5411; AbdulQader, Huthaifa/0000-0001-6677-0276; Aslam, Aneeqa/0000-0001-7110-5174; FEDHILA, MAYA/0000-0002-5100-9908; Trijonyte, Kriste/0000-0002-6817-9903; sirous, samin/0000-0002-5535-9083	Masaryk University [MUNI/IGA/1543/2020, MUNI/A/1608/2020]; INTER-EXCELLENCE [LTC20031]	This study was funded by Masaryk University, grant numbers MUNI/IGA/1543/2020 and MUNI/A/1608/2020. The work of A.R. and M.K. (Miloslav Klugar) was supported by the INTER-EXCELLENCE grant number LTC20031-"Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic".	Abalkhail MS, 2017, J INFECT PUBLIC HEAL, V10, P644, DOI 10.1016/j.jiph.2017.05.001; Alawia R., 2021, J ORAL MED ORAL SURG, V27, P17, DOI [10.1051/mbcb/2020056, DOI 10.1051/MBCB/2020056]; Alawia R, 2022, ORAL DIS, V28, P975, DOI 10.1111/odi.13593; Ali SN, 2021, LANCET, V397, P1443, DOI 10.1016/S0140-6736(21)00779-0; American Dental Association (ADA), DENT WORKF US; American Dental Association (ADA), DENT SCH STUD; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Bertoncello C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020276; Bonnevie E., 2021, Journal of Communication in Healthcare, V14, P12, DOI 10.1080/17538068.2020.1858222; Butler R, 2015, VACCINE, V33, P4176, DOI 10.1016/j.vaccine.2015.04.038; Centers for Disease Control and Prevention (CDC), EPI INFOTM WIND; Council of European Dentists (CED), 2014, EU MAN DENT PRACT; Crescitelli MED, 2020, PUBLIC HEALTH, V180, P38, DOI 10.1016/j.puhe.2019.10.027; de Paula SI, 2016, REV INST MED TROP SP, V58, DOI [10.1590/S1678-9946201658082, 10.1590/s1678-9946201658082]; de Souza RA, 2006, J PUBLIC HEALTH DENT, V66, P282; Dereje N., 2021, COVID 19 VACCINE HES, DOI [10.1101/2021.02.25.21252443, DOI 10.1101/2021.02.25.21252443]; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Farsi Nada J, 2020, Asian Pac J Cancer Prev, V21, P3595, DOI 10.31557/APJCP.2020.21.12.3595; Frank E, 2004, JAMA-J AM MED ASSOC, V291, P637, DOI 10.1001/jama.291.5.637; Gerussi V, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020172; Ghai S, 2020, J DENT EDUC, V84, P631, DOI 10.1002/jdd.12174; Grech Victor, 2020, Early Hum Dev, P105258, DOI 10.1016/j.earlhumdev.2020.105258; Grech Victor, 2020, Early Hum Dev, P105259, DOI 10.1016/j.earlhumdev.2020.105259; Griffith J, 2021, J MED INTERNET RES, V23, DOI 10.2196/26874; International Association of Dental Students (IADS), DEL LIST GOV; International Association of Dental Students (IADS), WORKF GOV; Jain J., 2021, COVID 19 VACCINE HES, DOI [10.1101/2021.03.12.21253444, DOI 10.1101/2021.03.12.21253444]; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Kelekar AK, 2021, J AM DENT ASSOC, V152, P596, DOI 10.1016/j.adaj.2021.03.006; KoBoToolbox, HARV HUM IN; Lam A, VACCINATION RECOMMEN; Laschinger HKS, 1999, NURS EDUC TODAY, V19, P408, DOI 10.1054/nedt.1999.0326; Li HOY, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002604; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Machado RA, 2020, BRAZ ORAL RES, V34, DOI 10.1590/1807-3107bor-2020.vol34.0083; Mahesh R., 2014, INT SCH RES NOT, V2014, P1, DOI [10.1155/2014/389274, DOI 10.1155/2014/389274]; Mahmud S., 2021, ARXIV210315206; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Mesch GS, 2015, AM J INFECT CONTROL, V43, P1161, DOI 10.1016/j.ajic.2015.06.031; Meyer MN, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.5344; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nouri K, 2014, REPROD BIOL ENDOCRIN, V12, DOI 10.1186/1477-7827-12-94; Oberg EB, 2009, J ROY COLL PHYS EDIN, V39, P290, DOI 10.4997/JRCPE.2009.422; Olomofe CO., 2021, PREDICTORS UPTAKE PO, DOI [10.1101/2020.12.28.20248965, DOI 10.1101/2020.12.28.20248965]; Pandey D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040619; Parkash H., 2006, J DENT EDUC, V70, P22, DOI [DOI 10.1002/J.0022-0337.2006.70.11_SUPPL.TB04212.X, 10.1002/j.0022-0337.2006.70.11_suppl.tb04212.x]; Pinelli Camila, 2016, Cad. saúde colet., V24, P162, DOI 10.1590/1414-462X201600020238; Prasanna JS, 2015, J ORAL RES REV, V7, P69, DOI [10.4103/2249-4987.172499, DOI 10.4103/2249-4987.172499]; Proton Technologies AG, GEN DATA PROTECTION; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Roser M., CORONAVIRUS PANDEMIC; Royal College of Physicians and Surgeons of Canada, PHYS COMP FRAM 2005; Rubin GJ, 2011, VACCINE, V29, P2421, DOI 10.1016/j.vaccine.2011.01.035; Rutkoski H, 2020, J CANCER EDUC, V35, P1017, DOI 10.1007/s13187-019-01561-y; Saied SM, 2021, J MED VIROL, V93, P4280, DOI 10.1002/jmv.26910; Sallam M, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18052407; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schernhammer E, 2022, J PUBLIC HEALTH-UK, V44, pE106, DOI 10.1093/pubmed/fdab122; Shetty S, 2019, HUM VACC IMMUNOTHER, V15, P1656, DOI 10.1080/21645515.2019.1565260; Shrirao N., DENT REACH; Singh A, 2011, J DENT EDUC, V75, P421; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; SPSS Inc, IBM SPSS STAT 27; Strategic Advisory Group of Experts on Immunization (SAGE), VACC HES SURV QUEST; Synnott K., 2020, SSRN, DOI [10.2139/ssrn.3753756, DOI 10.2139/SSRN.3753756]; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; The World Bank, WORLD BANK COUNTR LE; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Verger P, 2015, EBIOMEDICINE, V2, P891, DOI 10.1016/j.ebiom.2015.06.018; von Elm E, 2007, BMJ-BRIT MED J, V335, P806; Wicker S, 2013, VACCINE, V31, P5111, DOI 10.1016/j.vaccine.2013.08.070; World Dental Federation (FDI), REG ORG OUR MEMB; World Health Organization (WHO), VACC ACC NEXT HURDL	75	30	30	5	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							566	10.3390/vaccines9060566			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ4CO	34072500	gold, Green Submitted, Green Published			2022-04-29	WOS:000666515400001
J	Zurochka, A; Dobrinina, M; Zurochka, V; Hu, DS; Solovyev, A; Ryabova, L; Kritsky, I; Ibragimov, R; Sarapultsev, A				Zurochka, Alexandr; Dobrinina, Maria; Zurochka, Vladimir; Hu, Desheng; Solovyev, Alexandr; Ryabova, Liana; Kritsky, Igor; Ibragimov, Roman; Sarapultsev, Alexey			Seroprevalence of SARS-CoV-2 Antibodies in Symptomatic Individuals Is Higher than in Persons Who Are at Increased Risk Exposure: The Results of the Single-Center, Prospective, Cross-Sectional Study	VACCINES			English	Article						antibody; COVID-19; focus groups; global health; high-risk groups; seroprevalence	SEX-DIFFERENCES; IGG; POPULATION; INFECTION; RESPONSES; COVID-19; IMMUNITY	The present study aimed to assess antibody seropositivity prevalence among symptomatic individuals and individuals with a high risk of occupational exposure to SARS-CoV-2. Participants from Chelyabinsk (Russian Federation) who were at an increased risk of exposure to SARS-CoV-2 (high-risk group, n = 1091) and participants who either had symptoms consistent with COVID-19 or were suspected to have experienced COVID-19 in the past (symptomatic group, n = 692) were enrolled between 28 September and 30 December 2020. Blood samples were tested by enzyme-linked immunosorbent assay D-5501 SARS-Cov-2-IgG-EIA-BEST and D-5502 SARS-Cov-2-IgM-EIA-BEST (AO Vector-Best, Novosibirsk, Russia). The overall seropositivity rate was 28.33-28.53%. SARS-CoV-2 antibodies were detected in 17.23% (adjusted prevalence of 17.17-17.29%) of participants in the high-risk and 45.95% (adjusted prevalence of 45.91-46.24%) in the symptomatic group. Higher IgG and IgM titers were observed in women compared to men, as well as in participants in the symptomatic group compared to those in the high-risk group. The results indicate that the seroprevalence among residents in several Russian regions is low (28.38%) and inadequate to provide herd immunity. The lower seroprevalence among participants in the high-risk group may be attributed to the enforcement of healthcare protocols and the use of adequate personal protective equipment.	[Zurochka, Alexandr; Zurochka, Vladimir; Sarapultsev, Alexey] South Ural State Univ, Sch Med Biol, Chelyabinsk 454080, Russia; [Zurochka, Alexandr; Dobrinina, Maria; Zurochka, Vladimir; Kritsky, Igor; Ibragimov, Roman; Sarapultsev, Alexey] Russian Acad Sci, Inst Immunol & Physiol, Ural Branch, Ekaterinburg 620049, Russia; [Hu, Desheng] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Integrated Tradit Chinese & Western Med, Wuhan 200092, Peoples R China; [Solovyev, Alexandr] NPO Natl Med Assoc Dev Expert Act Field Lab Diagn, Moscow 117042, Russia; [Solovyev, Alexandr] LCC GMK MEDMA, Ekaterinburg 620102, Russia; [Ryabova, Liana] South Ural State Med Univ, Dept Propedeut Internal Dis, Chelyabinsk 454092, Russia; [Kritsky, Igor; Ibragimov, Roman] Ural Fed Univ, Inst Nat Sci & Math, Ekaterinburg 620026, Russia		Sarapultsev, A (通讯作者)，South Ural State Univ, Sch Med Biol, Chelyabinsk 454080, Russia.; Sarapultsev, A (通讯作者)，Russian Acad Sci, Inst Immunol & Physiol, Ural Branch, Ekaterinburg 620049, Russia.	zurochkaav@susu.ru; mdobrynina87@gmail.com; zurochkava@susu.ru; desheng.hu@hust.edu.cn; a.solovyev75@gmail.com; lianarabowa@rambler.ru; igor81218@gmail.com; Ibragimovroman98@yandex.ru; sarapultsevap@susu.ru	Sarapultsev, Alexey P./K-7220-2012	Sarapultsev, Alexey P./0000-0003-3101-9655; Kritsky, Igor/0000-0001-9402-051X; , Roman/0000-0002-2043-1743; Zurocka, Vladimir/0000-0001-8930-3742	RFBRRussian Foundation for Basic Research (RFBR); NSFCNational Natural Science Foundation of China (NSFC) [82161138003, 20-515-55003]; Institute of Immunology and Physiology [AAAA-A21-121012090090-9]	The reported study was funded by RFBR and NSFC (project No.20-515-55003), by the NSFC (project No. 82161138003), and partly by the Government contract of the Institute of Immunology and Physiology (AAAA-A21-121012090090-9).	[Anonymous], SPRAVOCHNIK ZAVEDUYU; Barchuk A., 2020, SEROPREVALENCE SARS, DOI [10.1101/2020.1111.1102.20221309, DOI 10.1101/2020.1111.1102.20221309]; Bunders MJ, 2020, IMMUNITY, V53, P487, DOI 10.1016/j.immuni.2020.08.003; CHEN X, 2020, MEDRXIV, DOI DOI 10.1016/S2214-109X(21)00026-7; Chvatal-Medina M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.633184; Fink AL, 2018, P NATL ACAD SCI USA, V115, P12477, DOI 10.1073/pnas.1805268115; Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111; Gadi N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02147; Gaitens J, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18041446; Gebhard C, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00304-9; Gomez-Ochoa SA, 2021, AM J EPIDEMIOL, V190, P161, DOI 10.1093/aje/kwaa191; Gonzalez-Quintela A, 2008, CLIN EXP IMMUNOL, V151, P42, DOI 10.1111/j.1365-2249.2007.03545.x; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI [10.1056/NEJMc2005203, 10.1056/NEJMoa2002032]; Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116; Hsueh PR, 2004, CLIN MICROBIOL INFEC, V10, P1062, DOI 10.1111/j.1469-0691.2004.01009.x; Huang AT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18450-4; Kadel S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01653; Kalish Heather, 2021, medRxiv, DOI 10.1101/2021.01.27.21250570; Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793; Klein SL, 2015, T ROY SOC TROP MED H, V109, P9, DOI 10.1093/trstmh/tru167; Komissarov AB, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20880-z; Korte W, 2021, J INFECTION, V82, pE11, DOI 10.1016/j.jinf.2020.08.032; Lai CC, 2020, INT J INFECT DIS, V101, P314, DOI 10.1016/j.ijid.2020.10.011; Lan FY, 2021, OCCUP ENVIRON MED, V78, P237, DOI 10.1136/oemed-2020-106774; Lan FY, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233588; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Luo CH, 2021, INT J INFECT DIS, V108, P57, DOI 10.1016/j.ijid.2021.04.078; Naaber P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237548; Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012; Orner EP, 2021, DIAGN MICR INFEC DIS, V99, DOI 10.1016/j.diagmicrobio.2020.115300; Pasqualotto AC, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249672; Piccoli L, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100013; Popova A. Yu, 2020, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P518, DOI 10.36233/0372-9311-2020-97-6-2; Popova Anna Yu, 2021, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P7, DOI 10.36233/0372-9311-92; Poustchi Hossein, 2021, Lancet Infect Dis, V21, P473, DOI 10.1016/S1473-3099(20)30858-6; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Robbiani Davide F, 2020, bioRxiv, DOI 10.1101/2020.05.13.092619; Rostami A, 2021, CLIN MICROBIOL INFEC, V27, P331, DOI 10.1016/j.cmi.2020.10.020; Sempos CT, 2021, AM J EPIDEMIOL, V190, P109, DOI 10.1093/aje/kwaa174; Shrock E, 2020, SCIENCE, V370, P1058, DOI 10.1126/science.abd4250; Smirnov, 2020, J MICROBIOL IMMUNOL, V97, P392, DOI [10.36233/0372-9311-2020-97-5-1, DOI 10.36233/0372-9311-2020-97-5-1]; Syangtan G, 2021, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.587374; Takahashi Takehiro, 2020, medRxiv, DOI 10.1101/2020.06.06.20123414; Varona JF, 2021, INT J EPIDEMIOL, V50, P400, DOI 10.1093/ije/dyaa277; Wang YA, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107271; Wolff F, 2020, DIAGN MICR INFEC DIS, V98, DOI 10.1016/j.diagmicrobio.2020.115140; Xu Y, 2020, EMERG MICROBES INFEC, V9, P924, DOI 10.1080/22221751.2020.1752610; Yang HS, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.4302; Zeng FF, 2020, J MED VIROL, V92, P2050, DOI 10.1002/jmv.25989; Zhou, 2020, ZHONGHUA LIU XING BI, V41, pE055, DOI [10.3760/cma.j.cn112338-20200228-00206, DOI 10.3760/CMA.J.CN112338-20200228-00206]	50	4	4	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							627	10.3390/vaccines9060627			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ4LG	34207919	Green Published, gold			2022-04-29	WOS:000666538000001
J	Di Donato, V; Caruso, G; Petrillo, M; Kontopantelis, E; Palaia, I; Perniola, G; Plotti, F; Angioli, R; Muzii, L; Panici, PB; Bogani, G				Di Donato, Violante; Caruso, Giuseppe; Petrillo, Marco; Kontopantelis, Evangelos; Palaia, Innocenza; Perniola, Giorgia; Plotti, Francesco; Angioli, Roberto; Muzii, Ludovico; Benedetti Panici, Pierluigi; Bogani, Giorgio			Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis	VACCINES			English	Review						cervical intraepithelial neoplasia; cervical dysplasia; conization; human papillomavirus; HPV; LEEP; vaccination	HUMAN-PAPILLOMAVIRUS VACCINE; INTRAEPITHELIAL NEOPLASIA; CYTOREDUCTIVE SURGERY; CROSS-PROTECTION; OVARIAN-CANCER; WOMEN; CONIZATION; MORTALITY; INFECTION; CYTOKINES	Objective: The aim of this meta-analysis was to discuss evidence supporting the efficacy of adjuvant human papillomavirus (HPV) vaccination in reducing the risk of recurrent cervical intraepithelial neoplasia (CIN) 2 or greater after surgical treatment. Methods: A systematic literature search was performed for studies reporting the impact of HPV vaccination on reducing the risk of recurrence of CIN 2+ after surgical excision. Results were reported as mean differences or pooled odds ratios (OR) with 95% confidence intervals (95% CI). Results: Eleven studies met the inclusion criteria and were selected for analysis. In total, 21,310 patients were included: 4039 (19%) received peri-operational adjuvant HPV vaccination while 17,271 (81%) received surgery alone. The recurrence of CIN 2+ after treatment was significantly lower in the vaccinated compared with the unvaccinated group (OR 0.35; 95% CI 0.21-0.56; p < 0.0001). The recurrence of CIN 1+ after treatment was significantly lower in the vaccinated compared with the unvaccinated group (OR 0.51; 95% CI 0.31-0.83; p = 0.006). A non-significant trend of reduction rate of HPV persistence was observed in the vaccinated compared with the unvaccinated cohorts (OR was 0.84; 95% CI 0.61-1.15; p = 0.28). Conclusions: HPV vaccination, in adjuvant setting, is associated with a reduced risk of recurrent CIN 1+ and CIN 2+ after surgical treatment.	[Di Donato, Violante; Caruso, Giuseppe; Palaia, Innocenza; Perniola, Giorgia; Muzii, Ludovico; Benedetti Panici, Pierluigi] Sapienza Univ Rome, Dept Maternal & Child Hlth & Urol Sci, Policlin Umberto 1, I-00161 Rome, Italy; [Petrillo, Marco] Univ Sassari, Dept Med Surg & Expt Sci, Gynecol & Obstet Unit, I-07100 Sassari, Italy; [Petrillo, Marco] Univ Sassari, PhD Sch Biomed Sci, I-07100 Sassari, Italy; [Kontopantelis, Evangelos] Univ Manchester, Div Informat Imaging & Data Sci, Manchester M13 9PL, Lancs, England; [Plotti, Francesco; Angioli, Roberto] Campus Biomed Univ Rome, Dept Obstet & Gynecol, I-00128 Rome, Italy; [Bogani, Giorgio] IRCCS Natl Canc Inst, Dept Gynecol Oncol, I-20133 Milan, Italy		Caruso, G (通讯作者)，Sapienza Univ Rome, Dept Maternal & Child Hlth & Urol Sci, Policlin Umberto 1, I-00161 Rome, Italy.	violante.didonato@uniroma1.it; g.caruso@uniroma1.it; marco.petrillo@gmail.com; e.kontopantelis@manchester.ac.uk; innocenza.palaia@uniroma1.it; giorgia.perniola@uniroma1.it; f.plotti@unicampus.it; r.angioli@unicampus.it; ludovico.muzii@uniroma1.it; pierluigi.benedettipanici@uniroma1.it; giorgio.bogani@istitutotumori.mi.it	Di Donato, Violante/O-1742-2019	Di Donato, Violante/0000-0002-9254-5790; Muzii, Ludovico/0000-0001-7195-9583; Kontopantelis, Evangelos/0000-0001-6450-5815; Bogani, Giorgio/0000-0001-8373-8569; Petrillo, Marco/0000-0003-0306-4328; Caruso, Giuseppe/0000-0001-5501-1936			Arbyn M, 2020, LANCET GLOB HEALTH, V8, pE191, DOI 10.1016/S2214-109X(19)30482-6; Arbyn M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009069.pub3; Athanasiou A, 2020, BEST PRACT RES CL OB, V65, P109, DOI 10.1016/j.bpobgyn.2020.02.009; Ault KA, 2007, GYNECOL ONCOL, V107, pS31, DOI 10.1016/j.ygyno.2007.08.059; Barra F, 2020, J OBSTET GYNAECOL RE, V46, P989, DOI 10.1111/jog.14276; Bartels HC, 2020, INT J GYNECOL CANCER, V30, P777, DOI 10.1136/ijgc-2020-001197; Bogani G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040717; Byun JM, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013606; Coskuner ER, 2014, J SEX MED, V11, P2785, DOI 10.1111/jsm.12670; de Martel C, 2020, LANCET GLOB HEALTH, V8, pE180, DOI 10.1016/S2214-109X(19)30488-7; De Vincenzo R, 2013, GYNECOL ONCOL, V130, P642, DOI 10.1016/j.ygyno.2013.05.033; del Pino M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020245; Di Donato V, 2021, GYNECOL ONCOL, V161, P11, DOI 10.1016/j.ygyno.2020.12.030; Di Donato V, 2020, EJSO-EUR J SURG ONC, V46, P694, DOI 10.1016/j.ejso.2019.11.516; Di Donato V, 2017, CRIT REV ONCOL HEMAT, V117, P1, DOI 10.1016/j.critrevonc.2017.06.005; Di Donato V, 2017, ANN SURG ONCOL, V24, P1688, DOI 10.1245/s10434-016-5680-7; Dostalek L, 2018, INT J GYNECOL CANCER, V28, P1226, DOI 10.1097/IGC.0000000000001314; Frazer IH, 2009, VIROLOGY, V384, P410, DOI 10.1016/j.virol.2008.10.004; Garland SM, 2016, INT J CANCER, V139, P2812, DOI 10.1002/ijc.30391; Ghelardi A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020083; Ghelardi A, 2018, GYNECOL ONCOL, V151, P229, DOI 10.1016/j.ygyno.2018.08.033; Grzes B., 2011, ONKOL POL, V14, P125; Hildesheim A, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.02.021; Huh WK, 2017, LANCET, V390, P2143, DOI 10.1016/S0140-6736(17)31821-4; Jentschke M, 2020, VACCINE, V38, P6402, DOI 10.1016/j.vaccine.2020.07.055; Joura EA, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1401; Kang WD, 2013, GYNECOL ONCOL, V130, P264, DOI 10.1016/j.ygyno.2013.04.050; Karimi-Zarchi M, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8371-z; Khan MJ, 2014, OBSTET GYNECOL, V123, P1339, DOI 10.1097/AOG.0000000000000287; Kocken M, 2011, LANCET ONCOL, V12, P441, DOI 10.1016/S1470-2045(11)70078-X; Koh WJ, 2019, J NATL COMPR CANC NE, V17, P64, DOI 10.6004/jnccn.2019.0001; Kontopantelis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069930; Lichter K, 2020, OBSTET GYNECOL, V135, P1070, DOI 10.1097/AOG.0000000000003833; Macdonald G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub3; Mariz FC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0165-x; Ortega-Quinonero P, 2019, EUR J GYNAECOL ONCOL, V40, P402, DOI 10.12892/ejgo4628.2019; Petrillo M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010045; Pieralli A, 2018, ARCH GYNECOL OBSTET, V298, P1205, DOI 10.1007/s00404-018-4926-y; Pils S, 2015, CLIN MICROBIOL INFEC, V21, P827, DOI 10.1016/j.cmi.2015.05.001; Priyadarshini M, 2021, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.624092; Radley D, 2016, HUM VACC IMMUNOTHER, V12, P768, DOI 10.1080/21645515.2015.1088616; Saftlas AF, 2015, J REPROD IMMUNOL, V109, P74, DOI 10.1016/j.jri.2015.01.002; Sand FL, 2020, INT J CANCER, V147, P641, DOI 10.1002/ijc.32752; Sankaranarayanan R, 2015, INT J GYNECOL OBSTET, V131, pS33, DOI 10.1016/j.ijgo.2015.02.014; Scott ME, 2013, INT J CANCER, V133, P1187, DOI 10.1002/ijc.28119; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590; Soderlund-Strand A, 2014, J MED VIROL, V86, P634, DOI 10.1002/jmv.23806; Tjalma WAA, 2018, FACTS VIEWS VIS OBGY, V10, P107; Wang RJ, 2020, CANCER LETT, V471, P88, DOI 10.1016/j.canlet.2019.11.039	50	4	4	7	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							410	10.3390/vaccines9050410			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1IU	33919003	Green Published, gold			2022-04-29	WOS:000654580600001
J	Fiorino, F; Pettini, E; Koeberling, O; Ciabattini, A; Pozzi, G; Martin, LB; Medaglini, D				Fiorino, Fabio; Pettini, Elena; Koeberling, Oliver; Ciabattini, Annalisa; Pozzi, Gianni; Martin, Laura B.; Medaglini, Donata			Long-Term Anti-Bacterial Immunity against Systemic Infection by Salmonella enterica Serovar Typhimurium Elicited by a GMMA-Based Vaccine	VACCINES			English	Article						GMMA vaccine; Salmonella Typhimurium; salmonellosis; antibody response; cellular immune response; systemic infection	INVASIVE NONTYPHOIDAL SALMONELLA; DISEASE CURRENT STATUS; GENERALIZED MODULES; MEMBRANE-ANTIGENS; MONOCLONAL-ANTIBODIES; BACTERICIDAL ACTIVITY; O-ANTIGEN; SERUM; MICE; EPIDEMIOLOGY	Salmonella Typhimurium (STm) represents the most prevalent cause of invasive non-typhoidal Salmonella (iNTS) disease, and currently no licensed vaccine is available. In this work we characterized the long-term anti-bacterial immunity elicited by a STm vaccine based on Generalized Modules of Membrane Antigens (GMMA) delivering O:4,5 antigen, using a murine model of systemic infection. Subcutaneous immunization of mice with STmGMMA/Alhydrogel elicited rapid, high, and persistent antigen-specific serum IgG and IgM responses. The serum was bactericidal in vitro. O:4,5-specific IgG were also detected in fecal samples after immunization and positively correlated with IgG observed in intestinal washes. Long-lived plasma cells and O:4,5-specific memory B cells were detected in spleen and bone marrow. After systemic STm challenge, a significant reduction of bacterial load in blood, spleen, and liver, as well as a reduction of circulating neutrophils and G-CSF glycoprotein was observed in STmGMMA/Alhydrogel immunized mice compared to untreated animals. Taken together, these data support the development of a GMMA-based vaccine for prevention of iNTS disease.	[Fiorino, Fabio; Pettini, Elena; Ciabattini, Annalisa; Pozzi, Gianni; Medaglini, Donata] Univ Siena, Dept Med Biotechnol, Lab Mol Microbiol & Biotechnol, I-53100 Siena, Italy; [Koeberling, Oliver; Martin, Laura B.] GSK Vaccines Inst Global Hlth Srl, I-53100 Siena, Italy		Medaglini, D (通讯作者)，Univ Siena, Dept Med Biotechnol, Lab Mol Microbiol & Biotechnol, I-53100 Siena, Italy.; Martin, LB (通讯作者)，GSK Vaccines Inst Global Hlth Srl, I-53100 Siena, Italy.	fiorino4@unisi.it; pettini5@unisi.it; OKoeberl@its.jnj.com; annalisa.ciabattini@unisi.it; gianni.pozzi@unisi.it; laura.b.martin@gsk.com; donata.medaglini@unisi.it	; MEDAGLINI, DONATA/R-1149-2018; POZZI, GIANNI/Q-2713-2018	CIABATTINI, ANNALISA/0000-0002-4585-7783; Fiorino, Fabio/0000-0002-1440-8061; MEDAGLINI, DONATA/0000-0003-1729-7325; POZZI, GIANNI/0000-0002-9557-4714	Regione Toscana, project S-AFRIVAC "Sviluppo di un vaccine contro la Salmonella non tifoide invasiva in Africa" [CUP B62F13000870007]	This study has been carried out with financial support from Regione Toscana, project S-AFRIVAC "Sviluppo di un vaccine contro la Salmonella non tifoide invasiva in Africa", CUP B62F13000870007.	Ao TT, 2015, EMERG INFECT DIS, V21, P941, DOI 10.3201/eid2106.140999; Balasubramanian R, 2019, HUM VACC IMMUNOTHER, V15, P1421, DOI 10.1080/21645515.2018.1504717; COLWELL DE, 1984, J IMMUNOL, V133, P950; Crump JA, 2015, CLIN INFECT DIS, V61, pS235, DOI 10.1093/cid/civ709; Crump JA, 2015, CLIN MICROBIOL REV, V28, P901, DOI 10.1128/CMR.00002-15; Cunningham AE, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00535; Cunningham AF, 2007, J IMMUNOL, V178, P6200, DOI 10.4049/jimmunol.178.10.6200; Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5; Feasey NA, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003748; Feasey NA, 2012, LANCET, V379, P2489, DOI 10.1016/S0140-6736(11)61752-2; Fiorino F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00168; Fiorino F, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00128; Fiorino F, 2012, VACCINE, V30, P6111, DOI 10.1016/j.vaccine.2012.05.081; Gerke C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134478; Gil-Cruz C, 2009, P NATL ACAD SCI USA, V106, P9803, DOI 10.1073/pnas.0812431106; Gilchrist James J, 2019, EcoSal Plus, V8, DOI 10.1128/ecosalplus.ESP-0007-2018; Goh YS, 2015, INFECT IMMUN, V83, P3722, DOI 10.1128/IAI.00547-15; Gondwe EN, 2010, P NATL ACAD SCI USA, V107, P3070, DOI 10.1073/pnas.0910497107; Gordon MA, 2008, J INFECTION, V56, P413, DOI 10.1016/j.jinf.2008.03.012; Gordon MA, 2011, CURR OPIN INFECT DIS, V24, P484, DOI 10.1097/QCO.0b013e32834a9980; Hammarlof DL, 2018, P NATL ACAD SCI USA, V115, pE2614, DOI 10.1073/pnas.1714718115; Haselbeck AH, 2017, CURR OPIN INFECT DIS, V30, P498, DOI 10.1097/QCO.0000000000000398; Kingsley RA, 2009, GENOME RES, V19, P2279, DOI 10.1101/gr.091017.109; Kirk MD, 2015, PLOS MED, V12, DOI [10.1371/journal.pmed.1001921, 10.1371/journal.pmed.1001940]; Kis Z, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201970055; Langereis JD, 2018, J CLIN IMMUNOL, V38, P185, DOI 10.1007/s10875-017-0474-7; Lanzilao L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139847; Launay O, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00335; Launay O, 2017, EBIOMEDICINE, V22, P164, DOI 10.1016/j.ebiom.2017.07.013; Ly KT, 2007, CELL MICROBIOL, V9, P2103, DOI 10.1111/j.1462-5822.2007.00992.x; MacLennan CA, 2008, J CLIN INVEST, V118, P1553, DOI 10.1172/JCI33998; MacLennan CA, 2014, HUM VACC IMMUNOTHER, V10, P1478, DOI 10.4161/hv.29054; MacLennan CA, 2014, P NATL ACAD SCI USA, V111, P12307, DOI 10.1073/pnas.1400473111; MacLennan CA, 2013, SEMIN IMMUNOL, V25, P114, DOI 10.1016/j.smim.2013.05.004; MacLennan CA, 2013, EXPERT REV ANTI-INFE, V11, P443, DOI [10.1586/ERI.13.27, 10.1586/eri.13.27]; MacLennan CA, 2010, SCIENCE, V328, P508, DOI 10.1126/science.1180346; Mancini F, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80421-y; Marshall JL, 2012, J IMMUNOL, V189, P5527, DOI 10.4049/jimmunol.1103166; MASTROENI P, 1993, INFECT IMMUN, V61, P3981, DOI 10.1128/IAI.61.9.3981-3984.1993; Mastroeni P, 2016, EXPERT REV VACCINES, V15, P1545, DOI 10.1080/14760584.2016.1189330; Mastroeni P, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001840; McSorley SJ, 2000, INFECT IMMUN, V68, P3344, DOI 10.1128/IAI.68.6.3344-3348.2000; Medaglini D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00878; Medaglini D, 2018, VACCINE, V36, P1136, DOI 10.1016/j.vaccine.2017.11.069; Meloni E, 2015, J BIOTECHNOL, V198, P46, DOI 10.1016/j.jbiotec.2015.01.020; Micoli F, 2018, P NATL ACAD SCI USA, V115, P10428, DOI 10.1073/pnas.1807655115; Nagy G, 2008, BIOL CHEM, V389, P513, DOI 10.1515/BC.2008.056; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Nyirenda TS, 2014, J INFECT DIS, V210, P56, DOI 10.1093/infdis/jiu045; Obiero CW, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01884; OBRIEN AD, 1980, J IMMUNOL, V124, P20; Pettini E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030289; Pettini E, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01340; Pollard AJ, 2009, NAT REV IMMUNOL, V9, P212, DOI 10.1038/nri2494; Rappuoli R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003826; ROBBINS JB, 1965, J EXP MED, V122, P385, DOI 10.1084/jem.122.2.385; Rondini S, 2015, INFECT IMMUN, V83, P996, DOI 10.1128/IAI.03079-14; Rondini S, 2013, MICROB PATHOGENESIS, V63, P19, DOI 10.1016/j.micpath.2013.05.014; Rossi O, 2016, CLIN VACCINE IMMUNOL, V23, P304, DOI 10.1128/CVI.00023-16; Rossi O, 2014, J BIOL CHEM, V289, P24922, DOI 10.1074/jbc.M114.566570; SAXEN H, 1984, J GEN MICROBIOL, V130, P2277; SAXEN H, 1982, IMMUNOL LETT, V5, P267, DOI 10.1016/0165-2478(82)90110-9; Scorza FB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035616; Secundino I, 2006, IMMUNOLOGY, V117, P59, DOI 10.1111/j.1365-2567.2005.02263.x; Simon R, 2012, HUM VACC IMMUNOTHER, V8, P494, DOI 10.4161/hv.19158; Song JM, 2010, CELL HOST MICROBE, V8, P369, DOI 10.1016/j.chom.2010.09.003; Stanaway JD, 2019, LANCET INFECT DIS, V19, P1312, DOI 10.1016/S1473-3099(19)30418-9; SVENSON SB, 1979, INFECT IMMUN, V25, P863, DOI 10.1128/IAI.25.3.863-872.1979; Szu SC, 2014, VACCINE, V32, P2359, DOI 10.1016/j.vaccine.2014.02.050; Tennant SM, 2016, VACCINE, V34, P2907, DOI 10.1016/j.vaccine.2016.03.072; Trammell RA, 2011, COMPARATIVE MED, V61, P492; Trebicka E, 2013, CLIN VACCINE IMMUNOL, V20, P1491, DOI 10.1128/CVI.00289-13; Uche Ifeanyi Valentine, 2017, PLoS Negl Trop Dis, V11, pe0005118, DOI 10.1371/journal.pntd.0005118; Uppington H, 2006, IMMUNOLOGY, V119, P147, DOI 10.1111/j.1365-2567.2006.02416.x	74	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							495	10.3390/vaccines9050495			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1LC	34065899	gold, Green Published			2022-04-29	WOS:000654586600001
J	Harris, PE; Brasel, T; Massey, C; Herst, CV; Burkholz, S; Lloyd, P; Blankenberg, T; Bey, TM; Carback, R; Hodge, T; Ciotlos, S; Wang, L; Comer, JE; Rubsamen, RM				Harris, Paul E.; Brasel, Trevor; Massey, Christopher; Herst, C. V.; Burkholz, Scott; Lloyd, Peter; Blankenberg, Tikoes; Bey, Thomas M.; Carback, Richard; Hodge, Thomas; Ciotlos, Serban; Wang, Lu; Comer, Jason E.; Rubsamen, Reid M.			A Synthetic Peptide CTL Vaccine Targeting Nucleocapsid Confers Protection from SARS-CoV-2 Challenge in Rhesus Macaques	VACCINES			English	Article						SARS-CoV-2; animal model; macaque; vaccine; MHC class I peptide; T cell	T-LYMPHOCYTE RESPONSES; NF-KAPPA-B; THORACIC RADIOGRAPHY; GENE-EXPRESSION; VIRUS-VACCINE; CLASS-I; DISEASE; ACTIVATION; SIGNATURES; COVID-19	Background: Persistent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has given rise to a COVID-19 pandemic. Several vaccines, conceived in 2020, that evoke protective spike antibody responses are being deployed in mass public health vaccination programs. Recent data suggests, however, that as sequence variation in the spike genome accumulates, some vaccines may lose efficacy. Methods: Using a macaque model of SARS-CoV-2 infection, we tested the efficacy of a peptide-based vaccine targeting MHC class I epitopes on the SARS-CoV-2 nucleocapsid protein. We administered biodegradable microspheres with synthetic peptides and adjuvants to rhesus macaques. Unvaccinated control and vaccinated macaques were challenged with 1 x 10(8) TCID50 units of SARS-CoV-2, followed by assessment of clinical symptoms and viral load, chest radiographs, and sampling of peripheral blood and bronchoalveolar lavage (BAL) fluid for downstream analysis. Results: Vaccinated animals were free of pneumonia-like infiltrates characteristic of SARS-CoV-2 infection and presented with lower viral loads relative to controls. Gene expression in cells collected from BAL samples of vaccinated macaques revealed a unique signature associated with enhanced development of adaptive immune responses relative to control macaques. Conclusions: We demonstrate that a room temperature stable peptide vaccine based on known immunogenic HLA class I bound CTL epitopes from the nucleocapsid protein can provide protection against SARS-CoV-2 infection in nonhuman primates.	[Harris, Paul E.] Columbia Univ, Dept Med, P&S 10-502,650 West 168th St, New York, NY 10032 USA; [Brasel, Trevor; Massey, Christopher; Comer, Jason E.] Univ Texas Med Branch, Dept Microbiol & Immunol, 301 Univ Blvd, Galveston, TX 77555 USA; [Herst, C. V.; Burkholz, Scott; Lloyd, Peter; Blankenberg, Tikoes; Carback, Richard; Hodge, Thomas; Ciotlos, Serban; Wang, Lu; Rubsamen, Reid M.] Flow Pharma Inc, 4829 Galaxy Pkwy,Suite K, Warrensville Hts, OH 44128 USA; [Blankenberg, Tikoes; Bey, Thomas M.] Dign Hlth Mercy Med Ctr, Redding, CA 96001 USA; [Rubsamen, Reid M.] Univ Hosp, Cleveland Med Ctr, Case Western Reserve Sch Med, Dept Anesthesiol & Perioperat Med, Cleveland, OH 44106 USA; [Rubsamen, Reid M.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 96001 USA		Comer, JE (通讯作者)，Univ Texas Med Branch, Dept Microbiol & Immunol, 301 Univ Blvd, Galveston, TX 77555 USA.; Rubsamen, RM (通讯作者)，Flow Pharma Inc, 4829 Galaxy Pkwy,Suite K, Warrensville Hts, OH 44128 USA.; Rubsamen, RM (通讯作者)，Univ Hosp, Cleveland Med Ctr, Case Western Reserve Sch Med, Dept Anesthesiol & Perioperat Med, Cleveland, OH 44106 USA.; Rubsamen, RM (通讯作者)，Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 96001 USA.	peh1@cumc.columbia.edu; trbrasel@utmb.edu; chmassey@utmb.edu; cvherst@flowpharma.com; sburkholz@flowpharma.com; plloyd@flowpharma.com; teakb@aol.com; docbey@gmail.com; rcarback@flowpharma.com; thodge@flowpharma.com; sciotlos@flowpharma.com; lwang@flowpharma.com; jscomer@utmb.edu; reid.rubsamen@UHHospitals.org		Carback, Richard/0000-0002-2330-6323			Aid M, 2020, CELL, V183, P1354, DOI 10.1016/j.cell.2020.10.005; Almazan F, 2004, J VIROL, V78, P12683, DOI 10.1128/JVI.78.22.12683-12688.2004; Amati F, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05143; An HZ, 2002, IMMUNOL LETT, V81, P165, DOI 10.1016/S0165-2478(02)00010-X; Blair RV, 2021, AM J PATHOL, V191, P274, DOI 10.1016/j.ajpath.2020.10.016; Bray M, 2001, J COMP PATHOL, V125, P243, DOI 10.1053/jcpa.2001.0503; Brining DL, 2010, COMPARATIVE MED, V60, P389; Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; CHIN J, 1969, AM J EPIDEMIOL, V89, P449, DOI 10.1093/oxfordjournals.aje.a120957; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Cunha-Neto E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00640; Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343; Dhiman N, 2003, SCAND J INFECT DIS, V35, P332, DOI 10.1080/00365540310007105; Dimonte S, 2021, PUBLIC HEALTH GENOM, V24, P54, DOI 10.1159/000513530; Fahlberg MD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19967-4; Feng LQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18077-5; Finch Courtney L, 2020, bioRxiv, DOI 10.1101/2020.05.14.096727; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Fukami-Kobayashi K, 2005, P NATL ACAD SCI USA, V102, P9230, DOI 10.1073/pnas.0500770102; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Georas SN, 2005, EUR RESPIR J, V26, P1119, DOI 10.1183/09031936.05.00006005; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002; Guebre-Xabier M, 2020, VACCINE, V38, P7892, DOI 10.1016/j.vaccine.2020.10.064; Herst CV, 2020, VACCINE, V38, P4464, DOI 10.1016/j.vaccine.2020.04.034; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893; Kared H, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145476; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Lampe AT, 2020, CELL IMMUNOL, V355, DOI 10.1016/j.cellimm.2020.104149; Lin L, 2004, SCIENCE, V303, P1017, DOI 10.1126/science.1093889; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Lu SY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00269-6; McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Mosca F, 2008, P NATL ACAD SCI USA, V105, P10501, DOI 10.1073/pnas.0804699105; Mothe BR, 2013, IMMUNOGENETICS, V65, P371, DOI 10.1007/s00251-013-0686-9; Mukhopadhyay L, 2021, INDIAN J MED RES, V153, P93, DOI 10.4103/ijmr.IJMR_4431_20; Munster VJ, 2020, NATURE, V585, P268, DOI 10.1038/s41586-020-2324-7; Olafsdottir T, 2015, VACCINE, V33, P5302, DOI 10.1016/j.vaccine.2015.04.099; Peng H, 2006, VIROLOGY, V351, P466, DOI 10.1016/j.virol.2006.03.036; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Poran A, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00767-w; Qin E, 2003, CHINESE SCI BULL, V48, P941, DOI 10.1007/BF03184203; Rabenstein H, 2014, J IMMUNOL, V192, P3507, DOI 10.4049/jimmunol.1302725; Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005; Rakhra K, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abd8003; Ramakrishnan Muthannan Andavar, 2016, World J Virol, V5, P85, DOI 10.5501/wjv.v5.i2.85; RAUH LW, 1965, AM J DIS CHILD, V109, P232, DOI 10.1001/archpedi.1965.02090020234007; Ravi RK, 2018, METHODS MOL BIOL, V1706, P223, DOI 10.1007/978-1-4939-7471-9_12; Ritchie H, CORONAVIRUS COVID 19; Rubsamen RM, 2014, VACCINE, V32, P4111, DOI 10.1016/j.vaccine.2014.05.071; Salguero FJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21389-9; Salyer ACD, 2018, HUM VACC IMMUNOTHER, V14, P1686, DOI 10.1080/21645515.2018.1480284; Shan C, 2020, CELL RES, V30, P670, DOI 10.1038/s41422-020-0364-z; SILVERMAN S, 1980, AM J VET RES, V41, P1704; Singh D.K., 2020, SARS COV 2 INFECT LE, DOI [10.1101/2020.06.05.136481, DOI 10.1101/2020.06.05.136481V1]; Singh DK, 2021, NAT MICROBIOL, V6, P73, DOI 10.1038/s41564-020-00841-4; Song TZ, 2020, ZOOL RES, V41, P503, DOI 10.24272/j.issn.2095-8137.2020.202; Stammes J, 2021, BRONCHOALVEOLAR LEVA, DOI [10.1101/2021.02.04.429761, DOI 10.1101/2021.02.04.429761]; Tjan LH, 2021, J INFECT DIS, V223, P1145, DOI 10.1093/infdis/jiab005; Trobaugh DW, 2010, EUR J IMMUNOL, V40, P1315, DOI 10.1002/eji.200839108; Uhlen M, 2019, SCIENCE, V366, P1471, DOI 10.1126/science.aax9198; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; van Doremalen Neeltje, 2021, bioRxiv, DOI 10.1101/2021.01.09.426058; van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wu KL, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0087588, 10.1371/journal.pone.0110033, 10.1371/journal.pone.0103267, 10.1371/journal.pone.0091910, 10.1371/journal.pone.0099366, 10.1371/journal.pone.0095536, 10.1371/journal.pone.0096514, 10.1371/journal.pone.0113637, 10.1371/journal.pone.0103480, 10.1371/journal.pone.0093049, 10.1371/journal.pone.0103535, 10.1371/journal.pone.0095422, 10.1371/journal.pone.0105072, 10.1371/journal.pone.0107196, 10.1371/journal.pone.0087348]; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Yu P, 2020, ANIM MODEL EXP MED, V3, P93, DOI 10.1002/ame2.12108; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zheng HW, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008949; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	79	5	5	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							520	10.3390/vaccines9050520			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1LF	34070152	gold, Green Published, Green Submitted			2022-04-29	WOS:000654586900001
J	Yang, JR; Firdaus, F; Azuar, A; Khalil, ZG; Marasini, N; Capon, RJ; Hussein, WM; Toth, I; Skwarczynski, M				Yang, Jieru; Firdaus, Farrhana; Azuar, Armira; Khalil, Zeinab G.; Marasini, Nirmal; Capon, Robert J.; Hussein, Waleed M.; Toth, Istvan; Skwarczynski, Mariusz			Cell-Penetrating Peptides-Based Liposomal Delivery System Enhanced Immunogenicity of Peptide-Based Vaccine against Group A Streptococcus	VACCINES			English	Article						cell-penetrating peptide; vaccine delivery; peptide-based vaccine; liposomes; group A streptococcus	CROSS-REACTIVE EPITOPES; M-PROTEIN; T-CELL; CANDIDATES; NANOPARTICLES; PATHOGENESIS; ANTIBODIES; INDUCTION; MECHANISM; MULTIPLE	Peptide-based vaccine development represents a highly promising strategy for preventing Group A Streptococcus (GAS) infection. However, these vaccines need to be administered with the help of a delivery system and/or immune adjuvant. Cell-penetrating peptides (CPPs) have been used as a powerful tool for delivering various therapeutic agents, including peptides, as they can overcome the permeability barrier of cell membranes. Here, we used CPPs to deliver our lead lipopeptide-based vaccine (LCP-1). CPPs were anchored through a spacer to LCP-1-bearing multilamellar and unilamellar liposomes and administered to Swiss outbred mice. Tat(47-57) conjugated to two palmitic acids via a (Gly)(6) spacer (to form a liposome-anchoring moiety) was the most efficient system for triggering immune responses when combined with multilamellar liposomes bearing LCP-1. The immunostimulatory potential of a variety of other CPPs was examined following intranasal administration in mice. Among them, LCP-1/liposomes/Tat(47-57) and LCP-1/liposomes/KALA induced the highest antibody titers. The antibodies produced showed high opsonic activity against clinically isolated GAS strains D3840 and GC2 203. The use of the CPP-liposome delivery system is a promising strategy for liposome-based GAS vaccine development.	[Yang, Jieru; Firdaus, Farrhana; Azuar, Armira; Hussein, Waleed M.; Toth, Istvan; Skwarczynski, Mariusz] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia; [Khalil, Zeinab G.; Capon, Robert J.; Toth, Istvan] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; [Marasini, Nirmal] Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; [Toth, Istvan] Univ Queensland, Sch Pharm, Woolloongabba, Qld 4102, Australia		Skwarczynski, M (通讯作者)，Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia.	j.yang@uq.net.au; farrhana.firdaus@uq.net.au; armira.azuar@uq.net.au; z.khalil@uq.edu.au; n.marasini@uq.edu.au; r.capon@imb.uq.edu.au; w.hussein@uq.edu.au; i.toth@uq.edu.au; m.skwarczynski@uq.edu.au	Skwarczynski, Mariusz/A-6707-2009; Marasini, Nirmal/A-4828-2017; Khalil, Zeinab/J-2150-2014	Skwarczynski, Mariusz/0000-0001-7257-807X; Marasini, Nirmal/0000-0002-1958-2050; Khalil, Zeinab/0000-0002-9285-1720; Azuar, Armira/0000-0002-5140-4297; Hussein, Waleed/0000-0001-5392-1880	National Health and Medical Research Council, Australia (NHMRC)National Health and Medical Research Council (NHMRC) of Australia [APP1132975]; University of Queensland, AustraliaUniversity of Queensland	This research was funded by National Health and Medical Research Council, Australia (NHMRC, APP1132975) and The University of Queensland, Australia.	Azmi F, 2014, HUM VACC IMMUNOTHER, V10, P778, DOI 10.4161/hv.27332; Azuar A, 2019, ACS MED CHEM LETT, V10, P1253, DOI 10.1021/acsmedchemlett.9b00239; Azuar A, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030058; Bahadoran A, 2017, INT J NANOMED, V12, P8573, DOI 10.2147/IJN.S139126; Bartlett S, 2020, CURR MED CHEM, V27, P2887, DOI 10.2174/0929867325666181026100849; Bashiri S, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12100965; Bauer MJ, 2012, VACCINE, V30, P2197, DOI 10.1016/j.vaccine.2011.12.115; Berditsch M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54212-z; Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X; Carapetis JR, 1999, CLIN INFECT DIS, V28, P205, DOI 10.1086/515114; Chan A, 2016, BIOORGAN MED CHEM, V24, P3095, DOI 10.1016/j.bmc.2016.03.063; Chen J, 2017, TOPICS CURR CHEM, V375, DOI 10.1007/s41061-017-0115-x; Chen XF, 2018, ADV DRUG DELIVER REV, V127, P85, DOI 10.1016/j.addr.2017.12.014; Coelho Mota C.C., 2010, PAEDIAT CARDIOLOGY, V3rd ed., P1091; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; CUNNINGHAM MW, 1989, J IMMUNOL, V143, P2677; Dale JB, 2013, VACCINE, V31, pB216, DOI 10.1016/j.vaccine.2012.09.045; DALE JB, 1985, J EXP MED, V161, P113, DOI 10.1084/jem.161.1.113; DALE JB, 1986, J EXP MED, V164, P1785, DOI 10.1084/jem.164.5.1785; Dale JB, 2016, STREPTOCOCCUS PYOGEN; Daudey GA, 2017, LANGMUIR, V33, P12443, DOI 10.1021/acs.langmuir.7b02931; Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0; Ebino K, 1999, INHAL TOXICOL, V11, P171, DOI 10.1080/089583799197131; Faruck MO, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010023; Freichel T, 2019, RSC ADV, V9, P23484, DOI 10.1039/c9ra05497a; Fyler D.C., 2006, NADAS PEDIAT CARDIOL, P387; Ghaffar KA, 2017, MED CHEM, V13, P22, DOI 10.2174/1573406412666160720093138; Ghaffar KA, 2016, ACTA BIOMATER, V41, P161, DOI 10.1016/j.actbio.2016.04.012; Good MF, 2015, EXPERT REV VACCINES, V14, P1459, DOI 10.1586/14760584.2015.1081817; Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4; Henningham A, 2012, DISCOV MED, V13, P329; Huang HC, 2018, ANTIVIR RES, V150, P69, DOI 10.1016/j.antiviral.2017.12.009; Hussein WM, 2019, NANOTECHNOLOGY, V30, DOI 10.1088/1361-6528/ab313d; Ji ZH, 2017, BIOMATERIALS, V128, P8, DOI 10.1016/j.biomaterials.2017.03.007; Khan M, 2012, VIRUS RES, V167, P236, DOI 10.1016/j.virusres.2012.05.004; Kunnapuu K, 2019, FASEB BIOADV, V1, P105, DOI 10.1096/fba.1026; Kwak HW, 2019, VACCINE, V37, P5191, DOI 10.1016/j.vaccine.2019.07.070; Lin X, 2021, CHEM-EUR J, V27, P3130, DOI 10.1002/chem.202004665; Liu BR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150439; Madani Fatemeh, 2011, J Biophys, V2011, P414729, DOI 10.1155/2011/414729; Marasini N, 2016, NANOMEDICINE-UK, V11, P3223, DOI 10.2217/nnm-2016-0291; Marasini N, 2016, INT J PHARMACEUT, V513, P410, DOI 10.1016/j.ijpharm.2016.09.057; MASSELL BF, 1969, J AMER MED ASSOC, V207, P1115, DOI 10.1001/jama.207.6.1115; Miller MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031359; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Muto K, 2016, J PHARM SCI-US, V105, P2014, DOI 10.1016/j.xphs.2016.03.026; Muttenthaler M, 2015, NAT PROTOC, V10, P1067, DOI 10.1038/nprot.2015.061; Nevagi RJ, 2019, EUR POLYM J, V114, P397, DOI 10.1016/j.eurpolymj.2019.03.009; NevagiRJ TothI, 2018, PEPTIDE APPL BIOMEDI, P327; PRUKSAKORN S, 1992, J IMMUNOL, V149, P2729; Radis-Baptista G, 2017, J BIOTECHNOL, V252, P15, DOI 10.1016/j.jbiotec.2017.05.002; Sekuloski S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198658; Shakya AK, 2016, J CONTROL RELEASE, V240, P394, DOI 10.1016/j.jconrel.2016.02.014; Shi ST, 2019, VACCINE, V37, P3167, DOI 10.1016/j.vaccine.2019.04.055; Skwarczynski M, 2020, EXPERT OPIN DRUG DEL, V17, P435, DOI 10.1080/17425247.2020.1731468; Skwarczynski M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax2285; Skwarczynski M, 2010, ANGEW CHEM INT EDIT, V49, P5742, DOI 10.1002/anie.201002221; Southam DS, 2002, AM J PHYSIOL-LUNG C, V282, pL833, DOI 10.1152/ajplung.00173.2001; Stupak E, 1997, U.S. Patent, Patent No. [5,679,356, 5679356]; Tang J, 2012, VACCINE, V30, P1071, DOI 10.1016/j.vaccine.2011.12.029; Watkins DA, 2017, NEW ENGL J MED, V377, P713, DOI 10.1056/NEJMoa1603693; Yang JR, 2019, CURR DRUG DELIV, V16, P430, DOI 10.2174/1567201816666190123120915; Yang Z, 2008, MOL IMMUNOL, V45, P1674, DOI 10.1016/j.molimm.2007.10.026; Zaman M, 2011, NANOMED-NANOTECHNOL, V7, P168, DOI 10.1016/j.nano.2010.10.002; Zha H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216163; Zhao B, 2019, IMMUNOL LETT, V213, P1, DOI 10.1016/j.imlet.2019.07.002; Zhao LL, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10050823; Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010	68	3	3	4	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							499	10.3390/vaccines9050499			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1JL	34066099	gold, Green Published			2022-04-29	WOS:000654582300001
J	Donofrio, G; Franceschi, V; Macchi, F; Russo, L; Rocci, A; Marchica, V; Costa, F; Giuliani, N; Ferrari, C; Missale, G				Donofrio, Gaetano; Franceschi, Valentina; Macchi, Francesca; Russo, Luca; Rocci, Anna; Marchica, Valentina; Costa, Federica; Giuliani, Nicola; Ferrari, Carlo; Missale, Gabriele			A Simplified SARS-CoV-2 Pseudovirus Neutralization Assay	VACCINES			English	Article						SARS-CoV-2; COVID-19; neutralizing antibody; pseudovirus; neutralization assay	RESPIRATORY SYNDROME CORONAVIRUS; SPIKE PROTEIN; ACE2; SARS; RNA	COVID-19 is an ongoing pandemic caused by the highly infectious coronavirus SARS-CoV-2 that is engaging worldwide scientific research to find a timely and effective eradication strategy. Great efforts have been put into anti-COVID-19 vaccine generation in an effort to protect the world population and block SARS-CoV-2 spread. To validate the protective efficacy of the vaccination campaign and effectively control the pandemic, it is necessary to quantify the induction of neutralizing antibodies by vaccination, as they have been established to be a correlate of protection. In this work, a SARS-CoV-2 pseudovirus neutralization assay, based on a replication-incompetent lentivirus expressing an adapted form of CoV-2 S protein and an ACE2/TMPRSS2 stably expressing cell line, has been minimized in terms of protocol steps without loss of accuracy. The goal of the present simplified neutralization system is to improve SARS-CoV-2 vaccination campaign by means of an easy and accessible approach to be performed in any medical laboratory, maintaining the sensitivity and quantitative reliability of classical serum neutralization assays. Further, this assay can be easily adapted to different coronavirus variants by simply modifying the pseudotyping vector.	[Donofrio, Gaetano; Franceschi, Valentina; Macchi, Francesca; Russo, Luca] Univ Parma, Dept Med Vet Sci, I-43126 Parma, Italy; [Rocci, Anna] Azienda Osped Univ Parma, Unit Angiol & Internal Med, I-43126 Parma, Italy; [Marchica, Valentina; Costa, Federica; Giuliani, Nicola; Ferrari, Carlo; Missale, Gabriele] Univ Parma, Dept Med & Surg, I-43126 Parma, Italy; [Marchica, Valentina; Costa, Federica] Azienda Osped Univ Parma, Unit Hematol, I-43126 Parma, Italy; [Ferrari, Carlo; Missale, Gabriele] Azienda Osped Univ Parma, Unit Infect Dis & Hepatol, Lab Viral Immunopathol, I-43126 Parma, Italy		Donofrio, G (通讯作者)，Univ Parma, Dept Med Vet Sci, I-43126 Parma, Italy.	gaetano.donofrio@unipr.it; valentina.franceschi@unipr.it; francesca.macchi@unipr.it; luca.russo@unipr.it; arocci@ao.pr.it; valentina.marchica@unipr.it; federica.costa@unipr.it; nicola.giuliani@unipr.it; carlo.ferrari@unipr.it; gabriele.missale@unipr.it	Marchica, Valentina/AAB-9869-2022; Costa, Federica/K-4754-2018	Marchica, Valentina/0000-0002-8536-5409; Giuliani, Nicola/0000-0003-3457-3774; Russo, Luca/0000-0003-4706-2105; Costa, Federica/0000-0002-1742-9212; franceschi, valentina/0000-0003-3945-2285			Bonam SR, 2021, NANO TODAY, V36, DOI 10.1016/j.nantod.2020.101051; Buchrieser J, 2020, EMBO J, V39, DOI 10.15252/embj.2020106267; Bussani R, 2020, EBIOMEDICINE, V61, DOI 10.1016/j.ebiom.2020.103104; Callaway E, 2020, NATURE, V580, P576, DOI 10.1038/d41586-020-01221-y; Case JB, 2020, CELL HOST MICROBE, V28, P475, DOI 10.1016/j.chom.2020.06.021; Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513; Franks TJ, 2003, HUM PATHOL, V34, P743, DOI 10.1016/S0046-8177(03)00367-8; Giroglou T, 2004, J VIROL, V78, P9007, DOI 10.1128/JVI.78.17.9007-9015.2004; Gustafsson C, 2004, TRENDS BIOTECHNOL, V22, P346, DOI 10.1016/j.tibtech.2004.04.006; Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105; Han QM, 2020, J INFECTION, V80, P373, DOI 10.1016/j.jinf.2020.02.010; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Iacob S, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01224; Jouvenet N, 2006, PLOS BIOL, V4, P2296, DOI 10.1371/journal.pbio.0040435; Kellam P, 2020, J GEN VIROL, V101, P791, DOI 10.1099/jgv.0.001439; Kudla G, 2006, PLOS BIOL, V4, P933, DOI 10.1371/journal.pbio.0040180; Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0; Lin Kaili, 2020, J Biosaf Biosecur, V2, P99, DOI 10.1016/j.jobb.2020.08.001; Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10; Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Qian ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076469; Ujike M, 2016, J GEN VIROL, V97, P1853, DOI 10.1099/jgv.0.000494; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x; Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762; Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035	29	5	5	7	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							389	10.3390/vaccines9040389			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4TA	33920999	Green Submitted, Green Published, gold			2022-04-29	WOS:000643772300001
J	Ko, E; Jeong, S; Jwa, MY; Kim, AR; Ha, YE; Kim, SK; Jeong, S; Ahn, KB; Seo, HS; Yun, CH; Han, SH				Ko, Eunbyeol; Jeong, Soyoung; Jwa, Min Yong; Kim, A. Reum; Ha, Ye-Eun; Kim, Sun Kyung; Jeong, Sungho; Ahn, Ki Bum; Seo, Ho Seong; Yun, Cheol-Heui; Han, Seung Hyun			Immune Responses to Irradiated Pneumococcal Whole Cell Vaccine	VACCINES			English	Article						Streptococcus pneumoniae; gamma-irradiation; whole-cell vaccine; intranasal immunization; immune responses	STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; INTRANASAL IMMUNIZATION; GAMMA-IRRADIATION; VIRULENCE FACTORS; DENDRITIC CELLS; POLYSACCHARIDE; COLONIZATION; PNEUMOLYSIN; ACTIVATION	Streptococcus pneumoniae (pneumococcus) can cause respiratory and systemic diseases. Recently, gamma-irradiation-inactivated, non-encapsulated, intranasal S. pneumoniae (r-SP) vaccine has been introduced as a novel serotype-independent and cost-effective vaccine. However, the immunogenic mechanism of r-SP is poorly understood. Here, we comparatively investigated the protective immunity and immunogenicity of r-SP to the heat-(h-SP) or formalin-inactivated vaccine (f-SP) without adjuvants. Mice were intranasally immunized with each vaccine three times and then challenged with a lethal dose of S. pneumoniae TIGR4 strain and then subsequently evaluated for their immune responses. Immunization with r-SP elicited modestly higher protection against S. pneumoniae than h-SP or f-SP. Immunization with r-SP enhanced pneumococcal-specific IgA in the nasal wash and IgG in bronchoalveolar lavage fluid. Immunization with r-SP enhanced S. pneumoniae-specific IgG, IgG1, and IgG2b in the serum. r-SP more potently induced the maturation of dendritic cells in the cervical lymph nodes than h-SP or f-SP. Interestingly, populations of follicular helper T cells and IL-4-producing cells were potently increased in cervical lymph nodes of r-SP-immunized mice. Collectively, r-SP could be an effective intranasal, inactivated whole-cell vaccine in that it elicits S. pneumoniae-specific antibody production and follicular helper T cell activation leading to protective immune responses against S. pneumoniae infection.	[Ko, Eunbyeol; Jeong, Soyoung; Jwa, Min Yong; Kim, A. Reum; Ha, Ye-Eun; Kim, Sun Kyung; Jeong, Sungho; Han, Seung Hyun] Seoul Natl Univ, Sch Dent, Dept Oral Microbiol & Immunol, Seoul 08826, South Korea; [Ko, Eunbyeol; Jeong, Soyoung; Jwa, Min Yong; Kim, A. Reum; Ha, Ye-Eun; Kim, Sun Kyung; Jeong, Sungho; Han, Seung Hyun] Seoul Natl Univ, Sch Dent, DRI, Seoul 08826, South Korea; [Ahn, Ki Bum; Seo, Ho Seong] Korea Atom Energy Res Inst, Radiat Res Div, Jeongeup 56212, South Korea; [Seo, Ho Seong] Univ Sci & Technol, Dept Radiat Biotechnol & Appl Radioisotope Sci, Daejeon 34113, South Korea; [Yun, Cheol-Heui] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 08826, South Korea; [Yun, Cheol-Heui] Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul 08826, South Korea		Han, SH (通讯作者)，Seoul Natl Univ, Sch Dent, Dept Oral Microbiol & Immunol, Seoul 08826, South Korea.; Han, SH (通讯作者)，Seoul Natl Univ, Sch Dent, DRI, Seoul 08826, South Korea.	whitebmilk@snu.ac.kr; syjeong94@snu.ac.kr; myou72j@snu.ac.kr; kimareum@snu.ac.kr; pure9502@naver.com; burnedpooh@gmail.com; ssgd33@snu.ac.kr; ahnkb@kaeri.re.kr; hoseongseo@kaeri.re.kr; cyun@snu.ac.kr; shhan-mi@snu.ac.kr		Han, Seung Hyun/0000-0001-9418-9278; YUN, Cheol-Heui/0000-0002-0041-2887; Seo, Ho Seong/0000-0002-7103-1344; Kim, A Reum/0000-0003-4246-4316; Ko, Eunbyeol/0000-0001-9569-6976	National Research Foundation of Korea - Korean governmentNational Research Foundation of KoreaKorean Government [NRF-2015M2A2A6A01044894, NRF-2018R1A5A2024418, NRF-2019R1A2C2007041]	This work was supported by grants from the National Research Foundation of Korea, which is funded by the Korean government (NRF-2015M2A2A6A01044894, NRF-2018R1A5A2024418, and NRF-2019R1A2C2007041).	Alloing G, 1998, MOL MICROBIOL, V29, P75, DOI 10.1046/j.1365-2958.1998.00904.x; Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7; Brooks LRK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01366; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Datta SK, 2006, IMMUNITY, V25, P143, DOI 10.1016/j.immuni.2006.05.013; de Roux A, 2008, CLIN INFECT DIS, V46, P1015, DOI 10.1086/529142; Fan YC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004167; Finkelstein JA, 2003, PEDIATRICS, V112, P862, DOI 10.1542/peds.112.4.862; Gaidamakova EK, 2012, CELL HOST MICROBE, V12, P117, DOI 10.1016/j.chom.2012.05.011; Gray C, 2014, MUCOSAL IMMUNOL, V7, P705, DOI 10.1038/mi.2013.89; Hvalbye BKR, 1999, INFECT IMMUN, V67, P4320, DOI 10.1128/IAI.67.9.4320-4325.1999; Hyams C, 2010, INFECT IMMUN, V78, P704, DOI 10.1128/IAI.00881-09; INGRAM LO, 1990, CRIT REV BIOTECHNOL, V9, P305; Inzana TJ, 2007, CLIN VACCINE IMMUNOL, V14, P323, DOI 10.1128/CVI.00302-06; Jedrzejas MJ, 2001, MICROBIOL MOL BIOL R, V65, P187, DOI 10.1128/MMBR.65.2.187-207.2001; Johnson HL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000348; Jwa MY, 2018, MICROB PATHOGENESIS, V124, P38, DOI 10.1016/j.micpath.2018.08.015; Jwa MY, 2018, J MICROBIOL, V56, P579, DOI 10.1007/s12275-018-8347-1; Kadioglu A, 2002, INFECT IMMUN, V70, P2886, DOI 10.1128/IAI.70.6.2886-2890.2002; Kadioglu A, 2008, NAT REV MICROBIOL, V6, P288, DOI 10.1038/nrmicro1871; Kim HY, 2018, MOL IMMUNOL, V101, P344, DOI 10.1016/j.molimm.2018.07.023; Linares J, 2010, CLIN MICROBIOL INFEC, V16, P402, DOI 10.1111/j.1469-0691.2010.03182.x; Ma CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994; Magnani DM, 2009, INFECT IMMUN, V77, P5181, DOI 10.1128/IAI.00231-09; Miller MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031359; Moffitt KL, 2011, CURR OPIN IMMUNOL, V23, P407, DOI 10.1016/j.coi.2011.04.002; Musher DM, 2010, J INFECT DIS, V201, P516, DOI 10.1086/649839; Ndlangisa K, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01149-17; Pace JL, 1998, VACCINE, V16, P1563, DOI 10.1016/S0264-410X(98)00046-2; Plotkin SA, 2005, NAT MED, V11, pS5, DOI 10.1038/nm1209; Pollard AJ, 2009, NAT REV IMMUNOL, V9, P212, DOI 10.1038/nri2494; Seo HS, 2015, CLIN EXP VACCINE RES, V4, P145, DOI 10.7774/cevr.2015.4.2.145; Seo HS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001047; Silva-Carvalho R, 2019, TOXICOL RES-GER, V35, P45, DOI 10.5487/TR.2019.35.1.045; Steinman RM, 2006, CURR TOP MICROBIOL, V311, P17; Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7; Wuerth BA, 2016, EMERG INFECT DIS, V22, P1624, DOI 10.3201/eid2209.150680; Xu XY, 2014, J MICROBIOL, V52, P315, DOI 10.1007/s12275-014-3583-5; Yamamoto T, 2000, JPN J INFECT DIS, V53, P181; Zapotoczna M, 2015, J INFECT DIS, V212, P1883, DOI 10.1093/infdis/jiv319	41	0	0	8	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							405	10.3390/vaccines9040405			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4UY	33921842	Green Published, gold			2022-04-29	WOS:000643777300001
J	Kwon, Y; Choe, YJ; Yun, JW; Kim, HK; Kim, S; Chun, C; Jung, YH; Kim, H; Oh, HK; Lee, Y; Lee, JY; Lee, SK; Park, YJ				Kwon, Yunhyung; Choe, Young June; Yun, Jae-Won; Kim, Hee Kyoung; Kim, Sungnam; Chun, Chaemin; Jung, Yeon Haw; Kim, HeeJung; Oh, Hyun-kyung; Lee, Yeonkyoeng; Lee, Jae Young; Lee, Seon Kui; Park, Young-Joon			Impact of Media Coverage on Influenza Vaccine Coverage in Elderly Individuals from 2020 to 2021 in the Republic of Korea	VACCINES			English	Article						influenza; vaccine; vaccination; safety; death; mortality		Increased awareness of adverse events following immunization (AEFI) can disrupt vaccination programs. In South Korea, a report of alleged influenza vaccine-related deaths attracted significant media attention in 2020. We retrieved the vaccination coverage and AEFI data to determine their association with media coverage. Between 2015 and 2019, the vaccination coverage rate ranged between 80.5% and 83.3%; however, the vaccination coverage rate declined significantly from 2020 to 2021 to 73.6% (p < 0.0001). During the 43rd week of 2020, following a large amount of media coverage on vaccine safety issues, the number of cases with AEFI reached 60. Between 2015 and 2020, the mortality rate ratios for influenza vaccines and non-vaccines ranged between 0.1296 (95% confidence interval (CI), 0.1262-0.1331, p < 0.0001) and 0.1608 (95% CI, 0.1572-0.1644, p < 0.0001). Vaccine safety surveillance should be continued in conjunction with investigation and transparent risk communication to maintain public trust in vaccines and vaccinations.	[Kwon, Yunhyung; Yun, Jae-Won; Kim, Hee Kyoung; Kim, Sungnam; Chun, Chaemin; Jung, Yeon Haw; Kim, HeeJung; Oh, Hyun-kyung; Lee, Yeonkyoeng; Lee, Jae Young; Lee, Seon Kui; Park, Young-Joon] Korea Dis Control & Prevent Agcy, Cheongju 28159, South Korea; [Choe, Young June] Korea Univ, Dept Pediat, Anam Hosp, Seoul 02841, South Korea		Park, YJ (通讯作者)，Korea Dis Control & Prevent Agcy, Cheongju 28159, South Korea.	yhhodori@korea.kr; choey@korea.ac.kr; yunjw@korea.kr; kyoung0309@korea.kr; ksn1907@korea.kr; chaem92@korea.kr; yhjung04@korea.kr; spleen55@korea.kr; ohhk525@korea.kr; brightlee97@korea.kr; pgzdtk198@korea.kr; byuly74@korea.kr; pahmun@korea.kr		Choe, Young June/0000-0003-2733-0715			Bahri P, 2019, VACCINE, V37, P401, DOI 10.1016/j.vaccine.2018.11.082; FINE PEM, 1992, AM J EPIDEMIOL, V136, P121, DOI 10.1093/oxfordjournals.aje.a116479; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Jung J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e378; Karafillakis E, 2019, HUM VACC IMMUNOTHER, V15, P1615, DOI 10.1080/21645515.2018.1564436; Levi M, 2017, HUM VACC IMMUNOTHER, V13, P379, DOI 10.1080/21645515.2017.1264738; McCarthy NL, 2013, AM J PREV MED, V45, P91, DOI 10.1016/j.amepre.2013.02.020; Morimoto A, 2015, INT J CLIN ONCOL, V20, P549, DOI 10.1007/s10147-014-0723-1; Remschmidt C, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1154-y; Rizzo C, 2006, VACCINE, V24, P6468, DOI 10.1016/j.vaccine.2006.06.052; Rosselli R, 2017, ADV EXP MED BIOL, V973, P125, DOI 10.1007/5584_2017_39; Signorelli C, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h116; Simms KT, 2020, LANCET PUBLIC HEALTH, V5, pE223, DOI 10.1016/S2468-2667(20)30010-4; Simonsen L, 2005, ARCH INTERN MED, V165, P265, DOI 10.1001/archinte.165.3.265; Yun JW, 2017, INFECT CHEMOTHER, V49, P247, DOI 10.3947/ic.2017.49.4.247	15	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							367	10.3390/vaccines9040367			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4OT	33920117	Green Published, gold			2022-04-29	WOS:000643761100001
J	Wang, Q; Xiu, SX; Zhao, SY; Wang, JL; Han, Y; Dong, SH; Huang, JX; Cui, TT; Yang, LQ; Shi, NY; Liu, MQ; Han, Y; Wang, XW; Shen, Y; Chen, EP; Lu, B; Jin, H; Lin, L				Wang, Qiang; Xiu, Shixin; Zhao, Shuangyu; Wang, Jianli; Han, Ying; Dong, Shuheng; Huang, Jinxin; Cui, Tingting; Yang, Liuqing; Shi, Naiyang; Liu, Minqi; Han, Yue; Wang, Xuwen; Shen, Yuan; Chen, Enpin; Lu, Bing; Jin, Hui; Lin, Leesa			Vaccine Hesitancy: COVID-19 and Influenza Vaccine Willingness among Parents in Wuxi, China - A Cross-Sectional Study	VACCINES			English	Article						parents; vaccine hesitancy; COVID-19 vaccine; influenza vaccine; willingness	CHILDREN; MEASLES	Objectives: We aimed to (1) assess parental hesitancy about category A (Expanded Program on Immunization (EPI)) and B (non-EPI) vaccines, (2) assess parental willingness for COVID-19 and influenza vaccinations, and (3) explore the association of vaccination hesitancy of parents and healthcare workers (HCWs). Methods: The study was performed in Wuxi, eastern China between 21 September 2020 and 17 October 2020. Parents of children aged <18 years and HCWs were recruited from the selected immunization clinics. Vaccine hesitancy was assessed using the Strategic Advisory Group of Experts (SAGE) vaccine hesitancy survey (VHS) by summing the total score for 10 items (maximum 50 points). Results: A total of 3009 parents and 86 HCWs were included in the analysis. The category A VHS scores were significantly higher than the category B VHS scores (p = 0.000). Overall, 59.3% and 52.4% of parents reported willingness to avail COVID-19 and influenza vaccination for their children, respectively; 51.2% of the HCWs wanted to be vaccinated against COVID-19. Parental category B VHS scores were associated with HCW category B VHS scores (r = 0.928, p = 0.008). Conclusions: In China, parents are more hesitant about category B vaccines than category A vaccines. More than 40% of parents showed hesitancy and a refusal to use COVID-19 and influenza vaccines.	[Wang, Qiang; Zhao, Shuangyu; Wang, Jianli; Han, Ying; Dong, Shuheng; Huang, Jinxin; Cui, Tingting; Yang, Liuqing; Shi, Naiyang; Liu, Minqi; Han, Yue; Jin, Hui] Southeast Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Nanjing 210009, Peoples R China; [Wang, Qiang; Zhao, Shuangyu; Wang, Jianli; Han, Ying; Dong, Shuheng; Huang, Jinxin; Cui, Tingting; Yang, Liuqing; Shi, Naiyang; Liu, Minqi; Han, Yue; Jin, Hui] Southeast Univ, Sch Publ Hlth, Key Lab Environm Med Engn, Minist Educ, Nanjing 210009, Peoples R China; [Xiu, Shixin; Wang, Xuwen; Shen, Yuan; Chen, Enpin; Lu, Bing] Wuxi Ctr Dis Control & Prevent, Wuxi 214023, Jiangsu, Peoples R China; [Lin, Leesa] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7TH, England		Jin, H (通讯作者)，Southeast Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Nanjing 210009, Peoples R China.; Jin, H (通讯作者)，Southeast Univ, Sch Publ Hlth, Key Lab Environm Med Engn, Minist Educ, Nanjing 210009, Peoples R China.	230198325@seu.edu.cn; wxcdcsx@163.com; 213181074@seu.edu.cn; 213171070@seu.edu.cn; 220193551@seu.edu.cn; 213172733@seu.edu.cn; 220183468@seu.edu.cn; 230189704@seu.edu.cn; 230208397@seu.edu.cn; 220183431@seu.edu.cn; 220193555@seu.edu.cn; 220193593@seu.edu.cn; wxmgwang@163.com; wxcdcshy@163.com; chenepxia@163.com; Lub19661023@163.com; jinhuihld@seu.edu.cn; Leesa.Lin@lshtm.ac.uk	Lin, Leesa/ABH-7167-2020	Lin, Leesa/0000-0003-4123-4762; Jin, Hui/0000-0003-0071-9755; Wang, Qiang/0000-0002-1393-2443	Wuxi City Technology Development Fund [N20191007]; Postgraduate Research and Practice Innovation Program of Jiangsu Province [KYCX20_0153]; Jiangsu Provincial Six Talent Peak [WSN-002]; Public Health Research Center of Jiangnan University [JUPH201845]; UK Foreign, Commonwealth and Development Office; Wellcome [215373/A/19/Z]	This work was supported by Wuxi City Technology Development Fund (N20191007); Postgraduate Research and Practice Innovation Program of Jiangsu Province (KYCX20_0153); Jiangsu Provincial Six Talent Peak (grant number: WSN-002); Public Health Research Center of Jiangnan University (No. JUPH201845); the UK Foreign, Commonwealth and Development Office; and Wellcome [215373/A/19/Z].	AlHajri B, 2021, J PEDIATR-US, V231, P298, DOI 10.1016/j.jpeds.2020.11.059; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; Picchio CA, 2019, EUROSURVEILLANCE, V24, P20, DOI 10.2807/1560-7917.ES.2019.24.6.1800117; Azizi FSM, 2017, VACCINE, V35, P2955, DOI 10.1016/j.vaccine.2017.04.010; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Bolker BM, 2009, TRENDS ECOL EVOL, V24, P127, DOI 10.1016/j.tree.2008.10.008; Corben P, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5389-6; Di Martino G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020248; Domek GJ, 2018, VACCINE, V36, P5273, DOI 10.1016/j.vaccine.2018.07.046; Fogel BN, 2020, CLIN PEDIATR, V59, P352, DOI 10.1177/0009922819901002; Glickman ME, 2014, J CLIN EPIDEMIOL, V67, P850, DOI 10.1016/j.jclinepi.2014.03.012; Goldman RD, 2021, J PEDIATR-US, V228, P87, DOI 10.1016/j.jpeds.2020.08.005; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Hu Y, 2019, HUM VACC IMMUNOTHER, V15, P1092, DOI 10.1080/21645515.2019.1572409; Jiangsu Province Bureau of Statistics, JIANGSU STAT YB; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Kempe A, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2019-3852; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lama Y, 2020, VACCINE, V38, P1032, DOI 10.1016/j.vaccine.2019.11.039; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin L, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003599; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Martinot A, 2021, INFECT DIS NOW, V51, P153, DOI 10.1016/j.medmal.2020.09.027; Morley, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab054, DOI 10.1093/cid/ciab054]; Nicolay N, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.31.2001390; Opel DJ, 2009, ARCH PEDIAT ADOL MED, V163, P432, DOI 10.1001/archpediatrics.2009.42; Paterson P, 2018, VACCINE, V36, P5397, DOI 10.1016/j.vaccine.2017.08.016; Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353; Rashid H, 2016, HEALTH AFFAIR, V35, P284, DOI 10.1377/hlthaff.2015.1087; Ren J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209117; Rong HG, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020265; Shang M, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-2918; Shapiro GK, 2018, VACCINE, V36, P660, DOI 10.1016/j.vaccine.2017.12.043; Tang XY, 2017, J EPIDEMIOL, V27, P317, DOI 10.1016/j.je.2016.08.006; Tuckerman J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230425; van Buuren S, 2011, J STAT SOFTW, V45, P1; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Wagner AL, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040155; Wang Q, 2018, VACCINE, V36, P7262, DOI 10.1016/j.vaccine.2018.10.045; Wilson R, 2020, VACCINE, V38, P1144, DOI 10.1016/j.vaccine.2019.11.018; World Health Organization (WHO), Coronavirus disease 2019 (COVID-19) weekly epidemiological update-5 October 2021; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Wuxi Municipal Bureau of Statistics, WUX DAT; Yang RH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040650; Yang W, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz4037; Yufika A, 2020, VACCINE, V38, P2592, DOI 10.1016/j.vaccine.2020.01.072	48	24	24	22	34	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							342	10.3390/vaccines9040342			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS6KU	33916277	gold, Green Published			2022-04-29	WOS:000643886400001
J	Al-Qahtani, WS; Alsafhi, FA				Al-Qahtani, Wedad Saeed; Alsafhi, Fatmah Ahmed			A Commentary on Realities of Developing COVID-19 Vaccines Discussed through the Global Health Safety Perspective	VACCINES			English	Editorial Material						COVID-19; SARS-CoV-2; vaccine; realities; possible concerns; health safety perspective	SARS-COV; CORONAVIRUS	SARS-CoV-2 (or simply COVID-19) remains to be a global pandemic issue affecting millions, thus urging the world's scientific community to develop efficient vaccine and design adequate measures of disease control. Currently, the most economically viable solution to infections and viruses is vaccination, despite the possible concerns about side effects from implementing quickly developed vaccine. The current commentary intends to explain the health and safety related to COVID-19 vaccines via a prism of global health safety. Scientists across the globe, along with companies from both public and private sectors, have predictably arranged cooperative programs to learn about COVID-19, along with taking simultaneous steps on devising vaccine and preparing effective treatments plans. Presently, several clinical trials to approve the efficiency of proposed vaccine solutions have been made successfully. Global health safety concerns on vaccine's efficiency such as high costs of production, provision of vaccine to developing countries, and its influence on the global economy are addressed. This commentary reflects on current efforts related to the development of vaccine against COVID-19, which currently affects the global health status and economy. In addition, the commentary aims at addressing potential risks related to the development of COVID-19 vaccine from the global health safety perspective.	[Al-Qahtani, Wedad Saeed] Naif Arab Univ Secur Sci, Dept Forens Sci, Coll Criminal Justice, Riyadh 11452, Saudi Arabia; [Alsafhi, Fatmah Ahmed] Princess Nourah Bint Abdulrahman Univ, Dept Biol, Coll Sci, Riyadh 11452, Saudi Arabia		Al-Qahtani, WS (通讯作者)，Naif Arab Univ Secur Sci, Dept Forens Sci, Coll Criminal Justice, Riyadh 11452, Saudi Arabia.	walqahtani@nauss.edu.sa; faalsafhi@pnu.edu.sa	Al-Qahtani, Wedad Saeed/ABH-7132-2020	Al-Qahtani, Wedad Saeed/0000-0002-7347-9804; Safhi, Fatmah Ahmed/0000-0002-0533-614X	Deanship of Scientific Research at Princess Nourah Bint Abdulrahman University through the Fast-track Research Funding ProgramPrincess Nourah bint Abdulrahman University	This research was funded by the Deanship of Scientific Research at Princess Nourah Bint Abdulrahman University through the Fast-track Research Funding Program.	Al-Qahtani WS, 2020, REV MEX ING QUIM, V19, P201, DOI 10.24275/rmiq/Bio1692; Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698; Bhagavathula AS, 2020, JMIR PUBLIC HLTH SUR, DOI 10.1101/2020.03.09.2003338; Bloom DE, 2017, P NATL ACAD SCI USA, V114, P4055, DOI 10.1073/pnas.1701410114; Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6; Chojnacky M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235777; Davis MM, 2011, VACCINE, V29, P9414, DOI 10.1016/j.vaccine.2011.09.128; Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P2913, DOI 10.1080/21645515.2020.1842034; Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090; Funk CD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00937; Gupta V, 2006, VIROLOGY, V347, P127, DOI 10.1016/j.virol.2005.11.042; Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011; Hu C., 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI DOI 10.1001/jama.2020.23370; Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007; Jung J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e378; Karpinski TM, 2021, THERANOSTICS, V11, P1690, DOI 10.7150/thno.53691; Konwarh R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01531; Liu L, 2022, IEEE T KNOWL DATA EN, V34, P2293, DOI [10.1101/2020.06.17.153486, 10.1109/TKDE.2020.3004939]; Lo, 2020, NATL BUR EC RES, DOI [10.3386/w27212, DOI 10.3386/W27212]; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Park JG, 2021, J VIROL METHODS, V287, DOI 10.1016/j.jviromet.2020.113995; Plotkin SA, 2005, NAT MED, V11, pS5, DOI 10.1038/nm1209; Pronker ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057755; Shoenfeld Y, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102538; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298; WHO, 2021, WHO LISTS 2 ADDITION; World Health Organization, DRAFT LANDSC COVID 1; Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123	30	2	2	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							274	10.3390/vaccines9030274			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6HO	33803704	Green Published, gold			2022-04-29	WOS:000634252800001
J	Chilimuri, S; Mantri, N; Gongati, S; Zahid, M; Sun, HZ				Chilimuri, Sridhar; Mantri, Nikhitha; Gongati, Sudharsan; Zahid, Maleeha; Sun, Haozhe			COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab	VACCINES			English	Article						COVID-19; vaccination; B-Cell; ocrelizumab; multiple sclerosis; humoral immunity		Vaccines will play a key role in ending the COVID-19 pandemic. Vaccination against infections remains an important part of the management of patients with multiple sclerosis. However, there are limited data about the safety and efficacy of the currently available COVID-19 mRNA vaccines in patients with multiple sclerosis receiving concurrent immunosuppressive therapies. Patients on B cell depleting therapy such as ocrelizumab have an attenuated vaccine response. We report the first case of COVID-19 vaccine failure in a patient with relapsing-remitting multiple sclerosis on B cell depleting therapy, ocrelizumab. We offer suggestions to improve vaccine efficacy in these patients.	[Chilimuri, Sridhar; Mantri, Nikhitha; Gongati, Sudharsan; Zahid, Maleeha; Sun, Haozhe] Icahn Sch Med Mt Sinai, Dept Med, BronxCare Hlth Syst, Bronx, NY 10457 USA		Sun, HZ (通讯作者)，Icahn Sch Med Mt Sinai, Dept Med, BronxCare Hlth Syst, Bronx, NY 10457 USA.	chilimuri@bronxcare.org; nmantri@bronxcare.org; sgongati@bronxcare.org; mzahid@bronxcare.org; hsun@bronxcare.org		Zahid, Maleeha/0000-0003-2304-0091; Chilimuri, Sridhar/0000-0001-9866-4785; gongati, sudharsan/0000-0002-4117-6462; Sun, Haozhe/0000-0002-3625-2870			Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baker D, 2020, CLIN EXP IMMUNOL, V202, P149, DOI 10.1111/cei.13495; Bar-Or A, 2020, NEUROLOGY, V95, pE1999, DOI 10.1212/WNL.0000000000010380; CDC, COVID DAT TRACK; Genentech Data on File, POSTMARKETING EXP CL; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; Louapre C, 2020, JAMA NEUROL, V77, P1079, DOI 10.1001/jamaneurol.2020.2581; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577	8	12	12	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							219	10.3390/vaccines9030219			3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6HU	33806646	gold, Green Published			2022-04-29	WOS:000634253400001
J	Liu, X; Sun, W; Wu, NA; Rong, N; Kang, C; Jian, SJ; Chen, CL; Chen, C; Zhang, XY				Liu, Xiang; Sun, Wei; Wu, Nana; Rong, Na; Kang, Chao; Jian, Sijie; Chen, Chunlin; Chen, Chen; Zhang, Xiaoying			Synthesis of Escherichia coli OmpA Oral Nanoparticles and Evaluation of Immune Functions against the Major Etiologic Agent of Cow Mastitis	VACCINES			English	Article						E. coli; cow mastitis; OmpA protein nanoparticles; immune function; oral vaccine		Background Escherichia coli is a major etiologic agent of cow mastitis, a condition that results in huge economic losses. There is a lack of an oral vaccine for cow mastitis. Previous studies have confirmed that the outer membrane protein A (OmpA) of E. coli is immunogenic and can be used for vaccine design. In the present study, OmpA was encapsulated into nanoparticles (NP-OmpA) for an oral vaccine for cow mastitis. Methods: OmpA was purified with Ni-NTA flow resin and encapsulated with chitosan (CS) to prepare NP-OmpA nanoparticles. The gastrointestinal tract was simulated in vitro (PBS, pH 1.2) to measure the protein release rate. The optimal preparation conditions for NP-OmpA were determined by analyzing the concentrations of OmpA and CS, magnetic mixing speed, mixing time, and the ratio of tripolyphosphate (TPP)/CS (w/w). NP-OmpA safety was assessed by function factors and histopathological examination of livers and kidneys. The immune activity of NP-OmpA was determined using qRT-PCR to assess immune-related gene expression, leukocyte phagocytosis of Staphylococcus aureus, ELISA to evaluate antiserum titer and immune recognition of E. coli, and the organ index. The immune protection function of NP-OmpA was assessed by the protection rate of NP-OmpA to E. coli in mice, qRT-PCR for inflammation-related gene expression, assay kits for antioxidant factors, and visceral injury in the histopathological sections. Results: NP-OmpA nanoparticles had a diameter of about 700 nm, loading efficiency (LE) of 79.27%, and loading capacity (LC) of 20.31%. The release rate of NP-OmpA (0 similar to 96 h) was less than 50% in vitro. The optimal preparation conditions for NP-OmpAs were OmpA protein concentration of 2 mg/mL, CS concentration of 5 mg/mL, TPP/CS (w/w) of 1:1, magnetic mixing speed of 150 r/min, and mixing time of 15 min. Histopathological sections and clinical analytes of uric acid (UA), creatinine (Cr), alanine aminotransferase (ALT), aspartate transaminase (AST), catalase (CAT), glutathione (GSH), and malondialdehyde (MDA) showed NP-OmpA did not damage mice livers or kidneys. NP-OmpA could enhance the immune-related gene expression of IFN-gamma and HSP70 in the spleen, liver, and kidney and the leukocyte phagocytosis of S. aureus. The antiserum titer (1:3200) was obtained from mice immunized with NP-OmpA, which had an immune recognition effect to E. coli. The immune protection rate of NP-OmpA was 71.43% (p < 0.05) to E. coli. NP-OmpA could down-regulate the inflammation-related gene expression of TNF-a, IL-6, and IL-10 in the spleen, liver, and kidney, and the antioxidant factors MDA and SOD in the liver, and reduce injury in the liver and kidney of mice induced by E. coli. Conclusions: A novel NP-OmpA nanoparticle was encapsulated, and the optimal preparation conditions were determined. The NP-OmpA was safe and had good immune functions. They are expected to induce a response that resists infection with the major etiologic agent (E. coli) of cow mastitis.	[Liu, Xiang; Zhang, Xiaoying] Northwest A&F Univ, Coll Vet Med, Yangling 712100, Shaanxi, Peoples R China; [Liu, Xiang; Sun, Wei; Wu, Nana; Rong, Na; Kang, Chao; Jian, Sijie; Chen, Chunlin; Chen, Chen; Zhang, Xiaoying] Shaanxi Univ Technol, Chinese German Joint Inst Nat Prod Res, Coll Biol Sci & Engn, Hanzhong 723000, Peoples R China		Zhang, XY (通讯作者)，Northwest A&F Univ, Coll Vet Med, Yangling 712100, Shaanxi, Peoples R China.; Chen, C; Zhang, XY (通讯作者)，Shaanxi Univ Technol, Chinese German Joint Inst Nat Prod Res, Coll Biol Sci & Engn, Hanzhong 723000, Peoples R China.	liuxiang888525@163.com; sww17809267113@163.com; wunana0413@163.com; rongna0628@163.com; m18142347756@163.com; jianjiesi123@gmail.com; chen2362505579@163.com; cchen2008@yahoo.com; zhang.xy@nwsuaf.edu.cn			Incubation Project on State Key Laboratory of Biological Resources and Ecological Environment of Qinba Areas [SLGPT2019KF04-04]; China Natural Science FoundationNational Natural Science Foundation of China (NSFC) [31873006]; Key Research and Development Program of Shaanxi [2020LSFP2-38]; Project of Shaanxi University of Technology [SLGQD1803]	This work was supported by the Incubation Project on State Key Laboratory of Biological Resources and Ecological Environment of Qinba Areas no. SLGPT2019KF04-04, the grand of China Natural Science Foundation no. 31873006, the Key Research and Development Program of Shaanxi no. 2020LSFP2-38 and Project of Shaanxi University of Technology no. SLGQD1803.	Aaby P, 2019, CLIN MICROBIOL INFEC, V25, P1459, DOI 10.1016/j.cmi.2019.08.011; Alhusaini AM, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5614803; Askari N, 2019, BMC VET RES, V15, DOI 10.1186/s12917-018-1771-y; Belotserkovsky I, 2018, CURR TOP MICROBIOL, V416, P1, DOI 10.1007/82_2018_104; Benfaremo D, 2018, CURR DRUG SAF, V13, P150, DOI 10.2174/1574886313666180508122332; Boags AT, 2019, STRUCTURE, V27, P713, DOI 10.1016/j.str.2019.01.001; Solana JC, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010141; Castillo JI, 2018, BIOORG MED CHEM LETT, V28, P3094, DOI 10.1016/j.bmcl.2018.07.037; Chaudhury A, 2017, P NATL ACAD SCI USA, V114, P12344, DOI 10.1073/pnas.1709228114; Chen C, 2020, TROP J PHARM RES, V19, P155, DOI 10.4314/tjpr.v19i1.23; Confer AW, 2013, VET MICROBIOL, V163, P207, DOI 10.1016/j.vetmic.2012.08.019; Dubey S, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040040; Ezz-Eldin YM, 2020, LIFE SCI, V242, DOI 10.1016/j.lfs.2019.117222; Fazel F, 2019, MICROB PATHOGENESIS, V132, P355, DOI 10.1016/j.micpath.2019.05.018; Gu H, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00172; Hsieh WS, 2016, J MICROBIOL IMMUNOL, V49, P843, DOI 10.1016/j.jmii.2015.05.019; Lavon Y, 2019, J DAIRY SCI, V102, P10587, DOI 10.3168/jds.2019-16673; Li XY, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-89; Liu X, 2020, INT J MED SCI, V17, P414, DOI 10.7150/ijms.38527; Liu X, 2018, J PROTEOME RES, V17, P2987, DOI 10.1021/acs.jproteome.8b00176; Liu X, 2017, TROP J PHARM RES, V16, P2477, DOI 10.4314/tjpr.v16i10.23; Marslin G, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10050541; Matias LLR, 2019, NUTRIENTS, V11, DOI 10.3390/nu11112770; Meehan Tracy L, 2015, Methods Mol Biol, V1328, P191, DOI 10.1007/978-1-4939-2851-4_14; Meng L, 2018, MOL IMMUNOL, V94, P7, DOI 10.1016/j.molimm.2017.12.008; Muxika A, 2017, INT J BIOL MACROMOL, V105, P1358, DOI 10.1016/j.ijbiomac.2017.07.087; Paunovska K, 2019, ADV MATER, V31, DOI 10.1002/adma.201902798; Roth N, 2019, POULTRY SCI, V98, P1791, DOI 10.3382/ps/pey539; Rowley CA, 2018, MBIO, V9, DOI 10.1128/mBio.01429-18; Santos KO, 2019, FISH SHELLFISH IMMUN, V93, P652, DOI 10.1016/j.fsi.2019.08.030; Sheen S, 2018, J FOOD SCI, V83, P740, DOI 10.1111/1750-3841.14059; Song WT, 2019, NAT NANOTECHNOL, V14, P1093, DOI 10.1038/s41565-019-0589-5; Wang DQ, 2019, INT J BIOL MACROMOL, V126, P1125, DOI 10.1016/j.ijbiomac.2018.12.243; Wassenaar TM, 2018, CRIT REV MICROBIOL, V44, P619, DOI 10.1080/1040841X.2018.1481013; Xu C, 2020, NANO LETT, V20, P372, DOI 10.1021/acs.nanolett.9b04024; Zhang EH, 2019, CARBOHYD POLYM, V222, DOI 10.1016/j.carbpol.2019.115004; Zhang Xue-mei, 2011, Zhonghua Yi Xue Za Zhi, V91, P1977; Zhang YS, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901778; Zhao WD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04637-3	39	2	2	8	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							304	10.3390/vaccines9030304			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5MM	33807110	Green Published, gold			2022-04-29	WOS:000634198000001
J	Tong, J; Zhu, CX; Lai, HY; Feng, CC; Zhou, DP				Tong, Jiao; Zhu, Chenxi; Lai, Hanyu; Feng, Chunchao; Zhou, Dapeng			Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19	VACCINES			English	Article						COVID-19; vaccine; neutralizing antibodies; adjuvant	HEPATITIS-B-VACCINE; INFLUENZA VACCINE; RABIES VACCINE; SURFACE-ANTIGEN; PHASE-I; SAFETY; IMMUNOGENICITY; EFFICACY; AGONIST; QUADRIVALENT	The structures of immunogens that elicit the most potent neutralization antibodies to prevent COVID-19 infection are still under investigation. In this study, we tested the efficacy of a recombinant trimeric Spike protein containing polyI:C (PIKA) adjuvant in mice immunized by a 0-7-14 day schedule. The results showed that a Spike protein-specific antibody was induced at Day 21 with titer of above 50,000 on average, as measured by direct binding. The neutralizing titer was above 1000 on average, as determined by a pseudo-virus using monoclonal antibodies (40592-MM57 and 40591-MM43) with IC50 at 1 mu g/mL as standards. The protein/peptide array-identified receptor-binding domain (RBD) was considered as immunodominant. No linear epitopes were found in the RBD, although several linear epitopes were found in the C-terminal domain right after the RBD and heptad repeat regions. Our study supports the efficacy of a recombinant trimeric Spike protein vaccine candidate for COVID-19 that is safe and ready for storage and distribution in developing countries.	[Tong, Jiao; Zhu, Chenxi; Lai, Hanyu; Feng, Chunchao; Zhou, Dapeng] Tongji Univ, Sch Med, Shanghai 200092, Peoples R China; [Tong, Jiao; Zhu, Chenxi; Lai, Hanyu; Feng, Chunchao; Zhou, Dapeng] Tongji Univ, Sch Med, Shanghai Pudong New Area Mental Hlth Ctr, 165 Sanlin Rd, Shanghai 200124, Peoples R China		Zhou, DP (通讯作者)，Tongji Univ, Sch Med, Shanghai 200092, Peoples R China.; Zhou, DP (通讯作者)，Tongji Univ, Sch Med, Shanghai Pudong New Area Mental Hlth Ctr, 165 Sanlin Rd, Shanghai 200124, Peoples R China.	tongjiao2109@outlook.com; chenxizhu614@hotmail.com; laihanyu@tongji.edu.cn; chunchao0420@outlook.com; dapengzhoulab@tongji.edu.cn			National Key Research and Development Plan grant [2017YFA0505901]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [22120200163]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31870972]; Shanghai Science and Technology CommissionShanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM) [15002360172]; Outstanding Clinical Discipline Project of Shanghai Pudong [PWYgy2018-10]	This work was funded by National Key Research and Development Plan grant 2017YFA0505901, Fundamental Research Funds for the Central Universities 22120200163, National Natural Science Foundation of China grant 31870972, Shanghai Science and Technology Commission grant 15002360172, and the Outstanding Clinical Discipline Project of Shanghai Pudong (PWYgy2018-10).	Alter Galit, 2021, Res Sq, DOI 10.21203/rs.3.rs-200342/v1; Atsmon J, 2014, VACCINE, V32, P5816, DOI 10.1016/j.vaccine.2014.08.031; Bangaru S, 2020, SCIENCE, V370, P1089, DOI 10.1126/science.abe1502; Champion CR, 2021, ANN PHARMACOTHER, V55, P783, DOI 10.1177/1060028020962050; Chen WH, 2020, VACCINE, V38, P7533, DOI 10.1016/j.vaccine.2020.09.061; Chen WH, 2020, HUM VACC IMMUNOTHER, V16, P1239, DOI 10.1080/21645515.2020.1740560; Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952; Cooper CL, 2004, J CLIN IMMUNOL, V24, P693, DOI 10.1007/s10875-004-6244-3; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Corder BN, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101186; Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035; Du S, 2020, CELL, V183, P1013, DOI 10.1016/j.cell.2020.09.035; Dunkle LM, 2017, NEW ENGL J MED, V376, P2427, DOI [10.1056/NEJMoa1608862, 10.1056/nejmoa1608862]; Shen EX, 2007, CELL MOL IMMUNOL, V4, P113; Farrera-Soler L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238089; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Garcon N, 2011, BIODRUGS, V25, P217, DOI 10.2165/11591760-000000000-00000; Guebre-Xabier M, 2020, VACCINE, V38, P7892, DOI 10.1016/j.vaccine.2020.10.064; Halperin SA, 2003, VACCINE, V21, P2461, DOI 10.1016/S0264-410X(03)00045-8; Haun BK, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.599587; Hauser MI, 2019, VACCINE, V37, P4246, DOI 10.1016/j.vaccine.2019.06.039; Hsieh CL, 2020, SCIENCE, V369, P1501, DOI 10.1126/science.abd0826; Huber VC, 2008, CURR OPIN MOL THER, V10, P75; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Kalimuddin S, 2017, VACCINE, V35, P7127, DOI 10.1016/j.vaccine.2017.10.097; Kassebaum NJ, 2014, LANCET, V384, P980, DOI 10.1016/S0140-6736(14)60696-6; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Kim E, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102743; Laczko D, 2020, IMMUNITY, V53, P724, DOI 10.1016/j.immuni.2020.07.019; Lau YF, 2010, VIROLOGY, V406, P80, DOI 10.1016/j.virol.2010.07.008; Lau YF, 2010, J VIROL, V84, P8639, DOI 10.1128/JVI.00596-10; Lehtinen M, 2015, VACCINE, V33, P1284, DOI 10.1016/j.vaccine.2014.12.019; LerouxRoels G, 1997, VACCINE, V15, P1724, DOI 10.1016/S0264-410X(97)00117-5; Li TT, 2020, EMERG MICROBES INFEC, V9, P2076, DOI 10.1080/22221751.2020.1821583; Li Y, 2020, CELL MOL IMMUNOL, V17, P1095, DOI 10.1038/s41423-020-00523-5; LIN HX, 1993, ARCH VIROL, V131, P307, DOI 10.1007/BF01378634; Liu XL, 2020, VACCINE, V38, P7205, DOI 10.1016/j.vaccine.2020.09.058; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Luxembourg A, 2015, HUM VACC IMMUNOTHER, V11, P1306, DOI 10.1080/21645515.2015.1009819; MISKOVSKY E, 1991, VACCINE, V9, P346, DOI 10.1016/0264-410X(91)90062-B; Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Portnoff AD, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010099; Qi XX, 2020, CHEM COMMUN, V56, P8683, DOI 10.1039/d0cc03263h; Schillie S, 2018, MMWR-MORBID MORTAL W, V67, P455, DOI 10.15585/mmwr.mm6715a5; Senders S, 2016, PEDIATR INFECT DIS J, V35, P548, DOI 10.1097/INF.0000000000001072; Shen Xiaoying, 2021, Cell Host Microbe, V29, P529, DOI [10.1101/2021.01.27.428516, 10.1016/j.chom.2021.03.002]; Stassijns J, 2016, VACCINE, V34, P714, DOI 10.1016/j.vaccine.2015.12.024; Su QD, 2021, VACCINE, V39, P1241, DOI 10.1016/j.vaccine.2021.01.044; Suryadevara Naveenchandra, 2021, Cell, V184, P2316, DOI [10.1101/2021.01.19.427324, 10.1016/j.cell.2021.03.029]; Tefit JN, 2014, VACCINE, V32, P6138, DOI 10.1016/j.vaccine.2014.08.070; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Treanor JJ, 2006, J INFECT DIS, V193, P1223, DOI 10.1086/503050; Treanor JJ, 2007, JAMA-J AM MED ASSOC, V297, P1577, DOI 10.1001/jama.297.14.1577; Treanor JJ, 2013, VACCINE, V31, P5760, DOI 10.1016/j.vaccine.2013.08.064; Van Damme P, 2016, CLIN CANCER RES, V22, P3238, DOI 10.1158/1078-0432.CCR-16-0085; Voss William N, 2020, bioRxiv, DOI 10.1101/2020.12.20.423708; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Wang YF, 2021, J MED VIROL, V93, P892, DOI 10.1002/jmv.26320; Ward BJ, 2020, LANCET, V396, P1491, DOI 10.1016/S0140-6736(20)32014-6; Weissman D., 2021, CELL HOST MICROBE, V29, P23, DOI [10.1016/j.chom.2020.11.012, DOI 10.1016/j.chom.2020.11.012]; Wijaya L, 2017, VACCINE, V35, P1175, DOI 10.1016/j.vaccine.2016.12.031; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Xu C, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe5575; Yoshikawa H, 2013, CANCER SCI, V104, P465, DOI 10.1111/cas.12106; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zhang Y, 2016, VIROLOGY, V489, P165, DOI 10.1016/j.virol.2015.10.029; Zhou DP, 2021, GLYCOBIOLOGY, V31, P69, DOI 10.1093/glycob/cwaa052; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3; ZHU QR, 1994, CHINESE MED J-PEKING, V107, P915	71	2	2	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							296	10.3390/vaccines9030296			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5HX	33810026	Green Published, Green Submitted, gold			2022-04-29	WOS:000634186100001
J	Kim, NH; Ko, DS; Ha, EJ; Ahn, S; Choi, KS; Kwon, HJ				Kim, Nam-Hyung; Ko, Dae-Sung; Ha, Eun-Jin; Ahn, Sunmin; Choi, Kang-Seuk; Kwon, Hyuk-Joon			Optimized Detoxification of a Live Attenuated Vaccine Strain (SG9R) to Improve Vaccine Strategy against Fowl Typhoid	VACCINES			English	Article						Salmonella enterica serovar Gallinarum biovar Gallinarum; SG9R; detoxification; lipid A; vaccines; pro-inflammatory cytokines		The live attenuated vaccine strain, SG9R, has been used against fowl typhoid worldwide, but it can revert to the pathogenic smooth strain owing to single nucleotide changes such as nonsense mutations in the rfaJ gene. As SG9R possesses an intact Salmonella plasmid with virulence genes, it exhibits dormant pathogenicity and can cause fowl typhoid in young chicks and stressed or immunocompromised brown egg-laying hens. To tackle these issues, we knocked out the rfaJ gene of SG9R (named Safe-9R) to eliminate the reversion risk and generated detoxified strains of Safe-9R by knocking out lpxL, lpxM, pagP, and phoP/phoQ genes to attenuate the virulence. Among the knockout strains, live Delta lpxL- (Dtx-9RL) and Delta lpxM-9R (Dtx-9RM) strains induced remarkably less expression of inflammatory cytokines in chicken macrophage cells, and oil emulsion (OE) Dtx-9RL did not cause body weight loss in chicks. Live Dtx-9RM exhibited efficacy against field strain challenge in one week without any bacterial re-isolation, while the un-detoxified strains showed the development of severe liver lesions and re-isolation of challenged strains. Thus, SG9R was optimally detoxified by knockout of lpxL and lpxM, and Dtx-9RL and Dtx-9RM might be applicable as OE and live vaccines, respectively, to prevent fowl typhoid irrespective of the age of chickens.	[Kim, Nam-Hyung; Ko, Dae-Sung; Ha, Eun-Jin; Ahn, Sunmin; Kwon, Hyuk-Joon] Seoul Natl Univ, Coll Vet Med, Lab Poultry Med, Seoul 08826, South Korea; [Kim, Nam-Hyung; Ko, Dae-Sung; Ha, Eun-Jin; Ahn, Sunmin; Choi, Kang-Seuk; Kwon, Hyuk-Joon] Coll Vet Med, Res Inst Vet Sci, BK21 Vet Sci, Seoul 08826, South Korea; [Choi, Kang-Seuk] Seoul Natl Univ, Coll Vet Med, Lab Avian Dis, Seoul 08826, South Korea; [Kwon, Hyuk-Joon] Seoul Natl Univ, Farm Anim Clin Training & Res Ctr FACTRC, GBST, Seoul 08826, South Korea		Kwon, HJ (通讯作者)，Seoul Natl Univ, Coll Vet Med, Lab Poultry Med, Seoul 08826, South Korea.; Choi, KS; Kwon, HJ (通讯作者)，Coll Vet Med, Res Inst Vet Sci, BK21 Vet Sci, Seoul 08826, South Korea.; Choi, KS (通讯作者)，Seoul Natl Univ, Coll Vet Med, Lab Avian Dis, Seoul 08826, South Korea.; Kwon, HJ (通讯作者)，Seoul Natl Univ, Farm Anim Clin Training & Res Ctr FACTRC, GBST, Seoul 08826, South Korea.	hyacinthus@snu.ac.kr; kdskos1@snu.ac.kr; flower678@snu.ac.kr; vicky.ahn@snu.ac.kr; kchoi0608@snu.ac.kr; kwonhj01@snu.ac.kr		Choi, Kang-Seuk/0000-0001-6825-6924; Kwon, Hyuk-Joon/0000-0001-9107-7860	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, and Forestry (IPET)	We are grateful to Jong-Man Kim, Hyung-Joon Moon, and Kyung-Yoon Park for their support in the protective efficacy test of the live Safe-9R vaccine. This work was supported by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, and Forestry (IPET).	BLATTEIS CM, 1974, TOXICOL APPL PHARM, V29, P249, DOI 10.1016/0041-008X(74)90062-3; Cheong HJ, 2007, J KOREAN MED SCI, V22, P773, DOI 10.3346/jkms.2007.22.5.773; Cho SunHee, 2015, Korean Journal of Veterinary Research, V55, P241, DOI 10.14405/kjvr.2015.55.4.241; Clements A, 2007, J BIOL CHEM, V282, P15569, DOI 10.1074/jbc.M701454200; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; De Carli S, 2017, VET MICROBIOL, V212, P80, DOI 10.1016/j.vetmic.2017.11.001; Feberwee A, 2001, AVIAN DIS, V45, P83, DOI 10.2307/1593015; Feodorova VA, 2007, VACCINE, V25, P7620, DOI 10.1016/j.vaccine.2007.08.055; Fisseha M, 2005, INFECT IMMUN, V73, P4070, DOI 10.1128/IAI.73.7.4070-4080.2005; Halstead SB, 2010, LANCET INFECT DIS, V10, P712, DOI 10.1016/S1473-3099(10)70166-3; Han D, 2017, J FOOD PROTECT, V80, P245, DOI [10.4315/0362-028X.JFP-16-306, 10.4315/0362-028x.jfp-16-306]; Jones BD, 1997, INFECT IMMUN, V65, P4778, DOI 10.1128/IAI.65.11.4778-4783.1997; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; Kim NH, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.598610; Kim NH, 2019, VET MICROBIOL, V235, P63, DOI 10.1016/j.vetmic.2019.05.019; Kim S, 2010, J KOREAN MED SCI, V25, P1893, DOI 10.3346/jkms.2010.25.12.1693; Kwon HJ, 2011, VACCINE, V29, P1311, DOI 10.1016/j.vaccine.2010.11.067; Lee SR, 2009, J MICROBIOL BIOTECHN, V19, P1271, DOI 10.4014/jmb.0901.055; Lee YJ, 2005, AVIAN PATHOL, V34, P362, DOI 10.1080/03079450500180895; Lee YoungJu, 2003, Journal of Veterinary Clinics, V20, P155; Matthews TD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126883; Mills G, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00068-17; Rabsch W, 2000, EMERG INFECT DIS, V6, P443, DOI 10.3201/eid0605.000501; Rajput IR, 2014, J CELL BIOCHEM, V115, P189, DOI 10.1002/jcb.24650; Rychlik I, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-268; SILVA EN, 1981, AVIAN DIS, V25, P38, DOI 10.2307/1589825; SMITH H. W., 1956, JOUR HYG, V54, P419; Sunshine MG, 1997, J BACTERIOL, V179, P5521, DOI 10.1128/jb.179.17.5521-5533.1997; Vaara M, 1999, ANTIMICROB AGENTS CH, V43, P1459, DOI 10.1128/AAC.43.6.1459; Van Immerseel F, 2013, VACCINE, V31, P4940, DOI 10.1016/j.vaccine.2013.08.033; Wigley Paul, 2005, BMC Vet Res, V1, P2; Xie H, 2000, POULTRY SCI, V79, P33, DOI 10.1093/ps/79.1.33; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	34	1	1	3	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							122	10.3390/vaccines9020122			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6VD	33546449	Green Published			2022-04-29	WOS:000623278300001
J	Krishnarajah, G; Divino, V; Postma, MJ; Pelton, SI; Anupindi, VR; DeKoven, M; Mould-Quevedo, J				Krishnarajah, Girishanthy; Divino, Victoria; Postma, Maarten J.; Pelton, Stephen, I; Anupindi, Vamshi Ruthwik; DeKoven, Mitch; Mould-Quevedo, Joaquin			Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018-19 Influenza Season in the United States	VACCINES			English	Article						influenza vaccine; cell-based; egg-based; relative vaccine effectiveness; retrospective studies; economic assessment; real-world evidence		Non-egg-based influenza vaccines eliminate the potential for egg-adapted mutations and potentially increase vaccine effectiveness. This retrospective study compared hospitalizations/emergency room (ER) visits and all-cause annualized healthcare costs among subjects aged 4-64 years who received cell-based quadrivalent (QIVc) or standard-dose egg-based quadrivalent (QIVe-SD) influenza vaccine during the 2018-19 influenza season. Administrative claims data (IQVIA PharMetrics(R) Plus, IQVIA, USA) were utilized to evaluate clinical and economic outcomes. Adjusted relative vaccine effectiveness (rVE) of QIVc vs. QIVe-SD among overall cohort, as well as for three subgroups (age 4-17 years, age 18-64 years, and high-risk) was evaluated using inverse probability of treatment weighting (IPTW) and Poisson regression models. Generalized estimating equation models among the propensity score matched sample were used to estimate annualized all-cause costs. A total of 669,030 recipients of QIVc and 3,062,797 of QIVe-SD were identified after IPTW adjustments. Among the overall cohort, QIVc had higher adjusted rVEs against hospitalizations/ER visits related to influenza, all-cause hospitalizations, and hospitalizations/ER visits associated with any respiratory event compared to QIVe-SD. The adjusted annualized all-cause total costs were higher for QIVe-SD compared to QIVc ((+$461); p < 0.05).	[Krishnarajah, Girishanthy; Mould-Quevedo, Joaquin] Seqirus USA Inc, Summit, NJ 07901 USA; [Divino, Victoria; Anupindi, Vamshi Ruthwik; DeKoven, Mitch] IQVIA, Falls Church, VA 22042 USA; [Postma, Maarten J.] Univ Groningen, Dept Pharm, Unit PharmacoTherapy Epidemiol & Econ PTE2, NL-9700 Groningen, Netherlands; [Postma, Maarten J.] Univ Groningen, Univ Med Ctr Groningen UMCG, Dept Hlth Sci, NL-9700 Groningen, Netherlands; [Postma, Maarten J.] Univ Groningen, Fac Econ & Business, Dept Econ Econometr & Finance, NL-9700 Groningen, Netherlands; [Pelton, Stephen, I] Boston Univ, Dept Epidemiol, Sch Med & Publ Hlth, Boston, MA 02118 USA; [Pelton, Stephen, I] Boston Med Ctr, Maxwell Finland Labs, Boston, MA 02118 USA		Mould-Quevedo, J (通讯作者)，Seqirus USA Inc, Summit, NJ 07901 USA.	Shanthy.Krishnarajah@seqirus.com; victoria.divino@iqvia.com; mj.postma@rug.nl; spelton@bu.edu; ruthwik.anupindi@iqvia.com; Mitch.DeKoven@iqvia.com; Joaquin.Mould-Quevedo@seqirus.com	Mould-Quevedo, Joaquin/AAT-7532-2021	Postma, Maarten/0000-0002-6306-3653	Seqirus USA Inc., Summit, NJ, USA	This work was supported by Seqirus USA Inc., Summit, NJ, USA. G.K. and J.M.-Q. employees of Seqirus and shareholders of CSL Limited. G.K. and J.M.-Q. were involved in study design, interpretation of the data, critical revision of the article, and in the decision to submit the article for publication.	Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Barr IG, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0079-z; Basu A, 2005, BIOSTATISTICS, V6, P93, DOI 10.1093/biostatistics/kxh020; Biggerstaff M, 2018, AM J EPIDEMIOL, V187, P1040, DOI 10.1093/aje/kwx334; Boikos C., 2018, P CAN IMM C OTT ON C; Bruxvoort KJ, 2019, VACCINE, V37, P5807, DOI 10.1016/j.vaccine.2019.08.024; Budd AP, 2019, J INFECT DIS, V220, P820, DOI 10.1093/infdis/jiz201; Chung JR, 2020, CLIN INFECT DIS, V71, pE368, DOI 10.1093/cid/ciz1244; Crown WH, 2014, APPL HEALTH ECON HEA, V12, P7, DOI 10.1007/s40258-013-0075-4; DeMarcus L, 2019, VACCINE, V37, P4015, DOI 10.1016/j.vaccine.2019.06.004; Divino V, 2020, VACCINE, V38, P6334, DOI 10.1016/j.vaccine.2020.07.023; Electronic Code of Federal Regulations, PROTECTION HUMAN SUB; Epperson S, 2019, MMWR-MORBID MORTAL W, V68, P880, DOI 10.15585/mmwr.mm6840a3; Ghosh D., 2012, P SURV RES METH JOIN; Grohskopf LA, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6908a1; Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1; Grohskopf LA, 2017, MMWR RECOMM REP, V66, P3, DOI 10.15585/mmwr.rr6602a1; Harding AT, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020019; Izurieta HS, 2020, J INFECT DIS, V222, P278, DOI 10.1093/infdis/jiaa080; Izurieta HS, 2019, J INFECT DIS, V220, P1255, DOI 10.1093/infdis/jiy716; Lozano J.E., **DATA OBJECT**, DOI [10.5281/zenodo.165983, DOI 10.5281/ZENODO.165983]; Office for Human Research Protections, UPDATED FAQS INFORM; Public Health England, 2019, GREEN BOOK; Rolfes MA, 2019, CLIN INFECT DIS, V69, P1845, DOI 10.1093/cid/ciz075; Rothman K.J., 2008, MODERN EPIDEMIOLOGY, V3rd; Thoemmes F, 2016, EMERG ADULTHOOD, V4, P40, DOI 10.1177/2167696815621645; Uyeki TM, 2019, CLIN INFECT DIS, V68, pE1, DOI 10.1093/cid/ciy866; van Aalst R, 2020, VACCINE, V38, P372, DOI 10.1016/j.vaccine.2019.09.105; Vaudry W, 2017, Can Commun Dis Rep, V43, P96	30	3	3	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							80	10.3390/vaccines9020080			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6RZ	33498724	Green Published, gold			2022-04-29	WOS:000623270100001
J	Wang, SJ; Wang, CS; Ren, X; Xue, WJ; He, HJ; Zhu, YZ; Wang, HF; Wang, G; Cai, XH				Wang, Shujie; Wang, Chunsheng; Ren, Xiao; Xue, Wenjiao; He, Haijuan; Zhu, Yanzhu; Wang, Hongfeng; Wang, Gang; Cai, Xuehui			Identification of Two Novel Linear Neutralizing Epitopes within the Hexon Protein of Canine Adenovirus Using Monoclonal Antibodies	VACCINES			English	Article						canine adenovirus; identification; hexon protein; monoclonal antibodies; novel epitopes		Canine adenovirus (CAdV) has a high prevalence in canine populations. High affinity neutralizing antibodies against conserved epitopes can provide protective immunity against CAdV and protect against future outbreaks. In this study, we identified two CAdV-2-specific neutralizing monoclonal antibodies (mAbs), 2C1 and 7D7, which recognized two linear-dependent epitopes. MAb 2C1 potently neutralized CAdV-2 with a 50% neutralization titer (NT50) of 4096, and mAb 7D7 partially neutralized CAdV-2 with a 50% NT50 of 64. Immunoprecipitation, Western blot and protein spectral analysis indicated that both neutralizing mAbs recognized the hexon protein (Hex) of CAdV-2. Through a 12-mer random peptide phage display and synthetic peptides analysis, we finely mapped the neutralizing epitopes to two 10-amino acid (aa) peptides within the CAdV Hex: (634)RIKQRETPAL(643) located on the surface region; and (PESYKDRMYS745)-P-736 located in the inner region of the expected 3D structure of trimeric Hex. Importantly, the two epitopes are highly conserved among all CAdV isolates by sequence alignment analysis. Thus, these results provide insights into the interaction between virus and mAbs at the aa level and may have potential applications in the development of novel therapeutic or epitope-based vaccines, antibody therapeutics and a diagnostic method suitable for the rapid detection of all CAdVs.	[Wang, Shujie; Ren, Xiao; Xue, Wenjiao; He, Haijuan; Wang, Hongfeng; Wang, Gang; Cai, Xuehui] Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin 150001, Peoples R China; [Wang, Chunsheng] Northeast Forestry Univ, Coll Life Sci, Harbin 150040, Peoples R China; [He, Haijuan] Heilongjiang Acad Agr Sci, Anim Husb Res Inst, Harbin 150086, Peoples R China; [Zhu, Yanzhu] Chinese Acad Agr Sci, Inst Special Anim & Plant Sci, Key Lab Special Anim Epidem Dis, Minist Agr, Changchun 130112, Peoples R China		Wang, SJ; Cai, XH (通讯作者)，Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin 150001, Peoples R China.	wangshujie@caas.cn; wangchunsheng79@nefu.edu.cn; rxbioclub@sina.com; xue5323@yeah.net; he_haijuan@haas.cn; zhuyanzhu@caas.cn; wanghongfeng01@caas.cn; wanggang@caas.cn; caixuehui@caas.cn		Ren, Xiao/0000-0002-9194-5856	National Key Research and Development Program of China [2017YFD0500600]; Key Program of Natural Science Foundation of Heilongjiang Province [ZD2017007]	This work was supported by the National Key Research and Development Program (2017YFD0500600) of China and the Key Program of Natural Science Foundation of Heilongjiang Province (ZD2017007).	Balboni A, 2014, RES VET SCI, V97, P631, DOI 10.1016/j.rvsc.2014.10.010; Balboni A, 2013, VET MICROBIOL, V162, P551, DOI 10.1016/j.vetmic.2012.11.015; Bulut O, 2013, SCI WORLD J, DOI 10.1155/2013/587024; Headley SA, 2019, BRAZ J MICROBIOL, V50, P859, DOI 10.1007/s42770-019-00082-6; Ibanes S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071032; Kouzmitcheva GA, 2001, CLIN DIAGN LAB IMMUN, V8, P150, DOI 10.1128/CDLI.8.1.150-160.2001; Li XM, 2008, VACCINE, V26, P2714, DOI 10.1016/j.vaccine.2008.03.020; Lian CY, 2020, AVIAN PATHOL, V49, P325, DOI 10.1080/03079457.2020.1746743; Liu WM, 2017, RES VET SCI, V115, P374, DOI 10.1016/j.rvsc.2017.07.001; Ma Q, 2015, VACCINE, V33, P6659, DOI 10.1016/j.vaccine.2015.10.117; Nowakowski AB, 2014, METALLOMICS, V6, P1068, DOI 10.1039/c4mt00033a; Roberts DM, 2006, NATURE, V441, P239, DOI 10.1038/nature04721; Rux JJ, 2003, J VIROL, V77, P9553, DOI 10.1128/JVI.77.17.9553-9566.2003; Saban SD, 2006, J VIROL, V80, P12049, DOI 10.1128/JVI.01652-06; Schoelm G, 2008, J VIROL, V82, P3192, DOI 10.1128/JVI.02393-07; Solanki M, 2016, J GEN VIROL, V97, P160, DOI 10.1099/jgv.0.000328; Sowman HR, 2018, NEW ZEAL VET J, V66, P236, DOI 10.1080/00480169.2018.1490214; STEWART PL, 1991, CELL, V67, P145, DOI 10.1016/0092-8674(91)90578-M; van Raaij MJ, 1999, NATURE, V401, P935, DOI 10.1038/44880; VERKHOVSKAYA L V, 1990, Biokhimiya, V55, P1996; Walker D, 2016, SCI REP-UK, V6, DOI 10.1038/srep36051; Wang HW, 2011, VET MICROBIOL, V148, P189, DOI 10.1016/j.vetmic.2010.09.013; Wang SJ, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02882; Xiao N, 2016, VET IMMUNOL IMMUNOP, V182, P22, DOI 10.1016/j.vetimm.2016.09.005; Xue M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049842; Zheng N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084516	26	1	1	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							135	10.3390/vaccines9020135			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6VU	33567652	gold, Green Published			2022-04-29	WOS:000623280100001
J	Date, I; Koya, T; Sakamoto, T; Togi, M; Kawaguchi, H; Watanabe, A; Kato, T; Shimodaira, S				Date, Ippei; Koya, Terutsugu; Sakamoto, Takuya; Togi, Misa; Kawaguchi, Haruhiko; Watanabe, Asuka; Kato, Tomohisa, Jr.; Shimodaira, Shigetaka			Interferon-alpha-Induced Dendritic Cells Generated with Human Platelet Lysate Exhibit Elevated Antigen Presenting Ability to Cytotoxic T Lymphocytes	VACCINES			English	Article						immunotherapy; dendritic cells; vaccine; human platelet lysate; tumor-associated antigens; cytotoxic T lymphocyte; endocytosis; proteolytic activity		Given the recent advancements of immune checkpoint inhibitors, there is considerable interest in cancer immunotherapy provided through dendritic cell (DC)-based vaccination. Although many studies have been conducted to determine the potency of DC vaccines against cancer, the clinical outcomes are not yet optimal, and further improvement is necessary. In this study, we evaluated the potential ability of human platelet lysate (HPL) to produce interferon-alpha-induced DCs (IFN-DCs). In the presence of HPL, IFN-DCs (HPL-IFN-DCs) displayed high viability, yield, and purity. Furthermore, HPL-IFN-DCs displayed increased CD14, CD56, and CCR7 expressions compared with IFN-DCs produced without HPL; HPL-IFN-DCs induced an extremely higher number of antigen-specific cytotoxic T lymphocytes (CTLs) than IFN-DCs, which was evaluated with a human leukocyte antigen (HLA)-restricted melanoma antigen recognized by T cells 1 (MART-1) peptide. Additionally, the endocytic and proteolytic activities of HPL-IFN-DCs were increased. Cytokine production of interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF)-alpha was also elevated in HPL-IFN-DCs, which may account for the enhanced CTL, endocytic, and proteolytic activities. Our findings suggest that ex-vivo-generated HPL-IFN-DCs are a novel monocyte-derived type of DC with high endocytic and proteolytic activities, thus highlighting a unique strategy for DC-based immunotherapies.	[Date, Ippei; Koya, Terutsugu; Sakamoto, Takuya; Togi, Misa; Kawaguchi, Haruhiko; Watanabe, Asuka; Shimodaira, Shigetaka] Kanazawa Med Univ, Dept Regenerat Med, Kahoku, Ishikawa 9200293, Japan; [Koya, Terutsugu; Sakamoto, Takuya; Togi, Misa; Shimodaira, Shigetaka] Kanazawa Med Univ Hosp, Ctr Regenerat Med, Kahoku, Ishikawa 9200293, Japan; [Kato, Tomohisa, Jr.] Kanazawa Med Univ, Med Res Inst, Kahoku, Ishikawa 9200293, Japan		Shimodaira, S (通讯作者)，Kanazawa Med Univ, Dept Regenerat Med, Kahoku, Ishikawa 9200293, Japan.; Shimodaira, S (通讯作者)，Kanazawa Med Univ Hosp, Ctr Regenerat Med, Kahoku, Ishikawa 9200293, Japan.	dat-pey@kanazawa-med.ac.jp; koya@kanazawa-med.ac.jp; taku0731@kanazawa-med.ac.jp; m-togi@kanazawa-med.ac.jp; harukawa@kanazawa-med.ac.jp; asuka-w@kanazawa-med.ac.jp; tkato@kanazawa-med.ac.jp; shimodai@kanazawa-med.ac.jp		Sakamoto, Takuya/0000-0003-2519-4510; Kato, Tomohisa/0000-0002-3047-9847	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP19K07330]; Program on Open Innovation Platform with Enterprises, Research Institute and Academia of the JST [JPMJOP1722]	This research was funded by JSPS KAKENHI grant number JP19K07330 and the Program on Open Innovation Platform with Enterprises, Research Institute and Academia of the JST grant number JPMJOP1722.	Akagawa KS, 1996, BLOOD, V88, P4029, DOI 10.1182/blood.V88.10.4029.bloodjournal88104029; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barratt-Boyes SM, 2000, J IMMUNOL, V164, P2487, DOI 10.4049/jimmunol.164.5.2487; BarrattBoyes SM, 1997, J IMMUNOL, V158, P4543; Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; Clausen BE, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00534; Collin M, 2013, IMMUNOLOGY, V140, P22, DOI 10.1111/imm.12117; COLLINS HL, 1992, EUR J IMMUNOL, V22, P1447, DOI 10.1002/eji.1830220617; Cox MC, 2019, CLIN CANCER RES, V25, P5231, DOI 10.1158/1078-0432.CCR-19-0709; Daniliuc S, 2018, CYTOTHERAPY, V20, pS86, DOI 10.1016/j.jcyt.2018.02.244; Del Vecchio M, 2007, CLIN CANCER RES, V13, P4677, DOI 10.1158/1078-0432.CCR-07-0776; Dikic I, 2003, BIOCHEM SOC T, V31, P1178; Dudek AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00438; Fekete N, 2012, CYTOTHERAPY, V14, P540, DOI 10.3109/14653249.2012.655420; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Fu CM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03059; Fujii S, 2001, BLOOD, V98, P2143, DOI 10.1182/blood.V98.7.2143; Granot T, 2017, IMMUNITY, V46, P504, DOI 10.1016/j.immuni.2017.02.019; Han P, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz1580; Hsu WY, 2011, J CELL PHYSIOL, V226, P2181, DOI 10.1002/jcp.22555; Klechevsky E, 2008, IMMUNITY, V29, P497, DOI 10.1016/j.immuni.2008.07.013; Korthals M, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-46; Koya T, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12040305; Koya T, 2017, SCI REP-UK, V7, DOI 10.1038/srep42145; Kral JB, 2016, TRANSFUS MED HEMOTH, V43, P78, DOI 10.1159/000444807; Li CY, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0066-5; Li DY, 2012, EXP THER MED, V4, P131, DOI 10.3892/etm.2012.565; Liu XC, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018-019-1529-7; McGovern N, 2014, IMMUNITY, V41, P465, DOI 10.1016/j.immuni.2014.08.006; MING JE, 1992, CLIN EXP IMMUNOL, V89, P148; Mosser DM, 2008, IMMUNOL REV, V226, P205, DOI 10.1111/j.1600-065X.2008.00706.x; Muthuswamy R, 2010, BLOOD, V116, P1454, DOI 10.1182/blood-2009-12-258038; Nesselhut J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3092; Padovan E, 2002, J LEUKOCYTE BIOL, V71, P669; Papewalis C, 2008, J IMMUNOL, V180, P1462, DOI 10.4049/jimmunol.180.3.1462; Peng Q, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18570-x; Pierret L, 2009, J CLIN ONCOL, V27; Presciutti SM, 2014, J ORTHOP RES, V32, P1181, DOI 10.1002/jor.22638; Rozera C, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0473-5; Rutella S, 2006, BLOOD, V108, P1435, DOI 10.1182/blood-2006-03-006403; Santin AD, 2000, J VIROL, V74, P4729, DOI 10.1128/JVI.74.10.4729-4737.2000; SCHEURICH P, 1987, J IMMUNOL, V138, P1786; Shimodaira S., 2015, PHARM ANAL ACTA, V7, P8, DOI [10.4172/2153-2435.1000465, DOI 10.4172/2153-2435.1000465]; Shimodaira S, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030120; Siegel G, 2018, TRANSFUSION, V58, P1132, DOI 10.1111/trf.14541; Spadaro F, 2012, BLOOD, V119, P1407, DOI 10.1182/blood-2011-06-363564; Strobl H, 1999, MICROBES INFECT, V1, P1283, DOI 10.1016/S1286-4579(99)00256-7; Svajger U, 2017, CYTOTHERAPY, V19, P486, DOI 10.1016/j.jcyt.2017.01.005; Tanyi JL, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao5931; Tekkatte C, 2011, STEM CELLS INT, V2011, DOI 10.4061/2011/504723; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; von Bonin M, 2009, BONE MARROW TRANSPL, V43, P245, DOI 10.1038/bmt.2008.316; Wylie B, 2019, CANCERS, V11, DOI 10.3390/cancers11040521; Yanagisawa R, 2018, ANTICANCER RES, V38, P2217, DOI 10.21873/anticanres.12464	54	2	2	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							10	10.3390/vaccines9010010			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6UR	33374342	Green Published, gold			2022-04-29	WOS:000610807600001
J	te Kamp, V; Friedrichs, V; Freuling, CM; Vos, A; Potratz, M; Klein, A; Zaeck, LM; Eggerbauer, E; Schuster, P; Kaiser, C; Ortmann, S; Kretzschmar, A; Bobe, K; Knittler, MR; Dorhoi, A; Finke, S; Muller, T				te Kamp, Verena; Friedrichs, Virginia; Freuling, Conrad M.; Vos, Ad; Potratz, Madlin; Klein, Antonia; Zaeck, Luca M.; Eggerbauer, Elisa; Schuster, Peter; Kaiser, Christian; Ortmann, Steffen; Kretzschmar, Antje; Bobe, Katharina; Knittler, Michael R.; Dorhoi, Anca; Finke, Stefan; Mueller, Thomas			Comparable Long-Term Rabies Immunity in Foxes after IntraMuscular and Oral Application Using a Third-Generation Oral Rabies Virus Vaccine	VACCINES			English	Article						foxes; oral vaccination; SPBN GASGAS; neutralizing and binding antibodies; immunoglobulin isotypes; interferon gamma	ATTENUATED RECOMBINANT RABIES; VULPES-VULPES; RACCOON DOGS; EFFICACY; PROTECTION; INFECTION; RESPONSES; SAFETY; IMMUNOGENICITY; ANTIBODIES	The live genetically-engineered oral rabies virus (RABV) variant SPBN GASGAS induces long-lasting immunity in foxes and protection against challenge with an otherwise lethal dose of RABV field strains both after experimental oral and parenteral routes of administration. Induction of RABV-specific binding antibodies and immunoglobulin isotypes (IgM, total IgG, IgG1, IgG2) were comparable in orally and parenterally vaccinated foxes. Differences were only observed in the induction of virus-neutralizing (VNA) titers, which were significantly higher in the parenterally vaccinated group. The dynamics of rabies-specific antibodies pre- and post-challenge (365 days post vaccination) suggest the predominance of type-1 immunity protection of SPBN GASGAS. Independent of the route of administration, in the absence of IgG1 the immune response to SPBN GAGAS was mainly IgG2 driven. Interestingly, vaccination with SPBN GASGAS does not cause significant differences in inducible IFN-gamma production in vaccinated animals, indicating a relatively weak cellular immune response during challenge. Notably, the parenteral application of SPBN GASGAS did not induce any adverse side effects in foxes, thus supporting safety studies of this oral rabies vaccine in various species.	[te Kamp, Verena; Freuling, Conrad M.; Potratz, Madlin; Klein, Antonia; Zaeck, Luca M.; Eggerbauer, Elisa; Finke, Stefan; Mueller, Thomas] Friedrich Loeffler Inst FLI, WHO Collaborating Ctr Rabies Surveillance & Res, OIE Reference Lab Rabies, Inst Mol Virol & Cell Biol, D-17493 Greifswald, Germany; [te Kamp, Verena] Boehringer Ingelheim GmbH & Co KG, D-55216 Ingelheim, Germany; [Friedrichs, Virginia; Knittler, Michael R.; Dorhoi, Anca] Friedrich Loeffler Inst FLI, Inst Immunol, D-17493 Greifswald, Germany; [Vos, Ad; Schuster, Peter; Kaiser, Christian; Ortmann, Steffen; Kretzschmar, Antje; Bobe, Katharina] Ceva Innovat Ctr, D-06861 Dessau Rosslau, Germany; [Eggerbauer, Elisa] Thuringer Landesamt Verbraucherschutz, D-99947 Bad Langensalza, Germany		Muller, T (通讯作者)，Friedrich Loeffler Inst FLI, WHO Collaborating Ctr Rabies Surveillance & Res, OIE Reference Lab Rabies, Inst Mol Virol & Cell Biol, D-17493 Greifswald, Germany.	verena.te_kamp@boehringer-ingelheim.com; virginia.friedrichs@fli.de; conrad.freuling@fli.de; ad.vos@ceva.com; madlin.potratz@fli.de; antonia.klein@fli.de; Luca.zaeck@fli.de; Elisa.Eggerbauer@gmx.de; peter.schuster@ceva.com; christian.kaiser@ceva.com; steffen.ortmann@ceva.com; antje.kretzschmar@ceva.com; katharina.bobe@ceva.com; michael.knittler@fli.de; anca.dorhoi@fli.de; stefan.finke@fli.de; thomas.mueller@fli.de	Zaeck, Luca M./AAO-4958-2020	Zaeck, Luca M./0000-0001-7997-493X; Muller, Thomas/0000-0002-0959-3653; Finke, Stefan/0000-0001-8716-2341; Dorhoi, Anca/0000-0003-1739-749X; Freuling, Conrad/0000-0002-1076-398X	Ceva Sante Animale, France; intramural collaborative research grant at the Friedrich-Loeffler-Institut	The project was funded in the frame of a research cooperation with IDT Biologika GmbH (now Ceva Sante Animale, France) into mechanisms of oral rabies vaccination. Parts of the project were supported by an intramural collaborative research grant at the Friedrich-Loeffler-Institut.	Bankovskiy D, 2008, DEV BIOLOGICALS, V131, P461; Bergeron LM, 2014, VET IMMUNOL IMMUNOP, V157, P31, DOI 10.1016/j.vetimm.2013.10.018; BLACK JG, 1980, CAN J COMP MED, V44, P169; BLANCOU J, 1989, ANN RECH VET, V20, P195; Bommier E, 2020, VET IMMUNOL IMMUNOP, V220, DOI 10.1016/j.vetimm.2019.109986; Bouvet J, 2018, VET IMMUNOL IMMUNOP, V205, P93, DOI 10.1016/j.vetimm.2018.11.001; BROCHIER BM, 1990, VET REC, V127, P165; Brown David, 2011, Adv Prev Med, V2011, P601789, DOI 10.4061/2011/601789; Brown LJ, 2014, VACCINE, V32, P3675, DOI 10.1016/j.vaccine.2014.04.029; Brown LJ, 2014, VACCINE, V32, P984, DOI 10.1016/j.vaccine.2013.12.015; Brown LJ, 2012, J WILDLIFE DIS, V48, P1010, DOI 10.7589/2012-01-023; Campbell J. B., 1985, Rabies in the tropics. Proceedings of an international conference on rabies control in the tropics, Tunis, Oct. 3-6, 1983, P285; Champion JM, 2000, J IMMUNOL METHODS, V235, P81, DOI 10.1016/S0022-1759(99)00223-9; Chapat L, 2017, VET IMMUNOL IMMUNOP, V189, P58, DOI 10.1016/j.vetimm.2017.06.001; CHO HC, 1972, INFECT IMMUN, V6, P483, DOI 10.1128/IAI.6.4.483-486.1972; Cliquet F, 2008, DEV BIOLOGICALS, V131, P257; Cliquet F, 2006, VACCINE, V24, P4386, DOI 10.1016/j.vaccine.2006.02.057; COE JE, 1977, INFECT IMMUN, V16, P915, DOI 10.1128/IAI.16.3.915-919.1977; DIETZSCHOLD B, 1987, VIROLOGY, V161, P29, DOI 10.1016/0042-6822(87)90167-X; Donaghy D, 2020, VET IMMUNOL IMMUNOP, V221, DOI 10.1016/j.vetimm.2020.110014; European Medicines Agency (EMA), 2000, AD GUID INT COOP HAR; Faber M, 2009, P NATL ACAD SCI USA, V106, P11300, DOI 10.1073/pnas.0905640106; Freuling CM, 2020, EMERG INFECT DIS, V26, P2982, DOI 10.3201/eid2612.203733; Freuling CM, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090790; Freuling CM, 2019, VACCINE, V37, P4750, DOI 10.1016/j.vaccine.2017.09.093; GERBER JD, 1985, VET IMMUNOL IMMUNOP, V9, P13, DOI 10.1016/0165-2427(85)90126-6; Ghislat G, 2018, CELL MOL IMMUNOL, V15, P944, DOI 10.1038/cmi.2018.2; Gilbert A, 2018, VACCINE, V36, P4919, DOI 10.1016/j.vaccine.2018.06.052; Gnanadurai CW, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004023; Hanlon CA, 2002, J WILDLIFE DIS, V38, P420, DOI 10.7589/0090-3558-38.2.420; Hartinger J, 2001, ALTEX-ALTERN TIEREXP, V18, P37; Hoffmann B, 2010, J CLIN MICROBIOL, V48, P3970, DOI 10.1128/JCM.00612-10; Hooper DC, 1998, J VIROL, V72, P3711, DOI 10.1128/JVI.72.5.3711-3719.1998; Hsu AP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184831; Johnson N, 2010, VACCINE, V28, P3896, DOI 10.1016/j.vaccine.2010.03.039; Knowlton FF, 2001, J WILDLIFE DIS, V37, P798, DOI 10.7589/0090-3558-37.4.798; Lambot M, 2001, VACCINE, V19, P1827, DOI 10.1016/S0264-410X(00)00321-2; LAWSON KF, 1982, CAN J COMP MED, V46, P382; LAWSON KF, 1989, CAN J VET RES, V53, P56; Lebrun A, 2017, TROP MED INFECT DIS, V2, DOI 10.3390/tropicalmed2030022; Lebrun A, 2015, J IMMUNOL, V195, P4358, DOI 10.4049/jimmunol.1501274; Leelahapongsathon K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040573; Li JW, 2012, J VIROL, V86, P3200, DOI 10.1128/JVI.06699-11; Mahl P, 2014, VET RES, V45, DOI 10.1186/s13567-014-0077-8; McGettigan JP, 2010, EXPERT REV VACCINES, V9, P1177, DOI [10.1586/erv.10.105, 10.1586/ERV.10.105]; Moore SM, 2017, TROP MED INFECT DIS, V2, DOI 10.3390/tropicalmed2030031; Muller T., 2020, RABIES RABIES VACCIN, P45; Neubert A, 2001, J VET MED B, V48, P179, DOI 10.1046/j.1439-0450.2001.00440.x; Nolden T, 2016, SCI REP-UK, V6, DOI 10.1038/srep23887; Overduin LA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030110; Overgaard NH, 2018, ILAR J, V59, P247, DOI 10.1093/ilar/ily014; Ph E., 2016, EMA MON; Riedhammer C, 2016, METHODS MOL BIOL, V1304, P53, DOI 10.1007/7651_2014_99; Rolland-Turner M, 2004, VACCINE, V22, P4163, DOI 10.1016/j.vaccine.2004.06.050; Rosatte R, 2001, J WILDLIFE DIS, V37, P265, DOI 10.7589/0090-3558-37.2.265; Rosatte R, 2007, J WILDLIFE DIS, V43, P300, DOI 10.7589/0090-3558-43.2.300; Rota A, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-2085-4; Roy A, 2007, J VIROL, V81, P7993, DOI 10.1128/JVI.00710-07; Rupprecht C.E., 2018, LAB TECHN RAB; SCHNELL MJ, 1994, EMBO J, V13, P4195, DOI 10.1002/j.1460-2075.1994.tb06739.x; Schuster P, 2001, ACTA VET HUNG, V49, P285, DOI 10.1556/AVet.49.2001.3.4; Schutsky K, 2013, J VIROL, V87, P1834, DOI 10.1128/JVI.02589-12; Sterner RT, 2009, EMERG INFECT DIS, V15, P1176, DOI 10.3201/eid1508.081061; te Kamp V, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59719-4; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Vogt Robert, 2011, IARC Sci Publ, P215; Waner T, 2003, VET REC, V152, P588, DOI 10.1136/vr.152.19.588; Wang HL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025414; Wang ZW, 2005, J VIROL, V79, P12554, DOI 10.1128/JVI.79.19.12554-12565.2005; Wasniewski M, 2013, J VIROL METHODS, V187, P264, DOI 10.1016/j.jviromet.2012.11.022; Zhang SN, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100919; Zhang SF, 2008, VACCINE, V26, P345, DOI 10.1016/j.vaccine.2007.11.029	72	1	1	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							49	10.3390/vaccines9010049			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7AK	33466701	Green Published, gold			2022-04-29	WOS:000610822800001
J	Pares-Badell, O; Martinez-Gomez, X; Pinos, L; Borras-Bermejo, B; Uriona, S; Otero-Romero, S; Rodrigo-Pendas, JA; Cossio-Gil, Y; Agusti, A; Aguilera, C; Campins, M				Pares-Badell, Oleguer; Martinez-Gomez, Xavier; Pinos, Laia; Borras-Bermejo, Blanca; Uriona, Sonia; Otero-Romero, Susana; Rodrigo-Pendas, Jose angel; Cossio-Gil, Yolima; Agusti, Antonia; Aguilera, Cristina; Campins, Magda			Local and Systemic Adverse Reactions to mRNA COVID-19 Vaccines Comparing Two Vaccine Types and Occurrence of Previous COVID-19 Infection	VACCINES			English	Article						SARS-CoV-2; COVID-19-vaccination; mRNA vaccines; adverse reactions; healthcare workers		The aim of this study was to assess adverse reactions to COVID-19 vaccines, comparing the BNT162b2 or the mRNA-1273 COVID-19 vaccines and the presence and seriousness of a previous COVID-19 infection. We conducted a cross-sectional online survey of vaccinated healthcare workers at a tertiary hospital in Barcelona (Spain). Thirty-eight percent of vaccine recipients responded to the questionnaire. We compared the prevalence of adverse reactions by vaccine type and history of COVID-19 infections. A total of 2373 respondents had received the BNT162b2 vaccine, and 506 the mRNA-1273 vaccine. The prevalence of at least one adverse reaction with doses 1 and 2 was 41% and 70%, respectively, in the BNT162b2 group, and 60% and 92% in the mRNA-1273 group (p < 0.001). The BNT162b2 group reported less prevalence of all adverse reactions. Need for medical leave was significantly more frequent among the mRNA-1273 group (12% versus 4.6% p < 0.001). Interestingly, respondents with a history of allergies or chronic illnesses did not report more adverse reactions. The frequency of adverse reactions with dose 2 was 96% (95% CI 88-100%) for those with a history of COVID-19 related hospitalization, and 86% (95% CI 83-89%) for those with mild or moderate symptomatic COVID-19, significantly higher than for participants with no history of COVID-19 infections (67%, 95% CI 65-69%). Our results could help inform vaccine recipients of the probability of their having adverse reactions to COVID-19 vaccines.	[Pares-Badell, Oleguer; Martinez-Gomez, Xavier; Pinos, Laia; Borras-Bermejo, Blanca; Uriona, Sonia; Otero-Romero, Susana; Rodrigo-Pendas, Jose angel; Campins, Magda] Vall dHebron Hosp Univ, Vall dHebron Barcelona Hosp Campus, Serv Med Prevent & Epidemiol, Passeig Vall dHebron 119-129, Barcelona 08035, Spain; [Pares-Badell, Oleguer] Univ Pompeu Fabra, Dept Expt Sci & Hlth, Barcelona 08005, Spain; [Martinez-Gomez, Xavier; Borras-Bermejo, Blanca; Otero-Romero, Susana; Rodrigo-Pendas, Jose angel; Campins, Magda] Univ Autonoma Barcelona, Unitat Docent Vall dHebron, Bellaterra 08193, Spain; [Cossio-Gil, Yolima] Hosp Univ Vall dHebron, Dept Informat Syst & Decis Support, Barcelona 08035, Spain; [Cossio-Gil, Yolima] Vall dHebron Inst Recerca VHIR, Res Grp Healthcare Syst Management, Barcelona 08035, Spain; [Agusti, Antonia; Aguilera, Cristina] Vall dHebron Inst Recerca VHIR, Serv Farmacol Clin, Barcelona 08035, Spain; [Agusti, Antonia] Univ Autonoma Barcelona, Dept Farmacol Terapeut & Toxicol, Bellaterra 08193, Spain		Martinez-Gomez, X (通讯作者)，Vall dHebron Hosp Univ, Vall dHebron Barcelona Hosp Campus, Serv Med Prevent & Epidemiol, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.; Martinez-Gomez, X (通讯作者)，Univ Autonoma Barcelona, Unitat Docent Vall dHebron, Bellaterra 08193, Spain.	opares@vhebron.net; xmartinez@vhebron.net; lpinos@vhebron.net; bborras@vhebron.net; smuriona@vhebron.net; sotero@vhebron.net; jarodrigo@vhebron.net; ycossio@vhebron.net; aagusti@vhebron.net; craguile@vhebron.net; mcampins@vhebron.net	Borras-Bermejo, Blanca/AFK-9069-2022; Campins Marti, Magda/N-9934-2017	Borras-Bermejo, Blanca/0000-0003-4111-5632; Campins Marti, Magda/0000-0002-8841-6195; Rodrigo Pendas, Jose Angel/0000-0002-2383-9904; Pares-Badell, Oleguer/0000-0003-2568-7550; Agusti, Antonia/0000-0003-4594-1122; Martinez-Gomez, Xavier/0000-0003-4583-9734			Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bae S, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e115; Bandyopadhyay S, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003097; Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P1423, DOI 10.1016/j.jaip.2020.12.047; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Centers for Disease Control and Prevention, REACT ADV EV PFIZ BI; Centers for Disease Control and Prevention Local Reactions, SYST REACT ADV EV SE; Centers for Disease Control and Prevention Vaccine Adverse Event Reporting System (VAERS), 2021, PUBLICATIONS; Chou R, 2020, ANN INTERN MED, V173, P120, DOI 10.7326/M20-1632; Debes AK, 2021, JAMA INTERN MED, V181, P1660, DOI 10.1001/jamainternmed.2021.4580; European Centre for Disease Prevention and Control, COR DIS 2019 COVID 1; European Medicines Agency, 2020, COM COVID 19 MRNA VA; European Medicines Agency, EMA REC COVID 19 VAC; European Medicines Agency, EMA REC 1 COVID 19 A; European Medicines Agency, 2021, COVID 19 VACC MOD CO; Ghebreyesus T.A, 2020, DIR GEN OP REM MED B; Grupo de Trabajo Tecnico de Vacunacion COVID-19, ESTR VAC FRENT COVID; Kadali RAK, 2021, INT J INFECT DIS, V106, P376, DOI 10.1016/j.ijid.2021.04.047; Kadali RAK, 2021, J MED VIROL, V93, P4420, DOI 10.1002/jmv.26996; Krammer F., 2021, ROBUST SPIKE ANTIBOD, DOI [10.1101/2021.01.29.21250653, DOI 10.1101/2021.01.29.21250653]; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Mathioudakis AG, 2021, LIFE-BASEL, V11, DOI 10.3390/life11030249; McNeil MM, 2018, J ALLERGY CLIN IMMUN, V141, P463, DOI 10.1016/j.jaci.2017.12.971; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Raw RK, 2021, J INFECTION, V83, P401, DOI 10.1016/j.jinf.2021.05.035; Schoenmaker L, 2021, INT J PHARMACEUT, V601, DOI 10.1016/j.ijpharm.2021.120586; Soriano V, 2021, INT J INFECT DIS, V107, P212, DOI 10.1016/j.ijid.2021.04.074; Stone CA, 2019, BRIT J CLIN PHARMACO, V85, P2694, DOI 10.1111/bcp.14112; Teijaro JR, 2021, NAT REV IMMUNOL, V21, P195, DOI 10.1038/s41577-021-00526-x; Tre-Hardy M, 2021, J INFECTION, V83, P277, DOI 10.1016/j.jinf.2021.03.025	30	0	0	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1463	10.3390/vaccines9121463			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YG3NQ	34960209	Green Published, gold			2022-04-29	WOS:000742399700001
J	Weinberger, B				Weinberger, Birgit			Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population	VACCINES			English	Article						SARS-CoV-2; COVID-19; vaccine; vaccination; elderly; aging	NCOV-19 AZD1222 VACCINE; COVID-19 VACCINE; CHADOX1 NCOV-19; BNT162B2; IMMUNOGENICITY; INFECTION; EFFICACY; ANTIBODY; INFLUENZA; WORKERS	Age is among the most prominent risk factors for developing severe COVID-19 disease, and therefore older adults are a major target group for vaccination against SARS-CoV-2. This review focusses on age-associated aspects of COVID-19 vaccines and vaccination strategies, and summarizes data on immunogenicity, efficacy and effectiveness of the four COVID-19 vaccines, which are licensed in the US and/or Europe; namely, the two mRNA vaccines by BioNTech/Pfizer (BNT162b2) and Moderna (mRNA-1273), and the adenovector vaccines developed by AstraZeneca/University Oxford (ChAdOx1-nCoV-19, AZD1222) and Janssen/Johnson&Johnson (Ad26.COV2-S), respectively. After very high protection rates in the first months after vaccination even in the older population, effectiveness of the vaccines, particularly against asymptomatic infection and mild disease, declined at later time points and with the emergence of virus variants. Many high-income countries have recently started administration of additional doses to older adults and other high-risk groups, whereas other parts of the world are still struggling to acquire and distribute vaccines for primary vaccination. Other vaccines are available in other countries and clinical development for more vaccine candidates is ongoing, but a complete overview of COVID-19 vaccine development is beyond the scope of this article.	[Weinberger, Birgit] Univ Innsbruck, Inst Biomed Aging Res, A-6020 Innsbruck, Austria		Weinberger, B (通讯作者)，Univ Innsbruck, Inst Biomed Aging Res, A-6020 Innsbruck, Austria.	birgit.weinberger@uibk.ac.at		Weinberger, Birgit/0000-0002-7084-946X	Innovative Medicines Initiative 2 Joint Undertaking [806776]; European UnionEuropean Commission; EFPIA	This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No [806776]. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.	Agrawal A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00896; Albrecht L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080886; Alter G, 2021, NATURE, V596, P268, DOI [10.21417/GA2021N, 10.1038/s41586-021-03681-2]; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P1423, DOI 10.1016/j.jaip.2020.12.047; Bar-On YM, 2021, NEW ENGL J MED, V385, P1393, DOI 10.1056/NEJMoa2114255; Barda N, 2021, LANCET, V398, P2093, DOI 10.1016/S0140-6736(21)02249-2; Barros-Martins J, 2021, NAT MED, V27, P1525, DOI 10.1038/s41591-021-01449-9; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Booth A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247461; Centers for Disease Control and Prevention, COVID 19 VACC BOOST; Choi A, 2021, NAT MED, V27, P2025, DOI 10.1038/s41591-021-01527-y; Choi A, 2021, J VIROL, V95, DOI 10.1128/JVI.01313-21; Cines DB, 2021, NEW ENGL J MED, V384, P2254, DOI 10.1056/NEJMe2106315; Clemens SAC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25982-w; Collier DA, 2021, NATURE, V596, P417, DOI 10.1038/s41586-021-03739-1; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Drew W, 2018, EXP GERONTOL, V105, P70, DOI 10.1016/j.exger.2017.12.020; Drijkoningen JJC, 2014, CLIN MICROBIOL INFEC, V20, P45, DOI 10.1111/1469-0691.12461; Earle KA, 2021, VACCINE, V39, P4423, DOI 10.1016/j.vaccine.2021.05.063; El Sahly HM, 2021, NEW ENGL J MED, V385, P1774, DOI 10.1056/NEJMoa2113017; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; European Centre for Disease Prevention and Control, FACTSH SEAS INFL; Falsey AR, 2021, NEW ENGL J MED, V385, P2348, DOI 10.1056/NEJMoa2105290; Falsey AR, 2021, NEW ENGL J MED, V385, P1627, DOI 10.1056/NEJMc2113468; Flaxman A, 2021, LANCET, V398, P981, DOI 10.1016/S0140-6736(21)01699-8; Flook M, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05992-1; Frasca D, 2020, INTERD T GERONT GERI, V43, P86, DOI 10.1159/000504440; Frasca D, 2014, CURR OPIN IMMUNOL, V29, P112, DOI 10.1016/j.coi.2014.05.008; Gavazzi G, 2002, LANCET INFECT DIS, V2, P659, DOI 10.1016/S1473-3099(02)00437-1; Goronzy JJ, 2015, J IMMUNOL, V194, P4073, DOI 10.4049/jimmunol.1500046; Gustafson CE, 2018, CLIN SCI, V132, P1925, DOI 10.1042/CS20171157; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Harder T, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.41.2100920; Harderi T, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.28.2100563; Hillus D, 2021, LANCET RESP MED, V9, P1255, DOI 10.1016/S2213-2600(21)00357-X; Jalkanen P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24285-4; Jergovic M, 2018, EXP GERONTOL, V105, P140, DOI 10.1016/j.exger.2018.01.011; Kawai K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004833; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Kwetkat A, 2020, INTERD T GERONT GERI, V43, P73, DOI 10.1159/000504491; Liu XX, 2021, LANCET, V398, P856, DOI 10.1016/S0140-6736(21)01694-9; Lorenzo EC, 2018, BIOGERONTOLOGY, V19, P437, DOI 10.1007/s10522-018-9754-8; Lv M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101102; Mateus J, 2021, SCIENCE, V374, P420, DOI 10.1126/science.abj9853; McDonald I, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00336-1; Ministry of Health, DECL VACC EFF INF SY; Montgomery J, 2021, JAMA CARDIOL, V6, P1202, DOI 10.1001/jamacardio.2021.2833; Noori M, 2022, REV MED VIROL, V32, DOI 10.1002/rmv.2277; Palmer S, 2021, J R SOC INTERFACE, V18, DOI 10.1098/rsif.2020.0982; Pangrazzi L, 2020, EXP GERONTOL, V134, DOI 10.1016/j.exger.2020.110887; Parry H., 2021, EXTENDED INTERVAL BN, DOI [10.1101/2021.05.15.21257017, DOI 10.1101/2021.05.15.21257017]; Pijls BG, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-044640; Pinti M, 2016, EUR J IMMUNOL, V46, P2286, DOI 10.1002/eji.201546178; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Promislow DEL, 2020, J GERONTOL A-BIOL, V75, pE30, DOI 10.1093/gerona/glaa094; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Saiag E, 2021, LANCET MICROBE, V2, pE650, DOI 10.1016/S2666-5247(21)00272-X; Schwarz T, 2021, EMERG INFECT DIS, V27, P2174, DOI 10.3201/eid2708.211145; Shimabukuro TT, 2021, JAMA-J AM MED ASSOC, V325, P1101, DOI 10.1001/jama.2021.1967; Silva-Cayetano A, 2021, MED-CAMBRIDGE, V2, P243, DOI 10.1016/j.medj.2020.12.006; Solforosi L, 2021, J EXP MED, V218, DOI 10.1084/jem.20202756; Sudre CH, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01292-y; Tao KM, 2021, NAT REV GENET, V22, P757, DOI 10.1038/s41576-021-00408-x; Tartof SY, 2021, LANCET, V398, P1407, DOI 10.1016/S0140-6736(21)02183-8; Thomas SJ, 2021, NEW ENGL J MED, V385, P1761, DOI 10.1056/NEJMoa2110345; Thompson EJ, RISK FACTORS LONG CO, DOI [10.1101/2021.06.24.21259277, DOI 10.1101/2021.06.24.21259277]; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; Tober-Lau P, 2021, LANCET RESP MED, V9, pE104, DOI 10.1016/S2213-2600(21)00456-2; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wagner A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00717; Wall EC, 2021, LANCET, V398, P207, DOI 10.1016/S0140-6736(21)01462-8; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Weinberger B, 2021, IMMUN AGEING, V18, DOI 10.1186/s12979-021-00249-6; Weinberger B, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-017-0107-2; World Health Organisation, COVID 19 VACC TRACK; World Health Organisation, 7 VACC APPR US WHO; World Health Organisation, TRACK SARS COV 2 VAR; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344	84	0	0	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1435	10.3390/vaccines9121435			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1YT	34960181	Green Published, gold			2022-04-29	WOS:000737456400001
J	Abdelzaher, HM; Gabr, AS; Saleh, BM; Gawad, RAM; Nour, AA; Abdelanser, A				Abdelzaher, Hana M.; Gabr, Asmaa S.; Saleh, Basma M.; Abdel Gawad, Rana M.; Nour, Ahmed A.; Abdelanser, Anwar			RNA Vaccines against Infectious Diseases: Vital Progress with Room for Improvement	VACCINES			English	Review						mRNA vaccines; infectious diseases; challenges; clinical trials; SARS-CoV-2	CHIKUNGUNYA VACCINE; SARS-COV-2 VACCINES; IMMUNE-RESPONSES; IN-VIVO; COVID-19; DELIVERY; IMMUNOGENICITY; NANOPARTICLES; POTENT; CHALLENGES	mRNA vaccines have amassed a strong interest from scientists and nonscientists alike for their potential in treating cancer and curbing the spread of infectious diseases. Their success has been bolstered by the COVID-19 pandemic as mRNA vaccines for the SARS-CoV-2 virus showed unrivaled efficiency and success. The strategy relies on the delivery of an RNA transcript that carries the sequence of an antigenic molecule into the body's cells where the antigen is manufactured. The lack of use of infectious pathogens and the fact that they are made of nucleic acids render these vaccines a favorable alternative to other vaccination modalities. However, mRNA vaccination still suffers from a great deal of hurdles starting from their safety, cellular delivery, uptake and response to their manufacturing, logistics and storage. In this review, we examine the premise of RNA vaccination starting from their conceptualization to their clinical applications. We also thoroughly discuss the advances in the field of RNA vaccination for infectious diseases. Finally, we discuss the challenges impeding their progress and shed light on potential areas of research in the field.	[Abdelzaher, Hana M.; Gabr, Asmaa S.; Saleh, Basma M.; Abdel Gawad, Rana M.; Nour, Ahmed A.; Abdelanser, Anwar] Amer Univ Cairo, Inst Global Publ Hlth, Sch Sci & Engn, Cairo 11835, Egypt		Abdelanser, A (通讯作者)，Amer Univ Cairo, Inst Global Publ Hlth, Sch Sci & Engn, Cairo 11835, Egypt.	hana-abdelzaher@aucegypt.edu; asmaasaeed@aucegypt.edu; basma_saleh@aucegypt.edu; ranagawad@aucegypt.edu; ahmed.adel.nour@aucegypt.edu; anwar.abdelnaser@aucegypt.edu			AUC COVID-19 Pandemic Research and Innovation Initiative Grant	This work is supported by an AUC COVID-19 Pandemic Research and Innovation Initiative Grant to A.A.	Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Alameh Mohamad-Gabriel, 2020, Curr Top Microbiol Immunol, DOI 10.1007/82_2020_202; Aldosari BN, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020206; Aldrich C, 2021, VACCINE, V39, P1310, DOI 10.1016/j.vaccine.2020.12.070; Alkandari D, 2021, LANCET MICROBE, V2, pE89, DOI 10.1016/S2666-5247(21)00034-3; [Anonymous], LATEST DEV CHULACOV1; [Anonymous], MODULE 2 OVERVIEW OU; [Anonymous], ISRCTN-ISRCTN17072692: Clinical Trial to Assess the Safety of a Coronavirus Vaccine in Healthy Men and Women; [Anonymous], STUDY MRNA VACCINE F; [Anonymous], Vaccine Types|NIH: National Institute of Allergy and Infectious Diseases; [Anonymous], Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates|Moderna, Inc; [Anonymous], Landmark Coronavirus Study to Trial Inhaled Imperial and Oxford Vaccines|Imperial News|Imperial College London; [Anonymous], DRAFT LANDSCAPE TRAC; [Anonymous], 2021, SANOFI PRESS RELEASE; [Anonymous], B CELL INTRINSIC TYP; [Anonymous], VACCINES IMMUNIZATIO; Armbruster N, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040132; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bloom K, 2021, GENE THER, V28, P117, DOI 10.1038/s41434-020-00204-y; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Cafri G, 2020, J CLIN INVEST, V130, P5976, DOI 10.1172/JCI134915; CDC, UND MRNA COVID 19 VA; Chahal JS, 2016, P NATL ACAD SCI USA, V113, pE4133, DOI 10.1073/pnas.1600299113; Chulalongkorn University, 2020, PHAS 1 2 DOS FIND ST; Chung JY, 2021, ADV DRUG DELIVER REV, V170, P1, DOI 10.1016/j.addr.2020.12.011; Cobb M, 2015, CURR BIOL, V25, pR526, DOI 10.1016/j.cub.2015.05.032; CONRY RM, 1995, CANCER RES, V55, P1397; Crommelin DJA, 2021, J PHARM SCI-US, V110, P997, DOI 10.1016/j.xphs.2020.12.006; CureVac A.G., 2021, COVID 19 PHAS 3 RAND; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; de Alwis R, 2021, MOL THER, V29, P1970, DOI 10.1016/j.ymthe.2021.04.001; de Jong W, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040209; Dolgin E, 2021, NATURE, V589, P189, DOI 10.1038/d41586-021-00019-w; FDA Office of Commissioner, COR COVID 19 UPD FDA; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Fuller DH, 2020, NEW ENGL J MED, V382, P2469, DOI 10.1056/NEJMcibr2009737; Gabor, 2020, PHASE 1 ASSESSMENT S, DOI [10.1101/2020.11.09.20228551, DOI 10.1101/2020.11.09.20228551]; Gandhi RT, 2016, JAIDS-J ACQ IMM DEF, V71, P246, DOI 10.1097/QAI.0000000000000852; Gay CL, 2018, AIDS RES HUM RETROV, V34, P111, DOI 10.1089/aid.2017.0071; Gilboa E, 2004, IMMUNOL REV, V199, P251, DOI 10.1111/j.0105-2896.2004.00139.x; Goel RR, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi6950; Goyal M, 2018, DRUG DES DEV THER, V12, P4195, DOI 10.2147/DDDT.S181574; Gruters R., 2019, PHASE 2A RANDOMIZED; Huttner A, 2018, EXPERT REV VACCINES, V17, P1105, DOI 10.1080/14760584.2018.1546582; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; JOHANNING FW, 1995, NUCLEIC ACIDS RES, V23, P1495, DOI 10.1093/nar/23.9.1495; John S, 2018, VACCINE, V36, P1689, DOI 10.1016/j.vaccine.2018.01.029; Kaczmarek JC, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0450-0; Kalnin KV, 2020, IMMUNOGENICITY NOVEL, DOI [10.1101/2020.10.14.337535., DOI 10.1101/2020.10.14.337535]; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Karch CP, 2016, BIOCHEM PHARMACOL, V120, P1, DOI 10.1016/j.bcp.2016.05.001; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kose N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw6647; Kowalczyk A, 2016, VACCINE, V34, P3882, DOI 10.1016/j.vaccine.2016.05.046; Kowalski PS, 2019, MOL THER, V27, P710, DOI 10.1016/j.ymthe.2019.02.012; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Kreiter S, 2010, CANCER RES, V70, P9031, DOI 10.1158/0008-5472.CAN-10-0699; Kubler H, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0068-y; Kyriakidis NC, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00292-w; Lee NH, 2012, CLIN EXP VACCINE RES, V1, P18, DOI 10.7774/cevr.2012.1.1.18; Malinis M, 2021, AM J TRANSPLANT, V21, P2916, DOI 10.1111/ajt.16713; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; MARTINON F, 1993, EUR J IMMUNOL, V23, P1719, DOI 10.1002/eji.1830230749; Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020; McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9; Meyer M, 2018, J INFECT DIS, V217, P451, DOI 10.1093/infdis/jix592; Midoux P, 2015, EXPERT REV VACCINES, V14, P221, DOI 10.1586/14760584.2015.986104; Muik A, 2021, SCIENCE, V371, P1152, DOI 10.1126/science.abg6105; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; National Institute of Allergy and Infectious Diseases (NIAID), 2021, PHAS 1 OP LAB RAND S; Ou MT, 2021, TRANSPLANTATION, V105, P2170, DOI 10.1097/TP.0000000000003780; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poland GA, 2021, VACCINE, V39, P457, DOI 10.1016/j.vaccine.2020.12.017; Probst J, 2007, GENE THER, V14, P1175, DOI 10.1038/sj.gt.3302964; Rauch S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00311-w; Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Rodrigues AF, 2015, BIOTECHNOL J, V10, P1329, DOI 10.1002/biot.201400387; Rosa SS, 2021, VACCINE, V39, P2190, DOI 10.1016/j.vaccine.2021.03.038; Sahin U, 2018, SCIENCE, V359, P1355, DOI 10.1126/science.aar7112; Schlake T, 2012, RNA BIOL, V9, P1319, DOI 10.4161/rna.22269; Shaw C, 2019, INT J INFECT DIS, V79, P17, DOI 10.1016/j.ijid.2018.11.058; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Shimabukuro TT, 2021, OBSTET GYNECOL SURV, V76, P729, DOI [10.1056/NEJMoa2104983, 10.1056/NEJMx210016, 10.1097/01.ogx.0000802676.57373.17]; Teijaro JR, 2021, NAT REV IMMUNOL, V21, P195, DOI 10.1038/s41577-021-00526-x; Tenforde MW, 2021, MMWR-MORBID MORTAL W, V70, P674, DOI 10.15585/mmwr.mm7018e1; Theobald N, 2020, DRUG DISCOV TODAY, V25, P1556, DOI 10.1016/j.drudis.2020.06.020; Thran M, 2017, EMBO MOL MED, V9, P1434, DOI 10.15252/emmm.201707678; Velikova T, 2021, RHEUMATOL INT, V41, P509, DOI 10.1007/s00296-021-04792-9; Wadhwa A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020102; Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298; Wang Y, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01311-z; Weide B, 2009, J IMMUNOTHER, V32, P498, DOI 10.1097/CJI.0b013e3181a00068; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; Wilder-Smith A, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1067-x; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Xu SQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186582; Zhang CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00594; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; ZHOU X, 1994, VACCINE, V12, P1510, DOI 10.1016/0264-410X(94)90074-4	104	1	1	12	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1211	10.3390/vaccines9111211			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG9VN	34835142	Green Published, gold			2022-04-29	WOS:000725093500001
J	Balut, MD; Chu, KR; Gin, JL; Dobalian, A; Der-Martirosian, C				Balut, Michelle D.; Chu, Karen; Gin, June L.; Dobalian, Aram; Der-Martirosian, Claudia			Predictors of COVID-19 Vaccination among Veterans Experiencing Homelessness	VACCINES			English	Article						COVID-19 vaccines; vaccine hesitancy; SARS-CoV-2; homeless persons; Veterans; public health	BEHAVIORAL-MODEL; MENTAL-ILLNESS; MEDICAL-CARE; ACCEPTANCE; HESITANCY; POPULATIONS; RATES; CITY	Sufficient uptake of the COVID-19 vaccine is key to slowing the spread of the coronavirus among the most vulnerable in society, including individuals experiencing homelessness. However, COVID-19 vaccination rates among the Veteran homeless population are currently unknown. This study examines the COVID-19 vaccination rate among homeless Veterans who receive care at the U.S. Department of Veterans Affairs (VA), and the factors that are associated with vaccine uptake. Using VA administrative and clinical data, bivariate and multivariate analyses were conducted to identify the sociodemographic, health-related, and healthcare and housing services utilization factors that influenced COVID-19 vaccine uptake during the first eight months of the vaccine rollout (December 2020-August 2021). Of the 83,528 Veterans experiencing homelessness included in the study, 45.8% were vaccinated for COVID-19. Non-white, older Veterans (65+), females, those who received the seasonal flu vaccine, and Veterans with multiple comorbidities and mental health conditions were more likely to be vaccinated. There was a strong association between COVID-19 vaccination and Veterans who utilized VA healthcare and housing services. VA healthcare and homeless service providers are particularly well-positioned to provide trusted information and overcome access barriers for homeless Veterans to receive the COVID-19 vaccine.	[Balut, Michelle D.; Chu, Karen; Gin, June L.; Dobalian, Aram; Der-Martirosian, Claudia] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, North Hills, CA 91343 USA; [Dobalian, Aram] Univ Memphis, Sch Publ Hlth, Div Hlth Syst Management & Policy, Memphis, TN 38152 USA		Balut, MD (通讯作者)，US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, North Hills, CA 91343 USA.	Michelle.Balut@va.gov; Karen.Chu@va.gov; June.Gin@va.gov; Aram.Dobalian@va.gov; Claudia.Der-Martirosian@va.gov		Balut, Michelle/0000-0002-2548-2283	Office of Population Health, Veterans Health Administration, U.S. Department of Veterans Affairs [XVA 65-2020]	VEMEC is funded by the Office of Population Health, Veterans Health Administration, U.S. Department of Veterans Affairs (XVA 65-2020). This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.	Andersen R. M., 1968, BEHAV MODEL FAMILIES; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], 2021, CBS NEWS; Beers L, 2019, NURSE PRACT, V44, P48, DOI 10.1097/01.NPR.0000586012.31046.c9; Bogart LM, 2021, JAIDS-J ACQ IMM DEF, V86, P200, DOI 10.1097/QAI.0000000000002570; Buechler CR, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03474; Centers for Disease Control and Prevention, 2021, COVID 19 VACC US; Centers for Disease Control and Prevention, 2021, INT GUID HLTH DEP CO; Centers for Disease Control Prevention, 2021, PEOPL CERT MED COND; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chor JSY, 2011, VACCINE, V29, P7364, DOI 10.1016/j.vaccine.2011.07.079; Culhane DP, 2002, HOUS POLICY DEBATE, V13, P107, DOI 10.1080/10511482.2002.9521437; Der-Martirosian C, 2014, PREHOSP DISASTER MED, V29, P134, DOI 10.1017/S1049023X1400020X; Frew PM, 2012, VACCINE, V30, P4200, DOI 10.1016/j.vaccine.2012.04.053; Gabrielian S, 2021, J PRIM CARE COMMUNIT, V12, DOI 10.1177/2150132721993654; Gabrielian S, 2016, PSYCHIAT SERV, V67, P86, DOI 10.1176/appi.ps.201400311; Gallardo KR, 2020, PREV SCI, V21, P937, DOI 10.1007/s11121-020-01131-5; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Gelberg L, 2000, HEALTH SERV RES, V34, P1273; Gin J.L., 2021, BMC PUBLIC HEALTH; Gin JL, 2021, J COMMUNITY PSYCHOL, V49, P2532, DOI 10.1002/jcop.22653; Gin JL, 2019, NAT HAZARDS REV, V20, DOI 10.1061/(ASCE)NH.1527-6996.0000330; Heslin KC, 2013, DISASTER MED PUBLIC, V7, P75, DOI 10.1001/dmp.2012.61; Iacoella C, 2021, EUR REV MED PHARMACO, V25, P3132, DOI 10.26355/eurrev_202104_25568; Institute of Medicine (US) Committee on Health Care for Homeless People, 1988, HOM HLTH HUM NEEDS; Jones AL, 2017, PSYCHOL SERV, V14, P174, DOI 10.1037/ser0000116; Kendall M., 2021, MERCURY NEWS 0713; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kirzinger A., 2021, KFF COVID 19 VACCINE; Kong KL, 2020, AUST NZ J PUBL HEAL, V44, P163, DOI 10.1111/1753-6405.12964; Kranke D., 2016, MIL BEHAV HLTH, V4, P75, DOI [10.1080/21635781.2015.1119771, DOI 10.1080/21635781.2015.1119771]; Kuhn R, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255246; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Leung CS, 2008, J URBAN HEALTH, V85, P402, DOI 10.1007/s11524-008-9270-2; Liebermann O., 2021, THE CNN; Longchamps C, 2021, VACCINE, V39, P3315, DOI 10.1016/j.vaccine.2021.05.012; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Madhav N, 2017, DIS CONTROL PRIORITI, V3a, P315, DOI 10.1596/978-1-4648-0527-1_ch17; Moakley P., 2021, DEATHS AM HOMELESS A; National Alliance to End Homelessness, 2021, NEW REP SHOWS RIS HO; National Alliance to End Homelessness, 2020, HOM RAC DISP; O'Donnell C., 2021, TAMPA BAY TIMES 0719; O'Toole TP, 2011, J GEN INTERN MED, V26, pS683, DOI 10.1007/s11606-011-1818-2; Oreskes B., 2021, LOS ANGELES TIMES; Oreskes B., 2020, LOS ANGELES TIM 0514; Pham O., 2021, RISKS VACCINE ACCESS; Quinn Sandra, 2016, PLoS Curr, V8, DOI 10.1371/currents.outbreaks.3e4a5ea39d8620494e2a2c874a3c4201; Reback CJ, 2007, ADDICT BEHAV, V32, P647, DOI 10.1016/j.addbeh.2006.06.008; Reback CJ, 2003, AIDS CARE, V15, P775, DOI 10.1080/09540120310001618621; Rodriguez-Barradas MC, 2008, CLIN INFECT DIS, V46, P1093, DOI 10.1086/529201; Settembrino M., 2017, INT J MASS EMERGENCI, V35, P30; Slack D., 2021, USA TODAY; Stein JA, 2010, HEALTH PSYCHOL, V29, P317, DOI 10.1037/a0019283; Steinhauer Jennifer, 2021, NEW YORK TIMES; Tsai J, 2020, LANCET PUBLIC HEALTH, V5, pE186, DOI 10.1016/S2468-2667(20)30053-0; Tsemberis S, 2004, AM J PUBLIC HEALTH, V94, P651, DOI 10.2105/AJPH.94.4.651; U.S. Centers for Medicare & Medicaid Services, COD COVID 19 VACC SH; U.S. Department of Housing and Urban Development, 2021, 2020 ANN HOM ASS REP; U.S. Department of Veterans Affairs, 2015, FED BEN VET DEP SURV; U.S. Department of Veterans Affairs, 2020, VA ANN IN PLANS COVI; U.S. Department of Veterans Affairs, 2020, COMM LIV CENT VA NUR; U.S. Department of Veterans Affairs, 2021, COVID 19 NAT SUMM; U.S. Department of Veterans Affairs, 2019, VA HOM PROGR; U.S. Department of Veterans Affairs, VA COVID 19 SHAR DAT; U.S. Department of Veterans Affairs, 2021, SSVF COVID 19 VACC P; U.S. Department of Veterans Affairs, 2020, VA HOM PROGR HLTH CA; U.S. Department of Veterans Affairs, 2021, VA REC JANSS COVID 1; U.S. Department of Veterans Affairs, 2021, DOM CAR HOM VET PROG; Van Ness L., 2021, STATES FAIL PRIORITI; Young-Xu YN, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.28391; Zimmerman RK, 2003, AM J MED, V114, P31, DOI 10.1016/S0002-9343(02)01421-3	71	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1268	10.3390/vaccines9111268			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XH2OR	34835200	gold, Green Published			2022-04-29	WOS:000725280800001
J	Chen, QT; Wu, N; Gao, YH; Wang, XJ; Wu, J; Ma, GH				Chen, Qiuting; Wu, Nan; Gao, Yuhui; Wang, Xiaojun; Wu, Jie; Ma, Guanghui			Alum Pickering Emulsion as Effective Adjuvant to Improve Malaria Vaccine Efficacy	VACCINES			English	Article						malaria vaccine; alum stabilized Pickering emulsion; adjuvant; immune response; M.RCAg-1	IMMUNOGENICITY; RESPONSES	Malaria is a life-threatening global epidemic disease and has caused more than 400,000 deaths in 2019. To control and prevent malaria, the development of a vaccine is a potential method. An effective malaria vaccine should either combine antigens from all stages of the malaria parasite's life cycle, or epitopes of multiple key antigens due to the complexity of the Plasmodium parasite. Malaria's random constructed antigen-1 (M.RCAg-1) is one of the recombinant vaccines, which was selected from a DNA library containing thousands of diverse multi-epitope chimeric antigen genes. Moreover, besides selecting an antigen, using an adjuvant is another important procedure for most vaccine development procedures. Freund's adjuvant is considered an effective vaccine adjuvant for malaria vaccine, but it cannot be used in clinical settings because of its serious side effects. Traditional adjuvants, such as alum adjuvant, are limited by their unsatisfactory immune effects in malaria vaccines, hence there is an urgent need to develop a novel, safe and efficient adjuvant. In recent years, Pickering emulsions have attracted increasing attention as novel adjuvant. In contrast to classical emulsions, Pickering emulsions are stabilized by solid particles instead of surfactant, having pliability and lateral mobility. In this study, we selected aluminum hydroxide gel (termed as "alum ") as a stabilizer to prepare alum-stabilized Pickering emulsions (ALPE) as a malaria vaccine adjuvant. In addition, monophosphoryl lipid A (MPLA) as an immunostimulant was incorporated into the Pickering emulsion (ALMPE) to further enhance the immune response. In vitro tests showed that, compared with alum, ALPE and ALMPE showed higher antigen load rates and could be effectively endocytosed by J774a.1 cells. In vivo studies indicated that ALMPE could induce as high antibody titers as Freund's adjuvant. The biocompatibility study also proved ALMPE with excellent biocompatibility. These results suggest that ALMPE is a potential adjuvant for a malaria vaccine.	[Chen, Qiuting; Wu, Nan; Wu, Jie; Ma, Guanghui] Inst Proc Engn, Chinese Acad Sci, State Key Lab Biochem Engn, Beijing 100190, Peoples R China; [Chen, Qiuting; Wang, Xiaojun] Xian Polytech Univ, Sch Environm & Chem Engn, Dept Biochem, Xian 710600, Shaanxi, Peoples R China; [Chen, Qiuting] Gunma Univ, Sch Sci & Technol, Gunma 3768515, Japan; [Gao, Yuhui] Capital Med Univ, Beijing Hosp Tradit Chinese Med, Beijing 100010, Peoples R China		Ma, GH (通讯作者)，Inst Proc Engn, Chinese Acad Sci, State Key Lab Biochem Engn, Beijing 100190, Peoples R China.	gaoyuhui@bjzhongyi.com			National Key R&D Program of China [2018YFC0311303]; National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [21776287, 22078335, 21821005]; International Cooperation Project of the Chinese Academy of Sciences [122111KYSB20180021]; National Science and Technology Major Project of China [2018ZX10301-103-003]	This research was funded by National Key R&D Program of China (No. 2018YFC0311303), National Natural Science Foundation of China (NSFC) projects (No. 21776287, 22078335 and 21821005), the International Cooperation Project of the Chinese Academy of Sciences (Grant No. 122111KYSB20180021), National Science and Technology Major Project of China (No. 2018ZX10301-103-003).	Alavala S, 2020, INFLAMMOPHARMACOLOGY, V28, P1579, DOI 10.1007/s10787-020-00736-0; Alving CR, 2012, EXPERT REV VACCINES, V11, P733, DOI [10.1586/ERV.12.35, 10.1586/erv.12.35]; Aveyard R, 2003, ADV COLLOID INTERFAC, V100, P503, DOI 10.1016/S0001-8686(02)00069-6; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Bell GJ, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09039-z; Binks BP, 2005, LANGMUIR, V21, P5307, DOI 10.1021/la050255w; Blin A, 2019, ACTUAL PHARMACEUT, V58, P52, DOI 10.1016/j.actpha.2019.01.020; Cai QL, 2007, VACCINE, V25, P5155, DOI 10.1016/j.vaccine.2007.04.085; Cai QL, 2004, VACCINE, V23, P267, DOI 10.1016/j.vaccine.2004.04.007; Calabrese V, 2018, CURR OPIN GREEN SUST, V12, P83, DOI 10.1016/j.cogsc.2018.07.002; Chen C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11121118; Cimica V, 2017, CLIN IMMUNOL, V183, P99, DOI 10.1016/j.clim.2017.08.004; Dai HJ, 2020, TRENDS FOOD SCI TECH, V102, P16, DOI 10.1016/j.tifs.2020.05.016; Dewey DC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5670; Dicko A, 2019, LANCET INFECT DIS, V19, P790, DOI 10.1016/S1473-3099(19)30282-8; Draper SJ, 2015, VACCINE, V33, P7433, DOI 10.1016/j.vaccine.2015.09.093; Frimpong A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02769; Garcia-Gonzalez PA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01171; Good MF, 2021, EXPERT REV VACCINES, V20, P93, DOI 10.1080/14760584.2021.1889094; Gu PF, 2020, VET MICROBIOL, V251, DOI 10.1016/j.vetmic.2020.108894; Guo FX, 2018, PROCESS BIOCHEM, V65, P213, DOI 10.1016/j.procbio.2017.10.013; Gupta S, 2020, J ETHNOPHARMACOL, V261, DOI 10.1016/j.jep.2020.113022; Hu XB, 2013, IMMUNOBIOLOGY, V218, P1524, DOI 10.1016/j.imbio.2013.05.006; Huang WC, 2018, ADV BIOSYST, V2, DOI 10.1002/adbi.201800011; Jin JW, 2018, ACTA BIOMATER, V78, P211, DOI 10.1016/j.actbio.2018.08.002; Mwangi WW, 2016, FOOD HYDROCOLLOID, V60, P543, DOI 10.1016/j.foodhyd.2016.04.023; Pirahmadi S, 2021, INT J PARASITOL, V51, P699, DOI 10.1016/j.ijpara.2021.01.006; Pritam M, 2020, INT J BIOL MACROMOL, V158, P159, DOI 10.1016/j.ijbiomac.2020.04.191; Schiess N, 2020, MALARIA J, V19, DOI 10.1186/s12936-020-03336-z; Serda RE, 2010, SMALL, V6, P2691, DOI 10.1002/smll.201000727; Smith DM, 2013, NAT REV IMMUNOL, V13, P592, DOI 10.1038/nri3488; Sokolovska A, 2007, VACCINE, V25, P4575, DOI 10.1016/j.vaccine.2007.03.045; Tinto HD, 2019, LANCET INFECT DIS, V19, P821, DOI 10.1016/S1473-3099(19)30300-7; Wang C, 2020, BRAIN RES BULL, V156, P58, DOI 10.1016/j.brainresbull.2020.01.004; Wang XL, 2019, ACTA BIOMATER, V83, P390, DOI 10.1016/j.actbio.2018.11.023; Xia YF, 2018, NAT MATER, V17, P187, DOI [10.1038/NMAT5057, 10.1038/nmat5057]; Zabel F, 2013, CURR OPIN VIROL, V3, P357, DOI 10.1016/j.coviro.2013.05.004	37	0	0	14	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1244	10.3390/vaccines9111244			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ5RJ	34835175	gold, Green Published			2022-04-29	WOS:000726844500001
J	Kim, AY; Park, SY; Park, SH; Jin, JS; Kim, ES; Kim, JY; Park, JH; Ko, YJ				Kim, Ah-Young; Park, Sun Young; Park, Sang Hyun; Jin, Jong Sook; Kim, Eun-Sol; Kim, Jae Young; Park, Jong-Hyeon; Ko, Young-Joon			Validation of Pretreatment Methods for the In-Process Quantification of Foot-and-Mouth Disease Vaccine Antigens	VACCINES			English	Article						foot-and-mouth disease (FMD); pretreatment; quantification; vaccine antigen; SE-HPLC	PROTEIN; VIRUSES	Foot-and-mouth disease (FMD), caused by the FMD virus (FMDV), is controlled by vaccine policy in many countries. For vaccine potency, the content of intact virus particles (146S antigens) is critical, and the sucrose density gradient (SDG) fractionation is the gold standard for the quantification of 146S antigens. However, this method has several drawbacks. Although size-exclusion high-performance liquid chromatography (SE-HPLC) was introduced to replace the classic method, its application is generally confined to purified samples owing to the interfering signals. Therefore, we aimed to develop optimal pretreatment methods for SE-HPLC quantification in less purified samples. Crude virus infection supernatant (CVIS) and semi-purified samples with PEG precipitation (PEG-P) were used. Chloroform pretreatment was essential to remove a high level of non-specific signals in CVIS, whereas it caused loss of 146S antigens without the distinctive removal of non-specific signals in PEG-P. Benzonase pretreatment was required to improve the resolution of the target peak in the chromatogram for both CVIS and PEG-P. Through spiking tests with pure 146S antigens, it was verified that the combined pretreatment with chloroform and benzonase was optimal for the CVIS, while the sole pretreatment of benzonase was beneficial for PEG-P.	[Kim, Ah-Young; Park, Sun Young; Park, Sang Hyun; Jin, Jong Sook; Kim, Eun-Sol; Kim, Jae Young; Park, Jong-Hyeon; Ko, Young-Joon] Anim & Plant Quarantine Agcy, Ctr FMD Vaccine Res, Gimcheon 39660, South Korea		Ko, YJ (通讯作者)，Anim & Plant Quarantine Agcy, Ctr FMD Vaccine Res, Gimcheon 39660, South Korea.	mochsha@korea.kr; sun3730@korea.kr; shpark0205@korea.kr; in75724@korea.kr; kesol13@korea.kr; ivorikim@korea.kr; parkjhvet@korea.kr; koyoungjoon@korea.kr		KO, YOUNGJOON/0000-0002-3436-8175; Park, Jong-Hyeon/0000-0003-0825-8121; Kim, Ah-Young/0000-0003-0600-1816	Animal and Plant Quarantine Agency, Republic of Korea [B-1543386-2020-21-01]	FundingThis research was supported by the Animal and Plant Quarantine Agency, Republic of Korea (grant number B-1543386-2020-21-01).	Aiewsakun P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72246-6; Ao D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125828; Mansilla FC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232782; DOEL TR, 1982, DEV BIOL STAND, V50, P209; Dong H, 2021, PROTEIN CELL, DOI 10.1007/s13238-021-00828-9; Feng X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149569; Gao Y, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0561-z; Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004; Hong P, 2012, J LIQ CHROMATOGR R T, V35, P2923, DOI 10.1080/10826076.2012.743724; Huang XW, 2019, J AGR FOOD CHEM, V67, P12237, DOI 10.1021/acs.jafc.9b03445; Kim MH, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030194; Kotecha A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31856-x; Lee G, 2020, ANTIVIR RES, V182, DOI 10.1016/j.antiviral.2020.104920; Nieva JL, 2012, NAT REV MICROBIOL, V10, P563, DOI 10.1038/nrmicro2820; Porterfield JZ, 2010, VIROLOGY, V407, P281, DOI 10.1016/j.virol.2010.08.015; Song Yanmin, 2019, Sheng Wu Gong Cheng Xue Bao, V35, P1441, DOI 10.13345/j.cjb.190047; Spitteler MA, 2019, VACCINE, V37, P5288, DOI 10.1016/j.vaccine.2019.07.051; Spitteler MA, 2011, VACCINE, V29, P7182, DOI 10.1016/j.vaccine.2011.05.078; VANMAANEN C, 1990, BIOLOGICALS, V18, P315, DOI 10.1016/1045-1056(90)90036-Y; Yang YL, 2015, VACCINE, V33, P1143, DOI 10.1016/j.vaccine.2015.01.031	20	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1361	10.3390/vaccines9111361			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH1CB	34835292	Green Published, gold			2022-04-29	WOS:000725178200001
J	Kitiyodom, S; Yata, T; Thompson, KD; Costa, J; Elumalai, P; Katagiri, T; Temisak, S; Namdee, K; Rodkhum, C; Pirarat, N				Kitiyodom, Sirikorn; Yata, Teerapong; Thompson, Kim D.; Costa, Janina; Elumalai, Preetham; Katagiri, Takayuki; Temisak, Sasithon; Namdee, Katawut; Rodkhum, Channarong; Pirarat, Nopadon			Immersion Vaccination by a Biomimetic-Mucoadhesive Nanovaccine Induces Humoral Immune Response of Red Tilapia (Oreochromis sp.) against Flavobacterium columnare Challenge	VACCINES			English	Article						red tilapia; systemic immune response; columnaris disease; nano-immersion vaccine	RAINBOW-TROUT; CHANNEL CATFISH; ANTIBODY; LIPOPOLYSACCHARIDE; INTERLEUKIN-1; IMMUNIZATION; MODULATION; NILOTICUS; DISEASE; ELISA	Immersion vaccination with a biomimetic mucoadhesive nanovaccine has been shown to induce a strong mucosal immune response against columnaris disease, a serious bacterial disease in farmed red tilapia caused by Flavobacterium columnare. However, the induction of a systemic immune response by the vaccine is yet to be investigated. Here, we examine if a specific humoral immune response is stimulated in tilapia by a biomimetic-mucoadhesive nanovaccine against Flavobacterium columnare using an indirect-enzyme-linked immunosorbent assay (ELISA), serum bactericidal activity (SBA) and the expression of immune-related genes within the head-kidney and spleen, together with assessing the relative percent survival of vaccinated fish after experimentally infecting them with F. columnare. The anti-IgM antibody titer of fish at 14 and 21 days post-vaccination was significantly higher in chitosan complex nanoemulsion (CS-NE) vaccinated fish compared to fish vaccinated with the formalin-killed vaccine or control fish, supporting the serum bactericidal activity results at these time points. The cumulative mortality of the unvaccinated control fish was 87% after challenging fish with the pathogen, while the cumulative mortality of the CS-NE vaccinated group was 24%, which was significantly lower than the formalin-killed vaccinated and control fish. There was a significant upregulation of IgM, IgT, TNF alpha, and IL1-beta genes in the spleen and kidney of vaccinated fish. Significant upregulation of IgM and IgT genes was observed in the spleen of CS-NE vaccinated fish. The study confirmed the charged-chitosan-based mucoadhesive nanovaccine to be an effective platform for immersion vaccination of tilapia, with fish generating a humoral systemic immune response against columnaris disease in vaccinated fish.	[Kitiyodom, Sirikorn; Pirarat, Nopadon] Chulalongkorn Univ, Fac Vet Sci, Dept Pathol, Wildlife Exot Aquat Anim Pathol Res Unit, Bangkok 10330, Thailand; [Yata, Teerapong] Chulalongkorn Univ, Fac Vet Sci, Dept Physiol, Biochem Unit, Bangkok 10330, Thailand; [Thompson, Kim D.; Costa, Janina] Moredun Res Inst, Pentlands Sci Pk, Penicuik EH26 0PZ, Midlothian, Scotland; [Elumalai, Preetham] Kerala Univ Fisheries & Ocean Studies, Sch Ocean Sci & Technol, Kochi 682506, Kerala, India; [Katagiri, Takayuki] Tokyo Univ Marine Sci & Technol, Course Aquat Biosci, Lab Fish Hlth Management, Tokyo 1088477, Japan; [Temisak, Sasithon] Natl Inst Metrol NIMT, Chem Metrol & Biometry Dept, Bio Anal Grp, Pathum Thani 12120, Thailand; [Namdee, Katawut] Natl Sci & Technol Dev Agcy NSTDA, Natl Nanotechnol Ctr NANOTEC, Pathum Thani 12120, Thailand; [Rodkhum, Channarong] Chulalongkorn Univ, Fac Vet Sci, Dept Microbiol, Bangkok 10330, Thailand		Pirarat, N (通讯作者)，Chulalongkorn Univ, Fac Vet Sci, Dept Pathol, Wildlife Exot Aquat Anim Pathol Res Unit, Bangkok 10330, Thailand.; Thompson, KD (通讯作者)，Moredun Res Inst, Pentlands Sci Pk, Penicuik EH26 0PZ, Midlothian, Scotland.	taregust@hotmail.com; Teerapong.Y@chula.ac.th; Kim.Thompson@moredun.ac.uk; janina.costa@moredun.ac.uk; preetham@kufos.ac.in; takakata@kaiyodai.ac.jp; sasithont@nimt.or.th; katawut@nanotec.or.th; Channarong.R@chula.ac.th; Nopadon.P@chula.ac.th	Thompson, Kim/O-7707-2015; Rodkhum, Channarong/S-5843-2017	Thompson, Kim/0000-0003-3550-4842; Rodkhum, Channarong/0000-0002-5711-9294	Second Century Fund; Bacterial Vaccines (BactiVac) Network; GCRF Networks in Vaccines Research and Development; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC); BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC); Chulalongkorn University (C2F scholarship)	This research received the Second Century Fund, Chulalongkorn University (C2F scholarship), and the Bacterial Vaccines (BactiVac) Network funded by the GCRF Networks in Vaccines Research and Development, which was co-funded by the MRC and BBSRC.	Agnihotri SA, 2004, J CONTROL RELEASE, V100, P5, DOI 10.1016/j.jconrel.2004.08.010; Austin B, 2012, WOODHEAD PUBL FOOD S, P218; BALM PHM, 1995, J COMP PHYSIOL B, V165, P85, DOI 10.1007/BF00301472; Biller-Takahashi JD, 2013, ARQ BRAS MED VET ZOO, V65, P1745, DOI 10.1590/S0102-09352013000600023; Borrow R, 2006, VACCINE, V24, P5093, DOI 10.1016/j.vaccine.2006.03.091; Brandtzaeg P, 2007, VACCINE, V25, P5467, DOI 10.1016/j.vaccine.2006.12.001; Castro R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003098; Crowther J.R., 2001, VALIDATION DIAGNOSTI, P301, DOI [10.1385/1592590497, DOI 10.1385/1592590497]; Dong HT, 2015, J FISH DIS, V38, P901, DOI 10.1111/jfd.12304; FUJIHARA MP, 1971, J FISH RES BOARD CAN, V28, P1739, DOI 10.1139/f71-257; Grabowski LD, 2004, J FISH DIS, V27, P573, DOI 10.1111/j.1365-2761.2004.00576.x; Khan I, 2019, ARAB J CHEM, V12, P908, DOI 10.1016/j.arabjc.2017.05.011; Kitiyodom S, 2021, FISH SHELLFISH IMMUN, V112, P81, DOI 10.1016/j.fsi.2021.02.017; Kitiyodom S, 2019, FISH SHELLFISH IMMUN, V95, P213, DOI 10.1016/j.fsi.2019.09.064; Kitiyodom S, 2019, FISH SHELLFISH IMMUN, V86, P635, DOI 10.1016/j.fsi.2018.12.005; Laanto E, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-170; LaFrentz BR, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00452; Lange MD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01175; Leal CAG, 2010, AQUACULT INT, V18, P657, DOI 10.1007/s10499-009-9287-x; LIEWES EW, 1982, VET IMMUNOL IMMUNOP, V3, P603, DOI 10.1016/0165-2427(82)90043-5; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mano N, 1996, FISH PATHOL, V31, P65, DOI 10.3147/jsfp.31.65; Mantovani A, 2019, IMMUNITY, V50, P778, DOI 10.1016/j.immuni.2019.03.012; Mohammed H, 2013, VACCINE, V31, P5276, DOI 10.1016/j.vaccine.2013.08.052; MOORE A A, 1990, Journal of Aquatic Animal Health, V2, P109, DOI 10.1577/1548-8667(1990)002&lt;0109:ATCCEI&gt;2.3.CO;2; Munang'andu HM, 2019, FISH SHELLFISH IMMUN, V85, P132, DOI 10.1016/j.fsi.2018.03.060; Ndungo E, 2020, HUM VACC IMMUNOTHER, V16, P197, DOI 10.1080/21645515.2019.1640427; Necchi F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172163; Pati R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02224; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pirarat N, 2011, RES VET SCI, V91, pE92, DOI 10.1016/j.rvsc.2011.02.014; RISTOW SS, 1993, DIS AQUAT ORGAN, V15, P109, DOI 10.3354/dao015109; ROMESTAND B, 1993, DIS AQUAT ORGAN, V15, P137, DOI 10.3354/dao015137; Rossi Omar, 2020, High Throughput, V9, DOI 10.3390/ht9020014; Mariya Sewaka, 2019, FISH SHELLFISH IMMUN, V86, P260, DOI 10.1016/j.fsi.2018.11.026; Shoemaker CA, 2003, J APPL AQUACULTURE, V14, P43; Shoemaker CA, 2015, FEMS MICROBIOL LETT, V362, DOI 10.1093/femsle/fnu060; Tanaka Y, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0015225, 10.1371/journal.pone.0015091]; Tongsri P, 2020, FISH SHELLFISH IMMUN, V99, P654, DOI 10.1016/j.fsi.2020.01.044; Welker TL, 2005, DIS AQUAT ORGAN, V63, P129, DOI 10.3354/dao063129; Xu DH, 2003, J FISH DIS, V26, P287, DOI 10.1046/j.1365-2761.2003.00463.x; Zhang CY, 2021, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.629077; Zhang Y, 2006, J FISH DIS, V29, P657, DOI 10.1111/j.1365-2761.2006.00760.x; Zheng Y, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.600730; Zhu WX, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/760730	45	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1253	10.3390/vaccines9111253			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH9SY	34835184	gold, Green Published			2022-04-29	WOS:000725766500001
J	Lukaszuk, K; Podolak, A; Jakiel, G; Kiewisz, J; Woclawek-Potocka, I; Lukaszuk, A; Rabalski, L				Lukaszuk, Krzysztof; Podolak, Amira; Jakiel, Grzegorz; Kiewisz, Jolanta; Woclawek-Potocka, Izabela; Lukaszuk, Aron; Rabalski, Lukasz			Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age	VACCINES			English	Article						SARS-CoV-2; COVID-19; mRNA vaccine		In the context of the ongoing COVID-19 pandemic, using a half-dose schedule vaccination can help to return to normalcy in a cost-efficient manner, which is especially important for low and middle-income countries. We undertook a study to confirm that in adults up to 55 years old, the humoral response to the half-dose (15 mu g, 35 participants between 18 and 55 years old) and to the recommended dose (30 mu g, 155 participants) in the two-dose three-week interval schedule would be comparable. Antibody levels were measured by the Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics, upper detection limit: 2570 BAU/mL) on the day of dose 2 of the vaccine and then 8-10 days later to assess peak response to dose 2. The difference in proportions between the participants who did and did not exceed the upper detection limit 8-10 days after dose 2 was not statistically significant (p = 0.152). We suggest that a half-dose schedule can help to achieve widespread vaccination coverage more quickly and cheaply.	[Lukaszuk, Krzysztof; Podolak, Amira; Lukaszuk, Aron] Invicta Res & Dev Ctr, PL-81740 Sopot, Poland; [Lukaszuk, Krzysztof] Med Univ Gdansk, Dept Obstet & Gynecol Nursing, PL-80210 Gdansk, Poland; [Jakiel, Grzegorz; Lukaszuk, Aron] Univ Gdansk, Ctr Postgrad Med Educ, Dept Obstet & Gynecol 1, PL-01004 Warsaw, Poland; [Kiewisz, Jolanta] Univ Warmia & Mazury, Coll Med, Med Fac, Dept Human Histol & Embryol, PL-10082 Olsztyn, Poland; [Woclawek-Potocka, Izabela] Polish Acad Sci, Inst Anim Reprod & Food Res, Dept Gamete & Embryo Biol, PL-10748 Olsztyn, Poland; [Rabalski, Lukasz] Univ Gdansk, Intercollegiate Fac Biotechnol, Lab Recombinant Vaccines, PL-80307 Gdansk, Poland		Podolak, A (通讯作者)，Invicta Res & Dev Ctr, PL-81740 Sopot, Poland.; Rabalski, L (通讯作者)，Univ Gdansk, Intercollegiate Fac Biotechnol, Lab Recombinant Vaccines, PL-80307 Gdansk, Poland.	luka@gumed.edu.pl; amira.podolak@invicta.pl; grzegorz.jakiell@o2.pl; jolanta.kiewisz@uwm.edu.pl; i.woclawek-potocka@pan.olsztyn.pl; lukaszuk.aron@gmail.com; lukasz.rabalski@biotech.ug.edu.pl	WOCLAWEK-POTOCKA, Izabela/H-7266-2017	WOCLAWEK-POTOCKA, Izabela/0000-0002-1270-3438; Podolak, Amira/0000-0002-1942-5522; Rabalski, Lukasz/0000-0002-5292-9263; Jakiel, Grzegorz/0000-0002-6094-2273; Kiewisz, Jolanta/0000-0002-2738-8952			Abbasi J, 2021, JAMA-J AM MED ASSOC, V326, P376, DOI 10.1001/jama.2021.11717; Ahmed S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080836; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Carter N, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92070-w; Casey RM, 2019, NEW ENGL J MED, V381, P444, DOI 10.1056/NEJMoa1710430; Xaquin D, 2022, J INTERN MED, V291, P32, DOI 10.1111/joim.13372; Chau CH, 2020, PHARMACOTHERAPY, V40, P857, DOI 10.1002/phar.2439; Dispinseri S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22958-8; Dolgin Elie, 2021, Nature, DOI 10.1038/d41586-021-01893-0; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006]; Gilbert Peter B, 2021, medRxiv, DOI 10.1101/2021.08.09.21261290; Hacisuleyman E, 2021, NEW ENGL J MED, V384, P2212, DOI [10.1056/NEJMc2107808, 10.1056/NEJMoa2105000]; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Lukaszuk K, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080840; Mateus J, 2021, LOW DOSE MRNA 1273 C, DOI [10.1101/2021.06.30.21259787, DOI 10.1101/2021.06.30.21259787]; Maxmen A, 2021, NATURE, V597, P455, DOI 10.1038/d41586-021-02383-z; Mullard Asher, 2020, Nature, DOI 10.1038/d41586-020-03370-6; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Oladimeji P, 2020, J CLIN VIROL, V130, DOI 10.1016/j.jcv.2020.104536; Oliveira BA, 2020, REV INST MED TROP SP, V62, DOI [10.1590/S1678-9946202062044, 10.1590/s1678-9946202062044]; Perkmann T, 2021, EUR J CLIN INVEST, V51, DOI 10.1111/eci.13632; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ritchie H., 2020, CORONAVIRUS PANDEMIC; van Kasteren Puck B, 2020, J Clin Virol, V128, P104412, DOI 10.1016/j.jcv.2020.104412; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; WHO, 2021, INT STAT DOS SPAR ST; WHO, 2021, VACC IN UND GLOB EC; Wiecek W., 2021, COULD VACCINE DOSE S; Younes N, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060582	33	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1277	10.3390/vaccines9111277			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG5QF	34835208	gold, Green Published			2022-04-29	WOS:000724806700001
J	Mori, Y; Miyatake, N; Suzuki, H; Okada, S; Tanimoto, K				Mori, Yoshiro; Miyatake, Nobuyuki; Suzuki, Hiromi; Okada, Setsuo; Tanimoto, Kiyotaka			A Text Mining-Based Survey of Pre-Impressions of Medical Staff toward COVID-19 Vaccination in a Designated Medical Institution for Class II Infectious Diseases	VACCINES			English	Article						COVID-19; vaccination; text mining; impression	GENERAL-PRACTITIONERS; INFLUENZA	The present study investigated the pre-impressions of medical staff toward coronavirus disease 2019 (COVID-19) vaccination in a designated medical institution for class II infectious diseases in Sakaide, Japan using a text mining analysis. A total of 387 medical staff were surveyed on their pre-vaccination impressions toward the COVID-19 vaccine using an open-ended questionnaire from March 1st to 7th (the first survey) and from March 22nd to 28th (the second survey) at Sakaide City Hospital, Sakaide, Japan. A total of 296 people answered the question for the first time and 234 people answered for the second time among the 387 people. The vaccination rate was slightly lower for the younger generation than for the older generation. Before the first vaccination, the younger generation expressed concerns about side effects as well as a negative impact on pregnancy. However, before the second vaccination, there were fewer concerns regarding side effects and words of reassurance were also noted. Nurses expressed more opinions about side effects in both the first and second vaccinations than other medical staff. Concerns regarding side effects among medical staff decreased with the progression of COVID-19 vaccination. These data may provide useful information about the promotion of COVID-19 vaccination to the public, particularly in the young generation and women.	[Mori, Yoshiro; Miyatake, Nobuyuki; Suzuki, Hiromi] Kagawa Univ, Fac Med, Dept Hyg, Miki, Kagawa 7610793, Japan; [Mori, Yoshiro; Okada, Setsuo; Tanimoto, Kiyotaka] Sakaide City Hosp, Sakaide 7628550, Japan		Mori, Y (通讯作者)，Kagawa Univ, Fac Med, Dept Hyg, Miki, Kagawa 7610793, Japan.; Mori, Y (通讯作者)，Sakaide City Hosp, Sakaide 7628550, Japan.	ym01m15d1988@gmail.com; miyarin@med.kagawa-u.ac.jp; tanzuki@med.kagawa-u.ac.jp; hosp02@city.sakaide.lg.jp; taka12ki05@gmail.com		Suzuki, Hiromi/0000-0003-3891-4855			Amit S, 2021, LANCET, V397, P875, DOI 10.1016/S0140-6736(21)00448-7; [Anonymous], Sakaide City Hospital Overview; [Anonymous], VACCINATIONS STARTED; Baack BN, 2021, MMWR-MORBID MORTAL W, V70, P928, DOI 10.15585/mmwr.mm7025e2; Chao CYH, 2009, J AEROSOL SCI, V40, P122, DOI 10.1016/j.jaerosci.2008.10.003; Chew NWS, 2021, INT J INFECT DIS, V106, P52, DOI 10.1016/j.ijid.2021.03.069; Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9; Doherty M, 2016, VACCINE, V34, P6681, DOI 10.1016/j.vaccine.2016.11.015; Guner R, 2020, TURK J MED SCI, V50, P571, DOI 10.3906/sag-2004-146; Harapan H, 2020, J INFECT PUBLIC HEAL, V13, P667, DOI 10.1016/j.jiph.2020.03.019; Hasegawa A, 2018, J RADIAT RES, V59, DOI 10.1093/jrr/rry027; Hemsley B, 2018, INT J SPEECH-LANG PA, V20, P50, DOI 10.1080/17549507.2017.1413137; Herve C, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0132-6; Higuchi K., 2016, RITSUMEIKAN SOC SCI, V52, P77; Klein SL, 2014, J INFECT DIS, V209, pS114, DOI 10.1093/infdis/jiu066; Koichi H., 2017, RITSUMEIKAN SOC SCI, V53, P137; Kosaka M, 2021, LANCET, V397, P2334, DOI 10.1016/S0140-6736(21)01220-4; Lerner AM, 2020, JAMA-J AM MED ASSOC, V324, P1935, DOI 10.1001/jama.2020.21946; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Okubo R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060662; Okuhara T, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00609; Opstelten W, 2008, VACCINE, V26, P5918, DOI 10.1016/j.vaccine.2008.08.049; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pulcini C, 2013, VACCINE, V31, P3943, DOI 10.1016/j.vaccine.2013.06.039; Sato R, 2020, HUM VACC IMMUNOTHER, V16, P2438, DOI 10.1080/21645515.2020.1723365; Sato Takeyuki, 2010, Masui, V59, P56; Vieira JM, 2020, REV ASSOC MED BRAS, V66, P534, DOI 10.1590/1806-9282.66.4.534; Watanabe M, 2020, SURG TODAY, V50, P787, DOI 10.1007/s00595-020-02033-3; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048; Yoshikawa Y, 2019, TRANSPL P, V51, P1415, DOI 10.1016/j.transproceed.2019.03.013; Yu F, 2020, MICROBES INFECT, V22, P74, DOI 10.1016/j.micinf.2020.01.003; Zhang RY, 2020, P NATL ACAD SCI USA, V117, P14857, DOI 10.1073/pnas.2009637117	32	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1282	10.3390/vaccines9111282			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH0HZ	34835212	Green Published, gold			2022-04-29	WOS:000725126000001
J	Qi, L; Yang, L; Ge, J; Yu, L; Li, XM				Qi, Li; Yang, Li; Ge, Jie; Yu, Lan; Li, Xiaomei			COVID-19 Vaccination Behavior of People Living with HIV: The Mediating Role of Perceived Risk and Vaccination Intention	VACCINES			English	Article						people living with HIV; COVID-19 vaccination behavior; perceived risk; behavioral intention; mediating role	FIT INDEXES; VACCINES; MODEL	The COVID-19 vaccination behavior of people living with HIV (PLWH) was examined via a cross-sectional web-based survey of PLWH aged 18 years and older. The survey was conducted from l May to 20 June 2021. The survey included social demographic information; vaccination behavior (B); and questions related to perceived usefulness (PU), perceived risk (PR), subjective norms (SNs), perceived behavior control (PBC), and behavior intention (BI). The associations between the questionnaire variables and COVID-19 vaccination behavior were assessed by calculating the descriptive data, correlation analysis, and structural equation modeling. In total, 43.71% of the 350 eligible respondents had received a COVID-19 vaccine. The differences in COVID-19 vaccination behavior according to age, gender, religious belief, marital status, income, education level, and occupation were not obvious (p > 0.05). PU had a significantly negative effect on PR (p < 0.05). PR had a significantly negative effect on BI (p < 0.05). SNs had a significantly positive effect on BI (p < 0.05). BI had a significantly positive effect on B (p < 0.05). PR fully mediated the effects of PU on BI, BI fully mediated the effects of PR on B, and BI fully mediated the effects of SNs on B (p < 0.05). Health policymakers and medical workers should provide more information about the risks of vaccine application to improve the vaccination behavior of PLWH.	[Qi, Li; Li, Xiaomei] Xi An Jiao Tong Univ, Sch Nursing, Hlth Sci Ctr, Xian 710049, Peoples R China; [Qi, Li] Qiqihar Med Univ, Sch Nursing, Qiqihar 161006, Peoples R China; [Yang, Li] Qingdao Univ, Sch Nursing, Qingdao 266073, Peoples R China; [Ge, Jie] Qiqihar Med Univ, Sch Publ Hlth, Qiqihar 161006, Peoples R China; [Yu, Lan] Heilongjiang Ctr Dis Control & Prevent, AIDS & STD Inst, Harbin 150030, Peoples R China		Li, XM (通讯作者)，Xi An Jiao Tong Univ, Sch Nursing, Hlth Sci Ctr, Xian 710049, Peoples R China.	liqi@qmu.edu.cn; yangli81@qdu.edu.cn; gejie@qmu.edu.cn; lanyu200406@yahoo.com; roselee@xjtu.edu.cn		Qi, Li/0000-0002-7224-1327	"Research Project of Nursing Discipline in Journal" of the Chinese Medical Association in 2019 [CMAPH-NRI2019002]; "Economic and Social Development Project" of Liaoning Province [2022lslybkt-062]	This study was funded by the "Research Project of Nursing Discipline in Journal" of the Chinese Medical Association in 2019 (NO. CMAPH-NRI2019002) and by the "Economic and Social Development Project" of Liaoning Province (No. 2022lslybkt-062).	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Akarsu B, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13891; Browne MW, 2002, PSYCHOL METHODS, V7, P403, DOI 10.1037//1082-989X.7.4.403; Bureau of Disease Control and Prevention of National Health Commission of the People's Republic of China, 2021, JOL CHIN VIRAL DIS, V11, P161; Byrne KA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251073; Chung JY, 2021, ADV DRUG DELIVER REV, V170, P1, DOI 10.1016/j.addr.2020.12.011; Dil S, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.8582; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Ferrer RA, 2015, CURR OPIN PSYCHOL, V5, P85, DOI 10.1016/j.copsyc.2015.03.012; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Germani A, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.567505; Hu LT, 1998, PSYCHOL METHODS, V3, P424, DOI 10.1037/1082-989X.3.4.424; Hursh SR, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.608852; Jaspal R, 2022, CURR PSYCHOL, V41, P492, DOI 10.1007/s12144-021-01681-z; Jin YuMing, 2021, China Tropical Medicine, V21, P365, DOI 10.13604/j.cnki.46-1064/r.2021.04.13; La Barbera F, 2020, EUR J PSYCHOL, V16, P401, DOI 10.5964/ejop.v16i3.2056; Lim JY, 2021, J MULTIDISCIP HEALTH, V14, P533, DOI 10.2147/JMDH.S288532; Liu Yuxin, 2021, BMJ Open, V11, pe043557, DOI 10.1136/bmjopen-2020-043557; Lobo AD, 2020, INT J INFECT DIS, V97, P382, DOI 10.1016/j.ijid.2020.06.044; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; Mailizar M, 2021, EDUC INF TECHNOL, V26, P7057, DOI 10.1007/s10639-021-10557-5; Mellor MM, 2021, AIDS, V35, pF1, DOI 10.1097/QAD.0000000000002836; Moore S, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1008849; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Rahimi B, 2018, APPL CLIN INFORM, V9, P604, DOI 10.1055/s-0038-1668091; Robertson E, 2021, BRAIN BEHAV IMMUN, V94, P41, DOI 10.1016/j.bbi.2021.03.008; Shmueli L, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10816-7; Singh JA, 2021, LANCET INFECT DIS, V21, pE103, DOI 10.1016/S1473-3099(20)30923-3; Stern PL, 2016, VACCINE, V34, P6653, DOI 10.1016/j.vaccine.2016.11.014; Storlie CB, 2021, MAYO CLIN PROC, V96, P1890, DOI 10.1016/j.mayocp.2021.04.012; Sun SF, 2021, PREV MED REP, V22, DOI 10.1016/j.pmedr.2021.101350; Utamura Motoaki, 2020, JMIR Public Health Surveill, V6, pe23624, DOI 10.2196/23624; Vallee A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040302; Wang Z.W., 2021, MOD PREV MED, V48, P732; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; Wentzell E, 2021, VACCINE, V39, P2445, DOI 10.1016/j.vaccine.2021.03.036; WHO, 2020, HIV AIDS FACT SHEET; World Health Organization (WHO), Coronavirus disease 2019 (COVID-19) weekly epidemiological update-5 October 2021; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; [吴国伟 Wu Guowei], 2021, [中国临床心理学杂志, Chinese Journal of Clinical Psychology], V29, P622; Xuejiao C, 2021, J MASS COMMUN MON, V7, P64	41	0	0	8	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1288	10.3390/vaccines9111288			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XH6CM	34835219	Green Published, gold			2022-04-29	WOS:000725520200001
J	Rivera-Patron, M; Moreno, M; Baz, M; Roehe, PM; Cibulski, SP; Silveira, F				Rivera-Patron, Mariana; Moreno, Maria; Baz, Mariana; Roehe, Paulo M.; Cibulski, Samuel P.; Silveira, Fernando			ISCOM-like Nanoparticles Formulated with Quillaja brasiliensis Saponins Are Promising Adjuvants for Seasonal Influenza Vaccines	VACCINES			English	Article						adjuvants; Quillaja brasiliensis; ISCOMs; influenza virus; dose-sparing effect	IMMUNE-RESPONSES; SYSTEMIC ANTIBODY; MUCOSAL; LEAVES; IMMUNIZATION; DELIVERY; FRACTION; QS-21	Vaccination is the most effective public health intervention to prevent influenza infections, which are responsible for an important burden of respiratory illnesses and deaths each year. Currently, licensed influenza vaccines are mostly split inactivated, although in order to achieve higher efficacy rates, some influenza vaccines contain adjuvants. Although split-inactivated vaccines induce mostly humoral responses, tailoring mucosal and cellular immune responses is crucial for preventing influenza infections. Quillaja brasiliensis saponin-based adjuvants, including ISCOM-like nanoparticles formulated with the QB-90 saponin fraction (IQB90), have been studied in preclinical models for more than a decade and have been demonstrated to induce strong humoral and cellular immune responses towards several viral antigens. Herein, we demonstrate that a split-inactivated IQB90 adjuvanted influenza vaccine triggered a protective immune response, stronger than that induced by a commercial unadjuvanted vaccine, when applied either by the subcutaneous or the intranasal route. Moreover, we reveal that this novel adjuvant confers up to a ten-fold dose-sparing effect, which could be crucial for pandemic preparedness. Last but not least, we assessed the role of caspase-1/11 in the generation of the immune response triggered by the IQB90 adjuvanted influenza vaccine in a mouse model and found that the cellular-mediated immune response triggered by the IQB90-Flu relies, at least in part, on a mechanism involving the casp-1/11 pathway but not the humoral response elicited by this formulation.	[Rivera-Patron, Mariana; Moreno, Maria; Silveira, Fernando] Univ Republ UdelaR, Fac Med, Inst Higiene, Dept Desarrollo Biotecnol, Montevideo 11600, Uruguay; [Baz, Mariana] CHU Quebec, Res Ctr Infect Dis, Quebec City, PQ G1V 4G2, Canada; [Baz, Mariana] Univ Laval, Quebec City, PQ G1V 4G2, Canada; [Roehe, Paulo M.; Cibulski, Samuel P.] Univ Fed Rio Grande do Sul, Lab Virol, Dept Microbiol Imunol & Parasitol, BR-90050170 Porto Alegre, RS, Brazil; [Cibulski, Samuel P.] Univ Fed Paraiba, Ctr Biotecnol CBiotec, Lab Biotecnol Celular & Mol, BR-58051900 Joao Pessoa, Paraiba, Brazil		Silveira, F (通讯作者)，Univ Republ UdelaR, Fac Med, Inst Higiene, Dept Desarrollo Biotecnol, Montevideo 11600, Uruguay.; Cibulski, SP (通讯作者)，Univ Fed Rio Grande do Sul, Lab Virol, Dept Microbiol Imunol & Parasitol, BR-90050170 Porto Alegre, RS, Brazil.; Cibulski, SP (通讯作者)，Univ Fed Paraiba, Ctr Biotecnol CBiotec, Lab Biotecnol Celular & Mol, BR-58051900 Joao Pessoa, Paraiba, Brazil.	mrivera@higiene.edu.uy; mmoreno@higiene.edu.uy; Mariana.Baz@crchudequebec.ulaval.ca; proehe@gmail.com; spcibulski@gmail.com; fsilveira@higiene.edu.uy	; Silveira, Fernando/H-5043-2016	Moreno, Maria/0000-0002-7294-6693; Cibulski, Samuel/0000-0003-0503-8692; Silveira, Fernando/0000-0002-6980-8265	Programa de Desarrollo de las Ciencias Basicas (PEDECIBA Uruguay); Agencia Nacional de Investigacion e Innovacion (ANII, Uruguay); conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); ANII [POS_NAC_2018_1_151537]; ANII	This research was supported by Programa de Desarrollo de las Ciencias Basicas (PEDECIBA Uruguay), the Agencia Nacional de Investigacion e Innovacion (ANII, Uruguay) and the conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil). P.M.R. is a CNPq research fellow. M.R.-P is recipient of a PhD fellowship granted by ANII (fellowship code: POS_NAC_2018_1_151537). M.R.-P and F.S. are recipients of an ANII research productivity fellowships, initiation and level 1, respectively.	Bigaeva E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154757; Cebon JS, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000410; Cibulski S, 2021, VACCINE, V39, P571, DOI 10.1016/j.vaccine.2020.12.004; Cibulski S, 2018, VACCINE, V36, P55, DOI 10.1016/j.vaccine.2017.11.030; Cibulski SP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31995-1; Cibulski SP, 2016, COMP IMMUNOL MICROB, V45, P1, DOI 10.1016/j.cimid.2016.01.004; Cibulski SP, 2016, VACCINE, V34, P1162, DOI 10.1016/j.vaccine.2016.01.029; DALSGAARD K, 1974, ARCH GES VIRUSFORSCH, V44, P243, DOI 10.1007/BF01240612; de Costa F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105374; De Magistnis MT, 2006, ADV DRUG DELIVER REV, V58, P52, DOI 10.1016/j.addr.2006.01.002; De Temmerman ML, 2011, DRUG DISCOV TODAY, V16, P569, DOI 10.1016/j.drudis.2011.04.006; Detienne S, 2016, SCI REP-UK, V6, DOI 10.1038/srep39475; Fernandez-Tejada A, 2016, ACCOUNTS CHEM RES, V49, P1741, DOI 10.1021/acs.accounts.6b00242; Fernandez-Tejada A, 2014, BIOORGAN MED CHEM, V22, P5917, DOI 10.1016/j.bmc.2014.09.016; Fleck JD, 2013, NAT PROD RES, V27, P907, DOI 10.1080/14786419.2012.666751; Fleck JD, 2006, VACCINE, V24, P7129, DOI 10.1016/j.vaccine.2006.06.059; Fleck JD, 2009, IN VITRO CELL DEV-PL, V45, P715, DOI 10.1007/s11627-009-9222-x; Heath PT, 2021, NEW ENGL J MED, V385, P1172, DOI 10.1056/NEJMoa2107659; HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Knudsen NPH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19570; Krammer F, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0002-y; Kunda NK, 2013, PHARM RES-DORDR, V30, P325, DOI 10.1007/s11095-012-0891-5; Lacaille-Dubois MA, 2019, PHYTOMEDICINE, V60, DOI 10.1016/j.phymed.2019.152905; Lendemans DG, 2005, J PHARM PHARMACOL, V57, P729, DOI 10.1211/0022357056280; Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17; Luebert Federico, 2014, Feddes Repertorium, V124, P157, DOI 10.1002/fedr.201400029; Lv J, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-197; Magedans YVS, 2019, FUTURE MED CHEM, V11, P1485, DOI 10.4155/fmc-2018-0438; McKenzie A, 2010, HUM VACCINES, V6, P237, DOI 10.4161/hv.6.3.10754; Mitragotri S, 2005, NAT REV IMMUNOL, V5, P905, DOI 10.1038/nri1728; MOREIN B, 1984, NATURE, V308, P457, DOI 10.1038/308457a0; O'Hagan DT, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101426; Paules CI, 2019, J INFECT DIS, V219, pS1, DOI 10.1093/infdis/jiy633; Podda A, 2001, VACCINE, V19, P2673, DOI 10.1016/S0264-410X(00)00499-0; Reber A, 2013, EXPERT REV VACCINES, V12, P519, DOI [10.1586/erv.13.35, 10.1586/ERV.13.35]; Seibert CW, 2013, J VIROL, V87, P7793, DOI 10.1128/JVI.00979-13; Silveira F, 2011, VACCINE, V29, P9177, DOI 10.1016/j.vaccine.2011.09.137; Sjolander S, 2001, VACCINE, V19, P4072, DOI 10.1016/S0264-410X(01)00110-4; Sun HX, 2009, VACCINE, V27, P4388, DOI 10.1016/j.vaccine.2009.05.032; Tomar J, 2018, J CONTROL RELEASE, V288, P199, DOI 10.1016/j.jconrel.2018.09.006; Tregoning JS, 2018, HUM VACC IMMUNOTHER, V14, P550, DOI 10.1080/21645515.2017.1415684; Wallace F, 2019, PHYTOCHEM ANALYSIS, V30, P644, DOI 10.1002/pca.2837; Wallace F, 2017, PHYTOCHEM LETT, V20, P228, DOI 10.1016/j.phytol.2017.04.020; Wilson NS, 2014, J IMMUNOL, V192, P3259, DOI 10.4049/jimmunol.1302011; World Health OrganisationX, 2019, GLOB INFLU STRATEG 2, V1, P2; Yendo ACA, 2017, METHODS MOL BIOL, V1494, P87, DOI 10.1007/978-1-4939-6445-1_6; Yendo ACA, 2016, VACCINE, V34, P2305, DOI 10.1016/j.vaccine.2016.03.070	49	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1350	10.3390/vaccines9111350			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH0AF	34835281	Green Published, gold			2022-04-29	WOS:000725105700001
J	Chupin, C; Pizzorno, A; Traversier, A; Brun, P; Ogonczyk-Makowska, D; Padey, B; Milesi, C; Duliere, V; Laurent, E; Julien, T; Galloux, M; Lina, B; Eleouet, JF; Moreau, K; Hamelin, ME; Terrier, O; Boivin, G; Dubois, J; Rosa-Calatrava, M				Chupin, Caroline; Pizzorno, Andres; Traversier, Aurelien; Brun, Pauline; Ogonczyk-Makowska, Daniela; Padey, Blandine; Milesi, Cedrine; Duliere, Victoria; Laurent, Emilie; Julien, Thomas; Galloux, Marie; Lina, Bruno; Eleouet, Jean-Francois; Moreau, Karen; Hamelin, Marie-Eve; Terrier, Olivier; Boivin, Guy; Dubois, Julia; Rosa-Calatrava, Manuel			Avian Cell Line DuckCelt(R)-T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate Metavac(R)	VACCINES			English	Article						DuckCelt-T17 avian cell line; in-suspension serum-free bioproduction; production process optimization; human metapneumovirus (HMPV); live-attenuated vaccine (LAV); SH protein; gene deletion	RESPIRATORY SYNCYTIAL VIRUS; YOUNG-CHILDREN; PROTEIN; INFECTION; LACKING; DISEASE; FUSION; MICE; MVA; SH	The development of a live-attenuated vaccine (LAV) for the prevention of human metapneumovirus (HMPV) infection is often hampered by the lack of highly efficient and scalable cell-based production systems that support eventual global vaccine production. Avian cell lines cultivated in suspension compete with traditional cell platforms used for viral vaccine manufacture. We investigated whether the DuckCelt(R)-T17 avian cell line (Vaxxel), previously described as an efficient production system for several influenza strains, could also be used to produce a new HMPV LAV candidate (Metavac(R), SH gene-deleted A1/C-85473 HMPV). To that end, we characterized the operational parameters of MOI, cell density, and trypsin addition to achieve the optimal production of Metavac(R), and demonstrated that the DuckCelt(R)-T17 cell line is permissive and well-adapted to the production of the wild-type A1/C-85473 HMPV and the Metavac(R) vaccine candidate. Moreover, our results confirmed that the LAV candidate produced in DuckCelt(R)-T17 cells conserves its advantageous replication properties in LLC-MK2 and 3D-reconstituted human airway epithelium models, and its capacity to induce efficient neutralizing antibodies in a BALB/c mouse model. Our results suggest that the DuckCelt(R)-T17 avian cell line is a very promising platform for the scalable in-suspension serum-free production of the HMPV-based LAV candidate Metavac(R).	[Chupin, Caroline; Pizzorno, Andres; Traversier, Aurelien; Brun, Pauline; Padey, Blandine; Milesi, Cedrine; Duliere, Victoria; Laurent, Emilie; Julien, Thomas; Lina, Bruno; Terrier, Olivier; Dubois, Julia; Rosa-Calatrava, Manuel] Univ Lyon, Univ Claude Bernard Lyon 1, Ctr Int Rech Infectiol, ENS Lyon,CIRI,CNRS,UMR5308,Inserm,U1111, F-69007 Lyon, France; [Chupin, Caroline; Dubois, Julia] Vaxxel, 43 Blvd Onze Novembre 1918, F-69100 Villeurbanne, France; [Chupin, Caroline; Pizzorno, Andres; Traversier, Aurelien; Brun, Pauline; Ogonczyk-Makowska, Daniela; Padey, Blandine; Milesi, Cedrine; Duliere, Victoria; Laurent, Emilie; Julien, Thomas; Lina, Bruno; Hamelin, Marie-Eve; Terrier, Olivier; Boivin, Guy; Dubois, Julia; Rosa-Calatrava, Manuel] Univ Laval, Int Associated Lab RespiVir, LIA VirPath LVMC France Quebec, Quebec City, PQ G1V 4G2, Canada; [Chupin, Caroline; Pizzorno, Andres; Traversier, Aurelien; Brun, Pauline; Ogonczyk-Makowska, Daniela; Padey, Blandine; Milesi, Cedrine; Duliere, Victoria; Laurent, Emilie; Julien, Thomas; Lina, Bruno; Hamelin, Marie-Eve; Terrier, Olivier; Boivin, Guy; Dubois, Julia; Rosa-Calatrava, Manuel] Univ Lyon, Univ Claude Bernard Lyon 1, F-69008 Lyon, France; [Traversier, Aurelien; Brun, Pauline; Milesi, Cedrine; Duliere, Victoria; Laurent, Emilie; Julien, Thomas; Rosa-Calatrava, Manuel] Univ Lyon, Univ Claude Bernard Lyon 1, Fac Med RTH Laennec, VirNext, F-69008 Lyon, France; [Ogonczyk-Makowska, Daniela; Hamelin, Marie-Eve; Boivin, Guy] Univ Laval, Ctr Hosp Univ Quebec, Ctr Rech Infectiol, Quebec City, PQ G1V 4G2, Canada; [Galloux, Marie; Eleouet, Jean-Francois] Univ Paris Saclay, Unite Virol & Immunol Mol, INRAE, UVSQ, F-78350 Jouy En Josas, France; [Moreau, Karen] Univ Lyon, Univ Claude Bernard Lyon 1, Ctr Int Rech Infectiol,Inserm,U1111, ENS Lyon,CNRS,UMR5308,CIRI,Team STAPHPATH, F-69007 Lyon, France		Dubois, J; Rosa-Calatrava, M (通讯作者)，Univ Lyon, Univ Claude Bernard Lyon 1, Ctr Int Rech Infectiol, ENS Lyon,CIRI,CNRS,UMR5308,Inserm,U1111, F-69007 Lyon, France.; Dubois, J (通讯作者)，Vaxxel, 43 Blvd Onze Novembre 1918, F-69100 Villeurbanne, France.; Dubois, J; Rosa-Calatrava, M (通讯作者)，Univ Laval, Int Associated Lab RespiVir, LIA VirPath LVMC France Quebec, Quebec City, PQ G1V 4G2, Canada.; Dubois, J; Rosa-Calatrava, M (通讯作者)，Univ Lyon, Univ Claude Bernard Lyon 1, F-69008 Lyon, France.; Rosa-Calatrava, M (通讯作者)，Univ Lyon, Univ Claude Bernard Lyon 1, Fac Med RTH Laennec, VirNext, F-69008 Lyon, France.	caroline.chupin@univ-lyon1.fr; mario-andres.pizzorno@univ-lyon1.fr; aurelien.traversier@univ-lyon1.fr; pauline.brun@univ-lyon1.fr; daniela.ogonczyk-makowska@crchudequebec.ulaval.ca; blandine.padey@univ-lyon1.fr; cedrine.milesi@univ-lyon1.fr; victoria.duliere@univ-lyon1.fr; emilielaurent@univ-lyon1.fr; thomas.julien@univ-lyon1.fr; marie.galloux@inrae.fr; bruno.lina@univ-lyon1.fr; jean-francois.eleouet@inrae.fr; karen.moreau@univ-lyon1.fr; marie-eve.hamelin@crchudequebec.ulaval.ca; olivietterrier@univ-lyon1.fr; guy.boivin@crchudequebec.ulaval.ca; julia.dubois@vaxxel.fr; manuel.rosa-calatrava@univ-lyon1.fr		Hamelin, Marie-Eve/0000-0002-7568-5097	Agence National de la RechercheFrench National Research Agency (ANR) [ANR AAP19 METAVAC-T17]; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [273261]; Universite Claude Bernard Lyon 1, Lyon, France; Region Auvergne-Rhone-Alpes (grant CMIRA Accueil Pro); Region Auvergne-Rhone-Alpes (grant CMIRA ExploRA'DOC); Consulat General de France a Quebec (Programme Frontenac); Association Nationale Recherche Technologie (ANRT)French National Research Agency (ANR)	This study was supported by a grant from Agence National de la Recherche (ANR AAP19 METAVAC-T17) to Manuel Rosa-Calatrava and a grant from Canadian Institutes of Health Research (No. 273261) to Guy Boivin and Universite Claude Bernard Lyon 1, Lyon, France. Andres Pizzorno received the support of the Region Auvergne-Rhone-Alpes (grant CMIRA Accueil Pro). Julia Dubois received the support of the Region Auvergne-Rhone-Alpes (grant CMIRA ExploRA'DOC) and of the Consulat General de France a Quebec (Programme Frontenac). Caroline Chupin received the support of the Association Nationale Recherche Technologie (ANRT).	Aerts L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120283; Aliprantis AO, 2021, HUM VACC IMMUNOTHER, V17, P1248, DOI 10.1080/21645515.2020.1829899; Marquez-Escobar VA, 2017, EXPERT REV VACCINES, V16, P419, DOI 10.1080/14760584.2017.1283223; Aubrit F, 2015, VACCINE, V33, P5905, DOI 10.1016/j.vaccine.2015.06.110; Biacchesi S, 2005, J VIROL, V79, P12608, DOI 10.1128/JVI.79.19.12608-12613.2005; Biacchesi S, 2004, J VIROL, V78, P12877, DOI 10.1128/JVI.78.23.12877-12887.2004; Bloom K, 2021, GENE THER, V28, P117, DOI 10.1038/s41434-020-00204-y; Brown Stephen W, 2010, PDA J Pharm Sci Technol, V64, P419; Cunningham CK, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz212; Dubois J, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040164; Dubois J, 2017, J GEN VIROL, V98, P1174, DOI 10.1099/jgv.0.000796; Espeseth AS, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0163-z; Feltes TF, 2003, J PEDIATR-US, V143, P532, DOI 10.1067/S0022-3476(03)00454-2; Feuillet F, 2012, J CLIN VIROL, V53, P97, DOI 10.1016/j.jcv.2011.10.002; Genzel Y, 2015, BIOTECHNOL J, V10, P728, DOI 10.1002/biot.201400388; Genzel Y, 2013, APPL MICROBIOL BIOT, V97, P111, DOI 10.1007/s00253-012-4238-2; Hamelin ME, 2007, J GEN VIROL, V88, P3391, DOI 10.1099/vir.0.83250-0; Hamelin ME, 2005, J VIROL, V79, P8894, DOI 10.1128/JVI.79.14.8894-8903.2005; Karron RA, 2018, J PEDIAT INF DIS SOC, V7, P86, DOI 10.1093/jpids/pix006; Karron RA, 2013, CURR TOP MICROBIOL, V372, P259, DOI 10.1007/978-3-642-38919-1_13; Leon A, 2016, VACCINE, V34, P5878, DOI 10.1016/j.vaccine.2016.10.043; Lohr V, 2009, VACCINE, V27, P4975, DOI 10.1016/j.vaccine.2009.05.083; Mazur NI, 2018, LANCET INFECT DIS, V18, pE295, DOI 10.1016/S1473-3099(18)30292-5; Noor A, 2018, EXPERT OPIN BIOL TH, V18, P1247, DOI 10.1080/14712598.2018.1544239; Papenburg J, 2010, REV MED VIROL, V20, P245, DOI 10.1002/rmv.651; Pau MG, 2001, VACCINE, V19, P2716, DOI 10.1016/S0264-410X(00)00508-9; Petiot E, 2018, VACCINE, V36, P3101, DOI 10.1016/j.vaccine.2017.03.102; Rima B, 2017, J GEN VIROL, V98, P2912, DOI 10.1099/jgv.0.000959; Rocca A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073703; Rodrigues AF, 2015, BIOTECHNOL J, V10, P1329, DOI 10.1002/biot.201400387; Schowalter RM, 2006, J VIROL, V80, P10931, DOI 10.1128/JVI.01287-06; Shafagati Nazly, 2018, F1000Res, V7, P135, DOI 10.12688/f1000research.12625.1; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/S0140-6736(17)30938-8, 10.1016/s0140-6736(17)30938-8]; van den Hoogen BG, 2004, EMERG INFECT DIS, V10, P658, DOI 10.3201/eid1004.030393; Verdijk P, 2020, VACCINE, V38, P6088, DOI 10.1016/j.vaccine.2020.07.029	35	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1190	10.3390/vaccines9101190			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR5OD		Green Published			2022-04-29	WOS:000714547700001
J	Dimitrov, KM; Taylor, TL; Marcano, VC; Williams-Coplin, D; Olivier, TL; Yu, QZ; Gogal, RM; Suarez, DL; Afonso, CL				Dimitrov, Kiril M.; Taylor, Tonya L.; Marcano, Valerie C.; Williams-Coplin, Dawn; Olivier, Timothy L.; Yu, Qingzhong; Gogal, Robert M., Jr.; Suarez, David L.; Afonso, Claudio L.			Novel Recombinant Newcastle Disease Virus-Based In Ovo Vaccines Bypass Maternal Immunity to Provide Full Protection from Early Virulent Challenge	VACCINES			English	Article						Newcastle disease; in ovo vaccine; maternal immunity; recombinant; cytokine; dose	AVIAN INFLUENZA-VIRUS; SHEDDING FOLLOWING VACCINATION; CLINICAL-DISEASE; CHICKENS; ANTIBODY; HEMAGGLUTININ; IMMUNOGENICITY; PATHOGENICITY; HERPESVIRUS; EFFICACY	Newcastle disease (ND) is one of the most economically important poultry diseases. Despite intensive efforts with current vaccination programs, this disease still occurs worldwide, causing significant mortality even in vaccinated flocks. This has been partially attributed to a gap in immunity during the post-hatch period due to the presence of maternal antibodies that negatively impact the replication of the commonly used live vaccines. In ovo vaccines have multiple advantages and present an opportunity to address this problem. Currently employed in ovo ND vaccines are recombinant herpesvirus of turkeys (HVT)-vectored vaccines expressing Newcastle disease virus (NDV) antigens. Although proven efficient, these vaccines have some limitations, such as delayed immunogenicity and the inability to administer a second HVT vaccine post-hatch. The use of live ND vaccines for in ovo vaccination is currently not applicable, as these are associated with high embryo mortality. In this study, recombinant NDV-vectored experimental vaccines containing an antisense sequence of avian interleukin 4 (IL4R) and their backbones were administered in ovo at different doses in 18-day-old commercial eggs possessing high maternal antibodies titers. The hatched birds were challenged with virulent NDV at 2 weeks-of-age. Post-hatch vaccine shedding, post-challenge survival, challenge virus shedding, and humoral immune responses were evaluated at multiple timepoints. Recombinant NDV (rNDV) vaccinated birds had significantly reduced post-hatch mortality compared with the wild-type LaSota vaccine. All rNDV vaccines were able to penetrate maternal immunity and induce a strong early humoral immune response. Further, the rNDV vaccines provided protection from clinical disease and significantly decreased virus shedding after early virulent NDV challenge at two weeks post-hatch. The post-challenge hemagglutination-inhibition antibody titers in the vaccinated groups remained comparable with the pre-challenge titers, suggesting the capacity of the studied vaccines to prevent efficient replication of the challenge virus. Post-hatch survival after vaccination with the rNDV-IL4R vaccines was dose-dependent, with an increase in survival as the dose decreased. This improved survival and the dose-dependency data suggest that novel attenuated in ovo rNDV-based vaccines that are able to penetrate maternal immunity to elicit a strong immune response as early as 14 days post-hatch, resulting in high or full protection from virulent challenge, show promise as a contributor to the control of Newcastle disease.</p>	[Dimitrov, Kiril M.; Taylor, Tonya L.; Marcano, Valerie C.; Williams-Coplin, Dawn; Olivier, Timothy L.; Suarez, David L.; Afonso, Claudio L.] ARS, Exot & Emerging Avian Viral Dis Res Unit, Southeast Poultry Res Lab, US Natl Poultry Res Ctr,USDA, 934 Coll Stn Rd, Athens, GA 30605 USA; [Dimitrov, Kiril M.] Texas A&M Vet Med Diagnost Lab, 483 Agron Rd, College Stn, TX 77843 USA; [Yu, Qingzhong] ARS, Endem Poultry Viral Dis Res Unit, Southeast Poultry Res Lab, US Natl Poultry Res Ctr,USDA, 934 Coll Stn Rd, Athens, GA 30605 USA; [Gogal, Robert M., Jr.] Univ Georgia, Coll Vet Med, Dept Vet Biosci & Diagnost Imaging, Athens, GA 30602 USA; [Marcano, Valerie C.] Elanco Anim Hlth, 2500 Innovat Way, Greenfield, IN 46140 USA; [Afonso, Claudio L.] BASE2BIO, 1945 Arlington Dr, Oshkosh, WI 54904 USA		Afonso, CL (通讯作者)，ARS, Exot & Emerging Avian Viral Dis Res Unit, Southeast Poultry Res Lab, US Natl Poultry Res Ctr,USDA, 934 Coll Stn Rd, Athens, GA 30605 USA.; Afonso, CL (通讯作者)，BASE2BIO, 1945 Arlington Dr, Oshkosh, WI 54904 USA.	kiril.dimitrov@tvmdl.tamu.edu; tonyaj@g.clemson.edu; Marcano_Valerie@Elanco.com; dawn.williamscoplin@usda.gov; tim.olivier@usda.gov; qingzhong.yu@usda.gov; rgogal@uga.edu; david.suarez@usda.gov; cafonso@uga.edu		Marcano, Valerie/0000-0003-2218-7577	U.S. Department of AgricultureUnited States Department of Agriculture (USDA); ARS CRISUnited States Department of Agriculture (USDA)USDA Agricultural Research Service	This research was funded by the U.S. Department of Agriculture, ARS CRIS Project 6612-32000-072-00D.	Abou Elazab MF, 2010, J VET MED SCI, V72, P257, DOI 10.1292/jvms.09-0298; AHMAD J, 1992, AM J VET RES, V53, P1999; Alexander D. J., 1988, Newcastle disease., P11; Alexander D. J., 1988, Newcastle disease., P1; Alexander D.J., 2004, TECHNOLOGY REV NEWCA, P1; Alexander DJ, 1997, AVIAN PATHOL, V26, P399, DOI 10.1080/03079459708419222; Amarasinghe GK, 2019, ARCH VIROL, V164, P1967, DOI 10.1007/s00705-019-04247-4; Armour N.K., 2014, POULTRY INFORM PROFE, P1; Avakian AP, 2007, EXPERT REV VACCINES, V6, P457, DOI 10.1586/14760584.6.3.457; Cardenas-Garcia S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159153; Czegledi A, 2006, VIRUS RES, V120, P36, DOI 10.1016/j.virusres.2005.11.009; Das A, 2009, J VET DIAGN INVEST, V21, P771, DOI 10.1177/104063870902100603; Dilaveris D, 2007, VACCINE, V25, P3792, DOI 10.1016/j.vaccine.2007.01.115; Dimitrov KM, 2017, VET MICROBIOL, V206, P126, DOI 10.1016/j.vetmic.2016.12.019; Dimitrov KM, 2016, INFECT GENET EVOL, V39, P22, DOI 10.1016/j.meegid.2016.01.008; Esaki M, 2013, AVIAN DIS, V57, P750, DOI 10.1637/10540-032613-Reg.1; Estevez C, 2007, VIRUS RES, V129, P182, DOI 10.1016/j.virusres.2007.07.008; Faulkner OB, 2013, VET IMMUNOL IMMUNOP, V152, P341, DOI 10.1016/j.vetimm.2013.01.006; Ge JY, 2014, VACCINE, V32, P1514, DOI 10.1016/j.vaccine.2014.01.020; International Committee on Taxonomy of Viruses, VIRUS TAXONOMY 2018; Jochemsen P, 2002, POULTRY SCI, V81, P1811, DOI 10.1093/ps/81.12.1811; Johnston PA, 1997, POULTRY SCI, V76, P165, DOI 10.1093/ps/76.1.165; Kapczynski DR, 2012, AVIAN DIS, V56, P555, DOI 10.1637/9980-110311-Reg.1; Kapczynski DR, 2005, VACCINE, V23, P3424, DOI 10.1016/j.vaccine.2005.01.140; Karaca K, 1998, VACCINE, V16, P1496, DOI 10.1016/S0264-410X(97)00295-8; Lamb R.A., 2013, FIELDS VIROLOGY, V6th ed., P957; Lancaster J.E., 1966, MONOGRAPH, V3, P80; Marcano VC, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090953; Mayers J, 2017, VACCINE, V35, P5974, DOI 10.1016/j.vaccine.2017.09.008; Mebatsion T, 2001, J VIROL, V75, P420, DOI 10.1128/JVI.75.1.420-428.2001; Miller P.J., 2013, DIS POULTRY, DOI [DOI 10.1002/9781119421481.CH3.(HTTPS://D0I.0RG/), 10.1002/9781119421481.ch3, DOI 10.1002/9781119421481.CH3]; Miller PJ, 2007, VACCINE, V25, P7238, DOI 10.1016/j.vaccine.2007.07.017; Miller PJ, 2013, DEV COMP IMMUNOL, V41, P505, DOI 10.1016/j.dci.2013.06.007; Miller PJ, 2009, AVIAN DIS, V53, P39, DOI 10.1637/8407-071208-Reg.1; OIE, WORLD AN HLTH INF DA; OIE OIE, 2012, NEW CASTL DIS OIE TE, V7 7, P555; Palya V, 2012, AVIAN DIS, V56, P282, DOI 10.1637/9935-091511-Reg.1; Palya V, 2014, VET IMMUNOL IMMUNOP, V158, P105, DOI 10.1016/j.vetimm.2013.11.008; Park MS, 2006, P NATL ACAD SCI USA, V103, P8203, DOI 10.1073/pnas.0602566103; Ramp K, 2012, AVIAN DIS, V56, P208, DOI 10.1637/9870-080311-Reg.1; Rautenschlein S, 1999, VACCINE, V18, P426, DOI 10.1016/S0264-410X(99)00254-6; Sarfati-Mizrahi D, 2010, AVIAN DIS, V54, P239, DOI 10.1637/8735-032509-Reg.1; Schat K.A., 2015, BACK VECTOR VACCINES, P1; Schroer D, 2011, AVIAN DIS, V55, P201, DOI 10.1637/9539-092710-Reg.1; Schultz-Cherry S, 2000, VIROLOGY, V278, P55, DOI 10.1006/viro.2000.0635; Senne DA, 2004, DEV BIOLOGICALS, V119, P165; Senne DA, 2008, LAB MANUAL ISOLATION, P204; Sonoda K, 2000, J VIROL, V74, P3217, DOI 10.1128/JVI.74.7.3217-3226.2000; Stanford MM, 2005, TRENDS IMMUNOL, V26, P339, DOI 10.1016/j.it.2005.04.001; Steel J, 2008, VACCINE, V26, P522, DOI 10.1016/j.vaccine.2007.11.032; Susta L, 2013, MICROB PATHOGENESIS, V61-62, P73, DOI 10.1016/j.micpath.2013.05.009; The TAFS forum, 2011, WORLD LIV DIS ATL QU; Toro H, 2008, VACCINE, V26, P2640, DOI 10.1016/j.vaccine.2008.02.056; United States Department of Agriculture Animal and Plant Health Inspection Service, 2019, VET BIOL PROD LIC ES, P1; United States Department of Agriculture Animal and Plant Health Inspection Service, 2014, 40705 USDA CVB SAM, P1; van Boven M, 2008, AVIAN PATHOL, V37, P1, DOI 10.1080/03079450701772391; Veits J, 2006, P NATL ACAD SCI USA, V103, P8197, DOI 10.1073/pnas.0602461103; Vrdoljak A, 2017, TIERAERZTL PRAX G N, V45, P151, DOI [10.15653/TPG-160661, 10.15653/tpg-160661]; Wakenell PS, 2002, AVIAN DIS, V46, P274, DOI 10.1637/0005-2086(2002)046[0274:EOIOVD]2.0.CO;2; Wen GY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172812; WESTBURY HA, 1984, AUST VET J, V61, P10, DOI 10.1111/j.1751-0813.1984.tb07121.x; Williams CJ, 2010, POULTRY SCI, V89, P189, DOI 10.3382/ps.2009-00093; Wise MG, 2004, J CLIN MICROBIOL, V42, P329, DOI 10.1128/JCM.42.1.329-338.2004; Xiao S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052751	64	0	0	7	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1189	10.3390/vaccines9101189			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR5FN	34696297	gold, Green Published			2022-04-29	WOS:000714525300001
J	Lv, M; Luo, XF; Shen, Q; Lei, RB; Liu, X; Liu, EM; Li, Q; Chen, YL				Lv, Meng; Luo, Xufei; Shen, Quan; Lei, Ruobing; Liu, Xiao; Liu, Enmei; Li, Qiu; Chen, Yaolong			Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Children and Adolescents: A Systematic Review	VACCINES			English	Review						COVID-19; vaccine; children; adolescents; systematic review	PANDEMIC INFLUENZA; DISEASE; H1N1	Aim: To identify the safety, immunogenicity, and protective efficacy of COVID-19 vaccines in children and adolescents. Methods: We conducted a systematic review of published studies and ongoing clinical studies related to the safety, immunogenicity, and efficacy of COVID-19 vaccine in children or adolescents (aged < 18 years). Databases including PubMed, Web of Science, WHO COVID-19 database, and China National Knowledge Infrastructure (CNKI) were searched on 23 July 2021. International Clinical Trials Registry Platform (ICTRP) was also searched to identify ongoing studies. Results: Eight published studies with a total of 2852 children and adolescents and 28 ongoing clinical studies were included. Of the eight published studies, two were RCTs, two case series, and four case reports. The investigated COVID-19 vaccines had good safety profiles in children and adolescents. Injection site pain, fatigue, headache, and chest pain were the most common adverse events. A limited number of cases of myocarditis and pericarditis were reported. The RCTs showed that the immune response to BNT162b2 in adolescents aged 12-15 years was non-inferior to that in young people aged 16-25 years, while with 3 mu g CoronaVac injection the immune response was stronger than with 1.5 mu g. The efficacy of BNT162b2 was 100% (95% CI: 75.3 to 100), based on one RCT. Of the 28 ongoing clinical studies, twenty-three were interventional studies. The interventional studies were being conducted in fifteen countries, among them, China (10, 43.5%) and United States(9, 39.1%) had the highest number of ongoing trials. BNT162b2 was the most commonly studied vaccine in the ongoing trials. Conclusion: Two COVID-19 vaccines have potential protective effects in children and adolescents, but awareness is needed to monitor possible adverse effects after injection. Clinical studies of the COVID-19 vaccination in children and adolescents with longer follow-up time, larger sample size, and a greater variety of vaccines are still urgently needed.</p>	[Lv, Meng; Li, Qiu] Chongqing Med Univ, Dept Nephrol, Childrens Hosp, Chongqing 400014, Peoples R China; [Lv, Meng; Shen, Quan; Lei, Ruobing; Liu, Enmei; Li, Qiu] Chongqing Med Univ, Natl Clin Res Ctr Child Hlth & Disorders, Minist Educ,Childrens Hosp, Key Lab Child Dev & Disorders,China Int Sci & Tec, Chongqing 400014, Peoples R China; [Lv, Meng; Shen, Quan; Lei, Ruobing; Liu, Enmei; Li, Qiu] Chongqing Key Lab Pediat, Chongqing 400014, Peoples R China; [Luo, Xufei; Liu, Xiao] Lanzhou Univ, Sch Publ Hlth, Lanzhou 730000, Peoples R China; [Shen, Quan; Lei, Ruobing] Chongqing Med Univ, Chevidence Lab Child & Adolescent Hlth, Dept Pediat, Res Inst,Childrens Hosp, Chongqing 400014, Peoples R China; [Liu, Enmei] Chongqing Med Univ, Dept Resp Med, Childrens Hosp, Chongqing 400014, Peoples R China; [Chen, Yaolong] Lanzhou Univ, Inst Hlth Data Sci, Lanzhou 730000, Peoples R China; [Chen, Yaolong] Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou 730000, Peoples R China; [Chen, Yaolong] WHO Collaborating Ctr Guideline Implementat & Kno, Lanzhou 730000, Peoples R China; [Chen, Yaolong] Guideline Int Network Asia, Lanzhou 730000, Peoples R China; [Chen, Yaolong] Lanzhou Univ, Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou 730000, Peoples R China; [Chen, Yaolong] Lanzhou Univ, GRADE Ctr, Lanzhou 730000, Peoples R China		Li, Q (通讯作者)，Chongqing Med Univ, Dept Nephrol, Childrens Hosp, Chongqing 400014, Peoples R China.; Li, Q (通讯作者)，Chongqing Med Univ, Natl Clin Res Ctr Child Hlth & Disorders, Minist Educ,Childrens Hosp, Key Lab Child Dev & Disorders,China Int Sci & Tec, Chongqing 400014, Peoples R China.; Li, Q (通讯作者)，Chongqing Key Lab Pediat, Chongqing 400014, Peoples R China.; Chen, YL (通讯作者)，Lanzhou Univ, Inst Hlth Data Sci, Lanzhou 730000, Peoples R China.; Chen, YL (通讯作者)，Lanzhou Univ, Sch Basic Med Sci, Evidence Based Med Ctr, Lanzhou 730000, Peoples R China.; Chen, YL (通讯作者)，WHO Collaborating Ctr Guideline Implementat & Kno, Lanzhou 730000, Peoples R China.; Chen, YL (通讯作者)，Guideline Int Network Asia, Lanzhou 730000, Peoples R China.; Chen, YL (通讯作者)，Lanzhou Univ, Key Lab Evidence Based Med & Knowledge Translat G, Lanzhou 730000, Peoples R China.; Chen, YL (通讯作者)，Lanzhou Univ, GRADE Ctr, Lanzhou 730000, Peoples R China.	lvm2016@163.com; luoxf2016@163.com; shenquan@whu.edu.cn; leiruobing1009@163.com; liuxiao20@lzu.edu.cn; emliu186@126.com; liqiu21@126.com; chenyaolong@vip.163.com		Luo, Xufei/0000-0003-0811-6326; Lv, Meng/0000-0001-6368-3919			CDC, VACC BAS; Centers for Disease Control and Prevention, COVID 19 VACC CHILDR; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; European Center for Disease Prevention and Control, 2021, INT PUBL HLTH CONS C; European Medicines Agency, 2021, COVID 19 VACC SPIK A; Food and Drug Administration, 2021, PFIZ BIONTECH COVID; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Goldman RD, 2021, HUM VACC IMMUNOTHER, V17, P1607, DOI 10.1080/21645515.2020.1834325; Hazlewood GS, 2021, J RHEUMATOL, V48, P1330, DOI 10.3899/jrheum.210288; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Kaur RJ, 2021, INDIAN J CLIN BIOCHE, V36, P427, DOI 10.1007/s12291-021-00968-z; Kaushik A, 2020, PEDIATR INFECT DIS J, V39, pE340, DOI 10.1097/INF.0000000000002888; Licciardi F, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-1711; Lu CY, 2010, VACCINE, V28, P5864, DOI 10.1016/j.vaccine.2010.06.059; Marshall M, 2021, PEDIATRICS, V148, DOI 10.1542/peds.2021-052478; McDonald I, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00336-1; McLean K, 2021, ACAD EMERG MED, V28, P918, DOI 10.1111/acem.14322; Minocha PK, 2021, J PEDIATR-US, V238, P321, DOI 10.1016/j.jpeds.2021.06.035; Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535; Murad MH, 2018, BMJ EVID-BASED MED, V23, P60, DOI 10.1136/bmjebm-2017-110853; Nour R, 2019, CUREUS, V11, DOI 10.7759/cureus.5067; O'Connell D., 2011, NEWCASTLE OTTAWA SCA, P1, DOI DOI 10.2307/632432; Opel DJ, 2021, JAMA PEDIATR, V175, P125, DOI 10.1001/jamapediatrics.2020.3019; Pfaar O, 2021, ALLERGOLOGIE, V44, P261, DOI [10.5414/ALX02241, 10.5414/ALX02241E]; Phuong LK, 2017, VACCINE, V35, P1770, DOI 10.1016/j.vaccine.2016.09.033; Pormohammad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050467; Revon-Riviere G, 2021, EUR J CANCER, V154, P30, DOI 10.1016/j.ejca.2021.06.002; Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/50140-6736(20)31094-1, 10.1016/S0140-6736(20)31094-1]; Ruf BR, 2014, EUR J PEDIATR, V173, P265, DOI 10.1007/s00431-013-2023-6; Schauer J, 2021, J PEDIATR-US, V238, P317, DOI 10.1016/j.jpeds.2021.06.083; Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046; Snapiri O, 2021, PEDIATR INFECT DIS J, V40, pE360, DOI 10.1097/INF.0000000000003235; The Canadian Paediatric Society, COVID 19 VACC CHICK; The Joanna Briggs Institute, 2017, CHECKL AN CROSS SECT; The World Bank, POP AG 0 14 TOT POP; Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X; Wang Q, 2021, PREV MED, V150, DOI 10.1016/j.ypmed.2021.106694; Wang Q, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040342; Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369; WHO, 2021, INT REC US IN COVID; Wijnans L, 2011, VACCINE, V29, P7559, DOI 10.1016/j.vaccine.2011.08.016; Xing Kai, 2021, Zhongguo Dang Dai Er Ke Za Zhi, V23, P221; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhou Q, 2021, TRANSL PEDIATR, V10, P177, DOI 10.21037/tp-20-290; Zimmermann P, 2021, ARCH DIS CHILD, V106, P429, DOI 10.1136/archdischild-2020-320338	45	6	6	39	39	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1102	10.3390/vaccines9101102			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO2OB	34696210	Green Published, gold			2022-04-29	WOS:000712297900001
J	Njuguna, DW; Mahrouseh, N; Isowamwen, OV; Varga, O				Njuguna, Diana Wangeshi; Mahrouseh, Nour; Isowamwen, Osarugue Victory; Varga, Orsolya			Knowledge, Attitude and Practice of Main Stakeholders towards Human Papilloma Virus Infection and Vaccination in Mombasa and Tana-River Counties in Kenya: A Qualitative Study	VACCINES			English	Article						HPV vaccination; cervical cancer; HPV vaccine; national immunization program; vaccine hesitancy	MIDDLE-INCOME COUNTRIES; HPV VACCINATION; CERVICAL-CANCER; BOYS; ACCEPTABILITY; IMPACT; IMPLEMENTATION; BURDEN; TRIALS; WOMEN	Following a successful Human Papilloma Virus (HPV) vaccination pilot in 2013-2015 in Kitui county, Kenya introduced the HPV vaccine in October 2019 with a goal to immunize approximately 800,000 girls annually against HPV. Our study assessed the knowledge, attitudes, and practice of affected groups towards HPV infection and vaccination in two counties of Kenya. Semi-structured interviews from children aged between nine and thirteen years and key informants comprising of parents, head teachers, community leaders and health workers involved in HPV vaccination in health facilities from Mombasa and Tana-River counties were conducted. Content was analyzed thematically and coded for emerging themes using the QRS Nvivo 12 Plus (QRS International, Doncaster, Australia) software package. From our findings, a significant proportion of participants, especially children, have limited knowledge of the subject. Vaccination of boys was opposed by most participants. Parents and the community members are not in favor of HPV vaccination, as compared to the other groups. A similar pattern of inadequate knowledge and strongly opposed attitudes was observed in Tana-River and Mombasa. Active community involvement in primary prevention strategies may promote the uptake of the vaccine which can be achieved by robust awareness, modifying the negative beliefs about HPV vaccine and encouraging the perceptibility of HPV vaccination.</p>	[Njuguna, Diana Wangeshi; Mahrouseh, Nour; Varga, Orsolya] Univ Debrecen, Fac Med, Dept Publ Hlth & Epidemiol, H-4032 Debrecen, Hungary; [Njuguna, Diana Wangeshi; Mahrouseh, Nour] Univ Debrecen, Doctoral Sch Hlth Sci, H-4032 Debrecen, Hungary; [Isowamwen, Osarugue Victory] Univ Debrecen, Fac Med, H-4032 Debrecen, Hungary; [Varga, Orsolya] Eotvos Lorand Res Network, Off Supported Res Grp, H-1052 Budapest, Hungary		Varga, O (通讯作者)，Univ Debrecen, Fac Med, Dept Publ Hlth & Epidemiol, H-4032 Debrecen, Hungary.; Varga, O (通讯作者)，Eotvos Lorand Res Network, Off Supported Res Grp, H-1052 Budapest, Hungary.	diana.njuguna@med.unideb.hu; nour.mahrouseh@med.unideb.hu; Isowamwen@mailbox.unideb.hu; varga.orsolya@med.unideb.hu	Njuguna, Diana Wangeshi/AAZ-7304-2021	Njuguna, Diana Wangeshi/0000-0001-7766-5164; Varga, Orsolya/0000-0001-8771-3975; Mahrouseh, Nour/0000-0002-1894-7847	Stipendium Hungaricum Scholarship; Hungarian Academy of Sciences (Premium Postdoctoral Research Program) [3134/2019/KP]	Diana Wangeshi Njuguna is supported by the Stipendium Hungaricum Scholarship. Orsolya Varga receives fellowship by the Hungarian Academy of Sciences (Premium Postdoctoral Research Program) grant number 3134/2019/KP.	Adams M, 2009, VACCINE, V27, P3391, DOI 10.1016/j.vaccine.2009.01.067; Anderson Edwin L, 2014, Mo Med, V111, P344; Arbyn M, 2021, INT J CANCER, V148, P277, DOI 10.1002/ijc.33189; Arbyn M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009069.pub3; Bastani R, 2011, CANCER EPIDEM BIOMAR, V20, P1463, DOI 10.1158/1055-9965.EPI-11-0267; Becker-Dreps S, 2010, VACCINE, V28, P4864, DOI 10.1016/j.vaccine.2010.05.034; Bednarczyk RA, 2019, HUM VACC IMMUNOTHER, V15, P1628, DOI 10.1080/21645515.2019.1565267; Bigaard J, 2021, MOL ONCOL, V15, P770, DOI 10.1002/1878-0261.12808; Bosire J., 2015, REGIONAL STATE COAST; Brisson M, 2020, LANCET, V395, P575, DOI 10.1016/S0140-6736(20)30068-4; Brotherton JML, 2019, PAPILLOMAVIRUS RES, V7, P138, DOI 10.1016/j.pvr.2019.04.004; Bruni L., 2019, ICO IARC INFORM CTR; Cordoba-Sanchez V, 2019, PREV MED REP, V16, DOI 10.1016/j.pmedr.2019.100977; Cunningham MS, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-005828; Daniels V, 2021, VACCINE, V39, P2731, DOI 10.1016/j.vaccine.2021.04.003; Datta S, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4108-y; de Sanjose S, 2019, SUMMARY REPORT; De Vuyst H, 2013, VACCINE, V31, pF32, DOI 10.1016/j.vaccine.2012.07.092; Deignan C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050496; Elfstrom KM, 2016, J INFECT DIS, V213, P199, DOI 10.1093/infdis/jiv368; Gallagher KE, 2018, VACCINE, V36, P4761, DOI 10.1016/j.vaccine.2018.02.003; Gallagher KE, 2017, PAPILLOMAVIRUS RES, V4, P72, DOI 10.1016/j.pvr.2017.09.001; Garland SM, 2009, J INFECT DIS, V199, P805, DOI 10.1086/597071; Global Alliance for Vaccines and Immunizations, KENY INTR CERV CANC; Government of Kenya, 2019, GOV ROLL OUT HPV VAC; Grandahl M, 2019, HUM VACC IMMUNOTHER, V15, P1794, DOI 10.1080/21645515.2018.1551670; Hopkins TG, 2013, VACCINE, V31, P1673, DOI 10.1016/j.vaccine.2013.01.028; Jedy-Agba E, 2020, BRIT J CANCER, V123, P148, DOI 10.1038/s41416-020-0831-9; Jindal HA, 2017, HUM VACC IMMUNOTHER, V13, P2723, DOI 10.1080/21645515.2017.1358837; Katz IT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072094; Kenya National Bureau of Statistics, GROSS COUNT PROD; Kimmel S.R., 2006, J FAM PRACTICE, V55, pS18; LaMontagne DS, 2017, INT J GYNECOL OBSTET, V138, P7, DOI 10.1002/ijgo.12186; Lindley MC, 2016, HUM VACC IMMUNOTHER, V12, P1519, DOI 10.1080/21645515.2016.1157673; Loke AY, 2017, J PRIM CARE COMMUNIT, V8, P349, DOI 10.1177/2150131917742299; Mabeya H, 2021, PAN AFR MED J, V38, DOI [10.11604/pamj.2021.38.126.21359, 10.11604/pamj.2021.38.126.19625]; Masika MM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135563; Masterson L, 2016, NAT REV CLIN ONCOL, V13, P721, DOI 10.1038/nrclinonc.2016.184; Mburu A, 2019, BIORESEARCH OPEN ACC, V8, P139, DOI 10.1089/biores.2019.0007; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Nabirye J, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8302-z; National Drought Management Authority, DROUGHT EARLY WARNIN; Nawrat A., 2019, PHARM TECHNOL; Njuguna DW, 2020, CANCERS, V12, DOI 10.3390/cancers12061520; O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388; Ogembo JG, 2014, VACCINE, V32, P4399, DOI 10.1016/j.vaccine.2014.06.064; Ogembo RK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122488; Otieno NA, 2021, IMPLEMENT SCI, V16, DOI 10.1186/s13012-021-01101-7; Otieno NA, 2020, HUM VACC IMMUNOTHER, V16, P2429, DOI 10.1080/21645515.2020.1723364; Patel C, 2018, EUROSURVEILLANCE, V23, P30, DOI 10.2807/1560-7917.ES.2018.23.41.1700737; Patel H, 2016, HEALTH AFFAIR, V35, P301, DOI 10.1377/hlthaff.2015.1416; Prue G., 2018, MED ACCESS POINT CAR, V2, DOI [10.1177/2399202618799691, DOI 10.1177/2399202618799691]; Schiller JT, 2012, VACCINE, V30, pF123, DOI 10.1016/j.vaccine.2012.04.108; Sipp D, 2018, CELL, V172, P1163, DOI 10.1016/j.cell.2018.02.045; Stanley M, 2014, HUM VACC IMMUNOTHER, V10, P2106, DOI 10.4161/hv.29137; Teguete I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172661; The Global Cancer Observatory, KENYA; Turiho Andrew Kampikaho, 2017, BMC Res Notes, V10, P431, DOI 10.1186/s13104-017-2749-8; Vamos CA, 2008, J SCHOOL HEALTH, V78, P302, DOI 10.1111/j.1746-1561.2008.00306.x; Walker KK, 2021, HUM VACC IMMUNOTHER, V17, P3355, DOI 10.1080/21645515.2021.1942713; Wigle J, 2013, VACCINE, V31, P3811, DOI 10.1016/j.vaccine.2013.06.016; World Health Organisation, 2019, MAJ MILEST REACH 100; World Health Organization, HUMAN PAPILLOMAVIRUS; Yamaguchi M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82354-6; Yoon D, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.m4931; Zhang XX, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10907-5; Zimet GD, 2013, PREV MED, V57, P414, DOI 10.1016/j.ypmed.2013.05.013	68	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1099	10.3390/vaccines9101099			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN4AB	34696206	Green Published, gold			2022-04-29	WOS:000711711500001
J	van Rijn, PA; Maris-Veldhuis, MA; Spedicato, M; Savini, G; van Gennip, RGP				van Rijn, Piet A.; Maris-Veldhuis, Mieke A.; Spedicato, Massimo; Savini, Giovanni; van Gennip, Rene G. P.			Pentavalent Disabled Infectious Single Animal (DISA)/DIVA Vaccine Provides Protection in Sheep and Cattle against Different Serotypes of Bluetongue Virus	VACCINES			English	Article						bluetongue virus; vaccine platform; DISA; DIVA; NS3; serotype exchange	COMPLETE NUCLEOTIDE-SEQUENCE; GENOME SEGMENT 10; CONTACT TRANSMISSION; NS3/NS3A EXPRESSION; GOATS; GENERATION; CHALLENGE; VIRULENT; REVEAL; STRAIN	Bluetongue (BT) is a midge-borne OIE-notifiable disease of ruminants caused by the bluetongue virus (BTV). There are at least 29 BTV serotypes as determined by serum neutralization tests and genetic analyses of genome segment 2 encoding serotype immunodominant VP2 protein. Large parts of the world are endemic for multiple serotypes. The most effective control measure of BT is vaccination. Conventionally live-attenuated and inactivated BT vaccines are available but have their specific pros and cons and are not DIVA compatible. The prototype Disabled Infectious Single Animal (DISA)/DIVA vaccine based on knockout of NS3/NS3a protein of live-attenuated BTV, shortly named DISA8, fulfills all criteria for modern veterinary vaccines of sheep. Recently, DISA8 with an internal in-frame deletion of 72 amino acid codons in NS3/NS3a showed a similar ideal vaccine profile in cattle. Here, the DISA/DIVA vaccine platform was applied for other serotypes, and pentavalent DISA/DIVA vaccine for "European " serotypes 1, 2, 3, 4, 8 was studied in sheep and cattle. Protection was demonstrated for two serotypes, and neutralization Ab titers indicate protection against other included serotypes. The DISA/DIVA vaccine platform is flexible in use and generates monovalent and multivalent DISA vaccines to combat specific field situations with respect to Bluetongue.</p>	[van Rijn, Piet A.; Maris-Veldhuis, Mieke A.; van Gennip, Rene G. P.] Wageningen Biovet Res WBVR, Dept Virol, NL-8200 RA Lelystad, Netherlands; [van Rijn, Piet A.] North West Univ, Ctr Human Metabol, Dept Biochem, ZA-2520 Potchefstroom, South Africa; [Spedicato, Massimo; Savini, Giovanni] Ist Zooprofilatt Sperimentale Abruzzo & Molise G, Publ Hlth Dept, I-64100 Teramo, Italy		van Rijn, PA (通讯作者)，Wageningen Biovet Res WBVR, Dept Virol, NL-8200 RA Lelystad, Netherlands.; van Rijn, PA (通讯作者)，North West Univ, Ctr Human Metabol, Dept Biochem, ZA-2520 Potchefstroom, South Africa.	piet.vanrijn@wur.nl; mieke.maris@wur.nl; m.spedicato@izs.it; g.savini@izs.it; rene.vangennip@wur.nl	Spedicato, Massimo/E-3476-2016	Spedicato, Massimo/0000-0001-6568-5504; van Gennip, Rene/0000-0002-5450-3493	European Union H2020 PALE-Blu grant [727393-2]	This research and APC were funded by supported by the European Union H2020 PALE-Blu grant (project no. 727393-2).	Attoui H., 2011, VIRUS TAXONOMY, VVolume 9, P1338; Batten CA, 2013, VET MICROBIOL, V162, P62, DOI 10.1016/j.vetmic.2012.08.014; Batten CA, 2008, VIRUS RES, V137, P56, DOI 10.1016/j.virusres.2008.05.016; Belhouchet M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025697; Breard E, 2018, TRANSBOUND EMERG DIS, V65, pe251, DOI 10.1111/tbed.12780; Bumbarov V, 2020, TRANSBOUND EMERG DIS, V67, P171, DOI 10.1111/tbed.13338; Celma CC, 2017, J VIROL, V91, DOI [10.1128/JVI.01892-16, 10.1128/jvi.01892-16]; Celma CCP, 2013, J VIROL, V87, P9856, DOI 10.1128/JVI.01514-13; Chaignat V, 2010, SMALL RUMINANT RES, V93, P157, DOI 10.1016/j.smallrumres.2010.05.016; Du Toit R. M., 1944, ONDERSTEPOORT JOUR VET SCI AND ANIMAL INDUST, V19, P7; Dungu B, 2004, Vet Ital, V40, P616; Erasmus B.J., 1990, VIRUS INFECT RUMINAN, V3; Feenstra F, 2017, CRIT REV MICROBIOL, V43, P142, DOI 10.1080/1040841X.2016.1186005; Feenstra F, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1063-3; Feenstra F, 2015, VACCINE, V33, P812, DOI 10.1016/j.vaccine.2014.12.003; Feenstra F, 2014, VACCINE, V32, P7108, DOI 10.1016/j.vaccine.2014.10.033; Feenstra F, 2014, J GEN VIROL, V95, P2019, DOI 10.1099/vir.0.065615-0; GIBBS EPJ, 1994, COMP IMMUNOL MICROB, V17, P207, DOI 10.1016/0147-9571(94)90044-2; GOULD AR, 1987, VIRUS RES, V7, P169, DOI 10.1016/0168-1702(87)90078-5; HAIG D. A., 1956, ONDER STEPOORT JOUR VET RES, V27, P171; HUISMANS H, 1981, ONDERSTEPOORT J VET, V48, P51; Labadie T, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8070965; Maan S, 2008, VIROLOGY, V377, P308, DOI 10.1016/j.virol.2008.04.028; Maan S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010323; MacLachlan NJ, 2008, VET PATHOL, V45, P310, DOI 10.1354/vp.45-3-310; Maclachlan NJ, 2009, J COMP PATHOL, V141, P1, DOI 10.1016/j.jcpa.2009.04.003; Marcacci M, 2018, TRANSBOUND EMERG DIS, V65, P370, DOI 10.1111/tbed.12822; Nunes SF, 2014, J VIROL, V88, P12222, DOI 10.1128/JVI.02183-14; OIE, 2019, TERR AN HLTH COD; OIE (Office International des Epizooties), 2019, MANUAL DIAGNOSTIC TE; PRITCHARD LI, 1995, VIRUS RES, V35, P247, DOI 10.1016/0168-1702(94)00072-K; Ratinier M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002477; Ries C, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050721; Ries C, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010042; Rojas JM, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.692069; SATO M, 1977, ARCH VIROL, V54, P333, DOI 10.1007/BF01314778; Savini G, 2004, Vet Ital, V40, P631; Savini G, 2010, VET MICROBIOL, V146, P44, DOI 10.1016/j.vetmic.2010.04.020; Savini G, 2009, VET MICROBIOL, V133, P1, DOI 10.1016/j.vetmic.2008.05.032; Savini G, 2008, COMP IMMUNOL MICROB, V31, P101, DOI 10.1016/j.cimid.2007.07.006; Savini G, 2017, INFECT GENET EVOL, V51, P108, DOI 10.1016/j.meegid.2017.03.021; Stewart M, 2015, J GEN VIROL, V96, P3280, DOI 10.1099/jgv.0.000267; Sun EC, 2016, TRANSBOUND EMERG DIS, V63, P585, DOI 10.1111/tbed.12560; Tacken MGJ, 2015, VACCINE, V33, P5539, DOI 10.1016/j.vaccine.2015.09.020; Tago D, 2014, PREV VET MED, V117, P577, DOI 10.1016/j.prevetmed.2014.10.010; van Gennip RGP, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3722-2; van Gennip RGP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044619; van Gennip RGP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030540; van Oirschot JT, 1999, J BIOTECHNOL, V73, P195, DOI 10.1016/S0168-1656(99)00121-2; van Rijn PA, 2013, VACCINE, V31, P5005, DOI 10.1016/j.vaccine.2013.08.089; van Rijn PA, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13050857; van Rijn PA, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00407; van Rijn PA, 2017, VACCINE, V35, P231, DOI 10.1016/j.vaccine.2016.11.081; van Rijn PA, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0574-7; van Rijn PA, 2012, VET MICROBIOL, V158, P23, DOI 10.1016/j.vetmic.2012.01.022; Velthuis AGJ, 2010, PREV VET MED, V93, P294, DOI 10.1016/j.prevetmed.2009.11.007; Wright I.M., 2014, THESIS NW U POTCHEFS	57	1	1	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1150	10.3390/vaccines9101150			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WU2CM	34696258	Green Published, gold			2022-04-29	WOS:000716358300001
J	Yan, ZP; Yang, M; Lai, CL				Yan, Zhipeng; Yang, Ming; Lai, Ching-Lung			COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations	VACCINES			English	Review						COVID-19 vaccinations; pregnancy; frailty; comorbidities	DIABETES-MELLITUS; SPIKE PROTEIN; VACCINE; CHILDREN; DISEASE; ANTIBODIES; CANCER; IMMUNOGENICITY; MORTALITY; SEVERITY	COVID-19 has been spreading worldwide since late 2019. There is no definitive cure to date. Global vaccination programs are urgently required to confer herd immunity, reducing the incidence of COVID-19 infections and associated morbidity and mortality. However, a significant proportion of special populations are hesitant to receive vaccination due to their special conditions, namely, age (pediatrics and geriatrics), immunocompromised state, autoimmune diseases, chronic cardiovascular and pulmonary conditions, active or treated cancers, and pregnancy. This review aims to evaluate the existing evidence of COVID-19 vaccinations on these special populations and to provide clues to guide vaccination decision making to balance the benefits and risks of vaccinations.	[Yan, Zhipeng; Lai, Ching-Lung] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China; [Yang, Ming] Univ Hong Kong, Li Ka Shing Fac Med, Dept Ophthalmol, Hong Kong, Peoples R China		Yan, ZP; Lai, CL (通讯作者)，Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Peoples R China.	u3537821@hku.hk; hrmeym@hku.hk; hrmelcl@hku.hk	Yang, Ming/AAU-5887-2020	Yang, Ming/0000-0001-8600-4325; Yan, Michael/0000-0003-1939-2772			Abdoli A., 2021, SAFETY POTENCY COVIR, DOI [10.1101/2021.06.10.447951, DOI 10.1101/2021.06.10.447951]; Abu Mouch S, 2021, VACCINE, V39, P3790, DOI 10.1016/j.vaccine.2021.05.087; Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Adhikari EH, 2021, JAMA-J AM MED ASSOC, V325, P1039, DOI 10.1001/jama.2021.1658; Adhikari EH, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.29256; Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; Albert Elisabeth, 2021, Radiol Case Rep, V16, P2142, DOI 10.1016/j.radcr.2021.05.033; American College of Obstretricians and Gynaecologist, COVID 19 VACC CONS O; American Diabetes Association, DIAB COR COVID 19 WH; American Society of Clinical Oncology, COVID 19 VACC PAT CA; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], STUD EV SAF IMM MVC; [Anonymous], 2020, CLIN FREQ ASK QUEST; Arad U, 2011, VACCINE, V29, P1643, DOI 10.1016/j.vaccine.2010.12.072; Arnold J, 2021, RHEUMATOLOGY, V60, P3496, DOI 10.1093/rheumatology/keab223; Arya A, 2021, TRANSPL P, V53, P1227, DOI 10.1016/j.transproceed.2021.02.014; Au L, 2020, CELL, V183, P4, DOI 10.1016/j.cell.2020.09.005; Bajaj JS, 2021, GUT, V70, P531, DOI 10.1136/gutjnl-2020-322118; Baker D, 2020, CLIN EXP IMMUNOL, V202, P149, DOI 10.1111/cei.13495; Balasubramanian S, 2020, INDIAN PEDIATR, V57, P435, DOI 10.1007/s13312-020-1819-5; Barda N, 2021, NEW ENGL J MED, V385, P1078, DOI 10.1056/NEJMoa2110475; BEHARIER O, 2021, J CLIN INVEST, V131, DOI [DOI 10.1172/JCI150319, 10.1172/JCI150319]; Beltramo G, 2021, EUR RESPIR J, V58, DOI 10.1183/13993003.04474-2020; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Bhopal SS, 2021, LANCET CHILD ADOLESC, V5, pE12, DOI 10.1016/S2352-4642(21)00066-3; Bingham CO, 2010, ARTHRITIS RHEUM-US, V62, P64, DOI 10.1002/art.25034; BIOTECH, FACT SHEET VACC REC; Bogart LM, 2021, JAIDS-J ACQ IMM DEF, V86, P200, DOI 10.1097/QAI.0000000000002570; Boivin Z, 2021, CUREUS, V13, DOI 10.7759/cureus.13651; Bourguignon A, 2021, NEW ENGL J MED, V385, P720, DOI 10.1056/NEJMoa2107051; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P1784, DOI 10.1001/jama.2021.4385; Bozkurt B, 2021, CIRCULATION, V144, P471, DOI 10.1161/CIRCULATIONAHA.121.056135; Braunstein SL, 2021, CLIN INFECT DIS, V72, pE1021, DOI 10.1093/cid/ciaa1793; British Thoracic Society, BTS GUID COVID 19 VA; Burd I, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI150790; Caillard S, 2021, AM J TRANSPLANT, V21, P1295, DOI 10.1111/ajt.16424; Cariou B, 2020, DIABETOLOGIA, V63, P1500, DOI 10.1007/s00125-020-05180-x; Carsetti R, 2020, LANCET CHILD ADOLESC, V4, P414, DOI 10.1016/S2352-4642(20)30135-8; Castro MC, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103700118; CDC U, 2021, VACC IMM INT CONS PR; Chakraborty C, 2021, AGING DIS, V12, P688, DOI 10.14336/AD.2021.0426; Chatterjee S, 2021, DIABETES METAB SYND, V15, P1055, DOI 10.1016/j.dsx.2021.04.006; Chee YJ, 2020, J DIABETES INVEST, V11, P1104, DOI 10.1111/jdi.13326; Collier ARY, 2021, JAMA-J AM MED ASSOC, V325, P2370, DOI 10.1001/jama.2021.7563; Curtis JR, 2021, ARTHRITIS RHEUMATOL, V73, P1093, DOI 10.1002/art.41734; de Souza FSH, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248580; Dey A, 2021, VACCINE, V39, P4108, DOI 10.1016/j.vaccine.2021.05.098; Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P2938, DOI 10.1080/21645515.2020.1842683; Dhochak N, 2020, INDIAN J PEDIATR, V87, P537, DOI 10.1007/s12098-020-03322-y; Diaz GA, 2021, JAMA-J AM MED ASSOC, V326, P1210, DOI 10.1001/jama.2021.13443; Dispinseri S, 2021, J CLIN ENDOCR METAB, V106, P1472, DOI 10.1210/clinem/dgab055; Dong YH, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000026573; E.M.A, SIGN ASS REP EMB THR; EMA, SUMMARY PRODUCT CHAR; Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680; Fischer L, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0663-9; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Furer V, 2021, RHEUMATOLOGY, V60, pSI90, DOI 10.1093/rheumatology/keab345; Garassino MC, 2021, ANN ONCOL, V32, P579, DOI 10.1016/j.annonc.2021.01.068; Gargano JW, 2021, MMWR-MORBID MORTAL W, V70, P977, DOI 10.15585/mmwr.mm7027e2; Gerayeli FV, 2021, ECLINICALMEDICINE, V33, DOI 10.1016/j.eclinm.2021.100789; Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI 10.1136/annrheumdis-2020-217871; Gray KJ, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.03.023; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Grimsholm O, 2020, CELL REP, V30, P2963, DOI 10.1016/j.celrep.2020.02.022; Grothmann, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab381, DOI 10.1093/CID/CIAB381]; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hacisuleyman E, 2021, NEW ENGL J MED, V384, P2212, DOI [10.1056/NEJMc2107808, 10.1056/NEJMoa2105000]; Heath PT, 2021, NEW ENGL J MED, V385, P1172, DOI 10.1056/NEJMoa2107659; Herzog LM, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.m4853; Ho FK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241824; Hsieh SM, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.100989; Huang I, 2020, DIABETES METAB SYND, V14, P395, DOI 10.1016/j.dsx.2020.04.018; Hwang JK, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01046-w; Hyams C, 2021, LANCET INFECT DIS, V21, P1539, DOI 10.1016/S1473-3099(21)00330-3; Iavarone M, 2020, J HEPATOL, V73, P1063, DOI 10.1016/j.jhep.2020.06.001; IRCT, PHAS 2 TRIAL SAF IMM; IRCT, COMP SAF EFF IMM FAK; Isaia G, 2020, AM J GERIAT PSYCHIAT, V28, P790, DOI [10.1016/j.jagp.2020.04.018, 10.1016/j.archger.2004.04.022]; Jain S, 2020, INDIAN PEDIATR, V57, P1015, DOI 10.1007/s13312-020-2026-0; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Jeewandara C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24579-7; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Kamidani S, 2021, CURR OPIN PEDIATR, V33, P144, DOI 10.1097/MOP.0000000000000978; Kelly JC, 2021, AM J OBSTET GYNECOL, V225, P101, DOI 10.1016/j.ajog.2021.03.031; Kim HW, 2021, JAMA CARDIOL, V6, P1196, DOI 10.1001/jamacardio.2021.2828; Kozlovskaya LI, 2021, EMERG MICROBES INFEC, V10, P1790, DOI 10.1080/22221751.2021.1971569; Lampasona V, 2020, DIABETOLOGIA, V63, P2548, DOI 10.1007/s00125-020-05284-4; Li GD, 2021, AGING-US, V13, P27, DOI 10.18632/aging.202456; Liu PP, 2020, CIRCULATION, V142, P68, DOI 10.1161/CIRCULATIONAHA.120.047549; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Ltd S.L.S.C, COVID 19 VACC VER CE; Ma LL, 2021, J CARDIOTHOR VASC AN, V35, P1860, DOI 10.1053/j.jvca.2020.04.041; MACKAY IR, 1984, CANCER, V53, P2619, DOI 10.1002/1097-0142(19840615)53:12<2619::AID-CNCR2820531209>3.0.CO;2-D; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n723; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4471; Malik JA, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111254; Mallapaty S, 2021, NATURE, V596, P475, DOI 10.1038/d41586-021-02216-z; Mallapaty S, 2020, NATURE, V585, P16, DOI 10.1038/d41586-020-02483-2; Marshall M, 2021, PEDIATRICS, V148, DOI 10.1542/peds.2021-052478; McArdle AJ, 2021, NEW ENGL J MED, V385, P11, DOI 10.1056/NEJMoa2102968; Mega Emiliano Rodriguez, 2021, Nature, DOI 10.1038/d41586-021-01126-4; Mithal A, 2021, DIABETES METAB SYND, V15, P169, DOI 10.1016/j.dsx.2020.12.029; Mithal LB, 2021, AM J OBSTET GYNECOL, V225, P192, DOI 10.1016/j.ajog.2021.03.035; Moderna, 2020, STUDY EVALUATE SAFET; Momin T, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101020; Monin L, 2021, LANCET ONCOL, V22, P765, DOI 10.1016/S1470-2045(21)00213-8; Montgomery J, 2021, JAMA CARDIOL, V6, P1202, DOI 10.1001/jamacardio.2021.2833; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; National Advisory Committee on Immunization (NACI), RECOMMENDATIONS USE; Pal R, 2021, DIABETES METAB SYND, V15, P505, DOI 10.1016/j.dsx.2021.02.026; Pal R, 2020, DIABETES METAB SYND, V14, P513, DOI 10.1016/j.dsx.2020.04.049; Park JK, 2018, ANN RHEUM DIS, V77, P898, DOI 10.1136/annrheumdis-2018-213222; Payne AB, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.16420; Perl SH, 2021, JAMA-J AM MED ASSOC, V325, P2013, DOI 10.1001/jama.2021.5782; Plotkin SA, 2021, PEDIATRICS, V147, DOI 10.1542/peds.2021-050531; Powers AC, 2021, LANCET DIABETES ENDO, V9, P140, DOI 10.1016/S2213-8587(21)00017-6; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Reuters, CUB SAYS ABD VACC 92; Ribas A, 2021, CANCER DISCOV, V11, P233, DOI 10.1158/2159-8290.CD-20-1817; Rosner CM, 2021, CIRCULATION, V144, P502, DOI 10.1161/CIRCULATIONAHA.121.055891; RPCEC R.P.C.b.d.E.C, ABDALA CLIN STUD PHA; Rubin R, 2020, JAMA-J AM MED ASSOC, V324, P1381, DOI 10.1001/jama.2020.17709; [Рыжиков А.Б. Ryzhikov A.B.], 2021, [Инфекция и иммунитет, Russian Journal of Infection and Immunity, Infektsiya i immunitet], V11, P283, DOI 10.15789/2220-7619-ASB-1699; [Рыжиков Александр Борисович Ryzhikov Aleksandr B.], 2021, [Вестник Российской академии медицинских наук, Annals of the Russian Academy of Medical Sciences, Vestnik Rossiiskoi akademii meditsinskikh nauk], V76, P5, DOI 10.15690/vramn1528; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sapkal GN, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab051; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; Shimabukuro TT, 2021, OBSTET GYNECOL SURV, V76, P729, DOI [10.1056/NEJMoa2104983, 10.1056/NEJMx210016, 10.1097/01.ogx.0000802676.57373.17]; Shinde V, 2021, NEW ENGL J MED, V384, P1899, DOI 10.1056/NEJMoa2103055; Skjefte M, 2021, EUR J EPIDEMIOL, V36, P197, DOI 10.1007/s10654-021-00728-6; Soiza RL, 2021, AGE AGEING, V50, P279, DOI 10.1093/ageing/afaa274; Sonani B, 2021, CLIN RHEUMATOL, V40, P797, DOI 10.1007/s10067-020-05547-w; Suarez-Garcia I, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255524; Terracina KA, 2021, LANCET RHEUMATOL, V3, pE469, DOI 10.1016/S2665-9913(21)00108-9; Thompson MG, 2021, NEW ENGL J MED, V385, P320, DOI 10.1056/NEJMoa2107058; Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069; Tsai R., 2021, COVID 19 VACCINE HES, DOI [10.1101/2021.04.06.21254014, DOI 10.1101/2021.04.06.21254014]; USCDC, ACIP COVID 19 VACC; USCDC, COVID 19 VACC WHIL P; USCDC, 2021, INT CLIN CONS US COV; USFDA, FACT SHEET HEALTHC P; Valdes-Balbin Y, 2021, ACS CHEM BIOL, V16, P1223, DOI 10.1021/acschembio.1c00272; Vallee A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040302; van der Heijde D, 2018, ARTHRITIS RHEUMATOL, V70, P826, DOI 10.1002/art.40448; van der Veldt AAM, 2021, NAT MED, V27, P568, DOI 10.1038/s41591-021-01240-w; Verma R, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0669-x; Vie P.c.e, APR CECM AUT US EM C; W.H.O, 2021, COVID 19 SUBC WHO GL; W.H.O, MOD COVID 19 MRNA 12; Waissengrin B, 2021, LANCET ONCOL, V22, P581, DOI 10.1016/S1470-2045(21)00155-8; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Watanabe M, 2022, DIABETES-METAB RES, V38, DOI 10.1002/dmrr.3465; West JA, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00122; WHO, WHO SIN COR COVID 19; WOLFE F, 1994, ARTHRITIS RHEUM-US, V37, P481, DOI 10.1002/art.1780370408; Wu SP, 2021, LANCET INFECT DIS, V21, P1654, DOI 10.1016/S1473-3099(21)00396-0; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Xiong XM, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.700014; Yan ZP, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14050406; Yan ZP, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9080966; Yanez ND, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09826-8; Yang SL, 2021, LANCET INFECT DIS, V21, P1107, DOI 10.1016/S1473-3099(21)00127-4; Yelin I, 2021, ASS BNT162B2 COVID 1, P2021, DOI [10.1101/2021.03.16.21253686, DOI 10.1101/2021.03.16.21253686]; Yusuf A, 2021, LANCET ONCOL, V22, P749, DOI 10.1016/S1470-2045(21)00244-8; Zambrano LD, 2020, MMWR-MORBID MORTAL W, V69, P1641, DOI 10.15585/mmwr.mm6944e3; Zhang CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00594; Zhao X, 2021, LANCET MICROBE, V2, pE494, DOI 10.1016/S2666-5247(21)00217-2; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	178	4	4	14	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1097	10.3390/vaccines9101097			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WM6QU	34696205	Green Published, gold			2022-04-29	WOS:000711208700001
J	Yang, Z; Luo, X; Jia, HP				Yang, Zheng; Luo, Xi; Jia, Hepeng			Is It All a Conspiracy? Conspiracy Theories and People's Attitude to COVID-19 Vaccination	VACCINES			English	Article						COVID-19; vaccination; conspiracy theories; vaccine literacy; scientific literacy; construal level theory	HIERARCHICAL REGRESSION; HESITANCY; BELIEF	A large body of research has found that people's beliefs in conspiracy theories about infectious diseases negatively impacts their health behaviors concerning vaccination. Conspiracy belief-based vaccination hesitancy has become more rampant after the global outbreak of COVID-19. However, some important questions remain unanswered. For instance, do different versions of conspiracy theories-particularly conspiracy theories about the origin of the epidemic (e.g., that the SARS-CoV-2 leaked from a Wuhan virology laboratory or that the virus was of foreign origin) and the general theories about vaccine conspiracies (e.g., pharmaceutical companies covered up the danger of vaccines or people are being deceived about the effectiveness of vaccines)-have the same effect on vaccination intentions? Through a national survey adopting quota sampling in China, the current study tested the relationship between people's conspiracy beliefs and their intention to receive the COVID-19 vaccination. The findings show that people's embrace of conspiracy theories did indeed affect their intention to take COVID-19 shots. However, only conspiracy theories related to vaccines had a significant impact, while belief in more general theories about COVID-19 did not significantly affect vaccination intentions. People's knowledge of vaccines (vaccine literacy) played an important role in this relationship. People with lower beliefs in vaccines conspiracy theories and higher levels of vaccine literacy were more likely to receive the COVID-19 vaccination.	[Yang, Zheng; Luo, Xi; Jia, Hepeng] Soochow Univ, Sch Commun, Suzhou 215127, Peoples R China		Luo, X (通讯作者)，Soochow Univ, Sch Commun, Suzhou 215127, Peoples R China.	zyang68@sheffield.ac.uk; luoqian1@suda.edu.cn; hpjia@suda.edu.cn		Yang, Zheng/0000-0002-2037-4689	National Social Science Foundation of China [21AZD013]	FundingThis research was funded by the Key Project Study on the permanent mechanism of communicating scientific spirit and professionalism in digital era of the National Social Science Foundation of China (No.21AZD013).	Ahmad AR, 2020, J MED INTERNET RES, V22, DOI 10.2196/19556; Allington D, 2021, PSYCHOL MED, V51, P1763, DOI [10.1017/S0033291721000593, 10.1017/S003329172000224X]; Arshad MS, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070720; Chen L, 2021, HEALTH COMMUN, V36, P1343, DOI 10.1080/10410236.2020.1751384; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Chu Y.J., 2020, SHANGHAI J REV, V447, P5; Devine D, 2021, POLIT STUD REV, V19, P274, DOI 10.1177/1478929920948684; Douglas KM, 2019, POLIT PSYCHOL, V40, P3, DOI 10.1111/pops.12568; Douglas KM, 2017, CURR DIR PSYCHOL SCI, V26, P538, DOI 10.1177/0963721417718261; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Germani F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247642; Goreis A, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.00205; Hornsey MJ, 2018, HEALTH PSYCHOL, V37, P307, DOI 10.1037/hea0000586; Hur J, 2020, J MED SYST, V44, DOI 10.1007/s10916-020-01586-7; Islam MS, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251605; Jennings W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060593; Jia HP, 2021, HEALTH COMMUN, DOI 10.1080/10410236.2021.1958982; Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177; Lazarevic LB, 2021, PERS INDIV DIFFER, V176, DOI 10.1016/j.paid.2021.110771; Leader AE, 2021, VACCINE, V39, P350, DOI 10.1016/j.vaccine.2020.11.058; Luo X, 2021, CHIN J COMMUN, DOI 10.1080/17544750.2021.1954963; Mallapaty S., CHINAS COVID VACCINE; Marinthe G, 2020, BRIT J HEALTH PSYCH, V25, P957, DOI 10.1111/bjhp.12449; Oleksy T, 2021, PERS INDIV DIFFER, V168, DOI 10.1016/j.paid.2020.110289; Penta MA, 2018, HEALTH COMMUN, V33, P299, DOI 10.1080/10410236.2016.1266574; Pierre JM, 2020, J SOC POLIT PSYCHOL, V8, P617, DOI 10.5964/jspp.v8i2.1362; Richardson DB, 2015, AM J EPIDEMIOL, V182, P459, DOI 10.1093/aje/kwv047; Rothmund T., 2020, SCI TRUST RISK ASSES, DOI [10.31234/osf.io/4nzuy, DOI 10.31234/OSF.IO/4NZUY]; Rutter CM, 2001, STAT MED, V20, P2865, DOI 10.1002/sim.942; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040382; Sallam M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144915; Swami V, 2014, COGNITION, V133, P572, DOI 10.1016/j.cognition.2014.08.006; Thigpen C., 2020, MOST AMERICANS EXPEC; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; Trope Y, 2003, PSYCHOL REV, V110, P403, DOI 10.1037/0033-295X.110.3.403; Trope Y, 2010, PSYCHOL REV, V117, P440, DOI 10.1037/a0018963; Ullah I, 2021, Vacunas, V22, P93, DOI 10.1016/j.vacun.2021.01.001; Valensise C.M., 2021, ARXIV2021210707946; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206; Wu K. J., 2020, NEW YORK TIMES; Xiao YH, 2020, LANCET INFECT DIS, V20, P523, DOI 10.1016/S1473-3099(20)30152-3; Zhang S, 2021, JMIR PUBLIC HLTH SUR, V7, DOI 10.2196/26090	44	3	3	14	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1051	10.3390/vaccines9101051			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WN5XM	34696159	Green Published, gold			2022-04-29	WOS:000711840900001
J	Frati, P; La Russa, R; Di Fazio, N; Del Fante, Z; Delogu, G; Fineschi, V				Frati, Paola; La Russa, Raffaele; Di Fazio, Nicola; Del Fante, Zoe; Delogu, Giuseppe; Fineschi, Vittorio			Compulsory Vaccination for Healthcare Workers in Italy for the Prevention of SARS-CoV-2 Infection	VACCINES			English	Article						compulsory vaccination; healthcare workers; SARS-CoV-2; Italian legislation		The European Convention on Human Rights (ECHR) judgement no. 116(2021) of 8 April 2021 establishes the principle of mandatory vaccination, indicating the criteria that national legislation must comply with, following the principle of non-interference in the private life of the individual. Vaccination for the prevention of SARS-CoV-2 infection appears to be an essential requirement for providing healthcare assistance. The European experience with compulsory vaccinations, offers a composite panorama, as the strategy of some European countries is to make vaccinations compulsory, including financial penalties for non-compliance. As in other countries, there is a clear need for Italy to impose compulsory vaccination for healthcare workers, in response to a pressing social need to protect individual and public health, and above all as a defense for vulnerable subjects or patients, for whom health workers have a specific position of guarantee and trust. The Italian Republic provided for mandatory vaccinations for health professionals by Decree-Law of 1 April 2021 no. 44, to guarantee public health and adequate safety conditions. As stated by ECHR, the Italian State, despite having initially opted for recommendation as regards to SARS-CoV-2 vaccination, had to adopt the mandatory system to achieve the highest possible degree of vaccination coverage among health professionals to guarantee the safety of treatments and protection of patients' health. We present the Italian situation on vaccine hesitation in healthcare workers, with updated epidemiological data as well as the doctrinaire, social, and political debate that is raging in Italy and Europe.	[Frati, Paola; Di Fazio, Nicola; Del Fante, Zoe; Delogu, Giuseppe; Fineschi, Vittorio] Sapienza Univ Rome, Dept Anat Histol Forens & Orthopaed Sci, Ple Verano 40, I-00161 Rome, Italy; [Frati, Paola; La Russa, Raffaele; Fineschi, Vittorio] Ist Ricovero & Cura Carattere Sci IRCCS Neuromed, Via Atinense 18, I-86077 Pozzilli, Italy; [La Russa, Raffaele] Univ Foggia, Dept Clin & Expt Med, I-71122 Foggia, Italy		Fineschi, V (通讯作者)，Sapienza Univ Rome, Dept Anat Histol Forens & Orthopaed Sci, Ple Verano 40, I-00161 Rome, Italy.; Fineschi, V (通讯作者)，Ist Ricovero & Cura Carattere Sci IRCCS Neuromed, Via Atinense 18, I-86077 Pozzilli, Italy.	paola.frati@uniroma1.it; raffaele.larussa@unifg.it; nicola.difazio@uniroma1.it; zoe.delfante@uniroma1.it; delogu.1637299@studenti.uniroma1.it; vittorio.fineschi@uniroma1.it		Frati, Paola/0000-0002-0358-7965; Fineschi, Vittorio/0000-0002-1686-3236			Agenzia Italiana del Farmaco (AIFA), 2021, **NON-TRADITIONAL**; [Anonymous], 2021, EP COVID 19 AGG NAZ; [Anonymous], 2021, EPID COVID 19 AGG NA; Arda B, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-87; Asma S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1528-9; D'Errico S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020110; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Evans G, 2006, CLIN INFECT DIS, V42, pS130, DOI 10.1086/499592; Giubilini A, 2019, PUBLIC HEALTH ETH-UK, V12, P237, DOI 10.1093/phe/phz014; Gostin LO, 2015, JAMA-J AM MED ASSOC, V313, P1099, DOI 10.1001/jama.2015.1518; Hollmeyer HG, 2009, VACCINE, V27, P3935, DOI 10.1016/j.vaccine.2009.03.056; Italian Superior Institute of Healthcare, 2021, COVID 19 EP; Khunti K, 2021, J ROY SOC MED, V114, P235, DOI 10.1177/01410768211013525; Li M, 2021, POSTGRAD MED J, DOI 10.1136/postgradmedj-2021-140195; Lin CJ, 2010, VACCINE, V28, P7706, DOI 10.1016/j.vaccine.2010.07.009; Looker C, 2011, B WORLD HEALTH ORGAN, V89, P371, DOI 10.2471/BLT.10.081901; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mandarelli G, 2012, J EMPIR RES HUM RES, V7, P63, DOI 10.1525/jer.2012.7.5.63; MARINER WK, 1992, HEALTH AFFAIR, V11, P255, DOI 10.1377/hlthaff.11.1.255; Mello MM, 2008, BIOETHICS, V22, P32, DOI 10.1111/j.1467-8519.2007.00590.x; Neufeind J, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10563-9; Panatto D, 2018, HUM VACC IMMUNOTHER, V14, P969, DOI 10.1080/21645515.2017.1407483; Paterlini M, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n905; Pitini E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060580; Qattan AMN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644300; Quotidianosanita.it, VACC COVID IND FAD 9; Rabaan Ali A, 2020, Infez Med, V28, P70; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Rubin GJ, 2011, VACCINE, V29, P2421, DOI 10.1016/j.vaccine.2011.01.035; Stojanovic J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060661; Stokel-Walker C, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1645; Talbot TR, 2021, JAMA-J AM MED ASSOC, V326, P23, DOI 10.1001/jama.2021.8901; Teece L, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-046392; Vaz OM, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-0620; Wise Jacqui, 2021, BMJ, V373, pn1056, DOI 10.1136/bmj.n1056; Woolf Katherine, 2021, Lancet Reg Health Eur, V9, P100180, DOI 10.1016/j.lanepe.2021.100180; Yang YT, 2015, JAMA-J AM MED ASSOC, V313, P247, DOI 10.1001/jama.2014.16286	38	4	4	4	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							966	10.3390/vaccines9090966			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3NT	34579203	gold, Green Published			2022-04-29	WOS:000702115800001
J	Marcano, VC; Cardenas-Garcia, S; Diel, DG; da Silva, LAH; Gogal, RM; Miller, PJ; Brown, CC; Butt, SL; Goraichuk, IV; Dimitrov, KM; Taylor, TL; Williams-Coplin, D; Olivier, TL; Stanton, JB; Afonso, CL				Marcano, Valerie C.; Cardenas-Garcia, Stivalis; Diel, Diego G.; Antoniassi da Silva, Luciana H.; Gogal, Robert M., Jr.; Miller, Patti J.; Brown, Corrie C.; Butt, Salman Latif; Goraichuk, Iryna V.; Dimitrov, Kiril M.; Taylor, Tonya L.; Williams-Coplin, Dawn; Olivier, Timothy L.; Stanton, James B.; Afonso, Claudio L.			A Novel Recombinant Newcastle Disease Vaccine Improves Post- In Ovo Vaccination Survival with Sustained Protection against Virulent Challenge	VACCINES			English	Article						Newcastle; NDV; in ovo vaccination; antisense; cytokines; chicken IL-4	IGG-MEDIATED SUPPRESSION; ANTIBODY-RESPONSES; MAREKS-DISEASE; IMMUNE-RESPONSE; VIRUS; EXPRESSION; EFFICACY; POULTRY; CELLS; GAMMA	In ovo vaccination has been employed by the poultry industry for over 20 years to control numerous avian diseases. Unfortunately, in ovo live vaccines against Newcastle disease have significant limitations, including high embryo mortality and the inability to induce full protection during the first two weeks of life. In this study, a recombinant live attenuated Newcastle disease virus vaccine containing the antisense sequence of chicken interleukin 4 (IL-4), rZJ1*L-IL4R, was used. The rZJ1*L-IL4R vaccine was administered in ovo to naive specific pathogen free embryonated chicken eggs (ECEs) and evaluated against a homologous challenge. Controls included a live attenuated recombinant genotype VII vaccine based on the virus ZJ1 (rZJ1*L) backbone, the LaSota vaccine and diluent alone. In the first of two experiments, ECEs were vaccinated at 18 days of embryonation (DOE) with either 10(4.5) or 10(3.5) 50% embryo infectious dose (EID50/egg) and chickens were challenged at 21 days post-hatch (DPH). In the second experiment, 10(3.5) EID50/egg of each vaccine was administered at 19 DOE, and chickens were challenged at 14 DPH. Chickens vaccinated with 10(3.5) EID50/egg of rZJ1*L-IL4R had hatch rates comparable to the group that received diluent alone, whereas other groups had significantly lower hatch rates. All vaccinated chickens survived challenge without displaying clinical disease, had protective hemagglutination inhibition titers, and shed comparable levels of challenge virus. The recombinant rZJ1*L-IL4R vaccine yielded lower post-vaccination mortality rates compared with the other in ovo NDV live vaccine candidates as well as provided strong protection post-challenge.	[Marcano, Valerie C.; Cardenas-Garcia, Stivalis; Diel, Diego G.; Antoniassi da Silva, Luciana H.; Miller, Patti J.; Butt, Salman Latif; Goraichuk, Iryna V.; Dimitrov, Kiril M.; Taylor, Tonya L.; Williams-Coplin, Dawn; Olivier, Timothy L.; Afonso, Claudio L.] USDA, US Natl Poultry Res Ctr, Agr Res Serv, Exot & Emerging Avian Viral Dis Res Unit,Southeas, 934 Coll Stn Rd, Athens, GA 30605 USA; [Marcano, Valerie C.; Cardenas-Garcia, Stivalis; Brown, Corrie C.; Butt, Salman Latif; Stanton, James B.] Univ Georgia, Coll Vet Med, Dept Vet Pathol, Athens, GA 30602 USA; [Gogal, Robert M., Jr.] Univ Georgia, Coll Vet Med, Dept Vet Biosci & Diagnost Imaging, Athens, GA 30602 USA; [Butt, Salman Latif] Univ Agr Faisalabad, Dept Pathol, UAF Sub Campus TTS, Faisalabad 38000, Punjab, Pakistan; [Goraichuk, Iryna V.] Natl Sci Ctr Inst Expt & Clin Vet Med, 83 Pushkinska St, UA-61023 Kharkiv, Ukraine		Afonso, CL (通讯作者)，USDA, US Natl Poultry Res Ctr, Agr Res Serv, Exot & Emerging Avian Viral Dis Res Unit,Southeas, 934 Coll Stn Rd, Athens, GA 30605 USA.	Marcano_Valerie@Elanco.com; stivalis@uga.edu; dgdiel@cornell.edu; luantoni@unicamp.br; rgogal@uga.edu; pjmdvm97@uga.edu; corbrown@uga.edu; drsalman@uaf.edu.pk; Goraichuk@outlook.com; kiril.dimitrov@tvmdl.tamu.edu; tonyaj@g.clemson.edu; Dawn.WilliamsCoplin@usda.gov; Tim.Olivier@usda.gov; jbs@uga.edu; cafonso@uga.edu	Diel, Diego G./ABC-6242-2021; Goraichuk, Iryna/AAC-5395-2019; Stanton, James/A-5277-2011	Diel, Diego G./0000-0003-3237-8940; Goraichuk, Iryna/0000-0002-5841-5765; Stanton, James/0000-0002-7661-2631; Cardenas Garcia, Stivalis/0000-0002-7613-8642; Marcano, Valerie/0000-0003-2218-7577	USDA-ARSUnited States Department of Agriculture (USDA)USDA Agricultural Research Service [CRIS 6040-32000-064]	This research was supported by USDA-ARS CRIS 6040-32000-064.	Absalon AE, 2019, TROP ANIM HEALTH PRO, V51, P1033, DOI 10.1007/s11250-019-01843-z; Afonso C.L., 2019, U.S. Patent, Patent No. [10,196,616, 10196616]; Alexander D.J., 2008, LAB MANUAL ISOLATION, V4th, P135; Amarasinghe GK, 2018, ARCH VIROL, V163, P2283, DOI 10.1007/s00705-018-3814-x; Cardenas-Garcia S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159153; Cardenas-Garcia S, 2015, BIOLOGICALS, V43, P136, DOI 10.1016/j.biologicals.2014.11.003; CHAN PL, 1973, IMMUNOLOGY, V24, P289; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COLTEY M, 1987, CELL DIFFER DEV, V22, P71, DOI 10.1016/0045-6039(87)90414-3; Cornax I, 2012, AVIAN DIS, V56, P464, DOI 10.1637/10043-122011-Reg.1; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Dilaveris D, 2007, VACCINE, V25, P3792, DOI 10.1016/j.vaccine.2007.01.115; Dimitrov KM, 2017, VET MICROBIOL, V206, P126, DOI 10.1016/j.vetmic.2016.12.019; Domenech J., 1988, NEWCASTLE DIS MANUAL; Dortmans JCFM, 2012, VET MICROBIOL, V160, P17, DOI 10.1016/j.vetmic.2012.05.003; Dunon D, 1997, J EXP MED, V186, P977, DOI 10.1084/jem.186.7.977; Esaki M, 2013, AVIAN DIS, V57, P750, DOI 10.1637/10540-032613-Reg.1; Gallili GE, 1998, BIOTECHNOL ADV, V16, P343, DOI 10.1016/S0734-9750(97)00081-5; Ganar K, 2014, VIRUS RES, V184, P71, DOI 10.1016/j.virusres.2014.02.016; GIAMBRONE JJ, 1990, AVIAN DIS, V34, P114, DOI 10.2307/1591341; Heyman B, 2000, ANNU REV IMMUNOL, V18, P709, DOI 10.1146/annurev.immunol.18.1.709; Jaganathan S, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0537-z; Jansen T, 2005, VACCINE, V23, P1053, DOI 10.1016/j.vaccine.2004.08.023; Kammon A, 2015, AVIAN DIS, V59, P422, DOI 10.1637/11068-032215-ResNote.1; Kapczynski DR, 2012, AVIAN DIS, V56, P555, DOI 10.1637/9980-110311-Reg.1; Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914; Karlsson MCI, 2001, J IMMUNOL, V167, P5558, DOI 10.4049/jimmunol.167.10.5558; Karlsson MCI, 1999, P NATL ACAD SCI USA, V96, P2244, DOI 10.1073/pnas.96.5.2244; Li JN, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-227; Liu YL, 2007, ARCH VIROL, V152, P1241, DOI 10.1007/s00705-007-0961-x; Liu Y, 2007, J NEURO-ONCOL, V81, P149, DOI 10.1007/s11060-006-9222-1; Marangon S, 2007, REV SCI TECH OIE, V26, P265, DOI 10.20506/rst.26.1.1742; Mast J, 2006, VACCINE, V24, P1756, DOI 10.1016/j.vaccine.2005.10.020; Miller P.J., 2013, NEWCASTLE DIS AVIAN; Miller PJ, 2015, INFECT GENET EVOL, V29, P216, DOI 10.1016/j.meegid.2014.10.032; Miller PJ, 2010, INFECT GENET EVOL, V10, P26, DOI 10.1016/j.meegid.2009.09.012; Nath B, 2016, MICROB PATHOGENESIS, V91, P85, DOI 10.1016/j.micpath.2015.11.026; Nemunaitis J, 2006, J CLIN ONCOL, V24, P4721, DOI 10.1200/JCO.2005.05.5335; Okwor G.O., 2014, WORLD J VACCINES, V04, P72, DOI [10.4236/wjv.2014.42009, DOI 10.4236/WJV.2014.42009]; Palya V, 2012, AVIAN DIS, V56, P282, DOI 10.1637/9935-091511-Reg.1; Pelechano V, 2013, NAT REV GENET, V14, P880, DOI 10.1038/nrg3594; Perozo F, 2012, J CLIN MICROBIOL, V50, P1204, DOI 10.1128/JCM.06506-11; SARMA G, 1995, AVIAN DIS, V39, P211, DOI 10.2307/1591862; Schat K.A., 2015, BACK VECTOR VACCINES, P1; Schijns V.E.J.C., 2013, AVIAN IMMUNOLOGY, P345; Shabbir MZ, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-170; SHARMA JM, 1982, AVIAN DIS, V26, P134, DOI 10.2307/1590032; SHARMA JM, 1985, AVIAN DIS, V29, P1155, DOI 10.2307/1590469; Siegrist CA, 2003, VACCINE, V21, P3406, DOI 10.1016/S0264-410X(03)00342-6; Sun MH, 2013, MICROBIOL RESOUR ANN, V1, DOI 10.1128/genomeA.00169-13; Susta L, 2013, MICROB PATHOGENESIS, V61-62, P73, DOI 10.1016/j.micpath.2013.05.009; Taylor TL, 2017, AVIAN DIS, V61, P245, DOI 10.1637/11555-120816-ResNote.1; Wajid A, 2017, PREV VET MED, V142, P1, DOI 10.1016/j.prevetmed.2017.04.010; Wise MG, 2004, J CLIN MICROBIOL, V42, P329, DOI 10.1128/JCM.42.1.329-338.2004; Xu ZY, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.1; Yang B, 2008, VACCINE, V26, P5477, DOI 10.1016/j.vaccine.2008.07.060; Yu WQ, 2008, NATURE, V451, P202, DOI 10.1038/nature06468	57	1	1	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							953	10.3390/vaccines9090953			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW0GL	34579191	Green Published, gold			2022-04-29	WOS:000699845700001
J	Federico, M				Federico, Maurizio			Virus-Induced CD8(+) T-Cell Immunity and Its Exploitation to Contain the SARS-CoV-2 Pandemic	VACCINES			English	Article						cross-presentation; CD8(+) T-cell immunity; SARS-CoV-2; extracellular vesicles	ACUTE RESPIRATORY SYNDROME; ENGINEERED EXOSOMES; PARTICULATE ANTIGENS; CROSS-PRESENTATION; PROTECTION; RESPONSES; CROSSPRESENTATION; RETROTRANSLOCATION; TRANSLOCATION; MACROPHAGES	The current battle against Severe Acute Respiratory Syndrome (SARS)-Coronavirus-2 benefits from the worldwide distribution of different vaccine formulations. All anti-SARS-CoV-2 vaccines in use are conceived to induce anti-Spike neutralizing antibodies. However, this strategy still has unresolved issues, the most relevant of which are: (i) the resistance to neutralizing antibodies of emerging SARS-CoV-2 variants and (ii) the waning of neutralizing antibodies. On the other hand, both pre-clinical evidence and clinical evidence support the idea that the immunity sustained by antigen-specific CD8(+) T lymphocytes can complement and also surrogate the antiviral humoral immunity. As a distinctive feature, anti-SARS-CoV-2 CD8(+) T-driven immunity maintains its efficacy even in the presence of viral protein mutations. In addition, on the basis of data obtained in survivors of the SARS-CoV epidemic, this immunity is expected to last for several years. In this review, both the mechanisms and role of CD8(+) T-cell immunity in viral infections, particularly those induced by SARS-CoV and SARS-CoV-2, are analyzed. Moreover, a CD8(+) T-cell-based vaccine platform relying on in vivo engineered extracellular vesicles is described. When applied to SARS-CoV-2, this strategy was proven to induce a strong immunogenicity, holding great promise for its translation into the clinic.	[Federico, Maurizio] Ist Super Sanita, Natl Ctr Global Hlth, I-00161 Rome, Italy		Federico, M (通讯作者)，Ist Super Sanita, Natl Ctr Global Hlth, I-00161 Rome, Italy.	maurizio.federico@iss.it	Federico, Maurizio/J-5867-2016	Federico, Maurizio/0000-0003-4154-1025			Ackerman AL, 2006, IMMUNITY, V25, P607, DOI 10.1016/j.immuni.2006.08.017; Anticoli S, 2018, BIOTECHNOL J, V13, DOI 10.1002/biot.201700443; Anticoli S, 2018, J MOL MED, V96, P211, DOI 10.1007/s00109-017-1617-2; Bange EM, 2021, NAT MED, V27, P1280, DOI 10.1038/s41591-021-01386-7; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Borges da Silva Henrique, 2021, Immunohorizons, V5, P338, DOI 10.4049/immunohorizons.2000102; Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14; Chiozzini C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040373; Chiozzini C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020243; Choi ES, 2019, MACROMOL BIOSCI, V19, DOI 10.1002/mabi.201900042; Di Bonito P, 2017, INT J NANOMED, V12, P4579, DOI 10.2147/IJN.S131309; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Ferrantelli F, 2021, CANCERS, V13, DOI 10.3390/cancers13092263; Ferrantelli F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030240; Ferretti AP, 2020, IMMUNITY, V53, P1095, DOI 10.1016/j.immuni.2020.10.006; Giodini A, 2008, EMBO J, V27, P201, DOI 10.1038/sj.emboj.7601941; Gonzalez-Galarza FF, 2020, NUCLEIC ACIDS RES, V48, pD783, DOI 10.1093/nar/gkz1029; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; HARDING CV, 1994, J IMMUNOL, V153, P4925; Harris PE, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050520; Hu ZZ, 2018, STRUCTURE, V26, P60, DOI 10.1016/j.str.2017.11.006; Imai T, 2011, P NATL ACAD SCI USA, V108, P16363, DOI 10.1073/pnas.1108372108; Jancic C, 2007, NAT CELL BIOL, V9, P367, DOI 10.1038/ncb1552; Joshi BS, 2020, ACS NANO, V14, P4444, DOI 10.1021/acsnano.9b10033; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kared H, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI145476; Kato Y, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/745962; Lattanzi L, 2012, VACCINE, V30, P7229, DOI 10.1016/j.vaccine.2012.10.010; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Li TS, 2004, J INFECT DIS, V189, P648, DOI 10.1086/381535; Mackay LK, 2013, NAT IMMUNOL, V14, P1294, DOI 10.1038/ni.2744; Mallajosyula V, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abg5669; Martinez-Pomares L, 2012, J LEUKOCYTE BIOL, V92, P1177, DOI 10.1189/jlb.0512231; Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556-018-0250-9; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; Menager J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089897; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Netland J, 2013, VIRUSES-BASEL, V5, P2573, DOI 10.3390/v5102573; Olinger GG, 2005, J VIROL, V79, P14189, DOI 10.1128/JVI.79.22.14189-14196.2005; Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; Redd Andrew D, 2021, Open Forum Infect Dis, V8, pofab143, DOI [10.1101/2021.02.11.21251585, 10.1093/ofid/ofab143]; Sakabe S, 2018, P NATL ACAD SCI USA, V115, pE7578, DOI 10.1073/pnas.1806200115; Savina A, 2006, CELL, V126, P205, DOI 10.1016/j.cell.2006.05.035; Schenkel JM, 2013, NAT IMMUNOL, V14, P509, DOI 10.1038/ni.2568; Schulien I, 2021, NAT MED, V27, P78, DOI 10.1038/s41591-020-01143-2; Shen LJ, 2004, IMMUNITY, V21, P155, DOI 10.1016/j.immuni.2004.07.004; Shimoda A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47760-x; Shrestha B, 2004, J VIROL, V78, P8312, DOI 10.1128/jvi.78.15.8312-8321.2004; Slutter B, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aag2031; Song R, 1996, J IMMUNOL, V156, P4182; Takamura S, 2019, J EXP MED, V216, P2736, DOI 10.1084/jem.20190557; Tan AT, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108728; Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490; Tarke Alison, 2021, bioRxiv, DOI 10.1101/2021.02.27.433180; Taylor ME, 2019, FEBS J, V286, P1800, DOI 10.1111/febs.14759; Valkenburg SA, 2016, P NATL ACAD SCI USA, V113, P4440, DOI 10.1073/pnas.1603106113; van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125; Wen J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01669-z; Westmeier J, 2020, MBIO, V11, DOI [10.1128/mBio.02243-20, 10.1128/mBio.02243-20.]; Williams C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1442985; Wilson JA, 2001, J VIROL, V75, P2660, DOI 10.1128/JVI.75.6.2660-2664.2001; Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358; Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576; Wu T, 2014, J LEUKOCYTE BIOL, V95, P215, DOI 10.1189/jlb.0313180; Yao X., 2020, NAT IMMUNOL, V21, P1336, DOI [DOI 10.1038/s41590-020-0782-6, 10.1038/s41590-020-0782-6]; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Yoshikawa T, 2009, J VIROL, V83, P3039, DOI 10.1128/JVI.01792-08; Zehner M, 2011, P NATL ACAD SCI USA, V108, P9933, DOI 10.1073/pnas.1102397108; Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10; Zhao JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000636; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhuang Z, 2021, J EXP MED, V218, DOI 10.1084/jem.20202187	75	2	2	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							922	10.3390/vaccines9080922			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH8SQ	34452047	gold, Green Published			2022-04-29	WOS:000690193600001
J	Moore, JX; Gilbert, KL; Lively, KL; Laurent, C; Chawla, R; Li, CT; Johnson, R; Petcu, R; Mehra, M; Spooner, A; Kolhe, R; Ledford, CJW				Moore, Justin Xavier; Gilbert, Keon L.; Lively, Katie L.; Laurent, Christian; Chawla, Rishab; Li, Cynthia; Johnson, Ryan; Petcu, Robert; Mehra, Mehul; Spooner, Antron; Kolhe, Ravindra; Ledford, Christy J. W.			Correlates of COVID-19 Vaccine Hesitancy among a Community Sample of African Americans Living in the Southern United States	VACCINES			English	Article						COVID-19; vaccine acceptance; race; disparities	HEALTH LITERACY; US COUNTIES; DISPARITIES; MORTALITY; PEOPLES; TRENDS; DETERMINANTS; POPULATION; DEFINITION; GOVERNMENT	In the United States, African Americans (AAs) have been disproportionately affected by COVID-19 mortality. However, AAs are more likely to be hesitant in receiving COVID-19 vaccinations when compared to non-Hispanic Whites. We examined factors associated with vaccine hesitancy among a predominant AA community sample. We performed a cross-sectional analysis on data collected from a convenience sample of 257 community-dwelling participants in the Central Savannah River Area from 5 December 2020, through 17 April 2021. Vaccine hesitancy was categorized as resistant, hesitant, and acceptant. We estimated relative odds of vaccine resistance and vaccine hesitancy using polytomous logistic regression models. Nearly one-third of the participants were either hesitant (n = 40, 15.6%) or resistant (n = 42, 16.3%) to receiving a COVID-19 vaccination. Vaccine-resistant participants were more likely to be younger and were more likely to have experienced housing insecurity due to COVID-19 when compared to both acceptant and hesitant participants, respectively. Age accounted for nearly 25% of the variation in vaccine resistance, with 21-fold increased odds (OR: 21.93, 95% CI: 8.97-5.26-91.43) of vaccine resistance in participants aged 18 to 29 compared to 50 and older adults. Housing insecurity accounted for 8% of the variation in vaccine resistance and was associated with 7-fold increased odds of vaccine resistance (AOR: 7.35, 95% CI: 1.99-27.10). In this sample, AAs under the age of 30 and those experiencing housing insecurity because of the COVID-19 pandemic were more likely to be resistant to receiving a free COVID-19 vaccination.	[Moore, Justin Xavier; Lively, Katie L.; Laurent, Christian; Chawla, Rishab; Li, Cynthia; Johnson, Ryan; Petcu, Robert; Mehra, Mehul; Spooner, Antron] Augusta Univ, Div Epidemiol, Dept Populat Hlth Sci, Augusta, GA 30912 USA; [Moore, Justin Xavier] Augusta Univ, Dept Med, Canc Prevent Control & Populat Hlth Program, Augusta, GA 30912 USA; [Moore, Justin Xavier] Augusta Univ, Med Coll Georgia, Inst Prevent & Publ Hlth, Augusta, GA 30912 USA; [Gilbert, Keon L.] St Louis Univ, Dept Behav Sci & Hlth Educ, St Louis, MO 63103 USA; [Kolhe, Ravindra] Augusta Univ, Dept Pathol, Sect Anat Pathol, Augusta, GA 30912 USA; [Ledford, Christy J. W.] Augusta Univ, Dept Family Med, Augusta, GA 30192 USA		Moore, JX (通讯作者)，Augusta Univ, Div Epidemiol, Dept Populat Hlth Sci, Augusta, GA 30912 USA.; Moore, JX (通讯作者)，Augusta Univ, Dept Med, Canc Prevent Control & Populat Hlth Program, Augusta, GA 30912 USA.; Moore, JX (通讯作者)，Augusta Univ, Med Coll Georgia, Inst Prevent & Publ Hlth, Augusta, GA 30912 USA.	jusmoore@augusta.edu; keon.gilbert@slu.edu; KLIVELY@augusta.edu; claurent@augusta.edu; RCHAWLA@augusta.edu; CYLI@augusta.edu; RYJOHNSON3@augusta.edu; RPETCU@augusta.edu; mmehra@augusta.edu; aspooner@augusta.edu; rkolhe@augusta.edu; Christy.Ledford@augusta.edu		KOLHE, RAVINDRA/0000-0002-8283-2403; Moore, Justin Xavier/0000-0002-5496-752X	National Institute on Minority Health and Health Disparities of the National Institutes of Health [K01MD015304]; National Institute of Allergy and Infectious Diseases, a component of the NIH, Department of Health and Human Services [75N93019C00052]	This research was supported by the National Institute on Minority Health and Health Disparities of the National Institutes of Health under Award Number K01MD015304. This project was also funded by the National Institute of Allergy and Infectious Diseases, a component of the NIH, Department of Health and Human Services, under contract 75N93019C00052. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Abdel-Latif MMM, 2020, PUBLIC HEALTH, V185, P95, DOI 10.1016/j.puhe.2020.06.030; [Anonymous], 2017, LANCET, V389, P881, DOI 10.1016/S0140-6736(17)30640-2; [Anonymous], 2021, CDC SOCIAL VULNERABI; Avtar R., 2021, UNDERSTANDING RACIAL; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bajaj SS, 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMpv2035827; Baltrus PT, 2021, SOUTH MED J, V114, P57, DOI 10.14423/SMJ.0000000000001212; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Brennen SJ, 2020, TYPES SOURCES CLAIMS; Britto MT, 2006, JT COMM J QUAL PATIE, V32, P426, DOI 10.1016/S1553-7250(06)32056-9; Burger AE, 2021, VACCINE, V39, P943, DOI 10.1016/j.vaccine.2020.12.069; CDC, 2021, DEMOGRAPHIC CHARACTE; CDC, 2021, RISK COVID 19 INF HO; Chafe W.H., 2011, REMEMBERING JIM CROW; Chaganti S., 2020, HLTH INSURANCE ESSEN; Cheng KJG, 2020, J RURAL HEALTH, V36, P602, DOI 10.1111/jrh.12511; Coughlin SS, 2020, AM J PUBLIC HEALTH, V110, P1157, DOI 10.2105/AJPH.2020.305764; Cox D.R., 1989, MONOGRAPHS STAT APPL, VVII, P236; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; El Bcheraoui C, 2018, JAMA-J AM MED ASSOC, V319, P1248, DOI 10.1001/jama.2018.2089; Evanega S., 2020, CORONAVIRUS MISINFOR; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Ford ChandraL., 2019, RACISM SCI TOOLS PUB; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Freimuth VS, 2017, SOC SCI MED, V193, P70, DOI 10.1016/j.socscimed.2017.10.001; Gamble VN, 1997, AM J PUBLIC HEALTH, V87, P1773, DOI 10.2105/AJPH.87.11.1773; Gee GC, 2019, AM J PUBLIC HEALTH, V109, pS43, DOI [10.2105/ajph.2018.304766, 10.2105/AJPH.2018.304766]; Gershon AA, 2017, J INFECTION, V74, pS27, DOI 10.1016/S0163-4453(17)30188-3; Gerussi V, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020172; Glynn RJ, 2004, J CLIN EPIDEMIOL, V57, P113, DOI 10.1016/j.jclinepi.2003.02.001; Grimes DR, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245900; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Heart MYHB, 2011, J PSYCHOACTIVE DRUGS, V43, P282, DOI 10.1080/02791072.2011.628913; Howard G, 2020, STROKE, V51, P742, DOI 10.1161/STROKEAHA.119.024155; Jamison AM, 2019, SOC SCI MED, V221, P87, DOI 10.1016/j.socscimed.2018.12.020; Karafillakis E, 2019, HUM VACC IMMUNOTHER, V15, P1615, DOI 10.1080/21645515.2018.1564436; Kennedy S., 1990, JIM CROW GUIDE US LA; Khanijahani A, 2021, ETHNIC HEALTH, V26, P22, DOI 10.1080/13557858.2020.1853067; Khose Swapnil, 2020, Res Sq, DOI 10.21203/rs.3.rs-131858/v1; Khose S, 2020, J COMMUN HEALTH, V45, P696, DOI 10.1007/s10900-020-00854-4; Kind AJH, 2018, NEW ENGL J MED, V378, P2456, DOI 10.1056/NEJMp1802313; Larson Heidi J, 2015, PLoS Curr, V7, DOI 10.1371/currents.outbreaks.ce0f6177bc97332602a8e3fe7d7f7cc4; Ledford CJW, 2020, FAM MED, V52, P320, DOI 10.22454/FamMed.2020.960734; Ledford CJW, 2012, J HEALTH COMMUN, V17, P105, DOI 10.1080/10810730.2011.585693; Lee C, 2016, VACCINE, V34, P3972, DOI 10.1016/j.vaccine.2016.06.048; Livingston Edward H, 2021, JAMA, V325, P1575, DOI 10.1001/jama.2021.2927; Lu H, 2020, RISK ANAL, V40, P2040, DOI 10.1111/risa.13459; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Marrett CB, 2021, J RACIAL ETHN HEALTH, V8, P794, DOI 10.1007/s40615-021-00988-8; Matthews KA, 2021, J RURAL HEALTH, V37, P272, DOI 10.1111/jrh.12555; Mokdad AH, 2017, JAMA-J AM MED ASSOC, V317, P388, DOI 10.1001/jama.2016.20324; Moore JX, 2020, JACEP OPEN, V1, P527, DOI 10.1002/emp2.12127; Moore JX, 2018, CANCER CAUSE CONTROL, V29, P737, DOI 10.1007/s10552-018-1051-y; Moore JX, 2016, CRIT CARE MED, V44, P1380, DOI 10.1097/CCM.0000000000001665; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Nguyen Long H, 2021, medRxiv, DOI 10.1101/2021.02.25.21252402; Nunn A, 2019, AIDS BEHAV, V23, P319, DOI 10.1007/s10461-019-02631-4; Paakkari L, 2020, LANCET PUBLIC HEALTH, V5, pE249, DOI 10.1016/S2468-2667(20)30086-4; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Porter G, 2021, HEALTH EQUITY, V5, P91, DOI 10.1089/heq.2020.0089; Quinn S. C., 2001, MINORITY HLTH TODAY, V2, P44; Quinn SC, 2019, VACCINE, V37, P1168, DOI 10.1016/j.vaccine.2019.01.033; Ratzan SC, 2020, PUBLIC HEALTH RES PR, V30, DOI 10.17061/phrp3022010; Razai MS, 2021, J ROY SOC MED, V114, P295, DOI 10.1177/01410768211018951; Rogers TN, 2020, WORLD MED HEALTH POL, V12, P311, DOI 10.1002/wmh3.358; Roth GA, 2017, JAMA-J AM MED ASSOC, V317, P1976, DOI 10.1001/jama.2017.4150; Scharff DP, 2010, J HEALTH CARE POOR U, V21, P879, DOI 10.1353/hpu.0.0323; Seehusen DA, 2020, FAM MED, V52, P471, DOI 10.22454/FamMed.2020.806737; Shah P, 2021, CRIT CARE MED, V49, P201, DOI 10.1097/CCM.0000000000004736; Shah P, 2020, ANN MED, V52, P354, DOI 10.1080/07853890.2020.1791356; Singer M, 2017, LANCET, V389, P941, DOI 10.1016/S0140-6736(17)30003-X; Tang Q, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87413-6; Tenforde MW, 2021, JAMA-J AM MED ASSOC, V325, P1464, DOI 10.1001/jama.2021.1995; Thomas SB, 2019, AM J PUBLIC HEALTH, V109, P1346, DOI 10.2105/AJPH.2019.305290; Tsai AC, 2017, LANCET, V389, P978, DOI 10.1016/S0140-6736(17)30403-8; Tyson, 2021, GROWING SHARE AMERIC; Viswanath K, 2020, HEALTH COMMUN, V35, P1743, DOI 10.1080/10410236.2020.1837445; Webster GR, 2008, SOUTHEAST GEOGR, V48, P3, DOI 10.1353/sgo.0.0007; Williams DR, 2019, HEALTH SERV RES, V54, P1374, DOI 10.1111/1475-6773.13222; Williams DR, 2012, J HEALTH SOC BEHAV, V53, P279, DOI 10.1177/0022146512455804; Wilson SL, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004206; Xu JJ, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18062921; Yearby R, 2020, J LAW MED ETHICS, V48, P518, DOI 10.1177/1073110520958876; Yearby R, 2020, J LAW BIOSCI, V7, DOI 10.1093/jlb/lsaa036; Zingg A, 2012, VACCINE, V30, P3771, DOI 10.1016/j.vaccine.2012.03.014	86	11	11	5	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							879	10.3390/vaccines9080879			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5SY	34452004	Green Published, gold			2022-04-29	WOS:000689991600001
J	Arshad, MS; Hussain, I; Mahmood, T; Hayat, K; Majeed, A; Imran, I; Saeed, H; Iqbal, MO; Uzair, M; Rehman, AU; Ashraf, W; Usman, A; Syed, SK; Akbar, M; Chaudhry, MO; Ramzan, B; Islam, M; Saleem, MU; Shakeel, W; Iqbal, I; Hashmi, F; Rasool, MF				Arshad, Muhammad Subhan; Hussain, Iltaf; Mahmood, Tahir; Hayat, Khezar; Majeed, Abdul; Imran, Imran; Saeed, Hamid; Iqbal, Muhammad Omer; Uzair, Muhammad; Rehman, Anees Ur; Ashraf, Waseem; Usman, Areeba; Syed, Shahzada Khurram; Akbar, Muqarrab; Chaudhry, Muhammad Omer; Ramzan, Basit; Islam, Muhammad; Saleem, Muhammad Usman; Shakeel, Waleed; Iqbal, Iram; Hashmi, Furqan; Rasool, Muhammad Fawad			A National Survey to Assess the COVID-19 Vaccine-Related Conspiracy Beliefs, Acceptability, Preference, and Willingness to Pay among the General Population of Pakistan	VACCINES			English	Article						COVID-19; COVID-19 vaccine; conspiracy theories; vaccine acceptance; vaccine hesitancy; general public	POLIO VACCINATION; HESITANCY; REFUSAL; HEALTH; IMPACT	The current study aims to assess the beliefs of the general public in Pakistan towards conspiracy theories, acceptance, willingness to pay, and preference for the COVID-19 vaccine. A cross-sectional study was conducted through an online self-administered questionnaire during January 2021. The Chi-square test or Fisher exact test was utilized for statistical data analysis. A total of 2158 respondents completed the questionnaire, among them 1192 (55.2%) were male with 23.87 (SD: +/- 6.23) years as mean age. The conspiracy beliefs circulating regarding the COVID-19 vaccine were believed by 9.3% to 28.4% of the study participants. Among them, 1040 (48.2%) agreed to vaccinate on its availability while 934 (43.3%) reported the Chinese vaccine as their preference. The conspiracy beliefs of the participants were significantly associated with acceptance of the COVID-19 vaccine. The existence of conspiracy beliefs and low vaccine acceptance among the general population is a serious threat to successful COVID-19 vaccination.	[Arshad, Muhammad Subhan; Hussain, Iltaf; Majeed, Abdul; Rehman, Anees Ur; Rasool, Muhammad Fawad] Bahauddin Zakariya Univ, Fac Pharm, Dept Pharm Practice, Multan 60800, Pakistan; [Mahmood, Tahir] Bahauddin Zakariya Univ, Dept Commun Studies, Multan 60800, Pakistan; [Hayat, Khezar] Univ Vet & Anim Sci, Inst Pharmaceut Sci, Lahore 54000, Pakistan; [Hayat, Khezar] Xi An Jiao Tong Univ, Sch Pharm, Dept Pharm Adm & Clin Pharm, Xian 710061, Peoples R China; [Imran, Imran; Ashraf, Waseem; Shakeel, Waleed; Iqbal, Iram] Bahauddin Zakariya Univ, Fac Pharm, Dept Pharmacol, Multan 60800, Pakistan; [Saeed, Hamid; Islam, Muhammad; Hashmi, Furqan] Univ Punjab, Univ Coll Pharm, Allama Iqbal Campus, Lahore 54000, Pakistan; [Iqbal, Muhammad Omer] Ocean Univ China Qingdao, Sch Med & Pharm, Key Lab Marine Drugs, Shandong Lab Glycosci & Glycoengn,Minist Educ, Qingdao 266003, Shandong, Peoples R China; [Uzair, Muhammad] Bahauddin Zakariya Univ, Fac Pharm, Dept Pharmaceut Chem, Multan 60800, Pakistan; [Usman, Areeba] Nishter Med Hosp, Multan 59070, Pakistan; [Syed, Shahzada Khurram] Univ Management & Technol Lahore, Sch Hlth Sci, Dept Basic Med Sci, Lahore 54770, Pakistan; [Akbar, Muqarrab] Bahauddin Zakariya Univ, Dept Polit Sci, Multan 60800, Pakistan; [Chaudhry, Muhammad Omer] Bahauddin Zakariya Univ, Sch Econ, Multan 60800, Pakistan; [Ramzan, Basit] Al Shifa Pharm, Multan 60650, Pakistan; [Saleem, Muhammad Usman] Bahauddin Zakariya Univ, Fac Vet Sci, Dept Biosci, Multan 60800, Pakistan		Rasool, MF (通讯作者)，Bahauddin Zakariya Univ, Fac Pharm, Dept Pharm Practice, Multan 60800, Pakistan.	m.subhan1995@gmail.com; altaf9216@gmail.com; tahirmahmood@bzu.edu.pk; khezar.hayat@uvas.edu.pk; abdulmajeed@bzu.edu.pk; imran.ch@bzu.edu.pk; hamid.pharmacy@pu.edu.pk; oiqbal133@gmail.com; muhammaduzair@bzu.edu.pk; aneesurrehman@bzu.edu.pk; chishtiwaseem@yahoo.com; drausman@outlook.com; shahzada.khurram@umt.edu.pk; mugarrabakbar@bzu.edu.pk; omer@bzu.edu.pk; basit.ramzan@hotmail.com; islam.pharmacy@pu.edu.pk; usmansaleem@bzu.edu.pk; waleed.shakeel@yahoo.com; iramiqbal.bzu@gmail.com; furqan.pharmacy@pu.edu.pk; fawadrasool@bzu.edu.pk	Chaudhry, Omer Muhammad/L-4380-2016; Hayat, Khezar/Y-2918-2019; Imran, Imran/AAL-5734-2020; Rasool, Muhammad Fawad/I-6610-2013; Hussain, Iltaf/AAY-5508-2020	Hayat, Khezar/0000-0001-7984-1870; Imran, Imran/0000-0003-1337-8574; Rasool, Muhammad Fawad/0000-0002-8607-8583; Hussain, Iltaf/0000-0003-0556-0181; Majeed, Abdul/0000-0002-6711-0832; Ashraf, Waseem/0000-0003-2295-6049; Arshad, Muhammad Subhan/0000-0003-0282-0216; iqbal, omer/0000-0002-7122-9422; Hashmi, Furqan/0000-0003-4921-3739			Abbas Q, 2021, AUTHOREA, V1, P1, DOI [DOI 10.22541/AU.161519250.03425961/V1, 10.22541/au.161519250.03425961/v1]; Afzal MS, 2021, J COMMUN HEALTH, V46, P476, DOI 10.1007/s10900-020-00875-z; Ahmed A, 2018, J INFECT PUBLIC HEAL, V11, P153, DOI 10.1016/j.jiph.2017.09.007; Ali M, 2019, LANCET, V394, P915, DOI 10.1016/S0140-6736(19)32101-4; Andrade GE, 2018, CUREUS, V10, DOI 10.7759/cureus.3502; Broniatowski DA., 2020, ARXIV200709682; Cameron MP, 2013, VACCINE, V31, P3712, DOI 10.1016/j.vaccine.2013.05.089; Chakraborty I, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138882; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Costill D., 2016, INFECT DISS CHILD, V29, P1; DRAP, APPR COVID 19 VACC; Eastwood K, 2010, MED J AUSTRALIA, V192, P33, DOI 10.5694/j.1326-5377.2010.tb03399.x; Enders AM, 2020, HARVARD KENNEDY SCH, DOI 10.37016/mr-2020-48; Eysenbach G, 2012, J MED INTERNET RES, V14, DOI 10.2196/jmir.2042; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freeman D, 2022, PSYCHOL MED, V52, P251, DOI 10.1017/S0033291720001890; Garon JR, 2015, LANCET INFECT DIS, V15, P1122, DOI 10.1016/S1473-3099(15)00008-0; Gouglas D, 2018, LANCET GLOB HEALTH, V6, pE1386, DOI 10.1016/S2214-109X(18)30346-2; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Han KY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050443; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Healthline, MUCH WILL IT COST GE; Hussain SF, 2016, GLOBALIZATION HEALTH, V12, DOI 10.1186/s12992-016-0195-3; Islam MS, 2020, AM J TROP MED HYG, V103, P1621, DOI 10.4269/ajtmh.20-0812; Jamison A.M., 2020, HARV KENNEDY SCH MIS, P1, DOI [10.37016/mr-2020-38, DOI 10.37016/MR-2020-38]; Jennings Will., 2021, LACK TRUST SOCIAL ME, DOI [10.1101/2021.01.26.21250246, DOI 10.1101/2021.01.26.21250246, 10.1101/2021.01.26.21250246v1, DOI 10.1101/2021.01.26.21250246V1]; Khan M.A., 2015, INT J DEV CONFL, V5, P32; Khan S, 2020, J MED VIROL, V92, P824, DOI 10.1002/jmv.25814; Khan TM, 2016, VACCINE, V34, P2074, DOI 10.1016/j.vaccine.2016.03.008; Khan TM, 2015, LANCET, V386, P1733, DOI 10.1016/S0140-6736(15)00689-3; Khan YH, 2020, AM J TROP MED HYG, V103, P603, DOI 10.4269/ajtmh.20-0654; Khattak FA, 2021, INT J INFECT DIS, V104, P117, DOI 10.1016/j.ijid.2020.12.029; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Koslap-Petraco M, 2019, J AM ASSOC NURSE PRA, V31, P624, DOI 10.1097/JXX.0000000000000342; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Lu J, 2020, CELL RES, V30, P936, DOI 10.1038/s41422-020-00392-7; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Martinez-Bravo M., 2021, J EUR ECON ASSOC, DOI [10.1093/jeea/jvab018, DOI 10.1093/JEEA/JVAB018]; Maurer J, 2009, VACCINE, V27, P5732, DOI 10.1016/j.vaccine.2009.07.080; Miller IF, 2020, NAT MED, V26, P1212, DOI 10.1038/s41591-020-0952-y; PBS, POP CENS; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Raude Jocelyn, 2010, PLoS Curr, V2, pRRN1188, DOI 10.1371/currents.RRN1188; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Rubin GJ, 2010, HEALTH TECHNOL ASSES, V14, P183, DOI 10.3310/hta14340-03; Rubinstein H, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1541-8; Salik A.N., 2020, I STRATEG STUD, V31, P1; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Sallam M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144915; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Shahsavari S, 2020, J COMPUT SOC SCI, V3, P279, DOI 10.1007/s42001-020-00086-5; Suarez-Lledo V, 2021, J MED INTERNET RES, V23, DOI 10.2196/17187; Taylor S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.575950; Tuite AR, 2020, ANN INTERN MED, V172, P699, DOI 10.7326/M20-0696; UK ER, US DOLL USD PAK RUP; Uscinski J.E., 2020, HARVARD KENNEDY SCH, V1, DOI 10.37016/mr-2020-015; von Elm E, 2007, LANCET, V370, P1453, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120, 10.1371/journal.pmed.0040296]; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; WHO, 2019, 10 THREATS GLOBAL HL; WHO, 2020, COR DIS COVID 19 SIT, P172; World Health Organization, COVID 19 SIT REP; Worldbank, DAT LOW MIDDL INC PA	66	8	8	2	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							720	10.3390/vaccines9070720			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7GE	34358136	Green Published, gold			2022-04-29	WOS:000677074300001
J	Roubidoux, EK; Schultz-Cherry, S				Roubidoux, Ericka Kirkpatrick; Schultz-Cherry, Stacey			Animal Models Utilized for the Development of Influenza Virus Vaccines	VACCINES			English	Review						animal models; vaccines; influenza; ferret; mouse; guinea pig	MESSENGER-RNA VACCINE; IMMUNE-RESPONSE; A VIRUS; COTTON RAT; B VIRUS; CONFERS PROTECTION; ANTIBODY-RESPONSE; EXPERIMENTAL-INFECTION; RESPIRATORY-DISEASE; PANDEMIC INFLUENZA	Animal models have been an important tool for the development of influenza virus vaccines since the 1940s. Over the past 80 years, influenza virus vaccines have evolved into more complex formulations, including trivalent and quadrivalent inactivated vaccines, live-attenuated vaccines, and subunit vaccines. However, annual effectiveness data shows that current vaccines have varying levels of protection that range between 40-60% and must be reformulated every few years to combat antigenic drift. To address these issues, novel influenza virus vaccines are currently in development. These vaccines rely heavily on animal models to determine efficacy and immunogenicity. In this review, we describe seasonal and novel influenza virus vaccines and highlight important animal models used to develop them.	[Roubidoux, Ericka Kirkpatrick; Schultz-Cherry, Stacey] St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA		Schultz-Cherry, S (通讯作者)，St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	ericka.roubidoux@stjude.org; Stacey.schultz-cherry@stjude.org		Roubidoux, Ericka/0000-0001-8878-744X; Schultz-Cherry, Stacey/0000-0002-2021-727X	National Institute of Allergy and Infectious Diseases under HHS [HHSN27220140006C, 75N93019C0052]	This work was supported by the National Institute of Allergy and Infectious Diseases under HHS contracts HHSN27220140006C for the St. Jude Center of Excellence for Influenza Research and Surveillance and 75N93019C0052 for the Center for Influenza Vaccine Research for High Risk Populations (CIVR-HRP) Collaborative Influenza Vaccine Innovation Center, National Institute of Allergy and ALSAC.	Albrecht RA, 2018, MBIO, V9, DOI 10.1128/mBio.01113-18; ALI MJ, 1982, ARCH VIROL, V72, P187, DOI 10.1007/BF01348964; Allen JD, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79590-7; Allen JD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204284; Ambrose CS, 2012, HUM VACC IMMUNOTHER, V8, P81, DOI 10.4161/hv.8.1.17623; [Anonymous], 2018, INFLUENZA VIRUS VACC; [Anonymous], 2017, WHO PREFERRED PRODUC; Antrobus RD, 2014, MOL THER, V22, P668, DOI 10.1038/mt.2013.284; Baranovich T, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.75; Barberis I, 2016, J Prev Med Hyg, V57, pE115; Bauer SA, 2011, COMPARATIVE MED, V61, P514; Baz M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51877-4; Belser JA, 2020, AM J PATHOL, V190, P11, DOI 10.1016/j.ajpath.2019.09.017; Belser JA, 2018, EMERG INFECT DIS, V24, P965, DOI 10.3201/eid2406.172114; Belser JA, 2016, MICROBIOL MOL BIOL R, V80, P733, DOI 10.1128/MMBR.00022-16; Belser JA, 2011, DIS MODEL MECH, V4, P575, DOI 10.1242/dmm.007823; Belshe RB, 2010, VACCINE, V28, pD45, DOI 10.1016/j.vaccine.2010.08.028; BERENDT RF, 1974, INFECT IMMUN, V9, P101, DOI 10.1128/IAI.9.1.101-105.1974; Bhide Y, 2020, IMMUN INFLAMM DIS, V8, P279, DOI 10.1002/iid3.303; Bodewes R, 2013, EMERG INFECT DIS, V19, P511, DOI 10.3201/eid1903.120965; Bodewes R, 2010, EXPERT REV VACCINES, V9, P59, DOI 10.1586/ERV.09.148; Bosaeed M, 2018, HUM VACC IMMUNOTHER, V14, P1311, DOI 10.1080/21645515.2018.1445446; Boukhvalova MS, 2009, BIOLOGICALS, V37, P152, DOI 10.1016/j.biologicals.2009.02.017; Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039; Bouvier NM, 2010, VIRUSES-BASEL, V2, P1530, DOI 10.3390/v20801530; Boyoglu-Barnum S, 2021, NATURE, V592, P623, DOI 10.1038/s41586-021-03365-x; Bradley SE, 1996, POSTGRAD MED, V99, P138; Brauer R, 2015, JOVE-J VIS EXP, DOI 10.3791/52421; Brehm MA, 2010, CURR OPIN ENDOCRINOL, V17, P120, DOI 10.1097/MED.0b013e328337282f; Broadbent AJ, 2015, VACCINE, V33, P193, DOI 10.1016/j.vaccine.2014.10.065; Broecker F, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0126-4; BRUNDAGEANGUISH LJ, 1982, AM J VET RES, V43, P869; de Mesquita PJB, 2020, INDOOR AIR, V30, P1189, DOI 10.1111/ina.12701; Bushnell RV, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-200; Carroll TD, 2018, J INFECT DIS, V218, P856, DOI 10.1093/infdis/jiy238; Carroll TD, 2014, J INFECT DIS, V209, P24, DOI 10.1093/infdis/jit540; Carter DM, 2016, J VIROL, V90, P4720, DOI 10.1128/JVI.03152-15; Chan KH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013757; Chen XY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00320; Chen YQ, 2018, CELL, V173, P417, DOI 10.1016/j.cell.2018.03.030; Cherukuri A, 2012, VACCINE, V30, P237, DOI 10.1016/j.vaccine.2011.11.001; Clemens EB, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020018; Coughlan L, 2018, EBIOMEDICINE, V29, P146, DOI 10.1016/j.ebiom.2018.02.011; Cox RJ, 2009, INFLUENZA OTHER RESP, V3, P107, DOI 10.1111/j.1750-2659.2009.00082.x; Crevar CJ, 2015, HUM VACC IMMUNOTHER, V11, P572, DOI 10.1080/21645515.2015.1012013; Danesh A, 2008, MOL IMMUNOL, V45, P1288, DOI 10.1016/j.molimm.2007.09.018; Davis AS, 2015, ANTIVIR RES, V117, P75, DOI 10.1016/j.antiviral.2015.02.011; de Vries RD, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030046; Dengler L, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-212; DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727; DiPiazza A, 2016, J VIROL, V90, P7991, DOI 10.1128/JVI.01001-16; Eichelberger MC, 2007, VIRAL IMMUNOL, V20, P243, DOI 10.1089/vim.2007.0017; Eichelberger MC, 2015, CURR TOP MICROBIOL, V386, P275, DOI 10.1007/82_2014_398; Eichelberger MC, 2011, EXPERT OPIN DRUG MET, V7, P1117, DOI 10.1517/17425255.2011.602065; Ellebedy AH, 2011, VACCINE, V29, P3335, DOI 10.1016/j.vaccine.2010.08.067; Engels G, 2017, CELL HOST MICROBE, V21, P321, DOI 10.1016/j.chom.2017.02.020; Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103; Ermler ME, 2017, J VIROL, V91, DOI 10.1128/JVI.00286-17; Fan JA, 2004, VACCINE, V22, P2993, DOI 10.1016/j.vaccine.2004.02.021; Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007; Flannery B, 2020, J INFECT DIS, V221, P8, DOI 10.1093/infdis/jiz543; Forero A, 2017, VACCINE, V35, P6112, DOI 10.1016/j.vaccine.2017.09.058; FRANCIS T, 1945, J CLIN INVEST, V24, P536, DOI 10.1172/JCI101633; Francis T, 1943, AM J HYG, V37, P294, DOI 10.1093/oxfordjournals.aje.a118866; Francis T, 1939, J EXP MED, V69, P283, DOI 10.1084/jem.69.2.283; FRANCIS T, 1946, JAMA-J AM MED ASSOC, V131, P275, DOI 10.1001/jama.1946.02870210011003; FRANCIS T Jr, 1953, Bull World Health Organ, V8, P725; Francis T, 1940, SCIENCE, V92, P405, DOI 10.1126/science.92.2392.405; Freyn AW, 2020, MOL THER, V28, P1569, DOI 10.1016/j.ymthe.2020.04.018; Fukuyama S, 2020, J INFECT DIS, V222, P1155, DOI 10.1093/infdis/jiaa267; Fullen DJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145902; Gerlach RL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078912; Gianchecchi E, 2016, FUTURE VIROL, V11, P379, DOI 10.2217/fvl-2016-0012; Gottesman ME, 2001, BIOESSAYS, V23, P409, DOI 10.1002/bies.1059; Gouma S, 2020, CLIN INFECT DIS, V71, P1447, DOI 10.1093/cid/ciz996; Green WD, 2017, ANN AM THORAC SOC, V14, pS406, DOI 10.1513/AnnalsATS.201706-447AW; Groves HT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00126; Gustin KM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125874; Hamouda T, 2011, CLIN VACCINE IMMUNOL, V18, P1167, DOI 10.1128/CVI.00035-11; Hampson AW, 2008, ANN ACAD MED SINGAP, V37, P510; Han A, 2019, CLIN INFECT DIS, V69, P2082, DOI 10.1093/cid/ciz141; Han A, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3220-8; Hannoun C, 2013, EXPERT REV VACCINES, V12, P1085, DOI 10.1586/14760584.2013.824709; Hashem AM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/414637; Hauser MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070251; Hay AJ, 2001, PHILOS T R SOC B, V356, P1861, DOI 10.1098/rstb.2001.0999; Henry C, 2018, TRENDS IMMUNOL, V39, P70, DOI 10.1016/j.it.2017.08.003; Hernandez-Vargas EA, 2014, J VIROL, V88, P4123, DOI 10.1128/JVI.03644-13; HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610; Holbrook BC, 2017, VACCINE, V35, P6137, DOI 10.1016/j.vaccine.2017.09.054; Holbrook BC, 2016, VACCINE, V34, P4712, DOI 10.1016/j.vaccine.2016.08.010; Holbrook BC, 2016, J IMMUNOL, V197, P555, DOI 10.4049/jimmunol.1600497; Holbrook BC, 2015, VIROLOGY, V476, P124, DOI 10.1016/j.virol.2014.12.007; Honce R, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a038604; Hu Z, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1227-4; Huber VC, 2006, J INFECT DIS, V193, P677, DOI 10.1086/500247; Hui DSC, 2008, RESPIROLOGY, V13, pS10, DOI 10.1111/j.1440-1843.2008.01247.x; Hulse-Post DJ, 2005, P NATL ACAD SCI USA, V102, P10682, DOI 10.1073/pnas.0504662102; Ilievski V, 2007, REPROD SCI, V14, P315, DOI 10.1177/1933719107302959; Ilyushina NA, 2012, J VIROL, V86, P11725, DOI 10.1128/JVI.01477-12; Innis BL, 2019, VACCINE, V37, P4823, DOI 10.1016/j.vaccine.2019.06.080; Isakova-Sivak I, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030061; Ito T, 1998, J VIROL, V72, P7367, DOI 10.1128/JVI.72.9.7367-7373.1998; Itoh Y, 2010, VACCINE, V28, P780, DOI 10.1016/j.vaccine.2009.10.067; Iwasaki A, 2014, NAT REV IMMUNOL, V14, P315, DOI 10.1038/nri3665; Iwatsuki-Horimoto K, 2018, J VIROL, V92, DOI 10.1128/JVI.01693-17; Iwatsuki-Horimoto K, 2017, J VIROL, V91, DOI [10.1128/jvi.01716-16, 10.1128/JVI.01716-16]; Jayaraman A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0027517; Jegaskanda S, 2013, J VIROL, V87, P13706, DOI 10.1128/JVI.01666-13; Jegerlehner A, 2004, J IMMUNOL, V172, P5598, DOI 10.4049/jimmunol.172.9.5598; JENNINGS R, 1975, J HYG-CAMBRIDGE, V75, P341, DOI 10.1017/S0022172400024402; JENNINGS R, 1974, MED MICROBIOL IMMUN, V160, P295, DOI 10.1007/BF02121445; JENNINGS R, 1973, ARCH GES VIRUSFORSCH, V42, P197, DOI 10.1007/BF01270840; Jeong JH, 2019, VACCINE, V37, P484, DOI 10.1016/j.vaccine.2018.11.064; Jia N, 2014, J BIOL CHEM, V289, P28489, DOI 10.1074/jbc.M114.588541; Jiang WB, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81389-z; Job ER, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0093-1; Jones JC, 2014, J VIROL, V88, P1175, DOI 10.1128/JVI.02526-13; Killingley B, 2012, J INFECT DIS, V205, P35, DOI 10.1093/infdis/jir701; Killingley B, 2011, LANCET INFECT DIS, V11, P879, DOI 10.1016/S1473-3099(11)70142-6; Kim JC, 2014, VIROLOGY, V448, P74, DOI 10.1016/j.virol.2013.10.001; Kim YH, 2012, J INFECT DIS, V205, P244, DOI 10.1093/infdis/jir731; Koday MT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189780; Kollmus H, 2018, MAMM GENOME, V29, P446, DOI 10.1007/s00335-018-9750-y; Koopman G, 2019, J GEN VIROL, V100, P738, DOI 10.1099/jgv.0.001251; Kou ZH, 2015, CELL RES, V25, P1372, DOI 10.1038/cr.2015.130; Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6; Krammer F, 2014, J VIROL, V88, P3432, DOI 10.1128/JVI.03004-13; Krammer F, 2013, J VIROL, V87, P6542, DOI [10.1128/JVI.00641-13, 10.1128/JVI.03183-13]; Kreijtz JHCM, 2009, J INFECT DIS, V199, P405, DOI 10.1086/595984; L'Huillier AG, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67172-6; Lambkin-Williams R, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0784-1; Lange E, 2009, J GEN VIROL, V90, P2119, DOI 10.1099/vir.0.014480-0; Lee BY, 2012, VACCINE, V30, P7443, DOI 10.1016/j.vaccine.2012.10.025; Lee YT, 2014, CLIN EXP VACCINE RES, V3, P12, DOI 10.7774/cevr.2014.3.1.12; Li R, 2018, JOVE-J VIS EXP, DOI 10.3791/56263; Liang F, 2017, MOL THER, V25, P2635, DOI 10.1016/j.ymthe.2017.08.006; Liebowitz D, 2020, LANCET INFECT DIS, V20, P435, DOI 10.1016/S1473-3099(19)30584-5; Littauer EQ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006757; Liu WC, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010040; Liu WC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00756; Ljungberg K, 2002, VACCINE, V20, P2045, DOI 10.1016/S0264-410X(02)00049-X; Lowen AC, 2014, CURR TOP MICROBIOL, V385, P157, DOI 10.1007/82_2014_390; Lu J, 2018, AGING DIS, V9, P358, DOI 10.14336/AD.2017.0701; Lutz Thomas A, 2012, Curr Protoc Pharmacol, VChapter 5, DOI 10.1002/0471141755.ph0561s58; Ma Wenjun, 2008, J Mol Genet Med, V3, P158; Maher JA, 2004, LAB ANIMAL, V33, P50, DOI 10.1038/laban1004-50; Gracia JCM, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00647; Marcelin G, 2011, J VIROL, V85, P11208, DOI 10.1128/JVI.00654-11; Margine I, 2013, J VIROL, V87, P10435, DOI 10.1128/JVI.01715-13; Margine I, 2014, PATHOGENS, V3, P845, DOI 10.3390/pathogens3040845; Marriott AC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094090; Martinez-Sobrido L, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008409; Matsuoka Yumiko, 2009, Curr Protoc Microbiol, VChapter 15, DOI [10.1002/9780471729259.mc15g03s13, 10.1002/9780471729259.mc15g02s13]; Maue AC, 2009, TRENDS IMMUNOL, V30, P301, DOI 10.1016/j.it.2009.04.007; McBride JM, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01154-17, 10.1128/aac.01154-17]; McMahon M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02005; McMahon M, 2019, MBIO, V10, DOI 10.1128/mBio.00560-19; Memoli MJ, 2016, MBIO, V7, DOI 10.1128/mBio.00417-16; Mena I, 2016, ELIFE, V5, DOI 10.7554/eLife.16777; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Mezhenskaya D, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0572-3; Miao JX, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02329; Miller LA, 2017, ILAR J, V58, P269, DOI 10.1093/ilar/ilx030; Milner JJ, 2012, P NUTR SOC, V71, P298, DOI 10.1017/S0029665112000158; Min JY, 2010, J VIROL, V84, P11950, DOI 10.1128/JVI.01305-10; Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046; Moncla LH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078750; Monto AS, 2015, J INFECT DIS, V212, P1191, DOI 10.1093/infdis/jiv195; Mooij P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126132; Nachbagauer R, 2021, NAT MED, V27, P106, DOI 10.1038/s41591-020-1118-7; Nachbagauer R, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030047; Nachbagauer R, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0026-4; Nachbagauer R, 2017, NAT IMMUNOL, V18, P464, DOI 10.1038/ni.3684; Nachbagauer R, 2016, J VIROL, V90, P3268, DOI 10.1128/JVI.02481-15; Nakata M, 2008, J VET MED SCI, V70, P543, DOI 10.1292/jvms.70.543; Narasaraju T, 2009, MICROBES INFECT, V11, P2, DOI 10.1016/j.micinf.2008.09.013; Nelson MI, 2018, AM J EPIDEMIOL, V187, P2498, DOI 10.1093/aje/kwy150; Nelson MI, 2014, J VIROL, V88, P10110, DOI 10.1128/JVI.01080-14; Nelson MI, 2012, J GEN VIROL, V93, P2195, DOI 10.1099/vir.0.044974-0; Neu KE, 2016, CURR OPIN IMMUNOL, V42, P48, DOI 10.1016/j.coi.2016.05.012; Ng S, 2019, NAT MED, V25, P962, DOI 10.1038/s41591-019-0463-x; Nguyen-Van-Tam JS, 2020, PLOS PATHOG, V16, DOI [10.1371/journal.ppat.1008704, 10.1371/journal.ppat.1008704.r001, 10.1371/journal.ppat.1008704.r002, 10.1371/journal.ppat.1008704.r003]; Ning ZY, 2009, VET RES COMMUN, V33, P895, DOI 10.1007/s11259-009-9307-3; O'Donnell CD, 2014, CLIN VACCINE IMMUNOL, V21, P737, DOI 10.1128/CVI.00790-13; Ochi A, 2008, DEV COMP IMMUNOL, V32, P890, DOI 10.1016/j.dci.2007.12.008; Ohmit SE, 2011, J INFECT DIS, V204, P1879, DOI 10.1093/infdis/jir661; Osterhaus ADME, 2000, SCIENCE, V288, P1051, DOI 10.1126/science.288.5468.1051; Ostrowsky J, 2020, CURR OPIN VIROL, V40, P28, DOI 10.1016/j.coviro.2020.02.003; Ottolini MG, 2005, J GEN VIROL, V86, P2823, DOI 10.1099/vir.0.81145-0; Ou HL, 2016, ONCOTARGET, V7, P81012, DOI 10.18632/oncotarget.12746; Paquette SG, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005173; Paquette SG, 2014, VIROLOGY, V464, P177, DOI 10.1016/j.virol.2014.07.013; Pardi N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05482-0; Park JK, 2020, NAT MED, V26, P1240, DOI 10.1038/s41591-020-0937-x; Parrish CR, 2015, J VIROL, V89, P2990, DOI 10.1128/JVI.03146-14; Pearce MB, 2011, VACCINE, V29, P2887, DOI 10.1016/j.vaccine.2011.02.014; Peng X, 2014, NAT BIOTECHNOL, V32, P1250, DOI 10.1038/nbt.3079; Penkert RR, 2017, VACCINE, V35, P6264, DOI 10.1016/j.vaccine.2017.09.069; Pharo EA, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060679; Pica N, 2011, J VIROL, V85, P12825, DOI 10.1128/JVI.05930-11; Pillet S, 2016, CLIN IMMUNOL, V168, P72, DOI 10.1016/j.clim.2016.03.008; POLLETT M, 1979, AUST J EXP BIOL MED, V57, P151, DOI 10.1038/icb.1979.16; POTTER CW, 1973, INFECT IMMUN, V8, P137, DOI 10.1128/IAI.8.2.137-144.1973; POTTER CW, 1979, BRIT MED BULL, V35, P69, DOI 10.1093/oxfordjournals.bmb.a071545; POWERS DC, 1993, J INFECT DIS, V167, P584, DOI 10.1093/infdis/167.3.584; Prokopyeva EA, 2016, INFECT GENET EVOL, V39, P265, DOI 10.1016/j.meegid.2016.01.022; Prokopyeva E, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040470; Qin JR, 2019, VIROL J, V16, DOI 10.1186/s12985-018-1109-1; Rajao DS, 2016, J GEN VIROL, V97, P1489, DOI 10.1099/jgv.0.000468; Rajao DS, 2015, ILAR J, V56, P44, DOI 10.1093/ilar/ilv002; Reber AJ, 2012, AGING DIS, V3, P68; Ren YY, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-149; Reperant LA, 2012, HUM VACC IMMUNOTHER, V8, P7, DOI 10.4161/hv.8.1.18672; Rimmelzwaan GF, 1997, J GEN VIROL, V78, P757, DOI 10.1099/0022-1317-78-4-757; Ritz BW, 2008, J NUTR, V138, P2269, DOI 10.3945/jn.108.093633; Robertson CA, 2016, EXPERT REV VACCINES, V15, P1495, DOI 10.1080/14760584.2016.1254044; Romanova J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005984; ROTA PA, 1990, VIROLOGY, V175, P59, DOI 10.1016/0042-6822(90)90186-U; Rutigliano JA, 2008, J IMMUNOL METHODS, V336, P71, DOI 10.1016/j.jim.2008.04.003; Saelens X, 2019, J INFECT DIS, V219, pS68, DOI 10.1093/infdis/jiz003; Sangesland M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020125; Sasaki Eita, 2018, Oncotarget, V9, P25751, DOI 10.18632/oncotarget.25399; Sautto GA, 2018, VIROL J, V15, DOI 10.1186/s12985-017-0918-y; Schultz-Cherry S, 2010, ADV VIRUS RES, V77, P63, DOI 10.1016/S0065-3527(10)77003-2; Seldeen KL, 2017, NUTR METAB, V14, DOI 10.1186/s12986-017-0174-6; Sherman AC, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00107; SMITH GL, 1983, P NATL ACAD SCI-BIOL, V80, P7155, DOI 10.1073/pnas.80.23.7155; Smith W, 1933, LANCET, V2, P66, DOI 10.1016/S0140-6736(00)78541-2; Soema PC, 2015, EUR J PHARM BIOPHARM, V94, P251, DOI 10.1016/j.ejpb.2015.05.023; Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10; STEPHENSEN CB, 1993, J NUTR, V123, P823, DOI 10.1093/jn/123.5.823; Stohr Klaus, 2012, Methods Mol Biol, V865, P147, DOI 10.1007/978-1-61779-621-0_9; Straight TM, 2006, VACCINE, V24, P6264, DOI 10.1016/j.vaccine.2006.05.092; Sun HL, 2020, P NATL ACAD SCI USA, V117, P17204, DOI 10.1073/pnas.1921186117; Sun WN, 2019, J VIROL, V93, DOI 10.1128/JVI.00333-19; Sun X, 2008, J CLIN INVEST, V118, P1578, DOI 10.1172/JCI34599; Sun YP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015537; Surman SL, 2016, CLIN VACCINE IMMUNOL, V23, P219, DOI 10.1128/CVI.00739-15; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Taylor AK, 2013, J INFECT DIS, V207, P501, DOI 10.1093/infdis/jis527; Taylor RM, 1941, J EXP MED, V73, P43, DOI 10.1084/jem.73.1.43; Teunis PFM, 2010, EPIDEMICS-NETH, V2, P215, DOI 10.1016/j.epidem.2010.10.001; Tregoning JS, 2018, HUM VACC IMMUNOTHER, V14, P550, DOI 10.1080/21645515.2017.1415684; van der Lubbe JEM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02350; van der Lubbe JEM, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0787-4; Van Reeth K, 2004, VIRUS RES, V103, P115, DOI 10.1016/j.virusres.2004.02.023; van Riel D, 2007, AM J PATHOL, V171, P1215, DOI 10.2353/ajpath.2007.070248; van Riel D, 2016, SEMIN IMMUNOPATHOL, V38, P719, DOI 10.1007/s00281-016-0580-2; Vermillion MS, 2018, AM J PHYSIOL-LUNG C, V315, pL517, DOI 10.1152/ajplung.00066.2018; Vidana B, 2021, INFLUENZA OTHER RESP, V15, P142, DOI 10.1111/irv.12784; Vincent AL, 2008, VET MICROBIOL, V126, P310, DOI 10.1016/j.vetmic.2007.07.011; Wang Y, 2018, EXPERT REV VACCINES, V17, P967, DOI 10.1080/14760584.2018.1541408; Watkins HC, 2017, MOL THER, V25, P989, DOI 10.1016/j.ymthe.2017.01.010; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; Wei CJ, 2010, SCIENCE, V329, P1060, DOI 10.1126/science.1192517; Weir JP, 2016, INFLUENZA OTHER RESP, V10, P354, DOI 10.1111/irv.12383; Whitley RJ, 2006, J INFECT DIS, V194, pS133, DOI 10.1086/507548; Wohlbold TJ, 2015, MBIO, V6, DOI 10.1128/mBio.02556-14; Wong SS, 2013, CLIN MICROBIOL REV, V26, P476, DOI 10.1128/CMR.00097-12; Wong SS, 2012, NAT BIOTECHNOL, V30, P1202, DOI 10.1038/nbt.2439; Wu R, 2009, VET MICROBIOL, V138, P85, DOI 10.1016/j.vetmic.2009.03.010; Xu LL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028901; Yasui H, 2004, CLIN DIAGN LAB IMMUN, V11, P675, DOI 10.1128/CDLI.11.4.675-679.2004; Yim K, 2012, VACCINE, V30, P1291, DOI 10.1016/j.vaccine.2011.12.084; Yoon SW, 2018, J INFECT DIS, V217, P438, DOI 10.1093/infdis/jix328; Yu CI, 2008, BLOOD, V112, P3671, DOI 10.1182/blood-2008-05-157016; Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114	268	1	1	4	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							787	10.3390/vaccines9070787			26	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8EE	34358203	Green Published			2022-04-29	WOS:000677136700001
J	Li, HZ; Dekker, A; Sun, SQ; Burman, A; Kortekaas, J; Harmsen, MM				Li, Haozhou; Dekker, Aldo; Sun, Shiqi; Burman, Alison; Kortekaas, Jeroen; Harmsen, Michiel M.			Novel Capsid-Specific Single-Domain Antibodies with Broad Foot-and-Mouth Disease Strain Recognition Reveal Differences in Antigenicity of Virions, Empty Capsids, and Virus-Like Particles	VACCINES			English	Article						foot-and-mouth disease; virus-like particles; vaccine; nanobody; single-domain antibody; immunogenicity	MONOCLONAL-ANTIBODIES; QUALITY-CONTROL; 12S PARTICLES; GUINEA-PIGS; 146S; QUANTIFICATION; SEROTYPE; FRAGMENTS; VACCINES; RECEPTOR	Foot-and-mouth disease (FMD) vaccine efficacy is mainly determined by the content of intact virions (146S) and empty capsids (75S). Both particles may dissociate into 12S subunits upon vaccine manufacturing, formulation, and storage, reducing vaccine potency. We report the isolation of capsid-specific llama single-domain antibodies (VHHs) with broad strain recognition that can be used to quantify intact capsids in FMD vaccines by double antibody sandwich (DAS) ELISA. One capsid-specific VHH displayed remarkably broad strain reactivity, recognizing 14 strains representing the 13 most important lineages of serotype A, and two VHHs cross-reacted with other serotypes. We additionally show that the newly isolated VHHs, as well as previously characterized VHHs, can be used to identify antigenic differences between authentic 146S and 75S capsids, as well as corresponding genetically engineered virus-like particles (VLPs). Our work underscores that VHHs are excellent tools for monitoring the quantity and stability of intact capsids during vaccine manufacturing, formulation, and storage, and additionally shows that VHHs can be used to predict the native-like structure of VLPs.	[Li, Haozhou; Kortekaas, Jeroen] Wageningen Univ & Res, Lab Virol, NL-6708 PB Wageningen, Netherlands; [Li, Haozhou; Sun, Shiqi] Chinese Acad Agr Sci, State Key Lab Vet Etiol Biol, Lanzhou 730046, Gansu, Peoples R China; [Li, Haozhou; Sun, Shiqi] Chinese Acad Agr Sci, Natl Foot & Mouth Dis Reference Lab, Lanzhou Vet Res Inst, Lanzhou 730046, Gansu, Peoples R China; [Dekker, Aldo; Kortekaas, Jeroen; Harmsen, Michiel M.] Wageningen Biovet Res, POB 65, NL-8200 AB Lelystad, Netherlands; [Burman, Alison] Pirbright Inst, Ash Rd, Pirbright GU24 0NF, Surrey, England		Harmsen, MM (通讯作者)，Wageningen Biovet Res, POB 65, NL-8200 AB Lelystad, Netherlands.	Haozhou.li@wur.nl; Aldo.Dekker@wur.nl; sunshiqi@caas.cn; alison.burman@pirbright.ac.uk; jeroen.kortekaas@wur.nl; michiel.harmsen@wur.nl		Harmsen, Michiel/0000-0003-4366-5187; Kortekaas, Jeroen/0000-0002-0329-0176; Dekker, Aldo/0000-0002-0519-9587	Ministry of Agriculture, Nature and Food Quality, the Netherlands [WOT-01-003-011]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [32072859, 32072847]; United Kingdom Department for Environment, Food and Rural AffairsDepartment for Environment, Food & Rural Affairs (DEFRA) [SE1129, SE1130]	The research done atWageningen Bioveterinary Research was funded by the Ministry of Agriculture, Nature and Food Quality, the Netherlands (project WOT-01-003-011). The research done at the Lanzhou Veterinary Research Institute was funded by the National Natural Science Foundation of China (32072859, 32072847). The research done at The Pirbright Institute was supported by the United Kingdom Department for Environment, Food and Rural Affairs, projects SE1129 and SE1130 to Donald P. King, https://www.gov.uk/government/organisations/department-for-environmentfood-rural-affairs.	ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; ALONSO A, 1994, VACCINE, V12, P682, DOI 10.1016/0264-410X(94)90216-X; Bakker SE, 2014, J VIROL, V88, P6093, DOI 10.1128/JVI.01979-13; BARTELING SJ, 1974, ARCH GES VIRUSFORSCH, V45, P362, DOI 10.1007/BF01242879; BAXT B, 1989, J VIROL, V63, P2143, DOI 10.1128/JVI.63.5.2143-2151.1989; CARTWRIGHT B, 1980, J GEN VIROL, V50, P369, DOI 10.1099/0022-1317-50-2-369; Mignaqui AC, 2019, CRIT REV BIOTECHNOL, V39, P306, DOI 10.1080/07388551.2018.1554619; CROWTHER J, 1995, VACCINE, V13, P1064, DOI 10.1016/0264-410X(95)00051-2; CROWTHER JR, 1979, J GEN VIROL, V42, P597, DOI 10.1099/0022-1317-42-3-597; Curry S, 1996, STRUCTURE, V4, P135, DOI 10.1016/S0969-2126(96)00017-2; Curry S, 1997, J VIROL, V71, P9743, DOI 10.1128/JVI.71.12.9743-9752.1997; Das B, 2016, INFECT GENET EVOL, V41, P36, DOI 10.1016/j.meegid.2016.03.024; DOEL TR, 1985, J BIOL STAND, V13, P335, DOI 10.1016/S0092-1157(85)80048-2; DOEL TR, 1982, ARCH VIROL, V73, P185, DOI 10.1007/BF01314726; Dong H, 2021, PROTEIN CELL, DOI 10.1007/s13238-021-00828-9; Du P, 2017, J CHROMATOGR B, V1049, P16, DOI 10.1016/j.jchromb.2016.12.033; Feng X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149569; Fry EE, 2005, J GEN VIROL, V86, P1909, DOI 10.1099/vir.0.80730-0; Guo HC, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-48; Harmsen MM, 2007, VET MICROBIOL, V120, P193, DOI 10.1016/j.vetmic.2006.10.029; Harmsen MM, 2015, VACCINE, V33, P2477, DOI 10.1016/j.vaccine.2015.03.066; Harmsen MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00960; Harmsen MM, 2000, MOL IMMUNOL, V37, P579, DOI 10.1016/S0161-5890(00)00081-X; Henstock M., 2018, OIE FAO FOOT AND MOU; Henstock M., 2017, OIE FAO FOOT AND MOU; Kim AY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030252; Kim MH, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030194; Kotecha A, 2015, NAT STRUCT MOL BIOL, V22, P788, DOI 10.1038/nsmb.3096; Lefranc MP, 2003, DEV COMP IMMUNOL, V27, P55, DOI 10.1016/S0145-305X(02)00039-3; Lin J, 2012, J VIROL, V86, P5959, DOI 10.1128/JVI.05990-11; Mohapatra JK, 2011, J GEN VIROL, V92, P873, DOI 10.1099/vir.0.028555-0; Paton DJ, 2019, VACCINE, V37, P5515, DOI 10.1016/j.vaccine.2019.07.102; Porta C, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003255; Quattrocchi V, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00594; RAO MG, 1994, VET MICROBIOL, V39, P135, DOI 10.1016/0378-1135(94)90094-9; ROWLANDS DJ, 1975, J GEN VIROL, V26, P227, DOI 10.1099/0022-1317-26-3-227; Schley D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030435; Scott KA, 2017, J VIROL, V91, DOI [10.1128/jvi.02312-16, 10.1128/JVI.02312-16]; Seki C, 2009, VET MICROBIOL, V133, P239, DOI 10.1016/j.vetmic.2008.07.011; Spitteler MA, 2019, VACCINE, V37, P5288, DOI 10.1016/j.vaccine.2019.07.051; Tekleghiorghis T, 2014, CLIN VACCINE IMMUNOL, V21, P674, DOI 10.1128/CVI.00034-14; VANMAANEN C, 1990, BIOLOGICALS, V18, P315, DOI 10.1016/1045-1056(90)90036-Y; Wang XL, 2018, J VIROL, V92, DOI 10.1128/JVI.01330-17; Yang M, 2008, VACCINE, V26, P3377, DOI 10.1016/j.vaccine.2008.04.062; Yang YL, 2015, VACCINE, V33, P1143, DOI 10.1016/j.vaccine.2015.01.031	45	1	1	5	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							620	10.3390/vaccines9060620			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY6BU	34201329	Green Published, gold			2022-04-29	WOS:000665971900001
J	Modenese, A; Paduano, S; Bargellini, A; Bellucci, R; Marchetti, S; Bruno, F; Grazioli, P; Vivoli, R; Gobba, F				Modenese, Alberto; Paduano, Stefania; Bargellini, Annalisa; Bellucci, Rossana; Marchetti, Simona; Bruno, Fulvio; Grazioli, Pietro; Vivoli, Roberto; Gobba, Fabriziomaria			Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart	VACCINES			English	Article						SARS-CoV-2; COVID-19; healthcare workers; vaccines; antibody titer; adverse effects; health surveillance; BNT162b2	1ST	Background: The immunization of healthcare workers (HCWs) plays a recognized key role in prevention in the COVID-19 pandemic: in Italy, the vaccination campaign began at the end of December 2020. A better knowledge of the on-field immune response in HCWs, of adverse effects and of the main factors involved is fundamental. Methods: We performed a study on workers at a nursing home in Northern Italy, vaccinated in January-February 2021 with two doses of the BNT162b2 vaccine four weeks apart, instead of the three weeks provided for in the original manufacturer protocol. One month after the second dose, the serological titer of IgG-neutralizing anti-RBD antibodies of the subunit S1 of the spike protein of SARS-CoV-2 was determined. The socio-demographic and clinical characteristics of the subjects and adverse effects of vaccination were collected by questionnaire. Results: In all of the workers, high antibody titer, ranging between 20 and 760 times the minimum protective level were observed. Titers were significantly higher in subjects with a previous COVID-19 diagnosis. Adverse effects after the vaccine were more frequent after the second dose, but no severe adverse effects were observed. Conclusions: The two doses of the BNT162b2 vaccine, even if administered four weeks apart, induced high titers of anti-SARS-CoV-2 neutralizing IgG in all the operators included in the study.	[Modenese, Alberto; Paduano, Stefania; Bargellini, Annalisa; Gobba, Fabriziomaria] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, I-41125 Modena, Italy; [Bellucci, Rossana; Marchetti, Simona; Vivoli, Roberto] Lab Anal TEST SrL, I-41121 Modena, Italy; [Bruno, Fulvio; Grazioli, Pietro] Fdn Scarpari Forattini Onlus, I-46020 Schivenoglia, MN, Italy		Modenese, A (通讯作者)，Univ Modena & Reggio Emilia, Dept Biomed Metab & Neural Sci, I-41125 Modena, Italy.	alberto.modenese@unimore.it; stefania.paduano@unimore.it; annalisa.bargellini@unimore.it; bellucci.rossana@laboratoriotest.it; marchetti.simona@laboratoriotest.it; fbruno@scarpari.it; graziolipietro@me.com; vivoli.roberto@laboratoriotest.it; fabriziomaria.gobba@unimore.it	Paduano, Stefania/AAB-8183-2020; Modenese, Alberto/F-7564-2017; Bargellini, Annalisa/O-7591-2015; Gobba, Fabriziomaria/G-7468-2016	Paduano, Stefania/0000-0003-3640-9177; Modenese, Alberto/0000-0002-0850-5615; Bargellini, Annalisa/0000-0002-7562-1472; Gobba, Fabriziomaria/0000-0002-1267-1632	UNIMORE FAR 2020 Mission Oriented	This study was supported by grant `UNIMORE FAR 2020 Mission Oriented'.	Agenzia Italiana del Farmaco, TERZ RAPP AIFA SULL; Agenzia Italiana del Farmaco (AIFA), VACC COVID 19; [Anonymous], 1 WHO INT STANDARD A; Chapin-Bardales J, 2021, JAMA-J AM MED ASSOC, V325, P2201, DOI 10.1001/jama.2021.5374; Chia WN, 2021, LANCET MICROBE, V2, pE179, DOI 10.1016/S2666-5247(21)00088-4; Colucci M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.602826; Euroimun, ANT COV 2 QUANTIVAC; Favresse J, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.05.004; Goel Rishi R, 2021, medRxiv, DOI 10.1101/2021.03.03.21252872; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Manisty C, 2021, LANCET, V397, P1057, DOI 10.1016/S0140-6736(21)00501-8; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; Ministero Della Salute, VACC DAY 27 DIC TUTT; Padoan A, 2021, CLIN CHIM ACTA, V519, P60, DOI 10.1016/j.cca.2021.04.006; Tre-Hardy M, 2021, J INFECTION, V83, P277, DOI 10.1016/j.jinf.2021.03.025; U.S. Food and Druhs Administration, PFIZ BIONTECH COVID; Watanabe M, 2022, DIABETES-METAB RES, V38, DOI 10.1002/dmrr.3465; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195	18	8	8	0	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							652	10.3390/vaccines9060652			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY8CN	34203652	Green Published, gold			2022-04-29	WOS:000666109200001
J	Costantino, A; Topa, M; Roncoroni, L; Doneda, L; Lombardo, V; Stocco, D; Gramegna, A; Costantino, C; Vecchi, M; Elli, L				Costantino, Andrea; Topa, Matilde; Roncoroni, Leda; Doneda, Luisa; Lombardo, Vincenza; Stocco, Davide; Gramegna, Andrea; Costantino, Claudio; Vecchi, Maurizio; Elli, Luca			COVID-19 Vaccine: A Survey of Hesitancy in Patients with Celiac Disease	VACCINES			English	Article						COVID-19 vaccines; COVID-19; vaccine hesitancy; celiac disease; vaccines	HEPATITIS-B-VACCINE; IMMUNE-RESPONSE; RISK; PREVALENCE; CHILDREN	(1) Background: COVID-19 vaccination campaigns offer the best hope of controlling the pandemic. However, the fast production of COVID-19 vaccines has caused concern among the general public regarding their safety and efficacy. In particular, patients with chronic illnesses, such as celiac disease (CD), may be more fearful. Information on vaccine hesitancy plays a pivotal role in the development of an efficient vaccination campaign. In our study, we aimed to evaluate COVID-19 vaccine hesitancy among Italian CD patients. (2) Methods: an anonymous questionnaire was sent to CD patients followed at our tertiary referral center for CD in Milan, Italy. Patients were defined as willing, hesitant and refusing. We evaluated the reasons for hesitancy/refusal and the possible determinants, calculating crude and adjusted odds ratios [AdjORs] with 95% confidence intervals [CIs]. (3) Results: the questionnaire was sent to 346 patients with a response rate of 29.8%. Twenty-six (25.2%) of the 103 respondents were hesitant, with a total refusal rate of 4.8%. The main reason was fear of adverse events related to vaccination (68.2%). Among hesitant patients, 23% declared that their opinion was influenced by their CD. The determinants positively influencing willingness to be vaccinated against COVID-19 were adherence to a GFD, perception of good knowledge about COVID-19 and its vaccines, and a positive attitude to previous vaccines (AdjOR 12.71, 95% CI 1.82-88.58, AdjOR 6.50, 95% CI 1.44-29.22, AdjOR 0.70, 95% CI 0.11-4.34, respectively). (4) Conclusions: CD patients should be vaccinated against COVID-19 and a specific campaign to address the determinants of hesitancy should be developed.	[Costantino, Andrea; Roncoroni, Leda; Lombardo, Vincenza; Vecchi, Maurizio; Elli, Luca] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Gastroenterol & Endoscopy Unit, I-20214 Milan, Italy; [Topa, Matilde; Gramegna, Andrea; Vecchi, Maurizio] Univ Milan, Dept Pathophysiol & Transplantat, I-20124 Milan, Italy; [Roncoroni, Leda; Doneda, Luisa] Univ Milan, Dept Biomed Surg & Dent Sci, I-20124 Milan, Italy; [Stocco, Davide] Politecn Milan, Dept Math, I-20124 Milan, Italy; [Gramegna, Andrea] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Internal Med, Resp Unit, I-20124 Milan, Italy; [Gramegna, Andrea] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Cyst Fibrosis Adult Ctr, I-20124 Milan, Italy; [Costantino, Claudio] Univ Palermo, Dept Hlth Promot Sci Maternal & Infant Care Inter, I-90145 Palermo, Italy; [Elli, Luca] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Ctr Prevent & Diag Celiac Dis, I-20124 Milan, Italy		Costantino, A; Elli, L (通讯作者)，Fdn IRCCS Ca Granda Osped Maggiore Policlin, Gastroenterol & Endoscopy Unit, I-20214 Milan, Italy.	andrea.costantino@policlinico.mi.it; matilde.topa@unimi.it; leda.roncoroni@unimi.it; luisa.doneda@unimi.it; vincenza.lombardo@policlinico.mi.it; davide.stocco@polimi.it; andrea.gramegna@unimi.it; claudio.costantino01@unipa.it; maurizio.vecchi@unimi.it; luca.elli@policlinico.mi.it	Elli, Luca/K-6084-2016; Costantino, Andrea/AAC-1655-2019; Gramegna, Andrea/AAC-2389-2022; Costantino, Claudio/F-4742-2018	Elli, Luca/0000-0002-0873-0759; Costantino, Andrea/0000-0003-4345-6051; Gramegna, Andrea/0000-0003-2315-5737; Stocco, Davide/0000-0003-4910-3580; Topa, Matilde/0000-0001-8761-1872; Costantino, Claudio/0000-0002-3397-7331			Agenzia italiana del farmaco, VACC COVID 19; Casella G, 2019, EXPERT REV GASTROENT, V13, P541, DOI 10.1080/17474124.2019.1607295; Costantino C, 2020, HUM VACC IMMUNOTHER, V16, P2415, DOI 10.1080/21645515.2020.1728157; Di Sabatino A, 2013, WORLD J GASTROENTERO, V19, P2313, DOI 10.3748/wjg.v19.i15.2313; Elli L, 2020, BMC GASTROENTEROL, V20, DOI 10.1186/s12876-020-01524-4; Elli L, 2020, CLIN RES HEPATOL GAS, V44, pE115, DOI [10.1016/j.clinre.2020.07.026, 10.1016/j.clinre.2020.07.076]; Ernst E, 2001, VACCINE, V20, pS90, DOI 10.1016/S0264-410X(01)00290-0; Ertem D, 2010, EUR J GASTROEN HEPAT, V22, P787, DOI 10.1097/MEG.0b013e32832e9d41; European Medicines Agency, TREATM VACC COVID 19 TREATM VACC COVID 19; Fasano A, 2003, ARCH INTERN MED, V163, P286, DOI 10.1001/archinte.163.3.286; FDA, COVID 19 VACC FDA HA; Galli G, 2021, DIGEST LIVER DIS, V53, P391, DOI 10.1016/j.dld.2021.01.007; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lionetti E, 2021, CLIN GASTROENTEROL H, V19, P1074, DOI 10.1016/j.cgh.2020.11.035; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malina D, 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMms2033790; Mallapaty S, 2020, NATURE, V586, P16, DOI 10.1038/d41586-020-02706-6; Myleus A, 2012, PEDIATRICS, V130, pE63, DOI 10.1542/peds.2011-2806; Nemes E, 2008, PEDIATRICS, V121, pE1570, DOI 10.1542/peds.2007-2446; Opri R, 2015, HUM VACC IMMUNOTHER, V11, P2800, DOI 10.1080/21645515.2015.1069448; Park SD, 2007, J PEDIATR GASTR NUTR, V44, P431, DOI 10.1097/MPG.0b013e3180320654; Passanisi S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020278; Schiepatti A, 2021, EUR J GASTROEN HEPAT, V33, P1361, DOI 10.1097/MEG.0000000000001969; Siniscalchi M, 2020, DIGEST LIVER DIS, V52, P1071, DOI 10.1016/j.dld.2020.05.014; SSCD, SSCD STAT COVID 19 V; THOMPSON NP, 1995, LANCET, V345, P1071, DOI 10.1016/S0140-6736(95)90816-1; William BM, 2007, HEMATOLOGY, V12, P89, DOI 10.1080/10245330600938463; Wraith DC, 2003, LANCET, V362, P1659, DOI 10.1016/S0140-6736(03)14802-7; Zhen JM, 2021, CLIN GASTROENTEROL H, V19, P391, DOI 10.1016/j.cgh.2020.10.009; Zingone F, 2013, CLIN VACCINE IMMUNOL, V20, P660, DOI 10.1128/CVI.00729-12	30	7	7	5	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							511	10.3390/vaccines9050511			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1NM	34065654	Green Published, gold			2022-04-29	WOS:000654592900001
J	Esposito, S; Antoniol, G; Labate, M; Passadore, L; Alvisi, P; Dacco, V; Ghizzi, C; Colombo, C; Principi, N				Esposito, Susanna; Antoniol, Giulia; Labate, Marialuisa; Passadore, Lucrezia; Alvisi, Patrizia; Dacco, Valeria; Ghizzi, Chiara; Colombo, Carla; Principi, Nicola			Vaccines in Children with Inflammatory Bowel Disease: Brief Review	VACCINES			English	Review						Crohn's disease; inflammatory bowel diseases; ulcerative colitis; vaccination; vaccine	PEDIATRIC CROHNS-DISEASE; FACTOR-ALPHA THERAPY; HEPATITIS-A VACCINE; INFLIXIMAB THERAPY; ULCERATIVE-COLITIS; IMMUNE-RESPONSE; OPPORTUNISTIC INFECTIONS; INFLUENZA VACCINATION; RECEIVING INFLIXIMAB; BOOSTER VACCINATION	Incidence of inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis (UC), is increasing worldwide. Children with IBDs have a dysfunctional immune system and they are frequently treated with immunomodulating drugs and biological therapy, which significantly impair immune system functions and lead to an increased risk of infections. Vaccines are essential to prevent at least part of these infections and this explains why strict compliance to the immunization guidelines specifically prepared for IBD patients is strongly recommended. However, several factors might lead to insufficient immunization. In this paper, present knowledge on the use of vaccines in children with IBDs is discussed. Literature review showed that despite a lack of detailed quantification of the risk of infections in children with IBDs, these children might have infections more frequently than age-matched healthy subjects, and at least in some cases, these infections might be even more severe. Fortunately, most of these infections could be prevented when recommended schedules of immunization are carefully followed. Vaccines given to children with IBDs generally have adequate immunogenicity and safety. Attention must be paid to live attenuated vaccines that can be administered only to children without or with mild immune system function impairment. Vaccination of their caregivers is also recommended. Unfortunately, compliance to these recommendations is generally low and multidisciplinary educational programs to improve vaccination coverage must be planned, in order to protect children with IBD from vaccine-preventable diseases.	[Esposito, Susanna; Antoniol, Giulia; Labate, Marialuisa; Passadore, Lucrezia] Univ Parma, Univ Hosp, Dept Med & Surg, Paediat Clin, I-43126 Parma, Italy; [Alvisi, Patrizia] Maggiore Hosp, Pediat Gastroenterol Unit, I-40133 Bologna, Italy; [Dacco, Valeria; Colombo, Carla] Univ Milan, Dept Pathophysiol & Transplantat, Cyst Fibrosis Ctr, Fdn IRCCS Ca Granda Osped Maggiore Policlin, I-20122 Milan, Italy; [Ghizzi, Chiara] Maggiore Hosp, Pediat Unit, I-40133 Bologna, Italy; [Principi, Nicola] Univ Milan, I-20122 Milan, Italy		Esposito, S (通讯作者)，Univ Parma, Univ Hosp, Dept Med & Surg, Paediat Clin, I-43126 Parma, Italy.	susannamariaroberta.esposito@unipr.it; giulia.antoniol@gmail.com; marialuisa.labate@libero.it; lucre.passadore@gmail.com; patrizia.alvisi@ausl.bo.it; valeria.dacco@policlinico.mi.it; chiara.ghizzi@ausl.bo.it; carla.colombo@unimi.it; nicola.principi@unimi.it	Esposito, Susanna/AAA-8275-2022	Principi, Nicola/0000-0002-3468-5568			Adams DJ, 2016, J PEDIATR-US, V171, P140, DOI 10.1016/j.jpeds.2015.12.072; Alexander JL, 2021, LANCET GASTROENTEROL, V6, P218, DOI 10.1016/S2468-1253(21)00024-8; Ardura MI, 2016, J PEDIATR GASTR NUTR, V63, P130, DOI 10.1097/MPG.0000000000001188; Baldassano R, 2003, AM J GASTROENTEROL, V98, P833, DOI 10.1016/S0002-9270(03)00007-8; Baldassano R, 2013, GASTROENTEROLOGY, V144, pS11; Banaszkiewicz A, 2015, INFLAMM BOWEL DIS, V21, P1607, DOI 10.1097/MIB.0000000000000406; Baranowska-Nowak M, 2020, CENT EUR J IMMUNOL, V45, P144, DOI 10.5114/ceji.2020.97902; Barbalho SM, 2021, GASTROENTEROL RES, V14, P1, DOI 10.14740/gr1358; Bittencourt VZ, 2021, J CROHNS COLITIS, V15, P1316, DOI 10.1093/ecco-jcc/jjab014; Brown SJ, 2007, AM J GASTROENTEROL, V102, P2058, DOI 10.1111/j.1572-0241.2007.01343.x; Brusaferro A, 2019, J INFECTION, V78, P1, DOI 10.1016/j.jinf.2018.10.005; Caldera F, 2020, INFLAMM BOWEL DIS, V26, P593, DOI 10.1093/ibd/izz164; Cezard JP, 2003, J PEDIATR GASTR NUTR, V36, P632, DOI 10.1097/00005176-200305000-00007; Chuang MH, 2010, J PEDIATR GASTR NUTR, V50, P337, DOI 10.1097/MPG.0b013e3181a70f3a; Crawford NW, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-87; Crombe V, 2011, INFLAMM BOWEL DIS, V17, P2144, DOI 10.1002/ibd.21615; Cucchiara S, 2008, DIGEST LIVER DIS, V40, pS260, DOI 10.1016/S1590-8658(08)60535-6; de Bie CI, 2011, ALIMENT PHARM THER, V33, P243, DOI 10.1111/j.1365-2036.2010.04507.x; de Ridder L, 2004, J PEDIATR GASTR NUTR, V39, P46, DOI 10.1097/00005176-200407000-00010; De Ridder L, 2008, INFLAMM BOWEL DIS, V14, P353, DOI 10.1002/ibd.20329; deBruyn JCC, 2019, INFLAMM BOWEL DIS, V25, P1218, DOI 10.1093/ibd/izy366; deBruyn JCC, 2012, INFLAMM BOWEL DIS, V18, P25, DOI 10.1002/ibd.21706; Dembinski L, 2021, HUM VACC IMMUNOTHER, V17, P2586, DOI 10.1080/21645515.2021.1884475; Dembinski L, 2020, PEDIATR INFECT DIS J, V39, P244, DOI 10.1097/INF.0000000000002547; DEUTSCH DE, 1995, J PEDIATR GASTR NUTR, V20, P351, DOI 10.1097/00005176-199504000-00016; Dipasquale V, 2017, VACCINE, V35, P6070, DOI 10.1016/j.vaccine.2017.09.031; Dotson JL, 2011, INFLAMM BOWEL DIS, V17, P56, DOI 10.1002/ibd.21378; Dulai PS, 2014, CLIN GASTROENTEROL H, V12, P1443, DOI 10.1016/j.cgh.2014.01.021; Eidelwein AP, 2005, INFLAMM BOWEL DIS, V11, P213, DOI 10.1097/01.MIB.0000160803.44449.a5; Esposito S, 2021, PEDIATR DRUGS, V23, P119, DOI 10.1007/s40272-020-00435-x; Esposito S, 2015, HUM VACC IMMUNOTHER, V11, P2564, DOI 10.1080/21645515.2015.1039208; Esteve M, 2004, GUT, V53, P1363, DOI 10.1136/gut.2004.040675; Fallahi G, 2014, GUT LIVER, V8, P24, DOI 10.5009/gnl.2014.8.1.24; Friesen CA, 2004, J PEDIATR GASTR NUTR, V39, P265, DOI 10.1097/00005176-200409000-00008; Gilca V, 2013, HUM VACC IMMUNOTHER, V9, P1685, DOI 10.4161/hv.25015; GOMES P, 1986, GUT, V27, P92, DOI 10.1136/gut.27.1.92; Grote V, 2008, ACTA PAEDIATR, V97, P187, DOI 10.1111/j.1651-2227.2007.00595.x; Guariso G, 2017, WORLD J GASTROENTERO, V23, P5469, DOI 10.3748/wjg.v23.i30.5469; Hou GQ, 2020, INFLAMM BOWEL DIS, V26, P653, DOI 10.1093/ibd/izz316; Huth K, 2015, INFLAMM BOWEL DIS, V21, P1761, DOI 10.1097/MIB.0000000000000425; Hyams J, 2007, GASTROENTEROLOGY, V132, P863, DOI 10.1053/j.gastro.2006.12.003; Hyams J, 2012, CLIN GASTROENTEROL H, V10, P391, DOI 10.1016/j.cgh.2011.11.026; Hyams J, 2011, CURR MED RES OPIN, V27, P651, DOI 10.1185/03007995.2010.547575; Hyams JS, 2010, AM J GASTROENTEROL, V105, P1430, DOI 10.1038/ajg.2009.759; Hyoms JS, 2009, INFLAMM BOWEL DIS, V15, P816, DOI 10.1002/ibd.20845; Jacobson, 2017, GASTROENTEROLOGY S1, V64, P501, DOI [10.1097/01.mpg.0000516381.25680.b4, DOI 10.1097/01.MPG.0000516381.25680.B4]; Jacobson DL, 2013, INFLAMM BOWEL DIS, V19, P1441, DOI 10.1097/MIB.0b013e318281341b; Jordan N, 2012, J PEDIATR GASTR NUTR, V54, P294, DOI 10.1097/MPG.0b013e31822938c3; Kennedy NA, 2021, GUT, V70, P865, DOI 10.1136/gutjnl-2021-324388; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Kmiec Z, 2017, ADV MED SCI-POLAND, V62, P1, DOI 10.1016/j.advms.2016.09.001; Kowalska-Duplaga K, 2019, ADV EXP MED BIOL, V1113, P83, DOI 10.1007/5584_2018_163; Kugathasan S, 2000, AM J GASTROENTEROL, V95, P3189; Kunz AN, 2011, CLIN PEDIATR, V50, P559, DOI 10.1177/0009922810380452; Kuter B, 2004, PEDIATR INFECT DIS J, V23, P132, DOI 10.1097/01.inf.0000109287.97518.67; Lamireau T, 2004, INFLAMM BOWEL DIS, V10, P745, DOI 10.1097/00054725-200411000-00008; Lee JH, 2002, ARTHRITIS RHEUM-US, V46, P2565, DOI 10.1002/art.10583; Lee MS, 2001, VACCINE, V19, P4644, DOI 10.1016/S0264-410X(01)00239-0; Lester R, 2015, J PEDIATR GASTR NUTR, V61, P47, DOI 10.1097/MPG.0000000000000730; Leung VS, 2004, AM J GASTROENTEROL, V99, P2503, DOI 10.1111/j.1572-0241.2004.41389_7.x; Long MD, 2013, AM J GASTROENTEROL, V108, P240, DOI 10.1038/ajg.2012.406; Longuet R, 2014, EUR J PEDIATR, V173, P603, DOI 10.1007/s00431-013-2207-0; Lu Y, 2010, J PEDIATR GASTR NUTR, V50, P562, DOI 10.1097/MPG.0b013e3181bab351; Lu Y, 2009, AM J GASTROENTEROL, V104, P444, DOI 10.1038/ajg.2008.120; Macaluso FS, 2020, DIGESTION, V101, P433, DOI 10.1159/000500798; Mamula P, 2004, J PEDIATR GASTR NUTR, V38, P298, DOI 10.1097/00005176-200403000-00013; Mamula P, 2007, CLIN GASTROENTEROL H, V5, P851, DOI 10.1016/j.cgh.2007.02.035; Martinelli M, 2020, INFLAMM BOWEL DIS, V26, P1407, DOI 10.1093/ibd/izz264; McGinnis JK, 2008, J CLIN GASTROENTEROL, V42, P875, DOI 10.1097/MCG.0b013e3181354417; Mehta M, 2017, INNATE IMMUN-LONDON, V23, P497, DOI 10.1177/1753425917722206; Moses J, 2012, AM J GASTROENTEROL, V107, P133, DOI 10.1038/ajg.2011.295; Moses J, 2011, INFLAMM BOWEL DIS, V17, pE160, DOI 10.1002/ibd.21892; Muzes G, 2012, WORLD J GASTROENTERO, V18, P5848, DOI 10.3748/wjg.v18.i41.5848; Nasir A, 2010, INFLAMM BOWEL DIS, V16, P7, DOI 10.1002/ibd.20928; Nobille S, 2009, JCR-J CLIN RHEUMATOL, V15, P101, DOI 10.1097/RHU.0b013e31819bca9e; Nuti F, 2014, PEDIATR DRUGS, V16, P343, DOI 10.1007/s40272-014-0084-2; Olbjorn C, 2020, PEDIATR DRUGS, V22, P409, DOI 10.1007/s40272-020-00396-1; Oliveira SB, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j2083; Ong C, 2018, J DIGEST DIS, V19, P395, DOI 10.1111/1751-2980.12641; Peloquin JM, 2016, ANNU REV IMMUNOL, V34, P31, DOI 10.1146/annurev-immunol-032414-112151; Perez-Alvarez R, 2011, MEDICINE, V90, P359, DOI 10.1097/MD.0b013e3182380a76; Pfizer Pfizer, PFIZ BIONTECH ANN PO; Pickering O, 2009, PEDIATR INFECT DIS J, V28, P556, DOI 10.1097/INF.0b013e3181a39571; Radzikowski A, 2011, INFLAMM BOWEL DIS, V17, P1117, DOI 10.1002/ibd.21465; Rahier JF, 2014, J CROHNS COLITIS, V8, P443, DOI 10.1016/j.crohns.2013.12.013; Reichardt P, 2002, EUR J PEDIATR, V161, P281, DOI 10.1007/s00431-002-0925-9; Rosen MJ, 2015, JAMA PEDIATR, V169, P1053, DOI 10.1001/jamapediatrics.2015.1982; Rosenbach Y, 2010, DIGEST DIS SCI, V55, P747, DOI 10.1007/s10620-009-0791-7; Rosh JR, 2009, AM J GASTROENTEROL, V104, P3042, DOI 10.1038/ajg.2009.493; Rubin LG, 2014, CLIN INFECT DIS, V58, P309, DOI [10.1093/cid/cit684, 10.1093/cid/cit816]; Ruemmele FM, 2009, INFLAMM BOWEL DIS, V15, P388, DOI 10.1002/ibd.20788; Russell RK, 2011, ALIMENT PHARM THER, V33, P946, DOI 10.1111/j.1365-2036.2011.04603.x; Sankarasubramanian J, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.606298; Sauer CG, 2009, GASTROENTEROL CLIN N, V38, P611, DOI 10.1016/j.gtc.2009.07.010; Seitel T, 2020, VACCINE, V38, P8024, DOI 10.1016/j.vaccine.2020.10.028; Serrano MS, 2001, ANN PHARMACOTHER, V35, P823; Shirai S, 2018, INFLAMM BOWEL DIS, V24, P1082, DOI 10.1093/ibd/izx101; Slifman NR, 2003, ARTHRITIS RHEUM, V48, P319, DOI 10.1002/art.10758; Soon IS, 2013, CAN J GASTROENTEROL, V27, P213, DOI 10.1155/2013/539524; Stephens MC, 2003, AM J GASTROENTEROL, V98, P104; STEVENS R, 1985, GASTROENTEROLOGY, V88, P1860, DOI 10.1016/0016-5085(85)90011-3; Sventoraityte J, 2008, MEDICINA-LITHUANIA, V44, P27, DOI 10.3390/medicina44010005; Tinsley A, 2019, INFLAMM BOWEL DIS, V25, P369, DOI 10.1093/ibd/izy243; Toruner M, 2008, GASTROENTEROLOGY, V134, P929, DOI 10.1053/j.gastro.2008.01.012; Toussi SS, 2013, CLIN INFECT DIS, V57, P1318, DOI 10.1093/cid/cit489; Tschudy J, 2010, J PEDIATR GASTR NUTR, V51, P221, DOI 10.1097/MPG.0b013e3181c2c10d; Urganci N, 2013, J PEDIATR GASTR NUTR, V56, P412, DOI 10.1097/MPG.0b013e31827dd87d; Van Limbergent J, 2008, GASTROENTEROLOGY, V135, P1114, DOI 10.1053/j.gastro.2008.06.081; Viola F, 2009, AM J GASTROENTEROL, V104, P2566, DOI 10.1038/ajg.2009.372; Wewer V, 2006, J PEDIATR GASTR NUTR, V42, P40, DOI 10.1097/01.mpg.0000189137.06151.33; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; Wintzell V, 2019, LANCET GASTROENTEROL, V4, P845, DOI 10.1016/S2468-1253(19)30266-3; Wiseman AC, 2016, CLIN J AM SOC NEPHRO, V11, P332, DOI 10.2215/CJN.08570814; Wynands J, 2008, J PEDIATR GASTR NUTR, V46, P293, DOI 10.1097/MPG.0b013e31815604cd; Wyneski MJ, 2008, J PEDIATR GASTR NUTR, V47, P19, DOI 10.1097/MPG.0b013e318174e886; Ye YZ, 2020, INFLAMM BOWEL DIS, V26, P619, DOI 10.1093/ibd/izz182; Zabana Y, 2019, J CROHNS COLITIS, V13, P828, DOI 10.1093/ecco-jcc/jjz013	117	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							487	10.3390/vaccines9050487			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1HC	34064576	gold, Green Published			2022-04-29	WOS:000654576200001
J	Pedroza-Saavedra, A; Rodriguez-Ocampo, AN; Salazar-Pina, A; Perez-Morales, AC; Chihu-Amparan, L; Maldonado-Gama, M; Cruz-Valdez, A; Esquivel-Guadarrama, F; Gutierrez-Xicotencatl, L				Pedroza-Saavedra, Adolfo; Rodriguez-Ocampo, Angelica Nallelhy; Salazar-Pina, Azucena; Perez-Morales, Aislinn Citlali; Chihu-Amparan, Lilia; Maldonado-Gama, Minerva; Cruz-Valdez, Aurelio; Esquivel-Guadarrama, Fernando; Gutierrez-Xicotencatl, Lourdes			Differential Antibody Response against Conformational and Linear Epitopes of the L1 Proteins from Human Papillomavirus Types 16/18 Is Observed in Vaccinated Women or with Uterine Cervical Lesions	VACCINES			English	Article						cervical cancer; human papillomavirus; L1 protein; VLPs; linear and conformational epitopes; HPV vaccine	VIRUS-LIKE PARTICLES; AS04-ADJUVANTED VACCINE; SUSTAINED EFFICACY; SERUM ANTIBODIES; HIGH-RISK; CANCER; IMMUNOGENICITY; PREVALENCE; SEROPREVALENCE; POPULATION	Antibodies against the Human Papillomavirus (HPV) L1 protein are associated with past infections and related to the evolution of the disease, whereas antibodies against L1 Virus-Like Particles (VLPs) are used to follow the neutralizing antibody response in vaccinated women. In this study, serum antibodies against conformational (VLPs) and linear epitopes of HPV16/18 L1 protein were assessed to distinguish HPV-vaccinated women from those naturally infected or those with uterine cervical lesions. The VLPs-16/18 were generated in baculovirus, and L1 proteins were obtained from denatured VLPs. Serum antibodies against VLPs and L1 proteins were evaluated by ELISA. The ELISA-VLPs and ELISA-L1 16/18 assays were validated with a vaccinated women group by ROC analysis and the regression analysis to distinguish the different populations of female patients. The anti-VLPs-16/18 and anti-L1-16/18 antibodies effectively detect vaccinated women (AUC = 1.0/0.79, and 0.94/0.84, respectively). The regression analysis showed that anti-VLPs-16/18 and anti-L1-16/18 antibodies were associated with the vaccinated group (OR = 2.11 x 10(8)/16.50 and 536.0/49.2, respectively). However, only the anti-L1-16 antibodies were associated with the high-grade lesions and cervical cancer (CIN3/CC) group (OR = 12.18). In conclusion, our results suggest that anti-VLPs-16/18 antibodies are effective and type-specific to detect HPV-vaccinated women, but anti-L1-16 antibodies better differentiate the CIN3/CC group. However, a larger population study is needed to validate these results.	[Pedroza-Saavedra, Adolfo; Perez-Morales, Aislinn Citlali; Chihu-Amparan, Lilia; Maldonado-Gama, Minerva; Gutierrez-Xicotencatl, Lourdes] Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca 62100, Morelos, Mexico; [Rodriguez-Ocampo, Angelica Nallelhy] Univ Autonoma Nayarit, Unidad Acad Quim Biol & Ciencias Farmaceut, Tepic 36715, Mexico; [Salazar-Pina, Azucena] Univ Autonoma Estado Morelos, Fac Nutr, Cuernavaca 62100, Morelos, Mexico; [Perez-Morales, Aislinn Citlali; Esquivel-Guadarrama, Fernando] Univ Autonoma Estado Morelos, Fac Med, Cuernavaca 62100, Morelos, Mexico; [Cruz-Valdez, Aurelio] Inst Nacl Salud Publ, Ctr Invest Salud Poblac, Cuernavaca 62100, Morelos, Mexico		Gutierrez-Xicotencatl, L (通讯作者)，Inst Nacl Salud Publ, Ctr Invest Enfermedades Infecciosas, Cuernavaca 62100, Morelos, Mexico.	apedroza@insp.mx; angelica.rodriguez@uan.edu.mx; azucena.salazarp@uaem.edu.mx; aislinn.perez@uaem.edu.mx; lchihu@insp.mx; mmaldona@insp.mx; acruz@insp.mx; fernando.esquivel@uaem.mx; mlxico@insp.mx	Gutierrez-Xicotencatl, Lourdes/AFN-8663-2022	Gutierrez-Xicotencatl, Lourdes/0000-0003-1828-0007; Rodriguez Ocampo, Angelica Nallelhy/0000-0003-0192-9789; Salazar Pina, Dolores Azucena/0000-0003-0800-7226	CONACYT-FOSISSS [290022]; PROMEP-PIFI [UAEMOR-CA-26]; PROMEP fellowship program of the UA Nayarit	This research was funded by CONACYT-FOSISSS, grant number 290022, and PROMEP-PIFI (UAEMOR-CA-26). A.N.R.-O. was supported by the PROMEP fellowship program of the UA Nayarit.	Achour M, 2008, J IMMUNOASS IMMUNOCH, V29, P266, DOI 10.1080/15321810802119638; Campos-Romero A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46543-8; Combita AL, 2002, INT J CANCER, V97, P796, DOI 10.1002/ijc.10153; Coseo SE, 2011, SEX TRANSM DIS, V38, P976, DOI 10.1097/OLQ.0b013e31822545c0; Dessy FJ, 2008, HUM VACCINES, V4, P425, DOI 10.4161/hv.4.6.6912; DILLNER L, 1991, J VIROL, V65, P6862, DOI 10.1128/JVI.65.12.6862-6871.1991; Ewaisha R, 2017, THERANOSTICS, V7, P3814, DOI 10.7150/thno.21098; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Giorgi Colomba, 2008, Infect Agent Cancer, V3, P9, DOI 10.1186/1750-9378-3-9; Godi A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140926; Goncalves AK, 2014, VIRAL IMMUNOL, V27, P471, DOI 10.1089/vim.2014.0033; Gutierrez-Xicotencatl L, 2016, VIRAL IMMUNOL, V29, P83, DOI 10.1089/vim.2015.0087; Harper D.M., 2004, LANCET, V364, DOI DOI 10.1016/S0140-6736(04)17398-4; Heim K, 2002, AM J OBSTET GYNECOL, V186, P705, DOI 10.1067/mob.2002.121898; Jin Y, 2018, CANCER MED-US, V7, P5655, DOI 10.1002/cam4.1810; Joura EA, 2008, VACCINE, V26, P6844, DOI 10.1016/j.vaccine.2008.09.073; Leung TF, 2018, VACCINE, V36, P98, DOI 10.1016/j.vaccine.2017.11.034; Lowy DR, 2006, J CLIN INVEST, V116, P1167, DOI 10.1172/JCI28607; Ludmerer SW, 1997, J VIROL, V71, P3834, DOI 10.1128/JVI.71.5.3834-3839.1997; McCarthy MP, 1998, J VIROL, V72, P32, DOI 10.1128/JVI.72.1.32-41.1998; Mehlhorn G, 2014, ANTICANCER RES, V34, P5127; Muller M, 1997, VIROLOGY, V234, P93, DOI 10.1006/viro.1997.8591; Naud PS, 2014, HUM VACC IMMUNOTHER, V10, P2147, DOI 10.4161/hv.29532; Opalka D, 2003, CLIN DIAGN LAB IMMUN, V10, P108, DOI 10.1128/CDLI.10.1.108-115.2003; Park JS, 1998, GYNECOL ONCOL, V69, P47, DOI 10.1006/gyno.1998.4963; Pedroza-Saavedra A, 2000, ARCH VIROL, V145, P603, DOI 10.1007/s007050050050; Petrosky EY, 2015, INT J INFECT DIS, V33, P137, DOI 10.1016/j.ijid.2015.01.010; Rocha-Zavaleta L, 2004, J GEN VIROL, V85, P2643, DOI 10.1099/vir.0.80077-0; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Schiller JT, 2009, J INFECT DIS, V200, P166, DOI 10.1086/599988; Skiba D, 2006, ANTICANCER RES, V26, P4921; Skjeldestad FE, 2008, ACTA OBSTET GYN SCAN, V87, P81, DOI 10.1080/00016340701714703; Stanley M, 2006, VACCINE, V24, P106, DOI 10.1016/j.vaccine.2006.05.110; Touze A, 2001, J CLIN MICROBIOL, V39, P4344, DOI 10.1128/JCM.39.12.4344-4348.2001; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Urquiza M, 2008, J CLIN MICROBIOL, V46, P3714, DOI 10.1128/JCM.00551-08; Van Doornum GJJ, 2003, BRIT J CANCER, V88, P1095, DOI 10.1038/sj.bjc.6600870; Villa LL, 2006, BRIT J CANCER, V95, P1459, DOI 10.1038/sj.bjc.6603469; Wang SS, 2003, BRIT J CANCER, V89, P1248, DOI 10.1038/sj.bjc.6601272; Xu YF, 2006, ARCH VIROL, V151, P2133, DOI 10.1007/s00705-006-0798-8; Yaddanapudi K, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23403; zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046	42	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							442	10.3390/vaccines9050442			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1QV	34063178	gold, Green Published			2022-04-29	WOS:000654601600001
J	Pormohammad, A; Zarei, M; Ghorbani, S; Mohammadi, M; Razizadeh, MH; Turner, DL; Turner, RJ				Pormohammad, Ali; Zarei, Mohammad; Ghorbani, Saied; Mohammadi, Mehdi; Razizadeh, Mohammad Hossein; Turner, Diana L.; Turner, Raymond J.			Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	VACCINES			English	Review						COVID-19; SARS-CoV-2; vaccines; efficacy; side effect; randomized clinical trial; meta-analysis	PUBLICATION BIAS; PROTEIN	The current study systematically reviewed, summarized and meta-analyzed the clinical features of the vaccines in clinical trials to provide a better estimate of their efficacy, side effects and immunogenicity. All relevant publications were systematically searched and collected from major databases up to 12 March 2021. A total of 25 RCTs (123 datasets), 58,889 cases that received the COVID-19 vaccine and 46,638 controls who received placebo were included in the meta-analysis. In total, mRNA-based and adenovirus-vectored COVID-19 vaccines had 94.6% (95% CI 0.936-0.954) and 80.2% (95% CI 0.56-0.93) efficacy in phase II/III RCTs, respectively. Efficacy of the adenovirus-vectored vaccine after the first (97.6%; 95% CI 0.939-0.997) and second (98.2%; 95% CI 0.980-0.984) doses was the highest against receptor-binding domain (RBD) antigen after 3 weeks of injections. The mRNA-based vaccines had the highest level of side effects reported except for diarrhea and arthralgia. Aluminum-adjuvanted vaccines had the lowest systemic and local side effects between vaccines' adjuvant or without adjuvant, except for injection site redness. The adenovirus-vectored and mRNA-based vaccines for COVID-19 showed the highest efficacy after first and second doses, respectively. The mRNA-based vaccines had higher side effects. Remarkably few experienced extreme adverse effects and all stimulated robust immune responses.	[Pormohammad, Ali; Mohammadi, Mehdi; Turner, Raymond J.] Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; [Zarei, Mohammad] Harvard TH Chan Sch Publ Hlth, John B Little Ctr Radiat Sci, Boston, MA 02115 USA; [Ghorbani, Saied; Razizadeh, Mohammad Hossein] Iran Univ Med Sci, Dept Virol, Fac Med, Tehran 1449614535, Iran; [Turner, Diana L.] Univ Calgary, Cumming Sch Med, Dept Family Med, Calgary, AB T2N 4N1, Canada		Turner, RJ (通讯作者)，Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada.	ali.pormohammad@ucalgary.ca; mzarei@hsph.harvard.edu; vet.s.ghorbani@gmail.com; mehdi.mohammadiashan@ucalgary.ca; razizadeh.mh@iums.ac.ir; dturner23@me.com; turnerr@ucalgary.ca	Razizadeh, Mohammad Hossein/AAA-2770-2021; Turner, Raymond J. J/M-3961-2015	Razizadeh, Mohammad Hossein/0000-0003-3232-6163; Turner, Raymond J. J/0000-0002-9263-0776; Mohammadi, Mehdi/0000-0001-8736-7259; ghorbani, saied/0000-0001-9284-6983			Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 2016, BMJ, V354, pi4086, DOI 10.1136/bmj.i4086; [Anonymous], SAFETY TOLERABILITY; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Blumenthal KG, 2021, JAMA-J AM MED ASSOC, V325, P1562, DOI 10.1001/jama.2021.3976; Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003; Carli G, 2021, INTERN EMERG MED, V16, P803, DOI 10.1007/s11739-021-02685-0; Centers for Disease Control and Prevention, COVID 19 VACC US; Chu LRC, 2021, VACCINE, V39, P2791, DOI 10.1016/j.vaccine.2021.02.007; Cines DB, 2021, NEW ENGL J MED, V384, P2254, DOI 10.1056/NEJMe2106315; Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Kounis NG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030221; Kremsner PG, 2021, WIEN KLIN WOCHENSCHR, V133, P931, DOI 10.1007/s00508-021-01922-y; Kyriakidis NC, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00292-w; Liang ZH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.589833; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n728; Mascola JR, 2021, JAMA-J AM MED ASSOC, V325, P1261, DOI [10.3171/2021.7.JNS211323, 10.1001/jama.2021.2088]; Muik A, 2021, SCIENCE, V371, P1152, DOI 10.1126/science.abg6105; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Nims RW, 2013, BIOLOGICALS, V41, P63, DOI 10.1016/j.biologicals.2012.09.011; Ong E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01581; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Richmond P, 2021, LANCET, V397, P682, DOI 10.1016/S0140-6736(21)00241-5; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Shen XY, 2021, CELL HOST MICROBE, V29, P529, DOI 10.1016/j.chom.2021.03.002; Sutton AJ, 2000, BMJ-BRIT MED J, V320, P1574, DOI 10.1136/bmj.320.7249.1574; V'kovski P, 2021, NAT REV MICROBIOL, V19, P155, DOI 10.1038/s41579-020-00468-6; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Ward B.J., 2020, PHASE 1 TRIAL CANDID, DOI [DOI 10.1101/2020.11.04.20226282, 10.1101/2020.11.04.20226282]; WHO, 2021, DRAFT LANDSC TRACK C; WHO WHO, 2020, EST MORT COVID 19 SC; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Yang SL, 2021, LANCET INFECT DIS, V21, P1107, DOI 10.1016/S1473-3099(21)00127-4; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	56	58	59	16	35	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							467	10.3390/vaccines9050467			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI3CX	34066475	Green Published, gold	Y	N	2022-04-29	WOS:000654704300001
J	Richardson, NI; Ravenscroft, N; Arato, V; Oldrini, D; Micoli, F; Kuttel, MM				Richardson, Nicole Inge; Ravenscroft, Neil; Arato, Vanessa; Oldrini, Davide; Micoli, Francesca; Kuttel, Michelle M.			Conformational and Immunogenicity Studies of the Shigella flexneri Serogroup 6 O-Antigen: The Effect of O-Acetylation	VACCINES			English	Article						O-antigen; conformation; Shigella flexneri; molecular modeling; GMMA; O-acetylation	VACCINATION; 2A	The pathogenic bacterium Shigella is a leading cause of diarrheal disease and mortality, disproportionately affecting young children in low-income countries. The increasing prevalence of antibiotic resistance in Shigella necessitates an effective vaccine, for which the bacterial lipopolysaccharide O-antigen is the primary target. S. flexneri serotype 6 has been proposed as a multivalent vaccine component to ensure broad protection against Shigella. We have previously explored the conformations of S. flexneri O-antigens from serogroups Y, 2, 3, and 5 that share a common saccharide backbone (serotype Y). Here we consider serogroup 6, which is of particular interest because of an altered backbone repeat unit with non-stoichiometric O-acetylation, the antigenic and immunogenic importance of which have yet to be established. Our simulations show significant conformational changes in serogroup 6 relative to the serotype Y backbone. We further find that O-acetylation has little effect on conformation and hence may not be essential for the antigenicity of serotype 6. This is corroborated by an in vivo study in mice, using Generalized Modules for Membrane Antigens (GMMA) as O-antigen delivery systems, that shows that O-acetylation does not have an impact on the immune response elicited by the S. flexneri serotype 6 O-antigen.	[Richardson, Nicole Inge; Ravenscroft, Neil] Univ Cape Town, Dept Chem, ZA-7701 Rondebosch, South Africa; [Arato, Vanessa; Oldrini, Davide; Micoli, Francesca] GSK Vaccines Inst Global Hlth GVGH Srl, Via Florentina 1, I-53100 Siena, Italy; [Kuttel, Michelle M.] Univ Cape Town, Dept Comp Sci, ZA-7701 Rondebosch, South Africa		Kuttel, MM (通讯作者)，Univ Cape Town, Dept Comp Sci, ZA-7701 Rondebosch, South Africa.	nicole.richardson.za@gmail.com; neil.ravenscroft@uct.ac.za; vanessa.x.arato@gsk.com; davide.x.oldrini@gsk.com; francesca.x.micoli@gsk.com; mkuttel@cs.uct.ac.za		Richardson, Nicole/0000-0002-9414-3293; Ravenscroft, Neil/0000-0001-8476-5630; Arato, Vanessa/0000-0002-5923-6320; Oldrini, Davide/0000-0001-7827-6582; Kuttel, Michelle/0000-0003-0554-4632	University of Cape Town; U.K. Department of Health and Social Care [EP/R013764/1]	This research was partially funded by the University of Cape Town (MSc scholarship for N.I.R.) and the U.K. Department of Health and Social Care, grant number EP/R013764/1.	Atherly DE, 2012, VACCINE, V30, pA7, DOI 10.1016/j.vaccine.2011.12.096; Barel LA, 2019, HUM VACC IMMUNOTHER, V15, P1338, DOI 10.1080/21645515.2019.1606972; CDC, 2019, ANTIBIOTIC RESISTANC; Chassagne P, 2013, EUR J ORG CHEM, V2013, P4085, DOI 10.1002/ejoc.201300180; Cross Simon, 2009, J Mol Graph Model, V28, P131, DOI 10.1016/j.jmgm.2009.04.010; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; De Benedetto G, 2017, VACCINE, V35, P419, DOI 10.1016/j.vaccine.2016.11.089; DISCHE Z, 1948, J BIOL CHEM, V175, P595; Farzam N, 2017, VACCINE, V35, P4990, DOI 10.1016/j.vaccine.2017.07.070; Gauthier C, 2014, ORG BIOMOL CHEM, V12, P4218, DOI 10.1039/c3ob42586j; Gerke C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134478; Gracia L., WMC PHYSBIO CLUSTERI; Grossfield A, 2009, ANN REP COMP CHEM, V5, P23, DOI 10.1016/S1574-1400(09)00502-7; Guvench O, 2008, J COMPUT CHEM, V29, P2543, DOI 10.1002/jcc.21004; Guvench O, 2009, J CHEM THEORY COMPUT, V5, P2353, DOI 10.1021/ct900242e; Haltiwanger RS, 2016, GLYCOBIOLOGY, V26, P217, DOI 10.1093/glycob/cww005; Hlozek J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040643; Hlozek J, 2020, J PHYS CHEM B, V124, P2806, DOI 10.1021/acs.jpcb.0c01595; Hlozek J, 2018, CARBOHYD RES, V465, P44, DOI 10.1016/j.carres.2018.06.007; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KABAT EA, 1966, J IMMUNOL, V97, P1; Khalil IA, 2018, LANCET INFECT DIS, V18, P1229, DOI [10.1016/s1473-3099(18)30475-4, 10.1016/S1473-3099(18)30475-4]; Knirel YA, 2015, BIOCHEMISTRY-MOSCOW+, V80, P901, DOI 10.1134/S0006297915070093; Knirel YA, 2014, BMC MICROBIOL, V14, DOI 10.1186/s12866-014-0266-7; Kotloff KL, 2018, LANCET, V391, P801, DOI 10.1016/S0140-6736(17)33296-8; Kotloff KL, 2017, VACCINE, V35, P6783, DOI 10.1016/j.vaccine.2017.07.036; Krone M., 2012, P EUR C VIS EUROVIS; Kuttel M., 2011, P 2011 IEEE 7 INT C; Kuttel MM, 2018, ACS SYM SER, V1290, P139; Kuttel MM, 2016, J COMPUT CHEM, V37, P2098, DOI 10.1002/jcc.24428; Lanzilao L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139847; Livio S, 2014, CLIN INFECT DIS, V59, P933, DOI 10.1093/cid/ciu468; Micoli F, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101433; Mulard L.A., 2018, CARBOHYDR CHEM, V43, P71; Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; Necchi F, 2018, J IMMUNOL METHODS, V461, P117, DOI 10.1016/j.jim.2018.06.025; Necchi F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172163; Neelamegham S, 2019, GLYCOBIOLOGY, V29, P620, DOI 10.1093/glycob/cwz045; Perepelov AV, 2012, FEMS IMMUNOL MED MIC, V66, P201, DOI 10.1111/j.1574-695X.2012.01000.x; Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289; Raso MM, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020160; Rossi Omar, 2020, High Throughput, V9, DOI 10.3390/ht9020014; Rossi O, 2015, GUT PATHOG, V7, DOI 10.1186/s13099-015-0061-5; Shrivastava S., 2018, J MED SOC, V32, P76, DOI [10.4103/jms.jms_25_17, DOI 10.4103/JMS.JMS_25_17]; Stone JE, 2007, J COMPUT CHEM, V28, P2618, DOI 10.1002/jcc.20829; Theillet FX, 2011, GLYCOBIOLOGY, V21, P109, DOI 10.1093/glycob/cwq136; Troeger C, 2018, LANCET INFECT DIS, V18, P1211, DOI 10.1016/S1473-3099(18)30362-1; Van Gunsteren WF, 1988, MOL SIMULAT, V1, P173, DOI 10.1080/08927028808080941	51	4	4	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							432	10.3390/vaccines9050432			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1TM	33925465	Green Published, gold			2022-04-29	WOS:000654608500001
J	Eltom, KH; Althoff, AC; Hansen, S; Bohlken-Fascher, S; Yousif, A; El-Sheikh, HA; ElWakeel, AA; Elgamal, MA; Mossa, HM; Aboul-Soud, EA; Wolff, J; Korthase, C; Hoffmann, B; Adam, NM; Abdelaziz, SA; Shalaby, MA; Abd El Wahed, A				Eltom, Kamal H.; Althoff, Anna Christina; Hansen, Soeren; Boehlken-Fascher, Susanne; Yousif, Ausama; El-Sheikh, Hussein A.; ElWakeel, Ahmed A.; Elgamal, Mahmoud A.; Mossa, Hadeer M.; Aboul-Soud, Emad A.; Wolff, Janika; Korthase, Christian; Hoffmann, Bernd; Adam, Nabawia M.; Abdelaziz, Sanaa A.; Shalaby, Mohamed A.; Abd El Wahed, Ahmed			Differentiation of Capripox Viruses by Nanopore Sequencing	VACCINES			English	Article						lumpy skin disease; capripox virus; nanopore sequencing	LUMPY SKIN-DISEASE; SHEEP POX VIRUS; GOAT POX; MECHANICAL TRANSMISSION; VACCINE; ASSAY; INFECTION; OUTBREAKS; STRAINS; CATTLE	The genus capripoxvirus (CaPV), family Poxviridae, includes three virus species: goatpox virus (GPV), sheeppox virus (SPV) and lumpy skin disease virus (LSDV). CaPV causes disease outbreaks with consequent economic losses in Africa and the Middle East. LSDV has recently spread to Southeast Europe. As CaPVs share 96-97% genetic similarity along the length of the entire genome and are difficult to distinguish using serological assays, simple, reliable and fast methods for diagnosis and species differentiation are crucial in cases of disease outbreak. The present study aimed to develop a field-applicable CaPV differentiation method. Nanopore technology was used for whole genome sequencing. A local database of complete CaPV genomes and partial sequences of three genes (RPO30, P32 and GPCR) was established for offline Basic Local Alignment Search Tool (BLAST). Specificities of 98.04% in whole genome and 97.86% in RPO30 gene runs were obtained among the three virus species, while other databases were less specific. The total run time was shortened to approximately 2 h. Functionality of the developed procedure was proved by samples with high host background sequences. Reliable differentiation options for the quality and capacity of hardware, and sample quality of suspected cases, were derived from these findings. The whole workflow can be performed rapidly with a mobile suitcase laboratory and mini-computer, allowing application at the point-of-need with limited resource settings.	[Eltom, Kamal H.] Univ Khartoum, Inst Studies & Promot Anim Exports, Unit Anim Hlth & Safety Anim Prod, Shambat 13314, Khartoum North, Sudan; [Althoff, Anna Christina; Hansen, Soeren; Boehlken-Fascher, Susanne; Abd El Wahed, Ahmed] Univ Goettingen, Div Microbiol & Anim Hyg, D-37077 Gottingen, Germany; [Yousif, Ausama; Elgamal, Mahmoud A.; Shalaby, Mohamed A.] Cairo Univ, Dept Virol, Fac Vet Med, Giza 12211, Egypt; [El-Sheikh, Hussein A.] Zagazig Univ, Dept Infect Dis, Fac Vet Med, Zagazig 44519, Egypt; [ElWakeel, Ahmed A.] Gen Org Vet Serv, Vet Med Directorate, Dept Epidemiol, Banha 13511, Egypt; [Mossa, Hadeer M.; Aboul-Soud, Emad A.] Vet Serum & Vaccine Res Inst, Dept Poxvirus Vaccines, Cairo 11517, Egypt; [Wolff, Janika; Korthase, Christian; Hoffmann, Bernd] Friedrich Loeffler Inst, Fed Res Inst Anim Hlth, Inst Diagnost Virol, Sudufer 10, D-17493 Greifswald, Germany; [Adam, Nabawia M.; Abdelaziz, Sanaa A.] Univ Khartoum, Fac Vet Med, Dept Microbiol, Shambat 13314, Khartoum North, Sudan; [Abd El Wahed, Ahmed] Univ Leipzig, Fac Vet Med, Inst Anim Hyg & Vet Publ Hlth, Tierkliniken 43, D-04103 Leipzig, Germany		Abd El Wahed, A (通讯作者)，Univ Goettingen, Div Microbiol & Anim Hyg, D-37077 Gottingen, Germany.; Abd El Wahed, A (通讯作者)，Univ Leipzig, Fac Vet Med, Inst Anim Hyg & Vet Publ Hlth, Tierkliniken 43, D-04103 Leipzig, Germany.	kamal@uofk.edu; Anna.Althoff@wlv.de; hansensoer@gmail.com; sboelkenfascher@uni-goettingen.de; ausama_yousif@cu.edu.eg; husseinelsheikhvet@gmail.com; ahmedabdelhaleem946@yahoo.com; mhmoudelgaml@yahoo.com; hadeervsvri@gmail.com; emadaboelsouad@gmail.com; janika.wolff@fli.de; christian.korthase@fli.de; bernd.hoffmann@fli.de; nabawiavet02011@gmail.com; sabdelaziz262@gmail.com; mshalaby43@gmail.com; abdelwahed@gwdg.de		Abd El Wahed, Ahmed/0000-0003-3347-6075; Yousif, Ausama/0000-0003-3782-0435; Wekeel, Ahmed/0000-0002-1046-3127; Hoffmann, Bernd/0000-0001-5358-6445	Open Access Publication Funds of the University of Goettingen, Germany	We acknowledge the support of the Open Access Publication Funds of the University of Goettingen, Germany.	Abd El Wahed A, 2015, J CLIN VIROL, V69, P16, DOI 10.1016/j.jcv.2015.05.004; Agianniotaki EI, 2017, MICROBIOL RESOUR ANN, V5, DOI [10.1128/genomeA.00550-17, 10.1128/genomea.00550-17]; Al-Salihi KA, 2015, TRANSBOUND EMERG DIS, V62, P457, DOI 10.1111/tbed.12386; Biswas S, 2020, TRANSBOUND EMERG DIS, V67, P80, DOI 10.1111/tbed.13322; Capstick P. B., 1959, Bulletin of epizootic diseases of Africa, V7, P51; CARN VM, 1993, VACCINE, V11, P1275, DOI 10.1016/0264-410X(93)90094-E; Chihota CM, 2001, EPIDEMIOL INFECT, V126, P317, DOI 10.1017/S0950268801005179; DAVIES FG, 1991, BRIT VET J, V147, P489, DOI 10.1016/0007-1935(91)90019-J; EFSA, 2018, EFSA J, V16, P5176; Friedrich-Loeffler-Institut F.L.I, NATL REFERENCE LAB S; Garner MG, 2000, TROP ANIM HEALTH PRO, V32, P205, DOI 10.1023/A:1005263601964; Hosamani M, 2004, VIRUS GENES, V29, P73, DOI 10.1023/B:VIRU.0000032790.16751.13; Jain M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1103-0; Kahana-Sutin E, 2017, MED VET ENTOMOL, V31, P150, DOI 10.1111/mve.12217; KITCHING RP, 1985, TROP ANIM HEALTH PRO, V17, P64, DOI 10.1007/BF02360774; KITCHING RP, 1986, RES VET SCI, V40, P255, DOI 10.1016/S0034-5288(18)30523-X; Kononov A, 2019, ARCH VIROL, V164, P1575, DOI 10.1007/s00705-019-04229-6; Lahens NF, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4011-0; Lamien C.E., 2009, P FAO IAEA INT S SUS, P323; Lamien CE, 2011, J VIROL METHODS, V171, P134, DOI 10.1016/j.jviromet.2010.10.014; Laver T, 2015, Biomol Detect Quantif, V3, P1; Mahmoud MA, 2016, VET WORLD, V9, P1445, DOI 10.14202/vetworld.2016.1445-1449; Menasherow S, 2014, J VIROL METHODS, V199, P95, DOI 10.1016/j.jviromet.2013.12.013; Moeller J, 2019, ARCH VIROL, V164, P2931, DOI 10.1007/s00705-019-04411-w; Molla W, 2017, PREV VET MED, V147, P100, DOI 10.1016/j.prevetmed.2017.09.003; Orlova ES, 2006, MOL BIOL+, V40, P158, DOI 10.1134/S0026893306010183; Oxford-Nanopore-Technologies, RAPID BARCODING SEQU; Santhamani R, 2013, VET WORLD, V6, P923, DOI 10.14202/vetworld.2013.923-925; Services G.O.F.V, OVERVIEW VECTOR BORN; Shalaby MA, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0875-5; Slatko Barton E, 2018, Curr Protoc Mol Biol, V122, pe59, DOI 10.1002/cpmb.59; Sprygin A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232584; Tulman ER, 2002, J VIROL, V76, P6054, DOI 10.1128/JVI.76.12.6054-6061.2002; Tulman ER, 2001, J VIROL, V75, P7122, DOI 10.1128/JVI.75.15.7122-7130.2001; Tuppurainen ESM, 2017, TRANSBOUND EMERG DIS, V64, P729, DOI 10.1111/tbed.12444; Tuppurainen ESM, 2013, EPIDEMIOL INFECT, V141, P425, DOI 10.1017/S0950268812000805; Tuppurainen ESM, 2014, ANTIVIR RES, V109, P1, DOI 10.1016/j.antiviral.2014.06.009; Tuppurainen ESM, 2013, TICKS TICK-BORNE DIS, V4, P329, DOI 10.1016/j.ttbdis.2013.01.006; Venkatesan Gnanavel, 2012, Virologica Sinica, V27, P353, DOI 10.1007/s12250-012-3277-2; Wolff J, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101098; World Organisation for Animal Health, LUMPY SKIN DIS LSD	41	0	0	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							351	10.3390/vaccines9040351			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5WY	33917413	gold, Green Published			2022-04-29	WOS:000643850300001
J	Fappani, C; Bianchi, S; Panatto, D; Petrelli, F; Colzani, D; Scuri, S; Gori, M; Amendola, A; Grappasonni, I; Tanzi, E; Amicizia, D				Fappani, Clara; Bianchi, Silvia; Panatto, Donatella; Petrelli, Fabio; Colzani, Daniela; Scuri, Stefania; Gori, Maria; Amendola, Antonella; Grappasonni, Iolanda; Tanzi, Elisabetta; Amicizia, Daniela			HPV Type-Specific Prevalence a Decade after the Implementation of the Vaccination Program: Results from a Pilot Study	VACCINES			English	Article						HPV infection; urine samples; HPV genotype distribution; vaccine-preventable diseases; Italy	HUMAN-PAPILLOMAVIRUS; NORMAL CYTOLOGY; WOMEN; CLASSIFICATION; INFECTIONS; CANCER; DNA	Human papillomavirus infection is a cause of the development of invasive cervical cancer. Three types of vaccine are currently available to prevent precancerous/cancerous lesions due to persistent infection, which is supported mainly by 7 different high-risk genotypes. The aim of this pilot study was to acquire preliminary data on type-specific prevalence 10 years after the implementation of the HPV vaccination program in Italy, in order to subsequently plan appropriate observational studies in the Italian population. First-voided urine samples were collected from 393 consenting subjects, both females and males, aged 18-40 years, and HPV DNA was detected by PCR amplification of a 450 bp L1 fragment. All amplified products were genotyped by means of the Restriction Fragment Length Polymorphism (RFLP) method. The female population was divided into three cohorts ("vaccine-eligible", "pre-screening" and "screening" cohorts) according to the preventive intervention scheduled by age; males were included in the same three cohorts according to their year of birth. The overall prevalence of HPV infection was 19%, being higher in females than in males (22.1% vs. 13.6%, p = 0.03729). In the female population, 10 years after the start of the national immunization program, we observed a reduction in the prevalence of vaccine types and the number of circulating genotypes, especially in the "vaccine-eligible" cohort. The frequency of HPV vaccine types increased with age, particularly in males in the "pre-screening" and "screening" cohorts. Our study highlights the importance of monitoring HPV infection in both genders, to validate the effect of the HPV vaccination program.	[Fappani, Clara; Colzani, Daniela; Gori, Maria; Amendola, Antonella; Tanzi, Elisabetta] Univ Milan, Dept Biomed Sci Hlth, I-20133 Milan, Italy; [Bianchi, Silvia] Univ Milan, Dept Hlth Sci, I-20142 Milan, Italy; [Panatto, Donatella; Amicizia, Daniela] Univ Genoa, Dept Hlth Sci, I-16100 Genoa, Italy; [Petrelli, Fabio; Scuri, Stefania; Grappasonni, Iolanda] Univ Camerino, Sch Med & Hlth Prod Sci, I-62032 Camerino, Italy; [Amendola, Antonella; Tanzi, Elisabetta] Univ Milan, Coordinated Res Ctr EpiSoMI, I-20133 Milan, Italy		Bianchi, S (通讯作者)，Univ Milan, Dept Hlth Sci, I-20142 Milan, Italy.	clara.fappani@studenti.unimi.it; silvia.bianchi@unimi.it; donatella.panatto@unige.it; fabio.petrelli@unicam.it; daniela.colzani@unimi.it; stefania.scuri@unicam.it; mgorimaria@gmail.com; antonella.amendola@unimi.it; iolanda.grappasonni@unicam.it; elisabetta.tanzi@unimi.it; daniela.amicizia@unige.it	Bianchi, Silvia/M-8586-2016; Tanzi, Elisabetta/M-9066-2016	Bianchi, Silvia/0000-0002-1365-9408; Tanzi, Elisabetta/0000-0002-4119-701X; scuri, stefania/0000-0003-4518-1653; GORI, MARIA/0000-0001-6478-2791; Panatto, Donatella/0000-0002-2677-0551; Amicizia, Daniela/0000-0002-9707-5214; Fappani, Clara/0000-0002-1573-5531			Bzhalava D, 2015, VIROLOGY, V476, P341, DOI 10.1016/j.virol.2014.12.028; Centers for Disease Control and Prevention, 2004, GENITAL HPV INFECT C; Cho HW, 2019, J VIROL METHODS, V269, P77, DOI 10.1016/j.jviromet.2019.04.012; Crochard A, 2009, GYNECOL ONCOL, V115, pS7, DOI 10.1016/j.ygyno.2009.06.003; Dalianis T, 2015, ORAL ONCOL, V51, P857, DOI 10.1016/j.oraloncology.2015.06.002; de Oliveira CM, 2019, ACTA CYTOL, V63, P159, DOI 10.1159/000497617; Dean A.G., OPENEPI OPEN SOURCE; Dehlendorff C, 2018, VACCINE, V36, P6373, DOI 10.1016/j.vaccine.2018.09.011; ECDC, GUID HPV VACC EU CON; Giambi C., 2013, STATO AVANZAMENTO CA; Howell-Jones R, 2010, BRIT J CANCER, V103, P209, DOI 10.1038/sj.bjc.6605747; International Agency for Research on Cancer (IARC), 2012, IARC MON EV CARC RIS, V100f, P309; Istituto Superiore di Sanita, STRATEGIE VACCINALI; Ljubojevic S, 2014, CLIN DERMATOL, V32, P227, DOI 10.1016/j.clindermatol.2013.08.007; Moscicki AB, 2006, VACCINE, V24, P42, DOI 10.1016/j.vaccine.2006.06.018; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Nordfors C, 2014, ORAL ONCOL, V50, P491, DOI 10.1016/j.oraloncology.2014.02.012; Orlando G., 2016, ANN VIROL RES, V2, P1013; Orlando G, 2014, HUM VACC IMMUNOTHER, V10, P986, DOI 10.4161/hv.27682; Panatto D, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-575; Panatto D, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-623; Paovonen J, 2009, LANCET, V374, P301, DOI 10.1016/S0140-6736(09)61248-4; Petca A, 2020, EXP THER MED, V20, DOI 10.3892/etm.2020.9316; Satterwhite CL, 2013, SEX TRANSM DIS, V40, P187, DOI 10.1097/OLQ.0b013e318286bb53; Schmeink CE, 2013, INT J CANCER, V133, P172, DOI 10.1002/ijc.27986; Schmitt M, 2006, J CLIN MICROBIOL, V44, P504, DOI 10.1128/JCM.44.2.504-512.2006; Sichero L, 2021, J MED VIROL, V93, P3835, DOI 10.1002/jmv.26503; Sinisgalli E, 2015, EPIDEMIOL PREV, V39, P51; Smith JS, 2011, J ADOLESCENT HEALTH, V48, P540, DOI 10.1016/j.jadohealth.2011.03.010; Tanzi E, 2013, J MED VIROL, V85, P91, DOI 10.1002/jmv.23434; Trucchi C, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6764154; Van Doorslaer K, 2017, NUCLEIC ACIDS RES, V45, pD499, DOI 10.1093/nar/gkw879; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Who, 2009, Biologicals, V37, P338, DOI 10.1016/j.biologicals.2009.04.005; WHO, CERV CANC FREE 1 EV; World Hlth Org, 2017, VACCINE, V35, P5753, DOI 10.1016/j.vaccine.2017.05.069; Yanofsky Valerie R, 2012, J Clin Aesthet Dermatol, V5, P25	37	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							336	10.3390/vaccines9040336			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5LO	33916132	Green Published, gold			2022-04-29	WOS:000643820700001
J	Ji, RR; Qu, YJ; Zhu, H; Yang, YM; Vogel, AB; Sahin, U; Qin, C; Hui, AM				Ji, Rui-Ru; Qu, Yajin; Zhu, Hua; Yang, Yumei; Vogel, Annette B.; Sahin, Ugur; Qin, Chuan; Hui, Aimin			BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19	VACCINES			English	Article						SARS-CoV-2; COVID-19; mRNA vaccine; efficacy; immunogenicity; challenge study	SPIKE	BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2, which correlated with viral clearance and alleviated lung lesions in these mice after viral challenge.	[Ji, Rui-Ru; Yang, Yumei; Hui, Aimin] Shanghai Fosun Pharmaceut Ind Dev Co Ltd, 1289 Yishan Rd, Shanghai 200233, Peoples R China; [Qu, Yajin; Zhu, Hua; Qin, Chuan] Chinese Acad Med Sci, Beijing Key Lab Anim Models Emerging & Remerging, Inst Lab Anim Sci, NHC Key Lab Human Dis Comparat Med, Beijing 100021, Peoples R China; [Qu, Yajin; Zhu, Hua; Qin, Chuan] Peking Union Med Coll, Comparat Med Ctr, Beijing 100021, Peoples R China; [Vogel, Annette B.; Sahin, Ugur] BioNTech, Goldgrube 12, D-55131 Mainz, Germany; [Sahin, Ugur] Johannes Gutenberg Univ Mainz, TRON gGmbH Translat Oncol, Univ Med Ctr, Freiligrathstr 12, D-55131 Mainz, Germany		Hui, AM (通讯作者)，Shanghai Fosun Pharmaceut Ind Dev Co Ltd, 1289 Yishan Rd, Shanghai 200233, Peoples R China.; Qin, C (通讯作者)，Chinese Acad Med Sci, Beijing Key Lab Anim Models Emerging & Remerging, Inst Lab Anim Sci, NHC Key Lab Human Dis Comparat Med, Beijing 100021, Peoples R China.; Qin, C (通讯作者)，Peking Union Med Coll, Comparat Med Ctr, Beijing 100021, Peoples R China.	ruiruji@msn.com; quyajin@pumc.edu.cn; zhuhua@pumc.edu.cn; yangyumei@fosunpharma.com; Annette.Vogel@biontech.de; Ugur.Sahin@biontech.de; qinchuan@pumc.edu.cn; aimin.hui@fosunpharma.com			Fosun Pharmaceuticals Co. Ltd.	Fosun Pharmaceuticals Co. Ltd. provided funding to this study; BioNTech supplied BNT162b2 vaccine for the study.	Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y; Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343; Grudzien-Nogalska Ewa, 2013, Methods Mol Biol, V969, P55, DOI 10.1007/978-1-62703-260-5_4; Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011; Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7; Maier MA, 2013, MOL THER, V21, P1570, DOI 10.1038/mt.2013.124; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Yang XH, 2007, COMPARATIVE MED, V57, P450; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	13	5	5	3	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							324	10.3390/vaccines9040324			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5IK	33915773	Green Published, gold			2022-04-29	WOS:000643812500001
J	Karacs, J; Reithofer, M; Kitzmuller, C; Kraller, M; Schmalz, S; Bleichert, S; Huppa, JB; Stockinger, H; Bohle, B; Jahn-Schmid, B				Karacs, Jasmine; Reithofer, Manuel; Kitzmueller, Claudia; Kraller, Markus; Schmalz, Stefanie; Bleichert, Sonja; Huppa, Johannes B.; Stockinger, Hannes; Bohle, Barbara; Jahn-Schmid, Beatrice			Adjuvants and Vaccines Used in Allergen-Specific Immunotherapy Induce Neutrophil Extracellular Traps	VACCINES			English	Article						adjuvants; allergen-specific immunotherapy; aluminum hydroxide; MPLA; neutrophil extracellular traps; monocytes	MONOPHOSPHORYL-LIPID-A; OXIDIZED MITOCHONDRIAL-DNA; ALUMINUM-HYDROXIDE; ANTIGEN PRESENTATION; NLRP3 INFLAMMASOME; NALP3 INFLAMMASOME; DENDRITIC CELLS; HUMAN MONOCYTES; ACTIVATION; DIFFERENTIATION	Aluminum hydroxide (alum) and monophosphoryl-lipid A (MPLA) are conventional adjuvants in vaccines for allergen-specific immunotherapy (AIT). Alum triggers the release of neutrophil extracellular traps (NETs) by neutrophils. NETs contain expelled decondensed chromatin associated with granular material and may act as danger-associated molecular patterns and activate antigen-presenting cells. We investigated whether adjuvant-induced NETs contribute to innate responses to AIT-vaccines. Human neutrophils were incubated with alum, MPLA and adjuvant-containing AIT-vaccine preparations. NETs were verified by time-lapse and confocal fluorescence microscopy and quantitatively assessed by DNA and elastase release and ROS production. In contrast to MPLA, alum represented a potent trigger for NET release. Vaccine formulations containing alum resulted in less NET release than alum alone, whereas the vaccine containing MPLA induced stronger NET responses than MPLA alone. NETs and alum alone and synergistically increased the expression of molecules involved in antigen presentation, i.e., CD80, CD86 and CD83, by peripheral blood monocytes. Monocyte priming with NETs resulted in individually differing IL-1 beta- and IL-6-responses. Thus, NETs induced by adjuvants in AIT-vaccines can provide autonomous and cooperative effects on early innate responses. The high diversity of individual innate responses to adjuvants and AIT-vaccines may affect their therapeutic efficacy.	[Karacs, Jasmine; Reithofer, Manuel; Kitzmueller, Claudia; Schmalz, Stefanie; Bohle, Barbara; Jahn-Schmid, Beatrice] Med Univ Vienna, Dept Pathophysiol & Allergy Res, A-1090 Vienna, Austria; [Kraller, Markus; Huppa, Johannes B.; Stockinger, Hannes] Med Univ Vienna, Inst Hyg & Appl Immunol, A-1090 Vienna, Austria; [Bleichert, Sonja] Med Univ Vienna, Dept Gen Surg, A-1090 Vienna, Austria		Jahn-Schmid, B (通讯作者)，Med Univ Vienna, Dept Pathophysiol & Allergy Res, A-1090 Vienna, Austria.	jasmine.karacs@meduniwien.ac.at; manuel.reithofer@meduniwien.ac.at; daudia.kitzmueller@meduniwien.ac.at; markus.kraller@meduniwien.ac.at; stefanie.schmalz@meduniwien.ac.at; sonja.bleichert@meduniwien.ac.at; johannes.huppa@meduniwien.ac.at; hannes.stockinger@meduniwien.ac.at; barbara.bohle@meduniwien.ac.at; beatrice.jahn-schmid@meduniwien.ac.at	Huppa, Johannes Bernhard/AAY-9471-2021; Stockinger, Hannes/E-5173-2011	Huppa, Johannes Bernhard/0000-0003-2634-8198; Bleichert, Sonja/0000-0002-3054-1751; Reithofer, Manuel/0000-0003-2845-1826; Stockinger, Hannes/0000-0001-6404-4430; Schmalz, Stefanie/0000-0003-4841-4942; Kitzmuller, Claudia/0000-0002-3829-8020	Austrian Science Fund (FWF)Austrian Science Fund (FWF) [MCCAW1248, CCHD-W1205-B09]; Austrian Central Bank (ONB, Anniversary Fund) [17582]; Medical University of Vienna	This research was funded by the Austrian Science Fund (FWF; Doctoral Program MCCAW1248 and Doctoral Program CCHD-W1205-B09), by the Austrian Central Bank (ONB, Anniversary Fund, project No. 17582) and the Medical University of Vienna.	Alving CR, 2012, CURR OPIN IMMUNOL, V24, P310, DOI 10.1016/j.coi.2012.03.008; Barrientos L, 2014, J IMMUNOL, V193, P5689, DOI 10.4049/jimmunol.1400586; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Brinkmann V, 2012, J CELL BIOL, V198, P773, DOI 10.1083/jcb.201203170; Chamilos G, 2012, BLOOD, V120, P3699, DOI 10.1182/blood-2012-01-401364; Chentouh R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25367-y; de Craen AJM, 2005, GENES IMMUN, V6, P167, DOI 10.1038/sj.gene.6364162; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Franchi L, 2008, EUR J IMMUNOL, V38, P2085, DOI 10.1002/eji.200838549; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Ghimire TR, 2012, IMMUNOL LETT, V147, P55, DOI 10.1016/j.imlet.2012.06.002; Hirano N, 2006, BLOOD, V107, P1528, DOI 10.1182/blood-2005-05-2073; Hoppenbrouwers T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176472; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Hutchison S, 2012, FASEB J, V26, P1272, DOI 10.1096/fj.11-184556; Impellizzieri D, 2019, J ALLERGY CLIN IMMUN, V144, P267, DOI 10.1016/j.jaci.2019.01.042; Jensen-Jarolim E, 2020, ALLERGY, V75, P746, DOI 10.1111/all.14134; Kenny EF, 2017, ELIFE, V6, DOI [10.7554/eLife.24437, 10.7554/elife.24437]; Keshari RS, 2012, CYTOM PART A, V81A, P238, DOI 10.1002/cyto.a.21178; Khan MA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03257-z; Kitzmuller C, 2015, J ALLERGY CLIN IMMUN, V136, P151, DOI 10.1016/j.jaci.2014.12.1928; Kool M, 2008, J IMMUNOL, V181, P3755, DOI 10.4049/jimmunol.181.6.3755; Leuthard DS, 2018, J IMMUNOL, V200, P3151, DOI 10.4049/jimmunol.1800035; Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17; Lood C, 2016, NAT MED, V22, P146, DOI 10.1038/nm.4027; Marichal T, 2011, NAT MED, V17, P996, DOI 10.1038/nm.2403; Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963; Mckee AS, 2013, P NATL ACAD SCI USA, V110, pE1122, DOI 10.1073/pnas.1300392110; Mckee AS, 2009, J IMMUNOL, V183, P4403, DOI 10.4049/jimmunol.0900164; Munks MW, 2010, BLOOD, V116, P5191, DOI 10.1182/blood-2010-03-275529; Oleszycka E, 2016, FEBS J, V283, P9, DOI 10.1111/febs.13546; Puggioni F, 2005, ALLERGY, V60, P678, DOI 10.1111/j.1398-9995.2005.00762.x; Reithofer M, 2020, FASEB J, V34, P14024, DOI 10.1096/fj.202001413R; Rimaniol AC, 2004, VACCINE, V22, P3127, DOI 10.1016/j.vaccine.2004.01.061; Rimaniol AC, 2007, VACCINE, V25, P6784, DOI 10.1016/j.vaccine.2007.06.051; Roberts G, 2018, ALLERGY, V73, P765, DOI 10.1111/all.13317; Scholler N, 2001, J IMMUNOL, V166, P3865, DOI 10.4049/jimmunol.166.6.3865; Seubert A, 2008, J IMMUNOL, V180, P5402, DOI 10.4049/jimmunol.180.8.5402; Sharp FA, 2009, P NATL ACAD SCI USA, V106, P870, DOI 10.1073/pnas.0804897106; Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009; Soehnlein O, 2010, NAT REV IMMUNOL, V10, P427, DOI 10.1038/nri2779; Stephen J, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-016-0001-5; Ulanova M, 2001, INFECT IMMUN, V69, P1151, DOI 10.1128/IAI.69.2.1151-1159.2001; Warnatsch A, 2015, SCIENCE, V349, P316, DOI 10.1126/science.aaa8064; Wong KY, 2018, J IMMUNOL, V200, P3383, DOI 10.4049/jimmunol.1700064; Yousefi S, 2009, CELL DEATH DIFFER, V16, P1438, DOI 10.1038/cdd.2009.96; Zawrotniak M, 2013, ACTA BIOCHIM POL, V60, P277	49	4	4	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							321	10.3390/vaccines9040321			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4PB	33915724	Green Published, gold			2022-04-29	WOS:000643761900001
J	Kukreti, S; Lu, MY; Lin, YH; Strong, C; Lin, CY; Ko, NY; Chen, PL; Ko, WC				Kukreti, Shikha; Lu, Mei-Yun; Lin, Yi-Hsuan; Strong, Carol; Lin, Chung-Ying; Ko, Nai-Ying; Chen, Po-Lin; Ko, Wen-Chien			Willingness of Taiwan's Healthcare Workers and Outpatients to Vaccinate against COVID-19 during a Period without Community Outbreaks	VACCINES			English	Article						COVID-19; healthcare workers; outpatient; willingness; vaccination	ACCEPTABILITY; ATTITUDES; INTENTION	To control the spread of the novel coronavirus disease 2019 (COVID-19), COVID-19 vaccination has been quickly developed. However, the COVID-19 pandemic will not be controlled if the COVID-19 vaccination uptake willingness is low. Therefore, the study aim was to explore the COVID-19 vaccination uptake willingness among the outpatient population and healthcare workers in Taiwan during the worldwide pandemic period without community outbreaks. A cross-sectional survey was conducted among healthcare workers (HCWs; n = 500; mean age = 32.96 years) of National Cheng Kung University Hospital (NCKUH) and outpatients (n = 238; mean age = 34.43 years) arriving at NCKUH. We used an online survey conducted between September 24 and 21 November 2020, for healthcare workers, and between 27 October and 31 December 2020, for the outpatient sample. Information regarding willingness to receive vaccination, willingness to rapid test, fear of COVID-19, risk perception, and preventive behaviors was collected in both samples; information regarding willingness to care for patients was collected in healthcare workers. Willingness to receive vaccination was the main variable in the present study; willingness to rapid test, willingness to care for patients, fear of COVID-19, risk perception, and preventive behaviors were the secondary variables in the study. The factors associated with vaccination willingness were identified through logistic regression analysis. The participants' willingness to receive vaccination was low for both healthcare workers (23.4%) and the outpatient sample (30.7%). Similarly, their willingness to take rapid tests was low (23.6% for healthcare workers and 28.6% for outpatient sample). Risk perception (crude odds ratio (COR) = 1.29; 95% confidence interval (CI) = 1.03, 1.63), willingness to take rapid test (COR = 9.24; 95% CI = 5.76, 14.83), and preventive COVID-19 infection behaviors (COR = 2.32; 95% CI = 1.52, 3.56) were significant factors explaining the healthcare workers' willingness to receive vaccination. Willingness to take a rapid test (COR = 8.91; 95% CI = 4.71, 16.87) and preventive COVID-19 infection behaviors (COR = 1.69; 95% CI = 1.09, 2.60) were significant factors explaining the outpatient sample's willingness to receive vaccination. Willingness to vaccinate against COVID-19 among HCWs and outpatients is low due to the relatively safe status of COVID-19 infection in Taiwan. These findings can help policymakers advocate for the effectiveness of and provide transparent information on COVID-19 vaccination uptake in a country/region with a relatively safe COVID-19 outbreak status.	[Kukreti, Shikha; Lu, Mei-Yun; Strong, Carol] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Publ Hlth, Tainan 701, Taiwan; [Lu, Mei-Yun] Natl Cheng Kung Univ Hosp, Ctr Infect Control, Tainan 701, Taiwan; [Lin, Yi-Hsuan; Ko, Nai-Ying] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Nursing, Tainan 701, Taiwan; [Lin, Chung-Ying] Natl Cheng Kung Univ, Coll Med, Inst Allied Hlth Sci, Tainan 701, Taiwan; [Lin, Chung-Ying] Natl Cheng Kung Univ, Coll Med, Dept Occupat Therapy, Tainan 701, Taiwan; [Ko, Nai-Ying] Natl Cheng Kung Univ, Coll Med, Dept Nursing, Int Doctoral Program Nursing, Tainan 701, Taiwan; [Chen, Po-Lin; Ko, Wen-Chien] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Ctr Infect Control,Dept Internal Med, Tainan 701, Taiwan		Lin, CY (通讯作者)，Natl Cheng Kung Univ, Coll Med, Inst Allied Hlth Sci, Tainan 701, Taiwan.; Lin, CY (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Occupat Therapy, Tainan 701, Taiwan.	t88087025@gs.ncku.edu.tw; n967733@mail.hosp.ncku.edu.tw; t26091018@gs.ncku.edu.tw; carolcj@ncku.edu.tw; cylin36933@gs.ncku.edu.tw; nyko@mail.ncku.edu.tw; cplin@mail.ncku.edu.tw; winston@mail.ncku.edu.tw	Ko, Wen-Chien/ABG-4316-2020; Lin, Chung-Ying/I-5434-2016; Kukreti, Shikha/ABD-1156-2021	Ko, Wen-Chien/0000-0001-7497-149X; Lin, Chung-Ying/0000-0002-2129-4242; Kukreti, Shikha/0000-0002-8370-3988; Ko, Nai-Ying/0000-0002-3007-2537	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST109-2327-B-006-005, 110-swf-01]	This study was supported in part by a research grant from the Ministry of Science and Technology, Taiwan (MOST109-2327-B-006-005) and in part by a research grant from the Taipei MunicipalWanfang Hospital Cross-Institutions Fund (110-swf-01).	Ahorsu DK, 2020, GERONTOL GERIATR MED, V6, DOI 10.1177/2333721420966081; Ahorsu DK, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00270-8; [Anonymous], 2020, WHO DRAFT LANDSC COV; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Chan KH, 2020, INT J EPIDEMIOL, V49, P1063, DOI 10.1093/ije/dyaa044; Chang KC, 2020, J FORMOS MED ASSOC, V119, P1772, DOI 10.1016/j.jfma.2020.07.032; Chen CY, 2021, CYBERPSYCH BEH SOC N, V24, P654, DOI 10.1089/cyber.2020.0497; Chen CY, 2021, INT J OBESITY, V45, P677, DOI 10.1038/s41366-021-00741-5; Chen IH, 2020, J AM ACAD CHILD PSY, V59, P1099, DOI 10.1016/j.jaac.2020.06.007; Cheng Y., 2020, SOCIAL HLTH BEHAV, V3, P72, DOI [10.4103/shb.Shb_18_20, DOI 10.4103/SHB.SHB_18_20]; Daly Michael, 2020, medRxiv, DOI 10.1101/2020.11.27.20239970; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; European Society for Child and Adolescent Psychiatry, 2020, MENT HLTH CHILDR AD; Fazeli Sara, 2020, Addict Behav Rep, V12, P100307, DOI [10.1016/j.abrep.2020.100322, 10.1016/j.abrep.2020.100307]; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Grech Victor, 2020, Early Hum Dev, P105259, DOI 10.1016/j.earlhumdev.2020.105259; Harapan H, 2020, HUM VACC IMMUNOTHER, V16, P3074, DOI 10.1080/21645515.2020.1819741; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; La Vecchia C, 2020, MED LAV, V111, P445, DOI 10.23749/mdl.v111i6.10813; Lin CY, 2020, BRIT J HEALTH PSYCH, V25, P981, DOI 10.1111/bjhp.12465; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Madabhavi I, 2020, MONALDI ARCH CHEST D, V90, P248, DOI 10.4081/monaldi.2020.1298; Mamun MA, 2021, J AFFECT DISORDERS, V279, P462, DOI 10.1016/j.jad.2020.10.036; Mamun MA, 2020, BRAIN BEHAV IMMUN, V87, P163, DOI 10.1016/j.bbi.2020.05.028; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Pagnini F, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.15821; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Pramukti I, 2020, J MED INTERNET RES, V22, DOI 10.2196/24487; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Reuben RC, 2021, J COMMUN HEALTH, V46, P457, DOI 10.1007/s10900-020-00881-1; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Taiwan Centers for Disease Control, 2021, COR DIS 2019 COVID 1; Tomar B., 2020, SOCIAL HLTH BEHAV, V3, P83, DOI [10.4103/shb.Shb_32_20, DOI 10.4103/SHB.SHB_32_20]; Tubiana S, 2020, HUM VACC IMMUNOTHER, V16, P851, DOI 10.1080/21645515.2019.1674598; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Wang XY, 2021, ACTA OTO-LARYNGOL, V141, P279, DOI 10.1080/00016489.2020.1844288; Weiss P, 2020, LANCET, V395, P1014, DOI 10.1016/S0140-6736(20)30633-4; WHO, 2020, CLIN MAN SEV AC RESP; Winter T, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00342-9; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Zhang KC, 2020, JMIR PEDIATR PARENT, V3, DOI 10.2196/24827	49	35	35	2	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							246	10.3390/vaccines9030246			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE5KJ	33808950	gold, Green Published			2022-04-29	WOS:000634192500001
J	Liu, RG; Zhang, YX; Nicholas, S; Leng, AL; Maitland, E; Wang, J				Liu, Rugang; Zhang, Yuxun; Nicholas, Stephen; Leng, Anli; Maitland, Elizabeth; Wang, Jian			COVID-19 Vaccination Willingness among Chinese Adults under the Free Vaccination Policy	VACCINES			English	Article						COVID-19; vaccination willingness; free vaccination policy; determinant	DETERMINANTS; PREFERENCES; ACCEPTANCE; INTENTION; TRUST	(1) Background: China will provide free coronavirus disease 2019 (COVID-19) vaccinations for the entire population. This study analyzed the COVID-19 vaccination willingness rate (VWR) and its determinants under China's free vaccination policy compared to a paid vaccine. (2) Methods: Data on 2377 respondents were collected through a nationwide questionnaire survey. Multivariate ordered logistic regression models were specified to explore the correlation between the VWR and its determinants. (3) Results: China's free vaccination policy for COVID-19 increased the VWR from 73.62% to 82.25% of the respondents. Concerns about the safety and side-effects were the primary reason for participants' unwillingness to be vaccinated against COVID-19. Age, medical insurance and vaccine safety were significant determinants of the COVID-19 VWR for both the paid and free vaccine. Income, occupation and vaccine effectiveness were significant determinants of the COVID-19 VWR for the free vaccine. (4) Conclusions: Free vaccinations increased the COVID-19 VWR significantly. People over the age of 58 and without medical insurance should be treated as the target intervention population for improving the COVID-19 VWR. Contrary to previous research, high-income groups and professional workers should be intervention targets to improve the COVID-19 VWR. Strengthening nationwide publicity and education on COVID-19 vaccine safety and effectiveness are recommended policies for decision-makers.	[Liu, Rugang; Zhang, Yuxun] Nanjing Med Univ, Sch Hlth Policy & Management, Nanjing 211166, Peoples R China; [Liu, Rugang; Zhang, Yuxun] Nanjing Med Univ, Ctr Global Hlth, Nanjing 211166, Peoples R China; [Nicholas, Stephen] Australian Natl Inst Management & Commerce, Eveleigh, NSW 2015, Australia; [Nicholas, Stephen] Guangdong Univ Foreign Studies, Res Inst Int Strategies, Guangzhou 510420, Peoples R China; [Nicholas, Stephen] Tianjin Normal Univ, Sch Econ & Sch Management, Tianjin 300074, Peoples R China; [Nicholas, Stephen] Univ Newcastle, Newcastle Business Sch, Newcastle, NSW 2308, Australia; [Leng, Anli] Shandong Univ, Sch Polit Sci & Publ Adm, Inst Governance, Qingdao 266237, Peoples R China; [Maitland, Elizabeth] Univ Liverpool, Sch Management, Chatham Bldg,Chatham St, Liverpool L69 7ZH, Merseyside, England; [Wang, Jian] Wuhan Univ, Dong Fureng Econ & Social Dev Sch, Wuhan 430072, Peoples R China; [Wang, Jian] Wuhan Univ, Ctr Hlth Econ & Management, Sch Econ & Management, Wuhan 430072, Peoples R China		Wang, J (通讯作者)，Wuhan Univ, Dong Fureng Econ & Social Dev Sch, Wuhan 430072, Peoples R China.; Wang, J (通讯作者)，Wuhan Univ, Ctr Hlth Econ & Management, Sch Econ & Management, Wuhan 430072, Peoples R China.	rugangliu@njmu.edu.cn; yuxunzhang@njmu.edu.cn; stephen.nicholas@newcastle.edu.au; lenganli@sdu.edu.cn; e.maitland@liverpool.ac.uk; wangjian993@whu.edu.cn	Leng, Anli/ABG-3086-2021; NICHOLAS, STEPHEN/ABE-4726-2021; Maitland, Elizabeth T/O-7703-2018	Maitland, Elizabeth T/0000-0003-1551-4787; Nicholas, Stephen/0000-0001-6770-7105; WANG, JIAN/0000-0001-8769-7928; leng, anli/0000-0002-6775-2085; Liu, Rugang/0000-0002-4270-9507	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [71904089]; NHC Key Laboratory of Health Economics and Policy Research (Shandong University) [NHC-HEPR2019006]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2019M662392]; Qingdao Postdoctoral Foundation	This research was funded by National Natural Science Foundation of China, grant number 71904089; the NHC Key Laboratory of Health Economics and Policy Research (Shandong University), grant number: NHC-HEPR2019006; the China Postdoctoral Science Foundation, grant number 2019M662392; and the Qingdao Postdoctoral Foundation.	Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alqudeimat Y, 2021, MED PRIN PRACT, V30, P262, DOI 10.1159/000514636; [Anonymous], 2020, PharmacoEcon Outcomes News, V858, P35, DOI 10.1007/s40274-020-7008-x; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Borriello A, 2021, VACCINE, V39, P473, DOI 10.1016/j.vaccine.2020.12.032; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Dong D, 2020, HEALTH EXPECT, V23, P1543, DOI 10.1111/hex.13140; Ehde DM, 2021, MULT SCLER RELAT DIS, V49, DOI 10.1016/j.msard.2021.102788; Garcia LY, 2020, VACCINE, V38, P5424, DOI 10.1016/j.vaccine.2020.06.068; Goldman RD, 2020, VACCINE, V38, P7668, DOI 10.1016/j.vaccine.2020.09.084; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Harapan H, 2020, HUM VACC IMMUNOTHER, V16, P3074, DOI 10.1080/21645515.2020.1819741; Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9; Leng AL, 2021, VACCINE, V39, P247, DOI 10.1016/j.vaccine.2020.12.009; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Liu ZL, 2021, HEALTH COMMUN, V36, P1188, DOI 10.1080/10410236.2020.1748834; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Miyachi T, 2020, LANCET, V395, P31, DOI 10.1016/S0140-6736(19)32686-8; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Sarasty O, 2020, VACCINE, V38, P8090, DOI 10.1016/j.vaccine.2020.11.013; Unroe KT, 2021, J AM GERIATR SOC, V69, P593, DOI 10.1111/jgs.17022; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048	27	26	26	21	45	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							292	10.3390/vaccines9030292			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE5FN	33801136	gold, Green Published			2022-04-29	WOS:000634179900001
J	Machida, M; Nakamura, I; Kojima, T; Saito, R; Nakaya, T; Hanibuchi, T; Takamiya, T; Odagiri, Y; Fukushima, N; Kikuchi, H; Amagasa, S; Watanabe, H; Inoue, S				Machida, Masaki; Nakamura, Itaru; Kojima, Takako; Saito, Reiko; Nakaya, Tomoki; Hanibuchi, Tomoya; Takamiya, Tomoko; Odagiri, Yuko; Fukushima, Noritoshi; Kikuchi, Hiroyuki; Amagasa, Shiho; Watanabe, Hidehiro; Inoue, Shigeru			Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic	VACCINES			English	Article						COVID-19; vaccine; public health; epidemiology; vaccine hesitancy		Vaccination could be a key protective measure against coronavirus disease 2019 (COVID-19), and it is important to understand the acceptability of the COVID-19 vaccine among the general public. However, there is no study on the acceptance of a COVID-19 vaccine in Japan. Therefore, this study aimed to describe the COVID-19 vaccine acceptance and hesitancy situation in Japan and assess the factors associated with such issues. This was a cross-sectional study based on an internet survey completed by 2956 people. Participants were asked to indicate how likely they were to get vaccinated for COVID-19. In addition, the participants responded to questions regarding sociodemographic factors, attitudes, and beliefs regarding COVID-19 infection and vaccination. The proportion of participants with a high likelihood of getting a COVID-19 vaccine was 62.1%. Multiple logistic regression analysis showed that vaccine acceptance was lower among several sociodemographic groups, such as women, adults aged 20-49 years, and those with a low-income level. Several psychological factors, especially the perceived effectiveness of the COVID-19 vaccine, and willingness to protect others by getting oneself vaccinated, were associated with vaccine acceptance. Our results indicate that the perceived effectiveness of the vaccine and willingness to protect others may play an important role in the acceptance of the COVID-19 vaccine.	[Machida, Masaki; Takamiya, Tomoko; Odagiri, Yuko; Fukushima, Noritoshi; Kikuchi, Hiroyuki; Amagasa, Shiho; Inoue, Shigeru] Tokyo Med Univ, Dept Prevent Med & Publ Hlth, Tokyo 1608402, Japan; [Machida, Masaki; Nakamura, Itaru; Watanabe, Hidehiro] Tokyo Med Univ Hosp, Dept Infect Prevent & Control, Tokyo 1600023, Japan; [Kojima, Takako] Tokyo Med Univ, Dept Int Med Commun, Tokyo 1600023, Japan; [Saito, Reiko] Niigata Univ, Div Int Hlth Publ Hlth, Grad Sch Med & Dent Sci, Niigata 9518510, Japan; [Nakaya, Tomoki; Hanibuchi, Tomoya] Tohoku Univ, Grad Sch Environm Studies, Sendai, Miyagi 9800845, Japan		Inoue, S (通讯作者)，Tokyo Med Univ, Dept Prevent Med & Publ Hlth, Tokyo 1608402, Japan.	machida@tokyo-med.ac.jp; task300@tokyo-med.ac.jp; tkojima@tokyo-med.ac.jp; jasmine@med.niigata-u.ac.jp; tomoki.nakaya.c8@tohoku.ac.jp; info@hanibuchi.com; takamiya@tokyo-med.ac.jp; odagiri@tokyo-med.ac.jp; fukufuku@tokyo-med.ac.jp; kikuchih@tokyo-med.ac.jp; amagasa@tokyo-med.ac.jp; hw-nabe4@tokyo-med.ac.jp; inoue@tokyo-med.ac.jp	Kojima, Takako/AAE-3926-2022	Hanibuchi, Tomoya/0000-0002-0447-7645; Amagasa, Shiho/0000-0002-6047-0771; Inoue, Shigeru/0000-0003-1931-2613; Machida, Masaki/0000-0002-7060-7305			Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; [Anonymous], US CTR DIS CONTROL P; [Anonymous], NATL HLTH SERVICE CO; [Anonymous], MINISTRY HLTH LABOUR; [Anonymous], PRIME MINISTER JAPAN; [Anonymous], NEW YORK TIMES; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Betsch C, 2020, LANCET, V395, P1255, DOI 10.1016/S0140-6736(20)30729-7; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Calina D, 2020, DARU, V28, P807, DOI 10.1007/s40199-020-00371-8; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Di Martino G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020248; Farsalinos Konstantinos, 2021, Toxicol Rep, V8, P1, DOI 10.1016/j.toxrep.2020.12.001; Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gargano LM, 2014, HEALTH PROMOT PRACT, V15, P556, DOI 10.1177/1524839913518222; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Grossman DC, 2017, JAMA-J AM MED ASSOC, V318, P167, DOI 10.1001/jama.2017.7171; Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Leng AL, 2021, VACCINE, V39, P247, DOI 10.1016/j.vaccine.2020.12.009; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; McRee AL, 2018, VACCINE, V36, P8158, DOI 10.1016/j.vaccine.2018.01.009; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nguyen KH, 2021, MMWR-MORBID MORTAL W, V70, P217, DOI 10.15585/mmwr.mm7006e3; O'Callaghan KP, 2020, JAMA-J AM MED ASSOC, V324, P437, DOI 10.1001/jama.2020.12190; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Qualls N, 2017, MMWR RECOMM REP, V66, P1, DOI 10.15585/mmwr.rr6601a1; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Sharpe HR, 2020, IMMUNOLOGY, V160, P223, DOI 10.1111/imm.13222; Shimizu K, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101609; Simms KT, 2020, LANCET PUBLIC HEALTH, V5, pE223, DOI 10.1016/S2468-2667(20)30010-4; Slaoui M, 2020, NEW ENGL J MED, V383, P1701, DOI 10.1056/NEJMp2027405; Szilagyi PG, 2021, JAMA-J AM MED ASSOC, V325, P396, DOI 10.1001/jama.2020.26419; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; World Health Organization, COR DIS COVID 19 PAN	43	68	68	18	31	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							210	10.3390/vaccines9030210			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5HB	33802285	gold, Green Published	Y	N	2022-04-29	WOS:000634183900001
J	Valarcher, JF; Hagglund, S; Naslund, K; Jouneau, L; Malmstrom, E; Boulesteix, O; Pinard, A; Leguere, D; Deslis, A; Gauthier, D; Dubuquoy, C; Pietralunga, V; Remot, A; Falk, A; Shevchenko, G; Lind, SB; Von Bromssen, C; Vargmar, K; Zhang, BS; Kwong, PD; Rodriguez, MJ; Duran, MG; Schwartz-Cornil, I; Taylor, G; Riffault, S				Valarcher, Jean Francois; Hagglund, Sara; Naslund, Katarina; Jouneau, Luc; Malmstrom, Ester; Boulesteix, Olivier; Pinard, Anne; Leguere, Dany; Deslis, Alain; Gauthier, David; Dubuquoy, Catherine; Pietralunga, Vincent; Remot, Aude; Falk, Alexander; Shevchenko, Ganna; Bergstrom Lind, Sara; Von Bromssen, Claudia; Vargmar, Karin; Zhang, Baoshan; Kwong, Peter D.; Rodriguez, Maria Jose; Garcia Duran, Marga; Schwartz-Cornil, Isabelle; Taylor, Geraldine; Riffault, Sabine			Single-Shot Vaccines against Bovine Respiratory Syncytial Virus (BRSV): Comparative Evaluation of Long-Term Protection after Immunization in the Presence of BRSV-Specific Maternal Antibodies	VACCINES			English	Article						respiratory syncytial virus; bovine; neonatal; subunit vaccine; pre-fusion; live-attenuated vaccine; deleted SHrBRSV; one-shot; duration of protection; correlate of protection		The induction of long-lasting clinical and virological protection is needed for a successful vaccination program against the bovine respiratory syncytial virus (BRSV). In this study, calves with BRSV-specific maternally derived antibodies were vaccinated once, either with (i) a BRSV pre-fusion protein (PreF) and Montanide(TM) ISA61 VG (ISA61, n = 6), (ii) BRSV lacking the SH gene (Delta SHrBRSV, n = 6), (iii) a commercial vaccine (CV, n = 6), or were injected with ISA61 alone (n = 6). All calves were challenged with BRSV 92 days later and were euthanized 13 days post-infection. Based on clinical, pathological, and proteomic data, all vaccines appeared safe. Compared to the controls, PreF induced the most significant clinical and virological protection post-challenge, followed by Delta SHrBRSV and CV, whereas the protection of PreF-vaccinated calves was correlated with BRSV-specific serum immunoglobulin (Ig)G antibody responses 84 days post-vaccination, and the IgG antibody titers of Delta SHrBRSV- and CV-vaccinated calves did not differ from the controls on this day. Nevertheless, strong anamnestic BRSV- and PreF-specific IgG responses occurred in calves vaccinated with either of the vaccines, following a BRSV challenge. In conclusion, PreF and Delta SHrBRSV are two efficient one-shot candidate vaccines. By inducing a protection for at least three months, they could potentially improve the control of BRSV in calves.	[Valarcher, Jean Francois; Hagglund, Sara; Naslund, Katarina; Malmstrom, Ester] Swedish Univ Agr Sci, Dept Clin Sci, S-75007 Uppsala, Sweden; [Jouneau, Luc; Dubuquoy, Catherine; Pietralunga, Vincent; Schwartz-Cornil, Isabelle; Riffault, Sabine] Univ Paris Saclay, INRAE, UVSQ, VIM, F-78350 Jouy En Josas, France; [Boulesteix, Olivier; Pinard, Anne; Leguere, Dany; Deslis, Alain; Gauthier, David] INRAE, PFIE, F-37380 Nouzilly, France; [Remot, Aude] Univ Tours, INRAE, ISP, F-37380 Nouzilly, France; [Falk, Alexander; Shevchenko, Ganna; Bergstrom Lind, Sara] Uppsala Univ, Dept Chem BMC, S-75237 Uppsala, Sweden; [Von Bromssen, Claudia] Swedish Univ Agr Sci, Dept Energy & Technol, S-75007 Uppsala, Sweden; [Vargmar, Karin] Swedish Univ Agr Sci, Dept Biomed & Vet Publ Hlth, S-75007 Uppsala, Sweden; [Zhang, Baoshan; Kwong, Peter D.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Rodriguez, Maria Jose; Garcia Duran, Marga] Inmunol & Genet Aplicada SA INGENASA, Madrid 28037, Spain; [Taylor, Geraldine] Pirbright Inst, Woking GU24 0NF, Surrey, England		Valarcher, JF (通讯作者)，Swedish Univ Agr Sci, Dept Clin Sci, S-75007 Uppsala, Sweden.	jean-francois.valarcher@slu.se; sara.hagglund@slu.se; katarina.naslund@slu.se; luc.jouneau@inrae.fr; estermalmstrom@gmail.com; olivier.boulesteix@inrae.fr; anne.pinard@inrae.fr; dany.leguere@inrae.fr; alain.deslis@inrae.fr; david.gauthier@inrae.fr; catherine.dubuquoy@gmail.com; vincent.pietralunga@gmail.com; aude.remot@inrae.fr; alexander.falk@kemi.uu.se; ganna.shevchenko@kemi.uu.se; sara.lind@uadm.uu.se; claudia.von.Bromssen@slu.se; karin.vargmar@slu.se; baoshan.zhang@nih.gov; pdkwong@nih.gov; mjrodriguez@ingenasa.com; mgarcia@ingenasa.com; isabelle.schwartz@inrae.fr; geraldine.taylor@pirbright.ac.uk; sabine.riffault@inrae.fr	schwartz-cornil, isabelle/D-8547-2011; von Brömssen, Claudia/AAX-6300-2020; Valarcher, Jean Francois/AAE-4857-2020	von Brömssen, Claudia/0000-0002-1452-8696; Kwong, Peter/0000-0003-3560-232X; Riffault, Sabine/0000-0003-3154-9162; Remot, Aude/0000-0001-9896-3216; Valarcher, Jean Francois/0000-0002-8564-5603; Jouneau, Luc/0000-0002-5094-7302; Vargmar, Karin/0000-0002-8013-2761	European UnionEuropean Commission [633184]; Swedish Foundation of Strategic ResearchSwedish Foundation for Strategic Research [SB160039]; Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) (USA)	This project received funding from the European Union's Horizon 2020 Program for research, technological development, and demonstration under Grant Agreement n633184 (Project's name SAPHIR). Funding was also provided by the Swedish Foundation of Strategic Research (SB160039) and the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) (USA). This publication reflects the views only of the authors and not the European Commission (EC) nor the NIH. The EC or the NIH is not liable for any use that may be made of the information contained herein.	[Anonymous], ICTV; [Anonymous], R PROJECT STAT COMPU; Antonis AFG, 2003, J VIROL, V77, P12067, DOI 10.1128/JVI.77.22.12067-12073.2003; BAKER JC, 1986, AM J VET RES, V47, P240; Beaudeau F, 2010, J DAIRY SCI, V93, P1523, DOI 10.3168/jds.2009-2511; BELKNAP EB, 1991, J INFECT DIS, V163, P470, DOI 10.1093/infdis/163.3.470; Bessueille L, 2020, BONE, V133, DOI 10.1016/j.bone.2020.115262; Bingle L, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-61; Blodorn K, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0389-6; Blodorn K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100392; Boyle LH, 2013, P NATL ACAD SCI USA, V110, P3465, DOI 10.1073/pnas.1222342110; Castilow EM, 2008, J IMMUNOL, V181, P6692, DOI 10.4049/jimmunol.181.10.6692; Chhikara N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047672; Ellis J, 2007, JAVMA-J AM VET MED A, V230, P233, DOI 10.2460/javma.230.2.233; Ellis JA, 2017, VET MICROBIOL, V206, P59, DOI 10.1016/j.vetmic.2016.11.030; Ellis JA, 2013, JAVMA-J AM VET MED A, V243, P1602, DOI 10.2460/javma.243.11.1602; Ellis JA, 2010, JAVMA-J AM VET MED A, V236, P991, DOI 10.2460/javma.236.9.991; Fricker M, 2019, J ALLERGY CLIN IMMUN, V144, P51, DOI 10.1016/j.jaci.2018.12.1020; Gershwin LJ, 1998, VACCINE, V16, P1225, DOI 10.1016/S0264-410X(98)80123-0; Goodwin E, 2018, IMMUNITY, V48, P339, DOI 10.1016/j.immuni.2018.01.005; Goris K, 2009, J VIROL, V83, P1962, DOI 10.1128/JVI.01271-08; Guzman E, 2015, MOL IMMUNOL, V66, P48, DOI 10.1016/j.molimm.2014.12.004; Hagglund S, 2004, VACCINE, V23, P646, DOI 10.1016/j.vaccine.2004.07.006; Hagglund S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186594; Hagglund S, 2011, VACCINE, V29, P8719, DOI 10.1016/j.vaccine.2011.07.146; Hakhverdyan M, 2005, J VIROL METHODS, V123, P195, DOI 10.1016/j.jviromet.2004.09.016; Harmeyer SS, 2006, VET REC, V159, P456, DOI 10.1136/vr.159.14.456; Herve PL, 2017, NANOMED-NANOTECHNOL, V13, P411, DOI 10.1016/j.nano.2016.08.006; Hornaeus K, 2016, DATA BRIEF, V8, P470, DOI 10.1016/j.dib.2016.05.073; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; KIMMAN TG, 1989, VET IMMUNOL IMMUNOP, V22, P145, DOI 10.1016/0165-2427(89)90057-3; KIMMAN TG, 1987, J CLIN MICROBIOL, V25, P1097, DOI 10.1128/JCM.25.6.1097-1106.1987; Klem TB, 2016, ACTA VET SCAND, V58, DOI 10.1186/s13028-016-0190-y; Kolb EA, 2020, VACCINE, V38, P298, DOI 10.1016/j.vaccine.2019.10.015; Le S, 2008, J STAT SOFTW, V25, P1, DOI 10.18637/jss.v025.i01; LEHMKUHL HD, 1979, AM J VET RES, V40, P124; Luna L.G., 1968, MANUAL HISTOLOGIC ST, V3rd; McGill JL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151083; Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446; Polewicz M, 2013, VACCINE, V31, P3148, DOI 10.1016/j.vaccine.2013.05.008; Rader BA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00897; Riffault S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020231; Rizvi SM, 2011, J IMMUNOL, V186, P2309, DOI 10.4049/jimmunol.1002959; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schneider-Ohrum K, 2019, J VIROL, V93, DOI 10.1128/JVI.00695-19; Schneider-Ohrum K, 2017, J VIROL, V91, DOI 10.1128/JVI.02180-16; Schreiber P, 2000, J VET MED B, V47, P535, DOI 10.1046/j.1439-0450.2000.00380.x; Steff AM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01092-4; TAYLOR G, 1992, J GEN VIROL, V73, P2217, DOI 10.1099/0022-1317-73-9-2217; Taylor G, 2005, VACCINE, V23, P1242, DOI 10.1016/j.vaccine.2004.09.005; TAYLOR G, 1984, IMMUNOLOGY, V52, P137; Taylor G, 2014, J GEN VIROL, V95, P1244, DOI 10.1099/vir.0.064931-0; Timsit E, 2009, VET REC, V165, P230; Valarcher JF, 2007, VET RES, V38, P153, DOI 10.1051/vetres:2006053; Vangeel I, 2007, VET J, V174, P627, DOI 10.1016/j.tvjl.2006.10.013; VERHOEFF J, 1984, VET REC, V114, P9, DOI 10.1136/vr.114.1.9; Windeyer MC, 2019, VET CLIN N AM-FOOD A, V35, P557, DOI 10.1016/j.cvfa.2019.07.004; Zhang BS, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0005-9; Zhang L, 2015, J DAIRY SCI, V98, P5339, DOI 10.3168/jds.2014-9279	59	1	1	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							236	10.3390/vaccines9030236			27	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5MQ	33803302	gold, Green Published			2022-04-29	WOS:000634198400001
J	Weerasuriya, CK; Harris, RC; Quaife, M; McQuaid, CF; White, RG; Gomez, GB				Weerasuriya, Chathika Krishan; Harris, Rebecca Claire; Quaife, Matthew; McQuaid, Christopher Finn; White, Richard G.; Gomez, Gabriela B.			Affordability of Adult Tuberculosis Vaccination in India and China: A Dynamic Transmission Model-Based Analysis	VACCINES			English	Article						tuberculosis; vaccine; model; affordability; budget; cost-effectiveness	COST-EFFECTIVENESS; VACCINES; IMPACT	New tuberculosis vaccines have made substantial progress in the development pipeline. Previous modelling suggests that adolescent/adult mass vaccination may cost-effectively contribute towards achieving global tuberculosis control goals. These analyses have not considered the budgetary feasibility of vaccine programmes. We estimate the maximum total cost that the public health sectors in India and China should expect to pay to introduce a M72/AS01(E)-like vaccine deemed cost-effective at country-specific willingness to pay thresholds for cost-effectiveness. To estimate the total disability adjusted life years (DALYs) averted by the vaccination programme, we simulated a 50% efficacy vaccine providing 10-years of protection in post-infection populations between 2027 and 2050 in India and China using a dynamic transmission model of M. tuberculosis. We investigated two mass vaccination strategies, both delivered every 10-years achieving 70% coverage: Vaccinating adults and adolescents (age >= 10y), or only the most efficient 10-year age subgroup (defined as greatest DALYs averted per vaccine given). We used country-specific thresholds for cost-effectiveness to estimate the maximum total cost (C-max) a government should be willing to pay for each vaccination strategy. Adult/adolescent vaccination resulted in a C-max of $21 billion (uncertainty interval [UI]: 16-27) in India, and $15B (UI:12-29) in China at willingness to pay thresholds of $264/DALY averted and $3650/DALY averted, respectively. Vaccinating the highest efficiency age group (India: 50-59y; China: 60-69y) resulted in a C-max of $5B (UI:4-6) in India and $6B (UI:4-7) in China. Mass vaccination against tuberculosis of all adults and adolescents, deemed cost-effective, will likely impose a substantial budgetary burden. Targeted tuberculosis vaccination, deemed cost-effective, may represent a more affordable approach.	[Weerasuriya, Chathika Krishan; Harris, Rebecca Claire; Quaife, Matthew; McQuaid, Christopher Finn; White, Richard G.] London Sch Hyg, TB Modelling Grp, TB Ctr, London WC1E 7HT, England; [Weerasuriya, Chathika Krishan; Harris, Rebecca Claire; Quaife, Matthew; McQuaid, Christopher Finn; White, Richard G.] London Sch Hyg, Ctr Math Modelling Infect Dis, Dept Infect Dis Epidemiol, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England; [Harris, Rebecca Claire] Sanofi Pasteur, COVID Med Franchise 19, Singapore 189767, Singapore; [Gomez, Gabriela B.] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, Dept Global Hlth & Dev, London WC1E 7HT, England; [Gomez, Gabriela B.] Sanofi Pasteur, Dept Modelling Epidemiol & Data Sci, F-69007 Lyon, France		Weerasuriya, CK (通讯作者)，London Sch Hyg, TB Modelling Grp, TB Ctr, London WC1E 7HT, England.; Weerasuriya, CK (通讯作者)，London Sch Hyg, Ctr Math Modelling Infect Dis, Dept Infect Dis Epidemiol, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England.	c.weerasuriya@lshtm.ac.uk; rebecca.harris@lshtm.ac.uk; matthew.quaife@lshtm.ac.uk; finn.mcquaid@lshtm.ac.uk; richard.white@lshtm.ac.uk; gabriela.gomez@lshtm.ac.uk	White, Richard G/D-5407-2009; McQuaid, Christopher Finn/F-9633-2015	White, Richard G/0000-0003-4410-6635; McQuaid, Christopher Finn/0000-0001-6199-0931; Quaife, Matthew/0000-0001-9291-1511; Weerasuriya, Chathika/0000-0001-7364-1026	UKRI/MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/N013638/1]; Welcome TrustWellcome Trust [218261/Z/19/Z]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01AI147321-01]; EDTCP [RIA208D-2505B]; UK MRC (SET Bloomsbury) [CCF17-7779]; ESRCUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/P008011/1]; BMGF [OPP1084276, OPP1135288, INV-001754]; WHOWorld Health Organization [2020/985800-0]; Bill and Melinda Gates FoundationBill & Melinda Gates Foundation [TB MAC OPP1135288]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [1923346] Funding Source: UKRI	C.K.W. is funded by UKRI/MRC (MR/N013638/1). R.G.W. is funded by the Welcome Trust (218261/Z/19/Z), NIH (1R01AI147321-01), EDTCP (RIA208D-2505B), UK MRC (CCF17-7779 via SET Bloomsbury), ESRC (ES/P008011/1), BMGF (OPP1084276, OPP1135288 and INV-001754), and the WHO (2020/985800-0). M.Q. is funded by BMGF (INV-001754). C.F.M is funded by the Bill and Melinda Gates Foundation (TB MAC OPP1135288).	Aggarwal R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176503; [Anonymous], 2017, NAT STRAT PLAN TUB E; [Anonymous], 2018, REP 1 NAT ANT DRUG R; Bahety H., 2014, INT, V2, P30; Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418; Bilinski A, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002397; Chatterjee S, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000794; Claxton K.P., 2014, GATES REFERENCE CASE; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; Harouna Djingarey M, 2014, 2014 P M STRAT ADV G; Harris RC, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax4607; Harris RC, 2019, LANCET GLOB HEALTH, V7, pE209, DOI 10.1016/S2214-109X(18)30452-2; Iyengar S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002032; Knight GM, 2014, P NATL ACAD SCI USA, V111, P15520, DOI 10.1073/pnas.1404386111; Langley I, 2015, LANCET GLOB HEALTH, V3, pE83, DOI 10.1016/S2214-109X(14)70370-5; Menzies NA, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001347; Ochalek J, 2021, EXPERT REV PHARM OUT, V21, P729, DOI 10.1080/14737167.2020.1812387; Ochalek J, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000964; Paulden M, 2017, MED DECIS MAKING, V37, P264, DOI 10.1177/0272989X16662242; Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8; Tait DR, 2019, NEW ENGL J MED, V381, P2429, DOI 10.1056/NEJMoa1909953; Uplekar M, 2015, LANCET, V385, P1799, DOI 10.1016/S0140-6736(15)60570-0; Wang LX, 2014, LANCET, V383, P2057, DOI 10.1016/S0140-6736(13)62639-2; Weerasuriya CK, 2020, J INTERN MED, V288, P661, DOI 10.1111/joim.13197; Weerasuriya CK, 2021, BMC MED, V19, DOI 10.1186/s12916-021-01932-7; World Health Organization, WHO TUB DAT; World Health Organization, WHO METR DIS ADJ LIF; Wu SQ, 2013, BMC PUBLIC HEALTH, V13, DOI [10.1186/1471-2458-13-320, 10.1186/1471-2458-13-636]; Yu WZ, 2018, VACCINE, V36, P3041, DOI 10.1016/j.vaccine.2018.04.008; Zheng Y, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003662	30	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							245	10.3390/vaccines9030245			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE4ZT	33799544	Green Published, gold			2022-04-29	WOS:000634164900001
J	Kyuregyan, KK; Kichatova, VS; Isaeva, OV; Potemkin, IA; Malinnikova, EY; Lopatukhina, MA; Karlsen, AA; Mobarhan, FAA; Mullin, EV; Slukinova, OS; Ignateva, ME; Sleptsova, SS; Oglezneva, EE; Shibrik, EV; Isaguliants, MG; Mikhailov, MI				Kyuregyan, Karen K.; Kichatova, Vera S.; Isaeva, Olga, V; Potemkin, Ilya A.; Malinnikova, Elena Yu; Lopatukhina, Maria A.; Karlsen, Anastasia A.; Mobarhan, Fedor A. Asadi; Mullin, Eugeniy, V; Slukinova, Olga S.; Ignateva, Margarita E.; Sleptsova, Snezhana S.; Oglezneva, Elena E.; Shibrik, Elena, V; Isaguliants, Maria G.; Mikhailov, Mikhail, I			Coverage with Timely Administered Vaccination against Hepatitis B Virus and Its Influence on the Prevalence of HBV Infection in the Regions of Different Endemicity	VACCINES			English	Article						hepatitis B vaccine; birth dose coverage; HBV prevalence; hepatitis B epidemiology; public health	CHILDREN	Universal hepatitis B vaccination of newborns was implemented in Russia starting from 1998. From 1998 to 2019, the incidence of acute hepatitis B reduced from 43.8 to 0.57 cases per 100,000 population. Here, we assessed the timely coverage of newborns with the birth dose (HepB-BD), second dose (HepB-2nd), and three vaccine doses (HepB3) in two remote regions of Russia with low (Belgorod Oblast) and high (Yakutia) levels of hepatitis B virus (HBV) endemicity. Vaccination data were obtained from the medical records of 1000 children in Yakutia and 2182 children in Belgorod Oblast. Sera of healthy volunteers from Belgorod Oblast (n = 1754) and Yakutia (n = 1072) across all age groups were tested for serological markers of HBV to assess the infection prevalence and herd immunity. Average HepB-BD coverage was 99.2% in Yakutia and 89.4% in Belgorod Oblast (p < 0.0001) and in both regions varied significantly, from 66% to 100%, between medical centers. The principal reason for the absence of HepB-BD was parent refusal, which accounted for 63.5% of cases of non-vaccination (83/123). While timely HepB-2nd coverage was only 55.4%-64.7%: HepB3 coverage by the age of one year exceeded 90% in both study regions. HBV surface antigen (HBsAg) prevalence in the 1998-2019 birth cohort was 0.2% (95% CI: 0.01-1.3%) in Belgorod Oblast and 3.2% (95% CI: 1.9-5.2%) in Yakutia. The proportion of persons testing negative for both antibodies to HBsAg (anti-HBs) and antibodies to HBV core antigen (anti-HBc) in the 1998-2019 birth cohort was 26.2% (125/481) in Belgorod Oblast and 32.3% (162/501) in Yakutia. We also assessed the knowledge of and attitude towards vaccination among 782 students and teachers of both medical and non-medical specialties from Belgorod State University. Only 60% of medical students knew that hepatitis B is a vaccine-preventable disease. Both medical and nonmedical students, 37.8% and 31.3%, respectively, expressed concerns about safety and actual necessity of vaccination. These data indicate the need to introduce a vaccine delivery audit system, improve medical education with respect to vaccination strategies and policies, and reinforce public knowledge on the benefits of vaccination.	[Kyuregyan, Karen K.; Kichatova, Vera S.; Isaeva, Olga, V; Potemkin, Ilya A.; Malinnikova, Elena Yu; Karlsen, Anastasia A.; Mikhailov, Mikhail, I] Russian Med Acad Continuous Profess Educ, Dept Viral Hepatitis, Moscow 125993, Russia; [Kyuregyan, Karen K.; Kichatova, Vera S.; Isaeva, Olga, V; Potemkin, Ilya A.; Malinnikova, Elena Yu; Lopatukhina, Maria A.; Karlsen, Anastasia A.; Mobarhan, Fedor A. Asadi; Mullin, Eugeniy, V; Slukinova, Olga S.; Mikhailov, Mikhail, I] Mechnikov Res Inst Vaccines & Sera, Lab Viral Hepatitis, Moscow 105064, Russia; [Ignateva, Margarita E.] Sakha Republ Yakutia Reg Dept Rospotrebnadzor, Yakutsk 677027, Russia; [Sleptsova, Snezhana S.] MK Ammosov North Eastern Fed Univ, Med Inst, Yakutsk 677010, Russia; [Oglezneva, Elena E.] Belgorod Reg Dept Rospotrebnadzor, Belgorod 308023, Russia; [Oglezneva, Elena E.] Belgorod State Natl Res Univ, Med Fac, Belgorod 308015, Russia; [Shibrik, Elena, V] Dept Hlth & Social Protect Populat Belgorod Reg, Belgorod 308005, Russia; [Isaguliants, Maria G.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Biomed, S-17165 Solna, Sweden; [Isaguliants, Maria G.] NF Gamaleja Res Ctr Epidemiol & Microbiol, Lab Mol Pathogenesis Chron Viral Infect, Moscow 123098, Russia; [Isaguliants, Maria G.] Riga Stradins Univ, Res Dept, LV-1007 Riga, Latvia		Kyuregyan, KK (通讯作者)，Russian Med Acad Continuous Profess Educ, Dept Viral Hepatitis, Moscow 125993, Russia.; Kyuregyan, KK (通讯作者)，Mechnikov Res Inst Vaccines & Sera, Lab Viral Hepatitis, Moscow 105064, Russia.	karen-kyuregyan@yandex.ru; vera_kichatova@mail.ru; isaeva.06@mail.ru; axi0ma@mail.ru; malinacgb@mail.ru; marialopatukhina@yandex.ru; a.carlsen@yandex.ru; 1amfa@bk.ru; caesusjuliar@yandex.ru; chvtku.ssv@yandex.ru; yakutia@14.rospotrebnadzor.ru; sssleptsova@yandex.ru; orgotd@31.rospotrebnadzor.ru; shibrik@belzdrav.ru; maria.issagouliantis@ki.se; michmich2@yandex.ru	, ISSAGOULIANTIS/AAI-3148-2021; Kichatova, Vera/AAP-5245-2020; Sleptsova, Snezhana/ABG-1459-2021; Kyuregyan, Karen/D-6300-2014; Mikhailov, Mikhail Ivanovich/AAD-6917-2022; Malinnikova, Elena/S-4622-2018	, ISSAGOULIANTIS/0000-0001-9382-2254; Kichatova, Vera/0000-0002-7838-6965; Kyuregyan, Karen/0000-0002-3599-117X; Mikhailov, Mikhail Ivanovich/0000-0002-6636-6801; Malinnikova, Elena/0000-0002-5501-5707; Asadi Mobarkhan, Fedor/0000-0002-1838-8037	Russian Science FoundationRussian Science Foundation (RSF) [ID-20-15-00148]	This research was funded by grant of the Russian Science Foundation (ID-20-15-00148).	Alexeeva M.N., 1998, RUSS J GASTROENTEROL, V5, P156; [Anonymous], 2017, Wkly Epidemiol Rec, V92, P369; [Anonymous], 2020, PREV MOTH CHILD TRAN; [Anonymous], 2017, GLOB HEP REP; [Anonymous], 2015, HEP B VACC REC; [Anonymous], 2020, LIST VACCINES PREVEN; [Anonymous], 2019, DEMOGRAPHY REPORT; [Anonymous], 2019, INFECT PARASITIC DIS; Davaalkham D, 2007, J EPIDEMIOL COMMUN H, V61, P578, DOI 10.1136/jech.2006.051375; Diminsky D, 1999, VACCINE, V18, P3, DOI 10.1016/S0264-410X(99)00149-8; Galazka A., 1998, WHIGPV9807 WHO; Galina NP, 2019, INFEKTSIYA IMMUN, V9, P779, DOI 10.15789/2220-7619-2019-5-6-779-786; Hajian-Tilaki K, 2011, CASP J INTERN MED, V2, P289; Ivaniushina V, 2001, J GEN VIROL, V82, P2709, DOI 10.1099/0022-1317-82-11-2709; Ji ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097474; Jiles RB, 2001, AM J PREV MED, V20, P75, DOI 10.1016/S0749-3797(01)00276-8; [Хотова Татьяна Юрьевна Khotova Tatyana Yu.], 2016, [Российский медицинский журнал, Rossiiskii meditsinskii zhurnal], V22, P85, DOI 10.18821/0869-2106-2016-22-2-85-90; Klushkina VV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157161; Le MH, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.22388; Le XTT, 2020, VACCINE, V38, P8343, DOI 10.1016/j.vaccine.2020.11.009; Leuridan E, 2011, CLIN INFECT DIS, V53, P68, DOI 10.1093/cid/cir270; Miao N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75338-5; Okenwa UJ, 2019, VACCINE, V37, P6894, DOI 10.1016/j.vaccine.2019.09.056; Ravna ZV, 2019, INT J CIRCUMPOL HEAL, V78, DOI 10.1080/22423982.2019.1586275; Salkic NN, 2007, EUR J GASTROEN HEPAT, V19, P113, DOI 10.1097/MEG.0b013e32801290f7; Smith PJ, 2006, PEDIATRICS, V118, pE1287, DOI 10.1542/peds.2006-0923; Tharmaphornpilas P, 2009, VACCINE, V27, P6110, DOI 10.1016/j.vaccine.2009.08.034; VALENZUELA P, 1982, NATURE, V298, P347, DOI 10.1038/298347a0; van den Ende C, 2017, EXPERT REV VACCINES, V16, P789, DOI 10.1080/14760584.2017.1338569; WHO, 2013, WORLD MALARIA REPORT 2013, P1	30	1	2	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							82	10.3390/vaccines9020082			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6SZ	33498794	gold, Green Published			2022-04-29	WOS:000623272700001
J	Motaze, NV; Mthombothi, ZE; Adetokunboh, O; Hazelbag, CM; Saldarriaga, EM; Mbuagbaw, L; Wiysonge, CS				Motaze, Nkengafac Villyen; Mthombothi, Zinhle E.; Adetokunboh, Olatunji; Hazelbag, C. Marijn; Saldarriaga, Enrique M.; Mbuagbaw, Lawrence; Wiysonge, Charles Shey			The Impact of Rubella Vaccine Introduction on Rubella Infection and Congenital Rubella Syndrome: A Systematic Review of Mathematical Modelling Studies	VACCINES			English	Review						rubella; congenital rubella syndrome; rubella-containing vaccines; systematic review; data synthesis	STRATEGIES; MEASLES; HEALTH; IMMUNIZATION; SIMULATION; TRANSMISSION; MUMPS; RISK	Introduction: Rubella vaccines have been used to prevent rubella and congenital rubella syndrome (CRS) in several World Health Organization (WHO) regions. Mathematical modelling studies have simulated introduction of rubella-containing vaccines (RCVs), and their results have been used to inform rubella introduction strategies in several countries. This systematic review aimed to synthesize the evidence from mathematical models regarding the impact of introducing RCVs. Methods: We registered the review in the international prospective register of systematic reviews (PROSPERO) with registration number CRD42020192638. Systematic review methods for classical epidemiological studies and reporting guidelines were followed as far as possible. A comprehensive search strategy was used to identify published and unpublished studies with no language restrictions. We included deterministic and stochastic models that simulated RCV introduction into the public sector vaccination schedule, with a time horizon of at least five years. Models focused only on estimating epidemiological parameters were excluded. Outcomes of interest were time to rubella and CRS elimination, trends in incidence of rubella and CRS, number of vaccinated individuals per CRS case averted, and cost-effectiveness of vaccine introduction strategies. The methodological quality of included studies was assessed using a modified risk of bias tool, and a qualitative narrative was provided, given that data synthesis was not feasible. Results: Seven studies were included from a total of 1393 records retrieved. The methodological quality was scored high for six studies and very high for one study. Quantitative data synthesis was not possible, because only one study reported point estimates and uncertainty intervals for the outcomes. All seven included studies presented trends in rubella incidence, six studies reported trends in CRS incidence, two studies reported the number vaccinated individuals per CRS case averted, and two studies reported an economic evaluation measure. Time to CRS elimination and time to rubella elimination were not reported by any of the included studies. Reported trends in CRS incidence showed elimination within five years of RCV introduction with scenarios involving mass vaccination of older children in addition to routine infant vaccination. CRS incidence was higher with RCV introduction than without RCV when public vaccine coverage was lower than 50% or only private sector vaccination was implemented. Although vaccination of children at a given age achieved slower declines in CRS incidence compared to mass campaigns targeting a wide age range, this approach resulted in the lowest number of vaccinated individuals per CRS case averted. Conclusion and recommendations: We were unable to conduct data synthesis of included studies due to discrepancies in outcome reporting. However, qualitative assessment of results of individual studies suggests that vaccination of infants should be combined with vaccination of older children to achieve rapid elimination of CRS. Better outcomes are obtained when rubella vaccination is introduced into public vaccination schedules at coverage figures of 80%, as recommended by WHO, or higher. Guidelines for reporting of outcomes in mathematical modelling studies and the conduct of systematic reviews of mathematical modelling studies are required.	[Motaze, Nkengafac Villyen] Natl Inst Communicable Dis NICD, ZA-2131 Johannesburg, South Africa; [Motaze, Nkengafac Villyen; Adetokunboh, Olatunji; Mbuagbaw, Lawrence; Wiysonge, Charles Shey] Stellenbosch Univ, Dept Global Hlth, Div Epidemiol & Biostat, ZA-7505 Cape Town, South Africa; [Motaze, Nkengafac Villyen; Mbuagbaw, Lawrence; Wiysonge, Charles Shey] Yaounde Cent Hosp, Ctr Dev Best Practices Hlth CDBPH, Yaounde 1211, Cameroon; [Mthombothi, Zinhle E.; Adetokunboh, Olatunji; Hazelbag, C. Marijn] South African Dept Sci & Innovat Natl Res Fdn DSI, Ctr Excellence Epidemiol Modelling & Anal SACEMA, ZA-7600 Stellenbosch, South Africa; [Saldarriaga, Enrique M.] Univ Washington, Comparat Hlth Outcomes Policy & Econ CHOICE Inst, Seattle, WA 98195 USA; [Mbuagbaw, Lawrence] McMaster Univ, Dept Hlth Res Methods Evidence & Impact HEI, Hamilton, ON L8S 4L8, Canada; [Mbuagbaw, Lawrence] St Josephs Healthcare, Biostat Unit, Res Inst, Hamilton, ON L8N 4A6, Canada; [Wiysonge, Charles Shey] South African Med Res Council, Cochrane South Africa, ZA-7505 Cape Town, South Africa; [Wiysonge, Charles Shey] Univ Cape Town, Sch Publ Hlth & Family Med, Anzio Rd, ZA-7935 Cape Town, South Africa		Motaze, NV (通讯作者)，Natl Inst Communicable Dis NICD, ZA-2131 Johannesburg, South Africa.; Motaze, NV (通讯作者)，Stellenbosch Univ, Dept Global Hlth, Div Epidemiol & Biostat, ZA-7505 Cape Town, South Africa.; Motaze, NV (通讯作者)，Yaounde Cent Hosp, Ctr Dev Best Practices Hlth CDBPH, Yaounde 1211, Cameroon.	villyen@yahoo.com; zinhlem@sun.ac.za; olatunji@sun.ac.za; marijnhazelbag@sun.ac.za; emsb@uw.edu; mbuagblc@mcmaster.ca; Charles.Wiysonge@mrc.ac.za	; Adetokunboh, Olatunji/O-7224-2018	Saldarriaga, Enrique M/0000-0001-8879-6354; Wiysonge, Charles/0000-0002-1273-4779; Adetokunboh, Olatunji/0000-0002-4608-3951; Mthombothi, Zinhle/0000-0002-0078-1260; Motaze, Nkengafac Villyen/0000-0003-0227-6425			Akobeng AK, 2005, ARCH DIS CHILD, V90, P837, DOI 10.1136/adc.2005.071761; Alford C, 2016, REMINGTON KLEINS INF, P894, DOI [10.1016/B978-0-323-24147-2.00029-8, DOI 10.1016/B978-0-323-24147-2.00029-8]; [Anonymous], 2013, GLOBAL VACCINE ACTIO, DOI [10.1016/j.vaccine.2013.02.015, DOI 10.1016/J.VACCINE.2013.02.015]; Bellan SE, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001295; Brisson M, 2020, LANCET, V395, P575, DOI 10.1016/S0140-6736(20)30068-4; Buonomo B, 2011, MATH BIOSCI ENG, V8, P677, DOI 10.3934/mbe.2011.8.677; Buraud G., 2016, MED MALADIES INFECT, V46, P4, DOI [10.1016/S0399-077X(16)30263-3, DOI 10.1016/S0399-077X(16)30263-3]; Caro JJ, 2014, VALUE HEALTH, V17, P174, DOI 10.1016/j.jval.2014.01.003; Centre for Reviews and Dissemination, 2009, CRDS GUIDANCE UNDERT; DUDGEON JA, 1985, REV INFECT DIS, V7, pS185; Edmunds WJ, 2000, EPIDEMIOL INFECT, V125, P617, DOI 10.1017/S0950268800004660; Edmunds WJ, 2000, EPIDEMIOL INFECT, V125, P635, DOI 10.1017/S0950268800004672; ELVEBACK L, 1965, PUBLIC HEALTH REP, V80, P1067, DOI 10.2307/4592614; Feng ZL, 2020, THEOR POPUL BIOL, V132, P24, DOI 10.1016/j.tpb.2020.01.005; Fone D, 2003, J PUBLIC HEALTH MED, V25, P325, DOI 10.1093/pubmed/fdg075; Gao L, 2006, MATH BIOSCI, V202, P371, DOI 10.1016/j.mbs.2006.02.005; Gao ZH, 2013, VACCINE, V31, P691, DOI 10.1016/j.vaccine.2012.11.043; Hachiya M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194931; HANAOKA M, 2020, THE J, DOI DOI 10.1007/S10389-020-01352-6; Harris RC, 2016, HUM VACC IMMUNOTHER, V12, P2813, DOI 10.1080/21645515.2016.1205769; Hincapié-Palacio Doracelly, 2010, Rev. salud pública, V12, P103; Jazbec A, 2004, APPL MATH COMPUT, V153, P75, DOI 10.1016/S0096-3003(03)00610-6; Jimenez G, 2007, PEDIATR INFECT DIS J, V26, P382, DOI 10.1097/01.inf.0000260000.84792.9e; Khan KS, 2003, J ROY SOC MED, V96, P118, DOI 10.1258/jrsm.96.3.118; Kopec JA, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-710; Lessler J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067639; Li T., 2019, COCHRANE HDB SYSTEMA, DOI [10.1002/9781119536604, DOI 10.1002/9781119536604, DOI 10.1002/9781119536604.CH7]; Metcalf CJE, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0756; Metcalf CJE, 2012, THEOR POPUL BIOL, V82, P275, DOI 10.1016/j.tpb.2011.12.001; Metcalf CJE, 2012, EPIDEMIOL INFECT, V140, P2290, DOI 10.1017/S0950268812000131; Metcalf CJE, 2011, J R SOC INTERFACE, V8, P369, DOI 10.1098/rsif.2010.0320; Motaze NV, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030383; Murad M Hassan, 2016, Evid Based Med, V21, P125, DOI 10.1136/ebmed-2016-110401; Panagiotopoulos T, 1999, BRIT MED J, V319, P1462, DOI 10.1136/bmj.319.7223.1462; Plotkin, 2018, PLOTKINS VACCINES, V295, P970, DOI [10.1016/S0140-6736(70)91553-9, DOI 10.1016/S0140-6736(70)91553-9]; R DEVELOPMENT CORE TEAM, 2008, R LANGUAGE ENV STAT; Reinert P, 2003, ARCH PEDIATRIE, V10, P948, DOI 10.1016/j.arcped.2003.09.028; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Takahashi S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15585; The World Bank, 2019, WORLD BANK COUNTRY L; Thompson KM, 2017, RISK ANAL, V37, P1109, DOI 10.1111/risa.12831; Thompson KM, 2016, RISK ANAL, V36, P1427, DOI 10.1111/risa.12454; Thompson KM, 2016, RISK ANAL, V36, P1357, DOI 10.1111/risa.12459; Vynnycky E, 2016, HUM VACC IMMUNOTHER, V12, P150, DOI 10.1080/21645515.2015.1060380; Wesolowski A, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2015.1101; Winter AK, 2018, EPIDEMIOL INFECT, V146, P65, DOI 10.1017/S0950268817002527; World Health Organization, 2020, WKLY EPIDEMIOL REC, V27, P306; World Health Organization, 2012, GLOBAL MEASLES RUBEL; Wu Y, 2016, VACCINE, V34, P5636, DOI 10.1016/j.vaccine.2016.09.010	50	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							84	10.3390/vaccines9020084			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO6RE	33503898	gold, Green Published			2022-04-29	WOS:000623268000001
J	Ng, KT; Mohd-Ismail, NK; Tan, YJ				Ng, Kim Tien; Mohd-Ismail, Nur Khairiah; Tan, Yee-Joo			Spike S2 Subunit: The Dark Horse in the Race for Prophylactic and Therapeutic Interventions against SARS-CoV-2	VACCINES			English	Review						severe acute respiratory syndrome coronavirus 2; SARS-CoV-2; coronavirus disease 2019; COVID-19; spike glycoprotein; S2 subunit	GENETIC DRIFT; SARS-COV; CORONAVIRUS; VACCINE; MECHANISM; ANIMALS; VIRUSES; PEPTIDE; REGIONS	In the midst of the unceasing COVID-19 pandemic, the identification of immunogenic epitopes in the SARS-CoV-2 spike (S) glycoprotein plays a vital role in the advancement and development of intervention strategies. S is expressed on the exterior of the SARS-CoV-2 virion and contains two subunits, namely the N-terminal S1 and C-terminal S2. It is the key element for mediating viral entry as well as a crucial antigenic determinant capable of stimulating protective immune response through elicitation of anti-SARS-CoV-2 antibodies and activation of CD4(+) and CD8(+) cells in COVID-19 patients. Given that S2 is highly conserved in comparison to the S1, here, we provide a review of the latest findings on the SARS-CoV-2 S2 subunit and further discuss its potential as an attractive and promising target for the development of prophylactic vaccines and therapeutic agents against COVID-19.	[Ng, Kim Tien; Mohd-Ismail, Nur Khairiah; Tan, Yee-Joo] Natl Univ Singapore, Yong Loo Lin Sch Med, Infect Dis Translat Res Program, Singapore 117545, Singapore; [Ng, Kim Tien; Mohd-Ismail, Nur Khairiah; Tan, Yee-Joo] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore 117545, Singapore; [Tan, Yee-Joo] ASTAR, Inst Mol & Cell Biol IMCB, Singapore 138673, Singapore		Tan, YJ (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Infect Dis Translat Res Program, Singapore 117545, Singapore.; Tan, YJ (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore 117545, Singapore.; Tan, YJ (通讯作者)，ASTAR, Inst Mol & Cell Biol IMCB, Singapore 138673, Singapore.	micnkt@nus.edu.sg; micnkmi@nus.edu.sg; mictyj@nus.edu.sg	Ng, Kim Tien/K-7667-2013	Ng, Kim Tien/0000-0002-4097-9984; Tan, Yee-Joo/0000-0002-2278-4497; Mohd Ismail, Nur Khairiah/0000-0002-6301-7876	NUHS Research Office [NUHSRO/2020/033/RO5+5/CORONAVIRUS/LOA (WBS R-571-000-071-733)]; NUSMed Post-Doctoral Fellowship	This work was supported by NUHS Research Office under Project Number NUHSRO/2020/033/RO5+5/CORONAVIRUS/LOA (WBS R-571-000-071-733). K.T.N. is supported by a NUSMed Post-Doctoral Fellowship.	Aanensen DM, 2020, LANCET MICROBE, V1, pE99, DOI 10.1016/S2666-5247(20)30054-9; Altmann DM, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6160; Arvin AM, 2020, NATURE, V584, P353, DOI 10.1038/s41586-020-2538-8; Barnes CO, 2020, NATURE, V588, P682, DOI 10.1038/s41586-020-2852-1; Benton DJ, 2020, NATURE, V588, DOI 10.1038/s41586-020-2772-0; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; Chen ZY, 2020, NAT REV IMMUNOL, V20, P529, DOI 10.1038/s41577-020-0402-6; Chibo D, 2006, J GEN VIROL, V87, P1203, DOI 10.1099/vir.0.81662-0; Cohen J, 2020, SCIENCE, V368, P456, DOI 10.1126/science.368.6490.456; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Funk CD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00937; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Guthmiller JJ, 2020, SCIENCE, V370, P1272, DOI 10.1126/science.abf4860; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Huang Y, 2020, ACTA PHARMACOL SIN, V41, P1141, DOI 10.1038/s41401-020-0485-4; Jain S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040649; Jiang SB, 2020, TRENDS IMMUNOL, V41, P545, DOI 10.1016/j.it.2020.04.008; Kandeel M, 2021, BIOMOL THER, V29, P282, DOI 10.4062/biomolther.2020.201; Kemp S., 2021, RECURRENT EMERGENCE, DOI [10.1101/2020.12.14.422555, DOI 10.1101/2020.12.14.422555]; Kemp S A, 2020, medRxiv, DOI 10.1101/2020.12.05.20241927; Konishi I., 2020, EFFECT RBD MUTATION, DOI [10.1101/2020.11.27.401893, DOI 10.1101/2020.11.27.401893]; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515; Li Y, 2020, CELL MOL IMMUNOL, V17, P1095, DOI 10.1038/s41423-020-00523-5; Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7; Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003; Lv M, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.15.2000125; Ma XC, 2020, IMMUNITY, V53, P1315, DOI 10.1016/j.immuni.2020.11.015; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283; Ng KW, 2020, SCIENCE, V370, P1339, DOI 10.1126/science.abe1107; Oran DP, 2020, ANN INTERN MED, V173, P362, DOI 10.7326/M20-3012; Outlaw VK, 2020, MBIO, V11, DOI 10.1128/mBio.01935-20; Padron-Regalado E, 2020, INFECT DIS THER, V9, P255, DOI 10.1007/s40121-020-00300-x; Nguyen-Contant P, 2020, MBIO, V11, DOI 10.1128/mBio.01991-20; Pleguezuelos O, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0174-9; Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Rausch JW, 2020, P NATL ACAD SCI USA, V117, P24614, DOI 10.1073/pnas.2017726117; Ren LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep11451; Robson B, 2020, COMPUT BIOL MED, V119, DOI 10.1016/j.compbiomed.2020.103670; Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618; Shrock E, 2020, SCIENCE, V370, P1058, DOI 10.1126/science.abd4250; Song Ge, 2020, bioRxiv, DOI [10.1101/2020.09.22.308965, 10.1038/s41467-021-23074-3]; Song HD, 2005, P NATL ACAD SCI USA, V102, P2430, DOI 10.1073/pnas.0409608102; Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775; Stamatatos Leonidas, 2021, medRxiv, DOI 10.1101/2021.02.05.21251182; Sun H, 2020, EMERG MICROBES INFEC, V9, P1238, DOI 10.1080/22221751.2020.1770631; Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792; Thomson EC., 2020, CIRCULATING SARS COV, DOI DOI 10.1101/2020.11.04.355842; VanPatten S, 2020, FUTURE MED CHEM, V12, P1647, DOI 10.4155/fmc-2020-0180; Vijgen L, 2005, VIROLOGY, V337, P85, DOI 10.1016/j.virol.2005.04.010; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114; Wang L, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12111289; Wang LF, 2019, CURR OPIN VIROL, V34, P79, DOI 10.1016/j.coviro.2018.12.007; Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Wei CC, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-020-01811-5; Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x; Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2; Xia XH, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010109; Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762; Yi ZG, 2020, EMERG MICROBES INFEC, V9, P1988, DOI 10.1080/22221751.2020.1815591; Yu F, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00318-0; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721; Zheng ZQ, 2020, EUROSURVEILLANCE, V25, P19, DOI 10.2807/1560-7917.ES.2020.25.28.2000291; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zhu YM, 2020, J VIROL, V94, DOI 10.1128/JVI.00635-20; Zost SJ, 2020, NATURE, V584, P443, DOI 10.1038/s41586-020-2548-6	78	1	1	4	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							178	10.3390/vaccines9020178			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6QA	33672450	Green Published, gold			2022-04-29	WOS:000623265000001
J	Sallam, M				Sallam, Malik			COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates	VACCINES			English	Review						vaccine hesitancy; vaccine acceptance; anti-vaccination; vaccination coverage rates; COVID-19; coronavirus; SARS-CoV-2; vaccine rejection	CONFIDENCE	Utility of vaccine campaigns to control coronavirus 2019 disease (COVID-19) is not merely dependent on vaccine efficacy and safety. Vaccine acceptance among the general public and healthcare workers appears to have a decisive role in the successful control of the pandemic. The aim of this review was to provide an up-to-date assessment of COVID-19 vaccination acceptance rates worldwide. A systematic search of the peer-reviewed English survey literature indexed in PubMed was done on 25 December 2020. Results from 31 peer-reviewed published studies met the inclusion criteria and formed the basis for the final COVID-19 vaccine acceptance estimates. Survey studies on COVID-19 vaccine acceptance rates were found from 33 different countries. Among adults representing the general public, the highest COVID-19 vaccine acceptance rates were found in Ecuador (97.0%), Malaysia (94.3%), Indonesia (93.3%) and China (91.3%). However, the lowest COVID-19 vaccine acceptance rates were found in Kuwait (23.6%), Jordan (28.4%), Italy (53.7), Russia (54.9%), Poland (56.3%), US (56.9%), and France (58.9%). Only eight surveys among healthcare workers (doctors and nurses) were found, with vaccine acceptance rates ranging from 27.7% in the Democratic Republic of the Congo to 78.1% in Israel. In the majority of survey studies among the general public stratified per country (29/47, 62%), the acceptance of COVID-19 vaccination showed a level of >= 70%. Low rates of COVID-19 vaccine acceptance were reported in the Middle East, Russia, Africa and several European countries. This could represent a major problem in the global efforts to control the current COVID-19 pandemic. More studies are recommended to address the scope of COVID-19 vaccine hesitancy. Such studies are particularly needed in the Middle East and North Africa, Sub-Saharan Africa, Eastern Europe, Central Asia, Middle and South America. Addressing the scope of COVID-19 vaccine hesitancy in various countries is recommended as an initial step for building trust in COVID-19 vaccination efforts.	[Sallam, Malik] Univ Jordan, Sch Med, Dept Pathol Microbiol & Forens Med, Amman 11942, Jordan; [Sallam, Malik] Jordan Univ Hosp, Dept Clin Labs & Forens Med, Amman 11942, Jordan		Sallam, M (通讯作者)，Univ Jordan, Sch Med, Dept Pathol Microbiol & Forens Med, Amman 11942, Jordan.; Sallam, M (通讯作者)，Jordan Univ Hosp, Dept Clin Labs & Forens Med, Amman 11942, Jordan.	malik.sallam@ju.edu.jo	Sallam, Malik/O-5021-2014	Sallam, Malik/0000-0002-0165-9670			Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Altman D.G., 2009, PRISMA STATEMENT PLO, V6, DOI [10.1371/journal.pmed.1000097, DOI 10.1371/JOURNAL.PMED.1000097]; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; [Anonymous], 2019, LANCET CHILD ADOLESC, V3, P281, DOI 10.1016/S2352-4642(19)30092-6; Arede M, 2019, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00381; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Benecke Olivia, 2019, Glob Pediatr Health, V6, p2333794X19862949, DOI 10.1177/2333794X19862949; Billah MA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242128; Borba RCN, 2015, AN ACAD BRAS CIENC, V87, P1311, DOI 10.1590/0001-3765201520140663; Britton T, 2020, SCIENCE, V369, P846, DOI 10.1126/science.abc6810; Browne M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132562; Calina D, 2020, INT J MOL MED, V46, P3, DOI 10.3892/ijmm.2020.4596; Conte C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020309; Dabak S.V., 2020, COVID VACCINATION LO; Daley MF, 2018, AM J PREV MED, V55, P44, DOI 10.1016/j.amepre.2018.04.010; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212; European Centre for Disease Prevention and Control, THREAT ASS BREIF RAP; Feng S, 2020, LANCET RESP MED, V8, P434, DOI 10.1016/S2213-2600(20)30134-X; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; Gowda C, 2013, HUM VACC IMMUNOTHER, V9, P1755, DOI 10.4161/hv.25085; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Grech Victor, 2020, Early Hum Dev, P105258, DOI 10.1016/j.earlhumdev.2020.105258; Grech Victor, 2020, Early Hum Dev, P105259, DOI 10.1016/j.earlhumdev.2020.105259; Grech Victor, 2020, Early Hum Dev, P105213, DOI 10.1016/j.earlhumdev.2020.105213; Grubaugh ND, 2020, CELL, V182, P794, DOI 10.1016/j.cell.2020.06.040; Habersaat KB, 2020, NAT HUM BEHAV, V4, P677, DOI 10.1038/s41562-020-0906-x; Hamadani JD, 2020, LANCET GLOB HEALTH, V8, pE1380, DOI 10.1016/S2214-109X(20)30366-1; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3; Head KJ, 2020, SCI COMMUN, V42, P698, DOI 10.1177/1075547020960463; Hornsey MJ, 2018, HEALTH PSYCHOL, V37, P307, DOI 10.1037/hea0000586; Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061; Karlsson LC, 2021, PERS INDIV DIFFER, V172, DOI 10.1016/j.paid.2020.110590; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Kumar D, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0062-y; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; La Vecchia C, 2020, MED LAV, V111, P445, DOI 10.23749/mdl.v111i6.10813; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nguyen LH, 2020, LANCET PUBLIC HEALTH, V5, pE475, DOI 10.1016/S2468-2667(20)30164-X; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Nie Q, 2020, VIRUS RES, V287, DOI 10.1016/j.virusres.2020.198098; Nyhan B, 2018, J POLIT, V80, P1400, DOI 10.1086/698663; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Olagoke AA, 2021, J RELIG HEALTH, V60, P65, DOI 10.1007/s10943-020-01090-9; Olson O, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040590; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Pelcic G, 2016, CROAT MED J, V57, P516, DOI 10.3325/cmj.2016.57.516; Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Pomares TD, 2020, HUM VACC IMMUNOTHER, V16, P1018, DOI 10.1080/21645515.2019.1698243; Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Reuben RC, 2021, J COMMUN HEALTH, V46, P457, DOI 10.1007/s10900-020-00881-1; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; SAGE Working Group on Vaccine Hesitancy, REP SAGE WORK GROUP; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Sallam M, 2021, HELIYON, V7, DOI 10.1016/j.heliyon.2021.e06035; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Sallam M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243264; Sallam M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144915; Salmon DA, 2015, AM J PREV MED, V49, pS391, DOI 10.1016/j.amepre.2015.06.009; Sarasty O, 2020, VACCINE, V38, P8090, DOI 10.1016/j.vaccine.2020.11.013; Sharma O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585354; Shaukat N, 2020, INT J EMERG MED, V13, DOI 10.1186/s12245-020-00299-5; Shay DK., 2018, AM J PUBLIC HEALTH, V108, pS445, DOI [10.2105/AJPH.2013.301704r, DOI 10.2105/AJPH.2013.301704R]; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Taylor S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.575950; The All-Party Parliamentary Group (APPG) on Vaccinations for All, NEXT DEC VACC ADDR C; Viner RM, 2020, LANCET CHILD ADOLESC, V4, P397, DOI 10.1016/S2352-4642(20)30095-X; Wagner AL, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040155; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; Weintraub RL, 2021, HEALTH AFFAIR, V40, P33, DOI 10.1377/hlthaff.2020.01523; Wellcome Global Monitor, DOES WORLD FEEL SCI; Wise J, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4857; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P1511, DOI 10.1080/21645515.2019.1706935; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; World Health Organization, COVID 19 WEEKL EP UP; World Health Organization, DRAFT LANDSC COVID 1; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018; Zhang KC, 2020, JMIR PEDIATR PARENT, V3, DOI 10.2196/24827	102	373	377	86	155	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							160	10.3390/vaccines9020160			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO7CB	33669441	gold, Green Published	Y	Y	2022-04-29	WOS:000623296800001
J	Hayat, M; Yusoff, MSM; Samad, MJ; Razak, ISA; Yasin, ISM; Thompson, KD; Hasni, K				Hayat, Mohammad; Mohd Yusoff, Md Sabri; Samad, Mohd Jamil; Abdul Razak, Intan Shameha; Md Yasin, Ina Salwany; Thompson, Kim D.; Hasni, Khalil			Efficacy of Feed-Based Formalin-Killed Vaccine of Streptococcus iniae Stimulates the Gut-Associated Lymphoid Tissues and Immune Response of Red Hybrid Tilapia	VACCINES			English	Article						oral vaccination; Streptococcus iniae; red hybrid tilapia; IgM; gut-associated lymphoid tissue; formalin-killed oral vaccine	NILE TILAPIA; OREOCHROMIS-NILOTICUS; CHANNEL CATFISH; PCR ASSAY; AGALACTIAE; IDENTIFICATION; CANDIDATE; INFECTION; ANTIGEN; PROTEIN	Red hybrid tilapia were fed a formalin-killed oral Streptococcus iniae vaccine (FKV) in the present study was assessed. Three hundred Red hybrid tilapia 80 +/- 10 g were divided into five groups (1A, 1B, 2A, 2B, and Cx), each consisting of 60 fish. Fish from Groups 1A, 1B, 2A, and 2B were fed with FKV over different periods of administration, while Group 2B was the only group of fish to receive an oral booster vaccination on day 14- and 21-days post-vaccination (dpv). Group Cx was fed with normal pellets containing no vaccine as a control group. At four weeks post-vaccination (wpv), all fish were experimentally infected with S. iniae. Groups 2A and 2B had the lowest level of mortalities following vaccination (45% and 30%, respectively) compared to Groups 1A and 1B (80% and 55%, respectively), while the level of mortalities in Group Cx was 100%. All vaccinated groups showed a significant increase in anti-S. iniae IgM levels (p < 0.05) in serum, mucus, and gut-lavage, while Group Cx did not (p > 0.05) and all fish in this group died by five weeks post-infection. In conclusion, fish fed with the S. iniae FKV had a greater level of protection against S. iniae, with increased specific antibody response to the vaccine and there was also evidence of GALT stimulation by the vaccine.	[Hayat, Mohammad; Mohd Yusoff, Md Sabri; Samad, Mohd Jamil] Univ Putra Malaysia, Fac Vet Med, Dept Vet Pathol & Microbiol, Upm Serdang 43400, Selangor, Malaysia; [Mohd Yusoff, Md Sabri; Md Yasin, Ina Salwany] Univ Putra Malaysia, Inst Biosci, Aquat Anim Hlth & Therapeut Lab, Upm Serdang 43400, Selangor, Malaysia; [Abdul Razak, Intan Shameha] Univ Putra Malaysia, Fac Vet Med, Dept Preclin Sci, Upm Serdang 43400, Selangor, Malaysia; [Md Yasin, Ina Salwany] Univ Putra Malaysia, Fac Vet Med, Dept Aquaculture, Upm Serdang 43400, Selangor, Malaysia; [Thompson, Kim D.] Moredun Res Inst, Aquaculture Res Grp, Pentland Sci Pk, Penicuik EH26 0PZ, Midlothian, Scotland; [Hasni, Khalil] Lasbela Univ Agr Water & Marine Sci, Fac Marine Sci, Uthal Dist Lasbela 90150, Balochistan, Pakistan		Yusoff, MSM (通讯作者)，Univ Putra Malaysia, Fac Vet Med, Dept Vet Pathol & Microbiol, Upm Serdang 43400, Selangor, Malaysia.; Yusoff, MSM (通讯作者)，Univ Putra Malaysia, Inst Biosci, Aquat Anim Hlth & Therapeut Lab, Upm Serdang 43400, Selangor, Malaysia.	hayatvet91@gmail.com; mdsabri@upm.edu.my; mjamil@upm.edu.my; intanshameha@upm.edu.my; salwany@upm.edu.my; kim.thompson@moredun.ac.uk; khalil_hasni1@yahoo.com	; Thompson, Kim/O-7707-2015	Md Yasin, Ina Salwany/0000-0003-2905-2915; Thompson, Kim/0000-0003-3550-4842; Abdul Razak, Intan Shameha/0000-0001-6787-3621	Universiti Putra Malaysia (UPM) [RUGS 9586100]	This research was funded by the Research Univesity Grant Scheme (RUGS 9586100), Universiti Putra Malaysia (UPM). We thank all staff of the Histopathology Laboratory and Aquatic Animal Health Unit, Faculty of Veterinary Medicine, UPM, for their excellent technical assistance.	Abdullah Syuhaidah, 2013, Springerplus, V2, P286, DOI 10.1186/2193-1801-2-286; Agnew W, 2007, VET MICROBIOL, V122, P1, DOI 10.1016/j.vetmic.2007.03.002; Al-Harbi AH, 2011, AQUACULTURE, V312, P15, DOI 10.1016/j.aquaculture.2010.12.014; Alcamo I.E., 1997, FUNDAMENTALS MICROBI, P766; Amal M. N. A., 2010, ONLINE J VET RES, V14, P153; Anshary H, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-627; Chettri JK, 2015, FISH SHELLFISH IMMUN, V44, P485, DOI 10.1016/j.fsi.2015.03.003; Chettri JK, 2013, VET IMMUNOL IMMUNOP, V154, P42, DOI 10.1016/j.vetimm.2013.04.001; Costa-Pierce BA, 2003, BIOL INVASIONS, V5, P71, DOI 10.1023/A:1024094606326; El Aamri F, 2010, J FISH DIS, V33, P901, DOI 10.1111/j.1365-2761.2010.01191.x; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Fawzy N, 2014, LIFE SCI J, V11, P1005; Figueiredo HCP, 2006, ARQ BRAS MED VET ZOO, V58, P678, DOI 10.1590/S0102-09352006000400036; Firdaus-Nawi M., 2011, Pertanika Journal of Tropical Agricultural Science, V34, P137; Firdaus-Nawi M, 2013, AQUAC RES, V45, P87, DOI 10.1111/j.1365-2109.2012.03207.x; Garcia JC, 2008, AQUACULTURE, V281, P151, DOI 10.1016/j.aquaculture.2008.05.028; Grabowski LD, 2004, J FISH DIS, V27, P573, DOI 10.1111/j.1365-2761.2004.00576.x; Holten-Andersen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049672; Huang T, 2019, FISH SHELLFISH IMMUN, V87, P714, DOI 10.1016/j.fsi.2019.02.003; Islam MA, 2019, BIOMATERIALS, V192, P75, DOI 10.1016/j.biomaterials.2018.10.041; Ismail MS, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0834-1; Kaattari S. L., 1996, The fish immune system: organism, pathogen, and environment, P207; Kahieshesfandiari M, 2019, AQUACULT INT, V27, P817, DOI 10.1007/s10499-019-00372-8; Kayansamruaj P, 2017, AQUAC RES, V48, P711, DOI 10.1111/are.12917; Kim Sae-Hae, 2012, Immune Netw, V12, P165, DOI 10.4110/in.2012.12.5.165; Klesius PH, 2008, 8 INT S TIL AQ CAIR, P83; Lokka G, 2016, DEV COMP IMMUNOL, V64, P138, DOI 10.1016/j.dci.2016.02.014; Mata AI, 2004, VET MICROBIOL, V101, P109, DOI 10.1016/j.vetmic.2004.03.012; Nur-Nazifah M, 2014, FISH SHELLFISH IMMUN, V37, P193, DOI 10.1016/j.fsi.2014.01.011; Ortega C, 2018, J FISH DIS, V41, P773, DOI 10.1111/jfd.12775; Parra D, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00354; Pereira UD, 2013, STAND GENOMIC SCI, V8, P188, DOI 10.4056/sigs.3687314; Phuong N.M., 2016, CAN THO U J SCI, V2, P84; Rahmatullah M, 2017, J AQUAT ANIM HEALTH, V29, P208, DOI 10.1080/08997659.2017.1360411; Rodkhum C, 2012, THAI J VET MED, V42, P153; Rombout JHWM, 2014, FISH VACCINATION, P56; Rombout JHWM, 2014, FISH SHELLFISH IMMUN, V40, P634, DOI 10.1016/j.fsi.2014.08.020; Salinas I, 2011, DEV COMP IMMUNOL, V35, P1346, DOI 10.1016/j.dci.2011.11.009; Shelby RA, 2002, J FISH DIS, V25, P1, DOI 10.1046/j.1365-2761.2002.00327.x; Shelby Richard A., 2001, Journal of Applied Aquaculture, V11, P35, DOI 10.1300/J028v11n03_03; Shoemaker CA, 2001, AM J VET RES, V62, P174, DOI 10.2460/ajvr.2001.62.174; Siti-Zahrah A., 2004, P 7 AS FISH FOR 04 T, P129; Tacchi L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6205; Tafalla C, 2013, FISH SHELLFISH IMMUN, V35, P1740, DOI 10.1016/j.fsi.2013.02.029; Wang EL, 2018, FISH SHELLFISH IMMUN, V73, P262, DOI 10.1016/j.fsi.2017.12.034; Wang J, 2014, FISH SHELLFISH IMMUN, V40, P392, DOI 10.1016/j.fsi.2014.07.028; Zhang Z, 2017, FISH SHELLFISH IMMUN, V63, P255, DOI 10.1016/j.fsi.2017.02.019; Zhou SM, 2011, J FISH DIS, V34, P265, DOI 10.1111/j.1365-2761.2010.01233.x	48	1	1	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							51	10.3390/vaccines9010051			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6WR	33466950	gold, Green Published			2022-04-29	WOS:000610813000001
J	Musico, A; Frigerio, R; Mussida, A; Barzon, L; Sinigaglia, A; Riccetti, S; Gobbi, F; Piubelli, C; Bergamaschi, G; Chiari, M; Gori, A; Cretich, M				Musico, Angelo; Frigerio, Roberto; Mussida, Alessandro; Barzon, Luisa; Sinigaglia, Alessandro; Riccetti, Silvia; Gobbi, Federico; Piubelli, Chiara; Bergamaschi, Greta; Chiari, Marcella; Gori, Alessandro; Cretich, Marina			SARS-CoV-2 Epitope Mapping on Microarrays Highlights Strong Immune-Response to N Protein Region	VACCINES			English	Article						SARS-CoV-2; Covid-19; serological test; epitope mapping; peptide microarrays; click chemistry		A workflow for rapid SARS-CoV-2 epitope discovery on peptide microarrays is herein reported. The process started with a proteome-wide screening of immunoreactivity based on the use of a high-density microarray followed by a refinement and validation phase on a restricted panel of probes using microarrays with tailored peptide immobilization through a click-based strategy. Progressively larger, independent cohorts of Covid-19 positive sera were tested in the refinement processes, leading to the identification of immunodominant regions on SARS-CoV-2 spike (S), nucleocapsid (N) protein and Orf1ab polyprotein. A summary study testing 50 serum samples highlighted an epitope of the N protein (region 155-71) providing good diagnostic performance in discriminating Covid-19 positive vs. healthy individuals. Using this epitope, 92% sensitivity and 100% specificity were reached for IgG detection in Covid-19 samples, and no cross-reactivity with common cold coronaviruses was detected. Likewise, IgM immunoreactivity in samples collected within the first month after symptoms onset showed discrimination ability. Overall, epitope 155-171 from N protein represents a promising candidate for further development and rapid implementation in serological tests.	[Musico, Angelo; Frigerio, Roberto; Mussida, Alessandro; Bergamaschi, Greta; Chiari, Marcella; Gori, Alessandro; Cretich, Marina] CNR, Natl Res Council Italy, Ist Sci & Tecnol Chimiche Giulio Natta, SCITEC, Via Mario Bianco 9, I-20131 Milan, Italy; [Barzon, Luisa; Sinigaglia, Alessandro; Riccetti, Silvia] Univ Padua, Dept Mol Med, Via Gabelli 63, I-35121 Padua, Italy; [Gobbi, Federico; Piubelli, Chiara] IRCCS Sacro Cuore Don Calabria Hosp, Dept Infect Trop Dis & Microbiol, Via Don A Sempreboni 5, I-37024 Negrar Di Valpolicella, Italy		Gori, A; Cretich, M (通讯作者)，CNR, Natl Res Council Italy, Ist Sci & Tecnol Chimiche Giulio Natta, SCITEC, Via Mario Bianco 9, I-20131 Milan, Italy.	angelo.musico94@gmail.com; roberto.frigerio94@gmail.com; alessandro.mussida@scitec.cnr.it; luisa.barzon@unipd.it; alessandro.sinigaglia@unipd.it; silvia.riccetti@unipd.it; federico.gobbi@sacrocuore.it; chiara.piubelli@sacrocuore.it; greta.bergamaschi@cnr.it; marcella.chiari@cnr.it; alessandro.gori@cnr.it; marina.cretich@cnr.it	Barzon, Luisa/K-7961-2016; Bergamaschi, Greta/O-5387-2018; Cretich, Marina/AAA-8780-2022; Piubelli, Chiara/AAM-7183-2021; Gori, Alessandro/A-1357-2019	Barzon, Luisa/0000-0003-0720-8456; Bergamaschi, Greta/0000-0002-4501-4057; Cretich, Marina/0000-0001-8251-5275; Piubelli, Chiara/0000-0002-5739-3795; Gori, Alessandro/0000-0003-1640-7238; Musico, Angelo/0000-0001-6193-4366	Regione Lombardia, project READY (Regional Network for developing diagnostic methods in rapid response to emerging epidemics and bio-emergencies) [229472]; European UnionEuropean Commission [874735]; Italian Ministry of Health "Fondi Ricerca corrente-L1P5	Work partially funded by Regione Lombardia, project READY (Regional Network for developing diagnostic methods in rapid response to emerging epidemics and bio-emergencies) ID 229472, and by the European Union's Horizon 2020 research and innovation programme, under grant agreement no. 874735 (project VEO). The work performed at IRCCS Sacro Cuore Don Calabria Hospital was supported by the Italian Ministry of Health "Fondi Ricerca corrente-L1P5.	[Anonymous], 2005, EBIOMEDICINE, DOI DOI 10.1086/430355; [Anonymous], 2009, TALANTA, DOI DOI 10.1021/AC900658C; [Anonymous], 2018, BIOCONJUGATE CHEM, DOI DOI 10.1021/ACSINFECDIS.8B00014; [Anonymous], 2020, EMERG INFECT DIS, DOI DOI 10.1016/J.EBIOM.2020.102911; [Anonymous], 2014, ANAL CHEM, DOI DOI 10.1016/J.SNB.2013.09.119; [Anonymous], 2015, ANALYST, DOI DOI 10.1074/MCP.M114.045906; [Anonymous], 2020, CELL RES, DOI DOI 10.1038/S41467-020-16638-2; [Anonymous], 2020, NAT COMMUN, DOI DOI 10.1371/JOURNAL.PONE.0238089; [Anonymous], 2019, PLOS ONE, DOI DOI 10.1039/C9AN01142K; [Anonymous], 2020, CLIN INFECT DIS, DOI DOI 10.1101/2020.03.18.20038059; [Anonymous], 2019, MOL CELL PROTEOMICS, DOI DOI 10.3390/ANTIB8010023; [Anonymous], 2016, ANTIBODIES, DOI DOI 10.1021/ACS.BIOCONJCHEM.6B00426; [Anonymous], 2019, ANAL CHIM ACTA, DOI DOI 10.1016/J.TALANTA.2019.120152; Carter LJ, 2020, ACS CENTRAL SCI, V6, P591, DOI 10.1021/acscentsci.0c00501; Casalino Lorenzo, 2020, bioRxiv, DOI 10.1101/2020.06.11.146522; Gori A, 2017, ANAL CHIM ACTA, V983, P189, DOI 10.1016/j.aca.2017.06.027; Li Y, 2020, CELL MOL IMMUNOL, V17, P1095, DOI 10.1038/s41423-020-00523-5; Long QX., 2020, NATURE, V26, P845, DOI 10.1038/s41591-020-0897-1; Phelan AL, 2020, LANCET, V395, P1595, DOI 10.1016/S0140-6736(20)31034-5; Shrock E, 2020, SCIENCE, V370, P1058, DOI 10.1126/science.abd4250; Wang HY, 2020, ACS CENTRAL SCI, V6, P2238, DOI 10.1021/acscentsci.0c00742; Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461; Zhang BZ, 2020, CELL RES, V30, P702, DOI 10.1038/s41422-020-0366-x	23	14	15	5	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							35	10.3390/vaccines9010035			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PY2AF	33440622	gold, Green Published, Green Submitted			2022-04-29	WOS:000611850900001
J	Cheng, CJ; Lu, CY; Chang, YH; Sun, Y; Chu, HJ; Lee, CY; Liu, CH; Lin, CH; Lu, CJ; Li, CY				Cheng, Chang-Jie; Lu, Chun-Yi; Chang, Ya-Hui; Sun, Yu; Chu, Hai-Jui; Lee, Chun-Yu; Liu, Chang-Hsiu; Lin, Cheng-Huai; Lu, Chien-Jung; Li, Chung-Yi			Effectiveness of the WHO-Authorized COVID-19 Vaccines: A Rapid Review of Global Reports till 30 June 2021	VACCINES			English	Review						COVID-19; COVID-19 vaccines; SARS-CoV-2 variants	BNT162B2 VACCINE; INFECTION	Large clinical trials have proven the efficacy of the COVID-19 vaccine, and the number of studies about the effectiveness rapidly grew in the first half of the year after mass vaccination was administrated globally. This rapid review aims to provide evidence syntheses as a means to complement the current evidence on the vaccine effectiveness (VE) against various outcomes in real-world settings. Databases (PubMed, EMBASE, and MedRxiv) were searched up to 30 June 2021, (PROSPERO ID: 266866). A total of 39 studies were included, covering over 15 million participants from 11 nations. Among the general population being fully vaccinated, the VE against symptomatic SARS-CoV-2 infection was estimated at 89-97%, 92% (95% CI, 78-97%), and 94% (95% CI, 86-97%) for BNT162b2, ChAdOx1, and mRNA-1273, respectively. As for the protective effects against B.1.617.2-related symptomatic infection, the VE was 88% (95% CI, 85.3-90.1%) by BNT162b2 and 67.0% (95% CI, 61.3-71.8%) by ChAdOx1 after full vaccination. This review revealed a consistently high effectiveness of certain vaccines among the general population in real-world settings. However, scarce data on the major variants of SARS-CoV-2 and the shortness of the study time may limit the conclusions to the mRNA vaccines and ChAdOx1.	[Cheng, Chang-Jie; Sun, Yu; Chu, Hai-Jui; Lee, Chun-Yu; Liu, Chang-Hsiu; Lin, Cheng-Huai; Lu, Chien-Jung] En Chu Kong Hosp, Dept Neurol, New Taipei 237, Taiwan; [Cheng, Chang-Jie; Sun, Yu; Chu, Hai-Jui; Lee, Chun-Yu; Lu, Chien-Jung] Natl Taiwan Univ Hosp, Dept Neurol, Taipei 100, Taiwan; [Lu, Chun-Yi] Natl Taiwan Univ Hosp, Dept Pediat, Div Pediat Infect Dis, Taipei 100, Taiwan; [Lu, Chun-Yi] Natl Taiwan Univ, Coll Med, Taipei 100, Taiwan; [Chang, Ya-Hui; Li, Chung-Yi] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 701, Taiwan; [Li, Chung-Yi] China Med Univ, Coll Publ Hlth, Dept Publ Hlth, Taichung 404, Taiwan; [Li, Chung-Yi] Asia Univ, Coll Med & Hlth Sci, Dept Hlthcare Adm, Taichung 413, Taiwan		Sun, Y (通讯作者)，En Chu Kong Hosp, Dept Neurol, New Taipei 237, Taiwan.; Sun, Y (通讯作者)，Natl Taiwan Univ Hosp, Dept Neurol, Taipei 100, Taiwan.; Li, CY (通讯作者)，Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 701, Taiwan.; Li, CY (通讯作者)，China Med Univ, Coll Publ Hlth, Dept Publ Hlth, Taichung 404, Taiwan.; Li, CY (通讯作者)，Asia Univ, Coll Med & Hlth Sci, Dept Hlthcare Adm, Taichung 413, Taiwan.	117223@ntuh.gov.tw; cylu@ntu.edu.tw; t88071016@gs.ncku.edu.tw; 00034@km.eck.org.tw; 01480@km.eck.org.tw; 01548@km.eck.org.tw; 00520@km.eck.org.tw; 00202@km.eck.org.tw; 01181@km.eck.org.tw; cyli99@mail.ncku.edu.tw		Li, Chung-Yi/0000-0002-0321-8908; LU, CHUN-YI/0000-0002-5240-2808			Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; Amit S, 2021, LANCET, V397, P875, DOI 10.1016/S0140-6736(21)00448-7; Angel Y, 2021, JAMA-J AM MED ASSOC, V325, P2457, DOI 10.1001/jama.2021.7152; Azamgarhi T, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23927-x; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baum U, 2021, EFFECTIVENESS VACCIN, DOI [10.1101/2021, DOI 10.1101/2021.06.21.21258686]; Benenson S, 2021, NEW ENGL J MED, V384, P1775, DOI 10.1056/NEJMc2101951; Bernal J.L., 2021, EFFECTIVENESS BNT162, DOI [10.1101/2021.05.14.21257218, DOI 10.1101/2021.05.14.21257218]; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Bianchi FP, 2021, J INFECT DIS, V224, P431, DOI 10.1093/infdis/jiab262; Bj  ork J, 2021, MEDRXIV2021202125463, V2021, P2021, DOI [10.1101/2021.04.20.21254636, DOI 10.1101/2021.04.20.21254636V1]; Brockman Mark A, 2021, medRxiv, DOI 10.1101/2021.03.17.21253773; Canaday David H, 2021, medRxiv, DOI 10.1101/2021.03.19.21253920; Chodick G, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.15985; Chodick G, 2022, CLIN INFECT DIS, V74, P472, DOI 10.1093/cid/ciab438; Chung H., 2021, EFFECTIVENESS BNT162, DOI [10.2139/ssrn.3845993, DOI 10.2139/SSRN.3845993]; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Daniel W, 2021, NEW ENGL J MED, V384, P1962, DOI 10.1056/NEJMc2102153; De Faria E., 2021, PERFORMANCE VACCINAT, DOI [10.1101/2021.04.12.21255308, DOI 10.1101/2021.04.12.21255308]; Emborg H.D., 2021, VACCINE EFFECTIVENES, DOI [10.1101/2021.05.27.21257583, DOI 10.1101/2021.05.27.21257583]; Fabiani M, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.17.2100420; Farhaan SV, 2021, REAL WORLD EFFECTIVE, V2021, DOI [10.1101/2021.04.21.21255873, DOI 10.1101/2021.04.21.21255873]; Flacco ME, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060628; Glampson B., 2021, N W LONDON COVID 19, DOI [10.1101/2021.04.08.21254580, DOI 10.1101/2021.04.08.21254580]; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Hitchings MDT., 2021, LANCET REG HLTH AM, P100025, DOI [10.1016/j.lana.2021.100025, DOI 10.1016/J.LANA.2021.100025]; Iacobucci Gareth, 2021, BMJ, V372, pn18, DOI 10.1136/bmj.n18; Jones NK, 2021, ELIFE, V10, DOI 10.7554/eLife.68808; Ledford H, 2021, NATURE, V594, P164, DOI 10.1038/d41586-021-01505-x; Lenehan P., 2021, REAL WORLD EFFECTIVE, DOI [10.2139/ssrn.3835737, DOI 10.2139/SSRN.3835737]; Lopez Bernal J, 2021, EARLY EFFECTIVENESS, V2021, DOI 10.1101/2021.03.01.21252652; Lumley SF, 2022, CLIN INFECT DIS, V74, P1208, DOI 10.1093/cid/ciab608; Mazagatos C, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.24.2100452; Moustsen-Helms I.R., 2021, VACCINE EFFECTIVENE, DOI [10.1101/2021.03.08.21252200, DOI 10.1101/2021.03.08.21252200]; Muller-Sedgwick U, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n522; Page MJ, 2021, J CLIN EPIDEMIOL, V134, P103, DOI 10.1016/j.jclinepi.2021.02.003; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n71; Pawlowski C, 2021, MED-CAMBRIDGE, V2, P979, DOI 10.1016/j.medj.2021.06.007; Pilishvili T, 2021, MMWR-MORBID MORTAL W, V70, P753, DOI 10.15585/mmwr.mm7020e2externalicon; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pritchard E, 2021, NAT MED, V27, P1370, DOI 10.1038/s41591-021-01410-w; Ranzani O, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2015; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Shrestha N.K., 2021, EFFECTIVENESS MRNA C, DOI [10.1101/2021.06.02.21258231, DOI 10.1101/2021.06.02.21258231]; Shrotri M, 2021, LANCET INFECT DIS, V21, P1529, DOI 10.1016/S1473-3099(21)00289-9; Skowronski D.M., 2021, SINGLE DOSE MRNA VAC, DOI [10.1101/2021.06.07.21258332, DOI 10.1101/2021.06.07.21258332V1]; Swift M.D., 2021, CLIN INFECT DIS, V73, pe1376, DOI [10.1093/cid/ciab361, DOI 10.1093/cid/ciab361]; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Teo SP, 2021, ANN GERIATR MED RES, V25, P4, DOI 10.4235/agmr.21.0011; Thompson MG, 2021, NEW ENGL J MED, V385, P320, DOI 10.1056/NEJMoa2107058; Van Praet JT, 2021, CLIN INFECT DIS, V73, P2145, DOI 10.1093/cid/ciab300; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1	56	2	2	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1489	10.3390/vaccines9121489			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YG3EP	34960235	Green Submitted, Green Published, gold			2022-04-29	WOS:000742375600001
J	Gawel, A; Mandziuk, M; Zmudzinski, M; Gosek, M; Krawczyk-Suszek, M; Pisarski, M; Adamski, A; Cyganik, W				Gawel, Arkadiusz; Mandziuk, Marzena; Zmudzinski, Marek; Gosek, Malgorzata; Krawczyk-Suszek, Marlena; Pisarski, Mariusz; Adamski, Andrzej; Cyganik, Weronika			Effects of Pope Francis' Religious Authority and Media Coverage on Twitter User's Attitudes toward COVID-19 Vaccination	VACCINES			English	Article						pope francis; COVID-19; SARS-CoV2; vaccines; Twitter; sentiment analysis; media and communication studies; catholic theology; religion leadership; social media; papal infallibility; mediatization of religion	VACCINES; 2019-NCOV; INTENTION; THREAT; HEALTH; IMPACT	This paper is interdisciplinary and combines the research perspective of medical studies with that of media and social communication studies and theological studies. The main goal of this article is to determine [from arguments on all sides of the issue] whether, and to what extent, statements issued by a religious authority can be used as an argument in the COVID-19 vaccination campaign. The authors also want to find answers to the questions of how the pope's comments affect public opinion when they concern the sphere of secular and everyday life, including issues related to health care. The main method used in this study is desktop research and the analysis of the Roman Catholic Church's teaching on vaccination and on the types and significance of the pope's statements on various topics. The auxiliary methods are sentiment analysis and network analysis made in the open source software Gephi. The authors are strongly interested in the communication and media aspect of the analyzed situation. Pope Francis' voice on the COVID-19 vaccination has certainly been noticed and registered worldwide, but the effectiveness of his message and direct impact on Catholics' decisions to accept or refuse the COVID-19 vaccination is quite questionable and would require further precise research. Comparing this to the regularities known from political marketing, one would think that the pope's statement would not convince the firm opponents of vaccination.	[Gawel, Arkadiusz] Univ Informat Technol & Management Rzeszow, Coll Appl Informat, 2 Sucharskiego Str, PL-35225 Rzeszow, Poland; [Mandziuk, Marzena; Krawczyk-Suszek, Marlena; Cyganik, Weronika] Univ Informat Technol & Management Rzeszow, Med Coll, 2 Sucharskiego Str, PL-35225 Rzeszow, Poland; [Zmudzinski, Marek] Univ Warm & Mazury Olsztyn, Fac Theol, Ul Oczapowskiego 2, PL-10719 Olsztyn, Poland; [Gosek, Malgorzata] Univ Informat Technol & Management Rzeszow, Inst Educ Anal, Coll Media & Social Commun, 2 Sucharskiego Str, PL-35225 Rzeszow, Poland; [Pisarski, Mariusz; Adamski, Andrzej] Univ Informat Technol & Management Rzeszow, Coll Med & Social Commun, Ul Sucharskiego 2, PL-35225 Rzeszow, Poland		Adamski, A (通讯作者)，Univ Informat Technol & Management Rzeszow, Coll Med & Social Commun, Ul Sucharskiego 2, PL-35225 Rzeszow, Poland.	agawel@wsiz.edu.pl; mmandziuk@wsiz.edu.pl; marek.zmudzinski@uwm.edu.pl; mgosek@wsiz.edu.pl; mkrawczyk@wsiz.edu.pl; mpisarski@wsiz.edu.pl; aadamski@wsiz.edu.pl; wcyganik@wsiz.edu.pl	Krawczyk-Suszek, Marlena/AAA-8396-2022; Adamski, Andrzej/AAC-6313-2021	Krawczyk-Suszek, Marlena/0000-0003-4100-588X; Adamski, Andrzej/0000-0002-4075-4224; Mandziuk, Marzena/0000-0001-6204-2335; Cyganik, Weronika/0000-0002-5517-7896; Pisarski, Mariusz/0000-0001-7038-0166			Abbas Y, 2020, ACS APPL NANO MATER, V3, P11383, DOI 10.1021/acsanm.0c02466; Adamski A., 2013, DIALOG WIARY NAUK KU, P41; Adamski A, 2020, RELIGIONS, V11, DOI 10.3390/rel11040190; Alenezi MN, 2021, FUTURE INTERNET, V13, DOI 10.3390/fi13100244; [Anonymous], Pope Francis and the Pope Emeritus Receive COVID-19 Vaccine; [Anonymous], VATICAN OBLIGE TRAVE; [Anonymous], A Phase III Randomized Double-Blind Placebo-Controlled Multicenter Study in Adults to Determine the Safety Efficacy and Immunogenicity of AZD1222 a Non-Replicating ChAdOx1 Vector Vaccine for the Prevention of COVID-19; [Anonymous], Papiez Zacheca do Szczepien i Zapowiada Kiedy sam sie Zaszczepi; [Anonymous], KOMUNIKAT MINISTRA Z; [Anonymous], COVID-19: Decree on Rules for Entry into the Vatican Published; [Anonymous], Pope Francis Urges People to Get Vaccinated against COVID-19; [Anonymous], 2014, 572014 FUND CTR BAD, P1; [Anonymous], RAPORT ZAKAZEN KORON; [Anonymous], 2020, NCT04368988 EVALUATI; [Anonymous], EMA Starts Rolling Review of COVID-19 Vaccine (Vero Cell) Inactivated; [Anonymous], Vatican: No Punishment for Those Who Refuse COVID-19 Vaccine; [Anonymous], Oxford Word of the Year 2016; [Anonymous], EMA recommends first COVID-19 vaccine for authorisation in the EU; [Anonymous], 2020, NOTE MORALITY USING; [Anonymous], Dla Kogo Trzecia Dawka Szczepionki; [Anonymous], EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU; [Anonymous], NEW YORK TIMES; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bartnik C., 1982, KOSCIOL JEZUSA CHRYS, P369; Bartnik C., 2003, DOGMATYKA KATOLICKA, VII, P239; Bednarczyk RA, 2017, AM J BIOETHICS, V17, P50, DOI 10.1080/15265161.2017.1284932; Bollen J., 2011, Computer, V44, P91, DOI 10.1109/MC.2011.323; Bollen J., 2009, MODELING PUBLIC MOOD; Bollen J, 2011, J COMPUT SCI-NETH, V2, P1, DOI 10.1016/j.jocs.2010.12.007; Britton A, 2021, MMWR-MORBID MORTAL W, V70, P396, DOI 10.15585/mmwr.mm7011e3; Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567; Bylina S, 2020, EUR J SCI THEOL, V16, P53; Card LF, 2021, LINACRE Q, V88, P114, DOI 10.1177/0024363921991263; Carson PJ, 2017, AM J BIOETHICS, V17, P36, DOI 10.1080/15265161.2017.1284914; Center of Countering Digital Hate, PAND PROF BUS ANT; CHMP, 2021, COVID 19 VACC MOD IN; Chung JY, 2021, ADV DRUG DELIVER REV, V170, P1, DOI 10.1016/j.addr.2020.12.011; Courth F., 1999, PODRECZNIK TEOLOGII, P498; Cramer H., 1946, MATH METHODS STAT; D'Andrea A., 2015, INT J COMPUT APPL, V125, P26, DOI [DOI 10.5120/IJCA2015905866, 10.5120/ijca2015905866]; Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575; EEAS SPECIAL REPORT UPDATE, SHORT ASS NARR DIS C; EMA, EMA REC APPL COND MA; Fani M, 2020, FUTURE VIROL, V15, P317, DOI 10.2217/fvl-2020-0050; Ferdek B., 2015, POZ STUD TEOL, V29, P183, DOI [10.14746/pst.2015.29.10, DOI 10.14746/PST.2015.29.10]; Fernandes N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101161; Fielding N.G., 2016, SAGE HDB ONLINE RES, P254; Grabenstein JD, 2013, VACCINE, V31, P2011, DOI 10.1016/j.vaccine.2013.02.026; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020; Guilford J.P., 1954, PSYCHOMETRIC METHODS; Guzik, 2018, CHURCH COMMUNICATION, V3, P106, DOI [10.1080/23753234.2018.1478230, DOI 10.1080/23753234.2018.1478230]; Han QM, 2020, J INFECTION, V80, P373, DOI 10.1016/j.jinf.2020.02.010; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Hu X., 2013, WSDM, P537; Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009; Imperial College London, COVID 19 GLOB ATT CO, P8; Jevtic M, 2007, POLIT RELIG J, V1, P59; Jones I, 2021, LANCET, V397, P642, DOI 10.1016/S0140-6736(21)00191-4; Jussila J, 2021, FUTURE INTERNET, V13, DOI 10.3390/fi13060157; Kashte S, 2021, HUM CELL, V34, P711, DOI 10.1007/s13577-021-00512-4; Kawka M., 2019, ROCZ MEDIOZNAWCZY, P9; Kelly CM, 2018, HORIZONS, V45, P287, DOI 10.1017/hor.2018.69; Koronawirus, PAP ZASZCZ COVID RP; Kosarkova A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101157; Krasinski J., 1998, KART MAGISTERIUM KOS; Landrum AR, 2020, WIRES CLIM CHANGE, V11, DOI 10.1002/wcc.674; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Leonowicz-Bukala I, 2021, RELIGIONS, V12, DOI 10.3390/rel12060421; Luno Angel Rodriguez, 2006, Natl Cathol Bioeth Q, V6, P453; Lyon A.J., 2018, FRANCIS GLOBAL ACTOR; Machingaidze S, 2021, NAT MED, V27, P1338, DOI 10.1038/s41591-021-01459-7; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; Meraz S, 2013, INT J PRESS/POLIT, V18, P138, DOI 10.1177/1940161212474472; Moshirpour M., 2018, LECT NOTES SOCIAL NE, P29, DOI [10.1007/978-3-319-95810-1_4, DOI 10.1007/978-3-319-95810-1_4]; Mrozek A., 2018, STUD PAEDAGOG IGNATI, V20, P33, DOI [10.12775/SPI.2017.5.002, DOI 10.12775/SPI.2017.5.002]; mudzinsk M., 2006, STUDIA ELBLASKIE, V7, P125; Munster VJ, 2020, NEW ENGL J MED, V382, P692, DOI 10.1056/NEJMp2000929; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Nagy S., 1997, PAPIEZ KRAKOWA SZKIC; Neff T., 2021, HARV KENNEDY SCH MIS, V2, DOI [10.37016/mr-2020-82, DOI 10.37016/MR-2020-82]; O'Dea Bridianne, 2015, Internet Interventions, V2, P183, DOI 10.1016/j.invent.2015.03.005; Ott L., 1974, FUNDAMENTALS CATHOLI, P287; Palakeel J.S., 2019, CHURCH COMMUN CULT, V4, P248, DOI [10.1080/23753234.2019.1616582, DOI 10.1080/23753234.2019.1616582]; Pawelczyk P., 2017, SROD STUDIA POLIT, V1, P197, DOI [10.14746/ssp.2017.1.11, DOI 10.14746/SSP.2017.1.11]; Pelcic G, 2016, CROAT MED J, V57, P516, DOI 10.3325/cmj.2016.57.516; Raciborski F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9091000; Radzik R., 2018, POSTPRAWDA SPOJRZENI, P41; Roberts K, 2012, LREC 2012 - EIGHTH INTERNATIONAL CONFERENCE ON LANGUAGE RESOURCES AND EVALUATION, P3806; Ruijs WLM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-511; Rutten LJF, 2021, MAYO CLIN PROC, V96, P699, DOI 10.1016/j.mayocp.2020.12.024; Sadilek A, 2012, AAAI; Sadilek A, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0045-1; Saif Hassan, 2012, The Semantic Web. 11th International Semantic Web Conference (ISWC 2012). Proceedings, P508, DOI 10.1007/978-3-642-35176-1_32; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sawicka Zofia, 2019, SOCIAL COMMUNICATION, V2, P45, DOI [10.2478/sc-2019-0008, DOI 10.2478/SC-2019-0008]; Seweryniak H., 2010, TEOLOGIA FUNDAMENTAL, V2, P19; Stasiuk K, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080933; Stato D., 2021, 439 ORDINANZA PRESID; Subramanian SV, 2021, EUR J EPIDEMIOL, V36, P1237, DOI 10.1007/s10654-021-00808-7; Tay M.Z., TRINITY COVID 19 IMM; Tumasjan A, 2011, SOC SCI COMPUT REV, V29, P402, DOI 10.1177/0894439310386557; TYRRELL DAJ, 1965, BMJ-BRIT MED J, V1, P1467, DOI 10.1136/bmj.1.5448.1467; VanDam C, 2016, PROCEEDINGS OF THE 2016 ACM WEB SCIENCE CONFERENCE (WEBSCI'16), P370, DOI 10.1145/2908131.2908179; Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7; Weiler J., 2003, EUROPA CRISTIANA SAG; Wombwell E, 2015, J COMMUN HEALTH, V40, P597, DOI 10.1007/s10900-014-9956-1; Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9; Xin MQ, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101204; Zwolnienie za Brak Szczepienia, WAT SIE WYC RP PL	110	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1487	10.3390/vaccines9121487			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ2JZ	34960233	Green Published, gold			2022-04-29	WOS:000737485600001
J	Han, BF; Liu, W; Du, J; Liu, HY; Zhao, TS; Yang, SB; Wang, S; Zhang, SH; Liu, B; Liu, YQ; Cui, FQ				Han, Bingfeng; Liu, Wu; Du, Juan; Liu, Hanyu; Zhao, Tianshuo; Yang, Shubo; Wang, Shuai; Zhang, Sihui; Liu, Bei; Liu, Yaqiong; Cui, Fuqiang			12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial	VACCINES			English	Article						diabetes mellitus; hepatitis B vaccines; vaccination; persistent immunogenicity; revaccination	LONG-TERM EFFICACY; ANTIBODY-RESPONSE; ADULT-POPULATION; SURFACE ANTIBODY; PREVENTION; INFECTION; STANDARD; ANTIGEN; SAFETY; CHINA	Background: In initial studies, the immunogenicity and safety of hepatitis B vaccines in patients with diabetes has been assessed in China. Methods: In six township health centers in Gansu Province, 232 diabetic patients and 77 healthy people were allocated to receive two 3-dose hepatitis B vaccines (Group D20SC 0-1-6; Group D20CHO 0-1-6; Group ND20SC 0-1-6). Participants were followed up at 12 months after being fully vaccinated. One dose of the vaccine was randomly administered to non-responders. Chi-square test was used to compare the differences in response rate between two groups. Results: The anti-HBs response rates of three groups decreased from 84.1%, 89.1% and 88.3% at one month to 64.6%, 79.8% and 71.4% at twelve months. There was no statistical difference in the immune response rates between Group D20SC 0-1-6 and Group ND20SC 0-1-6; however, that of Group D20CHO 0-1-6 was higher than that of Group D20SC 0-1-6. After revaccination, the geometric mean concentrations were 491.7 mIU/mL and 29.7 mIU/mL after using vaccines containing 60 mu g and 20 mu g HBsAg. Conclusions: At 12 months, immune response in diabetic patients were not significantly different from that in healthy people. Revaccination with one dose of hepatitis B vaccine containing 60 mu g HBsAg for non-responders was more satisfactory.	[Han, Bingfeng; Liu, Hanyu; Zhao, Tianshuo; Zhang, Sihui] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China; [Liu, Wu; Yang, Shubo] Jingyuan Cty Ctr Dis Control & Prevent, Baiyin 730600, Peoples R China; [Du, Juan; Liu, Bei; Liu, Yaqiong; Cui, Fuqiang] Peking Univ, Dept Lab Sci & Technol, Sch Publ Hlth, Beijing 100191, Peoples R China; [Du, Juan; Liu, Bei; Liu, Yaqiong; Cui, Fuqiang] Peking Univ, Sch Publ Hlth, Vaccine Res Ctr, Beijing 100191, Peoples R China; [Wang, Shuai] Capital Med Univ, Beijing Chao Yang Hosp, Dept Infect Dis & Clin Microbiol, Beijing 100020, Peoples R China		Cui, FQ (通讯作者)，Peking Univ, Dept Lab Sci & Technol, Sch Publ Hlth, Beijing 100191, Peoples R China.; Cui, FQ (通讯作者)，Peking Univ, Sch Publ Hlth, Vaccine Res Ctr, Beijing 100191, Peoples R China.	hanbingfeng@pku.edu.cn; bysjyxjkzx1@163.com; juandu@bjmu.edu.cn; liuhanyuu@bjmu.edu.cn; ztshuoshuo@163.com; zhangsihui@bjmu.edu.cn; wangpkq@163.com; zhangsihui@bjmu.edu.cn; 1916387057@bjmu.edu.cn; liuyaqiong@bjmu.edu.cn; cuifuq@126.com			National Science and Technology Major Project on Infectious Diseases [2018ZX10721202]; Fundamental Research Funds for the Central Universities and Peking University Health Science Center [BMU20170607]	This work was supported by the National Science and Technology Major Project on Infectious Diseases (Funding number: 2018ZX10721202), and the Fundamental Research Funds for the Central Universities and Peking University Health Science Center (Funding number: BMU20170607).	ANDRE FE, 1989, AM J MED, V87, pS14, DOI 10.1016/0002-9343(89)90525-1; [Anonymous], 2019, Journal of Clinical Hepatology, V35, P2648; Centers for Disease Control and Prevention (CDC), 2011, MMWR Morb Mortal Wkly Rep, V60, P1709; Cocchio S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040323; Cui FQ, 2007, JAMA-J AM MED ASSOC, V298, P506; Cui FQ, 2017, EMERG INFECT DIS, V23, P765, DOI 10.3201/eid2305.161477; DERAVE S, 1994, VACCINE, V12, P532, DOI 10.1016/0264-410X(94)90313-1; EGEA E, 1991, J EXP MED, V173, P531, DOI 10.1084/jem.173.3.531; Feng YL, 2017, HUM VACC IMMUNOTHER, V13, P1297, DOI 10.1080/21645515.2017.1283082; Fisman DN, 2002, CLIN INFECT DIS, V35, P1368, DOI 10.1086/344271; Godkin A, 2005, HEPATOLOGY, V41, P1383, DOI 10.1002/hep.20716; Han B F, 2018, Zhonghua Yu Fang Yi Xue Za Zhi, V52, P748, DOI 10.3760/cma.j.issn.0253-9624.2018.07.013; Han BF, 2021, VACCINE, V39, P3365, DOI 10.1016/j.vaccine.2021.04.058; Hao GY, 2017, J MED VIROL, V89, P450, DOI 10.1002/jmv.24649; Hou JL, 2017, J CLIN TRANSL HEPATO, V5, P297, DOI 10.14218/JCTH.2016.00019; Kakisaka K, 2019, INTERNAL MED, V58, P2349, DOI 10.2169/internalmedicine.2231-18; Lee KH, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0924-7; Liang XF, 2009, VACCINE, V27, P6550, DOI 10.1016/j.vaccine.2009.08.048; Liu J., 2013, CHIN J VACCINES IMMU, V19, P142; Liu J, 2019, B WORLD HEALTH ORGAN, V97, P230, DOI [10.2471/BLT.18.219469, 10.2471/blt.18.219469]; Lu JJ, 2019, HUM VACC IMMUNOTHER, V15, P1171, DOI 10.1080/21645515.2018.1554972; Ma RCW, 2018, DIABETOLOGIA, V61, P1249, DOI 10.1007/s00125-018-4557-7; Pan HX, 2014, VACCINE, V32, P3706, DOI 10.1016/j.vaccine.2014.02.094; Qiu Y, 2016, HUM VACC IMMUNOTHER, V12, P773, DOI 10.1080/21645515.2015.1086519; Reilly Meredith L, 2012, J Diabetes Sci Technol, V6, P858; Ren W, 2020, HUM VACC IMMUNOTHER, V16, P687, DOI 10.1080/21645515.2019.1666612; Roznovsky L, 2010, INFECTION, V38, P395, DOI 10.1007/s15010-010-0039-7; Vargas JI, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.20929; Wang F, 2015, VACCINE, V33, P294, DOI 10.1016/j.vaccine.2014.11.029; Wang F, 2012, VACCINE, V30, P2051, DOI 10.1016/j.vaccine.2012.01.052; Wang H, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4428-y; WHO, KEY FACTS HEP B; World Hlth Org, 2019, VACCINE, V37, P223, DOI 10.1016/j.vaccine.2017.07.046; Wu W L, 2016, Zhonghua Yu Fang Yi Xue Za Zhi, V50, P484, DOI 10.3760/cma.j.issn.0253-9624.2016.06.003; [颜丙玉 Yan Bingyu], 2012, [中华流行病学杂志, Chinese Journal of Epidemiology], V33, P988; Yang LN, 2016, IMMUNOL RES, V64, P242, DOI 10.1007/s12026-015-8742-1; Yang SG, 2016, SCI REP-UK, V6, DOI 10.1038/srep27251; ZAJAC BA, 1986, J INFECTION, V13, P39, DOI 10.1016/S0163-4453(86)92668-X; Zhang H, 2011, INT J MED SCI, V8, P321, DOI 10.7150/ijms.8.321; Zhang L, 2015, HUM VACC IMMUNOTHER, V11, P2716, DOI 10.1080/21645515.2015.1045172; Zhang W, 2011, VACCINE, V29, P6276, DOI 10.1016/j.vaccine.2011.06.045; Zhang Wei, 2010, Zhonghua Yu Fang Yi Xue Za Zhi, V44, P918; Zhang Y, 2011, VACCINE, V29, P3905, DOI 10.1016/j.vaccine.2011.03.030	43	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1407	10.3390/vaccines9121407			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0CT	34960153	gold, Green Published			2022-04-29	WOS:000737331500001
J	Li, ZM; Sun, XY				Li, Zeming; Sun, Xinying			Analysis of the Impact of Media Trust on the Public's Motivation to Receive Future Vaccinations for COVID-19 Based on Protection Motivation Theory	VACCINES			English	Article						COVID-19; vaccination; motivation; media trust; protection motivation theory	MASS-MEDIA; VACCINE UPTAKE; EFFICACY; THREAT; MODEL; WILLINGNESS; INFORMATION; INTENTIONS; KNOWLEDGE; ROLES	Object: Media trust is one of the essential factors affecting health behavior. Based on the protection motivation theory (PMT), this study explores the impact of different public media trust (traditional media, social media, interpersonal communication) on future COVID-19 vaccine motivation. Methods: The online survey was conducted from 14 April to 30 April 2021, and 2098 adults were recruited to participate in the online survey through the Wenjuanxing online survey platform. The survey included the PMT constructs (threat appraisal, coping appraisal, and motivation for future COVID-19 vaccination), trust in different media, vaccine hesitation reasons, and implementation of other non-pharmaceutical interventions. Structural equation model (SEM) was used for latent variable analysis, and Spearman linear correlation coefficient matrix was used to explore the relationships between variables. Results: In terms of trust in different media, participants who had a higher education level (p = 0.038), who was married (p = 0.002), and who had not been vaccinated against COVID-19 during the survey (p = 0.002) show greater trust in traditional media. Participants who were married (p = 0.001), who had a relatively high income (p = 0.020), and who had not been vaccinated (p = 0.044) show greater trust in social media. Older participants (p < 0.001) and married (p < 0.001) showed greater trust in interpersonal communication. In the structural equation, trust in traditional media had a direct positive impact on perceived severity (beta = 0.172, p < 0.001) and a direct negative impact on internal rewards (beta = -0.061, p < 0.05). Trust in both traditional and social media separately had a direct positive impact on self-efficacy (beta = 0.327, p < 0.001; beta = 0.138, p < 0.001) and response efficiency (beta = 0.250, p < 0.001; beta = 0.097, p < 0.05) and a direct negative impact on response costs (beta = -0.329, p < 0.001; beta = -0.114, p < 0.001). Trust in interpersonal communication had a direct positive impact on external rewards (beta = 0.186, p < 0.001) and response costs (beta = 0.091, p < 0.001). Overall, traditional media trust had an indirect positive influence on vaccine motivation (beta = 0.311), social media trust had an indirect positive influence on vaccine motivation (beta = 0.110), and interpersonal communication had an indirect negative influence on vaccine motivation (beta = -0.022). Conclusion: This study supports the use of PMT as an intermediate variable to explore the effect of media trust on vaccination intention. High trust in traditional media has helped reduce vaccine hesitation, increased the public's future COVID-19 vaccination motivation, and maintained other non-pharmacological interventions. Social media also had a certain promotion effect on vaccine motivation. In this context, attention should also be paid to interpersonal communication, and the science publicity work was suggested for an individual's family members and friends in the future to improve the quality and ability of interpersonal communication.	[Li, Zeming; Sun, Xinying] Peking Univ, Sch Publ Hlth, Dept Social Med & Hlth Educ, Beijing 100191, Peoples R China		Sun, XY (通讯作者)，Peking Univ, Sch Publ Hlth, Dept Social Med & Hlth Educ, Beijing 100191, Peoples R China.	xysun@bjmu.edu.cn			China Association for Science and Technology [20200608CG080740]	FundingThis work was supported by the China Association for Science and Technology [No.20200608CG080740].	Abbas KM, 2018, PEERJ, V6, DOI 10.7717/peerj.5171; Ardevol-Abreu A, 2018, JOURNALISM, V19, P611, DOI 10.1177/1464884917700447; BALLROKEACH SJ, 1976, COMMUN RES, V3, P3, DOI 10.1177/009365027600300101; Bangerter A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049806; Beaudoin CE, 2007, AM J PREV MED, V32, P217, DOI 10.1016/j.amepre.2006.11.002; Biener L, 2006, AM J PREV MED, V30, P217, DOI 10.1016/j.amepre.2005.10.026; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Brainard J, 2020, SIMUL-T SOC MOD SIM, V96, P365, DOI 10.1177/0037549719885021; Caskey R, 2009, J ADOLESCENT HEALTH, V45, P453, DOI 10.1016/j.jadohealth.2009.04.021; Cates JR, 2010, J ADOLESCENT HEALTH, V47, P305, DOI 10.1016/j.jadohealth.2010.04.003; Chan EYY, 2015, VACCINE, V33, P4737, DOI 10.1016/j.vaccine.2015.07.046; Chen XW, 2018, J HEALTH COMMUN, V23, P724, DOI 10.1080/10810730.2018.1511658; Dutta-Bergman MJ, 2005, HEALTH COMMUN, V17, P1, DOI 10.1207/s15327027hc1701_1; Farooq A, 2020, J MED INTERNET RES, V22, DOI 10.2196/19128; FLORA JA, 1989, ANNU REV PUBL HEALTH, V10, P181; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Hilton S, 2011, J EPIDEMIOL COMMUN H, V65, P941, DOI 10.1136/jech.2010.119875; Ho SS, 2012, MASS COMMUN SOC, V15, P695, DOI 10.1080/15205436.2011.616275; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Johnson TJ, 1998, JOURNALISM MASS COMM, V75, P325, DOI 10.1177/107769909807500208; Kim J, 1999, POLIT COMMUN, V16, P361, DOI 10.1080/105846099198541; Kim J, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15040673; Kouzy R, 2020, CUREUS, V12, DOI 10.7759/cureus.7255; Krieger JL, 2013, HEALTH COMMUN, V28, P5, DOI 10.1080/10410236.2012.734914; Larson HJ, 2018, HUM VACC IMMUNOTHER, V14, P1599, DOI 10.1080/21645515.2018.1459252; Liao QY, 2011, INT J BEHAV MED, V18, P93, DOI 10.1007/s12529-010-9123-8; Lin TTC, 2016, J HEALTH COMMUN, V21, P790, DOI 10.1080/10810730.2016.1157657; Liu RG, 2016, HUM VACC IMMUNOTHER, V12, P1155, DOI 10.1080/21645515.2015.1123358; LOGES WE, 1994, COMMUN RES, V21, P5, DOI 10.1177/009365094021001002; Lowrey W., 2004, MASS COMMUNICATION S, V7, P339, DOI [10.1207/s15327825mcs0703_5, DOI 10.1207/S15327825MCS0703_5]; MADDUX JE, 1983, J EXP SOC PSYCHOL, V19, P469, DOI 10.1016/0022-1031(83)90023-9; Marier P, 2017, AGEING SOC, V37, P1632, DOI 10.1017/S0144686X16000544; McLean H, 2014, JOURNALISM, V15, P307, DOI 10.1177/1464884913480873; Nioi M, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.756623; Noar SM, 2006, J HEALTH COMMUN, V11, P21, DOI 10.1080/10810730500461059; Okuhara T, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8040475; Poland GA, 2010, VACCINE, V28, pD3, DOI 10.1016/j.vaccine.2010.08.024; Prati G, 2011, HEALTH EDUC RES, V26, P761, DOI 10.1093/her/cyr035; Ranjit YS, 2021, J RISK RES, V24, P449, DOI 10.1080/13669877.2021.1887328; Rauchfleisch A, 2015, INFORM COMMUN SOC, V18, P139, DOI 10.1080/1369118X.2014.940364; Rimal RN, 2003, COMMUN THEOR, V13, P184, DOI 10.1111/j.1468-2885.2003.tb00288.x; Silver FL, 2003, STROKE, V34, P1965, DOI 10.1161/01.STR.0000083175.01126.62; STEIGER JH, 1990, MULTIVAR BEHAV RES, V25, P173, DOI 10.1207/s15327906mbr2502_4; Tai ZX, 2007, NEW MEDIA SOC, V9, P987, DOI 10.1177/1461444807082691; Teasdale E, 2012, BRIT J HEALTH PSYCH, V17, P44, DOI 10.1111/j.2044-8287.2011.02017.x; Tokuda Y, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-4; Prasetyo YT, 2020, INT J INFECT DIS, V99, P312, DOI 10.1016/j.ijid.2020.07.074; Tsfati Y, 2003, COMMUN RES, V30, P504, DOI 10.1177/0093650203253371; Wang PW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040380; Wang XT, 2021, CHIN J COMMUN, V14, P139, DOI 10.1080/17544750.2020.1807372; Ward PR, 2012, J SOCIOL, V48, P23, DOI 10.1177/1440783311407947; Webb TL, 2006, PSYCHOL BULL, V132, P249, DOI 10.1037/0033-2909.132.2.249; Wu Y, 2022, J HEALTH PSYCHOL, V27, P1445, DOI 10.1177/1359105321995964; Xiao XZ, 2020, VACCINE, V38, P5131, DOI 10.1016/j.vaccine.2020.04.076; Xu Yunan, 2016, Glob Health Res Policy, V1, P3, DOI 10.1186/s41256-016-0004-9; Zhao E, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-003323	56	0	0	15	15	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1401	10.3390/vaccines9121401			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0PF	34960147	Green Published, gold			2022-04-29	WOS:000737364000001
J	Murdaca, G; Noberasco, G; Olobardi, D; Lunardi, C; Maule, M; Delfino, L; Triggiani, M; Cardamone, C; Benfaremo, D; Moroncini, G; Vacca, A; Susca, N; Gangemi, S; Quattrocchi, P; Sticchi, L; Icardi, G; Orsi, A				Murdaca, Giuseppe; Noberasco, Giovanni; Olobardi, Dario; Lunardi, Claudio; Maule, Matteo; Delfino, Lorenzo; Triggiani, Massimo; Cardamone, Chiara; Benfaremo, Devis; Moroncini, Gianluca; Vacca, Angelo; Susca, Nicola; Gangemi, Sebastiano; Quattrocchi, Paola; Sticchi, Laura; Icardi, Giancarlo; Orsi, Andrea			Current Take on Systemic Sclerosis Patients' Vaccination Recommendations	VACCINES			English	Article						systemic sclerosis; SARS-CoV-2; influenza; S; pneumoniae; hepatitis; HZV; N; meningitidis; H; influenzae; HPV; diphtheria-tetanus-pertussis	RHEUMATOID-ARTHRITIS PATIENTS; HUMAN-PAPILLOMAVIRUS VACCINATION; PNEUMOCOCCAL POLYSACCHARIDE VACCINE; LUPUS-ERYTHEMATOSUS PATIENTS; HEPATITIS-A VACCINE; INFLUENZA VACCINATION; ACELLULAR PERTUSSIS; AUTOIMMUNE-DISEASES; IMMUNE-RESPONSE; HERPES-ZOSTER	Systemic sclerosis (SSc) is a rare autoimmune inflammatory rheumatic disease. The prevalence of SSc ranges from 7 to 700 cases per million worldwide. Due to multiple organ involvement and constant inflammatory state, this group of patients presents an increased risk of infectious diseases. This paper aimed to gather the up-to-date evidence on vaccination strategies for patients with SSc and to be a useful tool for the prevention and management of infectious diseases. The authors conducted a scoping review in which each paragraph presents data on a specific vaccine's safety, immunogenicity, and efficacy. The work deals with the following topics: SARS-CoV-2, seasonal influenza, S. pneumoniae, HAV, HBV, HZV, N. meningitidis, H. influenzae, HPV, and diphtheria-tetanus-pertussis.	[Murdaca, Giuseppe] Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy; [Noberasco, Giovanni; Olobardi, Dario; Sticchi, Laura; Icardi, Giancarlo; Orsi, Andrea] Univ Genoa, Dept Hlth Sci, I-16132 Genoa, Italy; [Lunardi, Claudio; Maule, Matteo; Delfino, Lorenzo] Univ Verona, Dept Med, I-37129 Verona, Italy; [Triggiani, Massimo; Cardamone, Chiara] Univ Salerno, Div Allergy & Clin Immunol, I-84084 Salerno, Italy; [Benfaremo, Devis; Moroncini, Gianluca] Osped Riuniti Ancona, Med Clin, I-60126 Ancona, Italy; [Benfaremo, Devis; Moroncini, Gianluca] Univ Politecn Marche, Dipartimento Sci Clin & Mol, I-60126 Ancona, Italy; [Vacca, Angelo; Susca, Nicola] Aldo Moro Univ Bari, Guido Baccelli Unit Internal Med, Dept Biomed Sci & Human Oncol, Sch Med, I-70121 Bari, Italy; [Gangemi, Sebastiano; Quattrocchi, Paola] Univ Messina, Dept Clin & Expt Med, Sch & Operat Unit Allergy & Clin Immunol, I-98124 Messina, Italy; [Sticchi, Laura; Icardi, Giancarlo; Orsi, Andrea] Osped Policlin San Martino IRCCS, Hyg Unit, I-16132 Genoa, Italy		Murdaca, G (通讯作者)，Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy.	Giuseppe.murdaca@unige.it; noberasco.giovanni@gmail.com; Dario.olobardi@gmail.com; claudio.lunardi@univr.it; matteo.maule@gmail.com; angelo.vacca@uniba.it; laura.sticchi@unige.it; andrea.orsi@unige.it	Vacca, Angelo/AAC-9558-2022; Olobardi, Dario/AAW-6334-2021; Orsi, Andrea/AAC-7431-2022	Vacca, Angelo/0000-0002-4567-8216; Olobardi, Dario/0000-0002-6167-0708; Orsi, Andrea/0000-0002-2433-9610; Cardamone, Chiara/0000-0002-5713-3993; Noberasco, Giovanni/0000-0001-6827-6191; Murdaca, Giuseppe/0000-0002-6403-6905; TRIGGIANI, MASSIMO/0000-0001-7318-2093; Benfaremo, Devis/0000-0002-9867-2360			Adler S, 2012, RHEUMATOLOGY, V51, P695, DOI 10.1093/rheumatology/ker389; Alba MA, 2014, MEDICINE, V93, P73, DOI 10.1097/MD.0000000000000018; Alyasin S, 2016, IRAN J IMMUNOL, V13, P204, DOI IJIv13i3A6; Anonymous, 2012, Morbidity and Mortality Weekly Report, V61, P394; [Anonymous], Comirnaty and Spikevax: EMA Recommendations on Extra Doses Boosters; [Anonymous], For Clinicians: Haemophilus Influenzae; Ansaldi F, 2016, ADV THER, V33, P1094, DOI 10.1007/s12325-016-0355-0; Arad U, 2011, VACCINE, V29, P1643, DOI 10.1016/j.vaccine.2010.12.072; Arnheim-Dahlstom L, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5906; Arnold J, 2021, RHEUMATOLOGY, V60, P3496, DOI 10.1093/rheumatology/keab223; Askling HH, 2014, TRAVEL MED INFECT DI, V12, P134, DOI 10.1016/j.tmaid.2014.01.005; Au K, 2011, ANN RHEUM DIS, V70, P785, DOI 10.1136/ard.2010.128637; Barahona-Correa Julián E., 2020, Rev.Colomb.Reumatol., V27, P62, DOI 10.1016/j.rcreue.2019.12.004; Battafarano DF, 1998, ARTHRITIS RHEUM, V41, P1828, DOI 10.1002/1529-0131(199810)41:10<1828::AID-ART15>3.0.CO;2-T; Batu ED, 2020, RHEUMATOL INT, V40, P1193, DOI 10.1007/s00296-020-04612-6; Ben Nessib D, 2021, THERAPIE, V76, P215, DOI 10.1016/j.therap.2020.08.002; Berical AC, 2016, ANN AM THORAC SOC, V13, P933, DOI 10.1513/AnnalsATS.201511-778FR; Bijlsma JWJ, 2021, ANN RHEUM DIS, V80, P411, DOI 10.1136/annrheumdis-2020-219773; Bingham CO, 2015, ANN RHEUM DIS, V74, P818, DOI 10.1136/annrheumdis-2013-204427; Bingham CO, 2010, ARTHRITIS RHEUM-US, V62, P64, DOI 10.1002/art.25034; Borba EF, 2012, RHEUMATOLOGY, V51, P1061, DOI 10.1093/rheumatology/ker427; Broyde A, 2016, J RHEUMATOL, V43, P267, DOI 10.3899/jrheum.150397; Buhler S, 2019, RHEUMATOLOGY, V58, P1585, DOI 10.1093/rheumatology/kez045; Buhler S, 2015, SWISS MED WKLY, V145, DOI 10.4414/smw.2015.14159; Carvalho LM, 2013, PEDIATR RHEUMATOL, V11, DOI 10.1186/1546-0096-11-10; Chao C, 2012, J INTERN MED, V271, P193, DOI 10.1111/j.1365-2796.2011.02467.x; Chapin-Bardales J, 2021, JAMA-J AM MED ASSOC, V325, P2201, DOI 10.1001/jama.2021.5374; Chatham W, 2017, LUPUS, V26, P1483, DOI 10.1177/0961203317703495; Cherry JD, 2005, PEDIATRICS, V115, P1422, DOI 10.1542/peds.2004-2648; Clarke KEN, 2019, EMERG INFECT DIS, V25, P1834, DOI 10.3201/eid2510.190271; Coulson E, 2011, ANN RHEUM DIS, V70, P1289, DOI 10.1136/ard.2010.144451; Creech CB, 2021, JAMA-J AM MED ASSOC, V325, P1318, DOI 10.1001/jama.2021.3199; Curtis JR, 2014, ARTHRIT CARE RES, V66, P990, DOI 10.1002/acr.22281; Curtis JR, 2016, ANN RHEUM DIS, V75, P1843, DOI 10.1136/annrheumdis-2016-209131; Daley MF, 2014, VACCINE, V32, P3019, DOI 10.1016/j.vaccine.2014.03.063; Dalstein W, 2003, INT J CANCER, V106, P396, DOI 10.1002/ijc.11222; Danza A, 2013, LUPUS, V22, P1286, DOI 10.1177/0961203313493032; Das S, 2019, J CLIN TRANSL HEPATO, V7, P165, DOI 10.14218/JCTH.2018.00037; De Carvalho N, 2010, VACCINE, V28, P6247, DOI 10.1016/j.vaccine.2010.07.007; Viladomiu ED, 2014, INDIAN J DERMATOL VE, V80, P259, DOI 10.4103/0378-6323.132259; Dhar JP, 2017, VACCINE, V35, P2642, DOI 10.1016/j.vaccine.2017.04.001; Drago F, 1998, CLIN EXP DERMATOL, V23, P142; Elhai M, 2016, ANN RHEUM DIS, V75, P163, DOI 10.1136/annrheumdis-2014-206386; Elkayam O, 2002, ANN RHEUM DIS, V61, P623, DOI 10.1136/ard.61.7.623; Elkayam O, 2010, SEMIN ARTHRITIS RHEU, V39, P442, DOI 10.1016/j.semarthrit.2008.12.002; Esposito S, 2016, HUM VACC IMMUNOTHER, V12, P1777, DOI 10.1080/21645515.2016.1150396; Feldman Charles, 2020, F1000Res, V9, DOI 10.12688/f1000research.22341.1; Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175; Fiore Anthony E., 2006, Morbidity and Mortality Weekly Report, V55, P1; Fischer L, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0663-9; Furer V, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-001041; Furer V, 2020, ANN RHEUM DIS, V79, P39, DOI 10.1136/annrheumdis-2019-215882; Gargano JW, 2021, MMWR-MORBID MORTAL W, V70, P977, DOI 10.15585/mmwr.mm7027e2; Geier DA, 2015, CLIN RHEUMATOL, V34, P1225, DOI 10.1007/s10067-014-2846-1; Gnann JW, 2002, NEW ENGL J MED, V347, P340, DOI 10.1056/NEJMcp1302674; Grijalva CG, 2010, RHEUMATOLOGY, V49, P82, DOI 10.1093/rheumatology/kep325; Grimaldi-Bensouda L, 2014, J INTERN MED, V275, P398, DOI 10.1111/joim.12155; Grimaldi-Bensouda L, 2017, J AUTOIMMUN, V79, P84, DOI 10.1016/j.jaut.2017.01.005; Gronlund O, 2016, J Intern Med, V280, P618, DOI 10.1111/joim.12535; Harrison N, 2018, VACCINE, V36, P4875, DOI 10.1016/j.vaccine.2018.06.065; Hazlewood GS, 2021, J RHEUMATOL, V48, P1330, DOI 10.3899/jrheum.210288; Hmamouchi I, 2015, VACCINE, V33, P1446, DOI 10.1016/j.vaccine.2015.01.065; Holt HD, 2014, CURR DRUG SAF, V9, P65, DOI 10.2174/15748863113086660062; Holvast A, 2009, RHEUMATOLOGY, V48, P1294, DOI 10.1093/rheumatology/kep200; Hou Jinlin, 2005, Int J Med Sci, V2, P50; Hsu CY, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1997-5; Hua C, 2014, ARTHRIT CARE RES, V66, P1016, DOI 10.1002/acr.22246; Huang WT, 2010, PEDIATRICS, V126, pE263, DOI 10.1542/peds.2009-1496; Ilyas S, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa274; Intongkam S, 2019, JCR-J CLIN RHEUMATOL, V25, P329, DOI 10.1097/RHU.0000000000000877; Jiang HY, 2019, VACCINE, V37, P3031, DOI 10.1016/j.vaccine.2019.04.049; Kaine JL, 2007, J RHEUMATOL, V34, P272; Kapetanovic MC, 2017, VACCINE, V35, P903, DOI 10.1016/j.vaccine.2016.12.068; Khaled A, 2012, PEDIATR DERMATOL, V29, P525, DOI 10.1111/j.1525-1470.2011.01548.x; Khedoe P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01990; Kivitz AJ, 2014, J RHEUMATOL, V41, P648, DOI 10.3899/jrheum.130945; Klein NP, 2021, JAMA-J AM MED ASSOC, V326, P1390, DOI 10.1001/jama.2021.15072; Kobashigawa T, 2013, SCAND J RHEUMATOL, V42, P445, DOI 10.3109/03009742.2013.788733; Kombe AJK, 2021, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.552028; Kronbichler A, 2021, NEPHROL DIAL TRANSPL, V36, P1160, DOI 10.1093/ndt/gfab064; Kuruma KAM, 2007, LUPUS, V16, P350, DOI 10.1177/0961203307078225; Lanternier F, 2008, ANN RHEUM DIS, V67, P1047, DOI 10.1136/ard.2007.081703; Lee YH, 2010, J KOREAN MED SCI, V25, P1431, DOI 10.3346/jkms.2010.25.10.1431; Liao ZF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147856; Loubet P, 2015, VACCINE, V33, P3703, DOI 10.1016/j.vaccine.2015.06.012; Loutan L, 2007, VACCINE, V25, P6310, DOI 10.1016/j.vaccine.2007.06.013; Lu PJ, 2018, VACCINE, V36, P890, DOI 10.1016/j.vaccine.2017.12.016; Luijten RKMAC, 2014, LUPUS, V23, P1512, DOI 10.1177/0961203314543918; Maltz Fraidy, 2019, P T, V44, P406; Marra F, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa005; Martin M, 2014, CLIN EXP RHEUMATOL, V32, pS145; Matsumoto M, 2015, ACTAS DERMO-SIFILOGR, V106, P150, DOI [10.1016/j.adengl.2014.06.006, 10.1016/j.ad.2014.06.012]; Mendoza-Pinto C, 2017, LUPUS, V26, P944, DOI 10.1177/0961203316686708; Migita K, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002184; Migita K, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0863-3; Migita K, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0662-x; Milanetti F, 2014, CLIN EXP IMMUNOL, V177, P287, DOI 10.1111/cei.12292; Milanovic M, 2013, TOHOKU J EXP MED, V229, P29, DOI 10.1620/tjem.229.29; Miranda S, 2017, VACCINE, V35, P4761, DOI 10.1016/j.vaccine.2017.06.030; Mlika RB, 2010, J AM ACAD DERMATOL, V63, P1111, DOI 10.1016/j.jaad.2009.02.047; Mok CC, 2018, VACCINE, V36, P3301, DOI 10.1016/j.vaccine.2018.04.056; Mok CC, 2013, ANN RHEUM DIS, V72, P659, DOI 10.1136/annrheumdis-2012-201393; Morgan MD, 2016, ARTHRIT CARE RES, V68, P853, DOI 10.1002/acr.22757; Mori S, 2013, ANN RHEUM DIS, V72, P1362, DOI 10.1136/annrheumdis-2012-202658; Mouthon L, 2010, RHEUMATOLOGY, V49, P600, DOI 10.1093/rheumatology/kep440; Murdaca G, 2014, AUTOIMMUN REV, V13, P75, DOI 10.1016/j.autrev.2013.07.007; Nagaraja V, 2020, ARTHRITIS RHEUMATOL, V72, P1049, DOI 10.1002/art.41246; Nakafero G, 2018, RHEUMATOLOGY, V57, P1726, DOI 10.1093/rheumatology/key156; Nguyen MTT, 2017, J RHEUMATOL, V44, P1794, DOI 10.3899/jrheum.161407; Nikpour M, 2014, CURR OPIN RHEUMATOL, V26, P131, DOI 10.1097/BOR.0000000000000027; Oren S, 2008, ANN RHEUM DIS, V67, P937, DOI 10.1136/ard.2007.077461; Paavonen J, 2007, LANCET, V369, P2161, DOI 10.1016/S0140-6736(07)60946-5; Papp KA, 2019, J CUTAN MED SURG, V23, P50, DOI 10.1177/1203475418811335; Payne AB, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.16420; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Poudel DR, 2018, RHEUMATOLOGY, V57, P1611, DOI 10.1093/rheumatology/key150; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Puges M, 2016, RHEUMATOLOGY, V55, P1664, DOI 10.1093/rheumatology/kew211; Raczynska A, 2019, AM J MENS HEALTH, V13, DOI 10.1177/1557988319895141; Rakoczi E, 2016, JOINT BONE SPINE, V83, P675, DOI 10.1016/j.jbspin.2015.10.017; Raposo A, 2016, ACTA REUMATOL PORT, V41, P184; Rezende RPV, 2016, LUPUS, V25, P1254, DOI 10.1177/0961203316636472; Rondaan C, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-001035; ROTA PA, 1995, J CLIN MICROBIOL, V33, P2485, DOI 10.1128/JCM.33.9.2485-2488.1995; Rubin LG, 2014, CLIN INFECT DIS, V58, P309, DOI [10.1093/cid/cit684, 10.1093/cid/cit816]; Rubio-Rivas M, 2014, SEMIN ARTHRITIS RHEU, V44, P208, DOI 10.1016/j.semarthrit.2014.05.010; Santana IU, 2011, CLIN RHEUMATOL, V30, P665, DOI 10.1007/s10067-010-1606-0; Scire CA, 2020, CLIN EXP RHEUMATOL, V38, P748; Segal Y, 2018, CELL MOL IMMUNOL, V15, P586, DOI 10.1038/cmi.2017.151; Setti M, 2009, VACCINE, V27, P3367, DOI 10.1016/j.vaccine.2009.01.078; Shea KM, 2014, OPEN FORUM INFECT DI, V1, DOI 10.1093/ofid/ofu024; Shearer WT, 2014, J ALLERGY CLIN IMMUN, V133, P961, DOI 10.1016/j.jaci.2013.11.043; Slade BA, 2009, JAMA-J AM MED ASSOC, V302, P750, DOI 10.1001/jama.2009.1201; Soldevilla HF, 2012, LUPUS, V21, P158, DOI 10.1177/0961203311429556; Soybilgic A, 2013, PEDIATR RHEUMATOL, V11, DOI 10.1186/1546-0096-11-29; Stasi C, 2020, CLIN EXP VACCINE RES, V9, P1, DOI 10.7774/cevr.2020.9.1.1; Sun YL, 2012, JAMA-J AM MED ASSOC, V307, P823, DOI 10.1001/jama.2012.165; Thomas RE, 2021, GERIATRICS-BASEL, V6, DOI 10.3390/geriatrics6010013; Top KA, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1112-0; Torrelo A, 2006, PEDIATR DERMATOL, V23, P484, DOI 10.1111/j.1525-1470.2006.00289.x; Torres A, 2018, RESP MED, V137, P6, DOI 10.1016/j.rmed.2018.02.007; Trombetta CM, 2018, HUM VACC IMMUNOTHER, V14, P657, DOI 10.1080/21645515.2017.1423153; Tsuru T, 2014, MOD RHEUMATOL, V24, P511, DOI 10.3109/14397595.2013.843743; Tyndall AJ, 2010, ANN RHEUM DIS, V69, P1809, DOI 10.1136/ard.2009.114264; Vadala M, 2017, EPMA J, V8, P295, DOI 10.1007/s13167-017-0101-y; van Assen S, 2011, ANN RHEUM DIS, V70, P414, DOI 10.1136/ard.2010.137216; van Assen S, 2010, ARTHRITIS RHEUM-US, V62, P75, DOI 10.1002/art.25033; van den Bijllaardt W, 2013, J TRAVEL MED, V20, P278, DOI 10.1111/jtm.12050; Vesikari T, 2010, PEDIATR INFECT DIS J, V29, P314, DOI 10.1097/INF.0b013e3181c177fb; Vichnin M, 2015, PEDIATR INFECT DIS J, V34, P983, DOI 10.1097/INF.0000000000000793; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Walker UA, 2016, ARTHRITIS RHEUMATOL, V68, P516, DOI 10.1002/art.39482; Wasley A, 2006, EPIDEMIOL REV, V28, P101, DOI 10.1093/epirev/mxj012; Watanabe R, 2014, TOHOKU J EXP MED, V233, P129, DOI 10.1620/tjem.233.129; Weston D, 2017, VACCINE, V35, P3875, DOI 10.1016/j.vaccine.2017.05.061; Wong PKK, 2017, INTERN MED J, V47, P491, DOI 10.1111/imj.13371; World Health Organization, 2019, HEP B; Yih WK, 2009, VACCINE, V27, P4257, DOI 10.1016/j.vaccine.2009.05.036; Yun HF, 2016, ARTHRITIS RHEUMATOL, V68, P2328, DOI 10.1002/art.39670; Zard E, 2014, AUTOIMMUN REV, V13, P730, DOI 10.1016/j.autrev.2014.03.001; Zonneveld-Huijssoon E, 2007, ARTHRITIS RHEUM-US, V56, P639, DOI 10.1002/art.22399	161	3	3	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1426	10.3390/vaccines9121426			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0SL	34960174	gold, Green Published			2022-04-29	WOS:000737372400001
J	Wang, B; Nolan, R; Marshall, H				Wang, Bing; Nolan, Rebecca; Marshall, Helen			COVID-19 Immunisation, Willingness to Be Vaccinated and Vaccination Strategies to Improve Vaccine Uptake in Australia	VACCINES			English	Article						COVID-19 vaccines; vaccine uptake; vaccine intention; vaccine policies	PARENTS	The COVID-19 vaccine rollout is crucial to lifting community and economic restrictions. This cross-sectional study aimed to assess: (a) COVID-19 vaccine uptake and associated factors; (b) COVID-19 vaccine intentions and associated factors; (c) community support for COVID-19 vaccination strategies and associated factors. The survey was conducted between May and July 2021 in Australia. Of 3003 participants, 30% reported they were already vaccinated and 39% indicated they would get vaccinated. Low socioeconomic and education levels, non-English speaking backgrounds and being parents were associated with decreased vaccine willingness and/or vaccination rates. High levels of support for vaccination strategies were demonstrated with mandatory vaccination being less preferable. Respondents from non-English speaking backgrounds were more likely to support a mandatory vaccination policy. Respondents with the highest socioeconomic level were more likely to support vaccination requirements for international travel, visiting nursing homes and working in healthcare settings. Respondents who were aged >= 70 years were more likely to support all proposed vaccination strategies. Targeted campaigns should be implemented for parents and those who live in socioeconomic disadvantaged areas and have lower educational attainment. Concise and clear vaccine information should be provided in lay and multiple languages to improve vaccine confidence. Vaccine enforcement policies should be considered and implemented with caution.	[Wang, Bing; Marshall, Helen] Womens & Childrens Hlth Network, Vaccinol & Immunol Res Trials Unit, Adelaide, SA 5006, Australia; [Wang, Bing; Marshall, Helen] Univ Adelaide, Robinson Res Inst, Adelaide, SA 5006, Australia; [Wang, Bing; Marshall, Helen] Univ Adelaide, Adelaide Med Sch, Adelaide, SA 5006, Australia; [Nolan, Rebecca] Wellbeing SA, Epidemiol Branch, Prevent & Populat Hlth Directorate, Adelaide, SA 5006, Australia		Marshall, H (通讯作者)，Womens & Childrens Hlth Network, Vaccinol & Immunol Res Trials Unit, Adelaide, SA 5006, Australia.; Marshall, H (通讯作者)，Univ Adelaide, Robinson Res Inst, Adelaide, SA 5006, Australia.; Marshall, H (通讯作者)，Univ Adelaide, Adelaide Med Sch, Adelaide, SA 5006, Australia.	bing.wang@adelaide.edu.au; rebecca.nolan@sa.gov.au; helen.marshall@adelaide.edu.au					Alley SJ, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020797; American Association for Public Opinion Research, 2016, STAND DEF FIN DISP C; [Anonymous], 2016, AUSTR BUREAU STAT 20; Attwell K., VACCINE PASSPORTS AR; Attwell K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245907; Australian Bureau of Statistics, 2016, CENS TABLEBUILDER; Baskin E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192594; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Biddle N., VACCINE WILLINGNESS; Biddle N., DETERMINANTS COVID 1; Burke PF, 2021, VACCINE, V39, P5116, DOI 10.1016/j.vaccine.2021.07.056; Dai HC, 2021, NATURE, V597, P404, DOI 10.1038/s41586-021-03843-2; Dal Grande E, 2015, AM J EPIDEMIOL, V182, P544, DOI 10.1093/aje/kwv080; Davis S.R., 2021, WILLINGNESS RECEIVE, DOI [10.1101/2021.07.22.21260551, DOI 10.1101/2021.07.22.21260551]; Dodd Rachael H, 2022, Vaccine, V40, P2484, DOI 10.1016/j.vaccine.2021.08.007; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Edwards B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248892; Eshun-Wilson I., 2021, STRATEGIES MAKE VACC, DOI [10.1101/2021.05.19.21257355, DOI 10.1101/2021.05.19.21257355]; Gualano MR, 2019, HUM VACC IMMUNOTHER, V15, P918, DOI 10.1080/21645515.2018.1564437; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; McBryde E.S., 2021, VACCINATION IS AUSTR, DOI [10.1101/2021.07.16.21260642, DOI 10.1101/2021.07.16.21260642]; Morris M., SHEPPARTON FOOD PROC; Nehal KR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101071; Rabb N., TEXT MESSAGES DO NOT; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Ritter AZ, 2021, J AM MED DIR ASSOC, V22, P1998, DOI 10.1016/j.jamda.2021.07.035; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Seale H, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05833-1; Smith DT, 2021, POLITICS-OXFORD, DOI 10.1177/02633957211009066; Sollis K., 2021, MEDRXIV2021202120022, DOI [10.1101/2021.02.17.21251957, DOI 10.1101/2021.02.17.21251957]; To QG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050479; Trent Mallory, 2022, Vaccine, V40, P2498, DOI 10.1016/j.vaccine.2021.06.048; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; Yoda T, 2021, HUM VACC IMMUNOTHER, V17, P4993, DOI 10.1080/21645515.2021.1981087	36	1	1	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1467	10.3390/vaccines9121467			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YI5TV	34960213	gold, Green Published			2022-04-29	WOS:000743911100001
J	Weng, YJ; Lu, D; Bollyky, J; Jain, V; Desai, M; Lindan, C; Boothroyd, D; Judson, T; Doernberg, SB; Holubar, M; Sample, H; Huang, BTC; Maldonado, Y; Rutherford, GW; Grumbach, K				Weng, Yingjie; Lu, Di; Bollyky, Jenna; Jain, Vivek; Desai, Manisha; Lindan, Christina; Boothroyd, Derek; Judson, Timothy; Doernberg, Sarah B.; Holubar, Marisa; Sample, Hannah; Huang, Beatrice; Maldonado, Yvonne; Rutherford, George W.; Grumbach, Kevin		California Pandemic Consortium	Race-ethnicity and COVID-19 Vaccination Beliefs and Intentions: A Cross-Sectional Study among the General Population in the San Francisco Bay Area	VACCINES			English	Article						COVID-19 vaccine intention; race-ethnicity; mediators; LASSO	BNT162B2; INFECTION; HESITANCY; VACCINES; LOCKDOWN; WORKERS	Objective: The study was designed to compare intentions to receive COVID-19 vaccination by race-ethnicity, to identify beliefs that may mediate the association between race-ethnicity and intention to receive the vaccine and to identify the demographic factors and beliefs most strongly predictive of intention to receive a vaccine. Design: Cross-sectional survey conducted from November 2020 to January 2021, nested within a longitudinal cohort study of the prevalence and incidence of SARS-CoV-2 among a general population-based sample of adults in six San Francisco Bay Area counties (called TrackCOVID). Study Cohort: In total, 3161 participants among the 3935 in the TrackCOVID parent cohort responded. Results: Rates of high vaccine willingness were significantly lower among Black (41%), Latinx (55%), Asian (58%), Multi-racial (59%), and Other race (58%) respondents than among White respondents (72%). Black, Latinx, and Asian respondents were significantly more likely than White respondents to endorse lack of trust of government and health agencies as a reason not to get vaccinated. Participants' motivations and concerns about COVID-19 vaccination only partially explained racial-ethnic differences in vaccination willingness. Concerns about a rushed government vaccine approval process and potential bad reactions to the vaccine were the two most important factors predicting vaccination intention. Conclusions: Vaccine outreach campaigns must ensure that the disproportionate toll of COVID-19 on historically marginalized racial-ethnic communities is not compounded by inequities in vaccination. Efforts must emphasize messages that speak to the motivations and concerns of groups suffering most from health inequities to earn their trust to support informed decision making.	[Weng, Yingjie; Lu, Di; Desai, Manisha; Boothroyd, Derek] Stanford Univ, Dept Med, Quantitat Sci Unit, Palo Alto, CA 94304 USA; [Bollyky, Jenna] Stanford Univ, Sch Med, Div Primary Care & Populat Hlth, Stanford, CA 94305 USA; [Jain, Vivek] San Francisco Gen Hosp, Div HIV, Infect Dis & Global Med, San Francisco, CA 94110 USA; [Lindan, Christina; Rutherford, George W.] Univ Calif San Francisco, Dept Epidemiol & Biostatist, San Francisco, CA 94134 USA; [Lindan, Christina; Rutherford, George W.] Univ Calif San Francisco, Inst Global Hlth Sci, San Francisco, CA 94134 USA; [Judson, Timothy] Univ Calif San Francisco, Dept Med, Div Hosp Med, San Francisco, CA 94117 USA; [Doernberg, Sarah B.] Univ Calif San Francisco, Dept Med, Div Infect Dis, San Francisco, CA 94117 USA; [Holubar, Marisa] Stanford Univ, Sch Med, Div Dis & Geog Med, Stanford, CA 94305 USA; [Sample, Hannah] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94134 USA; [Huang, Beatrice; Grumbach, Kevin] Univ Calif San Francisco, Dept Family & Commun Med, San Francisco, CA 94110 USA; [Maldonado, Yvonne] Stanford Univ, Sch Med, Div Pediat Infect Dis, Stanford, CA 94305 USA		Weng, YJ (通讯作者)，Stanford Univ, Dept Med, Quantitat Sci Unit, Palo Alto, CA 94304 USA.	isabelweng@stanford.edu; Di.Lu1@stanford.edu; jbollyky@stanford.edu; Vivek.Jain@ucsf.edu; manishad@stanford.edu; Krysia.Lindan@ucsf.edu; derekb@stanford.edu; Timothy.Judson@ucsf.edu; Sarah.Doernberg@ucsf.edu; mholubar@stanford.edu; hsample@mednet.ucla.edu; Beatrice.Huang@ucsf.edu; bonniem@stanford.edu; George.Rutherford@ucsf.edu; Kevin.Grumbach@ucsf.edu		Bollyky, Jennifer/0000-0002-2037-2843; Rutherford, George/0000-0002-0707-8287; Tang, Hilary/0000-0003-0365-6606	Chan Zuckerberg Initiative [CZIF2020-003870]; National Institutes of Health, Community Engagement Alliance Against COVID-19 Disparities programUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [21-312-0217571-66106L]	This work was supported by the Chan Zuckerberg Initiative (CZIF2020-003870). Grumbach & rsquo;s effort was partly supported by a grant from the National Institutes of Health, Community Engagement Alliance Against COVID-19 Disparities program (21-312-0217571-66106L). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.	Andrade C, 2020, INDIAN J PSYCHIAT, V62, P247, DOI 10.4103/psychiatry.IndianJPsychiatry_379_20; [Anonymous], 2020, MOD COVID 19 VACC CA; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barda N, 2021, NEW ENGL J MED, V385, P1078, DOI 10.1056/NEJMoa2110475; Bendau A, 2021, INT IMMUNOPHARMACOL, V97, DOI 10.1016/j.intimp.2021.107724; Bok K, 2021, IMMUNITY, V54, P1636, DOI 10.1016/j.immuni.2021.07.017; Boyd R, BLACK PEOPLE NEED BE; Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521; Callaghan T., 2020, CORRELATES DISPARITI, DOI DOI 10.2139/SSRN.3667971; Carpiano R.M., 2020, DEMOGRAPHIC DIFFEREN, DOI [10.1101/2020.09.07.20190058v1, DOI 10.1101/2020.09.07.20190058]; Cooper LA, 2020, J CLIN INVEST, V130, P5033, DOI 10.1172/JCI141562; Corbie-Smith G., 2021, JAMA HLTH FORUM, V2, pe210434, DOI [10.1001/jamahealthforum.2021.0434, DOI 10.1001/JAMAHEALTHFORUM.2021.0434]; Corey L, 2020, SCIENCE, V368, P948, DOI 10.1126/science.abc5312; Daly Michael, 2020, medRxiv, DOI 10.1101/2020.11.27.20239970; Fishbein M, 2011, PREDICTING AND CHANGING BEHAVIOR: THE REASONED ACTION APPROACH, P1; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Grumbach K, 2021, JAMA INTERN MED, V181, P1008, DOI 10.1001/jamainternmed.2021.1445; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Hamel L., 2020, KFF COVID 19 VACCINE; Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3; Kaiser Family Foundation, 2020, POLL MOST AM WORR PO; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Killgore WDS, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040339; Kricorian K, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2021.1950504; Kumar A, 2021, J MENT HEALTH, V30, P1, DOI 10.1080/09638237.2020.1757052; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Latkin CA, 2021, SOC SCI MED, V270, DOI 10.1016/j.socscimed.2021.113684; Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8; Lindan Christina P, 2022, Ann Epidemiol, V67, P81, DOI 10.1016/j.annepidem.2021.11.001; Lockyer B, 2021, HEALTH EXPECT, V24, P1158, DOI 10.1111/hex.13240; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4471; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Mercadante AR, 2021, RES SOC ADMIN PHARM, V17, P1596, DOI 10.1016/j.sapharm.2020.12.012; Morgan V., 2021, REV CONT PHILOS, V20, P128; Murphy J., 2020, PSYARXIV, DOI DOI 10.31234/OSF.IO/PEV2B; Napoli PE, 2021, RISK MANAG HEALTHC P, V14, P1629, DOI 10.2147/RMHP.S277067; National Institutes of Health, 2020, COMMUNITY ENGAGEMENT; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nioi M, 2021, SIGNA VITAE, V17, P79, DOI 10.22514/sv.2021.098; Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017; Phizer, 2020, PFIZ BIONT CONCL PHA; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Press Ganey, 2021, VACC HES ACC DAT SEG; Rimoin A.W., 2020, ASSESSMENT COVID 19, DOI [10.1101/2020.11.18.20234468, DOI 10.1101/2020.11.18.20234468]; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Rzymski P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020109; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Shaw J, 2021, CLIN INFECT DIS, V73, P1776, DOI 10.1093/cid/ciab054; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; UCSF School of Medicine, DEANS OFF POP HLTH H; Wake AD, 2021, RISK MANAG HEALTHC P, V14, P2609, DOI 10.2147/RMHP.S311074; Walker A., NEW YORK TIMES; WHO, 2014, SAG REP REP SG WORK; Wilkins CH, 2018, MED CARE, V56, pS6, DOI 10.1097/MLR.0000000000000953; Yang Y., GASSO PENALIZED LEAR	59	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1406	10.3390/vaccines9121406			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XZ0NA	34960152	gold, Green Published			2022-04-29	WOS:000737358300001
J	Voo, JYH; Lean, QY; Ming, LC; Hanafiah, NHM; Al-Worafi, YM; Ibrahim, B				Voo, James Yau Hon; Lean, Qi Ying; Ming, Long Chiau; Hanafiah, Nur Hafzan Md; Al-Worafi, Yaser Mohammed; Ibrahim, Baharudin			Vaccine Knowledge, Awareness and Hesitancy: A Cross Sectional Survey among Parents Residing at Sandakan District, Sabah	VACCINES			English	Article						vaccine hesitancy; immunization; questionnaire; vaccination	CHILDHOOD VACCINATION; IMMUNIZATION; ATTITUDES; MOTHERS; HEALTH	Background: Incomplete childhood immunization against communicable diseases is a major concern and vaccine hesitancy remains a hurdle to overcome in primary vaccination programs. This study was to examine the parents' vaccine knowledge, awareness and hesitancy in relation to their children's immunization status. Methods: A cross-sectional questionnaire study design was used. The parents who brought their children for immunization visit or follow-up at four public health clinics located in Sandakan district were invited to participate in this survey. Informed consent was obtained before each participant completed a hard copy of self-administered questionnaire in either English or Malay versions. Results: Of 405 parents responded, they generally had good knowledge and awareness of vaccines, only a small percentage (6.8%) of parents were found vaccine hesitant. There were significant differences in vaccine knowledge and awareness in those from different education levels and employment status; similarly, these two factors also significantly affected the vaccine hesitancy among the parents. The parents' knowledge score was found to be moderately associated with their awareness (r = 0.551, p < 0.01) and inversely correlated to vaccine hesitancy (r = -0.397, p < 0.01). Most of the children (n = 376, 92.8%) in the study were immunized. The children's immunization status was significantly associated with the parents' education level (p = 0.025). There was also a significant difference in the total vaccine knowledge scores between the groups of parents with different child immunization status (p = 0.05). Conclusion: This study revealed that parents with higher education had a better knowledge of vaccinations, were less vaccine hesitant and were more likely to ensure that their children complete the recommended course of immunization. It is crucial to ensure parents are well-informed about the safety and efficacy of vaccines so that the children are protected from communicable diseases by the child vaccination program.	[Voo, James Yau Hon; Hanafiah, Nur Hafzan Md; Ibrahim, Baharudin] Univ Sains Malaysia, Sch Pharmaceut Sci, Gelugor 11800, Malaysia; [Lean, Qi Ying] Univ Teknol MARA, Fac Pharm, Kampus Bertam, Kepala Batas 13200, Pulau Pinang, Malaysia; [Ming, Long Chiau] Univ Brunei Darussalam, PAP Rashidah Saadatul Bolkiah Inst Hlth Sci, BE-1410 Gadong, Bandar Seri Beg, Brunei; [Al-Worafi, Yaser Mohammed] Azal Univ Human Dev, Coll Med Sci, POB 447, Amran, Yemen; [Al-Worafi, Yaser Mohammed] Univ Sci & Technol Fujairah, Coll Pharm, POB 2202, Fujairah, U Arab Emirates; [Ibrahim, Baharudin] Univ Malaya, Fac Pharm, Kuala Lumpur 50603, Malaysia		Ibrahim, B (通讯作者)，Univ Sains Malaysia, Sch Pharmaceut Sci, Gelugor 11800, Malaysia.; Ibrahim, B (通讯作者)，Univ Malaya, Fac Pharm, Kuala Lumpur 50603, Malaysia.	jamesvooyh@moh.gov.my; leanqiying@yahoo.com; longchiauming@gmail.com; hafzanhanafiah@usm.my; yworafi@yahoo.com; baharudin.ibrahim@um.edu.my	Ibrahim, Baharudin/E-2411-2012; Ming, L C/J-5210-2015; Lean, Qi Ying/G-1680-2019	Ibrahim, Baharudin/0000-0001-8534-2517; Ming, L C/0000-0002-6971-1383; Al-Worafi, Yaser Mohammed/0000-0002-5752-2913; Voo, James Yau Hon/0000-0003-4660-4240; Lean, Qi Ying/0000-0003-0331-8607			Aa A., 2017, NEONATAL PEDIAT MED, V3, P1; Al-Lela OQB, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-20; Al-lela OQB, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-29; Awadh AI, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1107; Azizi FSM, 2017, VACCINE, V35, P2955, DOI 10.1016/j.vaccine.2017.04.010; Baharudin A, 2019, HLTH SCI J, V13, P1, DOI [10.21767/1791-809X.1000627, DOI 10.21767/1791-809X.1000627]; Bernsen R.M., 2011, J MED SCI, V4, P114, DOI [10.2174/1996327001104030114, DOI 10.2174/1996327001104030114]; Bocquier A, 2017, EXPERT REV VACCINES, V16, P1107, DOI 10.1080/14760584.2017.1381020; Bults M, 2011, VACCINE, V29, P6226, DOI 10.1016/j.vaccine.2011.06.075; Charron J, 2020, MED MALADIES INFECT, V50, P727, DOI 10.1016/j.medmal.2020.01.010; Department of Information Malaysia, DEM POP; Gill P.K., 2012, MALAYS J PAEDIAT CHI, V18, P30; Han K, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-203; Hussain A, 2018, CUREUS, V10, DOI 10.7759/cureus.2919; Kalok A, 2020, VACCINE, V38, P2183, DOI 10.1016/j.vaccine.2020.01.043; Keelan J, 2010, VACCINE, V28, P1535, DOI 10.1016/j.vaccine.2009.11.060; Khan TM, 2015, LANCET, V386, P1733, DOI 10.1016/S0140-6736(15)00689-3; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Lim KK, 2017, PUBLIC HEALTH, V153, P52, DOI 10.1016/j.puhe.2017.08.001; Lim W. Y., 2016, Cogent Medicine, V3, P1142410; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Madi D., 2014, ASIAN J MED SCI, V5, P52, DOI [10.3126/ajms.v5i4.10306, DOI 10.3126/AJMS.V5I4.10306]; Mapatano MA, 2008, S AFR FAM PRACT, V50, P61, DOI 10.1080/20786204.2008.10873699; Ministry of Health Malaysia, 2020, HLTH FACTS MAL; Noor Ani Ahmad, 2017, Journal of Vaccines and Vaccination, V8, P358, DOI 10.4172/2157-7560.1000358; Oladejo O, 2016, VACCINE, V34, P4964, DOI 10.1016/j.vaccine.2016.08.046; Olson O, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040590; Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483; Papazoglou A, 2013, GLOB J MED RES INTER, V13, P5; Remy Vanessa, 2015, J Mark Access Health Policy, V3, DOI 10.3402/jmahp.v3.27041; Richards A, 1999, AUST NZ J PUBL HEAL, V23, P315, DOI 10.1111/j.1467-842X.1999.tb01263.x; Rumetta J, 2020, J INFECT PUBLIC HEAL, V13, P199, DOI 10.1016/j.jiph.2019.07.027; Singh PK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073102; Smailbegovic MS, 2003, CHILD CARE HLTH DEV, V29, P303, DOI 10.1046/j.1365-2214.2003.00347.x; Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046; SteelFisher GK, 2021, NEW ENGL J MED, V384, P1483, DOI 10.1056/NEJMp2100351; Torun SD, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-125; UN Inter-agency Group for Child Mortality Estimation Levels & Trends in Child Mortality, 2020, LEV TRENDS CHILD MOR; Wang Yuan-yuan, 2007, Beijing Da Xue Xue Bao Yi Xue Ban, V39, P136; Ward JK, 2016, HUM VACC IMMUNOTHER, V12, P1924, DOI 10.1080/21645515.2016.1146430; Yakut S, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57050431; Zakaria, 2018, IJHSR, V8, P360; Zhang XL, 1999, SOC SCI MED, V49, P1125, DOI 10.1016/S0277-9536(99)00199-9	43	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1348	10.3390/vaccines9111348			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XI5MB	34835279	Green Published, gold			2022-04-29	WOS:000726154400001
J	Wang, JL; Ji, QQ; Dong, SH; Zhao, SY; Li, XC; Zhu, QQ; Long, SG; Zhang, JJ; Jin, H				Wang, Jianli; Ji, Qianqian; Dong, Shuheng; Zhao, Shuangyu; Li, Xinchen; Zhu, Qiuqi; Long, Sigui; Zhang, Jingjing; Jin, Hui			Factors Influencing Vaccine Hesitancy in China: A Qualitative Study	VACCINES			English	Article						COVID-19; qualitative study; Chinese adults; vaccine hesitancy	COVID-19 VACCINE; UNITED-STATES; PERCEPTIONS; ATTITUDES; SEPTEMBER	Vaccine hesitancy has become a significant issue. We aimed to elucidate the factors influencing vaccine hesitation in Chinese residents and to analyze and recommend promotional strategies and measures. In total, 92 Chinese residents from 10 provinces were interviewed using semi-structured face-to-face interviews following a predetermined survey framework in this qualitative study. We found trust in vaccine safety, access to professional advice, and vaccine price and effectiveness to be the main factors influencing vaccine hesitation. Additionally, residents in areas with a higher per capita GDP tend to receive more social support, believe that vaccination is beneficial and can prevent diseases, pay more attention to whether the vaccine is safe and has undergone various clinical trials, and are more likely to seek advice from individuals with vaccination experience as opposed to their counterparts in areas with a lower per capita GDP. Notably, as per capita GDP rises, individuals become more concerned about the price of vaccines. Measures such as clarifying vaccine safety and effectiveness, reducing self-funded vaccine prices, offering free vaccination for special groups, strengthening the publicity role of medical staff, and taking advantage of network platforms are essential to reduce vaccine hesitancy among Chinese residents.	[Wang, Jianli; Ji, Qianqian; Dong, Shuheng; Zhao, Shuangyu; Li, Xinchen; Zhu, Qiuqi; Long, Sigui; Jin, Hui] Southeast Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Nanjing 210009, Peoples R China; [Wang, Jianli; Ji, Qianqian; Dong, Shuheng; Zhao, Shuangyu; Li, Xinchen; Zhu, Qiuqi; Long, Sigui; Jin, Hui] Southeast Univ, Sch Publ Hlth, Key Lab Environm Med Engn, Minist Educ, Nanjing 210009, Peoples R China; [Zhang, Jingjing] Southeast Univ, Sch Humanities, Dept Sociol, Nanjing 210009, Peoples R China		Jin, H (通讯作者)，Southeast Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Nanjing 210009, Peoples R China.; Jin, H (通讯作者)，Southeast Univ, Sch Publ Hlth, Key Lab Environm Med Engn, Minist Educ, Nanjing 210009, Peoples R China.	213171070@seu.edu.cn; 213170986@seu.edu.cn; 213172733@seu.edu.cn; 213181074@seu.edu.cn; 213181160@seu.edu.cn; 213181178@seu.edu.cn; 213180365@seu.edu.cn; jingjingzhang@seu.edu.cn; jinhuihld@seu.edu.cn			General Program of National Natural Science Fund [81573258]; COVID-19 Fund of Southeast University [3225002001c1]	This research was supported by General Program of National Natural Science Fund (No. 81573258) and COVID-19 Fund of Southeast University (No. 3225002001c1).	Bahri P, 2019, VACCINE, V37, P401, DOI 10.1016/j.vaccine.2018.11.082; Black CL, 2018, MMWR-MORBID MORTAL W, V67, P1050, DOI 10.15585/mmwr.mm6738a2; Burke PF, 2021, VACCINE, V39, P5116, DOI 10.1016/j.vaccine.2021.07.056; Edler C, 2021, LEGAL MED-TOKYO, V51, DOI 10.1016/j.legalmed.2021.101895; French J, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165893; Han BH, 2021, LANCET INFECT DIS, V21, P1645, DOI 10.1016/S1473-3099(21)00319-4; He Ying-xia, 2021, Fudan Xuebao (Yixueban), V48, P136, DOI 10.3969/j.issn.1672-8467.2021.01.022; La Vecchia C, 2020, MED LAV, V111, P445, DOI 10.23749/mdl.v111i6.10813; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; [林声 Lin Sheng], 2015, [中华疾病控制杂志, Chinese Journal of Disease Control & Prevention], V19, P975; Liu XJ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17197170; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mallapaty S, 2021, NATURE, V594, P161, DOI 10.1038/d41586-021-01497-8; Mendonca SA, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00356-x; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Nguyen KH, 2021, MMWR-MORBID MORTAL W, V70, P217, DOI 10.15585/mmwr.mm7006e3; Ning J.Z., 2020, CHINA STAT YB 2020; Pomara C, 2021, HAEMATOLOGICA, V106, P2291, DOI 10.3324/haematol.2021.279075; Pomara C, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11060955; Rehm KE, 2009, IMMUNOLOGY, V128, P381, DOI 10.1111/j.1365-2567.2009.03120.x; Rodeghiero F, 2021, HAEMATOLOGICA, V106, P2040, DOI 10.3324/haematol.2021.279186; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Sanders Carolyn, 2003, Contemp Nurse, V14, P292; Schneider J, 2021, INT J LEGAL MED, V135, P2335, DOI 10.1007/s00414-021-02706-9; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Wagner AL, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040155; Wang H.F., 2019, PREV MED, V31, P930; Wang JL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070772; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P1511, DOI 10.1080/21645515.2019.1706935; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Zhang MX, 2021, EXPERT REV VACCINES, V20, P891, DOI 10.1080/14760584.2021.1925112; Zhang P.X., 2020, CHIN J HLTH ED, V36, P925; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4	35	2	2	9	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1291	10.3390/vaccines9111291			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG7WA	34835221	gold, Green Published			2022-04-29	WOS:000724958900001
J	Wu, HHL; Kalra, PA; Chinnadurai, R				Wu, Henry H. L.; Kalra, Philip A.; Chinnadurai, Rajkumar			New-Onset and Relapsed Kidney Histopathology Following COVID-19 Vaccination: A Systematic Review	VACCINES			English	Review						COVID-19 vaccination; new-onset; relapse; kidney disease; histopathology; systematic review; COVID-19; SARS-CoV-2	MINIMAL CHANGE DISEASE; GROSS HEMATURIA; IGA NEPHROPATHY; SARS-COV-2; RNA; VASCULITIS; NEPHRITIS; GLYCOSYLATION; PATHOGENESIS; PATIENT	Introduction: The introduction of COVID-19 vaccination programs has become an integral part of the major strategy to reduce COVID-19 numbers worldwide. New-onset and relapsed kidney histopathology have been reported following COVID-19 vaccination, sparking debate on whether there are causal associations. How these vaccines achieve an immune response to COVID-19 and the mechanism that this triggers kidney pathology remains unestablished. We describe the results of a systematic review for new-onset and relapsed kidney histopathology following COVID-19 vaccination. Methods: A systematic literature search of published data up until 31 August 2021 was completed through the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guideline. Research articles reporting new onset or relapsed kidney histopathology in adult patients (>18 years) following COVID-19 vaccination were included for qualitative review. Only full-text articles published in the English language were selected for review. Results: Forty-eight cases from thirty-six articles were included in the qualitative synthesis of this systematic review. Minimal change disease (19 cases) was the most frequent pathology observed, followed by IgA nephropathy (14 cases) and vasculitis (10 cases). Other cases include relapse of membranous nephropathy, acute rejection of kidney transplant, relapse of IgG4 nephritis, new-onset renal thrombotic microangiopathy, and scleroderma renal crisis following COVID-19 vaccination. There was no mortality reported in any of the included cases. Patients in all but one case largely recovered and did not require long-term renal replacement therapy. Conclusion: This systematic review provides insight into the relationship between various kidney pathologies that may have followed COVID-19 vaccination. Despite these reported cases, the protective benefits offered by COVID-19 vaccination far outweigh its risks. It would be recommended to consider early biopsy to identify histopathology amongst patients presenting with symptoms relating to new-onset kidney disease following vaccination and to monitor symptoms for those with potential relapsed disease.	[Wu, Henry H. L.] Lancashire Teaching Hosp NHS Fdn Trust, Dept Renal Med, Preston PR2 9HT, Lancs, England; [Wu, Henry H. L.; Kalra, Philip A.; Chinnadurai, Rajkumar] Univ Manchester, Fac Biol Med & Hlth, Manchester M13 9PL, Lancs, England; [Kalra, Philip A.; Chinnadurai, Rajkumar] Northern Care Alliance Fdn Trust, Salford Royal Hosp, Dept Renal Med, Salford M6 8HD, Lancs, England		Wu, HHL (通讯作者)，Lancashire Teaching Hosp NHS Fdn Trust, Dept Renal Med, Preston PR2 9HT, Lancs, England.; Wu, HHL (通讯作者)，Univ Manchester, Fac Biol Med & Hlth, Manchester M13 9PL, Lancs, England.	Henry.wu@lthtr.nhs.uk; Philip.Kalra@nca.nhs.uk; Rajkumar.Chinnadurai@nca.nhs.uk	Wu, Henry HL/B-9400-2019	Wu, Henry HL/0000-0002-4561-0844; Chinnadurai, Rajkumar/0000-0003-3973-6595			Abdel-Hafez M, 2009, AM J KIDNEY DIS, V54, P945, DOI 10.1053/j.ajkd.2009.03.019; Abramson M, 2021, KIDNEY MED, V3, P860, DOI 10.1016/j.xkme.2021.05.002; Anderegg MA, 2021, KIDNEY INT, V100, P474, DOI 10.1016/j.kint.2021.05.016; Anupama YJ, 2021, KIDNEY INT REP, V6, P2248, DOI 10.1016/j.ekir.2021.06.024; Aydin MF, 2021, KIDNEY INT, V100, P464, DOI 10.1016/j.kint.2021.05.001; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; BAKE AWLV, 1989, J CLIN INVEST, V84, P1070, DOI 10.1172/JCI114269; Barda N, 2021, NEW ENGL J MED, V385, P1078, DOI 10.1056/NEJMoa2110475; Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005; D'Agati VD, 2021, KIDNEY INT, V100, P461, DOI 10.1016/j.kint.2021.04.035; De Fabritiis M, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10081045; de la Flor Jose, 2021, Nefrologia (Engl Ed), DOI 10.1016/j.nefro.2021.05.004; Del Bello A, 2021, KIDNEY INT, V100, P238, DOI 10.1016/j.kint.2021.04.025; Dirim AB, 2021, CLIN KIDNEY J, V14, P2268, DOI 10.1093/ckj/sfab123; Dube GK, 2021, KIDNEY INT REP, V6, P3087, DOI 10.1016/j.ekir.2021.08.012; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Gillion V, 2021, KIDNEY INT, V100, P706, DOI 10.1016/j.kint.2021.06.033; Hanna C, 2021, KIDNEY INT, V100, P705, DOI 10.1016/j.kint.2021.06.032; Henry BM, 2020, INT UROL NEPHROL, V52, P1193, DOI 10.1007/s11255-020-02451-9; Hiki Y, 2001, KIDNEY INT, V59, P1077, DOI 10.1046/j.1523-1755.2001.0590031077.x; Holzworth A, 2021, KIDNEY INT, V100, P463, DOI 10.1016/j.kint.2021.05.007; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jeffs LS, 2016, CLIN RHEUMATOL, V35, P943, DOI 10.1007/s10067-015-3073-0; Kervella D, 2021, KIDNEY INT, V100, P457, DOI 10.1016/j.kint.2021.04.033; Kobayashi S, 2021, CLIN KIDNEY J, V14, P2606, DOI 10.1093/ckj/sfab156; Komaba H, 2021, AM J KIDNEY DIS, V78, P469, DOI 10.1053/j.ajkd.2021.05.006; Kudose S, 2021, KIDNEY INT, V100, P468, DOI 10.1016/j.kint.2021.06.011; Lai KN, 2012, NAT REV NEPHROL, V8, P275, DOI 10.1038/nrneph.2012.58; Lebedev L, 2021, AM J KIDNEY DIS, V78, P142, DOI 10.1053/j.ajkd.2021.03.010; Leclerc S, 2021, AM J KIDNEY DIS, V78, P607, DOI 10.1053/j.ajkd.2021.06.008; Lim JH, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e218; Maas RJ, 2021, AM J KIDNEY DIS, V78, P312, DOI 10.1053/j.ajkd.2021.05.003; Mancianti N, 2021, J NEPHROL, V34, P1039, DOI 10.1007/s40620-021-01091-1; Masset C, 2021, KIDNEY INT, V100, P465, DOI 10.1016/j.kint.2021.06.002; Morlidge C, 2021, KIDNEY INT, V100, P459, DOI 10.1016/j.kint.2021.06.005; Negrea L, 2021, KIDNEY INT, V99, P1487, DOI 10.1016/j.kint.2021.03.002; Ng JH, 2020, KIDNEY INT, V98, P1530, DOI 10.1016/j.kint.2020.07.030; Novak J, 2008, SEMIN NEPHROL, V28, P78, DOI 10.1016/j.semnephrol.2007.10.009; Obeid M, 2021, LANCET RHEUMATOL, V3, pE617, DOI 10.1016/S2665-9913(21)00211-3; Oniszczuk J, 2021, KIDNEY INT, V100, P940, DOI 10.1016/j.kint.2021.07.018; Park K, 2021, KIDNEY INT REP, V6, P2246, DOI 10.1016/j.ekir.2021.06.007; Patel C, 2019, SAUDI J KIDNEY DIS T, V30, P1002, DOI 10.4103/1319-2442.270254; Perrin P, 2021, KIDNEY INT, V100, P466, DOI 10.1016/j.kint.2021.05.022; Prendecki M, 2020, KIDNEY INT, V98, P780, DOI 10.1016/j.kint.2020.06.009; Rahim SEG, 2021, KIDNEY INT, V100, P238, DOI 10.1016/j.kint.2021.04.024; Reddy S, 2019, ADV CHRONIC KIDNEY D, V26, P72, DOI 10.1053/j.ackd.2018.10.002; Sacker A, 2021, KIDNEY INT, V100, P471, DOI 10.1016/j.kint.2021.06.006; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Salem F, 2021, KIDNEY INT REP, V6, P2523, DOI 10.1016/j.ekir.2021.07.017; Schena FP, 2018, SEMIN NEPHROL, V38, P435, DOI 10.1016/j.semnephrol.2018.05.013; Schwotzer N, 2021, KIDNEY INT, V100, P458, DOI 10.1016/j.kint.2021.05.006; Sekar A, 2021, KIDNEY INT, V100, P473, DOI 10.1016/j.kint.2021.05.017; Sette A, 2021, CELL, V184, P861, DOI 10.1016/j.cell.2021.01.007; Shakoor MT, 2021, AM J KIDNEY DIS, V78, P611, DOI 10.1053/j.ajkd.2021.06.016; Soiza RL, 2021, AGE AGEING, V50, P279, DOI 10.1093/ageing/afaa274; Tan HZ, 2021, KIDNEY INT, V100, P469, DOI 10.1016/j.kint.2021.05.009; Thomas SJ, 2021, NEW ENGL J MED, V385, P1761, DOI 10.1056/NEJMoa2110345; Tuschen K, 2021, KIDNEY INT, V100, P941, DOI 10.1016/j.kint.2021.07.019; Vivarelli M, 2017, CLIN J AM SOC NEPHRO, V12, P332, DOI 10.2215/CJN.05000516; Weijers J, 2021, KIDNEY INT, V100, P459, DOI 10.1016/j.kint.2021.06.004; Windpessl M, 2021, NAT REV NEPHROL, V17, P291, DOI 10.1038/s41581-021-00406-6; Wisnewski AV, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0249499	62	4	4	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1252	10.3390/vaccines9111252			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XJ0IG	34835183	gold, Green Published			2022-04-29	WOS:000726482600001
J	Zhang, L; Ye, X; Zhang, Y; Wang, FQ; Zhang, FQ; Jia, Y; Wu, DJ; Tohti, K; Cheng, ML; Zhu, JG				Zhang, Lei; Ye, Xin; Zhang, Yan; Wang, Fengqing; Zhang, Fanqing; Jia, Yan; Wu, Dangjin; Tohti, Kalbinur; Cheng, Manling; Zhu, Jianguo			Anti-Staphylococcus aureus Single-Chain Fragment Variables Play a Protective Anti-Inflammatory Role In Vitro and In Vivo	VACCINES			English	Article						bovine mastitis; Staphylococcus aureus (S. aureus); single-chain fragment variable (scFv); bovine mammary epithelial (MAC-T) cells; cytotoxicity; anti-inflammatory	S. AUREUS; INDUCED MASTITIS; TNF-ALPHA; APOPTOSIS; EXPRESSION; PATHOGENESIS; ANTIBODIES; INFECTION; IL-6; SCFV	Staphylococcus aureus is a causative agent of bovine mastitis, capable of causing significant economic losses to the dairy industry worldwide. This study focuses on obtaining single-chain fragment variables (scFvs) against the virulence factors of S. aureus and evaluates the protective effect of scFvs on bovine mammary epithelial (MAC-T) cells and mice mammary gland tissues infected by S. aureus. After five rounds of bio-panning, four scFvs targeting four virulence factors of S. aureus were obtained. The complementarity-determining regions (CDRs) of these scFvs exhibited significant diversities, especially CDR3 of the VH domain. In vitro, each of scFvs was capable of inhibiting S. aureus growth and reducing the damage of MAC-T cells infected by S. aureus. Preincubation of MAC-T cells with scFvs could significantly attenuate the effect of apoptosis and necrosis compared with the negative control group. In vivo, the qPCR and ELISA results demonstrated that scFvs reduced the transcription and expression of Tumor Necrosis Factor alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), IL-6, IL-8, and IL-18. Histopathology and myeloperoxidase (MPO) results showed that scFvs ameliorated the histopathological damages and reduced the inflammatory cells infiltration. The overall results demonstrated the positive anti-inflammatory effect of scFvs, revealing the potential role of scFvs in the prevention and treatment of S. aureus infections.	[Zhang, Lei; Wang, Fengqing; Zhang, Fanqing; Wu, Dangjin; Tohti, Kalbinur; Cheng, Manling; Zhu, Jianguo] Shanghai Jiao Tong Univ, Sch Agr & Biol, Shanghai Key Lab Vet Biotechnol, 800 Dongchuan Rd, Shanghai 200240, Peoples R China; [Ye, Xin; Zhang, Yan; Jia, Yan] Shanghai Jiao Tong Univ, Sch Pharm, Lab Regener, 800 Dongchuan Rd, Shanghai 200240, Peoples R China; [Zhang, Yan] Shanghai Vet Res Inst, Chinese Acad Agr Sci, Key Lab Anim Parasitol Minist Agr, Lab Qual & Safety Risk Assessment Anim Prod Bioha, Shanghai 200240, Peoples R China		Zhu, JG (通讯作者)，Shanghai Jiao Tong Univ, Sch Agr & Biol, Shanghai Key Lab Vet Biotechnol, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.; Zhang, Y (通讯作者)，Shanghai Jiao Tong Univ, Sch Pharm, Lab Regener, 800 Dongchuan Rd, Shanghai 200240, Peoples R China.	zhangyan@shvri.ac.cn			National Key Research and Development Program of China [2018YFD0501600]	This study was supported by the National Key Research and Development Program of China (grant No. 2018YFD0501600).	Alonzo F, 2013, NATURE, V493, P51, DOI 10.1038/nature11724; Alonzo F, 2012, MOL MICROBIOL, V83, P423, DOI 10.1111/j.1365-2958.2011.07942.x; Ascione A, 2009, ANTIVIR RES, V83, P238, DOI 10.1016/j.antiviral.2009.05.005; Boulanger D, 2007, VET MICROBIOL, V119, P330, DOI 10.1016/j.vetmic.2006.08.020; Chen FG, 2014, FEMS MICROBIOL LETT, V351, P95, DOI 10.1111/1574-6968.12354; Chen XX, 2018, INFLAMM RES, V67, P903, DOI 10.1007/s00011-018-1183-2; Foster TJ, 2014, NAT REV MICROBIOL, V12, P49, DOI 10.1038/nrmicro3161; Gao WQ, 2016, P NATL ACAD SCI USA, V113, pE4857, DOI 10.1073/pnas.1601700113; Ge BJ, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/j.jep.2020.113595; Ge SK, 2020, VET RES, V51, DOI 10.1186/s13567-020-00832-7; Guo MY, 2015, INT IMMUNOPHARMACOL, V29, P824, DOI 10.1016/j.intimp.2015.08.035; Guo XC, 2016, VET IMMUNOL IMMUNOP, V180, P45, DOI 10.1016/j.vetimm.2016.09.004; Gupta M, 2016, HUM PATHOL, V54, P82, DOI 10.1016/j.humpath.2016.03.006; Hammers CM, 2014, J INVEST DERMATOL, V134, DOI 10.1038/jid.2013.521; Herman-Bausier P, 2015, MBIO, V6, DOI 10.1128/mBio.00413-15; Holmes MA, 2011, J MAMMARY GLAND BIOL, V16, P373, DOI 10.1007/s10911-011-9237-x; Hua XD, 2015, ANAL CHIM ACTA, V890, P150, DOI 10.1016/j.aca.2015.07.056; Huang YY, 2019, BIOMATERIALS, V217, DOI 10.1016/j.biomaterials.2019.119231; IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7; Jenkins A, 2015, MBIO, V6, DOI 10.1128/mBio.02272-14; Jia F, 2020, J DAIRY SCI, V103, P2731, DOI 10.3168/jds.2019-17619; Kaplanski G, 2003, TRENDS IMMUNOL, V24, P25, DOI 10.1016/S1471-4906(02)00013-3; Kasprzak A, 2015, FOLIA MORPHOL, V74, P65, DOI 10.5603/FM.2015.0011; Kerro-Dego O, 2012, VET MICROBIOL, V156, P443, DOI 10.1016/j.vetmic.2011.11.018; Koksal H, 2020, CLIN RHEUMATOL, V39, P1671, DOI 10.1007/s10067-020-04925-8; Koti M, 2010, MOL IMMUNOL, V47, P953, DOI 10.1016/j.molimm.2009.11.011; Kumar S, 2013, MUCOSAL IMMUNOL, V6, P1006, DOI 10.1038/mi.2012.138; Li JN, 2019, MICROBIOLOGYOPEN, V8, DOI 10.1002/mbo3.910; Li MZ, 2020, J MATER CHEM B, V8, P1863, DOI 10.1039/c9tb02932j; Liu H, 2015, EXP MOL PATHOL, V99, P320, DOI 10.1016/j.yexmp.2015.08.002; Liu W, 2020, J BIOL CHEM, V295, P10842, DOI 10.1074/jbc.RA119.011840; Liu YX, 2014, TOXINS, V6, P3552, DOI 10.3390/toxins6123552; Merghni A, 2015, MICROB PATHOGENESIS, V86, P1, DOI 10.1016/j.micpath.2015.05.010; Miller LS, 2020, FEMS MICROBIOL REV, V44, P123, DOI 10.1093/femsre/fuz030; Mushtaq S, 2018, MICROB PATHOGENESIS, V114, P357, DOI 10.1016/j.micpath.2017.12.024; Naushad S, 2020, MSYSTEMS, V5, DOI 10.1128/mSystems.00063-20; Oliveira L, 2013, J DAIRY SCI, V96, P7538, DOI 10.3168/jds.2012-6078; Rouha H, 2015, MABS-AUSTIN, V7, P243, DOI 10.4161/19420862.2014.985132; Sagar A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060160; Sakwinska O, 2011, APPL ENVIRON MICROB, V77, P5908, DOI 10.1128/AEM.00238-11; Saw PE, 2019, PROTEIN CELL, V10, P787, DOI 10.1007/s13238-019-0639-7; Schmiedl A, 2000, PROTEIN ENG, V13, P725, DOI 10.1093/protein/13.10.725; Shao GX, 2015, INT IMMUNOPHARMACOL, V29, P263, DOI 10.1016/j.intimp.2015.11.011; Shaw I, 2008, ANAL CHEM, V80, P3205, DOI 10.1021/ac7024199; Shinefield HR, 2005, EXPERT REV VACCINES, V4, P669, DOI 10.1586/14760584.4.5.669; Sompunga P, 2019, TALANTA, V201, P397, DOI 10.1016/j.talanta.2019.04.034; Su YT, 2018, CLIN CANCER RES, V24, P1124, DOI 10.1158/1078-0432.CCR-17-2032; Thammavongsa V, 2015, NAT REV MICROBIOL, V13, P529, DOI 10.1038/nrmicro3521; Torres VJ, 2007, CELL HOST MICROBE, V1, P109, DOI 10.1016/j.chom.2007.03.001; Tuchscherr LPN, 2005, INFECT IMMUN, V73, P7932, DOI 10.1128/IAI.73.12.7932-7937.2005; Verdrengh M, 2004, MICROBES INFECT, V6, P1268, DOI 10.1016/j.micinf.2004.08.009; Viguier C, 2009, TRENDS BIOTECHNOL, V27, P486, DOI 10.1016/j.tibtech.2009.05.004; Vrieling M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37759; Vu KB, 1997, MOL IMMUNOL, V34, P1121, DOI 10.1016/S0161-5890(97)00146-6; Wang GZ, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00418; Wang M, 2019, APPL MICROBIOL BIOT, V103, P1703, DOI 10.1007/s00253-018-9548-6; Wang M, 2016, APPL MICROBIOL BIOT, V100, P2153, DOI 10.1007/s00253-015-7045-8; Wang TC, 2014, INT IMMUNOPHARMACOL, V22, P192, DOI 10.1016/j.intimp.2014.06.015; Wang-Bishop L, 2019, GASTROENTEROLOGY, V156, P662, DOI 10.1053/j.gastro.2018.10.030; Xu J, 2020, J INFLAMM RES, V13, P847, DOI 10.2147/JIR.S280091; Zhang FQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010058; Zhen YH, 2008, J APPL MICROBIOL, V105, P1529, DOI 10.1111/j.1365-2672.2008.03920.x; Zou YJ, 2020, VET SCI, V7, DOI 10.3390/vetsci7030112	63	1	1	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1300	10.3390/vaccines9111300			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF1HI	34835231	Green Published, gold			2022-04-29	WOS:000723827800001
J	Gonzalez-Dominguez, I; Lorenzo, E; Bernier, A; Cervera, L; Godia, F; Kamen, A				Gonzalez-Dominguez, Irene; Lorenzo, Elianet; Bernier, Alice; Cervera, Laura; Godia, Francesc; Kamen, Amine			A Four-Step Purification Process for Gag VLPs: From Culture Supernatant to High-Purity Lyophilized Particles	VACCINES			English	Article						Gag VLPs; purification; clarification; chromatography; lyophilization; EVs; nanoparticle quantification	VIRUS-LIKE PARTICLES; HIGH-YIELD PRODUCTION; TRANSIENT TRANSFECTION; VACCINES; CLARIFICATION; GENERATION; SEPARATION; VECTORS; ASSAY	Gag-based virus-like particles (VLPs) have high potential as scaffolds for the development of chimeric vaccines and delivery strategies. The production of purified preparations that can be preserved independently from cold chains is highly desirable to facilitate distribution and access worldwide. In this work, a nimble purification has been developed, facilitating the production of Gag VLPs. Suspension-adapted HEK 293 cells cultured in chemically defined cell culture media were used to produce the VLPs. A four-step downstream process (DSP) consisting of membrane filtration, ion-exchange chromatography, polishing, and lyophilization was developed. The purification of VLPs from other contaminants such as host cell proteins (HCP), double-stranded DNA, or extracellular vesicles (EVs) was confirmed after their DSP. A concentration of 2.2 & PLUSMN; 0.8 x 10(9) VLPs/mL in the lyophilized samples was obtained after its storage at room temperature for two months. Morphology and structural integrity of purified VLPs was assessed by cryo-TEM and NTA. Likewise, the purification methodologies proposed here could be easily scaled up and applied to purify similar enveloped viruses and vesicles.</p>	[Gonzalez-Dominguez, Irene; Lorenzo, Elianet; Cervera, Laura; Godia, Francesc] Univ Autonoma Barcelona, Dept Engn Quim Biol & Ambiental, Barcelona 08193, Spain; [Bernier, Alice; Kamen, Amine] McGill Univ, Dept Bioengn, Montreal, PQ H3A 0E9, Canada; [Gonzalez-Dominguez, Irene] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA		Gonzalez-Dominguez, I (通讯作者)，Univ Autonoma Barcelona, Dept Engn Quim Biol & Ambiental, Barcelona 08193, Spain.	irene.gonzalez.dominguez.phd@gmail.com; Elianet.Lorenzo@uab.cat; bernier.alice@videotron.ca; Laura.Cervera@uab.cat; Francesc.Godia@uab.cat; amine.kamen@mcgill.ca		Lorenzo, Elianet/0000-0002-5442-0831; Gonzalez-Dominguez, Irene/0000-0002-7920-5505; Kamen, Amine/0000-0001-9110-8815	Irene Gonzalez-Dominguez is recipient of FPU grant [FPU16/02555, EEBB (EST18/00463]; Ministerio de Educacion, Cultura y Deporte of Spain.	Funding Irene Gonzalez-Dominguez is recipient of FPU grant (FPU16/02555) and a EEBB (EST18/00463) grant from Ministerio de Educacion, Cultura y Deporte of Spain.	Aguilar PP, 2020, J CHROMATOGR A, V1627, DOI 10.1016/j.chroma.2020.461378; Aguilar PP, 2019, VACCINE, V37, P7070, DOI 10.1016/j.vaccine.2019.07.001; Aguilar PP, 2019, J SEP SCI, V42, P2640, DOI 10.1002/jssc.201900441; ANDERSON EC, 1970, BIOPHYS J, V10, P630, DOI 10.1016/S0006-3495(70)86325-1; Besnard L, 2016, BIOTECHNOL ADV, V34, P1, DOI 10.1016/j.biotechadv.2015.11.005; Carvalho SB, 2019, BIOTECHNOL J, V14, DOI 10.1002/biot.201800570; Carvalho SB, 2019, SEP PURIF TECHNOL, V218, P81, DOI 10.1016/j.seppur.2019.02.040; Cervera L, 2019, APPL MICROBIOL BIOT, V103, P7367, DOI 10.1007/s00253-019-10038-3; Cervera L, 2017, BIOTECHNOL BIOENG, V114, P2507, DOI 10.1002/bit.26367; Cervera L, 2015, APPL MICROBIOL BIOT, V99, P9935, DOI 10.1007/s00253-015-6842-4; Cervera L, 2013, J BIOTECHNOL, V166, P152, DOI 10.1016/j.jbiotec.2013.05.001; Chen Y, 2009, BIOPHYS J, V96, P1961, DOI 10.1016/j.bpj.2008.10.067; Donaldson B, 2018, EXPERT REV VACCINES, V17, P833, DOI 10.1080/14760584.2018.1516552; EATON LC, 1995, J CHROMATOGR A, V705, P105, DOI 10.1016/0021-9673(94)01249-E; Effio CL, 2015, BIOTECHNOL J, V10, P715, DOI 10.1002/biot.201400392; Gonzalez-Dominguez I, 2019, NEW BIOTECHNOL, V49, P88, DOI 10.1016/j.nbt.2018.09.005; Gonzalez-Dominguez I, 2020, BIOTECHNOL BIOENG, V117, P1929, DOI 10.1002/bit.27345; Gonzalez-Dominguez I, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020223; Gottlinger HG, 2001, HIV 1 GAG MOL MACHIN; Gutierrez-Granados S, 2013, J VIROL METHODS, V193, P85, DOI 10.1016/j.jviromet.2013.05.010; Hansen LJJ, 2015, VACCINE, V33, P5507, DOI 10.1016/j.vaccine.2015.08.085; Hill BD, 2018, CURR PROTEIN PEPT SC, V19, P112, DOI 10.2174/1389203718666161122113041; Hume HKC, 2019, BIOTECHNOL BIOENG, V116, P919, DOI 10.1002/bit.26890; Joshi PRH, 2019, MOL THER-METH CLIN D, V13, P279, DOI 10.1016/j.omtm.2019.02.003; Knezevic I, 2008, BIOLOGICALS, V36, P203, DOI 10.1016/j.biologicals.2007.11.005; Kumru OS, 2014, BIOLOGICALS, V42, P237, DOI 10.1016/j.biologicals.2014.05.007; Kutner RH, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-10; Lynch A, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-210; Malvern Instruments Limited, 2015, DET FLUOR LIM DET NA; McNally DJ, 2014, J CHROMATOGR A, V1340, P24, DOI 10.1016/j.chroma.2014.03.023; Moleirinho MG, 2020, EXPERT OPIN BIOL TH, V20, P451, DOI 10.1080/14712598.2020.1693541; Nestola P, 2015, BIOTECHNOL BIOENG, V112, P843, DOI 10.1002/bit.25545; Nestola P, 2014, J BIOTECHNOL, V181, P1, DOI 10.1016/j.jbiotec.2014.04.003; Pato TP, 2014, VACCINE, V32, P2789, DOI 10.1016/j.vaccine.2014.02.036; Reiter K, 2019, J CHROMATOGR A, V1588, P77, DOI 10.1016/j.chroma.2018.12.035; Steppert P, 2017, J SEP SCI, V40, P979, DOI 10.1002/jssc.201600765; Steppert P, 2016, J CHROMATOGR A, V1455, P93, DOI 10.1016/j.chroma.2016.05.053; Venereo-Sanchez A, 2017, VACCINE, V35, P4220, DOI 10.1016/j.vaccine.2017.06.024; Venereo-Sanchez A, 2016, VACCINE, V34, P3371, DOI 10.1016/j.vaccine.2016.04.089; Westoby M, 2011, BIOTECHNOL BIOENG, V108, P50, DOI 10.1002/bit.22923	40	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1154	10.3390/vaccines9101154			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR5WC	34696262	Green Published, gold			2022-04-29	WOS:000714568600001
J	Karami, A; Zhu, MC; Goldschmidt, B; Boyajieff, HR; Najafabadi, MM				Karami, Amir; Zhu, Michael; Goldschmidt, Bailey; Boyajieff, Hannah R.; Najafabadi, Mahdi M.			COVID-19 Vaccine and Social Media in the U.S.: Exploring Emotions and Discussions on Twitter	VACCINES			English	Article						COVID-19; vaccine; social media; text mining; topic modeling; sentiment analysis	HEALTH; DISCOVERY; CAMPAIGNS; HESITANCY; TEXT	The understanding of the public response to COVID-19 vaccines is the key success factor to control the COVID-19 pandemic. To understand the public response, there is a need to explore public opinion. Traditional surveys are expensive and time-consuming, address limited health topics, and obtain small-scale data. Twitter can provide a great opportunity to understand public opinion regarding COVID-19 vaccines. The current study proposes an approach using computational and human coding methods to collect and analyze a large number of tweets to provide a wider perspective on the COVID-19 vaccine. This study identifies the sentiment of tweets using a machine learning rule-based approach, discovers major topics, explores temporal trend and compares topics of negative and non-negative tweets using statistical tests, and discloses top topics of tweets having negative and non-negative sentiment. Our findings show that the negative sentiment regarding the COVID-19 vaccine had a decreasing trend between November 2020 and February 2021. We found Twitter users have discussed a wide range of topics from vaccination sites to the 2020 U.S. election between November 2020 and February 2021. The findings show that there was a significant difference between tweets having negative and non-negative sentiment regarding the weight of most topics. Our results also indicate that the negative and non-negative tweets had different topic priorities and focuses. This research illustrates that Twitter data can be used to explore public opinion regarding the COVID-19 vaccine.	[Karami, Amir] Univ South Carolina, Sch Informat Sci, Columbia, SC 29208 USA; [Zhu, Michael] Univ South Carolina, Dept Psychol, Columbia, SC 29208 USA; [Goldschmidt, Bailey] Univ South Carolina, Coll Nursing, Columbia, SC 29208 USA; [Boyajieff, Hannah R.] Univ South Carolina, Darla Moore Sch Business, Columbia, SC 29208 USA; [Najafabadi, Mahdi M.] CUNY, Grad Sch Publ Hlth, New York, NY 10010 USA		Karami, A (通讯作者)，Univ South Carolina, Sch Informat Sci, Columbia, SC 29208 USA.	karami@sc.edu; mz3@email.sc.edu; goldschb@email.sc.edu; boyajieh@email.sc.edu; Mahdi.Najafabadi@sph.cuny.edu	M. Najafabadi, Mahdi/M-8974-2014	M. Najafabadi, Mahdi/0000-0001-6095-8120; Goldschmidt, Bailey/0000-0003-4237-7183	Big Data Health Science Center (BDHSC) at the University of South Carolina	This research was partially supported by the Big Data Health Science Center (BDHSC) at the University of South Carolina. All opinions, findings, conclusions, and recommendations in this paper are those of the authors and do not necessarily reflect the views of the funding agency.	Abd-Alrazaq A, 2020, J MED INTERNET RES, V22, DOI 10.2196/19016; Anderson Mackenzie, 2020, Proc Assoc Inf Sci Technol, V57, pe378, DOI 10.1002/pra2.378; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; Asgary A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18010268; Asgary A, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8040469; Atehortua NA, 2021, HEALTH PROMOT INT, V36, P524, DOI 10.1093/heapro/daaa140; Bannister K., 2018, UNDERSTANDING SENTIM; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blei DM, 2003, J MACH LEARN RES, V3, P993, DOI 10.1162/jmlr.2003.3.4-5.993; Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567; Chen T, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.8221; Cheung ACK, 2016, EDUC RESEARCHER, V45, P283, DOI 10.3102/0013189X16656615; Chew C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014118; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd ed; Corley CD, 2010, INT J ENV RES PUB HE, V7, P596, DOI 10.3390/ijerph7020596; Criss S, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18115693; Dredze M, 2017, SYNTH LECT INF CONCE, V9, P1, DOI [DOI 10.2200/S00791ED1V01Y201707ICR060, 10.2200/s00791ed1v01y201707icr060]; Eibensteiner F, 2021, J MED INTERNET RES, V23, DOI 10.2196/28973; Funk C, 2021, GROWING SHARE AM SAY; GOOD IJ, 1982, J STAT COMPUT SIM, V16, P65, DOI 10.1080/00949658208810607; Griffith J, 2021, J MED INTERNET RES, V23, DOI 10.2196/26874; Harris JK, 2017, J PUBLIC HEALTH MAN, V23, P577, DOI 10.1097/PHH.0000000000000516; Hernandez RG, 2021, HUM VACC IMMUNOTHER, V17, P2962, DOI 10.1080/21645515.2021.1912551; Herrera-Peco I, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9060662; Hughes A., 2019, 10 FACTS AM TWITTER; Hussain A, 2021, J MED INTERNET RES, V23, DOI 10.2196/26627; Hutto C., 2014, P 8 INT C WEBL SOC M, V8, P216; Johns Hopkins University, 2021, COVID 19 DASHB; Jungherr A, 2016, J INF TECHNOL POLITI, V13, P72, DOI 10.1080/19331681.2015.1132401; Karami A., 2021, INT J INF MANAG DATA, V1, DOI [10.1016/j.jjimei.2021.100016, DOI 10.1016/J.JJIMEI.2021.100016]; Karami A, 2021, ELECTRONICS-SWITZ, V10, DOI 10.3390/electronics10151822; Karami A, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9050518; Karami A, 2021, INT J ENV RES PUB HE, V18, P2159, DOI 10.3390/ijerph18042159; Karami Amir, 2020, Proc Assoc Inf Sci Technol, V57, pe349, DOI 10.1002/pra2.349; Karami A, 2015, 2015 ANNUAL MEETING OF THE NORTH AMERICAN FUZZY INFORMATION PROCESSING SOCIETY DIGIPEN NAFIPS 2015; Karami A, 2020, IEEE ACCESS, V8, P67698, DOI 10.1109/ACCESS.2020.2983656; Karami A, 2018, INT J FUZZY SYST, V20, P1334, DOI 10.1007/s40815-017-0327-9; Kim JH, 2015, J EMPIR FINANC, V34, P1, DOI 10.1016/j.jempfin.2015.08.006; Kwok SWH, 2021, J MED INTERNET RES, V23, DOI 10.2196/26953; Lim BH, 2015, VIOLENCE AGAINST WOM, V21, P1065, DOI 10.1177/1077801215590670; Liu SR, 2021, J MED INTERNET RES, V23, DOI 10.2196/28118; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Massey PM, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.6670; McCallum A. K., 2002, MALLET MACHINE LEARN; McGraw T., 2020, SPENDING 2020 TOGETH; Moehring A., SURFACING NORMS INCR; Moorhead SA, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.1933; Pennebaker J.W., 2015, DEV PSYCHOMETRIC PRO; Piedrahita-Valdes H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010028; Pruim R., 2012; Ray J., 2021, 1 BILLION WORLDWIDE; Roder M, 2015, WSDM'15: PROCEEDINGS OF THE EIGHTH ACM INTERNATIONAL CONFERENCE ON WEB SEARCH AND DATA MINING, P399, DOI 10.1145/2684822.2685324; Rufai SR, 2020, J PUBLIC HEALTH-UK, V42, P510, DOI 10.1093/pubmed/fdaa049; Ruiz J., 2021, P 54 HAW INT C SYST, P3964; Salathe M, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002199; Samet A., 2020, CORONAVIRUS IS CHANG; Sawilowsky SS, 2009, J MOD APPL STAT METH, V8, P597, DOI 10.22237/jmasm/1257035100; Scanfeld D, 2010, AM J INFECT CONTROL, V38, P182, DOI 10.1016/j.ajic.2009.11.004; Shahi Gautam Kishore, 2021, Online Soc Netw Media, V22, P100104, DOI 10.1016/j.osnem.2020.100104; Sojka, 2010, P LREC 2010 WORKSH N, P45, DOI DOI 10.13140/2.1.2393.1847; Sullivan Gail M, 2012, J Grad Med Educ, V4, P279, DOI 10.4300/JGME-D-12-00156.1; Thelwall M, 2021, PROF INFORM, V30, DOI 10.3145/epi.2021.mar.12; To QG, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18084069; Tweetbinder, 2021, MAN TWEETS COV 19 CO; Wang C, 2021, VACCINE, V39, P2833, DOI 10.1016/j.vaccine.2021.04.020; Xue J, 2020, J MED INTERNET RES, V22, DOI 10.2196/20550; Yu M., 2021, CURR ISSUES TOUR, V20, P1075, DOI DOI 10.1080/13683500.2020.1752632; Zhao YX, 2020, J MED INTERNET RES, V22, DOI 10.2196/18825	68	4	4	13	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1059	10.3390/vaccines9101059			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP9AN	34696167	Green Published, Green Submitted, gold			2022-04-29	WOS:000713416800001
J	Pedersen, K; Kristensen, CS; Kvisgaard, LK; Larsen, LE				Pedersen, Kasper; Kristensen, Charlotte Sonne; Kvisgaard, Lise Kirstine; Larsen, Lars Erik			Impacts of Quarterly Sow Mass Vaccination with a Porcine Reproductive and Respiratory Syndrome Virus Type 1 (PRRSV-1) Modified Live Vaccine in Two Herds	VACCINES			English	Article						PRRSV; mass vaccination; serological assay; immune response	COMPLETE GENOMES; INOCULATION; EFFICACY; DENMARK; PERIOD; TRIAL; FARM	In recent years, there has been a considerable increase in the use of Modified Live PRRSV Vaccines (MLV) for mass vaccination in Denmark. The potential risks and negative impact of this strategy have been sparsely studied. The aim of this study was to investigate the impact of quarterly sow mass vaccination in two Danish sow herds. The study was performed as an observational prospective cohort of 120 sows in each of two commercial breeding herds in a paired design. Blood samples were taken from sows and oral fluid samples from nursery pigs (four to ten weeks old) before and after vaccination. The presence of PRRSV-1 RNA was measured by real time quantitative reverse transcription-polymerase chain reaction (RT-qPCR), and the level of PRRSV-1 specific antibodies was measured by two different serological assays. PRRS virus was not detected in the sow herds two days before and two weeks after vaccination, but the vaccine strain virus was detected in the nursery pigs. The prevalence of sows without antibodies towards PRRSV-1 went from 6-15% before vaccination to 1-4% after vaccination depending on the serological assay used, despite the fact that they had previously been repeatedly vaccinated. Four sows tested negative for antibodies in both assays after vaccination.</p>	[Pedersen, Kasper; Kristensen, Charlotte Sonne] SEGES Danish Pig Res Ctr, Agro Food Pk 15V, DK-8200 Aarhus N, Denmark; [Kvisgaard, Lise Kirstine; Larsen, Lars Erik] Univ Copenhagen, Fac Hlth & Med Sci, Dept Vet & Anim Sci, DK-1870 Frederiksberg C, Denmark		Larsen, LE (通讯作者)，Univ Copenhagen, Fac Hlth & Med Sci, Dept Vet & Anim Sci, DK-1870 Frederiksberg C, Denmark.	KAPE@seges.dk; CSK@seges.dk; likik@sund.ku.dk; LAEL@sund.ku.dk	Larsen, Lars Erik/G-3827-2015	Larsen, Lars Erik/0000-0003-0730-5555	Danish Pig Levy Fund	Impacts Quarterly Sow	Alexopoulos C, 2005, VET MICROBIOL, V111, P151, DOI 10.1016/j.vetmic.2005.10.007; Baker B., 1999, P 26 AD LEM SWIN C S, P31; Bassaganya-Riera J, 2004, VIRAL IMMUNOL, V17, P25, DOI 10.1089/088282404322875430; Cano JP, 2009, CAN J VET RES, V73, P303; Diaz I, 2013, VET J, V197, P438, DOI 10.1016/j.tvjl.2013.02.008; Diaz Ivan, 2020, Vet Rec, V186, P123, DOI 10.1136/vr.105432; Holtkamp DJ, 2011, J SWINE HEALTH PROD, V19, P44; Jeong J, 2014, AM J VET RES, V75, P260, DOI 10.2460/ajvr.75.3.260; Khurana S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11296-5; Kim T, 2015, CLIN VACCINE IMMUNOL, V22, P631, DOI 10.1128/CVI.00001-15; Kittawornrat A, 2014, VET MICROBIOL, V168, P331, DOI 10.1016/j.vetmic.2013.11.035; Kristensen CS, 2020, PORCINE HEALTH MANAG, V6, DOI 10.1186/s40813-020-00165-z; Kvisgaard LK, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050417; Kvisgaard LK, 2013, VET MICROBIOL, V167, P334, DOI 10.1016/j.vetmic.2013.09.023; Kvisgaard LK, 2013, VIRUS RES, V178, P197, DOI 10.1016/j.virusres.2013.10.009; Kvisgaard LK, 2020, TRANSBOUND EMERG DIS, V67, P1786, DOI 10.1111/tbed.13555; Lebret A, 2021, PORCINE HEALTH MANAG, V7, DOI 10.1186/s40813-020-00186-8; Lebret A, 2019, PORCINE HEALTH MANAG, V5, DOI 10.1186/s40813-019-0115-z; Linhares DCL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144265; Madapong A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58626-y; Morimoto N, 2018, VACCINE, V36, P949, DOI 10.1016/j.vaccine.2018.01.023; Ostrowski M, 2002, J VIROL, V76, P4241, DOI 10.1128/JVI.76.9.4241-4250.2002; Pejsak Z, 2006, VET REC, V158, P475, DOI 10.1136/vr.158.14.475; Rowland RRR, 2010, VIRUS RES, V154, P114, DOI 10.1016/j.virusres.2010.09.001; Skowronski DM, 2016, CLIN INFECT DIS, V63, P21, DOI 10.1093/cid/ciw176; Torrents D, 2019, PORCINE HEALTH MANAG, V5, DOI 10.1186/s40813-019-0134-9; Vilalta C, 2019, VET MICROBIOL, V237, DOI 10.1016/j.vetmic.2019.108406; Wagstrom EA, 2001, AM J VET RES, V62, P1876, DOI 10.2460/ajvr.2001.62.1876; Wernike K, 2012, J VET DIAGN INVEST, V24, P855, DOI 10.1177/1040638712452724; Wiedermann U, 2016, HUM VACC IMMUNOTHER, V12, P239, DOI 10.1080/21645515.2015.1093263; Zuckermann FA, 2007, VET MICROBIOL, V123, P69, DOI 10.1016/j.vetmic.2007.02.009	31	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1057	10.3390/vaccines9101057			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN2XU	34696165	Green Published			2022-04-29	WOS:000711637500001
J	Singanallur, NB; Dekker, A; Eble, PL; van Hemert-Kluitenberg, F; Weerdmeester, K; Horsington, JJ; Vosloo, W				Singanallur, Nagendrakumar Balasubramanian; Dekker, Aldo; Eble, Phaedra Lydia; van Hemert-Kluitenberg, Froukje; Weerdmeester, Klaas; Horsington, Jacquelyn J.; Vosloo, Wilna			Emergency FMD Serotype O Vaccines Protect Cattle against Heterologous Challenge with a Variant Foot-and-Mouth Disease Virus from the O/ME-SA/Ind2001 Lineage	VACCINES			English	Article						foot-and-mouth disease virus; vaccine efficacy; heterologous challenge; cattle; serotype O/ME-SA/Ind2001 variant	HIGH-POTENCY; VACCINATION; SHEEP; TRANSMISSION; CARRIERS; PIGS	Vaccination is one of the best approaches to control and eradicate foot-and-mouth disease (FMD). To achieve this goal, vaccines with inactivated FMD virus antigen in suitable adjuvants are being used in addition to other control measures. However, only a limited number of vaccine strains are commercially available, which often have a restricted spectrum of activity against the different FMD virus strains in circulation. As a result, when new strains emerge, it is important to measure the efficacy of the current vaccine strains against these new variants. This is important for countries where FMD is endemic but also for countries that hold an FMD vaccine bank, to ensure they are prepared for emergency vaccination. The emergence and spread of the O/ME-SA/Ind-2001 lineage of viruses posed a serious threat to countries with OIE-endorsed FMD control plans who had not reported FMD for many years. In vitro vaccine-matching results showed a poor match (r(1)-value < 0.3) with the more widely used vaccine strain O-1 Manisa and less protection in a challenge test. This paper describes the use of the O3039 vaccine strain as an alternative, either alone or in combination with the O-1 Manisa vaccine strain with virulent challenge by a O/ME-SA/Ind-2001d sub-lineage virus from Algeria (O/ALG/3/2014). The experiment included challenge at 7 days post-vaccination (to study protection and emergency use) and 21 days post-vaccination (as in standard potency studies). The results indicated that the O3039 vaccine strain alone, as well as the combination with O-1 Manisa, is effective against this strain of the O/ME-SA/Ind/2001d lineage, offering protection from clinical disease even after 7 days post-vaccination with a reduction in viraemia and virus excretion.	[Singanallur, Nagendrakumar Balasubramanian; Horsington, Jacquelyn J.; Vosloo, Wilna] CSIRO Hlth & Biosecur, Australian Ctr Dis Preparedness, 5 Portarlington Rd, Geelong, Vic 3220, Australia; [Dekker, Aldo; Eble, Phaedra Lydia; van Hemert-Kluitenberg, Froukje; Weerdmeester, Klaas] Wageningen Biovet Res, Lab Vesicular Dis, Dept Virol & Mol Biol, Houtribweg 39, NL-8221 RA Lelystad, Netherlands		Singanallur, NB (通讯作者)，CSIRO Hlth & Biosecur, Australian Ctr Dis Preparedness, 5 Portarlington Rd, Geelong, Vic 3220, Australia.	nagendra.singanallur@csiro.au; Aldo.Dekker@wur.nl; phaedra.eble@wur.nl; W.Hemert@upcmail.nl; KWeerd@hotmail.com; jacquelynjh@gmail.com; wilna.vosloo@csiro.au	SINGANALLUR, NAGENDRAKUMAR/G-9349-2013	SINGANALLUR, NAGENDRAKUMAR/0000-0002-0523-3853; Dekker, Aldo/0000-0002-0519-9587	Meat & Livestock Australia (MLA) through Australian Government Department of Agriculture, Water and the Environment as part of its Rural R&D for Profit program [P.PSH.0779, RRND4P-15-02-032]; Animal Health Australia (AHA); Ministry of Agriculture, Nature and Food Quality, the Netherlands [WOT-01-003-011]	This project is supported by Meat & Livestock Australia (MLA; P.PSH.0779), through funding from the Australian Government Department of Agriculture, Water and the Environment as part of its Rural R&D for Profit program (RRND4P-15-02-032), and by producer levies from Australian FMD-susceptible livestock (cattle, sheep, goats and pigs) industries and Charles Sturt University (CSU), leveraging significant in-kind support from the research partners. The research partners for this project are the Commonwealth Science and Industrial Research Organisation (CSIRO), CSU through the Graham Centre for Agricultural Innovation, the Bureau of Meteorology (BOM) and the Australian Department of Agriculture, Water and the Environment, supported by Animal Health Australia (AHA). The study was funded by the Ministry of Agriculture, Nature and Food Quality, the Netherlands (project WOT-01-003-011).	Arzt J, 2011, TRANSBOUND EMERG DIS, V58, P291, DOI 10.1111/j.1865-1682.2011.01204.x; Backer JA, 2012, PREV VET MED, V107, P41, DOI 10.1016/j.prevetmed.2012.05.013; Backer JA, 2012, PREV VET MED, V107, P27, DOI 10.1016/j.prevetmed.2012.05.012; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Bertram MR, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00174; Bouma A, 2004, VET MICROBIOL, V98, P29, DOI 10.1016/j.vetmic.2003.10.016; Brehm KE, 2008, VACCINE, V26, P1681, DOI 10.1016/j.vaccine.2008.01.038; Buetre B., 2013, POTENTIAL SOCIOECON; Clavijo A, 2017, TRANSBOUND EMERG DIS, V64, P31, DOI 10.1111/tbed.12345; Cox SJ, 1999, VACCINE, V17, P1858, DOI 10.1016/S0264-410X(98)00486-1; Dekker A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010024; DOEL TR, 1994, VACCINE, V12, P592, DOI 10.1016/0264-410X(94)90262-3; Domingo E, 2003, VIRUS RES, V91, P47, DOI 10.1016/S0168-1702(02)00259-9; Fishbourne E, 2017, VACCINE, V35, P2761, DOI 10.1016/j.vaccine.2017.02.047; Garland AJM, 2011, REV SCI TECH OIE, V30, P189; Geale DW, 2015, TRANSBOUND EMERG DIS, V62, P388, DOI 10.1111/tbed.12165; GOLDING SM, 1976, RES VET SCI, V20, P142, DOI 10.1016/S0034-5288(18)33445-3; Hicks HM, 2020, MICROBIOL RESOUR ANN, V9, DOI 10.1128/MRA.00165-20; Horsington J, 2017, VACCINE, V35, P5179, DOI 10.1016/j.vaccine.2017.07.102; Horsington J, 2015, VACCINE, V33, P422, DOI 10.1016/j.vaccine.2014.11.043; Jamal SM, 2021, TRANSBOUND EMERG DIS, V68, P3126, DOI 10.1111/tbed.14134; Knight-Jones TJD, 2013, PREV VET MED, V112, P161, DOI 10.1016/j.prevetmed.2013.07.013; Knowles NJ, 2016, TRANSBOUND EMERG DIS, V63, pE431, DOI 10.1111/tbed.12299; Moonen P, 2004, VET MICROBIOL, V103, P151, DOI 10.1016/j.vetmic.2004.07.005; Moonen P, 2003, J VIROL METHODS, V113, P35, DOI 10.1016/S0166-0934(03)00220-9; Nagendrakumar SB, 2015, VACCINE, V33, P4513, DOI 10.1016/j.vaccine.2015.07.014; OIE, 2017, OIE TERESTRIAL MANUA; OIE/FAO Foot-and-Mouth Disease Reference Laboratory Network, 2016, WRL FMD REP; OIE/-FAO Foot-and-Mouth Disease Reference Laboratory Network, 2015, WRL FMD REP; Orsel K, 2008, VET REC, V162, P753, DOI 10.1136/vr.162.23.753; Orsel K, 2007, VACCINE, V25, P327, DOI 10.1016/j.vaccine.2006.07.030; Qiu Y, 2018, TRANSBOUND EMERG DIS, V65, pe104, DOI 10.1111/tbed.12687; R Core Team, 2020, R LANGUAGE ENV STAT; RODRIGO MJ, 1995, J MOL EVOL, V40, P362, DOI 10.1007/BF00164022; Singanallur NB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010080; SUTMOLLER P, 1968, ARCH GES VIRUSFORSCH, V23, P227, DOI 10.1007/BF01241895; Tenzin, 2008, RISK ANAL, V28, P303, DOI 10.1111/j.1539-6924.2008.01020.x; Wilna V, 2015, VACCINE, V33, P2778, DOI 10.1016/j.vaccine.2015.04.045	38	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1110	10.3390/vaccines9101110			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN4LQ	34696216	Green Published, gold			2022-04-29	WOS:000711741700001
J	Trincado, V; Gala, RP; Morales, JO				Trincado, Valeria; Gala, Rikhav P.; Morales, Javier O.			Buccal and Sublingual Vaccines: A Review on Oral Mucosal Immunization and Delivery Systems	VACCINES			English	Review						mucosal immunity; buccal vaccines; sublingual vaccines; adjuvants; antigen delivery systems	HEAT-LABILE ENTEROTOXIN; IN-VIVO UPTAKE; IMMUNE-RESPONSES; M CELLS; CHITOSAN MICROPARTICLES; GENETIC IMMUNIZATION; COATED MICRONEEDLES; INFLUENZA VACCINE; LYMPHOID-TISSUES; SKIN DELIVERY	Currently, most vaccines available on the market are for parental use; however, this may not be the best option on several occasions. Mucosal routes of administration such as intranasal, sublingual, and buccal generate great interest due to the benefits they offer. These range from increasing patient compliance to inducing a more effective immune response than that achieved through conventional routes. Due to the activation of the common mucosal immune system, it is possible to generate an effective systemic and local immune response, which is not achieved through parenteral administration. Protection against pathogens that use mucosal entry routes is provided by an effective induction of mucosal immunity. Mucosal delivery systems are being developed, such as films and microneedles, which have proven to be effective, safe, and easy to administer. These systems have multiple advantages over commonly used injections, which are simple to manufacture, stable at room temperature, painless for the patient since they do not require puncture. Therefore, these delivery systems do not require to be administered by medical personnel; in fact, they could be self-administered.</p>	[Trincado, Valeria; Morales, Javier O.] Univ Chile, Dept Ciencias & Tecnol Farmaceut, Drug Delivery Lab, Santiago 8380494, Chile; [Trincado, Valeria; Morales, Javier O.] Adv Ctr Chron Dis ACCDiS, Santiago 8380494, Chile; [Trincado, Valeria; Morales, Javier O.] Ctr New Drugs Hypertens CENDHY, Santiago 8380494, Chile; [Gala, Rikhav P.] Fraunhofer USA, Biotechnol Div, Ctr Midatlant, Newark, DE 19702 USA		Morales, JO (通讯作者)，Univ Chile, Dept Ciencias & Tecnol Farmaceut, Drug Delivery Lab, Santiago 8380494, Chile.; Morales, JO (通讯作者)，Adv Ctr Chron Dis ACCDiS, Santiago 8380494, Chile.; Morales, JO (通讯作者)，Ctr New Drugs Hypertens CENDHY, Santiago 8380494, Chile.	valeria.trincado@ug.uchile.cl; Rikhav.Gala@fhcmb.org; jomorales@ciq.uchile.cl	; Morales, Javier/I-3902-2013	Trincado, Valeria/0000-0002-5134-3746; Morales, Javier/0000-0002-3190-2168; Gala, Rikhav Praful/0000-0003-2789-5804	Chilean National Agency for Research and Development (ANID) [1181689, ANID/PIA/ACT192144, 15130011]	This work was funded by FONDECYT Project 1181689, ANID/PIA/ACT192144, and FONDAP Project 15130011; all granted by Chilean National Agency for Research and Development (ANID).	Ahmed TA, 2016, DRUG DES DEV THER, V10, P483, DOI 10.2147/DDDT.S99651; Ali AA, 2017, NANOMED-NANOTECHNOL, V13, P921, DOI 10.1016/j.nano.2016.11.019; Ashkenazi S, 2006, PEDIATR INFECT DIS J, V25, P870, DOI 10.1097/01.inf.0000237829.66310.85; Bajrovic I, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aau4819; Bal SM, 2010, J CONTROL RELEASE, V147, P218, DOI 10.1016/j.jconrel.2010.07.104; Balmelli C, 2002, J VIROL, V76, P12596, DOI 10.1128/JVI.76.24.12596-12602.2002; Bankvall M, 2016, IMMUNOLOGY, V149, P98, DOI 10.1111/imm.12633; Belyakov IM, 1998, P NATL ACAD SCI USA, V95, P1709, DOI 10.1073/pnas.95.4.1709; Bolton DL, 2012, MUCOSAL IMMUNOL, V5, P41, DOI 10.1038/mi.2011.45; Borchard G, 1996, J CONTROL RELEASE, V39, P131, DOI 10.1016/0168-3659(95)00146-8; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Brandtzaeg P, 2010, IMMUNOL INVEST, V39, P303, DOI 10.3109/08820131003680369; Carroll EC, 2016, IMMUNITY, V44, P597, DOI 10.1016/j.immuni.2016.02.004; Cesta MF, 2006, TOXICOL PATHOL, V34, P599, DOI 10.1080/01926230600865531; Chang E, 2019, ORAL SCI INT, V16, P80, DOI 10.1002/osi2.1018; Chua BY, 2015, BIOMATERIALS, V53, P50, DOI 10.1016/j.biomaterials.2015.02.066; CLEMENTS JD, 1988, VACCINE, V6, P269, DOI 10.1016/0264-410X(88)90223-X; Croitoru K., 1994, HDB MUCOSAL IMMUNOLO, P141; Cuburu N, 2007, VACCINE, V25, P8598, DOI 10.1016/j.vaccine.2007.09.073; Cui ZR, 2002, PHARM RES-DORDR, V19, P947, DOI 10.1023/A:1016454003450; Czerkinsky C, 2011, HUM VACCINES, V7, P110, DOI 10.4161/hv.7.1.13739; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; Damjanovic Daniela, 2008, Genet Vaccines Ther, V6, P5, DOI 10.1186/1479-0556-6-5; Davitt CJH, 2015, ADV DRUG DELIVER REV, V91, P52, DOI 10.1016/j.addr.2015.03.007; De Koker S, 2016, ANGEW CHEM INT EDIT, V55, P1334, DOI 10.1002/anie.201508626; Durham SR, 2008, CURR OPIN ALLERGY CL, V8, P577, DOI 10.1097/ACI.0b013e3283196764; EFFROS RB, 1978, CELL IMMUNOL, V36, P345, DOI 10.1016/0008-8749(78)90278-2; Ellison TJ, 2020, VACCINE, V38, P6839, DOI 10.1016/j.vaccine.2020.07.040; Flynn O, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030299; Fong D, 2017, BIOMATERIALS, V129, P127, DOI 10.1016/j.biomaterials.2017.03.022; Frati F, 2010, DRUG DES DEV THER, V4, P99; Gala RP, 2017, AAPS PHARMSCITECH, V18, P283, DOI 10.1208/s12249-016-0566-3; Gallichan WS, 1996, J EXP MED, V184, P1879, DOI 10.1084/jem.184.5.1879; Gamazo C, 2015, EUR J PHARM BIOPHARM, V96, P454, DOI 10.1016/j.ejpb.2015.01.010; Gao T, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110888; Gill HS, 2008, CLIN J PAIN, V24, P585, DOI 10.1097/AJP.0b013e31816778f9; Gill HS, 2007, PHARM RES, V24, P1369, DOI 10.1007/s11095-007-9286-4; Gill HS, 2007, J CONTROL RELEASE, V117, P227, DOI 10.1016/j.jconrel.2006.10.017; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hervouet C, 2010, VACCINE, V28, P5582, DOI 10.1016/j.vaccine.2010.06.033; HILL AB, 1992, IMMUNOL CELL BIOL, V70, P259, DOI 10.1038/icb.1992.33; Hiroi T, 1998, EUR J IMMUNOL, V28, P3346, DOI 10.1002/(SICI)1521-4141(199810)28:10<3346::AID-IMMU3346>3.0.CO;2-P; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; HOLMGREN J, 1993, VACCINE, V11, P1179, DOI 10.1016/0264-410X(93)90039-Z; HOLT PG, 1988, CLIN ALLERGY, V18, P229, DOI 10.1111/j.1365-2222.1988.tb02864.x; Kim YC, 2010, J CONTROL RELEASE, V142, P187, DOI 10.1016/j.jconrel.2009.10.013; Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439; Kiyono H, 2015, P JPN ACAD B-PHYS, V91, P423, DOI 10.2183/pjab.91.423; Kotloff KL, 2001, INFECT IMMUN, V69, P3581, DOI 10.1128/IAI.69.6.3581-3590.2001; Kurono Y, 1999, J INFECT DIS, V180, P122, DOI 10.1086/314827; Kweon MN, 2011, CYTOKINE, V54, P1, DOI 10.1016/j.cyto.2010.12.014; Lal M, 2017, METHODS MOL BIOL, V1494, P153, DOI 10.1007/978-1-4939-6445-1_11; Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999; Li M, 2020, IMMUNOL LETT, V217, P116, DOI 10.1016/j.imlet.2019.10.013; Lou H, 2014, DRUG DEV IND PHARM, V40, P910, DOI 10.3109/03639045.2013.789907; Lundgren A, 2014, VACCINE, V32, P7077, DOI 10.1016/j.vaccine.2014.10.069; Lundholm P, 1999, VACCINE, V17, P2036, DOI 10.1016/S0264-410X(98)00404-6; Lycke N, 2005, IMMUNOL LETT, V97, P193, DOI 10.1016/j.imlet.2004.12.008; Lycke N, 2012, NAT REV IMMUNOL, V12, P592, DOI 10.1038/nri3251; Ma YZ, 2014, PHARM RES-DORDR, V31, P2393, DOI 10.1007/s11095-014-1335-1; Mabbott NA, 2013, MUCOSAL IMMUNOL, V6, P666, DOI 10.1038/mi.2013.30; MACKAY CR, 1993, CURR OPIN IMMUNOL, V5, P423, DOI 10.1016/0952-7915(93)90063-X; Martin SP, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00710; Masek J, 2017, J CONTROL RELEASE, V249, P183, DOI 10.1016/j.jconrel.2016.07.036; McCluskie MJ, 1998, J IMMUNOL, V161, P4463; McCluskie MJ, 2001, VACCINE, V19, P2657, DOI 10.1016/S0264-410X(00)00496-5; MCDERMOTT MR, 1989, J INFECT DIS, V159, P460, DOI 10.1093/infdis/159.3.460; McGhee JR, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001397; MESTECKY J, 1987, J CLIN IMMUNOL, V7, P265, DOI 10.1007/BF00915547; Michetti P, 1999, GASTROENTEROLOGY, V116, P804, DOI 10.1016/S0016-5085(99)70063-6; MULLBACHER A, 1994, J EXP MED, V179, P317, DOI 10.1084/jem.179.1.317; Munang'andu HM, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.11; Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595; Nardelli-Haefliger D, 2005, VACCINE, V23, P3634, DOI 10.1016/j.vaccine.2005.02.019; Negri DRM, 2010, VACCINE, V28, P4175, DOI 10.1016/j.vaccine.2010.04.013; NUGENT CT, 1994, J VIROL, V68, P7644, DOI 10.1128/JVI.68.11.7644-7648.1994; Nystrom J, 2006, MICROBES INFECT, V8, P442, DOI 10.1016/j.micinf.2005.07.010; Oh YJ, 2021, DRUG DELIV TRANSL RE, V11, P1390, DOI 10.1007/s13346-021-00964-z; Ohno H, 2010, GUT MICROBES, V1, P407, DOI 10.4161/gmic.1.6.14078; Ottsjo LS, 2017, IMMUNOLOGY, V150, P172, DOI 10.1111/imm.12676; Passalacqua G, 2004, CURR OPIN ALLERGY CL, V4, P31, DOI 10.1097/01.all.0000113675.18759.4e; Petaja T, 2011, INT J CANCER, V129, P2147, DOI 10.1002/ijc.25887; PICKER LJ, 1994, CURR OPIN IMMUNOL, V6, P394, DOI 10.1016/0952-7915(94)90118-X; Pinczewski J, 2005, VIRAL IMMUNOL, V18, P236, DOI 10.1089/vim.2005.18.236; Ramirez JEV, 2017, ADV DRUG DELIVER REV, V114, P116, DOI 10.1016/j.addr.2017.04.008; Rand JH, 2012, MBIO, V3, DOI 10.1128/mBio.00292-11; Rappuoli R, 1999, IMMUNOL TODAY, V20, P493, DOI 10.1016/S0167-5699(99)01523-6; Riese P, 2014, EXPERT OPIN DRUG DEL, V11, P1619, DOI 10.1517/17425247.2014.931936; Roan NR, 2006, P NATL ACAD SCI USA, V103, P12069, DOI 10.1073/pnas.0603866103; Ruehl-Fehlert C., 2018, FUNDAMENTALS TOXICOL, P273; Sato S, 2012, CURR OPIN VIROL, V2, P225, DOI 10.1016/j.coviro.2012.03.009; Seavey MM, 2009, VACCINE, V27, P2342, DOI 10.1016/j.vaccine.2009.02.025; Song JH, 2008, P NATL ACAD SCI USA, V105, P1644, DOI 10.1073/pnas.0708684105; Song KM, 2010, P NATL ACAD SCI USA, V107, P22213, DOI 10.1073/pnas.1015536108; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; SQUIER CA, 1986, ARCH ORAL BIOL, V31, P741, DOI 10.1016/0003-9969(86)90006-3; Tian Y, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030245; Ubale RV, 2013, J MICROENCAPSUL, V30, P28, DOI 10.3109/02652048.2012.692402; Uddin M, 2019, J PHARM PHARM SCI, V22, P388, DOI 10.18433/jpps30528; van der Lubben IM, 2001, BIOMATERIALS, V22, P687, DOI 10.1016/S0142-9612(00)00231-3; Van der Lubben IM, 2001, J DRUG TARGET, V9, P39, DOI 10.3109/10611860108995631; van der Maaden K, 2014, AAPS J, V16, P681, DOI 10.1208/s12248-014-9606-7; Wang J, 2001, CANCER GENE THER, V8, P705, DOI 10.1038/sj.cgt.7700363; Wang J, 2011, J IMMUNOL, V187, P5277, DOI 10.4049/jimmunol.1102077; Wang M, 2014, HUM VACC IMMUNOTHER, V10, P3544, DOI 10.4161/hv.36174; Wang T, 2015, COLLOID SURFACE B, V126, P520, DOI 10.1016/j.colsurfb.2015.01.005; Wang YY, 2008, ANGEW CHEM INT EDIT, V47, P9726, DOI 10.1002/anie.200803526; Woof JM, 2005, IMMUNOL REV, V206, P64, DOI 10.1111/j.0105-2896.2005.00290.x; Wu HY, 1997, IMMUNOL RES, V16, P187, DOI 10.1007/BF02786362; Xu QG, 2015, ACS NANO, V9, P9217, DOI 10.1021/acsnano.5b03876; Yuki Y, 2003, REV MED VIROL, V13, P293, DOI 10.1002/rmv.398; Zhan X, 2012, MOL PHARMACEUT, V9, P3442, DOI 10.1021/mp300190g; Zhang T, 2009, BIOCHEM BIOPH RES CO, V390, P937, DOI 10.1016/j.bbrc.2009.10.081; Zhao X, 2017, J CONTROL RELEASE, V265, P2, DOI 10.1016/j.jconrel.2017.03.015; Zhen YY, 2015, VACCINE, V33, P4330, DOI 10.1016/j.vaccine.2015.03.081	116	1	1	11	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1177	10.3390/vaccines9101177			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WT8NA	34696284	Green Published			2022-04-29	WOS:000716114800001
J	Wijesundara, DK; Williams, C; Sun, W; Furuya, AM; Furuya, Y				Wijesundara, Danushka K.; Williams, Clare; Sun, Wei; Furuya, Andrea Marias; Furuya, Yoichi			Fear of Influenza Resurgence amid COVID-19 Pandemic: Need for Effective Flu Vaccine Still Exists	VACCINES			English	Editorial Material									[Wijesundara, Danushka K.] Univ Queensland, Sch Chem & Mol Biosci, Australian Inst Bioengn & Nanotechnol, St Lucia, Qld 4072, Australia; [Williams, Clare; Sun, Wei; Furuya, Yoichi] Albany Med Coll, Dept Immunol & Microbial Dis, Albany, NY 12208 USA; [Furuya, Andrea Marias] Pictor Ltd, 40 Kenwyn St, Auckland 1052, New Zealand		Wijesundara, DK (通讯作者)，Univ Queensland, Sch Chem & Mol Biosci, Australian Inst Bioengn & Nanotechnol, St Lucia, Qld 4072, Australia.; Furuya, Y (通讯作者)，Albany Med Coll, Dept Immunol & Microbial Dis, Albany, NY 12208 USA.	d.wijesundara@uq.edu.au; willicla@upstate.edu; sunw@amc.edu; a.kinga@pictordx.com; furuyay@amc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AI146434]	Y.F. is supported by the NIH grant AI146434.	Gatti M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010019; Isaacs A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020071; McMillan CLD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010026; Paixao V, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020107; Reed C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118369; Roy S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040683; Roy S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030459; Sangesland M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020125; Sun Y, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040714	9	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1198	10.3390/vaccines9101198			3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR4JO	34696304	gold, Green Published			2022-04-29	WOS:000714468200001
J	Bertoncello, C; Nicolli, A; Maso, S; Fonzo, M; Crivellaro, M; Mason, P; Trevisan, A				Bertoncello, Chiara; Nicolli, Annamaria; Maso, Stefano; Fonzo, Marco; Crivellaro, Mariaangiola; Mason, Paola; Trevisan, Andrea			Uptake of Non-Mandatory Vaccinations in Future Physicians in Italy	VACCINES			English	Article						non mandatory vaccination; mandatory vaccination; future physicians; vaccination compliance	PERTUSSIS-VACCINE	In 2017 in Italy, a number of vaccinations became mandatory or started to be recommended and offered free of charge. In this study, we aimed at assessing the coverage rates for those vaccinations in the pre-mandatory era among students at the School of Medicine of Padua University studying the degree course in medicine and surgery (future physicians) on the basis of the vaccination certificates presented during health surveillance. The vaccinations considered were those against pertussis, rubella, mumps, measles, varicella, Haemophilus influenzae type b (which became mandatory in 2017), pneumococcus, meningococcus C and meningococcus B (only suggested and offered for free since 2017). The study enrolled 4706 students of medicine and surgery. High vaccine uptake was observed, especially in younger students (born after 1990), with vaccines against pertussis, rubella, mumps and measles. Good completion for Haemophilus influenzae type b and meningococcus C was also observed. Very low coverage rates (all under 10%) for vaccination against varicella, pneumococcus and meningococcus B were observed. In conclusion, uptake for some non-mandatory vaccines was below the recommended threshold, although younger generations showed a higher uptake, possibly as a results of policy implemented at the national level. Our findings support the idea to consider health surveillance visits also as an additional opportunity to overcome confidence and convenience barriers and offer vaccine administration.	[Bertoncello, Chiara; Nicolli, Annamaria; Maso, Stefano; Fonzo, Marco; Crivellaro, Mariaangiola; Mason, Paola; Trevisan, Andrea] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Via Giustiniani 2, I-35128 Padua, Italy		Trevisan, A (通讯作者)，Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Via Giustiniani 2, I-35128 Padua, Italy.	chiara.bertoncello@unipd.it; annamaria.nicolli@unipd.it; stefano.maso@unipd.it; marco.fonzo@unipd.it; mariaangiola.crivellaro@aopd.veneto.it; paola.mason.1@unipd.it; andrea.trevisan@unipd.it	MASON, PAOLA/AAE-9023-2019; Trevisan, Andrea/E-5325-2013	MASON, PAOLA/0000-0003-3941-6698; Trevisan, Andrea/0000-0002-0764-1084; Bertoncello, Chiara/0000-0003-4040-8601			[Anonymous], 1934, GAZZETTA UFFICIALE; [Anonymous], 1926, GAZZETTA UFFICIALE; [Anonymous], 2017, GAZZETTA UFFICIALE; [Anonymous], 2017, PIANO NAZL PREVENZIO; [Anonymous], 1991, GAZZETTA UFFICIALE; [Anonymous], 1966, GAZZETTA UFFICIALE; [Anonymous], 1939, GAZZETTA UFFICIALE; [Anonymous], 1963, GAZZETTA UFFICIALE; [Anonymous], 1888, GAZZETTA UFFICIALE R; [Anonymous], 2021, GAZZETTA UFFICIALE; [Anonymous], 1971, GAZZETTA UFFICIALE; Baldovin T, 2019, HUM VACC IMMUNOTHER, V15, P1641, DOI 10.1080/21645515.2018.1564432; Bechini A, 2019, EXPERT REV VACCINES, V18, P693, DOI 10.1080/14760584.2019.1639502; Berkman ND, 2011, ANN INTERN MED, V155, P97, DOI 10.7326/0003-4819-155-2-201107190-00005; Bertoncello C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020276; Bertoncello C, 2020, INT J EQUITY HEALTH, V19, DOI 10.1186/s12939-020-01174-8; Bester JC, 2015, J BIOETHIC INQ, V12, P555, DOI 10.1007/s11673-015-9673-1; Burioni R, 2018, NATURE, V555, P27, DOI 10.1038/d41586-018-02267-9; Cocchio S, 2020, HEALTH SOC CARE COMM, V28, P1514, DOI 10.1111/hsc.12974; Decreto Presidente Consiglio dei Ministri, 2001, PLAN NAZ EL MORB ROS; Di Martino G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020248; Ecarnot F, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-8044-y; Genovese C, 2019, J Prev Med Hyg, V60, pE12, DOI 10.15167/2421-4248/jpmh2019.60.1.1097; Gustafsson L, 2006, PEDIATRICS, V118, P978, DOI 10.1542/peds.2005-2746; Klein NP, 2012, NEW ENGL J MED, V367, P1012, DOI 10.1056/NEJMoa1200850; Ministero della Salute, 1999, 12 MIN SAL; Ministero della Salute, 2001, 11 MIN SAL; Ministero della Sanita, 1999, GAZZETTA UFFICIALE; Ministero della Sanita, 1995, 13 MIN SAN; Ministero della Sanita, 41 MIN SAN; Ministero della Sanita, 26 MIN SAN; Ministero della Sanita, 1976, 21 MIN SAN; Misegades LK, 2012, JAMA-J AM MED ASSOC, V308, P2126, DOI 10.1001/jama.2012.14939; Omer SB, 2019, NATURE, V571, P469, DOI 10.1038/d41586-019-02232-0; Rezza G, 2020, VACCINE, V38, P5089, DOI 10.1016/j.vaccine.2020.05.043; Savulescu J, 2021, J PEDIATR-US, V231, P10, DOI 10.1016/j.jpeds.2021.01.021; Signorelli C, 2018, LANCET INFECT DIS, V18, P26, DOI 10.1016/S1473-3099(17)30696-5; Trevisan A, 2020, INT J INFECT DIS, V96, P228, DOI 10.1016/j.ijid.2020.04.082; Trevisan A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010104; Vaz OM, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-0620	40	0	0	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1035	10.3390/vaccines9091035			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW2VS	34579272	Green Published, gold			2022-04-29	WOS:000700020800001
J	Haegeman, A; De Leeuw, I; Saduakassova, M; Van Campe, W; Aerts, L; Philips, W; Sultanov, A; Mostin, L; De Clercq, K				Haegeman, Andy; De Leeuw, Ilse; Saduakassova, Meruyert; Van Campe, Willem; Aerts, Laetitia; Philips, Wannes; Sultanov, Akhmetzhan; Mostin, Laurent; De Clercq, Kris			The Importance of Quality Control of LSDV Live Attenuated Vaccines for Its Safe Application in the Field	VACCINES			English	Article						vaccine; quality control; lumpy skin disease; recombinant	LUMPY SKIN-DISEASE; BLUETONGUE VIRUS; RECOMBINATION; SHEEP; VACCINATION; CAPRIPOXVIRUSES; VALIDATION; SEQUENCES; ANIMALS; STRAIN	Vaccination is an effective approach to prevent, control and eradicate diseases, including lumpy skin disease (LSD). One of the measures to address farmer hesitation to vaccinate is guaranteeing the quality of vaccine batches. The purpose of this study was to demonstrate the importance of a quality procedure via the evaluation of the LSD vaccine, Lumpivax (Kevevapi). The initial PCR screening revealed the presence of wild type LSD virus (LSDV) and goatpox virus (GTPV), in addition to vaccine LSDV. New phylogenetic PCRs were developed to characterize in detail the genomic content and a vaccination/challenge trial was conducted to evaluate the impact on efficacy and diagnostics. The characterization confirmed the presence of LSDV wild-, vaccine- and GTPV-like sequences in the vaccine vial and also in samples taken from the vaccinated animals. The analysis was also suggestive for the presence of GTPV-LSDV (vaccine/wild) recombinants. In addition, the LSDV status of some of the animal samples was greatly influenced by the differentiating real-PCR used and could result in misinterpretation. Although the vaccine was clinically protective, the viral genomic content of the vaccine (being it multiple Capripox viruses and/or recombinants) and the impact on the diagnostics casts serious doubts of its use in the field.	[Haegeman, Andy; De Leeuw, Ilse; De Clercq, Kris] Sciensano, Unit Exot & Particular Dis, Sci Directorate Infect Dis Anim, Groeselenberg 99, B-1180 Brussels, Belgium; [Saduakassova, Meruyert; Sultanov, Akhmetzhan] Kazakh Sci Res Vet Inst KazSRVI KazNIVI, Raiymbek Ave 223, Alma Ata 050016, Kazakhstan; [Van Campe, Willem; Mostin, Laurent] Sciensano, Expt Ctr Machelen, Sci Directorate Infect Dis Anim, Kerklaan 68, B-1830 Machelen, Belgium; [Aerts, Laetitia; Philips, Wannes] Sciensano, Sci Directorate Infect Dis Anim, EURL Dis Caused Capripox Viruses, Groeselenberg 99, B-1180 Brussels, Belgium		Haegeman, A (通讯作者)，Sciensano, Unit Exot & Particular Dis, Sci Directorate Infect Dis Anim, Groeselenberg 99, B-1180 Brussels, Belgium.	Andy.Haegeman@sciensano.be; Ilse.DeLeeuw@sciensano.be; mika.kazniyi@gmail.com; Willem.VanCampe@sciensano.be; Laetitia.Aerts@sciensano.be; wannes.philips@sciensano.be; akhmetzhan.sultanov@gmail.com; Laurent.Mostin@sciensano.be; kris.declercq@sciensano.be	Akhmetzhan, Sultanov/AAQ-9972-2020	Akhmetzhan, Sultanov/0000-0003-4590-5738; Haegeman, andy/0000-0003-4056-214X; De Clercq, Kris/0000-0002-2928-3521	Sciensano; EURL for Diseases Caused by Capripox Viruses	This study has received funding from Sciensano and EURL for Diseases Caused by Capripox Viruses.	Abera Z., 2015, INT J BASIC APPL VIR, V4, P8, DOI [10.5829/idosi.ijbav.2015.4.1.9117, DOI 10.5829/IDOSI.IJBAV.2015.4.1.9117]; Abutarbush SM, 2016, TRANSBOUND EMERG DIS, V63, pE213, DOI 10.1111/tbed.12257; Agianniotaki EI, 2017, MICROBIOL RESOUR ANN, V5, DOI [10.1128/genomeA.00550-17, 10.1128/genomea.00550-17]; Agianniotaki EI, 2017, J VIROL METHODS, V249, P48, DOI 10.1016/j.jviromet.2017.08.011; Aleksandr K, 2020, SCI REP-UK, V10, P7436, DOI 10.1038/s41598-020-64029-w; Alemayehu G, 2013, TROP ANIM HEALTH PRO, V45, P1153, DOI 10.1007/s11250-012-0340-9; Babiuk S, 2008, TRANSBOUND EMERG DIS, V55, P263, DOI 10.1111/j.1865-1682.2008.01043.x; Babiuk S, 2009, J GEN VIROL, V90, P105, DOI 10.1099/vir.0.004507-0; Barone PW, 2020, NAT BIOTECHNOL, V38, P563, DOI 10.1038/s41587-020-0507-2; BEDSON HS, 1964, J HYG-CAMBRIDGE, V62, P147, DOI 10.1017/S0022172400039887; Ben-Gera J, 2015, VACCINE, V33, P4837, DOI 10.1016/j.vaccine.2015.07.071; Bracho MA, 1998, J GEN VIROL, V79, P2921, DOI 10.1099/0022-1317-79-12-2921; Bumbarov V, 2016, VACCINE, V34, P3317, DOI 10.1016/j.vaccine.2016.03.097; Byadovskaya O, 2021, TRANSBOUND EMERG DIS, V68, P3020, DOI 10.1111/tbed.13942; Chibssa TR, 2018, VIROL J, V15, DOI 10.1186/s12985-018-0969-8; De Leeuw I, 2015, TRANSBOUND EMERG DIS, V62, P157, DOI 10.1111/tbed.12100; FAO, 2020, INTR SPREAD LUMP SKI, P183, DOI [10.4060/cb1892en, DOI 10.4060/CB1892EN]; Fox KA, 2019, J VET DIAGN INVEST, V31, P107, DOI 10.1177/1040638718814583; Gari G, 2011, PREV VET MED, V102, P274, DOI 10.1016/j.prevetmed.2011.07.003; Gelaye E, 2015, ANTIVIR RES, V119, P28, DOI 10.1016/j.antiviral.2015.04.008; GERSHON PD, 1989, J GEN VIROL, V70, P485, DOI 10.1099/0022-1317-70-2-485; Gethmann J, 2015, VACCINE, V33, P214, DOI 10.1016/j.vaccine.2014.10.025; Gibbs MJ, 2000, BIOINFORMATICS, V16, P573, DOI 10.1093/bioinformatics/16.7.573; GREEN H. F., 1959, Bulletin of epizootic diseases of Africa, V7, P63; Gupta T, 2020, VET RES COMMUN, V44, P111, DOI 10.1007/s11259-020-09780-1; Lam HM, 2018, MOL BIOL EVOL, V35, P247, DOI 10.1093/molbev/msx263; Haegeman A, 2016, TRANSBOUND EMERG DIS, V63, pE278, DOI 10.1111/tbed.12342; Haegeman A, 2013, J VIROL METHODS, V193, P446, DOI 10.1016/j.jviromet.2013.07.010; Haegeman A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050473; Haegeman A, 2020, J VIROL METHODS, V277, DOI 10.1016/j.jviromet.2019.113800; Hamdi J, 2020, VET MICROBIOL, V245, DOI 10.1016/j.vetmic.2020.108689; Klement E, 2020, PREV VET MED, V181, DOI 10.1016/j.prevetmed.2018.12.001; Lamien CE, 2011, VET MICROBIOL, V149, P30, DOI 10.1016/j.vetmic.2010.09.038; Lu G, 2021, TRANSBOUND EMERG DIS, V68, P216, DOI 10.1111/tbed.13898; Lucey BP, 2009, ARCH PATHOL LAB MED, V133, P1463, DOI 10.1043/1543-2165-133.9.1463; Martin D, 2000, BIOINFORMATICS, V16, P562, DOI 10.1093/bioinformatics/16.6.562; Martin DP, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev003; Martin DP, 2005, AIDS RES HUM RETROV, V21, P98, DOI 10.1089/aid.2005.21.98; Mathijs E, 2020, MICROBIOL RESOUR ANN, V9, DOI 10.1128/MRA.00977-20; Mathijs E, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.01255-16; Mathijs E, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.01113-16; McInerney Peter, 2014, Mol Biol Int, V2014, P287430, DOI 10.1155/2014/287430; Mirjalili A, 2005, BIOLOGICALS, V33, P81, DOI 10.1016/j.biologicals.2005.01.004; Molla W, 2017, PREV VET MED, V147, P100, DOI 10.1016/j.prevetmed.2017.09.003; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14; Nims RW, 2017, IN VITRO CELL DEV-AN, V53, P872, DOI 10.1007/s11626-017-0203-9; Obernier JA, 2006, ILAR J, V47, P364, DOI 10.1093/ilar.47.4.364; OIE (World Organization for Animal Health), 2019, MANUAL DIAGNOSTIC TE; Padidam M, 1999, VIROLOGY, V265, P218, DOI 10.1006/viro.1999.0056; Posada D, 2001, P NATL ACAD SCI USA, V98, P13757, DOI 10.1073/pnas.241370698; Qin L, 2014, J VIROL, V88, P5277, DOI 10.1128/JVI.00022-14; RAMASWAMY NS, 1994, REV SCI TECH OIE, V13, P195, DOI 10.20506/rst.13.1.758; Roy P, 2018, TRANSBOUND EMERG DIS, V65, P32, DOI 10.1111/tbed.12763; Rozen S, 2000, Methods Mol Biol, V132, P365; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sangula AK, 2011, EPIDEMIOL INFECT, V139, P189, DOI 10.1017/S0950268810000580; Savini G, 2014, TRANSBOUND EMERG DIS, V61, P69, DOI 10.1111/tbed.12004; SMITH JM, 1992, J MOL EVOL, V34, P126; Sohier C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56605-6; Sprygin A, 2018, TRANSBOUND EMERG DIS, V65, P1137, DOI 10.1111/tbed.12897; Sprygin A, 2020, ARCH VIROL, V165, P2675, DOI 10.1007/s00705-020-04756-7; Sprygin A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232584; Sprygin A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207480; STRAYER DS, 1983, J IMMUNOL, V130, P399; Su Q, 2019, POULTRY SCI, V98, P613, DOI 10.3382/ps/pey129; Tageldin MH, 2014, TROP ANIM HEALTH PRO, V46, P241, DOI 10.1007/s11250-013-0483-3; Tulman ER, 2002, J VIROL, V76, P6054, DOI 10.1128/JVI.76.12.6054-6061.2002; Tuppurainen E., 2017, FAO ANIMAL PRODUCTIO; Tuppurainen ESM, 2017, TRANSBOUND EMERG DIS, V64, P729, DOI 10.1111/tbed.12444; Tuppurainen ESM, 2014, ANTIVIR RES, V109, P1, DOI 10.1016/j.antiviral.2014.06.009; Vandenbussche F, 2010, METHODS MOL BIOL, V630, P97, DOI 10.1007/978-1-60761-629-0_7; Vidanovic D, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9061234; Wane A, 2020, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00488; Wang Y, 2021, TRANSBOUND EMERG DIS, DOI 10.1111/tbed.14159; WEISS K. E., 1968, Lumpy skin disease virus., P111; Wolff J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010004	76	2	2	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1019	10.3390/vaccines9091019			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ2SZ	34579256	Green Published, gold			2022-04-29	WOS:000702061400001
J	Niebel, D; Novak, N; Wilhelmi, J; Ziob, J; Wilsmann-Theis, D; Bieber, T; Wenzel, J; Braegelmann, C				Niebel, Dennis; Novak, Natalija; Wilhelmi, Jasmin; Ziob, Jana; Wilsmann-Theis, Dagmar; Bieber, Thomas; Wenzel, Joerg; Braegelmann, Christine			Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective	VACCINES			English	Review						vaccines; COVID-19; adverse event; exanthema	VACCINATION; SAFETY	(1) Background: Numerous vaccines are under preclinical and clinical development for prevention of severe course and lethal outcome of coronavirus disease 2019 (COVID-19). In light of high efficacy rates and satisfactory safety profiles, some agents have already reached approval and are now distributed worldwide, with varying availability. Real-world data on cutaneous adverse drug reactions (ADRs) remain limited. (2) Methods: We performed a literature research concerning cutaneous ADRs to different COVID-19 vaccines, and incorporated our own experiences. (3) Results: Injection site reactions are the most frequent side effects arising from all vaccine types. Moreover, delayed cutaneous ADRs may occur after several days, either as a primary manifestation or as a flare of a pre-existing inflammatory dermatosis. Cutaneous ADRs may be divided according to their cytokine profile, based on the preponderance of specific T-cell subsets (i.e., Th1, Th2, Th17/22, Tregs). Specific cutaneous ADRs mimic immunogenic reactions to the natural infection with SARS-CoV-2, which is associated with an abundance of type I interferons. (4) Conclusions: Further studies are required in order to determine the best suitable vaccine type for individual groups of patients, including patients suffering from chronic inflammatory dermatoses.	[Niebel, Dennis; Novak, Natalija; Wilhelmi, Jasmin; Ziob, Jana; Wilsmann-Theis, Dagmar; Bieber, Thomas; Wenzel, Joerg; Braegelmann, Christine] Univ Hosp Bonn, Dept Dermatol & Allergy, D-53127 Bonn, Germany		Niebel, D (通讯作者)，Univ Hosp Bonn, Dept Dermatol & Allergy, D-53127 Bonn, Germany.	dennis.niebel@ukbonn.de; Natalija.Novak@ukbonn.de; Jasmin.Wilhelmi@ukbonn.de; Jana.Ziob@ukbonn.de; Dagmar.Wilsmann-Theis@ukbonn.de; Thomas.Bieber@ukbonn.de; Joerg.Wenzel@ukbonn.de; Christine.Braegelmann@ukbonn.de	Niebel, Dennis/L-1203-2019	Niebel, Dennis/0000-0003-2069-0486; Ziob, Jana/0000-0002-6119-5943			Ackerman M, 2021, J EUR ACAD DERMATOL, V35, pE423, DOI 10.1111/jdv.17248; Akdas E, 2021, J EUR ACAD DERMATOL, V35, pE861, DOI 10.1111/jdv.17592; Akinosoglou K, 2021, CLIN IMMUNOL, V226, DOI 10.1016/j.clim.2021.108721; Al-Janabi A, 2020, J EUR ACAD DERMATOL, V34, P1440, DOI 10.1111/jdv.16246; Alpalhao M, 2021, DERMATITIS, V32, P133, DOI 10.1097/DER.0000000000000755; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bae S, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e115; Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P2135, DOI 10.1016/j.jaip.2021.03.053; Blumenthal KG, 2021, NEW ENGL J MED, V384, P1273, DOI 10.1056/NEJMc2102131; Bogdanov G, 2021, CLIN DERMATOL, V39, P523, DOI 10.1016/j.clindermatol.2021.04.001; Busto-Leis JM, 2021, J EUR ACAD DERMATOL, V35, pE489, DOI 10.1111/jdv.17301; Cabanillas B, 2021, ALLERGOL INT, V70, P313, DOI 10.1016/j.alit.2021.04.003; Cabanillas B, 2021, ALLERGY, V76, P1943, DOI 10.1111/all.14761; Catala A, 2022, BRIT J DERMATOL, V186, P142, DOI 10.1111/bjd.20639; Cebeci F, 2021, EUR J HOSP PHARM, DOI 10.1136/ejhpharm-2021-002794; Cohen SR, 2021, INT J DERMATOL, V60, P1032, DOI 10.1111/ijd.15623; Corbeddu M, 2021, J EUR ACAD DERMATOL, V35, pE483, DOI 10.1111/jdv.17268; Cunningham LS, 2020, CONTACT DERMATITIS, V83, P432, DOI 10.1111/cod.13685; Curtis JR, 2021, ARTHRITIS RHEUMATOL, V73, P1093, DOI 10.1002/art.41734; Darrigade AS, 2021, ALLERGY, V76, P3194, DOI 10.1111/all.14981; Dietrich LL, 2000, MED ONCOL, V17, P64, DOI 10.1007/BF02826219; Eyerich K, 2018, J EUR ACAD DERMATOL, V32, P692, DOI 10.1111/jdv.14673; Fernandez-Nieto D, 2021, J EUR ACAD DERMATOL, V35, pE425, DOI 10.1111/jdv.17250; Fischinger S, 2019, SEMIN IMMUNOPATHOL, V41, P239, DOI 10.1007/s00281-018-0726-5; Folster-Holst R, 2016, EXPERT REV ANTI-INFE, V14, P601, DOI 10.1080/14787210.2016.1184084; Frederiksen MS, 2004, SCAND J INFECT DIS, V36, P154, DOI 10.1080/00365540410019200; Furer V, 2021, RMD OPEN, V7, DOI 10.1136/rmdopen-2021-001594; Gabor, 2020, PHASE 1 ASSESSMENT S, DOI [10.1101/2020.11.09.20228551, DOI 10.1101/2020.11.09.20228551]; Casas CG, 2020, BRIT J DERMATOL, V183, P71, DOI 10.1111/bjd.19163; Gambichler T, 2021, J EUR ACAD DERMATOL, V35, pE415, DOI 10.1111/jdv.17225; Gelfand JM, 2021, J AM ACAD DERMATOL, V84, P1254, DOI 10.1016/j.jaad.2020.12.058; Gisondi P, 2021, J EUR ACAD DERMATOL, V35, pE361, DOI 10.1111/jdv.17200; Gringeri M, 2021, HUM VACC IMMUNOTHER, V17, P2969, DOI 10.1080/21645515.2021.1917236; He Q, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.669339; Hiltun I, 2021, J EUR ACAD DERMATOL, V35, pE414, DOI 10.1111/jdv.17221; Ishikawa M, 2020, J DERMATOL, V47, P1450, DOI 10.1111/1346-8138.15588; Jedlowski P.M., 2021, DERMATOL ONLINE J, V27, DOI 10.5070/D3271052044; Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6; Johnston MS, 2021, JAMA DERMATOL, V157, P716, DOI 10.1001/jamadermatol.2021.1214; Jovanovic M, 2005, J AM ACAD DERMATOL, V52, P367, DOI 10.1016/j.jaad.2004.07.061; Kang SY, 2021, KOREAN J INTERN MED, V36, P1537, DOI 10.3904/kjim.2021.198; Kaur SP, 2020, VIRUS RES, V288, DOI 10.1016/j.virusres.2020.198114; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Kha Connie, 2021, JAAD Case Rep, V12, P12, DOI 10.1016/j.jdcr.2021.03.046; Kim JE, 2021, J EUR ACAD DERMATOL, V35, pE711, DOI 10.1111/jdv.17476; Kounis NG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030221; Krajewski PK, 2021, J EUR ACAD DERMATOL, V35, pE632, DOI 10.1111/jdv.17449; Leasure AC, 2021, J EUR ACAD DERMATOL, V35, pE716, DOI 10.1111/jdv.17494; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Lopatynsky-Reyes EZ, 2021, CUREUS, V13, DOI 10.7759/cureus.14453; Lopez S, 2021, BRIT J DERMATOL, V185, P445, DOI 10.1111/bjd.20404; Lospinoso Kristen, 2021, JAAD Case Rep, V13, P134, DOI 10.1016/j.jdcr.2021.05.010; Malayala SV, 2021, CUREUS, V13, DOI 10.7759/cureus.14099; Manansala M, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.672028; McMahon DE, 2021, J AM ACAD DERMATOL, V85, P46, DOI 10.1016/j.jaad.2021.03.092; Mintoff D, 2020, CLIN EXP DERMATOL, V45, P450, DOI 10.1111/ced.14130; Munavalli GG, 2022, ARCH DERMATOL RES, V314, P1, DOI 10.1007/s00403-021-02190-6; Niebel D., 2021, J DERMATOL; Niebel D, 2021, DERMATOL THER, V34, DOI 10.1111/dth.15017; Novak N, 2021, ALLERGY, V76, P698, DOI 10.1111/all.14498; de Mattos ABN, 2021, LUPUS, V30, P833, DOI 10.1177/0961203321990087; Onsun N, 2021, HEALTH PROMOT PERSPE, V11, P261, DOI 10.34172/hpp.2021.32; Osborne GEN, 2003, J AM ACAD DERMATOL, V48, pS99, DOI 10.1067/mjd.2003.158; Pacifico A, 2021, CLIN EXP DERMATOL, V46, P1344, DOI 10.1111/ced.14723; Pascolo S, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020270; Pfaar O, 2021, ALLERGOLOGIE, V44, P261, DOI [10.5414/ALX02241, 10.5414/ALX02241E]; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Preissner KT, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.619221; Pulsipher KJ, 2021, J DRUGS DERMATOL, V20, P351, DOI 10.36849/JDD.5899; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Ramos CL, 2021, J ALLER CL IMM-PRACT, V9, P2480, DOI 10.1016/j.jaip.2021.03.055; Rice Shauna M, 2021, Int J Womens Dermatol, V7, P209, DOI 10.1016/j.ijwd.2021.01.007; Ring J, 2021, J EUR ACAD DERMATOL, V35, pE362, DOI 10.1111/jdv.17237; Rosenblatt AE, 2015, CLIN DERMATOL, V33, P327, DOI 10.1016/j.clindermatol.2014.12.009; Rutkowski K, 2021, CLIN EXP ALLERGY, V51, P770, DOI 10.1111/cea.13880; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Samarakoon U, 2021, NEW ENGL J MED, V385, P662, DOI 10.1056/NEJMc2108620; Schattner A, 2005, VACCINE, V23, P3876, DOI 10.1016/j.vaccine.2005.03.005; Simonetti O, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9040401; Sokolowska M, 2021, ALLERGY, V76, P1629, DOI 10.1111/all.14739; Solimani F, 2021, J EUR ACAD DERMATOL, V35, pE649, DOI 10.1111/jdv.17480; Song Eingun James, 2021, JAAD Case Rep, V13, P30, DOI 10.1016/j.jdcr.2021.04.032; Sprent J, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abj9256; Sun QS, 2021, DERMATOL CLIN, V39, P653, DOI 10.1016/j.det.2021.05.016; Teijaro JR, 2021, NAT REV IMMUNOL, V21, P195, DOI 10.1038/s41577-021-00526-x; Theodorou DJ, 2021, QJM-INT J MED, V114, P424, DOI 10.1093/qjmed/hcab043; Torrelo A, 2006, PEDIATR DERMATOL, V23, P484, DOI 10.1111/j.1525-1470.2006.00289.x; Varma Aakaash, 2020, JAAD Case Rep, V6, P217, DOI 10.1016/j.jdcr.2020.01.012; Velikova T, 2021, RHEUMATOL INT, V41, P509, DOI 10.1007/s00296-021-04792-9; Wei Nancy, 2021, JAAD Case Rep, V10, P92, DOI 10.1016/j.jdcr.2021.02.014; Wenzel J, 2019, NAT REV RHEUMATOL, V15, P519, DOI 10.1038/s41584-019-0272-0; Wolf F, 1998, EUR J DERMATOL, V8, P435; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Yan ZP, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14050406; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	96	10	10	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							944	10.3390/vaccines9090944			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW0JV	34579181	Green Published, gold			2022-04-29	WOS:000699854500001
J	Tripp, RA				Tripp, Ralph A.			Advances in Vaccine Development	VACCINES			English	Editorial Material									[Tripp, Ralph A.] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA		Tripp, RA (通讯作者)，Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA.	ratripp@uga.edu		Tripp, Ralph/0000-0002-2924-9956			Biagi C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040672; Cappellano G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060606; Chatterjee R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080812; Chiozzini C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040373; Cianci R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040636; Dunagan MM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060629; Lu LT, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060563; Muller C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030255; Penkert RR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080860; Pippa N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060558; Radwanska M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060603; Rijkers GT, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080848; Scarpini S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060551; Sousa SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060670; Stephens LM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060624; van Oosterwijk JG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070725; Velazquez-Moctezuma R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030291; Walkowski W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060589; Whitlow E, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040586; Zhang MD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070732	20	0	0	4	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1036	10.3390/vaccines9091036			5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3JT	34579273	Green Published, gold			2022-04-29	WOS:000702105400001
J	Baniak, LM; Luyster, FS; Raible, CA; McCray, EE; Strollo, PJ				Baniak, Lynn M.; Luyster, Faith S.; Raible, Claire A.; McCray, Ellesha E.; Strollo, Patrick J.			COVID-19 Vaccine Hesitancy and Uptake among Nursing Staff during an Active Vaccine Rollout	VACCINES			English	Article						Covid-19; vaccine uptake; nurses; United States		Even with the availability of COVID-19 vaccines, factors associated with vaccine hesitancy and uptake among nurses are unknown. This study evaluated COVID-19 vaccine hesitancy and uptake of nursing staff during one of the first COVID-19 vaccine rollouts in the United States. A cross-sectional survey was conducted during February 2021 among nursing staff working in a large medical center in central United States. There were 276 respondents; 81.9% of participants were willing to receive the vaccine during the initial rollout, 11.2% were hesitant, and only 5.1% were unwilling. The hesitant group was likely to report having inadequate information to make an informed decision about whether to receive the vaccine (45.2%) and about vaccine expectations (32.3%). The majority (83.3%) received at least one dose of the vaccine. Having greater than 10 years' work experience (OR 3.0, 95% CI 1.16-7.9) and confidence in vaccine safety (OR 7.78, 95% CI 4.49-13.5) were significantly associated with vaccine uptake. While our study indicates higher vaccine uptake among nursing staff during an active vaccine rollout, there remains sustained hesitancy and unwillingness to uptake. For those hesitant to receive the COVID-19 vaccine, public health efforts to provide more data on side effects and efficacy may help increase vaccine uptake.	[Baniak, Lynn M.; Luyster, Faith S.; Raible, Claire A.; McCray, Ellesha E.; Strollo, Patrick J.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA; [Baniak, Lynn M.; Luyster, Faith S.] Univ Pittsburgh, Sch Nursing, Dept Hlth & Community Syst, Pittsburgh, PA 15261 USA; [Strollo, Patrick J.] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15261 USA		Baniak, LM (通讯作者)，Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.; Baniak, LM (通讯作者)，Univ Pittsburgh, Sch Nursing, Dept Hlth & Community Syst, Pittsburgh, PA 15261 USA.	Lynn.Baniak@va.gov; fsl3@pitt.edu; Claire.Raible@va.gov; Ellesha.McCray@va.gov; strollopj@upmc.edu	Strollo, Patrick J/L-7062-2016				Biswas N, 2021, J COMMUN HEALTH, V46, P1244, DOI 10.1007/s10900-021-00984-3; Centers for Disease Control and Prevention, COVID DAT TRACK; Ciardi F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050516; Di Gennaro F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030371; Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442; Dzieciolowska S, 2021, AM J INFECT CONTROL, V49, P1152, DOI 10.1016/j.ajic.2021.04.079; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Haridi HK, 2017, J HOSP INFECT, V96, P268, DOI 10.1016/j.jhin.2017.02.005; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Karlsson LC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224330; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kose S, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13917; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lytras T, 2016, HUM VACC IMMUNOTHER, V12, P671, DOI 10.1080/21645515.2015.1106656; Morley, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab054, DOI 10.1093/cid/ciab054]; Papagiannis D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030200; Rashid H, 2016, HEALTH AFFAIR, V35, P284, DOI 10.1377/hlthaff.2015.1087; Schumacher S, 2021, INFECTION, V49, P387, DOI 10.1007/s15010-020-01555-9; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; World Health Organization, ESS PROGR IMM; Yeung MPS, 2016, J PUBLIC HEALTH-UK, V38, P746, DOI 10.1093/pubmed/fdv194	26	4	4	0	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							858	10.3390/vaccines9080858			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH8VS	34451983	Green Published, gold			2022-04-29	WOS:000690201600001
J	Maekawa, D; Riblet, SM; Whang, P; Hurley, DJ; Garcia, M				Maekawa, Daniel; Riblet, Sylva M.; Whang, Patrick; Hurley, David J.; Garcia, Maricarmen			Activation of Cytotoxic Lymphocytes and Presence of Regulatory T Cells in the Trachea of Non-Vaccinated and Vaccinated Chickens as a Recall to an Infectious Laryngotracheitis Virus (ILTV) Challenge	VACCINES			English	Article						infectious laryngotracheitis virus (ILTV); chicken embryo origin (CEO); tissue culture origin (TCO); recombinant herpesvirus of Turkey-laryngotracheitis (rHVT-LT); cytotoxic T lymphocytes (CTLs); natural killer (NK) cells; regulatory T cells (Tregs); protection	MAREKS-DISEASE VIRUS; HERPESVIRUS-INFECTION; RECOMBINANT HERPESVIRUS; PROTECTION EFFICACY; IN-OVO; TURKEY; IMMUNITY; CD8-ALPHA-BETA; IDENTIFICATION; REPLICATION	While the protective efficacy of the infectious laryngotracheitis virus (ILTV) vaccines is well established, little is known about which components of the immune response are associated with effective resistance and vaccine protection. Early studies have pointed to the importance of the T cell-mediated immune responses. This study aimed to evaluate the activation of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells and to quantify the presence of regulatory T cells (Tregs) in the larynx-trachea of chickens vaccinated with chicken embryo origin (CEO), tissue culture origin (TCO) and recombinant Herpesvirus of Turkey-laryngotracheitis (rHVT-LT) vaccines after challenge. Our results indicated that CEO vaccine protection was characterized by early CTLs and activated CTLs enhanced responses. TCO and rHVT-LT protection were associated with a moderate increase in resting and activated CTLs followed by an enhanced NK cell response. Tregs increase was only detected in the non-vaccinated challenged group, probably to support healing of the severe trachea epithelial damage. Taken together, our results revealed main differences in the cellular immune responses elicited by CEO, TCO, and rHVT-LT vaccination in the upper respiratory tract after challenge, and that activated CTLs rather than NK cells play a main role in vaccine protection.	[Maekawa, Daniel; Riblet, Sylva M.; Whang, Patrick; Garcia, Maricarmen] Univ Georgia, Coll Vet Med, Poultry Diagnost & Res Ctr, Dept Populat Hlth, Athens, GA 30602 USA; [Hurley, David J.] Univ Georgia, Dept Populat Hlth, Coll Vet Med, Food Anim Hlth & Management Program, Athens, GA 30602 USA		Garcia, M (通讯作者)，Univ Georgia, Coll Vet Med, Poultry Diagnost & Res Ctr, Dept Populat Hlth, Athens, GA 30602 USA.	daniel.maekawa@uga.edu; sriblet@uga.edu; Patrick.Whang@uga.edu; djhurley@uga.edu; mcgarcia@uga.edu		Garcia, Maricarmen/0000-0002-2175-0287; Hurley, David/0000-0003-2108-4496	Agriculture and Food Research Initiative Competitive Grant from the USDA National Institute of Food and Agriculture [2015-68004-23131]	This study was supported by Agriculture and Food Research Initiative Competitive Grant no. (2015-68004-23131) from the USDA National Institute of Food and Agriculture.	Bertzbach LD, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7120588; Betts MR, 2004, METHOD CELL BIOL, V75, P497; CALNEK BW, 1981, J NATL CANCER I, V66, P585; Coppo MJC, 2013, DEV COMP IMMUNOL, V41, P454, DOI 10.1016/j.dci.2013.03.022; Esaki M, 2013, AVIAN DIS, V57, P192, DOI 10.1637/10383-092412-Reg.1; FABRICANT J, 1982, AVIAN DIS, V26, P257, DOI 10.2307/1590094; FAHEY KJ, 1984, AVIAN PATHOL, V13, P265, DOI 10.1080/03079458408418530; FAHEY KJ, 1983, AVIAN PATHOL, V12, P505, DOI 10.1080/03079458308436195; Garcia M., 2020, DIS POULTRY, P189, DOI 10.1002/9781119371199.ch5; Garcia M, 2016, J GEN VIROL, V97, P2352, DOI 10.1099/jgv.0.000521; Gimeno IM, 2011, AVIAN PATHOL, V40, P395, DOI 10.1080/03079457.2011.588196; GOBEL TWF, 1994, EUR J IMMUNOL, V24, P1685, DOI 10.1002/eji.1830240734; Gurung A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006745; GUY JS, 1990, AVIAN DIS, V34, P106, DOI 10.2307/1591340; GUY JS, 1991, AVIAN DIS, V35, P348, DOI 10.2307/1591188; Hao XL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.645426; HIRAI K, 1981, J GEN VIROL, V53, P133, DOI 10.1099/0022-1317-53-1-133; HONDA T, 1994, J VET MED SCI, V56, P1051, DOI 10.1292/jvms.56.1051; Jansen CA, 2013, SCI REP-UK, V3, DOI 10.1038/srep02478; Jansen CA, 2010, DEV COMP IMMUNOL, V34, P759, DOI 10.1016/j.dci.2010.02.009; Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778; Kim T, 2018, IMMUNOGENETICS, V70, P599, DOI 10.1007/s00251-018-1066-2; Koyanagi N, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12121354; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luckheeram RV, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/925135; Luhtala M, 1998, POULTRY SCI, V77, P1858, DOI 10.1093/ps/77.12.1858; Maekawa D., 2021, IN PRESS; Maekawa D, 2019, AVIAN PATHOL, V48, P573, DOI 10.1080/03079457.2019.1644449; Maekawa D, 2019, AVIAN DIS, V63, P351, DOI 10.1637/12029-011119-Reg.1; Oldoni I, 2009, AVIAN PATHOL, V38, P47, DOI 10.1080/03079450802632031; REED L. J., 1938, AMER JOUR HYG, V27, P493; Rodriguez-Avila A, 2007, AVIAN DIS, V51, P905, DOI 10.1637/8011-041907-REGR.1; Rodriguez-Avila A, 2008, AVIAN PATHOL, V37, P287, DOI 10.1080/03079450802043742; Schenkel JM, 2014, IMMUNITY, V41, P886, DOI 10.1016/j.immuni.2014.12.007; Selvaraj RK, 2013, DEV COMP IMMUNOL, V41, P397, DOI 10.1016/j.dci.2013.04.018; Seo SH, 1997, J VIROL, V71, P5173, DOI 10.1128/JVI.71.7.5173-5177.1997; Seo SH, 2002, J VIROL, V76, P4886, DOI 10.1128/JVI.76.10.4886-4890.2002; Shanmugasundaram R, 2011, J IMMUNOL, V186, P1997, DOI 10.4049/jimmunol.1002040; Sharma A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00883; TREGASKES CA, 1995, J IMMUNOL, V154, P4485; Umthong S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040557; Uzhachenko RV, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01906; Vagnozzi A, 2012, AVIAN PATHOL, V41, P21, DOI 10.1080/03079457.2011.631983; van Dommelen SLH, 2006, IMMUNITY, V25, P835, DOI 10.1016/j.immuni.2006.09.010; Veiga-Parga T, 2013, IMMUNOL REV, V255, P182, DOI 10.1111/imr.12085; Vervelde L, 2013, VET IMMUNOL IMMUNOP, V151, P337, DOI 10.1016/j.vetimm.2012.11.012; Wattrang E, 2015, J IMMUNOL METHODS, V419, P35, DOI 10.1016/j.jim.2015.02.011; Williams CJ, 2011, POULTRY SCI, V90, P223, DOI 10.3382/ps.2010-00759; Yang Y, 2020, CELL MOL LIFE SCI, V77, P3103, DOI 10.1007/s00018-020-03477-z; YORK JJ, 1989, AVIAN PATHOL, V18, P643, DOI 10.1080/03079458908418639; Zavala G., 2011, POULT INF PROF, V118, P1	52	2	2	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							865	10.3390/vaccines9080865			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7AP	34451989	gold, Green Published			2022-04-29	WOS:000690079100001
J	Mahmud, I; Kabir, R; Rahman, MA; Alradie-Mohamed, A; Vinnakota, D; Al-Mohaimeed, A				Mahmud, Ilias; Kabir, Russell; Rahman, Muhammad Aziz; Alradie-Mohamed, Angi; Vinnakota, Divya; Al-Mohaimeed, Abdulrahman			The Health Belief Model Predicts Intention to Receive the COVID-19 Vaccine in Saudi Arabia: Results from a Cross-Sectional Survey	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccine hesitancy; health belief model; Saudi Arabia	INFLUENZA VACCINATION; POPULATION; ACCEPTANCE; PREVENT	We examined the intention and predictors of accepting the COVID-19 vaccine in Saudi Arabia. We conducted a nation-wide, cross-sectional online survey between February and March 2021. A total of 1387 people (>= 18 years) participated. Only 27.3% adults had a definite and 30.2% had a probable vaccination intent; 26.8% and 15.6% had a probable and definite negative vaccination intent. Older people (>= 50 years) (p < 0.01), healthcare workers/professionals (p < 0.001), and those who received flu vaccine (p < 0.001) were more likely to have a positive intent. People from Riyadh were less likely to receive the vaccine (p < 0.05). Among the health belief model constructs, perceived susceptibility to and severity of COVID-19 (p < 0.001), and perceived benefit of the vaccine (p < 0.001) were positively associated with vaccination intent, whereas perceived barriers had a negative association (p < 0.001). Individuals were more likely to receive the vaccine after obtaining complete information (p < 0.001) and when the vaccine uptake would be more common amongst the public (p < 0.001).	[Mahmud, Ilias] Qassim Univ, Coll Publ Hlth & Hlth Informat, Dept Publ Hlth, Al Bukairiyah 51941, Saudi Arabia; [Kabir, Russell; Vinnakota, Divya] Anglia Ruskin Univ, Fac Hlth Educ Med & Social Care, Sch Allied Hlth, Chelmsford CM1 1SQ, Essex, England; [Rahman, Muhammad Aziz] Federat Univ Australia, Sch Hlth, Berwick, Vic 3806, Australia; [Rahman, Muhammad Aziz] La Trobe Univ, Australia Inst Primary Care & Ageing AIPCA, Melbourne, Vic 3086, Australia; [Rahman, Muhammad Aziz] Univ Airlangga, Fac Publ Hlth, Surabaya 60115, Indonesia; [Alradie-Mohamed, Angi] United Arab Emirates Univ, POB 15551, Al Ain, U Arab Emirates; [Al-Mohaimeed, Abdulrahman] Qassim Univ, Coll Med, Dept Family & Community Med, Buraydah 52571, Saudi Arabia		Mahmud, I (通讯作者)，Qassim Univ, Coll Publ Hlth & Hlth Informat, Dept Publ Hlth, Al Bukairiyah 51941, Saudi Arabia.; Al-Mohaimeed, A (通讯作者)，Qassim Univ, Coll Med, Dept Family & Community Med, Buraydah 52571, Saudi Arabia.	i.emdadulhaque@qu.edu.sa; russell.kabir@aru.ac.uk; ma.rahman@federation.edu.au; Ngmotsim@gmail.com; drdivya0424@gmail.com; armoh@qu.edu.sa	Rahman, Muhammad Aziz/B-3380-2009; Vinnakota, Dr Divya/AAR-1301-2021; Kabir, Russell/H-9715-2019; Mahmud, Ilias/N-5085-2017	Rahman, Muhammad Aziz/0000-0003-1665-7966; Vinnakota, Dr Divya/0000-0002-9707-1491; Kabir, Russell/0000-0001-9257-2775; Mahmud, Ilias/0000-0003-1330-7813	Deanship of Scientific Research, Qassim University	The researchers would like to thank the Deanship of Scientific Research, Qassim University for funding the publication of this project.	Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alabbad AA, 2018, J INFECT PUBLIC HEAL, V11, P491, DOI 10.1016/j.jiph.2017.09.002; Alfageeh EI, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030226; Almaghaslah D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040330; Bartsch SM, 2020, AM J PREV MED, V59, P493, DOI 10.1016/j.amepre.2020.06.011; Bhartiya S., 2021, INT J COMMUN MED PUB, V8, P7, DOI [10.18203/2394-6040.ijcmph20210481, DOI 10.18203/2394-6040.IJCMPH20210481]; Chen MF, 2011, J COMMUN HEALTH NURS, V28, P29, DOI 10.1080/07370016.2011.539087; Coe Antoinette B, 2012, Innov Pharm, V3, P1; Daly Michael, 2020, medRxiv, DOI 10.1101/2020.11.27.20239970; Donadiki EM, 2014, PUBLIC HEALTH, V128, P268, DOI 10.1016/j.puhe.2013.12.004; Fall E, 2018, PSYCHOL HEALTH, V33, P746, DOI 10.1080/08870446.2017.1401623; Iboi EA, 2020, INFECT DIS MODEL, V5, P510, DOI 10.1016/j.idm.2020.07.006; Kabir R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050416; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Loomba S, 2021, NAT HUM BEHAV, V5, P337, DOI 10.1038/s41562-021-01056-1; Mahmud I, 2020, INT J HEALTH SCI-IJH, V14, P1; McArthur L, 2020, AM J TROP MED HYG, V103, P625, DOI 10.4269/ajtmh.20-0564; McGill University COVID19 Vaccine Tracker Team, COVID 19 VACC TRACK; Mercadante AR, 2021, RES SOC ADMIN PHARM, V17, P1596, DOI 10.1016/j.sapharm.2020.12.012; Mishra SK, 2021, ACTA TROP, V214, DOI 10.1016/j.actatropica.2020.105778; Mo PKH, 2015, HEALTH EDUC RES, V30, P706, DOI 10.1093/her/cyv038; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Nexoe J, 1999, SCAND J PRIM HEALTH, V17, P105, DOI 10.1080/028134399750002737; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; Obied DA, 2020, J INFECT DEV COUNTR, V14, P699, DOI 10.3855/jidc.13203; Qattan AMN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644300; Reno C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040378; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Smith PJ, 2011, PUBLIC HEALTH REP, V126, P135, DOI 10.1177/00333549111260S215; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Tran VD, 2021, PHARM PRACT-GRANADA, V19, DOI [10.18549/PharmPract.2021.1.2276, 10.18549/pharmpract.2021.1.2276]; van der Linden S, 2021, ECLINICALMEDICINE, V33, DOI 10.1016/j.eclinm.2021.100772; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; WHO, WHO COR COVID 19 DAS; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; World Health Organization, 2019, 10 THREATS GLOB HLTH; World Health Organization, 2021, WHO LISTS ADD COVID; World Health Organization World Health Organization, 2020, DRAFT LANDSCAPE COVI; Zampetakis LA, 2021, APPL PSYCHOL-HLTH WE, V13, P469, DOI 10.1111/aphw.12262; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	45	8	8	9	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							864	10.3390/vaccines9080864			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH2YW	34451991	Green Published, gold, Green Accepted			2022-04-29	WOS:000689804200001
J	Perepliotchikov, Y; Ziv-Baran, T; Hindiyeh, M; Manor, Y; Sofer, D; Moran-Gilad, J; Stephens, L; Mendelson, E; Weil, M; Bassal, R; Anis, E; Singer, SR; Kaliner, E; Cooper, G; Majumdar, M; Markovich, M; Ram, D; Grotto, I; Gamzu, R; Martin, J; Shulman, LM				Perepliotchikov, Yuri; Ziv-Baran, Tomer; Hindiyeh, Musa; Manor, Yossi; Sofer, Danit; Moran-Gilad, Jacob; Stephens, Laura; Mendelson, Ella; Weil, Merav; Bassal, Ravit; Anis, Emilia; Singer, Shepherd Roee; Kaliner, Ehud; Cooper, Gillian; Majumdar, Manasi; Markovich, Michal; Ram, Daniela; Grotto, Itamar; Gamzu, Ronni; Martin, Javier; Shulman, Lester M.			Inferring Numbers of Wild Poliovirus Excretors Using Quantitative Environmental Surveillance	VACCINES			English	Article						poliovirus; outbreaks; quantitative environmental surveillance; vaccination; oral poliovirus vaccine; inactivated poliovirus vaccine; asymptomatic infections; stools; sewage; composite sewage samples; vaccine-derived poliovirus	VACCINE-DERIVED POLIOVIRUSES; ACUTE FLACCID PARALYSIS; MIDDLE-EAST; DIGITAL PCR; ERADICATION; IDENTIFICATION; ISRAEL; SPECIMENS	Response to and monitoring of viral outbreaks can be efficiently focused when rapid, quantitative, kinetic information provides the location and the number of infected individuals. Environmental surveillance traditionally provides information on location of populations with contagious, infected individuals since infectious poliovirus is excreted whether infections are asymptomatic or symptomatic. Here, we describe development of rapid (1 week turnaround time, TAT), quantitative RT-PCR of poliovirus RNA extracted directly from concentrated environmental surveillance samples to infer the number of infected individuals excreting poliovirus. The quantitation method was validated using data from vaccination with bivalent oral polio vaccine (bOPV). The method was then applied to infer the weekly number of excreters in a large, sustained, asymptomatic outbreak of wild type 1 poliovirus in Israel (2013) in a population where >90% of the individuals received three doses of inactivated polio vaccine (IPV). Evidence-based intervention strategies were based on the short TAT for direct quantitative detection. Furthermore, a TAT shorter than the duration of poliovirus excretion allowed resampling of infected individuals. Finally, the method documented absence of infections after successful intervention of the asymptomatic outbreak. The methodologies described here can be applied to outbreaks of other excreted viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), where there are (1) significant numbers of asymptomatic infections; (2) long incubation times during which infectious virus is excreted; and (3) limited resources, facilities, and manpower that restrict the number of individuals who can be tested and re-tested.	[Perepliotchikov, Yuri; Hindiyeh, Musa; Manor, Yossi; Sofer, Danit; Mendelson, Ella; Weil, Merav; Ram, Daniela; Shulman, Lester M.] Cent Virol Lab, Sheba Med Ctr, Ramat Gan, Israel; [Ziv-Baran, Tomer; Hindiyeh, Musa; Mendelson, Ella; Gamzu, Ronni; Shulman, Lester M.] Tel Aviv Univ, Sch Publ Hlth, Sackler Fac Med, IL-6997801 Tel Aviv, Israel; [Moran-Gilad, Jacob; Anis, Emilia; Singer, Shepherd Roee; Kaliner, Ehud; Grotto, Itamar; Gamzu, Ronni] MOH, Publ Hlth Serv, IL-9101002 Jerusalem, Israel; [Moran-Gilad, Jacob; Singer, Shepherd Roee; Grotto, Itamar] Ben Gurion Univ Negev, Fac Hlth Sci, IL-8410501 Beer Sheva, Israel; [Stephens, Laura; Cooper, Gillian; Majumdar, Manasi; Martin, Javier] Natl Inst Biol Stand & Controls, Blanche Lane, Potters Bar, Herts, England; [Bassal, Ravit; Markovich, Michal] Israel Ctr Dis Control, Minist Hlth, Gertner Bldg, Ramat Gan, Israel; [Anis, Emilia] Hebrew Univ Jerusalem Hadassah Hosp & Med Sch, Braun Sch Publ Hlth & Community Med, Fac Med, Ein Kerem POB 12271, IL-9112102 Jerusalem, Israel; [Perepliotchikov, Yuri] Rhenium Ltd, IL-7171101 Modiin, Israel; [Hindiyeh, Musa] Augusta Victoria Hosp, IL-91191 Jerusalem, Israel; [Markovich, Michal] Israel Minist Agr & Rural Dev, Israel Vet Serv, IL-5025001 Bet Dagan, Israel; [Gamzu, Ronni] Tel Aviv Sourasky, Med Ctr, 6 Weizmann St, IL-64239 Tel Aviv, Israel; [Shulman, Lester M.] 11 Orange St, IL-7683000 Ganne Hadar, Israel		Shulman, LM (通讯作者)，Cent Virol Lab, Sheba Med Ctr, Ramat Gan, Israel.; Gamzu, R; Shulman, LM (通讯作者)，Tel Aviv Univ, Sch Publ Hlth, Sackler Fac Med, IL-6997801 Tel Aviv, Israel.; Gamzu, R (通讯作者)，MOH, Publ Hlth Serv, IL-9101002 Jerusalem, Israel.	yuriper1@gmail.com; zivtome@post.tau.ac.il; mhindiyeh@avh.org; y-manor@hotmail.com; danitso@sheba.health.gov.il; giladko@post.bgu.ac.il; laura.stephens@nibsc.org; ellamen@sheba.health.gov.il; Merav.Weil@sheba.health.gov.il; Ravit.Bassal@moh.gov.il; emilia.anis@moh.health.gov.il; roee.singer@moh.health.gov.il; ehud.kaliner@moh.health.gov.il; Gill.Cooper@nibsc.org; Manasi.Majumdar@nibsc.org; michaluch@yahoo.com; dr.daniela.ram@gmail.com; itamar.grotto@moh.health.gov.il; Ronni@tlvmc.gov.il; Javier.Martin@nibsc.org; lester.shulman@sheba.health.gov.il	Shulman, Lester M./AAU-4372-2021; Grotto, Itamar/F-2028-2012; Ziv-Baran, Tomer/AAA-8408-2022	Shulman, Lester M./0000-0002-6385-894X; Martin, Javier/0000-0001-5326-7081; Majumdar, Manasi/0000-0002-1413-1509; Weil, Merav/0000-0002-4472-4081; Bassal, Ravit/0000-0002-0086-2968; Peri Markovich, Michal/0000-0002-2061-5155	WHO, Geneva, SwitzerlandWorld Health Organization [18-TSA-032]; Central Virology Laboratory, Israel Public Health Services; National Institute for Biological Controls and Standards, UK	LMS: JM: Polio environmental surveillance involving simultaneous collections from multiple sites in central Israel in 2011 was funded in part by Grant 18-TSA-032 for Post Eradication Sewage Surveillance-determining limits for detecting persistent polio excretors in large populations provided by the WHO, Geneva, Switzerland. All other authors: Additional portions of the study were supported by internal resources of the Central Virology Laboratory, Israel Public Health Services, and the National Institute for Biological Controls and Standards, UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed W, 2020, SCI TOTAL ENVIRON, V741, DOI 10.1016/j.scitotenv.2020.140071; Alexander JP, 1997, J INFECT DIS, V175, pS176, DOI 10.1093/infdis/175.Supplement_1.S176; Berchenko Y, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf6786; BREMAN JG, 1980, NEW ENGL J MED, V303, P1263, DOI 10.1056/NEJM198011273032204; Brouwer AF, 2018, P NATL ACAD SCI USA, V115, pE10625, DOI 10.1073/pnas.1808798115; Centers for Disease Control and Prevention, 2019, GLOB CERT ER IND WIL; Chik AHS, 2021, J ENVIRON SCI, V107, P218, DOI 10.1016/j.jes.2021.01.029; Chumakov K, 2021, LANCET GLOB HEALTH, V9, pE1172, DOI 10.1016/S2214-109X(21)00205-9; Corman VM, 2016, CLIN INFECT DIS, V62, P477, DOI 10.1093/cid/civ951; Dowdle WR, 2003, REV MED VIROL, V13, P277, DOI 10.1002/rmv.401; Fine PEM, 1999, AM J EPIDEMIOL, V150, P1001, DOI 10.1093/oxfordjournals.aje.a009924; Fuschi C, 2021, ACS EST WATER, V1, P1352, DOI 10.1021/acsestwater.1c00050; Global Polio Eradication Initiative, 2021, PUBL HLTH EM STAT I; Global Polio Eradication Initiative, 2015, GLOB ER WILD POL TYP; Greenberger N.J., 2011, MERCK MANUAL DIAGNOS; Hay JA, 2021, SCIENCE, V373, DOI 10.1126/science.abh0635; Hovi T, 2001, EPIDEMIOL INFECT, V127, P101, DOI 10.1017/S0950268801005787; Hovi T, 2012, EPIDEMIOL INFECT, V140, P1, DOI 10.1017/S095026881000316X; Jorba J, 2018, MMWR-MORBID MORTAL W, V67, P1189, DOI 10.15585/mmwr.mm6742a5; Kanner E, 2015, LANCET INFECT DIS, V15, P1236, DOI 10.1016/S1473-3099(15)00064-X; Kew OM, 2014, MMWR-MORBID MORTAL W, V63, P1031; Kilpatrick DR, 2014, J VIROL METHODS, V197, P25, DOI 10.1016/j.jviromet.2013.11.017; Kilpatrick DR, 1998, J CLIN MICROBIOL, V36, P352, DOI 10.1128/JCM.36.2.352-357.1998; Kilpatrick DR, 2004, J CLIN MICROBIOL, V42, P4313, DOI 10.1128/JCM.42.9.4313-4315.2004; Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI [10.1016/j.gastro.2003.08.001, 10.1053/S0016-5085(03)01215-0]; Li X, 2021, CHEM ENG J, V415, DOI 10.1016/j.cej.2021.129039; Lodder WJ, 2012, APPL ENVIRON MICROB, V78, P3800, DOI 10.1128/AEM.07972-11; Lu DN, 2020, SCI TOTAL ENVIRON, V747, DOI 10.1016/j.scitotenv.2020.141245; Manor Y, 2014, EUROSURVEILLANCE, V19, P31, DOI 10.2807/1560-7917.ES2014.19.7.20710; Manor Y, 1999, J CLIN MICROBIOL, V37, P1670, DOI 10.1128/JCM.37.6.1670-1675.1999; Marx A, 2000, EPIDEMIOL REV, V22, P298, DOI 10.1093/oxfordjournals.epirev.a018041; Matrajt G, 2018, CLIN INFECT DIS, V67, pS90, DOI 10.1093/cid/ciy638; Mbaeyi C, 2017, MMWR-MORBID MORTAL W, V66, P27, DOI 10.15585/mmwr.mm6608a6; McGonigle D., 2020, TRANSMISSION COVID 1; Meade M., DIGESTION; Melnick JL, 1996, CLIN MICROBIOL REV, V9, P293, DOI 10.1128/CMR.9.3.293; Moran-Gilad J, 2015, J CLIN VIROL, V66, P51, DOI 10.1016/j.jcv.2015.03.005; Nathanson N, 2010, AM J EPIDEMIOL, V172, P1213, DOI 10.1093/aje/kwq320; Offit PA., 2008, VACCINES-BASEL, V5th, P631, DOI [10.1016/b978-1-4160-3611-1.50030-1, DOI 10.1016/B978-1-4160-3611-1.50030-1]; Pavsic J, 2016, ANAL BIOANAL CHEM, V408, P107, DOI 10.1007/s00216-015-9107-2; Plotkin S., 1999, VACCINES-BASEL, V3rd ed., P345; Racaniello VR, 1996, CURR TOP MICROBIOL, V206, P305; Racki N, 2014, ANAL BIOANAL CHEM, V406, P661, DOI 10.1007/s00216-013-7476-y; Ranta J, 2001, RISK ANAL, V21, P1087, DOI 10.1111/0272-4332.t01-1-216174; Schade J.P., 2006, COMPLETE ENCY MED HL, P280; Schiller L.R., 2002, SLEISENGER FORDTRANS, V7th ed., P131; Shulman L.M., 2012, J BIOTERR BIODEF, VS4, P004, DOI [10.4172/2157-2526.S4-004, DOI 10.4172/2157-2526.S4-004]; Shulman L.M., 2020, ENCY SUSTAINABILITY, P1; Shulman LM, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000069; Shulman LM, 2016, METHODS MOL BIOL, V1387, P55, DOI 10.1007/978-1-4939-3292-4_5; Shulman LM, 2014, J INFECT DIS, V210, pS304, DOI 10.1093/infdis/jiu294; Swartz TA, 2008, VACCINE, V26, P1083, DOI 10.1016/j.vaccine.2007.12.021; Swartz T.A., 2008, EPIDEMIOLOGY POLIO I; Teitelbaum D.H., 2012, PEDIAT SURG E BOOK, V7th ed., P179; TUCKER DM, 1981, GASTROENTEROLOGY, V81, P879; WHITTLE H, 1992, LANCET, V339, P429, DOI 10.1016/0140-6736(92)90114-I; WHO, 2020, WHO GLOBAL ACTION PL; World Health Organization, 2019, 2 OUT 3 WILD POL STA; World Health Organization, GUID ENV SURV DET PO; World Health Organization, 2003, GUID ENV SURV POL CI; World Health Organization, 2004, POL LAB MAN; World Health Organization, 2018, POL GLOB ER IN; Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055; Xu Y, 2020, NAT MED, V26, P502, DOI 10.1038/s41591-020-0817-4; Yaari R, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0637-z	65	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							870	10.3390/vaccines9080870			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7CP	34451995	gold, Green Published			2022-04-29	WOS:000690084300001
J	Pyasi, S; Sharma, V; Dipti, K; Jonniya, NA; Nayak, D				Pyasi, Shruti; Sharma, Vinita; Dipti, Kumari; Jonniya, Nisha Amarnath; Nayak, Debasis			Immunoinformatics Approach to Design Multi-Epitope-Subunit Vaccine against Bovine Ephemeral Fever Disease	VACCINES			English	Article						BEFV; Immunoinformatics; multi-epitopes vaccine; BoLA; Toll-like receptor 7	MOLECULAR-DYNAMICS; IMMUNE-RESPONSES; CODON USAGE; WEB SERVER; G-PROTEIN; VIRUS; PREDICTION; GLYCOPROTEIN; RECOGNITION; EXPRESSION	Bovine ephemeral fever virus (BEFV) is an overlooked pathogen, recently gaining widespread attention owing to its associated enormous economic impacts affecting the global livestock industries. High endemicity with rapid spread and morbidity greatly impacts bovine species, demanding adequate attention towards BEFV prophylaxis. Currently, a few suboptimum vaccines are prevailing, but were confined to local strains with limited protection. Therefore, we designed a highly efficacious multi-epitope vaccine candidate targeted against the geographically distributed BEFV population. By utilizing immunoinformatics technology, all structural proteins were targeted for B- and T-cell epitope prediction against the entire allele population of BoLA molecules. Prioritized epitopes were adjoined by linkers and adjuvants to effectively induce both cellular and humoral immune responses in bovine. Subsequently, the in silico construct was characterized for its physicochemical parameters, high immunogenicity, least allergenicity, and non-toxicity. The 3D modeling, refinement, and validation of ligand (vaccine construct) and receptor (bovine TLR7) then followed molecular docking and molecular dynamic simulation to validate their stable interactions. Moreover, in silico cloning of codon-optimized vaccine construct in the prokaryotic expression vector (pET28a) was explored. This is the first time HTL epitopes have been predicted using bovine datasets. We anticipate that the designed construct could be an effective prophylactic remedy for the BEF disease that may pave the way for future laboratory experiments.	[Pyasi, Shruti; Jonniya, Nisha Amarnath; Nayak, Debasis] Indian Inst Technol Indore, Discipline Biosci & Biomed Engn, Indore 452020, India; [Sharma, Vinita] Cent Univ Rajasthan, Dept Biochem, Ajmer 305817, Rajasthan, India; [Dipti, Kumari] Banasthali Vidyapith, Dept Biosci & Biotechnol, Vanasthali 304022, Rajasthan, India		Nayak, D (通讯作者)，Indian Inst Technol Indore, Discipline Biosci & Biomed Engn, Indore 452020, India.	phd1501171002@iiti.ac.in; vinusharma650@gmail.com; diptirkp255@gmail.com; phd1601271002@iiti.ac.in; nayakdn@iiti.ac.in	Jonniya, Nisha Amarnath/AAF-3385-2019	Jonniya, Nisha Amarnath/0000-0001-8022-3113; Nayak, Debasis/0000-0002-4762-4553	Science and Engineering Research Board, Govt. of India [SERB: ECR/2016/000130]	This study was partly supported by the Science and Engineering Research Board (SERB: ECR/2016/000130), Govt. of India.	Abayli H, 2017, ARCH VIROL, V162, P3233, DOI 10.1007/s00705-017-3470-6; Amanna IJ, 2011, VIROLOGY, V411, P206, DOI 10.1016/j.virol.2010.12.016; ARPIN C, 1995, SCIENCE, V268, P720, DOI 10.1126/science.7537388; Arturo CJ., 2017, VACCINES-BASEL; Askok KT, 2013, WIDE SPECTRUM, V1, P15; Aziz-Boaron O, 2014, VET MICROBIOL, V173, P1, DOI 10.1016/j.vetmic.2014.06.021; Bacchetta R, 2005, AUTOIMMUN REV, V4, P491, DOI 10.1016/j.autrev.2005.04.005; Bakhshesh M, 2018, BIOMED BIOTECH RES J, V2, P208, DOI 10.4103/bbrj.bbrj_71_18; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Bhattacharya D, 2016, NUCLEIC ACIDS RES, V44, pW406, DOI 10.1093/nar/gkw336; Borrego F, 2006, J IMMUNOL, V177, P5759, DOI 10.4049/jimmunol.177.9.5759; Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361; CaCano RLE L.H., 2013, INTRO T B LYMPHOCYTE; Case D. A, 2018, **NON-TRADITIONAL**; COOPER NR, 1984, J INVEST DERMATOL, V83, pS121, DOI 10.1111/1523-1747.ep12281847; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Bohorquez MD, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01293; Deb D., CANDIDATE MULTIEPITO; Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30; Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5; Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4; Farrell D, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000071; Fuse S, 2008, CRIT REV IMMUNOL, V28, P159, DOI 10.1615/CritRevImmunol.v28.i2.40; Gaafar BBM, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6124030; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Gasteiger E., 2005, PROTEOM PROTOC HDB, P571, DOI [10.1385/1-59259-890-0:571, 10.1385/1-59259-890, DOI 10.1385/1592598900]; Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376; Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957; Hajighahramani N, 2017, INFECT GENET EVOL, V48, P83, DOI 10.1016/j.meegid.2016.12.010; Hayashi T, 2017, J VET MED SCI, V79, P1552, DOI 10.1292/jvms.16-0601; He CQ, 2016, VET MICROBIOL, V182, P50, DOI 10.1016/j.vetmic.2015.10.029; Hernandez D, 2018, INDIAN J SCI TECHNOL, V11, P1, DOI [10.17485/ijst/2018/v11i24/128164, DOI 10.17485/ijst/2018/v11i24/128164]; Hsieh YC, 2005, J VET MED SCI, V67, P411, DOI 10.1292/jvms.67.411; Johal J, 2008, ARCH VIROL, V153, P1657, DOI 10.1007/s00705-008-0164-0; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kallberg M, 2014, METHODS MOL BIOL, V1137, P17, DOI 10.1007/978-1-4939-0366-5_2; Kallberg M, 2012, NAT PROTOC, V7, P1511, DOI 10.1038/nprot.2012.085; Khatoon N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08842-w; Kirland P., 1992, P 1 INT S BOV EPH FE; Kongsuwan K, 1998, J GEN VIROL, V79, P2573, DOI 10.1099/0022-1317-79-11-2573; Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Luckheeram RV, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/925135; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Maccari G, 2017, NUCLEIC ACIDS RES, V45, pD860, DOI 10.1093/nar/gkw1050; Mackenzie-Dyck S, 2014, CLIN VACCINE IMMUNOL, V21, P463, DOI 10.1128/CVI.00696-13; Magnan CN, 2009, BIOINFORMATICS, V25, P2200, DOI 10.1093/bioinformatics/btp386; Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255; Majee P, 2021, J BIOMOL STRUCT DYN, V39, P1461, DOI 10.1080/07391102.2020.1734088; MALVIYA HK, 1977, INDIAN VET J, V54, P440; McWilliam SM, 1997, J GEN VIROL, V78, P1309, DOI 10.1099/0022-1317-78-6-1309; Michel-Todo L, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010130; Mohan T, 2013, VACCINE, V31, P1707, DOI 10.1016/j.vaccine.2013.01.041; MURPHY FA, 1972, ARCH GES VIRUSFORSCH, V38, P234, DOI 10.1007/BF01249675; Nain Z, 2020, J BIOMOL STRUCT DYN, V38, P4850, DOI 10.1080/07391102.2019.1692072; Nandi S, 1999, COMP IMMUNOL MICROB, V22, P81, DOI 10.1016/S0147-9571(98)00027-7; Naz A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01663; Nielsen Morten, 2010, Immunome Res, V6, P9, DOI 10.1186/1745-7580-6-9; Niwa T, 2015, J VET MED SCI, V77, P455, DOI 10.1292/jvms.14-0492; Oppenheim JJ, 2003, ANN RHEUM DIS, V62, P17, DOI 10.1136/ard.62.suppl_2.ii17; Pandey RK, 2018, J CELL BIOCHEM, V119, P7631, DOI 10.1002/jcb.27110; Pandey RK, 2018, VACCINE, V36, P2262, DOI 10.1016/j.vaccine.2018.03.042; Pandey RK, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00206; PASTOR RW, 1988, MOL PHYS, V65, P1409, DOI 10.1080/00268978800101881; Patronov A, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120139; Pavitrakar DV, 2022, J BIOMOL STRUCT DYN, V40, P648, DOI 10.1080/07391102.2020.1816493; Pei HD, 2005, APPL MICROBIOL BIOT, V68, P220, DOI 10.1007/s00253-004-1869-y; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097; Rana A, 2016, IMMUNOBIOLOGY, V221, P544, DOI 10.1016/j.imbio.2015.12.004; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078; Shamriz S, 2016, COMPUT BIOL MED, V76, P24, DOI 10.1016/j.compbiomed.2016.06.015; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Shey RA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40833-x; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Sohail MU, 2019, HEPAT MON, V19, DOI 10.5812/hepatmon.92437; St George T.D., 1986, P 4 S BRISB AUSTR; STGEORGE TD, 1977, AUST VET J, V53, P17; Takeshima SN, 2006, ANIM SCI J, V77, P138, DOI 10.1111/j.1740-0929.2006.00332.x; Terry FE, 2015, EXPERT REV VACCINES, V14, P21, DOI 10.1586/14760584.2015.955478; ul Qamar MT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1672-7; Ullah MA, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2020.151949; Uren M.F., 1992, P 1 INT S BOV EPH FE; UREN MF, 1994, VACCINE, V12, P845, DOI 10.1016/0264-410X(94)90295-X; Walker PJ, 2015, VET RES, V46, DOI 10.1186/s13567-015-0262-4; WALKER PJ, 1991, J GEN VIROL, V72, P67, DOI 10.1099/0022-1317-72-1-67; Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290; Woolard SN, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/141657; Yanase T, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00168	91	1	1	5	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							925	10.3390/vaccines9080925			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5LS	34452050	gold, Green Published			2022-04-29	WOS:000689972800001
J	Yaqinuddin, A; Shafqat, A; Kashir, J; Alkattan, K				Yaqinuddin, Ahmed; Shafqat, Areez; Kashir, Junaid; Alkattan, Khaled			Effect of SARS-CoV-2 Mutations on the Efficacy of Antibody Therapy and Response to Vaccines	VACCINES			English	Review						mutations; SARS-CoV-2; vaccines; monoclonal antibodies; resistance	NEUTROPHIL EXTRACELLULAR TRAPS; COVID-19; DELIVERY; VARIANT; COCKTAIL	SARS-CoV-2 causes severe acute respiratory syndrome, which has led to significant morbidity and mortality around the world. Since its emergence, extensive prophylactic and therapeutic countermeasures have been employed to successfully prevent the spread of COVID-19. Extensive work has been undertaken on using monoclonal antibody therapies, mass vaccination programs, and antiviral drugs to prevent and treat COVID-19. However, since antiviral drugs could take years to become widely available, immunotherapy and vaccines currently appear to be the most feasible option. In December 2020, the first vaccine against SARS-CoV-2 was approved by the World Health Organization (WHO) and, subsequently, many other vaccines were approved for use by different international regulators in different countries. Most monoclonal antibodies (mAbs) and vaccines target the SARS-CoV-2 surface spike (S) protein. Recently, mutant (or variant) SARS-CoV-2 strains with increased infectivity and virulence that evade protective host antibodies present either due to infection, antibody therapy, or vaccine administration have emerged. In this manuscript, we discuss the different monoclonal antibody and vaccine therapies available against COVID-19 and how the efficacy of these therapies is affected by the emergence of variants of SARS-CoV-2. We also discuss strategies that might help society cope with variants that could neutralize the effects of immunotherapy and escape the protective immunity conferred by vaccines.	[Yaqinuddin, Ahmed; Shafqat, Areez; Kashir, Junaid; Alkattan, Khaled] Alfaisal Univ, Coll Med, Riyadh 11533, Saudi Arabia; [Kashir, Junaid] King Faisal Specialist Hosp & Res Ctr, Dept Comparat Med, Riyadh 11533, Saudi Arabia		Yaqinuddin, A (通讯作者)，Alfaisal Univ, Coll Med, Riyadh 11533, Saudi Arabia.	ayaqinuddin@alfaisal.edu; ashafqat@alfaisal.edu; jkashir@alfaisal.edu; KKattan@alfaisal.edu	Kashir, Junaid/AAD-2723-2020; Yaqinuddin, Ahmed/ABE-3689-2020	Kashir, Junaid/0000-0002-5056-8222; Yaqinuddin, Ahmed/0000-0001-7536-910X; Shafqat, Areez/0000-0002-1202-7214	Saudi Arabian Ministry of Health [951]	This work was supported by a COVID-19 project grant (#951) awarded by the Saudi Arabian Ministry of Health awarded to KK, JK, and AY.	Abraham, CONVERGENT EVOLUTION, DOI [10.1101/2021.04.22.440932v1, DOI 10.1101/2021.04.22.440932V1]; Adair BM, 2009, WIRES NANOMED NANOBI, V1, P405, DOI 10.1002/wnan.45; Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011; Al-Halifa S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00022; Angioletti-Uberti S, 2017, NPJ COMPUT MATER, V3, DOI 10.1038/s41524-017-0050-y; [Anonymous], 6 JULY 2021 EPISODE; Arunachalam PS, 2021, NATURE, V594, P253, DOI 10.1038/s41586-021-03530-2; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235; Batra M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83108-0; Baum A, 2020, SCIENCE, V370, P1110, DOI 10.1126/science.abe2402; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Bechnack S., INFECT VACCINE INDUC, DOI [10.1101/2021.05.09.443299v1, DOI 10.1101/2021.05.09.443299V1]; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Birkhoff M, 2009, INDIAN J PHARM SCI, V71, P729; Callaway E, 2021, NATURE, V589, P500, DOI 10.1038/d41586-021-00121-z; Chen P, 2021, NEW ENGL J MED, V384, P229, DOI 10.1056/NEJMoa2029849; Chen YX, 2021, LANCET INFECT DIS, V21, P1071, DOI 10.1016/S1473-3099(21)00287-5; Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952; Chiba S., 2020, COMMUN BIOL, V4, P1; Collier DA, 2021, NATURE, V593, P136, DOI 10.1038/s41586-021-03412-7; Connor BA, 2021, INT J INFECT DIS, V110, P232, DOI 10.1016/j.ijid.2021.07.029; Demento SL, 2009, VACCINE, V27, P3013, DOI 10.1016/j.vaccine.2009.03.034; Dolgin E, 2021, NATURE, V592, P340, DOI 10.1038/d41586-021-00958-4; Du S, 2020, CELL, V183, P1013, DOI 10.1016/j.cell.2020.09.035; Duan K, 2020, P NATL ACAD SCI USA, V117, P9490, DOI 10.1073/pnas.2004168117; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Frietze KM, 2016, CURR OPIN VIROL, V18, P44, DOI 10.1016/j.coviro.2016.03.001; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Guebre-Xabier M, 2020, VACCINE, V38, P7892, DOI 10.1016/j.vaccine.2020.10.064; Hassan AO, 2020, CELL, V183, P169, DOI 10.1016/j.cell.2020.08.026; Hoffmann M, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109415; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Ichinohe T, 2009, VACCINE, V27, P6276, DOI 10.1016/j.vaccine.2009.04.074; Johnson & Johnson, ANN SINGL SHOT JANSS; Johnson N., TITLE LY COV555 RAPI; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Kang SS, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23036-9; Kanojia G, 2017, HUM VACC IMMUNOTHER, V13, P2364, DOI [10.1080/21645515.2017.1359363, 10.1080/21645515.2017.1356952]; Kharb S, 2011, VET RES COMMUN, V35, P457, DOI 10.1007/s11259-011-9484-8; Koirala A, 2020, PAEDIATR RESPIR REV, V35, P43, DOI 10.1016/j.prrv.2020.06.010; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Kuzmina A, 2021, CELL HOST MICROBE, V29, P522, DOI 10.1016/j.chom.2021.03.008; Ledford H, 2021, NATURE, V590, P374, DOI 10.1038/d41586-021-00367-7; Lycke N, 2012, NAT REV IMMUNOL, V12, P592, DOI 10.1038/nri3251; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Mapletoft JW, 2010, CLIN VACCINE IMMUNOL, V17, P23, DOI 10.1128/CVI.00250-09; Marchell T.M., POLYMERSOMES DECORAT, DOI [10.1101/2021.04.08.438884v1, DOI 10.1101/2021.04.08.438884V1]; McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991; Pachioni-Vasconcelos JD, 2016, BIOMATER SCI-UK, V4, P205, DOI 10.1039/c5bm00360a; Parasher A, 2021, POSTGRAD MED J, V97, P312, DOI 10.1136/postgradmedj-2020-138577; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Plante JA, 2021, NATURE, V592, P116, DOI 10.1038/s41586-020-2895-3; Powell AE, 2021, ACS CENTRAL SCI, V7, P183, DOI 10.1021/acscentsci.0c01405; Reinke S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030554; Sahdev P, 2014, PHARM RES-DORDR, V31, P2563, DOI 10.1007/s11095-014-1419-y; Sato K., SARS COV 2 B1 617 EM, DOI [10.1101/2021.05.08.443253v2, DOI 10.1101/2021.05.08.443253V2]; Saturday G., INTRANASAL CHADOX1 N, DOI [10.1101/2021.01.09.426058v1, DOI 10.1101/2021.01.09.426058V1]; Saunders KO, 2021, NATURE, V594, P553, DOI 10.1038/s41586-021-03594-0; Schindewolf C., N501Y SPIKE SUBSTITU, DOI [10.1101/2021.03.08.434499v1, DOI 10.1101/2021.03.08.434499V1]; Schurink B, 2020, LANCET MICROBE, V1, pE290, DOI 10.1016/S2666-5247(20)30144-0; Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783; Shin MD, 2020, NAT NANOTECHNOL, V15, P646, DOI 10.1038/s41565-020-0737-y; Shinde V, 2021, NEW ENGL J MED, V384, P1899, DOI 10.1056/NEJMoa2103055; Skelly, VACCINE INDUCED IMMU; TARKE A, 2021, CELL REP MED, V2, DOI DOI 10.1016/J.XCRM.2021.100204; Tuccori M, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2020.1854149; Ucciferri C, 2020, WORLD J CLIN CASES, V8, P4280, DOI 10.12998/wjcc.v8.i19.4280; Venkadapathi J, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.637378; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Wang ZJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf1555; Wei D.Q., HIGHER INFECT SARS C; Weinreich DM, 2021, NEW ENGL J MED, V384, P238, DOI 10.1056/NEJMoa2035002; Yaqinuddin A, 2020, AFR J RESPIR MED, V15; Yaqinuddin A, 2020, RESPIR INVESTIG, V58, P419, DOI 10.1016/j.resinv.2020.06.001; Yaqinuddin A, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109906; Zhang Baoshan, 2020, bioRxiv, DOI [10.1101/2020.06.11.147496, 10.1038/s41598-020-74949-2]	79	5	5	6	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							914	10.3390/vaccines9080914			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH2SS	34452039	Green Published, gold			2022-04-29	WOS:000689788200001
J	King, I; Heidler, P; Marzo, RR				King, Isabel; Heidler, Petra; Marzo, Roy Rillera			The Long and Winding Road: Uptake, Acceptability, and Potential Influencing Factors of COVID-19 Vaccination in Austria	VACCINES			English	Article						COVID-19; vaccine; acceptance; vaccine hesitancy; public health; Austria	HESITANCY; TRUST	Acceptance of the COVID-19 vaccine will play a crucial role in combating the current pandemic. Vaccine rollouts have started in most countries. To reach the desirable vaccine coverage and to enhance its uptake, it is imperative to assess vaccine hesitancy. Methods: To assess the current vaccine acceptability in Austria and its influencing factors, an online survey was created and comprised fifteen questions segmented into a sociodemographic part and the acceptance and influencing factors of the approval of the COVID-19 vaccine. Results: In total, 70% of the 1350 respondents thought that the COVID-19 vaccine is an effective way to prevent and control the virus, while 13% disagreed and 17% were uncertain. Further, 71% approved the rapid development and rollout of the vaccine, while 55% were willing to accept the vaccine as soon as it became available, 18% did not want to get the vaccine, 17% wanted to delay, and 10% were already vaccinated. Conclusions: The results show a generally positive attitude towards the new COVID-19 vaccine. The doctor's recommendation greatly influences the decision-making process, and tailored vaccine information can support a higher vaccine coverage.	[King, Isabel] St Elizabeth Univ Hlth & Social Work, Dept Publ Hlth, Bratislava 81106, Slovakia; [King, Isabel] Univ Sunshine Coast, Sch Hlth & Behav Sci, Dept Exercise Physiol, Sunshine Coast, Ql 4558, Australia; [King, Isabel; Heidler, Petra] IMC Univ Appl Sci Krems, Dept Int Business & Export Management, A-3500 Krems An Der Donau, Austria; [Heidler, Petra] St Polten Univ Appl Sci, Dept Hlth Sci, A-3100 St Polten, Austria; [Marzo, Roy Rillera] Asia Metropolitan Univ, Fac Med, Dept Community Med, Johor Baharu 81750, Malaysia; [Marzo, Roy Rillera] Management & Sci Univ, Int Med Sch, Dept Community Med, Shah Alam 40100, Malaysia		Heidler, P (通讯作者)，IMC Univ Appl Sci Krems, Dept Int Business & Export Management, A-3500 Krems An Der Donau, Austria.; Heidler, P (通讯作者)，St Polten Univ Appl Sci, Dept Hlth Sci, A-3100 St Polten, Austria.	iking@usc.edu.au; petra.heidler@fh-krems.ac.at; rrmtexas@yahoo.com		King, Isabel/0000-0003-2227-8903; /0000-0001-9414-4010			[Anonymous], 2021, HLTH NEWS; Bauer A, 2021, WIEN KLIN WOCHENSCHR, V133, P703, DOI 10.1007/s00508-020-01777-9; Bundesministerium, 2021, SOZ SOZ; CBS News, CBS NEWS CBS NEWS; Daniel Benjamin S, 2021, Int J Womens Dermatol, V7, P228, DOI 10.1016/j.ijwd.2020.10.001; Davis J., 2021, STAT B, P26; Fadda M, 2020, INT J PUBLIC HEALTH, V65, P711, DOI 10.1007/s00038-020-01404-4; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Fridman A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250123; Global Change Data Lab, 2021, OUR WORLD DAT OUR WORLD DAT; Guay M, 2019, HUM VACC IMMUNOTHER, V15, P2527, DOI 10.1080/21645515.2019.1603563; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Larson HJ, 2018, HUM VACC IMMUNOTHER, V14, P1599, DOI 10.1080/21645515.2018.1459252; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; McIntyre P, 2021, AUST PRESCR, V44, P19, DOI 10.18773/austprescr.2020.084; OECD, OECD DAT CHILD VACC OECD DAT CHILD VACC; Ozawa S, 2013, HUM VACC IMMUNOTHER, V9, P1774, DOI 10.4161/hv.24961; Ranji U., 2021, ROLE MOTHERS ASSURIN; Rath B, 2018, HUM VACC IMMUNOTHER, V14, P1038, DOI 10.1080/21645515.2017.1412666; Rath Barbara, 2013, Infectious Disorders - Drug Targets, V13, P25; Reuben R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237755; Robertson E., 2021, BRAIN BEHAV IMMUN, V94, P41, DOI [10.1016/j.bbi.2021.03.008, DOI 10.1016/j.bbi.2021.03.008]; Sandhofer MJ, 2017, WIEN KLIN WOCHENSCHR, V129, P59, DOI 10.1007/s00508-016-1062-1; Schernhammer E, 2022, J PUBLIC HEALTH-UK, V44, pE106, DOI 10.1093/pubmed/fdab122; U. D. Center for Economic and Social Research, 2021, USC NEWS USC NEWS; WHO, 2021, WHO COVID 19 HOM; World Health Organization, 2015, VACC HES GROW CHALL	29	6	6	3	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							790	10.3390/vaccines9070790			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7HQ	34358206	gold, Green Published			2022-04-29	WOS:000677078100001
J	Shrestha, A; Sadeyen, JR; Lukosaityte, D; Chang, PX; Van Hulten, M; Iqbal, M				Shrestha, Angita; Sadeyen, Jean-Remy; Lukosaityte, Deimante; Chang, Pengxiang; Van Hulten, Marielle; Iqbal, Munir			Targeting Haemagglutinin Antigen of Avian Influenza Virus to Chicken Immune Cell Receptors Dec205 and CD11c Induces Differential Immune-Potentiating Responses	VACCINES			English	Article						targeted antigen delivery vaccine; antigen presenting cells; single chain fragment variable antibodies; dendritic cell receptor for endocytosis-205; cluster of differentiation 11c; avian influenza virus; haemagglutinin	DENDRITIC CELLS; ANTIBODY-RESPONSES; GENERATION; VACCINATION; DEC-205; DISEASE; IMPACT; CD4; MHC	Improving the immunogenicity and protective efficacy of vaccines is critical to reducing disease impacts. One strategy used to enhance the immunogenicity of vaccines is the selective delivery of protective antigens to the antigen presenting cells (APCs). In this study, we have developed a targeted antigen delivery vaccine (TADV) system by recombinantly fusing the ectodomain of hemagglutinin (HA) antigen of H9N2 influenza A virus to single chain fragment variable (scFv) antibodies specific for the receptors expressed on chicken APCs; Dec205 and CD11c. Vaccination of chickens with TADV containing recombinant H9HA Foldon-Dec205 scFv or H9HA Foldon-CD11c scFv proteins elicited faster (as early as day 6 post primary vaccination) and higher anti-H9HA IgM and IgY, haemagglutination inhibition, and virus neutralisation antibodies compared to the untargeted H9HA protein. Comparatively, CD11c scFv conjugated H9HA protein showed higher immunogenic potency compared to Dec205 scFv conjugated H9HA protein. The higher immune potentiating ability of CD11c scFv was also reflected in ex-vivo chicken splenocyte stimulation assay, whereby H9HA Foldon-CD11c scFv induced higher levels of cytokines (IFN gamma, IL6, IL1 beta, and IL4) compared to H9HA Foldon-Dec205 scFv. Overall, the results conclude that TADV could be a better alternative to the currently available inactivated virus vaccines.	[Shrestha, Angita; Sadeyen, Jean-Remy; Lukosaityte, Deimante; Chang, Pengxiang; Iqbal, Munir] Pirbright Inst, Ash Rd, Woking GU24 0NF, Surrey, England; [Shrestha, Angita] Univ Oxford, Dept Zool, Peter Medawar Bldg,South Pk Rd, Oxford OX1 3SY, England; [Van Hulten, Marielle] MSD Anim Hlth, Intervet Int BV, Global Poultry R&D Biolog Boxmeer, Wim Korverstr 35, NL-5831 AN Boxmeer, Netherlands		Iqbal, M (通讯作者)，Pirbright Inst, Ash Rd, Woking GU24 0NF, Surrey, England.	angita.shrestha@pirbright.ac.uk; jean-remy.sadeyen@pirbright.ac.uk; deimante.lukosaityte@pirbright.ac.uk; pengxiang.chang@pirbright.ac.uk; marielle.vanhulten@merck.com; munir.iqbal@pirbright.ac.uk		Iqbal, Munir/0000-0001-5165-5339	Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/R50595X/1, BB/P025803/1, BBS/E/I/00007032, BBS/E/I/00007039, BB/L018853/1, BB/S013792/1, BB/R012679/1]; GCRF One Health Poultry Hub award [BB/S011269/1]	This work was supported by funding from the Biotechnology and Biological Sciences Research Council awards (BB/R50595X/1, BB/P025803/1, BBS/E/I/00007032 BBS/E/I/00007039, BB/L018853/1, BB/S013792/1, BB/R012679/1) and the GCRF One Health Poultry Hub award (BB/S011269/1). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.	Ahmad ZA, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/980250; ANTIPAS BBB, 2012, EUR J EXP BIOL, V2, P2286; Arnaout M Amin, 2016, F1000Res, V5; Badillo-Godinez O, 2015, VACCINE, V33, P4228, DOI 10.1016/j.vaccine.2015.03.080; Berry JD, 2003, HYBRIDOMA HYBRIDOM, V22, P23, DOI 10.1089/153685903321538053; Boodhoo N, 2016, VET RES, V47, DOI 10.1186/s13567-016-0404-3; Caminschi I, 2012, TRENDS IMMUNOL, V33, P71, DOI 10.1016/j.it.2011.10.007; Capua I, 2008, VACCINE, V26, pD70, DOI 10.1016/j.vaccine.2008.07.044; CARAYANNIOTIS G, 1991, MOL IMMUNOL, V28, P261, DOI 10.1016/0161-5890(91)90072-R; Castro FVV, 2008, EUR J IMMUNOL, V38, P2263, DOI 10.1002/eji.200838302; Cheong C, 2010, BLOOD, V116, P3828, DOI 10.1182/blood-2010-06-288068; Chmielewski R, 2011, ANNU REV FOOD SCI T, V2, P37, DOI 10.1146/annurev-food-022510-133710; Dey S, 2019, VET MED-RES REP, V10, P85, DOI 10.2147/VMRR.S185159; Dhodapkar MV, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008068; Dickgreber N, 2009, J IMMUNOL, V182, P1260, DOI 10.4049/jimmunol.182.3.1260; Ejaz A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045102; Fatima M, 2015, 2015 12TH INTERNATIONAL BHURBAN CONFERENCE ON APPLIED SCIENCES AND TECHNOLOGY (IBCAST), P93; Food and Agriculture Organisation, MEAT MARKET REV; Geeraedts F, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000138; Geeraedts F, 2008, INFLUENZA OTHER RESP, V2, P41, DOI 10.1111/j.1750-2659.2008.00038.x; Guthe S, 2004, J MOL BIOL, V337, P905, DOI 10.1016/j.jmb.2004.02.020; Higgins Sarah C, 2010, Curr Infect Dis Rep, V12, P4, DOI 10.1007/s11908-009-0080-9; Phan HT, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00115; Hossain MK, 2019, CANCERS, V11, DOI 10.3390/cancers11030418; Janda A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00022; Jauregui-Zuniga D, 2017, RES VET SCI, V111, P55, DOI 10.1016/j.rvsc.2016.12.002; Kaspers B., 2014, ADV EXP MED BIOL, P169, DOI [10.1016/B978-0-12-396965-1.00009-1, DOI 10.1016/B978-0-12-396965-1.00009-1]; Keler T, 2007, ONCOGENE, V26, P3758, DOI 10.1038/sj.onc.1210375; Kim J.K., 2015, PEERJ PREPRINTS, V3, DOI [10.7287/peerj.preprints.1350v1, DOI 10.7287/PEERJ.PREPRINTS.1350V1]; LACAL PM, 1990, BIOCHEM J, V268, P707, DOI 10.1042/bj2680707; Lahoud MH, 2011, J IMMUNOL, V187, P842, DOI 10.4049/jimmunol.1101176; Lee SH, 2012, VET IMMUNOL IMMUNOP, V145, P527, DOI 10.1016/j.vetimm.2011.11.020; Nagy N, 2016, DEV COMP IMMUNOL, V58, P47, DOI 10.1016/j.dci.2015.12.020; Nelson AL, 2010, MABS-AUSTIN, V2, P77, DOI 10.4161/mabs.2.1.10786; Park HY, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0033-5; Peacock T, 2016, SCI REP-UK, V6, DOI 10.1038/srep18745; Pugholm L.H., 2016, IMMUNOTHER OPEN ACCE, V2, P1000119, DOI [10.4172/2471-9552.1000119, DOI 10.4172/2471-9552.1000119]; Quere P, 2013, VET IMMUNOL IMMUNOP, V153, P57, DOI 10.1016/j.vetimm.2013.02.007; Radford KJ, 2013, HUM VACC IMMUNOTHER, V9, P259, DOI 10.4161/hv.22487; Reuter A, 2015, J IMMUNOL, V194, P2696, DOI 10.4049/jimmunol.1402535; Sehgal K, 2014, IMMUNOL LETT, V162, P59, DOI 10.1016/j.imlet.2014.07.004; Shi JM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173871; Shirota H, 2014, EXPERT REV VACCINES, V13, P299, DOI 10.1586/14760584.2014.863715; Staines K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051799; Swayne DE, 2009, COMP IMMUNOL MICROB, V32, P351, DOI 10.1016/j.cimid.2008.01.006; Truelove S, 2016, INFLUENZA OTHER RESP, V10, P518, DOI 10.1111/irv.12408; Walker J.M., 2014, ANIMAL INFUENZA VIRU, V2nd, P6; Wang H, 2000, P NATL ACAD SCI USA, V97, P847, DOI 10.1073/pnas.97.2.847; Weldon WC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012466; White AL, 2010, IMMUNOLOGY, V131, P141, DOI 10.1111/j.1365-2567.2010.03285.x; Wu ZG, 2010, IMMUNOLOGY, V129, P133, DOI 10.1111/j.1365-2567.2009.03129.x; Zitzmann Jan, 2018, Biotechnology Reports, V19, pe00272, DOI 10.1016/j.btre.2018.e00272	52	0	0	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							784	10.3390/vaccines9070784			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO4YW	34358200	Green Published			2022-04-29	WOS:000676920100001
J	Bolton, JS; Klim, H; Wellens, J; Edmans, M; Obolski, U; Thompson, CP				Bolton, Jai S.; Klim, Hannah; Wellens, Judith; Edmans, Matthew; Obolski, Uri; Thompson, Craig P.			An Antigenic Thrift-Based Approach to Influenza Vaccine Design	VACCINES			English	Review						vaccine; vaccination; influenza; evolutionary theory; antigenic drift; antigenic thrift	A VIRUS; NUCLEOTIDE-SEQUENCES; POPULATION-DYNAMICS; WITHIN-HOST; ANTIBODY; EFFICACY; HEMAGGLUTININ; EVOLUTION; PROTECTION; IMMUNOGENICITY	The antigenic drift theory states that influenza evolves via the gradual accumulation of mutations, decreasing a host's immune protection against previous strains. Influenza vaccines are designed accordingly, under the premise of antigenic drift. However, a paradox exists at the centre of influenza research. If influenza evolved primarily through mutation in multiple epitopes, multiple influenza strains should co-circulate. Such a multitude of strains would render influenza vaccines quickly inefficacious. Instead, a single or limited number of strains dominate circulation each influenza season. Unless additional constraints are placed on the evolution of influenza, antigenic drift does not adequately explain these observations. Here, we explore the constraints placed on antigenic drift and a competing theory of influenza evolution - antigenic thrift. In contrast to antigenic drift, antigenic thrift states that immune selection targets epitopes of limited variability, which constrain the variability of the virus. We explain the implications of antigenic drift and antigenic thrift and explore their current and potential uses in the context of influenza vaccine design.	[Bolton, Jai S.; Klim, Hannah; Wellens, Judith; Edmans, Matthew; Thompson, Craig P.] Peter Medawar Bldg Pathogen Res, Oxford OX1 3SY, England; [Bolton, Jai S.; Klim, Hannah; Thompson, Craig P.] Univ Oxford, Dept Zool, Oxford OX1 3SZ, England; [Klim, Hannah] Univ Oxford, Future Humanity Inst, Dept Philosophy, Oxford OX2 0DJ, England; [Wellens, Judith; Edmans, Matthew] Univ Oxford, Nuffield Dept Med, Oxford OX3 7BN, England; [Wellens, Judith] Univ Hosp Leuven, Translat Res GastroIntestinal Disorders, B-3000 Leuven, Belgium; [Obolski, Uri] Tel Aviv Univ, Sch Publ Hlth, Fac Med, IL-69978 Tel Aviv, Israel; [Obolski, Uri] Tel Aviv Univ, Fac Exact Sci, Porter Sch Environm & Earth Sci, IL-69978 Tel Aviv, Israel		Thompson, CP (通讯作者)，Peter Medawar Bldg Pathogen Res, Oxford OX1 3SY, England.; Thompson, CP (通讯作者)，Univ Oxford, Dept Zool, Oxford OX1 3SZ, England.	jai.bolton@keble.ox.ac.uk; hannah.klim@zoo.ox.ac.uk; judith.wellens@ndm.ox.ac.uk; matthew.edmans@ndm.ox.ac.uk; uriobols@tauex.tau.ac.il; craig.thompson@zoo.ox.ac.uk		Klim, Hannah/0000-0002-7655-6449; Bolton, Jai/0000-0002-6738-7823; Thompson, Craig/0000-0001-9248-9365; Edmans, Matthew/0000-0002-2580-6620; Obolski, Uri/0000-0001-7594-9745; Wellens, Judith/0000-0002-1647-8151	Biotechnology and Biological Sciences Research Council (BBSRC)UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/M011224/1]; Future of Humanity Institute at the University of Oxford DPhil Scholarship program; Leona M. and Harry B. Helmsley Charitable Trust	J.S.B. was supported by funding from the Biotechnology and Biological Sciences Research Council (BBSRC) [grant number BB/M011224/1]. H.K. is supported by The Future of Humanity Institute at the University of Oxford DPhil Scholarship program. This work was supported by funding from the Biotechnology and Biological Sciences Research Council (BBSRC) [grant number BB/M011224/1]. M.E. and J.W. was supported by The Leona M. and Harry B. Helmsley Charitable Trust on 31 May 2021 for the project titled, ICARUS -IBD: International study of COVID-19 Antibody Response Under Sustained immune suppression in Inflammatory Bowel Disease.	Abascal F, 2010, NUCLEIC ACIDS RES, V38, pW7, DOI 10.1093/nar/gkq291; Allen JD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204284; Amitai A, 2020, CELL SYST, V11, P573, DOI 10.1016/j.cels.2020.09.005; Andrews SF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad0522; Bedford T, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-38; Bernstein DI, 2020, LANCET INFECT DIS, V20, P80, DOI 10.1016/S1473-3099(19)30393-7; Berthoud TK, 2011, CLIN INFECT DIS, V52, P1, DOI 10.1093/cid/ciq015; Blue Water Vaccinces, 2019, OUR VACC; Boni MF, 2008, VACCINE, V26, pC8, DOI 10.1016/j.vaccine.2008.04.011; Bouckaert R, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006650; Bush RM, 1999, SCIENCE, V286, P1921, DOI 10.1126/science.286.5446.1921; Capella-Gutierrez S, 2009, BIOINFORMATICS, V25, P1972, DOI 10.1093/bioinformatics/btp348; Carter DM, 2016, J VIROL, V90, P4720, DOI 10.1128/JVI.03152-15; Carter DM, 2013, J VIROL, V87, P1400, DOI 10.1128/JVI.02257-12; CATON AJ, 1982, CELL, V31, P417, DOI 10.1016/0092-8674(82)90135-0; Centers for Disease Control and Prevention, ACIP VOT US LAIV 201; Centers for Disease Control and Protection, TYP INFL VIR; Centers for Disease Control and Protection, 2019, FLU VIRUSES CAN CHAN; Chen YQ, 2018, CELL, V173, P417, DOI 10.1016/j.cell.2018.03.030; Choi Angela, 2019, Immunohorizons, V3, P133, DOI 10.4049/immunohorizons.1900022; Corder BN, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12101186; Coughlan L, 2018, EBIOMEDICINE, V29, P146, DOI 10.1016/j.ebiom.2018.02.011; Crevar CJ, 2015, HUM VACC IMMUNOTHER, V11, P572, DOI 10.1080/21645515.2015.1012013; Darriba D, 2020, MOL BIOL EVOL, V37, P291, DOI 10.1093/molbev/msz189; DIOSynVax, 2021, TECHN; Dou D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01581; Doud MB, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006271; Doyle TM, 2013, ANTIVIR RES, V100, P567, DOI 10.1016/j.antiviral.2013.09.018; Drummond AJ, 2005, MOL BIOL EVOL, V22, P1185, DOI [10.1093/molbev/msi103, 10.1093/molbev/mss075]; Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088; Eichelberger MC, 2015, CURR TOP MICROBIOL, V386, P275, DOI 10.1007/82_2014_398; El Bakkouri K, 2011, J IMMUNOL, V186, P1022, DOI 10.4049/jimmunol.0902147; Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103; Ferguson NM, 2003, NATURE, V422, P428, DOI 10.1038/nature01509; Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007; Figtree A.R., 2014, GRAPHICAL VIEWER PHY; Flouri T, 2015, SYST BIOL, V64, P356, DOI 10.1093/sysbio/syu084; Fonville JM, 2014, SCIENCE, V346, P996, DOI 10.1126/science.1256427; Fonville JM, 2016, J INFECT DIS, V213, P31, DOI 10.1093/infdis/jiv367; Gasbarra D, 2007, THEOR POPUL BIOL, V72, P305, DOI 10.1016/j.tpb.2007.06.004; Ghedin E, 2005, NATURE, V437, P1162, DOI 10.1038/nature04239; Han AX, 2019, NAT ECOL EVOL, V3, P302, DOI 10.1038/s41559-018-0741-x; Harding AT, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020019; Harris AK, 2013, P NATL ACAD SCI USA, V110, P4592, DOI 10.1073/pnas.1214913110; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Hayward AC, 2015, AM J RESP CRIT CARE, V191, P1422, DOI 10.1164/rccm.201411-1988OC; Holzer B, 2018, J IMMUNOL, V200, P4068, DOI 10.4049/jimmunol.1800142; Hu J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.517461; Huang KYA, 2015, J CLIN INVEST, V125, P2631, DOI 10.1172/JCI81104; Huang SSH, 2013, SCI REP-UK, V3, DOI 10.1038/srep01698; Huleatt JW, 2008, VACCINE, V26, P201, DOI 10.1016/j.vaccine.2007.10.062; ITO T, 1991, J VIROL, V65, P5491, DOI 10.1128/JVI.65.10.5491-5498.1991; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Kim KH, 2019, VIROLOGY, V535, P179, DOI 10.1016/j.virol.2019.07.008; Kirkpatrick E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28706-1; Koelle K, 2015, ELIFE, V4, DOI 10.7554/eLife.07361; Koelle K, 2006, SCIENCE, V314, P1898, DOI 10.1126/science.1132745; Krammer F, 2018, MBIO, V9, DOI 10.1128/mBio.02332-17; Landolt Gabriele A., 2007, Animal Health Research Reviews, V8, P1, DOI 10.1017/S1466252307001272; Lee JM, 2018, P NATL ACAD SCI USA, V115, pEB276, DOI 10.1073/pnas.1806133115; Li Y, 2013, J EXP MED, V210, P1493, DOI 10.1084/jem.20130212; Lillie PJ, 2012, CLIN INFECT DIS, V55, P19, DOI 10.1093/cid/cis327; Lumby CK, 2020, ELIFE, V9, DOI 10.7554/eLife.56915; Luo M, 2012, ADV EXP MED BIOL, V726, P201, DOI 10.1007/978-1-4614-0980-9_9; Luo SS, 2012, J R SOC INTERFACE, V9, P2603, DOI 10.1098/rsif.2012.0180; Ma Wenjun, 2008, J Mol Genet Med, V3, P158; Martinez-Sobrido L, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100560; Matsuzaki Y, 2014, J VIROL, V88, P12364, DOI 10.1128/JVI.01381-14; McAuley JL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00039; Mezhenskaya D, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0572-3; Morgan SB, 2016, J IMMUNOL, V196, P5014, DOI 10.4049/jimmunol.1502632; Morris DH, 2020, ELIFE, V9, DOI 10.7554/eLife.62105; Nachbagauer R, 2021, NAT MED, V27, P106, DOI 10.1038/s41591-020-1118-7; Nachbagauer R, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0026-4; Nachbagauer R, 2016, NPJ VACCINES, V1, DOI 10.1038/npjvaccines.2016.15; Neirynck S, 1999, NAT MED, V5, P1157, DOI 10.1038/13484; Nogales A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22307-8; O'Gorman WE, 2014, VACCINE, V32, P5989, DOI 10.1016/j.vaccine.2014.07.115; Obolski U, 2018, REP PROG PHYS, V81, DOI 10.1088/1361-6633/aa94d4; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Peacock T, 2016, SCI REP-UK, V6, DOI 10.1038/srep18745; Petrie JG, 2016, J INFECT DIS, V214, P1142, DOI 10.1093/infdis/jiw105; Petrova VN, 2018, NAT REV MICROBIOL, V16, P47, DOI 10.1038/nrmicro.2017.118; Pielak RM, 2011, BBA-BIOMEMBRANES, V1808, P522, DOI 10.1016/j.bbamem.2010.04.015; Powell TJ, 2012, J VIROL, V86, P13397, DOI 10.1128/JVI.01820-12; R Core Team, 2016, R LANG ENV STAT COMP; Rambaut A, 2008, NATURE, V453, P615, DOI 10.1038/nature06945; Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032; Raymond DD, 2018, P NATL ACAD SCI USA, V115, P168, DOI 10.1073/pnas.1715471115; Recker M, 2007, P NATL ACAD SCI USA, V104, P7711, DOI 10.1073/pnas.0702154104; Ross Ted M, 2011, PLoS Curr, V3, pRRN1265, DOI 10.1371/currents.RRN1265; Saunders-Hastings PR, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5040066; Shao WH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081650; Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211; Soema PC, 2015, EUR J PHARM BIOPHARM, V94, P251, DOI 10.1016/j.ejpb.2015.05.023; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; Subramanian R, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005204; Talbot HK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014442; Taylor N.P., GSK DUMPS UNIVERSAL; Thompson CP, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06228-8; Thompson CP, 2018, HUM VACC IMMUNOTHER, V14, P3005, DOI 10.1080/21645515.2018.1504596; Thompson RN, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0274; Tria F, 2005, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2005/07/P07008; Tricco AC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-153; Tsybalova LM, 2015, VACCINE, V33, P3398, DOI 10.1016/j.vaccine.2015.04.073; Turley CB, 2011, VACCINE, V29, P5145, DOI 10.1016/j.vaccine.2011.05.041; Vaccitech, 2020, PHAS 2 CLIN RES VACC; Volkov I, 2010, J R SOC INTERFACE, V7, P1311, DOI 10.1098/rsif.2009.0560; Wang W, 2021, CLIN INFECT DIS, V73, pE4312, DOI 10.1093/cid/ciaa1352; Wang ZF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7833; Whittle JRR, 2011, P NATL ACAD SCI USA, V108, P14216, DOI 10.1073/pnas.1111497108; Wikramaratna PS, 2014, P NATL ACAD SCI USA, V111, P10767, DOI 10.1073/pnas.1401849111; Wikramaratna PS, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0200; Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612; Wong TM, 2017, J VIROL, V91, DOI 10.1128/JVI.01581-17; World Health Organization, INFLUENZA; World Health Organization Regional Office for Europe, 2021, PAND INFL EM; Yu Guangchuang, 2020, Curr Protoc Bioinformatics, V69, pe96, DOI 10.1002/cpbi.96; Yu GC, 2018, MOL BIOL EVOL, V35, P3041, DOI 10.1093/molbev/msy194; Yu GC, 2017, METHODS ECOL EVOL, V8, P28, DOI 10.1111/2041-210X.12628; Yuan HY, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0204; ZEBEDEE SL, 1985, J VIROL, V56, P502, DOI 10.1128/JVI.56.2.502-511.1985; ZEBEDEE SL, 1989, NUCLEIC ACIDS RES, V17, P2870, DOI 10.1093/nar/17.7.2870; Zhang XS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114637; Zinder D, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003104	125	0	0	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							657	10.3390/vaccines9060657			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY7ID	34208489	Green Published, gold			2022-04-29	WOS:000666056100001
J	Galle, F; Sabella, EA; Roma, P; De Giglio, O; Caggiano, G; Tafuri, S; Da Molin, G; Ferracuti, S; Montagna, MT; Liguori, G; Orsi, GB; Napoli, C				Galle, Francesca; Sabella, Elita Anna; Roma, Paolo; De Giglio, Osvalda; Caggiano, Giuseppina; Tafuri, Silvio; Da Molin, Giovanna; Ferracuti, Stefano; Montagna, Maria Teresa; Liguori, Giorgio; Orsi, Giovanni Battista; Napoli, Christian			Knowledge and Acceptance of COVID-19 Vaccination among Undergraduate Students from Central and Southern Italy	VACCINES			English	Article						SARS-COV-2; COVID-19; vaccine hesitancy; vaccine acceptance; information; undergraduates	PHYSICAL-ACTIVITY; LOCKDOWN; BEHAVIOR; DISTRESS	At the end of 2020, the Italian Ministry of Health launched a national vaccination campaign to counteract the COVID-19 pandemic. The present study aimed at appraising levels of knowledge about and acceptance of COVID-19 vaccination in a sample of Italian undergraduates during the first phase of the immunization plan. A web-based questionnaire was administered to students attending universities in Bari, Naples, and Rome during the period February-April 2021. Of the total of 3226 participants, 91.9% were keen to receive a COVID-19 vaccination. More than 80% gave correct answers to questions about COVID-19 vaccine administration, functioning, and effects on community health. However, only 63.8% identified the correct composition of the available vaccines. Knowledge was found to be related to sociodemographic features and COVID-19 vaccination acceptance (p < 0.05). COVID-19 vaccination acceptance was found to be related to having a previous vaccination against influenza (OR 3.806, CI 95% 1.181-12.267; p = 0.025) and knowledge (OR 4.759, CI 95% 2.106-10.753; p = 0.000). These results show a good level of awareness about COVID-19 vaccination in this population, which may indicate the effectiveness of communication strategies accompanying the COVID-19 immunization campaign in Italy.	[Galle, Francesca; Liguori, Giorgio] Univ Naples Parthenope, Dept Movement Sci & Wellbeing, I-80133 Naples, Italy; [Sabella, Elita Anna; Da Molin, Giovanna] Univ Bari Aldo Moro, Interuniv Res Ctr Populat Environm & Hlth, I-70121 Bari, Italy; [Roma, Paolo; Ferracuti, Stefano] Sapienza Univ Rome, Dept Human Neurosci, I-00185 Rome, Italy; [De Giglio, Osvalda; Caggiano, Giuseppina; Tafuri, Silvio; Montagna, Maria Teresa] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy; [Orsi, Giovanni Battista] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, I-00185 Rome, Italy; [Napoli, Christian] Sapienza Univ Rome, Dept Med Surg Sci & Translat Med, I-00189 Rome, Italy		Galle, F (通讯作者)，Univ Naples Parthenope, Dept Movement Sci & Wellbeing, I-80133 Naples, Italy.	francesca.galle@uniparthenope.it; elita.sabella@uniba.it; paolo.roma@uniroma1.it; osvalda.degiglio@uniba.it; giuseppina.caggiano@uniba.it; silvio.tafuri@uniba.it; giovanna.damolin@uniba.it; stefano.ferracuti@uniroma1.it; mariateresa.montagna@uniba.it; giorgio.liguori@uniparthenope.it; giovanni.orsi@uniroma1.it; christian.napoli@uniroma1.it	napoli, christian/H-1862-2012; Gallè, Francesca/AAF-6054-2020; napoli, christian/B-9924-2018; Ferracuti, Stefano/K-8437-2012	napoli, christian/0000-0002-5775-2276; Gallè, Francesca/0000-0002-0504-9562; napoli, christian/0000-0002-5775-2276; Montagna, Maria Teresa/0000-0002-2958-5458; tafuri, silvio/0000-0003-4194-0210; Ferracuti, Stefano/0000-0003-1150-1460; Roma, Paolo/0000-0002-1031-0948; Caggiano, Giuseppina/0000-0003-3009-9147; Orsi, Giovanni Battista/0000-0002-9246-6216; De Giglio, Osvalda/0000-0002-0297-9502			Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Biasio LR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030268; Casula M, 2021, HEALTH POLICY, V125, P7, DOI 10.1016/j.healthpol.2020.11.004; Charron J, 2020, MED MALADIES INFECT, V50, P727, DOI 10.1016/j.medmal.2020.01.010; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040711; Galle F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17176171; Galle F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103481; Garcia-Montero C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050433; Italian Ministry of Health, VACC ANTISARS COV 2; Italian Ministry of Health, 241220 IT MIN HLTH; Kline P., 1999, HDB PSYCHOL TESTING, V2nd ed., P627; Lahner E, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124417; Lazarus JV, 2020, J HEALTH COMMUN, V25, P799, DOI 10.1080/10810730.2020.1868630; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Mazza C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17176236; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Nunnally J.C., 1978, PSYCHOMETRIC THEORY, V2nd ed.; Pai SM, 2021, J CLIN PHARMACOL, V61, P277, DOI 10.1002/jcph.1794; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Reno C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040378; Robinson E, 2021, APPETITE, V156, DOI 10.1016/j.appet.2020.104853; Roma P, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17218180; Roma P, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17197252; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Shmueli L, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10816-7; Soares P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030300; Taber KS, 2018, RES SCI EDUC, V48, P1273, DOI 10.1007/s11165-016-9602-2; WHO, COR DIS COVID 19 DAS; World Health Organization Regional Office for Europe, COR DIS COVID 19 PAN	30	34	34	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							638	10.3390/vaccines9060638			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY8WZ	34200835	Green Published, gold			2022-04-29	WOS:000666162700001
J	Kanwar, B; Lee, CJ; Lee, JH				Kanwar, Badar; Lee, Chul Joong; Lee, Jong-Hoon			Specific Treatment Exists for SARS-CoV-2 ARDS	VACCINES			English	Article						brainstem; inflammasome; oral DNA vaccine	ACUTE ISCHEMIC-STROKE; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; SENILE PLAQUES; DAPSONE; BRAIN; PENETRATION; CHILDREN; DELIVERY; THERAPY	The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seems to be difficult to overcome. A pandemic of such a scale has not been seen since the 1918 influenza pandemic. Although the predominant clinical presentation is respiratory disease, neurological manifestations and sequelae are increasingly being recognized. We observed a case series of rapid recovery of ARDS within 24 h in the preliminary clinical features of COVID-19 ARDS-associated neurological disease. It was also noted that by 15 April, 2021, there was no SARS-CoV-2 ARDS on Sorok Island in South Korea, where lepers had been living together. We compared each of dapsone's effects on humans and considered those of SARS-CoV-2. Dapsone showed different effects in the brain. The Sorokdo National Hospital reported a relationship between dapsone and the neuroinflammasome of Alzheimer's disease (AD) in Sorok Island from January 2005 to June 2020. AD prevalence was low in the leprosy patient group who took dapsone regularly. The preliminary cross-sectional study of the trial group (22 subjects) and the control group (22 subjects) in the Hunt Regional Hospital reported the following results: The chi-square statistic is 5.1836. The p-value is 0.022801. The result is considered significant at p < 0.05. The results from the medical treatment from 21 December to 29 December 2020 were considered. The mortality rates at the ARDS onset stage were 0% with dapsone administered as a standard COVID-19 treatment and 40% without dapsone administered as a standard COVID-19 treatment, respectively. Based on the respiratory failure and sudden high death rate originating from the involvement of the brainstem, especially the pre-Botzinger complex, dapsone can be used to significantly reduce the incidence of the cases of acute respiratory distress syndrome and other illnesses caused by SARS-CoV-2.	[Kanwar, Badar] Hunt Reg Hosp, Dept Pulm Crit Care Med, Greenville, TX 75401 USA; [Lee, Chul Joong] Zein Pain Clin Seongbuk, Seoul 02830, South Korea; [Lee, Jong-Hoon] Seoul Natl Univ, Coll Med, Sci & Res Ctr, Seoul 03080, South Korea		Lee, JH (通讯作者)，Seoul Natl Univ, Coll Med, Sci & Res Ctr, Seoul 03080, South Korea.	Bkanwar2@yahoo.com; cjlee.mdphd@gmail.com; science@research.re.kr	Lee, Jong-hoon/AAV-3512-2020	Lee, Jong-hoon/0000-0003-1775-5656; Lee, Chul Joong/0000-0001-5388-8945			Al-Aly Z, 2020, LANCET DIGIT HEALTH, V3, pE330, DOI 10.1038/s41586-021-03553-9; Alves-Rodrigues Edson Nogueira, 2005, Braz J Infect Dis, V9, P84, DOI 10.1590/S1413-86702005000100014; Bangash MN, 2020, LANCET GASTROENTEROL, V5, P529, DOI 10.1016/S2468-1253(20)30084-4; Blair-Johnson M, 2001, BIOCHEMISTRY-US, V40, P13990, DOI 10.1021/bi0111808; Cabinet Office, COR COVID 19 WHAT HA; Calderon-Garciduenas L, 2018, ENVIRON RES, V166, P348, DOI 10.1016/j.envres.2018.06.027; Chakraborty A, 2019, ARCH BIOCHEM BIOPHYS, V665, P107, DOI 10.1016/j.abb.2019.03.001; Cho Y.J., 2011, U.S. Patent, Patent No. [12/737,553, 12737553]; Consolato S, 2021, RES SQ, DOI [10.21203/rs.3.rs-509122/v4, DOI 10.21203/RS.3.RS-509122/V4]; Corp CC, 1998, J PEDIATR GASTR NUTR, V26, P103, DOI 10.1097/00005176-199801000-00017; Cruz-Cruz C, 2014, J PHARM HEALTH SERV, V5, P95, DOI 10.1111/jphs.12052; Eini M., 2007, U.S. Patent, Patent No. [11/732,547, 11732547]; Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0; Enache TA, 2017, BIOELECTROCHEMISTRY, V114, P13, DOI 10.1016/j.bioelechem.2016.11.003; Endoh M, 1999, J NEUROL SCI, V165, P28, DOI 10.1016/S0022-510X(99)00057-X; Francioso A, 2020, MOLECULES, V25, DOI 10.3390/molecules25040961; Frater JL, 2020, INT J LAB HEMATOL, V42, P11, DOI 10.1111/ijlh.13229; Gatti G, 1997, J ANTIMICROB CHEMOTH, V40, P113, DOI 10.1093/jac/40.1.113; Ghodke PP, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100444; Hacisuleyman E, 2021, NEW ENGL J MED, V384, P2212, DOI [10.1056/NEJMc2107808, 10.1056/NEJMoa2105000]; Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597; Johns Hopkins University C.R.C, NTR; Kang KS, 2016, CLIN EXP EMERG MED, V3, P41, DOI 10.15441/ceem.15.088; Kanwar, 2020, HUNT REGIONAL MED CT, DOI [10.31219/osf.io/9c7wz, DOI 10.31219/OSF.IO/9C7WZ]; Kast RE, 2020, EXP LUNG RES, V46, P157, DOI 10.1080/01902148.2020.1753266; Kast RE, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1441-5; Kast RE, 2012, BRIT J NEUROSURG, V26, P813, DOI 10.3109/02688697.2012.674577; Kiko T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049620; Kim SK, 2003, FEMS IMMUNOL MED MIC, V36, P27, DOI 10.1016/S0928-8244(03)00038-5; KIMURA T, 1993, LANCET, V342, P1364, DOI 10.1016/0140-6736(93)92274-W; Kissling S, 2020, KIDNEY INT, V98, P228, DOI 10.1016/j.kint.2020.04.006; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Lee JH, 2021, DEMENT GER COGN D EX, V11, P159, DOI 10.1159/000516074; Lee JH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21175953; Lee JH, 2020, DEMENT GER COGN D EX, V10, P1, DOI 10.1159/000504880; Liu FL, 2020, HIGHLY ACE2 EXPRESSI, DOI 10.1101/2020.02.28.20029181; Lorenz M, 2012, ACTA DERM-VENEREOL, V92, P194, DOI 10.2340/00015555-1268; Meinhardt J, 2021, NAT NEUROSCI, V24, P168, DOI 10.1038/s41593-020-00758-5; Mendes APS, 2011, J COMPUT THEOR NANOS, V8, P1428, DOI 10.1166/jctn.2011.1832; Miller DS, 2010, TRENDS PHARMACOL SCI, V31, P246, DOI 10.1016/j.tips.2010.03.003; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Nader-Kawachi J, 2007, NEUROL RES, V29, P331, DOI 10.1179/016164107X159234; NAMBA Y, 1992, LANCET, V340, P978, DOI 10.1016/0140-6736(92)92870-L; Nau R, 2010, CLIN MICROBIOL REV, V23, P858, DOI 10.1128/CMR.00007-10; Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787; Perl DP, 2021, NEW ENGL J MED, V384, P481, DOI 10.1056/NEJMc2033369; Rajendran ND, 2020, J MOL MODEL, V26, DOI 10.1007/s00894-020-04393-6; Rich JD, 1996, DIAGN MICR INFEC DIS, V24, P77, DOI 10.1016/0732-8893(95)00269-3; Riley S, 2021, SCIENCE, V372, P990, DOI 10.1126/science.abf0874; Roy M, 2020, CHEM COMMUN, V56, P4505, DOI 10.1039/c9cc09758a; Ruggiano A, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-020-01539-3; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; Salehzadeh F, 2012, IRAN J PEDIATR, V22, P23; Sang-Suk O., 2021, SCI REP-UK, DOI [10.21203/rs.3.rs-243831/v3, DOI 10.21203/RS.3.RS-243831/V3]; Schrodinger R, 1992, WHAT IS LIFE MIND MA; Schulzer M., 1996, U.S. Patent, Patent No. [5532219A, 5532219]; Shamova EV, 2020, MOL CELL BIOCHEM, V464, P119, DOI 10.1007/s11010-019-03654-0; Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6; Sulzer D, 2020, NPJ PARKINSONS DIS, V6, DOI 10.1038/s41531-020-00123-0; Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010; Tirado-Sanchez A, 2012, ALLERGOL IMMUNOPATH, V40, P152, DOI 10.1016/j.aller.2010.12.009; Varadarajan S, 1999, BRAIN RES BULL, V50, P133, DOI 10.1016/S0361-9230(99)00093-3; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wozel VEG, 2010, DERMATOL CLIN, V28, P599, DOI 10.1016/j.det.2010.03.014; Xiang Yufei, 2020, bioRxiv, DOI 10.1101/2020.08.24.264333; Yachou Y, 2020, NEUROL SCI, V41, P2657, DOI 10.1007/s10072-020-04575-3; Yang N, 2017, NEUROSCI LETT, V649, P85, DOI 10.1016/j.neulet.2017.04.019; Zhang FR, 2013, NEW ENGL J MED, V369, P1620, DOI 10.1056/NEJMoa1213096; Zhao K, 2020, P NATL ACAD SCI USA, V117, P20305, DOI 10.1073/pnas.1922741117; Zheng YY, 2020, NAT REV CARDIOL, V17, P259, DOI 10.1038/s41569-020-0360-5; Zhu KJ, 2009, J CLIN PHARM THER, V34, P489, DOI 10.1111/j.1365-2710.2008.00991.x	72	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							635	10.3390/vaccines9060635			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY8VS	34200720	Green Published, gold			2022-04-29	WOS:000666159300001
J	Kohli, MA; Maschio, M; Mould-Quevedo, JF; Ashraf, M; Drummond, MF; Weinstein, MC				Kohli, Michele A.; Maschio, Michael; Mould-Quevedo, Joaquin F.; Ashraf, Mansoor; Drummond, Michael F.; Weinstein, Milton C.			The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom	VACCINES			English	Article						influenza vaccine; cost-effectiveness; economic modeling	QUALITY-OF-LIFE; SEASONAL INFLUENZA; ENGLAND; HEALTH; IMPACT; PROGRAM; BURDEN; WALES	Background: In response to COVID-19, the UK National Health Service (NHS) extended influenza vaccination in 50- to 64-year-olds from at-risk only to all in this age group for the 2020/21 season. The objective of this research is to determine the cost-effectiveness of continuing to vaccinate all with a quadrivalent cell-based vaccine (QIVc) compared to returning to an at-risk only policy after the pandemic resolves. Methods: A dynamic transmission model, calibrated to match infection data from the UK, was used to estimate the clinical and economic impact of vaccination across 10 influenza seasons. The base case effectiveness of QIVc was 63.9% and the list price was GBP 9.94. Results: Vaccinating 50% of all 50- to 64-year-olds with QIVc reduced the average annual number of clinical infections (-682,000), hospitalizations (-5800) and deaths (-740) in the UK. The base case incremental cost per quality-adjusted life-year gained (ICER) of all compared to at-risk only was GBP6000 (NHS perspective). When the cost of lost productivity was considered, vaccinating all 50- to 64-year-olds with QIVc became cost-saving. Conclusion: Vaccinating all 50- to 64-year-olds with QIVc is likely to be cost-effective. The NHS should consider continuing this policy in future seasons.	[Kohli, Michele A.; Maschio, Michael] Quadrant Hlth Econ Inc, 92 Cottonwood Crescent, Cambridge, ON N1T 2J1, Canada; [Mould-Quevedo, Joaquin F.] Seqirus USA Inc, 25 Deforest Ave, Summit, NJ 07901 USA; [Ashraf, Mansoor] Seqirus UK, 29 Market St, Maidenhead SL6 8AD, Berks, England; [Drummond, Michael F.] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; [Weinstein, Milton C.] Harvard TH Chan Sch Publ Hlth, 718 Huntington Ave, Boston, MA 02115 USA		Kohli, MA (通讯作者)，Quadrant Hlth Econ Inc, 92 Cottonwood Crescent, Cambridge, ON N1T 2J1, Canada.	michele.kohli@quadranthe.com; michael.maschio@quadrantHE.com; joaquin.mould-quevedo@seqirus.com; mansoor.ashraf@seqirus.com; mike.drummond@york.ac.uk; mcw@hsph.harvard.edu			Seqirus USA Inc., Summit, NJ, USA	This study was funded by Seqirus USA Inc., Summit, NJ, USA.	Baguelin M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001527; Baguelin M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0452-y; Baguelin M, 2012, VACCINE, V30, P3459, DOI 10.1016/j.vaccine.2012.03.019; Boikos C, 2020, CLIN INFECT DIS, V71, pE665, DOI 10.1093/cid/ciaa371; British Medical Association Royal Pharmaceutical Society of Great Britain, 2021, BRIT NATL FORMULARY; British Medical Association Royal Pharmaceutical Society of Great Britain, 2021, BRIT NATL FORMULARY; Bruxvoort KJ, 2019, VACCINE, V37, P5807, DOI 10.1016/j.vaccine.2019.08.024; Carrat F, 2002, ARCH INTERN MED, V162, P1842, DOI 10.1001/archinte.162.16.1842; Coleman BL, 2021, INFLUENZA OTHER RESP, V15, P813, DOI 10.1111/irv.12871; Cromer D, 2014, J INFECTION, V68, P363, DOI 10.1016/j.jinf.2013.11.013; Curtis L, 2018, UNIT COSTS HLTH SOCI; DeMarcus L, 2019, VACCINE, V37, P4015, DOI 10.1016/j.vaccine.2019.06.004; Fleming DM, 2008, EPIDEMIOL INFECT, V136, P866, DOI 10.1017/S0950268807009910; Fragaszy EB, 2018, INFLUENZA OTHER RESP, V12, P171, DOI 10.1111/irv.12506; Izurieta HS, 2021, CLIN INFECT DIS, V73, pE4251, DOI 10.1093/cid/ciaa1727; Izurieta HS, 2020, J INFECT DIS, V222, P278, DOI 10.1093/infdis/jiaa080; Izurieta HS, 2019, J INFECT DIS, V220, P1255, DOI 10.1093/infdis/jiy716; Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053; Joint Committee on Vaccination and Immunisation (JCVI) Scientific Secretariat, 2012, JCVI STAT ANN INFL V; Joint Committee on Vaccination and Immunisation (JCVI) Scientific Secretariat, 2020, JCVI ADV INFL VACC 2; Keech M, 2008, PHARMACOECONOMICS, V26, P911, DOI 10.2165/00019053-200826110-00004; Mangen MJJ, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2302-3; Meier G, 2015, J MED ECON, V18, P746, DOI 10.3111/13696998.2015.1044456; Melegaro A, 2004, VACCINE, V22, P4203, DOI 10.1016/j.vaccine.2004.05.003; National Health Service, 2020, NAT FLU IMM PROGR 20; National Health Service, 2021, VACC REIMB PART NHS; National Institute for Health and Care Excellence, 2020, NIC METH HLTH TECHN; National Institute for Health and Clinical Excellence (NICE), 2013, GUID METH TECHN APPR; Newall AT, 2009, PHARMACOECONOMICS, V27, P439, DOI 10.2165/00019053-200927060-00001; NHS, 2020, NHS IMPR DIR ENH SER; Office for National Statistics, NAT LIF TABL UK; Office for National Statistics, 2020, ANN SURV HOURS EARN; Pitman RJ, 2013, VACCINE, V31, P927, DOI 10.1016/j.vaccine.2012.12.010; Public Health England, 2019, GUID US ANT AG TREAT; Public Health England, 2020, SURVEILLANCE INFLUEN; Ramsay M, 2018, IMMUNISATION INFECT; Tappenden P, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13110; Thorrington D, 2019, VACCINE, V37, P2051, DOI 10.1016/j.vaccine.2019.03.002; Thorrington D, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0932-3; Tilston NL, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-650; Turner DA, 2006, VACCINE, V24, P1035, DOI 10.1016/j.vaccine.2004.12.033; van Hoek AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017030; WHO, WHO REC COMP INFL VI; Yuasa A, 2021, EXPERT REV PHARM OUT, V21, P235, DOI 10.1080/14737167.2021.1881484	44	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							598	10.3390/vaccines9060598			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY6TV	34199912	Green Published, Green Accepted			2022-04-29	WOS:000666018800001
J	Machmud, PB; Glasauer, S; Gottschick, C; Mikolajczyk, R				Machmud, Putri Bungsu; Glasauer, Saskia; Gottschick, Cornelia; Mikolajczyk, Rafael			Knowledge, Vaccination Status, and Reasons for Avoiding Vaccinations against Hepatitis B in Developing Countries: A Systematic Review	VACCINES			English	Review						developing countries; hepatitis B; knowledge; vaccination status; risk population	HEALTH-CARE WORKERS; MEDICAL-STUDENTS; VIRAL-HEPATITIS; DENTAL STUDENTS; VIRUS INFECTION; PREGNANT-WOMEN; ATTITUDE; AWARENESS; PREVALENCE; COVERAGE	(1) Background: The coverage of hepatitis B vaccination remains low in developing countries to date. This systematic review thus analyzes the determinants of people's knowledge and vaccination status as well as the reasons why people in developing countries chose not to receive the hepatitis B vaccination. (2) Methods: We searched four databases to identify all studies from developing countries published within the past 10 years. Both low-risk and high-risk populations aged older than 15 years old were eligible for the study. The quality of studies was assessed by the Newcastle-Ottawa Scale assessment. (3) Results: This study identified 2443 articles, 89 of which were included in the analysis. Monthly income, occupational status, and profession as a health-care worker were the strongest predictive factors for both knowledge of hepatitis B and vaccination status. In addition, strong predictor variables of hepatitis B knowledge were knowing an infected person and level of education, while health insurance, management's protection at workplace, infection training, and experience of hepatitis B exposure were strong influencing factors for vaccine uptake. (4) Conclusions: Exposure to information, support from institutions, and financial support related to vaccination cost have a positive impact on the knowledge about hepatitis B infection and vaccination coverage.	[Machmud, Putri Bungsu; Glasauer, Saskia; Gottschick, Cornelia; Mikolajczyk, Rafael] Martin Luther Univ Halle Wittenberg, Inst Med Epidemiol Biometr & Informat IMEBI, Interdisciplinary Ctr Hlth Sci, Sch Med, Magdeburger Str 8, D-06112 Halle, Saale, Germany; [Machmud, Putri Bungsu] Univ Indonesia, Fac Publ Hlth, Dept Epidemiol, Jl Prof Dr Bahder Djohan, Depok 16424, Indonesia		Mikolajczyk, R (通讯作者)，Martin Luther Univ Halle Wittenberg, Inst Med Epidemiol Biometr & Informat IMEBI, Interdisciplinary Ctr Hlth Sci, Sch Med, Magdeburger Str 8, D-06112 Halle, Saale, Germany.	putri.machmud@uk-halle.de; saskia.glasauer@uk-halle.de; cornelia.gottschick@uk-halle.de; rafael.mikolajczyk@uk-halle.de	Mikolajczyk, Rafael/ABB-5259-2021	Mikolajczyk, Rafael/0000-0003-1271-7204; Glasauer, Saskia/0000-0002-2236-3545	Indonesia Lecturer Scholarship (BUDI) from the Indonesia Endowment Fund for Education (LPDP), the Republic of Indonesia; German Research Foundation (DFG)German Research Foundation (DFG)	The authors (P.B.M.) are grateful for the support from the Indonesia Lecturer Scholarship (BUDI) from the Indonesia Endowment Fund for Education (LPDP), the Republic of Indonesia. This research did not receive any specific grants from funding agencies in the public, commercial or not-for-profit sectors. The authors also acknowledge the financial support of the Open Access Publishing by the German Research Foundation (DFG).Y	Aaron D, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2893-8; Abeje G, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0756-8; Abiodun O, 2019, CLIN EPIDEMIOL GLOB, V7, P11, DOI 10.1016/j.cegh.2017.12.001; Abiola A O, 2013, West Afr J Med, V32, P257; Abiola AHO, 2016, PAN AFR MED J, V23, DOI 10.11604/pamj.2016.23.160.8710; Adekanle Olusegun, 2015, Hepat Res Treat, V2015, P439867, DOI 10.1155/2015/439867; Adenlewo OJ, 2017, PAN AFR MED J, V28, DOI 10.11604/pamj.2017.28.33.11662; Adeyemi AB, 2013, J OBSTET GYNAECOL, V33, P155, DOI 10.3109/01443615.2012.711389; Adjei CA, 2018, AM J TROP MED HYG, V99, P1469, DOI 10.4269/ajtmh.17-0752; Aghakhani A, 2016, INT J STD AIDS, V27, P967, DOI 10.1177/0956462415602419; Ahmad A, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3188-5; Akibu M, 2018, SCIENTIFICA, V2018, DOI 10.1155/2018/6705305; Al-Hazmi AH, 2015, ANN MED HEALTH SCI R, V5, P13, DOI 10.4103/2141-9248.149765; Alavian SM, 2011, J DENT EDUC, V75, P1627; Alese OO, 2016, J CLIN DIAGN RES, V10, pLC16, DOI 10.7860/JCDR/2016/15936.7329; Ali A, 2017, CUREUS, V9, DOI 10.7759/cureus.1049; Alqahtani JM, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-577; Aniaku JK, 2019, ANN GLOB HEALTH, V85, DOI 10.5334/aogh.750; [Anonymous], PROSPERO; Aroke D, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3673289; Asif M, 2011, J PAK MED ASSOC, V61, P680; Assuncao AA, 2012, REV SAUDE PUBL, V46, P665, DOI 10.1590/S0034-89102012005000042; Attaullah S, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-275; Aydemir O, 2016, VIRAL HEPAT DERG, V22, P82, DOI 10.4274/vhd.74936; Basuni AA, 2004, VACCINE, V22, P2791, DOI 10.1016/j.vaccine.2004.01.046; Bedaso Asres, 2018, BMC Res Notes, V11, P912, DOI 10.1186/s13104-018-4023-0; Bekele Abebe, 2014, Ethiop Med J, V52, P107; Bramer WM, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0644-y; Carvalho M, 2012, ARCH TOXICOL, V86, P1167, DOI 10.1007/s00204-012-0815-5; Celikel A, 2014, J CLIN NURS, V23, P2142, DOI 10.1111/jocn.12351; Chan OK, 2011, PATIENT EDUC COUNS, V85, P516, DOI 10.1016/j.pec.2010.11.006; Chao J, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-98; Chingle MP, 2017, ANN AFR MED, V16, P59, DOI 10.4103/aam.aam_49_16; Choudhary SK, 2017, INT J SCI STUDY, V4, P101, DOI 10.17354/ijss/2017/21; Chung PW, 2012, CHINESE MED J-PEKING, V125, P422, DOI 10.3760/cma.j.issn.0366-6999.2012.03.004; da Costa FM, 2013, REV LAT-AM ENFERM, V21, P316, DOI 10.1590/S0104-11692013000100005; de Souza EP, 2014, REV INST MED TROP SP, V56, P307, DOI 10.1590/S0036-46652014000400007; Debes JD, 2016, AM J TROP MED HYG, V94, P1100, DOI 10.4269/ajtmh.15-0797; Demsiss W, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196539; Dev Kansara, 2018, J Assoc Physicians India, V66, P27; Eni AO, 2019, ANN GLOB HEALTH, V85, DOI 10.5334/aogh.33; Ferreira Raquel Conceição, 2012, Rev. bras. epidemiol., V15, P315, DOI 10.1590/S1415-790X2012000200009; Ghomraoui FA, 2016, J INFECT PUBLIC HEAL, V9, P60, DOI 10.1016/j.jiph.2015.06.008; Guerra AB, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1753-x; Hebo Habtemu J, 2019, ScientificWorldJournal, V2019, P9482607, DOI 10.1155/2019/9482607; Hoffmann R, 2019, EUR J HEALTH ECON, V20, P27, DOI 10.1007/s10198-017-0950-2; Ibrahim Nazir, 2014, Hepat Res Treat, V2014, P131920, DOI 10.1155/2014/131920; Iqbal, 2019, PAK J MED HEALTH SCI, V13, P783; Jaquet A, 2017, AM J TROP MED HYG, V97, P389, DOI 10.4269/ajtmh.17-0065; Joukar F, 2018, HEPAT MON, V18, DOI 10.5812/hepatmon.65870; Juon HS, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-185; Kesieme Emeka B, 2011, Hepat Res Treat, V2011, P157089, DOI 10.1155/2011/157089; Khan N, 2010, J PAK MED ASSOC, V60, P450; Khandelwal Vishal, 2017, Int J Adolesc Med Health, V30, DOI 10.1515/ijamh-2016-0103; Ko K, 2017, KOREAN J FAM MED, V38, P21, DOI 10.4082/kjfm.2017.38.1.21; Kouassi D, 2017, J PUBLIC HEALTH AFR, V8, P144, DOI 10.4081/jphia.2017.715; Lee O, 2010, J TRANSCULT NURS, V21, P65, DOI 10.1177/1043659609348620; Li XY, 2015, HEPAT MON, V15, DOI 10.5812/hepatmon.15(5)2015.25079; Machiya T, 2015, INT HEALTH, V7, P256, DOI 10.1093/inthealth/ihu084; Meriki HD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200157; Mirzaei Alavijeh Mehdi, 2019, Middle East J Dig Dis, V11, P45, DOI 10.15171/mejdd.2018.127; Moezzi M, 2016, J CLIN DIAGN RES, V10, pLC1, DOI 10.7860/JCDR/2016/17758.7548; Mokaya J, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006629; Mungandi N, 2017, ANN OCCUP ENVIRON ME, V29, DOI 10.1186/s40557-017-0191-y; Mursy SMEM, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7982-8; Mustafa ASM, 2018, SUDAN J MED SCI, V13, P22, DOI 10.18502/sjms.v13i1.1686; Mustufa MA, 2010, J INFECT DEV COUNTR, V4, P616, DOI 10.3855/jidc.499; Noreen N, 2015, E MEDITERR HEALTH J, V21, P129, DOI 10.26719/2015.21.2.129; Noubiap Jean Jacques N, 2014, Int Arch Med, V7, P11, DOI 10.1186/1755-7682-7-11; Noubiap JJN, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-148; Ochu CL, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-015845; Ogoina D, 2014, INT J OCCUP ENV MED, V5, P51; Okwara EC, 2012, PAN AFR MED J, V13; Omotowo IB, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3191-9; Osei E, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7645106; Owiti JA, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1476-0; Oyewusi C.O., 2015, INT J CARING SCI, V8, P164; Park B, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-218; Park B, 2012, VACCINE, V30, P5844, DOI 10.1016/j.vaccine.2012.07.022; Pathoumthong K, 2014, VACCINE, V32, P4993, DOI 10.1016/j.vaccine.2014.07.022; Rajamoorthy Y, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-018-6375-8; Rathi A, 2018, J LAB PHYS, V10, P374, DOI 10.4103/JLP.JLP_93_18; Ray SS, 2017, J EVOL MED DENT SCI-, V6, P6460, DOI 10.14260/jemds/2017/1404; Resende VLS, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-154; Roushan N, 2013, IRAN RED CRESCENT ME, V15, DOI 10.5812/ircmj.11558; Sachdeva Sandeep, 2010, Journal of Communicable Diseases, V42, P147; Shahbaz T, 2014, PAK J MED HEALTH SCI, V8, P789; Shakeel S, 2015, BANGLADESH J MED SCI, V14, P376, DOI 10.3329/bjms.v14i4.25780; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Shukla A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-314; Shukla M, 2016, J RES MED DENT SCI, V4, P45, DOI 10.5455/jrmds.20164110; Singh A, 2011, J DENT EDUC, V75, P421; Tanga AT, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4220-z; Tatsilong HOP, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3388-z; Vo TQ, 2018, J PHARM PHARMACOGN R, V6, P458; Vo TQ, 2018, ASIAN J PHARM, V12, pS99; United Nations, 2020, WORLD EC SIT PROSP 2; Usmani Rabia Arshed, 2010, J Ayub Med Coll Abbottabad, V22, P36; Wells G.A., NEWCASTLE OTTAWA SCA; World Health Organization, 2017, GLOBAL HEPATITIS REP; World Health Organization, 2020, WORLD DAY HEP; Yamazhan T, 2011, INT NURS REV, V58, P181, DOI 10.1111/j.1466-7657.2010.00869.x; Yang Y, 2015, IRAN RED CRESCENT ME, V17, DOI 10.5812/ircmj.17(4)2015.26725; Yuan QL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216598; Zafrin N, 2019, VIRAL HEPAT DERG, V25, P6, DOI 10.4274/vhd.galenos.2018.0016; Zampino R, 2015, WORLD J GASTROENTERO, V21, P11941, DOI 10.3748/wjg.v21.i42.11941; Zheng YB, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1278-0	107	0	0	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							625	10.3390/vaccines9060625			26	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY8JE	34207829	Green Published, gold			2022-04-29	WOS:000666126500001
J	Signorazzi, A; Pennings, JLA; Etna, MP; Noya, M; Coccia, EM; Huckriede, A				Signorazzi, Aurora; Pennings, Jeroen L. A.; Etna, Marilena P.; Noya, Malou; Coccia, Eliana M.; Huckriede, Anke			In Vitro Characterization of the Innate Immune Pathways Engaged by Live and Inactivated Tick-Borne Encephalitis Virus	VACCINES			English	Article						tick-borne encephalitis virus; TBE vaccine; peripheral blood mononuclear cells; RNA sequencing; interferon; RIG-I; TLR	YELLOW-FEVER VACCINE; RIG-I; FUNCTIONAL-ANALYSIS; ANTIBODY-RESPONSES; INFLUENZA VACCINE; SYSTEMS BIOLOGY; STRANDED-RNA; CELLS; TLR; TBE	Tick-borne encephalitis virus (TBEV) infection can lead to inflammation of the central nervous system. The disease can be effectively prevented by whole inactivated virus vaccines. Here, we investigated the innate immune profile induced in vitro by the antigen component of the vaccines, inactivated TBEV (I-TBEV), to gain insights into the mechanism of action of the TBE vaccine as compared to the live virus. To this end, we exposed human peripheral blood mononuclear cells (PBMCs) to inactivated and live TBEV and assessed cellular responses by RNA sequencing. Both inactivated and live TBEV significantly induced an interferon-dominated gene signature and an increased RIG-I-like receptor (RLR) expression. Using pathway-specific inhibitors, we assessed the involvement of pattern recognition receptors in the sensing of inactivated or live TBEV. Only RLR pathway inhibition significantly suppressed the downstream cascade induced by I-TBEV, while responses to the replicating virus were impacted by the inhibition of RIG-I-like, as well as Toll-like, receptors. Our results show that inactivated and live TBEV predominantly engaged an interferon response in our in vitro PBMC platform, and indicate RLRs as the main pattern recognition receptors involved in I-TBEV sensing.	[Signorazzi, Aurora; Noya, Malou; Huckriede, Anke] Univ Groningen, Dept Med Microbiol & Infect Prevent, Univ Med Ctr Groningen, NL-9713GZ Groningen, Netherlands; [Pennings, Jeroen L. A.] Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect, NL-3721MA Bilthoven, Netherlands; [Etna, Marilena P.; Coccia, Eliana M.] Ist Super Sanita, Dept Infect Dis, I-000161 Rome, Italy		Huckriede, A (通讯作者)，Univ Groningen, Dept Med Microbiol & Infect Prevent, Univ Med Ctr Groningen, NL-9713GZ Groningen, Netherlands.	a.signorazzi@umcg.nl; jeroen.pennings@rivm.nl; marilenapaola.etna@iss.it; malou.noya@live.nl; eliana.coccia@iss.it; l.w.huckriede@umcg.nl	Etna, Marilena Paola/ABA-8433-2021; Coccia, Eliana M/B-4752-2013	Etna, Marilena Paola/0000-0003-2551-393X; Coccia, Eliana M/0000-0002-1606-2949; Pennings, Jeroen L.A./0000-0002-9188-6358; Signorazzi, Aurora/0000-0001-6757-7523	Innovative Medicines Initiative 2 Joint Undertaking [115924]; European UnionEuropean Commission; EFPIA	This project was performed in context of the Vac2Vac consortium, which received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115924. This Joint Undertaking received support from the European Union's Horizon 2020 research and innovation programme and EFPIA.	Aberle JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140545; Akkermans A, 2020, BIOLOGICALS, V68, P92, DOI 10.1016/j.biologicals.2020.07.010; Amicizia D, 2013, HUM VACC IMMUNOTHER, V9, P1163, DOI 10.4161/hv.23802; Andersen-Nissen E, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009363; Anderson J, 2019, J IMMUNOL METHODS, V465, P61, DOI 10.1016/j.jim.2018.11.006; Biffen M, 2012, BRIT J PHARMACOL, V166, P573, DOI 10.1111/j.1476-5381.2011.01790.x; Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101; Carletti T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11663-2; Carletti T, 2017, BIOCHEM BIOPH RES CO, V492, P533, DOI 10.1016/j.bbrc.2017.02.006; Chang TH, 2006, MICROBES INFECT, V8, P157, DOI 10.1016/j.micinf.2005.06.014; Chernokhaeva LL, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01487; Chowdhury F, 2010, CYTOM PART A, V77A, P328, DOI 10.1002/cyto.a.20872; Dorrbecker B, 2010, TRAVEL MED INFECT DI, V8, P213, DOI 10.1016/j.tmaid.2010.05.010; Duffy D, 2014, IMMUNITY, V40, P436, DOI 10.1016/j.immuni.2014.03.002; Etna MP, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009505; Fabregat A, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1559-2; Fares M, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01756-x; Feldman RI, 2005, J BIOL CHEM, V280, P19867, DOI 10.1074/jbc.M501367200; Formanova PP, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1596-z; Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292; Geeraedts F, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000138; Geeraedts F, 2008, INFLUENZA OTHER RESP, V2, P41, DOI 10.1111/j.1750-2659.2008.00038.x; Ghimire TR, 2012, IMMUNOL LETT, V147, P55, DOI 10.1016/j.imlet.2012.06.002; Gritsun TS, 2007, VIROLOGY, V366, P8, DOI 10.1016/j.virol.2007.04.011; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Heinz FX, 2007, VACCINE, V25, P7559, DOI 10.1016/j.vaccine.2007.08.024; Herrera-Rodriguez J, 2019, VACCINE, V37, P1630, DOI 10.1016/j.vaccine.2019.01.086; Hombach J., BACKGROUND DOCUMENT; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ichinohe T, 2010, EXPERT REV VACCINES, V9, P1315, DOI 10.1586/ERV.10.118; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kennedy Richard B, 2011, OMICS, V15, P533, DOI 10.1089/omi.2011.0012; Kofler RM, 2006, J VIROL, V80, P4099, DOI 10.1128/JVI.80.8.4099-4113.2006; Koyama S, 2007, J IMMUNOL, V179, P4711, DOI 10.4049/jimmunol.179.7.4711; Krylova NV, 2015, VIRAL IMMUNOL, V28, P272, DOI 10.1089/vim.2014.0083; Kubinski M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030451; Kunze U, 2016, TICKS TICK-BORNE DIS, V7, P399, DOI 10.1016/j.ttbdis.2015.12.018; Lee MK, 2016, NUCLEIC ACIDS RES, V44, P8407, DOI 10.1093/nar/gkw525; Lepej SZ, 2007, ACTA NEUROL SCAND, V115, P109, DOI 10.1111/j.1600-0404.2006.00726.x; Loiarro M, 2005, J BIOL CHEM, V280, P15809, DOI 10.1074/jbc.C400613200; Loo YM, 2008, J VIROL, V82, P335, DOI 10.1128/JVI.01080-07; Lu FJ, 2013, VACCINE, V31, P3979, DOI 10.1016/j.vaccine.2013.05.107; Lubick KJ, 2015, CELL HOST MICROBE, V18, P61, DOI 10.1016/j.chom.2015.06.007; Luciani F, 2012, TRENDS BIOTECHNOL, V30, P443, DOI 10.1016/j.tibtech.2012.05.005; Martikainen MV, 2020, TOXICOL IN VITRO, V67, DOI 10.1016/j.tiv.2020.104918; Mazeaud C, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00595; Meijerink M, 2011, J IMMUNOL METHODS, V373, P136, DOI 10.1016/j.jim.2011.08.010; Miorin L, 2013, J VIROL, V87, P6469, DOI 10.1128/JVI.03456-12; Miorin L, 2012, VIRUS RES, V163, P660, DOI 10.1016/j.virusres.2011.11.020; Nakaya HI, 2011, NAT IMMUNOL, V12, P786, DOI 10.1038/ni.2067; Niederberger E, 2013, CURR MOL MED, V13, P1089; Obermoser G, 2013, IMMUNITY, V38, P831, DOI 10.1016/j.immuni.2012.12.008; Overby AK, 2010, J VIROL, V84, P8470, DOI 10.1128/JVI.00176-10; Orlinger KK, 2011, J INFECT DIS, V203, P1556, DOI 10.1093/infdis/jir122; Palus M, 2017, VIROLOGY, V507, P110, DOI 10.1016/j.virol.2017.04.012; Panayiotou C, 2018, J VIROL, V92, DOI [10.1128/JVI.02054-17, 10.1128/jvi.02054-17]; Pham AM, 2010, VIRUSES-BASEL, V2, P55, DOI 10.3390/v2010055; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Rechtien A, 2017, CELL REP, V20, P2251, DOI 10.1016/j.celrep.2017.08.023; Riccardi N, 2019, EUR J INTERN MED, V62, P1, DOI 10.1016/j.ejim.2019.01.004; RIVM, TICK BORNE ENCEPHALI; Robertson SJ, 2014, J IMMUNOL, V192, P2744, DOI 10.4049/jimmunol.1302110; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Signorazzi A, 2021, ALTEX-ALTERN ANIM EX, V38, P431, DOI 10.14573/altex.2010081; Stephen J, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-016-0001-5; Stoel M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125228; Suss J, 2011, TICKS TICK-BORNE DIS, V2, P2, DOI 10.1016/j.ttbdis.2010.10.007; Talbot HK, 2015, CLIN INFECT DIS, V60, P1170, DOI 10.1093/cid/civ019; Tapia-Calle G, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5030021; Waickman AT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11634-7; Walther M, 2006, J IMMUNOL, V177, P5736, DOI 10.4049/jimmunol.177.8.5736; Yang Q, 2020, EMERG MICROBES INFEC, V9, P714, DOI 10.1080/22221751.2020.1745094; Ye J, 2013, VACCINE, V31, P461, DOI 10.1016/j.vaccine.2012.11.015; Zhang JN, 2015, HUM VACC IMMUNOTHER, V11, P739, DOI 10.1080/21645515.2015.1008884; Zlatkovic J, 2013, J VIROL, V87, P12187, DOI 10.1128/JVI.01690-13	76	0	0	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							664	10.3390/vaccines9060664			23	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5VE	34204532	gold, Green Published			2022-04-29	WOS:000665954500001
J	Turrini, M; Gardellini, A; Beretta, L; Buzzi, L; Ferrario, S; Vasile, S; Clerici, R; Colzani, A; Liparulo, L; Scognamiglio, G; Imperiali, G; Corrado, G; Strada, A; Galletti, M; Castiglione, N; Zanon, C				Turrini, Mauro; Gardellini, Angelo; Beretta, Livia; Buzzi, Lucia; Ferrario, Stefano; Vasile, Sabrina; Clerici, Raffaella; Colzani, Andrea; Liparulo, Luigi; Scognamiglio, Giovanni; Imperiali, Gianni; Corrado, Giovanni; Strada, Antonello; Galletti, Marco; Castiglione, Nunzio; Zanon, Claudio			Clinical Course and Risk Factors for In-Hospital Mortality of 205 Patients with SARS-CoV-2 Pneumonia in Como, Lombardy Region, Italy	VACCINES			English	Article						SARS-CoV 2; coronavirus disease 2019; pneumonia; therapy; treatment; mortality; risk factors	COVID-19 PNEUMONIA; TOCILIZUMAB; WUHAN	The aim of this study is to explore risk factors for in-hospital mortality and describe the effectiveness of different treatment strategies of 205 laboratory-confirmed cases infected with SARS-CoV-2 during the Lombardy outbreak. All patients received the best supportive care and specific interventions that included the main drugs being tested for repurposing to treat COVID-19, such as hydroxychloroquine, anticoagulation and antiviral drugs, steroids, and interleukin-6 pathway inhibitors. Clinical, laboratory, and treatment characteristics were analyzed with univariate and multivariate logistic regression methods to explore their impact on in-hospital mortality. Univariate analyses showed prognostic significance for age greater than 70 years, the presence of two or more relevant comorbidities, a P/F ratio less than 200 at presentation, elevated LDH (lactate dehydrogenase) and CRP (C-reactive protein) values, intermediate- or therapeutic-dose anticoagulation, hydroxychloroquine, early antiviral therapy with lopinavir/ritonavir, short courses of steroids, and tocilizumab therapy. Multivariable regression confirmed increasing odds of in-hospital death associated with age older than 70 years (OR 3.26) and a reduction in mortality for patients treated with anticoagulant (-0.37), antiviral lopinavir/ritonavir (-1.22), or steroid (-0.59) therapy. In contrast, hydroxychloroquine and tocilizumab have not been confirmed to have a significant effect in the treatment of SARS-CoV-2 pneumonia. Results from this real-life single-center experience are in agreement and confirm actual literature data on SARS-CoV-2 pneumonia in terms of both clinical risk factors for in-hospital mortality and the effectiveness of the different therapies proposed for the management of COVID19 disease.	[Turrini, Mauro; Gardellini, Angelo] Valduce Hosp, Dept Med, Div Hematol, I-22100 Como, Italy; [Beretta, Livia] Valduce Hosp, Risk Management, I-22100 Como, Italy; [Buzzi, Lucia] Valduce Hosp, Qual Management Syst, I-22100 Como, Italy; [Ferrario, Stefano; Colzani, Andrea] Valduce Hosp, Dept Med, Div Pneumol, I-22100 Como, Italy; [Vasile, Sabrina] Valduce Hosp, Dept Mother & Child, Div Paediat & Neonatol, I-22100 Como, Italy; [Clerici, Raffaella] Valduce Hosp, Dept Med, Div Neurol, I-22100 Como, Italy; [Liparulo, Luigi] Valduce Hosp, Dept Med, Div Internal Med, I-22100 Como, Italy; [Scognamiglio, Giovanni] Valduce Hosp, Dept Med, Div Oncol, I-22100 Como, Italy; [Imperiali, Gianni] Valduce Hosp, Dept Med, Div Gastroenterol, I-22100 Como, Italy; [Corrado, Giovanni] Valduce Hosp, Dept Med, Div Cardiol, I-22100 Como, Italy; [Strada, Antonello] Valduce Hosp, Dept Emergency Med, I-22100 Como, Italy; [Galletti, Marco] Valduce Hosp, Dept Intens Care Med, I-22100 Como, Italy; [Castiglione, Nunzio; Zanon, Claudio] Valduce Hosp, Hosp Hlth Management, I-22100 Como, Italy		Turrini, M (通讯作者)，Valduce Hosp, Dept Med, Div Hematol, I-22100 Como, Italy.	mturrini@valduce.it; agardellini@valduce.it; lberetta@valduce.it; lbuzzi@valduce.it; sferrario@valduce.it; svasile@valduce.it; rderici@valduce.it; acolzani@valduce.it; lliparulo@valduce.it; giosco@valduce.it; g.imperiali@libero.it; gcorrado@valduce.it; astrada@valduce.it; mgalletti@valduce.it; ncastiglione@valduce.it; zanondaudio762@gmail.com	Gardellini, Angelo/ABD-9408-2021; gardellini, angelo/ABE-4741-2021; Turrini, Mauro/AAN-5306-2021	Turrini, Mauro/0000-0001-5299-8456			Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI [10.15585/mmwr.mm6912e2, 10.15585/mmwr.mm6915e4]; Chan K. S., 2003, Hong Kong Medical Journal, V9, P399; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]; Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065; Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2; Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000; de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14; Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031; Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960; Ferri C, 2020, CLIN RHEUMATOL, V39, P3195, DOI 10.1007/s10067-020-05334-7; Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3; Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949; Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410; Giardini V, 2020, AM J HEMATOL, V95, pE188, DOI 10.1002/ajh.25882; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI [10.1056/NEJMc2005203, 10.1056/NEJMoa2002032]; Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926; Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013; Klopfenstein T, 2020, MED MALADIES INFECT, V50, P397, DOI 10.1016/j.medmal.2020.05.001; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Lechien JR, 2020, J INTERN MED, V288, P335, DOI 10.1111/joim.13089; Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9; Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199; Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024; Luo P, 2020, J MED VIROL, V92, P814, DOI 10.1002/jmv.25801; Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1844, 10.1136/bmj.m2328]; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001; Passamonti F, 2020, LANCET HAEMATOL, V7, pE737, DOI 10.1016/S2352-3026(20)30251-9; Perrone F, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02573-9; Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI [10.1136/bmj.m1966, 10.12890/2020_001747]; Rawson TM, 2020, CLIN INFECT DIS, V71, P2459, DOI 10.1093/cid/ciaa530; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529; Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4; Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Tang N, 2020, J THROMB HAEMOST, V18, P844, DOI 10.1111/jth.14768; Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849; Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Wong HYF, 2020, RADIOLOGY, V296, pE72, DOI 10.1148/radiol.2020201160; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang J., 2020, INT J INFECT DIS, V94, P91, DOI [10.1016/J.ijid.2020.03.017, DOI 10.1016/J.IJID.2020.03.017]; Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729; Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237; Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204; Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954; Zhang W, 2020, EMERG MICROBES INFEC, V9, DOI 10.1080/22221751.2020.1729071; Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	64	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							640	10.3390/vaccines9060640			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ3JP	34208017	Green Submitted, Green Published, gold			2022-04-29	WOS:000666466100001
J	Ueda, Y				Ueda, Yutaka			Challenges and Perspectives for Prevention of Infectious Diseases	VACCINES			English	Editorial Material									[Ueda, Yutaka] Osaka Univ, Dept Obstet & Gynecol, Grad Sch Med, Osaka 5650871, Japan		Ueda, Y (通讯作者)，Osaka Univ, Dept Obstet & Gynecol, Grad Sch Med, Osaka 5650871, Japan.	y.ueda@gyne.med.osaka-u.ac.jp		Ueda, Yutaka/0000-0001-8760-6379	Health and Labor Sciences Research GrantMinistry of Health, Labour and Welfare, Japan [20EA1025]	This study was supported by a Health and Labor Sciences Research Grant (20EA1025). The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.	Benis A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040315; Haque A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040739; Kudo R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020087; Papagiannis D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030200; Taniguchi M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030280; Yagi A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030502; Zhang MY, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030212	7	0	0	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							571	10.3390/vaccines9060571			2	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY8AZ	34205856	Green Published, gold			2022-04-29	WOS:000666105200001
J	Baines, A; Ittefaq, M; Abwao, M				Baines, Annalise; Ittefaq, Muhammad; Abwao, Mauryne			#Scamdemic, #Plandemic, or #Scaredemic: What Parler Social Media Platform Tells Us about COVID-19 Vaccine	VACCINES			English	Article						COVID-19 vaccine; echo chamber; online discussions; misinformation; Parler; social media	CONSPIRACY THEORIES; HPV VACCINE; MISINFORMATION; PERCEPTIONS; ATTITUDES; TWITTER; MODEL	This study aims to understand public discussions regarding COVID-19 vaccine on Parler, a newer social media platform that recently gained in popularity. Through analyzing a random sample (n = 400) of Parler posts using the hashtags #COVID19Vaccine and #NoCovidVaccine, we use the concept of echo chambers to understand users' discussions through a text analytics approach. Thematic analysis reveals five key themes: reasons to refuse the COVID-19 vaccine (40%), side effects of the COVID-19 vaccine (28%), population control through the COVID-19 vaccine (23%), children getting vaccinated without parental consent (5%), and comparison of other health issues with COVID-19 (2%). Textual analysis shows that the most frequently used words in the corpus were: nocovidvaccine (348); vaccine (264); covid (184); covid19 (157); and vaccines (128). These findings suggest that users adopted different terms and hashtags to express their beliefs regarding the COVID-19 vaccine. Further, findings revealed that users used certain hashtags such as "echo" to encourage like-minded people to reinforce their existing beliefs on COVID-19 vaccine efficacy and vaccine acceptance. These findings have implications for public health communication in attempts to correct false narratives on social media platforms. Through widely sharing the scientific findings of COVID-19 vaccine-related studies can help individuals understand the COVID-19 vaccines efficacy accurately.	[Baines, Annalise; Ittefaq, Muhammad; Abwao, Mauryne] Univ Kansas, William Allen White Sch Journalism & Mass Commun, Lawrence, KS 66045 USA		Baines, A (通讯作者)，Univ Kansas, William Allen White Sch Journalism & Mass Commun, Lawrence, KS 66045 USA.	annalise.baines@ku.edu; muhammadittefaq@ku.edu; mauryneabwao@ku.edu	Ittefaq, Muhammad/Q-7481-2017	Ittefaq, Muhammad/0000-0001-5334-7567	University of Kansas (KU) One University; KU Provost, KU Vice Chancellor for Research & Graduate Studies	The article processing charges related to the publication of this article were supported by The University of Kansas (KU) One University Open Access Author Fund sponsored jointly by the KU Provost, KU Vice Chancellor for Research & Graduate Studies, and KUMC Vice Chancellor for Research and managed jointly by the Libraries at the Medical Center and KU-Lawrence.	Abbott, 2021, WALL STREET J; Ahmadian S, 2020, DEATH STUD, V44, P759, DOI 10.1080/07481187.2019.1609137; Akthar A., EVERYTHING YOU NEED; Al Khaja KAJ, 2018, J PUBLIC HEALTH POL, V39, P343, DOI 10.1057/s41271-018-0131-2; Aliapoulios M., 2021, ARXIV210103820; Allam A, 2014, J MED INTERNET RES, V16, P237, DOI 10.2196/jmir.2642; [Anonymous], CTR COUNTERING DIGIT; [Anonymous], 2020, HARV KENNEDY SCH MIS, DOI DOI 10.37016/MR-2020-38; Artime O, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71231-3; BALLROKEACH SJ, 1976, COMMUN RES, V3, P3, DOI 10.1177/009365027600300101; Basch CH, 2020, HUM VACC IMMUNOTHER, V16, P2582, DOI 10.1080/21645515.2020.1790280; Bessi A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118093; Betsch C, 2010, J HEALTH PSYCHOL, V15, P446, DOI 10.1177/1359105309353647; Blair E., 2015, J METHODS MEAS SOC S, V6, P14, DOI [10.2458/v6i1.18772, DOI 10.2458/V6I1.18772]; Bonnevie E., 2021, Journal of Communication in Healthcare, V14, P12, DOI 10.1080/17538068.2020.1858222; Boodoosingh R, 2020, WORLD DEV, V136, DOI 10.1016/j.worlddev.2020.105177; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI DOI 10.1191/1478088706QP063OA; Burki T, 2020, LANCET DIGIT HEALTH, V2, pE504, DOI 10.1016/S2589-7500(20)30227-2; Carrieri V, 2019, HEALTH ECON, V28, P1377, DOI 10.1002/hec.3937; Castillo C, 2011, P 20 INT C WORLD WID, P675; Centers for Disease Control and Prevention, 10 ESS PUBL HLTH SER; Chen L, 2021, HEALTH COMMUN, V36, P1343, DOI 10.1080/10410236.2020.1751384; Chiacu D., TRUMP SAYS CORONAVIR; Chiou L., 2018, FAKE NEWS ADVERTISIN; Cirillo N, 2021, J ORAL PATHOL MED, V50, P424, DOI 10.1111/jop.13165; Colleoni E, 2014, J COMMUN, V64, P317, DOI 10.1111/jcom.12084; Cordina M, 2021, PHARM PRACT-GRANADA, V19, DOI [10.18549/pharmpract.2021.1.2317, 10.18549/PharmPract.2021.1.2317]; Deffuant G, 2006, JASSS-J ARTIF SOC S, V9; Fatima M., 2020, MEDIA ASIA, V47, P75, DOI [10.1080/01296612.2020.1817264, DOI 10.1080/01296612.2020.1817264]; Garrett RK, 2009, J COMMUN, V59, P676, DOI 10.1111/j.1460-2466.2009.01452.x; Gawronski B, 2012, SOC COGNITION, V30, P652, DOI 10.1521/soco.2012.30.6.652; Geiss S, 2021, DIGIT JOURNAL, V9, P660, DOI 10.1080/21670811.2021.1873811; Getman R, 2018, HEALTH EDUC BEHAV, V45, P599, DOI 10.1177/1090198117739673; Gillani N, 2018, WEB CONFERENCE 2018: PROCEEDINGS OF THE WORLD WIDE WEB CONFERENCE (WWW2018), P823, DOI 10.1145/3178876.3186130; Guess AM, 2020, NAT HUM BEHAV, V4, P472, DOI 10.1038/s41562-020-0833-x; Hendriks F, 2016, PROGR IS, P143, DOI 10.1007/978-3-319-28059-2_8; Holder J, TRACKING CORONAVIRUS; Hornsey MJ, 2020, J EXP SOC PSYCHOL, V88, DOI 10.1016/j.jesp.2019.103947; Hornsey MJ, 2018, HEALTH PSYCHOL, V37, P307, DOI 10.1037/hea0000586; Huang JS, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.184; Ittefaq M, 2021, VACCINE, V39, P480, DOI 10.1016/j.vaccine.2020.12.039; Khan ML, 2021, INT J COMMUN-US, V15, P1741; Lerman R., WASH POST; Lerman R., VACCINE HOAXES ARE R; Leskin P., TOP TRUMP OFFICIALS; Lincoln Yvonne S., 1999, NATURALISTIC INQUIRY; Lorenz J, 2011, P NATL ACAD SCI USA, V108, P9020, DOI 10.1073/pnas.1008636108; Munn Luke., 2021, 1 MONDAY, V26, DOI [10.5210/fm.v26i3.11574, DOI 10.5210/FM.V26I3.11574, 10.5210/ fm.v26i3.11574]; Nan XL, 2012, HEALTH COMMUN, V27, P829, DOI 10.1080/10410236.2012.661348; NBC News, NBC NEWS; Newhouse A., PBS NEWS HOUR; Nicolaou N., FINANCIAL TIMES; Nuzhath T., COVID 19 VACCINATION; Phillips B.C., 2020, ECHO CHAMBERS EARLY, DOI [10.1101/2020.10.17.20214312, DOI 10.1101/2020.10.17.20214312]; Piedrahita-Valdes H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010028; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Regan A, 2014, HEALTH RISK SOC, V16, P308, DOI 10.1080/13698575.2014.919993; Reuters,, REUTERS; Reynolds TW, 2010, RISK ANAL, V30, P1520, DOI 10.1111/j.1539-6924.2010.01448.x; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Sampsel L.J., 2018, MUSIC REFERENCE SERV, V21, P1, DOI [10.1080/10588167.2018.1496754, DOI 10.1080/10588167.2018.1496754]; Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040; Sunstein Cass R, 2009, GOING EXTREMES MINDS; Uscinski J.E., 2020, HARVARD KENNEDY SCH, V1, DOI 10.37016/mr-2020-015; Van Raemdonck N., 2019, I POLICY ADVOCACY GO; van Schalkwyk F, 2020, SCIENTOMETRICS, V125, P1499, DOI 10.1007/s11192-020-03551-0; Vraga EK, 2017, SCI COMMUN, V39, P621, DOI 10.1177/1075547017731776; Wang YX, 2019, SOC SCI MED, V240, DOI 10.1016/j.socscimed.2019.112552; Zimmerman RK, 2005, J MED INTERNET RES, V7, DOI 10.2196/jmir.7.2.e17	70	6	6	10	22	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							421	10.3390/vaccines9050421			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI3BR	33922343	Green Published, gold			2022-04-29	WOS:000654701100001
J	Kim, D; Moon, J; Ha, J; Kim, D; Yi, J				Kim, Daehyun; Moon, Joonho; Ha, Jaejung; Kim, Doyoon; Yi, Junkoo			Effect of Foot-and-Mouth Disease Vaccination on Acute Phase Immune Response and Anovulation in Hanwoo (Bos taurus coreanae)	VACCINES			English	Article						FMD vaccine; anovulation; acute phase immune response; artificial insemination; Hanwoo	VIRUS; CELLS; FMD	Vaccination against foot-and-mouth disease is the most common method for preventing the spread of the disease; the negative effects include miscarriage, early embryo death, lower milk production, and decreased growth of fattening cattle. Therefore, in this study, we analyze the side effects of vaccination by determining the acute immune response and ovulation rate after vaccinating cows for foot-and-mouth disease. The test axis was synchronized with ovulation using 100 Hanwoo (Bos taurus coreanae) cows from the Gyeongsangbuk-do Livestock Research Institute; only individuals with estrus confirmed by ovarian ultrasound were used for the test. All test axes were artificially inseminated 21 days after the previous estrus date. The control group was administered 0.9% normal saline, the negative control was injected intramuscularly with lipopolysaccharide (LPS; 0.5 mu g/kg), and the test group was administered a foot-and-mouth disease virus vaccine (FMDV vaccine; bioaftogen, O and A serotypes, inactivated vaccine) 2, 9, and 16 days before artificial insemination. White blood cells and neutrophils increased significantly 1 day after vaccination, and body temperature in the rumen increased for 16 h after vaccination. Ovulation was detected 1 day after artificial fertilization by ovarian ultrasound. The ovulation rates were as follows: control 89%, LPS 60%, FMDV vaccine (-2 d) 50%, FMDV vaccine (-9 d) 75%, and FMDV vaccine (-16 d) 75%. In particular, the FMDV vaccine (-2 d) test group confirmed that ovulation was delayed for 4 days after artificial insemination. In addition, it was confirmed that it took 9 days after inoculation for the plasma contents of haptoglobin and serum amyloid A to recover to the normal range as the main acute immune response factors. The conception rate of the FMDV vaccine (-2 d) group was 20%, which was significantly lower than that of the other test groups.	[Kim, Daehyun; Ha, Jaejung; Kim, Doyoon; Yi, Junkoo] Livestock Res Inst, 186 Daeryongsan Ro, Yeongju 36052, Gyeongsangbukd, South Korea; [Moon, Joonho] Lartbio Co Ltd, 12th Floor,234 Teheran Ro, Seoul 06221, South Korea		Yi, J (通讯作者)，Livestock Res Inst, 186 Daeryongsan Ro, Yeongju 36052, Gyeongsangbukd, South Korea.	kdy51311@naver.com; joonhomoon@lartbio.com; hjjggo@korea.kr; chunja2411@korea.kr; 79lee38@korea.kr		Ha, Jae Jung/0000-0001-6785-6346; Yi, JunKoo/0000-0003-2593-6529; Moon, Joonho/0000-0001-6513-557X; Kim, Dae Hyun/0000-0002-4820-4438; kim, doyoon/0000-0002-3028-7706	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry (IPET) through a Food, Agriculture, Technology convergence creative talent training project - Ministry of Agriculture, Food and Rural Affairs (MAFRA) [120011021]; National Research Foundation of Korea (NRF) - Korea government (MSIT) [NRF-2020R1F1A1052024]	Financial support for this study was granted by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry (IPET) through a Food, Agriculture, Technology convergence creative talent training project funded by the Ministry of Agriculture, Food and Rural Affairs (MAFRA) (120011021) and a National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT; No. NRF-2020R1F1A1052024).	de Campos FT, 2017, THERIOGENOLOGY, V89, P244, DOI 10.1016/j.theriogenology.2016.11.013; ELBELELY MS, 1994, BRIT VET J, V150, P595, DOI 10.1016/S0007-1935(94)80046-4; Ferreira LCL, 2016, J ANIM SCI, V94, P401, DOI 10.2527/jas.2015-9537; Gindri P, 2019, ANIM REPROD SCI, V211, DOI 10.1016/j.anireprosci.2019.106226; Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004; Hansen PJ, 2004, AM J REPROD IMMUNOL, V51, P294, DOI 10.1111/j.1600-0897.2004.00160.x; Kahn S, 2002, CAN VET J, V43, P349; Kamel M, 2019, ARCH VIROL, V164, P1501, DOI 10.1007/s00705-019-04216-x; Kim H., 2017, J KOREAN I INF TECHN, V15, P141, DOI [10.14801/jkiit.2017.15.5.141, DOI 10.14801/JKIIT.2017.15.5.141]; Kim HJ, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1223-7; Krininger CE, 2002, MOL REPROD DEV, V63, P335, DOI 10.1002/mrd.90017; Lavon Y, 2008, THERIOGENOLOGY, V70, P956, DOI 10.1016/j.theriogenology.2008.05.058; Lee Y, 2016, ASIAN AUSTRAL J ANIM, V29, P299, DOI 10.5713/ajas.15.0353; Parida S, 2009, EXPERT REV VACCINES, V8, P347, DOI 10.1586/14760584.8.3.347; Perumal P., 2013, Asian Pacific Journal of Reproduction, V2, P178; Rodrigues MC, 2015, J ANIM SCI, V93, P4443, DOI 10.2527/jas.2015-9277; Rodriguez LL, 2009, VACCINE, V27, pD90, DOI 10.1016/j.vaccine.2009.08.039; Shahriari A, 2018, Arch Razi Inst, V73, P1, DOI 10.22092/ARI.2018.114054; Singh RK, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030090; Suthar VS, 2012, J DAIRY SCI, V95, P2381, DOI 10.3168/jds.2011-4450; Takamatsu HH, 2006, VET IMMUNOL IMMUNOP, V112, P49, DOI 10.1016/j.vetimm.2006.03.011; Yeruham I, 2001, VET DERMATOL, V12, P197, DOI 10.1046/j.0959-4493.2001.00221.x; Zhang L, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-268	23	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							419	10.3390/vaccines9050419			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1MD	33922252	gold, Green Published			2022-04-29	WOS:000654589300001
J	To, QG; Stanton, R; Khalesi, S; Williams, SL; Alley, SJ; Thwaite, TL; Fenning, AS; Vandelanotte, C				To, Quyen G.; Stanton, Robert; Khalesi, Saman; Williams, Susan L.; Alley, Stephanie J.; Thwaite, Tanya L.; Fenning, Andrew S.; Vandelanotte, Corneel			Willingness to Vaccinate against COVID-19 Declines in Australia, Except in Lockdown Areas	VACCINES			English	Article						vaccine hesitancy; anti-vaccination; vaccine sentiment; pandemic; lockdown		This study investigates changes in willingness to vaccinate against COVID-19 and the effect of the extended restrictions in metropolitan Victoria on this change. Longitudinal and repeated cross-sectional data were collected from online surveys distributed in April, between July and August, and December 2020. Australian adults who were >= 18 years old were recruited through email lists, social media networks, and paid Facebook advertisement. Willingness to vaccinate against COVID-19 was self-reported. The results showed that participants were more willing to vaccinate if the vaccine was safe at survey 1 (longitudinal: adjusted OR (aOR) = 1.88, 95%CI = 1.38, 2.56; cross-sectional: aOR = 3.73, 95%CI = 2.55, 5.45) and survey 2 (longitudinal: aOR = 1.54, 95%CI = 1.19, 2.00; cross-sectional: aOR = 2.48, 1.67, 3.67), compared to survey 3. The change in willingness to vaccinate if the vaccine was safe and effective was not significant for those in Metropolitan Victoria; but was for those living in other Australian locations at survey 1 (OR = 2.13, 95%CI = 1.64, 2.76) and survey 2 (OR = 1.62, 95%CI = 1.30, 2.01), compared to survey 3. Willingness to vaccinate even if a vaccine had not been proven safe decreased at survey 3 (OR = 2.02, 95%CI = 1.14, 3.57) for those living in Metropolitan Victoria. In conclusion willingness to vaccinate against COVID-19 decreased over time among Australians, except for those living in metropolitan Victoria, where an additional strict and prolonged lockdown was implemented around the time of survey 2. Either the experience of the lockdown, or the presence of the COVID-19 virus itself had a positive influence on participants' willingness to vaccinate, even if such a vaccine was not yet proven to be safe and effective.	[To, Quyen G.; Stanton, Robert; Khalesi, Saman; Williams, Susan L.; Alley, Stephanie J.; Thwaite, Tanya L.; Vandelanotte, Corneel] Cent Queensland Univ, Appleton Inst, Rockhampton, Qld 4701, Australia; [To, Quyen G.; Stanton, Robert; Khalesi, Saman; Williams, Susan L.; Alley, Stephanie J.; Thwaite, Tanya L.; Fenning, Andrew S.] Cent Queensland Univ, Sch Hlth Med & Appl Sci, Rockhampton, Qld 4701, Australia		To, QG (通讯作者)，Cent Queensland Univ, Appleton Inst, Rockhampton, Qld 4701, Australia.; To, QG (通讯作者)，Cent Queensland Univ, Sch Hlth Med & Appl Sci, Rockhampton, Qld 4701, Australia.	q.to@cqu.edu.au; r.stanton@cqu.edu.au; s.khalesi@cqu.edu.au; s.p.williams@cqu.edu.au; s.alley@cqu.edu.au; t.thwaite@cqu.edu.au; a.fenning@cqu.edu.au; c.vandelanotte@cqu.edu.au	Vandelanotte, Corneel/ABF-5580-2020; To, Quyen G/F-1938-2015	Thwaite, Tanya/0000-0001-7667-2733; Stanton, Robert/0000-0002-6684-5087; To, Quyen G/0000-0002-3355-6326; Khalesi, Saman/0000-0002-8208-2518; Williams, Susan/0000-0003-4289-9248	National Heart Foundation of AustraliaNational Heart Foundation of Australia [102609, 102584]	This research received no external funding. S.J.A. is supported by an Early Career Fellowship from the National Heart Foundation of Australia (ID 102609). S.K. is also supported by an Early Career Fellowship from the National Heart Foundation of Australia (ID 102584).	Alley SJ, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020797; American Academy of Pediatrics, 2013, DOC PAR REF HAV THEI; [Anonymous], 2021, LIST WHOS RESP COVID; Australian Government Department of Health, 2020, COR COVID 19 CURR SI; Baumgaertner B, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003354; Bednarczyk RA, 2019, EXPERT REV VACCINES, V18, P175, DOI 10.1080/14760584.2019.1562344; Department of Health, 2021, AUSTR VACC AGR AUSTR; Dodd RH, 2021, LANCET INFECT DIS, V21, P161, DOI 10.1016/S1473-3099(20)30926-9; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Health and Human Services Victoria State Government, 2020, VICT RESTR LEV; Immunization Action Coalition, 2021, VACC TIM; Kahn Jeremy., 2021, FORTUNE; Mueller, 2020, NEW YORK TIMES; Oster E, 2018, J HEALTH ECON, V57, P90, DOI 10.1016/j.jhealeco.2017.10.003; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Stanton R, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17114065; Thaker J., 2020, AOTEAROA NZ PUBLIC A; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; WHO, 2019, 10 THREATS GLOBAL HL; Worldometer, COUNTR COVID 19 HAS	23	3	3	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							479	10.3390/vaccines9050479			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1TZ	34068479	Green Published, gold			2022-04-29	WOS:000654609800001
J	Zha, LS; Chang, XY; Zhao, HX; Mohsen, MO; Hong, L; Zhou, YH; Chen, HQ; Liu, XL; Zhang, J; Li, D; Wu, K; Martina, B; Wang, JF; Vogel, M; Bachmann, MF				Zha, Lisha; Chang, Xinyue; Zhao, Hongxin; Mohsen, Mona O.; Hong, Liang; Zhou, Yuhang; Chen, Hongquan; Liu, Xuelan; Zhang, Jie; Li, Dong; Wu, Ke; Martina, Byron; Wang, Junfeng; Vogel, Monique; Bachmann, Martin F.			Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles	VACCINES			English	Article						COVID-19; vaccine; virus-like particle; CuMVTT-RBD; BLI		The ongoing coronavirus disease (COVID-19) pandemic is caused by a new coronavirus (severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)) first reported in Wuhan City, China. From there, it has been rapidly spreading to many cities inside and outside China. Nowadays, more than 110 million cases with deaths surpassing 2 million have been recorded worldwide, thus representing a major health and economic issues. Rapid development of a protective vaccine against COVID-19 is therefore of paramount importance. Here, we demonstrated that the recombinantly expressed receptor-binding domain (RBD) of the spike protein can be coupled to immunologically optimized virus-like particles derived from cucumber mosaic virus (CuMVTT). The RBD displayed CuMVTT bound to ACE2, the viral receptor, demonstrating proper folding of RBD. Furthermore, a highly repetitive display of the RBD on CuMVTT resulted in a vaccine candidate that induced high levels of specific antibodies in mice, which were able to block binding of the spike protein to ACE2 and potently neutralize SARS-CoV-2 virus in vitro.	[Zha, Lisha; Hong, Liang; Chen, Hongquan; Liu, Xuelan; Bachmann, Martin F.] Anhui Agr Univ, Int Immunol Ctr, Hefei 230036, Peoples R China; [Chang, Xinyue; Mohsen, Mona O.; Liu, Xuelan; Vogel, Monique; Bachmann, Martin F.] Univ Hosp Bern, Dept Rheumatol & Immunol, CH-3010 Bern, Switzerland; [Chang, Xinyue; Mohsen, Mona O.; Vogel, Monique] Univ Bern, Dept BioMed Res, CH-3012 Bern, Switzerland; [Zhao, Hongxin; Wang, Junfeng] Chinese Acad Sci, High Magnet Field Lab, Hefei 230031, Peoples R China; [Mohsen, Mona O.] Saiba AG, CH-8808 Pfaffikon, Switzerland; [Zhou, Yuhang; Zhang, Jie] Shandong H&Z Lifesci Gmbh, Yantai 264000, Peoples R China; [Li, Dong] Beijing Key Lab Monoclonal Antibody Res & Dev, Beijing 100176, Peoples R China; [Wu, Ke] Southern Univ Sci & Technol, Acad Interdisciplinary & Adv Studies, Inst Risk Anal Predict & Management, Shenzhen 518055, Peoples R China; [Martina, Byron] Artemis Reserch One Heath Fdn, NL-7100 Delft, Netherlands; [Bachmann, Martin F.] Univ Oxford, Jenner Inst, Old Rd Campus,Roosevelt Dr, Oxford OX3 7BN, England		Bachmann, MF (通讯作者)，Anhui Agr Univ, Int Immunol Ctr, Hefei 230036, Peoples R China.; Bachmann, MF (通讯作者)，Univ Hosp Bern, Dept Rheumatol & Immunol, CH-3010 Bern, Switzerland.; Wang, JF (通讯作者)，Chinese Acad Sci, High Magnet Field Lab, Hefei 230031, Peoples R China.; Bachmann, MF (通讯作者)，Univ Oxford, Jenner Inst, Old Rd Campus,Roosevelt Dr, Oxford OX3 7BN, England.	zhalisha@ahamedu.cn; xinyue.chang@dbmr.unibe.ch; zhx@hmfl.ac.cn; mona.mohsen@dbmr.unibe.ch; hongliang@ahau.edu.cn; huangtsian@163.com; chqchq@ahau.edu.cn; xuelan.liu@dbmr.unibe.ch; jie_zhang@sinobiological.com; dong_li@sinobiological.com; wuk@sustech.edu.cn; b.martina@artemis-biosupport.com; junfeng@hmfl.ac.cn; Monique.vogel@dbmr.unibe.ch; martin.bachmann@dbmr.unibe.ch	Chen, Hongquan/AAJ-8602-2020	Chen, Hongquan/0000-0002-8426-0672; Martina, Byron/0000-0003-4980-4619; Bachmann, Martin/0000-0003-4370-2099; zha, lisha/0000-0003-0086-897X; Mohsen, Mona/0000-0003-3510-9148	Saiba AG; Swiss National Science Foundation (SNF)Swiss National Science Foundation (SNSF) [31003A_185114]; International Immunology Centre, Anhui Agricultural University, Hefei, China	The work was supported by Saiba AG, the Swiss National Science Foundation (SNF grant 31003A_185114), and the International Immunology Centre, Anhui Agricultural University, Hefei, China.	Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5; [Anonymous], 2020, SINOVAC ANNOUNCES PO, DOI 1474985/Vaccines/Sinovac-Announces-Positive-Preliminary-Results-of-Phase-I/II-Clinical-Trials-for-Inactivated-Vaccine-Candidate-Against-COVID-19.html; [Anonymous], 2020, MODERNA ANNOUNCES PH; Bachmann M.F., 2021, BIORXIV, DOI [10.1101/2021.03.04.433887, DOI 10.1101/2021.03.04.433887]; Bachmann MF, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-020-00264-6; Bachmann MF, 2018, J ALLERGY CLIN IMMUN, V142, P279, DOI 10.1016/j.jaci.2017.12.994; Bachmann MF, 2011, PHILOS T R SOC B, V366, P2815, DOI 10.1098/rstb.2011.0103; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Bachmann MF, 1997, ANNU REV IMMUNOL, V15, P235, DOI 10.1146/annurev.immunol.15.1.235; Bachmann MF, 1996, IMMUNOL TODAY, V17, P553, DOI 10.1016/S0167-5699(96)10066-9; Barnes CO, 2020, CELL, V182, P828, DOI [10.1016/j.cell.2020.06.025, 10.1101/2020.05.28.121533]; Bentivegna E, 2021, J MED VIROL, V93, P97, DOI 10.1002/jmv.26160; Berry JD, 2010, MABS-AUSTIN, V2, P53, DOI 10.4161/mabs.2.1.10788; CGTN, RECOVERED CORONAVIRU; Chackerian B, 2001, J CLIN INVEST, V108, P415, DOI 10.1172/JCI200111849; Chang XY, 2021, ALLERGY, V76, P2895, DOI 10.1111/all.14893; Cheng VCC, 2020, INFECT CONT HOSP EP, V41, P1258, DOI 10.1017/ice.2020.282; Edridge AWD, 2020, NAT MED, V26, P1691, DOI 10.1038/s41591-020-1083-1; Fettelschoss-Gabriel A, 2018, J ALLERGY CLIN IMMUN, V142, P1194, DOI 10.1016/j.jaci.2018.01.041; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006]; Gatto D, 2005, J EXP MED, V201, P993, DOI 10.1084/jem.20042239; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI [10.1056/NEJMc2005203, 10.1056/NEJMoa2002032]; Guardian T., LATEST VACCINE SUCCE; Johansson MA, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.35057; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Ke ZL, 2020, NATURE, V588, P498, DOI 10.1038/s41586-020-2665-2; Lau EHY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20247-4; Link A, 2012, J IMMUNOL, V188, P3724, DOI 10.4049/jimmunol.1103312; Mohamed MS, 2021, ENDOCRINE, V71, P3, DOI 10.1007/s12020-020-02536-6; Mohsen MO, 2020, IMMUNOL REV, V296, P155, DOI 10.1111/imr.12863; News B., 2021, COVID WHAT WE KNOW C; Ostergaard S., 2021, SCIENTIST, DOI [10.1016/s0140-6736(21)00762-5, DOI 10.1016/S0140-6736(21)00762-5, 10.1016/S0140-6736(21)00762-5]; Pharma G., ANTIBODIES SARS COV; Plummer EM, 2011, WIRES NANOMED NANOBI, V3, P174, DOI 10.1002/wnan.119; Rabaan Ali A, 2020, Infez Med, V28, P174; Salathe M, 2020, SWISS MED WKLY, V150, DOI [10.4414/smw.20457, 10.4414/smw.2020.20457]; Sariol A, 2020, IMMUNITY, V53, P248, DOI 10.1016/j.immuni.2020.07.005; Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y; Simmons-Duffin S., WHY DOES PFIZERS COV; Speiser DE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030404; Sternberg A, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118056; Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Thevarajan I, 2020, NAT MED, V26, P453, DOI 10.1038/s41591-020-0819-2; Vignuzzi M, 2008, NAT MED, V14, P154, DOI 10.1038/nm1726; Wee S., CORONAVIRUS VACCINE; Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582; Zeltins A, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0030-8	50	8	8	3	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							395	10.3390/vaccines9040395			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4WR	33923573	gold, Green Published			2022-04-29	WOS:000643781900001
J	Hwang, HS; Lee, YT; Kim, KH; Seo, HS; Yang, KS; Cho, H; Kang, SM				Hwang, Hye Suk; Lee, Young-Tae; Kim, Ki-Hye; Seo, Ho Seong; Yang, Kap Seung; Cho, Hoonsung; Kang, Sang-Moo			Roles of the Fc Receptor gamma-Chain in Inducing Protective Immune Responses after Heterologous Vaccination against Respiratory Syncytial Virus Infection	VACCINES			English	Article						Fc receptor; RSV F-virus-like particles; cytotoxic T-cells		The roles of the Fc receptor (FcR) in protection or inflammatory disease after respiratory syncytial virus (RSV) vaccination and infection remain unknown. Virus-like particles containing RSV fusion proteins (RSV F-VLPs) induce T-helper type 1 antibody responses and protection against RSV. Heterologous RSV F-VLP prime and formalin-inactivated RSV (FI-RSV) boost vaccination has been reported to be effective in providing protection without inflammatory disease. Here, we investigated whether the FcR gamma-chain is important for immune protection by the heterologous F-VLP and FI-RSV vaccination using FcR gamma-chain knockout (-/-) mice. RSV F-VLP-primed and FI-RSV-boosted FcR gamma -/- mice displayed less protective efficacy, as shown by higher lung viral titers upon RSV challenge, compared to RSV F-VLP-primed and FI-RSV-boosted immunized wild-type mice. RSV F-VLP and FI-RSV immunization induced lower levels of neutralizing activity and interferon-gamma-producing CD8 T-cells in the bronchoalveolar lavage cells of FcR gamma -/- mice than in those of wild-type mice. In addition, FcR gamma -/- mice displayed a trend of enhancing lung histopathology after RSV vaccination and infection. This study suggests that the FcR gamma-chain plays an important role in inducing antiviral protection and CD8 T-cell responses in RSV F-VLP prime and FI-RSV boost vaccination after RSV infections.	[Hwang, Hye Suk; Yang, Kap Seung; Cho, Hoonsung] Chonnam Natl Univ, Alan G MacDiarmid Energy Res Inst, Gwangju 61186, South Korea; [Hwang, Hye Suk; Cho, Hoonsung] Chonnam Natl Univ, Sch Mat Sci & Engn, Gwangju 61186, South Korea; [Hwang, Hye Suk; Lee, Young-Tae; Kim, Ki-Hye; Kang, Sang-Moo] Georgia State Univ, Inst Biomed Sci, Ctr Inflammat Immun & Infect, Atlanta, GA 30303 USA; [Seo, Ho Seong] Korea Atom Energy Res Inst, Res Div Radiat Sci, Jeongeup 56212, South Korea; [Yang, Kap Seung] Chonnam Natl Univ, Sch Polymer Sci & Engn, Grad Sch, Dept Polymer Engn, Gwangju 61186, South Korea		Cho, H (通讯作者)，Chonnam Natl Univ, Alan G MacDiarmid Energy Res Inst, Gwangju 61186, South Korea.; Cho, H (通讯作者)，Chonnam Natl Univ, Sch Mat Sci & Engn, Gwangju 61186, South Korea.; Kang, SM (通讯作者)，Georgia State Univ, Inst Biomed Sci, Ctr Inflammat Immun & Infect, Atlanta, GA 30303 USA.	hshwang33@chonnam.ac.kr; hshwang33@chonnam.ac.kr; kihyekim4282@gmail.com; hoseongseo@kaeri.re.kr; ksyang@jnu.ac.kr; cho.hoonsung@jnu.ac.kr; skang24@gsu.edu		Cho, Hoonsung/0000-0003-0778-5640; Seo, Ho Seong/0000-0002-7103-1344	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2019R1I1A1A01061532]; National Institutes of Health/National Institute of Allergy and Infectious DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI093772, AI147042, AI152800]	This research was partially supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2019R1I1A1A01061532) (H.S.H.), the National Institutes of Health/National Institute of Allergy and Infectious Diseases grants AI093772 (S.M.K.), AI147042 (S.M.K.), and AI152800 (S.M.K).	Acevedo OA, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00075; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Blanco JCG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04216-6; Bournazos S, 2020, NAT REV IMMUNOL, V20, P633, DOI 10.1038/s41577-020-00410-0; Bournazos S, 2017, IMMUNITY, V47, P224, DOI 10.1016/j.immuni.2017.07.009; Bukreyev A, 2008, J VIROL, V82, P12191, DOI 10.1128/JVI.01604-08; CANNON MJ, 1989, J GEN VIROL, V70, P79, DOI 10.1099/0022-1317-70-1-79; Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007; Cimica V, 2016, CLIN VACCINE IMMUNOL, V23, P451, DOI 10.1128/CVI.00720-15; Deng L, 2015, VACCINES-BASEL, V3, P105, DOI 10.3390/vaccines3010105; DiLillo DJ, 2016, J CLIN INVEST, V126, P605, DOI 10.1172/JCI84428; Gomez RS, 2016, IMMUNOLOGY, V147, P55, DOI 10.1111/imm.12541; GRAHAM BS, 1993, J IMMUNOL, V151, P2032; Halstead SB, 2010, LANCET INFECT DIS, V10, P712, DOI 10.1016/S1473-3099(10)70166-3; Hemann EA, 2013, J IMMUNOL, V191, P2486, DOI 10.4049/jimmunol.1300954; Hoffmann E, 2012, P NATL ACAD SCI USA, V109, P14556, DOI 10.1073/pnas.1203912109; Hoft DF, 2016, J INFECT DIS, V214, P1020, DOI 10.1093/infdis/jiw310; Hwang BS, 2017, VIROLOGY, V511, P142, DOI 10.1016/j.virol.2017.08.022; Hwang HS, 2014, ANTIVIR RES, V110, P115, DOI 10.1016/j.antiviral.2014.07.016; Jans J, 2014, REV MED VIROL, V24, P55, DOI 10.1002/rmv.1773; Jiang SS, 2002, J GEN VIROL, V83, P429, DOI 10.1099/0022-1317-83-2-429; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Kim KH, 2015, J VIROL, V89, P11692, DOI 10.1128/JVI.02018-15; Kim MC, 2014, MOL THER, V22, P1364, DOI 10.1038/mt.2014.33; Kim MC, 2013, ANTIVIR RES, V99, P328, DOI 10.1016/j.antiviral.2013.06.010; Ko EJ, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e51; Ko EJ, 2015, NANOMED-NANOTECHNOL, V11, P99, DOI 10.1016/j.nano.2014.07.013; Lambert L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00466; Lee YN, 2014, IMMUNOLOGY, V143, P300, DOI 10.1111/imm.12310; Lodoen MB, 2005, NAT REV MICROBIOL, V3, P59, DOI 10.1038/nrmicro1066; McGinnes Lori W, 2013, Curr Protoc Microbiol, V30, DOI 10.1002/9780471729259.mc1802s30; McGinnes LW, 2011, J VIROL, V85, P366, DOI 10.1128/JVI.01861-10; Mejias A, 2008, BIOL-TARGETS THER, V2, P433; Meyerholz DK, 2009, TOXICOL PATHOL, V37, P249, DOI 10.1177/0192623308329342; Morris AB, 2020, IMMUNITY, V52, P136, DOI 10.1016/j.immuni.2019.12.006; Murawski MR, 2010, J VIROL, V84, P1110, DOI 10.1128/JVI.01709-09; Olson MR, 2008, EXPERT REV VACCINES, V7, P1239, DOI 10.1586/14760584.7.8.1239; Polack FP, 2002, J EXP MED, V196, P859, DOI 10.1084/jem.20020781; Quan FS, 2011, J INFECT DIS, V204, P987, DOI 10.1093/infdis/jir474; Radu GU, 2010, J VIROL, V84, P9632, DOI 10.1128/JVI.00451-10; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Ruckwardt TJ, 2019, IMMUNITY, V51, P429, DOI 10.1016/j.immuni.2019.08.007; Skibinski DAG, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36703-7; Song AH, 2014, ANTIVIR RES, V111, P60, DOI 10.1016/j.antiviral.2014.08.016; Stokes KL, 2011, J VIROL, V85, P5782, DOI 10.1128/JVI.01693-10; Storni T, 2002, J IMMUNOL, V168, P2880, DOI 10.4049/jimmunol.168.6.2880; Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152; Tang AM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12137-1; Tay MZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00332; van Erp EA, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1112; van Erp EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00548; Win SJ, 2011, IMMUNOL CELL BIOL, V89, P681, DOI 10.1038/icb.2010.161; Zepeda-Cervantes J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01100	53	0	0	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							232	10.3390/vaccines9030232			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5AG	33800349	gold, Green Published			2022-04-29	WOS:000634166200001
J	Razim, A; Pyclik, M; Pacyga, K; Gorska, S; Xu, JT; Olszewski, MA; Gamian, A; Myc, A				Razim, Agnieszka; Pyclik, Marcelina; Pacyga, Katarzyna; Gorska, Sabina; Xu, Jintao; Olszewski, Michal A.; Gamian, Andrzej; Myc, Andrzej			Silicone Oil-Based Nanoadjuvants as Candidates for a New Formulation of Intranasal Vaccines	VACCINES			English	Article						adjuvant; intranasal administration; cationic surfactant; emulsion; antigen; bioadhesion		Many conventional vaccines are administered via a needle injection, while most pathogens primarily invade the host via mucosal surfaces. Moreover, protective IgA antibodies are insufficiently induced by parenteral vaccines. Mucosal immunity induces both local and systemic response to pathogens and typically lasts for long periods of time. Therefore, vaccination via mucosal routes has been increasingly explored. However, mucosal vaccines require potent adjuvants to become efficacious. Despite many efforts to develop safe and robust adjuvants for mucosal vaccines, only a few have been approved for use in human formulations. The aim of our study was to design, develop and characterize new silicone oil-based nanoadjuvant candidates for intranasal vaccines with potential to become mucosal adjuvants. We have developed an array of nanoadjuvant candidates (NACs), based on well-defined ingredients. NAC1, 2 and 3 are based on silicone oil, but differ in the used detergents and organic solvents, which results in variations in their droplet size and zeta potential. NACs' cytotoxicity, Tumor Necrosis Factor alpha (TNF-alpha) induction and their effect on antigen engulfment by immune cells were tested in vitro. Adjuvant properties of NACs were verified by intranasal vaccination of mice together with ovalbumin (OVA). NACs show remarkable stability and do not require any special storage conditions. They exhibit bio-adhesiveness and influence the degree of model protein engulfment by epithelial cells. Moreover, they induce high specific anti-OVA IgG antibody titers after two intranasal administrations. Nanoadjuvant candidates composed of silicone oil and cationic detergents are stable, exhibit remarkable adjuvant properties and can be used as adjuvants for intranasal immunization.	[Razim, Agnieszka; Pyclik, Marcelina; Pacyga, Katarzyna; Gorska, Sabina] Polish Acad Sci, Hirszfeld Inst Immunol & Expt Therapy, Dept Microbiol, PL-53114 Wroclaw, Poland; [Xu, Jintao; Olszewski, Michal A.] Univ Michigan Hlth Syst, Div Pulm & Crit Care Med, Dept Internal Med, Ann Arbor, MI 48109 USA; [Xu, Jintao; Olszewski, Michal A.] Dept Vet Affairs Ann Arbor Healthcare Syst, Res Serv, Ann Arbor, MI 48105 USA; [Gamian, Andrzej; Myc, Andrzej] Polish Acad Sci, Dept Immunol Infect Dis, Hirszfeld Inst Immunol & Expt Therapy, PL-53114 Wroclaw, Poland; [Myc, Andrzej] Univ Michigan, Dept Internal Med, MNIMBS, Ann Arbor, MI 48109 USA		Razim, A (通讯作者)，Polish Acad Sci, Hirszfeld Inst Immunol & Expt Therapy, Dept Microbiol, PL-53114 Wroclaw, Poland.	agnieszka.razim@hirszfeld.pl; marcelina.pyclik@hirszfeld.pl; katarzyna.pacyga@hirszfeld.pl; sabina.gorska@hirszfeld.pl; jintaoxu@med.umich.edu; olszewsm@med.umich.edu; andrzej.gamian@hirszfeld.pl; myca@umich.edu	Razim, Agnieszka/AAH-5637-2019	Razim, Agnieszka/0000-0001-5471-7013; Pacyga-Prus, Katarzyna/0000-0002-9400-9297; Gorska, Sabina/0000-0002-3206-0695; OLSZEWSKI, MICHAL/0000-0001-7474-0843; Pyclik, Marcelina/0000-0002-2783-2830; Gamian, Andrzej/0000-0002-2206-6591	National Science Centre PolandNational Science Centre, Poland [2015/17/N/NZ6/03512]; Ministry of Science and Higher Education Republic of Poland (KNOW); U.S. Department of Veteran's Affairs Grants [I01BX000656, IK6BX00361501]	This research was funded by grant 2015/17/N/NZ6/03512 funded by National Science Centre Poland, travel grant for AR financed by Ministry of Science and Higher Education Republic of Poland (KNOW) and by U.S. Department of Veteran's Affairs Grants (I01BX000656 and IK6BX00361501 to M.A.O.).	Aoshi T, 2017, VIRAL IMMUNOL, V30, P463, DOI 10.1089/vim.2017.0026; Arora P, 2002, DRUG DISCOV TODAY, V7, P967, DOI 10.1016/S1359-6446(02)02452-2; Bhattacharjee S, 2016, J CONTROL RELEASE, V235, P337, DOI 10.1016/j.jconrel.2016.06.017; Bielinska AU, 2014, J IMMUNOL, V192, P2722, DOI 10.4049/jimmunol.1301424; Boyaka PN, 2017, J IMMUNOL, V199, P9, DOI 10.4049/jimmunol.1601775; Chen DX, 2009, EXPERT REV VACCINES, V8, P547, DOI [10.1586/erv.09.20, 10.1586/ERV.09.20]; Christensen D, 2010, INT J PHARMACEUT, V390, P19, DOI 10.1016/j.ijpharm.2009.10.043; Cox JC, 1997, VACCINE, V15, P248, DOI 10.1016/S0264-410X(96)00183-1; Das SC, 2012, VACCINE, V30, P6871, DOI 10.1016/j.vaccine.2012.09.007; DAVENPORT FM, 1968, J IMMUNOL, V100, P1139; Even-Or O, 2011, VACCINE, V29, P2474, DOI 10.1016/j.vaccine.2011.01.009; Falkeborn T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070527; FDA, COMM INGR US LIC VAC; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Gregg KA, 2017, MBIO, V8, DOI [10.1128/mBio.00492-17, 10.1128/mbio.00492-17]; GUPTA RK, 1995, VACCINE, V13, P1263, DOI 10.1016/0264-410X(95)00011-O; Hanot CC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010054; He CB, 2010, BIOMATERIALS, V31, P3657, DOI 10.1016/j.biomaterials.2010.01.065; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Huber VC, 2006, CLIN VACCINE IMMUNOL, V13, P981, DOI 10.1128/CVI.00156-06; Jadhav K.R., NASAL DRUG DELIVERY; JERTBORN M, 1986, J CLIN MICROBIOL, V24, P203, DOI 10.1128/JCM.24.2.203-209.1986; Johnson-Weaver BT, 2020, MUCOSAL VACCINES: INNOVATION FOR PREVENTING INFECTIOUS DISEASES, 2ND EDITION, P167, DOI 10.1016/B978-0-12-811924-2.00010-9; Kesimer M, 2012, METHODS MOL BIOL, V842, P67, DOI 10.1007/978-1-61779-513-8_4; Khutoryanskiy VV, 2011, MACROMOL BIOSCI, V11, P748, DOI 10.1002/mabi.201000388; Kim SH, 2017, CLIN EXP VACCINE RES, V6, P15, DOI [10.7774/cevr.2017.6.1.15., 10.7774/cevr.2017.6.1.15]; Lambert SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051618; Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51; LEUNG SHS, 1990, J CONTROL RELEASE, V12, P187, DOI 10.1016/0168-3659(90)90099-F; Liu H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069649; Makidon PE, 2012, EUR J IMMUNOL, V42, P2073, DOI 10.1002/eji.201142346; Man AL, 2004, IMMUNOLOGY, V113, P15, DOI 10.1111/j.1365-2567.2004.01964.x; MCNEAL MM, 1994, VIROLOGY, V204, P642, DOI 10.1006/viro.1994.1579; Myc A, 2003, VACCINE, V21, P3801, DOI 10.1016/S0264-410X(03)00381-5; Myc A, 2013, VACCINE, V31, P1072, DOI 10.1016/j.vaccine.2012.12.033; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; Pine S, 2002, J CONTROL RELEASE, V85, P263, DOI 10.1016/S0168-3659(02)00274-2; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Reed SG, 2016, CURR OPIN IMMUNOL, V41, P85, DOI 10.1016/j.coi.2016.06.007; Schijns VEJC, 2001, CRIT REV IMMUNOL, V21, P75; Shao XR, 2015, CELL PROLIFERAT, V48, P465, DOI 10.1111/cpr.12192; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.2307/2333709; Shi Y, 2000, P NATL ACAD SCI USA, V97, P14590, DOI 10.1073/pnas.260497597; Skwarczynski M, 2020, EXPERT OPIN DRUG DEL, V17, P435, DOI 10.1080/17425247.2020.1731468; Slutter B, 2008, J DRUG TARGET, V16, P1, DOI [10.1080/10611860701637966, 10.1080/10611860701637966 ]; Splawn LM, 2018, DRUG TODAY, V54, P399, DOI 10.1358/dot.2018.54.7.2833984; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; Stenfeldt AL, 2004, IMMUNOLOGY, V112, P605, DOI 10.1111/j.1365-2567.2004.01906.x; Tritto E, 2009, VACCINE, V27, P3331, DOI 10.1016/j.vaccine.2009.01.084; Tropea C., 2007, SPRINGER HDB EXPT FL; Velazquez FR, 2000, J INFECT DIS, V182, P1602, DOI 10.1086/317619; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wanten GJ, 2001, JPEN-PARENTER ENTER, V25, P352, DOI 10.1177/0148607101025006352; Watanabe I, 2002, VACCINE, V20, P3443, DOI 10.1016/S0264-410X(02)00351-1; Wong PT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126120; Wong PT, 2014, MOL PHARMACEUT, V11, P531, DOI 10.1021/mp4005029; Yang SC, 2000, DRUG DEVELOP RES, V50, P476, DOI 10.1002/1098-2299(200007/08)50:3/4<476::AID-DDR31>3.0.CO;2-6	60	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							234	10.3390/vaccines9030234			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5DL	33800507	gold, Green Published			2022-04-29	WOS:000634174500001
J	Rogliani, P; Chetta, A; Cazzola, M; Calzetta, L				Rogliani, Paola; Chetta, Alfredo; Cazzola, Mario; Calzetta, Luigino			SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines	VACCINES			English	Review						COVID-19; network meta-analysis; neutralizing antibodies; SARS-CoV-2; vaccine	INCONSISTENCY; IMMUNOGENICITY; SAFETY	Background: There are no studies providing head-to-head comparison across SARS-CoV-2 vaccines. Therefore, we compared the efficacy of candidate vaccines in inducing neutralizing antibodies against SARS-CoV-2. Methods: A network meta-analysis was performed to compare the peak levels of SARS-CoV-2 neutralizing antibodies across candidate vaccines. Data were reported as standardized mean difference (SMD) since the outcome was assessed via different metrics and methods across the studies. Results: Data obtained from 836 healthy adult vaccine recipients were extracted from 11 studies. BBIBP-CorV, AZD1222, BNT162b2, New Crown COVID-19, and Sputnik V induced a very large effect on the level of neutralizing antibodies (SMD > 1.3); CoVLP, CoronaVac, NVX-CoV2373, and Ad5-nCoV induced a large effect (SMD > 0.8 to <= 1.3); and Ad26.COV2.S induced a medium effect (SMD > 0.5 to <= 0.8). BBIBP-CorV and AZD122 were more effective (p < 0.05) than Ad26.COV2.S, Ad5-nCoV, mRNA-1237, CoronaVac, NVX-CoV2373, CoVLP, and New Crown COVID-19; New Crown COVID-19 was more effective (p < 0.05) than Ad26.COV2.S, Ad5-nCoV, and mRNA-1237; CoronaVac was more effective (p < 0.05) than Ad26.COV2.S and Ad5-nCoV; and Sputnik V and BNT162b2 were more effective (p < 0.05) than Ad26.COV2.S. In recipients aged <= 60 years, AZD1222, BBIBP-CorV, and mRNA-1237 were the most effective candidate vaccines. Conclusion: All the candidate vaccines induced significant levels of SARS-CoV-2 neutralizing antibodies, but only AZD1222 and mRNA-1237 were certainly tested in patients aged >= 70 years. Compared with AZD1222, BNT162b and mRNA-1237 have the advantage that they can be quickly re-engineered to mimic new mutations of SARS-CoV-2.	[Rogliani, Paola; Cazzola, Mario] Univ Roma Tor Vergata, Dept Expt Med, Resp Med Unit, I-00133 Rome, Italy; [Chetta, Alfredo; Calzetta, Luigino] Univ Parma, Dept Med & Surg, Resp Dis & Lung Funct Unit, I-43126 Parma, Italy		Calzetta, L (通讯作者)，Univ Parma, Dept Med & Surg, Resp Dis & Lung Funct Unit, I-43126 Parma, Italy.	paola.rogliani@uniroma2.it; alfredoantonio.chetta@unipr.it; mario.cazzola@uniroma2.it; luigino.calzetta@unipr.it	Cazzola, Mario/ABD-9998-2021	Cazzola, Mario/0000-0003-4895-9707			ALJAZZERA, BAHR BEC 2 COUNTR AP; ALJAZZERA, MEX APPR EM US PFIZ; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Andrade C, 2020, J CLIN PSYCHIAT, V81, DOI 10.4088/JCP.20f13681; [Anonymous], TIMES ISRAEL; [Anonymous], NTR; [Anonymous], Q MEDIA; [Anonymous], RIO TIMES; [Anonymous], THE JAPAN TIMES; AstraZeneca, ASTRAZENECAS COVID 1; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Calzetta L, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0043-2016; Cohen J., 1992, CURR DIR PSYCHOL SCI, V1, P98, DOI [10.1007/978-94-011-2546-8_20, DOI 10.1007/978-94-011-2546-8_20, DOI 10.1111/1467-8721.EP10768783]; Cyranoski D, 2020, NATURE, V588, P548, DOI 10.1038/d41586-020-03563-z; Dias S, 2013, MED DECIS MAKING, V33, P641, DOI 10.1177/0272989X12455847; Dobler CC, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.00525-2018; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; European Medicines Agency, EMA REC COVID 19 VAC; European Medicines Agency, EMA REC 1 COVID 19 V; Gamaleya National Center of Epidemiology and Microbiology, ARGENTINA HAS REGIST; Gamaleya National Center of Epidemiology and Microbiology, BELARUS STARTS VACCI; Gavi, GAV COVAX AMC INV OP; Gianinazzi ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124290; Government of Canada, MOD COVID 19 VACC MR; Government of Canada, REG DEC SUMM PFIZ BI; Guyatt G, 2011, J CLIN EPIDEMIOL, V64, P383, DOI 10.1016/j.jclinepi.2010.04.026; Higgins J., 2019, COCHRANE HDB SYSTEMA, V2nd; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; INOVIO, PHARM INOVIO ADV ANN; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Ji ZH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02089; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Koppaka Ram, 2011, Morbidity and Mortality Weekly Report, V60, P619; Kuwait News Agency (KUNA), KUW AUTH EM US PFIZ; Le TT, 2020, NAT REV DRUG DISCOV, V19, P667, DOI 10.1038/d41573-020-00151-8; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Lu GB, 2006, J AM STAT ASSOC, V101, P447, DOI 10.1198/016214505000001302; McGuinness L.A., ROBVIS R PACKAGE WEB; Miller J., DRUGMAKERS EXPECT TE; Pedder H, 2016, SYST REV, V5, DOI 10.1186/s13643-016-0368-4; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Reuters,, REUTERS; Rogliani P, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00625-2020; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Schardt C, 2007, BMC MED INFORM DECIS, V7, DOI 10.1186/1472-6947-7-16; Schmall E., INDIA APPROVES OXFOR; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Spiegelhalter D.J., 2004, BAYESIAN APPROACHES, VVolume 13; Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898; Swiss Agency for Therapeutic Products, SWISSM GRANTS AUTH 1; Tanne JH, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4836; Thomas K., CLEARS PFIZER VACCIN; Truyers, 2020, SAFETY IMMUNOGENICIT, DOI [10.1101/2020.09.23.20199604, DOI 10.1101/2020.09.23.20199604, 10.1101/2020.09.23.20199604v1]; van Valkenhoef G, 2016, RES SYNTH METHODS, V7, P80, DOI 10.1002/jrsm.1167; van Valkenhoef G, 2012, RES SYNTH METHODS, V3, P285, DOI 10.1002/jrsm.1054; Vogler I, 2020, BNT 162B2 INDUCES SA, DOI [10.1101/2020.12.09.20245175, DOI 10.1101/2020.12.09.20245175]; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wallace BC, 2012, J STAT SOFTW, V49, P1, DOI 10.18637/jss.v049.i05; Ward B.J., 2020, PHASE 1 TRIAL CANDID, DOI [DOI 10.1101/2020.11.04.20226282, 10.1101/2020.11.04.20226282]; World Health Organization, DRAFT LANDSC COVID 1; Wu H., CHINA GIVES CONDITIO; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6	70	18	19	8	27	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							227	10.3390/vaccines9030227			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5AK	33807818	Green Published, gold			2022-04-29	WOS:000634166600001
J	Verelst, F; Kessels, R; Willem, L; Beutels, P				Verelst, Frederik; Kessels, Roselinde; Willem, Lander; Beutels, Philippe			No Such Thing as a Free-Rider? Understanding Drivers of Childhood and Adult Vaccination through a Multicountry Discrete Choice Experiment	VACCINES			English	Article						vaccination; infectious disease; behavior; free-riding; social norms; discrete choice experiment		Increased vaccine hesitancy and refusal negatively affects vaccine uptake, leading to the reemergence of vaccine preventable diseases. We aim to quantify the relative importance of factors people consider when making vaccine decisions for themselves, or for their child, with specific attention for underlying motives arising from context, such as required effort (accessibility) and opportunism (free riding on herd immunity). We documented attitudes towards vaccination and performed a discrete choice experiment in 4802 respondents in The United Kingdom, France and Belgium, eliciting preferences for six attributes: (1) vaccine effectiveness, (2) vaccine preventable disease burden, (3) vaccine accessibility in terms of copayment, vaccinator and administrative requirements, (4) frequency of mild vaccine-related side-effects, (5) vaccination coverage in the country's population and (6) local vaccination coverage in personal networks. We distinguished adults deciding on vaccination for themselves from parents deciding for their youngest child. While all attributes were found to be significant, vaccine effectiveness and accessibility stood out in all (sub)samples, followed by vaccine preventable disease burden. We confirmed that people attach more value to severity of disease compared to its frequency, and discovered that peer influence dominates free-rider motives, especially for the vaccination of children. These behavioral data are insightful for policy and are essential to parameterize dynamic vaccination behavior in simulation models. In contrast to what most game theoretical models assume, social norms dominate free-rider incentives. Policy-makers and healthcare workers should actively communicate on high vaccination coverage, and draw attention to the effectiveness of vaccines while optimizing their practical accessibility.	[Verelst, Frederik; Willem, Lander; Beutels, Philippe] Univ Antwerp, Vaccine & Infect Dis Inst VAXINFECTIO, Ctr Hlth Econ Res & Modelling Infect Dis CHERMID, B-2610 Antwerp, Belgium; [Kessels, Roselinde] Maastricht Univ, Dept Data Analyt & Digitalizat, NL-6200 MD Maastricht, Netherlands; [Kessels, Roselinde] Univ Antwerp, Dept Econ, B-2000 Antwerp, Belgium; [Beutels, Philippe] Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW 2052, Australia		Verelst, F (通讯作者)，Univ Antwerp, Vaccine & Infect Dis Inst VAXINFECTIO, Ctr Hlth Econ Res & Modelling Infect Dis CHERMID, B-2610 Antwerp, Belgium.	frederik.verelst@uantwerpen.be; r.kessels@maastrichtuniversity.nl; lander.willem@uantwerpen.be; philippe.beutels@uantwerpen.be	Kessels, Roselinde/N-8479-2016; Willem, Lander/AAC-4658-2019; Beutels, Philippe/A-1919-2010	Kessels, Roselinde/0000-0002-4534-0047; Willem, Lander/0000-0002-9210-1196; Beutels, Philippe/0000-0001-5034-3595; Verelst, Frederik/0000-0001-8399-743X	Antwerp Study Centre for Infectious Diseases (ASCID) at the University of Antwerp; Research Foundation Flanders (FWO)FWO [G043815N, 123460N]; JMP Division of SAS Institute (Cary, NA, USA)	P.B., F.V. and L.W. acknowledge support of the Antwerp Study Centre for Infectious Diseases (ASCID) at the University of Antwerp. F.V. and L.W. are supported by the Research Foundation Flanders (FWO), F.V. and L.W. by project no. G043815N and L.W. by his postdoctoral fellowship (123460N). R.K. is grateful for financial support from the JMP Division of SAS Institute (Cary, NA, USA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amirthalingam G, 2013, EUROSURVEILLANCE, V18, P19, DOI 10.2807/1560-7917.ES2013.18.38.20587; [Anonymous], 2019, JMP VERS PRO 14; Bishai D, 2007, PHARMACOECONOMICS, V25, P143, DOI 10.2165/00019053-200725020-00006; Bults M, 2011, BMC PUBLIC HEALTH, V11, DOI [10.1186/1471-2458-11-2, 10.1186/1471-2458-11-165]; CDC (Centers for Disease Control and Prevention), 2018, MEASL MUMPS RUB MMR; Chew LD, 2004, FAM MED, V36, P588; de Bekker-Grob EW, 2019, VALUE HEALTH, V22, P1050, DOI 10.1016/j.jval.2019.04.1924; de Bekker-Grob EW, 2012, HEALTH ECON, V21, P145, DOI 10.1002/hec.1697; de Bekker-Grob EW, 2010, VACCINE, V28, P6692, DOI 10.1016/j.vaccine.2010.08.001; Determann D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102505; European Centre for Disease Prevention and Control, 2019, WHO IS RISK MEASL EU; European Statistical System (ESS), 2011, CENS HUB 2011; Funk S, 2018, EPIDEMICS-NETH, V22, P56, DOI 10.1016/j.epidem.2016.11.003; Funk S, 2015, EPIDEMICS-NETH, V10, P21, DOI 10.1016/j.epidem.2014.09.005; Funk S, 2010, J R SOC INTERFACE, V7, P1247, DOI 10.1098/rsif.2010.0142; Gallup, 2019, WELLC GLOB MON 1 WAV; Gidengil C, 2012, VACCINE, V30, P3445, DOI 10.1016/j.vaccine.2012.03.022; Godlee F, 2011, BRIT MED J, V342, DOI 10.1136/bmj.c7452; Hakim H, 2011, VACCINE, V29, P5963, DOI 10.1016/j.vaccine.2011.06.041; Hall J, 2002, HEALTH ECON, V11, P457, DOI 10.1002/hec.694; Hoogink J, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08844-w; Hulsey E, 2015, VACCINE, V33, P2546, DOI 10.1016/j.vaccine.2015.04.020; Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022; Kessels R, 2011, APPL STOCH MODEL BUS, V27, P173, DOI 10.1002/asmb.906; Kuylen E, 2019, LECT NOTES COMPUT SC, V11536, P456, DOI 10.1007/978-3-030-22734-0_33; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Leask J, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-154; Lefevere E, 2016, EUR J HEALTH ECON, V17, P305, DOI 10.1007/s10198-015-0680-2; Nelson R, 2019, LANCET INFECT DIS, V19, P248, DOI 10.1016/S1473-3099(19)30074-X; Oteng B, 2011, SEX TRANSM INFECT, V87, P52, DOI 10.1136/sti.2009.041392; Patel M, 2019, MMWR-MORBID MORTAL W, V68, P402, DOI 10.15585/mmwr.mm6817e1; Peretti-Watel P, 2013, EUROSURVEILLANCE, V18, P15, DOI 10.2807/1560-7917.ES2013.18.44.20623; Poland GA, 2011, NEW ENGL J MED, V364, P97, DOI 10.1056/NEJMp1010594; Poulos C, 2018, VACCINE, V36, P969, DOI 10.1016/j.vaccine.2018.01.004; R Studio Team, 2015, RSTUDIO INT DEV ENV; Ruijs WLM, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-102; Sadique MZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054149; Shim E, 2012, J R SOC INTERFACE, V9, P2234, DOI 10.1098/rsif.2012.0115; Skea ZC, 2008, SOC SCI MED, V67, P1382, DOI 10.1016/j.socscimed.2008.07.006; Spier RE, 2001, VACCINE, V20, pS78, DOI 10.1016/S0264-410X(01)00306-1; Tafforeau J., 2015, GEZONDHEIDSENQUETE 2; Tjalma WAA, 2018, FACTS VIEWS VIS OBGY, V10, P101; Trentini F, 2017, LANCET INFECT DIS, V17, P1089, DOI 10.1016/S1473-3099(17)30421-8; Verelst F, 2019, VACCINE, V37, P2079, DOI 10.1016/j.vaccine.2019.02.056; Verelst F, 2018, SOC SCI MED, V207, P106, DOI 10.1016/j.socscimed.2018.04.038; Verelst F, 2016, J R SOC INTERFACE, V13, DOI 10.1098/rsif.2016.0820; Vermeulen C., 2017, VLAAMS INFECTIEZIEKT, V2, P6; Vietri JT, 2012, MED DECIS MAKING, V32, P447, DOI 10.1177/0272989X11427762; Ward JK, 2015, VACCINE, V33, P1063, DOI 10.1016/j.vaccine.2014.12.064; Wong CKH, 2018, VALUE HEALTH, V21, P622, DOI 10.1016/j.jval.2017.10.012; World Health Organization, 2019, GLOB VACC SAF ADV EV; World Health Organization (WHO), HLTH TOP IMM	53	2	2	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							264	10.3390/vaccines9030264			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	RE6DQ	33809589	Green Published, gold			2022-04-29	WOS:000634242600001
J	Wolf, J; Jannat, R; Dubey, S; Troth, S; Onorato, MT; Coller, BA; Hanson, ME; Simon, JK				Wolf, Jayanthi; Jannat, Risat; Dubey, Sheri; Troth, Sean; Onorato, Matthew T.; Coller, Beth-Ann; Hanson, Mary E.; Simon, Jakub K.			Development of Pandemic Vaccines: ERVEBO Case Study	VACCINES			English	Review						Ebolavirus vaccine; rVSVDG-ZEBOV-GP; vaccine development; regulatory strategy; vaccine manufacturing		Preventative vaccines are considered one of the most cost-effective and efficient means to contain outbreaks and prevent pandemics. However, the requirements to gain licensure and manufacture a vaccine for human use are complex, costly, and time-consuming. The 2013-2016 Ebola virus disease (EVD) outbreak was the largest EVD outbreak to date and the third Public Health Emergency of International Concern in history, so to prevent a pandemic, numerous partners from the public and private sectors combined efforts and resources to develop an investigational Zaire ebolavirus (EBOV) vaccine candidate (rVSV Delta G-ZEBOV-GP) as quickly as possible. The rVSV Delta G-ZEBOV-GP vaccine was approved as ERVEBO (TM) by the European Medicines Authority (EMA) and the United States Food and Drug Administration (FDA) in December 2019 after five years of development. This review describes the development program of this EBOV vaccine, summarizes what is known about safety, immunogenicity, and efficacy, describes ongoing work in the program, and highlights learnings applicable to the development of pandemic vaccines.	[Wolf, Jayanthi] Merck & Co Inc, Regulatory Affairs, Kenilworth, NJ 07033 USA; [Jannat, Risat] Merck & Co Inc, Global Vaccines & Biol Commercializat, Kenilworth, NJ 07033 USA; [Dubey, Sheri] Merck & Co Inc, Pharmacokinet Pharmacodynam & Drug Metab, Kenilworth, NJ 07033 USA; [Troth, Sean] Merck & Co Inc, Dept Safety Assessment & Lab Anim Resources, Kenilworth, NJ 07033 USA; [Onorato, Matthew T.] Merck & Co Inc, Global Clin Trial Operat, Vaccines, Kenilworth, NJ 07033 USA; [Coller, Beth-Ann; Simon, Jakub K.] Merck & Co Inc, Global Clin Dev, Kenilworth, NJ 07033 USA; [Hanson, Mary E.] Merck & Co Inc, Global Sci & Med Publicat, Kenilworth, NJ 07033 USA		Simon, JK (通讯作者)，Merck & Co Inc, Global Clin Dev, Kenilworth, NJ 07033 USA.	jayanthiwolf@gmail.com; risat_jannat@merck.com; sheri_dubey@merck.com; sean_troth@merck.com; matthew_onorato@merck.com; Beth-ann.coller@merck.com; mary.hanson@merck.com; jakub.simon@merck.com		Troth, Sean/0000-0002-4696-5129; Wolf, Jayanthi/0000-0002-2837-8262	Department of Health and Human Services; Office of the Assistant Secretary of Preparedness and Response; Biomedical Advanced Research and Development Authority [HHSO10201500002C, HHSO10201600031C, HHSO10201700012C]; Department of Defense, Defense Threat Reduction AgencyUnited States Department of DefenseDefense Threat Reduction Agency [HDTRA1-15-C-0058]	This project has been funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary of Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract Numbers HHSO10201500002C, HHSO10201600031C, and HHSO10201700012C, and from the Department of Defense, Defense Threat Reduction Agency, under Contract Number HDTRA1-15-C-0058.	Agnandji ST, 2016, NEW ENGL J MED, V374, P1647, DOI 10.1056/NEJMoa1502924; Agnandji ST, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002402; [Anonymous], 2016, RT QUESTION MORE 100; Antonello J, 2020, VACCINE, V38, P4885, DOI 10.1016/j.vaccine.2020.04.061; Baylor NW, 2016, METHODS MOL BIOL, V1404, P773, DOI 10.1007/978-1-4939-3389-1_51; Bolay FK, 2019, J INFECT DIS, V219, P1634, DOI 10.1093/infdis/jiy698; Boum Y, 2020, VACCINE, V38, P4877, DOI 10.1016/j.vaccine.2020.04.066; Burns DL, 2012, CURR OPIN VIROL, V2, P353, DOI 10.1016/j.coviro.2012.01.004; Chertow DS, 2019, NAT MED, V25, P714, DOI 10.1038/s41591-019-0444-0; Dahlke C, 2017, EBIOMEDICINE, V19, P107, DOI 10.1016/j.ebiom.2017.03.045; Eisele P., 2020, ERVEBO EBOLA ZAIRE V; ElSherif MS, 2017, CAN MED ASSOC J, V189, pE819, DOI 10.1503/cmaj.170074; European Medicine Agency, 2019, ERV EB ZAIR VACC RVS; Fuchs JD, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv082; Garbutt M, 2004, J VIROL, V78, P5458, DOI 10.1128/JVI.78.10.5458-5465.2004; Geisbert TW, 2009, J VIROL, V83, P7296, DOI 10.1128/JVI.00561-09; Geisbert TW, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000225; Gouglas D, 2018, LANCET GLOB HEALTH, V6, pE1386, DOI 10.1016/S2214-109X(18)30346-2; Grais RF, 2021, LANCET MICROBE, V2, pE70, DOI 10.1016/S2666-5247(20)30198-1; Grant-Klein RJ, 2019, AM J TROP MED HYG, V101, P207, DOI 10.4269/ajtmh.19-0076; Gsell PS, 2017, LANCET INFECT DIS, V17, P1276, DOI 10.1016/S1473-3099(17)30541-8; Halperin SA, 2019, J INFECT DIS, V220, P1127, DOI 10.1093/infdis/jiz241; Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6; Henao-Restrepo AM, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3740; Heppner DG, 2017, LANCET INFECT DIS, V17, P854, DOI [10.1016/s1473-3099(17)30313-4, 10.1016/S1473-3099(17)30313-4]; Hurford P., 2018, EFF ALTRUISM FORUM; Huttner A, 2015, LANCET INFECT DIS, V15, P1156, DOI 10.1016/S1473-3099(15)00154-1; Jasarevic T, 2019, WHO PREQUALIFIES EBO; Johnson & Johnson, 2020, JOHNS JOHNS ANN EUR; Jones SM, 2005, NAT MED, V11, P786, DOI 10.1038/nm1258; Kennedy SB, 2017, NEW ENGL J MED, V377, P1438, DOI 10.1056/NEJMoa1614067; Krause PR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8202; Liu A., 2017, CHINA APPROVES DOMES; Logue J, 2018, J VIROL METHODS, V255, P84, DOI 10.1016/j.jviromet.2018.02.018; Marzi A, 2013, P NATL ACAD SCI USA, V110, P1893, DOI 10.1073/pnas.1209591110; Merck Sharp & Dohme Corp. a subsidiary of Merck & Co. Inc, 2019, ERVEBO EB ZAIR VACC; Meyer M, 2019, TRENDS MICROBIOL, V27, P8, DOI 10.1016/j.tim.2018.08.008; Mire CE, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001567; Monath TP, 2019, VACCINE-X, V1, DOI 10.1016/j.jvacx.2019.100009; Nakayama E, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00267; Niemuth NA, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241016; Qiu XG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005547; Racine T, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0179-2; Regules JA, 2017, NEW ENGL J MED, V376, P330, DOI 10.1056/NEJMoa1414216; Ribacke KJB, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00222; Rudge TL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215457; Samai M, 2018, J INFECT DIS, V217, pS6, DOI 10.1093/infdis/jiy020; Sellers RS, 2020, TOXICOL PATHOL, V48, P257, DOI 10.1177/0192623319875085; Siragam V, 2018, ZOOL RES, V39, P15, DOI 10.24272/j.issn.2095-8137.2017.053; Smith JA, 2017, REJUV RES, V20, P1, DOI 10.1089/rej.2017.1932; St Claire MC, 2017, COMPARATIVE MED, V67, P253; TESTER PA, 1990, J EXP MAR BIOL ECOL, V141, P169, DOI 10.1016/0022-0981(90)90222-X; U.S. Food and Drug Administration, 2017, M4 ORG COMM TECHN DO; United States Food & Drug Administration, 2020, ERVEBO EB ZAIR VACC; WHO, 2019, ESS MED HLTH PROD WH; WHO, 2020, EB VIR DIS DEM REP C; Wolf J, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0204-7; World Health Organization, 2020, Weekly Epidemiological Record, V95, P369; World Health Organization, 2020, END NEGL ATT SUST DE, P1; World Health Organization, 2014, EB STRAT EB MARB VIR	60	12	12	3	13	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							190	10.3390/vaccines9030190			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6IH	33668698	gold, Green Published			2022-04-29	WOS:000634254700001
J	Ghelardi, A; Marrai, R; Bogani, G; Sopracordevole, F; Bay, P; Tonetti, A; Lombardi, S; Bertacca, G; Joura, EA				Ghelardi, Alessandro; Marrai, Roberto; Bogani, Giorgio; Sopracordevole, Francesco; Bay, Paola; Tonetti, Arianna; Lombardi, Stefania; Bertacca, Gloria; Joura, Elmar A.			Surgical Treatment of Vulvar HSIL: Adjuvant HPV Vaccine Reduces Recurrent Disease	VACCINES			English	Article						HPV vaccination; adjuvant HPV vaccination; vulvar HSIL; vulvar HSIL treatment		Data suggest that adjuvant human papillomavirus (HPV)-vaccination in women treated for cervical HPV diseases reduces recurrent disease. This study investigates adjuvant HPV-vaccination and the rate of recurrence in women undergoing surgery for vulvar high-grade squamous intraepithelial lesions (HSIL). From January 2013 to April 2020, we enrolled 149 women in a prospective case-control study. The control group (NV-group) was treated by standard surgery alone, while the study group received adjuvant vaccination soon after surgery (V-group). A follow-up was performed by vulvoscopy and HPV test. Statistical analysis was performed by Fisher's exact test. HSIL recurrence was observed in 24/76 (32%) patients in NV-group and in 8/42 patients (19%) of the vaccinated group. By analysing the recurrence rate related to the incident and reactivated latent HPV infection, we found a significant difference between (17/76) 22.3% in NV-group and (2/42) 4.8% in V-group (p = 0.01). A reduction of 78.5% in incident/reactivated HPV infections was demonstrated. Data results add to the current knowledge about the mechanism of post-surgical adjuvant HPV vaccination. Our prospective study is the first to document the vaccine clinical effectiveness in preventing "reactivation" of latent HPV infections. Quadrivalent HPV vaccine administered after the surgical treatment for vulvar HSIL appears to be useful in preventing recurrent disease.	[Ghelardi, Alessandro; Marrai, Roberto; Bay, Paola; Tonetti, Arianna] Azienda USL Toscana Nord Ovest, UOC Ostetricia & Ginecol, Osped Apuane, Via Enrico Mattei 21, I-54100 Massa, Italy; [Bogani, Giorgio] Fdn IRCCS Ist Nazl Tumori Milano, Gynecol Oncol Unit, Via Giacomo Venezian 1, I-20133 Milan, Italy; [Sopracordevole, Francesco] Natl Canc Inst, Ctr Riferimento Oncol, Gynecol Oncol Unit, Via Franco Gallini 2, I-33081 Aviano, Italy; [Lombardi, Stefania; Bertacca, Gloria] Azienda USL Toscana Nord Ovest, SSD Anal Chim Clin Immuno Allergol, Osped Apuane, Via Enrico Mattei 21, I-54100 Massa, Italy; [Joura, Elmar A.] Med Univ Vienna, Comprehens Canc Ctr, Dept Gynecol & Obstet, Austria Wahringer Gurtel 18-20, A-1090 Vienna, Austria		Ghelardi, A (通讯作者)，Azienda USL Toscana Nord Ovest, UOC Ostetricia & Ginecol, Osped Apuane, Via Enrico Mattei 21, I-54100 Massa, Italy.	ghelardi.alessandro@gmail.com; roberto.marrai@uslnordovest.toscana.it; giorgio.bogani@istitutotumori.mi.it; fsopracordevole@cro.it; paolabay@aliceposta.it; arianna.tonetti@uslnordovest.toscana.it; stefania.lombardi@uslnordovest.toscana.it; gloria.bertacca@uslnordovest.toscana.it; elmar.joura@meduniwien.ac.at		Bogani, Giorgio/0000-0001-8373-8569			Baandrup L, 2011, GYNECOL ONCOL, V122, P45, DOI 10.1016/j.ygyno.2011.03.016; Bartels HC, 2020, INT J GYNECOL CANCER, V30, P777, DOI 10.1136/ijgc-2020-001197; Bogani G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040717; Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086/657321; Chesson HW, 2014, SEX TRANSM DIS, V41, P660, DOI 10.1097/OLQ.0000000000000193; Ciavattini A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030354; Cohen PA, 2019, INT J GYNECOL CANCER, V29, P821, DOI 10.1136/ijgc-2018-000135; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; de Sanjose S, 2007, LANCET INFECT DIS, V7, P453, DOI 10.1016/S1473-3099(07)70158-5; de Sanjose S, 2013, EUR J CANCER, V49, P3450, DOI 10.1016/j.ejca.2013.06.033; de Witte CJ, 2015, GYNECOL ONCOL, V139, P377, DOI 10.1016/j.ygyno.2015.08.018; del Pino M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020245; Garbuglia AR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00188; Garland SM, 2018, OBSTET GYNECOL, V132, P261, DOI [10.1097/AOG.0000000000002736, 10.1097/aog.0000000000002736]; Garland SM, 2016, INT J CANCER, V139, P2812, DOI 10.1002/ijc.30391; Ghelardi A, 2018, GYNECOL ONCOL, V151, P229, DOI 10.1016/j.ygyno.2018.08.033; Grimes Chelsea, 2016, Int J Womens Dermatol, V2, P35, DOI 10.1016/j.ijwd.2015.12.007; Hartwig S, 2017, INFECT AGENTS CANCER, V12, DOI 10.1186/s13027-017-0129-6; Harvey G, 2019, CLIN EXP DERMATOL, V44, pE140, DOI 10.1111/ced.13874; Hillemanns P, 2006, GYNECOL ONCOL, V100, P271, DOI 10.1016/j.ygyno.2005.08.012; Jemal A, 2013, JNCI-J NATL CANCER I, V105, P175, DOI 10.1093/jnci/djs491; Jentschke M, 2020, VACCINE, V38, P6402, DOI 10.1016/j.vaccine.2020.07.055; Jones RW, 1997, OBSTET GYNECOL, V90, P448, DOI 10.1016/S0029-7844(97)00298-6; Joura EA, 2000, J REPROD MED, V45, P613; Joura EA, 2007, LANCET, V369, P1693, DOI 10.1016/S0140-6736(07)60777-6; Joura EA, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1401; Judson PL, 2006, OBSTET GYNECOL, V107, P1018, DOI 10.1097/01.AOG.0000210268.57527.a1; Karita HCS, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0819; Lawrie TA, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011837.pub2; Luna J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083431; Munoz N, 2004, INT J CANCER, V111, P278, DOI 10.1002/ijc.20244; Munoz N, 2009, LANCET, V373, P1949, DOI 10.1016/S0140-6736(09)60691-7; Origoni M, 2019, MINERVA GINECOL, V71, P442, DOI 10.23736/S0026-4784.19.04443-5; Paternotte J., 2015, Gynecol, V43, P528, DOI 10.1016/j.gyobfe.2015.04.005; Petrillo M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010045; Pieralli A, 2018, ARCH GYNECOL OBSTET, V298, P1205, DOI 10.1007/s00404-018-4926-y; Preti M, 2014, BEST PRACT RES CL OB, V28, P1051, DOI 10.1016/j.bpobgyn.2014.07.010; Sand FL, 2020, INT J CANCER, V147, P641, DOI 10.1002/ijc.32752; Sideri M, 2005, J REPROD MED, V50, P807; Smith JS, 2008, J ADOLESCENT HEALTH, V43, pS5, DOI 10.1016/j.jadohealth.2008.07.009; Sterling J C, 2005, J EUROPEAN ACAD D S2, V19, P22; Terlou A, 2011, GYNECOL ONCOL, V121, P157, DOI 10.1016/j.ygyno.2010.12.340; Tristram A, 2014, LANCET ONCOL, V15, P1361, DOI 10.1016/S1470-2045(14)70456-5; Valasoulis G, 2020, CANCERS, V12, DOI 10.3390/cancers12051164; van de Laar RLO, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07025-7; van de Nieuwenhof HP, 2009, EUR J CANCER, V45, P851, DOI 10.1016/j.ejca.2008.11.037; van Esch EMG, 2013, INT J GYNECOL CANCER, V23, P1476, DOI 10.1097/IGC.0b013e3182a57fd6; van Seters M, 2002, J REPROD MED, V47, P701; Velentzis LS, 2019, CLIMACTERIC, V22, P596, DOI 10.1080/13697137.2019.1600500; World Health Organization, 2009, WEEKLY EPIDEMIOLOGIC, V84, P117; Zhao S, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05560-z	51	6	6	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							83	10.3390/vaccines9020083			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7FO	33503866	gold, Green Published			2022-04-29	WOS:000623305900001
J	Kick, AR; Wolfe, ZC; Amaral, AE; Cortes, LM; Almond, GW; Crisci, E; Gauger, PC; Pittman, J; Kaser, T				Kick, Andrew R.; Wolfe, Zoe C.; Amaral, Amanda E.; Cortes, Lizette M.; Almond, Glen W.; Crisci, Elisa; Gauger, Phillip C.; Pittman, Jeremy; Kaeser, Tobias			Maternal Autogenous Inactivated Virus Vaccination Boosts Immunity to PRRSV in Piglets	VACCINES			English	Article						maternal vaccination; autogenous inactivated vaccine; transfer of immunity; humoral immune response; cell-mediated immune response; T cells; PRRSV; swine; IFN-gamma producing B cells; CD4 T-EMRA cells		Maternal-derived immunity is a critical component for the survival and success of offspring in pigs to protect from circulating pathogens such as Type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV-2). The purpose of this study is to investigate the transfer of anti-PRRSV immunity to piglets from gilts that received modified-live virus (MLV) alone (treatment (TRT) 0), or in combination with one of two autogenous inactivated vaccines (AIVs, TRT 1+2). Piglets from these gilts were challenged with the autogenous PRRSV-2 strain at two weeks of age and their adaptive immune response (IR) was evaluated until 4 weeks post inoculation (wpi). The systemic humoral and cellular IR was analyzed in the pre-farrow gilts, and in piglets, pre-inoculation, and at 2 and 4 wpi. Both AIVs partially protected the piglets with reduced lung pathology and increased weight gain; TRT 1 also lowered piglet viremia, best explained by the AIV-induced production of neutralizing antibodies in gilts and their transfer to the piglets. In piglets, pre-inoculation, the main systemic IFN-gamma producers were CD21 alpha(+) B cells. From 0 to 4 wpi, the role of these B cells declined and CD4 T cells became the primary systemic IFN-gamma producers. In the lungs, CD8 T cells were the primary and CD4 T cells were the secondary IFN-gamma producers, including a novel subset of porcine CD8 alpha(-)CCR7(-) CD4 T cells, potentially terminally differentiated CD4 T-EMRA cells. In summary, this study demonstrates that maternal AIV vaccination can improve protection of pre-weaning piglets against PRRSV-2; it shows the importance of transferring neutralizing antibodies to piglets, and it introduces two novel immune cell subsets in pigs-IFN-gamma producing CD21 alpha(+) B cells and CD8 alpha(-)CCR7(-) CD4 T cells.	[Kick, Andrew R.; Wolfe, Zoe C.; Amaral, Amanda E.; Cortes, Lizette M.; Almond, Glen W.; Crisci, Elisa; Kaeser, Tobias] North Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol, Raleigh, NC 27607 USA; [Kick, Andrew R.] US Mil Acad, Dept Chem & Life Sci, West Point, NY 10996 USA; [Gauger, Phillip C.] Iowa State Univ, Vet Diagnost & Prod Anim Med, Ames, IA 50011 USA; [Pittman, Jeremy] Smithfield Foods, Smithfield, VA 23430 USA		Kaser, T (通讯作者)，North Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol, Raleigh, NC 27607 USA.	andrew.kick@westpoint.edu; zcwolfe@ncsu.edu; afamaral@ncsu.edu; lmlorenz@ncsu.edu; gwalmond@ncsu.edu; ecrisci@ncsu.edu; pcgauger@iastate.edu; jpittman@smithfield.com; tekaeser@ncsu.edu	Crisci, Elisa/AAF-9263-2020; Gauger, Phillip/AAQ-9806-2021	Crisci, Elisa/0000-0002-4235-8508; Kaeser, Tobias/0000-0001-8764-7971; Lorenz, Lizette/0000-0002-5471-3909	Virginia Pork Council; United States ArmyUnited States Department of Defense	This research was funded by the Virginia Pork Council. A.R.K.'s graduate tuition and the salary was provided by the United States Army.	Balasch M, 2019, PORCINE HEALTH MANAG, V5, DOI 10.1186/s40813-018-0112-7; Balka G, 2016, PORCINE HEALTH MANAG, V2, DOI 10.1186/s40813-016-0037-y; Bandrick M, 2008, CLIN VACCINE IMMUNOL, V15, P540, DOI 10.1128/CVI.00466-07; Bandrick M, 2014, DEV COMP IMMUNOL, V43, P114, DOI 10.1016/j.dci.2013.11.005; Bao Y, 2014, CELL RES, V24, P161, DOI 10.1038/cr.2013.155; Butler JE, 2017, ANNU REV ANIM BIOSCI, V5, P255, DOI 10.1146/annurev-animal-022516-022818; Correas I, 2017, VACCINE, V35, P782, DOI 10.1016/j.vaccine.2016.12.040; Declerck I, 2016, J ANIM SCI, V94, P1633, DOI 10.2527/jas.2015-9564; Drigo M, 2018, VET IMMUNOL IMMUNOP, V200, P32, DOI 10.1016/j.vetimm.2018.04.007; Dvorak CMT, 2018, VIRAL IMMUNOL, V31, P40, DOI 10.1089/vim.2017.0058; Geldhof MF, 2013, VET MICROBIOL, V167, P260, DOI 10.1016/j.vetmic.2013.08.017; Gerner W, 2009, DEV COMP IMMUNOL, V33, P310, DOI 10.1016/j.dci.2008.06.003; HALBUR PG, 1995, VET PATHOL, V32, P648, DOI 10.1177/030098589503200606; Hamann D, 1997, J EXP MED, V186, P1407, DOI 10.1084/jem.186.9.1407; Han K, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-12; Harris DP, 2005, J IMMUNOL, V174, P6781, DOI 10.4049/jimmunol.174.11.6781; Holtkamp DJ, 2013, J SWINE HEALTH PROD, V21, P72; HOUBEN S, 1995, J VET MED B, V42, P209, DOI 10.1111/j.1439-0450.1995.tb00704.x; Hurley WL, 2011, NUTRIENTS, V3, P442, DOI 10.3390/nu3040442; Jennewein MF, 2017, SEMIN IMMUNOPATHOL, V39, P605, DOI 10.1007/s00281-017-0653-x; Jeong J, 2017, VET MICROBIOL, V208, P47, DOI 10.1016/j.vetmic.2017.07.016; Jeong J, 2016, VET MICROBIOL, V192, P102, DOI 10.1016/j.vetmic.2016.07.006; Kang S, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e33; Kick AR, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090796; Kraft C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223060; Lopez OJ, 2007, CLIN VACCINE IMMUNOL, V14, P269, DOI 10.1128/CVI.00304-06; Loving CL, 2015, VET IMMUNOL IMMUNOP, V167, P1, DOI 10.1016/j.vetimm.2015.07.003; Lunney JK, 2016, ANNU REV ANIM BIOSCI, V4, P129, DOI 10.1146/annurev-animal-022114-111025; Mair KH, 2015, VET MICROBIOL, V176, P352, DOI 10.1016/j.vetmic.2015.02.001; Meier WA, 2003, VIROLOGY, V309, P18, DOI 10.1016/S0042-6822(03)00009-6; Merriam-Webster Inc, 2019, MERRIAM WEBSTER DICT; Montaner-Tarbes S, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00038; Murphy K., 2008, JANEWAYS IMMUNOBIOLO; Ogawa S, 2016, ANIM SCI J, V87, P1511, DOI 10.1111/asj.12573; Osorio FA, 2002, VIROLOGY, V302, P9, DOI 10.1006/viro.2002.1612; Park C, 2020, VIROLOGY, V540, P172, DOI 10.1016/j.virol.2019.10.019; Park C, 2014, VET MICROBIOL, V172, P432, DOI 10.1016/j.vetmic.2014.05.030; Poonsuk K, 2018, ANIM HEALTH RES REV, V19, P31, DOI 10.1017/S1466252317000123; Rahe MC, 2017, VET IMMUNOL IMMUNOP, V186, P15, DOI 10.1016/j.vetimm.2017.02.002; Reutner K, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-18; Rodriguez-Carreno MP, 2002, J IMMUNOL METHODS, V259, P171, DOI 10.1016/S0022-1759(01)00511-7; SAALMULLER A, 1987, EUR J IMMUNOL, V17, P1297, DOI 10.1002/eji.1830170912; Saalmuller A, 2002, VET IMMUNOL IMMUNOP, V87, P137, DOI 10.1016/S0165-2427(02)00045-4; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Tian Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01728-5; VanderWaal K, 2018, P NATL ACAD SCI USA, V115, P11495, DOI 10.1073/pnas.1806068115; Wu WH, 2001, VIROLOGY, V287, P183, DOI 10.1006/viro.2001.1034; Yang S, 2020, COMP IMMUNOL MICROB, V69, DOI 10.1016/j.cimid.2020.101423; Yang S, 2019, VET MICROBIOL, V239, DOI 10.1016/j.vetmic.2019.108497	50	6	6	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							106	10.3390/vaccines9020106			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7AH	33572562	Green Published, Green Submitted			2022-04-29	WOS:000623292100001
J	Mo, PKH; Luo, ST; Wang, SH; Zhao, JF; Zhang, GH; Li, LJ; Li, LP; Xie, LY; Lau, OS				Mo, Phoenix Kit-han; Luo, Sitong; Wang, Suhua; Zhao, Junfeng; Zhang, Guohua; Li, Lijuan; Li, Liping; Xie, Luyao; Lau, Joseph T. F.			Intention to Receive the COVID-19 Vaccination in China: Application of the Diffusion of Innovations Theory and the Moderating Role of Openness to Experience	VACCINES			English	Article						COVID-19 vaccination; diffusion of innovations theory; perceived efficacy of vaccine; social media; openness to experience; descriptive norm		COVID-19 has caused a devastating impact on public health and made the development of the COVID-19 vaccination a top priority. Herd immunity through vaccination requires a sufficient number of the population to be vaccinated. Research on factors that promote intention to receive the COVID-19 vaccination is warranted. Based on Diffusion of Innovations Theory, this study examines the association between the perceived efficacy of the COVID-19 vaccination, use of social media for COVID-19 vaccine-related information, openness to experience and descriptive norm with the intention to receive the COVID-19 vaccination, and the moderating role of openness to experience among 6922 university students in mainland China. The intention to receive the free and self-paid COVID-19 vaccination is 78.9% and 60.2%, respectively. Results from path analyses show that perceived efficacy of the COVID-19 vaccination, use of social media for COVID-19 vaccine-related information, and openness to experience and descriptive norm are all positively associated with the intention to receive COVID-19 free and self-paid vaccination. The association between the perceived efficacy of the COVID-19 vaccination and descriptive norm with the intention to receive the COVID-19 vaccination is stronger among those with a lower level of openness to experience. Our findings support the usefulness of Diffusion of Innovations Theory and the moderating role of openness of experience in explaining intention to receive the COVID-19 vaccination.	[Mo, Phoenix Kit-han; Luo, Sitong; Xie, Luyao; Lau, Joseph T. F.] Chinese Univ Hong Kong, Ctr Hlth Behav Res, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China; [Wang, Suhua] Baotou Med Coll, Grad Sch, Baotou 014040, Peoples R China; [Zhao, Junfeng] Henan Univ, Sch Educ, Dept Psychol, Kaifeng 475100, Peoples R China; [Zhang, Guohua] Wenzhou Med Univ, Sch Psychiat, Dept Psychol, Wenzhou 325035, Peoples R China; [Li, Lijuan] Dali Univ, Sch Publ Hlth, Dali 671003, Peoples R China; [Li, Liping] Shantou Univ, Med Coll, Shantou 515041, Peoples R China		Lau, OS (通讯作者)，Chinese Univ Hong Kong, Ctr Hlth Behav Res, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China.	phoenix.mo@cuhk.edu.hk; sitongluo@cuhk.edu.hk; 101991063@btmc.edu.cn; zhaojf@henu.edu.cn; zghcnu@wmu.edu.cn; lelejuan@eastern-himalaya.cn; lpli@stu.edu.cn; 1155149225@link.cuhk.edu.hk; jlau@cuhk.edu.hk	Mo, Phoenix/K-2853-2013	Mo, Phoenix/0000-0001-9822-5424; Luo, Sitong/0000-0002-7450-5613; Lau, Joseph/0000-0003-2344-7107			Allington D, 2021, PSYCHOL MED, V51, P1763, DOI [10.1017/S0033291721000593, 10.1017/S003329172000224X]; Batey M, 2006, GENET SOC GEN PSYCH, V132, P355, DOI 10.3200/MONO.132.4.355-430; Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107; Briggs, 1997, HDB PERSONALITY PSYC, P825, DOI [DOI 10.1016/B978-012134645-4/50032-9, 10.1016/B978-012134645-4/50032-9]; Browne M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132562; Burger JM, 2011, SOC INFLUENCE, V6, P69, DOI 10.1080/15534510.2010.542305; Burger JM, 2010, J SOC CLIN PSYCHOL, V29, P228, DOI 10.1521/jscp.2010.29.2.228; Chan AKM, 2020, ANAESTHESIA, V75, P1579, DOI 10.1111/anae.15057; De Civita M, 2007, J PUBLIC HEALTH-UK, V29, P263, DOI 10.1093/pubmed/fdm033; Dearing JW, 2008, J PUBLIC HEALTH MAN, V14, P99, DOI 10.1097/01.PHH.0000311886.98627.b7; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Faasse K, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.551004; Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Godin G, 2010, INFECT CONT HOSP EP, V31, P689, DOI 10.1086/653614; Gosling SD, 2003, J RES PERS, V37, P504, DOI 10.1016/S0092-6566(03)00046-1; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Hammond MM, 2011, PSYCHOL AESTHET CREA, V5, P90, DOI 10.1037/a0018556; Hausmann JS, 2017, J ADOLESCENT HEALTH, V60, P714, DOI 10.1016/j.jadohealth.2016.12.025; Helitzer D, 2003, TELEMED J E-HEALTH, V9, P179, DOI 10.1089/153056203766437516; Holt M, 2019, AIDS BEHAV, V23, P1939, DOI 10.1007/s10461-018-2368-y; Iwasa H, 2009, J PSYCHOSOM RES, V66, P155, DOI 10.1016/j.jpsychores.2008.07.006; Kim D, 1998, PSYCHOL MARKET, V15, P507, DOI 10.1002/(SICI)1520-6793(199809)15:6<507::AID-MAR2>3.0.CO;2-A; Korda H, 2013, HEALTH PROMOT PRACT, V14, P15, DOI 10.1177/1524839911405850; Li HOY, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-002604; Li J, 2003, AM PSYCHOL, V58, P146, DOI 10.1037/0003-066X.58.2.146; MCCRAE RR, 1994, EUR J PERSONALITY, V8, P251, DOI 10.1002/per.2410080404; MCCRAE RR, 1992, J PERS, V60, P175, DOI 10.1111/j.1467-6494.1992.tb00970.x; MCCRAE RR, 1987, J PERS SOC PSYCHOL, V52, P1258, DOI 10.1037/0022-3514.52.6.1258; Mo PKH, 2019, J ADV NURS, V75, P1188, DOI 10.1111/jan.13894; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nolan A, 2019, PREV MED, V120, P107, DOI 10.1016/j.ypmed.2018.12.029; Okoli GN, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234702; Olagoke AA, 2021, J RELIG HEALTH, V60, P65, DOI 10.1007/s10943-020-01090-9; Padron-Regalado E, 2020, INFECT DIS THER, V9, P255, DOI 10.1007/s40121-020-00300-x; Pandhi N, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009738; Patterson F, 2017, ADV HEALTH SCI EDUC, V22, P417, DOI 10.1007/s10459-016-9731-4; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Roccas S, 2002, PERS SOC PSYCHOL B, V28, P789, DOI 10.1177/0146167202289008; Rogers E.M, 2010, DIFFUSION INNOVATION, V4th ed.; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Smith RA, 2018, J HEALTH COMMUN, V23, P264, DOI 10.1080/10810730.2018.1434259; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang LDL, 2017, PREV MED, V102, P24, DOI 10.1016/j.ypmed.2017.06.021; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; World Health Organization, 2020, WEEKLY EPIDEMIOLOGIC; Yang QH, 2021, HEALTH COMMUN, V36, P324, DOI 10.1080/10410236.2019.1692486; Zhang XJ, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0726-2	54	23	23	6	35	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							129	10.3390/vaccines9020129			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO6RJ	33562894	Green Published, gold			2022-04-29	WOS:000623268500001
J	Pavulraj, S; Bergmann, T; Trombetta, CM; Marchi, S; Montomoli, E; El Alami, SS; Ragni-Alunni, R; Osterrieder, N; Azab, W				Pavulraj, Selvaraj; Bergmann, Tobias; Trombetta, Claudia Maria; Marchi, Serena; Montomoli, Emanuele; Alami, Sidi Sefiane El; Ragni-Alunni, Roberto; Osterrieder, Nikolaus; Azab, Walid			Immunogenicity of Calvenza-03 EIV/EHV(R) Vaccine in Horses: Comparative In Vivo Study	VACCINES			English	Article						horses; equine influenza; vaccination; immunogenicity; Florida clade 2	EQUINE INFLUENZA VACCINE; EXPERIMENTAL-INFECTION; PROTECTIVE EFFICACY; VIRUS; H3N8; RESPONSES; DURATION; ANTIBODY; STRAIN	Equine influenza (EI) is a highly contagious acute respiratory disease of equines that is caused mainly by the H3N8 subtype of influenza A virus. Vaccinating horses against EI is the most effective strategy to prevent the infection. The current study aimed to compare the kinetics of EI-specific humoral- and cell-mediated immunity (CMI) in horses receiving either identical or mixed vaccinations. Two groups of horses were previously (six months prior) vaccinated with either Calvenza 03 EIV EHV(R) (G1) or Fluvac Innovator(R) (G2) vaccine. Subsequently, both groups received a booster single dose of Calvenza 03 EIV EHV(R). Immune responses were assessed after 10 weeks using single radial hemolysis (SRH), virus neutralization (VN), and EliSpot assays. Our results revealed that Calvenza-03 EIV/EHV(R)-immunized horses had significantly higher protective EI-specific SRH antibodies and VN antibodies. Booster immunization with Calvenza-03 EIV/EHV(R) vaccine significantly stimulated cell-mediated immune response as evidenced by significant increase in interferon-gamma-secreting peripheral blood mononuclear cells. In conclusion, Calvenza-03 EIV/EHV(R) vaccine can be safely and effectively used for booster immunization to elicit optimal long persisting humoral and CMI responses even if the horses were previously immunized with a heterogeneous vaccine.	[Pavulraj, Selvaraj; Bergmann, Tobias; Osterrieder, Nikolaus; Azab, Walid] Free Univ Berlin, Inst Virol, Robert von Ostertag Haus, Zentrum Infekt Med, Robert von Ostertag Str 7-13, D-14163 Berlin, Germany; [Trombetta, Claudia Maria; Marchi, Serena; Montomoli, Emanuele] Univ Siena, Dept Mol & Dev Med, I-53100 Siena, Italy; [Montomoli, Emanuele] VisMederi Srl, I-53100 Siena, Italy; [Alami, Sidi Sefiane El] AL REEF Stable, POB 5151, Abu Dhabi 5151, U Arab Emirates; [Ragni-Alunni, Roberto] Boehringer Ingelheim META, Equine Mkt Div, POB 507066, Dubai, U Arab Emirates; [Osterrieder, Nikolaus] City Univ Hong Kong, Dept Infect Dis & Publ Hlth, Jockey Club Coll Vet Med & Life Sci, Kowloon, Hong Kong 999077, Peoples R China; [Ragni-Alunni, Roberto] Boehringer Ingelheim META, Dubai, U Arab Emirates		Azab, W (通讯作者)，Free Univ Berlin, Inst Virol, Robert von Ostertag Haus, Zentrum Infekt Med, Robert von Ostertag Str 7-13, D-14163 Berlin, Germany.	pavulraj1vet@zedat.fu-berlin.de; tobias-bergmann@gmx.de; trombetta@unisi.it; serena.marchi2@unisi.it; montomoli@vismederi.com; sidisefiane@yahoo.com; leprotto1961@yahoo.it; no.34@fu-berlin.de; wfazab@zedat.fu-berlin.de	Selvaraj, Pavulraj/AAV-8266-2021	Azab, Walid/0000-0003-2880-7255; Osterrieder, Nikolaus/0000-0002-5313-2176; Marchi, Serena/0000-0002-6817-2461; raj, pavul/0000-0001-6804-0808	Boehringer Ingelheim META (Dubai); Netaji Subhas-ICAR International Fellowship from the Indian Council of Agricultural Research, Government of India - Freie Universitat Berlin	This research was funded by Boehringer Ingelheim META (Dubai). SP was supported by Netaji Subhas-ICAR International Fellowship from the Indian Council of Agricultural Research, Government of India. The publication of this article was funded by Freie Universitat Berlin.	Blanco-Lobo P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100933; Bryant NA, 2010, VET RES, V41, DOI 10.1051/vetres/2009067; Chambers TM, 2001, EQUINE VET J, V33, P630, DOI 10.2746/042516401776249291; Daly JM, 2013, VACCINE, V31, P6043, DOI 10.1016/j.vaccine.2013.06.070; Daly JM, 2011, VET J, V189, P7, DOI 10.1016/j.tvjl.2010.06.026; Daly JM, 2004, VET RES, V35, P411, DOI 10.1051/vetres:2004023; Dilai M, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6040071; Entenfellner J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030372; Fougerolle S, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040174; Gamoh K, 2017, J VET MED SCI, V79, P649, DOI 10.1292/jvms.16-0558; Gildea S, 2018, PATHOGENS, V7, DOI 10.3390/pathogens7020043; Gildea S, 2013, VACCINE, V31, P5216, DOI 10.1016/j.vaccine.2013.08.083; Holmes MA, 2006, VET IMMUNOL IMMUNOP, V111, P67, DOI 10.1016/j.vetimm.2006.01.010; Mathew MK, 2019, J VET MED SCI, V81, P1753, DOI 10.1292/jvms.19-0399; Mena J, 2018, TRANSBOUND EMERG DIS, V65, P1408, DOI 10.1111/tbed.12984; Mino S, 2019, J VIROL, V93, DOI 10.1128/JVI.00116-19; MORLEY PS, 1995, VET MICROBIOL, V44, P101, DOI 10.1016/0378-1135(94)00111-9; MUMFORD J, 1983, J HYG-CAMBRIDGE, V90, P385, DOI 10.1017/S0022172400029016; MUMFORD JA, 1992, DEV BIOL STAND, V79, P137; MUMFORD JA, 1988, EPIDEMIOL INFECT, V100, P501, DOI 10.1017/S0950268800067236; Olguin Perglione C, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5040061; Paillot R, 2007, VACCINE, V25, P7385, DOI 10.1016/j.vaccine.2007.08.033; Paillot R, 2006, VET IMMUNOL IMMUNOP, V112, P225, DOI 10.1016/j.vetimm.2006.02.007; Paillot R, 2013, VET MICROBIOL, V166, P22, DOI 10.1016/j.vetmic.2013.04.027; Paillot R, 2013, VET MICROBIOL, V162, P396, DOI 10.1016/j.vetmic.2012.10.019; Paillot R, 2019, VET REC, V184, DOI 10.1136/vr.l1203; Paillot R, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5040064; Paillot R, 2014, VACCINES-BASEL, V2, P797, DOI 10.3390/vaccines2040797; Pavulraj S, 2017, VET MICROBIOL, V210, P188, DOI 10.1016/j.vetmic.2017.08.013; Rash A, 2017, PATHOGENS, V6, DOI 10.3390/pathogens6010006; Reemers S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030501; Shittu I, 2020, VET MICROBIOL, V248, DOI 10.1016/j.vetmic.2020.108820; Sreenivasan CC, 2018, VIRUSES-BASEL, V10, DOI [10, 10.3390/v10010031]; Tabynov K, 2014, AUST VET J, V92, P450, DOI 10.1111/avj.12248; Tangri S, 2001, J EXP MED, V194, P833, DOI 10.1084/jem.194.6.833; Yamanaka T, 2018, J VET MED SCI, V80, P382, DOI 10.1292/jvms.17-0538; Yang HL, 2018, VET MICROBIOL, V214, P1, DOI 10.1016/j.vetmic.2017.11.033; Youngner JS, 2001, AM J VET RES, V62, P1290, DOI 10.2460/ajvr.2001.62.1290	38	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							166	10.3390/vaccines9020166			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7MJ	33671378	Green Published, gold			2022-04-29	WOS:000623323900001
J	Szmyd, B; Bartoszek, A; Karuga, FF; Staniecka, K; Blaszczyk, M; Radek, M				Szmyd, Bartosz; Bartoszek, Adrian; Karuga, Filip Franciszek; Staniecka, Katarzyna; Blaszczyk, Maciej; Radek, Maciej			Medical Students and SARS-CoV-2 Vaccination: Attitude and Behaviors	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccination; healthcare workers; depression; anxiety; stress		Since physicians play a key role in vaccination, the initial training of medical students (MS) should aim to help shape their attitude in this regard. The beginning of vaccination programs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an excellent time to assess the attitudes held by both medical and non-medical students regarding vaccination. A 51- to 53-item questionnaire including the Depression, Anxiety and Stress Scale was administered to 1971 students (49.21% male; 34.86% MS); two career-related questions were also addressed to the MS. The majority of surveyed students indicated a desire to get vaccinated against SARS-CoV-2, with more medical than non-medical students planning to get vaccinated (91.99% vs. 59.42%). The most common concern about SARS-CoV-2 infection was the risk of passing on the disease to elderly relatives. While conspiracy theories regarding the COVID-19 vaccine are less popular among MS, both groups indicated concerns that vaccines may cause autism is equally common (similar to 5%). Further studies exploring social attitudes towards the SARS-CoV-2 vaccine are a necessary first step to optimizing vaccination programs and achieving herd immunity.	[Szmyd, Bartosz; Bartoszek, Adrian; Karuga, Filip Franciszek; Staniecka, Katarzyna; Blaszczyk, Maciej; Radek, Maciej] Med Univ Lodz, Dept Neurosurg Spine & Peripheral Nerves Surg, PL-90549 Lodz, Poland; [Bartoszek, Adrian] Med Univ Lublin, Dept Pathophysiol, PL-20090 Lublin, Poland; [Karuga, Filip Franciszek] Med Univ Lodz, Dept Sleep Med & Metab Disorders, PL-92215 Lodz, Poland		Bartoszek, A (通讯作者)，Med Univ Lodz, Dept Neurosurg Spine & Peripheral Nerves Surg, PL-90549 Lodz, Poland.; Bartoszek, A (通讯作者)，Med Univ Lublin, Dept Pathophysiol, PL-20090 Lublin, Poland.	bartoszmyd@gmail.com; adrian.bartoszek@stud.umed.lodz.pl; filip.karuga@stud.umed.lodz.pl; katarzyna.staniecka@stud.umed.lodz.pl; maciej.blaszczyk@umed.lodz.pl; maciej.radek@umed.lodz.pl	Szmyd, Bartosz/AAM-8025-2021	Szmyd, Bartosz/0000-0002-4051-0887; Karuga, Filip/0000-0002-6551-6804; Bartoszek, Adrian/0000-0002-6840-7320; Radek, Maciej/0000-0003-3544-1482; Blaszczyk, Maciej/0000-0003-3430-6027	Department of Neurosurgery, Spine and Peripheral Nerves Surgery; Medical University of Lodz	The APC was funded by the Department of Neurosurgery, Spine and Peripheral Nerves Surgery and Medical University of Lodz.	Abalkhail MS, 2017, J INFECT PUBLIC HEAL, V10, P644, DOI 10.1016/j.jiph.2017.05.001; Alsoufi A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242905; Amanna I, 2005, VIRAL IMMUNOL, V18, P307, DOI 10.1089/vim.2005.18.307; [Anonymous], STUDENCI ZALICZ ZAJ; [Anonymous], OGRANICZENIE PROWADZ; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Bartoszek A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17207417; Bozzola E, 2020, RISK MANAG HEALTHC P, V13, P2819, DOI 10.2147/RMHP.S201279; Cebula G., 2020, J NEUROSCI COGN STUD, V4, P1015; Collange F, 2016, VACCINE, V34, P762, DOI 10.1016/j.vaccine.2015.12.054; de Laroche M, 2019, REV MED INTERNE, V40, P238, DOI 10.1016/j.revmed.2018.09.002; Esprit A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040776; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Gabryelska A, 2020, J CLIN SLEEP MED, V16, P1761, DOI 10.5664/jcsm.8682; Gabryelska A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051599; Glaser R, 2003, ARCH GEN PSYCHIAT, V60, P1009, DOI 10.1001/archpsyc.60.10.1009; Glasper Alan, 2019, Br J Nurs, V28, P588, DOI 10.12968/bjon.2019.28.9.588; Haagsma JA, 2012, OCCUP ENVIRON MED, V69, P140, DOI 10.1136/oemed-2011-100068; Hoffman BL, 2019, VACCINE, V37, P2216, DOI 10.1016/j.vaccine.2019.03.003; Kerneis S, 2017, AM J PREV MED, V53, pE97, DOI 10.1016/j.amepre.2017.01.014; Kumar B, 2019, CUREUS, V11, DOI 10.7759/cureus.4257; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; Lozano JM, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040692; Nechita F, 2014, ROM J MORPHOL EMBRYO, V55, P1263; Ozkaya E, 2010, EUR J PEDIATR, V169, P1397, DOI 10.1007/s00431-010-1247-y; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Popa GL, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040774; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Ramos-Morcillo AJ, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16234713; Riaz S, 2017, PAK J MED HEALTH SCI, V11, P1501; Rizal RE, 2015, ADV MED EDUC PRACT, V6, P471, DOI 10.2147/AMEP.S70294; Roszkiewicz J, 2021, SCAND J RHEUMATOL, V50, P213, DOI 10.1080/03009742.2020.1818821; Roszkiewicz J, 2020, INT J RHEUM DIS, V23, P1505, DOI 10.1111/1756-185X.13972; Sarnquist C, 2013, J PUBLIC HEALTH MAN, V19, P40, DOI 10.1097/PHH.0b013e3182495776; Sellens E, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6040083; Sochal M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092921; Szkopek P., 2020, PSYCHIATRIA, V18, P1, DOI [10.5603/PSYCH.a2020.0043, DOI 10.5603/PSYCH.A2020.0043]; Szmyd B, 2021, SLEEP MED REV, V55, DOI 10.1016/j.smrv.2020.101380; Tafuri S, 2014, VACCINE, V32, P4860, DOI 10.1016/j.vaccine.2013.11.006; Thakker Vaishnavi S, 2015, J Family Med Prim Care, V4, P582, DOI 10.4103/2249-4863.174298; Walker L, 2016, VACCINE, V34, P6193, DOI 10.1016/j.vaccine.2016.10.074; Yu JH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010002; Zarobkiewicz MK, 2017, HUM VACC IMMUNOTHER, V13, P2654, DOI 10.1080/21645515.2017.1365994	43	43	43	12	21	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							128	10.3390/vaccines9020128			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6VM	33562872	Green Published, gold	Y	N	2022-04-29	WOS:000623279300001
J	Wollner, CJ; Richner, JM				Wollner, Clayton J.; Richner, Justin M.			mRNA Vaccines against Flaviviruses	VACCINES			English	Review						flavivirus; mRNA vaccines; Dengue; Zika; tick-borne encephalitis		Numerous vaccines have now been developed using the mRNA platform. In this approach, mRNA coding for a viral antigen is in vitro synthesized and injected into the host leading to exogenous protein expression and robust immune responses. Vaccines can be rapidly developed utilizing the mRNA platform in the face of emerging pandemics. Additionally, the mRNA coding region can be easily manipulated to test novel hypotheses in order to combat viral infections which have remained refractory to traditional vaccine approaches. Flaviviruses are a diverse family of viruses that cause widespread disease and have pandemic potential. In this review, we discuss the mRNA vaccines which have been developed against diverse flaviviruses.	[Wollner, Clayton J.; Richner, Justin M.] Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA		Richner, JM (通讯作者)，Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA.	cwolln2@uic.edu; richner@uic.edu		Wollner, Clayton/0000-0001-5692-6249			Aberle JH, 2005, J VIROL, V79, P15107, DOI 10.1128/JVI.79.24.15107-15113.2005; Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3; ALLISON SL, 1995, J VIROL, V69, P695, DOI 10.1128/JVI.69.2.695-700.1995; Anderson BR, 2011, NUCLEIC ACIDS RES, V39, P9329, DOI 10.1093/nar/gkr586; Anderson BR, 2010, NUCLEIC ACIDS RES, V38, P5884, DOI 10.1093/nar/gkq347; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Baiersdorfer M, 2019, MOL THER-NUCL ACIDS, V15, P26, DOI 10.1016/j.omtn.2019.02.018; Balsitis SJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000790; Barbi L, 2018, BRAZ J INFECT DIS, V22, P137, DOI 10.1016/j.bjid.2018.02.005; Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365; Barrett ADT, 2017, VACCINE, V35, P5951, DOI 10.1016/j.vaccine.2017.03.032; Beissert T, 2017, HUM GENE THER, V28, P1138, DOI 10.1089/hum.2017.121; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Bloom K, 2021, GENE THER, V28, P117, DOI 10.1038/s41434-020-00204-y; Brazzoli M, 2016, J VIROL, V90, P332, DOI 10.1128/JVI.01786-15; Chahal JS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00193-w; Chareonsirisuthigul T, 2007, J GEN VIROL, V88, P365, DOI 10.1099/vir.0.82537-0; Cherrier MV, 2009, EMBO J, V28, P3269, DOI 10.1038/emboj.2009.245; Collins MH, 2017, CLIN THER, V39, P1519, DOI 10.1016/j.clinthera.2017.07.001; Cruz-Oliveira C, 2015, FEMS MICROBIOL REV, V39, P155, DOI 10.1093/femsre/fuu004; de Silva AM, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029371; Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058; Dejnirattisai W, 2010, SCIENCE, V328, P745, DOI 10.1126/science.1185181; do Rosario MS, 2016, AM J TROP MED HYG, V95, P1157, DOI 10.4269/ajtmh.16-0306; Ebel GD, 2010, ANNU REV ENTOMOL, V55, P95, DOI 10.1146/annurev-ento-112408-085446; Erasmus JH, 2018, MOL THER, V26, P2507, DOI 10.1016/j.ymthe.2018.07.010; Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036; Fleeton MN, 2001, J INFECT DIS, V183, P1395, DOI 10.1086/319857; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; HALSTEAD SB, 1970, YALE J BIOL MED, V42, P311; Halstead SB, 2017, VACCINE, V35, P6355, DOI 10.1016/j.vaccine.2017.09.089; Henein S, 2017, J INFECT DIS, V215, P351, DOI 10.1093/infdis/jiw576; Hermance ME, 2017, VECTOR-BORNE ZOONOT, V17, P453, DOI 10.1089/vbz.2017.2110; HOKE CH, 1988, NEW ENGL J MED, V319, P608, DOI 10.1056/NEJM198809083191004; Holbrook MR, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050097; Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024; Huang KJ, 2006, J IMMUNOL, V176, P2825, DOI 10.4049/jimmunol.176.5.2825; Huysmans H, 2019, MOL THER-NUCL ACIDS, V17, P867, DOI 10.1016/j.omtn.2019.08.001; ISAACS A, 1963, LANCET, V2, P113; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jackson NAC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0159-8; Kaiser JA, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090823; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kariko K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr695; Katzelnick LC, 2020, SCIENCE, V369, P1123, DOI 10.1126/science.abb6143; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; Kis Z, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010003; Kofler RM, 2004, P NATL ACAD SCI USA, V101, P1951, DOI 10.1073/pnas.0307145101; Kose N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw6647; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Li L, 2008, SCIENCE, V319, P1830, DOI 10.1126/science.1153263; Lindenbach B.D., 2013, FIELDS VIROLOGY, V6th ed., P712; Lindquist L, 2008, LANCET, V371, P1861, DOI 10.1016/S0140-6736(08)60800-4; Luisi K, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba5068; Mandl CW, 1998, NAT MED, V4, P1438, DOI 10.1038/4031; Metz SW, 2018, VIROL J, V15, DOI 10.1186/s12985-018-0970-2; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Musso D, 2019, NEW ENGL J MED, V381, P1444, DOI 10.1056/NEJMra1808246; Nelson CS, 2020, J VIROL, V94, DOI 10.1128/JVI.00186-20; Nikonov A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003610; Pardi N, 2019, MOL THER-NUCL ACIDS, V15, P36, DOI 10.1016/j.omtn.2019.03.003; Pardi N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05482-0; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007; Pierson T.C., 2013, FIELDS VIROLOGY, V6, P747; Pierson TC, 2020, NAT MICROBIOL, V5, P796, DOI 10.1038/s41564-020-0714-0; Plevka P, 2011, EMBO REP, V12, P602, DOI 10.1038/embor.2011.75; Rey FA, 2018, EMBO REP, V19, P206, DOI 10.15252/embr.201745302; Richner JM, 2018, CURR OPIN IMMUNOL, V53, P130, DOI 10.1016/j.coi.2018.04.024; Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; ROSS J, 1985, BLOOD, V66, P1149; Roth C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01424; Schnee M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004746; Shan C, 2018, CELL HOST MICROBE, V24, P12, DOI 10.1016/j.chom.2018.05.021; Shirai S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030433; SMORODINTSEFF A. A., 1941, ARCH GES VIRUSFORSCH, V2, P1, DOI 10.1007/BF01240711; Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505; Swaminathan G, 2016, VACCINE, V34, P110, DOI 10.1016/j.vaccine.2015.10.132; Theiler M, 1937, J EXP MED, V65, P787, DOI 10.1084/jem.65.6.787; Thomas SJ, 2015, AM J PREV MED, V49, pS334, DOI 10.1016/j.amepre.2015.09.006; Tsui NBY, 2002, CLIN CHEM, V48, P1647; VanBlargan LA, 2018, CELL REP, V25, P3382, DOI 10.1016/j.celrep.2018.11.082; Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017; Weissman Drew, 2013, Methods Mol Biol, V969, P43, DOI 10.1007/978-1-62703-260-5_3; Wen ZX, 2017, GENE DEV, V31, P849, DOI 10.1101/gad.298216.117; Wollner C.J., MRNA LNP VACCINE DEN, P2021, DOI [10.1101/2021.01.05.425517, DOI 10.1101/2021.01.05.425517]; World Health Organization, 2018, WKLY EPIDEMIOL REC, V36, P457; Yoshioka N, 2013, CELL STEM CELL, V13, P246, DOI 10.1016/j.stem.2013.06.001; Yun SI, 2014, HUM VACC IMMUNOTHER, V10, P263, DOI 10.4161/hv.26902; Zaitseva E, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001131; Zhang ML, 2020, MOL THER-METH CLIN D, V18, P702, DOI 10.1016/j.omtm.2020.07.013; Zhong ZF, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030096	97	6	6	11	18	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							148	10.3390/vaccines9020148			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7BH	33673131	gold, Green Published			2022-04-29	WOS:000623294800001
J	Zhu, CB; Li, JR; Tian, CN; Qin, MM; Wang, ZN; Shi, BJ; Qu, GG; Wu, CY; Nan, YC				Zhu, Chengbo; Li, Jingrui; Tian, Chaonan; Qin, Mengmeng; Wang, Zhenni; Shi, Bingjun; Qu, Guanggang; Wu, Chunyan; Nan, Yuchen			Proteomic Analysis of ISGylation in Immortalized Porcine Alveolar Macrophage Cell Lines Induced by Type I Interferon	VACCINES			English	Article						interferons; interferons-stimulated genes (ISGs); ISG15; ISGylation; ubiquitination		Interferon-stimulated gene product 15 (ISG15), a ubiquitin-like molecule, can be conjugated to protein substrates through a reversible process known as ISGylation. ISG15 and ISGylation are both strongly upregulated by type I interferons and play putative key roles in host innate immunity against viral infection. However, the function of ISGylation and identities of ISGylation substrates are largely unknown. Here, a novel monoclonal antibody (Mab) that specifically recognizes porcine ISG15 (pISG15) was employed to capture ISG15-conjugated proteins from IFNs-stimulated porcine cell lysates. Next, Mab-captured conjugates were analyzed using proteomics-based tools to identify potential ISGylation protein targets in order to elucidate the roles of ISG15 and ISGylation in porcine cells. Subsequently, 190 putative ISGylation sites were detected within 98 identified ISGylation candidates; several candidates contained more than one ISGylation-modifiable lysine residue, including pISG15 itself. Motif enrichment analysis of confirmed ISGylation sites demonstrated a moderate bias towards certain sites with specific upstream amino acid residues. Meanwhile, results of Gene Ontology (GO)-based annotation and functional enrichment and protein-protein interaction (PPI) network analyses of porcine ISG15-conjugated substrate proteins indicated that these substrates were mainly associated with the host metabolism, especially nucleotide metabolic pathways that ultimately may participate in cellular antiviral defenses. Notably, several ISGs (MX1, IFIT1, OAS1, ISG15 and putative ISG15 E3 ligase Herc6) were also identified as putative ISGylation substrates within a regulatory loop involving ISGylation of ISGs themselves. Taken together, proteomics analysis of porcine ISGylation substrates revealed putative functional roles of ISG15 and novel host ISGylation targets that may ultimately be involved in cellular antiviral responses.	[Zhu, Chengbo; Tian, Chaonan; Qin, Mengmeng; Wang, Zhenni; Shi, Bingjun; Wu, Chunyan; Nan, Yuchen] Northwest A&F Univ, Coll Vet Med, Dept Prevent Vet Med, Yangling 712100, Shaanxi, Peoples R China; [Li, Jingrui] China Agr Univ, Coll Biol Sci, State Key Lab Plant Physiol & Biochem, Beijing 100193, Peoples R China; [Shi, Bingjun] Shaanxi Anim Dis Control Ctr, Xian 710000, Peoples R China; [Qu, Guanggang] Binzhou Anim Sci & Vet Med Acad, Binzhou 256600, Peoples R China		Wu, CY; Nan, YC (通讯作者)，Northwest A&F Univ, Coll Vet Med, Dept Prevent Vet Med, Yangling 712100, Shaanxi, Peoples R China.; Qu, GG (通讯作者)，Binzhou Anim Sci & Vet Med Acad, Binzhou 256600, Peoples R China.	chengbozhu@nwafu.edu.cn; jrli@cau.edu.cn; ttttian121@163.com; qinmengmeng111@163.com; wzn02060207@163.com; 13333482298@163.com; Guanggangqu@163.com; chunyanwu@nwsuaLedu.cn; nanyuchen2015@nwsuaf.edu.cn	Nan, Yuchen/ABF-3746-2021; Nan, Yuchen/F-9917-2014	Nan, Yuchen/0000-0002-4442-8004	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC)	This research was funded by the National Natural Science Foundation of China, grant number 31672534. And The APC was funded by a grant from the National Natural Science Foundation of China awarded to Y.N.	Blouin CM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00267; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; Dengjel J, 2005, J MASS SPECTROM, V40, P100, DOI 10.1002/jms.780; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Durfee LA, 2010, MOL CELL, V38, P722, DOI 10.1016/j.molcel.2010.05.002; Dzimianski JV, 2019, J MOL BIOL, V431, P4203, DOI 10.1016/j.jmb.2019.03.013; Fensterl V, 2009, BIOFACTORS, V35, P14, DOI 10.1002/biof.6; Giannakopoulos NV, 2005, BIOCHEM BIOPH RES CO, V336, P496, DOI 10.1016/j.bbrc.2005.08.132; Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888; KNIGHT E, 1988, J BIOL CHEM, V263, P4520; Lenschow DJ, 2005, J VIROL, V79, P13974, DOI 10.1128/JVI.79.22.13974-13983.2005; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; Liu HB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12091009; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Lu G, 2006, CELL MOL BIOL, V52, P29, DOI 10.1170/T695; Malakhova OA, 2003, GENE DEV, V17, P455, DOI 10.1101/gad.1056303; Malakhova OA, 2008, J BIOL CHEM, V283, P8783, DOI 10.1074/jbc.C800030200; Mu Y, 2015, VIROLOGY, V484, P136, DOI 10.1016/j.virol.2015.05.019; Nan YC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01758; Okumura A, 2008, P NATL ACAD SCI USA, V105, P3974, DOI 10.1073/pnas.0710629105; Osiak A, 2005, MOL CELL BIOL, V25, P6338, DOI 10.1128/MCB.25.15.6338-6345.2005; Oudshoorn D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029870; Patel D, 2008, ANTIVIR RES, V77, P95, DOI 10.1016/j.antiviral.2007.09.002; Perng YC, 2018, NAT REV MICROBIOL, V16, P423, DOI 10.1038/s41579-018-0020-5; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Pincetic A, 2010, J VIROL, V84, P4725, DOI 10.1128/JVI.02478-09; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Prokunina-Olsson L, 2013, NAT GENET, V45, P164, DOI 10.1038/ng.2521; Sadler AJ, 2008, NAT REV IMMUNOL, V8, P559, DOI 10.1038/nri2314; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Seo EJ, 2012, ADV VIROL, V2012, DOI 10.1155/2012/532723; Shi HX, 2010, MOL CELL BIOL, V30, P2424, DOI 10.1128/MCB.01466-09; Sun Z, 2012, J VIROL, V86, P3839, DOI 10.1128/JVI.06466-11; Takeuchi T, 2006, FEBS LETT, V580, P4521, DOI 10.1016/j.febslet.2006.07.032; Takeuchi T, 2006, BIOCHEM BIOPH RES CO, V348, P473, DOI 10.1016/j.bbrc.2006.07.076; Uze G, 2007, CURR TOP MICROBIOL, V316, P71; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; Wong JJY, 2006, P NATL ACAD SCI USA, V103, P10735, DOI 10.1073/pnas.0600397103; Zhang DX, 2011, J INTERF CYTOK RES, V31, P119, DOI 10.1089/jir.2010.0110; Zhao C, 2005, P NATL ACAD SCI USA, V102, P10200, DOI 10.1073/pnas.0504754102	41	2	2	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							164	10.3390/vaccines9020164			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6XD	33671165	gold, Green Published			2022-04-29	WOS:000623283700001
J	Pruss, BM				Pruss, Birgit M.			Current State of the First COVID-19 Vaccines	VACCINES			English	Review						SARS CoV-2; COVID-19; vaccine development; phase III trial	MESSENGER-RNA VACCINES; BCG VACCINATION; EFFICACY; SAFETY	SARS CoV-2 and its associated disease COVID-19 has devastated the world during 2020. Masks and social distancing could be efficient if done by large proportions of the population, but pandemic fatigue has decreased their efficacy. Economic shut downs come with large price tags and cannot be a long term solution either. The announcements by three vaccine manufacturers in November that their vaccines are 90% or more effective has given hope to at least those in the population who plan to get vaccinated as soon as a scientifically and medically sound vaccine becomes available. This review summarizes the underlying design strategies and current status of development of the nine vaccines that were in phase III trial on 8 November 2020. Contracts between vaccine manufacturing companies and governments aim at distributing the vaccine to a large part of the world population. Questions remain how the temperature sensitive mRNA vaccines will be transported and/or stored and how vaccination will be prioritized within each country. Additionally, current contracts do not cover all countries, with a serious gap in Africa and South America. The second part of this review will detail current distribution plans and remaining challenges with vaccine accessibility and acceptance.	[Pruss, Birgit M.] North Dakota State Univ, Dept Microbiol Sci, Fargo, ND 58104 USA		Pruss, BM (通讯作者)，North Dakota State Univ, Dept Microbiol Sci, Fargo, ND 58104 USA.	Birgit.Pruess@ndsu.edu		Pruess, Birgit/0000-0002-5244-766X	USDA National Institute of Food and Agriculture, Hatch project [ND02438]	B.M.P. was supported by the USDA National Institute of Food and Agriculture, Hatch project number ND02438.	Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Anderson BR, 2011, NUCLEIC ACIDS RES, V39, P9329, DOI 10.1093/nar/gkr586; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 2020, COVID 19 VACCINATION; [Anonymous], 2020, JCVI UPDATED INTERIM; Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010; Bangaru S, 2020, SCIENCE, V370, P1089, DOI 10.1126/science.abe1502; Bos R, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00243-x; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Bucci E, 2020, LANCET, V396, pE53, DOI 10.1016/S0140-6736(20)31960-7; Burki TK, 2020, LANCET RESP MED, V8, pE85, DOI 10.1016/S2213-2600(20)30402-1; Callaway E, 2020, NATURE, V587, P337, DOI 10.1038/d41586-020-03248-7; Callaway Ewen, 2020, Nature, DOI 10.1038/d41586-020-03166-8; Callaway E, 2020, NATURE, V584, P334, DOI 10.1038/d41586-020-02386-2; Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9; Chung YH, 2020, ACS NANO, V14, P12522, DOI 10.1021/acsnano.0c07197; Cohen, 2020, SCIENCE, DOI [10.1126/science.abc7103, DOI 10.1126/SCIENCE.ABC7103]; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4; Diken M, 2017, CURR ISSUES MOL BIOL, V22, P113, DOI 10.21775/cimb.022.113; Dooling K., 2020, COVID 19 VACCINE PRI; El-Sadr WM, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2008193; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Fraser E, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3001; Gopalaswamy R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040612; Graham SP, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00221-3; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI [10.1056/NEJMc2005203, 10.1056/NEJMoa2002032]; Guebre-Xabier M, 2020, VACCINE, V38, P7892, DOI 10.1016/j.vaccine.2020.10.064; Haider N, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S0950268820000424; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Hsiang S, 2020, NATURE, V584, P262, DOI 10.1038/s41586-020-2404-8; Hu BY, 2021, J MED VIROL, V93, P250, DOI 10.1002/jmv.26232; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jahnel T, 2020, GESUNDHEITSWESEN, V82, P664, DOI 10.1055/a-1195-2474; Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Konturek PC, 2020, J PHYSIOL PHARMACOL, V71, DOI 10.26402/jpp.2020.2.02; Krause KL, 2020, NEW ZEAL MED J, V133, P107; Lazarus JV, 2020, NAT MED, V26, P1005, DOI 10.1038/s41591-020-0950-0; Ledford Heidi, 2020, Nature, DOI 10.1038/d41586-020-03593-7; Letko Michael, 2020, bioRxiv, DOI 10.1101/2020.01.22.915660; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Lu S, 2009, CURR OPIN IMMUNOL, V21, P346, DOI 10.1016/j.coi.2009.05.016; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4714; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3967; MALIK AA, 2020, CLIN MED, V26, DOI DOI 10.1016/J.ECLINM.2020.100495; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Moorlag SJCFM, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100073; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Munoz DC, 2015, INT J PUBLIC HEALTH, V60, P767, DOI 10.1007/s00038-015-0715-6; Ozdemir C, 2020, ALLERGY, V75, P1824, DOI 10.1111/all.14344; Palacios R, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04775-4; Pardi N, 2017, METHODS MOL BIOL, V1499, P109, DOI 10.1007/978-1-4939-6481-9_6; Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007; Payne C, 2020, NAT HUM BEHAV, V4, P436, DOI 10.1038/s41562-020-0870-5; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Prua&beta; B.M., 2020, MED RES ARCH, V8, DOI [10.18103/mra.v8i8.2203, DOI 10.18103/MRA.V8I8.2203]; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Ravi N, 2020, BIOSENS BIOELECTRON, V165, DOI 10.1016/j.bios.2020.112454; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; SALATHE M, 2020, SWISS MED WEEKLY, V150, DOI [DOI 10.4414/SMW.2020.20225, 10.4414/smw.2020.20225]; Steinbrook R, 2020, JAMA INTERN MED, V180, P1163, DOI 10.1001/jamainternmed.2020.2072; Tan WG, 2013, J VIROL, V87, P1359, DOI 10.1128/JVI.02055-12; Tanne JH, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4836; Tanne JH, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4799; Tobias A, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138539; Tostanoski LH, 2020, NAT MED, V26, P1694, DOI 10.1038/s41591-020-1070-6; Troyer EA, 2020, BRAIN BEHAV IMMUN, V87, P34, DOI 10.1016/j.bbi.2020.04.027; Tsivgoulis G, 2020, THER ADV NEUROL DISO, V13, DOI 10.1177/1756286420932036; Ura T, 2014, VACCINES, V2, P624, DOI 10.3390/vaccines2030624; van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walsh Edward E, 2020, medRxiv, DOI 10.1101/2020.08.17.20176651; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Winslow RL, 2017, JAMA-J AM MED ASSOC, V317, P1074, DOI 10.1001/jama.2016.20644; Wu SP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17972-1; Xu B, 2020, LANCET INFECT DIS, V20, P534, DOI 10.1016/S1473-3099(20)30119-5; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	84	24	24	5	28	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							30	10.3390/vaccines9010030			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6UN	33429880	gold, Green Published			2022-04-29	WOS:000610807200001
J	Bernea, L; Ailioaie, OR; Benhamouda, N; Tartour, E; Germain, DP				Bernea, Lavinia; Ailioaie, Oana R.; Benhamouda, Nadine; Tartour, Eric; Germain, Dominique P.			Humoral Immune Response to SARS-CoV-2 Vaccination after a Booster Vaccine Dose in Two Kidney Transplant Recipients with Fabry Disease and Variable Secondary Immunosuppressive Regimens	VACCINES			English	Article						COVID-19; vaccine; Fabry disease; renal transplant	NATURAL-HISTORY	The urgent need to fight the COVID-19 pandemic has accelerated the development of vaccines against SARS-CoV-2 and approval processes. Initial analysis of two-dose regimens with mRNA vaccines reported up to 95% efficacy against the original strain of the SARS-CoV-2 virus. Challenges arose with the appearance of new strains of the virus, and reports that solid organ transplant recipients may have reduced vaccination success rates after a two-dose mRNA vaccination regimen encouraged health authorities to recommend a booster in immunocompromised patients. Fabry disease is an X-linked inherited lysosomal disorder, which may lead to chronic end-stage renal disease. We report on two patients with advanced Fabry disease, renal graft and adjunctive immunosuppressive therapies who exhibited variable humoral vaccination-related immune responses against SARS-CoV-2 after three vaccine doses. The first patient developed mild COVID-19 infection, while the second patient did not seroconvert after three shots of an mRNA vaccine. Both cases emphasize that patients with Fabry disease and renal graft are susceptible to develop a weak response to COVID-19 vaccination and highlight the importance of maintaining barrier protection measures. Vaccination of family members should be encouraged to lower the risk of viral transmission to immunocompromised, transplanted patients, including vaccinated ones.	[Bernea, Lavinia; Ailioaie, Oana R.; Germain, Dominique P.] Paris Saclay Univ, AP HP, Div Med Genet, French Referral Ctr Fabry Dis, F-92380 Garches, France; [Benhamouda, Nadine; Tartour, Eric] Hop Europeen Georges Pompidou, AP HP, INSERM, Dept Immunol,U970, F-75015 Paris, France; [Benhamouda, Nadine; Tartour, Eric] Univ Paris, F-75015 Paris, France; [Germain, Dominique P.] Charles Univ Prague, Fac Med 1, Dept Internal Med 2, Prague 12808, Czech Republic; [Germain, Dominique P.] Univ Versailles, Div Med Genet, F-78180 Montigny, France		Germain, DP (通讯作者)，Paris Saclay Univ, AP HP, Div Med Genet, French Referral Ctr Fabry Dis, F-92380 Garches, France.; Germain, DP (通讯作者)，Charles Univ Prague, Fac Med 1, Dept Internal Med 2, Prague 12808, Czech Republic.; Germain, DP (通讯作者)，Univ Versailles, Div Med Genet, F-78180 Montigny, France.	lavinia-maria.bernea@aphp.fr; assistants.genetique.rpc@aphp.fr; nadine.benhamouda@aphp.fr; eric.tartour@aphp.fr; dominique.germain@uvsq.fr	tartour, eric/O-7957-2017	tartour, eric/0000-0002-7323-468X			Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Echevarria L, 2016, CLIN GENET, V89, P44, DOI 10.1111/cge.12613; Germain DP, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-30; Germain DP, 1999, BIOCHEM BIOPH RES CO, V257, P708, DOI 10.1006/bbrc.1999.0310; Grupper A, 2021, AM J TRANSPLANT, V21, P2719, DOI 10.1111/ajt.16615; Hagege A, 2019, ARCH CARDIOVASC DIS, V112, P278, DOI 10.1016/j.acvd.2019.01.002; Hall VG, 2021, AM J TRANSPLANT, V21, P3980, DOI 10.1111/ajt.16766; Hod T, 2021, TRANSPLANTATION, V105, pE234, DOI 10.1097/TP.0000000000003889; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Laney DA, 2020, CLIN KIDNEY J, V13, P913, DOI 10.1093/ckj/sfaa227; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Livingston Edward H, 2021, JAMA, V325, P1575, DOI 10.1001/jama.2021.2927; Magage S, 2007, J INHERIT METAB DIS, V30, P790, DOI 10.1007/s10545-007-0616-9; Mazzola A, 2022, CLIN INFECT DIS, V74, P1093, DOI 10.1093/cid/ciab580; Nagy A, 2021, COMPUT STRUCT BIOTEC, V19, P2508, DOI 10.1016/j.csbj.2021.04.061; Ortiz A, 2010, NEPHROL DIAL TRANSPL, V25, P769, DOI 10.1093/ndt/gfp554; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rader B, 2021, LANCET DIGIT HEALTH, V3, pE148, DOI 10.1016/S2589-7500(20)30293-4; Rost NS, 2016, NEUROLOGY, V86, P1880, DOI 10.1212/WNL.0000000000002673; Sharma O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585354; Stumpf J, 2021, LANCET REG HEALTH-EU, V9, DOI 10.1016/j.lanepe.2021.100178; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Werbel WA, 2021, ANN INTERN MED, V174, P1330, DOI 10.7326/L21-0282	25	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1412	10.3390/vaccines9121412			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ1YX	34960158	gold, Green Published			2022-04-29	WOS:000737456800001
J	Kok, A; Fouchier, RAM; Richard, M				Kok, Adinda; Fouchier, Ron A. M.; Richard, Mathilde			Cross-Reactivity Conferred by Homologous and Heterologous Prime-Boost A/H5 Influenza Vaccination Strategies in Humans: A Literature Review	VACCINES			English	Article						avian influenza A virus; H5 influenza virus; zoonosis; pandemic; vaccination	A H5N1 VACCINE; IMMUNE-RESPONSES; WHOLE-VIRUS; DOUBLE-BLIND; PHASE-I; CLADE IMMUNOGENICITY; ANTIBODY-RESPONSES; REVERSE-GENETICS; AS03 ADJUVANT; OPEN-LABEL	Avian influenza viruses from the A/H5 A/goose/Guangdong/1/1996 (GsGd) lineage pose a continuing threat to animal and human health. Since their emergence in 1997, these viruses have spread across multiple continents and have become enzootic in poultry. Additionally, over 800 cases of human infection with A/H5 GsGd viruses have been reported to date, which raises concerns about the potential for a new influenza virus pandemic. The continuous circulation of A/H5 GsGd viruses for over 20 years has resulted in the genetic and antigenic diversification of their hemagglutinin (HA) surface glycoprotein, which poses a serious challenge to pandemic preparedness and vaccine design. In the present article, clinical studies on A/H5 influenza vaccination strategies were reviewed to evaluate the breadth of antibody responses induced upon homologous and heterologous prime-boost vaccination strategies. Clinical data on immunological endpoints were extracted from studies and compiled into a dataset, which was used for the visualization and analysis of the height and breadth of humoral immune responses. Several aspects leading to high immunogenicity and/or cross-reactivity were identified, although the analysis was limited by the heterogeneity in study design and vaccine type used in the included studies. Consequently, crucial questions remain to be addressed in future studies on A/H5 GsGd vaccination strategies.	[Kok, Adinda; Fouchier, Ron A. M.; Richard, Mathilde] Erasmus MC, Dept Virosci, NL-3015 GD Rotterdam, Netherlands		Richard, M (通讯作者)，Erasmus MC, Dept Virosci, NL-3015 GD Rotterdam, Netherlands.	m.richard@erasmusmc.nl	Richard, Mathilde/F-5461-2017; Fouchier, Ron A/A-1911-2014	Richard, Mathilde/0000-0003-0240-9312; Fouchier, Ron A/0000-0001-8095-2869; Kok, Adinda/0000-0003-3635-7952			Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Ainai A, 2020, MICROBIOL IMMUNOL, V64, P313, DOI 10.1111/1348-0421.12775; Banzhoff A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004384; Belshe RB, 2014, JAMA-J AM MED ASSOC, V312, P1420, DOI 10.1001/jama.2014.12609; Beran J, 2010, CLIN THER, V32, P2186, DOI 10.1016/S0149-2918(11)00024-5; Beyer WEP, 1998, CLIN DRUG INVEST, V15, P1, DOI 10.2165/00044011-199815010-00001; Bihari I, 2012, CLIN VACCINE IMMUNOL, V19, P1943, DOI 10.1128/CVI.00373-12; Chu Daniel W. S., 2011, Hong Kong Medical Journal, V17, P39; Chu DWS, 2009, VACCINE, V27, P7428, DOI 10.1016/j.vaccine.2009.07.102; Cobey S, 2017, CURR OPIN VIROL, V22, P105, DOI 10.1016/j.coviro.2016.12.004; Couch RB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050830; Coudeville L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-18; de Vries RD, 2018, J INFECT DIS, V218, P614, DOI 10.1093/infdis/jiy214; deJong JC, 1997, NATURE, V389, P554, DOI 10.1038/39218; Ehrlich HJ, 2008, NEW ENGL J MED, V358, P2573, DOI 10.1056/NEJMoa073121; Ehrlich HJ, 2009, J INFECT DIS, V200, P1113, DOI 10.1086/605608; Fazekas G, 2009, CLIN VACCINE IMMUNOL, V16, P437, DOI 10.1128/CVI.00327-08; Fonville JM, 2014, SCIENCE, V346, P996, DOI 10.1126/science.1256427; Galli G, 2009, P NATL ACAD SCI USA, V106, P7962, DOI 10.1073/pnas.0903181106; Gillard P, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-142; Gillard P, 2013, INFLUENZA OTHER RESP, V7, P55, DOI 10.1111/j.1750-2659.2012.00349.x; Goji NA, 2008, J INFECT DIS, V198, P635, DOI 10.1086/590916; Govorkova EA, 2006, J INFECT DIS, V194, P159, DOI 10.1086/505225; Haveri A, 2021, VACCINE, V39, P402, DOI 10.1016/j.vaccine.2020.11.041; He XS, 2006, J VIROL, V80, P11756, DOI 10.1128/JVI.01460-06; Herfst S, 2012, SCIENCE, V336, P1534, DOI 10.1126/science.1213362; Hoffmann E, 2005, P NATL ACAD SCI USA, V102, P12915, DOI 10.1073/pnas.0506416102; Imai M, 2012, NATURE, V486, P420, DOI 10.1038/nature10831; Izurieta P, 2015, VACCINE, V33, P2800, DOI 10.1016/j.vaccine.2015.04.027; Jeong JH, 2019, VACCINE, V37, P484, DOI 10.1016/j.vaccine.2018.11.064; Khurana S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115476; Khurana S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095496; Krammer F, 2020, INFLUENZA OTHER RESP, V14, P237, DOI 10.1111/irv.12706; Kreijtz JHCM, 2014, LANCET INFECT DIS, V14, P1196, DOI [10.1016/S1473-3099(14)70963-6, 10.1016/s1473-3099(14)70963-6]; Kyriakidis NC, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00292-w; Landry N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015559; Langley JM, 2010, J INFECT DIS, V201, P1644, DOI 10.1086/652701; Lasko B, 2011, J INFECT DIS, V204, P574, DOI 10.1093/infdis/jir328; Layton RC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020641; Leroux-Roels I, 2010, VACCINE, V28, P849, DOI 10.1016/j.vaccine.2009.10.017; Levie K, 2008, J INFECT DIS, V198, P642, DOI 10.1086/590913; Levine MZ, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0114-8; Lin YJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29858-w; Linster M, 2014, CELL, V157, DOI 10.1016/j.cell.2014.02.040; Lipatov AS, 2006, J INFECT DIS, V194, P1040, DOI 10.1086/507709; Lofano G, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00336; Lopez P, 2013, CLIN VACCINE IMMUNOL, V20, P753, DOI 10.1128/CVI.00626-12; Luke CJ, 2014, EXPERT REV VACCINES, V13, P873, DOI 10.1586/14760584.2014.922416; Monto AS, 2020, CLIN INFECT DIS, V70, P951, DOI 10.1093/cid/ciz803; Mostafa A, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090497; Nagai H, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-338; Naruse T, 2015, VACCINE, V33, P6078, DOI 10.1016/j.vaccine.2015.09.022; Nolan TM, 2008, VACCINE, V26, P4160, DOI 10.1016/j.vaccine.2008.05.077; Oshansky CM, 2019, VACCINE, V37, P435, DOI 10.1016/j.vaccine.2018.11.069; Park SJ, 2016, VIROLOGY, V498, P36, DOI 10.1016/j.virol.2016.08.010; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Pitisuttithum P, 2017, LANCET INFECT DIS, V17, P833, DOI [10.1016/s1473-3099(17)30240-2, 10.1016/S1473-3099(17)30240-2]; Risi G, 2011, VACCINE, V29, P6408, DOI 10.1016/j.vaccine.2011.04.072; Rockman S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020211; Rudenko L, 2008, INFLUENZA OTHER RESP, V2, P203, DOI 10.1111/j.1750-2659.2008.00064.x; SAGE Working Group, WORK GROUP INFL VACC; Sansyzbay AR, 2013, CLIN VACCINE IMMUNOL, V20, P1314, DOI 10.1128/CVI.00096-13; Schuind A, 2015, J INFECT DIS, V212, P531, DOI 10.1093/infdis/jiv091; Schwarz TF, 2009, VACCINE, V27, P6284, DOI 10.1016/j.vaccine.2009.01.040; Smith GJD, 2015, INFLUENZA OTHER RESP, V9, P271, DOI 10.1111/irv.12324; Stephenson I, 2005, J INFECT DIS, V191, P1210, DOI 10.1086/428948; Sun XJ, 2017, VIROLOGY, V508, P164, DOI 10.1016/j.virol.2017.05.010; Tambyah PA, 2012, VACCINE, V30, P329, DOI 10.1016/j.vaccine.2011.10.088; Thongcharoen Prasert, 2011, Journal of the Medical Association of Thailand, V94, P916; Trombetta CM, 2014, VACCINES-BASEL, V2, P707, DOI 10.3390/vaccines2040707; Vela EM, 2012, INFLUENZA OTHER RESP, V6, P328, DOI 10.1111/j.1750-2659.2011.00321.x; Vesikari T, 2012, VACCINE, V30, P1388, DOI 10.1016/j.vaccine.2011.12.009; Wang J, 2021, MBIO, V12, DOI 10.1128/mBio.00449-21; WHO, 2021, CUM NUMB CONF HUM CA; WHO, 2021, ANT GEN CHAR ZOON IN; WHO, TABL CLIN EV INFL VA; WHO/OIE/FAO H5N1 Evolution Working Group, 2008, Emerg Infect Dis, V14, pe1, DOI 10.3201/eid1407.071681; Winokur PL, 2015, J INFECT DIS, V212, P525, DOI 10.1093/infdis/jiv087; Wu J, 2009, CLIN INFECT DIS, V48, P1087, DOI 10.1086/597401; Yang PC, 2012, J FORMOS MED ASSOC, V111, P333, DOI 10.1016/j.jfma.2011.02.006; Zheng D, 2019, HUM VACC IMMUNOTHER, V15, P80, DOI 10.1080/21645515.2018.1515454	81	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1465	10.3390/vaccines9121465			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0GD	34960210	Green Published, gold			2022-04-29	WOS:000737340300001
J	Najjar, H; Al-Jighefee, HT; Qush, A; Ahmed, MN; Awwad, S; Kamareddine, L				Najjar, Hoda; Al-Jighefee, Hadeel T.; Qush, Abeer; Ahmed, Muna Nizar; Awwad, Sara; Kamareddine, Layla			COVID-19 Vaccination: The Mainspring of Challenges and the Seed of Remonstrance	VACCINES			English	Article						SARS-CoV-2; COVID-19; vaccination; challenges; production; distribution; remonstrance; safety; public perception	HESITANCY; VACCINES; ACCESS	As of March 2020, the time when the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became a pandemic, our existence has been threatened and the lives of millions have been claimed. With this ongoing global issue, vaccines are considered of paramount importance in curtailing the outbreak and probably a prime gamble to bring us back to 'ordinary life'. To date, more than 200 vaccine candidates have been produced, many of which were approved by the Food and Drug Administration (FDA) for emergency use, with the research and discovery phase of their production process passed over. Capering such a chief practice in COVID-19 vaccine development, and manufacturing vaccines at an unprecedented speed brought many challenges into play and raised COVID-19 vaccine remonstrance. In this review, we highlight relevant challenges to global COVID-19 vaccine development, dissemination, and deployment, particularly at the level of large-scale production and distribution. We also delineate public perception on COVID-19 vaccination and outline the main facets affecting people's willingness to get vaccinated.	[Najjar, Hoda; Al-Jighefee, Hadeel T.; Qush, Abeer; Ahmed, Muna Nizar; Awwad, Sara; Kamareddine, Layla] Qatar Univ, Dept Biomed Sci, Coll Hlth Sci, QU Hlth, POB 2713, Doha, Qatar; [Al-Jighefee, Hadeel T.; Kamareddine, Layla] Qatar Univ, Biomed Res Ctr, POB 2713, Doha, Qatar; [Kamareddine, Layla] Qatar Univ, Biomed & Pharmaceut Res Unit, QU Hlth, POB 2713, Doha, Qatar		Kamareddine, L (通讯作者)，Qatar Univ, Dept Biomed Sci, Coll Hlth Sci, QU Hlth, POB 2713, Doha, Qatar.; Kamareddine, L (通讯作者)，Qatar Univ, Biomed Res Ctr, POB 2713, Doha, Qatar.; Kamareddine, L (通讯作者)，Qatar Univ, Biomed & Pharmaceut Res Unit, QU Hlth, POB 2713, Doha, Qatar.	hn1517144@student.qu.edu.qa; ha1510267@student.qu.edu.qa; 200050311@student.qu.edu.qa; ma1507488@student.qu.edu.qa; sa1900788@student.qu.edu.qa; lkamareddine@qu.edu.qa		Al-Jighefee, Hadeel/0000-0002-9484-7290; Kamareddine, Layla/0000-0002-4988-237X			Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688; Al-Jighefee HT, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101196; Altimmune, 2021, ALT ANN UPD ADCOVID; Anderson EJ, 2021, CLIN INFECT DIS, V73, P336, DOI 10.1093/cid/ciaa1425; [Anonymous], 2021, GENDER DIFFERENCES I; [Anonymous], 2021, NEWS; [Anonymous], MCGILL COVID19 VACCI; [Anonymous], MOD ANN SUBM IN DAT; [Anonymous], 2021, NEW YORK TIMES; [Anonymous], NEW YORK TIMES; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Arvin AM, 2020, NATURE, V584, P353, DOI 10.1038/s41586-020-2538-8; Bahans C, 2021, Ethics Med Public Health, V16, P100621, DOI 10.1016/j.jemep.2020.100621; Baldo V, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010021; Betsch C., 2015, SCOTTISH INDEX MULTI, V2, P61, DOI 10.1177/2372732215600716; Betsch C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208601; Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521; Brown D, 2009, WASH POST; Brumfiel G, 2021, ANTIVACCINE ACTIVIST; Burki T, 2020, LANCET DIGIT HEALTH, V2, pE504, DOI 10.1016/S2589-7500(20)30227-2; Carrieri V, 2019, HEALTH ECON, V28, P1377, DOI 10.1002/hec.3937; Castillo JC, 2021, SCIENCE, V371, P1107, DOI 10.1126/science.abg0889; Cheng SX, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000024971; Daoust JF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235590; de Figueiredo A., 2021, COVID 19 VACCINE ACC, DOI [10.1101/2021.05.30.21258074, DOI 10.1101/2021.05.30.21258074]; Deb B, 2020, J BIOSCIENCES, V45, DOI 10.1007/s12038-020-00053-2; Dobrowolski Z, 2021, EUR RES STUD J, V24, P532, DOI [10.35808/ersj/1978, DOI 10.35808/ERSJ/1978]; Dos Santos WG, 2021, BIOMED PHARMACOTHER, V136, DOI 10.1016/j.biopha.2021.111272; Doshi P, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3563; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Duffy S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000003; El-Mohandes A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-00794-6; European Centre for Disease Prevention and Control, 2020, KEY ASP REG INTR PRI; European Commission, 2020, PREP COVID 19 VACC S; Fajnzylber J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19057-5; Feng LQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18077-5; Fidler DP, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000247; Forman R, 2021, HEALTH POLICY, V125, P553, DOI 10.1016/j.healthpol.2021.03.013; Forman R, 2020, VACCINE, V38, P6075, DOI 10.1016/j.vaccine.2020.07.068; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Gavi, 2021, COLD SUPPL HOT DEM; Germani F, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247642; Greaney AJ, 2021, CELL HOST MICROBE, V29, P44, DOI 10.1016/j.chom.2020.11.007; Gribble J, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009226; Guner R, 2020, TURK J MED SCI, V50, P571, DOI 10.3906/sag-2004-146; Guo X, 2020, LONG TERM PERSISTENC, DOI DOI 10.1101/2020.02.12.20021386V1; Hansen J, 2021, UAB NEWS 0510; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Hotez PJ, 2020, NAT REV IMMUNOL, V20, P347, DOI 10.1038/s41577-020-0323-4; Jung F, 2020, CLIN HEMORHEOL MICRO, V75, P13, DOI 10.3233/CH-209006; Ko JY, 2021, CLIN INFECT DIS, V72, pE695, DOI 10.1093/cid/ciaa1419; Kojima N, 2022, LANCET INFECT DIS, V22, P12, DOI 10.1016/S1473-3099(21)00676-9; Koyama T, 2020, B WORLD HEALTH ORGAN, V98, P495, DOI 10.2471/BLT.20.253591; Krause PR, 2021, LANCET, V398, P1377, DOI 10.1016/S0140-6736(21)02046-8; Kyei-Barffour I, 2021, BIOMED PHARMACOTHER, V144, DOI 10.1016/j.biopha.2021.112282; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Lehmann BA, 2014, VACCINE, V32, P6986, DOI 10.1016/j.vaccine.2014.10.034; Lewis D, 2021, NATURE, V595, P344, DOI 10.1038/d41586-021-01805-2; Li T., 2021, FUNDAM RES, V1, P139, DOI 10.1016/j.fmre.2021.01.011; Li YD, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00695-2; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Machingaidze S, 2021, NAT MED, V27, P1338, DOI 10.1038/s41591-021-01459-7; Markus D, 2008, HARV J AFR AM PUBLIC, V14, P85; Megget K, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2184; Mello MM, 2020, NEW ENGL J MED, V383, P1296, DOI 10.1056/NEJMp2020926; Mereckiene J, 2012, EUROSURVEILLANCE, V17, P18; Moderna, 2021, MOD COVID 19 VACC RE; Mueller AL, 2020, AGING-US, V12, P9959, DOI 10.18632/aging.103344; Muik A, 2021, SCIENCE, V371, P1152, DOI 10.1126/science.abg6105; Mukumbang FC, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2020-004085; Murdin AD, 1996, VACCINE, V14, P735, DOI 10.1016/0264-410X(95)00211-I; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Nordstrom P., 2021, LANCET, DOI [10.2139/ssrn.3949410, DOI 10.2139/SSRN.3949410]; Pal Suman, 2021, Vaccines (Basel), V9, DOI 10.3390/vaccines9111358; Pepperrell T, 2021, GLOBAL HEALTH ACTION, V14, DOI 10.1080/16549716.2021.1892309; Persad G, 2020, JAMA-J AM MED ASSOC, V324, P1601, DOI 10.1001/jama.2020.18513; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Prado-Vivar B, 2020, COVID 19 REINFECTION; Public Health England, 2021, 36 PUBL HLTH ENGL; Redd Andrew D, 2021, Open Forum Infect Dis, V8, pofab143, DOI [10.1101/2021.02.11.21251585, 10.1093/ofid/ofab143]; Ripperger TJ, 2020, IMMUNITY, V53, P925, DOI 10.1016/j.immuni.2020.10.004; Ritchie H., 2020, STAT RES; Rutten LJF, 2021, MAYO CLIN PROC, V96, P699, DOI 10.1016/j.mayocp.2020.12.024; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Schmidt H, 2020, HASTINGS CENT REP, V50, P46, DOI 10.1002/hast.1113; Schoch-Spana M, 2021, VACCINE, V39, P6004, DOI 10.1016/j.vaccine.2020.10.059; Sharma O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585354; Simpson S, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00249-5; Soy A, 2021, BBC NEWS 0122; SteelFisher Gillian K, 2010, N Engl J Med, V362, pe65, DOI 10.1056/NEJMp1005102; Sze S, 2020, ECLINICALMEDICINE, V29-30, DOI 10.1016/j.eclinm.2020.100630; Tanne JH, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n232; Thomson A, 2016, VACCINE, V34, P1018, DOI 10.1016/j.vaccine.2015.11.065; Tillett RL, 2021, LANCET INFECT DIS, V21, P52, DOI 10.1016/S1473-3099(20)30764-7; To K.K., 2021, CLIN INFECT DIS, V73, pe2946, DOI [10.1093/cid/ciaa1275, DOI 10.1093/cid/ciaa1275]; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; Takeda CFV, 2020, AM J TROP MED HYG, V103, P1993, DOI 10.4269/ajtmh.20-0893; Van Elslande J, 2021, CLIN INFECT DIS, V73, P354, DOI 10.1093/cid/ciaa1330; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang Zijun, 2021, Nature, V592, P616, DOI [10.1101/2021.01.15.426911, 10.1038/s41586-021-03324-6]; WHALEN J, 2009, WALL STREET J; WHO, 2020, CLIN MAN SEV AC RESP; Wiysonge CS, 2022, HUM VACC IMMUNOTHER, V18, P1, DOI 10.1080/21645515.2021.1893062; World Health Organization, 2020, GLOBAL TUBERCULOSIS; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Wu Kai, 2021, bioRxiv, DOI 10.1101/2021.01.25.427948; Xie XP, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01270-4, 10.1101/2021.01.27.427998]; Yamey G, 2020, LANCET, V395, P1405, DOI 10.1016/S0140-6736(20)30763-7; Yan YX, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040349; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Zimet GD, 2021, J PEDIATR-US, V231, P254, DOI 10.1016/j.jpeds.2020.11.002	113	1	1	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1474	10.3390/vaccines9121474			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XZ4CM	34960220	Green Published, gold			2022-04-29	WOS:000737601300001
J	Oreshkova, N; Myeni, SK; Mishra, N; Albulescu, IC; Dalebout, TJ; Snijder, EJ; Bredenbeek, PJ; Dallmeier, K; Kikkert, M				Oreshkova, Nadia; Myeni, Sebenzile K.; Mishra, Niraj; Albulescu, Irina C.; Dalebout, Tim J.; Snijder, Eric J.; Bredenbeek, Peter J.; Dallmeier, Kai; Kikkert, Marjolein			A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses	VACCINES			English	Article						coronavirus; vaccine platform; YFV-17D; YF17D; MERS-CoV; SARS-CoV; SARS-CoV-2; S1; RBD; spike protein; neutralizing antibodies	GENETIC STABILITY; FOREIGN PROTEIN; RECOMBINANT; VECTOR; IMMUNOGENICITY; REPLICATION; PROTECTION; CANDIDATE; EPITOPES; ENVELOPE	The tremendous global impact of the current SARS-CoV-2 pandemic, as well as other current and recent outbreaks of (re)emerging viruses, emphasize the need for fast-track development of effective vaccines. Yellow fever virus 17D (YF17D) is a live-attenuated virus vaccine with an impressive efficacy record in humans, and therefore, it is a very attractive platform for the development of novel chimeric vaccines against various pathogens. In the present study, we generated a YF17D-based replicon vaccine platform by replacing the prM and E surface proteins of YF17D with antigenic subdomains from the spike (S) proteins of three different betacoronaviruses: MERS-CoV, SARS-CoV and MHV. The prM and E proteins were provided in trans for the packaging of these RNA replicons into single-round infectious particles capable of expressing coronavirus antigens in infected cells. YF17D replicon particles expressing the S1 regions of the MERS-CoV and SARS-CoV spike proteins were immunogenic in mice and elicited (neutralizing) antibody responses against both the YF17D vector and the coronavirus inserts. Thus, YF17D replicon-based vaccines, and their potential DNA- or mRNA-based derivatives, may constitute a promising and particularly safe vaccine platform for current and future emerging coronaviruses.	[Oreshkova, Nadia; Myeni, Sebenzile K.; Albulescu, Irina C.; Dalebout, Tim J.; Snijder, Eric J.; Bredenbeek, Peter J.; Kikkert, Marjolein] Leiden Univ, Med Ctr, Dept Med Microbiol, Ctr Infect Dis LU CID, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands; [Mishra, Niraj; Dallmeier, Kai] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Rega Inst, Lab Virol & Chemotherapy Mol Vaccinol & Vaccine D, Herestr 49,Box 1043, B-3000 Leuven, Belgium; [Oreshkova, Nadia] Wageningen Biovet Res, Sect Virol & Mol Biol, Houtribweg 39, NL-8221 RA Lelystad, Netherlands; [Mishra, Niraj] Intas Pharmaceut, Biopharma Div, Dept Cell & Gene Therapy, Ahmadabad 380054, Gujarat, India; [Albulescu, Irina C.] Univ Utrecht, Fac Vet Med, Dept Biomol Hlth Sci, Div Virol, Yalelaan 1, NL-3584 CL Utrecht, Netherlands		Kikkert, M (通讯作者)，Leiden Univ, Med Ctr, Dept Med Microbiol, Ctr Infect Dis LU CID, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	nadia.oreshkova@wur.nl; S.K.Myeni@lumc.nl; Niraj_Mishra@intaspharma.com; i.c.albulescu@uu.nl; T.J.Dalebout@lumc.nl; E.J.Snijder@lumc.nl; P.J.Bredenbeek@lumc.nl; kai.dallmeier@kuleuven.be; m.kikkert@lumc.nl	Snijder, Eric J./E-6073-2018	Snijder, Eric J./0000-0003-3297-2309; Oreshkova, Nadia/0000-0001-8830-7055; Dallmeier, Kai/0000-0002-8117-9166; Myeni, Sebenzile/0000-0002-5813-0065			Abdulla ZA, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10070788; Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903; [Anonymous], 2019, WHO YELLOW FEVER; Barba-Spaeth G, 2005, J EXP MED, V202, P1179, DOI 10.1084/jem.20051352; Barrett ADT, 2009, CURR OPIN IMMUNOL, V21, P308, DOI 10.1016/j.coi.2009.05.018; Bassi MR, 2015, J IMMUNOL, V194, P1141, DOI 10.4049/jimmunol.1402605; Bonaldo MC, 2006, CELL BIOCHEM BIOPHYS, V44, P313, DOI 10.1385/CBB:44:3:313; Bonaldo MC, 2005, J VIROL, V79, P8602, DOI 10.1128/JVI.79.13.8602-8613.2005; Bonaldo MC, 2014, HUM VACC IMMUNOTHER, V10, P1256, DOI 10.4161/hv.28117; Bonaldo MC, 2010, J VIROL, V84, P3699, DOI 10.1128/JVI.02255-09; Bonaldo MC, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-115; BRANDRISS MW, 1990, J INFECT DIS, V161, P1134, DOI 10.1093/infdis/161.6.1134; Bredenbeek PJ, 2006, VIROLOGY, V345, P299, DOI 10.1016/j.virol.2005.12.001; Bredenbeek PJ, 2003, J GEN VIROL, V84, P1261, DOI 10.1099/vir.0.18860-0; Cattaneo M, 2021, EUR J INTERN MED, V89, P22, DOI 10.1016/j.ejim.2021.05.031; Chambers TJ, 1999, J VIROL, V73, P3095, DOI 10.1128/JVI.73.4.3095-3101.1999; Cornelissen LAHM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044447; Corver J, 2003, J VIROL, V77, P2265, DOI 10.1128/JVI.77.3.2265-2270.2003; Cottin P, 2013, EXPERT REV VACCINES, V12, P1351, DOI 10.1586/14760584.2013.836320; De Beeck AO, 2004, J VIROL, V78, P12591, DOI 10.1128/JVI.78.22.12591-12602.2004; Draper SJ, 2010, NAT REV MICROBIOL, V8, P62, DOI 10.1038/nrmicro2240; EMA, 2021, COVID 19 VACC JANSS; Enjuanes L, 2008, VIRUS RES, V133, P45, DOI 10.1016/j.virusres.2007.01.021; Erickson AK, 2015, J GEN VIROL, V96, P1328, DOI 10.1099/vir.0.000075; Fayzulin R, 2006, VIROLOGY, V351, P196, DOI 10.1016/j.virol.2006.02.036; Franco D, 2010, VACCINE, V28, P5676, DOI 10.1016/j.vaccine.2010.06.052; Freyn AW, 2021, MOL THER-METH CLIN D, V22, DOI 10.1016/j.omtm.2021.06.003; Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292; Giel-Moloney M, 2017, HUM VACC IMMUNOTHER, V13, P2982, DOI 10.1080/21645515.2017.1373920; Gotuzzo E, 2013, AM J TROP MED HYG, V89, P434, DOI 10.4269/ajtmh.13-0264; Grobusch MP, 2017, TRAVEL MED INFECT DI, V15, P1, DOI 10.1016/j.tmaid.2016.12.003; Guirakhoo F, 2000, J VIROL, V74, P5477, DOI 10.1128/JVI.74.12.5477-5485.2000; Guirakhoo F, 1999, VIROLOGY, V257, P363, DOI 10.1006/viro.1999.9695; Guy B, 2010, VACCINE, V28, P632, DOI 10.1016/j.vaccine.2009.09.098; He X, 2021, CELL, V184, P3467, DOI 10.1016/j.cell.2021.05.040; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; Huang YT, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0181-8; Jiang X, 2015, J GEN VIROL, V96, P804, DOI 10.1099/jgv.0.000026; Jiang XH, 2011, VACCINE, V29, P1248, DOI 10.1016/j.vaccine.2010.11.079; Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Khromykh AA, 1997, J VIROL, V71, P1497, DOI 10.1128/JVI.71.2.1497-1505.1997; Kummerer BM, 2018, ADV EXP MED BIOL, V1062, P165, DOI 10.1007/978-981-10-8727-1_12; Kum DB, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0092-2; Kum DB, 2020, EMERG MICROBES INFEC, V9, P520, DOI 10.1080/22221751.2020.1730709; Kum Dieudonne Buh, 2019, Emerg Microbes Infect, V8, P1734, DOI 10.1080/22221751.2019.1694394; Kyriakidis NC, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00292-w; Leborgne C, 2020, NAT MED, V26, P1096, DOI 10.1038/s41591-020-0911-7; Lindenbach B.D., 2013, FIELDS VIROLOGY, V6th ed., P712; Lindsey NP, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw045; LOBIGS M, 1987, VIROLOGY, V161, P474, DOI 10.1016/0042-6822(87)90141-3; Long B, 2021, AM J EMERG MED, V49, P58, DOI 10.1016/j.ajem.2021.05.054; Martins MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054434; Mason PW, 2006, VIROLOGY, V351, P432, DOI 10.1016/j.virol.2006.04.003; McAllister A, 2000, J VIROL, V74, P9197, DOI 10.1128/JVI.74.19.9197-9205.2000; Meier KC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000614; Mishra N, 2020, MBIO, V11, DOI 10.1128/mBio.02494-19; Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030; Monath TP, 2012, EXPERT REV VACCINES, V11, P427, DOI [10.1586/erv.12.6, 10.1586/ERV.12.6]; Mou H, 2013, J VIROL, V87, P9379, DOI 10.1128/JVI.01277-13; Nogueira RT, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-127; Nogueira RT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059347; Okba NMA, 2017, CURR OPIN VIROL, V23, P49, DOI 10.1016/j.coviro.2017.03.007; Oreshkova N, 2014, VACCINE, V32, P5323, DOI 10.1016/j.vaccine.2014.07.051; Piras-Douce F, 2021, VACCINE, V39, P1846, DOI 10.1016/j.vaccine.2021.02.033; Pulendran B, 2009, NAT REV IMMUNOL, V9, P741, DOI 10.1038/nri2629; Pyankov OV, 2015, J INFECT DIS, V212, pS368, DOI 10.1093/infdis/jiv019; Querec T, 2006, J EXP MED, V203, P413, DOI 10.1084/jem.20051720; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005; Reisinger EC, 2018, LANCET, V392, P2718, DOI 10.1016/S0140-6736(18)32488-7; Reynard O, 2011, J INFECT DIS, V204, pS1060, DOI 10.1093/infdis/jir347; Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005; Rumyantsev AA, 2010, VIROLOGY, V396, P329, DOI 10.1016/j.virol.2009.10.033; Sanchez-Felipe L, 2021, NATURE, V590, DOI 10.1038/s41586-020-3035-9; Santos AP, 2008, CYTOKINE, V42, P152, DOI 10.1016/j.cyto.2008.02.007; Saxena M, 2013, MICROBIOL-SGM, V159, P1, DOI 10.1099/mic.0.049601-0; Schindewolf C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010074; Seidah NG, 2012, NAT REV DRUG DISCOV, V11, P367, DOI 10.1038/nrd3699; Seo YB, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040307; Shay DK, 2021, JAMA CARDIOL, V6, P1115, DOI 10.1001/jamacardio.2021.2821; Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Tao D, 2005, J EXP MED, V201, P201, DOI 10.1084/jem.20041526; Teo SP, 2021, J PHARM PRACT, DOI 10.1177/08971900211009650; Theiler M, 1937, J EXP MED, V65, P767, DOI 10.1084/jem.65.6.767; Thibodeaux BA, 2012, VACCINE, V30, P3180, DOI 10.1016/j.vaccine.2012.03.003; Thomas RE, 2012, AM J TROP MED HYG, V86, P359, DOI 10.4269/ajtmh.2012.11-0525; Touret F, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0161-7; Tu YQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086575; Uematsu Y, 2012, CLIN VACCINE IMMUNOL, V19, P991, DOI 10.1128/CVI.00031-12; van der Most RG, 2002, VIROLOGY, V296, P117, DOI 10.1006/viro.2002.1432; Watson AM, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9040077; WHO SAGE Working Group, BACKGR PAP YELL FEV; Wieten RW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149871; Xia XH, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13010109	96	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1492	10.3390/vaccines9121492			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XZ0CN	34960238	Green Published, gold			2022-04-29	WOS:000737330900001
J	Versage, E; van Twuijver, E; Jansen, W; Theeuwes, A; Sawlwin, D; Hohenboken, M				Versage, Eve; van Twuijver, Esther; Jansen, Wim; Theeuwes, Ad; Sawlwin, Daphne; Hohenboken, Matthew			Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults	VACCINES			English	Article						influenza; vaccine; pandemic; cell culture; MF59; adjuvant	DOSE-RANGE; IMMUNOGENICITY; ANTIGEN; TOLERABILITY; IMMUNIZATION; PERSISTENCE; VIRUSES; BLIND	Modern cell culture-based technology eliminates vaccine manufactures reliance on embryonated chicken eggs, which may become compromised during an avian influenza pandemic. Four studies (total N = 6230) assessed the immunogenicity and safety of mammalian cell-based, MF59(R)-adjuvanted, A/H5N1 vaccine (aH5N1c; AUDENZ (TM)) as two doses administered on Days 1 and 22 in children (NCT01776554), adults (NCT01776541; NCT02839330), and older adults (NCT01766921; NCT02839330). Immunogenicity of formulations at 7.5 mu g and 3.75 mu g antigen per dose were assessed by hemagglutination inhibition and microneutralization assays on Days 1, 22, 43, and 183 or 387. Solicited local and systemic adverse events (AEs) were recorded for 7 days after each vaccination. Unsolicited AEs were collected for 21 days after each vaccination, and serious and other selected AEs were recorded for one year. Antibody responses after two 7.5 mu g doses met CBER licensure criteria in all age groups. Overall, an age-related response was evident, with the highest responses observed in children <3 years old. In children, antibody titers met seroconversion criteria 12 months after vaccination. MF59 allowed for antigen dose sparing. Solicited AEs were mild to moderate in nature, of short duration, and less frequent after the second dose than the first, demonstrating a favorable risk-benefit profile.	[Versage, Eve; Hohenboken, Matthew] Seqirus USA Inc, Cambridge, MA 02139 USA; [van Twuijver, Esther; Jansen, Wim; Theeuwes, Ad] Seqirus Netherlands BV, NL-1105 BJ Amsterdam, Netherlands; [Sawlwin, Daphne] Seqirus Pty Ltd, Melbourne, Vic 3052, Australia		Versage, E (通讯作者)，Seqirus USA Inc, Cambridge, MA 02139 USA.	eve.versage@seqirus.com; esther.vantwuijver@seqirus.com; wim.jansen@seqirus.com; adrianus.theeuwes@seqirus.com; daphne.sawlwin@seqirus.com; matthew.hohenboken@seqirus.com			Seqirus USA Inc..(Cambridge, MA, USA)	This study was sponsored by Seqirus USA Inc. (Cambridge, MA 02139, USA).	Ampofo WK, 2012, INFLUENZA OTHER RESP, V6, P142, DOI 10.1111/j.1750-2659.2011.00277.x; [Anonymous], 2009, WHO PANDEMIC H1N1; Bart SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008761; Beran J, 2010, CLIN THER, V32, P2186, DOI 10.1016/S0149-2918(11)00024-5; Bihari I, 2012, CLIN VACCINE IMMUNOL, V19, P1943, DOI 10.1128/CVI.00373-12; Bin L, 2005, J VIROL, V79, P6763, DOI 10.1128/JVI.79.11.6763-6771.2005; Block SL, 2012, PEDIATR INFECT DIS J, V31, pE92, DOI 10.1097/INF.0b013e318257644f; Chanthavanich P, 2019, PEDIATR INFECT DIS J, V38, P757, DOI 10.1097/INF.0000000000002345; Czajka H, 2012, J Prev Med Hyg, V53, P136; Department of Health and Human Services, US GOV BIOM ADV RES; Donis RO, 2014, VACCINE, V32, P6583, DOI 10.1016/j.vaccine.2014.06.045; Dormitzer PR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006368; Doroshenko A, 2009, EXPERT REV VACCINES, V8, P679, DOI 10.1586/ERV.09.31; Frey SE, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz107; Fukase H, 2012, VACCINE, V30, P5030, DOI 10.1016/j.vaccine.2012.03.053; Galli G, 2009, P NATL ACAD SCI USA, V106, P7962, DOI 10.1073/pnas.0903181106; Gregersen JP, 2011, FUTURE MICROBIOL, V6, P143, DOI 10.2217/FMB.10.161; Hatz C, 2012, VACCINE, V30, P4820, DOI 10.1016/j.vaccine.2012.05.013; Hatz C, 2012, VACCINE, V30, P3470, DOI 10.1016/j.vaccine.2012.03.017; Johnson C, 2015, J INFECT DIS, V212, P72, DOI 10.1093/infdis/jiu826; Keitel W, 2010, VACCINE, V28, P840, DOI 10.1016/j.vaccine.2009.10.019; Khurana S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095496; Khurana S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002336; Khurana S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000624; Knuf M, 2015, HUM VACC IMMUNOTHER, V11, P358, DOI 10.4161/21645515.2014.987014; Knuf M, 2015, VACCINE, V33, P174, DOI 10.1016/j.vaccine.2014.10.085; Knuf M, 2014, PEDIATR INFECT DIS J, V33, pE320, DOI 10.1097/INF.0000000000000462; Nassim C, 2012, PEDIATR INFECT DIS J, V31, pE59, DOI 10.1097/INF.0b013e31824b9545; Rappuoli R, 2012, SCIENCE, V336, P1531, DOI 10.1126/science.1221466; Raymond DD, 2016, NAT MED, V22, P1465, DOI 10.1038/nm.4223; Reisinger KS, 2014, HUM VACC IMMUNOTHER, V10, P2395, DOI 10.4161/hv.29393; Saunders-Hastings PR, 2016, PATHOGENS, V5, DOI 10.3390/pathogens5040066; Stohr K, 2014, NATURE, V507, pS20, DOI 10.1038/507S20a; U.S. Food and Drug Administration, VACC LIC US US; Ulmer JB, 2006, NAT BIOTECHNOL, V24, P1377, DOI 10.1038/nbt1261; Vesikari T, 2012, HUM VACC IMMUNOTHER, V8, P921, DOI 10.4161/hv.20248; Vesikari T, 2012, VACCINE, V30, P1388, DOI 10.1016/j.vaccine.2011.12.009; World Health Organization, CUM NUMB CONF HUM CA; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Wu NC, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006682; Xu Jiaquan, 2018, Natl Vital Stat Rep, V67, P1; Yasuda Y, 2010, ADV THER, V27, P444, DOI 10.1007/s12325-010-0043-4; Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114	43	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	DEC	2021	9	12							1468	10.3390/vaccines9121468			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	YK5WB	34960214	gold, Green Published			2022-04-29	WOS:000745281500001
J	Baffa, ME; Maglie, R; Giovannozzi, N; Montefusco, F; Senatore, S; Massi, D; Antiga, E				Baffa, Maria Efenesia; Maglie, Roberto; Giovannozzi, Neri; Montefusco, Francesca; Senatore, Stefano; Massi, Daniela; Antiga, Emiliano			Sweet Syndrome Following SARS-CoV2 Vaccination	VACCINES			English	Article						Sweet's syndrome; mRNA vaccines; neutrophilic dermatoses; adverse event	FEBRILE NEUTROPHILIC DERMATOSIS; MOLECULES	Vaccines are today considered one of the most effective means against the Sars-CoV-2 pandemic. The BNT162b2 vaccine by Pfizer/BioNTech has been massively administered throughout the globe; since its approval, a wide spectrum of cutaneous reactions has been reported. Here we report the case of a 52-year-old Caucasian male who presented with an acute febrile eruption that arose 72 h after the first dose of the BNT162b2 vaccine. The clinicopathological findings were consistent with Sweet's syndrome. The short latency time suggested a possible role of the vaccine in triggering Sweet's syndrome in this case.	[Baffa, Maria Efenesia; Maglie, Roberto; Montefusco, Francesca; Senatore, Stefano; Antiga, Emiliano] Univ Florence, Dermatol Sect, Dept Hlth Sci, I-50125 Florence, Italy; [Giovannozzi, Neri; Massi, Daniela] Univ Florence, Sect Pathol Anat, Dept Hlth Sci, I-50139 Florence, Italy		Baffa, ME (通讯作者)，Univ Florence, Dermatol Sect, Dept Hlth Sci, I-50125 Florence, Italy.	mariaefenesia.baffa@unifi.it; roberto.maglie@unifi.it; nerigiova35@gmail.com; francesca.montefusco@unifi.it; stefano.senatore@unifi.it; daniela.massi@unifi.it; emiliano.antiga@unifi.it	Antiga, Emiliano/K-7632-2016	Antiga, Emiliano/0000-0001-7787-4433			Antiga E, 2017, CLIN EXP IMMUNOL, V189, P383, DOI 10.1111/cei.12989; Berro Simar, 2021, Acta Derm Venereol, V101, padv00486, DOI 10.2340/00015555-3850; Capassoni M, 2021, J MED VIROL, V93, P5718, DOI 10.1002/jmv.27175; Carpentier O, 2002, ACTA DERM-VENEREOL, V82, P221, DOI 10.1080/00015550260132604; Darrigade AS, 2021, ALLERGY, V76, P3194, DOI 10.1111/all.14981; European Medicine Agency, EUROPEAN COMMISSION; European Medicines Agency, COV 19 MRNA VACC COM; Heath MS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00414; Jovanovic M, 2005, J AM ACAD DERMATOL, V52, P367, DOI 10.1016/j.jaad.2004.07.061; Larson V, 2022, J CUTAN PATHOL, V49, P34, DOI 10.1111/cup.14104; MADDOX PR, 1990, BRIT J SURG, V77, P809, DOI 10.1002/bjs.1800770729; Marzano AV, 2014, CLIN EXP IMMUNOL, V178, P48, DOI 10.1111/cei.12394; McMahon DE, 2021, J AM ACAD DERMATOL, V85, P46, DOI 10.1016/j.jaad.2021.03.092; Pedrosa AF, 2013, CUTAN OCUL TOXICOL, V32, P260, DOI 10.3109/15569527.2012.759960; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; RADEFF B, 1986, ACTA DERM-VENEREOL, V66, P357; Ratzinger G, 2007, AM J DERMATOPATH, V29, P125, DOI 10.1097/01.dad.0000249887.59810.76; Rochet NM, 2013, J AM ACAD DERMATOL, V69, P557, DOI 10.1016/j.jaad.2013.06.023; Taskin B, 2020, J EUR ACAD DERMATOL, V34, pE534, DOI 10.1111/jdv.16662; Teijaro JR, 2021, NAT REV IMMUNOL, V21, P195, DOI 10.1038/s41577-021-00526-x; Torrealba-Acosta G, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2021-243173; Watad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050435; WHO, COR COVID 19 DASHB	23	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1212	10.3390/vaccines9111212			5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG0LZ	34835143	gold, Green Published			2022-04-29	WOS:000724454600001
J	Cai, WL; Arias, CR				Cai, Wenlong; Arias, Covadonga R.			Deciphering the Molecular Basis for Attenuation of Flavobacterium columnare Strain Fc1723 Used as Modified Live Vaccine against Columnaris Disease	VACCINES			English	Article						Flavobacterium columnare; columnaris disease; attenuated vaccine; rifampin; catfish	ENTERIC SEPTICEMIA; ESCHERICHIA-COLI; BRUCELLA-ABORTUS; CHANNEL CATFISH; PROTEASE-IV; RIFAMPICIN; ICTALURI; GENE; RESISTANCE; MUTATIONS	Vaccines are widely employed in aquaculture to prevent bacterial infections, but their use by the U.S. catfish industry is very limited. One of the main diseases affecting catfish aquaculture is columnaris disease, caused by the bacterial pathogen Flavobacterium columnare. In 2011, a modified-live vaccine against columnaris disease was developed by selecting mutants that were resistant to rifampin. The previous study has suggested that this vaccine is stable, safe, and effective, but the mechanisms that resulted in attenuation remained uncharacterized. To understand the molecular basis for attenuation, a comparative genomic analysis was conducted to identify specific point mutations. The PacBio RS long-read sequencing platform was used to obtain draft genomes of the mutant attenuated strain (Fc1723) and the parent virulent strain (FcB27). Sequence-based genome comparison identified 16 single nucleotide polymorphisms (SNP) unique to the mutant. Genes that contained mutations were involved in rifampin resistance, gliding motility, DNA transcription, toxin secretion, and extracellular protease synthesis. The results also found that the vaccine strain formed biofilm at a significantly lower rate than the parent strain. These observations suggested that the rifampin-resistant phenotype and the associated attenuation of the vaccine strain result from the altered activity of RNA polymerase (RpoB) and possible disrupted protein secretion systems.	[Cai, Wenlong] City Univ Hong Kong, Jockey Club Coll Vet Med & Life Sci, Dept Infect Dis & Publ Hlth, Kowloon, Hong Kong 999077, Peoples R China; [Arias, Covadonga R.] Auburn Univ, Sch Fisheries Aquaculture & Aquat Sci, Auburn, AL 36832 USA		Cai, WL (通讯作者)，City Univ Hong Kong, Jockey Club Coll Vet Med & Life Sci, Dept Infect Dis & Publ Hlth, Kowloon, Hong Kong 999077, Peoples R China.	wenlocai@cityu.edu.hk; ariascr@auburn.edu		CAI, Wenlong/0000-0003-0562-6363	Southeastern Cooperative Fish Parasite and Disease Project; Auburn University Intramural Program; Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong	This work was supported by the Southeastern Cooperative Fish Parasite and Disease Project and Auburn University Intramural Program. The APC was funded by Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong.	Alvarez B, 2006, APPL ENVIRON MICROB, V72, P4044, DOI 10.1128/AEM.00128-06; ANDREWS DL, 1988, BIOCHEM J, V252, P199, DOI 10.1042/bj2520199; Arias CR, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-266; Arias CR, 2003, J FISH DIS, V26, P415, DOI 10.1046/j.1365-2761.2003.00475.x; Austin B., 1999, BACTERIAL FISH PATHO; Aziz RK, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-75; Banerji S, 2004, MICROBIOL-SGM, V150, P522, DOI 10.1099/mic.0.26957-0; Brudeseth BE, 2013, FISH SHELLFISH IMMUN, V35, P1759, DOI 10.1016/j.fsi.2013.05.029; Cai WL, 2013, APPL ENVIRON MICROB, V79, P5633, DOI 10.1128/AEM.01192-13; Choi Y, 2015, BIOINFORMATICS, V31, P2745, DOI 10.1093/bioinformatics/btv195; Darling ACE, 2004, GENOME RES, V14, P1394, DOI 10.1101/gr.2289704; de Koning H, 2000, MOL MEMBR BIOL, V17, P75; Detmer A, 2006, MICROB CELL FACT, V5, DOI 10.1186/1475-2859-5-23; Dietrich G, 2008, BIOPHARM INT, P6; Engel LS, 1998, J BIOL CHEM, V273, P16792, DOI 10.1074/jbc.273.27.16792; Gliniewicz K, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0518-1; Goldstein BP, 2014, J ANTIBIOT, V67, P625, DOI 10.1038/ja.2014.107; Hermanson GT, 2013, BIOCONJUGATE TECHNIQUES, 3RD EDITION, P229, DOI 10.1016/B978-0-12-382239-0.00003-0; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; Klesius PH, 1999, ADV VETER MED AP, V41, P523; Kunttu HMT, 2011, J APPL MICROBIOL, V111, P1319, DOI 10.1111/j.1365-2672.2011.05149.x; Kunttu HMT, 2012, ENV MICROBIOL REP, V4, P398, DOI 10.1111/j.1758-2229.2012.00342.x; LaFrentz BR, 2014, J FISH DIS, V37, P657, DOI 10.1111/jfd.12166; LaFrentz BR, 2008, VACCINE, V26, P5582, DOI 10.1016/j.vaccine.2008.07.083; Minor PD, 2015, VIROLOGY, V479, P379, DOI 10.1016/j.virol.2015.03.032; Mohammed H, 2013, VACCINE, V31, P5276, DOI 10.1016/j.vaccine.2013.08.052; MONTARAZ JA, 1986, INFECT IMMUN, V53, P245, DOI 10.1128/IAI.53.2.245-251.1986; Mount David W, 2007, CSH Protoc, V2007, DOI 10.1101/pdb.top17; Olivares-Fuster O, 2011, J FISH DIS, V34, P385, DOI 10.1111/j.1365-2761.2011.01253.x; Olivares-Fuster O, 2007, SYST APPL MICROBIOL, V30, P624, DOI 10.1016/j.syapm.2007.07.003; OVCHINNIKOV YA, 1983, MOL GEN GENET, V190, P344, DOI 10.1007/BF00330662; Overbeek R, 2014, NUCLEIC ACIDS RES, V42, pD206, DOI 10.1093/nar/gkt1226; PEEK JA, 1992, P NATL ACAD SCI USA, V89, P6210, DOI 10.1073/pnas.89.13.6210; Phillips RM, 2003, J BIOL CHEM, V278, P41326, DOI 10.1074/jbc.M302472200; Sato H, 2003, EMBO J, V22, P2959, DOI 10.1093/emboj/cdg290; SCHURIG GG, 1991, VET MICROBIOL, V28, P171, DOI 10.1016/0378-1135(91)90091-S; Shoemaker CA, 2008, VET MICROBIOL, V127, P353, DOI 10.1016/j.vetmic.2007.09.003; Shoemaker CA, 1997, J FISH DIS, V20, P361, DOI 10.1046/j.1365-2761.1997.00310.x; Shoemaker CA, 2005, J AQUAT ANIM HEALTH, V17, P267, DOI 10.1577/H04-034.1; Shoemaker CA, 2011, FISH SHELLFISH IMMUN, V30, P304, DOI 10.1016/j.fsi.2010.11.001; Shoemaker CA, 2009, J WORLD AQUACULT SOC, V40, P573, DOI 10.1111/j.1749-7345.2009.00279.x; SMITH SW, 1957, J BIOL CHEM, V228, P915; SUZUKI T, 1987, J BACTERIOL, V169, P2523, DOI 10.1128/jb.169.6.2523-2528.1987; Tekedar HC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00588; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Thune RL, 1999, J AQUAT ANIM HEALTH, V11, P358, DOI 10.1577/1548-8667(1999)011&lt;0358:AAMOEI&gt;2.0.CO;2; Triyanto, 1999, FISH PATHOL, V34, P65, DOI 10.3147/jsfp.34.65; USDA, 2010, REF CATF HLTH PROD 1; Vemulapalli R, 1999, CLIN DIAGN LAB IMMUN, V6, P760, DOI 10.1128/CDLI.6.5.760-764.1999; VOGELS GD, 1976, BACTERIOL REV, V40, P403, DOI 10.1128/MMBR.40.2.403-468.1976; WEHRLI W, 1968, P NATL ACAD SCI USA, V61, P667, DOI 10.1073/pnas.61.2.667; Wei ZG, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2208-0; Weissman SJ, 2003, TRENDS MICROBIOL, V11, P115, DOI 10.1016/S0966-842X(03)00010-6; Woodrow KA, 2012, ANNU REV BIOMED ENG, V14, P17, DOI 10.1146/annurev-bioeng-071811-150054	54	0	0	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1370	10.3390/vaccines9111370			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH8YF	34835301	Green Published, gold			2022-04-29	WOS:000725712600001
J	Harrison, JJ; Hobson-Peters, J; Bielefeldt-Ohmann, H; Hall, RA				Harrison, Jessica J.; Hobson-Peters, Jody; Bielefeldt-Ohmann, Helle; Hall, Roy A.			Chimeric Vaccines Based on Novel Insect-Specific Flaviviruses	VACCINES			English	Review						flavivirus; vaccine platform; chimeric virus; dengue; yellow fever; Japanese encephalitis; Zika; West Nile virus disease; insect-specific flavivirus; Binjari virus	ENCEPHALITIS-VIRUS VACCINE; ANTIBODY-DEPENDENT ENHANCEMENT; NATURAL MOSQUITO POPULATION; TETRAVALENT DENGUE VACCINE; YELLOW-FEVER VACCINE; FUSING AGENT VIRUS; WEST-NILE; JAPANESE ENCEPHALITIS; AEDES-ALBOPICTUS; CULEX FLAVIVIRUS	Vector-borne flaviviruses are responsible for nearly half a billion human infections worldwide each year, resulting in millions of cases of debilitating and severe diseases and approximately 115,000 deaths. While approved vaccines are available for some of these viruses, the ongoing efficacy, safety and supply of these vaccines are still a significant problem. New technologies that address these issues and ideally allow for the safe and economical manufacture of vaccines in resource-poor countries where flavivirus vaccines are in most demand are urgently required. Preferably a new vaccine platform would be broadly applicable to all flavivirus diseases and provide new candidate vaccines for those diseases not yet covered, as well as the flexibility to rapidly pivot to respond to newly emerged flavivirus diseases. Here, we review studies conducted on novel chimeric vaccines derived from insect-specific flaviviruses that provide a potentially safe and simple system to produce highly effective vaccines against a broad spectrum of flavivirus diseases.	[Harrison, Jessica J.; Hobson-Peters, Jody; Bielefeldt-Ohmann, Helle; Hall, Roy A.] Univ Queensland, Australian Infect Dis Res Ctr, Sch Chem & Mol Biosci, Brisbane, Qld 4072, Australia; [Bielefeldt-Ohmann, Helle] Univ Queensland, Sch Vet Sci, Gatton, Qld 4343, Australia		Harrison, JJ (通讯作者)，Univ Queensland, Australian Infect Dis Res Ctr, Sch Chem & Mol Biosci, Brisbane, Qld 4072, Australia.	j.harrison1@uq.edu.au; j.peters2@uq.edu.au; h.bielefeldtohmannl@uq.edu.au; roy.hall@uq.edu.au		Hobson-Peters, Jody/0000-0003-0139-9829; Harrison, Jessica/0000-0002-3577-9910			Adam A, 2021, EMERG MICROBES INFEC, V10, P305, DOI [10.1080/22221751.2021.1886598, 10.6084/m9.figshare.14115632.v1]; Aliota MT, 2017, ANTIVIR RES, V144, P223, DOI 10.1016/j.antiviral.2017.06.001; Aliota MT, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-293; Amarilla AA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23779-5; [Anonymous], 2011, Wkly Epidemiol Rec, V86, P241; Arlian LG, 2002, ANNU REV ENTOMOL, V47, P395, DOI 10.1146/annurev.ento.47.091201.145224; Arroyo J, 2004, J VIROL, V78, P12497, DOI 10.1128/JVI.78.22.12497-12507.2004; Barrett ADT, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0061-9; Belshe RB, 2007, NEW ENGL J MED, V356, P685, DOI 10.1056/NEJMoa065368; Bhatt TR, 2000, AM J TROP MED HYG, V62, P480, DOI 10.4269/ajtmh.2000.62.480; Biswal S, 2020, LANCET, V395, P1423, DOI 10.1016/S0140-6736(20)30414-1; Blaney JE, 2006, VIRAL IMMUNOL, V19, P10, DOI 10.1089/vim.2006.19.10; Blitvich BJ, 2015, VIRUSES-BASEL, V7, P1927, DOI 10.3390/v7041927; Bolling BG, 2011, AM J TROP MED HYG, V85, P169, DOI 10.4269/ajtmh.2011.10-0474; Bolling BG, 2015, AM J TROP MED HYG, V92, P422, DOI 10.4269/ajtmh.14-0330; Bolling BG, 2012, VIROLOGY, V427, P90, DOI 10.1016/j.virol.2012.02.016; Calzolari M, 2016, INFECT GENET EVOL, V40, P381, DOI 10.1016/j.meegid.2015.07.032; Caminade C, 2012, J R SOC INTERFACE, V9, P2708, DOI 10.1098/rsif.2012.0138; CAMMISAPARKS H, 1992, VIROLOGY, V189, P511, DOI 10.1016/0042-6822(92)90575-A; Cavalcanti DP, 2007, TROP MED INT HEALTH, V12, P833, DOI 10.1111/j.1365-3156.2007.01851.x; Chambers TJ, 1999, J VIROL, V73, P3095, DOI 10.1128/JVI.73.4.3095-3101.1999; Chang TH, 2006, MICROBES INFECT, V8, P157, DOI 10.1016/j.micinf.2005.06.014; Charles J, 2017, ARCH VIROL, V162, P3913, DOI 10.1007/s00705-017-3552-5; Choo JJY, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00328-1; ClinicalTrials.gov, EFF SAF IMM TAK TETR; Colmant AMG, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040573; Colmant AMG, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008166; Colmant AMG, 2017, MSPHERE, V2, DOI [10.1128/mSphere.00262-17, 10.1128/msphere.00262-17]; Colmant AMG, 2016, J GEN VIROL, V97, P1087, DOI 10.1099/jgv.0.000430; Cook S, 2006, J GEN VIROL, V87, P735, DOI 10.1099/vir.0.81475-0; Cook S, 2009, J GEN VIROL, V90, P2669, DOI 10.1099/vir.0.014183-0; Cornish EF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.572567; Cortese V, 2013, J EQUINE VET SCI, V33, P1101, DOI 10.1016/j.jevs.2013.04.010; DALSGAARD K, 1974, ARCH GES VIRUSFORSCH, V44, P243, DOI 10.1007/BF01240612; Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515; Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824; El Garch H, 2008, VET IMMUNOL IMMUNOP, V123, P230, DOI 10.1016/j.vetimm.2008.02.002; Erasmus JH, 2018, J VIROL, V92, DOI 10.1128/JVI.01274-17; Erasmus JH, 2017, NAT MED, V23, P192, DOI 10.1038/nm.4253; Espinoza-Gomez F, 2011, ARCH VIROL, V156, P1263, DOI 10.1007/s00705-011-0967-2; Farfan-Ale JA, 2009, AM J TROP MED HYG, V80, P85, DOI 10.4269/ajtmh.2009.80.85; Fatima K, 2018, J GLOB HEALTH, V8, DOI [10.7189/jogh.08.020312, 10.7189/jogh.08-020312]; Ferreira CD, 2018, EXPERT REV VACCINES, V17, P79, DOI 10.1080/14760584.2018.1406800; Forster AH, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003024; Galindo P A, 1998, Allergol Immunopathol (Madr), V26, P251; Galler R, 2001, VIROLOGY, V290, P309, DOI 10.1006/viro.2001.1168; Goenaga S, 2015, VIRUSES-BASEL, V7, P5801, DOI 10.3390/v7112911; Goenaga S, 2014, J MED ENTOMOL, V51, P900, DOI 10.1603/ME13172; Grisenti M, 2015, J GEN VIROL, V96, P420, DOI 10.1099/vir.0.069625-0; Guabiraba R, 2014, IMMUNOLOGY, V141, P143, DOI 10.1111/imm.12188; Guirakhoo F, 2006, HUM VACCINES, V2, P60, DOI 10.4161/hv.2.2.2555; Guy B, 2011, VACCINE, V29, P7229, DOI 10.1016/j.vaccine.2011.06.094; Guy B, 2010, VACCINE, V28, P632, DOI 10.1016/j.vaccine.2009.09.098; Guzman H, 2018, AM J TROP MED HYG, V98, P410, DOI 10.4269/ajtmh.17-0350; Hacker K, 2009, J GEN VIROL, V90, P2097, DOI 10.1099/vir.0.012120-0; Haddow AD, 2013, VIROLOGY, V440, P134, DOI 10.1016/j.virol.2012.12.008; Hall RA, 2016, EVOL BIOINFORM, V12, P35, DOI 10.4137/EBO.S40740; Hall-Mendelin S, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1683-2; Halstead SB, 2007, LANCET, V370, P1644, DOI 10.1016/S0140-6736(07)61687-0; Hardy JM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22773-1; Harrison J.J., 2021, DETECTION INSE UNPUB; Harrison JJ, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00095-20; Hazlewood JE, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030496; Higgs S, 2006, AM J TROP MED HYG, V75, P986, DOI 10.4269/ajtmh.2006.75.986; Hobson-Peters J, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax7888; Hobson-Peters J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056534; Hoshino K, 2009, VIROLOGY, V391, P119, DOI 10.1016/j.virol.2009.06.025; Huhtamo E, 2014, VIROLOGY, V464, P320, DOI 10.1016/j.virol.2014.07.015; Huhtamo E, 2009, J VIROL, V83, P9532, DOI 10.1128/JVI.00529-09; Ishikawa T, 2014, VACCINE, V32, P1326, DOI 10.1016/j.vaccine.2014.01.040; Junglen S, 2017, MSPHERE, V2, DOI [10.1128/mSphere.00375-16, 10.1128/msphere.00375-16]; Junglen S, 2013, CURR OPIN MICROBIOL, V16, P507, DOI 10.1016/j.mib.2013.06.005; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; Kell AM, 2015, VIROLOGY, V479, P110, DOI 10.1016/j.virol.2015.02.017; Keller-Stanislawski B, 2014, VACCINE, V32, P7057, DOI 10.1016/j.vaccine.2014.09.052; Kim DY, 2009, VIROLOGY, V386, P154, DOI 10.1016/j.virol.2008.12.034; Kitchener S, 2006, VACCINE, V24, P1238, DOI 10.1016/j.vaccine.2005.09.029; Kolodziejek J, 2013, J GEN VIROL, V94, P2449, DOI 10.1099/vir.0.056200-0; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; Laris-Gonzalez A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010124; Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144; MASON PW, 1989, VIROLOGY, V169, P354, DOI 10.1016/0042-6822(89)90161-X; Mazurek Gerald H., 2010, Morbidity and Mortality Weekly Report, V59, P1; MCCORMACK DR, 1995, ANN ALLERG ASTHMA IM, V74, P39; McLean BJ, 2015, VIROLOGY, V486, P272, DOI 10.1016/j.virol.2015.07.021; Men RH, 1996, J VIROL, V70, P3930, DOI 10.1128/JVI.70.6.3930-3937.1996; Metz SW, 2018, VIROL J, V15, DOI 10.1186/s12985-018-0970-2; Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651; Monath T.P., 2008, VACCINES-BASEL, V5th ed., P959; Monath TP, 2010, VACCINE, V28, P3827, DOI 10.1016/j.vaccine.2010.03.023; Monath TP, 2000, J VIROL, V74, P1742, DOI 10.1128/JVI.74.4.1742-1751.2000; Monath TP, 2003, J INFECT DIS, V188, P1213, DOI 10.1086/378356; Monath TP, 2001, ANN NY ACAD SCI, V951, P1; Monath TP, 2002, VACCINE, V20, P1004, DOI 10.1016/S0264-410X(01)00457-1; Monath TP, 1999, VACCINE, V17, P1869, DOI 10.1016/S0264-410X(98)00487-3; Morales-Betoulle ME, 2008, J MED ENTOMOL, V45, P1187, DOI 10.1603/0022-2585(2008)45[1187:CFIFMI]2.0.CO;2; Muller DA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040189; Muller DA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13011-0; Muller DA, 2016, SCI REP-UK, V6, DOI 10.1038/srep22094; Murray KO, 2010, VET RES, V41, DOI 10.1051/vetres/2010039; Newman CM, 2011, VECTOR-BORNE ZOONOT, V11, P1099, DOI 10.1089/vbz.2010.0144; Ng T., 2003, VVolume 114, P221; Oliveira A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226141; Papa A, 2010, EUROSURVEILLANCE, V15; Piyasena TBH, 2019, J GEN VIROL, V100, P1580, DOI 10.1099/jgv.0.001326; Piyasena TBH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03120-1; Pletnev AG, 2003, VIROLOGY, V314, P190, DOI 10.1016/S0042-6822(03)00450-1; Prow NA, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006788; Rajaiah P, 2019, HUM VACC IMMUNOTHER, V15, P2243, DOI 10.1080/21645515.2019.1602431; Rizzo F, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-395; Roiz D, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-223; Romo H, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0180-4; Sabchareon A, 2004, PEDIATR INFECT DIS J, V23, P99, DOI 10.1097/01.inf.0000109289.55856.27; Saiyasombat R, 2010, ARCH VIROL, V155, P983, DOI 10.1007/s00705-010-0665-5; Sang RC, 2003, ARCH VIROL, V148, P1085, DOI 10.1007/s00705-003-0018-8; Sarno M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004517; Schuller E, 2008, VACCINE, V26, P4382, DOI 10.1016/j.vaccine.2008.05.081; Seino KK, 2007, CLIN VACCINE IMMUNOL, V14, P1465, DOI 10.1128/CVI.00249-07; Shan C, 2018, CELL HOST MICROBE, V24, P12, DOI 10.1016/j.chom.2018.05.021; Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322; Simon L.V., 2018, ENCEPHALITIS JAPANES; STOLLAR V, 1975, VIROLOGY, V64, P367, DOI 10.1016/0042-6822(75)90113-0; Sun P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14115-z; Suphatrakul A, 2015, VACCINE, V33, P5613, DOI 10.1016/j.vaccine.2015.08.090; Tangudu CS, 2021, VIROLOGY, V559, P30, DOI 10.1016/j.virol.2021.03.014; Theiler M, 1937, J EXP MED, V65, P787, DOI 10.1084/jem.65.6.787; Vazquez A, 2012, VECTOR-BORNE ZOONOT, V12, P223, DOI 10.1089/vbz.2011.0687; Ventura CV, 2016, LANCET, V387, P2502, DOI 10.1016/S0140-6736(16)30776-0; Vet LJ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020258; Wang HY, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-73; Whitman L, 1938, P SOC EXP BIOL MED, V37, P664; WHITMAN LORING, 1939, AMER JOUR TROP MED, V19, P19; Wilder-Smith A, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1067-x; Xie XP, 2017, MBIO, V8, DOI [10.1128/mBio.02134-16, 10.1128/mbio.02134-16]; Yan KX, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030368; YU YX, 1988, AM J TROP MED HYG, V39, P214, DOI 10.4269/ajtmh.1988.39.214; Yun KW, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-014-0744-4; Zakrzewski M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22945-y	138	1	1	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1230	10.3390/vaccines9111230			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF9QU	34835160	gold, Green Published			2022-04-29	WOS:000724399500001
J	Hokello, J; Sharma, AL; Tyagi, P; Bhushan, A; Tyagi, M				Hokello, Joseph; Sharma, Adhikarimayum Lakhikumar; Tyagi, Priya; Bhushan, Alok; Tyagi, Mudit			Human Immunodeficiency Virus Type-1 (HIV-1) Transcriptional Regulation, Latency and Therapy in the Central Nervous System	VACCINES			English	Review						HIV; transcriptional regulation; latency; therapy; central nervous system	NF-KAPPA-B; TAR-INDEPENDENT TRANSACTIVATION; ACTIVE ANTIRETROVIRAL THERAPY; NECROSIS-FACTOR-ALPHA; REVERSING AGENTS; CELLS; INFECTION; CNS; MECHANISMS; MICROGLIA	The central nervous system (CNS) is highly compartmentalized and serves as a specific site of human immunodeficiency virus (HIV) infection. Therefore, an understanding of the cellular populations that are infected by HIV or that harbor latent HIV proviruses is imperative in the attempts to address cure strategies, taking into account that HIV infection and latency in the CNS may differ considerably from those in the periphery. HIV replication in the CNS is reported to persist despite prolonged combination antiretroviral therapy due to the inability of the current antiretroviral drugs to penetrate and cross the blood-brain barrier. Consequently, as a result of sustained HIV replication in the CNS even in the face of combination antiretroviral therapy, there is a high incidence of HIV-associated neurocognitive disorders (HAND). This article, therefore, provides a comprehensive review of HIV transcriptional regulation, latency, and therapy in the CNS.	[Hokello, Joseph] Busitema Univ, Fac Sci & Educ, Dept Biol, POB 236, Tororo, Uganda; [Sharma, Adhikarimayum Lakhikumar; Tyagi, Mudit] Thomas Jefferson Univ, Ctr Translat Med, 1020 Locust St, Philadelphia, PA 19107 USA; [Tyagi, Priya] Cherry Hill East High Sch, 1750 Kresson Rd, Cherry Hill, NJ 08003 USA; [Bhushan, Alok] Thomas Jefferson Univ, Dept Pharmaceut Sci, Jefferson Coll Pharm, Philadelphia, PA 19107 USA		Tyagi, M (通讯作者)，Thomas Jefferson Univ, Ctr Translat Med, 1020 Locust St, Philadelphia, PA 19107 USA.	joseph.hokello@sci.busitema.ac.ug; LakhikumarSharma.Adhikarimayum@jefferson.edu; priya.tyagi@gmail.com; Alok.Bhushan@jefferson.edu; mudit.tyagi@jefferson.edu	Adhikarimayum, Lakhikumar Sharma/AAJ-4302-2020	Adhikarimayum, Lakhikumar Sharma/0000-0002-9969-8642	National Institute on Drug Abuse (NIDA), NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); FIC at the NIH through the Fogarty-AIDS International Training and Research Program (AITRP)	The work performed in the laboratories of the authors was supported by a grant from the National Institute on Drug Abuse (NIDA), NIH Grant 1R01DA041746-01 to M.T., and FIC at the NIH through the Fogarty-AIDS International Training and Research Program (AITRP) (Training Grant: #NIH 5D43 TW00011) to J.H. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Center for Research Resources or the U.S. National Institutes of Health.	Alqatawni A, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060584; Alvarez-Carbonell D, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008249; Alvarez-Carbonell D, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0335-8; Amano M, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.00466-19; Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b; Asahchop EL, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0370-5; ATWOOD WJ, 1994, AIDS RES HUM RETROV, V10, P1207, DOI 10.1089/aid.1994.10.1207; Beck SE, 2018, J NEUROVIROL, V24, P204, DOI 10.1007/s13365-017-0582-4; CHIODI F, 1987, J VIROL, V61, P1244, DOI 10.1128/JVI.61.4.1244-1247.1987; Chun TW, 1999, NATURE, V401, P874, DOI 10.1038/44755; Cosenza MA, 2002, BRAIN PATHOL, V12, P442, DOI 10.1111/j.1750-3639.2002.tb00461.x; CUPP C, 1993, ONCOGENE, V8, P2231; Dental C, 2017, J IMMUNOL, V198, P1229, DOI 10.4049/jimmunol.1600742; Edara VV, 2020, J VIROL, V94, DOI 10.1128/JVI.01563-19; FAUCI AS, 1993, J ACQ IMMUN DEF SYND, V6, P655; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; Fischer CP, 1999, BRAIN RES, V828, P119, DOI 10.1016/S0006-8993(99)01344-X; Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1; Freed Eric O., 2001, Somatic Cell and Molecular Genetics, V26, P13, DOI 10.1023/A:1021070512287; Gray LR, 2016, MOL PSYCHIATR, V21, P574, DOI 10.1038/mp.2015.111; Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727; Hokello J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060605; Hokello J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073697; Hokello J, 2021, FEBS LETT, V595, P577, DOI 10.1002/1873-3468.14033; Hokello J, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12080868; Hokello J, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8030137; Jayant RD, 2017, J NEUROVIROL, V23, P603, DOI 10.1007/s13365-017-0538-8; Jayant RD, 2015, INT J NANOMED, V10, P1077, DOI 10.2147/IJN.S76517; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; Kim YK, 2006, EMBO J, V25, P3596, DOI 10.1038/sj.emboj.7601248; Kingsman SM, 1996, EUR J BIOCHEM, V240, P491, DOI 10.1111/j.1432-1033.1996.0491h.x; Ko A, 2019, J NEUROIMMUNE PHARM, V14, P110, DOI 10.1007/s11481-018-9809-2; Kramer-Hammerle S, 2005, VIRUS RES, V111, P194, DOI 10.1016/j.virusres.2005.04.009; Kruize Z, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02828; Kumar A, 2014, VIRUSES-BASEL, V6, P1837, DOI 10.3390/v6041837; Kumar KP, 1998, P NATL ACAD SCI USA, V95, P9767, DOI 10.1073/pnas.95.17.9767; Kundu M, 1999, J HUMAN VIROL, V2, P72; Lawrence DMP, 2004, J VIROL, V78, P7319, DOI 10.1128/JVI.78.14.7319-7328.2004; Leon-Rivera R, 2021, MBIO, V12, DOI 10.1128/mBio.03633-20; Levine AJ, 2012, AM J MED GENET B, V159B, P669, DOI 10.1002/ajmg.b.32071; Li GH, 2016, CURR HIV RES, V14, P373, DOI 10.2174/1570162X14666161006121455; Li GH, 2015, AIDS, V29, P755, DOI 10.1097/QAD.0000000000000605; Llewellyn GN, 2018, J NEUROVIROL, V24, P192, DOI 10.1007/s13365-017-0604-2; Lustig G, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009871; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; Mdanda S, 2019, ASSAY DRUG DEV TECHN, V17, P322, DOI 10.1089/adt.2019.941; Mdanda S, 2020, XENOBIOTICA, V50, P570, DOI 10.1080/00498254.2019.1655605; Mothobi NZ, 2012, CURR OPIN INFECT DIS, V25, P4, DOI 10.1097/QCO.0b013e32834ef586; Nair M, 2016, ADV DRUG DELIVER REV, V103, P202, DOI 10.1016/j.addr.2016.02.008; North TW, 2010, J VIROL, V84, P2913, DOI 10.1128/JVI.02356-09; Peluso MJ, 2012, AIDS, V26, P1765, DOI 10.1097/QAD.0b013e328355e6b2; POLI G, 1993, CLIN INFECT DIS, V17, pS224; Rao KS, 2008, BIOMATERIALS, V29, P4429, DOI 10.1016/j.biomaterials.2008.08.004; Reu P, 2017, CELL REP, V20, P779, DOI 10.1016/j.celrep.2017.07.004; Reynolds JL, 2006, BRAIN RES, V1123, P226, DOI 10.1016/j.brainres.2006.09.034; Sahu G, 2015, VIROLOGY, V483, P185, DOI 10.1016/j.virol.2015.03.036; Sawaya BE, 1998, J NEUROIMMUNOL, V87, P33, DOI 10.1016/S0165-5728(98)00044-7; Saylor D, 2016, NAT REV NEUROL, V12, P234, DOI [10.1038/nrneurol.2016.53, 10.1038/nrneurol.2016.27]; Schulze-Gahmen U, 2018, P NATL ACAD SCI USA, V115, P12973, DOI 10.1073/pnas.1806438115; Sharma AL, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10070806; Sharma AL, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12091040; Sonti S, 2021, VIRUS RES, V303, DOI 10.1016/j.virusres.2021.198523; Spudich S, 2011, J INFECT DIS, V204, P753, DOI 10.1093/infdis/jir387; Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853; Swepson C, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00823; TAYLOR JP, 1994, J VIROL, V68, P3971, DOI 10.1128/JVI.68.6.3971-3981.1994; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; TAYLOR JP, 1995, ONCOGENE, V10, P395; Thomas SA, 2004, CURR PHARM DESIGN, V10, P1313, DOI 10.2174/1381612043384835; Thompson KA, 2011, AM J PATHOL, V179, P1623, DOI 10.1016/j.ajpath.2011.06.039; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Tyagi M, 2016, CURR HIV RES, V14, P442, DOI 10.2174/1570162X14666160324124736; Tyagi M, 2016, J NEUROVIROL, V22, P261, DOI 10.1007/s13365-015-0398-z; Tyagi M, 2012, MOL MED, V18, P1096, DOI 10.2119/molmed.2012.00194; Veenstra M, 2017, MBIO, V8, DOI 10.1128/mBio.01280-17; Wallet C, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00362; Whitney JB, 2014, NATURE, V512, P74, DOI 10.1038/nature13594; Yang LP, 1997, VIROLOGY, V235, P48, DOI 10.1006/viro.1997.8672; Zicari Sonia, 2020, Oncotarget, V11, P699, DOI 10.18632/oncotarget.27487	81	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1272	10.3390/vaccines9111272			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF5SW	34835203	gold, Green Published			2022-04-29	WOS:000724131300001
J	Kim, D; Ha, J; Moon, J; Kim, D; Lee, W; Lee, C; Kim, D; Yi, J				Kim, Daehyun; Ha, Jaejung; Moon, Joonho; Kim, Doyoon; Lee, Wonhee; Lee, Chanwoo; Kim, Danil; Yi, Junkoo			Increased Ruminoreticular Temperature and Body Activity after Foot-and-Mouth Vaccination in Pregnant Hanwoo (Bos taurus coreanae) Cows	VACCINES			English	Article						ruminal biocapsule sensor; FMD vaccination; ruminoreticular temperature; body activity; abortion; premature birth; Korean cattle	REPRODUCTIVE-PERFORMANCE; INFECTIOUS AGENTS; DISEASE VIRUS; CATTLE; ABORTIONS; HERD	How does vaccination against foot-and-mouth disease (FMD) affect pregnant cows? Vaccination is the most effective method of preventing the spread of FMD, but it is linked to sporadic side effects, such as abortion and premature birth, which result in economic loss. In this study, ruminoreticular temperature and body activity were measured before and after FMD vaccination using a ruminoreticular biocapsule sensor in Hanwoo cows at different stages of pregnancy. Compared to the unvaccinated groups, the ruminoreticular temperature increased 12 h after vaccination in the vaccinated groups. This increase in temperature is significantly correlated to vaccination. Compared to the nonpregnant and early pregnancy groups, the ruminoreticular temperature of the late pregnancy group increased sharply by more than 40 & DEG;C. Moreover, in nonpregnant and early pregnancy groups, a rapid increase in body activity was observed after FMD vaccinations. Of the 73 pregnant vaccinated cows in the study, a total of five cases had side effects (four abortions and one premature birth). Therefore, changes in the ruminoreticular temperature and activity in pregnant cows can be used as raw data to further clarify the association of FMD vaccination with the loss of a fetus and possibly predict abortion, miscarriage, and premature birth following FMD vaccination.	[Kim, Daehyun; Ha, Jaejung; Yi, Junkoo] Livestock Res Inst, 186 Daeryongsan Ro, Anjeong Myeon 36052, Yeongju, South Korea; [Moon, Joonho] Lartbio Co Ltd, 12th Floor,234 Teheran Ro, Seoul 06221, South Korea; [Kim, Doyoon] Kyungpook Natl Univ, Dept Anim Sci & Biotechnol, Sangju 41566, South Korea; [Lee, Wonhee; Lee, Chanwoo] Hankyong Natl Univ, Dept Biotechnol, Coll Agr & Life Sci, Ansung 17579, South Korea; [Kim, Danil] Seoul Natl Univ, Inst Green Biosci & Technol, Seoul 25354, South Korea		Yi, J (通讯作者)，Livestock Res Inst, 186 Daeryongsan Ro, Anjeong Myeon 36052, Yeongju, South Korea.; Kim, D (通讯作者)，Seoul Natl Univ, Inst Green Biosci & Technol, Seoul 25354, South Korea.	chunja2411@korea.kr; hjjggo@korea.kr; kuma618@gmail.com; kdy51311@naver.com; wonhee0625@naver.com; rhdaud2299@naver.com; danilkim73@snu.ac.kr; 79lee38@korea.kr		Yi, JunKoo/0000-0003-2593-6529; Kim, Dae Hyun/0000-0002-4820-4438	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry (IPET) - Ministry of Agriculture, Food, and Rural Affairs (MAFRA) [120011021]; National Research Foundation of Korea (NRF) - Korea government (MSIT) [NRF-2020R1F1A1052024]	Financial support for this study was granted by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry (IPET) through a Food, Agriculture, Technology convergence creative talent training project funded by the Ministry of Agriculture, Food, and Rural Affairs (MAFRA) (120011021) and a National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT; No. NRF-2020R1F1A1052024).	Bewley JM, 2008, J DAIRY SCI, V91, P3880, DOI 10.3168/jds.2008-1159; 김희진, 2017, [Journal of Korean Institute of Information Technology, 한국정보기술학회논문지], V15, P65, DOI 10.14801/jkiit.2017.15.11.65; Carpenter TE, 2006, PREV VET MED, V77, P215, DOI 10.1016/j.prevetmed.2006.07.005; Choi W, 2020, J VET MED SCI, V82, P1750, DOI 10.1292/jvms.20-0459; Cooper-Prado MJ, 2011, J ANIM SCI, V89, P1020, DOI 10.2527/jas.2010-3434; Ferreira LCL, 2016, J ANIM SCI, V94, P401, DOI 10.2527/jas.2015-9537; Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004; Hansen PJ, 2004, AM J REPROD IMMUNOL, V51, P294, DOI 10.1111/j.1600-0897.2004.00160.x; Hassig M, 1998, J VET MED B, V45, P435, DOI 10.1111/j.1439-0450.1998.tb00813.x; Kahn S, 2002, CAN VET J, V43, P349; Kamel M, 2019, ARCH VIROL, V164, P1501, DOI 10.1007/s00705-019-04216-x; Kim D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050419; Konnai S, 2008, ACTA TROP, V105, P269, DOI 10.1016/j.actatropica.2007.12.004; Lee JI, 2007, J VET SCI, V8, P283, DOI 10.4142/jvs.2007.8.3.283; Magamage Manjula Priyantha Sumith, 2021, [Journal of Animal Reproduciton and Biotechnology, 한국동물생명공학회지], V36, P45, DOI 10.12750/JARB.36.1.45; Omori H, 2014, NEUROSCI RES, V79, P13, DOI 10.1016/j.neures.2013.11.005; Perumal P., 2013, Asian Pacific Journal of Reproduction, V2, P178; Rodrigues MC, 2015, J ANIM SCI, V93, P4443, DOI 10.2527/jas.2015-9277; Rodriguez LL, 2009, VACCINE, V27, pD90, DOI 10.1016/j.vaccine.2009.08.039; Shahriari A, 2018, Arch Razi Inst, V73, P1, DOI 10.22092/ARI.2018.114054; Singh RK, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030090; Waldner CL, 2014, THERIOGENOLOGY, V81, P840, DOI 10.1016/j.theriogenology.2013.12.016; Yeruham I, 2001, VET DERMATOL, V12, P197, DOI 10.1046/j.0959-4493.2001.00221.x; Yoon H, 2012, TRANSBOUND EMERG DIS, V59, P517, DOI 10.1111/j.1865-1682.2011.01304.x; Zhang L, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-268	25	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1227	10.3390/vaccines9111227			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF4IT	34835159	gold, Green Published			2022-04-29	WOS:000724036500001
J	Knolle, PA; Huang, LR; Kosinska, A; Wohlleber, D; Protzer, U				Knolle, Percy A.; Huang, Li-Rung; Kosinska, Anna; Wohlleber, Dirk; Protzer, Ulrike			Improving Therapeutic Vaccination against Hepatitis B-Insights from Preclinical Models of Immune Therapy against Persistent Hepatitis B Virus Infection	VACCINES			English	Review						hepatitis B virus (HBV); vaccination; therapeutic vaccination	T-CELL-ACTIVATION; EXHAUSTED PHENOTYPE; ENDOTHELIAL-CELLS; BOOST VACCINATION; VIRAL CLEARANCE; INNATE IMMUNITY; LIVER; ANTIGEN; TOLERANCE; EXPRESSION	Chronic hepatitis B affects more than 250 million individuals worldwide, putting them at risk of developing liver cirrhosis and liver cancer. While antiviral immune responses are key to eliminating hepatitis B virus (HBV) infections, insufficient antiviral immunity characterized by failure to eliminate HBV-infected hepatocytes is associated with chronic hepatitis B. Prophylactic vaccination against hepatitis B successfully established protective immunity against infection with the hepatitis B virus and has been instrumental in controlling hepatitis B. However, prophylactic vaccination schemes have not been successful in mounting protective immunity to eliminate HBV infections in patients with chronic hepatitis B. Here, we discuss the current knowledge on the development and efficacy of therapeutic vaccination strategies against chronic hepatitis B with particular emphasis on the pathogenetic understanding of dysfunctional anti-viral immunity. We explore the development of additional immune stimulation measures within tissues, in particular activation of immunogenic myeloid cell populations, and their use for combination with therapeutic vaccination strategies to improve the efficacy of therapeutic vaccination against chronic hepatitis B.	[Knolle, Percy A.; Wohlleber, Dirk] Tech Univ Munich, Inst Mol Immunol & Expt Oncol, Sch Med, D-81675 Munich, Germany; [Knolle, Percy A.; Protzer, Ulrike] German Ctr Infect Res DZIF, Munich Site, D-81675 Munich, Germany; [Huang, Li-Rung] Natl Hlth Res Inst, Inst Mol & Gen Med, Miaoli 350, Taiwan; [Kosinska, Anna; Protzer, Ulrike] Tech Univ Munich, Inst Virol, Sch Med, D-81675 Munich, Germany		Knolle, PA (通讯作者)，Tech Univ Munich, Inst Mol Immunol & Expt Oncol, Sch Med, D-81675 Munich, Germany.; Knolle, PA (通讯作者)，German Ctr Infect Res DZIF, Munich Site, D-81675 Munich, Germany.	percy.knolle@tum.de; lrhuang@nhri.edu.tw; anna.kosinska@helmholtz-muenchen.de; dirk.wohlleber@tum.de; protzer@tum.de	Wohlleber, Dirk/J-2549-2017; Protzer, Ulrike/D-5915-2015	Wohlleber, Dirk/0000-0003-3861-5150; Protzer, Ulrike/0000-0002-9421-1911	German Research Foundation (DFG)German Research Foundation (DFG) [272983813-TRR179]	FundingThis research was funded by the German Research Foundation (DFG), grant number 272983813-TRR179.	Alfei F, 2019, NATURE, V571, P265, DOI 10.1038/s41586-019-1326-9; Allweiss L, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9060156; Anton LC, 2014, J LEUKOCYTE BIOL, V95, P551, DOI 10.1189/jlb.1113599; Backes S, 2016, VACCINE, V34, P923, DOI 10.1016/j.vaccine.2015.12.060; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Barros-Martins J, 2021, NAT MED, V27, P1525, DOI 10.1038/s41591-021-01449-9; Baudi I, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.721975; Baumann T, 2020, NAT IMMUNOL, V21, P555, DOI 10.1038/s41590-020-0666-9; Benechet AP, 2019, NATURE, V574, P200, DOI 10.1038/s41586-019-1620-6; Beyer M, 2016, NAT IMMUNOL, V17, P593, DOI 10.1038/ni.3399; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Boni C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112754; Boudewijns R, 2021, JHEP REP, V3, DOI 10.1016/j.jhepr.2021.100295; Bowen DG, 2004, J CLIN INVEST, V114, P701, DOI 10.1172/JCI200421593; Buchmann P, 2013, VACCINE, V31, P1197, DOI 10.1016/j.vaccine.2012.12.074; Carambia A, 2014, J HEPATOL, V61, P594, DOI 10.1016/j.jhep.2014.04.027; Carambia A, 2013, J HEPATOL, V58, P112, DOI 10.1016/j.jhep.2012.09.008; Cargill T, 2021, CLIN EXP IMMUNOL, V205, P106, DOI 10.1111/cei.13614; CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A; Cebula M, 2017, MOL THER, V25, P2289, DOI 10.1016/j.ymthe.2017.06.018; Champion CR, 2021, ANN PHARMACOTHER, V55, P783, DOI 10.1177/1060028020962050; Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043730; Cheng XM, 2017, HEPATOLOGY, V66, P1779, DOI 10.1002/hep.29348; Crispe IN, 2014, HEPATOLOGY, V60, P2109, DOI 10.1002/hep.27254; de Creus A, 2005, J IMMUNOL, V174, P2037, DOI 10.4049/jimmunol.174.4.2037; De Simone G, 2021, IMMUNITY, V54, P2089, DOI 10.1016/j.immuni.2021.05.005; Diehl L, 2008, HEPATOLOGY, V47, P296, DOI 10.1002/hep.21965; Ebert G, 2011, GASTROENTEROLOGY, V141, P696, DOI 10.1053/j.gastro.2011.05.001; Eickhoff S, 2015, CELL, V162, P1322, DOI 10.1016/j.cell.2015.08.004; Fernandez Guillermo, 2018, Euroasian J Hepatogastroenterol, V8, P133, DOI 10.5005/jp-journals-10018-1279; Fisicaro P, 2017, NAT MED, V23, P327, DOI 10.1038/nm.4275; Fisicaro P, 2010, GASTROENTEROLOGY, V138, P682, DOI 10.1053/j.gastro.2009.09.052; Fumagalli V, 2020, J EXP MED, V217, DOI 10.1084/jem.20200298; Gane E, 2019, J HEPATOL, V71, P900, DOI 10.1016/j.jhep.2019.06.028; Gehring AJ, 2019, GASTROENTEROLOGY, V156, P325, DOI 10.1053/j.gastro.2018.10.032; Gehring AJ, 2013, J CLIN INVEST, V123, P3766, DOI 10.1172/JCI66043; Gill US, 2020, J HEPATOL, V72, P9, DOI 10.1016/j.jhep.2019.10.008; Guidotti LG, 1996, IMMUNITY, V4, P25, DOI 10.1016/S1074-7613(00)80295-2; Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825; Guidotti LG, 2015, CURR OPIN IMMUNOL, V36, P61, DOI 10.1016/j.coi.2015.06.016; Heymann F, 2015, HEPATOLOGY, V62, P279, DOI 10.1002/hep.27793; Hosel M, 2009, HEPATOLOGY, V50, P1773, DOI 10.1002/hep.23226; Holz LE, 2008, GASTROENTEROLOGY, V135, P989, DOI 10.1053/j.gastro.2008.05.078; Horng JH, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00662-x; Huang LR, 2013, NAT IMMUNOL, V14, P574, DOI 10.1038/ni.2573; Iannacone M, 2022, NAT REV IMMUNOL, V22, P19, DOI 10.1038/s41577-021-00549-4; Iannacone M, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a021477; Iwasaki A, 2014, NAT REV IMMUNOL, V14, P315, DOI 10.1038/nri3665; Khan O, 2019, NATURE, V571, P211, DOI 10.1038/s41586-019-1325-x; Knolle PA, 1998, HEPATOLOGY, V27, P93, DOI 10.1002/hep.510270116; Knolle PA, 2014, GASTROENTEROLOGY, V146, P1193, DOI 10.1053/j.gastro.2013.12.036; Kosinska AD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080841; Kosinska AD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47149-w; Kosinska AD, 2017, CURR OPIN VIROL, V23, P75, DOI 10.1016/j.coviro.2017.03.011; Kosinska AD, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003391; Krenkel O, 2017, NAT REV IMMUNOL, V17, P306, DOI 10.1038/nri.2017.11; Kurts C, 2010, NAT REV IMMUNOL, V10, P403, DOI 10.1038/nri2780; Lee S, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2020.101969; Li L, 2018, J HEPATOL, V68, P912, DOI 10.1016/j.jhep.2017.12.008; Limmer A, 2000, NAT MED, V6, P1348, DOI 10.1038/82161; Lindenbach BD, 2005, NATURE, V436, P933, DOI 10.1038/nature04077; Liu J, 2010, GASTROENTEROLOGY, V139, P474, DOI 10.1053/j.gastro.2010.04.048; Liu J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003856; Lok AS, 2016, J HEPATOL, V65, P509, DOI 10.1016/j.jhep.2016.05.016; Loomba R, 2017, GASTROENTEROLOGY, V152, P1297, DOI 10.1053/j.gastro.2017.02.009; Lucifora J, 2016, J HEPATOL, V64, pS41, DOI 10.1016/j.jhep.2016.02.009; Lucifora J, 2014, SCIENCE, V343, P1221, DOI 10.1126/science.1243462; Luth S, 2008, J CLIN INVEST, V118, P3403, DOI 10.1172/JCI32132; Ma ZY, 2015, CELL MOL IMMUNOL, V12, P273, DOI 10.1038/cmi.2014.112; Mackman RL, 2020, J MED CHEM, V63, P10188, DOI 10.1021/acs.jmedchem.0c00100; MacLachlan JH, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a021410; Maier H, 2007, J IMMUNOL, V178, P2714, DOI 10.4049/jimmunol.178.5.2714; Maini MK, 2018, LANCET GASTROENTEROL, V3, P192, DOI 10.1016/S2468-1253(18)30007-4; Manske K, 2018, HEPATOLOGY, V68, P2089, DOI 10.1002/hep.30080; Martinez MG, 2020, LIVER INT, V40, P27, DOI 10.1111/liv.14364; Michel ML, 2015, MED MICROBIOL IMMUN, V204, P121, DOI 10.1007/s00430-014-0381-y; Michel ML, 2011, J HEPATOL, V54, P1286, DOI 10.1016/j.jhep.2010.12.031; Michler T, 2020, GASTROENTEROLOGY, V158, P1762, DOI 10.1053/j.gastro.2020.01.032; Mingozzi F, 2003, J CLIN INVEST, V111, P1347, DOI 10.1172/JCI200316887; Naggie S, 2021, ANNU REV MED, V72, P93, DOI 10.1146/annurev-med-080119-103356; Nassal M, 2015, GUT, V64, P1972, DOI 10.1136/gutjnl-2015-309809; Pallett LJ, 2015, NAT MED, V21, P591, DOI 10.1038/nm.3856; Pawlotsky JM, 2020, J HEPATOL, V73, P1170, DOI 10.1016/j.jhep.2020.08.018; Protzer U, 2017, NAT REV GASTRO HEPAT, V14, P327, DOI 10.1038/nrgastro.2017.44; Protzer U, 2012, NAT REV IMMUNOL, V12, P201, DOI 10.1038/nri3169; Pulendran B, 2021, NAT REV DRUG DISCOV, V20, P454, DOI 10.1038/s41573-021-00163-y; Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573; Rehermann B, 2013, NAT MED, V19, P859, DOI 10.1038/nm.3251; Sangare L, 2009, VACCINE, V27, P1777, DOI 10.1016/j.vaccine.2009.01.043; Sato S, 2015, IMMUNITY, V42, P123, DOI 10.1016/j.immuni.2014.12.016; Schildberg FA, 2011, HEPATOLOGY, V54, P262, DOI 10.1002/hep.24352; Shortman K, 2007, NAT REV IMMUNOL, V7, P19, DOI 10.1038/nri1996; Stross L, 2012, HEPATOLOGY, V56, P873, DOI 10.1002/hep.25765; Tenbusch M, 2021, LANCET INFECT DIS, V21, P1212, DOI 10.1016/S1473-3099(21)00420-5; Thimme R, 2003, J VIROL, V77, P68, DOI 10.1128/JVI.77.1.68-76.2003; Thomas E, 2016, NAT REV GASTRO HEPAT, V13, P362, DOI 10.1038/nrgastro.2016.37; Thomson AW, 2010, NAT REV IMMUNOL, V10, P753, DOI 10.1038/nri2858; Tsounis EP, 2021, WORLD J GASTROENTERO, V27, P2727, DOI 10.3748/wjg.v27.i21.2727; Urban S, 2021, GUT, V70, P1782, DOI 10.1136/gutjnl-2020-323888; Utzschneider DT, 2016, J EXP MED, V213, P1819, DOI 10.1084/jem.20150598; Utzschneider DT, 2013, NAT IMMUNOL, V14, P603, DOI 10.1038/ni.2606; Vandepapeliere P, 2007, VACCINE, V25, P8585, DOI 10.1016/j.vaccine.2007.09.072; Wang HL, 2020, J HEPATOL, V72, P45, DOI 10.1016/j.jhep.2019.08.024; Wang Q, 2020, CELL HOST MICROBE, V28, P335, DOI 10.1016/j.chom.2020.05.010; Wei L, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13081463; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wieland S, 2004, P NATL ACAD SCI USA, V101, P6669, DOI 10.1073/pnas.0401771101; Wieland SF, 2005, J VIROL, V79, P9369, DOI 10.1128/JVI.79.15.9369-9380.2005; Xia YC, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9010018; Yau T, 2019, J HEPATOL, V71, P543, DOI 10.1016/j.jhep.2019.05.014; Yewdell JW, 2003, NAT REV IMMUNOL, V3, P952, DOI 10.1038/nri1250; You Q, 2008, HEPATOLOGY, V48, P978, DOI 10.1002/hep.22395; Zhu DM, 2016, J IMMUNOL, V196, P3079, DOI 10.4049/jimmunol.1502061	113	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1333	10.3390/vaccines9111333			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK1TH	34835264	gold, Green Published			2022-04-29	WOS:000727255700001
J	Lim, J; Hong, S				Lim, Jongwon; Hong, Suhee			Transcriptome Analysis in the Head Kidney of Rainbow Trout (Oncorhynchus mykiss) Immunized with a Combined Vaccine of Formalin-Inactivated Aeromonas salmonicida and Vibrio anguillarum	VACCINES			English	Article						vaccine; <p>A. salmonicida</p>; <p>V. anguillarum</p>; transcriptome; immune	EXPRESSION ANALYSIS; FISH; SYSTEM; INFLAMMASOME; INFECTION; RESPONSES; BACTERIAL	This study aimed to identify the molecular mechanisms regulated by a combined vaccine against Aeromonas salmonicida and Vibrio anguillarum (O1 serotype). These bacteria cause furunculosis and vibriosis, respectively, and are associated with a high mortality in rainbow trout in Korea. The vaccine upregulated gene expression of TCR alpha, T-bet, sIgM, and mIgM, markers of an activated adaptive immune response. On days 1, 3, and 5, transcriptome analysis revealed 862 (430 up- and 432 downregulated), 492 (204 up- and 288 downregulated), and 741 (270 up- and 471 downregulated) differentially expressed genes (DEGs), respectively. Gene ontology (GO) enrichment analysis identified 377 (108 MF, 132 CC, 137 BP), 302 (60 MF, 180 CC, 62 BP), and 314 (115 MF, 129 CC, 70 BP) GOs at days 1, 3, and 5, respectively. Kyoto Encyclopedia of Genetic and Genomic enrichment analysis identified eight immune system-related pathways like cytokine-cytokine receptor interaction, NF-kappaB signaling pathway, TNF signaling pathway, NOD-like receptor signaling pathway, cytosolic DNA sensing pathway, cell adhesion molecule, complement and coagulation cascade, and antigen processing and presentation. In the analysis of the protein-protein interaction of immune-related DEGs, a total of 59, 21, and 21 interactional relationships were identified at days 1, 3, and 5, respectively, with TNF having the highest centrality at all three time points.	[Lim, Jongwon; Hong, Suhee] Gangneung Wonju Natl Univ, Dept Marine Biotechnol, Kangnung 25457, South Korea		Hong, S (通讯作者)，Gangneung Wonju Natl Univ, Dept Marine Biotechnol, Kangnung 25457, South Korea.	myobong@gwnu.ac.kr; s.hong@gwnu.ac.kr		im, jong-won/0000-0001-8558-1438	Ministry of Oceans and Fisheries, Korea	'Gangwon Sea Grant Program', funded by the Ministry of Oceans and Fisheries, Korea.	Aksnes A, 2006, AQUACULTURE, V261, P305, DOI 10.1016/j.aquaculture.2006.07.025; Alejo A, 2011, DEV COMP IMMUNOL, V35, P1215, DOI 10.1016/j.dci.2011.03.011; Aly SM, 2021, FISH SHELLFISH IMMUN, V111, P145, DOI 10.1016/j.fsi.2020.10.011; Antoniak S, 2018, RES PRACT THROMB HAE, V2, P549, DOI 10.1002/rth2.12109; Bao PC, 2019, FISH SHELLFISH IMMUN, V88, P84, DOI 10.1016/j.fsi.2019.02.014; Bobanga ID, 2013, VACCINES, V1, DOI 10.3390/vaccines1040444; Boshra H, 2006, FISH SHELLFISH IMMUN, V20, P239, DOI 10.1016/j.fsi.2005.04.004; Braden LM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00120; Brisse M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01586; Broere F., 2019, NIJKAMP PARNHAMS PRI, P23, DOI [10.1007/978-3-030-10811-3_3, DOI 10.1007/978-3-030-10811-3_3]; Caipang CMA, 2008, FISH SHELLFISH IMMUN, V24, P314, DOI 10.1016/j.fsi.2007.11.018; Chiu YH, 2009, CELL, V138, P576, DOI 10.1016/j.cell.2009.06.015; Chun Hye-Jin, 2018, [Korean Journal of Fisheries and Aquatic Sciences, 한국수산과학회지], V51, P254, DOI 10.5657/KFAS.2018.0254; Dallaire-Dufresne S, 2014, VET MICROBIOL, V169, P1, DOI 10.1016/j.vetmic.2013.06.025; Duff DCB, 1942, J IMMUNOL, V44, P87; Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139; Engelsma MY, 2002, VET IMMUNOL IMMUNOP, V87, P467, DOI 10.1016/S0165-2427(02)00077-6; Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703; Frans I, 2011, J FISH DIS, V34, P643, DOI 10.1111/j.1365-2761.2011.01279.x; Fu YW, 2019, FISH SHELLFISH IMMUN, V84, P865, DOI 10.1016/j.fsi.2018.10.083; Fujita T, 2004, IMMUNOL REV, V198, P185, DOI 10.1111/j.0105-2896.2004.0123.x; Gong XY, 2019, FISH SHELLFISH IMMUN, V86, P1058, DOI 10.1016/j.fsi.2018.12.063; Hayashi K., 1964, J FAC FISH PREF U MI, V6, P181; Hong S, 2013, J IMMUNOL, V191, P5959, DOI 10.4049/jimmunol.1301584; Hou ZS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.639489; Ji LQ, 2020, FISH SHELLFISH IMMUN, V98, P87, DOI 10.1016/j.fsi.2019.12.022; Kanhere A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2260; Kim J, 2021, ARCH VIROL, V166, P1057, DOI 10.1007/s00705-021-04980-9; Li J, 2020, AQUACULTURE, V524, DOI 10.1016/j.aquaculture.2020.735259; Lim J, 2020, J FISH DIS, V43, P609, DOI 10.1111/jfd.13158; Liu HY, 2018, ONCOTARGET, V9, P2887, DOI 10.18632/oncotarget.20812; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Lopez-Castejon G, 2007, MOL IMMUNOL, V44, P2772, DOI 10.1016/j.molimm.2006.10.027; Lovoll M, 2007, VET IMMUNOL IMMUNOP, V117, P284, DOI 10.1016/j.vetimm.2007.03.005; Lovoll M, 2007, FISH SHELLFISH IMMUN, V23, P721, DOI 10.1016/j.fsi.2007.01.019; Marana MH, 2019, FISH SHELLFISH IMMUN, V88, P344, DOI 10.1016/j.fsi.2019.03.001; Marana MH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171944; Martin SAM, 2006, MOL IMMUNOL, V43, P1900, DOI 10.1016/j.molimm.2005.10.007; Meloni M, 2015, FISH SHELLFISH IMMUN, V43, P82, DOI 10.1016/j.fsi.2014.12.016; Menanteau-Ledouble S, 2016, DIS AQUAT ORGAN, V120, P49, DOI 10.3354/dao03006; Meng XZ, 2019, FISH SHELLFISH IMMUN, V88, P189, DOI 10.1016/j.fsi.2019.02.061; Nomiyama H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-222; Origgi FC, 2017, FISH SHELLFISH IMMUN, V60, P334, DOI 10.1016/j.fsi.2016.12.006; Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002; Reis MIR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050450; Romstad AB, 2013, VACCINE, V31, P791, DOI 10.1016/j.vaccine.2012.11.069; Sakamaki K, 2009, J FISH BIOL, V74, P727, DOI 10.1111/j.1095-8649.2009.02184.x; Schulz P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030476; Soleto I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73999-w; Song LF, 2021, AQUACULT REP, V21, DOI 10.1016/j.aqrep.2021.100789; Torres-Corral Y, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080906; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; VALLEJO AN, 1992, DEV IMMUNOL, V3, P51, DOI 10.1155/1992/82525; Vinay DS, 2011, CELL MOL IMMUNOL, V8, P281, DOI 10.1038/cmi.2010.82; Wang TH, 2010, FISH SHELLFISH IMMUN, V29, P705, DOI 10.1016/j.fsi.2010.06.016; Xing J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00499; Yang Y, 2019, FISH SHELLFISH IMMUN, V87, P609, DOI 10.1016/j.fsi.2019.02.002; Zeng C, 2021, DEV COMP IMMUNOL, V118, DOI 10.1016/j.dci.2020.103987; Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073871; Zhang ZB, 2011, FISH SHELLFISH IMMUN, V31, P1, DOI 10.1016/j.fsi.2010.12.019; Zhou Y, 2019, FISH SHELLFISH IMMUN, V94, P871, DOI 10.1016/j.fsi.2019.10.010; Zmora N, 2017, MUCOSAL IMMUNOL, V10, P865, DOI 10.1038/mi.2017.19	62	0	0	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1234	10.3390/vaccines9111234			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF9VG	34835165	gold, Green Published			2022-04-29	WOS:000724411100001
J	Machado, BAS; Hodel, KVS; Fonseca, LMD; Mascarenhas, LAB; Andrade, LPCD; Rocha, VPC; Soares, MBP; Berglund, P; Duthie, MS; Reed, SG; Badaro, R				Machado, Bruna Aparecida Souza; Hodel, Katharine Valeria Saraiva; Fonseca, Larissa Moraes dos Santos; Mascarenhas, Luis Alberto Breda; Andrade, Leone Peter Correia da Silva; Rocha, Vinicius Pinto Costa; Soares, Milena Botelho Pereira; Berglund, Peter; Duthie, Malcolm S.; Reed, Steven G.; Badaro, Roberto			The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview	VACCINES			English	Review						RNA vaccines; mRNA vaccines; saRNA vaccines; COVID-19; SARS-CoV-2	DENDRITIC CELL IMMUNOTHERAPY; CORONAVIRUS SPIKE PROTEIN; RECEPTOR-BINDING DOMAIN; CYTOTOXIC T-LYMPHOCYTES; INFLUENZA-A VIRUS; MESSENGER-RNA; IN-VIVO; NEUTRALIZING ANTIBODIES; PROTECTIVE EFFICACY; SARS-COV-2 VARIANT	In recent years, vaccine development using ribonucleic acid (RNA) has become the most promising and studied approach to produce safe and effective new vaccines, not only for prophylaxis but also as a treatment. The use of messenger RNA (mRNA) as an immunogenic has several advantages to vaccine development compared to other platforms, such as lower coast, the absence of cell cultures, and the possibility to combine different targets. During the COVID-19 pandemic, the use of mRNA as a vaccine became more relevant; two out of the four most widely applied vaccines against COVID-19 in the world are based on this platform. However, even though it presents advantages for vaccine application, mRNA technology faces several pivotal challenges to improve mRNA stability, delivery, and the potential to generate the related protein needed to induce a humoral- and T-cell-mediated immune response. The application of mRNA to vaccine development emerged as a powerful tool to fight against cancer and non-infectious and infectious diseases, for example, and represents a relevant research field for future decades. Based on these advantages, this review emphasizes mRNA and self-amplifying RNA (saRNA) for vaccine development, mainly to fight against COVID-19, together with the challenges related to this approach.	[Machado, Bruna Aparecida Souza; Hodel, Katharine Valeria Saraiva; Fonseca, Larissa Moraes dos Santos; Mascarenhas, Luis Alberto Breda; Andrade, Leone Peter Correia da Silva; Rocha, Vinicius Pinto Costa; Soares, Milena Botelho Pereira; Badaro, Roberto] Univ Ctr SENAI CIMATEC, SENAI Inst Innovat ISI Hlth Adv Syst CIMATEC ISI, BR-41650010 Salvador, BA, Brazil; [Soares, Milena Botelho Pereira] Oswaldo Cruz Fdn IGM FIOCRUZ BA, Goncalo Moniz Inst, BR-40296710 Salvador, BA, Brazil; [Berglund, Peter; Duthie, Malcolm S.; Reed, Steven G.] HDT Bio, 1616 Eastlake Ave E, Seattle, WA 98102 USA		Machado, BAS (通讯作者)，Univ Ctr SENAI CIMATEC, SENAI Inst Innovat ISI Hlth Adv Syst CIMATEC ISI, BR-41650010 Salvador, BA, Brazil.	brunam@fieb.org.br; katharine.hodel@fieb.org.br; larissa.fonseca@fieb.org.br; breda@fieb.org.br; leone@fieb.org.br; vinicius.rocha@fieb.org.br; milena.soares@fieb.org.br; peter.berglund@hdt.bio; malcolm.duthie@hdt.bio; steven.reed@hdt.bio; badaro@fieb.org.br		Badaro, Roberto/0000-0002-2861-5061	SENAI CIMATEC; CNPq (Conselho Nacional de Desen-volvimento Cientifico e Tecnologico)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [315351/2018-7]	The authors thank SENAI CIMATEC and CNPq (Conselho Nacional de Desen-volvimento Cientifico e Tecnologico) (BAMS is a Technological fellow from CNPq 315351/2018-7)	Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Abdulla ZA, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10070788; Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Alberer M, 2017, LANCET, V390, P1511, DOI 10.1016/S0140-6736(17)31665-3; Aldrich C, 2021, VACCINE, V39, P1310, DOI 10.1016/j.vaccine.2020.12.070; Allen A, BILLION DOLLAR COVID; Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 2021, NAT BIOTECHNOL, V39, P1, DOI 10.1038/s41587-020-00807-1; ANONYMOUS, 2021, LANCET RESP MED, V9, P117, DOI DOI 10.1016/S2213-2600(21)00045-X; Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Arslan M, 2020, SCI TOTAL ENVIRON, V743, DOI 10.1016/j.scitotenv.2020.140709; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baker Noah, 2021, Nature, DOI 10.1038/d41586-021-01694-5; Ball P, 2020, NATURE, V581, P251, DOI 10.1038/d41586-020-01423-4; Ball RL, 2017, INT J NANOMED, V12, P305, DOI 10.2147/IJN.S123062; Barnes PJ, 1999, NATURE, V402, pB31, DOI 10.1038/35037026; Batty CJ, 2021, ADV DRUG DELIVER REV, V169, P168, DOI 10.1016/j.addr.2020.12.006; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Belete TM, 2021, INFECT DRUG RESIST, V14, P151, DOI 10.2147/IDR.S288877; Benotmane I, 2021, JAMA-J AM MED ASSOC, V326, P1063, DOI 10.1001/jama.2021.12339; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Bernstein DI, 2009, VACCINE, V28, P484, DOI 10.1016/j.vaccine.2009.09.135; Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101; Blakney AK, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020097; Blakney AK, 2019, GENE THER, V26, P363, DOI 10.1038/s41434-019-0095-2; Blakney AK, 2019, J CONTROL RELEASE, V304, P65, DOI 10.1016/j.jconrel.2019.04.043; Blasi F, 2021, RESP MED, V180, DOI 10.1016/j.rmed.2021.106355; Bloom K, 2021, GENE THER, V28, P117, DOI 10.1038/s41434-020-00204-y; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; Bol KF, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1019197; Borch TH, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1207842; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P1784, DOI 10.1001/jama.2021.4385; BRENNER S, 1961, NATURE, V190, P576, DOI 10.1038/190576a0; Brito LA, 2014, MOL THER, V22, P2118, DOI 10.1038/mt.2014.133; Burki T, 2021, LANCET INFECT DIS, V21, P1359, DOI 10.1016/S1473-3099(21)00574-0; Buschmann MD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010065; Cagigi A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010061; Cai CJ, 2021, MOL THER, V29, P2794, DOI 10.1016/j.ymthe.2021.08.001; Caillard S, 2021, KIDNEY INT, V100, P477, DOI 10.1016/j.kint.2021.05.011; Callaway E, 2021, NATURE, V590, P15, DOI 10.1038/d41586-021-00241-6; Chakraborty S, 2021, ADV DRUG DELIVER REV, V172, P314, DOI 10.1016/j.addr.2021.01.014; Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902; Chen S, 2016, J CONTROL RELEASE, V235, P236, DOI 10.1016/j.jconrel.2016.05.059; Chodick G, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.15985; Choi EM, 2021, T ROY SOC TROP MED H, V115, P447, DOI 10.1093/trstmh/trab045; Chu LRC, 2021, VACCINE, V39, P2791, DOI 10.1016/j.vaccine.2021.02.007; Clemens J, 1996, JAMA-J AM MED ASSOC, V275, P390, DOI 10.1001/jama.275.5.390; CONRY RM, 1995, CANCER RES, V55, P1397; Conte C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020309; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Coulie PG, 2014, NAT REV CANCER, V14, P135, DOI 10.1038/nrc3670; Ballesteros-Briones MC, 2020, CURR OPIN VIROL, V44, P145, DOI 10.1016/j.coviro.2020.08.003; Crommelin DJA, 2021, J PHARM SCI-US, V110, P997, DOI 10.1016/j.xphs.2020.12.006; Curin M, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0790-x; D'haese S, 2021, J CONTROL RELEASE, V330, P1016, DOI 10.1016/j.jconrel.2020.11.009; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; de Alwis R, 2021, MOL THER, V29, P1970, DOI 10.1016/j.ymthe.2021.04.001; de Jong S, 2007, CANCER IMMUNOL IMMUN, V56, P1251, DOI 10.1007/s00262-006-0276-x; Decroly E, 2012, NAT REV MICROBIOL, V10, P51, DOI 10.1038/nrmicro2675; Deering RP, 2014, EXPERT OPIN DRUG DEL, V11, P885, DOI 10.1517/17425247.2014.901308; Del Bello A, 2022, AM J TRANSPLANT, V22, P322, DOI 10.1111/ajt.16775; Dodd RH, 2021, LANCET INFECT DIS, V21, P161, DOI 10.1016/S1473-3099(20)30926-9; Dolgin E, 2021, NATURE, V594, P483, DOI 10.1038/d41586-021-01661-0; Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090; Durham, 2022, ENCY RESP MED, P491; Duthie MS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02420; Eckl J, 2019, BLOOD, V134, DOI 10.1182/blood-2019-129749; Egan KP, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008795; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Engelbrecht FA, 2021, ONE HEALTH-AMSTERDAM, V12, DOI 10.1016/j.onehlt.2020.100202; Erasmus JH, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc9396; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1126/science.abh2644Article, 10.1101/2021.02.26.21252554]; Favresse J, 2021, EMERG MICROBES INFEC, V10, P1495, DOI 10.1080/22221751.2021.1953403; Ferrara P, 2020, PUBLIC HEALTH, V185, P1, DOI 10.1016/j.puhe.2020.05.014; Fleeton MN, 2001, J INFECT DIS, V183, P1395, DOI 10.1086/319857; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Fuller DH, 2020, NEW ENGL J MED, V382, P2469, DOI 10.1056/NEJMcibr2009737; Gandhi RT, 2016, JAIDS-J ACQ IMM DEF, V71, P246, DOI 10.1097/QAI.0000000000000852; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Garcia AB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05041-7; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006]; Gilboa E, 2004, IMMUNOL REV, V199, P251, DOI 10.1111/j.0105-2896.2004.00139.x; Goldshtein I, 2021, JAMA-J AM MED ASSOC, V326, P728, DOI 10.1001/jama.2021.11035; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Granados-Riveron JT, 2021, BIOMED PHARMACOTHER, V142, DOI 10.1016/j.biopha.2021.111953; Guevara ML, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.589959; Habrant D, 2016, J MED CHEM, V59, P3046, DOI 10.1021/acs.jmedchem.5b01679; Hacknen D, QUE OS BRASILEIROS E; Hall VG, 2021, NEW ENGL J MED, V385, P1244, DOI 10.1056/NEJMc2111462; Hattinger E, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/797421; He YX, 2006, J VIROL, V80, P5757, DOI 10.1128/JVI.00083-06; He YX, 2005, J IMMUNOL, V174, P4908, DOI 10.4049/jimmunol.174.8.4908; He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106; Hitchings MDT., 2021, LANCET REG HLTH AM, P100025, DOI [10.1016/j.lana.2021.100025, DOI 10.1016/J.LANA.2021.100025]; Ho W, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001812; Hoerr I, 2000, EUR J IMMUNOL, V30, P1; Hoffmann D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24339-7; Hotez PJ, 2021, JAMA-J AM MED ASSOC, V325, P2337, DOI 10.1001/jama.2021.7439; Iavarone C, 2017, EXPERT REV VACCINES, V16, P871, DOI 10.1080/14760584.2017.1355245; Ikizler TA, 2021, KIDNEY INT, V99, P1275, DOI 10.1016/j.kint.2021.04.007; Irwin A, 2021, NATURE, V592, P176, DOI 10.1038/d41586-021-00727-3; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jacobson JM, 2016, JAIDS-J ACQ IMM DEF, V72, P31, DOI 10.1097/QAI.0000000000000926; Jahanafrooz Z, 2020, DRUG DISCOV TODAY, V25, P552, DOI 10.1016/j.drudis.2019.12.003; Jalkanen P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24285-4; Broseta JJ, 2021, NEPHROL DIAL TRANSPL, V36, P1754, DOI 10.1093/ndt/gfab195; Kallen KJ, 2013, HUM VACC IMMUNOTHER, V9, P2263, DOI 10.4161/hv.25181; Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kariko K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr695; Kavanagh MM, 2021, JAMA-J AM MED ASSOC, V326, P219, DOI 10.1001/jama.2021.10823; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Kierzek E, 2014, NUCLEIC ACIDS RES, V42, P3492, DOI 10.1093/nar/gkt1330; Kim J, 2021, ADV DRUG DELIVER REV, V170, P83, DOI 10.1016/j.addr.2020.12.014; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Kis Z, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010003; Knezevic I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020081; Kongsted P, 2017, CYTOTHERAPY, V19, P500, DOI 10.1016/j.jcyt.2017.01.007; Kowalski PS, 2019, MOL THER, V27, P710, DOI 10.1016/j.ymthe.2019.02.012; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Kremsner PG, 2021, WIEN KLIN WOCHENSCHR, V133, P931, DOI 10.1007/s00508-021-01922-y; Krienke Christina, 2021, Science, V371, P145, DOI 10.1126/science.aay3638; Kubler H, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0068-y; Lancet Infect Dis, 2021, LANCET INFECT DIS, V21, P1193, DOI 10.1016/S1473-3099(21)00486-2; Leal L, 2018, AIDS, V32, P2533, DOI [10.1097/QAD.0000000000002026, 10.1097/qad.0000000000002026]; Ledford Heidi, 2020, Nature, DOI 10.1038/d41586-020-03593-7; Ledford H, 2020, NATURE, V588, P377, DOI 10.1038/d41586-020-03542-4; Ledford H, 2020, NATURE, V588, P205, DOI 10.1038/d41586-020-03441-8; Lee H, 2012, NAT NANOTECHNOL, V7, P389, DOI [10.1038/nnano.2012.73, 10.1038/NNANO.2012.73]; Lesterhuis WJ, 2010, ANTICANCER RES, V30, P5091; Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583; Li DD, 2021, MILITARY MED RES, V8, DOI 10.1186/s40779-020-00296-y; Li JX, 2021, NAT MED, V27, P1062, DOI 10.1038/s41591-021-01330-9; Li YD, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00695-2; Linares-Fernandez S, 2020, TRENDS MOL MED, V26, P311, DOI 10.1016/j.molmed.2019.10.002; Linhart B, 2012, CURR OPIN IMMUNOL, V24, P354, DOI 10.1016/j.coi.2012.03.006; Liu Kunmeng, 2021, Int J Biol Sci, V17, P1588, DOI 10.7150/ijbs.58807; Liu MA, 2010, IMMUNITY, V33, P504, DOI 10.1016/j.immuni.2010.10.004; Liu Y, 2021, NEW ENGL J MED, V384, P1466, DOI 10.1056/NEJMc2102017; Ljungberg K, 2015, EXPERT REV VACCINES, V14, P177, DOI 10.1586/14760584.2015.965690; Lockhart, 2021, 6 MONTH SAFETY EFFIC, DOI [10.1101/2021.07.28.21261159, DOI 10.1101/2021.07.28.21261159]; Loveland BE, 2006, CLIN CANCER RES, V12, P869, DOI 10.1158/1078-0432.CCR-05-1574; Low J.G., 2021, MEDRXIV, DOI [10.1101/2021.07.01.21259831, DOI 10.1101/2021.07.01.21259831]; Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]; Lundstrom K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145130; Luo FJ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00605; Lutz J, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0032-6; Lyerly H., 2015, J IMMUNOTHER CANCER, V3, pP444, DOI [10.1186/2051-1426-3-S2-P444, DOI 10.1186/2051-1426-3-S2-P444]; Machingaidze S, 2021, NAT MED, V27, P1338, DOI 10.1038/s41591-021-01459-7; Malick M.S.S., 2021, ADV MOL PATHOL, DOI [10.1016/j.yamp.2021.06.006, DOI 10.1016/J.YAMP.2021.06.006]; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; Martin ME, 2007, AAPS J, V9, pE18, DOI 10.1208/aapsj0901003; MARTINON F, 1993, EUR J IMMUNOL, V23, P1719, DOI 10.1002/eji.1830230749; Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020; Maruggi G, 2017, VACCINE, V35, P361, DOI 10.1016/j.vaccine.2016.11.040; Mathioudakis AG, 2021, LIFE-BASEL, V11, DOI 10.3390/life11030249; Mauger DM, 2019, P NATL ACAD SCI USA, V116, P24075, DOI 10.1073/pnas.1908052116; Maxmen A, 2021, NATURE, V597, P455, DOI 10.1038/d41586-021-02383-z; McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9; McNamara MA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/794528; McNeel D.G., 2017, CANC THERAPEUTIC TAR, V1, P183; Meselson M, 2020, NEW ENGL J MED, V382, P2063, DOI 10.1056/NEJMc2009324; Meyer M, 2018, J INFECT DIS, V217, P451, DOI 10.1093/infdis/jix592; Mintzer MA, 2009, CHEM REV, V109, P259, DOI 10.1021/cr800409e; Moore JP, 2021, JAMA-J AM MED ASSOC, V325, P821, DOI 10.1001/jama.2021.1114; Mullard A, 2020, LANCET, V395, P1751, DOI 10.1016/S0140-6736(20)31252-6; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Murillo-Zamora E, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57080746; Nance KD, 2021, ACS CENTRAL SCI, V7, P748, DOI 10.1021/acscentsci.1c00197; Nelson CS, 2020, J VIROL, V94, DOI 10.1128/JVI.00186-20; Neumann PJ, 2021, HEALTH AFFAIR, V40, P53, DOI 10.1377/hlthaff.2020.01548; Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775; Padron-Regalado E, 2020, INFECT DIS THER, V9, P255, DOI 10.1007/s40121-020-00300-x; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Pardi N, 2020, CURR OPIN IMMUNOL, V65, P14, DOI 10.1016/j.coi.2020.01.008; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Pardi N, 2017, METHODS MOL BIOL, V1499, P143, DOI 10.1007/978-1-4939-6481-9_8; Park KS, 2021, ADV DRUG DELIVER REV, V169, P137, DOI 10.1016/j.addr.2020.12.008; Pascolo S, 2015, EXPERT REV VACCINES, V14, P153, DOI 10.1586/14760584.2015.1000871; Perche F, 2011, NANOMED-NANOTECHNOL, V7, P445, DOI 10.1016/j.nano.2010.12.010; Peretz SB, 2021, ULTRASOUND OBST GYN, V58, P450, DOI 10.1002/uog.23729; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Pinghui Z, CORONAVIRUS LATE STA; Piroth L, 2021, LANCET RESP MED, V9, P251, DOI 10.1016/S2213-2600(20)30527-0; Plotkin SA, 2005, NAT MED, V11, pS5, DOI 10.1038/nm1209; Pogocki D, 2000, J PHARM SCI-US, V89, P443, DOI 10.1002/(SICI)1520-6017(200004)89:4<443::AID-JPS2>3.0.CO;2-W; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Raj DK, 2020, NATURE, V582, P104, DOI 10.1038/s41586-020-2220-1; Rauch S., 2020, MRNA VACCINE CVNCOV, DOI [10.1101/2020.12.23.424138, DOI 10.1101/2020.12.23.424138]; Rauch S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00311-w; Rauch S, 2017, METHODS MOL BIOL, V1499, P89, DOI 10.1007/978-1-4939-6481-9_5; Reichmuth AM, 2016, THER DELIV, V7, P319, DOI 10.4155/tde-2016-0006; Roesler E, 2009, J ALLERGY CLIN IMMUN, V124, P1070, DOI 10.1016/j.jaci.2009.06.036; Romero PE, 2021, MICROBIOL SPECTR, V9, DOI 10.1128/Spectrum.00789-21; Rosa SS, 2021, VACCINE, V39, P2190, DOI 10.1016/j.vaccine.2021.03.038; Roth C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01424; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; Sandbrink JB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.608460; Santos AF, 2021, ENERGIES, V14, DOI 10.3390/en14071849; Scheiblhofer S, 2018, PEDIAT ALLERG IMM-UK, V29, P679, DOI 10.1111/pai.12964; Scheuber A, COVID 19 VACC SEC NE; Scheuber A., IMPERIAL SOCIAL ENTE; Schoenmaker L, 2021, INT J PHARMACEUT, V601, DOI 10.1016/j.ijpharm.2021.120586; Sebastian M, 2019, CANCER IMMUNOL IMMUN, V68, P799, DOI 10.1007/s00262-019-02315-x; Seib KL, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000612; Shaw C, 2019, INT J INFECT DIS, V79, P17, DOI 10.1016/j.ijid.2018.11.058; Shen Xiaoying, 2021, Cell Host Microbe, V29, P529, DOI [10.1101/2021.01.27.428516, 10.1016/j.chom.2021.03.002]; Shenoy Premnath, 2016, Perspect Clin Res, V7, P62, DOI 10.4103/2229-3485.179430; Slavov SN, 2021, J MED VIROL, V93, P6782, DOI 10.1002/jmv.27190; Steinle H, 2021, ADV DRUG DELIVER REV, V179, DOI 10.1016/j.addr.2021.114007; Steinman L, 2019, CURR OPIN IMMUNOL, V61, P46, DOI 10.1016/j.coi.2019.07.011; Subbaraman N, 2021, NATURE, V591, P193, DOI 10.1038/d41586-021-00578-y; Supasa P, 2021, CELL, V184, P2201, DOI 10.1016/j.cell.2021.02.033; Szurgot I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78009-7; Tenforde MW, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab687, 10.1101/2021.07.08.21259776]; Thi TTH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040359; Thalhamer J, 2012, GENE VACCINES, P1, DOI 10.1007/978-3-7091-0439-2; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; Therapeutics A, 2021, BIOPH DEAL, V2682, pB9; Timmerman JM, 2002, BLOOD, V99, P1517, DOI 10.1182/blood.V99.5.1517; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; Veiga N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06936-1; Verbeke R, 2021, J CONTROL RELEASE, V333, P511, DOI 10.1016/j.jconrel.2021.03.043; Victora CG, 2004, AM J PUBLIC HEALTH, V94, P400, DOI 10.2105/AJPH.94.3.400; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017; Volz A, 2015, J VIROL, V89, P8651, DOI 10.1128/JVI.00614-15; von Niessen AGO, 2019, MOL THER, V27, P824, DOI 10.1016/j.ymthe.2018.12.011; Walker PGT, 2020, SCIENCE, V369, P413, DOI 10.1126/science.abc0035; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang GL, 2021, NEW ENGL J MED, V384, P2354, DOI 10.1056/NEJMc2103022; Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7; Wang LF, 2015, J INTERN MED, V278, P369, DOI 10.1111/joim.12395; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006; Wang R, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01754-6; Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090; Wang Y, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01311-z; Wecker M, 2012, CLIN VACCINE IMMUNOL, V19, P1651, DOI 10.1128/CVI.00258-12; Wei CJ, 2020, NAT REV DRUG DISCOV, V19, P239, DOI 10.1038/s41573-019-0056-x; Weide B, 2008, J IMMUNOTHER, V31, P180, DOI 10.1097/CJI.0b013e31815ce501; Weide B, 2009, J IMMUNOTHER, V32, P498, DOI 10.1097/CJI.0b013e3181a00068; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; Wilgenhof S, 2013, ANN ONCOL, V24, P2686, DOI 10.1093/annonc/mdt245; Witzigmann D, 2020, ADV DRUG DELIVER REV, V159, P344, DOI 10.1016/j.addr.2020.06.026; Woldemeskel BA, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI149335; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001; Wu K, 2021, NEW ENGL J MED, V384, P1468, DOI 10.1056/NEJMc2102179; Xie XP, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01270-4, 10.1101/2021.01.27.427998]; Xu SQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186582; Yanagisawa R, 2018, ANTICANCER RES, V38, P2217, DOI 10.21873/anticanres.12464; Yang J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19238-2; Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269; Zacay Galia, 2021, Open Forum Infect Dis, V8, pofab262, DOI 10.1093/ofid/ofab262; Zani A, 2021, EMERG MICROBES INFEC, V10, P1241, DOI 10.1080/22221751.2021.1940305; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zhang NR, 2020, MICROBES INFECT, V22, P231, DOI 10.1016/j.micinf.2020.05.001; Zhang R, 2018, J CONTROL RELEASE, V292, P256, DOI 10.1016/j.jconrel.2018.10.008; Zhao J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.602256; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zhong ZF, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030096; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z; ZHOU X, 1994, VACCINE, V12, P1510, DOI 10.1016/0264-410X(94)90074-4; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737	276	3	3	10	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1345	10.3390/vaccines9111345			38	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XK8CQ	34835276	Green Published, gold			2022-04-29	WOS:000727686900001
J	Mangrolia, U; Osborne, JW				Mangrolia, Upasana; Osborne, Jabez W.			Probiotics in Counteracting the Role of Neutrophils in Cancer Metastasis	VACCINES			English	Review						neutrophils; NETs; cancer; metastasis; probiotics	EXTRACELLULAR TRAP FORMATION; BACILLUS-CALMETTE-GUERIN; STEM-CELLS; LACTOBACILLUS STRAINS; SUPPRESSOR-CELLS; IMMUNE-SYSTEM; TUMOR-CELLS; INFLAMMATION; BACTERIA; RELEASE	Neutrophils are known for their role geared towards pathogen clearance by different mechanisms that they initiate, primarily by the release of neutrophil extracellular traps (NETs). However, their immune-surveillance capacity accompanied with plasticity in existing as interchangeable subsets, discovered recently, has revealed their property to contribute to complex cancer pathologies including tumor initiation, growth, angiogenesis and metastasis. Although there is a growing body of evidence suggesting a critical balance between the protumoral and antitumoral neutrophil phenotypes, an in-depth signaling pathway analysis would aid in determination of anticipatory, diagnostic and therapeutic targets. This review presents a comprehensive overview of the potential pathways involved in neutrophil-triggered cancer metastasis and introduces the influence of the microbial load and avenues for probiotic intervention.	[Mangrolia, Upasana; Osborne, Jabez W.] Vellore Inst Technol VIT, Sch Bio Sci & Technol, Vellore 632014, Tamil Nadu, India		Osborne, JW (通讯作者)，Vellore Inst Technol VIT, Sch Bio Sci & Technol, Vellore 632014, Tamil Nadu, India.	upasanamangrolia@gmail.com; jabez.vit@gmail.com					Abdallah DSA, 2012, INFECT IMMUN, V80, P768, DOI 10.1128/IAI.05730-11; Acuff HB, 2006, CANCER RES, V66, P259, DOI 10.1158/0008-5472.CAN-05-2502; Al-Benna S, 2011, INT J MOL SCI, V12, P8027, DOI 10.3390/ijms12118027; Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227; Aldabbous L, 2016, ARTERIOSCL THROM VAS, V36, P2078, DOI 10.1161/ATVBAHA.116.307634; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.me.38.020187.001135; Andreyev J, 2014, LANCET ONCOL, V15, pE447, DOI 10.1016/S1470-2045(14)70006-3; Angulo S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016953; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Berger-Achituv S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00048; Binet F, 2020, SCIENCE, V369, P934, DOI 10.1126/science.aay5356; Borregaard N, 2007, TRENDS IMMUNOL, V28, P340, DOI 10.1016/j.it.2007.06.002; Bradbury P, 2017, CLIN LUNG CANCER, V18, P259, DOI 10.1016/j.cllc.2016.07.002; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; BURNET M, 1957, BRIT MED J, V1, P779, DOI 10.1136/bmj.1.5022.779; Carol M, 2006, J LEUKOCYTE BIOL, V79, P917, DOI 10.1189/jlb.0405188; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Cools-Lartigue J, 2013, J CLIN INVEST, V123, P3446, DOI 10.1172/JCI67484; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Demers M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22946; Demers M, 2012, P NATL ACAD SCI USA, V109, P13076, DOI 10.1073/pnas.1200419109; DeNardo D, 2010, CANCER METAST REV, V29, P309, DOI 10.1007/s10555-010-9223-6; Devaux CA, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01379; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; El Rayes T, 2015, P NATL ACAD SCI USA, V112, P16000, DOI 10.1073/pnas.1507294112; Elmer A, 2004, INTERNIST, V45, P935, DOI 10.1007/s00108-004-1205-8; FERRANTE A, 1989, INFECT IMMUN, V57, P2115, DOI 10.1128/IAI.57.7.2115-2122.1989; Fleming V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00398; Fridlender ZG, 2012, CARCINOGENESIS, V33, P949, DOI 10.1093/carcin/bgs123; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Fullerton JN, 2016, NAT REV DRUG DISCOV, V15, P551, DOI 10.1038/nrd.2016.39; Galdeano CM, 2006, CLIN VACCINE IMMUNOL, V13, P219, DOI 10.1128/CVI.13.2.219-226.2006; Galdiero MR, 2013, IMMUNOBIOLOGY, V218, P1402, DOI 10.1016/j.imbio.2013.06.003; Garley M, 2016, TUMOR BIOL, V37, P14355, DOI 10.1007/s13277-016-5328-z; Gasser S, 2006, CANCER RES, V66, P3959, DOI 10.1158/0008-5472.CAN-05-4603; Granot Z, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/701067; Hager M, 2010, J INTERN MED, V268, P25, DOI 10.1111/j.1365-2796.2010.02237.x; Hawes MC, 2015, CANCER RES, V75, P4260, DOI 10.1158/0008-5472.CAN-15-1546; Hazeldine J, 2013, AGEING RES REV, V12, P1069, DOI 10.1016/j.arr.2013.04.003; Hermant B, 2003, J BIOL CHEM, V278, P14002, DOI 10.1074/jbc.M300351200; Herr HW, 2008, J UROLOGY, V179, P53, DOI 10.1016/j.juro.2007.08.122; Ireland AS, 2020, IMMUNITY, V52, P729, DOI 10.1016/j.immuni.2020.04.009; Jaye DL, 2000, ANN NY ACAD SCI, V915, P151; Kajioka H, 2021, CANCER LETT, V497, P1, DOI 10.1016/j.canlet.2020.10.015; Kapila R, 2013, MICROBIOL IMMUNOL, V57, P778, DOI 10.1111/1348-0421.12092; Karakhanova S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.998519; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; Kuderer NM, 2006, CANCER-AM CANCER SOC, V106, P2258, DOI 10.1002/cncr.21847; Lajqi T, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.568685; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lasch M, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.576736; Le Garff-Tavernier M, 2010, AGING CELL, V9, P527, DOI 10.1111/j.1474-9726.2010.00584.x; Leifler KS, 2013, J IMMUNOL, V190, P4420, DOI 10.4049/jimmunol.1202610; Li CY, 2017, J CELL PHYSIOL, V232, P2312, DOI 10.1002/jcp.25726; Li LH, 2006, CANCER RES, V66, P4553, DOI 10.1158/0008-5472.CAN-05-3986; Li PS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18125-0; Manchanda K, 2018, ARTERIOSCL THROM VAS, V38, P1859, DOI 10.1161/ATVBAHA.118.311143; Maneerat S, 2013, J NUTR SCI, V2, DOI 10.1017/jns.2013.31; Martin CJ, 2014, CURR OPIN MICROBIOL, V17, P17, DOI 10.1016/j.mib.2013.10.007; Martins-Cardoso K, 2020, CANCERS, V12, DOI 10.3390/cancers12061542; Marx W, 2016, J ACAD NUTR DIET, V116, P819, DOI 10.1016/j.jand.2015.10.020; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Masson V, 2004, FASEB J, V18, P234, DOI 10.1096/fj.04-2140fje; Masuda H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220898; Matsumoto S, 2009, IMMUNOLOGY, V128, pe170, DOI 10.1111/j.1365-2567.2008.02942.x; MATSUZAKI T, 1987, CANCER IMMUNOL IMMUN, V24, P99; McDonald B, 2012, CELL HOST MICROBE, V12, P324, DOI 10.1016/j.chom.2012.06.011; Mehta HM, 2015, J IMMUNOL, V195, P1341, DOI 10.4049/jimmunol.1500861; Metzler KD, 2011, BLOOD, V117, P953, DOI 10.1182/blood-2010-06-290171; Miller LE, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030191; Mocchegiani E, 2009, J CLIN IMMUNOL, V29, P416, DOI 10.1007/s10875-009-9298-4; Monti M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082350; MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6; Munir H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-20982-2; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Nie M, 2019, CLIN CANCER RES, V25, P1867, DOI 10.1158/1078-0432.CCR-18-1226; Pages F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416; Papayannopoulos V, 2009, TRENDS IMMUNOL, V30, P513, DOI 10.1016/j.it.2009.07.011; Park J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1711; Petri B, 2018, CELL TISSUE RES, V371, P425, DOI 10.1007/s00441-017-2776-8; Pieterse E, 2017, ARTERIOSCL THROM VAS, V37, P1371, DOI 10.1161/ATVBAHA.117.309002; Pilsczek FH, 2010, J IMMUNOL, V185, P7413, DOI 10.4049/jimmunol.1000675; Raulet DH, 2004, NAT IMMUNOL, V5, P996, DOI 10.1038/ni1114; Rayes RF, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128008; Ribatti D, 2017, ONCOTARGET, V8, P7175, DOI 10.18632/oncotarget.12739; Rigoni A, 2015, CANCER MICROENVIRON, V8, P167, DOI 10.1007/s12307-014-0152-8; Romano F., 2013, J CANC THER, V4, P1018, DOI [10.4236/jct.2013.45116, DOI 10.4236/JCT.2013.45116]; Roselli M, 2006, BRIT J NUTR, V95, P1177, DOI 10.1079/BJN20051681; Salva S, 2014, INT IMMUNOPHARMACOL, V22, P209, DOI 10.1016/j.intimp.2014.06.017; Saxami G, 2017, BENEF MICROBES, V8, P615, DOI 10.3920/BM2016.0202; Schiffrin EJ, 2009, BRIT J NUTR, V101, P961, DOI 10.1017/S0007114508055591; Seddon A.R., 2020, NEUTROPHILS CANC REG; Shaw AC, 2010, CURR OPIN IMMUNOL, V22, P507, DOI 10.1016/j.coi.2010.05.003; Shinnoh M, 2013, INT J ONCOL, V42, P903, DOI 10.3892/ijo.2013.1790; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Steinberg BE., 2007, SCI STKE, V2007, pPE11, DOI [DOI 10.1126/STKE.3792007PE11, 10.1126/stke.3792007pe11]; Sustrova T, 2017, VET MED-CZECH, V62, P637, DOI 10.17221/72/2017-VETMED; Takagi A, 2001, CARCINOGENESIS, V22, P599, DOI 10.1093/carcin/22.4.599; Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001; Tian Y, 2019, ONCOL LETT, V17, P2836, DOI 10.3892/ol.2019.9906; Tohyama N, 2013, INT IMMUNOPHARMACOL, V15, P160, DOI 10.1016/j.intimp.2012.11.008; Tong H, 2009, SUPPORT CARE CANCER, V17, P83, DOI 10.1007/s00520-008-0472-7; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Verma R, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0669-x; von Kockritz-Blickwede M, 2009, J MOL MED, V87, P775, DOI 10.1007/s00109-009-0481-0; Vong L, 2014, J IMMUNOL, V192, P1870, DOI 10.4049/jimmunol.1302286; Wang WJ, 2016, ONCOL REP, V36, P428, DOI 10.3892/or.2016.4813; Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140; Wels J, 2008, GENE DEV, V22, P559, DOI 10.1101/gad.1636908; Wu Y, 2011, J PATHOL, V225, P438, DOI 10.1002/path.2947; Yang D, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02013-6; Yang LB, 2020, NATURE, V583, P133, DOI 10.1038/s41586-020-2394-6; Yang LY, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-019-0836-0; Yang LY, 2020, J CANCER, V11, P4384, DOI 10.7150/jca.44215; Yektaei-Karin E, 2007, PEDIAT ALLERG IMM-UK, V18, P643, DOI 10.1111/j.1399-3038.2007.00578.x; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Yousefi S, 2009, CELL DEATH DIFFER, V16, P1438, DOI 10.1038/cdd.2009.96; Yuan KL, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106902; Zamarron BF, 2011, INT J BIOL SCI, V7, P651, DOI 10.7150/ijbs.7.651; Zea AH, 2005, CANCER RES, V65, P3044, DOI 10.1158/0008-5472.CAN-04-4505; Zhang DC, 2015, NATURE, V525, P528, DOI 10.1038/nature15367	127	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1306	10.3390/vaccines9111306			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF8YA	34835236	gold, Green Published			2022-04-29	WOS:000724350700001
J	Mo, PKH; Yu, YQ; Luo, ST; Wang, SH; Zhao, JF; Zhang, GH; Li, LJ; Li, LP; Lau, JTF				Mo, Phoenix K. H.; Yu, Yanqiu; Luo, Sitong; Wang, Suhua; Zhao, Junfeng; Zhang, Guohua; Li, Lijuan; Li, Liping; Lau, Joseph T. F.			Dualistic Determinants of COVID-19 Vaccination Intention among University Students in China: From Perceived Personal Benefits to External Reasons of Perceived Social Benefits, Collectivism, and National Pride	VACCINES			English	Article						vaccination intention; university students; perceived personal benefits; perceived social benefits; collectivism; national pride	HEALTH BELIEF MODEL; INFLUENZA VACCINATION; COOPERATION; POPULATION; PSYCHOLOGY; NORM	Vaccination is one of the most effective ways of controlling the COVID-19 pandemic. However, vaccine hesitancy is prevalent, and relatively few studies have explored how variables related to personal and external motives have affected the intention to vaccinate. The present study investigated the association between perceived personal benefits, variables reflecting external motives (i.e., perceived social benefits, collectivism, and national pride) and intention to receive COVID-19 vaccination among university students in China. The interaction between perceived personal benefits and the three factors reflecting external motives on intention to receive COVID-19 vaccination was also examined. A total of 6922 university students from five provinces of China completed a cross-sectional survey. Results showed that adjusting for significant background variables, perceived personal benefits, perceived social benefits, collectivism, and national pride were all significant factors of intention to receive COVID-19 vaccination. Results from interaction analyses also showed that the association between perceived personal benefits and COVID-19 vaccination intention was stronger among those with lower levels of national pride. Findings highlighted the important role of self-directed interest and external motives in promoting uptake of COVID-19 vaccination.	[Mo, Phoenix K. H.; Yu, Yanqiu; Lau, Joseph T. F.] Chinese Univ Hong Kong, Ctr Hlth Behav Res, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China; [Luo, Sitong] Tsinghua Univ, Vanke Sch Publ Hlth, Beijing 100084, Peoples R China; [Wang, Suhua] Baotou Med Coll, Grad Sch, Baotou 014040, Peoples R China; [Zhao, Junfeng] Henan Univ, Sch Educ, Dept Psychol, Kaifeng 475004, Peoples R China; [Zhang, Guohua] Wenzhou Med Univ, Sch Psychiat, Dept Psychol, Wenzhou 325035, Peoples R China; [Li, Lijuan] Dali Univ, Sch Publ Hlth, Dali 671003, Peoples R China; [Li, Liping] Shantou Univ Med Coll, Sch Publ Hlth, Shantou 515063, Peoples R China		Lau, JTF (通讯作者)，Chinese Univ Hong Kong, Ctr Hlth Behav Res, Jockey Club Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China.	phoenix.mo@cuhk.edu.hk; yuyanqiu@link.cuhk.edu.hk; sitongluo@mail.tsinghua.edu.cn; bt_wangsuhua@163.com; jfzhao63@hotmail.com; zghcnu@wmu.edu.cn; lelejuan@126.com; lpli@stu.edu.cn; jlau@cuhk.edu.hk	; Mo, Phoenix/K-2853-2013	LI, Liping/0000-0003-3306-779X; Zhao, Junfeng/0000-0002-7171-5658; Mo, Phoenix/0000-0001-9822-5424; Lau, Joseph/0000-0003-2344-7107	Center for Health Behaviours Research of the Chinese University of Hong Kong	This study is supported by the internal funding of the Center for Health Behaviours Research of the Chinese University of Hong Kong.	Biddlestone M, 2020, BRIT J SOC PSYCHOL, V59, P663, DOI 10.1111/bjso.12397; Bogaert S, 2008, BRIT J SOC PSYCHOL, V47, P453, DOI 10.1348/014466607X244970; Borgonovi F, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113501; Chuang YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122970; Costello TH, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00185; Dorfman A, 2014, J EXP SOC PSYCHOL, V55, P105, DOI 10.1016/j.jesp.2014.06.003; Dovidio J.F., 2006, SOCIAL PSYCHOL PROSO, P408; Falk E.B., 2020, CULTURAL INFLUENCE C, DOI [10.31234/osf.io/fet6z, DOI 10.31234/OSF.IO/FET6Z]; Fredrickson BL, 2001, AM PSYCHOL, V56, P218, DOI 10.1037/0003-066X.56.3.218; Gerend MA, 2012, ANN BEHAV MED, V44, P171, DOI 10.1007/s12160-012-9366-5; Hakim H, 2011, VACCINE, V29, P5963, DOI 10.1016/j.vaccine.2011.06.041; Hart D., 2007, SELF CONSCIOUS EMOTI, P114; International Social Survey Programme, ISSP 2013 NAT ID ILL; Jung H, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2007538118; Kawachi I, 1999, ANN NY ACAD SCI, V896, P120, DOI 10.1111/j.1749-6632.1999.tb08110.x; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Li XN, 2021, EMERG MICROBES INFEC, V10, P1751, DOI 10.1080/22221751.2021.1969291; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Mascolo Michael F., 1995, P64; Mo PKH, 2019, J ADV NURS, V75, P1188, DOI 10.1111/jan.13894; Mo PKH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020129; Oyserman D, 2002, PSYCHOL BULL, V128, P110, DOI 10.1037/0033-2909.128.1.110; Oyserman D, 2002, PSYCHOL BULL, V128, P3, DOI 10.1037/0033-2909.128.1.3; Penner LA, 2005, ANNU REV PSYCHOL, V56, P365, DOI 10.1146/annurev.psych.56.091103.070141; Rappuoli R, 2011, NAT REV IMMUNOL, V11, P865, DOI 10.1038/nri3085; Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Sinkkonen E, 2013, CHINA QUART, P1045, DOI 10.1017/S0305741013001094; Smith TW, 2006, INT J PUBLIC OPIN R, V18, P127, DOI 10.1093/ijpor/edk007; Song G, 2014, RISK ANAL, V34, P541, DOI 10.1111/risa.12114; Sturm L, 2021, VACCINE, V39, P1921, DOI 10.1016/j.vaccine.2021.03.003; Sullivan GB., 2014, UNDERSTANDING COLLEC; Tajfel H., 1979, SOCIAL PSYCHOL INTER, P33; Thomas JM, 2017, HEALTH PSYCHOL, V36, P1026, DOI 10.1037/hea0000478; Vietri JT, 2012, MED DECIS MAKING, V32, P447, DOI 10.1177/0272989X11427762; Wally CM, 2017, ANN BEHAV MED, V51, P642, DOI 10.1007/s12160-017-9887-z; Wang C, 2021, VACCINE, V39, P2833, DOI 10.1016/j.vaccine.2021.04.020; Wang W, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4704; WHO, WHO COR COVID 19 DAS; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; Yoo B, 2011, J INT CONSUM MARK, V23, P193, DOI 10.1080/08961530.2011.578059; Yu YQ, 2021, INT J HEALTH POLICY, DOI 10.34172/ijhpm.2021.64	43	1	1	11	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1323	10.3390/vaccines9111323			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	XH3HK	34835254	gold, Green Published			2022-04-29	WOS:000725329500001
J	de Lejarazu-Leonardo, RO; Montomoli, E; Wojcik, R; Christopher, S; Mosnier, A; Pariani, E; Garcia, AT; Fickenscher, H; Gartner, BC; Jandhyala, R; Zambon, M; Moore, C				Ortiz de Lejarazu-Leonardo, Raul; Montomoli, Emanuele; Wojcik, Radek; Christopher, Solomon; Mosnier, Anne; Pariani, Elena; Trilla Garcia, Antoni; Fickenscher, Helmut; Gaertner, Barbara C.; Jandhyala, Ravi; Zambon, Maria; Moore, Catherine			Estimation of Reduction in Influenza Vaccine Effectiveness Due to Egg-Adaptation Changes-Systematic Literature Review and Expert Consensus	VACCINES			English	Review						influenza; vaccination; egg adaptations; antigenic; drift; effectiveness	SEASONAL INFLUENZA; IMPACT	Background: Influenza vaccines are the main tool to prevent morbidity and mortality of the disease; however, egg adaptations associated with the choice of the manufacturing process may reduce their effectiveness. This study aimed to estimate the impact of egg adaptations and antigenic drift on the effectiveness of trivalent (TIV) and quadrivalent (QIV) influenza vaccines. Methods: Nine experts in influenza virology were recruited into a Delphi-style exercise. In the first round, the experts were asked to answer questions on the impact of antigenic drift and egg adaptations on vaccine match (VM) and influenza vaccine effectiveness (IVE). In the second round, the experts were presented with the data from a systematic literature review on the same subject and aggregated experts' responses to round one questions. The experts were asked to review and confirm or amend their responses before the final summary statistics were calculated. Results: The experts estimated that, across Europe, the egg adaptations reduce, on average, VM to circulating viruses by 7-21% and reduce IVE by 4-16%. According to the experts, antigenic drift results in a similar impact on VM (8-24%) and IVE (5-20%). The highest reduction in IVE was estimated for the influenza virus A(H3N2) subtype for the under 65 age group. When asked about the frequency of the phenomena, the experts indicated that, on average, between the 2014 and 19 seasons, egg adaptation and antigenic drift were significant enough to impact IVE that occurred in two and three out of five seasons, respectively. They also agreed that this pattern is likely to reoccur in future seasons. Conclusions: Expert estimates suggest there is a potential for 9% on average (weighted average of "All strains " over three age groups adjusted by population size) and up to a 16% increase in IVE (against A(H3N2), the < 65 age group) if egg adaptations that arise when employing the traditional egg-based manufacturing process are avoided.	[Ortiz de Lejarazu-Leonardo, Raul] Valladolid Natl Influenza Ctr, Calle Rondilla Santa Teresa S-N, Valladolid 47009, Spain; [Montomoli, Emanuele] Univ Siena, Dept Mol Med, I-53100 Siena, Italy; [Wojcik, Radek; Christopher, Solomon; Jandhyala, Ravi] Medialis Ltd, Banbury OX16 0AH, England; [Mosnier, Anne] Open Rome, F-75008 Paris, France; [Pariani, Elena] Univ Milan, Dept BioMed Sci Hlth, I-20122 Milan, Italy; [Trilla Garcia, Antoni] Univ Barcelona, Hosp Clin, Prevent Med & Epidmiol, Barcelona 08007, Spain; [Fickenscher, Helmut] Univ Kiel, Inst Infect Med, D-24118 Kiel, Germany; [Fickenscher, Helmut] Univ Med Ctr Schleswig, D-24105 Kiel, Germany; [Gaertner, Barbara C.] Saarland Univ, Inst MicroBiol & Hyg, Fac Med, Bldg 43, D-66421 Homburg, Germany; [Gaertner, Barbara C.] Saarland Univ, Inst MicroBiol & Hyg, Med Ctr, Bldg 43, D-66421 Homburg, Germany; [Zambon, Maria] Publ Hlth England, London, England; [Moore, Catherine] Publ Hlth Wales, Wales Specialist Virol Ctr, Cardiff CF14 4XW, Wales		Wojcik, R (通讯作者)，Medialis Ltd, Banbury OX16 0AH, England.	lejarazu@gmail.com; montomoli@vismederi.com; radek@medialis.co.uk; solomon@medialis.co.uk; amos@openrome.org; Elena.Pariani@unimi.it; ATRILLA@clinic.cat; fickenscher@infmed.uni-kiel.de; barbara.gaertner@uks.eu; ravi@medialis.co.uk; maria.zambon@phe.gov.uk; catherine.moore2@wales.nhs.uk	PARIANI, ELENA/M-3491-2016	PARIANI, ELENA/0000-0001-5681-3455; Wojcik, Radek/0000-0002-3583-4545			Barr IG, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0079-z; Belongia EA, 2019, CLIN INFECT DIS, V69, P1817, DOI 10.1093/cid/ciz411; Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8; Boerner LK, 2020, ACS CENTRAL SCI, V6, P89, DOI 10.1021/acscentsci.0c00107; Boikos C, 2020, CLIN INFECT DIS, V71, pE665, DOI 10.1093/cid/ciaa371; Burnet F. M., 1943, AUSTRAL JOUR EXP BIOL AND MED SCI, V21, P55, DOI 10.1038/icb.1943.7; Centers for Disease Control and Prevention, INFL FLU VACC AR MAD; Centers for Disease Control and Prevention, PEOPL HIGH RISK FLU; Centers for Disease Control and Prevention, FLU VACC EFF EFF MEA; Centers for Disease Control and Prevention, CELL BAS FLU VACC; Centers for Disease Control and Prevention, VACC EFF WELL DO FLU; Cianci R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040645; Clayville Lisa R, 2011, P T, V36, P659; Divino V, 2020, VACCINE, V38, P6334, DOI 10.1016/j.vaccine.2020.07.023; European Centre for Disease Prevention and Control, FACTSH SEAS INFL; Harding AT, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020019; Hohmann E, 2018, ARTHROSCOPY, V34, P349, DOI 10.1016/j.arthro.2017.11.022; Izurieta HS, 2019, J INFECT DIS, V220, P1255, DOI 10.1093/infdis/jiy716; Jandhyala R, 2020, CURR MED RES OPIN, V36, P883, DOI 10.1080/03007995.2020.1734920; Jang H, 2019, EXPERT REV VACCINES, V18, P1043, DOI 10.1080/14760584.2019.1675519; Jester BJ, 2020, AM J PUBLIC HEALTH, V110, P669, DOI 10.2105/AJPH.2019.305557; Kissling E, 2019, VACCINE-X, V3, DOI 10.1016/j.jvacx.2019.100042; Klein NP, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229279; Liu F, 2018, J INFECT DIS, V218, P1571, DOI 10.1093/infdis/jiy376; McNutt, 2008, STRUCT EQU MODELING; Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535; Rubio AP, 2018, HUM VACC IMMUNOTHER, V14, P1874, DOI 10.1080/21645515.2018.1460297; Preaud E, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-813; Putri WCWS, 2018, VACCINE, V36, P3960, DOI 10.1016/j.vaccine.2018.05.057; Rajaram S., 2018, OPEN FORUM INFECT DI, V5, pX69, DOI [10.1093/ofid/ofy209.164, DOI 10.1093/OFID/OFY209.164]; Rajaram S, 2020, VACCINE, V38, P6047, DOI 10.1016/j.vaccine.2020.06.021; Rajaram Sankarasubramanian, 2020, Ther Adv Vaccines Immunother, V8, p2515135520908121, DOI 10.1177/2515135520908121; Raymond DD, 2016, NAT MED, V22, P1465, DOI 10.1038/nm.4223; Skowronski DM, 2015, EUROSURVEILLANCE, V20, P7, DOI 10.2807/1560-7917.ES2015.20.4.21022; Skowronski DM, 2022, J INFECT DIS, V225, P1387, DOI 10.1093/infdis/jiaa138; Skowronski DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092153; Thompson M. G., 2010, Morbidity and Mortality Weekly Report, V59, P1057; Uhart M, 2016, HUM VACC IMMUNOTHER, V12, P2259, DOI 10.1080/21645515.2016.1180490; Vogel AB, 2018, MOL THER, V26, P446, DOI 10.1016/j.ymthe.2017.11.017; Wu NC, 2019, CELL HOST MICROBE, V25, P836, DOI 10.1016/j.chom.2019.04.013	40	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1255	10.3390/vaccines9111255			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK8MC	34835186	Green Published, gold			2022-04-29	WOS:000727711500001
J	Rosamilia, F; Noberasco, G; Olobardi, D; Orsi, A; Icardi, G; Lantieri, F; Murdaca, G				Rosamilia, Francesca; Noberasco, Giovanni; Olobardi, Dario; Orsi, Andrea; Icardi, Giancarlo; Lantieri, Francesca; Murdaca, Giuseppe			Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review	VACCINES			English	Review						systemic sclerosis; scleroderma; coverage; pneumonia; influenza; systematic review; vaccine	INFLUENZA VACCINATION; AUTOIMMUNE-DISEASES; LARGE COHORT; SCLEROSIS; IMMUNOGENICITY; PREVENTION	Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease characterized by excessive production of collagen and multiorgan involvement. Scleroderma patients are at increased risk of influenza complications and pneumonia; thus, vaccinations are recommended. This systematic review evaluated the influenza and pneumococcus vaccination coverage for SSc patients. We included all studies from Pubmed reporting on influenza and pneumococcal vaccination rate in Scleroderma patients up to May 2021. The 14 studies thus selected identified a suboptimal vaccination rate in autoimmune and SSc patients, ranging from 28 to 59% for the flu vaccine, and from 11 to 58% for the pneumo vaccine in absence of specific vaccination campaigns, variously considering also other variables such as age, gender, vaccination settings, and possible vaccination campaigns. We also considered the reasons for low coverage and the approaches that might increase the vaccination rates. A lack of knowledge about the importance of vaccination in these patients and their doctors underlined the need to increase the awareness for vaccination in this patients' category. Current guidelines recommend vaccination in elderly people and people affected by particular conditions that widely overlap with SSc, yet autoimmune diseases are not always clearly mentioned. Improving this suboptimal vaccination rate with clear guidelines is crucial for SSc patients and for clinicians to immunize these categories based principally on the pathology, prior to the age. Recommendations by the immunologist and the direct link to the vaccine providers can highly improve the vaccine coverage.	[Rosamilia, Francesca; Lantieri, Francesca] Univ Genoa, Hlth Sci Dept DISSAL, Biostat Unit, Via Pastore 1, I-16132 Genoa, Italy; [Noberasco, Giovanni; Olobardi, Dario; Orsi, Andrea; Icardi, Giancarlo] Univ Genoa, Dept Hlth Sci, Vaccines & Clin Trials Unit, I-16132 Genoa, Italy; [Orsi, Andrea; Icardi, Giancarlo] Osped Policlin San Martino IRCCS, Hyg Unit, I-16132 Genoa, Italy; [Murdaca, Giuseppe] Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy		Murdaca, G (通讯作者)，Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy.	fra.rosamilia@gmail.com; giovanni.noberasco@galliera.it; dario.olobardi@gmail.com; andrea.orsi@unige.it; icardi@unige.it; f.lantieri@unige.it; 700212@unige.it	Orsi, Andrea/AAC-7431-2022; Olobardi, Dario/AAW-6334-2021; Rosamilia, Francesca/AAC-9171-2022	Orsi, Andrea/0000-0002-2433-9610; Olobardi, Dario/0000-0002-6167-0708; Rosamilia, Francesca/0000-0003-4979-9397			Aikawa NE, 2012, J RHEUMATOL, V39, P167, DOI 10.3899/jrheum.110721; Assala M, 2017, JOINT BONE SPINE, V84, P365, DOI 10.1016/j.jbspin.2016.03.013; Baker DW, 2016, J RHEUMATOL, V43, P1030, DOI 10.3899/jrheum.150984; Beck CR, 2012, J INFECT DIS, V206, P1250, DOI 10.1093/infdis/jis487; Bergamasco A, 2019, CLIN EPIDEMIOL, V11, P257, DOI 10.2147/CLEP.S191418; Blumentals WA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-158; Bosaeed M, 2018, HUM VACC IMMUNOTHER, V14, P1311, DOI 10.1080/21645515.2018.1445446; Centers for Disease Control and Prevention, REC AD IMM SCHED AG; Centers for Disease Control and Prevention, PNEUMOCOCCAL VACCINA; Chaisson NF, 2013, CHEST, V144, P1346, DOI 10.1378/chest.12-2396; Desai SP, 2011, RHEUMATOLOGY, V50, P366, DOI 10.1093/rheumatology/keq297; EpiCentro, VACC GRUPP DI POP GR; European Centre for Disease, 2018, PREV CONTR SEAS INFL; European Medical Agency Guideline on Influenza Vaccines, 2016, NONCL CLIN MOD; Fragoulis GE, 2021, RHEUMATOL INT, V41, P895, DOI 10.1007/s00296-021-04817-3; Furer V, 2020, ANN RHEUM DIS, V79, P39, DOI 10.1136/annrheumdis-2019-215882; Garg S, 2018, J RHEUMATOL, V45, P1656, DOI 10.3899/jrheum.171377; Grohskopf LA, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6505a1; Hachulla E, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023-021-01844-y; Hak E, 2002, CLIN INFECT DIS, V35, P370, DOI 10.1086/341403; Harris JG, 2015, PEDIATRICS, V136, pE680, DOI 10.1542/peds.2014-2512; Harrison N, 2018, VACCINE, V36, P4875, DOI 10.1016/j.vaccine.2018.06.065; Hayter SM, 2012, AUTOIMMUN REV, V11, P754, DOI 10.1016/j.autrev.2012.02.001; Juarez M, 2003, RHEUM DIS CLIN N AM, V29, P163, DOI 10.1016/S0889-857X(02)00100-X; Khedoe P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01990; Kostianovsky A, 2012, CLIN EXP RHEUMATOL, V30, pS83; Lanternier F, 2008, ANN RHEUM DIS, V67, P1047, DOI 10.1136/ard.2007.081703; Launay O, 2009, ANN NY ACAD SCI, V1173, P610, DOI 10.1111/j.1749-6632.2009.04800.x; Lejri-El Euchi H, 2019, EUR J INTERN MED, V69, P25, DOI 10.1016/j.ejim.2019.08.010; Litinsky I, 2012, CLIN EXP RHEUMATOL, V30, pS7; Loubet P, 2015, VACCINE, V33, P3703, DOI 10.1016/j.vaccine.2015.06.012; Meroni PL, 2018, CLIN EXP RHEUMATOL, V36, P317; Moulis G, 2015, AM J HEMATOL, V90, P301, DOI 10.1002/ajh.23930; Mouthon L, 2010, RHEUMATOLOGY, V49, P600, DOI 10.1093/rheumatology/kep440; Murdaca G., 2021, OSPEDALE POLICLINICO; Murdaca G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020204; Nihtyanova SI, 2020, J SCLERODERMA RELAT, V5, P6, DOI 10.1177/2397198320903867; Poudel DR, 2018, RHEUMATOLOGY, V57, P1611, DOI 10.1093/rheumatology/key150; Qendro T, 2020, J RHEUMATOL, V47, P770, DOI 10.3899/jrheum.181376; Rasmussen SL, 2020, SCAND J RHEUMATOL, V49, P353, DOI 10.1080/03009742.2020.1732459; Saad CGS, 2011, ANN RHEUM DIS, V70, P1068, DOI 10.1136/ard.2011.150250; Sampaio-Barros PD, 2018, RHEUMATOLOGY, V57, P1721, DOI 10.1093/rheumatology/kex330; Serre J, 2017, EUR J INTERN MED, V43, pE43, DOI 10.1016/j.ejim.2017.05.023; Services, HG USDOHH INCR PROP; Setti M, 2009, VACCINE, V27, P3367, DOI 10.1016/j.vaccine.2009.01.078; Sheikh Saira Z, 2019, Lupus (Los Angel), V4, DOI 10.35248/2684-1630.19.4.146; Sivaraman V, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2018-3141; Sowden E, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-58; Steen V, 2012, ARTHRITIS RHEUM-US, V64, P2986, DOI 10.1002/art.34482; Vadala M, 2017, EPMA J, V8, P295, DOI 10.1007/s13167-017-0101-y	50	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1330	10.3390/vaccines9111330			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XK7FM	34835261	gold, Green Published			2022-04-29	WOS:000727626700001
J	Vassilakopoulou, V; Karachaliou, CE; Evangelou, A; Zikos, C; Livaniou, E				Vassilakopoulou, Vyronia; Karachaliou, Chrysoula-Evangelia; Evangelou, Alexandra; Zikos, Christos; Livaniou, Evangelia			Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives	VACCINES			English	Review						vaccines; neurodegenerative diseases; Alzheimer's disease; beta-amyloid peptide; tau protein; alpha-synuclein; peptide epitopes; vaccine formulation; clinical trials; animal preclinical studies	TARGETING AMYLOID-BETA; ALZHEIMERS-DISEASE; ALPHA-SYNUCLEIN; ACTIVE IMMUNIZATION; TAU-PHOSPHORYLATION; PARKINSONS-DISEASE; MOUSE MODEL; IMMUNOGENICITY; IMMUNOTHERAPY; PATHOLOGY	The development of peptide-based vaccines for treating human neurodegenerative diseases has been the eventual aim of many research endeavors, although no active immunotherapies have been approved for clinical use till now. A typical example of such endeavors is the effort to develop vaccines for Alzheimer's disease based on the beta-amyloid peptide, which continues to be intensively investigated despite previous setbacks. In this paper, recent developments in peptide-based vaccines which target beta-amyloid as well as tau protein and alpha-synuclein are presented. Particular focus has been directed toward peptide epitopes and formulation systems selected/developed and employed to enhance vaccine efficacy and safety. Results from both, human clinical trials and animal preclinical studies conducted mainly in transgenic mice have been included. Future perspectives on the topic are also briefly discussed.	[Vassilakopoulou, Vyronia; Karachaliou, Chrysoula-Evangelia; Zikos, Christos; Livaniou, Evangelia] Natl Ctr Sci Res Demokritos, Inst Nucl & Radiol Sci & Technol Energy Safety IN, Immunopeptide Chem Lab, Patr Grigoriou E & 27 Neapoleos St, Aghia Paraskevi 15341, Greece; [Evangelou, Alexandra] Univ West Attica, Dept Wine Vine & Beverage, Athens 12243, Greece		Vassilakopoulou, V; Livaniou, E (通讯作者)，Natl Ctr Sci Res Demokritos, Inst Nucl & Radiol Sci & Technol Energy Safety IN, Immunopeptide Chem Lab, Patr Grigoriou E & 27 Neapoleos St, Aghia Paraskevi 15341, Greece.	vyrwniavassil@hotmail.com; xrisak15@rrp.demokritos.gr; aevangelou@uniwa.gr; chzikos@yahoo.gr; livanlts@rrp.demokritos.gr		Karachaliou, Chrysoula-Evangelia/0000-0002-0939-9009; VASSILAKOPOULOU, VYRONIA/0000-0003-4843-5604; Evangelou, Alexandra/0000-0003-4148-1253			Agrawal N, 2019, PROTEIN J, V38, P425, DOI 10.1007/s10930-019-09854-3; Al-Hilaly YK, 2020, FEBS LETT, V594, P944, DOI 10.1002/1873-3468.13675; Almandoz-Gil L, 2017, CELL MOL NEUROBIOL, V37, P1217, DOI 10.1007/s10571-016-0454-0; Apostolopoulos V, 2021, MOLECULES, V26, DOI 10.3390/molecules26020430; Armstrong RA, 2019, FOLIA NEUROPATHOL, V57, P87, DOI 10.5114/fn.2019.85929; Armstrong RA, 2013, FOLIA NEUROPATHOL, V51, P169, DOI 10.5114/fn.2013.37702; Ashton Nicholas J, 2021, Nat Commun, V12, P3400, DOI 10.1038/s41467-021-23620-z; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Azmi F, 2014, HUM VACC IMMUNOTHER, V10, P778, DOI 10.4161/hv.27332; Baek H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35030-1; Baig MH, 2018, BIOMED PHARMACOTHER, V103, P574, DOI 10.1016/j.biopha.2018.04.025; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bashiri S, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12100965; Benaki D, 2005, BIOCHEM BIOPH RES CO, V329, P152, DOI 10.1016/j.bbrc.2005.01.100; Bendor JT, 2013, NEURON, V79, P1044, DOI 10.1016/j.neuron.2013.09.004; Benhamron S, 2018, EXP NEUROL, V303, P48, DOI 10.1016/j.expneurol.2018.02.004; Bertram L, 2012, PROG MOL BIOL TRANSL, V107, P79, DOI 10.1016/B978-0-12-385883-2.00008-4; Birmpilis AI, 2019, CANCERS, V11, DOI 10.3390/cancers11111764; Bittar A, 2020, NEUROBIOL DIS, V134, DOI 10.1016/j.nbd.2019.104707; Boutajangout A, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.640677; Cacabelos R, 2020, EXPERT OPIN DRUG DIS, V15, P1, DOI 10.1080/17460441.2019.1667329; Chatterjee D, 2019, NEUROBIOL DIS, V132, DOI 10.1016/j.nbd.2019.104587; Chen SG, 2016, SCI REP-UK, V6, DOI 10.1038/srep34477; Corbett GT, 2020, ACTA NEUROPATHOL, V139, P503, DOI 10.1007/s00401-019-02114-9; Davtyan H, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0556-2; Davtyan H, 2016, SCI REP-UK, V6, DOI 10.1038/srep28912; Davtyan H, 2013, J NEUROSCI, V33, P4923, DOI 10.1523/JNEUROSCI.4672-12.2013; DeTure MA, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0333-5; Ding L, 2017, NEUROSCI RES, V119, P7, DOI 10.1016/j.neures.2017.01.003; Doucet M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181844; Drouin Emmanuel, 2017, Lancet Neurol, V16, P687, DOI 10.1016/S1474-4422(17)30258-2; Eisele YS, 2015, NAT REV DRUG DISCOV, V14, P759, DOI 10.1038/nrd4593; Farlow MR, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0108-3; Fitzpatrick AWP, 2017, NATURE, V547, P185, DOI 10.1038/nature23002; Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278; Freir DB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1341; Fu L, 2018, MOL IMMUNOL, V101, P259, DOI 10.1016/j.molimm.2018.07.019; Ghochikyan A, 2014, NEUROSCI LETT, V560, P86, DOI 10.1016/j.neulet.2013.12.028; Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498; Herline K, 2018, EXPERT REV VACCINES, V17, P707, DOI 10.1080/14760584.2018.1500905; Hoskin JL, 2019, EXPERT OPIN INV DRUG, V28, P545, DOI 10.1080/13543784.2019.1619694; Hovakimyan A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51809-2; Huang MZ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00028; Jack CR, 2020, LANCET NEUROL, V19, P31, DOI 10.1016/S1474-4422(19)30440-5; Jamal Fariha, 2020, Fed Pract, V37, P375, DOI 10.12788/fp.0026; Ji M, 2020, APPL MATER TODAY, V19, DOI 10.1016/j.apmt.2020.100575; Ji M, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0378-7; Joy-Amado A, 2020, NEUROBIOL DIS, V134, DOI 10.1016/j.nbd.2019.104636; Knopman DS, 2021, ALZHEIMERS DEMENT, V17, P696, DOI 10.1002/alz.12213; Kohyama K, 2015, IMMUNOTARGETS THER, V4, P27, DOI 10.2147/ITT.S49923; Kontsekova E, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt278; Kontsekova E, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt277; Kwan P, 2020, HUM VACC IMMUNOTHER, V16, P645, DOI 10.1080/21645515.2019.1665453; Kwon S, 2020, NEUROTHERAPEUTICS, V17, P935, DOI 10.1007/s13311-020-00853-2; Lacosta AM, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0340-8; Lashuel HA, 2013, NAT REV NEUROSCI, V14, P38, DOI 10.1038/nrn3406; Lei Y, 2019, PEERJ, V6, DOI 10.7717/peerj.6185; Li S, 2019, J BIOTECHNOL, V296, P83, DOI 10.1016/j.jbiotec.2019.03.013; Li XY, 2019, ACTA NEUROPATHOL, V137, P825, DOI 10.1007/s00401-019-01974-5; Lindblad EB, 2004, VACCINE, V22, P3658, DOI 10.1016/j.vaccine.2004.03.032; Liu DQ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030351; Malonis RJ, 2020, CHEM REV, V120, P3210, DOI 10.1021/acs.chemrev.9b00472; Mandaci SY, 2020, CHEM BIOL DRUG DES, V96, P659, DOI 10.1111/cbdd.13662; Mantile F, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9120425; Mantile F, 2021, AGING CLIN EXP RES, V33, P1383, DOI 10.1007/s40520-019-01414-0; Maphis NM, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0118-4; Marciani DJ, 2019, RESEARCH-CHINA, V2019, DOI 10.34133/2019/5341375; Marciani DJ, 2016, J NEUROCHEM, V137, P687, DOI 10.1111/jnc.13608; Marciani DJ, 2014, DRUG DISCOV TODAY, V19, P912, DOI 10.1016/j.drudis.2014.02.015; Masliah E, 2005, NEURON, V46, P857, DOI 10.1016/j.neuron.2005.05.010; McFarthing K, 2019, J PARKINSON DIS, V9, P5, DOI 10.3233/JPD-189004; Meissner WG, 2020, MOVEMENT DISORD, V35, P1957, DOI 10.1002/mds.28218; Mo JJ, 2017, ANN CLIN TRANSL NEUR, V4, P931, DOI 10.1002/acn3.469; Mortada I, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.654739; Mullard A, 2021, NATURE, V595, P162, DOI 10.1038/d41586-021-01763-9; Nakamura A, 2018, NATURE, V554, P249, DOI 10.1038/nature25456; Nelde A, 2021, MOL CELL PROTEOMICS, V20, DOI 10.1074/mcp.R120.002309; Nicoll JAR, 2019, BRAIN, V142, P2113, DOI 10.1093/brain/awz142; Novak P, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00798; Novak P, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0436-1; Novak P, 2017, LANCET NEUROL, V16, P123, DOI [10.1016/s1474-4422(16)30331-3, 10.1016/S1474-4422(16)30331-3]; Oberman K, 2020, J ALZHEIMERS DIS REP, V4, P261, DOI 10.3233/ADR-200213; Ogino S, 2019, ANNU REV PATHOL-MECH, V14, P83, DOI 10.1146/annurev-pathmechdis-012418-012818; Oscherwitz J, 2006, VACCINE, V24, P3018, DOI 10.1016/j.vaccine.2005.10.046; Pasquier F, 2016, J ALZHEIMERS DIS, V51, P1131, DOI 10.3233/JAD-150376; Petrovsky N, 2015, VACCINE, V33, P5920, DOI 10.1016/j.vaccine.2015.09.030; Petrushina I, 2020, NEUROBIOL DIS, V139, DOI 10.1016/j.nbd.2020.104823; Plotkin SS, 2020, NEUROBIOL DIS, V144, DOI 10.1016/j.nbd.2020.105010; Price D, 2020, BIOCHEMISTRY-US, V59, P1981, DOI 10.1021/acs.biochem.0c00274; Qu BX, 2010, VACCINE, V28, P5280, DOI 10.1016/j.vaccine.2010.05.054; Rajamohamedsait H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17313-1; Ramsingh AI, 2015, HUM MOL GENET, V24, P6186, DOI 10.1093/hmg/ddv335; Raoufi E, 2020, INT J PEPT RES THER, V26, P1155, DOI 10.1007/s10989-019-09918-z; Razzino CA, 2020, BIOSENS BIOELECTRON, V163, DOI 10.1016/j.bios.2020.112238; Rizzo SJS, 2017, ANNU REV ANIM BIOSCI, V5, P371, DOI 10.1146/annurev-animal-022516-022754; Rosler TW, 2019, PROG NEUROBIOL, V180, DOI 10.1016/j.pneurobio.2019.101644; Rosenberg RN, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0441-4; Sanchez-Trincado JL, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/2680160; Santos J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24039-2; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schneeberger A, 2015, J Prev Alzheimers Dis, V2, P103, DOI 10.14283/jpad.2015.63; Schneeberger A, 2009, J NUTR HEALTH AGING, V13, P264, DOI 10.1007/s12603-009-0070-5; Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323; Shahpasand K, 2018, HUM VACC IMMUNOTHER, V14, P277, DOI 10.1080/21645515.2017.1393594; Shi ST, 2019, VACCINE, V37, P3167, DOI 10.1016/j.vaccine.2019.04.055; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Spires-Jones TL, 2014, NEURON, V82, P756, DOI 10.1016/j.neuron.2014.05.004; Steeghs L, 2008, INFECT IMMUN, V76, P3801, DOI 10.1128/IAI.00005-08; Stefanis L, 2019, J NEUROCHEM, V150, P577, DOI 10.1111/jnc.14704; Stoiljkovic M, 2021, AGEING RES REV, V68, DOI 10.1016/j.arr.2021.101318; Sulzer D, 2017, NATURE, V546, P656, DOI 10.1038/nature22815; Sun DY, 2019, ACS CHEM NEUROSCI, V10, P2794, DOI 10.1021/acschemneuro.9b00020; Sun Y, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00416-z; Teng IT, 2018, J AM CHEM SOC, V140, P14314, DOI 10.1021/jacs.8b08645; Tolar M, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00663-w; Twohig D, 2019, MOL NEURODEGENER, V14, DOI 10.1186/s13024-019-0320-x; Valera E, 2016, NEUROTHERAPEUTICS, V13, P179, DOI 10.1007/s13311-015-0397-z; Vandenberghe Rik, 2017, Alzheimers Dement (N Y), V3, P10, DOI 10.1016/j.trci.2016.12.003; Volc D, 2020, LANCET NEUROL, V19, P591, DOI 10.1016/S1474-4422(20)30136-8; Wang Chang Yi, 2017, Alzheimers Dement (N Y), V3, P262, DOI 10.1016/j.trci.2017.03.005; Wang JC, 2020, NEURAL REGEN RES, V15, P519, DOI 10.4103/1673-5374.266061; Wang YQ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.577823; Wells C, 2021, INT J BIOL MACROMOL, V181, P582, DOI 10.1016/j.ijbiomac.2021.03.113; Willyard C, 2021, NATURE, V590, P22, DOI 10.1038/d41586-021-00260-3; Wisniewski T, 2015, NEURON, V85, P1162, DOI 10.1016/j.neuron.2014.12.064; Wong YC, 2017, NAT MED, V23, P151, DOI 10.1038/nm.4269; Wongta A, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/8821181; Yan DD, 2016, SCI REP-UK, V6, DOI 10.1038/srep32222; Yang P, 2019, BMC IMMUNOL, V20, DOI 10.1186/s12865-019-0289-9; Yu XL, 2020, BRIT J PHARMACOL, V177, P2860, DOI 10.1111/bph.15015; Zeng YF, 2021, CELL MOL LIFE SCI, V78, P1873, DOI 10.1007/s00018-020-03681-x; Zhai Pan, 2020, Int J Antimicrob Agents, V55, P105955, DOI 10.1016/j.ijantimicag.2020.105955; Zhang XY, 2021, BRAIN RES BULL, V174, P31, DOI 10.1016/j.brainresbull.2021.05.019; Zhou QH, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201910919; Zou P, 2003, PEPTIDES, V24, P679, DOI 10.1016/S0196-9781(03)00131-1	136	1	1	6	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1278	10.3390/vaccines9111278			27	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF6CE	34835209	Green Published, gold			2022-04-29	WOS:000724156100001
J	Al-Jighefee, HT; Najjar, H; Ahmed, MN; Qush, A; Awwad, S; Kamareddine, L				Al-Jighefee, Hadeel T.; Najjar, Hoda; Ahmed, Muna Nizar; Qush, Abeer; Awwad, Sara; Kamareddine, Layla			COVID-19 Vaccine Platforms: Challenges and Safety Contemplations	VACCINES			English	Review						SARS-CoV-2; COVID-19; vaccine platforms; challenges; safety; strengths; limitations	RESPIRATORY SYNCYTIAL VIRUS; NCOV-19 AZD1222 VACCINE; MESSENGER-RNA VACCINE; CORONAVIRUS VACCINE; IMMUNE-RESPONSES; HEALTHY-ADULTS; PLASMID DNA; NEUTRALIZING ANTIBODY; PROTECTIVE IMMUNITY; INFLUENZA VACCINES	The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic as of March 2020, creating a global crisis and claiming millions of lives. To halt the pandemic and alleviate its impact on society, economy, and public health, the development of vaccines and antiviral agents against SARS-CoV-2 was a dire need. To date, various platforms have been utilized for SARS-CoV-2 vaccine development, and over 200 vaccine candidates have been produced, many of which have obtained the United States Food and Drug Administration (FDA) approval for emergency use. Despite this successful development and licensure, concerns regarding the safety and efficacy of these vaccines have arisen, given the unprecedented speed of vaccine development and the newly emerging SARS-CoV-2 strains and variants. In this review, we summarize the different platforms used for Coronavirus Disease 2019 (COVID-19) vaccine development, discuss their strengths and limitations, and highlight the major safety concerns and potential risks associated with each vaccine type.</p>	[Al-Jighefee, Hadeel T.; Najjar, Hoda; Ahmed, Muna Nizar; Qush, Abeer; Awwad, Sara; Kamareddine, Layla] Qatar Univ, Dept Biomed Sci, Coll Hlth Sci, QU Hlth, POB 2713, Doha, Qatar; [Al-Jighefee, Hadeel T.; Kamareddine, Layla] Qatar Univ, Biomed Res Ctr, POB 2713, Doha, Qatar; [Kamareddine, Layla] Qatar Univ, Biomed & Pharmaceut Res Unit, QU Hlth, POB 2713, Doha, Qatar		Kamareddine, L (通讯作者)，Qatar Univ, Dept Biomed Sci, Coll Hlth Sci, QU Hlth, POB 2713, Doha, Qatar.; Kamareddine, L (通讯作者)，Qatar Univ, Biomed Res Ctr, POB 2713, Doha, Qatar.; Kamareddine, L (通讯作者)，Qatar Univ, Biomed & Pharmaceut Res Unit, QU Hlth, POB 2713, Doha, Qatar.	ha1510267@student.qu.edu.qa; hn1517144@student.qu.edu.qa; ma1507488@student.qu.edu.qa; 200050311@student.qu.edu.qa; sa1900788@student.qu.edu.qa; lkamareddine@qu.edu.qa		Al-Jighefee, Hadeel/0000-0002-9484-7290			Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; ACT, 2020, PHAS 12 RAND PLAC CO; Africa CDC, AFR REG TASKF END EM; Africa CDC, AFR UN AFR CDCS AFR; Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688; Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; Andre Francis, 2002, Expert Rev Vaccines, V1, P9, DOI 10.1586/14760584.1.1.9; [Anonymous], REUTERS; [Anonymous], WHO COR DIS COVID 19; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barouch DH, 2011, VACCINE, V29, P5203, DOI 10.1016/j.vaccine.2011.05.025; BBC, BBC; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Biotech B., COVAXIN IND 1 IND CO; BioWorld, STEM RAIS NEAR 200M; Bisht H, 2005, VIROLOGY, V334, P160, DOI 10.1016/j.virol.2005.01.042; Bjork J., 2021, EFFECTIVENESS BNT162, DOI [10.1101/2021.04.20.21254636, DOI 10.1101/2021.04.20.21254636]; Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11; Briggs DJ, 2013, RABIES: SCIENTIFIC BASIS OF THE DISEASE AND ITS MANAGEMENT, 3RD EDITION, P497, DOI 10.1016/B978-0-12-396547-9.00013-4; Bright RA, 2007, VACCINE, V25, P3871, DOI 10.1016/j.vaccine.2007.01.106; Cai XD, 2018, ANTIVIR RES, V149, P48, DOI 10.1016/j.antiviral.2017.11.007; Capone S, 2021, MOL THER, V29, P2412, DOI 10.1016/j.ymthe.2021.04.022; Carmen J.M., 2021, SPIKE FERRITIN NANOP, DOI [10.1101/2021.04.28.441763, DOI 10.1101/2021.04.28.441763]; CARPHA, CARPHA COVID 19 VACC; CARPHA, 145 CARPHA; Castilow EM, 2007, IMMUNOL RES, V39, P225, DOI 10.1007/s12026-007-0071-6; Chang-Monteagudo A., 2021, SINGLE DOSE SARS COV, DOI [DOI 10.1101/2021.02.22.21252091, 10.1101/2021.02.22.21252091]; Chappell KJ, 2021, LANCET INFECT DIS, V21, P1383, DOI 10.1016/S1473-3099(21)00200-0; Chemaitelly H, 2021, NAT MED, V27, P1614, DOI 10.1038/s41591-021-01446-y; ChiCTR, 2020, NAS SPRAY INFL VIR V; ChiCTR, RAND DOUBL BLIND PLA; ChiCTR, 2021, RAND DOUBL BLIND PLA; Chodick G., EFFECTIVENESS 1 DOSE; Chodick G, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.15985; Chung H., 2021, EFFECTIVENESS BNT162, DOI [10.1101/2021.05.24.21257744, DOI 10.1101/2021.05.24.21257744, 10.1101/2021.05.24.21257744v1]; Clem AS, 2011, J GLOB INFECT DIS, V3, P73, DOI 10.4103/0974-777X.77299; Coleman JR, 2008, SCIENCE, V320, P1784, DOI 10.1126/science.1155761; Conversation T., 2021, CONVERSATION T; Corchado-Garcia J., 2021, REAL WORLD EFFECTIVE, DOI [10.1101/2021.04.27.21256193, DOI 10.1101/2021.04.27.21256193]; Creech CB, 2021, JAMA-J AM MED ASSOC, V325, P1318, DOI 10.1001/jama.2021.3199; CTRI, PROSP RAND AD PHAS 1; CureVac, CUREVACS MRNA BAS VA; Cyprian F, 2021, INT J INFECT DIS, V105, P540, DOI 10.1016/j.ijid.2021.02.071; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Das S., 2021, BUSINESS STANDARD; Dey A, 2021, VACCINE, V39, P4108, DOI 10.1016/j.vaccine.2021.05.098; Dolzhikova IV, 2017, HUM VACC IMMUNOTHER, V13, P613, DOI 10.1080/21645515.2016.1238535; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Du LY, 2008, DRUG TODAY, V44, P63, DOI 10.1358/dot.2008.44.1.1131830; Dudek T, 2006, VIROLOGY, V344, P230, DOI 10.1016/j.virol.2005.09.020; Ella R., 2021, EFFICACY SAFETY LOT, DOI [10.1101/2021.06.30.21259439, DOI 10.1101/2021.06.30.21259439]; Ella R, 2021, LANCET INFECT DIS, V21, P637, DOI [10.1016/S1473-3099(20)30942-7, 10.1016/S1473-3099(21)00070-0]; EMA, COVID 19 VACC; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Enjuanes L, 2016, ADV VIRUS RES, V96, P245, DOI 10.1016/bs.aivir.2016.08.003; EurekAlert, BAT PROGR COVID 19 C; FDA, 2020, VACC REL BIOL PROD A; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Fuenmayor J, 2017, NEW BIOTECHNOL, V39, P174, DOI 10.1016/j.nbt.2017.07.010; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Gao WT, 2003, LANCET, V362, P1895, DOI 10.1016/S0140-6736(03)14962-8; Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143; Groenke N, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107586; Guner R, 2020, TURK J MED SCI, V50, P571, DOI 10.3906/sag-2004-146; Hall VJ., 2021, SSRN ELECT J, DOI [10.2139/ssrn.3790399, DOI 10.2139/SSRN.3790399]; Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4; Heath PT, 2021, NEW ENGL J MED, V385, P1172, DOI 10.1056/NEJMoa2107659; Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6; Hobernik D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113605; Holdings A.T., 2021, BIOPHARMA DEAL; Hsieh SM, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.100989; Hu TT, 2020, PEERJ, V8, DOI 10.7717/peerj.9725; ImmunityBio, 2021, BIOPHARMA DEAL; Imperial College London, COVAC1 TRIAL WORKS; Institute E.R., QAZCOVID IN; IRCT, 2021, PHAS 2 SAF IMM RAZI; IRCT, 2021, PHAS 2 RAND 2 ARM DO; IRCT, DOUBL BLIND RAND PLA; IRCT, PHAS 2 TRIAL SAF IMM; ISRCTN Registry, 2020, CLIN TRIAL ASS SAF C; Jones I, 2021, LANCET, V397, P642, DOI 10.1016/S0140-6736(21)00191-4; Joyce Michael G, 2021, bioRxiv, DOI 10.1101/2021.03.24.436523; JRCT, PHAS 1 2 RAND DOUBL; JRCT, PLACEB CONTR MULT DO; Jung F, 2020, CLIN HEMORHEOL MICRO, V75, P13, DOI 10.3233/CH-209006; Kalnin KV, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00324-5; KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Lan JM, 2015, EBIOMEDICINE, V2, P1438, DOI 10.1016/j.ebiom.2015.08.031; Lanini S., 2021, FRAD COV2 GORILLA AD, DOI [10.1101/2021.04.10.21255202, DOI 10.1101/2021.04.10.21255202]; Levin MJ, 2008, VACCINE, V26, P4210, DOI 10.1016/j.vaccine.2008.05.054; Li YD, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00695-2; Liang JG, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21634-1; Lidder P, 2012, ADV GENET, V78, P1, DOI 10.1016/B978-0-12-394394-1.00001-8; Lin JT, 2007, ANTIVIR THER, V12, P1107; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Lokugamage KG, 2008, VACCINE, V26, P797, DOI 10.1016/j.vaccine.2007.11.092; Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Madhi SAB, 2021, MEDRXIV, DOI [10.1101/2021.02.10.21251247, DOI 10.1101/2021.02.10.21251247, 10.21251247]; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n309; Mak TW, 2006, IMMUNE RESPONSE: BASIC AND CLINICAL PRINCIPLES, P695, DOI 10.1016/B978-012088451-3/50025-9; Mammen M.P., 2021, SAFETY IMMUNOGENICIT, DOI [10.1101/2021.05.07.21256652, DOI 10.1101/2021.05.07.21256652]; Manam S, 2000, INTERVIROLOGY, V43, P273, DOI 10.1159/000053994; Mariano G, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.605236; Martin JE, 2008, VACCINE, V26, P6338, DOI 10.1016/j.vaccine.2008.09.026; Medicine N., 2021, NOVAVAX VACCINE RESU; Moustsen-Helms I.R., 2021, VACCINE EFFECTIVENE, DOI [10.1101/2021.03.08.21252200, DOI 10.1101/2021.03.08.21252200]; Mueller S, 2020, VACCINE, V38, P2943, DOI 10.1016/j.vaccine.2020.02.056; Murdin AD, 1996, VACCINE, V14, P735, DOI 10.1016/0264-410X(95)00211-I; MURPHY BR, 1988, J CLIN MICROBIOL, V26, P1595, DOI 10.1128/JCM.26.8.1595-1597.1988; Murphy FA., 2017, FENNER WHITES MED VI, P155, DOI [10.1016/B978-0-12-375156-0.00011-4, DOI 10.1016/B978-0-12-375156-0.00011-4]; Naqvi AA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165878; Nasreen S., 2021, EFFECTIVENESS COVID, DOI [10.1101/2021.06.28.21259420, DOI 10.1101/2021.06.28.21259420]; NATHANSON N, 1963, AM J HYG, V78, P29, DOI 10.1093/oxfordjournals.aje.a120328; National Institutes of Health, ACC COVID 19 THER IN; News D., NEWS D; News G.E.B., NEWS G E B; NIH, NATL COH STUD EFF SA; NIH, STUD EV SAF IMM EFF; NIH, EFF SAF IMM STUD IN; NIH, GLOB PHAS 3 CLIN TRI; NIH, 2021, STUD ASS SAF IMM COR; NIH, 2021, IMM BRIDG IMM SCH ST; NIH, IMM EFF SAF QAZCOVID; Palacios R., 2021, EFFICACY SAFETY COVI, DOI [10.2139/ssrn.3822780, DOI 10.2139/SSRN.3822780]; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Petersen E, 2020, LANCET INFECT DIS, V20, pE238, DOI [10.1016/S1473-3099(20)30484-9, 10.1016/S1473-3099(20)30648-4]; PHE, EF COVID 19 VACC HOS; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poland GA, 2020, MAYO CLIN PROC, V95, P2172, DOI 10.1016/j.mayocp.2020.07.021; Pu J, 2020, IN DEPTH INVESTIGATI, DOI [10.1101/2020.09.27.20189548, DOI 10.1101/2020.09.27.20189548]; Public Health England, ANN REP JCV EST EFF; Ramasamy MN, 2021, LANCET, V398, P186, DOI 10.1016/S0140-6736(21)01543-9; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Rauch S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00311-w; Registry C.C.T., PHAS 3 CLIN TRIAL IN; Reichmuth AM, 2016, THER DELIV, V7, P319, DOI 10.4155/tde-2016-0006; Restifo NP, 2000, GENE THER, V7, P89, DOI 10.1038/sj.gt.3301117; Richmond P, 2021, LANCET, V397, P682, DOI 10.1016/S0140-6736(21)00241-5; Robert-Guroff M, 2007, CURR OPIN BIOTECH, V18, P546, DOI 10.1016/j.copbio.2007.10.010; Roper RL, 2009, EXPERT REV VACCINES, V8, P887, DOI 10.1586/ERV.09.43; RPCEC, 2021, MAMBISA STUD; RPCEC, SOBERANA 02 FAS; RPCEC, SOBERANA 01; RPCEC, ABDALA CLIN STUD PHA; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sanders B., 2014, VACCINE ANAL STRATEG, P45, DOI [10.1007/978-3- 662-45024-6_2, DOI 10.1007/978-3-662-45024-6_2]; Sciences G.L., NUCL AC VACC; Sharma O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585354; Shinde V, 2021, NEW ENGL J MED, V384, P1899, DOI 10.1056/NEJMoa2103055; Singh A, 2014, ANIM BIOTECHNOL, P491, DOI DOI 10.1016/B978-0-12-416002-6.00026-2; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242; Soundararajan, 2021, FDA AUTHORIZED COVID, DOI [10.1101/2021.02.15.21251623, DOI 10.1101/2021.02.15.21251623]; Spellberg B, 2021, JAMA INTERN MED, V181, P460, DOI 10.1001/jamainternmed.2020.7986; Sun WN, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040771; Susha Cheriyedath M.S., SARS COV 2 MRNA VACC; Tanaka S., 2020, BIORXIV, DOI [10.1101/2020.07.29.227595, DOI 10.1101/2020.07.29.227595]; Thompson M.G., 2021, PREVENTION ATTENUATI, DOI [10.1101/2021.06.01.21257987, DOI 10.1101/2021.06.01.21257987]; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; Tiboni M, 2021, INT J PHARMACEUT, V603, DOI 10.1016/j.ijpharm.2021.120686; Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002; Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421; Tucker S.N, 2020, PRECLINICAL STUDIES, DOI [10.1101/2020.09.04.283853, DOI 10.1101/2020.09.04.283853]; U.S. Food and Drug Administration, JANSS COVID 19 VAC; U.S. Food and Drug Administration, MOD COVID 19 VACC; U.S. Food and Drug Administration, PFIZ BIONT COVID 19; Ura T, 2014, VACCINES, V2, P624, DOI 10.3390/vaccines2030624; V'kovski P, 2021, NAT REV MICROBIOL, V19, P155, DOI 10.1038/s41579-020-00468-6; Vaccinations P., CONV VACC; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; Vellozzi C, 2009, VACCINE, V27, P2114, DOI 10.1016/j.vaccine.2009.01.125; Vignuzzi M, 2008, NAT MED, V14, P154, DOI 10.1038/nm1726; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang FZ, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.924700; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7; Wang Z, 2004, GENE THER, V11, P711, DOI 10.1038/sj.gt.3302213; Ward BJ, 2021, NAT MED, V27, P1071, DOI 10.1038/s41591-021-01370-1; Watterson D, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1269; WHO, MODULE 2 TYP VACC AD; WHO, BACKGR DOC IN VACC S; WHO, WHO VACC SAF BAS; WHO, INT REC US IN COVID; Wise N., LATEST DEV CHULACOV1; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; World Health Organization, STAT COVID 19 VACC W; World Health Organization World Health Organization, 2020, DRAFT LANDSCAPE COVI; World News, 2021, HINDUSTAN TIMES; Wu K., 2021, PRELIMINARY ANAL SAF, DOI [DOI 10.1101/2021.05.05.21256716, 10.1101/2021.05.05.21256716v1]; Wu SP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17972-1; Wu ZL, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2171; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Xie XP, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01270-4, 10.1101/2021.01.27.427998]; Yahalom-Ronen Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20228-7; Yan ZP, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14050406; Yang SL, 2021, LANCET INFECT DIS, V21, P1107, DOI 10.1016/S1473-3099(21)00127-4; Zakhartchouk AN, 2005, VACCINE, V23, P4385, DOI 10.1016/j.vaccine.2005.04.011; ZAWYA, CUB ENC EARL EFF RES; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3	209	3	3	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1196	10.3390/vaccines9101196			38	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WQ2XJ	34696306	Green Published, gold			2022-04-29	WOS:000713683200001
J	Badr, H; Zhang, XT; Oluyomi, A; Woodard, LD; Adepoju, OE; Raza, SA; Amos, CI				Badr, Hoda; Zhang, Xiaotao; Oluyomi, Abiodun; Woodard, LeChauncy D.; Adepoju, Omolola E.; Raza, Syed Ahsan; Amos, Christopher I.			Overcoming COVID-19 Vaccine Hesitancy: Insights from an Online Population-Based Survey in the United States	VACCINES			English	Article						COVID-19; vaccine hesitancy; Health Belief Model; Theory of Planned Behavior	BEHAVIOR; MODEL	This study sought to identify individual-level determinants of COVID-19 vaccine hesitancy based on the Health Belief Model (HBM) and Theory of Planned Behavior (TPB). An online population-based survey was distributed in English and Spanish. Data were derived from 1208 U.S. adults (52% female; 38.7% minorities), 43.5% of whom reported vaccine hesitancy. Multivariable analysis revealed that unemployed individuals were more likely (OR = 1.78, 95% CI: 1.16-2.73, p = 0.009) and married (OR = 0.57, 95% CI: 0.39-0.81, p = 0.002) and higher income individuals (OR = 0.52, 95% CI 0.32-0.84, p = 0.008) were less likely to be hesitant. Individuals with greater perceived susceptibility to COVID-19 (OR = 0.82, 95% CI: 0.71-0.94, p = 0.006), who perceived vaccination as being convenient (OR = 0.86, 95% CI: 0.74-1.00, p = 0.047), and who afforded greater importance to cues to action from government (OR = 0.84, 95% CI: 0.74-0.95, p = 0.005), public health (OR = 0.70, 95% CI: 0.59-0.82, p < 0.001), and healthcare experts (OR = 0.59, 95% CI: 0.50-0.69, p < 0.001) were also less likely to be hesitant. Findings suggest that HBM and TPB constructs may be useful in informing strategies to improve COVID-19 vaccine uptake. Specifically, framing appeals based on perceptions of COVID-19 susceptibility, making vaccination convenient, and rebuilding trust through unified cues to action may help to overcome vaccine hesitancy.</p>	[Badr, Hoda; Zhang, Xiaotao; Oluyomi, Abiodun; Raza, Syed Ahsan; Amos, Christopher I.] Baylor Coll Med, Dept Med, Sect Epidemiol & Populat Sci, Houston, TX 77030 USA; [Woodard, LeChauncy D.; Adepoju, Omolola E.] Univ Houston, Coll Med, Dept Hlth Syst & Populat Hlth Sci, Houston, TX 77004 USA; [Woodard, LeChauncy D.; Adepoju, Omolola E.] Univ Houston, Humana Integrated Hlth Syst Sci Inst, Houston, TX 77004 USA; [Amos, Christopher I.] Baylor Coll Med, Inst Clin & Translat Res, Houston, TX 77030 USA		Badr, H (通讯作者)，Baylor Coll Med, Dept Med, Sect Epidemiol & Populat Sci, Houston, TX 77030 USA.	xiaotao.zhang@bcm.edu; abiodun.oluyomi@bcm.edu	Raza, Syed Ahsan/AAH-4078-2019; Zhang, Xiaotao/K-1581-2019	Raza, Syed Ahsan/0000-0002-2043-3757; Zhang, Xiaotao/0000-0002-3968-5030; Amos, Christopher/0000-0002-8540-7023; Badr, Hoda/0000-0002-4549-9111	NHLBI RF [50087-2021-0309-S9, 20-312-0217571-66102L]; Cancer Prevention and Research Institute of Texas [RP160097]; Dan L Duncan Comprehensive Cancer Center [P30 CA125123]	H.B. and CAs work on this study was supported by NHLBI RF 5008720210309-S9 and NHLBI 20312021757166102L. S.A.R. and X.Z. were supported by a post-graduate training award from the Cancer Prevention and Research Institute of Texas (RP160097). This study was also supported by the facilities and resources of the Dan L Duncan Comprehensive Cancer Center P30 CA125123 (PI: Heslop).	Ahern S, 2021, BMJ LEAD, V5, P266, DOI 10.1136/leader-2020-000271; Ajzen I, 2011, PSYCHOL HEALTH, V26, P1113, DOI 10.1080/08870446.2011.613995; Albarracin D, 2000, J PERS SOC PSYCHOL, V79, P5, DOI 10.1037//0022-3514.79.1.5; Allen J., FAUCI SAYS HERD IMMU; Badr H, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-044642; Bartsch Sarah M, 2020, medRxiv, DOI 10.1101/2020.05.29.20117184; Betsch C., 2015, SCOTTISH INDEX MULTI, V2, P61, DOI 10.1177/2372732215600716; Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136; Britton T, 2020, SCIENCE, V369, P846, DOI 10.1126/science.abc6810; Butler R, 2015, VACCINE, V33, P4176, DOI 10.1016/j.vaccine.2015.04.038; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Glanz K., 2008, HLTH BEHAV HLTH ED T, V4; Hamel L., KFF HLTH TRACKING PO; Holder J, TRACKING CORONAVIRUS; Hornsey MJ, 2018, HEALTH PSYCHOL, V37, P307, DOI 10.1037/hea0000586; Hotez PJ, 2020, MICROBES INFECT, V22, P162, DOI 10.1016/j.micinf.2020.05.010; JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101; Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198; Kaiser Family Foundation (KFF), NEARL 6 10 OLD AM DO; Kaiser Family Foundation (KFF), KFF HLTH TRACK POLL; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kimmel SR, 2007, J FAM PRACTICE, V56, pS61; King WC, 2021, TIME TRENDS FACTORS, V2021, DOI [10.1101/2021.07.20.21260795, DOI 10.1101/2021.07.20.21260795]; Lewis MA, 2007, J APPL SOC PSYCHOL, V37, P298, DOI 10.1111/j.0021-9029.2007.00161.x; Luz PM, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311X00136620, 10.1590/0102-311x00136620]; McCormack LA, 2021, PUBLIC HEALTH REP, V136, P107, DOI 10.1177/0033354920970182; Nan XL, 2016, HEALTH COMMUN, V31, P798, DOI 10.1080/10410236.2015.1005280; National Foundation for Infectious Diseases, COVID 19 COMM PROM P; Nguyen KH, 2021, MMWR-MORBID MORTAL W, V70, P217, DOI 10.15585/mmwr.mm7006e3; Piltch-Loeb R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010076; Remmel A, 2021, NATURE, V590, P538, DOI 10.1038/d41586-021-00290-x; Rothman AJ, 2006, J COMMUN, V56, pS202, DOI 10.1111/j.1460-2466.2006.00290.x; Schalet BD, 2016, J CLIN EPIDEMIOL, V73, P119, DOI 10.1016/j.jclinepi.2015.08.036; Schoenborn Charlotte A, 2004, Adv Data, P1; Shore DA, 2003, J HEALTH COMMUN, V8, P13, DOI 10.1080/10810730390224839; Siegrist M, 2014, EUR PSYCHOL, V19, P23, DOI 10.1027/1016-9040/a000169; US Census Bureau, QUICK FACTS; Vlaev I, 2012, J ECON PSYCHOL, V33, P963, DOI 10.1016/j.joep.2012.05.005; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; World Health Organisation, INF MAN INF HOC TECH	42	2	2	10	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1100	10.3390/vaccines9101100			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WO2VW	34696208	Green Published, gold			2022-04-29	WOS:000712318400001
J	Basu, S				Basu, Sankar			Special Issue on 'Coronavirus: Vaccines and Other Therapeutics' (2020-2021)	VACCINES			English	Editorial Material									[Basu, Sankar] Calcutta Univ, Asutosh Coll, Dept Microbiol, 92,Shyama Prasad Mukherjee Rd, Kolkata 700026, India; [Basu, Sankar] ULB, 3BIO Grp External Sci Collaborator, B-1050 Brussels, Belgium		Basu, S (通讯作者)，Calcutta Univ, Asutosh Coll, Dept Microbiol, 92,Shyama Prasad Mukherjee Rd, Kolkata 700026, India.; Basu, S (通讯作者)，ULB, 3BIO Grp External Sci Collaborator, B-1050 Brussels, Belgium.	nemo8130@gmail.com	Basu, Sankar/AAD-7202-2019	Basu, Sankar/0000-0003-1393-1982			Andersen KG, 2020, NAT MED, V26, P450, DOI 10.1038/s41591-020-0820-9; Antonio AD, 2020, RSC ADV, V10, P23379, DOI 10.1039/d0ra03774e; Balaram P, 2021, CURR SCI INDIA, V121, P441; Balcells ME, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003415; Basu S, 2021, J MOL MODEL, V27, DOI 10.1007/s00894-021-04779-0; Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251; Callaway E, 2021, NATURE, V595, P17, DOI 10.1038/d41586-021-01696-3; Cao LX, 2020, SCIENCE, V370, P426, DOI 10.1126/science.abd9909; Chen N, 2020, LANCET, V395, P507, DOI [DOI 10.1016/S0140-6736(20)30183-5, 10.1016/S0140-6736(20)30183-5]; Chu KB, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080920; Faruqui AR, 2021, INDIAN J MED RES, V153, P219, DOI 10.4103/ijmr.IJMR_2294_20; Gonzalez-Candelas F, 2021, INFECT GENET EVOL, V92, DOI 10.1016/j.meegid.2021.104869; Huang JQ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.588508; Huo JD, 2020, NAT STRUCT MOL BIOL, V27, P846, DOI 10.1038/s41594-020-0469-6; Imperiale MJ, 2020, MBIO, V11, DOI 10.1128/mBio.01868-20; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Malladi SK, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.016284; Omrani M, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.586993; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pollet J, 2021, ADV DRUG DELIVER REV, V170, P71, DOI 10.1016/j.addr.2021.01.001; Ren W, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111310; Ritchie H., 2020, CORONAVIRUS PANDEMIC; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Zhang G., 2020, INVESTIGATION ACE2 N, DOI DOI 10.1101/2020.03.19.999318; Zhang LB, 2020, AGING-US, V12, P6536, DOI 10.18632/aging.103102	28	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1083	10.3390/vaccines9101083			4	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP0SQ	34696191	Green Published, gold			2022-04-29	WOS:000712852700001
J	Bauernfeind, S; Salzberger, B; Hitzenbichler, F; Scigala, K; Einhauser, S; Wagner, R; Gessner, A; Koestler, J; Peterhoff, D				Bauernfeind, Stilla; Salzberger, Bernd; Hitzenbichler, Florian; Scigala, Karolina; Einhauser, Sebastian; Wagner, Ralf; Gessner, Andre; Koestler, Josef; Peterhoff, David			Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2	VACCINES			English	Article						COVID-19; vaccination; BNT162b2; immunogenicity; reactogenicity; sex		It is not clear whether there is an association between adverse reactions and immune response after vaccination. Seven hundred and thirty-five vaccinees from our University Medical Center vaccination clinic provided information about sex, age and adverse reactions after first and second vaccination with BNT162b2. Adverse reactions were categorized into three groups: no or minor on the injection side, moderate (not further classified) and severe-defined as any symptom(s) resulting in sick leave. We chose 38 vaccinees with the most severe adverse reactions and compared their humoral and T-cell-mediated immune responses after second vaccination with those of 38 sex and age matched controls without or only minor injection-side related adverse reactions. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-receptor binding domain (RBD) IgG titers were detectable in all participants (median 5528; range 958-26,285). Men with severe adverse reactions had 1.5-fold higher median SARS-CoV-2 RBD IgG titers compared to men without adverse reactions (median 7406 versus 4793; p < 0.001). Similarly; neutralization activity was significantly higher in men with severe adverse reactions (half maximal inhibitory concentrations (IC50) median 769 versus 485; p < 0.001). Reactogenicity did not influence humoral immune response in women nor T-cell-mediated immune response in any sex. To conclude; adverse reactions after vaccination with BNT162b2 do influence humoral immune response yet only in men and are not a prerequisite for a robust antibody response.	[Bauernfeind, Stilla; Salzberger, Bernd; Hitzenbichler, Florian; Scigala, Karolina] Univ Med Ctr Regensburg, Dept Infect Prevent & Infect Dis, D-93053 Regensburg, Germany; [Einhauser, Sebastian; Wagner, Ralf; Gessner, Andre; Peterhoff, David] Univ Regensburg, Inst Med Microbiol & Hyg, D-93053 Regensburg, Germany; [Wagner, Ralf; Gessner, Andre; Koestler, Josef; Peterhoff, David] Univ Med Ctr Regensburg, Inst Clin Microbiol & Hyg, D-93053 Regensburg, Germany		Bauernfeind, S (通讯作者)，Univ Med Ctr Regensburg, Dept Infect Prevent & Infect Dis, D-93053 Regensburg, Germany.	stilla.bauernfeind@ukr.de; bernd.salzberger@ukr.de; florian.hitzenbichler@ukr.de; karolina.scigala@stud.uni-regensburg.de; sebastian.einhauser@ukr.de; ralf.wagner@ukr.de; andre.gessner@ukr.de; josef.koestler@ukr.de; david.peterhoff@ukr.de	Peterhoff, David/ABD-6746-2020	Peterhoff, David/0000-0001-5911-6233; Einhauser, Sebastian/0000-0003-4177-4451			Abu Jabal K, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.6.2100096; Altmann DM, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6160; Bayart JL, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9061340; Burny W, 2019, VACCINE, V37, P2004, DOI 10.1016/j.vaccine.2019.02.015; Coggins SA, 2022, OPEN FORUM INFECT DI, V9, DOI [10.1093/ofid/ofab575, 10.1101/2021.06.25.21259544]; Earle KA, 2021, VACCINE, V39, P4423, DOI 10.1016/j.vaccine.2021.05.063; Hahnel V, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243967; Herve C, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0132-6; Hwang YH, 2021, KOREAN J INTERN MED, V36, P1486, DOI 10.3904/kjim.2021.210; Karbiener M, 2021, TRANSFUSION, V61, P1141, DOI 10.1111/trf.16291; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Klein S, 2020, J CLIN INVEST, V130, P6141, DOI 10.1172/JCI142004; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Mitchell TC, 2017, CURR OPIN IMMUNOL, V47, P17, DOI 10.1016/j.coi.2017.06.009; Naaber P., 2021, DECLINED ANTIBODY RE, DOI [10.1101/2021.04.19.21255714, DOI 10.1101/2021.04.19.21255714]; Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063; Pellini R, 2021, ECLINICALMEDICINE, V36, DOI 10.1016/j.eclinm.2021.100928; Peterhoff D, 2021, INFECTION, V49, P75, DOI 10.1007/s15010-020-01503-7; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Schlickeiser S, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.628971; Schmidt F, 2020, J EXP MED, V217, DOI 10.1084/jem.20201181; Takeuchi M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257668; Vogler I, 2020, BNT 162B2 INDUCES SA, DOI [10.1101/2020.12.09.20245175, DOI 10.1101/2020.12.09.20245175]; WHO Expert Committee on Biological Standardization, 2017, GUID CLIN EV VACC RE, V924; Wuliji T., 2019, 1 WHO	27	4	4	3	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1089	10.3390/vaccines9101089			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WV3FK	34696197	Green Published, gold			2022-04-29	WOS:000717121900001
J	Liang, Y; Bai, XX; Liu, XY; Zhang, Z; Pang, XH; Nie, L; Qiu, WQ; Zhao, W; Hu, GY				Liang, Yan; Bai, Xinxin; Liu, Xinyao; Zhang, Zheng; Pang, Xinghuo; Nie, Li; Qiu, Wuqi; Zhao, Wei; Hu, Guangyu			Hepatitis B Vaccination Coverage Rates and Associated Factors: A Community-Based, Cross-Sectional Study Conducted in Beijing, 2019-2020	VACCINES			English	Article						hepatitis B virus; vaccination; associated factors; China	VIRUS INFECTION; RURAL CHINA; EPIDEMIOLOGY; BARRIERS; DISEASE	Hepatitis B vaccination coverage rates are low throughout most populations in China. Factors influencing low coverage rates, including population-specific hepatitis B vaccination barriers, may inform policies that promote vaccination. A cross-sectional survey of residents from 43 communities assessed their vaccination status and identified associated factors via uni- and multivariable logistic regression and subgroup analyses. In total, 11,280 of 36,007 respondents received a hepatitis B vaccine, indicating a 31.33% coverage rate. Multivariable logistic regression revealed non-Beijing (odds ratio (OR) = 0.81; 95% confidence interval (CI): 0.76-0.85) and residents who self-rated their health as very healthy (OR = 0.82; 95% CI: 0.68-0.99) were unlikely to be vaccinated. Farmers (OR = 1.68; 95% CI: 1.51-1.86), commerce and service workers (OR = 1.82; 95% CI, 1.63-2.04), government employees (OR = 1.56; 95% CI: 1.38-1.77), professionals and technicians (OR = 1.85; 95% CI: 1.63-2.09), and students (OR = 1.69; 95% CI: 1.10-2.59) had increased hepatitis B vaccination rates. The multivariable assessment revealed hepatitis B vaccination coverage rates are associated with confirmed or suspected family cases, vaccination unwillingness or uncertainty, and unawareness of its prevention of the hepatitis B virus. Low hepatitis B vaccination coverage rates among Beijing subpopulations highlight the need for improved strategies, including those that target specific populations.	[Liang, Yan; Zhang, Zheng; Zhao, Wei] Chaoyang Dist Ctr Dis Prevent & Control Beijing, Beijing 100020, Peoples R China; [Bai, Xinxin; Zhao, Wei] Hebei Med Univ, Sch Publ Hlth, Shijiazhuang 050011, Hebei, Peoples R China; [Liu, Xinyao; Qiu, Wuqi; Hu, Guangyu] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Informat, Ctr Hlth Policy & Management, Beijing 100020, Peoples R China; [Nie, Li] Beijing Ctr Dis Prevent & Control, Beijing 100013, Peoples R China		Zhao, W (通讯作者)，Chaoyang Dist Ctr Dis Prevent & Control Beijing, Beijing 100020, Peoples R China.; Zhao, W (通讯作者)，Hebei Med Univ, Sch Publ Hlth, Shijiazhuang 050011, Hebei, Peoples R China.; Qiu, WQ; Hu, GY (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Informat, Ctr Hlth Policy & Management, Beijing 100020, Peoples R China.	liu.xinyao@imicams.ac.cn; qiu.wuqi@imicams.ac.cn; hu-hugy@sph.pumc.edu.cn	Hu, Guangyu/T-8710-2019; hu, guangyu/AFQ-7186-2022	Hu, Guangyu/0000-0002-0339-4522; hu, guangyu/0000-0002-0339-4522	Development Center for Medical Science & Technology National Health Commission of the People's Republic of China; Viral Hepatitis Infectious Diseases Prevention and Control Science and Technology Major Project [2018ZX10715005]	This study was funded by the Development Center for Medical Science & Technology National Health Commission of the People's Republic of China. Aids and Viral Hepatitis Infectious Diseases Prevention and Control Science and Technology Major Project (2018ZX10715005).	Awoke N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241226; Burns GS, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a024935; Chen WQ, 2012, CHINESE J CANCER RES, V24, P1, DOI 10.1007/s11670-012-0001-6; Cui FQ, 2017, EMERG INFECT DIS, V23, P765, DOI 10.3201/eid2305.161477; Cui Y, 2013, J GASTROEN HEPATOL, V28, P7, DOI 10.1111/jgh.12220; Guo YW, 2021, HUM VACC IMMUNOTHER, V17, P1196, DOI 10.1080/21645515.2020.1807812; Guo YW, 2020, HUM VACC IMMUNOTHER, V16, P148, DOI 10.1080/21645515.2019.1640428; Herrscher C, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061486; Hur K, 2012, J COMMUN HEALTH, V37, P1119, DOI 10.1007/s10900-012-9553-0; Kilmer G.A., 2020, JMIR PUBLIC HLTH SUR, V6; Kilmer GA, 2019, CLIN INFECT DIS, V68, P256, DOI 10.1093/cid/ciy479; Koc O, 2019, EUROSURVEILLANCE, V24, P21, DOI 10.2807/1560-7917.ES.2019.24.30.1900064; Liu JH, 2020, ANN EPIDEMIOL, V49, P13, DOI 10.1016/j.annepidem.2020.05.011; Liu J, 2019, B WORLD HEALTH ORGAN, V97, P230, DOI [10.2471/BLT.18.219469, 10.2471/blt.18.219469]; Liu J, 2016, LANCET INFECT DIS, V16, P80, DOI 10.1016/S1473-3099(15)00218-2; Nelson NP, 2016, CLIN LIVER DIS, V20, P607, DOI 10.1016/j.cld.2016.06.006; Song C, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.5718; Tan SHS, 2020, VACCINE, V38, P5447, DOI 10.1016/j.vaccine.2020.06.045; Wang H, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4428-y; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang SN, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003693; Wibabara Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214732; Wu SP, 2021, LANCET INFECT DIS, V21, P1654, DOI 10.1016/S1473-3099(21)00396-0; Xiao J, 2019, J HEPATOL, V71, P212, DOI 10.1016/j.jhep.2019.03.004; Yan SJ, 2021, HUM VACC IMMUNOTHER, V17, P1403, DOI 10.1080/21645515.2020.1826250; Ye CC, 2018, HUM VACC IMMUNOTHER, V14, P2715, DOI 10.1080/21645515.2018.1491246; Zhu DW, 2014, VACCINE, V32, P6705, DOI 10.1016/j.vaccine.2013.06.095; Zhu H, 2010, OSTEOPOROSIS INT, V21, P765, DOI 10.1007/s00198-009-1010-2	28	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1070	10.3390/vaccines9101070			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP4UI	34696178	Green Published			2022-04-29	WOS:000713128400001
J	Manolescu, LSC; Zaharia, CN; Dumitrescu, AI; Prasacu, I; Radu, MC; Boeru, AC; Boidache, L; Nita, I; Necsulescu, A; Chivu, RD				Manolescu, Loredana Sabina Cornelia; Zaharia, Corneliu Nicolae; Dumitrescu, Anca Irina; Prasacu, Irina; Radu, Mihaela Corina; Boeru, Adrian Calin; Boidache, Liliana; Nita, Irina; Necsulescu, Andrei; Chivu, Razvan Daniel			Early COVID-19 Vaccination of Romanian Medical and Social Personnel	VACCINES			English	Article						COVID-19 vaccines; medical and social staff vaccination; mRNA vaccine	INFLUENZA VACCINATION; INFECTION; INTENTION; STUDENTS	Background: In December 2020, the first doses of COVID-19 vaccines arrived in Romania and were made available to medical and social staff. Vaccine hesitancy appeared as a barrier to effectively ending the pandemic. The opinions of medical and social staff influence the opinion of the general population. This study assesess the attitudes, knowledge, and opinion of medical and social personnel toward COVID-19 vaccines and vaccination and the influencing factors. Methods: 1025 persons participated in an online cross-sectional study from March until July 2021. Results: Out of 1021 eligible responders, 719 (70.42%) had been vaccinated: 227 with one dose (22.23%) and 492 with two doses (48.18%). There were 302 responders who were not vaccinated at all. Out of them, 188 refused vaccinations. The participants showed a good understanding and knowledge of SARScoV-2 transmission and treatment. Geographic area, medical profession, and medical experience influenced COVID-19 vaccination (p < 0.001). There were no associations between willingness to vaccinate and vaccine/virus knowledge. Most of the responders who were vaccinated or wanted to be vaccinated indicated an mRNA vaccine as their first choice. The variables that were significantly associated with reporting COVID-19 vaccine acceptance after logistic regression were: living in an urban area (Ora = 1.58, 95% CI: 0.98-2.56), being female (Ora = 1.59; 95% CI:1.03-2.44), and being a medical doctor (Ora = 3.40; 95% CI: 1.84-6.26). Conclusions: These findings show that vaccine hesitancy persists in medical and social personnel in Romania, and, hence, it may be reflected in the hesitancy of the general population toward vaccination.	[Manolescu, Loredana Sabina Cornelia; Radu, Mihaela Corina; Boidache, Liliana; Nita, Irina] Carol Davila Univ Med & Pharm, Fac Midw & Nursing, Dept Microbiol Parasitol & Virol, Bucharest 050474, Romania; [Manolescu, Loredana Sabina Cornelia; Zaharia, Corneliu Nicolae] Inst Virol Stefan S Nicolau, Dept Virol, Bucharest 030304, Romania; [Dumitrescu, Anca Irina; Prasacu, Irina] Carol Davila Univ Med & Pharm, Fac Pharm, Dept Fundamental Sci, Bucharest 050474, Romania; [Radu, Mihaela Corina; Boeru, Adrian Calin] Obstet & Gynecol Hosp, Dept Birth, Ploiesti 100409, Romania; [Nita, Irina] Elias Univ Emergency Hosp, Dept Med Oncol, Bucharest 011461, Romania; [Necsulescu, Andrei] Cent Mil Emergency Univ Hosp Dr Carol Davila, Dept Emergency, Bucharest 010825, Romania; [Chivu, Razvan Daniel] Carol Davila Univ Med & Pharm, Fac Midwives & Nursing, Dept Publ Hlth & Hlth Management, Bucharest 050474, Romania		Manolescu, LSC; Radu, MC (通讯作者)，Carol Davila Univ Med & Pharm, Fac Midw & Nursing, Dept Microbiol Parasitol & Virol, Bucharest 050474, Romania.; Manolescu, LSC (通讯作者)，Inst Virol Stefan S Nicolau, Dept Virol, Bucharest 030304, Romania.; Radu, MC (通讯作者)，Obstet & Gynecol Hosp, Dept Birth, Ploiesti 100409, Romania.	loredana.manolescu@umfcd.ro; corneliu.zaharia@gmail.com; ancairinadumitrescu@yahoo.com; irinaprasacu@yahoo.com; radu_mihaela72@yahoo.com; calinboeru@yahoo.com; liliana.boidache@yahoo.com; irina.nita0910@gmail.com; andrei.neck@gmail.com; razvan.chivu@umfcd.ro	Manolescu, Loredana/AAC-5584-2020; Radu, Mihaela Corina/AAA-7991-2022; Radu, Mihaela Corina/ABD-7359-2021	Manolescu, Loredana/0000-0001-8694-6195; 	European UnionEuropean Commission [883441]	This paper was supported by the STAMINA project, which received funding from the European Unions Horizon 2020 research and innovation program under grant agreement No. 883441. All authors have equally contributed to the writing and editing of the manuscript.	Al-Jayyousi GF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060548; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Balan A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080854; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Dragomirescu CC, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9010031; Fabricius D, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080918; Fontanet A, 2020, NAT REV IMMUNOL, V20, P583, DOI 10.1038/s41577-020-00451-5; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Hollmeyer HG, 2009, VACCINE, V27, P3935, DOI 10.1016/j.vaccine.2009.03.056; Kerneis S, 2017, AM J PREV MED, V53, pE97, DOI 10.1016/j.amepre.2017.01.014; Keske S, 2020, VACCINE, V38, P8357, DOI 10.1016/j.vaccine.2020.11.003; Kowalska JD, 2021, INT J INFECT DIS, V104, P293, DOI 10.1016/j.ijid.2020.12.026; Marinescu P, 2012, ROM BIOTECH LETT, V17, P7817; Nita I, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56110600; Olashore A., 2021, ASIAN J SOC HLTH BEH, V4, P85, DOI DOI 10.4103/SHB.SHB_32_21; Papagiannis D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144925; Pless A, 2017, BMC NURS, V16, DOI 10.1186/s12912-017-0215-5; Popa GL, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040774; Radu MC, 2021, CUREUS, V13, DOI 10.7759/cureus.12811; Raude J, 2016, EXPERT REV VACCINES, V15, P937, DOI 10.1080/14760584.2016.1184092; Ricco M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080889; Rieger MO., 2021, ASIAN J SOCIAL HLTH, V4, P81, DOI [10.4103/shb.shb_7_21, DOI 10.4103/SHB.SHB_7_21]; Sharma R., 2021, ASIAN J SOC HLTH BEH, V4, P98, DOI [10.4103/shb.shb_9_21, DOI 10.4103/SHB.SHB_9_21]; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021	24	3	3	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1127	10.3390/vaccines9101127			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN6TL	34696235	Green Published, gold			2022-04-29	WOS:000711899900001
J	Marlet, J; Gatault, P; Maakaroun, Z; Longuet, H; Stefic, K; Handala, L; Eymieux, S; Gyan, E; Dartigeas, C; Gaudy-Graffin, C				Marlet, Julien; Gatault, Philippe; Maakaroun, Zoha; Longuet, Helene; Stefic, Karl; Handala, Lynda; Eymieux, Sebastien; Gyan, Emmanuel; Dartigeas, Caroline; Gaudy-Graffin, Catherine			Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia	VACCINES			English	Article						COVID-19; vaccine; kidney transplant; chronic lymphocytic leukemia; antibody		The impact of a third dose of COVID-19 vaccine on antibody responses is unclear in immunocompromised patients. The objective of this retrospective study was to characterize antibody responses induced by a third dose of mRNA COVID-19 vaccine in 160 kidney transplant recipients and 20 patients treated for chronic lymphocytic leukemia (CLL). Prevalence of anti-spike IgG & GE; 7.1 and & GE; 30 BAU/mL after the third dose were 47% (75/160) and 39% (63/160) in kidney transplant recipients, and 57% (29/51) and 50% (10/20) in patients treated for CLL. Longitudinal follow-up identified a moderate increase in SARS-CoV-2 anti-spike IgG levels after a third dose of vaccine in kidney transplant recipients (0.19 vs. 5.28 BAU/mL, p = 0.03) and in patients treated for CLL (0.63 vs. 10.7 BAU/mL, p = 0.0002). This increase in IgG levels had a limited impact on prevalence of anti-spike IgG & GE; 30 BAU/mL in kidney transplant recipients (17%, 2/12 vs. 33%, 4/12, p = 0.64) and in patients treated for CLL (5%, 1/20 vs. 45%, 9/20, p = 0.008). These results highlight the need for vaccination of the general population and the importance of non-medical preventive measures to protect immunocompromised patients.</p>	[Marlet, Julien; Stefic, Karl; Handala, Lynda; Eymieux, Sebastien; Gaudy-Graffin, Catherine] Univ Tours, INSERM U1259, F-37000 Tours, France; [Marlet, Julien; Stefic, Karl; Handala, Lynda; Eymieux, Sebastien; Gaudy-Graffin, Catherine] CHRU Tours, F-37000 Tours, France; [Marlet, Julien; Stefic, Karl; Handala, Lynda; Gaudy-Graffin, Catherine] CHRU Tours, Serv Bacteriol Virol Hyg, F-37000 Tours, France; [Gatault, Philippe; Longuet, Helene] CHRU Tours, Transplantat Renale Immunol Clin, F-37000 Tours, France; [Maakaroun, Zoha] CHRU Tours, Ctr Vaccinat, F-37000 Tours, France; [Maakaroun, Zoha] CHRU Tours, Serv Med Pediat, F-37000 Tours, France; [Eymieux, Sebastien] Univ Tours, Plate Forme IBiSA Microscopie Elect, F-37000 Tours, France; [Gyan, Emmanuel; Dartigeas, Caroline] CHRU Tours, Hematol & Therapie Cellulaire, F-37000 Tours, France		Marlet, J (通讯作者)，Univ Tours, INSERM U1259, F-37000 Tours, France.; Marlet, J (通讯作者)，CHRU Tours, F-37000 Tours, France.; Marlet, J (通讯作者)，CHRU Tours, Serv Bacteriol Virol Hyg, F-37000 Tours, France.	Julien.marlet@univ-tours.fr; philippe.gatault@univ-tours.fr; Z.MAAKAROUN-VERMESSE@chu-tours.fr; H.LONGUET@chu-tours.fr; karl.stefic@univ-tours.fr; L.HANDALA@chu-tours.fr; sebastien.eymieux@univ-tours.fr; E.GYAN@chu-tours.fr; c.dartigeas@chu-tours.fr; catherine.gaudy-graffin@univ-tours.fr	Marlet, Julien/ABF-1619-2020; Stefic, Karl/C-5052-2019	Marlet, Julien/0000-0002-8645-8703; Stefic, Karl/0000-0002-9686-9194; Eymieux, Sebastien/0000-0002-4738-510X			Agha Mounzer, 2021, medRxiv, DOI 10.1101/2021.04.06.21254949; Benotmane I, 2021, JAMA-J AM MED ASSOC, V326, P1063, DOI 10.1001/jama.2021.12339; Bernal JL, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1088; Danthu C, 2021, J AM SOC NEPHROL, V32, P2154, DOI 10.1681/ASN.2021040490; Ebinger Joseph E, 2021, medRxiv, DOI 10.1101/2021.02.23.21252230; Feng S, 2021, NAT MED, V27, P2032, DOI 10.1038/s41591-021-01540-1; Gobbi F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030422; Grupper A, 2021, AM J TRANSPLANT, V21, P2719, DOI 10.1111/ajt.16615; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Herishanu Y, 2021, BLOOD, V137, P3165, DOI 10.1182/blood.2021011568; Kamar N, 2021, NEW ENGL J MED, V385, P661, DOI 10.1056/NEJMc2108861; Kristiansen PA, 2021, LANCET, V397, P1347, DOI 10.1016/S0140-6736(21)00527-4; Perkmann T, 2021, MICROBIOL SPECTR, V9, DOI 10.1128/Spectrum.00247-21; Prendecki M, 2021, LANCET, V397, P1178, DOI 10.1016/S0140-6736(21)00502-X; Qin CX, 2021, TRANSPLANTATION, V105, pE265, DOI 10.1097/TP.0000000000003907; Raj E, 2021, CLIN EVALUATION ABBO, DOI [10.1101/2021.02.17.21251940, DOI 10.1101/2021.02.17.21251940]; Roeker LE, 2021, LEUKEMIA, V35, P2703, DOI 10.1038/s41375-021-01270-w; Stumpf J, 2021, LANCET REG HEALTH-EU, V9, DOI 10.1016/j.lanepe.2021.100178; Tenforde MW, 2021, MMWR-MORBID MORTAL W, V70, P674, DOI 10.15585/mmwr.mm7018e1; Werbel WA, 2021, ANN INTERN MED, V174, P1330, DOI 10.7326/L21-0282	20	5	5	4	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1055	10.3390/vaccines9101055			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN8TF	34696163	Green Published, gold			2022-04-29	WOS:000712039100001
J	Nehal, KR; Steendam, LM; Ponce, MC; van der Hoeven, M; Smit, GSA				Nehal, Kimberly R.; Steendam, Lieke M.; Ponce, Maiza Campos; van der Hoeven, Marinka; Smit, G. Suzanne A.			Worldwide Vaccination Willingness for COVID-19: A Systematic Review and Meta-Analysis	VACCINES			English	Review						COVID-19; SARS-CoV-2; vaccine; vaccination willingness; vaccination hesitancy; determinants	INTENTION; ACCEPTANCE; HESITANCY	Countries across the globe are currently experiencing a third or fourth wave of SARS-CoV-2 infections; therefore, the need for effective vaccination campaigns is higher than ever. However, effectiveness of these campaigns in disease reduction is highly dependent on vaccination uptake and coverage in susceptible populations. Therefore, this systematic review and meta-analysis estimated the vaccination intention and identified determinants of willingness and hesitancy. This study updates the existing body of literature on vaccination willingness, and was conducted according to the PRISMA guidelines. PubMed was searched for publications, selecting only studies published between 20 October 2020 and 1 March 2021, in English, with participants aged > 16 years of age. The search identified 411 articles, of which 63 surveys were included that accounted for more than 30 countries worldwide. The global COVID-19 vaccination willingness was estimated at 66.01% [95% CI: 60.76-70.89% I-2 = 99.4% [99.3%; 99.4%]; tau(2) = 0.83]. The vaccination willingness varied within as well as between countries. Age, gender, education, attitudes and perceptions about vaccines were most frequently observed to be significantly associated with vaccine acceptance or refusal.	[Nehal, Kimberly R.; Steendam, Lieke M.; Ponce, Maiza Campos; van der Hoeven, Marinka; Smit, G. Suzanne A.] Vrije Univ, Dept Hlth Sci Infect Dis & Publ Hlth, NL-1081 HV Amsterdam, Netherlands		Ponce, MC (通讯作者)，Vrije Univ, Dept Hlth Sci Infect Dis & Publ Hlth, NL-1081 HV Amsterdam, Netherlands.	k.r.nehal@vu.nl; l.m.steendam@student.vu.nl; m.camposponce@vu.nl; m.vander.hoeven@vu.nl; g.s.a.smit@vu.nl	Smit, Suzanne/AAE-8057-2022	Smit, Suzanne/0000-0002-8254-7688; van der Hoeven, Marinka/0000-0003-0566-6592			Afolabi AA, 2021, PAN AFR MED J, V38, DOI 10.11604/pamj.2021.38.3.27401; Akarsu B, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13891; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Al-Qerem WA, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.632914; Alley SJ, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020797; [Anonymous], 2019, LANCET CHILD ADOLESC, V3, P281, DOI 10.1016/S2352-4642(19)30092-6; Attwell K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245907; Bianconi V, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05304; Biasio LR, 2021, HUM VACC IMMUNOTHER, V17, P1304, DOI 10.1080/21645515.2020.1829315; Bono SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050515; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; Chen MS, 2021, HUM VACC IMMUNOTHER, V17, P2279, DOI 10.1080/21645515.2020.1853449; Cochrane Consumers and Communication Review Group, RYAN R HET SUBGR AN; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dinga JN, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020175; Ditekemena JD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020153; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Eguia H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020170; Elfil M, 2017, EMERGENCY, V5; Feleszko W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010044; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Gan L, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18041993; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Harapan H, 2020, HUM VACC IMMUNOTHER, V16, P3074, DOI 10.1080/21645515.2020.1819741; Head KJ, 2020, SCI COMMUN, V42, P698, DOI 10.1177/1075547020960463; Heidari S, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-006854; Hogan C, 2020, INT J EMERG MED, V13, DOI 10.1186/s12245-020-00309-6; Joanna Briggs Institute Faculty of Health and Medical Sciences The University of Adelaide., CRIT APPR TOOLS JOAN; Khaled SM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050471; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kourlaba G, 2021, GLOB HEALTH RES POL, V6, DOI 10.1186/s41256-021-00188-1; Kreps S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00335-2; La Vecchia C, 2020, MED LAV, V111, P445, DOI 10.23749/mdl.v111i6.10813; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Latkin CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246970; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Male V, 2021, NAT REV IMMUNOL, V21, P200, DOI 10.1038/s41577-021-00525-y; Mouchtouri VA, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17238854; Muqattash R, 2020, DATA BRIEF, V33, DOI 10.1016/j.dib.2020.106446; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Prati G, 2020, HEALTH EDUC RES, V35, P505, DOI 10.1093/her/cyaa043; R Core Team, 2020, R LANGUAGE ENV STAT; Raja A.S., 2021, VACCINE HESITANCY RE, DOI [10.1101/2021.02.28.21252610, DOI 10.1101/2021.02.28.21252610]; Robertson E., 2021, BRAIN BEHAV IMMUN, V94, P41, DOI [10.1016/j.bbi.2021.03.008, DOI 10.1016/j.bbi.2021.03.008]; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Sanyaolu A, 2019, INQUIRY-J HEALTH CAR, V56, DOI 10.1177/0046958019894098; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Thomson A, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004264; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; Turhan Z, 2021, CURR PSYCHOL, DOI 10.1007/s12144-021-02105-8; Vai B, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.563426; Wang JH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030191; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Wang Q, 2021, PREV MED, V150, DOI 10.1016/j.ypmed.2021.106694; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; Williams L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010017; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048; Rivas DRZ, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245859	70	17	17	16	16	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1071	10.3390/vaccines9101071			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	WU7QC	34696179	Green Published, gold			2022-04-29	WOS:000716734900001
J	Rossi, C; Lanuti, P; Cicalini, I; De Bellis, D; Pierdomenico, L; Del Boccio, P; Zucchelli, M; Natale, L; Sinjari, B; Catitti, G; Vespa, S; Simeone, P; Bologna, G; Bucci, I; Falasca, K; Vecchiet, J; Stuppia, L; De Laurenzi, V; Pieragostino, D				Rossi, Claudia; Lanuti, Paola; Cicalini, Ilaria; De Bellis, Domenico; Pierdomenico, Laura; Del Boccio, Piero; Zucchelli, Mirco; Natale, Luca; Sinjari, Bruna; Catitti, Giulia; Vespa, Simone; Simeone, Pasquale; Bologna, Giuseppina; Bucci, Ines; Falasca, Katia; Vecchiet, Jacopo; Stuppia, Liborio; De Laurenzi, Vincenzo; Pieragostino, Damiana			BNT162b2 mRNA Vaccination Leads to Long-Term Protection from COVID-19 Disease	VACCINES			English	Article						BNT162b2; SARS-CoV-2; vaccines; anti-S1 IgG; spike-specific T-cells	CELLS	The efficacy of SARS-CoV-2 mRNA-based vaccines in preventing COVID-19 disease has been extensively demonstrated; however, it is of uttermost importance to acquire knowledge on the persistence of immune-protection both in terms of levels of neutralizing antibodies and specialized memory cells. This can provide important scientific basis for decisions on the need of additional vaccine doses and on when these should be administered thus resulting in an improvement in vaccination schedules. Here, we briefly report the changes in antibody levels and cellular immunity following BNT162b2 administration. We show an important fall in anti S1-Spike antibodies in BNT162b2 vaccinated subjects overtime, paralleled by a contextual consolidation of specific spike (S) T-cells, mainly of the CD8+ compartment. Contrariwise, CD4+ S-specific response shows a considerable interindividual variability. These data suggest that the well-known antibody drop in vaccinated subjects is replaced by memory cell consolidation that can protect from severe adverse effects of SARS-CoV-2 infection.</p>	[Rossi, Claudia; Lanuti, Paola; Cicalini, Ilaria; De Bellis, Domenico; Pierdomenico, Laura; Del Boccio, Piero; Zucchelli, Mirco; Natale, Luca; Catitti, Giulia; Vespa, Simone; Simeone, Pasquale; Bologna, Giuseppina; Bucci, Ines; Stuppia, Liborio; De Laurenzi, Vincenzo; Pieragostino, Damiana] G dAnnunzio Univ Chieti Pescara, Ctr Adv Studies & Technol CAST, I-66100 Chieti, Italy; [Rossi, Claudia; Stuppia, Liborio] G dAnnunzio Univ Chieti Pescara, Sch Med & Hlth Sci, Dept Psychol Hlth & Terr Sci, I-66100 Chieti, Italy; [Lanuti, Paola; Pierdomenico, Laura; Catitti, Giulia; Vespa, Simone; Simeone, Pasquale; Bologna, Giuseppina; Bucci, Ines; Falasca, Katia; Vecchiet, Jacopo] G dAnnunzio Univ Chieti Pescara, Dept Med & Aging Sci, I-66100 Chieti, Italy; [Cicalini, Ilaria; De Bellis, Domenico; Zucchelli, Mirco; Sinjari, Bruna; De Laurenzi, Vincenzo; Pieragostino, Damiana] G dAnnunzio Univ Chieti Pescara, Dept Innovat Technol Med & Dent, I-66100 Chieti, Italy; [Del Boccio, Piero] G dAnnunzio Univ Chieti Pescara, Dept Pharm, I-66100 Chieti, Italy; [Falasca, Katia; Vecchiet, Jacopo] SS Annunziata Hosp, Clin Infect Dis, I-66100 Chieti, Italy		Pieragostino, D (通讯作者)，G dAnnunzio Univ Chieti Pescara, Ctr Adv Studies & Technol CAST, I-66100 Chieti, Italy.; Pieragostino, D (通讯作者)，G dAnnunzio Univ Chieti Pescara, Dept Innovat Technol Med & Dent, I-66100 Chieti, Italy.	claudia.rossi@unich.it; paola.lanuti@unich.it; ilaria.cicalini@unich.it; domenico.debellis@studenti.unich.it; laura.pierdomenico@unich.it; piero.delboccio@unich.it; m.zucchelli@unich.it; lucanatale1989@gmail.com; b.sinjari@unich.it; catittig@gmail.com; sv85@libero.it; simeone.pasquale@gmail.com; giuseppina.bologna@hotmail.it; ines.bucci@unich.it; katia.falasca@unich.it; jacopo.vecchiet@unich.it; stuppia@unich.it; delaurenzi@unich.it; damiana.pieragostino@unich.it	Sinjari, Bruna/AAG-5781-2019; DEL BOCCIO, PIERO/AAC-7392-2022; Simeone, Pasquale/K-7549-2016	Sinjari, Bruna/0000-0002-4444-3343; DEL BOCCIO, PIERO/0000-0003-1653-2194; Simeone, Pasquale/0000-0003-4430-480X; Rossi, Claudia/0000-0003-0949-0280; Pieragostino, Damiana/0000-0003-1015-3484; Vespa, Simone/0000-0001-6146-9302; Cicalini, Ilaria/0000-0002-9792-2225			Aiello A, 2021, INT J INFECT DIS, V106, P338, DOI 10.1016/j.ijid.2021.04.034; Andryukov BG, 2021, AIMS PUBLIC HEALTH, V8, P388, DOI 10.3934/publichealth.2021030; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Cassaniti I, 2021, CLIN MICROBIOL INFEC, V27, P1029, DOI 10.1016/j.cmi.2021.03.010; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Fisher E, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.602254; Gallais F, 2021, EMERG INFECT DIS, V27, P113, DOI 10.3201/eid2701.203611; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Koch T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030238; Lanuti P, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9081035; Lanuti P, 2012, NEUROBIOL AGING, V33, P2599, DOI 10.1016/j.neurobiolaging.2012.01.004; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Martin MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02692; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Percivalle E, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.24.2001031; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Samji T, 2017, IMMUNOL LETT, V185, P32, DOI 10.1016/j.imlet.2017.02.012; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242; Soiza RL, 2021, AGE AGEING, V50, P279, DOI 10.1093/ageing/afaa274; Tarke Alison, 2020, bioRxiv, DOI 10.1101/2020.12.08.416750; Thevarajan I, 2020, NAT MED, V26, P453, DOI 10.1038/s41591-020-0819-2; Tosif S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19545-8; Turner JS, 2021, NATURE, V596, P109, DOI 10.1038/s41586-021-03738-2; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195	28	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1164	10.3390/vaccines9101164			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WS8YF	34696272	Green Published, gold			2022-04-29	WOS:000715462700001
J	Vitale, M; Parodi, M				Vitale, Massimo; Parodi, Monica			Blocking HIF to Enhance NK Cells: Hints for New Anti-Tumor Therapeutic Strategies?	VACCINES			English	Article						NK cells; tumors; HIF	MHC CLASS-I; CYTOMEGALOVIRUS-INFECTION; INHIBITORY RECEPTORS; HYPOXIA; EXPRESSION; TRANSCRIPTION; RESPONSES; EDUCATION; TARGET	Natural Killer (NK) cells are becoming an ever more promising tool to design new anti-tumor strategies. However, two major issues are still a challenge to obtain versatile and effective NK-based therapies: the way to maximize the persistency of powerful NK effectors in the patient, and the way to overcome the multiple escape mechanisms that keep away or suppress NK cells at the tumor site. In this regard, targeting the hypoxia-inducible factors (HIFs), which is important for both tumor progression and immune suppression, may be an opportunity. Especially, in the context of the ongoing studies focused on more effective NK-based therapeutic products.	[Vitale, Massimo; Parodi, Monica] IRCCS Osped Polidin San Martino Genova, UO Immunol, I-16132 Genoa, Italy		Vitale, M (通讯作者)，IRCCS Osped Polidin San Martino Genova, UO Immunol, I-16132 Genoa, Italy.	massimo.vitale@hsanmartino.it; monica.parodi@hsanmartino.it	Parodi, Monica/J-3463-2018; Vitale, Massimo/G-5135-2016	Parodi, Monica/0000-0001-9606-2190; Vitale, Massimo/0000-0001-5372-7885	Fondazione AIRCFondazione AIRC per la ricerca sul cancro [25023]; Italian Ministry of HealthMinistry of Health, Italy [RF-2018-12366714]; Italian Ministry of Health (Ricerca Corrente)Ministry of Health, Italy; Italian Ministry of Health (5 10002016)	This work was supported by: Fondazione AIRC, grant number IG 2020 id. 25023 (M.V.); Italian Ministry of Health (project RF-2018-12366714 (M.V.); Italian Ministry of Health (Ricerca Corrente); Italian Ministry of Health (5 10002016).	Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Baginska J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00490; Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110; Balsamo M, 2013, EUR J IMMUNOL, V43, P2756, DOI 10.1002/eji.201343448; Berchem G, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1062968; Berrien-Elliott MM, 2020, CANCER DISCOV, V10, P1854, DOI 10.1158/2159-8290.CD-20-0312; Beziat V, 2013, BLOOD, V121, P2678, DOI 10.1182/blood-2012-10-459545; Blengio F, 2013, IMMUNOBIOLOGY, V218, P76, DOI 10.1016/j.imbio.2012.02.002; Boudreau JE, 2016, IMMUNITY, V45, P280, DOI 10.1016/j.immuni.2016.07.005; Chambers AM, 2019, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00060; Chiu DKC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00530-7; Choi C, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02377-8; Cichocki F, 2016, LEUKEMIA, V30, P456, DOI 10.1038/leu.2015.260; Cichocki F, 2018, J EXP MED, V215, P2379, DOI 10.1084/jem.20172168; Clambey ET, 2012, P NATL ACAD SCI USA, V109, pE2784, DOI 10.1073/pnas.1202366109; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; da Silva IP, 2014, CANCER IMMUNOL RES, V2, P410, DOI 10.1158/2326-6066.CIR-13-0171; Demaria O, 2021, EUR J IMMUNOL, V51, P1934, DOI 10.1002/eji.202048953; Elia AR, 2008, J LEUKOCYTE BIOL, V84, P1472, DOI 10.1189/jlb.0208082; Elliott JM, 2010, J EXP MED, V207, P2073, DOI 10.1084/jem.20100986; Fallah J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0752-z; Freud AG, 2017, IMMUNITY, V47, P820, DOI 10.1016/j.immuni.2017.10.008; Gleason MK, 2012, MOL CANCER THER, V11, P2674, DOI 10.1158/1535-7163.MCT-12-0692; Guma M, 2004, BLOOD, V104, P3664, DOI 10.1182/blood-2004-05-2058; Joncker NT, 2010, J EXP MED, V207, P2065, DOI 10.1084/jem.20100570; Karagiannis P, 2021, MOL CELLS, V44, P541, DOI 10.14348/molcells.2021.0078; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Lequeux A, 2021, ONCOGENE, V40, P4725, DOI 10.1038/s41388-021-01846-x; Li Y, 2018, CELL STEM CELL, V23, P181, DOI 10.1016/j.stem.2018.06.002; Mas-Bargues C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051195; Nakagawa Y, 2015, IMMUNOL LETT, V167, P72, DOI 10.1016/j.imlet.2015.07.003; Ni J, 2020, IMMUNITY, V52, P1075, DOI 10.1016/j.immuni.2020.05.001; Noman MZ, 2015, AM J PHYSIOL-CELL PH, V309, pC569, DOI 10.1152/ajpcell.00207.2015; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Parodi M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02358; Pende D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01179; Pesce S, 2017, J ALLERGY CLIN IMMUN, V139, P335, DOI 10.1016/j.jaci.2016.04.025; Pfeifer C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03020; Prager I, 2019, J LEUKOCYTE BIOL, V105, P1319, DOI 10.1002/JLB.MR0718-269R; Romee R, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2341; Sanchez-Martinez D, 2014, INT J BIOCHEM CELL B, V49, P42, DOI 10.1016/j.biocel.2014.01.003; Sarvaria A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00329; Schlums H, 2015, IMMUNITY, V42, P443, DOI 10.1016/j.immuni.2015.02.008; Scoville SD, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00360; Shiroishi M, 2003, P NATL ACAD SCI USA, V100, P8856, DOI 10.1073/pnas.1431057100; Shohet RV, 2007, J MOL MED, V85, P1309, DOI 10.1007/s00109-007-0279-x; Sivori S, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101702; Sun JC, 2010, J EXP MED, V207, P2049, DOI 10.1084/jem.20101748; Terren I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02278; Velasquez SY, 2016, J BIOL CHEM, V291, P12960, DOI 10.1074/jbc.M116.721753; Vitale M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01415; Vitale M, 2014, EUR J IMMUNOL, V44, P1582, DOI 10.1002/eji.201344272; Wrangle JM, 2018, LANCET ONCOL, V19, P694, DOI 10.1016/S1470-2045(18)30148-7; Yaghi L, 2016, ONCOTARGET, V7, P63690, DOI 10.18632/oncotarget.11628; Yamada N, 2012, INT J ONCOL, V41, P2005, DOI 10.3892/ijo.2012.1630; Zhang Q, 2018, NAT IMMUNOL, V19, P723, DOI 10.1038/s41590-018-0132-0; Zheng XH, 2019, NAT IMMUNOL, V20, P1656, DOI 10.1038/s41590-019-0511-1	57	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1144	10.3390/vaccines9101144			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WU8QS	34696251	Green Published			2022-04-29	WOS:000716804700001
J	Xu, L; Li, N; Zhang, L; Ma, R; Fang, T; Liu, ZK; Zhan, SY				Xu, Lu; Li, Ning; Zhang, Liang; Ma, Rui; Fang, Ting; Liu, Zhike; Zhan, Siyan			Febrile Seizures and Measles-Containing Vaccines in China: A Self-Controlled Case Series Study	VACCINES			English	Article						febrile seizures; measles-mumps-rubella vaccine; self-controlled case series study; relative incidence	EVENT FOLLOWING IMMUNIZATION; RUBELLA-VARICELLA VACCINE; MUMPS-RUBELLA; DATA-COLLECTION; CASE-DEFINITION; RISK; CONTRAINDICATIONS; GUIDELINES; CHILDREN	Little is known about the risk of febrile seizures (FS) after vaccination with measles-containing vaccines (MCVs) in middle- and low-income countries. This self-controlled case series study aimed to evaluate the risk of FSs in Chinese children using data from the Ningbo Regional Health Information Platform. The observation period was 0-12 and 13-24 months of age for the MR and MMR vaccines, respectively. The relative incidences (RIs) within 0-6 days, 7-13 days, 14-27 days, and 28-42 days after vaccination with MCVs were estimated. The remaining observation period was the control period. The RIs within 0-6 days, 7-13 days, 14-27 days, and 28-42 days after MR vaccination were 1.11 [95% confidence interval (CI) 0.33 to 3.70], 0.80 (95% CI 0.23 to 2.86), 1.67 (95% CI 0.81 to 3.42), and 1.02 (95% CI 0.49 to 2.14), respectively. The corresponding RIs after MMR vaccination were 0.99 (95% CI 0.56 to 1.75), 1.17 (95% CI 0.68 to 2.01), 0.87 (95% CI 0.54 to 1.39), and 0.85 (95% CI 0.54 to 1.34), respectively. This study suggests that China's vaccination schedule for MCVs, as suggested by the World Health Organization (WHO) for countries with a high risk of measles mortality and ongoing transmission, does not increase the risk of FSs.</p>	[Xu, Lu; Liu, Zhike; Zhan, Siyan] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China; [Li, Ning; Zhang, Liang; Ma, Rui; Fang, Ting] Ningbo Municipal Ctr Dis Control & Prevent, Ningbo 315010, Zhejiang, Peoples R China; [Zhan, Siyan] Peking Univ Third Hosp, Res Ctr Clin Epidemiol, Beijing 100191, Peoples R China; [Zhan, Siyan] Peking Univ, Inst Artificial Intelligence, Ctr Intelligent Publ Hlth, Beijing 100191, Peoples R China		Zhan, SY (通讯作者)，Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China.; Zhan, SY (通讯作者)，Peking Univ Third Hosp, Res Ctr Clin Epidemiol, Beijing 100191, Peoples R China.; Zhan, SY (通讯作者)，Peking Univ, Inst Artificial Intelligence, Ctr Intelligent Publ Hlth, Beijing 100191, Peoples R China.	luxu@bjmu.edu.cn; lin@nbcdc.org.cn; zhangl@nbcdc.org.cn; mar@nbcdc.org.cn; fangt@nbcdc.org.cn; zkliu@bjmu.edu.cn; siyan-zhan@bjmu.edu.cn		Zhan, Siyan/0000-0001-7252-5349	Advanced Project of the Beijing Natural Science Foundation [BMU2019GJJXK003]; Innovation Fund for Outstanding Doctoral Candidates of Peking University Health Science Center (China)	This research was funded by the Advanced Project of the Beijing Natural Science Foundation (grant number, BMU2019GJJXK003) and the Innovation Fund for Outstanding Doctoral Candidates of Peking University Health Science Center (China) (grant number, not applicable). The funders had no role in the study design, the collection, analysis, and interpretation of data, the writing of the report, or the decision to submit the manuscript for publication.	Barlow WE, 2001, NEW ENGL J MED, V345, P656, DOI 10.1056/NEJMoa003077; Bonhoeffer J, 2004, VACCINE, V22, P557, DOI 10.1016/j.vaccine.2003.09.008; CHEN RT, 1991, VACCINE, V9, P297, DOI 10.1016/0264-410X(91)90053-9; Davis RL, 1997, PEDIATRICS, V100, P767, DOI 10.1542/peds.100.5.767; Deng L, 2020, AUST J GEN PRACT, V49, P644, DOI 10.31128/AJGP-02-20-5236; Di Pietrantonj C, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004407.pub4; Farrington CP, 2009, BIOSTATISTICS, V10, P3, DOI 10.1093/biostatistics/kxn013; Feenstra B, 2014, NAT GENET, V46, P1274, DOI 10.1038/ng.3129; GALAZKA AM, 1984, B WORLD HEALTH ORGAN, V62, P357; Hawken S, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0225-0; Kariuki Symon M, 2017, Epilepsia Open, V2, P8, DOI 10.1002/epi4.12035; Leung A.K., 2018, DRUGS CONTEXT, V7, DOI [10.7573/dic.212536, DOI 10.7573/DIC.212536]; Liu SJ, 2017, HUM VACC IMMUNOTHER, V13, P1539, DOI 10.1080/21645515.2017.1304868; Liu ZK, 2020, J MED INTERNET RES, V22, DOI 10.2196/17446; Ma C, 2018, HUM VACC IMMUNOTHER, V14, P1392, DOI 10.1080/21645515.2018.1428508; Macartney K, 2017, JAMA PEDIATR, V171, P992, DOI 10.1001/jamapediatrics.2017.1965; MacDonald SE, 2014, CAN MED ASSOC J, V186, P824, DOI 10.1503/cmaj.140078; Marcy SM, 2004, VACCINE, V22, P551, DOI 10.1016/j.vaccine.2003.09.007; McClure DL, 2019, VACCINE, V37, P76, DOI 10.1016/j.vaccine.2018.11.038; Miller E, 2007, AM J EPIDEMIOL, V165, P704, DOI 10.1093/aje/kwk045; Patel N, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4240; Perez SC, 2018, EPIDEMIOL INFECT, V146, P1584, DOI 10.1017/S0950268818001474; Principi N, 2013, EXPERT REV VACCINES, V12, P885, DOI 10.1586/14760584.2013.814781; Sawyer MH, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0976; Sridhar S, 2014, VACCINE, V32, P6870, DOI 10.1016/j.vaccine.2014.10.063; Vestergaard M, 2004, JAMA-J AM MED ASSOC, V292, P351, DOI 10.1001/jama.292.3.351; Ward KN, 2007, PEDIATRICS, V120, P314, DOI 10.1542/peds.2006-3743; Whitaker HJ, 2006, STAT MED, V25, P1768, DOI 10.1002/sim.2302; Zheng YM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3422-0	29	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1073	10.3390/vaccines9101073			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN6PP	34696181	Green Published			2022-04-29	WOS:000711889500001
J	Zhao, YM; Liu, L; Sun, J; Yan, W; Yuan, K; Zheng, YB; Lu, ZA; Liu, L; Ni, SY; Su, SZ; Zhu, XM; Zeng, N; Gong, YM; Wu, P; Ran, MS; Leng, Y; Shi, J; Shi, L; Lu, L; Bao, YP				Zhao, Yi-Miao; Liu, Lin; Sun, Jie; Yan, Wei; Yuan, Kai; Zheng, Yong-Bo; Lu, Zheng-An; Liu, Lin; Ni, Shu-Yu; Su, Si-Zhen; Zhu, Xi-Mei; Zeng, Na; Gong, Yi-Miao; Wu, Ping; Ran, Mao-Sheng; Leng, Yue; Shi, Jie; Shi, Le; Lu, Lin; Bao, Yan-Ping			Public Willingness and Determinants of COVID-19 Vaccination at the Initial Stage of Mass Vaccination in China	VACCINES			English	Article						COVID-19 vaccine; vaccine hesitancy; vaccine resistance; determinants	HESITANCY; VACCINES	The present study assessed the willingness of the general population to receive COVID-19 vaccines and identified factors that influence vaccine hesitancy and resistance. A national online survey was conducted from 29 January 2021 to 26 April 2021 in China. Multinomial logistic regression analyses were conducted to identify factors that influence vaccine hesitancy and resistance. Of the 34,041 participants surveyed, 18,810 (55.3%) were willing to get vaccinated, 13,736 (40.3%) were hesitant, and 1495 (4.4%) were resistant. Rates of vaccine acceptance increased over time, with geographical discrepancies in vaccine hesitancy and resistance between provinces in China. Vaccine safety was the greatest concern expressed by most participants (24,461 [71.9%]), and the major reason for participants' refusing vaccination (974 [65.2%]). Government agencies (23,131 [68.0%]) and social media (20,967 [61.6%]) were the main sources of COVID-19 vaccine information. Compared with vaccination acceptance, female, young and middle-aged, high income, and perceived low-risk of infection were associated with vaccine hesitancy. Histories of allergic reactions to other vaccines and depression symptoms were related to vaccine resistance. Common factors that influenced vaccine hesitancy and resistance were residing in cities and perceiving less protection with vaccines than with other protective measures. The results indicate that the rate of vaccine resistance is relatively low, but vaccine hesitancy is common. Individuals who are female, young and middle-aged, with a high income, and residing in cities are more likely to be hesitant for vaccination and should be the target populations for vaccination campaigns. Specific vaccine messaging from the government and social media could alleviate public concerns about vaccine safety and efficacy.	[Zhao, Yi-Miao; Liu, Lin; Ni, Shu-Yu; Zeng, Na; Wu, Ping; Shi, Jie; Lu, Lin; Bao, Yan-Ping] Peking Univ, Natl Inst Drug Dependence, Beijing 100191, Peoples R China; [Zhao, Yi-Miao; Liu, Lin; Ni, Shu-Yu; Zeng, Na; Wu, Ping; Shi, Jie; Lu, Lin; Bao, Yan-Ping] Peking Univ, Beijing Key Lab Drug Dependence, Beijing 100191, Peoples R China; [Zhao, Yi-Miao; Liu, Lin; Ni, Shu-Yu; Zeng, Na; Bao, Yan-Ping] Peking Univ, Sch Publ Hlth, Beijing 100191, Peoples R China; [Liu, Lin; Yan, Wei; Yuan, Kai; Zheng, Yong-Bo; Lu, Zheng-An; Su, Si-Zhen; Zhu, Xi-Mei; Gong, Yi-Miao; Shi, Le; Lu, Lin] Peking Univ, Natl Clin Res Ctr Mental Disorders, Peking Univ Hosp 6, Inst Mental Hlth,NHC Key Lab Mental Hlth, Beijing 100191, Peoples R China; [Sun, Jie] Peking Univ Third Hosp, Pain Med Ctr, Beijing 100191, Peoples R China; [Zheng, Yong-Bo; Lu, Lin] Peking Univ, Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China; [Zheng, Yong-Bo; Lu, Lin] Peking Univ, PKU IDG McGovern Inst Brain Res, Beijing 100871, Peoples R China; [Zeng, Na] Capital Med Univ, Beijing Friendship Hosp, Beijing 100050, Peoples R China; [Ran, Mao-Sheng] Univ Hong Kong, Dept Social Work & Social Adm, Hong Kong, Peoples R China; [Leng, Yue] Univ Calif San Francisco, Dept Psychiat & Behav Sci, San Francisco, CA 94121 USA		Lu, L; Bao, YP (通讯作者)，Peking Univ, Natl Inst Drug Dependence, Beijing 100191, Peoples R China.; Lu, L; Bao, YP (通讯作者)，Peking Univ, Beijing Key Lab Drug Dependence, Beijing 100191, Peoples R China.; Bao, YP (通讯作者)，Peking Univ, Sch Publ Hlth, Beijing 100191, Peoples R China.; Shi, L; Lu, L (通讯作者)，Peking Univ, Natl Clin Res Ctr Mental Disorders, Peking Univ Hosp 6, Inst Mental Hlth,NHC Key Lab Mental Hlth, Beijing 100191, Peoples R China.; Lu, L (通讯作者)，Peking Univ, Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China.; Lu, L (通讯作者)，Peking Univ, PKU IDG McGovern Inst Brain Res, Beijing 100871, Peoples R China.	2011210099@stu.pku.edu.cn; linliu@bjmu.edu.cn; sunjie0615@pku.edu.cn; weiyan@bjmu.edu.cn; yuankai@pku.edu.cn; yongbozheng@bjmu.edu.cn; 1911210616@bjmu.edu.cn; 1510306117@pku.edu.cn; nishuyu@pku.edu.cn; sizhensu@bjmu.edu.cn; ximeizhu@bjmu.edu.cn; zengna2017@163.com; 1801111460@pku.edu.cn; wuping@bjmu.edu.cn; msran@hku.hk; Yue.Leng@ucsf.edu; shijie@bjmu.edu.cn; leshi@bjmu.edu.cn; linlu@bjmu.edu.cn; baoyp@bjmu.edu.cn	Zheng, Yongbo/AFR-0439-2022; /I-7957-2013	Sun, Jie/0000-0002-0702-9880; /0000-0001-7343-3729	National Key Research and Development Program of China [2021YFC0863700, 2019YFA0706200]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81761128036, 82171514, 81821092, 31900805]; Postdoctoral Fellowship of Peking-Tsinghua Center for Life Sciences	FundingThis study is supported by grants from the National Key Research and Development Program of China (No. 2021YFC0863700 and 2019YFA0706200), the National Natural Science Foundation of China (No. 81761128036, 82171514, 81821092 and 31900805), and the Postdoctoral Fellowship of Peking-Tsinghua Center for Life Sciences.	Arce JSS, 2021, NAT MED, V27, P1385, DOI 10.1038/s41591-021-01454-y; Bao YP, 2020, LANCET, V395, pE37, DOI 10.1016/S0140-6736(20)30309-3; Bono SA, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050515; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Grasselli G, 2020, JAMA INTERN MED, V180, P1345, DOI 10.1001/jamainternmed.2020.3539; Habibovic M., 2021, HEART MIND, V5, P33, DOI [10.4103/hm.hm_15_21, DOI 10.4103/HM.HM_15_21]; Kalok A, 2020, VACCINE, V38, P2183, DOI 10.1016/j.vaccine.2020.01.043; Khan MS, 2021, LANCET, V397, P1863, DOI 10.1016/S0140-6736(21)00938-7; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Li H., 2020, J CELL MOL MED, V24, P6558, DOI [10.1111/jcmm.15364, DOI 10.1111/jcmm.15364]; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; [曲姗 Qu Shan], 2015, [中国心理卫生杂志, Chinese Mental Health Journal], V29, P939; Ratzan S, 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMp2106137; Rhodes A, 2021, LANCET INFECT DIS, V21, pE110, DOI 10.1016/S1473-3099(20)30724-6; Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Shi L, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.14053; Sun X Y, 2017, Zhonghua Liu Xing Bing Xue Za Zhi, V38, P110, DOI 10.3760/cma.j.issn.0254-6450.2017.01.021; Urrunaga-Pastor D, 2021, TRAVEL MED INFECT DI, V41, DOI 10.1016/j.tmaid.2021.102059; Verger P, 2021, LANCET PUBLIC HEALTH, V6, pE195, DOI 10.1016/S2468-2667(21)00029-3; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang YH, 2021, MOL PSYCHIATR, V26, P4813, DOI 10.1038/s41380-021-01019-y; Wei FF, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-18; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8; Zhang HJ., ZHONGGUO YI MIAO HE, P1, DOI [10.19914/j.CJVI.2021030, DOI 10.19914/J.CJVI.2021030]; Zhu H, 2010, OSTEOPOROSIS INT, V21, P765, DOI 10.1007/s00198-009-1010-2	33	6	6	13	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1172	10.3390/vaccines9101172			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR5PB	34696281	Green Published, gold			2022-04-29	WOS:000714550100001
J	Cavanna, L; Citterio, C; Toscani, I				Cavanna, Luigi; Citterio, Chiara; Toscani, Ilaria			COVID-19 Vaccines in Cancer Patients. Seropositivity and Safety. Systematic Review and Meta-Analysis	VACCINES			English	Review						cancer; hematologic malignances; COVID-19; vaccines; antibodies	VACCINATION	Patients with cancer are among the most vulnerable groups of the COVID-19 pandemic, whereas vaccinations can represent a cornerstone in overcoming the pandemic itself. However, cancer patients were excluded from clinical trials for COVID-19 vaccinations, and thus the data on the immunogenicity and safety of COVID-19 vaccines in cancer patients are limited. In this systematic review, we assessed the seroconversion rate and the safety of COVID-19 vaccinations in cancer patients. We searched a bibliographic database up until 31 July 2021. Utilizing inclusion criteria, six studies were selected and analyzed for this meta-analysis. This included 621 cancer patients and 256 controls. Results show that patients with solid tumors show adequate antibody responses (>90%), though the antibody titers were significantly lower than those of healthy controls. Similarly, a significantly lower rate of seroconversion was registered in patients with hematologic malignances. The vaccines showed a good safety profile; no grade 3-4 adverse events were registered. This review demonstrates generally high immunogenicity from COVID-19 vaccines in patients with cancer, with better results for solid tumors than hematological malignances, and with a good safety profile.	[Cavanna, Luigi; Citterio, Chiara; Toscani, Ilaria] Piacenza Gen Hosp, Dept Hematol & Oncol, Via Taverna 49, I-29121 Piacenza, Italy		Cavanna, L (通讯作者)，Piacenza Gen Hosp, Dept Hematol & Oncol, Via Taverna 49, I-29121 Piacenza, Italy.	luigicavanna53@gmail.com		Citterio, Chiara/0000-0002-2119-775X; CAVANNA, LUIGI/0000-0002-0303-3778			AIOM CIPOMO COMU, DOC AIOM CIPOMP COMU; [Anonymous], 2021, LANCET ONCOL, V22, P411, DOI 10.1016/S1470-2045(21)00148-0; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bitar N., CARING CANC PATIENTS; Cavanna L, 2021, FUTUR SCI OA, V7, DOI 10.2144/fsoa-2020-0157; Chamilos G, 2021, CLIN INFECT DIS, V72, P351, DOI 10.1093/cid/ciaa1079; Desai A, 2021, NAT REV CLIN ONCOL, V18, P313, DOI 10.1038/s41571-021-00487-z; Garassino MC, 2021, ANN ONCOL, V32, P579, DOI 10.1016/j.annonc.2021.01.068; Herishanu Y, 2021, BLOOD, V137, P3165, DOI 10.1182/blood.2021011568; Iacono D, 2021, J GERIATR ONCOL, V12, P1253, DOI 10.1016/j.jgo.2021.06.002; Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6; Massarweh A, 2021, JAMA ONCOL, V7, P1133, DOI 10.1001/jamaoncol.2021.2155; Monin L, 2021, LANCET ONCOL, V22, P765, DOI 10.1016/S1470-2045(21)00213-8; National Comprehensive Cancer Network, PREL REC NCCN COVID; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Ong M.B.H., CANC GROUPS URGE CDC; Pimpinelli F, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01090-6; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ribas A, 2021, CANCER DISCOV, V11, P233, DOI 10.1158/2159-8290.CD-20-1817; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.g7647, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1016/j.ijsu.2010.02.007]; Shroff Rachna T, 2021, medRxiv, DOI 10.1101/2021.05.13.21257129; Sociedad Espanola de Oncologia Medica (SEOM), POS REC SEOM REL CON; Stroppa EM, 2020, FUTURE ONCOL, V16, P1425, DOI 10.2217/fon-2020-0369; Thakkar A, 2021, CANCER CELL, V39, P1081, DOI 10.1016/j.ccell.2021.06.002; Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560; US Centers for Disease Control and Prevention, INT CLIN CONS US COV	27	6	6	8	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1048	10.3390/vaccines9091048			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UW3YD	34579285	Green Published, gold			2022-04-29	WOS:000700094700001
J	Sato, R; Takasaki, Y				Sato, Ryoko; Takasaki, Yoshito			Vaccine Hesitancy and Refusal: Behavioral Evidence from Rural Northern Nigeria	VACCINES			English	Article						vaccine hesitancy; vaccine refusal; field experiment; northern Nigeria	PUBLISHED LITERATURE	It is widely believed that vaccine hesitancy is prevalent in African countries, although this belief is without rigorous evidence. Our field experiment in rural northern Nigeria behaviorally measured the prevalence of vaccine hesitancy-the non-uptake of vaccines despite their availability due to non-monetary factors directly associated with vaccination. We randomly assigned two tasks to women: answering a short survey at their house vs. additionally receiving a free tetanus vaccine by submitting a voucher. The differences in their completion rates captured vaccine hesitancy, showing the rate to be about 13%. Our study reveals that absolute refusers with negative willingness to pay (WTP) for vaccines, who are likely to have strong misperceptions or a distrust of vaccines, account for about half of vaccine hesitaters, while floating refusers with zero or weakly positive WTP, who are likely to be indifferent about vaccines, account for the other half. A simple intervention, such as a door-to-door vaccination campaign, is likely to be effective for floating refusers, while interventions for absolute refusers need to effectively change their misperceptions or distrust of vaccines.	[Sato, Ryoko] Harvard TH Chan Sch Publ Hlth, Ctr Hlth Decis Sci, 90 Smith St,332-1, Boston, MA 02120 USA; [Takasaki, Yoshito] Univ Tokyo, Grad Sch Econ, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan		Sato, R (通讯作者)，Harvard TH Chan Sch Publ Hlth, Ctr Hlth Decis Sci, 90 Smith St,332-1, Boston, MA 02120 USA.	rsato@hsph.harvard.edu; takasaki@e.u-tokyo.ac.jp		Takasaki, Yoshito/0000-0002-4324-4668	Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [25257106]	This project was supported with research grants from the Japan Society for the Promotion of Science (25257106).	[Anonymous], 2019, LANCET CHILD ADOLESC, V3, P281, DOI 10.1016/S2352-4642(19)30092-6; [Anonymous], 2013, Wkly Epidemiol Rec, V88, P477; Blattman C, 2014, Q J ECON, V129, P697, DOI 10.1093/qje/qjt057; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P408; Drexler A, 2014, AM ECON J-APPL ECON, V6, P1, DOI 10.1257/app.6.2.1; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Ehreth J, 2003, VACCINE, V21, P596, DOI 10.1016/S0264-410X(02)00623-0; Feldman-Savelsberg P, 2000, MED ANTHROPOL Q, V14, P159, DOI 10.1525/maq.2000.14.2.159; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Jegede AS, 2007, PLOS MED, V4, P417, DOI 10.1371/journal.pmed.0040073; Jheeta M, 2008, B WORLD HEALTH ORGAN, V86, P419, DOI 10.2471/BLT.07.047159; Karlan D, 2011, REV ECON STAT, V93, P510, DOI 10.1162/REST_a_00074; Kaufmann JR, 2009, HEALTH AFFAIR, V28, P1091, DOI 10.1377/hlthaff.28.4.1091; Kurosky SK, 2016, VACCINE, V34, P387, DOI 10.1016/j.vaccine.2015.11.011; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Orimadegun AE, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00024; Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096; Sato R, 2019, WORLD BANK ECON REV, V33, P622, DOI 10.1093/wber/lhx025; Smith TC, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx146; Steele F, 1996, J ROY STAT SOC A STA, V159, P289, DOI 10.2307/2983175; Thysen SM, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1037; UNICEF, 2001, COMB ANT RUM LESS LE; UNICEF, 2010, MAT NEON TET EL IN; WHO, 2017, IMM COV, pN378; WHO, 2017, WKLY EPIDEMIOL REC, V92, P53	27	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1023	10.3390/vaccines9091023			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UW4XY	34579260	Green Published			2022-04-29	WOS:000700161900001
J	Alshahrani, NZ; Alshahrani, SM; Farag, S; Rashid, H				Alshahrani, Najim Z.; Alshahrani, Sultan M.; Farag, Shehata; Rashid, Harunor			Domestic Saudi Arabian Travellers' Understanding about COVID-19 and Its Vaccination	VACCINES			English	Article						airlines; COVID-19; preventive measures; travellers; vaccination; vaccine hesitancy	RESTRICTIONS; PREDICTORS; PASSPORTS; IMMUNITY	Background: There is a lack of data on Saudi domestic air travellers' understanding regarding COVID-19 and their attitude towards the COVID-19 vaccination. Objectives: This study aimed to assess Saudi domestic air travellers' understanding regarding COVID-19 and attitude towards mandating the COVID-19 vaccination for travellers. Methods: A survey using a self-administered, structured, and closed-ended questionnaire was conducted among domestic air travellers in Saudi Arabia. Participants' socio-demographic information, travel history, health status, and attitudes and willingness to accept the COVID-19 vaccination were collected and analysed. Results: Of the 2236 respondents who participated in the survey, 542 (24.25%) had a history of COVID-19, 803 (35.9%) were exposed to a COVID-19 case, 1425 (63.7%) were concerned about catching COVID-19 during air travel, 796 (35.6%) thought the COVID-19 vaccination should be obligatory for travellers, 1105 (49.4%) thought it should be optional, and 335 (15.0%) thought the vaccination was unnecessary. Being of the male gender (adjusted odds ratio [aOR] 1.41, 95% confidence interval [95% CI] 1.14-1.69), being concerned about contracting COVID-19 (aOR 1.34, 95% CI 1.12-2.10) and frequent travelling (aOR 1.40, 95% CI 1.10-3.40) were predictors of vaccination uptake. Conclusion: This study demonstrates that although domestic Saudi travellers were concerned about COVID-19 infection, vaccine hesitancy was prevalent among them.	[Alshahrani, Najim Z.] Univ Jeddah, Dept Family & Community Med, Fac Med, Jeddah 21589, Saudi Arabia; [Alshahrani, Sultan M.] King Khalid Univ, Coll Pharm, Abha 61421, Saudi Arabia; [Farag, Shehata] King Khalid Univ, Dept Family & Community Med, Abha 62529, Saudi Arabia; [Farag, Shehata] Alexandria Univ, High Inst Publ Hlth, Biostat Dept, Alexandria 21526, Egypt; [Rashid, Harunor] Natl Ctr Immunisat Res & Surveillance NCIRS, Westmead, NSW 2145, Australia; [Rashid, Harunor] Westmead Clin Sch, Childrens Hosp, Discipline Child & Adolescent Hlth, Westmead, NSW 2145, Australia; [Rashid, Harunor] Univ Sydney, Sch Biol Sci, Marie Bashir Inst Infect Dis & Biosecur, Westmead, NSW 2145, Australia; [Rashid, Harunor] Univ Sydney, Sydney Med Sch, Westmead, NSW 2145, Australia		Alshahrani, NZ (通讯作者)，Univ Jeddah, Dept Family & Community Med, Fac Med, Jeddah 21589, Saudi Arabia.	nalshahrani@uj.edu.sa; shahrani@kku.edu.sa; shehatafarag@yahoo.com; harunor.rashid@health.nsw.gov.au	Alshahrani, Najim Z./AAS-2783-2021	Alshahrani, Najim Z./0000-0002-2163-004X; Rashid, Harunor/0000-0003-2286-5139			Al-Hanawi MK, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00217; Al-Hanawi MK, 2020, RISK MANAG HEALTHC P, V13, P733, DOI 10.2147/RMHP.S264037; Alfageeh EI, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030226; Alobaidi S, 2021, J MULTIDISCIP HEALTH, V14, P1119, DOI 10.2147/JMDH.S306654; Alshahrani NZ, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taaa205; Baghdadi LR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050465; Bielecki M, 2021, TRAVEL MED INFECT DI, V39, DOI 10.1016/j.tmaid.2020.101915; Bish A, 2010, BRIT J HEALTH PSYCH, V15, P797, DOI 10.1348/135910710X485826; Callaghan T, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2020.113638; Chadeau-Hyam M, 2020, INT J EPIDEMIOL, V49, P1454, DOI 10.1093/ije/dyaa134; Chiodini J, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101824; Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397; Devi S, 2020, LANCET, V395, P1331, DOI 10.1016/S0140-6736(20)30967-3; Eldin C, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101643; Freedman DO, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa178; Glaesser D, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax007; Gossling S, 2021, J SUSTAIN TOUR, V29, P1, DOI 10.1080/09669582.2020.1758708; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lytras T, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa054; Marcus L.J., 2020, ASSESSMENT RISKS SAR; Memish ZA, 2021, TRAVEL MED INFECT DI, V42, DOI 10.1016/j.tmaid.2021.102049; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Pavli A, 2020, TRAVEL MED INFECT DI, V38, DOI 10.1016/j.tmaid.2020.101882; Phelan AL, 2020, LANCET, V395, P1595, DOI 10.1016/S0140-6736(20)31034-5; Radic A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18063104; Rashid H, 2012, CURR OPIN INFECT DIS, V25, P243, DOI 10.1097/QCO.0b013e328352f727; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Reiter PL, 2013, AM J PUBLIC HEALTH, V103, P1419, DOI 10.2105/AJPH.2012.301189; Reiter PL, 2011, HUM VACCINES, V7, P67, DOI 10.4161/hv.7.1.13500; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Shaban RZ, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2019.101528; Shaban RZ, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2019.07.009; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Suau-Sanchez P, 2020, J TRANSP GEOGR, V86, DOI 10.1016/j.jtrangeo.2020.102749; Verger P, 2020, EXPERT REV VACCINES, V19, P991, DOI 10.1080/14760584.2020.1825945; WHO, 2020, PUBL HLTH CONS WHIL; Yezli S, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101692; Zhou M, 2020, FRONT MED-PRC, V14, P126, DOI 10.1007/s11684-020-0767-8	39	0	0	0	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							895	10.3390/vaccines9080895			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3RA	34452020	Green Published, gold			2022-04-29	WOS:000689851400001
J	Ash, MK; Al-Harthi, L; Schneider, JR				Ash, Michelle K.; Al-Harthi, Lena; Schneider, Jeffrey R.			HIV in the Brain: Identifying Viral Reservoirs and Addressing the Challenges of an HIV Cure	VACCINES			English	Review						HIV; CNS; reservoir; cure; astrocytes; microglia; inflammation	HUMAN-IMMUNODEFICIENCY-VIRUS; LATENCY REVERSAL AGENTS; CD4(+) T-CELLS; HUMAN ASTROCYTES; IN-VIVO; INFECTION; EXPRESSION; BARRIER; SYSTEM; NEUROPATHOGENESIS	Advances in antiretroviral therapy have prolonged the life of people living with HIV and diminished the level of virus in these individuals. Yet, HIV quickly rebounds after disruption and/or cessation of treatment due to significant cellular and anatomical reservoirs for HIV, which underscores the challenge for HIV cure strategies. The central nervous system (CNS), in particular, is seeded with HIV within 1-2 weeks of infection and is a reservoir for HIV. In this review, we address the paradigm of HIV reservoirs in the CNS and the relevant cell types, including astrocytes and microglia, that have been shown to harbor viral infection even with antiretroviral treatment. In particular, we focus on developmental aspects of astrocytes and microglia that lead to their susceptibility to infection, and how HIV infection propagates among these cells. We also address challenges of measuring the HIV latent reservoir, advances in viral detection assays, and how curative strategies have evolved in regard to the CNS reservoir. Current curative strategies still require optimization to reduce or eliminate the HIV CNS reservoir, and may also contribute to levels of neuroinflammation that lead to cognitive decline. With this in mind, the latent HIV reservoir in the brain should remain a prominent focus when assessing treatment options and overall viral burden in the clinic, especially in the context of HIV-associated neurocognitive disorders (HAND).	[Ash, Michelle K.; Al-Harthi, Lena; Schneider, Jeffrey R.] Rush Univ, Med Ctr, Dept Microbial Pathogens & Immun, Chicago, IL 60612 USA; [Schneider, Jeffrey R.] Rush Univ, Dept Microbial Pathogens & Immun, Jeffrey Schneider, Cohn Res Bldg,1735 W Harrison St, Chicago, IL 60612 USA		Schneider, JR (通讯作者)，Rush Univ, Med Ctr, Dept Microbial Pathogens & Immun, Chicago, IL 60612 USA.; Schneider, JR (通讯作者)，Rush Univ, Dept Microbial Pathogens & Immun, Jeffrey Schneider, Cohn Res Bldg,1735 W Harrison St, Chicago, IL 60612 USA.	michelle_k_ash@rush.edu; lena_al-harthi@rush.edu; jeffrey_schneider@rush.edu		Schneider, Jeffrey/0000-0001-9091-7653; Ash, Michelle/0000-0001-9601-5570	 [K01OD024882-01];  [R21MH125339-01];  [1R01NS108796];  [R01NS060632];  [R01 NIMH100628]	This work was supported by K01OD024882-01 (J.R.S.), R21MH125339-01 (J.R.S.), 1R01NS108796 (L.A.-H.), R01NS060632 (L.A.-H.), and R01 NIMH100628 (L.A.-H.).	Abdullahi AM, 2020, CUREUS, V12, DOI 10.7759/cureus.9674; Al-Harthi L, 2019, J NEUROVIROL, V25, P616, DOI 10.1007/s13365-019-00726-1; Al-Harthi L, 2012, J NEUROIMMUNE PHARM, V7, P725, DOI 10.1007/s11481-012-9412-x; Aljawai Y, 2014, CURR HIV RES, V12, P164, DOI 10.2174/1570162X12666140526122249; Alvarez-Carbonell D, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008249; [Anonymous], 2020, BBC NEWS 0930; Asahchop EL, 2017, RETROVIROLOGY, V14, DOI 10.1186/s12977-017-0370-5; Avalos CR, 2017, MBIO, V8, DOI 10.1128/mBio.01186-17; Bednar MM, 2015, CURR HIV-AIDS REP, V12, P262, DOI 10.1007/s11904-015-0265-9; Bertin J, 2014, VIROLOGY, V454, P128, DOI 10.1016/j.virol.2014.02.007; Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024; Bosman KJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep13811; Brennan TP, 2009, J VIROL, V83, P8470, DOI 10.1128/JVI.02568-08; Castellano P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12758-w; Chauhan A, 2015, MICROB PATHOGENESIS, V78, P1, DOI 10.1016/j.micpath.2014.11.003; Chong PF, 2018, CLIN INFECT DIS, V66, P653, DOI 10.1093/cid/cix860; Chun TW, 2008, J INFECT DIS, V197, P714, DOI 10.1086/527324; Chun TW, 2000, NAT MED, V6, P757, DOI 10.1038/77481; Churchill MJ, 2006, J NEUROVIROL, V12, P146, DOI 10.1080/13550280600748946; Dash PK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10366-y; Eggers C, 2017, J NEUROL, V264, P1715, DOI 10.1007/s00415-017-8503-2; Emsley JG, 2006, NEURON GLIA BIOL, V2, P175, DOI 10.1017/S1740925X06000202; Estes JD, 2017, NAT MED, V23, P1271, DOI 10.1038/nm.4411; Eugenin EA, 2011, J NEUROSCI, V31, P9456, DOI 10.1523/JNEUROSCI.1460-11.2011; Fitting S, 2010, J PROTEOME RES, V9, P1795, DOI 10.1021/pr900926n; Fu X, 2016, BIOSENS BIOELECTRON, V78, P530, DOI 10.1016/j.bios.2015.11.099; Gama L, 2017, AIDS, V31, P5, DOI 10.1097/QAD.0000000000001267; GENDELMAN HE, 1994, J LEUKOCYTE BIOL, V56, P389, DOI 10.1002/jlb.56.3.389; Ginhoux F, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00045; Gray LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090620; Gupta RK, 2019, NATURE, V568, P244, DOI 10.1038/s41586-019-1027-4; Guttenplan KA, 2019, J EXP MED, V216, P71, DOI 10.1084/jem.20180200; GYORKEY F, 1987, J INFECT DIS, V155, P870, DOI 10.1093/infdis/155.5.870; Hellmuth J, 2019, J INFECT DIS, V220, P1885, DOI 10.1093/infdis/jiz030; Henrich TJ, 2014, ANN INTERN MED, V161, P319, DOI 10.7326/M14-1027; Ho YC, 2013, CELL, V155, P540, DOI 10.1016/j.cell.2013.09.020; Hong SZ, 2015, BRAIN BEHAV IMMUN, V45, P1, DOI 10.1016/j.bbi.2014.10.008; Huang ZH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06269-x; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Joseph SB, 2015, J NEUROVIROL, V21, P276, DOI 10.1007/s13365-014-0287-x; Katsumoto A, 2014, J IMMUNOL, V193, P2615, DOI 10.4049/jimmunol.1400716; Kessing CF, 2017, CELL REP, V21, P600, DOI 10.1016/j.celrep.2017.09.080; Kunze C, 2018, GLIA, V66, P413, DOI 10.1002/glia.23254; Lamers SL, 2016, J NEUROVIROL, V22, P275, DOI 10.1007/s13365-015-0399-y; Letendre S, 2008, ARCH NEUROL-CHICAGO, V65, P65, DOI 10.1001/archneurol.2007.31; Li GH, 2020, AIDS, V34, P963, DOI 10.1097/QAD.0000000000002512; Luo XY, 2015, J NEUROVIROL, V21, P66, DOI 10.1007/s13365-014-0304-0; Lutgen V, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008381; Lutgen V, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0691-7; Mendez C, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0451-0; Molofsky AV, 2012, GENE DEV, V26, P891, DOI 10.1101/gad.188326.112; Narasipura SD, 2014, J VIROL, V88, P3031, DOI 10.1128/JVI.03333-13; Prinz M, 2019, CELL, V179, P292, DOI 10.1016/j.cell.2019.08.053; Ragin AB, 2015, ANN CLIN TRANSL NEUR, V2, P12, DOI 10.1002/acn3.136; RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004; Roberts ES, 2004, J NEUROIMMUNOL, V157, P81, DOI 10.1016/j.jneuroim.2004.08.030; Rothenaigner I, 2007, AIDS, V21, P2271, DOI 10.1097/QAD.0b013e3282f12f27; Sandrone S, 2019, NAT MED, V25, P538, DOI 10.1038/s41591-019-0417-3; Schneider M, 2015, AIDS, V29, P1147, DOI 10.1097/QAD.0000000000000691; Spivak AM, 2018, ANNU REV MED, V69, P421, DOI 10.1146/annurev-med-052716-031710; Sturdevant CB, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004720; Thompson KA, 2004, ANN NEUROL, V56, P873, DOI 10.1002/ana.20304; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; Uzasci L, 2013, J NEUROIMMUNE PHARM, V8, P1167, DOI 10.1007/s11481-013-9444-x; Valcour V, 2012, J INFECT DIS, V206, P275, DOI 10.1093/infdis/jis326; van Marle G, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-87; Vansant G, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010084; Vincendeau M, 2010, AIDS, V24, P2432, DOI 10.1097/QAD.0b013e32833e8758; Walker-Sperling VE, 2016, EBIOMEDICINE, V8, P217, DOI 10.1016/j.ebiom.2016.04.019; Walsh JG, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-35; Wang X, 2009, BLOOD, V113, P671, DOI 10.1182/blood-2008-09-175000; Williams DW, 2014, CURR HIV RES, V12, P85, DOI 10.2174/1570162X12666140526114526; Yu CJ, 2017, AGING CELL, V16, P956, DOI 10.1111/acel.12593; Zhang W, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02358; Zhou Y, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-89	75	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							867	10.3390/vaccines9080867			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9CC	34451992	gold, Green Published			2022-04-29	WOS:000690218200001
J	Cardenas-Garcia, S; Caceres, CJ; Jain, A; Geiger, G; Mo, JS; Jasinskas, A; Nakajima, R; Rajao, DS; Davies, DH; Perez, DR				Cardenas-Garcia, Stivalis; Caceres, C. Joaquin; Jain, Aarti; Geiger, Ginger; Mo, Jong-Suk; Jasinskas, Algimantas; Nakajima, Rie; Rajao, Daniela S.; Davies, D. Huw; Perez, Daniel R.			FluB-RAM and FluB-RANS: Genome Rearrangement as Safe and Efficacious Live Attenuated Influenza B Virus Vaccines	VACCINES			English	Article						LAIV; influenza; HA; IgA; IgG; vaccine; genome rearrangement	SEASONAL INFLUENZA; RNA; INFECTION	Influenza B virus (IBV) is considered a major respiratory pathogen responsible for seasonal respiratory disease in humans, particularly severe in children and the elderly. Seasonal influenza vaccination is considered the most efficient strategy to prevent and control IBV infections. Live attenuated influenza virus vaccines (LAIVs) are thought to induce both humoral and cellular immune responses by mimicking a natural infection, but their effectiveness has recently come into question. Thus, the opportunity exists to find alternative approaches to improve overall influenza vaccine effectiveness. Two alternative IBV backbones were developed with rearranged genomes, rearranged M (FluB-RAM) and a rearranged NS (FluB-RANS). Both rearranged viruses showed temperature sensitivity in vitro compared with the WT type B/Bris strain, were genetically stable over multiple passages in embryonated chicken eggs and were attenuated in vivo in mice. In a prime-boost regime in naive mice, both rearranged viruses induced antibodies against HA with hemagglutination inhibition titers considered of protective value. In addition, antibodies against NA and NP were readily detected with potential protective value. Upon lethal IBV challenge, mice previously vaccinated with either FluB-RAM or FluB-RANS were completely protected against clinical disease and mortality. In conclusion, genome re-arrangement renders efficacious LAIV candidates to protect mice against IBV.	[Cardenas-Garcia, Stivalis; Caceres, C. Joaquin; Geiger, Ginger; Mo, Jong-Suk; Rajao, Daniela S.; Perez, Daniel R.] Univ Georgia, Coll Vet Med, Dept Populat Hlth, Athens, GA 30602 USA; [Jain, Aarti; Jasinskas, Algimantas; Nakajima, Rie; Davies, D. Huw] Univ Calif Irvine, Dept Physiol & Biophys, Sch Med, Irvine, CA 92697 USA		Perez, DR (通讯作者)，Univ Georgia, Coll Vet Med, Dept Populat Hlth, Athens, GA 30602 USA.	stivalis@uga.edu; cjoaquincaceres@uga.edu; aartij@hs.uci.edu; imginger@uga.edu; jm45001@uga.edu; ajasinsk@hs.uci.edu; rie3@hs.uci.edu; daniela.rajao@uga.edu; ddavies@uci.edu; dperez1@uga.edu	Caceres, C. Joaquin/AAR-1810-2021; Perez, Daniel/D-5044-2016	Caceres, C. Joaquin/0000-0001-8508-6592; Cardenas Garcia, Stivalis/0000-0002-7613-8642; Geiger, Ginger/0000-0002-4927-8084; Perez, Daniel/0000-0002-6569-5689	Center for Research on Influenza Pathogenesis (CRIP) from the National Institute of Allergy and Infectious Diseases (NIAID) Centers for Influenza Research and Surveillance (CEIRS) [HHSN272201400008C]; NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [1R21AI146448]; Georgia Research Alliance; Caswell S. Eidson endowment funds	This study was supported by a subcontract from the Center for Research on Influenza Pathogenesis (CRIP) to D.R.P. under contract HHSN272201400008C from the National Institute of Allergy and Infectious Diseases (NIAID) Centers for Influenza Research and Surveillance (CEIRS) and grant 1R21AI146448-01 from NIAID to D.R.P. In addition, D.R.P. receives additional support from the Georgia Research Alliance and from the Caswell S. Eidson endowment funds.	Ambrose CS, 2012, HUM VACC IMMUNOTHER, V8, P81, DOI 10.4161/hv.8.1.17623; [Anonymous], 2019, FLUVIEW NATL REGIONA; [Anonymous], 2020, FLUVIEW INFLUENZA HO; [Anonymous], FLUVIEW INFLUENZA AS; Arencibia A, 2018, INFECT GENET EVOL, V58, P110, DOI 10.1016/j.meegid.2017.12.004; Arsenovic-Ranin N, 2019, BIOGERONTOLOGY, V20, P475, DOI 10.1007/s10522-019-09811-8; Beran J, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-2; Betakova T, 1996, J GEN VIROL, V77, P2689, DOI 10.1099/0022-1317-77-11-2689; Bodewes R, 2011, CLIN VACCINE IMMUNOL, V18, P469, DOI 10.1128/CVI.00396-10; BRIEDIS DJ, 1981, VIROLOGY, V112, P417, DOI 10.1016/0042-6822(81)90289-0; Cardenas-Garcia S, 2020, CURR OPIN VIROL, V44, P191, DOI 10.1016/j.coviro.2020.10.005; Chen GL, 2011, P NATL ACAD SCI USA, V108, P1140, DOI 10.1073/pnas.1009908108; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Engler RJM, 2008, ARCH INTERN MED, V168, P2405, DOI 10.1001/archinternmed.2008.513; Fink AL, 2018, P NATL ACAD SCI USA, V115, P12477, DOI 10.1073/pnas.1805268115; Francis T, 1940, SCIENCE, V92, P405, DOI 10.1126/science.92.2392.405; Frey S, 2010, CLIN INFECT DIS, V51, P997, DOI 10.1086/656578; Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1; Hai R, 2008, J VIROL, V82, P10580, DOI 10.1128/JVI.01213-08; Heikkinen T, 2014, CLIN INFECT DIS, V59, P1519, DOI 10.1093/cid/ciu664; HORVATH CM, 1990, EMBO J, V9, P2639, DOI 10.1002/j.1460-2075.1990.tb07446.x; Klein SL, 2012, J LEUKOCYTE BIOL, V92, P67, DOI 10.1189/jlb.0811427; Korem M, 2019, CLIN INFECT DIS, V69, P1049, DOI 10.1093/cid/ciz053; Loconsole D, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/4643260; Mena I, 2016, ELIFE, V5, DOI 10.7554/eLife.16777; Mo J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070800; Moser MJ, 2019, VACCINE, V37, P4533, DOI 10.1016/j.vaccine.2019.06.043; Nakajima R, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00592-18; Nogales A, 2017, METHODS MOL BIOL, V1602, P205, DOI 10.1007/978-1-4939-6964-7_14; Noh JY, 2018, VACCINE, V36, P5304, DOI 10.1016/j.vaccine.2018.07.021; Palekar R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219595; Pena L, 2013, J VIROL, V87, P5118, DOI 10.1128/JVI.02490-12; Pica N, 2011, J VIROL, V85, P12825, DOI 10.1128/JVI.05930-11; Puzelli S, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4621-z; RACANIELLO VR, 1979, J VIROL, V29, P361, DOI 10.1128/JVI.29.1.361-373.1979; REED L. J., 1938, AMER JOUR HYG, V27, P493; RITCHEY MB, 1976, J VIROL, V18, P738, DOI 10.1128/JVI.18.2.738-744.1976; Santos JJS, 2017, J VIROL, V91, DOI 10.1128/JVI.00056-17; SHAW MW, 1983, P NATL ACAD SCI-BIOL, V80, P4879, DOI 10.1073/pnas.80.16.4879; Srivastava B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004857; Stech J, 2011, J INFECT DIS, V204, P1483, DOI 10.1093/infdis/jir613; Subbarao K, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a038653; Sun WN, 2019, J VIROL, V93, DOI 10.1128/JVI.00333-19; Sutton TC, 2014, VIRUS RES, V189, P14, DOI 10.1016/j.virusres.2014.05.003; Voigt EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00180; Wan Z, 2018, J VIROL, V92, DOI 10.1128/JVI.01025-18; Wressnigg N, 2009, VACCINE, V27, P2851, DOI 10.1016/j.vaccine.2009.02.087; Zhou B, 2014, J CLIN MICROBIOL, V52, P1330, DOI 10.1128/JCM.03265-13	48	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							897	10.3390/vaccines9080897			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH5WR	34452022	gold, Green Submitted, Green Published			2022-04-29	WOS:000690001300001
J	Cassaniti, I; Ferrari, A; Comolli, G; Sarasini, A; Gregorini, M; Rampino, T; Lilleri, D; Baldanti, F				Cassaniti, Irene; Ferrari, Alessandro; Comolli, Giuditta; Sarasini, Antonella; Gregorini, Marilena; Rampino, Teresa; Lilleri, Daniele; Baldanti, Fausto			Characterization of Varicella-Zoster (VZV) Specific T Cell Response in Healthy Subjects and Transplanted Patients by Using Enzyme Linked Immunospot (ELISpot) Assays	VACCINES			English	Article						varicella-zoster virus; T effector and T central memory response; transplant	KIDNEY-TRANSPLANTATION; VIRUS; IMMUNITY; PATHOGENESIS; VACCINATION; DYSFUNCTION; LYMPHOCYTES; INFECTION	Solid organ transplant recipients, due to the administration of post-transplant immunosuppressive therapies, are at greater risk of viral reactivation episodes, mainly from herpes viruses, including varicella-zoster virus (VZV). The aim of this pilot study was to develop functional immunological assays (VZV-ELISpot) for the quantification and characterization of the VZV-specific effector-memory and central-memory responses in healthy subjects and transplanted patients. Glycoprotein gE and immediate-early 63 (IE-63) were used as antigens for in vitro stimulation. VZV-seropositive healthy subjects showed higher responses in respect to seronegative subjects. Even if differences were observed between VZV-seropositive healthy subjects and transplanted subjects at pre-transplant, the VZV-specific T-cell response was reduced at 60 days after transplant, mainly for the high level of immunosuppression. Phenotypical characterization revealed that response against VZV was mainly mediated by CD4 T cells. The results obtained in this study might be useful for the definition of personalized follow-up of the transplanted patients, providing useful information on the status of the patient potentially at risk of viral reactivation or other opportunistic infections.	[Cassaniti, Irene; Ferrari, Alessandro; Comolli, Giuditta; Sarasini, Antonella; Lilleri, Daniele; Baldanti, Fausto] IRCCS Policlin San Matteo, Microbiol & Virol Dept, Mol Virol Unit, I-27100 Pavia, Italy; [Cassaniti, Irene; Baldanti, Fausto] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, I-27100 Pavia, Italy; [Comolli, Giuditta] Fdn IRCCS Policlin San Matteo, Lab Biochem Biotechnol & Adv Diagnost, I-27100 Pavia, Italy; [Gregorini, Marilena; Rampino, Teresa] Fdn IRCCS Policlin San Matteo, Unit Nephrol Dialysis & Transplantat, I-27100 Pavia, Italy; [Gregorini, Marilena; Rampino, Teresa] Univ Pavia, Dept Internal Med & Therapeut, I-27100 Pavia, Italy		Lilleri, D (通讯作者)，IRCCS Policlin San Matteo, Microbiol & Virol Dept, Mol Virol Unit, I-27100 Pavia, Italy.	i.cassaniti@smatteo.pv.it; alessandro.ferrari@smatteo.pv.it; g.comolli@smatteo.pv.it; a.sarasini@smatteo.pv.it; m.gregorini@smatteo.pv.it; t.rampino@smatteo.pv.it; d.lilleri@smatteo.pv.it; fausto.baldanti@unipv.it	Rampino, Teresa/AAF-3988-2022; Cassaniti, Irene/J-4849-2018; Ferrari, Alessandro/AAZ-3089-2021; Baldanti, Fausto/J-4924-2018	Rampino, Teresa/0000-0002-5311-9174; Cassaniti, Irene/0000-0002-3385-2088; Ferrari, Alessandro/0000-0003-2397-7079; Baldanti, Fausto/0000-0002-3358-8969; Lilleri, Daniele/0000-0001-7747-7622	Ricerca Corrente Fondazione IRCCS Policlinico San Matteo [80207]	This research was funded by Ricerca Corrente Fondazione IRCCS Policlinico San Matteo, grant number 80207.	Arness T, 2008, TRANSPL INFECT DIS, V10, P260, DOI 10.1111/j.1399-3062.2007.00289.x; ARVIN AM, 1991, J IMMUNOL, V146, P257; Arvin A, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P700; Arvin AM, 2008, J INFECT DIS, V197, pS58, DOI 10.1086/522123; Betjes MGH, 2013, NAT REV NEPHROL, V9, P255, DOI 10.1038/nrneph.2013.44; Calarota SA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/637649; Cassaniti I, 2016, HUM VACC IMMUNOTHER, V12, P2927, DOI 10.1080/21645515.2016.1204500; Crespo JF, 2002, TRANSPLANT P, V34, P77, DOI 10.1016/S0041-1345(01)02673-2; De Castro N, 2011, AIDS RES HUM RETROV, V27, P1089, DOI [10.1089/aid.2010.0340, 10.1089/AID.2010.0340]; Duncan CJA, 2015, J INFECTION, V71, pS47, DOI 10.1016/j.jinf.2015.04.015; Ellis D.L., 2015, DERMATOL ONLINE J, V21, P16, DOI [10.5070/D3213022994, DOI 10.5070/D3213022994]; Esser MT, 2003, VACCINE, V21, P419, DOI 10.1016/S0264-410X(02)00407-3; Fishman JA, 2017, AM J TRANSPLANT, V17, P856, DOI 10.1111/ajt.14208; Galetta KM, 2015, J NEUROL SCI, V358, P38, DOI 10.1016/j.jns.2015.10.004; Geel AL, 2006, TRANSPLANT P, V38, P3418, DOI 10.1016/j.transproceed.2006.10.090; Gershon Anne A, 2016, Trans Am Clin Climatol Assoc, V127, P282; Gershon AA, 2013, CLIN MICROBIOL REV, V26, P728, DOI 10.1128/CMR.00052-13; Karlsson AC, 2003, J IMMUNOL METHODS, V283, P141, DOI 10.1016/j.jim.2003.09.001; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Lehmann PV, 2012, METHODS MOL BIOL, V792, P3, DOI 10.1007/978-1-61779-325-7_1; Levin MJ, 2003, J INFECT DIS, V188, P1336, DOI 10.1086/379048; Okamoto S, 2009, J INFECT DIS, V200, P1606, DOI 10.1086/644646; Ouwendijk WJD, 2015, J PATHOL, V235, P298, DOI 10.1002/path.4451; Roderick M, 2012, ARCH DIS CHILD, V97, P587, DOI 10.1136/archdischild-2012-301684; Rondaan C, 2018, ANTIVIR RES, V158, P206, DOI 10.1016/j.antiviral.2018.08.006; Rondaan C, 2014, ARTHRITIS RHEUMATOL, V66, P3122, DOI 10.1002/art.38804; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; SMETANA Z, 1991, AM J NEPHROL, V11, P229, DOI 10.1159/000168308	28	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							875	10.3390/vaccines9080875			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH4PF	34451999	Green Published			2022-04-29	WOS:000689914300001
J	Giuliani, M; Ichino, A; Bonomi, A; Martoni, R; Cammino, S; Gorini, A				Giuliani, Mattia; Ichino, Anna; Bonomi, Alice; Martoni, Riccardo; Cammino, Stefania; Gorini, Alessandra			Who Is Willing to Get Vaccinated? A Study into the Psychological, Socio-Demographic, and Cultural Determinants of COVID-19 Vaccination Intentions	VACCINES			English	Article						COVID-19; COVID-19 vaccination; psychology; motivation; health locus of control; anxiety symptoms; psychological wellbeing	GENERALIZED ANXIETY DISORDER; GAD-7	Crucial to the success of the COVID-19 vaccination campaign is the rate of people who adhere to it. This study aimed to investigate the reasons underlying people's willingness to get vaccinated in a sample of Italian adults, considering the effects of different individual characteristics and psychological variables upon positive vs. negative/hesitant vaccination intentions, as well as subjects' self-reported motivations for such intentions. An anonymous cross-sectional survey was distributed online in February 2021. The results showed that trust in science, number of vaccinations received in 2019, and belief that COVID-19 is more severe than the common flu, were associated with positive vaccination intentions. "Chance externality" health locus of control showed both direct and indirect effects upon positive vaccination intentions. Anxiety symptoms and participants' perceived psychological status also showed indirect positive effects. Subjects' self-reported motivations varied interestingly across positive vs. negative/hesitant intentions. Implications of these findings for identifying effective pro-vaccination messages are discussed in the final section of the paper.	[Giuliani, Mattia; Bonomi, Alice] IRCCS Ctr Cardiol Monzino, I-20138 Milan, Italy; [Ichino, Anna] Univ Milan, Dept Philosophy Piero Martinetti, I-20122 Milan, Italy; [Martoni, Riccardo; Cammino, Stefania] IRCCS San Raffaele VilleTurro, Dept Clin Neurosci, I-20127 Milan, Italy; [Gorini, Alessandra] Univ Milan, Dept Oncol & Hemato Oncol, I-20122 Milan, Italy		Gorini, A (通讯作者)，Univ Milan, Dept Oncol & Hemato Oncol, I-20122 Milan, Italy.	mattia.giuliani@ccfm.it; anna.ichino@unimi.it; alice.bonomi@ccfm.it; martoni.riccardo@hsr.it; cammino.stefania@hsr.it; alessandra.gorini@unimi.it	Gorini, Alessandra/C-6689-2011	Gorini, Alessandra/0000-0003-3216-1784	University of Milan through the APC initiative	The authors acknowledge support from the University of Milan through the APC initiative.	Abalakina-Paap M, 1999, POLIT PSYCHOL, V20, P637, DOI 10.1111/0162-895X.00160; [Anonymous], 2020, LANCET INFECT DIS, V20, P875, DOI 10.1016/S1473-3099(20)30565-X; Baron-Epel O, 2019, HEALTH PROMOT INT, V34, P248, DOI 10.1093/heapro/dax078; Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8., 10.1016/S0140-6736(20)30460-8]; D'Souza G., WHAT IS HERD IMMUNIT; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; GOODMAN LA, 1961, ANN MATH STAT, V32, P148, DOI 10.1214/aoms/1177705148; Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923; Hornsey MJ, 2018, HEALTH PSYCHOL, V37, P307, DOI 10.1037/hea0000586; Hotez PJ, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002153; Kertz S, 2013, CLIN PSYCHOL PSYCHOT, V20, P456, DOI 10.1002/cpp.1802; Kim E, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102743; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lowe B, 2008, MED CARE, V46, P266, DOI 10.1097/MLR.0b013e318160d093; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Nazareth M, 2016, PREV CHRONIC DIS, V13, DOI 10.5888/pcd13.160046; Olagoke AA, 2021, J RELIG HEALTH, V60, P65, DOI 10.1007/s10943-020-01090-9; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Patel M, 2019, MMWR-MORBID MORTAL W, V68, P893, DOI 10.15585/mmwr.mm6840e2; Rieger M., 2020, SOC HLTH BEHAV, V3, P78, DOI [10.4103/SHB.SHB_39_20, DOI 10.4103/SHB.SHB_39_20]; Rutter LA, 2017, J PSYCHOPATHOL BEHAV, V39, P140, DOI 10.1007/s10862-016-9571-9; Salali Gul Deniz, 2020, Psychol Med, P1, DOI 10.1017/S0033291720004067; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Sunstein CR, 2009, J POLIT PHILOS, V17, P202, DOI 10.1111/j.1467-9760.2008.00325.x; Uscinski J.E., 2018, CONSPIRACY THEORIES, P1, DOI [10.1093/oso/9780190844073.001.0001, DOI 10.1093/OSO/9780190844073.003.0030]; Van Prooijen JW, 2015, APPL COGNITIVE PSYCH, V29, P753, DOI 10.1002/acp.3161; WALLSTON KA, 1994, J PERS ASSESS, V63, P534, DOI 10.1207/s15327752jpa6303_10; Wang HL, 2020, LANCET, V395, P1190, DOI 10.1016/S0140-6736(20)30755-8; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Zhang JC, 2020, BRAIN BEHAV IMMUN, V87, P59, DOI 10.1016/j.bbi.2020.04.046	34	4	4	3	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							810	10.3390/vaccines9080810			21	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH9XT	34451935	Green Published, gold			2022-04-29	WOS:000690274500001
J	Koonpaew, S; Kaewborisuth, C; Srisutthisamphan, K; Wanitchang, A; Thaweerattanasinp, T; Saenboonrueng, J; Poonsuk, S; Jengarn, J; Viriyakitkosol, R; Kramyu, J; Jongkaewwattana, A				Koonpaew, Surapong; Kaewborisuth, Challika; Srisutthisamphan, Kanjana; Wanitchang, Asawin; Thaweerattanasinp, Theeradej; Saenboonrueng, Janya; Poonsuk, Sukontip; Jengarn, Juggragarn; Viriyakitkosol, Ratchanont; Kramyu, Jarin; Jongkaewwattana, Anan			A Single-Cycle Influenza A Virus-Based SARS-CoV-2 Vaccine Elicits Potent Immune Responses in a Mouse Model	VACCINES			English	Article						SARS-CoV-2; single-cycle influenza virus-based vaccine; spike RBD; spike-pseudotyped virus	REPLICATION; GENERATION; PROTEIN; SYSTEM	The use of virus-vectored platforms has increasingly gained attention in vaccine development as a means for delivering antigenic genes of interest into target hosts. Here, we describe a single-cycle influenza virus-based SARS-CoV-2 vaccine designated as scPR8-RBD-M2. The vaccine utilizes the chimeric gene encoding 2A peptide-based bicistronic protein cassette of the SARS-CoV-2 receptor-binding domain (RBD) and influenza matrix 2 (M2) protein. The C-terminus of the RBD was designed to link with the cytoplasmic domain of the influenza virus hemagglutinin (HA) to anchor the RBD on the surface of producing cells and virus envelope. The chimeric RBD-M2 gene was incorporated in place of the HA open-reading frame (ORF) between the 3 ' and 5 ' UTR of HA gene for the virus rescue in MDCK cells stably expressing HA. The virus was also constructed with the disrupted M2 ORF in segment seven to ensure that M2 from the RBD-M2 was utilized. The chimeric gene was intact and strongly expressed in infected cells upon several passages, suggesting that the antigen was stably maintained in the vaccine candidate. Mice inoculated with scPR8-RBD-M2 via two alternative prime-boost regimens (intranasal-intranasal or intranasal-intramuscular routes) elicited robust mucosal and systemic humoral immune responses and cell-mediated immunity. Notably, we demonstrated that immunized mouse sera exhibited neutralizing activity against pseudotyped viruses bearing SARS-CoV-2 spikes from various variants, albeit with varying potency. Our study warrants further development of a replication-deficient influenza virus as a promising SARS-CoV-2 vaccine candidate.	[Koonpaew, Surapong; Kaewborisuth, Challika; Srisutthisamphan, Kanjana; Wanitchang, Asawin; Thaweerattanasinp, Theeradej; Saenboonrueng, Janya; Poonsuk, Sukontip; Jengarn, Juggragarn; Kramyu, Jarin; Jongkaewwattana, Anan] Natl Sci & Technol Dev Agcy NSTDA, Natl Ctr Genet Engn & Biotechnol BIOTEC, Virol & Cell Technol Res Team, Pathum Thani 12120, Thailand; [Viriyakitkosol, Ratchanont] Chulalongkorn Univ, Fac Vet Sci, Bangkok 10330, Thailand		Jongkaewwattana, A (通讯作者)，Natl Sci & Technol Dev Agcy NSTDA, Natl Ctr Genet Engn & Biotechnol BIOTEC, Virol & Cell Technol Res Team, Pathum Thani 12120, Thailand.	Surapong.koo@biotec.or.th; Challika.kae@biotec.or.th; Kanjana.sri@biotec.or.th; Asawin.wan@biotec.or.th; theeradej.tha@biotec.or.th; Janya@biotec.or.th; Sukontip.poo@biotec.or.th; Juggragarn.jen@biotec.or.th; ratchanont.v@student.chula.ac.th; Jarin@biotec.or.th; Anan.jon@biotec.or.th		Kaewborisuth, Challika/0000-0003-3477-3784; Viriyakitkosol, Ratchanont/0000-0003-2879-4810; Koonpaew, Surapong/0000-0003-3817-2118; Jongkaewwattana, Anan/0000-0003-2354-9883; Jengarn, Juggragarn/0000-0003-2443-3727	Research Development Innovation Management (RDI), National Science and Technology Development Agency (NSTDA) [P2051806]; National Vaccine Institute (NVI), Thailand [P2150344]	This work was supported by Research Development Innovation Management (RDI), National Science and Technology Development Agency (NSTDA) under grant number "P2051806" and National Vaccine Institute (NVI), Thailand, under grant number "P2150344".	Altenburg AF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24820-2; BEARE AS, 1975, LANCET, V2, P729; Dudek T, 2006, VIROLOGY, V344, P230, DOI 10.1016/j.virol.2005.09.020; Fausther-Bovendo H, 2014, HUM VACC IMMUNOTHER, V10, P2875, DOI 10.4161/hv.29594; Ferrara F, 2018, METHOD PROTOCOL, V1, DOI 10.3390/mps1010008; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Harding AT, 2017, MBIO, V8, DOI 10.1128/mBio.00669-17; Hoffmann E, 2000, J GEN VIROL, V81, P2843, DOI 10.1099/0022-1317-81-12-2843; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; Hoffmann E, 2001, ARCH VIROL, V146, P2275, DOI 10.1007/s007050170002; Kou YM, 2017, IMMUNOL LETT, V190, P51, DOI 10.1016/j.imlet.2017.07.007; Leong ML, 2009, INFECT IMMUN, V77, P3958, DOI 10.1128/IAI.01274-08; Li JW, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00170; Li ZN, 2005, J VIROL, V79, P10003, DOI 10.1128/JVI.79.15.10003-10012.2005; Martina BEE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018995; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; MUSTER T, 1995, J VIROL, V69, P6678, DOI 10.1128/JVI.69.11.6678-6686.1995; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Reed LJ., 1938, AM J HYG, V27, P493, DOI [10.1093/oxfordjournals.aje.a118408, DOI 10.1093/OXFORDJOURNALS.AJE.A118408]; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0; Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010; Takeda M, 2002, J VIROL, V76, P1391, DOI 10.1128/JVI.76.3.1391-1399.2002; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; Teijaro JR, 2021, NAT REV IMMUNOL, V21, P195, DOI 10.1038/s41577-021-00526-x; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wanitchang A, 2016, VIROLOGY, V498, P99, DOI 10.1016/j.virol.2016.08.016; Watanabe T, 2003, J VIROL, V77, P10575, DOI 10.1128/JVI.77.19.10575-10583.2003; Wise HM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002998; Wongthida P, 2010, CANCER RES, V70, P4539, DOI 10.1158/0008-5472.CAN-09-4658	30	1	1	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							850	10.3390/vaccines9080850			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH8MB	34451975	Green Published, gold			2022-04-29	WOS:000690176500001
J	Gracia, JCM; Smutzer, M; Taylor, L; Balasch, M; Bandrick, M				Mancera Gracia, Jose Carlos; Smutzer, Megan; Taylor, Lucas; Balasch, Monica; Bandrick, Meggan			One Dose of a Novel Vaccine Containing Two Genotypes of Porcine Circovirus (PCV2a and PCV2b) and Mycoplasma hyopneumoniae Conferred a Duration of Immunity of 23 Weeks	VACCINES			English	Article						swine; porcine circovirus 2; Mycoplasma hyopneumoniae; vaccine; duration of immunity	GENETIC-VARIABILITY; RESPIRATORY-DISEASE; TYPE-2; PIGS; INFECTION; REVEALS; SWINE	Porcine circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae (Mhyo) are important swine pathogens for which vaccination is a key control strategy. Three separate studies were performed to evaluate the duration of immunity (DOI) conferred by a novel vaccine combining PCV2a/PCV2b and Mhyo into a ready-to-use formulation. In each study, three-week-old naive piglets were vaccinated (Day 0) and challenged 23-weeks later (Day 159) with either PCV2a, PCV2b or Mhyo. Pigs were euthanized three-to-four-weeks post-challenge. Vaccinated pigs had significantly lower PCV2 viremia from Day 168 until Day 175 (PCV2a study) or until euthanasia (PCV2b study), respectively. Fecal shedding was significantly lower for PCV2a-challenged from Day 171 until Day 178, and for PCV2b-challenged from Day 172 until euthanasia. In the PCV2a challenge study, there were no differences among vaccinates and controls in terms of percent of pigs positive for PCV2 immunohistochemistry, histiocytic replacement, or lymphoid depletion. However, significant differences for immunohistochemistry and histiocytic replacement, not lymphoid depletion, were observed among vaccinates and controls following PCV2b challenge. Vaccination supposed a significant reduction in the mean percentage of Mhyo-like lesions in the lung. Percentages of lung tissues positive for Mhyo via immunohistochemistry were 49.3% and 67.1% for vaccinated and control groups, respectively. One dose of the novel PCV2a/PCV2b/Mhyo vaccine conferred robust protection against challenge 23-weeks later for all three fractions.	[Mancera Gracia, Jose Carlos] Zoetis Belgium SA, Mercuriusstraat 20, B-1930 Zaventem, Belgium; [Smutzer, Megan; Taylor, Lucas; Bandrick, Meggan] Zoetis Inc, Vet Med Res & Dev, 333 Portage St, Kalamazoo, MI 49007 USA; [Balasch, Monica] Zoetis Mfg & Res Spain SL, Ctra. Camprodon s n, Vall Bianya 17813, Spain		Gracia, JCM (通讯作者)，Zoetis Belgium SA, Mercuriusstraat 20, B-1930 Zaventem, Belgium.	pepe.mancera@zoetis.com; megan.smutzer@zoetis.com; lucas.p.taylor@zoetis.com; monica.balasch@zoetis.com; meggan.bandrick@zoetis.com			Zoetis	This research was funded by Zoetis.	Afghah Z, 2017, VET MICROBIOL, V206, P21, DOI 10.1016/j.vetmic.2016.10.002; Alarcon P, 2013, PREV VET MED, V110, P103, DOI 10.1016/j.prevetmed.2012.12.006; Allan GM, 1998, J VET DIAGN INVEST, V10, P3, DOI 10.1177/104063879801000102; [Anonymous], SUVAXYN CIRCO MH RTU; [Anonymous], MYOSPHERE PCV ID; [Anonymous], CIRCOVAC; [Anonymous], INGELVAC CIRCOFLEX; [Anonymous], PORCILIS PCV M HYO; Bandrick M, 2020, VET IMMUNOL IMMUNOP, V223, DOI 10.1016/j.vetimm.2020.110034; Bao F, 2018, TRANSBOUND EMERG DIS, V65, P432, DOI 10.1111/tbed.12721; Beach NM, 2012, VIRUS RES, V164, P33, DOI 10.1016/j.virusres.2011.09.041; Chae C, 2016, VET J, V212, P1, DOI 10.1016/j.tvjl.2015.10.030; Cheung AK, 2007, ARCH VIROL, V152, P1035, DOI 10.1007/s00705-006-0909-6; Constans M, 2015, BIOINFORM BIOL INSIG, V9, P1, DOI 10.4137/BBI.S30226; Correa-Fiz F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74627-3; Cortey M, 2011, VET J, V187, P363, DOI 10.1016/j.tvjl.2009.12.023; Dupont K, 2008, VET MICROBIOL, V128, P56, DOI 10.1016/j.vetmic.2007.09.016; Firth C, 2009, J VIROL, V83, P12813, DOI 10.1128/JVI.01719-09; Franzo G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208585; Franzo G, 2016, MOL PHYLOGENET EVOL, V100, P269, DOI 10.1016/j.ympev.2016.04.028; Gagnon CA, 2007, CAN VET J, V48, P811; Gava D, 2018, BRAZ J MICROBIOL, V49, P351, DOI 10.1016/j.bjm.2017.08.007; Gillespie J, 2009, J VET INTERN MED, V23, P1151, DOI 10.1111/j.1939-1676.2009.0389.x; Guo LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041463; Hernandez-Caravaca I, 2017, RES VET SCI, V114, P69, DOI 10.1016/j.rvsc.2017.03.006; Karuppannan AK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050099; Kekarainen T, 2014, J GEN VIROL, V95, P1734, DOI 10.1099/vir.0.065318-0; Kurtz S, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-29; Madson DM, 2009, CLIN VACCINE IMMUNOL, V16, P830, DOI 10.1128/CVI.00455-08; Maes D, 2008, VET MICROBIOL, V126, P297, DOI 10.1016/j.vetmic.2007.09.008; Maes D, 2018, TRANSBOUND EMERG DIS, V65, P110, DOI 10.1111/tbed.12677; Opriessnig T., 2011, Animal Health Research Reviews, V12, P133, DOI 10.1017/S1466252311000120; Opriessnig T, 2014, VACCINE, V32, P4342, DOI 10.1016/j.vaccine.2014.06.004; Pagot E, 2017, PORCINE HEALTH MANAG, V3, DOI 10.1186/s40813-016-0051-0; Reiner G, 2015, VET MICROBIOL, V180, P41, DOI 10.1016/j.vetmic.2015.07.026; Saha D, 2012, J GEN VIROL, V93, P1548, DOI 10.1099/vir.0.042085-0; Saha D, 2012, VET MICROBIOL, V157, P13, DOI 10.1016/j.vetmic.2011.11.030; Segales J, 2015, EXPERT REV VACCINES, V14, P473, DOI 10.1586/14760584.2015.983084; Sibila M, 2020, PORCINE HEALTH MANAG, V6, DOI 10.1186/s40813-020-00148-0; Sibila M, 2012, J COMP PATHOL, V147, P285, DOI 10.1016/j.jcpa.2012.01.003; Sibila M, 2009, VET J, V181, P221, DOI 10.1016/j.tvjl.2008.02.020; Sorden SD, 1999, J VET DIAGN INVEST, V11, P528, DOI 10.1177/104063879901100607; Ssemadaali MA, 2015, RES VET SCI, V103, P179, DOI 10.1016/j.rvsc.2015.10.006; Wang F, 2009, VIRUS RES, V145, P151, DOI 10.1016/j.virusres.2009.05.015; Xiao CT, 2016, VET MICROBIOL, V197, P72, DOI 10.1016/j.vetmic.2016.11.009	45	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							834	10.3390/vaccines9080834			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7DL	34451959	gold, Green Published			2022-04-29	WOS:000690086500001
J	Mor, O; Mandelboim, M; Fleishon, S; Bucris, E; Bar-Ilan, D; Linial, M; Nemet, I; Kliker, L; Lustig, Y; Mendelson, ES; Zuckerman, NS				Mor, Orna; Mandelboim, Michal; Fleishon, Shay; Bucris, Efrat; Bar-Ilan, Dana; Linial, Michal; Nemet, Ital; Kliker, Limor; Lustig, Yaniv; Mendelson, Ella S.; Zuckerman, Neta S.		Israel Natl Consortium SARS CoV 2	The Rise and Fall of a Local SARS-CoV-2 Variant with the Spike Protein Mutation L452R	VACCINES			English	Article						SARS-CoV-2; variant; mutation; sequencing; neutralization	ALIGNMENT	Emerging SARS-CoV-2 variants may threaten global vaccination efforts and the awaited reduction in outbreak burden. In this study, we report a novel variant carrying the L452R mutation that emerged from a local B.1.362 lineage, B.1.362+L452R. The L452R mutation is associated with the Delta and Epsilon variants and was shown to cause increased infection and reduction in neutralization in pseudoviruses. Indeed, the B.1.362+L452R variant demonstrated a X4-fold reduction in neutralization capacity of sera from BNT162b2-vaccinated individuals compared to a wild-type strain. The variant infected 270 individuals in Israel between December 2020 and March 2021, until diminishing due to the gain in dominance of the Alpha variant in February 2021. This study demonstrates an independent, local emergence of a variant carrying a critical mutation, L452R, which may have the potential of becoming a variant of concern and emphasizes the importance of routine surveillance and detection of novel variants among efforts undertaken to prevent further disease spread.	[Mor, Orna; Mandelboim, Michal; Fleishon, Shay; Bucris, Efrat; Bar-Ilan, Dana; Nemet, Ital; Kliker, Limor; Lustig, Yaniv; Mendelson, Ella S.; Zuckerman, Neta S.] Sheba Med Ctr, Cent Virol Lab, Publ Hlth Serv, Minist Hlth, IL-52621 Tel Hashomer, Israel; [Mor, Orna; Mandelboim, Michal; Mendelson, Ella S.] Tel Aviv Univ, Sch Publ Hlth, Dept Epidemiol & Prevent Med, Sackler Fac Med, IL-69978 Tel Aviv, Israel; [Linial, Michal] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel		Zuckerman, NS (通讯作者)，Sheba Med Ctr, Cent Virol Lab, Publ Hlth Serv, Minist Hlth, IL-52621 Tel Hashomer, Israel.	orna.mor@sheba.health.gov.il; michal.mandelboim@sheba.health.gov.il; s.fleishon@gmail.com; efrat.bucris@sheaba.health.gov.il; dana.barilan@sheba.health.gov.il; michall@mail.huji.ac.il; ital.nemet@sheba.health.gov.il; limor.klikder@sheba.health.gov.il; yaniv.lustig@sheba.health.gov.il; ella.mendelson@sheba.health.gov.il; neta.zuckerman@sheba.health.gov.il		Linial, Michal/0000-0002-9357-4526; Mor, Orna/0000-0003-3207-4226; Bar-Ilan, Dana/0000-0002-3677-9402			Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Callaway E, 2021, NATURE, V595, P17, DOI 10.1038/d41586-021-01696-3; Charif D., 2007, STRUCTURAL APPROACHE, P207, DOI [10.1007/978-3-540-35306-5_10, DOI 10.1007/978-3-540-35306-5_10]; Cherian S., CONVERGENT EVOLUTION, DOI [10.1101/2021.04.22.440932(2021, DOI 10.1101/2021.04.22.440932]; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Deng XD, 2021, CELL, V184, P3426, DOI 10.1016/j.cell.2021.04.025; Ewels P, 2016, BIOINFORMATICS, V32, P3047, DOI 10.1093/bioinformatics/btw354; Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Hu J, 2021, CELL MOL IMMUNOL, V18, P1061, DOI 10.1038/s41423-021-00648-1; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Li H, 2011, BIOINFORMATICS, V27, P2987, DOI 10.1093/bioinformatics/btr509; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Li QQ, 2020, CELL, V182, P1284, DOI 10.1016/j.cell.2020.07.012; Pritchard E, 2021, NAT MED, V27, P1370, DOI 10.1038/s41591-021-01410-w; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Sabino EC, 2021, LANCET, V397, P452, DOI 10.1016/S0140-6736(21)00183-5; Sagulenko P, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vex042; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494; Simon-Loriere, 2021, POT NEW LIN CAUS CLU; Tang JLW, 2021, J INFECTION, V82, pE27, DOI 10.1016/j.jinf.2020.12.024; Tchesnokova V, 2021, J CLIN MICROBIOL, V59, DOI [10.1128/JCM.00921-21, 10.1101/2021.02.22.432189]; Tegally H., 2020, EMERGENCE RAPID SPRE, DOI [10.1101/2020.12.21.20248640, DOI 10.1101/2020.12.21.20248640]; Underwood A, PANGOLIN LINEAGE ASS; Wall EC, 2021, LANCET, V397, P2331, DOI 10.1016/S0140-6736(21)01290-3; Zhang WJ, 2021, JAMA-J AM MED ASSOC, V325, P1324, DOI 10.1001/jama.2021.1612; Zuckerman NS, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060616	31	3	3	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							937	10.3390/vaccines9080937			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6TK	34452062	gold, Green Published			2022-04-29	WOS:000690060400001
J	Okuda, S; Hirooka, Y; Sugiyama, M				Okuda, Saki; Hirooka, Yasuaki; Sugiyama, Masafumi			Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis after COVID-19 Vaccination	VACCINES			English	Article						propylthiouracil; ANCA-associated vasculitis; relapsing polychondritis; COVID-19 vaccine	RELAPSING POLYCHONDRITIS	We report the case of a patient who developed antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) after receiving the coronavirus disease 2019 (COVID-19) vaccine BNT162b (Pfizer-BioNTech). A 37-year-old Japanese woman had been taking propylthiouracil for Graves' disease. She had erythema on her forearm on the 12th day after receiving the first dose of the vaccine, fever on the 13th day, and redness and swelling of her left auricle on the 25th day. Her serum myeloperoxidase-ANCA and proteinase 3-ANCA levels, which were negative before the Graves' disease treatment, were elevated. She had unilateral auricular symptoms but no other typical relapsing polychondritis findings. She was diagnosed with propylthiouracil-induced AAV. She was treated with oral glucocorticoids, and her symptoms improved. Propylthiouracil is considered to be the main cause of the onset of AAV in this case, but it cannot be ruled out that BNT162b may have had some effect on the onset of the disease. Although the development of propylthiouracil-induced AAV in this case may have been incidental and unrelated to the vaccination, this report provides important data for evaluating the safety of the vaccine.	[Okuda, Saki; Hirooka, Yasuaki; Sugiyama, Masafumi] Kindai Univ, Nara Hosp, Dept Rheumatol, 1248-1,Otodacho, Ikoma 6300293, Japan		Hirooka, Y (通讯作者)，Kindai Univ, Nara Hosp, Dept Rheumatol, 1248-1,Otodacho, Ikoma 6300293, Japan.	2095C8@med.kindai.ac.jp; nagare@med.kindai.ac.jp; m-sugi@med.kindai.ac.jp		Hirooka, Yasuaki/0000-0001-9472-4103			Allena N, 2021, CUREUS, V13, DOI 10.7759/cureus.15259; Chen M, 2012, NAT REV NEPHROL, V8, P476, DOI 10.1038/nrneph.2012.108; Coronavirus Resource Center, J HOPK U MED; Duran TI, 2021, RHEUMATOL INT, V41, P1523, DOI 10.1007/s00296-021-04914-3; Fueyo-Rodriguez O, 2021, BMJ CASE REP, V14, DOI 10.1136/bcr-2021-242220; Gao Y, 2009, NEPHROLOGY, V14, P33, DOI 10.1111/j.1440-1797.2009.01100.x; Gapud EJ, 2020, EUR J RHEUMATOL, V7, pS121, DOI 10.5152/eurjrheum.2020.2067; Geetha D, 2020, AM J KIDNEY DIS, V75, P124, DOI 10.1053/j.ajkd.2019.04.031; Gulati K, 2021, ARTHRITIS RHEUMATOL, V73, P1091, DOI 10.1002/art.41671; Hernandez Antonio F, 2021, Toxicol Rep, V8, P871, DOI 10.1016/j.toxrep.2021.04.003; Idogun PO, 2021, CUREUS, V13, DOI 10.7759/cureus.14853; Lamb YN, 2021, DRUGS, V81, P495, DOI 10.1007/s40265-021-01480-7; Lee EJ, 2021, AM J HEMATOL, V96, P534, DOI 10.1002/ajh.26132; MCADAM LP, 1976, MEDICINE, V55, P193, DOI 10.1097/00005792-197605000-00001; MICHET CJ, 1986, ANN INTERN MED, V104, P74, DOI 10.7326/0003-4819-104-1-74; Misra D.P., 2021, CLIN RHEUMATOL, V9, P1; Noh JY, 2009, J CLIN ENDOCR METAB, V94, P2806, DOI 10.1210/jc.2008-2700; PAPO T, 1993, ANN RHEUM DIS, V52, P384, DOI 10.1136/ard.52.5.384-b; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Segal Y, 2018, CELL MOL IMMUNOL, V15, P586, DOI 10.1038/cmi.2017.151; Sera N, 2000, THYROID, V10, P595, DOI 10.1089/thy.2000.10.595; Talotta R, 2021, CLIN IMMUNOL, V224, DOI 10.1016/j.clim.2021.108665; Tarawneh O, 2021, AM J HEMATOL, V96, pE133, DOI 10.1002/ajh.26106; Trentham DE, 1998, ANN INTERN MED, V129, P114, DOI 10.7326/0003-4819-129-2-199807150-00011; Vojdani A, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.617089; Vojdani A, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108480; Xuan YY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000009378; Yates M, 2016, ANN RHEUM DIS, V75, P1583, DOI 10.1136/annrheumdis-2016-209133	29	3	3	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							842	10.3390/vaccines9080842			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3EZ	34451967	gold, Green Published			2022-04-29	WOS:000689820100001
J	Rajendran, M; Krammer, F; McMahon, M				Rajendran, Madhusudan; Krammer, Florian; McMahon, Meagan			The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination	VACCINES			English	Review						neuraminidase; antibodies; influenza	DEPENDENT CELLULAR CYTOTOXICITY; RECEPTOR-BINDING SITE; PANDEMIC H1N1; A VIRUS; MONOCLONAL-ANTIBODIES; VIRAL NEURAMINIDASE; IMMUNE-RESPONSES; N2 NEURAMINIDASE; ACTIVE-SITE; HEMAGGLUTININ	The influenza virus neuraminidase (NA) is primarily involved in the release of progeny viruses from infected cells-a critical role for virus replication. Compared to the immuno-dominant hemagglutinin, there are fewer NA subtypes, and NA experiences a slower rate of antigenic drift and reduced immune selection pressure. Furthermore, NA inhibiting antibodies prevent viral egress, thus preventing viral spread. Anti-NA immunity can lessen disease severity, reduce viral shedding, and decrease viral lung titers in humans and various animal models. As a result, there has been a concerted effort to investigate the possibilities of incorporating immunogenic forms of NA as a vaccine antigen in future vaccine formulations. In this review, we discuss NA-based immunity and describe several human NA-specific monoclonal antibodies (mAbs) that have a broad range of protection. We also review vaccine platforms that are investigating NA antigens in pre-clinical models and their potential use for next-generation influenza virus vaccines. The evidence presented here supports the inclusion of immunogenic NA in future influenza virus vaccines.	[Rajendran, Madhusudan; Krammer, Florian; McMahon, Meagan] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA; [Krammer, Florian] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA		Krammer, F; McMahon, M (通讯作者)，Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.; Krammer, F (通讯作者)，Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA.	madhusudan.rajendran@gmail.com; florian.krammer@mssm.edu; meagan.mcmahon@mssm.edu		McMahon, Meagan/0000-0002-7450-6624; Krammer, Florian/0000-0003-4121-776X; Rajendran, Madhusudan/0000-0003-4451-9608	National Institute of Allergy and Infectious Disease (NIAID) Centers of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400008C]; NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [RO1 A146101]	This work was supported in part by the National Institute of Allergy and Infectious Disease (NIAID) Centers of Excellence for Influenza Research and Surveillance (CEIRS) contract (HHSN272201400008C) and NIAID RO1 A146101.	AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; Bangaru S, 2019, CELL, V177, P1136, DOI 10.1016/j.cell.2019.04.011; Belongia EA, 2015, VACCINE, V33, P246, DOI 10.1016/j.vaccine.2014.06.052; Bernstein DI, 2020, LANCET INFECT DIS, V20, P80, DOI 10.1016/S1473-3099(19)30393-7; Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039; Brett IC, 2005, VIROLOGY, V339, P273, DOI 10.1016/j.virol.2005.06.006; Broecker F, 2019, J VIROL, V93, DOI 10.1128/JVI.00840-19; CDC, 2018, WHO IS HIGH RISK FLU; CDC, 2020, VACC EFF WELL DO FLU; CDC, 2018, PAND; Changsom D, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00248-17, 10.1128/cvi.00248-17]; Chen YQ, 2018, CELL, V173, P417, DOI 10.1016/j.cell.2018.03.030; Chen Z, 2000, VACCINE, V18, P3214, DOI 10.1016/S0264-410X(00)00149-3; Choi Y, 2013, CLIN EXP VACCINE RES, V2, P97, DOI 10.7774/cevr.2013.2.2.97; Cohen M, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-321; Corti D, 2017, CURR OPIN VIROL, V24, P60, DOI 10.1016/j.coviro.2017.03.002; COUCH RB, 1974, J INFECT DIS, V129, P411, DOI 10.1093/infdis/129.4.411; Couch RB, 2013, J INFECT DIS, V207, P974, DOI 10.1093/infdis/jis935; Couch RB, 2012, VACCINE, V31, P190, DOI 10.1016/j.vaccine.2012.10.065; Couzens L, 2014, J VIROL METHODS, V210, P7, DOI 10.1016/j.jviromet.2014.09.003; de Jong JC, 2000, J MED VIROL, V61, P94, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt;94::AID-JMV15&gt;3.0.CO;2-C; Easterbrook JD, 2012, VIROLOGY, V432, P39, DOI 10.1016/j.virol.2012.06.003; Ehrlich HJ, 2012, VACCINE, V30, P4543, DOI 10.1016/j.vaccine.2012.03.061; Eichelberger MC, 2019, J INFECT DIS, V219, pS75, DOI 10.1093/infdis/jiz017; Eichelberger MC, 2015, CURR TOP MICROBIOL, V386, P275, DOI 10.1007/82_2014_398; Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839; Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Freyn AW, 2020, MOL THER, V28, P1569, DOI 10.1016/j.ymthe.2020.04.018; Gao Zhizeng, 2020, Vaccine, V38, P715, DOI 10.1016/j.vaccine.2019.11.041; Getie-Kebtie M, 2013, INFLUENZA OTHER RESP, V7, P521, DOI 10.1111/irv.12001; GHENDON Y, 1990, ACTA VIROL, V34, P295; Gilchuk IM, 2019, CELL HOST MICROBE, V26, P715, DOI 10.1016/j.chom.2019.10.003; Gross PA, 1997, CLIN DIAGN LAB IMMUN, V4, P491, DOI 10.1128/CDLI.4.4.491-492.1997; Gross PA, 1996, CLIN DIAGN LAB IMMUN, V3, P361, DOI 10.1128/CDLI.3.3.361-362.1996; Halbherr SJ, 2015, J VIROL, V89, P1550, DOI 10.1128/JVI.02949-14; Heaton NS, 2013, P NATL ACAD SCI USA, V110, P20248, DOI 10.1073/pnas.1320524110; Hensley SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015190; Hoelscher MA, 2006, LANCET, V367, P475, DOI 10.1016/S0140-6736(06)68076-8; Jagadesh A, 2016, ARCH VIROL, V161, P2087, DOI 10.1007/s00705-016-2907-7; Jegaskanda S, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020027; Jegaskanda S, 2014, J IMMUNOL, V193, P469, DOI 10.4049/jimmunol.1400432; Jegaskanda S, 2013, J VIROL, V87, P5512, DOI 10.1128/JVI.03030-12; Jegerlehner A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078947; Jiang LL, 2016, J VIROL, V90, P117, DOI 10.1128/JVI.01756-15; Job ER, 2019, MBIO, V10, DOI 10.1128/mBio.01667-19; Job ER, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0093-1; JOHANSSON BE, 1989, J VIROL, V63, P1239, DOI 10.1128/JVI.63.3.1239-1246.1989; JOHANSSON BE, 1987, J IMMUNOL, V139, P2010; Johansson BE, 2008, HUM VACCINES, V4, P420, DOI 10.4161/hv.4.6.6201; Kilbourne ED, 1995, VACCINE, V13, P1799, DOI 10.1016/0264-410X(95)00127-M; KILBOURNE ED, 1990, P NATL ACAD SCI USA, V87, P786, DOI 10.1073/pnas.87.2.786; Kim JH, 2009, CURR TOP MICROBIOL, V333, P197, DOI 10.1007/978-3-540-92165-3_10; Kim KH, 2019, VIROLOGY, V535, P179, DOI 10.1016/j.virol.2019.07.008; Kirkpatrick E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28706-1; Kositanont U, 2012, VIRAL IMMUNOL, V25, P471, DOI 10.1089/vim.2012.0024; Krammer F, 2019, CELL HOST MICROBE, V26, P712, DOI 10.1016/j.chom.2019.11.006; Krammer F, 2018, MBIO, V9, DOI 10.1128/mBio.02332-17; Krammer F, 2015, NAT REV DRUG DISCOV, V14, P167, DOI 10.1038/nrd4529; Krammer F, 2013, CURR OPIN VIROL, V3, P521, DOI 10.1016/j.coviro.2013.07.007; Laguio-Vila MR, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofu115; Liu WC, 2015, J VIROL, V89, P7224, DOI 10.1128/JVI.00585-15; Liu Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08165-y; Lorenzo MMG, 2013, CHEST, V143, P502, DOI 10.1378/chest.12-1711; Lundstrom K, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040039; Ma J, 2018, CHEST, V154, P169, DOI 10.1016/j.chest.2017.11.008; Madsen A, 2020, IMMUNITY, V53, P852, DOI 10.1016/j.immuni.2020.08.015; Maier HE, 2020, CLIN INFECT DIS, V70, P2290, DOI 10.1093/cid/ciz639; Matrosovich MN, 2004, J VIROL, V78, P12665, DOI 10.1128/JVI.78.22.12665-12667.2004; Matthew J., 2009, VACCINES PANDEMIC IN, V333, P512; McAuley JL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00039; McMahon M, 2019, MBIO, V10, DOI 10.1128/mBio.00560-19; Memoli MJ, 2016, MBIO, V7, DOI 10.1128/mBio.00417-16; Meseda CA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23712-9; Mohn KGI, 2018, HUM VACC IMMUNOTHER, V14, P571, DOI 10.1080/21645515.2017.1377376; Monto AS, 2015, J INFECT DIS, V212, P1191, DOI 10.1093/infdis/jiv195; Mooney AJ, 2017, J VIROL, V91, DOI 10.1128/JVI.01579-17; MURPHY BR, 1972, NEW ENGL J MED, V286, P1329, DOI 10.1056/NEJM197206222862502; Nachbagauer R, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0026-4; Nachbagauer R, 2017, NAT IMMUNOL, V18, P464, DOI 10.1038/ni.3684; Nicholson K.G., 1998, TXB INFLUENZA, P333; Petrie JG, 2015, J INFECT DIS, V212, P1914, DOI 10.1093/infdis/jiv313; Piepenbrink MS, 2019, MBIO, V10, DOI 10.1128/mBio.00066-19; Puig-Barbera J, 2017, VACCINE, V35, P5799, DOI 10.1016/j.vaccine.2017.09.035; Rajendran M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194830; Rajendran M, 2017, MBIO, V8, DOI [10.1128/mBio.02281-16, 10.1128/mbio.02281-16]; RASTOGI S, 1995, CLIN DIAGN LAB IMMUN, V2, P120, DOI 10.1128/CDLI.2.1.120-121.1995; Rijal P, 2020, J VIROL, V94, DOI 10.1128/JVI.01182-19; Rodriguez-Gascon A, 2014, INT J NANOMED, V9, P1833, DOI 10.2147/IJN.S39810; Roldao A, 2010, EXPERT REV VACCINES, V9, P1149, DOI [10.1586/erv.10.115, 10.1586/ERV.10.115]; Sandbulte MR, 2007, PLOS MED, V4, P265, DOI 10.1371/journal.pmed.0040059; SCHILD GC, 1969, J HYG-CAMB, V67, P353, DOI 10.1017/S0022172400041759; SCHULMAN JL, 1968, J VIROL, V2, P778, DOI 10.1128/JVI.2.8.778-786.1968; SCHULMAN JL, 1969, P NATL ACAD SCI USA, V63, P326, DOI 10.1073/pnas.63.2.326; Shaw M, 2013, FIELDS VIROLOGY, P1691; Shcherbik S, 2018, VIROLOGY, V522, P65, DOI 10.1016/j.virol.2018.07.005; Shen CG, 2019, THERANOSTICS, V9, P210, DOI 10.7150/thno.28434; Shtyrya YA, 2009, ACTA NATURAE, V1, P26, DOI 10.32607/20758251-2009-1-2-26-32; SMITH AJ, 1976, J HYG-CAMBRIDGE, V77, P271, DOI 10.1017/S0022172400024712; Smith GE, 2017, VIROLOGY, V509, P90, DOI 10.1016/j.virol.2017.06.006; Smith W, 1933, LANCET, V2, P66, DOI 10.1016/S0140-6736(00)78541-2; Stadlbauer D, 2019, SCIENCE, V366, P499, DOI 10.1126/science.aay0678; Su B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008495; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Sultana I, 2014, VACCINE, V32, P2225, DOI 10.1016/j.vaccine.2014.01.078; Tay MZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00332; Ulmer JB, 2012, VACCINE, V30, P4414, DOI 10.1016/j.vaccine.2012.04.060; Valkenburg SA, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1092; VANDEUSEN RA, 1983, AVIAN DIS, V27, P745, DOI 10.2307/1590317; Von Holle TA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01457; Wan HQ, 2017, J VIROL METHODS, V244, P23, DOI 10.1016/j.jviromet.2017.02.015; Wan HQ, 2013, J VIROL, V87, P9290, DOI 10.1128/JVI.01203-13; WEBSTER RG, 1968, J GEN VIROL, V3, P315, DOI 10.1099/0022-1317-3-3-315; Westgeest KB, 2014, J VIROL, V88, P2844, DOI 10.1128/JVI.02163-13; Westgeest KB, 2012, J GEN VIROL, V93, P1996, DOI 10.1099/vir.0.043059-0; Whittle JRR, 2011, P NATL ACAD SCI USA, V108, P14216, DOI 10.1073/pnas.1111497108; WHO (World Health Organization), 2018, INFL SEAS; Williams TL, 2012, VACCINE, V30, P2475, DOI 10.1016/j.vaccine.2011.12.056; Wohlbold TJ, 2016, J VIROL, V90, P851, DOI 10.1128/JVI.02275-15; Wohlbold TJ, 2015, MBIO, V6, DOI 10.1128/mBio.02556-14; Wohlbold TJ, 2014, VIRUSES-BASEL, V6, P2465, DOI 10.3390/v6062465; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Xie H, 2015, SCI REP-UK, V5, DOI 10.1038/srep15279; Yang SG, 2009, VACCINE, V27, P7451, DOI 10.1016/j.vaccine.2009.05.014; Zhao QJ, 2013, TRENDS BIOTECHNOL, V31, P654, DOI 10.1016/j.tibtech.2013.09.002; Zheng A, 2020, J VIROL, V94, DOI 10.1128/JVI.00742-20; Zhu XY, 2019, CELL HOST MICROBE, V26, P729, DOI 10.1016/j.chom.2019.10.002; Zimmer G, 2010, VIRUSES-BASEL, V2, P413, DOI 10.3390/v2020413; Zost SJ, 2019, CELL REP, V29, P4460, DOI 10.1016/j.celrep.2019.11.084	128	0	0	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							846	10.3390/vaccines9080846			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3DU	34451971	Green Published, gold			2022-04-29	WOS:000689817000001
J	Vitrat, V; Maillard, A; Raybaud, A; Wackenheim, C; Chanzy, B; Nguyen, S; Valran, A; Bosch, A; Noret, M; Delory, T				Vitrat, Virginie; Maillard, Alexis; Raybaud, Alain; Wackenheim, Chloe; Chanzy, Bruno; Nguyen, Sophie; Valran, Amelie; Bosch, Alexie; Noret, Marion; Delory, Tristan			Effect of Professional and Extra-Professional Exposure on Seroprevalence of SARS-CoV-2 Infection among Healthcare Workers of the French Alps: A Multicentric Cross-Sectional Study	VACCINES			English	Article						COVID-19; SARS-CoV-2; healthcare workers; cross-sectional survey; serologic testing		We aimed to report SARS-CoV-2 seroprevalence after the first wave of the pandemic among healthcare workers, and to explore factors associated with an increased infection rate. We conducted a multicentric cross-sectional survey from 27 June to 31 September 2020. For this survey, we enrolled 3454 voluntary healthcare workers across four participating hospitals, of which 83.4% were female, with a median age of 40.6 years old (31.8-50.3). We serologically screened the employees for SARS-CoV-2, estimated the prevalence of infection, and conducted binomial logistic regression with random effect on participating hospitals to investigate associations. We estimated the prevalence of SARS-CoV-2 infection at 5.0% (95 CI, 4.3%-5.8%). We found the lowest prevalence in health professional management support (4.3%) staff. Infections were more frequent in young professionals below 30 years old (aOR = 1.59, (95 CI, 1.06-2.37)), including paramedical students and residents (aOR = 3.38, (95 CI, 1.62-7.05)). In this group, SARS-CoV-2 prevalence was up 16.9%. The location of work and patient-facing role were not associated with increased infections. Employees reporting contacts with COVID-19 patients without adequate protective equipment had a higher rate of infection (aOR = 1.66, (95 CI, 1.12-2.44)). Aerosol-generating tasks were associated with a similar to 1.7-fold rate of infection, regardless of the uptake of FFP2. Those exposed to clusters of infected colleagues (aOR = 1.77, (95 CI, 1.24-2.53)) or intra-familial COVID-19 relatives (aOR = 2.09, (95 CI, 1.15-3.80)) also had a higher likelihood of infection. This report highlights that a sustained availability of personal protective equipment limits the SARS-CoV-2 infection rate to what is measured in the general population. It also pinpoints the need for dedicated hygiene training among young professionals, justifies the systematic eviction of infected personnel, and stresses the need for interventions to increase vaccination coverage among any healthcare workers.	[Vitrat, Virginie; Valran, Amelie] Annecy Genevois Hosp, Dept Infect Dis, F-74370 Epagny Metz Tessy, France; [Maillard, Alexis; Noret, Marion; Delory, Tristan] Annecy Genevois Hosp, Clin Res Unit, F-74370 Epagny Metz Tessy, France; [Raybaud, Alain] Alpes Leman Hosp, Dept Occupat Med, F-74130 Contamine Arves, France; [Wackenheim, Chloe] Alpes Leman Hosp, Dept Infect Dis, F-74130 Contamine Arves, France; [Chanzy, Bruno] Annecy Genevois Hosp, Virol Lab, F-74370 Epagny Metz Tessy, France; [Nguyen, Sophie] Annecy Genevois Hosp, Hyg Unit, F-74370 Epagny Metz Tessy, France; [Bosch, Alexie] Metropole Savoie Hosp, Dept Infect Dis, F-73000 Chambery, France		Vitrat, V (通讯作者)，Annecy Genevois Hosp, Dept Infect Dis, F-74370 Epagny Metz Tessy, France.	vvitrat@ch-annecygenevois.fr; maillard.alexis@laposte.net; araybaud@ch-alpes-leman.fr; cwackenheim@ch-alpes-leman.fr; bchanzy@ch-annecygenevois.fr; snguyen@ch-annecygenevois.fr; avalran@ch-annecygenevois.fr; alexie.bosch@ch-metropole-savoie.fr; mnoret@ch-annecygenevois.fr; tdelory@ch-annecygenevois.fr	DELORY, Tristan/H-8110-2019	DELORY, Tristan/0000-0002-0165-8934; Vitrat, virginie/0000-0001-8595-6834; Maillard, Alexis/0000-0002-7165-4103	Alpine Arc area	The study was funded by a grant from the Alpine Arc area, obtained in 2020.	Contejean A, 2021, CLIN INFECT DIS, V72, P257, DOI 10.1093/cid/ciaa977; Delmas C, 2021, INFECT CONT HOSP EP, V42, P1406, DOI 10.1017/ice.2020.1309; Dimeglio C, 2021, J INFECTION, V82, pE29, DOI 10.1016/j.jinf.2020.09.035; Eyre DW, 2020, ELIFE, V9, DOI 10.7554/eLife.60675; Food and Drug Administration, 2021, EUA AUTH SER TEST PE; Guery R, 2020, MED MALADIES INFECT, V50, P748, DOI 10.1016/j.medmal.2020.04.020; Hausfater P., 2021, CUMULATIVE INCIDENCE, DOI [10.1101/2021.03.09.21253200, DOI 10.1101/2021.03.09.21253200]; Iversen K, 2020, LANCET INFECT DIS, V20, P1401, DOI 10.1016/S1473-3099(20)30589-2; Jespersen S, 2021, CLIN INFECT DIS, V73, pE2853, DOI 10.1093/cid/ciaa1471; Le Vu Stephane, 2021, Nat Commun, V12, P3025, DOI 10.1038/s41467-021-23233-6; Lidstrom AK, 2020, UPSALA J MED SCI, V125, P305, DOI 10.1080/03009734.2020.1793039; Martin C, 2020, J HOSP INFECT, V106, P102, DOI 10.1016/j.jhin.2020.06.028; Moscola J, 2020, JAMA-J AM MED ASSOC, V324, P893, DOI 10.1001/jama.2020.14765; Olivier C., 2020, B EPIDEMIOL HEBD, V35, P690; Pere H, 2020, J CLIN VIROL, V132, DOI 10.1016/j.jcv.2020.104617; Piccoli L, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100013; Plebani M, 2020, CLIN CHEM LAB MED, V58, P2107, DOI 10.1515/cclm-2020-1236; Post N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0244126; Rudberg AS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18848-0; Self WH, 2020, MMWR-MORBID MORTAL W, V69, P1221, DOI 10.15585/mmwr.mm6935e2; Shah ASV, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3582; Shields A, 2020, THORAX, V75, P1089, DOI 10.1136/thoraxjnl-2020-215414; Sims MD, 2021, CLIN INFECT DIS, V73, pS154, DOI 10.1093/cid/ciaa1684; Solodky ML, 2020, ANN ONCOL, V31, P1087, DOI 10.1016/j.annonc.2020.04.475; Steensels D, 2020, JAMA-J AM MED ASSOC, V324, P195, DOI 10.1001/jama.2020.11160	25	2	2	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							824	10.3390/vaccines9080824			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3KU	34451949	gold, Green Published			2022-04-29	WOS:000689835200001
J	Cabreira, V; Abreu, P; Soares-dos-Reis, R; Guimaraes, J; Sa, MJ				Cabreira, Veronica; Abreu, Pedro; Soares-dos-Reis, Ricardo; Guimaraes, Joana; Sa, Maria Jose			Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations	VACCINES			English	Review						COVID-19; vaccines; multiple sclerosis; immunosuppression; multiple sclerosis; therapy	CLADRIBINE TABLETS	Understanding the risks of COVID-19 in patients with Multiple Sclerosis (MS) receiving disease-modifying therapies (DMTs) and their immune reactions is vital to analyze vaccine response dynamics. A systematic review on COVID-19 course and outcomes in patients receiving different DMTs was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Emerging data on SARS-CoV-2 vaccines was used to elaborate recommendations. Data from 4417 patients suggest that MS per se do not portend a higher risk of severe COVID-19. As for the general population, advanced age, comorbidities, and higher disability significantly impact COVID-19 outcomes. Most DMTs have a negligible influence on COVID-19 incidence and outcome, while for those causing severe lymphopenia and hypogammaglobulinemia, such as anti-CD20 therapies, there might be a tendency of increased hospitalization, worse outcomes and a higher risk of re-infection. Blunted immune responses have been reported for many DMTs, with vaccination implications. Clinical evidence does not support an increased risk of MS relapse or vaccination failure, but vaccination timing needs to be individually tailored. For cladribine and alemtuzumab, it is recommended to wait 3-6 months after the last cycle until vaccination. For the general anti-CD20 therapies, vaccination must be deferred toward the end of the cycle and the next dose administered at least 4-6 weeks after completing vaccination. Serological status after vaccination is highly encouraged. Growing clinical evidence and continuous surveillance are extremely important to continue guiding future treatment strategies and vaccination protocols.	[Cabreira, Veronica; Abreu, Pedro; Soares-dos-Reis, Ricardo; Guimaraes, Joana; Sa, Maria Jose] Ctr Hosp Univ Sao Joao, Serv Neurol, P-4200319 Porto, Portugal; [Cabreira, Veronica; Abreu, Pedro; Soares-dos-Reis, Ricardo; Guimaraes, Joana] Univ Porto, Fac Med, Dept Neurociencias Clin & Saude Mental, P-4200319 Porto, Portugal; [Soares-dos-Reis, Ricardo] Univ Porto, i3S Inst Invest & Inovacao, P-4200135 Porto, Portugal; [Sa, Maria Jose] Univ Fernando Pessoa, Fac Ciencias, P-4249004 Porto, Portugal		Cabreira, V (通讯作者)，Ctr Hosp Univ Sao Joao, Serv Neurol, P-4200319 Porto, Portugal.; Cabreira, V (通讯作者)，Univ Porto, Fac Med, Dept Neurociencias Clin & Saude Mental, P-4200319 Porto, Portugal.	veronica.cabreira@chsj.min-saude.pt; pedro.abreu@chsj.min-saude.pt; ricardo.soares.reis@chsj.min-saude.pt; joana.guimaraes@chsj.min-saude.pt; mjsa@med.up.pt	Abreu, Pedro/AAU-8889-2020; Soares-dos-Reis, Ricardo/H-7863-2013	Abreu, Pedro/0000-0002-7927-0294; Sa, Maria Jose/0000-0003-0825-2977; Cabreira, Veronica/0000-0001-9945-7681; Soares-dos-Reis, Ricardo/0000-0001-6878-8568			Achiron A, 2021, MULT SCLER J, V27, P864, DOI 10.1177/13524585211003476; Aguirre C, 2020, MULT SCLER RELAT DIS, V44, DOI 10.1016/j.msard.2020.102250; Alonso R, 2021, MULT SCLER RELAT DIS, V51, DOI 10.1016/j.msard.2021.102886; Amor S, 2020, ANN NEUROL, V87, P794, DOI 10.1002/ana.25770; Anne H., 2021, NEUROLOGY, V96; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baker D, 2020, CLIN EXP IMMUNOL, V202, P149, DOI 10.1111/cei.13495; Bar-Or A, 2020, NEUROLOGY, V95, pE1999, DOI 10.1212/WNL.0000000000010380; Barzegar M, 2020, MULT SCLER RELAT DIS, V45, DOI 10.1016/j.msard.2020.102276; Barzegar M, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000753; Berger JR, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000761; Bhise V, 2021, NEUROTHERAPEUTICS, V18, P244, DOI 10.1007/s13311-021-01008-7; Bollo L, 2020, J NEUROL SCI, V416, DOI 10.1016/j.jns.2020.117011; Borriello G, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.102165; Bose G, 2021, MULT SCLER RELAT DIS, V52, DOI 10.1016/j.msard.2021.102922; Bowen JD, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000783; Buttari F, 2021, MULT SCLER RELAT DIS, V52, DOI 10.1016/j.msard.2021.102983; Capone F, 2021, J NEUROL, V268, P3132, DOI 10.1007/s00415-021-10446-4; Capone F, 2021, MULT SCLER RELAT DIS, V48, DOI 10.1016/j.msard.2020.102734; Carandini T, 2020, MULT SCLER J, V26, P1268, DOI 10.1177/1352458520926459; Alvarez FC, 2020, MED CLIN-BARCELONA, V155, P362, DOI 10.1016/j.medcli.2020.06.021; Celius EG, 2020, MULT SCLER RELAT DIS, V46, DOI 10.1016/j.msard.2020.102476; Chaudhry F, 2020, J NEUROL SCI, V418, DOI 10.1016/j.jns.2020.117147; Chiarini M, 2020, J NEUROIMMUNOL, V345, DOI 10.1016/j.jneuroim.2020.577282; Chilimuri S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030219; Ciampi E, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102204; Ciardi MR, 2020, J NEUROIMMUNOL, V346, DOI 10.1016/j.jneuroim.2020.577323; Ciotti JR, 2020, MULT SCLER RELAT DIS, V45, DOI 10.1016/j.msard.2020.102439; Conte WL, 2020, MULT SCLER RELAT DIS, V44, DOI 10.1016/j.msard.2020.102315; Cook S, 2011, MULT SCLER J, V17, P578, DOI 10.1177/1352458510391344; Corbett KS, 2020, NATURE, V586, P567, DOI 10.1038/s41586-020-2622-0; Crescenzo F, 2020, MULT SCLER RELAT DIS, V44, DOI 10.1016/j.msard.2020.102372; Dalla Costa G, 2020, NEUROL SCI, V41, P1647, DOI 10.1007/s10072-020-04519-x; De Angelis M, 2020, MULT SCLER RELAT DIS, V45, DOI 10.1016/j.msard.2020.102452; Dersch R, 2020, MULT SCLER J, V26, P1264, DOI 10.1177/1352458520943783; Devogelaere J, 2020, NEUROL SCI, V41, P1981, DOI 10.1007/s10072-020-04522-2; Ehde DM, 2021, MULT SCLER RELAT DIS, V49, DOI 10.1016/j.msard.2021.102788; Evangelou N, 2021, J NEUROL NEUROSUR PS, V92, P107, DOI [10.1136/jnnp-2020-324449, 10.13039/501100000381]; Fernandez-Diaz E, 2020, MULT SCLER RELAT DIS, V45, DOI 10.1016/j.msard.2020.102402; Fiorella C, 2020, MULT SCLER RELAT DIS, V46, DOI 10.1016/j.msard.2020.102447; Flores-Gonzalez RE, 2021, MULT SCLER RELAT DIS, V49, DOI 10.1016/j.msard.2021.102777; Foerch C, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102180; Gelibter S, 2021, MULT SCLER RELAT DIS, V49, DOI 10.1016/j.msard.2021.102775; Gemcioglu E, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102196; Ghaderi S, 2020, EUR J EPIDEMIOL, V35, P355, DOI 10.1007/s10654-019-00595-2; Ghajarzadeh M, 2020, MULT SCLER RELAT DIS, V43, DOI 10.1016/j.msard.2020.102222; Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015; Giovannoni G, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2020.102073; Gomez-Mayordomo V, 2021, J MED VIROL, V93, P546, DOI 10.1002/jmv.26279; Guevara C, 2020, MULT SCLER RELAT DIS, V44, DOI 10.1016/j.msard.2020.102314; Han MF, 2020, MED MICROBIOL IMMUN, V209, P657, DOI 10.1007/s00430-020-00693-z; Hughes R, 2021, MULT SCLER RELAT DIS, V49, DOI 10.1016/j.msard.2020.102725; Hughes R, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102192; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Iannetta M, 2020, MULT SCLER RELAT DIS, V45, DOI 10.1016/j.msard.2020.102442; Ilya Kister K.M., 2021, P AM AC NEUR AAN 202 P AM AC NEUR AAN 202; Iovino A, 2021, MULT SCLER RELAT DIS, V51, DOI 10.1016/j.msard.2021.102908; Jack D, 2021, MULT SCLER RELAT DIS, V51, DOI 10.1016/j.msard.2021.102929; Jack D, 2020, MULT SCLER RELAT DIS, V46, DOI 10.1016/j.msard.2020.102469; Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6; Kataria Saurabh, 2020, eNeurologicalSci, V21, P100287, DOI 10.1016/j.ensci.2020.100287; Khayat-Khoei M, 2021, J NEUROL, V268, P3592, DOI 10.1007/s00415-021-10463-3; Korsukewitz C, 2020, NAT REV NEUROL, V16, P493, DOI 10.1038/s41582-020-0385-8; Langer-Gould A, 2021, ANN CLIN TRANSL NEUR, V8, P938, DOI 10.1002/acn3.51342; Laroni A, 2021, MULT SCLER J, V27, P2126, DOI 10.1177/1352458520971817; Loonstra FC, 2020, MULT SCLER J, V26, P1256, DOI 10.1177/1352458520942198; Louapre C, 2020, JAMA NEUROL, V77, P1079, DOI 10.1001/jamaneurol.2020.2581; Lucchini M, 2020, MULT SCLER RELAT DIS, V44, DOI 10.1016/j.msard.2020.102323; Maghzi AH, 2020, J NEUROL, V267, P2790, DOI 10.1007/s00415-020-09944-8; Mallucci G, 2020, MULT SCLER RELAT DIS, V45, DOI 10.1016/j.msard.2020.102414; Mantero V, 2021, J NEUROL, V268, P2029, DOI 10.1007/s00415-020-10196-9; Mantero V, 2020, MULT SCLER RELAT DIS, V46, DOI 10.1016/j.msard.2020.102453; Mantero V, 2021, J NEUROL, V268, P2023, DOI 10.1007/s00415-020-10015-1; Matias-Guiu J, 2020, MULT SCLER RELAT DIS, V44, DOI 10.1016/j.msard.2020.102297; Meca-Lallana V, 2020, MULT SCLER RELAT DIS, V44, DOI 10.1016/j.msard.2020.102306; Mohn N, 2020, J NEUROL, V267, P2803, DOI 10.1007/s00415-020-09921-1; Mohammadpour M.F.M., 2021, J NEUROL NEUROSCI, V44; Montero-Escribano P, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102185; Nesbitt C, 2020, MULT SCLER RELAT DIS, V45, DOI 10.1016/j.msard.2020.102338; Novi G, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102120; Olberg HK, 2018, EUR J NEUROL, V25, P527, DOI 10.1111/ene.13537; Parrotta E, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000835; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Preziosa P, 2021, J NEUROL, V268, P2697, DOI 10.1007/s00415-020-10309-4; Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1; Reder AT, 2021, CNS DRUGS, V35, P317, DOI 10.1007/s40263-021-00804-1; REDONE Br-Neuroimmunology Brazi, 2021, MULT SCLER J, V27, P1615, DOI 10.1177/1352458520978354; Reyes S, 2020, PRACT NEUROL, V20, P435, DOI 10.1136/practneurol-2020-002527; Rimmer K, 2020, MULT SCLER J-EXP TRA, V6, DOI 10.1177/2055217320942931; Riva A, 2021, MULT SCLER J, V27, P347, DOI 10.1177/1352458520952310; Safavi F, 2020, MULT SCLER RELAT DIS, V43, DOI 10.1016/j.msard.2020.102195; Sahraian MA, 2020, MULT SCLER RELAT DIS, V46, DOI 10.1016/j.msard.2020.102472; Salter A, 2021, JAMA NEUROL, V78, P699, DOI 10.1001/jamaneurol.2021.0688; Seliner J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020099; Serrazina F, 2021, MULT SCLER RELAT DIS, V51, DOI 10.1016/j.msard.2021.102880; Soresina A, 2020, PEDIAT ALLERG IMM-UK, V31, P565, DOI 10.1111/pai.13263; Sormani MP, 2021, ANN NEUROL, V89, P780, DOI 10.1002/ana.26028; Stertz S, 2021, TRENDS MICROBIOL, V29, P973, DOI 10.1016/j.tim.2021.03.001; Suwanwongse K, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102201; Thornton JR, 2020, MULT SCLER RELAT DIS, V44, DOI 10.1016/j.msard.2020.102341; Tillett RL, 2021, LANCET INFECT DIS, V21, P52, DOI 10.1016/S1473-3099(20)30764-7; Torjesen I, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n523; Valencia-Sanchez C, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102182; von Hehn C, 2018, NEUROL-NEUROIMMUNOL, V5, DOI 10.1212/NXI.0000000000000409; Wang J, 2020, J LEUKOCYTE BIOL, V108, P17, DOI 10.1002/JLB.3COVR0520-272R; Woo MS, 2021, J NEUROL, V268, P5, DOI 10.1007/s00415-020-10046-8; Wurm H, 2020, MULT SCLER J, V26, P1261, DOI 10.1177/1352458520943791; Yetkin MF, 2021, NEUROL SCI, V42, P1661, DOI 10.1007/s10072-021-05097-2; Zabalza A, 2021, EUR J NEUROL, V28, P3384, DOI 10.1111/ene.14690; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	110	7	7	2	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							773	10.3390/vaccines9070773			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5YT	34358189	gold, Green Published			2022-04-29	WOS:000676987400001
J	da Luz, JCD; Antunes, F; Clavijo-Salomon, MA; Signori, E; Tessarollo, NG; Strauss, BE				Luz, Jean Carlos dos Santos da; Antunes, Fernanda; Clavijo-Salomon, Maria Alejandra; Signori, Emanuela; Tessarollo, Nayara Gusmao; Strauss, Bryan E.			Clinical Applications and Immunological Aspects of Electroporation-Based Therapies	VACCINES			English	Review						bleomycin; electrochemotherapy; electroporation; gene electrotransfer; vaccines	STANDARD OPERATING PROCEDURES; IL-12 GENE ELECTROTRANSFER; IN-VIVO ELECTROPORATION; DENDRITIC CELLS; ELECTRIC-FIELD; T-CELLS; ANTITUMOR EFFECTIVENESS; SPONTANEOUS NEOPLASMS; INTERFERON-GAMMA; MELANOMA-CELLS	Reversible electropermeabilization (RE) is an ultrastructural phenomenon that transiently increases the permeability of the cell membrane upon application of electrical pulses. The technique was described in 1972 by Neumann and Rosenheck and is currently used in a variety of applications, from medicine to food processing. In oncology, RE is applied for the intracellular transport of chemotherapeutic drugs as well as the delivery of genetic material in gene therapies and vaccinations. This review summarizes the physical changes of the membrane, the particularities of bleomycin, and the immunological aspects involved in electrochemotherapy and gene electrotransfer, two important EP-based cancer therapies in human and veterinary oncology.	[Luz, Jean Carlos dos Santos da; Antunes, Fernanda; Tessarollo, Nayara Gusmao; Strauss, Bryan E.] Univ Sao Paulo, Canc Inst Sao Paulo, Viral Vector Lab, BR-01246000 Sao Paulo, Brazil; [Clavijo-Salomon, Maria Alejandra] Univ Sao Paulo, Canc Inst Sao Paulo, Lab Expt Oncol, BR-01246000 Sao Paulo, Brazil; [Signori, Emanuela] CNR, Inst Translat Pharmacol, I-00133 Rome, Italy		Strauss, BE (通讯作者)，Univ Sao Paulo, Canc Inst Sao Paulo, Viral Vector Lab, BR-01246000 Sao Paulo, Brazil.	jc.santosluz@usp.br; fernanda.antunes@hc.fm.usp.br; mariasalomon@usp.br; emanuela.signori@cnr.it; nayara.tessarollo@hc.fm.usp.br; bstrauss@usp.br	Strauss, Bryan/AAO-6653-2021; Signori, Emanuela/H-5134-2019; Antunes, Fernanda/F-5353-2018	Strauss, Bryan/0000-0002-4113-9450; Signori, Emanuela/0000-0003-0286-7401; , Nayara/0000-0003-4735-6971; Antunes, Fernanda/0000-0001-7261-451X; LUZ, JEAN CARLOS DOS SANTOS/0000-0001-5088-7808	Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [15/265809, 17/25290-2]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [134305/2018-3, 302888/2017/9]	This research was funded by the Sao Paulo Research Foundation (FAPESP) grant 15/265809 (B.E.S.) and fellowships 17/25290-2 (N.G.T.). Funding was also provided by the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; fellowships 134305/2018-3 (J.C.d.S.d.L.) and 302888/2017/9 (B.E.S.)).	Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867; Alberts B, 2015, MOLECULAR BIOLOGY OF THE CELL, SIXTH EDITION, P597; Algazi AP, 2020, CLIN CANCER RES, V26, P2827, DOI 10.1158/1078-0432.CCR-19-2217; Andersen MH, 2003, SEMIN CANCER BIOL, V13, P449, DOI 10.1016/j.semcancer.2003.09.009; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; [Anonymous], AAHSD AVMA AM VET ME; Ayman, 2012, PULSED ELECT FIELDS; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Basu G, 2014, J GENE MED, V16, P55, DOI 10.1002/jgm.2759; Beebe SJ, 2003, DNA CELL BIOL, V22, P785, DOI 10.1089/104454903322624993; Beebe Stephen J, 2013, Cells, V2, P136, DOI 10.3390/cells2010136; Belizario JE., 2009, OPEN IMMUNOL J, V2, P79, DOI [10.2174/1874226200902010079, DOI 10.2174/1874226200902010079]; Bhatia S, 2020, CLIN CANCER RES, V26, P598, DOI 10.1158/1078-0432.CCR-19-0972; Bisceglia B, 2013, COMPEL, V32, P1912, DOI 10.1108/COMPEL-11-2012-0305; Bonaventura P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00168; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brizio M, 2015, EUR J DERMATOL, V25, P271, DOI 10.1684/ejd.2015.2522; Buckow R, 2013, COMPR REV FOOD SCI F, V12, P455, DOI 10.1111/1541-4337.12026; Calvet Christophe Y, 2014, Oncoimmunology, V3, pe28131; Calvet CY, 2016, CANCER METAST REV, V35, P165, DOI 10.1007/s10555-016-9615-3; Calvet CY, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.45; Campana LG, 2016, EJSO-EUR J SURG ONC, V42, P1914, DOI 10.1016/j.ejso.2016.06.399; Campana LG, 2019, EJSO-EUR J SURG ONC, V45, P92, DOI 10.1016/j.ejso.2018.11.023; Campana LG, 2016, RADIOL ONCOL, V50, P1, DOI 10.1515/raon-2016-0006; Campana LG, 2009, ANN SURG ONCOL, V16, P191, DOI 10.1245/s10434-008-0204-8; Ciria HMC, 2013, CHINESE J CANCER RES, V25, P223, DOI 10.3978/j.issn.1000-9604.2013.03.03; Cemazar M, 2018, BIOELECTROCHEMISTRY, V122, P69, DOI 10.1016/j.bioelechem.2018.03.005; Cemazar M, 2017, VET COMP ONCOL, V15, P641, DOI 10.1111/vco.12208; Cemazar M., 2015, ELECTROMAGNETIC FIEL, P395; Cemazar M, 2019, BIOELECTRICITY, V1, P204, DOI 10.1089/bioe.2019.0028; Chiarella Pieranna, 2008, Recent Pat Antiinfect Drug Discov, V3, P93, DOI 10.2174/157489108784746623; Chiarella P, 2008, EXPERT OPIN BIOL TH, V8, P1645, DOI 10.1517/14712598.8.11.1645 ; Chiarella P, 2011, NON-VIRAL GENE THERAPY, P169; Chiarella P, 2013, CURR DRUG METAB, V14, P291, DOI 10.2174/1389200211314030004; Chicaybam L, 2020, GENE THER, V27, P85, DOI 10.1038/s41434-020-0121-4; Choi Ji-Na, 2019, Chonnam Med J, V55, P31, DOI 10.4068/cmj.2019.55.1.31; Corovic S, 2013, BIOMED ENG ONLINE, V12, DOI 10.1186/1475-925X-12-16; Cutrera J, 2015, J CELL MOL MED, V19, P664, DOI 10.1111/jcmm.12382; Daugimont L, 2010, J MEMBRANE BIOL, V236, P117, DOI 10.1007/s00232-010-9283-0; Davalos RV, 2005, ANN BIOMED ENG, V33, P223, DOI 10.1007/s10439-005-8981-8; De Robertis M, 2018, CANCERS, V10, DOI 10.3390/cancers10110405; De Virgilio A, 2018, ONCOL LETT, V16, P3415, DOI 10.3892/ol.2018.9140; Dezawa M, 2002, MICRON, V33, P1, DOI 10.1016/S0968-4328(01)00002-6; Di Gennaro P, 2016, CLIN EXP METASTAS, V33, P787, DOI 10.1007/s10585-016-9814-x; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; Dunn GP, 2005, IMMUNOL RES, V32, P231, DOI 10.1385/IR:32:1-3:231; Esmaeili N, 2019, J HEALTHC ENG, V2019, DOI 10.1155/2019/2784516; Feng T, 2011, GASTROENTEROLOGY, V140, P2031, DOI 10.1053/j.gastro.2011.03.009; Ferraro B, 2009, MOL THER, V17, P651, DOI 10.1038/mt.2009.12; GABRIEL B, 1994, EUR J BIOCHEM, V223, P25, DOI 10.1111/j.1432-1033.1994.tb18962.x; Galluzzi L, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000337corr1; Geboers B, 2020, RADIOLOGY, V295, P254, DOI 10.1148/radiol.2020192190; Gehl J, 2018, ACTA ONCOL, V57, P874, DOI 10.1080/0284186X.2018.1454602; Gerlini G, 2012, ONCOIMMUNOLOGY, V1, P1655, DOI 10.4161/onci.21991; Gerlini G, 2013, CLIN EXP METASTAS, V30, P37, DOI 10.1007/s10585-012-9505-1; Ginn SL, 2018, J GENE MED, V20, DOI 10.1002/jgm.3015; Gissel H, 2011, CLINICAL ASPECTS OF ELECTROPORATION, P9, DOI 10.1007/978-1-4419-8363-3_2; Gothelf A, 2011, BIOELECTROCHEMISTRY, V82, P95, DOI 10.1016/j.bioelechem.2011.06.001; Granata V, 2017, WORLD J GASTROENTERO, V23, P4767, DOI 10.3748/wjg.v23.i26.4767; Groselj A, 2018, BASIC CLIN PHARMACOL, V123, P247, DOI 10.1111/bcpt.13012; Haen SP, 2020, NAT REV CLIN ONCOL, V17, P595, DOI 10.1038/s41571-020-0387-x; Heath WR, 2004, IMMUNOL REV, V199, P9, DOI 10.1111/j.0105-2896.2004.00142.x; Hecht SM, 2000, J NAT PROD, V63, P158, DOI 10.1021/np990549f; Heller LC, 2007, GENE THER, V14, P275, DOI 10.1038/sj.gt.3302867; Heller L.C., 2017, PRINCIPLES ELECTROPO; Heller LC, 2010, CURR GENE THER, V10, P312; Henry CJ, 2008, J IMMUNOL, V181, P8576, DOI 10.4049/jimmunol.181.12.8576; Heppt MV, 2016, CANCER IMMUNOL IMMUN, V65, P951, DOI 10.1007/s00262-016-1856-z; Herndler-Brandstetter D, 2018, IMMUNITY, V48, P716, DOI 10.1016/j.immuni.2018.03.015; Hofmann GA, 2000, METH MOLEC MED, V37, P37, DOI 10.1385/1-59259-080-2:37; Hu N, 2013, SENSOR ACTUAT B-CHEM, V178, P63, DOI 10.1016/j.snb.2012.12.034; Jakstys B, 2020, BIOELECTROCHEMISTRY, V135, DOI 10.1016/j.bioelechem.2020.107550; Jarm T, 2010, EXPERT REV ANTICANC, V10, P729, DOI [10.1586/era.10.43, 10.1586/ERA.10.43]; Jourabchi N., 2014, GASTROINTEST INTERV, V3, P8, DOI [10.1016/j.gii.2014.02.002, DOI 10.1016/J.GII.2014.02.002]; Kamensek U, 2018, CANCERS, V10, DOI 10.3390/cancers10030060; Karaca B, 2018, ANTI-CANCER DRUG, V29, P190, DOI 10.1097/CAD.0000000000000580; Kepp O, 2020, NAT REV CLIN ONCOL, V17, P49, DOI 10.1038/s41571-019-0272-7; Kis EG, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41026-2; Kishida T, 2003, MOL THER, V8, P738, DOI 10.1016/j.ymthe.2003.08.002; Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215; Kos B., 2017, TREATMENT PLANNING E, P1; Kos S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217762; Kos S, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.65; Kotnik T, 2019, ANNU REV BIOPHYS, V48, P63, DOI 10.1146/annurev-biophys-052118-115451; Lambricht L, 2016, EXPERT OPIN DRUG DEL, V13, P295, DOI 10.1517/17425247.2016.1121990; Lamolinara A, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/159145; Landstrom F, 2015, ANTICANCER RES, V35, P5813; Lasek W, 2014, CANCER IMMUNOL IMMUN, V63, P419, DOI 10.1007/s00262-014-1523-1; Lee EW, 2010, GUT LIVER, V4, pS99, DOI 10.5009/gnl.2010.4.S1.S99; Levine ZA, 2010, J MEMBRANE BIOL, V236, P27, DOI 10.1007/s00232-010-9277-y; Li SL, 2005, MOL THER, V12, P942, DOI 10.1016/j.ymthe.2005.03.037; Lu Y, 2020, NAT MED, V26, P732, DOI 10.1038/s41591-020-0840-5; Lucas ML, 2002, MOL THER, V5, P668, DOI 10.1006/mthe.2002.0601; Maglietti F, 2016, RADIOL ONCOL, V50, P58, DOI 10.1515/raon-2016-0015; Mali B, 2013, EJSO-EUR J SURG ONC, V39, P4, DOI 10.1016/j.ejso.2012.08.016; Mandal R, 2016, CANCER DISCOV, V6, P703, DOI 10.1158/2159-8290.CD-16-0146; Markov, 2015, ELECTROMAGNETIC FIEL; Taques MM, 2021, ARTIF ORGANS, V45, P309, DOI 10.1111/aor.13820; Marty M, 2006, EJC SUPPL, V4, P3, DOI 10.1016/j.ejcsup.2006.08.002; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Mekid H, 2003, BRIT J CANCER, V88, P1763, DOI 10.1038/sj.bjc.6600959; Miklavcic D, 2012, MED BIOL ENG COMPUT, V50, P1213, DOI 10.1007/s11517-012-0991-8; Miklavcic D., 2016, ELECT FIELD DISTRIBU; Miklavcic D, 2015, BIOMED ENG ONLINE, V14, DOI 10.1186/1475-925X-14-S3-I1; Miklavcic D, 2014, BIOMED ENG ONLINE, V13, DOI 10.1186/1475-925X-13-29; Miklavcic D, 2010, J MEMBRANE BIOL, V236, P1, DOI 10.1007/s00232-010-9287-9; Milevoj N, 2019, RES VET SCI, V122, P40, DOI 10.1016/j.rvsc.2018.11.001; Mir LM, 2006, EJC SUPPL, V4, P38, DOI 10.1016/j.ejcsup.2006.08.005; Mir LM, 2006, EJC SUPPL, V4, P14, DOI 10.1016/j.ejcsup.2006.08.003; MIR LM, 1991, CR ACAD SCI III-VIE, V313, P613; MIR LM, 1991, EUR J CANCER, V27, P68, DOI 10.1016/0277-5379(91)90064-K; Mir LM, 1997, BRIT J CANCER, V76, P1617, DOI 10.1038/bjc.1997.606; Mir LM, 1996, GEN PHARMACOL-VASC S, V27, P745, DOI 10.1016/0306-3623(95)02101-9; Mittal L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64128-8; Mlakar V, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-299; Mozzillo N, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008842; Mukhopadhyay A, 2019, GENE THER, V26, P1, DOI 10.1038/s41434-018-0044-5; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; NEUMANN E, 1972, J MEMBRANE BIOL, V10, P279, DOI 10.1007/BF01867861; Neumann E., 1989, ELECTROPORATION ELEC; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Pasquet L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0638-5; Pavlin D, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-234; Pavlin D, 2009, CANCER BIOL THER, V8, P2114, DOI 10.4161/cbt.8.22.9734; Pavselj N, 2008, RADIOL ONCOL, V42, P159, DOI 10.2478/v10019-008-0008-2; Peng BW, 2007, VACCINE, V25, P2064, DOI 10.1016/j.vaccine.2006.11.042; Peri D, 2020, COMPUT METH PROG BIO, V186, DOI 10.1016/j.cmpb.2019.105204; Pichi B, 2018, ACTA OTORHINOLARYNGO, V38, P181, DOI 10.14639/0392-100X-1262; Pradeu T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00287; Prevc A, 2016, J MEMBRANE BIOL, V249, P703, DOI 10.1007/s00232-016-9915-0; Probst U, 2018, TECHNOL CANCER RES T, V17, P1, DOI 10.1177/1533033818785329; Quaglino P, 2011, PIGM CELL MELANOMA R, V24, P734, DOI 10.1111/j.1755-148X.2011.00879.x; Rangel MMM, 2019, AUSTRAL J VET SCI, V51, P45, DOI 10.4067/S0719-81322019000200045; Reed SD, 2010, CANCER GENE THER, V17, P457, DOI 10.1038/cgt.2010.6; Rems L., 2016, LIPID PORES MOL CONT, P1; Rieder A, 2008, J APPL MICROBIOL, V105, P2035, DOI 10.1111/j.1365-2672.2008.03972.x; Rols M.-P., 2016, PARAMETERS AFFECTING, P1; Rossi C.R., 2014, ANN ONCOL         S4, V25, pIV510, DOI [10.1093/annonc/mdu354.51, DOI 10.1093/ANNONC/MDU354.51]; Roux S, 2008, CANCER IMMUNOL IMMUN, V57, P1291, DOI 10.1007/s00262-008-0462-0; Ruzgys P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33912-y; Schultheis K, 2018, HUM GENE THER METHOD, V29, P177, DOI 10.1089/hgtb.2017.105; Sedlar A, 2012, RADIOL ONCOL, V46, P302, DOI 10.2478/v10019-012-0044-9; Sersa G, 2008, EJSO-EUR J SURG ONC, V34, P232, DOI 10.1016/j.ejso.2007.05.016; Sersa G, 1997, BIOELECTROCH BIOENER, V43, P279, DOI 10.1016/S0302-4598(96)05194-X; SERSA G, 1994, BIOELECTROCH BIOENER, V35, P23, DOI 10.1016/0302-4598(94)87006-3; Sersa G., 2016, EFFECTS REVERSIBLE I; Sersa G, 2006, EJC SUPPL, V4, P52, DOI 10.1016/j.ejcsup.2006.08.007; Sersa G, 2021, EJSO-EUR J SURG ONC, V47, P1836, DOI 10.1016/j.ejso.2021.03.229; Sersa G, 2015, CANCER IMMUNOL IMMUN, V64, P1315, DOI 10.1007/s00262-015-1724-2; Shi GL, 2018, CANCERS, V10, DOI 10.3390/cancers10120498; Shibata MA, 2006, J GENE MED, V8, P335, DOI 10.1002/jgm.854; Shirley SA, 2015, CURR GENE THER, V15, P32; Sieni E, 2020, CANCERS, V12, DOI 10.3390/cancers12041043; Sin JI, 2012, CANCER IMMUNOL IMMUN, V61, P1671, DOI 10.1007/s00262-012-1214-8; Singh J., 2017, ELECTROPORATION DERM, P105; Smith TRF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16505-0; Spugnini EP, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-48; Spugnini EP, 2020, OPEN VET J, V10, P267, DOI 10.4314/ovj.v10i3.4; Spugnini EP, 2017, J CELL PHYSIOL, V232, P490, DOI 10.1002/jcp.25505; Spugnini EP, 2014, METHODS MOL BIOL, V1121, P247, DOI 10.1007/978-1-4614-9632-8_22; Spugnini EP, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-114; Spugnini EP, 2019, VET CLIN N AM-SMALL, V49, P967, DOI 10.1016/j.cvsm.2019.04.006; Spugnini EP, 2012, FUTURE ONCOL, V8, P829, DOI [10.2217/FON.12.64, 10.2217/fon.12.64]; Steding CE, 2011, IMMUNOLOGY, V133, P221, DOI 10.1111/j.1365-2567.2011.03429.x; Teissie J, 2005, BBA-GEN SUBJECTS, V1724, P270, DOI 10.1016/j.bbagen.2005.05.006; Todorovic V, 2014, BIOELECTROCHEMISTRY, V100, P119, DOI 10.1016/j.bioelechem.2013.12.002; Touchard E, 2012, MOL THER, V20, P1559, DOI 10.1038/mt.2011.304; TOUNEKTI O, 1993, CANCER RES, V53, P5462; Tounekti O, 2001, BRIT J CANCER, V84, P1272, DOI 10.1054/bjoc.2001.1786; Tozon N, 2016, JOVE-J VIS EXP, DOI 10.3791/54760; Trainito C., 2015, STUDY CELL MEMBRANE; Tratar UL, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/5285890; TSONG TY, 1991, BIOPHYS J, V60, P297, DOI 10.1016/S0006-3495(91)82054-9; Tu Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep24648; Ursic K, 2021, J CONTROL RELEASE, V332, P623, DOI 10.1016/j.jconrel.2021.03.009; Venereau E, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00422; Walter P., 2015, UNIVERSAL FEATURES C, P2; Xu ML, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/832454; Yarmush ML, 2014, ANNU REV BIOMED ENG, V16, P295, DOI 10.1146/annurev-bioeng-071813-104622; Yue FY, 1999, EUR J IMMUNOL, V29, P1762; Zamora AE, 2018, J IMMUNOL, V200, P392, DOI 10.4049/jimmunol.1701413; Zhan YH, 2012, ANAL CHEM, V84, P8102, DOI 10.1021/ac302462s; Zhao JX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046241; Zhou JF, 2020, FRONT ENV SCI ENG, V14, DOI 10.1007/s11783-020-1253-x	184	1	1	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							727	10.3390/vaccines9070727			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7LW	34358144	Green Published			2022-04-29	WOS:000677089100001
J	Manukyan, H; Tritama, E; Wahid, R; Ansari, A; Konz, J; Chumakov, K; Laassri, M				Manukyan, Hasmik; Tritama, Erman; Wahid, Rahnuma; Ansari, Azeem; Konz, John; Chumakov, Konstantin; Laassri, Majid			Development of a Quantitative One-Step RT-PCR Method for the Detection of Sabin 2 Virus Contamination in a Novel Oral Poliovirus Vaccine Type 2	VACCINES			English	Article						release test; quality control; OPV; nOPV; Sabin 2 virus contaminant	ATTENUATED POLIOVIRUS; MUCOSAL IMMUNITY; OPEN-LABEL; IDENTIFICATION; POLIOMYELITIS; EXCRETION; RNA	To control circulating vaccine-derived type 2 poliovirus outbreaks, a more genetically stable novel Oral Poliovirus Vaccine type 2 (nOPV2) was developed by targeted modifications of Sabin 2 genome. Since the use of OPV2 made of Sabin 2 strain has been stopped, it is important to exclude the possibility that batches of nOPV2 are contaminated with Sabin 2 virus. Here, we report the development of a simple quantitative one-step reverse-transcription polymerase chain reaction assay for the detection and quantitation of Sabin 2 virus in the presence of overwhelming amounts of nOPV2 strain. The method is specific and linear within 8 log(10) range even in the presence of relevant amounts of nOPV2 virus. It is sensitive, with a lower limit of detection of 0.2 CCID50/mL (an equivalent of 198 genome copies per mL), and generates reproducible results. This assay can be used for quality control and lot release of the nOPV2.	[Manukyan, Hasmik; Chumakov, Konstantin; Laassri, Majid] US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA; [Tritama, Erman] PT Bio Farma, Res & Dev Div, Bandung 40161, Indonesia; [Wahid, Rahnuma; Ansari, Azeem; Konz, John] PATH, Ctr Vaccine Innovat & Access, Seattle, WA 98121 USA		Laassri, M (通讯作者)，US FDA, Div Viral Prod, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA.	hasmik.manukyan@fda.hhs.gov; erman.tritama@biofarma.co.id; rwahid@path.org; aansari@path.org; jkonz@path.org; konstantin.chumakov@fda.hhs.gov; majid.laassri@fda.hhs.gov		Laassri, Majid/0000-0002-0110-5504	Bill and Melinda Gates FoundationBill & Melinda Gates Foundation	This work was supported in part by grant from the Bill and Melinda Gates Foundation.	Baicus Anda, 2012, World J Virol, V1, P108, DOI 10.5501/wjv.v1.i4.108; Brickley EB, 2018, J INFECT DIS, V217, P371, DOI 10.1093/infdis/jix556; Buonagurio DA, 1999, J CLIN MICROBIOL, V37, P283, DOI 10.1128/JCM.37.2.283-289.1999; Burns CC, 2014, J INFECT DIS, V210, pS283, DOI 10.1093/infdis/jiu295; Chard AN, 2020, MMWR-MORBID MORTAL W, V69, P784, DOI 10.15585/mmwr.mm6925a4; DE L, 1995, J CLIN MICROBIOL, V33, P562, DOI 10.1128/JCM.33.3.562-571.1995; DUNN G, 1990, J MED VIROL, V32, P92, DOI 10.1002/jmv.1890320205; FADEN H, 1990, J INFECT DIS, V162, P1291, DOI 10.1093/infdis/162.6.1291; John J, 2014, LANCET, V384, P1505, DOI 10.1016/S0140-6736(14)60934-X; Kew OM, 2005, ANNU REV MICROBIOL, V59, P587, DOI 10.1146/annurev.micro.58.030603.123625; Kilpatrick DR, 2009, J CLIN MICROBIOL, V47, P1939, DOI 10.1128/JCM.00702-09; Konopka-Anstadt JL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0176-7; Laassri M, 2006, J INFECT DIS, V193, P1344, DOI 10.1086/503366; Laassri M, 2005, J INFECT DIS, V192, P2092, DOI 10.1086/498172; Laassri M, 2018, BIOLOGICALS, V55, P63, DOI 10.1016/j.biologicals.2018.06.002; Laassri M, 2013, J VIROL METHODS, V189, P7, DOI 10.1016/j.jviromet.2012.12.015; Macadam AJ, 2006, J VIROL, V80, P8653, DOI 10.1128/JVI.00370-06; Manukyan H, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1233-6; MODLIN JF, 1991, PEDIATR INFECT DIS J, V10, P976, DOI 10.1097/00006454-199112000-00031; Platt LR, 2014, J INFECT DIS, V210, pS380, DOI 10.1093/infdis/jiu184; Rubin J, 2017, J INFECT DIS, V216, pS40, DOI 10.1093/infdis/jiw571; Simonyan V, 2014, GENES-BASEL, V5, P957, DOI 10.3390/genes5040957; Thompson KM, 2017, J INFECT DIS, V216, pS176, DOI 10.1093/infdis/jix108; VANDERAVOORT HGAM, 1995, J CLIN MICROBIOL, V33, P2562, DOI 10.1128/JCM.33.10.2562-2566.1995; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; WHO, 2019, 2 OUT 3 WILD POL STR; Wright PF, 2016, LANCET INFECT DIS, V16, P1377, DOI 10.1016/S1473-3099(16)30169-4	27	0	0	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							688	10.3390/vaccines9070688			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO8DM	34201447	Green Published			2022-04-29	WOS:000677134900001
J	Pellini, R; Venuti, A; Pimpinelli, F; Abril, E; Blandino, G; Campo, F; Conti, L; De Virgilio, A; De Marco, F; Di Domenico, EG; Di Bella, O; Di Martino, S; Ensoli, F; Giannarelli, D; Mandoj, C; Manciocco, V; Marchesi, P; Mazzola, F; Moretto, S; Petruzzi, G; Petrone, F; Pichi, B; Pontone, M; Zocchi, J; Vidiri, A; Vujovic, B; Piaggio, G; Morrone, A; Ciliberto, G				Pellini, Raul; Venuti, Aldo; Pimpinelli, Fulvia; Abril, Elva; Blandino, Giovanni; Campo, Flaminia; Conti, Laura; De Virgilio, Armando; De Marco, Federico; Di Domenico, Enea Gino; Di Bella, Ornella; Di Martino, Simona; Ensoli, Fabrizio; Giannarelli, Diana; Mandoj, Chiara; Manciocco, Valentina; Marchesi, Paolo; Mazzola, Francesco; Moretto, Silvia; Petruzzi, Gerardo; Petrone, Fabrizio; Pichi, Barbara; Pontone, Martina; Zocchi, Jacopo; Vidiri, Antonello; Vujovic, Branka; Piaggio, Giulia; Morrone, Aldo; Ciliberto, Gennaro			Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccine; obesity; antibodies; serum titer	B-CELLS; OBESITY; INFLUENZA; VACCINATION; INFECTION; TITERS	Background: The first goal of the study was to analyse the antibody titre 21 days after the first dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second goal was to analyse how the antibody titre changes in correlation with age, gender and body mass index (BMI). Methods: Participants had a nasopharyngeal swab for SARS-CoV-2 and were assessed for the presence of SARS-CoV-2 antibodies at baseline and 21 days after the BNT162b2 priming dose. Results: First dose of BNT162b2 activated immune responses in 98% of the participants. Five HWC had no increase in antibody titre 21 days after the first dose. Antibody titre was greater in young (<38 years) vs. older participants (p = 0.002; 56 p = 0.001). Higher antibody levels were detected in underweight vs. pre-obesity group (p = 0.026) and in normal-weight vs. pre-obesity group (p = 0.007). This association was confirmed after adjusting for age (p = 0.0001) and gender (p = 0.00001). Conclusions: Our study demonstrates that a single dose of BNT162b2 activates the immune response, and being young and normal-weight correlate positively with this response. Larger specifically designed clinical trials are needed to validate these results.	[Pellini, Raul; Campo, Flaminia; Manciocco, Valentina; Marchesi, Paolo; Mazzola, Francesco; Moretto, Silvia; Petruzzi, Gerardo; Pichi, Barbara; Zocchi, Jacopo] IRCCS Regina Elena Natl Canc Inst, Dept Otolaryngol Head & Neck Surg, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Venuti, Aldo] IRCCS Regina Elena Natl Canc Inst, HPV Unit, Ist Fisioterap Ospitalieri IFO, UOSD Tumor Immunol & Immunotherapy, I-00144 Rome, Italy; [Pimpinelli, Fulvia; Abril, Elva; Di Domenico, Enea Gino; Ensoli, Fabrizio; Pontone, Martina] IRCCS San Gallicano Dermatol Inst, Dept Microbiol & Virol, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Blandino, Giovanni] IRCCS Regina Elena Natl Canc Inst, Oncogen & Epigenet Unit, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Conti, Laura; Mandoj, Chiara] IRCCS Regina Elena Natl Canc Inst, Dept Clin Pathol & Canc Biobank, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [De Virgilio, Armando] Humanitas Univ, Dept Biomed Sci, I-20089 Milan, Italy; [De Marco, Federico] IRCCS Regina Elena Natl Canc Inst, Dept RiDAIT, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Di Bella, Ornella; Vujovic, Branka] Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Di Martino, Simona] IRCCS Regina Elena Natl Canc Inst, Dept Pathol, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Giannarelli, Diana] IRCCS Regina Elena Natl Canc Inst, Biostat Unit, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Petrone, Fabrizio] UOC DITRAR IRCCS Regina Elena Natl Canc Inst, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Vidiri, Antonello] IRCCS Regina Elena Natl Canc Inst, Dept Radiol & Diagnost Imaging, Ist Fisioterap Ospitalieri IFO, I-00144 Rome, Italy; [Piaggio, Giulia] IRCCS Regina Elena Natl Canc Inst, Ist Fisioterap Ospitalieri IFO, UOSD SAFU, I-00144 Rome, Italy; [Morrone, Aldo] IRCCS San Gallicano Dermatol Inst, Ist Fisioterap Ospitalieri IFO, Sci Direct, I-00144 Rome, Italy; [Ciliberto, Gennaro] IRCCS Regina Elena Natl Canc Inst, Ist Fisioterap Ospitalieri IFO, Sci Direct, I-00144 Rome, Italy		Venuti, A (通讯作者)，IRCCS Regina Elena Natl Canc Inst, HPV Unit, Ist Fisioterap Ospitalieri IFO, UOSD Tumor Immunol & Immunotherapy, I-00144 Rome, Italy.	raul.pellini@ifo.gov.it; aldo.venuti@ifo.gov.it; fulvia.pimpinelli@ifo.gov.it; elva.abril@ifo.gov.it; giovanni.blandino@ifo.gov.it; flaminiacampo@gmail.com; laura.conti@ifo.gov.it; armando.devirgilio@gmail.com; federico.demarco@ifo.gov.it; enea.didomenico@ifo.gov.it; ornella.dibella@ifo.gov.it; simona.dimartino@ifo.gov.it; fabrizio.ensoli@ifo.gov.it; diana.giannarelli@ifo.govit; Chiara.mandoj@ifo.gov.it; valentina.manciocco@ifo.gov.it; Paolo.marchesi@ifo.gov.it; francesco.mazzola@ifo.gov.it; silvia.moretto@ifo.gov.it; gerardo.petruzzi@ifo.gov.it; fabrizio.petrone@ifo.gov.it; barbara.pichi@ifo.gov.it; martina.pontone@ifo.gov.it; jacopo.zocchi@ifo.gov.it; antonello.vidiri@ifo.gov.it; branka.vujovic@ifo.gov.it; giulia.piaggio@ifo.gov.it; aldo.morrone@ifo.gov.it; gennaro.ciliberto@ifo.gov.it	Ciliberto, Gennaro/J-4131-2017; Petruzzi, Gerardo/AAD-4276-2022; Piaggio, Giulia/AAD-7336-2022; Giannarelli, Diana/T-5507-2017; Pontone, Martina/J-9740-2018; Di Domenico, Enea Gino/G-9387-2018; Venuti, Aldo/K-9637-2016	Ciliberto, Gennaro/0000-0003-2851-8605; Petruzzi, Gerardo/0000-0003-0371-7667; De Marco, Federico/0000-0002-1173-2843; Giannarelli, Diana/0000-0002-6085-1195; Pontone, Martina/0000-0002-3293-0443; Di Domenico, Enea Gino/0000-0001-6295-6006; Abril, Elva Ermita/0000-0001-9256-4820; Campo, Flaminia/0000-0002-9249-7573; Venuti, Aldo/0000-0003-2322-6857; pellini, raul/0000-0001-6051-3041; De Virgilio, Armando/0000-0003-0738-8223			Abu Jabal K, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.6.2100096; Amit S, 2021, LANCET, V397, P875, DOI 10.1016/S0140-6736(21)00448-7; Banga N, 2014, VACCINE, V32, P979, DOI 10.1016/j.vaccine.2013.12.019; Bonelli F, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01224-20; Bradley T, 2021, NEW ENGL J MED, V384, P1959, DOI 10.1056/NEJMc2102051; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; DeFuria J, 2013, P NATL ACAD SCI USA, V110, P5133, DOI 10.1073/pnas.1215840110; Eliakim A, 2006, AUTOIMMUNITY, V39, P137, DOI 10.1080/08916930600597326; Frasca D, 2016, VACCINE, V34, P2834, DOI 10.1016/j.vaccine.2016.04.023; Frasca D, 2016, OBESITY, V24, P615, DOI 10.1002/oby.21383; Frasca D, 2015, J IMMUNOL, V195, P2134, DOI 10.4049/jimmunol.1500520; Frasca D, 2010, VACCINE, V28, P8077, DOI 10.1016/j.vaccine.2010.10.023; Garcia-Hernandez MH, 2018, OBES RES CLIN PRACT, V12, P513, DOI 10.1016/j.orcp.2018.07.001; Gilbert, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa1863, DOI 10.1093/CID/CIAA1863]; Grigoryan L, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101422; Hagan T, 2019, CELL, V178, P1313, DOI 10.1016/j.cell.2019.08.010; Hao Y, 2011, BLOOD, V118, P1294, DOI 10.1182/blood-2011-01-330530; Ledford H, 2020, NATURE, V586, P488, DOI 10.1038/d41586-020-02946-6; Manisty C, 2021, LANCET, V397, P1057, DOI 10.1016/S0140-6736(21)00501-8; Neidich SD, 2017, INT J OBESITY, V41, P1324, DOI 10.1038/ijo.2017.131; Nipper AJ, 2018, CLIN IMMUNOL, V193, P80, DOI 10.1016/j.clim.2018.02.003; Petruzzi G, 2020, HEAD NECK-J SCI SPEC, V42, P1303, DOI 10.1002/hed.26212; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poland GA, 2018, VACCINE, V36, P5350, DOI 10.1016/j.vaccine.2017.07.062; Raval Forum M, 2013, Discoveries (Craiova), V1, pe6; Rubtsov AV, 2011, BLOOD, V118, P1305, DOI 10.1182/blood-2011-01-331462; Sheridan PA, 2012, INT J OBESITY, V36, P1072, DOI 10.1038/ijo.2011.208; Tauzin Alexandra, 2021, bioRxiv, DOI 10.1101/2021.03.18.435972; Verschoor CP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131531; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; WEBER DJ, 1985, JAMA-J AM MED ASSOC, V254, P3187, DOI 10.1001/jama.254.22.3187; Weir CB., 2020, STATPEARLS INTERNET; Winer DA, 2011, NAT MED, V17, P610, DOI 10.1038/nm.2353; Wouters OJ, 2021, LANCET, V397, P1023, DOI 10.1016/S0140-6736(21)00306-8	35	9	9	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							685	10.3390/vaccines9070685			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO4ZU	34206312	Green Published, gold			2022-04-29	WOS:000676922500001
J	Bosbach, WA; Heinrich, M; Kolisch, R; Heiss, C				Bosbach, Wolfram A.; Heinrich, Martin; Kolisch, Rainer; Heiss, Christian			Maximization of Open Hospital Capacity under Shortage of SARS-CoV-2 Vaccines-An Open Access, Stochastic Simulation Tool	VACCINES			English	Article						SARS-CoV-2 vaccine shortage; hospital vaccine rollout; hospital management	HEALTH-CARE WORKERS; VACCINATION POLICIES; UNITED-STATES; STRATEGIES; FACILITIES	Motive. The Covid-19 pandemic has led to the novel situation that hospitals must prioritize staff for a vaccine rollout while there is acute shortage of the vaccine. In spite of the availability of guidelines from state agencies, there is partial confusion about what an optimal rollout plan is. This study investigates effects in a hospital model under different rollout schemes. Methods. A simulation model is implemented in VBA, and is studied for parameter variation in a predefined hospital setting. The implemented code is available as open access supplement. Main results. A rollout scheme assigning vaccine doses to staff primarily by staff's pathogen exposure maximizes the predicted open hospital capacity when compared to a rollout based on a purely hierarchical prioritization. The effect increases under resource scarcity and greater disease activity. Nursing staff benefits most from an exposure focused rollout. Conclusions. The model employs SARS-CoV-2 parameters; nonetheless, effects observable in the model are transferable to other infectious diseases. Necessary future prioritization plans need to consider pathogen characteristics and social factors.	[Bosbach, Wolfram A.; Heinrich, Martin; Heiss, Christian] Justus Liebig Univ Giessen, Expt Trauma Surg, D-35392 Giessen, Germany; [Bosbach, Wolfram A.; Heinrich, Martin; Heiss, Christian] Univ Hosp Giessen, Dept Trauma Hand & Reconstruct Surg, D-35385 Giessen, Germany; [Heinrich, Martin] Univ Hosp Giessen, Covid 19 Emergency Taskforce, D-35385 Giessen, Germany; [Kolisch, Rainer] Tech Univ Munich, TUM Sch Management, D-80333 Munich, Germany		Bosbach, WA (通讯作者)，Justus Liebig Univ Giessen, Expt Trauma Surg, D-35392 Giessen, Germany.; Bosbach, WA (通讯作者)，Univ Hosp Giessen, Dept Trauma Hand & Reconstruct Surg, D-35385 Giessen, Germany.	wolfram.bosbach@med.uni-giessen.de; martin.heinrich@chiru.med.uni-giessen.de; rainer.kolisch@tum.de; christian.heiss@chiru.med.uni-giessen.de	Kolisch, Rainer/W-7505-2019	Kolisch, Rainer/0000-0002-8001-3009; Bosbach, Wolfram/0000-0003-4182-3516; Heinrich, Martin/0000-0003-0858-1551	Deutsch Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [BO 4961/6-1]	This research was funded by the Deutsch Forschungsgemeinschaft (DFG), grant number BO 4961/6-1.	[Anonymous], 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMclde2101987; Baraniuk C, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n421; Bubar KM, 2021, SCIENCE, V371, P916, DOI 10.1126/science.abe6959; Bundesamt fur Gesundheit (BAG), 2021, COVID 19 SWITZ LAB C; Burki T, 2020, LANCET INFECT DIS, V20, P785, DOI 10.1016/S1473-3099(20)30501-6; Centers for Disease Control and Prevention, 2020, CDC IS MAK COVID 19; Centers for Disease Control and Prevention, 2021, CDCS COV 19 VACC ROL; Centers for Disease Control and Prevention (CDC), 2021, RISK COVID 19 INF HO; Charlett, 2021, DO ANTIBODY POSITIVE, DOI [DOI 10.1101/2021.01.13.21249642, 10.1101/2021.01.13.21249642]; Ching F, 2018, SARS 130 YEARS MED H, P381; Dray L, 2014, TRANSPORT POLICY, V34, P75, DOI 10.1016/j.tranpol.2014.02.021; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; European Centre for Disease Prevention and Control, 2021, OVERVIEW IMPLEMENTAT; Foy BH, 2021, INT J INFECT DIS, V103, P431, DOI 10.1016/j.ijid.2020.12.075; Gershman MD, 2017, MMWR-MORBID MORTAL W, V66, P457, DOI 10.15585/mmwr.mm6617e2; Gharpure R, 2021, MMWR-MORBID MORTAL W, V70, P178, DOI 10.15585/mmwr.mm7005e2; Guo E, 2020, THIS IS STANFORD VAC; Halsey, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab068, DOI 10.1093/CID/CIAB068]; Hart A, 2020, BR J GUID COUNS, P1; Haviari S, 2015, HUM VACC IMMUNOTHER, V11, P2522, DOI 10.1080/21645515.2015.1082014; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Krieger MGM., 2021, COMMUNITY HLTH WORKE, P1; Mahase E, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3846; Maltezou HC, 2014, VACCINE, V32, P4876, DOI 10.1016/j.vaccine.2013.10.046; Maltezou HC, 2011, VACCINE, V29, P9557, DOI 10.1016/j.vaccine.2011.09.076; Martin CA., 2021, ASS DEMOGRAPHIC OCCU, DOI DOI 10.1101/2021.02.11.21251548; Mills MC, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100674; Nabavi N, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n261; Piraveenan M., 2020, ARXIV201106455; Prematunge C, 2012, VACCINE, V30, P4733, DOI 10.1016/j.vaccine.2012.05.018; Rodriguez J., 2021, COVID 19 VACCINATION, DOI [10.1101/2020.10.12.20211094, DOI 10.1101/2020.10.12.20211094]; Rogers K., 2021, WHY IS IT IMPORTANT; Schmidt H, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m3795; Sickinger S, 2009, HEALTH CARE MANAG SC, V12, P408, DOI 10.1007/s10729-009-9098-7; Stead Sellers F, 2020, WASH POST; U.S. Food & Drug Administration, 2021, COR DIS 2019 COVID 1; World Health Organization, 2020, FRAM DEC MAK IMPL MA FRAM DEC MAK IMPL MA	37	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							546	10.3390/vaccines9060546			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ4KU	34067405	Green Submitted, Green Published, gold			2022-04-29	WOS:000666536800001
J	Okubo, R; Yoshioka, T; Ohfuji, S; Matsuo, T; Tabuchi, T				Okubo, Ryo; Yoshioka, Takashi; Ohfuji, Satoko; Matsuo, Takahiro; Tabuchi, Takahiro			COVID-19 Vaccine Hesitancy and Its Associated Factors in Japan	VACCINES			English	Article						COVID-19; vaccine; vaccine hesitancy; Japan; longitudinal study; psychological distress; social determinants of health; socioeconomic status	TRENDS	The vaccine confidence index in Japan is one of the lowest worldwide. This study aimed to examine the proportion of COVID-19 vaccine hesitancy in the Japanese population using a larger sample and more robust statistical methods than previously, and to identify factors associated with vaccine hesitancy. We conducted a nationwide, cross-sectional Internet survey on 8-26 February 2021, and calculated the proportion and odds ratios for vaccine hesitancy. Among 23,142 responses analyzed, the proportion of COVID-19 vaccine hesitancy was 11.3% (10.9-11.7%). The proportion was higher among younger respondents and female respondents, and especially among younger female respondents (15.6%) compared with the lowest proportion among older male respondents (4.8%). The most cited reason for not getting vaccinated was concerns about adverse reactions in more than 70% of the respondents. The proportion of COVID-19 vaccine hesitancy in Japan was comparable to that in previous studies overseas, and the proportion among younger respondents was more than double that among older respondents. Factors associated with the hesitancy were female sex, living alone, low socioeconomic status, and presence of severe psychological distress, especially among older respondents. Thus, adequate measures should be taken to ensure that vaccines are delivered to people with these factors.	[Okubo, Ryo] Natl Ctr Neurol & Psychiat, Translat Med Ctr, Dept Clin Epidemiol, Tokyo 1878551, Japan; [Yoshioka, Takashi] Fukushima Med Univ, Ctr Innovat Res Communities & Clin Excellence CiR, Fukushima 9601295, Japan; [Ohfuji, Satoko] Osaka City Univ, Grad Sch Med, Dept Publ Hlth, Osaka 5458585, Japan; [Matsuo, Takahiro] St Lukes Int Hosp, Div Infect Dis, Tokyo 1048560, Japan; [Tabuchi, Takahiro] Osaka Int Canc Inst, Canc Control Ctr, Osaka 5418567, Japan		Okubo, R (通讯作者)，Natl Ctr Neurol & Psychiat, Translat Med Ctr, Dept Clin Epidemiol, Tokyo 1878551, Japan.	ryo-okubo@ncnp.go.jp; yoshioka.takashi.52a@kyoto-u.jp; satop@med.osaka-cu.ac.jp; takahirom1226@gmail.com; tabuchitak@gmail.com	Okubo, Ryo/AAC-8156-2022	Okubo, Ryo/0000-0002-1254-1926; Tabuchi, Takahiro/0000-0002-1050-3125; Ohfuji, Satoko/0000-0003-3239-5249	Japan Society for the Promotion of Science (JSPS) KAKENHI Grants [18H03062, 19K22788]; JSPSMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [19K20171]; Japan Health Research Promotion Bureau Research Fund [2020-B-09]	This study was funded by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grants (Grant Nos. 18H03062, 19K22788), a JSPS Grant-in-Aid for Young Scientists (Grant No. 19K20171), and the Japan Health Research Promotion Bureau Research Fund (2020-B-09). The sponsors had no role in data collection and interpretation of our data. Findings and conclusions of this article are the sole responsibility of the authors and do not represent the official views of the research funders.	[Anonymous], Rakuten Insight, Inc., Tokyo, Japan; [Anonymous], Trends in Number of COVID-19 Cases in the US Reported to CDC, by State/Territory; Booth A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247461; Centers for Disease Control and Prevention, ESS WOK; Chou WYS, 2020, HEALTH COMMUN, V35, P1718, DOI 10.1080/10410236.2020.1838096; Coronavirus Resource Center, J HOPK U MED; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Edwards B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248892; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freeman D, 2022, PSYCHOL MED, V52, P251, DOI 10.1017/S0033291720001890; Furukawa TA, 2008, INT J METH PSYCH RES, V17, P152, DOI 10.1002/mpr.257; Gilmour S, 2013, LANCET, V382, P768, DOI 10.1016/S0140-6736(13)61831-0; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Liu Zuyun, 2018, PLoS Med, V15, pe1002718, DOI 10.1371/journal.pmed.1002718; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Okubo R, 2021, J AFFECT DISORDERS, V287, P89, DOI 10.1016/j.jad.2021.03.028; Robinson E, 2021, VACCINE, V39, P2024, DOI 10.1016/j.vaccine.2021.02.005; Roozenbeek J, 2020, ROY SOC OPEN SCI, V7, DOI 10.1098/rsos.201199; Shimizu K, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101609; Simms KT, 2020, LANCET PUBLIC HEALTH, V5, pE223, DOI 10.1016/S2468-2667(20)30010-4; Tabuchi T, 2019, J EPIDEMIOL, V29, P444, DOI 10.2188/jea.JE20180116; Tabuchi T, 2018, TOB CONTROL, V27, pE25, DOI 10.1136/tobaccocontrol-2017-053947; Tabuchi T, 2018, J EPIDEMIOL, V28, P170, DOI 10.2188/jea.JE20160206; World Health Organization, 2020, BEH CONS ACC UPT COV; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048; Yoshioka Takashi, 2021, medRxiv, DOI 10.1101/2021.02.27.21252458	30	19	19	6	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							662	10.3390/vaccines9060662			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ2ZQ	34204465	gold, Green Published			2022-04-29	WOS:000666440200001
J	Pratesi, F; Caruso, T; Testa, D; Tarpanelli, T; Gentili, A; Gioe, D; Migliorini, P				Pratesi, Federico; Caruso, Teresita; Testa, Davide; Tarpanelli, Tiziano; Gentili, Alessandra; Gioe, Davide; Migliorini, Paola			BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers	VACCINES			English	Article						SARS-CoV-2; vaccine; immune response; neutralizing antibodies; antibody avidity	IGA ANTIBODIES; BINDING; ELISA	The BNT162b2 vaccine, containing lipid nanoparticles-formulated mRNA encoding the full-length spike protein of SARS-CoV-2, has been employed to immunize health care workers in Italy, administered in two doses 21 days apart. In this study, we characterized the antibody response induced by the BNT162b2 vaccine in a group of health care workers, tested at baseline, after the first dose and after the booster. Thirty-nine subjects without previous exposure to SARS-CoV-2 were vaccinated with the BNT162b2 vaccine. IgM, IgG, and IgA anti-receptor binding domain (RBD) were tested by ELISA. Neutralizing antibodies were evaluated testing the inhibition of RBD binding to ACE2. Antibody avidity was measured by urea avidity ELISA. IgM anti-RBD are produced after the first dose of vaccine and persist after the booster. IgG and IgA anti-RBD antibodies are detected in high amounts in all the subjects after the first dose and further increase after the booster. A few subjects, already after the first dose, produce antibodies inhibiting RBD interaction with ACE2. After the booster, high levels of inhibitory antibodies are detected in all the subjects. Affinity maturation takes place with boosting and IgG anti-RBD avidity increases with the number of immunizations. A less pronounced increase is observed with IgA. These data indicate that the BNT162b2 vaccine can induce high levels of protective antibodies of high avidity in vaccinated subjects; both IgG and IgA anti-RBD antibodies are produced. Further studies are needed to evaluate antibody persistence over time.	[Pratesi, Federico; Caruso, Teresita; Testa, Davide; Migliorini, Paola] Univ Pisa, Dept Clin & Expt Med, I-56126 Pisa, Italy; [Tarpanelli, Tiziano; Gentili, Alessandra; Gioe, Davide] Dia Metra Srl Immuno Diagnost Syst, I-06038 Perugia, Italy		Pratesi, F (通讯作者)，Univ Pisa, Dept Clin & Expt Med, I-56126 Pisa, Italy.	federico.pratesi@med.unipi.it; teresita.caruso@outlook.it; testa93davide@gmail.com; tiziano.tarpanelli@idsplc.com; alessandra.gentili@idsplc.com; davide.gioe@idsplc.com; paola.migliorini@med.unipi.it		Testa, Davide/0000-0002-5332-3781; PRATESI, FEDERICO/0000-0002-7226-0907	Italian Ministry of HealthMinistry of Health, Italy [COVID-2020-12371849]	The work was funded by Italian Ministry of Health grant COVID-2020-12371849.	Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Anichini G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050517; Bauer G, 2021, J MED VIROL, V93, P3092, DOI 10.1002/jmv.26863; Benner SE, 2020, J INFECT DIS, V222, P1974, DOI 10.1093/infdis/jiaa581; Dauner JG, 2012, MOL CELL PROBE, V26, P73, DOI 10.1016/j.mcp.2012.01.002; Di Resta C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050522; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; Fialova L, 2017, J CLIN LAB ANAL, V31, DOI 10.1002/jcla.22121; Furuya AKM, 2019, CLIN SCI, V133, P859, DOI 10.1042/CS20180874; Gaspar EB, 2021, VACCINE, V39, P1473, DOI 10.1016/j.vaccine.2021.02.003; Gobbi F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030422; Gray KJ, 2021, AM J OBSTET GYNECOL, V225, DOI 10.1016/j.ajog.2021.03.023; Grothmann, 2021, CLIN INFECT DIS, DOI [10.1093/cid/ciab381, DOI 10.1093/CID/CIAB381]; Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6; Ketas Thomas J, 2021, bioRxiv, DOI [10.20411/pai.v6i1.441, 10.1101/2021.03.11.434841]; Kohmer N, 2021, J CLIN MED, V10, DOI 10.3390/jcm10102128; Kowalzik F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040390; Lange A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050488; McCloskey N, 1997, J IMMUNOL METHODS, V205, P67, DOI 10.1016/S0022-1759(97)00059-8; Padoan A, 2021, CLIN CHIM ACTA, V519, P60, DOI 10.1016/j.cca.2021.04.006; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; POLANEC J, 1994, J CLIN LAB ANAL, V8, P16, DOI 10.1002/jcla.1860080105; Quinti I, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.655896; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Salvagno GL, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11050832; Schasfoort RBM, 2021, BIOSENS BIOELECTRON, V183, DOI 10.1016/j.bios.2021.113165; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; Vicenti I, 2021, INT J INFECT DIS, V108, P176, DOI 10.1016/j.ijid.2021.05.033	30	5	5	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							672	10.3390/vaccines9060672			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY9VA	34207300	Green Published, gold			2022-04-29	WOS:000666225400001
J	Riad, A; Pokorna, A; Mekhemar, M; Conrad, J; Klugarova, J; Koscik, M; Klugar, M; Attia, S				Riad, Abanoub; Pokorna, Andrea; Mekhemar, Mohamed; Conrad, Jonas; Klugarova, Jitka; Koscik, Michal; Klugar, Miloslav; Attia, Sameh			Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States	VACCINES			English	Article						AZD1222; ChAdOx1 nCoV-19; COVID-19; Czech Republic; drug-related side effects and adverse reactions; Germany; health personnel; mass vaccination; Oxford-AstraZeneca vaccine	ASTRAZENECA VACCINE; COVID-19; IMPACT	Recent reports of thrombosis following AstraZeneca COVID-19 vaccine in young females (<55 years-old) led to temporary suspension and urgent investigation by the European Medicines Agency (EMA) that concluded that vaccine benefits still outweigh its side effects (SEs). Therefore, this study aims to provide early independent evidence on the vaccine SEs' prevalence and their potential risk factors; a cross-sectional survey-based study was carried out between February and March 2021 in Germany and Czech Republic among healthcare workers who recently received the AstraZeneca COVID-19 vaccine. The study used a validated self-administered questionnaire composed of twenty-eight multiple-choice items covering demographic variables, medical anamneses, and local, systemic, oral, and skin related SEs of the vaccine. Out of the ninety-two included participants, 77.2% were females and 79.3% were from Germany. Their mean age was 35.37 +/- 12.62 (19-64) years-old, 15.2% had chronic illnesses and 22.8% were receiving medical treatments. Overall, 94.6% of the participants reported at least one SE. The most common local SE was injection site pain (72.8%), and the most common systemic SEs were fatigue (73.9%), muscle pain (55.4%), chills (48.9%), feeling unwell (46.7%), nausea (45.7%), and headache (29.3%). The vast majority (91.9%) resolved within 1-3 days, and the below 35 years-old group was the least affected age group. The SEs' frequency was insignificantly higher in females and previously infected participants; the vaccine safety for the elderly was supported by the early findings of this study. Chronic illnesses and medical treatments were not associated with an increased risk of SE incidence and frequency. No blood disorder SEs were reported in our sample. Further independent studies are highly required to evaluate the safety of the AstraZeneca vaccine and to explore whether gender or previous infection could be associated with the vaccine SEs.	[Riad, Abanoub; Klugarova, Jitka; Koscik, Michal; Klugar, Miloslav] Masaryk Univ, Fac Med, Dept Publ Hlth, Kamenice 5, Brno 62500, Czech Republic; [Riad, Abanoub; Pokorna, Andrea; Klugarova, Jitka; Klugar, Miloslav] Masaryk Univ, Czech Natl Ctr Evidence Based Healthcare & Knowle, Czech EBHC JBI Ctr Excellence Masaryk Univ GRADE, Inst Biostat & Analyses,Fac Med, Kamenice 5, Brno 62500, Czech Republic; [Pokorna, Andrea; Klugarova, Jitka; Klugar, Miloslav] Masaryk Univ, Fac Med, Dept Nursing & Midwifery, Kamenice 5, Brno 62500, Czech Republic; [Pokorna, Andrea; Klugarova, Jitka; Klugar, Miloslav] Inst Hlth Informat & Stat Czech Republ, Palackeho Namesti 375-4, Prague 12801, Czech Republic; [Mekhemar, Mohamed; Conrad, Jonas] Univ Kiel, Sch Dent Med, Clin Conservat Dent & Periodontol, D-24105 Kiel, Germany; [Koscik, Michal] Masaryk Univ, Czech Clin Res Infrastruct Network, Dept Pharmacol, Fac Med, Kamenice 5, Brno 62500, Czech Republic; [Attia, Sameh] Justus Liebig Univ, Dept Oral & Maxillofacial Surg, Klinik St 33, D-35392 Giessen, Germany		Klugar, M (通讯作者)，Masaryk Univ, Fac Med, Dept Publ Hlth, Kamenice 5, Brno 62500, Czech Republic.; Klugar, M (通讯作者)，Masaryk Univ, Czech Natl Ctr Evidence Based Healthcare & Knowle, Czech EBHC JBI Ctr Excellence Masaryk Univ GRADE, Inst Biostat & Analyses,Fac Med, Kamenice 5, Brno 62500, Czech Republic.; Klugar, M (通讯作者)，Masaryk Univ, Fac Med, Dept Nursing & Midwifery, Kamenice 5, Brno 62500, Czech Republic.; Klugar, M (通讯作者)，Inst Hlth Informat & Stat Czech Republ, Palackeho Namesti 375-4, Prague 12801, Czech Republic.	abanoub.riad@med.muni.cz; apokorna@med.muni.cz; mekhemar@konspar.uni-kiel.de; conrad@konspar.uni-kiel.de; klugarova@med.muni.cz; koscik@med.muni.cz; klugar@med.muni.cz; sameh.attia@dentist.med.uni-giessen.de	Pokorna, Andrea/E-5483-2019; Klugarova, Jitka/V-1108-2019; Riad, Abanoub/AAU-7046-2020; Attia, Sameh/Z-4369-2019; Klugar, Miloslav/E-5748-2018	Pokorna, Andrea/0000-0002-1305-6455; Klugarova, Jitka/0000-0001-7254-9586; Riad, Abanoub/0000-0001-5918-8966; Attia, Sameh/0000-0002-9174-6435; Klugar, Miloslav/0000-0002-2804-7295; Mekhemar, Mohamed/0000-0003-4294-757X; Koscik, Michal/0000-0002-9243-6391	Masaryk University [MUNI/IGA/1543/2020, MUNI/A/1608/2020]; INTEREXCELLENCE grant [LTC20031]; European Regional Development Fund-Project CZECRIN_4 PACIENTY [CZ.02.1.01/0.0/0.0/16_013/0001826]; project Large Research infrastructure CZECRIN [LM2018128]	This study was funded by Masaryk University, grants number MUNI/IGA/1543/2020 and MUNI/A/1608/2020. The work of A.R., A.P., J.K. and M.K. was supported by the INTEREXCELLENCE grant number LTC20031-"Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic". The work of M.K. was supported by the European Regional Development Fund-Project CZECRIN_4 PACIENTY (No. CZ.02.1.01/0.0/0.0/16_013/0001826) and the project Large Research infrastructure CZECRIN (LM2018128).	Ammar N, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18041445; Ammar N, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239961; [Anonymous], ASTRAZENECA IMPFUNG; [Anonymous], Regulatory approval of Pfizer/BioNTech vaccine for COVID-19; Attia S, 2021, J CLIN MED, V10, DOI 10.3390/jcm10020288; Badrah M, 2021, J MED VIROL, V93, P2616, DOI 10.1002/jmv.26866; Boytchev H, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n619; Centres for Diseases Control and Prevention (CDC), REACT ADV EV PFIZ BI; CHMP, 2021, COVID 19 VACC ASTRAZ; CZECRIN, CZECH CLIN RES INFR; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; European Medicines Agency (EMA), COVID 19 VACC ASTRAZ; European Medicines Agency (EMA), EMA REC COVID 19 VAC; Frederiksen LSF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01817; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Habersaat KB, 2020, BUNDESGESUNDHEITSBLA, V63, P32, DOI 10.1007/s00103-019-03063-0; Heggie H., 2021, COVID 19 VACCINE PRO; Hockova B, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040581; Hung IFN, 2021, LANCET, V397, P854, DOI 10.1016/S0140-6736(21)00528-6; Jeskowiak I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050502; Knoll MD, 2021, LANCET, V397, P72, DOI 10.1016/S0140-6736(20)32623-4; KoBoToolbox, HARV HUM IN; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n774; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n728; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n86; Masaryk University, OR SID EFF COVID 19; Mekhemar M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10051008; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Proton Technologies AG, 7917271 PROT TECHN A; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122629; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071428; Riad A, 2021, J COSMET DERMATOL-US, V20, P1580, DOI 10.1111/jocd.14066; Riad A, 2021, DERMATOL THER, V34, DOI 10.1111/dth.14735; Riad A, 2021, SPEC CARE DENT, V41, P282, DOI 10.1111/scd.12547; Riad A, 2022, ORAL DIS, V28, P999, DOI 10.1111/odi.13675; Riad A, 2022, ORAL DIS, V28, P940, DOI 10.1111/odi.13516; Sawires L., EFFECTS INFLUENZA VA; Schaffer DeRoo S, 2020, JAMA-J AM MED ASSOC, V323, P2458, DOI 10.1001/jama.2020.8711; SPSS Inc, IBM SPSS STAT 27; Tarakji B, 2014, ANN MED HEALTH SCI R, V4, P829, DOI 10.4103/2141-9248.144870; Ustav Zdravotnickych Informaci a Statistiky eske Republiky (UZIS R), SYST HLAS NEZ UD SHN; von Elm E, 2007, BMJ-BRIT MED J, V335, P806; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699; Wollina U, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13549	46	22	22	4	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							673	10.3390/vaccines9060673			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY6MU	34207369	Green Published, gold			2022-04-29	WOS:000666000500001
J	Wagner, AL; Gresh, L; Sanchez, N; Kuan, G; Kubale, J; Lopez, R; Ojeda, S; Azziz-Baumgartner, E; Balmaseda, A; Gordon, A				Wagner, Abram L.; Gresh, Lionel; Sanchez, Nery; Kuan, Guillermina; Kubale, John; Lopez, Roger; Ojeda, Sergio; Azziz-Baumgartner, Eduardo; Balmaseda, Angel; Gordon, Aubree			Influenza Illness and Partial Vaccination in the First Two Years of Life	VACCINES			English	Article						vaccine effectiveness; human influenza; fever; hospitalization; vaccination	SEASONAL INFLUENZA; BURDEN; VACCINES; COHORT; VIRUSES	More information about influenza in low- and middle-income countries could guide the establishment of pediatric influenza vaccine programs. This study (1) characterizes the burden of influenza in infants, and (2) compares signs and symptoms by prior influenza vaccination or influenza illness. Newborns from Managua, Nicaragua, were followed for two years. Data came from primary medical appointments, PCR testing, and parents' daily symptom diaries. Logistic regression models estimated associations between preceding vaccination or illness and influenza incidence. Linear models compared duration of illness by prior vaccination or influenza illness. Among 833 infants, 31% had PCR-positive influenza, and 28% were vaccinated against influenza. Four (<0.5%) were fully vaccinated. Overall, influenza incidence was 21.0 (95% confidence interval (CI): 18.8, 23.2) per 100 person-years. Incidence was lower among those with prior influenza compared with those without preceding illness or vaccination (OR: 0.64, 95% CI: 0.44, 0.94). Partially vaccinated children had 1 day less fever than those without prior illness or vaccination (p = 0.049). A large proportion of children <2 years in Nicaragua contract influenza. Illness was attenuated for those partially vaccinated. Since few children were fully vaccinated, future studies will need to consider the effectiveness of a two-dose vaccination schedule.	[Wagner, Abram L.; Kubale, John; Gordon, Aubree] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 1415 Washington Hts, Ann Arbor, MI 48109 USA; [Gresh, Lionel; Sanchez, Nery; Kuan, Guillermina; Lopez, Roger; Ojeda, Sergio; Balmaseda, Angel] Sustainable Sci Inst, Managua 14007, Nicaragua; [Sanchez, Nery; Kuan, Guillermina; Ojeda, Sergio] Minist Hlth, Ctr Salud Socrates Flores Vivas, Managua 12014, Nicaragua; [Lopez, Roger; Balmaseda, Angel] Minist Hlth, Lab Nacl Virol, Ctr Nacl Diagnost & Referencia, Managua 16064, Nicaragua; [Azziz-Baumgartner, Eduardo] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA		Gordon, A (通讯作者)，Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 1415 Washington Hts, Ann Arbor, MI 48109 USA.	awag@umich.edu; lionel.gresh@gmail.com; nerysanchez@icsnicaragua.org; drakuan@yahoo.com.mx; jkubale@umich.edu; influenzacndr@minsa.gob.ni; sojeda@icsnicaragua.org; eha9@cdc.gov; abalmaseda@minsa.gob.ni; gordonal@umich.edu	Kubale, John/ABC-1076-2021	Kubale, John/0000-0001-5571-9774; Gordon, Aubree/0000-0002-9352-7877; Gresh, Lionel/0000-0002-2333-1748; Wagner, Abram/0000-0003-4691-7802	US Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [1U01GH000028-04]; National Institute of Allergy and Infectious Diseases, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [HHSN272201400006C]	This work was supported by the US Centers for Disease Control and Prevention (cooperative agreement 1U01GH000028-04) and by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (contract number HHSN272201400006C).	Arriola CS, 2019, VACCINE-X, V3, DOI 10.1016/j.jvacx.2019.100047; Belongia EA, 2010, JAMA-J AM MED ASSOC, V304, P1091, DOI 10.1001/jama.2010.1277; Bhan MK, 2019, LANCET GLOB HEALTH, V7, pE827, DOI 10.1016/S2214-109X(19)30195-0; Centers for Disease Control and Prevention, SEASONAL INFLUENZA V; Choi SM, 2011, BLOOD, V117, P5050, DOI 10.1182/blood-2010-11-319186; Dawa J, 2019, VACCINE, V37, P464, DOI 10.1016/j.vaccine.2018.11.062; Dawa JA, 2018, INFLUENZA OTHER RESP, V12, P30, DOI 10.1111/irv.12488; Dellepiane N, 2019, VACCINE, V37, P2982, DOI 10.1016/j.vaccine.2019.03.025; Descalzo MA, 2016, INFLUENZA OTHER RESP, V10, P340, DOI 10.1111/irv.12385; Gaglani M, 2016, J INFECT DIS, V213, P1546, DOI 10.1093/infdis/jiv577; Gordon A, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1256-6; Gordon A, 2010, CLIN INFECT DIS, V50, P1462, DOI 10.1086/652647; Gresh L, 2016, PEDIATR INFECT DIS J, V35, P152, DOI 10.1097/INF.0000000000000944; Grohskopf LA, 2020, JAMA-J AM MED ASSOC, V324, P1029, DOI 10.1001/jama.2020.15845; Grohskopf LA, 2018, MMWR RECOMM REP, V67, DOI 10.15585/mmwr.rr6703a1; Hannoun C, 2013, EXPERT REV VACCINES, V12, P1085, DOI 10.1586/14760584.2013.824709; Heikkinen T, 2014, CLIN INFECT DIS, V59, P1519, DOI 10.1093/cid/ciu664; Howard N, 2018, VACCINE, V36, P5536, DOI 10.1016/j.vaccine.2018.07.063; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jain VK, 2013, NEW ENGL J MED, V369, P2481, DOI 10.1056/NEJMoa1215817; Krammer F, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0002-y; Kumar D, 2010, LANCET INFECT DIS, V10, P521, DOI 10.1016/S1473-3099(10)70133-X; Marcone DN, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1213-4; Melendi GA, 2010, ACTA PAEDIATR, V99, P1517, DOI 10.1111/j.1651-2227.2010.01862.x; Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9; Nyamusore J, 2018, INFLUENZA OTHER RESP, V12, P38, DOI 10.1111/irv.12494; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Rasmussen SA, 2011, AM J OBSTET GYNECOL, V204, pS13, DOI 10.1016/j.ajog.2011.01.048; Ropero-Alvarez AM, 2016, HUM VACC IMMUNOTHER, V12, P2206, DOI 10.1080/21645515.2016.1157240; Schlaudecker EP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070867; The DHS Program, DHS PROGR WEALTH IND; Tinoco YO, 2017, CLIN INFECT DIS, V65, P1532, DOI 10.1093/cid/cix565; Wagner AL, 2020, VACCINE, V38, P4325, DOI 10.1016/j.vaccine.2020.04.028; Wang X, 2020, LANCET GLOB HEALTH, V8, pE497, DOI 10.1016/S2214-109X(19)30545-5; WHO, INTEGRATED MANAGEMEN; WHO, INFL SEAS; Zimmerman RK, 2016, CLIN INFECT DIS, V63, P1564, DOI 10.1093/cid/ciw635	37	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							676	10.3390/vaccines9060676			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ6TH	34203000	Green Published, gold			2022-04-29	WOS:000666694600001
J	Wilson, HL; Haddadi, A; Mutwiri, GK				Wilson, Heather L.; Haddadi, Azita; Mutwiri, George K.			Vaccine Formulation for Infectious Diseases and Adjuvant Mechanisms of Action	VACCINES			English	Editorial Material									[Wilson, Heather L.; Mutwiri, George K.] Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada; [Wilson, Heather L.; Mutwiri, George K.] Univ Saskatchewan, Sch Publ Hlth, Saskatoon, SK S7N 5E3, Canada; [Haddadi, Azita] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK S7N 5E3, Canada		Wilson, HL (通讯作者)，Univ Saskatchewan, Vaccine & Infect Dis Org, Saskatoon, SK S7N 5E3, Canada.; Wilson, HL (通讯作者)，Univ Saskatchewan, Sch Publ Hlth, Saskatoon, SK S7N 5E3, Canada.	heather.wilson@usask.ca; azita.haddadi@usask.ca; george.mutwiri@usask.ca		Haddadi, Azita/0000-0002-9997-7756; Wilson, Heather/0000-0002-1261-0901			Bao YL, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040762; Cao H, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040310; Castro LS, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040328; Chaffey A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050507; Fourie KR, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040773; Gogoi H, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030453; Haddadi A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040569; Lu L, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040754; Razim A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030234; Wang PF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030222; Wang YR, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030395	11	0	0	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							667	10.3390/vaccines9060667			3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ8AY	34207033	Green Published, gold			2022-04-29	WOS:000666782100001
J	Zuckerman, NS; Fleishon, S; Bucris, E; Bar-Ilan, D; Linial, M; Bar-Or, I; Indenbaum, V; Weil, M; Lustig, Y; Mendelson, E; Mandelboim, M; Mor, O; Zuckerman, N				Zuckerman, Neta S.; Fleishon, Shay; Bucris, Efrat; Bar-Ilan, Dana; Linial, Michal; Bar-Or, Itay; Indenbaum, Victoria; Weil, Merav; Lustig, Yaniv; Mendelson, Ella; Mandelboim, Michal; Mor, Orna; Zuckerman, Neta		Israel Natl Conso	A Unique SARS-CoV-2 Spike Protein P681H Variant Detected in Israel	VACCINES			English	Article						SARS-CoV-2; sequencing; virus neutralization; Covid-19; variant of concern	ALIGNMENT	The routine detection, surveillance, and reporting of novel SARS-CoV-2 variants is crucial, as these threaten to hinder global vaccination efforts. Herein we report a novel local variant with a non-synonymous mutation in the spike (S) protein P681H. This local Israeli variant was not associated with a higher infection rate or higher prevalence. Furthermore, the local variant was successfully neutralized by sera from fully vaccinated individuals at a comparable level to the B.1.1.7 variant and an Israel wild-type strain. While it is not a variant of concern, routine monitoring by sequencing is still required.	[Zuckerman, Neta S.; Fleishon, Shay; Bucris, Efrat; Bar-Ilan, Dana; Bar-Or, Itay; Indenbaum, Victoria; Weil, Merav; Lustig, Yaniv; Mendelson, Ella; Mandelboim, Michal; Mor, Orna; Zuckerman, Neta] Sheba Med Ctr, Israel Minist Hlth, Cent Virol Lab, IL-52621 Tel Hashomer, Israel; [Linial, Michal] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; [Mendelson, Ella; Mandelboim, Michal; Mor, Orna] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, IL-69978 Tel Aviv, Israel		Zuckerman, NS (通讯作者)，Sheba Med Ctr, Israel Minist Hlth, Cent Virol Lab, IL-52621 Tel Hashomer, Israel.	neta.zuckerman@sheba.health.gov.il; s.fleishon@gmail.com; efrat.bucris@sheba.health.gov.il; dana.barilan@sheba.health.gov.il; michall@mail.huji.ac.il; itay.baror@sheba.health.gov.il; viki.indenbaum@sheba.health.gov.il; merav.weil@sheba.health.gov.il; yaniv.lustig@sheba.health.gov.il; ella.mendelson@sheba.health.gov.il; michal.mandelboim@sheba.health.gov.il; orna.mor@sheba.health.gov.il; tozaot.negifim@sheba.health.gov.il		Bar-Ilan, Dana/0000-0002-3677-9402; Linial, Michal/0000-0002-9357-4526; Weil, Merav/0000-0002-4472-4081			Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Brielle ES, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050497; Bugembe D. L., 2021, MEDRXIV, DOI DOI 10.1101/2021.02.08.21251393; Charif D., 2007, STRUCTURAL APPROACHE, P207, DOI [10.1007/978-3-540-35306-5_10, DOI 10.1007/978-3-540-35306-5_10]; Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742; Davies Nicholas G, 2021, Science, V372, DOI 10.1126/science.abg3055; Edara Venkata Viswanadh, 2021, medRxiv, DOI 10.1101/2021.02.02.21250799; Ewels P, 2016, BIOINFORMATICS, V32, P3047, DOI 10.1093/bioinformatics/btw354; Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436; Lasek-Nesselquist E., 2021, TALE 3 SARS COV 2 VA, DOI [10.1101/2021.03.10.21253285, DOI 10.1101/2021.03.10.21253285]; Li H, 2011, BIOINFORMATICS, V27, P2987, DOI 10.1093/bioinformatics/btr509; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]; Morgan M., RSAMTOOLS BINARY ALI; Nguyen Lam-Tung, 2015, Mol Biol Evol, V32, P268, DOI 10.1093/molbev/msu300; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Sabino EC, 2021, LANCET, V397, P452, DOI 10.1016/S0140-6736(21)00183-5; Sagulenko P, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vex042; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494; Shulman LM, 2016, METHODS MOL BIOL, V1387, P55, DOI 10.1007/978-1-4939-3292-4_5; Tang JLW, 2021, J INFECTION, V82, pE27, DOI 10.1016/j.jinf.2020.12.024; Tegally H., 2020, EMERGENCE RAPID SPRE, DOI [10.1101/2020.12.21.20248640, DOI 10.1101/2020.12.21.20248640]; Tian F., 2021, MUTATION N501Y RBD S, DOI [10.1101/2021.02.14.431117, DOI 10.1101/2021.02.14.431117]; Underwood A, PANGOLIN LINEAGE ASS; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]	28	12	12	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							616	10.3390/vaccines9060616			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY8AK	34201088	Green Published, gold			2022-04-29	WOS:000666103700001
J	Lange, A; Borowik, A; Bochenska, J; Rossowska, J; Jaskula, E				Lange, Andrzej; Borowik, Agata; Bochenska, Jolanta; Rossowska, Joanna; Jaskula, Emilia			Immune Response to COVID-19 mRNA Vaccine-A Pilot Study	VACCINES			English	Article						COVID-19; SARS-COV-2; mRNA vaccine; antibodies response; IFN gamma blood cells release		Twenty individuals (17 females, 3 males, aged 31-65 years (range), median: 46) who received both doses of the BioNTech Pfizer mRNA vaccine were examined (11 to 31 days, median: 25) after the second dose for the presence of antibodies against peptides of SARS-COV-2 and some of MERS-CoV, SARS-CoV1, HCov229E, and HCoVNL63. Clinical evaluation revealed that six people had COVID-19 in the past. We found that: (i) Six people claimed the presence of unwanted effects of vaccination, which were more frequent in those with a history of COVID-19 (4 out of 6 vs. 2 out of 14, p = 0.037); (ii) All individuals independent of the past history of COVID-19 responded equally well in IgG but those who experienced the disease tended to do better in IgA class (729.04 vs. 529.78 U/mL, p = 0.079); (iii) All those who had experienced the disease had IgG antibodies against nucleocapsid antigens but also 5 out of 14 who had not had the disease (6/6 vs. 5/14, p = 0.014); (iv) Anti S2 antibodies were present in the patients having COVID-19 in the past but also were found in those who had not had the disease (6/6 vs. 8/14, p = 0.144); (v) All vaccinated people were highly positive in the IGRA and the level of released IFN gamma was correlated with the numbers of HLADR positive lymphocytes in the blood (R = 0.5766, p = 0.008).	[Lange, Andrzej; Rossowska, Joanna; Jaskula, Emilia] Polish Acad Sci, Hirszfeld Inst Immunol & Expt Therapy, PL-53114 Wroclaw, Poland; [Borowik, Agata; Bochenska, Jolanta; Jaskula, Emilia] Lower Silesian Ctr Cellular Transplantat Natl Bon, PL-53439 Wroclaw, Poland		Lange, A (通讯作者)，Polish Acad Sci, Hirszfeld Inst Immunol & Expt Therapy, PL-53114 Wroclaw, Poland.	andrzej.lange@hirszfeld.pl; borowik@dctk.wroc.pl; bochenska@dctk.wroc.pl; joanna.rossowska@hirszfeld.pl; emilia.jaskula@hirszfeld.pl	Jaskuła, Emilia/AAA-4515-2020; Lange, Andrzej/AAR-3247-2021; Rossowska, Joanna/Y-6164-2019	Jaskuła, Emilia/0000-0002-4894-7522; Lange, Andrzej/0000-0003-3544-1853; Rossowska, Joanna/0000-0002-3682-7160	Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences	This research was supported by Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences.	Angyal A., 2021, T CELL ANTIBODY RESP, DOI DOI 10.2139/SSRN.3812375; de Assis RR, 2021, NAT COMMUN, V12, DOI [10.1038/s41467-020-20095-2, 10.1101/2020.04.15.043364]; Forni G, 2021, CELL DEATH DIFFER, V28, P626, DOI 10.1038/s41418-020-00720-9; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Thieme CJ, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100092; Verbeke R, 2019, NANO TODAY, V28, DOI 10.1016/j.nantod.2019.100766	7	6	6	7	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							488	10.3390/vaccines9050488			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1RR	34064613	Green Published, gold			2022-04-29	WOS:000654603800001
J	Almaghaslah, D; Alsayari, A; Kandasamy, G; Vasudevan, R				Almaghaslah, Dalia; Alsayari, Abdulrhman; Kandasamy, Geetha; Vasudevan, Rajalakshimi			COVID-19 Vaccine Hesitancy among Young Adults in Saudi Arabia: A Cross-Sectional Web-Based Study	VACCINES			English	Article						vaccination hesitancy; Saudi Arbia; COVID-19; vaccine reluctance		Ending the COVID-19 pandemic requires achieving herd immunity, either by previous infection or by vaccination. However, concerns about the COVID-19 vaccine are growing around the globe. The current study was conducted to investigate young the adult population's hesitancy towards the vaccine. The study used a prospective cross-sectional design. Data was collected using an online self-administered questionnaire. A total of 862 Saudi adults participated. Information was gathered on the participants' perspectives towards the severity and susceptibility of the COVID-19 infection, reasons for their hesitancy to receive the vaccine, perceived benefits, and reasons for action. Just under a quarter (19.6%) of respondents had previously tested positive for COVID-19. A small minority of the participants had already received the vaccine (2.1%), while 20.3% had registered in the Sehaty app (application) to receive the vaccine. Just under half of them (48%) will take the vaccine when mass vaccination is achieved and approximately the same number (46.7%) will only take it if it is made mandatory. Vaccine reluctance is highly prevalent among the general public in Saudi Arabia during the COVID-19 pandemic. While many are aware of a high likelihood of getting the infection, the efficacy and safety of the COVID-19 vaccine were reported as barriers to vaccination.	[Almaghaslah, Dalia; Kandasamy, Geetha] King Khalid Univ, Coll Pharm, Dept Clin Pharm, POB 1882, Abha 61441, Saudi Arabia; [Alsayari, Abdulrhman] King Khalid Univ, Coll Pharm, Dept Pharmacognosy, POB 1882, Abha 61441, Saudi Arabia; [Vasudevan, Rajalakshimi] King Khalid Univ, Coll Pharm, Dept Pharmacol, POB 1882, Abha 61441, Saudi Arabia		Almaghaslah, D (通讯作者)，King Khalid Univ, Coll Pharm, Dept Clin Pharm, POB 1882, Abha 61441, Saudi Arabia.; Alsayari, A (通讯作者)，King Khalid Univ, Coll Pharm, Dept Pharmacognosy, POB 1882, Abha 61441, Saudi Arabia.	damoazle@kku.edu.sa; alsayari@kku.edu.sa; glakshmi@kku.edu.sa; raja@kku.edu.sa		, ABDULRHMAN/0000-0002-5479-9319; Vasudevan, Rajalakshimi/0000-0002-1173-7724; almaghaslah, Dalia/0000-0002-3094-0808			Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alkhamees AA, 2020, COMPR PSYCHIAT, V102, DOI 10.1016/j.comppsych.2020.152192; Almaghaslah D, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13637; Almaghaslah D, 2020, RISK MANAG HEALTHC P, V13, P795, DOI 10.2147/RMHP.S260918; Badiani A A, 2020, Public Health Pract (Oxf), V1, P100061, DOI 10.1016/j.puhip.2020.100061; Centers for Disease Control and Prevention (CDC), COVID 19 VACC; Coustasse A, 2021, J AMBUL CARE MANAG, V44, P71, DOI 10.1097/JAC.0000000000000360; De Kock JH, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-020-10070-3; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Largent EA, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.33324; Lawes-Wickwar S, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020072; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Mello MM, 2020, NEW ENGL J MED, V383, P1296, DOI 10.1056/NEJMp2020926; Minisitry of Health (MOH), MOH ANN RESCH COVID; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Savulescu J, 2021, J MED ETHICS, V47, P78, DOI 10.1136/medethics-2020-106821; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; World Health Organization, COR DIS COVID 19 VAC	23	26	26	4	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							330	10.3390/vaccines9040330			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4ZL	33915890	Green Published, gold			2022-04-29	WOS:000643789100001
J	De la Sen, M; Alonso-Quesada, S; Ibeas, A; Nistal, R				De la Sen, Manuel; Alonso-Quesada, Santiago; Ibeas, Asier; Nistal, Raul			On a Discrete SEIR Epidemic Model with Two-Doses Delayed Feedback Vaccination Control on the Susceptible	VACCINES			English	Article						discrete epidemic model; delayed feedback vaccination control; vaccination doses; COVID-19 pandemic	COVID-19; STABILITY; SYSTEMS	A new discrete susceptible-exposed-infectious-recovered (SEIR) epidemic model is presented subject to a feedback vaccination effort involving two doses. Both vaccination doses, which are subject to a non-necessarily identical effectiveness, are administrated by respecting a certain mutual delay interval, and their immunity effect is registered after a certain delay since the second dose. The delays and the efficacies of the doses are parameters, which can be fixed in the model for each concrete experimentation. The disease-free equilibrium point is characterized as well as its stability properties, while it is seen that no endemic equilibrium point exists. The exposed subpopulation is supposed to be infective eventually, under a distinct transmission rate of that of the infectious subpopulation. Some simulation examples are presented by using disease parameterizations of the COVID-19 pandemic under vaccination efforts requiring two doses.	[De la Sen, Manuel; Alonso-Quesada, Santiago; Nistal, Raul] Univ Basque Country, Fac Sci & Technol, Inst Res & Dev Proc IIDP, Leioa 48940, Spain; [Ibeas, Asier] Univ Autonoma Barcelona, Dept Telecommun & Syst Engn, Barcelona 08193, Spain		De la Sen, M (通讯作者)，Univ Basque Country, Fac Sci & Technol, Inst Res & Dev Proc IIDP, Leioa 48940, Spain.	manuel.delasen@ehu.eus; santiago.alonso@ehu.eus; Asier.Ibeas@uab.cat; raul.nistal@gmail.com	de la Sen, manuel/A-8803-2008; Ibeas, Asier/N-9703-2014; Alonso-Quesada, Santiago/F-1389-2015; Nistal, Raul/G-7945-2015	de la Sen, manuel/0000-0001-9320-9433; Ibeas, Asier/0000-0001-5094-3152; Alonso-Quesada, Santiago/0000-0002-4724-7583; Nistal, Raul/0000-0003-2196-1989	Spanish Government (MCIU/AEI/FEDER, UE)Spanish Government [RTI2018-094336-B-I00]; Basque GovernmentBasque Government [IT1207-19]; Spanish Institute of Health Carlos IIIInstituto de Salud Carlos III [COV 20/01213]	The authors are grateful to the Spanish Government for Grant RTI2018-094336-B-I00 (MCIU/AEI/FEDER, UE) and to the Basque Government for Grant IT1207-19. They also thank the Spanish Institute of Health Carlos III for its support through Grant COV 20/01213.	Abbasi Z, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110054; Alrashed Saleh, 2020, Inform Med Unlocked, V20, P100420, DOI 10.1016/j.imu.2020.100420; Anderez DO, 2020, SENSORS-BASEL, V20, DOI 10.3390/s20174967; Balabdaoui F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77420-4; Barcena, 2004, APPL ANAL, V83, P157, DOI [10.1080/00036810310001632844, DOI 10.1080/00036810310001632844]; Beardon A., 1979, COMPLEX ANAL ARGUMEN; Cao H, 2020, ADV DIFFER EQU-NY, V2020, DOI 10.1186/s13662-020-2510-9; Casella F, 2021, IEEE CONTR SYST LETT, V5, P1079, DOI 10.1109/LCSYS.2020.3009912; Chinwenyi, 2019, INT J MATH COMPUT SC, V13, P74; Conway A, 1978, FUNCTIONS ONE COMPLE; Cooper I, 2020, CHAOS SOLITON FRACT, V139, DOI 10.1016/j.chaos.2020.110057; Cordova-Lepe F, 2020, J DIFFER EQU APPL, V26, P1, DOI 10.1080/10236198.2019.1696323; Darti I, 2020, COMMUN MATH BIOL NEU, DOI 10.28919/cmbn/4710; De la Sen M, 2012, COMMUN NONLINEAR SCI, V17, P2637, DOI 10.1016/j.cnsns.2011.10.012; De la Sen M, 2021, MATHEMATICS-BASEL, V9, DOI 10.3390/math9050520; de la sen M, 2020, ALGORITHMS, V13, DOI 10.3390/a13120322; De la sen M, 2020, DISCRETE DYN NAT SOC, V2020, DOI 10.1155/2020/1382870; de la Sen M, 2020, SYMMETRY-BASEL, V12, DOI 10.3390/sym12101646; De la Sen M, 2020, ENTROPY-SWITZ, V22, DOI 10.3390/e22050534; DELASEN M, 1994, INT J CONTROL, V59, P529, DOI 10.1080/00207179408923091; Dodds PS, 2005, J THEOR BIOL, V232, P587, DOI 10.1016/j.jtbi.2004.09.006; Dutt A, 2020, PLANT PATHOL, V69, P1108, DOI 10.1111/ppa.13180; Etxeberria-Etxaniz M, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10228296; Geromel J.C, 2020, SOC BRAS AUTOM, V2, P2020; Hethcote HW, 2000, SIAM REV, V42, P599, DOI 10.1137/S0036144500371907; Iacobucci Gareth, 2021, BMJ, V372, pn18, DOI 10.1136/bmj.n18; Ibeas A, 2018, 2018 UKACC 12TH INTERNATIONAL CONFERENCE ON CONTROL (CONTROL), P456, DOI 10.1109/CONTROL.2018.8516767; Jiao HM, 2020, IEEE ACCESS, V8, P174507, DOI 10.1109/ACCESS.2020.3026089; Liu F, 2020, CHIN CONTR CONF, P724, DOI 10.23919/CCC50068.2020.9188952; Lorin E., 2020, MATH MODELING COMPUT, DOI [10.13140/RG.2.2.13857.22882, DOI 10.13140/RG.2.2.13857.22882]; Mendel J.M., 1973, DISCRETE TECHNIQUES; Ng KY, 2020, PHYSICA D, V411, DOI 10.1016/j.physd.2020.132599; Ng M.K.Y., SEIRS BASED COVID 19; Ngo KT, 1997, IEEE T AUTOMAT CONTR, V42, P538, DOI 10.1109/9.566665; Niamsup P, 2015, NEUROCOMPUTING, V160, P281, DOI 10.1016/j.neucom.2015.02.030; Nistal R, 2019, MATHEMATICS-BASEL, V7, DOI 10.3390/math7010018; Parsamanesh M, 2019, FILOMAT, V33, P2393, DOI 10.2298/FIL1908393P; Phat VN, 2012, LINEAR ALGEBRA APPL, V436, P243, DOI 10.1016/j.laa.2011.07.016; Radha R., 2020, INT J CONTROL AUTOMA, V13, P1088; Rohith G, 2020, NONLINEAR DYNAM, V101, P2013, DOI 10.1007/s11071-020-05774-5; Shalan Rehab Noori, 2021, Journal of Interdisciplinary Mathematics, V24, P1201, DOI 10.1080/09720502.2020.1814496; Singh RK, 2020, IEEE ACCESS, V8, P186932, DOI 10.1109/ACCESS.2020.3029614; Suryanto A, 2021, AIMS MATH, V6, P141, DOI 10.3934/math.2021010; Tuite AR, 2020, LANCET INFECT DIS, V20, P537, DOI 10.1016/S1473-3099(20)30227-9; Wang XH, 2020, PHYSICA A, V539, DOI 10.1016/j.physa.2019.122991; Wang Y, 2020, NONLINEAR DYNAM, V101, P1801, DOI 10.1007/s11071-020-05867-1; Wang Y, 2021, SCI CHINA INFORM SCI, V64, DOI 10.1007/s11432-019-2656-2; Youssef HM, 2020, MATH BIOSCI ENG, V17, P7018, DOI 10.3934/mbe.2020362; Zhai SD, 2021, NONLINEAR DYNAM, V106, P1133, DOI 10.1007/s11071-020-05961-4	49	4	3	3	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							398	10.3390/vaccines9040398			26	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4RN	33919501	Green Published, gold			2022-04-29	WOS:000643768300001
J	Eclercy, J; Renson, P; Hirchaud, E; Andraud, M; Beven, V; Paboeuf, F; Rose, N; Blanchard, Y; Bourry, O				Eclercy, Julie; Renson, Patricia; Hirchaud, Edouard; Andraud, Mathieu; Beven, Veronique; Paboeuf, Frederic; Rose, Nicolas; Blanchard, Yannick; Bourry, Olivier			Phenotypic and Genetic Evolutions of a Porcine Reproductive and Respiratory Syndrome Modified Live Vaccine after Limited Passages in Pigs	VACCINES			English	Article						PRRS virus; modified live vaccine; attenuation; variants; mutation	NUCLEAR-LOCALIZATION SIGNAL; SYNDROME VIRUS; PRRS VIRUS; ATTENUATION; MUTATIONS; DISEASE; PROTEIN; GENOME; RECOMBINATION; VIRULENCE	Modified live vaccines (MLVs) against the porcine reproductive and respiratory syndrome virus (PRRSV) have been regularly associated with safety issues, such as reversion to virulence. In order to characterize the phenotypic and genetic evolution of the PRRSV-1 DV strain from the Porcilis(R) PRRS MLV after limited passages in pigs, three in vivo experiments were performed. Trial#1 aimed (i) at studying transmission of the vaccine strain from vaccinated to unvaccinated contact pigs. Trial#2 and Trial#3 were designed (ii) to assess the reproducibility of Trial#1, using another vaccine batch, and (iii) to compare the virulence levels of two DV strains isolated from vaccinated (passage one) and diseased contact pigs (passage two) from Trial#1. DV strain isolates from vaccinated and contact pigs from Trial#1 and Trial#2 were submitted to Next-Generation Sequencing (NGS) full-genome sequencing. All contact animals from Trial#1 were infected and showed significantly increased viremia compared to vaccinated pigs, whereas no such change was observed during Trial#2. In Trial#3, viremia and transmission were higher for inoculated pigs with passage two of the DV strain, compared with passage one. In this study, we showed that the re-adaptation of the DV strain to pigs is associated with faster replication and increased transmission of the vaccine strain. Punctually, a decrease of attenuation of the DV vaccine strain associated with clinical signs and increased viremia may occur after limited passages in pigs. Furthermore, we identified three mutations linked to pig re-adaptation and five other mutations as potential virulence determinants.	[Eclercy, Julie; Renson, Patricia; Hirchaud, Edouard; Andraud, Mathieu; Beven, Veronique; Paboeuf, Frederic; Rose, Nicolas; Blanchard, Yannick; Bourry, Olivier] Agence Natl Securite Sanit Alimentat Environm & T, Lab Ploufragan Plouzane Niort, BP 53, F-22440 Ploufragan, France		Bourry, O (通讯作者)，Agence Natl Securite Sanit Alimentat Environm & T, Lab Ploufragan Plouzane Niort, BP 53, F-22440 Ploufragan, France.	julie.eclercy@gmail.com; patricia.renson@anses.fr; edouard.hirchaud@anses.fr; mathieu.andraud@anses.fr; veronique.beven@anses.fr; frederic.paboeuf@anses.fr; nicolas.rose@anses.fr; yannick.blanchard@anses.fr; olivier.bourry@anses.fr	Andraud, Mathieu/AAD-5844-2022	Patricia, RENSON/0000-0001-8329-8479; BOURRY, Olivier/0000-0003-0220-0922	Anses (CRD funding); Conseil regional de BretagneRegion Bretagne	This work was supported by Anses (CRD funding) and the "Conseil regional de Bretagne".	Allende R, 2000, ARCH VIROL, V145, P1149, DOI 10.1007/s007050070115; An TQ, 2011, VET MICROBIOL, V149, P104, DOI 10.1016/j.vetmic.2010.11.001; Balasuriya UBR, 2017, CURR OPIN VIROL, V27, P57, DOI 10.1016/j.coviro.2017.11.005; Botner A, 1999, VET MICROBIOL, V68, P187, DOI 10.1016/S0378-1135(99)00053-X; Botner A, 1997, VET REC, V141, P497, DOI 10.1136/vr.141.19.497; Charerntantanakul Wasin, 2012, World J Virol, V1, P23, DOI 10.5501/wjv.v1.i1.23; Charpin C, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-69; Chastagner A, 2018, J VIROL, V92, DOI [10.1128/JVI.00988-18, 10.1128/jvi.00988-18]; Cortey M, 2018, VET RES, V49, DOI 10.1186/s13567-018-0603-1; Eclercy J, 2020, VET MICROBIOL, V244, DOI 10.1016/j.vetmic.2020.108656; Eclercy J, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030296; Grebennikova TV, 2004, VIROLOGY, V321, P383, DOI 10.1016/j.virol.2004.01.001; Holtkamp DJ, 2013, J SWINE HEALTH PROD, V21, P72; Kappes MA, 2015, VIROLOGY, V479, P475, DOI 10.1016/j.virol.2015.02.012; Khatun A, 2016, J VIROL, V90, P4454, DOI 10.1128/JVI.02836-15; Kimman TG, 2009, VACCINE, V27, P3704, DOI 10.1016/j.vaccine.2009.04.022; Kvisgaard L.K., 2015, P 7 INT S EM REEM PI; Kvisgaard LK, 2020, TRANSBOUND EMERG DIS, V67, P1786, DOI 10.1111/tbed.13555; Kwon B, 2008, VIROLOGY, V380, P371, DOI 10.1016/j.virol.2008.07.030; Lee C, 2006, VIROLOGY, V346, P238, DOI 10.1016/j.virol.2005.11.005; Lunney JK, 2010, VIRUS RES, V154, P1, DOI 10.1016/j.virusres.2010.10.009; Madsen KG, 1998, ARCH VIROL, V143, P1683, DOI 10.1007/s007050050409; Martin-Valls GE, 2014, J VIROL, V88, P3170, DOI 10.1128/JVI.02858-13; Murtaugh MP, 2010, VIRUS RES, V154, P18, DOI 10.1016/j.virusres.2010.08.015; Nan YC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01635; Nathues H, 2017, PREV VET MED, V142, P16, DOI 10.1016/j.prevetmed.2017.04.006; Ni YY, 2013, J VIROL, V87, P304, DOI 10.1128/JVI.01789-12; Nielsen HS, 2001, J GEN VIROL, V82, P1263, DOI 10.1099/0022-1317-82-6-1263; Oh W.T., 2017, J AGR SCI TECH-IRAN, V7, P282, DOI [10.17265/2161-6256/2017.04.006, DOI 10.17265/2161-6256/2017.04.006]; OIE, 2015, MANUAL DIAGNOSTIC TE; Pei Y, 2008, VIRUS RES, V135, P107, DOI 10.1016/j.virusres.2008.02.012; Renson P, 2019, VACCINE, V37, P4318, DOI 10.1016/j.vaccine.2019.06.045; Ropp SL, 2004, J VIROL, V78, P3684, DOI 10.1128/JVI.78.7.3684-3703.2004; Rose N, 2015, VACCINE, V33, P2493, DOI 10.1016/j.vaccine.2015.03.040; Siddell SG, 2019, ARCH VIROL, V164, P943, DOI 10.1007/s00705-018-04136-2; Song JW, 2019, J VIROL, V93, DOI 10.1128/JVI.01436-19; Spear A, 2018, VIROLOGY, V516, P30, DOI 10.1016/j.virol.2017.12.029; Storgaard T, 1999, ARCH VIROL, V144, P2389, DOI 10.1007/s007050050652; Wang FX, 2013, RES VET SCI, V95, P1, DOI 10.1016/j.rvsc.2013.03.015; WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296; Xie JX, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010036; Yu XL, 2013, CLIN VACCINE IMMUNOL, V20, P613, DOI 10.1128/CVI.00672-12; Yuan SS, 2001, VIRUS RES, V74, P99, DOI 10.1016/S0168-1702(00)00250-1	43	1	1	1	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							392	10.3390/vaccines9040392			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4OW	33923464	gold, Green Published			2022-04-29	WOS:000643761400001
J	Ghazali, DA; Choquet, C; Bouzid, D; Colosi, L; Ben Hammouda, A; Wargon, M; Gay, M; Ayar, PV; Douay, B; Revue, E; Soulat, L; Hellmann, R; Casalino, E				Ghazali, Daniel Aiham; Choquet, Christophe; Bouzid, Donia; Colosi, Luisa; Ben Hammouda, Arsalene; Wargon, Mathias; Gay, Matthieu; Ayar, Prabakar Vaittinada; Douay, Bendecite; Revue, Eric; Soulat, Louis; Hellmann, Romain; Casalino, Enrique			Analysis of the Feasibility of a Vaccination Campaign against Influenza Epidemic and COVID-19 Pandemic in French Emergency Departments: A National Survey	VACCINES			English	Article						influenza; COVID-19; vaccination campaign; emergency departments; healthcare workers; patients	PRACTICE TRANSFORMATION PROGRAM; HEALTH-CARE WORKERS; SEASONAL INFLUENZA; KNOWLEDGE; COMMUNICATION; IMMUNIZATION; AWARENESS; PESHAWAR; ATTITUDE	Background: Vaccination is one of the most effective ways to fight the influenza epidemic and the coronavirus disease 2019 (COVID-19) pandemic, which represent a major public issue. The objective was to investigate the adherence of heads of French emergency departments (ED) and nursing departments on a potential vaccination campaign of healthcare workers (HCW) and patients in ED. Method: In February 2021, ED and nursing department heads were asked to answer a national survey. It included 24 questions designed to cover some dimensions, including characteristics of the hospital and emergency departments (ED) and questions on vaccination. Results: 414 responses out of 800 questionnaires (51.8%) were collected. Scores out of 10 were, respectively, 7 (6-8) and 8 (6-9) for vaccination against influenza and COVID-19 for HCW and 2 (2-3) and 2 (2-4) for ED patients (H = 989.3; p < 0.0001). Multivariate logistic regression found that the existence of a vaccine program in the hospital and the use of point of care influenza PCR in ED were positively associated with the acceptance of influenza vaccination campaign for HCW (p = 0.003) and patients (p = 0.015). Factors limiting adherence to a vaccination program of HCW and patients were lack of medical staff (p = 0.041 for HCW and p < 0.0001 for patients), overcrowded ED (p < 0.001), and the inability to follow up with patients after the ED visit (p < 0.0001). Conclusions: There have been many missed opportunities for influenza vaccination, and there is pressure to vaccinate against COVID-19 as soon as possible. Vaccination campaigns in ED could help to improve vaccination coverage. ED staff are more likely to vaccinate HCW than patients. There are factors that support the implementation of such programs, which can be grouped into a culture of diagnosis, control, and prevention of viral infectious diseases within the hospital and ED. On the other hand, there are limiting factors, such as overcrowding and lack of personnel.	[Ghazali, Daniel Aiham; Choquet, Christophe; Bouzid, Donia; Colosi, Luisa; Hellmann, Romain; Casalino, Enrique] Univ Hosp Bichat, AP HP, Emergency Dept, F-75018 Paris, France; [Ghazali, Daniel Aiham; Choquet, Christophe; Bouzid, Donia; Colosi, Luisa; Hellmann, Romain; Casalino, Enrique] Univ Hosp Bichat, AP HP, EMS, F-75018 Paris, France; [Ghazali, Daniel Aiham; Choquet, Christophe; Bouzid, Donia; Colosi, Luisa; Ben Hammouda, Arsalene; Wargon, Mathias; Revue, Eric; Hellmann, Romain; Casalino, Enrique] Univ Paris, French Natl Study Grp Efficiency & Qual Emergency, F-75018 Paris, France; [Ghazali, Daniel Aiham; Bouzid, Donia; Casalino, Enrique] Univ Paris, INSERM, UMR1137, IAME Infect Antimicrobial Modeling Evaluat, F-75018 Paris, France; [Ghazali, Daniel Aiham; Douay, Bendecite; Casalino, Enrique] Hop Beaujon, Emergency Med Serv, F-92110 Clichy, France; [Ben Hammouda, Arsalene] Hop Cote Fleurie, Emergency Dept, F-14113 Cricquebceuf, France; [Wargon, Mathias] Hop Delafontaine, Emergency Dept, F-93200 St Denis, France; [Gay, Matthieu; Ayar, Prabakar Vaittinada] Hop Beaujon, Emergency Dept, F-92110 Clichy, France; [Revue, Eric] Hop Lariboisiere, AP HP, Emergency Dept, F-75010 Paris, France; [Soulat, Louis] CHU Rennes, Hop PONCHAILLOU, SAMUSMUR Urgences, Emergengy Dept, F-35000 Rennes, France; [Hellmann, Romain] Reg Hlth Agcy Ile France, F-93200 St Denis, France		Ghazali, DA (通讯作者)，Univ Hosp Bichat, AP HP, Emergency Dept, F-75018 Paris, France.; Ghazali, DA (通讯作者)，Univ Hosp Bichat, AP HP, EMS, F-75018 Paris, France.; Ghazali, DA (通讯作者)，Univ Paris, French Natl Study Grp Efficiency & Qual Emergency, F-75018 Paris, France.; Ghazali, DA (通讯作者)，Univ Paris, INSERM, UMR1137, IAME Infect Antimicrobial Modeling Evaluat, F-75018 Paris, France.; Ghazali, DA (通讯作者)，Hop Beaujon, Emergency Med Serv, F-92110 Clichy, France.	danielaiham.ghazali@aphp.fr; Christophe.choquet@aphp.fr; donia.bouzid@aphp.fr; luisa.colosi@aphp.fr; abenhammouda@ch-cotefleurie.fr; mathias.wargon@ch-stdenis.fr; matthieu.gay@aphp.fr; prabakar.vaittinadaayar@aphp.fr; benedicte.douay@aphp.fr; eric.revue@aphp.fr; Louis.SOULAT@chu-rennes.fr; Romain.HELLMANN@ars.sante.fr; enrique.casalino@aphp.fr	GHAZALI, Daniel Aiham/ABC-7430-2021; Bouzid, Donia/AAC-9054-2022	GHAZALI, Daniel Aiham/0000-0003-0129-4322; Bouzid, Donia/0000-0002-7538-3320; Wargon, Mathias/0000-0003-0116-5571; Hellmann, Romain/0000-0002-0574-8152; louis, soulat/0000-0002-7222-3006; VAITTINADA AYAR, Prabakar/0000-0003-2043-3391			Ali I, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00173; Anton F, 2016, Semergen, V42, P147, DOI 10.1016/j.semerg.2015.02.014; Bechini A, 2017, HUM VACC IMMUNOTHER, V13, P369, DOI 10.1080/21645515.2017.1268008; Casalino Enrique, 2020, Disaster Med Public Health Prep, P1, DOI 10.1017/dmp.2020.331; Casalino E, 2018, INTERN EMERG MED, V13, P673, DOI 10.1007/s11739-018-1852-8; Casalino E, 2018, PLOS ONE, V13, DOI [10.1371/journal.pone.0193029, 10.1371/journa.pone.0193029]; Cheng PY, 2015, INFLUENZA OTHER RESP, V9, P13, DOI 10.1111/irv.12317; Grohskopf LA, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6505a1; Hulo S, 2017, VACCINE, V35, P205, DOI 10.1016/j.vaccine.2016.11.086; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Khan TM, 2016, VACCINE, V34, P1393, DOI 10.1016/j.vaccine.2016.01.045; Lee K, 2009, GLOB INST, P1; Li YD, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00695-2; Lin CJ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1940-1; Ministere des Solidarites et de la Sante, 2021, TABL BORD VACC; Ministere des Solidarites et de la Sante Statistique Annuelle des Etablissements de Sante, CAR STRUCT URG IMPL; Nowalk MP, 2016, VACCINE, V34, P5026, DOI 10.1016/j.vaccine.2016.07.053; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Palache A, 2014, VACCINE, V32, P6369, DOI 10.1016/j.vaccine.2014.07.012; Pavia AT, 2010, CLIN INFECT DIS, V50, P465, DOI 10.1086/650753; Pichon M, 2019, J CLIN VIROL, V116, P29, DOI 10.1016/j.jcv.2019.04.008; Rashid H, 2016, HEALTH AFFAIR, V35, P284, DOI 10.1377/hlthaff.2015.1087; Rosselli R, 2017, ADV EXP MED BIOL, V973, P125, DOI 10.1007/5584_2017_39; Sante Publique France, 2021, COVID 19 POINT EP 11; Sante Publique France, 2020, COVID 19 POINT EP 17; Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034; World Health Organization, 2020, 2019 NCOV OUTBR IS E; Zimmerman RK, 2017, J AM GERIATR SOC, V65, P114, DOI 10.1111/jgs.14451	28	0	0	3	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							400	10.3390/vaccines9040400			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4PO	33921563	gold, Green Published			2022-04-29	WOS:000643763200001
J	Konopinska, J; Obuchowska, I; Lisowski, L; Dub, N; Kozera, M; Rekas, M				Konopinska, Joanna; Obuchowska, Iwona; Lisowski, Lukasz; Dub, Natalia; Kozera, Milena; Rekas, Marek			Intention to Get COVID-19 Vaccinations among Ophthalmology Residents in Poland: A Cross-Sectional Survey	VACCINES			English	Article						COVID-19 vaccine; vaccine acceptance and hesitancy; ophthalmology residents; Poland	VACCINE HESITANCY; CARE	This study aimed to evaluate the acceptability of coronavirus disease of 2019 (COVID-19) vaccination among ophthalmology residents in Poland. An online, self-administered, anonymous survey was distributed among Polish ophthalmology residents in early 2021. Of 126 residents who completed the survey, 71.4% indicated that they would get vaccinated, 17.5% were unsure, and 11.1% would refuse vaccination. Married respondents with children (p = 0.036) and respondents living with their families (p = 0.310) were more likely to accept vaccination, believing that the vaccine is effective (p = 0.002 and p = 0.001, respectively), and fearing for themselves (p = 0.031 and p = 0.023, respectively) or their families (p = 0.032 and 0.055, respectively) getting infected. Respondents who contracted COVID-19 often reported the expected relief in sanitization (p = 0.011) as their reason for vaccination, and the previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (p = 0.050) as their reason for not vaccinating. Unmarried residents and residents living alone often declared that they were waiting for the effectiveness and long-term complications of the vaccine to be assessed (p = 0.005, both). Residents living with their families were significantly less likely to report COVID-19 as the reason for refusing vaccination (p = 0.022). In conclusion, most ophthalmology residents expressed a willingness to get vaccinated. Marital status and cohabitants affect vaccination acceptance. People with COVID-19 have different reasons for accepting or refusing vaccination. Medical authorities should persuade citizens more to vaccinate.	[Konopinska, Joanna; Obuchowska, Iwona; Lisowski, Lukasz; Dub, Natalia] Med Univ Bialystok, Dept Ophthalmol, PL-15276 Bialystok, Poland; [Kozera, Milena; Rekas, Marek] Mil Inst Med, Dept Ophthalmol, PL-04141 Warsaw, Poland		Konopinska, J (通讯作者)，Med Univ Bialystok, Dept Ophthalmol, PL-15276 Bialystok, Poland.	joannakonopinska@o2.pl; iwonaobu@wp.pl; lisowski@vp.pl; natalkand@wp.pl; m.kozera@onet.eu; rekaspl@gmail.com	Konopinska, Joanna/ABC-6118-2021	Konopinska, Joanna/0000-0002-9088-6938; Obuchowska, Iwona/0000-0002-8164-3782			CONVERSE PE, 1986, SCIENCE, V234, P1094, DOI 10.1126/science.234.4780.1094; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Felice C, 2020, J COMMUN HEALTH, V45, P675, DOI 10.1007/s10900-020-00845-5; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Kaur R, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03231-8; Lyson T, 2021, ADV MED SCI-POLAND, V66, P221, DOI 10.1016/j.advms.2021.03.001; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Nguyen LH, 2020, LANCET PUBLIC HEALTH, V5, pE475, DOI 10.1016/S2468-2667(20)30164-X; Nzaji MK, 2020, PRAGMAT OBS RES, V11, P103, DOI 10.2147/POR.S271096; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030218; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047	14	9	9	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							371	10.3390/vaccines9040371			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5FR	33920462	Green Published, gold			2022-04-29	WOS:000643805400001
J	Blondin-Ladrie, L; Aranguren, M; Doyon-Laliberte, K; Poudrier, J; Roger, M				Blondin-Ladrie, Laurence; Aranguren, Matheus; Doyon-Laliberte, Kim; Poudrier, Johanne; Roger, Michel			The Importance of Regulation in Natural Immunity to HIV	VACCINES			English	Review						natural immunity; HIV; highly exposed seronegative (HESN); regulatory cells	HUMAN-IMMUNODEFICIENCY-VIRUS; COMMERCIAL SEX WORKERS; FEMALE GENITAL-TRACT; T-CELL RESPONSES; DENDRITIC CELLS; MUCOSAL IMMUNITY; TH17 CELLS; BACTERIAL VAGINOSIS; REPRODUCTIVE-TRACT; NEUTRALIZING ANTIBODIES	Worldwide, most Human Immunodeficiency Virus (HIV) infections are acquired through heterosexual intercourse, and in sub-Saharan Africa, 59% of new HIV infections affect women. Vaccines and microbicides hold promise for preventing the acquisition of HIV. To this end, the study of HIV highly exposed seronegative (HESN) female commercial sex workers (CSWs), who constitute a model of natural immunity to HIV, provides an exceptional opportunity to determine important clues for the development of preventive strategies. Studies using both female genital tract (FGT) and peripheral blood samples of HESN CSWs, have allowed identifying distinct features, notably low-inflammatory patterns associated with resistance to infection. How this seemingly regulated response is achieved at the initial site of HIV infection remains unknown. One hypothesis is that populations presenting regulatory profiles contribute to the orchestration of potent anti-viral and low-inflammatory responses at the initial site of HIV transmission. Here, we view to update our knowledge regarding this issue.	[Blondin-Ladrie, Laurence; Aranguren, Matheus; Doyon-Laliberte, Kim; Poudrier, Johanne; Roger, Michel] Ctr Rech Ctr Hosp Univ Montreal CRCHUM, Axe Immunopathol, Montreal, PQ H2X0A9, Canada; [Blondin-Ladrie, Laurence; Aranguren, Matheus; Doyon-Laliberte, Kim; Poudrier, Johanne; Roger, Michel] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ H3C3J7, Canada; [Roger, Michel] Inst Natl Sante Publ Quebec, Montreal, PQ H2P1E2, Canada		Poudrier, J; Roger, M (通讯作者)，Ctr Rech Ctr Hosp Univ Montreal CRCHUM, Axe Immunopathol, Montreal, PQ H2X0A9, Canada.; Poudrier, J; Roger, M (通讯作者)，Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ H3C3J7, Canada.; Roger, M (通讯作者)，Inst Natl Sante Publ Quebec, Montreal, PQ H2P1E2, Canada.	laurence.blondin-ladrie@umontreal.ca; mat.aranguren@gmail.com; K.DOYONLALIBERTE@VIDEOTRON.CA; johanne.poudrier@crchum.qc.ca; michel.roger@ssss.gouv.qc.ca		Naegele Aranguren, Matheus/0000-0002-1966-796X	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Reseau SIDA et Maladies Infectieuses, Fonds de Recherche du Quebec en Sante (FRQS)	This work was supported by Grants from the Canadian Institutes of Health Research (CIHR) and the Reseau SIDA et Maladies Infectieuses, Fonds de Recherche du Quebec en Sante (FRQS).	Abdulhaqq SA, 2016, MUCOSAL IMMUNOL, V9, P1027, DOI 10.1038/mi.2015.116; Abel AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01869; Alcaide ML, 2017, INT J WOMENS HEALTH, V9, P123, DOI 10.2147/IJWH.S125883; Aldunate M, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00164; Alexander R, 2007, CURR HIV RES, V5, P588, DOI 10.2174/157016207782418452; Alimonti JB, 2005, J INFECT DIS, V191, P20, DOI 10.1086/425998; Alimonti JB, 2006, IMMUNOL CELL BIOL, V84, P482, DOI 10.1111/j.1440-1711.2006.01455.x; Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Amabebe E, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00181; Amodio G, 2015, HAEMATOLOGICA, V100, P551, DOI 10.3324/haematol.2014.113803; Amodio G, 2012, TRANSPLANT RES, V1, DOI 10.1186/2047-1440-1-14; Anahtar MN, 2015, IMMUNITY, V42, P965, DOI 10.1016/j.immuni.2015.04.019; Attanasio J, 2016, IMMUNITY, V44, P1052, DOI 10.1016/j.immuni.2016.04.022; Ayad MW, 2015, MOL DIAGN THER, V19, P99, DOI 10.1007/s40291-015-0134-7; Baban B, 2009, J IMMUNOL, V183, P2475, DOI 10.4049/jimmunol.0900986; Ball TB, 2007, AIDS, V21, P1091, DOI 10.1097/QAD.0b013e3280ef6ae1; Barr FD, 2018, MUCOSAL IMMUNOL, V11, P1420, DOI 10.1038/s41385-018-0045-0; Batraville LA, 2014, AIDS RES HUM RETROV, V30, P1145, DOI 10.1089/aid.2014.0163; Bautista CT, 2016, MILITARY MED RES, V3, DOI 10.1186/s40779-016-0074-5; Bertram KM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10697-w; Bialecki E, 2009, J IMMUNOL, V182, P6105, DOI 10.4049/jimmunol.0802273; Bienenstock J, 1978, Adv Exp Med Biol, V107, P53; Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42; Bomsel M, 2011, IMMUNITY, V34, P269, DOI 10.1016/j.immuni.2011.01.015; Borges S, 2014, ARCH GYNECOL OBSTET, V289, P479, DOI 10.1007/s00404-013-3064-9; Boulet S, 2008, AIDS, V22, P1487, DOI 10.1097/QAD.0b013e3282ffde7e; Boulet S, 2019, P NATL ACAD SCI USA, V116, P15150, DOI 10.1073/pnas.1821296116; Bouschbacher M, 2008, AIDS, V22, P1257, DOI 10.1097/QAD.0b013e3282f736f4; Bradshaw CS, 2006, J INFECT DIS, V193, P1478, DOI 10.1086/503780; BREEN EC, 1990, J IMMUNOL, V144, P480; Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301; Bruxelle JF, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9020228; Card CM, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-141; Card CM, 2009, J INFECT DIS, V199, P1318, DOI 10.1086/597801; Cecchinato V, 2010, CURR OPIN HIV AIDS, V5, P141, DOI 10.1097/COH.0b013e32833653ec; Cerutti A, 2013, NAT REV IMMUNOL, V13, P118, DOI 10.1038/nri3383; Chagnon-Choquet J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101949; Chang CC, 2002, NAT IMMUNOL, V3, P237, DOI 10.1038/ni760; Chew GM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005349; Cleret-Buhot A, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0226-9; Connell BJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71699-z; Corey L., 2008, SEX TRANSM DIS, V4; Cremel M, 2005, J LEUKOCYTE BIOL, V78, P158, DOI 10.1189/jlb.0305147; Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012; den Dunnen J, 2009, CANCER IMMUNOL IMMUN, V58, P1149, DOI 10.1007/s00262-008-0615-1; Devito C, 2000, J IMMUNOL, V165, P5170, DOI 10.4049/jimmunol.165.9.5170; Dold L, 2021, J MOL MED, V99, P147, DOI 10.1007/s00109-020-01996-7; Dold L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134158; Dorrell L, 2000, AIDS, V14, P1117, DOI 10.1097/00002030-200006160-00008; Doyon-Laliberte K, 2019, ANTIBODIES, V8, DOI 10.3390/antib8040050; Duchemin M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01141; Dupont M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050492; Duren RP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150450; Eastment MC, 2018, AIDS, V32, P687, DOI 10.1097/QAD.0000000000001768; Favre D, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000295; Fenizia C, 2018, INFECT GENET EVOL, V66, P325, DOI 10.1016/j.meegid.2017.12.014; Fontaine J, 2011, BLOOD, V117, P145, DOI 10.1182/blood-2010-08-301887; Fontenot D, 2009, P NATL ACAD SCI USA, V106, P16776, DOI 10.1073/pnas.0907347106; Fourcade L, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007840; Fourcade L, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040215; Gaynor LM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00467; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Gill N, 2010, NAT IMMUNOL, V11, P558, DOI 10.1038/ni0710-558; Girard A, 2019, AIDS, V33, P411, DOI 10.1097/QAD.0000000000002099; Gonzalez SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00144; Gosmann C, 2017, IMMUNITY, V46, P29, DOI 10.1016/j.immuni.2016.12.013; Goulder PJR, 2012, IMMUNITY, V37, P426, DOI 10.1016/j.immuni.2012.09.005; Grant-Tschudy KS, 2005, J REPROD IMMUNOL, V67, P1, DOI 10.1016/j.jri.2005.06.001; Gray GE, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax1880; Gregori S, 2010, BLOOD, V116, P935, DOI 10.1182/blood-2009-07-234872; Gribar SC, 2008, MOL MED, V14, P645, DOI 10.2119/2008-00035.Gribar; Gringhuis SI, 2009, NAT IMMUNOL, V10, P1081, DOI 10.1038/ni.1778; Gunn BM, 2016, MUCOSAL IMMUNOL, V9, P1549, DOI 10.1038/mi.2016.8; Haase AT, 2011, ANNU REV MED, V62, P127, DOI 10.1146/annurev-med-080709-124959; Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757; Hanna RN, 2011, NAT IMMUNOL, V12, P778, DOI 10.1038/ni.2063; Happel AU, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12080832; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; He B, 2006, J IMMUNOL, V176, P3931, DOI 10.4049/jimmunol.176.7.3931; Hertoghs N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226651; Hibino S, 2018, CANCER RES, V78, P3027, DOI 10.1158/0008-5472.CAN-17-3102; Hladik F, 2007, IMMUNITY, V26, P257, DOI 10.1016/j.immuni.2007.01.007; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Horton RE, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00200; HU PF, 1995, J ACQ IMMUN DEF SYND, V10, P331; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jackson E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185160; Jalbert E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075500; Ji HZ, 2010, SCAND J INFECT DIS, V42, P389, DOI 10.3109/00365540903496536; Jiang XW, 2015, J VIROL, V89, P11457, DOI 10.1128/JVI.01384-15; Kader M, 2009, MUCOSAL IMMUNOL, V2, P439, DOI 10.1038/mi.2009.90; Kamya P, 2011, J VIROL, V85, P5949, DOI 10.1128/JVI.02652-10; Karuna ST, 2020, ANNU REV MED, V71, P329, DOI 10.1146/annurev-med-110118-045506; Kaul R, 1999, AIDS, V13, P23, DOI 10.1097/00002030-199901140-00004; Kaul R, 2001, J CLIN INVEST, V107, P341, DOI 10.1172/JCI10714; Khaitan A, 2016, JAIDS-J ACQ IMM DEF, V72, P474, DOI 10.1097/QAI.0000000000001000; Kim JH, 2015, ANNU REV MED, V66, P423, DOI 10.1146/annurev-med-052912-123749; King A, 1991, Dev Immunol, V1, P169, DOI 10.1155/1991/83493; Kulkarni V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01581; Kutteh WH, 1998, AIDS RES HUM RETROV, V14, pS51; Lajoie J, 2008, MUCOSAL IMMUNOL, V1, P309, DOI 10.1038/mi.2008.18; Lajoie J, 2014, J INFECT DIS, V210, P319, DOI 10.1093/infdis/jiu023; Lajoie J, 2010, J CLIN IMMUNOL, V30, P90, DOI 10.1007/s10875-009-9343-3; Lambert JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082599; Lambotte O, 2009, AIDS, V23, P897, DOI 10.1097/QAD.0b013e328329f97d; Lazarus Erica, 2019, South. Afr. j. HIV med. (Online), V20, P1, DOI 10.4102/sajhivmed.v20i1.866; LeMaoult J, 2004, P NATL ACAD SCI USA, V101, P7064, DOI 10.1073/pnas.0401922101; Lester RT, 2008, AIDS, V22, P685, DOI 10.1097/QAD.0b013e3282f4de35; Levings MK, 2001, J IMMUNOL, V166, P5530, DOI 10.4049/jimmunol.166.9.5530; Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831; Li ZL, 2011, P NATL ACAD SCI USA, V108, P4388, DOI 10.1073/pnas.1012861108; Loiseau C, 2016, MUCOSAL IMMUNOL, V9, P1137, DOI 10.1038/mi.2016.7; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934; Masese L, 2015, AIDS, V29, P1077, DOI 10.1097/QAD.0000000000000646; Masson L, 2015, CLIN INFECT DIS, V61, P260, DOI 10.1093/cid/civ298; Mavilio D, 2005, P NATL ACAD SCI USA, V102, P2886, DOI 10.1073/pnas.0409872102; Mayr LM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01590; Mbuya W, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240154; McClelland RS, 2018, LANCET INFECT DIS, V18, P554, DOI 10.1016/S1473-3099(18)30058-6; McKinnon LR, 2019, AIDS RES HUM RETROV, V35, P219, DOI [10.1089/aid.2018.0304, 10.1089/AID.2018.0304]; McLaren PJ, 2010, J INFECT DIS, V202, pS339, DOI 10.1086/655968; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Merino A, 2011, J INFECT DIS, V203, P487, DOI 10.1093/infdis/jiq075; Mestecky J, 2011, AIDS RES HUM RETROV, V27, P469, DOI 10.1089/aid.2010.0169; Mijac VD, 2006, EUR J OBSTET GYN R B, V129, P69, DOI 10.1016/j.ejogrb.2005.11.036; Mildner A, 2017, IMMUNITY, V46, P849, DOI 10.1016/j.immuni.2017.04.018; Miller CJ, 2005, J VIROL, V79, P9217, DOI 10.1128/JVI.79.14.9217-9227.2005; Min WP, 2003, J IMMUNOL, V170, P1304, DOI 10.4049/jimmunol.170.3.1304; Monzani M V, 1997, Boll Chim Farm, V136, P272; Moreau P, 1999, INT IMMUNOL, V11, P803, DOI 10.1093/intimm/11.5.803; de Lara LM, 2021, CURR OPIN PHYSIOL, V19, P32, DOI 10.1016/j.cophys.2020.07.021; Moreno-Fernandez ME, 2012, J VIROL, V86, P10262, DOI 10.1128/JVI.00993-12; Mselle TF, 2009, J VIROL, V83, P11188, DOI 10.1128/JVI.00562-09; Mwatelah R, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25346; Nag P, 2004, J INFECT DIS, V190, P1970, DOI 10.1086/425582; Noyan K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00019; O'Leary S, 2004, REPRODUCTION, V128, P237, DOI 10.1530/rep.1.00160; Oleinika K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02911-y; Om K, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008764; Pala P, 2009, MUCOSAL IMMUNOL, V2, P300, DOI 10.1038/mi.2009.23; Passmore JAS, 2016, CURR OPIN HIV AIDS, V11, P156, DOI 10.1097/COH.0000000000000232; Poudrier J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131513; Poudrier J, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/875821; Poudrier J, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/592187; Quayle AJ, 2002, J REPROD IMMUNOL, V57, P61, DOI 10.1016/S0165-0378(02)00019-0; Randolph GJ, 2002, J EXP MED, V196, P517, DOI 10.1084/jem.20011608; Lenicov FR, 2012, J IMMUNOL, V189, P4777, DOI 10.4049/jimmunol.1202089; Remick DG, 2005, INFECT IMMUN, V73, P2751, DOI 10.1128/IAI.73.5.2751-2757.2005; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Rescigno M, 2009, J CLIN INVEST, V119, P2441, DOI 10.1172/JCI39134; Ristich V, 2007, HUM IMMUNOL, V68, P264, DOI 10.1016/j.humimm.2006.11.008; Robertson MJ, 2002, J LEUKOCYTE BIOL, V71, P173; Rodriguez-Garcia M, 2017, MUCOSAL IMMUNOL, V10, P531, DOI 10.1038/mi.2016.72; Rodriguez-Garcia M, 2014, MUCOSAL IMMUNOL, V7, P1375, DOI 10.1038/mi.2014.26; Rodriguez-Garcia M, 2013, J REPROD IMMUNOL, V97, P74, DOI 10.1016/j.jri.2012.10.010; Sabourin-Poirier C, 2016, SCI REP-UK, V6, DOI 10.1038/srep32318; Safe S, 2016, J STEROID BIOCHEM, V157, P48, DOI 10.1016/j.jsbmb.2015.04.016; Sallusto F, 2012, EUR J IMMUNOL, V42, P2215, DOI 10.1002/eji.201242741; Schellenberg JJ, 2012, INT J INFLAMM, V2012, DOI 10.1155/2012/131243; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; Shang L, 2017, MUCOSAL IMMUNOL, V10, P508, DOI 10.1038/mi.2016.62; Sholukh AM, 2015, VACCINE, V33, P2086, DOI 10.1016/j.vaccine.2015.02.020; Smith SA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76976-5; Songok EM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030048; Steinbrink K, 2002, BLOOD, V99, P2468, DOI 10.1182/blood.V99.7.2468; Steri M, 2017, NEW ENGL J MED, V376, P1615, DOI 10.1056/NEJMoa1610528; Stieh DJ, 2016, CELL HOST MICROBE, V19, P529, DOI 10.1016/j.chom.2016.03.005; Teijeira A, 2014, SEMIN IMMUNOPATHOL, V36, P261, DOI 10.1007/s00281-013-0410-8; Tel-Karthaus N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01797; Thibodeau V, 2017, SCI REP-UK, V7, DOI 10.1038/srep43857; Hoang T, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008236; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; UNAIDS, GLOB HIV AIDS STAT 2; Vaidya NK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01326; van de Wijgert JHHM, 2009, SEX TRANSM DIS, V36, P357, DOI 10.1097/OLQ.0b013e3181a4f695; van den Berg LM, 2015, J IMMUNOL, V195, P1763, DOI 10.4049/jimmunol.1402356; Vendrame E, 2020, AIDS, V34, P801, DOI 10.1097/QAD.0000000000002488; Victora GD, 2012, ANNU REV IMMUNOL, V30, P429, DOI 10.1146/annurev-immunol-020711-075032; Wacleche VS, 2018, BLOOD ADV, V2, P2862, DOI 10.1182/bloodadvances.2018020123; Wacleche VS, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020065; Wan PKT, 2020, CANCERS, V12, DOI 10.3390/cancers12103044; Watkins JD, 2013, AIDS, V27, pF13, DOI 10.1097/QAD.0b013e328360eac6; Wen XS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026536; Williams WB, 2015, SCIENCE, V349, DOI 10.1126/science.aab1253; Wills S, 2018, J VIROL, V92, DOI 10.1128/JVI.01552-17; Wira CR, 2015, NAT REV IMMUNOL, V15, P217, DOI 10.1038/nri3819; Xu FY, 2017, CURR DRUG METAB, V18, P769, DOI 10.2174/1389200218666170724112412; Yao XD, 2014, MUCOSAL IMMUNOL, V7, P268, DOI 10.1038/mi.2013.44; Yao X, 2014, PHARMACOL THERAPEUT, V141, P125, DOI 10.1016/j.pharmthera.2013.09.004; Yu XC, 2013, J IMMUNOL, V190, P205, DOI 10.4049/jimmunol.1201469; Zayed RA, 2013, ANN CLIN LAB SCI, V43, P289; Zhang Q, 2018, NAT IMMUNOL, V19, P723, DOI 10.1038/s41590-018-0132-0; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zhao NQ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238347; Zheng YY, 2012, J IMMUNOL, V188	197	1	1	3	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							271	10.3390/vaccines9030271			22	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5TL	33803543	gold, Green Published			2022-04-29	WOS:000634216100001
J	Gonelli, CA; King, HAD; Mackenzie, C; Sonza, S; Center, RJ; Purcell, DFJ				Gonelli, Christopher A.; King, Hannah A. D.; Mackenzie, Charlene; Sonza, Secondo; Center, Rob J.; Purcell, Damian F. J.			Immunogenicity of HIV-1-Based Virus-Like Particles with Increased Incorporation and Stability of Membrane-Bound Env	VACCINES			English	Article						HIV-1; virus-like particle; VLP; mature form; Env incorporation; SOSIP		An optimal prophylactic vaccine to prevent human immunodeficiency virus (HIV-1) transmission should elicit protective antibody responses against the HIV-1 envelope glycoprotein (Env). Replication-incompetent HIV-1 virus-like particles (VLPs) offer the opportunity to present virion-associated Env with a native-like structure during vaccination that closely resembles that encountered on infectious virus. Here, we optimized the incorporation of Env into previously designed mature-form VLPs (mVLPs) and assessed their immunogenicity in mice. The incorporation of Env into mVLPs was increased by replacing the Env transmembrane and cytoplasmic tail domains with those of influenza haemagglutinin (HA-TMCT). Furthermore, Env was stabilized on the VLP surface by introducing an interchain disulfide and proline substitution (SOSIP) mutations typically employed to stabilize soluble Env trimers. The resulting mVLPs efficiently presented neutralizing antibody epitopes while minimizing exposure of non-neutralizing antibody sites. Vaccination of mice with mVLPs elicited a broader range of Env-specific antibody isotypes than Env presented on immature VLPs or extracellular vesicles. The mVLPs bearing HA-TMCT-modified Env consistently induced anti-Env antibody responses that mediated modest neutralization activity. These mVLPs are potentially useful immunogens for eliciting neutralizing antibody responses that target native Env epitopes on infectious HIV-1 virions.	[Gonelli, Christopher A.; King, Hannah A. D.; Mackenzie, Charlene; Sonza, Secondo; Center, Rob J.; Purcell, Damian F. J.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic 3000, Australia; [King, Hannah A. D.; Center, Rob J.] Burnet Inst, Viral Entry & Vaccines Lab, Dis Eliminat, Melbourne, Vic 3004, Australia; [Gonelli, Christopher A.] NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA		Purcell, DFJ (通讯作者)，Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic 3000, Australia.	chris.gonelli@gmail.com; hannah.alexandra.king@gmail.com; charlene.mackenzie@mh.org.au; secondo.sonza@unimelb.edu.au; rob.center@burnet.edu.au; dfjp@unimelb.edu.au		Purcell, Damian/0000-0002-4485-1726; Center, Rob/0000-0002-4466-1922; Gonelli, Christopher/0000-0002-7521-8528	National Health and Medical Research Council (NHMRC) of AustraliaNational Health and Medical Research Council (NHMRC) of Australia [1115828, 1052979]; Australian Centre for HIV and Hepatitis Virology (ACH2)	This research was funded by grants to D.F.J.P. by Horizon 2020 grant 1115828 and program grant 1052979 from the National Health and Medical Research Council (NHMRC) of Australia, and a project grant from Australian Centre for HIV and Hepatitis Virology (ACH2).	Abrahamyan LG, 2003, J VIROL, V77, P5829, DOI 10.1128/JVI.77.10.5829-5836.2003; Aguilar PP, 2020, J CHROMATOGR A, V1627, DOI 10.1016/j.chroma.2020.461378; Alsahafi N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122111; Anderson JL, 2007, J VIROL, V81, P4664, DOI 10.1128/JVI.01028-06; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Bale S, 2017, J VIROL, V91, DOI 10.1128/JVI.00443-17; Benen TD, 2014, J BIOMED SCI, V21, DOI 10.1186/s12929-014-0079-x; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; Bianchi M, 2018, IMMUNITY, V49, P288, DOI 10.1016/j.immuni.2018.07.009; Binley JM, 2003, J VIROL, V77, P5678, DOI 10.1128/JVI.77.10.5678-5684.2003; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; Blattner C, 2014, IMMUNITY, V40, P669, DOI 10.1016/j.immuni.2014.04.008; Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014; Brandenberg OF, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004595; Byland R, 2007, MOL BIOL CELL, V18, P414, DOI 10.1091/mbc.E06-06-0535; Cantin R, 2008, J IMMUNOL METHODS, V338, P21, DOI 10.1016/j.jim.2008.07.007; Castillo-Menendez LR, 2018, J VIROL, V92, DOI 10.1128/JVI.00277-18; Cavacini LA, 1998, AIDS RES HUM RETROV, V14, P1271, DOI 10.1089/aid.1998.14.1271; Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745; Center RJ, 2000, J VIROL, V74, P4448, DOI 10.1128/JVI.74.10.4448-4455.2000; Center RJ, 2009, VACCINE, V27, P6605, DOI 10.1016/j.vaccine.2009.08.016; Chakrabarti BK, 2002, J VIROL, V76, P5357, DOI 10.1128/JVI.76.11.5357-5368.2002; Chapman R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010054; Chertova E, 2002, J VIROL, V76, P5315, DOI 10.1128/JVI.76.11.5315-5325.2002; Cho SG, 1995, AIDS RES HUM RETROV, V11, P1487, DOI 10.1089/aid.1995.11.1487; Chojnacki J, 2012, SCIENCE, V338, P524, DOI 10.1126/science.1226359; Chung AW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007736; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; Cronin J, 2005, CURR GENE THER, V5, P387, DOI 10.2174/1566523054546224; Crooks ET, 2017, VIROLOGY, V505, P193, DOI 10.1016/j.virol.2017.02.024; Crooks ET, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004932; Crooks ET, 2011, J VIROL, V85, P5825, DOI 10.1128/JVI.00154-11; Crooks ET, 2007, VIROLOGY, V366, P245, DOI 10.1016/j.virol.2007.04.033; Dale CJ, 2004, VACCINE, V23, P188, DOI 10.1016/j.vaccine.2004.05.024; Desmet FO, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp215; Devitt G, 2007, VIROLOGY, V361, P465, DOI 10.1016/j.virol.2006.11.029; Doria-Rose NA, 2014, NATURE, V509, P55, DOI 10.1038/nature13036; Drummer HE, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003218; Du SX, 2008, PROTEIN EXPRES PURIF, V59, P223, DOI 10.1016/j.pep.2008.02.002; Effio CL, 2015, BIOTECHNOL J, V10, P715, DOI 10.1002/biot.201400392; EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978; Escolano A, 2017, J EXP MED, V214, P3, DOI 10.1084/jem.20161765; Esser MT, 2001, J VIROL, V75, P6173, DOI 10.1128/JVI.75.13.6173-6182.2001; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; FREED EO, 1995, J VIROL, V69, P3949, DOI 10.1128/JVI.69.6.3949-3954.1995; FU YK, 1993, J VIROL, V67, P3818, DOI 10.1128/JVI.67.7.3818-3825.1993; Gao F, 1996, J VIROL, V70, P7013, DOI 10.1128/JVI.70.10.7013-7029.1996; Garnier L, 1998, J VIROL, V72, P4667, DOI 10.1128/JVI.72.6.4667-4677.1998; Gautam R, 2012, J VIROL, V86, P8516, DOI 10.1128/JVI.00644-12; Georgiev IS, 2018, ACS INFECT DIS, V4, P788, DOI 10.1021/acsinfecdis.7b00192; Georgiev IS, 2015, J VIROL, V89, P5318, DOI 10.1128/JVI.03451-14; GlaxoSmithKline, BIOL ENGERIX B HEP B; GlaxoSmithKline, BIOL CERV HUM PAP BI; Gonelli CA, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060507; GORNY MK, 1992, J VIROL, V66, P7538, DOI 10.1128/JVI.66.12.7538-7542.1992; Hammonds J, 2005, J VIROL, V79, P14804, DOI 10.1128/JVI.79.23.14804-14814.2005; He DD, 2015, NEW BIOTECHNOL, V32, P651, DOI 10.1016/j.nbt.2014.12.006; He LL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12041; Holtkotte D, 2006, AIDS RES HUM RETROV, V22, P57, DOI 10.1089/aid.2006.22.57; Huang JH, 2014, NATURE, V515, P138, DOI 10.1038/nature13601; Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544; Huang Y, 2001, J VIROL, V75, P4947, DOI 10.1128/JVI.75.10.4947-4951.2001; Ingale J, 2016, CELL REP, V15, P1986, DOI 10.1016/j.celrep.2016.04.078; Julien JP, 2015, P NATL ACAD SCI USA, V112, P11947, DOI 10.1073/pnas.1507793112; Kesavardhana S, 2014, J VIROL, V88, P9590, DOI 10.1128/JVI.00494-14; Kim YM, 2006, P NATL ACAD SCI USA, V103, P3327, DOI 10.1073/pnas.0511315103; Klein JS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000908; Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19; Korber B., 1998, HUMAN RETROVIRUSES A, P102; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; Kramski M, 2012, ANTIMICROB AGENTS CH, V56, P4310, DOI 10.1128/AAC.00453-12; Kwong PD, 2018, IMMUNITY, V48, P855, DOI 10.1016/j.immuni.2018.04.029; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; Lavado-Garcia J, 2020, J PROTEOME RES, V19, P4516, DOI 10.1021/acs.jproteome.0c00581; Linde ME, 2013, J PROTEOME RES, V12, P2045, DOI 10.1021/pr300918r; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Lynch RM, 2009, AIDS RES HUM RETROV, V25, P237, DOI 10.1089/aid.2008.0219; Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984; Martinez-Murillo P, 2017, IMMUNITY, V46, P804, DOI 10.1016/j.immuni.2017.04.021; McCoy LE, 2016, CELL REP, V16, P2327, DOI 10.1016/j.celrep.2016.07.074; Merck & Co. Inc, GARDASIL HUMAN PAPIL; Merck & Co. Inc, RECOMBIVAX HB HEPATI; Miguet L, 2006, PROTEOMICS, V6, P153, DOI 10.1002/pmic.200500133; Minguet S, 2010, INT IMMUNOL, V22, P205, DOI 10.1093/intimm/dxp129; Moore PL, 2006, J VIROL, V80, P2515, DOI 10.1128/JVI.80.5.2515-2528.2006; Morris CD, 2017, MBIO, V8, DOI 10.1128/mBio.00036-17; Munro JB, 2014, SCIENCE, V346, P759, DOI 10.1126/science.1254426; Nelson JD, 2007, J VIROL, V81, P4033, DOI 10.1128/JVI.02588-06; Nguyen HT, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0704-x; Ott David E., 2009, V485, P15, DOI 10.1007/978-1-59745-170-3_2; Pancera M, 2010, P NATL ACAD SCI USA, V107, P1166, DOI 10.1073/pnas.0911004107; Poignard P, 2003, J VIROL, V77, P353, DOI 10.1128/JVI.77.1.353-365.2003; Popkov M, 2003, J MOL BIOL, V325, P325, DOI 10.1016/S0022-2836(02)01232-9; POSNER MR, 1993, J ACQ IMMUN DEF SYND, V6, P7; Pugach P, 2015, J VIROL, V89, P3380, DOI 10.1128/JVI.03473-14; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679; Reuven EM, 2012, BIOCHEMISTRY-US, V51, P2867, DOI 10.1021/bi201721r; Ringe RP, 2019, J VIROL, V93, DOI 10.1128/JVI.01656-18; Ross TM, 2001, AIDS RES HUM RETROV, V17, P829, DOI 10.1089/088922201750252025; Sanders RW, 2015, SCIENCE, V349, DOI 10.1126/science.aac4223; Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022; Schiller J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004254; Sliepen K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10262-5; Sliepen K, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0210-4; SNAPPER CM, 1992, J EXP MED, V175, P1367, DOI 10.1084/jem.175.5.1367; Stavnezer J, 2014, J IMMUNOL, V193, P5370, DOI 10.4049/jimmunol.1401849; Steppert P, 2017, J SEP SCI, V40, P979, DOI 10.1002/jssc.201600765; Steppert P, 2016, J CHROMATOGR A, V1455, P93, DOI 10.1016/j.chroma.2016.05.053; THALI M, 1992, J VIROL, V66, P5516, DOI 10.1128/JVI.66.9.5516-5524.1992; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thomson MM, 2002, LANCET INFECT DIS, V2, P461, DOI 10.1016/S1473-3099(02)00343-2; Thyagarajan R, 2003, J IMMUNOL, V170, P6099, DOI 10.4049/jimmunol.170.12.6099; Tokatlian T, 2019, SCIENCE, V363, P649, DOI 10.1126/science.aat9120; Tokatlian T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34853-2; Tong T, 2014, VIROLOGY, V456, P55, DOI 10.1016/j.virol.2014.03.015; Tong T, 2012, J VIROL, V86, P3574, DOI 10.1128/JVI.06938-11; TRONO D, 1990, EMBO J, V9, P4155, DOI 10.1002/j.1460-2075.1990.tb07638.x; Trubey CM, 2003, J VIROL, V77, P12699, DOI 10.1128/JVI.77.23.12699-12709.2003; Tsunetsugu-Yokota Y, 2003, J VIROL, V77, P10250, DOI 10.1128/JVI.77.19.10250-10259.2003; Verkerke HP, 2016, J VIROL, V90, P9471, DOI 10.1128/JVI.01351-16; Walker LM, 2011, P NATL ACAD SCI USA, V108, P20125, DOI 10.1073/pnas.1117531108; Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373; Walker LM, 2009, SCIENCE, V326, P285, DOI 10.1126/science.1178746; Wang BZ, 2007, J VIROL, V81, P10869, DOI 10.1128/JVI.00542-07; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Yuste E, 2004, J VIROL, V78, P6775, DOI 10.1128/JVI.78.13.6775-6785.2004; Zhou TQ, 2017, CELL REP, V19, P719, DOI 10.1016/j.celrep.2017.04.013; Zhu P, 2003, P NATL ACAD SCI USA, V100, P15812, DOI 10.1073/pnas.2634931100; Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817	136	1	1	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							239	10.3390/vaccines9030239			36	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE6OR	33801906	Green Published, gold			2022-04-29	WOS:000634271400001
J	Chae, C				Chae, Chanhee			Commercial PRRS Modified-Live Virus Vaccines	VACCINES			English	Review						modified-live virus vaccine; porcine reproductive; respiratory syndrome virus	RESPIRATORY SYNDROME VIRUS; TYPE-1 EUROPEAN GENOTYPE; MYSTERY SWINE DISEASE; REPRODUCTIVE-PERFORMANCE; CONCURRENT VACCINATION; IMMUNE-RESPONSES; FOSTERA PRRS; FIELD STRAIN; TRANSPLACENTAL INFECTION; NEUTRALIZING ANTIBODIES	Porcine reproductive and respiratory syndrome (PRRS) virus (PRRSV) presents one of the challenging viral pathogens in the global pork industry. PRRS is characterized by two distinct clinical presentations; reproductive failure in breeding animals (gilts, sows, and boars), and respiratory disease in growing pigs. PRRSV is further divided into two species: PRRSV-1 (formerly known as the European genotype 1) and PRRSV-2 (formerly known as the North American genotype 2). A PRRSV-2 modified-live virus (MLV) vaccine was first introduced in North America in 1994, and, six years later, a PRRSV-1 MLV vaccine was also introduced in Europe. Since then, MLV vaccination is the principal strategy used to control PRRSV infection. Despite the fact that MLV vaccines have shown some efficacy, they were problematic as the efficacy of vaccine was often unpredictable and depended highly on the field virus. This paper focused on the efficacy of commercially available MLV vaccines at a global level based on respiratory disease in growing pigs, and maternal and paternal reproductive failure in breeding animals.	[Chae, Chanhee] Seoul Natl Univ, Coll Vet Med, Dept Vet Pathol, 1 Gwanak Ro, Seoul 08826, South Korea		Chae, C (通讯作者)，Seoul Natl Univ, Coll Vet Med, Dept Vet Pathol, 1 Gwanak Ro, Seoul 08826, South Korea.	swine@snu.ac.kr		Chae, Chanhee/0000-0002-0190-1957	Research Institute for Veterinary Science (RIVS) from the College of Veterinary Medicine; BK 21 FOUR Future Veterinary Medicine Leading Education and Research Center [A0449-20200100]	The author's research was supported by contract research funds of the Research Institute for Veterinary Science (RIVS) from the College of Veterinary Medicine and by the BK 21 FOUR Future Veterinary Medicine Leading Education and Research Center (Grant no. A0449-20200100).	Adams MJ, 2016, ARCH VIROL, V161, P2921, DOI 10.1007/s00705-016-2977-6; Alexopoulos C, 2005, VET MICROBIOL, V111, P151, DOI 10.1016/j.vetmic.2005.10.007; Balka G, 2008, VET MICROBIOL, V127, P128, DOI 10.1016/j.vetmic.2007.08.001; Bautista EM, 1999, ARCH VIROL, V144, P1191, DOI 10.1007/s007050050578; Benfield D, 2000, AMERICAN ASSOCIATION OF SWINE PRACTITIONERS 2000, PROCEEDINGS, P405; Bitsouni V, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220738; BLECHA F, 1983, J ANIM SCI, V56, P396, DOI 10.2527/jas1983.562396x; Bonckaert C, 2016, PORCINE HEALTH MANAG, V2, DOI 10.1186/s40813-016-0029-y; Calvert JG, 2017, VET MICROBIOL, V205, P80, DOI 10.1016/j.vetmic.2017.03.037; Canelli E, 2018, VET MICROBIOL, V226, P89, DOI 10.1016/j.vetmic.2018.10.001; Canelli E, 2017, VET MICROBIOL, V210, P124, DOI 10.1016/j.vetmic.2017.09.002; Cavanagh D, 1997, ARCH VIROL, V142, P629; Chand RJ, 2012, CURR OPIN VIROL, V2, P256, DOI 10.1016/j.coviro.2012.02.002; Charerntantanakul Wasin, 2012, World J Virol, V1, P23, DOI 10.5501/wjv.v1.i1.23; Charoenchanikran P, 2016, TROP ANIM HEALTH PRO, V48, P1351, DOI 10.1007/s11250-016-1099-1; Chaudhari J, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12111245; Chen NH, 2011, J GEN VIROL, V92, P880, DOI 10.1099/vir.0.027995-0; Cheon DS, 2001, J COMP PATHOL, V124, P231, DOI 10.1053/jcpa.2000.0457; Choi K, 2016, VET REC, V178, P291, DOI 10.1136/vr.103529; Choi K, 2015, J COMP PATHOL, V152, P317, DOI 10.1016/j.jcpa.2015.03.002; CHRISTIANSON WT, 1993, CAN J VET RES, V57, P262; Christopher-Hennings J, 2001, J VET DIAGN INVEST, V13, P133, DOI 10.1177/104063870101300207; CHRISTOPHERHENNINGS J, 1995, J VET DIAGN INVEST, V7, P456, DOI 10.1177/104063879500700406; COLLINS JE, 1992, J VET DIAGN INVEST, V4, P117, DOI 10.1177/104063879200400201; Diaz I, 2005, J GEN VIROL, V86, P1943, DOI 10.1099/vir.0.80959-0; Do DT, 2015, VET MICROBIOL, V179, P233, DOI 10.1016/j.vetmic.2015.06.013; Frydas IS, 2016, VET MICROBIOL, V182, P156, DOI 10.1016/j.vetmic.2015.11.016; Gradil C, 1996, VET REC, V138, P521, DOI 10.1136/vr.138.21.521; Greiser-Wilke I, 2010, VET MICROBIOL, V143, P213, DOI 10.1016/j.vetmic.2009.12.006; Guerin B, 2005, THERIOGENOLOGY, V63, P556, DOI 10.1016/j.theriogenology.2004.09.030; Han K, 2014, J COMP PATHOL, V150, P297, DOI 10.1016/j.jcpa.2013.11.205; Han K, 2013, VET RES COMMUN, V37, P155, DOI 10.1007/s11259-013-9558-x; Han K, 2013, VET J, V195, P313, DOI 10.1016/j.tvjl.2012.06.035; Han K, 2012, J COMP PATHOL, V147, P275, DOI 10.1016/j.jcpa.2011.12.010; Han K, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-12; Han K, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-156; Han K, 2011, CLIN VACCINE IMMUNOL, V18, P1600, DOI 10.1128/CVI.05213-11; Harding JCS, 2017, VET MICROBIOL, V209, P114, DOI 10.1016/j.vetmic.2017.02.019; Hou FH, 2020, PEERJ, V8, DOI 10.7717/peerj.8840; Jeong J, 2018, TRANSBOUND EMERG DIS, V65, P1227, DOI 10.1111/tbed.12862; Jeong J, 2018, VET MICROBIOL, V223, P119, DOI 10.1016/j.vetmic.2018.08.008; Jeong J, 2018, TRANSBOUND EMERG DIS, V65, P1641, DOI 10.1111/tbed.12921; Jeong J, 2018, VET REC, V182, P485, DOI 10.1136/vr.104397; Jeong J, 2017, VET MICROBIOL, V208, P47, DOI 10.1016/j.vetmic.2017.07.016; Jeong J, 2017, CAN J VET RES, V81, P108; Jeong J, 2016, VET MICROBIOL, V192, P102, DOI 10.1016/j.vetmic.2016.07.006; Johnson W, 2004, VET IMMUNOL IMMUNOP, V102, P233, DOI 10.1016/j.vetimm.2004.09.010; Kang I, 2017, THAI J VET MED, V47, P109; Kang I, 2017, J SWINE HEALTH PROD, V25, P24; Karniychuk UU, 2012, THERIOGENOLOGY, V78, P1527, DOI 10.1016/j.theriogenology.2012.06.015; Karniychuk UU, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-95; Karniychuk UU, 2011, MICROB PATHOGENESIS, V51, P194, DOI 10.1016/j.micpath.2011.04.001; Karniychuk UU, 2010, BMC VET RES, V6, DOI 10.1186/1746-6148-6-30; Keffaber K., 1989, AM ASS SWINE PRACT N, V1, P1; Kim T, 2015, CLIN VACCINE IMMUNOL, V22, P631, DOI 10.1128/CVI.00001-15; Kimman TG, 2009, VACCINE, V27, P3704, DOI 10.1016/j.vaccine.2009.04.022; Klinge KL, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-177; Ko SS, 2016, VET IMMUNOL IMMUNOP, V172, P43, DOI 10.1016/j.vetimm.2016.02.016; Kranker S, 1998, VET MICROBIOL, V61, P21, DOI 10.1016/S0378-1135(98)00176-X; Kristensen CS, 2018, VACCINE, V36, P227, DOI 10.1016/j.vaccine.2017.11.059; Kuhn JH, 2016, ARCH VIROL, V161, P755, DOI 10.1007/s00705-015-2672-z; Labarque G. G., 2000, Veterinary Research (Paris), V31, P97, DOI 10.1051/vetres:2000026; Labarque GG, 2000, J GEN VIROL, V81, P1327, DOI 10.1099/0022-1317-81-5-1327; Ladinig A, 2015, VET RES, V46, DOI 10.1186/s13567-015-0251-7; Ladinig A, 2015, VIRUS RES, V203, P24, DOI 10.1016/j.virusres.2015.03.005; Lager KM, 2014, VACCINE, V32, P6457, DOI 10.1016/j.vaccine.2014.09.046; Lager KM, 1999, AM J VET RES, V60, P1022; Lager KM, 1997, VET MICROBIOL, V58, P113, DOI 10.1016/S0378-1135(97)00160-0; Li YF, 2007, VET J, V174, P577, DOI 10.1016/j.tvjl.2007.07.032; Lopez OJ, 2007, CLIN VACCINE IMMUNOL, V14, P269, DOI 10.1128/CVI.00304-06; Lopez OJ, 2004, VET IMMUNOL IMMUNOP, V102, P155, DOI 10.1016/j.vetimm.2004.09.005; Loving CL, 2015, VET IMMUNOL IMMUNOP, V167, P1, DOI 10.1016/j.vetimm.2015.07.003; Lunney JK, 2016, ANNU REV ANIM BIOSCI, V4, P129, DOI 10.1146/annurev-animal-022114-111025; Madapong A, 2020, VET MICROBIOL, V244, DOI 10.1016/j.vetmic.2020.108655; Madapong A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58626-y; Martelli P, 2009, VACCINE, V27, P3788, DOI 10.1016/j.vaccine.2009.03.028; Mateu E, 2008, VET J, V177, P345, DOI 10.1016/j.tvjl.2007.05.022; Mengeling WL, 1999, AM J VET RES, V60, P796; Mengeling WL, 2003, VET MICROBIOL, V93, P25, DOI 10.1016/S0378-1135(02)00426-1; MENGELING WL, 1994, AM J VET RES, V55, P1391; Murtaugh M., 2012, P ALL D LEM SWIND C, VVolume 39, P49; Murtaugh MP, 2011, VACCINE, V29, P8192, DOI 10.1016/j.vaccine.2011.09.013; Nan YC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01635; NELSON EA, 1994, J VET DIAGN INVEST, V6, P410, DOI 10.1177/104063879400600402; Nielsen HS, 2001, J GEN VIROL, V82, P1263, DOI 10.1099/0022-1317-82-6-1263; Nielsen TL, 1997, VET MICROBIOL, V54, P101, DOI 10.1016/S0378-1135(96)01272-2; Nodelijk G, 2001, VACCINE, V19, P3636, DOI 10.1016/S0264-410X(01)00099-8; Novakovic P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173360; Oh T, 2019, COMP IMMUNOL MICROB, V63, P66, DOI 10.1016/j.cimid.2018.12.010; Opriessnig T, 2005, J SWINE HEALTH PROD, V13, P246; Osorio FA, 2002, VIROLOGY, V302, P9, DOI 10.1006/viro.2002.1612; Papatsiros V, 2020, VIRAL IMMUNOL, V33, P565, DOI 10.1089/vim.2020.0087; Park C, 2017, TRANSBOUND EMERG DIS, V64, P194, DOI 10.1111/tbed.12361; Park C, 2015, RES VET SCI, V103, P193, DOI 10.1016/j.rvsc.2015.10.011; Park C, 2015, VET MICROBIOL, V177, P87, DOI 10.1016/j.vetmic.2015.02.020; Park C, 2014, VET MICROBIOL, V172, P432, DOI 10.1016/j.vetmic.2014.05.030; PATON DJ, 1991, VET REC, V128, P617, DOI 10.1136/vr.128.26.617; Pejsak Z, 2006, VET REC, V158, P475, DOI 10.1136/vr.158.14.475; Piontkowski MD, 2016, CAN J VET RES, V80, P269; Prieto C, 2005, THERIOGENOLOGY, V63, P1, DOI 10.1016/j.theriogenology.2004.03.018; Prieto C, 1996, VET REC, V138, P536, DOI 10.1136/vr.138.22.536; Prieto C, 1997, VET MICROBIOL, V57, P301, DOI 10.1016/S0378-1135(97)00112-0; Prieto C, 1997, THERIOGENOLOGY, V47, P647, DOI 10.1016/S0093-691X(97)00023-X; Prieto C, 2008, VET J, V175, P356, DOI 10.1016/j.tvjl.2007.01.021; Renson P, 2017, VET MICROBIOL, V204, P133, DOI 10.1016/j.vetmic.2017.04.021; Renukaradhya GJ, 2015, VACCINE, V33, P4069, DOI 10.1016/j.vaccine.2015.06.092; Renukaradhya GJ, 2015, VACCINE, V33, P3065, DOI 10.1016/j.vaccine.2015.04.102; Roca M, 2012, VET J, V193, P92, DOI 10.1016/j.tvjl.2011.11.019; Rowland RRR, 2010, VIRUS RES, V154, P114, DOI 10.1016/j.virusres.2010.09.001; Rowland RRR, 2001, ARCH VIROL, V146, P539, DOI 10.1007/s007050170161; Savard C, 2016, CAN J VET RES, V80, P1; Scortti M, 2006, VET J, V172, P506, DOI 10.1016/j.tvjl.2005.07.015; Scortti M, 2006, THERIOGENOLOGY, V66, P1884, DOI 10.1016/j.theriogenology.2006.04.043; Sirisereewan C, 2018, TROP ANIM HEALTH PRO, V50, P1509, DOI 10.1007/s11250-018-1589-4; Stadler J, 2016, VACCINE, V34, P3862, DOI 10.1016/j.vaccine.2016.05.042; Sur JH, 1997, J VIROL, V71, P9170, DOI 10.1128/JVI.71.12.9170-9179.1997; Swenson S. L., 1994, Swine Health and Production, V2, P19; TERPSTRA C, 1991, VET QUART, V13, P131, DOI 10.1080/01652176.1991.9694297; Tian KG, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000526; Tong GZ, 2007, EMERG INFECT DIS, V13, P1434, DOI 10.3201/eid1309.070399; Trus I, 2014, VACCINE, V32, P2995, DOI 10.1016/j.vaccine.2014.03.077; van der Linden IFA, 2003, VACCINE, V21, P1952, DOI 10.1016/S0264-410X(02)00822-8; van Woensel PAM, 1998, ADV EXP MED BIOL, V440, P713; van Woensel PAM, 1998, VET REC, V142, P510, DOI 10.1136/vr.142.19.510; Wei ZZ, 2013, VACCINE, V31, P2062, DOI 10.1016/j.vaccine.2013.02.012; WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296; Yaeger M. J., 1993, Swine Health and Production, V1, P7; Yang S, 2020, CAN J VET RES, V84, P172; Yang S, 2020, COMP IMMUNOL MICROB, V69, DOI 10.1016/j.cimid.2020.101423; Yang S, 2019, VET MICROBIOL, V239, DOI 10.1016/j.vetmic.2019.108497; Zimmerman J.J., 2019, DIS SWINE, P685, DOI DOI 10.1002/9781119350927.CH41	131	8	8	7	11	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							185	10.3390/vaccines9020185			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6SU	33671826	gold, Green Published			2022-04-29	WOS:000623272200001
J	Galen, JE; Wahid, R; Buskirk, AD				Galen, James E.; Wahid, Rezwanul; Buskirk, Amanda D.			Strategies for Enhancement of Live-Attenuated Salmonella-Based Carrier Vaccine Immunogenicity	VACCINES			English	Review						Salmonella; Typhi; carrier vaccine; immunogenicity; homeostasis; inflammation	ENTERICA SEROVAR TYPHI; SERUM ANTIBODY-RESPONSES; ANTIGEN-PRESENTING CELLS; SHIGELLA-SONNEI VACCINE; INNATE LYMPHOID-CELLS; TOXIN-B-SUBUNIT; HELICOBACTER-PYLORI; VECTOR VACCINES; INTESTINAL HOMEOSTASIS; COMMENSAL BACTERIA	The use of live-attenuated bacterial vaccines as carriers for the mucosal delivery of foreign antigens to stimulate the mucosal immune system was first proposed over three decades ago. This novel strategy aimed to induce immunity against at least two distinct pathogens using a single bivalent carrier vaccine. It was first tested using a live-attenuated Salmonella enterica serovar Typhi strain in clinical trials in 1984, with excellent humoral immune responses against the carrier strain but only modest responses elicited against the foreign antigen. Since then, clinical trials with additional Salmonella-based carrier vaccines have been conducted. As with the original trial, only modest foreign antigen-specific immunity was achieved in most cases, despite the incorporation of incremental improvements in antigen expression technologies and carrier design over the years. In this review, we will attempt to deconstruct carrier vaccine immunogenicity in humans by examining the basis of bacterial immunity in the human gastrointestinal tract and how the gut detects and responds to pathogens versus benign commensal organisms. Carrier vaccine design will then be explored to determine the feasibility of retaining as many characteristics of a pathogen as possible to elicit robust carrier and foreign antigen-specific immunity, while avoiding over-stimulation of unacceptably reactogenic inflammatory responses.	[Galen, James E.; Wahid, Rezwanul] Univ Maryland, Ctr Vaccine Dev & Global Hlth, Sch Med, Baltimore, MD 21201 USA; [Buskirk, Amanda D.] US FDA, Ctr Drug Evaluat & Res, Off Pharmaceut Qual, Off Proc & Facil,Div Microbiol Assessment 2, Silver Spring, MD 20903 USA		Galen, JE (通讯作者)，Univ Maryland, Ctr Vaccine Dev & Global Hlth, Sch Med, Baltimore, MD 21201 USA.	jgalen@som.umaryland.edu; rwahid@som.umaryland.edu; abuskirk02@gmail.com		Wahid, Rezwanul/0000-0002-5623-1903	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01AI095309-01A1, 1R56AI125388-01A1]	J.E.G. was supported in the preparation of this manuscript by grants from the National Institutes of Health, 1R01AI095309-01A1 and 1R56AI125388-01A1.	Alroqi FJ, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0606-9; Attridge SR, 2005, MICROB PATHOGENESIS, V39, P1, DOI 10.1016/j.micpath.2005.05.004; Azimi T, 2020, INFECT DRUG RESIST, V13, P11, DOI 10.2147/IDR.S230604; Bailey J E, 1993, Adv Biochem Eng Biotechnol, V48, P29; Bain CC, 2014, IMMUNOL REV, V260, P102, DOI 10.1111/imr.12192; BLACK RE, 1987, J INFECT DIS, V155, P1260, DOI 10.1093/infdis/155.6.1260; BLER JM, 2012, NAT REV IMMUNOL, V12, P215, DOI DOI 10.1038/NRI3167; BOE L, 1987, J BACTERIOL, V169, P4646, DOI 10.1128/jb.169.10.4646-4650.1987; Boraschi D, 2014, IMMUNOL LETT, V162, P346, DOI 10.1016/j.imlet.2014.06.006; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; Bumann D, 2001, VACCINE, V20, P845, DOI 10.1016/S0264-410X(01)00391-7; Bumann D, 2010, VACCINE, V28, P707, DOI 10.1016/j.vaccine.2009.10.080; Bunker JJ, 2018, IMMUNITY, V49, P211, DOI 10.1016/j.immuni.2018.08.011; Caballero S, 2015, ANNU REV IMMUNOL, V33, P227, DOI 10.1146/annurev-immunol-032713-120238; Cheng HY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00607; Chinchilla M, 2007, INFECT IMMUN, V75, P3769, DOI 10.1128/IAI.00356-07; Corchero JL, 1998, BIOTECHNOL BIOENG, V58, P625, DOI 10.1002/(SICI)1097-0290(19980620)58:6<625::AID-BIT8>3.3.CO;2-1; Cullender TC, 2013, CELL HOST MICROBE, V14, P571, DOI 10.1016/j.chom.2013.10.009; CURTISS R, 1990, RES MICROBIOL, V141, P797, DOI 10.1016/0923-2508(90)90113-5; Daliri EBM, 2017, CRIT REV FOOD SCI, V57, P3565, DOI 10.1080/10408398.2016.1220913; DiPetrillo MD, 1999, VACCINE, V18, P449, DOI 10.1016/S0264-410X(99)00246-7; Donaldson GP, 2016, NAT REV MICROBIOL, V14, P20, DOI 10.1038/nrmicro3552; Donowitz JR, 2015, TRENDS MOL MED, V21, P6, DOI 10.1016/j.molmed.2014.11.001; Flannigan KL, 2015, AM J PATHOL, V185, P1809, DOI 10.1016/j.ajpath.2015.02.024; Frey SE, 2013, VACCINE, V31, P4874, DOI 10.1016/j.vaccine.2013.07.049; Galen JE, 2015, INFECT IMMUN, V83, P161, DOI 10.1128/IAI.02443-14; Galen JE, 2014, VACCINE, V32, P4376, DOI 10.1016/j.vaccine.2013.12.026; Galen James E, 2009, Immunol Cell Biol, V87, P400, DOI 10.1038/icb.2009.31; Galen JE, 2009, J INFECT DIS, V199, P326, DOI 10.1086/596066; Galen JE, 2004, INFECT IMMUN, V72, P7096, DOI 10.1128/IAI.72.12.7096-7106.2004; Galen JE, 1999, INFECT IMMUN, V67, P6424; Galen JE, 2001, TRENDS MICROBIOL, V9, P372, DOI 10.1016/S0966-842X(01)02096-0; Galen JE, 1997, VACCINE, V15, P700, DOI 10.1016/S0264-410X(96)00227-7; Gan JY, 2021, CURR OPIN MICROBIOL, V59, P58, DOI 10.1016/j.mib.2020.07.015; Gause KT, 2017, ACS NANO, V11, P54, DOI 10.1021/acsnano.6b07343; GERMANIER R, 1975, J INFECT DIS, V131, P553, DOI 10.1093/infdis/131.5.553; Geva-Zatorsky N, 2017, CELL, V168, P928, DOI 10.1016/j.cell.2017.01.022; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gilmartin AA, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0143; GLICK BR, 1995, BIOTECHNOL ADV, V13, P247, DOI 10.1016/0734-9750(95)00004-A; GONZALEZ C, 1994, J INFECT DIS, V169, P927, DOI 10.1093/infdis/169.4.927; Goto Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02057; GOTUZZO E, 1993, INFECT IMMUN, V61, P3994, DOI 10.1128/IAI.61.9.3994-3997.1993; Grainger JR, 2014, IMMUNOL REV, V259, P75, DOI 10.1111/imr.12167; Hecht AL, 2017, CELL HOST MICROBE, V22, P443, DOI 10.1016/j.chom.2017.08.007; HERRINGTON DA, 1990, VACCINE, V8, P353, DOI 10.1016/0264-410X(90)90094-3; Hess J, 1996, P NATL ACAD SCI USA, V93, P1458, DOI 10.1073/pnas.93.4.1458; Hill A V, 2000, Dev Biol (Basel), V104, P171; Honda K, 2016, NATURE, V535, P75, DOI 10.1038/nature18848; Hughes SM, 2009, J IMMUNOL, V183, P2818, DOI 10.4049/jimmunol.0803518; Iacob S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01676; Jiang BY, 2019, APPL MICROBIOL BIOT, V103, P3941, DOI 10.1007/s00253-019-09770-7; Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047; Kanekiyo M, 2015, CELL, V162, P1090, DOI 10.1016/j.cell.2015.07.043; Kang HY, 2003, FEMS IMMUNOL MED MIC, V37, P99, DOI 10.1016/S0928-8244(03)00063-4; Kasturi SP, 2011, NATURE, V470, P543, DOI 10.1038/nature09737; Khan S, 2007, VACCINE, V25, P4175, DOI 10.1016/j.vaccine.2007.03.007; Killig M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00142; Kitamoto S, 2016, J GASTROENTEROL, V51, P195, DOI 10.1007/s00535-015-1141-5; Kmiec Z, 2017, ADV MED SCI-POLAND, V62, P1, DOI 10.1016/j.advms.2016.09.001; Kopecko DJ, 2009, INT J MED MICROBIOL, V299, P233, DOI 10.1016/j.ijmm.2008.09.003; Lagos R, 1999, J INFECT DIS, V180, P1709, DOI 10.1086/315051; Lee JS, 2000, NAT BIOTECHNOL, V18, P645, DOI 10.1038/76494; Levine MM, 2001, MICROBES INFECT, V3, P1271, DOI 10.1016/S1286-4579(01)01487-3; Levine MM, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-129; Liu H, 2016, SCI REP-UK, V6, DOI 10.1038/srep22040; Londono-Arcila P, 2002, INFECT IMMUN, V70, P5096, DOI 10.1128/IAI.70.9.5096-5106.2002; Macpherson AJ, 2004, SCIENCE, V303, P1662, DOI 10.1126/science.1091334; Mathias A, 2014, GUT MICROBES, V5, P688, DOI 10.4161/19490976.2014.983763; Metzger WG, 2004, VACCINE, V22, P2273, DOI 10.1016/j.vaccine.2003.11.020; Micoli F, 2018, P NATL ACAD SCI USA, V115, P10428, DOI 10.1073/pnas.1807655115; Mowat AM, 2014, NAT REV IMMUNOL, V14, P667, DOI 10.1038/nri3738; NardelliHaefliger D, 1996, INFECT IMMUN, V64, P5219, DOI 10.1128/IAI.64.12.5219-5224.1996; Odendall C, 2017, MICROBES INFECT, V19, P229, DOI 10.1016/j.micinf.2017.01.003; Omenetti S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00639; Pandiyan P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00426; Pasetti MF, 2000, VACCINE, V18, P3208, DOI 10.1016/S0264-410X(00)00142-0; Pasetti MF, 2003, VACCINE, V21, P401, DOI 10.1016/S0264-410X(02)00472-3; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Pickett TE, 2000, INFECT IMMUN, V68, P205, DOI 10.1128/IAI.68.1.205-213.2000; Prendergast AJ, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0141; Qadri F, 2013, VACCINE, V31, P452, DOI 10.1016/j.vaccine.2012.11.012; Ramshaw IA, 2000, IMMUNOL TODAY, V21, P163, DOI 10.1016/S0167-5699(00)01612-1; Roberts M, 1999, INFECT IMMUN, V67, P3810, DOI 10.1128/IAI.67.8.3810-3815.1999; Roberts M, 1998, INFECT IMMUN, V66, P3080, DOI 10.1128/IAI.66.7.3080-3087.1998; Rogers AWL, 2021, MICROBIOL MOL BIOL R, V85, DOI 10.1128/MMBR.00027-19; Rol N, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.405001; Roland KL, 2013, EXPERT REV VACCINES, V12, P1033, DOI 10.1586/14760584.2013.825454; Rossi O, 2013, CURR TOP MICROBIOL, V358, P291, DOI 10.1007/82_2011_191; Russmann H, 1998, SCIENCE, V281, P565, DOI 10.1126/science.281.5376.565; Russmann H, 2001, J IMMUNOL, V167, P357, DOI 10.4049/jimmunol.167.1.357; Sander LE, 2011, NATURE, V474, P385, DOI 10.1038/nature10072; Satoh-Takayama N, 2016, INT IMMUNOL, V28, P29, DOI 10.1093/intimm/dxv054; Sawa S, 2011, NAT IMMUNOL, V12, P320, DOI 10.1038/ni.2002; SER LE, 2012, BIOESSAYS, V34, P876, DOI DOI 10.1002/BIES.201200057; SERS TJ, 2017, MICROBIOL SPECTR, DOI DOI 10.1128/MICROBIOLSPEC.MCHD-0047-2016; Sorbara MT, 2019, MUCOSAL IMMUNOL, V12, P1, DOI 10.1038/s41385-018-0053-0; Stelekati E, 2012, CELL HOST MICROBE, V12, P458, DOI 10.1016/j.chom.2012.10.001; SU GF, 1992, MICROB PATHOGENESIS, V13, P465, DOI 10.1016/0882-4010(92)90013-E; SUHARYONO, 1992, LANCET, V340, P689, DOI 10.1016/0140-6736(92)92231-4; Sun M, 2015, MUCOSAL IMMUNOL, V8, P969, DOI 10.1038/mi.2015.49; Sztein MB, 2007, CLIN INFECT DIS, V45, pS15, DOI 10.1086/518140; Sztein MB, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00516; SZTEIN MB, 1995, J IMMUNOL, V155, P3987; TACKET CO, 1992, INFECT IMMUN, V60, P536, DOI 10.1128/IAI.60.2.536-541.1992; Tacket CO, 2000, INFECT IMMUN, V68, P1196, DOI 10.1128/IAI.68.3.1196-1201.2000; Tacket CO, 1997, INFECT IMMUN, V65, P3381, DOI 10.1128/IAI.65.8.3381-3385.1997; TACKET CO, 1990, INFECT IMMUN, V58, P1620, DOI 10.1128/IAI.58.6.1620-1627.1990; Tacket CO, 1997, INFECT IMMUN, V65, P452, DOI 10.1128/IAI.65.2.452-456.1997; TACKET CO, 1992, VACCINE, V10, P443, DOI 10.1016/0264-410X(92)90392-W; Tacket CO, 2000, CLIN IMMUNOL, V97, P146, DOI 10.1006/clim.2000.4924; TRAMONT EC, 1984, J INFECT DIS, V149, P133, DOI 10.1093/infdis/149.2.133; Tzschaschel BD, 1996, NAT BIOTECHNOL, V14, P765, DOI 10.1038/nbt0696-765; Uche IV, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005118; Ugolini M, 2019, CURR OPIN IMMUNOL, V56, P60, DOI 10.1016/j.coi.2018.09.018; Valguarnera E, 2020, J MOL BIOL, V432, P765, DOI 10.1016/j.jmb.2019.12.003; Vindurampulle CJ, 2004, VACCINE, V22, P3744, DOI 10.1016/j.vaccine.2004.03.025; Vindurampulle CJ, 2003, INFECT IMMUN, V71, P2258, DOI 10.1128/IAI.71.4.2258-2261.2003; Vindurampulle CJ, 2003, INFECT IMMUN, V71, P287, DOI 10.1128/IAI.71.1.287-297.2003; Wang SF, 2013, MICROB PATHOGENESIS, V58, P17, DOI 10.1016/j.micpath.2012.10.006; Watanabe K, 2016, EBIOMEDICINE, V10, P25, DOI 10.1016/j.ebiom.2016.07.030; Wilson RL, 2005, ADV DRUG DELIVER REV, V57, P1392, DOI 10.1016/j.addr.2005.01.015; Worbs T, 2017, NAT REV IMMUNOL, V17, P30, DOI 10.1038/nri.2016.116; Yang J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.02029; Zahn K, 1996, J BACTERIOL, V178, P2926, DOI 10.1128/jb.178.10.2926-2933.1996; Zhang GM, 1999, CLIN INFECT DIS, V29, P590, DOI 10.1086/598639; Zhang XM, 2017, NAT REV IMMUNOL, V17, P495, DOI 10.1038/nri.2017.54	127	1	2	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							162	10.3390/vaccines9020162			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7JV	33671124	Green Published, gold			2022-04-29	WOS:000623317100001
J	Pastorino, R; Villani, L; Mariani, M; Ricciardi, W; Graffigna, G; Boccia, S				Pastorino, Roberta; Villani, Leonardo; Mariani, Marco; Ricciardi, Walter; Graffigna, Guendalina; Boccia, Stefania			Impact of COVID-19 Pandemic on Flu and COVID-19 Vaccination Intentions among University Students	VACCINES			English	Article						COVID-19 vaccination; flu vaccination; students		Flu vaccination for the general population, and specifically for vulnerable subgroups, brings the potential to reduce the impact of the COVID-19 pandemic in terms of mobility, mortality, and hospitalizations. In Italy, flu vaccination is recommended to all >= 6 months of age, even if it is only free of charge for specific categories. We investigated the intentions towards flu and COVID-19 vaccinations from a sample of 436 Italian university students. Results of a web-based survey show that 77.52% of them were willing to get the flu vaccine and 94.73% were willing to be vaccinated against COVID-19 when available. We identified positive predictive factors to undertake flu vaccination as being a medical student, having undertaken a previous vaccination against flu, and having a high level of concern and perceived vulnerability to the COVID-19 pandemic. Reinforced public health activities might consider engaging university students a as possible "positive influencer" towards flu and COVID-19 vaccination programs.	[Pastorino, Roberta; Ricciardi, Walter; Boccia, Stefania] Fdn Policlin Univ A Gemelli IRCCS, Dept Woman & Child Hlth & Publ Hlth, Publ Hlth Area, I-00168 Rome, Italy; [Villani, Leonardo; Mariani, Marco; Ricciardi, Walter; Boccia, Stefania] Univ Cattolica Sacro Cuore, Sect Hyg, Univ Dept Life Sci & Publ Hlth, I-00168 Rome, Italy; [Graffigna, Guendalina] Univ Cattolica Sacro Cuore, Dipartimento Psicol, I-20123 Milan, Italy; [Graffigna, Guendalina] Univ Cattolica Sacro Cuore, Food & Hlth Engagement Res Ctr, EngageMinds HUB Consumer, I-26100 Cremona, Italy		Villani, L (通讯作者)，Univ Cattolica Sacro Cuore, Sect Hyg, Univ Dept Life Sci & Publ Hlth, I-00168 Rome, Italy.	roberta.pastorino@policlinicogemell.it; leonardovillani92@gmail.com; marcomariani1990@hotmail.it; walter.Ricciardi@unicatt.it; guendalina.graffigna@unicatt.it; stefania.Boccia@unicatt.it	PASTORINO, Roberta/AAC-1866-2022; Mariani, Marco/H-2409-2017	PASTORINO, Roberta/0000-0001-5013-0733; GRAFFIGNA, GUENDALINA/0000-0003-4378-7467; Mariani, Marco/0000-0001-7799-4291; Villani, Leonardo/0000-0001-9375-8731			Andrews JL, 2020, TRENDS COGN SCI, V24, P585, DOI 10.1016/j.tics.2020.05.001; Barari S., 2020, EVALUATING COVID 19, DOI [10.1101/2020.03.27.20042820, DOI 10.1101/2020.03.27.20042820]; Barello S, 2020, EUR J EPIDEMIOL, V35, P781, DOI 10.1007/s10654-020-00670-z; Bellato Alessio, 2020, Soc Sci Humanit Open, V2, P100062, DOI 10.1016/j.ssaho.2020.100062; Boccia S, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00167; Boccia S, 2020, JAMA INTERN MED, V180, P927, DOI 10.1001/jamainternmed.2020.1447; Cassini A, 2018, EUROSURVEILLANCE, V23, P15, DOI 10.2807/1560-7917.ES.2018.23.16.17-00454; Centers for Disease Control and Prevention, 2020, WHO NEEDS FLIU VACC; Cohen AK, 2020, J ADOLESCENT HEALTH, V67, P369, DOI 10.1016/j.jadohealth.2020.06.009; Costantino C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040686; Di Pietro ML, 2017, ANN I SUPER SANITA, V53, P157, DOI 10.4415/ANN_17_02_13; Domnich A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040711; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Goldman RD, 2021, J PEDIATR-US, V228, P87, DOI 10.1016/j.jpeds.2020.08.005; Graffigna G, 2020, VACCINE, V38, P7585, DOI 10.1016/j.vaccine.2020.10.025; Graffigna G, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040576; Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3; Iannone P, 2020, RECOMMENDATIONS PROT, P2020020016, DOI [10.20944/preprints202002.0016.v1, DOI 10.20944/PREPRINTS202002.0016.V1]; Jaklevic MC, 2020, JAMA-J AM MED ASSOC, V324, P926, DOI 10.1001/jama.2020.15444; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Manzoli L, 2018, EUR J PUBLIC HEALTH, V28, P740, DOI 10.1093/eurpub/cky053; Ministero della Salute, 2020, ULT ACC, V1, P1; Ministero della salute, 2020, DAT COP VACC; Ministero della salute, 2017, PIAN NAZ PREV VACC P; Ng TWY, 2020, VACCINE, V38, P690, DOI 10.1016/j.vaccine.2019.10.041; Nivette A, 2021, SOC SCI MED, V268, DOI 10.1016/j.socscimed.2020.113370; Palamenghi L, 2020, EUR J EPIDEMIOL, V35, P785, DOI 10.1007/s10654-020-00675-8; Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130; Park CL, 2020, J GEN INTERN MED, V35, P2296, DOI 10.1007/s11606-020-05898-9; Piltch-Loeb R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010076; Rosano A, 2019, INT J INFECT DIS, V88, P127, DOI 10.1016/j.ijid.2019.08.003; World Health Organization, 2010, EV SEAS INFL VACC PO; World Health Organization, 2019, 10 THREATS GLOB HLTH	33	31	32	19	36	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							70	10.3390/vaccines9020070			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	QO7JZ	33498282	gold, Green Published			2022-04-29	WOS:000623317500001
J	Gatti, M; Raschi, E; Moretti, U; Ardizzoni, A; Poluzzi, E; Diemberger, I				Gatti, Milo; Raschi, Emanuel; Moretti, Ugo; Ardizzoni, Andrea; Poluzzi, Elisabetta; Diemberger, Igor			Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase	VACCINES			English	Article						influenza vaccine; immune checkpoint inhibitors; myocarditis; pericarditis; pharmacovigilance; drug&#8211; vaccine interaction; adverse event following immunization	CANCER-PATIENTS; IMMUNOTHERAPY; RISK; OUTCOMES; SAFETY; FLU	Background: Evidence on whether the influenza vaccine could exacerbate immune-related adverse events, including myopericarditis (MP), in patients treated with immune checkpoint inhibitors (ICIs), is still conflicting. We explored this issue through a global real-world approach. Methods: We queried the Vaccine Adverse Event Reporting System (VAERS) and VigiBase to retrieve cases of MP in which the influenza vaccine and ICIs were recorded as suspect and were concomitantly reported. For the included cases, causality assessment and Drug Interaction Probability Scale (DIPS) algorithms were applied. Results: There were 191 and 399 reports of MP with the influenza vaccine that were retrieved (VAERS and VigiBase, respectively). No case of MP reporting the concomitant use of ICIs and the influenza vaccine was found in VAERS, while three cases of myocarditis were retrieved in VigiBase. All of the cases were unclassifiable for a causality assessment because of the lack of data concerning latency. According to the DIPS, one report was categorized as possible and two as doubtful. Conclusion: The paucity of cases coupled with the doubtful causality assessment make the potential interaction between influenza vaccines and ICIs in cancer patients negligible from clinical and epidemiological standpoints. These findings support the cardiovascular safety of the influenza vaccination, which remains strongly recommended in cancer patients, especially in the current COVID-19 era.	[Gatti, Milo; Raschi, Emanuel; Poluzzi, Elisabetta] Alma Mater Studiorum Univ Bologna, Dept Med & Surg Sci, I-40138 Bologna, Italy; [Moretti, Ugo] Univ Verona, Dept Publ Hlth & Community Med, I-37134 Verona, Italy; [Ardizzoni, Andrea] Alma Mater Studiorum Univ Bologna, Policlin S Orsola Malpighi, Dept Expt Diagnost & Specialty Med, Med Oncol Unit, I-40138 Bologna, Italy; [Diemberger, Igor] Alma Mater Studiorum Univ Bologna, Dept Expt Diagnost & Specialty Med, Cardiol Unit, I-40138 Bologna, Italy		Diemberger, I (通讯作者)，Alma Mater Studiorum Univ Bologna, Dept Expt Diagnost & Specialty Med, Cardiol Unit, I-40138 Bologna, Italy.	milo.gatti2@unibo.it; emanuel.raschi@unibo.it; ugo.moretti@univr.it; andrea.ardizzoni2@unibo.it; elisabetta.poluzzi@unibo.it; igor.diemberger@unibo.it		Gatti, Milo/0000-0003-3018-3779; Raschi, Emanuel/0000-0003-0487-7996			Adler Y, 2015, EUR HEART J, V36, P2921, DOI 10.1093/eurheartj/ehv318; Antonazzo IC, 2020, ACTA DIABETOL, V57, P71, DOI 10.1007/s00592-019-01378-7; Awadalla M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0535-y; Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P1139, DOI 10.2217/imt-2020-0211; Bersanelli M, 2020, IMMUNOTHERAPY-UK, V12, P151, DOI 10.2217/imt-2019-0180; Bersanelli M, 2019, CRIT REV ONCOL HEMAT, V139, P87, DOI 10.1016/j.critrevonc.2019.05.003; Bitterman R, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008983.pub3; Blank PR, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-272; Butany J, 2009, J CLIN PATHOL, V62, P1074, DOI 10.1136/jcp.2008.058255; Caforio ALP, 2013, EUR HEART J, V34, P2636, DOI 10.1093/eurheartj/eht210; Capone A, 2020, INT J INFECT DIS, V99, P393, DOI 10.1016/j.ijid.2020.07.077; Carnovale C, 2018, EXPERT REV VACCINES, V17, P363, DOI 10.1080/14760584.2018.1442718; Chong CR, 2020, CLIN INFECT DIS, V70, P193, DOI 10.1093/cid/ciz202; Chung C, 2019, J ONCOL PHARM PRACT, V25, P663, DOI 10.1177/1078155218786365; Cooksley CD, 2005, CANCER-AM CANCER SOC, V104, P618, DOI 10.1002/cncr.21203; Del Riccio M, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17217870; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Emens LA, 2017, EUR J CANCER, V81, P116, DOI 10.1016/j.ejca.2017.01.035; Failing JJ, 2020, JCO ONCOL PRACT, V16, P375, DOI 10.1200/JOP.19.00495; Gatti M, 2021, CLIN NUTR, V40, P1176, DOI 10.1016/j.clnu.2020.07.028; Gwynn ME, 2020, J ONCOL PHARM PRACT, V26, P647, DOI 10.1177/1078155219868758; Horn JR, 2007, ANN PHARMACOTHER, V41, P674, DOI 10.1345/aph.1H423; Laubli H, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0353-7; Mamas MA, 2008, INT J CARDIOL, V130, P304, DOI 10.1016/j.ijcard.2008.04.044; Arias LHM, 2015, VACCINE, V33, P3773, DOI 10.1016/j.vaccine.2015.05.013; Martins F, 2019, NAT REV CLIN ONCOL, V16, P563, DOI 10.1038/s41571-019-0218-0; Mei R, 2018, INT J CARDIOL, V273, P183, DOI 10.1016/j.ijcard.2018.09.054; Mei R, 2018, BMC PHARMACOL TOXICO, V19, DOI 10.1186/s40360-018-0211-8; Moslehi JJ, 2018, LANCET, V391, P933, DOI 10.1016/S0140-6736(18)30533-6; Muller D, 2007, INFECTION, V35, P308, DOI 10.1007/s15010-007-6218-5; Pellegrino P, 2015, DRUG SAFETY, V38, P781, DOI 10.1007/s40264-015-0330-8; Poeppl W, 2015, VACCINE, V33, P1682, DOI 10.1016/j.vaccine.2015.02.029; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMra1703481, 10.1056/NEJMc1801663]; Raschi E, 2020, TARGET ONCOL, V15, P449, DOI 10.1007/s11523-020-00738-6; Raschi E, 2018, LANCET, V392, P383, DOI 10.1016/S0140-6736(18)31549-6; Salem JE, 2018, LANCET ONCOL, V19, P1579, DOI 10.1016/S1470-2045(18)30608-9; Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035; Singleton JA, 1999, VACCINE, V17, P2908, DOI 10.1016/S0264-410X(99)00132-2; Supakornnumporn Songkit, 2017, J Clin Neuromuscul Dis, V19, P80, DOI 10.1097/CND.0000000000000193; Udell JA, 2013, JAMA-J AM MED ASSOC, V310, P1711, DOI 10.1001/jama.2013.279206; Wijn DH, 2018, EUR J CANCER, V104, P182, DOI 10.1016/j.ejca.2018.09.012; Yuen Carlen, 2019, J Clin Neuromuscul Dis, V20, P194, DOI 10.1097/CND.0000000000000230	42	5	5	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							19	10.3390/vaccines9010019			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6VZ	33406694	gold, Green Published			2022-04-29	WOS:000610811100001
J	Mertes, V; Bekkelund, AK; Lagos, L; Ciani, E; Colquhoun, D; Haslene-Hox, H; Sletta, H; Sorum, H; Winther-Larsen, HC				Mertes, Verena; Bekkelund, Alexander Kashulin; Lagos, Leidy; Ciani, Elia; Colquhoun, Duncan; Haslene-Hox, Hanne; Sletta, Havard; Sorum, Henning; Winther-Larsen, Hanne Cecilie			The Use of Extracellular Membrane Vesicles for Immunization against Francisellosis in Nile Tilapia (Oreochromis niloticus) and Atlantic Cod (Gadus morhua L.)	VACCINES			English	Article						francisellosis; vaccine; membrane vesicles; fish disease; Atlantic cod; tilapia		Francisellosis in fish is caused by the facultative intracellular Gram-negative bacterial pathogens Francisella noatunensis ssp. noatunensis and Francisella orientalis. The disease is affecting both farmed and wild fish worldwide and no commercial vaccines are currently available. In this study, we tested isolated membrane vesicles (MVs) as possible vaccine candidates based on previous trials in zebrafish (Danio rerio) indicating promising vaccine efficacy. Here, the MV vaccine-candidates were tested in their natural hosts, Atlantic cod (Gadus morhua L.) and Nile tilapia (Oreochromis niloticus). Injection of MVs did not display any toxicity or other negative influence on the fish and gene expression analysis indicated an influence on the host immune response. However, unlike in other tested fish species, a protective immunity following vaccine application and immunization period could not be detected in the Atlantic cod or tilapia. Further in vivo studies are required to achieve a better understanding of the development of immunological memory in different fish species.	[Mertes, Verena; Lagos, Leidy; Ciani, Elia; Winther-Larsen, Hanne Cecilie] Univ Oslo, Sect Pharmacol & Pharmaceut Biosci, N-0315 Oslo, Norway; [Mertes, Verena; Lagos, Leidy; Ciani, Elia; Winther-Larsen, Hanne Cecilie] Univ Oslo, Ctr Integrat Microbial Evolut, Dept Pharm, N-0315 Oslo, Norway; [Bekkelund, Alexander Kashulin; Sorum, Henning] Norwegian Univ Life Sci, Dept Food Safety & Infect Biol, N-1430 As, Norway; [Colquhoun, Duncan] Norwegian Vet Inst, Fish Hlth Res Grp, N-4045 Oslo, Norway; [Haslene-Hox, Hanne; Sletta, Havard] SINTEF Ind, Dept Biotechnol & Nanomed, N-7034 Trondheim, Norway		Winther-Larsen, HC (通讯作者)，Univ Oslo, Sect Pharmacol & Pharmaceut Biosci, N-0315 Oslo, Norway.; Winther-Larsen, HC (通讯作者)，Univ Oslo, Ctr Integrat Microbial Evolut, Dept Pharm, N-0315 Oslo, Norway.	verename@uio.no; a.bekkelund@creek-bio.com; leidy.lagos@nmbu.no; elia.ciani@farmasi.uio.no; duncan.colquhoun@vetinst.no; Hanne.Haslene-Hox@sintef.no; Havard.Sletta@sintef.no; henning.sorum@nmbu.no; h.c.winther-larsen@farmasi.uio.no			University of Oslo; Research Council of Norway (RCN) Biotek2021 ProgramResearch Council of Norway [233849]; RCN FORNY program [267845]	The work was financially supported by the University of Oslo, The Research Council of Norway (RCN) Biotek2021 Program grant no. 233849 and the RCN FORNY program grant no. 267845.	Aoki M, 2007, VACCINE, V25, P561, DOI 10.1016/j.vaccine.2006.07.047; Asare R, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2010.00145; Bakkemo KR, 2011, FISH SHELLFISH IMMUN, V31, P993, DOI 10.1016/j.fsi.2011.08.020; Birkbeck TH, 2011, J FISH DIS, V34, P173, DOI 10.1111/j.1365-2761.2010.01226.x; BLADEN HA, 1963, J BACTERIOL, V86, P1339, DOI 10.1128/JB.86.6.1339-1344.1963; Brudal E, 2015, FISH SHELLFISH IMMUN, V42, P50, DOI 10.1016/j.fsi.2014.10.025; Brudal E, 2014, INFECT IMMUN, V82, P2180, DOI 10.1128/IAI.00077-14; Brudal Espen, 2013, BMC Res Notes, V6, P76, DOI 10.1186/1756-0500-6-76; CHEN SC, 1994, J FISH DIS, V17, P591, DOI 10.1111/j.1365-2761.1994.tb00257.x; CHERN RS, 1994, FISH PATHOL, V29, P61, DOI 10.3147/jsfp.29.61; Chuang WL, 2011, J AGR FOOD CHEM, V59, P9532, DOI 10.1021/jf2017308; Colquhoun DJ, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-47; Cowley SC, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00026; Duodu S, 2012, DIS AQUAT ORGAN, V101, P225, DOI 10.3354/dao02514; Ellingsen T, 2011, FISH SHELLFISH IMMUN, V31, P326, DOI 10.1016/j.fsi.2011.05.021; Furevik A, 2011, FISH SHELLFISH IMMUN, V30, P488, DOI 10.1016/j.fsi.2010.11.019; Gallage S, 2016, FISH SHELLFISH IMMUN, V51, P271, DOI 10.1016/j.fsi.2016.02.024; Gjessing MC, 2012, FISH SHELLFISH IMMUN, V32, P141, DOI 10.1016/j.fsi.2011.11.003; Gogos CA, 2000, J INFECT DIS, V181, P176, DOI 10.1086/315214; Gonzalez S, 2006, VACCINE, V24, P1633, DOI 10.1016/j.vaccine.2005.09.050; Hamdan AM, 2016, J APPL MICROBIOL, V120, P1061, DOI 10.1111/jam.13081; Holst J, 2005, VACCINE, V23, P2202, DOI 10.1016/j.vaccine.2005.01.058; Jantrakajorn S, 2016, J AQUAT ANIM HEALTH, V28, P97, DOI 10.1080/08997659.2015.1135198; Jeffery KR, 2010, DIS AQUAT ORGAN, V91, P161, DOI 10.3354/dao02260; Jones CL, 2012, MICROBIOL MOL BIOL R, V76, P383, DOI 10.1128/MMBR.05027-11; Lagos L, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00557-16; LAMERS CHJ, 1985, DEV COMP IMMUNOL, V9, P65, DOI 10.1016/0145-305X(85)90060-6; Lampe EO, 2017, VACCINE, V35, P7264, DOI 10.1016/j.vaccine.2017.11.009; Lampe EO, 2017, DIS AQUAT ORGAN, V123, P123, DOI 10.3354/dao03087; Leal CAG, 2014, GENET MOL RES, V13, P5704, DOI 10.4238/2014.July.25.26; Liu CZ, 2016, FISH SHELLFISH IMMUN, V50, P160, DOI 10.1016/j.fsi.2016.01.027; Mauel MJ, 2007, J AQUAT ANIM HEALTH, V19, P27, DOI 10.1577/H06-025.1; Mauel MJ, 2003, DIS AQUAT ORGAN, V53, P249, DOI 10.3354/dao053249; Mauel MJ, 2005, J VET DIAGN INVEST, V17, P601, DOI 10.1177/104063870501700616; McCoy G, 1912, J INFECT DIS, V10, P61, DOI 10.1093/infdis/10.1.61; Mikalsen Jarle, 2009, Int J Syst Evol Microbiol; Muller M, 2011, ARCH MED VET, V43, P73, DOI 10.4067/S0301-732X2011000100010; Munang'andu HM, 2016, VACCINES-BASEL, V4, DOI 10.3390/vaccines4040048; Nylund A, 2006, ARCH MICROBIOL, V185, P383, DOI 10.1007/s00203-006-0109-5; Olsen AB, 2006, J FISH DIS, V29, P307, DOI 10.1111/j.1365-2761.2006.00714.x; Olsvik Pal A, 2008, BMC Res Notes, V1, P47, DOI 10.1186/1756-0500-1-47; Park SB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017629; Perez-Casanova JC, 2010, MAR ENVIRON RES, V70, P26, DOI 10.1016/j.marenvres.2010.02.005; Perez-Cruz C, 2013, APPL ENVIRON MICROB, V79, P1874, DOI 10.1128/AEM.03657-12; Pirarat N, 2011, RES VET SCI, V91, pE92, DOI 10.1016/j.rvsc.2011.02.014; Prentice E.F., 1990, AM FISHERIES SOC S, V7, P335; Roberts R, 2008, VACCINE, V26, P4639, DOI 10.1016/j.vaccine.2008.07.004; Schroder MB, 2009, FISH SHELLFISH IMMUN, V27, P112, DOI 10.1016/j.fsi.2008.11.016; Seppola M, 2008, MOL IMMUNOL, V45, P887, DOI 10.1016/j.molimm.2007.08.003; Shahin K, 2019, FISH SHELLFISH IMMUN, V89, P217, DOI 10.1016/j.fsi.2019.03.071; Solbakken MH, 2019, COMP BIOCHEM PHYS D, V30, P333, DOI 10.1016/j.cbd.2019.04.004; Soto E, 2013, J FISH DIS, V36, P411, DOI 10.1111/j.1365-2761.2012.01425.x; Soto E, 2009, J FISH DIS, V32, P713, DOI 10.1111/j.1365-2761.2009.01070.x; Soto E, 2014, J ZOO WILDLIFE MED, V45, P727, DOI 10.1638/2014-0059R.1; Soto E, 2011, VACCINE, V29, P593, DOI 10.1016/j.vaccine.2010.06.040; Star B, 2011, NATURE, V477, P207, DOI 10.1038/nature10342; Steiner DJ, 2014, INFECT DRUG RESIST, V7, P239, DOI 10.2147/IDR.S53700; Svensson K, 2005, J BACTERIOL, V187, P3903, DOI 10.1128/JB.187.11.3903-3908.2005; van de Waterbeemd B, 2010, VACCINE, V28, P4810, DOI 10.1016/j.vaccine.2010.04.082; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vojtech LN, 2009, INFECT IMMUN, V77, P914, DOI 10.1128/IAI.01201-08; Wang B, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030348; Wen CM, 2016, FISH SHELLFISH IMMUN, V49, P442, DOI 10.1016/j.fsi.2016.01.013; Ye JM, 2013, FISH SHELLFISH IMMUN, V35, P1719, DOI 10.1016/j.fsi.2013.10.015	64	3	3	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							34	10.3390/vaccines9010034			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6UI	33435503	Green Published			2022-04-29	WOS:000610806700001
J	Yu, JH; Jeong, HJ; Kim, SJ; Lee, JY; Choe, YJ; Choi, EH; Cho, EH				Yu, Jeong Hee; Jeong, Hang Jin; Kim, Seon Ju; Lee, Jae Young; Choe, Young June; Choi, Eun Hwa; Cho, En Hi			Sustained Vaccination Coverage during the Coronavirus Disease 2019 Epidemic in the Republic of Korea	VACCINES			English	Article						SARS-CoV-2; coronavirus; COVID-19; vaccination; vaccine coverage; vaccine-preventable disease		Amid the COVID-19 pandemic, vaccination coverage may decline due to limited accessibility to healthcare. We assessed the impact of the COVID-19 pandemic on vaccination coverage and the incidence of vaccine-preventable diseases (VPDs) in the Republic of Korea. National vaccination coverage of 10 essential vaccines administered to children between January-June 2019 and January-June 2020 was analyzed. The national incidence of selected VPDs was compared for the corresponding periods. During the COVID-19 outbreak, the vaccination rate in children aged 0-35 months in Korea did not decrease significantly, whereas the vaccination rate for children aged 4-6 years decreased by 1.4-1.9%. The overall incidence of VPDs decreased by 10-50% between 2019 and 2020, especially with varicella. Thus, the COVID-19 pandemic did not result in a decrease in vaccination coverage among Korean children, which prevented a surge in VPD incidence. Maintaining essential vaccination coverage without interruption is important during the response to the COVID-19 pandemic.	[Yu, Jeong Hee; Jeong, Hang Jin; Kim, Seon Ju; Lee, Jae Young; Cho, En Hi] Korea Dis Control & Prevent Agcy, Div Natl Immunizat Program & Vaccine Preventable, Cheongju 28159, South Korea; [Choe, Young June] Hallym Univ, Coll Med, Dept Social & Prevent Med, Chunchon 24252, South Korea; [Choi, Eun Hwa] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul 03080, South Korea		Cho, EH (通讯作者)，Korea Dis Control & Prevent Agcy, Div Natl Immunizat Program & Vaccine Preventable, Cheongju 28159, South Korea.	cheeyu@korea.kr; jhjin9035@korea.kr; ektjtwkd@korea.kr; pgzdtk198@korea.kr; ychoe@hallym.ac.kr; eunchoi@snu.ac.kr; cho6404@korea.kr	Choe, Young June/AAG-6632-2021				Cha SH, 2012, CLIN EXP VACCINE RES, V1, P3, DOI 10.7774/cevr.2012.1.1.3; Choe YJ, 2014, VACCINE, V32, P6049, DOI 10.1016/j.vaccine.2014.09.009; Hill HA, 2018, MMWR-MORBID MORTAL W, V67, P1123, DOI 10.15585/mmwr.mm6740a4; Hull B, 2019, COMMUN DIS INTELL, V43, DOI 10.33321/cdi.2019.43.47; Korea Centers for Disease Control and Prevention (KCDC), 2019, 2019 2020 SEAS INFL; Korea Centers for Disease Control and Prevention (KCDC), 2020, NAT IMM PROGR SUPP P; Korea Centers for Disease Control and Prevention (KCDC), 2020, WHIT PAP DIS CONTR P; Masresha BG, 2020, PAN AFR MED J, V35, P31, DOI 10.11604/pamj.supp.2020.35.1.19059; National Statistics, 2019, CHILDH VACC COV STAT; Park Bomi, 2018, J Prev Med Public Health, V51, P173, DOI 10.3961/jpmph.18.063; Statics Korea, 2020, NAT IMM RAT KOR 2019; WHO, 2020, GUIDING PRINCIPLES I; Yun HE, 2021, J MED VIROL, V93, P1814, DOI 10.1002/jmv.26614	13	6	7	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							2	10.3390/vaccines9010002			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7BC	33375172	gold, Green Published			2022-04-29	WOS:000610824600001
J	Awad, SF; Musuka, G; Mukandavire, Z; Froass, D; MacKinnon, NJ; Cuadros, DF				Awad, Susanne F.; Musuka, Godfrey; Mukandavire, Zindoga; Froass, Dillon; MacKinnon, Neil J.; Cuadros, Diego F.			Implementation of a Vaccination Program Based on Epidemic Geospatial Attributes: COVID-19 Pandemic in Ohio as a Case Study and Proof of Concept	VACCINES			English	Article						vaccination program; geospatial attributes; spatial epidemiology; disease mapping; COVID-19; mathematical model	DYNAMICS; IMPACT; HESITANCY; COVERAGE; HEALTH	Geospatial vaccine uptake is a critical factor in designing strategies that maximize the population-level impact of a vaccination program. This study uses an innovative spatiotemporal model to assess the impact of vaccination distribution strategies based on disease geospatial attributes and population-level risk assessment. For proof of concept, we adapted a spatially explicit COVID-19 model to investigate a hypothetical geospatial targeting of COVID-19 vaccine rollout in Ohio, United States, at the early phase of COVID-19 pandemic. The population-level deterministic compartmental model, incorporating spatial-geographic components at the county level, was formulated using a set of differential equations stratifying the population according to vaccination status and disease epidemiological characteristics. Three different hypothetical scenarios focusing on geographical subpopulation targeting (areas with high versus low infection intensity) were investigated. Our results suggest that a vaccine program that distributes vaccines equally across the entire state effectively averts infections and hospitalizations (2954 and 165 cases, respectively). However, in a context with equitable vaccine allocation, the number of COVID-19 cases in high infection intensity areas will remain high; the cumulative number of cases remained > 30,000 cases. A vaccine program that initially targets high infection intensity areas has the most significant impact in reducing new COVID-19 cases and infection-related hospitalizations (3756 and 213 infections, respectively). Our approach demonstrates the importance of factoring geospatial attributes to the design and implementation of vaccination programs in a context with limited resources during the early stage of the vaccine rollout.	[Awad, Susanne F.] Cornell Univ, Weill Cornell Med Qatar, Infect Dis Epidemiol Grp, Doha 24144, Qatar; [Awad, Susanne F.] Cornell Univ, Weill Cornell Med Qatar, Who Collaborating Ctr Dis Epidemiol Analyt HIV Ai, Doha 24144, Qatar; [Awad, Susanne F.] Cornell Univ, Dept Populat Hlth Sci, Weill Cornell Med, New York, NY 10065 USA; [Musuka, Godfrey] Columbia Univ, ICAP, Harare, Zimbabwe; [Mukandavire, Zindoga] Emirates Aviat Univ, Ctr Data Sci & Artificial Intelligence, Dubai 53044, U Arab Emirates; [Froass, Dillon] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; [MacKinnon, Neil J.] Augusta Univ, Med Coll Georgia, Dept Populat Hlth Sci, Augusta, GA 30912 USA; [Cuadros, Diego F.] Univ Cincinnati, Dept Geog & Geog Informat Sci, Cincinnati, OH 45221 USA; [Cuadros, Diego F.] Univ Cincinnati, Hlth Geog & Dis Modeling Lab, Cincinnati, OH 45221 USA		Cuadros, DF (通讯作者)，Univ Cincinnati, Dept Geog & Geog Informat Sci, Cincinnati, OH 45221 USA.; Cuadros, DF (通讯作者)，Univ Cincinnati, Hlth Geog & Dis Modeling Lab, Cincinnati, OH 45221 USA.	sua2006@qatar-med.cornell.edu; gm2660@cumc.columbia.edu; zindoga.mukandavire@emirates.com; froassdc@mail.uc.edu; nmackinnon@augusta.edu; diego.cuadros@uc.edu		Cuadros, Diego/0000-0001-7060-4203; Musuka, Godfrey/0000-0001-9077-4429; mackinnon, neil/0000-0001-8111-6651	Biomedical Research Program - NPRP [10-1208-160017, 7-627-3-167]; Qatar National Research Fund	Acknowledgments :Susanne F. Awad is grateful for support provided by the Biomedical ResearchProgram and the Biostatistics, Epidemiology, and Biomathematics Research Core, at Weill CornellMedicine-Qatar. The developed mathematical model was informed by previous funded by NPRPgrant number 10-1208-160017 and NPRP grant number 7-627-3-167 from the Qatar National ResearchFund (a member of Qatar Foundation; https://www.qnrf.org accessed on 15 August 2021).	Ali D, 2020, VACCINE, V38, P1408, DOI 10.1016/j.vaccine.2019.12.002; Asghar RJ, 2020, LANCET GLOB HEALTH, V8, pE177, DOI 10.1016/S2214-109X(19)30524-8; Ayoub, 2020, CHARACTERIZING KEY A, DOI DOI 10.1101/2020.04.08.20058214; Barau I, 2014, J INFECT DIS, V210, pS102, DOI 10.1093/infdis/jiu010; Caini S, 2018, INFLUENZA OTHER RESP, V12, P344, DOI 10.1111/irv.12544; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P465, DOI 10.15585/mmwr.mm6915e4; Correa-Agudelo E, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18084021; Cuadros DF, 2021, ANN EPIDEMIOL, V59, P16, DOI 10.1016/j.annepidem.2021.04.007; Cuadros DF, 2020, HEALTH PLACE, V64, DOI 10.1016/j.healthplace.2020.102404; Department of Health and Social Care, JOINT COMM VACC IMM; Department of Health Ohio, COVID 19 DASHB; ESRI, 2004, ARCGIS 10 X; Green CA, 2016, ARCH DIS CHILD, V101, P140, DOI 10.1136/archdischild-2015-308723; Janssen Medical Information, JANSS COVID 19 VACC; Kazi AM, 2017, INT J MED INFORM, V107, P48, DOI 10.1016/j.ijmedinf.2017.09.004; Kim H, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2020-004089; Kim H, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001922; Lagarias JC, 1998, SIAM J OPTIMIZ, V9, P112, DOI 10.1137/S1052623496303470; Li X, 2021, LANCET, V397, P398, DOI 10.1016/S0140-6736(20)32657-X; Mukandavire Z, 2020, INT J INFECT DIS, V96, P222, DOI 10.1016/j.ijid.2020.03.077; Mukandavire Z, 2011, P NATL ACAD SCI USA, V108, P8767, DOI 10.1073/pnas.1019712108; Park M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040967; Patel PR, 2013, HUM VACC IMMUNOTHER, V9, P2649, DOI 10.4161/hv.26224; Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963; Real LA, 2007, J R SOC INTERFACE, V4, P935, DOI 10.1098/rsif.2007.1041; Rosencrans LC, 2017, J INFECT DIS, V216, pS337, DOI 10.1093/infdis/jix008; Shaikh H, 2020, VACCINE, V38, pA118, DOI 10.1016/j.vaccine.2019.12.011; Simms KT, 2020, LANCET PUBLIC HEALTH, V5, pE223, DOI 10.1016/S2468-2667(20)30010-4; Sloan C, 2011, CTS-CLIN TRANSL SCI, V4, P48, DOI 10.1111/j.1752-8062.2010.00257.x; The MathWorks Inc., 2020, MATLAB LANG TECHN CO; United States Census Bureau, WEEK 34 HOUS PULS SU; van Dorn A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X; World Health Organization, ACC ALL WILL THER BE; Wu X, 2020, MANAGEMENT TRANSFORMATION OF HUAWEI, P1, DOI 10.1017/9781108550987	34	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1242	10.3390/vaccines9111242			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XG6KI	34835173	gold, Green Published			2022-04-29	WOS:000724859200001
J	Diesterbeck, US; Ahsendorf, HP; Frenzel, A; Sharifi, AR; Schirrmann, T; Czerny, CP				Diesterbeck, Ulrike S.; Ahsendorf, Henrike P.; Frenzel, Andre; Sharifi, Ahmad Reza; Schirrmann, Thomas; Czerny, Claus-Peter			Characterization of an In Vivo Neutralizing Anti-Vaccinia Virus D8 Single-Chain Fragment Variable (scFv) from a Human Anti-Vaccinia Virus-Specific Recombinant Library	VACCINES			English	Article						scFv; vaccinia virus; recombinant antibody; D8	IMMUNE GLOBULIN; MONOCLONAL-ANTIBODIES; SMALLPOX VACCINATION; ENVELOPE PROTEIN; INFECTION; EPITOPE; SURFACE; EFFICACY; MICE; IDENTIFICATION	A panel of potent neutralizing antibodies are protective against orthopoxvirus (OPXV) infections. For the development of OPXV-specific recombinant human single-chain antibodies (scFvs), the IgG repertoire of four vaccinated donors was amplified from peripheral B-lymphocytes. The resulting library consisted of & GE;4 x 10(8) independent colonies. The immuno-screening against vaccinia virus (VACV) Elstree revealed a predominant selection of scFv clones specifically binding to the D8 protein. The scFv-1.2.2.H9 was engineered into larger human scFv-Fc-1.2.2.H9 and IgG1-1.2.2.H9 formats to improve the binding affinity and to add effector functions within the human immune response. Similar binding kinetics were calculated for scFv-1.2.2.H9 and scFv-Fc-1.2.2.H9 (1.61 nM and 7.685 nM, respectively), whereas, for IgG1-1.2.2.H9, the Michaelis-Menten kinetics revealed an increased affinity of 43.8 pM. None of the purified recombinant 1.2.2.H9 formats were able to neutralize VACV Elstree in vitro. After addition of 1% human complement, the neutralization of & GE;50% of VACV Elstree was achieved with 0.0776 mu M scFv-Fc-1.2.2.H9 and 0.01324 mu M IgG1-1.2.2.H9, respectively. In an in vivo passive immunization NMRI mouse model, 100 mu g purified scFv-1.2.2.H9 and the IgG1-1.2.2.H9 partially protected against the challenge with 4 LD50 VACV Munich 1, as 3/6 mice survived. In contrast, in the scFv-Fc-1.2.2.H9 group, only one mouse survived the challenge.	[Diesterbeck, Ulrike S.; Ahsendorf, Henrike P.; Czerny, Claus-Peter] Univ Gottingen, Dept Anim Sci, Div Microbiol & Anim Hyg, Burckhardtweg 2, D-37077 Gottingen, Germany; [Frenzel, Andre; Schirrmann, Thomas] Yumab GmbH, Sci Campus Braunschweig Sued,Inhoffenstr 7, D-38124 Braunschweig, Germany; [Sharifi, Ahmad Reza] Univ Gottingen, Dept Anim Sci, Ctr Integrated Breeding Res, Albrecht Thaer Weg 3, D-37075 Gottingen, Germany; [Czerny, Claus-Peter] Verovaccines GmbH, Blucherstr 26, D-06120 Halle, Saale, Germany; [Ahsendorf, Henrike P.] Hannover Med Sch, Inst Virol, Carl Neuberg Str 1, D-30625 Hannover, Germany; [Ahsendorf, Henrike P.] Hannover Med Sch, Cluster Excellence RESIST EXC2155, Carl Neuberg Str 1, D-30625 Hannover, Germany		Diesterbeck, US (通讯作者)，Univ Gottingen, Dept Anim Sci, Div Microbiol & Anim Hyg, Burckhardtweg 2, D-37077 Gottingen, Germany.	rsharif@gwdg.de		Ahsendorf, Henrike Paula/0000-0003-1745-2137	Bundesamt fuer Wehrtechnik und Beschaffung [E/UR3G/4A030/4A800]	The study was funded by the Bundesamt fuer Wehrtechnik und Beschaffung under the grant number E/UR3G/4A030/4A800.	Ahsendorf HP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060493; Aldaz-Carroll L, 2005, J VIROL, V79, P6260, DOI 10.1128/JVI.79.10.6260-6271.2005; Becker C, 2009, DTSCH ARZTEBL INT, V106, P329, DOI 10.3238/arztebl.2009.0329; Benhnia MREI, 2008, J VIROL, V82, P3751, DOI 10.1128/JVI.02244-07; Benhnia MREI, 2009, J VIROL, V83, P12355, DOI 10.1128/JVI.01593-09; Benhnia MREI, 2009, J VIROL, V83, P1201, DOI 10.1128/JVI.01797-08; BLASCO R, 1992, J VIROL, V66, P4170, DOI 10.1128/JVI.66.7.4170-4179.1992; Boulter E A, 1973, Prog Med Virol, V16, P86; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Campe H, 2009, EMERG INFECT DIS, V15, P777, DOI 10.3201/eid1505.090159; Chen ZC, 2006, P NATL ACAD SCI USA, V103, P1882, DOI 10.1073/pnas.0510598103; Czerny C P, 1989, Zentralbl Veterinarmed B, V36, P100; Czerny C.-P., 2001, RAPID REAL TIME PCR, P371; CZERNY CP, 1994, VIROLOGY, V200, P764, DOI 10.1006/viro.1994.1240; CZERNY CP, 1990, J GEN VIROL, V71, P2341, DOI 10.1099/0022-1317-71-10-2341; Czerny CP, 1997, ARCH VIROL, V142, P807, DOI 10.1007/s007050050120; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Eto A, 2019, VACCINE, V37, P6588, DOI 10.1016/j.vaccine.2019.09.006; FEERY BJ, 1976, VOX SANG, V31, P68, DOI 10.1111/j.1423-0410.1976.tb02224.x; Fenner F., 1988, SMALLPOX ITS ERADICA, P1; Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7; Fulginiti VA, 2003, JAMA-J AM MED ASSOC, V290, P1452, DOI 10.1001/jama.290.11.1452-a; Fulginiti VA, 2003, CLIN INFECT DIS, V37, P251, DOI 10.1086/375825; Gilchuk I, 2016, CELL, V167, P684, DOI 10.1016/j.cell.2016.09.049; Giudicelli Veronique, 2011, Cold Spring Harb Protoc, V2011, P695, DOI 10.1101/pdb.prot5633; Hoogenboom HR, 1998, IMMUNOTECHNOLOGY, V4, P1, DOI 10.1016/S1380-2933(98)00007-4; Hopkins RJ, 2004, CLIN INFECT DIS, V39, P819, DOI 10.1086/422999; Hopkins RJ, 2004, CLIN INFECT DIS, V39, P759, DOI 10.1086/422998; Hsiao JC, 1999, J VIROL, V73, P8750, DOI 10.1128/JVI.73.10.8750-8761.1999; Hurteau GJ, 2002, ANAL BIOCHEM, V307, P304, DOI 10.1016/S0003-2697(02)00058-1; Ichihashi Y, 1996, VIROLOGY, V220, P491, DOI 10.1006/viro.1996.0337; Jager V, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-52; Kaever T, 2016, J VIROL, V90, P4334, DOI 10.1128/JVI.02878-15; KEMPE CH, 1960, PEDIATRICS, V26, P176; Cono Joanne, 2003, MMWR Recomm Rep, V52, P1; Kurth A, 2008, EMERG INFECT DIS, V14, P670, DOI 10.3201/eid1404.070817; Ladnyi I D, 1978, Dev Biol Stand, V41, P281; LADNYJ ID, 1972, B WORLD HEALTH ORGAN, V46, P593; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin CL, 2000, J VIROL, V74, P3353, DOI 10.1128/JVI.74.7.3353-3365.2000; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAA JS, 1990, J BIOL CHEM, V265, P1569; Matho MH, 2018, J BIOL CHEM, V293, P390, DOI 10.1074/jbc.M117.814541; Matho MH, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004495; Matho MH, 2012, J VIROL, V86, P8050, DOI 10.1128/JVI.00836-12; McCausland MM, 2010, ANTIVIR THER, V15, P661, DOI 10.3851/IMP1573; Michaelis L, 1913, BIOCHEM Z, V49, P333; Mirzakhanyan Y, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007508; Moss B, 2006, VIROLOGY, V344, P48, DOI 10.1016/j.virol.2005.09.037; NILES EG, 1988, J VIROL, V62, P3772, DOI 10.1128/JVI.62.10.3772-3778.1988; Ramirez JC, 2002, J GEN VIROL, V83, P1059, DOI 10.1099/0022-1317-83-5-1059; Reed KD, 2004, NEW ENGL J MED, V350, P342, DOI 10.1056/NEJMoa032299; RODRIGUEZ JF, 1985, J VIROL, V56, P482, DOI 10.1128/JVI.56.2.482-488.1985; RODRIGUEZ JR, 1992, J VIROL, V66, P183, DOI 10.1128/JVI.66.1.183-189.1992; Sakhatskyy P, 2006, VIROLOGY, V355, P164, DOI 10.1016/j.virol.2006.07.017; Sawyer LA, 2000, ANTIVIR RES, V47, P57, DOI 10.1016/S0166-3542(00)00111-X; Schmaljohn C, 1999, VIROLOGY, V258, P189, DOI 10.1006/viro.1999.9701; SLIFKA MK, 1995, J VIROL, V69, P1895, DOI 10.1128/JVI.69.3.1895-1902.1995; Smith GL, 1998, ADV EXP MED BIOL, V440, P395; Smith GL, 2002, J GEN VIROL, V83, P2915, DOI 10.1099/0022-1317-83-12-2915; Steinwand M, 2014, MABS-AUSTIN, V6, P204, DOI 10.4161/mabs.27227; Vaughan A, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.38.1800509; Vorou RM, 2008, CURR OPIN INFECT DIS, V21, P153, DOI 10.1097/QCO.0b013e3282f44c74; Wallengren K, 2001, VIROLOGY, V290, P143, DOI 10.1006/viro.2001.1131; WOLFFE EJ, 1995, VIROLOGY, V211, P53, DOI 10.1006/viro.1995.1378; Xu CG, 2011, VIROLOGY, V418, P67, DOI 10.1016/j.virol.2011.06.029	67	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1308	10.3390/vaccines9111308			27	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XF5TB	34835240	gold, Green Published			2022-04-29	WOS:000724131800001
J	Vasilyev, K; Shurygina, AP; Zabolotnykh, N; Sergeeva, M; Romanovskaya-Romanko, E; Pulkina, A; Buzitskaya, J; Dogonadze, MZ; Vinogradova, TI; Stukova, MA				Vasilyev, Kirill; Shurygina, Anna-Polina; Zabolotnykh, Natalia; Sergeeva, Mariia; Romanovskaya-Romanko, Ekaterina; Pulkina, Anastasia; Buzitskaya, Janna; Dogonadze, Marine Z.; Vinogradova, Tatiana, I; Stukova, Marina A.			Enhancement of the Local CD8(+) T-Cellular Immune Response to Mycobacterium tuberculosis in BCG-Primed Mice after Intranasal Administration of Influenza Vector Vaccine Carrying TB10.4 and HspX Antigens	VACCINES			English	Article						M. tuberculosis vaccine; TB10.4; HspX; influenza vector; mucosal immunization; innate immune response; T-cellular immune response; flow cytometry	INTERFERON-GAMMA; A VIRUSES; CELLS; PROTECTION; IMMUNOGENICITY; CORRELATE; MACROPHAGES; ACTIVATION; EFFICACY; SUBSETS	BCG is the only licensed vaccine against Mycobacterium tuberculosis (M.tb) infection. Due to its intramuscular administration route, BCG is unable to induce a local protective immune response in the respiratory system. Moreover, BCG has a diminished ability to induce long-lived memory T-cells which are indispensable for antituberculosis protection. Recently we described the protective efficacy of new mucosal TB vaccine candidate based on recombinant attenuated influenza vector (Flu/THSP) co-expressing TB10.4 and HspX proteins of M.tb within an NS1 influenza protein open reading frame. In the present work, the innate and adaptive immune response to immunization with the Flu/THSP and the immunological properties of vaccine candidate in the BCG-prime & RARR; Flu/THSP vector boost vaccination scheme are studied in mice. It was shown that the mucosal administration of Flu/THSP induces the incoming of interstitial macrophages in the lung tissue and stimulates the expression of co-stimulatory CD86 and CD83 molecules on antigen-presenting cells. The T-cellular immune response to Flu/THSP vector was mediated predominantly by the IFN gamma-producing CD8(+) lymphocytes. BCG-prime & RARR; Flu/THSP vector boost immunization scheme was shown to protect mice from severe lung injury caused by M.tb infection due to the enhanced T-cellular immune response, mediated by antigen-specific effector and central memory CD4(+) and CD8(+) T-lymphocytes.	[Vasilyev, Kirill; Shurygina, Anna-Polina; Sergeeva, Mariia; Romanovskaya-Romanko, Ekaterina; Pulkina, Anastasia; Buzitskaya, Janna; Stukova, Marina A.] Minist Hlth Russian Federat, Smorodintsev Res Inst Influenza, St Petersburg 197376, Russia; [Zabolotnykh, Natalia; Dogonadze, Marine Z.; Vinogradova, Tatiana, I] Minist Hlth Russian Federat, St Petersburg State Res Inst Phthisiopulmonol, St Petersburg 191036, Russia		Vasilyev, K (通讯作者)，Minist Hlth Russian Federat, Smorodintsev Res Inst Influenza, St Petersburg 197376, Russia.	kirillv5@yandex.ru; ann-polin@yandex.ru; zabol-natal@yandex.ru; mari.v.sergeeva@gmail.com; romromka@yandex.ru; pureska@mail.ru; janna.buzitskaya@influenza.spb.ru; marine-md@mail.ru; vinogradova@spbniif.ru; marina.stukova@influenza.spb.ru	Vasilev, Kirill/I-8895-2018; Sergeeva, Mariia/F-8963-2017; Romanovskaya-Romanko, Ekaterina/J-1022-2018; Shurygina, Anna-Polina/C-4948-2014	Vasilev, Kirill/0000-0002-7750-9652; Sergeeva, Mariia/0000-0003-0411-9896; Romanovskaya-Romanko, Ekaterina/0000-0001-7560-398X; Shurygina, Anna-Polina/0000-0003-3685-7068	Ministry of Education and Science of the Russian FederationMinistry of Education and Science, Russian Federation [14.N08.11.0173]	This research was funded by the Ministry of Education and Science of the Russian Federation, government contract number 14.N08.11.0173 (20172019).	Beverley PCL, 2014, MUCOSAL IMMUNOL, V7, P20, DOI 10.1038/mi.2013.99; Caccamo N, 2015, EUR J IMMUNOL, V45, P1069, DOI 10.1002/eji.201445193; Caccamo N, 2010, EUR J IMMUNOL, V40, P2211, DOI 10.1002/eji.201040455; COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243; Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592; de Sousa EM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047781; Derrick SC, 2011, VACCINE, V29, P2902, DOI 10.1016/j.vaccine.2011.02.010; Egorov A, 1998, J VIROL, V72, P6437, DOI 10.1128/JVI.72.8.6437-6441.1998; Ferko B, 2004, J VIROL, V78, P13037, DOI 10.1128/JVI.78.23.13037-13045.2004; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Flynn JL, 2004, TUBERCULOSIS, V84, P93, DOI 10.1016/j.tube.2003.08.010; Forbes EK, 2008, J IMMUNOL, V181, P4955, DOI 10.4049/jimmunol.181.7.4955; Garcia-Sastre A, 1998, VIROLOGY, V252, P324, DOI 10.1006/viro.1998.9508; Henao-Tamayo MI, 2010, CLIN VACCINE IMMUNOL, V17, P618, DOI 10.1128/CVI.00368-09; Hervas-Stubbs S, 2006, INFECT IMMUN, V74, P3396, DOI 10.1128/IAI.02086-05; Kim TH, 2015, CYTOKINE, V71, P139, DOI 10.1016/j.cyto.2014.09.010; Lalvani T, 1998, P NATL ACAD SCI USA, V95, P270, DOI 10.1073/pnas.95.1.270; Lechmann M, 2002, TRENDS IMMUNOL, V23, P273, DOI 10.1016/S1471-4906(02)02214-7; Lewinsohn DA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01262; Li JL, 2020, EUR J CLIN MICROBIOL, V39, P1405, DOI 10.1007/s10096-020-03843-6; Li Q, 2011, SCAND J IMMUNOL, V73, P568, DOI 10.1111/j.1365-3083.2011.02531.x; Lin MY, 2007, INFECT IMMUN, V75, P3523, DOI 10.1128/IAI.01999-06; Lyadova IV, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/854507; Misharin AV, 2013, AM J RESP CELL MOL, V49, P503, DOI 10.1165/rcmb.2013-0086MA; Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345; O'Garra A, 2013, ANNU REV IMMUNOL, V31, P475, DOI 10.1146/annurev-immunol-032712-095939; Orme IM, 2010, TUBERCULOSIS, V90, P329, DOI 10.1016/j.tube.2010.06.002; Rafi W, 2012, CURR OPIN HIV AIDS, V7, P239, DOI 10.1097/COH.0b013e3283524dc5; Romanova J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005984; Ryan AA, 2009, J IMMUNOL, V182, P7172, DOI 10.4049/jimmunol.0801694; Sable SB, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00100-19; Salgame P, 2005, CURR OPIN IMMUNOL, V17, P374, DOI 10.1016/j.coi.2005.06.006; Schrager LK, 2020, LANCET INFECT DIS, V20, pE28, DOI 10.1016/S1473-3099(19)30625-5; Schweitzer AN, 1997, J IMMUNOL, V158, P2713; Sereinig S, 2006, CLIN VACCINE IMMUNOL, V13, P898, DOI 10.1128/CVI.00056-06; Sergeeva M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040394; Singh S, 2014, VACCINE, V32, P712, DOI 10.1016/j.vaccine.2013.11.065; Soleimanpour S, 2015, APPL MICROBIOL BIOT, V99, P10467, DOI 10.1007/s00253-015-6952-z; Stasakova J, 2005, J GEN VIROL, V86, P185, DOI 10.1099/vir.0.80422-0; Stukova MA, 2006, TUBERCULOSIS, V86, P236, DOI 10.1016/j.tube.2006.01.010; Stylianou E, 2019, EXPERT REV VACCINES, V18, P1271, DOI 10.1080/14760584.2019.1692657; Vasilyev K.A., 2020, MICROBIOL INDEP RES, V7, P24, DOI [10.18527/2500-2236-2020-7-1-24-33, DOI 10.18527/2500-2236-2020-7-1-24-33]; Vasilyev K.A., 2018, MIR J, V5, P48, DOI 10.18527/2500-2236-2018-5-1-48-58; Vasilyev K, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9040690; Yousefi-Avarvand Arshid, 2018, [Frontiers in Biology, 生物学前沿], V13, P293; Yu YRA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150606; Zeng GC, 2018, CELL MOL IMMUNOL, V15, P206, DOI 10.1038/cmi.2017.113	47	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1273	10.3390/vaccines9111273			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XH1AO	34835204	Green Published, gold			2022-04-29	WOS:000725174300001
J	Wong, MCS; Wong, ELY; Cheung, AWL; Huang, JJ; Lai, CKC; Yeoh, EK; Chan, PKS				Wong, Martin C. S.; Wong, Eliza L. Y.; Cheung, Annie W. L.; Huang, Junjie; Lai, Christopher K. C.; Yeoh, Eng Kiong; Chan, Paul K. S.			COVID-19 Vaccine Hesitancy in a City with Free Choice and Sufficient Doses	VACCINES			English	Article						COVID-19; vaccine hesitancy; vaccine choice; barriers; incentives; compulsory vaccination		Background: Vaccine hesitancy represents one of the major global health issues around the world. We examined the perception, attitude, perceived barriers and facilitation measures of receiving the COVID-19 vaccine in a Chinese population with free vaccine choices (Sinovac [Coronavac] vs. BioNTech/Fosun [Comirnaty]) and adequate doses. Method: We conducted a random telephone survey of the general population in 1195 subjects aged 18 years or above from 23 April 2021 to 8 May 2021 after two months of vaccine rollout. A descriptive analysis of the levels of enabling factors, obstacles and perception of COVID-19 vaccination was conducted using ANOVA and Chi-square tests for trend. Results: Only 10.1% and 13.5% had received one and two COVID-19 vaccine doses, respectively. Among those who had not received any COVID-19 vaccine (75.4%), only 25.1% expressed their intention to receive in the coming 6 months. The barriers with the highest scores included "having heard of cases with serious adverse events or death after vaccination " (score: 8.17 out 10, 95% C.I. 7.99, 8.35), "lack of confidence on governmental recommendations " (7.69, 95% C.I. 7.47, 7.91), and "waiting for a better vaccine " (7.29, 95% C.I. 7.07, 7.52). The highest score for the impact of various incentives for vaccination was for "vaccine passports for overseas travel " (4.44, 95% C.I. 4.18, 4.71). Conclusions: Vaccine hesitancy is commonly observed in this Chinese population despite adequate provision of vaccine doses and choices. No single incentive is strong enough to promote vaccination, and multiple facilitation measures for different groups of population are needed to encourage vaccine uptake. Active clarification and promotion by medical professionals together with a variety of incentives are needed to drive vaccine uptake.	[Wong, Martin C. S.; Huang, Junjie] Chinese Univ Hong Kong, Fac Med, JC Sch Publ Hlth, Hong Kong, Peoples R China; [Wong, Eliza L. Y.; Cheung, Annie W. L.; Yeoh, Eng Kiong] Chinese Univ Hong Kong, Fac Med, Ctr Hlth Syst & Policy Res, JC Sch Publ Hlth, Hong Kong, Peoples R China; [Lai, Christopher K. C.; Chan, Paul K. S.] Chinese Univ Hong Kong, Fac Med, Dept Microbiol, Hong Kong, Peoples R China		Yeoh, EK (通讯作者)，Chinese Univ Hong Kong, Fac Med, Ctr Hlth Syst & Policy Res, JC Sch Publ Hlth, Hong Kong, Peoples R China.; Chan, PKS (通讯作者)，Chinese Univ Hong Kong, Fac Med, Dept Microbiol, Hong Kong, Peoples R China.	wong_martin@cuhk.edu.hk; lywong@cuhk.edu.hk; anniewlcheung@cuhk.edu.hk; junjie_huang@link.cuhk.edu.hk; chris.kclai@cuhk.edu.hk; yeoh_ek@cuhk.edu.hk; paulkschan@cuhk.edu.hk	Chan, Paul KS/J-9360-2013; Wong, Martin/L-4568-2014	Chan, Paul KS/0000-0002-6360-4608; Wong, Eliza/0000-0001-9983-6219; Wong, Martin/0000-0001-7706-9370; Lai, Christopher/0000-0001-8591-5944			[Anonymous], POPULATION ESTIMATES; [Anonymous], OUR WORLD DATA CORON; Daly, 2020, INT ESTIMATES INTEND, DOI [10.1101/2020.12.01.20241729, DOI 10.1101/2020.12.01.20241729]; Department of Health, HONG KONG VACC DASHB; Doroftei B, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11040579; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Frielitz FS, 2021, DEUT MED WOCHENSCHR, V146, P206, DOI 10.1055/a-1332-9841; Gieysztor S., COVID 19 VACCINE DEP; Global Change Data Lab, OUR WORLD DAT STAT R; Institute of Global Health Innovation, IMPERIAL COLL LONDON; Johns Hopkins University, INTERACTIVE WEB BASE; Kennedy J, 2019, EUR J PUBLIC HEALTH, V29, P512, DOI 10.1093/eurpub/ckz004; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Li L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050490; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Menni C, 2021, LANCET INFECT DIS, V21, P939, DOI 10.1016/S1473-3099(21)00224-3; Meyer C., 2020, POLICY I CORONAVIRUS; Moorthy G., 2020, VOICES BIOETHICS, V6, DOI [10.7916/vib.v6i.7301, DOI 10.7916/VIB.V6I.7301]; Office of the Communications Authority, NUMB PLAN TEL SERV H; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Qattan AMN, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.644300; Volpp KG, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMp2107719; Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Wong MCS, 2021, VACCINE, V39, P1148, DOI 10.1016/j.vaccine.2020.12.083; World Health Organization World Health Organization, 10 THREATS GLOB HLTH; Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737	28	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	NOV	2021	9	11							1250	10.3390/vaccines9111250			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	XI6RG	34835181	Green Published, gold			2022-04-29	WOS:000726235500001
J	Badalyan, AR; Hovhannisyan, M; Ghavalyan, G; Ter-Stepanyan, MM; Cave, R; Cole, J; Farlow, AWK; Mkrtchyan, HV				Badalyan, Arman R.; Hovhannisyan, Marine; Ghavalyan, Gayane; Ter-Stepanyan, Mary M.; Cave, Rory; Cole, Jennifer; Farlow, Andrew W. K.; Mkrtchyan, Hermine, V			Knowledge, Attitude, and Practice of Physicians Regarding Vaccinations in Yerevan, Armenia: A Case Study of HPV	VACCINES			English	Article						immunization; vaccine confidence; vaccine hesitancy; HPV; cervical cancer; Gardasil	HUMAN-PAPILLOMAVIRUS; VACCINE	This paper highlights the low levels of vaccine coverage and high levels of reported vaccination hesitancy in Yerevan, Armenia, that present profound challenges to the control of disease through routine vaccination programmes. We draw on investigations of hesitancy towards the introduction of new vaccines, using the Human Papillomavirus (HPV) vaccine Gardasil as a case study, to interrogate underlying challenges to vaccine acceptance. We analyse primary data from the introduction of Gardasil, first used in Armenia in 2017, to investigate how levels of medical knowledge amongst physicians in 20 health facilities in Yerevan, Armenia, regarding vaccine science influence attitudes towards the introduction of a newly developed vaccine. A questionnaire-based cross-sectional study was completed by 348 physicians between December 2017 and September 2018. The responding physicians displayed a respectable level of knowledge and awareness regarding vaccination with respect to some characteristics (e.g., more than 81% knew that HPV infection was commonly asymptomatic, 73% knew that HPV infection was implicated in most cervical cancers, and 87% knew that cervical cancer is the most prevalent cancer amongst women) but low knowledge and poor understanding of other key issues such as the age at which women were most likely to develop cervical cancer (only 15% answered correctly), whether or not the vaccine should be administered to people who had already been infected (27% answered correctly) and whether sexually active young people should be treated for infection before vaccination (26% answered correctly). The study suggests that the drivers of vaccine hesitancy are complex and may not be consistent from vaccine to vaccine. The Armenian healthcare sector may need to provide additional training, awareness-raising and educational activities alongside the introduction of new vaccines to improve understanding of and trust in vaccination programmes.</p>	[Badalyan, Arman R.; Hovhannisyan, Marine; Ghavalyan, Gayane; Ter-Stepanyan, Mary M.] Yerevan State Med Univ, Fac Publ Hlth, Dept Epidemiol, Yerevan 0025, Armenia; [Cave, Rory; Mkrtchyan, Hermine, V] Univ West London, Sch Biomed Sci, London W5 5RF, England; [Cole, Jennifer] Royal Holloway Univ London, Dept Hlth Studies, Egham Hill, Egham TW20 0EX, Surrey, England; [Farlow, Andrew W. K.] Univ Oxford, Oxford Martin Sch, Broad St, Oxford OX1 3BD, England; [Farlow, Andrew W. K.] Museum Nat Kunde, D-10115 Berlin, Germany		Mkrtchyan, HV (通讯作者)，Univ West London, Sch Biomed Sci, London W5 5RF, England.	armanfcj@yahoo.com; mhovannis@yahoo.com; gayane_ghavalyan@yahoo.com; tsmary@mail.ru; rory.cave@uwl.ac.uk; Jennifer.cole@rhul.ac.uk; andrew.farlow@ndm.ox.ac.uk; hermine.mkrtchyan@uwl.ac.uk		Cole, Jennifer/0000-0001-8787-8892	National Centre for Disease Control and Prevention of Ministry of Health of Republic of Armenia; Yerevan State Medical University	The authors thank the National Centre for Disease Control and Prevention of Ministry of Health of Republic of Armenia and Yerevan State Medical University for supporting the implementation of the research	Agopian A, 2020, VACCINE, V38, P4671, DOI 10.1016/j.vaccine.2020.05.032; Arbyn M, 2020, LANCET GLOB HEALTH, V8, pE191, DOI 10.1016/S2214-109X(19)30482-6; Aronsson A, 2020, ANTHROPOCENE REV, DOI 10.1177/2053019620979326; Brotherton JML, 2019, PAPILLOMAVIRUS RES, V7, P138, DOI 10.1016/j.pvr.2019.04.004; Cadeddu C, 2020, VACCINE, V38, P6609, DOI 10.1016/j.vaccine.2020.07.076; Center of Insight in Survey Research, 2021, PUBL OP SURV RES ARM; Centers for Disease Control and Prevention, 2019, HPV VACC INF CLIN; Cole J., 2021, BMJ OPINION; Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397; de Figueiredo A, 2020, LANCET, V396, P898, DOI 10.1016/S0140-6736(20)31558-0; Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055; Hartwig S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-30; Howard N, 2018, VACCINE, V36, P5536, DOI 10.1016/j.vaccine.2018.07.063; Kluge H, 2021, LANCET, V397, P1689, DOI 10.1016/S0140-6736(21)00709-1; Lehtinen M, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-015867; Luyten J, 2014, EUR J PUBLIC HEALTH, V24, P310, DOI 10.1093/eurpub/ckt080; Maani E., 2018, CANC CERVICAL; McBride AA, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0273; Ministry of Health Armenia, VACC CONT; Ministry of Health Armenia, ORD MIN HLTH REP ARM; Ministry of Health of Armenia, 2017, NATL GUID VACC HUM P; Ministry of Health of Armenia, 2016, HLTH SYSTEM PERFORMA, P190; Ministry of Health of Armenia, 2018, HLTH HLTH CAR; Nikolic Z, 2015, J PEDIATR ADOL GYNEC, V28, P12, DOI 10.1016/j.jpag.2014.01.107; Petravic L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030247; Shapiro G., 2018, NEWSLETTER 72; Tadevosyan A., 2019, BASICS BIOSTATISTICS, P144; Tisi G, 2013, ANN I SUPER SANITA, V49, P286, DOI 10.4415/ANN_13_03_09; UNICEF, IMM DAT 2021; Valasoulis G, 2020, CANCERS, V12, DOI 10.3390/cancers12051164; Vu M, 2018, CURR PROB CANCER, V42, P457, DOI 10.1016/j.currproblcancer.2018.06.003; White Leah, 2016, Pediatr Nurs, V42, P21; World Health Organization, 2013, COMPR CERV CANC CONT, V2nd ed.	33	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1188	10.3390/vaccines9101188			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WU0QP	34696296	Green Published, gold, Green Accepted			2022-04-29	WOS:000716259500001
J	Bhatt, DK; Chammas, R; Daemen, T				Bhatt, Darshak K.; Chammas, Roger; Daemen, Toos			Resistance Mechanisms Influencing Oncolytic Virotherapy, a Systematic Analysis	VACCINES			English	Review						oncolytic virotherapy; therapeutic resistance; stromal cells; cancer cells; resistance mechanisms	VESICULAR STOMATITIS-VIRUS; PANCREATIC-CANCER CELLS; I INTERFERON RESPONSE; VACCINIA VIRUS; VIRAL THERAPY; TUMOR-CELLS; ADENOVIRUS; GENE; INHIBITOR; NEUTRALIZATION	Resistance to therapy is a frequently observed phenomenon in the treatment of cancer, and as with other cancer therapeutics, therapies based on oncolytic viruses also face the challenges of resistance, such as humoral and cellular antiviral responses, and tumor-associated interferon-mediated resistance. In order to identify additional mechanisms of resistance that may contribute to therapeutic failure, we developed a systematic search strategy for studies published in PubMed. We analyzed 6143 articles on oncolytic virotherapy and found that approximately 8% of these articles use resistance terms in the abstract and/or title. Of these 439 articles, 87 were original research. Most of the findings reported pertain to resistance mediated by tumor-cell-dependent interferon signaling. Yet, mechanisms such as epigenetic modifications, hypoxia-mediated inhibition, APOBEC-mediated resistance, virus entry barriers, and spatiotemporal restriction to viral spread, although not frequently assessed, were demonstrated to play a major role in resistance. Similarly, our results suggest that the stromal compartment consisting of, but not limited to, myeloid cells, fibroblasts, and epithelial cells requires more study in relation to therapy resistance using oncolytic viruses. Thus, our findings emphasize the need to assess the stromal compartment and to identify novel mechanisms that play an important role in conferring resistance to oncolytic virotherapy.</p>	[Bhatt, Darshak K.; Daemen, Toos] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol & Infect Prevent, NL-9713 AV Groningen, Netherlands; [Bhatt, Darshak K.; Chammas, Roger] Univ Sao Paulo, Ctr Translat Res Oncol, Inst Canc Hosp Clin, Fac Med, BR-01246000 Sao Paulo, Brazil		Daemen, T (通讯作者)，Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol & Infect Prevent, NL-9713 AV Groningen, Netherlands.	c.a.h.h.daemen@umcg.nl	Bhatt, Darshak Kartikey/ABC-2767-2021; Chammas, Roger/A-8004-2011	Bhatt, Darshak Kartikey/0000-0003-0923-2353; Chammas, Roger/0000-0003-0342-8726	CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [305700/2017-0]; CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [001]; ATTP-GSMS scholarship (Abel Tasman Talent Program)	The authors' work was supported by CNPq (Grant Award 305700/2017-0 to R.C.), CAPES (Finance Code 001, to D.B.), and an ATTP-GSMS scholarship (Abel Tasman Talent Program to D.K.B.).	Aktipis CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026100; Allagui F, 2016, CURR GENE THER, V16, P419, DOI 10.2174/1566523217666170102110502; Arwert EN, 2020, NAT CELL BIOL, V22, P758, DOI 10.1038/s41556-020-0527-7; Berchtold S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207618; Bieler A, 2006, HUM GENE THER, V17, P55, DOI 10.1089/hum.2006.17.55; Biswas M, 2012, J VIROL, V86, P12708, DOI 10.1128/JVI.00886-12; Bommareddy PK, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aau0417; Buijs PRA, 2015, HUM VACC IMMUNOTHER, V11, P1573, DOI 10.1080/21645515.2015.1037058; Carey BL, 2008, J VIROL, V82, P12104, DOI 10.1128/JVI.01508-08; Cataldi M, 2015, VIROLOGY, V485, P340, DOI 10.1016/j.virol.2015.08.003; Choi AH, 2018, MOL THER-ONCOLYTICS, V9, P22, DOI 10.1016/j.omto.2018.04.001; Colunga A, 2014, GENE THER, V21, P371, DOI 10.1038/gt.2014.6; Cronin M, 2014, MOL THER, V22, P1188, DOI 10.1038/mt.2014.23; Demsar J, 2013, J MACH LEARN RES, V14, P2349; Diallo JS, 2010, MOL THER, V18, P1123, DOI 10.1038/mt.2010.67; Dobson CC, 2017, ONCOTARGET, V8, P3495, DOI 10.18632/oncotarget.13849; Dold C, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.21; Eisenstein S, 2013, CANCER RES, V73, P5003, DOI 10.1158/0008-5472.CAN-12-1597; Evgin L, 2019, CANCER IMMUNOL RES, V7, P828, DOI 10.1158/2326-6066.CIR-18-0013; Felt SA, 2017, J VIROL, V91, DOI 10.1128/JVI.00461-17; Fu XP, 2011, INT J CANCER, V129, P1503, DOI 10.1002/ijc.25808; Gholami S, 2014, CANCER GENE THER, V21, P283, DOI 10.1038/cgt.2014.28; Gil M, 2013, P NATL ACAD SCI USA, V110, pE1291, DOI 10.1073/pnas.1220580110; Guillerme JB, 2013, CLIN CANCER RES, V19, P1147, DOI 10.1158/1078-0432.CCR-12-2733; Hastie E, 2015, VIROLOGY, V483, P126, DOI 10.1016/j.virol.2015.04.017; Hoang HD, 2019, CELL REP, V29, P4010, DOI 10.1016/j.celrep.2019.11.072; Hou WZ, 2016, CANCER CELL, V30, P108, DOI 10.1016/j.ccell.2016.05.012; Huff AL, 2018, MOL THER-ONCOLYTICS, V11, P1, DOI 10.1016/j.omto.2018.08.003; Ilett EJ, 2011, CLIN CANCER RES, V17, P2767, DOI 10.1158/1078-0432.CCR-10-3266; Ilkow CS, 2015, NAT MED, V21, P530, DOI 10.1038/nm.3848; Janelle V, 2011, J VIROL, V85, P6513, DOI 10.1128/JVI.02484-10; Jennings VA, 2014, INT J CANCER, V134, P1091, DOI 10.1002/ijc.28450; Jiang K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-551; Kaowinn S, 2015, BIOCHEM BIOPH RES CO, V459, P313, DOI 10.1016/j.bbrc.2015.02.107; Kaufman HL, 2015, NAT REV DRUG DISCOV, V14, P642, DOI 10.1038/nrd4663; Kilinc MO, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1096-1; Kleinlutzum D, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00127; Kurokawa C, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djy033; Le Boeuf F, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2974; Li I, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0975-5; Li L, 2018, ACTA PHARMACOL SIN, V39, P251, DOI 10.1038/aps.2017.100; Li WK, 2019, MOL THER-ONCOLYTICS, V14, P188, DOI 10.1016/j.omto.2019.05.006; Li Y, 2017, BIOCHEM BIOPH RES CO, V491, P134, DOI 10.1016/j.bbrc.2017.07.062; Liikanen I, 2011, MOL THER, V19, P1858, DOI 10.1038/mt.2011.144; Liu YP, 2013, SCI REP-UK, V3, DOI 10.1038/srep02375; Lucas T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117254; Lv CW, 2016, BIOCHEM BIOPH RES CO, V476, P21, DOI 10.1016/j.bbrc.2016.05.088; Lypova N, 2019, CANCERS, V11, DOI 10.3390/cancers11050684; Mauri, 2017, P 12 BIANN C IT SIGC, P1; Melero I, 2015, CANCER RES, V75, P497, DOI 10.1158/0008-5472.CAN-13-3356; Moerdyk-Schauwecker M, 2013, VIROLOGY, V436, P221, DOI 10.1016/j.virol.2012.11.014; Muscolini M, 2019, J VIROL, V93, DOI 10.1128/JVI.00626-19; Nakatake M, 2019, MOL THER-ONCOLYTICS, V14, P159, DOI 10.1016/j.omto.2019.05.003; Noll M, 2013, INT J ONCOL, V43, P103, DOI 10.3892/ijo.2013.1914; Paglino JC, 2014, J VIROL, V88, P4932, DOI 10.1128/JVI.03508-13; Paglino JC, 2011, J VIROL, V85, P9346, DOI 10.1128/JVI.00723-11; Patel KMR, 2019, CANCER GENE THER, V26, P411, DOI 10.1038/s41417-018-0074-6; Pinto AK, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002407; Reinblatt M, 2004, ANN SURG, V239, P892, DOI 10.1097/01.sla.0000128308.36393.38; Saloura V, 2010, HUM GENE THER, V21, P51, DOI 10.1089/hum.2009.088; Selman M, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao1613; Shulak L, 2014, J VIROL, V88, P2927, DOI 10.1128/JVI.03406-13; Sivanandam V, 2019, MOL THER-ONCOLYTICS, V13, P93, DOI 10.1016/j.omto.2019.04.003; Song TJ, 2012, CANCER GENE THER, V19, P38, DOI 10.1038/cgt.2011.64; Su BH, 2015, ONCOTARGET, V6, P38308, DOI 10.18632/oncotarget.5702; Sun CW, 2016, FRONT ONCOL, V6, DOI [10.3389/fonc.2015.00166, 10.3389/fonc.2016.00166]; Sunamura M, 2004, PANCREAS, V28, P326, DOI 10.1097/00006676-200404000-00022; Tarasova IA, 2018, ONCOTARGET, V9, P1785, DOI 10.18632/oncotarget.22751; Tong JG, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3600-2; Tong Y, 2014, ONCOL REP, V31, P1581, DOI 10.3892/or.2014.3020; Toribio R, 2020, J VIROL, V94, DOI 10.1128/JVI.01630-19; Trus I, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050579; Tseng JC, 2010, CANCER GENE THER, V17, P244, DOI 10.1038/cgt.2009.70; Tuzmen C, 2020, MOL THER-METH CLIN D, V16, P145, DOI 10.1016/j.omtm.2019.12.013; Twumasi-Boateng K, 2018, NAT REV CANCER, V18, P419, DOI 10.1038/s41568-018-0009-4; Udayakumar TS, 2020, MOL CANCER RES, V18, P1232, DOI 10.1158/1541-7786.MCR-19-0836; Urbiola C, 2018, INT J CANCER, V143, P1786, DOI 10.1002/ijc.31556; Vaha-Koskela M, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2014.6; Vaha-Koskela MJV, 2013, J VIROL, V87, P2363, DOI 10.1128/JVI.01609-12; Valyi-Nagy K, 2010, CANCER GENE THER, V17, P223, DOI 10.1038/cgt.2009.73; van Asten SD, 2018, J VIROL, V92, DOI 10.1128/JVI.00260-18; Voros Andras, 2013, ISRN Oncol, V2013, P104913, DOI 10.1155/2013/104913; Watanabe Y, 2010, ONCOGENE, V29, P1145, DOI 10.1038/onc.2009.415; Westcott MM, 2015, J VIROL, V89, P7944, DOI 10.1128/JVI.00757-15; Xiao X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06771-4; Yumul R, 2016, HUM GENE THER, V27, P325, DOI 10.1089/hum.2016.022; Zamarin D, 2018, J CLIN INVEST, V128, P1413, DOI 10.1172/JCI98047; Zemp FJ, 2014, CANCER RES, V74, P7260, DOI 10.1158/0008-5472.CAN-14-0876	88	0	0	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1166	10.3390/vaccines9101166			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WR9EW	34696274	Green Published			2022-04-29	WOS:000714797000001
J	Elnaem, MH; Taufek, NHM; Ab Rahman, NS; Nazar, NIM; Zin, CS; Nuffer, W; Turner, CJ				Elnaem, Mohamed Hassan; Mohd Taufek, Nor Hidayah; Ab Rahman, Norny Syafinaz; Mohd Nazar, Nor Ilyani; Zin, Che Suraya; Nuffer, Wesley; Turner, Christopher John			COVID-19 Vaccination Attitudes, Perceptions, and Side Effect Experiences in Malaysia: Do Age, Gender, and Vaccine Type Matter?	VACCINES			English	Article						COVID-19; vaccine; Malaysia; attitudes; perceptions; experience; side effects		This study aimed to investigate the attitudes, perceptions, and experiences of side effects with the COVID-19 vaccines in Malaysia among participants in the National Vaccination Program. A cross-sectional survey was conducted among a sample of vaccine-eligible and vaccinated individuals in Malaysia between May and July 2021. A total of 428 respondents completed the survey. A vast majority (98.6%) of the respondents had registered to be vaccinated. Twenty participants (4.7%) expressed concerns about either registering or receiving the COVID-19 vaccination, mainly due to their uncertainty of vaccine safety. Approximately 77.5% received their vaccinations. Of them, 76.8% had experienced vaccine-related side effects. About 40% of the side effects occurred more with the second dose, particularly those who received the Pfizer-BioNTech vaccine (p < 0.001). Pain at the injection site (61.1%) and tiredness (48.8%) were the most reported side effects. Compared to those aged & GE;60 years, all age groups were more likely to exhibit vaccine-related side effects; meanwhile, males (OR: 0.51, 95% CI: 0.27-0.93) were less likely to experience side effects than females. Those who received the Sinovac vaccine were at lower risk of experiencing side effects (OR: 0.08, 95% CI: 0.03-0.22) and were more likely to report fewer side effects than Pfizer-BioNTech (p = 0.012) and Oxford-AstraZeneca groups (p= 0.001). The overall attitudes toward the COVID-19 vaccination program were positive. Several differences in the experiences of vaccine-related side effects, in terms of prevalence and numbers, were attributed to age, gender, and received vaccine type.</p>	[Elnaem, Mohamed Hassan; Mohd Taufek, Nor Hidayah; Ab Rahman, Norny Syafinaz; Mohd Nazar, Nor Ilyani; Zin, Che Suraya] Int Islamic Univ Malaysia, Fac Pharm, Dept Pharm Practice, Kuantan 25200, Pahang, Malaysia; [Nuffer, Wesley] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Clin Pharm, Anschutz Med Campus, Aurora, CO 80045 USA; [Turner, Christopher John] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Anschutz Med Campus, Aurora, CO 80045 USA		Elnaem, MH (通讯作者)，Int Islamic Univ Malaysia, Fac Pharm, Dept Pharm Practice, Kuantan 25200, Pahang, Malaysia.	drmelnaem@iium.edu.my; hidayahtaufek@iium.edu.my; norny@iium.edu.my; norilyani@iium.edu.my; chesuraya@iium.edu.my; WESLEY.NUFFER@cuanschutz.edu; Christopher.Turner@ucdenver.edu	Elnaem, Mohamed Hassan/O-9248-2017	Elnaem, Mohamed Hassan/0000-0003-0873-6541; Ab Rahman, Norny Syafinaz/0000-0001-8358-0925			Albert Elisabeth, 2021, Radiol Case Rep, V16, P2142, DOI 10.1016/j.radcr.2021.05.033; Bianco A, 2019, VACCINE, V37, P984, DOI 10.1016/j.vaccine.2018.12.062; Chen H, 2021, HUM VACC IMMUNOTHER, V17, P443, DOI 10.1080/21645515.2020.1780093; Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9; Di Giuseppe G, 2021, EXPERT REV VACCINES, V20, P881, DOI 10.1080/14760584.2021.1922081; Di Giuseppe G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030275; Dube E, 2019, HUM VACC IMMUNOTHER, V15, P113, DOI 10.1080/21645515.2018.1509647; Dula J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080828; Elnaem MH, 2021, RES SOC ADMIN PHARM, V17, P1938, DOI 10.1016/j.sapharm.2020.05.030; Grimm P., 2010, WILEY INT ENCY MARKE, DOI 10.1002/9781444316568.wiem02057; Habersaat KB, 2020, BUNDESGESUNDHEITSBLA, V63, P32, DOI 10.1007/s00103-019-03063-0; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; He Q, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.669339; Kadali RAK, 2021, INT J INFECT DIS, V106, P376, DOI 10.1016/j.ijid.2021.04.047; Latkin CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246970; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Machida M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030210; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Ministry of Health Malaysia, 2021, CLIN GUID COVID 19 V; Ministry of Health Malaysia Vaccinations in Malaysia, COVIDNOW; Ministry of Health (MOH), MY SEJ; Ministry of Health (MOH) Malaysia, 2021, NAT COVID 19 IMM PRO; Napolitano F, 2018, HUM VACC IMMUNOTHER, V14, P1558, DOI 10.1080/21645515.2018.1463943; Oh SS, 2021, J MED INTERNET RES, V23, DOI 10.2196/26145; Patil U, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18063301; Razai MS, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1138; Repajic Michael, 2021, Brain Behav Immun Health, V13, P100217, DOI 10.1016/j.bbih.2021.100217; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10122629; Riad A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10071428; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Schmidt H, 2020, JAMA-J AM MED ASSOC, V324, P2023, DOI 10.1001/jama.2020.20571; Society M.P., IMM ADV CHAPT; Stefanati A, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020778; Tao LL, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-8101-6; Verger P, 2021, LANCET PUBLIC HEALTH, V6, pE195, DOI 10.1016/S2468-2667(21)00029-3; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Wee L H, 2016, Med J Malaysia, V71, P29; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699; Yan YX, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040349	43	3	3	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1156	10.3390/vaccines9101156			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WQ8ER	34696264	gold, Green Published			2022-04-29	WOS:000714044400001
J	Le, CTT; Ahn, SY; Kang, SM; Ko, EJ				Le, Chau Thuy Tien; Ahn, So Yeon; Kang, Sang-Moo; Ko, Eun-Ju			Functional NK Cell Activation by Ovalbumin Immunization with a Monophosphoryl Lipid A and Poly I:C Combination Adjuvant Promoted Dendritic Cell Maturation	VACCINES			English	Article						natural killer cell; dendritic cell; monophosphoryl lipid A; poly I:C; adjuvant	NATURAL-KILLER-CELLS; DOUBLE-STRANDED-RNA; TOLL-LIKE RECEPTORS; IN-VIVO; INTERFERON-GAMMA; IMMUNE-RESPONSES; VACCINE PROTECTS; T-CELLS; INNATE; CYTOKINE	Natural killer (NK) cells are one of the types of innate immune cells to remove pathogen-infected cells and modulate inflammatory immune responses. Recent studies have revealed that NK cells could enhance vaccine efficacy by coordinating the innate and adaptive immune responses. In this study, we have evaluated the efficacy of intranasal ovalbumin (OVA) immunization with a monophosphoryl lipid A (MPL) and polyriboinosinic polyribocytidylic acid (poly I:C) combination adjuvant in promoting NK cell recruitment, differentiation, and activation. The frequencies of NK cells were positively correlated with those of dendritic cells (DCs) at the site of immunization. Moreover, the activated NK cells and DCs by the MPL + poly I:C combination adjuvant induced activations of each other cells in vitro. Taken together, this study suggested that the MPL and poly I:C combination adjuvant in OVA vaccination mediated NK cell activation and cellular crosstalk between NK cells and DCs, suggesting a promising vaccine adjuvant candidate for promoting cellular immune responses.	[Le, Chau Thuy Tien; Ko, Eun-Ju] Jeju Natl Univ, Interdisciplinary Grad Program Adv Convergence Te, Jeju 63243, South Korea; [Ahn, So Yeon; Ko, Eun-Ju] Jeju Natl Univ, Dept Vet Med, Coll Vet Med, Jeju 63243, South Korea; [Kang, Sang-Moo] Georgia State Univ, Inst Biomed Sci, Ctr Inflammat Immun & Infect, Atlanta, GA 30303 USA		Ko, EJ (通讯作者)，Jeju Natl Univ, Interdisciplinary Grad Program Adv Convergence Te, Jeju 63243, South Korea.; Ko, EJ (通讯作者)，Jeju Natl Univ, Dept Vet Med, Coll Vet Med, Jeju 63243, South Korea.	thuytienle102@gmail.com; asy0078@gmail.com; skang24@gsu.edu; eunju@jejunu.ac.kr		Kang, SAng Moo/0000-0001-6198-331X	National Research Foundation of Korea (NRF) - Korea government (MSIT) [2020R1F1A1073040]; Basic Science Research Program to Research Institute for Basic Sciences (RIBS) of Jeju National University through the NRF - Ministry of Education [2019R1A6A1A10072987]; NIH/NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI154656]	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2020R1F1A1073040), the Basic Science Research Program to Research Institute for Basic Sciences (RIBS) of Jeju National University through the NRF funded by the Ministry of Education (2019R1A6A1A10072987), and partially supported by NIH/NIAID grant AI154656 (S.-M.K.).	Ahn SY, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10090908; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arguedas A, 2011, HUM VACCINES, V7, P58, DOI 10.4161/hv.7.1.13411; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Blanco JCG, 2014, VACCINE, V32, P1495, DOI 10.1016/j.vaccine.2013.11.032; Carson WE, 1995, J CLIN INVEST, V96, P2578, DOI 10.1172/JCI118321; Cooper MA, 2009, P NATL ACAD SCI USA, V106, P1915, DOI 10.1073/pnas.0813192106; Degli-Esposti MA, 2005, NAT REV IMMUNOL, V5, P112, DOI 10.1038/nri1549; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Fehniger TA, 1999, J IMMUNOL, V162, P4511; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6.5.723; Gerosa F, 2002, J EXP MED, V195, P327, DOI 10.1084/jem.20010938; Guillerey C, 2016, NAT IMMUNOL, V17, P1025, DOI 10.1038/ni.3518; Hancock GE, 2003, VACCINE, V21, P4348, DOI 10.1016/S0264-410X(03)00482-1; Hanna J, 2004, J CLIN INVEST, V114, P1612, DOI 10.1172/JCI22787; Hayakawa Y, 2006, J IMMUNOL, V176, P1517, DOI 10.4049/jimmunol.176.3.1517; Ichinohe T, 2005, J VIROL, V79, P2910, DOI 10.1128/JVI.79.5.2910-2919.2005; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Keppel MP, 2013, J IMMUNOL, V190, P4754, DOI 10.4049/jimmunol.1201742; Kim S, 2002, NAT IMMUNOL, V3, P523, DOI 10.1038/ni796; Ko EJ, 2018, ANTIVIR RES, V156, P107, DOI 10.1016/j.antiviral.2018.06.004; Ko EJ, 2017, IMMUNE NETW, V17, P326, DOI 10.4110/in.2017.17.5.326; Lee Y, 2019, VIROLOGY, V534, P1, DOI 10.1016/j.virol.2019.05.010; Mailliard RB, 2003, J IMMUNOL, V171, P2366, DOI 10.4049/jimmunol.171.5.2366; Marquardt N, 2010, EUR J IMMUNOL, V40, P1428, DOI 10.1002/eji.200940056; Mckee AS, 2007, IMMUNITY, V27, P687, DOI 10.1016/j.immuni.2007.11.003; Miller E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f794; Morvan MG, 2016, NAT REV CANCER, V16, P7, DOI 10.1038/nrc.2015.5; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Pahl JHW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02796; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Rappuoli R, 2011, NAT REV IMMUNOL, V11, P865, DOI 10.1038/nri3085; Raulet DH, 2006, NAT REV IMMUNOL, V6, P520, DOI 10.1038/nri1863; Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409; Romee R, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2341; Shekhar S, 2015, EUR J IMMUNOL, V45, P2810, DOI 10.1002/eji.201445390; Steinhagen F, 2011, VACCINE, V29, P3341, DOI 10.1016/j.vaccine.2010.08.002; STEINSTREILEIN J, 1986, J IMMUNOL, V136, P1435; Terren I, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85960-6; Terren I, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00737; Trinchieri G, 1995, Semin Immunol, V7, P83, DOI 10.1006/smim.1995.0012; Uppendahl LD, 2019, GYNECOL ONCOL, V153, P149, DOI 10.1016/j.ygyno.2019.01.006; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Wilkins AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01760; Wu SY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01238-x; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6; Zhao L, 2011, IMMUNOLOGY, V134, P172, DOI 10.1111/j.1365-2567.2011.03477.x	51	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1061	10.3390/vaccines9101061			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP3HR	34696169	Green Published			2022-04-29	WOS:000713027600001
J	Parray, A; Mir, FA; Doudin, A; Iskandarani, A; Danjuma, IM; Kuni, RAT; Abdelmajid, A; Abdelhafez, I; Arif, R; Mulhim, M; Abukhattab, M; Dar, SR; Al Moustafa, AE; Elkord, E; Al Khal, AL; Elzouki, AN; Cyprian, F				Parray, Aijaz; Mir, Fayaz Ahmad; Doudin, Asmma; Iskandarani, Ahmad; Danjuma, Ibn Mohammed Masud; Kuni, Rahim Ayadathil Thazhhe; Abdelmajid, Alaaedin; Abdelhafez, Ibrahim; Arif, Rida; Mulhim, Mohammad; Abukhattab, Mohammad; Dar, Shoukat Rashhid; Al Moustafa, Ala-Eddin; Elkord, Eyad; Al Khal, Abdul Latif; Elzouki, Abdel-Naser; Cyprian, Farhan			SnoRNAs and miRNAs Networks Underlying COVID-19 Disease Severity	VACCINES			English	Article						snoRNA; miRNA; SARS-CoV-2; COVID-19; biomarkers	SARS-COV-2; MICRORNAS; GENOME	There is a lack of predictive markers for early and rapid identification of disease progression in COVID-19 patients. Our study aims at identifying microRNAs (miRNAs)/small nucleolar RNAs (snoRNAs) as potential biomarkers of COVID-19 severity. Using differential expression analysis of microarray data (n = 29), we identified hsa-miR-1246, ACA40, hsa-miR-4532, hsa-miR-145-5p, and ACA18 as the top five differentially expressed transcripts in severe versus asymptomatic, and ACA40, hsa-miR-3609, ENSG00000212378 (SNORD78), hsa-miR-1231, hsa-miR-885-3p as the most significant five in severe versus mild cases. Moreover, we found that white blood cell (WBC) count, absolute neutrophil count (ANC), neutrophil (%), lymphocyte (%), red blood cell (RBC) count, hemoglobin, hematocrit, D-Dimer, and albumin are significantly correlated with the identified differentially expressed miRNAs and snoRNAs. We report a unique miRNA and snoRNA profile that is associated with a higher risk of severity in a cohort of SARS-CoV-2 infected patients. Altogether, we present a differential expression analysis of COVID-19-associated microRNA (miRNA)/small nucleolar RNA (snoRNA) signature, highlighting their importance in SARS-CoV-2 infection.</p>	[Parray, Aijaz; Kuni, Rahim Ayadathil Thazhhe] Hamad Med Corp, Neurosci Inst, Acad Hlth Syst, Doha 3050, Qatar; [Mir, Fayaz Ahmad; Iskandarani, Ahmad] Hamad Med Corp, Qatar Metab Inst, Acad Hlth Syst, Doha 3050, Qatar; [Doudin, Asmma] Community Coll Qatar, Dept Math & Sci, Doha 7344, Qatar; [Danjuma, Ibn Mohammed Masud; Abdelhafez, Ibrahim; Arif, Rida; Al Moustafa, Ala-Eddin; Elzouki, Abdel-Naser; Cyprian, Farhan] Qatar Univ, Coll Med, QU Hlth, Doha 2713, Qatar; [Danjuma, Ibn Mohammed Masud; Elzouki, Abdel-Naser] Hamad Gen Hosp, Internal Med Dept, Hamad Med Corp, Doha 3050, Qatar; [Abdelmajid, Alaaedin; Mulhim, Mohammad; Abukhattab, Mohammad; Al Khal, Abdul Latif] Hamad Med Corp, Communicable Dis Ctr, Doha 3050, Qatar; [Abdelhafez, Ibrahim] Hamad Med Corp, Dept Neurosurg, Doha 3050, Qatar; [Dar, Shoukat Rashhid] Hamad Med Corp, Dept Emergency, Doha 3050, Qatar; [Al Moustafa, Ala-Eddin; Cyprian, Farhan] Qatar Univ, BioMed & Pharmaceut Res Unit, QU Hlth, Doha 2713, Qatar; [Al Moustafa, Ala-Eddin] Qatar Univ, BioMed Res Ctr, QU Hlth, Doha 2713, Qatar; [Elkord, Eyad] Univ Nizwa, Nat & Med Sci Res Ctr, Nizwa 208, Oman; [Elkord, Eyad] Univ Salford, BioMed Res Ctr, Sch Sci Engn & Environm, Manchester M5 4BR, Lancs, England		Cyprian, F (通讯作者)，Qatar Univ, Coll Med, QU Hlth, Doha 2713, Qatar.; Cyprian, F (通讯作者)，Qatar Univ, BioMed & Pharmaceut Res Unit, QU Hlth, Doha 2713, Qatar.	aparray@hamad.qa; FMir1@hamad.qa; asmma.doudin@ccq.edu.qa; AIskandarani@hamad.qa; MDanjuma@hamad.qa; RKuni1@hamad.qa; aabdelmajid@hamad.qa; AIskandarani@hamad.qa; msaleh@hamad.qa; MABUKHATTAB@hamad.qa; Sdar1@hamad.qa; aalmoustafa@qu.edu.qa; E.Elkord@salford.ac.uk; aalkhal@hamad.qa; AElzouki@hamad.qa; fcyprian@qu.edu.qa		Mir, Fayaz/0000-0003-1104-0852; Elkord, Eyad/0000-0002-3868-0318; Abukhattab, Mohammed/0000-0002-3335-0563; danjuma, mohammed/0000-0003-2198-5278; Al Moustafa, Ala-Eddin/0000-0003-4452-3439	Qatar University [QUST-1-CMED-2021-2]	Qatar University QUST-1-CMED-2021-2 (FC).	Barbu MG, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00143; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernier A, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080440; Bratkovic T, 2020, NUCLEIC ACIDS RES, V48, P1627, DOI 10.1093/nar/gkz1140; Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787; Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; De Gonzalo-Calvo D, 2021, TRANSL RES, V236, P147, DOI 10.1016/j.trsl.2021.05.004; Drury RE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01182; Ferreira-Gomes M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22210-3; Fulzele S, 2020, AGING DIS, V11, P509, DOI 10.14336/AD.2020.0428; Girardit E, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00439; Haunsberger SJ, 2017, BIOINFORMATICS, V33, P592, DOI 10.1093/bioinformatics/btw660; Henzinger H, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12121374; Hua H, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00904-3; Huang HY, 2020, NUCLEIC ACIDS RES, V48, pD148, DOI 10.1093/nar/gkz896; Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]; Hum C, 2021, DRUGS, V81, P517, DOI 10.1007/s40265-021-01474-5; Hutzinger R, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000547; Jafarinejad-Farsangi S, 2020, NON-CODING RNA RES, V5, P222, DOI 10.1016/j.ncrna.2020.11.005; Khan MAA, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00765; Kim YM, 2021, EXP MOL MED, V53, P750, DOI 10.1038/s12276-021-00592-0; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Licursi V, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3105-x; Marchi R, 2021, INFECT GENET EVOL, V91, DOI 10.1016/j.meegid.2021.104832; Natarelli L, 2021, NON-CODING RNA, V7, DOI 10.3390/ncrna7010014; Nersisyan S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235987; Pierce JB, 2020, GENES-BASEL, V11, DOI 10.3390/genes11111354; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Ru YB, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku631; Saini S, 2020, MOL BIOL RES COMMUN, V9, P83, DOI 10.22099/mbrc.2020.36507.1487; Shaath H, 2021, HELIYON, V7, DOI 10.1016/j.heliyon.2021.e06866; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Stamm S, 2019, NON-CODING RNA RES, V4, P46, DOI 10.1016/j.ncrna.2019.02.001; Tang H, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.200; Zhang S, 2021, BRIEF BIOINFORM, V22, P1137, DOI 10.1093/bib/bbab062	36	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1056	10.3390/vaccines9101056			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WP1BF	34696164	Green Published, gold			2022-04-29	WOS:000712875000001
J	Ruan, Z; Tang, YL; Li, CH; Sun, C; Zhu, Y; Li, ZY; Chang, T				Ruan, Zhe; Tang, Yonglan; Li, Chunhong; Sun, Chao; Zhu, Ying; Li, Zhuyi; Chang, Ting			COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series	VACCINES			English	Article						myasthenia gravis; COVID-19; vaccination; SARS-CoV-2 infection; safety	INFLUENZA VACCINATION; IMMUNE-RESPONSE; SAFETY; IMMUNOGENICITY; INFECTION	In this study, we report the safety of coronavirus disease 2019 (COVID-19) vaccine in patients with myasthenia gravis (MG). Patients who were vaccinated against COVID-19 were included. Demographics, clinical characteristics, medications, and vaccination information were collected. The main observation outcome is the worsening of MG symptoms within 4 weeks following COVID-19 vaccination. A total of 22 patients with MG vaccinated for COVID-19 were included. Ten (45.5%) patients had ocular MG (OMG), and 12 (55.5%) patients had generalized MG (GMG). Six (27.3%) patients were female, and the mean (SD) onset age was 45.4 (11.8) years. Nineteen (86.4%) patients were seropositive for acetylcholine receptors (AChR) antibody. Seven (31.8%) patients underwent thymectomy, and four of them confirmed thymoma pathologically. Twenty-one patients were administrated with inactivated vaccines, and the remaining one was administrated with recombinant subunit vaccine. Twenty (90.9%) patients did not present MG symptom worsening within 4 weeks of COVID-19 vaccination, and two (9.1%) patients reported slight symptom worsening but resolved quickly within a few days. Our findings suggest inactivated COVID-19 vaccines might be safe in MG patients with Myasthenia Gravis Foundation of America (MGFA) classification I to II, supporting the recommendation to promote vaccination for MG patients during the still expanding COVID-19 pandemic.	[Ruan, Zhe; Tang, Yonglan; Li, Chunhong; Sun, Chao; Zhu, Ying; Li, Zhuyi; Chang, Ting] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian 710038, Peoples R China		Li, ZY; Chang, T (通讯作者)，Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian 710038, Peoples R China.	ruanzhe573291596@126.com; tangyl2011@163.com; lichunhong0581@163.com; biyfhyk666@163.com; zz15399088127@163.com; lizhuyiafu@163.com; changting1981@163.com		Chang, Ting/0000-0002-7546-8017; Ruan, Zhe/0000-0002-8190-4022	Discipline innovation and development plan of Tangdu Hospital-major clinical research projects [2021LCYJ002]	This research was funded by the Discipline innovation and development plan of Tangdu Hospital-major clinical research projects, grant number 2021LCYJ002.	Auriel E, 2011, MUSCLE NERVE, V43, P893, DOI 10.1002/mus.22077; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bonaccorsi G, 2020, P NATL ACAD SCI USA, V117, P15530, DOI 10.1073/pnas.2007658117; Detmer A, 2006, MICROB CELL FACT, V5, DOI 10.1186/1475-2859-5-23; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Gummi RR, 2019, MUSCLE NERVE, V60, P693, DOI 10.1002/mus.26689; Hua C, 2014, ARTHRIT CARE RES, V66, P1016, DOI 10.1002/acr.22246; Jakubikova Michala, 2021, European Journal of Neurology, V28, DOI 10.1111/ene.14951; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Jaretzki A, 2000, NEUROLOGY, V55, P16, DOI 10.1212/WNL.55.1.16; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Kelly H, 2021, J NEUROIMMUNOL, V356, DOI 10.1016/j.jneuroim.2021.577599; Li XN, 2021, EMERG MICROBES INFEC, V10, P1751, DOI 10.1080/22221751.2021.1969291; Mok CC, 2013, ANN RHEUM DIS, V72, P659, DOI 10.1136/annrheumdis-2012-201393; Muppidi S, 2020, LANCET NEUROL, V19, P970, DOI 10.1016/S1474-4422(20)30413-0; Pasoto SG, 2013, VACCINE, V31, P1793, DOI 10.1016/j.vaccine.2013.01.057; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Saeed BQ, 2021, INT J INFECT DIS, V111, P219, DOI 10.1016/j.ijid.2021.08.013; Seok HY, 2017, J CLIN NEUROL, V13, P325, DOI 10.3988/jcn.2017.13.4.325; Shinjo SK, 2012, VACCINE, V31, P202, DOI 10.1016/j.vaccine.2012.10.063; Sole G, 2021, NEUROLOGY, V96, pE2109, DOI 10.1212/WNL.0000000000011669; Spinner CD, 2020, JAMA-J AM MED ASSOC, V324, P1048, DOI 10.1001/jama.2020.16349; Strijbos E, 2019, VACCINE, V37, P919, DOI 10.1016/j.vaccine.2019.01.007; Strijbos E, 2017, VACCINE, V35, P6290, DOI 10.1016/j.vaccine.2017.09.078; Subesinghe S, 2018, J RHEUMATOL, V45, P733, DOI 10.3899/jrheum.170710; Tackenberg B, 2018, EBIOMEDICINE, V28, P143, DOI 10.1016/j.ebiom.2018.01.007; Tagliaferri AR, 2021, CUREUS, V13, DOI 10.7759/cureus.15581; Vadala M, 2017, EPMA J, V8, P295, DOI 10.1007/s13167-017-0101-y; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; Watad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050435; WHO Solidarity Trial Consortium, 2021, NEW ENGL J MED, V384, P497, DOI 10.1056/NEJMoa2023184; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Zinman L, 2009, MUSCLE NERVE, V40, P947, DOI 10.1002/mus.21440	33	4	4	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1112	10.3390/vaccines9101112			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WM9GG	34696220	Green Published, gold			2022-04-29	WOS:000711385100001
J	Wang, S; Li, L; Yan, FH; Gao, YW; Yang, ST; Xia, XZ				Wang, Shen; Li, Ling; Yan, Feihu; Gao, Yuwei; Yang, Songtao; Xia, Xianzhu			COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects	VACCINES			English	Review						COVID-19; SARS-CoV-2; animal model application; vaccine development	VESICULAR STOMATITIS-VIRUS; RECEPTOR-BINDING DOMAIN; SPIKE PROTEIN; NEUTRALIZING ANTIBODY; SARS-COV-2 INFECTION; NANOPARTICLE VACCINES; RAPID TRANSMISSION; NONHUMAN-PRIMATES; SARS CORONAVIRUS; IMMUNE-RESPONSES	The worldwide pandemic of coronavirus disease 2019 (COVID-19) has become an unprecedented challenge to global public health. With the intensification of the COVID-19 epidemic, the development of vaccines and therapeutic drugs against the etiological agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is also widespread. To prove the effectiveness and safety of these preventive vaccines and therapeutic drugs, available animal models that faithfully recapitulate clinical hallmarks of COVID-19 are urgently needed. Currently, animal models including mice, golden hamsters, ferrets, nonhuman primates, and other susceptible animals have been involved in the study of COVID-19. Moreover, 117 vaccine candidates have entered clinical trials after the primary evaluation in animal models, of which inactivated vaccines, subunit vaccines, virus-vectored vaccines, and messenger ribonucleic acid (mRNA) vaccines are promising vaccine candidates. In this review, we summarize the landscape of animal models for COVID-19 vaccine evaluation and advanced vaccines with an efficacy range from about 50% to more than 95%. In addition, we point out future directions for COVID-19 animal models and vaccine development, aiming at providing valuable information and accelerating the breakthroughs confronting SARS-CoV-2.</p>	[Wang, Shen; Yan, Feihu; Gao, Yuwei; Yang, Songtao; Xia, Xianzhu] Chinese Acad Agr Sci, Changchun Vet Res Inst, Key Lab Jilin Prov Zoonosis Prevent & Control, Changchun 130122, Peoples R China; [Li, Ling] China Anim Hlth & Epidemiol Ctr, Natl Res Ctr Exot Anim Dis, Qingdao 266000, Peoples R China		Yan, FH; Gao, YW; Yang, ST (通讯作者)，Chinese Acad Agr Sci, Changchun Vet Res Inst, Key Lab Jilin Prov Zoonosis Prevent & Control, Changchun 130122, Peoples R China.	18203762077@163.com; lling@cahec.cn; yanfh1990@163.com; yuwei0901@outlook.com; yst62041@163.com; xiaxzh@cae.cn			Project of Granular Vaccine for Severe Infectious Diseases of Animal Origin [2019SWAQ05-6-3]	This research was funded by Project of Granular Vaccine for Severe Infectious Diseases of Animal Origin (grant number: 2019SWAQ05-6-3).	Abreu-Mota T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06741-w; Al Kaabi N, 2021, JAMA-J AM MED ASSOC, V326, P35, DOI 10.1001/jama.2021.8565; Alharbi NK, 2017, VACCINE, V35, P3780, DOI 10.1016/j.vaccine.2017.05.032; Ashraf MU, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020171; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525; Biotech, COVAXIN IND 1 IND CO; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Blaney JE, 2011, J VIROL, V85, P10605, DOI 10.1128/JVI.00558-11; Boudewijns R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19684-y; Brouwer PJM, 2021, CELL, V184, P1188, DOI 10.1016/j.cell.2021.01.035; Carrion R, 2007, J VIROL, V81, P6482, DOI 10.1128/JVI.02876-06; Case James Brett, 2020, bioRxiv, DOI 10.1101/2020.05.18.102038; Chan JFW, 2020, CLIN INFECT DIS, V71, P2428, DOI 10.1093/cid/ciaa325; Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776; Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x; Charitos IA, 2020, WORLD J CLIN CASES, V8, P3920, DOI 10.12998/wjcc.v8.i18.3920; Chiba S, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02128-8; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Dai LP, 2020, CELL, V182, P722, DOI 10.1016/j.cell.2020.06.035; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; DeLiberto, SARS COV 2 EXPOSURE, DOI [10.1101/2021.07.29.454326v1, DOI 10.1101/2021.07.29.454326V1]; Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343; Dieterle M Eugenia, 2020, bioRxiv, DOI 10.1101/2020.05.20.105247; Enkirch T, 2015, VIROLOGY, V479, P259, DOI 10.1016/j.virol.2015.03.017; Faber M, 2005, J GEN VIROL, V86, P1435, DOI 10.1099/vir.0.80844-0; FDA, NEW DRUG BIOL DRUG P; Feng LQ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18077-5; Gao GF., 2021, BIORXIV; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Geisbert TW, 2011, J VIROL, V85, P4222, DOI 10.1128/JVI.02407-10; Geisbert TW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010690; Geisbert TW, 2008, VACCINE, V26, P6894, DOI 10.1016/j.vaccine.2008.09.082; Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143; Graham SP, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00221-3; Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135; Gross R., 2021, HETEROLOGOUS CHADOX1, DOI [10.1101/2021.05.30.21257971, DOI 10.1101/2021.05.30.21257971]; Gu HJ, 2020, SCIENCE, V369, P1603, DOI 10.1126/science.abc4730; Hammer AS, 2021, EMERG INFECT DIS, V27, P547, DOI 10.3201/eid2702.203794; Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011; He YX, 2004, J IMMUNOL, V173, P4050, DOI 10.4049/jimmunol.173.6.4050; Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hong WQ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00451-w; Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042; Hu J., 2020, D614G MUTATION SARS, DOI [10.1101/2020.06.20.161323, DOI 10.1101/2020.06.20.161323]; Hu J, 2021, CELL MOL IMMUNOL, V18, P1061, DOI 10.1038/s41423-021-00648-1; Hume HKC, 2017, VACCINE, V35, P4480, DOI 10.1016/j.vaccine.2017.02.069; Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027; Jones SM, 2005, NAT MED, V11, P786, DOI 10.1038/nm1258; Kang Zhuang, 2020, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V37, P373, DOI 10.7507/1001-5515.202004025; Kato H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223684; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Kesbwara R, 2019, J VIROL, V93, DOI 10.1128/JVI.01865-18; Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023; Klasse PJ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe8065; Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043; Koyama T, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050324; Kurup D, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009383; Kurup D, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00248-6; Lambe T, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02443-0; Larsen HD, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.5.210009; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; Leist SR, 2020, CELL, V183, P1070, DOI 10.1016/j.cell.2020.09.050; Li ET, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010125; Li H, 2021, BIOCONJUGATE CHEM, V32, P1034, DOI 10.1021/acs.bioconjchem.1c00208; Li JW, 2013, BIOENGINEERED, V4, P9, DOI 10.4161/bioe.21950; Li YZ, 2021, EMERG MICROBES INFEC, V10, P342, DOI 10.1080/22221751.2021.1887767; Liang JG, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21634-1; LIHUA W, 2017, HUMAN VACCINES IMMUN, V13, P2078; Liu, TANDEM REPEAT DIMERI, DOI [10.1101/2021.03.11.434928v1, DOI 10.1101/2021.03.11.434928V1]; Liu JY, 2021, NATURE, V596, P273, DOI 10.1038/s41586-021-03693-y; Liu RQ, 2018, ANTIVIR RES, V150, P30, DOI 10.1016/j.antiviral.2017.12.007; Liu YF, 2021, CELL, V184, P3452, DOI 10.1016/j.cell.2021.05.032; Logunov DY, 2021, LANCET, V397, P671, DOI 10.1016/S0140-6736(21)00234-8; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Luo SX, 2021, EMERG MICROBES INFEC, V10, P1002, DOI 10.1080/22221751.2021.1931466; Mallapaty S, 2021, NATURE, V591, P26, DOI 10.1038/d41586-021-00531-z; McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Munster VJ, 2020, NATURE, V585, P268, DOI 10.1038/s41586-020-2324-7; Munster VJ, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0029-1; Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7; Nomura, SARS COV 2 LAMBDA VA, DOI [10.1101/2021.07.28.454085v1, DOI 10.1101/2021.07.28.454085V1]; Oreshkova N, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.23.2001005; Palmer MV, 2021, J VIROL, V95, DOI 10.1128/JVI.00083-21; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Park JG, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102941; Patel A, 2020, INTRADERMAL DELIVERE, DOI [10.1101/2020.07.28.225649., DOI 10.1101/2020.07.28.225649]; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poznansky, CIRCULATING SARS COV, DOI [10.1101/2021.02.14.21251704v1, DOI 10.1101/2021.02.14.21251704V1]; Qiu XG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005547; Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963; Richmond P, 2021, LANCET, V397, P682, DOI 10.1016/S0140-6736(21)00241-5; Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005; Rockx Barry, 2020, Science, V368, P1012, DOI 10.1126/science.abb7314; Ryan KA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20439-y; Safronetz D, 2013, J INFECT DIS, V207, P1316, DOI 10.1093/infdis/jit004; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Sanjana, D614G MUTATION SARS, DOI [10.1101/2020.06.14.151357v1, DOI 10.1101/2020.06.14.151357V1]; Sariol CA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00452; Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015; Shriner SA, 2021, EMERG INFECT DIS, V27, P988, DOI 10.3201/eid2703.204444; Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5; Sit THC, 2020, NATURE, V586, P776, DOI 10.1038/s41586-020-2334-5; Su S, 2021, NAT REV MICROBIOL, V19, P211, DOI 10.1038/s41579-020-00462-y; Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010; Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020; Sun SH, 2021, CELL MOL IMMUNOL, V18, P1070, DOI 10.1038/s41423-021-00658-z; Sun Weina, 2020, bioRxiv, DOI 10.1101/2020.07.26.221861; Tai WB, 2020, CELL RES, V30, P932, DOI 10.1038/s41422-020-0387-5; Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4; Tarke A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100355; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Tillett RL, 2021, LANCET INFECT DIS, V21, P52, DOI 10.1016/S1473-3099(20)30764-7; Tostanoski LH, 2020, NAT MED, V26, P1694, DOI 10.1038/s41591-020-1070-6; Ulrich L, 2021, EMERG INFECT DIS, V27, P1193, DOI 10.3201/eid2704.204945; Ura T, 2014, VACCINES, V2, P624, DOI 10.3390/vaccines2030624; van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Walls AC, 2020, CELL, V183, P1367, DOI 10.1016/j.cell.2020.10.043; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wang JL, 2020, PROTEIN CELL, V11, P776, DOI 10.1007/s13238-020-00767-x; Wang PF, 2021, NATURE, V593, P130, DOI [10.1038/s41586-021-03398-2, 10.1101/2021.01.25.428137]; Washington NL, 2021, CELL, V184, P2587, DOI 10.1016/j.cell.2021.03.052; Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071; Weyenbergh J.V., STAT2 SIGNALING DOUB, DOI [10.1101/2020.04.23.056838v1.full.pdf+html, DOI 10.1101/2020.04.23.056838V1.FULL.PDF+HTML]; Widge AT, 2021, NEW ENGL J MED, V384, P80, DOI 10.1056/NEJMc2032195; Wirblich C, 2017, J VIROL, V91, DOI 10.1128/JVI.02040-16; World Health Organization, WHO DIR GEN RAM MED; Wu, SARS COV 2 SPIKE P68, DOI [10.1101/2021.06.17.448820v1, DOI 10.1101/2021.06.17.448820V1]; Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001; Wu SP, 2016, J INFECT DIS, V214, pS326, DOI 10.1093/infdis/jiw250; Wu ZW, 2021, LANCET INFECT DIS, V21, P803, DOI 10.1016/S1473-3099(20)30987-7; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543; Yang SL, 2021, LANCET INFECT DIS, V21, P1107, DOI 10.1016/S1473-3099(21)00127-4; Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284; Yu P, 2020, ANIM MODEL EXP MED, V3, P93, DOI 10.1002/ame2.12108; Zakhartchouk AN, 2007, VACCINE, V25, P136, DOI 10.1016/j.vaccine.2006.06.084; Zhang BZ, 2021, EMERG MICROBES INFEC, V10, P874, DOI 10.1080/22221751.2021.1921621; Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726; Zhang M, 2021, CHINA CDC WEEKLY, V3, P584, DOI 10.46234/ccdcw2021.148; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zhang ZQ, 2020, INT J BIOL MACROMOL, V165, P239, DOI 10.1016/j.ijbiomac.2020.09.187; Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3; Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037; Zhou DY, 2021, CELL HOST MICROBE, V29, P551, DOI 10.1016/j.chom.2021.02.019; Zhou P., 2020, NATURE, V579, P270, DOI [10.1038/s41586-020-2012-7, DOI 10.1038/s41586-020-2012-7]; Zhou YS, 2018, EXPERT REV VACCINES, V17, P677, DOI 10.1080/14760584.2018.1506702; Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6; Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3; Zhu FC, 2017, LANCET, V389, P621, DOI [10.1016/S0140-6736(16)32617-4, 10.1016/s0140-6736(16)32617-4]; Zhu FC, 2015, LANCET, V385, P2272, DOI 10.1016/S0140-6736(15)60553-0; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zhu YF, 2021, ASIAN J PHARM SCI, V16, P4, DOI 10.1016/j.ajps.2020.06.001	164	0	0	16	16	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	OCT	2021	9	10							1082	10.3390/vaccines9101082			24	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	WN6ND	34696190	Green Published, gold			2022-04-29	WOS:000711882600001
J	Jeeva, S; Kim, KH; Shin, CH; Wang, BZ; Kang, SM				Jeeva, Subbiah; Kim, Ki-Hye; Shin, Chong Hyun; Wang, Bao-Zhong; Kang, Sang-Moo			An Update on mRNA-Based Viral Vaccines	VACCINES			English	Review						mRNA vaccines; SARS-CoV-2; influenza	ENHANCED PROTEIN EXPRESSION; IN-VITRO; POLY(A)-BINDING PROTEIN; TRANSLATION INITIATION; PROTECTIVE EFFICACY; CODON USAGE; KINASE PKR; VIRUS; PSEUDOURIDINE; IMMUNOGENICITY	With the success of COVID-19 vaccines, newly created mRNA vaccines against other infectious diseases are beginning to emerge. Here, we review the structural elements required for designing mRNA vaccine constructs for effective in vitro synthetic transcription reactions. The unprecedently speedy development of mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was enabled with previous innovations in nucleoside modifications during in vitro transcription and lipid nanoparticle delivery materials of mRNA. Recent updates are briefly described in the status of mRNA vaccines against SARS-CoV-2, influenza virus, and other viral pathogens. Unique features of mRNA vaccine platforms and future perspectives are discussed.	[Jeeva, Subbiah; Kim, Ki-Hye; Shin, Chong Hyun; Wang, Bao-Zhong; Kang, Sang-Moo] Georgia State Univ, Inst Biomed Sci, Ctr Inflammat Immun & Infect, Atlanta, GA 30303 USA		Kang, SM (通讯作者)，Georgia State Univ, Inst Biomed Sci, Ctr Inflammat Immun & Infect, Atlanta, GA 30303 USA.	jsubbiah@gsu.edu; kkim39@gsu.edu; cshin@gsu.edu; bwang23@gsu.edu; skang24@gsu.edu		Wang, Bao-Zhong/0000-0002-1561-4318; Kang, SAng Moo/0000-0001-6198-331X; Shin, Chong/0000-0002-6385-5992	NIH/NIAIDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI093772, AI154656]	This preparation of review was partially supported by NIH/NIAID grants AI093772 (S.M.K.) and AI154656 (S.M.K).	Feldman RA, 2019, VACCINE, V37, P3326, DOI 10.1016/j.vaccine.2019.04.074; Abbasi J, 2020, JAMA-J AM MED ASSOC, V324, P1125, DOI 10.1001/jama.2020.16866; Adams D, 2018, NEW ENGL J MED, V379, P11, DOI 10.1056/NEJMoa1716153; Akira S, 2006, CURR TOP MICROBIOL, V311, P1; Al-Saif M, 2012, MOL THER, V20, P954, DOI 10.1038/mt.2012.29; Al-Zoghaibi F, 2007, GENE, V391, P130, DOI 10.1016/j.gene.2006.12.013; Aldrich C, 2021, VACCINE, V39, P1310, DOI 10.1016/j.vaccine.2020.12.070; Aliprantis AO, 2021, HUM VACC IMMUNOTHER, V17, P1248, DOI 10.1080/21645515.2020.1829899; Anderson BR, 2010, NUCLEIC ACIDS RES, V38, P5884, DOI 10.1093/nar/gkq347; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Andries O, 2015, J CONTROL RELEASE, V217, P337, DOI 10.1016/j.jconrel.2015.08.051; Ashraf MU, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020171; Asrani KH, 2018, RNA BIOL, V15, P756, DOI 10.1080/15476286.2018.1450054; Babendure JR, 2006, RNA, V12, P851, DOI 10.1261/rna.2309906; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Barral PM, 2009, PHARMACOL THERAPEUT, V124, P219, DOI 10.1016/j.pharmthera.2009.06.012; Baumbach J., 2021, PLATELET EXPRESSION, DOI [10.1101/2021.05.18.21257324, DOI 10.1101/2021.05.18.21257324]; Benteyn D, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.54; Bettini E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020147; Blakney AK, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020097; Bongiovanni D, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-020-03333-9; Boros G, 2013, J PHOTOCH PHOTOBIO B, V129, P93, DOI 10.1016/j.jphotobiol.2013.09.010; Brazzoli M, 2016, J VIROL, V90, P332, DOI 10.1128/JVI.01786-15; Buschmann MD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010065; Cabanillas B, 2021, ALLERGY, V76, P1617, DOI 10.1111/all.14711; CHAMBERL.M, 1970, NATURE, V228, P227, DOI 10.1038/228227a0; CHAMBERLIN M, 1983, METHOD ENZYMOL, V101, P540; Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; CureVac, 2021, DIS LAT STAG RES CUR; de Alwis R, 2021, MOL THER, V29, P1970, DOI 10.1016/j.ymthe.2021.04.001; Dotan A, 2021, J AUTOIMMUN, V121, DOI 10.1016/j.jaut.2021.102663; Durbin AF, 2016, MBIO, V7, DOI 10.1128/mBio.00833-16; Espeseth AS, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0163-z; Freund I, 2019, GENES-BASEL, V10, DOI 10.3390/genes10020092; Freyn AW, 2020, MOL THER, V28, P1569, DOI 10.1016/j.ymthe.2020.04.018; Gallie DR, 2001, J VIROL, V75, P12141, DOI 10.1128/JVI.75.24.12141-12152.2001; Garcia MA, 2007, BIOCHIMIE, V89, P799, DOI 10.1016/j.biochi.2007.03.001; Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109; Gebre MS, 2021, CELL, V184, P1589, DOI 10.1016/j.cell.2021.02.030; Goldstrohm AC, 2008, NAT REV MOL CELL BIO, V9, P337, DOI 10.1038/nrm2370; Goodarzi H, 2012, NATURE, V485, P264, DOI 10.1038/nature11013; Griswold KE, 2003, PROTEIN EXPRES PURIF, V27, P134, DOI 10.1016/S1046-5928(02)00578-8; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hassan AO, 2020, CELL, V183, P169, DOI 10.1016/j.cell.2020.08.026; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Henderson Jordana M, 2021, Curr Protoc, V1, pe39, DOI 10.1002/cpz1.39; Hinnebusch AG, 2016, SCIENCE, V352, P1413, DOI 10.1126/science.aad9868; Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024; Huang QR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21037-2; Islam MA, 2018, NAT BIOMED ENG, V2, P850, DOI 10.1038/s41551-018-0284-0; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Jemielity J, 2003, RNA, V9, P1108, DOI 10.1261/rna.5430403; Ji RR, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040324; Jiang Y, 2006, MOL CELL BIOL, V26, P2419, DOI 10.1128/MCB.26.6.2419-2429.2006; John S, 2018, VACCINE, V36, P1689, DOI 10.1016/j.vaccine.2018.01.029; Kahvejian A, 2005, GENE DEV, V19, P104, DOI 10.1101/gad.1262905; Kalnin KV, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00324-5; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kariko K, 2012, MOL THER, V20, P948, DOI 10.1038/mt.2012.7; Kariko K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr695; Kimoto M, 2017, CHEM COMMUN, V53, P12309, DOI 10.1039/c7cc06661a; Kirchdoerfer RN, 2016, NATURE, V531, P118, DOI 10.1038/nature17200; Koirala A, 2020, PAEDIATR RESPIR REV, V35, P43, DOI 10.1016/j.prrv.2020.06.010; Komar AA, 2011, CELL CYCLE, V10, P229, DOI 10.4161/cc.10.2.14472; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kozak M, 2005, GENE, V361, P13, DOI 10.1016/j.gene.2005.06.037; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Kwon H, 2018, BIOMATERIALS, V156, P172, DOI 10.1016/j.biomaterials.2017.11.034; Laczko D, 2020, IMMUNITY, V53, P724, DOI 10.1016/j.immuni.2020.07.019; Lederer K, 2020, IMMUNITY, V53, P1281, DOI 10.1016/j.immuni.2020.11.009; Li B, 2016, BIOCONJUGATE CHEM, V27, P849, DOI 10.1021/acs.bioconjchem.6b00090; Liang F, 2017, MOL THER, V25, P2635, DOI 10.1016/j.ymthe.2017.08.006; Lindgren G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01539; Lorenz C, 2011, RNA BIOL, V8, P627, DOI 10.4161/rna.8.4.15394; Lutz J, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0032-6; MARTINON F, 1993, EUR J IMMUNOL, V23, P1719, DOI 10.1002/eji.1830230749; Maruggi Giulietta, 2021, Curr Top Microbiol Immunol, DOI 10.1007/82_2021_233; Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020; Matoulkova E, 2012, RNA BIOL, V9, P563, DOI 10.4161/rna.20231; Mauger DM, 2019, P NATL ACAD SCI USA, V116, P24075, DOI 10.1073/pnas.1908052116; McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9; Migliore A, 2021, RISK MANAG HEALTHC P, V14, P2079, DOI 10.2147/RMHP.S309707; Mignone F, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews0004; Milisavljevic N, 2018, ORG BIOMOL CHEM, V16, P5800, DOI 10.1039/c8ob01498a; Mitarai N, 2008, J MOL BIOL, V382, P236, DOI 10.1016/j.jmb.2008.06.068; Mu X, 2018, NUCLEIC ACIDS RES, V46, P5239, DOI 10.1093/nar/gky177; Muir KL, 2021, NEW ENGL J MED, V384, P1964, DOI 10.1056/NEJMc2105869; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Mustoe AM, 2018, BIOCHEMISTRY-US, V57, P3537, DOI 10.1021/acs.biochem.8b00395; Nance KD, 2021, ACS CENTRAL SCI, V7, P748, DOI 10.1021/acscentsci.1c00197; Nelson CS, 2020, J VIROL, V94, DOI 10.1128/JVI.00186-20; Nelson J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6893; Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114; Pardi N, 2020, CURR OPIN IMMUNOL, V65, P14, DOI 10.1016/j.coi.2020.01.008; Pardi N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05482-0; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Pasquinelli AE, 1995, RNA, V1, P957; Petsch B, 2012, NAT BIOTECHNOL, V30, P1210, DOI 10.1038/nbt.2436; Phua KKL, 2014, SCI REP-UK, V4, DOI 10.1038/srep05128; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ramanathan A, 2016, NUCLEIC ACIDS RES, V44, P7511, DOI 10.1093/nar/gkw551; Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016; Rauch S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00311-w; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Roncati L, 2021, J MED VIROL, V93, P4054, DOI 10.1002/jmv.26924; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Sahin U, 2020, NATURE, V586, P594, DOI 10.1038/s41586-020-2814-7; Sample PJ, 2019, NAT BIOTECHNOL, V37, P803, DOI 10.1038/s41587-019-0164-5; Saunders KO, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00307-6; Schnee M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004746; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Schwertz H, 2018, ARTERIOSCL THROM VAS, V38, P801, DOI 10.1161/ATVBAHA.117.310552; Scully M, 2021, NEW ENGL J MED, V384, P2202, DOI 10.1056/NEJMoa2105385; Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Stitz L, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006108; Svitkin YV, 2017, NUCLEIC ACIDS RES, V45, P6023, DOI 10.1093/nar/gkx135; Tai WB, 2020, CELL RES, V30, P932, DOI 10.1038/s41422-020-0387-5; Tan XH, 2008, HUM IMMUNOL, V69, P32, DOI 10.1016/j.humimm.2007.11.009; Thess A, 2015, MOL THER, V23, P1456, DOI 10.1038/mt.2015.103; Tian JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20653-8; Topol EJ, 2021, CELL, V184, P1401, DOI 10.1016/j.cell.2020.12.039; Trepotec Z, 2019, RNA, V25, P507, DOI 10.1261/rna.069286.118; Vaidyanathan S, 2018, MOL THER-NUCL ACIDS, V12, P530, DOI 10.1016/j.omtn.2018.06.010; van Doremalen Neeltje, 2021, bioRxiv, DOI 10.1101/2021.01.09.426058; Victor MP, 2019, GENOMICS, V111, P1292, DOI 10.1016/j.ygeno.2018.08.009; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; von Niessen AGO, 2019, MOL THER, V27, P824, DOI 10.1016/j.ymthe.2018.12.011; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Wang J, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz751; Wang Y, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01311-z; Wang ZR, 1999, MOL CELL BIOL, V19, P4552; Weissman D, 2015, MOL THER, V23, P1416, DOI 10.1038/mt.2015.138; Weissman D, 2015, EXPERT REV VACCINES, V14, P265, DOI 10.1586/14760584.2015.973859; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Wylon K, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0172-7; Yang Q, 2019, NUCLEIC ACIDS RES, V47, P9243, DOI 10.1093/nar/gkz710; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zhong ZF, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030096; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	147	1	1	37	48	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							965	10.3390/vaccines9090965			17	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3QP	34579202	Green Published, gold			2022-04-29	WOS:000702123300001
J	Kamada, M; Kenzaka, T				Kamada, Momoka; Kenzaka, Tsuneaki			A Case of Rubella Caused by Rubella Vaccination	VACCINES			English	Article						rubella; vaccine; adverse reaction; genotyping; vaccine strain; measles-rubella; rash; case report		We present an extremely rare case of rubella that developed after rubella vaccine administration. A 54-year-old man complained of back and neck pain for some days. He presented with generalized rash and arthralgia that had persisted for two days before his visit. His vital signs were normal, and arthralgia had disappeared during an examination, but lymphadenopathy in the left posterior neck and pink papules were observed throughout the body. He had received his first Rubella vaccination 17 days before this visit and had attended a crowded festival. Owing to the rubella epidemic in that prefecture, we performed a rubella antibody test and polymerase chain reaction assay using blood, urine, and pharyngeal swab specimens. Rubella IgG and IgM antibody titers were 3 and 1.48, respectively. The pharyngeal swab yielded positive results for the 1a vaccine strain. Therefore, he was diagnosed with rubella due to rubella vaccination. His symptoms improved eventually. His clinical course was uncomplicated. Symptoms resolved within one week without specific treatment. The vaccine rubella strain is not as highly infectious as wild-type rubella strains. If rubella symptoms appear after vaccination, it must be investigated whether these are vaccine-specific adverse reactions, wild-strain rubella onset, or other eruptive viral infections.	[Kamada, Momoka; Kenzaka, Tsuneaki] Hyogo Prefectural Tamba Med Ctr, Dept Internal Med, 2002-7 Iso, Hikami, Tamba 6693495, Japan; [Kenzaka, Tsuneaki] Kobe Univ, Div Community Med & Career Dev, Grad Sch Med, Hyogo Ku, 2-1-5 Arata Cho, Kobe, Hyogo 6520032, Japan		Kenzaka, T (通讯作者)，Hyogo Prefectural Tamba Med Ctr, Dept Internal Med, 2002-7 Iso, Hikami, Tamba 6693495, Japan.; Kenzaka, T (通讯作者)，Kobe Univ, Div Community Med & Career Dev, Grad Sch Med, Hyogo Ku, 2-1-5 Arata Cho, Kobe, Hyogo 6520032, Japan.	m08018mo@jichi.ac.jp; smile.kenzaka@jichi.ac.jp		Kenzaka, Tsuneaki/0000-0002-3120-6605			[Anonymous], Urgent Information about the Rubella Epidemic; [Anonymous], Urgent Information about the Rubella Epidemic; [Anonymous], Urgent Information about the Rubella Epidemic; Bennett J.E., 2019, MANDELL DOUGLAS BENN, V9th ed, P2007; Kawashima H., 2013, MOD MEDIA, V59, P223; Kimberlin D.W., 2021, RED BOOK 2021 REP CO, V32nd ed.; Ministry of Health Labour and Welfare Japan, REP STAT SUSP ADV RE; National Institute of Infectious Diseases, 2013, INFECT AGENTS SURVEI, V34, P99; Ong SWX, 2021, HUM VACC IMMUNOTHER, V17, P224, DOI 10.1080/21645515.2020.1765623; Remington J.S., 2011, INFECT DIS FETUS NEW, V7th ed., P861; Tago S, 2019, INT J INFECT DIS, V82, P7, DOI 10.1016/j.ijid.2019.02.034; The Japanese Association for Infectious Disease, 2017, RUB, VI, P873; Watson J C, 1998, MMWR Recomm Rep, V47, P1	13	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1040	10.3390/vaccines9091040			5	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3GK	34579277	Green Published, gold			2022-04-29	WOS:000702096600001
J	Sobia, P; Archary, D				Sobia, Parveen; Archary, Derseree			Preventive HIV Vaccines-Leveraging on Lessons from the Past to Pave the Way Forward	VACCINES			English	Review						vaccines; HIV; antibodies; mucosal; immune responses	HUMAN-IMMUNODEFICIENCY-VIRUS; BROADLY NEUTRALIZING ANTIBODIES; HUMAN MONOCLONAL-ANTIBODIES; T-CELL RESPONSES; FEMALE REPRODUCTIVE-TRACT; TEST-OF-CONCEPT; HUMORAL IMMUNE-RESPONSES; HIGHLY PATHOGENIC SIV; DNA-BASED VACCINE; PBL-SCID MICE	Almost four decades on, since the 1980's, with hundreds of HIV vaccine candidates tested in both non-human primates and humans, and several HIV vaccines trials later, an efficacious HIV vaccine continues to evade us. The enormous worldwide genetic diversity of HIV, combined with HIV's inherent recombination and high mutation rates, has hampered the development of an effective vaccine. Despite the advent of antiretrovirals as pre-exposure prophylaxis and preventative treatment, which have shown to be effective, HIV infections continue to proliferate, highlighting the great need for a vaccine. Here, we provide a brief history for the HIV vaccine field, with the most recent disappointments and advancements. We also provide an update on current passive immunity trials, testing proof of the concept of the most clinically advanced broadly neutralizing monoclonal antibodies for HIV prevention. Finally, we include mucosal immunity, the importance of vaccine-elicited immune responses and the challenges thereof in the most vulnerable environment-the female genital tract and the rectal surfaces of the gastrointestinal tract for heterosexual and men who have sex with men transmissions, respectively.	[Sobia, Parveen; Archary, Derseree] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa CAPRISA, Nelson Mandela Sch Med, ZA-4001 Durban, South Africa; [Archary, Derseree] Univ KwaZulu Natal, Dept Med Microbiol, ZA-4001 Durban, South Africa		Archary, D (通讯作者)，Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa CAPRISA, Nelson Mandela Sch Med, ZA-4001 Durban, South Africa.; Archary, D (通讯作者)，Univ KwaZulu Natal, Dept Med Microbiol, ZA-4001 Durban, South Africa.	parveen.sobia@caprisa.org; desh.archary@caprisa.org			Department of Science and Innovation (DSI)-National Research Foundation (NRF) Centre of Excellence in HIV Prevention [96354]; South African Medical Research Council (SAMRC) Special Initiative [96151]; S&F Scarce Skills Postdoctoral Fellowships [132714]; NRF of South Africa Thuthuka [TTK160517165310]; NRF Research Career Advancement Fellowship [RCA13101656388]; Polio Research Foundation (PRF) of South Africa [PRF 17/02]; European and Developing Countries Clinical Trials Partnership (EDCTP) Senior Fellowship [TMA2017SF-1960]	Parveen Sobia and Derseree Archary received support from the Department of Science and Innovation (DSI)-National Research Foundation (NRF) Centre of Excellence in HIV Prevention (Grant No. 96354). Parveen Sobia received support from the South African Medical Research Council (SAMRC) Special Initiative (Grant No. 96151) and S&F Scarce Skills Postdoctoral Fellowships (Grant No. 132714). Derseree Archary was also funded through the SAMRC Self-Initiated Grant and the NRF of South Africa Thuthuka (grant#TTK160517165310), the NRF Research Career Advancement Fellowship (grant#RCA13101656388), the Polio Research Foundation (PRF) of South Africa (PRF 17/02) and a European and Developing Countries Clinical Trials Partnership (EDCTP) Senior Fellowship (grant#TMA2017SF-1960).	Aguiar JC, 2001, VACCINE, V20, P275, DOI 10.1016/S0264-410X(01)00273-0; Alam SM, 2007, J IMMUNOL, V178, P4424, DOI 10.4049/jimmunol.178.7.4424; Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257; Alpert MD, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002890; Angel CJL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008663; [Anonymous], 2020, UNAIDS DATA; Aravantinou M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161730; Armbruster C, 2002, AIDS, V16, P227, DOI 10.1097/00002030-200201250-00012; Armbruster C, 2004, J ANTIMICROB CHEMOTH, V54, P915, DOI 10.1093/jac/dkh428; Arnold KB, 2016, MUCOSAL IMMUNOL, V9, P194, DOI 10.1038/mi.2015.51; Badamchi-Zadeh A, 2018, J VIROL, V92, DOI 10.1128/JVI.01925-17; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baden LR, 2020, LANCET HIV, V7, pE688, DOI 10.1016/S2352-3018(20)30229-0; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Balazs AB, 2012, NATURE, V481, P81, DOI 10.1038/nature10660; Barnetta SW, 2008, AIDS, V22, P339, DOI 10.1097/QAD.0b013e3282f3ca57; Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/S0140-6736(18)31364-3, 10.1016/s0140-6736(18)31364-3]; Barouch DH, 2013, CELL, V155, P531, DOI 10.1016/j.cell.2013.09.061; Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744; Barouch DH, 2010, CURR OPIN HIV AIDS, V5, P386, DOI 10.1097/COH.0b013e32833cfe4c; Barouch DH, 2000, P NATL ACAD SCI USA, V97, P4192, DOI 10.1073/pnas.050417697; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Barr FD, 2018, MUCOSAL IMMUNOL, V11, P1420, DOI 10.1038/s41385-018-0045-0; Basu U, 2011, CELL, V144, P353, DOI 10.1016/j.cell.2011.01.001; Bekker LG, 2018, LANCET HIV, V5, pE366, DOI 10.1016/S2352-3018(18)30071-7; Belyakov IM, 2001, NAT MED, V7, P1320, DOI 10.1038/nm1201-1320; Bertley FMN, 2004, J IMMUNOL, V172, P3745, DOI 10.4049/jimmunol.172.6.3745; Binley JA, 2004, J VIROL, V78, P13232, DOI 10.1128/JVI.78.23.13232-13252.2004; Birx DL, 2000, J INFECT DIS, V181, P881, DOI 10.1086/315308; Blaschitz C, 2010, J CLIN IMMUNOL, V30, P196, DOI 10.1007/s10875-010-9368-7; Bolduc JF, 2017, J VIROL, V91, DOI 10.1128/JVI.01402-16; Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42; Borducchi EN, 2018, NATURE, V563, P360, DOI 10.1038/s41586-018-0600-6; Boyer JD, 1999, CLIN IMMUNOL, V90, P100, DOI 10.1006/clim.1998.4616; Bracq L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00260; Braibant M, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-103; Brandtzaeg P, 2010, IMMUNOL INVEST, V39, P303, DOI 10.3109/08820131003680369; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3; Buffa V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050529; Burton DR, 2019, NAT REV IMMUNOL, V19, P77, DOI 10.1038/s41577-018-0103-6; Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515; BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134; CAMERON DW, 1989, LANCET, V2, P403; Cao AT, 2015, MUCOSAL IMMUNOL, V8, P1072, DOI 10.1038/mi.2014.134; Caron G, 2005, J IMMUNOL, V175, P1551, DOI 10.4049/jimmunol.175.3.1551; Cassol E, 2010, J LEUKOCYTE BIOL, V87, P599, DOI 10.1189/jlb.1009673; Catanzaro AT, 2007, VACCINE, V25, P4085, DOI 10.1016/j.vaccine.2007.02.050; Catanzaro AT, 2006, J INFECT DIS, V194, P1638, DOI 10.1086/509258; Cecchinato V, 2010, CURR OPIN HIV AIDS, V5, P141, DOI 10.1097/COH.0b013e32833653ec; Chevalier MF, 2013, BLOOD, V121, P29, DOI 10.1182/blood-2012-07-409755; Christensen D, 2017, MUCOSAL IMMUNOL, V10, P260, DOI 10.1038/mi.2016.28; Chung AW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007736; Cicala C, 2009, P NATL ACAD SCI USA, V106, P20877, DOI 10.1073/pnas.0911796106; Cohen J, 2007, SCIENCE, V318, P28, DOI 10.1126/science.318.5847.28; Cone RA, 2014, J INFECT DIS, V210, pS616, DOI 10.1093/infdis/jiu459; Conti HR, 2015, J IMMUNOL, V195, P780, DOI 10.4049/jimmunol.1500909; Corey L, 2021, NEW ENGL J MED, V384, P1003, DOI 10.1056/NEJMoa2031738; Cram JA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225622; Curlin ME, 2020, VACCINE, V38, P5814, DOI 10.1016/j.vaccine.2020.06.043; Czerkinsky C, 2012, CURR TOP MICROBIOL, V354, P1, DOI 10.1007/82_2010_112; Dann SM, 2015, EXP PARASITOL, V156, P68, DOI 10.1016/j.exppara.2015.06.003; Davenport TM, 2016, STRUCTURE, V24, P1346, DOI 10.1016/j.str.2016.06.012; de Jong SE, 2020, CELL HOST MICROBE, V28, P169, DOI 10.1016/j.chom.2020.06.014; DeCamp AC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185959; DePaolo RW, 2012, J EXP MED, V209, P1437, DOI 10.1084/jem.20112339; DOLIN R, 1991, ANN INTERN MED, V114, P119, DOI 10.7326/0003-4819-114-2-119; Doria-Rose NA, 2014, NATURE, V509, P55, DOI 10.1038/nature13036; Dosenovic P, 2015, CELL, V161, P1505, DOI 10.1016/j.cell.2015.06.003; Duluc D, 2013, MUCOSAL IMMUNOL, V6, P626, DOI 10.1038/mi.2012.104; Dupont A, 2014, GUT MICROBES, V5, P761, DOI 10.4161/19490976.2014.972238; Elizaldi SR, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00824-19; Emu B, 2008, J VIROL, V82, P5398, DOI 10.1128/JVI.02176-07; Esparza J, 2013, VACCINE, V31, P3502, DOI 10.1016/j.vaccine.2013.05.018; Excler JL, 2016, CURR OPIN HIV AIDS, V11, P607, DOI 10.1097/COH.0000000000000312; Fan SR, 2008, INT J GYNECOL OBSTET, V103, P50, DOI 10.1016/j.ijgo.2008.05.020; Fazekas de St Groth B, 2008, AIDS, V22, P671, DOI 10.1097/QAD.0b013e3282f466da; Feinen B, 2010, MUCOSAL IMMUNOL, V3, P312, DOI 10.1038/mi.2009.139; Felber BK, 2014, VACCINES-BASEL, V2, P354, DOI 10.3390/vaccines2020354; Fenyo EM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004505; Fisher KL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01274; Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404; Forthal DN, 2007, J IMMUNOL, V178, P6596, DOI 10.4049/jimmunol.178.10.6596; Forthal DN, 2009, CURR OPIN HIV AIDS, V4, P388, DOI 10.1097/COH.0b013e32832f0a89; Fuller DH, 2002, J VIROL, V76, P3309, DOI 10.1128/JVI.76.7.3309-3317.2002; Gallorini S, 2014, VACCINE, V32, P2382, DOI 10.1016/j.vaccine.2013.12.043; Ganesh L, 2004, J VIROL, V78, P11980, DOI 10.1128/JVI.78.21.11980-11987.2004; Ganor Y, 2010, MUCOSAL IMMUNOL, V3, P506, DOI 10.1038/mi.2010.32; Gardner MR, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00176; GAUDUIN MC, 1995, J INFECT DIS, V171, P1203, DOI 10.1093/infdis/171.5.1203; Gauduin MC, 1997, NAT MED, V3, P1389, DOI 10.1038/nm1297-1389; Gautam R, 2018, NAT MED, V24, P610, DOI 10.1038/s41591-018-0001-2; Gautam R, 2016, NATURE, V533, P105, DOI 10.1038/nature17677; Gebril A, 2012, EXPERT REV VACCINES, V11, P1139, DOI [10.1586/ERV.12.81, 10.1586/erv.12.81]; Genesca M, 2009, J INTERN MED, V265, P67, DOI 10.1111/j.1365-2796.2008.02051.x; Givan AL, 1997, AM J REPROD IMMUNOL, V38, P350; GOEDERT JJ, 1989, LANCET, V2, P1351; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Gray G, 2010, CURR OPIN HIV AIDS, V5, P357, DOI 10.1097/COH.0b013e32833d2d2b; Gray GE, 2011, LANCET INFECT DIS, V11, P507, DOI 10.1016/S1473-3099(11)70098-6; GRIFFISS JM, 1975, J IMMUNOL, V114, P1779; Gupta S, 2015, J VIROL, V89, P4158, DOI 10.1128/JVI.02904-14; Haase AT, 2011, ANNU REV MED, V62, P127, DOI 10.1146/annurev-med-080709-124959; Hagan T, 2019, CELL, V178, P1313, DOI 10.1016/j.cell.2019.08.010; Halper-Stromberg A, 2014, CELL, V158, P989, DOI 10.1016/j.cell.2014.07.043; Hammer SM, 2013, NEW ENGL J MED, V369, P2083, DOI 10.1056/NEJMoa1310566; Hansen SG, 2013, NATURE, V502, P100, DOI 10.1038/nature12519; Hansen SG, 2011, NATURE, V473, P523, DOI 10.1038/nature10003; Hansen SG, 2009, NAT MED, V15, P293, DOI 10.1038/nm.1935; Harrer T, 1996, AIDS RES HUM RETROV, V12, P585, DOI 10.1089/aid.1996.12.585; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Henrick BM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00426; Hessell AJ, 2018, EXPERT REV VACCINES, V17, P127, DOI 10.1080/14760584.2018.1425619; Hessell AJ, 2016, NAT MED, V22, P362, DOI 10.1038/nm.4063; Heyndrickx L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036438; Hirota K, 2013, NAT IMMUNOL, V14, P372, DOI 10.1038/ni.2552; Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302; Hocini H, 1997, AIDS RES HUM RETROV, V13, P1179, DOI 10.1089/aid.1997.13.1179; Hua CK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01655; Huang DL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19650-8; Huang JH, 2016, IMMUNITY, V45, P1108, DOI 10.1016/j.immuni.2016.10.027; Huang JH, 2012, NATURE, V491, P406, DOI 10.1038/nature11544; Huang YD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108631; Hutnick NA, 2011, CURR OPIN VIROL, V1, P233, DOI 10.1016/j.coviro.2011.08.003; International AIDS Vaccine Initiative, 2021, 1 IN HUM CLIN TRIAL; Iwasaki A, 2010, NAT REV IMMUNOL, V10, P699, DOI 10.1038/nri2836; Iyer SS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178193; JACOBSON JM, 1993, J INFECT DIS, V168, P298, DOI 10.1093/infdis/168.2.298; Jalah R, 2012, HUM VACC IMMUNOTHER, V8, P1620, DOI 10.4161/hv.21407; Jardine JG, 2015, SCIENCE, V349, P156, DOI 10.1126/science.aac5894; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Joos B, 2006, ANTIMICROB AGENTS CH, V50, P1773, DOI 10.1128/AAC.50.5.1773-1779.2006; Julg B, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4235; Julg B, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1321; KAETZEL CS, 1991, P NATL ACAD SCI USA, V88, P8796, DOI 10.1073/pnas.88.19.8796; Kaldensjo T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021344; KAMAT BR, 1987, AM J PATHOL, V127, P66; KARPAS A, 1988, P NATL ACAD SCI USA, V85, P9234, DOI 10.1073/pnas.85.23.9234; Kasturi SP, 2017, J VIROL, V91, DOI 10.1128/JVI.01844-16; KEEFER MC, 1994, AIDS RES HUM RETROV, V10, P1713, DOI 10.1089/aid.1994.10.1713; Ketas Thomas J, 2021, bioRxiv, DOI [10.20411/pai.v6i1.441, 10.1101/2021.03.11.434841]; Khan SN, 2018, J VIROL, V92, DOI 10.1128/JVI.00384-18; Klein F, 2013, CELL, V153, P126, DOI 10.1016/j.cell.2013.03.018; Klein F, 2012, NATURE, V492, P118, DOI 10.1038/nature11604; Klenerman P, 2016, NAT REV IMMUNOL, V16, P367, DOI 10.1038/nri.2016.38; Ko SY, 2014, NATURE, V514, P642, DOI 10.1038/nature13612; Kolodkin-Gal D, 2013, J VIROL, V87, P13589, DOI 10.1128/JVI.03108-12; Komai-Koma M, 2004, P NATL ACAD SCI USA, V101, P3029, DOI 10.1073/pnas.0400171101; Kourtis AP, 2012, NEW ENGL J MED, V367, P2260, DOI 10.1056/NEJMc1202292; Kozlowski PA, 2002, J IMMUNOL, V169, P566, DOI 10.4049/jimmunol.169.1.566; Kozlowski PA, 1997, INFECT IMMUN, V65, P1387, DOI 10.1128/IAI.65.4.1387-1394.1997; Kozlowski Pamela A., 2019, Current Immunology Reviews, V15, P102, DOI 10.2174/1573395514666180605092054; Kraehenbuhl JP, 2013, CURR TOP MED CHEM, V13, P2609, DOI 10.2174/15680266113136660186; Kulkarni V, 2014, J MED PRIMATOL, V43, P329, DOI 10.1111/jmp.12123; Kunkel EJ, 2003, NAT REV IMMUNOL, V3, P822, DOI 10.1038/nri1203; Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432; Kwon YD, 2016, J VIROL, V90, P5899, DOI 10.1128/JVI.03246-15; Laher F, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003038; Lambour J, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.97; Levinson P, 2009, AIDS, V23, P309, DOI 10.1097/QAD.0b013e328321809c; LEVY J, 1994, BLOOD, V84, P2130; Li HR, 2017, J VIROL, V91, DOI 10.1128/JVI.02425-16; Li M, 2020, IMMUNOL LETT, V217, P116, DOI 10.1016/j.imlet.2019.10.013; Li QS, 2014, J IMMUNOL, V193, P3113, DOI 10.4049/jimmunol.1400820; Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083; Lindsay RW, 2013, VACCINE, V31, P4749, DOI 10.1016/j.vaccine.2013.08.011; Liu JY, 2008, J VIROL, V82, P5643, DOI 10.1128/JVI.02564-07; Liu JY, 2016, SCIENCE, V353, P1045, DOI 10.1126/science.aag0491; Liu J, 2020, VACCINE, V38, P2149, DOI 10.1016/j.vaccine.2020.01.050; Liu J, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0165-8; Liu MA, 2003, J INTERN MED, V253, P402, DOI 10.1046/j.1365-2796.2003.01140.x; Lu S, 2009, HUM GENE THER, V20, P1101, DOI 10.1089/hum.2009.910; MacGregor RB, 2002, AIDS, V16, P2137, DOI 10.1097/00002030-200211080-00005; MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613; Machado JR, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/350195; Mahomed S, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-042247; Mahomed S, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030283; Makitalo B, 2004, J GEN VIROL, V85, P2407, DOI 10.1099/vir.0.79869-0; Malbec M, 2013, J EXP MED, V210, P2813, DOI 10.1084/jem.20131244; Manrique A, 2007, J VIROL, V81, P8793, DOI 10.1128/JVI.00598-07; Margolis L, 2006, NAT REV MICROBIOL, V4, P312, DOI 10.1038/nrmicro1387; Martin N, 2010, J VIROL, V84, P3516, DOI 10.1128/JVI.02651-09; Martinez-Navio JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00449; Mascola JR, 2013, IMMUNOL REV, V254, P225, DOI 10.1111/imr.12075; Massanella M, 2009, AIDS, V23, P183, DOI 10.1097/QAD.0b013e32831ef1a3; Matoba N, 2004, P NATL ACAD SCI USA, V101, P13584, DOI 10.1073/pnas.0405297101; Mazurov D, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000788; McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2; McEnery Regina, 2011, IAVI Rep, V15, P17; Mckay PF, 2017, J CONTROL RELEASE, V249, P74, DOI 10.1016/j.jconrel.2017.01.018; McKinnon LR, 2015, JAIDS-J ACQ IMM DEF, V68, P6, DOI 10.1097/QAI.0000000000000389; McKinnon LR, 2011, J IMMUNOL, V187, P6032, DOI 10.4049/jimmunol.1101836; McMichael A, 2002, NAT REV IMMUNOL, V2, P283, DOI 10.1038/nri779; McMichael AJ, 2010, NAT REV IMMUNOL, V10, P11, DOI 10.1038/nri2674; Meng FL, 2014, CELL, V159, P1538, DOI 10.1016/j.cell.2014.11.014; Mestecky H, 2007, J REPROD IMMUNOL, V73, P85, DOI 10.1016/j.jri.2007.01.005; MESTECKY J, 1994, AIDS RES HUM RETROV, V10, pS11; Miglietta R, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0346-3; Miller CJ, 2005, J VIROL, V79, P9217, DOI 10.1128/JVI.79.14.9217-9227.2005; Moldoveanu Z, 2005, J IMMUNOL, V175, P4127, DOI 10.4049/jimmunol.175.6.4127; Moldt B, 2012, P NATL ACAD SCI USA, V109, P18921, DOI 10.1073/pnas.1214785109; de Lara LM, 2021, CURR OPIN PHYSIOL, V19, P32, DOI 10.1016/j.cophys.2020.07.021; Moreno-Fernandez ME, 2012, AIDS RES HUM RETROV, V28, P49, DOI [10.1089/aid.2011.0265, 10.1089/AID.2011.0265]; Mouquet H, 2012, P NATL ACAD SCI USA, V109, pE3268, DOI 10.1073/pnas.1217207109; Mouquet H, 2010, NATURE, V467, P591, DOI 10.1038/nature09385; Mselle TF, 2007, CLIN IMMUNOL, V124, P69, DOI 10.1016/j.clim.2007.04.008; Mudd PA, 2012, NATURE, V491, P129, DOI 10.1038/nature11443; MUSTER T, 1993, J VIROL, V67, P6642, DOI 10.1128/JVI.67.11.6642-6647.1993; Nakanishi Y, 2009, NATURE, V462, P510, DOI 10.1038/nature08511; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Neutra MR, 2001, NAT IMMUNOL, V2, P1004, DOI 10.1038/ni1101-1004; Nguyen PV, 2014, CELL MOL IMMUNOL, V11, P410, DOI 10.1038/cmi.2014.41; OLEARY AD, 1986, HISTOPATHOLOGY, V10, P267, DOI 10.1111/j.1365-2559.1986.tb02481.x; Orr MT, 2015, VACCINE, V33, P6570, DOI 10.1016/j.vaccine.2015.10.115; PARREN PWHI, 1995, AIDS, V9, pF1, DOI 10.1097/00002030-199506000-00001; Parren PWHI, 2001, J VIROL, V75, P8340, DOI 10.1128/JVI.75.17.8340-8347.2001; Parsons MS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1483; Pasetti MF, 2011, IMMUNOL REV, V239, P125, DOI 10.1111/j.1600-065X.2010.00970.x; Pavri R, 2010, CELL, V143, P122, DOI 10.1016/j.cell.2010.09.017; Pegu A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008992; Pena-Cruz V, 2018, J CLIN INVEST, V128, P3439, DOI 10.1172/JCI98943; Perreau M, 2008, J EXP MED, V205, P2717, DOI 10.1084/jem.20081786; Pietzsch J, 2012, P NATL ACAD SCI USA, V109, P15859, DOI 10.1073/pnas.1213409109; Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748; Pitisuttithum P, 2020, LANCET HIV, V7, pE238, DOI 10.1016/S2352-3018(19)30406-0; Pitisuttithum P, 2013, PROCEDIA VACCINOL, V7, P49, DOI 10.1016/j.provac.2013.06.010; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Prabhakaran M, 2021, J IMMUNOL METHODS, V491, DOI 10.1016/j.jim.2021.112995; Ramsuran V, 2011, CLIN INFECT DIS, V52, P1248, DOI 10.1093/cid/cir119; Reh L, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004966; Rerks-Ngarm S, 2017, J INFECT DIS, V215, P1255, DOI 10.1093/infdis/jix099; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Rocha CS, 2018, J VIROL, V92, DOI 10.1128/JVI.00167-18; Rodriguez-Garcia M, 2017, MUCOSAL IMMUNOL, V10, P531, DOI 10.1038/mi.2016.72; Rodriguez-Garcia M, 2014, MUCOSAL IMMUNOL, V7, P1375, DOI 10.1038/mi.2014.26; Rodriguez-Garcia M, 2018, AGING CELL, V17, DOI 10.1111/acel.12733; Rosati M, 2008, VACCINE, V26, P5223, DOI 10.1016/j.vaccine.2008.03.090; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; Roy MJ, 2000, VACCINE, V19, P764, DOI 10.1016/S0264-410X(00)00302-9; Rudicell RS, 2014, J VIROL, V88, P12669, DOI 10.1128/JVI.02213-14; Salle B, 2010, J INFECT DIS, V202, P337, DOI 10.1086/653619; Sanders RW, 2015, SCIENCE, V349, DOI 10.1126/science.aac4223; Sandler NG, 2012, NAT REV MICROBIOL, V10, P655, DOI 10.1038/nrmicro2848; Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022; Saunders KO, 2015, J VIROL, V89, P8334, DOI 10.1128/JVI.00908-15; Scheid JF, 2016, NATURE, V535, P556, DOI 10.1038/nature18929; Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227; Scheid JF, 2009, J IMMUNOL METHODS, V343, P65, DOI 10.1016/j.jim.2008.11.012; Schmitt N, 2015, CURR OPIN IMMUNOL, V34, P130, DOI 10.1016/j.coi.2015.03.007; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Schoenly KA, 2008, J VIROL, V82, P3166, DOI 10.1128/JVI.01634-07; Selvarajah S, 2005, J VIROL, V79, P12148, DOI 10.1128/JVI.79.19.12148-12163.2005; Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729; Shen R, 2009, J VIROL, V83, P3258, DOI 10.1128/JVI.01796-08; Shingai M, 2014, J EXP MED, V211, P2061, DOI 10.1084/jem.20132494; Shingai M, 2013, NATURE, V503, P277, DOI 10.1038/nature12746; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; Singh S, 2014, VACCINE, V32, P6934, DOI 10.1016/j.vaccine.2014.10.051; Skowronski DM, 2021, NEW ENGL J MED, V384, P1576, DOI 10.1056/NEJMc2036242; Sok D, 2014, P NATL ACAD SCI USA, V111, P17624, DOI 10.1073/pnas.1415789111; Sourisseau M, 2007, J VIROL, V81, P1000, DOI 10.1128/JVI.01629-06; Sparrow E, 2017, B WORLD HEALTH ORGAN, V95, P235, DOI [10.2471/BLT.16.178061, 10.2471/blt.16.178061]; Steichen JM, 2019, SCIENCE, V366, P1216, DOI 10.1126/science.aax4380; Steinhagen F, 2011, VACCINE, V29, P3341, DOI 10.1016/j.vaccine.2010.08.002; Stephenson KE, 2016, CURR HIV-AIDS REP, V13, P31, DOI 10.1007/s11904-016-0299-7; Stiegler G, 2002, AIDS, V16, P2019, DOI 10.1097/00002030-200210180-00006; Stieh DJ, 2019, J INT AIDS SOC, V22, P98; Stieh DJ, 2016, CELL HOST MICROBE, V19, P529, DOI 10.1016/j.chom.2016.03.005; Swain W E, 2000, Dev Biol (Basel), V104, P115; Thiam HR, 2020, ANNU REV CELL DEV BI, V36, P191, DOI 10.1146/annurev-cellbio-020520-111016; Thibault S, 2007, J IMMUNOL, V179, P4357, DOI 10.4049/jimmunol.179.7.4357; Tomaras G.S.X., 2013, P 13 AIDS VACC C BAR; Trifonova RT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02719; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Tuero I, 2014, VIRUSES-BASEL, V6, P3129, DOI 10.3390/v6083129; Tuyishime M, 2020, CURR OPIN HIV AIDS, V15, P290, DOI 10.1097/COH.0000000000000640; Vajdy Michael, 2008, P23, DOI 10.1007/978-1-4020-8412-6_2; van den Berg FT, 2019, MOL THER-METH CLIN D, V14, P100, DOI 10.1016/j.omtm.2019.06.002; Van Roey GA, 2012, EUR J IMMUNOL, V42, P353, DOI 10.1002/eji.201141787; van Schooten J, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0457-7; Vargas-Inchaustegui DA, 2013, CURR HIV RES, V11, P407, DOI 10.2174/1570162X113116660063; Vasan S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019252; Vcelar B, 2007, AIDS, V21, P2161, DOI 10.1097/QAD.0b013e328285da15; Veazey RS, 2015, HUM VACC IMMUNOTHER, V11, P2913, DOI 10.1080/21645515.2015.1070998; Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833; Veazey RS, 2004, J EXP MED, V200, P697, DOI 10.1084/jem.20041464; Verma A, 2020, J VIROL, V94, DOI 10.1128/JVI.01737-19; VITTECOQ D, 1995, P NATL ACAD SCI USA, V92, P1195, DOI 10.1073/pnas.92.4.1195; Walker Bruce D, 2007, Top HIV Med, V15, P134; Walker LM, 2011, NATURE, V477, P466, DOI 10.1038/nature10373; Wang D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9387; Wang XH, 2003, J IMMUNOL, V171, P4717, DOI 10.4049/jimmunol.171.9.4717; Ward ES, 2009, ADV IMMUNOL, V103, P77, DOI 10.1016/S0065-2776(09)03004-1; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Wassen L, 1996, SCAND J IMMUNOL, V44, P408, DOI 10.1046/j.1365-3083.1996.d01-320.x; Watkins DI, 2008, MEM I OSWALDO CRUZ, V103, P119, DOI 10.1590/S0074-02762008000200001; Whaley KJ, 2014, J INFECT DIS, V210, pS674, DOI 10.1093/infdis/jiu398; Wilks AB, 2010, J IMMUNOL, V185, P7097, DOI 10.4049/jimmunol.1002751; Williams WB, 2018, CURR OPIN HIV AIDS, V13, P9, DOI [10.1097/COH.0000000000000423, 10.1097/coh.0000000000000423]; Williams WB, 2015, SCIENCE, V349, DOI 10.1126/science.aab1253; Wilson-Welder JH, 2009, J PHARM SCI-US, V98, P1278, DOI 10.1002/jps.21523; Wira CR, 2008, AIDS, V22, P1909, DOI 10.1097/QAD.0b013e3283060ea4; Wira CR, 2005, IMMUNOL REV, V206, P306, DOI 10.1111/j.0105-2896.2005.00287.x; Woof JM, 2005, IMMUNOL REV, V206, P64, DOI 10.1111/j.0105-2896.2005.00290.x; Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659; Xin KQ, 1999, CLIN IMMUNOL, V92, P90, DOI 10.1006/clim.1999.4730; Yamamoto M, 2012, CURR TOP MICROBIOL, V354, P39, DOI 10.1007/82_2011_134; Yamane A, 2011, NAT IMMUNOL, V12, P62, DOI 10.1038/ni.1964; Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730; Yeaman GR, 1997, J LEUKOCYTE BIOL, V61, P427, DOI 10.1002/jlb.61.4.427; Yeaman GR, 2001, IMMUNOLOGY, V102, P434, DOI 10.1046/j.1365-2567.2001.01199.x; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353; Zhou TQ, 2010, SCIENCE, V329, P811, DOI 10.1126/science.1192819; Zhou ZC, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002100; Zhu TF, 1996, J VIROL, V70, P3098, DOI 10.1128/JVI.70.5.3098-3107.1996; Zimmermann P, 2018, VACCINE, V36, P4433, DOI 10.1016/j.vaccine.2018.04.066; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	318	1	1	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	SEP	2021	9	9							1001	10.3390/vaccines9091001			32	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UZ3NU	34579238	Green Published, gold			2022-04-29	WOS:000702115900001
J	Acheampong, T; Akorsikumah, EA; Osae-Kwapong, J; Khalid, M; Appiah, A; Amuasi, JH				Acheampong, Theophilus; Akorsikumah, Eli A.; Osae-Kwapong, John; Khalid, Musah; Appiah, Alfred; Amuasi, John H.			Examining Vaccine Hesitancy in Sub-Saharan Africa: A Survey of the Knowledge and Attitudes among Adults to Receive COVID-19 Vaccines in Ghana	VACCINES			English	Article						COVID-19; public health; vaccine hesitancy; willingness; attitude; Ghana; Sub-Saharan Africa	HERD-IMMUNITY; SEROPREVALENCE; ANTIBODIES	The impact of COVID-19 vaccination programmes on disease transmission, morbidity and mortality relies heavily on the population's willingness to accept the vaccine. We explore Ghanaian adult citizens' vaccine hesitancy attitudes and identify the likelihood of participation or non-participation in the government's effort to get citizens vaccinated. A fully anonymised cross-sectional online survey of 2345 adult Ghanaians was conducted from 23 to 28 February 2021. Differences in intentions regarding COVID-19 vaccination were explored using Pearson Chi-square tests. Additionally, multinomial logistic regression was used to analyse the factors associated with willingness to receive vaccines. Responses were weighted using the iterative proportional fitting technique to generate a representative sample. About half (51%) of mostly urban adult Ghanaians over 15 years are likely to take the COVID-19 vaccine if made generally available. Almost a fifth (21%) of the respondents were unlikely to take the vaccine, while another 28% were undecided. Additionally, we find differences in vaccine hesitancy among some socio-demographic characteristics such as age, gender, and primary sources of information. Attaining the proverbial 63% to 70% herd immunity threshold in Ghana is only possible if the preventive vaccination programmes are combined with an enhanced and coordinated public education campaign. Such a campaign should focus on promoting the individual and population-level benefits of vaccination and pre-emptive efforts towards addressing misinformation about vaccines.	[Acheampong, Theophilus; Osae-Kwapong, John; Khalid, Musah; Appiah, Alfred] iRIS Res Consortium, 6 Ashur Suites, North Legon, Accra, Ghana; [Akorsikumah, Eli A.] Univ Dev Studies, Dept Agr & Food Econ, POB 1350, Nyankpala Tamale, Ghana; [Amuasi, John H.] Kwame Nkrumah Univ Sci & Technol KNUST, Sch Publ Hlth, Dept Global Hlth, Kumasi 00233, Ghana; [Amuasi, John H.] Kumasi Ctr Collaborat Res Trop Med KCCR, Kumasi, Ghana; [Amuasi, John H.] Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany		Acheampong, T (通讯作者)，iRIS Res Consortium, 6 Ashur Suites, North Legon, Accra, Ghana.	theo.acheampong@gmail.com; akorsikumah@gmail.com; josaekwapong@gmail.com; khalid.musah@live.com; alfredappiah17@gmail.com; amuasi@kccr.de	Acheampong, Theophilus/AAF-7984-2022	Acheampong, Theophilus/0000-0002-8026-9071; Amuasi, John/0000-0002-8640-2662; Akorsikumah, Eli Andreaws/0000-0002-3871-7184			Abdelhafiz AS, 2020, J COMMUN HEALTH, V45, P881, DOI 10.1007/s10900-020-00827-7; Abedin M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250495; Afolabi AA, 2021, PAN AFR MED J, V38, DOI 10.11604/pamj.2021.38.3.27401; Agyekum MW, 2021, ADV PUBLIC HLTH, V2021, DOI 10.1155/2021/9998176; Ahmad H., 2017, SELANGOR BUSINESS RE, V2, P20; Allcott H, 2019, RES POLITICS, V6, DOI 10.1177/2053168019848554; Amuasi J.H., 2021, DOES DATA TELL TRUE, DOI [10.1101/2021.05.02.21256473, DOI 10.1101/2021.05.02.21256473]; Apuke OD, 2021, TELEMAT INFORM, V56, DOI 10.1016/j.tele.2020.101475; Aschwanden C, 2021, NATURE, V591, P520, DOI 10.1038/d41586-021-00728-2; BBC,, 2021, BBC; Bloom DE, 2011, ADV EXP MED BIOL, V697, P1, DOI 10.1007/978-1-4419-7185-2_1; Carrieri V, 2019, HEALTH ECON, V28, P1377, DOI 10.1002/hec.3937; CDC, 2020, COVID 19 YOUR HLTH; Cerda AA, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.626852; Chen MS, 2021, HUM VACC IMMUNOTHER, V17, P2279, DOI 10.1080/21645515.2020.1853449; Chou WYS, 2018, JAMA-J AM MED ASSOC, V320, P2417, DOI 10.1001/jama.2018.16865; Chow MYK, 2017, AUST FAM PHYSICIAN, V46, P145; Colbourn T, 2020, LANCET PUBLIC HEALTH, V5, pE236, DOI 10.1016/S2468-2667(20)30072-4; Cordina M, 2021, PHARM PRACT-GRANADA, V19, DOI [10.18549/pharmpract.2021.1.2317, 10.18549/PharmPract.2021.1.2317]; D'-Souza G., 2021, WHAT IS HERD IMMUNIT; Dontoh E, 2021, GHANA GETS 2 BATCH A; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dube E, 2020, EXPERT REV VACCINES, V19, P899, DOI 10.1080/14760584.2020.1825944; Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Dzinamarira T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030250; Edwards B, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248892; Fisher D, 2020, LANCET, V396, P653, DOI 10.1016/S0140-6736(20)31601-9; Gagneux-Brunon A, 2021, J HOSP INFECT, V108, P168, DOI [10.1016/j.jhin.2020.11.0200195-6701, 10.1016/j.jhin.2020.11.020]; Gaythorpe K.A., 2021, CAN PUBLIC HLTH IMPA, DOI [10.1101/2021.01.08.21249378, DOI 10.1101/2021.01.08.21249378]; George J.A., 2021, SENTINEL SEROPREVALE, DOI [10.1101/2021.04.27.21256099, DOI 10.1101/2021.04.27.21256099]; Ghana Health Service, 2021, COVID 19 UPD; Ghana Statistical Service, 2020, PROJ POP AG SEX 260; Ghebreyesus T.A, 2020, DIR GEN OP REM MED B; Greene W. H., 2003, ECONOMETRIC ANAL, V5th; Hansen PR, 2021, J BUS ECON STAT, V39, P259, DOI 10.1080/07350015.2019.1623045; Hartley DM, 2020, JAMA-J AM MED ASSOC, V323, P1908, DOI 10.1001/jama.2020.5910; He ZY, 2021, LANCET, V397, P1075, DOI 10.1016/S0140-6736(21)00238-5; Heidarzadeh A, 2020, SEROPREVALENCE COVID, DOI [10.1101/2020.04.26.20079244, DOI 10.1101/2020.04.26.20079244]; Inglehart R, 2000, INT POLIT SCI REV, V21, P441, DOI 10.1177/0192512100214007; Jennings W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060593; Johnson T.P, 2014, WILEY STATSREF STAT, DOI 10.1002/9781118445112.stat05720; Kasiuleviius V., 2006, GERONTOLOGIJA, V7, P225; Kemp S, 2021, DIGITAL GHANA ALL ST; Kennedy C, 2018, DIFFERENT WEIGHTING; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Kolenikov S, 2014, STATA J, V14, P22, DOI 10.1177/1536867X1401400104; Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037; Latkin CA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246970; Latkin CA, 2021, SOC SCI MED, V270, DOI 10.1016/j.socscimed.2021.113684; Le XTT, 2021, TROP MED INT HEALTH, V26, P228, DOI 10.1111/tmi.13515; MacDonald NE, 2018, HUM VACC IMMUNOTHER, V14, P218, DOI 10.1080/21645515.2017.1394533; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; McNeil D.G., 2020, NEW YORK TIMES; Meleo-Erwin Z, 2017, HUM VACC IMMUNOTHER, V13, P1895, DOI 10.1080/21645515.2017.1321182; ModernGhana, 2021, MODERNGHANA; Muhammad A.T., 2020, SEROPREVALENCE SARS, DOI [10.1101/2020.08.04.20168112, DOI 10.1101/2020.08.04.20168112]; Mulenga LB, 2021, LANCET GLOB HEALTH, V9, pE773, DOI 10.1016/S2214-109X(21)00053-X; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130; Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6; Poustchi Hossein, 2021, Lancet Infect Dis, V21, P473, DOI 10.1016/S1473-3099(20)30858-6; Preaud E, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-813; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Quakyi N.K., 2021, GHANAS COVID 19 VACC; Quakyi NK, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-005569; Rampersad G, 2020, J INF TECHNOL POLITI, V17, P1, DOI 10.1080/19331681.2019.1686676; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Reuters,, 2021, REUTERS; Rufai N.A, 2021, BOTCHED EBOLA VACCIN; Salathe M, 2008, J R SOC INTERFACE, V5, P1505, DOI 10.1098/rsif.2008.0271; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Scally G, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1932; Schuchat A, 2020, MMWR-MORBID MORTAL W, V69, P551, DOI 10.15585/mmwr.mm6918e2; Schwarzinger M, 2021, LANCET PUBLIC HEALTH, V6, pE210, DOI 10.1016/S2468-2667(21)00012-8; Sevencan S, 2021, GHANA RECEIVER I0000; Tabari P, 2020, IRAN J MED SCI, V45, P157, DOI [10.30476/IJMS.2020.85810.1537, 10.30476/ijms.2020.85810.1537]; Thayer WM, 2021, HEALTH POLICY PLANN, V36, P620, DOI 10.1093/heapol/czab027; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; UK Government, 2021, COVID 19 SARS COV 2; Uyoga S, 2021, SCIENCE, V371, P79, DOI 10.1126/science.abe1916; WHO, 2021, COVID 19 VACC DOS SH; Wiysonge CS, 2022, HUM VACC IMMUNOTHER, V18, P1, DOI 10.1080/21645515.2021.1893062; WOOLSON RF, 1986, BIOMETRICS, V42, P927, DOI 10.2307/2530706; World Bank, 2021, GNI PER CAP ATL METH; World Health Organization, 2020, STAT 2 M INT HLTH RE; World Health Organization, 2014, REP SAGE WORK GROUP; Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018	88	13	13	1	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							814	10.3390/vaccines9080814			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	UH8OH	34451939	Green Published, gold			2022-04-29	WOS:000690182300001
J	Castaneda, S; Patino, LH; Munoz, M; Ballesteros, N; Guerrero-Araya, E; Paredes-Sabja, D; Florez, C; Gomez, S; Ramirez-Santana, C; Salguero, G; Gallo, JE; Paniz-Mondolfi, AE; Ramirez, JD				Castaneda, Sergio; Patino, Luz H.; Munoz, Marina; Ballesteros, Nathalia; Guerrero-Araya, Enzo; Paredes-Sabja, Daniel; Florez, Carolina; Gomez, Sergio; Ramirez-Santana, Carolina; Salguero, Gustavo; Gallo, Juan E.; Paniz-Mondolfi, Alberto E.; Ramirez, Juan David			Evolution and Epidemic Spread of SARS-CoV-2 in Colombia: A Year into the Pandemic	VACCINES			English	Article						SARS-CoV-2; epidemic models; genomic surveillance; Colombia	COVID-19	Current efforts to understand the epidemiology, transmission dynamics and emergence of novel SARS-CoV-2 variants worldwide has enabled the scientific community to generate critical information aimed at implementing disease surveillance and control measures, as well as to reduce the social, economic and health impact of the pandemic. Herein, we applied an epidemic model coupled with genomic analysis to assess the SARS-CoV-2 transmission dynamics in Colombia. This epidemic model allowed to identify the geographical distribution, Rt dynamics and predict the course of the pandemic considering current implementation of countermeasures. The analysis of the incidence rate per 100,000 inhabitants carried out across different regions of Colombia allowed visualizing the changes in the geographic distribution of cases. The cumulative incidence during the timeframe March 2020 to March 2021 revealed that Bogota (8063.0), Quindio (5482.71), Amazonas (5055.68), Antioquia (4922.35) and Tolima (4724.41) were the departments with the highest incidence rate. The highest median Rt during the first period evaluated was 2.13 and 1.09 in the second period; with this model, we identified improving opportunities in health decision making related to controlling the pandemic, diagnostic testing capacity, case registration and reporting, among others. Genomic analysis revealed 52 circulating SARS-CoV-2 lineages in Colombia detected from 774 genomes sequenced throughout the first year of the pandemic. The genomes grouped into four main clusters and exhibited 19 polymorphisms. Our results provide essential information on the spread of the pandemic countrywide despite implementation of early containment measures. In addition, we aim to provide deeper phylogenetic insights to better understand the evolution of SARS-CoV-2 in light of the latent emergence of novel variants and how these may potentially influence transmissibility and infectivity.	[Castaneda, Sergio; Patino, Luz H.; Munoz, Marina; Ballesteros, Nathalia; Ramirez, Juan David] Univ Rosario, Fac Ciencias Nat, Ctr Invest Microbiol & Biotecnol UR CIMBIUR, Bogota 111221, Colombia; [Munoz, Marina; Guerrero-Araya, Enzo; Paredes-Sabja, Daniel] Millennium Nucleus Biol Intestinal Microbiota, Millennium Sci Initiat Program, ANID, Santiago 7510689, Chile; [Guerrero-Araya, Enzo] Univ Andres Bello, Fac Ciencias Vida, Microbiota Host Interact & Clostridia Res Grp, Santiago 7510689, Chile; [Paredes-Sabja, Daniel] Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; [Florez, Carolina; Gomez, Sergio] Inst Nacl Salud, Bogota 111321, Colombia; [Ramirez-Santana, Carolina] Univ Rosario, Escuela Med & Ciencias Salud, Ctr Estudio Enfermedades Autoinmunes CREA, Bogota 111221, Colombia; [Salguero, Gustavo] Inst Dist Ciencia Biotecnol & Innovac Salud IDCBI, Bogota 111611, Colombia; [Gallo, Juan E.] Univ CES, Genoma Ces Biotechnol, Medellin 050021, Colombia; [Paniz-Mondolfi, Alberto E.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA		Ramirez, JD (通讯作者)，Univ Rosario, Fac Ciencias Nat, Ctr Invest Microbiol & Biotecnol UR CIMBIUR, Bogota 111221, Colombia.	sergio.castaneda@urosario.edu.co; luzh.patino@urosario.edu.co; claudia.munoz@urosario.edu.co; nathalia.ballesteros@urosario.edu.co; e.guerreroaraya@uandresbello.edu; dparedes-sabja@bio.tamu.edu; aflorez@ins.gov.co; sgomez@ins.gov.co; heily.ramirez@urosario.edu.co; gsalguero@idcbis.org.co; jegallo@ces.edu.co; Alberto.Paniz-mondolfi@mountsinai.org; juand.ramirez@urosario.edu.co	; Ramirez, Juan David/F-3524-2016	Paniz-Mondolfi, Alberto E./0000-0003-1259-1736; Ramirez, Juan David/0000-0002-1344-9312; Munoz, Marina/0000-0002-4216-6928	University of Glasgow; Scottish Funding Council; Global Challenges Research Fund (GCRF) [EP/T003782/1]; GCRF Research Network [EP/T003782/1]; Universidad del Rosario; EPSRCUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/T003782/1] Funding Source: UKRI	This work was supported by the University of Glasgow, Scottish Funding Council and the Global Challenges Research Fund (GCRF) and GCRF Research Network EP/T003782/1 (JDR and APM). This project was funded by the Universidad del Rosario in the framework of its strategic plan RUTA2025. Thanks to President and the University council for leading the strategic projects. (JDR).	Ahmed F, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5446-1; Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5; Brauner J. M., 2020, EFFECTIVENESS 8 NONP, DOI [10.1101/2020.05.28.20116129, DOI 10.1101/2020.05.28.20116129]; Burki T, 2020, LANCET INFECT DIS, V20, P547, DOI 10.1016/S1473-3099(20)30303-0; Caicedo-Ochoa Y, 2020, INT J INFECT DIS, V95, P316, DOI 10.1016/j.ijid.2020.04.069; Cheng HY, 2020, JAMA INTERN MED, V180, P1156, DOI 10.1001/jamainternmed.2020.2020; Contreras S, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.556689; Cori A, 2013, AM J EPIDEMIOL, V178, P1505, DOI 10.1093/aje/kwt133; Ramirez JD, 2021, J MED VIROL, V93, P1158, DOI 10.1002/jmv.26393; Ramirez JD, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9070580; De la Hoz-Restrepo F, 2020, INT J INFECT DIS, V99, P522, DOI 10.1016/j.ijid.2020.08.017; Dinnes J, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013705; Dreher N, 2021, AM J MED SCI, V361, P575, DOI 10.1016/j.amjms.2021.01.007; Ebrahim S, 2020, J MED INTERNET RES, V22, DOI 10.2196/24614; Faria NR, GENOMIC CHARACTERISA; de Magalhaes JF, 2020, TRAVEL MED INFECT DI, V38, DOI 10.1016/j.tmaid.2020.101884; Flaxman S, 2020, NATURE, V584, P257, DOI 10.1038/s41586-020-2405-7; Glass DH, 2020, MATH BIOSCI, V330, DOI 10.1016/j.mbs.2020.108472; Gomez J, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245787; Gomez-Rios D, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101699; Gostic KM, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1008409; Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407; Hellewell J, 2020, LANCET GLOB HEALTH, V8, pE488, DOI 10.1016/S2214-109X(20)30074-7; Jaja IF, 2020, EMERG MICROBES INFEC, V9, P1077, DOI 10.1080/22221751.2020.1769501; Kennedy DM, 2020, J CLIN VIROL, V128, DOI [10.1016/j.jcv.2020.104440, DOI 10.1016/J.JCV.2020.104440]; Martinez-Valle A, 2021, J PUBLIC HEALTH POL, V42, P27, DOI 10.1057/s41271-020-00269-4; Munoz M, 2021, INT J INFECT DIS, V105, P329, DOI 10.1016/j.ijid.2021.02.073; Nishiura H, 2020, INT J INFECT DIS, V93, P284, DOI 10.1016/j.ijid.2020.02.060; Okonechnikov K, 2012, BIOINFORMATICS, V28, P1166, DOI 10.1093/bioinformatics/bts091; Ortiz-Prado E, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0008958; Page AJ, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000056; Paniz-Mondolfi A, 2020, INFECT GENET EVOL, V86, DOI 10.1016/j.meegid.2020.104616; Ramirez JD, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008686; Rockett RJ, 2020, NAT MED, V26, DOI [10.1038/s41591-020-1000-7., 10.1038/s41591-020-1000-7]; Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101613; Rojas J.H., 2020, MATH MODELING TRANSM, DOI 10.1101/2020.05.06.20093526; Rojas-Gallardo D.M., 2020, MOL EPIDEMIOLOGY COV, DOI [10.1101/2020.05.23.20111443, DOI 10.1101/2020.05.23.20111443]; RStudio Team, RSTUDIO INT DEV R RS; Systrom K., GITHUB REPOSITORY; Taylor L, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3575; Teheran AA, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-042122; Thompson RN, 2019, EPIDEMICS-NETH, V29, DOI 10.1016/j.epidem.2019.100356; Huynh TLD, 2020, SAFETY SCI, V130, DOI 10.1016/j.ssci.2020.104872; Toro-Londono MA, 2019, PEERJ, V7, DOI 10.7717/peerj.6200; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Vial MR, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05665-5; World Health Organization WHO, WHO COR DIS COVID 19; Xie KF, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17176256; Xu B, 2020, SCI DATA, V7, DOI 10.1038/s41597-020-0448-0; Zhang JJ, 2020, LANCET INFECT DIS, V20, P793, DOI 10.1016/S1473-3099(20)30230-9; Zhang RH, 2020, ACTA VIROL, V64, P496, DOI 10.4149/av_2020_403; Zhao SL, 2020, QUANT BIOL, V8, P11, DOI 10.1007/s40484-020-0199-0	52	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							837	10.3390/vaccines9080837			18	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH3BP	34451962	gold, Green Published			2022-04-29	WOS:000689811300001
J	Kromer, C; Wellmann, P; Siemer, R; Klein, S; Mohr, J; Pinter, A; Wilsmann-Theis, D; Mossner, R				Kromer, Christian; Wellmann, Phoebe; Siemer, Ralf; Klein, Selina; Mohr, Johannes; Pinter, Andreas; Wilsmann-Theis, Dagmar; Mossner, Rotraut			Influenza Vaccination in Psoriatic Patients-Epidemiology and Patient Perceptions: A German Multicenter Study (Vac-Pso)	VACCINES			English	Article						psoriasis; atopic dermatitis; influenza; vaccination; pneumonia	RISK	The risk of developing severe complications from an influenza virus infection is increased in patients with chronic inflammatory diseases such as psoriasis (PsO) and atopic dermatitis (AD). However, low influenza vaccination rates have been reported. The aim of this study was to determine vaccination rates in PsO compared to AD patients and explore patient perceptions of vaccination. A multicenter cross-sectional study was performed in 327 and 98 adult patients with PsO and AD, respectively. Data on vaccination, patient and disease characteristics, comorbidity, and patient perceptions was collected with a questionnaire. Medical records and vaccination certificates were reviewed. A total of 49.8% of PsO and 32.7% of AD patients were vaccinated at some point, while in season 2018/2019, 30.9% and 13.3% received an influenza vaccination, respectively. There were 96.6% and 77.6% of PsO and AD patients who had an indication for influenza vaccination due to age, immunosuppressive therapy, comorbidity, occupation, and/or pregnancy. Multivariate regression analysis revealed higher age (p < 0.001) and a history of bronchitis (p = 0.023) as significant predictors of influenza vaccination in PsO patients. Considering that most patients had an indication for influenza vaccination, the rate of vaccinated patients was inadequately low.	[Kromer, Christian; Mohr, Johannes; Mossner, Rotraut] Univ Med Ctr Gottingen, Dept Dermatol, D-37075 Gottingen, Germany; [Wellmann, Phoebe] Univ Gottingen, Fac Med, D-37073 Gottingen, Germany; [Siemer, Ralf] Univ Gottingen, Fac Math & Comp Sci, D-37073 Gottingen, Germany; [Klein, Selina; Wilsmann-Theis, Dagmar] Univ Bonn, Dept Dermatol & Allergy, D-53127 Bonn, Germany; [Pinter, Andreas] Goethe Univ Frankfurt, Dept Dermatol Venereol & Allergol, D-60590 Frankfurt, Germany		Mossner, R (通讯作者)，Univ Med Ctr Gottingen, Dept Dermatol, D-37075 Gottingen, Germany.	christian.kromer@med.uni-goettingen.de; phoebe.wellmann@stud.uni-goettingen.de; ralf.siemer@stud.uni-goettingen.de; Selina.klein@ukbonn.de; johannes.mohr@med.uni-goettingen.de; andreas.pinter@kgu.de; dagmar.wilsmann-theis@ukbonn.de; rmoessn@gwdg.de		Pinter, Andreas/0000-0002-1330-1502	Novartis Pharma	This research was partially funded by a research grant from Novartis Pharma. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.	Aberumand B, 2020, INT J RHEUM DIS, V23, P1526, DOI 10.1111/1756-185X.13971; [Anonymous], 2013, Kidney Int Suppl (2011), V3, P19; [Anonymous], 2019, WKLY EPIDEMIOL REC, V80, P277; [Anonymous], 2018, EPIDEMIOL B, V34, P355, DOI [10.17886/EpiBull-2018-042.5, DOI 10.17886/EPIBULL-2018-042.5]; Boehncke WH, 2015, LANCET, V386, P983, DOI 10.1016/S0140-6736(14)61909-7; Boucher VG, 2021, CLIN RHEUMATOL, V40, P477, DOI 10.1007/s10067-020-05059-7; Coleman BL, 2018, INFLUENZA OTHER RESP, V12, P22, DOI 10.1111/irv.12504; Falkenhorst G., 2018, EPIDEMIOL B, V2, P19, DOI [10.17886/EpiBull-2018-002, DOI 10.17886/EPIBULL-2018-002]; Figueroa-Parra G, 2021, HUM VACC IMMUNOTHER, V17, P1420, DOI 10.1080/21645515.2020.1816108; Grohskopf LA, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6908a1; Gunes AT, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/258430; Kao LT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116077; Langenbruch A, 2021, J EUR ACAD DERMATOL, V35, P1536, DOI 10.1111/jdv.17220; Nast A, 2012, ARCH DERMATOL RES, V304, P87, DOI 10.1007/s00403-012-1214-8; Noe MH, 2019, J INVEST DERMATOL, V139, P473, DOI 10.1016/j.jid.2018.09.012; Poehling KA, 2013, PEDIATRICS, V131, P207, DOI 10.1542/peds.2012-1255; Poethko-Muller C, 2013, BUNDESGESUNDHEITSBLA, V56, P845, DOI 10.1007/s00103-013-1693-6; Radtke MA, 2013, J DTSCH DERMATOL GES, V11, P837, DOI 10.1111/ddg.12010; Rahier JF, 2010, RHEUMATOLOGY, V49, P1815, DOI 10.1093/rheumatology/keq183; Rieck T., 2020, EPIDEMIOL B, V47, P3, DOI [10.25646/7658, DOI 10.25646/7658]; Rothberg MB, 2008, AM J MED, V121, P258, DOI 10.1016/j.amjmed.2007.10.040; Takeshita J, 2018, J INVEST DERMATOL, V138, P1726, DOI 10.1016/j.jid.2018.01.039; Wagner N, 2019, BUNDESGESUNDHEITSBLA, V62, P494, DOI 10.1007/s00103-019-02905-1; Wakkee M, 2011, J AM ACAD DERMATOL, V65, P1135, DOI 10.1016/j.jaad.2010.08.036; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053	25	1	1	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							843	10.3390/vaccines9080843			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7QA	34451968	Green Published, gold			2022-04-29	WOS:000690119200001
J	Schulze, C; Welker, A; Kuhn, A; Schwertz, R; Otto, B; Moraldo, L; Dentz, U; Arends, A; Welk, E; Wendorff, JJ; Koller, H; Kuss, D; Ries, M				Schulze, Christoph; Welker, Andreas; Kuehn, Anne; Schwertz, Rainer; Otto, Benjamin; Moraldo, Laura; Dentz, Udo; Arends, Albertus; Welk, Eckhard; Wendorff, Jean-Jacques; Koller, Hans; Kuss, Doreen; Ries, Markus			Public Health Leadership in a VUCA World Environment: Lessons Learned during the Regional Emergency Rollout of SARS-CoV-2 Vaccinations in Heidelberg, Germany, during the COVID-19 Pandemic	VACCINES			English	Review						SARS-CoV-2; COVID-19; disaster; disaster management; disaster response; resilience; pandemic; leadership; organizational psychology; learning organization; VUCA world; vaccination; vulnerable populations; public health		The purpose of this work is to share methods used and lessons learned during a comprehensive inter-institutional pandemic disaster response in Heidelberg, Germany, conveying experiences of the regional SARS-CoV-2 vaccination rollout campaign for up to 1,000,000 vaccines in the year 2020. In this volatile, uncertain, complex, and ambiguous (VUCA) environment, the following five strategic elements were pertinent for institutional arrangements so that specific contributions of the various project partners would be available fast without the necessity of extensive negotiations or information exchange: (1) robust mandate, (2) use of established networks, (3) fast onboarding and securing of commitment of project partners, (4) informed planning of supply capacity, and (5) securing the availability of critical items. Planning tools included analyses through a VUCA lens, analyses of stakeholders and their management, possible failures, and management of main risks including mitigation strategies. The method of the present analysis (VUCA factors combined with analyses of possible failures, and management of stakeholders and risks) can theoretically be adjusted to any public health care emergency anywhere across the globe. Lessons learned include ten tactical leadership priorities and ten major pitfalls.	[Schulze, Christoph; Welker, Andreas; Kuehn, Anne; Schwertz, Rainer; Otto, Benjamin; Moraldo, Laura; Kuss, Doreen] Publ Hlth Serv Rhein Neckar Dist & Heidelberg, D-69115 Heidelberg, Germany; [Otto, Benjamin; Arends, Albertus] Heidelberg Univ, Med Fac, D-69120 Heidelberg, Germany; [Dentz, Udo] Fire & Disaster Management Agcy Rhein Neckar Dist, D-68526 Ladenburg, Germany; [Welk, Eckhard; Ries, Markus] German Fed Armed Forces, CIMIC Dist Liaison Commands Heidelberg & Rhein Ne, Med Regiment 3, D-89160 Dornstadt, Germany; [Wendorff, Jean-Jacques] German Fed Armed Forces, CIMIC Dist Liaison Command Heidelberg, D-70374 Stuttgart, Germany; [Koller, Hans] Helmut Schmidt Univ, Univ German Fed Armed Forces Hamburg, Inst Technol & Innovat Management, D-22043 Hamburg, Germany; [Ries, Markus] Univ Hosp Heidelberg, Pediat Neurol & Metab Med, Ctr Pediat & Adolescent Med, D-69120 Heidelberg, Germany; [Ries, Markus] Heidelberg Univ, Med Fac, Ctr Virtual Patients, D-69120 Heidelberg, Germany		Ries, M (通讯作者)，Ctr Pediat & Adolescent Med, D-69120 Heidelberg, Germany.	c.schulze@rhein-neckar-kreis.de; awelker@icloud.com; a.kuehn@rhein-neckar-kreis.de; r.schwertz@rhein-neckar-kreis.de; b.otto2@rhein-neckar-kreis.de; l.moraldo@rhein-neckar-kreis.de; u.dentz@rhein-neckar-kreis.de; kontakt@praxis-arends.de; eckhard-welk@t-online.de; jjwendorff@web.de; koller@hsu-hh.de; d.kuss@rhein-neckar-kreis.de; markus.ries@uni-heidelberg.de	Ries, Markus/AAE-4934-2020	Ries, Markus/0000-0002-5054-5741	Open Access Publishing Fund of Ruprecht-Karls-Universitat Heidelberg	We acknowledge financial support by the Open Access Publishing Fund of Ruprecht-Karls-Universitat Heidelberg.	Alkhaldi Khaldoon H, 2017, Am J Disaster Med, V12, P107, DOI 10.5055/ajdm.2017.0265; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baran BE, 2021, ORGAN DYN, V50, DOI 10.1016/j.orgdyn.2020.100787; Bennett N, 2014, BUS HORIZONS, V57, P311, DOI 10.1016/j.bushor.2014.01.001; Brennenstuhl H, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-046359; Casey George W Jr, 2014, Fortune, V169, P75; Coase RH, 1937, ECONOMICA-NEW SER, V4, P386, DOI 10.1111/j.1468-0335.1937.tb00002.x; Creswell J.W., 2012, QUAL INQ, P76; Creswell J.W., 2012, QUAL INQ, P70; DONALDSON T, 1995, ACAD MANAGE REV, V20, P65, DOI 10.5465/AMR.1995.9503271992; European Medicines Agency, EMA REC 1 COVID 19 V; Garcia-Lopez J, 2021, BLOOD TRANSFUS-ITALY, V19, P158, DOI 10.2450/2021.0259-20; Johns Hopkins University, COVID 19 DASHB CTR S; Levey J, 2019, CLIN RADIOL, V74, P739, DOI 10.1016/j.crad.2019.06.026; Maini A, 2020, MED TEACH, V42, P1308, DOI 10.1080/0142159X.2020.1788713; Mink O.G., 1993, COMPREHENSIVE MANAGE, P440; Nicholson PJ, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5504; Olofsson Anna, 2019, RES RISK UNCERTAINTY; Onaca N, 2020, CLIN COLON RECT SURG, V33, P228, DOI 10.1055/s-0040-1709457; Partners in Health, OUR APPR PIHS 5 SS; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Ries M, 2020, J CLIN PHARMACOL, V60, P826, DOI 10.1002/jcph.1643; Ries M, 2019, DISASTER MED PUBLIC, V13, P958, DOI 10.1017/dmp.2019.24; Robert Koch Institut, NAT IMPFSTR COVID 19; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sturmberg JP, 2021, INT J HEALTH POLICY, V10, P277, DOI 10.34172/ijhpm.2020.45; Thomas Cliff, 2020, J Bus Contin Emer Plan, V14, P82; Till A, 2016, BRIT J HOSP MED, V77, P471, DOI 10.12968/hmed.2016.77.8.471; Varvasovszky Z, 2000, HEALTH POLICY PLANN, V15, P338, DOI 10.1093/heapol/15.3.338; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Williamson OE, 2010, AM ECON REV, V100, P673, DOI 10.1257/aer.100.3.673; Williamsson O.E., 1985, EC I CAPITALISM FIRM; Yoder-Wise PS, 2021, NURS EDUC PERSPECT, V42, P1, DOI 10.1097/01.NEP.0000000000000774	33	1	1	3	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							887	10.3390/vaccines9080887			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH7WE	34452012	Green Published, gold			2022-04-29	WOS:000690135200001
J	Shoeb, E; Badar, U; Venkataraman, S; Hefferon, K				Shoeb, Erum; Badar, Uzma; Venkataraman, Srividhya; Hefferon, Kathleen			Frontiers in Bioengineering and Biotechnology: Plant Nanoparticles for Anti-Cancer Therapy	VACCINES			English	Review						nanoparticles; plant virus-like particles; therapeutics; imaging; cancer	POTATO-VIRUS-X; TOBACCO-MOSAIC-VIRUS; VIRAL NANOPARTICLES; ENHANCED PERMEABILITY; PROTEIN NANOPARTICLES; MAGNETIC-RESONANCE; IN-VITRO; DELIVERY; RNA; PARTICLES	Naturally occurring viral nanomaterials have gained popularity owing to their biocompatible and biodegradable nature. Plant virus nanoparticles (VNPs) can be used as nanocarriers for a number of biomedical applications. Plant VNPs are inexpensive to produce, safe to administer and efficacious as treatments. The following review describes how plant virus architecture facilitates the use of VNPs for imaging and a variety of therapeutic applications, with particular emphasis on cancer. Examples of plant viruses which have been engineered to carry drugs and diagnostic agents for specific types of cancer are provided. The drug delivery system in response to the internal conditions is known as stimuli response, recently becoming more applicable using plant viruses based VNPs. The review concludes with a perspective of the future of plant VNPs and plant virus-like particles (VLPs) in cancer research and therapy.	[Shoeb, Erum; Badar, Uzma; Venkataraman, Srividhya; Hefferon, Kathleen] Univ Toronto, Dept Cell & Syst Biol, Toronto, ON M5S IA1, Canada; [Shoeb, Erum; Badar, Uzma] Univ Karachi, Dept Genet, Karachi 75270, Pakistan		Hefferon, K (通讯作者)，Univ Toronto, Dept Cell & Syst Biol, Toronto, ON M5S IA1, Canada.	erumsh@uok.edu.pk; uzmabadar.ca@gmail.com; byokem@hotmail.com; kathleen.hefferon@alumni.utoronto.ca		Shoeb, Erum/0000-0002-6252-3005			Adams MJ, 2004, ARCH VIROL, V149, P1045, DOI [10.1007/s00705-003-0304-0, 10.1007/s00705-004-0304-0]; Aljabali AAA, 2013, MOL PHARMACEUT, V10, P3, DOI 10.1021/mp3002057; Aljabali AAA, 2011, INTEGR BIOL-UK, V3, P119, DOI 10.1039/c0ib00056f; Alonso JM, 2013, TRENDS BIOTECHNOL, V31, P530, DOI 10.1016/j.tibtech.2013.05.013; Atabekov J, 2011, J GEN VIROL, V92, P453, DOI 10.1099/vir.0.024356-0; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Beatty PH, 2019, ADV DRUG DELIVER REV, V145, P130, DOI 10.1016/j.addr.2019.04.005; Bittner Alexander M, 2013, Subcell Biochem, V68, P667, DOI 10.1007/978-94-007-6552-8_22; Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014; Bruckman MA, 2016, J CONTROL RELEASE, V231, P103, DOI 10.1016/j.jconrel.2016.02.045; Bruckman MA, 2013, J MATER CHEM B, V1, P1482, DOI 10.1039/c3tb00461a; Brun MJ, 2017, J CONTROL RELEASE, V267, P80, DOI 10.1016/j.jconrel.2017.08.021; Campos EVR, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00685-4; Cao Y, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/674219; Cho CF, 2014, METHODS MOL BIOL, V1108, P211, DOI 10.1007/978-1-62703-751-8_16; Chroboczek J, 2014, ACTA BIOCHIM POL, V61, P531; Chung HJ, 2020, NEUROBIOL DIS, V136, DOI 10.1016/j.nbd.2019.104706; Comellas-Aragones M, 2007, NAT NANOTECHNOL, V2, P635, DOI 10.1038/nnano.2007.299; Culver JN, 2015, VIROLOGY, V479, P200, DOI 10.1016/j.virol.2015.03.008; Czapar AE, 2018, ADV SCI, V5, DOI 10.1002/advs.201700991; Czapar AE, 2016, ACS NANO, V10, P4119, DOI 10.1021/acsnano.5b07360; Destito G, 2009, CURR TOP MICROBIOL, V327, P95; DiMaio F, 2015, NAT STRUCT MOL BIOL, V22, P642, DOI 10.1038/nsmb.3054; Ficai D, 2015, NANOMATERIALS - TOXICITY AND RISK ASSESSMENT, P1; Finbloom JA, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8121007; Flynn CE, 2003, ACTA MATER, V51, P5867, DOI 10.1016/j.actamat.2003.08.031; Franke CE, 2018, MOL PHARMACEUT, V15, P2922, DOI 10.1021/acs.molpharmaceut.7b00466; Frolova OY, 2010, VIROLOGY, V407, P7, DOI 10.1016/j.virol.2010.08.005; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gamper C, 2019, CANCERS, V11, DOI 10.3390/cancers11101609; Ge P, 2011, P NATL ACAD SCI USA, V108, P9637, DOI 10.1073/pnas.1018104108; Hansen AE, 2015, ACS NANO, V9, P6985, DOI 10.1021/acsnano.5b01324; Hema M, 2019, RECENT DEVELOPMENTS IN APPLIED MICROBIOLOGY AND BIOCHEMISTRY, P61, DOI 10.1016/B978-0-12-816328-3.00006-4; Hu H, 2017, ACS NANO, V11, P9249, DOI 10.1021/acsnano.7b04472; Iyer AK, 2006, DRUG DISCOV TODAY, V11, P812, DOI 10.1016/j.drudis.2006.07.005; Jobsri J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118096; Kaiser CR, 2007, INT J NANOMED, V2, P715; Kernan KF, 2017, INT IMMUNOL, V29, P401, DOI 10.1093/intimm/dxx031; Kerstetter-Fogle A, 2019, CANCERS, V11, DOI 10.3390/cancers11040515; Key J, 2014, INT J NANOMED, V9, P711, DOI 10.2147/IJN.S53717; Koch C, 2016, BEILSTEIN J NANOTECH, V7, DOI 10.3762/bjnano.7.54; Koudelka KJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000417; Koyani CN, 2017, BIOCHEM PHARMACOL, V145, P64, DOI 10.1016/j.bcp.2017.08.021; Kumar S, 2009, VIROLOGY, V388, P185, DOI 10.1016/j.virol.2009.02.051; Kwon SJ, 2005, VIROLOGY, V334, P83, DOI 10.1016/j.virol.2005.01.018; Lam P, 2018, J MATER CHEM B, V6, P5888, DOI [10.1039/C8TB01191E, 10.1039/c8tb01191e]; Le DHT, 2017, NANOSCALE, V9, P2348, DOI 10.1039/c6nr09099k; Lebel C., 2017, NMR BIOMEDICINE; Li RT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069643; Li RT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024172; Liepold LO, 2005, PHYS BIOL, V2, pS166, DOI 10.1088/1478-3975/2/4/S11; Lin RD, 2018, NANOSCALE, V10, P16307, DOI 10.1039/c8nr04142c; Liu CK, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00012; Liu RL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060621; Liu XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep24567; Liu Z, 2012, CHEM SOC REV, V41, P6178, DOI 10.1039/c2cs35108k; Lizotte PH, 2016, NAT NANOTECHNOL, V11, P295, DOI [10.1038/nnano.2015.292, 10.1038/NNANO.2015.292]; Ma YY, 2017, CONTRAST MEDIA MOL I, DOI 10.1155/2017/1026270; Masarapu H, 2017, BIOMACROMOLECULES, V18, P4141, DOI 10.1021/acs.biomac.7b01196; Massumi Hossain, 2014, VirusDisease, V25, P338, DOI 10.1007/s13337-014-0222-z; Medeiros SD, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-99; Medintz IL, 2008, INT J NANOMED, V3, P151; Miermont A, 2008, CHEM-EUR J, V14, P4939, DOI 10.1002/chem.200800203; Narayanan KB, 2017, ADV COLLOID INTERFAC, V248, P1, DOI 10.1016/j.cis.2017.08.005; Narayanan KB, 2017, RES CHEM INTERMEDIAT, V43, P5665, DOI 10.1007/s11164-017-2954-z; Nemykh MA, 2008, VIROLOGY, V373, P61, DOI 10.1016/j.virol.2007.11.024; Niehl A, 2016, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.01244; Nikitin N, 2016, FEBS LETT, V590, P1543, DOI 10.1002/1873-3468.12184; Nikitin N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142415; Nikitin N, 2013, MICROSC MICROANAL, V19, P808, DOI 10.1017/S1431927613000597; Park MR, 2008, VIROLOGY, V378, P133, DOI 10.1016/j.virol.2008.05.004; Parker L, 2002, VIROLOGY, V300, P291, DOI 10.1006/viro.2002.1483; Petrova EK, 2015, BIOCHIMIE, V115, P116, DOI 10.1016/j.biochi.2015.05.012; Pitek AS, 2016, BIOMATERIALS, V89, P89, DOI 10.1016/j.biomaterials.2016.02.032; Pokorski JK, 2011, J AM CHEM SOC, V133, P9242, DOI 10.1021/ja203286n; Pokorski JK, 2011, MOL PHARMACEUT, V8, P29, DOI 10.1021/mp100225y; Roder J, 2019, FRONT PLANT SCI, V10, DOI 10.3389/fpls.2019.00158; Roder J, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9328671; Rong JH, 2011, CURR OPIN COLLOID IN, V16, P441, DOI 10.1016/j.cocis.2011.09.001; Sanchez Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6812; Scholthof KBG, 2011, MOL PLANT PATHOL, V12, P938, DOI [10.1111/j.1364-3703.2011.00752.x, 10.1111/J.1364-3703.2011.00752.X]; Shoeb E, 2019, FUTUR SCI OA, V5, DOI 10.2144/fsoa-2019-0001; Shukla AK, 2019, CELL REP, V26, P131, DOI 10.1016/j.celrep.2018.12.025; Shukla S, 2020, BIOMATER SCI-UK, V8, P5489, DOI 10.1039/d0bm01219j; Shukla S, 2020, BIOMATER SCI-UK, V8, P3935, DOI 10.1039/d0bm00683a; Shukla S, 2013, MOL PHARMACEUT, V10, P33, DOI 10.1021/mp300240m; Singh P, 2007, J CONTROL RELEASE, V120, P41, DOI 10.1016/j.jconrel.2007.04.003; Sokullu E, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11050211; Steinmetz NF, 2007, ORG BIOMOL CHEM, V5, P2891, DOI 10.1039/b708175h; Steinmetz NF, 2010, NANOMED-NANOTECHNOL, V6, P634, DOI 10.1016/j.nano.2010.04.005; Steinmetz NF, 2009, SMALL, V5, P813, DOI 10.1002/smll.200801348; Steinmetz NF, 2009, BIOMACROMOLECULES, V10, P784, DOI 10.1021/bm8012742; Strable E, 2009, CURR TOP MICROBIOL, V327, P1; Sun J, 2007, P NATL ACAD SCI USA, V104, P1354, DOI 10.1073/pnas.0610542104; Tian Y, 2018, NANO LETT, V18, P5453, DOI 10.1021/acs.nanolett.8b01805; Vernekar AA, 2018, J AM CHEM SOC, V140, P4279, DOI 10.1021/jacs.7b12697; Wang C, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801288; Wen AM, 2015, J MATER CHEM B, V3, P6037, DOI 10.1039/c5tb00879d; Wen AM, 2015, BIOCONJUGATE CHEM, V26, P51, DOI 10.1021/bc500524f; Wen J, 2015, CHEM COMMUN, V51, P11346, DOI 10.1039/c5cc02887f; Yildiz I, 2013, J CONTROL RELEASE, V172, P568, DOI 10.1016/j.jconrel.2013.04.023; Yin ZJ, 2012, BIOCONJUGATE CHEM, V23, P1694, DOI 10.1021/bc300244a; Zeng QB, 2013, BIOMATERIALS, V34, P4632, DOI 10.1016/j.biomaterials.2013.03.017; Zhou JC, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-18; Zhu L, 2013, INTEGR BIOL-UK, V5, P96, DOI 10.1039/c2ib20135f	105	0	0	12	14	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	AUG	2021	9	8							830	10.3390/vaccines9080830			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	UH6FL	34451955	gold, Green Published			2022-04-29	WOS:000690024100001
J	Abdelwahab, SF; Issa, UH; Ashour, HM				Abdelwahab, Sayed F.; Issa, Usama H.; Ashour, Hossam M.			A Novel Vaccine Selection Decision-Making Model (VSDMM) for COVID-19	VACCINES			English	Article						analytic hierarchy process; COVID-19; decision-making model; vaccines	COMBINED FUZZY AHP; MULTICRITERIA; CHOICE	Selecting a vaccine for fighting a pandemic is one of the serious issues in healthcare. Novel decision models for vaccine selection need to be developed. In this study, a novel vaccine selection decision-making model (VSDMM) was proposed and developed, based on the analytic hierarchy process (AHP) technique, which assesses many alternatives (vaccines) using multi-criteria to support decision making. To feed data to the VSDMM, six coronavirus disease-19 (COVID-19) vaccines were selected in a case study to highlight the applicability of the proposed model. Each vaccine was compared to the others with respect to six criteria and all criteria were compared to calculate the relative weights. The proposed criteria include (1) vaccine availability; (2) vaccine formula; (3) vaccine efficacy; (4) vaccine-related side effects; (5) cost savings, and (6) host-related factors. Using the selected criteria, experts responded to questions and currently available COVID-19 vaccines were ranked according to their weight in the model. A sensitivity analysis was introduced to assess the model robustness and the impacts of changing criteria weights on the results. The VSDMM is flexible in terms of its ability to accept more vaccine alternatives and/or more criteria. It could also be applied to other current or future pandemics/epidemics in the world. In conclusion, this is the first report to propose a VSDMM for selecting the most suitable vaccines in pandemic/epidemic situations or any other situations in which vaccine selection and usage may be deemed necessary.	[Abdelwahab, Sayed F.] Taif Univ, Coll Pharm, Dept Pharmaceut & Ind Pharm, At Taif 21944, Saudi Arabia; [Issa, Usama H.] Taif Univ, Coll Engn, Dept Civil Engn, At Taif 21944, Saudi Arabia; [Ashour, Hossam M.] Univ S Florida, Coll Arts & Sci, Dept Integrat Biol, St Petersburg, FL 33701 USA		Ashour, HM (通讯作者)，Univ S Florida, Coll Arts & Sci, Dept Integrat Biol, St Petersburg, FL 33701 USA.	s.fekry@tu.edu.sa; u.issa@tu.edu.sa; hossamking@mailcity.com	Abdelwahab, Sayed/P-1481-2016	Abdelwahab, Sayed/0000-0002-9636-7485; Issa, Usama Hamed/0000-0003-2972-5649	Taif University, Taif, Saudi Arabia [TURSP-2020/51]	We would like to acknowledge Taif University Researchers Supporting Project number (TURSP-2020/51), Taif University, Taif, Saudi Arabia.	Ahmed A., 2013, J CIV ENV RES, V3, P74; Amenta P, 2021, EUR J OPER RES, V288, P294, DOI 10.1016/j.ejor.2020.05.048; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bokemper SE, 2021, VACCINE, V39, P825, DOI 10.1016/j.vaccine.2020.12.048; Buyukozkan G, 2021, SOCIO-ECON PLAN SCI, V74, DOI 10.1016/j.seps.2020.100929; Buyukozkan G, 2012, EXPERT SYST APPL, V39, P2341, DOI 10.1016/j.eswa.2011.08.061; Buyukozkan G, 2011, EXPERT SYST APPL, V38, P9407, DOI 10.1016/j.eswa.2011.01.103; Dal-Re R, 2021, EUR J INTERN MED, V87, P104, DOI 10.1016/j.ejim.2021.01.030; El Mokrini A, 2016, IFAC PAPERSONLINE, V49, P114, DOI 10.1016/j.ifacol.2016.11.020; Foy BH, 2021, INT J INFECT DIS, V103, P431, DOI 10.1016/j.ijid.2020.12.075; Garrido A., 2021, INFORM MED UNLOCKED, V24, DOI [10.1016/j.imu.2021.100576, DOI 10.1016/J.IMU.2021.100576]; Hillerman T, 2017, J COMPUT SCI-NETH, V19, P97, DOI 10.1016/j.jocs.2017.02.007; Hung IFN, 2021, LANCET, V397, P854, DOI 10.1016/S0140-6736(21)00528-6; Issa UH, 2021, RISKS, V9, DOI 10.3390/risks9020038; Issa UH, 2020, STRUCTURES, V27, P361, DOI 10.1016/j.istruc.2020.05.049; Issa UH, 2019, J CIV ENG MANAG, V25, P100, DOI 10.3846/jcem.2019.7551; Khanmohammadi S, 2014, PROCEDIA COMPUT SCI, V36, P328, DOI 10.1016/j.procs.2014.09.101; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Logunov DY, 2020, LANCET, V396, P887, DOI 10.1016/S0140-6736(20)31866-3; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; McGhan WF, 2011, VALUE HEALTH, V14, pA148, DOI 10.1016/j.jval.2011.02.822; McPhedran R, 2021, ECON LETT, V200, DOI 10.1016/j.econlet.2021.109747; Moon J.S, 2015, INTEGR MED RES, V4, P118, DOI DOI 10.1016/J.IMR.2015.04.214; Orturk N, 2017, VALUE HEALTH, V20, pA698; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Presley A., 2006, MANAG RES NEWS, V29, P273, DOI [10.1108/01409170610674400, DOI 10.1108/01409170610674400]; Ruiz HS, 2020, ENERGY REP, V6, P3249, DOI 10.1016/j.egyr.2020.11.198; Saaty T.L., 1980, ANAL HIERARCHY PROCE; SAATY TL, 1986, MANAGE SCI, V32, P841, DOI 10.1287/mnsc.32.7.841; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Saivaew N, 2020, MATER TODAY-PROC, V26, P2265, DOI 10.1016/j.matpr.2020.02.491; Samanlioglu F, 2020, J HEALTHC ENG, V2020, DOI 10.1155/2020/8835258; Samanlioglu F, 2019, J HEALTHC ENG, V2019, DOI 10.1155/2019/9486070; Schoch-Spana M, 2021, VACCINE, V39, P6004, DOI 10.1016/j.vaccine.2020.10.059; Singh JA, 2021, LANCET INFECT DIS, V21, pE103, DOI 10.1016/S1473-3099(20)30923-3; Singh RK, 2007, ECOL INDIC, V7, P565, DOI 10.1016/j.ecolind.2006.06.004; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang F, 2021, J WATER PROCESS ENG, V40, DOI 10.1016/j.jwpe.2021.101948; Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008; Wang JR, 2010, EXPERT SYST APPL, V37, P8516, DOI 10.1016/j.eswa.2010.05.024	40	2	2	4	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							718	10.3390/vaccines9070718			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7IX	34358134	Green Published, gold			2022-04-29	WOS:000677081400001
J	Del Rosario, JMM; da Costa, KAS; Asbach, B; Ferrara, F; Ferrari, M; Wells, DA; Mann, GS; Ameh, VO; Sabeta, CT; Banyard, AC; Kinsley, R; Scott, SD; Wagner, R; Heeney, JL; Carnell, GW; Temperton, NJ				Del Rosario, Joanne Marie M.; da Costa, Kelly A. S.; Asbach, Benedikt; Ferrara, Francesca; Ferrari, Matteo; Wells, David A.; Mann, Gurdip Singh; Ameh, Veronica O.; Sabeta, Claude T.; Banyard, Ashley C.; Kinsley, Rebecca; Scott, Simon D.; Wagner, Ralf; Heeney, Jonathan L.; Carnell, George W.; Temperton, Nigel J.			Exploiting Pan Influenza A and Pan Influenza B Pseudotype Libraries for Efficient Vaccine Antigen Selection	VACCINES			English	Article						influenza; hemagglutinin; pseudotype; vaccine; immunogenicity; monoclonal anti-body; neutralization	HEMAGGLUTININ MEMBRANE GLYCOPROTEIN; PATHOGENIC AVIAN INFLUENZA; RECEPTOR-BINDING; GLOBAL MORTALITY; GENE DELIVERY; VIRUS; ANTIBODY; NEUTRALIZATION; H5N1; EVOLUTION	We developed an influenza hemagglutinin (HA) pseudotype library encompassing Influenza A subtypes HA1-18 and Influenza B subtypes (both lineages) to be employed in influenza pseudotype microneutralization (pMN) assays. The pMN is highly sensitive and specific for detecting virus-specific neutralizing antibodies against influenza viruses and can be used to assess antibody functionality in vitro. Here we show the production of these viral HA pseudotypes and their employment as substitutes for wildtype viruses in influenza neutralization assays. We demonstrate their utility in detecting serum responses to vaccination with the ability to evaluate cross-subtype neutralizing responses elicited by specific vaccinating antigens. Our findings may inform further preclinical studies involving immunization dosing regimens in mice and may help in the creation and selection of better antigens for vaccine design. These HA pseudotypes can be harnessed to meet strategic objectives that contribute to the strengthening of global influenza surveillance, expansion of seasonal influenza prevention and control policies, and strengthening pandemic preparedness and response.	[Del Rosario, Joanne Marie M.; da Costa, Kelly A. S.; Ferrara, Francesca; Mann, Gurdip Singh; Scott, Simon D.; Temperton, Nigel J.] Univ Greenwich & Kent Medway, Medway Sch Pharm, Viral Pseudotype Unit, Chatham ME4 413F, Kent, England; [Del Rosario, Joanne Marie M.] Univ Philippines Manila, Coll Arts & Sci, Dept Phys Sci & Math, Manila 1000, Philippines; [Del Rosario, Joanne Marie M.; Ferrari, Matteo; Wells, David A.; Kinsley, Rebecca; Heeney, Jonathan L.; Carnell, George W.; Temperton, Nigel J.] DIOSynVax, Cambridge CB3 0ES, England; [Asbach, Benedikt; Wagner, Ralf] Univ Regensburg, Inst Med Microbiol & Hyg, D-93053 Regensburg, Germany; [Ferrara, Francesca] St Jude Childrens Res Hosp, Vector Dev & Prod Lab, Memphis, TN 38105 USA; [Ferrari, Matteo; Wells, David A.; Kinsley, Rebecca; Heeney, Jonathan L.; Carnell, George W.] Univ Cambridge, Dept Vet Med, Cambridge CB3 0ES, England; [Ameh, Veronica O.] Fed Univ Agr Makurdi, Coll Vet Med, Dept Vet Publ Hlth & Prevent Med, PMB 2373, Makurdi, Bene State, Nigeria; [Ameh, Veronica O.; Sabeta, Claude T.] Univ Pretoria, Fac Vet Sci, Dept Vet Trop Dis, P Bag X04, ZA-0110 Onderstepoort, South Africa; [Sabeta, Claude T.] Agr Res Council Onderstepoort Vet Res, OIE Rabies Reference Lab, ZA-0110 Onderstepoort, South Africa; [Banyard, Ashley C.] Anim & Plant Hlth Agcy APHA, Dept Virol, Weybridge KT15 3NB, Surrey, England; [Wagner, Ralf] Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, D-93053 Regensburg, Germany		Temperton, NJ (通讯作者)，Univ Greenwich & Kent Medway, Medway Sch Pharm, Viral Pseudotype Unit, Chatham ME4 413F, Kent, England.; Temperton, NJ (通讯作者)，DIOSynVax, Cambridge CB3 0ES, England.	J.M.Del-Rosario@kent.ac.uk; k.da-costa@kent.ac.uk; Benedikt.Asbach@klinik.uni-regensburg.de; francescalerrara@stjude.org; matteo@diosvax.com; david@diosvax.com; g.s.mann@kent.ac.uk; amehodinya@gmail.com; SabetaC@arc.agric.za; ashley.banyard@apha.gov.uk; rebecca@diosvax.com; S.D.Scott@kent.ac.uk; ralf.wagner@klinik.uni-regensburg.de; jlh66@cam.ac.uk; gwc26@cam.ac.uk; n.temperton@kent.ac.uk	Carnell, George/AAB-4421-2022; Ferrara, Francesca/I-3686-2014; Temperton, Nigel/M-1164-2019; Banyard, Ashley C/C-7998-2011	Carnell, George/0000-0001-8875-0989; Ferrara, Francesca/0000-0002-4973-1520; Temperton, Nigel/0000-0002-7978-3815; Scott, Simon/0000-0002-8290-0461; Banyard, Ashley C/0000-0002-1286-9825; Del Rosario, Joanne Marie/0000-0002-2623-4628; Heeney, Jonathan/0000-0003-2702-1621; Asbach, Benedikt/0000-0003-1056-8591; da Costa, Kelly Andreia Sullivan/0000-0001-6352-3843; Ameh, Veronica Odinya/0000-0002-8737-6494; Ferrari, Matteo/0000-0002-4224-8835	Bill and Melinda Gates FoundationBill & Melinda Gates Foundation [G101404]; Innovate UKUK Research & Innovation (UKRI)Innovate UK; UK Research and Innovation (UKRI) [105078]; EC FETopen [899619]; Department of Science and Technology of South Africa [P10000029]; UK Department for the Environment, Food and Rural Affairs (Defra)Department for Environment, Food & Rural Affairs (DEFRA); Scottish government [SE2213]; Welsh government [SE2213]	N.J.T., K.A.S.d.C. and G.W.C. receive funding from the Bill and Melinda Gates Foundation: Grand Challenges Universal Influenza Vaccines Award: Ref: G101404. N.J.T. and J.M.M.D.R. receive funding from Innovate UK, UK Research and Innovation (UKRI) for the project: Digital Immune Optimized and Selected Pan-Influenza Vaccine Antigens (DIOS-PIVa) Award Ref: 105078. R.W. receives funding from EC FETopen (Virofight, Grant 899619). C.T.S. receives funding from the Department of Science and Technology of South Africa cost Centre P10000029. A.C.B. was part funded by the UK Department for the Environment, Food and Rural Affairs (Defra) and the devolved Scottish and Welsh governments under grant SE2213.	Agor JK, 2018, HUM VACC IMMUNOTHER, V14, P678, DOI 10.1080/21645515.2017.1423152; Alladi CSH, 2019, VIRAL IMMUNOL, V32, P230, DOI 10.1089/vim.2019.0010; Benton DJ, 2018, P NATL ACAD SCI USA, V115, P10112, DOI 10.1073/pnas.1810927115; Beran J, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-224; Bertram S, 2010, J VIROL, V84, P10016, DOI 10.1128/JVI.00239-10; BIZEBARD T, 1995, NATURE, V376, P92, DOI 10.1038/376092a0; Bodewes R, 2013, EMERG INFECT DIS, V19, P511, DOI 10.3201/eid1903.120965; BOSCH FX, 1981, VIROLOGY, V113, P725, DOI 10.1016/0042-6822(81)90201-4; Bottcher E, 2006, J VIROL, V80, P9896, DOI 10.1128/JVI.01118-06; Bottcher-Friebertshauser E., 2014, INFLUENZA PATHOGENES, P3; Bouvier NM, 2008, VACCINE, V26, pD49, DOI 10.1016/j.vaccine.2008.07.039; Carnell GW, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020100; Carnell GW, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00161; Cauldwell AV, 2014, J GEN VIROL, V95, P1193, DOI 10.1099/vir.0.062836-0; Chatziprodromidou IP, 2018, SYST REV-LONDON, V7, DOI 10.1186/s13643-018-0691-z; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; Cox RJ, 2013, HUM VACC IMMUNOTHER, V9, P405, DOI 10.4161/hv.22908; Cox RJ, 2002, SCAND J IMMUNOL, V55, P14, DOI 10.1046/j.1365-3083.2002.01015.x; Dalby AR, 2015, PEERJ, V3, DOI 10.7717/peerj.934; de Vries RP, 2010, VIROLOGY, V403, P17, DOI 10.1016/j.virol.2010.03.047; Del Rosario JMM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00627; Dreyfus C, 2012, SCIENCE, V337, P1343, DOI 10.1126/science.1222908; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Ekiert DC, 2012, NATURE, V489, P526, DOI 10.1038/nature11414; Estrada LD, 2019, J IMMUNOL, V202, P392, DOI 10.4049/jimmunol.1801054; Ferrara F, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.661379; Ferrara F, 2018, METHOD PROTOCOL, V1, DOI 10.3390/mps1010008; Ferrara Francesca, 2012, J Mol Genet Med, V7, P309; Gamblin SJ, 2010, J BIOL CHEM, V285, P28403, DOI 10.1074/jbc.R110.129809; Gao J, 2019, MBIO, V10, DOI 10.1128/mBio.00307-19; Garten W, 1999, TRENDS MICROBIOL, V7, P99, DOI 10.1016/S0966-842X(99)01460-2; Guo L, 2016, SCI REP-UK, V6, DOI 10.1038/srep22045; Guthmiller JJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abg4535; Han LF, 2019, COMPUT STRUCT BIOTEC, V17, P475, DOI 10.1016/j.csbj.2019.03.009; Hillaire MLB, 2011, J GEN VIROL, V92, P2339, DOI 10.1099/vir.0.033076-0; Hobbelen PHF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68623-w; HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610; Isoda N, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12121439; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Kanjilal S, 2019, LANCET RESP MED, V7, P922, DOI 10.1016/S2213-2600(19)30265-6; Kasson PM, 2009, PACIFIC SYMPOSIUM ON BIOCOMPUTING 2009, P492; Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324; Kirkpatrick E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28706-1; Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6; Krammer F, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0002-y; Krammer F, 2015, NAT REV DRUG DISCOV, V14, P167, DOI 10.1038/nrd4529; Lee PS, 2012, P NATL ACAD SCI USA, V109, P17040, DOI 10.1073/pnas.1212371109; Lee VJ, 2007, EMERG INFECT DIS, V13, P1052, DOI 10.3201/eid1307.061313; Lewis NS, 2021, EMERG MICROBES INFEC, V10, P148, DOI 10.1080/22221751.2021.1872355; Li YQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.638573; Long JS, 2019, NAT REV MICROBIOL, V17, P67, DOI 10.1038/s41579-018-0115-z; Manenti A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010043; Mather ST, 2014, J VIROL METHODS, V210, P51, DOI 10.1016/j.jviromet.2014.09.021; Miller M.A., 2010, P GAT COMP ENV WORKS, P1, DOI [10.1109/GCE.2010.5676129, DOI 10.1109/GCE.2010.5676129]; Nachbagauer R, 2021, NAT MED, V27, P106, DOI 10.1038/s41591-020-1118-7; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Osterhaus ADME, 2000, SCIENCE, V288, P1051, DOI 10.1126/science.288.5468.1051; Pepin S, 2013, VACCINE, V31, P5572, DOI 10.1016/j.vaccine.2013.08.069; Petrova VN, 2018, NAT REV MICROBIOL, V16, P47, DOI 10.1038/nrmicro.2017.118; Popova L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041895; Raab David, 2010, Syst Synth Biol, V4, P215, DOI 10.1007/s11693-010-9062-3; ROTA PA, 1990, VIROLOGY, V175, P59, DOI 10.1016/0042-6822(90)90186-U; Russell CJ, 2018, TRENDS MICROBIOL, V26, P841, DOI 10.1016/j.tim.2018.03.005; Russell RJ, 2004, VIROLOGY, V325, P287, DOI 10.1016/j.virol.2004.04.040; Sautto Giuseppe A, 2018, Immunohorizons, V2, P226, DOI 10.4049/immunohorizons.1800044; Shi JZ, 2017, CELL RES, V27, P1409, DOI 10.1038/cr.2017.129; Shih ACC, 2007, P NATL ACAD SCI USA, V104, P6283, DOI 10.1073/pnas.0701396104; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Smith GJD, 2014, INFLUENZA OTHER RESP, V8, P384, DOI 10.1111/irv.12230; Strohmeier S, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040199; Subbarao K, 2018, CELL RES, V28, P1, DOI 10.1038/cr.2017.154; Subbarao K, 2013, TRENDS MICROBIOL, V21, P350, DOI 10.1016/j.tim.2013.04.003; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Taubenberger JK, 2010, PUBLIC HEALTH REP, V125, P16, DOI 10.1177/00333549101250S305; Temperton NJ, 2007, INFLUENZA OTHER RESP, V1, P105, DOI 10.1111/j.1750-2659.2007.00016.x; Throsby M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003942; Tong SX, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003657; Toon K, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020217; Uyeki TM, 2019, CLIN INFECT DIS, V68, pE1, DOI 10.1093/cid/ciy866; Viboud C, 2016, J INFECT DIS, V213, P738, DOI 10.1093/infdis/jiv534; Vigeveno RM, 2020, J VIROL, V94, DOI 10.1128/JVI.00375-20; Wallerstrom Sofie, 2014, Infection Ecology & Epidemiology, V4, P23011, DOI 10.3402/iee.v4.23011; Wang W, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222436; Wang W, 2016, J INFECT DIS, V213, P403, DOI 10.1093/infdis/jiv407; *WHO, INFL VIR INF HUM; WHO, INFL SEAS; WHO, 2005, AV INFL ASS PAND THR; WHO Global Influenza Surveillance Network, MAN LAB DIAGN VIR SU; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wilson JR, 2015, VIROLOGY, V485, P252, DOI 10.1016/j.virol.2015.08.004; Wolff T, 2021, ENCY VIROL, P561; World Health Organization, 2017, EV INFL VACC EFF GUI; World Health Organization (WHO), 2019, GLOB INFL STRAT 2019; Yamayoshi S, 2017, EBIOMEDICINE, V17, P182, DOI 10.1016/j.ebiom.2017.03.007; Zhang Y, 2017, NUCLEIC ACIDS RES, V45, pD466, DOI 10.1093/nar/gkw857; Zhou L, 2018, EMERG INFECT DIS, V24, P397, DOI 10.3201/eid2402.171565; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	99	0	0	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							741	10.3390/vaccines9070741			26	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7AM	34358157	Green Accepted, Green Published, gold			2022-04-29	WOS:000677059500001
J	Lin, C; Mullen, J; Smith, D; Kotarba, M; Kaplan, SJ; Tu, P				Lin, Cheryl; Mullen, Jewel; Smith, Danielle; Kotarba, Michaela; Kaplan, Samantha J.; Tu, Pikuei			Healthcare Providers' Vaccine Perceptions, Hesitancy, and Recommendation to Patients: A Systematic Review	VACCINES			English	Review						immunization; vaccine hesitancy; healthcare personnel; communication; pandemic; communicable diseases; infectious diseases; epidemiology; health behavior; health knowledge; attitudes; practice	HUMAN-PAPILLOMAVIRUS VACCINATION; CROSS-SECTIONAL SURVEY; FRENCH GENERAL-PRACTITIONERS; PANDEMIC INFLUENZA A/H1N1; MENINGOCOCCAL B VACCINE; NATIONAL-SURVEY; HPV VACCINATION; LOW-INCOME; PEDIATRICIANS INTENTION; PHYSICIAN PERSPECTIVES	Despite vaccines' effectiveness in reducing the rate of preventable diseases, vaccine hesitancy has threatened public health and economies worldwide. Healthcare providers' (HCP) communications and behavior strongly influence patient receptivity and uptake. The goal of this review was to examine HCP vaccine perceptions, knowledge, and reservations and how these attitudes affect their recommendations and vaccination practices. Primary research studies published by 16 September 2020 were searched in PubMed, Web of Science, Embase, CINAHL, and PsycINFO. A 14-item scale was developed for survey study and risk of bias appraisal (SSRBA). In total, 96 papers from 34 countries were included, covering 17 vaccines (HPV and influenza vaccines the most studied). Recommendation was positively associated with provider knowledge and experience, beliefs about disease risk, and perceptions of vaccine safety, necessity, and efficacy. HCP vaccination attitudes and practices varied across specialties, vaccines, and countries; demographic impact was inconclusive. Barriers included anticipation of patient/parental concerns or refusal, lacking clear guidelines, time constraints, and cost. For HPV, vaccines were more often recommended to older, female adolescents and by physicians who discussed sexual health. HCPs are vital advocates for patients and the public, but studies indicated a prevalence of provider hesitancy pertaining to inadequate knowledge, low vaccine confidence, and suboptimal uptake themselves. Improving HCP knowledge and assuring their access to information they deem trustworthy are essential to supporting HCPs' role as "trusted messengers" to promote vaccine acceptance.	[Lin, Cheryl; Smith, Danielle; Kotarba, Michaela; Tu, Pikuei] Duke Univ, Policy & Org Management Program, Durham, NC 27705 USA; [Mullen, Jewel] Univ Texas Austin, Dell Med Sch, Austin, TX 78712 USA; [Kaplan, Samantha J.] Duke Univ, Med Ctr Lib & Arch, Durham, NC 27710 USA		Tu, P (通讯作者)，Duke Univ, Policy & Org Management Program, Durham, NC 27705 USA.	c.lin@duke.edu; jewel.mullen@austin.utexas.edu; danielle.c.smith@duke.edu; michaela.kotarba@duke.edu; samantha.kaplan@duke.edu; Pikuei.tu@duke.edu		Kotarba, Michaela/0000-0001-9934-8231			Agrinier N, 2017, CLIN MICROBIOL INFEC, V23, P311, DOI 10.1016/j.cmi.2016.08.019; Allison MA, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2488; Allison MA, 2013, ACAD PEDIATR, V13, P466, DOI 10.1016/j.acap.2013.03.006; Almughais ES, 2018, INFECT DRUG RESIST, V11, P2257, DOI 10.2147/IDR.S179642; Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089; [Anonymous], 2021, COV SYST REV SOFTW; Arnell TL, 2021, J CANCER EDUC, V36, P299, DOI 10.1007/s13187-019-01628-w; Barnack JL, 2010, WOMEN HEALTH ISS, V20, P28, DOI 10.1016/j.whi.2009.08.007; Bean SJ, 2013, QUAL HEALTH RES, V23, P1251, DOI 10.1177/1049732313501891; Best Evidence Topics (BestBETs), SURV CHECKL CRIT APP SURV CHECKL CRIT APP; Best Evidence Topics (BestBETs), QUAL CHECKL CRIT APP QUAL CHECKL CRIT APP; Betsch C, 2014, VACCINE, V32, P4478, DOI 10.1016/j.vaccine.2014.06.046; Bohm S, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4437-y; Bovier PA, 2005, SWISS MED WKLY, V135, P192; Brewer NT, 2007, PREV MED, V45, P107, DOI 10.1016/j.ypmed.2007.05.013; Bruno DM, 2014, VACCINE, V32, P4149, DOI 10.1016/j.vaccine.2014.05.058; Bynum SA, 2014, J ADOLESCENT HEALTH, V54, P190, DOI 10.1016/j.jadohealth.2013.08.006; Canon C, 2017, J CANCER EDUC, V32, P382, DOI 10.1007/s13187-016-0999-0; Ciardi F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050516; Ciftci F, 2018, HUM VACC IMMUNOTHER, V14, P111, DOI 10.1080/21645515.2017.1387703; Collange F, 2016, HUM VACC IMMUNOTHER, V12, P1282, DOI 10.1080/21645515.2015.1138024; Collange F, 2016, VACCINE, V34, P762, DOI 10.1016/j.vaccine.2015.12.054; Daley MF, 2006, PEDIATRICS, V118, P2280, DOI 10.1542/peds.2006-1946; Davis MM, 2003, J AM BOARD FAM PRACT, V16, P363, DOI 10.3122/jabfm.16.5.363; Deogaonkar R, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-878; Doherty M, 2016, VACCINE, V34, P6707, DOI 10.1016/j.vaccine.2016.10.025; Dombkowski KJ, 2008, AMBUL PEDIATR, V8, P294, DOI 10.1016/j.ambp.2008.06.005; Dube E, 2011, VACCINE, V29, P3177, DOI 10.1016/j.vaccine.2011.02.044; Dube E, 2019, J OBSTET GYNAECOL CA, V41, P479, DOI 10.1016/j.jogc.2018.09.007; Dube E, 2015, VACCINE, V33, P4191, DOI 10.1016/j.vaccine.2015.04.041; Dube E, 2011, HUM VACCINES, V7, P429, DOI 10.4161/hv.7.4.14141; Dube E, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-128; Dube Eve, 2010, BMC Res Notes, V3, P102, DOI 10.1186/1756-0500-3-102; Duval B, 2009, J ADV NURS, V65, P499, DOI 10.1111/j.1365-2648.2008.04900.x; Ehresmann KR, 2000, AM J PUBLIC HEALTH, V90, P1917, DOI 10.2105/AJPH.90.12.1917; Eilers R, 2014, PREV MED, V69, P224, DOI 10.1016/j.ypmed.2014.10.017; Esposito S, 2007, VACCINE, V25, P6437, DOI 10.1016/j.vaccine.2007.06.053; Esteves-Jaramillo A, 2009, ARCH MED RES, V40, P705, DOI 10.1016/j.arcmed.2010.01.004; Fagnan LJ, 2011, J RURAL HEALTH, V27, P385, DOI 10.1111/j.1748-0361.2010.00356.x; Farias AJ, 2017, PREV MED, V105, P219, DOI 10.1016/j.ypmed.2017.07.016; Feemster KA, 2008, J ADOLESCENT HEALTH, V43, P408, DOI 10.1016/j.jadohealth.2008.06.012; Ferrara P, 2018, MEDICINA-LITHUANIA, V54, DOI 10.3390/medicina54060100; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Flicoteaux R, 2014, VACCINE, V32, P2281, DOI 10.1016/j.vaccine.2014.02.074; Foss HS, 2019, SYST REV-LONDON, V8, DOI 10.1186/s13643-019-1100-y; Gargano LM, 2013, HUM VACC IMMUNOTHER, V9, P2627, DOI 10.4161/hv.25823; Gauthier B., ASSESSING SURVEY RES; Gesser-Edelsburg A, 2017, AM J INFECT CONTROL, V45, P436, DOI 10.1016/j.ajic.2016.11.025; Gilca V, 2009, INT J NURS STUD, V46, P1219, DOI 10.1016/j.ijnurstu.2009.02.013; Glavier M, 2019, MED MALADIES INFECT, V49, P586, DOI 10.1016/j.medmal.2019.09.004; Grumbach K, 2021, JAMA INTERN MED, V181, P1008, DOI 10.1001/jamainternmed.2021.1445; Gust D, 2008, J HEALTH COMMUN, V13, P573, DOI 10.1080/10810730802281726; Herzog R, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-154; Hobeika E, 2018, HUM VACC IMMUNOTHER, V14, P1501, DOI 10.1080/21645515.2018.1440163; Hofmann F, 2006, INFECTION, V34, P142, DOI 10.1007/s15010-006-5109-5; Hofstetter AM, 2017, J PEDIATR ADOL GYNEC, V30, P88, DOI 10.1016/j.jpag.2016.08.005; Hopkins TG, 2009, J PAEDIATR CHILD H, V45, P652, DOI 10.1111/j.1440-1754.2009.01589.x; Hoque ME, 2016, AFR HEALTH SCI, V16, P567, DOI 10.4314/ahs.v16i2.26; Hurley LP, 2008, J INFECT DIS, V197, pS216, DOI 10.1086/522153; Inoue Yusuke, 2011, Environmental Health and Preventive Medicine, V16, P320, DOI 10.1007/s12199-010-0202-x; Jaoude JA, 2018, VACCINE, V36, P7562, DOI 10.1016/j.vaccine.2018.10.065; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Jennings W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060593; Joanna Briggs Institute (JBI), CHECKL QUAL RES CHECKL QUAL RES; Kahn JA, 2005, J ADOLESCENT HEALTH, V37, P502, DOI 10.1016/j.jadohealth.2005.07.014; Kao C.-C., FACTORS ASS INTENTIO; Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061; Karlsson LC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224330; Kassianos G, 2018, VACCINE, V36, P6546, DOI 10.1016/j.vaccine.2018.02.031; Kempe A, 2007, PEDIATRICS, V119, P1, DOI 10.1542/peds.2006-1874; Kempe A, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-0344; Killian M, 2016, EUR J CLIN MICROBIOL, V35, P1837, DOI 10.1007/s10096-016-2735-4; Klett-Tammen CJ, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0502-3; Konstantinou P, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060607; Kreidl P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040610; Kreps S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.25594; Krishnaswamy S, 2019, AUST NZ J OBSTET GYN, V59, P408, DOI 10.1111/ajo.12888; Lama Y, 2020, VACCINE, V38, P1032, DOI 10.1016/j.vaccine.2019.11.039; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Le Marechal M, 2018, MED MALADIES INFECT, V48, P44, DOI 10.1016/j.medmal.2017.09.018; Le Marechal M, 2017, PEDIATR INFECT DIS J, V36, pE181, DOI 10.1097/INF.0000000000001553; Lehmann BA, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0511-7; Leung SOA, 2019, VACCINE-X, V3, DOI 10.1016/j.jvacx.2019.100037; Levi M, 2018, HUM VACC IMMUNOTHER, V14, P1342, DOI 10.1080/21645515.2018.1430543; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lo NC, 2017, JAMA PEDIATR, V171, P887, DOI 10.1001/jamapediatrics.2017.1695; Lutringer-Magnin D, 2011, VACCINE, V29, P5322, DOI 10.1016/j.vaccine.2011.05.006; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; MacDougall D, 2015, HUM VACC IMMUNOTHER, V11, P2167, DOI 10.1080/21645515.2015.1046662; Vilca LM, 2018, MATERN CHILD HLTH J, V22, P1016, DOI 10.1007/s10995-018-2481-6; Massin S, 2015, VACCINE, V33, P610, DOI 10.1016/j.vaccine.2014.12.038; Meghani SH, 2009, ETHNIC HEALTH, V14, P107, DOI 10.1080/13557850802227031; Miller K., HERES WHAT EXPERTS K; Mui LWH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078210; Napolitano F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194920; Neufeind J, 2020, VACCINE, V38, P4252, DOI 10.1016/j.vaccine.2020.04.052; Newman RD, 1998, ARCH PEDIAT ADOL MED, V152, P792; Nikolic Z, 2015, J PEDIATR ADOL GYNEC, V28, P12, DOI 10.1016/j.jpag.2014.01.107; Noh JY, 2016, J KOREAN MED SCI, V31, P1063, DOI 10.3346/jkms.2016.31.7.1063; Nutman A, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0112-5; Page Matthew J, 2021, BMJ, V372, pn71, DOI 10.1136/bmj.n71; Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042; Pavia M, 2003, PUBLIC HEALTH, V117, P202, DOI 10.1016/S0033-3506(03)00066-0; Pelullo CP, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020148; Perkins RB, 2012, WOMEN HEALTH ISS, V22, pE379, DOI 10.1016/j.whi.2012.04.001; Power ML, 2009, AM J PREV MED, V37, P231, DOI 10.1016/j.amepre.2009.05.019; Praphasiri P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169221; Raude J, 2016, EXPERT REV VACCINES, V15, P937, DOI 10.1080/14760584.2016.1184092; Riedesel J M, 2005, J Pediatr Adolesc Gynecol, V18, P391, DOI 10.1016/j.jpag.2005.09.004; Rosen BL, 2018, ACAD PEDIATR, V18, pS53, DOI 10.1016/j.acap.2017.10.007; Rutten LJF, 2017, VACCINE, V35, P164, DOI 10.1016/j.vaccine.2016.11.012; Schmittdiel J, 2000, J GEN INTERN MED, V15, P761, DOI 10.1046/j.1525-1497.2000.91156.x; Shibli R, 2019, VACCINE, V37, P524, DOI 10.1016/j.vaccine.2018.11.051; Shibli R, 2017, VACCINE, V35, P633, DOI 10.1016/j.vaccine.2016.12.005; Smith PJ, 2006, PEDIATRICS, V118, pE1287, DOI 10.1542/peds.2006-0923; Soon Reni, 2015, Hawaii J Med Public Health, V74, P234; Stefanoff P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232722; Stern AM, 2005, HEALTH AFFAIR, V24, P611, DOI 10.1377/hlthaff.24.3.611; Suryadevara M, 2015, VACCINE, V33, P6629, DOI 10.1016/j.vaccine.2015.10.096; Szilagyi PG, 2020, VACCINE, V38, P6027, DOI 10.1016/j.vaccine.2020.06.074; Tabacchi G, 2016, HUM VACC IMMUNOTHER, V12, P1909, DOI 10.1080/21645515.2016.1151990; Takeshita J, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.24583; Taylor KA, 2014, VACCINE, V32, P4214, DOI 10.1016/j.vaccine.2014.04.046; Tong A, 2008, J OBSTET GYNAECOL CA, V30, P404, DOI 10.1016/S1701-2163(16)32825-0; Topuridze M, 2010, INFECT CONT HOSP EP, V31, P158, DOI 10.1086/649795; Torun SD, 2010, VACCINE, V28, P5703, DOI 10.1016/j.vaccine.2010.06.049; Tuckerman J, 2020, J PAEDIATR CHILD H, V56, P1388, DOI 10.1111/jpc.14943; Vadaparampil ST, 2016, CANCER EPIDEM BIOMAR, V25, P1435, DOI 10.1158/1055-9965.EPI-15-1294; Vadaparampil ST, 2013, CANCER-AM CANCER SOC, V119, P621, DOI 10.1002/cncr.27735; Vasilevska M, 2014, INFECT CONT HOSP EP, V35, P699, DOI 10.1086/676427; Verger P, 2016, EUROSURVEILLANCE, V21, P14, DOI 10.2807/1560-7917.ES.2016.21.47.30406; Verger P, 2015, EBIOMEDICINE, V2, P891, DOI 10.1016/j.ebiom.2015.06.018; Vezzosi Luigi, 2019, Acta Biomed, V90, P71, DOI 10.23750/abm.v90i9-S.8704; Wagner A, 2015, ACTA PAEDIATR, V104, pE439, DOI 10.1111/apa.13100; Wilcox CR, 2020, BRIT J GEN PRACT, V70, pE179, DOI 10.3399/bjgp20X708113; Wilcox CR, 2019, PEDIATR INFECT DIS J, V38, P944, DOI 10.1097/INF.0000000000002384; Wilder-Smith AB, 2020, J EPIDEMIOL GLOB HEA, V10, P46, DOI 10.2991/jegh.k.191117.001; Wilson R, 2019, HUM VACC IMMUNOTHER, V15, P2423, DOI 10.1080/21645515.2019.1587274; Wong LP, 2017, J OBSTET GYNAECOL, V37, P937, DOI 10.1080/01443615.2017.1317239; Yang TU, 2014, INFECT CHEMOTHER, V46, P194, DOI 10.3947/ic.2014.46.3.194; Ye LX, 2018, HUM VACC IMMUNOTHER, V14, P2979, DOI 10.1080/21645515.2018.1496767; Young JL, 2011, J PEDIATR ADOL GYNEC, V24, P380, DOI 10.1016/j.jpag.2011.06.016; Zhang J, 2012, VACCINE, V30, P4813, DOI 10.1016/j.vaccine.2012.05.012; Zimmerman RK, 1998, ARCH PEDIAT ADOL MED, V152, P12; Zimmerman RK, 2002, PREV MED, V35, P135, DOI 10.1006/pmed.2002.1068; Zimmerman RK, 1997, ARCH PEDIAT ADOL MED, V151, P657, DOI 10.1001/archpedi.1997.02170440019004	146	4	4	2	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							713	10.3390/vaccines9070713			19	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	TO4MU	34358132	Green Published, gold			2022-04-29	WOS:000676888700001
J	Neumann, F; Rose, R; Rompke, J; Grobe, O; Lorentz, T; Fickenscher, H; Krumbholz, A				Neumann, Franziska; Rose, Ruben; Roempke, Janine; Grobe, Olaf; Lorentz, Thomas; Fickenscher, Helmut; Krumbholz, Andi			Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination	VACCINES			English	Article						COVID-19; virus variants; vaccination; humoral immune response; IgG; titer; virus-neutralizing antibodies; avidity		The humoral immunity after SARS-CoV-2 infection or vaccination was examined. Convalescent sera after infection with variants of concern (VOCs: B.1.1.7, n = 10; B.1.351, n = 1) and sera from 100 vaccinees (Pfizer/BioNTech, BNT162b2, n = 33; Moderna, mRNA-1273, n = 11; AstraZeneca, ChAdOx1 nCoV-19/AZD1222, n = 56) were tested for the presence of immunoglobulin G (IgG) directed against the viral spike (S)-protein, its receptor-binding domain (RBD), the nucleoprotein (N) and for virus-neutralizing antibodies (VNA). For the latter, surrogate assays (sVNT) and a Vero-cell based neutralization test (cVNT) were used. Maturity of IgG was determined by measuring the avidity in an immunoblot (IB). Past VOC infection resulted in a broad reactivity of anti-S IgG (100%), anti-RBD IgG (100%), and anti-N IgG (91%), while latter were absent in 99% of vaccinees. Starting approximately two weeks after the first vaccine dose, anti-S IgG (75-100%) and particularly anti-RBD IgG (98-100%) were detectable. After the second dose, their titers increased and were higher than in the convalescents. The sVNT showed evidence of VNA in 91% of convalescents and in 80-100%/100% after first/second vaccine dose, respectively. After the second dose, an increase in VNA titer and IgGs of high avidity were demonstrated by cVNT and IB, respectively. Re-vaccination contributes to a more robust immune response.	[Neumann, Franziska; Grobe, Olaf; Lorentz, Thomas; Krumbholz, Andi] Labor Dr Krause & Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany; [Rose, Ruben; Fickenscher, Helmut; Krumbholz, Andi] Christian Albrechts Univ Kiel, Inst Infekt Med, Campus Kiel,Brunswiker Str 4, D-24105 Kiel, Germany; [Rose, Ruben; Fickenscher, Helmut; Krumbholz, Andi] Univ Klinikum Schleswig Holstein, Campus Kiel,Brunswiker Str 4, D-24105 Kiel, Germany; [Roempke, Janine] Stadtisches Krankenhaus Kiel, Chemnitzstr 33, D-24116 Kiel, Germany		Krumbholz, A (通讯作者)，Labor Dr Krause & Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany.; Krumbholz, A (通讯作者)，Christian Albrechts Univ Kiel, Inst Infekt Med, Campus Kiel,Brunswiker Str 4, D-24105 Kiel, Germany.; Krumbholz, A (通讯作者)，Univ Klinikum Schleswig Holstein, Campus Kiel,Brunswiker Str 4, D-24105 Kiel, Germany.	neumann@labor-krause.de; rose@infmed.uni-kiel.de; janine.roempke@krankenhaus-kiel.de; grobe@labor-krause.de; lorentz@labor-krause.de; fickenscher@infmed.uni-kiel.de; krumbholz@infmed.uni-kiel.de	Krumbholz, Andi/ABB-8634-2020	Krumbholz, Andi/0000-0002-1094-350X			Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Bauer G, 2021, INT J INFECT DIS, V106, P61, DOI 10.1016/j.ijid.2021.01.061; Bauer G, 2021, J MED VIROL, V93, P3092, DOI 10.1002/jmv.26863; Bauer G, 2021, J MED VIROL, V93, P311, DOI 10.1002/jmv.26262; Bradley T, 2021, NEW ENGL J MED, V384, P1959, DOI 10.1056/NEJMc2102051; Creech CB, 2021, JAMA-J AM MED ASSOC, V325, P1318, DOI 10.1001/jama.2021.3199; Emary KRW, 2021, LANCET, V397, P1351, DOI 10.1016/S0140-6736(21)00628-0; Embregts C.W.E., 2021, EVALUATION MULTISPEC, DOI [10.1101/2021.05.07.21252267, DOI 10.1101/2021.05.07.21252267]; EU, SAF COVID 19 VACC EU; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hedman K., 1993, REV MED MICROBIOL, V4, P123; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Iacobucci G, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1068; Klasse PJ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe8065; Kristiansen PA, 2021, LANCET, V397, P1347, DOI 10.1016/S0140-6736(21)00527-4; Kyriakidis NC, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00292-w; Li MC, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00592-6; Meyer B, 2020, EMERG MICROBES INFEC, V9, P2394, DOI 10.1080/22221751.2020.1835448; Pritchard E., 2021, IMPACT VACCINATION S, DOI [10.1101/2021.04.22.21255913, DOI 10.1101/2021.04.22.21255913]; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; STIKO, STELL STAND IMPFK ZU; Stromer A, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9010058; Stromer A, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8101572; Torjesen I, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n523; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; von Rhein C, 2021, J VIROL METHODS, V288, DOI 10.1016/j.jviromet.2020.114031; Wei J., 2021, IMPACT SARS COV 2 VA, DOI [10.1101/2021.04.22.21255911, DOI 10.1101/2021.04.22.21255911]; WHO, WHO COR COVID 19 DAS	28	6	6	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							700	10.3390/vaccines9070700			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO7BN	34202276	Green Published, gold			2022-04-29	WOS:000677062200001
J	Sei, CJ; Rao, M; Schuman, RF; Daum, LT; Matyas, GR; Rikhi, N; Muema, K; Anderson, A; Jobe, O; Kroscher, KA; Alving, CR; Fischer, GW				Sei, Clara J.; Rao, Mangala; Schuman, Richard F.; Daum, Luke T.; Matyas, Gary R.; Rikhi, Nimisha; Muema, Kevin; Anderson, Alexander; Jobe, Ousman; Kroscher, Kellie A.; Alving, Carl R.; Fischer, Gerald W.			Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies	VACCINES			English	Article						peptides; influenza; ALFQ; liposomes; QS21 (also known as QS-21); universal vaccine; immune responses; broadly reactive antibodies; neutralizing antibodies; Th1/Th2 responses	MONOPHOSPHORYL-LIPID-A; EXTRACELLULAR DOMAIN; LIPOSOMES; RESPONSES; HAPTEN; HEROIN; SYSTEM; VIRUS	A universal influenza candidate vaccine that targets multiple conserved influenza virus epitopes from hemagglutinin (HA), neuraminidase (NA) and matrix (M2e) proteins was combined with the potent Army liposomal adjuvant (ALFQ) to promote induction of broad immunity to seasonal and pandemic influenza strains. The unconjugated and CRM-conjugated composite peptides formulated with ALFQ were highly immunogenic and induced both humoral and cellular immune responses in mice. Broadly reactive serum antibodies were induced across various IgG isotypes. Mice immunized with the unconjugated composite peptide developed antibody responses earlier than mice immunized with conjugated peptides, and the IgG antibodies were broadly reactive and neutralizing across Groups 1 and 2 influenza viruses. Multi-epitope unconjugated influenza composite peptides formulated with ALFQ provide a novel strategy for the development of a universal influenza vaccine. These synthetic peptide vaccines avoid the pitfalls of egg-produced influenza vaccines and production can be scaled up rapidly and economically.	[Sei, Clara J.; Rikhi, Nimisha; Muema, Kevin; Kroscher, Kellie A.; Fischer, Gerald W.] Longhorn Vaccines & Diagnost, Gaithersburg, MD 20878 USA; [Rao, Mangala; Matyas, Gary R.; Anderson, Alexander; Jobe, Ousman; Alving, Carl R.] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD 20910 USA; [Schuman, Richard F.] Antibody & Immunoassay Consultants, Rockville, MD 20850 USA; [Daum, Luke T.] Longhorn Vaccines & Diagnost, San Antonio, TX 78209 USA; [Anderson, Alexander] Oak Ridge Inst Sci & Educ, Oak Ridge, TN 37831 USA; [Jobe, Ousman] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD 20817 USA		Sei, CJ (通讯作者)，Longhorn Vaccines & Diagnost, Gaithersburg, MD 20878 USA.	cs@lhnvd.com; mrao@hivresearch.org; rfs@aicbiotech.com; longhorn-vandd@sbcglobal.net; gmatyas@hivresearch.org; nr@lhnvd.com; kevin@lhnvd.com; aanderson@hivresearch.org; ojobe@hivresearch.org; kellie@lhnvd.com; calving@hivresearch.org; gwf@lhnvd.com		Anderson, Alexander/0000-0002-0000-7734; Matyas, Gary/0000-0002-2074-2373	Longhorn Vaccines and Diagnostics, LLC.; U.S. Department of DefenseUnited States Department of Defense [W81XWH-18-2-0040]; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. [W81XWH-18-2-0040]	This research received funding from Longhorn Vaccines and Diagnostics, LLC. This work was also partially executed through a cooperative agreement between the U.S. Department of Defense and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (W81XWH-18-2-0040).	Abed Y, 2002, J MED VIROL, V67, P589, DOI 10.1002/jmv.10143; Air GM, 2012, INFLUENZA OTHER RESP, V6, P245, DOI 10.1111/j.1750-2659.2011.00304.x; Alving CR, 2020, EXPERT REV VACCINES, V19, P279, DOI 10.1080/14760584.2020.1745636; Alving CR, 2012, EXPERT REV VACCINES, V11, P733, DOI [10.1586/ERV.12.35, 10.1586/erv.12.35]; ALVING CR, 1995, IMMUNOL REV, V145, P5, DOI 10.1111/j.1600-065X.1995.tb00075.x; Beck Z, 2015, VACCINE, V33, P5578, DOI 10.1016/j.vaccine.2015.09.001; Chen YQ, 2018, CELL, V173, P417, DOI 10.1016/j.cell.2018.03.030; Cho KJ, 2015, J VIROL, V89, P3700, DOI 10.1128/JVI.02576-14; Deng L, 2015, VACCINES-BASEL, V3, P105, DOI 10.3390/vaccines3010105; Eichelberger MC, 2019, J INFECT DIS, V219, pS75, DOI 10.1093/infdis/jiz017; Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Hermanson GT, 2013, BIOCONJUGATE TECHNIQUES, 3RD EDITION, P1; Kirkpatrick E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28706-1; Matyas GR, 2013, VACCINE, V31, P2804, DOI 10.1016/j.vaccine.2013.04.027; McMillan CLD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010026; Neirynck S, 1999, NAT MED, V5, P1157, DOI 10.1038/13484; Ostrowsky J, 2020, CURR OPIN VIROL, V40, P28, DOI 10.1016/j.coviro.2020.02.003; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Sulima A, 2018, J MED CHEM, V61, P329, DOI 10.1021/acs.jmedchem.7b01427; Torres OB, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0013-9; Tsilibary EP, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010047; Wang W, 2019, CLIN INFECT DIS, V68, P2067, DOI 10.1093/cid/ciy818; WHITE WI, 1995, VACCINE, V13, P1111, DOI 10.1016/0264-410X(94)00058-U; World Health Organisation, CUM NUMB CONF HUM CA; World Health Organisation, INFL SEAS	25	1	2	2	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUL	2021	9	7							698	10.3390/vaccines9070698			16	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TO5GS	34202178	gold, Green Published			2022-04-29	WOS:000676940500001
J	Al-Jayyousi, GF; Sherbash, MAM; Ali, LAM; El-Heneidy, A; Alhussaini, NWZ; Elhassan, MEA; Nazzal, MA				Al-Jayyousi, Ghadir Fakhri; Sherbash, Mohamed Abdelhady Mabrouk; Ali, Lamees Abdullah Mohammed; El-Heneidy, Asmaa; Alhussaini, Nour Waleed Zuhair; Elhassan, Manar Elsheikh Abdelrahman; Nazzal, Maisa Ayman			Factors Influencing Public Attitudes towards COVID-19 Vaccination: A Scoping Review Informed by the Socio-Ecological Model	VACCINES			English	Review						COVID-19; vaccine; hesitancy; acceptance; refusal; willingness; ecological model; scoping review	UNITED-STATES; HESITANCY; DETERMINANTS; ACCEPTABILITY; ASSOCIATION; ACCEPTANCE; SEPTEMBER; INTENTION	Major hindrances to getting a COVID-19 vaccine include vaccine hesitancy, skepticism, refusal, and anti-vaccine movements. Several studies have been conducted on attitudes of the public towards COVID-19 vaccines and the potential influencing factors. The purpose of this scoping review is to summarize the data available on the various factors influencing public attitudes towards COVID-19 vaccination. This scoping review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Statement. PubMed, Embase, Web of Science, and Cochrane Central were searched without restrictions to reclaim all publications on the factors that shape individuals' attitudes towards COVID-19 vaccines from 1 January 2020 to 15 February 2021. Fifty studies were included. The scoping review revealed that the factors influencing public attitudes towards COVID-19 vaccines were embedded within the different levels of the socio-ecological model. These factors included the sociodemographic characteristics of the individuals, individual factors, social and organizational factors. In addition, certain characteristics of COVID-19 vaccines themselves influenced public attitudes towards accepting the vaccines. Understanding various population needs and the factors shaping public attitudes towards the vaccines would support planning for evidence-based multilevel interventions in order to enhance global vaccine uptake.	[Al-Jayyousi, Ghadir Fakhri; Sherbash, Mohamed Abdelhady Mabrouk; Ali, Lamees Abdullah Mohammed; Alhussaini, Nour Waleed Zuhair; Elhassan, Manar Elsheikh Abdelrahman] Qatar Univ, Dept Publ Hlth, Coll Hlth Sci, QU Hlth, POB 2713, Doha, Qatar; [El-Heneidy, Asmaa] Griffith Univ, Sch Med & Dent, Gold Coast Campus, Southport, Qld 4222, Australia; [El-Heneidy, Asmaa] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast Campus, Southport, Qld 4222, Australia; [Nazzal, Maisa Ayman] Najah Natl Univ, Dept Pharm, Fac Med & Hlth Sci, Nablus 44839, West Bank, Palestine		Al-Jayyousi, GF (通讯作者)，Qatar Univ, Dept Publ Hlth, Coll Hlth Sci, QU Hlth, POB 2713, Doha, Qatar.	g.aljayyousi@qu.edu.qa; msherbash@qu.edu.qa; la1605823@qu.edu.qa; a.el-heneidy@griffith.edu.au; nwaleed@qu.edu.qa; melhassan@qu.edu.qa; s11525766@stu.najah.edu	Abdel-Rahman, Manar/R-4652-2016	Abdel-Rahman, Manar/0000-0001-9968-9853; Al-Jayyousi, Ghadir Fakhri/0000-0001-5995-1693; El-Heneidy, Asmaa/0000-0003-4937-1673; Ali, Lamees/0000-0002-4455-5601; Sherbash, Mohamed/0000-0003-4209-2460			Akarsu B, 2021, INT J CLIN PRACT, V75, DOI 10.1111/ijcp.13891; Al-Mohaithef M, 2020, J MULTIDISCIP HEALTH, V13, P1657, DOI 10.2147/JMDH.S276771; Alley SJ, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020797; Alqudeimat Y, 2021, MED PRIN PRACT, V30, P262, DOI 10.1159/000514636; Ashfield S, 2020, J MED INTERNET RES, V22, DOI 10.2196/20002; Bell S, 2020, VACCINE, V38, P7789, DOI 10.1016/j.vaccine.2020.10.027; Bendau A, 2021, INT IMMUNOPHARMACOL, V97, DOI 10.1016/j.intimp.2021.107724; Benecke Olivia, 2019, Glob Pediatr Health, V6, p2333794X19862949, DOI 10.1177/2333794X19862949; Bertin P, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.565128; Biasio LR, 2021, HUM VACC IMMUNOTHER, V17, P1304, DOI 10.1080/21645515.2020.1829315; Bish A, 2010, BRIT J HEALTH PSYCH, V15, P797, DOI 10.1348/135910710X485826; Bogart LM, 2021, JAIDS-J ACQ IMM DEF, V86, P200, DOI 10.1097/QAI.0000000000002570; Butter S, 2022, BRIT J HEALTH PSYCH, V27, P13, DOI 10.1111/bjhp.12530; Caserotti M, 2021, SOC SCI MED, V272, DOI 10.1016/j.socscimed.2021.113688; Centers for Disease Control and Prevention, VACC BAS; Chen MS, 2021, HUM VACC IMMUNOTHER, V17, P2279, DOI 10.1080/21645515.2020.1853449; Chen TE, 2021, HEALTH COMMUN, DOI 10.1080/10410236.2021.1876814; Corpuz R, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01857; Coustasse A, 2021, J AMBUL CARE MANAG, V44, P71, DOI 10.1097/JAC.0000000000000360; Dahlgren G., 1991, POLICIES STRATEGIES; Danchin M, 2020, AUST J GEN PRACT, V49, P625, DOI 10.31128/AJGP-08-20-5559; Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; Dror AA, 2020, EUR J EPIDEMIOL, V35, P775, DOI 10.1007/s10654-020-00671-y; Dube E, 2020, EXPERT REV VACCINES, V19, P899, DOI 10.1080/14760584.2020.1825944; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Feleszko W, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010044; Ferguson N. M., 2020, IMPACT NONPHARMACEUT, V10, P77482, DOI DOI 10.25561/77482; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; Geoghegan S, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00372; Guidry JPD, 2021, AM J INFECT CONTROL, V49, P137, DOI 10.1016/j.ajic.2020.11.018; Habersaat KB, 2020, NAT HUM BEHAV, V4, P677, DOI 10.1038/s41562-020-0906-x; Harapan H, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00381; Hursh SR, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.608852; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; Jung H, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2007538118; Kourlaba G, 2021, GLOB HEALTH RES POL, V6, DOI 10.1186/s41256-021-00188-1; La Vecchia C, 2020, MED LAV, V111, P445, DOI 10.23749/mdl.v111i6.10813; Largent EA, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.33324; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Ling R, 2020, DIGIT JOURNAL, V8, P596, DOI 10.1080/21670811.2020.1766987; Marco-Franco JE, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020744; McCaffery KJ, 2020, PUBLIC HEALTH RES PR, V30, DOI 10.17061/phrp30342012; Murphy J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20226-9; Nguyen KH, 2021, MMWR-MORBID MORTAL W, V70, P217, DOI 10.15585/mmwr.mm7006e3; Nguyen Trang, 2011, Infect Drug Resist, V4, P197, DOI 10.2147/IDR.S23174; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Orenstein WA, 2017, P NATL ACAD SCI USA, V114, P4031, DOI 10.1073/pnas.1704507114; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Phadke VK, 2016, JAMA-J AM MED ASSOC, V315, P1149, DOI 10.1001/jama.2016.1353; Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2; Pogue K, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040582; Popa GL, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040774; Prati G, 2020, HEALTH EDUC RES, V35, P505, DOI 10.1093/her/cyaa043; Puri N, 2020, HUM VACC IMMUNOTHER, V16, P2586, DOI 10.1080/21645515.2020.1780846; Reiter PL, 2020, VACCINE, V38, P6500, DOI 10.1016/j.vaccine.2020.08.043; Reuben RC, 2021, J COMMUN HEALTH, V46, P457, DOI 10.1007/s10900-020-00881-1; Robles AS, 2021, J INVEST MED, V69, P235, DOI 10.1136/jim-2021-WRMC.296; Roller-Wirnsberger R, 2021, AGING CLIN EXP RES, V33, P2123, DOI 10.1007/s40520-021-01793-3; Romer D, 2020, SOC SCI MED, V263, DOI 10.1016/j.socscimed.2020.113356; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020160; Sallam M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010042; Santhanes D, 2018, HUM VACC IMMUNOTHER, V14, P124, DOI 10.1080/21645515.2017.1381811; Seale H, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-05833-1; Sherman SM, 2021, HUM VACC IMMUNOTHER, V17, P1612, DOI 10.1080/21645515.2020.1846397; Taylor S, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.575950; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; UK Government Scientific Advisory Group for Emergencies, 2020, FACTORS INFLUENCING; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Ward JK, 2020, SOC SCI MED, V265, DOI 10.1016/j.socscimed.2020.113414; Williams L, 2020, BRIT J HEALTH PSYCH, V25, P1039, DOI 10.1111/bjhp.12468; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; World Health Organization, MOD TRANSM IR CAUS C; World Health Organization (WHO), COR; Worldometer, COVID 19 COR PAND; Yamey G, 2020, LANCET, V395, P1405, DOI 10.1016/S0140-6736(20)30763-7; Yin FL, 2021, J MED INTERNET RES, V23, DOI 10.2196/26089; Zhu HB, 2020, GLOB HEALTH RES POL, V5, DOI 10.1186/s41256-020-00135-6	81	20	20	16	25	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							548	10.3390/vaccines9060548			27	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TB4PO	34073757	Green Published, gold			2022-04-29	WOS:000667927600001
J	Borena, W; Kimpel, J; Gierer, M; Rossler, A; Riepler, L; Oehler, S; von Laer, D; Miholits, M				Borena, Wegene; Kimpel, Janine; Gierer, Melanie; Roessler, Annika; Riepler, Lydia; Oehler, Susanne; von Laer, Dorothee; Miholits, Markus			Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay	VACCINES			English	Article						human coronaviruses; multiplex immunoassay; cross-reaction; bead-based immunoassay	PREVALENCE	Serological assays that simultaneously detect antibodies to multiple targets of SARS-CoV-2 and to other structurally related coronaviruses provide a holistic picture of antibody response patterns. Well-validated multiplex immunoassays are scarce. Here, we evaluated the performance of an 11-plex serological assay capable of detecting antibodies directed to four antigenic targets of SARS-CoV-2 and to S1 proteins of other human pathogenic coronaviruses. We used 620 well-characterized sera (n = 458 seropositive and n = 110 seronegative for SARS-CoV-2 in the pre-SARS-CoV-2 era and n = 52 seronegative for SARS-CoV-2 in the era of SARS-CoV-2) as positive and negative standards. We calculated the sensitivity, specificity, as well as positive and negative predictive values, including a 95% confidence interval. The difference in mean fluorescence intensity (95% CI) was used to assess a potential cross-reaction between antibodies to SARS-CoV-2 and the other coronaviruses. The sensitivity (95% CI) of detecting anti-SARS-CoV-2 antibodies to four antigenic targets ranged from 83.4% (76.7-86.7) to 93.7% (91.0-95.7) and the specificity from 98.2% (93.6-99.8) to 100% (96.7-100). We observed no obvious cross-reaction between anti-SARS-CoV-2 antibodies and antibodies to the other coronaviruses except for SARS-CoV-1. The high sensitivity and specificity warrant a reliable utilization of the assay in population-based seroprevalence surveys or vaccine efficacy studies.	[Borena, Wegene; Kimpel, Janine; Roessler, Annika; Riepler, Lydia; von Laer, Dorothee] Med Univ Innsbruck, Dept Hyg Microbiol & Publ Hlth, Inst Virol, A-6020 Innsbruck, Austria; [Gierer, Melanie; Oehler, Susanne; Miholits, Markus] Bender MedSyst GmbH, Thermo Fisher Sci, Campus Vienna Bioctr 2, A-1030 Vienna, Austria		Borena, W (通讯作者)，Med Univ Innsbruck, Dept Hyg Microbiol & Publ Hlth, Inst Virol, A-6020 Innsbruck, Austria.	wegene.borena@i-med.ac.at; janine.kimpel@i-med.ac.at; melanie.gierer@thermofisher.com; Annika.Roessler@i-med.ac.at; lydia.riepler@i-med.ac.at; susanne.oehler@thermofisher.com; dorothee.von-laer@i-med.ac.at; markus.miholits@thermofisher.com		Rossler, Annika/0000-0002-5298-0288; Riepler, Lydia/0000-0002-7879-5566; Borena, Wegene/0000-0001-8011-5825; Kimpel, Janine/0000-0002-5210-7905			Akobeng AK, 2007, ACTA PAEDIATR, V96, P338, DOI 10.1111/j.1651-2227.2006.00180.x; [Anonymous], 2020, SCI BRIEF 0709; Borena W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178175; Dong YT, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00352-y; Gorse GJ, 2010, CLIN VACCINE IMMUNOL, V17, P1875, DOI 10.1128/CVI.00278-10; Gupta RK, 2021, NAT REV IMMUNOL, V21, P340, DOI 10.1038/s41577-021-00556-5; HASONY HJ, 1982, J MED VIROL, V9, P209, DOI 10.1002/jmv.1890090308; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang AT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18450-4; Johns Hopkins University, 2020, **NON-TRADITIONAL**; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Knabl L., 2020, HIGH SARS COV 2 SERO, DOI [10.1101/2020.08.20.20178533, DOI 10.1101/2020.08.20.20178533]; Lipsitch M, 2020, NAT REV IMMUNOL, V20, P709, DOI 10.1038/s41577-020-00460-4; Ma ZR, 2020, LANCET MICROBE, V1, pE151, DOI 10.1016/S2666-5247(20)30098-7; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Riepler L, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010013; Tso FY, 2021, INT J INFECT DIS, V102, P577, DOI 10.1016/j.ijid.2020.10.104; U.S. Food & Drug Administration, EUA AUTH SER TEST PE; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Zost SJ, 2020, NATURE, V584, P443, DOI 10.1038/s41586-020-2548-6	20	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							611	10.3390/vaccines9060611			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY6AO	34200301	gold, Green Published			2022-04-29	WOS:000665968600001
J	Chavda, VP; Feehan, J; Apostolopoulos, V				Chavda, Vivek P.; Feehan, Jack; Apostolopoulos, Vasso			A Veterinary Vaccine for SARS-CoV-2: The First COVID-19 Vaccine for Animals	VACCINES			English	Editorial Material									[Chavda, Vivek P.] LM Coll Pharm, Dept Pharmaceut & Pharmaceut Technol, Ahmadabad 380008, Gujarat, India; [Feehan, Jack; Apostolopoulos, Vasso] Victoria Univ, Inst Hlth & Sport, Melbourne, Vic 3030, Australia		Apostolopoulos, V (通讯作者)，Victoria Univ, Inst Hlth & Sport, Melbourne, Vic 3030, Australia.	jack.feehan@vu.edu.au; jack.feehan@vu.edu.au; vasso.apostolopoulos@vu.edu.au		Apostolopoulos, Vasso/0000-0001-6788-2771; Feehan, Jack/0000-0002-9627-1299	Mechanisms and Interventions in Health and Disease Program within the Institute for Health and Sport, Victoria University, Australia; Immunology and Translational Research Group, Victoria University, Australia; L.M. College of Pharmacy, Ahmedabad, India	The authors would like to thank the Immunology and Translational Research Group for their significant contribution. The Mechanisms and Interventions in Health and Disease Program within the Institute for Health and Sport, Victoria University, Australia, are also appreciated for their support. J.F was supported by the Immunology and Translational Research Group, Victoria University, Australia. V.P. is grateful to the L.M. College of Pharmacy, Ahmedabad, India, for providing necessary support in carrying out the literature search.	Andrew E. Kramer, 2021, NEW YORK TIMES  0331; [Anonymous], 2021, REUTERS; National Center for Immunization and Respiratory Diseases (NCIRD), 2021, DIV VIR DIS, P2021; Sinelschikova Y., 2021, RUSS; Swelum AA, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00578; TETRAULT-FARBER G., 2021, REUTERS; WION Web Team, 2021, WION	7	6	6	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							631	10.3390/vaccines9060631			3	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ7AU	34200587	Green Published, gold			2022-04-29	WOS:000666714100001
J	Coppeta, L; Balbi, O; Grattagliano, Z; Mina, GG; Pietroiusti, A; Magrini, A; Bolcato, M; Aurilio, MT				Coppeta, Luca; Balbi, Ottavia; Grattagliano, Zaira; Mina, Grazia Genga; Pietroiusti, Antonio; Magrini, Andrea; Bolcato, Matteo; Trabucco Aurilio, Marco			First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers	VACCINES			English	Article						SARS-CoV-2; healthcare workers; COVID-19; vaccine; mRNA vaccine; first dose administration		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than one hundred million people since the beginning of the worldwide pandemic. In this study, data from a large hospital in central Italy was used to evaluate the impact of the first dose of the BNT162b2 mRNA vaccine on SARS-CoV-2 infections in terms of the prevalence of symptomatic cases, symptom duration, and viral clearance timing. All vaccinated Healthcare Workers (HCWs) with positive RT-PCR by nasopharyngeal (NP) swabs were divided into two cohorts (positive RT-PCR within day 12 and positive RT-PCR between day 13 and day 21 after first dose administration) and compared for the presence and duration of symptoms and the timing of viral clearance. The same variables were evaluated across HCWs with positive RT-PCR within 6 days after first dose administration and non-vaccinated HCWs with positive RT-PCR between 1 October 2020 and 28 February 2021. Eighteen HCWs tested positive on RT-PCR by NP swab from day 1 to day 12 after the 1st dose administration (incidence rate 6.2 x 10(-4)) and 5 HCWs from day 13 to day 21 (incidence rate 2.3 x 10(-4)). Symptom duration and viral clearance timing are significantly shorter in the cohort of HCWs with positive RT-PCR 12 days after the first dose of the BNT162b2 mRNA vaccine. The administration of the first dose proved effective in reducing presence, symptom duration, and viral clearance even in HCWs vaccinated for less than 6 days. These results could have implications on public health and post-exposure prophylaxis.	[Coppeta, Luca; Balbi, Ottavia; Grattagliano, Zaira; Mina, Grazia Genga; Pietroiusti, Antonio; Magrini, Andrea] Univ Roma Tor Vergata, Dept Occupat Med, I-00188 Rome, Italy; [Bolcato, Matteo] Univ Padua, Legal Med, I-35121 Padua, Italy; [Trabucco Aurilio, Marco] Univ Molise, Dept Med & Hlth Sci Vincenzo Tiberio, I-86100 Campobasso, Italy		Bolcato, M (通讯作者)，Univ Padua, Legal Med, I-35121 Padua, Italy.	lcoppeta@gmail.com; ottaventidue@hotmail.it; zaira.grattagliano33@gmail.com; graziagmina@gmail.com; pietroiu@uniroma2.it; andrea.magrini@uniroma2.it; matteo.bolcato@unipd.it; marco.trabuccoaurilio@unimol.it	coppeta, luca/X-6052-2019	coppeta, luca/0000-0003-2470-6107; , Matteo Bolcato/0000-0002-8784-8463; Trabucco Aurilio, Marco/0000-0003-2327-1455			Amit S, 2021, EMERG INFECT DIS, V27, P1220, DOI 10.3201/eid2704.210016; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bolcato M., 2021, VACCINES-BASEL, V9, P538; Ghebreyesus T.A, 2020, DIR GEN OP REM MED B; Hunter P.R., ESTIMATING EFFECTIVE, DOI [10.1101/2021.02.01.21250957v1, DOI 10.1101/2021.02.01.21250957V1]; Johansson MA, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.35057; Johns Hopkins University Coronavirus Resource Center, 2020, COVID 19 DASHB CTR S; Jones NK, 2021, ELIFE, V10, DOI 10.7554/eLife.68808; Lamb YN, 2021, DRUGS, V81, P495, DOI 10.1007/s40265-021-01480-7; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Marty FM, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMvcm2010260; Mehrotra DV, 2021, ANN INTERN MED, V174, P221, DOI 10.7326/M20-6169; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Tande AJ, 2022, CLIN INFECT DIS, V74, P59, DOI 10.1093/cid/ciab229; Aurilio MT, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050500; Yu P, 2020, J INFECT DIS, V221, P1757, DOI 10.1093/infdis/jiaa077	17	5	5	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							659	10.3390/vaccines9060659			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY5VV	34204252	Green Published, gold			2022-04-29	WOS:000665956200001
J	Flacco, ME; Soldato, G; Martellucci, CA; Carota, R; Di Luzio, R; Caponetti, A; Manzoli, L				Flacco, Maria Elena; Soldato, Graziella; Martellucci, Cecilia Acuti; Carota, Roberto; Di Luzio, Rossano; Caponetti, Antonio; Manzoli, Lamberto			Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province	VACCINES			English	Article						COVID-19; SARS-CoV-2; vaccine effectiveness; vaccine hesitancy; cohort study; Italy	BNT162B2	This retrospective cohort study compared the rates of virologically-confirmed SARS-CoV-2 infections, symptomatic or lethal COVID-19 among the residents of the Italian province of Pescara who received one or two doses of COVID-19 vaccines, versus the unvaccinated. The official data of the National Health System were used, and a total of 69,539 vaccinated adults were compared with 175,687 unvaccinated. Among the subjects who received at least one vaccine dose, 85 infections (0.12%), 18 severe and 3 lethal COVID-19 cases were recorded after an average follow-up of 38 days. Among the unvaccinated, the numbers were 6948 (4.00%), 933 (0.53%) and 241 (0.14%), respectively. The serious adverse event reports-yet unconfirmed-were 24 out of 102,394 administered doses. In a Cox model, adjusting for age, gender, and selected comorbidities, the effectiveness of either BNT162b2, ChAdOx1 nCoV-19 or mRNA-1273 vaccines was higher than 95% in preventing infections (mostly due to B.1.1.7 variant), symptomatic or lethal COVID-19. No differences were observed across genders, and among the 691 subjects who received the second dose of vaccine later than the recommended date. Although preliminary, these findings support current immunization policies and may help reducing vaccine hesitancy.	[Flacco, Maria Elena; Martellucci, Cecilia Acuti; Manzoli, Lamberto] Univ Ferrara, Dept Med Sci, I-44121 Ferrara, Italy; [Soldato, Graziella; Carota, Roberto; Di Luzio, Rossano; Caponetti, Antonio] Local Hlth Unit Pescara, I-65124 Pescara, Italy		Manzoli, L (通讯作者)，Univ Ferrara, Dept Med Sci, I-44121 Ferrara, Italy.	mariaelena.flacco@unife.it; graziella.soldato@ausl.pe.it; cecilia.martellucci@unife.it; roberto.carota@ausl.pe.it; rossano.diluzio@ausl.pe.it; antonio.caponetti@ausl.pe.it; lmanzoli@post.harvard.edu	Martellucci, Cecilia Acuti/AAW-5903-2020; Flacco, Maria Elena/E-3306-2017; Manzoli, Lamberto/K-1895-2018	Martellucci, Cecilia Acuti/0000-0002-4308-2144; Flacco, Maria Elena/0000-0003-1404-4314; Manzoli, Lamberto/0000-0002-8129-9344			Karim SAS, 2021, NEW ENGL J MED, V384, P1866, DOI 10.1056/NEJMc2100362; Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bae S, 2021, J KOREAN MED SCI, V36, DOI 10.3346/jkms.2021.36.e115; Bravi F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235248; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; European Centre for Disease Prevention and Control, COVID 19 VACC TRACK; Fabiani M, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.17.2100420; Flacco ME, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa556; Freeman D, 2021, LANCET PUBLIC HEALTH, V6, pE416, DOI 10.1016/S2468-2667(21)00096-7; Gee J, 2021, MMWR-MORBID MORTAL W, V70, P283, DOI 10.15585/mmwr.mm7008e3; Haas EJ, 2021, LANCET, V397, P1819, DOI 10.1016/S0140-6736(21)00947-8; Hall VJ, 2021, LANCET, V397, P1725, DOI 10.1016/S0140-6736(21)00790-X; Harrison, 2021, CEREBRAL VENOS THROM; Iacobucci Gareth, 2021, BMJ, V372, pn18, DOI 10.1136/bmj.n18; Italian Ministry of Health, 2020, PIAN VACC ANT COVID; Italian National Institute of Health, COVID 19 VACC FAQ; Kelly BJ, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06023-9; Killgore WDS, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040339; Kriss JL, 2021, MMWR-MORBID MORTAL W, V70, P389, DOI 10.15585/mmwr.mm7011e2; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n226; Martellucci Cecilia Acuti, 2020, Advances in Biological Regulation, V77, P100730, DOI [10.1016/j.jbior.2020.100730, 10.1016/j.jbior.2020.100736]; Moss, 2021, EXTENDED INTERVAL BN, DOI [10.1101/2021.05.15.21257017, DOI 10.1101/2021.05.15.21257017]; Nohl A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050424; Norwegian Medicines Agency, REP SUSP SID EFF SAR; Paul E, 2021, LANCET REG HEALTH-EU, V1, DOI 10.1016/j.lanepe.2020.100012; Pimenta D, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n710; Planas D, 2021, NAT MED, V27, P917, DOI 10.1038/s41591-021-01318-5; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pormohammad A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050467; Reno C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040378; Reuters Staff, REUTERS; Robertson E, 2021, BRAIN BEHAV IMMUN, V94, P41, DOI 10.1016/j.bbi.2021.03.008; Rota M.C., ITALIAN NATL I HLTH; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Stamatatos L, 2021, SCIENCE, V372, P1413, DOI 10.1126/science.abg9175; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; Torjesen I, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1005; Troiano G, 2021, PUBLIC HEALTH, V194, P245, DOI 10.1016/j.puhe.2021.02.025; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wang JH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030191; Worldometer, 2020, COVID 19 CORONAVIRUS	43	11	11	2	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							628	10.3390/vaccines9060628			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SZ2ST	34200538	Green Published, gold			2022-04-29	WOS:000666422300001
J	Jang, AY; Choi, MJ; Zhi, Y; Ji, HJ; Noh, JY; Yoon, JG; Cheong, HJ; Kim, WJ; Seo, HS; Song, JY				Jang, A-Yeung; Choi, Min-Joo; Zhi, Yong; Ji, Hyun-Jung; Noh, Ji-Yun; Yoon, Jin-Gu; Cheong, Hee-Jin; Kim, Woo-Joo; Seo, Ho-Seong; Song, Joon-Young			Development and Validation of Enzyme-Linked Immunosorbent Assay for Group B Streptococcal Polysaccharide Vaccine	VACCINES			English	Article						Streptococcus agalactiae; capsular polysaccharide; enzyme-linked immunosorbent assay; validation; vaccine	QUANTITATIVE ESTIMATION; CONJUGATE VACCINE; SIALIC ACIDS; IMMUNOGENICITY; INFANTS; DISEASE; SAFETY; HEALTHY; WOMEN	Streptococcus agalactiae (group B Streptococcus, GBS) is a leading cause of neonatal sepsis and meningitis in infants. Limitations of prenatal GBS screening and intrapartum antibiotic prophylaxis render developing GBS vaccines a high priority. In this study, we developed an enzyme-linked immunosorbent assay (ELISA) for the practical and large-scale evaluation of GBS capsular polysaccharide (PS) vaccine immunogenicity against three main serotypes, Ia, III, and V. GBS-ELISA was developed and subsequently validated using a standardized curve-fitting four-parameter logistic method. Specificity was measured using adsorption of serum with homologous and heterologous PS. Homologous adsorption showed a >= 75% inhibition of all three serotypes, whereas with heterologous PS, IgG GBS-ELISA inhibited only <= 25% of serotypes III and V. However, with serotype Ia, IgG antibody levels decreased by >50%, even after adsorption with heterologous PS (III or V). In comparison, the inhibition opsonophagocytic killing assay (OPA) of serotypes Ia GBS exhibited a reduction in opsonophagocytic activity of only 20% and 1.1% for serotypes III and V GBS, respectively. The precision of the GBS-ELISA was assessed in five independent experiments using four serum samples. The coefficient of variation was <5% for all three serotypes. This standardized GBS-ELISA would be useful for GBS vaccine development and its evaluation.	[Jang, A-Yeung; Noh, Ji-Yun; Yoon, Jin-Gu; Cheong, Hee-Jin; Kim, Woo-Joo; Song, Joon-Young] Korea Univ, Dept Internal Med, Div Infect Dis, Coll Med, Seoul 08308, South Korea; [Choi, Min-Joo] Catholic Kwandong Univ, Dept Internal Med, Coll Med, Int St Marys Hosp, Incheon 22711, South Korea; [Zhi, Yong; Ji, Hyun-Jung; Seo, Ho-Seong] Korea Atom Energy Res Inst, Res Div Radiat Sci, Jeongeup 56212, South Korea; [Zhi, Yong; Seo, Ho-Seong] Univ Sci & Technol, Dept Radiat Sci, Daejeon 34113, South Korea; [Ji, Hyun-Jung] Seoul Natl Univ, Sch Dent, Dept Oral Microbiol & Immunol, DRI, Seoul 08826, South Korea; [Ji, Hyun-Jung] Seoul Natl Univ, Sch Dent, BK21 Plus Program, Seoul 08826, South Korea		Song, JY (通讯作者)，Korea Univ, Dept Internal Med, Div Infect Dis, Coll Med, Seoul 08308, South Korea.; Seo, HS (通讯作者)，Korea Atom Energy Res Inst, Res Div Radiat Sci, Jeongeup 56212, South Korea.; Seo, HS (通讯作者)，Univ Sci & Technol, Dept Radiat Sci, Daejeon 34113, South Korea.	esooyun@nate.com; cowgow@naver.com; yongzhi@kaeri.re.kr; hyunjung@kaeri.re.kr; jynoh@korea.ac.kr; zephirisj9@gmail.com; heejinmd@korea.ac.kr; wjkim@korea.ac.kr; hoseongseo@kaeri.re.kr; infection@korea.ac.kr	; Kim, Woo Joo/D-2733-2015	Yoon, Jin Gu/0000-0003-3283-1880; Seo, Ho Seong/0000-0002-7103-1344; Kim, Woo Joo/0000-0002-4546-3880; A-Yeung, Jang/0000-0002-4050-2107; Song, Joon Young/0000-0002-0148-7194	Ministry of Food and Drug SafetyMinistry of Food & Drug Safety (MFDS) [20172MFDS282]; National Research Foundation of KoreaNational Research Foundation of Korea [NRF-2017M2A2A6A 02020925, NRF-2018K2A206023828, NRF-2020M2A206023828]	This work was supported by the Ministry of Food and Drug Safety under Grants and [20172MFDS282] to J.Y.S and National Research Foundation of Korea grants NRF-2017M2A2A6A 02020925, NRF-2018K2A206023828, and NRF-2020M2A206023828 to H.S.S.	Absalon J, 2021, LANCET INFECT DIS, V21, P263, DOI 10.1016/S1473-3099(20)30478-3; Balmer P, 2002, J MED MICROBIOL, V51, P717, DOI 10.1099/0022-1317-51-9-717; Berner R, 2021, LANCET INFECT DIS, V21, P158, DOI 10.1016/S1473-3099(20)30451-5; Buffi G, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00273-19; Burton RL, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00457-16; Richmond Jonathan Y, 2002, MMWR Recomm Rep, V51, P1; Choi MJ, 2020, HUM VACC IMMUNOTHER, V16, P1338, DOI 10.1080/21645515.2019.1688036; Choi MJ, 2018, HUM VACC IMMUNOTHER, V14, P67, DOI 10.1080/21645515.2017.1377379; Dangor Z, 2015, VACCINE, V33, P6793, DOI 10.1016/j.vaccine.2015.10.019; Edmond KM, 2012, LANCET, V379, P547, DOI 10.1016/S0140-6736(11)61651-6; Fabbrini M, 2016, CLIN INFECT DIS, V63, P746, DOI 10.1093/cid/ciw377; Huerta-Cepas J, 2019, NUCLEIC ACIDS RES, V47, pD309, DOI 10.1093/nar/gky1085; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; Kobayashi M, 2019, VACCINE, V37, P7307, DOI 10.1016/j.vaccine.2016.12.029; Kwatra G, 2015, Clin Microbiol Infect, V21, DOI 10.1016/j.cmi.2015.01.030; Le Doare K, 2019, LANCET INFECT DIS, V19, pE162, DOI 10.1016/S1473-3099(18)30659-5; Lin SM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-56141-3; Madhi SA, 2016, LANCET INFECT DIS, V16, P923, DOI 10.1016/S1473-3099(16)00152-3; Richter M, 2009, P NATL ACAD SCI USA, V106, P19126, DOI 10.1073/pnas.0906412106; Russell NJ, 2017, CLIN INFECT DIS, V65, pS152, DOI 10.1093/cid/cix655; Seemann T, 2014, BIOINFORMATICS, V30, P2068, DOI 10.1093/bioinformatics/btu153; Song JY, 2018, HUM VACC IMMUNOTHER, V14, P2669, DOI 10.1080/21645515.2018.1493326; Song JY, 2013, J INFECT CHEMOTHER, V19, P412, DOI 10.1007/s10156-013-0601-1; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; Swamy GK, 2020, VACCINE, V38, P6930, DOI 10.1016/j.vaccine.2020.08.056; Vekemans J, 2019, VACCINE, V37, P3190, DOI 10.1016/j.vaccine.2019.04.039; World Health Organization, 2002, TRAIN MAN ENZ LINK I	27	0	0	4	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							545	10.3390/vaccines9060545			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	TB3TH	34064299	Green Published, gold			2022-04-29	WOS:000667869200001
J	Lu, LT; Duong, VT; Shalash, AO; Skwarczynski, M; Toth, I				Lu, Lantian; Duong, Viet Tram; Shalash, Ahmed O.; Skwarczynski, Mariusz; Toth, Istvan			Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines	VACCINES			English	Review						conjugation strategies; protein subunit vaccines; nanovaccines; vaccine delivery; nanoparticulate delivery systems	INFLUENZA HEMAGGLUTININ TRIMERS; AZIDE-ALKYNE CYCLOADDITION; GOLD NANOPARTICLES; CLICK CHEMISTRY; LYMPH-NODE; COVALENT IMMOBILIZATION; VACCINE ADJUVANTS; SURFACE-CHARGE; CROSS-LINKING; IN-VITRO	The production of subunit nanovaccines relies heavily on the development of a vaccine delivery system that is safe and efficient at delivering antigens to the target site. Nanoparticles have been extensively investigated for vaccine delivery over the years, as they often possess self-adjuvanting properties. The conjugation of antigens to nanoparticles by covalent bonds ensures co-delivery of these components to the same subset of immune cells in order to trigger the desired immune responses. Herein, we review covalent conjugation strategies for grafting protein or peptide antigens onto other molecules or nanoparticles to obtain subunit nanovaccines. We also discuss the advantages of chemical conjugation in developing these vaccines.	[Lu, Lantian; Duong, Viet Tram; Shalash, Ahmed O.; Skwarczynski, Mariusz; Toth, Istvan] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia		Skwarczynski, M; Toth, I (通讯作者)，Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia.	l.lu@uq.edu.au; tram.duong@uq.edut.au; a.shalash@uq.net.au; m.skwarczynski@uq.edu.au; i.toth@uq.edu.au	Shalash, Ahmed O./AAS-2440-2021; Skwarczynski, Mariusz/A-6707-2009	Shalash, Ahmed O./0000-0003-3819-4798; Skwarczynski, Mariusz/0000-0001-7257-807X	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council (NHMRC) of Australia [APP1132975]	This work was supported by the National Health and Medical Research Council (NHMRC Program Grant APP1132975).	Agard NJ, 2004, J AM CHEM SOC, V126, P15046, DOI 10.1021/ja044996f; Alavi Mehran, 2019, Drug Metabolism and Personalized Therapy, V34, P20180032, DOI 10.1515/dmpt-2018-0032; Alavi SE, 2020, BIOCONJUGATE CHEM, V31, P1820, DOI 10.1021/acs.bioconjchem.0c00291; Altinbasak I, 2020, POLYM CHEM-UK, V11, P7603, DOI 10.1039/d0py01215g; An M, 2017, ACS APPL MATER INTER, V9, P23466, DOI 10.1021/acsami.7b06024; Bale S, 2017, J VIROL, V91, DOI 10.1128/JVI.00443-17; Bartlett S, 2020, CURR MED CHEM, V27, P2887, DOI 10.2174/0929867325666181026100849; Bashiri S, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12100965; Baskin JM, 2007, P NATL ACAD SCI USA, V104, P16793, DOI 10.1073/pnas.0707090104; Bernardi DS, 2016, NANOMED-NANOTECHNOL, V12, P2439, DOI 10.1016/j.nano.2016.07.001; Brisse M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583077; Bros M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01760; Caprifico AE, 2021, MACROMOL BIOSCI, V21, DOI 10.1002/mabi.202000312; Carter J. Mark, 1996, P679, DOI 10.1007/978-1-60327-259-9_117; Champion JA, 2006, P NATL ACAD SCI USA, V103, P4930, DOI 10.1073/pnas.0600997103; Chen JF, 2019, J AM CHEM SOC, V141, P9693, DOI 10.1021/jacs.9b04181; Clem AS, 2011, J GLOB INFECT DIS, V3, P73, DOI 10.4103/0974-777X.77299; Courant T, 2017, BIOMATERIALS, V136, P29, DOI 10.1016/j.biomaterials.2017.05.001; Dai C., 2020, PEPTIDE SYNTHESIS ME, P1327; Danaei M, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10020057; DELGADO C, 1990, BIOTECHNOL APPL BIOC, V12, P119; DELGADO C, 1989, SEPARATIONS USING AQ, P211; Dhoot NO, 2004, J BIOMED MATER RES A, V71A, P191, DOI 10.1002/jbm.a.30103; Dommerholt J, 2016, TOPICS CURR CHEM, V374, DOI 10.1007/s41061-016-0016-4; Esfahani K, 2020, CURR ONCOL, V27, pS87, DOI 10.3747/co.27.5223; Esparza J, 2020, VACCINE, V38, P1450, DOI 10.1016/j.vaccine.2019.11.077; Facciola A, 2019, EUR REV MED PHARMACO, V23, P7163, DOI 10.26355/eurrev_201908_18763; Faruck MO, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010023; Flanary S, 2009, BIOCONJUGATE CHEM, V20, P241, DOI 10.1021/bc800317a; Foged C, 2005, INT J PHARMACEUT, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035; Frampton JP, 2011, BIOMED MATER, V6, DOI 10.1088/1748-6041/6/1/015002; Francis MJ, 2018, VET CLIN N AM-SMALL, V48, P231, DOI 10.1016/j.cvsm.2017.10.002; Fuaad AAHA, 2013, MOLECULES, V18, P13148, DOI 10.3390/molecules181113148; Gao Y, 2008, BIOCONJUGATE CHEM, V19, P1945, DOI 10.1021/bc800051c; Gargett T, 2018, CANCER IMMUNOL IMMUN, V67, P1461, DOI 10.1007/s00262-018-2207-z; Gevrek TN, 2018, ACS APPL MATER INTER, V10, P14399, DOI 10.1021/acsami.8b00802; Ghaffar KA, 2014, CURR TOP MED CHEM, V14, P1194, DOI 10.2174/1568026614666140329232757; Giddam AK, 2012, NANOMEDICINE-UK, V7, P1877, DOI [10.2217/NNM.12.157, 10.2217/nnm.12.157]; Giri SS, 2021, REV AQUACULT, V13, P1844, DOI 10.1111/raq.12547; Greene MK, 2018, CHEM SCI, V9, P79, DOI 10.1039/c7sc02747h; Gregory AE, 2012, VACCINE, V30, P6777, DOI 10.1016/j.vaccine.2012.09.021; Gregory AE, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00013; Guo ZR, 2020, FISH SHELLFISH IMMUN, V99, P548, DOI 10.1016/j.fsi.2020.02.055; Han JA, 2014, NANOMED-NANOTECHNOL, V10, P561, DOI 10.1016/j.nano.2013.11.003; Han Y, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020299; Hanley Kathryn A, 2011, Evolution (N Y), V4, P635; Hermanson GT, 2013, BIOCONJUGATE TECHNIQUES, 3RD EDITION, P951, DOI 10.1016/B978-0-12-382239-0.00022-4; Hermanson GT, 2013, BIOCONJUGATE TECHNIQUES, 3RD EDITION, P275, DOI 10.1016/B978-0-12-382239-0.00005-4; Hermanson GT, 2008, BIOCONJUGATE TECHNIQUES, 2ND EDITION, P276; Hossain MK, 2019, ACS OMEGA, V4, P5204, DOI 10.1021/acsomega.9b00029; Hu F, 2020, FISH SHELLFISH IMMUN, V98, P810, DOI 10.1016/j.fsi.2019.11.035; Hua S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00790; Hussein WM, 2016, BIOORGAN MED CHEM, V24, P4372, DOI 10.1016/j.bmc.2016.07.036; Hussein WM, 2016, CHEM SCI, V7, P2308, DOI 10.1039/c5sc03859f; Irvine DJ, 2020, ADV DRUG DELIVER REV, V158, P91, DOI 10.1016/j.addr.2020.06.019; Jain A, 2010, INT J PHARMACEUT, V401, P87, DOI 10.1016/j.ijpharm.2010.09.003; Jia YJ, 2020, FISH SHELLFISH IMMUN, V100, P317, DOI 10.1016/j.fsi.2020.03.025; Jones DS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0138761; Kakami Y, 2019, COLLOID SURFACE A, V566, P128, DOI 10.1016/j.colsurfa.2019.01.023; Kang S, 2017, J CONTROL RELEASE, V256, P56, DOI 10.1016/j.jconrel.2017.04.024; Kar UK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038553; Kar UK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018758; Karandikar S, 2017, NANO STR MED, P263; Kennedy DC, 2011, J AM CHEM SOC, V133, P17993, DOI 10.1021/ja2083027; Kim KS, 2016, ADV FUNCT MATER, V26, P2512, DOI 10.1002/adfm.201504879; Kim SH, 2019, INT J NANOMED, V14, P5229, DOI 10.2147/IJN.S210546; Kraft JC, 2014, J PHARM SCI-US, V103, P29, DOI 10.1002/jps.23773; Kreutz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040208; Kuai R, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aao1736; Kuai R, 2018, BIOCONJUGATE CHEM, V29, P771, DOI 10.1021/acs.bioconjchem.7b00761; Kuai R, 2017, NAT MATER, V16, P489, DOI [10.1038/NMAT4822, 10.1038/nmat4822]; Lanciotti J, 2003, MOL THER, V8, P99, DOI 10.1016/S1525-0016(03)00139-4; Le HT, 2005, J CONTROL RELEASE, V108, P161, DOI 10.1016/j.jconrel.2005.07.019; Lee BR, 2016, SCI REP-UK, V6, DOI 10.1038/srep35182; Lee JY, 2020, ACS APPL MATER INTER, V12, P34658, DOI 10.1021/acsami.0c09484; Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51; Li L, 2016, MOLECULES, V21, DOI 10.3390/molecules21101393; Li SH, 2017, CHEM SCI, V8, P2107, DOI [10.1039/c6sc02297a, 10.1039/C6SC02297A]; Liu HP, 2015, BIOCONJUGATE CHEM, V26, P791, DOI 10.1021/acs.bioconjchem.5b00103; Liu LX, 2020, ACS APPL BIO MATER, V3, P5633, DOI 10.1021/acsabm.0c00668; Liu QF, 2015, J MED VIROL, V87, P1807, DOI 10.1002/jmv.24253; Liu QF, 2014, VACCINE, V32, P2582, DOI 10.1016/j.vaccine.2014.03.041; Liu QQ, 2020, COLLOID SURFACE B, V185, DOI 10.1016/j.colsurfb.2019.110588; Liu XF, 2019, POLYM CHEM-UK, V10, P705, DOI 10.1039/c8py01721b; Lovalenti PM, 2016, PHARM RES-DORDR, V33, P1144, DOI 10.1007/s11095-016-1860-1; Ma YF, 2011, NANOSCALE, V3, P2307, DOI 10.1039/c1nr10166h; Madler S, 2009, J MASS SPECTROM, V44, P694, DOI 10.1002/jms.1544; Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984; Meng J, 2008, SMALL, V4, P1364, DOI 10.1002/smll.200701059; Mills JLS, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00222-2; Molino NM, 2016, BIOMATERIALS, V86, P83, DOI 10.1016/j.biomaterials.2016.01.056; Molino NM, 2014, CURR OPIN BIOTECH, V28, P75, DOI 10.1016/j.copbio.2013.12.007; Molino NM, 2013, ACS NANO, V7, P9743, DOI 10.1021/nn403085w; Moyle PM, 2013, CHEMMEDCHEM, V8, P360, DOI 10.1002/cmdc.201200487; Neek M, 2019, NANOMED-NANOTECHNOL, V15, P164, DOI 10.1016/j.nano.2018.09.004; Neek M, 2018, BIOMATERIALS, V156, P194, DOI 10.1016/j.biomaterials.2017.11.022; Nembrini C, 2011, P NATL ACAD SCI USA, V108, pE989, DOI 10.1073/pnas.1104264108; Nevagi RJ, 2019, EUR POLYM J, V114, P397, DOI 10.1016/j.eurpolymj.2019.03.009; Niikura K, 2013, ACS NANO, V7, P3926, DOI 10.1021/nn3057005; NILSSON K, 1984, METHOD ENZYMOL, V104, P56; Nogueira JCF, 2019, CHEM COMMUN, V55, P7671, DOI 10.1039/c9cc02655j; Oltolina F, 2015, LANGMUIR, V31, P1766, DOI 10.1021/la503747s; Pandey M, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1260; Pandey M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14157-7; Pashine A, 2005, NAT MED, V11, pS63, DOI 10.1038/nm1210; Pati R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02224; Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0392-8; Pauthner M, 2017, IMMUNITY, V46, P1073, DOI 10.1016/j.immuni.2017.05.007; Petri L, 2020, RSC ADV, V10, P14928, DOI 10.1039/d0ra02934c; Pickens CJ, 2018, BIOCONJUGATE CHEM, V29, P686, DOI 10.1021/acs.bioconjchem.7b00633; Qiu DK, 2021, AQUACULTURE, V533, DOI 10.1016/j.aquaculture.2020.736152; Ravasco JMJM, 2019, CHEM-EUR J, V25, P43, DOI 10.1002/chem.201803174; Rezaei M, 2019, ARTIF CELL NANOMED B, V47, P1543, DOI 10.1080/21691401.2019.1577888; Sahin S, 2020, J PHARMACEUT BIOMED, V184, DOI 10.1016/j.jpba.2020.113195; Sakulkhu U, 2015, BIOMATER SCI-UK, V3, P265, DOI 10.1039/c4bm00264d; Sanchez-Villamil JI, 2019, MBIO, V10, DOI 10.1128/mBio.01869-19; Sander VA, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00288; Scaria PV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190312; Scheetz L, 2020, CLIN CANCER RES, V26, P4369, DOI 10.1158/1078-0432.CCR-20-0341; Sekimukai H, 2020, MICROBIOL IMMUNOL, V64, P33, DOI 10.1111/1348-0421.12754; Sekuloski S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198658; Shi ST, 2019, VACCINE, V37, P3167, DOI 10.1016/j.vaccine.2019.04.055; Shin MD, 2020, NAT NANOTECHNOL, V15, P646, DOI 10.1038/s41565-020-0737-y; Skwarczynski M, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax2285; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Skwarczynski M, 2014, NANOMEDICINE-UK, V9, P2657, DOI [10.2217/NNM.14.187, 10.2217/nnm.14.187]; Skwarczynski M, 2010, ANGEW CHEM INT EDIT, V49, P5742, DOI 10.1002/anie.201002221; Slutter B, 2010, MOL PHARMACEUT, V7, P2207, DOI 10.1021/mp100210g; Song FY, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/49/494006; Spicer CD, 2018, CHEM REV, V118, P7702, DOI 10.1021/acs.chemrev.8b00253; Stano A, 2013, BIOMATERIALS, V34, P4339, DOI 10.1016/j.biomaterials.2013.02.024; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; Steenpass T, 2006, BBA-BIOMEMBRANES, V1758, P20, DOI 10.1016/j.bbamem.2005.12.010; Stone J, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957-4484/24/29/295102; Tang Xiaoting, 2009, V492, P283, DOI 10.1007/978-1-59745-493-3_17; Thalhauser S, 2020, J PHARM SCI-US, V109, P911, DOI 10.1016/j.xphs.2019.10.059; Thorek DLJ, 2009, MOL IMAGING, V8, P221, DOI 10.2310/7290.2009.00021; Tokatlian T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34853-2; Toyota H, 2015, ONCOL REP, V33, P292, DOI 10.3892/or.2014.3603; Tsuchikama K, 2018, PROTEIN CELL, V9, P33, DOI 10.1007/s13238-016-0323-0; Valdes-Balbin Y., 2021, SARS COV 2 RBD TETAN, DOI [10.1101/2021.02.08.430146, DOI 10.1101/2021.02.08.430146]; van der Vlies AJ, 2010, BIOCONJUGATE CHEM, V21, P653, DOI 10.1021/bc9004443; Verma A, 2008, NAT MATER, V7, P588, DOI 10.1038/nmat2202; Wang C, 2018, NANOMED-NANOTECHNOL, V14, P1349, DOI 10.1016/j.nano.2018.03.007; Wang C, 2017, INT J NANOMED, V12, P4747, DOI 10.2147/IJN.S137222; Wang Q, 2003, J AM CHEM SOC, V125, P3192, DOI 10.1021/ja021381e; Wang ZB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010128; Wilson DS, 2019, NAT MATER, V18, P175, DOI 10.1038/s41563-018-0256-5; Wilson JT, 2013, ACS NANO, V7, P3912, DOI 10.1021/nn305466z; Wilson KL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00331; Xu ZH, 2018, BIOCONJUGATE CHEM, V29, P572, DOI 10.1021/acs.bioconjchem.7b00478; Yadav HKS, 2018, J DRUG DELIV SCI TEC, V44, P380, DOI 10.1016/j.jddst.2018.01.015; Yanase N, 2014, VACCINE, V32, P5918, DOI 10.1016/j.vaccine.2014.08.059; Yang JR, 2019, CURR DRUG DELIV, V16, P430, DOI 10.2174/1567201816666190123120915; Yang R, 2018, ACS NANO, V12, P5121, DOI 10.1021/acsnano.7b09041; Yuba E, 2014, BIOMATERIALS, V35, P3091, DOI 10.1016/j.biomaterials.2013.12.024; Yusuf H, 2017, HUM VACC IMMUNOTHER, V13, P34, DOI 10.1080/21645515.2016.1239668; Zeng DX, 2013, J NUCL MED, V54, P829, DOI 10.2967/jnumed.112.115550; Zhang LH, 2019, NANO LETT, V19, P4237, DOI 10.1021/acs.nanolett.9b00030; Zhang L, 2019, TALANTA, V204, P875, DOI 10.1016/j.talanta.2019.05.104; Zhang YN, 2019, NANO LETT, V19, P7226, DOI 10.1021/acs.nanolett.9b02834; Zhao GZ, 2017, EUR POLYM J, V93, P670, DOI 10.1016/j.eurpolymj.2017.02.014; Zhao LL, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10050823; Zhao LL, 2019, ACS BIOMATER SCI ENG, V5, P4937, DOI 10.1021/acsbiomaterials.9b01135; Zhao Z, 2020, FISH SHELLFISH IMMUN, V97, P432, DOI 10.1016/j.fsi.2019.12.072	165	5	5	17	25	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							563	10.3390/vaccines9060563			24	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY8OY	34071482	gold, Green Published			2022-04-29	WOS:000666141600001
J	Peterhoff, D; Thalhauser, S; Sobczak, JM; Mohsen, MO; Voigt, C; Seifert, N; Neckermann, P; Hauser, A; Ding, S; Sattentau, Q; Bachmann, MF; Breunig, M; Wagner, R				Peterhoff, David; Thalhauser, Stefanie; Sobczak, Jan M.; Mohsen, Mona O.; Voigt, Christoph; Seifert, Nicole; Neckermann, Patrick; Hauser, Alexandra; Ding, Song; Sattentau, Quentin; Bachmann, Martin F.; Breunig, Miriam; Wagner, Ralf			Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery	VACCINES			English	Article						HIV vaccine; silica nanoparticles; stabilized envelope trimer; Env	ENHANCING HUMORAL RESPONSES; NEUTRALIZING ANTIBODIES; GERMINAL CENTER; VACCINE; CELLS	The delivery of HIV-1 envelope (Env) trimer-based immunogens on the surface of nanoparticles holds promise to promote immunogenicity with the aim of inducing a potent, durable and broad neutralizing antibody (bnAb) response. Towards that goal, we examined the covalent conjugation of Env to 100 nm and 200 nm silica nanoparticles (SiNPs) to optimize conjugation density and attachment stability. Env was redesigned to enable site-specific cysteine-mediated covalent conjugation while maintaining its structural integrity and antigenicity. Env was anchored to different sized SiNPs with a calculated spacing of 15 nm between adjacent trimers. Both particle sizes exhibited high in vitro stability over a seven-day period. After attachment, 100 nm particles showed better colloidal stability compared to 200 nm particles. Importantly, the antigenic profile of Env was not impaired by surface attachment, indicating that the quaternary structure was maintained. In vitro Env uptake by dendritic cells was significantly enhanced when Env was delivered on the surface of nanoparticles compared to soluble Env. Furthermore, multivalent Env displayed efficiently activated B cells even at Env concentrations in the low nanomolar range. In mice, antibody responses to nanoparticle-coupled Env were stronger compared to the free protein and had equivalent effects at lower doses and without adjuvant.	[Peterhoff, David; Voigt, Christoph; Seifert, Nicole; Neckermann, Patrick; Hauser, Alexandra; Wagner, Ralf] Univ Regensburg, Inst Med Microbiol & Hyg Mol Microbiol Virol, D-93053 Regensburg, Germany; [Peterhoff, David; Wagner, Ralf] Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, D-93053 Regensburg, Germany; [Thalhauser, Stefanie] Univ Regensburg, Inst Pharmaceut Technol, D-93053 Regensburg, Germany; [Sobczak, Jan M.; Mohsen, Mona O.; Bachmann, Martin F.] Univ Bern, Dept BioMed Res, CH-3010 Bern, Switzerland; [Sobczak, Jan M.; Mohsen, Mona O.; Bachmann, Martin F.] Univ Hosp Bern, Dept Immunol RI, CH-3010 Bern, Switzerland; [Ding, Song] EuroVacc Fdn, CH-1002 Lausanne, Switzerland; [Sattentau, Quentin] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Bachmann, Martin F.] Univ Oxford, Jenner Inst, Nuffield Dept Med, Oxford OX3 7DQ, England		Peterhoff, D; Wagner, R (通讯作者)，Univ Regensburg, Inst Med Microbiol & Hyg Mol Microbiol Virol, D-93053 Regensburg, Germany.; Peterhoff, D; Wagner, R (通讯作者)，Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, D-93053 Regensburg, Germany.	david.peterhoff@ur.de; stefanie.thalhauser@gmail.com; jan.sobczak@dbmr.unibe.ch; mona.mohsen@dbmr.unibe.ch; christoph.voigt@stud.uni-regensburg.de; nicole.seifert@uni-hohenheim.de; patrick.neckermann@klinik.uni-regensburg.de; alexandra.hauser@klinik.uni-regensburg.de; song.ding@eurovacc.org; quentin.sattentau@path.ox.ac.uk; martin.bachmann@dbmr.unibe.ch; miriam.breunig@chemie.uni-regensburg.de; ralf.wagner@ur.de	Breunig, Miriam/K-2978-2016; Peterhoff, David/ABD-6746-2020	Breunig, Miriam/0000-0002-1320-6820; Bachmann, Martin/0000-0003-4370-2099; Hauser, Alexandra/0000-0002-9738-392X; Seifert, Nicole/0000-0002-2191-523X; Peterhoff, David/0000-0001-5911-6233	European UnionEuropean Commission [681032]	This research was funded by the European Union's horizon 2020 research and innovation programme under grant agreement No. 681032.	Alkilany AM, 2019, ADV DRUG DELIVER REV, V143, P22, DOI 10.1016/j.addr.2019.05.010; An M, 2017, ACS APPL MATER INTER, V9, P23466, DOI 10.1021/acsami.7b06024; Asbach B, 2017, CURR OPIN HIV AIDS, V12, P265, DOI 10.1097/COH.0000000000000366; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Bale S, 2017, J VIROL, V91, DOI 10.1128/JVI.00443-17; Brinkkemper M, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030076; Brouwer PJM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12080-1; Brouwer PJM, 2019, CURR OPIN HIV AIDS, V14, P302, DOI 10.1097/COH.0000000000000549; Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515; Casella CR, 2008, CELL MOL LIFE SCI, V65, P3231, DOI 10.1007/s00018-008-8228-6; Cruz LJ, 2012, METHOD ENZYMOL, V509, P143, DOI 10.1016/B978-0-12-391858-1.00008-3; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; Foged C, 2005, INT J PHARMACEUT, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035; Galimidi RP, 2015, CELL, V160, P433, DOI 10.1016/j.cell.2015.01.016; Harwood NE, 2010, ANNU REV IMMUNOL, V28, P185, DOI 10.1146/annurev-immunol-030409-101216; Hauser A., STEPWISE CONFORMA TI; Havenar-Daughton C, 2019, CELL REP, V29, P1756, DOI 10.1016/j.celrep.2019.10.008; Havenar-Daughton C, 2016, CELL REP, V17, P2195, DOI 10.1016/j.celrep.2016.10.085; Haynes BF, 2017, SCIENCE, V355, P1129, DOI 10.1126/science.aan0662; Ingale J, 2016, CELL REP, V15, P1986, DOI 10.1016/j.celrep.2016.04.078; Jiang W, 2008, NAT NANOTECHNOL, V3, P145, DOI 10.1038/nnano.2008.30; Koff WC, 2012, VACCINE, V30, P4310, DOI 10.1016/j.vaccine.2011.11.014; Kulp DW, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01549-6; Kwong PD, 2013, NAT REV IMMUNOL, V13, P693, DOI 10.1038/nri3516; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984; Martinez-Murillo P, 2017, IMMUNITY, V46, P804, DOI 10.1016/j.immuni.2017.04.021; Figueroa SM, 2020, MACROMOL BIOSCI, V20, DOI 10.1002/mabi.201900427; Mata-Haro V, 2007, SCIENCE, V316, P1628, DOI 10.1126/science.1138963; McCoy LE, 2013, J EXP MED, V210, P209, DOI 10.1084/jem.20121827; Minguet S, 2017, NAT IMMUNOL, V18, P1150, DOI 10.1038/ni.3813; Mody KT, 2013, NANOSCALE, V5, P5167, DOI 10.1039/c3nr00357d; Moon JJ, 2012, P NATL ACAD SCI USA, V109, P1080, DOI 10.1073/pnas.1112648109; Packard Thomas A, 2013, F1000Prime Rep, V5, P40, DOI 10.12703/P5-40; Pancera M, 2017, CURR OPIN HIV AIDS, V12, P229, DOI 10.1097/COH.0000000000000360; Perciani CT, 2007, J CLIN LAB ANAL, V21, P201, DOI 10.1002/jcla.20172; Peterhoff D, 2017, CURR OPIN HIV AIDS, V12, P257, DOI 10.1097/COH.0000000000000356; Poteet E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136862; Qin Q, 2016, BIOMATERIALS, V101, P189, DOI 10.1016/j.biomaterials.2016.05.050; Rancan F, 2012, ACS NANO, V6, P6829, DOI 10.1021/nn301622h; Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI 10.1038/nbtl332; Ringe RP, 2020, J VIROL, V94, DOI 10.1128/JVI.01883-19; Sanders RW, 2015, SCIENCE, V349, DOI 10.1126/science.aac4223; Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618; Shang L, 2014, J NANOBIOTECHNOL, V12, DOI 10.1186/1477-3155-12-5; Sharma SK, 2015, CELL REP, V11, P539, DOI 10.1016/j.celrep.2015.03.047; Sliepen K, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0210-4; Stoddart A, 2005, MOL BIOL CELL, V16, P2339, DOI 10.1091/mbc.E05-01-0025; Suen WLL, 2014, J PHARM PHARMACOL, V66, P564, DOI 10.1111/jphp.12134; Thalhauser S, 2020, J CONTROL RELEASE, V317, P322, DOI 10.1016/j.jconrel.2019.11.035; Thalhauser S, 2020, J PHARM SCI-US, V109, P911, DOI 10.1016/j.xphs.2019.10.059; Nguyen TL, 2019, ADV MATER, V31, DOI 10.1002/adma.201803953; Tjandra KC, 2019, BIOCONJUGATE CHEM, V30, P503, DOI 10.1021/acs.bioconjchem.8b00804; Tokatlian T, 2019, SCIENCE, V363, P649, DOI 10.1126/science.aat9120; Tokatlian T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34853-2; Tolar P, 2017, NAT REV IMMUNOL, V17, P621, DOI 10.1038/nri.2017.67; Tu J, 2017, PHARM RES-DORDR, V34, P1693, DOI 10.1007/s11095-017-2177-4; Wilen CB, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006866; Wykes M, 1998, J IMMUNOL, V161, P1313; Yang LF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01631	61	1	1	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JUN	2021	9	6							642	10.3390/vaccines9060642			24	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SY4XA	34208059	Green Published			2022-04-29	WOS:000665891700001
J	Bae, JY; Kim, JI; Park, MS; Lee, GE; Park, H; Song, KJ; Park, MS				Bae, Joon-Yong; Kim, Jin Il; Park, Mee Sook; Lee, Gee Eun; Park, Heedo; Song, Ki-Joon; Park, Man-Seong			The Immune Correlates of Orthohantavirus Vaccine	VACCINES			English	Review						antigenicity; glycoprotein; orthohantavirus; pandemic; vaccine	VIRUS NUCLEOCAPSID PROTEIN; INACTIVATED HANTAVIRUS VACCINE; NEUTRALIZING ANTIBODY-RESPONSE; HEMORRHAGIC-FEVER; HANTAAN-VIRUS; RENAL SYNDROME; SIN-NOMBRE; ANDES HANTAVIRUS; PROTECTIVE EFFECTIVENESS; ETIOLOGIC AGENT	Zoonotic transmission of orthohantaviruses from rodent reservoirs to humans has been the cause of severe fatalities. Human infections are reported worldwide, but vaccines have been approved only in China and Korea. Orthohantavirus vaccine development has been pursued with no sense of urgency due to the relative paucity of cases in countries outside China and Korea. However, the orthohantaviruses continuously evolve in hosts and thus the current vaccine may not work as well against some variants. Therefore, a more effective vaccine should be prepared against the orthohantaviruses. In this review, we discuss the issues caused by the orthohantavirus vaccine. Given the pros and cons of the orthohantavirus vaccine, we suggest strategies for the development of better vaccines in terms of pandemic preparedness.	[Bae, Joon-Yong; Kim, Jin Il; Park, Mee Sook; Lee, Gee Eun; Park, Heedo; Song, Ki-Joon; Park, Man-Seong] Korea Univ, Coll Med, Dept Microbiol, Inst Viral Dis,Biosafety Ctr, Seoul 02841, South Korea		Park, MS (通讯作者)，Korea Univ, Coll Med, Dept Microbiol, Inst Viral Dis,Biosafety Ctr, Seoul 02841, South Korea.	harbe3103@korea.ac.kr; jinil_kim@korea.ac.kr; parkmees@korea.ac.kr; geeeun950606@gmail.com; phd0919@naver.com; songmicr@korea.ac.kr; manseong.park@gmail.com		Lee, Geeeun/0000-0002-3523-6326; PARK, Mee Sook/0000-0002-0665-3964; PARK, Heedo/0000-0001-9992-5131	National Research Foundation of Korea (NRF) - Ministry of Science and ICT, Republic of Korea [NRF-2017M3A9E4061995]	This study was supported by a grant from the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT, Republic of Korea (grant No. NRF-2017M3A9E4061995.	Araki K, 2001, J CLIN MICROBIOL, V39, P2397, DOI 10.1128/JCM.39.7.2397-2404.2001; Auladell M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01400; Bostik P, 2000, EMERG INFECT DIS, V6, P184, DOI 10.3201/eid0602.000213; Brocato RL, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070610; Bucht G, 2001, VACCINE, V19, P3820, DOI 10.1016/S0264-410X(01)00151-7; Caddy SL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008732; Carragher DM, 2008, J IMMUNOL, V181, P4168, DOI 10.4049/jimmunol.181.6.4168; Cho HW, 2002, INTERVIROLOGY, V45, P328, DOI 10.1159/000067925; Cho HW, 1999, VACCINE, V17, P2569, DOI 10.1016/S0264-410X(99)00057-2; Choi Y, 2003, VACCINE, V21, P1867, DOI 10.1016/S0264-410X(03)00005-7; Choi Y, 2008, VIROLOGY, V381, P178, DOI 10.1016/j.virol.2008.08.035; Clement J, 2012, EUR J CLIN MICROBIOL, V31, P1, DOI 10.1007/s10096-011-1456-y; Colbert JD, 2020, CURR OPIN IMMUNOL, V64, P1, DOI 10.1016/j.coi.2019.12.005; Dalrymple NA, 2014, CURR OPIN VIROL, V7, P134, DOI 10.1016/j.coviro.2014.06.006; Elgh F, 1996, J VIROL METHODS, V59, P161, DOI 10.1016/0166-0934(96)02042-3; Elgh F, 1997, J CLIN MICROBIOL, V35, P1122, DOI 10.1128/JCM.35.5.1122-1130.1997; Elliott R.M., 2013, FIELDS VIROLOGY, V6th ed., P1244; Fazilleau N, 2009, IMMUNITY, V30, P324, DOI 10.1016/j.immuni.2009.03.003; Ferres M, 2007, J INFECT DIS, V195, P1563, DOI 10.1086/516786; Getahun A, 2006, IMMUNOL LETT, V104, P38, DOI 10.1016/j.imlet.2005.11.005; Ghebrehiwet B, 2016, IMMUNOL REV, V274, P281, DOI 10.1111/imr.12469; Golden JW, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/793257; Harris A, 2006, P NATL ACAD SCI USA, V103, P19123, DOI 10.1073/pnas.0607614103; Heyman B, 2014, CURR TOP MICROBIOL, V382, P201, DOI 10.1007/978-3-319-07911-0_9; Hooper JW, 2014, CLIN MICROBIOL INFEC, V20, P110, DOI 10.1111/1469-0691.12553; Hooper JW, 2013, VACCINE, V31, P4314, DOI 10.1016/j.vaccine.2013.07.025; Hooper JW, 2006, VIROLOGY, V347, P208, DOI 10.1016/j.virol.2005.11.035; Hooper JW, 2001, J VIROL, V75, P8469, DOI 10.1128/JVI.75.18.8469-8477.2001; Hooper JW, 2001, VIROLOGY, V289, P6, DOI 10.1006/viro.2001.1133; Jonsson CB, 2010, CLIN MICROBIOL REV, V23, P412, DOI 10.1128/CMR.00062-09; Jung J, 2018, J INFECT DIS, V217, P1417, DOI 10.1093/infdis/jiy037; Kang JI, 2001, VIRUS GENES, V23, P183, DOI 10.1023/A:1011896223601; Kim JI, 2013, J VIROL, V87, P7539, DOI 10.1128/JVI.00373-13; Krarup A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9143; Lee HW, 2014, VIRUS RES, V187, P2, DOI 10.1016/j.virusres.2013.12.019; LEE HW, 1982, J INFECT DIS, V146, P638, DOI 10.1093/infdis/146.5.638; LEE HW, 1978, J INFECT DIS, V137, P298, DOI 10.1093/infdis/137.3.298; LEE HW, 1989, REV INFECT DIS, V11, pS864; LEE PW, 1985, J CLIN MICROBIOL, V22, P940, DOI 10.1128/JCM.22.6.940-944.1985; Leifer CA, 2016, J LEUKOCYTE BIOL, V100, P927, DOI 10.1189/jlb.2MR0316-117RR; Lillie PJ, 2012, CLIN INFECT DIS, V55, P19, DOI 10.1093/cid/cis327; Lin XD, 2012, J VIROL, V86, P972, DOI 10.1128/JVI.00725-11; Lindkvist M, 2008, VIRUS RES, V137, P97, DOI 10.1016/j.virusres.2008.06.003; Liu RR, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02989; LUNDKVIST A, 1992, ARCH VIROL, V126, P93, DOI 10.1007/BF01309687; LUNDKVIST A, 1993, ARCH VIROL, V130, P121, DOI 10.1007/BF01319001; Mackow ER, 2001, CURR TOP MICROBIOL, V256, P91; Maes P, 2006, INTERVIROLOGY, V49, P253, DOI 10.1159/000093454; Martinez VP, 2005, EMERG INFECT DIS, V11, P1848, DOI 10.3201/eid1112.050501; Martinez-Valdebenito C, 2014, EMERG INFECT DIS, V20, P1629, DOI 10.3201/eid2010.140353; Miller M, 2017, B WORLD HEALTH ORGAN, V95, P62, DOI 10.2471/BLT.16.175984; Molenaar-de Backer MWA, 2016, J CLIN VIROL, V84, P19, DOI 10.1016/j.jcv.2016.09.004; Nicacio CD, 2000, J GEN VIROL, V81, P1453, DOI 10.1099/0022-1317-81-6-1453; Nicacio CD, 2002, J VIROL, V76, P6669, DOI 10.1128/JVI.76.13.6669-6677.2002; Park K, 2004, EMERG INFECT DIS, V10, P2218, DOI 10.3201/eid1012.040684; Park MS, 2020, LAB ANIM RES, V36, DOI 10.1186/s42826-020-00040-6; Park MS, 2016, IMMUNE NETW, V16, P261, DOI 10.4110/in.2016.16.5.261; Plyusnina A, 2012, J MED VIROL, V84, P1298, DOI 10.1002/jmv.23321; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Rissanen I, 2017, J VIROL, V91, DOI 10.1128/JVI.00378-17; Safronetz D, 2009, J VIROL, V83, P7285, DOI 10.1128/JVI.00373-09; Schmaljohn C, 2009, VACCINE, V27, pD61, DOI 10.1016/j.vaccine.2009.07.096; SCHMALJOHN CS, 1985, SCIENCE, V227, P1041, DOI 10.1126/science.2858126; Schmidt J, 2006, INTERVIROLOGY, V49, P173, DOI 10.1159/000089378; Schountz T, 2014, J VIROL, V88, P8319, DOI 10.1128/JVI.00004-14; Schountz T, 2014, VIRUSES-BASEL, V6, P1317, DOI 10.3390/v6031317; Schubert J, 2001, J CLIN VIROL, V21, P63, DOI 10.1016/S1386-6532(00)00187-6; Serris A, 2020, CELL, V183, P442, DOI 10.1016/j.cell.2020.08.023; Shaw MLPP, 2013, FIELDS VIROLOGY, P1151; SHESHBERADARAN H, 1988, J GEN VIROL, V69, P2645, DOI 10.1099/0022-1317-69-10-2645; Sohn YM, 2001, YONSEI MED J, V42, P278, DOI 10.3349/ymj.2001.42.3.278; Sohn Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092924; Song JW, 2009, J VIROL, V83, P6184, DOI 10.1128/JVI.00371-09; Song JY, 2020, VACCINE, V38, P8016, DOI 10.1016/j.vaccine.2020.10.035; Song JY, 2016, VACCINE, V34, P1289, DOI 10.1016/j.vaccine.2016.01.031; Spengler JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055310; St John AL, 2019, NAT REV IMMUNOL, V19, P218, DOI 10.1038/s41577-019-0123-x; Swanink C, 2018, EMERG INFECT DIS, V24, P2158, DOI 10.3201/eid2412.180229; Phan TG, 2017, CURR OPIN IMMUNOL, V45, P132, DOI 10.1016/j.coi.2017.03.005; Valdivieso F, 2006, EMERG INFECT DIS, V12, P166, DOI 10.3201/eid1201.050930; Wang ML, 2009, J INFECT DIS, V199, P188, DOI 10.1086/595834; YAMANAKA K, 1990, J BIOL CHEM, V265, P11151; Yanagihara R, 2014, VIRUS RES, V187, P6, DOI 10.1016/j.virusres.2013.12.038; YAO JS, 1992, ARCH VIROL, V122, P107, DOI 10.1007/BF01321121; Youngblood B, 2013, IMMUNOLOGY, V139, P277, DOI 10.1111/imm.12074; Zheng Y, 2018, INFECT DIS-NOR, V50, P21, DOI 10.1080/23744235.2017.1353704	86	1	1	3	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							518	10.3390/vaccines9050518			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1NH	34069997	Green Published, gold			2022-04-29	WOS:000654592400001
J	Esposito, S; Chiopris, G; Messina, G; D'Alvano, T; Perrone, S; Principi, N				Esposito, Susanna; Chiopris, Giulia; Messina, Giulia; D'Alvano, Tiziana; Perrone, Serafina; Principi, Nicola			Prevention of Congenital Cytomegalovirus Infection with Vaccines: State of the Art	VACCINES			English	Review						CMV; CMV infection; congenital infection; vaccination; vaccine	COST-EFFECTIVENESS; ADOLESCENT GIRLS; PREGNANT-WOMEN; DNA VACCINE; CMV; ANTIBODY; COMPLEX; SAFETY; LIVE; IMMUNOGENICITY	Cytomegalovirus (CMV) is the most common cause of congenital infection and non-genetic sensorineural hearing loss in childhood. Up to 2% of neonates, with the highest percentages found in developing countries, are congenitally infected with CMV. At birth, most of these infants are asymptomatic. However, approximately 10% have signs and symptoms of the disease, and 40-60% of symptomatic neonates will later develop permanent neurologic sequelae. To reduce congenital CMV (cCMV) infection, a vaccine able to prevent primary infection is essential. In this narrative review, actual ongoing research about the development of a CMV vaccine is discussed. The progressive increase in knowledge on the ways in which the host's immune system and CMV relate has made it possible to clarify that the development of a vaccine that is certainly capable of reducing the risk of cCMV infection, and preventing both primary and nonprimary infections is extremely difficult. Many of the ways in which the virus evades the immune system and causes cCMV infection are not yet fully understood, especially in cases of nonprimary infection. Moreover, the schedule that should be recommended and that subjects must be vaccinated to obtain the greatest effect have not been precisely defined. Further studies are needed before the problem of cCMV infection and its related challenges can be totally solved.	[Esposito, Susanna; Chiopris, Giulia; Messina, Giulia; D'Alvano, Tiziana] Univ Parma, Pietro Barilla Childrens Hosp, Pediat Clin, Via Gramsci 14, I-43126 Parma, Italy; [Perrone, Serafina] Univ Parma, Pietro Barilla Childrens Hosp, Neonatol Unit, Dept Med & Surg, I-43126 Parma, Italy; [Principi, Nicola] Univ Milan, I-20122 Milan, Italy		Esposito, S (通讯作者)，Univ Parma, Pietro Barilla Childrens Hosp, Pediat Clin, Via Gramsci 14, I-43126 Parma, Italy.	susannamariaroberta.esposito@unipr.it; giulia.chiopris@gmail.com; messina.giulia@gmail.com; tiziana.dalvano@gmail.com; Serafina.perrone@unipr.it; nicola.principi@unimi.it	Perrone, Serafina/AAC-2592-2022; Esposito, Susanna/AAA-8275-2022	Principi, Nicola/0000-0002-3468-5568	Ri.Cli.Ped.-University of Parma, Parma, Italy	Ri.Cli.Ped.-University of Parma, Parma, Italy.	Adler SP, 1999, J INFECT DIS, V180, P843, DOI 10.1086/314951; Adler SP, 2016, J INFECT DIS, V214, P1341, DOI 10.1093/infdis/jiw365; Ahlfors K, 1999, SCAND J INFECT DIS, V31, P443, DOI 10.1080/00365549950163969; Aldoss I, 2020, ANN INTERN MED, V172, P306, DOI 10.7326/M19-2511; Arav-Boger R, 2015, INFECT DIS CLIN N AM, V29, P401, DOI 10.1016/j.idc.2015.05.009; Bernstein DI, 2016, VACCINE, V34, P313, DOI 10.1016/j.vaccine.2015.11.056; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Boppana SB, 1999, PEDIATRICS, V104, P55, DOI 10.1542/peds.104.1.55; Boppana SB, 2013, CLIN INFECT DIS, V57, pS178, DOI 10.1093/cid/cit629; Cannon MJ, 2010, REV MED VIROL, V20, P202, DOI 10.1002/rmv.655; Centers for Disease Control and Prevention, VACC PREV DIS ADM HP; Cerboni C, 2000, J IMMUNOL, V164, P4775, DOI 10.4049/jimmunol.164.9.4775; Chevillotte M, 2009, J VIROL, V83, P2480, DOI 10.1128/JVI.01818-08; Collins-McMillen D, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00476; Contreras H, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040182; Coppola T, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040129; Cui XL, 2018, VACCINE, V36, P5580, DOI 10.1016/j.vaccine.2018.07.056; Davis NL, 2017, BIRTH DEFECTS RES, V109, P336, DOI 10.1002/bdra.23601; Dempsey AF, 2012, VACCINE, V30, P4060, DOI 10.1016/j.vaccine.2012.04.011; Fehr T, 2015, TRANSPL INT, V28, P1351, DOI 10.1111/tri.12629; Fornara C, 2017, CLIN INFECT DIS, V65, P1659, DOI 10.1093/cid/cix622; Forrest C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030394; Forte E, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00130; Fowler KB, 2006, PEDIATRICS, V118, pE286, DOI 10.1542/peds.2005-1142; FOWLER KB, 1991, J INFECT DIS, V164, P259, DOI 10.1093/infdis/164.2.259; FOWLER KB, 1992, NEW ENGL J MED, V326, P663, DOI 10.1056/NEJM199203053261003; Garcon N, 2011, EXPERT REV VACCINES, V10, P471, DOI [10.1586/ERV.11.29, 10.1586/erv.11.29]; Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109; Hyde TB, 2010, REV MED VIROL, V20, P311, DOI 10.1002/rmv.659; John S, 2018, VACCINE, V36, P1689, DOI 10.1016/j.vaccine.2018.01.029; Johnson JM, 2013, AM J PERINAT, V30, P121, DOI 10.1055/s-0032-1333133; Kabanova A, 2014, P NATL ACAD SCI USA, V111, P17965, DOI 10.1073/pnas.1415310111; Kemble G., 2002, P ABSTR 27 HERP SIMP; Krause PR, 2013, VACCINE, V32, P4, DOI 10.1016/j.vaccine.2013.09.042; La Rosa C, 2017, BLOOD, V129, P114, DOI 10.1182/blood-2016-07-729756; La Rosa C, 2012, J INFECT DIS, V205, P1294, DOI 10.1093/infdis/jis107; Leong CC, 1998, J EXP MED, V187, P1681, DOI 10.1084/jem.187.10.1681; Lilleri D, 2018, J MED VIROL, V90, P1620, DOI 10.1002/jmv.25225; Lilleri D, 2017, REV MED VIROL, V27, DOI 10.1002/rmv.1921; Mocarski E., 2013, FIELDS VIROLOGY, P1960; Moderna, MOD ANN CLIN PROGR I; N'Diaye DS, 2018, VACCINE, V36, P1285, DOI 10.1016/j.vaccine.2018.01.042; N'Diaye DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089857; Nelson CS, 2020, J VIROL, V94, DOI 10.1128/JVI.00186-20; Nelson CS, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0074-4; Nelson CS, 2018, P NATL ACAD SCI USA, V115, P6267, DOI 10.1073/pnas.1800177115; O'Hagan DT, 2013, EXPERT REV VACCINES, V12, P13, DOI [10.1586/ERV.12.140, 10.1586/erv.12.140]; Pass RF, 2009, NEW ENGL J MED, V360, P1191, DOI 10.1056/NEJMoa0804749; Paulus C, 2009, VIRUSES-BASEL, V1, P760, DOI 10.3390/v1030760; Perotti M, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009169; Perotti M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010035; PLOTKIN SA, 1984, LANCET, V1, P528; PLOTKIN SA, 1989, J INFECT DIS, V159, P860, DOI 10.1093/infdis/159.5.860; Plotkin SA, 2020, J INFECT DIS, V221, P123, DOI 10.1093/infdis/jiz448; PORATH A, 1990, REV INFECT DIS, V12, P31; Prichard MN, 2001, REV MED VIROL, V11, P191, DOI 10.1002/rmv.315; Rasmussen KM, 2009, WEIGHT GAIN DURING PREGNANCY: REEXAMINING THE GUIDELINES, P1; Rieder F, 2014, CLIN MICROBIOL INFEC, V20, P95, DOI 10.1111/1469-0691.12449; Ryckman BJ, 2008, J VIROL, V82, P60, DOI 10.1128/JVI.01910-07; Sabbaj S, 2011, J INFECT DIS, V203, P1534, DOI 10.1093/infdis/jir138; Schleiss MR, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030526; Slobedman B, 1999, J VIROL, V73, P4806, DOI 10.1128/JVI.73.6.4806-4812.1999; Smith LR, 2013, VACCINES-BASEL, V1, DOI 10.3390/vaccines1040398; STAGNO S, 1986, JAMA-J AM MED ASSOC, V256, P1904, DOI 10.1001/jama.256.14.1904; Tomasec P, 2005, NAT IMMUNOL, V6, P181, DOI 10.1038/ni1156; Torre-Cisneros J, 2016, TRANSPLANT REV-ORLAN, V30, P119, DOI 10.1016/j.trre.2016.04.001; U.S. National Library of Medicine, CLINICALTRIALS GOV S; van Zuylen WJ, 2014, OBSTET MED, V7, P140, DOI 10.1177/1753495X14552719; Wang D, 2005, P NATL ACAD SCI USA, V102, P18153, DOI 10.1073/pnas.0509201102; Wloch MK, 2008, J INFECT DIS, V197, P1634, DOI 10.1086/588385	70	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							523	10.3390/vaccines9050523			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1ZM	34069321	gold, Green Published			2022-04-29	WOS:000654624100001
J	Hildreth, JEK; Alcendor, DJ				Hildreth, James E. K.; Alcendor, Donald J.			Targeting COVID-19 Vaccine Hesitancy in Minority Populations in the US: Implications for Herd Immunity	VACCINES			English	Review						health disparities; coronavirus; vaccine hesitancy; SARS-CoV-2; COVID-19; minorities populations; health inequities		There has been a continuous underrepresentation of minorities in healthcare research and vaccine trials, along with long-standing systemic racism and discrimination that have been fueling the distrust of the healthcare system among these communities for decades. The history and legacy of racial injustices and negative experiences within a culturally insensitive healthcare system have greatly contributed to vaccine hesitancy among ethnic minorities. COVID-19 vaccine hesitancy will impact vaccine uptake in the US, subsequently hindering the establishment of herd immunity (75-85% of the population vaccinated) to mitigate SARS-CoV-2 infection and transmission. Information targeting underserved racial/ethnic minorities in the US in a culturally competent manner has been lacking. This information is crucial for educating these communities about COVID-19 vaccines and their distribution as well as dispelling misinformation regarding vaccine trials, safety, and efficacy. This lack of education has greatly contributed to COVID-19 vaccine hesitancy and will increase disparities in vaccine uptake. Moreover, timely vaccinations are also essential to curtailing virus transmission and the emergence of SARS-CoV-2 variants that may evade the immune response produced by the three existing COVID-19 vaccines.	[Hildreth, James E. K.; Alcendor, Donald J.] Meharry Med Coll, Ctr AIDS Hlth Dispar Res, Dept Microbiol & Immunol, Sch Med, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA; [Hildreth, James E. K.] Meharry Med Coll, Sch Med, Dept Internal Med, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA; [Hildreth, James E. K.; Alcendor, Donald J.] Meharry Med Coll, Sch Med, Ctr AIDS Hlth Dispar Res, Dept Microbiol Immunol & Physiol, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA		Alcendor, DJ (通讯作者)，Meharry Med Coll, Ctr AIDS Hlth Dispar Res, Dept Microbiol & Immunol, Sch Med, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA.; Alcendor, DJ (通讯作者)，Meharry Med Coll, Sch Med, Ctr AIDS Hlth Dispar Res, Dept Microbiol Immunol & Physiol, 1005 Dr DB Todd Jr Blvd, Nashville, TN 37208 USA.	jhildreth@mmc.edu; dalcendor@mmc.edu			Research Centers in Minority Institutions (RCMI) program grant [U54MD007586-01]; Meharry Medical College Zika virus Research Startup Award	D.J.A. is supported by the Research Centers in Minority Institutions (RCMI) program grant (U54MD007586-01) and by the Meharry Medical College Zika virus Research Startup Award.	Abrams EM, 2020, LANCET RESP MED, V8, P659, DOI 10.1016/S2213-2600(20)30234-4; Ahmed I, 2021, NAT MED, V27, P366, DOI 10.1038/s41591-021-01260-6; Alcendor DJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082442; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; [Anonymous], 2021, VACCINE MONITOR NEAR; [Anonymous], 2020, KFF COVID 19 VACCINE; [Anonymous], 2011, CHANGING CHILD POPUL; Ashton J, 2021, J ROY SOC MED, V114, P42, DOI 10.1177/0141076820986065; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baker JP, 2003, VACCINE, V21, P4003, DOI 10.1016/S0264-410X(03)00302-5; Bambra C, 2020, J EPIDEMIOL COMMUN H, V74, P964, DOI 10.1136/jech-2020-214401; Banerji A, 2021, J ALLER CL IMM-PRACT, V9, P1423, DOI 10.1016/j.jaip.2020.12.047; Boodoosingh R, 2020, WORLD DEV, V136, DOI 10.1016/j.worlddev.2020.105177; Brennan J, 2018, J MED ETHICS, V44, P37, DOI 10.1136/medethics-2016-103486; Chowkwanyun M, 2020, NEW ENGL J MED, V383, P201, DOI 10.1056/NEJMp2012910; Coustasse A, 2021, J AMBUL CARE MANAG, V44, P71, DOI 10.1097/JAC.0000000000000360; Davies P, 2002, ARCH DIS CHILD, V87, P22, DOI 10.1136/adc.87.1.22; Doherty IA, 2021, PLOS ONE, V16, DOI [10.1101/2021.02.21.21252163, 10.1371/journal.pone.0248542]; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Durbach N, 2000, SOC HIST MED, V13, P45, DOI 10.1093/shm/13.1.45; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Freeman Daniel, 2020, Psychol Med, P1, DOI [10.1017/S0033291721002609, 10.1017/S0033291720005188]; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; GAVI, S AFR IS PREP ITS CO; Hotez P, 2021, NATURE, V592, P661, DOI 10.1038/d41586-021-01084-x; Karlsson LC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224330; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Kertscher T, MELANIN DOESNT PROTE; Khubchandani J, 2021, J COMMUN HEALTH, V46, P270, DOI 10.1007/s10900-020-00958-x; Laurencin CT, 2020, J RACIAL ETHN HEALTH, V7, P398, DOI 10.1007/s40615-020-00756-0; Livingston Edward H, 2021, JAMA, V325, P1575, DOI 10.1001/jama.2021.2927; Lucia VC, 2021, J PUBLIC HEALTH-UK, V43, P445, DOI 10.1093/pubmed/fdaa230; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; Mercado NB, 2020, NATURE, V586, P583, DOI 10.1038/s41586-020-2607-z; Millett GA, 2020, ANN EPIDEMIOL, V47, P37, DOI 10.1016/j.annepidem.2020.05.003; Mullard A, 2020, LANCET, V395, P1751, DOI 10.1016/S0140-6736(20)31252-6; Neergaard L, 2020, AP NORC POLL HALF AM; Nguyen KH, 2021, MMWR-MORBID MORTAL W, V70, P217, DOI 10.15585/mmwr.mm7006e3; Nkwihoreze H., 2021, CLIN INFECT DIS, pCIAB102, DOI [10.1093/cid/ciab102, DOI 10.1093/CID/CIAB102]; Noah Parker, 2021, LATEST DATA COVID 19; Oliver SE, 2021, MMWR-MORBID MORTAL W, V69, P1653, DOI 10.15585/mmwr.mm695152e1; Oliver SE, 2020, MMWR-MORBID MORTAL W, V69, P1922, DOI 10.15585/mmwr.mm6950e2; Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477; Oxner R, WHITE REPUBLICANS AR; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; PORTER D, 1988, MED HIST, V32, P231, DOI 10.1017/S0025727300048225; Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686; Raifman MA, 2020, AM J PREV MED, V59, P137, DOI 10.1016/j.amepre.2020.04.003; Raine S, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17218115; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Shekhar R, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020119; Shimabukuro T, 2021, MMWR-MORBID MORTAL W, V70, P46, DOI 10.15585/mmwr.mm7002e1; Shimabukuro TT, 2021, NEW ENGL J MED, V384, P2273, DOI 10.1056/NEJMoa2104983; Slaoui M, 2020, NEW ENGL J MED, V383, P1701, DOI 10.1056/NEJMp2027405; Tozivepi S.N., 2020, COVID 19 VACCINE HES; U.S. Centers for Disease Control and Prevention, RISK COVID 19 INF HO; van Dorn A, 2020, LANCET, V395, P1243, DOI 10.1016/S0140-6736(20)30893-X; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; Walsh Edward E, 2020, medRxiv, DOI 10.1101/2020.08.17.20176651; Wang KL, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010062; Webb Hooper M, 2020, JAMA-J AM MED ASSOC, V323, P2466, DOI 10.1001/jama.2020.8598; WHO, 2019, 10 THREATS GLOBAL HL; Wolfe RM, 2002, BMJ-BRIT MED J, V325, P430, DOI 10.1136/bmj.325.7361.430; Wolfe RM, 2002, JAMA-J AM MED ASSOC, V287, P3245, DOI 10.1001/jama.287.24.3245; World Health Organisation (WHO), 2020, MAN COVID 19 INF PRO; Yehia BR, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.18039; Zimmer C., 2020, NEW YORK TIMES	68	18	18	9	19	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							489	10.3390/vaccines9050489			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI1FN	34064726	Green Published, gold			2022-04-29	WOS:000654572000001
J	Jeskowiak, I; Wiatrak, B; Grosman-Dziewiszek, P; Szelag, A				Jeskowiak, Izabela; Wiatrak, Benita; Grosman-Dziewiszek, Patrycja; Szelag, Adam			The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19	VACCINES			English	Article						vaccination; COVID19; adverse reaction after vaccination	INTENTION; IMMUNITY	The pandemic of COVID-19 might be limited by vaccination. Society should be vaccinated to prevent the spread of coronavirus disease 2019 (COVID-19) and to protect persons who are at high risk for complications. In Poland, the National Vaccination Program has been introduced, which is a strategy for planning activities to ensure safe and effective vaccinations among Polish citizens. It includes not only the purchase of an appropriate number of vaccines, their distribution but also monitoring of the course and effectiveness of vaccination and the safety of Poles. The national COVID-19 immunization program has been divided into four stages. Stage 0 covers the healthcare workers to be vaccinated first, as they are most at risk of being infected with the coronavirus. The study aims to prove the thesis that GIS statistical data on the incidence of COVID-19 post-vaccination reactions should be verified, as patients do not report their occurrence through the procedure indicated by GIS. In March 2021, an anonymous questionnaire survey was conducted using an electronic questionnaire among persons belonging to group zero of the National Vaccination Program. The survey consisted of 19 short questions concerning, inter alia, getting COVID-19, post-vaccination reactions after receiving the first and second doses of the COVID-19 vaccine, and motivation to proceed with vaccination. A total of 1678 complete responses were received. It has been shown that only a small number of post-vaccination reactions are reported to the Sanitary Inspection, which makes GIS statistics on the incidence of post-vaccination reactions in COVID-19 unreliable. In addition, having earlier suffered from COVID-19 had an impact on the occurrence of more severe side effects after the first dose of the COVID-19 vaccine.	[Jeskowiak, Izabela; Wiatrak, Benita; Grosman-Dziewiszek, Patrycja; Szelag, Adam] Wroclaw Med Univ, Fac Med, Dept Pharmacol, Mikulicza Radeckiego 2, PL-50345 Wroclaw, Poland		Jeskowiak, I (通讯作者)，Wroclaw Med Univ, Fac Med, Dept Pharmacol, Mikulicza Radeckiego 2, PL-50345 Wroclaw, Poland.	izabela.jeskowiak@umed.wroc.pl; benita.wiatrak@umed.wroc.pl; patrycja.grosman-dziewiszek@umed.wroc.pl; adam.szelag@umed.wroc.pl	Szelag, Adam/AAS-8198-2021; Wiatrak, Benita/T-3402-2018; Jęśkowiak, Izabela/ABC-8438-2021	Wiatrak, Benita/0000-0002-1404-2274; Szelag, Adam/0000-0001-8104-5267; Jeskowiak, Izabela/0000-0002-8829-4482; Grosman-Dziewiszek, Patrycja/0000-0001-7362-6571			Alley SJ, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18020797; Berlin DA, 2020, NEW ENGL J MED, V383, P2451, DOI 10.1056/NEJMcp2009575; Caban-Martinez AJ, 2021, J OCCUP ENVIRON MED, V63, P369, DOI 10.1097/JOM.0000000000002152; Danchin A, 2021, MATH BIOSCI, V331, DOI 10.1016/j.mbs.2020.108499; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Giacomelli A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040669; Gottlieb RL, 2021, JAMA-J AM MED ASSOC, V325, P632, DOI 10.1001/jama.2021.0202; Gudi SK, 2020, DRUGS THER PERSPECT, V36, P413, DOI 10.1007/s40267-020-00752-8; Hellerstein M, 2020, VACCINE-X, V6, DOI 10.1016/j.jvacx.2020.100076; Kwok KO, 2021, INT J NURS STUD, V114, DOI 10.1016/j.ijnurstu.2020.103854; Lin YL, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008961; Meo SA, 2021, EUR REV MED PHARMACO, V25, P1663, DOI 10.26355/eurrev_202102_24877; Neumann-Bohme S, 2020, EUR J HEALTH ECON, V21, P977, DOI 10.1007/s10198-020-01208-6; Ruiz JB, 2021, VACCINE, V39, P1080, DOI 10.1016/j.vaccine.2021.01.010; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030218; Szmyd B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9020128; Veiga VC, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n84; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Yoda T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010048	22	18	18	16	32	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							502	10.3390/vaccines9050502			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1HI	34067955	Green Published, gold			2022-04-29	WOS:000654576800001
J	Stoecker, C				Stoecker, Charles			Shooting from the 'Scrip: Scope of Practice Laws and Access to Immunizations in the Pharmacy Setting	VACCINES			English	Article						scope of practice law; occupational licensing; regulation; immunization; influenza	INFLUENZA VACCINATION; CARE; RATES	In the past two decades, most states in the United States have added authorization for pharmacists to administer some vaccinations. Expansions of this authority have also come with prescription requirements or other regulatory burdens. The objective of this study was to evaluate the impact of these expansions on influenza immunization rates in adults age 65 and over. A panel data, differences-in-differences regression framework to control for state-level unobserved confounders and shocks at the national level was used on a combination of a dataset of state-level statute and regulatory changes and influenza immunization data from the Behavioral Risk Factor Surveillance System. Giving pharmacists permission to vaccinate had a positive impact on adult influenza immunization rates of 1.4 percentage points for adults age 65 and over. This effect was diminished by the presence of laws requiring pharmacists to obtain patient-specific prescriptions. There was no evidence that allowing pharmacists to administer vaccinations led patients to have fewer annual check-ups with physicians or not have a usual source of health care. Expanding pharmacists' scope of practice laws to include administering the influenza vaccine had a positive impact on influenza shot uptake. This may have implications for relaxing restrictions on other forms of care that could be provided by pharmacists.	[Stoecker, Charles] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Global Hlth Management & Policy, New Orleans, LA 70112 USA		Stoecker, C (通讯作者)，Tulane Univ, Sch Publ Hlth & Trop Med, Dept Global Hlth Management & Policy, New Orleans, LA 70112 USA.	cfstoecker@tulane.edu					[Anonymous], 1993, MMWR Recomm Rep, V42, P1; Autor DH, 2003, J LABOR ECON, V21, P1, DOI 10.1086/344122; Baroy J, 2016, J AM PHARM ASSOC, V56, P418, DOI 10.1016/j.japh.2016.03.006; Centers for Disease Control and Prevention (CDC), 1993, BEH RISK FACT SURV S; Centers for Disease Control and Prevention (CDC), 2003, MMWR MORB MORTAL WKL, V52, P987; Deslandes R, 2020, RES SOC ADMIN PHARM, V16, P497, DOI 10.1016/j.sapharm.2019.06.016; Ecarnot F, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-8044-y; Nuorti J. Pekka, 2010, Morbidity and Mortality Weekly Report, V59, P1; Grabenstein J D, 2001, J Am Pharm Assoc (Wash), V41, P46; Grabenstein J.D., 1993, INTJ PHARM PRACT, V2, P5, DOI 10.1111/j.2042-7174.1993.tb00710.x; GRABENSTEIN JD, 1992, MED CARE, V30, P503, DOI 10.1097/00005650-199206000-00004; Hadley J, 2004, HEALTH SERV RES, V39, P1527, DOI 10.1111/j.1475-6773.2004.00302.x; Isenor JE, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5697-x; Kimura AC, 2007, AM J PUBLIC HEALTH, V97, P684, DOI 10.2105/AJPH.2005.082073; Mangtani P, 2007, EPIDEMIOL INFECT, V135, P139, DOI 10.1017/S0950268806006479; McConeghy KW, 2016, VACCINE, V34, P3463, DOI 10.1016/j.vaccine.2016.04.076; Moniz MH, 2013, OBSTET GYNECOL, V121, P734, DOI 10.1097/AOG.0b013e31828642b1; Ndiaye SM, 2003, PUBLIC HEALTH, V117, P88, DOI 10.1016/S0033-3506(02)00022-7; Perkins RB, 2014, PEDIATRICS, V134, pE666, DOI 10.1542/peds.2014-0442; StataCorp, 2021, STATA STAT SOFTWARE; Stockwell MS, 2012, JAMA-J AM MED ASSOC, V307, P1702, DOI 10.1001/jama.2012.502; Wooldridge JM, 2010, ECONOMETRIC ANALYSIS OF CROSS SECTION AND PANEL DATA, 2ND EDITION, P1; Zimmerman RK, 2003, VACCINE, V21, P1486, DOI 10.1016/S0264-410X(02)00700-4	23	1	1	0	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							444	10.3390/vaccines9050444			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	SI1PW	34063185	Green Published, gold			2022-04-29	WOS:000654599100001
J	Vernet, R; Charrier, E; Cosset, E; Fievre, S; Tomasello, U; Grogg, J; Mach, N				Vernet, Remi; Charrier, Emily; Cosset, Erika; Fievre, Sabine; Tomasello, Ugo; Grogg, Julien; Mach, Nicolas			Local Sustained GM-CSF Delivery by Genetically Engineered Encapsulated Cells Enhanced Both Cellular and Humoral SARS-CoV-2 Spike-Specific Immune Response in an Experimental Murine Spike DNA Vaccination Model	VACCINES			English	Article						SARS-CoV-2; COVID 19; DNA vaccine; GM-CSF; adjuvant	PROTECTIVE IMMUNITY; PLASMID DNA; VIRUS; ADJUVANTS; VACCINES; CORONAVIRUS; IMMUNOGENICITY; IMMUNIZATION; INDUCTION; PROTEINS	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic with recurrences. Therefore, finding a vaccine for this virus became a priority for the scientific community. The SARS-CoV-2 spike protein has been described as the keystone for viral entry into cells and effective immune protection against SARS-CoV-2 is elicited by this protein. Consequently, many commercialized vaccines focus on the spike protein and require the use of an optimal adjuvant during vaccination. Granulocyte-macrophage colony-stimulating factor (GM-CSF) has demonstrated a powerful enhancement of acquired immunity against many pathogens when delivered in a sustained and local manner. In this context, we developed an encapsulated cell-based technology consisting of a biocompatible, semipermeable capsule for secretion of GM-CSF. In this study, we investigated whether murine GM-CSF (muGM-CSF) represents a suitable adjuvant for SARS-CoV-2 immunization, and which delivery strategy for muGM-CSF could be most beneficial. To test this, different groups of mice were immunized with intra-dermal (i.d.) electroporated spike DNA in the absence or presence of recombinant or secreted muGM-CSF. Results demonstrated that adjuvanting a spike DNA vaccine with secreted muGM-CSF resulted in enhancement of specific cellular and humoral immune responses against SARS-CoV-2. Our data also highlighted the importance of delivery strategies to the induction of cellular and humoral-mediated responses.	[Vernet, Remi; Charrier, Emily; Mach, Nicolas] Geneva Univ Hosp & Med Sch, Dept Oncol, CH-1211 Geneva, Switzerland; [Vernet, Remi; Charrier, Emily; Cosset, Erika; Mach, Nicolas] Geneva Univ Hosp, Ctr Translat Res Oncohematol, Div Oncol, CH-1211 Geneva, Switzerland; [Vernet, Remi; Charrier, Emily; Cosset, Erika; Mach, Nicolas] Univ Geneva, CH-1211 Geneva, Switzerland; [Charrier, Emily; Grogg, Julien] MaxiVAX SA, CH-1202 Geneva, Switzerland; [Fievre, Sabine; Tomasello, Ugo] Univ Geneva, Dept Basic Neurosci, CH-1211 Geneva, Switzerland		Vernet, R (通讯作者)，Geneva Univ Hosp & Med Sch, Dept Oncol, CH-1211 Geneva, Switzerland.; Vernet, R (通讯作者)，Geneva Univ Hosp, Ctr Translat Res Oncohematol, Div Oncol, CH-1211 Geneva, Switzerland.; Vernet, R (通讯作者)，Univ Geneva, CH-1211 Geneva, Switzerland.	remi.vernet@hcuge.ch; emily.charrier@unige.ch; erika.cosset@unige.ch; sabine.fievre@unige.ch; ugo.tomasello@unige.ch; jgrogg@maxivax.ch; nicolas.mach@hcuge.ch	mach, nicolas/AAZ-5302-2021; COSSET, erika/Y-2469-2018	Charrier, Emily/0000-0001-6143-509X; Fievre, Sabine/0000-0001-6690-2283; Grogg, Julien/0000-0002-9479-0933; VERNET, Remi/0000-0003-0213-3539; COSSET, erika/0000-0001-5481-6556	MaxiVAX	This work was funded by MaxiVAX. This financial support has not played any role in the study design; collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.	Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y; Barouch DH, 2002, J IMMUNOL, V168, P562, DOI 10.4049/jimmunol.168.2.562; Bhattacharya P, 2015, J INTERF CYTOK RES, V35, P585, DOI 10.1089/jir.2014.0149; Bowen WS, 2018, EXPERT REV VACCINES, V17, P207, DOI 10.1080/14760584.2018.1434000; Brave A, 2010, VACCINE, V28, P2080, DOI 10.1016/j.vaccine.2009.12.040; Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101; Dinnon KH, 2020, NATURE, V586, P560, DOI 10.1038/s41586-020-2708-8; Encke J, 2006, WORLD J GASTROENTERO, V12, P7118, DOI 10.3748/wjg.v12.i44.7118; Gong JY, 2013, BIOMED REP, V1, P251, DOI 10.3892/br.2012.47; Gouttefangeas C, 2018, CANCER IMMUNOL IMMUN, V67, P1911, DOI 10.1007/s00262-018-2158-4; Heller R, 2010, HUM GENE THER, V21, P357, DOI 10.1089/hum.2009.065; Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007; Kumar Suresh, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00637-4; Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432; Kwissa M, 2007, J EXP MED, V204, P2733, DOI 10.1084/jem.20071211; Liu DW, 2005, INT J CANCER, V113, P93, DOI 10.1002/ijc.20530; Lu S, 2008, EXPERT REV VACCINES, V7, P175, DOI 10.1586/14760584.7.2.175; Manara C, 2019, VACCINE, V37, P4204, DOI 10.1016/j.vaccine.2019.04.028; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; Mubarak A, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6491738; Okada E, 1997, J IMMUNOL, V159, P3638; Othman H, 2020, BIOCHEM BIOPH RES CO, V527, P702, DOI 10.1016/j.bbrc.2020.05.028; Parmiani G, 2007, ANN ONCOL, V18, P226, DOI 10.1093/annonc/mdl158; Reali E, 2005, VACCINE, V23, P2909, DOI 10.1016/j.vaccine.2004.11.060; Sajadian A, 2014, ARCH VIROL, V159, P1951, DOI 10.1007/s00705-014-2024-4; Santana VC, 2015, MEM I OSWALDO CRUZ, V110, P1010, DOI 10.1590/0074-02760150283; Sardesai NY, 2011, CURR OPIN IMMUNOL, V23, P421, DOI 10.1016/j.coi.2011.03.008; Serafini P, 2004, CANCER RES, V64, P6337, DOI 10.1158/0008-5472.CAN-04-0757; Suschak JJ, 2018, J INFECT DIS, V218, pS519, DOI 10.1093/infdis/jiy378; Wang DL, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030355; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; Wang XL, 2017, ANTIVIR RES, V144, P322, DOI 10.1016/j.antiviral.2017.07.004; Weiss WR, 1998, J IMMUNOL, V161, P2325; Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x; Xu XJ, 2004, CELL MOL IMMUNOL, V1, P119; Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463; Zhou M, 2015, ONCOTARGET, V6, P38504, DOI 10.18632/oncotarget.5904; Zhou P, 2020, NATURE, V588, pE6, DOI 10.1038/s41586-020-2951-z	38	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAY	2021	9	5							484	10.3390/vaccines9050484			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	SI1ML	34068677	gold, Green Published			2022-04-29	WOS:000654590200001
J	Cocchio, S; Baldo, V; Volpin, A; Fonzo, M; Floreani, A; Furlan, P; Mason, P; Trevisan, A; Scapellato, ML				Cocchio, Silvia; Baldo, Vincenzo; Volpin, Anna; Fonzo, Marco; Floreani, Annarosa; Furlan, Patrizia; Mason, Paola; Trevisan, Andrea; Scapellato, Maria Luisa			Persistence of Anti-Hbs after up to 30 Years in Health Care Workers Vaccinated against Hepatitis B Virus	VACCINES			English	Article						HBV; vaccination; anti-HBs; health care workers	IMMUNOGENICITY; RISK; IMMUNIZATION; ANTIBODIES; OBESITY	The burden of hepatitis B virus (HBV) infection is a serious public health problem all over the world. Vaccination remains the most effective prevention measure, and safe and effective HBV vaccines have been available since 1982. Health care workers (HCWs) vaccinated against HBV and prospectively followed up for at least 14 years were classified by their antibody titers after primary vaccination as: poor responders (10-99 mIU/mL); moderate responders (100-999 mIU/mL); and good responders (>= 1000 mIU/mL). The incidence of antibody loss was calculated for 1000 person-years and the anti-HBs persistence was calculated. The analysis concerned 539 HCWs: 494 good responders (91.7%); 37 moderate responders (6.9%); and eight poor responders (1.5%). The incidence of anti-HBs loss was 52.1 per 1000 person-years for the poor responders, 11.3 per 1000 person-years for the moderate responders, and 1.4 per 1000 person-years for the good responders. The mean persistence of anti-HBs differed significantly between the three groups, being: 19.2 years (95% CI: 15.6-22.8), 25.4 years (95% CI: 23.0-27.9), and 31.0 years (95% CI: 30.5-31.5) for the poor, moderate and good responders, respectively. In conclusion, our findings demonstrate a good persistence of protective anti-HBs titers in HCWs exposed to occupational risk for up to 30 years after a primary vaccination cycle (even without a booster dose) if their titer was initially higher than 100 mIU/mL.	[Cocchio, Silvia; Baldo, Vincenzo; Volpin, Anna; Fonzo, Marco; Furlan, Patrizia; Mason, Paola; Trevisan, Andrea; Scapellato, Maria Luisa] Univ Padua, Dept Cardiac Thorac & Vasc Sci, I-35100 Padua, Italy; [Cocchio, Silvia; Baldo, Vincenzo; Volpin, Anna; Fonzo, Marco; Furlan, Patrizia; Mason, Paola; Trevisan, Andrea; Scapellato, Maria Luisa] Univ Padua, Publ Hlth, I-35100 Padua, Italy; [Floreani, Annarosa] Sci Inst Res Hospitalizat & Healthcare Negrar, I-37024 Negrar, Italy; [Floreani, Annarosa] Univ Padua, Dept Surg Oncol & Gastroenterol Sci, I-35124 Padua, Italy		Baldo, V (通讯作者)，Univ Padua, Dept Cardiac Thorac & Vasc Sci, I-35100 Padua, Italy.; Baldo, V (通讯作者)，Univ Padua, Publ Hlth, I-35100 Padua, Italy.	silvia.cocchio@unipd.it; vincenzo.baldo@unipd.it; anna.volpin@aopd.veneto.it; marco.fonzo@unipd.it; annarosa.floreani@unipd.it; patrizia.furlan@unipd.it; paola.mason.1@unipd.it; andrea.trevisan@unipd.it; marialuisa.scapellato@unipd.it	Trevisan, Andrea/E-5325-2013; MASON, PAOLA/AAE-9023-2019; Baldo, Vincenzo/D-7822-2018	Trevisan, Andrea/0000-0002-0764-1084; MASON, PAOLA/0000-0003-3941-6698; Baldo, Vincenzo/0000-0001-6012-9453			Averhoff F, 1998, AM J PREV MED, V15, P1, DOI 10.1016/S0749-3797(98)00003-8; Banatvala J, 2000, LANCET, V355, P561, DOI 10.1016/S0140-6736(99)07239-6; Bruce MG, 2016, J INFECT DIS, V214, P16, DOI 10.1093/infdis/jiv748; Burnett RJ, 2011, VACCINE, V29, P4293, DOI 10.1016/j.vaccine.2011.03.001; CDC, HEP B FAQS PUBL; Chiara F, 2013, VACCINE, V32, P62, DOI 10.1016/j.vaccine.2013.10.074; Chiara F, 2013, VACCINE, V31, P1696, DOI 10.1016/j.vaccine.2013.01.046; Coppola N, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0874-3; Datta S, 2012, J CLIN EXP HEPATOL, V2, P353, DOI 10.1016/j.jceh.2012.10.003; De Schryver A, 2011, EUR J PUBLIC HEALTH, V21, P338, DOI 10.1093/eurpub/ckq122; Dini G, 2017, HUM VACC IMMUNOTHER, V13, P440, DOI 10.1080/21645515.2017.1264788; Elseviers MM, 2014, J RENAL CARE, V40, P150, DOI 10.1111/jorc.12050; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; European Centre for Disease Surveillance and Control, HEPATITIS B ANN EPID; Floreani A, 2004, VACCINE, V22, P607, DOI 10.1016/j.vaccine.2003.09.001; Gara N, 2015, CLIN INFECT DIS, V60, P505, DOI 10.1093/cid/ciu867; Garzillo EM, 2020, J INFECT PREVENT, V21, P23, DOI 10.1177/1757177419873043; Immunization Action Coalition (IAC), HEPATITIS B; Immunization of health-care personnel, 2011, MMWR, V60, P1; JILG W, 1988, J HEPATOL, V6, P201, DOI 10.1016/S0168-8278(88)80032-1; Khafagy A, 2020, CLIN LAB, V66, P1351, DOI 10.7754/Clin.Lab.2019.191202; Lamberti M, 2015, J OCCUP MED TOXICOL, V10, DOI 10.1186/s12995-015-0083-4; Liu F, 2017, HUM VACC IMMUNOTHER, V13, P1014, DOI 10.1080/21645515.2016.1274475; Mast Eric E., 2006, Morbidity and Mortality Weekly Report, V55, P1; Middleman AB, 2014, PEDIATRICS, V133, pE1500, DOI 10.1542/peds.2013-2940; Nashibi R, 2015, JUNDISHAPUR J MICROB, V8, DOI 10.5812/jjm.19579; Nicolini LA, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16183307; Sahana HV, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/1327492; Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8; Trevisan A, 2020, HUM VACC IMMUNOTHER, V16, P460, DOI 10.1080/21645515.2019.1656483; Tripathy S., 2011, INDIAN J PREV SOC ME, V42, P315; TRIVELLO R, 1995, VACCINE, V13, P139, DOI 10.1016/0264-410X(95)93126-T; Tufon Kukwah Anthony, 2019, Oman Med J, V34, P313, DOI 10.5001/omj.2019.62; WEBER DJ, 1985, JAMA-J AM MED ASSOC, V254, P3187, DOI 10.1001/jama.254.22.3187; WOOD RC, 1993, JAMA-J AM MED ASSOC, V270, P2935, DOI 10.1001/jama.270.24.2935; World Health Organization Geneva Switzerland, GLOBAL HEPATITIS REP; Wu JS, 1999, J INFECT DIS, V179, P1319, DOI 10.1086/314768; Yang SG, 2016, SCI REP-UK, V6, DOI 10.1038/srep27251; Yoshioka N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187661; Yu AS, 2006, INFECT DIS CLIN N AM, V20, P27, DOI 10.1016/j.idc.2006.01.004; Zhao YL, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4134-9	41	4	4	2	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							323	10.3390/vaccines9040323			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4PX	33915763	Green Published, gold			2022-04-29	WOS:000643764100001
J	De Brun, L; Leites, M; Furtado, A; Campos, F; Roehe, P; Puentes, R				De Brun, Laureana; Leites, Mauro; Furtado, Agustin; Campos, Fabricio; Roehe, Paulo; Puentes, Rodrigo			Field Evaluation of Commercial Vaccines against Infectious Bovine Rhinotracheitis (Ibr) Virus Using Different Immunization Protocols	VACCINES			English	Article						BoHV-1; BoHV-1 vaccines in a field herd; Clostridial; FMD		Bovine alphaherpesvirus 1 is ubiquitous in cattle populations and is associated with several clinical syndromes, including respiratory disease, genital disease, infertility and abortions. Control of the virus in many parts of the world is achieved primarily through vaccination with either inactivated or live modified viral vaccines. The objective of this study was to evaluate the performance of four commercially available BoHV-1 vaccines commonly used in Central and South America. Animals were divided into eight groups and vaccinated on days 0 and 30. Groups 1 to 4 received two doses of four different BoHV-1 commercial vaccines (named A to D). Groups 5 and 6 received vaccine D plus a vaccine for either Clostridial or Food-and-Mouth-Disease (FMD), respectively. Group 7 received one dose of two different brands of reproductive vaccines. Serum samples were collected from all animals on days 0, 30 and 60 to evaluate neutralizing and isotype-specific (IgG1 and IgG2) antibodies. Of the four commercial vaccines evaluated, only vaccine A induced neutralizing antibodies to titers >= 1:8 in 13/15 (86%) of the animals 60 days post-vaccination. Levels of IgG2 antibody increased in all groups, except for group 2 after the first dose of vaccine B. These results show that only vaccine A induced significant and detectable levels of BoHV-1-neutralizing antibodies. The combination of vaccine D with Clostridial or FMD vaccines did not affect neutralizing antibody responses to BoHV-1. The antibody responses of three of the four commercial vaccines analyzed here were lower than admissible by vaccine A. These results may be from vaccination failure, but means to identify the immune signatures predictive of clinical protection against BoHV-1 in cattle should also be considered.	[De Brun, Laureana; Leites, Mauro; Furtado, Agustin; Puentes, Rodrigo] Univ Republica, Fac Vet, Dept Patobiol, Montevideo 11600, Uruguay; [Campos, Fabricio] Univ Fed Tocantins, Lab Bioinformat & Biotecnol, Campus Gurupi, BR-77410530 Gurupi, Brazil; [Roehe, Paulo] Univ Fed Rio Grande do Sul, Inst Ciencias Basicas Saude, BR-90050170 Porto Alegre, RS, Brazil		Puentes, R (通讯作者)，Univ Republica, Fac Vet, Dept Patobiol, Montevideo 11600, Uruguay.	laureana@fvet.edu.uy; maurolei@gmail.com; afurtado@fvet.edu.uy; camposvet@gmail.com; proehe@gmail.com; rpuentes@fvet.edu.uy	Campos, Fabricio S/D-8819-2014	Campos, Fabricio S/0000-0002-5948-472X; De Brun, Laureana/0000-0002-3331-9566; Puentes, Rodrigo/0000-0002-4618-9721	Agencia Nacional de Investigacion e Innovacion (ANII) of Uruguay [FSSA_X_2014_1_105283]	This research was funded by Agencia Nacional de Investigacion e Innovacion (ANII) of Uruguay, grant number FSSA_X_2014_1_105283.	ACKERMANN M, 1982, AM J VET RES, V43, P36; Alonzo P., 2012, Veterinaria (Montevideo), V48, P5; Anziliero D, 2015, CIENC RURAL, V45, P58, DOI 10.1590/0103-8478cr20130167; Baccili CC, 2019, PESQUI VET BRASIL, V39, P870, DOI [10.1590/1678-5150-PVB-6208, 10.1590/1678-5150-pvb-6208]; Campos FS, 2011, VET MICROBIOL, V148, P18, DOI 10.1016/j.vetmic.2010.08.004; Silva Letícia Frizzo da, 2007, Cienc. Rural, V37, P1471, DOI 10.1590/S0103-84782007000500042; Engels M, 1996, VET MICROBIOL, V53, P3, DOI 10.1016/S0378-1135(96)01230-8; Estes DM, 2002, VET IMMUNOL IMMUNOP, V90, P1, DOI 10.1016/S0165-2427(02)00201-5; Firacative C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21039-z; Guarino H, 2008, PREV VET MED, V85, P34, DOI 10.1016/j.prevetmed.2007.12.012; International Committee on Taxonomy of Viruses Universal Virus Database [ICTVdB], 2015, MAN VIR TAX 2015 REL; Leites M., 2017, P 12 C ARG VIR BUEN; Lemaire M, 2000, J CLIN MICROBIOL, V38, P1885, DOI 10.1128/JCM.38.5.1885-1894.2000; Mackenzie-Dyck S, 2014, CLIN VACCINE IMMUNOL, V21, P463, DOI 10.1128/CVI.00696-13; Manoj S, 2003, VIROLOGY, V313, P296, DOI 10.1016/S0042-6822(03)00325-8; Muylkens B, 2007, VET RES, V38, P181, DOI 10.1051/vetres:2006059; Newcomer BW, 2017, PREV VET MED, V138, P1, DOI 10.1016/j.prevetmed.2017.01.005; OIE-(World Organization for Animal Health), 2020, MANUAL DIAGNOSTIC TE; Petzhold S. A., 2001, Brazilian Journal of Veterinary Research and Animal Science, V38, P184, DOI 10.1590/S1413-95962001000400007; Puentes R, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0749-x; Ros C, 2002, VIRUS GENES, V24, P99, DOI 10.1023/A:1014504730475; Silva AD, 2009, PESQUI VET BRASIL, V29, P545, DOI 10.1590/S0100-736X2009000700008; Spilki FR, 2012, BRAZ J MICROBIOL, V43, P586, DOI 10.1590/S1517-83822012000200021; Todryk SM, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6040084; Varela APM, 2010, VET MICROBIOL, V142, P254, DOI 10.1016/j.vetmic.2009.10.016; Vogel Fernanda Silveira Flores, 2002, Cienc. Rural, V32, P881, DOI 10.1590/S0103-84782002000500022; Walz PH, 2017, VACCINE, V35, P1046, DOI 10.1016/j.vaccine.2017.01.006	27	1	1	0	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							408	10.3390/vaccines9040408			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5GE	33924141	Green Published, gold			2022-04-29	WOS:000643806700001
J	Kim, J; Yoon, J; Park, JE				Kim, Jihee; Yoon, Jaewon; Park, Jung-Eun			Construction of Porcine Epidemic Diarrhea Virus-Like Particles and Its Immunogenicity in Mice	VACCINES			English	Article						porcine epidemic diarrhea; virus-like particle; vaccine; immunogenicity		Porcine epidemic diarrhea (PED), a highly contagious and lethal enteric disease in piglets, is characterized by diarrhea, vomiting, and dehydration, with high mortality in neonatal piglets. Despite the nationwide use of attenuated and inactivated vaccines, the outbreak of PED is still a major problem in the swine industry. Virus-like particles (VLPs) are artificial nanoparticles similar to viruses that are devoid of genetic material and are unable to replicate. VLPs have good safety profiles and elicit robust cellular and humoral immune responses. Here, we generated PED VLPs in eukaryotic cells and examined their immune responses in mice. We found that the M protein is essential for the formation of PED VLPs. Interestingly, PED VLP formation was decreased in the presence of E proteins and increased in the presence of N proteins. Both IgG and IgA antibodies were induced in mice immunized with PED VLPs. Moreover, these antibodies protected against PED virus infection in Vero cells. PED VLPs immunization induced Th2-dominant immune responses in mice. Our results indicate that PED VLPs induce strong immune responses in mice, suggesting that the VLP-based vaccine is a promising vaccine candidate.	[Kim, Jihee; Yoon, Jaewon; Park, Jung-Eun] Chungnam Natl Univ, Coll Vet Med, Lab Vet Publ Hlth, Daejeon 34134, South Korea; [Park, Jung-Eun] Chungnam Natl Univ, Res Inst Vet Sci, Daejeon 34134, South Korea		Park, JE (通讯作者)，Chungnam Natl Univ, Coll Vet Med, Lab Vet Publ Hlth, Daejeon 34134, South Korea.; Park, JE (通讯作者)，Chungnam Natl Univ, Res Inst Vet Sci, Daejeon 34134, South Korea.	wlgm10721@naver.com; hopewj@naver.com; jepark@cnu.ac.kr		Yoon, Jae Won/0000-0003-1316-7136	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [NRF-2017R1D1A3B03033883]; Chungnam National University	This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2017R1D1A3B03033883). This work was also supported by the Research Fund of Chungnam National University and the Research Scholarship of Chungnam National University.	Chen Q, 2014, J CLIN MICROBIOL, V52, P234, DOI 10.1128/JCM.02820-13; Crawford K, 2016, VIRUS RES, V226, P108, DOI 10.1016/j.virusres.2016.08.005; de Arriba ML, 2002, VET IMMUNOL IMMUNOP, V85, P85, DOI 10.1016/S0165-2427(01)00417-2; de Haan CAM, 2005, ADV VIRUS RES, V64, P165, DOI 10.1016/S0065-3527(05)64006-7; DEBOUCK P, 1980, AM J VET RES, V41, P219; DUARTE M, 1993, ADV EXP MED BIOL, V342, P55; Gerdts V, 2017, VET MICROBIOL, V206, P45, DOI 10.1016/j.vetmic.2016.11.029; Gong L, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1042-3; HOFMANN M, 1988, J CLIN MICROBIOL, V26, P2235, DOI 10.1128/JCM.26.11.2235-2239.1988; Hsieh PK, 2005, J VIROL, V79, P13848, DOI 10.1128/JVI.79.22.13848-13855.2005; Huang YW, 2013, MBIO, V4, DOI 10.1128/mBio.00737-13; Kirchdoerfer RN, 2021, STRUCTURE, V29, P385, DOI 10.1016/j.str.2020.12.003; KLUMPERMAN J, 1994, J VIROL, V68, P6523, DOI 10.1128/JVI.68.10.6523-6534.1994; Kocherhans R, 2001, VIRUS GENES, V23, P137, DOI 10.1023/A:1011831902219; Kweon CH, 1993, KOREAN J VET RES, V33, P249; Lee HM, 2000, J VET MED SCI, V62, P333, DOI 10.1292/jvms.62.333; Lee SH, 2018, CLIN EXP VACCINE RES, V7, P61, DOI 10.7774/cevr.2018.7.1.61; Liu C, 2015, J VIROL, V89, P6121, DOI 10.1128/JVI.00430-15; McBride R, 2014, VIRUSES-BASEL, V6, P2991, DOI 10.3390/v6082991; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021; Nieto-Torres JL, 2011, VIROLOGY, V415, P69, DOI 10.1016/j.virol.2011.03.029; Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7; Park JE, 2018, VET MICROBIOL, V221, P19, DOI 10.1016/j.vetmic.2018.05.012; Park JE, 2011, ARCH VIROL, V156, P1749, DOI 10.1007/s00705-011-1044-6; PENSAERT MB, 1978, ARCH VIROL, V58, P243, DOI 10.1007/BF01317606; Ruch TR, 2012, VIRUSES-BASEL, V4, P363, DOI 10.3390/v4030363; Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0; Singh G, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00347; Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08; Song DS, 2007, RES VET SCI, V82, P134, DOI 10.1016/j.rvsc.2006.03.007; Song D, 2012, VIRUS GENES, V44, P167, DOI 10.1007/s11262-012-0713-1; SUEYOSHI M, 1995, J COMP PATHOL, V113, P59, DOI 10.1016/S0021-9975(05)80069-6; Syomin BV, 2019, MOL BIOL+, V53, P323, DOI 10.1134/S0026893319030154; TURGEON DC, 1980, CAN VET J, V21, P100; Venkatagopalan P, 2015, VIROLOGY, V478, P75, DOI 10.1016/j.virol.2015.02.005; Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x; Wang C, 2017, ONCOTARGET, V8, P12686, DOI 10.18632/oncotarget.8475; Wang CL, 2017, VIRUS GENES, V53, P548, DOI 10.1007/s11262-017-1450-2; Wang QH, 2019, CURR OPIN VIROL, V34, P39, DOI 10.1016/j.coviro.2018.12.001; Won H, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040642; Xu RD, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00862; Zhao P, 2005, VIROLOGY, V331, P128, DOI 10.1016/j.virol.2004.10.016	43	0	0	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							370	10.3390/vaccines9040370			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4PH	33920460	Green Published, gold			2022-04-29	WOS:000643762500001
J	Pedote, PD; Termite, S; Gigliobianco, A; Lopalco, PL; Bianchi, FP				Pedote, Pasquale Domenico; Termite, Stefano; Gigliobianco, Andrea; Lopalco, Pier Luigi; Bianchi, Francesco Paolo			Influenza Vaccination and Health Outcomes in COVID-19 Patients: A Retrospective Cohort Study	VACCINES			English	Article						COVID-19; influenza vaccine; prevention; cause-effect relationship	VACCINES	COVID-19 is an infectious disease caused by the novel coronavirus SARS-CoV-2. Several measures aimed at containing the spread of this virus have been recommended by international and nation public health institutions, but whether the influenza vaccine, while not protective against COVID-19, nonetheless reduces disease severity is unclear. This study evaluated the potential role of influenza vaccine in reducing the rate of hospitalization and death in COVID-19 patients. COVID-19 cases recorded in the province of Brindisi (Apulia, Southern Italy) during the first pandemic wave (February-May 2020) and occurring in patients vaccinated with the influenza vaccine during the 2019-2020 influenza season were considered. From February 2020 to May 2020, 3872 inhabitants of the province of Brindisi underwent SARS-CoV-2 PCR testing and 664 (8.7%) tested positive. A multivariate analysis showed that among COVID-19 patients neither hospitalization nor death was significantly associated with influenza vaccination (p > 0.05), whereas within this group male sex, older age, and chronic diseases were identified as risk factors for morbidity and mortality. Our study did not show an association between the influenza vaccine and complications of COVID-19. Nonetheless, influenza vaccination must be promoted as a central public health measure, because by reducing the burden on hospitals it can greatly benefit the management of COVID-19 patients.	[Pedote, Pasquale Domenico; Bianchi, Francesco Paolo] Brindisi Local Hlth Author, Epidemiol Unit, I-72015 Fasano, Italy; [Termite, Stefano] Brindisi Local Hlth Author, Publ Hlth Unit, I-72100 Brindisi, Italy; [Gigliobianco, Andrea] Brindisi Local Hlth Author, Hlth Management, I-72100 Brindisi, Italy; [Lopalco, Pier Luigi] Dept Hlth, I-70100 Apulia, Italy; [Bianchi, Francesco Paolo] Univ Bari, Dept Biomed Sci & Human Oncol, I-70121 Bari, Italy		Bianchi, FP (通讯作者)，Brindisi Local Hlth Author, Epidemiol Unit, I-72015 Fasano, Italy.; Bianchi, FP (通讯作者)，Univ Bari, Dept Biomed Sci & Human Oncol, I-70121 Bari, Italy.	pasquale.pedote@asl.brindisi.it; stefano.termite@asl.brindisi.it; andrea.gigliobianco@asl.brindisi.it; pierluigi.lopalco@unipi.it; dr.francesco.bianchi@gmail.com	Bianchi, Francesco Paolo/AAU-2597-2020	Bianchi, Francesco Paolo/0000-0002-9659-0193; tafuri, silvio/0000-0003-4194-0210			Apulia Government, COVID 19 EM SUIRV AC; Armocida B, 2020, LANCET PUBLIC HEALTH, V5, pE253, DOI 10.1016/S2468-2667(20)30074-8; Belingheri M, 2020, OCCUP MED-OXFORD, V70, P665, DOI 10.1093/occmed/kqaa197; Bianchi FP, 2018, ANN IG MED PREV COMU, V30, P490, DOI 10.7416/ai.2018.2260; Boersma C, 2021, VALUE HEALTH, V24, P1, DOI 10.1016/j.jval.2020.11.006; CDC, COVID 19 OLD AD GREA; Cocco P, 2021, PREV MED, V143, DOI 10.1016/j.ypmed.2020.106351; European Centre Disease Control and Prevention (ECDC), COVID 19 SIT UPD EU; Istituto Superiore di Sanita, EP PUBL HLTH COVID 1; Italian Ministry of Health, GUID COD SDO COV 19; Martinelli D, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00037; Massoudi N, 2021, J CLIN IMMUNOL, V41, P324, DOI 10.1007/s10875-020-00925-0; Paget J, 2020, VACCINE, V38, P6485, DOI 10.1016/j.vaccine.2020.08.024; Ragni P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040675; Takahashi T, 2021, SCIENCE, V371, P347, DOI 10.1126/science.abe7199; Thindwa D, 2020, VACCINE, V38, P5398, DOI 10.1016/j.vaccine.2020.06.047; Wehenkel C, 2020, PEERJ, V8, DOI 10.7717/peerj.10112; WHO Collaborating Centre for Drug Statistics Methodology, ATC STRUCT PRINC; World Health Organization, 2020, WHO COVID 19 CAS DEF; World Health Organization, GO DAT MAN COMPL DAT; Zanettini Claudio, 2020, medRxiv, DOI 10.1101/2020.06.24.20129817; Zein JG, 2021, J CLIN TRANSL SCI, V5, DOI 10.1017/cts.2020.543	22	7	7	1	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							358	10.3390/vaccines9040358			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS4VD	33917898	gold, Green Published			2022-04-29	WOS:000643777800001
J	Tobaiqy, M; Elkout, H; MacLure, K				Tobaiqy, Mansour; Elkout, Hajer; MacLure, Katie			Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database	VACCINES			English	Article						COVID-19; adverse events; adverse drug reaction; thrombotic; vaccine	EVENTS	The development of safe, effective, affordable vaccines against COVID-19 remains the cornerstone to mitigating this pandemic. Early in December 2020, multiple research groups had designed potential vaccines. From 11 March 2021, several European countries temporarily suspended the use of the Oxford-AstraZeneca vaccine amid reports of blood clot events and the death of a vaccinated person, despite the European Medicines Agency (EMA) and the World Health Organization's assurance that there was no indication that vaccination was linked. This study aimed to identify and analyse the thrombotic adverse reactions associated with the Oxford-AstraZeneca vaccine. This was a retrospective descriptive study using spontaneous reports submitted to the EudraVigilance database in the period from 17 February to 12 March 2021. There were 54,571 adverse reaction reports, of which 28 were associated with thrombotic adverse reactions. Three fatalities were related to pulmonary embolism; one fatality to thrombosis. With 17 million people having had the AstraZeneca vaccine, these are extremely rare events The EMA's Pharmacovigilance Risk Assessment Committee (18 March 2021) concluded that the vaccine was safe, effective and the benefits outweighed the risks. Conducting further analyses based on more detailed thrombotic adverse event reports, including patients' characteristics and comorbidities, may enable assessment of the causality with higher specificity.	[Tobaiqy, Mansour] Univ Jeddah, Coll Med, Dept Pharmacol, Jeddah 45311, Saudi Arabia; [Elkout, Hajer] Univ Tripoli, Med Fac, Dept Family & Community Med, Tripoli 13275, Libya		Tobaiqy, M (通讯作者)，Univ Jeddah, Coll Med, Dept Pharmacol, Jeddah 45311, Saudi Arabia.	mtobaiqy@uj.edu.sa; H.elkout@yahoo.com; katiemadure@outlook.com		MacLure, Katie/0000-0003-0686-948X; Tobaiqy, Mansour/0000-0002-4292-0900			Alhumaid S, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5040180; AstraZeneca, UPD SAF COVID 19 VAC; AstraZeneca, COVID 19 VACC SUMM P; Barletta JF, 2010, CRIT CARE MED, V38, pS198, DOI 10.1097/CCM.0b013e3181de11f9; Baumann P, 2000, HEMATOL ONCOL CLIN N, V14, P431, DOI 10.1016/S0889-8588(05)70143-X; Boytchev H, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n619; Chung EH, 2014, CLIN EXP VACCINE RES, V3, P50, DOI 10.7774/cevr.2014.3.1.50; Daou F, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18030955; EMA, REC COVID 19 VACC AS; European Medicines Agency, EM M PHARM RISK ASS; European Medicines Agency, ACC EUDRAVIGILANCE D; Joint Council on Vaccination and Immunisation, STAT IMM PRIOR; Mahase E, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n728; O'Connell KA, 2006, JAMA-J AM MED ASSOC, V295, P293, DOI 10.1001/jama.295.3.293; Palma G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02094; Postigo R, 2018, DRUG SAFETY, V41, P665, DOI 10.1007/s40264-018-0647-1; Sardella M, 2019, THER ADV DRUG SAF, V10, DOI 10.1177/2042098619882819; Schafer AI, 2003, HEMATOL AM SOC HEMAT, P520, DOI [10.1182/asheducation-2003.1.520, DOI 10.1182/ASHEDUCATION-2003.1.520]; Sliskovic A.M., 2021, CARDIOL CROATICA, V16, P71, DOI [10.15836/ccar2021.71, DOI 10.15836/CCAR2021.71]; Stegeman BH, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5298; Stewart JA, 1997, HUM REPROD, V12, P2167, DOI 10.1093/humrep/12.10.2167; Tapson Victor F, 2005, Proc Am Thorac Soc, V2, P71, DOI 10.1513/pats.200407-038MS; Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5; The European Medicines Agency, EUDRAVIGILANCE EUR D; Tobaiqy M, 2020, Infect Prev Pract, V2, P100061, DOI 10.1016/j.infpip.2020.100061; UK Government, MHRA ISS NEW ADV CON; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; WHO Official Website, DRAFT LANDSC COVID 1; Wise J, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n699	29	28	30	8	20	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	APR	2021	9	4							393	10.3390/vaccines9040393			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RS5DN	33923530	Green Submitted, Green Published, gold			2022-04-29	WOS:000643799700001
J	Folegatti, PM; Flaxman, A; Jenkin, D; Makinson, R; Kingham-Page, L; Bellamy, D; Lopez, FR; Sheridan, J; Poulton, I; Aboagye, J; Tran, N; Mitton, C; Roberts, R; Lawrie, AM; Hill, AVS; Ewer, KJ; Gilbert, S				Folegatti, Pedro M.; Flaxman, Amy; Jenkin, Daniel; Makinson, Rebecca; Kingham-Page, Lucy; Bellamy, Duncan; Ramos Lopez, Fernando; Sheridan, Jonathan; Poulton, Ian; Aboagye, Jeremy; Tran, Nguyen; Mitton, Celia; Roberts, Rachel; Lawrie, Alison M.; Hill, Adrian V. S.; Ewer, Katie J.; Gilbert, Sarah			Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies	VACCINES			English	Article						viral vector; T-Cell; vaccine		Heterologous prime-boost strategies are known to substantially increase immune responses in viral vectored vaccines. Here we report on safety and immunogenicity of the poxvirus Modified Vaccinia Ankara (MVA) vectored vaccine expressing four Mycobacterium avium subspecies paratuberculosis antigens as a single dose or as a booster vaccine following a simian adenovirus (ChAdOx2) prime. We demonstrate that a heterologous prime-boost schedule is well tolerated and induced T-cell immune responses.	[Folegatti, Pedro M.; Flaxman, Amy; Jenkin, Daniel; Makinson, Rebecca; Kingham-Page, Lucy; Bellamy, Duncan; Ramos Lopez, Fernando; Sheridan, Jonathan; Poulton, Ian; Aboagye, Jeremy; Tran, Nguyen; Mitton, Celia; Roberts, Rachel; Lawrie, Alison M.; Hill, Adrian V. S.; Ewer, Katie J.; Gilbert, Sarah] Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England		Folegatti, PM (通讯作者)，Univ Oxford, Jenner Inst, Oxford OX3 7DQ, England.	pedro.folegatti@ndm.ox.ac.uk; amy.flaxman@ndm.ox.ac.uk; daniel.jenkin@ndm.ox.ac.uk; rebecca.makinson@ndm.ox.ac.uk; lucy.kingham-page@cardiov.ox.ac.uk; duncan.bellamy@ndm.ox.ac.uk; fernando.ramoslopez@ndm.ox.ac.uk; jsheridan1@sheffield.ac.uk; ian.poulton@ndm.ox.ac.uk; jeremy.aboagye@ndm.ox.ac.uk; nguyen.tran@ndm.ox.ac.uk; mitton@hotmail.co.uk; rachel.roberts@ndm.ox.ac.uk; alison.lawrie@ndm.ox.ac.uk; adrian.hill@ndm.ox.ac.uk; katie.ewer@ndm.ox.ac.uk; sarah.gilbert@ndm.ox.ac.uk	Folegatti, Pedro/AAD-5238-2019; Jenkin, Daniel/AAB-7042-2022; Ewer, Katie/B-4328-2011	Folegatti, Pedro/0000-0001-5330-0240; Gilbert, Sarah/0000-0002-6823-9750; Flaxman, Amy/0000-0001-6460-1372; Ramos Lopez, Fernando/0000-0002-9997-7879; Hill, Adrian/0000-0003-0900-9629; Bellamy, Duncan/0000-0003-3614-0032; Ewer, Katie/0000-0001-9827-9836; Sheridan, Jonathan/0000-0002-6806-2609; Makinson, Rebecca/0000-0001-7582-9073; Jenkin, Daniel/0000-0003-3088-310X; Kingham, Lucy/0000-0001-7891-6359	HAV Vaccines Ltd.; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)National Institute for Health Research (NIHR)	This research was funded by HAV Vaccines Ltd. The research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.	Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/S0140-6736(18)31364-3, 10.1016/s0140-6736(18)31364-3]; Folegatti PM, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020040; HOCHSTEINMINTZEL V, 1975, ZBL BAKT-INT J MED M, V230, P283; Kardani K, 2016, VACCINE, V34, P413, DOI 10.1016/j.vaccine.2015.11.062; Milligan ID, 2016, JAMA-J AM MED ASSOC, V315, P1610, DOI 10.1001/jama.2016.4218; Morris SJ, 2016, FUTURE VIROL, V11, P649, DOI 10.2217/fvl-2016-0070; Sechi LA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00096; Tiono AB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208328; Wilkie M, 2020, VACCINE, V38, P779, DOI 10.1016/j.vaccine.2019.10.102	9	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							262	10.3390/vaccines9030262			8	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5UM	33809415	Green Published, gold			2022-04-29	WOS:000634218800001
J	Muller, C; Hrynkiewicz, R; Bebnowska, D; Maldonado, J; Baratelli, M; Kollner, B; Niedzwiedzka-Rystwej, P				Mueller, Claudia; Hrynkiewicz, Rafal; Bebnowska, Dominika; Maldonado, Jaime; Baratelli, Massimiliano; Koellner, Bernd; Niedzwiedzka-Rystwej, Paulina			Immunity against Lagovirus europaeus and the Impact of the Immunological Studies on Vaccination	VACCINES			English	Review						Lagovirus europaeus; hemorrhagic fever; RHDV; rabbit; vaccination	RABBIT-HEMORRHAGIC-DISEASE; VIRUS-LIKE PARTICLES; BROWN HARE SYNDROME; PERIPHERAL-BLOOD LEUKOCYTES; WILD EUROPEAN RABBITS; PARTIAL CROSS-PROTECTION; ORYCTOLAGUS-CUNICULUS; YOUNG-RABBITS; MOLECULAR EPIDEMIOLOGY; CALICIVIRUS INFECTION	In the early 1980s, a highly contagious viral hemorrhagic fever in rabbits (Oryctolagus cuniculus) emerged, causing a very high rate of mortality in these animals. Since the initial occurrence of the rabbit hemorrhagic disease virus (RHDV), several hundred million rabbits have died after infection. The emergence of genetically-different virus variants (RHDV GI.1 and GI.2) indicated the very high variability of RHDV. Moreover, with these variants, the host range broadened to hare species (Lepus). The circulation of RHDV genotypes displays different virulences and a limited induction of cross-protective immunity. Interestingly, juvenile rabbits (<9 weeks of age) with an immature immune system display a general resistance to RHDV GI.1, and a limited resistance to RHDV GI.2 strains, whereas less than 3% of adult rabbits survive an infection by either RHDV GI.1. or GI.2. Several not-yet fully understood phenomena characterize the RHD. A very low infection dose followed by an extremely rapid viral replication could be simplified to the induction of a disseminated intravascular coagulopathy (DIC), a severe loss of lymphocytes-especially T-cells-and death within 36 to 72 h post infection. On the other hand, in animals surviving the infection or after vaccination, very high titers of RHDV-neutralizing antibodies were induced. Several studies have been conducted in order to deepen the knowledge about the virus' genetics, epidemiology, RHDV-induced pathology, and the anti-RHDV immune responses of rabbits in order to understand the phenomenon of the juvenile resistance to this virus. Moreover, several approaches have been used to produce efficient vaccines in order to prevent an infection with RHDV. In this review, we discuss the current knowledge about anti-RHDV resistance and immunity, RHDV vaccination, and the further need to establish rationally-based RHDV vaccines.	[Mueller, Claudia] Friedrich Loeffler Inst, Dept Expt Anim Facil & Biorisk Management, D-17493 Greifswald, Germany; [Hrynkiewicz, Rafal; Bebnowska, Dominika; Niedzwiedzka-Rystwej, Paulina] Univ Szczecin, Inst Biol, Felczaka 3c, PL-71412 Szczecin, Poland; [Maldonado, Jaime; Baratelli, Massimiliano] HIPRA, Amer 17170, Spain; [Koellner, Bernd] Friedrich Loeffler Inst, Inst Immunol, D-17493 Greifswald, Germany		Niedzwiedzka-Rystwej, P (通讯作者)，Univ Szczecin, Inst Biol, Felczaka 3c, PL-71412 Szczecin, Poland.; Kollner, B (通讯作者)，Friedrich Loeffler Inst, Inst Immunol, D-17493 Greifswald, Germany.	claudia.mueller@fli.de; rafal.hrynkiewicz@usz.edu.pl; dominika.bebnowska@usz.edu.pl; jaime.maldonado@hipra.com; massimiliano.baratelli@hipra.com; bernd.koellner@fli.de; paulina.niedzwiedzka-rystwej@usz.edu.pl	Hrynkiewicz, Rafał/AAG-2054-2021; Bębnowska, Dominika/AAK-9564-2021	Hrynkiewicz, Rafał/0000-0002-0688-6928; Bębnowska, Dominika/0000-0003-3689-2381; Niedzwiedzka-Rystwej, Paulina/0000-0003-4065-3842			dos Santos FAA, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11010040; Abrantes J, 2008, ARCH VIROL, V153, P329, DOI 10.1007/s00705-007-1084-0; Abrantes J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71303-4; Abrantes J, 2014, ARCH VIROL, V159, P321, DOI 10.1007/s00705-013-1808-2; Abrantes J, 2013, EMERG INFECT DIS, V19, P1900, DOI 10.3201/eid1911.130908; Abrantes J, 2013, BMC GENET, V14, DOI 10.1186/1471-2156-14-73; Abrantes J, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-12; Alda F, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-347; Alonso C, 1998, ARCH VIROL, V143, P321, DOI 10.1007/s007050050289; Arguello Villares J, 1988, REV MED VET, V5, P645; Arguello Villares J L, 1991, Rev Sci Tech, V10, P459; Asgari S, 1998, VIRUS RES, V54, P123, DOI 10.1016/S0168-1702(98)00017-3; Astakhova NM, 2009, IMMUNOGENETICS, V61, P529, DOI 10.1007/s00251-009-0381-z; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Baratelli M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030484; Barcena J, 2015, VET RES, V46, DOI 10.1186/s13567-015-0245-5; Bergin IL, 2009, EMERG INFECT DIS, V15, P1955, DOI 10.3201/eid1512.090839; Bertagnoli S, 1996, VACCINE, V14, P506, DOI 10.1016/0264-410X(95)00232-P; Bertagnoli S, 1996, J VIROL, V70, P5061, DOI 10.1128/JVI.70.8.5061-5066.1996; Boehm T, 2012, ANNU REV IMMUNOL, V30, P203, DOI 10.1146/annurev-immunol-020711-075038; BOEVER F, 1948, ARCH INT PHARMACOD T, V77, P1; Bousarghin L, 2005, J GEN VIROL, V86, P1297, DOI 10.1099/vir.0.80559-0; Braciale TJ, 2013, IMMUNOL REV, V255, P5, DOI 10.1111/imr.12109; Calvete C, 2018, VET MICROBIOL, V219, P87, DOI 10.1016/j.vetmic.2018.04.018; Camarda A, 2014, RES VET SCI, V97, P642, DOI 10.1016/j.rvsc.2014.10.008; Cancellotti F.M., 1991, Revue Scientifique et Technique Office International des Epizooties, V10, P409; Capucci L, 1996, J VIROL, V70, P8614, DOI 10.1128/JVI.70.12.8614-8623.1996; Capucci L, 1991, Rev Sci Tech, V10, P347; CAPUCCI L, 1995, VIRUS RES, V37, P221, DOI 10.1016/0168-1702(95)00033-M; Capucci L, 1998, VIRUS RES, V58, P115, DOI 10.1016/S0168-1702(98)00106-3; Castanon S, 1999, J VIROL, V73, P4452; Chachu KA, 2008, J VIROL, V82, P6610, DOI 10.1128/JVI.00141-08; CHASEY D, 1992, ARCH VIROL, V124, P363, DOI 10.1007/BF01309816; Chen Q, 2013, HUM VACC IMMUNOTHER, V9, P26, DOI 10.4161/hv.22218; COLLINS BJ, 1995, VET MICROBIOL, V43, P85, DOI 10.1016/0378-1135(94)00082-8; Cooke BD, 2000, EPIDEMIOL INFECT, V124, P563, DOI 10.1017/S0950268899003994; Cooke BD, 2002, WILDLIFE RES, V29, P689, DOI 10.1071/WR02010; Cooke BD, 2002, REV SCI TECH OIE, V21, P347, DOI 10.20506/rst.21.2.1337; Cox TE, 2017, J WILDLIFE DIS, V53, P472, DOI 10.7589/2016-06-148; Crisci E, 2009, VIROLOGY, V387, P303, DOI 10.1016/j.virol.2009.02.045; Dalton KP, 2014, VET MICROBIOL, V169, P67, DOI 10.1016/j.vetmic.2013.12.015; Dalton KP, 2012, EMERG INFECT DIS, V18, P2009, DOI 10.3201/eid1812.120341; Danilova N, 2012, ADV EXP MED BIOL, V738, P218, DOI 10.1007/978-1-4614-1680-7_13; de Matos AL, 2014, IMMUNOGENETICS, V66, P43, DOI 10.1007/s00251-013-0740-7; de Sousa-Pereira P, 2016, IMMUNOGENETICS, V68, P477, DOI 10.1007/s00251-016-0909-y; Delibes-Mateos M, 2007, BIOL CONSERV, V137, P149, DOI 10.1016/j.biocon.2007.01.024; Di Giallonardo F, 2015, TRENDS MICROBIOL, V23, P83, DOI 10.1016/j.tim.2014.10.004; Elfeil WMK, 2016, CENT EUR J IMMUNOL, V41, P236, DOI 10.5114/ceji.2016.63121; Elsworth PG, 2012, EPIDEMIOL INFECT, V140, P1972, DOI 10.1017/S0950268811002743; Elsworth P, 2014, VIROLOGY, V464, P415, DOI 10.1016/j.virol.2014.06.037; Esteves PJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005087; Farber DL, 2016, NAT REV IMMUNOL, V16, P124, DOI 10.1038/nri.2016.13; Farnos O, 2007, ARCH VIROL, V152, P1215, DOI 10.1007/s00705-006-0926-5; Fenner F, 2010, REV SCI TECH OIE, V29, P103, DOI 10.20506/rst.29.1.1964; Fernandez E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056417; Fernandez E, 2011, VET IMMUNOL IMMUNOP, V142, P179, DOI 10.1016/j.vetimm.2011.05.007; Ferreira PG, 2008, VET IMMUNOL IMMUNOP, V121, P364, DOI 10.1016/j.vetimm.2007.09.005; Ferreira PG, 2006, RES VET SCI, V80, P218, DOI 10.1016/j.rvsc.2005.05.007; Ferreira PG, 2005, VET IMMUNOL IMMUNOP, V103, P217, DOI 10.1016/j.vetimm.2004.09.028; Ferreira PG, 2004, RES VET SCI, V76, P83, DOI 10.1016/j.rvsc.2003.08.003; Fischer L, 1997, VACCINE, V15, P90, DOI 10.1016/S0264-410X(96)00102-8; Fitzner A, 2016, POL J VET SCI, V19, P597, DOI 10.1515/pjvs-2016-0075; Fiuza TS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00816; Forrester NL, 2007, VIROLOGY, V358, P18, DOI 10.1016/j.virol.2006.09.011; Forrester NL, 2009, VIROLOGY, V393, P42, DOI 10.1016/j.virol.2009.07.008; Forrester NL, 2006, VIROLOGY, V344, P277, DOI 10.1016/j.virol.2005.10.006; FUCHS A, 1992, J COMP PATHOL, V107, P103, DOI 10.1016/0021-9975(92)90100-9; Furukawa S, 2014, J TOXICOL PATHOL, V27, P11, DOI 10.1293/tox.2013-0060; Gall A, 2007, VET MICROBIOL, V120, P17, DOI 10.1016/j.vetmic.2006.10.006; Garcia-Lastra R, 2010, VET RES, V41, DOI 10.1051/vetres/2009050; Gavier-Widen D., 1991, Revue Scientifique et Technique Office International des Epizooties, V10, P453; GEHRMANN B, 1991, BERL MUNCH TIERARZTL, V104, P192; Gibb John A., 1994, P158; GRANZOW H, 1989, MONATSH VETERINARMED, V44, P379; Gregg D A, 1991, Rev Sci Tech, V10, P435; Grgacic EVL, 2006, METHODS, V40, P60, DOI 10.1016/j.ymeth.2006.07.018; GuErski J., 1988, YCIE WET, V63, P266; Guo HM, 2016, ANTIVIR RES, V131, P85, DOI 10.1016/j.antiviral.2016.04.011; Hall RN, 2017, VET REC, V180, DOI 10.1136/vr.104034; Hall RN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173727; HAYWARD AR, 1978, J EXP MED, V148, P1367, DOI 10.1084/jem.148.5.1367; House Rabbit Society, RABB HEM DIS VIR RHD; Hrynkiewicz R, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10091581; Hu B, 2017, ARCH VIROL, V162, P269, DOI 10.1007/s00705-016-3082-6; Hu ZJ, 2010, PROTEIN CELL, V1, P48, DOI 10.1007/s13238-010-0007-0; Huang H B, 1991, Rev Sci Tech, V10, P481; International Committee on Taxonomy of Viruses (ICTV), GENUS LAGOVIRUS; Jain S, 2019, MED MICROBIOL IMMUN, V208, P227, DOI 10.1007/s00430-019-00584-y; Jasper PJ, 2003, J IMMUNOL, V171, P6372, DOI 10.4049/jimmunol.171.12.6372; Jennewein MF, 2017, SEMIN IMMUNOPATHOL, V39, P605, DOI 10.1007/s00281-017-0653-x; Tunon MJ, 2011, J VIROL, V85, P13124, DOI 10.1128/JVI.05725-11; Jung JY, 2000, J COMP PATHOL, V123, P135, DOI 10.1053/jcpa.2000.0403; Kajikawa O, 2005, GENE, V344, P193, DOI 10.1016/j.gene.2004.09.032; Kerr PJ, 2009, J VIROL, V83, P12129, DOI 10.1128/JVI.01523-09; Kimura T, 2001, J COMP PATHOL, V124, P134, DOI 10.1053/jcpa.2000.0440; Kinnear M, 2010, J GEN VIROL, V91, P174, DOI 10.1099/vir.0.014076-0; Knight KL, 1997, CURR OPIN IMMUNOL, V9, P228, DOI 10.1016/S0952-7915(97)80140-9; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083; Lai CY, 2014, VACCINE, V32, P5593, DOI 10.1016/j.vaccine.2014.07.104; Laliena A, 2012, J PINEAL RES, V53, P270, DOI 10.1111/j.1600-079X.2012.00995.x; Lavazza A, 1996, J VET MED B, V43, P401, DOI 10.1111/j.1439-0450.1996.tb00332.x; Lavinder JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101322; Le Gall G, 1998, J GEN VIROL, V79, P11, DOI 10.1099/0022-1317-79-1-11; Le Gall-Recule G, 2011, VET REC, V168, P137, DOI 10.1136/vr.d697; Le Gall-Recule G, 2003, ARCH VIROL, V148, P65, DOI 10.1007/s00705-002-0908-1; Le Gall-Recule G, 2017, VET RES, V48, DOI 10.1186/s13567-017-0473-y; Le Gall-Recule G, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-81; Le Gall-Recule G, 2011, VIROLOGY, V410, P395, DOI 10.1016/j.virol.2010.12.001; Le Pendu J, 2017, J GEN VIROL, V98, P1658, DOI 10.1099/jgv.0.000840; LI JN, 1990, J ANIM QUAR, V3, P19; Lindesmith LC, 2019, IMMUNITY, V50, P1530, DOI 10.1016/j.immuni.2019.05.007; Liu J, 2012, COMP IMMUNOL MICROB, V35, P443, DOI 10.1016/j.cimid.2012.03.008; Liu S. J., 1984, Animal Husbandry and Veterinary Medicine (Xumu yu Shouyi), V16, P253; Loliger H.-C., 1991, Revue Scientifique et Technique Office International des Epizooties, V10, P423; Lopes AM, 2015, J GEN VIROL, V96, P1309, DOI 10.1099/vir.0.000070; Lopes AM, 2014, VIROLOGY, V468, P104, DOI 10.1016/j.virol.2014.08.002; Lopes AM, 2014, VET RES, V45, DOI 10.1186/s13567-014-0094-7; Makhluf H, 2015, CRIT REV IMMUNOL, V35, P253, DOI 10.1615/CritRevImmunol.2015014251; Marcato P.S., 1991, Revue Scientifique et Technique Office International des Epizooties, V10, P371; Marchandeau S, 2000, WILDLIFE BIOL, V6, P141, DOI 10.2981/wlb.2000.009; Marin MS, 1995, VIRUS RES, V39, P119, DOI 10.1016/0168-1702(95)00074-7; Marino A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090819; Marques RM, 2012, VET IMMUNOL IMMUNOP, V150, P181, DOI 10.1016/j.vetimm.2012.09.038; Marques RM, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-14; Marques RM, 2010, VET RES COMMUN, V34, P659, DOI 10.1007/s11259-010-9437-7; MARTENS CL, 1984, J IMMUNOL, V133, P1022; MCELROY PJ, 1981, EUR J IMMUNOL, V11, P76, DOI 10.1002/eji.1830110203; Merchan T, 2011, INFECT GENET EVOL, V11, P1469, DOI 10.1016/j.meegid.2011.05.001; Metz SW, 2013, VACCINE, V31, P6092, DOI 10.1016/j.vaccine.2013.09.045; MEYERS G, 1991, VIROLOGY, V184, P664, DOI 10.1016/0042-6822(91)90436-F; Mikami D, 1999, RES VET SCI, V66, P237, DOI 10.1053/rvsc.1998.0266; Mikschofsky H, 2009, PLANT BIOTECHNOL J, V7, P537, DOI 10.1111/j.1467-7652.2009.00422.x; Mohsen MO, 2017, SEMIN IMMUNOL, V34, P123, DOI 10.1016/j.smim.2017.08.014; Monterroso P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36072; Morisse J.-P., 1991, Revue Scientifique et Technique Office International des Epizooties, V10, P269; Moss SR, 2002, J GEN VIROL, V83, P2461, DOI 10.1099/0022-1317-83-10-2461; MOUSSA A, 1992, VET MICROBIOL, V33, P375, DOI 10.1016/0378-1135(92)90065-2; Muller C, 2019, VACCINE, V37, P4195, DOI 10.1016/j.vaccine.2019.04.061; Muller C, 2019, ARCH VIROL, V164, P137, DOI 10.1007/s00705-018-4032-2; Mutze G, 1998, J WILDLIFE DIS, V34, P221, DOI 10.7589/0090-3558-34.2.221; NAGESHA HS, 1995, ARCH VIROL, V140, P1095, DOI 10.1007/BF01315418; Neave MJ, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10090512; Neimanis AS, 2018, TRANSBOUND EMERG DIS, V65, P213, DOI 10.1111/tbed.12650; Neimanis AS, 2018, BMC VET RES, V14, DOI 10.1186/s12917-018-1694-7; Niedwiedzka-Rystwej P., 2019, ACTA BIOL, V26, P83, DOI [10.18276/ab.2019.26-08, DOI 10.18276/AB.2019.26-08]; Niedzwiedzka-Rystwej P, 2013, POL J VET SCI, V16, P223, DOI 10.2478/pjvs-2013-0032; Niedzwiedzka-Rystwej P, 2010, POL J VET SCI, V13, P157; Niedzwiedzka-Rystwej P, 2013, MED WETER, V69, P484; Niedzwiedzka-Rystwej P, 2013, CENT EUR J IMMUNOL, V38, P231, DOI 10.5114/ceji.2013.35039; Niedzwiedzka-Rystwej P, 2013, ACTA BIOCHIM POL, V60, P65; Niedzwiedzka-Rystwej P, 2012, VET IMMUNOL IMMUNOP, V149, P54, DOI 10.1016/j.vetimm.2012.06.012; Niedzwiedzka-Rystwej P, 2010, CENT EUR J BIOL, V5, P613, DOI 10.2478/s11535-010-0049-6; Nowotny N, 1997, ARCH VIROL, V142, P657, DOI 10.1007/s007050050109; NOWOTNY N, 1990, WIEN TIERARZTL MONAT, V77, P19; O'Keefe JS, 1998, NEW ZEAL VET J, V46, P42, DOI 10.1080/00480169.1998.36053; OHLINGER VF, 1989, TIERAERZTL UMSCHAU, V44, P284; OHLINGER VF, 1993, VET RES, V24, P103; OHLINGER VF, 1990, J VIROL, V64, P3331, DOI 10.1128/JVI.64.7.3331-3336.1990; Park NY, 1987, J KOREAN VET MED ASS, V23, P603; PARRA F, 1990, J VIROL, V64, P4013, DOI 10.1128/JVI.64.8.4013-4015.1990; Penaflor-Tellez Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02334; PlanaDuran J, 1996, ARCH VIROL, V141, P1423, DOI 10.1007/BF01718245; Prieto JM, 2000, RES VET SCI, V68, P181, DOI 10.1053/rvsc.1999.0357; Prieto MB, 2017, COMP IMMUNOL MICROB, V54, P38, DOI 10.1016/j.cimid.2017.08.002; Puggioni G, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-96; Raeven RHM, 2019, IMMUNOLOGY, V156, P33, DOI 10.1111/imm.13012; Rahali N, 2019, ARCH VIROL, V164, P2327, DOI 10.1007/s00705-019-04311-z; Ramiro-Ibanez F, 1999, VIRUS RES, V60, P21, DOI 10.1016/S0168-1702(98)00144-0; Rappuoli R, 2000, CURR OPIN MICROBIOL, V3, P445, DOI 10.1016/S1369-5274(00)00119-3; Rouco C, 2018, TRANSBOUND EMERG DIS, V65, pe373, DOI 10.1111/tbed.12767; Rouco C, 2019, TRANSBOUND EMERG DIS, V66, P1762, DOI 10.1111/tbed.13189; Ruvoen-Clouet N, 2000, J VIROL, V74, P11950, DOI 10.1128/JVI.74.24.11950-11954.2000; Sanchez-Campos S, 2004, J LAB CLIN MED, V144, P215, DOI 10.1016/j.lab.2004.07.006; Schirrmeier H, 1999, ARCH VIROL, V144, P719, DOI 10.1007/s007050050538; Schwensow NI, 2017, MOL ECOL, V26, P4551, DOI 10.1111/mec.14228; Semerjyan AB, 2019, VET WORLD, V12, P1332, DOI 10.14202/vetworld.2019.1332-1340; Serradell MC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08265-9; SMID B, 1991, VET MICROBIOL, V26, P77, DOI 10.1016/0378-1135(91)90043-F; Strive T, 2010, VIROLOGY, V398, P125, DOI 10.1016/j.virol.2009.11.045; Strive T, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-51; Teifke JP, 2002, J COMP PATHOL, V126, P231, DOI 10.1053/jcpa.2001.0534; Teixeira L, 2012, VET IMMUNOL IMMUNOP, V148, P343, DOI 10.1016/j.vetimm.2012.05.006; Thompson J., 1997, Surveillance (Wellington), V24, P5; Tokarz-Deptula, 2009, POL J ENVIRON STUD, V7, P1; Trzeciak-Ryczek A, 2017, DEV COMP IMMUNOL, V76, P310, DOI 10.1016/j.dci.2017.07.005; Trzeciak-Ryczek A, 2016, VET MICROBIOL, V186, P71, DOI 10.1016/j.vetmic.2016.02.021; Trzeciak-Ryczek A, 2015, ACTA BIOCHIM POL, V62, P169, DOI 10.18388/abp.2014_943; UEDA K, 1992, JPN J VET RES, V40, P133; Ulsenheimer A, 2005, HEPATOLOGY, V41, P643, DOI 10.1002/hep.20592; USGS Science for a Changing World, UPD NWHC SUPP WILDL; Vallejo D, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-15; Velarde R, 2017, TRANSBOUND EMERG DIS, V64, P1750, DOI 10.1111/tbed.12562; Villafuerte R, 1995, MAMMALIA, V59, P651, DOI 10.1515/mamm.1995.59.4.651; Vinje J, 2019, J GEN VIROL, V100, P1469, DOI 10.1099/jgv.0.001332; Wang X, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003132; Westcott DG, 2014, VET REC, V174, DOI 10.1136/vr.g2345; White PJ, 2004, EPIDEMIOL INFECT, V132, P555, DOI 10.1017/S0950268804002109; Wilkins C, 2010, CURR OPIN IMMUNOL, V22, P41, DOI 10.1016/j.coi.2009.12.003; WIRBLICH C, 1994, J VIROL, V68, P5164, DOI 10.1128/JVI.68.8.5164-5173.1994; Xu W Y, 1991, Rev Sci Tech, V10, P393; XU ZJ, 1989, VET RES COMMUN, V13, P205, DOI 10.1007/BF00142046; Zepeda-Cervantes J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01100; Zheng XX, 2016, INT IMMUNOPHARMACOL, V40, P164, DOI 10.1016/j.intimp.2016.08.016	204	3	3	5	5	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							255	10.3390/vaccines9030255			25	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5LQ	33805607	gold, Green Published			2022-04-29	WOS:000634195800001
J	Papagiannis, D; Rachiotis, G; Malli, F; Papathanasiou, IV; Kotsiou, O; Fradelos, EC; Giannakopoulos, K; Gourgoulianis, KI				Papagiannis, Dimitrios; Rachiotis, George; Malli, Foteini; Papathanasiou, Ioanna, V; Kotsiou, Ourania; Fradelos, Evangelos C.; Giannakopoulos, Konstantinos; Gourgoulianis, Konstantinos, I			Acceptability of COVID-19 Vaccination among Greek Health Professionals	VACCINES			English	Article						Covid-19; vaccination; acceptability; health care workers	CARE WORKERS; ATTITUDES; KNOWLEDGE	Health Care Workers are at the front line of the fight against Covid-19. The aim of this study was to evaluate the acceptability of vaccination against COVID-19 among health professionals (physicians, dentists, pharmacists) two weeks prior to the start of the Greek vaccination campaign against COVID-19. A cross-sectional online survey was conducted over the period 15-22 December 2020 in 340 health professionals in Central Greece. We found a high level of acceptance for COVID-19 vaccine (78.5%) and a high vaccination coverage for the influenza vaccine (74%). Age > 45 years (OR = 2.01; 95% C.I. = 2.01-4.3), absence of fear over vaccine safety (OR = 4.09; 95% C.I. = 1.36-12.3), and information received from the Greek public health authorities (OR = 11.14; 95% C.I. = 5.48-22.6), were factors independently associated with the likelihood of COVID-19 vaccination acceptance. Our study indicates a high level of the COVID-19 vaccination acceptance among physicians, dentists and pharmacists. Nevertheless, several interventions can be implemented to increase acceptance of vaccine among health-care workers (HCWs) and could be especially directed at younger and vaccine-hesitant health care workers due to fear of vaccine side-effects. Last, our results provide some evidence that receiving vaccine-related information from the Greek Center for Diseases Control (E.O.D.Y.) could reduce the drivers of hesitancy and enhance the acceptability of COVID-19 vaccination.	[Papagiannis, Dimitrios] Univ Thessaly, Fac Nursing, Sch Hlth Sci, Publ Hlth & Vaccines Lab, Larisa 41500, Greece; [Rachiotis, George] Univ Thessaly, Fac Med, Sch Hlth Sci, Dept Hyg & Epidemiol, Larisa 41222, Greece; [Malli, Foteini] Univ Thessaly, Fac Nursing, Resp Disorders Lab, Larisa 41500, Greece; [Papathanasiou, Ioanna, V] Univ Thessaly, Fac Nursing, Community Nursing Lab, Larisa 41500, Greece; [Kotsiou, Ourania; Fradelos, Evangelos C.] Univ Thessaly, Fac Nursing, Larisa 41500, Greece; [Giannakopoulos, Konstantinos] Med Assoc Larissa Hippocrates, Larisa 41222, Greece; [Gourgoulianis, Konstantinos, I] Univ Thessaly, Fac Med, Resp Med Dept, Larisa 41500, Greece		Papagiannis, D (通讯作者)，Univ Thessaly, Fac Nursing, Sch Hlth Sci, Publ Hlth & Vaccines Lab, Larisa 41500, Greece.	dpapajohn@uth.gr; grach@uth.gr; fmalli@uth.gr; iopapathanasiou@uth.gr; okotsiou@uth.gr; efradelos@uth.gr; artgiann@gmail.com; kgourg@med.uth.gr	C., Evangelos Fradelos/AAD-2903-2019; Kotsiou, Ourania/V-5423-2019	C., Evangelos Fradelos/0000-0003-0244-9760; Kotsiou, Ourania/0000-0001-5219-6971; Papathanasiou, Ioanna V./0000-0002-8874-8085; Malli, Foteini/0000-0002-7595-6715			Detoc M, 2020, VACCINE, V38, P7002, DOI 10.1016/j.vaccine.2020.09.041; European Centre for Diseases Prevention and Control (ECDC), TECHNICAL REPORT; European Food Safety Authority, 2019, EFSA J, V17, DOI 10.2903/j.efsa.2019.5926; Lin C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010016; Liu Q, 2020, LANCET GLOB HEALTH, V8, pE790, DOI 10.1016/S2214-109X(20)30204-7; Maltezou HC, 2019, FUTURE MICROBIOL, V14, P55, DOI 10.2217/fmb-2018-0266; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Papagiannis D, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17144925; Rachiotis G, 2010, EUROSURVEILLANCE, V15, P8; Ricco M, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5030117; Verger P, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.3.2002047; World Health Organization, COR DIS COVID 19 VAC; Zarocostas J, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2877	13	35	36	3	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							200	10.3390/vaccines9030200			7	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5JE	33670913	gold, Green Published			2022-04-29	WOS:000634189400001
J	Su, F; Wu, YG; Li, JX; Huang, Y; Yu, B; Xu, LH; Xue, Y; Xiao, CN; Yuan, XF				Su, Fei; Wu, Yige; Li, Junxing; Huang, Yee; Yu, Bin; Xu, Lihua; Xue, Yin; Xiao, Chenwen; Yuan, Xiufang			Escherichia coli Heat-Labile Enterotoxin B Subunit Combined with Ginsenoside Rg1 as an Intranasal Adjuvant Triggers Type I Interferon Signaling Pathway and Enhances Adaptive Immune Responses to an Inactivated PRRSV Vaccine in ICR Mice	VACCINES			English	Article						PRRSV; intranasal adjuvant; LTB; Rg1; type I interferon		Porcine reproductive and respiratory syndrome virus (PRRSV) is a major pathogen that has threatened the global swine industry for almost 30 years. Because current vaccines do not provide complete protection, exploration of new preventive strategies is urgently needed. Here, we combined a heat-labile enterotoxin B subunit of Escherichia coli (LTB) and ginsenoside Rg1 to form an intranasal adjuvant and evaluated its enhancement of immune responses in mice when added to an inactivated-PRRSV vaccine. The combination adjuvant synergistically elicited higher neutralizing and non-neutralizing (immunoglobulin G and A) antibody responses in the circulatory system and respiratory tract, and enhanced T and B lymphocyte proliferation, CD4(+) T-cell priming, and cytotoxic CD4(+) T cell activities in mononuclear cells from spleen and lung tissues when compared to the PRRSV vaccine alone, and it resulted in balanced Th1/Th2/Th17 responses. More importantly, we observed that the combination adjuvant also up-regulated type I interferon signaling, which may contribute to improvement in adaptive immune responses. These results highlight the potential value of a combined adjuvant approach for improving the efficacy of vaccination against PRRSV. Further study is required to evaluate the efficacy of this combined adjuvant in swine.	[Su, Fei; Wu, Yige; Li, Junxing; Huang, Yee; Yu, Bin; Xu, Lihua; Xiao, Chenwen; Yuan, Xiufang] Zhejiang Acad Agr Sci, Inst Anim Husb & Vet Sci, Hangzhou 310002, Peoples R China; [Xue, Yin] Zhejiang Ctr Anim Dis Control, Hangzhou 310020, Peoples R China		Yuan, XF (通讯作者)，Zhejiang Acad Agr Sci, Inst Anim Husb & Vet Sci, Hangzhou 310002, Peoples R China.	sufei@zaas.ac.cn; d_count@126.com; lijunx@zaas.ac.cn; huangye@zaas.ac.cn; yub@zaas.ac.cn; xulihua@zaas.ac.cn; schroyen@163.com; xiaochenwen@zaas.ac.cn; yuanxf@zaas.ac.cn			National Natural Scientific Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31802235]; Zhejiang Basic Public Welfare Research Program (Agriculture and Rural Project) [LGN21C180001]; Talents Training Program of Zhejiang Academy of Agricultural Sciences [2017R22R08E03]	This work was supported by the National Natural Scientific Foundation of China (Grant No. 31802235), Zhejiang Basic Public Welfare Research Program (Agriculture and Rural Project) (Grant No. LGN21C180001), and the Talents Training Program of Zhejiang Academy of Agricultural Sciences (Grant No. 2017R22R08E03).	Albert MJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142090; Alshweiat A, 2019, CURR MED CHEM, V26, P6459, DOI 10.2174/0929867326666190827151741; Aman AT, 2001, P NATL ACAD SCI USA, V98, P8536, DOI 10.1073/pnas.161273098; Barranco I, 2012, VET IMMUNOL IMMUNOP, V149, P262, DOI 10.1016/j.vetimm.2012.07.011; Batista L, 2004, CAN J VET RES, V68, P267; Beura LK, 2010, J VIROL, V84, P1574, DOI 10.1128/JVI.01326-09; Binjawadagi B, 2014, INT J NANOMED, V9, P679, DOI 10.2147/IJN.S56127; Cheng Y, 2005, ACTA PHARMACOL SIN, V26, P143, DOI 10.1111/j.1745-7254.2005.00034.x; Duan QD, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00292; Evans AB, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050113; Fontanella E, 2017, VACCINE, V35, P125, DOI 10.1016/j.vaccine.2016.11.020; Gao XL, 2013, MOL MED, V19, P346, DOI 10.2119/molmed.2013.00035; Geffner L, 2014, CLIN EXP IMMUNOL, V175, P235, DOI 10.1111/cei.12227; Hagiwar Y, 2001, VACCINE, V19, P2071, DOI 10.1016/S0264-410X(00)00414-X; Hagiwara Y, 2001, VACCINE, V19, P1652, DOI 10.1016/S0264-410X(00)00412-6; Huang C, 2014, J VIROL, V88, P10934, DOI 10.1128/JVI.01396-14; HUSSAIN R, 1995, IMMUNOLOGY, V84, P290; Ji J, 2015, J CELL MOL MED, V19, P2019, DOI 10.1111/jcmm.12599; Jiang LY, 2018, ONCOL LETT, V15, P3429, DOI 10.3892/ol.2018.7794; Jie ZL, 2018, NAT IMMUNOL, V19, P1224, DOI 10.1038/s41590-018-0206-z; Johnson S, 2015, J VIROL, V89, P7494, DOI 10.1128/JVI.00438-15; Katakam AK, 2015, P NATL ACAD SCI USA, V112, P14664, DOI 10.1073/pnas.1520627112; Laforge M, 2018, J CLIN INVEST, V128, P1627, DOI 10.1172/JCI95127; Lei H, 2015, J MED VIROL, V87, P39, DOI 10.1002/jmv.23983; Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999; Li X, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/416727; Li X, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00697-19; Linhares DCL, 2012, VACCINE, V30, P407, DOI 10.1016/j.vaccine.2011.10.075; Liu L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091419; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loving CL, 2015, VET IMMUNOL IMMUNOP, V167, P1, DOI 10.1016/j.vetimm.2015.07.003; Lunney JK, 2016, ANNU REV ANIM BIOSCI, V4, P129, DOI 10.1146/annurev-animal-022114-111025; Ma YP, 2016, EXPERT REV VACCINES, V15, P1361, DOI 10.1080/14760584.2016.1182868; Marchioro SB, 2014, VET MICROBIOL, V173, P166, DOI 10.1016/j.vetmic.2014.07.009; Muir WI, 1998, POULTRY SCI, V77, P1874, DOI 10.1093/ps/77.12.1874; Nashar TO, 1996, P NATL ACAD SCI USA, V93, P226, DOI 10.1073/pnas.93.1.226; Newsted D, 2015, VACCINE, V33, P2399, DOI 10.1016/j.vaccine.2015.03.096; Ni JX, 2016, ANTIVIR RES, V132, P92, DOI 10.1016/j.antiviral.2016.05.018; Nieuwenhuis N, 2012, VET REC, V170, P225, DOI 10.1136/vr.100101; Pandey MK, 2007, BLOOD, V110, P3517, DOI 10.1182/blood-2007-03-079616; Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238; Rahe MC, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9060148; Renukaradhya GJ, 2015, VACCINE, V33, P4069, DOI 10.1016/j.vaccine.2015.06.092; Renukaradhya GJ, 2015, VACCINE, V33, P3065, DOI 10.1016/j.vaccine.2015.04.102; Sainz T, 2013, AIDS, V27, P1513, DOI 10.1097/QAD.0b013e32835faa72; Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078; Shi KC, 2010, VET MICROBIOL, V140, P155, DOI 10.1016/j.vetmic.2009.07.021; Soghoian DZ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003165; Su F, 2019, J VET MED SCI, V81, P1475, DOI 10.1292/jvms.19-0057; Su F, 2015, ANTIMICROB AGENTS CH, V59, P5654, DOI 10.1128/AAC.01381-15; Su F, 2012, VACCINE, V30, P4106, DOI 10.1016/j.vaccine.2012.03.052; Sun Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168314; Sun Z, 2012, J VIROL, V86, P3839, DOI 10.1128/JVI.06466-11; Tangye SG, 2002, J IMMUNOL, V169, P4298, DOI 10.4049/jimmunol.169.8.4298; Terahara K, 2014, J VIROL, V88, P14232, DOI 10.1128/JVI.02032-14; Thanasarasakulpong A, 2015, J VET MED SCI, V77, P321, DOI 10.1292/jvms.14-0532; Vedantam G, 2011, GASTROENTEROLOGY, V141, P795, DOI 10.1053/j.gastro.2011.07.022; Wang HL, 2019, J VIROL, V93, DOI 10.1128/JVI.01100-19; Wang Y, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/2714257; Wong PT, 2021, MOL PHARMACEUT, V18, P679, DOI 10.1021/acs.molpharmaceut.0c00315; Yang LP, 2017, VET MICROBIOL, V209, P57, DOI 10.1016/j.vetmic.2016.12.036; Yang LP, 2017, J VIROL, V91, DOI [10.1128/JVI.02087-16, 10.1128/jvi.02087-16]; Zhang L, 2016, VET MICROBIOL, V189, P75, DOI 10.1016/j.vetmic.2016.05.001; Zhou YL, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005019; Zoeteweij JP, 2006, J IMMUNOL, V177, P1197, DOI 10.4049/jimmunol.177.2.1197	65	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	MAR	2021	9	3							266	10.3390/vaccines9030266			20	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	RE5PI	33809809	gold, Green Published			2022-04-29	WOS:000634205400001
J	Dinga, JN; Sinda, LK; Titanji, VPK				Dinga, Jerome Nyhalah; Sinda, Leontine Kouemou; Titanji, Vincent P. K.			Assessment of Vaccine Hesitancy to a COVID-19 Vaccine in Cameroonian Adults and Its Global Implication	VACCINES			English	Article						COVID-19 pandemic; vaccine hesitancy; vaccine acceptance; clinical trials; Cameroon		Since the outbreak of COVID-19 in December 2019, no global consensus treatment has been developed and generally accepted for the disease. However, eradicating the disease will require a safe and efficacious vaccine. In order to prepare for the eventual development of a safe and efficacious COVID-19 vaccine and to enhance its uptake, it is imperative to assess vaccine hesitancy in Cameroonians. After obtaining ethical clearance from the Institutional Review Board of the University of Buea, a questionnaire was administered (May-August 2020) to consenting adults either online or in person. A qualitative thematic analysis was done to analyze the participants' answers to the open questions. A deductive approach was used, that is, the codes and patterns according to the World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) Working Group Matrix of Determinants of vaccine hesitancy. The number of consenting adult Cameroonians who completed the questionnaire were 2512 (Two thousand five hundred and twelve). Vaccine hesitancy to a COVID-19 vaccine was 84.6% in Cameroonians. Using the WHO recommended Matrix of Determinant of Vaccine hesitancy, the most prominent determinants observed in this study were: Communication and Media Environment, Perception of pharmaceutical industry, Reliability and/or source of vaccine and cost. Most Cameroonians agree that even though there are benefits of a clinical trial, they will prefer it should be done out of the continent and involving African scientists for eventual acceptance and uptake. The concerns of safety, efficacy and confidence has to be addressed using a Public Engagement approach if a COVID-19 vaccine has to be administered successfully in Africa or Cameroon specifically. Since this study was carried out following WHO standards, its result can be compared to those of other studies carried out in different cultural settings using similar standards.	[Dinga, Jerome Nyhalah; Titanji, Vincent P. K.] Univ Buea, Fac Sci, Biotechnol Unit, POB 63, Buea, Cameroon; [Sinda, Leontine Kouemou] Univ Buea, Dept Microbiol & Parasitol, Fac Sci, POB 63, Buea, Cameroon; [Titanji, Vincent P. K.] Cameroon Christian Univ Inst, Fac Sci Engn & Technol, POB 5, Bali, Cameroon		Dinga, JN (通讯作者)，Univ Buea, Fac Sci, Biotechnol Unit, POB 63, Buea, Cameroon.	djnyhalah@yahoo.com; leontinesinda@yahoo.com; vpk.titanji@yahoo.com					[Anonymous], 2020, WHO; Bennett S., 2019, NEW PLACES NEW CULTU; Betsch C, 2012, VACCINE, V30, P3723, DOI 10.1016/j.vaccine.2012.03.078; Betsch C, 2012, VACCINE, V30, P3727, DOI 10.1016/j.vaccine.2012.02.025; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI DOI 10.1191/1478088706QP063OA; Cooper LZ, 2008, PEDIATRICS, V122, P149, DOI 10.1542/peds.2008-0987; Dube E, 2016, Can Commun Dis Rep, V42, P246; Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039; Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657; Freelon DG, 2010, INT J INTERNET SCI, V5, P20; Hallgren Kevin A, 2012, Tutor Quant Methods Psychol, V8, P23; Hobson-West P, 2003, HEALTH RISK SOC, V5, P273, DOI 10.1080/13698570310001606978; Kahan DM, 2013, SCIENCE, V342, P53, DOI 10.1126/science.1245724; Kang GJ, 2017, VACCINE, V35, P3621, DOI 10.1016/j.vaccine.2017.05.052; Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112; Kennedy A, 2011, HEALTH AFFAIR, V30, P1151, DOI 10.1377/hlthaff.2011.0396; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Marti M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172310; Miko D, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55060282; MINSANTE, HLTH SECT STRAT 2016; Murrero M., 2013, INTERNET HLTH CARE T; Ropeik D, 2013, HUM VACC IMMUNOTHER, V9, P1815, DOI 10.4161/hv.25250; Shapiro GK, 2018, VACCINE, V36, P660, DOI 10.1016/j.vaccine.2017.12.043; Streefland P, 1999, SOC SCI MED, V49, P1705, DOI 10.1016/S0277-9536(99)00239-7; Taddio Anna, 2015, Clin J Pain, V31, pS1, DOI 10.1097/AJP.0000000000000274; Universidad John Hopkins, 2020, COVID 19 DASHB CTR S; World Health Organization, 2019, 10 THREATS GLOB HLTH; World Health Organization, REP SAGE WORK GROUP; World Health Organization, 2018, 2018 ASS REP GLOB VA; Worldometer, 2020, CAMEROON DEMOGRAPHIC	32	20	21	1	9	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							175	10.3390/vaccines9020175			14	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7FL	33669659	gold, Green Published			2022-04-29	WOS:000623305600001
J	Fereig, RM; Abdelbaky, HH; Nishikawa, Y				Fereig, Ragab M.; Abdelbaky, Hanan H.; Nishikawa, Yoshifumi			Vaccination with Neospora GRA6 Interrupts the Vertical Transmission and Partially Protects Dams and Offspring against Neospora caninum Infection in Mice	VACCINES			English	Article						N. caninum; vaccine; neosporosis; NcGRA6; abortion	C57BL/6 MICE; INTERFERON-GAMMA; IMMUNE-RESPONSE; PREVENTION; CATTLE; INTERLEUKIN-4; VACCINES; ABORTION	Vaccination is the mainstay of preventative measures for numerous infectious diseases. Neospora caninum infection induces storms of abortion in pregnant cows and ewes, resulting in drastic economic losses because of fetal losses and culling of the dams. Herein, we evaluated the potential of recombinant protein of N. caninum dense granule protein 6 fused with glutathione-S-transferase (NcGRA6+GST) as a vaccine candidate against neosporosis in a pregnant mouse model. The protective efficacy was investigated by subcutaneous inoculation of BALB/c mice with recombinant NcGRA6+GST (25 pmol), and GST alone (25 pmol) or phosphate-buffered saline (PBS) as the controls. This study revealed the partial ability of NcGRA6+GST to protect the dams and offspring from N. caninum infection during the critical period of pregnancy. This ability was revealed by higher survival rate and lower parasite burden in brains of offspring of the NcGRA6+GST-immunized group in comparison with the control groups. In addition, mouse dams from NcGRA6+GST-immunized groups exhibited lower clinical score and minimum alteration in body weight in comparison with PBS or GST groups after challenge with N. caninum tachyzoites. Taken together, our results suggest the efficacy of recombinant NcGRA6 for interrupting the vertical transmission of N. caninum in mice by reducing the severity of infections in dams and offspring.	[Fereig, Ragab M.; Abdelbaky, Hanan H.; Nishikawa, Yoshifumi] Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Inada Cho, Obihiro, Hokkaido 0808555, Japan; [Fereig, Ragab M.] South Valley Univ, Fac Vet Med, Dept Anim Med, Qena City 83523, Qena, Egypt		Nishikawa, Y (通讯作者)，Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Inada Cho, Obihiro, Hokkaido 0808555, Japan.	ragabfereig2018@gmail.com; hananragabegypt@gmail.com; nisikawa@obihiro.ac.jp	Fereig, Ragab/AAA-2500-2022	nishikawa, yoshifumi/0000-0001-5005-6377; Fereig, Ragab Makhlouf/0000-0003-1845-1312	Ministry of Education, Culture, Sports, Science and Technology KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18H02335, 20K21359]	This research was supported by a Grant-in-Aid for Scientific Research (B) 18H02335 and Challenging Research (Exploratory) 20K21359 from the Ministry of Education, Culture, Sports, Science and Technology KAKENHI (Y.N.).	Aguado-Martinez A, 2017, INT J PARASITOL, V47, P723, DOI 10.1016/j.ijpara.2017.09.001; Ashkar AA, 1999, BIOL REPROD, V61, P493, DOI 10.1095/biolreprod61.2.493; Debache K, 2009, INT J PARASITOL, V39, P1373, DOI 10.1016/j.ijpara.2009.04.006; DELASSUS S, 1994, J IMMUNOL, V152, P2411; Dubey JP, 2011, VET PARASITOL, V180, P90, DOI 10.1016/j.vetpar.2011.05.031; Dubey J.P., 2003, KOREAN J PARASITOL, V41, P1, DOI [10.3347/kjp.2003.41.1.1, DOI 10.3347/KJP.2003.41.1.1]; Ellis J, 2008, VACCINE, V26, P5989, DOI 10.1016/j.vaccine.2008.08.043; Fereig RM, 2019, VET PARASITOL, V267, P61, DOI 10.1016/j.vetpar.2019.02.003; Fereig RM, 2019, VACCINE, V37, P937, DOI 10.1016/j.vaccine.2019.01.005; Gao QL, 1996, TRANSPLANTATION, V62, P1847, DOI 10.1097/00007890-199612270-00029; Innes EA, 2002, TRENDS PARASITOL, V18, P497, DOI 10.1016/S1471-4922(02)02372-3; Innes EA, 2007, PARASITOLOGY, V134, P1903, DOI 10.1017/S0031182007000194; Kano R, 2007, J VET MED SCI, V69, P1095, DOI 10.1292/jvms.69.1095; Klevar S, 2007, INT J PARASITOL, V37, P329, DOI 10.1016/j.ijpara.2006.11.002; Liddell S, 1999, J PARASITOL, V85, P1072, DOI 10.2307/3285670; Marugan-Hernandez V, 2011, VACCINE, V29, P7867, DOI 10.1016/j.vaccine.2011.07.091; Monney T, 2014, EXP PARASITOL, V140, P52, DOI 10.1016/j.exppara.2014.02.015; Nishikawa Y, 2001, CLIN DIAGN LAB IMMUN, V8, P811, DOI 10.1128/CDLI.8.4.811-817.2001; Nishikawa Y, 2003, VET PARASITOL, V116, P175, DOI 10.1016/j.vetpar.2003.07.001; Nishikawa Y, 2002, J VET MED SCI, V64, P1, DOI 10.1292/jvms.64.1; Nishikawa Y, 2001, VACCINE, V19, P1710, DOI 10.1016/S0264-410X(00)00407-2; Nishikawa Y, 2018, APPL ENVIRON MICROB, V84, DOI [10.1128/AEM.01350-18, 10.1128/aem.01350-18]; Nishikawa Y, 2017, J VET MED SCI, V79, P1374, DOI 10.1292/jvms.17-0285; Nishikawa Y, 2009, CLIN VACCINE IMMUNOL, V16, P792, DOI 10.1128/CVI.00032-09; Nishimura M, 2013, VACCINE, V31, P3528, DOI 10.1016/j.vaccine.2013.05.083; Pastor-Fernandez I, 2015, VET PARASITOL, V207, P203, DOI 10.1016/j.vetpar.2014.12.009; Ramamoorthy S, 2007, INT J PARASITOL, V37, P1531, DOI 10.1016/j.ijpara.2007.04.021; Ramamoorthy S, 2007, INT J PARASITOL, V37, P1521, DOI 10.1016/j.ijpara.2007.04.020; Reichel MP, 2006, VET PARASITOL, V142, P23, DOI 10.1016/j.vetpar.2006.06.027; Reichel MP, 2013, INT J PARASITOL, V43, P133, DOI 10.1016/j.ijpara.2012.10.022; Rojo-Montejo S, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-62; Thurmond MC, 1997, AM J VET RES, V58, P1381; Williams DJL, 2000, PARASITOLOGY, V121, P347, DOI 10.1017/S0031182099006587; Zhang HS, 2010, EXP PARASITOL, V125, P130, DOI 10.1016/j.exppara.2010.01.008	34	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							155	10.3390/vaccines9020155			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6YJ	33671937	Green Published, gold			2022-04-29	WOS:000623287000001
J	Gawrys, A; Golebiowski, T; Zielinska, D; Augustyniak-Bartosik, H; Kuriata-Kordek, M; Szenborn, L; Krajewska, M				Gawrys, Ada; Golebiowski, Tomasz; Zielinska, Dorota; Augustyniak-Bartosik, Hanna; Kuriata-Kordek, Magdalena; Szenborn, Leszek; Krajewska, Magdalena			Knowledge, Attitudes and Practices of Flu Vaccination in Hemodialysis Patients	VACCINES			English	Article						hemodialysis; vaccinations; infections	SEASONAL INFLUENZA VACCINATION; DISEASE PATIENTS; RISK; STAGE; MORTALITY; IMMUNIZATION; INFECTIONS; DIABETICS; ADULTS	Background: Hemodialysis (HD) patients have an increased risk of morbidity and mortality due to infections. Despite the positive effect of vaccinations, the implementation of this method of prophylaxis is low. Objectives: This study aimed to explore the knowledge, attitudes and practices of flu vaccination among HD patients of two different dialysis centers. Methods: A total of 193 patients (mean age 63.6 years), who voluntarily agreed to participate in an anonymous survey related to influenza vaccination, were enrolled in this cross-sectional study. Results: A total of 45% of patients declared that they took regular, annual flu vaccination. In this group, 87.4% believed that vaccinations were effective. This opinion strongly correlated with the frequency of regular vaccinations (r = 0.56, p < 0.01). Multivariate logistic regression revealed that this opinion is an independent predictor of regular vaccinations with adjusted OR 9.86 (95% CI 4.36, 22.33). Groups of patients who had been irregularly or never vaccinated reject vaccinations for the following reasons: fear of adverse events-29.2%, conviction that vaccination was ineffective-26.4%, and lack of information about vaccination-22.6%. Conclusion: Knowledge among HD patients about the benefits of vaccinations is poor. Therefore, educational activities are required. Active vaccination promotion and education of patients rejecting this method of prevention play a key role in improving standards of care for HD patients.	[Gawrys, Ada; Golebiowski, Tomasz; Zielinska, Dorota; Augustyniak-Bartosik, Hanna; Kuriata-Kordek, Magdalena; Krajewska, Magdalena] Wroclaw Med Univ, Dept Nephrol & Transplantat Med, PL-50556 Wroclaw, Poland; [Szenborn, Leszek] Wroclaw Med Univ, Dept Pediat Infect Dis, PL-50368 Wroclaw, Poland		Golebiowski, T (通讯作者)，Wroclaw Med Univ, Dept Nephrol & Transplantat Med, PL-50556 Wroclaw, Poland.	adagawrys@gmail.com; tomasz.golebiowski@umed.wroc.pl; melirus@wp.pl; hanna.augustyniak-bartosik@umed.wroc.pl; magdalena.kuriata-kordek@umed.wroc.pl; leszek.szenborn@umed.wroc.pl; magdalena.krajewska@umed.wroc.pl	Gołębiowski, Tomasz/ADD-5771-2022	Szenborn, Leszek/0000-0001-6574-8229; Augustyniak-Bartosik, Hanna/0000-0003-3969-396X; Krajewska, Magdalena/0000-0002-2632-2409	 [SUB.C160.19.055]	The study is supported by theWroclaw Medical University statutory funds (SUB.C160.19.055). It was an investigator-initiated research. The funding body had no role in the study design, data collection, analyses, and interpretation, or in writing the manuscript.	[Anonymous], 1997, MMWR Recomm Rep, V46, P1; Bertoldo G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215978; Bodeker B, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1970-4; Bohlke K, 2003, PEDIATRICS, V112, P815, DOI 10.1542/peds.112.4.815; Bond TC, 2012, AM J KIDNEY DIS, V60, P959, DOI 10.1053/j.ajkd.2012.04.018; Casalino E, 2018, PLOS ONE, V13, DOI [10.1371/journal.pone.0193029, 10.1371/journa.pone.0193029]; Dalrymple LS, 2008, CLIN J AM SOC NEPHRO, V3, P1487, DOI 10.2215/CJN.01290308; DaRoza G, 2003, AM J KIDNEY DIS, V42, P1184, DOI 10.1053/j.ajkd.2003.08.019; Dowera J, 2011, VACCINE, V29, P3031, DOI 10.1016/j.vaccine.2011.01.116; Durlik M., 2007, NEFROLOGIA DIALIZOTE, V11, P141; Fiore Anthony E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Garthwaite E, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1529-1; Giese C, 2016, VACCINE, V34, P3657, DOI 10.1016/j.vaccine.2016.05.028; Gilbertson DT, 2003, KIDNEY INT, V63, P738, DOI 10.1046/j.1523-1755.2003.00787.x; Grau AJ, 2005, STROKE, V36, P1501, DOI 10.1161/01.STR.0000170674.45136.80; Grzegorzewska AE, 2015, HUM VACC IMMUNOTHER, V11, P2599, DOI 10.1080/21645515.2015.1034915; Grzegorzewska AE, 2014, EXPERT REV VACCINES, V13, P1317, DOI 10.1586/14760584.2014.944508; Grzegorzewska AE, 2012, HEPAT MON, V12, DOI 10.5812/hepatmon.7359; Hui-Chen L., 2014, INT J ENV RES PUB HE, V11, P3639; Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Kli A., 2019, NEPHROL FORUM, V12, P133; Lee KR, 2017, NEUROEPIDEMIOLOGY, V48, P103, DOI 10.1159/000478017; Levin A, 2013, KIDNEY INT, V83, P1001, DOI 10.1038/ki.2013.91; Lindsberg PJ, 2003, STROKE, V34, P2518, DOI 10.1161/01.STR.0000089015.51603.CC; Luz PM, 2017, VACCINE, V35, P5890, DOI 10.1016/j.vaccine.2017.08.078; Malhi G, 2015, J CROHNS COLITIS, V9, P439, DOI 10.1093/ecco-jcc/jjv064; Mathew R, 2014, EXPERT REV VACCINES, V13, P285, DOI 10.1586/14760584.2014.874950; Naqvi SB, 2006, ADV CHRONIC KIDNEY D, V13, P199, DOI 10.1053/j.ackd.2006.04.004; Neovius M, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004251; Nitsch-Osuch A., 2017, ADV EXP MED BIOL, V10, P968; Olatunbosun OD, 2017, VACCINE, V35, P6375, DOI 10.1016/j.vaccine.2017.10.006; Ortiz A, 2014, LANCET, V383, P1831, DOI 10.1016/S0140-6736(14)60384-6; Pesanti EL, 2001, INFECT DIS CLIN N AM, V15, P813, DOI 10.1016/S0891-5520(05)70174-4; Sarnak MJ, 2001, CHEST, V120, P1883, DOI 10.1378/chest.120.6.1883; Sarnak MJ, 2000, KIDNEY INT, V58, P1758, DOI 10.1046/j.1523-1755.2000.00337.x; Siriwardena AN, 2010, CAN MED ASSOC J, V182, P1617, DOI 10.1503/cmaj.091891; Tan EK, 2010, SINGAP MED J, V51, P623; Wang IK, 2013, VACCINE, V31, P718, DOI 10.1016/j.vaccine.2012.11.017	39	0	0	2	3	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							77	10.3390/vaccines9020077			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7LJ	33498996	Green Published, gold			2022-04-29	WOS:000623321300001
J	Sawada, A; Ito, T; Yamaji, Y; Nakayama, T				Sawada, Akihito; Ito, Takashi; Yamaji, Yoshiaki; Nakayama, Tetsuo			Chimeric Measles Virus (MV/RSV), Having Ectodomains of Respiratory Syncytial Virus (RSV) F and G Proteins Instead of Measles Envelope Proteins, Induced Protective Antibodies against RSV	VACCINES			English	Article						measles AIK-C; respiratory syncytial virus (RSV); ectodomain; recombinant chimeric virus	AIK-C; VACCINE; RESPONSES; INFANTS; DISEASE; IMMUNOGENICITY; REPLICATION; STABILITY; INFECTION; RISK	In our previous study, fusion (F) or glyco (G) protein coding sequence of respiratory syncytial virus (RSV) was inserted at the P/M junction of the measles AIK-C vector (MVAIK), and the recombinant measles virus induced protective immune responses. In the present study, the ectodomains of measles fusion (F) and hemagglutinin (HA) proteins were replaced with those of RSV F and G proteins, and a chimeric MV/RSV vaccine was developed. It expressed F and G proteins of RSV and induced cytopathic effect (CPE) in epithelial cell lines (Vero, A549, and HEp-2 cells), but not in lymphoid cell lines (B95a, Jurkat, and U937 cells). A chimeric MV/RSV grew similarly to AIK-C with no virus growth at 39 degrees C. It induced NT antibodies against RSV in cotton rats three weeks after immunization through intramuscular route and enhanced response was observed after the second dose at eight weeks. After the RSV challenge with 10(6) PFU, significantly lower virus (10(1.4 +/- 0.1) PFU of RSV) was recovered from lung tissue in the chimeric MV/RSV vaccine group than in the MVAIK control group with 10(4.6 +/- 0.2) PFU (p < 0.001) and no obvious inflammatory pathological finding was noted. The strategy of ectodomain replacement in the measles virus vector is expected to lead to the development of safe and effective vaccines for other enveloped viruses.	[Sawada, Akihito; Ito, Takashi; Yamaji, Yoshiaki; Nakayama, Tetsuo] Kitasato Univ, Omura Satoshi Mem Inst, Lab Viral Infect 1, Tokyo 1088641, Japan		Nakayama, T (通讯作者)，Kitasato Univ, Omura Satoshi Mem Inst, Lab Viral Infect 1, Tokyo 1088641, Japan.	akihito@lisci.kitasato-u.ac.jp; itot@lisci.kitasato-u.ac.jp; di12004@st.kitasato-u.ac.jp; tetsuo-n@lisci.kitasato-u.ac.jp			 [16K21354]	The study was supported by Grants-in-Aid for scientific research for Young Scientists (16K21354).	Anderson LJ, 2013, VACCINE, V31, pB209, DOI 10.1016/j.vaccine.2012.11.106; BOLOTOVSKI VM, 1994, INT J EPIDEMIOL, V23, P1069, DOI 10.1093/ije/23.5.1069; Brady MT, 2014, PEDIATRICS, V134, pE620, DOI [10.1542/peds.2014-1665, 10.1542/peds.2014-1666]; Christiaansen AF, 2014, IMMUNOL RES, V59, P109, DOI 10.1007/s12026-014-8540-1; De Baets S, 2013, J VIROL, V87, P3314, DOI 10.1128/JVI.03019-12; Hong DT, 2019, VACCINE, V37, P4576, DOI 10.1016/j.vaccine.2019.04.025; Figueras-Aloy J, 2016, INFECT DIS THER, V5, P417, DOI 10.1007/s40121-016-0130-1; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; Haga T, 2009, COMP IMMUNOL MICROB, V32, P395, DOI 10.1016/j.cimid.2007.11.011; Higuchi A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150213; Ito T, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020149; Kim E, 2014, J VIROL, V88, P5100, DOI 10.1128/JVI.03194-13; Komase K, 2006, VACCINE, V24, P826, DOI 10.1016/j.vaccine.2005.06.036; Liang B, 2014, J VIROL, V88, P4237, DOI 10.1128/JVI.03481-13; Luongo C, 2012, J VIROL, V86, P10792, DOI 10.1128/JVI.01227-12; Manzoni P, 2017, INFECT DIS THER, V6, P383, DOI 10.1007/s40121-017-0160-3; Modjarrad K, 2016, VACCINE, V34, P190, DOI 10.1016/j.vaccine.2015.05.093; MURPHY BR, 1986, J CLIN MICROBIOL, V24, P197, DOI 10.1128/JCM.24.2.197-202.1986; Nakayama T, 2016, VACCINE, V34, P292, DOI 10.1016/j.vaccine.2015.10.127; NICHOLAS JA, 1990, J VIROL, V64, P4232, DOI 10.1128/JVI.64.9.4232-4241.1990; Nkrumah FK, 1998, B WORLD HEALTH ORGAN, V76, P353; Olszewska W, 2004, VACCINE, V23, P215, DOI 10.1016/j.vaccine.2004.05.015; Oshansky CM, 2009, FUTURE MICROBIOL, V4, P279, DOI [10.2217/fmb.09.1, 10.2217/FMB.09.1]; Reisinger EC, 2018, LANCET, V392, P2718, DOI 10.1016/S0140-6736(18)32488-7; Sato TA, 1997, ARCH VIROL, V142, P1971, DOI 10.1007/s007050050215; Sawada A, 2016, MICROBIOL IMMUNOL, V60, P234, DOI 10.1111/1348-0421.12365; Sawada A, 2011, VACCINE, V29, P1481, DOI 10.1016/j.vaccine.2010.12.028; Shaw CA, 2013, CURR OPIN VIROL, V3, P332, DOI 10.1016/j.coviro.2013.05.003; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/S0140-6736(17)30938-8, 10.1016/s0140-6736(17)30938-8]; Spielhofer P, 1998, J VIROL, V72, P2150, DOI 10.1128/JVI.72.3.2150-2159.1998; Swett-Tapia C, 2016, J GEN VIROL, V97, P2117, DOI 10.1099/jgv.0.000523; Tahara M, 2007, J VIROL, V81, P6827, DOI 10.1128/JVI.00248-07; TIDJANI O, 1989, LANCET, V2, P1357; Yamaji Y, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010027; Yamaji Y, 2014, VACCINE, V32, P4529, DOI 10.1016/j.vaccine.2014.06.024; Yang CF, 2013, VACCINE, V31, P2822, DOI 10.1016/j.vaccine.2013.04.006; Zhan XY, 2015, INT IMMUNOL, V27, P229, DOI 10.1093/intimm/dxu107	37	1	1	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							156	10.3390/vaccines9020156			13	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO7CL	33669275	Green Published, gold			2022-04-29	WOS:000623297800001
J	Todryk, SM; Bassendine, MF; Bridge, SH				Todryk, Stephen M.; Bassendine, Margaret F.; Bridge, Simon H.			Revisiting the Elusive Hepatitis C Vaccine	VACCINES			English	Editorial Material									[Todryk, Stephen M.; Bridge, Simon H.] Northumbria Univ, Fac Hlth & Life Sci, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England; [Todryk, Stephen M.; Bassendine, Margaret F.; Bridge, Simon H.] Newcastle Univ, Sch Med, Translat & Clin Res Inst, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England		Todryk, SM; Bridge, SH (通讯作者)，Northumbria Univ, Fac Hlth & Life Sci, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England.; Todryk, SM; Bassendine, MF; Bridge, SH (通讯作者)，Newcastle Univ, Sch Med, Translat & Clin Res Inst, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	stephen.todryk@northumbria.ac.uk; margaret.bassendine@newcastle.ac.uk; simon.bridge@northumbria.ac.uk		Bridge, Simon/0000-0002-6212-3255			Akache B, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040204; Baumert TF, 2020, J HEPATOL, V73, P1303, DOI 10.1016/j.jhep.2020.10.017; Budkowska A, 2017, GUT, V66, P1351, DOI 10.1136/gutjnl-2016-313184; Cox AL PK., 2019, OPEN FORUM INFECT DI, V6, pS997, DOI [DOI 10.1093/OFID/OFZ415.2493, 10.1093/ofid/ofz415.2493]; Czarnota A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020294; Folgori A, 2006, NAT MED, V12, P190, DOI 10.1038/nm1353; Frey SE, 2010, VACCINE, V28, P6367, DOI 10.1016/j.vaccine.2010.06.084; Mekonnen ZA, 2019, J VIROL, V93, DOI 10.1128/JVI.00202-19; Shrestha AC, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020038; Swadling L, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009185; Urbanelli L, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030102	11	2	2	1	1	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							114	10.3390/vaccines9020114			6	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6SF	33540927	Green Published, Green Accepted			2022-04-29	WOS:000623270700001
J	Trovato, CM; Montuori, M; Sansone, A; Morelli, A; Russo, G; Pietropaoli, N; Oliva, S				Trovato, Chiara Maria; Montuori, Monica; Sansone, Andrea; Morelli, Annalisa; Russo, Giusy; Pietropaoli, Nicoletta; Oliva, Salvatore			Association between Elevated TGA-IgA Titers and Older Age at Diagnosis with Absence of HBV Seroconversion in Celiac Children	VACCINES			English	Article						celiac disease; HBV seroconversion; children; anti-transglutaminase titers		Patients with celiac disease can have a low rate of protective hepatitis B (HBV) antibody titers after vaccination. We aimed to evaluate the HBV seroconversion in celiac disease (CD) children at the time of diagnosis as well as to identify the presence of possible predictive factors. Celiac disease children were prospectively enrolled and tested for antibodies against the S protein of HBV (HBsAg) at time of diagnosis between January 2009 and February 2020. Based on the serologic response to the vaccine, "responders" and "non-responders" were identified. Statistical analysis has been performed through R statistical software (3.5.1 version, R core Team) Of 96 CD children evaluated, 41.7% (n = 40) showed non-protective or absent antibody titers against HBV. Elevated IgA-antibodies against transglutaminase 2 (TGA-IgA) values and older age at diagnosis were associated with an absent seroconversion to HBV vaccine, while presenting symptoms were not significant. An elevated prevalence of absent seroconversion to HBV vaccine exists in this cohort of CD patients at the time of disease diagnosis. Elevated TGA-IgA titers and older age at diagnosis seem to negatively predict seroconversion. Further studies are needed to identify the real profile of "non-responders", aiming to organize surveillance and eventual revaccination strategy.	[Trovato, Chiara Maria; Montuori, Monica; Morelli, Annalisa; Russo, Giusy; Pietropaoli, Nicoletta; Oliva, Salvatore] Sapienza Univ Rome, Maternal & Child Hlth Dept, Pediat Gastroenterol & Liver Unit, I-00161 Rome, Italy; [Sansone, Andrea] Univ Roma Tor Vergata, Dept Syst Med, Chair Endocrinol & Med Sexol ENDOSEX, I-00161 Rome, Italy		Oliva, S (通讯作者)，Sapienza Univ Rome, Maternal & Child Hlth Dept, Pediat Gastroenterol & Liver Unit, I-00161 Rome, Italy.	chiaramaria.trovato@uniroma1.it; m.montuori@policlinicoumberto1.it; andrea.sansone@uniroma2.it; morelli.1578837@studenti.uniroma1.it; giusy.russo@uniroma1.it; nicoletta.pietropaoli@uniroma1.it; salvatore.oliva@uniroma1.it	Trovato, Chiara Maria/AAR-9938-2021; Oliva, Salvatore/K-1567-2016; Sansone, Andrea/H-6451-2016	Oliva, Salvatore/0000-0003-2348-2308; Sansone, Andrea/0000-0002-1210-2843; Morelli, Annalisa/0000-0002-9052-0266; Trovato, Chiara Maria/0000-0003-3869-1815; Pietropaoli, Nicoletta/0000-0002-6307-9989			Anania C, 2017, WORLD J GASTROENTERO, V23, P3205, DOI 10.3748/wjg.v23.i18.3205; Ertekin V, 2011, HEPAT MON, V11, P634, DOI 10.5812/kowsar.1735143X.715; Filippelli M, 2016, WORLD J HEPATOL, V8, P1105, DOI 10.4254/wjh.v8.i26.1105; Filippelli M, 2014, IMMUNOTHERAPY-UK, V6, P945, DOI [10.2217/IMT.14.64, 10.2217/imt.14.64]; Filippelli M, 2014, WORLD J GASTROENTERO, V20, P10383, DOI 10.3748/wjg.v20.i30.10383; Godkin A, 2005, HEPATOLOGY, V41, P1383, DOI 10.1002/hep.20716; Green PHR, 2008, GASTROINTEST ENDOSC, V67, P1088, DOI 10.1016/j.gie.2007.12.035; Green PHR, 2015, DIGEST DIS, V33, P137, DOI 10.1159/000370204; Heshin-Bekenstein M, 2015, J PEDIATR GASTR NUTR, V61, P400, DOI 10.1097/MPG.0000000000000856; Husby S, 2012, J PEDIATR GASTR NUTR, V54, P136, DOI 10.1097/MPG.0b013e31821a23d0; Husby S, 2020, J PEDIATR GASTR NUTR, V70, P141, DOI 10.1097/MPG.0000000000002497; Inoue T, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030456; Jabri B, 2009, NAT REV IMMUNOL, V9, P858, DOI 10.1038/nri2670; Leonardi S, 2009, VACCINE, V27, P6030, DOI 10.1016/j.vaccine.2009.07.099; Li ZK, 2013, VACCINE, V31, P4355, DOI 10.1016/j.vaccine.2013.06.108; Lionetti E, 2018, J PEDIATR-US, V194, P116, DOI 10.1016/j.jpeds.2017.10.062; Ludvigsson JF, 2013, GUT, V62, P43, DOI 10.1136/gutjnl-2011-301346; Lundin KEA, 2015, NAT REV GASTRO HEPAT, V12, P507, DOI 10.1038/nrgastro.2015.136; Martinetti M, 2000, CLIN IMMUNOL, V97, P234, DOI 10.1006/clim.2000.4933; Mormile MDR, 2017, MED HYPOTHESES, V104, P45, DOI 10.1016/j.mehy.2017.05.020; Nemes E, 2008, PEDIATRICS, V121, pE1570, DOI 10.1542/peds.2007-2446; Oberhuber G, 1999, EUR J GASTROEN HEPAT, V11, P1185, DOI 10.1097/00042737-199910000-00019; Opri R, 2015, HUM VACC IMMUNOTHER, V11, P2800, DOI 10.1080/21645515.2015.1069448; Papadopoli R, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020227; Passanisi S, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020278; Popp A, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00357; Rousseff T, 2019, ACTA GASTRO-ENT BELG, V82, P27; Saco TV, 2018, ANN ALLERG ASTHMA IM, V121, P320, DOI 10.1016/j.anai.2018.03.017; Silvestri Francesca, 2019, Minerva Pediatr, DOI 10.23736/S0026-4946.19.05678-0; Thio CL, 2003, J VIROL, V77, P12083, DOI 10.1128/JVI.77.22.12083-12087.2003; Tiberti C, 2020, PEDIATR DIABETES, V21, P774, DOI 10.1111/pedi.13054; Tiberti C, 2017, DIABETES CARE, V40, pE10, DOI 10.2337/dc16-2095; Trovato CM, 2014, J PEDIATR GASTR NUTR, V59, P799, DOI 10.1097/MPG.0000000000000541; Trovato CM, 2020, DIGEST LIVER DIS, V52, P464, DOI 10.1016/j.dld.2020.02.004; Trovato CM, 2019, EPILEPSY BEHAV, V99, DOI 10.1016/j.yebeh.2019.06.036; Valitutti F, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040396; Valitutti F, 2017, ADV NUTR, V8, P356, DOI 10.3945/an.116.013292; Vitaliti G, 2013, WORLD J GASTROENTERO, V19, P838, DOI 10.3748/wjg.v19.i6.838; Wainwright RB, 1997, J INFECT DIS, V175, P674, DOI 10.1093/infdis/175.3.674; Wang CB, 2004, HEPATOLOGY, V39, P978, DOI 10.1002/hep.20142; Watts A, 2017, J PEDIATR GASTR NUTR, V65, P551, DOI 10.1097/MPG.0000000000001580; Zanoni G, 2015, HUM VACC IMMUNOTHER, V11, P58, DOI 10.4161/hv.34309; Zifman E, 2020, PEDIATR GASTROENTERO, V23, P132, DOI 10.5223/pghn.2020.23.2.132; Zingone F, 2013, CLIN VACCINE IMMUNOL, V20, P660, DOI 10.1128/CVI.00729-12; Zingone F, 2011, VACCINE, V29, P1005, DOI 10.1016/j.vaccine.2010.11.060	45	0	0	0	0	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	FEB	2021	9	2							101	10.3390/vaccines9020101			9	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	QO6TH	33525661	Green Published, gold			2022-04-29	WOS:000623273500001
J	Contreras, M; Rubio, CP; de la Fuente, J; Villar, M; Merino, O; Mosqueda, J; Ceron, JJ				Contreras, Marinela; Peres Rubio, Camila; de la Fuente, Jose; Villar, Margarita; Merino, Octavio; Mosqueda, Juan; Ceron, Jose Joaquin			Changes in Serum Biomarkers of Oxidative Stress in Cattle Vaccinated with Tick Recombinant Antigens: A Pilot Study	VACCINES			English	Article						cattle; tick; vaccine; antioxidant; biomarker; oxidant; antibody		Tick vaccination is an environmentally friendly alternative for tick control, pathogen infection, and transmission. Tick vaccine protection is sometimes incomplete, which may be due to problems in the stability, conformation, and activity of antibodies. This might be related to oxidative stress, but more studies are needed about the possible relationships between oxidative stress and immune function. The objective of this study was to evaluate and compare various serum biomarkers of antioxidant response and oxidative damage in cattle vaccinated with two recombinant antigens, the chimera of Subolesin- BM95 (homologue antigen of BM86)-MSP1a and BM86, and a control consisting in the adjuvant of the vaccines. Cupric reducing antioxidant capacity (CUPRAC), ferric reducing ability of the plasma (FRAP), trolox equivalent antioxidant capacity (TEAC), total thiol concentrations, and uric acid were evaluated in serum to determine the antioxidant response. To evaluate oxidative status, ferrous oxidation-xylenol orange (FOX), total oxidant status (TOS), advanced oxidation protein products (AOPP) and hydrogen peroxide (H2O2) concentrations in serum were determined. In addition, correlations between biomarkers of oxidative stress and antibody titers were evaluated. A significant decrease in all antioxidant biomarkers, with exception of thiol, and also a decrease in the oxidant markers TOS, AOPP and H2O2 was observed in cattle vaccinated with BM86, that also showed the highest antibody titers response whereas no significant differences in any of the biomarkers were detected in the Subolesin-Bm95-MSP1a and control groups. In addition, the dynamics of Cuprac and H2O2 with time showed significant differences between the groups. Although this is a pilot study and the results should be interpreted with caution and corroborated by studies involving a large number of animals, our results indicate that, in our experimental conditions, those vaccines able to induce a lower oxidative stress produce a higher concentration of antigen-specific antibodies. Overall, the results of the study provided information on the behavior of different biomarkers related to antioxidant defense, and the oxidative damage in cattle in response to vaccination.	[Contreras, Marinela; Peres Rubio, Camila; Ceron, Jose Joaquin] Univ Murcia, Interdisciplinary Lab Clin Anal Interlab UMU, Campus Int Excellence Mare Nostrum, E-30100 Murcia, Spain; [de la Fuente, Jose; Villar, Margarita] IREC CSIC UCLM JCCM, Inst Invest Recursos Cineget, SaBio, Ronda Toledo 12, Ciudad Real 13071, Spain; [de la Fuente, Jose] Oklahoma State Univ, Dept Vet Pathobiol, Ctr Vet Hlth Sci, Stillwater, OK 74078 USA; [Villar, Margarita] Univ Castilla La Mancha, Fac Sci & Chem Technol, Biochem Sect, Ciudad Real 13071, Spain; [Villar, Margarita] Univ Castilla La Mancha, Reg Ctr Biomed Res CRIB, Ciudad Real 13071, Spain; [Merino, Octavio] Univ Tamaulipas, Fac Vet Med, Ciudad Victoria 87000, Tamaulipas, Mexico; [Mosqueda, Juan] Autonomus Univ Queretaro, Fac Vet Med, Santiago De Queretaro 76010, Mexico		Contreras, M (通讯作者)，Univ Murcia, Interdisciplinary Lab Clin Anal Interlab UMU, Campus Int Excellence Mare Nostrum, E-30100 Murcia, Spain.	marinela.contreras@um.es; camila.peres@um.es; jose_delafuente@yahoo.com; margaritam.villar@uclm.es; mero840125@hotmail.com; joel.mosqueda@uaq.mx; jjceron@um.es	Villar-Rayo, Marga M/J-4155-2012; Peres Rubio, Camila/B-7551-2019; Ceron, Jose/H-9043-2015	Villar-Rayo, Marga M/0000-0003-4172-9079; Mosqueda, Juan/0000-0001-8892-6390; Peres Rubio, Camila/0000-0002-9293-4147; Ceron, Jose/0000-0002-8654-1793; de la Fuente, Jose/0000-0001-7383-9649	Seneca Foundation-Regional Agency for Science and Technology of the Government of Murcia, Spain [19894/GERM/15]; Ministerio de Ciencia, Innovacion y Universidades, Spain [FJC-2018-038277-I]	This research was funded by Seneca Foundation-Regional Agency for Science and Technology of the Government of Murcia, Spain, grant number 19894/GERM/15 and Marinela Contreras is funded by the Ministerio de Ciencia, Innovacion y Universidades, Spain, grant FJC-2018-038277-I.	Achkar JM, 2018, CURR OPIN IMMUNOL, V53, P30, DOI 10.1016/j.coi.2018.04.004; Almazan C, 2012, VACCINE, V30, P265, DOI 10.1016/j.vaccine.2011.10.102; Apak R, 2005, FREE RADICAL RES, V39, P949, DOI 10.1080/10715760500210145; Arab K, 2004, ANAL BIOCHEM, V325, P158, DOI 10.1016/j.ab.2003.10.022; Artigas-Jeronimo S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01612; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Bigagli E, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5953685; Bottari NB, 2016, MICROB PATHOGENESIS, V92, P26, DOI 10.1016/j.micpath.2015.11.030; Boulanger N, 2019, MED MALADIES INFECT, V49, P87, DOI 10.1016/j.medmal.2019.01.007; Brader ML, 2015, MOL PHARMACEUT, V12, P1005, DOI 10.1021/mp400666b; CAMICAS J.L., 1998, TICKS WORLD ACARIDA; Campos C, 2009, ANAL BIOCHEM, V392, P37, DOI 10.1016/j.ab.2009.05.024; Canales M, 2008, J BIOTECHNOL, V135, P326, DOI 10.1016/j.jbiotec.2008.05.006; Canales M, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-29; Costa Carolina M. da, 2006, J. Bras. Patol. Med. Lab., V42, P345, DOI 10.1590/S1676-24442006000500006; de la Fuente J, 1999, GENET ANAL-BIOMOL E, V15, P143, DOI 10.1016/S1050-3862(99)00018-2; de la Fuente J., 2013, BIOL TICKS, V2nd, P333; de la Fuente J, 2018, TICKS TICK-BORNE DIS, V9, P1354, DOI 10.1016/j.ttbdis.2018.04.001; Dickinson DA, 2002, BIOCHEM PHARMACOL, V64, P1019, DOI 10.1016/S0006-2952(02)01172-3; Elias SC, 2013, J IMMUNOL, V190, P1135, DOI 10.4049/jimmunol.1201455; Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008; FOSSATI P, 1980, CLIN CHEM, V26, P227; Gao ML, 2014, SCI WORLD J, DOI 10.1155/2014/801346; Gazzinelli-Guimaraes AC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02535; Han S, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1480463; Hanssen SA, 2013, ECOL EVOL, V3, P5157, DOI 10.1002/ece3.891; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; Karasuyama H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.601504; Kasaija PD, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020319; Kiss T, 2012, VET PARASITOL, V187, P357, DOI 10.1016/j.vetpar.2012.02.010; Kumar R, 2019, EXP APPL ACAROL, V78, P149, DOI 10.1007/s10493-019-00394-0; Lew-Tabor AE, 2016, TICKS TICK-BORNE DIS, V7, P573, DOI 10.1016/j.ttbdis.2015.12.012; Liljeroos L, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/156241; Margiloff L, 1998, FREE RADICAL BIO MED, V25, P780, DOI 10.1016/S0891-5849(98)00130-0; Moreno-Cid JA, 2010, VACCINE, V29, P77, DOI 10.1016/j.vaccine.2010.10.011; Ndawula C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030457; Nuttall PA, 2006, PARASITE IMMUNOL, V28, P155, DOI 10.1111/j.1365-3024.2006.00806.x; Rubio CP, 2018, RES VET SCI, V121, P85, DOI 10.1016/j.rvsc.2018.09.007; Rubio CP, 2016, COMP IMMUNOL MICROB, V49, P51, DOI 10.1016/j.cimid.2016.09.003; Peter RJ, 2005, VET PARASITOL, V132, P205, DOI 10.1016/j.vetpar.2005.07.004; Rezaie A, 2007, DIGEST DIS SCI, V52, P2015, DOI 10.1007/s10620-006-9622-2; Rhee SG, 2010, MOL CELLS, V29, P539, DOI 10.1007/s10059-010-0082-3; Rodriguez Valle M, 2001, BMC Biotechnol, V1, P2; Schaefer JV, 2018, MABS-AUSTIN, V10, P607, DOI 10.1080/19420862.2018.1450126; Shokri M, 2016, MOL IMMUNOL, V76, P108, DOI 10.1016/j.molimm.2016.06.010; Tatzber F, 2003, ANAL BIOCHEM, V316, P147, DOI 10.1016/S0003-2697(02)00652-8; Valle Manuel Rodriguez, 2018, Front Biosci (Elite Ed), V10, P122; Willadsen P, 1996, PARASITE IMMUNOL, V18, P241, DOI 10.1046/j.1365-3024.1996.d01-90.x; WitkoSarsat V, 1996, KIDNEY INT, V49, P1304, DOI 10.1038/ki.1996.186; Yardim-Akaydin S, 2003, CLIN CHIM ACTA, V338, P99, DOI 10.1016/j.cccn.2003.07.021	50	1	1	2	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							5	10.3390/vaccines9010005			10	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW7AD	33374141	Green Published, gold			2022-04-29	WOS:000610822100001
J	Lazarte, JMS; Kim, YR; Lee, JS; Chun, JH; Kim, SW; Jung, JW; Kim, J; Kayansamruaj, P; Thompson, KD; Kim, H; Jung, TS				Lazarte, Jassy Mary S.; Kim, Young Rim; Lee, Jung Seok; Chun, Jin Hong; Kim, Si Won; Jung, Jae Wook; Kim, Jaesung; Kayansamruaj, Pattanapon; Thompson, Kim D.; Kim, Hyeongsu; Jung, Tae Sung			Passive Immunization with Recombinant Antibody VLRB-PirA(vp)/PirB(vp)-Enriched Feeds against Vibrio parahaemolyticus Infection in Litopenaeus vannamei Shrimp	VACCINES			English	Article						AHPND; variable lymphocyte receptor (VLR); VLRB antibody; passive vaccine; Vibrio parahaemolyticus; Photorhabdus insect-related PirAB(vp)		The causative agent of acute hepatopancreatic necrosis disease (AHPND) is the bacterium, Vibrio parahaemolyticus, which secretes toxins into the gastrointestinal tract of its host. Vibrio parahaemolyticus toxins A and B (PirA(vp)/PirB(vp)) have been implicated in the pathogenesis of this disease, and are, therefore, the focus of studies developing treatments for AHPND. We previously produced recombinant antibodies based on the hagfish variable lymphocyte receptor B (VLRB) capable of neutralizing some viruses, suggesting that this type of antibody may have a potential application for treatment of AHPND. Here, recombinant PirA(vp)/PirB(vp), produced using a bacterial expression system, were used as antigens to screen a hagfish VLRB cDNA library to obtain PirA(vp)/PirB(vp)-specific antibodies. A cell line secreting these antibodies was established by screening and cloning the DNA extracted from hagfish B cells. Supernatants collected from cells secreting the PirA(vp)/PirB(vp) antibodies were collected and concentrated, and used to passively immunize shrimp to neutralize the toxins PirA(vp) or PirB(vp) associated with AHPND. Briefly, 10 mu g of PirA(vp) and PirB(vp) antibodies, 7C12 and 9G10, respectively, were mixed with the shrimp feed, and fed to shrimp for three days consecutive days prior to experimentally infecting the shrimp with V. parahaemolyticus (containing toxins A and B), and resulting mortalities recorded for six days. Results showed significantly higher level of survival in shrimp fed with the PirB(vp)-9G10 antibody (60%) compared to the group fed the PirA(vp)-7C12 antibody (3%) and the control group (0%). This suggests that VLRB antibodies may be a suitable alternative to immunoglobulin-based antibodies, as passive immunization treatments for effective management of AHPND outbreaks within shrimp farms.	[Lazarte, Jassy Mary S.; Kim, Young Rim; Lee, Jung Seok; Chun, Jin Hong; Kim, Si Won; Jung, Jae Wook; Kim, Jaesung; Jung, Tae Sung] Gyeongsang Natl Univ, Res Inst Nat Sci, Coll Vet Med, Lab Aquat Anim Dis, Jinju Si 52828, Gyeongsangnam D, South Korea; [Kayansamruaj, Pattanapon] Kasetsart Univ, Ctr Excellence Aquat Anim Hlth Management, Fac Fisheries, 50 Ngamwongwan Rd, Bangkok 10900, Thailand; [Thompson, Kim D.] Moredun Res Inst, Pentlands Sci Pk, Penicuik EH26 0PZ, Midlothian, Scotland; [Kim, Hyeongsu] Natl Inst Fisheries Sci, Inland Aquaculture Res, 55,25gil Yeomyeong Ro, Changwon Si 51688, Kyeongsangnam D, South Korea; [Jung, Tae Sung] Flinders Univ S Australia, Ctr Marine Bioprod Dev, Bedford Pk, SA 5042, Australia		Jung, TS (通讯作者)，Gyeongsang Natl Univ, Res Inst Nat Sci, Coll Vet Med, Lab Aquat Anim Dis, Jinju Si 52828, Gyeongsangnam D, South Korea.; Jung, TS (通讯作者)，Flinders Univ S Australia, Ctr Marine Bioprod Dev, Bedford Pk, SA 5042, Australia.	jassylazarte@yahoo.com; yl0808@nate.com; leejs058@gmail.com; hilanamang@naver.com; ksw0017@hanmail.net; wjdwodnr0605@gmail.com; afteru70@gmail.com; pattanapon.k@ku.th; Kim.Thompson@moredun.ac.uk; kimk2k@korea.kr; jungts@gnu.ac.kr	Jung, Tae Sung/G-8245-2017; Thompson, Kim/O-7707-2015	Jung, Tae Sung/0000-0001-6028-0946; Kayansamruaj, Pattanapon/0000-0002-6187-2772; Thompson, Kim/0000-0003-3550-4842	Korea Research FoundationKorea Research Foundation [NRF-2018 R1A2B2005505]; National Institute of Fisheries Science [R2020013]	This research was funded by Korea Research Foundation, grant number NRF-2018 R1A2B2005505 and National Institute of Fisheries Science, grant number R2020013.	Adang MJ, 2014, ADV INSECT PHYSIOL, V47, P39, DOI 10.1016/B978-0-12-800197-4.00002-6; Alder MN, 2008, NAT IMMUNOL, V9, P319, DOI 10.1038/ni1562; Alder MN, 2005, SCIENCE, V310, P1970, DOI 10.1126/science.1119420; [Anonymous], 2012, NACA REPORT ASIA PAC; Bravo A, 2007, TOXICON, V49, P423, DOI 10.1016/j.toxicon.2006.11.022; Bravo A, 2013, MICROB BIOTECHNOL, V6, P17, DOI 10.1111/j.1751-7915.2012.00342.x; Broberg CA, 2011, MICROBES INFECT, V13, P992, DOI 10.1016/j.micinf.2011.06.013; Dal Peraro M, 2016, NAT REV MICROBIOL, V14, P77, DOI 10.1038/nrmicro.2015.3; de la Pena LD, 2015, DIS AQUAT ORGAN, V116, P251, DOI 10.3354/dao02919; De Schryver P, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003919; FUJII T, 1979, DEV COMP IMMUNOL, V3, P441, DOI 10.1016/S0145-305X(79)80040-3; Gao XJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050723; Gomez-Gil B, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.00055-14; GOTTSTEIN B, 1985, Z PARASITENKD, V71, P273, DOI 10.1007/BF00926279; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; Herrin BR, 2008, P NATL ACAD SCI USA, V105, P2040, DOI 10.1073/pnas.0711619105; Hu BC, 2019, J SCI FOOD AGR, V99, P2565, DOI 10.1002/jsfa.9470; Im SP, 2018, J IMMUNOL, V201, P3119, DOI 10.4049/jimmunol.1800981; Joshi J, 2014, AQUACULTURE, V428, P297, DOI 10.1016/j.aquaculture.2014.03.030; Jung JW, 2020, J IMMUNOL, V204, P718, DOI 10.4049/jimmunol.1900675; Kim J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29197-w; Kitami M, 2011, BIOSCI BIOTECH BIOCH, V75, P305, DOI 10.1271/bbb.100689; Kumaran T, 2018, FISH SHELLFISH IMMUN, V74, P349, DOI 10.1016/j.fsi.2017.12.062; Lai HC, 2015, FISH SHELLFISH IMMUN, V47, P1006, DOI 10.1016/j.fsi.2015.11.008; Lee CT, 2015, P NATL ACAD SCI USA, V112, P10798, DOI 10.1073/pnas.1503129112; Lee JS, 2018, MOL IMMUNOL, V99, P30, DOI 10.1016/j.molimm.2018.04.006; Li JX, 2013, P NATL ACAD SCI USA, V110, P15013, DOI 10.1073/pnas.1314540110; Lin SJ, 2017, MAR DRUGS, V15, DOI 10.3390/md15120373; Tran L, 2013, DIS AQUAT ORGAN, V105, P45, DOI 10.3354/dao02621; Nakamura R, 2019, J FISH DIS, V42, P1125, DOI 10.1111/jfd.13024; Nunan L, 2014, DIS AQUAT ORGAN, V111, P81, DOI 10.3354/dao02776; Pardo-Lopez L, 2013, FEMS MICROBIOL REV, V37, P3, DOI 10.1111/j.1574-6976.2012.00341.x; Pigott CR, 2007, MICROBIOL MOL BIOL R, V71, P255, DOI 10.1128/MMBR.00034-06; Poole JRM, 2017, DEV COMP IMMUNOL, V75, P120, DOI 10.1016/j.dci.2017.02.011; Restrepo L, 2016, GENOM DATA, V9, P143, DOI 10.1016/j.gdata.2016.08.008; Sirikharin R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126987; Soberon M, 2010, ADV EXP MED BIOL, V677, P127; Tinwongger S, 2016, J APPL MICROBIOL, V121, P1755, DOI 10.1111/jam.13256; Waterfield N, 2005, FEMS MICROBIOL LETT, V245, P47, DOI 10.1016/j.femsle.2005.02.018; Zhang LL, 2013, CURR OPIN MICROBIOL, V16, P70, DOI 10.1016/j.mib.2013.02.002; Zhang Y, 2009, FISH SHELLFISH IMMUN, V26, P183, DOI 10.1016/j.fsi.2008.03.008	41	1	1	2	4	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							55	10.3390/vaccines9010055			11	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6VB	33467013	Green Published, gold			2022-04-29	WOS:000610808700001
J	Piedrahita-Valdes, H; Piedrahita-Castillo, D; Bermejo-Higuera, J; Guillem-Saiz, P; Bermejo-Higuera, JR; Guillem-Saiz, J; Sicilia-Montalvo, JA; Machio-Regidor, F				Piedrahita-Valdes, Hilary; Piedrahita-Castillo, Diego; Bermejo-Higuera, Javier; Guillem-Saiz, Patricia; Ramon Bermejo-Higuera, Juan; Guillem-Saiz, Javier; Antonio Sicilia-Montalvo, Juan; Machio-Regidor, Francisco			Vaccine Hesitancy on Social Media: Sentiment Analysis from June 2011 to April 2019	VACCINES			English	Article						vaccine hesitancy; vaccination; opinion mining; sentiment analysis; content analysis; machine learning; social media; Twitter		Vaccine hesitancy was one of the ten major threats to global health in 2019, according to the World Health Organisation. Nowadays, social media has an important role in the spread of information, misinformation, and disinformation about vaccines. Monitoring vaccine-related conversations on social media could help us to identify the factors that contribute to vaccine confidence in each historical period and geographical area. We used a hybrid approach to perform an opinion-mining analysis on 1,499,227 vaccine-related tweets published on Twitter from 1st June 2011 to 30th April 2019. Our algorithm classified 69.36% of the tweets as neutral, 21.78% as positive, and 8.86% as negative. The percentage of neutral tweets showed a decreasing tendency, while the proportion of positive and negative tweets increased over time. Peaks in positive tweets were observed every April. The proportion of positive tweets was significantly higher in the middle of the week and decreased during weekends. Negative tweets followed the opposite pattern. Among users with >= 2 tweets, 91.83% had a homogeneous polarised discourse. Positive tweets were more prevalent in Switzerland (71.43%). Negative tweets were most common in the Netherlands (15.53%), Canada (11.32%), Japan (10.74%), and the United States (10.49%). Opinion mining is potentially useful to monitor online vaccine-related concerns and adapt vaccine promotion strategies accordingly.	[Piedrahita-Valdes, Hilary] Univ Valencia, Dept Prevent Med & Publ Hlth Bromatol Toxicol & L, Valencia 46010, Spain; [Piedrahita-Castillo, Diego; Bermejo-Higuera, Javier; Ramon Bermejo-Higuera, Juan; Antonio Sicilia-Montalvo, Juan; Machio-Regidor, Francisco] Int Univ La Rioja, Fac Engn & Technol, Logrono 26006, Spain; [Guillem-Saiz, Patricia] European Univ Valencia, Dept Prevent Dent Epidemiol & Publ Hlth, Valencia 46010, Spain; [Guillem-Saiz, Patricia] Inst Hlth Carlos III, CIBER Physiopathol Obes & Nutr CIBERobn, Madrid 28029, Spain; [Guillem-Saiz, Javier] Int Univ Valencia, Dept Psychol, Valencia 46002, Spain		Piedrahita-Valdes, H (通讯作者)，Univ Valencia, Dept Prevent Med & Publ Hlth Bromatol Toxicol & L, Valencia 46010, Spain.	piedrahita_hil@gva.es; diego.piedrahita@comunidadunir.net; javier.bermejo@unir.net; patricia.guillem@universidadeuropea.es; juanramon.bermejo@unir.net; javier.guillem@campusviu.es; juanantonio.sicilia@unir.net; francisco.machio@unir.net	Bermejo, Javier/AAO-9844-2020; Piedrahita, Diego/ABA-8131-2021; Sicilia, Juan Antonio/H-9297-2018; Machio, Francisco/H-3686-2017; GS, Javier/AAS-3579-2021; Higuera, Juan Ramon Bermejo/AAO-2990-2020; Piedrahita-Valdés, Hilary/ABA-8129-2021	Piedrahita, Diego/0000-0001-9252-1994; Sicilia, Juan Antonio/0000-0002-5962-4147; Machio, Francisco/0000-0001-6429-9708; GS, Javier/0000-0002-5438-9715; Higuera, Juan Ramon Bermejo/0000-0002-0197-8663; Piedrahita-Valdés, Hilary/0000-0001-9053-1101; javier, Bermejo/0000-0003-3681-2572			Aftab S., 2017, INT J MULTIDISCIPLIN, V8, P28; Almatarneh S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197816; Azizi FSM, 2017, VACCINE, V35, P2955, DOI 10.1016/j.vaccine.2017.04.010; Behdenna S., 2018, EAI ENDORSED T CONTE, V4, P1, DOI [10.4108/eai.14-3-2018.154339, DOI 10.4108/EAI.14-3-2018.154339]; Betsch C, 2013, HEALTH PSYCHOL, V32, P146, DOI 10.1037/a0027387; Blankenship Elizabeth B, 2018, Perm J, V22, P17, DOI 10.7812/TPP/17-138; Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567; Cambria E, 2016, IEEE INTELL SYST, V31, P102, DOI 10.1109/MIS.2016.31; Celebi ME., 2016, UNSUPERVISED LEARNIN, DOI [10.1007/978-3-319-24211-8, DOI 10.1007/978-3-319-24211-8]; Colon-~Ruiz C. I., 2019, PROCES LENG NATURAL, V63, P15, DOI [10.26342/2019-63-1, DOI 10.26342/2019-63-1]; D'Andrea E, 2019, EXPERT SYST APPL, V116, P209, DOI 10.1016/j.eswa.2018.09.009; Deiner MS, 2019, HEALTH INFORM J, V25, P1116, DOI 10.1177/1460458217740723; Du JC, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0469-6; European Centre for Disease Prevention and Control, 2020, SYT SCOP REV SOC MED, DOI [10.2900/260624, DOI 10.2900/260624]; Henriquez Miranda C., 2017, PROCES LENG NAT, V59, P49; Kamble S.S., 2018, INT RES J ENG TECHNO, P3045; Lane S, 2018, VACCINE, V36, P3861, DOI 10.1016/j.vaccine.2018.03.063; Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042; MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036; Massey PM, 2018, PREV CHRONIC DIS, V15, DOI 10.5888/pcd15.170320; Massey PM, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.6670; Medhat W, 2014, AIN SHAMS ENG J, V5, P1093, DOI 10.1016/j.asej.2014.04.011; Meyer SB, 2019, VACCINE, V37, P1769, DOI 10.1016/j.vaccine.2019.02.028; Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017; Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365; Pineiro Perez R., 2017, ANN PEDIATRIA, V86, P314, DOI [10.1016/j.anpedi.2016.06.004, DOI 10.1016/J.ANPEDI.2016.06.004]; Priyavrat, 2017, INT J RES APPL SCI E, V5, P80, DOI [DOI 10.22214/IJRASET.2017.11011, 10.22214/ijraset.2017.11011]; Raghupathi V, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103464; Rosselli R, 2016, J Prev Med Hyg, V57, pE47; Samal BR, 2017, 2017 IEEE 3RD INTERNATIONAL CONFERENCE ON SENSING, SIGNAL PROCESSING AND SECURITY (ICSSS), P128, DOI 10.1109/SSPS.2017.8071579; Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040; Sinnenberg L, 2017, AM J PUBLIC HEALTH, V107, pE1, DOI 10.2105/AJPH.2016.303512; Tavoschi L, 2020, HUM VACC IMMUNOTHER, V16, P1062, DOI 10.1080/21645515.2020.1714311; Tomeny TS, 2017, SOC SCI MED, V191, P168, DOI 10.1016/j.socscimed.2017.08.041; Wiemken TL, 2020, ANNU REV PUBL HEALTH, V41, P21, DOI 10.1146/annurev-publhealth-040119-094437; World Health Organization, 2019, 10 THREATS GLOB HLTH; Yadollahi A, 2017, ACM COMPUT SURV, V50, DOI 10.1145/3057270; Zhang AJ, 2018, INT J QUAL METH, V17, DOI 10.1177/1609406917750782; Zhou J, 2018, PERSPECT PUBLIC HEAL, V138, P173, DOI 10.1177/1757913918760359	39	18	18	7	12	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							28	10.3390/vaccines9010028			12	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Immunology; Research & Experimental Medicine	PY1ZZ	33430428	Green Published, gold			2022-04-29	WOS:000611850300001
J	Wang, KL; Wong, ELY; Ho, KF; Cheung, AWL; Yau, PS; Dong, D; Wong, SYS; Yeoh, EK				Wang, Kailu; Wong, Eliza Lai-Yi; Ho, Kin-Fai; Cheung, Annie Wai-Ling; Yau, Peter Sen-Yung; Dong, Dong; Wong, Samuel Yeung-Shan; Yeoh, Eng-Kiong			Change of Willingness to Accept COVID-19 Vaccine and Reasons of Vaccine Hesitancy of Working People at Different Waves of Local Epidemic in Hong Kong, China: Repeated Cross-Sectional Surveys	VACCINES			English	Article						COVID-19 vaccine; vaccine acceptance; vaccine hesitancy; vaccine safety; health behaviour; occupation		Vaccine hesitancy is among the major threats to the effectiveness of vaccination programmes. This study aimed to report the trend in response to willingness to accept the COVID-19 vaccine between two waves of the local epidemic and examine differences among occupations. Two cross-sectional surveys were conducted online during the first wave (February) and third wave (August to September) of the local epidemic in 2020. Acceptance of the COVID-19 vaccine was measured along with personal protection behaviours and occupations. A total of 2047 participants provided valid responses. The willingness to accept the COVID-19 vaccine among the participants was lower in the third wave (34.8%) than the first wave (44.2%). There were more concerns over vaccine safety in the third wave. Clerical/service/sales workers were less likely to accept the vaccine (adjusted odds ratio: 0.62, 95% confidence interval: 0.43-0.91). A high-level compliance of facemask wearing was found, and more people maintained social distancing and used alcohol hand rub in the third wave. Decreasing willingness to accept the COVID-19 vaccine may be associated with increasing concerns about vaccine safety and growing compliance of personal protection behaviours. The rush of vaccine development with higher risks of safety issues may jeopardize the public's trust and lower uptake rates. Education and favourable policy should be provided to the general working population for the vaccination, especially for those who are not professional and are frequently exposed to crowds.	[Wang, Kailu; Wong, Eliza Lai-Yi; Ho, Kin-Fai; Cheung, Annie Wai-Ling; Yau, Peter Sen-Yung; Dong, Dong; Wong, Samuel Yeung-Shan; Yeoh, Eng-Kiong] Chinese Univ Hong Kong, Fac Med, JC Sch Publ Hlth & Primary Care, Ctr Hlth Syst & Policy Res, Hong Kong, Peoples R China		Wong, ELY (通讯作者)，Chinese Univ Hong Kong, Fac Med, JC Sch Publ Hlth & Primary Care, Ctr Hlth Syst & Policy Res, Hong Kong, Peoples R China.	kailuwang@cuhk.edu.hk; lywong@cuhk.edu.hk; kfho@cuhk.edu.hk; anniewlcheung@cuhk.edu.hk; b144754@cuhk.edu.hk; dongdong@cuhk.edu.hk; yeungshanwong@cuhk.edu.hk; yeoh_ek@cuhk.edu.hk	Ho, Kin Fai/E-6131-2011	Ho, Kin Fai/0000-0001-7464-3437; Dong, Dong/0000-0001-9784-6472; Wang, Kailu/0000-0002-3462-4677; Wong, Eliza/0000-0001-9983-6219			Alrubaiee GG, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09644-y; Alwan NA, 2020, LANCET, V396, pE24, DOI 10.1016/S0140-6736(20)31823-7; Anderson RM, 2020, LANCET, V396, P1614, DOI 10.1016/S0140-6736(20)32318-7; [Anonymous], 2020, COR RES CTR; Burki T, 2020, LANCET DIGIT HEALTH, V2, pE504, DOI 10.1016/S2589-7500(20)30227-2; Census and Statistics Department, 2020, 2019 REP ANN EARN HO; Centre for Health Protection, 2020, RECOMMENDATIONS SEAS; Centre for Health Protection, 2020, COVID 19 THEM WEBS H; Chor JSY, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3391; Dodd RH, 2021, LANCET INFECT DIS, V21, P318, DOI 10.1016/S1473-3099(20)30559-4; Frank K., 2020, CANADIANS WILLINGNES; Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932; Ghebreyesus T.A, 2020, DIR GEN OP REM MED B; Gudi SK, 2020, DRUGS THER PERSPECT, V36, P413, DOI 10.1007/s40267-020-00752-8; Hodgson SH, 2021, LANCET INFECT DIS, V21, pE26, DOI 10.1016/S1473-3099(20)30773-8; Hotez P, 2019, PEDIATR RES, V85, P912, DOI 10.1038/s41390-019-0354-3; Jarrett C, 2015, VACCINE, V33, P4180, DOI 10.1016/j.vaccine.2015.04.040; Johnson NF, 2020, NATURE, V582, P230, DOI 10.1038/s41586-020-2281-1; Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177; Kim TH, 2011, SCAND J INFECT DIS, V43, P683, DOI 10.3109/00365548.2011.582247; Lahariya Chandrakant, 2016, J Family Med Prim Care, V5, P7, DOI 10.4103/2249-4863.184616; Lan FY, 2021, OCCUP ENVIRON MED, V78, P237, DOI 10.1136/oemed-2020-106774; Lan FY, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233588; Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081; Lazarus JV, 2021, NAT MED, V27, P225, DOI 10.1038/s41591-020-1124-9; Loskutova NY, 2020, BMC FAM PRACT, V21, DOI 10.1186/s12875-020-01115-y; Malik AA., 2020, ECLINICALMEDICINE, V26, DOI [10.1016/j.eclinm.2020.100495, DOI 10.1016/J.ECLINM.2020.100495]; Manuel DG, 2002, INFECT CONT HOSP EP, V23, P609, DOI 10.1086/501980; Marinaccio A, 2020, OCCUP ENVIRON MED, V77, P818, DOI 10.1136/oemed-2020-106844; Naing N N, 2000, Malays J Med Sci, V7, P10; Nguyen LH, 2020, LANCET PUBLIC HEALTH, V5, pE475, DOI 10.1016/S2468-2667(20)30164-X; O'Halloran AC, 2017, AM J INFECT CONTROL, V45, P410, DOI 10.1016/j.ajic.2017.01.005; Poland GA, 2020, LANCET, V396, P1595, DOI 10.1016/S0140-6736(20)32137-1; Raab M, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-8433-2; Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013; Trogen B, 2020, JAMA-J AM MED ASSOC, V323, P2460, DOI 10.1001/jama.2020.8917; Utazi CE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09611-1; Wang JH, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030482; Wang KL, 2020, VACCINE, V38, P7049, DOI 10.1016/j.vaccine.2020.09.021; Whibley A, 2020, ACTA PAEDIATR, V109, P1706, DOI 10.1111/apa.15285; WHO, 2020, REPURPOSED ANTIVIRAL, P2020; Wong LP, 2020, HUM VACC IMMUNOTHER, V16, P2204, DOI 10.1080/21645515.2020.1790279; World Health Organization, 2020, GETT YOUR WORKPL REA; Zhang M, 2020, J HOSP INFECT, V105, P183, DOI 10.1016/j.jhin.2020.04.012	44	75	76	16	34	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2076-393X		VACCINES-BASEL	Vaccines	JAN	2021	9	1							62	10.3390/vaccines9010062			15	Immunology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Research & Experimental Medicine	PW6WE	33477725	Green Published, gold	Y	N	2022-04-29	WOS:000610811600001
